{"generated":"2026-09-30T06:46:19.404Z","total":32546,"checked":32546,"broken":5855,"gone":100,"blocked":5534,"unreachable":221,"moved":4616,"archived":579,"results":[{"url":"http://ambrx.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","field":"links","label":"Official website"},{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","field":"website"}],"archive":"https://web.archive.org/web/20251211160406/https://ambrx.com/"},{"url":"http://telik.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","field":"links","label":"Official website"},{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","field":"website"}],"archive":"https://web.archive.org/web/20260610003321/https://www.telik.com/"},{"url":"http://www.chuis.ma","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","field":"links","label":"CHU Ibn Sina"},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","field":"website"}],"archive":"https://web.archive.org/web/20231014141753/http://www.chuis.ma/"},{"url":"http://www.cyclacel.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","field":"links","label":"Official website"},{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","field":"website"}],"archive":"https://web.archive.org/web/20250926104105/https://www.cyclacel.com/"},{"url":"http://www.immunitor.mn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","field":"links","label":"Official website"},{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","field":"website"}],"archive":"https://web.archive.org/web/20201028140646/http://immunitor.mn/"},{"url":"http://www.koranyi.hu","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"links","label":"National Korányi Institute for Pulmonology website"},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"profiles","label":"National Korányi Institute for Pulmonology website"},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","field":"links","label":"Official website"},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","field":"website"}],"archive":"https://web.archive.org/web/20260114035910/https://www.koranyi.hu/"},{"url":"http://www.sanmatteo.org/site/home.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","field":"links","label":"Fondazione IRCCS Policlinico San Matteo website"},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","field":"profiles","label":"Fondazione IRCCS Policlinico San Matteo website"}],"archive":"https://web.archive.org/web/20251201025645/https://www.sanmatteo.org/site/home.html"},{"url":"https://businesswire.com/news/home/20251016096352/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-CABINET-Phase-3-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Advanced-Lung-and-Thymic-Neuroendocrine-Tumors-at-ESMO-2025","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"links","label":"ESMO 2025 subgroup (Exelixis)"}],"archive":"https://web.archive.org/web/20260122163752/https://www.businesswire.com/news/home/20251016096352/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-CABINET-Phase-3-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Advanced-Lung-and-Thymic-Neuroendocrine-Tumors-at-ESMO-2025"},{"url":"https://cancer.research.purdue.edu/directory/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","route":"/people/andrew-mesecar/","field":"links","label":"Source: Purdue Institute for Cancer Research directory (senior leadership)"}],"archive":"https://web.archive.org/web/20260606233351/https://cancer.research.purdue.edu/directory/"},{"url":"https://cancer.research.purdue.edu/directory/andrew-mesecar/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","route":"/people/andrew-mesecar/","field":"profiles","label":"PICR directory profile"}],"archive":"https://web.archive.org/web/20260606232323/https://cancer.research.purdue.edu/directory/andrew-mesecar/"},{"url":"https://cancerbiology.sites.vib.be","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","field":"links","label":"VIB-KU Leuven Center for Cancer Biology"}],"archive":"https://web.archive.org/web/20260923053218/https://cancerbiology.sites.vib.be/"},{"url":"https://cancercentrum.se/omrcc/kontaktochorganisation/rccstockholmgotland.1334.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","route":"/institutions/sgccn/","field":"links","label":"Official website"},{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","route":"/institutions/sgccn/","field":"website"}],"archive":"https://web.archive.org/web/20260907042815/https://cancercentrum.se/omrcc/kontaktochorganisation/rccstockholmgotland.1334.html"},{"url":"https://cdsco.gov.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","route":"/institutions/cdsco/","field":"links","label":"CDSCO"},{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","route":"/institutions/cdsco/","field":"website"}],"archive":"https://web.archive.org/web/20240707203530/https://cdsco.gov.in/"},{"url":"https://cdsco.gov.in/opencms/opencms/en/Home/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"india-new-drugs-rules-2019","kind":"term","name":"India New Drugs and Clinical Trials Rules 2019","route":"/terms/india-new-drugs-rules-2019/","field":"links","label":"CDSCO (Central Drugs Standard Control Organisation)"}],"archive":"https://web.archive.org/web/20260925050418/https://cdsco.gov.in/opencms/opencms/en/Home/"},{"url":"https://cegat.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cegat","kind":"company","name":"CeGaT","route":"/companies/cegat/","field":"links","label":"Official website"},{"id":"cegat","kind":"company","name":"CeGaT","route":"/companies/cegat/","field":"website"}],"archive":"https://web.archive.org/web/20260905203648/https://cegat.com/"},{"url":"https://crcm.fr","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","field":"links","label":"CRCM"}],"archive":"https://web.archive.org/web/20180118051217/http://crcm.fr/"},{"url":"https://cu.edu.eg","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","field":"links","label":"Cairo University"}],"archive":"https://web.archive.org/web/20260906171242/https://www.cu.edu.eg/"},{"url":"https://dantari.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","field":"links","label":"Official website"},{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","field":"website"}],"archive":"https://web.archive.org/web/20260215224016/http://dantari.com/"},{"url":"https://doi.org/10.5334/ijic.2058","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"papers","label":"Electronic consultation as an essential implement for Continuity of Care"}],"archiveRequested":true},{"url":"https://elevartherapeutics.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20250318210207/https://elevartherapeutics.com/"},{"url":"https://ellok.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","field":"links","label":"Hellenic Cancer Federation (ELLOK) website"},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","field":"profiles","label":"Hellenic Cancer Federation (ELLOK) website"},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","field":"links","label":"Official website"},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","field":"website"}],"archive":"https://web.archive.org/web/20260912165128/https://ellok.org/"},{"url":"https://en.tums.ac.ir","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","field":"links","label":"Tehran University of Medical Sciences"}],"archiveRequested":false},{"url":"https://essapharma.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","field":"links","label":"Official website"},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","field":"website"}],"archive":"https://web.archive.org/web/20251122034006/https://www.essapharma.com/"},{"url":"https://faculty.mdanderson.org/search?q=Albert%20C.%20Koong","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"links","label":"MD Anderson faculty"},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":true},{"url":"https://faculty.mdanderson.org/search?q=Anirban%20Maitra","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"links","label":"MD Anderson faculty"},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":true},{"url":"https://faculty.mdanderson.org/search?q=Christopher%20R.%20Flowers","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"links","label":"MD Anderson faculty"},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Debu%20Tripathy","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"links","label":"MD Anderson faculty"},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":true},{"url":"https://faculty.mdanderson.org/search?q=Funda%20Meric-Bernstam","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"links","label":"MD Anderson faculty"},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Giulio%20Draetta","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"links","label":"MD Anderson faculty"},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Hagop%20M.%20Kantarjian","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"links","label":"MD Anderson faculty"},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=James%20P.%20Allison","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"links","label":"MD Anderson faculty"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"links","label":"MD Anderson faculty"},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":true},{"url":"https://faculty.mdanderson.org/search?q=John%20V.%20Heymach","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"links","label":"MD Anderson faculty"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Mariana%20Chavez-MacGregor","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"links","label":"MD Anderson faculty"},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":true},{"url":"https://faculty.mdanderson.org/search?q=Padmanee%20Sharma","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"links","label":"MD Anderson faculty"},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://faculty.mdanderson.org/search?q=Peter%20W.%20T.%20Pisters","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"links","label":"MD Anderson faculty"},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"profiles","label":"MD Anderson faculty"}],"archiveRequested":false},{"url":"https://fnkc.ru","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","route":"/institutions/rogachev-centre/","field":"links","label":"Official website (Russian)"},{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","route":"/institutions/rogachev-centre/","field":"website"}],"archive":"https://web.archive.org/web/20260721013646/https://fnkc.ru/"},{"url":"https://fnkc.ru/o-tsentre/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","route":"/institutions/rogachev-centre/","field":"links","label":"About the centre (Russian)"}],"archiveRequested":false},{"url":"https://ikhc.tums.ac.ir","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","field":"links","label":"Imam Khomeini Hospital Complex"},{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","field":"website"}],"archive":"https://web.archive.org/web/20260823072950/https://ikhc.tums.ac.ir/"},{"url":"https://ikhc.tums.ac.ir/%D8%A8%DB%8C%D9%85%D8%A7%D8%B1%D8%B3%D8%AA%D8%A7%D9%86-%D8%A7%D9%86%D8%B3%D8%AA%DB%8C%D8%AA%D9%88-%DA%A9%D8%A7%D9%86%D8%B3%D8%B1","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","route":"/people/seyed-rouhollah-miri/","field":"links","label":"Source: IKHC Cancer Institute hospital page"},{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","route":"/people/seyed-rouhollah-miri/","field":"profiles","label":"Institution page (Persian)"}],"archive":"https://web.archive.org/web/20240530060129/https://ikhc.tums.ac.ir/%d8%a8%db%8c%d9%85%d8%a7%d8%b1%d8%b3%d8%aa%d8%a7%d9%86-%d8%a7%d9%86%d8%b3%d8%aa%db%8c%d8%aa%d9%88-%da%a9%d8%a7%d9%86%d8%b3%d8%b1"},{"url":"https://incan.salud.gob.mx/directorio/direccion-general","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","field":"profiles","label":"Institution directory"}],"archive":"https://web.archive.org/web/20260923052237/https://incan.salud.gob.mx/directorio/direccion-general"},{"url":"https://interiusbio.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","field":"website"}],"archive":"https://web.archive.org/web/20260306170338/https://interiusbio.com/"},{"url":"https://interiusbio.com/press-release/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-car-gene-therapy-for-b-cell-malignancies/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","field":"links","label":"First patient dosed"}],"archive":"https://web.archive.org/web/20251018110211/https://interiusbio.com/press-release/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-car-gene-therapy-for-b-cell-malignancies/"},{"url":"https://jcog.jp","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/","field":"links","label":"Official website"},{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/","field":"website"}],"archive":"https://web.archive.org/web/20260909200211/https://jcog.jp/"},{"url":"https://jcog.jp/en/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","field":"links","label":"JCOG"},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","field":"profiles","label":"JCOG"},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","field":"links","label":"JCOG"},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","field":"profiles","label":"JCOG"}],"archive":"https://web.archive.org/web/20251117001629/https://jcog.jp/en/"},{"url":"https://kidwai.karnataka.gov.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","field":"links","label":"Kidwai Memorial Institute of Oncology"},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","field":"website"}],"archiveRequested":false},{"url":"https://lacog.org.br","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"links","label":"LACOG"},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"profiles","label":"LACOG"},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","field":"links","label":"LACOG"}],"archive":"https://web.archive.org/web/20200506120631/http://www.lacog.org.br:80/"},{"url":"https://mcodeinitiative.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"links","label":"mCODE: Minimal Common Oncology Data Elements"},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","field":"links","label":"mCODE (minimal Common Oncology Data Elements)"},{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/","field":"links","label":"mCODE"},{"id":"idea-moon-patient-held-cancer-record","kind":"idea","name":"A patient-owned, portable complete cancer record in a standard format","route":"/ideas/idea-moon-patient-held-cancer-record/","field":"links","label":"mCODE initiative"}],"archive":"https://web.archive.org/web/20220226045440/https://mcodeinitiative.org/"},{"url":"https://nha.gov.in/PM-JAY","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","route":"/institutions/nha-pmjay/","field":"links","label":"National Health Authority: PM-JAY"},{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","route":"/institutions/nha-pmjay/","field":"website"}],"archive":"https://web.archive.org/web/20251207150703/https://nha.gov.in/PM-JAY"},{"url":"https://onco.tnimc.ru","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","route":"/institutions/tomsk-cancer-research-institute/","field":"links","label":"Official website (Russian)"},{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","route":"/institutions/tomsk-cancer-research-institute/","field":"website"}],"archive":"https://web.archive.org/web/20250324044421/https://onco.tnimc.ru/"},{"url":"https://onkologia.org.pl","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","field":"links","label":"Polish National Cancer Registry"}],"archive":"https://web.archive.org/web/20221028071920/http://onkologia.org.pl/"},{"url":"https://pgimer.edu.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/","field":"links","label":"PGIMER Chandigarh"},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/","field":"website"}],"archive":"https://web.archive.org/web/20260831033329/https://www.pgimer.edu.in/"},{"url":"https://pmssy.mohfw.gov.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","route":"/institutions/aiims-network/","field":"links","label":"PMSSY, Ministry of Health and Family Welfare"},{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","route":"/institutions/aiims-network/","field":"website"}],"archiveRequested":false},{"url":"https://pmssy.mohfw.gov.in/index4.php?lang=1&level=0&linkid=1&lid=1","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ankita-mishra-bundela","kind":"person","name":"Ankita Mishra Bundela","route":"/people/ankita-mishra-bundela/","field":"links","label":"Source: PMSSY division contact page, Ministry of Health and Family Welfare"},{"id":"ankita-mishra-bundela","kind":"person","name":"Ankita Mishra Bundela","route":"/people/ankita-mishra-bundela/","field":"profiles","label":"PMSSY contact page listing division officers"}],"archive":"https://web.archive.org/web/20260711053554/https://pmssy.mohfw.gov.in/index4.php?lang=1&level=0&linkid=1&lid=1"},{"url":"https://ramot.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","field":"links","label":"Ramot at Tel Aviv University"}],"archive":"https://web.archive.org/web/20260620214145/https://ramot.org/"},{"url":"https://senginemedicine.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/","field":"website"}],"archive":"https://web.archive.org/web/20260112064519/https://senginemedicine.com/"},{"url":"https://tennonc.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/","field":"links","label":"Tennessee Oncology"},{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/","field":"website"}],"archiveRequested":false},{"url":"https://view-health-screening-recommendations.service.gov.uk/lung-cancer/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"UK National Screening Committee: lung cancer screening recommendation (June 2022 review)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"UK National Screening Committee: lung cancer screening recommendation (June 2022 review)"},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","field":"links","label":"UK National Screening Committee: lung cancer screening recommendation (June 2022 review)"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","field":"links","label":"UK National Screening Committee recommendation on lung cancer screening"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","field":"links","label":"UK National Screening Committee: lung cancer screening recommendation (June 2022 review)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"UK National Screening Committee: lung cancer screening recommendation (June 2022 review)"}],"archive":"https://web.archive.org/web/20260825141801/https://view-health-screening-recommendations.service.gov.uk/lung-cancer/"},{"url":"https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"UK National Screening Committee: prostate cancer recommendation"}],"archive":"https://web.archive.org/web/20260730193519/https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/"},{"url":"https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","field":"links","label":"Sino Biopharmaceutical / Chia Tai Tianqing (archived copy)"},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","field":"links","label":"Official website (archived copy)"}],"archiveRequested":false},{"url":"https://www.301hospital.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"links","label":"Chinese PLA General Hospital"},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260611040912/http://301hospital.com.cn/"},{"url":"https://www.abbisko.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","field":"links","label":"Official website"},{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","field":"website"}],"archive":"https://web.archive.org/web/20260909155716/https://www.abbisko.com/"},{"url":"https://www.aezsinc.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","field":"links","label":"Official website"},{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","field":"website"}],"archive":"https://web.archive.org/web/20180316125448/http://aezsinc.com/"},{"url":"https://www.alltrials.net/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"links","label":"AllTrials"}],"archive":"https://web.archive.org/web/20250817122533/http://www.alltrials.net/"},{"url":"https://www.anti-cancer.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","field":"links","label":"Henan Cancer Hospital"},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20251201193339/http://www.anti-cancer.com.cn/"},{"url":"https://www.apollocancercentres.com/proton","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","field":"links","label":"Apollo Proton Cancer Centre"}],"archiveRequested":false},{"url":"https://www.apotecachemo.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"loccioni","kind":"company","name":"Loccioni","route":"/companies/loccioni/","field":"links","label":"APOTECA"},{"id":"loccioni","kind":"company","name":"Loccioni","route":"/companies/loccioni/","field":"website"}],"archiveRequested":false},{"url":"https://www.ararisbiotech.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/","field":"website"}],"archive":"https://web.archive.org/web/20260719153008/https://www.ararisbiotech.com/"},{"url":"https://www.aslimnica.lv","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"links","label":"Riga East University Hospital / Oncology Centre of Latvia website"},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"profiles","label":"Riga East University Hospital / Oncology Centre of Latvia website"},{"id":"riga-east-university-hospital","kind":"institution","name":"Riga East University Hospital / Oncology Centre of Latvia","route":"/institutions/riga-east-university-hospital/","field":"links","label":"Official website"},{"id":"riga-east-university-hospital","kind":"institution","name":"Riga East University Hospital / Oncology Centre of Latvia","route":"/institutions/riga-east-university-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260831095923/https://aslimnica.lv/"},{"url":"https://www.ausl.re.it","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ausl-irccs-reggio-emilia","kind":"institution","name":"AUSL-IRCCS di Reggio Emilia","route":"/institutions/ausl-irccs-reggio-emilia/","field":"links","label":"Official website"},{"id":"ausl-irccs-reggio-emilia","kind":"institution","name":"AUSL-IRCCS di Reggio Emilia","route":"/institutions/ausl-irccs-reggio-emilia/","field":"website"}],"archive":"https://web.archive.org/web/20260912162335/https://www.ausl.re.it/"},{"url":"https://www.bartscancer.london","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/","field":"links","label":"Barts Cancer Institute"},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/","field":"website"}],"archive":"https://web.archive.org/web/20240715213332/https://www.bartscancer.london/"},{"url":"https://www.bartscancer.london/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","field":"links","label":"Barts Cancer Institute"},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","field":"profiles","label":"Barts Cancer Institute"},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","field":"links","label":"Barts Cancer Institute"},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","field":"profiles","label":"Barts Cancer Institute"}],"archive":"https://web.archive.org/web/20240715213332/https://www.bartscancer.london/"},{"url":"https://www.baxter.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","field":"links","label":"Official website"},{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","field":"website"}],"archive":"https://web.archive.org/web/20260912172507/https://www.baxter.com/"},{"url":"https://www.bigagainstbreastcancer.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"links","label":"Breast International Group"},{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/","field":"links","label":"Official website"},{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/","field":"website"}],"archive":"https://web.archive.org/web/20260912133906/http://www.bigagainstbreastcancer.org/"},{"url":"https://www.biocon.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","field":"links","label":"Biocon"},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","field":"profiles","label":"Biocon"},{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/","field":"links","label":"Official website"},{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/","field":"website"}],"archive":"https://web.archive.org/web/20260816163113/https://www.biocon.com/"},{"url":"https://www.bioconbiologics.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","field":"links","label":"Official website"},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","field":"website"}],"archive":"https://web.archive.org/web/20260713192124/https://www.bioconbiologics.com/"},{"url":"https://www.biostar.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/","field":"links","label":"Official website"},{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260809110611/http://www.biostar.com.cn/"},{"url":"https://www.bjcancer.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"links","label":"Peking University Cancer Hospital"},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"profiles","label":"Peking University Cancer Hospital"},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","field":"links","label":"Peking University Cancer Hospital"},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","field":"profiles","label":"Peking University Cancer Hospital"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","field":"links","label":"Peking University Cancer Hospital"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260913002331/https://www.bjcancer.org/"},{"url":"https://www.bjcancer.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","field":"links","label":"Peking University Cancer Hospital"},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","field":"profiles","label":"Peking University Cancer Hospital"}],"archive":"https://web.archive.org/web/20260913002331/https://www.bjcancer.org/"},{"url":"https://www.bjcancer.org/Html/News/Columns/1/Index.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","field":"links","label":"Institution profile"},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","field":"profiles","label":"Institution profile"},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","field":"links","label":"Institution profile"},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","field":"profiles","label":"Institution profile"}],"archive":"https://web.archive.org/web/20260521013211/https://www.bjcancer.org/Html/News/Columns/1/Index.html"},{"url":"https://www.bjmu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","field":"links","label":"Peking University Health Science Center"}],"archive":"https://web.archive.org/web/20260911043803/https://www.bjmu.edu.cn/"},{"url":"https://www.bovaxbio.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/","field":"links","label":"Official website"},{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/","field":"website"}],"archive":"https://web.archive.org/web/20260923055437/https://www.bovaxbio.com/"},{"url":"https://www.caca.org.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","route":"/institutions/caca/","field":"links","label":"CACA"},{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","route":"/institutions/caca/","field":"website"}],"archive":"https://web.archive.org/web/20260831134656/http://www.caca.org.cn/"},{"url":"https://www.cancerimagingarchive.net","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","field":"links","label":"The Cancer Imaging Archive (TCIA)"},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","field":"url"}],"archiveRequested":false},{"url":"https://www.cancerimagingarchive.net/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"idea-data-open-deidentification-pipeline","kind":"idea","name":"One certified open-source de-identification pipeline for scans and slides","route":"/ideas/idea-data-open-deidentification-pipeline/","field":"links","label":"The Cancer Imaging Archive"},{"id":"radiology-imaging-modality","kind":"term","name":"Radiology imaging as a data modality (CT, MRI, TCIA)","route":"/terms/radiology-imaging-modality/","field":"links","label":"The Cancer Imaging Archive (TCIA)"}],"archive":"https://web.archive.org/web/20260920151637/https://www.cancerimagingarchive.net/"},{"url":"https://www.cancerinstitutewia.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","field":"links","label":"Cancer Institute (WIA)"},{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","field":"profiles","label":"Cancer Institute (WIA)"},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/","field":"links","label":"Cancer Institute (WIA)"},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/","field":"website"}],"archive":"https://web.archive.org/web/20260810034923/https://cancerinstitutewia.in/"},{"url":"https://www.cancerresearch.purdue.edu","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","field":"links","label":"Purdue Institute for Cancer Research"},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","field":"website"}],"archive":"https://web.archive.org/web/20190610184221/http://www.cancerresearch.purdue.edu:80/"},{"url":"https://www.cardinalhealth.com","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","field":"links","label":"Official website"},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","field":"website"}],"archive":"https://web.archive.org/web/20150421113101/http://www.cardinalhealth.com/"},{"url":"https://www.ccc.ukw.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"CCC Mainfranken"},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"website"}],"archive":"https://web.archive.org/web/20150717014740/http://www.ccc.ukw.de:80/"},{"url":"https://www.cccz.ch","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"links","label":"Comprehensive Cancer Center Zurich"}],"archive":"https://web.archive.org/web/20221129071317/http://cccz.ch/"},{"url":"https://www.cdh.gov.zm","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","route":"/institutions/cancer-diseases-hospital-lusaka/","field":"links","label":"Official website"},{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","route":"/institutions/cancer-diseases-hospital-lusaka/","field":"website"}],"archive":"https://web.archive.org/web/20260911213429/https://www.cdh.gov.zm/"},{"url":"https://www.cdh.gov.zm/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","route":"/people/susan-msadabwe/","field":"links","label":"Source: Cancer Diseases Hospital homepage naming the Senior Medical Superintendent"},{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","route":"/people/susan-msadabwe/","field":"profiles","label":"Cancer Diseases Hospital website"}],"archive":"https://web.archive.org/web/20260911213429/https://www.cdh.gov.zm/"},{"url":"https://www.chinancpcn.org.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","field":"links","label":"National Cancer Center"},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","field":"website"}],"archive":"https://web.archive.org/web/20260909231326/http://www.chinancpcn.org.cn/"},{"url":"https://www.chipscreen.com/en/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","field":"links","label":"Chipscreen Biosciences"},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/","field":"links","label":"Official website"},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/","field":"website"}],"archive":"https://web.archive.org/web/20260606071444/https://chipscreen.com/en/"},{"url":"https://www.chulabhornhospital.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","field":"links","label":"Chulabhorn Hospital"},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260718213101/https://www.chulabhornhospital.com/"},{"url":"https://www.cqch.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","route":"/institutions/chongqing-university-cancer-hospital/","field":"links","label":"Official website"},{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","route":"/institutions/chongqing-university-cancer-hospital/","field":"website"}],"archiveRequested":false},{"url":"https://www.cqch.cn/intos_yylds/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"wang-ying","kind":"person","name":"Wang Ying","route":"/people/wang-ying/","field":"links","label":"Source: Chongqing University Cancer Hospital leadership page"},{"id":"wang-ying","kind":"person","name":"Wang Ying","route":"/people/wang-ying/","field":"profiles","label":"Hospital leadership page (Chinese)"}],"archive":"https://web.archive.org/web/20251113093301/https://www.cqch.cn/intos_yylds/"},{"url":"https://www.crob.it","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"crob-rionero","kind":"institution","name":"IRCCS CROB, Centro di Riferimento Oncologico della Basilicata","route":"/institutions/crob-rionero/","field":"links","label":"Official website"},{"id":"crob-rionero","kind":"institution","name":"IRCCS CROB, Centro di Riferimento Oncologico della Basilicata","route":"/institutions/crob-rionero/","field":"website"}],"archive":"https://web.archive.org/web/20260202023307/https://www.crob.it/"},{"url":"https://www.csu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","field":"links","label":"Central South University"}],"archive":"https://web.archive.org/web/20260915023827/https://www.csu.edu.cn/"},{"url":"https://www.ctong.org.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/","field":"links","label":"CTONG"},{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/","field":"website"}],"archiveRequested":false},{"url":"https://www.cytivalifesciences.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/","field":"links","label":"Official website"},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/","field":"website"}],"archive":"https://web.archive.org/web/20240719074518/https://www.cytivalifesciences.com/"},{"url":"https://www.dbcg.dk","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"dbcg","kind":"company","name":"Danish Breast Cancer Group","route":"/companies/dbcg/","field":"website"}],"archive":"https://web.archive.org/web/20260710193825/https://dbcg.dk/"},{"url":"https://www.dbcg.dk/about-dbcg/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"dbcg","kind":"company","name":"Danish Breast Cancer Group","route":"/companies/dbcg/","field":"links","label":"DBCG: About DBCG"}],"archive":"https://web.archive.org/web/20260710204422/https://dbcg.dk/about-dbcg/"},{"url":"https://www.engeneic.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"engeneic","kind":"company","name":"EnGeneIC","route":"/companies/engeneic/","field":"links","label":"Official website"},{"id":"engeneic","kind":"company","name":"EnGeneIC","route":"/companies/engeneic/","field":"website"}],"archive":"https://web.archive.org/web/20260923054023/https://engeneic.com/"},{"url":"https://www.etop-eu.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/","field":"links","label":"ETOP"}],"archive":"https://web.archive.org/web/20240620052803/https://www.etop-eu.org/"},{"url":"https://www.fah-sysu.org.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","field":"links","label":"First Affiliated Hospital of SYSU"},{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","field":"website"}],"archiveRequested":false},{"url":"https://www.frazierlifesciences.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","field":"links","label":"Official website"}],"archive":"https://web.archive.org/web/20260308172259/http://frazierlifesciences.com/"},{"url":"https://www.fudan.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","field":"links","label":"Fudan University"}],"archive":"https://web.archive.org/web/20260912165808/https://fudan.edu.cn/"},{"url":"https://www.futurechem.co.kr","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"links","label":"Official website"},{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"website"}],"archive":"https://web.archive.org/web/20260327024940/https://futurechem.co.kr/"},{"url":"https://www.gesetze-im-internet.de/amg_1976/__4b.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"links","label":"Section 4b AMG"}],"archive":"https://web.archive.org/web/20260509214807/https://www.gesetze-im-internet.de/amg_1976/__4b.html"},{"url":"https://www.gesetze-im-internet.de/amg_1976/__77.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"links","label":"Section 77 AMG"}],"archive":"https://web.archive.org/web/20250821003705/https://www.gesetze-im-internet.de/amg_1976/__77.html"},{"url":"https://www.gesetze-im-internet.de/bkrg/BJNR270700009.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"links","label":"Bundeskrebsregisterdatengesetz"}],"archiveRequested":false},{"url":"https://www.gesetze-im-internet.de/sgb_5/__130b.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"links","label":"Gesetze im Internet: SGB V section 130b, the negotiation and the seventh-month rule (German)"}],"archive":"https://web.archive.org/web/20260911051650/https://www.gesetze-im-internet.de/sgb_5/__130b.html"},{"url":"https://www.gesetze-im-internet.de/sgb_5/__35a.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"links","label":"Gesetze im Internet: SGB V section 35a (German)"}],"archive":"https://web.archive.org/web/20251205041418/https://www.gesetze-im-internet.de/sgb_5/__35a.html"},{"url":"https://www.gesetze-im-internet.de/sgb_5/__64e.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","route":"/institutions/dnpm/","field":"links","label":"Section 64e SGB V"}],"archive":"https://web.archive.org/web/20260101112935/https://www.gesetze-im-internet.de/sgb_5/__64e.html"},{"url":"https://www.gesetze-im-internet.de/sgb_5/__65c.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"links","label":"Section 65c SGB V"}],"archive":"https://web.archive.org/web/20260623003453/https://www.gesetze-im-internet.de/sgb_5/__65c.html"},{"url":"https://www.gi-innovation.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/","field":"links","label":"Official website"},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/","field":"website"}],"archive":"https://web.archive.org/web/20210506162936/http://gi-innovation.com/"},{"url":"https://www.hamad.qa","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","field":"links","label":"Hamad Medical Corporation"},{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","field":"website"}],"archive":"https://web.archive.org/web/20250114025502/https://www.hamad.qa/"},{"url":"https://www.hamad.qa/EN/Hospitals-and-services/NCCCR/Pages/default.aspx","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","field":"links","label":"NCCCR"}],"archive":"https://web.archive.org/web/20260611215730/https://www.hamad.qa/EN/Hospitals-and-services/NCCCR/Pages/default.aspx"},{"url":"https://www.hamad.qa/EN/news/2026/January/Pages/Qatar-Health-Congress-2026-inaugurated-to-Advance-Healthcare-Quality-and-Patient-Safety.aspx","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"mohammed-bin-khalifa-al-suwaidi","kind":"person","name":"Mohammed bin Khalifa Al Suwaidi","route":"/people/mohammed-bin-khalifa-al-suwaidi/","field":"links","label":"Source: HMC press release, Qatar Health Congress 2026 (January 2026)"},{"id":"mohammed-bin-khalifa-al-suwaidi","kind":"person","name":"Mohammed bin Khalifa Al Suwaidi","route":"/people/mohammed-bin-khalifa-al-suwaidi/","field":"profiles","label":"HMC press release naming the Managing Director (January 2026)"}],"archive":"https://web.archive.org/web/20260911213312/https://www.hamad.qa/EN/news/2026/January/Pages/Qatar-Health-Congress-2026-inaugurated-to-Advance-Healthcare-Quality-and-Patient-Safety.aspx"},{"url":"https://www.harbingerhealth.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/","field":"website"}],"archive":"https://web.archive.org/web/20250124041304/http://harbingerhealth.com/"},{"url":"https://www.health.gov.au/our-work/breastscreen-australia-program","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","field":"links","label":"BreastScreen Australia"}],"archive":"https://web.archive.org/web/20260822173657/https://www.health.gov.au/our-work/breastscreen-australia-program"},{"url":"https://www.health.gov.au/our-work/national-bowel-cancer-screening-program","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","field":"links","label":"Australia's national cancer screening programs"},{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","field":"url"}],"archive":"https://web.archive.org/web/20260608153712/https://www.health.gov.au/our-work/national-bowel-cancer-screening-program"},{"url":"https://www.health.gov.au/our-work/national-cervical-screening-program","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","field":"links","label":"National Cervical Screening Program"}],"archive":"https://web.archive.org/web/20260610005117/https://www.health.gov.au/our-work/national-cervical-screening-program"},{"url":"https://www.hookipapharma.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","route":"/companies/hookipa-pharma/","field":"links","label":"Official website"},{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","route":"/companies/hookipa-pharma/","field":"website"}],"archive":"https://web.archive.org/web/20260314055734/https://www.hookipapharma.com/"},{"url":"https://www.hutch-med.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/","field":"links","label":"Hutchmed"},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/","field":"profiles","label":"Hutchmed"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","field":"links","label":"Hutchmed: Orpathys"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/","field":"links","label":"Official website"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/","field":"website"}],"archive":"https://web.archive.org/web/20260907142654/https://www.hutch-med.com/"},{"url":"https://www.ialch.co.za","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","route":"/institutions/inkosi-albert-luthuli-hospital/","field":"links","label":"Official website"},{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","route":"/institutions/inkosi-albert-luthuli-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20250919135652/https://www.ialch.co.za/"},{"url":"https://www.icmr.gov.in","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","field":"links","label":"ICMR"},{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","field":"website"},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","route":"/institutions/icmr-nicpr/","field":"links","label":"ICMR institutes"},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","route":"/institutions/icmr-nicpr/","field":"website"}],"archive":"https://web.archive.org/web/20260921125225/https://www.icmr.gov.in/"},{"url":"https://www.incan.salud.gob.mx","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","field":"links","label":"INCan"},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","field":"website"}],"archive":"https://web.archive.org/web/20260902002748/http://www.incan.salud.gob.mx/"},{"url":"https://www.incancer.cl","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","field":"links","label":"Official website"},{"id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","field":"website"}],"archive":"https://web.archive.org/web/20250825181617/http://www.incancer.cl/"},{"url":"https://www.institut-strauss.fr/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"links","label":"Institut Strauss website"},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"profiles","label":"Institut Strauss website"},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","field":"links","label":"Official website"},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","field":"website"}],"archive":"https://web.archive.org/web/20260513153935/https://www.institut-strauss.fr/"},{"url":"https://www.ipolisboa.min-saude.pt","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","field":"links","label":"Homepage"},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","field":"website"}],"archive":"https://web.archive.org/web/20260831024906/https://www.ipolisboa.min-saude.pt/"},{"url":"https://www.ipolisboa.min-saude.pt/ipo/governacao/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","route":"/people/carla-goncalo/","field":"profiles","label":"Institution governance page"}],"archive":"https://web.archive.org/web/20241130104001/https://www.ipolisboa.min-saude.pt/ipo/governacao/"},{"url":"https://www.ipolisboa.min-saude.pt/noticias/ipo-lisboa-tem-nova-administracao/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","route":"/people/carla-goncalo/","field":"links","label":"Source: IPO Lisboa news, new administration"},{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","route":"/people/carla-goncalo/","field":"profiles","label":"Institution news: new board announced"}],"archive":"https://web.archive.org/web/20250401020517/https://www.ipolisboa.min-saude.pt/noticias/ipo-lisboa-tem-nova-administracao/"},{"url":"https://www.isotopia.co.il","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","field":"links","label":"Official website"},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","field":"website"}],"archive":"https://web.archive.org/web/20260514223723/https://www.isotopia.co.il/"},{"url":"https://www.istitutotumori.mi.it","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","field":"links","label":"Official website"},{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","field":"website"},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"links","label":"Fondazione IRCCS Istituto Nazionale dei Tumori website"},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"profiles","label":"Fondazione IRCCS Istituto Nazionale dei Tumori website"}],"archive":"https://web.archive.org/web/20260910092514/https://www.istitutotumori.mi.it/"},{"url":"https://www.jlszlyy.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","field":"links","label":"Jilin Cancer Hospital"},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","field":"profiles","label":"Jilin Cancer Hospital"},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/","field":"links","label":"Official website"},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260811000454/https://www.jlszlyy.com/"},{"url":"https://www.jszlyy.com.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","route":"/institutions/jiangsu-cancer-hospital/","field":"links","label":"Official website"},{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","route":"/institutions/jiangsu-cancer-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260510173435/https://www.jszlyy.com.cn/"},{"url":"https://www.juventas.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","field":"links","label":"Juventas Cell Therapy"}],"archive":"https://web.archive.org/web/20260603192916/http://www.juventas.cn/"},{"url":"https://www.juventascell.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/","field":"links","label":"Official website"},{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/","field":"website"}],"archiveRequested":false},{"url":"https://www.kanser.hacettepe.edu.tr","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","field":"links","label":"Homepage"},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","field":"website"}],"archive":"https://web.archive.org/web/20240817042033/https://kanser.hacettepe.edu.tr/"},{"url":"https://www.kznhealth.gov.za/provincial-hospitals/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","route":"/people/lp-mtshali/","field":"links","label":"Source: KwaZulu-Natal Department of Health provincial hospitals listing"}],"archive":"https://web.archive.org/web/20260911213345/https://www.kznhealth.gov.za/provincial-hospitals/"},{"url":"https://www.lafe.san.gva.es","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"links","label":"Homepage"},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"website"}],"archive":"https://web.archive.org/web/20251014130117/https://lafe.san.gva.es/"},{"url":"https://www.lung-map.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/","field":"links","label":"Lung-MAP"}],"archive":"https://web.archive.org/web/20260825053502/https://lung-map.org/"},{"url":"https://www.med.hku.hk","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","field":"links","label":"HKU Li Ka Shing Faculty of Medicine"}],"archive":"https://web.archive.org/web/20241008095506/http://www.med.hku.hk/"},{"url":"https://www.med.hku.hk/en/about-hkumed/leadership","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"links","label":"Source: HKUMed leadership page"}],"archive":"https://web.archive.org/web/20260826030958/https://www.med.hku.hk/en/about-hkumed/leadership"},{"url":"https://www.med.hku.hk/en/about-hkumed/leadership/professor-lau-chak-sing","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"profiles","label":"HKUMed Dean's Corner"}],"archive":"https://web.archive.org/web/20260826031028/https://www.med.hku.hk/en/about-hkumed/leadership/professor-lau-chak-sing"},{"url":"https://www.medpacto.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"medpacto","kind":"company","name":"MedPacto","route":"/companies/medpacto/","field":"links","label":"Official website"},{"id":"medpacto","kind":"company","name":"MedPacto","route":"/companies/medpacto/","field":"website"}],"archive":"https://web.archive.org/web/20260411143155/http://medpacto.com/"},{"url":"https://www.merckgroup.com","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/","field":"website"}],"archive":"https://web.archive.org/web/20070827000546/http://www.merckgroup.com:80/"},{"url":"https://www.miracogen.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/","field":"links","label":"Official website"},{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/","field":"website"}],"archive":"https://web.archive.org/web/20260515142001/http://www.miracogen.com/"},{"url":"https://www.molecularneuropathology.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sarcoma-methylation-classifier","kind":"technology","name":"Methylation classifier for sarcomas","route":"/technologies/sarcoma-methylation-classifier/","field":"links","label":"Molecular Neuropathology classifier (Heidelberg), including the sarcoma classifier"}],"archiveRequested":false},{"url":"https://www.mri.tum.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"martin-siess","kind":"person","name":"Martin Siess","route":"/people/martin-siess/","field":"links","label":"Institution profile"},{"id":"martin-siess","kind":"person","name":"Martin Siess","route":"/people/martin-siess/","field":"profiles","label":"Institution profile"},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"Homepage"},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"website"}],"archive":"https://web.archive.org/web/20250312143951/https://www.mri.tum.de/"},{"url":"https://www.mycancergenome.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","field":"links","label":"My Cancer Genome"}],"archive":"https://web.archive.org/web/20260222035126/https://www.mycancergenome.org/"},{"url":"https://www.nasdaq.com/articles/gritstone-bio-files-bankruptcy-and-auctions-assets","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","field":"links","label":"Bankruptcy and asset sale"}],"archive":"https://web.archive.org/web/20260911211816/https://www.nasdaq.com/articles/gritstone-bio-files-bankruptcy-and-auctions-assets"},{"url":"https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/","field":"links","label":"Genmab acquisition announcement (Nasdaq copy)"}],"archive":"https://web.archive.org/web/20260923053640/https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio"},{"url":"https://www.navidea.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"website"}],"archive":"https://web.archive.org/web/20260614203428/https://www.navidea.com/"},{"url":"https://www.navignostics.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"navignostics","kind":"company","name":"Navignostics","route":"/companies/navignostics/","field":"links","label":"Official website"},{"id":"navignostics","kind":"company","name":"Navignostics","route":"/companies/navignostics/","field":"website"}],"archiveRequested":false},{"url":"https://www.nct-suedwest.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","field":"links","label":"NCT SouthWest"}],"archiveRequested":false},{"url":"https://www.nct-wera.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"NCT WERA"}],"archiveRequested":false},{"url":"https://www.nct-west.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"NCT West"}],"archiveRequested":false},{"url":"https://www.nhpco.org/hospice-care-overview/hospice-facts-figures/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","field":"links","label":"NHPCO Facts and Figures"}],"archive":"https://web.archive.org/web/20250502142251/https://www.nhpco.org/hospice-care-overview/hospice-facts-figures"},{"url":"https://www.nmpa.gov.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","field":"links","label":"NMPA"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","field":"links","label":"NMPA (National Medical Products Administration)"},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","field":"links","label":"NMPA (National Medical Products Administration)"}],"archive":"https://web.archive.org/web/20260304224604/https://www.nmpa.gov.cn/"},{"url":"https://www.oncoresponse.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"oncoresponse","kind":"company","name":"OncoResponse","route":"/companies/oncoresponse/","field":"links","label":"Official website"},{"id":"oncoresponse","kind":"company","name":"OncoResponse","route":"/companies/oncoresponse/","field":"website"}],"archive":"https://web.archive.org/web/20260612145102/https://oncoresponse.com/"},{"url":"https://www.orci.or.tz","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","field":"links","label":"Ocean Road Cancer Institute"},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","field":"website"}],"archive":"https://web.archive.org/web/20260616151750/https://www.orci.or.tz/"},{"url":"https://www.panbela.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/","field":"links","label":"Official website"},{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260521201509/http://www.panbela.com/"},{"url":"https://www.phanestherapeutics.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/","field":"links","label":"Official website"},{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/","field":"website"}],"archiveRequested":false},{"url":"https://www.pkuph.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","field":"links","label":"Peking University People's Hospital"},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","field":"profiles","label":"Peking University People's Hospital"},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","field":"links","label":"Official website"},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260309002003/https://www.pkuph.cn/"},{"url":"https://www.protominternational.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"protom","kind":"company","name":"ProTom International","route":"/companies/protom/","field":"links","label":"Official website"},{"id":"protom","kind":"company","name":"ProTom International","route":"/companies/protom/","field":"website"}],"archiveRequested":false},{"url":"https://www.rarecancerseurope.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","field":"links","label":"Rare Cancers Europe"}],"archive":"https://web.archive.org/web/20230606132556/https://www.rarecancerseurope.org/"},{"url":"https://www.rarecarenet.eu/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","field":"links","label":"RARECARE / RARECAREnet"}],"archive":"https://web.archive.org/web/20241013000711/https://www.rarecarenet.eu/"},{"url":"https://www.recamo.cz","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","field":"links","label":"RECAMO"}],"archive":"https://web.archive.org/web/20260610235628/http://www.recamo.cz/"},{"url":"https://www.reger-medizintechnik.de/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","route":"/companies/capnomed/","field":"links","label":"Reger Medizintechnik"},{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","route":"/companies/capnomed/","field":"website"}],"archiveRequested":false},{"url":"https://www.reparerx.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","field":"links","label":"Official website"},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260212221539/https://www.reparerx.com/"},{"url":"https://www.rjh.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","field":"links","label":"Ruijin Hospital"},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20220831011307/http://www.rjh.com.cn/"},{"url":"https://www.rjh.com.cn/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","field":"links","label":"Ruijin Hospital"},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","field":"profiles","label":"Ruijin Hospital"},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","field":"links","label":"Ruijin Hospital"},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","field":"profiles","label":"Ruijin Hospital"}],"archive":"https://web.archive.org/web/20220831011307/http://www.rjh.com.cn/"},{"url":"https://www.samsarabiocapital.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","field":"links","label":"Official website"},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","field":"website"}],"archive":"https://web.archive.org/web/20260521052626/https://samsarabiocapital.com/"},{"url":"https://www.samsungbioepis.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"samsung-bioepis","kind":"company","name":"Samsung Bioepis","route":"/companies/samsung-bioepis/","field":"links","label":"Official website"},{"id":"samsung-bioepis","kind":"company","name":"Samsung Bioepis","route":"/companies/samsung-bioepis/","field":"website"}],"archive":"https://web.archive.org/web/20251115091707/https://www.samsungbioepis.com/"},{"url":"https://www.saskcancer.ca","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"saskatchewan-cancer-agency","kind":"institution","name":"Saskatchewan Cancer Agency","route":"/institutions/saskatchewan-cancer-agency/","field":"links","label":"Official website"},{"id":"saskatchewan-cancer-agency","kind":"institution","name":"Saskatchewan Cancer Agency","route":"/institutions/saskatchewan-cancer-agency/","field":"website"}],"archive":"https://web.archive.org/web/20260613212255/https://saskcancer.ca/"},{"url":"https://www.saskcancer.ca/about-us/who-we-are/executive-leadership-team","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"deb-bulych","kind":"person","name":"Deb Bulych","route":"/people/deb-bulych/","field":"links","label":"Source: Saskatchewan Cancer Agency executive leadership team page"},{"id":"deb-bulych","kind":"person","name":"Deb Bulych","route":"/people/deb-bulych/","field":"profiles","label":"Saskatchewan Cancer Agency executive leadership team"}],"archive":"https://web.archive.org/web/20260911213235/https://saskcancer.ca/about-us/who-we-are/executive-leadership-team"},{"url":"https://www.sdfmu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"links","label":"Shandong First Medical University"}],"archive":"https://web.archive.org/web/20260911225317/https://www.sdfmu.edu.cn/"},{"url":"https://www.sdzlyy.org.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"links","label":"Shandong Cancer Hospital"},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"website"}],"archiveRequested":false},{"url":"https://www.shsmu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","field":"links","label":"Shanghai Jiao Tong University School of Medicine"},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","field":"links","label":"Shanghai Jiao Tong University School of Medicine"}],"archive":"https://web.archive.org/web/20260815230921/https://www.shsmu.edu.cn/"},{"url":"https://www.shxkyy.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","field":"links","label":"Shanghai Chest Hospital"},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","field":"profiles","label":"Shanghai Chest Hospital"},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","field":"links","label":"Shanghai Chest Hospital"},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20210515230206/https://www.shxkyy.com/"},{"url":"https://www.sinobiopharm.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","field":"website"}],"archive":"https://web.archive.org/web/20260226112936/https://www.sinobiopharm.com/"},{"url":"https://www.spectrumpharm.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260107160619/http://www.spectrumpharm.com/"},{"url":"https://www.sphchina.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","route":"/companies/shanghai-pharmaceuticals/","field":"links","label":"Official website"},{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","route":"/companies/shanghai-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20180531002812/http://www.sphchina.com:80/"},{"url":"https://www.stcube.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"stcube","kind":"company","name":"STCube","route":"/companies/stcube/","field":"links","label":"Official website"},{"id":"stcube","kind":"company","name":"STCube","route":"/companies/stcube/","field":"website"}],"archive":"https://web.archive.org/web/20251118075624/https://www.stcube.com/"},{"url":"https://www.surgimab.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"surgimab","kind":"company","name":"Surgimab","route":"/companies/surgimab/","field":"links","label":"Official website"},{"id":"surgimab","kind":"company","name":"Surgimab","route":"/companies/surgimab/","field":"website"}],"archive":"https://web.archive.org/web/20260418094039/https://www.surgimab.com/"},{"url":"https://www.sysu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","field":"links","label":"Sun Yat-sen University"}],"archive":"https://web.archive.org/web/20260910082811/https://www.sysu.edu.cn/"},{"url":"https://www.tays.fi","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","route":"/institutions/tays-cancer-centre/","field":"links","label":"Official website"},{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","route":"/institutions/tays-cancer-centre/","field":"website"}],"archive":"https://web.archive.org/web/20150503043644/http://www.tays.fi:80/"},{"url":"https://www.tga.gov.au","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-09-30","refs":[{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/","field":"links","label":"TGA"},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/","field":"website"}],"archive":"https://web.archive.org/web/20260910081103/https://www.tga.gov.au/"},{"url":"https://www.tjh.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","field":"links","label":"Tongji Hospital"},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","field":"website"}],"archive":"https://web.archive.org/web/20260904195852/https://www.tjh.com.cn/"},{"url":"https://www.tjh.com.cn/CurrentLeader/51393.html","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","field":"links","label":"Source: Tongji Hospital current leadership page for the President"},{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","field":"profiles","label":"Tongji Hospital current leadership page (Chinese)"}],"archive":"https://web.archive.org/web/20240918233323/https://www.tjh.com.cn/CurrentLeader/51393.html"},{"url":"https://www.tjmu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","field":"links","label":"Tongji Medical College, HUST"},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","field":"links","label":"Tongji Medical College, HUST"}],"archive":"https://web.archive.org/web/20260831081945/http://www.tjmu.edu.cn/"},{"url":"https://www.tjmuch.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","field":"links","label":"TMUCIH"},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","field":"website"}],"archive":"https://web.archive.org/web/20260919070644/http://www.tjmuch.com/"},{"url":"https://www.tmu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","field":"links","label":"Tianjin Medical University"}],"archive":"https://web.archive.org/web/20260831025714/https://www.tmu.edu.cn/"},{"url":"https://www.tongji.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","field":"links","label":"Tongji University"}],"archiveRequested":false},{"url":"https://www.transtherabio.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"transthera","kind":"company","name":"TransThera Sciences","route":"/companies/transthera/","field":"links","label":"Official website"},{"id":"transthera","kind":"company","name":"TransThera Sciences","route":"/companies/transthera/","field":"website"}],"archive":"https://web.archive.org/web/20211206093852/http://transtherabio.com/"},{"url":"https://www.uhcancercenter.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","field":"links","label":"University of Hawai'i Cancer Center"},{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","field":"website"}],"archive":"https://web.archive.org/web/20260905042942/https://www.uhcancercenter.org/"},{"url":"https://www.uhcancercenter.org/about-us/leadership","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","field":"links","label":"Source: University of Hawai'i Cancer Center leadership page"},{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","field":"profiles","label":"UH Cancer Center leadership page"}],"archive":"https://web.archive.org/web/20260505162954/https://uhcancercenter.org/about-us/leadership"},{"url":"https://www.uhcancercenter.org/clinical-trials","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","field":"links","label":"Clinical trials"}],"archive":"https://web.archive.org/web/20260923053008/https://www.uhcancercenter.org/clinical-trials"},{"url":"https://www.uhcancercenter.org/ueno-naoto","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","field":"profiles","label":"UH Cancer Center profile"}],"archive":"https://web.archive.org/web/20260715040338/https://www.uhcancercenter.org/ueno-naoto"},{"url":"https://www.uhnresearch.ca/researcher/aaron-d-schimmer","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","field":"links","label":"UHN profile"},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260307185653/http://www.uhnresearch.ca/researcher/aaron-d-schimmer"},{"url":"https://www.uhnresearch.ca/researcher/amit-m-oza","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"links","label":"UHN profile"},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260216090353/https://www.uhnresearch.ca/researcher/amit-m-oza"},{"url":"https://www.uhnresearch.ca/researcher/john-e-dick","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"links","label":"Dick lab"},{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"profiles","label":"Dick lab"}],"archive":"https://web.archive.org/web/20260412102754/https://www.uhnresearch.ca/researcher/john-e-dick"},{"url":"https://www.uhnresearch.ca/researcher/lillian-l-siu","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"links","label":"UHN profile"},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260316204515/https://www.uhnresearch.ca/researcher/lillian-l-siu"},{"url":"https://www.uhnresearch.ca/researcher/natasha-b-leighl","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","field":"links","label":"UHN profile"},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","field":"profiles","label":"UHN profile"}],"archiveRequested":false},{"url":"https://www.uhnresearch.ca/researcher/pamela-s-ohashi","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","field":"links","label":"UHN profile"},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260412094439/https://www.uhnresearch.ca/researcher/pamela-s-ohashi"},{"url":"https://www.uhnresearch.ca/researcher/tak-w-mak","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","field":"links","label":"UHN profile"},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260307173601/http://www.uhnresearch.ca/researcher/tak-w-mak"},{"url":"https://www.uhnresearch.ca/researcher/trevor-j-pugh","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","field":"links","label":"UHN profile"},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","field":"profiles","label":"UHN profile"}],"archive":"https://web.archive.org/web/20260923051916/https://www.uhnresearch.ca/researcher/trevor-j-pugh"},{"url":"https://www.uonbi.ac.ke","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","field":"links","label":"University of Nairobi"}],"archive":"https://web.archive.org/web/20260902132404/https://uonbi.ac.ke/"},{"url":"https://www.vasgene.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","field":"links","label":"Official website"},{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260514014002/http://vasgene.com/"},{"url":"https://www.viccompcancerctr.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","field":"links","label":"Victorian Comprehensive Cancer Centre"}],"archive":"https://web.archive.org/web/20210926011604/https://www.viccompcancerctr.org/"},{"url":"https://www.wjog.jp","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"wjog","kind":"company","name":"West Japan Oncology Group","route":"/companies/wjog/","field":"links","label":"WJOG"},{"id":"wjog","kind":"company","name":"West Japan Oncology Group","route":"/companies/wjog/","field":"website"}],"archiveRequested":false},{"url":"https://www.wjog.jp/en/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","field":"links","label":"Society page"},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","field":"profiles","label":"Society page"}],"archive":"https://web.archive.org/web/20260613031637/https://www.wjog.jp/en/"},{"url":"https://www.x-zell.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/","field":"links","label":"Official website"},{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/","field":"website"}],"archive":"https://web.archive.org/web/20260613191158/https://www.x-zell.com/"},{"url":"https://www.xynomicpharma.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/","field":"links","label":"Official website"},{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/","field":"website"}],"archiveRequested":false},{"url":"https://www.yingli-pharma.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","route":"/companies/shanghai-yingli/","field":"links","label":"Official website"},{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","route":"/companies/shanghai-yingli/","field":"website"}],"archiveRequested":false},{"url":"https://www.zchospital.com/cn/survey","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","field":"profiles","label":"Zhejiang Cancer Hospital overview and leadership (Chinese)"}],"archive":"https://web.archive.org/web/20260422134059/https://www.zchospital.com/cn/survey"},{"url":"https://www.zjcc.org.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","field":"links","label":"Zhejiang Cancer Hospital"},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260124051120/http://mailto:Fengjf@zjcc.org.cn/"},{"url":"https://www.zzu.edu.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-09-30","refs":[{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","field":"links","label":"Zhengzhou University"}],"archive":"https://web.archive.org/web/20260923054455/https://www.zzu.edu.cn/"},{"url":"https://doi.org/10.2471/BLT.23.289714","status":200,"ok":false,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10452934/pdf/BLT.23.289714.pdf","contentType":"text/html; charset=utf-8","softPdf404":true,"domainMoved":true,"checked":"2026-09-30","refs":[{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"links","label":"Pooled procurement initiative (Bull WHO 2023)"},{"id":"paper-pramesh-ncg-pooled-procurement-2023","kind":"paper","name":"A National Cancer Grid pooled procurement initiative, India","route":"/key-papers/paper-pramesh-ncg-pooled-procurement-2023/","field":"links","label":"Bull WHO 2023"}],"archiveRequested":false},{"url":"https://doi.org/10.2471/blt.24.292230","status":200,"ok":false,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12057217/pdf/BWHO-103-5-BLT.24.292230.pdf","contentType":"text/html; charset=utf-8","softPdf404":true,"domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pramesh-bull-world-health-organ","kind":"paper","name":"National Cancer Grid initiative for electronic medical records, India","route":"/key-papers/paper-pramesh-bull-world-health-organ/","field":"links","label":"Bull World Health Organ 2025"}],"archiveRequested":false},{"url":"https://doi.org/10.2471/BLT.24.292230","status":200,"ok":false,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12057217/pdf/BWHO-103-5-BLT.24.292230.pdf","contentType":"text/html; charset=utf-8","softPdf404":true,"domainMoved":true,"checked":"2026-09-30","refs":[{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"links","label":"EMR initiative (Bull WHO 2025)"}],"archiveRequested":false},{"url":"https://gettingitrightfirsttime.co.uk/wp-content/uploads/2021/09/DermatologyReport-Sept21o.pdf","status":202,"ok":false,"contentType":"text/html","softPdf404":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"GIRFT dermatology national specialty report"}],"archive":"https://web.archive.org/web/20260721181642/https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/09/DermatologyReport-Sept21o.pdf"},{"url":"https://doi.org/10.7314/apjcp.2014.15.2.1011","status":400,"ok":false,"finalUrl":"https://koreascience.or.kr/article/JAKO201417638007745.page","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"papers","label":"Increasing frequency of soft tissue sarcomas in Vojvodina - comparison with the literature"}]},{"url":"https://www.bfarm.de","status":400,"ok":false,"finalUrl":"https://www.bfarm.de/error_path/400.html?al_req_id=aryfEb_iyumkZGensyla9QAAAAE","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"links","label":"BfArM"},{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"website"}]},{"url":"https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Genehmigungsverfahren/_node.html","status":400,"ok":false,"finalUrl":"https://www.bfarm.de/error_path/400.html?al_req_id=aryfFk6xJDVdoP6GQhWKawAAF0c","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"links","label":"Clinical trial authorisation"}]},{"url":"https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Modellvorhaben-Genomsequenzierung/_node.html","status":400,"ok":false,"finalUrl":"https://www.bfarm.de/error_path/400.html?al_req_id=aryfEvI2vXDwqIVOmr3AYAAAGek","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"links","label":"Modellvorhaben Genomsequenzierung"}]},{"url":"https://www.bfarm.de/EN/BfArM/Tasks/_node.html","status":400,"ok":false,"finalUrl":"https://www.bfarm.de/error_path/400.html?al_req_id=aryfFpRooIbUA29fbSacywAAATw","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","field":"links","label":"Tasks"}]},{"url":"https://www.ed.ac.uk/cancer-centre","status":400,"ok":false,"finalUrl":"https://idp.ed.ac.uk/idp/profile/SAML2/Redirect/SSO?SAMLRequest=rVLBTsMwDP2VKvc2XUuHGm2TBhyYNMS0Dg5ckJd4W0SblthBfD5dB2Jw4MTJek7e8%2FOTJwRN3al54INb42tA4ui9qR2p4WEqgneqBbKkHDRIirWq5ndLlSWp6nzLrW5rcUb5mwFE6Nm2TkSLm6l4vtS60Bcw0jkUhS5G22xbXmTlaItlYcbZLhtDnkNpUhDRI3rqmVPRC%2FV0ooALRwyO%2B1aajeO0jPN0kxYqT9UofRLRTb%2BNdcAD68DckZLSmi5Bk4BOwssRyH6Lna1RHk1mco3GetQsq%2BpeRPMvv9eto9Cgr9C%2FWY0P6%2BWZYu%2FCcmCM9%2BiQraZYg9Pov%2BeQbboaj%2FnIpjWhxqQ7dHLAdKpZDJqGrsEdhJpj6kS0%2Bkz4yjpj3f7vcLenT6RuN5tVvLqvNmI2OWqrISw%2F%2BzfDDTIYYPjldyLPp53Qz9uafQA%3D&RelayState=https%3A%2F%2Finstitute-genetics-cancer.ed.ac.uk%2Fsaml_login%3Fdestination%3D%252Fresearch%252Ffunded-centres%252Fedinburgh-cancer-research","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","field":"links","label":"Edinburgh Cancer Research Centre"},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","field":"website"}]},{"url":"https://www.isrctn.com/ISRCTN3826061","status":400,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","field":"links","label":"ISRCTN3826061"}]},{"url":"https://www.krebsdaten.de","status":400,"ok":false,"finalUrl":"https://www.krebsdaten.de/error_path/400.html?al_req_id=aryfF_t2A8V1YEugbY1hzwAABbI","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"links","label":"Zentrum für Krebsregisterdaten"},{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"website"}]},{"url":"https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2025.pdf?__blob=publicationFile","status":400,"ok":false,"finalUrl":"https://www.krebsdaten.de/error_path/400.html?al_req_id=aryfGSPe-pQXQmMAGpdT6QAADlM","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"links","label":"Krebs in Deutschland 2025 (PDF)"}]},{"url":"https://www.krebsdaten.de/Krebs/DE/Content/ZfKD/Aufgaben/aufgaben_node.html","status":400,"ok":false,"finalUrl":"https://www.krebsdaten.de/error_path/400.html?al_req_id=aryfGb8IAuZ2bhyiPDD8HwAABfg","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","field":"links","label":"Tasks"}]},{"url":"https://www.pei.de","status":400,"ok":false,"finalUrl":"https://www.pei.de/error_path/400.html?al_req_id=aryfE0CGDDARX2hLOwcDlgAAAIU","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"links","label":"Paul-Ehrlich-Institut"},{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"website"}]},{"url":"https://www.pei.de/DE/arzneimittel/atmp/gentherapeutika/gentherapeutika-node.html","status":400,"ok":false,"finalUrl":"https://www.pei.de/error_path/400.html?al_req_id=aryfFkCGDDARX2hLOwcDqAAAAIo","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"links","label":"Gene therapy medicinal products authorised in Germany"}]},{"url":"https://www.pei.de/DE/regulation/genehmigungen/atmp-4b-amg/atmp-4b-amg-node.html","status":400,"ok":false,"finalUrl":"https://www.pei.de/error_path/400.html?al_req_id=aryfFkCGDDARX2hLOwcDqwAAAIU","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"links","label":"Permissions under section 4b(3) AMG"}]},{"url":"https://www.pei.de/EN/institute/institute-node.html","status":400,"ok":false,"finalUrl":"https://www.pei.de/error_path/400.html?al_req_id=aryfFeQMKTbehagsfkVZKgAAAj4","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","field":"links","label":"The institute"}]},{"url":"https://www.uci.or.ug","status":400,"ok":false,"finalUrl":"https://www.uci.or.ug/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","field":"links","label":"Uganda Cancer Institute"},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","field":"website"}]},{"url":"https://www.oncologico.bari.it","status":401,"ok":false,"finalUrl":"https://www.oncologico.bari.it/web/irccs","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"istituto-tumori-bari","kind":"institution","name":"IRCCS Istituto Tumori Giovanni Paolo II","route":"/institutions/istituto-tumori-bari/","field":"links","label":"Official website"},{"id":"istituto-tumori-bari","kind":"institution","name":"IRCCS Istituto Tumori Giovanni Paolo II","route":"/institutions/istituto-tumori-bari/","field":"website"}]},{"url":"http://www.diffusionpharma.com","status":403,"ok":false,"finalUrl":"http://www.diffusionpharma.com/","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","field":"links","label":"Official website"},{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","field":"website"}]},{"url":"http://www.insysrx.com","status":403,"ok":false,"finalUrl":"http://www.insysrx.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","field":"links","label":"Official website"},{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","field":"website"}]},{"url":"http://www.medigene.com","status":403,"ok":false,"finalUrl":"http://www.medigene.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","field":"links","label":"Official website"},{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","field":"website"}]},{"url":"http://www.rijnstate.nl/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","field":"links","label":"Rijnstate website"},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","field":"profiles","label":"Rijnstate website"}]},{"url":"http://www.thresholdpharm.com","status":403,"ok":false,"finalUrl":"https://www.thresholdpharm.com/","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","field":"links","label":"Official website"},{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","field":"website"}]},{"url":"http://www.vionpharm.com","status":403,"ok":false,"finalUrl":"http://www.vionpharm.com/","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","field":"links","label":"Official website"},{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","field":"website"}]},{"url":"https://5amventures.com/portfolio/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://5amventures.com/strategy/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","field":"links","label":"Strategy"}]},{"url":"https://aacrjournals.org","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","field":"links","label":"AACR Journals"},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","field":"links","label":"AACR Journals"},{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","field":"links","label":"AACR Journals"},{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","route":"/journals/molecular-cancer-therapeutics/","field":"links","label":"AACR Journals"},{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","field":"links","label":"AACR Journals"}]},{"url":"https://aacrjournals.org/bloodcancerdiscov","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/","field":"links","label":"Homepage"},{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/","field":"url"}]},{"url":"https://aacrjournals.org/cancerdiscovery","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","field":"url"}]},{"url":"https://aacrjournals.org/cancerdiscovery/article/13/5/1117/725648","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adu-s100","kind":"drug","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","field":"links","label":"ADU-S100 phase 1 (Cancer Discov 2023)"}]},{"url":"https://aacrjournals.org/cancerimmunolres","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","field":"url"}]},{"url":"https://aacrjournals.org/cancerpreventionresearch","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/","field":"links","label":"Homepage"},{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/","field":"url"}]},{"url":"https://aacrjournals.org/cancerres","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","field":"url"}]},{"url":"https://aacrjournals.org/cancerrescommun","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","field":"links","label":"Homepage"},{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","field":"url"}]},{"url":"https://aacrjournals.org/cebp","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","field":"url"}]},{"url":"https://aacrjournals.org/clincancerres","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","field":"url"}]},{"url":"https://aacrjournals.org/clincancerres/article/18/2/510/76892/A-Deep-Look-at-the-PARP-Inhibitor-Iniparib","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/","field":"links","label":"Iniparib is not a PARP inhibitor (Clin Cancer Res 2012)"}]},{"url":"https://aacrjournals.org/clincancerres/article/30/15/3100/746597/FDA-Approval-Summary-Fruquintinib-for-the","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","field":"links","label":"FDA approval summary, Clinical Cancer Research"}]},{"url":"https://aacrjournals.org/mcr","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","route":"/journals/molecular-cancer-research/","field":"links","label":"Homepage"},{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","route":"/journals/molecular-cancer-research/","field":"url"}]},{"url":"https://aacrjournals.org/mct","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","route":"/journals/molecular-cancer-therapeutics/","field":"url"}]},{"url":"https://academic.oup.com/carcin","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","route":"/journals/carcinogenesis/","field":"links","label":"Homepage"},{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","route":"/journals/carcinogenesis/","field":"url"}]},{"url":"https://academic.oup.com/jbi","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","route":"/journals/journal-of-breast-imaging/","field":"links","label":"Homepage"},{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","route":"/journals/journal-of-breast-imaging/","field":"url"}]},{"url":"https://academic.oup.com/jjco","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","route":"/journals/japanese-journal-of-clinical-oncology/","field":"links","label":"Homepage"},{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","route":"/journals/japanese-journal-of-clinical-oncology/","field":"url"}]},{"url":"https://academic.oup.com/jnci","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","field":"url"}]},{"url":"https://academic.oup.com/jncics","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","field":"links","label":"JNCI Cancer Spectrum (open access sister)"},{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","field":"links","label":"Homepage"},{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","field":"url"}]},{"url":"https://academic.oup.com/jncimono","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","route":"/journals/jnci-monographs/","field":"links","label":"Homepage"},{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","route":"/journals/jnci-monographs/","field":"url"}]},{"url":"https://academic.oup.com/jrr","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","field":"links","label":"Homepage"},{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","field":"url"}]},{"url":"https://academic.oup.com/nar/article/48/3/e14/5651325","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","route":"/technologies/stride-dna-break-detection/","field":"links","label":"Nucleic Acids Research 2020: STRIDE, a fluorescence method for direct, specific in situ detection of individual single- or double-strand DNA breaks in fixed cells"}]},{"url":"https://academic.oup.com/narcancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","field":"links","label":"Homepage"},{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","field":"url"}]},{"url":"https://academic.oup.com/neuro-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","field":"url"}]},{"url":"https://academic.oup.com/oncolo","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","field":"links","label":"Homepage"},{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","field":"url"}]},{"url":"https://acsjournals.onlinelibrary.wiley.com","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/","field":"links","label":"American Cancer Society journals"}]},{"url":"https://acsjournals.onlinelibrary.wiley.com/journal/10970142","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/","field":"url"}]},{"url":"https://acsjournals.onlinelibrary.wiley.com/journal/15424863","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","field":"links","label":"Cancer Statistics 2026 (CA Cancer J Clin)"},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/","field":"url"}]},{"url":"https://acsjournals.onlinelibrary.wiley.com/journal/19346638","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","route":"/journals/cancer-cytopathology/","field":"links","label":"Homepage"},{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","route":"/journals/cancer-cytopathology/","field":"url"}]},{"url":"https://ascopubs.org","status":403,"ok":false,"finalUrl":"https://ascopubs.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/","field":"links","label":"ASCO Publications"},{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","route":"/journals/jco-oncology-practice/","field":"links","label":"ASCO Publications"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-24-02086","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-00272","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","field":"links","label":"JCO 2025"},{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-00760","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","field":"outcomes.source (Progression-free at 5 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-00925","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"links","label":"5-year JCO 2025"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"outcomes.source (Progression-free survival at 5 years)"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-01328","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","field":"outcomes.source (5-year overall survival rate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-01957","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","field":"outcomes.source (Progression-free survival (dual primary))"},{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","field":"outcomes.source (Overall response rate (dual primary))"},{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","field":"outcomes.source (Complete response rate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-02027","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","field":"links","label":"Phase 1/1b two-year results, JCO 2025"},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","field":"links","label":"JCO 2025 two-year results"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO-25-02600","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","field":"links","label":"JCO"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.18.01896","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","field":"links","label":"JCO 2019"},{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.19.00066","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/","field":"outcomes.source (7-year disease-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.19.00210","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"links","label":"Toripalimab plus axitinib (JCO 2019)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.19.00261","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"interfant-06","kind":"trial","name":"Interfant-06","route":"/trials/interfant-06/","field":"outcomes.source (Event-free survival at 6 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.19.00799","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","field":"outcomes.source (Radiographic progression-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.19.03054","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","field":"links","label":"JCO 2020"},{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","field":"outcomes.source (Objective response rate (recurrent or metastatic cohort))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.20.02514","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","field":"outcomes.source (Invasive disease-free survival at 2 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.20.03128","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","field":"outcomes.source (HN002: progression-free survival at 2 years (randomised phase II vs 85% historical control))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.20.03614","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","field":"links","label":"10-year outcomes, JCO 2021"},{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","field":"outcomes.source (Overall survival at 10 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2009.25.9899","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/","field":"links","label":"Imatinib in DFSP, pooled EORTC and SWOG trials (JCO 2010)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2011.39.2779","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","field":"links","label":"Esserman et al., Journal of Clinical Oncology 2012: pathologic complete response predicts recurrence-free survival more effectively by cancer subset (I-SPY 1)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2014.55.5730","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","field":"outcomes.source (10-year overall survival (B-31/N9831))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2016.67.9258","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"links","label":"Pooled nivolumab analysis in mucosal melanoma (JCO 2017)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2017.75.6155","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2017.77.6112","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2022.40.17_suppl.LBA1","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","field":"links","label":"ASCO 2022 plenary"},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","field":"outcomes.source (Overall survival, left-sided)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA4619","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","field":"outcomes.source (Overall survival (cohort 1))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","field":"outcomes.source (Progression-free survival (non-tBRCAm ITT))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2500","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3509","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","field":"outcomes.source (Objective response rate (phase 2))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.9500","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","field":"links","label":"Final analysis, ASCO 2024"},{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","field":"outcomes.source (Relapse-free survival at 10 years)"},{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","field":"outcomes.source (Distant metastasis-free survival at 10 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA8002","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","field":"links","label":"ASCO 2024 LBA8002"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","field":"links","label":"Final OS, ASCO 2025"},{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","field":"links","label":"ASCO 2025 LBA1"},{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","field":"outcomes.source (Progression-free survival, ESR1-mutant (BICR))"},{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","field":"outcomes.source (Progression-free survival, ITT)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1008","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","field":"outcomes.source (Progression-free survival (BICR), T-DXd + pertuzumab vs THP)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA3500","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"links","label":"ASCO 2025 LBA3500"},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"outcomes.source (Overall survival (EC + mFOLFOX6))"},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"outcomes.source (Progression-free survival (EC + mFOLFOX6))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.TPS507","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","field":"links","label":"ASCO GI 2025 trial-in-progress"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS5144","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xaluritamig","kind":"drug","name":"Xaluritamig","route":"/drugs/xaluritamig/","field":"links","label":"XALience trial in progress (ASCO 2026)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA3503","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"links","label":"ASCO 2026 LBA3503 (FOLFIRI)"},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"outcomes.source (Progression-free survival (EC + FOLFIRI cohort))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA5","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"JCO abstract LBA5"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.LBA285","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","field":"links","label":"ASCO GI 2026 LBA285"},{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.00174","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","field":"outcomes.source (KEYNOTE-024: overall survival at 5 years, PD-L1 ≥50%)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.00217","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.00714","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"links","label":"JCO 2022"},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"outcomes.source (Complete remission at 18 months)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.01308","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.01440","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"ASCO guideline on immune-related adverse events (2021)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.01604","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.02233","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","field":"outcomes.source (Overall survival (long-term))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.00193","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.00338","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","field":"outcomes.source (Progression-free survival (ESR1-mutant))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.00642","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.00687","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"structured-exercise-survivorship","kind":"technology","name":"Structured exercise programmes after curative treatment","route":"/technologies/structured-exercise-survivorship/","field":"links","label":"ASCO exercise, diet and weight guideline 2022"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.00975","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","field":"outcomes.source (KEYNOTE-189: overall survival, non-squamous)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01002","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01064","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","field":"outcomes.source (12-year disease-free survival (TEXT+SOFT))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01549","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"links","label":"7-year OS, JCO 2023"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"outcomes.source (Overall survival at 7 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01649","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","field":"outcomes.source (Radiographic progression-free survival, BRCA1/2 subgroup)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01651","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"euro-ewing-2012","kind":"trial","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","field":"outcomes.source (Event-free survival at 3 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01725","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01763","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","field":"links","label":"JCO 2023"},{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"links","label":"DREAMseq (JCO 2023)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.22.01792","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.00172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","field":"links","label":"PIVOT IO-001 (J Clin Oncol 2023)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.00810","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","field":"links","label":"Final OS, JCO 2023"},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","field":"outcomes.source (Overall survival (all comers))"},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","field":"outcomes.source (Overall survival (CPS ≥1))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.00933","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"g8-geriatric-screening","kind":"technology","name":"G8 geriatric screening tool","route":"/technologies/g8-geriatric-screening/","field":"links","label":"ASCO guideline update 2023: Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.01000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","field":"outcomes.source (Overall survival (final, 5-year))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.01569","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.02005","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"links","label":"JCO 2024"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"outcomes.source (Objective response rate, endometrial cohort)"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"outcomes.source (Objective response rate, cervical cohort)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.02132","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","field":"links","label":"JCO 2023"},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","field":"outcomes.source (Progression-free survival (dMMR, durvalumab))"},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","field":"outcomes.source (Progression-free survival (pMMR, durvalumab + olaparib))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.02231","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","field":"outcomes.source (8-year invasive disease-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.02355","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"outcomes.source (Distant metastasis-free survival at 36 months (final DMFS analysis))"},{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"outcomes.source (Recurrence-free survival at 36 months)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00340","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00546","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","field":"regulatoryEvents.source (2023-12-13)"},{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00581","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","field":"outcomes.source (Progression-free survival at 5 years (BICR))"},{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","field":"outcomes.source (Intracranial progression at 5 years)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00821","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/","field":"outcomes.source (Objective response rate (BICR))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00826","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","field":"outcomes.source (CR + CRh (KMT2Ar cohort))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.00920","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.01124","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","field":"links","label":"3-year OS, JCO 2024"},{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","field":"outcomes.source (Progression-free survival)"},{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","field":"outcomes.source (Overall survival (3-year))"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.24.01544","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","field":"outcomes.source (Overall survival)"},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","field":"outcomes.source (Progression-free survival, non-squamous)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.25.00361","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ascopubs.org/doi/10.1200/PO-25-00501","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/","field":"links","label":"JCO Precision Oncology 2026"}]},{"url":"https://ascopubs.org/doi/abs/10.1200/JCO.22.01003","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","field":"links","label":"JCO 2022"},{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","field":"outcomes.source (Progression-free survival (ITT))"}]},{"url":"https://ascopubs.org/journal/cci","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","route":"/journals/jco-clinical-cancer-informatics/","field":"links","label":"Homepage"},{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","route":"/journals/jco-clinical-cancer-informatics/","field":"url"}]},{"url":"https://ascopubs.org/journal/edbk","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","route":"/journals/asco-educational-book/","field":"links","label":"Homepage"},{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","route":"/journals/asco-educational-book/","field":"url"}]},{"url":"https://ascopubs.org/journal/go","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","field":"links","label":"Homepage"},{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","field":"url"}]},{"url":"https://ascopubs.org/journal/jco","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"url"}]},{"url":"https://ascopubs.org/journal/op","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","route":"/journals/jco-oncology-practice/","field":"url"}]},{"url":"https://ascopubs.org/journal/po","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/","field":"url"}]},{"url":"https://ascopubs.org/topics/asco-guidelines/breast-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","field":"links","label":"ASCO breast cancer guidelines"},{"id":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","kind":"paper","name":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","route":"/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/","field":"links","label":"ASCO breast cancer guidelines"}]},{"url":"https://ascopubs.org/topics/asco-guidelines/gastrointestinal-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/","field":"links","label":"ASCO gastrointestinal cancer guidelines"}]},{"url":"https://ascpt.onlinelibrary.wiley.com/journal/15326535","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","field":"url"}]},{"url":"https://ashpublications.org/ashclinicalnews/news/8659/Five-Year-Results-of-SEQUOIA-Trial-Show","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"outcomes.source (Progression-free survival at 5 years, del(17p) (arm C))"}]},{"url":"https://ashpublications.org/blood","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","field":"url"}]},{"url":"https://ashpublications.org/blood/article/131/25/2745/36953","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"links","label":"iwCLL guidelines (Blood 2018)"}]},{"url":"https://ashpublications.org/blood/article/139/22/3278/484118","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","field":"outcomes.source (Complete response (fixed-duration cohort))"}]},{"url":"https://ashpublications.org/blood/article/140/12/1345/485817","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"links","label":"ELN 2022 recommendations"},{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","route":"/terms/eln-risk/","field":"links","label":"ELN 2022 (Döhner et al., Blood 2022)"}]},{"url":"https://ashpublications.org/blood/article/141/14/1675/493918","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","field":"outcomes.source (Event-free survival (median))"}]},{"url":"https://ashpublications.org/blood/article/144/18/1924/516941/Venetoclax-obinutuzumab-for-previously-untreated","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://ashpublications.org/blood/article/146/11/1276/536611/Acalabrutinib-obinutuzumab-improves-survival-vs","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","field":"outcomes.source (Progression-free survival (median, 6-year follow-up))"}]},{"url":"https://ashpublications.org/blood/article/146/Supplement%201/5691/550156/CaDAnCe-304-a-phase-3-open-label-randomized-study","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/","field":"links","label":"CaDAnCe-304 design (Blood 2025)"},{"id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","field":"links","label":"Trial design (Blood 2025 abstract)"}]},{"url":"https://ashpublications.org/bloodadvances","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","field":"url"}]},{"url":"https://ccg.ai","status":403,"ok":false,"finalUrl":"https://www.atom.com/name/CCG.ai","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","route":"/companies/cambridge-cancer-genomics/","field":"links","label":"Official website"},{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","route":"/companies/cambridge-cancer-genomics/","field":"website"}]},{"url":"https://costplusdrugs.com/","status":403,"ok":false,"finalUrl":"https://www.costplusdrugs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-transparent-generic-pricing","kind":"idea","name":"Transparent cost-plus pricing for every oral oncology generic","route":"/ideas/idea-cost-transparent-generic-pricing/","field":"links","label":"Mark Cuban Cost Plus Drug Company"}]},{"url":"https://csg.lshtm.ac.uk/research/themes/concord-programme/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-allemani-concord-3-lancet-2018","kind":"paper","name":"Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014","route":"/key-papers/paper-allemani-concord-3-lancet-2018/","field":"links","label":"CONCORD programme"}]},{"url":"https://dailynews.ascopubs.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","field":"links","label":"ASCO Daily News"},{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","field":"url"}]},{"url":"https://dailynews.ascopubs.org/do/updated-checkmate-8hw-results-nivolumab-ipilimumab-shows-sustained-pfs-benefit-msi-h","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","field":"outcomes.source (Progression-free survival, first line)"}]},{"url":"https://digital.nhs.uk/ndrs","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-automatic-outcome-linkage","kind":"idea","name":"Automatic weekly linkage of cancer registries to deaths, prescriptions and imaging","route":"/ideas/idea-data-automatic-outcome-linkage/","field":"links","label":"NHS National Disease Registration Service"}]},{"url":"https://digital.nhs.uk/ndrs/data/data-sets/sact","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"links","label":"NHS Systemic Anti-Cancer Therapy dataset"},{"id":"idea-data-mcode-payment-condition","kind":"idea","name":"No mCODE, no payment: tie oncology reimbursement to a minimal structured record","route":"/ideas/idea-data-mcode-payment-condition/","field":"links","label":"NHS SACT dataset"}]},{"url":"https://doaj.org/toc/0171-5216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/0265-6736","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/0340-7004","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/0449-3060","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1009-3419","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1010-4283","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1073-2748","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1075-122X","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1110-0362","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1198-0052","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1349-7006","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1465-5411","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1470-7330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1471-2407","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1476-4598","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1477-7819","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1513-7368","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1522-8002","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1532-2807","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1532-3080","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1533-0346","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1534-7354","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1538-4047","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1549-490X","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1574-7891","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1581-3207","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1651-226X","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1658-3876","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1724-6008","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1748-717X","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1756-8722","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1756-9966","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/1759-7714","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2005-0380","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2044-5385","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2045-0907","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2045-7634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2095-3941","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2162-402X","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2190-6009","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2210-7177","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2235-0802","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2369-1999","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2468-2942","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2515-5091","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2523-3548","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2573-8348","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2632-8674","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2666-6790","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2687-8941","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","field":"links","label":"DOAJ record"}]},{"url":"https://doaj.org/toc/2767-9764","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","field":"links","label":"DOAJ record"}]},{"url":"https://doi.org/10.1001/2013.jamadermatol.541","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/2013.jamadermatol.541","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-skin-directed-therapy","kind":"term","name":"Skin-directed therapy in mycosis fungoides: creams, light and small radiotherapy fields","route":"/terms/lymphoma-tx-skin-directed-therapy/","field":"links","label":"Lessin et al., mechlorethamine 0.02 per cent gel in mycosis fungoides, JAMA Dermatology 2013"},{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","field":"links","label":"JAMA Dermatology 2013"},{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","field":"outcomes.source (CAILS response rate)"},{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","field":"outcomes.source (Modified SWAT response rate)"},{"id":"paper-study-201-jama-dermatol-2013","kind":"paper","name":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","route":"/key-papers/paper-study-201-jama-dermatol-2013/","field":"links","label":"JAMA Dermatology 2013"},{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","field":"links","label":"Study 201 (JAMA Dermatol 2013)"}]},{"url":"https://doi.org/10.1001/archderm.136.12.1524","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/archderm.136.12.1524","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Marcil and Stern, risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: review and meta-analysis (Arch Dermatol 2000)"},{"id":"second-primary-skin-cancer","kind":"term","name":"The next skin cancer: second primaries after a keratinocyte cancer","route":"/terms/second-primary-skin-cancer/","field":"links","label":"Marcil and Stern, risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: review and meta-analysis (Arch Dermatol 2000)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Marcil and Stern, risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: review and meta-analysis (Arch Dermatol 2000)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Marcil and Stern, risk of developing a subsequent non-melanoma skin cancer in patients with a history of non-melanoma skin cancer: review and meta-analysis (Arch Dermatol 2000)"}]},{"url":"https://doi.org/10.1001/archderm.140.1.17","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/archderm.140.1.17","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"links","label":"One-year results (Archives of Dermatology 2004)"}]},{"url":"https://doi.org/10.1001/archderm.143.7.854","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/archderm.143.7.854","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"links","label":"Criscione and Weinstock 2007, Arch Dermatol: incidence of cutaneous T-cell lymphoma in the United States 1973 to 2002"}]},{"url":"https://doi.org/10.1001/archderm.143.9.1131","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/archderm.143.9.1131","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"links","label":"Five-year follow-up (Archives of Dermatology 2007)"},{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"outcomes.source (Lesion recurrence at 5 years)"},{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"outcomes.source (Sustained lesion complete response at 5 years)"},{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"outcomes.source (Excellent or good cosmetic outcome at 5 years)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (The same choice for a nodular tumour, where it goes worse)"}]},{"url":"https://doi.org/10.1001/archderm.1987.01660270078019","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/archderm.1987.01660270078019","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"surgical-margins-keratinocyte-cancer","kind":"term","name":"The margin in skin cancer surgery","route":"/terms/surgical-margins-keratinocyte-cancer/","field":"links","label":"Surgical margins for basal cell carcinoma (Archives of Dermatology 1987, PubMed 3813602)"}]},{"url":"https://doi.org/10.1001/jama.1950.02910390001001","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.1950.02910390001001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950","kind":"paper","name":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","route":"/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/","field":"links","label":"JAMA 1950"}]},{"url":"https://doi.org/10.1001/jama.1982.03320430047030","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.1982.03320430047030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"concordance-index","kind":"term","name":"C-index (concordance index), Harrell's and Uno's","route":"/terms/concordance-index/","field":"links","label":"Harrell et al., Evaluating the yield of medical tests (JAMA 1982)"}]},{"url":"https://doi.org/10.1001/jama.1983.03340170049027","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.1983.03340170049027","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Diehl, JAMA 1983: gallstone size and the risk of gallbladder cancer"}]},{"url":"https://doi.org/10.1001/jama.2009.1498","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2009.1498","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"papers","label":"Rethinking screening for breast cancer and prostate cancer"}]},{"url":"https://doi.org/10.1001/jama.2009.1568","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2009.1568","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"Gartner et al., prevalence of and factors associated with persistent pain following breast cancer surgery (JAMA 2009)"},{"id":"numbness-after-breast-surgery","kind":"term","name":"Numbness and nerve pain after breast surgery","route":"/terms/numbness-after-breast-surgery/","field":"links","label":"Gartner et al., prevalence of and factors associated with persistent pain following breast cancer surgery (JAMA 2009)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Gartner et al., prevalence of and factors associated with persistent pain following breast cancer surgery (JAMA 2009)"}]},{"url":"https://doi.org/10.1001/jama.2010.1237","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2010.1237","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"papers","label":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers"},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1001/jama.2010.1275","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2010.1275","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/","field":"outcomes.source (Overall survival, pancreatic ductal adenocarcinoma cohort)"},{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/","field":"outcomes.source (Patients with treatment-related serious adverse events)"},{"id":"paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010","kind":"paper","name":"ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection","route":"/key-papers/paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010/","field":"links","label":"JAMA 2010"}]},{"url":"https://doi.org/10.1001/jama.2010.1705","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2010.1705","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-annema-jama","kind":"paper","name":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","route":"/key-papers/paper-annema-jama/","field":"links","label":"JAMA 2010"},{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/","field":"links","label":"Annema et al., Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomised trial (JAMA 2010)"}]},{"url":"https://doi.org/10.1001/jama.2011.1591","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2011.1591","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011","kind":"paper","name":"Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial","route":"/key-papers/paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011/","field":"links","label":"JAMA 2011"}]},{"url":"https://doi.org/10.1001/jama.2012.13088","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2012.13088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-moreira-lynch-syndrome-identification-jama-2012","kind":"paper","name":"Identification of Lynch syndrome among patients with colorectal cancer","route":"/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/","field":"links","label":"Moreira et al., JAMA 2012: identification of Lynch syndrome among 10,206 colorectal cancer probands"}]},{"url":"https://doi.org/10.1001/jama.2012.347","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2012.347","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","field":"papers","label":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour"},{"id":"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012","kind":"paper","name":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","route":"/key-papers/paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012/","field":"links","label":"JAMA 2012"}]},{"url":"https://doi.org/10.1001/jama.2012.385","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2012.385","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"n0147","kind":"trial","name":"Alliance N0147","route":"/trials/n0147/","field":"links","label":"N0147: oxaliplatin, fluorouracil and leucovorin with or without cetuximab in resected stage III colon cancer (JAMA 2012)"},{"id":"n0147","kind":"trial","name":"Alliance N0147","route":"/trials/n0147/","field":"outcomes.source (Disease-free survival at 3 years (KRAS wild-type))"}]},{"url":"https://doi.org/10.1001/jama.2012.5535","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2012.5535","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-palliation-breathlessness-effusion-obstruction","kind":"term","name":"Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain","route":"/terms/lung-palliation-breathlessness-effusion-obstruction/","field":"links","label":"TIME2 (JAMA 2012)"},{"id":"time2","kind":"trial","name":"TIME2","route":"/trials/time2/","field":"links","label":"TIME2 (JAMA 2012)"},{"id":"time2","kind":"trial","name":"TIME2","route":"/trials/time2/","field":"outcomes.source (Mean breathlessness, 0-42 days (100 mm visual analogue scale))"}]},{"url":"https://doi.org/10.1001/jama.2012.7352","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2012.7352","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-neoptolemos-jama","kind":"paper","name":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","route":"/key-papers/paper-neoptolemos-jama/","field":"links","label":"JAMA 2012"},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"links","label":"ESPAC-3 periampullary (JAMA 2012)"},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"standardOfCare.guideline (Adjuvant)"}]},{"url":"https://doi.org/10.1001/jama.2013.278932","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278932","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"targeted-axillary-dissection","kind":"term","name":"Targeted axillary dissection","route":"/terms/targeted-axillary-dissection/","field":"links","label":"ACOSOG Z1071 (JAMA 2013)"},{"id":"acosog-z1071","kind":"trial","name":"ACOSOG Z1071 (Alliance)","route":"/trials/acosog-z1071/","field":"links","label":"ACOSOG Z1071 (JAMA 2013)"},{"id":"acosog-z1071","kind":"trial","name":"ACOSOG Z1071 (Alliance)","route":"/trials/acosog-z1071/","field":"outcomes.source (False-negative rate of sentinel node surgery after chemotherapy (two or more sentinel nodes removed))"},{"id":"acosog-z1071","kind":"trial","name":"ACOSOG Z1071 (Alliance)","route":"/trials/acosog-z1071/","field":"outcomes.source (Pathological complete nodal response)"}]},{"url":"https://doi.org/10.1001/jama.2013.279201","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2013.279201","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/","field":"outcomes.source (Disease-free survival)"},{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013","kind":"paper","name":"CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/","field":"links","label":"JAMA 2013"}]},{"url":"https://doi.org/10.1001/jama.2013.285718","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2013.285718","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-primrose-jama","kind":"paper","name":"Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial","route":"/key-papers/paper-primrose-jama/","field":"links","label":"JAMA 2014"},{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/","field":"links","label":"JAMA 2014: Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer, the FACS randomized clinical trial"}]},{"url":"https://doi.org/10.1001/jama.2014.15704","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2014.15704","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-hepatitis-b-reactivation","kind":"term","name":"Hepatitis B reactivation before rituximab and other anti-CD20 antibodies","route":"/terms/lymphoma-tx-hepatitis-b-reactivation/","field":"links","label":"Huang et al., entecavir against lamivudine for prevention of hepatitis B reactivation during R-CHOP, JAMA 2014 (121 patients)"}]},{"url":"https://doi.org/10.1001/jama.2014.3741","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2014.3741","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/","field":"links","label":"Kris et al., JAMA 2014: multiplexed driver testing in 1,007 lung adenocarcinomas (Lung Cancer Mutation Consortium)"}]},{"url":"https://doi.org/10.1001/jama.2015.4559","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2015.4559","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Nogueira, JAMA 2015: aflatoxin and gallbladder cancer in Chile"}]},{"url":"https://doi.org/10.1001/jama.2016.20939","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2016.20939","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","field":"links","label":"Nangia et al., scalp cooling device and alopecia in women having chemotherapy for breast cancer, SCALP randomised trial (JAMA 2017)"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"SCALP randomised trial (JAMA 2017)"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Nangia et al., scalp cooling device and alopecia in women having chemotherapy for breast cancer, SCALP randomised trial (JAMA 2017)"},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/","field":"links","label":"SCALP randomised trial (JAMA 2017)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Nangia et al., scalp cooling device and alopecia in women having chemotherapy for breast cancer, SCALP randomised trial (JAMA 2017)"},{"id":"paxman","kind":"company","name":"Paxman","route":"/companies/paxman/","field":"links","label":"Paper: SCALP randomised trial (JAMA 2017)"}]},{"url":"https://doi.org/10.1001/jama.2016.21038","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2016.21038","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","field":"links","label":"Rugo et al., scalp cooling and alopecia after chemotherapy for breast cancer, DigniCap cohort (JAMA 2017)"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"DigniCap cohort with concurrent controls (JAMA 2017)"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Rugo et al., scalp cooling and alopecia after chemotherapy for breast cancer, DigniCap cohort (JAMA 2017)"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"papers","label":"Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer"},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/","field":"links","label":"DigniCap prospective cohort with concurrent controls (JAMA 2017)"}]},{"url":"https://doi.org/10.1001/jama.2016.4324","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2016.4324","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016","kind":"paper","name":"LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine","route":"/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016/","field":"links","label":"JAMA 2016"},{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/","field":"outcomes.source (Overall survival from first randomisation, chemoradiotherapy against chemotherapy (second randomisation))"},{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/","field":"outcomes.source (Overall survival, gemcitabine against gemcitabine plus erlotinib (first randomisation))"},{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/","field":"outcomes.source (Local progression)"}]},{"url":"https://doi.org/10.1001/jama.2016.9839","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2016.9839","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Brain metastases: radiosurgery, whole-brain radiotherapy, surgery and drugs)"},{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","field":"papers","label":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases"},{"id":"paper-alliance-n0574-brown-jama-2016","kind":"paper","name":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","route":"/key-papers/paper-alliance-n0574-brown-jama-2016/","field":"links","label":"JAMA 2016"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"links","label":"Brown et al., radiosurgery alone versus radiosurgery with whole-brain radiotherapy for 1 to 3 brain metastases (JAMA 2016)"},{"id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","field":"links","label":"JAMA 2016"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"links","label":"Alliance N0574: radiosurgery with or without whole-brain radiotherapy (JAMA 2016)"}]},{"url":"https://doi.org/10.1001/jama.2017.11470","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.11470","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"links","label":"Z0011 ten-year overall survival (JAMA 2017)"},{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"outcomes.source (Disease-free survival at 10 years)"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"Giuliano et al., axillary dissection versus no axillary dissection, 10-year results of ACOSOG Z0011 (JAMA 2017)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Giuliano et al., axillary dissection versus no axillary dissection, 10-year results of ACOSOG Z0011 (JAMA 2017)"}]},{"url":"https://doi.org/10.1001/jama.2017.17426","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.17426","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-palliation-breathlessness-effusion-obstruction","kind":"term","name":"Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain","route":"/terms/lung-palliation-breathlessness-effusion-obstruction/","field":"links","label":"AMPLE (JAMA 2017)"},{"id":"ample","kind":"trial","name":"AMPLE","route":"/trials/ample/","field":"links","label":"AMPLE (JAMA 2017)"},{"id":"ample","kind":"trial","name":"AMPLE","route":"/trials/ample/","field":"outcomes.source (Total days in hospital to death or 12 months (median))"}]},{"url":"https://doi.org/10.1001/jama.2017.18718","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.18718","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"metrics (Median overall survival with tumour-treating fields added to temozolomide (EF-14), the only phase 3 survival gain in glioblastoma since 2005)"},{"id":"paper-stupp-jama","kind":"paper","name":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","route":"/key-papers/paper-stupp-jama/","field":"links","label":"JAMA 2017"},{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/","field":"links","label":"EF-14: tumour treating fields plus temozolomide in glioblastoma (JAMA 2017)"}]},{"url":"https://doi.org/10.1001/jama.2017.3438","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.3438","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/","field":"links","label":"JAMA 2017"}]},{"url":"https://doi.org/10.1001/jama.2017.7105","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.7105","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/","field":"links","label":"JAMA 2017"},{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/","field":"links","label":"CALGB/SWOG 80405: first-line chemotherapy with cetuximab or bevacizumab in KRAS wild-type advanced colorectal cancer (JAMA 2017)"},{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/","field":"outcomes.source (Overall survival)"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"papers","label":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jama.2017.7156","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.7156","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"links","label":"Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"metrics (Median overall survival with routine patient-reported symptom monitoring vs usual care during chemotherapy for metastatic cancer (randomised))"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"metrics (Median overall survival with routine patient-reported symptom monitoring vs usual care during chemotherapy (randomised))"},{"id":"idea-moon-plain-language-consent","kind":"idea","name":"Two-page plain-language consent with teach-back for every cancer trial and treatment","route":"/ideas/idea-moon-plain-language-consent/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-results-in-plain-words","kind":"idea","name":"Every pathology and genomic report ships with a signed plain-language version","route":"/ideas/idea-moon-results-in-plain-words/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-certified-decision-aids","kind":"idea","name":"Certified decision aids required for every preference-sensitive cancer decision","route":"/ideas/idea-moon-certified-decision-aids/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-goals-conversation-trigger","kind":"idea","name":"Algorithm-triggered goals-of-care conversations before crisis","route":"/ideas/idea-moon-goals-conversation-trigger/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-funded-second-opinion","kind":"idea","name":"A funded expert second opinion for every new high-stakes or rare cancer diagnosis","route":"/ideas/idea-moon-funded-second-opinion/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-recorded-consultations","kind":"idea","name":"Recorded, AI-summarised consultations given to patients by default","route":"/ideas/idea-moon-recorded-consultations/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-peer-navigator-workforce","kind":"idea","name":"Paid survivor peer-navigators as a recognised health workforce role","route":"/ideas/idea-moon-peer-navigator-workforce/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days a treatment consumes, in every trial and decision aid","route":"/ideas/idea-moon-time-toxicity-reporting/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-preference-studies-before-phase3","kind":"idea","name":"Quantitative patient preference studies set the benefit-risk bar before phase 3","route":"/ideas/idea-moon-preference-studies-before-phase3/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-caregiver-in-the-plan","kind":"idea","name":"Formal caregiver assessment and training written into every treatment plan","route":"/ideas/idea-moon-caregiver-in-the-plan/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-literacy-first-design-standard","kind":"idea","name":"A health-literacy certification standard for oncology portals, letters and apps","route":"/ideas/idea-moon-literacy-first-design-standard/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/","field":"links","label":"Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017)"},{"id":"remote-patient-monitoring","kind":"technology","name":"Electronic patient-reported outcomes and remote monitoring","route":"/technologies/remote-patient-monitoring/","field":"links","label":"Basch: asking patients to report symptoms online during chemotherapy improved survival (JAMA 2017)"},{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","field":"links","label":"Basch 2017 survival (JAMA)"},{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1001/jama.2018.11597","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2018.11597","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"papers","label":"Effect of a Strategy of a Supraglottic Airway Device vs Tracheal Intubation During Out-of-Hospital Cardiac Arrest on Functional Outcome: The AIRWAYS-2 Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jama.2018.3710","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2018.3710","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-uspstf-prostate-screening-jama-2018","kind":"paper","name":"USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)","route":"/key-papers/paper-uspstf-prostate-screening-jama-2018/","field":"links","label":"JAMA 2018"},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","field":"links","label":"US Preventive Services Task Force, JAMA 2018: screening for prostate cancer, recommendation statement"},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"links","label":"US Preventive Services Task Force, JAMA 2018: screening for prostate cancer, recommendation statement"},{"id":"number-needed-to-screen","kind":"term","name":"Number needed to screen (and number needed to diagnose)","route":"/terms/number-needed-to-screen/","field":"links","label":"US Preventive Services Task Force, JAMA 2018: screening for prostate cancer, recommendation statement"},{"id":"other-cause-mortality","kind":"term","name":"Other-cause mortality","route":"/terms/other-cause-mortality/","field":"links","label":"US Preventive Services Task Force, JAMA 2018: screening for prostate cancer, recommendation statement"}]},{"url":"https://doi.org/10.1001/jama.2018.6228","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2018.6228","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Hu, JAMA 2018: inherited germline mutations in cancer predisposition genes and pancreatic cancer risk (3,030 patients)"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Hu, JAMA 2018: inherited germline mutations in cancer predisposition genes and pancreatic cancer risk (3,030 patients)"},{"id":"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","kind":"paper","name":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","route":"/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/","field":"links","label":"JAMA 2018"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1001/jama.2018.7855","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2018.7855","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","field":"links","label":"FRESCO: fruquintinib versus placebo in previously treated metastatic colorectal cancer (JAMA 2018)"},{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1001/jama.2018.8907","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2018.8907","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"papers","label":"Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jama.2019.10232","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2740727","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"US Preventive Services Task Force, JAMA 2019: screening for pancreatic cancer, reaffirmation (recommendation against, grade D)"}]},{"url":"https://doi.org/10.1001/jama.2019.11642","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2748795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"papers","label":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial"},{"id":"paper-anbl0532-tandem-transplant-park-jama-2019","kind":"paper","name":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","route":"/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/","field":"links","label":"JAMA 2019"}]},{"url":"https://doi.org/10.1001/jama.2019.17913","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2756290","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","field":"links","label":"SCORAD III (JAMA 2019)"},{"id":"paper-hoskin-jama","kind":"paper","name":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial","route":"/key-papers/paper-hoskin-jama/","field":"links","label":"JAMA 2019"}]},{"url":"https://doi.org/10.1001/jama.2019.2402","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.2019.2402","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ng-jama","kind":"paper","name":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial","route":"/key-papers/paper-ng-jama/","field":"links","label":"JAMA 2019"},{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","field":"links","label":"SUNSHINE (JAMA 2019)"}]},{"url":"https://doi.org/10.1001/jama.2020.0254","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2761003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"papers","label":"Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock"}]},{"url":"https://doi.org/10.1001/jama.2020.0572","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2761645","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-comstock-jama","kind":"paper","name":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening","route":"/key-papers/paper-comstock-jama/","field":"links","label":"JAMA 2020"},{"id":"breast-mri-coils-abbreviated-mri","kind":"technology","name":"Breast MRI coils and abbreviated breast MRI","route":"/technologies/breast-mri-coils-abbreviated-mri/","field":"links","label":"Comstock et al., Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening (JAMA 2020)"}]},{"url":"https://doi.org/10.1001/jama.2020.1166","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2762311","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"links","label":"Wouters et al., Estimated research and development investment needed to bring a new medicine to market (JAMA 2020)"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"metrics (Median estimated R&D investment to bring a new drug to market (all areas, 2009-2018), capitalised)"},{"id":"paper-wouters-jama","kind":"paper","name":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","route":"/key-papers/paper-wouters-jama/","field":"links","label":"JAMA 2020"}]},{"url":"https://doi.org/10.1001/jama.2020.23370","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2774295","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"links","label":"Wang et al., JAMA 2021: SYSUCC-001 primary results"},{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"outcomes.source (Disease-free survival at 5 years)"}]},{"url":"https://doi.org/10.1001/jama.2021.0377","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2777242","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people)"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people)"},{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","field":"links","label":"Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people)"},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","field":"links","label":"Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people)"}]},{"url":"https://doi.org/10.1001/jama.2021.0669","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2776879","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Disease-free survival at 2 years, high- and intermediate-risk relapse)"},{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Overall survival at 2 years, high- and intermediate-risk relapse)"},{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Serious infection as an adverse event, high- and intermediate-risk relapse)"},{"id":"paper-aall1331-brown-jama-2021","kind":"paper","name":"AALL1331: blinatumomab versus chemotherapy consolidation in high- and intermediate-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-brown-jama-2021/","field":"links","label":"JAMA 2021"}]},{"url":"https://doi.org/10.1001/jama.2021.1117","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2777244","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for lung cancer, recommendation statement (annual low-dose CT at 50 to 80 with 20 pack-years, grade B)"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for lung cancer, recommendation statement (annual low-dose CT at 50 to 80 with 20 pack-years, grade B)"},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for lung cancer, recommendation statement (annual low-dose CT at 50 to 80 with 20 pack-years, grade B)"},{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/","field":"links","label":"JAMA 2021"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for lung cancer, recommendation statement (annual low-dose CT at 50 to 80 with 20 pack-years, grade B)"}]},{"url":"https://doi.org/10.1001/jama.2021.6238","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2779985","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for colorectal cancer (start at 45, grade B; 50 to 75, grade A)"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"US Preventive Services Task Force, JAMA 2021: screening for colorectal cancer (start at 45, grade B; 50 to 75, grade A)"},{"id":"paper-uspstf-crc-screening-45-jama-2021","kind":"paper","name":"US Preventive Services Task Force recommendation: colorectal cancer screening from age 45","route":"/key-papers/paper-uspstf-crc-screening-45-jama-2021/","field":"links","label":"JAMA 2021"}]},{"url":"https://doi.org/10.1001/jama.2022.16464","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2796691","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-astrum-005-jama-2022","kind":"paper","name":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","route":"/key-papers/paper-astrum-005-jama-2022/","field":"links","label":"JAMA 2022"}]},{"url":"https://doi.org/10.1001/jama.2022.6147","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2792615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"links","label":"Goodwin et al., Effect of metformin vs placebo on invasive disease-free survival in breast cancer (MA.32, JAMA 2022)"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"metrics (Effect of metformin on invasive disease-free survival in high-risk operable breast cancer (MA.32, 3,649 patients))"},{"id":"paper-goodwin-jama","kind":"paper","name":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","route":"/key-papers/paper-goodwin-jama/","field":"links","label":"JAMA 2022"}]},{"url":"https://doi.org/10.1001/jama.2022.9009","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2793220","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aminian-jama","kind":"paper","name":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity","route":"/key-papers/paper-aminian-jama/","field":"links","label":"JAMA 2022"},{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","field":"links","label":"SPLENDID (JAMA 2022)"}]},{"url":"https://doi.org/10.1001/jama.2022.9265","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2793279","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","field":"links","label":"PRO-TECT (JAMA 2022)"},{"id":"paper-basch-jama","kind":"paper","name":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-basch-jama/","field":"links","label":"JAMA 2022"}]},{"url":"https://doi.org/10.1001/jama.2023.12914","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2810754","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","field":"links","label":"AABB red cell transfusion guideline 2023"},{"id":"paper-carson-jama","kind":"paper","name":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","route":"/key-papers/paper-carson-jama/","field":"links","label":"JAMA 2023"}]},{"url":"https://doi.org/10.1001/jama.2023.19918","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2812482","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-xu-jama","kind":"paper","name":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","route":"/key-papers/paper-xu-jama/","field":"links","label":"JAMA 2023"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"links","label":"ORIENT-16 (JAMA 2023)"},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","field":"links","label":"JAMA 2023"},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","field":"outcomes.source (Overall survival, all randomised)"}]},{"url":"https://doi.org/10.1001/jama.2023.20181","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2812324","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mai-jama","kind":"paper","name":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","route":"/key-papers/paper-mai-jama/","field":"links","label":"JAMA 2023"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"links","label":"JUPITER-02 (JAMA 2023)"}]},{"url":"https://doi.org/10.1001/jama.2023.21019","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2810756","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"papers","label":"Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jama.2023.24735","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2813880","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/","field":"links","label":"Neotorch (JAMA 2024)"},{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/","field":"outcomes.source (Event-free survival (stage III population))"}]},{"url":"https://doi.org/10.1001/jama.2023.4428","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2803803","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/","field":"links","label":"JAMA 2023"}]},{"url":"https://doi.org/10.1001/jama.2024.10613","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2819600","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-harmoni-a-jama-2024","kind":"paper","name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","route":"/key-papers/paper-harmoni-a-jama-2024/","field":"links","label":"JAMA 2024"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","field":"links","label":"JAMA 2024"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1001/jama.2024.13964","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2823624","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","field":"links","label":"REACH PC (JAMA 2024)"},{"id":"paper-greer-jama","kind":"paper","name":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial","route":"/key-papers/paper-greer-jama/","field":"links","label":"JAMA 2024"}]},{"url":"https://doi.org/10.1001/jama.2024.26698","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2828218","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-comet-dcis-jama-2025","kind":"paper","name":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","route":"/key-papers/paper-comet-dcis-jama-2025/","field":"links","label":"JAMA 2025"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"COMET trial (JAMA 2024)"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"standardOfCare.guideline (Low-risk DCIS)"},{"id":"comet-dcis","kind":"trial","name":"COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)","route":"/trials/comet-dcis/","field":"outcomes.source (Ipsilateral invasive cancer at 2 years (non-inferiority))"}]},{"url":"https://doi.org/10.1001/jama.2024.26886","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2829800","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/","field":"links","label":"Ignatiadis et al., JAMA 2025: adjuvant atezolizumab for early triple-negative breast cancer, ALEXANDRA/IMpassion030"},{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/","field":"outcomes.source (Invasive disease-free survival)"}]},{"url":"https://doi.org/10.1001/jama.2024.28312","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2830131","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","field":"outcomes.source (Complete remission)"},{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","field":"outcomes.source (Event-free survival (median))"}]},{"url":"https://doi.org/10.1001/jama.2024.3056","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2816923","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/","field":"links","label":"JAMA 2024"},{"id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","field":"links","label":"Leon-Ferre et al., Tumour-infiltrating lymphocytes in triple-negative breast cancer treated without chemotherapy (JAMA 2024)"}]},{"url":"https://doi.org/10.1001/jama.2024.3841","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2817323","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"links","label":"Auvinen et al., JAMA 2024 (ProScreen): prostate cancer screening with PSA, kallikrein panel and MRI"}]},{"url":"https://doi.org/10.1001/jama.2024.4011","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2817322","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-martin-jama","kind":"paper","name":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","route":"/key-papers/paper-martin-jama/","field":"links","label":"JAMA 2024"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","field":"links","label":"CAP trial 15-year follow-up (JAMA 2024)"}]},{"url":"https://doi.org/10.1001/jama.2025.24784","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2842903","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wisdom-trial-jama-2026","kind":"paper","name":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","route":"/key-papers/paper-wisdom-trial-jama-2026/","field":"links","label":"JAMA 2026"}]},{"url":"https://doi.org/10.1001/jama.2025.7515","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jama/fullarticle/2834891","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/","field":"links","label":"PREEMPT CRC (JAMA 2025)"},{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","field":"links","label":"JAMA 2025"},{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","field":"outcomes.source (Sensitivity for colorectal cancer)"},{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","field":"outcomes.source (Specificity for advanced colorectal neoplasia)"},{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","field":"outcomes.source (Sensitivity for advanced precancerous lesions (secondary))"},{"id":"paper-preempt-crc-shaukat-jama-2025","kind":"paper","name":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","route":"/key-papers/paper-preempt-crc-shaukat-jama-2025/","field":"links","label":"JAMA 2025"}]},{"url":"https://doi.org/10.1001/jama.280.11.969","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.280.11.969","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-damico-risk-groups-jama-1998","kind":"paper","name":"D'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy","route":"/key-papers/paper-damico-risk-groups-jama-1998/","field":"links","label":"JAMA 1998"}]},{"url":"https://doi.org/10.1001/jama.291.9.1092","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.291.9.1092","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-symptom-control","kind":"term","name":"Symptom control in advanced gallbladder cancer: pain, ascites and nutrition","route":"/terms/gallbladder-cancer-symptom-control/","field":"links","label":"Wong et al., JAMA 2004: neurolytic coeliac plexus block versus opioids alone, randomised controlled trial (100 patients)"}]},{"url":"https://doi.org/10.1001/jama.295.21.2483","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.295.21.2483","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/","field":"links","label":"JROSG 99-1 (JAMA 2006)"},{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/","field":"outcomes.source (Overall survival (median))"},{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/","field":"outcomes.source (Brain tumour recurrence at 12 months)"}]},{"url":"https://doi.org/10.1001/jama.295.21.2492","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.295.21.2492","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Carey, JAMA 2006: race, breast cancer subtypes and survival in the Carolina Breast Cancer Study"},{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"links","label":"Carey, JAMA 2006: race, breast cancer subtypes and survival in the Carolina Breast Cancer Study"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Carey, JAMA 2006: race, breast cancer subtypes and survival in the Carolina Breast Cancer Study"},{"id":"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","kind":"paper","name":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","route":"/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/","field":"links","label":"JAMA 2006"}]},{"url":"https://doi.org/10.1001/jama.297.3.267","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.297.3.267","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-conko-001-adjuvant-gemcitabine-observation-jama-2007","kind":"paper","name":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/","field":"links","label":"JAMA 2007"}]},{"url":"https://doi.org/10.1001/jama.298.3.289","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.298.3.289","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-whel-jama-2007","kind":"paper","name":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial","route":"/key-papers/paper-whel-jama-2007/","field":"links","label":"JAMA 2007"},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","field":"links","label":"Pierce et al. (JAMA 2007)"},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","field":"outcomes.source (Invasive breast cancer event (recurrence or new primary))"}]},{"url":"https://doi.org/10.1001/jama.300.8.915","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jama.300.8.915","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-saper-jama","kind":"paper","name":"Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet","route":"/key-papers/paper-saper-jama/","field":"links","label":"JAMA 2008"},{"id":"ayurvedic-medicine-cancer","kind":"technology","name":"Ayurvedic medicine and cancer","route":"/technologies/ayurvedic-medicine-cancer/","field":"links","label":"Lead, mercury and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the internet (JAMA 2008)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2013.2139","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2013.2139","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Schmults et al., factors predictive of recurrence and death from cutaneous squamous cell carcinoma: 10-year, single-institution cohort study of 985 patients (JAMA Dermatology 2013)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Schmults et al., factors predictive of recurrence and death from cutaneous squamous cell carcinoma: 10-year, single-institution cohort study of 985 patients (JAMA Dermatology 2013)"},{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","field":"links","label":"Schmults et al., factors predictive of recurrence and death from cutaneous squamous cell carcinoma: 10-year, single-institution cohort study of 985 patients (JAMA Dermatology 2013)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2013.2456","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2013.2456","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"links","label":"Jambusaria-Pahlajani et al., JAMA Dermatology 2013;149:402 to 410: evaluation of AJCC tumour staging for cutaneous squamous cell carcinoma and a proposed alternative tumour staging system (256 primary high-risk tumours; the derivation of the Brigham and Women's Hospital system)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Jambusaria-Pahlajani et al., JAMA Dermatology 2013;149:402 to 410: evaluation of AJCC tumour staging for cutaneous squamous cell carcinoma and a proposed alternative tumour staging system (256 primary high-risk tumours; the derivation of the Brigham and Women's Hospital system)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2016.4920","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2016.4920","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Garrett et al., incidence of and risk factors for skin cancer in organ transplant recipients in the United States, 10,649 recipients (JAMA Dermatology 2017)"},{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"Garrett et al., incidence of and risk factors for skin cancer in organ transplant recipients in the United States, 10,649 recipients (JAMA Dermatology 2017)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Garrett et al., incidence of and risk factors for skin cancer in organ transplant recipients in the United States, 10,649 recipients (JAMA Dermatology 2017)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2017.3960","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2017.3960","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"links","label":"Karia et al., JAMA Dermatology 2018;154:175 to 181: comparison of tumour classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th versus the 8th edition of the AJCC staging manual (680 tumours in 459 patients)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Karia et al., JAMA Dermatology 2018;154:175 to 181: comparison of tumour classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th versus the 8th edition of the AJCC staging manual (680 tumours in 459 patients)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2018.0454","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2018.0454","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-jama-dermatol","kind":"paper","name":"Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer","route":"/key-papers/paper-freites-martinez-jama-dermatol/","field":"links","label":"JAMA Dermatol 2018"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","field":"links","label":"Endocrine therapy-induced alopecia in patients with breast cancer (JAMA Dermatol 2018)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2019.0032","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2019.0032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"links","label":"Ruiz, Karia, Besaw and Schmults, JAMA Dermatology 2019;155:819 to 825: performance of the AJCC staging manual 8th edition versus the Brigham and Women's Hospital tumour classification system for cutaneous squamous cell carcinoma"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Ruiz, Karia, Besaw and Schmults, JAMA Dermatology 2019;155:819 to 825: performance of the AJCC staging manual 8th edition versus the Brigham and Women's Hospital tumour classification system for cutaneous squamous cell carcinoma"}]},{"url":"https://doi.org/10.1001/jamadermatol.2020.1988","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2767662","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Tokez, Wakkee, Kuijpers et al., JAMA Dermatology 2020;156(9):973 to 981: incidence of cutaneous squamous cell carcinoma in situ and the risk of developing invasive disease, 88,754 patients, the Netherlands 1989 to 2017"}]},{"url":"https://doi.org/10.1001/jamadermatol.2022.1570","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2792714","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pellacani-jama-dermatol","kind":"paper","name":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial","route":"/key-papers/paper-pellacani-jama-dermatol/","field":"links","label":"JAMA Dermatol 2022"},{"id":"confocal-oct-skin-imaging","kind":"technology","name":"Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)","route":"/technologies/confocal-oct-skin-imaging/","field":"links","label":"Pellacani et al., Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma: a randomised clinical trial (JAMA Dermatology 2022)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2024.5572","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2829496","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scin-trial","kind":"trial","name":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma)","route":"/trials/scin-trial/","field":"links","label":"Five-year results (JAMA Dermatology 2025)"},{"id":"scin-trial","kind":"trial","name":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma)","route":"/trials/scin-trial/","field":"outcomes.source (Free from treatment failure at 5 years)"}]},{"url":"https://doi.org/10.1001/jamadermatol.2025.3238","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2838591","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"Nicotinamide in 33,822 patients including 1,334 transplant recipients (JAMA Dermatology 2025)"}]},{"url":"https://doi.org/10.1001/jamainternmed.2014.1824","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2014.1824","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"papers","label":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011"}]},{"url":"https://doi.org/10.1001/jamainternmed.2015.2829","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.2829","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","field":"papers","label":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival"},{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","field":"papers","label":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"links","label":"Prasad et al., Strength of association between surrogate endpoints and survival in oncology (JAMA Intern Med 2015)"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"metrics (Trial-level correlations between surrogate endpoints and overall survival in oncology rated weak vs strong (systematic review))"},{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1001/jamainternmed.2015.4838","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.4838","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-predimed-breast-jama-im-2015","kind":"paper","name":"PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers","route":"/key-papers/paper-predimed-breast-jama-im-2015/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1001/jamainternmed.2015.5868","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.5868","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/","field":"links","label":"Kim and Prasad: FDA approvals on surrogates (2015)"}]},{"url":"https://doi.org/10.1001/jamainternmed.2019.0462","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2019.0462","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"links","label":"Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"metrics (Cancer drug indications granted FDA accelerated approval 1992-2017 that later demonstrated an overall survival benefit in a confirmatory trial)"},{"id":"idea-data-rwe-rct-calibration-library","kind":"idea","name":"An open library pairing completed cancer trials with real-world emulations","route":"/ideas/idea-data-rwe-rct-calibration-library/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-accelerated-approval-registry-condition","kind":"idea","name":"Every patient on an accelerated-approval drug enrolled in a registry until confirmation","route":"/ideas/idea-data-accelerated-approval-registry-condition/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-registry-based-rcts","kind":"idea","name":"Registry-based randomised trials for oncology comparative effectiveness","route":"/ideas/idea-data-registry-based-rcts/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-excluded-populations-rwe-mandate","kind":"idea","name":"Mandatory real-world reporting for patients excluded from pivotal trials","route":"/ideas/idea-data-excluded-populations-rwe-mandate/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-wearable-endpoints-validation","kind":"idea","name":"Wearable activity data as a validated real-world endpoint","route":"/ideas/idea-data-wearable-endpoints-validation/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","route":"/ideas/idea-data-external-control-arm-standard/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"},{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/","field":"links","label":"JAMA Intern Med 2019"},{"id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/","field":"links","label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2019.16910","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2757250","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-garcia-jama-netw-open","kind":"paper","name":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-garcia-jama-netw-open/","field":"links","label":"JAMA Netw Open 2019"},{"id":"acupuncture-xerostomia","kind":"technology","name":"Acupuncture for dry mouth after head and neck radiotherapy","route":"/technologies/acupuncture-xerostomia/","field":"links","label":"Acupuncture for radiation-induced xerostomia in head and neck cancer, randomised trial (JAMA Netw Open 2019)"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2019.2535","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2019.2535","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"links","label":"Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"metrics (US patients with cancer eligible for a checkpoint inhibitor (2018))"},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"metrics (US patients with cancer estimated to respond to a checkpoint inhibitor (2018))"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","field":"links","label":"Haslam & Prasad (JAMA Network Open 2019)"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","field":"metrics (US patients with cancer eligible for checkpoint inhibitors vs estimated responders (2018))"},{"id":"idea-bio2-trem2-myeloid-reprogramming","kind":"idea","name":"Reprogramme suppressive macrophages instead of trying to delete them","route":"/ideas/idea-bio2-trem2-myeloid-reprogramming/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-in-situ-vaccination-solid","kind":"idea","name":"Turn one tumour into a vaccine to treat all the others","route":"/ideas/idea-bio2-in-situ-vaccination-solid/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-engineered-bacteria-payloads","kind":"idea","name":"Engineered bacteria that live in tumours and manufacture drugs there","route":"/ideas/idea-bio2-engineered-bacteria-payloads/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-lactate-acid-axis","kind":"idea","name":"De-acidify the tumour so T cells can work in it","route":"/ideas/idea-bio2-lactate-acid-axis/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-radiotherapy-sting-fractionation","kind":"idea","name":"Pick the radiation dose that switches the immune alarm on, not off","route":"/ideas/idea-bio2-radiotherapy-sting-fractionation/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-implantable-microdevice-screen","kind":"idea","name":"Implant a tiny device that tests twenty drugs inside the patient's own tumour","route":"/ideas/idea-bio2-implantable-microdevice-screen/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-vascular-normalisation-window","kind":"idea","name":"Use imaging to find the window when tumour blood vessels are working properly","route":"/ideas/idea-bio2-vascular-normalisation-window/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-hypoxia-guided-adenosine","kind":"idea","name":"Use a hypoxia scan to pick patients for adenosine-pathway drugs","route":"/ideas/idea-bio2-hypoxia-guided-adenosine/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-histotripsy-immune-priming","kind":"idea","name":"Mechanically pulverise one tumour with ultrasound to wake the immune system","route":"/ideas/idea-bio2-histotripsy-immune-priming/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-trained-immunity-priming","kind":"idea","name":"Train the bone marrow to make better anti-tumour immune cells","route":"/ideas/idea-bio2-trained-immunity-priming/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-fmt-plus-checkpoint-phase3","kind":"idea","name":"Take faecal transplant plus immunotherapy to a definitive trial","route":"/ideas/idea-bio2-fmt-plus-checkpoint-phase3/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-antibiotic-stewardship-io","kind":"idea","name":"Protect the gut flora of patients about to start immunotherapy","route":"/ideas/idea-bio2-antibiotic-stewardship-io/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-ctdna-six-week-io-switch","kind":"idea","name":"Use a blood test at six weeks to decide whether to keep going","route":"/ideas/idea-bio2-ctdna-six-week-io-switch/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-epigenetic-priming-cold-tumours","kind":"idea","name":"Unmask hidden antigens with a short epigenetic course before immunotherapy","route":"/ideas/idea-bio2-epigenetic-priming-cold-tumours/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-bio2-fibre-diet-io-trial","kind":"idea","name":"Test a high-fibre diet as an immunotherapy adjunct","route":"/ideas/idea-bio2-fibre-diet-io-trial/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"},{"id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/","field":"links","label":"Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019)"},{"id":"paper-haslam-jama-netw-open","kind":"paper","name":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","route":"/key-papers/paper-haslam-jama-netw-open/","field":"links","label":"JAMA Netw Open 2019"},{"id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/","field":"links","label":"Bottleneck evidence (No one can predict who responds to immunotherapy): Haslam & Prasad (JAMA Network Open 2019)"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2019.4337","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2019.4337","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"links","label":"Metter et al., Trends in the US and Canadian pathologist workforces 2007-2017 (JAMA Netw Open 2019)"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"metrics (Change in the US pathologist workforce 2007-2017)"},{"id":"paper-metter-jama-netw-open","kind":"paper","name":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017","route":"/key-papers/paper-metter-jama-netw-open/","field":"links","label":"JAMA Netw Open 2019"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2020.33972","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775667","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"links","label":"Danchev et al., Evaluation of data sharing after implementation of the ICMJE requirement (JAMA Netw Open 2021)"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"metrics (Trials with ICMJE data-sharing statements whose individual participant data could actually be obtained by requesters)"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"links","label":"Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"metrics (Trials with ICMJE data-sharing statements whose individual participant data could be obtained by requesters)"},{"id":"idea-fund-antitrust-safe-harbour","kind":"idea","name":"An antitrust safe harbour for cross-company combination trials and data pooling","route":"/ideas/idea-fund-antitrust-safe-harbour/","field":"links","label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","field":"links","label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/","field":"links","label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/","field":"links","label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"idea-fund-scoop-protection-policy","kind":"idea","name":"Scoop protection and co-publication norms to reduce academic secrecy","route":"/ideas/idea-fund-scoop-protection-policy/","field":"links","label":"Bottleneck evidence (Secrecy and intellectual property block collaboration): Danchev et al., Evaluation of data sharing after implementation of the ICMJE data sharing statement requirement (JAMA Netw Open 2021)"},{"id":"paper-danchev-jama-netw-open","kind":"paper","name":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement","route":"/key-papers/paper-danchev-jama-netw-open/","field":"links","label":"JAMA Netw Open 2021"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2020.5143","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765996","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020","kind":"paper","name":"Outcomes of Gallbladder Polyps and Their Association With Gallbladder Cancer in a 20-Year Cohort","route":"/key-papers/paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020/","field":"links","label":"JAMA Netw Open 2020"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2021.36128","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786903","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"papers","label":"Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2021.4708","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2778204","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Rahib, JAMA Netw Open 2021: estimated projection of US cancer incidence and death to 2040"},{"id":"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021","kind":"paper","name":"Estimated Projection of US Cancer Incidence and Death to 2040","route":"/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/","field":"links","label":"JAMA Netw Open 2021"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2024.49798","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Reid, JAMA Netw Open 2024: West African genetic ancestry and breast cancer outcomes among young Black women"}]},{"url":"https://doi.org/10.1001/jamanetworkopen.2026.16780","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848862","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Rockwell JAMA Network Open 2026"},{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"links","label":"Rockwell JAMA Network Open 2026"},{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","field":"links","label":"Rockwell JAMA Network Open 2026"},{"id":"paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026","kind":"paper","name":"Ivermectin-benzimidazole prescribing following celebrity endorsement","route":"/key-papers/paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026/","field":"links","label":"Rockwell JAMA Network Open 2026"}]},{"url":"https://doi.org/10.1001/jamaoncol.2015.0373","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.0373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"links","label":"Mailankody & Prasad, Five years of cancer drug approvals: innovation, efficacy, and costs (JAMA Oncology 2015)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"metrics (Relationship between price and novelty (first-in-class vs next-in-class) or benefit for cancer drugs approved by FDA 2009-2013)"},{"id":"paper-mailankody-jama-oncol","kind":"paper","name":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","route":"/key-papers/paper-mailankody-jama-oncol/","field":"links","label":"JAMA Oncol 2015"}]},{"url":"https://doi.org/10.1001/jamaoncol.2015.3101","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.3101","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","field":"links","label":"Chawla et al., first-line aldoxorubicin vs doxorubicin in advanced soft tissue sarcoma, phase 2b (JAMA Oncology 2015)"},{"id":"paper-chawla-jama-oncol","kind":"paper","name":"First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial","route":"/key-papers/paper-chawla-jama-oncol/","field":"links","label":"JAMA Oncol 2015"},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/","field":"links","label":"Chawla et al., phase 2b first-line trial (JAMA Oncology 2015)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2015.3856","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.3856","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"papers","label":"Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.0164","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.0164","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-marinac-jama-oncol","kind":"paper","name":"Prolonged Nightly Fasting and Breast Cancer Prognosis","route":"/key-papers/paper-marinac-jama-oncol/","field":"links","label":"JAMA Oncol 2016"},{"id":"time-restricted-eating","kind":"technology","name":"Time-restricted eating in cancer prevention and survivorship","route":"/technologies/time-restricted-eating/","field":"links","label":"Nightly fasting and breast cancer prognosis (JAMA Oncol 2016)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.1373","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","field":"links","label":"Brown et al., Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis (JAMA Oncology 2016)"},{"id":"paper-brown-jama-oncol","kind":"paper","name":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","route":"/key-papers/paper-brown-jama-oncol/","field":"links","label":"JAMA Oncol 2016"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.1828","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1828","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"papers","label":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.3797","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.3797","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","kind":"paper","name":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","route":"/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/","field":"links","label":"Tejpar et al., JAMA Oncol 2017: primary tumour location in the RAS wild-type populations of CRYSTAL and FIRE-3"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.3916","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.3916","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017","kind":"paper","name":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017/","field":"links","label":"Connor et al., JAMA Oncol 2017: mutational signatures and immune activity in 160 plus 95 whole genomes"}]},{"url":"https://doi.org/10.1001/jamaoncol.2016.5688","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.5688","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017","kind":"paper","name":"Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015","route":"/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.0013","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0013","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rimm-pd-l1-assay-comparison-jama-oncol-2017","kind":"paper","name":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","route":"/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/","field":"links","label":"Rimm et al., JAMA Oncol 2017: 13 pathologists scoring four PD-L1 assays on 90 non-small-cell lung cancers"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.0595","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0595","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-huo-tcga-ancestry-breast-jama-oncol-2017","kind":"paper","name":"Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas","route":"/key-papers/paper-huo-tcga-ancestry-breast-jama-oncol-2017/","field":"links","label":"Huo et al., JAMA Oncol 2017: breast cancer molecular features by African and European ancestry in TCGA"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.1007","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.1007","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","kind":"paper","name":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","route":"/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/","field":"links","label":"Hahnen et al., JAMA Oncol 2017: germline status and response in 291 GeparSixto TNBC patients"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.3420","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.3420","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018","kind":"paper","name":"Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma","route":"/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/","field":"links","label":"Qian et al., JAMA Oncol 2018: the four driver genes and outcome in 356 resected cancers"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.4298","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4298","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Weiss, JAMA Oncol 2018: validation of the AJCC 8th edition prognostic stage against the anatomic stage"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"Weiss, JAMA Oncol 2018: validation of the AJCC 8th edition prognostic stage against the anatomic stage"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.4510","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4510","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bia-alcl","kind":"term","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/terms/bia-alcl/","field":"links","label":"Breast implants and the risk of anaplastic large-cell lymphoma (JAMA Oncology 2018)"},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"papers","label":"Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast"}]},{"url":"https://doi.org/10.1001/jamaoncol.2017.5029","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.5029","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018","kind":"paper","name":"VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis","route":"/key-papers/paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018/","field":"links","label":"JAMA Oncol 2018"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.0977","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0977","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Estimated total cost of CAR-T therapy including list price and management of adverse events (2018 US analysis))"},{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","route":"/ideas/idea-reg-two-day-cart-rapid-release/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-cart-potency-reference-standards","kind":"idea","name":"Public reference standards and potency assays for CAR-T so every lab measures alike","route":"/ideas/idea-reg-cart-potency-reference-standards/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-vein-to-vein-public-benchmark","kind":"idea","name":"Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product","route":"/ideas/idea-reg-vein-to-vein-public-benchmark/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","route":"/ideas/idea-reg-hpapi-continuous-flow/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","route":"/ideas/idea-reg-open-source-lentiviral-vectors/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-manufacturing-slot-exchange","kind":"idea","name":"A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient","route":"/ideas/idea-reg-manufacturing-slot-exchange/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-ai-process-control-cell-manufacturing","kind":"idea","name":"Digital batch records and AI process control to halve cell therapy batch failures","route":"/ideas/idea-reg-ai-process-control-cell-manufacturing/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","route":"/ideas/idea-reg-comparability-by-design-digital-twin/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/","field":"links","label":"JAMA Oncol 2018"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.1621","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.1621","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018","kind":"paper","name":"Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer","route":"/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/","field":"links","label":"Scher et al., JAMA Oncol 2018: nuclear-localised AR-V7 protein in circulating tumour cells and the taxane against androgen receptor signalling inhibitor choice (142 patients)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.2487","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2487","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alternative-medicine-instead-of-treatment","kind":"technology","name":"Alternative medicine used instead of standard treatment","route":"/technologies/alternative-medicine-instead-of-treatment/","field":"links","label":"Complementary medicine, refusal of conventional cancer therapy, and survival (JAMA Oncol 2018)"},{"id":"paper-johnson-alternative-medicine-jnci-2018","kind":"paper","name":"Use of alternative medicine for cancer and its impact on survival","route":"/key-papers/paper-johnson-alternative-medicine-jnci-2018/","field":"links","label":"Companion analysis: complementary medicine, refusal of conventional therapy and survival (JAMA Oncol 2018)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.2969","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2969","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","kind":"paper","name":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","route":"/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/","field":"links","label":"Oxnard et al., JAMA Oncol 2018: resistance mechanisms after osimertinib in T790M-positive lung cancer (143 and 110 patients)"},{"id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","field":"links","label":"Oxnard et al., JAMA Oncol 2018: resistance mechanisms after osimertinib in T790M-positive lung cancer (143 and 110 patients)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.3039","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.3039","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alter-0303-jama-oncol-2018","kind":"paper","name":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-alter-0303-jama-oncol-2018/","field":"links","label":"JAMA Oncol 2018"},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","field":"links","label":"ALTER 0303 (JAMA Oncol 2018)"},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","field":"links","label":"JAMA Oncol 2018"},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.4305","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.4305","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","kind":"paper","name":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","route":"/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/","field":"links","label":"Aggarwal et al., JAMA Oncol 2019: plasma-based genotyping and the delivery of matched treatment in 323 metastatic lung cancers"},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","field":"papers","label":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.4628","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.4628","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"papers","label":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC (CONDOR)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.5080","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.5080","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/","field":"links","label":"Cremolini, JAMA Oncol 2019: CRICKET, cetuximab and irinotecan rechallenge in RAS and BRAF wild-type metastatic colorectal cancer (28 patients)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.5526","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.5526","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-jama-oncol","kind":"paper","name":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","route":"/key-papers/paper-chen-jama-oncol/","field":"links","label":"JAMA Oncol 2019"},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"links","label":"Response-adapted SNUC treatment (JAMA Oncol 2019)"},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"standardOfCare.guideline (Sinonasal undifferentiated carcinoma)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.5801","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.5801","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","kind":"paper","name":"Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","route":"/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/","field":"links","label":"Abida et al., JAMA Oncol 2019: microsatellite instability in 1,033 assessable prostate tumours and response to checkpoint blockade"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.6727","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"papers","label":"Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial"},{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","field":"papers","label":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival"},{"id":"paper-klass-01-kim-jama-oncol-2019","kind":"paper","name":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","route":"/key-papers/paper-klass-01-kim-jama-oncol-2019/","field":"links","label":"JAMA Oncol 2019"},{"id":"klass-01","kind":"trial","name":"KLASS-01","route":"/trials/klass-01/","field":"outcomes.source (Overall survival at 5 years (non-inferiority))"},{"id":"klass-01","kind":"trial","name":"KLASS-01","route":"/trials/klass-01/","field":"outcomes.source (Cancer-specific survival at 5 years)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.6752","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6752","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"papers","label":"Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.6760","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6760","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019","kind":"paper","name":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","route":"/key-papers/paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019/","field":"links","label":"Nicolosi et al., JAMA Oncol 2019: germline variants in 3,607 men with prostate cancer referred for testing, against the testing guidelines"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0096","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0096","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","kind":"paper","name":"Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial","route":"/key-papers/paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019/","field":"links","label":"Fendler et al., JAMA Oncol 2019: prospective accuracy of gallium-68 PSMA-11 PET in 635 men with biochemically recurrent prostate cancer"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"papers","label":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"papers","label":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0270","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0270","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"Shroff et al., JAMA Oncology 2019: phase 2 of gemcitabine, cisplatin and nab-paclitaxel"},{"id":"gap-phase2-mdacc","kind":"trial","name":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)","route":"/trials/gap-phase2-mdacc/","field":"links","label":"Shroff et al., JAMA Oncology 2019"},{"id":"gap-phase2-mdacc","kind":"trial","name":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)","route":"/trials/gap-phase2-mdacc/","field":"outcomes.source (Progression-free survival)"},{"id":"gap-phase2-mdacc","kind":"trial","name":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)","route":"/trials/gap-phase2-mdacc/","field":"outcomes.source (Overall survival)"},{"id":"paper-gap-phase2-mdacc-jama-oncol-2019","kind":"paper","name":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","route":"/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/","field":"links","label":"JAMA Oncol 2019"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0528","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2733132","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019","kind":"paper","name":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","route":"/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/","field":"links","label":"Reinert et al., JAMA Oncol 2019: ultradeep sequencing of plasma cell-free DNA in 130 stage I-III colorectal cancers"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0826","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0826","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dess-black-race-prostate-mortality-jama-oncol-2019","kind":"paper","name":"Association of Black race with prostate cancer-specific and other-cause mortality","route":"/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/","field":"links","label":"JAMA Oncol 2019"},{"id":"other-cause-mortality","kind":"term","name":"Other-cause mortality","route":"/terms/other-cause-mortality/","field":"links","label":"Dess et al., JAMA Oncology 2019: association of Black race with prostate cancer-specific and other-cause mortality"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0892","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0892","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-murphy-jama-oncol","kind":"paper","name":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","route":"/key-papers/paper-murphy-jama-oncol/","field":"links","label":"JAMA Oncol 2019"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Murphy et al., Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer (JAMA Oncology 2019)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.1402","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2737091","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019","kind":"paper","name":"Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers","route":"/key-papers/paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019/","field":"links","label":"JAMA Oncol 2019"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.1588","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2738420","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","kind":"paper","name":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","route":"/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/","field":"links","label":"O'Reilly et al., JAMA Oncol 2019: durvalumab with or without tremelimumab in 65 metastatic patients"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.1838","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2740685","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/","field":"links","label":"Garcia-Murillas et al., JAMA Oncol 2019: molecular relapse detection in 101 early breast cancer patients"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.1870","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2748395","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"links","label":"Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"metrics (Black and Hispanic participants in trials supporting FDA cancer drug approvals 2008-2018)"},{"id":"idea-tr1-incidence-weighted-enrolment-targets","kind":"idea","name":"Set trial enrolment targets from who actually gets the disease, and publish progress live","route":"/ideas/idea-tr1-incidence-weighted-enrolment-targets/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-parallel-comorbidity-cohorts","kind":"idea","name":"Parallel real-world cohorts for sicker patients alongside every pivotal trial","route":"/ideas/idea-tr1-parallel-comorbidity-cohorts/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-community-health-worker-recruitment","kind":"idea","name":"Community health workers and trusted local organisations paid to recruit for trials","route":"/ideas/idea-tr1-community-health-worker-recruitment/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-site-equity-index","kind":"idea","name":"A public equity index for trial sites and sponsors, tied to funding","route":"/ideas/idea-tr1-site-equity-index/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-sex-stratified-pk-and-dosing","kind":"idea","name":"Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose","route":"/ideas/idea-tr1-sex-stratified-pk-and-dosing/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-disability-and-mental-illness-inclusion","kind":"idea","name":"Remove blanket exclusions for mental illness and dementia; support consent instead","route":"/ideas/idea-tr1-disability-and-mental-illness-inclusion/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-diverse-investigator-pipeline","kind":"idea","name":"Fund investigators from under-represented communities and community sites to lead trials","route":"/ideas/idea-tr1-diverse-investigator-pipeline/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-paid-community-advisory-boards","kind":"idea","name":"Paid community advisory boards with power to change protocol burden","route":"/ideas/idea-tr1-paid-community-advisory-boards/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-post-marketing-safety-by-ancestry-and-sex","kind":"idea","name":"Post-marketing safety monitoring stratified by ancestry and sex, with label updates","route":"/ideas/idea-tr1-post-marketing-safety-by-ancestry-and-sex/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-ecog-2-dedicated-cohorts","kind":"idea","name":"Dedicated cohorts for patients with performance status 2 in first-line trials","route":"/ideas/idea-tr1-ecog-2-dedicated-cohorts/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"idea-tr1-trial-desert-map","kind":"idea","name":"A public map of trial deserts to steer where new sites open","route":"/ideas/idea-tr1-trial-desert-map/","field":"links","label":"Bottleneck evidence (Trials do not represent the people who get cancer): Loree et al., Disparity of race reporting and representation in trials leading to cancer drug approvals (JAMA Oncology 2019)"},{"id":"paper-loree-jama-oncol","kind":"paper","name":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","route":"/key-papers/paper-loree-jama-oncol/","field":"links","label":"JAMA Oncol 2019"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.4782","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2752266","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"papers","label":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial"},{"id":"paper-nct02107703-jama-oncol-2020-update","kind":"paper","name":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","route":"/key-papers/paper-nct02107703-jama-oncol-2020-update/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.5868","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2758575","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020","kind":"paper","name":"Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)","route":"/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.6143","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2760432","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","field":"links","label":"Molinaro et al., Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma (JAMA Oncology 2020)"},{"id":"paper-molinaro-jama-oncol","kind":"paper","name":"Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma","route":"/key-papers/paper-molinaro-jama-oncol/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.6152","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2758838","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kelly-jama-oncol","kind":"paper","name":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","route":"/key-papers/paper-kelly-jama-oncol/","field":"links","label":"JAMA Oncol 2020"},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"T-VEC plus pembrolizumab in sarcoma (JAMA Oncol 2020)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.6650","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2761193","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-i-spy-2-jama-oncol-2020","kind":"paper","name":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","route":"/key-papers/paper-i-spy-2-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.6716","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2761957","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","field":"links","label":"Global Retinoblastoma Study (JAMA Oncol 2020)"},{"id":"paper-global-retinoblastoma-study-jama-oncol","kind":"paper","name":"Global Retinoblastoma Presentation and Analysis by National Income Level","route":"/key-papers/paper-global-retinoblastoma-study-jama-oncol/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.0147","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2763312","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","field":"links","label":"ORIOLE: observation versus stereotactic ablative radiation for oligometastatic prostate cancer (JAMA Oncology 2020)"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"links","label":"ORIOLE (JAMA Oncology 2020)"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"outcomes.source (Progression at 6 months)"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"outcomes.source (Progression-free survival (median))"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"outcomes.source (New lesions at 6 months by total PSMA consolidation)"},{"id":"paper-phillips-jama-oncol","kind":"paper","name":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","route":"/key-papers/paper-phillips-jama-oncol/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.0237","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2763864","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","field":"links","label":"MYSTIC (JAMA Oncology 2020)"},{"id":"paper-nct02453282-jama-oncol-2020","kind":"paper","name":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct02453282-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.1024","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2766213","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","field":"links","label":"Reardon et al., Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial (JAMA Oncology 2020)"},{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","field":"outcomes.source (Overall survival, first recurrence of glioblastoma)"},{"id":"paper-reardon-jama-oncol","kind":"paper","name":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-reardon-jama-oncol/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.2295","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2768007","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020","kind":"paper","name":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","route":"/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.3161","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2772174","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.3362","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2769127","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020","kind":"paper","name":"Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition","route":"/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.3370","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"papers","label":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer"},{"id":"paper-keynote-062-shitara-jama-oncol-2020","kind":"paper","name":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","route":"/key-papers/paper-keynote-062-shitara-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","field":"outcomes.source (Overall survival, PD-L1 CPS >=1 (non-inferiority))"},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","field":"outcomes.source (Overall survival, PD-L1 CPS >=10)"},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","field":"outcomes.source (Overall survival, PD-L1 CPS >=1)"},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","field":"outcomes.source (Progression-free survival, PD-L1 CPS >=1)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.4515","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2771011","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","field":"papers","label":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer"},{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"},{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","field":"outcomes.source (Objective response rate (blinded independent central review), mismatch repair-deficient endometrial cancer)"},{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","field":"outcomes.source (Confirmed complete response)"},{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","field":"outcomes.source (Probability of maintaining response at 12 months)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.4564","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2771012","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nivolumab-hcc-jama-oncol-2020","kind":"paper","name":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","route":"/key-papers/paper-nivolumab-hcc-jama-oncol-2020/","field":"links","label":"JAMA Oncol 2020"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.5161","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2772786","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021","kind":"paper","name":"Association of clonal haematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","route":"/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/","field":"links","label":"Jensen et al., JAMA Oncol 2021: clonal haematopoiesis in DNA repair genes interfering with prostate cancer plasma cell-free DNA testing (69 men, paired whole-blood control)"},{"id":"ctdna-tumour-fraction","kind":"biomarker","name":"Circulating tumour DNA fraction (and what a negative plasma result means)","route":"/biomarkers/ctdna-tumour-fraction/","field":"links","label":"Jensen et al., JAMA Oncol 2021: clonal haematopoiesis in DNA repair genes interfering with prostate cancer plasma cell-free DNA testing (69 men, paired whole-blood control)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.7328","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2775174","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/","field":"links","label":"Sohal et al., SWOG S1505 (JAMA Oncology 2021)"},{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/","field":"outcomes.source (Overall survival at 2 years (eligible patients))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.2209","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2781889","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lung-map-s1400i-jama-oncol-2021","kind":"paper","name":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-lung-map-s1400i-jama-oncol-2021/","field":"links","label":"JAMA Oncol 2021"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","field":"links","label":"Gettinger et al., JAMA Oncology 2021: nivolumab plus ipilimumab vs nivolumab for previously treated stage IV squamous cell lung cancer (Lung-MAP S1400I)"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","field":"outcomes.source (Overall survival)"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","field":"outcomes.source (Investigator-assessed progression-free survival)"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.2224","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","field":"papers","label":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma"},{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/","field":"links","label":"JAMA Oncol 2021"},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","field":"outcomes.source (Event-free survival at 5 years)"},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","field":"outcomes.source (Event-free survival at 5 years, group 3 medulloblastoma)"},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","field":"outcomes.source (Overall survival at 5 years, all evaluable participants)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.2915","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2783005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","field":"links","label":"CAVE: cetuximab plus avelumab as rechallenge therapy in RAS wild-type metastatic colorectal cancer (JAMA Oncology 2021)"},{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","field":"outcomes.source (Overall survival)"},{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","field":"outcomes.source (Overall survival by baseline plasma RAS and BRAF status)"},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"papers","label":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.3523","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2783490","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","field":"links","label":"eXalt3 (JAMA Oncol 2021)"},{"id":"paper-nct02767804-jama-oncol-2021","kind":"paper","name":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-nct02767804-jama-oncol-2021/","field":"links","label":"JAMA Oncol 2021"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"links","label":"JAMA Oncology 2021"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"outcomes.source (Progression-free survival (blinded independent review, intent-to-treat))"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"outcomes.source (Intracranial response rate (blinded independent review, target brain metastases at baseline))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.3547","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2790727","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","field":"outcomes.source (Progression-free survival (blinded independent review))"},{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","field":"outcomes.source (Epistaxis (all grades))"},{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","field":"outcomes.source (Anaemia (all grades))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.3771","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2783766","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"papers","label":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial"},{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","field":"links","label":"PSMA-PreRP (JAMA Oncology 2021)"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"links","label":"JAMA Oncology 2021"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"outcomes.source (Sensitivity for pelvic nodal metastasis (per patient, nodal-region correlation, versus histopathology))"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"outcomes.source (Specificity for pelvic nodal metastasis (per patient, nodal-region correlation, versus histopathology))"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"outcomes.source (Positive predictive value for pelvic nodal metastasis)"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"outcomes.source (Negative predictive value for pelvic nodal metastasis)"},{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/","field":"links","label":"JAMA Oncology 2021"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.4158","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2784405","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"metrics (Grade 3-5 chemotherapy toxicity with geriatric assessment-driven intervention vs standard care (GAIN))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.4761","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2784882","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/","field":"links","label":"JAMA Oncol 2021"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.5148","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2785677","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"papers","label":"Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.7239","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2788567","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","field":"links","label":"Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","field":"metrics (Pathologist concordance in classifying HER2 IHC 0 vs 1+ (the HER2-low boundary) across 18 pathologists)"},{"id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-marker-stratified-default","kind":"idea","name":"Test the drug in biomarker-negative patients too, so the biomarker can be validated","route":"/ideas/idea-tr2-marker-stratified-default/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-bicr-discordance-public","kind":"idea","name":"Publish the disagreement between trial doctors and independent reviewers for every trial","route":"/ideas/idea-tr2-bicr-discordance-public/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-biomarker-evidence-grading","kind":"idea","name":"Label every biomarker claim with an evidence phase, like drugs","route":"/ideas/idea-tr2-biomarker-evidence-grading/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-preanalytics-in-report","kind":"idea","name":"Record how long tissue waited before fixation in every pathology report","route":"/ideas/idea-tr2-preanalytics-in-report/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-cutpoint-lock","kind":"idea","name":"Lock the biomarker cut-off before phase 3, and publish it","route":"/ideas/idea-tr2-cutpoint-lock/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-prospective-retrospective-path","kind":"idea","name":"A formal regulatory route for validating a biomarker on archived trial samples","route":"/ideas/idea-tr2-prospective-retrospective-path/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-biomarker-study-registry","kind":"idea","name":"Pre-register biomarker validation studies the way trials are registered","route":"/ideas/idea-tr2-biomarker-study-registry/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-label-assay-concordance","kind":"idea","name":"Drug labels must state which biomarker assays were validated and how they compare","route":"/ideas/idea-tr2-label-assay-concordance/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-biomarker-negative-arms","kind":"idea","name":"Randomised trials to test whether biomarker-negative patients really do not benefit","route":"/ideas/idea-tr2-biomarker-negative-arms/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-tr2-positivity-rate-surveillance","kind":"idea","name":"Monitor biomarker positivity rates across labs in real time to catch assay drift","route":"/ideas/idea-tr2-positivity-rate-surveillance/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"idea-moon-biomarker-validation-utility","kind":"idea","name":"A public biomarker validation utility with pre-diagnostic biobanks and blinded testing","route":"/ideas/idea-moon-biomarker-validation-utility/","field":"links","label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)"},{"id":"paper-fernandez-jama-oncol","kind":"paper","name":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","route":"/key-papers/paper-fernandez-jama-oncol/","field":"links","label":"JAMA Oncol 2022"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.0039","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2790373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alchemist-jama-oncol-2022","kind":"paper","name":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","route":"/key-papers/paper-alchemist-jama-oncol-2022/","field":"links","label":"JAMA Oncol 2022"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.1981","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2793565","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","kind":"paper","name":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","route":"/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/","field":"links","label":"Ricciuti et al., JAMA Oncol 2022: tumour mutational burden and PD-(L)1 blockade across PD-L1 levels in 1,552 patients"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.2319","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2794338","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alliance-a021501","kind":"trial","name":"Alliance A021501","route":"/trials/alliance-a021501/","field":"links","label":"Katz et al., A021501 (JAMA Oncology 2022)"},{"id":"alliance-a021501","kind":"trial","name":"Alliance A021501","route":"/trials/alliance-a021501/","field":"outcomes.source (Overall survival at 18 months (evaluable patients))"},{"id":"paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022","kind":"paper","name":"Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/","field":"links","label":"JAMA Oncol 2022"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.3829","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2795978","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","field":"links","label":"Conroy et al., PRODIGE 24 five-year outcomes (JAMA Oncology 2022)"},{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","field":"links","label":"Conroy et al., five-year outcomes of PRODIGE 24/CCTG PA6 (JAMA Oncology 2022)"},{"id":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","kind":"paper","name":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/","field":"links","label":"JAMA Oncol 2022"},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"papers","label":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.5843","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2797843","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mascia-jama-oncol","kind":"paper","name":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","route":"/key-papers/paper-mascia-jama-oncol/","field":"links","label":"JAMA Oncol 2023"},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"papers","label":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial"},{"id":"flash-research-accelerators","kind":"technology","name":"FLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)","route":"/technologies/flash-research-accelerators/","field":"links","label":"Mascia et al., Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 trial (JAMA Oncology 2023)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2022.6558","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2800541","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/","field":"links","label":"MIRAGE: MRI-guided versus CT-guided stereotactic body radiotherapy for prostate cancer (JAMA Oncology 2023)"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"papers","label":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial"},{"id":"paper-kishan-jama-oncol","kind":"paper","name":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","route":"/key-papers/paper-kishan-jama-oncol/","field":"links","label":"JAMA Oncol 2023"}]},{"url":"https://doi.org/10.1001/jamaoncol.2023.0016","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2802825","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"NIFTY updated analysis, JAMA Oncology 2023"},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","field":"links","label":"Hyung et al., JAMA Oncology 2023: NIFTY updated analysis"},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","field":"outcomes.source (Progression-free survival by masked independent central review (updated, re-read))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2023.1962","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2805800","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02864992-jama-oncol-2023-update","kind":"paper","name":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02864992-jama-oncol-2023-update/","field":"links","label":"JAMA Oncol 2023"}]},{"url":"https://doi.org/10.1001/jamaoncol.2023.3759","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2809872","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sound","kind":"trial","name":"SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound)","route":"/trials/sound/","field":"links","label":"SOUND (JAMA Oncology 2023)"},{"id":"sound","kind":"trial","name":"SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound)","route":"/trials/sound/","field":"outcomes.source (Distant disease-free survival at 5 years)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2023.5033","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2812294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/","field":"links","label":"Sharma et al., JAMA Oncology 2024: NeoPACT clinical and biomarker findings"},{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/","field":"outcomes.source (Pathological complete response)"},{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/","field":"outcomes.source (Event-free survival at 3 years)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2024.4879","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2826068","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-jama-oncol","kind":"paper","name":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","route":"/key-papers/paper-li-jama-oncol/","field":"links","label":"JAMA Oncol 2024"},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","field":"links","label":"FUMANBA-1 (JAMA Oncol 2024)"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"links","label":"JAMA Oncol 2024"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"outcomes.source (Overall response rate (efficacy-evaluable))"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"outcomes.source (Complete response or better)"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"outcomes.source (MRD negativity (10^-5))"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"outcomes.source (Progression-free survival at 12 months)"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"outcomes.source (Cytokine release syndrome, any grade)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2025.1916","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2835771","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/","field":"links","label":"JAMA Oncol 2025"}]},{"url":"https://doi.org/10.1001/jamaoncol.2025.2738","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2837869","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"outcomes.source (Weight change from baseline at 1 year)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2025.3700","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2839158","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-natalee-jama-oncol-2025-update","kind":"paper","name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","route":"/key-papers/paper-natalee-jama-oncol-2025-update/","field":"links","label":"JAMA Oncol 2025"}]},{"url":"https://doi.org/10.1001/jamaoncol.2025.4736","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2841674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"links","label":"Final results from HERIZON-BTC-01, JAMA Oncology 2026"}]},{"url":"https://doi.org/10.1001/jamaoncol.2026.2833","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2852936","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026","kind":"paper","name":"c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer","route":"/key-papers/paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026/","field":"links","label":"JAMA Oncology 2026"}]},{"url":"https://doi.org/10.1001/jamaoncol.2026.3329","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2853843","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/","field":"links","label":"JAMA Oncol 2026"}]},{"url":"https://doi.org/10.1001/jamaoto.2014.1570","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoto.2014.1570","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"metrics (Median overall survival gain of cancer drugs approved by FDA 2002-2014)"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"metrics (Median overall survival gain of cancer drugs approved by FDA 2002-2014)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"metrics (Median overall survival gain of cancer drugs approved by FDA 2002-2014)"}]},{"url":"https://doi.org/10.1001/jamasurg.2014.3848","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2014.3848","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"papers","label":"Sustainability and long-term effectiveness of the WHO surgical safety checklist combined with pulse oximetry in a resource-limited setting: two-year update from Moldova"}]},{"url":"https://doi.org/10.1001/jamasurg.2016.3642","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2016.3642","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Ethun, JAMA Surg 2017: timing of re-resection for incidental gallbladder cancer"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Ethun, JAMA Surg 2017: timing of re-resection for incidental gallbladder cancer"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Ethun, JAMA Surg 2017: timing of re-resection for incidental gallbladder cancer"},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Ethun et al., JAMA Surgery 2017: timing of re-resection for incidental gallbladder cancer (207 patients, 10 US centres)"},{"id":"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","kind":"paper","name":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium","route":"/key-papers/paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017/","field":"links","label":"JAMA Surg 2017"}]},{"url":"https://doi.org/10.1001/jamasurg.2018.1153","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2018.1153","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-patel-jama-surg","kind":"paper","name":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules","route":"/key-papers/paper-patel-jama-surg/","field":"links","label":"JAMA Surg 2018"},{"id":"afirma","kind":"drug","name":"Afirma Genomic Sequencing Classifier","route":"/drugs/afirma/","field":"links","label":"Afirma GSC validation (JAMA Surg 2018)"}]},{"url":"https://doi.org/10.1001/jamasurg.2018.1677","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2018.1677","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"MROC patient-reported outcomes at two years (JAMA Surgery 2018)"},{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","field":"links","label":"MROC long-term patient-reported outcomes (JAMA Surgery 2018)"},{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","field":"outcomes.source (Satisfaction with breasts at 2 years, adjusted difference on the BREAST-Q)"}]},{"url":"https://doi.org/10.1001/jamasurg.2018.1687","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2018.1687","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","field":"links","label":"MROC two-year complication rates (JAMA Surgery 2018)"},{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","field":"outcomes.source (Any complication within 2 years, deep inferior epigastric perforator flap against expander-implant)"},{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","field":"outcomes.source (Reconstruction failure within 2 years)"}]},{"url":"https://doi.org/10.1001/jamasurg.2020.5060","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamasurgery/fullarticle/2772854","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","field":"outcomes.source (SENTOR: sensitivity of the sentinel-node algorithm in intermediate/high-grade endometrial cancer)"}]},{"url":"https://doi.org/10.1001/jamasurg.2020.5618","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamasurgery/fullarticle/2774478","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"papers","label":"Laparoscopic Lavage vs Primary Resection for Acute Perforated Diverticulitis: Long-term Outcomes From the Scandinavian Diverticulitis (SCANDIV) Randomized Clinical Trial"}]},{"url":"https://doi.org/10.1001/jamasurg.2023.0198","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamasurgery/fullarticle/2803109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"PREHAB trial (JAMA Surg 2023)"},{"id":"paper-molenaar-jama-surg","kind":"paper","name":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial","route":"/key-papers/paper-molenaar-jama-surg/","field":"links","label":"JAMA Surg 2023"},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","field":"links","label":"Molenaar et al. (JAMA Surg 2023)"},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","field":"outcomes.source (Severe postoperative complications (Comprehensive Complication Index > 20))"},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","field":"outcomes.source (Medical complications)"},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","field":"outcomes.source (6-minute walking distance at 4 weeks post-operatively (change from baseline))"}]},{"url":"https://doi.org/10.1002/(SICI)1097-0258(19990915/30)18:17/18<2529::AID-SIM274>3.0.CO;2-5","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0258(19990915/30)18:17/18%3C2529::AID-SIM274%3E3.0.CO;2-5","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calibration","kind":"term","name":"Calibration: reliability diagrams and the Brier score","route":"/terms/calibration/","field":"links","label":"Graf et al., Assessment and comparison of prognostic classification schemes for survival data (Statistics in Medicine 1999)"}]},{"url":"https://doi.org/10.1002/1097-0142(197601)37:1<141::AID-CNCR2820370121>3.0.CO;2-Y","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197601)37:1%3C141::AID-CNCR2820370121%3E3.0.CO;2-Y","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nevin-gallbladder-carcinoma-staging-cancer-1976","kind":"paper","name":"Carcinoma of the gallbladder: staging, treatment, and prognosis","route":"/key-papers/paper-nevin-gallbladder-carcinoma-staging-cancer-1976/","field":"links","label":"Cancer 1976"}]},{"url":"https://doi.org/10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197603)37:3%3C1571::AID-CNCR2820370347%3E3.0.CO;2-L","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976","kind":"paper","name":"Kadish staging: olfactory neuroblastoma, a clinical analysis of 17 cases","route":"/key-papers/paper-kadish-olfactory-neuroblastoma-staging-cancer-1976/","field":"links","label":"Cancer 1976"}]},{"url":"https://doi.org/10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19811201)48:11%3C2485::AID-CNCR2820481123%3E3.0.CO;2-R","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-masaoka-thymoma-clinical-staging-cancer-1981","kind":"paper","name":"Masaoka staging: follow-up study of thymomas with special reference to their clinical stages","route":"/key-papers/paper-masaoka-thymoma-clinical-staging-cancer-1981/","field":"links","label":"Cancer 1981"}]},{"url":"https://doi.org/10.1002/1097-0142(19910501)67:9<2258::aid-cncr2820670908>3.0.co;2-g","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19910501)67:9%3C2258::AID-CNCR2820670908%3E3.0.CO;2-G","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"papers","label":"A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus"}]},{"url":"https://doi.org/10.1002/14651858.cd002285.pub2","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD002285.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ezzo-cochrane-database-syst-rev","kind":"paper","name":"Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","route":"/key-papers/paper-ezzo-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2006"}]},{"url":"https://doi.org/10.1002/14651858.CD002285.pub2","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD002285.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","field":"links","label":"Cochrane: acupuncture-point stimulation for chemotherapy-induced nausea or vomiting (2006)"}]},{"url":"https://doi.org/10.1002/14651858.cd003297.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD003297.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-horneber-cochrane-database-syst-rev","kind":"paper","name":"Mistletoe therapy in oncology","route":"/key-papers/paper-horneber-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2008"}]},{"url":"https://doi.org/10.1002/14651858.CD003297.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD003297.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","field":"links","label":"Cochrane: mistletoe therapy in oncology (2008)"}]},{"url":"https://doi.org/10.1002/14651858.CD003412.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD003412.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Choosing between surgery, curettage, freezing, a cream and photodynamic therapy)"},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"Thomson et al., interventions for basal cell carcinoma of the skin: Cochrane review of 52 randomised trials and 6,690 participants (2020)"}]},{"url":"https://doi.org/10.1002/14651858.cd004540.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004540.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-taixiang-cochrane-database-syst-rev","kind":"paper","name":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients","route":"/key-papers/paper-taixiang-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2005"}]},{"url":"https://doi.org/10.1002/14651858.CD004540.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004540.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"traditional-chinese-herbal-medicine","kind":"technology","name":"Traditional Chinese herbal medicine alongside treatment","route":"/technologies/traditional-chinese-herbal-medicine/","field":"links","label":"Cochrane: Chinese medical herbs for chemotherapy side effects in colorectal cancer patients (2005)"}]},{"url":"https://doi.org/10.1002/14651858.cd004597.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004597.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dewey-cochrane-database-syst-rev","kind":"paper","name":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","route":"/key-papers/paper-dewey-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2007"}]},{"url":"https://doi.org/10.1002/14651858.CD004597.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004597.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"omega3-epa-cachexia","kind":"technology","name":"Fish oil (EPA) for cancer weight loss","route":"/technologies/omega3-epa-cachexia/","field":"links","label":"Cochrane: eicosapentaenoic acid (EPA, an omega-3 fatty acid) for cancer cachexia (2007)"}]},{"url":"https://doi.org/10.1002/14651858.cd004845.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004845.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kassab-cochrane-database-syst-rev","kind":"paper","name":"Homeopathic medicines for adverse effects of cancer treatments","route":"/key-papers/paper-kassab-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2009"}]},{"url":"https://doi.org/10.1002/14651858.CD004845.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD004845.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"homeopathy-cancer","kind":"technology","name":"Homeopathy","route":"/technologies/homeopathy-cancer/","field":"links","label":"Cochrane: homeopathic medicines for adverse effects of cancer treatments (2009)"}]},{"url":"https://doi.org/10.1002/14651858.cd005004.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005004.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-filippini-cochrane-database-syst-rev","kind":"paper","name":"Green tea (Camellia sinensis) for the prevention of cancer","route":"/key-papers/paper-filippini-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2020"}]},{"url":"https://doi.org/10.1002/14651858.CD005004.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005004.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"green-tea-egcg","kind":"technology","name":"Green tea and EGCG extracts","route":"/technologies/green-tea-egcg/","field":"links","label":"Cochrane: green tea (Camellia sinensis) for the prevention of cancer (2020)"}]},{"url":"https://doi.org/10.1002/14651858.cd005005.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005005.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bennett-cochrane-database-syst-rev","kind":"paper","name":"Hyperbaric oxygen therapy for late radiation tissue injury","route":"/key-papers/paper-bennett-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2016"}]},{"url":"https://doi.org/10.1002/14651858.CD005005.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005005.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperbaric-oxygen-radiation-injury","kind":"technology","name":"Hyperbaric oxygen for late radiation injury","route":"/technologies/hyperbaric-oxygen-radiation-injury/","field":"links","label":"Cochrane: hyperbaric oxygen therapy for late radiation tissue injury (2016)"}]},{"url":"https://doi.org/10.1002/14651858.cd005476.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005476.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-milazzo-cochrane-database-syst-rev","kind":"paper","name":"Laetrile treatment for cancer","route":"/key-papers/paper-milazzo-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2015"}]},{"url":"https://doi.org/10.1002/14651858.CD005476.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD005476.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"laetrile-amygdalin","kind":"technology","name":"Laetrile (amygdalin, 'vitamin B17')","route":"/technologies/laetrile-amygdalin/","field":"links","label":"Cochrane: laetrile treatment for cancer (2015)"}]},{"url":"https://doi.org/10.1002/14651858.cd006911.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD006911.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev-2021","kind":"paper","name":"Music interventions for improving psychological and physical outcomes in people with cancer","route":"/key-papers/paper-bradt-cochrane-database-syst-rev-2021/","field":"links","label":"Cochrane Database Syst Rev 2021"}]},{"url":"https://doi.org/10.1002/14651858.CD006911.pub4","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD006911.pub4","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"music-therapy-cancer","kind":"technology","name":"Music therapy and music medicine","route":"/technologies/music-therapy-cancer/","field":"links","label":"Cochrane: music interventions for improving psychological and physical outcomes in people with cancer (2021)"}]},{"url":"https://doi.org/10.1002/14651858.cd007103.pub3","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD007103.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev","kind":"paper","name":"Dance/movement therapy for improving psychological and physical outcomes in cancer patients","route":"/key-papers/paper-bradt-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2015"}]},{"url":"https://doi.org/10.1002/14651858.CD007103.pub3","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD007103.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dance-movement-therapy","kind":"technology","name":"Dance and movement therapy","route":"/technologies/dance-movement-therapy/","field":"links","label":"Cochrane: dance/movement therapy for improving psychological and physical outcomes in cancer patients (2015)"}]},{"url":"https://doi.org/10.1002/14651858.cd007731.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD007731.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jin-cochrane-database-syst-rev","kind":"paper","name":"Ganoderma lucidum (Reishi mushroom) for cancer treatment","route":"/key-papers/paper-jin-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2016"}]},{"url":"https://doi.org/10.1002/14651858.CD007731.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD007731.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"medicinal-mushrooms-reishi-turkey-tail","kind":"technology","name":"Medicinal mushrooms: reishi, turkey tail, shiitake and others","route":"/technologies/medicinal-mushrooms-reishi-turkey-tail/","field":"links","label":"Cochrane: Ganoderma lucidum (reishi mushroom) for cancer treatment (2016)"}]},{"url":"https://doi.org/10.1002/14651858.cd008831.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD008831.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wei-cochrane-database-syst-rev","kind":"paper","name":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer","route":"/key-papers/paper-wei-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2018"}]},{"url":"https://doi.org/10.1002/14651858.CD008831.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD008831.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"probiotics-treatment-diarrhoea","kind":"technology","name":"Probiotics for chemotherapy and radiotherapy diarrhoea","route":"/technologies/probiotics-treatment-diarrhoea/","field":"links","label":"Cochrane: probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea (2018)"}]},{"url":"https://doi.org/10.1002/14651858.cd008879.pub2","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD008879.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-burden-cochrane-database-syst-rev","kind":"paper","name":"Pre-operative nutrition support in patients undergoing gastrointestinal surgery","route":"/key-papers/paper-burden-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2012"}]},{"url":"https://doi.org/10.1002/14651858.CD008879.pub2","status":403,"ok":false,"finalUrl":"https://doi.wiley.com/10.1002/14651858.CD008879.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immunonutrition-perioperative","kind":"technology","name":"Immunonutrition before cancer surgery","route":"/technologies/immunonutrition-perioperative/","field":"links","label":"Cochrane: immunonutrition in GI surgery"}]},{"url":"https://doi.org/10.1002/14651858.cd009873.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD009873.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shin-cochrane-database-syst-rev","kind":"paper","name":"Massage with or without aromatherapy for symptom relief in people with cancer","route":"/key-papers/paper-shin-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2016"}]},{"url":"https://doi.org/10.1002/14651858.CD009873.pub3","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD009873.pub3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aromatherapy-cancer","kind":"technology","name":"Aromatherapy","route":"/technologies/aromatherapy-cancer/","field":"links","label":"Cochrane: massage with or without aromatherapy for symptom relief in people with cancer (2016)"}]},{"url":"https://doi.org/10.1002/14651858.cd010802.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD010802.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cramer-cochrane-database-syst-rev","kind":"paper","name":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer","route":"/key-papers/paper-cramer-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2017"}]},{"url":"https://doi.org/10.1002/14651858.CD010802.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD010802.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","field":"links","label":"Cochrane: yoga for improving health-related quality of life, mental health and cancer-related symptoms in women with breast cancer (2017)"}]},{"url":"https://doi.org/10.1002/14651858.cd011552.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD011552.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-riley-cochrane-database-syst-rev","kind":"paper","name":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy","route":"/key-papers/paper-riley-cochrane-database-syst-rev/","field":"links","label":"Cochrane Database Syst Rev 2015"}]},{"url":"https://doi.org/10.1002/14651858.CD011552.pub2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1002/14651858.CD011552.pub2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oral-cryotherapy-mucositis","kind":"technology","name":"Oral cryotherapy (ice chips) to prevent mucositis","route":"/technologies/oral-cryotherapy-mucositis/","field":"links","label":"Cochrane: oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment (2015)"}]},{"url":"https://doi.org/10.1002/1878-0261.12155","status":403,"ok":false,"finalUrl":"https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12155","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-mol-oncol-2018","kind":"paper","name":"Emerging functions of the EGFR in cancer","route":"/key-papers/paper-egfr-glioblastoma-mol-oncol-2018/","field":"links","label":"Mol Oncol 2018"}]},{"url":"https://doi.org/10.1002/acm2.13533","status":403,"ok":false,"finalUrl":"https://aapm.onlinelibrary.wiley.com/doi/10.1002/acm2.13533","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"papers","label":"MR relaxation times of agar-based tissue-mimicking phantoms"}]},{"url":"https://doi.org/10.1002/ajh.24451","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ajh.24451","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1002/ajh.26301","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ajh.26301","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-am-j-hematol-2021","kind":"paper","name":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","route":"/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/","field":"links","label":"Am J Hematol 2021"}]},{"url":"https://doi.org/10.1002/ajmg.a.33139","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.33139","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"Evans et al., American Journal of Medical Genetics A 2010;152A(2):327 to 332: birth incidence and prevalence of tumour-prone syndromes, estimates from a UK family genetic register service"}]},{"url":"https://doi.org/10.1002/bco2.60","status":403,"ok":false,"finalUrl":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.60","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Ranasinha et al., BJUI Compass 2021: ductal adenocarcinoma of the prostate, a systematic review and meta-analysis of incidence, presentation, prognosis and management"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"links","label":"Ranasinha et al., BJUI Compass 2021: ductal adenocarcinoma of the prostate, a systematic review and meta-analysis of incidence, presentation, prognosis and management"}]},{"url":"https://doi.org/10.1002/bies.201100025","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/bies.201100025","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-soto-bioessays","kind":"paper","name":"The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory","route":"/key-papers/paper-soto-bioessays/","field":"links","label":"Bioessays 2011"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"links","label":"Soto and Sonnenschein, The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory (BioEssays 2011)"}]},{"url":"https://doi.org/10.1002/bies.201100049","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/bies.201100049","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vincent-bioessays","kind":"paper","name":"Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer","route":"/key-papers/paper-vincent-bioessays/","field":"links","label":"Bioessays 2012"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Vincent, Cancer: a de-repression of a default survival program common to all cells? (BioEssays 2012)"}]},{"url":"https://doi.org/10.1002/bies.201400070","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/bies.201400070","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lineweaver-bioessays","kind":"paper","name":"Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model","route":"/key-papers/paper-lineweaver-bioessays/","field":"links","label":"Bioessays 2014"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Lineweaver, Davies and Vincent, Targeting cancer's weaknesses (not its strengths): therapeutic strategies suggested by the atavistic model (BioEssays 2014)"}]},{"url":"https://doi.org/10.1002/bjs.11035","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/106/1/32/6092772","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"standardOfCare.guideline (T1b, T2 or T3, no metastases)"},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"port-site-metastasis","kind":"term","name":"Port-site metastasis","route":"/terms/port-site-metastasis/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","field":"links","label":"Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy"},{"id":"paper-soreide-incidental-gallbladder-cancer-review-bjs-2019","kind":"paper","name":"Systematic review of management of incidental gallbladder cancer after cholecystectomy","route":"/key-papers/paper-soreide-incidental-gallbladder-cancer-review-bjs-2019/","field":"links","label":"Br J Surg 2019"}]},{"url":"https://doi.org/10.1002/bjs.11379","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/107/3/289/6120893","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Open versus laparoscopic re-resection of incidental gallbladder cancer (BJS 2020, 255 patients)"}]},{"url":"https://doi.org/10.1002/bjs.1800691019","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/69/10/613/6186032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Heald, Br J Surg 1982: the mesorectum in rectal cancer surgery, the clue to pelvic recurrence?"},{"id":"paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982","kind":"paper","name":"The mesorectum in rectal cancer surgery: the clue to pelvic recurrence?","route":"/key-papers/paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982/","field":"links","label":"Br J Surg 1982"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"Heald, Br J Surg 1982: the mesorectum in rectal cancer surgery, the clue to pelvic recurrence?"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Heald, Br J Surg 1982: the mesorectum in rectal cancer surgery, the clue to pelvic recurrence?"}]},{"url":"https://doi.org/10.1002/bjs.5397","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/93/10/1232/6149642","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Verbeke, Br J Surg 2006: redefining the R1 resection in pancreatic cancer"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Verbeke, Br J Surg 2006: redefining the R1 resection in pancreatic cancer"}]},{"url":"https://doi.org/10.1002/bjs.7032","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/97/7/1110/6150535","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Morris, Br J Surg 2010: surgical management and outcomes of colorectal cancer liver metastases (England)"},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","field":"links","label":"Morris, Br J Surg 2010: surgical management and outcomes of colorectal cancer liver metastases (England)"}]},{"url":"https://doi.org/10.1002/bjs.9969","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/103/3/179/6136782","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","field":"links","label":"Giovinazzo, Br J Surg 2016: meta-analysis of portal and superior mesenteric vein resection in pancreatic resection (9,005 patients)"}]},{"url":"https://doi.org/10.1002/cam4.2474","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.2474","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"papers","label":"Are 90% of deaths from cancer caused by metastases?"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"links","label":"Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"metrics (Share of cancer deaths attributable to metastatic disease (registry-based analysis))"},{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-net-blockade-perioperative","kind":"idea","name":"Break the neutrophil DNA nets that catch tumour cells after surgery","route":"/ideas/idea-bio2-net-blockade-perioperative/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-perioperative-betablocker-nsaid","kind":"idea","name":"Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress","route":"/ideas/idea-bio2-perioperative-betablocker-nsaid/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-premetastatic-niche-assay","kind":"idea","name":"A blood test for the pre-metastatic niche","route":"/ideas/idea-bio2-premetastatic-niche-assay/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-inhaled-lung-niche-immunotherapy","kind":"idea","name":"Inhaled immune therapy to make the lung hostile to arriving tumour cells","route":"/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-liver-niche-kupffer-reprogramming","kind":"idea","name":"Reprogramme the liver's own immune cells to refuse metastases","route":"/ideas/idea-bio2-liver-niche-kupffer-reprogramming/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-cxcr4-mobilise-then-kill","kind":"idea","name":"Flush dormant cells out of bone marrow, then kill them","route":"/ideas/idea-bio2-cxcr4-mobilise-then-kill/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-platelet-cloak-aspirin-mrd","kind":"idea","name":"Strip the platelet coat off travelling tumour cells in ctDNA-positive patients","route":"/ideas/idea-bio2-platelet-cloak-aspirin-mrd/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","route":"/ideas/idea-bio2-matrix-stiffness-prevention/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"idea-moon-metastasis-prevention-indication","kind":"idea","name":"Metastasis prevention as a formal indication with its own trials and regulatory pathway","route":"/ideas/idea-moon-metastasis-prevention-indication/","field":"links","label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)"},{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/","field":"links","label":"Cancer Med 2019"}]},{"url":"https://doi.org/10.1002/cam4.3094","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.3094","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","field":"links","label":"Reverse swing-M phase 1 2020"},{"id":"paper-patil-mebendazole-glioma-phase-1-cancer-med-2020","kind":"paper","name":"Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma","route":"/key-papers/paper-patil-mebendazole-glioma-phase-1-cancer-med-2020/","field":"links","label":"Reverse swing-M phase 1 2020"}]},{"url":"https://doi.org/10.1002/cam4.3269","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.3269","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Vadhan-Raj et al., CASSINI pancreatic subgroup (Cancer Medicine 2020)"}]},{"url":"https://doi.org/10.1002/cam4.3686","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.3686","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/","field":"links","label":"Cancer Med 2021"},{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","field":"links","label":"RELIANCE (Cancer Med 2021)"},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/","field":"links","label":"Cancer Med 2021"},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1002/cam4.5336","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.5336","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"papers","label":"Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?"}]},{"url":"https://doi.org/10.1002/cam4.5893","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.5893","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","field":"papers","label":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma"},{"id":"paper-luca-gianni-cancer-med-2023","kind":"paper","name":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","route":"/key-papers/paper-luca-gianni-cancer-med-2023/","field":"links","label":"Cancer Med 2023"}]},{"url":"https://doi.org/10.1002/cam4.915","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.915","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Koshiol, Cancer Med 2016: Salmonella Typhi and gallbladder cancer, case-control and meta-analysis"},{"id":"salmonella-typhi-gallbladder-cancer","kind":"term","name":"Salmonella Typhi carriage and gallbladder cancer","route":"/terms/salmonella-typhi-gallbladder-cancer/","field":"links","label":"Koshiol et al., Cancer Med 2016: Salmonella Typhi and gallbladder cancer, case-control study and meta-analysis"},{"id":"paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016","kind":"paper","name":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","route":"/key-papers/paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016/","field":"links","label":"Cancer Med 2016"}]},{"url":"https://doi.org/10.1002/cncr.10638","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.10638","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kothari-paget-disease-nipple-multifocal-cancer-2002","kind":"paper","name":"Paget disease of the nipple as a marker of multifocal, higher-risk underlying breast cancer","route":"/key-papers/paper-kothari-paget-disease-nipple-multifocal-cancer-2002/","field":"links","label":"Cancer 2002"}]},{"url":"https://doi.org/10.1002/cncr.10798","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.10798","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"papers","label":"Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography"}]},{"url":"https://doi.org/10.1002/cncr.11407","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.11407","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","field":"links","label":"Swain et al., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials (Cancer 2003)"},{"id":"paper-swain-cancer","kind":"paper","name":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","route":"/key-papers/paper-swain-cancer/","field":"links","label":"Cancer 2003"}]},{"url":"https://doi.org/10.1002/cncr.22618","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.22618","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Bauer, Cancer 2007: the triple-negative phenotype in the California Cancer Registry"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Bauer, Cancer 2007: the triple-negative phenotype in the California Cancer Registry"},{"id":"paper-bauer-triple-negative-california-registry-cancer-2007","kind":"paper","name":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","route":"/key-papers/paper-bauer-triple-negative-california-registry-cancer-2007/","field":"links","label":"Cancer 2007"}]},{"url":"https://doi.org/10.1002/cncr.23930","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.23930","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Lin, Cancer 2008: sites of distant recurrence in metastatic triple-negative breast cancer, high incidence of CNS metastases"},{"id":"paper-lin-tnbc-cns-metastases-dfci-cancer-2008","kind":"paper","name":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","route":"/key-papers/paper-lin-tnbc-cns-metastases-dfci-cancer-2008/","field":"links","label":"Cancer 2008"}]},{"url":"https://doi.org/10.1002/cncr.24284","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.24284","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Criscione, Weinstock, Naylor et al., Cancer 2009;115(11):2523 to 2530: actinic keratoses, natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial (7,784 lesions in 169 participants)"}]},{"url":"https://doi.org/10.1002/cncr.25826","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.25826","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","field":"links","label":"Cancer 2011: TP53 R337H and paediatric choroid plexus carcinoma in southeast Brazil"}]},{"url":"https://doi.org/10.1002/cncr.27581","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.27581","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Lin, Cancer 2012: clinicopathological features, recurrence and survival of triple-negative breast cancer in NCCN centres"},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"links","label":"Lin, Cancer 2012: clinicopathological features, recurrence and survival of triple-negative breast cancer in NCCN centres"}]},{"url":"https://doi.org/10.1002/cncr.27674","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.27674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zibotentan","kind":"drug","name":"Zibotentan","route":"/drugs/zibotentan/","field":"links","label":"ENTHUSE M1 (Cancer 2012)"},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"links","label":"ENTHUSE M1 (Cancer 2012)"},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"outcomes.source (Overall survival (median))"},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"outcomes.source (Cardiac failure, any grade)"}]},{"url":"https://doi.org/10.1002/cncr.28461","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.28461","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1002/cncr.29032","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.29032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/","field":"links","label":"Messinger 2015, Cancer: 350 central pathology-confirmed pleuropulmonary blastoma cases, International PPB Registry"}]},{"url":"https://doi.org/10.1002/cncr.29062","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.29062","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-english-cancer","kind":"paper","name":"Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo","route":"/key-papers/paper-english-cancer/","field":"links","label":"Cancer 2015"},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"links","label":"Messinger 2015: PPB types and outcomes (Cancer)"},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"standardOfCare.guideline (Type II or III pleuropulmonary blastoma)"}]},{"url":"https://doi.org/10.1002/cncr.29567","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.29567","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"papers","label":"Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer"}]},{"url":"https://doi.org/10.1002/cncr.29649","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.29649","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","field":"links","label":"Cancer 2015: long-term visual outcome after chemotherapy for optic pathway glioma in children"}]},{"url":"https://doi.org/10.1002/cncr.30254","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30254","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-javle-biliary-ngs-cancer-2016","kind":"paper","name":"Biliary cancer: utility of next-generation sequencing for clinical management","route":"/key-papers/paper-javle-biliary-ngs-cancer-2016/","field":"links","label":"Javle et al., Cancer 2016: comprehensive genomic profiling of 554 biliary cancers including 85 gallbladder carcinomas"},{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1002/cncr.30321","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30321","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","field":"links","label":"Cancer 2017"},{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","field":"outcomes.source (Survival (overdose patients))"},{"id":"paper-vistogard-cancer-2017","kind":"paper","name":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","route":"/key-papers/paper-vistogard-cancer-2017/","field":"links","label":"Cancer 2017"},{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","field":"links","label":"Vistogard Studies 1 and 2 (Cancer 2017)"}]},{"url":"https://doi.org/10.1002/cncr.30473","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30473","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"links","label":"Cancer 2017: vulvar and vaginal melanoma, molecular analysis of 51 cases against 2,253 non-gynaecological melanomas"},{"id":"vaginal-melanoma","kind":"cancer","name":"Vaginal melanoma","route":"/cancers/vaginal-melanoma/","field":"links","label":"Cancer 2017: vulvar and vaginal melanoma, molecular analysis of 51 cases against 2,253 non-gynaecological melanomas"}]},{"url":"https://doi.org/10.1002/cncr.30496","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30496","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-promise-talhouk-cancer-2017","kind":"paper","name":"Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer","route":"/key-papers/paper-promise-talhouk-cancer-2017/","field":"links","label":"Cancer 2017"}]},{"url":"https://doi.org/10.1002/cncr.31850","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.31850","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/","field":"links","label":"Narayan et al., Cancer 2019: regional differences in gallbladder cancer mutations (Chile, Japan, United States)"},{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1002/cncr.32207","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32207","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Scott, Cancer 2019: triple-negative breast cancer disparities, US Cancer Statistics 2010 to 2014"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Scott, Cancer 2019: triple-negative breast cancer disparities, US Cancer Statistics 2010 to 2014"},{"id":"paper-scott-tnbc-disparities-uscs-cancer-2019","kind":"paper","name":"Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014","route":"/key-papers/paper-scott-tnbc-disparities-uscs-cancer-2019/","field":"links","label":"Cancer 2019"}]},{"url":"https://doi.org/10.1002/cncr.32552","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32552","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","field":"links","label":"Orgel 2020, Cancer: mixed-phenotype acute leukaemia, Children's Oncology Group cohort and research strategy"}]},{"url":"https://doi.org/10.1002/cncr.32881","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32881","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020","kind":"paper","name":"The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms","route":"/key-papers/paper-chicago-consensus-appendiceal-neoplasms-cancer-2020/","field":"links","label":"Cancer 2020"}]},{"url":"https://doi.org/10.1002/cncr.33100","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33100","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-elad-cancer","kind":"paper","name":"MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","route":"/key-papers/paper-elad-cancer/","field":"links","label":"Cancer 2020"},{"id":"glutamine-mucositis-neuropathy","kind":"technology","name":"Glutamine for mucositis and neuropathy","route":"/technologies/glutamine-mucositis-neuropathy/","field":"links","label":"MASCC/ISOO clinical practice guidelines for mucositis (Cancer 2020)"},{"id":"honey-radiation-mucositis","kind":"technology","name":"Honey for radiation mucositis","route":"/technologies/honey-radiation-mucositis/","field":"links","label":"MASCC/ISOO clinical practice guidelines for mucositis (Cancer 2020)"},{"id":"oral-cryotherapy-mucositis","kind":"technology","name":"Oral cryotherapy (ice chips) to prevent mucositis","route":"/technologies/oral-cryotherapy-mucositis/","field":"links","label":"MASCC/ISOO clinical practice guidelines for mucositis (Cancer 2020)"},{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/","field":"links","label":"MASCC/ISOO clinical practice guidelines for mucositis (Cancer 2020)"}]},{"url":"https://doi.org/10.1002/cncr.33247","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33247","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sirolimus-ehe-stacchiotti-cancer-2021","kind":"paper","name":"Activity of sirolimus in progressive epithelioid haemangioendothelioma (Italian Rare Cancer Network)","route":"/key-papers/paper-sirolimus-ehe-stacchiotti-cancer-2021/","field":"links","label":"Cancer 2021"}]},{"url":"https://doi.org/10.1002/cncr.35187","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","field":"links","label":"EA1131 patient-reported outcomes (Cancer 2024)"}]},{"url":"https://doi.org/10.1002/cncr.70292","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70292","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tamrakar-cancer","kind":"paper","name":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","route":"/key-papers/paper-tamrakar-cancer/","field":"links","label":"Cancer 2026"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","field":"links","label":"Cervical cancer elimination in India (Cancer 2026)"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","field":"access.source (IN)"}]},{"url":"https://doi.org/10.1002/cpt.2479","status":403,"ok":false,"finalUrl":"https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2479","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","field":"papers","label":"Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value"}]},{"url":"https://doi.org/10.1002/cpt.3596","status":403,"ok":false,"finalUrl":"https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3596","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","field":"papers","label":"Clinical Evidence 2030"}]},{"url":"https://doi.org/10.1002/gcc.20886","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.20886","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-errani-wwtr1-camta1-ehe-gcc-2011","kind":"paper","name":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid haemangioendothelioma","route":"/key-papers/paper-errani-wwtr1-camta1-ehe-gcc-2011/","field":"links","label":"Genes Chromosomes Cancer 2011"}]},{"url":"https://doi.org/10.1002/hon.3165_632","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3165_632","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","field":"links","label":"IMAGINE B-NHL subanalysis (Hematol Oncol 2023)"},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","field":"links","label":"IMAGINE B-NHL subanalysis (Hematol Oncol 2023)"}]},{"url":"https://doi.org/10.1002/hsr2.73080","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.73080","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Health Sci Rep 2026: lung cancer in never smokers, an underappreciated public health burden"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"Health Sci Rep 2026: lung cancer in never smokers, an underappreciated public health burden"}]},{"url":"https://doi.org/10.1002/ijc.21683","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.21683","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Randi, Int J Cancer 2006: gallbladder cancer worldwide, geographical distribution and risk factors"}]},{"url":"https://doi.org/10.1002/ijc.25794","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.25794","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Genkinger, Int J Cancer 2011: pooled analysis of 14 cohorts, body size and pancreatic cancer risk"}]},{"url":"https://doi.org/10.1002/ijc.26031","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.26031","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-langley-int-j-cancer","kind":"paper","name":"The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs","route":"/key-papers/paper-langley-int-j-cancer/","field":"links","label":"Int J Cancer 2011"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Langley and Fidler, The seed and soil hypothesis revisited: the role of tumor-stroma interactions in metastasis to different organs (International Journal of Cancer 2011)"}]},{"url":"https://doi.org/10.1002/ijc.27454","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.27454","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-serrated-adenocarcinoma","kind":"cancer","name":"Serrated adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-serrated-adenocarcinoma/","field":"links","label":"International Journal of Cancer 2012: serrated adenocarcinoma, oncogene mutations and MSI in 89 cases"}]},{"url":"https://doi.org/10.1002/ijc.27765","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.27765","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Krynitz et al., risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008, Swedish population-based study of 10,476 recipients (Int J Cancer 2013)"},{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"Krynitz et al., risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008, Swedish population-based study of 10,476 recipients (Int J Cancer 2013)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Krynitz et al., risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008, Swedish population-based study of 10,476 recipients (Int J Cancer 2013)"}]},{"url":"https://doi.org/10.1002/ijc.2910330108","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.2910330108","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","field":"links","label":"FNCLCC histopathological grading system (Trojani et al., Int J Cancer 1984)"},{"id":"paper-trojani-int-j-cancer","kind":"paper","name":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","route":"/key-papers/paper-trojani-int-j-cancer/","field":"links","label":"Int J Cancer 1984"}]},{"url":"https://doi.org/10.1002/ijc.29210","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.29210","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ferlay-globocan-2012-methods-ijc-2015","kind":"paper","name":"Ferlay 2015: sources, methods and major patterns in GLOBOCAN 2012","route":"/key-papers/paper-ferlay-globocan-2012-methods-ijc-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1002/ijc.30084","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.30084","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Pirie, Int J Cancer 2016: lung cancer in never smokers in the UK Million Women Study (634,039 never smokers, 1,469 lung cancers over 14 years)"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"Pirie, Int J Cancer 2016: lung cancer in never smokers in the UK Million Women Study (634,039 never smokers, 1,469 lung cancers over 14 years)"}]},{"url":"https://doi.org/10.1002/ijc.30152","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.30152","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/","field":"links","label":"International Journal of Cancer 2016: is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?"}]},{"url":"https://doi.org/10.1002/ijc.31937","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.31937","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ferlay-globocan-2018-methods-ijc-2019","kind":"paper","name":"Ferlay 2019: GLOBOCAN 2018 sources and methods","route":"/key-papers/paper-ferlay-globocan-2018-methods-ijc-2019/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1002/ijc.33013","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.33013","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"links","label":"Piha-Paul et al., Int J Cancer 2020: pembrolizumab for advanced biliary cancer, KEYNOTE-158 and KEYNOTE-028"},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"outcomes.source (Objective response rate, biliary adenocarcinoma cohort (independent central review))"},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"outcomes.source (Overall survival, biliary cohort)"},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"outcomes.source (Progression-free survival, biliary cohort)"}]},{"url":"https://doi.org/10.1002/ijc.33588","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.33588","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ferlay-cancer-statistics-2020-overview-ijc-2021","kind":"paper","name":"Ferlay 2021: cancer statistics for the year 2020, an overview","route":"/key-papers/paper-ferlay-cancer-statistics-2020-overview-ijc-2021/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1002/ijc.34424","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.34424","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/","field":"links","label":"Int J Cancer 2023"}]},{"url":"https://doi.org/10.1002/ijc.34850","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.34850","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ians-anal-cancer-screening-guidelines-ijc-2024","kind":"paper","name":"International Anal Neoplasia Society consensus guidelines for anal cancer screening","route":"/key-papers/paper-ians-anal-cancer-screening-guidelines-ijc-2024/","field":"links","label":"Int J Cancer 2024"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"links","label":"IANS screening guidelines 2024"}]},{"url":"https://doi.org/10.1002/ijc.70561","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.70561","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Int J Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (prostate at section 10.1)"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"Int J Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (prostate at section 10.1)"},{"id":"extraprostatic-extension","kind":"term","name":"Extraprostatic extension and seminal vesicle invasion","route":"/terms/extraprostatic-extension/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (prostate at section 10.1)"},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"breast-tumour-size-on-the-report","kind":"term","name":"Tumour size on a breast report, and why it differs from the scan","route":"/terms/breast-tumour-size-on-the-report/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"links","label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (prostate at section 10.1)"}]},{"url":"https://doi.org/10.1002/ijc.70592","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.70592","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/","field":"links","label":"Worthington et al., Int J Cancer 2026: early detection biomarkers for high-risk individuals, PRECEDE"}]},{"url":"https://doi.org/10.1002/ijgo.12610","status":403,"ok":false,"finalUrl":"https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.12610","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","kind":"paper","name":"FIGO Cancer Report 2018: cancer of the vagina","route":"/key-papers/paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018/","field":"links","label":"Int J Gynaecol Obstet 2018"}]},{"url":"https://doi.org/10.1002/ijgo.13877","status":403,"ok":false,"finalUrl":"https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.13877","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021","kind":"paper","name":"FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease","route":"/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/","field":"links","label":"Int J Gynaecol Obstet 2021"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"links","label":"FIGO cancer report: gestational trophoblastic disease (2021)"}]},{"url":"https://doi.org/10.1002/jat.70166","status":403,"ok":false,"finalUrl":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jat.70166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Yilmaz toxicity review 2026"},{"id":"paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026","kind":"paper","name":"Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management","route":"/key-papers/paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026/","field":"links","label":"Yilmaz toxicity review 2026"}]},{"url":"https://doi.org/10.1002/jbmr.4233","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jbmr/article/36/4/627-635/7516640","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/","field":"links","label":"UX023T-CL201 (J Bone Miner Res 2021)"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"links","label":"Journal of Bone and Mineral Research 2021"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"outcomes.source (Mean serum phosphorus at week 144 (tumour-induced osteomalacia cohort))"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"outcomes.source (Baseline fractures or pseudofractures fully healed at week 144)"},{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/","field":"links","label":"Journal of Bone and Mineral Research 2021"}]},{"url":"https://doi.org/10.1002/jcsm.12368","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12368","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"J Cachexia Sarcopenia Muscle 2019: the IMPACT study, early loss of skeletal muscle mass in advanced pancreatic cancer"}]},{"url":"https://doi.org/10.1002/jhbp.12187","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Shirai, J Hepatobiliary Pancreat Sci 2025: prevalence of pancreaticobiliary maljunction and gallbladder cancer incidence"},{"id":"anomalous-pancreaticobiliary-junction","kind":"term","name":"Anomalous pancreaticobiliary junction (pancreaticobiliary maljunction)","route":"/terms/anomalous-pancreaticobiliary-junction/","field":"links","label":"Shirai, J Hepatobiliary Pancreat Sci 2025: prevalence of pancreaticobiliary maljunction and gallbladder cancer incidence"}]},{"url":"https://doi.org/10.1002/jhbp.512","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.512","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"Kiriyama et al., Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (J Hepatobiliary Pancreat Sci 2018)"}]},{"url":"https://doi.org/10.1002/jhbp.593","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.593","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kim-t1b-gallbladder-cancer-international-jhbps-2018","kind":"paper","name":"Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study","route":"/key-papers/paper-kim-t1b-gallbladder-cancer-international-jhbps-2018/","field":"links","label":"J Hepatobiliary Pancreat Sci 2018"}]},{"url":"https://doi.org/10.1002/jhbp.870","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.870","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021","kind":"paper","name":"Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition","route":"/key-papers/paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021/","field":"links","label":"J Hepatobiliary Pancreat Sci 2021"}]},{"url":"https://doi.org/10.1002/jso.20527","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.20527","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplasia-dysplasia-carcinoma-sequence","kind":"term","name":"Metaplasia, dysplasia, carcinoma in situ: the flat route to gallbladder cancer","route":"/terms/metaplasia-dysplasia-carcinoma-sequence/","field":"links","label":"Roa et al., J Surg Oncol 2006: preneoplastic lesions in gallbladder cancer"},{"id":"intracholecystic-papillary-tubular-neoplasm","kind":"term","name":"Intracholecystic papillary-tubular neoplasm (ICPN)","route":"/terms/intracholecystic-papillary-tubular-neoplasm/","field":"links","label":"Roa et al., J Surg Oncol 2006: preneoplastic lesions in gallbladder cancer"},{"id":"paper-roa-gallbladder-preneoplastic-lesions-jso-2006","kind":"paper","name":"Preneoplastic lesions in gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-preneoplastic-lesions-jso-2006/","field":"links","label":"Roa et al., J Surg Oncol 2006: preneoplastic lesions in gallbladder cancer"}]},{"url":"https://doi.org/10.1002/jso.24065","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.24065","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"links","label":"Song, J Surg Oncol 2015: squamous and adenosquamous carcinoma of the gallbladder, 34 cases"}]},{"url":"https://doi.org/10.1002/jso.25112","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.25112","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"links","label":"Hester, J Surg Oncol 2018: comparative outcomes of adenosquamous carcinoma of the pancreas, National Cancer Database"}]},{"url":"https://doi.org/10.1002/jso.25269","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.25269","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adamantinoma","kind":"cancer","name":"Adamantinoma of bone","route":"/cancers/adamantinoma/","field":"links","label":"Journal of Surgical Oncology 2018: adamantinoma of bone, long-term follow-up of 46 consecutive patients"}]},{"url":"https://doi.org/10.1002/jso.26726","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.26726","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Chan, J Surg Oncol 2022: intraoperative frozen section for suspected gallbladder cancer (Liverpool)"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Chan, J Surg Oncol 2022: intraoperative frozen section for suspected gallbladder cancer (Liverpool)"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Chan, J Surg Oncol 2022: intraoperative frozen section for suspected gallbladder cancer (Liverpool)"}]},{"url":"https://doi.org/10.1002/jso.70163","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/jso.70163","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"surgical-margins-keratinocyte-cancer","kind":"term","name":"The margin in skin cancer surgery","route":"/terms/surgical-margins-keratinocyte-cancer/","field":"links","label":"Specimen shrinkage at every stage of processing (Journal of Surgical Oncology 2026)"}]},{"url":"https://doi.org/10.1002/mp.12810","status":403,"ok":false,"finalUrl":"https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.12810","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-miften-med-phys","kind":"paper","name":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","route":"/key-papers/paper-miften-med-phys/","field":"links","label":"Med Phys 2018"},{"id":"radiotherapy-qa-phantoms-dosimeters","kind":"technology","name":"Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)","route":"/technologies/radiotherapy-qa-phantoms-dosimeters/","field":"links","label":"Miften et al., AAPM Task Group 218: tolerance limits and methodologies for IMRT measurement-based verification QA (Medical Physics 2018)"}]},{"url":"https://doi.org/10.1002/mp.15532","status":403,"ok":false,"finalUrl":"https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.15532","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-al-hallaq-med-phys","kind":"paper","name":"AAPM task group report 302: Surface-guided radiotherapy","route":"/key-papers/paper-al-hallaq-med-phys/","field":"links","label":"Med Phys 2022"},{"id":"patient-positioning-surface-guidance-systems","kind":"technology","name":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","route":"/technologies/patient-positioning-surface-guidance-systems/","field":"links","label":"Al-Hallaq et al., AAPM Task Group 302: surface-guided radiotherapy (Medical Physics 2022)"}]},{"url":"https://doi.org/10.1002/onco.13690","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/26/4/292/6445553","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","field":"links","label":"Dilawari et al., does scalp cooling have the same efficacy in Black patients receiving chemotherapy for breast cancer? (The Oncologist 2021)"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Dilawari et al., does scalp cooling have the same efficacy in Black patients receiving chemotherapy for breast cancer? (The Oncologist 2021)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Dilawari et al., does scalp cooling have the same efficacy in Black patients receiving chemotherapy for breast cancer? (The Oncologist 2021)"}]},{"url":"https://doi.org/10.1002/path.1808","status":403,"ok":false,"finalUrl":"https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.1808","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"micronodular-thymoma","kind":"cancer","name":"Micronodular thymoma with lymphoid stroma","route":"/cancers/micronodular-thymoma/","field":"links","label":"Journal of Pathology 2005: micronodular thymoma, abnormal chemokine expression and lymphoma development"}]},{"url":"https://doi.org/10.1002/path.2913","status":403,"ok":false,"finalUrl":"https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.2913","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-amary-idh-cartilaginous-tumours-j-pathol-2011","kind":"paper","name":"IDH1 and IDH2 mutations are frequent in central chondrosarcoma and central and periosteal chondromas","route":"/key-papers/paper-amary-idh-cartilaginous-tumours-j-pathol-2011/","field":"links","label":"J Pathol 2011"}]},{"url":"https://doi.org/10.1002/path.2919","status":403,"ok":false,"finalUrl":"https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.2919","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","field":"links","label":"Journal of Pathology 2011: OCT2, SSX and SAGE1 reveal the spermatogonial origin of spermatocytic seminoma"}]},{"url":"https://doi.org/10.1002/path.4679","status":403,"ok":false,"finalUrl":"https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4679","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","kind":"paper","name":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","route":"/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/","field":"links","label":"Richman et al., J Pathol 2016: HER2 amplification in 3,256 patients from QUASAR, FOCUS and PICCOLO"}]},{"url":"https://doi.org/10.1002/pbc.23349","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.23349","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","field":"links","label":"Pediatric Blood and Cancer 2012: choroid plexus tumours and Li-Fraumeni syndrome, Children's Hospital Los Angeles 1991 to 2010"}]},{"url":"https://doi.org/10.1002/pbc.24407","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.24407","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hesseling-pediatr-blood-cancer","kind":"paper","name":"Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting","route":"/key-papers/paper-hesseling-pediatr-blood-cancer/","field":"links","label":"Pediatr Blood Cancer 2013"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"links","label":"SIOP PODC adapted treatment guidelines for Burkitt lymphoma in low-income settings"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"standardOfCare.guideline (Resource-limited settings)"}]},{"url":"https://doi.org/10.1002/pbc.24433","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.24433","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"papers","label":"Children's Oncology Group's 2013 blueprint for research: neuroblastoma"}]},{"url":"https://doi.org/10.1002/pbc.29112","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.29112","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bien-pediatr-blood-cancer","kind":"paper","name":"Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations","route":"/key-papers/paper-bien-pediatr-blood-cancer/","field":"links","label":"Pediatr Blood Cancer 2021"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"links","label":"EXPeRT consensus on pancreatoblastoma (2021)"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"standardOfCare.guideline (Resectable at diagnosis)"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"standardOfCare.guideline (Unresectable at diagnosis)"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"standardOfCare.guideline (Metastatic or relapsed)"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"standardOfCare.guideline (Survivorship)"}]},{"url":"https://doi.org/10.1002/pbc.31876","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31876","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/","field":"links","label":"Gilene paediatric case 2025"}]},{"url":"https://doi.org/10.1002/pon.4551","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pon.4551","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"papers","label":"Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia"}]},{"url":"https://doi.org/10.1002/pon.5214","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pon.5214","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cillessen-psychooncology","kind":"paper","name":"Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials","route":"/key-papers/paper-cillessen-psychooncology/","field":"links","label":"Psychooncology 2019"},{"id":"mindfulness-based-interventions","kind":"technology","name":"Mindfulness-based stress reduction and cognitive therapy","route":"/technologies/mindfulness-based-interventions/","field":"links","label":"Mindfulness-based interventions for psychological and physical health outcomes in cancer: meta-analysis (Psycho-Oncology 2019)"}]},{"url":"https://doi.org/10.1002/pros.23484","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/pros.23484","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018","kind":"paper","name":"Intraductal and ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","route":"/key-papers/paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018/","field":"links","label":"Isaacsson Velho et al., The Prostate 2018: intraductal or ductal histology and lymphovascular invasion associated with germline DNA-repair gene mutations in 150 consecutively tested men"}]},{"url":"https://doi.org/10.1002/sim.4154","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1002/sim.4154","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"concordance-index","kind":"term","name":"C-index (concordance index), Harrell's and Uno's","route":"/terms/concordance-index/","field":"links","label":"Uno et al., On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data (Statistics in Medicine 2011)"}]},{"url":"https://doi.org/10.1002/ski2.61","status":403,"ok":false,"finalUrl":"https://academic.oup.com/skinhd/article/doi/10.1002/ski2.61/7733964","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Kwiatkowska et al., Skin Health and Disease 2021;1(4):e61: an updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013 to 2018"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"links","label":"Kwiatkowska et al., Skin Health and Disease 2021;1(4):e61: an updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013 to 2018"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Kwiatkowska et al., Skin Health and Disease 2021;1(4):e61: an updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013 to 2018"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Kwiatkowska et al., Skin Health and Disease 2021;1(4):e61: an updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013 to 2018"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Kwiatkowska et al., Skin Health and Disease 2021;1(4):e61: an updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013 to 2018"}]},{"url":"https://doi.org/10.1016/j.ejcts.2011.05.050","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ejcts/article-lookup/doi/10.1016/j.ejcts.2011.05.050","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/","field":"links","label":"Maeda 2012, Eur J Cardiothorac Surg: adenosquamous carcinoma of the lung, surgical results in 4,668 resections"}]},{"url":"https://doi.org/10.1016/j.ijscr.2017.07.002","status":403,"ok":false,"finalUrl":"https://journals.lww.com/01612930-201738000-00008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neuroendocrine-neoplasms-breast","kind":"cancer","name":"Neuroendocrine neoplasms of the breast","route":"/cancers/neuroendocrine-neoplasms-breast/","field":"links","label":"Int J Surg Case Rep 2017: primary small cell neuroendocrine carcinoma of the breast, case and review"}]},{"url":"https://doi.org/10.1016/j.jamcollsurg.2014.01.069","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00019464-201409000-00010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Butte et al., J Am Coll Surg 2014: residual disease predicts outcome after definitive resection (135 patients)"}]},{"url":"https://doi.org/10.1016/j.jamcollsurg.2017.11.026","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00019464-201806000-00027","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"DesJardins, J Am Coll Surg 2018: is observation of porcelain gallbladder safe"},{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","field":"links","label":"DesJardins, J Am Coll Surg 2018: is observation of porcelain gallbladder safe"}]},{"url":"https://doi.org/10.1016/j.juro.2008.11.032","status":403,"ok":false,"finalUrl":"https://www.jurology.com/doi/10.1016/j.juro.2008.11.032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-8794","kind":"trial","name":"SWOG 8794","route":"/trials/swog-8794/","field":"links","label":"SWOG 8794 long-term follow-up (Journal of Urology 2009)"},{"id":"swog-8794","kind":"trial","name":"SWOG 8794","route":"/trials/swog-8794/","field":"outcomes.source (Metastasis-free survival)"},{"id":"swog-8794","kind":"trial","name":"SWOG 8794","route":"/trials/swog-8794/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S0020-7292(02)00063-2","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1016/S0020-7292%2802%2900063-2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002","kind":"paper","name":"FIGO staging for gestational trophoblastic neoplasia 2000","route":"/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/","field":"links","label":"Int J Gynaecol Obstet 2002"}]},{"url":"https://doi.org/10.1016/S0020-7292(06)60029-5","status":403,"ok":false,"finalUrl":"https://obgyn.onlinelibrary.wiley.com/doi/10.1016/S0020-7292%2806%2960029-5","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","kind":"paper","name":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","route":"/key-papers/paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006/","field":"links","label":"Int J Gynaecol Obstet 2006"}]},{"url":"https://doi.org/10.1021/acs.jmedchem.6b00975","status":403,"ok":false,"finalUrl":"https://pubs.acs.org/jmcmar/article/60/5/1620/697421/The-Essential-Medicinal-Chemistry-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nelson-j-med-chem","kind":"paper","name":"The Essential Medicinal Chemistry of Curcumin","route":"/key-papers/paper-nelson-j-med-chem/","field":"links","label":"J Med Chem 2017"},{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","field":"links","label":"The essential medicinal chemistry of curcumin (J Med Chem 2017)"}]},{"url":"https://doi.org/10.1021/bc0502917","status":403,"ok":false,"finalUrl":"https://pubs.acs.org/doi/10.1021/bc0502917","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-doronina-bioconjug-chem","kind":"paper","name":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","route":"/key-papers/paper-doronina-bioconjug-chem/","field":"links","label":"Bioconjug Chem 2006"},{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","field":"links","label":"mcMMAF non-cleavable linker (Doronina et al., Bioconjugate Chem 2006)"}]},{"url":"https://doi.org/10.1021/bc100480a","status":403,"ok":false,"finalUrl":"https://pubs.acs.org/doi/10.1021/bc100480a","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kellogg-bioconjug-chem","kind":"paper","name":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","route":"/key-papers/paper-kellogg-bioconjug-chem/","field":"links","label":"Bioconjug Chem 2011"},{"id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","field":"links","label":"Disulfide-linked antibody-maytansinoid conjugates incl. sulfo-SPDB (Kellogg et al., Bioconjugate Chem 2011)"}]},{"url":"https://doi.org/10.1021/jm020017n","status":403,"ok":false,"finalUrl":"https://pubs.acs.org/doi/10.1021/jm020017n","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-veber-oral-bioavailability-jmedchem-2002","kind":"paper","name":"Veber 2002: molecular properties that influence the oral bioavailability of drug candidates","route":"/key-papers/paper-veber-oral-bioavailability-jmedchem-2002/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1021/jm060319f","status":403,"ok":false,"finalUrl":"https://pubs.acs.org/doi/10.1021/jm060319f","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-widdison-j-med-chem","kind":"paper","name":"Semisynthetic maytansine analogues for the targeted treatment of cancer","route":"/key-papers/paper-widdison-j-med-chem/","field":"links","label":"J Med Chem 2006"},{"id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","field":"links","label":"Semisynthetic maytansine analogues incl. DM4 (Widdison et al., J Med Chem 2006)"}]},{"url":"https://doi.org/10.1038/sj.jcbfm.9600433","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1038/sj.jcbfm.9600433","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","field":"papers","label":"Cerebral Glutamine and Glutamate Levels in Relation to Compromised Energy Metabolism: A Microdialysis Study in Subarachnoid Hemorrhage Patients"}]},{"url":"https://doi.org/10.1039/d0cs00556h","status":403,"ok":false,"finalUrl":"https://pubs.rsc.org/cs/article/50/3/1480-1494/681982","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cooper-chem-soc-rev","kind":"paper","name":"Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)","route":"/key-papers/paper-cooper-chem-soc-rev/","field":"links","label":"Chem Soc Rev 2021"}]},{"url":"https://doi.org/10.1039/D0CS00556H","status":403,"ok":false,"finalUrl":"https://pubs.rsc.org/cs/article/50/3/1480-1494/681982","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","field":"links","label":"Cooper et al., Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (Chemical Society Reviews 2021)"}]},{"url":"https://doi.org/10.1046/j.1365-2184.2000.00177.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2184.2000.00177.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-swanson-cell-prolif","kind":"paper","name":"A quantitative model for differential motility of gliomas in grey and white matter","route":"/key-papers/paper-swanson-cell-prolif/","field":"links","label":"Cell Prolif 2000"},{"id":"reaction-diffusion-glioma-model","kind":"technology","name":"Proliferation-invasion (reaction-diffusion) models of glioma","route":"/technologies/reaction-diffusion-glioma-model/","field":"links","label":"Swanson, Alvord and Murray 2000, Cell Proliferation"}]},{"url":"https://doi.org/10.1046/j.1440-1746.2003.03066.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1046/j.1440-1746.2003.03066.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Malik, J Gastroenterol Hepatol 2003: 233 gallbladder cancers in Pakistan"}]},{"url":"https://doi.org/10.1046/j.1524-4741.2003.09409.x","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.1046/j.1524-4741.2003.09409.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","field":"links","label":"Breast Journal 2003: tubular carcinoma of the breast, institutional experience and review"}]},{"url":"https://doi.org/10.1056/evidoa2100056","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2100056","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barnabas-nejm-evid","kind":"paper","name":"Efficacy of single-dose HPV vaccination among young African women","route":"/key-papers/paper-barnabas-nejm-evid/","field":"links","label":"NEJM Evid 2022"}]},{"url":"https://doi.org/10.1056/EVIDoa2100056","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2100056","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/","field":"links","label":"KEN SHE single-dose HPV vaccine trial (NEJM Evidence 2022)"}]},{"url":"https://doi.org/10.1056/EVIDoa2100070","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2100070","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"outcomes.source (Overall survival)"},{"id":"paper-himalaya-nejm-evidence-2022","kind":"paper","name":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","route":"/key-papers/paper-himalaya-nejm-evidence-2022/","field":"links","label":"NEJM Evid 2022"}]},{"url":"https://doi.org/10.1056/EVIDoa2200006","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200006","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","field":"outcomes.source (Undetectable MRD in bone marrow at 3 months post-treatment)"}]},{"url":"https://doi.org/10.1056/EVIDoa2200008","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/","field":"links","label":"NEJM Evid 2022"}]},{"url":"https://doi.org/10.1056/EVIDoa2200015","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200015","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"outcomes.source (Overall survival (updated))"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"outcomes.source (24-month overall survival)"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"outcomes.source (Overall survival (primary analysis))"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"TOPAZ-1 (NEJM Evidence 2022)"},{"id":"paper-topaz-1-nejm-evidence-2022","kind":"paper","name":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","route":"/key-papers/paper-topaz-1-nejm-evidence-2022/","field":"links","label":"NEJM Evid 2022"}]},{"url":"https://doi.org/10.1056/evidoa2200043","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200043","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-clarke-nejm-evid","kind":"paper","name":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-clarke-nejm-evid/","field":"links","label":"NEJM Evid 2022"}]},{"url":"https://doi.org/10.1056/EVIDoa2200043","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200043","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","field":"links","label":"PROpel: abiraterone and olaparib for metastatic castration-resistant prostate cancer (NEJM Evidence 2022)"}]},{"url":"https://doi.org/10.1056/evidoa2200167","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200167","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chamie-nejm-evid","kind":"paper","name":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","route":"/key-papers/paper-chamie-nejm-evid/","field":"links","label":"NEJM Evid 2023"}]},{"url":"https://doi.org/10.1056/EVIDoa2200167","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200167","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","field":"outcomes.source (Complete response rate (CIS))"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","field":"links","label":"QUILT-3.032 (NEJM Evidence 2023)"}]},{"url":"https://doi.org/10.1056/evidoa2200239","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200239","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/","field":"links","label":"NEJM Evid 2023"}]},{"url":"https://doi.org/10.1056/evidoa2200333","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200333","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-smith-nejm-evid","kind":"paper","name":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","route":"/key-papers/paper-smith-nejm-evid/","field":"links","label":"NEJM Evid 2023"}]},{"url":"https://doi.org/10.1056/EVIDoa2200333","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200333","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","field":"links","label":"INSITE (NEJM Evidence 2023)"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"links","label":"NEJM Evidence 2023"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"outcomes.source (Patients in whom fluorescence-guided margins removed residual cancer after standard lumpectomy)"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"outcomes.source (Per-margin specificity)"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"outcomes.source (Per-margin sensitivity)"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"outcomes.source (Second surgeries avoided among patients with positive margins)"}]},{"url":"https://doi.org/10.1056/EVIDoa2200339","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2200339","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","kind":"paper","name":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","route":"/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/","field":"links","label":"NEJM Evid 2023"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"links","label":"PIONEER: avapritinib in indolent SM (NEJM Evidence 2023)"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"standardOfCare.guideline (Indolent SM, symptomatic)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"links","label":"PIONEER (NEJM Evidence 2023)"}]},{"url":"https://doi.org/10.1056/EVIDoa2300018","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2300018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Donovan et al., patient-reported outcomes 12 years after localized prostate cancer treatment (NEJM Evidence 2023)"},{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/","field":"links","label":"Donovan et al., patient-reported outcomes 12 years after localized prostate cancer treatment (NEJM Evidence 2023)"}]},{"url":"https://doi.org/10.1056/evidoa2300171","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/doi/10.1056/EVIDoa2300171","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/","field":"links","label":"NEJM Evid 2024"}]},{"url":"https://doi.org/10.1056/NEJM197104222841604","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM197104222841604","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971","kind":"paper","name":"Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumour appearance in young women","route":"/key-papers/paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971/","field":"links","label":"N Engl J Med 1971"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"links","label":"Herbst 1971 (NEJM)"}]},{"url":"https://doi.org/10.1056/NEJM198203043060906","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198203043060906","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"papers","label":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody"}]},{"url":"https://doi.org/10.1056/nejm198501173120301","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198501173120301","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-moertel-n-engl-j-med","kind":"paper","name":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","route":"/key-papers/paper-moertel-n-engl-j-med/","field":"links","label":"N Engl J Med 1985"}]},{"url":"https://doi.org/10.1056/NEJM198501173120301","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198501173120301","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/","field":"links","label":"High-dose vitamin C versus placebo in advanced cancer with no prior chemotherapy, randomised double-blind trial (NEJM 1985)"}]},{"url":"https://doi.org/10.1056/NEJM198503143121106","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198503143121106","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"papers","label":"Etoposide (VP-16-213). Current status of an active anticancer drug"}]},{"url":"https://doi.org/10.1056/nejm198612253152606","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198612253152606","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dvorak-n-engl-j-med","kind":"paper","name":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","route":"/key-papers/paper-dvorak-n-engl-j-med/","field":"links","label":"N Engl J Med 1986"}]},{"url":"https://doi.org/10.1056/NEJM198612253152606","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198612253152606","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Dvorak, Tumors: wounds that do not heal (NEJM 1986)"}]},{"url":"https://doi.org/10.1056/NEJM198706043162302","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198706043162302","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-williams-bep-vs-pvb-nejm-1987","kind":"paper","name":"Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide","route":"/key-papers/paper-williams-bep-vs-pvb-nejm-1987/","field":"links","label":"N Engl J Med 1987"}]},{"url":"https://doi.org/10.1056/nejm198710083171501","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198710083171501","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stamey-psa-serum-marker-nejm-1987","kind":"paper","name":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","route":"/key-papers/paper-stamey-psa-serum-marker-nejm-1987/","field":"links","label":"N Engl J Med 1987"}]},{"url":"https://doi.org/10.1056/nejm198809013190901","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198809013190901","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Vogelstein, N Engl J Med 1988: genetic alterations during colorectal tumour development (172 specimens)"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"links","label":"Vogelstein, N Engl J Med 1988: genetic alterations during colorectal tumour development (172 specimens)"}]},{"url":"https://doi.org/10.1056/NEJM198809013190901","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM198809013190901","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","kind":"paper","name":"Genetic alterations during colorectal-tumor development","route":"/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/","field":"links","label":"N Engl J Med 1988"}]},{"url":"https://doi.org/10.1056/NEJM199002083220602","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199002083220602","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990","kind":"paper","name":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","route":"/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/","field":"links","label":"N Engl J Med 1990"}]},{"url":"https://doi.org/10.1056/nejm199104253241702","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199104253241702","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-catalona-psa-screening-test-nejm-1991","kind":"paper","name":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","route":"/key-papers/paper-catalona-psa-screening-test-nejm-1991/","field":"links","label":"N Engl J Med 1991"}]},{"url":"https://doi.org/10.1056/NEJM199106133242402","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199106133242402","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-va-larynx-induction-chemotherapy-nejm-1991","kind":"paper","name":"Department of Veterans Affairs Laryngeal Cancer Study: induction chemotherapy plus radiation versus surgery plus radiation","route":"/key-papers/paper-va-larynx-induction-chemotherapy-nejm-1991/","field":"links","label":"N Engl J Med 1991"}]},{"url":"https://doi.org/10.1056/NEJM199301213280306","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199301213280306","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"papers","label":"Head and neck cancer"}]},{"url":"https://doi.org/10.1056/nejm199305133281901","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199305133281901","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Mandel, N Engl J Med 1993: reducing mortality from colorectal cancer by screening for faecal occult blood (Minnesota, 46,551 people)"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"Mandel, N Engl J Med 1993: reducing mortality from colorectal cancer by screening for faecal occult blood (Minnesota, 46,551 people)"},{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","field":"links","label":"Mandel, N Engl J Med 1993: reducing mortality from colorectal cancer by screening for faecal occult blood (Minnesota, 46,551 people)"}]},{"url":"https://doi.org/10.1056/NEJM199305133281901","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199305133281901","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"minnesota-fob","kind":"trial","name":"Minnesota Colon Cancer Control Study","route":"/trials/minnesota-fob/","field":"links","label":"Minnesota: reducing mortality from colorectal cancer by screening for fecal occult blood (New England Journal of Medicine 1993)"},{"id":"minnesota-fob","kind":"trial","name":"Minnesota Colon Cancer Control Study","route":"/trials/minnesota-fob/","field":"outcomes.source (Cumulative colorectal cancer mortality at 13 years)"},{"id":"paper-minnesota-fobt-nejm-1993","kind":"paper","name":"Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third","route":"/key-papers/paper-minnesota-fobt-nejm-1993/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/nejm199312303292701","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199312303292701","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Winawer, N Engl J Med 1993: prevention of colorectal cancer by colonoscopic polypectomy (National Polyp Study, 1,418 patients)"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"links","label":"Winawer, N Engl J Med 1993: prevention of colorectal cancer by colonoscopic polypectomy (National Polyp Study, 1,418 patients)"}]},{"url":"https://doi.org/10.1056/NEJM199505253322101","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199505253322101","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995","kind":"paper","name":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","route":"/key-papers/paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995/","field":"links","label":"Taplin et al., N Engl J Med 1995: androgen-receptor gene mutation in metastatic androgen-independent prostate cancer (10 patients)"},{"id":"ar-ligand-binding-domain-mutation","kind":"biomarker","name":"AR ligand-binding-domain mutation (L702H, W742C, H875Y, T878A, F877L)","route":"/biomarkers/ar-ligand-binding-domain-mutation/","field":"links","label":"Taplin et al., N Engl J Med 1995: androgen-receptor gene mutation in metastatic androgen-independent prostate cancer (10 patients)"}]},{"url":"https://doi.org/10.1056/NEJM199603143341104","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199603143341104","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mazzaferro-milan-criteria-nejm-1996","kind":"paper","name":"Liver transplantation for small hepatocellular carcinomas in patients with cirrhosis (the Milan criteria)","route":"/key-papers/paper-mazzaferro-milan-criteria-nejm-1996/","field":"links","label":"N Engl J Med 1996"}]},{"url":"https://doi.org/10.1056/NEJM199605023341802","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199605023341802","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996","kind":"paper","name":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","route":"/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/","field":"links","label":"N Engl J Med 1996"}]},{"url":"https://doi.org/10.1056/NEJM199704033361402","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199704033361402","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997","kind":"paper","name":"Improved survival with preoperative radiotherapy in resectable rectal cancer (Swedish Rectal Cancer Trial)","route":"/key-papers/paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997/","field":"links","label":"N Engl J Med 1997"},{"id":"swedish-rectal-cancer-trial","kind":"trial","name":"Swedish Rectal Cancer Trial","route":"/trials/swedish-rectal-cancer-trial/","field":"links","label":"Swedish Rectal Cancer Trial: improved survival with preoperative radiotherapy in resectable rectal cancer (New England Journal of Medicine 1997)"},{"id":"swedish-rectal-cancer-trial","kind":"trial","name":"Swedish Rectal Cancer Trial","route":"/trials/swedish-rectal-cancer-trial/","field":"outcomes.source (Local recurrence at 5 years)"}]},{"url":"https://doi.org/10.1056/nejm199705153362001","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199705153362001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"links","label":"Struewing, N Engl J Med 1997: cancer risk with the BRCA1 and BRCA2 founder mutations among Ashkenazi Jews (5,318 volunteers)"}]},{"url":"https://doi.org/10.1056/NEJM199705153362001","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199705153362001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997","kind":"paper","name":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","route":"/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/","field":"links","label":"N Engl J Med 1997"}]},{"url":"https://doi.org/10.1056/NEJM199707313370502","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199707313370502","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bolla-eortc-22863-nejm-1997","kind":"paper","name":"EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer","route":"/key-papers/paper-bolla-eortc-22863-nejm-1997/","field":"links","label":"N Engl J Med 1997"}]},{"url":"https://doi.org/10.1056/nejm199710023371401","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199710023371401","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-overgaard-n-engl-j-med","kind":"paper","name":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial","route":"/key-papers/paper-overgaard-n-engl-j-med/","field":"links","label":"N Engl J Med 1997"}]},{"url":"https://doi.org/10.1056/NEJM199710023371401","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199710023371401","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/","field":"links","label":"NEJM 1997"}]},{"url":"https://doi.org/10.1056/NEJM199710093371501","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199710093371501","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tallman-atra-apl-nejm-1997","kind":"paper","name":"North American Intergroup: all-trans retinoic acid in acute promyelocytic leukaemia","route":"/key-papers/paper-tallman-atra-apl-nejm-1997/","field":"links","label":"N Engl J Med 1997"}]},{"url":"https://doi.org/10.1056/NEJM199901283400403","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199901283400403","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999","kind":"paper","name":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","route":"/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/","field":"links","label":"N Engl J Med 1999"},{"id":"turrisi-intergroup-0096","kind":"trial","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","route":"/trials/turrisi-intergroup-0096/","field":"links","label":"Intergroup 0096 (New England Journal of Medicine 1999)"},{"id":"turrisi-intergroup-0096","kind":"trial","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","route":"/trials/turrisi-intergroup-0096/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"turrisi-intergroup-0096","kind":"trial","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","route":"/trials/turrisi-intergroup-0096/","field":"outcomes.source (Grade 3 oesophagitis)"}]},{"url":"https://doi.org/10.1056/NEJM199904153401502","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199904153401502","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999","kind":"paper","name":"GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-rose-cisplatin-chemoradiation-cervical-nejm-1999/","field":"links","label":"N Engl J Med 1999"}]},{"url":"https://doi.org/10.1056/NEJM199908123410703","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199908123410703","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","kind":"paper","name":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","route":"/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/","field":"links","label":"N Engl J Med 1999"},{"id":"pci-overview-1999","kind":"trial","name":"Prophylactic Cranial Irradiation Overview (Auperin meta-analysis)","route":"/trials/pci-overview-1999/","field":"links","label":"Prophylactic Cranial Irradiation Overview (New England Journal of Medicine 1999)"},{"id":"pci-overview-1999","kind":"trial","name":"Prophylactic Cranial Irradiation Overview (Auperin meta-analysis)","route":"/trials/pci-overview-1999/","field":"outcomes.source (Overall survival at 3 years)"}]},{"url":"https://doi.org/10.1056/NEJM199910143411601","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199910143411601","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"papers","label":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group"}]},{"url":"https://doi.org/10.1056/nejm199912303412706","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199912303412706","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hutchins-n-engl-j-med","kind":"paper","name":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","route":"/key-papers/paper-hutchins-n-engl-j-med/","field":"links","label":"N Engl J Med 1999"}]},{"url":"https://doi.org/10.1056/NEJM199912303412706","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199912303412706","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"links","label":"Hutchins et al., Underrepresentation of patients 65 years of age or older in cancer-treatment trials (NEJM 1999)"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"metrics (Patients aged 65 or older in SWOG treatment trials 1993-1996 vs their share of US cancer incidence)"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"metrics (Patients aged 65 or older in SWOG treatment trials 1993-1996 vs their share of US cancer incidence)"}]},{"url":"https://doi.org/10.1056/nejm200010193431604","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM200010193431604","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"papers","label":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis"}]},{"url":"https://doi.org/10.1056/NEJM200103153441101","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM200103153441101","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"papers","label":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2"},{"id":"paper-slamon-trastuzumab-nejm-2001","kind":"paper","name":"Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer","route":"/key-papers/paper-slamon-trastuzumab-nejm-2001/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJM200104053441401","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM200104053441401","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","field":"papers","label":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia"},{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMc1609993","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMc1609993","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"papers","label":"Adaptive Randomization of Neratinib in Early Breast Cancer"}]},{"url":"https://doi.org/10.1056/nejmoa003216","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa003216","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"papers","label":"Oral Contraceptives and the Risk of Myocardial Infarction"}]},{"url":"https://doi.org/10.1056/nejmoa010187","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa010187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-macdonald-n-engl-j-med","kind":"paper","name":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","route":"/key-papers/paper-macdonald-n-engl-j-med/","field":"links","label":"N Engl J Med 2001"}]},{"url":"https://doi.org/10.1056/NEJMoa010187","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa010187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/","field":"links","label":"NEJM 2001"}]},{"url":"https://doi.org/10.1056/NEJMoa010580","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa010580","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001","kind":"paper","name":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)","route":"/key-papers/paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001/","field":"links","label":"N Engl J Med 2001"},{"id":"dutch-tme-trial","kind":"trial","name":"Dutch TME trial","route":"/trials/dutch-tme-trial/","field":"links","label":"Dutch TME trial: preoperative radiotherapy combined with total mesorectal excision (New England Journal of Medicine 2001)"},{"id":"dutch-tme-trial","kind":"trial","name":"Dutch TME trial","route":"/trials/dutch-tme-trial/","field":"outcomes.source (Local recurrence at 2 years)"}]},{"url":"https://doi.org/10.1056/nejmoa011871","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa011871","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-goodwin-n-engl-j-med","kind":"paper","name":"The effect of group psychosocial support on survival in metastatic breast cancer","route":"/key-papers/paper-goodwin-n-engl-j-med/","field":"links","label":"N Engl J Med 2001"}]},{"url":"https://doi.org/10.1056/NEJMoa011871","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa011871","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Supportive-expressive group therapy and survival in metastatic breast cancer (NEJM 2001)"}]},{"url":"https://doi.org/10.1056/NEJMoa011954","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa011954","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002","kind":"paper","name":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","route":"/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/","field":"links","label":"N Engl J Med 2002"}]},{"url":"https://doi.org/10.1056/NEJMoa020128","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa020128","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/","field":"links","label":"NSABP B-04 twenty-five-year follow-up (New England Journal of Medicine 2002)"},{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/","field":"outcomes.source (Death from any cause at 25 years, node-negative women: total mastectomy with radiation against radical mastectomy)"},{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/","field":"outcomes.source (Death from any cause at 25 years, node-negative women: total mastectomy alone against radical mastectomy)"},{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/","field":"outcomes.source (Death from any cause at 25 years, node-positive women)"}]},{"url":"https://doi.org/10.1056/NEJMoa020152","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa020152","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002","kind":"paper","name":"Germline mutations in nonsyndromic pheochromocytoma","route":"/key-papers/paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002/","field":"links","label":"N Engl J Med 2002"}]},{"url":"https://doi.org/10.1056/NEJMoa020461","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa020461","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-demetri-imatinib-gist-nejm-2002","kind":"paper","name":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours","route":"/key-papers/paper-demetri-imatinib-gist-nejm-2002/","field":"links","label":"N Engl J Med 2002"}]},{"url":"https://doi.org/10.1056/NEJMoa020989","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa020989","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-conserving-surgery-versus-mastectomy","kind":"term","name":"Breast conservation or mastectomy","route":"/terms/breast-conserving-surgery-versus-mastectomy/","field":"links","label":"Milan I at twenty years (New England Journal of Medicine 2002)"},{"id":"milan-i","kind":"trial","name":"Milan I (quadrantectomy against radical mastectomy)","route":"/trials/milan-i/","field":"links","label":"Milan I twenty-year follow-up (New England Journal of Medicine 2002)"},{"id":"milan-i","kind":"trial","name":"Milan I (quadrantectomy against radical mastectomy)","route":"/trials/milan-i/","field":"outcomes.source (Crude cumulative incidence of ipsilateral breast recurrence at 20 years)"},{"id":"milan-i","kind":"trial","name":"Milan I (quadrantectomy against radical mastectomy)","route":"/trials/milan-i/","field":"outcomes.source (Death from any cause at 20 years)"},{"id":"milan-i","kind":"trial","name":"Milan I (quadrantectomy against radical mastectomy)","route":"/trials/milan-i/","field":"outcomes.source (Death from breast cancer at 20 years)"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"Veronesi et al., twenty-year follow-up of breast-conserving surgery versus radical mastectomy, Milan trial (NEJM 2002)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Veronesi et al., twenty-year follow-up of breast-conserving surgery versus radical mastectomy, Milan trial (NEJM 2002)"}]},{"url":"https://doi.org/10.1056/NEJMoa021423","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa021423","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-calle-obesity-cancer-mortality-nejm-2003","kind":"paper","name":"Calle 2003: overweight, obesity and death from cancer in 900,000 US adults","route":"/key-papers/paper-calle-obesity-cancer-mortality-nejm-2003/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa022148","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa022148","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-swog-8710-neoadjuvant-mvac-nejm-2003","kind":"paper","name":"SWOG 8710: neoadjuvant MVAC chemotherapy before cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/","field":"links","label":"N Engl J Med 2003"}]},{"url":"https://doi.org/10.1056/NEJMoa022152","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa022152","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-conserving-surgery-versus-mastectomy","kind":"term","name":"Breast conservation or mastectomy","route":"/terms/breast-conserving-surgery-versus-mastectomy/","field":"links","label":"NSABP B-06 at twenty years (New England Journal of Medicine 2002)"},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/","field":"links","label":"NSABP B-06 twenty-year follow-up (New England Journal of Medicine 2002)"},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/","field":"outcomes.source (Cumulative incidence of recurrent tumour in the ipsilateral breast at 20 years)"},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/","field":"outcomes.source (Death from any cause at 20 years, lumpectomy alone against total mastectomy)"},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/","field":"outcomes.source (Death from any cause at 20 years, lumpectomy with irradiation against total mastectomy)"},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","field":"papers","label":"Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"Fisher et al., twenty-year follow-up of total mastectomy, lumpectomy, and lumpectomy plus irradiation, NSABP B-06 (NEJM 2002)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Fisher et al., twenty-year follow-up of total mastectomy, lumpectomy, and lumpectomy plus irradiation, NSABP B-06 (NEJM 2002)"}]},{"url":"https://doi.org/10.1056/NEJMoa022457","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa022457","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","field":"papers","label":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia"},{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa031237","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa031237","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shattuck-n-engl-j-med","kind":"paper","name":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","route":"/key-papers/paper-shattuck-n-engl-j-med/","field":"links","label":"N Engl J Med 2003"}]},{"url":"https://doi.org/10.1056/NEJMoa031237","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa031237","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","field":"links","label":"CDC73 in parathyroid carcinoma (NEJM 2003)"}]},{"url":"https://doi.org/10.1056/NEJMoa031317","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa031317","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-91-11-forastiere-nejm-2003","kind":"paper","name":"RTOG 91-11: concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","route":"/key-papers/paper-rtog-91-11-forastiere-nejm-2003/","field":"links","label":"N Engl J Med 2003"},{"id":"rtog-91-11","kind":"trial","name":"RTOG 91-11","route":"/trials/rtog-91-11/","field":"links","label":"NEJM 2003"}]},{"url":"https://doi.org/10.1056/NEJMoa031644","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa031644","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ialt","kind":"trial","name":"IALT (International Adjuvant Lung Cancer Trial)","route":"/trials/ialt/","field":"links","label":"IALT (New England Journal of Medicine 2004)"},{"id":"ialt","kind":"trial","name":"IALT (International Adjuvant Lung Cancer Trial)","route":"/trials/ialt/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa032295","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032295","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004","kind":"paper","name":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","route":"/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/","field":"links","label":"N Engl J Med 2004"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Neoptolemos et al., ESPAC-1 (NEJM 2004)"},{"id":"espac-1","kind":"trial","name":"ESPAC-1","route":"/trials/espac-1/","field":"links","label":"Neoptolemos et al., a randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, ESPAC-1 (NEJM 2004)"},{"id":"espac-1","kind":"trial","name":"ESPAC-1","route":"/trials/espac-1/","field":"outcomes.source (Overall survival at 5 years, chemotherapy factor)"},{"id":"espac-1","kind":"trial","name":"ESPAC-1","route":"/trials/espac-1/","field":"outcomes.source (Overall survival at 5 years, chemoradiotherapy factor)"}]},{"url":"https://doi.org/10.1056/NEJMoa032641","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032641","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bernier-eortc-22931-nejm-2004","kind":"paper","name":"EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer","route":"/key-papers/paper-bernier-eortc-22931-nejm-2004/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa032646","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032646","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cooper-rtog-9501-nejm-2004","kind":"paper","name":"RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma","route":"/key-papers/paper-cooper-rtog-9501-nejm-2004/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa032691","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032691","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/","field":"links","label":"AVF2107g: bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer (New England Journal of Medicine 2004)"},{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/","field":"outcomes.source (Overall survival)"},{"id":"paper-hurwitz-bevacizumab-crc-nejm-2004","kind":"paper","name":"Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life","route":"/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa032709","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032709","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa032709","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa032709","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/","field":"links","label":"N Engl J Med 2004"},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","field":"links","label":"MOSAIC: oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer (New England Journal of Medicine 2004)"},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","field":"outcomes.source (Disease-free survival at 3 years)"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","field":"links","label":"MOSAIC (NEJM 2004)"}]},{"url":"https://doi.org/10.1056/nejmoa040587","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040587","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hughes-n-engl-j-med","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","route":"/key-papers/paper-hughes-n-engl-j-med/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa040587","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040587","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","field":"links","label":"NEJM 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa040694","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040694","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004","kind":"paper","name":"Sauer 2004: chemoradiotherapy before rather than after surgery for rectal cancer (CAO/ARO/AIO-94)","route":"/key-papers/paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004/","field":"links","label":"Full text (DOI)"},{"id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","field":"links","label":"NEJM 2004"}]},{"url":"https://doi.org/10.1056/nejmoa040720","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040720","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa040720","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040720","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"links","label":"TAX 327 (New England Journal of Medicine 2004)"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","field":"links","label":"TAX 327 (New England Journal of Medicine 2004)"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","field":"outcomes.source (Overall survival (median))"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","field":"outcomes.source (Pain response)"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","field":"outcomes.source (Quality of life improvement)"}]},{"url":"https://doi.org/10.1056/nejmoa040766","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040766","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cristofanilli-n-engl-j-med","kind":"paper","name":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","route":"/key-papers/paper-cristofanilli-n-engl-j-med/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa040766","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040766","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cellsearch-ctc-count","kind":"technology","name":"CellSearch circulating tumour cell count","route":"/technologies/cellsearch-ctc-count/","field":"links","label":"New England Journal of Medicine 2004: Circulating tumor cells, disease progression, and survival in metastatic breast cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa040938","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa040938","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","kind":"paper","name":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/","field":"links","label":"N Engl J Med 2004"},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"papers","label":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"papers","label":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib"},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"papers","label":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib"}]},{"url":"https://doi.org/10.1056/nejmoa041318","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa041318","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","kind":"paper","name":"SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","route":"/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/","field":"links","label":"N Engl J Med 2004"}]},{"url":"https://doi.org/10.1056/NEJMoa041318","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa041318","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","field":"links","label":"SWOG 9916 (New England Journal of Medicine 2004)"},{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","field":"outcomes.source (Overall survival (median))"},{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","field":"outcomes.source (Time to progression (median))"}]},{"url":"https://doi.org/10.1056/NEJMoa041943","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa041943","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Shahinian et al., risk of fracture after androgen deprivation for prostate cancer (NEJM 2005)"},{"id":"treatment-induced-bone-loss","kind":"term","name":"Treatment-induced bone loss","route":"/terms/treatment-induced-bone-loss/","field":"links","label":"Shahinian et al., risk of fracture after androgen deprivation for prostate cancer (NEJM 2005)"}]},{"url":"https://doi.org/10.1056/NEJMoa041974","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa041974","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"papers","label":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype"},{"id":"paper-falini-npm1-nejm-2005","kind":"paper","name":"Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype","route":"/key-papers/paper-falini-npm1-nejm-2005/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa043330","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa043330","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","field":"papers","label":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma"},{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","field":"papers","label":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma"},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","field":"papers","label":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma"},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","field":"papers","label":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"links","label":"Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"metrics (Median overall survival in newly diagnosed glioblastoma with radiotherapy plus temozolomide (Stupp regimen), still the standard of care)"},{"id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-robotic-convection-delivery","kind":"idea","name":"Robot-placed catheters and live imaging for drug infusion into brain tumours","route":"/ideas/idea-bio2-robotic-convection-delivery/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-implanted-ultrasound-repeat-dosing","kind":"idea","name":"A skull ultrasound implant that opens the barrier at every cycle","route":"/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-csf-ctdna-monitoring","kind":"idea","name":"Read the spinal fluid to track brain tumours without opening the skull","route":"/ideas/idea-bio2-csf-ctdna-monitoring/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-brain-exposure-disclosure","kind":"idea","name":"Require every oncology candidate to publish how much reaches the brain","route":"/ideas/idea-bio2-brain-exposure-disclosure/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-intranasal-delivery","kind":"idea","name":"Deliver drugs and cells to the brain through the nose","route":"/ideas/idea-bio2-intranasal-delivery/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-blood-csf-barrier-model","kind":"idea","name":"Build a human model of the barrier that guards the brain fluid","route":"/ideas/idea-bio2-blood-csf-barrier-model/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-fus-for-cell-entry","kind":"idea","name":"Open the barrier so engineered immune cells can enter the brain","route":"/ideas/idea-bio2-fus-for-cell-entry/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"idea-moon-brain-delivery-platform","kind":"idea","name":"A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics","route":"/ideas/idea-moon-brain-delivery-platform/","field":"links","label":"Bottleneck evidence (The brain: barrier and sanctuary): Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (NEJM 2005)"},{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/","field":"links","label":"NEJM 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa043331","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa043331","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/","field":"links","label":"Hegi et al. NEJM 2005 (MGMT)"},{"id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/","field":"links","label":"Hegi et al. 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa043445","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa043445","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"papers","label":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma"}]},{"url":"https://doi.org/10.1056/NEJMoa043623","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa043623","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jbr-10","kind":"trial","name":"JBR.10 (NCIC CTG)","route":"/trials/jbr-10/","field":"links","label":"JBR.10 (New England Journal of Medicine 2005)"}]},{"url":"https://doi.org/10.1056/NEJMoa044238","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa044238","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/","field":"links","label":"N Engl J Med 2005"},{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/","field":"links","label":"Kobayashi et al., N Engl J Med 2005: EGFR T790M and resistance of non-small-cell lung cancer to gefitinib"}]},{"url":"https://doi.org/10.1056/NEJMoa050092","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa050092","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-curtin-melanoma-genetic-alterations-nejm-2005","kind":"paper","name":"Distinct sets of genetic alterations in melanoma","route":"/key-papers/paper-curtin-melanoma-genetic-alterations-nejm-2005/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/nejmoa050434","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa050434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braun-n-engl-j-med","kind":"paper","name":"A pooled analysis of bone marrow micrometastasis in breast cancer","route":"/key-papers/paper-braun-n-engl-j-med/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa050434","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa050434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"disseminated-tumor-cells","kind":"term","name":"Disseminated tumour cells (DTCs)","route":"/terms/disseminated-tumor-cells/","field":"links","label":"Braun et al., A pooled analysis of bone marrow micrometastasis in breast cancer (NEJM 2005)"}]},{"url":"https://doi.org/10.1056/nejmoa051113","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa051113","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kralovics-n-engl-j-med","kind":"paper","name":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","route":"/key-papers/paper-kralovics-n-engl-j-med/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa051113","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa051113","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","field":"links","label":"Kralovics 2005 (NEJM)"},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1056/nejmoa052122","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa052122","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa052122","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa052122","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","field":"outcomes.source (Disease-free survival (B-31/N9831))"}]},{"url":"https://doi.org/10.1056/nejmoa052306","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa052306","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","route":"/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/","field":"links","label":"N Engl J Med 2005"}]},{"url":"https://doi.org/10.1056/NEJMoa053422","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa053422","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bonner-cetuximab-radiotherapy-nejm-2006","kind":"paper","name":"Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck","route":"/key-papers/paper-bonner-cetuximab-radiotherapy-nejm-2006/","field":"links","label":"N Engl J Med 2006"},{"id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","field":"links","label":"NEJM 2006"}]},{"url":"https://doi.org/10.1056/NEJMoa061884","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa061884","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","kind":"paper","name":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","route":"/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/","field":"links","label":"N Engl J Med 2006"}]},{"url":"https://doi.org/10.1056/NEJMoa065447","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa065447","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"papers","label":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer"}]},{"url":"https://doi.org/10.1056/nejmoa070594","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa070594","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007","kind":"paper","name":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007/","field":"links","label":"N Engl J Med 2007"}]},{"url":"https://doi.org/10.1056/NEJMoa0707377","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0707377","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","field":"links","label":"MNTX 302 (NEJM 2008)"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"links","label":"NEJM 2008"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"outcomes.source (Laxation within 4 hours of the first dose)"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"outcomes.source (Laxation without rescue laxative within 4 hours after two or more of the first four doses)"},{"id":"paper-mntx-302-thomas-nejm-2008","kind":"paper","name":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","route":"/key-papers/paper-mntx-302-thomas-nejm-2008/","field":"links","label":"NEJM 2008"}]},{"url":"https://doi.org/10.1056/NEJMoa0708857","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0708857","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","field":"outcomes.source (Overall survival)"},{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","field":"outcomes.source (Time to radiologic progression)"},{"id":"paper-sharp-sorafenib-nejm-2008","kind":"paper","name":"SHARP: sorafenib in advanced hepatocellular carcinoma","route":"/key-papers/paper-sharp-sorafenib-nejm-2008/","field":"links","label":"N Engl J Med 2008"}]},{"url":"https://doi.org/10.1056/nejmoa071366","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa071366","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","field":"papers","label":"Hydrocortisone therapy for patients with septic shock"}]},{"url":"https://doi.org/10.1056/nejmoa071780","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa071780","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-slotman-n-engl-j-med","kind":"paper","name":"Prophylactic cranial irradiation in extensive small-cell lung cancer","route":"/key-papers/paper-slotman-n-engl-j-med/","field":"links","label":"N Engl J Med 2007"}]},{"url":"https://doi.org/10.1056/NEJMoa071780","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa071780","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/","field":"links","label":"NEJM 2007"}]},{"url":"https://doi.org/10.1056/NEJMoa071834","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa071834","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"co-17","kind":"trial","name":"NCIC CO.17","route":"/trials/co-17/","field":"links","label":"CO.17: cetuximab for the treatment of colorectal cancer (New England Journal of Medicine 2007)"},{"id":"co-17","kind":"trial","name":"NCIC CO.17","route":"/trials/co-17/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa0802656","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0802656","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-extreme-vermorken-nejm-2008","kind":"paper","name":"EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-extreme-vermorken-nejm-2008/","field":"links","label":"N Engl J Med 2008"}]},{"url":"https://doi.org/10.1056/NEJMoa0804385","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0804385","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kind":"paper","name":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","route":"/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/","field":"links","label":"Karapetis et al., N Engl J Med 2008: K-ras mutation and benefit from cetuximab (CO.17, 394 tumours)"},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","field":"papers","label":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa0805019","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0805019","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"links","label":"CRYSTAL: cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (New England Journal of Medicine 2009)"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"outcomes.source (CRYSTAL: progression-free survival (KRAS wild-type))"},{"id":"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","kind":"paper","name":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","route":"/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0808253","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0808253","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mullighan-ikzf1-nejm-2009","kind":"paper","name":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia","route":"/key-papers/paper-mullighan-ikzf1-nejm-2009/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0808516","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0808516","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","field":"papers","label":"HPV screening for cervical cancer in rural India (Osmanabad)"},{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/","field":"links","label":"Sankaranarayanan et al., NEJM 2009"},{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/","field":"outcomes.source (Cervical cancer deaths)"},{"id":"paper-sankaranarayanan-hpv-screening-nejm-2009","kind":"paper","name":"HPV screening for cervical cancer in rural India (Osmanabad)","route":"/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/","field":"links","label":"NEJM 2009"}]},{"url":"https://doi.org/10.1056/nejmoa0810084","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810084","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schroder-erspc-screening-mortality-nejm-2009","kind":"paper","name":"ERSPC: screening and prostate cancer mortality in a randomised European study","route":"/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/","field":"links","label":"N Engl J Med 2009"},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","field":"links","label":"Schroder et al., New England Journal of Medicine 2009 (ERSPC): screening and prostate cancer mortality in a randomised European study"},{"id":"number-needed-to-screen","kind":"term","name":"Number needed to screen (and number needed to diagnose)","route":"/terms/number-needed-to-screen/","field":"links","label":"Schroder et al., New England Journal of Medicine 2009 (ERSPC): screening and prostate cancer mortality in a randomised European study"}]},{"url":"https://doi.org/10.1056/NEJMoa0810084","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810084","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"links","label":"ERSPC at 9 years (New England Journal of Medicine 2009)"},{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"outcomes.source (Death from prostate cancer, core age group 55 to 69, median 9 years)"},{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"outcomes.source (Cumulative incidence of prostate cancer, median 9 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa0810095","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810095","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","field":"links","label":"EORTC 22961 (New England Journal of Medicine 2009)"},{"id":"eortc-22961","kind":"trial","name":"EORTC 22961","route":"/trials/eortc-22961/","field":"links","label":"EORTC 22961 (New England Journal of Medicine 2009)"},{"id":"eortc-22961","kind":"trial","name":"EORTC 22961","route":"/trials/eortc-22961/","field":"outcomes.source (Overall mortality at 5 years)"}]},{"url":"https://doi.org/10.1056/nejmoa0810118","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810118","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schmitz-n-engl-j-med","kind":"paper","name":"Weight lifting in women with breast-cancer-related lymphedema","route":"/key-papers/paper-schmitz-n-engl-j-med/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0810118","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810118","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"Weight lifting in women with breast-cancer-related lymphedema (NEJM 2009)"}]},{"url":"https://doi.org/10.1056/NEJMoa0810613","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810613","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","field":"outcomes.source (Complete resection (intention to treat))"},{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","field":"outcomes.source (Event-free survival at 3 years)"},{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","field":"outcomes.source (Acute grade 3 or 4 adverse events)"},{"id":"paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009","kind":"paper","name":"SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","route":"/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/nejmoa0810696","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810696","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andriole-plco-prostate-screening-nejm-2009","kind":"paper","name":"PLCO: mortality results from a randomised prostate cancer screening trial","route":"/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/","field":"links","label":"N Engl J Med 2009"},{"id":"number-needed-to-screen","kind":"term","name":"Number needed to screen (and number needed to diagnose)","route":"/terms/number-needed-to-screen/","field":"links","label":"Andriole et al., New England Journal of Medicine 2009 (PLCO): mortality results from a randomised prostate cancer screening trial"}]},{"url":"https://doi.org/10.1056/NEJMoa0810696","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810696","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","field":"links","label":"PLCO prostate mortality (New England Journal of Medicine 2009)"},{"id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","field":"outcomes.source (Death from prostate cancer at 7 years)"},{"id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","field":"outcomes.source (Prostate cancer incidence at 7 years)"}]},{"url":"https://doi.org/10.1056/nejmoa0810699","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810699","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0810699","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0810699","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","field":"links","label":"N Engl J Med 2009"},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","field":"papers","label":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","field":"links","label":"IPASS (NEJM 2009)"}]},{"url":"https://doi.org/10.1056/NEJMoa0902542","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0902542","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shah-foxl2-granulosa-nejm-2009","kind":"paper","name":"Mutation of FOXL2 in granulosa cell tumours of the ovary","route":"/key-papers/paper-shah-foxl2-granulosa-nejm-2009/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0902579","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0902579","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","field":"papers","label":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2"},{"id":"paper-plotkin-bevacizumab-nf2-nejm-2009","kind":"paper","name":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","route":"/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/","field":"links","label":"N Engl J Med 2009"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"links","label":"Bevacizumab in NF2 vestibular schwannomas (NEJM 2009)"}]},{"url":"https://doi.org/10.1056/nejmoa0906085","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0906085","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-van-klaveren-n-engl-j-med","kind":"paper","name":"Management of lung nodules detected by volume CT scanning","route":"/key-papers/paper-van-klaveren-n-engl-j-med/","field":"links","label":"N Engl J Med 2009"}]},{"url":"https://doi.org/10.1056/NEJMoa0906085","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0906085","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumour-doubling-time","kind":"technology","name":"Tumour volume doubling time","route":"/technologies/tumour-doubling-time/","field":"links","label":"NELSON volume-based management, van Klaveren 2009"}]},{"url":"https://doi.org/10.1056/nejmoa0907667","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0907667","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adenoma-detection-rate","kind":"term","name":"Adenoma detection rate","route":"/terms/adenoma-detection-rate/","field":"links","label":"Kaminski, N Engl J Med 2010: quality indicators for colonoscopy and the risk of interval cancer (45,026 people, 186 endoscopists)"},{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","field":"links","label":"Kaminski, N Engl J Med 2010: quality indicators for colonoscopy and the risk of interval cancer (45,026 people, 186 endoscopists)"}]},{"url":"https://doi.org/10.1056/NEJMoa0907667","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0907667","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010","kind":"paper","name":"Quality indicators for colonoscopy and the risk of interval cancer","route":"/key-papers/paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa0908721","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0908721","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"outcomes.source (Overall survival)"},{"id":"paper-abc-02-gemcitabine-cisplatin-nejm-2010","kind":"paper","name":"ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer","route":"/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/nejmoa0909530","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0909530","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-n-engl-j-med-2010","kind":"paper","name":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","route":"/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/nejmoa0910383","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa0910383","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011","kind":"paper","name":"Adjuvant trastuzumab in HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011/","field":"links","label":"N Engl J Med 2011"}]},{"url":"https://doi.org/10.1056/NEJMoa0911123","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0911123","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"papers","label":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma"},{"id":"paper-yu-anti-gd2-neuroblastoma-nejm-2010","kind":"paper","name":"Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)","route":"/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa0912217","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa0912217","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ang-hpv-oropharyngeal-nejm-2010","kind":"paper","name":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","route":"/key-papers/paper-ang-hpv-oropharyngeal-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa1000067","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1000067","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/","field":"links","label":"N Engl J Med 2010"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"links","label":"GHSG HD10 (NEJM 2010)"}]},{"url":"https://doi.org/10.1056/NEJMoa1000678","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1000678","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010)"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010)"},{"id":"pain-with-biliary-cancer","kind":"term","name":"Pain with gallbladder and bile duct cancer","route":"/terms/pain-with-biliary-cancer/","field":"links","label":"Temel et al., early palliative care in metastatic lung cancer (NEJM 2010)"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"links","label":"Temel et al., Early palliative care for patients with metastatic NSCLC (NEJM 2010)"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"metrics (Median overall survival with early palliative care vs standard care in metastatic NSCLC)"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Temel et al., early palliative care in metastatic lung cancer (NEJM 2010)"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010)"},{"id":"paper-temel-early-palliative-care-nejm-2010","kind":"paper","name":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","route":"/key-papers/paper-temel-early-palliative-care-nejm-2010/","field":"links","label":"DOI"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010)"}]},{"url":"https://doi.org/10.1056/nejmoa1001294","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1001294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kantoff-n-engl-j-med","kind":"paper","name":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","route":"/key-papers/paper-kantoff-n-engl-j-med/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa1001294","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1001294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","field":"links","label":"IMPACT (New England Journal of Medicine 2010)"},{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","field":"outcomes.source (Overall survival (median))"},{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","field":"outcomes.source (Survival at 36 months)"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","field":"links","label":"IMPACT (NEJM 2010)"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","field":"links","label":"IMPACT (New England Journal of Medicine 2010)"}]},{"url":"https://doi.org/10.1056/NEJMoa1001527","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1001527","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","kind":"paper","name":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa1002011","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1002011","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"papers","label":"Inhibition of mutated, activated BRAF in metastatic melanoma"}]},{"url":"https://doi.org/10.1056/nejmoa1002315","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1002315","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","field":"outcomes.source (Confirmed complete cytogenetic response by 12 months)"},{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","field":"outcomes.source (Major molecular response by 12 months)"},{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","field":"outcomes.source (Progression to accelerated or blast phase)"}]},{"url":"https://doi.org/10.1056/NEJMoa1003466","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1003466","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","field":"links","label":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma (New England Journal of Medicine 2010)"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"papers","label":"Improved survival with ipilimumab in patients with metastatic melanoma"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"papers","label":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma"},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"papers","label":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"papers","label":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma"},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1003825","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1003825","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-raymond-sunitinib-pnet-nejm-2011","kind":"paper","name":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumours","route":"/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/","field":"links","label":"N Engl J Med 2011"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"links","label":"Sunitinib in pancreatic NET (NEJM 2011)"}]},{"url":"https://doi.org/10.1056/NEJMoa1005143","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1005143","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","field":"prevalence.source"},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","field":"papers","label":"DNMT3A mutations in acute myeloid leukemia"}]},{"url":"https://doi.org/10.1056/NEJMoa1006448","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1006448","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","kind":"paper","name":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","route":"/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa1008433","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1008433","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wiegand-arid1a-clear-cell-nejm-2010","kind":"paper","name":"ARID1A mutations in endometriosis-associated ovarian carcinomas","route":"/key-papers/paper-wiegand-arid1a-clear-cell-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMoa1009290","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1009290","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"outcomes.source (Progression-free survival (RADIANT-3))"},{"id":"paper-radiant-3-everolimus-pnet-yao-nejm-2011","kind":"paper","name":"RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours","route":"/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/","field":"links","label":"N Engl J Med 2011"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"links","label":"RADIANT-3 (NEJM 2011)"}]},{"url":"https://doi.org/10.1056/NEJMoa1011923","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1011923","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Conroy et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, PRODIGE 4/ACCORD 11 (NEJM 2011)"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","field":"links","label":"Conroy et al., PRODIGE 4/ACCORD 11 (NEJM 2011)"},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","field":"links","label":"Conroy et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (NEJM 2011)"},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","field":"outcomes.source (Overall survival)"},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","field":"outcomes.source (Progression-free survival)"},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","field":"outcomes.source (Objective response rate)"},{"id":"paper-conroy-folfirinox-pancreatic-nejm-2011","kind":"paper","name":"Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","route":"/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1012348","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1012348","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"links","label":"RTOG 94-08 (New England Journal of Medicine 2011)"},{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"outcomes.source (Disease-specific mortality at 10 years)"},{"id":"paper-rtog-9408-short-term-adt-jones-nejm-2011","kind":"paper","name":"RTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer","route":"/key-papers/paper-rtog-9408-short-term-adt-jones-nejm-2011/","field":"links","label":"N Engl J Med 2011"}]},{"url":"https://doi.org/10.1056/nejmoa1014209","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1014209","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tiacci-n-engl-j-med","kind":"paper","name":"BRAF mutations in hairy-cell leukemia","route":"/key-papers/paper-tiacci-n-engl-j-med/","field":"links","label":"N Engl J Med 2011"}]},{"url":"https://doi.org/10.1056/NEJMoa1014209","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1014209","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","field":"links","label":"Tiacci 2011 NEJM"}]},{"url":"https://doi.org/10.1056/NEJMoa1014618","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1014618","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","field":"links","label":"COU-AA-301 (New England Journal of Medicine 2011)"},{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","field":"outcomes.source (Overall survival (median))"},{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"paper-cou-aa-301-abiraterone-de-bono-nejm-2011","kind":"paper","name":"COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel","route":"/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/","field":"links","label":"N Engl J Med 2011"}]},{"url":"https://doi.org/10.1056/nejmoa1100370","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1100370","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Zauber, N Engl J Med 2012: colonoscopic polypectomy and long-term prevention of colorectal cancer deaths (National Polyp Study, 2,602 patients)"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"links","label":"Zauber, N Engl J Med 2012: colonoscopic polypectomy and long-term prevention of colorectal cancer deaths (National Polyp Study, 2,602 patients)"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"Zauber, N Engl J Med 2012: colonoscopic polypectomy and long-term prevention of colorectal cancer deaths (National Polyp Study, 2,602 patients)"}]},{"url":"https://doi.org/10.1056/NEJMoa1100370","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1100370","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012","kind":"paper","name":"Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths (National Polyp Study)","route":"/key-papers/paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012/","field":"links","label":"N Engl J Med 2012"},{"id":"national-polyp-study","kind":"trial","name":"National Polyp Study","route":"/trials/national-polyp-study/","field":"links","label":"National Polyp Study: colonoscopic polypectomy and long-term prevention of colorectal cancer deaths (New England Journal of Medicine 2012)"},{"id":"national-polyp-study","kind":"trial","name":"National Polyp Study","route":"/trials/national-polyp-study/","field":"outcomes.source (Colorectal cancer mortality against the general population)"}]},{"url":"https://doi.org/10.1056/nejmoa1102873","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1102873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"},{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people)"}]},{"url":"https://doi.org/10.1056/NEJMoa1102873","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1102873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","route":"/people/harry-de-koning/","field":"papers","label":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"links","label":"NLST, Reduced lung-cancer mortality with low-dose CT screening (NEJM 2011)"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"metrics (Reduction in lung cancer mortality with low-dose CT screening vs chest X-ray in heavy smokers (NLST))"},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/NEJMoa1103782","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1103782","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","field":"papers","label":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation"},{"id":"paper-chapman-vemurafenib-nejm-2011","kind":"paper","name":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","route":"/key-papers/paper-chapman-vemurafenib-nejm-2011/","field":"links","label":"N Engl J Med 2011"}]},{"url":"https://doi.org/10.1056/NEJMoa1103849","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1103849","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"papers","label":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia"},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","field":"links","label":"First CLL patient report (Porter 2011)"}]},{"url":"https://doi.org/10.1056/nejmoa1109653","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1109653","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bolero-2-n-engl-j-med-2012","kind":"paper","name":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","route":"/key-papers/paper-bolero-2-n-engl-j-med-2012/","field":"links","label":"N Engl J Med 2012"},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","field":"outcomes.source (Progression-free survival, local investigator assessment (interim analysis))"},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","field":"outcomes.source (Progression-free survival, central assessment (interim analysis))"},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","field":"outcomes.source (Grade 3-4 stomatitis)"}]},{"url":"https://doi.org/10.1056/NEJMoa1110556","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1110556","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"comfort-ii","kind":"trial","name":"COMFORT-II","route":"/trials/comfort-ii/","field":"outcomes.source (Spleen volume reduction of 35% or more at week 48 (MRI or CT))"},{"id":"paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012","kind":"paper","name":"COMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","route":"/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/NEJMoa1110557","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1110557","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","field":"papers","label":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis"},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","field":"papers","label":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","field":"links","label":"COMFORT-I (NEJM 2012)"},{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/","field":"links","label":"Full text (DOI)"},{"id":"comfort-i","kind":"trial","name":"COMFORT-I","route":"/trials/comfort-i/","field":"outcomes.source (Spleen volume reduction of 35% or more at week 24 (MRI))"}]},{"url":"https://doi.org/10.1056/nejmoa1112088","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1112088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"papers","label":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1112088","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1112088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cross-nejm-2012","kind":"paper","name":"CROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer","route":"/key-papers/paper-cross-nejm-2012/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/NEJMoa1113205","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1113205","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"papers","label":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour"},{"id":"christina-curtis","kind":"person","name":"Christina Curtis","route":"/people/christina-curtis/","field":"papers","label":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"links","label":"Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"metrics (Somatic mutations not detectable across every region of a renal tumour (multi-region sequencing))"},{"id":"idea-bio1-ctdna-clone-report","kind":"idea","name":"A clone report from blood at every treatment cycle","route":"/ideas/idea-bio1-ctdna-clone-report/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-outlier-lesion-biopsy","kind":"idea","name":"Biopsy the one lesion that is growing while the others shrink","route":"/ideas/idea-bio1-outlier-lesion-biopsy/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-evolvability-index","kind":"idea","name":"A standard evolvability score for every tumour","route":"/ideas/idea-bio1-evolvability-index/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-collateral-sensitivity-atlas","kind":"idea","name":"An open atlas of collateral sensitivity for every approved targeted drug","route":"/ideas/idea-bio1-collateral-sensitivity-atlas/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-evolutionary-double-bind","kind":"idea","name":"Design drug pairs where resisting one makes you vulnerable to the other","route":"/ideas/idea-bio1-evolutionary-double-bind/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-methylation-clone-tracking","kind":"idea","name":"Track clones in blood with methylation patterns instead of mutations","route":"/ideas/idea-bio1-methylation-clone-tracking/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-clonal-clearance-endpoint","kind":"idea","name":"Make clonal clearance, not tumour shrinkage, a trial endpoint","route":"/ideas/idea-bio1-clonal-clearance-endpoint/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-evolution-forecasting","kind":"idea","name":"Forecast the next resistance mutation like the weather","route":"/ideas/idea-bio1-evolution-forecasting/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-apobec-inhibitor-adjunct","kind":"idea","name":"Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy","route":"/ideas/idea-bio1-apobec-inhibitor-adjunct/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-clone-to-lesion-mapping","kind":"idea","name":"Match each blood-detected clone to the lesion it comes from on the scan","route":"/ideas/idea-bio1-clone-to-lesion-mapping/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-rebiopsy-before-switch","kind":"idea","name":"Re-test the metastasis, not the old primary, before every change of treatment","route":"/ideas/idea-bio1-rebiopsy-before-switch/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"idea-bio1-clonal-neoantigen-vaccines","kind":"idea","name":"Vaccines aimed only at mutations shared by every tumour cell","route":"/ideas/idea-bio1-clonal-neoantigen-vaccines/","field":"links","label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)"},{"id":"paper-gerlinger-intratumour-heterogeneity-nejm-2012","kind":"paper","name":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","route":"/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/","field":"links","label":"DOI"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Gerlinger et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing (NEJM 2012)"}]},{"url":"https://doi.org/10.1056/nejmoa1113216","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1113216","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cleopatra-n-engl-j-med-2012","kind":"paper","name":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","route":"/key-papers/paper-cleopatra-n-engl-j-med-2012/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/NEJMoa1113713","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1113713","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","field":"papers","label":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma"},{"id":"hedgehog","kind":"pathway","name":"Hedgehog signalling","route":"/pathways/hedgehog/","field":"links","label":"Sekulic et al., Vismodegib in advanced basal-cell carcinoma (NEJM 2012)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"ERIVANCE (NEJM 2012)"},{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","field":"links","label":"ERIVANCE (NEJM 2012)"},{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/nejmoa1114885","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1114885","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","field":"links","label":"Koskela 2012, NEJM: somatic STAT3 mutations in large granular lymphocytic leukaemia"}]},{"url":"https://doi.org/10.1056/NEJMoa1200690","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1200690","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"papers","label":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"papers","label":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"papers","label":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer"},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"papers","label":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","field":"papers","label":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","field":"papers","label":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1200694","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1200694","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brahmer-anti-pd-l1-phase-1-nejm-2012","kind":"paper","name":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","route":"/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/","field":"links","label":"Brahmer et al., N Engl J Med 2012: anti-PD-L1 in 207 patients, none of 14 pancreatic responded"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/","field":"links","label":"Companion anti-PD-L1 paper (Brahmer 2012)"}]},{"url":"https://doi.org/10.1056/NEJMoa1200966","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1200966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"links","label":"FIRM-ACT (NEJM 2012)"},{"id":"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012","kind":"paper","name":"FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma","route":"/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/","field":"links","label":"N Engl J Med 2012"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"links","label":"FIRM-ACT (NEJM 2012)"}]},{"url":"https://doi.org/10.1056/nejmoa1204166","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1204166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","field":"outcomes.source (New cutaneous squamous cell carcinoma)"},{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","field":"outcomes.source (Serious adverse events per patient)"}]},{"url":"https://doi.org/10.1056/NEJMoa1204166","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1204166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"TUMORAPA (New England Journal of Medicine 2012)"},{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/","field":"links","label":"Euvrard et al., sirolimus and secondary skin-cancer prevention in kidney transplantation, TUMORAPA (New England Journal of Medicine 2012)"},{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","field":"links","label":"Primary report (New England Journal of Medicine 2012)"}]},{"url":"https://doi.org/10.1056/nejmoa1207506","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1207506","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/NEJMoa1207506","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1207506","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"links","label":"AFFIRM (New England Journal of Medicine 2012)"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"outcomes.source (Overall survival (median))"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"outcomes.source (PSA decline of 50 percent or more)"},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"papers","label":"Increased survival with enzalutamide in prostate cancer after chemotherapy"}]},{"url":"https://doi.org/10.1056/nejmoa1209096","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1209096","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-n-engl-j-med-2013","kind":"paper","name":"Abiraterone in metastatic prostate cancer without previous chemotherapy","route":"/key-papers/paper-abiraterone-acetate-prostate-n-engl-j-med-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/NEJMoa1209096","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1209096","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","field":"links","label":"COU-AA-302 (New England Journal of Medicine 2013)"},{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1056/NEJMoa1209825","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1209825","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"deep-inspiration-breath-hold","kind":"term","name":"Deep inspiration breath-hold (DIBH)","route":"/terms/deep-inspiration-breath-hold/","field":"links","label":"Major coronary events rise 7.4 percent per gray of mean heart dose (New England Journal of Medicine 2013)"}]},{"url":"https://doi.org/10.1056/NEJMoa1210093","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1210093","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"papers","label":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations"}]},{"url":"https://doi.org/10.1056/nejmoa1212299","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1212299","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013","kind":"paper","name":"SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer","route":"/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/","field":"links","label":"N Engl J Med 2013"},{"id":"intermittent-androgen-deprivation","kind":"term","name":"Intermittent androgen deprivation (IAD)","route":"/terms/intermittent-androgen-deprivation/","field":"links","label":"Hussain et al., New England Journal of Medicine 2013 (SWOG 9346): intermittent versus continuous androgen deprivation in metastatic prostate cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1212299","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1212299","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","field":"links","label":"SWOG 9346 (New England Journal of Medicine 2013)"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","field":"links","label":"SWOG 9346 (New England Journal of Medicine 2013)"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1056/NEJMoa1213755","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1213755","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"papers","label":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases"},{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/NEJMoa1214514","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1214514","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","route":"/targets/csf3r/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1056/NEJMoa1214561","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1214561","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013","kind":"paper","name":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","route":"/key-papers/paper-dunleavy-da-epoch-r-pmbcl-nejm-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/nejmoa1214886","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1214886","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alk-nsclc-n-engl-j-med-2013","kind":"paper","name":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","route":"/key-papers/paper-alk-nsclc-n-engl-j-med-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/NEJMoa1300720","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1300720","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-minnesota-fobt-nejm-1993","kind":"paper","name":"Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third","route":"/key-papers/paper-minnesota-fobt-nejm-1993/","field":"links","label":"30-year follow-up (Shaukat 2013)"}]},{"url":"https://doi.org/10.1056/NEJMoa1300874","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1300874","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","field":"papers","label":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia"},{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","field":"links","label":"APL0406 (NEJM 2013)"},{"id":"paper-apl0406-lo-coco-nejm-2013","kind":"paper","name":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia","route":"/key-papers/paper-apl0406-lo-coco-nejm-2013/","field":"links","label":"N Engl J Med 2013"},{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/","field":"outcomes.source (Event-free survival at 2 years)"},{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/","field":"outcomes.source (Complete remission)"}]},{"url":"https://doi.org/10.1056/NEJMoa1304369","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1304369","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Von Hoff et al., increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, MPACT (NEJM 2013)"},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"links","label":"Von Hoff et al., increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (NEJM 2013)"},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"outcomes.source (Overall survival)"},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"outcomes.source (Progression-free survival (independent review))"},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"outcomes.source (Grade 3 or worse peripheral neuropathy)"},{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1305275","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1305275","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/","field":"links","label":"Douillard, N Engl J Med 2013: PRIME, panitumumab with FOLFOX4 and RAS mutations in colorectal cancer (the extended RAS analysis)"},{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/","field":"links","label":"Douillard, N Engl J Med 2013: PRIME, panitumumab with FOLFOX4 and RAS mutations in colorectal cancer (the extended RAS analysis)"}]},{"url":"https://doi.org/10.1056/NEJMoa1305275","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1305275","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-douillard-prime-panitumumab-ras-nejm-2013","kind":"paper","name":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)","route":"/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/","field":"links","label":"N Engl J Med 2013"},{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","field":"links","label":"PRIME: panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (New England Journal of Medicine 2013)"},{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","field":"outcomes.source (Overall survival (RAS wild-type))"},{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","field":"outcomes.source (Progression-free survival (RAS wild-type))"},{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/","field":"links","label":"Douillard et al., PRIME extended RAS analysis (NEJM 2013)"}]},{"url":"https://doi.org/10.1056/NEJMoa1306494","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1306494","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pace-ponatinib-nejm-2013","kind":"paper","name":"PACE: ponatinib in Philadelphia chromosome-positive leukaemias resistant to earlier tyrosine kinase inhibitors","route":"/key-papers/paper-pace-ponatinib-nejm-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/nejmoa1308345","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1308345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","field":"papers","label":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma"},{"id":"paper-olivier-chinot-n-engl-j-med-2014","kind":"paper","name":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","route":"/key-papers/paper-olivier-chinot-n-engl-j-med-2014/","field":"links","label":"N Engl J Med 2014"},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","field":"outcomes.source (Progression-free survival (investigator-assessed))"},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","field":"outcomes.source (Overall survival)"},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","field":"outcomes.source (Grade 3 or higher adverse events)"}]},{"url":"https://doi.org/10.1056/nejmoa1309086","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1309086","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adenoma-detection-rate","kind":"term","name":"Adenoma detection rate","route":"/terms/adenoma-detection-rate/","field":"links","label":"Corley, N Engl J Med 2014: adenoma detection rate and risk of colorectal cancer and death (314,872 colonoscopies, 136 endoscopists)"},{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","field":"links","label":"Corley, N Engl J Med 2014: adenoma detection rate and risk of colorectal cancer and death (314,872 colonoscopies, 136 endoscopists)"}]},{"url":"https://doi.org/10.1056/NEJMoa1309748","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1309748","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","field":"papers","label":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer"},{"id":"paper-gog-240-bevacizumab-cervical-nejm-2014","kind":"paper","name":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","route":"/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/nejmoa1311194","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1311194","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1311194","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1311194","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","field":"links","label":"N Engl J Med 2014"},{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","field":"links","label":"DeeP-C (NEJM 2014)"},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","field":"links","label":"DeeP-C (NEJM 2014)"},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","field":"outcomes.source (Sensitivity for colorectal cancer)"}]},{"url":"https://doi.org/10.1056/nejmoa1315815","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1315815","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","field":"links","label":"Antonarakis et al., New England Journal of Medicine 2014: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer"},{"id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1315815","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1315815","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/","field":"links","label":"Antonarakis et al., N Engl J Med 2014: AR-V7 in circulating tumour cells and resistance to enzalutamide and abiraterone (62 patients)"}]},{"url":"https://doi.org/10.1056/NEJMoa1316158","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1316158","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1400376","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1400376","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","field":"outcomes.source (Progression-free survival (median, 6-year follow-up))"}]},{"url":"https://doi.org/10.1056/NEJMoa1403088","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1403088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roberts-ph-like-all-nejm-2014","kind":"paper","name":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukaemia","route":"/key-papers/paper-roberts-ph-like-all-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1403108","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1403108","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","field":"links","label":"TRIBE: initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer (New England Journal of Medicine 2014)"},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"links","label":"TRIBE: initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer (New England Journal of Medicine 2014)"},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"outcomes.source (Progression-free survival)"},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa1405095","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1405095","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1405095","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1405095","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"links","label":"PREVAIL (New England Journal of Medicine 2014)"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"outcomes.source (Radiographic progression-free survival at 12 months)"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"outcomes.source (Overall survival)"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"outcomes.source (PSA decline of 50 percent or more)"}]},{"url":"https://doi.org/10.1056/nejmoa1406037","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1406037","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-combi-d-n-engl-j-med-2014","kind":"paper","name":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","route":"/key-papers/paper-combi-d-n-engl-j-med-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1406281","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1406281","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"papers","label":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer"},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"papers","label":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer"},{"id":"paper-apt-tolaney-nejm-2015","kind":"paper","name":"APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer","route":"/key-papers/paper-apt-tolaney-nejm-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1406470","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1406470","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-select-lenvatinib-nejm-2015","kind":"paper","name":"SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-select-lenvatinib-nejm-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1406498","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1406498","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"papers","label":"Genetic basis for clinical response to CTLA-4 blockade in melanoma"}]},{"url":"https://doi.org/10.1056/NEJMoa1406766","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1406766","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","field":"links","label":"Crizotinib in ROS1-rearranged NSCLC (New England Journal of Medicine 2014)"},{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","field":"outcomes.source (Objective response rate)"},{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","field":"outcomes.source (Progression-free survival)"},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","field":"papers","label":"Crizotinib in ROS1-rearranged non-small-cell lung cancer"},{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1407222","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1407222","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"papers","label":"Chimeric antigen receptor T cells for sustained remissions in leukemia"},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","field":"papers","label":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL"},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"papers","label":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL"},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","field":"papers","label":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL"},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1408440","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1408440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-solomon-n-engl-j-med","kind":"paper","name":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","route":"/key-papers/paper-solomon-n-engl-j-med/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1408440","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1408440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"profile-1014","kind":"trial","name":"PROFILE 1014","route":"/trials/profile-1014/","field":"links","label":"PROFILE 1014 (New England Journal of Medicine 2014)"},{"id":"profile-1014","kind":"trial","name":"PROFILE 1014","route":"/trials/profile-1014/","field":"outcomes.source (Progression-free survival (independent radiological review))"},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","field":"links","label":"PROFILE 1014 (NEJM 2014)"}]},{"url":"https://doi.org/10.1056/NEJMoa1408617","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1408617","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"papers","label":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence"},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","field":"papers","label":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70"},{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","field":"links","label":"Jaiswal et al., Age-related clonal hematopoiesis associated with adverse outcomes (NEJM 2014)"},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","field":"links","label":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70 (New England Journal of Medicine 2014)"},{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/","field":"links","label":"DOI"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Jaiswal et al., Age-related clonal hematopoiesis associated with adverse outcomes (NEJM 2014)"}]},{"url":"https://doi.org/10.1056/NEJMoa1408648","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1408648","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","kind":"paper","name":"RAPID: PET-directed therapy for early-stage Hodgkin lymphoma","route":"/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/","field":"links","label":"N Engl J Med 2015"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"links","label":"RAPID (NEJM 2015)"}]},{"url":"https://doi.org/10.1056/nejmoa1408868","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1408868","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cobrim-n-engl-j-med-2014","kind":"paper","name":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","route":"/key-papers/paper-cobrim-n-engl-j-med-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1409405","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1409405","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/","field":"links","label":"Genovese 2014 companion paper"}]},{"url":"https://doi.org/10.1056/nejmoa1411321","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1411321","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015","kind":"paper","name":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1411321","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1411321","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","field":"papers","label":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma"}]},{"url":"https://doi.org/10.1056/nejmoa1412082","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1412082","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braf-melanoma-n-engl-j-med-2015","kind":"paper","name":"Nivolumab in previously untreated melanoma without BRAF mutation","route":"/key-papers/paper-braf-melanoma-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/nejmoa1412379","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1412379","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-soft-text-n-engl-j-med-2015","kind":"paper","name":"Adjuvant ovarian suppression in premenopausal breast cancer","route":"/key-papers/paper-soft-text-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1413204","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1413204","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Moore et al., goserelin for ovarian protection during breast cancer adjuvant chemotherapy, POEMS/S0230 (NEJM 2015)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Moore et al., goserelin for ovarian protection during breast cancer adjuvant chemotherapy, POEMS/S0230 (NEJM 2015)"}]},{"url":"https://doi.org/10.1056/NEJMoa1414325","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1414325","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mayer-recourse-tas-102-nejm-2015","kind":"paper","name":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)","route":"/key-papers/paper-mayer-recourse-tas-102-nejm-2015/","field":"links","label":"N Engl J Med 2015"},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","field":"links","label":"RECOURSE: randomized trial of TAS-102 for refractory metastatic colorectal cancer (New England Journal of Medicine 2015)"},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa1414799","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1414799","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","field":"papers","label":"Somatic mutations and clonal hematopoiesis in aplastic anemia"}]},{"url":"https://doi.org/10.1056/nejmoa1415340","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1415340","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ma-20-n-engl-j-med-2015","kind":"paper","name":"Regional Nodal Irradiation in Early-Stage Breast Cancer","route":"/key-papers/paper-ma-20-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1415340","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1415340","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","field":"links","label":"NEJM 2015"}]},{"url":"https://doi.org/10.1056/nejmoa1415369","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1415369","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-n-engl-j-med-2015","kind":"paper","name":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer","route":"/key-papers/paper-eortc-22922-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1415369","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1415369","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","field":"links","label":"NEJM 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1500596","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1500596","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"papers","label":"PD-1 blockade in tumors with mismatch-repair deficiency"},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"papers","label":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ"},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"papers","label":"PD-1 blockade in tumors with mismatch-repair deficiency"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1500925","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1500925","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","field":"papers","label":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma"},{"id":"paper-rtog-9802-buckner-nejm-2016","kind":"paper","name":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","route":"/key-papers/paper-rtog-9802-buckner-nejm-2016/","field":"links","label":"N Engl J Med 2016"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"links","label":"RTOG 9802: radiation plus PCV in low-grade glioma (NEJM 2016)"}]},{"url":"https://doi.org/10.1056/NEJMoa1501824","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1501824","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-001-pembrolizumab-nsclc-nejm-2015","kind":"paper","name":"KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off","route":"/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1502309","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1502309","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-n-engl-j-med-2015","kind":"paper","name":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","route":"/key-papers/paper-braf-thyroid-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1503093","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1503093","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1503747","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1503747","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"links","label":"CHAARTED (New England Journal of Medicine 2015)"},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"outcomes.source (Overall survival (median))"},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"outcomes.source (Time to biochemical, symptomatic or radiographic progression (median))"},{"id":"paper-chaarted-nejm-2015","kind":"paper","name":"CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-chaarted-nejm-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/nejmoa1504030","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1504030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1504030","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1504030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","field":"links","label":"Original report (Larkin 2015)"}]},{"url":"https://doi.org/10.1056/NEJMoa1504627","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1504627","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-017","kind":"trial","name":"CheckMate 017","route":"/trials/checkmate-017/","field":"links","label":"CheckMate 017 (New England Journal of Medicine 2015)"},{"id":"checkmate-017","kind":"trial","name":"CheckMate 017","route":"/trials/checkmate-017/","field":"outcomes.source (Overall survival)"},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"papers","label":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer"},{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1505917","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1505917","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-papillary-rcc-nejm-2016","kind":"paper","name":"Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-papillary-rcc-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1506007","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1506007","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"elective-neck-dissection-tmh","kind":"trial","name":"Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)","route":"/trials/elective-neck-dissection-tmh/","field":"links","label":"D'Cruz et al., NEJM 2015"},{"id":"elective-neck-dissection-tmh","kind":"trial","name":"Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)","route":"/trials/elective-neck-dissection-tmh/","field":"outcomes.source (3-year overall survival)"},{"id":"paper-dcruz-elective-neck-dissection-nejm-2015","kind":"paper","name":"Elective versus therapeutic neck dissection in node-negative oral cancer","route":"/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/","field":"links","label":"NEJM 2015"}]},{"url":"https://doi.org/10.1056/nejmoa1506859","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1506859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1506859","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1506859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"papers","label":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1507471","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1507471","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ivey-npm1-mrd-nejm-2016","kind":"paper","name":"Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)","route":"/key-papers/paper-ivey-npm1-mrd-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1507643","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1507643","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","field":"links","label":"CheckMate 057 (New England Journal of Medicine 2015)"},{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","field":"outcomes.source (Overall survival)"},{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-checkmate-057-nejm-2015","kind":"paper","name":"CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer","route":"/key-papers/paper-checkmate-057-nejm-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1508887","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1508887","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shaw-alk-l1198f-resensitisation-nejm-2016","kind":"paper","name":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","route":"/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/","field":"links","label":"Shaw et al., N Engl J Med 2016: resensitisation to crizotinib by the lorlatinib resistance mutation ALK L1198F"},{"id":"alk-resistance-mutation","kind":"biomarker","name":"ALK kinase-domain resistance mutation (G1202R and the rest)","route":"/biomarkers/alk-resistance-mutation/","field":"links","label":"Shaw et al., N Engl J Med 2016: resensitisation to crizotinib by the lorlatinib resistance mutation ALK L1198F"}]},{"url":"https://doi.org/10.1056/nejmoa1508913","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1508913","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-amant-n-engl-j-med","kind":"paper","name":"Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy","route":"/key-papers/paper-amant-n-engl-j-med/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMoa1508913","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1508913","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","field":"links","label":"INCIP (Amant, NEJM 2015)"}]},{"url":"https://doi.org/10.1056/NEJMoa1509277","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1509277","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","field":"outcomes.source (Overall survival (median))"},{"id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","field":"links","label":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL (New England Journal of Medicine 2016)"},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"papers","label":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia"},{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1509388","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1509388","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","field":"papers","label":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia"},{"id":"paper-jan-burger-n-engl-j-med-2015","kind":"paper","name":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","route":"/key-papers/paper-jan-burger-n-engl-j-med-2015/","field":"links","label":"N Engl J Med 2015"},{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","field":"outcomes.source (Progression-free survival (independent review committee))"},{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","field":"outcomes.source (Overall survival at 24 months)"},{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","field":"outcomes.source (Overall response rate)"}]},{"url":"https://doi.org/10.1056/nejmoa1509981","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1509981","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-n-engl-j-med-2016","kind":"paper","name":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","route":"/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1510093","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1510093","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","field":"papers","label":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma"},{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/nejmoa1510665","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1510665","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","field":"outcomes.source (Overall survival)"},{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","field":"outcomes.source (Objective response rate)"},{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","field":"outcomes.source (Progression-free survival)"},{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","field":"outcomes.source (Grade 3-4 treatment-related adverse events)"}]},{"url":"https://doi.org/10.1056/nejmoa1510795","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1510795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-armstrong-n-engl-j-med","kind":"paper","name":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer","route":"/key-papers/paper-armstrong-n-engl-j-med/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1510795","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1510795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"links","label":"Armstrong et al., NEJM 2016"},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"outcomes.source (15-year cumulative all-cause mortality by treatment era)"},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"outcomes.source (15-year health-related mortality by treatment era)"}]},{"url":"https://doi.org/10.1056/NEJMoa1513098","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1513098","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016","kind":"paper","name":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","route":"/key-papers/paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016/","field":"links","label":"N Engl J Med 2016"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"links","label":"Midostaurin in advanced SM (NEJM 2016)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"links","label":"Midostaurin in advanced SM (NEJM 2016)"}]},{"url":"https://doi.org/10.1056/nejmoa1515725","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1515725","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-navari-n-engl-j-med","kind":"paper","name":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","route":"/key-papers/paper-navari-n-engl-j-med/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1515725","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1515725","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","field":"links","label":"Olanzapine (NEJM 2016)"}]},{"url":"https://doi.org/10.1056/NEJMoa1602252","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1602252","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","field":"papers","label":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum"},{"id":"paper-checkmate-141-ferris-nejm-2016","kind":"paper","name":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","route":"/key-papers/paper-checkmate-141-ferris-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/nejmoa1602253","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1602253","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cardoso-n-engl-j-med","kind":"paper","name":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","route":"/key-papers/paper-cardoso-n-engl-j-med/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1602253","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1602253","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","field":"links","label":"MINDACT (NEJM 2016)"},{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","field":"outcomes.source (5-year distant metastasis-free survival, clinical-high / genomic-low risk, no chemotherapy)"}]},{"url":"https://doi.org/10.1056/nejmoa1603144","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1603144","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","kind":"paper","name":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","route":"/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1603144","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1603144","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","kind":"paper","name":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","route":"/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/","field":"links","label":"Pritchard et al., N Engl J Med 2016: inherited DNA-repair gene mutations in 692 men with metastatic prostate cancer unselected for family history"},{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","field":"links","label":"Pritchard et al., N Engl J Med 2016: inherited DNA-repair gene mutations in 692 men with metastatic prostate cancer unselected for family history"}]},{"url":"https://doi.org/10.1056/nejmoa1603702","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1603702","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","field":"papers","label":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma"},{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/nejmoa1604958","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1604958","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zaretsky-n-engl-j-med","kind":"paper","name":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","route":"/key-papers/paper-zaretsky-n-engl-j-med/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1604958","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1604958","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"papers","label":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma"},{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","field":"links","label":"Zaretsky et al., Mutations associated with acquired resistance to PD-1 blockade (NEJM 2016)"}]},{"url":"https://doi.org/10.1056/NEJMoa1606220","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1606220","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"links","label":"ProtecT 10-year outcomes (New England Journal of Medicine 2016)"},{"id":"paper-protect-nejm-2016","kind":"paper","name":"ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer","route":"/key-papers/paper-protect-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1606221","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1606221","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Donovan et al., patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer (NEJM 2016)"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"links","label":"ProtecT patient-reported outcomes (New England Journal of Medicine 2016)"},{"id":"prostate-treatment-choice-localised","kind":"term","name":"Choosing treatment for localised prostate cancer: what each option costs","route":"/terms/prostate-treatment-choice-localised/","field":"links","label":"ProtecT patient-reported outcomes (New England Journal of Medicine 2016)"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","field":"links","label":"Donovan et al., patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer (NEJM 2016)"}]},{"url":"https://doi.org/10.1056/NEJMoa1606774","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1606774","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","field":"links","label":"KEYNOTE-024: pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (NEJM 2016)"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","field":"metrics (Objective response rate to pembrolizumab vs chemotherapy in untreated NSCLC selected by PD-L1 TPS 50% or more (KEYNOTE-024): even the best-selected group has a majority of non-responders)"},{"id":"paper-keynote-024-nejm-2016","kind":"paper","name":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","route":"/key-papers/paper-keynote-024-nejm-2016/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1607303","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607303","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paloma-2-n-engl-j-med-2016","kind":"paper","name":"Palbociclib and Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-paloma-2-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1607303","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607303","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa1607427","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607427","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"links","label":"Strosberg et al., Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumours (NEJM 2017)"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"outcomes.source (Progression-free survival at 20 months)"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"outcomes.source (Objective response rate)"},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"links","label":"NETTER-1 (NEJM 2017)"}]},{"url":"https://doi.org/10.1056/nejmoa1607529","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607529","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-9601-n-engl-j-med-2017","kind":"paper","name":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","route":"/key-papers/paper-rtog-9601-n-engl-j-med-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1607529","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607529","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","field":"links","label":"NEJM 2017"}]},{"url":"https://doi.org/10.1056/nejmoa1607751","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607751","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016","kind":"paper","name":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1609279","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1609279","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"papers","label":"T-cell transfer therapy targeting mutant KRAS in cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1609324","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1609324","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","field":"links","label":"10-year follow-up (Hochhaus 2017)"}]},{"url":"https://doi.org/10.1056/nejmoa1609709","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1609709","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2016","kind":"paper","name":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/nejmoa1609783","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1609783","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","kind":"paper","name":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","route":"/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1609783","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1609783","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","field":"outcomes.source (Complete remission within 12 weeks)"},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"papers","label":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia"}]},{"url":"https://doi.org/10.1056/nejmoa1610497","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1610497","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brown-n-engl-j-med","kind":"paper","name":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","route":"/key-papers/paper-brown-n-engl-j-med/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1610497","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1610497","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","field":"links","label":"Brown et al., Regression of glioblastoma after IL13Ralpha2 CAR T-cell therapy (NEJM 2016)"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"papers","label":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy"},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"papers","label":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy"}]},{"url":"https://doi.org/10.1056/nejmoa1611310","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1611310","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-niraparib-ovarian-n-engl-j-med-2016","kind":"paper","name":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","route":"/key-papers/paper-niraparib-ovarian-n-engl-j-med-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1611750","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1611750","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","field":"papers","label":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma"},{"id":"paper-ifm-2009-attal-nejm-2017","kind":"paper","name":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","route":"/key-papers/paper-ifm-2009-attal-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","field":"outcomes.source (Progression-free survival)"},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","field":"outcomes.source (Complete response)"},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","field":"outcomes.source (Minimal residual disease not detected)"},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","field":"outcomes.source (Overall survival at 4 years)"}]},{"url":"https://doi.org/10.1056/nejmoa1611977","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1611977","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-perry-n-engl-j-med","kind":"paper","name":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","route":"/key-papers/paper-perry-n-engl-j-med/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1611977","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1611977","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","field":"links","label":"Perry et al., Short-course radiation plus temozolomide in elderly patients with glioblastoma (NEJM 2017)"}]},{"url":"https://doi.org/10.1056/nejmoa1612645","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1612645","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1612645","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1612645","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Masuda et al., adjuvant capecitabine after preoperative chemotherapy, CREATE-X (NEJM 2017)"},{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/","field":"links","label":"CREATE-X (NEJM 2017)"},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"links","label":"Masuda et al., NEJM 2017: adjuvant capecitabine for breast cancer after preoperative chemotherapy (CREATE-X)"},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"outcomes.source (Disease-free survival at 5 years)"},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"outcomes.source (Disease-free survival at 5 years, triple-negative subgroup)"},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"outcomes.source (Overall survival at 5 years, triple-negative subgroup)"},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Masuda et al., adjuvant capecitabine after preoperative chemotherapy, CREATE-X (NEJM 2017)"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","field":"links","label":"CREATE-X (NEJM 2017)"}]},{"url":"https://doi.org/10.1056/nejmoa1612674","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1612674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2017","kind":"paper","name":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1612674","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1612674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"links","label":"AURA3 (New England Journal of Medicine 2017)"},{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"outcomes.source (Progression-free survival (investigator assessed))"}]},{"url":"https://doi.org/10.1056/NEJMoa1613210","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1613210","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"metrics (Melanoma-specific survival benefit of completion lymphadenectomy after a positive sentinel node (MSLT-II), a practice used for decades before it was tested)"},{"id":"paper-mslt-ii-faries-nejm-2017","kind":"paper","name":"MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma","route":"/key-papers/paper-mslt-ii-faries-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1613493","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1613493","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-026-first-line-nivolumab-nejm-2017","kind":"paper","name":"CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer","route":"/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/","field":"links","label":"Carbone et al., N Engl J Med 2017: CheckMate 026, first-line nivolumab in PD-L1-positive non-small-cell lung cancer"},{"id":"checkmate-026","kind":"trial","name":"CheckMate 026","route":"/trials/checkmate-026/","field":"links","label":"CheckMate 026 (New England Journal of Medicine 2017)"},{"id":"checkmate-026","kind":"trial","name":"CheckMate 026","route":"/trials/checkmate-026/","field":"outcomes.source (Progression-free survival (PD-L1 5 percent or more))"},{"id":"checkmate-026","kind":"trial","name":"CheckMate 026","route":"/trials/checkmate-026/","field":"outcomes.source (Overall survival (PD-L1 5 percent or more))"}]},{"url":"https://doi.org/10.1056/nejmoa1613683","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1613683","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-n-engl-j-med-2017","kind":"paper","name":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","route":"/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1614359","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1614359","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","field":"outcomes.source (4-year overall survival)"},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","field":"papers","label":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation"},{"id":"paper-ratify-midostaurin-nejm-2017","kind":"paper","name":"RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation","route":"/key-papers/paper-ratify-midostaurin-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1614598","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1614598","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"outcomes.source (Progression-free survival at 3 years, follicular lymphoma (investigator-assessed))"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"outcomes.source (Overall response rate)"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"outcomes.source (Grade 3 to 5 adverse events)"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"outcomes.source (Infusion-related events attributed to the antibody)"},{"id":"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017","kind":"paper","name":"GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma","route":"/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/nejmoa1615869","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1615869","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","kind":"paper","name":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","route":"/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1615869","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1615869","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","field":"links","label":"PIVOT extended follow-up (New England Journal of Medicine 2017)"},{"id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","field":"outcomes.source (Death from any cause (median 12.7 years))"},{"id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","field":"outcomes.source (Death from prostate cancer or its treatment)"}]},{"url":"https://doi.org/10.1056/NEJMoa1616288","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1616288","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"papers","label":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"metrics (Association of elevated copy-number intratumour heterogeneity with recurrence or death in resected NSCLC (TRACERx))"},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","field":"links","label":"Jamal-Hanjani et al., Tracking the evolution of non-small-cell lung cancer (NEJM 2017)"},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","field":"links","label":"DOI"},{"id":"clonal-evolution-models","kind":"technology","name":"Clonal evolution and branching models","route":"/technologies/clonal-evolution-models/","field":"links","label":"TRACERx, Jamal-Hanjani 2017"}]},{"url":"https://doi.org/10.1056/nejmoa1701717","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1701717","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chan-n-engl-j-med","kind":"paper","name":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","route":"/key-papers/paper-chan-n-engl-j-med/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1701717","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1701717","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","field":"links","label":"EBV DNA screening (NEJM 2017)"},{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/","field":"links","label":"Chan 2017 screening (NEJM)"}]},{"url":"https://doi.org/10.1056/NEJMoa1701769","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1701769","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-maintenance","kind":"term","name":"Maintenance and consolidation in lymphoma: where it works and where it does not","route":"/terms/lymphoma-tx-maintenance/","field":"links","label":"LyMa: rituximab after autologous transplant in mantle cell lymphoma, New England Journal of Medicine 2017"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (First-line mantle cell lymphoma in younger, fitter patients after TRIANGLE: ibrutinib in, transplant optional)"}]},{"url":"https://doi.org/10.1056/nejmoa1701830","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1701830","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pan-n-engl-j-med","kind":"paper","name":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","route":"/key-papers/paper-pan-n-engl-j-med/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1701830","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1701830","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","field":"links","label":"Pan et al., 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years (NEJM 2017)"},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","field":"links","label":"Pan et al., 20-year risks of breast-cancer recurrence (NEJM 2017)"},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","field":"metrics (Risk of distant recurrence in years 5-20 for ER-positive breast cancer after 5 years of endocrine therapy, by original stage)"}]},{"url":"https://doi.org/10.1056/NEJMoa1702900","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1702900","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"James et al., NEJM 2017: abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, abiraterone comparison)"},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","field":"links","label":"STAMPEDE abiraterone (New England Journal of Medicine 2017)"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"papers","label":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer"},{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","route":"/people/mahesh-parmar/","field":"papers","label":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer"},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","field":"links","label":"NEJM 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1703643","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1703643","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aphinity-nejm-2017","kind":"paper","name":"APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer","route":"/key-papers/paper-aphinity-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","field":"links","label":"APHINITY (NEJM 2017)"}]},{"url":"https://doi.org/10.1056/NEJMoa1704174","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1704174","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-latitude-nejm-2017","kind":"paper","name":"LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-latitude-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/nejmoa1704795","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1704795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1704795","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1704795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","field":"links","label":"New England Journal of Medicine 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1706450","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1706450","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","field":"papers","label":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation"},{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/","field":"links","label":"N Engl J Med 2017"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","field":"links","label":"OlympiAD (NEJM 2017)"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"links","label":"Robson et al., OlympiAD (NEJM 2017)"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/nejmoa1707447","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1707447","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Objective response rate)"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Complete response rate)"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Ongoing response at median follow-up of 15.4 months)"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Overall survival at 18 months)"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Grade 3 or higher cytokine release syndrome)"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"outcomes.source (Grade 3 or higher neurologic events)"}]},{"url":"https://doi.org/10.1056/NEJMoa1707447","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1707447","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","field":"links","label":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma (New England Journal of Medicine 2017)"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"papers","label":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma"},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","field":"papers","label":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma"},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1708539","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1708539","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-combi-ad-nejm-2017","kind":"paper","name":"COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","route":"/key-papers/paper-combi-ad-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1708984","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1708984","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","field":"links","label":"Full text (DOI)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"links","label":"ECHELON-1 (NEJM 2018)"}]},{"url":"https://doi.org/10.1056/NEJMoa1709030","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1709030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","field":"papers","label":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma"},{"id":"paper-checkmate-238-nejm-2017","kind":"paper","name":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","route":"/key-papers/paper-checkmate-238-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1709866","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1709866","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"outcomes.source (Overall survival at 12 months)"},{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","field":"links","label":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL (New England Journal of Medicine 2018)"},{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"papers","label":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL"},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","field":"papers","label":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"Maude et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA, NEJM 2018)"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Patients in ELIANA for whom tisagenlecleucel could not be manufactured)"},{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1709919","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1709919","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","field":"papers","label":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia"}]},{"url":"https://doi.org/10.1056/NEJMoa1709937","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1709937","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/","field":"links","label":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer (New England Journal of Medicine 2017)"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"papers","label":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer"},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","field":"links","label":"NEJM 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1712126","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1712126","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","field":"outcomes.source (Overall survival, ITT (8-year follow-up))"},{"id":"paper-checkmate-214-nejm-2018","kind":"paper","name":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","route":"/key-papers/paper-checkmate-214-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1713137","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1713137","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","field":"links","label":"FLAURA: osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (NEJM 2018)"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"papers","label":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"papers","label":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","field":"links","label":"Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","field":"metrics (Median progression-free survival with first-line osimertinib in EGFR-mutant NSCLC (FLAURA), the benchmark single-agent targeted therapy)"},{"id":"idea-bio1-mandatory-progression-biopsy","kind":"idea","name":"Fund a biopsy at progression, every time, as standard care","route":"/ideas/idea-bio1-mandatory-progression-biopsy/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-pre-randomised-sequencing-trials","kind":"idea","name":"Randomise the next line of treatment before the first one fails","route":"/ideas/idea-bio1-pre-randomised-sequencing-trials/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-dual-antigen-adc-escape","kind":"idea","name":"Two-target antibody drugs to close the antigen escape route","route":"/ideas/idea-bio1-dual-antigen-adc-escape/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-drug-holiday-resensitisation","kind":"idea","name":"Pause a failed drug so the tumour becomes sensitive to it again","route":"/ideas/idea-bio1-drug-holiday-resensitisation/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-persister-ferroptosis","kind":"idea","name":"Kill the sleeping survivor cells with iron-dependent cell death","route":"/ideas/idea-bio1-persister-ferroptosis/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-epigenetic-persister-blockade","kind":"idea","name":"Block the chemical switch that lets cells hide from treatment","route":"/ideas/idea-bio1-epigenetic-persister-blockade/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-mutagenesis-blockade-rev1","kind":"idea","name":"Turn off the error-prone repair that manufactures resistance mutations","route":"/ideas/idea-bio1-mutagenesis-blockade-rev1/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-stress-response-blockade","kind":"idea","name":"Cut off the emergency programme cancer cells use to survive treatment","route":"/ideas/idea-bio1-stress-response-blockade/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-senolytics-after-therapy","kind":"idea","name":"Clear the zombie cells left behind by chemotherapy and radiotherapy","route":"/ideas/idea-bio1-senolytics-after-therapy/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-persister-metabolic-vulnerability","kind":"idea","name":"Starve the survivors: target the energy pathway drug-tolerant cells switch to","route":"/ideas/idea-bio1-persister-metabolic-vulnerability/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-resistance-platform-trial","kind":"idea","name":"A standing platform trial that assigns treatment by how the tumour escaped","route":"/ideas/idea-bio1-resistance-platform-trial/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-slfn11-payload-guidance","kind":"idea","name":"Use SLFN11 status to decide which antibody-drug payload to give next","route":"/ideas/idea-bio1-slfn11-payload-guidance/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-stromal-resistance-blockade","kind":"idea","name":"Block the survival signals the tumour's neighbours provide","route":"/ideas/idea-bio1-stromal-resistance-blockade/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-real-world-resistance-surveillance","kind":"idea","name":"Treat resistance like an infectious disease and run national surveillance","route":"/ideas/idea-bio1-real-world-resistance-surveillance/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-approval-linked-progression-sampling","kind":"idea","name":"Make post-progression sampling a condition of accelerated approval","route":"/ideas/idea-bio1-approval-linked-progression-sampling/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-drug-exposure-sanctuary-mapping","kind":"idea","name":"Find the parts of a tumour the drug never reaches","route":"/ideas/idea-bio1-drug-exposure-sanctuary-mapping/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-bio1-immunopeptidome-timing","kind":"idea","name":"Time immunotherapy to the moment targeted drugs make tumours visible","route":"/ideas/idea-bio1-immunopeptidome-timing/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/","field":"links","label":"Bottleneck evidence (Acquired resistance to every therapy): Soria et al., Osimertinib in untreated EGFR-mutated NSCLC (FLAURA, NEJM 2018)"},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","field":"links","label":"NEJM 2018"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"links","label":"New England Journal of Medicine 2018"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa1713709","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1713709","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","kind":"paper","name":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","route":"/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/","field":"links","label":"N Engl J Med 2018"},{"id":"idea-collaboration","kind":"trial","name":"IDEA collaboration","route":"/trials/idea-collaboration/","field":"links","label":"IDEA: duration of adjuvant chemotherapy for stage III colon cancer (New England Journal of Medicine 2018)"},{"id":"idea-collaboration","kind":"trial","name":"IDEA collaboration","route":"/trials/idea-collaboration/","field":"outcomes.source (Disease-free survival at 3 years (overall))"},{"id":"idea-collaboration","kind":"trial","name":"IDEA collaboration","route":"/trials/idea-collaboration/","field":"outcomes.source (Disease-free survival at 3 years (T1-3 N1))"}]},{"url":"https://doi.org/10.1056/nejmoa1713976","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1713976","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","field":"outcomes.source (Progression-free survival at 2 years (investigator-assessed))"},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","field":"outcomes.source (Progression-free survival at 2 years, chromosome 17p deletion)"},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","field":"outcomes.source (Progression-free survival at 2 years, no 17p deletion)"},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","field":"outcomes.source (Grade 3-4 tumour lysis syndrome)"}]},{"url":"https://doi.org/10.1056/NEJMoa1713976","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1713976","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1714448","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1714448","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","field":"links","label":"Drilon et al., Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children (NEJM 2018)"},{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","field":"outcomes.source (Objective response rate (independent review, pooled with LOXO-TRK-14001 and SCOUT))"},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"papers","label":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"links","label":"Drilon 2018 (NEJM)"},{"id":"paper-drilon-larotrectinib-nejm-2018","kind":"paper","name":"Larotrectinib in TRK fusion-positive cancers in adults and children","route":"/key-papers/paper-drilon-larotrectinib-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1715546","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1715546","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metastasis-free-survival","kind":"term","name":"Metastasis-free survival (MFS)","route":"/terms/metastasis-free-survival/","field":"links","label":"Smith et al., New England Journal of Medicine 2018 (SPARTAN): apalutamide treatment and metastasis-free survival in prostate cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1715546","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1715546","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-spartan-nejm-2018","kind":"paper","name":"SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-spartan-nejm-2018/","field":"links","label":"N Engl J Med 2018"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"links","label":"SPARTAN (New England Journal of Medicine 2018)"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"outcomes.source (Metastasis-free survival (median))"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"outcomes.source (Time to symptomatic progression)"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"outcomes.source (Fracture, any grade)"}]},{"url":"https://doi.org/10.1056/NEJMoa1716078","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1716078","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"papers","label":"Neoadjuvant PD-1 blockade in resectable lung cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1716948","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1716948","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impower150","kind":"trial","name":"IMpower150","route":"/trials/impower150/","field":"links","label":"IMpower150 (New England Journal of Medicine 2018)"},{"id":"impower150","kind":"trial","name":"IMpower150","route":"/trials/impower150/","field":"outcomes.source (Progression-free survival (EGFR and ALK wild-type))"}]},{"url":"https://doi.org/10.1056/NEJMoa1716984","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1716984","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ivosidenib-idh1-dinardo-nejm-2018","kind":"paper","name":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-ivosidenib-idh1-dinardo-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1717002","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1717002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","field":"outcomes.source (Overall survival)"},{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa1800536","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1800536","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","field":"papers","label":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer"},{"id":"paper-prosper-nejm-2018","kind":"paper","name":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-prosper-nejm-2018/","field":"links","label":"N Engl J Med 2018"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Metastasis-free survival)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Time to PSA progression)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Time to first subsequent antineoplastic therapy)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Grade 3 or higher adverse events)"}]},{"url":"https://doi.org/10.1056/nejmoa1801005","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"KEYNOTE-189 (Gandhi 2018, NEJM): pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC"}]},{"url":"https://doi.org/10.1056/NEJMoa1801005","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"papers","label":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation"},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/","field":"links","label":"NEJM 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1801109","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brock-n-engl-j-med","kind":"paper","name":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","route":"/key-papers/paper-brock-n-engl-j-med/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1801109","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","field":"links","label":"SIOPEL-6 (NEJM 2018)"},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","field":"standardOfCare.guideline (Very low / standard risk (PRETEXT I-III, resectable, AFP >100))"},{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","field":"links","label":"SIOPEL-6 (NEJM 2018)"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"links","label":"SIOPEL 6: sodium thiosulfate otoprotection (NEJM 2018)"}]},{"url":"https://doi.org/10.1056/NEJMoa1801445","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801445","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"papers","label":"Genetics and pathogenesis of diffuse large B-cell lymphoma"}]},{"url":"https://doi.org/10.1056/nejmoa1801946","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801946","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-n-engl-j-med-2018","kind":"paper","name":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","route":"/key-papers/paper-checkmate-227-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1801993","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1801993","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-precision-mri-targeted-biopsy-nejm-2018","kind":"paper","name":"PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis","route":"/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1802357","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1802357","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-054-eggermont-nejm-2018","kind":"paper","name":"KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma","route":"/key-papers/paper-keynote-054-eggermont-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1802905","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1802905","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-embraca-n-engl-j-med-2018","kind":"paper","name":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","route":"/key-papers/paper-embraca-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1802905","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1802905","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"papers","label":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"links","label":"Litton et al., EMBRACA (NEJM 2018)"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/nejmoa1803675","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1803675","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carmena","kind":"trial","name":"CARMENA","route":"/trials/carmena/","field":"outcomes.source (Overall survival (planned interim analysis, non-inferiority))"}]},{"url":"https://doi.org/10.1056/nejmoa1803955","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1803955","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mcneil-n-engl-j-med","kind":"paper","name":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","route":"/key-papers/paper-mcneil-n-engl-j-med/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1803955","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1803955","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"ASPREE cancer outcomes (NEJM 2018)"},{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","field":"links","label":"Mortality results (NEJM 2018)"},{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","field":"outcomes.source (Death from cancer)"}]},{"url":"https://doi.org/10.1056/NEJMoa1804710","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1804710","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"links","label":"TAILORx (NEJM 2018)"},{"id":"paper-tailorx-nejm-2018","kind":"paper","name":"TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer","route":"/key-papers/paper-tailorx-nejm-2018/","field":"links","label":"N Engl J Med 2018"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","field":"links","label":"TAILORx (NEJM 2018)"}]},{"url":"https://doi.org/10.1056/NEJMoa1804980","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1804980","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1805104","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1805104","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","field":"papers","label":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"outcomes.source (Complete or unconfirmed complete response at 120 weeks (independent review))"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"outcomes.source (Progression-free survival at 3 years (interim))"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"outcomes.source (Grade 3 or 4 neutropenia)"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"outcomes.source (Grade 3 or 4 cutaneous reactions)"},{"id":"paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018","kind":"paper","name":"RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma","route":"/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1805131","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1805131","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","field":"papers","label":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)"},{"id":"paper-empower-cscc-1-cemiplimab-migden-nejm-2018","kind":"paper","name":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","route":"/key-papers/paper-empower-cscc-1-cemiplimab-migden-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1805453","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1805453","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-n-engl-j-med-2018","kind":"paper","name":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","route":"/key-papers/paper-checkmate-204-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1806395","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1806395","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lacc-nejm-2018","kind":"paper","name":"LACC: minimally invasive versus open radical hysterectomy for early cervical cancer","route":"/key-papers/paper-lacc-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1807801","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1807801","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bill-axelson-spcg-4-29-year-nejm-2018","kind":"paper","name":"SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up","route":"/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1807801","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1807801","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spcg-4","kind":"trial","name":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4)","route":"/trials/spcg-4/","field":"links","label":"SPCG-4 at 29 years (New England Journal of Medicine 2018)"},{"id":"spcg-4","kind":"trial","name":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4)","route":"/trials/spcg-4/","field":"outcomes.source (Death from prostate cancer at 29 years)"},{"id":"spcg-4","kind":"trial","name":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4)","route":"/trials/spcg-4/","field":"outcomes.source (Death from any cause at 29 years)"}]},{"url":"https://doi.org/10.1056/nejmoa1809064","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809064","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-impower133-n-engl-j-med-2018","kind":"paper","name":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","route":"/key-papers/paper-impower133-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1809064","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809064","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/nejmoa1809615","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"Schmid, N Engl J Med 2018: IMpassion130, atezolizumab and nab-paclitaxel by PD-L1 immune-cell status"},{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","field":"links","label":"Schmid, N Engl J Med 2018: IMpassion130, atezolizumab and nab-paclitaxel by PD-L1 immune-cell status"},{"id":"paper-impassion130-n-engl-j-med-2018","kind":"paper","name":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-impassion130-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1809615","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2019-03)"},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"links","label":"IMpassion130 primary analysis (NEJM 2018)"},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"outcomes.source (Overall survival, ITT)"}]},{"url":"https://doi.org/10.1056/nejmoa1809697","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809697","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pacific-n-engl-j-med-2018-update","kind":"paper","name":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","route":"/key-papers/paper-pacific-n-engl-j-med-2018-update/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1809697","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809697","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","field":"links","label":"NEJM 2018 (OS)"}]},{"url":"https://doi.org/10.1056/nejmoa1809775","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809775","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clinical-benefit-response","kind":"term","name":"Clinical benefit response (the gemcitabine trial endpoint)","route":"/terms/clinical-benefit-response/","field":"links","label":"Conroy, N Engl J Med 2018: PRODIGE 24, modified FOLFIRINOX or gemcitabine as adjuvant therapy (disease-free survival primary endpoint)"},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","field":"links","label":"Conroy, N Engl J Med 2018: PRODIGE 24, modified FOLFIRINOX or gemcitabine as adjuvant therapy (disease-free survival primary endpoint)"},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"papers","label":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1809775","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809775","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Conroy et al., FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, PRODIGE 24/CCTG PA6 (NEJM 2018)"},{"id":"paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018","kind":"paper","name":"PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer","route":"/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1809944","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809944","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-manson-n-engl-j-med","kind":"paper","name":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease","route":"/key-papers/paper-manson-n-engl-j-med/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1809944","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1809944","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","field":"links","label":"VITAL (NEJM 2019)"},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","field":"links","label":"Vitamin D results (NEJM 2019)"},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","field":"outcomes.source (Invasive cancer of any type)"}]},{"url":"https://doi.org/10.1056/nejmoa1810171","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1810171","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alta-1l-n-engl-j-med-2018","kind":"paper","name":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-alta-1l-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1810171","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1810171","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"links","label":"ALTA-1L (NEJM 2018)"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","field":"links","label":"New England Journal of Medicine 2018"}]},{"url":"https://doi.org/10.1056/NEJMoa1810858","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1810858","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"papers","label":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer"},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/","field":"links","label":"NEJM 2018"}]},{"url":"https://doi.org/10.1056/nejmoa1810865","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1810865","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-407-n-engl-j-med-2018","kind":"paper","name":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-407-n-engl-j-med-2018/","field":"links","label":"N Engl J Med 2018"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","field":"outcomes.source (Overall survival)"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","field":"outcomes.source (Progression-free survival)"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","field":"outcomes.source (Grade 3 or higher adverse events)"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","field":"outcomes.source (Discontinuation for adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa1810865","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1810865","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","field":"papers","label":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa1813904","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1813904","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-solar-1-alpelisib-nejm-2019","kind":"paper","name":"SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-solar-1-alpelisib-nejm-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1814017","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1814017","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"papers","label":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"papers","label":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"papers","label":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer"},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/","field":"links","label":"NEJM 2019"},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","field":"links","label":"KATHERINE (NEJM 2019)"}]},{"url":"https://doi.org/10.1056/nejmoa1814213","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1814213","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019","kind":"paper","name":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/nejmoa1815105","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1815105","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pemmaraju-n-engl-j-med","kind":"paper","name":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","route":"/key-papers/paper-pemmaraju-n-engl-j-med/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1815105","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1815105","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/","field":"links","label":"Tagraxofusp pivotal (NEJM 2019)"}]},{"url":"https://doi.org/10.1056/NEJMoa1815281","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1815281","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","field":"outcomes.source (Progression-free survival at 6 years)"},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","field":"outcomes.source (Undetectable MRD in blood at end of treatment)"},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa1815671","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1815671","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"papers","label":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer"},{"id":"paper-aramis-nejm-2019","kind":"paper","name":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-aramis-nejm-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","field":"outcomes.source (Metastasis-free survival (planned primary analysis))"},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","field":"outcomes.source (Discontinuation for adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa1816714","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1816714","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-keynote-426-nejm-2019","kind":"paper","name":"KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","route":"/key-papers/paper-keynote-426-nejm-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1817249","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1817249","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/","field":"links","label":"Full text (DOI)"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","field":"outcomes.source (Progression-free survival at 30 months)"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","field":"outcomes.source (Complete response or better)"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","field":"outcomes.source (Minimal residual disease negativity (10^-5))"}]},{"url":"https://doi.org/10.1056/NEJMoa1817323","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1817323","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1056/NEJMoa1902688","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1902688","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","field":"outcomes.source (CR/CRh)"},{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1903307","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903307","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02489318-n-engl-j-med-2019","kind":"paper","name":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","route":"/key-papers/paper-nct02489318-n-engl-j-med-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1903307","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903307","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"links","label":"TITAN (New England Journal of Medicine 2019)"},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"outcomes.source (Radiographic progression-free survival at 24 months)"},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"outcomes.source (Overall survival at 24 months)"}]},{"url":"https://doi.org/10.1056/NEJMoa1903387","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903387","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Golan et al., maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, POLO (NEJM 2019)"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Golan et al., maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, POLO (NEJM 2019)"},{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/nejmoa1903765","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903765","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"papers","label":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer"}]},{"url":"https://doi.org/10.1056/nejmoa1903835","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903835","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-enzamet-n-engl-j-med-2019","kind":"paper","name":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","route":"/key-papers/paper-enzamet-n-engl-j-med-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"outcomes.source (Overall survival at 3 years (Kaplan-Meier))"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"outcomes.source (PSA progression-free survival)"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"outcomes.source (Clinical progression-free survival)"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"outcomes.source (Seizures)"}]},{"url":"https://doi.org/10.1056/nejmoa1903986","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903986","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bakker-n-engl-j-med","kind":"paper","name":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue","route":"/key-papers/paper-bakker-n-engl-j-med/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1903986","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1903986","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-mri-coils-abbreviated-mri","kind":"technology","name":"Breast MRI coils and abbreviated breast MRI","route":"/technologies/breast-mri-coils-abbreviated-mri/","field":"links","label":"Bakker et al., Supplemental MRI screening for women with extremely dense breast tissue (NEJM 2019)"}]},{"url":"https://doi.org/10.1056/NEJMoa1905287","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1905287","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019","kind":"paper","name":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"links","label":"Induction gemcitabine-cisplatin (NEJM 2019)"}]},{"url":"https://doi.org/10.1056/NEJMoa1908075","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1908075","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","kind":"paper","name":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)","route":"/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"links","label":"New England Journal of Medicine 2019"}]},{"url":"https://doi.org/10.1056/nejmoa1908892","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1908892","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","field":"papers","label":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes"},{"id":"paper-amer-zeidan-n-engl-j-med-2020","kind":"paper","name":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","route":"/key-papers/paper-amer-zeidan-n-engl-j-med-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","field":"outcomes.source (Transfusion independence >=8 weeks, weeks 1-24)"},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","field":"outcomes.source (Transfusion independence >=12 weeks, weeks 1-24)"},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","field":"outcomes.source (Transfusion independence >=12 weeks, weeks 1-48)"}]},{"url":"https://doi.org/10.1056/nejmoa1910231","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910231","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","field":"papers","label":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer"},{"id":"paper-keunchil-park-n-engl-j-med-2019","kind":"paper","name":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keunchil-park-n-engl-j-med-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Overall survival, PD-L1 >=1%)"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Overall survival at 2 years, PD-L1 >=1%)"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Overall survival, PD-L1 <1%)"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Overall survival, all randomised patients)"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Duration of response, PD-L1 >=1%)"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"outcomes.source (Grade 3-4 treatment-related adverse events)"}]},{"url":"https://doi.org/10.1056/nejmoa1910549","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910549","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"Schmid, N Engl J Med 2020: KEYNOTE-522, pembrolizumab for early triple-negative breast cancer"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","field":"links","label":"Schmid, N Engl J Med 2020: KEYNOTE-522, pembrolizumab for early triple-negative breast cancer"},{"id":"paper-keynote-522-n-engl-j-med-2020","kind":"paper","name":"Pembrolizumab for Early Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1910549","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910549","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Schmid et al., pembrolizumab for early triple-negative breast cancer, KEYNOTE-522 (NEJM 2020)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"KEYNOTE-522 pathological complete response (NEJM 2020)"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","field":"links","label":"NEJM 2020 (pCR)"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","field":"links","label":"KEYNOTE-522 (NEJM 2020)"}]},{"url":"https://doi.org/10.1056/nejmoa1910607","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910607","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-liu-n-engl-j-med","kind":"paper","name":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","route":"/key-papers/paper-liu-n-engl-j-med/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1910607","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910607","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","field":"links","label":"Liu et al., CAR-transduced natural killer cells in CD19-positive lymphoid tumours (NEJM 2020)"}]},{"url":"https://doi.org/10.1056/NEJMoa1910962","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1910962","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prima-niraparib-nejm-2019","kind":"paper","name":"PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer","route":"/key-papers/paper-prima-niraparib-nejm-2019/","field":"links","label":"N Engl J Med 2019"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","field":"links","label":"PRIMA: niraparib maintenance in advanced ovarian cancer, with the largest benefit in HRD-positive tumours (New England Journal of Medicine 2019)"}]},{"url":"https://doi.org/10.1056/NEJMoa1911206","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1911206","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/","field":"links","label":"CARD (New England Journal of Medicine 2019)"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"links","label":"CARD (New England Journal of Medicine 2019)"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"outcomes.source (Imaging-based progression-free survival (median))"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"outcomes.source (Overall survival (median))"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"outcomes.source (PSA response)"}]},{"url":"https://doi.org/10.1056/NEJMoa1911361","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1911361","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/","field":"links","label":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours (New England Journal of Medicine 2019)"},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","field":"papers","label":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours"},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/","field":"links","label":"NEJM 2019"}]},{"url":"https://doi.org/10.1056/NEJMoa1911440","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1911440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-profound-nejm-2020","kind":"paper","name":"PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations","route":"/key-papers/paper-profound-nejm-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/nejmoa1911793","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1911793","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women)"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women)"},{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","field":"links","label":"de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women)"},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","field":"links","label":"de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women)"}]},{"url":"https://doi.org/10.1056/NEJMoa1911793","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1911793","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nelson-nejm-2020","kind":"paper","name":"NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms","route":"/key-papers/paper-nelson-nejm-2020/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/NEJMoa1912735","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1912735","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"papers","label":"Selumetinib in children with inoperable plexiform neurofibromas"}]},{"url":"https://doi.org/10.1056/nejmoa1913662","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1913662","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2020","kind":"paper","name":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1913662","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1913662","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","field":"papers","label":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC"},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","field":"links","label":"NEJM 2020 (OS)"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"links","label":"New England Journal of Medicine 2020 (overall survival)"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa1914347","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1914347","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Objective response (independent review, primary efficacy analysis))"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Complete response (primary efficacy analysis))"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Objective response (intention to treat))"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Progression-free survival at 12 months)"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Overall survival at 12 months)"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Grade 3 or higher cytokine release syndrome)"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"outcomes.source (Grade 3 or higher neurologic events)"}]},{"url":"https://doi.org/10.1056/NEJMoa1914347","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1914347","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","field":"links","label":"ZUMA-2 (NEJM 2020)"},{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa1914510","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1914510","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020","kind":"paper","name":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1914609","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1914609","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","field":"outcomes.source (Overall survival)"},{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","field":"papers","label":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases"},{"id":"paper-her2climb-nejm-2020","kind":"paper","name":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases","route":"/key-papers/paper-her2climb-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","field":"links","label":"HER2CLIMB (NEJM 2020)"}]},{"url":"https://doi.org/10.1056/nejmoa1915315","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1915315","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-minard-colin-n-engl-j-med","kind":"paper","name":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children","route":"/key-papers/paper-minard-colin-n-engl-j-med/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1915315","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1915315","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"links","label":"Inter-B-NHL Ritux 2010: rituximab in high-risk paediatric B-NHL (NEJM 2020)"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"standardOfCare.guideline (Children and adolescents, all stages)"},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/","field":"links","label":"Minard-Colin et al., NEJM 2020"},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/","field":"outcomes.source (3-year event-free survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa1915745","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1915745","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"outcomes.source (Overall survival (updated))"},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"outcomes.source (Progression-free survival)"},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"outcomes.source (Objective response rate)"},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","field":"papers","label":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer"},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","field":"papers","label":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer"},{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/","field":"links","label":"NEJM 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa1917338","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1917338","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/","field":"papers","label":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17"},{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/NEJMoa1917346","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1917346","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"impower110","kind":"trial","name":"IMpower110","route":"/trials/impower110/","field":"links","label":"IMpower110 (New England Journal of Medicine 2020)"},{"id":"impower110","kind":"trial","name":"IMpower110","route":"/trials/impower110/","field":"outcomes.source (Overall survival (highest PD-L1 expression, EGFR and ALK wild-type))"}]},{"url":"https://doi.org/10.1056/NEJMoa2002787","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2002787","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wolf-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","field":"links","label":"GEOMETRY mono-1 (NEJM 2020)"},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/","field":"links","label":"New England Journal of Medicine 2020"},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/","field":"outcomes.source (Objective response rate, MET exon 14 skipping)"}]},{"url":"https://doi.org/10.1056/NEJMoa2002788","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2002788","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-javelin-bladder-100-nejm-2020","kind":"paper","name":"JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer","route":"/key-papers/paper-javelin-bladder-100-nejm-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa2004325","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2004325","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Shore et al., oral relugolix for androgen-deprivation therapy in advanced prostate cancer (HERO, NEJM 2020)"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"links","label":"HERO (New England Journal of Medicine 2020)"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"outcomes.source (Sustained castration through 48 weeks)"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"outcomes.source (Castrate testosterone on day 4)"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"outcomes.source (Major adverse cardiovascular events)"}]},{"url":"https://doi.org/10.1056/NEJMoa2004407","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2004407","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","field":"papers","label":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations"},{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","field":"links","label":"VISION (NEJM 2020)"},{"id":"paper-vision-tepotinib-paik-nejm-2020","kind":"paper","name":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","route":"/key-papers/paper-vision-tepotinib-paik-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"links","label":"NEJM 2020"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"outcomes.source (Objective response rate by independent review, combined-biopsy group (at least 9 months of follow-up))"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"outcomes.source (Median duration of response by independent review, combined-biopsy group)"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"outcomes.source (Objective response rate by independent review, liquid-biopsy group)"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"outcomes.source (Objective response rate by independent review, tissue-biopsy group)"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"outcomes.source (Grade 3 or higher treatment-related adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa2004413","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2004413","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-gastric01-nejm-2020","kind":"paper","name":"DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","route":"/key-papers/paper-destiny-gastric01-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/","field":"outcomes.source (Objective response (independent central review))"},{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa2004444","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2004444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"quazar-aml-001","kind":"trial","name":"QUAZAR AML-001","route":"/trials/quazar-aml-001/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa2004444","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2004444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quazar-aml-001-wei-nejm-2020","kind":"paper","name":"QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission","route":"/key-papers/paper-quazar-aml-001-wei-nejm-2020/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/nejmoa2005493","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2005493","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-combi-ad-n-engl-j-med-2020-update","kind":"paper","name":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","route":"/key-papers/paper-combi-ad-n-engl-j-med-2020-update/","field":"links","label":"N Engl J Med 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa2005653","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2005653","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-libretto-001-selpercatinib-nsclc-nejm-2020","kind":"paper","name":"LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","field":"links","label":"LIBRETTO-001 (New England Journal of Medicine 2020)"}]},{"url":"https://doi.org/10.1056/NEJMoa2012971","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2012971","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","field":"outcomes.source (Complete remission)"},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","field":"outcomes.source (Composite CR (CR + CRi))"},{"id":"idea-shortened-venetoclax","kind":"idea","name":"Shorter venetoclax courses in unfit AML","route":"/ideas/idea-shortened-venetoclax/","field":"links","label":"VIALE-A: azacitidine and venetoclax in previously untreated acute myeloid leukaemia (NEJM 2020)"},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2016272","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2016272","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","field":"outcomes.source (Disease-free survival at 18 months)"},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"papers","label":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults"}]},{"url":"https://doi.org/10.1056/NEJMoa2017699","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2017699","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","field":"papers","label":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"papers","label":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"papers","label":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"papers","label":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"papers","label":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"metrics (Median progression-free survival with pembrolizumab vs chemotherapy in MSI-high colorectal cancer (KEYNOTE-177), showing the gain when a cold cancer is immunogenic)"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","field":"links","label":"NEJM 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa2026982","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2026982","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://doi.org/10.1056/NEJMoa2027071","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2027071","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","field":"papers","label":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer"},{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","field":"papers","label":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer"},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","field":"papers","label":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/","field":"links","label":"NEJM 2020"}]},{"url":"https://doi.org/10.1056/NEJMoa2027187","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2027187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/","field":"links","label":"N Engl J Med 2020"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"papers","label":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer"},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","field":"papers","label":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer"},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","field":"papers","label":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer"},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","field":"papers","label":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer"}]},{"url":"https://doi.org/10.1056/nejmoa2028485","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2028485","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"links","label":"Bardia, N Engl J Med 2021: ASCENT, sacituzumab govitecan in metastatic triple-negative breast cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2028485","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2028485","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","field":"links","label":"Bardia et al., sacituzumab govitecan in metastatic triple-negative breast cancer, ASCENT (NEJM 2021)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Neutropenia (grade 3 or higher))"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Diarrhoea (grade 3 or higher))"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Febrile neutropenia (grade 3 or higher))"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"links","label":"ASCENT primary analysis (NEJM 2021)"},{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"},{"id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"papers","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer"},{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/","field":"links","label":"NEJM 2021"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","field":"links","label":"ASCENT (NEJM 2021)"}]},{"url":"https://doi.org/10.1056/NEJMoa2032125","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2032125","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-577-nejm-2021","kind":"paper","name":"CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer","route":"/key-papers/paper-checkmate-577-nejm-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2034442","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2034442","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","field":"outcomes.source (Overall survival (ITT))"}]},{"url":"https://doi.org/10.1056/NEJMoa2035716","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2035716","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","field":"links","label":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer (New England Journal of Medicine 2021)"},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","field":"papers","label":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer"},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"papers","label":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer"},{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/","field":"links","label":"NEJM 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2103294","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"papers","label":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer"},{"id":"paper-desktop-iii-nejm-2021","kind":"paper","name":"DESKTOP III: secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer","route":"/key-papers/paper-desktop-iii-nejm-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2103425","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103425","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","field":"papers","label":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease"},{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","field":"links","label":"Belzutifan in VHL (NEJM 2021)"},{"id":"paper-belzutifan-vhl-jonasch-nejm-2021","kind":"paper","name":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","route":"/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/","field":"links","label":"N Engl J Med 2021"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"links","label":"Belzutifan in VHL (NEJM 2021)"}]},{"url":"https://doi.org/10.1056/nejmoa2103485","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103485","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2103485","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103485","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","field":"links","label":"Tebentafusp IMCgp100-202 (NEJM 2021)"}]},{"url":"https://doi.org/10.1056/nejmoa2103695","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103695","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-n-engl-j-med-2021","kind":"paper","name":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","route":"/key-papers/paper-kras-nsclc-n-engl-j-med-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/nejmoa2105215","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2105215","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/","field":"links","label":"Tutt, N Engl J Med 2021: OlympiA, adjuvant olaparib for BRCA1- or BRCA2-mutated breast cancer (invasive disease-free survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa2105215","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2105215","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Tutt et al., adjuvant olaparib for BRCA1- or BRCA2-mutated breast cancer, OlympiA (NEJM 2021)"},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/","field":"links","label":"OlympiA (NEJM 2021)"},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","field":"papers","label":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer"},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"papers","label":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/","field":"links","label":"NEJM 2021"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","field":"links","label":"OlympiA (NEJM 2021)"}]},{"url":"https://doi.org/10.1056/NEJMoa2106391","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2106391","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","field":"papers","label":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery"},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"papers","label":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma"},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","field":"links","label":"NEJM 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2107322","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2107322","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"papers","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"papers","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"papers","label":"Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","field":"links","label":"NEJM 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2108330","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2108330","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","field":"papers","label":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer"},{"id":"paper-keynote-775-nejm-2022","kind":"paper","name":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","route":"/key-papers/paper-keynote-775-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/nejmoa2108873","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2108873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rxponder-n-engl-j-med-2021","kind":"paper","name":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","route":"/key-papers/paper-rxponder-n-engl-j-med-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2108873","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2108873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","field":"outcomes.source (5-year iDFS, premenopausal)"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"papers","label":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2109970","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2109970","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-relativity-047-nejm-2022","kind":"paper","name":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","route":"/key-papers/paper-relativity-047-nejm-2022/","field":"links","label":"NEJM 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2111380","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2111380","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","field":"papers","label":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma"},{"id":"paper-checkmate-648-nejm-2022","kind":"paper","name":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","route":"/key-papers/paper-checkmate-648-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2111953","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2111953","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-estimabl2-leboulleux-nejm-2022","kind":"paper","name":"ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer","route":"/key-papers/paper-estimabl2-leboulleux-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2112187","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2112187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","field":"papers","label":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum"},{"id":"paper-empower-cervical-1-cemiplimab-nejm-2022","kind":"paper","name":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","route":"/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2112431","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2112431","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","field":"papers","label":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer"},{"id":"paper-destiny-lung01-nejm-2022","kind":"paper","name":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung01-nejm-2022/","field":"links","label":"N Engl J Med 2022"},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"outcomes.source (Objective response (independent central review), HER2-mutant cohort)"},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"outcomes.source (Duration of response)"},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"outcomes.source (Progression-free survival)"},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"outcomes.source (Overall survival)"},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"outcomes.source (Adjudicated drug-related interstitial lung disease)"}]},{"url":"https://doi.org/10.1056/NEJMoa2112435","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2112435","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-826-nejm-2021","kind":"paper","name":"KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer","route":"/key-papers/paper-keynote-826-nejm-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2112651","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2112651","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"KEYNOTE-522 event-free survival (NEJM 2022)"},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","field":"links","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer (New England Journal of Medicine 2022)"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","field":"papers","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer"},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","field":"papers","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer"},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","field":"papers","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"papers","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer"},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","field":"papers","label":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","field":"links","label":"NEJM 2022 (EFS)"}]},{"url":"https://doi.org/10.1056/nejmoa2114663","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2114663","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2022-update","kind":"paper","name":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2115022","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2115022","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","field":"links","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer (New England Journal of Medicine 2022)"},{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","field":"links","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer (New England Journal of Medicine 2022)"},{"id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","field":"links","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer (New England Journal of Medicine 2022)"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","field":"papers","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"papers","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"papers","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"papers","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"papers","label":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer"},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/","field":"links","label":"NEJM 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2115304","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2115304","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2116133","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2116133","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","field":"links","label":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early (New England Journal of Medicine 2022)"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"papers","label":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma"},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","field":"papers","label":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2116596","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2116596","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"papers","label":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma"}]},{"url":"https://doi.org/10.1056/NEJMoa2117344","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2117344","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","field":"outcomes.source (Overall survival (median))"},{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","field":"outcomes.source (Complete remission)"},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","field":"papers","label":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy"},{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2119115","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2119115","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","field":"papers","label":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer"},{"id":"paper-arasens-nejm-2022","kind":"paper","name":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-arasens-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2200075","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2200075","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","field":"links","label":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer (New England Journal of Medicine 2022)"},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"papers","label":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer"},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","field":"links","label":"Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","field":"metrics (Adjuvant chemotherapy use with ctDNA-guided vs standard management in stage II colon cancer (DYNAMIC), with non-inferior recurrence-free survival)"},{"id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-autophagy-block-mrd","kind":"idea","name":"Block the recycling that keeps dormant cells alive","route":"/ideas/idea-bio2-autophagy-block-mrd/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-pro-dormancy-therapy","kind":"idea","name":"Keep dormant cells asleep instead of trying to kill them","route":"/ideas/idea-bio2-pro-dormancy-therapy/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-il1-awakening-blockade","kind":"idea","name":"Blunt the inflammation that wakes sleeping cancer cells","route":"/ideas/idea-bio2-il1-awakening-blockade/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-mrd-triggered-neoantigen-vaccine","kind":"idea","name":"Personalised vaccines given only when the blood test turns positive","route":"/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-marrow-niche-on-chip","kind":"idea","name":"A bone marrow niche on a chip to study human dormancy","route":"/ideas/idea-bio2-marrow-niche-on-chip/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-localise-the-mrd","kind":"idea","name":"When the blood test is positive, hunt for the lesion with sensitive imaging","route":"/ideas/idea-bio2-localise-the-mrd/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-mrd-guided-endocrine-duration","kind":"idea","name":"Use residual disease tests to decide who needs ten years of hormone therapy","route":"/ideas/idea-bio2-mrd-guided-endocrine-duration/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-mrd-coverage-with-evidence","kind":"idea","name":"Pay for residual disease tests only inside a trial or registry","route":"/ideas/idea-bio2-mrd-coverage-with-evidence/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-bio2-survivor-plasma-biobank","kind":"idea","name":"Bank yearly blood from cancer survivors so future tests can be validated","route":"/ideas/idea-bio2-survivor-plasma-biobank/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-moon-mrd-weather-service","kind":"idea","name":"A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled","route":"/ideas/idea-moon-mrd-weather-service/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"idea-moon-dormancy-eradication-programme","kind":"idea","name":"Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells","route":"/ideas/idea-moon-dormancy-eradication-programme/","field":"links","label":"Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022)"},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/NEJMoa2201048","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2201048","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"links","label":"ANCHOR (NEJM 2022)"},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"standardOfCare.guideline (Precancer (HSIL) in people with HIV)"},{"id":"paper-anchor-anal-hsil-treatment-nejm-2022","kind":"paper","name":"ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV","route":"/key-papers/paper-anchor-anal-hsil-treatment-nejm-2022/","field":"links","label":"N Engl J Med 2022"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"links","label":"ANCHOR (NEJM 2022)"},{"id":"anchor","kind":"trial","name":"ANCHOR","route":"/trials/anchor/","field":"outcomes.source (Incidence of anal cancer)"},{"id":"anchor","kind":"trial","name":"ANCHOR","route":"/trials/anchor/","field":"outcomes.source (Reduction in the rate of progression to anal cancer with treatment)"}]},{"url":"https://doi.org/10.1056/NEJMoa2201445","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2201445","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","field":"papers","label":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer"},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"papers","label":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency"},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/","field":"papers","label":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency"},{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2201817","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2201817","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/","field":"links","label":"SHINE: ibrutinib with bendamustine and rituximab in untreated mantle cell lymphoma, New England Journal of Medicine 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2202170","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2202170","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"papers","label":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery"},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"papers","label":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery"},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"papers","label":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer"},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"papers","label":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery"},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","field":"papers","label":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery"},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/","field":"links","label":"NEJM 2022"}]},{"url":"https://doi.org/10.1056/nejmoa2202809","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2202809","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","field":"links","label":"Cortes, N Engl J Med 2022: KEYNOTE-355 overall survival by PD-L1 combined positive score"},{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"Cortes, N Engl J Med 2022: KEYNOTE-355 overall survival by PD-L1 combined positive score"}]},{"url":"https://doi.org/10.1056/NEJMoa2202809","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2202809","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cortes et al., pembrolizumab plus chemotherapy in advanced triple-negative breast cancer, KEYNOTE-355 (NEJM 2022)"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"links","label":"KEYNOTE-355 overall survival (NEJM 2022)"},{"id":"paper-keynote-355-nejm-2022","kind":"paper","name":"KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer","route":"/key-papers/paper-keynote-355-nejm-2022/","field":"links","label":"N Engl J Med 2022"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","field":"links","label":"KEYNOTE-355 (NEJM 2022)"}]},{"url":"https://doi.org/10.1056/NEJMoa2203478","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2203478","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","field":"links","label":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma (New England Journal of Medicine 2022)"},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"papers","label":"Teclistamab in relapsed or refractory multiple myeloma"},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/nejmoa2203690","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2203690","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"links","label":"Modi, N Engl J Med 2022: DESTINY-Breast04, trastuzumab deruxtecan in HER2-low advanced breast cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2203690","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2203690","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","field":"links","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group (New England Journal of Medicine 2022)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Drug-related interstitial lung disease or pneumonitis (adjudicated))"},{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","field":"links","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group (New England Journal of Medicine 2022)"},{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"papers","label":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/","field":"links","label":"NEJM 2022"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","field":"links","label":"DESTINY-Breast04 (NEJM 2022)"}]},{"url":"https://doi.org/10.1056/NEJMoa2204591","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2204591","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","field":"outcomes.source (Objective response rate)"},{"id":"paper-monumental-1-talquetamab-nejm-2022","kind":"paper","name":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","route":"/key-papers/paper-monumental-1-talquetamab-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/nejmoa2204619","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2204619","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03785249-n-engl-j-med-2022","kind":"paper","name":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","route":"/key-papers/paper-nct03785249-n-engl-j-med-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2204619","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2204619","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"papers","label":"Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation"}]},{"url":"https://doi.org/10.1056/nejmoa2204925","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2204925","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","field":"outcomes.source (Progression-free survival)"},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","field":"outcomes.source (Complete response or better)"},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","field":"outcomes.source (Grade 3 or higher treatment-related adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa2204925","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2204925","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","field":"papers","label":"Triplet therapy, transplantation, and maintenance until progression in myeloma"}]},{"url":"https://doi.org/10.1056/NEJMoa2206125","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2206125","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","field":"links","label":"6-year overall survival (Ansell 2022)"}]},{"url":"https://doi.org/10.1056/NEJMoa2206660","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2206660","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/","field":"outcomes.source (Event-free survival at 3 years)"},{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/","field":"outcomes.source (Patients given involved-site radiotherapy)"},{"id":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","kind":"paper","name":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","route":"/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2206834","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2206834","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","field":"outcomes.source (Objective response rate)"},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","field":"outcomes.source (Progression-free survival)"},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa2206913","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2206913","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/nejmoa2207586","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2207586","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kunkler-n-engl-j-med","kind":"paper","name":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","route":"/key-papers/paper-kunkler-n-engl-j-med/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2207586","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2207586","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","field":"links","label":"NEJM 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2208375","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2208375","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bretthauer, N Engl J Med 2022: NordICC, effect of colonoscopy screening on risks of colorectal cancer and related death (84,585 people)"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"Bretthauer, N Engl J Med 2022: NordICC, effect of colonoscopy screening on risks of colorectal cancer and related death (84,585 people)"},{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"links","label":"Bretthauer, N Engl J Med 2022: NordICC, effect of colonoscopy screening on risks of colorectal cancer and related death (84,585 people)"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"Bretthauer, N Engl J Med 2022: NordICC, effect of colonoscopy screening on risks of colorectal cancer and related death (84,585 people)"}]},{"url":"https://doi.org/10.1056/NEJMoa2208375","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2208375","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","field":"links","label":"DOI"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"links","label":"NordICC (NEJM 2022)"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"outcomes.source (Colorectal cancer incidence at 10 years (intention to screen))"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"outcomes.source (Colorectal cancer death at 10 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa2208470","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2208470","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"links","label":"Strickler et al., sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer (NEJM 2023)"},{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"outcomes.source (Objective response (central review))"},{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"outcomes.source (Overall survival)"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"links","label":"Strickler et al., CodeBreaK 100 pancreatic cohort (NEJM 2023)"},{"id":"paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023","kind":"paper","name":"CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","route":"/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2209454","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2209454","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-goteborg-2-n-engl-j-med-2022","kind":"paper","name":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","route":"/key-papers/paper-goteborg-2-n-engl-j-med-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/NEJMoa2209454","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2209454","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"goteborg-2","kind":"trial","name":"GÖTEBORG-2 (MRI-based prostate cancer screening)","route":"/trials/goteborg-2/","field":"links","label":"GÖTEBORG-2 (NEJM 2022)"},{"id":"goteborg-2","kind":"trial","name":"GÖTEBORG-2 (MRI-based prostate cancer screening)","route":"/trials/goteborg-2/","field":"outcomes.source (Detection of clinically insignificant prostate cancer)"}]},{"url":"https://doi.org/10.1056/nejmoa2209813","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2209813","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"outcomes.source (Pathological complete response on independent review)"},{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"outcomes.source (Pathological major response on independent review)"},{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"outcomes.source (Objective response on imaging)"}]},{"url":"https://doi.org/10.1056/NEJMoa2209813","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2209813","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"links","label":"Primary report (New England Journal of Medicine 2022)"},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","field":"papers","label":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma"},{"id":"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022","kind":"paper","name":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","route":"/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/nejmoa2210140","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2210140","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gounder-n-engl-j-med","kind":"paper","name":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors","route":"/key-papers/paper-gounder-n-engl-j-med/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2210140","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2210140","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","field":"outcomes.source (Objective response rate)"},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"links","label":"DeFi trial (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2210233","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2210233","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","field":"papers","label":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma"},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2210859","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2210859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","field":"outcomes.source (Overall survival at 3 years)"}]},{"url":"https://doi.org/10.1056/nejmoa2211437","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2211437","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-swog-s1801-n-engl-j-med-2023","kind":"paper","name":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","route":"/key-papers/paper-swog-s1801-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2211582","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2211582","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-n-engl-j-med-2023","kind":"paper","name":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","route":"/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2211582","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2211582","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","field":"outcomes.source (Overall response rate)"},{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","field":"outcomes.source (Atrial fibrillation/flutter)"}]},{"url":"https://doi.org/10.1056/nejmoa2212083","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212083","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sublobar-resection","kind":"term","name":"Sublobar resection (segmentectomy and wedge)","route":"/terms/sublobar-resection/","field":"links","label":"Altorki, N Engl J Med 2023: CALGB 140503, lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer (697 patients)"},{"id":"paper-calgb-140503-n-engl-j-med-2023","kind":"paper","name":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","route":"/key-papers/paper-calgb-140503-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2212083","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212083","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","field":"links","label":"New England Journal of Medicine 2023"},{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","field":"outcomes.source (Disease-free survival at 5 years)"},{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1056/nejmoa2212419","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212419","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"papers","label":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C"}]},{"url":"https://doi.org/10.1056/NEJMoa2212419","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212419","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","field":"papers","label":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer"},{"id":"paper-krystal-1-crc-yaeger-nejm-2023","kind":"paper","name":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","route":"/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2212856","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212856","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-partridge-n-engl-j-med","kind":"paper","name":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","route":"/key-papers/paper-partridge-n-engl-j-med/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2212856","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2212856","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"papers","label":"Interrupting endocrine therapy to attempt pregnancy after breast cancer"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"POSITIVE trial (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2213093","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2213093","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","field":"outcomes.source (Progression-free survival at 5 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa2213614","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2213614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","field":"papers","label":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma"},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","field":"papers","label":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma"},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2214122","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214122","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Hamdy et al., fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (NEJM 2023)"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"links","label":"ProtecT 15-year outcomes (New England Journal of Medicine 2023)"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"outcomes.source (Death from prostate cancer at 15 years)"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"outcomes.source (Metastases at 15 years)"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"outcomes.source (Clinical progression at 15 years)"},{"id":"prostate-treatment-choice-localised","kind":"term","name":"Choosing treatment for localised prostate cancer: what each option costs","route":"/terms/prostate-treatment-choice-localised/","field":"links","label":"ProtecT 15-year outcomes (New England Journal of Medicine 2023)"},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"metrics (Prostate cancer-specific mortality at 15 years with active monitoring vs surgery vs radiotherapy in PSA-detected disease (ProtecT))"},{"id":"paper-protect-15-year-nejm-2023","kind":"paper","name":"ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer","route":"/key-papers/paper-protect-15-year-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2214131","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214131","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","field":"outcomes.source (Progression-free survival (AKT-pathway-altered))"},{"id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","field":"links","label":"CAPItello-291: capivasertib in hormone receptor-positive advanced breast cancer (NEJM 2023)"},{"id":"paper-capitello-291-nejm-2023","kind":"paper","name":"CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-capitello-291-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","field":"links","label":"CAPItello-291 (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2214171","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214171","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","field":"papers","label":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia"},{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2214676","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214676","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2214676","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214676","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"links","label":"TRITON3 (New England Journal of Medicine 2023)"},{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/","field":"links","label":"TRITON3 (New England Journal of Medicine 2023)"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","field":"links","label":"TRITON3 (New England Journal of Medicine 2023)"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"links","label":"TRITON3 (New England Journal of Medicine 2023)"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"outcomes.source (Imaging-based progression-free survival, BRCA subgroup (median))"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"outcomes.source (Imaging-based progression-free survival, intention to treat (median))"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"outcomes.source (Imaging-based progression-free survival, ATM subgroup (median))"}]},{"url":"https://doi.org/10.1056/NEJMoa2214963","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2214963","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","kind":"paper","name":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)","route":"/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","field":"papers","label":"SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2215530","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2215530","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","kind":"paper","name":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2216334","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2216334","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/","field":"links","label":"NEJM 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2301665","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2301665","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","field":"links","label":"Overall survival analysis (Westin 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2302299","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302299","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"papers","label":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer"},{"id":"paper-trident-1-repotrectinib-nejm-2024","kind":"paper","name":"TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-trident-1-repotrectinib-nejm-2024/","field":"links","label":"N Engl J Med 2024"},{"id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","field":"links","label":"TRIDENT-1 (New England Journal of Medicine 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2302312","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302312","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nrg-gy018-nejm-2023","kind":"paper","name":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","route":"/key-papers/paper-nrg-gy018-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2302344","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302344","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2302344","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302344","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","field":"links","label":"Whelan et al., New England Journal of Medicine 2023;389:612 to 619: omitting radiotherapy after breast-conserving surgery in luminal A breast cancer"}]},{"url":"https://doi.org/10.1056/nejmoa2302983","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302983","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-671-n-engl-j-med-2023","kind":"paper","name":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-671-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2302983","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2302983","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"papers","label":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2303269","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303269","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prospect-nejm-2023","kind":"paper","name":"PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer","route":"/key-papers/paper-prospect-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","field":"links","label":"New England Journal of Medicine 2023"},{"id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","field":"outcomes.source (Disease-free survival at 5 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa2303379","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303379","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","field":"outcomes.source (Overall survival)"},{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","field":"links","label":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy (New England Journal of Medicine 2023)"},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2303383","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303383","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","field":"papers","label":"Atezolizumab for advanced alveolar soft part sarcoma"},{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2303810","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303810","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"papers","label":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation"}]},{"url":"https://doi.org/10.1056/nejmoa2303815","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303815","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bouffet-n-engl-j-med","kind":"paper","name":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","route":"/key-papers/paper-bouffet-n-engl-j-med/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2303815","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303815","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","field":"links","label":"TADPOLE: dabrafenib plus trametinib in BRAF V600E pLGG (NEJM 2023)"},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","field":"links","label":"Bouffet et al., NEJM 2023"},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","field":"outcomes.source (Overall response rate (independent review, RANO))"},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa2303974","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2303974","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","field":"papers","label":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer"},{"id":"paper-embark-nejm-2023","kind":"paper","name":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","route":"/key-papers/paper-embark-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2304194","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304194","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/","field":"links","label":"NEJM 2023"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"links","label":"INDIGO: vorasidenib in IDH-mutant grade 2 glioma (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/nejmoa2304714","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304714","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eclipse-shield-n-engl-j-med-2024","kind":"paper","name":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","route":"/key-papers/paper-eclipse-shield-n-engl-j-med-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2304714","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304714","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","field":"links","label":"ECLIPSE (NEJM 2024)"},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","field":"outcomes.source (Sensitivity for colorectal cancer)"},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","field":"outcomes.source (Specificity for advanced neoplasia)"}]},{"url":"https://doi.org/10.1056/nejmoa2304753","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304753","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2304875","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304875","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2304875","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2304875","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"papers","label":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2305488","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2305488","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cdk46-plus-endocrine","kind":"pairing","name":"CDK4/6 inhibitor + endocrine therapy","route":"/pairings/cdk46-plus-endocrine/","field":"links","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer (New England Journal of Medicine 2024)"},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","field":"papers","label":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/","field":"links","label":"NEJM 2024"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","field":"links","label":"NATALEE (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2306434","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2306434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"papers","label":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC"}]},{"url":"https://doi.org/10.1056/nejmoa2306441","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2306441","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04538664-n-engl-j-med-2023","kind":"paper","name":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","route":"/key-papers/paper-nct04538664-n-engl-j-med-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/nejmoa2307563","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2307563","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lincoff-n-engl-j-med","kind":"paper","name":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","route":"/key-papers/paper-lincoff-n-engl-j-med/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2307563","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2307563","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","field":"links","label":"SELECT (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2307980","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2307980","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","field":"links","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer (New England Journal of Medicine 2023)"},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","field":"papers","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"papers","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","field":"papers","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","field":"papers","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"papers","label":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","field":"links","label":"NEJM 2023"},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","field":"links","label":"DeLLphi-301 (New England Journal of Medicine 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2308795","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2308795","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","field":"links","label":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer (New England Journal of Medicine 2023)"},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","field":"papers","label":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"papers","label":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer"},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","field":"links","label":"NEJM 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2308900","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2308900","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","field":"papers","label":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer"},{"id":"paper-shape-nejm-2024","kind":"paper","name":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","route":"/key-papers/paper-shape-nejm-2024/","field":"links","label":"N Engl J Med 2024"},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","field":"outcomes.source (Pelvic recurrence at 3 years (non-inferiority))"},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","field":"outcomes.source (Urinary incontinence beyond 4 weeks after surgery)"},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","field":"outcomes.source (Urinary retention beyond 4 weeks after surgery)"}]},{"url":"https://doi.org/10.1056/NEJMoa2309169","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2309169","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","field":"papers","label":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer"},{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","route":"/key-papers/paper-mirasol-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2309457","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2309457","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-libretto-431-nejm-2023","kind":"paper","name":"LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer","route":"/key-papers/paper-libretto-431-nejm-2023/","field":"links","label":"N Engl J Med 2023"}]},{"url":"https://doi.org/10.1056/NEJMoa2309719","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2309719","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","field":"papers","label":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer"},{"id":"paper-libretto-531-nejm-2023","kind":"paper","name":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","route":"/key-papers/paper-libretto-531-nejm-2023/","field":"links","label":"N Engl J Med 2023"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"links","label":"LIBRETTO-531 (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/nejmoa2310336","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2310336","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blue-c-n-engl-j-med-2024","kind":"paper","name":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","route":"/key-papers/paper-blue-c-n-engl-j-med-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2310336","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2310336","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cologuard-plus","kind":"drug","name":"Cologuard Plus","route":"/drugs/cologuard-plus/","field":"links","label":"BLUE-C (NEJM 2024)"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"links","label":"BLUE-C (NEJM 2024)"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"outcomes.source (Sensitivity for colorectal cancer)"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"outcomes.source (Specificity for advanced neoplasia)"}]},{"url":"https://doi.org/10.1056/nejmoa2310532","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2310532","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2310532","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2310532","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/nejmoa2311926","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2311926","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04025879-n-engl-j-med-2024","kind":"paper","name":"Perioperative Nivolumab in Resectable Lung Cancer","route":"/key-papers/paper-nct04025879-n-engl-j-med-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2311926","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2311926","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","field":"links","label":"CheckMate 77T (New England Journal of Medicine 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2312054","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2312054","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","field":"outcomes.source (MRD negativity (10⁻⁵))"},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2312117","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2312117","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","field":"papers","label":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer"},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","field":"papers","label":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer"},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","field":"papers","label":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer"},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2312695","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2312695","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","field":"links","label":"NEJM 2024 (OS)"}]},{"url":"https://doi.org/10.1056/NEJMoa2312948","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2312948","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","field":"outcomes.source (Relapse-free survival at 3 years)"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"papers","label":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults"},{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","route":"/people/nicola-gokbuget/","field":"papers","label":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission"},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1056/NEJMoa2313487","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2313487","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"senomac","kind":"trial","name":"SENOMAC","route":"/trials/senomac/","field":"links","label":"SENOMAC (New England Journal of Medicine 2024)"},{"id":"senomac","kind":"trial","name":"SENOMAC","route":"/trials/senomac/","field":"outcomes.source (Recurrence-free survival at 5 years)"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"de Boniface et al., omitting axillary dissection in breast cancer with sentinel-node metastases, SENOMAC (NEJM 2024)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"de Boniface et al., omitting axillary dissection in breast cancer with sentinel-node metastases, SENOMAC (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2313811","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2313811","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-innovatv-301-tisotumab-nejm-2024","kind":"paper","name":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","route":"/key-papers/paper-innovatv-301-tisotumab-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2313906","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2313906","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","field":"outcomes.source (Objective response rate)"},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"papers","label":"Belzutifan versus everolimus for advanced renal-cell carcinoma"}]},{"url":"https://doi.org/10.1056/NEJMoa2400634","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2400634","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","field":"papers","label":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients"},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","field":"papers","label":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients"},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","field":"papers","label":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2400985","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2400985","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/","field":"outcomes.source (Radiographic response rate, target tumours (brigatinib sub-study))"},{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/","field":"outcomes.source (Radiographic response rate, all tumours (brigatinib sub-study))"},{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/","field":"outcomes.source (Hearing improvement in eligible ears (brigatinib sub-study))"},{"id":"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024","kind":"paper","name":"INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours","route":"/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/nejmoa2402141","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2402141","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2402141","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2402141","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2402604","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2402604","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","field":"papers","label":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma"},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/nejmoa2402614","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2402614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2402614","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2402614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/nejmoa2403365","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2403365","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-van-as-n-engl-j-med","kind":"paper","name":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","route":"/key-papers/paper-van-as-n-engl-j-med/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2403365","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2403365","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-radiotherapy-fractionation","kind":"term","name":"How many radiotherapy visits: the prostate fractionation trials","route":"/terms/prostate-radiotherapy-fractionation/","field":"links","label":"PACE-B (New England Journal of Medicine 2024)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"links","label":"NEJM 2024"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"links","label":"PACE-B (New England Journal of Medicine 2024)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"outcomes.source (Freedom from biochemical or clinical failure at 5 years)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"outcomes.source (Late RTOG grade 2 or higher genitourinary toxicity at 5 years)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"outcomes.source (Late RTOG grade 2 or higher gastrointestinal toxicity at 5 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa2403614","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2403614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","field":"papers","label":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"papers","label":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","field":"papers","label":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"papers","label":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2403991","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2403991","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"outcomes.source (Progression-free survival (pancreatic NET))"},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"outcomes.source (Progression-free survival (extra-pancreatic NET))"},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","field":"papers","label":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours"},{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","field":"links","label":"N Engl J Med 2025"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"links","label":"CABINET (NEJM 2024)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"links","label":"CABINET (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2404512","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2404512","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2404625","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2404625","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2024","kind":"paper","name":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2404625","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2404625","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","field":"outcomes.source (Objective response rate)"},{"id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","field":"links","label":"INAVO120: inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (NEJM 2024)"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","field":"links","label":"INAVO120 (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2404873","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2404873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","field":"outcomes.source (Progression-free survival)"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/","field":"links","label":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer (New England Journal of Medicine 2024)"},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/","field":"links","label":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer (New England Journal of Medicine 2024)"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"papers","label":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer"},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/","field":"papers","label":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer"},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2405008","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2405008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"links","label":"Schram et al., efficacy of zenocutuzumab in NRG1 fusion-positive cancer (NEJM 2025)"},{"id":"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","kind":"paper","name":"eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer","route":"/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/","field":"links","label":"N Engl J Med 2025"},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"links","label":"Schram et al., efficacy of zenocutuzumab in NRG1 fusion-positive cancer (NEJM 2025)"},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"links","label":"eNRGy (New England Journal of Medicine 2025)"},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"outcomes.source (Objective response, pancreatic cancer)"},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"outcomes.source (Objective response, all evaluable tumour types)"}]},{"url":"https://doi.org/10.1056/NEJMoa2405090","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2405090","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/NEJMoa2405888","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2405888","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","field":"outcomes.source (Any-grade peripheral neuropathy)"},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"papers","label":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma"},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/","field":"links","label":"Full text (DOI)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"links","label":"SWOG S1826 (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/NEJMoa2407417","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2407417","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","field":"papers","label":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma"},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","field":"papers","label":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma"},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","field":"papers","label":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"papers","label":"Long-term survival with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma (CheckMate 067)"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"papers","label":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma"},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","field":"links","label":"NEJM 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2407934","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2407934","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"links","label":"McHugh et al., New England Journal of Medicine 2025 (BARCODE1): assessment of a polygenic risk score in screening for prostate cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2408154","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2408154","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","field":"outcomes.source (Overall survival)"},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","field":"papers","label":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer"},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/","field":"links","label":"NEJM 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2409029","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409029","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","field":"papers","label":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma"},{"id":"paper-aquila-daratumumab-smouldering-nejm-2025","kind":"paper","name":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","route":"/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/","field":"links","label":"N Engl J Med 2025"},{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/","field":"outcomes.source (Progression-free survival at 5 years (progression to active myeloma or death))"},{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1056/nejmoa2409408","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409408","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","field":"outcomes.source (Progression-free survival at 3 years)"},{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","field":"outcomes.source (Mortality at 90 days after surgery)"}]},{"url":"https://doi.org/10.1056/nejmoa2409515","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409515","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2409515","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409515","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","field":"links","label":"N Engl J Med 2024"},{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Groarke et al., ponsegromab for cancer cachexia (NEJM 2024)"},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"links","label":"Groarke et al., Ponsegromab for cancer cachexia (NEJM 2024)"},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"metrics (Weight gain with the GDF-15 antibody ponsegromab vs placebo at 12 weeks in cancer cachexia (highest dose))"},{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","field":"links","label":"Groarke et al., Ponsegromab for the treatment of cancer cachexia (NEJM 2024)"},{"id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","route":"/ideas/idea-cachexia-gdf15-prevention/","field":"links","label":"Groarke et al., Ponsegromab for the treatment of cancer cachexia (NEJM 2024)"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Ponsegromab phase 2 (NEJM 2024)"},{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","field":"links","label":"Ponsegromab phase 2 (NEJM 2024)"},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","field":"links","label":"Groarke et al. (NEJM 2024)"},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","field":"outcomes.source (Change in body weight at 12 weeks (placebo-adjusted))"}]},{"url":"https://doi.org/10.1056/NEJMoa2409804","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409804","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"outcomes.source (Progression-free survival (AV vs CIT))"}]},{"url":"https://doi.org/10.1056/nejmoa2409932","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409932","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"Schmid, N Engl J Med 2024: KEYNOTE-522 overall survival"},{"id":"paper-keynote-522-n-engl-j-med-2024-update","kind":"paper","name":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2024-update/","field":"links","label":"N Engl J Med 2024"}]},{"url":"https://doi.org/10.1056/NEJMoa2409932","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2409932","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Schmid et al., overall survival with pembrolizumab in early-stage triple-negative breast cancer, KEYNOTE-522 (NEJM 2024)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"KEYNOTE-522 overall survival (NEJM 2024)"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","field":"links","label":"KEYNOTE-522 overall survival (NEJM 2024)"}]},{"url":"https://doi.org/10.1056/nejmoa2410858","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2410858","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ember-3-n-engl-j-med-2025","kind":"paper","name":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","route":"/key-papers/paper-ember-3-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2411680","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2411680","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"papers","label":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children"}]},{"url":"https://doi.org/10.1056/NEJMoa2412063","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2412063","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"links","label":"INSEMA primary results (New England Journal of Medicine 2025)"},{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"outcomes.source (Invasive disease-free survival at 5 years)"},{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"outcomes.source (Axillary recurrence as a first primary-outcome event)"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"Reimer et al., axillary surgery in breast cancer, primary results of the INSEMA trial (NEJM 2025)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Reimer et al., axillary surgery in breast cancer, primary results of the INSEMA trial (NEJM 2025)"}]},{"url":"https://doi.org/10.1056/NEJMoa2412225","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2412225","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"post-mastectomy-radiotherapy","kind":"term","name":"Radiotherapy after mastectomy","route":"/terms/post-mastectomy-radiotherapy/","field":"links","label":"SUPREMO ten-year survival (New England Journal of Medicine 2025)"},{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"links","label":"SUPREMO ten-year survival (New England Journal of Medicine 2025)"},{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"outcomes.source (Chest-wall recurrence)"},{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"outcomes.source (Disease-free survival at 10 years)"}]},{"url":"https://doi.org/10.1056/NEJMoa2414859","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2414859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsabp-b51","kind":"trial","name":"NSABP B-51 / RTOG 1304","route":"/trials/nsabp-b51/","field":"links","label":"NSABP B-51/RTOG 1304 (New England Journal of Medicine 2025)"},{"id":"nsabp-b51","kind":"trial","name":"NSABP B-51 / RTOG 1304","route":"/trials/nsabp-b51/","field":"outcomes.source (Invasive breast cancer recurrence-free interval)"}]},{"url":"https://doi.org/10.1056/NEJMoa2415434","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2415434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-689-nejm-2025","kind":"paper","name":"KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer","route":"/key-papers/paper-keynote-689-nejm-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2415566","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2415566","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05587296-n-engl-j-med-2025","kind":"paper","name":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","route":"/key-papers/paper-nct05587296-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2501796","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2501796","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2025-update/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2502099","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502099","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tarlatamab-sclc-n-engl-j-med-2025","kind":"paper","name":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","route":"/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2502099","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502099","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1056/nejmoa2502449","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502449","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"outcomes.source (Disease-free survival at 24 months)"},{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"outcomes.source (Freedom from locoregional recurrence)"},{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"outcomes.source (Freedom from distant recurrence)"},{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"outcomes.source (Grade 3 or higher adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa2502449","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502449","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"links","label":"Primary report (New England Journal of Medicine 2025)"},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","field":"papers","label":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"C-POST (NEJM 2025)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (High-risk after surgery and radiotherapy)"},{"id":"paper-c-post-adjuvant-cemiplimab-nejm-2025","kind":"paper","name":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","route":"/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/","field":"links","label":"N Engl J Med 2025"},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"links","label":"C-POST (NEJM 2025)"},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"standardOfCare.guideline (Adjuvant after surgery and radiotherapy)"}]},{"url":"https://doi.org/10.1056/NEJMoa2502760","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502760","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","field":"links","label":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer (New England Journal of Medicine 2025)"},{"id":"idea-exercise-as-adjuvant","kind":"idea","name":"Structured exercise prescribed like a drug in all curative-intent cancer care","route":"/ideas/idea-exercise-as-adjuvant/","field":"links","label":"CHALLENGE: structured exercise after adjuvant chemotherapy for colon cancer (NEJM 2025)"},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"papers","label":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer"},{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","route":"/people/kerry-courneya/","field":"papers","label":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer"},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","field":"papers","label":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer"},{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","field":"links","label":"DOI"},{"id":"structured-exercise-survivorship","kind":"technology","name":"Structured exercise programmes after curative treatment","route":"/technologies/structured-exercise-survivorship/","field":"links","label":"CHALLENGE (NEJM 2025)"},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","field":"links","label":"Courneya et al. (NEJM 2025)"},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","field":"outcomes.source (Disease-free survival at 5 years)"},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","field":"outcomes.source (Overall survival at 8 years)"}]},{"url":"https://doi.org/10.1056/nejmoa2502929","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502929","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-serena-6-n-engl-j-med-2025","kind":"paper","name":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","route":"/key-papers/paper-serena-6-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2502931","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2502931","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-816-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","route":"/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2503701","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2503701","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-matterhorn-nejm-2025","kind":"paper","name":"MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer","route":"/key-papers/paper-matterhorn-nejm-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2503704","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2503704","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-beamion-lung-1-zongertinib-nejm-2025","kind":"paper","name":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/","field":"links","label":"N Engl J Med 2025"},{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","field":"links","label":"New England Journal of Medicine 2025"},{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","field":"outcomes.source (Confirmed objective response rate)"}]},{"url":"https://doi.org/10.1056/nejmoa2504650","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2504650","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2504650","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2504650","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"ALASCCA (NEJM 2025)"},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","field":"links","label":"Martling et al. (NEJM 2025)"},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","field":"outcomes.source (Time to recurrence at 3 years, group A (PIK3CA exon 9/20))"},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","field":"outcomes.source (Time to recurrence at 3 years, group B (other PI3K-pathway alterations))"}]},{"url":"https://doi.org/10.1056/nejmoa2505783","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2505783","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05379985-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","route":"/key-papers/paper-nct05379985-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/NEJMoa2505783","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2505783","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"Wolpin et al., daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer, phase 1 (NEJM 2026)"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","field":"links","label":"Wolpin et al., daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer (NEJM 2026)"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","field":"outcomes.source (Objective response, second-line RAS G12 pancreatic cancer at 300 mg)"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","field":"outcomes.source (Overall survival, second-line RAS G12 pancreatic cancer at 300 mg)"}]},{"url":"https://doi.org/10.1056/nejmoa2507874","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2507874","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atomic-n-engl-j-med-2026","kind":"paper","name":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","route":"/key-papers/paper-atomic-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2508668","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2508668","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-breast09-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","route":"/key-papers/paper-destiny-breast09-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/NEJMoa2508668","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2508668","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","field":"outcomes.source (Objective response rate)"},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa2508820","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2508820","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2508959","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2508959","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ascent-04-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-04-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/NEJMoa2508959","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2508959","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","field":"links","label":"ASCENT-04/KEYNOTE-D19 (NEJM 2026)"},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","field":"outcomes.source (Objective response rate)"},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1056/nejmoa2511065","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2511065","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-soho-01-n-engl-j-med-2025","kind":"paper","name":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","route":"/key-papers/paper-soho-01-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/nejmoa2511218","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2511218","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-patina-n-engl-j-med-2026","kind":"paper","name":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","route":"/key-papers/paper-patina-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","field":"outcomes.source (Progression-free survival (investigator-assessed))"},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","field":"outcomes.source (Grade 3 adverse events)"},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","field":"outcomes.source (Grade 4 adverse events)"}]},{"url":"https://doi.org/10.1056/nejmoa2511734","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2511734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ascent-03-n-engl-j-med-2025","kind":"paper","name":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-03-n-engl-j-med-2025/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMoa2511734","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2511734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"links","label":"ASCENT-03 (NEJM 2025)"}]},{"url":"https://doi.org/10.1056/nejmoa2512071","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2512071","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/NEJMoa2512275","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2512275","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","field":"links","label":"TRANSCEND (NEJM 2026)"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"links","label":"NEJM 2026"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"outcomes.source (Mean percent change in body-mass index at 52 weeks after dose escalation (pivotal cohort))"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"outcomes.source (Change in the weekly average of maximal daily hunger score at 52 weeks (participants aged 12 and older; scale 0 to 10))"},{"id":"paper-transcend-miller-nejm-2026","kind":"paper","name":"Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)","route":"/key-papers/paper-transcend-miller-nejm-2026/","field":"links","label":"NEJM 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2514661","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2514661","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-breast05-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","route":"/key-papers/paper-destiny-breast05-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2602628","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2602628","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2603878","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2603878","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03767244-n-engl-j-med-2026","kind":"paper","name":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","route":"/key-papers/paper-nct03767244-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2604126","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2604126","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2604461","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2604461","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05668988-n-engl-j-med-2026","kind":"paper","name":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","route":"/key-papers/paper-nct05668988-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmoa2605555","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2605555","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/NEJMoa2605555","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2605555","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"O'Reilly et al., RASolute 302 (NEJM 2026)"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"O'Reilly et al., daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer, RASolute 302 (NEJM 2026)"}]},{"url":"https://doi.org/10.1056/nejmoa2610229","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2610229","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","field":"links","label":"N Engl J Med 2026"}]},{"url":"https://doi.org/10.1056/nejmp1409841","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMp1409841","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ahn-n-engl-j-med","kind":"paper","name":"Korea's thyroid-cancer \"epidemic\"--screening and overdiagnosis","route":"/key-papers/paper-ahn-n-engl-j-med/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMp1409841","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMp1409841","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-thyroid-overdiagnosis-reversal","kind":"idea","name":"Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis","route":"/ideas/idea-thyroid-overdiagnosis-reversal/","field":"links","label":"Ahn et al., Korea's thyroid cancer epidemic: screening and overdiagnosis (NEJM 2014)"},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"links","label":"Ahn, Kim & Welch, Korea's thyroid-cancer epidemic (NEJM 2014)"},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"metrics (Increase in thyroid cancer incidence in South Korea 1993-2011 with no change in mortality)"}]},{"url":"https://doi.org/10.1056/NEJMp2109826","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMp2109826","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","field":"papers","label":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"Shah, Rahman, Theoret & Pazdur, The drug-dosing conundrum in oncology: when less is more (NEJM 2021)"},{"id":"paper-drug-dosing-conundrum-nejm-2021","kind":"paper","name":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","route":"/key-papers/paper-drug-dosing-conundrum-nejm-2021/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1056/nejmra021562","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMra021562","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"papers","label":"Prostate Cancer"}]},{"url":"https://doi.org/10.1056/NEJMra043186","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMra043186","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"papers","label":"Trastuzumab--mechanism of action and use in clinical practice"}]},{"url":"https://doi.org/10.1056/NEJMra0901557","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMra0901557","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","field":"links","label":"N Engl J Med 2010"}]},{"url":"https://doi.org/10.1056/NEJMra1400972","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1400972","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hunger-mullighan-all-children-nejm-2015","kind":"paper","name":"Acute lymphoblastic leukaemia in children (review)","route":"/key-papers/paper-hunger-mullighan-all-children-nejm-2015/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/nejmra1406184","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1406184","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dohner-n-engl-j-med","kind":"paper","name":"Acute Myeloid Leukemia","route":"/key-papers/paper-dohner-n-engl-j-med/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMra1406184","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1406184","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","field":"links","label":"Review: Acute Myeloid Leukemia (NEJM 2015)"}]},{"url":"https://doi.org/10.1056/nejmra1510062","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1510062","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-woodcock-n-engl-j-med","kind":"paper","name":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","route":"/key-papers/paper-woodcock-n-engl-j-med/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMra1510062","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1510062","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/","field":"links","label":"Woodcock and LaVange, Master protocols to study multiple therapies, multiple diseases, or both (NEJM 2017)"},{"id":"umbrella-trial","kind":"term","name":"Umbrella trial","route":"/terms/umbrella-trial/","field":"links","label":"Woodcock and LaVange, Master protocols to study multiple therapies, multiple diseases, or both (NEJM 2017)"}]},{"url":"https://doi.org/10.1056/NEJMra1813254","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra1813254","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-morice-mucinous-ovarian-carcinoma-nejm-2019","kind":"paper","name":"Mucinous ovarian carcinoma (review)","route":"/key-papers/paper-morice-mucinous-ovarian-carcinoma-nejm-2019/","field":"links","label":"N Engl J Med 2019"}]},{"url":"https://doi.org/10.1056/NEJMra2020394","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra2020394","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carlson-link-vestibular-schwannomas-nejm-2021","kind":"paper","name":"Vestibular schwannomas (review)","route":"/key-papers/paper-carlson-link-vestibular-schwannomas-nejm-2021/","field":"links","label":"N Engl J Med 2021"}]},{"url":"https://doi.org/10.1056/NEJMra2200869","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMra2200869","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sinicrope-early-onset-crc-nejm-2022","kind":"paper","name":"Increasing incidence of early-onset colorectal cancer (review)","route":"/key-papers/paper-sinicrope-early-onset-crc-nejm-2022/","field":"links","label":"N Engl J Med 2022"}]},{"url":"https://doi.org/10.1056/nejmsa012337","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa012337","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-birkmeyer-n-engl-j-med","kind":"paper","name":"Hospital volume and surgical mortality in the United States","route":"/key-papers/paper-birkmeyer-n-engl-j-med/","field":"links","label":"N Engl J Med 2002"}]},{"url":"https://doi.org/10.1056/NEJMsa012337","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa012337","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"centralisation","kind":"term","name":"Centralisation and high-volume centres","route":"/terms/centralisation/","field":"links","label":"Birkmeyer et al., Hospital volume and surgical mortality in the United States (NEJM 2002)"}]},{"url":"https://doi.org/10.1056/nejmsa060185","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa060185","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oeffinger-n-engl-j-med","kind":"paper","name":"Chronic health conditions in adult survivors of childhood cancer","route":"/key-papers/paper-oeffinger-n-engl-j-med/","field":"links","label":"N Engl J Med 2006"}]},{"url":"https://doi.org/10.1056/NEJMsa060185","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa060185","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"links","label":"Oeffinger et al., Chronic health conditions in adult survivors of childhood cancer (NEJM 2006)"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"metrics (Adult survivors of childhood cancer with at least one chronic health condition, and with a severe or life-threatening condition (CCSS))"}]},{"url":"https://doi.org/10.1056/nejmsa1200223","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa1200223","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-downing-n-engl-j-med","kind":"paper","name":"Regulatory review of novel therapeutics--comparison of three regulatory agencies","route":"/key-papers/paper-downing-n-engl-j-med/","field":"links","label":"N Engl J Med 2012"}]},{"url":"https://doi.org/10.1056/NEJMsa1200223","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMsa1200223","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"links","label":"Downing et al., Regulatory review of novel therapeutics: comparison of three regulatory agencies (NEJM 2012)"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"metrics (Median total review time for novel therapeutics at FDA vs EMA vs Health Canada, 2001-2010)"}]},{"url":"https://doi.org/10.1056/nejmsa1409364","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMsa1409364","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-anderson-n-engl-j-med","kind":"paper","name":"Compliance with results reporting at ClinicalTrials.gov","route":"/key-papers/paper-anderson-n-engl-j-med/","field":"links","label":"N Engl J Med 2015"}]},{"url":"https://doi.org/10.1056/NEJMsa1409364","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMsa1409364","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"links","label":"Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"metrics (Applicable trials reporting results on ClinicalTrials.gov within 12 months of completion, 2008-2013)"},{"id":"idea-tr2-preclinical-negative-registry","kind":"idea","name":"A registry for preclinical experiments that did not work","route":"/ideas/idea-tr2-preclinical-negative-registry/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-negative-results-journal","kind":"idea","name":"A funder-backed, indexed journal of negative and inconclusive cancer results","route":"/ideas/idea-tr2-negative-results-journal/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-irb-results-gate","kind":"idea","name":"No new trial approval until the sponsor has reported its old ones","route":"/ideas/idea-tr2-irb-results-gate/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","route":"/ideas/idea-tr2-termination-reports/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-failed-trial-biobank","kind":"idea","name":"Rescue the biological samples from failed trials for biomarker research","route":"/ideas/idea-tr2-failed-trial-biobank/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-writeup-grants","kind":"idea","name":"Small grants that pay scientists to write up abandoned projects","route":"/ideas/idea-tr2-writeup-grants/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-null-result-reporting","kind":"idea","name":"Grant progress reports must list what did not work","route":"/ideas/idea-tr2-null-result-reporting/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-model-report-cards","kind":"idea","name":"Score every preclinical model by how often it predicted the clinical result","route":"/ideas/idea-tr2-model-report-cards/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-tr2-reversal-registry","kind":"idea","name":"A public registry of cancer treatments that were later shown not to work","route":"/ideas/idea-tr2-reversal-registry/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"},{"id":"idea-moon-negative-results-ledger","kind":"idea","name":"A global ledger of negative results and failed compounds with mandatory deposition","route":"/ideas/idea-moon-negative-results-ledger/","field":"links","label":"Bottleneck evidence (Failures are hidden): Anderson et al., Compliance with results reporting at ClinicalTrials.gov (NEJM 2015)"}]},{"url":"https://doi.org/10.1056/NEJMsr1606602","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMsr1606602","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/","field":"links","label":"DOI"},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","field":"links","label":"IARC Handbook: body fatness and cancer (NEJM 2016)"},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/","field":"links","label":"IARC Handbook: body fatness and cancer (NEJM 2016)"}]},{"url":"https://doi.org/10.1073/pnas.0506580102","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0506580102","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","field":"links","label":"Subramanian et al., Gene set enrichment analysis (PNAS 2005)"}]},{"url":"https://doi.org/10.1073/pnas.0530291100","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0530291100","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","field":"papers","label":"Prospective identification of tumorigenic breast cancer cells"},{"id":"paper-al-hajj-breast-cancer-stem-cells-pnas-2003","kind":"paper","name":"Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells","route":"/key-papers/paper-al-hajj-breast-cancer-stem-cells-pnas-2003/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1073/pnas.0700746104","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0700746104","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"papers","label":"Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties"}]},{"url":"https://doi.org/10.1073/pnas.0710370104","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0710370104","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","field":"papers","label":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib"}]},{"url":"https://doi.org/10.1073/pnas.0909114106","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0909114106","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","field":"links","label":"Persson, PNAS 2009: recurrent MYB-NFIB fusion in adenoid cystic carcinomas of the breast and head and neck"},{"id":"paper-persson-myb-nfib-pnas-2009","kind":"paper","name":"Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma","route":"/key-papers/paper-persson-myb-nfib-pnas-2009/","field":"links","label":"Proc Natl Acad Sci U S A 2009"}]},{"url":"https://doi.org/10.1073/pnas.0932692100","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.0932692100","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003","kind":"paper","name":"Repeated observation of breast tumor subtypes in independent gene expression data sets","route":"/key-papers/paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003/","field":"links","label":"Proc Natl Acad Sci 2003"}]},{"url":"https://doi.org/10.1073/pnas.1118046108","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1118046108","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011","kind":"paper","name":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways","route":"/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/","field":"links","label":"Wu et al., PNAS 2011: exomes of neoplastic pancreatic cysts, RNF43 in IPMN and MCN"}]},{"url":"https://doi.org/10.1073/pnas.1121623109","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1121623109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"papers","label":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors"}]},{"url":"https://doi.org/10.1073/pnas.1213353109","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1213353109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stylianopoulos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","route":"/key-papers/paper-stylianopoulos-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 2012"},{"id":"tumour-mechanics-models","kind":"technology","name":"Solid stress and tumour mechanobiology models","route":"/technologies/tumour-mechanics-models/","field":"links","label":"Stylianopoulos and colleagues 2012, PNAS"}]},{"url":"https://doi.org/10.1073/pnas.1213968110","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1213968110","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mcfarland-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Impact of deleterious passenger mutations on cancer progression","route":"/key-papers/paper-mcfarland-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 2013"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"links","label":"McFarland et al., Impact of deleterious passenger mutations on cancer progression (PNAS 2013)"}]},{"url":"https://doi.org/10.1073/pnas.1303559111","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1303559111","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"papers","label":"ARF1-GTP regulates Asrij to provide endocytic control of Drosophila blood cell homeostasis"}]},{"url":"https://doi.org/10.1073/pnas.1320318110","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1320318110","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","kind":"paper","name":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","route":"/key-papers/paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013/","field":"links","label":"Feig et al., PNAS 2013: CXCL12 from FAP-positive fibroblasts excludes T cells and blocks checkpoint therapy"}]},{"url":"https://doi.org/10.1073/pnas.141230798","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.141230798","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","field":"links","label":"The first PROTAC: a chimeric molecule that tags a protein for destruction (PNAS 2001)"},{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1073/pnas.1415979111","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1415979111","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"links","label":"Gabai-Kapara et al., Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 (PNAS 2014)"},{"id":"paper-gabai-kapara-population-brca-screening-pnas-2014","kind":"paper","name":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","route":"/key-papers/paper-gabai-kapara-population-brca-screening-pnas-2014/","field":"links","label":"PNAS 2014"}]},{"url":"https://doi.org/10.1073/pnas.1501713112","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1501713112","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rozhok-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations","route":"/key-papers/paper-rozhok-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 2015"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Rozhok and DeGregori, Toward an evolutionary model of cancer: considering the mechanisms that govern the fate of somatic mutations (PNAS 2015)"}]},{"url":"https://doi.org/10.1073/pnas.1617743114","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1617743114","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trigos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors","route":"/key-papers/paper-trigos-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 2017"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Trigos et al., Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors (PNAS 2017)"}]},{"url":"https://doi.org/10.1073/pnas.1704961114","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1704961114","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017","kind":"paper","name":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","route":"/key-papers/paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017/","field":"links","label":"Cohen et al., PNAS 2017: KRAS ctDNA plus protein markers in 221 resectable cancers"}]},{"url":"https://doi.org/10.1073/pnas.1706990114","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1706990114","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bussey-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Ancestral gene regulatory networks drive cancer","route":"/key-papers/paper-bussey-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 2017"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Bussey et al., Ancestral gene regulatory networks drive cancer (PNAS 2017)"}]},{"url":"https://doi.org/10.1073/pnas.1902651116","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.1902651116","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","kind":"paper","name":"Genomic correlates of clinical outcome in advanced prostate cancer","route":"/key-papers/paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019/","field":"links","label":"Abida et al., PNAS 2019: genomic correlates of clinical outcome in 429 patients with metastatic castration-resistant prostate cancer (SU2C/PCF)"}]},{"url":"https://doi.org/10.1073/pnas.191367098","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.191367098","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sorlie-breast-carcinoma-subclasses-pnas-2001","kind":"paper","name":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","route":"/key-papers/paper-sorlie-breast-carcinoma-subclasses-pnas-2001/","field":"links","label":"Proc Natl Acad Sci 2001"}]},{"url":"https://doi.org/10.1073/pnas.192461099","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.192461099","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"papers","label":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"papers","label":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack"},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","field":"papers","label":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack"},{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1073/pnas.2106682118","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.2106682118","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","field":"links","label":"Mourragui et al., TRANSACT (PNAS 2021)"}]},{"url":"https://doi.org/10.1073/pnas.68.4.820","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.68.4.820","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-knudson-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Mutation and cancer: statistical study of retinoblastoma","route":"/key-papers/paper-knudson-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 1971"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Knudson, Mutation and cancer: statistical study of retinoblastoma (PNAS 1971)"}]},{"url":"https://doi.org/10.1073/pnas.72.9.3585","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.72.9.3585","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mintz-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Normal genetically mosaic mice produced from malignant teratocarcinoma cells","route":"/key-papers/paper-mintz-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 1975"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Mintz and Illmensee, Normal genetically mosaic mice produced from malignant teratocarcinoma cells (PNAS 1975)"}]},{"url":"https://doi.org/10.1073/pnas.86.24.10024","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.86.24.10024","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","field":"links","label":"Gross, Waks and Eshhar, the first chimeric antigen receptor (PNAS 1989)"},{"id":"paper-gross-eshhar-chimeric-receptor-pnas-1989","kind":"paper","name":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","route":"/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/","field":"links","label":"PNAS 1989"}]},{"url":"https://doi.org/10.1073/pnas.89.24.12180","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.89.24.12180","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"papers","label":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic"}]},{"url":"https://doi.org/10.1073/pnas.95.12.6870","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.95.12.6870","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998","kind":"paper","name":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","route":"/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/","field":"links","label":"Herman et al., PNAS 1998: hMLH1 promoter hypermethylation in sporadic colorectal carcinoma"}]},{"url":"https://doi.org/10.1073/pnas.95.23.13692","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.95.23.13692","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-duesberg-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Genetic instability of cancer cells is proportional to their degree of aneuploidy","route":"/key-papers/paper-duesberg-proc-natl-acad-sci-u-s-a/","field":"links","label":"Proc Natl Acad Sci U S A 1998"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Duesberg et al., Genetic instability of cancer cells is proportional to their degree of aneuploidy (PNAS 1998)"}]},{"url":"https://doi.org/10.1073/pnas.96.15.8681","status":403,"ok":false,"finalUrl":"https://pnas.org/doi/full/10.1073/pnas.96.15.8681","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cimp","kind":"term","name":"CpG island methylator phenotype (CIMP)","route":"/terms/cimp/","field":"links","label":"Toyota, PNAS 1999: CpG island methylator phenotype in colorectal cancer"}]},{"url":"https://doi.org/10.1080/00325481.2026.2672183","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/00325481.2026.2672183","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Saperstein case report 2026"},{"id":"paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026","kind":"paper","name":"Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report","route":"/key-papers/paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026/","field":"links","label":"Saperstein case report 2026"}]},{"url":"https://doi.org/10.1080/01621459.1993.10476296","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/abs/10.1080/01621459.1993.10476296","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"papers","label":"Survival Trees by Goodness of Split"}]},{"url":"https://doi.org/10.1080/10428194.2017.1339880","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1339880","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","field":"links","label":"Leukemia and Lymphoma 2018: clinical features and treatment outcomes in 204 patients with large granular lymphocytic leukaemia"}]},{"url":"https://doi.org/10.1080/14712598.2021.1840547","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1840547","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021","kind":"paper","name":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021/","field":"links","label":"Expert Opin Biol Ther 2021"}]},{"url":"https://doi.org/10.1080/14796694.2024.2357534","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/14796694.2024.2357534","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","field":"links","label":"OptimICE-RD design (Future Oncology 2024)"}]},{"url":"https://doi.org/10.1080/14796694.2026.2719409","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/14796694.2026.2719409","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/","field":"links","label":"Future Oncol 2026"}]},{"url":"https://doi.org/10.1080/15563650.2022.2134788","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/15563650.2022.2134788","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Hoang poison centre series 2022"},{"id":"paper-hoang-ivermectin-toxicity-clin-toxicol-2022","kind":"paper","name":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19","route":"/key-papers/paper-hoang-ivermectin-toxicity-clin-toxicol-2022/","field":"links","label":"Hoang poison centre series 2022"}]},{"url":"https://doi.org/10.1080/17474124.2025.2509797","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/17474124.2025.2509797","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Expert Rev Gastroenterol Hepatol 2025: the serrated pathway and colorectal cancer, what the gastroenterologist should know"},{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","field":"links","label":"Expert Rev Gastroenterol Hepatol 2025: the serrated pathway and colorectal cancer, what the gastroenterologist should know"}]},{"url":"https://doi.org/10.1080/2162402x.2015.1129483","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1129483","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gpc3-hcc-oncoimmunology-2016","kind":"paper","name":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","route":"/key-papers/paper-gpc3-hcc-oncoimmunology-2016/","field":"links","label":"Oncoimmunology 2016"}]},{"url":"https://doi.org/10.1083/jcb.137.1.231","status":403,"ok":false,"finalUrl":"https://rupress.org/jcb/article/137/1/231/15446/Reversion-of-the-Malignant-Phenotype-of-Human","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weaver-j-cell-biol","kind":"paper","name":"Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies","route":"/key-papers/paper-weaver-j-cell-biol/","field":"links","label":"J Cell Biol 1997"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"links","label":"Weaver et al., Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies (Journal of Cell Biology 1997)"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Weaver et al., Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies (Journal of Cell Biology 1997)"}]},{"url":"https://doi.org/10.1083/jcb.201311112","status":403,"ok":false,"finalUrl":"https://rupress.org/jcb/article/204/3/291/37534/Traversing-the-basement-membrane-in-vivo-A","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kelley-j-cell-biol","kind":"paper","name":"Traversing the basement membrane in vivo: a diversity of strategies","route":"/key-papers/paper-kelley-j-cell-biol/","field":"links","label":"J Cell Biol 2014"},{"id":"basement-membrane-tissue-barriers","kind":"pathway","name":"Basement membrane & tissue barriers","route":"/pathways/basement-membrane-tissue-barriers/","field":"links","label":"Kelley et al., Traversing the basement membrane in vivo (J Cell Biol 2014)"}]},{"url":"https://doi.org/10.1084/jem.20060772","status":403,"ok":false,"finalUrl":"https://rupress.org/jem/article/203/7/1701/46415/CD127-expression-inversely-correlates-with-FoxP3","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"papers","label":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells"}]},{"url":"https://doi.org/10.1084/jem.20111512","status":403,"ok":false,"finalUrl":"https://rupress.org/jem/article/209/4/679/41340/MYC-pathway-activation-in-triple-negative-breast","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012","kind":"paper","name":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","route":"/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/","field":"links","label":"Horiuchi et al., J Exp Med 2012: MYC pathway activation in TNBC is synthetic lethal with CDK inhibition"}]},{"url":"https://doi.org/10.1084/jem.20162024","status":403,"ok":false,"finalUrl":"https://rupress.org/jem/article/214/3/579/42197/Distinct-populations-of-inflammatory-fibroblasts","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","kind":"paper","name":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","route":"/key-papers/paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017/","field":"links","label":"Ohlund et al., J Exp Med 2017: myofibroblastic and inflammatory fibroblasts (myCAF, iCAF)"},{"id":"caf-subtypes-pancreatic","kind":"term","name":"Fibroblast subtypes in the pancreatic cancer stroma (myCAF, iCAF and apCAF)","route":"/terms/caf-subtypes-pancreatic/","field":"links","label":"Ohlund et al., J Exp Med 2017: myofibroblastic and inflammatory fibroblasts (myCAF, iCAF)"}]},{"url":"https://doi.org/10.1086/315498","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jid/article-lookup/doi/10.1086/315498","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"papers","label":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection"}]},{"url":"https://doi.org/10.1089/thy.2013.0367","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1089/thy.2013.0367","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","field":"links","label":"Ito et al., Patient age is significantly related to the progression of papillary microcarcinoma under observation (Thyroid 2014)"},{"id":"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014","kind":"paper","name":"Active surveillance of papillary thyroid microcarcinoma at Kuma Hospital: patient age and progression","route":"/key-papers/paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014/","field":"links","label":"Thyroid 2014"}]},{"url":"https://doi.org/10.1089/thy.2014.0335","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1089/thy.2014.0335","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","field":"papers","label":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma"},{"id":"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015","kind":"paper","name":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","route":"/key-papers/paper-ata-medullary-thyroid-guideline-wells-thyroid-2015/","field":"links","label":"Thyroid 2015"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"links","label":"ATA medullary thyroid carcinoma guideline (2015)"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (MEN2 carriers (RET-positive))"},{"id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/","field":"links","label":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma (Thyroid 2015)"},{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","field":"links","label":"Wells 2015, Thyroid: revised American Thyroid Association guidelines for medullary thyroid carcinoma"}]},{"url":"https://doi.org/10.1089/thy.2015.0020","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1089/thy.2015.0020","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","field":"links","label":"Haugen et al., 2015 American Thyroid Association management guidelines for thyroid nodules and differentiated thyroid cancer (Thyroid 2016)"},{"id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","field":"links","label":"2015 ATA guidelines for thyroid nodules and differentiated thyroid cancer (Haugen et al., Thyroid 2016)"},{"id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","field":"links","label":"Haugen et al., 2015 American Thyroid Association management guidelines for thyroid nodules and differentiated thyroid cancer (Thyroid 2016)"},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","field":"papers","label":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer"},{"id":"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016","kind":"paper","name":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","route":"/key-papers/paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016/","field":"links","label":"Thyroid 2016"},{"id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/","field":"links","label":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer (Thyroid 2016)"}]},{"url":"https://doi.org/10.1089/thy.2020.0944","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1089/thy.2020.0944","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","field":"papers","label":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer"},{"id":"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021","kind":"paper","name":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","route":"/key-papers/paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021/","field":"links","label":"Thyroid 2021"}]},{"url":"https://doi.org/10.1089/thy.2023.0141","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/full/10.1089/thy.2023.0141","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","field":"links","label":"Ali et al., The 2023 Bethesda System for Reporting Thyroid Cytopathology (Thyroid 2023)"},{"id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","field":"links","label":"The 2023 Bethesda System for Reporting Thyroid Cytopathology (Ali et al., Thyroid 2023)"},{"id":"paper-ali-thyroid","kind":"paper","name":"The 2023 Bethesda System for Reporting Thyroid Cytopathology","route":"/key-papers/paper-ali-thyroid/","field":"links","label":"Thyroid 2023"}]},{"url":"https://doi.org/10.1093/aje/kwae027","status":403,"ok":false,"finalUrl":"https://academic.oup.com/aje/article/193/8/1197/7639887","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024","kind":"paper","name":"Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?","route":"/key-papers/paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024/","field":"links","label":"Am J Epidemiol 2024"}]},{"url":"https://doi.org/10.1093/bib/bbac100","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bib/article/doi/10.1093/bib/bbac100/6554594","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","field":"links","label":"Jiang et al., DeepTTA: a transformer-based model for predicting cancer drug response (Briefings in Bioinformatics 2022)"}]},{"url":"https://doi.org/10.1093/bioinformatics/btab299","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bioinformatics/article/37/Supplement_1/i76/6277145","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","field":"links","label":"Peres da Silva et al., TUGDA: task uncertainty guided domain adaptation for robust generalization of cancer drug response prediction (Bioinformatics 2021)"}]},{"url":"https://doi.org/10.1093/bioinformatics/bts635","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bioinformatics/article/29/1/15/272537","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"star-salmon","kind":"term","name":"STAR and Salmon (RNA-seq alignment and quantification)","route":"/terms/star-salmon/","field":"links","label":"Dobin et al., STAR: ultrafast universal RNA-seq aligner (Bioinformatics 2013)"}]},{"url":"https://doi.org/10.1093/bioinformatics/btz372","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bioinformatics/article/35/14/i510/5529136","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","field":"links","label":"Mourragui et al., PRECISE (Bioinformatics 2019)"}]},{"url":"https://doi.org/10.1093/biostatistics/kxj037","status":403,"ok":false,"finalUrl":"https://academic.oup.com/biostatistics/article/8/1/118/252073","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"batch-effects","kind":"term","name":"Batch effects and harmonisation","route":"/terms/batch-effects/","field":"links","label":"Johnson, Li and Rabinovic, Adjusting batch effects in microarray expression data using empirical Bayes methods (ComBat, Biostatistics 2007)"}]},{"url":"https://doi.org/10.1093/biostatistics/kxx069","status":403,"ok":false,"finalUrl":"https://academic.oup.com/biostatistics/article/20/2/273/4817524","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"links","label":"Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"metrics (Probability that an oncology drug entering phase 1 is eventually approved)"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"metrics (Probability that an oncology drug entering phase 1 is eventually approved)"},{"id":"idea-bio1-immune-matched-humanised-mice","kind":"idea","name":"Humanised mice with an immune system matched to the tumour donor","route":"/ideas/idea-bio1-immune-matched-humanised-mice/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-co-clinical-avatar-trials","kind":"idea","name":"Run the mouse or organoid trial at the same time as the human trial","route":"/ideas/idea-bio1-co-clinical-avatar-trials/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-tumour-on-chip-penetration","kind":"idea","name":"Tumour-on-a-chip with blood flow to test whether big drugs actually get in","route":"/ideas/idea-bio1-tumour-on-chip-penetration/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-multicentre-mouse-trials","kind":"idea","name":"Multi-centre randomised animal trials before committing to a human trial","route":"/ideas/idea-bio1-multicentre-mouse-trials/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-model-predictivity-benchmark","kind":"idea","name":"Score every model system on how well it predicted real trial results","route":"/ideas/idea-bio1-model-predictivity-benchmark/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-negative-preclinical-repository","kind":"idea","name":"A home for the animal and organoid experiments that failed","route":"/ideas/idea-bio1-negative-preclinical-repository/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-tumour-slice-cultures","kind":"idea","name":"Test drugs on freshly cut slices of the patient's own tumour","route":"/ideas/idea-bio1-tumour-slice-cultures/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-metastatic-niche-models","kind":"idea","name":"Build laboratory models of the organs cancer spreads to","route":"/ideas/idea-bio1-metastatic-niche-models/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-aged-comorbid-models","kind":"idea","name":"Test cancer drugs in old and unhealthy animals, not just young fit ones","route":"/ideas/idea-bio1-aged-comorbid-models/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-zebrafish-avatars","kind":"idea","name":"Zebrafish avatars for a drug answer within a week","route":"/ideas/idea-bio1-zebrafish-avatars/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-multi-organ-chip-tox","kind":"idea","name":"Linked human organ chips to predict side effects before people are dosed","route":"/ideas/idea-bio1-multi-organ-chip-tox/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-somatic-crispr-gemms","kind":"idea","name":"Make bespoke mouse cancer models in weeks with in vivo gene editing","route":"/ideas/idea-bio1-somatic-crispr-gemms/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-reverse-translation-resistance-models","kind":"idea","name":"Every resistance mechanism found in a patient must be rebuilt in the laboratory","route":"/ideas/idea-bio1-reverse-translation-resistance-models/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-ex-vivo-perfused-tumour","kind":"idea","name":"Keep a freshly removed tumour alive on a pump and test drugs in it","route":"/ideas/idea-bio1-ex-vivo-perfused-tumour/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/","field":"links","label":"Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019)"},{"id":"paper-wong-biostatistics","kind":"paper","name":"Estimation of clinical trial success rates and related parameters","route":"/key-papers/paper-wong-biostatistics/","field":"links","label":"Biostatistics 2019"}]},{"url":"https://doi.org/10.1093/bjd/ljac042","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/188/2/186/6788751","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Sharma et al., British Journal of Dermatology 2023;188:186 to 194: British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022"},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"standardOfCare.guideline (Typical lesion)"}]},{"url":"https://doi.org/10.1093/bjd/ljad033","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/188/6/777/7051650","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"van Bodegraven et al., British Journal of Dermatology 2023;188(6):777 to 784: 'Get Data Out' Skin, national cancer registry incidence and survival rates for all registered skin tumour groups for 2013 to 2019 in England"}]},{"url":"https://doi.org/10.1093/bjd/ljae444","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/192/4/611/7900902","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/","field":"links","label":"Phase 2A report (British Journal of Dermatology 2025)"},{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/","field":"outcomes.source (New surgically eligible basal cell carcinomas over 6 months)"}]},{"url":"https://doi.org/10.1093/bjd/ljaf352","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/194/2/273/8250360","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Ahmed et al., British Journal of Dermatology 2026;194:273 to 282: ethnicity and the epidemiology of skin cancer incidence, a national retrospective population-based study in England, 2013 to 2020"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Ahmed et al., British Journal of Dermatology 2026;194:273 to 282: ethnicity and the epidemiology of skin cancer incidence, a national retrospective population-based study in England, 2013 to 2020"}]},{"url":"https://doi.org/10.1093/bjd/ljag315","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljag315/8743690","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Mistry, Levell, Karponis, Wakkee, Whiteman, Proby and Venables, British Journal of Dermatology 2026: trends in keratinocyte cancers in England 2013 to 2022, basal cell carcinoma incidence, cutaneous squamous cell carcinoma incidence and non-melanoma skin cancer mortality"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Mistry, Levell, Karponis, Wakkee, Whiteman, Proby and Venables, British Journal of Dermatology 2026: trends in keratinocyte cancers in England 2013 to 2022, basal cell carcinoma incidence, cutaneous squamous cell carcinoma incidence and non-melanoma skin cancer mortality"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Mistry, Levell, Karponis, Wakkee, Whiteman, Proby and Venables, British Journal of Dermatology 2026: trends in keratinocyte cancers in England 2013 to 2022, basal cell carcinoma incidence, cutaneous squamous cell carcinoma incidence and non-melanoma skin cancer mortality"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Mistry, Levell, Karponis, Wakkee, Whiteman, Proby and Venables, British Journal of Dermatology 2026: trends in keratinocyte cancers in England 2013 to 2022, basal cell carcinoma incidence, cutaneous squamous cell carcinoma incidence and non-melanoma skin cancer mortality"}]},{"url":"https://doi.org/10.1093/bjr/tqaf161","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjr/article/98/1174/1543/8202914","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"malignant-pleural-effusion","kind":"term","name":"Malignant pleural effusion","route":"/terms/malignant-pleural-effusion/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025)"}]},{"url":"https://doi.org/10.1093/bjs/znac077","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/109/6/530/6563440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","field":"links","label":"Pre-BRA three-month safety (British Journal of Surgery 2022)"},{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","field":"outcomes.source (Implant loss within 3 months)"},{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","field":"outcomes.source (Any complication within 3 months)"}]},{"url":"https://doi.org/10.1093/bjs/znac141","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/109/11/1073/6672717","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Hill, Br J Surg 2022: CReST, colorectal endoscopic stenting trial for obstructing left-sided colorectal cancer (245 patients)"},{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","field":"links","label":"Hill, Br J Surg 2022: CReST, colorectal endoscopic stenting trial for obstructing left-sided colorectal cancer (245 patients)"}]},{"url":"https://doi.org/10.1093/bjs/znad124","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/110/9/1161/7223848","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"papers","label":"Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE"}]},{"url":"https://doi.org/10.1093/bjs/znaf032","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/doi/10.1093/bjs/znaf032/8041950","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","field":"links","label":"Pre-BRA patient-reported outcomes at 3 and 18 months (British Journal of Surgery 2025)"}]},{"url":"https://doi.org/10.1093/bjs/znag050","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjs/article/doi/10.1093/bjs/znag050/8660326","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CAPBIL: incidental gallbladder cancer in the UK (Br J Surg 2026)"},{"id":"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","kind":"paper","name":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/","field":"links","label":"Br J Surg 2026"}]},{"url":"https://doi.org/10.1093/bjsopen/zrae013","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjsopen/article/doi/10.1093/bjsopen/zrae013/7633087","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"van Dooren, BJS Open 2024: referral of incidental gallbladder cancer from 27 Dutch secondary centres"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"van Dooren, BJS Open 2024: referral of incidental gallbladder cancer from 27 Dutch secondary centres"}]},{"url":"https://doi.org/10.1093/bjsopen/zrae138","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjsopen/article/doi/10.1093/bjsopen/zrae138/7922431","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Monaghan, BJS Open 2024: tumour biology and survival in young women with breast cancer (UK single centre)"}]},{"url":"https://doi.org/10.1093/carcin/bgp268","status":403,"ok":false,"finalUrl":"https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgp268","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"papers","label":"Telomeres and telomerase in cancer"}]},{"url":"https://doi.org/10.1093/eurheartj/ehac244","status":403,"ok":false,"finalUrl":"https://academic.oup.com/eurheartj/article/43/41/4229/6673995","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lyon-eur-heart-j","kind":"paper","name":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","route":"/key-papers/paper-lyon-eur-heart-j/","field":"links","label":"Eur Heart J 2022"},{"id":"cardiac-biomarker-monitoring","kind":"technology","name":"Troponin and natriuretic peptide monitoring during cancer treatment","route":"/technologies/cardiac-biomarker-monitoring/","field":"links","label":"2022 ESC Guidelines on cardio-oncology (European Heart Journal 2022)"},{"id":"strain-echocardiography-gls","kind":"technology","name":"Strain echocardiography (global longitudinal strain)","route":"/technologies/strain-echocardiography-gls/","field":"links","label":"2022 ESC Guidelines on cardio-oncology (European Heart Journal 2022)"}]},{"url":"https://doi.org/10.1093/eurheartj/ehae179","status":403,"ok":false,"finalUrl":"https://academic.oup.com/eurheartj/article/45/36/3538/7738955","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"papers","label":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases"}]},{"url":"https://doi.org/10.1093/icvts/ivt271","status":403,"ok":false,"finalUrl":"https://academic.oup.com/icvts/article-lookup/doi/10.1093/icvts/ivt271","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"papers","label":"Tuberculous ascending aortic pseudoaneurysm"}]},{"url":"https://doi.org/10.1093/ije/dyn094","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyn094","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"papers","label":"Vulnerability to heat-related mortality in Latin America: a case-crossover study in Sao Paulo, Brazil, Santiago, Chile and Mexico City, Mexico"}]},{"url":"https://doi.org/10.1093/jjco/hyad113","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jjco/article/53/12/1170/7254636","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"papers","label":"The association of miR-204 and mir-483 5p expression with clinicopathological features of Wilms tumor: Could this provide foresight?"}]},{"url":"https://doi.org/10.1093/jnci/85.5.365","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/85.5.365","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aaronson-eortc-qlq-c30-jnci-1993","kind":"paper","name":"Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire","route":"/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1093/jnci/88.13.890","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/88.13.890","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996","kind":"paper","name":"EORTC 24891: larynx preservation with induction chemotherapy in pyriform sinus (hypopharyngeal) cancer","route":"/key-papers/paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996/","field":"links","label":"J Natl Cancer Inst 1996"}]},{"url":"https://doi.org/10.1093/jnci/90.18.1371","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/90/18/1371/897928","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Fisher, JNCI 1998: tamoxifen for prevention of breast cancer, NSABP P-1"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"Fisher, JNCI 1998: tamoxifen for prevention of breast cancer, NSABP P-1"},{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/","field":"links","label":"NSABP P-1 (Fisher 1998)"}]},{"url":"https://doi.org/10.1093/jnci/92.1.54","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/92.1.54","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"Hartmann 2000, JNCI: haematological disorders with primary mediastinal non-seminomatous germ cell tumours"},{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"links","label":"Hartmann 2000, JNCI: haematological disorders with primary mediastinal non-seminomatous germ cell tumours"}]},{"url":"https://doi.org/10.1093/jnci/92.3.205","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/jnci/article/2965042/New","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1093/jnci/94.16.1247","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/94.16.1247","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mathijssen-j-natl-cancer-inst","kind":"paper","name":"Effects of St. John's wort on irinotecan metabolism","route":"/key-papers/paper-mathijssen-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2002"},{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/","field":"links","label":"Effects of St. John's wort on irinotecan metabolism (JNCI 2002)"}]},{"url":"https://doi.org/10.1093/jnci/djaa061","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/113/1/27/5825735","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exceptional-responder","kind":"term","name":"Exceptional responder","route":"/terms/exceptional-responder/","field":"links","label":"Conley, JNCI 2021: the Exceptional Responders Initiative, feasibility of an NCI pilot study"}]},{"url":"https://doi.org/10.1093/jnci/djaa114","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/113/3/258/5889955","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mcneil-j-natl-cancer-inst","kind":"paper","name":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults","route":"/key-papers/paper-mcneil-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2021"},{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","field":"links","label":"ASPREE cancer outcomes, JNCI 2021"}]},{"url":"https://doi.org/10.1093/jnci/djaa155","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/113/3/244/5918345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"metrics (Patients who agree to participate when a trial is offered to them)"},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"metrics (Patients who agree to join a trial when one is offered to them, showing the deficit is in offering, not willingness)"}]},{"url":"https://doi.org/10.1093/jnci/djaa201","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/113/7/808/6053794","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/","field":"links","label":"Nielsen, JNCI 2021: International Ki67 in Breast Cancer Working Group updated recommendations"}]},{"url":"https://doi.org/10.1093/jnci/djab108","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/113/12/1733/6294407","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","field":"links","label":"Rugo, JNCI 2021: PD-L1 immunohistochemistry assay comparison (SP142, SP263, 22C3) in IMpassion130"},{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/","field":"links","label":"J Natl Cancer Inst 2021"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1093/jnci/djab141","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/114/7/1036/6323231","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"links","label":"Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"metrics (Most popular cancer articles on social media (2018-2019) containing misinformation, and share of those with potentially harmful content)"},{"id":"idea-moon-clinician-creator-programme","kind":"idea","name":"Train and fund oncology clinicians as public content creators","route":"/ideas/idea-moon-clinician-creator-programme/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-prebunking-at-diagnosis","kind":"idea","name":"Inoculate newly diagnosed patients against common cancer scams","route":"/ideas/idea-moon-prebunking-at-diagnosis/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-integrative-oncology-bridge","kind":"idea","name":"Evidence-based integrative oncology in every cancer centre to meet demand safely","route":"/ideas/idea-moon-integrative-oncology-bridge/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-ai-cancer-answer-audit","kind":"idea","name":"A public benchmark and audit of chatbot answers to cancer questions","route":"/ideas/idea-moon-ai-cancer-answer-audit/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-hype-index","kind":"idea","name":"An independent hype index grading cancer press releases and news stories","route":"/ideas/idea-moon-hype-index/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-patient-community-moderators","kind":"idea","name":"Trained moderators with evidence tools in online patient communities","route":"/ideas/idea-moon-patient-community-moderators/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-living-plain-evidence-summaries","kind":"idea","name":"Living plain-language evidence summaries for every common cancer question in 20 languages","route":"/ideas/idea-moon-living-plain-evidence-summaries/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-moon-treatment-refusal-pathway","kind":"idea","name":"A structured pathway for patients declining proven treatment","route":"/ideas/idea-moon-treatment-refusal-pathway/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"paper-johnson-j-natl-cancer-inst","kind":"paper","name":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report","route":"/key-papers/paper-johnson-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2022"},{"id":"idea-nl-ketogenic-gbm-definitive-trial","kind":"idea","name":"One definitive ketogenic diet trial in glioblastoma, then stop","route":"/ideas/idea-nl-ketogenic-gbm-definitive-trial/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"},{"id":"idea-nl-ask-about-diet-prebunking","kind":"idea","name":"Ask about diet at diagnosis, and prebunk the myths before the internet does","route":"/ideas/idea-nl-ask-about-diet-prebunking/","field":"links","label":"Bottleneck evidence (Misinformation and unproven therapies): Johnson et al., Cancer misinformation and harmful information on Facebook and other social media (JNCI 2022)"}]},{"url":"https://doi.org/10.1093/jnci/djac117","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/114/12/1706/6611725","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Jung, JNCI 2022: reproductive risk profiles for intrinsic-like breast cancer subtypes (Breast Cancer Association Consortium)"}]},{"url":"https://doi.org/10.1093/jnci/djac126","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/114/12/1720/6631230","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","field":"papers","label":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab"},{"id":"paper-luca-gianni-j-natl-cancer-inst-2022","kind":"paper","name":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","route":"/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/","field":"links","label":"J Natl Cancer Inst 2022"}]},{"url":"https://doi.org/10.1093/jnci/djg050","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djg050","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-foulkes-brca1-basal-phenotype-jnci-2003","kind":"paper","name":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","route":"/key-papers/paper-foulkes-brca1-basal-phenotype-jnci-2003/","field":"links","label":"J Natl Cancer Inst 2003"}]},{"url":"https://doi.org/10.1093/jnci/djj158","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/98/9/599/2522073/Randomized-Multicenter-Trial-of-Sentinel-Node","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-cancer-related-lymphoedema","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/breast-cancer-related-lymphoedema/","field":"links","label":"ALMANAC arm morbidity (Journal of the National Cancer Institute 2006)"},{"id":"almanac","kind":"trial","name":"ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance)","route":"/trials/almanac/","field":"links","label":"ALMANAC (Journal of the National Cancer Institute 2006)"},{"id":"almanac","kind":"trial","name":"ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance)","route":"/trials/almanac/","field":"outcomes.source (Any lymphoedema at 12 months)"},{"id":"almanac","kind":"trial","name":"ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance)","route":"/trials/almanac/","field":"outcomes.source (Sensory loss at 12 months)"}]},{"url":"https://doi.org/10.1093/jnci/djm024","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm024","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","field":"links","label":"Punt, JNCI 2007: endpoints in adjuvant treatment trials, systematic review and proposed definitions (disease-free survival)"}]},{"url":"https://doi.org/10.1093/jnci/djm106","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm106","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-montgomery-j-natl-cancer-inst","kind":"paper","name":"A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients","route":"/key-papers/paper-montgomery-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2007"},{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","field":"links","label":"Presurgical hypnosis before breast cancer surgery, randomised trial (JNCI 2007)"}]},{"url":"https://doi.org/10.1093/jnci/djp001","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-draisma-lead-time-overdiagnosis-psa-jnci-2009","kind":"paper","name":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","route":"/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/","field":"links","label":"J Natl Cancer Inst 2009"},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","field":"links","label":"Draisma et al., Journal of the National Cancer Institute 2009: lead time and overdiagnosis in prostate-specific antigen screening, importance of methods and context"},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"links","label":"Draisma et al., Journal of the National Cancer Institute 2009: lead time and overdiagnosis in prostate-specific antigen screening, importance of methods and context"}]},{"url":"https://doi.org/10.1093/jnci/djp278","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp278","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009","kind":"paper","name":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005","route":"/key-papers/paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009/","field":"links","label":"J Natl Cancer Inst 2009"},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","field":"links","label":"Welch and Albertsen, Journal of the National Cancer Institute 2009: prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005"},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"links","label":"Welch and Albertsen, Journal of the National Cancer Institute 2009: prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005"}]},{"url":"https://doi.org/10.1093/jnci/djq099","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djq099","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"links","label":"Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-thyroid-no-screening-no-small-biopsy","kind":"idea","name":"Stop biopsying small thyroid nodules and never screen the thyroid","route":"/ideas/idea-prev-thyroid-no-screening-no-small-biopsy/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-low-risk-dcis-surveillance-pathway","kind":"idea","name":"After the COMET trial: surveillance pathways and a new name for low-risk DCIS","route":"/ideas/idea-prev-low-risk-dcis-surveillance-pathway/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-gleason6-terminology-rct","kind":"idea","name":"Test whether calling Gleason 6 'not cancer' changes what men choose","route":"/ideas/idea-prev-gleason6-terminology-rct/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-prostate-as-triggered-biopsy","kind":"idea","name":"Prostate active surveillance without scheduled biopsies: MRI and blood tests decide","route":"/ideas/idea-prev-prostate-as-triggered-biopsy/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-small-renal-mass-surveillance","kind":"idea","name":"Watch small kidney tumours rather than remove them, with a national registry","route":"/ideas/idea-prev-small-renal-mass-surveillance/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-annual-overdiagnosis-reporting","kind":"idea","name":"Every screening programme must publish its overdiagnosis rate each year","route":"/ideas/idea-prev-annual-overdiagnosis-reporting/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-screening-stop-by-life-expectancy","kind":"idea","name":"Stop screening by life expectancy, not birthday, with a tool in the record","route":"/ideas/idea-prev-screening-stop-by-life-expectancy/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-mced-pretest-decision-aid","kind":"idea","name":"A mandatory decision aid before any multi-cancer blood test","route":"/ideas/idea-prev-mced-pretest-decision-aid/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-barrett-surveillance-deescalation","kind":"idea","name":"Stop routine endoscopies for non-dysplastic Barrett's oesophagus","route":"/ideas/idea-prev-barrett-surveillance-deescalation/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-melanoma-ai-thick-melanoma-metric","kind":"idea","name":"Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds","route":"/ideas/idea-prev-melanoma-ai-thick-melanoma-metric/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-incidentaloma-natural-history-cohort","kind":"idea","name":"A ten-year cohort of incidental findings to calibrate follow-up guidelines","route":"/ideas/idea-prev-incidentaloma-natural-history-cohort/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-ipmn-surveillance-stop-rule","kind":"idea","name":"Stop watching stable low-risk pancreatic cysts after five years","route":"/ideas/idea-prev-ipmn-surveillance-stop-rule/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-frail-elderly-primary-endocrine-breast","kind":"idea","name":"Hormone tablets instead of surgery for small breast cancers in the frail over-80s","route":"/ideas/idea-prev-frail-elderly-primary-endocrine-breast/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-omit-radiotherapy-low-risk-breast-default","kind":"idea","name":"Make skipping radiotherapy the default for very low-risk breast cancer","route":"/ideas/idea-prev-omit-radiotherapy-low-risk-breast-default/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-prev-modern-autopsy-reservoir-studies","kind":"idea","name":"Modern autopsy studies to measure how much silent cancer people carry","route":"/ideas/idea-prev-modern-autopsy-reservoir-studies/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"idea-moon-indolence-classifiers-with-screening","kind":"idea","name":"Molecular indolence classifiers bundled with every screening programme","route":"/ideas/idea-moon-indolence-classifiers-with-screening/","field":"links","label":"Bottleneck evidence (Overdiagnosis and false alarms): Welch & Black, Overdiagnosis in cancer (JNCI 2010)"},{"id":"paper-welch-j-natl-cancer-inst","kind":"paper","name":"Overdiagnosis in cancer","route":"/key-papers/paper-welch-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2010"}]},{"url":"https://doi.org/10.1093/jnci/djq179","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djq179","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lu-j-natl-cancer-inst","kind":"paper","name":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","route":"/key-papers/paper-lu-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2010"},{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/","field":"links","label":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: randomised phase III trial (JNCI 2010)"}]},{"url":"https://doi.org/10.1093/jnci/djt181","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djt181","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barton-j-natl-cancer-inst","kind":"paper","name":"Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2","route":"/key-papers/paper-barton-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2013"},{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","field":"links","label":"Wisconsin ginseng to improve cancer-related fatigue, randomised double-blind trial N07C2 (JNCI 2013)"}]},{"url":"https://doi.org/10.1093/jnci/dju009","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju009","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shastri-j-natl-cancer-inst","kind":"paper","name":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","route":"/key-papers/paper-shastri-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2014"},{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","route":"/trials/mumbai-via-screening/","field":"links","label":"Shastri et al., JNCI 2014"},{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","route":"/trials/mumbai-via-screening/","field":"outcomes.source (Cervical cancer mortality (rate ratio))"}]},{"url":"https://doi.org/10.1093/jnci/dju055","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju055","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Howlader, JNCI 2014: US incidence of breast cancer subtypes by joint hormone receptor and HER2 status"},{"id":"paper-howlader-us-incidence-breast-subtypes-jnci-2014","kind":"paper","name":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","route":"/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/","field":"links","label":"J Natl Cancer Inst 2014"}]},{"url":"https://doi.org/10.1093/jnci/dju229","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju229","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"metrics (Adult cancer trials in ClinicalTrials.gov that failed to complete, most often for poor accrual)"}]},{"url":"https://doi.org/10.1093/jnci/dju237","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju237","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Palmer, JNCI 2014: parity, lactation and breast cancer subtypes in African American women (AMBER)"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"Palmer, JNCI 2014: parity, lactation and breast cancer subtypes in African American women (AMBER)"}]},{"url":"https://doi.org/10.1093/jnci/dju402","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju402","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-church-pole-endometrial-jnci-2015","kind":"paper","name":"Prognostic significance of POLE proofreading mutations in endometrial cancer","route":"/key-papers/paper-church-pole-endometrial-jnci-2015/","field":"links","label":"J Natl Cancer Inst 2015"}]},{"url":"https://doi.org/10.1093/jnci/dju413","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju413","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"links","label":"Goldstein et al., MPACT long-term survival (JNCI 2015)"}]},{"url":"https://doi.org/10.1093/jnci/djw177","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/doi/10.1093/jnci/djw177/2905636","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Kotsopoulos, JNCI 2017: bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 carriers"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"Kotsopoulos, JNCI 2017: bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 carriers"}]},{"url":"https://doi.org/10.1093/jnci/djw322","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/doi/10.1093/jnci/djw322/3053481","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017","kind":"paper","name":"Colorectal cancer incidence patterns in the United States, 1974-2013","route":"/key-papers/paper-siegel-colorectal-incidence-birth-cohort-jnci-2017/","field":"links","label":"J Natl Cancer Inst 2017"}]},{"url":"https://doi.org/10.1093/jnci/djx015","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx015","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clocc","kind":"trial","name":"CLOCC","route":"/trials/clocc/","field":"links","label":"CLOCC: local treatment of unresectable colorectal liver metastases, randomised phase 2 trial (Journal of the National Cancer Institute 2017)"},{"id":"clocc","kind":"trial","name":"CLOCC","route":"/trials/clocc/","field":"outcomes.source (Overall survival at 8 years)"}]},{"url":"https://doi.org/10.1093/jnci/djx118","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/doi/10.1093/jnci/djx118/3902934","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","kind":"paper","name":"Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer","route":"/key-papers/paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017/","field":"links","label":"Wyatt et al., J Natl Cancer Inst 2017: concordance of circulating tumour DNA and matched metastatic tissue biopsy in 45 men with mCRPC"},{"id":"ctdna-tumour-fraction","kind":"biomarker","name":"Circulating tumour DNA fraction (and what a negative plasma result means)","route":"/biomarkers/ctdna-tumour-fraction/","field":"links","label":"Wyatt et al., J Natl Cancer Inst 2017: concordance of circulating tumour DNA and matched metastatic tissue biopsy in 45 men with mCRPC"}]},{"url":"https://doi.org/10.1093/jnci/djx145","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/110/1/121/4064136","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"links","label":"Johnson et al., Use of alternative medicine for cancer and its impact on survival (JNCI 2018)"},{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"metrics (Risk of death for patients with curable cancers choosing alternative medicine instead of conventional treatment (US National Cancer Database))"},{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","field":"links","label":"Alternative medicine and survival (JNCI 2018)"},{"id":"unproven-diet-claims","kind":"term","name":"Unproven diet claims (alkaline, juice, 'anti-cancer' diets)","route":"/terms/unproven-diet-claims/","field":"links","label":"Alternative medicine use and survival (JNCI 2018)"},{"id":"alternative-medicine-instead-of-treatment","kind":"technology","name":"Alternative medicine used instead of standard treatment","route":"/technologies/alternative-medicine-instead-of-treatment/","field":"links","label":"Johnson et al., Use of alternative medicine for cancer and its impact on survival (JNCI 2018)"},{"id":"paper-johnson-alternative-medicine-jnci-2018","kind":"paper","name":"Use of alternative medicine for cancer and its impact on survival","route":"/key-papers/paper-johnson-alternative-medicine-jnci-2018/","field":"links","label":"Johnson et al., Use of alternative medicine for cancer and its impact on survival (JNCI 2018)"}]},{"url":"https://doi.org/10.1093/jnci/djx178","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/110/2/141/4443215","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hanai-j-natl-cancer-inst","kind":"paper","name":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial","route":"/key-papers/paper-hanai-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2018"},{"id":"frozen-gloves-compression-taxane","kind":"technology","name":"Frozen gloves, socks and compression for taxane nail and nerve damage","route":"/technologies/frozen-gloves-compression-taxane/","field":"links","label":"Frozen gloves and socks to prevent paclitaxel-induced peripheral neuropathy, self-controlled trial (JNCI 2018)"}]},{"url":"https://doi.org/10.1093/jnci/djx273","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/110/6/568/4791841","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"receptor-conversion-breast","kind":"term","name":"Receptor conversion: when the receptors change between the primary and a recurrence","route":"/terms/receptor-conversion-breast/","field":"links","label":"Schrijver et al., Journal of the National Cancer Institute 2018: receptor conversion in distant breast cancer metastases, a systematic review and meta-analysis of 39 studies"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Schrijver et al., Journal of the National Cancer Institute 2018: receptor conversion in distant breast cancer metastases, a systematic review and meta-analysis of 39 studies"}]},{"url":"https://doi.org/10.1093/jnci/djy024","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/110/10/1067/4915401","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","kind":"paper","name":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","route":"/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/","field":"links","label":"Lowery et al., JNCI 2018: prospective germline testing of 615 exocrine pancreatic neoplasms (MSK)"}]},{"url":"https://doi.org/10.1093/jnci/djy106","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/110/8/855/5062996","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shimelis-tnbc-risk-genes-jnci-2018","kind":"paper","name":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","route":"/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/","field":"links","label":"Shimelis et al., JNCI 2018: TNBC risk genes from panel testing of 10,901 patients"}]},{"url":"https://doi.org/10.1093/jnci/djy221","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/111/3/245/5307078","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","field":"links","label":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes (JNCI: Journal of the National Cancer Institute 2019)"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"links","label":"Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"metrics (Adults with cancer participating in treatment trials (US, meta-analysis))"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"metrics (Adults with cancer participating in treatment trials, and hence the share of patients whose outcomes systematically feed evidence)"},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","route":"/ideas/idea-tr1-remote-consent-tele-screening/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-lay-trial-navigators","kind":"idea","name":"Lay trial navigators funded per centre, evaluated in a randomised trial","route":"/ideas/idea-tr1-lay-trial-navigators/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-rare-cancer-trial-in-a-box","kind":"idea","name":"Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer","route":"/ideas/idea-tr1-rare-cancer-trial-in-a-box/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-public-screen-fail-reasons","kind":"idea","name":"Publish why patients were screened out of each trial","route":"/ideas/idea-tr1-public-screen-fail-reasons/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-universal-routine-cost-coverage","kind":"idea","name":"Every payer covers routine care costs for trial participants, in every country","route":"/ideas/idea-tr1-universal-routine-cost-coverage/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-protected-physician-time-for-enrolment","kind":"idea","name":"Pay oncologists for the time it takes to enrol a patient","route":"/ideas/idea-tr1-protected-physician-time-for-enrolment/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-mobile-research-units","kind":"idea","name":"Mobile research units bring trial visits to rural towns","route":"/ideas/idea-tr1-mobile-research-units/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/","field":"links","label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)"},{"id":"decentralised-clinical-trials","kind":"technology","name":"Decentralised and hybrid clinical trials","route":"/technologies/decentralised-clinical-trials/","field":"links","label":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes (JNCI: Journal of the National Cancer Institute 2019)"},{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/","field":"links","label":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes (JNCI: Journal of the National Cancer Institute 2019)"},{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1093/jnci/djy225","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/111/9/923/5272614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hu-j-natl-cancer-inst","kind":"paper","name":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening","route":"/key-papers/paper-hu-j-natl-cancer-inst/","field":"links","label":"J Natl Cancer Inst 2019"},{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/","field":"links","label":"Hu et al., An observational study of deep learning and automated evaluation of cervical images for cancer screening (JNCI 2019)"}]},{"url":"https://doi.org/10.1093/jnci/djz208","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jnci/article/112/7/708/5609116","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bareche-tnbc-microenvironment-jnci-2020","kind":"paper","name":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","route":"/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/","field":"links","label":"Bareche et al., JNCI 2020: tumour microenvironment heterogeneity across 1,512 TNBC samples"}]},{"url":"https://doi.org/10.1093/nar/gkaa407","status":403,"ok":false,"finalUrl":"https://academic.oup.com/nar/article/48/W1/W509/5842187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-timer2-nar-2020","kind":"paper","name":"Li 2020: TIMER2.0 for analysis of tumour-infiltrating immune cells","route":"/key-papers/paper-li-timer2-nar-2020/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1093/nar/gkab1061","status":403,"ok":false,"finalUrl":"https://academic.oup.com/nar/article/50/D1/D439/6430488","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"papers","label":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models"}]},{"url":"https://doi.org/10.1093/nar/gkh359","status":403,"ok":false,"finalUrl":"https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkh359","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"papers","label":"NRPS-PKS: a knowledge-based resource for analysis of NRPS/PKS megasynthases"}]},{"url":"https://doi.org/10.1093/nar/gks1111","status":403,"ok":false,"finalUrl":"https://academic.oup.com/nar/article/41/D1/D955/1059448/Genomics-of-Drug-Sensitivity-in-Cancer-GDSC-a","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/","field":"links","label":"Yang et al., GDSC: a resource for therapeutic biomarker discovery in cancer cells (Nucleic Acids Research 2013)"}]},{"url":"https://doi.org/10.1093/neuonc/5.2.96","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/5/2/96/1070084/A-randomized-doubleblind-placebocontrolled-phase-2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2003","kind":"paper","name":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2003/","field":"links","label":"Neuro Oncol 2003"}]},{"url":"https://doi.org/10.1093/neuonc/noaa106","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/22/8/1073/5824407","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","field":"papers","label":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions"},{"id":"paper-andrew-lassman-neuro-oncol-2020","kind":"paper","name":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","route":"/key-papers/paper-andrew-lassman-neuro-oncol-2020/","field":"links","label":"Neuro Oncol 2020"}]},{"url":"https://doi.org/10.1093/neuonc/noab106","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/23/8/1231/6311214","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-who-2021-cns-louis-neuro-oncology-2021","kind":"paper","name":"The 2021 WHO classification of tumours of the central nervous system: a summary","route":"/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/","field":"links","label":"Neuro Oncol 2021"},{"id":"1p19q-codeletion-readout","kind":"biomarker","name":"1p/19q codeletion","route":"/biomarkers/1p19q-codeletion-readout/","field":"links","label":"WHO CNS5 (Louis et al. 2021)"}]},{"url":"https://doi.org/10.1093/neuonc/noab150","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/23/11/1821/6310843","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eano-meningioma-goldbrunner-neuro-oncology-2021","kind":"paper","name":"EANO guideline on the diagnosis and management of meningiomas (2021)","route":"/key-papers/paper-eano-meningioma-goldbrunner-neuro-oncology-2021/","field":"links","label":"Neuro Oncol 2021"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"links","label":"EANO guideline on meningiomas (Neuro-Oncology 2021)"}]},{"url":"https://doi.org/10.1093/neuonc/noab270","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/24/6/974/6446106","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-acns1123-germinoma-neuro-oncology-2022","kind":"paper","name":"ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma","route":"/key-papers/paper-acns1123-germinoma-neuro-oncology-2022/","field":"links","label":"Neuro Oncol 2022"}]},{"url":"https://doi.org/10.1093/neuonc/noac099","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/25/1/123/6568419","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/","field":"links","label":"Omuro et al., Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial (Neuro-Oncology 2023)"},{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/","field":"outcomes.source (Overall survival, MGMT-unmethylated glioblastoma)"},{"id":"paper-omuro-neuro-oncol","kind":"paper","name":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","route":"/key-papers/paper-omuro-neuro-oncol/","field":"links","label":"Neuro Oncol 2023"}]},{"url":"https://doi.org/10.1093/neuonc/noac116","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/24/11/1935/6577049","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/","field":"links","label":"Lim et al., Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter (Neuro-Oncology 2022)"},{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/","field":"outcomes.source (Overall survival, MGMT-methylated glioblastoma)"},{"id":"paper-lim-neuro-oncol","kind":"paper","name":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","route":"/key-papers/paper-lim-neuro-oncol/","field":"links","label":"Neuro Oncol 2022"}]},{"url":"https://doi.org/10.1093/neuonc/noac193","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/25/5/940/6664041","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","field":"links","label":"Karschnia et al., Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group (Neuro-Oncology 2023)"},{"id":"paper-karschnia-neuro-oncol","kind":"paper","name":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","route":"/key-papers/paper-karschnia-neuro-oncol/","field":"links","label":"Neuro Oncol 2023"}]},{"url":"https://doi.org/10.1093/neuonc/not019","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/not019","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013","kind":"paper","name":"SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy","route":"/key-papers/paper-siop-cns-gct-96-calaminus-neuro-oncology-2013/","field":"links","label":"Neuro Oncol 2013"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"links","label":"SIOP CNS GCT 96 germinoma results (Neuro-Oncology 2013)"}]},{"url":"https://doi.org/10.1093/neuonc/nov104","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/nov104","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2015","kind":"paper","name":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2015/","field":"links","label":"Neuro Oncol 2015"}]},{"url":"https://doi.org/10.1093/neuonc/noz244","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/22/7/1006/5688769","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fruhwald-neuro-oncol","kind":"paper","name":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors","route":"/key-papers/paper-fruhwald-neuro-oncol/","field":"links","label":"Neuro Oncol 2020"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"links","label":"EU-RHAB registry outcomes (Neuro-Oncology 2020)"}]},{"url":"https://doi.org/10.1093/noajnl/vdac056","status":403,"ok":false,"finalUrl":"https://academic.oup.com/noa/article/doi/10.1093/noajnl/vdac056/6568539","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/","field":"links","label":"Neuro-Oncology Advances 2022: paediatric pineoblastoma, pooled outcomes of 178 North American and Australian cases"}]},{"url":"https://doi.org/10.1097/01.ju.0000104671.20863.47","status":403,"ok":false,"finalUrl":"https://www.jurology.com/doi/10.1097/01.ju.0000104671.20863.47","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","field":"links","label":"DiMarco 2004, J Urol: surgical treatment of primary melanoma of the female urethra"}]},{"url":"https://doi.org/10.1097/01.ju.0000159207.91737.53","status":403,"ok":false,"finalUrl":"https://www.jurology.com/doi/10.1097/01.ju.0000159207.91737.53","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","field":"links","label":"Sanchez-Ortiz 2005, J Urol: melanoma of the penis, scrotum and male urethra"}]},{"url":"https://doi.org/10.1097/ccm.0000000000006556","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/CCM.0000000000006556","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"papers","label":"A Core Outcome Set for Adult General ICU Patients"}]},{"url":"https://doi.org/10.1097/coc.0000000000000239","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000421-201602000-00017","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pd-1-nsclc-am-j-clin-oncol-2016","kind":"paper","name":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","route":"/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/","field":"links","label":"Am J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1097/COC.0000000000000633","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/COC.0000000000000633","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Abrams et al., RTOG 0848 step 1 (Am J Clin Oncol 2020)"},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/","field":"links","label":"Abrams et al., RTOG 0848 step 1: adjuvant erlotinib plus gemcitabine (Am J Clin Oncol 2020)"},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","field":"links","label":"Abrams et al., RTOG 0848 step 1 (Am J Clin Oncol 2020)"}]},{"url":"https://doi.org/10.1097/coc.0000000000000918","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/COC.0000000000000918","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Low, Am J Clin Oncol 2022: SEER trends in gallbladder cancer incidence 1973 to 2015"}]},{"url":"https://doi.org/10.1097/dcr.0000000000002334","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/DCR.0000000000002334","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"papers","label":"High Risk of Low Anterior Resection Syndrome in Long-term Follow-up After Anastomotic Leakage in Anterior Resection for Rectal Cancer"}]},{"url":"https://doi.org/10.1097/DSS.0000000000000394","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00042728-201507000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (When the excision is incomplete)"},{"id":"surgical-margins-keratinocyte-cancer","kind":"term","name":"The margin in skin cancer surgery","route":"/terms/surgical-margins-keratinocyte-cancer/","field":"links","label":"Long-term follow-up of positive margins in facial basal cell carcinoma (Dermatologic Surgery 2015)"}]},{"url":"https://doi.org/10.1097/js9.0000000000001456","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/JS9.0000000000001456","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Banh, Int J Surg 2024: single-stage management of suspected gallbladder cancer with frozen section (London)"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Banh, Int J Surg 2024: single-stage management of suspected gallbladder cancer with frozen section (London)"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Banh, Int J Surg 2024: single-stage management of suspected gallbladder cancer with frozen section (London)"}]},{"url":"https://doi.org/10.1097/mcp.0000000000000068","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00063198-201407000-00004","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","field":"links","label":"Rekhtman 2014, Curr Opin Pulm Med: large cell carcinoma redefined by immunohistochemistry and genomics"}]},{"url":"https://doi.org/10.1097/md.0000000000022292","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/MD.0000000000022292","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Zhu, Medicine 2020: survival of 2,433 SEER gallbladder cancer patients 2010 to 2015"}]},{"url":"https://doi.org/10.1097/mnm.0000000000001405","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/MNM.0000000000001405","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Parida, Nucl Med Commun 2021: FDG PET-CT in staging gallbladder cancer, meta-analysis"}]},{"url":"https://doi.org/10.1097/mpa.0000000000000061","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00006676-201404000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"links","label":"Law, Pancreas 2014: systematic review of 2,744 solid-pseudopapillary neoplasms"}]},{"url":"https://doi.org/10.1097/mpa.0000000000000392","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00006676-201602000-00023","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"McWilliams, Pancreas 2016: risk factors for early-onset and very-early-onset pancreatic adenocarcinoma (PanC4)"}]},{"url":"https://doi.org/10.1097/mpa.0000000000000786","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00006676-201705000-00010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Matsuda, Pancreas 2017: prevalence of high-grade PanIN in 173 autopsy pancreata"},{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/","field":"links","label":"Matsuda, Pancreas 2017: prevalence of high-grade PanIN in 173 autopsy pancreata"}]},{"url":"https://doi.org/10.1097/MPA.0000000000001079","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00006676-201808000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Saito et al., randomised trial of pancreatic enzyme replacement in unresectable pancreatic cancer (Pancreas 2018)"},{"id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","field":"links","label":"Saito et al., randomised trial of pancreatic enzyme replacement in unresectable pancreatic cancer (Pancreas 2018)"}]},{"url":"https://doi.org/10.1097/pai.0000000000000922","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/PAI.0000000000000922","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-patil-gallbladder-immune-microenvironment-aimm-2021","kind":"paper","name":"Immune microenvironment in gallbladder adenocarcinomas","route":"/key-papers/paper-patil-gallbladder-immune-microenvironment-aimm-2021/","field":"links","label":"Patil et al., Appl Immunohistochem Mol Morphol 2021: immune microenvironment in 47 gallbladder adenocarcinomas"}]},{"url":"https://doi.org/10.1097/pas.0000000000000134","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201404000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","field":"links","label":"Kadota 2014, Am J Surg Pathol: prognosis of adenocarcinoma in situ, minimally invasive and lepidic predominant adenocarcinoma in 1,038 stage I cases"}]},{"url":"https://doi.org/10.1097/pas.0000000000000208","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201406000-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/","field":"links","label":"Epstein et al., American Journal of Surgical Pathology 2014: proposed morphologic classification of prostate cancer with neuroendocrine differentiation"}]},{"url":"https://doi.org/10.1097/PAS.0000000000000208","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201406000-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014","kind":"paper","name":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","route":"/key-papers/paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014/","field":"links","label":"Epstein et al., Am J Surg Pathol 2014: proposed morphologic classification of prostate cancer with neuroendocrine differentiation (Prostate Cancer Foundation working committee)"},{"id":"nepc-transformation","kind":"biomarker","name":"Treatment-emergent neuroendocrine transformation (recognising it)","route":"/biomarkers/nepc-transformation/","field":"links","label":"Epstein et al., Am J Surg Pathol 2014: proposed morphologic classification of prostate cancer with neuroendocrine differentiation (Prostate Cancer Foundation working committee)"}]},{"url":"https://doi.org/10.1097/pas.0000000000000262","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201410000-00011","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"links","label":"Am J Surg Pathol 2014: somatic-type malignancies from testicular germ cell tumours, 124 cases, frequent yolk sac tumour origin"}]},{"url":"https://doi.org/10.1097/pas.0000000000000328","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201502000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","field":"links","label":"Song 2015, Am J Surg Pathol: lymphomatoid granulomatosis, the National Cancer Institute series of 55 patients"}]},{"url":"https://doi.org/10.1097/pas.0000000000000432","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201508000-00013","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"links","label":"Am J Surg Pathol 2015: yolk sac tumour of the testis in infants and children, 33 cases"}]},{"url":"https://doi.org/10.1097/pas.0000000000000508","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201601000-00009","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eosinophilic-solid-cystic-renal-cell-carcinoma","kind":"cancer","name":"Eosinophilic solid and cystic renal cell carcinoma","route":"/cancers/eosinophilic-solid-cystic-renal-cell-carcinoma/","field":"links","label":"Am J Surg Pathol 2016: eosinophilic, solid and cystic renal cell carcinoma, 16 sporadic cases in women"}]},{"url":"https://doi.org/10.1097/PAS.0000000000000530","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201602000-00010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Epstein et al., American Journal of Surgical Pathology 2016: the 2014 ISUP consensus conference on Gleason grading, and the grade group system"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","field":"links","label":"Epstein et al., American Journal of Surgical Pathology 2016: the 2014 ISUP consensus conference on Gleason grading, and the grade group system"},{"id":"percentage-gleason-pattern-4","kind":"term","name":"Percentage of Gleason pattern 4","route":"/terms/percentage-gleason-pattern-4/","field":"links","label":"Epstein et al., American Journal of Surgical Pathology 2016: the 2014 ISUP consensus conference on Gleason grading, and the grade group system"}]},{"url":"https://doi.org/10.1097/pas.0000000000000533","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201512000-00016","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Basturk, Am J Surg Pathol 2015: Baltimore consensus, revised classification of pancreatic precursor lesions"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"links","label":"Basturk, Am J Surg Pathol 2015: Baltimore consensus, revised classification of pancreatic precursor lesions"},{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/","field":"links","label":"Basturk, Am J Surg Pathol 2015: Baltimore consensus, revised classification of pancreatic precursor lesions"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"Basturk, Am J Surg Pathol 2015: Baltimore consensus, revised classification of pancreatic precursor lesions"}]},{"url":"https://doi.org/10.1097/PAS.0000000000000533","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201512000-00016","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015","kind":"paper","name":"A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas","route":"/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/","field":"links","label":"Basturk et al., Am J Surg Pathol 2015: Baltimore consensus, two-tier grading of precursor lesions"}]},{"url":"https://doi.org/10.1097/PAS.0000000000000535","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201601000-00004","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","field":"links","label":"PSOGI consensus (Am J Surg Pathol 2016)"},{"id":"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016","kind":"paper","name":"PSOGI consensus for classification and pathological reporting of pseudomyxoma peritonei and associated appendiceal neoplasia","route":"/key-papers/paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016/","field":"links","label":"Am J Surg Pathol 2016"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"links","label":"PSOGI classification (Am J Surg Pathol 2016)"}]},{"url":"https://doi.org/10.1097/pas.0000000000000617","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201607000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"Am J Surg Pathol 2016: fumarate hydratase-deficient RCC is strongly correlated with FH mutation and HLRCC"}]},{"url":"https://doi.org/10.1097/pas.0000000000000689","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201609000-00005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"links","label":"Muraki, Am J Surg Pathol 2016: undifferentiated carcinoma with osteoclastic giant cells of the pancreas, 38 cases"}]},{"url":"https://doi.org/10.1097/pas.0000000000000719","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201611000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"Am J Surg Pathol 2016: tubulocystic carcinoma with poorly differentiated foci, a pattern of FH-deficient RCC"}]},{"url":"https://doi.org/10.1097/pas.0000000000000838","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201710000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eosinophilic-solid-cystic-renal-cell-carcinoma","kind":"cancer","name":"Eosinophilic solid and cystic renal cell carcinoma","route":"/cancers/eosinophilic-solid-cystic-renal-cell-carcinoma/","field":"links","label":"Am J Surg Pathol 2017: eosinophilic solid and cystic RCC, further characterisation of 19 cases"}]},{"url":"https://doi.org/10.1097/pas.0000000000001150","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201812000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mucinous-tubular-spindle-cell-carcinoma","kind":"cancer","name":"Mucinous tubular and spindle cell carcinoma of the kidney","route":"/cancers/mucinous-tubular-spindle-cell-carcinoma/","field":"links","label":"Am J Surg Pathol 2018: VSTM2A overexpression as a marker of mucinous tubular and spindle cell carcinoma"}]},{"url":"https://doi.org/10.1097/pas.0000000000001237","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201906000-00007","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"links","label":"Akita, Am J Surg Pathol 2019: intracholecystic papillary neoplasms are distinct from papillary gallbladder cancers"}]},{"url":"https://doi.org/10.1097/pas.0000000000001501","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/PAS.0000000000001501","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dedifferentiated-chordoma","kind":"cancer","name":"Dedifferentiated chordoma","route":"/cancers/dedifferentiated-chordoma/","field":"links","label":"Am J Surg Pathol 2020: dedifferentiated chordoma, clinicopathologic and molecular characteristics"}]},{"url":"https://doi.org/10.1097/pas.0b013e3181b63d66","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-200911000-00008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","field":"links","label":"Albores-Saavedra, Am J Surg Pathol 2009: mucin-containing Rokitansky-Aschoff sinuses simulating mucinous carcinoma"},{"id":"rokitansky-aschoff-sinus","kind":"term","name":"Rokitansky-Aschoff sinus","route":"/terms/rokitansky-aschoff-sinus/","field":"links","label":"Albores-Saavedra, Am J Surg Pathol 2009: mucin-containing Rokitansky-Aschoff sinuses simulating mucinous carcinoma"}]},{"url":"https://doi.org/10.1097/pas.0b013e3181e5060a","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201007000-00018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","field":"links","label":"Am J Surg Pathol 2010: IgM distinguishes primary cutaneous large B-cell lymphoma, leg type from follicle centre lymphoma"}]},{"url":"https://doi.org/10.1097/pas.0b013e318262787c","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201209000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"links","label":"Adsay, Am J Surg Pathol 2012: intracholecystic papillary-tubular neoplasms, 123 cases"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"Adsay, Am J Surg Pathol 2012: intracholecystic papillary-tubular neoplasms, 123 cases"},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"links","label":"Adsay, Am J Surg Pathol 2012: intracholecystic papillary-tubular neoplasms, 123 cases"},{"id":"intracholecystic-papillary-tubular-neoplasm","kind":"term","name":"Intracholecystic papillary-tubular neoplasm (ICPN)","route":"/terms/intracholecystic-papillary-tubular-neoplasm/","field":"links","label":"Adsay et al., Am J Surg Pathol 2012: intracholecystic papillary-tubular neoplasms, 123 cases"},{"id":"paper-adsay-icpn-gallbladder-ajsp-2012","kind":"paper","name":"Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are at least 1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases","route":"/key-papers/paper-adsay-icpn-gallbladder-ajsp-2012/","field":"links","label":"Adsay et al., Am J Surg Pathol 2012: intracholecystic papillary-tubular neoplasms, 123 cases"}]},{"url":"https://doi.org/10.1097/PAS.0b013e318263209d","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201212000-00005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012","kind":"paper","name":"La Rosa 2012: clinicopathologic study of 62 acinar cell carcinomas of the pancreas","route":"/key-papers/paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012/","field":"links","label":"Am J Surg Pathol 2012"}]},{"url":"https://doi.org/10.1097/pas.0b013e3182635954","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201209000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"Am J Surg Pathol 2012: collecting duct carcinoma and renal medullary carcinoma, 52 cases"},{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"Am J Surg Pathol 2012: collecting duct carcinoma and renal medullary carcinoma, 52 cases"}]},{"url":"https://doi.org/10.1097/pas.0b013e31829cdbc6","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201401000-00008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"links","label":"Am J Surg Pathol 2014: frequent CTNNB1 mutation and nuclear beta-catenin in Sertoli cell tumours of the testis"}]},{"url":"https://doi.org/10.1097/pas.0b013e3182a2926e","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000478-201401000-00014","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","field":"links","label":"Am J Surg Pathol 2014: choriocarcinoma as a pure or predominant component of testicular germ cell tumour, 1,010 orchiectomies"}]},{"url":"https://doi.org/10.1097/ppo.0000000000000500","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/PPO.0000000000000500","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Howard and Olopade, Cancer J 2021: epidemiology of triple-negative breast cancer, a review"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Howard and Olopade, Cancer J 2021: epidemiology of triple-negative breast cancer, a review"}]},{"url":"https://doi.org/10.1097/PRS.0000000000010195","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/PRS.0000000000010195","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bia-alcl","kind":"term","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/terms/bia-alcl/","field":"links","label":"No cases after transient exposure to a textured tissue expander, 3,310 patients (Plastic and Reconstructive Surgery 2023)"}]},{"url":"https://doi.org/10.1097/rti.0b013e3180592af8","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00005382-200711000-00014","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"papers","label":"High-resolution Computed Tomography Findings of Diffuse Pulmonary Involvement by Mycosis Fungoides"}]},{"url":"https://doi.org/10.1097/sla.0000000000000728","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201504000-00018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Shindoh, Ann Surg 2015: tumour location in T2 gallbladder cancer (hepatic versus peritoneal side)"},{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","field":"links","label":"Shindoh, Ann Surg 2015: tumour location in T2 gallbladder cancer (hepatic versus peritoneal side)"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"links","label":"Shindoh, Ann Surg 2015: tumour location in T2 gallbladder cancer (hepatic versus peritoneal side)"}]},{"url":"https://doi.org/10.1097/SLA.0000000000000728","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201504000-00018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015","kind":"paper","name":"Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study","route":"/key-papers/paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015/","field":"links","label":"Ann Surg 2015"}]},{"url":"https://doi.org/10.1097/sla.0000000000001193","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201604000-00018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Battersby, Ann Surg 2016: MERCURY II, prospective validation of a low rectal cancer magnetic resonance imaging staging system (279 patients)"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"Battersby, Ann Surg 2016: MERCURY II, prospective validation of a low rectal cancer magnetic resonance imaging staging system (279 patients)"}]},{"url":"https://doi.org/10.1097/SLA.0000000000001346","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201601000-00006","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"papers","label":"Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01)"}]},{"url":"https://doi.org/10.1097/SLA.0000000000001447","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201605000-00030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016","kind":"paper","name":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG)","route":"/key-papers/paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016/","field":"links","label":"Ann Surg 2016"}]},{"url":"https://doi.org/10.1097/sla.0000000000001731","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201703000-00021","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Strobel, Ann Surg 2017: pancreatic cancer surgery, the new R-status counts (561 patients)"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Strobel, Ann Surg 2017: pancreatic cancer surgery, the new R-status counts (561 patients)"}]},{"url":"https://doi.org/10.1097/sla.0000000000001763","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201701000-00030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Allen, Ann Surg 2017: multi-institutional validation of the AJCC 8th edition T and N staging for pancreatic adenocarcinoma"}]},{"url":"https://doi.org/10.1097/sla.0000000000002353","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201802000-00001","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"papers","label":"Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial"}]},{"url":"https://doi.org/10.1097/sla.0000000000002511","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201805000-00010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"papers","label":"ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)"}]},{"url":"https://doi.org/10.1097/sla.0000000000002542","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201903000-00009","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"papers","label":"Use of Prophylactic Mesh When Creating a Colostomy Does Not Prevent Parastomal Hernia"}]},{"url":"https://doi.org/10.1097/sla.0000000000002557","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201903000-00022","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Ghaneh, Ann Surg 2019: positive resection margins, survival and recurrence in ESPAC-3 (1,151 patients)"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Ghaneh, Ann Surg 2019: positive resection margins, survival and recurrence in ESPAC-3 (1,151 patients)"},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","field":"links","label":"Ghaneh, Ann Surg 2019: positive resection margins, survival and recurrence in ESPAC-3 (1,151 patients)"}]},{"url":"https://doi.org/10.1097/sla.0000000000002979","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201901000-00002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/","field":"links","label":"de Rooij, Ann Surg 2019: LEOPARD, minimally invasive versus open distal pancreatectomy"}]},{"url":"https://doi.org/10.1097/sla.0000000000003404","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/SLA.0000000000003404","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"papers","label":"Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases"}]},{"url":"https://doi.org/10.1097/sla.0b013e31811f4449","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-200804000-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"links","label":"Crippa, Ann Surg 2008: mucinous cystic neoplasm of the pancreas is not an aggressive entity, 163 resected patients"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"Crippa, Ann Surg 2008: mucinous cystic neoplasm of the pancreas is not an aggressive entity, 163 resected patients"}]},{"url":"https://doi.org/10.1097/sla.0b013e3181cf8a19","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201003000-00014","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"links","label":"Poultsides, Ann Surg 2010: histopathologic basis for the favourable survival of IPMN-associated invasive adenocarcinoma"}]},{"url":"https://doi.org/10.1097/sla.0b013e318214bcb4","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201105000-00019","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"links","label":"Yopp, Ann Surg 2011: invasive carcinoma arising in IPMN, matched comparison with ductal adenocarcinoma"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"links","label":"Yopp, Ann Surg 2011: invasive carcinoma arising in IPMN, matched comparison with ductal adenocarcinoma"}]},{"url":"https://doi.org/10.1097/SLA.0b013e31826cbbbd","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201210000-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012","kind":"paper","name":"ANBL00P2: expectant observation as primary therapy for neuroblastoma in young infants","route":"/key-papers/paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012/","field":"links","label":"Ann Surg 2012"}]},{"url":"https://doi.org/10.1097/SLA.0b013e318271497e","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201308000-00019","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Agarwal et al., Annals of Surgery 2013: staging laparoscopy in 409 gallbladder cancer patients"}]},{"url":"https://doi.org/10.1097/sla.0b013e3182777fa4","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00000658-201304000-00009","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"papers","label":"Implementation of the World Health Organization surgical safety checklist, including introduction of pulse oximetry, in a resource-limited setting"}]},{"url":"https://doi.org/10.1098/rstb.2014.0219","status":403,"ok":false,"finalUrl":"https://royalsocietypublishing.org/rstb/article/22675","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aktipis-philos-trans-r-soc-lond-b-biol-sci","kind":"paper","name":"Cancer across the tree of life: cooperation and cheating in multicellularity","route":"/key-papers/paper-aktipis-philos-trans-r-soc-lond-b-biol-sci/","field":"links","label":"Philos Trans R Soc Lond B Biol Sci 2015"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Aktipis et al., Cancer across the tree of life: cooperation and cheating in multicellularity (Philosophical Transactions B 2015)"}]},{"url":"https://doi.org/10.1101/cshperspect.a019505","status":403,"ok":false,"finalUrl":"http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a019505","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","field":"links","label":"Baylin & Jones, Epigenetic determinants of cancer (Cold Spring Harbor Perspectives 2016)"},{"id":"paper-baylin-cold-spring-harb-perspect-biol","kind":"paper","name":"Epigenetic Determinants of Cancer","route":"/key-papers/paper-baylin-cold-spring-harb-perspect-biol/","field":"links","label":"Cold Spring Harb Perspect Biol 2016"},{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/","field":"links","label":"Baylin and Jones, Epigenetic determinants of cancer (Cold Spring Harbor Perspectives 2016)"}]},{"url":"https://doi.org/10.1101/gad.13.12.1501","status":403,"ok":false,"finalUrl":"https://genesdev.cshlp.org/cgi/doi/10.1101/gad.13.12.1501","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sherr-roberts-cdk-inhibitors-genesdev-1999","kind":"paper","name":"Sherr and Roberts 1999: CDK inhibitors as regulators of the G1 phase","route":"/key-papers/paper-sherr-roberts-cdk-inhibitors-genesdev-1999/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1101/gad.1941310","status":403,"ok":false,"finalUrl":"https://genesdev.cshlp.org/lookup/doi/10.1101/gad.1941310","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","field":"papers","label":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model"}]},{"url":"https://doi.org/10.1101/gad.261982.115","status":403,"ok":false,"finalUrl":"https://genesdev.cshlp.org/lookup/doi/10.1101/gad.261982.115","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","field":"papers","label":"Cancer stem cells in glioblastoma"}]},{"url":"https://doi.org/10.1111/aas.13228","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/aas.13228","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"papers","label":"Elevated serum S‐100β in patients with septic shock is associated with delirium"}]},{"url":"https://doi.org/10.1111/aos.13007","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/aos.13007","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"conjunctival-melanoma","kind":"cancer","name":"Conjunctival melanoma","route":"/cancers/conjunctival-melanoma/","field":"links","label":"Acta Ophthalmologica 2016: BRAF mutations, incidence and prognosis of conjunctival melanoma in Denmark"}]},{"url":"https://doi.org/10.1111/apt.12655","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/apt.12655","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014","kind":"paper","name":"Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer","route":"/key-papers/paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014/","field":"links","label":"Aliment Pharmacol Ther 2014"}]},{"url":"https://doi.org/10.1111/bjd.12420","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/169/3/502/6615233","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Werner, Sammain, Erdmann, Hartmann, Stockfleth and Nast, British Journal of Dermatology 2013;169(3):502 to 518: the natural history of actinic keratosis, a systematic review"}]},{"url":"https://doi.org/10.1111/bjd.12766","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/170/2/245/6614755","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Morton et al., British Journal of Dermatology 2014;170(2):245 to 260: British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014, superseded by the 2022 version"}]},{"url":"https://doi.org/10.1111/bjd.13066","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/171/6/1501/6616257","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"topical-and-destructive-treatment-bcc","kind":"term","name":"Creams, light and cold for basal cell carcinoma","route":"/terms/topical-and-destructive-treatment-bcc/","field":"links","label":"Cost-effectiveness alongside the trial (British Journal of Dermatology 2014)"}]},{"url":"https://doi.org/10.1111/bjd.13443","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/172/5/1384/6616293","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-glaser-br-j-dermatol","kind":"paper","name":"Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial","route":"/key-papers/paper-glaser-br-j-dermatol/","field":"links","label":"Br J Dermatol 2015"},{"id":"bimatoprost-eyelash-regrowth","kind":"technology","name":"Bimatoprost for eyelash and eyebrow regrowth","route":"/technologies/bimatoprost-eyelash-regrowth/","field":"links","label":"Bimatoprost 0.03% for idiopathic and chemotherapy-induced eyelash hypotrichosis, randomised controlled trial (Br J Dermatol 2015)"}]},{"url":"https://doi.org/10.1111/bjd.15107","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/176/1/20/6747903","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"de Berker, McGregor, Mohd Mustapa, Exton and Hughes, British Journal of Dermatology 2017;176(1):20 to 43: British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017"}]},{"url":"https://doi.org/10.1111/bjd.16892","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/179/4/824/6753794","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Keohane, Proby, Newlands, Motley, Nasr and Mohd Mustapa, British Journal of Dermatology 2018;179:824 to 828: the new 8th edition of TNM staging and its implications for skin cancer, a review by the British Association of Dermatologists and the Royal College of Pathologists, UK"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Keohane, Proby, Newlands, Motley, Nasr and Mohd Mustapa, British Journal of Dermatology 2018;179:824 to 828: the new 8th edition of TNM staging and its implications for skin cancer, a review by the British Association of Dermatologists and the Royal College of Pathologists, UK"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"links","label":"Keohane, Proby, Newlands, Motley, Nasr and Mohd Mustapa, British Journal of Dermatology 2018;179:824 to 828: the new 8th edition of TNM staging and its implications for skin cancer, a review by the British Association of Dermatologists and the Royal College of Pathologists, UK"}]},{"url":"https://doi.org/10.1111/bjd.17873","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/181/3/474/6764911","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Venables et al., British Journal of Dermatology 2019;181(3):474 to 482: epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013 to 2015, a cohort study (the paper that introduced the first-per-person-per-annum count)"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Venables et al., British Journal of Dermatology 2019;181(3):474 to 482: epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013 to 2015, a cohort study (the paper that introduced the first-per-person-per-annum count)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Venables et al., British Journal of Dermatology 2019;181(3):474 to 482: epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013 to 2015, a cohort study (the paper that introduced the first-per-person-per-annum count)"}]},{"url":"https://doi.org/10.1111/bjd.19621","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/184/3/401/6702204","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Keohane et al., British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020 (Br J Dermatol)"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"Keohane et al., British Journal of Dermatology 2021;184(3):401 to 414: British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Keohane et al., British Journal of Dermatology 2021;184(3):401 to 414: British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"links","label":"Keohane et al., British Journal of Dermatology 2021;184(3):401 to 414: British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Keohane et al., British Journal of Dermatology 2021;184(3):401 to 414: British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020"}]},{"url":"https://doi.org/10.1111/bjd.20524","status":403,"ok":false,"finalUrl":"https://academic.oup.com/bjd/article/185/5/899/6599942","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Nasr et al., British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021 (Br J Dermatol)"},{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"Nasr et al., British Journal of Dermatology 2021;185(5):899 to 920: British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Nasr et al., British Journal of Dermatology 2021;185(5):899 to 920: British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"links","label":"Nasr et al., British Journal of Dermatology 2021;185(5):899 to 920: British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Nasr et al., British Journal of Dermatology 2021;185(5):899 to 920: British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021"}]},{"url":"https://doi.org/10.1111/bjh.13403","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.13403","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-tumour-lysis","kind":"term","name":"Tumour lysis syndrome in lymphoma: who is at risk, and rasburicase","route":"/terms/lymphoma-tx-tumour-lysis/","field":"links","label":"Jones et al., management of tumour lysis syndrome in adults and children with haematological malignancies, British Committee for Standards in Haematology, British Journal of Haematology 2015"}]},{"url":"https://doi.org/10.1111/bjh.17421","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.17421","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shah-br-j-haematol","kind":"paper","name":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline","route":"/key-papers/paper-shah-br-j-haematol/","field":"links","label":"Br J Haematol 2021"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"links","label":"BSH guideline on PTLD (Br J Haematol 2021)"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"standardOfCare.guideline (All PTLD, first step)"}]},{"url":"https://doi.org/10.1111/bjh.19170","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19170","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-martinez-cibrian-br-j-haematol","kind":"paper","name":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-martinez-cibrian-br-j-haematol/","field":"links","label":"Br J Haematol 2024"},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","field":"links","label":"ARI-0001 academic CAR-T review (Br J Haematol 2023)"}]},{"url":"https://doi.org/10.1111/bjh.19754","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19754","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"links","label":"British Journal of Haematology 2024: understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli"}]},{"url":"https://doi.org/10.1111/bju.13705","status":403,"ok":false,"finalUrl":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.13705","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"BJU International 2017: management and outcomes of 52 patients with renal medullary carcinoma"}]},{"url":"https://doi.org/10.1111/bju.15535","status":403,"ok":false,"finalUrl":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15535","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"links","label":"Benafif et al., BJU International 2022: the BARCODE1 pilot, a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening"}]},{"url":"https://doi.org/10.1111/bju.70261","status":403,"ok":false,"finalUrl":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.70261","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-protect-bju-int-2026-update","kind":"paper","name":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","route":"/key-papers/paper-protect-bju-int-2026-update/","field":"links","label":"BJU Int 2026"}]},{"url":"https://doi.org/10.1111/bpa.12282","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/bpa.12282","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"papillary-tumour-pineal-region","kind":"cancer","name":"Papillary tumour of the pineal region","route":"/cancers/papillary-tumour-pineal-region/","field":"links","label":"Brain Pathology 2016: papillary tumour of the pineal region, a distinct molecular entity (24 cases)"}]},{"url":"https://doi.org/10.1111/cas.12966","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/cas.12966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","field":"links","label":"Ogitani et al., Bystander killing effect of DS-8201a, a HER2-targeting antibody-drug conjugate (Cancer Science 2016)"},{"id":"paper-ogitani-cancer-sci","kind":"paper","name":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","route":"/key-papers/paper-ogitani-cancer-sci/","field":"links","label":"Cancer Sci 2016"}]},{"url":"https://doi.org/10.1111/cas.14926","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/cas.14926","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/","field":"links","label":"CIRCULATE-Japan: ctDNA-guided adaptive platform trials (Cancer Science 2021)"}]},{"url":"https://doi.org/10.1111/cen.12714","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/cen.12714","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"links","label":"Singh Ospina 2016, Clin Endocrinol: parathyroid carcinoma in 348 patients with MEN1"}]},{"url":"https://doi.org/10.1111/cen.13480","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/cen.13480","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"links","label":"Ye 2017, Clin Endocrinol: thymic neuroendocrine tumours in MEN1, meta-analysis"}]},{"url":"https://doi.org/10.1111/cts.70082","status":403,"ok":false,"finalUrl":"https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70082","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","field":"links","label":"Ubamatamab translational study (Zhu et al., Clin Transl Sci 2024)"},{"id":"paper-zhu-clin-transl-sci","kind":"paper","name":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer","route":"/key-papers/paper-zhu-clin-transl-sci/","field":"links","label":"Clin Transl Sci 2024"},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","field":"links","label":"Ubamatamab translational study (Zhu et al., Clin Transl Sci 2024)"}]},{"url":"https://doi.org/10.1111/dsu.12122","status":403,"ok":false,"finalUrl":"https://journals.lww.com/00042728-201305000-00004","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"links","label":"Aggressive histological subtypes treated with curettage alone (Dermatologic Surgery 2013)"}]},{"url":"https://doi.org/10.1111/ecc.12365","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/ecc.12365","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"papers","label":"Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project"}]},{"url":"https://doi.org/10.1111/ejh.14443","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14443","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Nodular lymphocyte-predominant Hodgkin lymphoma: a different disease that keeps the name)"}]},{"url":"https://doi.org/10.1111/ene.13676","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/ene.13676","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"papers","label":"Ictal and interictal electric source imaging in pre-surgical evaluation: a prospective study"}]},{"url":"https://doi.org/10.1111/his.12055","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.12055","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bettington, Histopathology 2013: the serrated pathway to colorectal carcinoma, current concepts and challenges"},{"id":"paper-bettington-serrated-pathway-colorectal-histopathology-2013","kind":"paper","name":"The serrated pathway to colorectal carcinoma: current concepts and challenges","route":"/key-papers/paper-bettington-serrated-pathway-colorectal-histopathology-2013/","field":"links","label":"Bettington et al., Histopathology 2013: the serrated pathway to colorectal carcinoma"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"links","label":"Bettington, Histopathology 2013: the serrated pathway to colorectal carcinoma, current concepts and challenges"},{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","field":"links","label":"Bettington, Histopathology 2013: the serrated pathway to colorectal carcinoma, current concepts and challenges"},{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","field":"links","label":"Bettington, Histopathology 2013: the serrated pathway to colorectal carcinoma, current concepts and challenges"},{"id":"cimp","kind":"term","name":"CpG island methylator phenotype (CIMP)","route":"/terms/cimp/","field":"links","label":"Bettington, Histopathology 2013: the serrated pathway to colorectal carcinoma, current concepts and challenges"}]},{"url":"https://doi.org/10.1111/his.12428","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.12428","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"micronodular-thymoma","kind":"cancer","name":"Micronodular thymoma with lymphoid stroma","route":"/cancers/micronodular-thymoma/","field":"links","label":"Histopathology 2015: micronodular thymoma with lymphoid stroma, Langerhans and dendritic cells in six patients"}]},{"url":"https://doi.org/10.1111/his.12725","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.12725","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"links","label":"Histopathology 2016: adenoma-like adenocarcinoma, a subtype of colorectal carcinoma with good prognosis and deceptive appearance on biopsy (35 tumours)"}]},{"url":"https://doi.org/10.1111/his.12876","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.12876","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tan-phyllodes-consensus-histopathology-2016","kind":"paper","name":"Phyllodes tumours of the breast: a consensus review","route":"/key-papers/paper-tan-phyllodes-consensus-histopathology-2016/","field":"links","label":"Histopathology 2016"}]},{"url":"https://doi.org/10.1111/his.12958","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.12958","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","field":"links","label":"Histopathology 2016: germ cell neoplasia in situ, evolution of the nomenclature"}]},{"url":"https://doi.org/10.1111/his.13183","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.13183","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"Histopathology 2017: a low-grade oncocytic FH-deficient RCC resembling SDH-deficient RCC"},{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","field":"links","label":"Histopathology 2017: a low-grade oncocytic FH-deficient RCC resembling SDH-deficient RCC"}]},{"url":"https://doi.org/10.1111/his.13669","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.13669","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-neyaz-pdl1-gallbladder-histopathology-2018","kind":"paper","name":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","route":"/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/","field":"links","label":"Neyaz et al., Histopathology 2018: PD-L1 (SP263) in 174 Indian gallbladder cancers"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1111/his.13975","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.13975","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"cystic-duct-carcinoma","kind":"cancer","name":"Cystic duct carcinoma","route":"/cancers/cystic-duct-carcinoma/","field":"links","label":"Nagtegaal, Histopathology 2020: the 2019 WHO classification of tumours of the digestive system"},{"id":"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020","kind":"paper","name":"The 2019 WHO classification of tumours of the digestive system","route":"/key-papers/paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020/","field":"links","label":"Histopathology 2020"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"links","label":"Nagtegaal 2020, Histopathology: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","field":"links","label":"Nagtegaal 2020, Histopathology: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","field":"links","label":"Nagtegaal 2020, Histopathology: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","field":"links","label":"Nagtegaal 2020, Histopathology: the 2019 WHO classification of tumours of the digestive system"},{"id":"colorectal-serrated-adenocarcinoma","kind":"cancer","name":"Serrated adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-serrated-adenocarcinoma/","field":"links","label":"Nagtegaal 2020, Histopathology: the 2019 WHO classification of tumours of the digestive system"}]},{"url":"https://doi.org/10.1111/his.14091","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.14091","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Tan, Histopathology 2020: the 2019 WHO classification of tumours of the breast"},{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Tan, Histopathology 2020: the 2019 WHO classification of tumours of the breast"},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Tan et al., Histopathology 2020: the 2019 WHO classification of tumours of the breast (5th edition)"},{"id":"terminal-duct-lobular-unit","kind":"term","name":"Ducts, lobules and the terminal duct lobular unit","route":"/terms/terminal-duct-lobular-unit/","field":"links","label":"Tan et al., Histopathology 2020: the 2019 WHO classification of tumours of the breast (5th edition)"},{"id":"who-breast-classification","kind":"term","name":"The WHO classification of breast tumours, and what the 6th edition changed","route":"/terms/who-breast-classification/","field":"links","label":"Tan et al., Histopathology 2020: the 2019 WHO classification of tumours of the breast (5th edition)"},{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/","field":"links","label":"Tan et al., Histopathology 2020: the 2019 WHO classification of tumours of the breast (5th edition)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Tan et al., Histopathology 2020: the 2019 WHO classification of tumours of the breast (5th edition)"},{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"mucinous-carcinoma-breast","kind":"cancer","name":"Mucinous carcinoma of the breast","route":"/cancers/mucinous-carcinoma-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"papillary-carcinoma-breast","kind":"cancer","name":"Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)","route":"/cancers/papillary-carcinoma-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"invasive-micropapillary-carcinoma-breast","kind":"cancer","name":"Invasive micropapillary carcinoma of the breast","route":"/cancers/invasive-micropapillary-carcinoma-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"neuroendocrine-neoplasms-breast","kind":"cancer","name":"Neuroendocrine neoplasms of the breast","route":"/cancers/neuroendocrine-neoplasms-breast/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"},{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"links","label":"Tan 2020, Histopathology: the 2019 WHO classification of tumours of the breast"}]},{"url":"https://doi.org/10.1111/his.14711","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.14711","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"prostate-acinar-adenocarcinoma","kind":"term","name":"Acinar adenocarcinoma of the prostate","route":"/terms/prostate-acinar-adenocarcinoma/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"intraductal-carcinoma-prostate","kind":"term","name":"Intraductal carcinoma of the prostate (IDC-P)","route":"/terms/intraductal-carcinoma-prostate/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"cribriform-prostate-cancer","kind":"term","name":"Cribriform growth pattern in prostate cancer","route":"/terms/cribriform-prostate-cancer/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"high-grade-pin","kind":"term","name":"High-grade prostatic intraepithelial neoplasia (HGPIN)","route":"/terms/high-grade-pin/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"links","label":"Kench et al., Histopathology 2022: WHO Classification of Tumours fifth edition, evolving issues in the classification, diagnosis and prognostication of prostate cancer"}]},{"url":"https://doi.org/10.1111/his.15562","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.15562","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"Histopathology 2026;88:555 to 568: WHO classification of skin tumours, key updates in the fifth edition (open-access summary of what the 2025 volume changed)"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"Histopathology 2026;88:555 to 568: WHO classification of skin tumours, key updates in the fifth edition (open-access summary of what the 2025 volume changed)"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"Histopathology 2026;88:555 to 568: WHO classification of skin tumours, key updates in the fifth edition (open-access summary of what the 2025 volume changed)"}]},{"url":"https://doi.org/10.1111/his.70149","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.70149","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"},{"id":"who-breast-classification","kind":"term","name":"The WHO classification of breast tumours, and what the 6th edition changed","route":"/terms/who-breast-classification/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"},{"id":"her2-testing-uk-breast","kind":"term","name":"HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP","route":"/terms/her2-testing-uk-breast/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"},{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"Quinn et al., Histopathology 2026;89(2):199 to 218: World Health Organization classification of tumours of the breast, 6th edition 2026"}]},{"url":"https://doi.org/10.1111/his.70179","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/his.70179","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"links","label":"Gasparello, Histopathology 2026: molecular profile of adenosquamous gallbladder carcinoma"}]},{"url":"https://doi.org/10.1111/j.1365-2141.2009.07606.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07606.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1111/j.1365-2265.2011.03967.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2011.03967.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glucagonoma","kind":"cancer","name":"Glucagonoma","route":"/cancers/glucagonoma/","field":"links","label":"Clinical Endocrinology 2011: glucagonoma and the glucagonoma syndrome, 25 years of experience"}]},{"url":"https://doi.org/10.1111/j.1365-2559.1983.tb02265.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.1983.tb02265.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","field":"links","label":"Page 1983, Histopathology: invasive cribriform carcinoma of the breast, 51 of 1,003 carcinomas"}]},{"url":"https://doi.org/10.1111/j.1365-2559.1991.tb00229.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.1991.tb00229.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/","field":"links","label":"Elston and Ellis, Histopathology 1991;19:403 to 410: pathological prognostic factors in breast cancer, the value of histological grade, with long-term follow-up of 1,831 graded patients"},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","field":"links","label":"Elston and Ellis, Histopathology 1991;19:403 to 410: pathological prognostic factors in breast cancer, the value of histological grade, with long-term follow-up of 1,831 graded patients"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Elston and Ellis, Histopathology 1991;19:403 to 410: pathological prognostic factors in breast cancer, the value of histological grade, with long-term follow-up of 1,831 graded patients"}]},{"url":"https://doi.org/10.1111/j.1365-2559.2009.03376.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2009.03376.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Campbell, Histopathology 2009: classification of R1 resections, tumour within 1 mm of a margin"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Campbell, Histopathology 2009: classification of R1 resections, tumour within 1 mm of a margin"},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","field":"links","label":"Campbell, Histopathology 2009: classification of R1 resections, tumour within 1 mm of a margin"}]},{"url":"https://doi.org/10.1111/j.1365-2559.2011.03821.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2011.03821.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-serrated-adenocarcinoma","kind":"cancer","name":"Serrated adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-serrated-adenocarcinoma/","field":"links","label":"Histopathology 2011: KRAS and BRAF mutations in colorectal serrated adenocarcinoma"}]},{"url":"https://doi.org/10.1111/j.1365-2559.2012.04228.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2012.04228.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"Histopathology 2012: SMARCB1/INI1 inactivation in renal medullary carcinoma"}]},{"url":"https://doi.org/10.1111/j.1440-1746.2007.05053.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2007.05053.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"somatostatinoma","kind":"cancer","name":"Somatostatinoma","route":"/cancers/somatostatinoma/","field":"links","label":"J Gastroenterol Hepatol 2008: somatostatinoma, three cases and literature review"}]},{"url":"https://doi.org/10.1111/j.1440-1819.2006.01511.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1819.2006.01511.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","field":"papers","label":"Brief posturographic test as an indicator of fatigue"}]},{"url":"https://doi.org/10.1111/j.1540-8175.2011.01597.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1540-8175.2011.01597.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"papers","label":"Does longitudinal strain predict left ventricular remodeling after myocardial infarction?"}]},{"url":"https://doi.org/10.1111/j.1582-4934.2010.01236.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1582-4934.2010.01236.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-iozzo-j-cell-mol-med","kind":"paper","name":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis","route":"/key-papers/paper-iozzo-j-cell-mol-med/","field":"links","label":"J Cell Mol Med 2011"},{"id":"proteoglycans-in-cancer","kind":"pathway","name":"Proteoglycans in cancer","route":"/pathways/proteoglycans-in-cancer/","field":"links","label":"Review: Proteoglycans in cancer biology, tumour microenvironment and angiogenesis"}]},{"url":"https://doi.org/10.1111/j.1753-5174.2011.00035.x","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/j.1753-5174.2011.00035.x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","route":"/drugs/epoetin-theta/","field":"links","label":"XM01-22 (Archives of Drug Information 2011)"},{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","field":"links","label":"Archives of Drug Information 2011"},{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","field":"outcomes.source (Complete haemoglobin response (increase of at least 2 g/dL without transfusion in the previous 4 weeks))"},{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","field":"outcomes.source (Patients transfused after randomisation)"},{"id":"paper-xm01-22-tjulandin-arch-drug-inf-2011","kind":"paper","name":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22)","route":"/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/","field":"links","label":"Archives of Drug Information 2011"}]},{"url":"https://doi.org/10.1111/jdv.13752","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.13752","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glucagonoma","kind":"cancer","name":"Glucagonoma","route":"/cancers/glucagonoma/","field":"links","label":"JEADV 2016: glucagonoma syndrome, review and update on treatment"}]},{"url":"https://doi.org/10.1111/jdv.14542","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.14542","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","kind":"paper","name":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","route":"/key-papers/paper-bolt-j-eur-acad-dermatol-venereol-2018-update/","field":"links","label":"J Eur Acad Dermatol Venereol 2018"}]},{"url":"https://doi.org/10.1111/jdv.16446","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.16446","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hedgehog-inhibitor-tolerability","kind":"term","name":"Why people stop taking hedgehog inhibitors","route":"/terms/hedgehog-inhibitor-tolerability/","field":"links","label":"Quality of life on intermittent vismodegib, the MIKIE study (Journal of the European Academy of Dermatology and Venereology 2020)"}]},{"url":"https://doi.org/10.1111/liv.14326","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1111/liv.14326","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"van Erp, Liver Int 2020: gallbladder polyps and cancer risk in primary sclerosing cholangitis"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"van Erp, Liver Int 2020: gallbladder polyps and cancer risk in primary sclerosing cholangitis"},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"links","label":"van Erp, Liver Int 2020: gallbladder polyps and cancer risk in primary sclerosing cholangitis"}]},{"url":"https://doi.org/10.1118/1.2349696","status":403,"ok":false,"finalUrl":"https://aapm.onlinelibrary.wiley.com/doi/10.1118/1.2349696","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keall-med-phys","kind":"paper","name":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","route":"/key-papers/paper-keall-med-phys/","field":"links","label":"Med Phys 2006"},{"id":"respiratory-gating-tumour-tracking-systems","kind":"technology","name":"Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)","route":"/technologies/respiratory-gating-tumour-tracking-systems/","field":"links","label":"Keall et al., AAPM Task Group 76: the management of respiratory motion in radiation oncology (Medical Physics 2006)"}]},{"url":"https://doi.org/10.1118/1.598373","status":403,"ok":false,"finalUrl":"https://aapm.onlinelibrary.wiley.com/doi/10.1118/1.598373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"treatment-planning-systems","kind":"technology","name":"Radiotherapy treatment planning and QA software","route":"/technologies/treatment-planning-systems/","field":"links","label":"AAPM Task Group 53: quality assurance for clinical radiotherapy treatment planning (Medical Physics 1998)"},{"id":"paper-fraass-med-phys","kind":"paper","name":"American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning","route":"/key-papers/paper-fraass-med-phys/","field":"links","label":"Med Phys 1998"}]},{"url":"https://doi.org/10.1126/science.1059817","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1059817","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","field":"papers","label":"HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing"}]},{"url":"https://doi.org/10.1126/science.1062538","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1062538","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"papers","label":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification"}]},{"url":"https://doi.org/10.1126/science.1079666","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1079666","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","field":"papers","label":"PDGFRA activating mutations in gastrointestinal stromal tumours"},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","field":"links","label":"Heinrich 2003 (Science)"},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","field":"prevalence.source"},{"id":"paper-heinrich-pdgfra-gist-science-2003","kind":"paper","name":"PDGFRA activating mutations in gastrointestinal stromal tumours","route":"/key-papers/paper-heinrich-pdgfra-gist-science-2003/","field":"links","label":"Science 2003"}]},{"url":"https://doi.org/10.1126/science.1099314","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1099314","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/","field":"links","label":"Science 2004"},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"papers","label":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy"}]},{"url":"https://doi.org/10.1126/science.1104819","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1104819","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jain-science","kind":"paper","name":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","route":"/key-papers/paper-jain-science/","field":"links","label":"Science 2005"},{"id":"angiogenesis-models","kind":"technology","name":"Angiogenesis and vascular normalisation models","route":"/technologies/angiogenesis-models/","field":"links","label":"Jain 2005, Science"}]},{"url":"https://doi.org/10.1126/science.1105891","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1105891","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","field":"papers","label":"Noise in gene expression: origins, consequences, and control"}]},{"url":"https://doi.org/10.1126/science.1117679","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1117679","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tomlins-tmprss2-ets-fusion-science-2005","kind":"paper","name":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","route":"/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/","field":"links","label":"Science 2005"},{"id":"tmprss2-erg-fusion","kind":"biomarker","name":"TMPRSS2-ERG fusion (and the other ETS rearrangements)","route":"/biomarkers/tmprss2-erg-fusion/","field":"links","label":"Tomlins et al., Science 2005: recurrent fusion of TMPRSS2 to ERG or ETV1 in prostate cancer (29 samples by fluorescence in situ hybridisation)"},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"papers","label":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer"}]},{"url":"https://doi.org/10.1126/science.1129003","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1129003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"papers","label":"Cancer regression in patients after transfer of genetically engineered lymphocytes"}]},{"url":"https://doi.org/10.1126/science.1129139","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1129139","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-galon-immune-contexture-colorectal-science-2006","kind":"paper","name":"Galon 2006: the type, density and location of immune cells in colorectal tumours predict outcome","route":"/key-papers/paper-galon-immune-contexture-colorectal-science-2006/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.1141478","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1141478","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","kind":"paper","name":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","route":"/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/","field":"links","label":"Engelman et al., Science 2007: MET amplification causes gefitinib resistance by activating ERBB3 signalling"}]},{"url":"https://doi.org/10.1126/science.1160809","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1160809","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","field":"papers","label":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation"},{"id":"paper-vander-heiden-science","kind":"paper","name":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","route":"/key-papers/paper-vander-heiden-science/","field":"links","label":"Science 2009"},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","field":"links","label":"Vander Heiden, Cantley and Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation (Science 2009)"}]},{"url":"https://doi.org/10.1126/science.1164368","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1164368","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jones-pancreatic-core-pathways-science-2008","kind":"paper","name":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","route":"/key-papers/paper-jones-pancreatic-core-pathways-science-2008/","field":"links","label":"Jones et al., Science 2008: core signalling pathways in 24 pancreatic cancers"}]},{"url":"https://doi.org/10.1126/science.1168175","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1168175","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"papers","label":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer"}]},{"url":"https://doi.org/10.1126/science.1171362","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1171362","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009","kind":"paper","name":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","route":"/key-papers/paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009/","field":"links","label":"Olive et al., Science 2009: hedgehog inhibition improves gemcitabine delivery in the mouse model"}]},{"url":"https://doi.org/10.1126/science.1178331","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1178331","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"papers","label":"Development of monocytes, macrophages, and dendritic cells"}]},{"url":"https://doi.org/10.1126/science.1196333","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1196333","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jones-arid1a-clear-cell-science-2010","kind":"paper","name":"Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","route":"/key-papers/paper-jones-arid1a-clear-cell-science-2010/","field":"links","label":"Science 2010"}]},{"url":"https://doi.org/10.1126/science.1198443","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1198443","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","field":"papers","label":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans"}]},{"url":"https://doi.org/10.1126/science.1203486","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1203486","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","field":"papers","label":"Schreiber, Old and Smyth 2011: cancer immunoediting"},{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","field":"links","label":"Schreiber, Old & Smyth, Cancer immunoediting (Science 2011)"},{"id":"paper-schreiber-cancer-immunoediting-science-2011","kind":"paper","name":"Schreiber, Old and Smyth 2011: cancer immunoediting","route":"/key-papers/paper-schreiber-cancer-immunoediting-science-2011/","field":"links","label":"Full text (DOI)"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Schreiber, Old and Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion (Science 2011)"}]},{"url":"https://doi.org/10.1126/science.1206727","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1206727","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"papers","label":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy"}]},{"url":"https://doi.org/10.1126/science.123.3191.309","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.123.3191.309","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-warburg-science","kind":"paper","name":"On the origin of cancer cells","route":"/key-papers/paper-warburg-science/","field":"links","label":"Science 1956"},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","field":"links","label":"Warburg, On the origin of cancer cells (Science 1956)"}]},{"url":"https://doi.org/10.1126/science.1231143","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1231143","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","field":"papers","label":"Multiplex genome engineering using CRISPR/Cas systems"}]},{"url":"https://doi.org/10.1126/science.1235122","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1235122","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"Cancer genome landscapes"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"papers","label":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful"},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","field":"papers","label":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful"},{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","field":"papers","label":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful"},{"id":"paper-vogelstein-cancer-genome-landscapes-science-2013","kind":"paper","name":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","route":"/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/","field":"links","label":"DOI"},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/","field":"links","label":"Vogelstein et al., Cancer genome landscapes (Science 2013)"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"links","label":"Vogelstein et al., Cancer genome landscapes (Science 2013)"}]},{"url":"https://doi.org/10.1126/science.1244851","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1244851","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"papers","label":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells"}]},{"url":"https://doi.org/10.1126/science.1254257","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1254257","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","field":"papers","label":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma"}]},{"url":"https://doi.org/10.1126/science.1260825","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1260825","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tomasetti-science","kind":"paper","name":"Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions","route":"/key-papers/paper-tomasetti-science/","field":"links","label":"Science 2015"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Tomasetti and Vogelstein, Variation in cancer risk among tissues can be explained by the number of stem cell divisions (Science 2015)"}]},{"url":"https://doi.org/10.1126/science.1352912","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1352912","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"papers","label":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones"}]},{"url":"https://doi.org/10.1126/science.183.4124.534","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.183.4124.534","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stutman-science","kind":"paper","name":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","route":"/key-papers/paper-stutman-science/","field":"links","label":"Science 1974"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Stutman, Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice (Science 1974)"}]},{"url":"https://doi.org/10.1126/science.1851332","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1851332","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-martuza-engineered-hsv-glioma-science-1991","kind":"paper","name":"Martuza 1991: the first genetically engineered virus built to treat a cancer","route":"/key-papers/paper-martuza-engineered-hsv-glioma-science-1991/","field":"links","label":"Science 1991"}]},{"url":"https://doi.org/10.1126/science.1905840","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.1905840","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"Hollstein 1991: p53 mutations in human cancers"},{"id":"paper-hollstein-p53-mutations-science-1991","kind":"paper","name":"Hollstein 1991: p53 mutations in human cancers","route":"/key-papers/paper-hollstein-p53-mutations-science-1991/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.2470152","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.2470152","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"papers","label":"Slamon 1989: HER2/neu in human breast and ovarian cancer"},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.270.5238.985","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.270.5238.985","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","field":"papers","label":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4"}]},{"url":"https://doi.org/10.1126/science.271.5256.1734","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.271.5256.1734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","field":"links","label":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours (Science 1996)"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"papers","label":"Enhancement of antitumor immunity by CTLA-4 blockade"},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"papers","label":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours"},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1126/science.274.5286.373","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.274.5286.373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/","field":"links","label":"Science 1996"}]},{"url":"https://doi.org/10.1126/science.275.5308.1943","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.275.5308.1943","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","field":"papers","label":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer"}]},{"url":"https://doi.org/10.1126/science.279.5350.577","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.279.5350.577","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hirota-kit-gist-science-1998","kind":"paper","name":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours","route":"/key-papers/paper-hirota-kit-gist-science-1998/","field":"links","label":"Science 1998"}]},{"url":"https://doi.org/10.1126/science.282.5392.1332","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.282.5392.1332","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-coffey-reovirus-ras-science-1998","kind":"paper","name":"Coffey 1998: reovirus grows in cells with an activated Ras pathway, which describes a great many cancers","route":"/key-papers/paper-coffey-reovirus-ras-science-1998/","field":"links","label":"Science 1998"}]},{"url":"https://doi.org/10.1126/science.284.5416.974","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.284.5416.974","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"papers","label":"Discovery of a small molecule insulin mimetic with antidiabetic activity in mice"}]},{"url":"https://doi.org/10.1126/science.286.5439.531","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.286.5439.531","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"papers","label":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring"}]},{"url":"https://doi.org/10.1126/science.3798106","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.3798106","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"papers","label":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene"},{"id":"paper-slamon-her2-amplification-science-1987","kind":"paper","name":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","route":"/key-papers/paper-slamon-her2-amplification-science-1987/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.7761852","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.7761852","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995","kind":"paper","name":"Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability","route":"/key-papers/paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995/","field":"links","label":"Markowitz et al., Science 1995: TGF-beta receptor II inactivation in colon cancer cells with microsatellite instability"}]},{"url":"https://doi.org/10.1126/science.8197455","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.8197455","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-darnell-jak-stat-science-1994","kind":"paper","name":"Darnell, Kerr and Stark 1994: JAK-STAT pathways and transcriptional activation by interferons","route":"/key-papers/paper-darnell-jak-stat-science-1994/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.959840","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.959840","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nowell-science","kind":"paper","name":"The clonal evolution of tumor cell populations","route":"/key-papers/paper-nowell-science/","field":"links","label":"Science 1976"},{"id":"clonal-evolution-models","kind":"technology","name":"Clonal evolution and branching models","route":"/technologies/clonal-evolution-models/","field":"links","label":"Nowell 1976, Science"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Nowell, The clonal evolution of tumor cell populations (Science 1976)"}]},{"url":"https://doi.org/10.1126/science.aaa1348","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaa1348","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"papers","label":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer"},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","field":"papers","label":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer"},{"id":"paper-rizvi-mutational-landscape-pd1-science-2015","kind":"paper","name":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer","route":"/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.aaa6090","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaa6090","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"Chen et al., MERFISH: spatially resolved, highly multiplexed RNA profiling in single cells (Science 2015)"}]},{"url":"https://doi.org/10.1126/science.aaa6806","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaa6806","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","field":"papers","label":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones"},{"id":"idea-field-interception","kind":"idea","name":"Intercept cancer at the field stage","route":"/ideas/idea-field-interception/","field":"links","label":"Martincorena et al., High burden and pervasive positive selection of somatic mutations in normal human skin (Science 2015)"},{"id":"paper-martincorena-somatic-mutations-normal-skin-science-2015","kind":"paper","name":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones","route":"/key-papers/paper-martincorena-somatic-mutations-normal-skin-science-2015/","field":"links","label":"DOI"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Martincorena et al., High burden and pervasive positive selection of somatic mutations in normal human skin (Science 2015)"}]},{"url":"https://doi.org/10.1126/science.aaa8172","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaa8172","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"papers","label":"The future of immune checkpoint therapy"}]},{"url":"https://doi.org/10.1126/science.aab1433","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aab1433","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/","field":"links","label":"In vivo small-molecule degrader dBET1 (Winter 2015)"}]},{"url":"https://doi.org/10.1126/science.aad0095","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aad0095","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","field":"papers","label":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma"}]},{"url":"https://doi.org/10.1126/science.aag0299","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aag0299","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","kind":"paper","name":"Mutational signatures associated with tobacco smoking in human cancer","route":"/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/","field":"links","label":"Alexandrov et al., Science 2016: mutational signatures associated with tobacco smoking in 5,243 cancers"}]},{"url":"https://doi.org/10.1126/science.aah4199","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aah4199","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","kind":"paper","name":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","route":"/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/","field":"links","label":"Ku et al., Science 2017: Rb1 and Trp53 loss cooperating to allow lineage plasticity, metastasis and antiandrogen resistance in mouse prostate cancer"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"links","label":"Ku et al., Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance (Science 2017)"}]},{"url":"https://doi.org/10.1126/science.aah4307","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aah4307","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/","field":"links","label":"Science 2017"}]},{"url":"https://doi.org/10.1126/science.aah5072","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aah5072","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/","field":"links","label":"Zahalka et al., Adrenergic nerves activate an angio-metabolic switch in prostate cancer (Science 2017)"},{"id":"paper-zahalka-science","kind":"paper","name":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","route":"/key-papers/paper-zahalka-science/","field":"links","label":"Science 2017"}]},{"url":"https://doi.org/10.1126/science.aal2380","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aal2380","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-flavahan-science","kind":"paper","name":"Epigenetic plasticity and the hallmarks of cancer","route":"/key-papers/paper-flavahan-science/","field":"links","label":"Science 2017"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"links","label":"Flavahan, Gaskell and Bernstein, Epigenetic plasticity and the hallmarks of cancer (Science 2017)"}]},{"url":"https://doi.org/10.1126/science.aam7344","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aam7344","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lord-science","kind":"paper","name":"PARP inhibitors: Synthetic lethality in the clinic","route":"/key-papers/paper-lord-science/","field":"links","label":"Science 2017"},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/","field":"links","label":"Lord & Ashworth, PARP inhibitors: synthetic lethality in the clinic (Science 2017)"},{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/","field":"links","label":"Lord & Ashworth, PARP inhibitors: synthetic lethality in the clinic (Science 2017)"},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/","field":"links","label":"Lord & Ashworth, PARP inhibitors: synthetic lethality in the clinic (Science 2017)"}]},{"url":"https://doi.org/10.1126/science.aan3706","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aan3706","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"papers","label":"Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors"}]},{"url":"https://doi.org/10.1126/science.aan4673","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aan4673","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jaiswal-science","kind":"paper","name":"Clonal hematopoiesis in human aging and disease","route":"/key-papers/paper-jaiswal-science/","field":"links","label":"Science 2019"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Jaiswal and Ebert, Clonal hematopoiesis in human aging and disease (Science 2019)"}]},{"url":"https://doi.org/10.1126/science.aan6733","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aan6733","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"papers","label":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade"},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"papers","label":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval"},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","field":"links","label":"Full text (DOI)"},{"id":"mismatch-repair-msi","kind":"pathway","name":"Mismatch repair & microsatellite instability","route":"/pathways/mismatch-repair-msi/","field":"links","label":"Le et al., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (Science 2017)"}]},{"url":"https://doi.org/10.1126/science.aao4227","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aao4227","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/","field":"links","label":"Albrengues et al., Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells (Science 2018)"},{"id":"paper-albrengues-science","kind":"paper","name":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","route":"/key-papers/paper-albrengues-science/","field":"links","label":"Science 2018"}]},{"url":"https://doi.org/10.1126/science.aao6047","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aao6047","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","field":"papers","label":"BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis"}]},{"url":"https://doi.org/10.1126/science.aar3247","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aar3247","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","kind":"paper","name":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","route":"/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/","field":"links","label":"Cohen et al., Science 2018: CancerSEEK in 1,005 patients with eight cancer types"},{"id":"detect-a-study","kind":"term","name":"DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms","route":"/terms/detect-a-study/","field":"links","label":"Cohen et al., Science 2018: CancerSEEK in 1,005 patients with eight cancer types"},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"Detection and localization of surgically resectable cancers with a multi-analyte blood test"}]},{"url":"https://doi.org/10.1126/science.aar3593","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aar3593","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","field":"links","label":"Cristescu et al., Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy (Science 2018)"},{"id":"paper-cristescu-science","kind":"paper","name":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","route":"/key-papers/paper-cristescu-science/","field":"links","label":"Science 2018"}]},{"url":"https://doi.org/10.1126/science.aar4060","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aar4060","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"papers","label":"Cancer immunotherapy using checkpoint blockade"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"papers","label":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade"},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1126/science.aat5749","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aat5749","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"papers","label":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage"}]},{"url":"https://doi.org/10.1126/science.aau3879","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aau3879","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/","field":"links","label":"Martincorena et al., Somatic mutant clones colonize the human esophagus with age (Science 2018)"},{"id":"paper-martincorena-science","kind":"paper","name":"Somatic mutant clones colonize the human esophagus with age","route":"/key-papers/paper-martincorena-science/","field":"links","label":"Science 2018"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Martincorena et al., Somatic mutant clones colonize the human esophagus with age (Science 2018)"}]},{"url":"https://doi.org/10.1126/science.aay9040","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aay9040","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"links","label":"Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mced-registry-randomised","kind":"idea","name":"Registry-based randomised MCED trial: a million people, no study visits","route":"/ideas/idea-prev-mced-registry-randomised/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mced-change-control-plan","kind":"idea","name":"Pre-agreed update rules so an MCED test is not obsolete when its trial reads out","route":"/ideas/idea-prev-mced-change-control-plan/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mced-positive-resolution-pathway","kind":"idea","name":"A 28-day national pathway for people with a positive multi-cancer blood test","route":"/ideas/idea-prev-mced-positive-resolution-pathway/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-interval-cancer-audit-blood-tests","kind":"idea","name":"Mandatory interval-cancer audit for every blood-based screening test","route":"/ideas/idea-prev-interval-cancer-audit-blood-tests/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-opportunistic-ct-ai-registry","kind":"idea","name":"Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway","route":"/ideas/idea-prev-opportunistic-ct-ai-registry/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-urine-dna-haematuria-triage","kind":"idea","name":"A urine DNA test to decide who with blood in the urine needs a camera test","route":"/ideas/idea-prev-urine-dna-haematuria-triage/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-cgm-glycaemic-drift-pancreas","kind":"idea","name":"Glucose monitor data as an early pancreatic cancer signal","route":"/ideas/idea-prev-cgm-glycaemic-drift-pancreas/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-ehr-symptom-signature-prompts","kind":"idea","name":"Cancer risk scores running automatically in GP records to prompt urgent referral","route":"/ideas/idea-prev-ehr-symptom-signature-prompts/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mced-non-specific-symptom-triage","kind":"idea","name":"Multi-cancer blood test as the first step for patients with non-specific symptoms","route":"/ideas/idea-prev-mced-non-specific-symptom-triage/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-fit-risk-adapted-thresholds","kind":"idea","name":"Personalised stool-test cut-offs by age, sex and prior results","route":"/ideas/idea-prev-fit-risk-adapted-thresholds/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-capsule-sponge-pharmacy","kind":"idea","name":"A swallowable sponge test for reflux patients, offered in pharmacies","route":"/ideas/idea-prev-capsule-sponge-pharmacy/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-gastric-serology-migrant-screening","kind":"idea","name":"Stomach cancer serology screening for high-risk migrant communities in low-incidence countries","route":"/ideas/idea-prev-gastric-serology-migrant-screening/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-oral-cancer-community-smartphone-ai","kind":"idea","name":"Community health workers with smartphone AI screen for mouth cancer in South Asia","route":"/ideas/idea-prev-oral-cancer-community-smartphone-ai/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-live-stage-dashboard","kind":"idea","name":"A live national dashboard of stage at diagnosis as the scorecard for early detection","route":"/ideas/idea-prev-live-stage-dashboard/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-emergency-department-cancer-test","kind":"idea","name":"A cancer blood test for older people arriving at A&E with unexplained symptoms","route":"/ideas/idea-prev-emergency-department-cancer-test/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-ebv-dna-npc-screening-scaleup","kind":"idea","name":"Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia","route":"/ideas/idea-prev-ebv-dna-npc-screening-scaleup/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-dental-oral-exam-standard","kind":"idea","name":"Make a two-minute mouth cancer check part of every dental visit","route":"/ideas/idea-prev-dental-oral-exam-standard/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-prev-bundled-cancer-check-at-60","kind":"idea","name":"A single 'cancer check at 60' appointment bundling all screening tests","route":"/ideas/idea-prev-bundled-cancer-check-at-60/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"idea-moon-population-interception","kind":"idea","name":"A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early","route":"/ideas/idea-moon-population-interception/","field":"links","label":"Bottleneck evidence (The hardest cancers are found late): Crosby et al., Early detection of cancer (Science 2022)"},{"id":"paper-crosby-science","kind":"paper","name":"Early detection of cancer","route":"/key-papers/paper-crosby-science/","field":"links","label":"Science 2022"}]},{"url":"https://doi.org/10.1126/science.aaz0868","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaz0868","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nia-science","kind":"paper","name":"Physical traits of cancer","route":"/key-papers/paper-nia-science/","field":"links","label":"Science 2020"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Nia, Munn and Jain, Physical traits of cancer (Science 2020)"}]},{"url":"https://doi.org/10.1126/science.aaz7015","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aaz7015","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-spencer-science","kind":"paper","name":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","route":"/key-papers/paper-spencer-science/","field":"links","label":"Science 2021"},{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/","field":"links","label":"Spencer et al. (Science 2021)"}]},{"url":"https://doi.org/10.1126/science.abb5920","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.abb5920","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","field":"links","label":"Baruch et al., Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma (Science 2021)"},{"id":"paper-baruch-science","kind":"paper","name":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","route":"/key-papers/paper-baruch-science/","field":"links","label":"Science 2021"},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","field":"links","label":"Baruch et al., Sheba (Science 2021)"}]},{"url":"https://doi.org/10.1126/science.abb9601","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.abb9601","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"detect-a-study","kind":"term","name":"DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms","route":"/terms/detect-a-study/","field":"links","label":"Lennon et al., Science 2020: DETECT-A, blood testing plus PET-CT in 10,006 women"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","field":"links","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms (Science 2020)"},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","field":"links","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms (Science 2020)"},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","field":"links","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms (Science 2020)"},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"papers","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms"},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1126/science.abf3363","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.abf3363","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/","field":"links","label":"Davar et al., Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma (Science 2021)"},{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","field":"links","label":"Davar et al., Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma (Science 2021)"},{"id":"paper-davar-science","kind":"paper","name":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","route":"/key-papers/paper-davar-science/","field":"links","label":"Science 2021"},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","field":"links","label":"Davar et al. (Science 2021)"},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","field":"links","label":"Davar et al. (Science 2021)"},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","field":"outcomes.source (Clinical benefit (objective response or SD over 12 months))"}]},{"url":"https://doi.org/10.1126/science.ade2574","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.ade2574","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genomic-and-protein-language-models","kind":"term","name":"Genomic and protein language models: Evo 2, Enformer, ESM","route":"/terms/genomic-and-protein-language-models/","field":"links","label":"Lin et al., Evolutionary-scale prediction of atomic-level protein structure with a language model (ESM-2, Science 2023)"}]},{"url":"https://doi.org/10.1126/science.adg7492","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.adg7492","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cheng-science","kind":"paper","name":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","route":"/key-papers/paper-cheng-science/","field":"links","label":"Science 2023"},{"id":"alphamissense","kind":"technology","name":"AlphaMissense","route":"/technologies/alphamissense/","field":"links","label":"Science 2023"}]},{"url":"https://doi.org/10.1126/science.adi5798","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.adi5798","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","field":"links","label":"Montoya et al., Kinase-impaired BTK mutations are susceptible to the clinical-stage BTK and IKZF1/3 degrader NX-2127 (Science 2024)"},{"id":"paper-montoya-science","kind":"paper","name":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127","route":"/key-papers/paper-montoya-science/","field":"links","label":"Science 2024"}]},{"url":"https://doi.org/10.1126/science.ads0018","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.ads0018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hayes-science","kind":"paper","name":"Simulating 500 million years of evolution with a language model","route":"/key-papers/paper-hayes-science/","field":"links","label":"Science 2025"},{"id":"esm3","kind":"technology","name":"ESM3 (EvolutionaryScale)","route":"/technologies/esm3/","field":"links","label":"Science 2025"}]},{"url":"https://doi.org/10.1126/science.adv9817","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.adv9817","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lewis-science","kind":"paper","name":"Scalable emulation of protein equilibrium ensembles with generative deep learning","route":"/key-papers/paper-lewis-science/","field":"links","label":"Science 2025"},{"id":"bioemu","kind":"technology","name":"BioEmu (Microsoft)","route":"/technologies/bioemu/","field":"links","label":"Science 2025"}]},{"url":"https://doi.org/10.1126/scisignal.287re6","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scisignal.287re6","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-sci-signal-2009","kind":"paper","name":"Oncogenic EGFR signaling networks in glioma","route":"/key-papers/paper-egfr-glioblastoma-sci-signal-2009/","field":"links","label":"Sci Signal 2009"}]},{"url":"https://doi.org/10.1126/scitranslmed.3001451","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.3001451","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010","kind":"paper","name":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","route":"/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/","field":"links","label":"Weiss et al., Sci Transl Med 2010: frequent and focal FGFR1 amplification in squamous cell lung cancer"},{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1126/scitranslmed.3002003","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.3002003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","field":"links","label":"Sequist et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (Science Translational Medicine 2011)"},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","field":"links","label":"Sequist et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (Science Translational Medicine 2011)"},{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/","field":"links","label":"Sci Transl Med 2011"},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"papers","label":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors"}]},{"url":"https://doi.org/10.1126/scitranslmed.3002543","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.3002543","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wu-gnas-ipmn-sci-transl-med-2011","kind":"paper","name":"Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development","route":"/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/","field":"links","label":"Wu et al., Sci Transl Med 2011: recurrent GNAS mutations in IPMN"}]},{"url":"https://doi.org/10.1126/scitranslmed.3005930","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.3005930","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","field":"papers","label":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia"}]},{"url":"https://doi.org/10.1126/scitranslmed.aab0021","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.aab0021","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015","kind":"paper","name":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","route":"/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/","field":"links","label":"Garcia-Murillas et al., Sci Transl Med 2015: mutation tracking in ctDNA predicts relapse in 55 early breast cancer patients"}]},{"url":"https://doi.org/10.1126/scitranslmed.aaf6219","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.aaf6219","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","kind":"paper","name":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","route":"/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/","field":"links","label":"Sci Transl Med 2016"}]},{"url":"https://doi.org/10.1126/scitranslmed.aan4488","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.aan4488","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"papers","label":"Eradication of spontaneous malignancy by local immunotherapy"}]},{"url":"https://doi.org/10.1126/scitranslmed.aao1641","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.aao1641","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018","kind":"paper","name":"Bourgeois-Daigneault 2018: giving the virus before surgery, not after everything else has failed","route":"/key-papers/paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018/","field":"links","label":"Sci Transl Med 2018"}]},{"url":"https://doi.org/10.1126/scitranslmed.aba4373","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/scitranslmed.aba4373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yala-sci-transl-med","kind":"paper","name":"Toward robust mammography-based models for breast cancer risk","route":"/key-papers/paper-yala-sci-transl-med/","field":"links","label":"Sci Transl Med 2021"},{"id":"mirai","kind":"technology","name":"Mirai (MIT breast cancer risk from mammograms)","route":"/technologies/mirai/","field":"links","label":"Sci Transl Med 2021"}]},{"url":"https://doi.org/10.1128/mcb.14.3.1815-1823.1994","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.1128/mcb.14.3.1815-1823.1994","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"papers","label":"DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways"}]},{"url":"https://doi.org/10.1128/msphere.00389-21","status":403,"ok":false,"finalUrl":"https://journals.asm.org/doi/10.1128/mSphere.00389-21","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"papers","label":"Overlapping of Independent SARS-CoV-2 Nosocomial Transmissions in a Complex Outbreak"}]},{"url":"https://doi.org/10.1128/spectrum.01532-21","status":403,"ok":false,"finalUrl":"https://journals.asm.org/doi/10.1128/spectrum.01532-21","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"papers","label":"Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers"}]},{"url":"https://doi.org/10.1136/bmj-2023-077310","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj-2023-077310","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lane-bmj","kind":"paper","name":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","route":"/key-papers/paper-lane-bmj/","field":"links","label":"BMJ 2024"},{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","field":"links","label":"UPF umbrella review (BMJ 2024)"}]},{"url":"https://doi.org/10.1136/bmj.1.4877.1451","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.1.4877.1451","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-doll-hill-mortality-of-doctors-smoking-bmj-1954","kind":"paper","name":"The mortality of doctors in relation to their smoking habits; a preliminary report","route":"/key-papers/paper-doll-hill-mortality-of-doctors-smoking-bmj-1954/","field":"links","label":"BMJ 1954"},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/","field":"links","label":"British Doctors Study preliminary report (1954)"}]},{"url":"https://doi.org/10.1136/bmj.1.5022.779","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.1.5022.779","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-burnet-br-med-j","kind":"paper","name":"Cancer; a biological approach. I. The processes of control","route":"/key-papers/paper-burnet-br-med-j/","field":"links","label":"Br Med J 1957"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Burnet, Cancer: a biological approach (BMJ 1957)"}]},{"url":"https://doi.org/10.1136/bmj.2.4682.739","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.2.4682.739","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","route":"/people/richard-peto/","field":"papers","label":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer"},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1136/bmj.321.7257.323","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.321.7257.323","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000","kind":"paper","name":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","route":"/key-papers/paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000/","field":"links","label":"BMJ 2000"}]},{"url":"https://doi.org/10.1136/bmj.38142.554479.AE","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.38142.554479.AE","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-doll-peto-50-year-doctors-bmj-2004","kind":"paper","name":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","route":"/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1136/bmj.38937.646400.55","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.38937.646400.55","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"MERCURY Study Group, BMJ 2006: diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer (408 patients)"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"MERCURY Study Group, BMJ 2006: diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer (408 patients)"}]},{"url":"https://doi.org/10.1136/bmj.c951","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.c951","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"links","label":"MDT effectiveness review (BMJ 2010)"},{"id":"paper-taylor-bmj","kind":"paper","name":"Multidisciplinary team working in cancer: what is the evidence?","route":"/key-papers/paper-taylor-bmj/","field":"links","label":"BMJ 2010"}]},{"url":"https://doi.org/10.1136/bmj.d7292","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.d7292","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"links","label":"Ross et al., Publication of NIH funded trials registered in ClinicalTrials.gov (BMJ 2012)"},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"metrics (NIH-funded trials published in a peer-reviewed journal within 30 months of completion)"},{"id":"paper-ross-bmj","kind":"paper","name":"Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis","route":"/key-papers/paper-ross-bmj/","field":"links","label":"BMJ 2012"}]},{"url":"https://doi.org/10.1136/bmj.e4110","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.e4110","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"molemate","kind":"trial","name":"MoleMate UK Trial","route":"/trials/molemate/","field":"links","label":"BMJ 2012 (DOI)"}]},{"url":"https://doi.org/10.1136/bmj.f6153","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.f6153","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Lansbury et al., interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies (BMJ 2013)"},{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"links","label":"Lansbury et al., interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies (BMJ 2013)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Lansbury et al., interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies (BMJ 2013)"}]},{"url":"https://doi.org/10.1136/bmj.j4530","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.j4530","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"links","label":"Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"metrics (Cancer drug indications approved by the EMA 2009-2013 with no evidence of survival or quality-of-life benefit at approval)"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"metrics (Cancer drug indications approved by the EMA 2009-2013 still lacking evidence of survival or quality-of-life benefit after a median 5.4 years)"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"links","label":"Davis et al., Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"metrics (Cancer drug indications approved by the EMA 2009-2013 with no evidence of quality-of-life or survival benefit at approval)"},{"id":"idea-tr1-seamless-2-3-with-prespecified-go","kind":"idea","name":"Seamless phase 2/3 with pre-registered go rules as the default for new agents","route":"/ideas/idea-tr1-seamless-2-3-with-prespecified-go/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-ctdna-guided-stop-in-metastatic-disease","kind":"idea","name":"Use tumour DNA in blood to decide when to pause treatment in metastatic cancer","route":"/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-shared-control-arms-across-sponsors","kind":"idea","name":"Competing sponsors share one control arm in the same indication","route":"/ideas/idea-tr1-shared-control-arms-across-sponsors/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-shrinkage-subgroup-analysis","kind":"idea","name":"Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories","route":"/ideas/idea-tr1-shrinkage-subgroup-analysis/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-aggregated-n-of-1-supportive-care","kind":"idea","name":"Aggregated single-patient crossover trials for symptom and supportive treatments","route":"/ideas/idea-tr1-aggregated-n-of-1-supportive-care/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-window-of-opportunity-default","kind":"idea","name":"A short pre-surgery drug window as the default early test of new agents","route":"/ideas/idea-tr1-window-of-opportunity-default/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-randomised-phase-2-before-phase-3","kind":"idea","name":"Require a randomised phase 2 before any phase 3","route":"/ideas/idea-tr1-randomised-phase-2-before-phase-3/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-tumour-agnostic-approval-standard","kind":"idea","name":"A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling","route":"/ideas/idea-tr1-tumour-agnostic-approval-standard/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/","field":"links","label":"Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017)"},{"id":"paper-davis-bmj","kind":"paper","name":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","route":"/key-papers/paper-davis-bmj/","field":"links","label":"BMJ 2017"}]},{"url":"https://doi.org/10.1136/bmj.j5024","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.j5024","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-poole-bmj","kind":"paper","name":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","route":"/key-papers/paper-poole-bmj/","field":"links","label":"BMJ 2017"},{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","field":"links","label":"Umbrella review (BMJ 2017)"}]},{"url":"https://doi.org/10.1136/bmj.k322","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.k322","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fiolet-bmj","kind":"paper","name":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort","route":"/key-papers/paper-fiolet-bmj/","field":"links","label":"BMJ 2018"},{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","field":"links","label":"NutriNet-Sante UPF and cancer (BMJ 2018)"}]},{"url":"https://doi.org/10.1136/bmj.k4823","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.k4823","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/","field":"papers","label":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening"},{"id":"paper-hpv-self-sampling-bmj-2018","kind":"paper","name":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","route":"/key-papers/paper-hpv-self-sampling-bmj-2018/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1136/bmj.m2836","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.m2836","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"links","label":"TARGIT-A long-term results (BMJ 2020)"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"outcomes.source (Local recurrence at 5 years)"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"outcomes.source (Overall survival, long-term follow-up (median 8.6 years))"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"outcomes.source (Mortality from causes other than breast cancer)"},{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","field":"links","label":"TARGIT-A long-term (BMJ 2020)"},{"id":"paper-vaidya-bmj","kind":"paper","name":"Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial","route":"/key-papers/paper-vaidya-bmj/","field":"links","label":"BMJ 2020"}]},{"url":"https://doi.org/10.1136/bmj.m4087","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.m4087","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"links","label":"Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"metrics (Increase in mortality per four-week delay in cancer treatment (surgery, systemic, radiotherapy) across seven cancers)"},{"id":"idea-acc-one-stop-breast-diagnostic-clinic","kind":"idea","name":"One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit","route":"/ideas/idea-acc-one-stop-breast-diagnostic-clinic/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-funded-navigator-per-diagnosis","kind":"idea","name":"A paid patient navigator for every new cancer diagnosis, reimbursed as a service","route":"/ideas/idea-acc-funded-navigator-per-diagnosis/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-reflex-genomic-profiling-at-diagnosis","kind":"idea","name":"Pathologists order genomic profiling automatically at diagnosis of advanced cancer","route":"/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-guideline-concordance-dashboards","kind":"idea","name":"Live guideline-concordance dashboards for every tumour board, generated from the record","route":"/ideas/idea-acc-guideline-concordance-dashboards/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-national-virtual-mdt-rare-complex","kind":"idea","name":"Mandatory national virtual tumour boards for rare and complex cancers","route":"/ideas/idea-acc-national-virtual-mdt-rare-complex/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-portable-treatment-summary","kind":"idea","name":"A machine-readable treatment summary handed to every patient and readable by any hospital","route":"/ideas/idea-acc-portable-treatment-summary/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-primary-care-shared-care-agreements","kind":"idea","name":"Formal shared-care agreements between oncology and family doctors, with same-day e-consult","route":"/ideas/idea-acc-primary-care-shared-care-agreements/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-tumour-board-implementation-audit","kind":"idea","name":"Audit whether tumour board recommendations were actually carried out","route":"/ideas/idea-acc-tumour-board-implementation-audit/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-acute-oncology-assessment-units","kind":"idea","name":"Acute oncology assessment units so sick cancer patients bypass the emergency department","route":"/ideas/idea-acc-acute-oncology-assessment-units/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-diagnostic-interval-public-registry","kind":"idea","name":"Record and publish the symptom-to-diagnosis interval for every cancer, by hospital","route":"/ideas/idea-acc-diagnostic-interval-public-registry/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-reflex-biomarker-panels-by-tumour","kind":"idea","name":"Standing reflex biomarker panels per tumour type, run without an oncologist's order","route":"/ideas/idea-acc-reflex-biomarker-panels-by-tumour/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-embedded-decision-aids","kind":"idea","name":"Decision aids built into the record for every preference-sensitive cancer choice","route":"/ideas/idea-acc-embedded-decision-aids/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-universal-asynchronous-second-opinion","kind":"idea","name":"An asynchronous expert second opinion for every new advanced-cancer diagnosis","route":"/ideas/idea-acc-universal-asynchronous-second-opinion/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-episode-payment-tied-to-concordance","kind":"idea","name":"Bundled episode payments for cancer care with bonuses for guideline concordance","route":"/ideas/idea-acc-episode-payment-tied-to-concordance/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-transition-handoff-medication-reconciliation","kind":"idea","name":"A standard handoff with medication reconciliation at every cancer care transition","route":"/ideas/idea-acc-transition-handoff-medication-reconciliation/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"idea-acc-pathway-capacity-simulation","kind":"idea","name":"Simulate each hospital's cancer pathway as a queue to find and remove the waits","route":"/ideas/idea-acc-pathway-capacity-simulation/","field":"links","label":"Bottleneck evidence (Fragmented care and guideline gaps): Hanna et al., Mortality due to cancer treatment delay: systematic review and meta-analysis (BMJ 2020)"},{"id":"paper-hanna-bmj","kind":"paper","name":"Mortality due to cancer treatment delay: systematic review and meta-analysis","route":"/key-papers/paper-hanna-bmj/","field":"links","label":"BMJ 2020"}]},{"url":"https://doi.org/10.1136/bmj.m689","status":403,"ok":false,"finalUrl":"https://www.bmj.com/lookup/doi/10.1136/bmj.m689","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"links","label":"Nagendran et al., Artificial intelligence versus clinicians: systematic review (BMJ 2020)"},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"metrics (Deep-learning studies comparing AI with clinicians that were randomised trials (systematic review, 2010-2019))"},{"id":"paper-nagendran-bmj","kind":"paper","name":"Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies","route":"/key-papers/paper-nagendran-bmj/","field":"links","label":"BMJ 2020"}]},{"url":"https://doi.org/10.1136/bmjgast-2021-000643","status":403,"ok":false,"finalUrl":"https://bmjopengastro.bmj.com/lookup/doi/10.1136/bmjgast-2021-000643","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Phillips et al., consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines (BMJ Open Gastroenterology 2021)"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Phillips et al., consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines (BMJ Open Gastroenterology 2021)"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Phillips et al., consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines (BMJ Open Gastroenterology 2021)"}]},{"url":"https://doi.org/10.1136/bmjgh-2021-006196","status":403,"ok":false,"finalUrl":"https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2021-006196","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhang-bmj-glob-health","kind":"paper","name":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China","route":"/key-papers/paper-zhang-bmj-glob-health/","field":"links","label":"BMJ Glob Health 2021"},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","field":"links","label":"Zhang Y, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health 2021"}]},{"url":"https://doi.org/10.1136/bmjonc-2024-000686","status":403,"ok":false,"finalUrl":"https://bmjoncology.bmj.com/lookup/doi/10.1136/bmjonc-2024-000686","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"papers","label":"Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study"}]},{"url":"https://doi.org/10.1136/bmjopen-2018-028147","status":403,"ok":false,"finalUrl":"https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-028147","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polcagb","kind":"trial","name":"POLCAGB","route":"/trials/polcagb/","field":"links","label":"Engineer et al., BMJ Open 2019: POLCAGB protocol"},{"id":"paper-polcagb-protocol-bmj-open-2019","kind":"paper","name":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol","route":"/key-papers/paper-polcagb-protocol-bmj-open-2019/","field":"links","label":"BMJ Open 2019"}]},{"url":"https://doi.org/10.1136/bmjopen-2021-050886","status":403,"ok":false,"finalUrl":"https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-050886","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"best-bra","kind":"trial","name":"Best-BRA","route":"/trials/best-bra/","field":"links","label":"Best-BRA protocol (BMJ Open 2021)"}]},{"url":"https://doi.org/10.1136/bmjopen-2021-054365","status":403,"ok":false,"finalUrl":"https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-054365","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"posnoc","kind":"trial","name":"POSNOC","route":"/trials/posnoc/","field":"links","label":"POSNOC protocol (BMJ Open 2021)"}]},{"url":"https://doi.org/10.1136/bmjresp-2025-003966","status":403,"ok":false,"finalUrl":"https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2025-003966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"BMJ Open Respir Res 2026: observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE), study protocol"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"BMJ Open Respir Res 2026: observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE), study protocol"}]},{"url":"https://doi.org/10.1136/bmjspcare-2017-001440","status":403,"ok":false,"finalUrl":"https://spcare.bmj.com/lookup/doi/10.1136/bmjspcare-2017-001440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-solheim-bmj-support-palliat-care","kind":"paper","name":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","route":"/key-papers/paper-solheim-bmj-support-palliat-care/","field":"links","label":"BMJ Support Palliat Care 2018"},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","field":"links","label":"MENAC feasibility (BMJ Support Palliat Care 2018)"}]},{"url":"https://doi.org/10.1136/emj.2005.029231","status":403,"ok":false,"finalUrl":"https://emj.bmj.com/lookup/doi/10.1136/emj.2005.029231","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"papers","label":"Effect of an extended scope physiotherapy service on patient satisfaction and the outcome of soft tissue injuries in an adult emergency department"}]},{"url":"https://doi.org/10.1136/gut.2010.232272","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gut.2010.232272","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"links","label":"Mino-Kenudson, Gut 2011: prognosis of invasive IPMN depends on histological and precursor epithelial subtypes"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"links","label":"Mino-Kenudson, Gut 2011: prognosis of invasive IPMN depends on histological and precursor epithelial subtypes"}]},{"url":"https://doi.org/10.1136/gutjnl-2014-307992","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2014-307992","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","field":"links","label":"Sanduleanu, Gut 2015: definition and taxonomy of interval colorectal cancers, a World Endoscopy Organization proposal"}]},{"url":"https://doi.org/10.1136/gutjnl-2015-309675","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2015-309675","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Moller, Gut 2017: cancer incidence and survival in Lynch syndrome under surveillance, the Prospective Lynch Syndrome Database (1,942 carriers)"},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","field":"links","label":"Moller, Gut 2017: cancer incidence and survival in Lynch syndrome under surveillance, the Prospective Lynch Syndrome Database (1,942 carriers)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"Moller, Gut 2017: cancer incidence and survival in Lynch syndrome under surveillance, the Prospective Lynch Syndrome Database (1,942 carriers)"}]},{"url":"https://doi.org/10.1136/gutjnl-2016-313127","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2016-313127","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Kromrey, Gut 2018: prevalence, incidence and 5-year outcome of pancreatic cysts in a population MRCP study (SHIP)"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"Kromrey, Gut 2018: prevalence, incidence and 5-year outcome of pancreatic cysts in a population MRCP study (SHIP)"}]},{"url":"https://doi.org/10.1136/gutjnl-2017-315062","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2017-315062","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018","kind":"paper","name":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives","route":"/key-papers/paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018/","field":"links","label":"Felsenstein et al., Gut 2018: IPMNs with co-occurring invasive cancers, related in 51% and independent in 18%"}]},{"url":"https://doi.org/10.1136/gutjnl-2018-316027","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316027","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018","kind":"paper","name":"European evidence-based guidelines on pancreatic cystic neoplasms (2018)","route":"/key-papers/paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018/","field":"links","label":"Gut 2018"}]},{"url":"https://doi.org/10.1136/gutjnl-2018-317592","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-317592","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vuik-early-onset-colorectal-europe-gut-2019","kind":"paper","name":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","route":"/key-papers/paper-vuik-early-onset-colorectal-europe-gut-2019/","field":"links","label":"Gut 2019"}]},{"url":"https://doi.org/10.1136/gutjnl-2019-319352","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-319352","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Goggins, Gut 2020: CAPS consortium updated recommendations for individuals at increased risk of familial pancreatic cancer"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Goggins, Gut 2020: CAPS consortium updated recommendations for individuals at increased risk of familial pancreatic cancer"},{"id":"paper-caps-consortium-surveillance-recommendations-gut-2020","kind":"paper","name":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","route":"/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/","field":"links","label":"Gut 2020"},{"id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","route":"/terms/caps-consortium-pancreatic-screening/","field":"links","label":"Goggins et al., Gut 2020: CAPS consortium updated recommendations"}]},{"url":"https://doi.org/10.1136/gutjnl-2019-319511","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-319511","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Siegel, Gut 2019: global patterns and trends in colorectal cancer incidence in young adults (36 countries)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"links","label":"Siegel, Gut 2019: global patterns and trends in colorectal cancer incidence in young adults (36 countries)"}]},{"url":"https://doi.org/10.1136/gutjnl-2019-319858","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-319858","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"},{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"},{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"},{"id":"colonoscopy-surveillance-intervals","kind":"term","name":"Surveillance intervals after polypectomy","route":"/terms/colonoscopy-surveillance-intervals/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"},{"id":"adenoma-detection-rate","kind":"term","name":"Adenoma detection rate","route":"/terms/adenoma-detection-rate/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"Rutter, Gut 2020: BSG, ACPGBI and Public Health England post-polypectomy and post-resection surveillance guidelines"}]},{"url":"https://doi.org/10.1136/gutjnl-2019-319915","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-319915","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Monahan, Gut 2020: BSG, ACPGBI and UKCGG guidelines for the management of hereditary colorectal cancer"},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","field":"links","label":"Monahan, Gut 2020: BSG, ACPGBI and UKCGG guidelines for the management of hereditary colorectal cancer"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"Monahan, Gut 2020: BSG, ACPGBI and UKCGG guidelines for the management of hereditary colorectal cancer"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"Monahan, Gut 2020: BSG, ACPGBI and UKCGG guidelines for the management of hereditary colorectal cancer"}]},{"url":"https://doi.org/10.1136/gutjnl-2020-320726","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320726","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021","kind":"paper","name":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","route":"/key-papers/paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021/","field":"links","label":"Luchini et al., Gut 2021: systematic review of mismatch repair deficient pancreatic cancer (34 studies, 8,323 patients)"}]},{"url":"https://doi.org/10.1136/gutjnl-2020-323450","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-323450","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021","kind":"paper","name":"Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women","route":"/key-papers/paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021/","field":"links","label":"Gut 2021"}]},{"url":"https://doi.org/10.1136/gutjnl-2020-323611","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-323611","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Overbeek, Gut 2022: long-term yield of pancreatic cancer surveillance in 366 Dutch high-risk individuals"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Overbeek, Gut 2022: long-term yield of pancreatic cancer surveillance in 366 Dutch high-risk individuals"}]},{"url":"https://doi.org/10.1136/gutjnl-2023-330029","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2023-330029","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bsg-cholangiocarcinoma-guideline-gut-2023","kind":"paper","name":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","route":"/key-papers/paper-bsg-cholangiocarcinoma-guideline-gut-2023/","field":"links","label":"Gut 2023"}]},{"url":"https://doi.org/10.1136/ijgc-2024-005401","status":403,"ok":false,"finalUrl":"https://international-journal-of-gynecological-cancer.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/","field":"outcomes.source (Objective response rate)"},{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/","field":"outcomes.source (Overall survival (final analysis))"}]},{"url":"https://doi.org/10.1136/jcp-2022-208632","status":403,"ok":false,"finalUrl":"https://jcp.bmj.com/lookup/doi/10.1136/jcp-2022-208632","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"links","label":"Rakha et al., Journal of Clinical Pathology 2023;76:217 to 227: UK recommendations for HER2 assessment in breast cancer, an update"},{"id":"her2-testing-uk-breast","kind":"term","name":"HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP","route":"/terms/her2-testing-uk-breast/","field":"links","label":"Rakha et al., Journal of Clinical Pathology 2023;76:217 to 227: UK recommendations for HER2 assessment in breast cancer, an update"},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","field":"links","label":"Rakha et al., Journal of Clinical Pathology 2023;76:217 to 227: UK recommendations for HER2 assessment in breast cancer, an update"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Rakha et al., Journal of Clinical Pathology 2023;76:217 to 227: UK recommendations for HER2 assessment in breast cancer, an update"}]},{"url":"https://doi.org/10.1136/jitc-2019-000147","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2019-000147","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","field":"links","label":"Merino et al., Establishing guidelines to harmonize tumor mutational burden (JITC 2020)"},{"id":"paper-merino-j-immunother-cancer","kind":"paper","name":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","route":"/key-papers/paper-merino-j-immunother-cancer/","field":"links","label":"J Immunother Cancer 2020"}]},{"url":"https://doi.org/10.1136/jitc-2020-002255","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002255","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-j-immunother-cancer-2021","kind":"paper","name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","route":"/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/","field":"links","label":"J Immunother Cancer 2021"}]},{"url":"https://doi.org/10.1136/jitc-2021-002478","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002478","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/","field":"links","label":"J Immunother Cancer 2021"}]},{"url":"https://doi.org/10.1136/jitc-2021-002646","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002646","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","field":"outcomes.source (Objective response rate (part B, first line))"}]},{"url":"https://doi.org/10.1136/jitc-2021-002990","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002990","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wagner-j-immunother-cancer","kind":"paper","name":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","route":"/key-papers/paper-wagner-j-immunother-cancer/","field":"links","label":"J Immunother Cancer 2021"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"links","label":"DART S1609 angiosarcoma cohort (J Immunother Cancer 2021)"}]},{"url":"https://doi.org/10.1136/jitc-2022-004991","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-004991","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/","field":"links","label":"J Immunother Cancer 2022"}]},{"url":"https://doi.org/10.1136/jitc-2023-007637","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2023-007637","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","field":"links","label":"CK-301-101 metastatic cohort (JITC 2023)"},{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"links","label":"Journal for ImmunoTherapy of Cancer 2023 (metastatic cohort)"},{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"outcomes.source (Objective response rate, independent central review (metastatic cohort))"},{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/","field":"links","label":"Journal for ImmunoTherapy of Cancer 2023"}]},{"url":"https://doi.org/10.1136/jitc-2025-012034","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-012034","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","field":"links","label":"J Immunother Cancer 2025"}]},{"url":"https://doi.org/10.1136/jitc-2025-012478","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-012478","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"links","label":"Primary report (Journal for ImmunoTherapy of Cancer 2025)"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"outcomes.source (Objective response rate)"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"outcomes.source (Median progression-free survival)"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"outcomes.source (Grade 3 immune-related adverse events)"}]},{"url":"https://doi.org/10.1136/jitc-2025-014702","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1136/jitc-2025-014702","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/","field":"links","label":"J Immunother Cancer 2026"}]},{"url":"https://doi.org/10.1136/jme-2025-110730","status":403,"ok":false,"finalUrl":"https://jme.bmj.com/lookup/doi/10.1136/jme-2025-110730","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pugh-self-experimentation-publication-jme-2026","kind":"paper","name":"Pugh 2026: should a journal publish a scientist's experiment on herself?","route":"/key-papers/paper-pugh-self-experimentation-publication-jme-2026/","field":"links","label":"J Med Ethics 2026 (open access)"}]},{"url":"https://doi.org/10.1136/jmg.30.6.460","status":403,"ok":false,"finalUrl":"https://jmg.bmj.com/lookup/doi/10.1136/jmg.30.6.460","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"Evans, Ladusans, Rimmer, Burnell, Thakker and Farndon, Journal of Medical Genetics 1993;30(6):460 to 464: complications of the naevoid basal cell carcinoma syndrome, results of a population-based study of 84 UK cases"}]},{"url":"https://doi.org/10.1146/annurev-med-042921-024707","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev-med-042921-024707","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023","kind":"paper","name":"FGFR2 Inhibition in Cholangiocarcinoma","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023/","field":"links","label":"Annu Rev Med 2023"}]},{"url":"https://doi.org/10.1146/annurev-pathol-052016-100127","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev-pathol-052016-100127","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/","field":"links","label":"Aster, Pear & Blacklow, The varied roles of Notch in cancer (Annual Review of Pathology 2017)"},{"id":"paper-aster-annu-rev-pathol","kind":"paper","name":"The Varied Roles of Notch in Cancer","route":"/key-papers/paper-aster-annu-rev-pathol/","field":"links","label":"Annu Rev Pathol 2017"}]},{"url":"https://doi.org/10.1146/annurev.biochem.71.110601.135425","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev.biochem.71.110601.135425","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bell-annu-rev-biochem","kind":"paper","name":"DNA replication in eukaryotic cells","route":"/key-papers/paper-bell-annu-rev-biochem/","field":"links","label":"Annu Rev Biochem 2002"},{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/","field":"links","label":"Bell & Dutta, DNA replication in eukaryotic cells (Annu Rev Biochem 2002)"}]},{"url":"https://doi.org/10.1146/annurev.biochem.77.062706.153223","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev.biochem.77.062706.153223","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","field":"papers","label":"The biology of chromatin remodeling complexes"}]},{"url":"https://doi.org/10.1146/annurev.med.57.080904.190431","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev.med.57.080904.190431","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"papers","label":"Molecular imaging in the development of cancer therapeutics"}]},{"url":"https://doi.org/10.1148/radiol.13131184","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.13131184","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Al-Hawary, Radiology 2014: pancreatic ductal adenocarcinoma radiology reporting template (SAR and APA consensus)"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"Al-Hawary, Radiology 2014: pancreatic ductal adenocarcinoma radiology reporting template (SAR and APA consensus)"},{"id":"pancreas-protocol-ct","kind":"term","name":"Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)","route":"/terms/pancreas-protocol-ct/","field":"links","label":"Al-Hawary, Radiology 2014: pancreatic ductal adenocarcinoma radiology reporting template (SAR and APA consensus)"}]},{"url":"https://doi.org/10.1148/radiol.2015142631","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.2015142631","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mccollough-radiology","kind":"paper","name":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications","route":"/key-papers/paper-mccollough-radiology/","field":"links","label":"Radiology 2015"},{"id":"dual-energy-spectral-ct","kind":"technology","name":"Dual-energy and spectral CT","route":"/technologies/dual-energy-spectral-ct/","field":"links","label":"McCollough et al., Dual- and multi-energy CT: principles, technical approaches and clinical applications (Radiology 2015)"}]},{"url":"https://doi.org/10.1148/radiol.2016152835","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.2016152835","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"panfire-2","kind":"trial","name":"PANFIRE-2","route":"/trials/panfire-2/","field":"links","label":"Scheffer et al., PANFIRE phase 1/2 (Radiology 2017)"}]},{"url":"https://doi.org/10.1148/radiol.2019191109","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.2019191109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"panfire-2","kind":"trial","name":"PANFIRE-2","route":"/trials/panfire-2/","field":"links","label":"Ruarus et al., PANFIRE-2 (Radiology 2020)"},{"id":"panfire-2","kind":"trial","name":"PANFIRE-2","route":"/trials/panfire-2/","field":"outcomes.source (Overall survival from diagnosis, locally advanced cohort)"}]},{"url":"https://doi.org/10.1148/radiol.2021201948","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.2021201948","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jochelson-radiology","kind":"paper","name":"Contrast-enhanced Mammography: State of the Art","route":"/key-papers/paper-jochelson-radiology/","field":"links","label":"Radiology 2021"},{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/","field":"links","label":"Jochelson and Lobbes, Contrast-enhanced mammography: state of the art (Radiology 2021)"}]},{"url":"https://doi.org/10.1148/radiol.2381042117","status":403,"ok":false,"finalUrl":"https://pubs.rsna.org/doi/10.1148/radiol.2381042117","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"papers","label":"Diagnostic architectural and dynamic features at breast MR imaging: multicenter study"}]},{"url":"https://doi.org/10.1152/ajpgi.00094.2017","status":403,"ok":false,"finalUrl":"https://journals.physiology.org/doi/10.1152/ajpgi.00094.2017","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","field":"papers","label":"Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis"}]},{"url":"https://doi.org/10.1155/2014/680126","status":403,"ok":false,"finalUrl":"https://www.hindawi.com/journals/jce/2014/680126/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/","field":"links","label":"Journal of Cancer Epidemiology 2014: incidence and outcomes of desmoplastic small round cell tumour, SEER"}]},{"url":"https://doi.org/10.1155/2019/1761030","status":403,"ok":false,"finalUrl":"https://www.hindawi.com/journals/ije/2019/1761030/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"Torresan 2019, Int J Endocrinol: clinical features, treatment and surveillance of HPT-JT (review)"}]},{"url":"https://doi.org/10.1155/tbj/2657384","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1155/tbj/2657384","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","kind":"paper","name":"Implementation and audit of mainstream genetic testing within a high-volume UK breast unit for pathogenic variations associated with breast cancer using the R208 and R444.1 National Test Directory criterion","route":"/key-papers/paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026/","field":"links","label":"Conroy et al., Breast J 2026: audit of mainstream genetic testing under the NHS R208 and R444.1 criteria"}]},{"url":"https://doi.org/10.1158/0008-5472.can-03-3823","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/64/7/2634/512494/Prospective-Risk-of-Pancreatic-Cancer-in-Familial","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Klein, Cancer Res 2004: prospective risk of pancreatic cancer in familial pancreatic cancer kindreds"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Klein, Cancer Res 2004: prospective risk of pancreatic cancer in familial pancreatic cancer kindreds"}]},{"url":"https://doi.org/10.1158/0008-5472.can-05-4654","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/66/14/7341/525806/Identification-and-Clinical-Significance-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"papers","label":"Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer"}]},{"url":"https://doi.org/10.1158/0008-5472.can-07-6611","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/68/21/8643/541799/A-History-of-Cancer-Chemotherapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-devita-cancer-res","kind":"paper","name":"A history of cancer chemotherapy","route":"/key-papers/paper-devita-cancer-res/","field":"links","label":"Cancer Res 2008"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-07-6611","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/68/21/8643/541799/A-History-of-Cancer-Chemotherapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/","field":"links","label":"DeVita and Chu, A history of cancer chemotherapy (Cancer Research 2008)"}]},{"url":"https://doi.org/10.1158/0008-5472.can-08-3658","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/69/11/4894/549572/Adaptive-Therapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gatenby-cancer-res","kind":"paper","name":"Adaptive therapy","route":"/key-papers/paper-gatenby-cancer-res/","field":"links","label":"Cancer Res 2009"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-08-3658","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/69/11/4894/549572/Adaptive-Therapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/","field":"links","label":"Gatenby 2009, Cancer Research"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Gatenby et al., Adaptive therapy (Cancer Research 2009)"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-14-0155","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/74/11/2913/592763/Projecting-Cancer-Incidence-and-Deaths-to-2030-The","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014","kind":"paper","name":"Rahib 2014: projecting US cancer incidence and deaths to 2030","route":"/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-14-2533","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/75/1/22/599688/Oncolytic-Measles-Virus-Expressing-the-Sodium","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"papers","label":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer"}]},{"url":"https://doi.org/10.1158/0008-5472.can-15-0129","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/75/16/3365/605922/A-Polymer-Based-Antibody-Vinca-Drug-Conjugate","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yurkovetskiy-cancer-res","kind":"paper","name":"A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy","route":"/key-papers/paper-yurkovetskiy-cancer-res/","field":"links","label":"Cancer Res 2015"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-15-0129","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/75/16/3365/605922/A-Polymer-Based-Antibody-Vinca-Drug-Conjugate","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/","field":"links","label":"Yurkovetskiy et al., A polymer-based antibody-vinca drug conjugate platform (Dolaflexin): characterisation and preclinical efficacy (Cancer Research 2015)"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-15-1743","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/76/6/1381/616056/Neutralization-of-Tumor-Acidity-Improves-Antitumor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","field":"papers","label":"Neutralization of tumor acidity improves antitumor responses to immunotherapy"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-17-0307","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/77/21/e108/662567/TIMER-A-Web-Server-for-Comprehensive-Analysis-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017","kind":"paper","name":"Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data","route":"/key-papers/paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1158/0008-5472.can-19-3682","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/80/14/2969/640657/The-Frequency-of-Ras-Mutations-in-CancerRas-Cancer","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prior-cancer-res","kind":"paper","name":"The Frequency of Ras Mutations in Cancer","route":"/key-papers/paper-prior-cancer-res/","field":"links","label":"Cancer Res 2020"}]},{"url":"https://doi.org/10.1158/0008-5472.CAN-19-3682","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/80/14/2969/640657/The-Frequency-of-Ras-Mutations-in-CancerRas-Cancer","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","field":"links","label":"Prior et al., The frequency of Ras mutations in cancer (Cancer Research 2020)"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","field":"metrics (Cancers carrying a RAS mutation (US incidence-weighted estimate))"}]},{"url":"https://doi.org/10.1158/0008-5472.can-22-1336","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerres/article/83/7/1147/718990/A-Systematic-Review-and-Multilevel-Regression","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"papers","label":"A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer"}]},{"url":"https://doi.org/10.1158/1055-9965.epi-11-0775","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/21/1/134/158061/Pathology-of-Breast-and-Ovarian-Cancers-among","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Mavaddat, Cancer Epidemiol Biomarkers Prev 2012: pathology of breast cancers in BRCA1 and BRCA2 carriers (CIMBA)"},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Mavaddat, Cancer Epidemiol Biomarkers Prev 2012: pathology of breast cancers in BRCA1 and BRCA2 carriers (CIMBA)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Mavaddat, Cancer Epidemiol Biomarkers Prev 2012: pathology of breast cancers in BRCA1 and BRCA2 carriers (CIMBA)"}]},{"url":"https://doi.org/10.1158/1055-9965.EPI-12-0042","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/21/9/1497/69263/The-TMPRSS2-ERG-Rearrangement-ERG-Expression-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012","kind":"paper","name":"The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis","route":"/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/","field":"links","label":"Pettersson et al., Cancer Epidemiol Biomarkers Prev 2012: TMPRSS2-ERG, ERG expression and outcome in a 1,180-man cohort and a meta-analysis of 48 studies"},{"id":"tmprss2-erg-fusion","kind":"biomarker","name":"TMPRSS2-ERG fusion (and the other ETS rearrangements)","route":"/biomarkers/tmprss2-erg-fusion/","field":"links","label":"Pettersson et al., Cancer Epidemiol Biomarkers Prev 2012: TMPRSS2-ERG, ERG expression and outcome in a 1,180-man cohort and a meta-analysis of 48 studies"}]},{"url":"https://doi.org/10.1158/1055-9965.epi-15-0199","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/24/9/1319/155913/Gallbladder-Cancer-Incidence-and-Mortality-United","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Henley, Cancer Epidemiol Biomarkers Prev 2015: gallbladder cancer incidence and mortality, United States 1999 to 2011"}]},{"url":"https://doi.org/10.1158/1055-9965.epi-16-0693","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/26/3/404/71285/Prevalence-and-Penetrance-of-Major-Genes-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Win, Cancer Epidemiol Biomarkers Prev 2017: prevalence and penetrance of major genes and polygenes for colorectal cancer (5,744 families)"},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","field":"links","label":"Win, Cancer Epidemiol Biomarkers Prev 2017: prevalence and penetrance of major genes and polygenes for colorectal cancer (5,744 families)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"Win, Cancer Epidemiol Biomarkers Prev 2017: prevalence and penetrance of major genes and polygenes for colorectal cancer (5,744 families)"},{"id":"paper-win-cancer-epidemiol-biomarkers-prev","kind":"paper","name":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer","route":"/key-papers/paper-win-cancer-epidemiol-biomarkers-prev/","field":"links","label":"Cancer Epidemiol Biomarkers Prev 2017"}]},{"url":"https://doi.org/10.1158/1055-9965.EPI-16-0693","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/26/3/404/71285/Prevalence-and-Penetrance-of-Major-Genes-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"links","label":"Win et al., Prevalence and penetrance of major genes for colorectal cancer (CEBP 2017)"},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"metrics (Estimated population prevalence of Lynch syndrome)"}]},{"url":"https://doi.org/10.1158/1055-9965.EPI-17-0627","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cebp/article/27/6/619/71580/Differences-in-Breast-Cancer-Survival-by-Molecular","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Howlader, Cancer Epidemiol Biomarkers Prev 2018: breast cancer survival by molecular subtype in the United States"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-03-0801","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/10/12/3937/182171/MesothelinA-New-Target-for-Immunotherapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","kind":"paper","name":"Mesothelin: a new target for immunotherapy","route":"/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/","field":"links","label":"Clin Cancer Res 2004"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-06-1707","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/12/21/6323/191035/Is-the-Type-I-Insulin-Like-Growth-Factor-Receptor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-06-3045","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/13/15/4429/194334/Triple-Negative-Breast-Cancer-Clinical-Features","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Dent, Clin Cancer Res 2007: clinical features and patterns of recurrence of triple-negative breast cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-06-3045","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/13/15/4429/194334/Triple-Negative-Breast-Cancer-Clinical-Features","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dent-tnbc-clinical-features-recurrence-ccr-2007","kind":"paper","name":"Triple-negative breast cancer: clinical features and patterns of recurrence","route":"/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/","field":"links","label":"Clin Cancer Res 2007"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-07-4246","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/14/9/2775/73503/CS1-a-Potential-New-Therapeutic-Antibody-Target","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-08-2904","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/15/10/3484/73539/Combined-Vascular-Endothelial-Growth-Factor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"papers","label":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-10-2939","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/17/10/3157/11728/Humanized-Anti-Trop-2-IgG-SN-38-Conjugate-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cardillo-clin-cancer-res","kind":"paper","name":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","route":"/key-papers/paper-cardillo-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2011"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-10-2939","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/17/10/3157/11728/Humanized-Anti-Trop-2-IgG-SN-38-Conjugate-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","field":"links","label":"Humanized anti-Trop-2 IgG-SN-38 (CL2A) conjugate (Cardillo et al., Clin Cancer Res 2011)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-11-0485","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/17/20/6448/76555/SAR3419-An-Anti-CD19-Maytansinoid-Immunoconjugate","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/","field":"links","label":"Clin Cancer Res 2011"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-12-2246","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/8/2240/207432/Analysis-of-Tumor-Specimens-at-the-Time-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/","field":"links","label":"Yu et al., Clin Cancer Res 2013: rebiopsy at acquired resistance in 155 patients with EGFR-mutant lung cancer"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"papers","label":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-12-3327","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/19/5505/78041/Phase-II-Trial-of-Bicalutamide-in-Patients-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Gucalp, Clin Cancer Res 2013: phase II bicalutamide in androgen receptor-positive, ER-negative metastatic breast cancer"},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","field":"links","label":"Gucalp, Clin Cancer Res 2013: phase II bicalutamide in androgen receptor-positive, ER-negative metastatic breast cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-12-3327","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/19/5505/78041/Phase-II-Trial-of-Bicalutamide-in-Patients-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","kind":"paper","name":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","route":"/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/","field":"links","label":"Gucalp et al., Clin Cancer Res 2013: bicalutamide in AR-positive, ER-negative metastatic breast cancer (TBCRC 011)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-12-3791","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/13/3621/208522/Platinum-Based-Chemotherapy-for-Variant-Castrate","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aparicio-aggressive-variant-ccr-2013","kind":"paper","name":"Platinum-based chemotherapy for variant castration-resistant prostate cancer (aggressive variant criteria)","route":"/key-papers/paper-aparicio-aggressive-variant-ccr-2013/","field":"links","label":"Clin Cancer Res 2013"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-13-0380","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/17/4792/77930/Adoptive-Transfer-of-Tumor-Infiltrating","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","field":"links","label":"Besser et al., intent-to-treat analysis of TIL therapy at Sheba (Clin Cancer Res 2013)"},{"id":"paper-besser-til-melanoma-intent-to-treat-ccr-2013","kind":"paper","name":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","route":"/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/","field":"links","label":"Clin Cancer Res 2013"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-13-0739","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/16/4488/77976/Phase-II-Randomized-Trial-Comparing-High-Dose-IFN","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013","kind":"paper","name":"Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma","route":"/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/","field":"links","label":"Clin Cancer Res 2013"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-13-0799","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/19/19/5533/77963/Differential-Response-to-Neoadjuvant-Chemotherapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"links","label":"Masuda, Clin Cancer Res 2013: differential response to neoadjuvant chemotherapy among 7 triple-negative subtypes"},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/","field":"links","label":"Masuda, Clin Cancer Res 2013: differential response to neoadjuvant chemotherapy among 7 triple-negative subtypes"},{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Masuda, Clin Cancer Res 2013: differential response to neoadjuvant chemotherapy among 7 triple-negative subtypes"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","field":"links","label":"Masuda, Clin Cancer Res 2013: differential response to neoadjuvant chemotherapy among 7 triple-negative subtypes"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-13-3473","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/7/1514/247880/Lung-Master-Protocol-Lung-MAP-A-Biomarker-Driven","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herbst-clin-cancer-res","kind":"paper","name":"Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400","route":"/key-papers/paper-herbst-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2015"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-13-3473","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/7/1514/247880/Lung-Master-Protocol-Lung-MAP-A-Biomarker-Driven","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"links","label":"Herbst et al., Clinical Cancer Research 2015: Lung Master Protocol (Lung-MAP), a biomarker-driven protocol for squamous cell lung cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-14-0332","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/20/20/5322/116596/Mismatch-Repair-Status-and-BRAF-Mutation-Status-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014","kind":"paper","name":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies","route":"/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/","field":"links","label":"Venderbosch et al., Clin Cancer Res 2014: mismatch repair and BRAF status pooled across CAIRO, CAIRO2, COIN and FOCUS (3,063 patients)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-14-0432","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/7/1688/248479/Comprehensive-Genomic-Analysis-Identifies-Novel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"},{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"},{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"},{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"},{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","field":"links","label":"Burstein, Clin Cancer Res 2015: four triple-negative subtypes (LAR, MES, BLIS, BLIA) with distinct prognoses"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-14-0432","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/7/1688/248479/Comprehensive-Genomic-Analysis-Identifies-Novel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-burstein-tnbc-genomic-subtypes-ccr-2015","kind":"paper","name":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","route":"/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/","field":"links","label":"Clin Cancer Res 2015"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-14-0459","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/20/22/5777/116988/Lung-Squamous-Cell-Carcinomas-with-Basaloid","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","field":"links","label":"Brambilla 2014, Clin Cancer Res: lung squamous cell carcinomas with basaloid histology are a specific molecular entity"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-14-1348","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/6/1487/128551/PEST-Domain-Mutations-in-Notch-Receptors-Comprise","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wang-notch-pest-mutations-tnbc-ccr-2015","kind":"paper","name":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor","route":"/key-papers/paper-wang-notch-pest-mutations-tnbc-ccr-2015/","field":"links","label":"Wang et al., Clin Cancer Res 2015: PEST domain Notch mutations as a TNBC driver segment"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-14-2258","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/5/995/247889/CDK-4-6-Inhibitor-Palbociclib-PD0332991-in-Rb","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","field":"papers","label":"CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-14-2662","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/8/1797/79108/KRAS-as-a-Therapeutic-TargetKRAS-as-a-Therapeutic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"papers","label":"KRAS as a Therapeutic Target"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-0428","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/18/4062/117790/Bioactivity-and-Safety-of-IL13R-2-Redirected","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"papers","label":"Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-1259","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/6/1520/120857/Combined-Tumor-Suppressor-Defects-Characterize","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016","kind":"paper","name":"Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers","route":"/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/","field":"links","label":"Aparicio et al., Clin Cancer Res 2016: combined RB1, TP53 and PTEN defects characterise clinically defined aggressive variant prostate cancer (59 samples from 40 trial participants)"},{"id":"nepc-transformation","kind":"biomarker","name":"Treatment-emergent neuroendocrine transformation (recognising it)","route":"/biomarkers/nepc-transformation/","field":"links","label":"Aparicio et al., Clin Cancer Res 2016: combined RB1, TP53 and PTEN defects characterise clinically defined aggressive variant prostate cancer (59 samples from 40 trial participants)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-15-1465","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/15/3971/79178/Effectiveness-of-Prophylactic-Surgeries-in-BRCA1","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Li, Clin Cancer Res 2016: effectiveness of prophylactic surgeries in BRCA1 or BRCA2 carriers, meta-analysis"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Li, Clin Cancer Res 2016: effectiveness of prophylactic surgeries in BRCA1 or BRCA2 carriers, meta-analysis"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"Li, Clin Cancer Res 2016: effectiveness of prophylactic surgeries in BRCA1 or BRCA2 carriers, meta-analysis"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-1846","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/21/19_Supplement/S1/247198/AACR-Cancer-Progress-Report-2015","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"papers","label":"AACR Cancer Progress Report 2015"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-15-2477","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/15/3764/79354/Homologous-Recombination-Deficiency-HRD-Score","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"links","label":"Telli, Clin Cancer Res 2016: HRD score predicts response to platinum neoadjuvant chemotherapy in triple-negative breast cancer"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","field":"links","label":"Telli, Clin Cancer Res 2016: HRD score predicts response to platinum neoadjuvant chemotherapy in triple-negative breast cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-2477","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/15/3764/79354/Homologous-Recombination-Deficiency-HRD-Score","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-telli-hrd-score-platinum-tnbc-ccr-2016","kind":"paper","name":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","route":"/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/","field":"links","label":"Telli et al., Clin Cancer Res 2016: HRD score predicts platinum response in three neoadjuvant TNBC trials"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-15-2822","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/20/5097/124857/DS-8201a-A-Novel-HER2-Targeting-ADC-with-a-Novel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ogitani-clin-cancer-res","kind":"paper","name":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","route":"/key-papers/paper-ogitani-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2016"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-2822","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/20/5097/124857/DS-8201a-A-Novel-HER2-Targeting-ADC-with-a-Novel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","field":"links","label":"DS-8201a with GGFG-DXd linker-payload (Ogitani et al., Clin Cancer Res 2016)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-15-3101","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/22/18/4585/13031/EGFR-Mutations-and-ALK-Rearrangements-Are","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"papers","label":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-16-0162","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/23/3/649/80425/Efficacy-of-Neoadjuvant-Carboplatin-plus-Docetaxel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"papers","label":"Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-16-0806","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/23/1/116/122543/Plasma-Circulating-Tumor-DNA-in-Pancreatic-Cancer","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017","kind":"paper","name":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","route":"/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/","field":"links","label":"Pietrasz et al., Clin Cancer Res 2017: plasma ctDNA is prognostic in 135 patients"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-16-2126","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/23/8/2093/123140/Tumor-Thickness-and-Mitotic-Rate-Robustly-Predict","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"links","label":"Clin Cancer Res 2017: tumour thickness and mitotic rate predict survival in 100 primary vulvar melanomas"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-17-0764","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/4/737/81136/Adaptive-Global-Innovative-Learning-Environment","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alexander-clin-cancer-res","kind":"paper","name":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","route":"/key-papers/paper-alexander-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2018"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-0764","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/4/737/81136/Adaptive-Global-Innovative-Learning-Environment","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","field":"links","label":"Alexander et al., Clinical Cancer Research 2018: Adaptive Global Innovative Learning Environment for Glioblastoma, GBM AGILE"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-0955","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/23/22/6863/80065/MSH2-Loss-in-Primary-Prostate-CancerMSH2-Loss-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-guedes-msh2-loss-primary-prostate-ccr-2017","kind":"paper","name":"MSH2 loss in primary prostate cancer","route":"/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/","field":"links","label":"Guedes et al., Clin Cancer Res 2017: MSH2 loss by immunohistochemistry in 1,133 primary prostatic adenocarcinomas and 43 small-cell carcinomas"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-1841","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/2/334/122882/Effects-of-Co-occurring-Genomic-Alterations-on","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","kind":"paper","name":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","route":"/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/","field":"links","label":"Arbour et al., Clin Cancer Res 2018: co-occurring alterations and outcomes in 330 KRAS-mutant lung cancers"},{"id":"stk11-keap1-loss","kind":"biomarker","name":"STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma","route":"/biomarkers/stk11-keap1-loss/","field":"links","label":"Arbour et al., Clin Cancer Res 2018: co-occurring alterations and outcomes in 330 KRAS-mutant lung cancers"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-2484","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/5/1062/81237/Classifying-Colorectal-Cancer-by-Tumor-Location","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-loree-tumour-location-continuum-colorectal-ccr-2018","kind":"paper","name":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","route":"/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/","field":"links","label":"Loree et al., Clin Cancer Res 2018: tumour location rather than sidedness, a continuum of mutation profiles in 1,876 patients"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-17-2994","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/6/1344/474/Genomics-Driven-Precision-Medicine-for-Advanced","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"Aung, Clin Cancer Res 2018: COMPASS trial early results, classical versus basal-like subtype and response to first-line chemotherapy"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-2994","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/6/1344/474/Genomics-Driven-Precision-Medicine-for-Advanced","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aung-compass-early-results-ccr-2018","kind":"paper","name":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","route":"/key-papers/paper-aung-compass-early-results-ccr-2018/","field":"links","label":"Aung et al., Clin Cancer Res 2018: COMPASS, real-time whole-genome and RNA sequencing of 63 advanced patients"},{"id":"gata6-classical-basal-marker","kind":"term","name":"GATA6 as the marker of classical versus basal-like pancreatic cancer","route":"/terms/gata6-classical-basal-marker/","field":"links","label":"Aung et al., Clin Cancer Res 2018: COMPASS, real-time whole-genome and RNA sequencing of 63 advanced patients"},{"id":"compass-study-pancreatic","kind":"term","name":"COMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection","route":"/terms/compass-study-pancreatic/","field":"links","label":"Aung et al., Clin Cancer Res 2018: COMPASS, real-time whole-genome and RNA sequencing of 63 advanced patients"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-17-3089","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/10/2251/80575/DICER1-and-Associated-Conditions-Identification-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schultz-clin-cancer-res","kind":"paper","name":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies","route":"/key-papers/paper-schultz-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2018"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-3089","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/10/2251/80575/DICER1-and-Associated-Conditions-Identification-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"links","label":"Schultz 2018: DICER1 syndrome surveillance consensus (Clinical Cancer Research)"},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"standardOfCare.guideline (DICER1 carriers)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-17-3099","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/6/1326/458/Evaluating-Mismatch-Repair-Deficiency-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018","kind":"paper","name":"Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations","route":"/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/","field":"links","label":"Clin Cancer Res 2018"},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-17-3296","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/24/9/2044/81246/A-Model-Linking-Sickle-Cell-Hemoglobinopathies-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"Clin Cancer Res 2018: a model linking sickle cell haemoglobinopathies and SMARCB1 loss in renal medullary carcinoma"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-18-1833","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/2/506/125166/PTEN-Expression-Not-Mutation-Status-in-TSC1-TSC2","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-18-2992","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/18/5493/81641/Results-from-a-Phase-IIb-Randomized-Multicenter","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Le et al., ECLIPSE (Clinical Cancer Research 2019)"},{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/","field":"links","label":"Le et al., ECLIPSE (Clinical Cancer Research 2019)"},{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/","field":"outcomes.source (Overall survival, primary cohort (2 or more prior lines))"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-18-3643","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/13/3793/81967/Safety-and-Feasibility-of-Repeated-and-Transient","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-idbaih-clin-cancer-res","kind":"paper","name":"Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma","route":"/key-papers/paper-idbaih-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2019"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-18-3643","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/13/3793/81967/Safety-and-Feasibility-of-Repeated-and-Transient","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"transcranial-focused-ultrasound-systems","kind":"technology","name":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","route":"/technologies/transcranial-focused-ultrasound-systems/","field":"links","label":"Idbaih et al., Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma (Clinical Cancer Research 2019)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-0160","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/16/4966/124940/Detection-of-NRG1-Gene-Fusions-in-Solid-TumorsNRG1","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","kind":"paper","name":"Detection of NRG1 gene fusions in solid tumors","route":"/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/","field":"links","label":"Jonna et al., Clin Cancer Res 2019: NRG1 fusions in 41 of 21,858 solid tumours profiled by RNA sequencing"},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/","field":"links","label":"Jonna et al., Clin Cancer Res 2019: NRG1 fusions in 41 of 21,858 solid tumours profiled by RNA sequencing"},{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-0191","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/15/4674/81597/NRG1-Gene-Fusions-Are-Recurrent-Clinically","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","kind":"paper","name":"Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","route":"/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/","field":"links","label":"Clin Cancer Res 2019"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-0197","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/16/4973/125128/Circulating-Tumor-DNA-as-a-Clinical-Test-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","kind":"paper","name":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","route":"/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/","field":"links","label":"Groot et al., Clin Cancer Res 2019: KRAS ctDNA as a clinical laboratory test in 59 resected patients"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-0624","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/15/4691/81630/Clinical-Utility-of-Comprehensive-Cell-free-DNA","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","kind":"paper","name":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","route":"/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/","field":"links","label":"Leighl et al., Clin Cancer Res 2019: NILE, cell-free DNA against tissue genotyping in 282 newly diagnosed metastatic lung cancers"},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","field":"papers","label":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-19-1026","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/23/6939/82129/Phase-I-Trial-of-Well-Differentiated","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-reidy-lagunes-clin-cancer-res","kind":"paper","name":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan","route":"/key-papers/paper-reidy-lagunes-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2019"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-1026","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/23/6939/82129/Phase-I-Trial-of-Well-Differentiated","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","field":"links","label":"Reidy-Lagunes et al., Phase 1 trial of the SSTR antagonist radioligand 177Lu-satoreotide tetraxetan in neuroendocrine tumours (Clinical Cancer Research 2019)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-19-1133","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/23/6958/82239/Efficacy-and-Safety-of-Rovalpituzumab-Tesirine-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dll3-sclc-clin-cancer-res-2019","kind":"paper","name":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","route":"/key-papers/paper-dll3-sclc-clin-cancer-res-2019/","field":"links","label":"Clin Cancer Res 2019"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-19-1457","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/5/984/83195/Probody-Therapeutics-An-Emerging-Class-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-autio-clin-cancer-res","kind":"paper","name":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","route":"/key-papers/paper-autio-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2020"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-1457","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/5/984/83195/Probody-Therapeutics-An-Emerging-Class-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","field":"links","label":"Autio et al., Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumour toxicity (Clinical Cancer Research 2020)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-1467","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/1/82/82534/Purity-Independent-Subtyping-of-Tumors-PurIST-A","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020","kind":"paper","name":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","route":"/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/","field":"links","label":"Rashid et al., Clin Cancer Res 2020: PurIST single-sample classifier"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-3356","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/10/2290/82362/A-Phase-II-Basket-Trial-of-Dual-Anti-CTLA-4-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020","kind":"paper","name":"DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort","route":"/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/","field":"links","label":"Clin Cancer Res 2020"},{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/","field":"links","label":"Patel et al., Clinical Cancer Research 2020: a phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609), neuroendocrine cohort"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"links","label":"DART neuroendocrine cohort (Clinical Cancer Research 2020)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-3507","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/11/2565/284746/Tumor-Mutational-Burden-and-PTEN-Alterations-as","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","kind":"paper","name":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer","route":"/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/","field":"links","label":"Barroso-Sousa et al., Clin Cancer Res 2020: TMB and PTEN alterations and checkpoint response in 62 metastatic TNBC patients"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-3517","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/17/4503/82705/A-Frameshift-Peptide-Neoantigen-Based-Vaccine-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","field":"links","label":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers (Clinical Cancer Research 2020)"},{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-19-3724","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/18/4901/9541/GATA6-Expression-Distinguishes-Classical-and-Basal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"O'Kane, Clin Cancer Res 2020: GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer (COMPASS, 195 patients)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-3724","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/18/4901/9541/GATA6-Expression-Distinguishes-Classical-and-Basal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-okane-gata6-basal-like-compass-ccr-2020","kind":"paper","name":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","route":"/key-papers/paper-okane-gata6-basal-like-compass-ccr-2020/","field":"links","label":"O'Kane et al., Clin Cancer Res 2020: GATA6 and the basal-like subtype in 195 COMPASS patients"},{"id":"gata6-classical-basal-marker","kind":"term","name":"GATA6 as the marker of classical versus basal-like pancreatic cancer","route":"/terms/gata6-classical-basal-marker/","field":"links","label":"O'Kane et al., Clin Cancer Res 2020: GATA6 and the basal-like subtype in 195 COMPASS patients"},{"id":"compass-study-pancreatic","kind":"term","name":"COMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection","route":"/terms/compass-study-pancreatic/","field":"links","label":"O'Kane et al., Clin Cancer Res 2020: GATA6 and the basal-like subtype in 195 COMPASS patients"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-0168","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/13/3230/82598/Oncogenic-Genomic-Alterations-Clinical-Phenotypes","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020","kind":"paper","name":"Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/","field":"links","label":"Stopsack et al., Clin Cancer Res 2020: oncogenic alterations, phenotypes and outcomes in 424 men with metastatic castration-sensitive prostate cancer"},{"id":"spop-mutation","kind":"biomarker","name":"SPOP mutation","route":"/biomarkers/spop-mutation/","field":"links","label":"Stopsack et al., Clin Cancer Res 2020: oncogenic alterations, phenotypes and outcomes in 424 men with metastatic castration-sensitive prostate cancer"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-0418","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/13/3239/82515/Genomic-Methods-Identify-Homologous-Recombination","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-park-hrd-pancreatic-platinum-ccr-2020","kind":"paper","name":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","route":"/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/","field":"links","label":"Park et al., Clin Cancer Res 2020: homologous recombination deficiency in 262 advanced patients and first-line platinum"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-1825","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/26/21/5701/266213/The-Genomic-Landscape-of-SMARCA4-Alterations-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schoenfeld-smarca4-alterations-lung-ccr-2020","kind":"paper","name":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","route":"/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/","field":"links","label":"Schoenfeld et al., Clin Cancer Res 2020: the genomic landscape of SMARCA4 alterations in 4,813 lung cancers"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-20-2500","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/4/1048/125075/Randomized-Phase-II-and-Biomarker-Study-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2021","kind":"paper","name":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/","field":"links","label":"Clin Cancer Res 2021"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-2831","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/1/150/83395/Subtype-Discordant-Pancreatic-Ductal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-topham-subtype-discordant-pancreatic-ccr-2021","kind":"paper","name":"Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics","route":"/key-papers/paper-topham-subtype-discordant-pancreatic-ccr-2021/","field":"links","label":"Topham et al., Clin Cancer Res 2021: subtype-discordant tumours in 574 cases"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-3646","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/4/975/125183/Randomized-Phase-II-Trial-of-Anthracycline-free","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"papers","label":"Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-3909","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/8/2179/672055/Long-Term-Follow-up-of-a-Phase-III-Study-of-ch14","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"papers","label":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-20-4805","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/11/3094/671454/Genomic-Analysis-of-Circulating-Tumor-DNA-in-3-334","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021","kind":"paper","name":"Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","route":"/key-papers/paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021/","field":"links","label":"Tukachinsky et al., Clin Cancer Res 2021: circulating tumour DNA profiling in 3,334 men with advanced prostate cancer, including 1,674 TRITON screening samples"},{"id":"ar-ligand-binding-domain-mutation","kind":"biomarker","name":"AR ligand-binding-domain mutation (L702H, W742C, H875Y, T878A, F877L)","route":"/biomarkers/ar-ligand-binding-domain-mutation/","field":"links","label":"Tukachinsky et al., Clin Cancer Res 2021: circulating tumour DNA profiling in 3,334 men with advanced prostate cancer, including 1,674 TRITON screening samples"},{"id":"ctdna-tumour-fraction","kind":"biomarker","name":"Circulating tumour DNA fraction (and what a negative plasma result means)","route":"/biomarkers/ctdna-tumour-fraction/","field":"links","label":"Tukachinsky et al., Clin Cancer Res 2021: circulating tumour DNA profiling in 3,334 men with advanced prostate cancer, including 1,674 TRITON screening samples"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-0159","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/13/3641/671482/ZEBRA-A-Multicenter-Phase-II-Study-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021","kind":"paper","name":"ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma","route":"/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/","field":"links","label":"Clin Cancer Res 2021"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-1704","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/27/23/6323/675036/The-MAGNOLIA-Trial-Zanubrutinib-a-Next-Generation","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-magnolia-zanubrutinib-mzl-ccr-2021","kind":"paper","name":"MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma","route":"/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/","field":"links","label":"Clin Cancer Res 2021"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-21-2096","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/7/1412/682202/Pan-cancer-Analysis-of-Homologous-Recombination","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"links","label":"Westphalen et al., Clinical Cancer Research 2022: pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-2404","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/3/507/678026/Circulating-Tumor-DNA-in-Stage-III-Colorectal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022","kind":"paper","name":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","route":"/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/","field":"links","label":"Henriksen et al., Clin Cancer Res 2022: IMPROVE-IT, serial ctDNA in 168 stage III colorectal cancers"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-2577","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/2/318/675596/Differences-in-Prostate-Cancer-Genomes-by-Self","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stopsack-prostate-genomes-by-race-ccr-2022","kind":"paper","name":"Differences in prostate cancer genomes by self-reported race","route":"/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/","field":"links","label":"Stopsack et al., Clin Cancer Res 2022: differences in prostate cancer genomes by self-reported race in 2,069 men sequenced at one centre"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-3581","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/12/2704/699283/Molecular-Characterization-of-KRAS-Wild-type","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/","field":"links","label":"Philip et al., Clin Cancer Res 2022: KRAS wild-type tumours among 2,483 pancreatic adenocarcinomas"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-3762","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/5/928/681689/Detecting-Neuroendocrine-Prostate-Cancer-Through","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","kind":"paper","name":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","route":"/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/","field":"links","label":"Berchuck et al., Clin Cancer Res 2022: tissue-informed cell-free DNA methylation to detect neuroendocrine prostate cancer (101 plasma samples in two cohorts)"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-21-4176","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/12/2488/699269/FDA-Approval-Summary-Belumosudil-for-Adult-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","field":"links","label":"FDA approval summary (Clinical Cancer Research 2022)"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"links","label":"FDA approval summary (Clinical Cancer Research 2022)"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"outcomes.source (Overall response rate through cycle 7 day 1 (FDA approval analysis))"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-22-1954","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/28/24/5359/711462/Comprehensive-Molecular-Characterization-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Giraldo et al., Clin Cancer Res 2022: MSK-IMPACT profiling of 244 gallbladder carcinoma samples"},{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/","field":"links","label":"Giraldo et al., Clin Cancer Res 2022: MSK-IMPACT profiling of 244 gallbladder carcinoma samples"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-22-3713","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/29/17/3262/728536/FDA-Approval-Summary-Amivantamab-for-the-Treatment","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","field":"outcomes.source (Overall response rate, EGFR exon 20 insertion cohort after platinum chemotherapy (FDA approval summary))"},{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","field":"outcomes.source (Duration of response, EGFR exon 20 insertion cohort)"},{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","field":"outcomes.source (Infusion-related reactions)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-23-0983","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/30/4/786/734214/Tumor-Specific-Activity-of-Precision-Medicines-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhou-clin-cancer-res","kind":"paper","name":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial","route":"/key-papers/paper-zhou-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2024"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-23-0983","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/30/4/786/734214/Tumor-Specific-Activity-of-Precision-Medicines-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"Tumor-specific activity of precision medicines in the NCI-MATCH trial, Clinical Cancer Research 2024"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-23-1696","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/29/23/4751/730229/Olaparib-and-Ceralasertib-AZD6738-in-Patients-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ring-clin-cancer-res","kind":"paper","name":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)","route":"/key-papers/paper-ring-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2023"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-23-1696","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/29/23/4751/730229/Olaparib-and-Ceralasertib-AZD6738-in-Patients-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"links","label":"Olaparib and ceralasertib in triple-negative advanced breast cancer, cohort E of plasmaMATCH, Clinical Cancer Research 2023"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-24-0226","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/30/16/3459/746776/Tissue-Free-Liquid-Biopsies-Combining-Genomic-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tracc-clin-cancer-res-2024","kind":"paper","name":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","route":"/key-papers/paper-tracc-clin-cancer-res-2024/","field":"links","label":"Clin Cancer Res 2024"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-24-0378","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/30/14/2865/746337/FDA-Approval-Summary-Ciltacabtagene-Autoleucel-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","kind":"paper","name":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/","field":"links","label":"Clin Cancer Res 2024"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-24-0465","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/30/19/4329/748552/Ipatasertib-plus-Paclitaxel-for-Patients-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"links","label":"Dent et al., Clinical Cancer Research 2024: ipatasertib plus paclitaxel in PIK3CA/AKT1/PTEN-altered TNBC, IPATunity130 cohort A"},{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"outcomes.source (Progression-free survival (investigator), cohort A)"},{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"outcomes.source (Overall survival, cohort A)"},{"id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","field":"links","label":"IPATunity130 cohort A (Clinical Cancer Research 2024)"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-24-0651","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/32/1/148/771265/The-Prognostic-and-Predictive-Impact-of-ctDNA","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-browne-clin-cancer-res","kind":"paper","name":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","route":"/key-papers/paper-browne-clin-cancer-res/","field":"links","label":"Clin Cancer Res 2026"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-24-0651","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/32/1/148/771265/The-Prognostic-and-Predictive-Impact-of-ctDNA","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"links","label":"Prognostic and predictive impact of ctDNA levels in patients enrolled on the plasmaMATCH trial, Clinical Cancer Research 2026"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-24-1629","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/31/2/316/751104/Re-Irradiation-Plus-Pembrolizumab-A-Phase-II-Study","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025","kind":"paper","name":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2025/","field":"links","label":"Clin Cancer Res 2025"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-25-4564","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/32/13/2722/786107/A-New-CA19-9-Cutoff-Value-Identifies-Lewis-Antigen","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026","kind":"paper","name":"A new CA19-9 cutoff value identifies Lewis antigen status and refines prognostic stratification in PDAC","route":"/key-papers/paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026/","field":"links","label":"Yeh et al., Clin Cancer Res 2026: FUT3-null (Lewis-negative) patients and a CA 19-9 cut-off in 615 patients"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-26-0428","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/32/18/4166/787869/Molecular-and-Clinical-Determinants-of-Targeted","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/","field":"links","label":"Cowzer et al., Clin Cancer Res 2026: molecular determinants of targeted therapy in 1,254 biliary tract cancers"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-26-0975","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-26-0975/787356/Tumor-Infiltrating-Lymphocytes-as-a-Predictor-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/","field":"links","label":"Dieci et al., Clinical Cancer Research 2026: TILs as a predictor of adjuvant avelumab efficacy in A-BRAVE"},{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/","field":"outcomes.source (Distant disease-free survival at 3 years, stratum B, baseline TILs 30 percent or more (exploratory))"}]},{"url":"https://doi.org/10.1158/1078-0432.ccr-26-1066","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-26-1066/788445/Safety-and-Efficacy-of-Ceralasertib-plus-Olaparib","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03330847-clin-cancer-res-2026","kind":"paper","name":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","route":"/key-papers/paper-nct03330847-clin-cancer-res-2026/","field":"links","label":"Clin Cancer Res 2026"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-26-1610","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-26-1610/788397/Extended-Follow-up-of-Botensilimab-plus","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","field":"links","label":"Botensilimab plus balstilimab in previously treated microsatellite-stable metastatic colorectal cancer without liver metastases (Clinical Cancer Research 2026)"}]},{"url":"https://doi.org/10.1158/1535-7163.mct-13-0926","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/mct/article/13/6/1537/91847/Anetumab-Ravtansine-A-Novel-Mesothelin-Targeting","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-golfier-mol-cancer-ther","kind":"paper","name":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","route":"/key-papers/paper-golfier-mol-cancer-ther/","field":"links","label":"Mol Cancer Ther 2014"}]},{"url":"https://doi.org/10.1158/1535-7163.MCT-13-0926","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/mct/article/13/6/1537/91847/Anetumab-Ravtansine-A-Novel-Mesothelin-Targeting","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","field":"links","label":"Golfier et al., preclinical characterisation of BAY 94-9343 (Mol Cancer Ther 2014)"}]},{"url":"https://doi.org/10.1158/1535-7163.mct-14-0983","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/mct/article/14/4/847/91937/PD-L1-Expression-as-a-Predictive-Biomarker-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/","field":"links","label":"Mol Cancer Ther 2015"}]},{"url":"https://doi.org/10.1158/1535-7163.mct-17-0437","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/mct/article/17/3/591/92322/Histone-Methyltransferase-EZH2-A-Therapeutic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ezh2-ovarian-mol-cancer-ther-2018","kind":"paper","name":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","route":"/key-papers/paper-ezh2-ovarian-mol-cancer-ther-2018/","field":"links","label":"Mol Cancer Ther 2018"}]},{"url":"https://doi.org/10.1158/1541-7786.mcr-18-1235","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/mcr/article/17/8/1613/89982/TFE3-Xp11-2-Translocation-Renal-Cell-Carcinoma","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","field":"links","label":"Molecular Cancer Research 2019: TFE3 Xp11.2 translocation RCC mouse model and GPNMB as a diagnostic marker"}]},{"url":"https://doi.org/10.1158/1940-6207.capr-13-0424","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerpreventionresearch/article/7/9/867/50328/Metformin-and-Cancer-Risk-and-Mortality-A","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","field":"papers","label":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders"},{"id":"paper-andrea-decensi-cancer-prev-res-phila-2014","kind":"paper","name":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","route":"/key-papers/paper-andrea-decensi-cancer-prev-res-phila-2014/","field":"links","label":"Cancer Prev Res (Phila) 2014"}]},{"url":"https://doi.org/10.1158/2159-8274.CD-11-0005","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/1/1/78/2248/Mutations-in-the-DDR2-Kinase-Gene-Identify-a-Novel","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-11-0109","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/1/6/508/2300/A-Molecularly-Annotated-Platform-of-Patient","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/","field":"links","label":"Bertotti et al., Cancer Discov 2011: xenopatients identify HER2 amplification in cetuximab-resistant colorectal cancer"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-11-0130","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/1/6/487/2270/Molecular-Characterization-of-Neuroendocrine","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-beltran-nepc-aurka-mycn-cancer-discov-2011","kind":"paper","name":"Molecular characterisation of neuroendocrine prostate cancer and identification of new drug targets","route":"/key-papers/paper-beltran-nepc-aurka-mycn-cancer-discov-2011/","field":"links","label":"Beltran et al., Cancer Discov 2011: molecular characterisation of neuroendocrine prostate cancer, with AURKA and MYCN co-amplification in 40%"},{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-11-0341","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/2/3/227/37286/EGFR-Mediated-Reactivation-of-MAPK-Signaling","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","field":"papers","label":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-13-0633","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/4/4/415/4448/CD74-NRG1-Fusions-in-Lung-AdenocarcinomaCD74-NRG1","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014","kind":"paper","name":"CD74-NRG1 fusions in lung adenocarcinoma","route":"/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/","field":"links","label":"Fernandez-Cuesta et al., Cancer Discov 2014: CD74-NRG1 fusions in invasive mucinous lung adenocarcinoma"},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/","field":"links","label":"Fernandez-Cuesta et al., Cancer Discov 2014: CD74-NRG1 fusions in invasive mucinous lung adenocarcinoma"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-13-0830","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/4/10/1154/4232/Discovery-of-Biomarkers-Predictive-of-GSI-Response","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014","kind":"paper","name":"Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma","route":"/key-papers/paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014/","field":"links","label":"Stoeck et al., Cancer Discov 2014: NOTCH1 and NOTCH2 rearrangements in 6 of 66 TNBCs"},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-14-0617","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/4/12/1398/4313/Comprehensive-Genomic-Profiling-of-Pancreatic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014","kind":"paper","name":"Chmielecki 2014: comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","route":"/key-papers/paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014/","field":"links","label":"Cancer Discov 2014"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-14-0736","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/5/3/316/4732/JAK-STAT-Pathway-Activation-in-Malignant-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","field":"papers","label":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response"},{"id":"paper-raajit-rampal-cancer-discov-2015","kind":"paper","name":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","route":"/key-papers/paper-raajit-rampal-cancer-discov-2015/","field":"links","label":"Cancer Discov 2015"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-14-1236","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/5/8/860/5019/Co-occurring-Genomic-Alterations-Define-Major","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","kind":"paper","name":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","route":"/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/","field":"links","label":"Skoulidis et al., Cancer Discov 2015: co-occurring alterations define the KL, KP and KC subsets of KRAS-mutant lung adenocarcinoma"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-15-0285","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/5/8/850/5045/Activation-of-MET-via-Diverse-Exon-14-Splicing","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-frampton-met-exon-14-cancer-discov-2015","kind":"paper","name":"MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors","route":"/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/","field":"links","label":"Cancer Discov 2015"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-15-0402","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/6/2/166/5432/Whole-Genome-Sequencing-Defines-the-Genetic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016","kind":"paper","name":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","route":"/key-papers/paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016/","field":"links","label":"Roberts et al., Cancer Discov 2016: whole genomes of 638 familial pancreatic cancer patients"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-15-0583","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/6/2/133/5265/Mesothelin-Targeted-CARs-Driving-T-Cells-to-Solid","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-cancer-discov-2016","kind":"paper","name":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","route":"/key-papers/paper-mesothelin-mesothelioma-cancer-discov-2016/","field":"links","label":"Cancer Discov 2016"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-16-0241","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/2/165/6158/Cellular-Senescence-Promotes-Adverse-Effects-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-demaria-cancer-discov","kind":"paper","name":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","route":"/key-papers/paper-demaria-cancer-discov/","field":"links","label":"Cancer Discov 2017"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-16-0241","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/2/165/6158/Cellular-Senescence-Promotes-Adverse-Effects-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/","field":"links","label":"Demaria et al., Cellular senescence promotes adverse effects of chemotherapy and cancer relapse (Cancer Discovery 2017)"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-16-0267","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/6/11/1258/5533/Biallelic-Alteration-and-Dysregulation-of-the","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mucinous-tubular-spindle-cell-carcinoma","kind":"cancer","name":"Mucinous tubular and spindle cell carcinoma of the kidney","route":"/cancers/mucinous-tubular-spindle-cell-carcinoma/","field":"links","label":"Cancer Discovery 2016: biallelic Hippo pathway alteration in mucinous tubular and spindle cell carcinoma"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-16-0330","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/4/369/5954/The-Genetic-Basis-of-Hepatosplenic-T-cell","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","field":"links","label":"McKinney 2017, Cancer Discovery: the genetic basis of hepatosplenic T-cell lymphoma, 68 cases"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-16-0596","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/6/10/1118/5429/Molecular-Mechanisms-of-Resistance-to-First-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gainor-alk-resistance-mutations-cancer-discov-2016","kind":"paper","name":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","route":"/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/","field":"links","label":"Gainor et al., Cancer Discov 2016: 103 repeat biopsies and the resistance mutations of first- and second-generation ALK inhibitors"},{"id":"alk-resistance-mutation","kind":"biomarker","name":"ALK kinase-domain resistance mutation (G1202R and the rest)","route":"/biomarkers/alk-resistance-mutation/","field":"links","label":"Gainor et al., Cancer Discov 2016: 103 repeat biopsies and the resistance mutations of first- and second-generation ALK inhibitors"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-16-1337","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/6/596/5950/Prospective-Comprehensive-Molecular","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/","field":"links","label":"Jordan et al., Cancer Discov 2017: prospective molecular characterisation of 860 metastatic lung adenocarcinomas (MSK-IMPACT)"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-17-0146","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/9/999/6159/Analysis-of-Circulating-Cell-Free-DNA-Identifies","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017","kind":"paper","name":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","route":"/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/","field":"links","label":"Quigley et al., Cancer Discov 2017: multiclonal BRCA2 reversion mutations in cell-free DNA and resistance to PARP inhibitors in prostate cancer"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-17-0716","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/7/12/1394/40329/Early-Detection-of-Molecular-Residual-Disease-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"papers","label":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-17-0937","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/4/444/9617/Circulating-Tumor-DNA-Genomics-Correlate-with","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","kind":"paper","name":"Circulating tumour DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","route":"/key-papers/paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018/","field":"links","label":"Annala et al., Cancer Discov 2018: circulating tumour DNA genomics and resistance to abiraterone or enzalutamide in 202 randomised men with treatment-naive mCRPC"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-17-1327","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/6/730/10157/Genetic-Mechanisms-of-Immune-Evasion-in-Colorectal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-grasso-immune-evasion-colorectal-cancer-discov-2018","kind":"paper","name":"Genetic mechanisms of immune evasion in colorectal cancer","route":"/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/","field":"links","label":"Grasso et al., Cancer Discov 2018: genetic mechanisms of immune evasion in 1,211 colorectal cancers"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-17-1417","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/8/944/10003/Antitumor-Activity-Associated-with-Prolonged","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018","kind":"paper","name":"NY-ESO-1 c259 T-cell receptor therapy in synovial sarcoma: prolonged persistence and antitumour activity","route":"/key-papers/paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018/","field":"links","label":"Cancer Discov 2018"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-18-0036","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/9/1087/10152/NRG1-Fusions-in-KRAS-Wild-Type-Pancreatic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","kind":"paper","name":"Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer","route":"/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/","field":"links","label":"Cancer Discov 2018"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-18-0099","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/7/822/10083/STK11-LKB1-Mutations-and-PD-1-Inhibitor-Resistance","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-cancer-discov-2018","kind":"paper","name":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","route":"/key-papers/paper-kras-nsclc-cancer-discov-2018/","field":"links","label":"Cancer Discov 2018"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-18-0099","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/7/822/10083/STK11-LKB1-Mutations-and-PD-1-Inhibitor-Resistance","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stk11-keap1-loss","kind":"biomarker","name":"STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma","route":"/biomarkers/stk11-keap1-loss/","field":"links","label":"Skoulidis et al., Cancer Discov 2018: STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-18-0275","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/9/1096/10443/Real-time-Genomic-Characterization-of-Advanced","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","kind":"paper","name":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","route":"/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/","field":"links","label":"Aguirre et al., Cancer Discov 2018: real-time exome and RNA sequencing of 71 advanced patients"},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","field":"papers","label":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-18-0349","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/9/1112/10165/Organoid-Profiling-Identifies-Common-Responders-to","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tiriac-cancer-discov","kind":"paper","name":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","route":"/key-papers/paper-tiriac-cancer-discov/","field":"links","label":"Cancer Discov 2018"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-18-0349","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/8/9/1112/10165/Organoid-Profiling-Identifies-Common-Responders-to","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","field":"links","label":"Tiriac et al., Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (Cancer Discovery 2018)"},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"papers","label":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-18-0825","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/9/4/500/10745/Detection-and-Surveillance-of-Bladder-Cancer-Using","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dudley-cancer-discov","kind":"paper","name":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","route":"/key-papers/paper-dudley-cancer-discov/","field":"links","label":"Cancer Discov 2019"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-18-0825","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/9/4/500/10745/Detection-and-Surveillance-of-Bladder-Cancer-Using","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-urine-ctdna-surveillance","kind":"idea","name":"Urine tumour DNA to replace surveillance cystoscopy in NMIBC","route":"/ideas/idea-urine-ctdna-surveillance/","field":"links","label":"Dudley et al., Detection and surveillance of bladder cancer using urine tumour DNA (Cancer Discovery 2019)"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-19-0094","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/9/8/1102/42174/Cross-Species-Single-Cell-Analysis-of-Pancreatic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019","kind":"paper","name":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","route":"/key-papers/paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019/","field":"links","label":"Elyada et al., Cancer Discov 2019: antigen-presenting fibroblasts by single-cell sequencing"},{"id":"caf-subtypes-pancreatic","kind":"term","name":"Fibroblast subtypes in the pancreatic cancer stroma (myCAF, iCAF and apCAF)","route":"/terms/caf-subtypes-pancreatic/","field":"links","label":"Elyada et al., Cancer Discov 2019: antigen-presenting fibroblasts by single-cell sequencing"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-21-0331","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/11/11/2738/666401/Efficacy-Safety-and-Biomarker-Analysis-of-Combined","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021","kind":"paper","name":"Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma","route":"/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/","field":"links","label":"Cancer Discov 2021"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-21-0407","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/11/11/2748/666400/A-Phase-I-Trial-of-Regional-Mesothelin-Targeted","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-adusumilli-cancer-discov","kind":"paper","name":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","route":"/key-papers/paper-adusumilli-cancer-discov/","field":"links","label":"Cancer Discov 2021"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-21-0407","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/11/11/2748/666400/A-Phase-I-Trial-of-Regional-Mesothelin-Targeted","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/","field":"links","label":"Adusumilli et al., Phase 1 trial of regional mesothelin-targeted CAR T-cell therapy with pembrolizumab in malignant pleural disease (Cancer Discovery 2021)"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-21-0450","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/3/654/681885/Atezolizumab-Treatment-of-Tumors-with-High-Tumor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-friedman-cancer-discov","kind":"paper","name":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-friedman-cancer-discov/","field":"links","label":"Cancer Discov 2022"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-21-0450","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/3/654/681885/Atezolizumab-Treatment-of-Tumors-with-High-Tumor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"links","label":"Friedman et al., Cancer Discovery 2022: atezolizumab treatment of tumors with high tumor mutational burden from MyPathway"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-21-0538","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/2/372/678469/Functional-Precision-Medicine-Provides-Clinical","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kornauth-cancer-discov","kind":"paper","name":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","route":"/key-papers/paper-kornauth-cancer-discov/","field":"links","label":"Cancer Discov 2022"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-21-0538","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/2/372/678469/Functional-Precision-Medicine-Provides-Clinical","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"functional-precision-medicine-haematology","kind":"technology","name":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","route":"/technologies/functional-precision-medicine-haematology/","field":"links","label":"Cancer Discovery 2022: Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders (EXALT)"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-21-1059","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/1/31/675608/Hallmarks-of-Cancer-New-DimensionsHallmarks-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"evading-growth-suppressors","kind":"term","name":"Hallmark: evading growth suppressors","route":"/terms/evading-growth-suppressors/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"resisting-cell-death","kind":"term","name":"Hallmark: resisting cell death","route":"/terms/resisting-cell-death/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"enabling-replicative-immortality","kind":"term","name":"Hallmark: enabling replicative immortality","route":"/terms/enabling-replicative-immortality/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"inducing-angiogenesis","kind":"term","name":"Hallmark: inducing or accessing vasculature","route":"/terms/inducing-angiogenesis/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"activating-invasion-metastasis","kind":"term","name":"Hallmark: activating invasion and metastasis","route":"/terms/activating-invasion-metastasis/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"deregulating-cellular-energetics","kind":"term","name":"Hallmark: reprogramming cellular metabolism","route":"/terms/deregulating-cellular-energetics/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"avoiding-immune-destruction","kind":"term","name":"Hallmark: avoiding immune destruction","route":"/terms/avoiding-immune-destruction/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"genome-instability-mutation","kind":"term","name":"Enabling characteristic: genome instability and mutation","route":"/terms/genome-instability-mutation/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"tumor-promoting-inflammation","kind":"term","name":"Enabling characteristic: tumour-promoting inflammation","route":"/terms/tumor-promoting-inflammation/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"unlocking-phenotypic-plasticity","kind":"term","name":"Hallmark (2022): unlocking phenotypic plasticity","route":"/terms/unlocking-phenotypic-plasticity/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"nonmutational-epigenetic-reprogramming","kind":"term","name":"Hallmark (2022): non-mutational epigenetic reprogramming","route":"/terms/nonmutational-epigenetic-reprogramming/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"polymorphic-microbiomes","kind":"term","name":"Hallmark (2022): polymorphic microbiomes","route":"/terms/polymorphic-microbiomes/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/","field":"links","label":"DOI"},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","field":"links","label":"Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022)"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-22-0138","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/12/11/2530/710001/African-Ancestry-Associated-Gene-Expression","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-martini-african-ancestry-tnbc-cancer-discov-2022","kind":"paper","name":"African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent","route":"/key-papers/paper-martini-african-ancestry-tnbc-cancer-discov-2022/","field":"links","label":"Martini et al., Cancer Discov 2022: African ancestry-associated expression profiles in TNBC"}]},{"url":"https://doi.org/10.1158/2159-8290.cd-23-0669","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/13/11/2412/729848/MRTX1719-Is-an-MTA-Cooperative-PRMT5-Inhibitor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-engstrom-cancer-discov","kind":"paper","name":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","route":"/key-papers/paper-engstrom-cancer-discov/","field":"links","label":"Cancer Discov 2023"}]},{"url":"https://doi.org/10.1158/2159-8290.CD-23-0669","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerdiscovery/article/13/11/2412/729848/MRTX1719-Is-an-MTA-Cooperative-PRMT5-Inhibitor","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/","field":"links","label":"MRTX1719 first-in-human (Cancer Discov 2023)"}]},{"url":"https://doi.org/10.1158/2326-6066.CIR-14-0027","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerimmunolres/article/2/7/616/467656/Immunotherapy-Converts-Nonimmunogenic-Pancreatic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"papers","label":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation"}]},{"url":"https://doi.org/10.1158/2767-9764.crc-24-0568","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerrescommun/article/5/1/94/751115/First-in-Human-Study-of-23ME-00610-an-Antagonistic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","field":"links","label":"Cancer Res Commun 2025"}]},{"url":"https://doi.org/10.1158/2767-9764.crc-25-0332","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/cancerrescommun/article/5/11/2039/767326/Phase-II-Clinical-Trial-and-Preclinical-Evaluation","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancer-res-commun-2025","kind":"paper","name":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","route":"/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/","field":"links","label":"Cancer Res Commun 2025"}]},{"url":"https://doi.org/10.1159/000016107","status":403,"ok":false,"finalUrl":"https://karger.com/article/doi/10.1159/000016107","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"papers","label":"Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke"}]},{"url":"https://doi.org/10.1159/000351007","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/etj/article/2/2/76/3906/2013-European-Thyroid-Association-Guidelines-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","field":"links","label":"European Thyroid Journal 2013: ETA guidelines for thyrotropin-secreting pituitary tumours"}]},{"url":"https://doi.org/10.1159/000386035","status":403,"ok":false,"finalUrl":"https://karger.com/chapter/doi/10.1159/000386035","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-burnet-prog-exp-tumor-res","kind":"paper","name":"The concept of immunological surveillance","route":"/key-papers/paper-burnet-prog-exp-tumor-res/","field":"links","label":"Prog Exp Tumor Res 1970"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Burnet, The concept of immunological surveillance (Progress in Experimental Tumor Research 1970)"}]},{"url":"https://doi.org/10.1159/000533650","status":403,"ok":false,"finalUrl":"https://karger.com/article/doi/10.1159/000533650","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024","kind":"paper","name":"PHOCUS: an oncolytic vaccinia virus before sorafenib in liver cancer did worse than sorafenib alone","route":"/key-papers/paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024/","field":"links","label":"Liver Cancer 2024"}]},{"url":"https://doi.org/10.1159/000546362","status":403,"ok":false,"finalUrl":"https://karger.com/article/doi/10.1159/000546362","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-makis-fenbendazole-case-series-retracted-2025","kind":"paper","name":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","route":"/key-papers/paper-makis-fenbendazole-case-series-retracted-2025/","field":"links","label":"Makis case series 2025, retracted"}]},{"url":"https://doi.org/10.1159/000549387","status":403,"ok":false,"finalUrl":"https://karger.com/article/doi/10.1159/000549387","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"links","label":"Retraction notice 2026"},{"id":"paper-makis-fenbendazole-case-series-retracted-2025","kind":"paper","name":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","route":"/key-papers/paper-makis-fenbendazole-case-series-retracted-2025/","field":"links","label":"Retraction notice 2026"}]},{"url":"https://doi.org/10.1161/01.str.0000015345.61324.3f","status":403,"ok":false,"finalUrl":"https://www.ahajournals.org/doi/10.1161/01.STR.0000015345.61324.3F","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"papers","label":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study"}]},{"url":"https://doi.org/10.1161/01.str.27.11.2059","status":403,"ok":false,"finalUrl":"https://www.ahajournals.org/doi/10.1161/01.STR.27.11.2059","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"papers","label":"Abnormal heart rate variability as a manifestation of autonomic dysfunction in hemispheric brain infarction"}]},{"url":"https://doi.org/10.1161/01.str.30.9.1875","status":403,"ok":false,"finalUrl":"https://www.ahajournals.org/doi/10.1161/01.STR.30.9.1875","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"papers","label":"Poststroke depression correlates with cognitive impairment and neurological deficits"}]},{"url":"https://doi.org/10.1161/strokeaha.109.560342","status":403,"ok":false,"finalUrl":"https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.560342","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"papers","label":"Vasa Vasorum and Plaque Neovascularization on Contrast-Enhanced Carotid Ultrasound Imaging Correlates With Cardiovascular Disease and Past Cardiovascular Events"}]},{"url":"https://doi.org/10.1164/rccm.200601-037oc","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ajrccm/article/173/12/1309/8527304","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"papers","label":"Airflow limitation and airway dimensions in chronic obstructive pulmonary disease"}]},{"url":"https://doi.org/10.1164/rccm.201106-0992oc","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ajrccm/article/185/1/44/8507574","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"papers","label":"Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease"}]},{"url":"https://doi.org/10.1165/rcmb.2007-0424oc","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ajrcmb/article/39/6/673/8494109","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"papers","label":"Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease"}]},{"url":"https://doi.org/10.1177/00333549231201679","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/00333549231201679","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ghai-california-poison-control-ivermectin-2024","kind":"paper","name":"Exposures to bleach, peroxide, disinfectants, antimalarials, and ivermectin reported to the California Poison Control System before and during the COVID-19 pandemic, 2015 to 2021","route":"/key-papers/paper-ghai-california-poison-control-ivermectin-2024/","field":"links","label":"Ghai poison centre trends 2024"}]},{"url":"https://doi.org/10.1177/0267659118815291","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/0267659118815291","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"papers","label":"Long-term quality of life in patients treated with extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock"}]},{"url":"https://doi.org/10.1177/0300891620923790","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/0300891620923790","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"papers","label":"Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano"}]},{"url":"https://doi.org/10.1177/0969141315604659","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/0969141315604659","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"links","label":"J Med Screen 2016: uptake of bowel scope (flexible sigmoidoscopy) screening in the English national programme, the first 14 months (21,187 invitations)"}]},{"url":"https://doi.org/10.1177/1457496918818984","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/1457496918818984","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"papers","label":"Parastomal Hernia Repair; Seldom Performed and Seldom Reported: Results From a Nationwide Survey"}]},{"url":"https://doi.org/10.1177/1534735411425484","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/1534735411425484","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-seely-integr-cancer-ther","kind":"paper","name":"Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials","route":"/key-papers/paper-seely-integr-cancer-ther/","field":"links","label":"Integr Cancer Ther 2012"},{"id":"melatonin-cancer","kind":"technology","name":"Melatonin as a cancer adjunct","route":"/technologies/melatonin-cancer/","field":"links","label":"Melatonin as adjuvant cancer care with and without chemotherapy: systematic review and meta-analysis (Integr Cancer Ther 2012)"}]},{"url":"https://doi.org/10.1177/17407745211069879","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/17407745211069879","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brown-clin-trials","kind":"paper","name":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer","route":"/key-papers/paper-brown-clin-trials/","field":"links","label":"Clin Trials 2022"},{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"links","label":"Experiences of running a stratified medicine adaptive platform trial: challenges and lessons learned from 10 years of the FOCUS4 trial, Clinical Trials 2022"}]},{"url":"https://doi.org/10.1177/17588359241248336","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/17588359241248336","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","field":"links","label":"TROPION-Breast03 design"}]},{"url":"https://doi.org/10.1177/17588359251316176","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/17588359251316176","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","field":"links","label":"TROPION-Breast04 design"}]},{"url":"https://doi.org/10.1177/17588359251327992","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1177/17588359251327992","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","field":"links","label":"TROPION-Breast05 design"}]},{"url":"https://doi.org/10.1177/2050640620938987","status":403,"ok":false,"finalUrl":"https://onlinelibrary.wiley.com/doi/10.1177/2050640620938987","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Iglesia et al., exocrine insufficiency and enzyme replacement in advanced pancreatic cancer, meta-analysis (UEG Journal 2020)"},{"id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","field":"links","label":"Iglesia et al., meta-analysis (UEG Journal 2020)"}]},{"url":"https://doi.org/10.1182/blood-2002-09-2876","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/101/8/3052/16656/CD56bright-natural-killer-cells-are-present-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"papers","label":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity"}]},{"url":"https://doi.org/10.1182/blood-2004-02-0405","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/104/10/3009/18728/Adult-Burkitt-leukemia-and-lymphoma","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"links","label":"Blum 2004, Blood: adult Burkitt leukaemia and lymphoma"}]},{"url":"https://doi.org/10.1182/blood-2005-10-4073","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/108/1/88/133551/Improved-leukemia-free-survival-after","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"study-0201","kind":"trial","name":"Study 0201","route":"/trials/study-0201/","field":"links","label":"Blood 2006"},{"id":"study-0201","kind":"trial","name":"Study 0201","route":"/trials/study-0201/","field":"outcomes.source (Leukaemia-free survival at 3 years, first complete remission subgroup)"},{"id":"paper-study-0201-blood-2006","kind":"paper","name":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","route":"/key-papers/paper-study-0201-blood-2006/","field":"links","label":"Blood 2006"},{"id":"histamine-dihydrochloride","kind":"drug","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","field":"links","label":"Study 0201 (Blood 2006)"}]},{"url":"https://doi.org/10.1182/blood-2007-03-055749","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/110/6/1713/24087/Revisions-to-the-staging-and-classification-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-olsen-mycosis-fungoides-staging-blood-2007","kind":"paper","name":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","route":"/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/","field":"links","label":"Blood 2007"}]},{"url":"https://doi.org/10.1182/blood-2007-09-077438","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/112/3/461/25260/Human-natural-killer-cells","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"papers","label":"Human natural killer cells"}]},{"url":"https://doi.org/10.1182/blood-2007-10-116327","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/111/10/4902/24209/Development-and-validation-of-a-predictive-model","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","field":"links","label":"Khorana score (Blood 2008)"},{"id":"paper-khorana-blood","kind":"paper","name":"Development and validation of a predictive model for chemotherapy-associated thrombosis","route":"/key-papers/paper-khorana-blood/","field":"links","label":"Blood 2008"}]},{"url":"https://doi.org/10.1182/blood-2009-06-225326","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/114/16/3367/26244/The-microenvironment-in-mature-Bcell-malignancies","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","field":"papers","label":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies"},{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/","field":"links","label":"Blood 2009"}]},{"url":"https://doi.org/10.1182/blood-2009-08-231613","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/115/15/3008/26878/Rituximab-plus-concurrent-infusional-EPOCH","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sparano-blood","kind":"paper","name":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-sparano-blood/","field":"links","label":"Blood 2010"},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"links","label":"AMC 034: rituximab plus EPOCH in HIV-associated lymphoma (Blood 2010)"},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"standardOfCare.guideline (HIV-associated DLBCL)"}]},{"url":"https://doi.org/10.1182/blood-2009-08-239681","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/116/23/4874/28350/Identification-of-novel-cluster-groups-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"papers","label":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome"}]},{"url":"https://doi.org/10.1182/blood-2009-10-249128","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/115/9/1850/27232/Allogeneic-transplantation-for-therapyrelated","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"papers","label":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia"}]},{"url":"https://doi.org/10.1182/blood-2010-04-279083","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/116/11/1919/27436/Recurrent-BRAF-mutations-in-Langerhans-cell","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-badalian-very-braf-mutations-lch-blood-2010","kind":"paper","name":"Recurrent BRAF mutations in Langerhans cell histiocytosis","route":"/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/","field":"links","label":"Blood 2010"}]},{"url":"https://doi.org/10.1182/blood-2011-02-339556","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/119/3/e9/135128/Nodal-marginal-zone-lymphoma-gene-expression-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"links","label":"Blood 2012: nodal marginal zone lymphoma gene expression and miRNA profiling"}]},{"url":"https://doi.org/10.1182/blood-2011-05-356063","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/118/18/4771/29339/Cereblon-expression-is-required-for-the","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1182/blood-2011-08-372854","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/118/22/5799/29147/Alemtuzumab-therapy-in-Tcell-prolymphocytic","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"links","label":"Dearden 2011, Blood: alemtuzumab in T-PLL, intravenous against subcutaneous"}]},{"url":"https://doi.org/10.1182/blood-2012-08-234492","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/121/7/1077/31525/The-myth-of-the-second-remission-of-acute-leukemia","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"papers","label":"The myth of the second remission of acute leukemia in the adult"}]},{"url":"https://doi.org/10.1182/blood-2012-09-455774","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/121/25/5006/125577/Therapy-prolongation-improves-outcome-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013","kind":"paper","name":"LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","route":"/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/","field":"links","label":"Blood 2013"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"links","label":"LCH-III: prolonged therapy in multisystem LCH (Blood 2013)"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"standardOfCare.guideline (Multisystem LCH (first line))"},{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","field":"links","label":"Gadner et al., Blood 2013"},{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","field":"outcomes.source (5-year reactivation rate, risk-organ-negative)"},{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","field":"outcomes.source (5-year reactivation rate, risk-organ-positive (both arms, 12 months))"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"links","label":"LCH-III (Blood 2013)"}]},{"url":"https://doi.org/10.1182/blood-2012-10-461848","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/121/14/2715/31153/CD30-expression-defines-a-novel-subgroup-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","field":"prevalence.source"},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1182/blood-2014-01-550905","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/123/18/2791/32505/Somatic-mutations-in-MYD88-and-CXCR4-are","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","field":"links","label":"CXCR4 in WM (Blood 2014)"},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","field":"prevalence.source"},{"id":"paper-treon-blood","kind":"paper","name":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","route":"/key-papers/paper-treon-blood/","field":"links","label":"Blood 2014"}]},{"url":"https://doi.org/10.1182/blood-2014-02-554634","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/123/22/e123/32558/Integrated-genomic-analysis-illustrates-the","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","field":"papers","label":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis"},{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/","field":"links","label":"Blood 2014"}]},{"url":"https://doi.org/10.1182/blood-2014-05-577361","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/124/10/1655/32977/High-prevalence-of-somatic-MAP2K1-mutations-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1182/blood-2014-10-606038","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/125/16/2497/33768/Threeyear-followup-of-treatmentna%C3%AFve-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","field":"papers","label":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib"},{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/","field":"links","label":"Blood 2015"}]},{"url":"https://doi.org/10.1182/blood-2014-12-580068","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/125/26/4017/34313/CD19targeted-chimeric-antigen-receptor-Tcell","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/","field":"links","label":"Blood 2015"}]},{"url":"https://doi.org/10.1182/blood-2015-01-621664","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/126/3/291/34530/International-phase-3-study-of-azacitidine-vs","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","field":"papers","label":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts"},{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/","field":"links","label":"Blood 2015"}]},{"url":"https://doi.org/10.1182/blood-2015-06-651380","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/127/11/1410/34993/Phase-2-study-of-the-bispecific-Tcell-engager-BiTE","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","field":"links","label":"Polatuzumab (Blood 2015)"},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","field":"prevalence.source"},{"id":"paper-viardot-blood","kind":"paper","name":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-viardot-blood/","field":"links","label":"Blood 2016"}]},{"url":"https://doi.org/10.1182/blood-2015-08-664706","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/128/8/1050/35720/Autologous-hematopoietic-cell-transplantation-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","field":"outcomes.source (Overall survival at 1 year)"},{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","field":"outcomes.source (Progression-free survival at 2 years)"},{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","field":"outcomes.source (Transplant-related mortality at 1 year)"},{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/","field":"links","label":"Blood 2016"}]},{"url":"https://doi.org/10.1182/blood-2015-10-676924","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/127/13/1656/34776/Phase-3-trial-of-defibrotide-for-the-treatment-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"links","label":"Blood 2016"},{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"outcomes.source (Survival at day 100 after transplant)"},{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"outcomes.source (Complete response by day 100 after transplant)"},{"id":"paper-defibrotide-2005-01-blood-2016","kind":"paper","name":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","route":"/key-papers/paper-defibrotide-2005-01-blood-2016/","field":"links","label":"Blood 2016"},{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","field":"links","label":"Study 2005-01 (Blood 2016)"}]},{"url":"https://doi.org/10.1182/blood-2015-11-684225","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/128/7/971/35892/DOT1L-as-a-therapeutic-target-for-the-treatment-of","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"papers","label":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia"}]},{"url":"https://doi.org/10.1182/blood-2015-12-686725","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/127/24/2980/35453/Phase-1-studies-of-central-memoryderived-CD19-CAR","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"papers","label":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL"}]},{"url":"https://doi.org/10.1182/blood-2016-01-690636","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/127/22/2672/35156/Revised-classification-of-histiocytoses-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-emile-revised-classification-of-histiocytoses-blood-2016","kind":"paper","name":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","route":"/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/","field":"links","label":"Blood 2016"}]},{"url":"https://doi.org/10.1182/blood-2016-02-696757","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/128/10/1362/35315/The-genetics-of-nodal-marginal-zone-lymphoma","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"links","label":"Spina 2016, Blood: the genetics of nodal marginal zone lymphoma"}]},{"url":"https://doi.org/10.1182/blood-2017-01-764324","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/129/25/3304/107607/Improved-outcomes-for-myeloid-leukemia-of-Down","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","field":"links","label":"Taub 2017, Blood: improved outcomes for myeloid leukaemia of Down syndrome, COG AAML0431"}]},{"url":"https://doi.org/10.1182/blood-2017-04-779405","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/130/6/722/36814/Enasidenib-in-mutant-IDH2-relapsed-or-refractory","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-enasidenib-idh2-stein-blood-2017","kind":"paper","name":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-enasidenib-idh2-stein-blood-2017/","field":"links","label":"Blood 2017"}]},{"url":"https://doi.org/10.1182/blood-2017-05-785790","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/130/17/1889/36509/Ruxolitinib-vs-best-available-therapy-for-ET","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","field":"outcomes.source (Complete response within 1 year)"}]},{"url":"https://doi.org/10.1182/blood-2017-10-811224","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/131/11/1183/36457/Interim-results-of-brentuximab-vedotin-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"papers","label":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma"},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","kind":"paper","name":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/","field":"links","label":"Blood 2018"}]},{"url":"https://doi.org/10.1182/blood-2017-10-813493","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/131/10/1094/36428/ADCT402-a-PBD-dimercontaining-antibody-drug","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zammarchi-blood","kind":"paper","name":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","route":"/key-papers/paper-zammarchi-blood/","field":"links","label":"Blood 2018"},{"id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","field":"links","label":"Zammarchi et al., ADCT-402 (loncastuximab tesirine), a PBD dimer ADC with a valine-alanine cleavable linker (Blood 2018)"}]},{"url":"https://doi.org/10.1182/blood-2018-01-791376","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/131/25/2761/37138/Biology-and-treatment-of-Richter-syndrome","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rossi-richter-syndrome-blood-2018","kind":"paper","name":"Biology and treatment of Richter syndrome","route":"/key-papers/paper-rossi-richter-syndrome-blood-2018/","field":"links","label":"Blood 2018"}]},{"url":"https://doi.org/10.1182/blood-2018-03-839753","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/131/26/2877/39185/Consensus-recommendations-for-the-diagnosis-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","kind":"paper","name":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","route":"/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/","field":"links","label":"Blood 2018"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"standardOfCare.guideline (Rosai-Dorfman disease)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"links","label":"RDD consensus recommendations (Blood 2018)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"standardOfCare.guideline (Asymptomatic nodal or cutaneous disease)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"standardOfCare.guideline (Single or compressive extranodal lesion)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"standardOfCare.guideline (Multifocal or organ-threatening disease)"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"standardOfCare.guideline (MAPK-mutant or refractory disease)"}]},{"url":"https://doi.org/10.1182/blood-2018-10-881961","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","field":"links","label":"CALGB 10403 (Blood 2019)"},{"id":"paper-stock-blood","kind":"paper","name":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","route":"/key-papers/paper-stock-blood/","field":"links","label":"Blood 2019"}]},{"url":"https://doi.org/10.1182/blood-2019-01-894980","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/133/15/1630/273295/Management-of-acute-promyelocytic-leukemia-updated","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","field":"papers","label":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)"},{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","route":"/key-papers/paper-eln-apl-sanz-blood-2019/","field":"links","label":"Blood 2019"}]},{"url":"https://doi.org/10.1182/blood-2020-140174","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/136/Supplement%201/38/470130/Clinical-Impacts-of-Germline-DDX41-Mutations-on","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"papers","label":"Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms"}]},{"url":"https://doi.org/10.1182/blood-2023-181120","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/142/Supplement%201/6859/504680/The-Bengaluru-Score-a-Prognostic-Predictive-Score","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","field":"links","label":"Bengaluru Score (Blood 2023, ASH abstract)"},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","field":"outcomes.source (Overall response rate at the primary endpoint)"}]},{"url":"https://doi.org/10.1182/blood-2023-181585","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/142/Supplement%201/6862/505464/Cytokine-Profile-Following-Varnimcabtagene","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/","field":"links","label":"IMAGINE study (ASH 2023 abstract)"},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","field":"links","label":"IMAGINE study cytokine analysis (ASH 2023)"},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","field":"links","label":"Cytokine profile (Blood 2023, ASH abstract)"},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","field":"outcomes.source (Cytokine release syndrome, any grade)"}]},{"url":"https://doi.org/10.1182/blood.2019000402","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/134/14/1132/374897/Consensus-criteria-for-diagnosis-staging-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"links","label":"Staber 2019, Blood: consensus criteria for diagnosis, staging and response assessment of T-PLL"}]},{"url":"https://doi.org/10.1182/blood.2019003507","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/135/22/1929/452713/ErdheimChester-disease-consensus-recommendations","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-erdheim-chester-disease-consensus-recommendations-blood-2020","kind":"paper","name":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era","route":"/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/","field":"links","label":"Blood 2020"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"links","label":"Consensus recommendations for ECD (Blood 2020)"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"standardOfCare.guideline (ECD, BRAF V600E-mutant, needing treatment)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"links","label":"ECD consensus recommendations (Blood 2020)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"standardOfCare.guideline (BRAF V600E-mutant symptomatic disease)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"standardOfCare.guideline (BRAF wild-type symptomatic disease)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"standardOfCare.guideline (Second-choice or intolerant)"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"standardOfCare.guideline (Asymptomatic bone-limited disease)"}]},{"url":"https://doi.org/10.1182/blood.2019004000","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/136/8/925/461120/How-I-prevent-infections-in-patients-receiving","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/","field":"links","label":"Blood 2020"}]},{"url":"https://doi.org/10.1182/blood.2020006844","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"links","label":"ASPEN (Blood 2020)"},{"id":"paper-tam-blood","kind":"paper","name":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study","route":"/key-papers/paper-tam-blood/","field":"links","label":"Blood 2020"}]},{"url":"https://doi.org/10.1182/blood.2020010387","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/138/3/213/475653/Outcomes-and-prognostic-factors-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"links","label":"Advani 2021, Blood: outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma, the international T-cell Project"}]},{"url":"https://doi.org/10.1182/blood.2021012021","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/138/22/2278/476399/Belumosudil-for-chronic-graft-versus-host-disease","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","field":"links","label":"ROCKstar (Blood 2021)"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"links","label":"Blood 2021"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"outcomes.source (Best overall response rate (2014 NIH criteria))"},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"outcomes.source (Symptom improvement (Lee Symptom Scale))"},{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/","field":"links","label":"Blood 2021"}]},{"url":"https://doi.org/10.1182/blood.2021012852","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/139/12/1863/483214/Molecular-features-encoded-in-the-ctDNA-reveal","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"papers","label":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma"}]},{"url":"https://doi.org/10.1182/blood.2021012888","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/139/3/413/477056/Single-route-CNS-prophylaxis-for-aggressive-non","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Central nervous system prophylaxis: who is offered it, and the evidence against it)"},{"id":"lymphoma-tx-cns-prophylaxis","kind":"term","name":"CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it","route":"/terms/lymphoma-tx-cns-prophylaxis/","field":"links","label":"Orellana-Noia et al., single-route CNS prophylaxis in 1,162 patients across 21 US centres, Blood 2022"}]},{"url":"https://doi.org/10.1182/blood.2021013626","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/138/26/2753/477736/2021-Update-on-MRD-in-acute-myeloid-leukemia-a","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","field":"links","label":"Heuser et al., 2021 update on MRD in acute myeloid leukaemia: ELN MRD Working Party consensus (Blood 2021)"},{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/","field":"links","label":"Blood 2021"}]},{"url":"https://doi.org/10.1182/blood.2021014488","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/139/22/3278/484114/Fixed-duration-ibrutinib-plus-venetoclax-for-first","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","field":"outcomes.source (Undetectable MRD in peripheral blood)"}]},{"url":"https://doi.org/10.1182/blood.2022015850","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/140/11/1200/485730/International-Consensus-Classification-of-Myeloid","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","route":"/key-papers/paper-icc-2022-arber-blood-2022/","field":"links","label":"Blood 2022"}]},{"url":"https://doi.org/10.1182/blood.2022016867","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","field":"links","label":"Dohner et al., Diagnosis and management of AML in adults: 2022 ELN recommendations (Blood 2022)"},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","field":"papers","label":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN"},{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/","field":"links","label":"Blood 2022"}]},{"url":"https://doi.org/10.1182/blood.2022018730","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/141/14/1675/493847/Lisocabtagene-maraleucel-as-second-line-therapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-car-t-pathway","kind":"term","name":"The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting","route":"/terms/lymphoma-tx-car-t-pathway/","field":"links","label":"TRANSFORM primary analysis, Blood 2023: complete response 74 against 43 per cent, progression-free survival hazard ratio 0.400"}]},{"url":"https://doi.org/10.1182/blood.2024026830","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/145/15/1621/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/","field":"links","label":"Blood 2025"}]},{"url":"https://doi.org/10.1182/blood.v88.7.2480.bloodjournal8872480","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/88/7/2480/125201/A-randomized-trial-of-hydroxyurea-versus-VP16-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wattel-blood","kind":"paper","name":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group","route":"/key-papers/paper-wattel-blood/","field":"links","label":"Blood 1996"}]},{"url":"https://doi.org/10.1182/blood.V88.7.2480.bloodjournal8872480","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/88/7/2480/125201/A-randomized-trial-of-hydroxyurea-versus-VP16-in","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"links","label":"Hydroxyurea vs etoposide in CMML (Blood 1996)"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"standardOfCare.guideline (Proliferative CMML with symptomatic leucocytosis or splenomegaly)"}]},{"url":"https://doi.org/10.1182/blood.v89.6.2015","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/89/6/2015/139088/p53-Abnormalities-in-BCell-Prolymphocytic-Leukemia","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"links","label":"Lens 1997, Blood: p53 abnormalities in B-cell prolymphocytic leukaemia"}]},{"url":"https://doi.org/10.1182/bloodadvances.2017009928","status":403,"ok":false,"finalUrl":"https://ashpublications.org/bloodadvances/article/1/25/2348/15773/Blockade-of-CD7-expression-in-T-cells-for","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1183/13993003.00172-2016","status":403,"ok":false,"finalUrl":"https://publications.ersnet.org/lookup/doi/10.1183/13993003.00172-2016","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-blastoma","kind":"cancer","name":"Pulmonary blastoma (adult)","route":"/cancers/pulmonary-blastoma/","field":"links","label":"European Respiratory Journal 2016: somatic DICER1 mutations in adult-onset pulmonary blastoma"}]},{"url":"https://doi.org/10.1183/13993003.00610-2018","status":403,"ok":false,"finalUrl":"https://publications.ersnet.org/lookup/doi/10.1183/13993003.00610-2018","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"papers","label":"ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe"}]},{"url":"https://doi.org/10.1183/20734735.0004-2024","status":403,"ok":false,"finalUrl":"https://publications.ersnet.org/lookup/doi/10.1183/20734735.0004-2024","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"papers","label":"Small cell lung cancer and neuroendocrine tumours"}]},{"url":"https://doi.org/10.1186/s40425-017-0310-x","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/lookup/doi/10.1186/s40425-017-0310-x","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/","field":"links","label":"J Immunother Cancer 2018"}]},{"url":"https://doi.org/10.1200/go-25-00332","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/GO-25-00332","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Suryavanshi et al., JCO Glob Oncol 2025: genomic profiling of 376 Indian gallbladder carcinomas"},{"id":"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","kind":"paper","name":"Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population","route":"/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/","field":"links","label":"Suryavanshi et al., JCO Glob Oncol 2025: genomic profiling of 376 Indian gallbladder carcinomas"}]},{"url":"https://doi.org/10.1200/go.20.00014","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/GO.20.00014","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","field":"papers","label":"Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study"}]},{"url":"https://doi.org/10.1200/GO.20.00122","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/GO.20.00122","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-registries-surveillance","kind":"technology","name":"Cancer registries and population surveillance","route":"/technologies/cancer-registries-surveillance/","field":"links","label":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India (JCO Global Oncology 2020)"},{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","field":"links","label":"Cancer Statistics 2020 (JCO Glob Oncol)"},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","field":"links","label":"Cancer Statistics 2020 (JCO Glob Oncol)"},{"id":"paper-mathur-ncrp-cancer-statistics-2020","kind":"paper","name":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India","route":"/key-papers/paper-mathur-ncrp-cancer-statistics-2020/","field":"links","label":"JCO Global Oncology 2020"}]},{"url":"https://doi.org/10.1200/go.23.00159","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/GO.23.00159","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"papers","label":"Africa Guidelines for Hepatocellular Carcinoma Buildup Process"}]},{"url":"https://doi.org/10.1200/go.24.00090","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/GO.24.00090","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Mondaca et al., JCO Glob Oncol 2024: ERBB2-altered gallbladder cancer in an American and a Chilean cohort"},{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/","field":"links","label":"Mondaca et al., JCO Glob Oncol 2024: ERBB2-altered gallbladder cancer in an American and a Chilean cohort"},{"id":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","kind":"paper","name":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","route":"/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/","field":"links","label":"Mondaca et al., JCO Glob Oncol 2024: ERBB2-altered gallbladder cancer in an American and a Chilean cohort"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/jco-24-01266","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01266","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06106308-j-clin-oncol-2025","kind":"paper","name":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","route":"/key-papers/paper-nct06106308-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/jco-24-01269","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01269","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04129502-j-clin-oncol-2025","kind":"paper","name":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial","route":"/key-papers/paper-nct04129502-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO-24-01283","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01283","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","field":"links","label":"KEYNOTE-921 (Journal of Clinical Oncology 2025)"},{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1200/jco-24-01349","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01349","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tropion-lung05-j-clin-oncol-2025","kind":"paper","name":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","route":"/key-papers/paper-tropion-lung05-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO-24-01373","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01373","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ielsg37-pmbcl-martelli-jco-2024","kind":"paper","name":"IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan","route":"/key-papers/paper-ielsg37-pmbcl-martelli-jco-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO-24-01383","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01383","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/","field":"links","label":"SWOG S1815 (JCO 2025): 16% gallbladder cancer, subgroup interaction tests"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"SWOG S1815, JCO 2025"},{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/","field":"links","label":"Shroff et al., JCO 2025: SWOG S1815"},{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/","field":"outcomes.source (Overall survival)"},{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1200/JCO-24-01502","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-01502","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","field":"links","label":"Fietkau et al., CONKO-007 (JCO 2025)"},{"id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","field":"outcomes.source (R0 resection rate, all randomised patients)"},{"id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","field":"outcomes.source (Overall survival (randomised intention to treat))"}]},{"url":"https://doi.org/10.1200/jco-24-02138","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-24-02138","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"outcomes.source (Objective response, recurrent or metastatic Merkel cell carcinoma cohort)"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"outcomes.source (Duration of response, Merkel cell carcinoma cohort)"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"outcomes.source (Progression-free survival, Merkel cell carcinoma cohort)"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"outcomes.source (Overall survival, Merkel cell carcinoma cohort)"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"outcomes.source (Grade 3-4 treatment-related adverse events, Merkel cell carcinoma cohort)"}]},{"url":"https://doi.org/10.1200/JCO-25-00112","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00112","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","field":"papers","label":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer"},{"id":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","kind":"paper","name":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO-25-00204","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00204","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Advanced Hodgkin lymphoma in the United States: nivolumab with AVD)"}]},{"url":"https://doi.org/10.1200/jco-25-00559","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00559","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04561362-j-clin-oncol-2025","kind":"paper","name":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation","route":"/key-papers/paper-nct04561362-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/jco-25-00746","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00746","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO-25-00746","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00746","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","field":"links","label":"Babiker et al., PANOVA-3 (JCO 2025)"},{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","field":"outcomes.source (Pain-free survival)"},{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","field":"links","label":"J Clin Oncol 2025"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"links","label":"Babiker et al., PANOVA-3 (JCO 2025)"},{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/","field":"links","label":"PANOVA-3 (Journal of Clinical Oncology 2025)"}]},{"url":"https://doi.org/10.1200/jco-25-00763","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00763","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/jco-25-00788","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00788","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03974022-j-clin-oncol-2025","kind":"paper","name":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","route":"/key-papers/paper-nct03974022-j-clin-oncol-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/jco-25-00872","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00872","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hammel-j-clin-oncol","kind":"paper","name":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma","route":"/key-papers/paper-hammel-j-clin-oncol/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO-25-00872","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00872","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","field":"links","label":"Hammel et al., Journal of Clinical Oncology 2025: TRYbeCA-1, eryaspase with chemotherapy as second-line treatment"},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","field":"outcomes.source (Overall survival)"},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","field":"outcomes.source (Progression-free survival)"},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1200/JCO-25-00929","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-00929","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"outcomes.source (Progression-free survival, part B)"},{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"outcomes.source (Objective response rate, part B)"},{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"outcomes.source (Overall survival, part B)"},{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"outcomes.source (Grade 3 or worse treatment-related adverse events, part B)"},{"id":"paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026","kind":"paper","name":"NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer","route":"/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/jco-25-01137","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-01137","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wen-j-clin-oncol","kind":"paper","name":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial","route":"/key-papers/paper-wen-j-clin-oncol/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO-25-01137","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-01137","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","field":"links","label":"Evaluation of regorafenib in newly diagnosed and recurrent glioblastoma: GBM AGILE phase II/III Bayesian randomized platform trial, Journal of Clinical Oncology 2026"}]},{"url":"https://doi.org/10.1200/jco-25-01153","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-01153","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO-25-01346","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-01346","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wong-ignyte-rp1-nivolumab-jco-2025","kind":"paper","name":"IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy","route":"/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/","field":"links","label":"JCO 2025"}]},{"url":"https://doi.org/10.1200/jco-25-02187","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05379595-j-clin-oncol-2026","kind":"paper","name":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","route":"/key-papers/paper-nct05379595-j-clin-oncol-2026/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/jco-25-02600","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02600","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-her2climb-05-j-clin-oncol-2026","kind":"paper","name":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","route":"/key-papers/paper-her2climb-05-j-clin-oncol-2026/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO-25-02659","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02659","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"Updated outcomes, J Clin Oncol 2026"},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/","field":"links","label":"AEGEAN updated outcomes (Journal of Clinical Oncology 2026)"}]},{"url":"https://doi.org/10.1200/jco-25-02777","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02777","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peters-j-clin-oncol","kind":"paper","name":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer","route":"/key-papers/paper-peters-j-clin-oncol/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO-25-02777","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02777","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","field":"links","label":"SKYSCRAPER-01: tiragolumab plus atezolizumab in previously untreated PD-L1-high non-small-cell lung cancer, phase 3 (Journal of Clinical Oncology 2026)"}]},{"url":"https://doi.org/10.1200/JCO-25-02849","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-25-02849","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Relapsed and not fit for transplant or CAR-T: bispecific antibodies and antibody-drug conjugates)"}]},{"url":"https://doi.org/10.1200/jco-26-00434","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/jco-26-00444","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ballman-j-clin-oncol","kind":"paper","name":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma","route":"/key-papers/paper-ballman-j-clin-oncol/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO-26-00444","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","field":"links","label":"Lessons from GBM AGILE's regorafenib experience, Journal of Clinical Oncology 2026"}]},{"url":"https://doi.org/10.1200/jco-26-00602","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00602","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/jco-26-00788","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00788","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","field":"outcomes.source (Progression-free survival)"},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","field":"outcomes.source (Objective response rate)"},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","field":"outcomes.source (Duration of response)"},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/jco-26-00835","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00835","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/jco-26-00852","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO-26-00852","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/","field":"links","label":"J Clin Oncol 2026"}]},{"url":"https://doi.org/10.1200/JCO.18.00353","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.00353","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-amit-induction-chemotherapy-response-snuc-jco-2019","kind":"paper","name":"Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/","field":"links","label":"J Clin Oncol 2019"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"links","label":"Induction chemotherapy in SNUC (JCO 2019)"}]},{"url":"https://doi.org/10.1200/JCO.18.00545","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.00545","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019","kind":"paper","name":"Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma","route":"/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.00771","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.00771","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019","kind":"paper","name":"Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary","route":"/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.01010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/","field":"links","label":"Loi et al., J Clin Oncol 2019: pooled analysis of stromal TILs in 2,148 early TNBC patients"}]},{"url":"https://doi.org/10.1200/jco.18.01265","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01265","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-158-j-clin-oncol-2019","kind":"paper","name":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","route":"/key-papers/paper-keynote-158-j-clin-oncol-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.01585","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01585","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/","field":"links","label":"Marcoux et al., J Clin Oncol 2019: clinical outcomes of 67 EGFR-mutant adenocarcinomas that transformed to small-cell carcinoma"}]},{"url":"https://doi.org/10.1200/JCO.18.01731","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01731","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prophecy-arv7-validation-jco-2019","kind":"paper","name":"PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer","route":"/key-papers/paper-prophecy-arv7-validation-jco-2019/","field":"links","label":"Armstrong et al., J Clin Oncol 2019: PROPHECY, prospective multicentre validation of circulating tumour cell AR-V7 in 118 men with high-risk mCRPC"}]},{"url":"https://doi.org/10.1200/JCO.18.01765","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01765","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"links","label":"ACNS0121: conformal radiotherapy in childhood ependymoma (JCO 2019)"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"standardOfCare.guideline (Newly diagnosed intracranial ependymoma, age one year and over)"},{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/","field":"outcomes.source (Event-free survival at 5 years by treatment group)"},{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/","field":"outcomes.source (Event-free survival at 5 years, infratentorial tumours by 1q status)"},{"id":"paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019","kind":"paper","name":"ACNS0121: conformal radiotherapy for paediatric ependymoma, chemotherapy for incompletely resected tumours and observation after complete resection","route":"/key-papers/paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.01859","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019","kind":"paper","name":"Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma","route":"/key-papers/paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.18.01972","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01972","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol","kind":"paper","name":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report","route":"/key-papers/paper-dix-j-clin-oncol/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.01972","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01972","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","field":"links","label":"Dix et al., JCO 2019 (LOH 1p/16q)"},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","field":"outcomes.source (4-year event-free survival, LOH 1p/16q stage III-IV, Regimen M)"}]},{"url":"https://doi.org/10.1200/JCO.18.01994","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.01994","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Advanced stage, IPI 0 to 1: R-CHOP for six cycles)"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"standardOfCare.guideline (Treatments that did not work, and are worth not being offered)"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/","field":"links","label":"Alliance/CALGB 50303: DA-EPOCH-R against R-CHOP in DLBCL, Journal of Clinical Oncology 2019"},{"id":"lymphoma-tx-failed-and-negative","kind":"term","name":"Lymphoma treatments that did not work: the negative trials worth knowing","route":"/terms/lymphoma-tx-failed-and-negative/","field":"links","label":"Alliance/CALGB 50303, Journal of Clinical Oncology 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.02031","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02031","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostvac","kind":"drug","name":"PROSTVAC","route":"/drugs/prostvac/","field":"links","label":"PROSPECT (Journal of Clinical Oncology 2019)"},{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/","field":"links","label":"PROSPECT (Journal of Clinical Oncology 2019)"},{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1200/jco.18.02142","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02142","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bohlius-j-clin-oncol","kind":"paper","name":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","route":"/key-papers/paper-bohlius-j-clin-oncol/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.02142","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02142","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","field":"links","label":"ASCO/ASH ESA guideline 2019"}]},{"url":"https://doi.org/10.1200/JCO.18.02158","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02158","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rtog-0521","kind":"trial","name":"NRG Oncology RTOG 0521","route":"/trials/rtog-0521/","field":"links","label":"RTOG 0521 (Journal of Clinical Oncology 2019)"},{"id":"rtog-0521","kind":"trial","name":"NRG Oncology RTOG 0521","route":"/trials/rtog-0521/","field":"outcomes.source (Overall survival at 4 years)"},{"id":"rtog-0521","kind":"trial","name":"NRG Oncology RTOG 0521","route":"/trials/rtog-0521/","field":"outcomes.source (Distant metastasis at 6 years)"}]},{"url":"https://doi.org/10.1200/JCO.18.02236","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02236","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","kind":"paper","name":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","route":"/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/","field":"links","label":"Shaw et al., J Clin Oncol 2019: ALK resistance mutations and the efficacy of lorlatinib in 198 patients"},{"id":"alk-resistance-mutation","kind":"biomarker","name":"ALK kinase-domain resistance mutation (G1202R and the rest)","route":"/biomarkers/alk-resistance-mutation/","field":"links","label":"Shaw et al., J Clin Oncol 2019: ALK resistance mutations and the efficacy of lorlatinib in 198 patients"}]},{"url":"https://doi.org/10.1200/JCO.18.02258","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.18.02258","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lenz-cms-calgb-swog-80405-jco-2019","kind":"paper","name":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","route":"/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/","field":"links","label":"Lenz et al., J Clin Oncol 2019: consensus molecular subtype and survival in 581 CALGB/SWOG 80405 patients"}]},{"url":"https://doi.org/10.1200/JCO.19.00010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","field":"papers","label":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma"},{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/","field":"links","label":"J Clin Oncol 2019"},{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/","field":"outcomes.source (Progression-free survival (independent radiology review))"},{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/","field":"outcomes.source (Grade 3-4 neutropenia)"}]},{"url":"https://doi.org/10.1200/JCO.19.00172","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00172","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"papers","label":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma"}]},{"url":"https://doi.org/10.1200/JCO.19.00261","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00261","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","field":"papers","label":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia"},{"id":"paper-interfant-06-pieters-jco-2019","kind":"paper","name":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-06-pieters-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.19.00308","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00308","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cao-aro-aio-12","kind":"trial","name":"CAO/ARO/AIO-12","route":"/trials/cao-aro-aio-12/","field":"links","label":"CAO/ARO/AIO-12: chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy (Journal of Clinical Oncology 2019)"},{"id":"cao-aro-aio-12","kind":"trial","name":"CAO/ARO/AIO-12","route":"/trials/cao-aro-aio-12/","field":"outcomes.source (Pathological complete response)"}]},{"url":"https://doi.org/10.1200/jco.19.00368","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00368","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"papers","label":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial"}]},{"url":"https://doi.org/10.1200/JCO.19.00368","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00368","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schmid-pakt-capivasertib-tnbc-jco-2020","kind":"paper","name":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","route":"/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/","field":"links","label":"Schmid et al., J Clin Oncol 2020: PAKT, capivasertib plus paclitaxel in 140 metastatic TNBC patients"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"links","label":"Schmid et al., JCO 2020: capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic TNBC, the PAKT trial"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"outcomes.source (Progression-free survival)"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"outcomes.source (Overall survival)"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"outcomes.source (Progression-free survival, PIK3CA/AKT1/PTEN-altered tumours)"},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/JCO.19.00456","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00456","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019","kind":"paper","name":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","route":"/key-papers/paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019/","field":"links","label":"J Clin Oncol 2019"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"links","label":"Vemurafenib in refractory BRAF V600E LCH (JCO 2019)"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"standardOfCare.guideline (Refractory risk-organ disease or reactivation)"}]},{"url":"https://doi.org/10.1200/JCO.19.00701","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00701","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","field":"outcomes.source (Progression-free survival at 3 years, non-germinomatous germ cell tumours given reduced radiotherapy after chemotherapy response)"},{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","field":"outcomes.source (Overall survival at 3 years, non-germinomatous stratum)"},{"id":"acns0122","kind":"trial","name":"ACNS0122","route":"/trials/acns0122/","field":"outcomes.source (Progression-free survival at 3 years (as reported in the ACNS1123 comparison))"},{"id":"acns0122","kind":"trial","name":"ACNS0122","route":"/trials/acns0122/","field":"outcomes.source (Overall survival at 3 years (as reported in the ACNS1123 comparison))"},{"id":"paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019","kind":"paper","name":"ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours","route":"/key-papers/paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.19.00739","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00739","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-358-j-clin-oncol-2019","kind":"paper","name":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","route":"/key-papers/paper-checkmate-358-j-clin-oncol-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.19.00799","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00799","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-arches-j-clin-oncol-2019","kind":"paper","name":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","route":"/key-papers/paper-arches-j-clin-oncol-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.19.00818","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00818","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-azad-j-clin-oncol","kind":"paper","name":"Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study","route":"/key-papers/paper-azad-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.00818","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00818","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"Azad et al., Journal of Clinical Oncology 2020: nivolumab in mismatch repair-deficient non-colorectal cancers (arm Z1D)"},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"outcomes.source (Objective response, nivolumab in dMMR non-colorectal tumours (arm Z1D))"}]},{"url":"https://doi.org/10.1200/JCO.19.00904","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00904","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"geicam-ciboma","kind":"trial","name":"GEICAM/2003-11_CIBOMA/2004-01","route":"/trials/geicam-ciboma/","field":"links","label":"Lluch et al., JCO 2020: adjuvant capecitabine after standard neo/adjuvant chemotherapy in early TNBC (GEICAM/CIBOMA)"},{"id":"geicam-ciboma","kind":"trial","name":"GEICAM/2003-11_CIBOMA/2004-01","route":"/trials/geicam-ciboma/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://doi.org/10.1200/JCO.19.00919","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00919","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-anbl0531-twist-jco-2019","kind":"paper","name":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-anbl0531-twist-jco-2019/","field":"links","label":"J Clin Oncol 2019"},{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","field":"outcomes.source (Overall survival at 3 years, all evaluable patients)"},{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","field":"outcomes.source (Event-free survival at 3 years, all evaluable patients)"},{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","field":"outcomes.source (Event-free survival at 3 years, infants with stage 4 disease by biology)"}]},{"url":"https://doi.org/10.1200/JCO.19.00946","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00946","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019","kind":"paper","name":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/JCO.19.00964","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00964","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/","field":"links","label":"HD16: PET-guided omission of radiotherapy in early favourable Hodgkin lymphoma, Journal of Clinical Oncology 2019"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Early favourable Hodgkin lymphoma: two cycles of ABVD and 20 Gy, and the argument about leaving the radiotherapy out)"}]},{"url":"https://doi.org/10.1200/JCO.19.00986","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.00986","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020","kind":"paper","name":"Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials","route":"/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.01073","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01073","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-maintenance","kind":"term","name":"Maintenance and consolidation in lymphoma: where it works and where it does not","route":"/terms/lymphoma-tx-maintenance/","field":"links","label":"PRIMA final analysis at nine years, Journal of Clinical Oncology 2019"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Advanced follicular lymphoma needing treatment: which induction, and whether to add maintenance)"}]},{"url":"https://doi.org/10.1200/JCO.19.01124","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01124","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019","kind":"paper","name":"Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)","route":"/key-papers/paper-pietrantonio-msi-gastric-meta-analysis-jco-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.19.01154","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01154","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-noronha-j-clin-oncol","kind":"paper","name":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer","route":"/key-papers/paper-noronha-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.01154","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01154","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","route":"/trials/gefitinib-chemo-tmh/","field":"links","label":"Noronha et al., JCO 2020"},{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","route":"/trials/gefitinib-chemo-tmh/","field":"outcomes.source (Median progression-free survival)"}]},{"url":"https://doi.org/10.1200/jco.19.01203","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01203","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ambrosone-j-clin-oncol","kind":"paper","name":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)","route":"/key-papers/paper-ambrosone-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.01203","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01203","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","field":"links","label":"DELCaP: supplements during chemotherapy (JCO 2020)"}]},{"url":"https://doi.org/10.1200/JCO.19.01304","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01304","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"papers","label":"Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant"}]},{"url":"https://doi.org/10.1200/JCO.19.01389","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01389","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","field":"papers","label":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma"},{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/","field":"links","label":"J Clin Oncol 2019"},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"links","label":"Journal of Clinical Oncology 2019"},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"outcomes.source (Objective response rate)"},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"outcomes.source (Complete response rate)"}]},{"url":"https://doi.org/10.1200/JCO.19.01461","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01461","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"papers","label":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update"}]},{"url":"https://doi.org/10.1200/jco.19.01472","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01472","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","field":"papers","label":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update"},{"id":"paper-andrea-decensi-j-clin-oncol-2019","kind":"paper","name":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-andrea-decensi-j-clin-oncol-2019/","field":"links","label":"J Clin Oncol 2019"}]},{"url":"https://doi.org/10.1200/jco.19.01638","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01638","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-antonarakis-keynote-199-pembrolizumab-jco-2020","kind":"paper","name":"KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.01740","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01740","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020","kind":"paper","name":"E3A06: lenalidomide versus observation in smouldering multiple myeloma","route":"/key-papers/paper-e3a06-lenalidomide-smouldering-lonial-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.01758","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01758","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"papers","label":"Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk"}]},{"url":"https://doi.org/10.1200/JCO.19.01776","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01776","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"links","label":"ACNS0333: intensive multimodal therapy for ATRT (JCO 2020)"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"standardOfCare.guideline (Newly diagnosed, any age)"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","field":"outcomes.source (Event-free survival, patients under 36 months against a historical cooperative group cohort)"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","field":"outcomes.source (Event-free survival at 4 years, entire cohort)"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","field":"outcomes.source (Overall survival at 4 years, entire cohort)"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","field":"outcomes.source (Treatment-related deaths)"},{"id":"paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020","kind":"paper","name":"ACNS0333: high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumour","route":"/key-papers/paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.01907","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.01907","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Yang, J Clin Oncol 2020: cancer risks with germline PALB2 pathogenic variants, 524 families"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Yang, J Clin Oncol 2020: cancer risks with germline PALB2 pathogenic variants, 524 families"}]},{"url":"https://doi.org/10.1200/jco.19.02085","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02085","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hassan-j-clin-oncol","kind":"paper","name":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","route":"/key-papers/paper-hassan-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.02085","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02085","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","field":"links","label":"Hassan et al., first-in-human phase 1 of anetumab ravtansine (JCO 2020)"}]},{"url":"https://doi.org/10.1200/JCO.19.02105","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02105","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"links","label":"Marabelle et al., pembrolizumab in non-colorectal MSI-H/dMMR cancer, KEYNOTE-158 (JCO 2020)"},{"id":"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","kind":"paper","name":"KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer","route":"/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.02274","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02274","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.02274","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02274","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","field":"links","label":"PREOPANC-1 primary analysis, JCO 2020 (NTR3709)"},{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","field":"outcomes.source (Overall survival (primary analysis, intention to treat))"},{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","field":"outcomes.source (R0 resection rate among resected patients)"},{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.02309","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02309","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Allison, J Clin Oncol 2020: ASCO/CAP guideline update on ER and PR testing (1 percent threshold, ER Low Positive)"},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"links","label":"Allison, J Clin Oncol 2020: ASCO/CAP guideline update on ER and PR testing (1 percent threshold, ER Low Positive)"},{"id":"grade-stage-receptor-breast","kind":"term","name":"Grade, stage and receptor status: three different things on one breast report","route":"/terms/grade-stage-receptor-breast/","field":"links","label":"Allison et al., Journal of Clinical Oncology 2020;38:1346 to 1366: oestrogen and progesterone receptor testing in breast cancer, ASCO/CAP guideline update"},{"id":"er-pr-scoring-breast","kind":"term","name":"How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item)","route":"/terms/er-pr-scoring-breast/","field":"links","label":"Allison et al., Journal of Clinical Oncology 2020;38:1346 to 1366: oestrogen and progesterone receptor testing in breast cancer, ASCO/CAP guideline update"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Allison et al., Journal of Clinical Oncology 2020;38:1346 to 1366: oestrogen and progesterone receptor testing in breast cancer, ASCO/CAP guideline update"}]},{"url":"https://doi.org/10.1200/JCO.19.02309","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02309","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"er-status","kind":"biomarker","name":"ER status (oestrogen receptor by IHC)","route":"/biomarkers/er-status/","field":"links","label":"ASCO/CAP estrogen and progesterone receptor testing guideline, 2020 update (Allison et al., J Clin Oncol)"},{"id":"pr-status","kind":"biomarker","name":"PR status (progesterone receptor by IHC)","route":"/biomarkers/pr-status/","field":"links","label":"ASCO/CAP estrogen and progesterone receptor testing guideline, 2020 update (Allison et al., J Clin Oncol)"}]},{"url":"https://doi.org/10.1200/jco.19.02444","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chera-j-clin-oncol","kind":"paper","name":"Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer","route":"/key-papers/paper-chera-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.02444","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02444","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cthpv-dna","kind":"technology","name":"Circulating tumour HPV DNA (ctHPV-DNA)","route":"/technologies/cthpv-dna/","field":"links","label":"Chera et al., Plasma circulating tumour HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer (Journal of Clinical Oncology 2020)"}]},{"url":"https://doi.org/10.1200/JCO.19.02750","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02750","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fast-trial","kind":"trial","name":"FAST (5-fraction whole-breast radiotherapy)","route":"/trials/fast-trial/","field":"links","label":"FAST ten-year results (Journal of Clinical Oncology 2020)"},{"id":"fast-trial","kind":"trial","name":"FAST (5-fraction whole-breast radiotherapy)","route":"/trials/fast-trial/","field":"outcomes.source (Change in photographic breast appearance at 5 years against 50 Gy in 25 fractions)"},{"id":"fast-trial","kind":"trial","name":"FAST (5-fraction whole-breast radiotherapy)","route":"/trials/fast-trial/","field":"outcomes.source (Any moderate or marked physician-assessed normal-tissue effect against 50 Gy in 25 fractions)"}]},{"url":"https://doi.org/10.1200/JCO.19.02767","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02767","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","field":"papers","label":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases"},{"id":"paper-nrg-cc001-brown-jco-2020","kind":"paper","name":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases","route":"/key-papers/paper-nrg-cc001-brown-jco-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","field":"links","label":"JCO 2020"},{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","field":"outcomes.source (Time to cognitive function failure)"},{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","field":"outcomes.source (Deterioration in executive function at 4 months)"}]},{"url":"https://doi.org/10.1200/JCO.19.02931","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.02931","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","field":"papers","label":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation"},{"id":"paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020","kind":"paper","name":"O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation","route":"/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.03010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-flaherty-j-clin-oncol","kind":"paper","name":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","route":"/key-papers/paper-flaherty-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.03010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"Flaherty et al., Journal of Clinical Oncology 2020: molecular landscape and actionable alterations in NCI-MATCH"},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"outcomes.source (Assigned to a treatment arm)"}]},{"url":"https://doi.org/10.1200/JCO.19.03054","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03054","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","field":"papers","label":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma"},{"id":"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020","kind":"paper","name":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.19.03120","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03120","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hassett-j-clin-oncol","kind":"paper","name":"Management of Male Breast Cancer: ASCO Guideline","route":"/key-papers/paper-hassett-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.19.03120","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03120","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"links","label":"ASCO guideline: management of male breast cancer (JCO 2020)"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"standardOfCare.guideline (Early stage)"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"standardOfCare.guideline (Adjuvant endocrine, ER-positive)"}]},{"url":"https://doi.org/10.1200/JCO.19.03266","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.19.03266","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"links","label":"InterAACT (JCO 2020)"},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"outcomes.source (Best overall response rate by 24 weeks)"},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"outcomes.source (Overall survival)"},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"outcomes.source (Progression-free survival)"},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"outcomes.source (Serious adverse events)"},{"id":"paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020","kind":"paper","name":"InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer","route":"/key-papers/paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.1989.7.11.1748","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1989.7.11.1748","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-calvert-j-clin-oncol","kind":"paper","name":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","route":"/key-papers/paper-calvert-j-clin-oncol/","field":"links","label":"J Clin Oncol 1989"}]},{"url":"https://doi.org/10.1200/JCO.1989.7.11.1748","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1989.7.11.1748","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pkpd-modelling","kind":"technology","name":"Pharmacokinetic and pharmacodynamic modelling","route":"/technologies/pkpd-modelling/","field":"links","label":"Calvert formula, 1989"}]},{"url":"https://doi.org/10.1200/jco.1991.9.6.970","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1991.9.6.970","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"papers","label":"A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix."}]},{"url":"https://doi.org/10.1200/JCO.1993.11.3.570","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1993.11.3.570","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cella-fact-g-jco-1993","kind":"paper","name":"Cella 1993: the Functional Assessment of Cancer Therapy (FACT-G) quality of life scale","route":"/key-papers/paper-cella-fact-g-jco-1993/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1200/jco.1995.13.4.974","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1995.13.4.974","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-grever-j-clin-oncol","kind":"paper","name":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","route":"/key-papers/paper-grever-j-clin-oncol/","field":"links","label":"J Clin Oncol 1995"}]},{"url":"https://doi.org/10.1200/JCO.1995.13.4.974","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1995.13.4.974","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pentostatin","kind":"drug","name":"Pentostatin","route":"/drugs/pentostatin/","field":"links","label":"Grever 1995, JCO: pentostatin versus interferon alfa in hairy cell leukaemia"}]},{"url":"https://doi.org/10.1200/JCO.1996.14.3.859","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1996.14.3.859","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"papers","label":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma"}]},{"url":"https://doi.org/10.1200/JCO.1997.15.2.594","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1997.15.2.594","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-igcccg-classification-jco-1997","kind":"paper","name":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","route":"/key-papers/paper-igcccg-classification-jco-1997/","field":"links","label":"J Clin Oncol 1997"}]},{"url":"https://doi.org/10.1200/jco.1997.15.6.2403","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1997.15.6.2403","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clinical-benefit-response","kind":"term","name":"Clinical benefit response (the gemcitabine trial endpoint)","route":"/terms/clinical-benefit-response/","field":"links","label":"Burris, J Clin Oncol 1997: gemcitabine versus fluorouracil in advanced pancreas cancer, the clinical benefit response trial"}]},{"url":"https://doi.org/10.1200/JCO.1997.15.6.2403","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1997.15.6.2403","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-burris-gemcitabine-pancreatic-jco-1997","kind":"paper","name":"Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer","route":"/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1200/JCO.1997.15.7.2636","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1997.15.7.2636","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/","field":"links","label":"J Clin Oncol 1997"}]},{"url":"https://doi.org/10.1200/JCO.1998.16.12.3843","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1998.16.12.3843","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"papers","label":"Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma"}]},{"url":"https://doi.org/10.1200/JCO.1998.16.4.1310","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.1998.16.4.1310","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998","kind":"paper","name":"Intergroup 0099: chemoradiotherapy versus radiotherapy in advanced nasopharyngeal cancer","route":"/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/","field":"links","label":"J Clin Oncol 1998"}]},{"url":"https://doi.org/10.1200/jco.20.00147","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00147","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Progression-free survival (central review))"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Overall survival)"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Objective response rate)"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Duration of response)"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Intervention for CNS disease (cumulative incidence))"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"outcomes.source (Diarrhoea (all grades))"}]},{"url":"https://doi.org/10.1200/JCO.20.00203","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00203","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","field":"outcomes.source (Objective response, all patients given dinutuximab (randomised and expansion))"},{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","field":"outcomes.source (Progression-free survival at 1 year, all dinutuximab patients)"},{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","field":"outcomes.source (Overall survival at 1 year, all dinutuximab patients)"},{"id":"paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020","kind":"paper","name":"ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma","route":"/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00256","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00256","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","field":"papers","label":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults"},{"id":"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020","kind":"paper","name":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","field":"outcomes.source (Disease-free survival at 5 years (nelarabine randomisation))"},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","field":"outcomes.source (Isolated or combined CNS relapse)"},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","field":"outcomes.source (Event-free survival at 5 years, all patients)"},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","field":"outcomes.source (Overall survival at 5 years, all patients)"}]},{"url":"https://doi.org/10.1200/JCO.20.00299","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00299","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-hereditary-breast-cancer-guideline-jco-2020","kind":"paper","name":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","route":"/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00303","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00303","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/","field":"links","label":"Risk-adapted DA-EPOCH-R in adult Burkitt lymphoma, Journal of Clinical Oncology 2020"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"standardOfCare.guideline (Burkitt lymphoma in adults: which intensive regimen, and the pre-phase that prevents tumour lysis)"}]},{"url":"https://doi.org/10.1200/JCO.20.00549","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00549","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.20.00590","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00590","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00590","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00590","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (The failed or stopped programmes)"},{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Van Cutsem et al., HALO 109-301 (JCO 2020)"},{"id":"pegvorhyaluronidase-alfa","kind":"drug","name":"Pegvorhyaluronidase alfa","route":"/drugs/pegvorhyaluronidase-alfa/","field":"links","label":"Van Cutsem et al., HALO 109-301 (JCO 2020)"},{"id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/","field":"links","label":"Van Cutsem et al., HALO 109-301 (JCO 2020)"},{"id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/","field":"outcomes.source (Overall survival)"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Van Cutsem et al., Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine (HALO 109-301, JCO 2020)"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Van Cutsem et al., Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine (HALO 109-301, JCO 2020)"}]},{"url":"https://doi.org/10.1200/jco.20.00611","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00611","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roeland-j-clin-oncol","kind":"paper","name":"Management of Cancer Cachexia: ASCO Guideline","route":"/key-papers/paper-roeland-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00611","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00611","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Roeland et al., management of cancer cachexia, ASCO guideline (JCO 2020)"},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"links","label":"Roeland et al., ASCO guideline on management of cancer cachexia (JCO 2020)"},{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","field":"links","label":"ASCO cachexia guideline 2020"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Roeland et al., management of cancer cachexia, ASCO guideline (JCO 2020)"}]},{"url":"https://doi.org/10.1200/jco.20.00762","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00762","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-salama-j-clin-oncol","kind":"paper","name":"Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","route":"/key-papers/paper-salama-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00762","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00762","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"Salama et al., Journal of Clinical Oncology 2020: dabrafenib and trametinib in BRAF V600 tumours (arm H)"},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"outcomes.source (Objective response, dabrafenib plus trametinib in BRAF V600 tumours (arm H))"}]},{"url":"https://doi.org/10.1200/JCO.20.00775","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00775","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"papers","label":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial"},{"id":"paper-her2climb-brain-lin-jco-2020","kind":"paper","name":"HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib","route":"/key-papers/paper-her2climb-brain-lin-jco-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","field":"links","label":"HER2CLIMB brain metastasis analysis (JCO 2020)"}]},{"url":"https://doi.org/10.1200/JCO.20.00803","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00803","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"links","label":"TROPHIMMUN (JCO 2020)"},{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/","field":"outcomes.source (hCG normalisation, cohort A (resistance to single-agent chemotherapy))"},{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/","field":"outcomes.source (Treatment-related grade 1 to 2 adverse events, cohort A)"},{"id":"paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020","kind":"paper","name":"TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy","route":"/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/jco.20.00818","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00818","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-palma-j-clin-oncol","kind":"paper","name":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","route":"/key-papers/paper-palma-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.00818","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.00818","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","field":"links","label":"Long-term results (JCO 2020)"},{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1200/jco.20.01035","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01035","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","field":"links","label":"J Clin Oncol 2020"},{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"links","label":"Abida et al., Journal of Clinical Oncology 2020 (TRITON2): rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration"}]},{"url":"https://doi.org/10.1200/JCO.20.01035","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01035","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","field":"links","label":"Abida et al., J Clin Oncol 2020: TRITON2, rucaparib in 115 men with BRCA-altered metastatic castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1200/jco.20.01342","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01342","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.01342","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01342","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","field":"links","label":"Ramos et al., Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma (Journal of Clinical Oncology 2020)"}]},{"url":"https://doi.org/10.1200/JCO.20.01364","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01364","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Maintenance after first-line platinum: germline BRCA carriers)"},{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.01399","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01399","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Loprinzi et al., ASCO guideline update on chemotherapy-induced peripheral neuropathy (JCO 2020)"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Loprinzi et al., ASCO guideline update on chemotherapy-induced peripheral neuropathy (JCO 2020)"}]},{"url":"https://doi.org/10.1200/jco.20.01632","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01632","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","field":"papers","label":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia"},{"id":"paper-amer-zeidan-j-clin-oncol-2021","kind":"paper","name":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","route":"/key-papers/paper-amer-zeidan-j-clin-oncol-2021/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.20.01820","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01820","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"papers","label":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial"}]},{"url":"https://doi.org/10.1200/JCO.20.01994","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.01994","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/","field":"links","label":"SWOG S1406: irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Journal of Clinical Oncology 2021)"},{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1200/jco.20.02088","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tabernero-j-clin-oncol","kind":"paper","name":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","route":"/key-papers/paper-tabernero-j-clin-oncol/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.20.02088","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02088","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"links","label":"Journal of Clinical Oncology 2021 (updated survival)"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"outcomes.source (Overall survival (updated analysis))"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"outcomes.source (Confirmed objective response rate)"}]},{"url":"https://doi.org/10.1200/jco.20.02151","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02151","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Tung, J Clin Oncol 2020: TBCRC 048, olaparib for metastatic breast cancer with germline PALB2 or somatic BRCA mutations"},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"links","label":"Tung, J Clin Oncol 2020: TBCRC 048, olaparib for metastatic breast cancer with germline PALB2 or somatic BRCA mutations"}]},{"url":"https://doi.org/10.1200/JCO.20.02232","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02232","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"links","label":"Hecht et al., SEQUOIA (JCO 2021)"},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"outcomes.source (Overall survival)"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Hecht et al., SEQUOIA (JCO 2021)"},{"id":"pegilodecakin","kind":"drug","name":"Pegilodecakin","route":"/drugs/pegilodecakin/","field":"links","label":"Hecht et al., SEQUOIA (JCO 2021)"}]},{"url":"https://doi.org/10.1200/JCO.20.02514","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02514","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","field":"links","label":"monarchE (JCO 2020)"}]},{"url":"https://doi.org/10.1200/jco.20.02672","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02672","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gordan-j-clin-oncol","kind":"paper","name":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","route":"/key-papers/paper-gordan-j-clin-oncol/","field":"links","label":"J Clin Oncol 2020"}]},{"url":"https://doi.org/10.1200/JCO.20.02672","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02672","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"ZGDH3 (J Clin Oncol 2021)"},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","field":"links","label":"J Clin Oncol 2021"},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.20.02730","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02730","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","field":"standardOfCare.guideline (Average risk (≥3 years, M0, <1.5 cm² residual, no MYC amp))"},{"id":"paper-acns0331-michalski-jco-2021","kind":"paper","name":"ACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma","route":"/key-papers/paper-acns0331-michalski-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","field":"links","label":"Michalski et al., JCO 2021"},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","field":"outcomes.source (5-year event-free survival: boost volume)"},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","field":"outcomes.source (5-year event-free survival: CSI dose (age 3-7))"}]},{"url":"https://doi.org/10.1200/jco.20.02759","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02759","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","kind":"paper","name":"TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer","route":"/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"bipolar-androgen-therapy","kind":"term","name":"Bipolar androgen therapy (BAT)","route":"/terms/bipolar-androgen-therapy/","field":"links","label":"Denmeade et al., Journal of Clinical Oncology 2021 (TRANSFORMER): bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1200/JCO.20.03237","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03237","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","field":"links","label":"CSCO/ASCO NPC guideline (JCO 2021)"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","field":"standardOfCare.guideline (Stage I)"},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","field":"links","label":"CSCO/ASCO NPC guideline (JCO 2021)"},{"id":"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021","kind":"paper","name":"CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma","route":"/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"links","label":"CSCO-ASCO NPC guideline 2021"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Staging)"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Stage III to IVA, standard)"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (After chemoradiotherapy)"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Immunotherapy in the curative setting)"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Follow-up)"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"links","label":"CSCO-ASCO NPC guideline 2021"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Resectable local recurrence)"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Unresectable local recurrence)"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Metastatic disease, first line)"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (After platinum and PD-1 therapy)"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"standardOfCare.guideline (Oligometastatic disease)"}]},{"url":"https://doi.org/10.1200/jco.20.03282","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03282","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-murthy-j-clin-oncol","kind":"paper","name":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","route":"/key-papers/paper-murthy-j-clin-oncol/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.20.03282","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03282","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","field":"links","label":"JCO 2021"}]},{"url":"https://doi.org/10.1200/jco.20.03296","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03296","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"papers","label":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium"}]},{"url":"https://doi.org/10.1200/JCO.20.03296","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03296","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","field":"links","label":"IGCCCG Update (JCO 2021)"},{"id":"paper-igcccg-update-gillessen-jco-2021","kind":"paper","name":"IGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours","route":"/key-papers/paper-igcccg-update-gillessen-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"germ-cell-tumour-markers","kind":"technology","name":"AFP, hCG and LDH in germ cell tumours (IGCCCG risk groups)","route":"/technologies/germ-cell-tumour-markers/","field":"links","label":"Journal of Clinical Oncology 2021: Predicting outcomes in men with metastatic nonseminomatous germ cell tumors, the IGCCCG update consortium"}]},{"url":"https://doi.org/10.1200/JCO.20.03329","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03329","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/","field":"links","label":"Dahan et al., PANOPTIMOX-PRODIGE 35 (JCO 2021)"},{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/","field":"outcomes.source (Progression-free survival at 6 months)"},{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.20.03380","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03380","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bmt-ctn-1102","kind":"trial","name":"BMT CTN 1102","route":"/trials/bmt-ctn-1102/","field":"outcomes.source (Overall survival at 3 years (intention to treat, adjusted))"},{"id":"bmt-ctn-1102","kind":"trial","name":"BMT CTN 1102","route":"/trials/bmt-ctn-1102/","field":"outcomes.source (Leukaemia-free survival at 3 years)"},{"id":"paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021","kind":"paper","name":"BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome","route":"/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/jco.20.03399","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03399","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","field":"papers","label":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline"}]},{"url":"https://doi.org/10.1200/JCO.20.03399","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03399","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/jco.20.03613","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03613","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/","field":"links","label":"Tolaney, J Clin Oncol 2021: STEEP version 2.0"}]},{"url":"https://doi.org/10.1200/jco.20.03639","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03639","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-penelope-b-j-clin-oncol-2021","kind":"paper","name":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","route":"/key-papers/paper-penelope-b-j-clin-oncol-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"penelope-b","kind":"trial","name":"PENELOPE-B","route":"/trials/penelope-b/","field":"outcomes.source (Invasive disease-free survival)"}]},{"url":"https://doi.org/10.1200/jco.2002.07.062","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2002.07.062","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"Bokemeyer 2002, JCO: extragonadal germ cell tumours of the mediastinum and retroperitoneum, 635 patients"},{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"links","label":"Bokemeyer 2002, JCO: extragonadal germ cell tumours of the mediastinum and retroperitoneum, 635 patients"}]},{"url":"https://doi.org/10.1200/JCO.2002.11.050","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2002.11.050","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002","kind":"paper","name":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial","route":"/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/","field":"links","label":"J Clin Oncol 2002"}]},{"url":"https://doi.org/10.1200/jco.2003.04.187","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.04.187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cytoreductive-surgery","kind":"term","name":"Cytoreductive surgery","route":"/terms/cytoreductive-surgery/","field":"links","label":"Verwaal, J Clin Oncol 2003: randomised trial of cytoreduction with hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery (105 patients)"},{"id":"peritoneal-carcinomatosis-index","kind":"term","name":"Peritoneal cancer index","route":"/terms/peritoneal-carcinomatosis-index/","field":"links","label":"Verwaal, J Clin Oncol 2003: randomised trial of cytoreduction with hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery (105 patients)"}]},{"url":"https://doi.org/10.1200/JCO.2003.04.187","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.04.187","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003","kind":"paper","name":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","route":"/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/","field":"links","label":"J Clin Oncol 2003"},{"id":"netherlands-hipec","kind":"trial","name":"Netherlands Cancer Institute HIPEC trial","route":"/trials/netherlands-hipec/","field":"links","label":"Verwaal: randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in peritoneal carcinomatosis of colorectal cancer (Journal of Clinical Oncology 2003)"},{"id":"netherlands-hipec","kind":"trial","name":"Netherlands Cancer Institute HIPEC trial","route":"/trials/netherlands-hipec/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.2003.04.190","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.04.190","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","field":"papers","label":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour"},{"id":"paper-heinrich-kit-mutation-imatinib-response-jco-2003","kind":"paper","name":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","route":"/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/","field":"links","label":"J Clin Oncol 2003"}]},{"url":"https://doi.org/10.1200/JCO.2003.06.006","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.06.006","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"papers","label":"Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer"}]},{"url":"https://doi.org/10.1200/jco.2003.09.081","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.09.081","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-citron-j-clin-oncol","kind":"paper","name":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741","route":"/key-papers/paper-citron-j-clin-oncol/","field":"links","label":"J Clin Oncol 2003"}]},{"url":"https://doi.org/10.1200/JCO.2003.09.081","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.09.081","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"norton-simon-hypothesis","kind":"technology","name":"Norton-Simon hypothesis and dose-dense chemotherapy","route":"/technologies/norton-simon-hypothesis/","field":"links","label":"CALGB 9741, Citron 2003"}]},{"url":"https://doi.org/10.1200/JCO.2003.11.136","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2003.11.136","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vogelzang-pemetrexed-mesothelioma-jco-2003","kind":"paper","name":"Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","route":"/key-papers/paper-vogelzang-pemetrexed-mesothelioma-jco-2003/","field":"links","label":"J Clin Oncol 2003"}]},{"url":"https://doi.org/10.1200/jco.2004.04.188","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2004.04.188","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Rebbeck, J Clin Oncol 2004: bilateral prophylactic mastectomy in BRCA1 and BRCA2 carriers (PROSE)"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"Rebbeck, J Clin Oncol 2004: bilateral prophylactic mastectomy in BRCA1 and BRCA2 carriers (PROSE)"}]},{"url":"https://doi.org/10.1200/JCO.2004.07.188","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2004.07.188","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","field":"papers","label":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals"},{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","field":"links","label":"J Clin Oncol 2004"}]},{"url":"https://doi.org/10.1200/jco.2004.10.907","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2004.10.907","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"papers","label":"Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?"}]},{"url":"https://doi.org/10.1200/jco.2005.01.5180","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2005.01.5180","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"papers","label":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast"}]},{"url":"https://doi.org/10.1200/JCO.2005.02.7888","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2005.02.7888","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"papers","label":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer"}]},{"url":"https://doi.org/10.1200/jco.2005.02.857","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2005.02.857","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-j-clin-oncol-2005","kind":"paper","name":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","route":"/key-papers/paper-kras-nsclc-j-clin-oncol-2005/","field":"links","label":"J Clin Oncol 2005"}]},{"url":"https://doi.org/10.1200/JCO.2005.04.5252","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2005.04.5252","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"papers","label":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer"}]},{"url":"https://doi.org/10.1200/JCO.2005.05.3025","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2005.05.3025","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-laurie-licitra-salivary-systemic-jco-2006","kind":"paper","name":"Systemic therapy in the palliative management of advanced salivary gland cancers (review)","route":"/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/","field":"links","label":"J Clin Oncol 2006"}]},{"url":"https://doi.org/10.1200/JCO.2006.06.2497","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2006.06.2497","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Keating et al., diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer (JCO 2006)"}]},{"url":"https://doi.org/10.1200/JCO.2006.06.2984","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2006.06.2984","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-curtin-kit-melanoma-jco-2006","kind":"paper","name":"Somatic activation of KIT in distinct subtypes of melanoma","route":"/key-papers/paper-curtin-kit-melanoma-jco-2006/","field":"links","label":"J Clin Oncol 2006"}]},{"url":"https://doi.org/10.1200/jco.2006.10.3523","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2006.10.3523","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/","field":"links","label":"Hudis, J Clin Oncol 2007: standardised definitions for efficacy end points in adjuvant breast cancer trials (STEEP)"}]},{"url":"https://doi.org/10.1200/JCO.2006.10.3523","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2006.10.3523","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"papers","label":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system"}]},{"url":"https://doi.org/10.1200/jco.2007.10.6823","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.10.6823","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-symmans-j-clin-oncol","kind":"paper","name":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","route":"/key-papers/paper-symmans-j-clin-oncol/","field":"links","label":"J Clin Oncol 2007"}]},{"url":"https://doi.org/10.1200/JCO.2007.10.6823","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.10.6823","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","field":"links","label":"Residual cancer burden index (Symmans et al., J Clin Oncol 2007)"}]},{"url":"https://doi.org/10.1200/JCO.2007.11.3324","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.11.3324","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"papers","label":"Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks"}]},{"url":"https://doi.org/10.1200/JCO.2007.11.9958","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.11.9958","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (Adult T-cell leukaemia/lymphoma (HTLV-1))"}]},{"url":"https://doi.org/10.1200/jco.2007.12.4487","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.12.4487","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"links","label":"Scher et al., Journal of Clinical Oncology 2008 (PCWG2): design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone"},{"id":"radiographic-progression-free-survival","kind":"term","name":"Radiographic progression-free survival (rPFS)","route":"/terms/radiographic-progression-free-survival/","field":"links","label":"Scher et al., Journal of Clinical Oncology 2008 (PCWG2): design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone"}]},{"url":"https://doi.org/10.1200/jco.2007.12.7027","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.12.7027","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Nagtegaal and Quirke, J Clin Oncol 2008: what is the role for the circumferential margin in the modern treatment of rectal cancer? (more than 17,500 patients)"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"Nagtegaal and Quirke, J Clin Oncol 2008: what is the role for the circumferential margin in the modern treatment of rectal cancer? (more than 17,500 patients)"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Nagtegaal and Quirke, J Clin Oncol 2008: what is the role for the circumferential margin in the modern treatment of rectal cancer? (more than 17,500 patients)"}]},{"url":"https://doi.org/10.1200/jco.2007.12.9098","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.12.9098","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hillmen-j-clin-oncol","kind":"paper","name":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","route":"/key-papers/paper-hillmen-j-clin-oncol/","field":"links","label":"J Clin Oncol 2007"}]},{"url":"https://doi.org/10.1200/JCO.2007.12.9098","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.12.9098","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","field":"links","label":"CAM307 (JCO 2007)"}]},{"url":"https://doi.org/10.1200/JCO.2007.13.4403","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.13.4403","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"papers","label":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT"}]},{"url":"https://doi.org/10.1200/JCO.2007.13.4452","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.13.4452","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"papers","label":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033"}]},{"url":"https://doi.org/10.1200/JCO.2007.13.8925","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.13.8925","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"papers","label":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study"}]},{"url":"https://doi.org/10.1200/JCO.2007.13.9030","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.13.9030","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008","kind":"paper","name":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","route":"/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/","field":"links","label":"J Clin Oncol 2008"},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/","field":"links","label":"LACE pooled analysis (Journal of Clinical Oncology 2008)"},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/","field":"outcomes.source (Overall survival, all stages)"},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/","field":"outcomes.source (Overall survival, stage IA)"},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/","field":"outcomes.source (Overall survival, stage II)"}]},{"url":"https://doi.org/10.1200/JCO.2007.14.0566","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.14.0566","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008","kind":"paper","name":"GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer","route":"/key-papers/paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/jco.2007.14.4147","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.14.4147","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Liedtke, J Clin Oncol 2008: response to neoadjuvant therapy and long-term survival in triple-negative breast cancer"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","field":"links","label":"Liedtke, J Clin Oncol 2008: response to neoadjuvant therapy and long-term survival in triple-negative breast cancer"}]},{"url":"https://doi.org/10.1200/JCO.2007.14.4147","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.14.4147","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008","kind":"paper","name":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","route":"/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/jco.2007.14.7116","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.14.7116","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2008","kind":"paper","name":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/JCO.2007.14.9021","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.14.9021","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/","field":"links","label":"RTOG 92-02 at 10 years (Journal of Clinical Oncology 2008)"},{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/","field":"outcomes.source (Overall survival at 10 years, all patients)"},{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/","field":"outcomes.source (Overall survival at 10 years, Gleason 8 to 10)"},{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/","field":"outcomes.source (Distant metastasis at 10 years)"}]},{"url":"https://doi.org/10.1200/JCO.2007.15.0235","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.15.0235","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","field":"papers","label":"Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27"}]},{"url":"https://doi.org/10.1200/JCO.2007.15.0375","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.15.0375","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","kind":"paper","name":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","route":"/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/jco.2007.15.9749","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.15.9749","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-attard-abiraterone-phase-1-cyp17-jco-2008","kind":"paper","name":"Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven","route":"/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/JCO.2008.16.3691","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.3691","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"papers","label":"American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment"}]},{"url":"https://doi.org/10.1200/jco.2008.16.6231","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.6231","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Atchley, J Clin Oncol 2008: clinical and pathological characteristics of BRCA-positive and BRCA-negative breast cancer"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Atchley, J Clin Oncol 2008: clinical and pathological characteristics of BRCA-positive and BRCA-negative breast cancer"},{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"links","label":"Atchley, J Clin Oncol 2008: clinical and pathological characteristics of BRCA-positive and BRCA-negative breast cancer"}]},{"url":"https://doi.org/10.1200/JCO.2008.16.6231","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.6231","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atchley-brca-status-triple-negative-jco-2008","kind":"paper","name":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","route":"/key-papers/paper-atchley-brca-status-triple-negative-jco-2008/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/jco.2008.16.6389","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.6389","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-elkins-j-clin-oncol","kind":"paper","name":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","route":"/key-papers/paper-elkins-j-clin-oncol/","field":"links","label":"J Clin Oncol 2008"}]},{"url":"https://doi.org/10.1200/JCO.2008.16.6389","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.6389","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","field":"links","label":"Hypnosis for hot flashes among breast cancer survivors, randomised trial (JCO 2008)"}]},{"url":"https://doi.org/10.1200/JCO.2008.16.6785","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.16.6785","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"papers","label":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report"},{"id":"paper-inrg-cohn-jco-2009","kind":"paper","name":"The International Neuroblastoma Risk Group (INRG) classification system","route":"/key-papers/paper-inrg-cohn-jco-2009/","field":"links","label":"J Clin Oncol 2009"},{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/","field":"links","label":"INRG classification (Cohn et al. 2009)"}]},{"url":"https://doi.org/10.1200/JCO.2008.17.3146","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.17.3146","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","kind":"paper","name":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","route":"/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/","field":"links","label":"J Clin Oncol 2008"},{"id":"angiotax","kind":"trial","name":"ANGIOTAX","route":"/trials/angiotax/","field":"links","label":"Journal of Clinical Oncology 2008"}]},{"url":"https://doi.org/10.1200/JCO.2008.17.7188","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.17.7188","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009","kind":"paper","name":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","route":"/key-papers/paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009/","field":"links","label":"Iacobuzio-Donahue et al., J Clin Oncol 2009: DPC4 (SMAD4) status and pattern of failure in 76 rapid autopsies"}]},{"url":"https://doi.org/10.1200/JCO.2008.18.0802","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.18.0802","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","field":"papers","label":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control"},{"id":"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009","kind":"paper","name":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","route":"/key-papers/paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009/","field":"links","label":"J Clin Oncol 2009"}]},{"url":"https://doi.org/10.1200/jco.2008.18.1370","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.18.1370","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-parker-j-clin-oncol","kind":"paper","name":"Supervised risk predictor of breast cancer based on intrinsic subtypes","route":"/key-papers/paper-parker-j-clin-oncol/","field":"links","label":"J Clin Oncol 2009"}]},{"url":"https://doi.org/10.1200/JCO.2008.18.1370","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.18.1370","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","field":"links","label":"PAM50 intrinsic-subtype predictor (Parker et al., J Clin Oncol 2009)"},{"id":"logistic-regression-term","kind":"term","name":"Logistic regression and nearest-centroid classifiers","route":"/terms/logistic-regression-term/","field":"links","label":"Parker et al., Supervised risk predictor of breast cancer based on intrinsic subtypes (JCO 2009)"}]},{"url":"https://doi.org/10.1200/JCO.2008.19.0694","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.19.0694","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"papers","label":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study"}]},{"url":"https://doi.org/10.1200/jco.2008.19.6873","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.19.6873","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Huo, J Clin Oncol 2009: over-representation of triple-negative breast cancer in indigenous West African women"}]},{"url":"https://doi.org/10.1200/JCO.2008.19.7145","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.19.7145","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009","kind":"paper","name":"Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","route":"/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/","field":"links","label":"J Clin Oncol 2009"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"links","label":"CAPOX phase 2 in small bowel adenocarcinoma (JCO 2009)"}]},{"url":"https://doi.org/10.1200/JCO.2008.20.6771","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.20.6771","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","field":"links","label":"MOSAIC six-year overall survival (Journal of Clinical Oncology 2009)"},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","field":"outcomes.source (Overall survival at 6 years (stage III))"}]},{"url":"https://doi.org/10.1200/JCO.2008.21.2514","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.21.2514","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009","kind":"paper","name":"AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children","route":"/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/","field":"links","label":"J Clin Oncol 2009"}]},{"url":"https://doi.org/10.1200/jco.2008.21.4809","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.21.4809","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heng-j-clin-oncol","kind":"paper","name":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","route":"/key-papers/paper-heng-j-clin-oncol/","field":"links","label":"J Clin Oncol 2009"}]},{"url":"https://doi.org/10.1200/JCO.2008.21.4809","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.21.4809","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","field":"links","label":"IMDC (Heng) prognostic model for metastatic RCC (Heng et al., J Clin Oncol 2009)"}]},{"url":"https://doi.org/10.1200/JCO.2008.21.6663","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2008.21.6663","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"petacc-3","kind":"trial","name":"PETACC-3","route":"/trials/petacc-3/","field":"links","label":"PETACC-3: irinotecan added to adjuvant fluorouracil and leucovorin in stage III colon cancer (Journal of Clinical Oncology 2009)"},{"id":"petacc-3","kind":"trial","name":"PETACC-3","route":"/trials/petacc-3/","field":"outcomes.source (Disease-free survival at 5 years (stage III))"}]},{"url":"https://doi.org/10.1200/JCO.2009.21.9618","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.21.9618","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"papers","label":"Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099"}]},{"url":"https://doi.org/10.1200/JCO.2009.22.8510","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.22.8510","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","field":"outcomes.source (Time to tumour progression)"},{"id":"paper-promid-rinke-jco-2009","kind":"paper","name":"PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours","route":"/key-papers/paper-promid-rinke-jco-2009/","field":"links","label":"J Clin Oncol 2009"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"links","label":"PROMID (JCO 2009)"}]},{"url":"https://doi.org/10.1200/jco.2009.23.3452","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.23.3452","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2010","kind":"paper","name":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2010/","field":"links","label":"J Clin Oncol 2010"}]},{"url":"https://doi.org/10.1200/jco.2009.23.5051","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.23.5051","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","field":"links","label":"Rakha 2010, JCO: tubular carcinoma of the breast, further evidence for its excellent prognosis"}]},{"url":"https://doi.org/10.1200/jco.2009.23.8329","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.23.8329","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-azacitidine-aml-j-clin-oncol-2010","kind":"paper","name":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","route":"/key-papers/paper-azacitidine-aml-j-clin-oncol-2010/","field":"links","label":"J Clin Oncol 2010"}]},{"url":"https://doi.org/10.1200/JCO.2009.23.9640","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.23.9640","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009","kind":"paper","name":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry","route":"/key-papers/paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009/","field":"links","label":"J Clin Oncol 2009"}]},{"url":"https://doi.org/10.1200/JCO.2009.25.2981","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.25.2981","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","field":"papers","label":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours"},{"id":"paper-wagner-sirolimus-pecoma-jco-2010","kind":"paper","name":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/","field":"links","label":"J Clin Oncol 2010"}]},{"url":"https://doi.org/10.1200/JCO.2009.25.6529","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.25.6529","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-cap-er-pr-testing-guideline-jco-2010","kind":"paper","name":"American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","route":"/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/","field":"links","label":"J Clin Oncol 2010"}]},{"url":"https://doi.org/10.1200/JCO.2009.25.7899","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.25.7899","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","field":"papers","label":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)"},{"id":"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010","kind":"paper","name":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","route":"/key-papers/paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010/","field":"links","label":"J Clin Oncol 2010"}]},{"url":"https://doi.org/10.1200/JCO.2009.25.9655","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.25.9655","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"papers","label":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients"}]},{"url":"https://doi.org/10.1200/JCO.2009.25.9820","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.25.9820","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"papers","label":"Metastatic behavior of breast cancer subtypes"}]},{"url":"https://doi.org/10.1200/jco.2009.26.6791","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.26.6791","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"links","label":"Meinhardt 2010, JCO: rituximab window study in paediatric mature B-cell lymphoma and Burkitt leukaemia"}]},{"url":"https://doi.org/10.1200/JCO.2009.27.5644","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.27.5644","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/JCO.2009.27.7665","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.27.7665","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"standardOfCare.guideline (Mycosis fungoides: staging first, because stage decides everything)"}]},{"url":"https://doi.org/10.1200/JCO.2010.29.5477","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.29.5477","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010","kind":"paper","name":"Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases","route":"/key-papers/paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010/","field":"links","label":"J Clin Oncol 2010"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"links","label":"Neoadjuvant TIP phase 2 (JCO 2010)"}]},{"url":"https://doi.org/10.1200/JCO.2010.30.4386","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.30.4386","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011","kind":"paper","name":"GOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia","route":"/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/","field":"links","label":"J Clin Oncol 2011"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"links","label":"GOG 174 (JCO 2011)"}]},{"url":"https://doi.org/10.1200/JCO.2010.32.2750","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.32.2750","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Wyse et al., randomised double-blind trial of early EUS-guided coeliac plexus neurolysis to prevent pain progression in pancreatic cancer (JCO 2011)"},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","field":"links","label":"Wyse et al., randomised double-blind trial of early EUS-guided coeliac plexus neurolysis to prevent pain progression in pancreatic cancer (JCO 2011)"},{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Wyse et al., early EUS-guided coeliac plexus neurolysis, randomised (JCO 2011)"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"Wyse et al., randomised double-blind trial of early EUS-guided coeliac plexus neurolysis to prevent pain progression in pancreatic cancer (JCO 2011)"}]},{"url":"https://doi.org/10.1200/jco.2010.32.7270","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.32.7270","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-j-clin-oncol-2011","kind":"paper","name":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","route":"/key-papers/paper-blinatumomab-all-leukemia-j-clin-oncol-2011/","field":"links","label":"J Clin Oncol 2011"}]},{"url":"https://doi.org/10.1200/JCO.2010.33.0738","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.33.0738","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","field":"papers","label":"Single-injection depot progesterone before surgery and survival in operable breast cancer"},{"id":"progesterone-preop-tmh","kind":"trial","name":"Single-injection depot progesterone before breast surgery (Tata Memorial)","route":"/trials/progesterone-preop-tmh/","field":"links","label":"Badwe et al., JCO 2011"},{"id":"progesterone-preop-tmh","kind":"trial","name":"Single-injection depot progesterone before breast surgery (Tata Memorial)","route":"/trials/progesterone-preop-tmh/","field":"outcomes.source (5-year disease-free survival, node-positive subgroup)"},{"id":"paper-badwe-progesterone-jco-2011","kind":"paper","name":"Single-injection depot progesterone before surgery and survival in operable breast cancer","route":"/key-papers/paper-badwe-progesterone-jco-2011/","field":"links","label":"JCO 2011"}]},{"url":"https://doi.org/10.1200/jco.2010.33.5091","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.33.5091","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2011","kind":"paper","name":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2011/","field":"links","label":"J Clin Oncol 2011"}]},{"url":"https://doi.org/10.1200/JCO.2010.33.8020","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.33.8020","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011","kind":"paper","name":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","route":"/key-papers/paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011/","field":"links","label":"J Clin Oncol 2011"}]},{"url":"https://doi.org/10.1200/JCO.2010.33.8038","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2010.33.8038","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-crane-smad4-progression-pattern-locally-advanced-jco-2011","kind":"paper","name":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression","route":"/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/","field":"links","label":"Crane et al., J Clin Oncol 2011: Smad4 immunostaining and progression pattern in 69 locally advanced patients"}]},{"url":"https://doi.org/10.1200/jco.2011.35.0660","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.35.0660","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"papers","label":"Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer"}]},{"url":"https://doi.org/10.1200/JCO.2011.35.5040","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.35.5040","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","field":"papers","label":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer"},{"id":"paper-zeta-vandetanib-mtc-wells-jco-2012","kind":"paper","name":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","route":"/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/","field":"links","label":"J Clin Oncol 2012"},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","field":"outcomes.source (Progression-free survival (independent central RECIST))"},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","field":"outcomes.source (Overall survival (immature at data cutoff))"},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","field":"outcomes.source (Diarrhoea (any grade))"}]},{"url":"https://doi.org/10.1200/JCO.2011.35.6287","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.35.6287","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (Extranodal NK/T-cell lymphoma, nasal type: asparaginase, and why anthracyclines do not work)"}]},{"url":"https://doi.org/10.1200/JCO.2011.35.6345","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.35.6345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","field":"prevalence.source"},{"id":"paper-bergethon-ros1-rearrangements-lung-jco-2012","kind":"paper","name":"ROS1 rearrangements define a unique molecular class of lung cancers","route":"/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/","field":"links","label":"Bergethon et al., J Clin Oncol 2012: ROS1 rearrangements define a unique molecular class of lung cancers (1,073 screened)"}]},{"url":"https://doi.org/10.1200/jco.2011.37.3647","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.37.3647","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"links","label":"Federico 2013, JCO: angioimmunoblastic T-cell lymphoma in the International Peripheral T-cell Lymphoma Project"}]},{"url":"https://doi.org/10.1200/JCO.2011.37.9990","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.37.9990","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-p9641-low-risk-neuroblastoma-strother-jco-2012","kind":"paper","name":"COG P9641: surgery alone or with restricted chemotherapy for low-risk neuroblastoma","route":"/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/","field":"links","label":"J Clin Oncol 2012"}]},{"url":"https://doi.org/10.1200/JCO.2011.39.2779","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.39.2779","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","field":"outcomes.source (Recurrence-free survival, pathological complete response versus no pCR (172 patients treated without trastuzumab))"},{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","field":"outcomes.source (Pathological complete response by receptor subset (190 patients treated without trastuzumab))"}]},{"url":"https://doi.org/10.1200/JCO.2011.39.4767","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.39.4767","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","field":"links","label":"CALGB 90401 (Journal of Clinical Oncology 2012)"},{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","field":"outcomes.source (Overall survival (median))"},{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","field":"outcomes.source (Progression-free survival (median))"},{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","field":"outcomes.source (Treatment-related deaths)"}]},{"url":"https://doi.org/10.1200/jco.2011.39.7166","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.39.7166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chua-j-clin-oncol","kind":"paper","name":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","route":"/key-papers/paper-chua-j-clin-oncol/","field":"links","label":"J Clin Oncol 2012"}]},{"url":"https://doi.org/10.1200/JCO.2011.39.7166","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.39.7166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"links","label":"PMP registry (JCO 2012)"}]},{"url":"https://doi.org/10.1200/JCO.2011.40.1836","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.40.1836","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","field":"links","label":"CAO/ARO/AIO-94 at eleven years (Journal of Clinical Oncology 2012)"}]},{"url":"https://doi.org/10.1200/JCO.2011.41.5703","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2011.41.5703","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aews0031","kind":"trial","name":"AEWS0031","route":"/trials/aews0031/","field":"outcomes.source (Event-free survival at 5 years)"},{"id":"paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012","kind":"paper","name":"AEWS0031: randomised trial of interval-compressed chemotherapy for localised Ewing sarcoma","route":"/key-papers/paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012/","field":"links","label":"J Clin Oncol 2012"}]},{"url":"https://doi.org/10.1200/JCO.2012.42.8201","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.42.8201","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","field":"links","label":"VELOUR: aflibercept added to FOLFIRI after an oxaliplatin-based regimen (Journal of Clinical Oncology 2012)"},{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.2012.43.1882","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.43.1882","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-castro-germline-brca-prostate-outcomes-jco-2013","kind":"paper","name":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer","route":"/key-papers/paper-castro-germline-brca-prostate-outcomes-jco-2013/","field":"links","label":"Castro et al., J Clin Oncol 2013: germline BRCA1 and BRCA2 mutations and outcome in 2,019 men with prostate cancer"}]},{"url":"https://doi.org/10.1200/JCO.2012.43.2229","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.43.2229","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/","field":"links","label":"J Clin Oncol 2013"},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/","field":"links","label":"JCO 2013"},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/","field":"outcomes.source (Overall survival)"},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/","field":"outcomes.source (Overall survival, 1p/19q co-deleted (80 patients))"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"links","label":"EORTC 26951 long-term results (JCO 2013)"}]},{"url":"https://doi.org/10.1200/JCO.2012.43.2674","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.43.2674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-9402-cairncross-jco-2013","kind":"paper","name":"RTOG 9402: PCV chemotherapy before radiotherapy for anaplastic oligodendroglioma, long-term results","route":"/key-papers/paper-rtog-9402-cairncross-jco-2013/","field":"links","label":"J Clin Oncol 2013"},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","field":"links","label":"JCO 2013"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"links","label":"RTOG 9402 long-term results (JCO 2013)"}]},{"url":"https://doi.org/10.1200/JCO.2012.43.3680","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.43.3680","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/","field":"links","label":"Ueno et al., GEST: S-1 non-inferior to gemcitabine in advanced disease (JCO 2013)"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","field":"links","label":"Ueno et al., GEST (JCO 2013)"}]},{"url":"https://doi.org/10.1200/JCO.2012.43.6097","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.43.6097","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-91-11-long-term-forastiere-jco-2013","kind":"paper","name":"Long-term results of RTOG 91-11: three non-surgical strategies to preserve the larynx","route":"/key-papers/paper-rtog-91-11-long-term-forastiere-jco-2013/","field":"links","label":"J Clin Oncol 2013"}]},{"url":"https://doi.org/10.1200/JCO.2012.44.2806","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.44.2806","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/","field":"links","label":"LUX-Lung 3 (Journal of Clinical Oncology 2013)"},{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/","field":"outcomes.source (Progression-free survival (independent review))"},{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/","field":"outcomes.source (Progression-free survival, exon 19 deletion or L858R)"}]},{"url":"https://doi.org/10.1200/jco.2012.45.2615","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.45.2615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hughes-j-clin-oncol","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","route":"/key-papers/paper-hughes-j-clin-oncol/","field":"links","label":"J Clin Oncol 2013"}]},{"url":"https://doi.org/10.1200/JCO.2012.45.2615","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.45.2615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","field":"links","label":"JCO 2013 update"}]},{"url":"https://doi.org/10.1200/JCO.2012.47.7836","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.47.7836","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hodi-imatinib-kit-melanoma-jco-2013","kind":"paper","name":"Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin","route":"/key-papers/paper-hodi-imatinib-kit-melanoma-jco-2013/","field":"links","label":"J Clin Oncol 2013"}]},{"url":"https://doi.org/10.1200/jco.2012.47.8313","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.47.8313","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Phillips, J Clin Oncol 2013: tamoxifen and contralateral breast cancer risk in BRCA1 and BRCA2 carriers"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Phillips, J Clin Oncol 2013: tamoxifen and contralateral breast cancer risk in BRCA1 and BRCA2 carriers"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"Phillips, J Clin Oncol 2013: tamoxifen and contralateral breast cancer risk in BRCA1 and BRCA2 carriers"}]},{"url":"https://doi.org/10.1200/JCO.2012.48.4659","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.48.4659","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","field":"papers","label":"EXAM: cabozantinib in progressive medullary thyroid cancer"},{"id":"paper-exam-cabozantinib-mtc-elisei-jco-2013","kind":"paper","name":"EXAM: cabozantinib in progressive medullary thyroid cancer","route":"/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/","field":"links","label":"J Clin Oncol 2013"},{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","field":"outcomes.source (Progression-free survival)"},{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","field":"outcomes.source (Objective response rate)"},{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","field":"outcomes.source (Alive and progression-free at 1 year)"}]},{"url":"https://doi.org/10.1200/JCO.2012.48.5052","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.48.5052","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhukova-tp53-medulloblastoma-jco-2013","kind":"paper","name":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","route":"/key-papers/paper-zhukova-tp53-medulloblastoma-jco-2013/","field":"links","label":"J Clin Oncol 2013"}]},{"url":"https://doi.org/10.1200/jco.2012.48.5326","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2012.48.5326","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"links","label":"Karia et al., Journal of Clinical Oncology 2014;32:327 to 334: evaluation of AJCC, UICC and Brigham and Women's Hospital tumour staging for cutaneous squamous cell carcinoma (1,818 primary tumours, 2000 to 2009)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Karia et al., Journal of Clinical Oncology 2014;32:327 to 334: evaluation of AJCC, UICC and Brigham and Women's Hospital tumour staging for cutaneous squamous cell carcinoma (1,818 primary tumours, 2000 to 2009)"}]},{"url":"https://doi.org/10.1200/jco.2013.50.0322","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.50.0322","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-j-clin-oncol-2013","kind":"paper","name":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-j-clin-oncol-2013/","field":"links","label":"J Clin Oncol 2013"}]},{"url":"https://doi.org/10.1200/JCO.2013.51.4489","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.51.4489","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"outcomes.source (Progression-free survival)"},{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"outcomes.source (Objective response rate (RECIST))"},{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"outcomes.source (Overall survival)"},{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"outcomes.source (Gastrointestinal perforation)"},{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/","field":"links","label":"J Clin Oncol 2014"}]},{"url":"https://doi.org/10.1200/JCO.2013.51.8480","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.51.8480","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"metrics (US oncologists reporting at least one symptom of burnout (2013 survey))"}]},{"url":"https://doi.org/10.1200/jco.2013.52.5386","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.52.5386","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kuhl-j-clin-oncol","kind":"paper","name":"Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI","route":"/key-papers/paper-kuhl-j-clin-oncol/","field":"links","label":"J Clin Oncol 2014"}]},{"url":"https://doi.org/10.1200/JCO.2013.52.5386","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.52.5386","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-mri-coils-abbreviated-mri","kind":"technology","name":"Breast MRI coils and abbreviated breast MRI","route":"/technologies/breast-mri-coils-abbreviated-mri/","field":"links","label":"Kuhl et al., Abbreviated breast MRI for supplemental screening (JCO 2014)"}]},{"url":"https://doi.org/10.1200/JCO.2013.53.6995","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.53.6995","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","field":"links","label":"Oettle et al., CONKO-003 (JCO 2014)"},{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/","field":"links","label":"Oettle et al., CONKO-003 (JCO 2014)"},{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/jco.2013.54.8800","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.54.8800","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cheson-j-clin-oncol","kind":"paper","name":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","route":"/key-papers/paper-cheson-j-clin-oncol/","field":"links","label":"J Clin Oncol 2014"}]},{"url":"https://doi.org/10.1200/JCO.2013.54.8800","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2013.54.8800","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","field":"links","label":"Cheson et al., Lugano classification: recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma (Journal of Clinical Oncology 2014)"},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/","field":"links","label":"Cheson et al., Lugano classification: recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma (Journal of Clinical Oncology 2014)"}]},{"url":"https://doi.org/10.1200/JCO.2014.55.1192","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.55.1192","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-klotz-active-surveillance-jco-2015","kind":"paper","name":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)","route":"/key-papers/paper-klotz-active-surveillance-jco-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.55.1978","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.55.1978","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rueth-inflammatory-breast-trimodality-jco-2014","kind":"paper","name":"Underuse of trimodality treatment and survival in inflammatory breast cancer (National Cancer Data Base)","route":"/key-papers/paper-rueth-inflammatory-breast-trimodality-jco-2014/","field":"links","label":"J Clin Oncol 2014"}]},{"url":"https://doi.org/10.1200/JCO.2014.55.3628","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.55.3628","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aaml0531-gemtuzumab-gamis-jco-2014","kind":"paper","name":"AAML0531: gemtuzumab ozogamicin added to chemotherapy for children and adolescents with acute myeloid leukaemia","route":"/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/","field":"links","label":"J Clin Oncol 2014"},{"id":"aaml0531","kind":"trial","name":"COG AAML0531","route":"/trials/aaml0531/","field":"links","label":"Gamis et al., JCO 2014"},{"id":"aaml0531","kind":"trial","name":"COG AAML0531","route":"/trials/aaml0531/","field":"outcomes.source (3-year event-free survival)"}]},{"url":"https://doi.org/10.1200/jco.2014.56.3247","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.56.3247","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/","field":"links","label":"J Clin Oncol 2014"}]},{"url":"https://doi.org/10.1200/JCO.2014.57.0572","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.0572","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015","kind":"paper","name":"Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","route":"/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/","field":"links","label":"J Clin Oncol 2015"},{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/","field":"links","label":"Sikov et al., JCO 2015: primary pCR results"}]},{"url":"https://doi.org/10.1200/jco.2014.57.1414","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.1414","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Couch, J Clin Oncol 2015: inherited mutations in 17 genes among 1,824 triple-negative breast cancers unselected for family history"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Couch, J Clin Oncol 2015: inherited mutations in 17 genes among 1,824 triple-negative breast cancers unselected for family history"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"Couch, J Clin Oncol 2015: inherited mutations in 17 genes among 1,824 triple-negative breast cancers unselected for family history"}]},{"url":"https://doi.org/10.1200/JCO.2014.57.1414","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.1414","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-couch-tnbc-germline-17-genes-jco-2015","kind":"paper","name":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","route":"/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/","field":"links","label":"Couch et al., J Clin Oncol 2015: germline mutations in 17 genes among 1,824 unselected TNBC patients"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/JCO.2014.57.7510","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.7510","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/","field":"links","label":"NCIC CTG PR.3 / MRC PR07 final report (Journal of Clinical Oncology 2015)"},{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/","field":"outcomes.source (Overall survival)"},{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/","field":"outcomes.source (Death from prostate cancer)"}]},{"url":"https://doi.org/10.1200/jco.2014.57.9334","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.9334","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-di-maio-j-clin-oncol","kind":"paper","name":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","route":"/key-papers/paper-di-maio-j-clin-oncol/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.57.9334","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.57.9334","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"metrics (Physician under-reporting of symptomatic toxicities compared with patient self-report across three randomised trials)"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"links","label":"Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"metrics (Agreement between physician and patient reporting of symptomatic toxicities (anorexia, nausea, vomiting, constipation, diarrhoea, hair loss) in three randomised trials)"},{"id":"idea-moon-toxicity-first-endpoints","kind":"idea","name":"Tolerability as a co-primary endpoint with its own label claim","route":"/ideas/idea-moon-toxicity-first-endpoints/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-cardioprotection-by-default","kind":"idea","name":"Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy","route":"/ideas/idea-moon-cardioprotection-by-default/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","route":"/ideas/idea-moon-quality-adjusted-pricing/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-cognitive-toxicity-programme","kind":"idea","name":"Measure and treat chemo brain with objective digital cognitive testing","route":"/ideas/idea-moon-cognitive-toxicity-programme/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-irae-prediction-and-prevention","kind":"idea","name":"Predict immune side-effects before they happen and pre-empt them","route":"/ideas/idea-moon-irae-prediction-and-prevention/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-fertility-preservation-default","kind":"idea","name":"Fertility preservation offered and funded by default before gonadotoxic treatment","route":"/ideas/idea-moon-fertility-preservation-default/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-hearing-protection-cisplatin","kind":"idea","name":"Protect hearing from cisplatin in adults as we now do in children","route":"/ideas/idea-moon-hearing-protection-cisplatin/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-hair-preservation-for-all","kind":"idea","name":"Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen","route":"/ideas/idea-moon-hair-preservation-for-all/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-oncology-hospital-at-home","kind":"idea","name":"Oncology hospital-at-home with remote monitoring for toxicity","route":"/ideas/idea-moon-oncology-hospital-at-home/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-supportive-care-platform-trial","kind":"idea","name":"A permanent platform trial for supportive-care interventions inside cooperative groups","route":"/ideas/idea-moon-supportive-care-platform-trial/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-mucositis-taste-programme","kind":"idea","name":"Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity","route":"/ideas/idea-moon-mucositis-taste-programme/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"},{"id":"idea-moon-quality-adjusted-survival-standard","kind":"idea","name":"Quality-adjusted survival reported in every trial publication and label","route":"/ideas/idea-moon-quality-adjusted-survival-standard/","field":"links","label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)"}]},{"url":"https://doi.org/10.1200/jco.2014.58.3369","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.58.3369","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-frazier-j-clin-oncol","kind":"paper","name":"Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States","route":"/key-papers/paper-frazier-j-clin-oncol/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.58.3369","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.58.3369","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"links","label":"MaGIC risk classification (JCO 2015)"}]},{"url":"https://doi.org/10.1200/JCO.2014.58.3377","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.58.3377","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andtbacka-optim-talimogene-jco-2015","kind":"paper","name":"OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus","route":"/key-papers/paper-andtbacka-optim-talimogene-jco-2015/","field":"links","label":"JCO 2015"}]},{"url":"https://doi.org/10.1200/jco.2014.59.1081","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.59.1081","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-van-waart-j-clin-oncol","kind":"paper","name":"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial","route":"/key-papers/paper-van-waart-j-clin-oncol/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.59.1081","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.59.1081","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","field":"links","label":"PACES trial (JCO 2015)"}]},{"url":"https://doi.org/10.1200/JCO.2014.59.5256","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.59.5256","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"papers","label":"Ewing Sarcoma: Current Management and Future Approaches Through Collaboration"}]},{"url":"https://doi.org/10.1200/JCO.2014.59.7534","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.59.7534","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-pod24","kind":"term","name":"POD24: progression of follicular lymphoma within two years, and why it changes the plan","route":"/terms/lymphoma-tx-pod24/","field":"links","label":"Casulo et al., early progression after R-CHOP in follicular lymphoma, National LymphoCare Study, Journal of Clinical Oncology 2015"}]},{"url":"https://doi.org/10.1200/jco.2014.60.0734","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.0734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bielack-j-clin-oncol","kind":"paper","name":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","route":"/key-papers/paper-bielack-j-clin-oncol/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.60.0734","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.0734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"links","label":"Bielack et al., JCO 2015 (good responders)"},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"outcomes.source (3-year event-free survival, good responders (all randomised))"}]},{"url":"https://doi.org/10.1200/JCO.2014.60.1591","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.1591","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","field":"papers","label":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)"},{"id":"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015","kind":"paper","name":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)","route":"/key-papers/paper-robinson-vismodegib-shh-medulloblastoma-jco-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.60.2219","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.2219","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","field":"links","label":"Ben-Josef et al., JCO 2015: SWOG S0809"},{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","field":"outcomes.source (2-year overall survival by margin)"},{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","field":"outcomes.source (Median overall survival)"},{"id":"paper-swog-s0809-adjuvant-chemoradiation-jco-2015","kind":"paper","name":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","route":"/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/jco.2014.60.3969","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.3969","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015","kind":"paper","name":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2014.60.4165","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2014.60.4165","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"papers","label":"Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials"}]},{"url":"https://doi.org/10.1200/jco.2015.60.9412","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.60.9412","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol-2015","kind":"paper","name":"Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial","route":"/key-papers/paper-mao-j-clin-oncol-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2015.60.9412","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.60.9412","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","field":"links","label":"Electroacupuncture versus gabapentin for hot flashes in breast cancer survivors (JCO 2015)"}]},{"url":"https://doi.org/10.1200/JCO.2015.61.2267","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.61.2267","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","field":"links","label":"Palumbo et al., Revised International Staging System for multiple myeloma: IMWG report (Journal of Clinical Oncology 2015)"},{"id":"paper-r-iss-palumbo-jco-2015","kind":"paper","name":"Revised International Staging System (R-ISS) for multiple myeloma","route":"/key-papers/paper-r-iss-palumbo-jco-2015/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/jco.2015.61.4743","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.61.4743","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"links","label":"King 2015, JCO: lobular carcinoma in situ, a 29-year longitudinal experience of 1,060 patients"}]},{"url":"https://doi.org/10.1200/jco.2015.62.0674","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.62.0674","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"links","label":"Liu 2016, JCO: sequencing of pulmonary sarcomatoid carcinoma reveals frequent MET exon 14 mutations"}]},{"url":"https://doi.org/10.1200/jco.2015.62.3488","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.62.3488","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-smith-j-clin-oncol","kind":"paper","name":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-smith-j-clin-oncol/","field":"links","label":"J Clin Oncol 2015"}]},{"url":"https://doi.org/10.1200/JCO.2015.62.3488","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.62.3488","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"papers","label":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update"},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","field":"links","label":"ASCO WBC growth factors guideline 2015"}]},{"url":"https://doi.org/10.1200/JCO.2015.62.4544","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.62.4544","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aall0232-larsen-jco-2016","kind":"paper","name":"AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0232-larsen-jco-2016/","field":"links","label":"J Clin Oncol 2016"},{"id":"aall0232","kind":"trial","name":"AALL0232","route":"/trials/aall0232/","field":"outcomes.source (Event-free survival at 5 years, methotrexate randomisation (mature data))"},{"id":"aall0232","kind":"trial","name":"AALL0232","route":"/trials/aall0232/","field":"outcomes.source (Event-free survival at 5 years, patients aged 1 to 9 by regimen)"}]},{"url":"https://doi.org/10.1200/JCO.2015.62.4734","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.62.4734","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trabectedin-vs-dacarbazine-demetri-jco-2016","kind":"paper","name":"Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure","route":"/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2015.63.0830","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.0830","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","field":"links","label":"Primary report (JCO 2016)"}]},{"url":"https://doi.org/10.1200/jco.2015.63.1010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.1010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","field":"links","label":"Symmans, J Clin Oncol 2017: long-term prognosis by residual cancer burden and breast cancer subtype"}]},{"url":"https://doi.org/10.1200/JCO.2015.63.1010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.1010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Symmans et al., long-term prognostic risk after neoadjuvant chemotherapy by residual cancer burden and subtype (JCO 2017)"},{"id":"paper-symmans-rcb-long-term-prognosis-subtype-jco-2017","kind":"paper","name":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","route":"/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2015.63.1929","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.1929","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/jco.2015.63.4238","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.4238","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"papers","label":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study"}]},{"url":"https://doi.org/10.1200/JCO.2015.63.4600","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.63.4600","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/","field":"links","label":"Awad et al., J Clin Oncol 2016: MET exon 14 mutations across 6,376 cancers, with age, amplification and c-Met overexpression"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.0094","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.0094","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"targeted-axillary-dissection","kind":"term","name":"Targeted axillary dissection","route":"/terms/targeted-axillary-dissection/","field":"links","label":"Targeted axillary dissection (Journal of Clinical Oncology 2016)"},{"id":"targeted-axillary-dissection-md-anderson","kind":"trial","name":"Targeted axillary dissection (MD Anderson prospective study)","route":"/trials/targeted-axillary-dissection-md-anderson/","field":"links","label":"Targeted axillary dissection (Journal of Clinical Oncology 2016)"},{"id":"targeted-axillary-dissection-md-anderson","kind":"trial","name":"Targeted axillary dissection (MD Anderson prospective study)","route":"/trials/targeted-axillary-dissection-md-anderson/","field":"outcomes.source (False-negative rate after chemotherapy)"}]},{"url":"https://doi.org/10.1200/jco.2015.64.2702","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.2702","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"links","label":"Scher et al., Journal of Clinical Oncology 2016 (PCWG3): trial design and objectives for castration-resistant prostate cancer, updated recommendations"},{"id":"metastasis-free-survival","kind":"term","name":"Metastasis-free survival (MFS)","route":"/terms/metastasis-free-survival/","field":"links","label":"Scher et al., Journal of Clinical Oncology 2016 (PCWG3): trial design and objectives for castration-resistant prostate cancer, updated recommendations"},{"id":"radiographic-progression-free-survival","kind":"term","name":"Radiographic progression-free survival (rPFS)","route":"/terms/radiographic-progression-free-survival/","field":"links","label":"Scher et al., Journal of Clinical Oncology 2016 (PCWG3): trial design and objectives for castration-resistant prostate cancer, updated recommendations"},{"id":"paper-scher-j-clin-oncol","kind":"paper","name":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","route":"/key-papers/paper-scher-j-clin-oncol/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.2702","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.2702","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"links","label":"PCWG3 trial design recommendations incl. PSA response reporting (Scher et al., J Clin Oncol 2016)"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.2710","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.2710","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","field":"papers","label":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma"}]},{"url":"https://doi.org/10.1200/jco.2015.64.6620","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.6620","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ramsey-j-clin-oncol","kind":"paper","name":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer","route":"/key-papers/paper-ramsey-j-clin-oncol/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.6620","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.6620","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","field":"links","label":"Ramsey 2016 bankruptcy and survival (JCO)"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.8055","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.8055","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-22991","kind":"trial","name":"EORTC 22991","route":"/trials/eortc-22991/","field":"links","label":"EORTC 22991 (Journal of Clinical Oncology 2016)"},{"id":"eortc-22991","kind":"trial","name":"EORTC 22991","route":"/trials/eortc-22991/","field":"outcomes.source (Biochemical disease-free survival)"},{"id":"eortc-22991","kind":"trial","name":"EORTC 22991","route":"/trials/eortc-22991/","field":"outcomes.source (Clinical progression-free survival)"}]},{"url":"https://doi.org/10.1200/JCO.2015.65.5597","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.65.5597","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/","field":"links","label":"COMET-1 (Journal of Clinical Oncology 2016)"},{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","field":"links","label":"COMET-1 (Journal of Clinical Oncology 2016)"},{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","field":"outcomes.source (Overall survival (median))"},{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","field":"outcomes.source (Bone scan response at week 12)"},{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","field":"outcomes.source (Radiographic progression-free survival (median))"}]},{"url":"https://doi.org/10.1200/JCO.2015.65.6520","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.65.6520","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-cns-prophylaxis","kind":"term","name":"CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it","route":"/terms/lymphoma-tx-cns-prophylaxis/","field":"links","label":"Schmitz et al., CNS International Prognostic Index, Journal of Clinical Oncology 2016 (2,164 patients, validated in 1,597)"}]},{"url":"https://doi.org/10.1200/JCO.2016.66.9697","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.66.9697","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tasquinimod","kind":"drug","name":"Tasquinimod","route":"/drugs/tasquinimod/","field":"links","label":"10TASQ10 (Journal of Clinical Oncology 2016)"},{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","route":"/trials/tasquinimod-10tasq10/","field":"links","label":"10TASQ10 (Journal of Clinical Oncology 2016)"},{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","route":"/trials/tasquinimod-10tasq10/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","route":"/trials/tasquinimod-10tasq10/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1200/JCO.2016.67.0448","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.67.0448","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","field":"links","label":"RTOG 0415 (Journal of Clinical Oncology 2016)"},{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","field":"outcomes.source (Disease-free survival at 5 years)"}]},{"url":"https://doi.org/10.1200/JCO.2016.67.1529","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.67.1529","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","field":"papers","label":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma"}]},{"url":"https://doi.org/10.1200/JCO.2016.67.9258","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.67.9258","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dangelo-mucosal-melanoma-pooled-jco-2017","kind":"paper","name":"Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis","route":"/key-papers/paper-dangelo-mucosal-melanoma-pooled-jco-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/jco.2016.68.2518","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.2518","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schnipper-j-clin-oncol","kind":"paper","name":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","route":"/key-papers/paper-schnipper-j-clin-oncol/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2016.68.2518","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.2518","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cost-indication-based-pricing","kind":"idea","name":"Price a cancer drug by how well it works in each cancer","route":"/ideas/idea-cost-indication-based-pricing/","field":"links","label":"ASCO Value Framework update (JCO 2016)"}]},{"url":"https://doi.org/10.1200/jco.2016.68.3573","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.3573","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-morrow-j-clin-oncol","kind":"paper","name":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ","route":"/key-papers/paper-morrow-j-clin-oncol/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2016.68.3573","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.3573","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"SSO-ASTRO-ASCO margin guideline for DCIS (JCO 2016)"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"standardOfCare.guideline (Localised DCIS, breast conservation)"}]},{"url":"https://doi.org/10.1200/jco.2016.68.3672","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.3672","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-j-clin-oncol-2016","kind":"paper","name":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","route":"/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/jco.2016.68.5206","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.5206","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paice-j-clin-oncol","kind":"paper","name":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","route":"/key-papers/paper-paice-j-clin-oncol/","field":"links","label":"J Clin Oncol 2016"}]},{"url":"https://doi.org/10.1200/JCO.2016.68.5206","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.5206","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"ASCO chronic pain in survivors 2016"}]},{"url":"https://doi.org/10.1200/JCO.2016.68.5776","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.5776","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","field":"links","label":"Gill et al., PANCREOX (JCO 2016)"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Gill et al., PANCREOX (JCO 2016)"},{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/","field":"links","label":"Gill et al., PANCREOX (JCO 2016)"}]},{"url":"https://doi.org/10.1200/JCO.2016.68.6394","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.68.6394","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/","field":"links","label":"EORTC/LYSA/FIL H10 final results, Journal of Clinical Oncology 2017"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Early unfavourable Hodgkin lymphoma: more chemotherapy, and PET-guided intensification)"}]},{"url":"https://doi.org/10.1200/JCO.2016.69.3564","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.69.3564","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"links","label":"PTLD-1 risk-stratified sequential treatment (JCO 2017)"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"standardOfCare.guideline (CD20-positive PTLD not responding to reduced immunosuppression)"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"outcomes.source (Overall response rate (complete or partial response after risk-stratified sequential treatment))"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"outcomes.source (Complete response rate)"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"outcomes.source (Response duration at 3 years)"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"outcomes.source (Overall survival)"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"outcomes.source (Treatment-related mortality)"},{"id":"paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017","kind":"paper","name":"PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphoproliferative disorder","route":"/key-papers/paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/jco.2016.70.1474","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.70.1474","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ferrell-j-clin-oncol","kind":"paper","name":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-ferrell-j-clin-oncol/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2016.70.1474","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.70.1474","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"links","label":"Ferrell et al., ASCO guideline on integration of palliative care into standard oncology care (JCO 2017)"}]},{"url":"https://doi.org/10.1200/jco.2016.70.1524","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.70.1524","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","kind":"paper","name":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","route":"/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2016.70.6994","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.70.6994","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","field":"standardOfCare.guideline (Marginal zone lymphoma that is advanced, symptomatic or has relapsed)"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"standardOfCare.guideline (Gastric MALT lymphoma that does not respond to eradication, and MALT at other sites)"}]},{"url":"https://doi.org/10.1200/jco.2016.70.8297","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.70.8297","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017","kind":"paper","name":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/jco.2016.71.0285","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.0285","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-irwin-j-clin-oncol","kind":"paper","name":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial","route":"/key-papers/paper-irwin-j-clin-oncol/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.0285","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.0285","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cbt-insomnia-cancer","kind":"technology","name":"Cognitive behavioural therapy for insomnia (CBT-I)","route":"/technologies/cbt-insomnia-cancer/","field":"links","label":"Tai chi chih versus CBT-I for insomnia in breast cancer survivors (JCO 2017)"},{"id":"tai-chi-qigong","kind":"technology","name":"Tai chi and qigong","route":"/technologies/tai-chi-qigong/","field":"links","label":"Tai chi chih versus CBT-I for insomnia in breast cancer survivors (JCO 2017)"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.0632","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.0632","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","field":"papers","label":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum"},{"id":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","kind":"paper","name":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","route":"/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/jco.2016.71.3495","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.3495","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Traina, J Clin Oncol 2018: enzalutamide for androgen receptor-expressing triple-negative breast cancer"},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","field":"links","label":"Traina, J Clin Oncol 2018: enzalutamide for androgen receptor-expressing triple-negative breast cancer"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.3495","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.3495","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-traina-enzalutamide-ar-tnbc-jco-2018","kind":"paper","name":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","route":"/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/","field":"links","label":"Traina et al., J Clin Oncol 2018: enzalutamide in AR-expressing TNBC"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.4394","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.4394","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jones-non-v600-braf-colorectal-jco-2017","kind":"paper","name":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","route":"/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/","field":"links","label":"Jones et al., J Clin Oncol 2017: non-V600 BRAF mutations in 9,643 sequenced metastatic colorectal cancers"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.5904","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.5904","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"links","label":"ALTA (JCO 2017)"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"links","label":"Journal of Clinical Oncology 2017"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"outcomes.source (Confirmed objective response rate (investigator))"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"outcomes.source (Progression-free survival (investigator))"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"outcomes.source (Intracranial objective response rate (independent review, measurable brain metastases))"},{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/","field":"links","label":"Journal of Clinical Oncology 2017"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.7397","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.7397","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"profit-trial","kind":"trial","name":"PROFIT (Prostate Fractionated Irradiation Trial)","route":"/trials/profit-trial/","field":"links","label":"PROFIT (Journal of Clinical Oncology 2017)"},{"id":"profit-trial","kind":"trial","name":"PROFIT (Prostate Fractionated Irradiation Trial)","route":"/trials/profit-trial/","field":"outcomes.source (Biochemical or clinical failure-free survival at 5 years)"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.9096","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.9096","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lee-clonal-history-small-cell-transformation-jco-2017","kind":"paper","name":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","route":"/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/","field":"links","label":"Lee et al., J Clin Oncol 2017: clonal history and genetic predictors of small-cell transformation from lung adenocarcinoma"}]},{"url":"https://doi.org/10.1200/JCO.2016.71.9807","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.71.9807","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","kind":"paper","name":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","route":"/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/","field":"links","label":"Sepulveda et al., J Clin Oncol 2017: ASCP, CAP, AMP and ASCO guideline on molecular biomarkers for colorectal cancer"}]},{"url":"https://doi.org/10.1200/JCO.2016.72.0177","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.72.0177","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"papers","label":"Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting"}]},{"url":"https://doi.org/10.1200/JCO.2016.72.1068","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.72.1068","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/","field":"links","label":"FIRSTANA (Journal of Clinical Oncology 2017)"},{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/","field":"outcomes.source (Overall survival (median))"},{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/","field":"outcomes.source (Grade 3 or 4 treatment-emergent adverse events)"}]},{"url":"https://doi.org/10.1200/JCO.2016.72.1076","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2016.72.1076","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"links","label":"PROSELICA (Journal of Clinical Oncology 2017)"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","field":"links","label":"PROSELICA (Journal of Clinical Oncology 2017)"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","field":"outcomes.source (Overall survival (median))"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","field":"outcomes.source (Grade 3 or 4 treatment-emergent adverse events)"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","field":"outcomes.source (PSA response)"}]},{"url":"https://doi.org/10.1200/jco.2017.72.3502","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.72.3502","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Shindo, J Clin Oncol 2017: deleterious germline mutations in apparently sporadic pancreatic adenocarcinoma"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Shindo, J Clin Oncol 2017: deleterious germline mutations in apparently sporadic pancreatic adenocarcinoma"}]},{"url":"https://doi.org/10.1200/JCO.2017.72.3502","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.72.3502","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shindo-germline-sporadic-pancreatic-jco-2017","kind":"paper","name":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","route":"/key-papers/paper-shindo-germline-sporadic-pancreatic-jco-2017/","field":"links","label":"Shindo et al., J Clin Oncol 2017: germline mutations in 854 apparently sporadic pancreatic cancers (Johns Hopkins)"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1200/JCO.2017.72.6463","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.72.6463","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Sinn et al., CONKO-005 (JCO 2017)"},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/","field":"links","label":"Sinn et al., CONKO-005 (JCO 2017)"},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/","field":"outcomes.source (Disease-free survival)"},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/","field":"outcomes.source (Overall survival)"},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","field":"links","label":"Sinn et al., CONKO-005 (JCO 2017)"}]},{"url":"https://doi.org/10.1200/JCO.2017.72.6984","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.72.6984","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-maintenance","kind":"term","name":"Maintenance and consolidation in lymphoma: where it works and where it does not","route":"/terms/lymphoma-tx-maintenance/","field":"links","label":"REMARC: lenalidomide maintenance after R-CHOP, Journal of Clinical Oncology 2017"},{"id":"lymphoma-tx-failed-and-negative","kind":"term","name":"Lymphoma treatments that did not work: the negative trials worth knowing","route":"/terms/lymphoma-tx-failed-and-negative/","field":"links","label":"REMARC, Journal of Clinical Oncology 2017"}]},{"url":"https://doi.org/10.1200/JCO.2017.73.3402","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.3402","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-failed-and-negative","kind":"term","name":"Lymphoma treatments that did not work: the negative trials worth knowing","route":"/terms/lymphoma-tx-failed-and-negative/","field":"links","label":"GOYA: obinutuzumab-CHOP against R-CHOP, Journal of Clinical Oncology 2017"}]},{"url":"https://doi.org/10.1200/jco.2017.73.6314","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.6314","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-childers-j-clin-oncol","kind":"paper","name":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","route":"/key-papers/paper-childers-j-clin-oncol/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2017.73.6314","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.6314","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"links","label":"Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"metrics (US women with a history of breast or ovarian cancer meeting NCCN criteria who had undergone genetic testing (2005-2015 NHIS))"},{"id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-prs-screening-start-age","kind":"idea","name":"Use a polygenic risk score to set when screening starts","route":"/ideas/idea-prev-prs-screening-start-age/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-brca1-denosumab-prevention","kind":"idea","name":"A bone drug to prevent breast cancer in BRCA1 carriers","route":"/ideas/idea-prev-brca1-denosumab-prevention/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-vus-saturation-editing-consortium","kind":"idea","name":"Test every possible mutation in every cancer gene so no result is 'uncertain'","route":"/ideas/idea-prev-vus-saturation-editing-consortium/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-genetic-counselling-chatbot","kind":"idea","name":"A chatbot for pre-test genetic counselling so counsellors see only who needs them","route":"/ideas/idea-prev-genetic-counselling-chatbot/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-family-history-auto-match","kind":"idea","name":"Family history collected by app and matched to testing criteria automatically","route":"/ideas/idea-prev-family-history-auto-match/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-prev-genetic-non-discrimination-insurance","kind":"idea","name":"Ban life and disability insurers from using genetic results","route":"/ideas/idea-prev-genetic-non-discrimination-insurance/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"},{"id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/","field":"links","label":"Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017)"}]},{"url":"https://doi.org/10.1200/JCO.2017.73.6785","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.6785","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","field":"papers","label":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)"},{"id":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","kind":"paper","name":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","route":"/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/jco.2017.73.7585","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.7585","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02107703-j-clin-oncol-2017","kind":"paper","name":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","route":"/key-papers/paper-nct02107703-j-clin-oncol-2017/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/jco.2017.73.7916","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.7916","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kim-j-clin-oncol","kind":"paper","name":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","route":"/key-papers/paper-kim-j-clin-oncol/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2017.73.7916","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.7916","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"links","label":"Kim et al., Broadening eligibility criteria to make clinical trials more representative (JCO 2017)"}]},{"url":"https://doi.org/10.1200/jco.2017.73.9987","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.73.9987","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metastasis-free-survival","kind":"term","name":"Metastasis-free survival (MFS)","route":"/terms/metastasis-free-survival/","field":"links","label":"Xie et al., Journal of Clinical Oncology 2017 (ICECaP): metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.3384","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.3384","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/","field":"links","label":"Rizvi et al., J Clin Oncol 2018: targeted sequencing of 240 non-small-cell lung cancers treated with PD-(L)1 blockade"}]},{"url":"https://doi.org/10.1200/jco.2017.75.3780","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.3780","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hainsworth-j-clin-oncol","kind":"paper","name":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-hainsworth-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.3780","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.3780","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"links","label":"Hainsworth et al., Journal of Clinical Oncology 2018: targeted therapy for advanced solid tumors on the basis of molecular profiles, results from MyPathway"}]},{"url":"https://doi.org/10.1200/jco.2017.75.4614","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.4614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-van-poznak-j-clin-oncol","kind":"paper","name":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","route":"/key-papers/paper-van-poznak-j-clin-oncol/","field":"links","label":"J Clin Oncol 2017"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.4614","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.4614","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","field":"links","label":"ASCO bone-modifying agents guideline"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.4853","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.4853","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stomp-oligorecurrence","kind":"trial","name":"STOMP","route":"/trials/stomp-oligorecurrence/","field":"links","label":"STOMP (Journal of Clinical Oncology 2018)"},{"id":"stomp-oligorecurrence","kind":"trial","name":"STOMP","route":"/trials/stomp-oligorecurrence/","field":"outcomes.source (Androgen deprivation-free survival (median))"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.6155","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.6155","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","field":"outcomes.source (Overall survival)"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"papers","label":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"metrics (Patients requiring dose reduction of abemaciclib for adverse events in first-line MONARCH 3)"}]},{"url":"https://doi.org/10.1200/jco.2017.76.0611","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.0611","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","field":"outcomes.source (Event-free survival (central radiology review))"},{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","field":"outcomes.source (Overall survival)"},{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","field":"outcomes.source (Serious adverse events)"}]},{"url":"https://doi.org/10.1200/JCO.2017.76.0793","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.0793","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","field":"outcomes.source (Objective response rate)"},{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/jco.2017.76.4381","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.4381","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-szmulewitz-j-clin-oncol","kind":"paper","name":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","route":"/key-papers/paper-szmulewitz-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2017.76.4381","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.4381","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cost-low-dose-abiraterone-food","kind":"idea","name":"Prescribe a quarter dose of abiraterone with breakfast","route":"/ideas/idea-cost-low-dose-abiraterone-food/","field":"links","label":"Szmulewitz et al., JCO 2018: low-fat meal abiraterone"}]},{"url":"https://doi.org/10.1200/JCO.2017.76.5966","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.5966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","field":"papers","label":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma"},{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/jco.2017.76.8192","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.8192","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","field":"outcomes.source (Complete remission)"},{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","field":"outcomes.source (Event-free survival at 5 years)"},{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","field":"outcomes.source (Event-free survival at 5 years by age)"}]},{"url":"https://doi.org/10.1200/JCO.2017.76.8192","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.8192","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-graall-2005-huguet-jco-2018","kind":"paper","name":"GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol","route":"/key-papers/paper-graall-2005-huguet-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2017.76.9901","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.76.9901","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","field":"links","label":"CheckMate 142: durable clinical benefit with nivolumab plus ipilimumab in dMMR metastatic colorectal cancer (Journal of Clinical Oncology 2018)"},{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","field":"outcomes.source (Objective response rate (dMMR, nivolumab plus ipilimumab))"}]},{"url":"https://doi.org/10.1200/jco.2017.77.0941","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.0941","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","field":"outcomes.source (Freedom from locoregional relapse at 5 years)"},{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","field":"outcomes.source (Freedom from locoregional relapse at 2 years)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (Radiotherapy after surgery, and what not to add to it)"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.0941","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.0941","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiotherapy-for-skin-cancer","kind":"term","name":"Radiotherapy for skin cancer","route":"/terms/radiotherapy-for-skin-cancer/","field":"links","label":"TROG 05.01 (Journal of Clinical Oncology 2018)"},{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","field":"links","label":"Primary report (Journal of Clinical Oncology 2018)"}]},{"url":"https://doi.org/10.1200/jco.2017.77.1931","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.1931","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol-2018","kind":"paper","name":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study","route":"/key-papers/paper-dix-j-clin-oncol-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.1931","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.1931","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","field":"links","label":"Dix et al., JCO 2018 (lung metastases)"},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","field":"outcomes.source (4-year event-free survival (all lung-metastasis patients))"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.5841","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.5841","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"links","label":"Journal of Clinical Oncology 2018 (brain metastases, exploratory)"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.6112","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.6112","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","field":"papers","label":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia"},{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.6880","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.6880","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"papers","label":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study"},{"id":"paper-aggarwal-t-sccpc-jco-2018","kind":"paper","name":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","route":"/key-papers/paper-aggarwal-t-sccpc-jco-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/jco.2018.77.8613","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.8613","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ishigami-j-clin-oncol","kind":"paper","name":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","route":"/key-papers/paper-ishigami-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.77.8613","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.8613","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-peritoneal-directed-gastric","kind":"idea","name":"Peritoneal-directed therapy for gastric cancer","route":"/ideas/idea-peritoneal-directed-gastric/","field":"links","label":"PHOENIX-GC: intraperitoneal plus intravenous paclitaxel with S-1 versus standard chemotherapy in gastric cancer with peritoneal metastasis (Journal of Clinical Oncology 2018)"}]},{"url":"https://doi.org/10.1200/jco.2018.77.8738","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.8738","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Wolff, J Clin Oncol 2018: ASCO/CAP HER2 testing guideline focused update"},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"links","label":"Wolff, J Clin Oncol 2018: ASCO/CAP HER2 testing guideline focused update"},{"id":"paper-wolff-j-clin-oncol-2018","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","route":"/key-papers/paper-wolff-j-clin-oncol-2018/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.77.8738","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.8738","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/","field":"links","label":"Wolff et al., HER2 testing in breast cancer: ASCO/CAP clinical practice guideline focused update, including fixation requirements (Journal of Clinical Oncology 2018)"},{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/","field":"links","label":"ASCO/CAP HER2 testing in breast cancer guideline, 2018 focused update (Wolff et al., J Clin Oncol)"},{"id":"her2-ihc-2-plus","kind":"biomarker","name":"HER2 IHC 2+ (equivocal, reflex to ISH)","route":"/biomarkers/her2-ihc-2-plus/","field":"links","label":"ASCO/CAP HER2 testing in breast cancer guideline, 2018 focused update (Wolff et al., J Clin Oncol)"},{"id":"her2-ihc-1-plus","kind":"biomarker","name":"HER2 IHC 1+","route":"/biomarkers/her2-ihc-1-plus/","field":"links","label":"ASCO/CAP HER2 testing in breast cancer guideline, 2018 focused update (Wolff et al., J Clin Oncol)"},{"id":"her2-ihc-0","kind":"biomarker","name":"HER2 IHC 0 (HER2-negative, including ultralow)","route":"/biomarkers/her2-ihc-0/","field":"links","label":"ASCO/CAP HER2 testing in breast cancer guideline, 2018 focused update (Wolff et al., J Clin Oncol)"},{"id":"her2-ish-amplified","kind":"biomarker","name":"HER2 ISH amplified (ERBB2 gene amplification)","route":"/biomarkers/her2-ish-amplified/","field":"links","label":"ASCO/CAP HER2 testing in breast cancer guideline, 2018 focused update (Wolff et al., J Clin Oncol)"}]},{"url":"https://doi.org/10.1200/JCO.2018.77.9694","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.9694","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"papers","label":"Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group"}]},{"url":"https://doi.org/10.1200/JCO.2018.77.9892","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.77.9892","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Stage I and contiguous stage II follicular lymphoma: radiotherapy with curative intent)"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.0858","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.0858","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Lambertini et al., GnRH agonists during chemotherapy for preservation of ovarian function and fertility, individual patient-level meta-analysis of 873 patients (JCO 2018)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Lambertini et al., GnRH agonists during chemotherapy for preservation of ovarian function and fertility, individual patient-level meta-analysis of 873 patients (JCO 2018)"}]},{"url":"https://doi.org/10.1200/jco.2018.78.1914","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.1914","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oktay-j-clin-oncol","kind":"paper","name":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-oktay-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.1914","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.1914","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"ASCO fertility preservation guideline 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.3977","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.3977","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zheng-nigerian-inherited-breast-cancer-jco-2018","kind":"paper","name":"Inherited breast cancer in Nigerian women","route":"/key-papers/paper-zheng-nigerian-inherited-breast-cancer-jco-2018/","field":"links","label":"Zheng et al., J Clin Oncol 2018: inherited breast cancer in 1,136 Nigerian women"}]},{"url":"https://doi.org/10.1200/jco.2018.78.5246","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.5246","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kurtz-j-clin-oncol","kind":"paper","name":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-kurtz-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.5246","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.5246","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","field":"links","label":"Kurtz et al., Circulating tumour DNA measurements as early outcome predictors in diffuse large B-cell lymphoma (Journal of Clinical Oncology 2018)"},{"id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/","field":"links","label":"Kurtz et al., Circulating tumour DNA measurements as early outcome predictors in diffuse large B-cell lymphoma (Journal of Clinical Oncology 2018)"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.7994","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.7994","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","field":"links","label":"ARCHER 1050 overall survival (JCO 2018)"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"Journal of Clinical Oncology 2018 (overall survival)"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"outcomes.source (Overall survival (mature analysis))"},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/","field":"links","label":"Journal of Clinical Oncology 2018"}]},{"url":"https://doi.org/10.1200/jco.2018.78.8687","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.8687","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mohile-j-clin-oncol","kind":"paper","name":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","route":"/key-papers/paper-mohile-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.8687","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.8687","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"links","label":"Mohile et al., ASCO guideline: practical assessment and management of vulnerabilities in older patients receiving chemotherapy (JCO 2018)"}]},{"url":"https://doi.org/10.1200/JCO.2018.78.9636","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.78.9636","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/","field":"links","label":"The 2018 update this built on (J Clin Oncol 2018)"}]},{"url":"https://doi.org/10.1200/jco.2018.79.2721","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.79.2721","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lyman-j-clin-oncol","kind":"paper","name":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline","route":"/key-papers/paper-lyman-j-clin-oncol/","field":"links","label":"J Clin Oncol 2018"}]},{"url":"https://doi.org/10.1200/JCO.2018.79.2721","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2018.79.2721","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","field":"links","label":"ASCO endorsement of the SIO breast cancer guideline (JCO 2018)"}]},{"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.1094","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.1094","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","field":"links","label":"Ladiratuzumab vedotin (JCO 2019 abstract)"}]},{"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.4005","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)"}]},{"url":"https://doi.org/10.1200/jco.2023.41.16_suppl.1022","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.1022","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","field":"links","label":"Abelman et al., Sequential use of antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (ASCO 2023, abstract 1022)"}]},{"url":"https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS5632","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS5632","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","field":"links","label":"Ubamatamab phase 1/2 study design (JCO 2024, TPS5632)"},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","field":"links","label":"Ubamatamab phase 1/2 study design (JCO 2024, TPS5632)"}]},{"url":"https://doi.org/10.1200/JCO.2026.44.16_suppl.11565","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11565","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","field":"links","label":"Cardiac safety of aldoxorubicin vs doxorubicin, integrated analysis (ASCO 2026 abstract 11565)"}]},{"url":"https://doi.org/10.1200/JCO.21.00003","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021","kind":"paper","name":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","route":"/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/","field":"links","label":"Reiss et al., J Clin Oncol 2021: maintenance rucaparib in 42 BRCA1, BRCA2 or PALB2 patients"}]},{"url":"https://doi.org/10.1200/JCO.21.00006","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00006","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","field":"links","label":"GROINSS-V II (JCO 2021)"},{"id":"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021","kind":"paper","name":"GROINSS-V II: radiotherapy versus inguinofemoral lymphadenectomy for vulvar cancer with sentinel node micrometastases","route":"/key-papers/paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"links","label":"GROINSS-V II (JCO 2021)"}]},{"url":"https://doi.org/10.1200/jco.21.00174","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00174","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-024-189-j-clin-oncol-2021-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50","route":"/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.21.00612","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00612","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"papers","label":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma"}]},{"url":"https://doi.org/10.1200/jco.21.00662","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00662","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-park-j-clin-oncol","kind":"paper","name":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","route":"/key-papers/paper-park-j-clin-oncol/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.21.00662","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00662","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","field":"links","label":"CHRYSALIS: amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer (Journal of Clinical Oncology 2021)"}]},{"url":"https://doi.org/10.1200/jco.21.00896","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00896","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","field":"papers","label":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study"},{"id":"paper-luca-gianni-j-clin-oncol-2022","kind":"paper","name":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","route":"/key-papers/paper-luca-gianni-j-clin-oncol-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.01210","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01210","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-j-clin-oncol-2021","kind":"paper","name":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","route":"/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.21.01308","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01308","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.01435","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01435","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-seligmann-j-clin-oncol","kind":"paper","name":"Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring","route":"/key-papers/paper-seligmann-j-clin-oncol/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.21.01435","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01435","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"links","label":"Seligmann et al., Journal of Clinical Oncology 2021: inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer (FOCUS4-C)"},{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"outcomes.source (Progression-free survival, FOCUS4-C (RAS and TP53 mutant))"}]},{"url":"https://doi.org/10.1200/jco.21.01436","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01436","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-adams-j-clin-oncol","kind":"paper","name":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial","route":"/key-papers/paper-adams-j-clin-oncol/","field":"links","label":"J Clin Oncol 2021"}]},{"url":"https://doi.org/10.1200/JCO.21.01436","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01436","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"links","label":"Adams et al., Journal of Clinical Oncology 2021: capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy (FOCUS4-N)"},{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"outcomes.source (Progression-free survival, FOCUS4-N)"}]},{"url":"https://doi.org/10.1200/JCO.21.01440","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Schneider et al., ASCO guideline on immune-related adverse events (JCO 2021)"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","field":"links","label":"Schneider et al., ASCO guideline on immune-related adverse events (JCO 2021)"}]},{"url":"https://doi.org/10.1200/JCO.21.01506","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01506","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/","field":"links","label":"Shepherd et al., JCO 2022: long-term outcomes and genomic correlates"},{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/","field":"outcomes.source (Event-free survival at 5 years by pathological response)"}]},{"url":"https://doi.org/10.1200/JCO.21.01604","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01604","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","field":"links","label":"Kindler et al., POLO overall survival (JCO 2022)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"Kindler et al., POLO overall survival (JCO 2022)"},{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.01612","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01612","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"outcomes.source (Event-free survival from study entry, high allelic ratio FLT3-ITD (hazard for patients not given sorafenib against sorafenib cohorts 2 and 3))"},{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"outcomes.source (Relapse risk from complete remission, high allelic ratio FLT3-ITD (hazard for patients not given sorafenib))"}]},{"url":"https://doi.org/10.1200/JCO.21.01612","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01612","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aaml1031-sorafenib-flt3-pollard-jco-2022","kind":"paper","name":"AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.01657","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01657","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bre12-158","kind":"trial","name":"BRE12-158 (Hoosier Oncology Group)","route":"/trials/bre12-158/","field":"links","label":"Radovich, Schneider et al., JCO 2022: BRE12-158 personalized therapy versus treatment of physician's choice for residual TNBC"},{"id":"bre12-158","kind":"trial","name":"BRE12-158 (Hoosier Oncology Group)","route":"/trials/bre12-158/","field":"outcomes.source (Disease-free survival at 2 years (randomised population))"}]},{"url":"https://doi.org/10.1200/JCO.21.01667","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01667","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stellar-rectal","kind":"trial","name":"STELLAR (rectal cancer)","route":"/trials/stellar-rectal/","field":"links","label":"STELLAR: short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (Journal of Clinical Oncology 2022)"},{"id":"stellar-rectal","kind":"trial","name":"STELLAR (rectal cancer)","route":"/trials/stellar-rectal/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://doi.org/10.1200/JCO.21.01728","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01728","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","field":"papers","label":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours"},{"id":"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","kind":"paper","name":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/","field":"links","label":"J Clin Oncol 2021"},{"id":"ampect","kind":"trial","name":"AMPECT","route":"/trials/ampect/","field":"links","label":"Journal of Clinical Oncology 2021"},{"id":"ampect","kind":"trial","name":"AMPECT","route":"/trials/ampect/","field":"outcomes.source (Objective response rate (independent review))"}]},{"url":"https://doi.org/10.1200/JCO.21.01752","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01752","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","field":"papers","label":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer"},{"id":"paper-e3311-transoral-surgery-ferris-jco-2022","kind":"paper","name":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","route":"/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.01874","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01874","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","field":"papers","label":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study"},{"id":"paper-antoine-italiano-j-clin-oncol-2022","kind":"paper","name":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","route":"/key-papers/paper-antoine-italiano-j-clin-oncol-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.01926","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01926","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shen-j-clin-oncol","kind":"paper","name":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","route":"/key-papers/paper-shen-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.01926","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.01926","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","field":"links","label":"J Clin Oncol 2022"},{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.21.02050","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02050","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gog-0261-carcinosarcoma-powell-jco-2022","kind":"paper","name":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","route":"/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.02233","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02233","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"Versteijne, J Clin Oncol 2022: PREOPANC long-term results, neoadjuvant chemoradiotherapy versus upfront surgery"}]},{"url":"https://doi.org/10.1200/JCO.21.02233","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02233","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Versteijne et al., neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer, PREOPANC long-term results (JCO 2022)"},{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","field":"links","label":"PREOPANC-1 long-term results, JCO 2022"},{"id":"paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022","kind":"paper","name":"PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer","route":"/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.02314","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02314","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","field":"papers","label":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline"},{"id":"paper-andrew-lassman-j-clin-oncol-2022","kind":"paper","name":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.02371","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02371","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","field":"links","label":"Alliance A071401 (J Clin Oncol 2023)"},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","field":"links","label":"Journal of Clinical Oncology 2023"},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","field":"outcomes.source (Progression-free survival at 6 months, grade 1 NF2-mutant meningioma)"},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","field":"outcomes.source (Progression-free survival at 6 months, grade 2 to 3 NF2-mutant meningioma)"},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","field":"outcomes.source (Best response by Macdonald criteria, all grades)"},{"id":"paper-a071401-brastianos-jco-2023","kind":"paper","name":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","route":"/key-papers/paper-a071401-brastianos-jco-2023/","field":"links","label":"Journal of Clinical Oncology 2023"}]},{"url":"https://doi.org/10.1200/JCO.21.02528","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02528","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"papers","label":"Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline"}]},{"url":"https://doi.org/10.1200/JCO.21.02554","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02554","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","field":"papers","label":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)"}]},{"url":"https://doi.org/10.1200/JCO.21.02568","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02568","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"links","label":"Bridgewater et al., JCO 2022: long-term outcomes of BILCAP"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Overall survival (ITT, long-term analysis, median follow-up 106 months))"}]},{"url":"https://doi.org/10.1200/jco.21.02641","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02641","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.02641","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02641","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","field":"links","label":"AENEAS (J Clin Oncol 2022)"},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","field":"links","label":"J Clin Oncol 2022"},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1200/jco.21.02678","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02678","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"outcomes.source (Event-free survival at 4 years, all randomised patients)"},{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"outcomes.source (Overall survival at 4 years, all randomised patients)"},{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"outcomes.source (Event-free survival at 4 years, T-lymphoblastic lymphoma)"},{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"outcomes.source (Overall survival at 4 years, T-lymphoblastic lymphoma)"}]},{"url":"https://doi.org/10.1200/JCO.21.02678","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02678","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aall1231-bortezomib-t-all-teachey-jco-2022","kind":"paper","name":"AALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed","route":"/key-papers/paper-aall1231-bortezomib-t-all-teachey-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.21.02838","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02838","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-parsons-j-clin-oncol","kind":"paper","name":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial","route":"/key-papers/paper-parsons-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.02838","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02838","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"links","label":"Parsons et al., JCO 2022 (screening results)"},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"outcomes.source (Actionable alteration detected (first 1,000 tumours))"},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"outcomes.source (Enrolled on a treatment arm)"}]},{"url":"https://doi.org/10.1200/jco.21.02840","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02840","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eckstein-j-clin-oncol","kind":"paper","name":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial","route":"/key-papers/paper-eckstein-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.21.02840","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02840","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"links","label":"Eckstein et al., JCO 2022 (selumetinib arm)"}]},{"url":"https://doi.org/10.1200/jco.21.02885","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.02885","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-042-j-clin-oncol-2023-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study","route":"/key-papers/paper-keynote-042-j-clin-oncol-2023-update/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.00032","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Garcia-Aguilar, J Clin Oncol 2022: OPRA, organ preservation in rectal adenocarcinoma treated with total neoadjuvant therapy (324 patients)"},{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/","field":"links","label":"J Clin Oncol 2022"},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","field":"links","label":"Garcia-Aguilar, J Clin Oncol 2022: OPRA, organ preservation in rectal adenocarcinoma treated with total neoadjuvant therapy (324 patients)"}]},{"url":"https://doi.org/10.1200/JCO.22.00032","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00032","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/","field":"links","label":"J Clin Oncol 2022"},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","field":"links","label":"Garcia-Aguilar et al., OPRA: organ preservation in rectal adenocarcinoma treated with total neoadjuvant therapy (Journal of Clinical Oncology 2022)"},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","field":"links","label":"Journal of Clinical Oncology 2022"},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","field":"outcomes.source (Survival without total mesorectal excision at 3 years)"},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://doi.org/10.1200/jco.22.00046","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00046","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"FOxTROT Collaborative Group, J Clin Oncol 2023: preoperative chemotherapy for operable colon cancer, mature results (699 patients allocated to preoperative chemotherapy, randomised 2:1)"},{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","field":"links","label":"FOxTROT Collaborative Group, J Clin Oncol 2023: preoperative chemotherapy for operable colon cancer, mature results (699 patients allocated to preoperative chemotherapy, randomised 2:1)"}]},{"url":"https://doi.org/10.1200/JCO.22.00046","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00046","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023","kind":"paper","name":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","route":"/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.00069","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00069","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andre-j-clin-oncol","kind":"paper","name":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-andre-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.22.00069","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00069","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/","field":"links","label":"ASCO biomarker guideline update (2022)"}]},{"url":"https://doi.org/10.1200/JCO.22.00184","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00184","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"papers","label":"Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results"}]},{"url":"https://doi.org/10.1200/jco.22.00194","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00194","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Klatte, J Clin Oncol 2022: 20 years of surveillance in 347 germline CDKN2A carriers"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Klatte, J Clin Oncol 2022: 20 years of surveillance in 347 germline CDKN2A carriers"}]},{"url":"https://doi.org/10.1200/jco.22.00227","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00227","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herbst-j-clin-oncol","kind":"paper","name":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","route":"/key-papers/paper-herbst-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.22.00227","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00227","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/","field":"links","label":"COAST (JCO 2022)"}]},{"url":"https://doi.org/10.1200/JCO.22.00294","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","field":"papers","label":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib"},{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.22.00298","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00298","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Dbouk, J Clin Oncol 2022: the multicenter CAPS5 study, impact of surveillance on stage and survival"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Dbouk, J Clin Oncol 2022: the multicenter CAPS5 study, impact of surveillance on stage and survival"}]},{"url":"https://doi.org/10.1200/JCO.22.00298","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00298","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dbouk-caps5-stage-survival-jco-2022","kind":"paper","name":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","route":"/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/","field":"links","label":"J Clin Oncol 2022"},{"id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","route":"/terms/caps-consortium-pancreatic-screening/","field":"links","label":"Dbouk et al., J Clin Oncol 2022: CAPS5, stage and survival in 1,461 high-risk individuals"}]},{"url":"https://doi.org/10.1200/JCO.22.00338","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00338","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","field":"outcomes.source (Progression-free survival (all patients))"},{"id":"paper-emerald-elacestrant-jco-2022","kind":"paper","name":"EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor","route":"/key-papers/paper-emerald-elacestrant-jco-2022/","field":"links","label":"J Clin Oncol 2022"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","field":"links","label":"EMERALD (JCO 2022)"}]},{"url":"https://doi.org/10.1200/jco.22.00343","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00343","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chesney-j-clin-oncol","kind":"paper","name":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","route":"/key-papers/paper-chesney-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.00343","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00343","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","field":"links","label":"MASTERKEY-265: talimogene laherparepvec plus pembrolizumab in advanced melanoma, phase 3 (Journal of Clinical Oncology 2023)"}]},{"url":"https://doi.org/10.1200/JCO.22.00503","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00503","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022","kind":"paper","name":"Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update","route":"/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.22.00686","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00686","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"papers","label":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study"}]},{"url":"https://doi.org/10.1200/jco.22.00690","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00690","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023","kind":"paper","name":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.00912","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00912","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-reckamp-j-clin-oncol","kind":"paper","name":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A","route":"/key-papers/paper-reckamp-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.22.00912","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00912","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/","field":"links","label":"Reckamp et al., Journal of Clinical Oncology 2022: phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced NSCLC previously treated with immunotherapy (Lung-MAP S1800A)"},{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1200/JCO.22.00975","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.00975","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","field":"links","label":"POSEIDON (Journal of Clinical Oncology 2023)"}]},{"url":"https://doi.org/10.1200/JCO.22.01002","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01002","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","field":"outcomes.source (Overall survival)"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"papers","label":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer"}]},{"url":"https://doi.org/10.1200/JCO.22.01015","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01015","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"papers","label":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)"},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","field":"papers","label":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)"},{"id":"idea-cost-low-dose-immunotherapy-trials","kind":"idea","name":"Test one-tenth-dose immunotherapy where the full dose is unaffordable","route":"/ideas/idea-cost-low-dose-immunotherapy-trials/","field":"links","label":"Patil et al., JCO 2023: low-dose nivolumab with metronomic chemotherapy"},{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/","field":"links","label":"Patil et al., JCO 2023"},{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/","field":"outcomes.source (Overall survival at 1 year)"},{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/","field":"outcomes.source (Median overall survival)"},{"id":"paper-patil-low-dose-nivolumab-jco-2023","kind":"paper","name":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","route":"/key-papers/paper-patil-low-dose-nivolumab-jco-2023/","field":"links","label":"JCO 2023"},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","field":"links","label":"Patil et al., low-dose nivolumab with triple metronomic chemotherapy (JCO 2023)"}]},{"url":"https://doi.org/10.1200/JCO.22.01063","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01063","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","kind":"paper","name":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/jco.22.01065","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01065","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-soft-text-j-clin-oncol-2023-update","kind":"paper","name":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","route":"/key-papers/paper-soft-text-j-clin-oncol-2023-update/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01134","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01134","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/","field":"links","label":"Tempero et al., APACT (JCO 2023)"},{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/","field":"outcomes.source (Disease-free survival (independent review))"},{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/","field":"outcomes.source (Overall survival (5-year follow-up, 88% mature))"}]},{"url":"https://doi.org/10.1200/jco.22.01345","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mikhael-j-clin-oncol","kind":"paper","name":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography","route":"/key-papers/paper-mikhael-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01345","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"papers","label":"Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography"},{"id":"sybil","kind":"technology","name":"Sybil (MIT/MGH lung cancer risk from CT)","route":"/technologies/sybil/","field":"links","label":"JCO 2023"}]},{"url":"https://doi.org/10.1200/jco.22.01357","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01357","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol","kind":"paper","name":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-mao-j-clin-oncol/","field":"links","label":"J Clin Oncol 2022"}]},{"url":"https://doi.org/10.1200/JCO.22.01357","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01357","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","field":"links","label":"SIO-ASCO pain guideline 2022"},{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"acupuncture-chemotherapy-neuropathy","kind":"technology","name":"Acupuncture for chemotherapy-induced neuropathy","route":"/technologies/acupuncture-chemotherapy-neuropathy/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"relaxation-guided-imagery","kind":"technology","name":"Relaxation training and guided imagery","route":"/technologies/relaxation-guided-imagery/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"massage-therapy-cancer","kind":"technology","name":"Massage therapy in cancer care","route":"/technologies/massage-therapy-cancer/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"reflexology-cancer","kind":"technology","name":"Reflexology","route":"/technologies/reflexology-cancer/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"},{"id":"frozen-gloves-compression-taxane","kind":"technology","name":"Frozen gloves, socks and compression for taxane nail and nerve damage","route":"/technologies/frozen-gloves-compression-taxane/","field":"links","label":"SIO-ASCO guideline: integrative medicine for pain management in oncology (JCO 2022)"}]},{"url":"https://doi.org/10.1200/JCO.22.01565","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01565","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-cancer-related-lymphoedema","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/breast-cancer-related-lymphoedema/","field":"links","label":"AMAROS ten-year results with five-year morbidity (Journal of Clinical Oncology 2023)"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"links","label":"AMAROS ten-year results (Journal of Clinical Oncology 2023)"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"outcomes.source (Cumulative incidence of axillary recurrence at 10 years)"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"outcomes.source (Lymphoedema at 5 years)"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"outcomes.source (Second primary cancers at 10 years (exploratory))"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"Bartels et al., radiotherapy or surgery of the axilla after a positive sentinel node, 10-year results of AMAROS (JCO 2023)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Bartels et al., radiotherapy or surgery of the axilla after a positive sentinel node, 10-year results of AMAROS (JCO 2023)"}]},{"url":"https://doi.org/10.1200/jco.22.01649","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01649","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-magnitude-j-clin-oncol-2023","kind":"paper","name":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-magnitude-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01725","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01725","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","field":"outcomes.source (Complete response rate)"},{"id":"lymphoma-tx-bispecific-step-up","kind":"term","name":"CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one","route":"/terms/lymphoma-tx-bispecific-step-up/","field":"links","label":"Epcoritamab dose expansion in relapsed large B-cell lymphoma, Journal of Clinical Oncology 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01763","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01763","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","field":"papers","label":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma"},{"id":"paper-dreamseq-jco-2023","kind":"paper","name":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","route":"/key-papers/paper-dreamseq-jco-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.01900","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01900","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023","kind":"paper","name":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.01935","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01935","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-harrison-j-clin-oncol","kind":"paper","name":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","route":"/key-papers/paper-harrison-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01935","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01935","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","field":"links","label":"JCO 2023"}]},{"url":"https://doi.org/10.1200/jco.22.01966","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-badwe-j-clin-oncol","kind":"paper","name":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","route":"/key-papers/paper-badwe-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01966","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01966","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lidocaine-peritumoral-tmh","kind":"trial","name":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial)","route":"/trials/lidocaine-peritumoral-tmh/","field":"links","label":"Badwe et al., JCO 2023"},{"id":"lidocaine-peritumoral-tmh","kind":"trial","name":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial)","route":"/trials/lidocaine-peritumoral-tmh/","field":"outcomes.source (5-year disease-free survival)"},{"id":"lidocaine-peritumoral-tmh","kind":"trial","name":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial)","route":"/trials/lidocaine-peritumoral-tmh/","field":"outcomes.source (5-year overall survival)"}]},{"url":"https://doi.org/10.1200/jco.22.01990","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01990","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-407-j-clin-oncol-2023-update","kind":"paper","name":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","route":"/key-papers/paper-keynote-407-j-clin-oncol-2023-update/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.01997","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01997","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sandhya-j-clin-oncol","kind":"paper","name":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer","route":"/key-papers/paper-sandhya-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.01997","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.01997","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","field":"links","label":"Olanzapine for anorexia (JCO 2023)"},{"id":"olanzapine-appetite-tmh","kind":"trial","name":"Low-dose olanzapine for cancer anorexia (Tata Memorial)","route":"/trials/olanzapine-appetite-tmh/","field":"links","label":"Sandhya et al. (JCO 2023)"},{"id":"olanzapine-appetite-tmh","kind":"trial","name":"Low-dose olanzapine for cancer anorexia (Tata Memorial)","route":"/trials/olanzapine-appetite-tmh/","field":"outcomes.source (Weight gain greater than 5% at 12 weeks)"}]},{"url":"https://doi.org/10.1200/jco.22.02200","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02200","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Disease-free survival at 4 years, low-risk relapse)"},{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Overall survival at 4 years, low-risk relapse)"},{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"outcomes.source (Disease-free survival at 4 years, low-risk relapse involving the bone marrow)"}]},{"url":"https://doi.org/10.1200/JCO.22.02200","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02200","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aall1331-low-risk-hogan-jco-2023","kind":"paper","name":"AALL1331: blinatumomab added to chemotherapy in low-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-low-risk-hogan-jco-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.22.02630","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02630","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-qin-j-clin-oncol","kind":"paper","name":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer","route":"/key-papers/paper-qin-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.02630","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02630","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","field":"links","label":"Qin et al., Journal of Clinical Oncology 2023: nimotuzumab plus gemcitabine for K-Ras wild-type pancreatic cancer (NOTABLE)"},{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","field":"outcomes.source (Overall survival)"},{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1200/JCO.22.02761","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02761","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"papers","label":"Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200"}]},{"url":"https://doi.org/10.1200/jco.22.02864","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02864","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Wolff, J Clin Oncol 2023: ASCO-CAP HER2 testing update (IHC 0 versus 1+ after DESTINY-Breast04)"},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"links","label":"Wolff, J Clin Oncol 2023: ASCO-CAP HER2 testing update (IHC 0 versus 1+ after DESTINY-Breast04)"},{"id":"paper-wolff-j-clin-oncol","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","route":"/key-papers/paper-wolff-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.22.02864","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.22.02864","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-testing-assays","kind":"drug","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","route":"/drugs/her2-testing-assays/","field":"links","label":"ASCO/CAP HER2 testing guideline update (2023)"}]},{"url":"https://doi.org/10.1200/jco.23.00294","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-key-j-clin-oncol","kind":"paper","name":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-key-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.23.00294","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00294","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","field":"links","label":"ASCO VTE guideline update 2023"}]},{"url":"https://doi.org/10.1200/JCO.23.00434","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00434","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"links","label":"Bekaii-Saab et al., adagrasib in KRAS G12C solid tumours, KRYSTAL-1 (JCO 2023)"},{"id":"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","kind":"paper","name":"KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer","route":"/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/","field":"links","label":"J Clin Oncol 2023"},{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","route":"/trials/nct03785249/","field":"links","label":"Bekaii-Saab et al., adagrasib in advanced solid tumours harbouring a KRAS G12C mutation (JCO 2023)"},{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","route":"/trials/nct03785249/","field":"outcomes.source (Objective response, pancreatic cancer cohort)"}]},{"url":"https://doi.org/10.1200/JCO.23.00558","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00558","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","field":"papers","label":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma"},{"id":"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023","kind":"paper","name":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","route":"/key-papers/paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.23.00606","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00606","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04579380-j-clin-oncol-2023","kind":"paper","name":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","route":"/key-papers/paper-nct04579380-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.23.00774","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00774","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","field":"papers","label":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer"},{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/","field":"links","label":"J Clin Oncol 2023"},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/","field":"links","label":"Journal of Clinical Oncology 2023"},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/","field":"outcomes.source (Objective response rate (independent review))"}]},{"url":"https://doi.org/10.1200/jco.23.00857","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00857","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carlson-j-clin-oncol","kind":"paper","name":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-carlson-j-clin-oncol/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.23.00857","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.00857","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mindfulness-based-interventions","kind":"technology","name":"Mindfulness-based stress reduction and cognitive therapy","route":"/technologies/mindfulness-based-interventions/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"},{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"},{"id":"relaxation-guided-imagery","kind":"technology","name":"Relaxation training and guided imagery","route":"/technologies/relaxation-guided-imagery/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"},{"id":"music-therapy-cancer","kind":"technology","name":"Music therapy and music medicine","route":"/technologies/music-therapy-cancer/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of anxiety and depression (JCO 2023)"}]},{"url":"https://doi.org/10.1200/jco.23.01059","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01059","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","field":"papers","label":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults"},{"id":"paper-andrew-lassman-j-clin-oncol-2023","kind":"paper","name":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/jco.23.01134","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01134","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-arrillaga-romany-j-clin-oncol","kind":"paper","name":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma","route":"/key-papers/paper-arrillaga-romany-j-clin-oncol/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.01134","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01134","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","field":"links","label":"Arrillaga-Romany et al., ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma: pooled analysis behind the accelerated approval (Journal of Clinical Oncology 2024)"}]},{"url":"https://doi.org/10.1200/jco.23.01208","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01208","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Verheij, J Clin Oncol 2024: long-term results of the OPRA trial (median follow-up 5.1 years)"},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","field":"links","label":"Verheij, J Clin Oncol 2024: long-term results of the OPRA trial (median follow-up 5.1 years)"},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","field":"links","label":"Verheij, J Clin Oncol 2024: long-term results of the OPRA trial (median follow-up 5.1 years)"},{"id":"paper-opra-j-clin-oncol-2024","kind":"paper","name":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","route":"/key-papers/paper-opra-j-clin-oncol-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.01361","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01361","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-goto-jco-2023","kind":"paper","name":"DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung02-goto-jco-2023/","field":"links","label":"J Clin Oncol 2023"},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/","field":"links","label":"Journal of Clinical Oncology 2023"},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/","field":"outcomes.source (Confirmed objective response rate)"}]},{"url":"https://doi.org/10.1200/jco.23.01476","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01476","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/","field":"links","label":"J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1200/JCO.23.01476","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01476","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tki-then-adc-lung","kind":"pairing","name":"EGFR TKI → ADC on progression","route":"/pairings/tki-then-adc-lung/","field":"links","label":"HERTHENA-Lung01: patritumab deruxtecan in EGFR-mutated NSCLC after EGFR TKI (Journal of Clinical Oncology 2023)"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"papers","label":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy"}]},{"url":"https://doi.org/10.1200/jco.23.01498","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01498","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"outcomes.source (Kidney rejection or graft loss)"},{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"outcomes.source (Objective response)"},{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"outcomes.source (Treatment-related grade 3 or higher adverse events)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (The transplant recipient and the immunosuppressed patient)"}]},{"url":"https://doi.org/10.1200/JCO.23.01498","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01498","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"Cemiplimab in kidney transplant recipients (Journal of Clinical Oncology 2024)"},{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"links","label":"Primary report (Journal of Clinical Oncology 2024)"}]},{"url":"https://doi.org/10.1200/jco.23.01500","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.01500","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04576455-j-clin-oncol-2024","kind":"paper","name":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","route":"/key-papers/paper-nct04576455-j-clin-oncol-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.02005","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02005","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"papers","label":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial"},{"id":"paper-destiny-pantumor02-jco-2024","kind":"paper","name":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","route":"/key-papers/paper-destiny-pantumor02-jco-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/jco.23.02010","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","kind":"paper","name":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","route":"/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/","field":"links","label":"Ohba et al., J Clin Oncol 2024: trastuzumab deruxtecan in HER2-expressing biliary tract cancer (HERB)"}]},{"url":"https://doi.org/10.1200/JCO.23.02132","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02132","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","field":"papers","label":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer"},{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.02225","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02225","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","kind":"paper","name":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","route":"/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/","field":"links","label":"Bedrosian et al., J Clin Oncol 2024: ASCO-SSO guideline on germline testing in breast cancer"}]},{"url":"https://doi.org/10.1200/jco.23.02474","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02474","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/","field":"outcomes.source (Relapse-free survival)"},{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/","field":"outcomes.source (Relapse-free survival, MRD detectable before or after transplant (prespecified subgroup, 50.5% of participants))"},{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/","field":"outcomes.source (Relapse-free survival, MRD not detectable)"}]},{"url":"https://doi.org/10.1200/JCO.23.02474","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02474","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-morpho-gilteritinib-levis-jco-2024","kind":"paper","name":"MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-morpho-gilteritinib-levis-jco-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/jco.23.02503","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02503","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03157128-j-clin-oncol-2024-update","kind":"paper","name":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","route":"/key-papers/paper-nct03157128-j-clin-oncol-2024-update/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/jco.23.02505","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02505","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aphinity-j-clin-oncol-2024-update","kind":"paper","name":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update","route":"/key-papers/paper-aphinity-j-clin-oncol-2024-update/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/jco.23.02596","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02596","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braun-j-clin-oncol","kind":"paper","name":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","route":"/key-papers/paper-braun-j-clin-oncol/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.02596","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02596","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cannabinoids-nausea","kind":"technology","name":"Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)","route":"/technologies/cannabinoids-nausea/","field":"links","label":"ASCO guideline: cannabis and cannabinoids in adults with cancer (JCO 2024)"},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","field":"links","label":"ASCO guideline: cannabis and cannabinoids in adults with cancer (JCO 2024)"}]},{"url":"https://doi.org/10.1200/jco.23.02659","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02659","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-philip-j-clin-oncol","kind":"paper","name":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study","route":"/key-papers/paper-philip-j-clin-oncol/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.23.02659","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.23.02659","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","field":"links","label":"Philip et al., Journal of Clinical Oncology 2024: devimistat with modified FOLFIRINOX versus FOLFIRINOX (AVENGER 500)"},{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","field":"outcomes.source (Overall survival)"},{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1200/jco.24.00542","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00542","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sanders-j-clin-oncol","kind":"paper","name":"Palliative Care for Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-sanders-j-clin-oncol/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.24.00542","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00542","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"ASCO guideline update 2024"}]},{"url":"https://doi.org/10.1200/jco.24.00720","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00720","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.24.00720","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00720","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"luminosity","kind":"trial","name":"LUMINOSITY","route":"/trials/luminosity/","field":"links","label":"Camidge et al., Telisotuzumab vedotin monotherapy in previously treated c-Met protein-overexpressing non-squamous NSCLC: LUMINOSITY (Journal of Clinical Oncology 2024)"},{"id":"luminosity","kind":"trial","name":"LUMINOSITY","route":"/trials/luminosity/","field":"outcomes.source (Objective response rate (independent review))"}]},{"url":"https://doi.org/10.1200/jco.24.00731","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00731","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/","field":"links","label":"J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1200/JCO.24.00826","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00826","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","field":"outcomes.source (Overall response rate)"}]},{"url":"https://doi.org/10.1200/JCO.24.00920","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00920","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","field":"outcomes.source (Objective response rate)"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"papers","label":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer (TROPION-Breast01)"}]},{"url":"https://doi.org/10.1200/jco.24.00975","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00975","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cll12","kind":"trial","name":"CLL12","route":"/trials/cll12/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"cll12","kind":"trial","name":"CLL12","route":"/trials/cll12/","field":"outcomes.source (Estimated overall survival at 10 years from diagnosis)"},{"id":"cll12","kind":"trial","name":"CLL12","route":"/trials/cll12/","field":"outcomes.source (Serious adverse events)"}]},{"url":"https://doi.org/10.1200/JCO.24.00975","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.00975","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025","kind":"paper","name":"CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial","route":"/key-papers/paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025/","field":"links","label":"J Clin Oncol 2025"}]},{"url":"https://doi.org/10.1200/JCO.24.01008","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.01008","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1200/JCO.24.01118","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.24.01118","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"Palmer et al., ESPAC4 long-term outcomes (JCO 2025)"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"links","label":"Palmer et al., ESPAC4 long-term outcomes (JCO 2025)"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"outcomes.source (Overall survival, long-term follow-up (median 104 months))"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"outcomes.source (Overall survival after R0 resection (long-term))"}]},{"url":"https://doi.org/10.1200/jop.2013.001319","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JOP.2013.001319","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yang-j-oncol-pract","kind":"paper","name":"Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage","route":"/key-papers/paper-yang-j-oncol-pract/","field":"links","label":"J Oncol Pract 2014"}]},{"url":"https://doi.org/10.1200/JOP.2013.001319","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JOP.2013.001319","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"links","label":"Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"metrics (Projected US shortage of oncologists by 2025 (ASCO workforce model))"},{"id":"idea-acc-clinical-officer-oncology-track","kind":"idea","name":"An 18-month oncology track for clinical officers and physician associates","route":"/ideas/idea-acc-clinical-officer-oncology-track/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-oncology-pharmacist-prescribing","kind":"idea","name":"Oncology pharmacists as protocol prescribers for supportive care and dose adjustments","route":"/ideas/idea-acc-oncology-pharmacist-prescribing/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-remote-medical-physics-qa","kind":"idea","name":"One medical physicist covering many radiotherapy machines through remote quality assurance","route":"/ideas/idea-acc-remote-medical-physics-qa/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-retention-packages-oncology","kind":"idea","name":"Retention packages so trained oncology staff stay: bonds, top-ups, working equipment","route":"/ideas/idea-acc-retention-packages-oncology/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-regional-oncology-training-hubs","kind":"idea","name":"Regional training hubs that produce oncologists, physicists and radiographers in-region","route":"/ideas/idea-acc-regional-oncology-training-hubs/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-ambient-ai-documentation-oncology","kind":"idea","name":"Ambient AI note-taking to give oncologists back a day a week","route":"/ideas/idea-acc-ambient-ai-documentation-oncology/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-advanced-practice-radiation-therapists","kind":"idea","name":"Advanced-practice radiation therapists doing contouring and on-treatment reviews","route":"/ideas/idea-acc-advanced-practice-radiation-therapists/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-nurse-led-follow-up-clinics","kind":"idea","name":"Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment","route":"/ideas/idea-acc-nurse-led-follow-up-clinics/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-acc-district-surgeon-oncology-mentorship","kind":"idea","name":"Structured mentorship so district general surgeons perform common cancer operations safely","route":"/ideas/idea-acc-district-surgeon-oncology-mentorship/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"},{"id":"idea-moon-task-shifting-ai-oncology-capacity","kind":"idea","name":"Double oncology capacity in low-resource settings with task-shifting and AI decision support","route":"/ideas/idea-moon-task-shifting-ai-oncology-capacity/","field":"links","label":"Bottleneck evidence (Not enough oncologists, nurses, pathologists, physicists): Yang et al., Projected supply of and demand for oncologists and radiation oncologists through 2025 (JOP 2014)"}]},{"url":"https://doi.org/10.1200/JOP.2015.009134","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JOP.2015.009134","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"papers","label":"American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology"}]},{"url":"https://doi.org/10.1200/OA-25-00177","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/OA-25-00177","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","field":"links","label":"EA1131: race, socioeconomic status and outcomes (JCO Oncology Advances 2026)"}]},{"url":"https://doi.org/10.1200/op-25-01248","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/OP-25-01248","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06099782-jco-oncol-pract-2026","kind":"paper","name":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","route":"/key-papers/paper-nct06099782-jco-oncol-pract-2026/","field":"links","label":"JCO Oncol Pract 2026"}]},{"url":"https://doi.org/10.1200/op.21.00438","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/OP.21.00438","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zon-jco-oncol-pract","kind":"paper","name":"Telehealth in Oncology: ASCO Standards and Practice Recommendations","route":"/key-papers/paper-zon-jco-oncol-pract/","field":"links","label":"JCO Oncol Pract 2021"}]},{"url":"https://doi.org/10.1200/OP.21.00438","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/OP.21.00438","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"telemedicine-teleoncology","kind":"technology","name":"Telemedicine, teleoncology, and telepathology","route":"/technologies/telemedicine-teleoncology/","field":"links","label":"Zon et al., Telehealth in oncology: ASCO standards and practice recommendations (JCO Oncology Practice 2021)"},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","field":"links","label":"ASCO telehealth standards 2021"}]},{"url":"https://doi.org/10.1200/po-24-00443","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO-24-00443","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025","kind":"paper","name":"Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection","route":"/key-papers/paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025/","field":"links","label":"JCO Precis Oncol 2025"}]},{"url":"https://doi.org/10.1200/po-24-00818","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO-24-00818","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/","field":"links","label":"JCO Precis Oncol 2025"}]},{"url":"https://doi.org/10.1200/po.17.00011","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.17.00011","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"papers","label":"OncoKB: A Precision Oncology Knowledge Base"},{"id":"paper-chakravarty-jco-precis-oncol","kind":"paper","name":"OncoKB: A Precision Oncology Knowledge Base","route":"/key-papers/paper-chakravarty-jco-precis-oncol/","field":"links","label":"JCO Precis Oncol 2017"}]},{"url":"https://doi.org/10.1200/PO.17.00011","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.17.00011","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","field":"links","label":"Chakravarty et al., OncoKB: a precision oncology knowledge base (JCO Precision Oncology 2017)"}]},{"url":"https://doi.org/10.1200/po.18.00283","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.18.00283","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/","field":"links","label":"JCO Precis Oncol 2019"},{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/","field":"links","label":"Chung et al., JCO Precision Oncology 2019: prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours"},{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"links","label":"Chung et al., JCO Precision Oncology 2019: prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours"}]},{"url":"https://doi.org/10.1200/po.18.00324","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.18.00324","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mody-biliary-ctdna-profiling-jco-po-2019","kind":"paper","name":"Circulating tumor DNA profiling of advanced biliary tract cancers","route":"/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/","field":"links","label":"Mody et al., JCO Precis Oncol 2019: circulating tumour DNA profiling of 124 biliary tract cancers"}]},{"url":"https://doi.org/10.1200/po.19.00345","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.19.00345","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"links","label":"Sokol et al., JCO Precision Oncology 2020: pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity"}]},{"url":"https://doi.org/10.1200/po.20.00037","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.20.00037","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ahn-jco-precis-oncol","kind":"paper","name":"Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","route":"/key-papers/paper-ahn-jco-precis-oncol/","field":"links","label":"JCO Precis Oncol 2020"}]},{"url":"https://doi.org/10.1200/PO.20.00037","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.20.00037","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","field":"links","label":"Ahn et al., JCO Precision Oncology 2020: palbociclib in non-small-cell lung cancer with CDKN2A alterations (TAPUR)"}]},{"url":"https://doi.org/10.1200/po.20.00495","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.20.00495","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"links","label":"Molecular tumour boards (JCO Precision Oncology)"},{"id":"paper-larson-jco-precis-oncol","kind":"paper","name":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","route":"/key-papers/paper-larson-jco-precis-oncol/","field":"links","label":"JCO Precis Oncol 2021"}]},{"url":"https://doi.org/10.1200/po.22.00306","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.22.00306","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gupta-jco-precis-oncol","kind":"paper","name":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study","route":"/key-papers/paper-gupta-jco-precis-oncol/","field":"links","label":"JCO Precis Oncol 2022"}]},{"url":"https://doi.org/10.1200/PO.22.00306","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.22.00306","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","field":"links","label":"Gupta et al., JCO Precision Oncology 2022: pertuzumab plus trastuzumab in colorectal cancer with ERBB2 amplification or ERBB2/3 mutations (TAPUR)"}]},{"url":"https://doi.org/10.1200/po.23.00615","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.23.00615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-perez-jco-precis-oncol","kind":"paper","name":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study","route":"/key-papers/paper-perez-jco-precis-oncol/","field":"links","label":"JCO Precis Oncol 2024"}]},{"url":"https://doi.org/10.1200/PO.23.00615","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/PO.23.00615","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","field":"links","label":"Concordance in molecular tumor board case reviews in the ASCO TAPUR study, JCO Precision Oncology 2024"}]},{"url":"https://doi.org/10.1210/clinem/dgaa520","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/105/11/3459/5891780","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","field":"links","label":"JCEM 2020: immune landscape of pituitary tumours, macrophages and gonadotroph tumour invasion"}]},{"url":"https://doi.org/10.1210/er.2002-0032","status":403,"ok":false,"finalUrl":"https://academic.oup.com/edrv/article/25/2/276/2355261","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-endocr-rev-2004","kind":"paper","name":"Androgen receptor in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-endocr-rev-2004/","field":"links","label":"Endocr Rev 2004"}]},{"url":"https://doi.org/10.1210/er.2007-0007","status":403,"ok":false,"finalUrl":"https://academic.oup.com/edrv/article/28/7/742/2355006","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-rev-2007","kind":"paper","name":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","route":"/key-papers/paper-braf-thyroid-endocr-rev-2007/","field":"links","label":"Endocr Rev 2007"}]},{"url":"https://doi.org/10.1210/jc.2006-0183","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/91/8/3071/2656604","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","field":"links","label":"JCEM 2006: adult Leydig cell tumours of the testis caused by germline fumarate hydratase mutations"}]},{"url":"https://doi.org/10.1210/jc.2012-1230","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/97/9/2990/2536740","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-thakker-j-clin-endocrinol-metab","kind":"paper","name":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","route":"/key-papers/paper-thakker-j-clin-endocrinol-metab/","field":"links","label":"J Clin Endocrinol Metab 2012"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"links","label":"MEN1 clinical practice guidelines (JCEM 2012)"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (MEN1 carriers)"},{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"links","label":"Thakker 2012, JCEM: clinical practice guidelines for MEN1"}]},{"url":"https://doi.org/10.1210/jc.2013-2383","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/98/9/E1562/2833058","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","field":"links","label":"Landa et al., Frequent somatic TERT promoter mutations in thyroid cancer (Journal of Clinical Endocrinology and Metabolism 2013)"},{"id":"paper-landa-j-clin-endocrinol-metab","kind":"paper","name":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","route":"/key-papers/paper-landa-j-clin-endocrinol-metab/","field":"links","label":"J Clin Endocrinol Metab 2013"}]},{"url":"https://doi.org/10.1210/jc.2014-1498","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/99/6/1915/2537399","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014","kind":"paper","name":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","route":"/key-papers/paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014/","field":"links","label":"J Clin Endocrinol Metab 2014"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"links","label":"Endocrine Society guideline 2014"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"standardOfCare.guideline (Localised, secreting)"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"standardOfCare.guideline (All patients)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"links","label":"Endocrine Society PPGL guideline 2014"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Genetic diagnosis)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Biochemical and imaging work-up)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Adrenal tumours in VHL and MEN2)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Head and neck paragangliomas)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Surveillance of carriers)"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"standardOfCare.guideline (Advanced disease in carriers)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"links","label":"Endocrine Society PPGL guideline 2014"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (All patients)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (Staging)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (Indolent disease)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (Progressive disease, radionuclide therapy)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (Progressive disease, systemic drugs)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"standardOfCare.guideline (Trials)"}]},{"url":"https://doi.org/10.1210/jc.2014-2700","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2014-2700","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"standardOfCare.guideline (Acromegaly, Cushing disease, symptomatic non-functioning tumours)"}]},{"url":"https://doi.org/10.1210/jc.2018-01956","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2018-01956/5253711","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","field":"links","label":"JCEM 2018: recurrence in silent corticotroph adenomas after primary treatment, meta-analysis of 297 patients"}]},{"url":"https://doi.org/10.1212/01.wnl.0000435745.95155.b8","status":403,"ok":false,"finalUrl":"https://www.neurology.org/doi/10.1212/01.wnl.0000435745.95155.b8","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","field":"links","label":"Neurology 2013: functional outcome measures for NF1-associated optic pathway glioma trials (REiNS)"}]},{"url":"https://doi.org/10.1242/dmm.010835","status":403,"ok":false,"finalUrl":"https://journals.biologists.com/dmm/article/doi/10.1242/dmm.010835/261885/Transmembrane-voltage-potential-is-an-essential","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chernet-dis-model-mech","kind":"paper","name":"Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model","route":"/key-papers/paper-chernet-dis-model-mech/","field":"links","label":"Dis Model Mech 2013"},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"links","label":"Chernet and Levin, Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model (Disease Models and Mechanisms 2013)"}]},{"url":"https://doi.org/10.1242/jcs.01000","status":403,"ok":false,"finalUrl":"https://journals.biologists.com/jcs/article/117/8/1495/28278/The-stroma-as-a-crucial-target-in-rat-mammary","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-maffini-j-cell-sci","kind":"paper","name":"The stroma as a crucial target in rat mammary gland carcinogenesis","route":"/key-papers/paper-maffini-j-cell-sci/","field":"links","label":"J Cell Sci 2004"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"links","label":"Maffini et al., The stroma as a crucial target in rat mammary gland carcinogenesis (Journal of Cell Science 2004)"}]},{"url":"https://doi.org/10.1242/jcs.025742","status":403,"ok":false,"finalUrl":"https://journals.biologists.com/jcs/article/121/Supplement_1/1/2844/Concerning-the-Origin-of-Malignant-Tumours-by","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-boveri-j-cell-sci","kind":"paper","name":"Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris","route":"/key-papers/paper-boveri-j-cell-sci/","field":"links","label":"J Cell Sci 2008"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Boveri, Concerning the origin of malignant tumours, translated and annotated by Henry Harris (Journal of Cell Science 2008)"}]},{"url":"https://doi.org/10.1258/jrsm.2011.110180","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1258/jrsm.2011.110180","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"links","label":"Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"metrics (Estimated average time for research evidence to reach clinical practice)"},{"id":"idea-data-structured-trial-results-deposit","kind":"idea","name":"Deposit trial results as structured data, not just PDFs","route":"/ideas/idea-data-structured-trial-results-deposit/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-provenance-first-decision-support","kind":"idea","name":"Decision support that cites the exact trial and guideline line it relies on","route":"/ideas/idea-data-provenance-first-decision-support/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-guideline-concordance-dashboards","kind":"idea","name":"Real-time guideline-concordance feedback for every cancer centre","route":"/ideas/idea-data-guideline-concordance-dashboards/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-patient-explainers-per-recommendation","kind":"idea","name":"A plain-language explainer for every guideline recommendation, in every major language","route":"/ideas/idea-data-patient-explainers-per-recommendation/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-living-llm-oncology-benchmark","kind":"idea","name":"A monthly-updated benchmark for AI answers to oncology questions with citation accuracy","route":"/ideas/idea-data-living-llm-oncology-benchmark/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-rapid-guideline-translation","kind":"idea","name":"Expert-verified translation of guideline updates into 20 languages within 30 days","route":"/ideas/idea-data-rapid-guideline-translation/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-toxicity-cds-for-nurses","kind":"idea","name":"Toxicity-management decision support for nurses and pharmacists","route":"/ideas/idea-data-toxicity-cds-for-nurses/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-72-hour-second-opinion-network","kind":"idea","name":"A digital second-opinion network answering community oncologists within 72 hours","route":"/ideas/idea-data-72-hour-second-opinion-network/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-standard-of-care-change-alerts","kind":"idea","name":"Subscribable alerts when the standard of care changes for a patient's situation","route":"/ideas/idea-data-standard-of-care-change-alerts/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-implementation-trials-programme","kind":"idea","name":"Randomised trials of how to spread proven cancer treatments, not just what works","route":"/ideas/idea-data-implementation-trials-programme/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-order-set-defaults-30-days","kind":"idea","name":"Update hospital order sets within 30 days of a guideline change","route":"/ideas/idea-data-order-set-defaults-30-days/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/","field":"links","label":"Bottleneck evidence (Knowledge reaches practice too slowly): Morris, Wooding & Grant, The answer is 17 years, what is the question (JRSM 2011)"},{"id":"paper-morris-j-r-soc-med","kind":"paper","name":"The answer is 17 years, what is the question: understanding time lags in translational research","route":"/key-papers/paper-morris-j-r-soc-med/","field":"links","label":"J R Soc Med 2011"}]},{"url":"https://doi.org/10.12998/wjcc.v10.i23.8212","status":403,"ok":false,"finalUrl":"https://www.wjgnet.com/2307-8960/full/v10/i23/8212.htm","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"links","label":"Cai and Wu, World J Clin Cases 2022: gallbladder neuroendocrine carcinoma in SEER"}]},{"url":"https://doi.org/10.1377/hlthaff.2012.1263","status":403,"ok":false,"finalUrl":"https://www.healthaffairs.org/doi/10.1377/hlthaff.2012.1263","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"links","label":"Ramsey et al., Washington State cancer patients found to be at greater risk for bankruptcy (Health Affairs 2013)"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"metrics (Likelihood of bankruptcy among US patients with cancer vs matched controls (Washington State))"},{"id":"idea-cost-financial-toxicity-screening","kind":"idea","name":"Screen every patient for money trouble the way we screen for pain","route":"/ideas/idea-cost-financial-toxicity-screening/","field":"links","label":"Ramsey et al., Health Affairs 2013: Washington State cancer patients and bankruptcy"},{"id":"paper-ramsey-health-aff-millwood","kind":"paper","name":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","route":"/key-papers/paper-ramsey-health-aff-millwood/","field":"links","label":"Health Aff (Millwood) 2013"}]},{"url":"https://doi.org/10.1510/icvts.2007.152298","status":403,"ok":false,"finalUrl":"https://academic.oup.com/icvts/article-lookup/doi/10.1510/icvts.2007.152298","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"papers","label":"Surgical removal of an embolised patent ductus arteriosus amplatzer occluding device in a 4-year-old girl"}]},{"url":"https://doi.org/10.1510/icvts.2011.266890","status":403,"ok":false,"finalUrl":"https://academic.oup.com/icvts/article-lookup/doi/10.1510/icvts.2011.266890","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"papers","label":"Risk stratification analysis of operative mortality in isolated coronary artery bypass graft patients in Pakistan: comparison between additive and logistic EuroSCORE models"}]},{"url":"https://doi.org/10.1530/eje-17-0796","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ejendo/article/178/1/G1/6655223","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-raverot-eur-j-endocrinol","kind":"paper","name":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","route":"/key-papers/paper-raverot-eur-j-endocrinol/","field":"links","label":"Eur J Endocrinol 2018"}]},{"url":"https://doi.org/10.1530/EJE-17-0796","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ejendo/article/178/1/G1/6655223","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"links","label":"ESE guideline: aggressive pituitary tumours and carcinomas (2018)"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"standardOfCare.guideline (Aggressive PitNET or pituitary carcinoma)"}]},{"url":"https://doi.org/10.1530/EJE-18-0608","status":403,"ok":false,"finalUrl":"https://academic.oup.com/ejendo/article/179/4/G1/6655445","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"links","label":"ESE/ENSAT ACC guideline 2018"},{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"standardOfCare.guideline (Localised (ENSAT I-III))"},{"id":"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018","kind":"paper","name":"European Society of Endocrinology and ENSAT clinical practice guidelines on the management of adrenocortical carcinoma in adults","route":"/key-papers/paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018/","field":"links","label":"Eur J Endocrinol 2018"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"links","label":"ESE/ENSAT guideline 2018"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"standardOfCare.guideline (Resectable disease)"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"standardOfCare.guideline (After complete resection, low risk)"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"standardOfCare.guideline (After resection, high risk)"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"standardOfCare.guideline (Local recurrence)"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"links","label":"ESE/ENSAT guideline 2018"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"standardOfCare.guideline (All patients)"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"standardOfCare.guideline (Low-burden, indolent disease)"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"standardOfCare.guideline (High-burden or progressive disease, first line)"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"standardOfCare.guideline (After EDP-M)"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"standardOfCare.guideline (Trials)"}]},{"url":"https://doi.org/10.1530/erc-14-0472","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/erc/article/22/1/111-119/33853","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","field":"links","label":"Endocrine-Related Cancer 2015: SSTR3 as a target for the medical treatment of gonadotroph adenomas, 108 patients"}]},{"url":"https://doi.org/10.1530/ERC-15-0119","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/erc/article/22/4/657-664/33952","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-heetfeld-grade-3-net-erc-2015","kind":"paper","name":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","route":"/key-papers/paper-heetfeld-grade-3-net-erc-2015/","field":"links","label":"Endocr Relat Cancer 2015"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"links","label":"Heetfeld et al. (Endocrine-Related Cancer 2015)"}]},{"url":"https://doi.org/10.1530/erc-23-0337","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/erc/article/25861","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","field":"outcomes.source (Progression-free survival on lanreotide across double-blind and open-label phases (adapted primary endpoint))"},{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","field":"outcomes.source (Progression-free survival, double-blind phase)"},{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","field":"outcomes.source (Progression-free survival, double-blind phase, typical carcinoids)"}]},{"url":"https://doi.org/10.1634/theoncologist.2009-0029","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/15/8/799/6399417","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"papers","label":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study"}]},{"url":"https://doi.org/10.1634/theoncologist.2012-0279","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/18/4/381/6398748","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Zafar 2013 (Oncologist)"},{"id":"paper-zafar-oncologist","kind":"paper","name":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","route":"/key-papers/paper-zafar-oncologist/","field":"links","label":"Oncologist 2013"}]},{"url":"https://doi.org/10.1634/theoncologist.2012-0397","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/18/2/123/6398754","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Prat, Oncologist 2013: molecular characterisation of basal-like and non-basal-like triple-negative breast cancer"},{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"links","label":"Prat, Oncologist 2013: molecular characterisation of basal-like and non-basal-like triple-negative breast cancer"}]},{"url":"https://doi.org/10.1634/theoncologist.2018-0266","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/24/5/691/6439151","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Hendifar, Oncologist 2019: pancreas cancer-associated weight loss"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Hendifar, Oncologist 2019: pancreas cancer-associated weight loss"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Hendifar, Oncologist 2019: pancreas cancer-associated weight loss"}]},{"url":"https://doi.org/10.1634/theoncologist.2018-0383","status":403,"ok":false,"finalUrl":"https://academic.oup.com/oncolo/article/24/4/549/6439154","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-taha-oncologist","kind":"paper","name":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies","route":"/key-papers/paper-taha-oncologist/","field":"links","label":"Oncologist 2019"},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","field":"links","label":"Cannabis impacts tumour response rate to nivolumab (Oncologist 2019)"}]},{"url":"https://doi.org/10.1677/erc.1.0978","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/erc/article/12/2/245/26629/BRAF-mutation-in-thyroid-cancer","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-relat-cancer-2005","kind":"paper","name":"BRAF mutation in thyroid cancer","route":"/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/","field":"links","label":"Endocr Relat Cancer 2005"}]},{"url":"https://doi.org/10.18632/oncotarget.2454","status":403,"ok":false,"finalUrl":"https://www.oncotarget.com/article/2454/text/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"papers","label":"Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes"}]},{"url":"https://doi.org/10.18632/oncotarget.8036","status":403,"ok":false,"finalUrl":"https://www.oncotarget.com/article/8036/text/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chernet-oncotarget","kind":"paper","name":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis","route":"/key-papers/paper-chernet-oncotarget/","field":"links","label":"Oncotarget 2016"},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"links","label":"Chernet, Adams, Lobikin and Levin, Use of genetically encoded, light-gated ion translocators to control tumorigenesis (Oncotarget 2016)"}]},{"url":"https://doi.org/10.2174/1874471011666180416161908","status":403,"ok":false,"finalUrl":"https://www.eurekaselect.com/161324/article","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Historic global actinium-225 supply from thorium-229 stockpiles)"}]},{"url":"https://doi.org/10.21873/anticanres.18194","status":403,"ok":false,"finalUrl":"https://ar.iiarjournals.org/content/46/6/3243","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Hulscher cohort 2026"},{"id":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","kind":"paper","name":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","route":"/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/","field":"links","label":"Hulscher cohort 2026"}]},{"url":"https://doi.org/10.21873/anticanres.18276","status":403,"ok":false,"finalUrl":"https://ar.iiarjournals.org/content/46/6/e3243","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Anticancer Research expression of concern 2026"},{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","field":"links","label":"Anticancer Research expression of concern 2026"},{"id":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","kind":"paper","name":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","route":"/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/","field":"links","label":"Anticancer Research expression of concern 2026"}]},{"url":"https://doi.org/10.2217/fon-2017-0338","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.2217/fon-2017-0338","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"Trial design rationale (Future Oncol 2018)"}]},{"url":"https://doi.org/10.2217/fon-2021-1096","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.2217/fon-2021-1096","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"papers","label":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer"}]},{"url":"https://doi.org/10.2337/dc16-0985","status":403,"ok":false,"finalUrl":"https://diabetesjournals.org/care/article/40/4/468/3980/Trends-in-Drug-Utilization-Glycemic-Control-and","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"papers","label":"Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013"}]},{"url":"https://doi.org/10.3109/02841868809090333","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.3109/02841868809090333","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-withers-acta-oncol","kind":"paper","name":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","route":"/key-papers/paper-withers-acta-oncol/","field":"links","label":"Acta Oncol 1988"},{"id":"fractionation-repopulation-models","kind":"technology","name":"The four Rs and accelerated repopulation","route":"/technologies/fractionation-repopulation-models/","field":"links","label":"Withers, Taylor and Maciejewski 1988, Acta Oncologica"}]},{"url":"https://doi.org/10.3109/0284186x.2014.895036","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/full/10.3109/0284186X.2014.895036","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-acta-oncol-2014","kind":"paper","name":"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis","route":"/key-papers/paper-pik3ca-colorectal-acta-oncol-2014/","field":"links","label":"Acta Oncol 2014"}]},{"url":"https://doi.org/10.3171/2011.2.jns10998","status":403,"ok":false,"finalUrl":"https://thejns.org/view/journals/j-neurosurg/115/1/article-p3.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","field":"links","label":"Sanai et al., An extent of resection threshold for newly diagnosed glioblastomas (Journal of Neurosurgery 2011)"},{"id":"paper-sanai-j-neurosurg","kind":"paper","name":"An extent of resection threshold for newly diagnosed glioblastomas","route":"/key-papers/paper-sanai-j-neurosurg/","field":"links","label":"J Neurosurg 2011"}]},{"url":"https://doi.org/10.3171/2012.8.peds12132","status":403,"ok":false,"finalUrl":"https://thejns.org/view/journals/j-neurosurg-pediatr/10/5/article-p398.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","field":"links","label":"J Neurosurg Pediatrics 2012: treatment of choroid plexus tumours, 20-year single-institution experience"}]},{"url":"https://doi.org/10.3171/2013.8.jns13844","status":403,"ok":false,"finalUrl":"https://thejns.org/view/journals/j-neurosurg/119/6/article-p1537.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"papers","label":"A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia"}]},{"url":"https://doi.org/10.3171/2014.7.jns1471","status":403,"ok":false,"finalUrl":"https://thejns.org/view/journals/j-neurosurg/121/6/article-p1462.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","field":"links","label":"J Neurosurg 2014: thyrotropin-secreting pituitary adenomas, 90 cases treated by transsphenoidal surgery"}]},{"url":"https://doi.org/10.3171/2020.10.jns203236","status":403,"ok":false,"finalUrl":"https://thejns.org/view/journals/j-neurosurg/135/6/article-p1706.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","field":"links","label":"J Neurosurg 2021: silent corticotroph adenomas, 100 patients against 841 other non-functioning adenomas"}]},{"url":"https://doi.org/10.3322/ca.2007.0010","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/CA.2007.0010","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jemal-cancer-statistics-2008-cacancer-2008","kind":"paper","name":"Jemal 2008: Cancer statistics, 2008","route":"/key-papers/paper-jemal-cancer-statistics-2008-cacancer-2008/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.20107","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/caac.20107","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"papers","label":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)"},{"id":"paper-jemal-global-cancer-statistics-2011-cacancer","kind":"paper","name":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)","route":"/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.20111","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/caac.20111","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","field":"links","label":"Freeman patient navigation (CA Cancer J Clin 2011)"},{"id":"paper-paskett-ca-cancer-j-clin","kind":"paper","name":"Patient navigation: an update on the state of the science","route":"/key-papers/paper-paskett-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2011"}]},{"url":"https://doi.org/10.3322/caac.20114","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/caac.20114","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-agostinis-ca-cancer-j-clin","kind":"paper","name":"Photodynamic therapy of cancer: an update","route":"/key-papers/paper-agostinis-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2011"},{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/","field":"links","label":"Agostinis et al., Photodynamic therapy of cancer: an update (CA: A Cancer Journal for Clinicians 2011)"}]},{"url":"https://doi.org/10.3322/caac.20138","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.20138","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2012-cacancer-2012","kind":"paper","name":"Siegel 2012: Cancer statistics, 2012","route":"/key-papers/paper-siegel-cancer-statistics-2012-cacancer-2012/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21166","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21166","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2013-cacancer-2013","kind":"paper","name":"Siegel 2013: Cancer statistics, 2013","route":"/key-papers/paper-siegel-cancer-statistics-2013-cacancer-2013/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21208","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21208","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2014-cacancer-2014","kind":"paper","name":"Siegel 2014: Cancer statistics, 2014","route":"/key-papers/paper-siegel-cancer-statistics-2014-cacancer-2014/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21254","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21254","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2015-cacancer-2015","kind":"paper","name":"Siegel 2015: Cancer statistics, 2015","route":"/key-papers/paper-siegel-cancer-statistics-2015-cacancer-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21262","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21262","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"papers","label":"Torre 2015: Global cancer statistics, 2012"},{"id":"paper-torre-global-cancer-statistics-2012-cacancer-2015","kind":"paper","name":"Torre 2015: Global cancer statistics, 2012","route":"/key-papers/paper-torre-global-cancer-statistics-2012-cacancer-2015/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21332","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21332","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2016-cacancer-2016","kind":"paper","name":"Siegel 2016: Cancer statistics, 2016","route":"/key-papers/paper-siegel-cancer-statistics-2016-cacancer-2016/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21338","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21338","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-cancer-statistics-china-2015-cacancer-2016","kind":"paper","name":"Chen 2016: Cancer statistics in China, 2015","route":"/key-papers/paper-chen-cancer-statistics-china-2015-cacancer-2016/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21387","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21387","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2017-cacancer-2017","kind":"paper","name":"Siegel 2017: Cancer statistics, 2017","route":"/key-papers/paper-siegel-cancer-statistics-2017-cacancer-2017/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21393","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21393","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Giuliano, CA Cancer J Clin 2017: major changes in the AJCC 8th edition breast cancer staging manual"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"Giuliano, CA Cancer J Clin 2017: major changes in the AJCC 8th edition breast cancer staging manual"}]},{"url":"https://doi.org/10.3322/caac.21397","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21397","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-greenlee-ca-cancer-j-clin","kind":"paper","name":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","route":"/key-papers/paper-greenlee-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2017"},{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","field":"links","label":"SIO clinical practice guideline: integrative therapies during and after breast cancer treatment (CA Cancer J Clin 2017)"},{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","field":"links","label":"SIO clinical practice guideline: integrative therapies during and after breast cancer treatment (CA Cancer J Clin 2017)"},{"id":"reflexology-cancer","kind":"technology","name":"Reflexology","route":"/technologies/reflexology-cancer/","field":"links","label":"SIO clinical practice guideline: integrative therapies during and after breast cancer treatment (CA Cancer J Clin 2017)"},{"id":"reiki-energy-therapies","kind":"technology","name":"Reiki, healing touch and other energy therapies","route":"/technologies/reiki-energy-therapies/","field":"links","label":"SIO clinical practice guideline: integrative therapies during and after breast cancer treatment (CA Cancer J Clin 2017)"}]},{"url":"https://doi.org/10.3322/caac.21409","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21409","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","field":"links","label":"Gershenwald et al., Melanoma staging: evidence-based changes in the AJCC eighth edition (CA: A Cancer Journal for Clinicians 2017)"},{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","field":"papers","label":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual"},{"id":"paper-ajcc-8-melanoma-gershenwald-ca-2017","kind":"paper","name":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","route":"/key-papers/paper-ajcc-8-melanoma-gershenwald-ca-2017/","field":"links","label":"CA Cancer J Clin 2017"}]},{"url":"https://doi.org/10.3322/caac.21440","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21440","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"links","label":"Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"metrics (Share of US cancer cases and deaths attributable to potentially modifiable risk factors (2014))"},{"id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hpylori-family-test-and-treat","kind":"idea","name":"Family-based H. pylori test-and-treat to prevent stomach cancer","route":"/ideas/idea-prev-hpylori-family-test-and-treat/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-opt-out-cessation-in-lung-screening","kind":"idea","name":"Every lung screening visit includes stop-smoking medicine, opt-out","route":"/ideas/idea-prev-opt-out-cessation-in-lung-screening/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-cytisine-essential-medicine","kind":"idea","name":"Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list","route":"/ideas/idea-prev-cytisine-essential-medicine/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-alcohol-cancer-warning-labels","kind":"idea","name":"Cancer warnings on alcohol labels, evaluated as a natural experiment","route":"/ideas/idea-prev-alcohol-cancer-warning-labels/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-chemoprevention-master-protocol","kind":"idea","name":"One master trial for cancer prevention drugs across many precancers","route":"/ideas/idea-prev-chemoprevention-master-protocol/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-commercial-sunbed-ban","kind":"idea","name":"Ban commercial sunbeds","route":"/ideas/idea-prev-commercial-sunbed-ban/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-screening-default-appointments","kind":"idea","name":"Send screening invitations with a pre-booked time, not a request to call","route":"/ideas/idea-prev-screening-default-appointments/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-pharmacy-prevention-hub","kind":"idea","name":"Community pharmacies as one-stop cancer prevention hubs","route":"/ideas/idea-prev-pharmacy-prevention-hub/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-pay-for-prevention-outcomes","kind":"idea","name":"Pay insurers and health systems for cancers prevented and caught early","route":"/ideas/idea-prev-pay-for-prevention-outcomes/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-precursor-endpoints-for-approval","kind":"idea","name":"Regulators accept shrinking of precancer as the endpoint for prevention drug approval","route":"/ideas/idea-prev-precursor-endpoints-for-approval/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-hpv-male-catchup-oropharynx","kind":"idea","name":"Catch-up HPV vaccination for men to prevent throat cancer","route":"/ideas/idea-prev-hpv-male-catchup-oropharynx/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2018"},{"id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"},{"id":"idea-nl-upf-controlled-feeding-trial","kind":"idea","name":"Controlled feeding trials to separate ultra-processing from calories","route":"/ideas/idea-nl-upf-controlled-feeding-trial/","field":"links","label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)"}]},{"url":"https://doi.org/10.3322/caac.21442","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21442","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2018-cacancer-2018","kind":"paper","name":"Siegel 2018: Cancer statistics, 2018","route":"/key-papers/paper-siegel-cancer-statistics-2018-cacancer-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21492","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21492","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"papers","label":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers"},{"id":"paper-bray-globocan-2018-cacancer-2018","kind":"paper","name":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","route":"/key-papers/paper-bray-globocan-2018-cacancer-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21551","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21551","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2019-cacancer-2019","kind":"paper","name":"Siegel 2019: Cancer statistics, 2019","route":"/key-papers/paper-siegel-cancer-statistics-2019-cacancer-2019/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21591","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21591","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rock-ca-cancer-j-clin","kind":"paper","name":"American Cancer Society guideline for diet and physical activity for cancer prevention","route":"/key-papers/paper-rock-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2020"},{"id":"mediterranean-plant-forward-diet","kind":"technology","name":"Mediterranean and plant-forward dietary patterns","route":"/technologies/mediterranean-plant-forward-diet/","field":"links","label":"ACS nutrition and physical activity guideline 2020"}]},{"url":"https://doi.org/10.3322/caac.21638","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21638","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"links","label":"Sedrak et al., Older adult participation in cancer clinical trials: systematic review (CA 2021)"},{"id":"paper-sedrak-ca-cancer-j-clin","kind":"paper","name":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","route":"/key-papers/paper-sedrak-ca-cancer-j-clin/","field":"links","label":"CA Cancer J Clin 2021"}]},{"url":"https://doi.org/10.3322/caac.21654","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21654","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2021-cacancer-2021","kind":"paper","name":"Siegel 2021: Cancer statistics, 2021","route":"/key-papers/paper-siegel-cancer-statistics-2021-cacancer-2021/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21660","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"links","label":"GLOBOCAN 2020 (Sung 2021)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"GLOBOCAN 2020 (Sung 2021)"},{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/","field":"links","label":"GLOBOCAN 2020 (Sung 2021)"},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"papers","label":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer"},{"id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21708","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21708","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2022-cacancer-2022","kind":"paper","name":"Siegel 2022: Cancer statistics, 2022","route":"/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21763","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21763","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2023-cacancer-2023","kind":"paper","name":"Siegel 2023: Cancer statistics, 2023","route":"/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21772","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21772","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Colorectal cancer statistics, 2023 (American Cancer Society, CA: a Cancer Journal for Clinicians)"},{"id":"paper-siegel-colorectal-cancer-statistics-ca-2023","kind":"paper","name":"Colorectal cancer statistics, 2023","route":"/key-papers/paper-siegel-colorectal-cancer-statistics-ca-2023/","field":"links","label":"CA Cancer J Clin 2023"}]},{"url":"https://doi.org/10.3322/caac.21820","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21820","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2024-cacancer-2024","kind":"paper","name":"Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report","route":"/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.21834","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"metrics (New cancer cases and cancer deaths worldwide, 2022)"},{"id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.70067","status":403,"ok":false,"finalUrl":"https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70067","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Colorectal cancer statistics, 2026 (American Cancer Society, CA: a Cancer Journal for Clinicians)"},{"id":"colibactin","kind":"term","name":"Colibactin","route":"/terms/colibactin/","field":"links","label":"Colorectal cancer statistics, 2026 (American Cancer Society, CA: a Cancer Journal for Clinicians)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"links","label":"Colorectal cancer statistics, 2026 (American Cancer Society, CA: a Cancer Journal for Clinicians)"}]},{"url":"https://doi.org/10.3322/canjclin.22.4.232","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/canjclin.22.4.232","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-huggins-hodges-castration-serum-phosphatases-prostate-1941","kind":"paper","name":"Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","route":"/key-papers/paper-huggins-hodges-castration-serum-phosphatases-prostate-1941/","field":"links","label":"CA Cancer J Clin 1972 reprint of the 1941 article"}]},{"url":"https://doi.org/10.3322/canjclin.55.2.74","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/canjclin.55.2.74","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"papers","label":"Parkin 2005: Global cancer statistics, 2002"},{"id":"paper-parkin-global-cancer-statistics-2002-cacancer-2005","kind":"paper","name":"Parkin 2005: Global cancer statistics, 2002","route":"/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/canjclin.57.1.43","status":403,"ok":false,"finalUrl":"http://doi.wiley.com/10.3322/canjclin.57.1.43","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jemal-cancer-statistics-2007-cacancer-2007","kind":"paper","name":"Jemal 2007: Cancer statistics, 2007","route":"/key-papers/paper-jemal-cancer-statistics-2007-cacancer-2007/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3390/biomedicines14030600","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2227-9059/14/3/600","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bia-alcl","kind":"term","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/terms/bia-alcl/","field":"links","label":"Genetic susceptibility and current prevention guidance in BIA-ALCL (Biomedicines 2026)"}]},{"url":"https://doi.org/10.3390/cancers10100365","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/10/10/365","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"papers","label":"Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data"}]},{"url":"https://doi.org/10.3390/cancers11070971","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/11/7/971","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/","field":"links","label":"Cancers (Basel) 2019"}]},{"url":"https://doi.org/10.3390/cancers12030733","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/12/3/733","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neuroendocrine-neoplasms-breast","kind":"cancer","name":"Neuroendocrine neoplasms of the breast","route":"/cancers/neuroendocrine-neoplasms-breast/","field":"links","label":"Cancers 2020: primary neuroendocrine neoplasms of the breast, case series and literature review"}]},{"url":"https://doi.org/10.3390/cancers13030498","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/13/3/498","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/","field":"links","label":"Cancers 2021: desmoplastic small round cell tumour, molecular abnormalities and emerging therapy (review)"}]},{"url":"https://doi.org/10.3390/cancers13030547","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/13/3/547","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Giannis, Cancers 2021: AJCC 8th edition validation in the National Cancer Database"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"links","label":"Giannis, Cancers 2021: AJCC 8th edition validation in the National Cancer Database"},{"id":"paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021","kind":"paper","name":"Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors","route":"/key-papers/paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021/","field":"links","label":"Cancers 2021"}]},{"url":"https://doi.org/10.3390/cancers13071682","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/13/7/1682","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-albrecht-pdl1-western-gallbladder-cancers-2021","kind":"paper","name":"Programmed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancer","route":"/key-papers/paper-albrecht-pdl1-western-gallbladder-cancers-2021/","field":"links","label":"Albrecht et al., Cancers 2021: PD-L1 in 131 Western gallbladder cancers"}]},{"url":"https://doi.org/10.3390/cancers13225694","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/13/22/5694","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cserni, Cancers 2021: triple-negative breast cancer histological subtypes with a favourable prognosis (European Working Group for Breast Screening Pathology)"},{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Cserni, Cancers 2021: triple-negative breast cancer histological subtypes with a favourable prognosis (European Working Group for Breast Screening Pathology)"},{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","field":"links","label":"Cserni, Cancers 2021: triple-negative breast cancer histological subtypes with a favourable prognosis (European Working Group for Breast Screening Pathology)"},{"id":"secretory-carcinoma-breast","kind":"cancer","name":"Secretory carcinoma of the breast","route":"/cancers/secretory-carcinoma-breast/","field":"links","label":"Cserni, Cancers 2021: triple-negative breast cancer histological subtypes with a favourable prognosis (European Working Group for Breast Screening Pathology)"}]},{"url":"https://doi.org/10.3390/cancers14071598","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/14/7/1598","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"papers","label":"Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer"}]},{"url":"https://doi.org/10.3390/cancers14194818","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/14/19/4818","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","field":"links","label":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test (Cancers 2022)"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","field":"links","label":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test (Cancers 2022)"},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/","field":"papers","label":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test"},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.3390/cancers15164033","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/15/16/4033","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Zollner, Cancers 2023: Mapuche ancestry and gallbladder cancer, Mendelian randomisation"}]},{"url":"https://doi.org/10.3390/cancers16030494","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/16/3/494","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","field":"links","label":"Genotype-specific phenotype in MEN2 against the guideline predictions, Cancers 2024"}]},{"url":"https://doi.org/10.3390/cancers16040800","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/16/4/800","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/","field":"links","label":"Zimmerman and Esteva, Cancers 2024: next-generation HER2-targeted antibody-drug conjugates (table of payloads and linkers)"}]},{"url":"https://doi.org/10.3390/cancers17243921","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/17/24/3921","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Morecroft et al., immunotherapy and radiation for clinical perineural invasion in cutaneous squamous cell carcinoma (Cancers 2025)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Morecroft et al., immunotherapy and radiation for clinical perineural invasion in cutaneous squamous cell carcinoma (Cancers 2025)"},{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","field":"links","label":"Morecroft et al., immunotherapy and radiation for clinical perineural invasion in cutaneous squamous cell carcinoma (Cancers 2025)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Ibrahim et al., immunotherapy and radiation for clinical perineural invasion in cutaneous squamous cell carcinoma (Cancers 2025)"}]},{"url":"https://doi.org/10.3390/cancers18010054","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/18/1/54","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancers-basel-2025","kind":"paper","name":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review","route":"/key-papers/paper-cd47-colorectal-cancers-basel-2025/","field":"links","label":"Cancers (Basel) 2025"}]},{"url":"https://doi.org/10.3390/cancers18030531","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/18/3/531","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026","kind":"paper","name":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-cancers-basel-2026/","field":"links","label":"Cancers (Basel) 2026"}]},{"url":"https://doi.org/10.3390/cancers8060056","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2072-6694/8/6/56","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","field":"papers","label":"Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer"}]},{"url":"https://doi.org/10.3390/curroncol31060243","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1718-7729/31/6/243","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd47-neuroblastoma-curr-oncol-2024","kind":"paper","name":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma","route":"/key-papers/paper-cd47-neuroblastoma-curr-oncol-2024/","field":"links","label":"Curr Oncol 2024"}]},{"url":"https://doi.org/10.3390/healthcare11050746","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2227-9032/11/5/746","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"Healthcare 2023: invasive lobular carcinoma, a review of imaging modalities and pathology concordance"}]},{"url":"https://doi.org/10.3390/healthcare12111057","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2227-9032/12/11/1057","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"papers","label":"Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities"}]},{"url":"https://doi.org/10.3390/healthcare14172833","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2227-9032/14/17/2833","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Psychological symptoms, quality of life and resilience in patients with recurrent non-melanoma skin cancer, 160 patients after surgery for facial disease (Healthcare 2026)"}]},{"url":"https://doi.org/10.3390/ijms17091433","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1422-0067/17/9/1433","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"papers","label":"Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type"}]},{"url":"https://doi.org/10.3390/ijms22063132","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1422-0067/22/6/3132","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"papers","label":"Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs"}]},{"url":"https://doi.org/10.3390/ijms23169324","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1422-0067/23/16/9324","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"papers","label":"The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer"}]},{"url":"https://doi.org/10.3390/ijms262110755","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1422-0067/26/21/10755","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025","kind":"paper","name":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025/","field":"links","label":"Int J Mol Sci 2025"}]},{"url":"https://doi.org/10.3390/jcm10153317","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2077-0383/10/15/3317","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021","kind":"paper","name":"Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021/","field":"links","label":"J Clin Med 2021"}]},{"url":"https://doi.org/10.3390/jcm14030934","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2077-0383/14/3/934","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"papers","label":"Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes"}]},{"url":"https://doi.org/10.3390/jcm9051484","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2077-0383/9/5/1484","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020","kind":"paper","name":"Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis","route":"/key-papers/paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020/","field":"links","label":"J Clin Med 2020"}]},{"url":"https://doi.org/10.3390/jpm13061009","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2075-4426/13/6/1009","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"links","label":"Khan, J Pers Med 2023: surgery and adjuvant chemotherapy in gallbladder neuroendocrine carcinoma"}]},{"url":"https://doi.org/10.3390/jpm16060298","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2075-4426/16/6/298","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"curesponse","kind":"company","name":"Curesponse","route":"/companies/curesponse/","field":"links","label":"Clinical utility study (2026)"},{"id":"paper-bar-j-pers-med","kind":"paper","name":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment","route":"/key-papers/paper-bar-j-pers-med/","field":"links","label":"J Pers Med 2026"}]},{"url":"https://doi.org/10.3390/nursrep13010030","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2039-4403/13/1/30","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Loja survey 2023"},{"id":"paper-jimenez-gaona-ivermectin-loja-ecuador-2023","kind":"paper","name":"Outcome of ivermectin in cancer treatment: an experience in Loja, Ecuador","route":"/key-papers/paper-jimenez-gaona-ivermectin-loja-ecuador-2023/","field":"links","label":"Loja survey 2023"}]},{"url":"https://doi.org/10.3390/pharmaceutics13020252","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1999-4923/13/2/252","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"papers","label":"Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area"}]},{"url":"https://doi.org/10.3390/v14030525","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1999-4915/14/3/525","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hietanen-rigvir-echovirus-viruses-2022","kind":"paper","name":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","route":"/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/","field":"links","label":"Viruses 2022"}]},{"url":"https://doi.org/10.3390/v14092078","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1999-4915/14/9/2078","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hietanen-rigvir-echovirus-viruses-2022","kind":"paper","name":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","route":"/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/","field":"links","label":"Authors' reply to the manufacturer's comment"}]},{"url":"https://doi.org/10.3390/vaccines12090958","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2076-393X/12/9/958","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/","field":"links","label":"Vaccines 2024 (open access)"}]},{"url":"https://doi.org/10.3390/vaccines14020140","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/2076-393X/14/2/140","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-akgor-vaccines-basel","kind":"paper","name":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review","route":"/key-papers/paper-akgor-vaccines-basel/","field":"links","label":"Vaccines (Basel) 2026"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","field":"links","label":"New HPV vaccines on the market (Vaccines 2026)"}]},{"url":"https://doi.org/10.3747/co.20.1230","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/1718-7729/20/3/1230","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"Current Oncology 2013: management of renal collecting duct carcinoma, systematic review"}]},{"url":"https://doi.org/10.3748/wjg.v18.i22.2775","status":403,"ok":false,"finalUrl":"https://www.wjgnet.com/1007-9327/full/v18/i22/2775.htm","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Regional lymphadenectomy for gallbladder cancer: rational extent (World J Gastroenterol 2012, 152 patients)"}]},{"url":"https://doi.org/10.3928/01477447-20070301-04","status":403,"ok":false,"finalUrl":"https://journals.healio.com/doi/10.3928/01477447-20070301-04","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adamantinoma","kind":"cancer","name":"Adamantinoma of bone","route":"/cancers/adamantinoma/","field":"links","label":"Orthopedics 2007: clinicopathological features, diagnosis and treatment of adamantinoma of the long bones"}]},{"url":"https://doi.org/10.4067/s0034-98872019000700860","status":403,"ok":false,"finalUrl":"http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000700860&lng=en&nrm=iso&tlng=en","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019","kind":"paper","name":"Changes in gallbladder cancer mortality and hospital discharges due to preventive cholecystectomy in Chile","route":"/key-papers/paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019/","field":"links","label":"Rev Med Chile 2019"}]},{"url":"https://doi.org/10.4067/s0034-98872024001001028","status":403,"ok":false,"finalUrl":"http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872024001001028&lng=en&nrm=iso&tlng=en","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024","kind":"paper","name":"Gallbladder Cancer: Is It Time to Modify the Explicit Health Guarantees (GES) Program?","route":"/key-papers/paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024/","field":"links","label":"Rev Med Chile 2024"}]},{"url":"https://doi.org/10.4161/21624011.2014.945378","status":403,"ok":false,"finalUrl":"https://www.tandfonline.com/doi/abs/10.4161/21624011.2014.945378","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"papers","label":"Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using <i>ex vivo</i> myeloid-derived suppressor cells as a readout of therapeutic efficacy"}]},{"url":"https://doi.org/10.4240/wjgs.v14.i11.1272","status":403,"ok":false,"finalUrl":"https://www.wjgnet.com/1948-9366/full/v14/i11/1272.htm","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Sinha, World J Gastrointest Surg 2022: CA 19-9, CEA, CA 125 and CA 242 in gallbladder cancer"}]},{"url":"https://doi.org/10.4269/ajtmh.16-0302","status":403,"ok":false,"finalUrl":"https://www.ajtmh.org/view/journals/tpmd/97/1/article-p3.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"papers","label":"Precisely Tracking Childhood Death"}]},{"url":"https://doi.org/10.5301/tj.5000366","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.5301/tj.5000366","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"papers","label":"Hope in Cancer Patients: The Relational Domain as a Crucial Factor"}]},{"url":"https://doi.org/10.5301/tj.5000709","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.5301/tj.5000709","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"papers","label":"Thirty-day mortality and five-year survival in thoracic surgery: “real-world” assessment of outcomes from a single-institution audit"}]},{"url":"https://doi.org/10.5858/2007-131-796-accotb","status":403,"ok":false,"finalUrl":"https://aplm.kglmeridian.com/view/journals/arpa/131/5/article-p796.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bartholin-gland-carcinoma","kind":"cancer","name":"Bartholin gland carcinoma","route":"/cancers/bartholin-gland-carcinoma/","field":"links","label":"Archives of Pathology 2007: adenoid cystic carcinoma of the Bartholin gland, an overview"}]},{"url":"https://doi.org/10.5858/arpa.2011-0447-oa","status":403,"ok":false,"finalUrl":"https://aplm.kglmeridian.com/view/journals/arpa/136/11/article-p1347.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"Dursun, Arch Pathol Lab Med 2012: mucinous carcinomas of the gallbladder, 15 of 606 carcinomas"},{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","field":"links","label":"Dursun, Arch Pathol Lab Med 2012: mucinous carcinomas of the gallbladder, 15 of 606 carcinomas"}]},{"url":"https://doi.org/10.5858/arpa.2013-0452-oa","status":403,"ok":false,"finalUrl":"https://aplm.kglmeridian.com/view/journals/arpa/138/8/article-p1015.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","field":"links","label":"Archives of Pathology 2014: cadherin-17 and SATB2 in medullary carcinoma of the large intestine"}]},{"url":"https://doi.org/10.5858/arpa.2016-0040-ra","status":403,"ok":false,"finalUrl":"https://aplm.kglmeridian.com/view/journals/arpa/140/8/article-p799.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-micropapillary-carcinoma-breast","kind":"cancer","name":"Invasive micropapillary carcinoma of the breast","route":"/cancers/invasive-micropapillary-carcinoma-breast/","field":"links","label":"Archives of Pathology 2016: invasive micropapillary carcinoma of the breast, an update"}]},{"url":"https://doi.org/10.6004/jnccn.2017.0058","status":403,"ok":false,"finalUrl":"https://jnccn.org/doi/10.6004/jnccn.2017.0058","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017","kind":"paper","name":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/","field":"links","label":"Singhi et al., JNCCN 2017: ALK rearrangements in 5 of 3,170 pancreatic ductal adenocarcinomas"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"prevalence.source"}]},{"url":"https://doi.org/10.6004/jnccn.2021.0017","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/19/4/article-p439.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Tempero, JNCCN 2021: NCCN pancreatic adenocarcinoma guidelines, version 2.2021"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"Tempero, JNCCN 2021: NCCN pancreatic adenocarcinoma guidelines, version 2.2021"},{"id":"paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021","kind":"paper","name":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","route":"/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/","field":"links","label":"JNCCN 2021"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"Tempero, JNCCN 2021: NCCN pancreatic adenocarcinoma guidelines, version 2.2021"}]},{"url":"https://doi.org/10.6004/jnccn.2021.0058","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/19/12/article-p1441.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"papers","label":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology"}]},{"url":"https://doi.org/10.6004/jnccn.2025.0042","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/23/9/article-p403.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025","kind":"paper","name":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025/","field":"links","label":"JNCCN 2025"}]},{"url":"https://doi.org/10.6004/jnccn.2025.5012","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/23/Supplement/article-e255012.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors"}]},{"url":"https://doi.org/10.6004/jnccn.2026.0033","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nccn-breast-cancer-v4-2026-jnccn-2026","kind":"paper","name":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/","field":"links","label":"JNCCN 2026"}]},{"url":"https://doi.org/10.7326/0003-4819-125-5-199609010-00003","status":403,"ok":false,"finalUrl":"https://www.acpjournals.org/doi/10.7326/0003-4819-125-5-199609010-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"papers","label":"A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group"}]},{"url":"https://doi.org/10.7326/0003-4819-149-6-200809160-00003","status":403,"ok":false,"finalUrl":"https://www.acpjournals.org/doi/10.7326/0003-4819-149-6-200809160-00003","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kutner-ann-intern-med","kind":"paper","name":"Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial","route":"/key-papers/paper-kutner-ann-intern-med/","field":"links","label":"Ann Intern Med 2008"},{"id":"massage-therapy-cancer","kind":"technology","name":"Massage therapy in cancer care","route":"/technologies/massage-therapy-cancer/","field":"links","label":"Massage therapy versus simple touch to improve pain and mood in advanced cancer, randomised trial (Ann Intern Med 2008)"}]},{"url":"https://doi.org/10.7326/0003-4819-157-2-201207170-00459","status":403,"ok":false,"finalUrl":"https://www.acpjournals.org/doi/10.7326/0003-4819-157-2-201207170-00459","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-moyer-uspstf-prostate-screening-ann-intern-med-2012","kind":"paper","name":"USPSTF 2012: screening for prostate cancer, recommendation statement (grade D)","route":"/key-papers/paper-moyer-uspstf-prostate-screening-ann-intern-med-2012/","field":"links","label":"Ann Intern Med 2012"}]},{"url":"https://doi.org/10.7326/m21-0252","status":403,"ok":false,"finalUrl":"https://www.acpjournals.org/doi/10.7326/M21-0252","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sheikh-ann-intern-med","kind":"paper","name":"Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study","route":"/key-papers/paper-sheikh-ann-intern-med/","field":"links","label":"Ann Intern Med 2021"}]},{"url":"https://doi.org/10.7326/M21-0252","status":403,"ok":false,"finalUrl":"https://www.acpjournals.org/doi/10.7326/M21-0252","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","field":"links","label":"Smoking cessation after early lung cancer diagnosis (Ann Intern Med 2021)"}]},{"url":"https://doi.org/10.7759/cureus.108896","status":403,"ok":false,"finalUrl":"https://www.cureus.com/articles/478304-drug-induced-liver-injury-following-co-ingestion-of-veterinary-fenbendazole-and-ivermectin-for-prostate-cancer-a-case-report","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Powderly case report 2026"},{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"links","label":"Powderly case report 2026"},{"id":"paper-powderly-fenbendazole-ivermectin-liver-injury-2026","kind":"paper","name":"Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report","route":"/key-papers/paper-powderly-fenbendazole-ivermectin-liver-injury-2026/","field":"links","label":"Powderly case report 2026"}]},{"url":"https://doi.org/10.7759/cureus.113927","status":403,"ok":false,"finalUrl":"https://www.cureus.com/articles/509930-daraxonrasib-a-breakthrough-in-pancreatic-ductal-adenocarcinoma","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-cureus-2026","kind":"paper","name":"Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma","route":"/key-papers/paper-daraxonrasib-pancreatic-cureus-2026/","field":"links","label":"Cureus 2026"}]},{"url":"https://doi.org/10.7759/cureus.21884","status":403,"ok":false,"finalUrl":"https://www.cureus.com/articles/83821-synergistic-anti-tumor-effect-of-dichloroacetate-and-ivermectin","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ishiguro-dichloroacetate-ivermectin-cureus-2022","kind":"paper","name":"Synergistic anti-tumor effect of dichloroacetate and ivermectin","route":"/key-papers/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022/","field":"links","label":"Ishiguro case series 2022"}]},{"url":"https://ecri.mcmaster.ca","status":403,"ok":false,"finalUrl":"https://ecri.mcmaster.ca/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","field":"links","label":"Escarpment Cancer Research Institute"}]},{"url":"https://euoncology.europeanurology.com","status":403,"ok":false,"finalUrl":"https://euoncology.europeanurology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","field":"url"}]},{"url":"https://europepmc.org","status":403,"ok":false,"finalUrl":"https://europepmc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10577699","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chart-lung","kind":"trial","name":"CHART","route":"/trials/chart-lung/","field":"links","label":"Radiotherapy and Oncology 1999 (mature results)"}]},{"url":"https://europepmc.org/article/MED/1059147","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mintz-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Normal genetically mosaic mice produced from malignant teratocarcinoma cells","route":"/key-papers/paper-mintz-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10615079","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hutchins-n-engl-j-med","kind":"paper","name":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","route":"/key-papers/paper-hutchins-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10676951","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alizadeh-nature","kind":"paper","name":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","route":"/key-papers/paper-alizadeh-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10791373","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-der-zee-lancet","kind":"paper","name":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group","route":"/key-papers/paper-van-der-zee-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10817793","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"big-lung-trial","kind":"trial","name":"Big Lung Trial","route":"/trials/big-lung-trial/","field":"links","label":"Thorax 2000 (recruitment)"}]},{"url":"https://europepmc.org/article/MED/10888934","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/10963602","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Perou et al.: molecular portraits of human breast tumours (Nature 2000)"}]},{"url":"https://europepmc.org/article/MED/11063134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-swanson-cell-prolif","kind":"paper","name":"A quantitative model for differential motility of gliomas in grey and white matter","route":"/key-papers/paper-swanson-cell-prolif/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/11323675","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shankaran-nature","kind":"paper","name":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","route":"/key-papers/paper-shankaran-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/11547741","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-macdonald-n-engl-j-med","kind":"paper","name":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","route":"/key-papers/paper-macdonald-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/11597399","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-gastric-eur-j-cancer-2001","kind":"paper","name":"EGFR and cancer prognosis","route":"/key-papers/paper-egfr-gastric-eur-j-cancer-2001/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/11742045","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-goodwin-n-engl-j-med","kind":"paper","name":"The effect of group psychosocial support on survival in metastatic breast cancer","route":"/key-papers/paper-goodwin-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/11948273","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-birkmeyer-n-engl-j-med","kind":"paper","name":"Hospital volume and surgical mortality in the United States","route":"/key-papers/paper-birkmeyer-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12045100","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bell-annu-rev-biochem","kind":"paper","name":"DNA replication in eukaryotic cells","route":"/key-papers/paper-bell-annu-rev-biochem/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12128137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jaffray-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Flat-panel cone-beam computed tomography for image-guided radiation therapy","route":"/key-papers/paper-jaffray-int-j-radiat-oncol-biol-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12189228","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mathijssen-j-natl-cancer-inst","kind":"paper","name":"Effects of St. John's wort on irinotecan metabolism","route":"/key-papers/paper-mathijssen-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12407406","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dunn-nat-immunol","kind":"paper","name":"Cancer immunoediting: from immunosurveillance to tumor escape","route":"/key-papers/paper-dunn-nat-immunol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/1247951","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Nevin et al.: carcinoma of the gallbladder, staging, treatment and prognosis (Cancer 1976)"}]},{"url":"https://europepmc.org/article/MED/12668651","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-citron-j-clin-oncol","kind":"paper","name":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741","route":"/key-papers/paper-citron-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12672281","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2003","kind":"paper","name":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2003/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12731504","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-contopoulos-ioannidis-am-j-med","kind":"paper","name":"Translation of highly promising basic science research into clinical applications","route":"/key-papers/paper-contopoulos-ioannidis-am-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12767102","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-swain-cancer","kind":"paper","name":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","route":"/key-papers/paper-swain-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12778055","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-doronina-nat-biotechnol","kind":"paper","name":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","route":"/key-papers/paper-doronina-nat-biotechnol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12778130","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bergers-nat-rev-cancer","kind":"paper","name":"Tumorigenesis and the angiogenic switch","route":"/key-papers/paper-bergers-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12778135","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fidler-nat-rev-cancer","kind":"paper","name":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited","route":"/key-papers/paper-fidler-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/12829800","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Sorlie et al.: repeated observation of breast tumour subtypes; BRCA1 predisposes to the basal subtype (PNAS 2003)"}]},{"url":"https://europepmc.org/article/MED/13172380","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-armitage-br-j-cancer","kind":"paper","name":"The age distribution of cancer and a multi-stage theory of carcinogenesis","route":"/key-papers/paper-armitage-br-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/13205425","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Glenn and Hays: the scope of radical surgery in malignant tumours of the extrahepatic biliary tract (Surg Gynecol Obstet 1954)"}]},{"url":"https://europepmc.org/article/MED/13298683","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-warburg-science","kind":"paper","name":"On the origin of cancer cells","route":"/key-papers/paper-warburg-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/13404306","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-burnet-br-med-j","kind":"paper","name":"Cancer; a biological approach. I. The processes of control","route":"/key-papers/paper-burnet-br-med-j/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/14219541","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-laird-br-j-cancer","kind":"paper","name":"DYNAMICS OF TUMOR GROWTH","route":"/key-papers/paper-laird-br-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/14551293","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-peritoneal-disease-found-early-and-treated-in-networks","kind":"idea","name":"Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy","route":"/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/","field":"links","label":"Verwaal et al.: cytoreduction and HIPEC (J Clin Oncol 2003)"}]},{"url":"https://europepmc.org/article/MED/14585940","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shattuck-n-engl-j-med","kind":"paper","name":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","route":"/key-papers/paper-shattuck-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/14996910","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-maffini-j-cell-sci","kind":"paper","name":"The stroma as a crucial target in rat mammary gland carcinogenesis","route":"/key-papers/paper-maffini-j-cell-sci/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15082523","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-endocr-rev-2004","kind":"paper","name":"Androgen receptor in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-endocr-rev-2004/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15175436","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15200998","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"big-lung-trial","kind":"trial","name":"Big Lung Trial","route":"/trials/big-lung-trial/","field":"links","label":"European Journal of Cardio-Thoracic Surgery 2004 (surgical setting)"}]},{"url":"https://europepmc.org/article/MED/15217868","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-doll-hill-mortality-of-doctors-smoking-bmj-1954","kind":"paper","name":"The mortality of doctors in relation to their smoking habits; a preliminary report","route":"/key-papers/paper-doll-hill-mortality-of-doctors-smoking-bmj-1954/","field":"links","label":"BMJ 2004 reprint of the 1954 report"}]},{"url":"https://europepmc.org/article/MED/15217923","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","kind":"paper","name":"Mesothelin: a new target for immunotherapy","route":"/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/1522903","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-delattre-nature","kind":"paper","name":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","route":"/key-papers/paper-delattre-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15317891","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cristofanilli-n-engl-j-med","kind":"paper","name":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","route":"/key-papers/paper-cristofanilli-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15342805","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hughes-n-engl-j-med","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","route":"/key-papers/paper-hughes-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15343276","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-burden-to-funding-audit-and-dedicated-call","kind":"idea","name":"A burden-to-funding audit for gallbladder cancer and a dedicated research call","route":"/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/","field":"links","label":"Wistuba and Gazdar: gallbladder cancer, lessons from a rare tumour (Nat Rev Cancer 2004)"}]},{"url":"https://europepmc.org/article/MED/15454647","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"big-lung-trial","kind":"trial","name":"Big Lung Trial","route":"/trials/big-lung-trial/","field":"links","label":"Thorax 2004 (supportive care setting)"}]},{"url":"https://europepmc.org/article/MED/15470213","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15601557","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-xia-h101-head-neck-aizheng-2004","kind":"paper","name":"Xia 2004: the randomised trial behind China's approval of the oncolytic adenovirus H101","route":"/key-papers/paper-xia-h101-head-neck-aizheng-2004/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15637262","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jain-science","kind":"paper","name":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","route":"/key-papers/paper-jain-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15674951","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-taixiang-cochrane-database-syst-rev","kind":"paper","name":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients","route":"/key-papers/paper-taixiang-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15719031","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ren-nat-rev-cancer","kind":"paper","name":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","route":"/key-papers/paper-ren-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15744408","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950","kind":"paper","name":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","route":"/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/","field":"links","label":"WHO Bulletin republication (2005)"}]},{"url":"https://europepmc.org/article/MED/15858187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kralovics-n-engl-j-med","kind":"paper","name":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","route":"/key-papers/paper-kralovics-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15947100","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-relat-cancer-2005","kind":"paper","name":"BRAF mutation in thyroid cancer","route":"/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/15988530","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-michor-nature","kind":"paper","name":"Dynamics of chronic myeloid leukaemia","route":"/key-papers/paper-michor-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16043828","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-j-clin-oncol-2005","kind":"paper","name":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","route":"/key-papers/paper-kras-nsclc-j-clin-oncol-2005/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16049480","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-minn-nature","kind":"paper","name":"Genes that mediate breast cancer metastasis to lung","route":"/key-papers/paper-minn-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16083707","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-new-onset-diabetes-risk-score-pathway","kind":"idea","name":"Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers","route":"/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/","field":"links","label":"Chari et al.: probability of pancreatic cancer following diabetes (Gastroenterology 2005)"}]},{"url":"https://europepmc.org/article/MED/16120859","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braun-n-engl-j-med","kind":"paper","name":"A pooled analysis of bone marrow micrometastasis in breast cancer","route":"/key-papers/paper-braun-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16133112","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sakamoto-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials","route":"/key-papers/paper-sakamoto-cancer-immunol-immunother/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16169468","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paszek-cancer-cell","kind":"paper","name":"Tensional homeostasis and the malignant phenotype","route":"/key-papers/paper-paszek-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16236737","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","route":"/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16236738","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16325696","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-lancet-2005","kind":"paper","name":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","route":"/key-papers/paper-jak2-polycythaemia-vera-lancet-2005/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16341007","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kaplan-nature","kind":"paper","name":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","route":"/key-papers/paper-kaplan-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16369569","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet-2006","kind":"paper","name":"The epigenetic progenitor origin of human cancer","route":"/key-papers/paper-feinberg-nat-rev-genet-2006/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16417259","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-doronina-bioconjug-chem","kind":"paper","name":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","route":"/key-papers/paper-doronina-bioconjug-chem/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16625560","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ezzo-cochrane-database-syst-rev","kind":"paper","name":"Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","route":"/key-papers/paper-ezzo-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16648043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stummer-lancet-oncol","kind":"paper","name":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","route":"/key-papers/paper-stummer-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16757721","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Carey et al.: race, breast cancer subtypes and survival in the Carolina Breast Cancer Study (JAMA 2006)"}]},{"url":"https://europepmc.org/article/MED/16821799","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-widdison-j-med-chem","kind":"paper","name":"Semisynthetic maytansine analogues for the targeted treatment of cancer","route":"/key-papers/paper-widdison-j-med-chem/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16883312","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-huang-bone-marrow-transplant","kind":"paper","name":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","route":"/key-papers/paper-huang-bone-marrow-transplant/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/16984925","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mercury","kind":"trial","name":"MERCURY","route":"/trials/mercury/","field":"links","label":"BMJ 2006"}]},{"url":"https://europepmc.org/article/MED/17035650","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-oeffinger-n-engl-j-med","kind":"paper","name":"Chronic health conditions in adult survivors of childhood cancer","route":"/key-papers/paper-oeffinger-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17060945","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-calin-nat-rev-cancer","kind":"paper","name":"MicroRNA signatures in human cancers","route":"/key-papers/paper-calin-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17089851","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keall-med-phys","kind":"paper","name":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","route":"/key-papers/paper-keall-med-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17106715","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-oba-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer","route":"/key-papers/paper-oba-cancer-immunol-immunother/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17109012","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-merlo-nat-rev-cancer","kind":"paper","name":"Cancer as an evolutionary and ecological process","route":"/key-papers/paper-merlo-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17189716","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-weaver-cancer-cell","kind":"paper","name":"Aneuploidy acts both oncogenically and as a tumor suppressor","route":"/key-papers/paper-weaver-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17253515","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dewey-cochrane-database-syst-rev","kind":"paper","name":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","route":"/key-papers/paper-dewey-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17426725","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-musacchio-nat-rev-mol-cell-biol","kind":"paper","name":"The spindle-assembly checkpoint in space and time","route":"/key-papers/paper-musacchio-nat-rev-mol-cell-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17635889","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-whel-jama-2007","kind":"paper","name":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial","route":"/key-papers/paper-whel-jama-2007/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17671126","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Dent et al.: triple-negative breast cancer, clinical features and patterns of recurrence (Clin Cancer Res 2007)"}]},{"url":"https://europepmc.org/article/MED/17679017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet","kind":"paper","name":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","route":"/key-papers/paper-sankaranarayanan-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17699816","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-slotman-n-engl-j-med","kind":"paper","name":"Prophylactic cranial irradiation in extensive small-cell lung cancer","route":"/key-papers/paper-slotman-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17721432","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007","kind":"paper","name":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","route":"/key-papers/paper-jak2-polycythaemia-vera-nat-rev-cancer-2007/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17728216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-montgomery-j-natl-cancer-inst","kind":"paper","name":"A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients","route":"/key-papers/paper-montgomery-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17785706","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-symmans-j-clin-oncol","kind":"paper","name":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","route":"/key-papers/paper-symmans-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17846848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Pawlik et al.: residual disease at re-resection for incidental gallbladder carcinoma (J Gastrointest Surg 2007)"}]},{"url":"https://europepmc.org/article/MED/17856666","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935","kind":"paper","name":"Treatment of carcinoma of the ampulla of Vater","route":"/key-papers/paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935/","field":"links","label":"Europe PMC full text (PMC1391173)"}]},{"url":"https://europepmc.org/article/MED/17940185","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-rev-2007","kind":"paper","name":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","route":"/key-papers/paper-braf-thyroid-endocr-rev-2007/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/17984186","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hillmen-j-clin-oncol","kind":"paper","name":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","route":"/key-papers/paper-hillmen-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18032762","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007","kind":"paper","name":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18083404","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/","field":"links","label":"Lancet 2007"},{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/","field":"outcomes.source (All-cause mortality)"}]},{"url":"https://europepmc.org/article/MED/18089652","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-boveri-j-cell-sci","kind":"paper","name":"Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris","route":"/key-papers/paper-boveri-j-cell-sci/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18216292","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-khorana-blood","kind":"paper","name":"Development and validation of a predictive model for chemotherapy-associated thrombosis","route":"/key-papers/paper-khorana-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18316791","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2008","kind":"paper","name":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2008/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18425885","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-horneber-cochrane-database-syst-rev","kind":"paper","name":"Mistletoe therapy in oncology","route":"/key-papers/paper-horneber-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18472276","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sonnenschein-semin-cancer-biol","kind":"paper","name":"Theories of carcinogenesis: an emerging perspective","route":"/key-papers/paper-sonnenschein-semin-cancer-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18539529","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-prado-lancet-oncol","kind":"paper","name":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","route":"/key-papers/paper-prado-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18548043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18626472","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-caldecott-nat-rev-genet","kind":"paper","name":"Single-strand break repair and genetic disease","route":"/key-papers/paper-caldecott-nat-rev-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18628784","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schafer-nat-rev-mol-cell-biol","kind":"paper","name":"Cancer as an overhealing wound: an old hypothesis revisited","route":"/key-papers/paper-schafer-nat-rev-mol-cell-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18670422","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Diehl et al.: circulating mutant DNA to assess tumour dynamics (Nature Medicine 2008)"}]},{"url":"https://europepmc.org/article/MED/18728265","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-saper-jama","kind":"paper","name":"Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet","route":"/key-papers/paper-saper-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18779615","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-uk-trial-access-and-germline-testing-audit","kind":"idea","name":"A UK audit of trial access and germline testing uptake in triple-negative breast cancer","route":"/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/","field":"links","label":"Atchley et al.: BRCA status and triple-negative breast cancer (J Clin Oncol 2008)"}]},{"url":"https://europepmc.org/article/MED/18794556","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kutner-ann-intern-med","kind":"paper","name":"Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial","route":"/key-papers/paper-kutner-ann-intern-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18809612","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-elkins-j-clin-oncol","kind":"paper","name":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","route":"/key-papers/paper-elkins-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18813320","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-epstein-nat-rev-cancer","kind":"paper","name":"Basal cell carcinomas: attack of the hedgehog","route":"/key-papers/paper-epstein-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/18833576","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-brain-metastasis-trials","kind":"idea","name":"Trials that include, and report, brain metastases in triple-negative breast cancer","route":"/ideas/idea-tnbc-brain-metastasis-trials/","field":"links","label":"Lin et al.: sites of distant recurrence in metastatic triple-negative breast cancer, high incidence of central nervous system metastases (Cancer 2008)"}]},{"url":"https://europepmc.org/article/MED/18875018","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Mandel and Metais: nucleic acids in human blood plasma (C R Seances Soc Biol Fil 1948)"}]},{"url":"https://europepmc.org/article/MED/18974103","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-devita-cancer-res","kind":"paper","name":"A history of cancer chemotherapy","route":"/key-papers/paper-devita-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19052619","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-quintana-nature","kind":"paper","name":"Efficient tumour formation by single human melanoma cells","route":"/key-papers/paper-quintana-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19204204","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-parker-j-clin-oncol","kind":"paper","name":"Supervised risk predictor of breast cancer based on intrinsic subtypes","route":"/key-papers/paper-parker-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19238148","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-malumbres-nat-rev-cancer","kind":"paper","name":"Cell cycle, CDKs and cancer: a changing paradigm","route":"/key-papers/paper-malumbres-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19269519","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cr07","kind":"trial","name":"MRC CR07","route":"/trials/cr07/","field":"links","label":"Lancet 2009"},{"id":"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009","kind":"paper","name":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)","route":"/key-papers/paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009/","field":"links","label":"Europe PMC full text (PMC2668947)"}]},{"url":"https://europepmc.org/article/MED/19360079","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stratton-nature","kind":"paper","name":"The cancer genome","route":"/key-papers/paper-stratton-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19370613","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kassab-cochrane-database-syst-rev","kind":"paper","name":"Homeopathic medicines for adverse effects of cancer treatments","route":"/key-papers/paper-kassab-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19460998","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vander-heiden-science","kind":"paper","name":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","route":"/key-papers/paper-vander-heiden-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19487300","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gatenby-cancer-res","kind":"paper","name":"Adaptive therapy","route":"/key-papers/paper-gatenby-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19538134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/","field":"links","label":"Croft 2009, Immunol Rev (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/19556163","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sjostrom-lancet-oncol","kind":"paper","name":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","route":"/key-papers/paper-sjostrom-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19636060","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19675330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schmitz-n-engl-j-med","kind":"paper","name":"Weight lifting in women with breast-cancer-related lymphedema","route":"/key-papers/paper-schmitz-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19692680","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19734877","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gupta-nat-med","kind":"paper","name":"Cancer stem cells: mirage or reality?","route":"/key-papers/paper-gupta-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19738203","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-sci-signal-2009","kind":"paper","name":"Oncogenic EGFR signaling networks in glioma","route":"/key-papers/paper-egfr-glioblastoma-sci-signal-2009/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19773751","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-colorectal-br-j-cancer-2009","kind":"paper","name":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis","route":"/key-papers/paper-ezh2-colorectal-br-j-cancer-2009/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19782876","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mcculloch-lancet","kind":"paper","name":"No surgical innovation without evaluation: the IDEAL recommendations","route":"/key-papers/paper-mcculloch-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19826129","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-heng-j-clin-oncol","kind":"paper","name":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","route":"/key-papers/paper-heng-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19931152","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-levental-cell","kind":"paper","name":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","route":"/key-papers/paper-levental-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/19955524","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-klaveren-n-engl-j-med","kind":"paper","name":"Management of lung nodules detected by volume CT scanning","route":"/key-papers/paper-van-klaveren-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20008640","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2010","kind":"paper","name":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2010/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20023215","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sparano-blood","kind":"paper","name":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-sparano-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20026804","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-azacitidine-aml-j-clin-oncol-2010","kind":"paper","name":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","route":"/key-papers/paper-azacitidine-aml-j-clin-oncol-2010/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20171515","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bentzen-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","route":"/key-papers/paper-bentzen-int-j-radiat-oncol-biol-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20181022","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-seyfried-nutr-metab-lond","kind":"paper","name":"Cancer as a metabolic disease","route":"/key-papers/paper-seyfried-nutr-metab-lond/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20332315","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-taylor-bmj","kind":"paper","name":"Multidisciplinary team working in cancer: what is the evidence?","route":"/key-papers/paper-taylor-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20355252","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lazebnik-nat-rev-cancer","kind":"paper","name":"What are the hallmarks of cancer?","route":"/key-papers/paper-lazebnik-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20371346","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sharma-cell","kind":"paper","name":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","route":"/key-papers/paper-sharma-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20375404","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ABC-02: cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (NEJM 2010)"}]},{"url":"https://europepmc.org/article/MED/20413742","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-welch-j-natl-cancer-inst","kind":"paper","name":"Overdiagnosis in cancer","route":"/key-papers/paper-welch-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20428194","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","kind":"paper","name":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","route":"/key-papers/paper-jak2-myeloproliferative-neoplasms-leukemia-2010/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20430429","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukfss","kind":"trial","name":"UK Flexible Sigmoidoscopy Screening Trial","route":"/trials/ukfss/","field":"links","label":"Lancet 2010"}]},{"url":"https://europepmc.org/article/MED/20434400","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-issels-lancet-oncol","kind":"paper","name":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","route":"/key-papers/paper-issels-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20463339","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-screening-uptake-and-age-extension","kind":"idea","name":"Treat screening uptake, not test sensitivity, as the thing to optimise, and settle the age extension with a trial rather than a model","route":"/ideas/idea-crc-screening-uptake-and-age-extension/","field":"links","label":"Kaminski et al.: quality indicators and interval cancer (N Engl J Med 2010)"}]},{"url":"https://europepmc.org/article/MED/20505152","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lu-j-natl-cancer-inst","kind":"paper","name":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","route":"/key-papers/paper-lu-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20573926","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-n-engl-j-med-2010","kind":"paper","name":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","route":"/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20601955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barretina-nat-genet","kind":"paper","name":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","route":"/key-papers/paper-barretina-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20818862","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kantoff-n-engl-j-med","kind":"paper","name":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","route":"/key-papers/paper-kantoff-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20871596","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-filippakopoulos-nature","kind":"paper","name":"Selective inhibition of BET bromodomains","route":"/key-papers/paper-filippakopoulos-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/20888993","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rustin-lancet","kind":"paper","name":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial","route":"/key-papers/paper-rustin-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21098770","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-annema-jama","kind":"paper","name":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","route":"/key-papers/paper-annema-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21144578","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rothwell-lancet","kind":"paper","name":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","route":"/key-papers/paper-rothwell-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21155971","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-iozzo-j-cell-mol-med","kind":"paper","name":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis","route":"/key-papers/paper-iozzo-j-cell-mol-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21163703","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-lancet-oncol-2011","kind":"paper","name":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-lancet-oncol-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21215367","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stephens-cell","kind":"paper","name":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","route":"/key-papers/paper-stephens-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21296615","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials","kind":"idea","name":"Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints","route":"/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/","field":"links","label":"Fearon et al.: definition and classification of cancer cachexia (Lancet Oncol 2011)"},{"id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21301065","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-davies-phys-biol","kind":"paper","name":"Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors","route":"/key-papers/paper-davies-phys-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21365651","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-langley-int-j-cancer","kind":"paper","name":"The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs","route":"/key-papers/paper-langley-int-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21372224","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cardillo-clin-cancer-res","kind":"paper","name":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","route":"/key-papers/paper-cardillo-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21376385","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cortes-lancet","kind":"paper","name":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","route":"/key-papers/paper-cortes-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21383745","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bissell-nat-med","kind":"paper","name":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression","route":"/key-papers/paper-bissell-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21417701","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sanai-j-neurosurg","kind":"paper","name":"An extent of resection threshold for newly diagnosed glioblastomas","route":"/key-papers/paper-sanai-j-neurosurg/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21425776","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kellogg-bioconjug-chem","kind":"paper","name":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","route":"/key-papers/paper-kellogg-bioconjug-chem/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21430269","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21502544","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2011","kind":"paper","name":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21503935","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-soto-bioessays","kind":"paper","name":"The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory","route":"/key-papers/paper-soto-bioessays/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21576633","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-j-clin-oncol-2011","kind":"paper","name":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","route":"/key-papers/paper-blinatumomab-all-leukemia-j-clin-oncol-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21609503","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-bmc-med-2011","kind":"paper","name":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications","route":"/key-papers/paper-ezh2-sarcoma-bmc-med-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21617154","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-agostinis-ca-cancer-j-clin","kind":"paper","name":"Photodynamic therapy of cancer: an update","route":"/key-papers/paper-agostinis-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21633166","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Lehmann et al.: identification of human triple-negative breast cancer subtypes (J Clin Invest 2011)"}]},{"url":"https://europepmc.org/article/MED/21641636","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"coin","kind":"trial","name":"MRC COIN","route":"/trials/coin/","field":"links","label":"Lancet 2011"}]},{"url":"https://europepmc.org/article/MED/21659419","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paskett-ca-cancer-j-clin","kind":"paper","name":"Patient navigation: an update on the state of the science","route":"/key-papers/paper-paskett-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21663470","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tiacci-n-engl-j-med","kind":"paper","name":"BRAF mutations in hairy-cell leukemia","route":"/key-papers/paper-tiacci-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21742485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21818642","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ryan-support-care-cancer","kind":"paper","name":"Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients","route":"/key-papers/paper-ryan-support-care-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21868284","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-senft-lancet-oncol","kind":"paper","name":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","route":"/key-papers/paper-senft-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/2188735","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fearon-cell","kind":"paper","name":"A genetic model for colorectal tumorigenesis","route":"/key-papers/paper-fearon-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/21991949","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011","kind":"paper","name":"Adjuvant trastuzumab in HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22003072","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22019490","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-seely-integr-cancer-ther","kind":"paper","name":"Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials","route":"/key-papers/paper-seely-integr-cancer-ther/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22033323","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22057348","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22067404","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive","kind":"idea","name":"A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection","route":"/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/","field":"links","label":"Wang et al.: nomogram for adjuvant chemoradiotherapy benefit in resected gallbladder cancer (J Clin Oncol 2011)"}]},{"url":"https://europepmc.org/article/MED/22089420","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-glunde-nat-rev-cancer","kind":"paper","name":"Choline metabolism in malignant transformation","route":"/key-papers/paper-glunde-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22105565","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vincent-bioessays","kind":"paper","name":"Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer","route":"/key-papers/paper-vincent-bioessays/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22118458","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-friedl-cell","kind":"paper","name":"Cancer invasion and the microenvironment: plasticity and reciprocity","route":"/key-papers/paper-friedl-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22149875","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cleopatra-n-engl-j-med-2012","kind":"paper","name":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","route":"/key-papers/paper-cleopatra-n-engl-j-med-2012/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22149876","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bolero-2-n-engl-j-med-2012","kind":"paper","name":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","route":"/key-papers/paper-bolero-2-n-engl-j-med-2012/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22152853","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"EBCTCG: polychemotherapy regimens for early breast cancer, 100,000 women in 123 trials (Lancet 2012)"}]},{"url":"https://europepmc.org/article/MED/22153890","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22173060","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trappe-lancet-oncol","kind":"paper","name":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","route":"/key-papers/paper-trappe-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22179294","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-morris-j-r-soc-med","kind":"paper","name":"The answer is 17 years, what is the question: understanding time lags in translational research","route":"/key-papers/paper-morris-j-r-soc-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22214755","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ross-bmj","kind":"paper","name":"Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis","route":"/key-papers/paper-ross-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22250183","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bellera-ann-oncol","kind":"paper","name":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","route":"/key-papers/paper-bellera-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22258609","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-greaves-nature","kind":"paper","name":"Clonal evolution in cancer","route":"/key-papers/paper-greaves-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22285168","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-lancet-oncol-2012","kind":"paper","name":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","route":"/key-papers/paper-egfr-nsclc-lancet-oncol-2012/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22356322","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012","kind":"paper","name":"Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths (National Polyp Study)","route":"/key-papers/paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012/","field":"links","label":"Europe PMC full text (PMC3322371)"}]},{"url":"https://europepmc.org/article/MED/22439926","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hanahan-cancer-cell","kind":"paper","name":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","route":"/key-papers/paper-hanahan-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22460880","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-begley-nature","kind":"paper","name":"Drug development: Raise standards for preclinical cancer research","route":"/key-papers/paper-begley-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22591257","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-downing-n-engl-j-med","kind":"paper","name":"Regulatory review of novel therapeutics--comparison of three regulatory agencies","route":"/key-papers/paper-downing-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22614976","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chua-j-clin-oncol","kind":"paper","name":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","route":"/key-papers/paper-chua-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22648714","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nechuta-am-j-clin-nutr","kind":"paper","name":"Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women","route":"/key-papers/paper-nechuta-am-j-clin-nutr/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22723327","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-thakker-j-clin-endocrinol-metab","kind":"paper","name":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","route":"/key-papers/paper-thakker-j-clin-endocrinol-metab/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22782416","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-neoptolemos-jama","kind":"paper","name":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","route":"/key-papers/paper-neoptolemos-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22810696","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","field":"links","label":"Europe PMC full text (PMC3401966)"}]},{"url":"https://europepmc.org/article/MED/22877848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-malmstrom-lancet-oncol","kind":"paper","name":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","route":"/key-papers/paper-malmstrom-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22932871","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stylianopoulos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","route":"/key-papers/paper-stylianopoulos-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/22995653","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2012","kind":"paper","name":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23117178","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-independent-uk-panel-on-breast-cancer-lancet","kind":"paper","name":"The benefits and harms of breast cancer screening: an independent review","route":"/key-papers/paper-independent-uk-panel-on-breast-cancer-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23152265","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-burden-cochrane-database-syst-rev","kind":"paper","name":"Pre-operative nutrition support in patients undergoing gastrointestinal surgery","route":"/key-papers/paper-burden-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23153379","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sun-bmc-cancer","kind":"paper","name":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials","route":"/key-papers/paper-sun-bmc-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23192950","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hesseling-pediatr-blood-cancer","kind":"paper","name":"Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting","route":"/key-papers/paper-hesseling-pediatr-blood-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23228172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-n-engl-j-med-2013","kind":"paper","name":"Abiraterone in metastatic prostate cancer without previous chemotherapy","route":"/key-papers/paper-abiraterone-acetate-prostate-n-engl-j-med-2013/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23388632","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mcfarland-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Impact of deleterious passenger mutations on cancer progression","route":"/key-papers/paper-mcfarland-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23433739","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rummel-lancet","kind":"paper","name":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","route":"/key-papers/paper-rummel-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23442307","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zafar-oncologist","kind":"paper","name":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","route":"/key-papers/paper-zafar-oncologist/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23471912","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chernet-dis-model-mech","kind":"paper","name":"Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model","route":"/key-papers/paper-chernet-dis-model-mech/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23484797","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Dawson et al.: analysis of circulating tumour DNA to monitor metastatic breast cancer (NEJM 2013)"}]},{"url":"https://europepmc.org/article/MED/23547284","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-authors-nat-methods","kind":"paper","name":"Method of the Year 2012","route":"/key-papers/paper-authors-nat-methods/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23602601","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23676531","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ramsey-health-aff-millwood","kind":"paper","name":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","route":"/key-papers/paper-ramsey-health-aff-millwood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23690420","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hughes-j-clin-oncol","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","route":"/key-papers/paper-hughes-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23724913","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alk-nsclc-n-engl-j-med-2013","kind":"paper","name":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","route":"/key-papers/paper-alk-nsclc-n-engl-j-med-2013/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23805382","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bozic-elife","kind":"paper","name":"Evolutionary dynamics of cancer in response to targeted combination therapy","route":"/key-papers/paper-bozic-elife/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23813932","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peccatori-ann-oncol","kind":"paper","name":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-peccatori-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23833040","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-landa-j-clin-endocrinol-metab","kind":"paper","name":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","route":"/key-papers/paper-landa-j-clin-endocrinol-metab/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23853057","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barton-j-natl-cancer-inst","kind":"paper","name":"Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2","route":"/key-papers/paper-barton-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/23948351","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shi-lancet-oncol","kind":"paper","name":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","route":"/key-papers/paper-shi-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24055415","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-haviland-lancet-oncol","kind":"paper","name":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","route":"/key-papers/paper-haviland-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24062397","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-j-clin-oncol-2013","kind":"paper","name":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-j-clin-oncol-2013/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24149174","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Copson et al.: ethnicity and outcome of young breast cancer patients in the UK, the POSH study (Br J Cancer 2014)"},{"id":"idea-tnbc-disparities-in-access-and-outcomes","kind":"idea","name":"Close the gap between who gets triple-negative breast cancer and who is in its trials","route":"/ideas/idea-tnbc-disparities-in-access-and-outcomes/","field":"links","label":"Copson et al.: POSH, ethnicity and outcome in young UK breast cancer patients (Br J Cancer 2014)"},{"id":"idea-tnbc-uk-ethnicity-stratified-outcome-reporting","kind":"idea","name":"Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics","route":"/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/","field":"links","label":"Copson et al.: POSH, ethnicity and outcome (Br J Cancer 2014)"}]},{"url":"https://europepmc.org/article/MED/24413733","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brastianos-nat-genet","kind":"paper","name":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","route":"/key-papers/paper-brastianos-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24430319","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-primrose-jama","kind":"paper","name":"Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial","route":"/key-papers/paper-primrose-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24443733","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yang-j-oncol-pract","kind":"paper","name":"Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage","route":"/key-papers/paper-yang-j-oncol-pract/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24493586","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kelley-j-cell-biol","kind":"paper","name":"Traversing the basement membrane in vivo: a diversity of strategies","route":"/key-papers/paper-kelley-j-cell-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24529560","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Cortazar et al.: pathological complete response and long-term benefit, CTNeoBC pooled analysis (Lancet 2014)"}]},{"url":"https://europepmc.org/article/MED/24552318","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-n-engl-j-med-2014","kind":"paper","name":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","route":"/key-papers/paper-olivier-chinot-n-engl-j-med-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24553142","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mack-nature","kind":"paper","name":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy","route":"/key-papers/paper-mack-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24553177","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-treon-blood","kind":"paper","name":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","route":"/key-papers/paper-treon-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24553385","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Bettegowda et al.: detection of circulating tumour DNA in early- and late-stage human malignancies (Science Translational Medicine 2014)"}]},{"url":"https://europepmc.org/article/MED/24563518","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shastri-j-natl-cancer-inst","kind":"paper","name":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","route":"/key-papers/paper-shastri-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24612190","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance","kind":"idea","name":"Cholecystectomy or ultrasound surveillance for chronic typhoid carriers in endemic regions","route":"/ideas/idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance/","field":"links","label":"Nagaraja and Eslick: chronic S. Typhi carrier state and gallbladder cancer, meta-analysis (Aliment Pharmacol Ther 2014)"}]},{"url":"https://europepmc.org/article/MED/24629334","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mesri-cell-host-microbe","kind":"paper","name":"Human viral oncogenesis: a cancer hallmarks analysis","route":"/key-papers/paper-mesri-cell-host-microbe/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24645800","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24666267","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-acta-oncol-2014","kind":"paper","name":"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis","route":"/key-papers/paper-pik3ca-colorectal-acta-oncol-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24667714","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","route":"/key-papers/paper-mindact-ann-oncol-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24714131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-golfier-mol-cancer-ther","kind":"paper","name":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","route":"/key-papers/paper-golfier-mol-cancer-ther/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24731888","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-lancet-oncol","kind":"paper","name":"Delivery of affordable and equitable cancer care in India","route":"/key-papers/paper-pramesh-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24739582","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-korolev-nat-rev-cancer","kind":"paper","name":"Turning ecology and evolution against cancer","route":"/key-papers/paper-korolev-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24740812","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24794243","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24833561","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barton-radiother-oncol","kind":"paper","name":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012","route":"/key-papers/paper-barton-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24854451","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Shindoh et al.: tumour location predicts survival in T2 gallbladder cancer (Ann Surg 2015)"}]},{"url":"https://europepmc.org/article/MED/24856586","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-stromal-reprogramming-not-depletion","kind":"idea","name":"Reprogramme the stroma rather than remove it: second-generation stromal trials with a stromal biomarker and a survival endpoint","route":"/ideas/idea-pdac-stromal-reprogramming-not-depletion/","field":"links","label":"Özdemir et al.: fibroblast depletion accelerates pancreas cancer (Cancer Cell 2014)"}]},{"url":"https://europepmc.org/article/MED/24909511","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-acta-pharmacol-sin-2015","kind":"paper","name":"Androgen receptor: structure, role in prostate cancer and drug discovery","route":"/key-papers/paper-androgen-receptor-prostate-acta-pharmacol-sin-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24958821","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kuhl-j-clin-oncol","kind":"paper","name":"Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI","route":"/key-papers/paper-kuhl-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/24985407","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-cancer-prev-res-phila-2014","kind":"paper","name":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","route":"/key-papers/paper-andrea-decensi-cancer-prev-res-phila-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25043755","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lineweaver-bioessays","kind":"paper","name":"Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model","route":"/key-papers/paper-lineweaver-bioessays/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25075216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pantziarka-ecancermedicalscience","kind":"paper","name":"The Repurposing Drugs in Oncology (ReDO) Project","route":"/key-papers/paper-pantziarka-ecancermedicalscience/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25113753","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cheson-j-clin-oncol","kind":"paper","name":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","route":"/key-papers/paper-cheson-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25118602","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sosa-nat-rev-cancer","kind":"paper","name":"Mechanisms of disseminated cancer cell dormancy: an awakening field","route":"/key-papers/paper-sosa-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25171411","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aceto-cell","kind":"paper","name":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","route":"/key-papers/paper-aceto-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25175478","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sharpe-lancet","kind":"paper","name":"Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial","route":"/key-papers/paper-sharpe-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25231953","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bolero-2-ann-oncol-2014-update","kind":"paper","name":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†","route":"/key-papers/paper-bolero-2-ann-oncol-2014-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25240283","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-nat-genet-2014","kind":"paper","name":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","route":"/key-papers/paper-anthony-nichols-nat-genet-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25251053","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-english-cancer","kind":"paper","name":"Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo","route":"/key-papers/paper-english-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25265492","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-combi-d-n-engl-j-med-2014","kind":"paper","name":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","route":"/key-papers/paper-combi-d-n-engl-j-med-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25265494","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cobrim-n-engl-j-med-2014","kind":"paper","name":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","route":"/key-papers/paper-cobrim-n-engl-j-med-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25296533","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-glaser-br-j-dermatol","kind":"paper","name":"Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial","route":"/key-papers/paper-glaser-br-j-dermatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25302175","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","field":"links","label":"Torres-Poveda et al. 2014 (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/25336795","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-indian-j-med-paediatr-oncol","kind":"paper","name":"The national cancer grid of India","route":"/key-papers/paper-pramesh-indian-j-med-paediatr-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25361443","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paganetti-phys-med-biol","kind":"paper","name":"Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer","route":"/key-papers/paper-paganetti-phys-med-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25372084","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ahn-n-engl-j-med","kind":"paper","name":"Korea's thyroid-cancer \"epidemic\"--screening and overdiagnosis","route":"/key-papers/paper-ahn-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25385737","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25399552","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braf-melanoma-n-engl-j-med-2015","kind":"paper","name":"Nivolumab in previously untreated melanoma without BRAF mutation","route":"/key-papers/paper-braf-melanoma-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25440090","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-trends-mol-med-2015","kind":"paper","name":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","route":"/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25446896","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shelley-hwang-cancer-cell-2014","kind":"paper","name":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","route":"/key-papers/paper-shelley-hwang-cancer-cell-2014/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25452439","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-frazier-j-clin-oncol","kind":"paper","name":"Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States","route":"/key-papers/paper-frazier-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25470694","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-solomon-n-engl-j-med","kind":"paper","name":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","route":"/key-papers/paper-solomon-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25482145","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015","kind":"paper","name":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25495490","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-soft-text-n-engl-j-med-2015","kind":"paper","name":"Adjuvant ovarian suppression in premenopausal breast cancer","route":"/key-papers/paper-soft-text-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25517747","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jain-cancer-cell","kind":"paper","name":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","route":"/key-papers/paper-jain-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25524798","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-palbociclib-breast-hr-positive-lancet-oncol-2015","kind":"paper","name":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study","route":"/key-papers/paper-palbociclib-breast-hr-positive-lancet-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25524800","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-lancet-oncol-2015","kind":"paper","name":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-blinatumomab-all-leukemia-lancet-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25533674","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-knowles-nat-rev-cancer","kind":"paper","name":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","route":"/key-papers/paper-knowles-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25554788","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tomasetti-science","kind":"paper","name":"Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions","route":"/key-papers/paper-tomasetti-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25565627","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev","kind":"paper","name":"Dance/movement therapy for improving psychological and physical outcomes in cancer patients","route":"/key-papers/paper-bradt-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25568920","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-murray-nat-rev-cancer","kind":"paper","name":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","route":"/key-papers/paper-murray-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25572172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-cancer-discov-2015","kind":"paper","name":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","route":"/key-papers/paper-raajit-rampal-cancer-discov-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25601341","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2015","kind":"paper","name":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25601342","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25624439","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-di-maio-j-clin-oncol","kind":"paper","name":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","route":"/key-papers/paper-di-maio-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25638683","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stacchiotti-lancet-oncol","kind":"paper","name":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","route":"/key-papers/paper-stacchiotti-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25642709","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ashkenazi-j-clin-invest","kind":"paper","name":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions","route":"/key-papers/paper-ashkenazi-j-clin-invest/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25665006","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sottoriva-nat-genet","kind":"paper","name":"A Big Bang model of human colorectal tumor growth","route":"/key-papers/paper-sottoriva-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25680375","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-clin-cancer-res","kind":"paper","name":"Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400","route":"/key-papers/paper-herbst-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25695955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25700432","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25760355","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-anderson-n-engl-j-med","kind":"paper","name":"Compliance with results reporting at ClinicalTrials.gov","route":"/key-papers/paper-anderson-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25918291","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-waart-j-clin-oncol","kind":"paper","name":"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial","route":"/key-papers/paper-van-waart-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25918920","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-milazzo-cochrane-database-syst-rev","kind":"paper","name":"Laetrile treatment for cancer","route":"/key-papers/paper-milazzo-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25939061","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25964250","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive","kind":"idea","name":"A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection","route":"/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/","field":"links","label":"SWOG S0809 (J Clin Oncol 2015)"}]},{"url":"https://europepmc.org/article/MED/25965575","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pajtler-cancer-cell","kind":"paper","name":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups","route":"/key-papers/paper-pajtler-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25970248","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-spranger-nature","kind":"paper","name":"Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity","route":"/key-papers/paper-spranger-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/25999455","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26027431","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26028255","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/","field":"links","label":"Le et al.: PD-1 blockade in mismatch-repair deficiency (N Engl J Med 2015)"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","field":"links","label":"Europe PMC full text (PMC4481136)"}]},{"url":"https://europepmc.org/article/MED/26033801","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bielack-j-clin-oncol","kind":"paper","name":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","route":"/key-papers/paper-bielack-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26056363","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aktipis-philos-trans-r-soc-lond-b-biol-sci","kind":"paper","name":"Cancer across the tree of life: cooperation and cheating in multicellularity","route":"/key-papers/paper-aktipis-philos-trans-r-soc-lond-b-biol-sci/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26057340","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-freedman-plos-biol","kind":"paper","name":"The Economics of Reproducibility in Preclinical Research","route":"/key-papers/paper-freedman-plos-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26113086","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yurkovetskiy-cancer-res","kind":"paper","name":"A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy","route":"/key-papers/paper-yurkovetskiy-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26130744","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2015","kind":"paper","name":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26169616","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-smith-j-clin-oncol","kind":"paper","name":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-smith-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26181265","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mailankody-jama-oncol","kind":"paper","name":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","route":"/key-papers/paper-mailankody-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26195720","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015","kind":"paper","name":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26195756","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rozhok-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations","route":"/key-papers/paper-rozhok-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26200977","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ma-20-n-engl-j-med-2015","kind":"paper","name":"Regional Nodal Irradiation in Early-Stage Breast Cancer","route":"/key-papers/paper-ma-20-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26200978","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-n-engl-j-med-2015","kind":"paper","name":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer","route":"/key-papers/paper-eortc-22922-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26205583","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wherry-nat-rev-immunol","kind":"paper","name":"Molecular and cellular insights into T cell exhaustion","route":"/key-papers/paper-wherry-nat-rev-immunol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26211824","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet","kind":"paper","name":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26287849","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-n-engl-j-med-2015","kind":"paper","name":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","route":"/key-papers/paper-braf-thyroid-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26302388","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mccollough-radiology","kind":"paper","name":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications","route":"/key-papers/paper-mccollough-radiology/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26304905","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol-2015","kind":"paper","name":"Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial","route":"/key-papers/paper-mao-j-clin-oncol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26321679","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chang-cell","kind":"paper","name":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","route":"/key-papers/paper-chang-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26376137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dohner-n-engl-j-med","kind":"paper","name":"Acute Myeloid Leukemia","route":"/key-papers/paper-dohner-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26378637","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chawla-jama-oncol","kind":"paper","name":"First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial","route":"/key-papers/paper-chawla-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26399631","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jacques-grill-acta-neuropathol-2015","kind":"paper","name":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","route":"/key-papers/paper-jacques-grill-acta-neuropathol-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26415085","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-amant-n-engl-j-med","kind":"paper","name":"Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy","route":"/key-papers/paper-amant-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26419354","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-atun-lancet-oncol","kind":"paper","name":"Expanding global access to radiotherapy","route":"/key-papers/paper-atun-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26427363","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26434673","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-johnson-sleep-med-rev","kind":"paper","name":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors","route":"/key-papers/paper-johnson-sleep-med-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26503962","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-cancer-discov-2016","kind":"paper","name":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","route":"/key-papers/paper-mesothelin-mesothelioma-cancer-discov-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26514947","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bouvard-lancet-oncol","kind":"paper","name":"Carcinogenicity of consumption of red and processed meat","route":"/key-papers/paper-bouvard-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26558876","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pd-1-nsclc-am-j-clin-oncol-2016","kind":"paper","name":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","route":"/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26563462","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-nat-rev-cancer-2015","kind":"paper","name":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-nat-rev-cancer-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26581137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nagata-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403","route":"/key-papers/paper-nagata-int-j-radiat-oncol-biol-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26598545","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gebhart-ann-oncol","kind":"paper","name":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","route":"/key-papers/paper-gebhart-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26639149","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-n-engl-j-med-2015","kind":"paper","name":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","route":"/key-papers/paper-jan-burger-n-engl-j-med-2015/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26641137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-n-engl-j-med-2016","kind":"paper","name":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","route":"/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26652797","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet-oncol","kind":"paper","name":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","route":"/key-papers/paper-sankaranarayanan-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26694935","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-morvan-nat-rev-cancer","kind":"paper","name":"NK cells and cancer: you can teach innate cells new tricks","route":"/key-papers/paper-morvan-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26695736","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-riley-cochrane-database-syst-rev","kind":"paper","name":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy","route":"/key-papers/paper-riley-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26719232","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stampede-lancet-2016","kind":"paper","name":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","route":"/key-papers/paper-stampede-lancet-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/2673568","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paget-cancer-metastasis-rev","kind":"paper","name":"The distribution of secondary growths in cancer of the breast. 1889","route":"/key-papers/paper-paget-cancer-metastasis-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26755709","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-viardot-blood","kind":"paper","name":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-viardot-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26761625","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-armstrong-n-engl-j-med","kind":"paper","name":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer","route":"/key-papers/paper-armstrong-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26771115","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pavlova-cell-metab","kind":"paper","name":"The Emerging Hallmarks of Cancer Metabolism","route":"/key-papers/paper-pavlova-cell-metab/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26773095","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-huggins-hodges-castration-serum-phosphatases-prostate-1941","kind":"paper","name":"Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","route":"/key-papers/paper-huggins-hodges-castration-serum-phosphatases-prostate-1941/","field":"links","label":"Cancer Research commentary on Huggins and Hodges (Nelson, 2016)"}]},{"url":"https://europepmc.org/article/MED/26791720","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-massague-nature","kind":"paper","name":"Metastatic colonization by circulating tumour cells","route":"/key-papers/paper-massague-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26811521","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ramsey-j-clin-oncol","kind":"paper","name":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer","route":"/key-papers/paper-ramsey-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/2681557","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-calvert-j-clin-oncol","kind":"paper","name":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","route":"/key-papers/paper-calvert-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26903579","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-scher-j-clin-oncol","kind":"paper","name":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","route":"/key-papers/paper-scher-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26906526","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26919435","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jacques-grill-cell-2016","kind":"paper","name":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","route":"/key-papers/paper-jacques-grill-cell-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26950094","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bonilla-nat-genet","kind":"paper","name":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","route":"/key-papers/paper-bonilla-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26970723","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-lancet-2016","kind":"paper","name":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26972587","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet","kind":"paper","name":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","route":"/key-papers/paper-feinberg-nat-rev-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/26988909","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chernet-oncotarget","kind":"paper","name":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis","route":"/key-papers/paper-chernet-oncotarget/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27009393","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-steeg-nat-rev-cancer","kind":"paper","name":"Targeting metastasis","route":"/key-papers/paper-steeg-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27026201","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ogitani-clin-cancer-res","kind":"paper","name":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","route":"/key-papers/paper-ogitani-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27032109","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-marinac-jama-oncol","kind":"paper","name":"Prolonged Nightly Fasting and Breast Cancer Prognosis","route":"/key-papers/paper-marinac-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27045603","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jin-cochrane-database-syst-rev","kind":"paper","name":"Ganoderma lucidum (Reishi mushroom) for cancer treatment","route":"/key-papers/paper-jin-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27093365","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27111235","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27123955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bennett-cochrane-database-syst-rev","kind":"paper","name":"Hyperbaric oxygen therapy for late radiation tissue injury","route":"/key-papers/paper-bennett-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27125352","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shain-nat-rev-cancer","kind":"paper","name":"From melanocytes to melanomas","route":"/key-papers/paper-shain-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27158978","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27166974","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ogitani-cancer-sci","kind":"paper","name":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","route":"/key-papers/paper-ogitani-cancer-sci/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27179402","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27188790","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-weller-nat-rev-dis-primers","kind":"paper","name":"Glioma","route":"/key-papers/paper-weller-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27194046","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-baylin-cold-spring-harb-perspect-biol","kind":"paper","name":"Epigenetic Determinants of Cancer","route":"/key-papers/paper-baylin-cold-spring-harb-perspect-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27224642","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukls","kind":"trial","name":"UKLS","route":"/trials/ukls/","field":"links","label":"Health Technology Assessment 2016"}]},{"url":"https://europepmc.org/article/MED/27225120","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-nature-2016","kind":"paper","name":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","route":"/key-papers/paper-chen-nature-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27240885","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27247218","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schnipper-j-clin-oncol","kind":"paper","name":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","route":"/key-papers/paper-schnipper-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27258432","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shin-cochrane-database-syst-rev","kind":"paper","name":"Massage with or without aromatherapy for symptom relief in people with cancer","route":"/key-papers/paper-shin-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27291997","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-robin-jones-lancet-2016","kind":"paper","name":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","route":"/key-papers/paper-robin-jones-lancet-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27310651","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brown-jama-oncol","kind":"paper","name":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","route":"/key-papers/paper-brown-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27318851","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-loomis-lancet-oncol","kind":"paper","name":"Carcinogenicity of drinking coffee, mate, and very hot beverages","route":"/key-papers/paper-loomis-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27384348","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","kind":"paper","name":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","route":"/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/","field":"links","label":"Europe PMC full text (PMC5346159)"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Tie et al.: ctDNA detects minimal residual disease and predicts recurrence in stage II colon cancer (Science Translational Medicine 2016)"}]},{"url":"https://europepmc.org/article/MED/27410922","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-navari-n-engl-j-med","kind":"paper","name":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","route":"/key-papers/paper-navari-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27433843","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zaretsky-n-engl-j-med","kind":"paper","name":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","route":"/key-papers/paper-zaretsky-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27451390","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27458286","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paice-j-clin-oncol","kind":"paper","name":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","route":"/key-papers/paper-paice-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27467945","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gpc3-hcc-oncoimmunology-2016","kind":"paper","name":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","route":"/key-papers/paper-gpc3-hcc-oncoimmunology-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27480103","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27492215","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-altman-nat-rev-cancer","kind":"paper","name":"From Krebs to clinic: glutamine metabolism to cancer therapy","route":"/key-papers/paper-altman-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27501770","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-villani-lancet-oncol","kind":"paper","name":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","route":"/key-papers/paper-villani-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27511158","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kumar-lancet-oncol","kind":"paper","name":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","route":"/key-papers/paper-kumar-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27528719","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-morrow-j-clin-oncol","kind":"paper","name":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ","route":"/key-papers/paper-morrow-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27550820","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kalluri-nat-rev-cancer","kind":"paper","name":"The biology and function of fibroblasts in cancer","route":"/key-papers/paper-kalluri-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27557300","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cardoso-n-engl-j-med","kind":"paper","name":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","route":"/key-papers/paper-cardoso-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27569442","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-marina-lancet-oncol","kind":"paper","name":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","route":"/key-papers/paper-marina-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27574444","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-onco-targets-ther-2016","kind":"paper","name":"PD-L1 expression in human cancers and its association with clinical outcomes","route":"/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27592805","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27637832","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arends-clin-nutr","kind":"paper","name":"ESPEN guidelines on nutrition in cancer patients","route":"/key-papers/paper-arends-clin-nutr/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27658529","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rohrig-nat-rev-cancer","kind":"paper","name":"The multifaceted roles of fatty acid synthesis in cancer","route":"/key-papers/paper-rohrig-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27663933","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lutz-pract-radiat-oncol","kind":"paper","name":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","route":"/key-papers/paper-lutz-pract-radiat-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27686946","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27705267","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016","kind":"paper","name":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27717299","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-niraparib-ovarian-n-engl-j-med-2016","kind":"paper","name":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","route":"/key-papers/paper-niraparib-ovarian-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27717303","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2016","kind":"paper","name":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27726295","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance","kind":"idea","name":"Cholecystectomy or ultrasound surveillance for chronic typhoid carriers in endemic regions","route":"/ideas/idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance/","field":"links","label":"Koshiol et al.: S. Typhi and gallbladder cancer, case-control and meta-analysis (Cancer Med 2016)"}]},{"url":"https://europepmc.org/article/MED/27799157","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-win-cancer-epidemiol-biomarkers-prev","kind":"paper","name":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer","route":"/key-papers/paper-win-cancer-epidemiol-biomarkers-prev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27863199","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-j-clin-oncol-2016","kind":"paper","name":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","route":"/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27913228","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hirsch-j-thorac-oncol","kind":"paper","name":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","route":"/key-papers/paper-hirsch-j-thorac-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27932801","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-goodnow-nat-rev-drug-discov","kind":"paper","name":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","route":"/key-papers/paper-goodnow-nat-rev-drug-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27959613","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paloma-2-n-engl-j-med-2016","kind":"paper","name":"Palbociclib and Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-paloma-2-n-engl-j-med-2016/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27959635","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aster-annu-rev-pathol","kind":"paper","name":"The Varied Roles of Notch in Cancer","route":"/key-papers/paper-aster-annu-rev-pathol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27959700","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2017","kind":"paper","name":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27979383","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-lancet-2017","kind":"paper","name":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27979832","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-demaria-cancer-discov","kind":"paper","name":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","route":"/key-papers/paper-demaria-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/27981460","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-report-gallbladder-separately-in-biliary-trials","kind":"idea","name":"Report gallbladder cancer as its own population in every biliary trial","route":"/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/","field":"links","label":"Galdy et al.: HER2 in biliary tract cancers by site (Cancer Metastasis Rev 2017)"}]},{"url":"https://europepmc.org/article/MED/27993330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-li-j-mol-diagn","kind":"paper","name":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","route":"/key-papers/paper-li-j-mol-diagn/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28029927","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brown-n-engl-j-med","kind":"paper","name":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","route":"/key-papers/paper-brown-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28034065","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ferrell-j-clin-oncol","kind":"paper","name":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-ferrell-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28045199","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cramer-cochrane-database-syst-rev","kind":"paper","name":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer","route":"/key-papers/paper-cramer-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28052061","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cancer-genome-atlas-research-nature","kind":"paper","name":"Integrated genomic characterization of oesophageal carcinoma","route":"/key-papers/paper-cancer-genome-atlas-research-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28059767","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","kind":"paper","name":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","route":"/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28067913","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-nat-genet-2017","kind":"paper","name":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","route":"/key-papers/paper-anthony-nichols-nat-genet-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28074653","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nelson-j-med-chem","kind":"paper","name":"The Essential Medicinal Chemistry of Curcumin","route":"/key-papers/paper-nelson-j-med-chem/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28102259","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-nature","kind":"paper","name":"Elements of cancer immunity and the cancer-immune set point","route":"/key-papers/paper-chen-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28110982","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"promis","kind":"trial","name":"PROMIS","route":"/trials/promis/","field":"links","label":"Lancet 2017"}]},{"url":"https://europepmc.org/article/MED/28138153","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-griffith-nat-genet","kind":"paper","name":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","route":"/key-papers/paper-griffith-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28146658","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-9601-n-engl-j-med-2017","kind":"paper","name":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","route":"/key-papers/paper-rtog-9601-n-engl-j-med-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28147224","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jun-gastroenterology","kind":"paper","name":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality","route":"/key-papers/paper-jun-gastroenterology/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28178237","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-turner-nature","kind":"paper","name":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","route":"/key-papers/paper-turner-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28187284","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mcgranahan-cell","kind":"paper","name":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","route":"/key-papers/paper-mcgranahan-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28187285","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bradner-cell","kind":"paper","name":"Transcriptional Addiction in Cancer","route":"/key-papers/paper-bradner-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28209992","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bcl-2-cll-nat-rev-drug-discov-2017","kind":"paper","name":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","route":"/key-papers/paper-bcl-2-cll-nat-rev-drug-discov-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28212060","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-n-engl-j-med-2017","kind":"paper","name":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","route":"/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28215665","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-lancet-2017-update","kind":"paper","name":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","route":"/key-papers/paper-hera-b31-n9831-lancet-2017-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28236467","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukfss","kind":"trial","name":"UK Flexible Sigmoidoscopy Screening Trial","route":"/trials/ukfss/","field":"links","label":"Lancet 2017: 17-year follow-up"},{"id":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","kind":"paper","name":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","route":"/key-papers/paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017/","field":"links","label":"Europe PMC full text (PMC6168937)"}]},{"url":"https://europepmc.org/article/MED/28249141","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","kind":"paper","name":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","route":"/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28258693","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hhla2","kind":"target","name":"HHLA2 (B7-H7)","route":"/targets/hhla2/","field":"links","label":"Janakiram et al. 2017, Immunol Rev (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/28276433","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28288110","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-davies-nat-med","kind":"paper","name":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","route":"/key-papers/paper-davies-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28290490","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28291390","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017","kind":"paper","name":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28296618","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-perry-n-engl-j-med","kind":"paper","name":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","route":"/key-papers/paper-perry-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28302823","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lord-science","kind":"paper","name":"PARP inhibitors: Synthetic lethality in the clinic","route":"/key-papers/paper-lord-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28303905","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peinado-nat-rev-cancer","kind":"paper","name":"Pre-metastatic niches: organ-specific homes for metastases","route":"/key-papers/paper-peinado-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28328302","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","kind":"paper","name":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","route":"/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28343976","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-takahashi-lancet-oncol","kind":"paper","name":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-takahashi-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28376186","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017","kind":"paper","name":"Colorectal cancer incidence patterns in the United States, 1974-2013","route":"/key-papers/paper-siegel-colorectal-incidence-birth-cohort-jnci-2017/","field":"links","label":"Europe PMC full text (PMC6059239)"},{"id":"idea-crc-early-onset-cause-hunt","kind":"idea","name":"Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further","route":"/ideas/idea-crc-early-onset-cause-hunt/","field":"links","label":"Siegel et al.: colorectal cancer incidence patterns 1974-2013 (JNCI 2017)"}]},{"url":"https://europepmc.org/article/MED/28407110","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/","field":"links","label":"Europe PMC full text (PMC6246616)"}]},{"url":"https://europepmc.org/article/MED/28436999","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-greenlee-ca-cancer-j-clin","kind":"paper","name":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","route":"/key-papers/paper-greenlee-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28445112","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"links","label":"New England Journal of Medicine 2017"}]},{"url":"https://europepmc.org/article/MED/28484005","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trigos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors","route":"/key-papers/paper-trigos-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28489508","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-irwin-j-clin-oncol","kind":"paper","name":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial","route":"/key-papers/paper-irwin-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28492898","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28511673","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-erivance-bmc-cancer-2017-update","kind":"paper","name":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","route":"/key-papers/paper-erivance-bmc-cancer-2017-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28512351","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chang-nat-rev-mol-cell-biol","kind":"paper","name":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","route":"/key-papers/paper-chang-nat-rev-mol-cell-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28564564","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","field":"links","label":"Europe PMC"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"CREATE-X: adjuvant capecitabine after preoperative chemotherapy (NEJM 2017)"}]},{"url":"https://europepmc.org/article/MED/28580882","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02107703-j-clin-oncol-2017","kind":"paper","name":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","route":"/key-papers/paper-nct02107703-j-clin-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28584134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bussey-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Ancestral gene regulatory networks drive cancer","route":"/key-papers/paper-bussey-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28586279","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28596308","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","field":"links","label":"Europe PMC full text (PMC5576142)"}]},{"url":"https://europepmc.org/article/MED/28632865","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/","field":"links","label":"Europe PMC full text (PMC5545896)"}]},{"url":"https://europepmc.org/article/MED/28638976","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","field":"links","label":"van der Touw et al. 2017 (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/28642008","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28643779","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dang-nat-rev-cancer","kind":"paper","name":"Drugging the 'undruggable' cancer targets","route":"/key-papers/paper-dang-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28649001","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","kind":"paper","name":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report","route":"/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28678785","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-viswanathan-nature","kind":"paper","name":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","route":"/key-papers/paper-viswanathan-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28679092","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-woodcock-n-engl-j-med","kind":"paper","name":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","route":"/key-papers/paper-woodcock-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28705916","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pandit-taskar-j-nucl-med","kind":"paper","name":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","route":"/key-papers/paper-pandit-taskar-j-nucl-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28729483","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-flavahan-science","kind":"paper","name":"Epigenetic plasticity and the hallmarks of cancer","route":"/key-papers/paper-flavahan-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28730595","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/","field":"links","label":"Kučan Brlić et al. 2017, Cell Mol Immunol (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/28741564","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-obenauf-trends-cancer","kind":"paper","name":"Surviving at a Distance: Organ-Specific Metastasis","route":"/key-papers/paper-obenauf-trends-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28752469","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Chun, Pawlik, Vauthey: AJCC 8th edition, pancreas and hepatobiliary cancers (Ann Surg Oncol 2018)"}]},{"url":"https://europepmc.org/article/MED/28776080","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-diabetologia-2017","kind":"paper","name":"Repurposing metformin for the prevention of cancer and cancer recurrence","route":"/key-papers/paper-andrea-decensi-diabetologia-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28779963","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-coles-lancet","kind":"paper","name":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","route":"/key-papers/paper-coles-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28792880","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chan-n-engl-j-med","kind":"paper","name":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","route":"/key-papers/paper-chan-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28814435","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alexander-clin-cancer-res","kind":"paper","name":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","route":"/key-papers/paper-alexander-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28820644","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-childers-j-clin-oncol","kind":"paper","name":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","route":"/key-papers/paper-childers-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28846163","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","kind":"paper","name":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","route":"/key-papers/paper-bolt-j-eur-acad-dermatol-venereol-2018-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28855077","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ridker-lancet","kind":"paper","name":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-ridker-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28882536","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-seddon-lancet-oncol","kind":"paper","name":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","route":"/key-papers/paper-seddon-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28885612","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28886379","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kastenhuber-cell","kind":"paper","name":"Putting p53 in Context","route":"/key-papers/paper-kastenhuber-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28890946","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chakravarty-jco-precis-oncol","kind":"paper","name":"OncoKB: A Precision Oncology Knowledge Base","route":"/key-papers/paper-chakravarty-jco-precis-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28923526","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lichtman-j-pain-symptom-manage","kind":"paper","name":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain","route":"/key-papers/paper-lichtman-j-pain-symptom-manage/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28948213","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ligibel-npj-breast-cancer","kind":"paper","name":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design","route":"/key-papers/paper-ligibel-npj-breast-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28967485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-lancet-oncol-2017","kind":"paper","name":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-pembrolizumab-urothelial-lancet-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28967920","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-romero-nat-med","kind":"paper","name":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","route":"/key-papers/paper-romero-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28968170","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kim-j-clin-oncol","kind":"paper","name":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","route":"/key-papers/paper-kim-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28978555","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-davis-bmj","kind":"paper","name":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","route":"/key-papers/paper-davis-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28985214","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-batlle-nat-med","kind":"paper","name":"Cancer stem cells revisited","route":"/key-papers/paper-batlle-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/28985563","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-faubert-cell","kind":"paper","name":"Lactate Metabolism in Human Lung Tumors","route":"/key-papers/paper-faubert-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29032993","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-knaul-lancet","kind":"paper","name":"Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report","route":"/key-papers/paper-knaul-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29033130","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shailender-bhatia-cell-2017","kind":"paper","name":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","route":"/key-papers/paper-shailender-bhatia-cell-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29035643","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-poznak-j-clin-oncol","kind":"paper","name":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","route":"/key-papers/paper-van-poznak-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29046323","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-raverot-eur-j-endocrinol","kind":"paper","name":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","route":"/key-papers/paper-raverot-eur-j-endocrinol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29051371","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zahalka-science","kind":"paper","name":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","route":"/key-papers/paper-zahalka-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29056346","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-martincorena-cell","kind":"paper","name":"Universal Patterns of Selection in Cancer and Somatic Tissues","route":"/key-papers/paper-martincorena-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29088702","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hangauer-nature","kind":"paper","name":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","route":"/key-papers/paper-hangauer-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29089605","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-den-heuvel-eibrink-nat-rev-urol","kind":"paper","name":"Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","route":"/key-papers/paper-van-den-heuvel-eibrink-nat-rev-urol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29092024","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cardoso-ann-oncol","kind":"paper","name":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","route":"/key-papers/paper-cardoso-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29117335","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-ann-oncol-2017","kind":"paper","name":"Improved survival using specialized multidisciplinary board in sarcoma patients","route":"/key-papers/paper-florence-duffaud-ann-oncol-2017/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29117498","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pan-n-engl-j-med","kind":"paper","name":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","route":"/key-papers/paper-pan-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29124875","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-mol-oncol-2018","kind":"paper","name":"Emerging functions of the EGFR in cancer","route":"/key-papers/paper-egfr-glioblastoma-mol-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29160902","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29167102","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-poole-bmj","kind":"paper","name":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","route":"/key-papers/paper-poole-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29175149","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29180633","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-nat-commun","kind":"paper","name":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","route":"/key-papers/paper-zhang-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29229594","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","kind":"paper","name":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29245013","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29254698","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tdo2","kind":"target","name":"TDO2","route":"/targets/tdo2/","field":"links","label":"Cheong and Sun 2018 (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/29260225","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stupp-jama","kind":"paper","name":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","route":"/key-papers/paper-stupp-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29298756","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zammarchi-blood","kind":"paper","name":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","route":"/key-papers/paper-zammarchi-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29320312","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hainsworth-j-clin-oncol","kind":"paper","name":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-hainsworth-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29342134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bakhoum-nature","kind":"paper","name":"Chromosomal instability drives metastasis through a cytosolic DNA response","route":"/key-papers/paper-bakhoum-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29343557","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schultz-clin-cancer-res","kind":"paper","name":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies","route":"/key-papers/paper-schultz-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29347993","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29364287","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-nature","kind":"paper","name":"The biology and management of non-small cell lung cancer","route":"/key-papers/paper-herbst-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29394327","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wong-biostatistics","kind":"paper","name":"Estimation of clinical trial success rates and related parameters","route":"/key-papers/paper-wong-biostatistics/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29440149","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-solheim-bmj-support-palliat-care","kind":"paper","name":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","route":"/key-papers/paper-solheim-bmj-support-palliat-care/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29443390","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-miften-med-phys","kind":"paper","name":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","route":"/key-papers/paper-miften-med-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29443960","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mariathasan-nature","kind":"paper","name":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","route":"/key-papers/paper-mariathasan-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29443964","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","kind":"paper","name":"TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis","route":"/key-papers/paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29444771","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fiolet-bmj","kind":"paper","name":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort","route":"/key-papers/paper-fiolet-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29474446","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ghaffarizadeh-plos-comput-biol","kind":"paper","name":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems","route":"/key-papers/paper-ghaffarizadeh-plos-comput-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29501363","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29509546","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-makvandi-j-clin-invest","kind":"paper","name":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","route":"/key-papers/paper-makvandi-j-clin-invest/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29550029","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wilson-lancet","kind":"paper","name":"Access to pathology and laboratory medicine services: a crucial gap","route":"/key-papers/paper-wilson-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29577784","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gehl-acta-oncol","kind":"paper","name":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","route":"/key-papers/paper-gehl-acta-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29590007","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-szmulewitz-j-clin-oncol","kind":"paper","name":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","route":"/key-papers/paper-szmulewitz-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29590544","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","kind":"paper","name":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","route":"/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/","field":"links","label":"Europe PMC full text (PMC6426127)"}]},{"url":"https://europepmc.org/article/MED/29611518","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scot","kind":"trial","name":"SCOT","route":"/trials/scot/","field":"links","label":"Lancet Oncology 2018"},{"id":"scot","kind":"trial","name":"SCOT","route":"/trials/scot/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://europepmc.org/article/MED/29620997","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-oktay-j-clin-oncol","kind":"paper","name":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-oktay-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29641806","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-jama-dermatol","kind":"paper","name":"Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer","route":"/key-papers/paper-freites-martinez-jama-dermatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29643473","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-robey-nat-rev-cancer","kind":"paper","name":"Revisiting the role of ABC transporters in multidrug-resistant cancer","route":"/key-papers/paper-robey-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29658845","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-n-engl-j-med-2018","kind":"paper","name":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","route":"/key-papers/paper-checkmate-227-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29659330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol-2018","kind":"paper","name":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study","route":"/key-papers/paper-dix-j-clin-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29660423","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-j-am-acad-dermatol","kind":"paper","name":"Hair disorders in cancer survivors","route":"/key-papers/paper-freites-martinez-j-am-acad-dermatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29669701","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schoffski-lancet-respir-med","kind":"paper","name":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","route":"/key-papers/paper-schoffski-lancet-respir-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29710129","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29713086","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29726819","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-ovarian-mol-cancer-ther-2018","kind":"paper","name":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","route":"/key-papers/paper-ezh2-ovarian-mol-cancer-ther-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29746229","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ishigami-j-clin-oncol","kind":"paper","name":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","route":"/key-papers/paper-ishigami-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29758241","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","route":"/targets/adora2a/","field":"links","label":"Allard et al. 2019, Immunol Rev (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/29773717","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-cancer-discov-2018","kind":"paper","name":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","route":"/key-papers/paper-kras-nsclc-cancer-discov-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29775599","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-new-onset-diabetes-risk-score-pathway","kind":"idea","name":"Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers","route":"/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/","field":"links","label":"Sharma et al.: ENDPAC model (Gastroenterology 2018)"}]},{"url":"https://europepmc.org/article/MED/29782209","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mohile-j-clin-oncol","kind":"paper","name":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","route":"/key-papers/paper-mohile-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29799911","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-patel-jama-surg","kind":"paper","name":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules","route":"/key-papers/paper-patel-jama-surg/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29846122","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wolff-j-clin-oncol-2018","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","route":"/key-papers/paper-wolff-j-clin-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29846498","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-robin-jones-ann-oncol-2018","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-robin-jones-ann-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29853643","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tiriac-cancer-discov","kind":"paper","name":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","route":"/key-papers/paper-tiriac-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/2988749","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"links","label":"Retroperitoneal germ cell tumours in childhood, Cancer 1985 (PMID 2988749)"}]},{"url":"https://europepmc.org/article/MED/29889605","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lyman-j-clin-oncol","kind":"paper","name":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline","route":"/key-papers/paper-lyman-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29906429","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gilligan-am-j-med","kind":"paper","name":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer","route":"/key-papers/paper-gilligan-am-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29924336","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hanai-j-natl-cancer-inst","kind":"paper","name":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial","route":"/key-papers/paper-hanai-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29924955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brock-n-engl-j-med","kind":"paper","name":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","route":"/key-papers/paper-brock-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/29945191","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tetzlaff-ann-oncol","kind":"paper","name":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","route":"/key-papers/paper-tetzlaff-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30013179","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bielski-nat-genet","kind":"paper","name":"Genome doubling shapes the evolution and prognosis of advanced cancers","route":"/key-papers/paper-bielski-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30078747","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kahles-cancer-cell","kind":"paper","name":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","route":"/key-papers/paper-kahles-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30098152","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alter-0303-jama-oncol-2018","kind":"paper","name":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-alter-0303-jama-oncol-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30110579","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-embraca-n-engl-j-med-2018","kind":"paper","name":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","route":"/key-papers/paper-embraca-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30125215","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kurtz-j-clin-oncol","kind":"paper","name":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-kurtz-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30134131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-n-engl-j-med-2018","kind":"paper","name":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","route":"/key-papers/paper-checkmate-204-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30137606","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kamath-neurosurgery","kind":"paper","name":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes","route":"/key-papers/paper-kamath-neurosurgery/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30168576","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wei-cochrane-database-syst-rev","kind":"paper","name":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer","route":"/key-papers/paper-wei-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30193109","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bakhoum-cell","kind":"paper","name":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","route":"/key-papers/paper-bakhoum-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30219628","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30221595","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mcneil-n-engl-j-med","kind":"paper","name":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","route":"/key-papers/paper-mcneil-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30224381","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pfeiffer-embo-mol-med","kind":"paper","name":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","route":"/key-papers/paper-pfeiffer-embo-mol-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30262472","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-albrengues-science","kind":"paper","name":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","route":"/key-papers/paper-albrengues-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30266309","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-boeve-eur-urol","kind":"paper","name":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","route":"/key-papers/paper-boeve-eur-urol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30280635","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-407-n-engl-j-med-2018","kind":"paper","name":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-407-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30280641","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impower133-n-engl-j-med-2018","kind":"paper","name":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","route":"/key-papers/paper-impower133-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30280657","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alta-1l-n-engl-j-med-2018","kind":"paper","name":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-alta-1l-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30280658","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pacific-n-engl-j-med-2018-update","kind":"paper","name":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","route":"/key-papers/paper-pacific-n-engl-j-med-2018-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30309915","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cristescu-science","kind":"paper","name":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","route":"/key-papers/paper-cristescu-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30337457","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-martincorena-science","kind":"paper","name":"Somatic mutant clones colonize the human esophagus with age","route":"/key-papers/paper-martincorena-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30345906","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impassion130-n-engl-j-med-2018","kind":"paper","name":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-impassion130-n-engl-j-med-2018/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30348537","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-henricks-lancet-oncol","kind":"paper","name":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","route":"/key-papers/paper-henricks-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30355464","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-parker-lancet","kind":"paper","name":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","route":"/key-papers/paper-parker-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30377213","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-castroviejo-bermejo-embo-mol-med","kind":"paper","name":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","route":"/key-papers/paper-castroviejo-bermejo-embo-mol-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30385188","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-enzyme-replacement-prescribing-by-default","kind":"idea","name":"Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival","route":"/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/","field":"links","label":"Roberts et al.: enzyme replacement and survival in pancreatic cancer (Pancreatology 2019)"}]},{"url":"https://europepmc.org/article/MED/30415629","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-manson-n-engl-j-med","kind":"paper","name":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease","route":"/key-papers/paper-manson-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30477937","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-lancet-oncol-2019","kind":"paper","name":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30478423","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bensch-nat-med","kind":"paper","name":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","route":"/key-papers/paper-bensch-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30489609","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-jama-oncol","kind":"paper","name":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","route":"/key-papers/paper-chen-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30509740","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30509763","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-johnson-mpmri-individual-foci-eur-urol-2019","kind":"paper","name":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","route":"/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30522922","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30554720","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mavaddat-am-j-hum-genet","kind":"paper","name":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","route":"/key-papers/paper-mavaddat-am-j-hum-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30562839","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-t1b-simple-cholecystectomy-prospective-study","kind":"idea","name":"Test whether T1b gallbladder cancer needs the second operation at all","route":"/ideas/idea-gbc-t1b-simple-cholecystectomy-prospective-study/","field":"links","label":"Kim et al.: optimal surgical treatment of T1b gallbladder cancer, 14 centres (J Hepatobiliary Pancreat Sci 2018)"}]},{"url":"https://europepmc.org/article/MED/30572922","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhao-j-hematol-oncol","kind":"paper","name":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","route":"/key-papers/paper-zhao-j-hematol-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30578357","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dudley-cancer-discov","kind":"paper","name":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","route":"/key-papers/paper-dudley-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30582640","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Soreide et al.: systematic review of incidental gallbladder cancer management (Br J Surg 2019)"}]},{"url":"https://europepmc.org/article/MED/30592986","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lee-biol-blood-marrow-transplant","kind":"paper","name":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","route":"/key-papers/paper-lee-biol-blood-marrow-transplant/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30629194","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hu-j-natl-cancer-inst","kind":"paper","name":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening","route":"/key-papers/paper-hu-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30632023","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paloma-2-breast-cancer-res-treat-2019-update","kind":"paper","name":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","route":"/key-papers/paper-paloma-2-breast-cancer-res-treat-2019-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30655533","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30658992","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stock-blood","kind":"paper","name":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","route":"/key-papers/paper-stock-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30670598","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-taha-oncologist","kind":"paper","name":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies","route":"/key-papers/paper-taha-oncologist/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30674905","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mainprize-sci-rep","kind":"paper","name":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study","route":"/key-papers/paper-mainprize-sci-rep/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30689707","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-olympiad-ann-oncol-2019-update","kind":"paper","name":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","route":"/key-papers/paper-olympiad-ann-oncol-2019-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30718830","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-denardo-nat-rev-immunol","kind":"paper","name":"Macrophages as regulators of tumour immunity and immunotherapy","route":"/key-papers/paper-denardo-nat-rev-immunol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30733314","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-badawi-j-nucl-med","kind":"paper","name":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner","route":"/key-papers/paper-badawi-j-nucl-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30739743","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019","kind":"paper","name":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30760854","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shay-nat-rev-genet","kind":"paper","name":"Telomeres and telomerase: three decades of progress","route":"/key-papers/paper-shay-nat-rev-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30770291","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30786188","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019","kind":"paper","name":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30824296","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hugosson-eur-urol","kind":"paper","name":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","route":"/key-papers/paper-hugosson-eur-urol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30857956","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30867592","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-diamond-nature","kind":"paper","name":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","route":"/key-papers/paper-diamond-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30890548","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-idbaih-clin-cancer-res","kind":"paper","name":"Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma","route":"/key-papers/paper-idbaih-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30930117","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shelley-hwang-cancer-cell-2019","kind":"paper","name":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","route":"/key-papers/paper-shelley-hwang-cancer-cell-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30943124","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-158-j-clin-oncol-2019","kind":"paper","name":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","route":"/key-papers/paper-keynote-158-j-clin-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30954939","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kratochwil-j-nucl-med","kind":"paper","name":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer","route":"/key-papers/paper-kratochwil-j-nucl-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30955977","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-lancet-2019","kind":"paper","name":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","route":"/key-papers/paper-keynote-042-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30964527","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ng-jama","kind":"paper","name":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial","route":"/key-papers/paper-ng-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30969847","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bohlius-j-clin-oncol","kind":"paper","name":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","route":"/key-papers/paper-bohlius-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30971823","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chan-nature","kind":"paper","name":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","route":"/key-papers/paper-chan-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30982687","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sabr-comet-lancet-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","route":"/key-papers/paper-sabr-comet-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30987939","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/30998813","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gap-phase2-mdacc-jama-oncol-2019","kind":"paper","name":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","route":"/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31011204","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rothwell-nat-med","kind":"paper","name":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","route":"/key-papers/paper-rothwell-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31011205","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rodon-nat-med","kind":"paper","name":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","route":"/key-papers/paper-rodon-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31011206","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sicklick-nat-med","kind":"paper","name":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","route":"/key-papers/paper-sicklick-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31018069","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pemmaraju-n-engl-j-med","kind":"paper","name":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","route":"/key-papers/paper-pemmaraju-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31027636","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cardenas-semin-radiat-oncol","kind":"paper","name":"Advances in Auto-Segmentation","route":"/key-papers/paper-cardenas-semin-radiat-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31030981","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schuetz-lancet","kind":"paper","name":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","route":"/key-papers/paper-schuetz-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31036468","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jiang-lancet-oncol","kind":"paper","name":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-jiang-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31050774","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-haslam-jama-netw-open","kind":"paper","name":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","route":"/key-papers/paper-haslam-jama-netw-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31076762","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rennert-neurosurgery","kind":"paper","name":"Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization","route":"/key-papers/paper-rennert-neurosurgery/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31097539","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vuik-early-onset-colorectal-europe-gut-2019","kind":"paper","name":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","route":"/key-papers/paper-vuik-early-onset-colorectal-europe-gut-2019/","field":"links","label":"Europe PMC full text (PMC6839794)"},{"id":"idea-crc-early-onset-cause-hunt","kind":"idea","name":"Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further","route":"/ideas/idea-crc-early-onset-cause-hunt/","field":"links","label":"Vuik et al.: rising incidence in young adults in Europe (Gut 2019)"}]},{"url":"https://europepmc.org/article/MED/31135808","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31145418","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-murphy-jama-oncol","kind":"paper","name":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","route":"/key-papers/paper-murphy-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31150073","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-metter-jama-netw-open","kind":"paper","name":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017","route":"/key-papers/paper-metter-jama-netw-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31150574","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02489318-n-engl-j-med-2019","kind":"paper","name":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","route":"/key-papers/paper-nct02489318-n-engl-j-med-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31157964","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-enzamet-n-engl-j-med-2019","kind":"paper","name":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","route":"/key-papers/paper-enzamet-n-engl-j-med-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31175338","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","field":"links","label":"Author correction (2019)"}]},{"url":"https://europepmc.org/article/MED/31178152","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31196207","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019","kind":"paper","name":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","route":"/key-papers/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31209238","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-menden-nat-commun","kind":"paper","name":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","route":"/key-papers/paper-menden-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31218271","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31227373","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-widmark-lancet","kind":"paper","name":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","route":"/key-papers/paper-widmark-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31229240","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tap-lancet","kind":"paper","name":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","route":"/key-papers/paper-tap-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31240302","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peter-thuss-patience-ann-oncol-2019","kind":"paper","name":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","route":"/key-papers/paper-peter-thuss-patience-ann-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31267971","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alyami-lancet-oncol","kind":"paper","name":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","route":"/key-papers/paper-alyami-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31281097","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-iarc-monographs-vol-124-group-lancet-oncol","kind":"paper","name":"Carcinogenicity of night shift work","route":"/key-papers/paper-iarc-monographs-vol-124-group-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31282032","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-disparities-in-access-and-outcomes","kind":"idea","name":"Close the gap between who gets triple-negative breast cancer and who is in its trials","route":"/ideas/idea-tnbc-disparities-in-access-and-outcomes/","field":"links","label":"Scott et al.: triple-negative breast cancer disparities in the United States, 2010 to 2014 (Cancer 2019)"}]},{"url":"https://europepmc.org/article/MED/31286228","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zadik-support-care-cancer","kind":"paper","name":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","route":"/key-papers/paper-zadik-support-care-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31302234","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31303340","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bourhis-radiother-oncol","kind":"paper","name":"Treatment of a first patient with FLASH-radiotherapy","route":"/key-papers/paper-bourhis-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31315034","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-greten-immunity","kind":"paper","name":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","route":"/key-papers/paper-greten-immunity/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31329516","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arches-j-clin-oncol-2019","kind":"paper","name":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","route":"/key-papers/paper-arches-j-clin-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31336704","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31378662","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31397113","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31411950","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-noronha-j-clin-oncol","kind":"paper","name":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer","route":"/key-papers/paper-noronha-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31412220","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/","field":"links","label":"Vonderheide 2020, Annu Rev Med (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/31415071","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-loree-jama-oncol","kind":"paper","name":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","route":"/key-papers/paper-loree-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31416685","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-lancet-oncol-2019","kind":"paper","name":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","route":"/key-papers/paper-anthony-nichols-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31439583","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-reidy-lagunes-clin-cancer-res","kind":"paper","name":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan","route":"/key-papers/paper-reidy-lagunes-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31449468","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol","kind":"paper","name":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report","route":"/key-papers/paper-dix-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31464026","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cillessen-psychooncology","kind":"paper","name":"Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials","route":"/key-papers/paper-cillessen-psychooncology/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31479306","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-j-clin-oncol-2019","kind":"paper","name":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-andrea-decensi-j-clin-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31484488","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions","kind":"idea","name":"Risk-targeted ultrasound screening in high-incidence regions, tested against usual care","route":"/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/","field":"links","label":"Dutta et al.: epidemiology of gallbladder cancer in India (Chin Clin Oncol 2019)"}]},{"url":"https://europepmc.org/article/MED/31487218","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-358-j-clin-oncol-2019","kind":"paper","name":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","route":"/key-papers/paper-checkmate-358-j-clin-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31506387","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dll3-sclc-clin-cancer-res-2019","kind":"paper","name":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","route":"/key-papers/paper-dll3-sclc-clin-cancer-res-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31534219","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-venkataramani-nature","kind":"paper","name":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","route":"/key-papers/paper-venkataramani-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31534222","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-venkatesh-nature","kind":"paper","name":"Electrical and synaptic integration of glioma into neural circuits","route":"/key-papers/paper-venkatesh-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31537697","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lungsearch","kind":"trial","name":"Lung-SEARCH","route":"/trials/lungsearch/","field":"links","label":"European Respiratory Journal 2019"}]},{"url":"https://europepmc.org/article/MED/31540791","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31548545","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31548659","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ben-david-nat-rev-genet","kind":"paper","name":"Context is everything: aneuploidy in cancer","route":"/key-papers/paper-ben-david-nat-rev-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31562043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bisogno-lancet-oncol","kind":"paper","name":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-bisogno-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31562796","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-n-engl-j-med-2019","kind":"paper","name":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keunchil-park-n-engl-j-med-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31563959","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02107703-jama-oncol-2020-update","kind":"paper","name":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","route":"/key-papers/paper-nct02107703-jama-oncol-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31590988","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31591063","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31601568","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-autio-clin-cancer-res","kind":"paper","name":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","route":"/key-papers/paper-autio-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31601988","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arvanitis-nat-rev-cancer","kind":"paper","name":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","route":"/key-papers/paper-arvanitis-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31626055","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-campbell-med-sci-sports-exerc","kind":"paper","name":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","route":"/key-papers/paper-campbell-med-sci-sports-exerc/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31631858","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31645726","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-johnston-nature","kind":"paper","name":"VISTA is an acidic pH-selective ligand for PSGL-1","route":"/key-papers/paper-johnston-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31666715","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roumenina-nat-rev-cancer","kind":"paper","name":"Context-dependent roles of complement in cancer","route":"/key-papers/paper-roumenina-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31672839","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-surveillance-for-every-germline-carrier","kind":"idea","name":"Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception","route":"/ideas/idea-pdac-surveillance-for-every-germline-carrier/","field":"links","label":"CAPS Consortium recommendations (Gut 2020)"}]},{"url":"https://europepmc.org/article/MED/31672865","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jaiswal-science","kind":"paper","name":"Clonal hematopoiesis in human aging and disease","route":"/key-papers/paper-jaiswal-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31723286","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vasan-nature","kind":"paper","name":"A view on drug resistance in cancer","route":"/key-papers/paper-vasan-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31741109","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-national-incidental-cancer-pathway","kind":"idea","name":"A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight","route":"/ideas/idea-gbc-national-incidental-cancer-pathway/","field":"links","label":"de Savornin Lohman et al.: re-resection rate 24 percent in the Netherlands (Ann Surg Oncol 2020)"}]},{"url":"https://europepmc.org/article/MED/31751012","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2020","kind":"paper","name":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31765263","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-azad-j-clin-oncol","kind":"paper","name":"Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study","route":"/key-papers/paper-azad-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31768065","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-durham-nat-med","kind":"paper","name":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","route":"/key-papers/paper-durham-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31774954","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bakker-n-engl-j-med","kind":"paper","name":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue","route":"/key-papers/paper-bakker-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31786121","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31794625","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hoskin-jama","kind":"paper","name":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial","route":"/key-papers/paper-hoskin-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31808921","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-jama-netw-open","kind":"paper","name":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-garcia-jama-netw-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31812554","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31813636","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31825192","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020","kind":"paper","name":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31855498","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ambrosone-j-clin-oncol","kind":"paper","name":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)","route":"/key-papers/paper-ambrosone-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31883020","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fruhwald-neuro-oncol","kind":"paper","name":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors","route":"/key-papers/paper-fruhwald-neuro-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31900462","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-depil-nat-rev-drug-discov","kind":"paper","name":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","route":"/key-papers/paper-depil-nat-rev-drug-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31908301","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31914241","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-amer-zeidan-n-engl-j-med-2020","kind":"paper","name":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","route":"/key-papers/paper-amer-zeidan-n-engl-j-med-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31942077","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-nature-2020","kind":"paper","name":"B cells are associated with survival and immunotherapy response in sarcoma","route":"/key-papers/paper-antoine-italiano-nature-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31952975","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31971541","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kelly-jama-oncol","kind":"paper","name":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","route":"/key-papers/paper-kelly-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31980749","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sahai-nat-rev-cancer","kind":"paper","name":"A framework for advancing our understanding of cancer-associated fibroblasts","route":"/key-papers/paper-sahai-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/31996850","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yoshida-nature","kind":"paper","name":"Tobacco smoking and somatic mutations in human bronchial epithelium","route":"/key-papers/paper-yoshida-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32014125","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gisslinger-lancet-haematol","kind":"paper","name":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","route":"/key-papers/paper-gisslinger-lancet-haematol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32014447","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-cytotherapy-2020","kind":"paper","name":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","route":"/key-papers/paper-cd19-dlbcl-cytotherapy-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32017652","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chera-j-clin-oncol","kind":"paper","name":"Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer","route":"/key-papers/paper-chera-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32023374","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-liu-n-engl-j-med","kind":"paper","name":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","route":"/key-papers/paper-liu-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32025003","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cortes-ciriano-nat-genet","kind":"paper","name":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","route":"/key-papers/paper-cortes-ciriano-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32025018","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alexandrov-nature","kind":"paper","name":"The repertoire of mutational signatures in human cancer","route":"/key-papers/paper-alexandrov-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32027343","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-molinaro-jama-oncol","kind":"paper","name":"Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma","route":"/key-papers/paper-molinaro-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32042067","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-laconi-br-j-cancer","kind":"paper","name":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","route":"/key-papers/paper-laconi-br-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32053137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-i-spy-2-jama-oncol-2020","kind":"paper","name":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","route":"/key-papers/paper-i-spy-2-jama-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32055000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32058842","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hassett-j-clin-oncol","kind":"paper","name":"Management of Male Breast Cancer: ASCO Guideline","route":"/key-papers/paper-hassett-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32078813","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-lancet-oncol-2020","kind":"paper","name":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32096852","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-comstock-jama","kind":"paper","name":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening","route":"/key-papers/paper-comstock-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32101663","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-522-n-engl-j-med-2020","kind":"paper","name":"Pembrolizumab for Early Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32105305","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-global-retinoblastoma-study-jama-oncol","kind":"paper","name":"Global Retinoblastoma Presentation and Analysis by National Income Level","route":"/key-papers/paper-global-retinoblastoma-study-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32105518","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32117737","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-malouff-front-oncol","kind":"paper","name":"Carbon Ion Therapy: A Modern Review of an Emerging Technology","route":"/key-papers/paper-malouff-front-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32118296","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-filippini-cochrane-database-syst-rev","kind":"paper","name":"Green tea (Camellia sinensis) for the prevention of cancer","route":"/key-papers/paper-filippini-cochrane-database-syst-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32125404","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wouters-jama","kind":"paper","name":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","route":"/key-papers/paper-wouters-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32135080","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32209560","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-prior-cancer-res","kind":"paper","name":"The Frequency of Ras Mutations in Cancer","route":"/key-papers/paper-prior-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32213105","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hassan-j-clin-oncol","kind":"paper","name":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","route":"/key-papers/paper-hassan-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32213531","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nagendran-bmj","kind":"paper","name":"Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies","route":"/key-papers/paper-nagendran-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32215577","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-phillips-jama-oncol","kind":"paper","name":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","route":"/key-papers/paper-phillips-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32217756","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-merino-j-immunother-cancer","kind":"paper","name":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","route":"/key-papers/paper-merino-j-immunother-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32251400","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32271377","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02453282-jama-oncol-2020","kind":"paper","name":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct02453282-jama-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32302564","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-monje-cell","kind":"paper","name":"Roadmap for the Emerging Field of Cancer Neuroscience","route":"/key-papers/paper-monje-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32328653","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-neuro-oncol-2020","kind":"paper","name":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","route":"/key-papers/paper-andrew-lassman-neuro-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32335505","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-cancer-treat-rev-2020","kind":"paper","name":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","route":"/key-papers/paper-olivier-chinot-cancer-treat-rev-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32359489","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32361713","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-klichinsky-nat-biotechnol","kind":"paper","name":"Human chimeric antigen receptor macrophages for cancer immunotherapy","route":"/key-papers/paper-klichinsky-nat-biotechnol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32376951","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yamamoto-nature","kind":"paper","name":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","route":"/key-papers/paper-yamamoto-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32388150","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lievens-radiother-oncol","kind":"paper","name":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","route":"/key-papers/paper-lievens-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32418886","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alex-ann-oncol-2020-update","kind":"paper","name":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","route":"/key-papers/paper-alex-ann-oncol-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32424352","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hu-nat-genet","kind":"paper","name":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","route":"/key-papers/paper-hu-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32432946","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roeland-j-clin-oncol","kind":"paper","name":"Management of Cancer Cachexia: ASCO Guideline","route":"/key-papers/paper-roeland-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32437507","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-reardon-jama-oncol","kind":"paper","name":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-reardon-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32484754","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-palma-j-clin-oncol","kind":"paper","name":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","route":"/key-papers/paper-palma-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32488200","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-phan-nat-rev-cancer","kind":"paper","name":"The dormant cancer cell life cycle","route":"/key-papers/paper-phan-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32492302","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-minard-colin-n-engl-j-med","kind":"paper","name":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children","route":"/key-papers/paper-minard-colin-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32504078","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-logsdon-nat-rev-genet","kind":"paper","name":"Long-read human genome sequencing and its applications","route":"/key-papers/paper-logsdon-nat-rev-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32515498","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rock-ca-cancer-j-clin","kind":"paper","name":"American Cancer Society guideline for diet and physical activity for cancer prevention","route":"/key-papers/paper-rock-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32534646","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-2020","kind":"paper","name":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-imspire150-lancet-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32534647","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","field":"links","label":"Europe PMC full text (PMC7294238)"}]},{"url":"https://europepmc.org/article/MED/32576828","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-de-groot-nat-commun","kind":"paper","name":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial","route":"/key-papers/paper-de-groot-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32580883","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-murray-brunt-lancet","kind":"paper","name":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-murray-brunt-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32582924","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32619561","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-voss-int-j-radiat-oncol-biol-phys","kind":"paper","name":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma","route":"/key-papers/paper-voss-int-j-radiat-oncol-biol-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32644110","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-ctdna-guided-adjuvant-decisions","kind":"idea","name":"ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative","route":"/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/","field":"links","label":"Radovich et al.: ctDNA and circulating tumour cells after neoadjuvant chemotherapy, BRE12-158 (JAMA Oncol 2020)"}]},{"url":"https://europepmc.org/article/MED/32669708","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-middleton-nature","kind":"paper","name":"The National Lung Matrix Trial of personalized therapy in lung cancer","route":"/key-papers/paper-middleton-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32678716","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32701411","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32706635","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"Europe PMC"},{"id":"idea-pdac-stromal-reprogramming-not-depletion","kind":"idea","name":"Reprogramme the stroma rather than remove it: second-generation stromal trials with a stromal biomarker and a survival endpoint","route":"/ideas/idea-pdac-stromal-reprogramming-not-depletion/","field":"links","label":"HALO 109-301 (JCO 2020)"}]},{"url":"https://europepmc.org/article/MED/32731259","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tam-blood","kind":"paper","name":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study","route":"/key-papers/paper-tam-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32738571","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","route":"/key-papers/paper-timbergen-eur-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32738955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fitzgerald-lancet","kind":"paper","name":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial","route":"/key-papers/paper-fitzgerald-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32758030","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-salama-j-clin-oncol","kind":"paper","name":"Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","route":"/key-papers/paper-salama-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32771088","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32778876","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mcneil-j-natl-cancer-inst","kind":"paper","name":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults","route":"/key-papers/paper-mcneil-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32781263","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32786044","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-elad-cancer","kind":"paper","name":"MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","route":"/key-papers/paper-elad-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32816842","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vaidya-bmj","kind":"paper","name":"Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial","route":"/key-papers/paper-vaidya-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32818466","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32827483","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-patil-lancet-glob-health","kind":"paper","name":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-patil-lancet-glob-health/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32836172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-clover-eur-j-cancer","kind":"paper","name":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)","route":"/key-papers/paper-clover-eur-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32861308","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32873422","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-centore-trends-genet","kind":"paper","name":"Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","route":"/key-papers/paper-centore-trends-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32877599","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-combi-ad-n-engl-j-med-2020-update","kind":"paper","name":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","route":"/key-papers/paper-combi-ad-n-engl-j-med-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32919527","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32961119","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32966830","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impassion031-lancet-2020","kind":"paper","name":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-impassion031-lancet-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/32983960","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cldn18-gastric-front-oncol-2020","kind":"paper","name":"The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-cldn18-gastric-front-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33001135","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nivolumab-hcc-jama-oncol-2020","kind":"paper","name":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","route":"/key-papers/paper-nivolumab-hcc-jama-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33002206","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sedrak-ca-cancer-j-clin","kind":"paper","name":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","route":"/key-papers/paper-sedrak-ca-cancer-j-clin/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33015372","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rieke-npj-digit-med","kind":"paper","name":"The future of digital health with federated learning","route":"/key-papers/paper-rieke-npj-digit-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33035459","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gounder-lancet-oncol","kind":"paper","name":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","route":"/key-papers/paper-gounder-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33038342","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wells-cell","kind":"paper","name":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","route":"/key-papers/paper-wells-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33048619","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-flaherty-j-clin-oncol","kind":"paper","name":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","route":"/key-papers/paper-flaherty-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/3308077","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tempero-ca19-9-lewis-antigens-cancer-res-1987","kind":"paper","name":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","route":"/key-papers/paper-tempero-ca19-9-lewis-antigens-cancer-res-1987/","field":"links","label":"Europe PMC record"}]},{"url":"https://europepmc.org/article/MED/33089726","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021","kind":"paper","name":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33106634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bolton-nat-genet","kind":"paper","name":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","route":"/key-papers/paper-bolton-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33106665","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-burd-nat-med","kind":"paper","name":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","route":"/key-papers/paper-burd-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33116311","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-nature-2020","kind":"paper","name":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","route":"/key-papers/paper-raajit-rampal-nature-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33119479","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-amer-zeidan-j-clin-oncol-2021","kind":"paper","name":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","route":"/key-papers/paper-amer-zeidan-j-clin-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33122355","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nia-science","kind":"paper","name":"Physical traits of cancer","route":"/key-papers/paper-nia-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33125909","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-redman-lancet-oncol","kind":"paper","name":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","route":"/key-papers/paper-redman-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33148535","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hanna-bmj","kind":"paper","name":"Mortality due to cancer treatment delay: systematic review and meta-analysis","route":"/key-papers/paper-hanna-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33152277","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33186528","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shen-cell","kind":"paper","name":"Persistent Cancer Cells: The Deadly Survivors","route":"/key-papers/paper-shen-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33186684","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hirose-radiother-oncol","kind":"paper","name":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ( 10 B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial","route":"/key-papers/paper-hirose-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33194700","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02152631-front-oncol-2020","kind":"paper","name":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER","route":"/key-papers/paper-nct02152631-front-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33197225","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gordan-j-clin-oncol","kind":"paper","name":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","route":"/key-papers/paper-gordan-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33199490","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2021","kind":"paper","name":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33217316","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rubin-mol-cell","kind":"paper","name":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","route":"/key-papers/paper-rubin-mol-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33239190","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-ann-oncol-2020","kind":"paper","name":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33246021","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-solar-1-ann-oncol-2021-update","kind":"paper","name":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","route":"/key-papers/paper-solar-1-ann-oncol-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33278935","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-355-lancet-2020","kind":"paper","name":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","route":"/key-papers/paper-keynote-355-lancet-2020/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33285097","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33293629","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-nat-rev-clin-oncol-2021","kind":"paper","name":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","route":"/key-papers/paper-olivier-chinot-nat-rev-clin-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33303685","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-baruch-science","kind":"paper","name":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","route":"/key-papers/paper-baruch-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33316117","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tabrizian-am-j-transplant","kind":"paper","name":"PD-1 inhibitor as bridge therapy to liver transplantation?","route":"/key-papers/paper-tabrizian-am-j-transplant/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33346298","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cooper-chem-soc-rev","kind":"paper","name":"Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)","route":"/key-papers/paper-cooper-chem-soc-rev/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33347829","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33358989","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-ann-oncol-2021","kind":"paper","name":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33369848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"Europe PMC: paladin and VEGFR2 (EMBO Reports 2021)"}]},{"url":"https://europepmc.org/article/MED/33382529","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33397968","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-her2-ultralow-testing-uptake","kind":"idea","name":"Reflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan","route":"/ideas/idea-tnbc-her2-ultralow-testing-uptake/","field":"links","label":"Schettini et al.: clinical, pathological and PAM50 features of HER2-low breast cancer (NPJ Breast Cancer 2021)"}]},{"url":"https://europepmc.org/article/MED/33408396","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-authors-nat-methods-2021","kind":"paper","name":"Method of the Year 2020: spatially resolved transcriptomics","route":"/key-papers/paper-authors-nat-methods-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33446664","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33460574","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33476595","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-peritoneal-disease-found-early-and-treated-in-networks","kind":"idea","name":"Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy","route":"/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/","field":"links","label":"Quénet et al.: PRODIGE 7 (Lancet Oncol 2021)"}]},{"url":"https://europepmc.org/article/MED/33479224","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33479225","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-koelsche-nat-commun","kind":"paper","name":"Sarcoma classification by DNA methylation profiling","route":"/key-papers/paper-koelsche-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33497252","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-murthy-j-clin-oncol","kind":"paper","name":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","route":"/key-papers/paper-murthy-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33503393","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tabernero-j-clin-oncol","kind":"paper","name":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","route":"/key-papers/paper-tabernero-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33504648","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yala-sci-transl-med","kind":"paper","name":"Toward robust mammography-based models for breast cancer risk","route":"/key-papers/paper-yala-sci-transl-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33507256","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-danchev-jama-netw-open","kind":"paper","name":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement","route":"/key-papers/paper-danchev-jama-netw-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33507815","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33542131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-davar-science","kind":"paper","name":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","route":"/key-papers/paper-davar-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33581798","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33581820","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-langley-lancet","kind":"paper","name":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","route":"/key-papers/paper-langley-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33581821","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-2021","kind":"paper","name":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","route":"/key-papers/paper-empower-lung-1-lancet-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33627798","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kakiuchi-nat-rev-cancer","kind":"paper","name":"Clonal expansion in non-cancer tissues","route":"/key-papers/paper-kakiuchi-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33650905","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-jochelson-radiology","kind":"paper","name":"Contrast-enhanced Mammography: State of the Art","route":"/key-papers/paper-jochelson-radiology/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33667670","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021","kind":"paper","name":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33721561","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-piccart-lancet-oncol","kind":"paper","name":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","route":"/key-papers/paper-piccart-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33773526","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-national-incidental-cancer-pathway","kind":"idea","name":"A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight","route":"/ideas/idea-gbc-national-incidental-cancer-pathway/","field":"links","label":"Khan et al.: selective versus routine histology of cholecystectomy specimens, systematic review (Asian Pac J Cancer Prev 2021)"}]},{"url":"https://europepmc.org/article/MED/33793299","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-penelope-b-j-clin-oncol-2021","kind":"paper","name":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","route":"/key-papers/paper-penelope-b-j-clin-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33798493","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ABC-06: second-line FOLFOX versus active symptom control (Lancet Oncol 2021)"}]},{"url":"https://europepmc.org/article/MED/33820998","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33826908","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-levin-cell","kind":"paper","name":"Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer","route":"/key-papers/paper-levin-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33845035","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-orecchia-lancet-oncol","kind":"paper","name":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","route":"/key-papers/paper-orecchia-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33857412","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33872070","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-024-189-j-clin-oncol-2021-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50","route":"/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33877688","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shah-br-j-haematol","kind":"paper","name":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline","route":"/key-papers/paper-shah-br-j-haematol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33879601","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33882206","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tnbc-adc-sequencing-trial","kind":"idea","name":"A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer","route":"/ideas/idea-tnbc-adc-sequencing-trial/","field":"links","label":"ASCENT (NEJM 2021)"}]},{"url":"https://europepmc.org/article/MED/3390344","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-withers-acta-oncol","kind":"paper","name":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","route":"/key-papers/paper-withers-acta-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33931919","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"CIRCULATE-Japan: ctDNA-guided adaptive platform trials, design of GALAXY, VEGA and ALTAIR (Cancer Science 2021)"}]},{"url":"https://europepmc.org/article/MED/33946039","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-muscaritoli-clin-nutr","kind":"paper","name":"ESPEN practical guideline: Clinical Nutrition in cancer","route":"/key-papers/paper-muscaritoli-clin-nutr/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/33958435","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021","kind":"paper","name":"Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women","route":"/key-papers/paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021/","field":"links","label":"Europe PMC full text (PMC8571123)"}]},{"url":"https://europepmc.org/article/MED/33991479","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-menon-lancet","kind":"paper","name":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","route":"/key-papers/paper-menon-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34019819","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34096690","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-n-engl-j-med-2021","kind":"paper","name":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","route":"/key-papers/paper-kras-nsclc-n-engl-j-med-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34097070","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Rugo et al.: PD-L1 assay comparison in IMpassion130 (J Natl Cancer Inst 2021)"},{"id":"idea-tnbc-pd-l1-assay-harmonisation","kind":"idea","name":"Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance","route":"/ideas/idea-tnbc-pd-l1-assay-harmonisation/","field":"links","label":"Rugo et al.: PD-L1 assay comparison in IMpassion130 (J Natl Cancer Inst 2021)"}]},{"url":"https://europepmc.org/article/MED/34103352","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-j-immunother-cancer-2021","kind":"paper","name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","route":"/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34112795","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yamazaki-nat-commun","kind":"paper","name":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","route":"/key-papers/paper-yamazaki-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34143971","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ren-lancet-oncol","kind":"paper","name":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","route":"/key-papers/paper-ren-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34174157","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bien-pediatr-blood-cancer","kind":"paper","name":"Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations","route":"/key-papers/paper-bien-pediatr-blood-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34216541","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","route":"/key-papers/paper-ranganathan-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34219000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impassion131-ann-oncol-2021","kind":"paper","name":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","route":"/key-papers/paper-impassion131-ann-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34225076","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021","kind":"paper","name":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34237031","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-navigate-j-clin-invest-2021","kind":"paper","name":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","route":"/key-papers/paper-navigate-j-clin-invest-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34264316","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lung-map-s1400i-jama-oncol-2021","kind":"paper","name":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-lung-map-s1400i-jama-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34266848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-bmj-glob-health","kind":"paper","name":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China","route":"/key-papers/paper-zhang-bmj-glob-health/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34266984","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-adusumilli-cancer-discov","kind":"paper","name":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","route":"/key-papers/paper-adusumilli-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34291289","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-johnson-j-natl-cancer-inst","kind":"paper","name":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report","route":"/key-papers/paper-johnson-j-natl-cancer-inst/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34294911","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34310171","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sheikh-ann-intern-med","kind":"paper","name":"Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study","route":"/key-papers/paper-sheikh-ann-intern-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34310172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-j-clin-oncol-2021","kind":"paper","name":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","route":"/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34310745","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-am-j-hematol-2021","kind":"paper","name":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","route":"/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34319760","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zon-jco-oncol-pract","kind":"paper","name":"Telehealth in Oncology: ASCO Standards and Practice Recommendations","route":"/key-papers/paper-zon-jco-oncol-pract/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34339292","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-park-j-clin-oncol","kind":"paper","name":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","route":"/key-papers/paper-park-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34341537","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fabbri-nat-rev-cancer","kind":"paper","name":"The plasticity of mRNA translation during cancer progression and therapy resistance","route":"/key-papers/paper-fabbri-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34362101","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-t2a-spare-liver-resection-trial","kind":"idea","name":"A trial of sparing the liver resection in peritoneal-side (T2a) gallbladder cancer","route":"/ideas/idea-gbc-t2a-spare-liver-resection-trial/","field":"links","label":"Kang et al.: prognostic significance of tumour location in T2 gallbladder cancer, meta-analysis (J Clin Med 2021)"}]},{"url":"https://europepmc.org/article/MED/34380663","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wagner-j-immunother-cancer","kind":"paper","name":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","route":"/key-papers/paper-wagner-j-immunother-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34391922","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chalasani-clin-gastroenterol-hepatol","kind":"paper","name":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","route":"/key-papers/paper-chalasani-clin-gastroenterol-hepatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34413145","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-farwell-j-nucl-med","kind":"paper","name":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","route":"/key-papers/paper-farwell-j-nucl-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34424113","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-validity-acta-oncol-2021","kind":"paper","name":"Comparability and validity of cancer registry data in the north-west of Russia","route":"/key-papers/paper-barchuk-registry-validity-acta-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34426958","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-t2a-spare-liver-resection-trial","kind":"idea","name":"A trial of sparing the liver resection in peritoneal-side (T2a) gallbladder cancer","route":"/ideas/idea-gbc-t2a-spare-liver-resection-trial/","field":"links","label":"Khan et al.: tumour location and liver resection in T2 gallbladder cancer, meta-analysis (Updates Surg 2021)"}]},{"url":"https://europepmc.org/article/MED/34473194","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02767804-jama-oncol-2021","kind":"paper","name":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-nct02767804-jama-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34508258","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dhanasekaran-nat-rev-clin-oncol","kind":"paper","name":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","route":"/key-papers/paper-dhanasekaran-nat-rev-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34516759","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-adams-j-clin-oncol","kind":"paper","name":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial","route":"/key-papers/paper-adams-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34537440","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-camidge-j-thorac-oncol","kind":"paper","name":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","route":"/key-papers/paper-camidge-j-thorac-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34538072","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-seligmann-j-clin-oncol","kind":"paper","name":"Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring","route":"/key-papers/paper-seligmann-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34551229","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34555333","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34560242","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-casali-ann-oncol","kind":"paper","name":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-casali-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34600602","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34608324","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-avsec-z-nat-methods","kind":"paper","name":"Effective gene expression prediction from sequence by integrating long-range interactions","route":"/key-papers/paper-avsec-z-nat-methods/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34632252","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-larson-jco-precis-oncol","kind":"paper","name":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","route":"/key-papers/paper-larson-jco-precis-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34635570","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kornauth-cancer-discov","kind":"paper","name":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","route":"/key-papers/paper-kornauth-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34637527","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev-2021","kind":"paper","name":"Music interventions for improving psychological and physical outcomes in people with cancer","route":"/key-papers/paper-bradt-cochrane-database-syst-rev-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34647988","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34724563","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34737452","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34774225","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34780711","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34806061","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukls","kind":"trial","name":"UKLS","route":"/trials/ukls/","field":"links","label":"Lancet Regional Health Europe 2021"},{"id":"ukls","kind":"trial","name":"UKLS","route":"/trials/ukls/","field":"outcomes.source (Lung cancer mortality)"}]},{"url":"https://europepmc.org/article/MED/34824210","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hu-signal-transduct-target-ther","kind":"paper","name":"The JAK/STAT signaling pathway: from bench to clinic","route":"/key-papers/paper-hu-signal-transduct-target-ther/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34826411","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-haematol-2021","kind":"paper","name":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34876409","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-friedman-cancer-discov","kind":"paper","name":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-friedman-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34890214","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-j-clin-oncol-2022","kind":"paper","name":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","route":"/key-papers/paper-luca-gianni-j-clin-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34902530","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-atezolizumab-hcc-j-hepatol-2022","kind":"paper","name":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","route":"/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34914339","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rxponder-n-engl-j-med-2021","kind":"paper","name":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","route":"/key-papers/paper-rxponder-n-engl-j-med-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34918177","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Joint European guideline on gallbladder polyps (Eur Radiol 2022)"}]},{"url":"https://europepmc.org/article/MED/34932393","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-j-clin-oncol-2022","kind":"paper","name":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34941392","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-spencer-science","kind":"paper","name":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","route":"/key-papers/paper-spencer-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/34990208","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-j-clin-oncol-2022","kind":"paper","name":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","route":"/key-papers/paper-antoine-italiano-j-clin-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35026411","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roar-ann-oncol-2022-update","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","route":"/key-papers/paper-roar-ann-oncol-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35038432","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35042991","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bekes-nat-rev-drug-discov","kind":"paper","name":"PROTAC targeted protein degraders: the past is prologue","route":"/key-papers/paper-bekes-nat-rev-drug-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35050752","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ahn-jco-precis-oncol","kind":"paper","name":"Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","route":"/key-papers/paper-ahn-jco-precis-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35065058","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","kind":"paper","name":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","route":"/key-papers/paper-nct03916627-lancet-gastroenterol-hepatol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35083924","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brown-clin-trials","kind":"paper","name":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer","route":"/key-papers/paper-brown-clin-trials/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35113160","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fernandez-jama-oncol","kind":"paper","name":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","route":"/key-papers/paper-fernandez-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35118423","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-nat-cancer-2021","kind":"paper","name":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","route":"/key-papers/paper-antoine-italiano-nat-cancer-2021/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35121890","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ackerman-nat-cancer","kind":"paper","name":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","route":"/key-papers/paper-ackerman-nat-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35123658","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pavlova-cell-metab-2022","kind":"paper","name":"The hallmarks of cancer metabolism: Still emerging","route":"/key-papers/paper-pavlova-cell-metab-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35130560","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-majzner-nature","kind":"paper","name":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","route":"/key-papers/paper-majzner-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35145263","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35179229","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-al-hallaq-med-phys","kind":"paper","name":"AAPM task group report 302: Surface-guided radiotherapy","route":"/key-papers/paper-al-hallaq-med-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35228755","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dizman-nat-med","kind":"paper","name":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","route":"/key-papers/paper-dizman-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35245446","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wang-cancer-cell","kind":"paper","name":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","route":"/key-papers/paper-wang-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35263519","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2022-update","kind":"paper","name":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35287967","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-gynecol-oncol-2022","kind":"paper","name":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","route":"/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35297944","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alchemist-jama-oncol-2022","kind":"paper","name":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","route":"/key-papers/paper-alchemist-jama-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35298272","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-crosby-science","kind":"paper","name":"Early detection of cancer","route":"/key-papers/paper-crosby-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35353553","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-parsons-j-clin-oncol","kind":"paper","name":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial","route":"/key-papers/paper-parsons-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35358455","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kindler-lancet-oncol","kind":"paper","name":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","route":"/key-papers/paper-kindler-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35363510","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-eckstein-j-clin-oncol","kind":"paper","name":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial","route":"/key-papers/paper-eckstein-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/3537791","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dvorak-n-engl-j-med","kind":"paper","name":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","route":"/key-papers/paper-dvorak-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35397864","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35397952","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35398754","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-breast-2022","kind":"paper","name":"\"The emerging role of capivasertib in breast cancer\"","route":"/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35405085","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peace-1-lancet-2022","kind":"paper","name":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design","route":"/key-papers/paper-peace-1-lancet-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35419607","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-omuro-neuro-oncol","kind":"paper","name":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","route":"/key-papers/paper-omuro-neuro-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35427471","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35439025","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andre-j-clin-oncol","kind":"paper","name":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-andre-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35442766","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shen-j-clin-oncol","kind":"paper","name":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","route":"/key-papers/paper-shen-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35452273","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-j-clin-oncol","kind":"paper","name":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","route":"/key-papers/paper-herbst-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35483010","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/","field":"links","label":"Europe PMC full text (PMC9362876)"},{"id":"idea-crc-organ-preservation-randomised-in-pmmr-rectal","kind":"idea","name":"Randomise organ preservation against surgery in mismatch repair-proficient rectal cancer, with bowel function as a co-primary endpoint","route":"/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/","field":"links","label":"Garcia-Aguilar et al.: OPRA (J Clin Oncol 2022)"}]},{"url":"https://europepmc.org/article/MED/35511454","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lim-neuro-oncol","kind":"paper","name":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","route":"/key-papers/paper-lim-neuro-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35562406","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ferreri-leukemia","kind":"paper","name":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","route":"/key-papers/paper-ferreri-leukemia/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35576956","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35576957","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cho-lancet-oncol","kind":"paper","name":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","route":"/key-papers/paper-cho-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35580297","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35597384","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-pancreatic-pharmacol-res-2022","kind":"paper","name":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade","route":"/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35608580","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-goodwin-jama","kind":"paper","name":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","route":"/key-papers/paper-goodwin-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35648432","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pellacani-jama-dermatol","kind":"paper","name":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial","route":"/key-papers/paper-pellacani-jama-dermatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35657320","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-ctdna-de-escalation-beyond-stage-ii","kind":"idea","name":"Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps","route":"/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/","field":"links","label":"Tie et al.: DYNAMIC (N Engl J Med 2022)"},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","field":"links","label":"Europe PMC full text (PMC9701133)"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"DYNAMIC: ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM, 16 June 2022)"}]},{"url":"https://europepmc.org/article/MED/35657620","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aminian-jama","kind":"paper","name":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity","route":"/key-papers/paper-aminian-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35658002","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-reckamp-j-clin-oncol","kind":"paper","name":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A","route":"/key-papers/paper-reckamp-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35658005","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03785249-n-engl-j-med-2022","kind":"paper","name":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","route":"/key-papers/paper-nct03785249-n-engl-j-med-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35661856","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-basch-jama","kind":"paper","name":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-basch-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35662408","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35671327","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stampede-plos-med-2022-update","kind":"paper","name":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","route":"/key-papers/paper-stampede-plos-med-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35671774","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","kind":"paper","name":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","route":"/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35676445","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-esteva-npj-digit-med","kind":"paper","name":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","route":"/key-papers/paper-esteva-npj-digit-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35680043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-158-ann-oncol-2022-update","kind":"paper","name":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","route":"/key-papers/paper-keynote-158-ann-oncol-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35693874","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barnabas-nejm-evid","kind":"paper","name":"Efficacy of single-dose HPV vaccination among young African women","route":"/key-papers/paper-barnabas-nejm-evid/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35704792","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-surveillance-for-every-germline-carrier","kind":"idea","name":"Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception","route":"/ideas/idea-pdac-surveillance-for-every-germline-carrier/","field":"links","label":"CAPS5: stage and survival (JCO 2022)"}]},{"url":"https://europepmc.org/article/MED/35714587","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-saxena-mol-cell","kind":"paper","name":"Hallmarks of DNA replication stress","route":"/key-papers/paper-saxena-mol-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35717045","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022","kind":"paper","name":"Lutetium-177 DOTATATE: A Practical Review","route":"/key-papers/paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35777775","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/","field":"links","label":"European Respiratory Journal 2022 (participation)"}]},{"url":"https://europepmc.org/article/MED/35789270","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-j-natl-cancer-inst-2022","kind":"paper","name":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","route":"/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35803244","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stockwell-cell","kind":"paper","name":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","route":"/key-papers/paper-stockwell-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35810754","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35817480","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35882839","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"Europe PMC: paladin in colon cancer metastasis (Oncogenesis 2022)"}]},{"url":"https://europepmc.org/article/MED/35917647","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-orient-11-lung-cancer-2022-update","kind":"paper","name":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","route":"/key-papers/paper-orient-11-lung-cancer-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35961053","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-karschnia-neuro-oncol","kind":"paper","name":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","route":"/key-papers/paper-karschnia-neuro-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35963179","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-powell-esmo-open","kind":"paper","name":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","route":"/key-papers/paper-powell-esmo-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35995953","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/35998300","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chesney-j-clin-oncol","kind":"paper","name":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","route":"/key-papers/paper-chesney-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36013184","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/","field":"links","label":"Panagiotou et al. 2022, Cancers (Europe PMC)"}]},{"url":"https://europepmc.org/article/MED/36017568","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lyon-eur-heart-j","kind":"paper","name":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","route":"/key-papers/paper-lyon-eur-heart-j/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36045302","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schmitt-nat-rev-clin-oncol","kind":"paper","name":"Senescence and cancer - role and therapeutic opportunities","route":"/key-papers/paper-schmitt-nat-rev-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36113498","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36119032","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022","kind":"paper","name":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36122322","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol","kind":"paper","name":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-mao-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36166026","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-astrum-005-jama-2022","kind":"paper","name":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","route":"/key-papers/paper-astrum-005-jama-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36170665","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023","kind":"paper","name":"FGFR2 Inhibition in Cholangiocarcinoma","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36214590","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-screening-uptake-and-age-extension","kind":"idea","name":"Treat screening uptake, not test sensitivity, as the thing to optimise, and settle the age extension with a trial rather than a model","route":"/ideas/idea-crc-screening-uptake-and-age-extension/","field":"links","label":"Bretthauer et al.: NordICC (N Engl J Med 2022)"}]},{"url":"https://europepmc.org/article/MED/36252599","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-atlantis-lancet-respir-med-2023","kind":"paper","name":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-atlantis-lancet-respir-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/362580","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Piehler and Crichlow: primary carcinoma of the gallbladder, 6,222 reported patients (Surg Gynecol Obstet 1978)"}]},{"url":"https://europepmc.org/article/MED/36265502","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36269898","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023","kind":"paper","name":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36270461","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-haanen-ann-oncol","kind":"paper","name":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-haanen-ann-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36273324","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mascia-jama-oncol","kind":"paper","name":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","route":"/key-papers/paper-mascia-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36306479","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-j-clin-oncol-2023-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study","route":"/key-papers/paper-keynote-042-j-clin-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36315917","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gupta-jco-precis-oncol","kind":"paper","name":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study","route":"/key-papers/paper-gupta-jco-precis-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36372281","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ESMO Clinical Practice Guideline: biliary tract cancer (Ann Oncol 2023)"}]},{"url":"https://europepmc.org/article/MED/36423745","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"c-TRAK TN: ctDNA surveillance and pembrolizumab in early triple-negative breast cancer (Ann Oncol 2023)"},{"id":"idea-tnbc-ctdna-guided-adjuvant-decisions","kind":"idea","name":"ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative","route":"/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/","field":"links","label":"c-TRAK TN (Ann Oncol 2023)"}]},{"url":"https://europepmc.org/article/MED/36460017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36477032","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-goteborg-2-n-engl-j-med-2022","kind":"paper","name":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","route":"/key-papers/paper-goteborg-2-n-engl-j-med-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36493334","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-soft-text-j-clin-oncol-2023-update","kind":"paper","name":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","route":"/key-papers/paper-soft-text-j-clin-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36493792","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36495879","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast03-lancet-2023-update","kind":"paper","name":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","route":"/key-papers/paper-destiny-breast03-lancet-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36507690","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36511784","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-n-engl-j-med-2023","kind":"paper","name":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","route":"/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36527382","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cai-j-glob-health","kind":"paper","name":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study","route":"/key-papers/paper-cai-j-glob-health/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36535300","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-crown-lancet-respir-med-2023-update","kind":"paper","name":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","route":"/key-papers/paper-crown-lancet-respir-med-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36567082","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-herpen-esmo-open","kind":"paper","name":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-van-herpen-esmo-open/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36621000","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36627445","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bradley-nat-rev-cancer","kind":"paper","name":"RNA splicing dysregulation and the hallmarks of cancer","route":"/key-papers/paper-bradley-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36633877","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kishan-jama-oncol","kind":"paper","name":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","route":"/key-papers/paper-kishan-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36634294","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mikhael-j-clin-oncol","kind":"paper","name":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography","route":"/key-papers/paper-mikhael-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36641093","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36646210","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36646802","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-ctdna-de-escalation-beyond-stage-ii","kind":"idea","name":"Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps","route":"/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/","field":"links","label":"Kotani et al.: GALAXY (Nat Med 2023)"},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","field":"links","label":"Europe PMC full text (PMC9873552)"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"GALAXY: molecular residual disease and efficacy of adjuvant chemotherapy in colorectal cancer (Nature Medicine 2023)"}]},{"url":"https://europepmc.org/article/MED/36657089","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","field":"links","label":"Journal of Clinical Oncology 2023"},{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","field":"outcomes.source (Residual or recurrent disease within 2 years)"},{"id":"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023","kind":"paper","name":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","route":"/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/","field":"links","label":"Europe PMC full text (PMC10022855)"}]},{"url":"https://europepmc.org/article/MED/36709053","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","field":"links","label":"Lancet Public Health 2023 (uptake)"}]},{"url":"https://europepmc.org/article/MED/36716407","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023","kind":"paper","name":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36735893","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-407-j-clin-oncol-2023-update","kind":"paper","name":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","route":"/key-papers/paper-keynote-407-j-clin-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36746507","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rodolakis-int-j-gynecol-cancer","kind":"paper","name":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","route":"/key-papers/paper-rodolakis-int-j-gynecol-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36780674","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-calgb-140503-n-engl-j-med-2023","kind":"paper","name":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","route":"/key-papers/paper-calgb-140503-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36791159","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kunkler-n-engl-j-med","kind":"paper","name":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","route":"/key-papers/paper-kunkler-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36856617","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-swog-s1801-n-engl-j-med-2023","kind":"paper","name":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","route":"/key-papers/paper-swog-s1801-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36858202","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-karius-radiother-oncol","kind":"paper","name":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy","route":"/key-papers/paper-karius-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36858723","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36884323","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gounder-n-engl-j-med","kind":"paper","name":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors","route":"/key-papers/paper-gounder-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36917948","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-de-visser-cancer-cell","kind":"paper","name":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","route":"/key-papers/paper-de-visser-cancer-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36948246","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-li-j-thorac-oncol","kind":"paper","name":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","route":"/key-papers/paper-li-j-thorac-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36952634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-magnitude-j-clin-oncol-2023","kind":"paper","name":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-magnitude-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36977285","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sandhya-j-clin-oncol","kind":"paper","name":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer","route":"/key-papers/paper-sandhya-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36988937","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-molenaar-jama-surg","kind":"paper","name":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial","route":"/key-papers/paper-molenaar-jama-surg/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/36991390","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37023374","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-badwe-j-clin-oncol","kind":"paper","name":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","route":"/key-papers/paper-badwe-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37046096","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"links","label":"Nature 2023"}]},{"url":"https://europepmc.org/article/MED/37059065","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37071094","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37075273","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-key-j-clin-oncol","kind":"paper","name":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-key-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37096188","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37119523","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-cancer-med-2023","kind":"paper","name":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","route":"/key-papers/paper-luca-gianni-cancer-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37126762","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-harrison-j-clin-oncol","kind":"paper","name":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","route":"/key-papers/paper-harrison-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37133584","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-partridge-n-engl-j-med","kind":"paper","name":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","route":"/key-papers/paper-partridge-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37142371","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-attard-lancet-oncol","kind":"paper","name":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","route":"/key-papers/paper-attard-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37142373","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sonabend-lancet-oncol","kind":"paper","name":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","route":"/key-papers/paper-sonabend-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37146426","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","kind":"paper","name":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","route":"/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/","field":"links","label":"JCO 2023 reprint"}]},{"url":"https://europepmc.org/article/MED/37258680","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-theodoris-nature","kind":"paper","name":"Transfer learning enables predictions in network biology","route":"/key-papers/paper-theodoris-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37260300","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prophylactic-cholecystectomy","kind":"term","name":"Prophylactic (preventive) cholecystectomy","route":"/terms/prophylactic-cholecystectomy/","field":"links","label":"Boekstegers et al, Development and internal validation of a multifactorial risk prediction model for gallbladder cancer in a high-incidence country, Int J Cancer 2023"}]},{"url":"https://europepmc.org/article/MED/37270698","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02864992-jama-oncol-2023-update","kind":"paper","name":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02864992-jama-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37272513","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-671-n-engl-j-med-2023","kind":"paper","name":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-671-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37276871","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"HERIZON-BTC-01: zanidatamab in HER2-amplified biliary tract cancer (Lancet Oncol 2023)"},{"id":"idea-gbc-reflex-her2-testing-advanced-biliary","kind":"idea","name":"Reflex HER2 testing of every advanced gallbladder and extrahepatic biliary cancer","route":"/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/","field":"links","label":"HERIZON-BTC-01 (Lancet Oncol 2023)"},{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37284804","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wolff-j-clin-oncol","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","route":"/key-papers/paper-wolff-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37285865","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2023","kind":"paper","name":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","route":"/key-papers/paper-talapro-2-lancet-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37308716","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-franklin-nat-rev-cancer","kind":"paper","name":"Insights into recent findings and clinical application of YAP and TAZ in cancer","route":"/key-papers/paper-franklin-nat-rev-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37322121","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-o-dwyer-nat-med","kind":"paper","name":"The NCI-MATCH trial: lessons for precision oncology","route":"/key-papers/paper-o-dwyer-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37322367","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37331369","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37390980","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37414012","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37414899","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37427847","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ali-thyroid","kind":"paper","name":"The 2023 Bethesda System for Reporting Thyroid Cytopathology","route":"/key-papers/paper-ali-thyroid/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37429302","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-blay-lancet-oncol","kind":"paper","name":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","route":"/key-papers/paper-blay-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37433327","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-watson-nature","kind":"paper","name":"De novo design of protein structure and function with RFdiffusion","route":"/key-papers/paper-watson-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37467930","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02486718-ann-oncol-2023-update","kind":"paper","name":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","route":"/key-papers/paper-nct02486718-ann-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37499670","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-qin-lancet","kind":"paper","name":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","route":"/key-papers/paper-qin-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37501016","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37541451","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-biochem-pharmacol-2023","kind":"paper","name":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","route":"/key-papers/paper-ezh2-sarcoma-biochem-pharmacol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37548831","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-int-j-clin-oncol-2023-update","kind":"paper","name":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","route":"/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37552839","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-engstrom-cancer-discov","kind":"paper","name":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","route":"/key-papers/paper-engstrom-cancer-discov/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37564196","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-b7-h3-glioblastoma-int-j-biol-sci-2023","kind":"paper","name":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy","route":"/key-papers/paper-b7-h3-glioblastoma-int-j-biol-sci-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37582238","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-carlson-j-clin-oncol","kind":"paper","name":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-carlson-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37585627","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37591293","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37592036","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roohani-nat-biotechnol","kind":"paper","name":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","route":"/key-papers/paper-roohani-nat-biotechnol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37597091","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-drugs-2023","kind":"paper","name":"Epcoritamab: First Approval","route":"/key-papers/paper-epcoritamab-dlbcl-drugs-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37627062","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated","kind":"idea","name":"Redesign Chile's prophylactic cholecystectomy programme around risk, and evaluate it properly","route":"/ideas/idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated/","field":"links","label":"Zollner et al.: Mapuche ancestry and gallbladder cancer risk, instrumental variable analysis (Cancers 2023)"}]},{"url":"https://europepmc.org/article/MED/37633306","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tropics-02-lancet-2023","kind":"paper","name":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-tropics-02-lancet-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37647576","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-qin-j-clin-oncol","kind":"paper","name":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer","route":"/key-papers/paper-qin-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37658205","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keam-mol-diagn-ther","kind":"paper","name":"Equecabtagene Autoleucel: First Approval","route":"/key-papers/paper-keam-mol-diagn-ther/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37670148","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-petersenn-nat-rev-endocrinol","kind":"paper","name":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","route":"/key-papers/paper-petersenn-nat-rev-endocrinol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37689979","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37710001","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37714168","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37733309","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bouffet-n-engl-j-med","kind":"paper","name":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","route":"/key-papers/paper-bouffet-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37733863","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cheng-science","kind":"paper","name":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","route":"/key-papers/paper-cheng-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37751561","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04579380-j-clin-oncol-2023","kind":"paper","name":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","route":"/key-papers/paper-nct04579380-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37770126","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/","field":"links","label":"BSG cholangiocarcinoma guideline (Gut 2023)"}]},{"url":"https://europepmc.org/article/MED/37773077","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ring-clin-cancer-res","kind":"paper","name":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)","route":"/key-papers/paper-ring-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37774317","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-j-clin-oncol-2023","kind":"paper","name":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37805216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"PATHFINDER: blood-based tests for multicancer early detection (The Lancet 2023)"}]},{"url":"https://europepmc.org/article/MED/37824153","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-carson-jama","kind":"paper","name":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","route":"/key-papers/paper-carson-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37853404","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-completeness-bmc-cancer-2023","kind":"paper","name":"Completeness of regional cancer registry data in north-west Russia, 2008 to 2017","route":"/key-papers/paper-barchuk-registry-completeness-bmc-cancer-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37870955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37870974","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37870976","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04538664-n-engl-j-med-2023","kind":"paper","name":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","route":"/key-papers/paper-nct04538664-n-engl-j-med-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37872225","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mackensen-nat-med","kind":"paper","name":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","route":"/key-papers/paper-mackensen-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37883738","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-opra-j-clin-oncol-2024","kind":"paper","name":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","route":"/key-papers/paper-opra-j-clin-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37905734","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-martinez-cibrian-br-j-haematol","kind":"paper","name":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-martinez-cibrian-br-j-haematol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37952131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lincoff-n-engl-j-med","kind":"paper","name":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","route":"/key-papers/paper-lincoff-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/37978284","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kilburn-nat-med","kind":"paper","name":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","route":"/key-papers/paper-kilburn-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/3798106","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Slamon et al.: HER-2/neu amplification and survival in breast cancer (Science 1987)"}]},{"url":"https://europepmc.org/article/MED/38015220","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mai-jama","kind":"paper","name":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","route":"/key-papers/paper-mai-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38043558","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38051328","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-xu-jama","kind":"paper","name":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","route":"/key-papers/paper-xu-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38065203","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zeidan-lancet-haematol","kind":"paper","name":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-zeidan-lancet-haematol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38101437","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38101773","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ESMO Clinical Practice Guideline: early breast cancer (Ann Oncol 2024)"}]},{"url":"https://europepmc.org/article/MED/38109210","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhou-clin-cancer-res","kind":"paper","name":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial","route":"/key-papers/paper-zhou-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38164586","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05413850-j-nucl-med-2024","kind":"paper","name":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","route":"/key-papers/paper-nct05413850-j-nucl-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38195752","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38253604","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ma-nat-commun","kind":"paper","name":"Segment anything in medical images","route":"/key-papers/paper-ma-nat-commun/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38301010","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-montoya-science","kind":"paper","name":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127","route":"/key-papers/paper-montoya-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38319202","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"violet","kind":"trial","name":"VIOLET","route":"/trials/violet/","field":"links","label":"NEJM Evidence 2022"}]},{"url":"https://europepmc.org/article/MED/38319800","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-clarke-nejm-evid","kind":"paper","name":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-clarke-nejm-evid/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38320011","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chamie-nejm-evid","kind":"paper","name":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","route":"/key-papers/paper-chamie-nejm-evid/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38320023","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38320161","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-smith-nejm-evid","kind":"paper","name":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","route":"/key-papers/paper-smith-nejm-evid/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38320513","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38321218","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-garralda-nat-med","kind":"paper","name":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","route":"/key-papers/paper-garralda-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38335473","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arrillaga-romany-j-clin-oncol","kind":"paper","name":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma","route":"/key-papers/paper-arrillaga-romany-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38351187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38388873","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-drugs-2024","kind":"paper","name":"Capivasertib: First Approval","route":"/key-papers/paper-capivasertib-breast-hr-positive-drugs-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38409223","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cui-nat-methods","kind":"paper","name":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","route":"/key-papers/paper-cui-nat-methods/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38418082","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lane-bmj","kind":"paper","name":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","route":"/key-papers/paper-lane-bmj/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38454126","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-brown-nat-med","kind":"paper","name":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","route":"/key-papers/paper-brown-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38477985","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-eclipse-shield-n-engl-j-med-2024","kind":"paper","name":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","route":"/key-papers/paper-eclipse-shield-n-engl-j-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38477986","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-blue-c-n-engl-j-med-2024","kind":"paper","name":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","route":"/key-papers/paper-blue-c-n-engl-j-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38478773","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-braun-j-clin-oncol","kind":"paper","name":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","route":"/key-papers/paper-braun-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38504017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lu-nat-med","kind":"paper","name":"A visual-language foundation model for computational pathology","route":"/key-papers/paper-lu-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38504018","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-nat-med","kind":"paper","name":"Towards a general-purpose foundation model for computational pathology","route":"/key-papers/paper-chen-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38519155","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kraljevic-lancet-digit-health","kind":"paper","name":"Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study","route":"/key-papers/paper-kraljevic-lancet-digit-health/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38521132","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38537155","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04576455-j-clin-oncol-2024","kind":"paper","name":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","route":"/key-papers/paper-nct04576455-j-clin-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38563834","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/","field":"links","label":"Europe PMC"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Leon-Ferre et al.: tumour-infiltrating lymphocytes in triple-negative breast cancer treated without chemotherapy (JAMA 2024)"},{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/","field":"links","label":"Leon-Ferre et al.: tumour-infiltrating lymphocytes and outcome without chemotherapy (JAMA 2024)"}]},{"url":"https://europepmc.org/article/MED/38564684","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-perez-jco-precis-oncol","kind":"paper","name":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study","route":"/key-papers/paper-perez-jco-precis-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38581198","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-martin-jama","kind":"paper","name":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","route":"/key-papers/paper-martin-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38582092","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-2024-update","kind":"paper","name":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-phergain-lancet-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38589574","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","field":"links","label":"Holderfield et al.: concurrent inhibition of oncogenic and wild-type RAS-GTP (Nature 2024)"}]},{"url":"https://europepmc.org/article/MED/38598794","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38636970","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/","field":"links","label":"European Respiratory Journal 2024 (stop-smoking service)"}]},{"url":"https://europepmc.org/article/MED/38704501","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zager-ann-surg-oncol","kind":"paper","name":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","route":"/key-papers/paper-zager-ann-surg-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38710187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38713595","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","kind":"paper","name":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38718835","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-abramson-nature","kind":"paper","name":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","route":"/key-papers/paper-abramson-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38748941","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-sanders-j-clin-oncol","kind":"paper","name":"Palliative Care for Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-sanders-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38749033","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04025879-n-engl-j-med-2024","kind":"paper","name":"Perioperative Nivolumab in Resectable Lung Cancer","route":"/key-papers/paper-nct04025879-n-engl-j-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38778098","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-xu-nature","kind":"paper","name":"A whole-slide foundation model for digital pathology from real-world data","route":"/key-papers/paper-xu-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/3880867","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-moertel-n-engl-j-med","kind":"paper","name":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","route":"/key-papers/paper-moertel-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38820549","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-harmoni-a-jama-2024","kind":"paper","name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","route":"/key-papers/paper-harmoni-a-jama-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38822758","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38823398","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","kind":"paper","name":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","route":"/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38824244","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38828946","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38843488","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38843860","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gelderblom-lancet","kind":"paper","name":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-gelderblom-lancet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38844628","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hao-nat-methods","kind":"paper","name":"Large-scale foundation model on single-cell transcriptomics","route":"/key-papers/paper-hao-nat-methods/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38864835","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tracc-clin-cancer-res-2024","kind":"paper","name":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","route":"/key-papers/paper-tracc-clin-cancer-res-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38865361","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salmonella-typhi-gallbladder-cancer","kind":"term","name":"Salmonella Typhi carriage and gallbladder cancer","route":"/terms/salmonella-typhi-gallbladder-cancer/","field":"links","label":"Qureshi et al, The frequency and associated factors of typhoid carriage in patients undergoing cholecystectomy for gallbladder disease in Pakistan, PLoS Negl Trop Dis 2024"}]},{"url":"https://europepmc.org/article/MED/38870931","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38870977","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-naliricc-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","route":"/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38871975","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/","field":"links","label":"Europe PMC full text (PMC11405281)"},{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/","field":"links","label":"Bullock et al.: botensilimab plus balstilimab in MSS colorectal cancer (Nat Med 2024)"}]},{"url":"https://europepmc.org/article/MED/38888762","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","route":"/key-papers/paper-dhillon-mol-diagn-ther/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/38920727","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-neuroblastoma-curr-oncol-2024","kind":"paper","name":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma","route":"/key-papers/paper-cd47-neuroblastoma-curr-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39036382","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-han-j-natl-cancer-cent","kind":"paper","name":"Cancer incidence and mortality in China, 2022","route":"/key-papers/paper-han-j-natl-cancer-cent/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39039250","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-vorontsov-nat-med","kind":"paper","name":"A foundation model for clinical-grade computational pathology and rare cancers detection","route":"/key-papers/paper-vorontsov-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39048638","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04068610-br-j-cancer-2024","kind":"paper","name":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","route":"/key-papers/paper-nct04068610-br-j-cancer-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39088774","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-philip-j-clin-oncol","kind":"paper","name":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study","route":"/key-papers/paper-philip-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39094065","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03157128-j-clin-oncol-2024-update","kind":"paper","name":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","route":"/key-papers/paper-nct03157128-j-clin-oncol-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39111731","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kozono-j-thorac-oncol","kind":"paper","name":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","route":"/key-papers/paper-kozono-j-thorac-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39116902","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39127176","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhou-j-thorac-oncol","kind":"paper","name":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","route":"/key-papers/paper-zhou-j-thorac-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39232164","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wang-nature","kind":"paper","name":"A pathology foundation model for cancer diagnosis and prognosis prediction","route":"/key-papers/paper-wang-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39245360","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","kind":"paper","name":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","route":"/key-papers/paper-empower-cscc-1-j-am-acad-dermatol-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39259563","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-greer-jama","kind":"paper","name":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial","route":"/key-papers/paper-greer-jama/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39259927","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aphinity-j-clin-oncol-2024-update","kind":"paper","name":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update","route":"/key-papers/paper-aphinity-j-clin-oncol-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39270701","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-shuch-lancet-oncol","kind":"paper","name":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-shuch-lancet-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39271844","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39282906","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-522-n-engl-j-med-2024-update","kind":"paper","name":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39282907","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","field":"links","label":"Europe PMC"},{"id":"idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials","kind":"idea","name":"Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints","route":"/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/","field":"links","label":"Groarke et al.: ponsegromab for cancer cachexia (NEJM 2024)"}]},{"url":"https://europepmc.org/article/MED/39293462","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39302614","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39339989","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39362249","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39413377","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-van-as-n-engl-j-med","kind":"paper","name":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","route":"/key-papers/paper-van-as-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39427441","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39475591","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06106308-j-clin-oncol-2025","kind":"paper","name":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","route":"/key-papers/paper-nct06106308-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39476340","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2024","kind":"paper","name":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39481395","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39509090","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-li-jama-oncol","kind":"paper","name":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","route":"/key-papers/paper-li-jama-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39513953","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025","kind":"paper","name":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39521433","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39550172","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39581197","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04379635-lancet-respir-med-2025","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","route":"/key-papers/paper-nct04379635-lancet-respir-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39602630","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39609566","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dalla-torre-nat-methods","kind":"paper","name":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics","route":"/key-papers/paper-dalla-torre-nat-methods/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39622410","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39651931","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39652449","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhu-clin-transl-sci","kind":"paper","name":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer","route":"/key-papers/paper-zhu-clin-transl-sci/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39660834","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ember-3-n-engl-j-med-2025","kind":"paper","name":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","route":"/key-papers/paper-ember-3-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39665585","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-comet-dcis-jama-2025","kind":"paper","name":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","route":"/key-papers/paper-comet-dcis-jama-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39709114","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/","field":"links","label":"Journal of Thoracic Oncology 2025 (eligibility)"}]},{"url":"https://europepmc.org/article/MED/39761483","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tropion-lung05-j-clin-oncol-2025","kind":"paper","name":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","route":"/key-papers/paper-tropion-lung05-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39762419","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39772829","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-ctdna-residual-disease-guided-adjuvant-trial","kind":"idea","name":"A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection","route":"/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/","field":"links","label":"Yu et al.: ctDNA and early recurrence after biliary resection (JCO Precis Oncol 2025)"}]},{"url":"https://europepmc.org/article/MED/39779851","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-xiang-nature","kind":"paper","name":"A vision-language foundation model for precision oncology","route":"/key-papers/paper-xiang-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39779956","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-linder-nat-genet","kind":"paper","name":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation","route":"/key-papers/paper-linder-nat-genet/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39792928","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39802701","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-halder-lancet-reg-health-southeast-asia","kind":"paper","name":"Access to timely cancer treatment initiation in India: extent, determinants and trends","route":"/key-papers/paper-halder-lancet-reg-health-southeast-asia/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39805350","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","field":"links","label":"Annals of Oncology 2025: the extended biomarker analysis"}]},{"url":"https://europepmc.org/article/MED/39818825","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hayes-science","kind":"paper","name":"Simulating 500 million years of evolution with a language model","route":"/key-papers/paper-hayes-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39833722","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"precision-panc","kind":"trial","name":"Precision-Panc","route":"/trials/precision-panc/","field":"links","label":"STARPAC2 protocol (PRIMUS 005), BMC Cancer 2025"}]},{"url":"https://europepmc.org/article/MED/39838117","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39839782","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-splash-front-oncol-2024","kind":"paper","name":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","route":"/key-papers/paper-splash-front-oncol-2024/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39863775","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39864547","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39879577","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04129502-j-clin-oncol-2025","kind":"paper","name":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial","route":"/key-papers/paper-nct04129502-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/39904652","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-masai-lancet-digit-health-2025","kind":"paper","name":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study","route":"/key-papers/paper-masai-lancet-digit-health-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40052976","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Samaniego et al.: is it time to modify Chile's GES preventive cholecystectomy programme (Rev Med Chile 2024)"},{"id":"idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated","kind":"idea","name":"Redesign Chile's prophylactic cholecystectomy programme around risk, and evaluate it properly","route":"/ideas/idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated/","field":"links","label":"Samaniego et al.: is it time to modify the GES programme (Rev Med Chile 2024)"}]},{"url":"https://europepmc.org/article/MED/40055522","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/","field":"links","label":"Europe PMC"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"DYNAMIC five-year outcomes (Nature Medicine 2025)"}]},{"url":"https://europepmc.org/article/MED/40064481","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-neoadjuvant-for-high-risk-incidental-cancer","kind":"idea","name":"Chemotherapy before the second operation for high-risk incidental gallbladder cancer","route":"/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/","field":"links","label":"Varshney et al.: neoadjuvant treatment for incidental gallbladder cancer, systematic review (Ann Hepatobiliary Pancreat Surg 2025)"}]},{"url":"https://europepmc.org/article/MED/40154514","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","field":"links","label":"Lancet Oncology 2025"}]},{"url":"https://europepmc.org/article/MED/40157574","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40180412","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","field":"links","label":"Protocol, BMJ Open 2025"}]},{"url":"https://europepmc.org/article/MED/40204778","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40209019","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023","kind":"paper","name":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40217078","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40267983","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025","kind":"paper","name":"Geographic and age variations in mutational processes in colorectal cancer","route":"/key-papers/paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025/","field":"links","label":"Europe PMC full text (PMC12221974)"},{"id":"idea-crc-early-onset-cause-hunt","kind":"idea","name":"Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further","route":"/ideas/idea-crc-early-onset-cause-hunt/","field":"links","label":"Díaz-Gay et al.: geographic and age variations in mutational processes (Nature 2025)"}]},{"url":"https://europepmc.org/article/MED/40293177","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/","field":"links","label":"Europe PMC full text (PMC12661660)"},{"id":"idea-crc-organ-preservation-randomised-in-pmmr-rectal","kind":"idea","name":"Randomise organ preservation against surgery in mismatch repair-proficient rectal cancer, with bowel function as a co-primary endpoint","route":"/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/","field":"links","label":"Cercek et al.: nonoperative management of mismatch repair-deficient tumours (N Engl J Med 2025)"}]},{"url":"https://europepmc.org/article/MED/40342845","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-bull-world-health-organ","kind":"paper","name":"National Cancer Grid initiative for electronic medical records, India","route":"/key-papers/paper-pramesh-bull-world-health-organ/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40381735","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"TOPAZ-1 three-year overall survival update (J Hepatol 2025)"}]},{"url":"https://europepmc.org/article/MED/40448572","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40450142","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40450572","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40450658","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-crc-exercise-as-a-funded-treatment","kind":"idea","name":"Fund structured exercise after colon cancer surgery as a treatment, because a randomised trial says it works as well as a drug","route":"/ideas/idea-crc-exercise-as-a-funded-treatment/","field":"links","label":"Courneya et al.: CHALLENGE (N Engl J Med 2025)"}]},{"url":"https://europepmc.org/article/MED/40454634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05587296-n-engl-j-med-2025","kind":"paper","name":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","route":"/key-papers/paper-nct05587296-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40454637","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-serena-6-n-engl-j-med-2025","kind":"paper","name":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","route":"/key-papers/paper-serena-6-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40454641","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40454642","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-816-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","route":"/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40454646","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tarlatamab-sclc-n-engl-j-med-2025","kind":"paper","name":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","route":"/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40461383","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40466026","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40466642","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-med-2025","kind":"paper","name":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study","route":"/key-papers/paper-pembrolizumab-glioblastoma-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40467898","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40468352","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40473449","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-imforte-lancet-2025","kind":"paper","name":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","route":"/key-papers/paper-imforte-lancet-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40480428","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40481574","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04152499-j-hematol-oncol-2025","kind":"paper","name":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","route":"/key-papers/paper-nct04152499-j-hematol-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40523369","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40523897","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40541865","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-report-gallbladder-separately-in-biliary-trials","kind":"idea","name":"Report gallbladder cancer as its own population in every biliary trial","route":"/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/","field":"links","label":"Zhu et al.: population-specific immunogenomics of gallbladder cancer (Mod Pathol 2025)"}]},{"url":"https://europepmc.org/article/MED/40550238","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04143607-lancet-respir-med-2025","kind":"paper","name":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","route":"/key-papers/paper-nct04143607-lancet-respir-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40592848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40608313","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40633690","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40638710","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lewis-science","kind":"paper","name":"Scalable emulation of protein equilibrium ensembles with generative deep learning","route":"/key-papers/paper-lewis-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40645660","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40683290","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2025-update","kind":"paper","name":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","route":"/key-papers/paper-talapro-2-lancet-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40735836","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-burden-to-funding-audit-and-dedicated-call","kind":"idea","name":"A burden-to-funding audit for gallbladder cancer and a dedicated research call","route":"/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/","field":"links","label":"Scherer et al.: EULAT Eradicate GBC, the European-Latin American research consortium (Int J Epidemiol 2025)"}]},{"url":"https://europepmc.org/article/MED/40749900","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40795521","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40830660","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40876501","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40923280","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03974022-j-clin-oncol-2025","kind":"paper","name":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","route":"/key-papers/paper-nct03974022-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40923969","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40945523","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease","kind":"idea","name":"Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed","route":"/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/","field":"links","label":"PREOPANC-2 (Lancet Oncol 2025)"}]},{"url":"https://europepmc.org/article/MED/40961426","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/40996773","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-natalee-jama-oncol-2025-update","kind":"paper","name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","route":"/key-papers/paper-natalee-jama-oncol-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41029877","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-exp-hematol-oncol","kind":"paper","name":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","route":"/key-papers/paper-chen-exp-hematol-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41043438","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41057655","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41060609","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025","kind":"paper","name":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41062831","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41072918","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"St Gallen 2025 consensus on early breast cancer (Ann Oncol 2025)"}]},{"url":"https://europepmc.org/article/MED/41104928","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-soho-01-n-engl-j-med-2025","kind":"paper","name":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","route":"/key-papers/paper-soho-01-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41109920","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41110697","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-monarche-ann-oncol-2026-update","kind":"paper","name":"Overall survival with abemaciclib in early breast cancer","route":"/key-papers/paper-monarche-ann-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41120017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capitello-281-ann-oncol-2026","kind":"paper","name":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","route":"/key-papers/paper-capitello-281-ann-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41124204","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"IMvigor011: ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer (NEJM 2025)"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/","field":"links","label":"IMvigor011: ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer (NEJM 2025), tumour-informed Signatera"}]},{"url":"https://europepmc.org/article/MED/41124220","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41124233","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ascent-03-n-engl-j-med-2025","kind":"paper","name":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-03-n-engl-j-med-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41125109","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2025","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct05840016-lancet-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41130252","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05425940-lancet-2025","kind":"paper","name":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct05425940-lancet-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41130363","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026","kind":"paper","name":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41132955","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41139117","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41159912","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-browne-clin-cancer-res","kind":"paper","name":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","route":"/key-papers/paper-browne-clin-cancer-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41160818","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast09-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","route":"/key-papers/paper-destiny-breast09-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41167216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41171165","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancer-res-commun-2025","kind":"paper","name":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","route":"/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41173143","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41187298","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-hammel-j-clin-oncol","kind":"paper","name":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma","route":"/key-papers/paper-hammel-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41197088","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04561362-j-clin-oncol-2025","kind":"paper","name":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation","route":"/key-papers/paper-nct04561362-j-clin-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41226789","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025","kind":"paper","name":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41237686","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions","kind":"idea","name":"Risk-targeted ultrasound screening in high-incidence regions, tested against usual care","route":"/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/","field":"links","label":"Patkar et al.: Tata Memorial gallbladder cancer registry, 60 percent metastatic at presentation (Cancer Epidemiol 2025)"}]},{"url":"https://europepmc.org/article/MED/41248848","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41260264","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-02-ann-oncol-2026","kind":"paper","name":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","route":"/key-papers/paper-her2climb-02-ann-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41289548","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41325755","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41344593","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04379635-ann-oncol-2026-update","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","route":"/key-papers/paper-nct04379635-ann-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41354932","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41369677","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-05-j-clin-oncol-2026","kind":"paper","name":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","route":"/key-papers/paper-her2climb-05-j-clin-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41370739","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast05-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","route":"/key-papers/paper-destiny-breast05-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41385349","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wisdom-trial-jama-2026","kind":"paper","name":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","route":"/key-papers/paper-wisdom-trial-jama-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41422862","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"CAPItello-290: capivasertib plus paclitaxel first line (Ann Oncol 2026)"}]},{"url":"https://europepmc.org/article/MED/41501023","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","route":"/key-papers/paper-santosh-kesari-nat-commun-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41514569","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancers-basel-2025","kind":"paper","name":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review","route":"/key-papers/paper-cd47-colorectal-cancers-basel-2025/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41526345","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41539318","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41564397","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ascent-04-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-04-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41604639","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-patina-n-engl-j-med-2026","kind":"paper","name":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","route":"/key-papers/paper-patina-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41633900","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41645272","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tamrakar-cancer","kind":"paper","name":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","route":"/key-papers/paper-tamrakar-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41682001","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026","kind":"paper","name":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-cancers-basel-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41740031","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41740463","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","field":"links","label":"Outcomes paper, European Journal of Cancer 2026"}]},{"url":"https://europepmc.org/article/MED/41746062","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-akgor-vaccines-basel","kind":"paper","name":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review","route":"/key-papers/paper-akgor-vaccines-basel/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41820335","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41880612","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-atomic-n-engl-j-med-2026","kind":"paper","name":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","route":"/key-papers/paper-atomic-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41896648","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41896701","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-protect-bju-int-2026-update","kind":"paper","name":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","route":"/key-papers/paper-protect-bju-int-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41937088","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"TROPION-Breast02: datopotamab deruxtecan first line (Ann Oncol 2026)"},{"id":"idea-tnbc-adc-sequencing-trial","kind":"idea","name":"A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer","route":"/ideas/idea-tnbc-adc-sequencing-trial/","field":"links","label":"TROPION-Breast02 (Ann Oncol 2026)"}]},{"url":"https://europepmc.org/article/MED/41950998","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41968137","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41980234","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wen-j-clin-oncol","kind":"paper","name":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial","route":"/key-papers/paper-wen-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/41981308","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-mahalingam-nat-med","kind":"paper","name":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","route":"/key-papers/paper-mahalingam-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42013358","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"CAPBIL: management of incidental gallbladder cancer in the UK (Br J Surg 2026)"},{"id":"idea-gbc-national-incidental-cancer-pathway","kind":"idea","name":"A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight","route":"/ideas/idea-gbc-national-incidental-cancer-pathway/","field":"links","label":"CAPBIL: 67.7 percent liver resection across 24 UK centres (Br J Surg 2026)"}]},{"url":"https://europepmc.org/article/MED/42013403","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05379595-j-clin-oncol-2026","kind":"paper","name":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","route":"/key-papers/paper-nct05379595-j-clin-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42013573","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42031067","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42034003","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42035578","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-gpc3-gastric-pathol-res-pract-2026","kind":"paper","name":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","route":"/key-papers/paper-gpc3-gastric-pathol-res-pract-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42056508","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"links","label":"Nature 2026 (PEACE)"}]},{"url":"https://europepmc.org/article/MED/42090791","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05379985-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","route":"/key-papers/paper-nct05379985-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42097144","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42102826","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nordicc-lancet-2026-update","kind":"paper","name":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","route":"/key-papers/paper-nordicc-lancet-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42119048","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ballman-j-clin-oncol","kind":"paper","name":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma","route":"/key-papers/paper-ballman-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42140743","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42167437","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03742102-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study","route":"/key-papers/paper-nct03742102-ann-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42212913","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05668988-n-engl-j-med-2026","kind":"paper","name":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","route":"/key-papers/paper-nct05668988-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42214392","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06448312-lancet-2026","kind":"paper","name":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct06448312-lancet-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42218899","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2026-update","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","route":"/key-papers/paper-nct05840016-lancet-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42223064","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42223072","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42223077","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03767244-n-engl-j-med-2026","kind":"paper","name":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","route":"/key-papers/paper-nct03767244-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42223087","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42223134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42225101","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42234938","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06099782-jco-oncol-pract-2026","kind":"paper","name":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","route":"/key-papers/paper-nct06099782-jco-oncol-pract-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42260101","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ALTAIR: post-adjuvant trifluridine/tipiracil in ctDNA-positive resected colorectal cancer, primary endpoint not met (Nature Medicine 2026)"}]},{"url":"https://europepmc.org/article/MED/42296979","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42308452","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kapoor-jco-glob-oncol","kind":"paper","name":"Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)","route":"/key-papers/paper-kapoor-jco-glob-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42346609","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bar-j-pers-med","kind":"paper","name":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment","route":"/key-papers/paper-bar-j-pers-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42368479","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42385760","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42410111","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42443515","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42480250","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42507968","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-peters-j-clin-oncol","kind":"paper","name":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer","route":"/key-papers/paper-peters-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42561994","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-psmaddition-lancet-2026","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","route":"/key-papers/paper-psmaddition-lancet-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42579833","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42583118","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-ctdna-residual-disease-guided-adjuvant-trial","kind":"idea","name":"A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection","route":"/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/","field":"links","label":"Malla et al.: real-world ctDNA after resection of stage I to III biliary tract cancer (ESMO GI Oncol 2026)"}]},{"url":"https://europepmc.org/article/MED/42586872","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42587052","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42595189","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-gbc-reflex-her2-testing-advanced-biliary","kind":"idea","name":"Reflex HER2 testing of every advanced gallbladder and extrahepatic biliary cancer","route":"/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/","field":"links","label":"Angerilli et al.: HER2 status and heterogeneity in 140 resected biliary cancers (Hum Pathol 2026)"}]},{"url":"https://europepmc.org/article/MED/42612509","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42628840","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-671-ann-oncol-2026-update","kind":"paper","name":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","route":"/key-papers/paper-keynote-671-ann-oncol-2026-update/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42633754","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"star-trec","kind":"trial","name":"STAR-TREC","route":"/trials/star-trec/","field":"links","label":"Lancet Oncology 2026: 12-month results"}]},{"url":"https://europepmc.org/article/MED/42636833","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42636977","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"OlympiA six-year update: sustained benefit of adjuvant olaparib (Ann Oncol 2026)"},{"id":"idea-tnbc-uk-trial-access-and-germline-testing-audit","kind":"idea","name":"A UK audit of trial access and germline testing uptake in triple-negative breast cancer","route":"/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/","field":"links","label":"OlympiA six-year update (Ann Oncol 2026)"}]},{"url":"https://europepmc.org/article/MED/42637134","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42675036","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42690668","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42694779","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-cureus-2026","kind":"paper","name":"Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma","route":"/key-papers/paper-daraxonrasib-pancreatic-cureus-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42727044","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42734213","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42765908","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nct03330847-clin-cancer-res-2026","kind":"paper","name":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","route":"/key-papers/paper-nct03330847-clin-cancer-res-2026/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/42773209","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"NHS-Galleri: performance of a multi-cancer early detection test across three annual rounds (Nature Medicine, 22 September 2026)"}]},{"url":"https://europepmc.org/article/MED/4588620","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stutman-science","kind":"paper","name":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","route":"/key-papers/paper-stutman-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/4921480","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-burnet-prog-exp-tumor-res","kind":"paper","name":"The concept of immunological surveillance","route":"/key-papers/paper-burnet-prog-exp-tumor-res/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/5279523","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-knudson-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Mutation and cancer: statistical study of retinoblastoma","route":"/key-papers/paper-knudson-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/6185846","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nature","kind":"paper","name":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","route":"/key-papers/paper-feinberg-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/6632129","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prophylactic-cholecystectomy","kind":"term","name":"Prophylactic (preventive) cholecystectomy","route":"/terms/prophylactic-cholecystectomy/","field":"links","label":"Diehl, Gallstone size and the risk of gallbladder cancer, JAMA 1983"}]},{"url":"https://europepmc.org/article/MED/6693192","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-trojani-int-j-cancer","kind":"paper","name":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","route":"/key-papers/paper-trojani-int-j-cancer/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/7509044","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-lapidot-nature","kind":"paper","name":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","route":"/key-papers/paper-lapidot-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/7580546","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995","kind":"paper","name":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","route":"/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/","field":"links","label":"BMJ 1995"}]},{"url":"https://europepmc.org/article/MED/7707126","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-grever-j-clin-oncol","kind":"paper","name":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","route":"/key-papers/paper-grever-j-clin-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/782269","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Traverso: Carl Langenbuch and the first cholecystectomy (Am J Surg 1976)"}]},{"url":"https://europepmc.org/article/MED/8186756","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kuznetsov-bull-math-biol","kind":"paper","name":"Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis","route":"/key-papers/paper-kuznetsov-bull-math-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/837366","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Leon et al.: free DNA in the serum of cancer patients and the effect of therapy (Cancer Research 1977)"}]},{"url":"https://europepmc.org/article/MED/8466463","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"Hardy: Carl Langenbuch and the Lazarus Hospital, the first cholecystectomy in July 1882 (Aust N Z J Surg 1993)"}]},{"url":"https://europepmc.org/article/MED/8625043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salmonella-typhi-gallbladder-cancer","kind":"term","name":"Salmonella Typhi carriage and gallbladder cancer","route":"/terms/salmonella-typhi-gallbladder-cancer/","field":"links","label":"Strom et al, Risk factors for gallbladder cancer: an international collaborative case-control study (La Paz and Mexico City), Cancer 1995"}]},{"url":"https://europepmc.org/article/MED/8682968","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-duvic-j-am-acad-dermatol","kind":"paper","name":"A randomized trial of minoxidil in chemotherapy-induced alopecia","route":"/key-papers/paper-duvic-j-am-acad-dermatol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/8733766","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"links","label":"Oliva and Young 1996, Modern Pathology: clear cell adenocarcinoma of the urethra, 19 cases (PMID 8733766)"}]},{"url":"https://europepmc.org/article/MED/8839839","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-wattel-blood","kind":"paper","name":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group","route":"/key-papers/paper-wattel-blood/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/8942775","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nottingham-fob","kind":"trial","name":"Nottingham faecal occult blood screening trial","route":"/trials/nottingham-fob/","field":"links","label":"Lancet 1996"}]},{"url":"https://europepmc.org/article/MED/9105051","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-weaver-j-cell-biol","kind":"paper","name":"Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies","route":"/key-papers/paper-weaver-j-cell-biol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9126728","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kinzler-nature","kind":"paper","name":"Cancer-susceptibility genes. Gatekeepers and caretakers","route":"/key-papers/paper-kinzler-nature/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9145676","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"Struewing et al.: cancer risk of BRCA1 and BRCA2 founder mutations among Ashkenazi Jews (NEJM 1997)"}]},{"url":"https://europepmc.org/article/MED/9212098","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bonnet-nat-med","kind":"paper","name":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","route":"/key-papers/paper-bonnet-nat-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9250182","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chart-lung","kind":"trial","name":"CHART","route":"/trials/chart-lung/","field":"links","label":"Lancet 1997"},{"id":"chart-lung","kind":"trial","name":"CHART","route":"/trials/chart-lung/","field":"outcomes.source (Two-year overall survival)"}]},{"url":"https://europepmc.org/article/MED/9395428","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-overgaard-n-engl-j-med","kind":"paper","name":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial","route":"/key-papers/paper-overgaard-n-engl-j-med/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9510041","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-overgaard-radiother-oncol","kind":"paper","name":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","route":"/key-papers/paper-overgaard-radiother-oncol/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/959840","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-nowell-science","kind":"paper","name":"The clonal evolution of tumor cell populations","route":"/key-papers/paper-nowell-science/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9800687","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fraass-med-phys","kind":"paper","name":"American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning","route":"/key-papers/paper-fraass-med-phys/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/MED/9811862","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-duesberg-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Genetic instability of cancer cells is proportional to their degree of aneuploidy","route":"/key-papers/paper-duesberg-proc-natl-acad-sci-u-s-a/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/article/PPR/PPR499502","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-almogy-biorxiv","kind":"paper","name":"Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform","route":"/key-papers/paper-almogy-biorxiv/","field":"links","label":"Europe PMC"}]},{"url":"https://europepmc.org/articles/PMC11435696","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/","field":"links","label":"Europe PMC full text"}]},{"url":"https://europepmc.org/articles/PMC7618749","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-pugh-self-experimentation-publication-jme-2026","kind":"paper","name":"Pugh 2026: should a journal publish a scientist's experiment on herself?","route":"/key-papers/paper-pugh-self-experimentation-publication-jme-2026/","field":"links","label":"Europe PMC full text"}]},{"url":"https://europepmc.org/search?query=AUTH%3A%22Ciechanover%20A%22%20AND%20AFF%3A%22Technion%22","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","field":"links","label":"Ciechanover et al., The landscape of the ubiquitin-proteasome system in cancer"}]},{"url":"https://europepmc.org/search?query=AUTH%3A%22Gabizon%20A%22%20AND%20liposomal","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"links","label":"Europe PMC author and affiliation search"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"profiles","label":"Europe PMC author and affiliation search"}]},{"url":"https://evidence.nejm.org","status":403,"ok":false,"finalUrl":"https://evidence.nejm.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","field":"url"}]},{"url":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","field":"links","label":"HIMALAYA (NEJM Evidence 2022)"}]},{"url":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200006","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","field":"links","label":"IPSS-M (NEJM Evidence 2022)"}]},{"url":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200015","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","field":"links","label":"TOPAZ-1 (NEJM Evidence 2022)"}]},{"url":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"outcomes.source (Radiographic progression-free survival (investigator), all comers)"}]},{"url":"https://febs.onlinelibrary.wiley.com/journal/18780261","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","field":"links","label":"Molecular Oncology"},{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","field":"links","label":"Homepage"},{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","field":"url"}]},{"url":"https://genesdev.cshlp.org","status":403,"ok":false,"finalUrl":"https://genesdev.cshlp.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","field":"url"}]},{"url":"https://gut.bmj.com","status":403,"ok":false,"finalUrl":"https://gut.bmj.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gut","kind":"journal","name":"Gut","route":"/journals/gut/","field":"links","label":"Gut, BMJ Group"},{"id":"gut","kind":"journal","name":"Gut","route":"/journals/gut/","field":"url"}]},{"url":"https://health.ec.europa.eu/health-technology-assessment/regulation-health-technology-assessment_en","status":403,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"links","label":"EU Regulation on Health Technology Assessment"},{"id":"idea-reg-joint-regulator-hta-plan","kind":"idea","name":"One evidence plan agreed by regulator and payer before the pivotal trial","route":"/ideas/idea-reg-joint-regulator-hta-plan/","field":"links","label":"EU HTA Regulation"}]},{"url":"https://heliogenomics.com/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","field":"links","label":"Official website"},{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","field":"website"}]},{"url":"https://heliogenomics.com/news-media","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","field":"links","label":"News and media"}]},{"url":"https://heliogenomics.com/news/fulgent-helio-strategic-partnership-early-cancer-detection","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","field":"links","label":"Fulgent Genetics partnership and strategic investment (Aug 2021)"}]},{"url":"https://hospitals.clalit.co.il/rabin","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/","field":"links","label":"Davidoff Cancer Center, Rabin Medical Center"},{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/","field":"profiles","label":"Davidoff Cancer Center, Rabin Medical Center"},{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","route":"/institutions/rabin-davidoff-center/","field":"links","label":"Official website"},{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","route":"/institutions/rabin-davidoff-center/","field":"website"}]},{"url":"https://hub.jhu.edu/2016/03/29/cancer-immunotherapy-center-bloomberg-kimmel/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/","field":"links","label":"Johns Hopkins Hub: cancer immunotherapy institute launch (2016)"},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/","field":"links","label":"Johns Hopkins Hub: cancer immunotherapy institute launch (2016)"}]},{"url":"https://international-journal-of-gynecological-cancer.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/","field":"links","label":"Homepage"},{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/","field":"url"}]},{"url":"https://jamanetwork.com","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","field":"links","label":"JAMA Network"}]},{"url":"https://jamanetwork.com/collections/44045/less-is-more","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","field":"links","label":"Less Is More series"}]},{"url":"https://jamanetwork.com/collections/5644/oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"links","label":"JAMA Network oncology"}]},{"url":"https://jamanetwork.com/journals/jama","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"url"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/1105059","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","field":"outcomes.source (Recurrence-free survival at 5 years)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2630810","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-patient-reported-toxicity-dose-algorithms","kind":"idea","name":"Dose adjustments driven by patients' own symptom reports, tested against clinician judgement","route":"/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/","field":"links","label":"Symptom monitoring with patient-reported outcomes during routine cancer treatment (JAMA 2017)"},{"id":"idea-acc-electronic-pro-monitoring-standard","kind":"idea","name":"Weekly electronic symptom reporting as a standard of care during systemic therapy","route":"/ideas/idea-acc-electronic-pro-monitoring-standard/","field":"links","label":"Basch et al., JAMA 2017: overall survival with PRO monitoring"},{"id":"idea-data-pro-as-structured-standard","kind":"idea","name":"Patient-reported symptoms captured as standard structured data in every clinic","route":"/ideas/idea-data-pro-as-structured-standard/","field":"links","label":"Basch et al., JAMA 2017 (ePRO and survival)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2666504","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","field":"outcomes.source (Progression-free survival)"},{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","field":"outcomes.source (Overall survival)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2751686","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/","field":"outcomes.source (Event-free survival at 3 years)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2763325","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"announce","kind":"trial","name":"ANNOUNCE","route":"/trials/announce/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2784143","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","field":"links","label":"JAMA 2021"},{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","field":"outcomes.source (Overall survival)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2796605","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/","field":"outcomes.source (Overall survival)"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2819187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/","field":"outcomes.source (MRD-negative complete remission at end of induction)"}]},{"url":"https://jamanetwork.com/journals/jamainternalmedicine","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","field":"url"}]},{"url":"https://jamanetwork.com/journals/jamaoncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","field":"url"}]},{"url":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2760405","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","field":"links","label":"Nanda et al., JAMA Oncology 2020: pembrolizumab plus standard neoadjuvant therapy in the I-SPY2 trial"}]},{"url":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2795896","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","field":"outcomes.source (Overall survival (5-year update))"}]},{"url":"https://jitc.bmj.com","status":403,"ok":false,"finalUrl":"https://jitc.bmj.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","field":"url"}]},{"url":"https://jnccn.org","status":403,"ok":false,"finalUrl":"https://jnccn.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","field":"url"}]},{"url":"https://jnccn.org/view/journals/jnccn/24/3/article-p68.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"links","label":"NCCN CLL/SLL Insights v2.2026"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"standardOfCare.guideline (Early stage, asymptomatic (Rai 0-II, Binet A-B))"}]},{"url":"https://journals.bioscientifica.com/erc","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/","field":"links","label":"Homepage"},{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/","field":"url"}]},{"url":"https://journals.lww.com/amjclinicaloncology/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","route":"/journals/american-journal-of-clinical-oncology/","field":"links","label":"Homepage"},{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","route":"/journals/american-journal-of-clinical-oncology/","field":"url"}]},{"url":"https://journals.lww.com/cancernursingonline/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","route":"/journals/cancer-nursing/","field":"links","label":"Homepage"},{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","route":"/journals/cancer-nursing/","field":"url"}]},{"url":"https://journals.lww.com/co-oncology/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","route":"/journals/current-opinion-in-oncology/","field":"links","label":"Homepage"},{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","route":"/journals/current-opinion-in-oncology/","field":"url"}]},{"url":"https://journals.lww.com/eurjcancerprev/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","route":"/journals/european-journal-of-cancer-prevention/","field":"links","label":"Homepage"},{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","route":"/journals/european-journal-of-cancer-prevention/","field":"url"}]},{"url":"https://journals.lww.com/hosct/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","field":"links","label":"Homepage"},{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","field":"url"}]},{"url":"https://journals.lww.com/indianjcancer/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/","field":"links","label":"Homepage"},{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/","field":"url"}]},{"url":"https://journals.lww.com/journalppo/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/","field":"links","label":"Homepage"},{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/","field":"url"}]},{"url":"https://journals.lww.com/jpho-online/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/","field":"url"}]},{"url":"https://journals.lww.com/melanomaresearch/pages/default.aspx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma-research","kind":"journal","name":"Melanoma research","route":"/journals/melanoma-research/","field":"links","label":"Homepage"},{"id":"melanoma-research","kind":"journal","name":"Melanoma research","route":"/journals/melanoma-research/","field":"url"}]},{"url":"https://journals.sagepub.com/doi/10.1177/17588359241248336","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","field":"links","label":"TROPION-Breast03 design (Ther Adv Med Oncol 2024)"}]},{"url":"https://journals.sagepub.com/home/cbm","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","route":"/journals/cancer-biomarkers/","field":"links","label":"Homepage"},{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","route":"/journals/cancer-biomarkers/","field":"url"}]},{"url":"https://journals.sagepub.com/home/cbr","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"links","label":"Homepage"},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"url"}]},{"url":"https://journals.sagepub.com/home/ccx","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","field":"links","label":"Homepage"},{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","field":"url"}]},{"url":"https://journals.sagepub.com/home/ict","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","field":"links","label":"Homepage"},{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","field":"url"}]},{"url":"https://journals.sagepub.com/home/jay","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","route":"/journals/journal-of-adolescent-and-young-adult-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","route":"/journals/journal-of-adolescent-and-young-adult-oncology/","field":"url"}]},{"url":"https://journals.sagepub.com/home/jbm","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","field":"links","label":"Homepage"},{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","field":"url"}]},{"url":"https://journals.sagepub.com/home/jpo","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","route":"/journals/journal-of-pediatric-hematology-oncology-nursing/","field":"links","label":"Homepage"},{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","route":"/journals/journal-of-pediatric-hematology-oncology-nursing/","field":"url"}]},{"url":"https://journals.sagepub.com/home/opp","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","field":"links","label":"Homepage"},{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","field":"url"}]},{"url":"https://journals.sagepub.com/home/tct","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","field":"links","label":"Homepage"},{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","field":"url"}]},{"url":"https://journals.sagepub.com/home/tmj","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumori","kind":"journal","name":"Tumori","route":"/journals/tumori/","field":"links","label":"Homepage"},{"id":"tumori","kind":"journal","name":"Tumori","route":"/journals/tumori/","field":"url"}]},{"url":"https://journals.sagepub.com/home/tub","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","field":"links","label":"Homepage"},{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","field":"url"}]},{"url":"https://karger.com/ocl","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","field":"links","label":"Homepage"},{"id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","field":"url"}]},{"url":"https://karger.com/ort","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","route":"/journals/oncology-research-and-treatment/","field":"links","label":"Homepage"},{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","route":"/journals/oncology-research-and-treatment/","field":"url"}]},{"url":"https://le.ac.uk/cancer-research-centre","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leicester-cancer-research-centre","kind":"institution","name":"Leicester Cancer Research Centre / University Hospitals of Leicester","route":"/institutions/leicester-cancer-research-centre/","field":"links","label":"Official website"},{"id":"leicester-cancer-research-centre","kind":"institution","name":"Leicester Cancer Research Centre / University Hospitals of Leicester","route":"/institutions/leicester-cancer-research-centre/","field":"website"}]},{"url":"https://leaps.bayer.com/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/","field":"links","label":"Official website"},{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/","field":"website"}]},{"url":"https://mahidol.ac.th","status":403,"ok":false,"finalUrl":"https://mahidol.ac.th/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","field":"links","label":"Mahidol University"},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","field":"links","label":"Mahidol University"}]},{"url":"https://medicine.umich.edu/dept/radiation-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"links","label":"Michigan Medicine"},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"profiles","label":"Michigan Medicine"}]},{"url":"https://oncology.med.wayne.edu/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","field":"links","label":"Source: Wayne State Department of Oncology page (Chair)"},{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","field":"profiles","label":"Wayne State University Department of Oncology"}]},{"url":"https://onlinelibrary.wiley.com/journal/10969098","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","route":"/journals/journal-of-surgical-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","route":"/journals/journal-of-surgical-oncology/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10970215","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/","field":"links","label":"Homepage"},{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10970347","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","route":"/journals/head-and-neck-journal/","field":"links","label":"Homepage"},{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","route":"/journals/head-and-neck-journal/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10982264","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","route":"/journals/genes-chromosomes-and-cancer/","field":"links","label":"Homepage"},{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","route":"/journals/genes-chromosomes-and-cancer/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10982744","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","route":"/journals/molecular-carcinogenesis/","field":"links","label":"Homepage"},{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","route":"/journals/molecular-carcinogenesis/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10991069","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","route":"/journals/hematological-oncology/","field":"links","label":"Homepage"},{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","route":"/journals/hematological-oncology/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/10991611","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","route":"/journals/psycho-oncology-journal/","field":"links","label":"Homepage"},{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","route":"/journals/psycho-oncology-journal/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/13497006","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","field":"links","label":"Homepage"},{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/1353921906009","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","field":"links","label":"Homepage"},{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/14765829","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/","field":"links","label":"Homepage"},{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/15244741","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","field":"links","label":"Homepage"},{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/15455017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/17437563","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","route":"/journals/asia-pacific-journal-of-clinical-oncology/","field":"links","label":"Homepage"},{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","route":"/journals/asia-pacific-journal-of-clinical-oncology/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/17549485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/1755148x","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","route":"/journals/pigment-cell-and-melanoma-research/","field":"links","label":"Homepage"},{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","route":"/journals/pigment-cell-and-melanoma-research/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/17597714","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","field":"links","label":"Homepage"},{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/20457634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","field":"links","label":"Homepage"},{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/25738348","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","field":"links","label":"Homepage"},{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","field":"url"}]},{"url":"https://onlinelibrary.wiley.com/journal/2641","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","field":"links","label":"Homepage"},{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","field":"url"}]},{"url":"https://pitchbook.com/profiles/company/1161350-47","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/","field":"links","label":"Official website"},{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/","field":"website"}]},{"url":"https://pubs.rsna.org/journal/radiology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","field":"url"}]},{"url":"https://pubs.rsna.org/journal/radiology-ic","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","route":"/journals/radiology-imaging-cancer/","field":"links","label":"Homepage"},{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","route":"/journals/radiology-imaging-cancer/","field":"url"}]},{"url":"https://rmhc.org/","status":403,"ok":false,"finalUrl":"https://ronaldmcdonaldhouse.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-mcdonald-house-charities","kind":"collection","name":"Ronald McDonald House Charities","route":"/collections/ronald-mcdonald-house-charities/","field":"links","label":"Ronald McDonald House Charities"},{"id":"ronald-mcdonald-house-charities","kind":"collection","name":"Ronald McDonald House Charities","route":"/collections/ronald-mcdonald-house-charities/","field":"url"}]},{"url":"https://scholar.google.com/scholar?q=Alan%20Ashworth","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"links","label":"Google Scholar"},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Alan%20P.%20Venook","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"links","label":"Google Scholar"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Albert%20C.%20Koong","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"links","label":"Google Scholar"},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Alex%20F.%20Herrera","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"links","label":"Google Scholar"},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Alice%20L.%20Yu","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"links","label":"Google Scholar"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Amar%20U.%20Kishan","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"links","label":"Google Scholar"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Anirban%20Maitra","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"links","label":"Google Scholar"},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Anne%20C.%20Chiang","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"links","label":"Google Scholar"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Antoni%20Ribas","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"links","label":"Google Scholar"},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"links","label":"Google Scholar"},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Behnam%20Badie","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"links","label":"Google Scholar"},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Charles%20D.%20Blanke","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"links","label":"Google Scholar"},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Charles%20E.%20Geyer%20Jr.","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"links","label":"Google Scholar"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Cheryl%20L.%20Willman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"links","label":"Google Scholar"},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Christine%20E.%20Brown","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"links","label":"Google Scholar"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Christopher%20R.%20Flowers","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"links","label":"Google Scholar"},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Clifford%20A.%20Hudis","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"links","label":"Google Scholar"},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Crystal%20L.%20Mackall","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"links","label":"Google Scholar"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Dawn%20L.%20Hershman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"links","label":"Google Scholar"},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Deborah%20Watkins%20Bruner","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"links","label":"Google Scholar"},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Debu%20Tripathy","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"links","label":"Google Scholar"},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Denise%20A.%20Galloway","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"links","label":"Google Scholar"},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Dennis%20J.%20Slamon","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"links","label":"Google Scholar"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Douglas%20S.%20Hawkins","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"links","label":"Google Scholar"},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"Google Scholar"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Eric%20J.%20Small","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"links","label":"Google Scholar"},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Evanthia%20Galanis","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"links","label":"Google Scholar"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Everett%20E.%20Vokes","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"links","label":"Google Scholar"},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Frank%20McCormick","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"links","label":"Google Scholar"},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Funda%20Meric-Bernstam","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"links","label":"Google Scholar"},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Gary%20H.%20Lyman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"links","label":"Google Scholar"},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Giulio%20Draetta","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"links","label":"Google Scholar"},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Hagen%20F.%20Kennecke","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"links","label":"Google Scholar"},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Hagop%20M.%20Kantarjian","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"links","label":"Google Scholar"},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Hans-Peter%20Kiem","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"links","label":"Google Scholar"},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Heather%20A.%20Wakelee","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"links","label":"Google Scholar"},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Hope%20S.%20Rugo","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"links","label":"Google Scholar"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Irving%20L.%20Weissman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"links","label":"Google Scholar"},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=James%20P.%20Allison","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"links","label":"Google Scholar"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"links","label":"Google Scholar"},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Jeremie%20Calais","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"Google Scholar"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Johannes%20Czernin","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"Google Scholar"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=John%20V.%20Heymach","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"links","label":"Google Scholar"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Julie%20R.%20Park","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"links","label":"Google Scholar"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"Google Scholar"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Kathy%20S.%20Albain","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"links","label":"Google Scholar"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Kevan%20M.%20Shokat","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"links","label":"Google Scholar"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Laura%20J.%20Esserman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"links","label":"Google Scholar"},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Lori%20J.%20Pierce","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"links","label":"Google Scholar"},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Lynn%20M.%20Schuchter","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"links","label":"Google Scholar"},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Margaret%20Foti","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"links","label":"Google Scholar"},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Mariana%20Chavez-MacGregor","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"links","label":"Google Scholar"},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Mark%20R.%20Litzow","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"links","label":"Google Scholar"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Matthew%20P.%20Goetz","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"links","label":"Google Scholar"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Maximilian%20Diehn","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"links","label":"Google Scholar"},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Michael%20A.%20Caligiuri","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"links","label":"Google Scholar"},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Michael%20A.%20Teitell","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"links","label":"Google Scholar"},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Michael%20LeBlanc","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"links","label":"Google Scholar"},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Mitchell%20D.%20Schnall","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"links","label":"Google Scholar"},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Neeraj%20Agarwal","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"links","label":"Google Scholar"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Owen%20N.%20Witte","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"links","label":"Google Scholar"},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Padmanee%20Sharma","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"links","label":"Google Scholar"},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Peter%20J.%20O'Dwyer","status":403,"ok":false,"finalUrl":"https://scholar.google.com/scholar?q=Peter%20J.%20O%27Dwyer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"links","label":"Google Scholar"},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Peter%20W.%20T.%20Pisters","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"links","label":"Google Scholar"},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Philip%20D.%20Greenberg","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"links","label":"Google Scholar"},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Primo%20N.%20Lara%20Jr.","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"links","label":"Google Scholar"},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Priyanka%20Sharma","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"links","label":"Google Scholar"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Rachel%20E.%20Rau","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"links","label":"Google Scholar"},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"Google Scholar"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Robert%20W.%20Stone","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"links","label":"Google Scholar"},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Robin%20T.%20Zon","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"links","label":"Google Scholar"},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Ronald%20Levy","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"links","label":"Google Scholar"},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"links","label":"Google Scholar"},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Sara%20A.%20Hurvitz","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"links","label":"Google Scholar"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Shaji%20K.%20Kumar","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"links","label":"Google Scholar"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Stanley%20R.%20Riddell","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"links","label":"Google Scholar"},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Stephen%20J.%20Forman","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"links","label":"Google Scholar"},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Steven%20E.%20Artandi","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"links","label":"Google Scholar"},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Steven%20T.%20Rosen","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"links","label":"Google Scholar"},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Susan%20L.%20Cohn","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"links","label":"Google Scholar"},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Tanios%20Bekaii-Saab","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"links","label":"Google Scholar"},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"Google Scholar"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Thomas%20J.%20Lynch%20Jr.","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"links","label":"Google Scholar"},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Virginia%20Sun","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"links","label":"Google Scholar"},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"profiles","label":"Google Scholar"}]},{"url":"https://sharsheret.org/","status":403,"ok":false,"finalUrl":"https://www.sharsheret.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sharsheret","kind":"collection","name":"Sharsheret","route":"/collections/sharsheret/","field":"links","label":"Sharsheret"},{"id":"sharsheret","kind":"collection","name":"Sharsheret","route":"/collections/sharsheret/","field":"url"}]},{"url":"https://spj.science.org/journal/cancomm","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","field":"links","label":"Homepage"},{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","field":"url"}]},{"url":"https://sunpharma.com","status":403,"ok":false,"finalUrl":"https://sunpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/","field":"links","label":"Official website"},{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/","field":"website"}]},{"url":"https://synaffix.com","status":403,"ok":false,"finalUrl":"https://www.lonza.com/advanced-synthesis/adc-technologies-platform","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/","field":"website"}]},{"url":"https://www.57357.org","status":403,"ok":false,"finalUrl":"https://www.57357.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/","field":"links","label":"CCHE 57357"},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/","field":"website"}]},{"url":"https://www.57357.org/en/board-of-directors-afnci","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","field":"profiles","label":"57357 board of directors page"}]},{"url":"https://www.abbvie.com","status":403,"ok":false,"finalUrl":"https://www.abbvie.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","field":"links","label":"Official website"},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","field":"website"}]},{"url":"https://www.abbvie.com/partnerships/abbvie-ventures.html","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abbvie-ventures","kind":"company","name":"AbbVie Ventures","route":"/companies/abbvie-ventures/","field":"links","label":"Official website"},{"id":"abbvie-ventures","kind":"company","name":"AbbVie Ventures","route":"/companies/abbvie-ventures/","field":"website"}]},{"url":"https://www.accamargo.org.br","status":403,"ok":false,"finalUrl":"https://www.accamargo.org.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","route":"/institutions/ac-camargo/","field":"links","label":"A.C. Camargo Cancer Center"},{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","route":"/institutions/ac-camargo/","field":"website"}]},{"url":"https://www.acpjournals.org/journal/aim","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","field":"url"}]},{"url":"https://www.acpjournals.org/topic/category/oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","field":"links","label":"Oncology topic"}]},{"url":"https://www.acpmp.org/","status":403,"ok":false,"finalUrl":"https://acpmp.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","field":"links","label":"Appendix Cancer / PMP Research Foundation"}]},{"url":"https://www.agilent.com/en/product/liquid-biopsy/resolution-ctdx-first","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"resolution-ctdx-first","kind":"drug","name":"Resolution ctDx FIRST","route":"/drugs/resolution-ctdx-first/","field":"links","label":"Agilent: Resolution ctDx FIRST"}]},{"url":"https://www.alexslemonade.org","status":403,"ok":false,"finalUrl":"https://www.alexslemonade.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","field":"website"}]},{"url":"https://www.alexslemonade.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","field":"links","label":"Alex's Lemonade Stand Foundation"},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","field":"profiles","label":"Alex's Lemonade Stand Foundation"},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","field":"links","label":"ALSF"},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","field":"url"},{"id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","field":"links","label":"Alex's Lemonade Stand Foundation"}]},{"url":"https://www.annalsofoncology.org","status":403,"ok":false,"finalUrl":"https://www.annalsofoncology.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","field":"url"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(21)02012-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","field":"outcomes.source (Progression-free survival, PD-L1+ (investigator))"},{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","field":"outcomes.source (Overall survival, PD-L1+)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(21)02073-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","field":"links","label":"Annals of Oncology 2021"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(21)04434-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/","field":"links","label":"TULIP (Ann Oncol 2021 abstract)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(22)04165-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"outcomes.source (Overall survival at 4 years)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(23)00658-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","field":"outcomes.source (Overall survival at 5 years (HRD-positive))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)00721-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","field":"links","label":"OS, Annals of Oncology 2024"},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","field":"outcomes.source (Overall survival (overall population))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)01516-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","field":"links","label":"CheckMate 214 8-year follow-up"},{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","field":"outcomes.source (Overall survival, intermediate/poor risk (8-year follow-up))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)03843-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","field":"outcomes.source (3-year disease-free survival)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)03910-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","field":"links","label":"10-year follow-up, Annals of Oncology 2024"},{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"links","label":"KEYNOTE-006 ten-year follow-up (Annals of Oncology 2024)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)04258-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","field":"outcomes.source (Overall survival, all randomised)"},{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","field":"outcomes.source (Overall survival, CPS ≥10)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)04949-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","field":"links","label":"5-year follow-up, Annals of Oncology 2024"},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","field":"outcomes.source (Overall survival (5-year follow-up))"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","field":"links","label":"Five-year follow-up (Ann Oncol 2024)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(25)03159-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"links","label":"5-year follow-up, Annals of Oncology 2025"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(25)04862-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","field":"links","label":"ESMO 2025 LBA10"},{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","field":"outcomes.source (Overall survival (interim))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(25)04871-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"Annals of Oncology LBA6 (ESMO 2025)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(25)06289-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","field":"outcomes.source (Progression-free survival (imlunestrant + abemaciclib vs imlunestrant))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(26)00059-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"links","label":"5-year follow-up, Annals of Oncology 2026"},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"outcomes.source (Overall survival, PD-L1 CPS ≥5)"},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"outcomes.source (Overall survival at 5 years, CPS ≥5)"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(26)00067-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(26)00130-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.apollohospitals.com","status":403,"ok":false,"finalUrl":"https://www.apollohospitals.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"links","label":"Apollo Hospitals"},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"profiles","label":"Apollo Hospitals"},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","field":"links","label":"Apollo Hospitals"},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","field":"website"}]},{"url":"https://www.ashp.org/drug-shortages/current-shortages","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","field":"links","label":"ASHP current drug shortages"},{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","field":"links","label":"ASHP current drug shortages"}]},{"url":"https://www.astrazeneca.com","status":403,"ok":false,"finalUrl":"https://www.astrazeneca.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"links","label":"Official website"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"website"},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","field":"links","label":"Official website"},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","field":"website"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","field":"links","label":"AstraZeneca and Hutchmed"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/","field":"links","label":"Licence announcement"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-demonstrated-an-unprecedented-median-overall-survival-improvement-of-five-months-vs-chemotherapy-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-for-whom-immunotherapy-was-not-an-option-in-tropion-breast02.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-reduced-the-risk-of-disease-recurrence-or-death-by-53-vs-t-dm1-in-patients-with-high-risk-her2-positive-early-breast-cancer.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","field":"outcomes.source (3-year invasive disease-free survival)"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-plus-imjudo-combined-with-lenvatinib-and-tace-reduced-the-risk-of-disease-progression-or-death-in-emerald-3-phase-iii-trial.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.astro.org","status":403,"ok":false,"finalUrl":"https://www.astro.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","field":"links","label":"ASTRO"},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","field":"links","label":"ASTRO"},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","field":"website"}]},{"url":"https://www.astro.org/meetings-and-education/annual-meeting","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","route":"/collections/src-astro/","field":"links","label":"ASTRO Annual Meeting"},{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","route":"/collections/src-astro/","field":"url"}]},{"url":"https://www.astro.org/patient-care-and-research/clinical-practice-statements","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","field":"links","label":"Guidelines"}]},{"url":"https://www.bayer.com","status":403,"ok":false,"finalUrl":"https://www.bayer.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"links","label":"Official website"},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"website"}]},{"url":"https://www.bayer.com/en/us/news-stories/hyrnuo","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","field":"links","label":"Bayer approval release"},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","field":"links","label":"FDA approval (Bayer)"}]},{"url":"https://www.bd.com","status":403,"ok":false,"finalUrl":"https://www.bd.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","route":"/companies/becton-dickinson/","field":"links","label":"Official website"},{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","route":"/companies/becton-dickinson/","field":"website"}]},{"url":"https://www.bdbiosciences.com","status":403,"ok":false,"finalUrl":"https://www.bdbiosciences.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/","field":"links","label":"BD Biosciences: flow cytometers"}]},{"url":"https://www.beckman.com","status":403,"ok":false,"finalUrl":"https://www.beckman.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beckman-coulter","kind":"company","name":"Beckman Coulter","route":"/companies/beckman-coulter/","field":"links","label":"Official website"},{"id":"beckman-coulter","kind":"company","name":"Beckman Coulter","route":"/companies/beckman-coulter/","field":"website"}]},{"url":"https://www.benthamscience.com/journal/38","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/","field":"links","label":"Homepage"},{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/","field":"url"}]},{"url":"https://www.biopharmadive.com/news/jnj-firefly-acquisition-deal-cancer-degrader-antibody-conjugate/822223/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","field":"links","label":"BioPharma Dive: J&J to acquire Firefly for $1B"}]},{"url":"https://www.blueprintmedicines.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","field":"links","label":"Official website"},{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","field":"website"}]},{"url":"https://www.bmj.com","status":403,"ok":false,"finalUrl":"https://www.bmj.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","field":"url"}]},{"url":"https://www.bmj.com/specialties/oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","field":"links","label":"BMJ cancer collection"}]},{"url":"https://www.cancer.gov.co","status":403,"ok":false,"finalUrl":"https://www.cancer.gov.co/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"links","label":"Instituto Nacional de Cancerología (Colombia) website"},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"profiles","label":"Instituto Nacional de Cancerología (Colombia) website"},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","field":"links","label":"Instituto Nacional de Cancerología Colombia"},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","field":"website"}]},{"url":"https://www.cancercareontario.ca","status":403,"ok":false,"finalUrl":"https://www.cancercareontario.ca/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ontario-health-cancer-care-ontario","kind":"institution","name":"Ontario Health (Cancer Care Ontario)","route":"/institutions/ontario-health-cancer-care-ontario/","field":"links","label":"Official website"},{"id":"ontario-health-cancer-care-ontario","kind":"institution","name":"Ontario Health (Cancer Care Ontario)","route":"/institutions/ontario-health-cancer-care-ontario/","field":"website"}]},{"url":"https://www.cdc.gov/vaccines-for-children/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","route":"/collections/us-vaccines-for-children/","field":"links","label":"Vaccines for Children program (US)"},{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","route":"/collections/us-vaccines-for-children/","field":"url"}]},{"url":"https://www.cell.com","status":403,"ok":false,"finalUrl":"https://www.cell.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","field":"links","label":"Cell Press"},{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","field":"links","label":"Cell Press"},{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","field":"links","label":"Cell Press"}]},{"url":"https://www.cell.com/cancer-cell/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","field":"url"}]},{"url":"https://www.cell.com/cell-stem-cell/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","field":"url"}]},{"url":"https://www.cell.com/cell/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","field":"url"}]},{"url":"https://www.cell.com/trends/cancer/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","route":"/journals/trends-in-cancer/","field":"links","label":"Homepage"},{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","route":"/journals/trends-in-cancer/","field":"url"}]},{"url":"https://www.cff.org/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/","field":"links","label":"Cystic Fibrosis Foundation"}]},{"url":"https://www.cityofhope.org","status":403,"ok":false,"finalUrl":"https://www.cityofhope.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/","field":"links","label":"Official website"},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/","field":"website"},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","field":"links","label":"City of Hope"}]},{"url":"https://www.cityofhope.org/orange-county","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","field":"links","label":"City of Hope Orange County"},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","field":"website"}]},{"url":"https://www.cityofhope.org/research/find-a-researcher","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"links","label":"City of Hope research faculty"},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"profiles","label":"City of Hope research faculty"},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"links","label":"City of Hope research faculty"},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"profiles","label":"City of Hope research faculty"},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"links","label":"City of Hope research faculty"},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"profiles","label":"City of Hope research faculty"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"links","label":"City of Hope research faculty"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"profiles","label":"City of Hope research faculty"},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"links","label":"City of Hope research faculty"},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"profiles","label":"City of Hope research faculty"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"links","label":"City of Hope research faculty"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"profiles","label":"City of Hope research faculty"},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"links","label":"City of Hope research faculty"},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"profiles","label":"City of Hope research faculty"},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"links","label":"City of Hope research faculty"},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"profiles","label":"City of Hope research faculty"},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"links","label":"City of Hope research faculty"},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"profiles","label":"City of Hope research faculty"}]},{"url":"https://www.clinical-breast-cancer.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","route":"/journals/clinical-breast-cancer/","field":"links","label":"Homepage"},{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","route":"/journals/clinical-breast-cancer/","field":"url"}]},{"url":"https://www.clinical-colorectal-cancer.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/","field":"links","label":"Homepage"},{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/","field":"url"}]},{"url":"https://www.clinical-genitourinary-cancer.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","route":"/journals/clinical-genitourinary-cancer/","field":"links","label":"Homepage"},{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","route":"/journals/clinical-genitourinary-cancer/","field":"url"}]},{"url":"https://www.clinical-lung-cancer.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/","field":"links","label":"Homepage"},{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/","field":"url"}]},{"url":"https://www.clinical-lymphoma-myeloma-leukemia.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/","field":"links","label":"Homepage"},{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/","field":"url"}]},{"url":"https://www.clinicaloncologyonline.net/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","route":"/journals/clinical-oncology-rcr/","field":"links","label":"Homepage"},{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","route":"/journals/clinical-oncology-rcr/","field":"url"}]},{"url":"https://www.congress.gov/bill/104th-congress/house-bill/3103","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","field":"links","label":"Congress.gov: H.R.3103, HIPAA (Public Law 104-191)"}]},{"url":"https://www.congress.gov/bill/110th-congress/house-bill/493","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","field":"links","label":"Congress.gov: H.R.493, GINA (Public Law 110-233)"}]},{"url":"https://www.congress.gov/bill/111th-congress/house-bill/1256","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","field":"links","label":"Congress.gov: H.R.1256, Tobacco Control Act (Public Law 111-31)"}]},{"url":"https://www.congress.gov/bill/112th-congress/senate-bill/3187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","field":"links","label":"Congress.gov: S.3187, FDASIA (Public Law 112-144)"}]},{"url":"https://www.congress.gov/bill/114th-congress/house-bill/34","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","field":"links","label":"Congress.gov: H.R.34, 21st Century Cures Act (Public Law 114-255)"}]},{"url":"https://www.congress.gov/bill/115th-congress/house-bill/2430","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"race-for-children-act","kind":"term","name":"RACE for Children Act","route":"/terms/race-for-children-act/","field":"links","label":"FDARA 2017 (Public Law 115-52)"}]},{"url":"https://www.congress.gov/bill/115th-congress/senate-bill/204","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","field":"links","label":"Congress.gov: S.204, Right to Try Act (Public Law 115-176)"}]},{"url":"https://www.congress.gov/bill/116th-congress/house-bill/1865","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","field":"links","label":"Congress.gov: H.R.1865, Further Consolidated Appropriations Act, 2020 (Public Law 116-94)"}]},{"url":"https://www.congress.gov/bill/117th-congress/house-bill/2617","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdora-2022","kind":"term","name":"FDORA 2022 accelerated approval reforms","route":"/terms/fdora-2022/","field":"links","label":"Congress.gov: H.R.2617, Consolidated Appropriations Act, 2023 (Public Law 117-328)"}]},{"url":"https://www.congress.gov/bill/117th-congress/house-bill/5376","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","field":"links","label":"Congress.gov: H.R.5376, Inflation Reduction Act of 2022 (Public Law 117-169)"}]},{"url":"https://www.congress.gov/bill/118th-congress/house-bill/1730","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-federal-oral-parity","kind":"idea","name":"Federal oral chemotherapy parity for self-funded employer plans","route":"/ideas/idea-cost-federal-oral-parity/","field":"links","label":"Congress.gov: Cancer Drug Parity Act, H.R. 1730 (118th Congress)"}]},{"url":"https://www.congress.gov/bill/118th-congress/house-bill/8333","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","field":"links","label":"BIOSECURE Act (US Congress)"}]},{"url":"https://www.criver.com","status":403,"ok":false,"finalUrl":"https://www.criver.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","field":"links","label":"Official website"},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","field":"website"}]},{"url":"https://www.donga-st.com","status":403,"ok":false,"finalUrl":"https://www.donga-st.com/","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","field":"links","label":"Official website"},{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","field":"website"}]},{"url":"https://www.drugs.com/history/tevimbra.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","field":"dosing.source"}]},{"url":"https://www.einstein.br","status":403,"ok":false,"finalUrl":"https://www.einstein.br/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","field":"links","label":"Official website"},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","field":"website"},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","field":"links","label":"Hospital Israelita Albert Einstein"},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","field":"profiles","label":"Hospital Israelita Albert Einstein"}]},{"url":"https://www.eisai.com","status":403,"ok":false,"finalUrl":"https://www.eisai.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","field":"links","label":"Official website"},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","field":"website"}]},{"url":"https://www.ejcancer.com","status":403,"ok":false,"finalUrl":"https://www.ejcancer.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","field":"url"}]},{"url":"https://www.ejcancer.com/article/S0959-8049(25)00329-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","field":"links","label":"4-year update, EJC 2025"}]},{"url":"https://www.ejoncologynursing.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","route":"/journals/european-journal-of-oncology-nursing/","field":"links","label":"Homepage"},{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","route":"/journals/european-journal-of-oncology-nursing/","field":"url"}]},{"url":"https://www.ejso.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","route":"/journals/european-journal-of-surgical-oncology/","field":"links","label":"Homepage"},{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","route":"/journals/european-journal-of-surgical-oncology/","field":"url"}]},{"url":"https://www.esmoopen.com","status":403,"ok":false,"finalUrl":"https://www.esmoopen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","field":"url"}]},{"url":"https://www.esmoopen.com/article/S2059-7029(25)01723-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","field":"outcomes.source (Overall survival at 5-year follow-up)"}]},{"url":"https://www.eurekaselect.com/journal/7","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/","field":"links","label":"Homepage"},{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/","field":"url"}]},{"url":"https://www.eurofarma.com.br","status":403,"ok":false,"finalUrl":"https://eurofarma.com.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","field":"links","label":"Official website"},{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","field":"website"}]},{"url":"https://www.europeanurology.com","status":403,"ok":false,"finalUrl":"https://www.europeanurology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","field":"url"},{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","field":"links","label":"European Urology family"}]},{"url":"https://www.fjd.es","status":403,"ok":false,"finalUrl":"https://www.fjd.es/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fundacion-jimenez-diaz","kind":"institution","name":"Hospital Universitario Fundación Jiménez Díaz","route":"/institutions/fundacion-jimenez-diaz/","field":"links","label":"Official website"},{"id":"fundacion-jimenez-diaz","kind":"institution","name":"Hospital Universitario Fundación Jiménez Díaz","route":"/institutions/fundacion-jimenez-diaz/","field":"website"}]},{"url":"https://www.fjd.es/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"links","label":"Hospital Universitario Fundación Jiménez Díaz website"},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"profiles","label":"Hospital Universitario Fundación Jiménez Díaz website"}]},{"url":"https://www.fnmotol.cz","status":403,"ok":false,"finalUrl":"https://www.fnmotol.cz/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","field":"links","label":"Motol University Hospital website"},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","field":"profiles","label":"Motol University Hospital website"},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","field":"links","label":"Official website"},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","field":"website"}]},{"url":"https://www.foghorntx.com/","status":403,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","field":"links","label":"Official website"},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","field":"website"}]},{"url":"https://www.foghorntx.com/pipeline/","status":403,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://www.gao.gov/products/gao-15-442","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-cost-340b-pass-through","kind":"idea","name":"Pass 340B discounts on cancer drugs through to the patient's bill","route":"/ideas/idea-cost-340b-pass-through/","field":"links","label":"GAO-15-442: Medicare Part B drugs and 340B hospitals (2015)"}]},{"url":"https://www.gastrojournal.org","status":403,"ok":false,"finalUrl":"https://www.gastrojournal.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastroenterology","kind":"journal","name":"Gastroenterology","route":"/journals/gastroenterology/","field":"links","label":"Gastroenterology (AGA), Elsevier"},{"id":"gastroenterology","kind":"journal","name":"Gastroenterology","route":"/journals/gastroenterology/","field":"url"}]},{"url":"https://www.gehealthcare.com","status":403,"ok":false,"finalUrl":"https://www.gehealthcare.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"links","label":"Official website"},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"website"}]},{"url":"https://www.gehealthcare.com/products/molecular-imaging/spect-ct","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"links","label":"GE HealthCare: SPECT/CT systems"}]},{"url":"https://www.geriatriconcology.net/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","route":"/journals/journal-of-geriatric-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","route":"/journals/journal-of-geriatric-oncology/","field":"url"}]},{"url":"https://www.goc.com.cy","status":403,"ok":false,"finalUrl":"https://www.goc.com.cy/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","route":"/institutions/german-oncology-center-limassol/","field":"links","label":"Official website"},{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","route":"/institutions/german-oncology-center-limassol/","field":"website"}]},{"url":"https://www.goc.com.cy/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"links","label":"German Oncology Center website"},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"profiles","label":"German Oncology Center website"}]},{"url":"https://www.gov.il/en/departments/units/icdc-cancer-registry","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","route":"/institutions/israel-national-cancer-registry/","field":"links","label":"Israel Center for Disease Control, cancer registry (Ministry of Health)"},{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","route":"/institutions/israel-national-cancer-registry/","field":"website"}]},{"url":"https://www.gynecologiconcology-online.net","status":403,"ok":false,"finalUrl":"https://www.gynecologiconcology-online.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","field":"url"}]},{"url":"https://www.hadassah.org.il/en/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","field":"links","label":"Institution profile"},{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","field":"profiles","label":"Institution profile"},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/","field":"links","label":"Hadassah Medical Center"},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/","field":"profiles","label":"Hadassah Medical Center"},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","field":"links","label":"Homepage"},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","field":"website"}]},{"url":"https://www.hadassah.org.il/en/departments/sharett-institute-of-oncology/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","field":"links","label":"Sharett Institute of Oncology"}]},{"url":"https://www.hellojasper.com","status":403,"ok":false,"finalUrl":"https://www.hellojasper.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jasper-health","kind":"company","name":"Jasper Health","route":"/companies/jasper-health/","field":"links","label":"Official website"},{"id":"jasper-health","kind":"company","name":"Jasper Health","route":"/companies/jasper-health/","field":"website"}]},{"url":"https://www.hemonc.theclinics.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/","field":"links","label":"Homepage"},{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/","field":"url"}]},{"url":"https://www.hhmi.org/scientists","status":403,"ok":false,"finalUrl":"https://www.hhmi.org/search/people","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","field":"links","label":"Investigators"}]},{"url":"https://www.hhs.gov/hipaa/for-professionals/privacy/index.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","field":"links","label":"HHS: the HIPAA Privacy Rule"}]},{"url":"https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","field":"links","label":"US Office for Human Research Protections: 45 CFR 46 (the Common Rule)"},{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","field":"links","label":"HHS Office for Human Research Protections: 45 CFR 46"}]},{"url":"https://www.hhs.gov/surgeongeneral/reports-and-publications/alcohol-cancer/index.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","field":"links","label":"US Surgeon General advisory on alcohol and cancer (2025)"}]},{"url":"https://www.hopkinsmedicine.org/henrietta-lacks","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"links","label":"Johns Hopkins Medicine: Henrietta Lacks"},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"profiles","label":"Johns Hopkins Medicine: Henrietta Lacks"}]},{"url":"https://www.hopkinsmedicine.org/kimmel-cancer-center","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"links","label":"Official website"},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"website"},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"links","label":"Kimmel Cancer Center"},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"profiles","label":"Kimmel Cancer Center"}]},{"url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/bloomberg-kimmel-institute-cancer-immunotherapy","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"links","label":"Bloomberg~Kimmel Institute"},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"profiles","label":"Bloomberg~Kimmel Institute"}]},{"url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"links","label":"Ludwig Center"},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"profiles","label":"Ludwig Center"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"links","label":"Ludwig Center"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"profiles","label":"Ludwig Center"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/dung-le","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"links","label":"Hopkins profile"},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/elizabeth-jaffee","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"links","label":"Hopkins profile"},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/julie-brahmer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"links","label":"Hopkins profile"},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/kellie-smith","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","field":"links","label":"Hopkins profile"},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/patrick-forde","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"links","label":"Hopkins profile"},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/stephen-baylin","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"links","label":"Hopkins profile"},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hopkinsmedicine.org/profiles/details/suzanne-topalian","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"links","label":"Hopkins profile"},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"profiles","label":"Hopkins profile"}]},{"url":"https://www.hotspotthera.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","route":"/companies/hotspot-therapeutics/","field":"links","label":"Official website"},{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","route":"/companies/hotspot-therapeutics/","field":"website"}]},{"url":"https://www.hrsa.gov/opa","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-cost-340b-pass-through","kind":"idea","name":"Pass 340B discounts on cancer drugs through to the patient's bill","route":"/ideas/idea-cost-340b-pass-through/","field":"links","label":"HRSA: 340B Drug Pricing Program"},{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","field":"links","label":"HRSA 340B"}]},{"url":"https://www.hsr.it","status":403,"ok":false,"finalUrl":"https://www.hsr.it/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","field":"links","label":"IRCCS Ospedale San Raffaele website"},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","field":"profiles","label":"IRCCS Ospedale San Raffaele website"},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","field":"links","label":"Homepage"},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","field":"website"}]},{"url":"https://www.iaea.org/newscenter/news/actinium-225-production-and-supply","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","field":"links","label":"IAEA on actinium-225 supply"}]},{"url":"https://www.iaea.org/publications/7451/quality-assurance-for-radioactivity-measurement-in-nuclear-medicine","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"IAEA: quality assurance for radioactivity measurement in nuclear medicine (Technical Reports Series 454)"}]},{"url":"https://www.iaea.org/publications/7892/cyclotron-produced-radionuclides-principles-and-practice","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"IAEA: cyclotron produced radionuclides"}]},{"url":"https://www.iaea.org/services/rays-of-hope","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","field":"links","label":"Institution profile"},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","field":"profiles","label":"Institution profile"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-acc-open-hardware-linac","kind":"idea","name":"An open-hardware radiotherapy machine built for unreliable power and dust","route":"/ideas/idea-acc-open-hardware-linac/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-acc-linac-uptime-contracts","kind":"idea","name":"Pay for radiotherapy machine uptime, not for the machine","route":"/ideas/idea-acc-linac-uptime-contracts/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-acc-pooled-procurement-radiotherapy","kind":"idea","name":"A Gavi-style pooled purchaser for radiotherapy equipment and service","route":"/ideas/idea-acc-pooled-procurement-radiotherapy/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/","field":"links","label":"IAEA Rays of Hope"},{"id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","field":"links","label":"IAEA Rays of Hope"},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"links","label":"Rays of Hope"},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"website"}]},{"url":"https://www.iaea.org/topics/cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"links","label":"IAEA cancer"}]},{"url":"https://www.icr.ac.uk","status":403,"ok":false,"finalUrl":"https://www.icr.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","field":"links","label":"Official website"},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","field":"website"}]},{"url":"https://www.icr.ac.uk/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","field":"links","label":"ICR"},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","field":"profiles","label":"ICR"}]},{"url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","field":"links","label":"ICR profile"},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","field":"profiles","label":"ICR profile"}]},{"url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-johann-de-bono","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"links","label":"ICR profile"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"profiles","label":"ICR profile"}]},{"url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-nicholas-turner","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","field":"links","label":"ICR profile"},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","field":"profiles","label":"ICR profile"}]},{"url":"https://www.iczmp.edu.pl","status":403,"ok":false,"finalUrl":"https://www.iczmp.edu.pl/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","route":"/institutions/polish-mothers-memorial-hospital/","field":"links","label":"Official website"},{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","route":"/institutions/polish-mothers-memorial-hospital/","field":"website"}]},{"url":"https://www.iczmp.edu.pl/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"links","label":"Polish Mother's Memorial Hospital Research Institute website"},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"profiles","label":"Polish Mother's Memorial Hospital Research Institute website"}]},{"url":"https://www.illumina.com/products/by-type/clinical-research-products/","status":403,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"trusight-oncology-comprehensive","kind":"drug","name":"TruSight Oncology Comprehensive","route":"/drugs/trusight-oncology-comprehensive/","field":"links","label":"Illumina: TruSight Oncology Comprehensive (page moved; nearest live section)"}]},{"url":"https://www.imperial.nhs.uk","status":403,"ok":false,"finalUrl":"https://www.imperial.nhs.uk/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imperial-cancer-centre","kind":"institution","name":"Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","route":"/institutions/imperial-cancer-centre/","field":"links","label":"Official website"},{"id":"imperial-cancer-centre","kind":"institution","name":"Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","route":"/institutions/imperial-cancer-centre/","field":"website"}]},{"url":"https://www.imperial.nhs.uk/about-us/how-we-are-run/our-executive-team","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"julian-redhead","kind":"person","name":"Julian Redhead","route":"/people/julian-redhead/","field":"links","label":"Source: Imperial College Healthcare NHS Trust executive team page"},{"id":"julian-redhead","kind":"person","name":"Julian Redhead","route":"/people/julian-redhead/","field":"profiles","label":"Imperial College Healthcare executive team page"}]},{"url":"https://www.imperial.nhs.uk/consultants/shahid-khan","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","route":"/people/shahid-khan/","field":"links","label":"Imperial College Healthcare consultant page"},{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","route":"/people/shahid-khan/","field":"profiles","label":"Imperial College Healthcare consultant page"}]},{"url":"https://www.ipocoimbra.min-saude.pt","status":403,"ok":false,"finalUrl":"https://www.ipocoimbra.min-saude.pt/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"links","label":"IPO Coimbra website"},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"profiles","label":"IPO Coimbra website"},{"id":"ipo-coimbra","kind":"institution","name":"Instituto Português de Oncologia de Coimbra Francisco Gentil","route":"/institutions/ipo-coimbra/","field":"links","label":"Official website"},{"id":"ipo-coimbra","kind":"institution","name":"Instituto Português de Oncologia de Coimbra Francisco Gentil","route":"/institutions/ipo-coimbra/","field":"website"}]},{"url":"https://www.journal-of-hepatology.eu/article/S0168-8278(25)02201-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"3-year update"}]},{"url":"https://www.journal-of-hepatology.eu/article/S0168-8278(26)00017-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","field":"links","label":"Updated data (J Hepatol 2026)"}]},{"url":"https://www.jto.org","status":403,"ok":false,"finalUrl":"https://www.jto.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","field":"url"}]},{"url":"https://www.jto.org/article/S1556-0864(21)02264-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","field":"links","label":"TAHOE phase 3 (J Thorac Oncol 2021)"}]},{"url":"https://www.komen.org/","status":403,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","field":"links","label":"Susan G. Komen"},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","field":"profiles","label":"Susan G. Komen"},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","field":"links","label":"Susan G. Komen"},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","field":"url"}]},{"url":"https://www.lilly.com","status":403,"ok":false,"finalUrl":"https://www.lilly.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","field":"links","label":"Official website"},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","field":"website"}]},{"url":"https://www.lilly.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","route":"/companies/emergence-therapeutics/","field":"links","label":"Official website"},{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","route":"/companies/emergence-therapeutics/","field":"website"},{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","route":"/companies/mablink-bioscience/","field":"links","label":"Official website"},{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","route":"/companies/mablink-bioscience/","field":"website"},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Official website"},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"website"}]},{"url":"https://www.lilly.com/science/partners","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","route":"/companies/lilly-ventures/","field":"links","label":"Lilly partnering"}]},{"url":"https://www.lilly.com/science/partners/catalyze-360","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","route":"/companies/lilly-ventures/","field":"links","label":"Official website"},{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","route":"/companies/lilly-ventures/","field":"website"}]},{"url":"https://www.lls.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","field":"links","label":"LLS"},{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","field":"url"}]},{"url":"https://www.lls.org/therapy-acceleration-program","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/","field":"links","label":"LLS Therapy Acceleration Program"},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/","field":"links","label":"Official website"},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/","field":"website"}]},{"url":"https://www.longwoodfund.com","status":403,"ok":false,"finalUrl":"https://www.longwoodfund.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","field":"links","label":"Official website"},{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","field":"website"}]},{"url":"https://www.lonza.com","status":403,"ok":false,"finalUrl":"https://www.lonza.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","field":"links","label":"Official website"},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","field":"website"}]},{"url":"https://www.lonza.com/advanced-synthesis/adc-technologies-platform","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/","field":"links","label":"Lonza ADC technology platform"}]},{"url":"https://www.mater.ie","status":403,"ok":false,"finalUrl":"https://www.mater.ie/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","field":"links","label":"Mater Misericordiae University Hospital website"},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","field":"profiles","label":"Mater Misericordiae University Hospital website"},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","field":"links","label":"Official website"},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","field":"website"}]},{"url":"https://www.maxhealthcare.in","status":403,"ok":false,"finalUrl":"https://www.maxhealthcare.in/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"max-healthcare","kind":"institution","name":"Max Healthcare (Max Institute of Cancer Care)","route":"/institutions/max-healthcare/","field":"links","label":"Max Healthcare"},{"id":"max-healthcare","kind":"institution","name":"Max Healthcare (Max Institute of Cancer Care)","route":"/institutions/max-healthcare/","field":"website"}]},{"url":"https://www.mayo.edu/research/centers-programs/cancer-research/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/","field":"links","label":"Mayo Clinic Comprehensive Cancer Center"},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","field":"links","label":"Mayo Clinic Comprehensive Cancer Center"}]},{"url":"https://www.mayo.edu/research/faculty","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"links","label":"Mayo Clinic research faculty"},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"links","label":"Mayo Clinic research faculty"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"links","label":"Mayo Clinic research faculty"},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"links","label":"Mayo Clinic research faculty"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"links","label":"Mayo Clinic research faculty"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"links","label":"Mayo Clinic research faculty"},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"links","label":"Mayo Clinic research faculty"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"profiles","label":"Mayo Clinic research faculty"},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"links","label":"Mayo Clinic research faculty"},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"profiles","label":"Mayo Clinic research faculty"}]},{"url":"https://www.mayoclinic.org","status":403,"ok":false,"finalUrl":"https://www.mayoclinic.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"links","label":"Official website"},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"website"}]},{"url":"https://www.mayoclinic.org/patient-visitor-guide/arizona","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","field":"links","label":"Mayo Clinic Arizona"},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","field":"website"}]},{"url":"https://www.mayoclinic.org/patient-visitor-guide/florida","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/","field":"links","label":"Mayo Clinic Florida"},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/","field":"website"}]},{"url":"https://www.mdpi.com","status":403,"ok":false,"finalUrl":"https://www.mdpi.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","field":"links","label":"MDPI"}]},{"url":"https://www.mdpi.com/journal/cancers","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","field":"url"}]},{"url":"https://www.mdpi.com/journal/curroncol","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","field":"links","label":"Homepage"},{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","field":"url"}]},{"url":"https://www.mdproton.com","status":403,"ok":false,"finalUrl":"https://mdproton.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","field":"links","label":"Maryland Proton Treatment Center"}]},{"url":"https://www.medtronic.com","status":403,"ok":false,"finalUrl":"https://www.medtronic.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medtronic","kind":"company","name":"Medtronic","route":"/companies/medtronic/","field":"links","label":"Official website"},{"id":"medtronic","kind":"company","name":"Medtronic","route":"/companies/medtronic/","field":"website"}]},{"url":"https://www.medtronic.com/covidien/en-us/products/capsule-endoscopy.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capsule-endoscopy-systems","kind":"technology","name":"Capsule endoscopy (PillCam, EndoCapsule, CapsoCam)","route":"/technologies/capsule-endoscopy-systems/","field":"links","label":"Medtronic: PillCam capsule endoscopy"}]},{"url":"https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/laser-ablation/visualase.html","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/","field":"links","label":"Medtronic: Visualase MRI-guided laser ablation"}]},{"url":"https://www.mesoblast.com","status":403,"ok":false,"finalUrl":"https://www.mesoblast.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesoblast","kind":"company","name":"Mesoblast","route":"/companies/mesoblast/","field":"website"}]},{"url":"https://www.moffitt.org","status":403,"ok":false,"finalUrl":"https://www.moffitt.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","field":"links","label":"Official website"},{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","field":"website"}]},{"url":"https://www.moffitt.org/about-moffitt/leadership/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","field":"links","label":"Moffitt leadership"},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","field":"profiles","label":"Moffitt leadership"}]},{"url":"https://www.moffitt.org/providers/amod-sarnaik/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"links","label":"Moffitt profile"},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/providers/christine-chung/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","field":"links","label":"Moffitt profile"},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/providers/eric-haura/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","field":"links","label":"Moffitt profile"},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/providers/frederick-locke/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"links","label":"Moffitt profile"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/providers/hatem-soliman/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","field":"links","label":"Moffitt profile"},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/research-science/researchers/robert-gatenby/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","field":"links","label":"Moffitt profile"},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.moffitt.org/research-science/researchers/shari-pilon-thomas/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","field":"links","label":"Moffitt profile"},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","field":"profiles","label":"Moffitt profile"}]},{"url":"https://www.nasonline.org","status":403,"ok":false,"finalUrl":"https://www.nasonline.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","field":"links","label":"National Academy of Sciences"}]},{"url":"https://www.nec-bio.com/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/","field":"links","label":"Official website"},{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/","field":"website"}]},{"url":"https://www.nejm.org","status":403,"ok":false,"finalUrl":"https://www.nejm.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"url"}]},{"url":"https://www.nejm.org/browse/specialty/hematology-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"links","label":"Hematology/Oncology specialty page"}]},{"url":"https://www.nejm.org/doi/abs/10.1056/NEJMoa2400634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","field":"links","label":"NEJM 2024"},{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","field":"outcomes.source (Pathologic complete response)"}]},{"url":"https://www.nejm.org/doi/abs/10.1056/NEJMoa2402141","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","field":"links","label":"NEJM 2024"}]},{"url":"https://www.nejm.org/doi/abs/10.1056/NEJMoa2501796","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","field":"links","label":"NEJM OS analysis"},{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJM194806032382301","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","field":"links","label":"Farber et al., NEJM 1948"},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","field":"profiles","label":"Farber et al., NEJM 1948"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJM199603143341104","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","field":"links","label":"Milan criteria (NEJM 1996)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJM200104053441401","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/","field":"links","label":"Druker et al., imatinib in CML (NEJM 2001)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa020890","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"int-0091","kind":"trial","name":"INT-0091 (Ewing sarcoma)","route":"/trials/int-0091/","field":"outcomes.source (Event-free survival at 5 years (localised))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa043330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa043800","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","field":"links","label":"NEJM 2005"},{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","field":"outcomes.source (Arterial or venous thrombosis, serious haemorrhage, or death from thrombotic or haemorrhagic causes)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0708857","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","field":"links","label":"SHARP (NEJM 2008)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0802656","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","field":"links","label":"NEJM 2008"},{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0805019","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"links","label":"CRYSTAL, NEJM 2009"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"outcomes.source (Overall survival, KRAS wild-type (CRYSTAL))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0908721","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"links","label":"NEJM 2010"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0911123","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","field":"outcomes.source (Event-free survival at 2 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0912217","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","field":"links","label":"NEJM 2010"},{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","field":"outcomes.source (Overall survival at 3 years by HPV status)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1000678","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-automatic-early-palliative-triggers","kind":"idea","name":"Automatic palliative care referral triggered by diagnosis, not by decline","route":"/ideas/idea-acc-automatic-early-palliative-triggers/","field":"links","label":"Temel et al., NEJM 2010"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1102873","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","field":"outcomes.source (NLST: relative reduction in lung cancer mortality)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1103782","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"links","label":"BRIM-3, NEJM 2011"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"toxicity.source (Cutaneous squamous cell carcinoma / keratoacanthoma)"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"toxicity.source (Arthralgia)"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"toxicity.source (Photosensitivity)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1104390","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","field":"links","label":"GOG-0218, NEJM 2011"},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","field":"outcomes.source (Progression-free survival (GOG-0218))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1109589","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"links","label":"NEJM 2012"},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"outcomes.source (Successful ablation)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1112088","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","field":"links","label":"NEJM 2012"},{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1113216","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1113713","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"links","label":"ERIVANCE (NEJM 2012)"},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","field":"links","label":"NEJM 2012"},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","field":"outcomes.source (Objective response rate (locally advanced))"},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","field":"outcomes.source (Objective response rate (metastatic))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1208500","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","field":"links","label":"NEJM 2013"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1213755","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1308789","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the cancer registry: registry-based trials for everyday questions","route":"/ideas/idea-tr1-registry-embedded-randomisation/","field":"links","label":"TASTE registry-based randomised trial (NEJM 2013)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1400376","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1406037","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"links","label":"NEJM 2014"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1406470","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"links","label":"NEJM 2015"},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"outcomes.source (Progression-free survival)"},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1408868","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","field":"links","label":"NEJM 2014"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1409002","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","field":"links","label":"NEJM 2015"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1503747","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1504030","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","field":"outcomes.source (Progression-free survival (co-primary))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1509277","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","field":"outcomes.source (Complete remission / CRi)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1510093","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","field":"outcomes.source (Progression-free survival at 3 years (PET2-negative))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1513749","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","field":"links","label":"Rugo et al., NEJM 2016: adaptive randomization of veliparib-carboplatin treatment in breast cancer"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1513750","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","field":"links","label":"Park et al., NEJM 2016: adaptive randomization of neratinib in early breast cancer"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1602252","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","field":"links","label":"NEJM 2016"},{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1603702","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","field":"links","label":"NEJM 2016"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1607303","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1609709","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1609783","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1611977","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","field":"outcomes.source (Overall survival, age 65 or older)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1613210","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","field":"links","label":"NEJM 2017"},{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","field":"outcomes.source (Melanoma-specific survival at 3 years)"},{"id":"surgery-roadmap","kind":"roadmap","name":"Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work","route":"/roadmaps/surgery-roadmap/","field":"links","label":"MSLT-II (NEJM 2017)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1614359","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","field":"links","label":"NEJM 2017"},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1708618","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","field":"links","label":"NEJM 2018"},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1708984","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","field":"outcomes.source (Modified PFS at 2 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1709030","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"links","label":"CheckMate 238 (NEJM 2017)"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","field":"links","label":"NEJM 2017"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","field":"outcomes.source (Recurrence-free survival at 12 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1709866","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"outcomes.source (Overall remission rate within 3 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1709937","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/","field":"links","label":"PACIFIC (NEJM 2017)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1801993","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/","field":"outcomes.source (Detection of clinically significant cancer)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1802357","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"links","label":"KEYNOTE-054 (NEJM 2018)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1804710","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/","field":"outcomes.source (Invasive disease-free survival at 9 years (RS 11-25))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1805131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"links","label":"EMPOWER-CSCC-1 (NEJM 2018)"},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","field":"links","label":"NEJM 2018"},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","field":"outcomes.source (Objective response rate (metastatic group))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1805453","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","field":"links","label":"NEJM 2018"},{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","field":"outcomes.source (Intracranial clinical benefit rate (asymptomatic cohort))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1806395","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","field":"links","label":"NEJM 2018"},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","field":"outcomes.source (Disease-free survival at 4.5 years)"},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","field":"outcomes.source (Overall survival at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1809064","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1809615","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"outcomes.source (Progression-free survival, PD-L1+ (SP142 IC ≥1%))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1809775","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1810858","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"links","label":"NEJM 2018"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1813904","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","field":"outcomes.source (Progression-free survival (PIK3CA-mutant))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1814017","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","field":"outcomes.source (3-year invasive disease-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1902688","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","field":"links","label":"NEJM 2019"},{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1903387","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1904059","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"links","label":"Pooled 5-year analysis, NEJM 2019"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1910549","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"outcomes.source (Pathologic complete response (ypT0/Tis ypN0))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1910962","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","field":"links","label":"NEJM 2019"},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","field":"outcomes.source (Progression-free survival (HRD-positive))"},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","field":"outcomes.source (Progression-free survival (overall))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1911361","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","field":"links","label":"NEJM 2019"},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","field":"outcomes.source (Progression-free survival (HRD-positive))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1911440","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","field":"outcomes.source (Radiographic progression-free survival, cohort A (BRCA1/2, ATM))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1911793","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","field":"links","label":"NELSON, NEJM 2020"},{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","field":"outcomes.source (NELSON: relative reduction in lung cancer mortality at 10 years (men))"},{"id":"paper-nelson-nejm-2020","kind":"paper","name":"NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms","route":"/key-papers/paper-nelson-nejm-2020/","field":"links","label":"NEJM full text"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1914609","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1915745","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","field":"links","label":"IMbrave150 (NEJM 2020)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2004413","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","field":"links","label":"DESTINY-Gastric01 (NEJM 2020)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2012971","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","field":"links","label":"NEJM 2020"},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2016272","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","field":"links","label":"NEJM 2020"},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","field":"outcomes.source (Overall survival at 18 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2017699","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2022485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","field":"outcomes.source (Overall survival, cohort A)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2026982","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2027071","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"outcomes.source (Disease-free survival, stage II to IIIA)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2028485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"outcomes.source (Progression-free survival (patients without brain metastases))"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"outcomes.source (Overall survival)"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032125","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2035716","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2103294","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","field":"links","label":"NEJM 2021"},{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2103485","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","field":"links","label":"NEJM 2021"},{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2105215","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"outcomes.source (Invasive disease-free survival at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2106391","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107322","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"outcomes.source (Overall survival)"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"outcomes.source (Radiographic progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2108330","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","field":"links","label":"NEJM 2022"},{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","field":"outcomes.source (Overall survival (all comers))"},{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","field":"outcomes.source (Progression-free survival (all comers))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2108873","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","field":"outcomes.source (5-year iDFS, postmenopausal)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2111380","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","field":"outcomes.source (Overall survival, PD-L1 ≥1% (nivolumab + chemotherapy))"},{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","field":"outcomes.source (Overall survival, PD-L1 ≥1% (nivolumab + ipilimumab))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2111953","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"NEJM 2022"},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"outcomes.source (Patients without events at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2112187","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","field":"links","label":"NEJM 2022"},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2114663","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2115022","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2115304","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"links","label":"NEJM 2022"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"outcomes.source (Progression-free survival at 2 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2116133","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","field":"outcomes.source (Event-free survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2116596","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/","field":"outcomes.source (Event-free survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2117344","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","field":"links","label":"NEJM 2022"},{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2119115","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2200075","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","field":"links","label":"NEJM 2022"},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","field":"outcomes.source (Recurrence-free survival at 2 years (non-inferiority))"},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","field":"outcomes.source (Patients receiving adjuvant chemotherapy)"},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/","field":"links","label":"DYNAMIC trial (NEJM 2022)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2202170","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"outcomes.source (Pathologic complete response)"},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2202809","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"outcomes.source (Overall survival, PD-L1 CPS ≥10)"},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"outcomes.source (Progression-free survival, PD-L1 CPS ≥10)"},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"outcomes.source (Overall survival, CPS ≥1)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2203478","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2203690","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"outcomes.source (Progression-free survival, HR+ cohort (BICR))"},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"outcomes.source (Overall survival, all patients)"},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"outcomes.source (Progression-free survival, HR-negative (TNBC) cohort)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206125","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","field":"outcomes.source (Overall survival at 6 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206834","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","field":"links","label":"NEJM 2023"},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","field":"links","label":"NEJM 2023"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","field":"links","label":"FOENIX-CCA2 (NEJM 2023)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2209813","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"links","label":"Neoadjuvant cemiplimab (NEJM 2022)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2210140","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2210233","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"links","label":"Dutch TIL trial (NEJM 2022)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2210859","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2211437","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","field":"links","label":"NEJM 2023"},{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","field":"outcomes.source (Event-free survival at 2 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2211582","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2212851","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2213093","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","field":"outcomes.source (Undetectable MRD at month 15 (blood))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2213614","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2214122","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"outcomes.source (Prostate-cancer-specific mortality at 15 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2214131","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","field":"outcomes.source (Progression-free survival (overall))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2214963","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2216334","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","field":"links","label":"NEJM 2023"},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","field":"outcomes.source (Progression-free survival at 24 months (dMMR/MSI-H))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301665","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","field":"links","label":"OS analysis NEJM 2023"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","field":"outcomes.source (Overall survival at 4 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2302312","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","field":"links","label":"NEJM 2023"},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","field":"outcomes.source (Progression-free survival (dMMR))"},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","field":"outcomes.source (Progression-free survival (pMMR))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2302983","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2303379","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2303974","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","field":"outcomes.source (Metastasis-free survival, enzalutamide + leuprolide vs leuprolide)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2304194","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/","field":"outcomes.source (Progression-free survival (BIRC))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2304594","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"outcomes.source (Overall survival at 5 years, stage II to IIIA)"},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"outcomes.source (Overall survival at 5 years, stage IB to IIIA)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2305488","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","field":"outcomes.source (Invasive disease-free survival at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2306434","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","field":"outcomes.source (Progression-free survival (investigator))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2308795","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","field":"outcomes.source (Progression-free survival (BICR), sotorasib 960 mg + panitumumab)"},{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309169","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","field":"links","label":"NEJM 2023"},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","field":"outcomes.source (Progression-free survival)"},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309457","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"libretto-431","kind":"trial","name":"LIBRETTO-431","route":"/trials/libretto-431/","field":"outcomes.source (Progression-free survival (BICR), ITT-pembrolizumab population)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309719","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","field":"links","label":"NEJM 2023"},{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","field":"outcomes.source (Progression-free survival at 12 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2310532","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/","field":"outcomes.source (Disease-free survival, stage II to IIIA)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312054","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","field":"links","label":"NEJM 2024"},{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","field":"outcomes.source (Progression-free survival at 48 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312117","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","field":"outcomes.source (Overall survival)"},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312948","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","field":"links","label":"NEJM 2024"},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","field":"outcomes.source (Overall survival at 3 years (MRD-negative cohort))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2313811","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","field":"links","label":"NEJM 2024"},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","field":"outcomes.source (Overall survival)"},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2313906","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2400634","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgery-roadmap","kind":"roadmap","name":"Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work","route":"/roadmaps/surgery-roadmap/","field":"links","label":"NICHE-2 (NEJM 2024)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2400712","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/","field":"outcomes.source (Progression-free survival at 60 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2402604","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","field":"links","label":"NEJM 2024"},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","field":"outcomes.source (Event-free survival at 12 months)"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"links","label":"NADINA (NEJM 2024)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2402614","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2403407","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/","field":"outcomes.source (Progression-free survival at 12 months)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2403614","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2404625","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2404873","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2405090","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2405888","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","field":"outcomes.source (Progression-free survival at 2 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2406070","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","field":"outcomes.source (Overall survival (7-year))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2406526","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","field":"outcomes.source (Overall remission (CR + CRi))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2407086","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","field":"outcomes.source (Progression-free survival, HER2-low (BICR))"},{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","field":"outcomes.source (Progression-free survival, ITT (HER2-low + ultralow))"},{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","field":"outcomes.source (Objective response rate, HER2-low)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2407417","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","field":"outcomes.source (Median overall survival)"},{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","field":"outcomes.source (Melanoma-specific survival at 10 years)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"links","label":"CheckMate 067 ten-year results (NEJM 2025)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2408154","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2409932","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"outcomes.source (Event-free survival at 5 years)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2410858","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","field":"outcomes.source (Progression-free survival, ESR1-mutant (imlunestrant vs standard ET))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2411680","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","field":"links","label":"NEJM 2024"},{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2502256","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2502760","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/","field":"links","label":"CHALLENGE trial (NEJM 2025)"},{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/","field":"links","label":"CHALLENGE trial (NEJM 2025)"},{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/","field":"links","label":"CHALLENGE trial (NEJM 2025)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2502929","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/","field":"links","label":"SERENA-6 (NEJM 2025)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2504650","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-aspirin-pik3ca-implementation","kind":"idea","name":"Get biomarker-directed aspirin after colorectal surgery into labels and guidelines","route":"/ideas/idea-reg-aspirin-pik3ca-implementation/","field":"links","label":"ALASCCA trial, NEJM 2025"},{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/","field":"links","label":"ALASCCA: aspirin in PIK3CA-mutated colorectal cancer (NEJM 2025)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2518245","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","field":"outcomes.source (Disease-free survival at 24 months (investigator-assessed))"},{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","field":"outcomes.source (Overall survival at 24 months (interim, 29% of final events))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2601486","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","field":"outcomes.source (Event-free survival at 2 years)"},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","field":"outcomes.source (Pathological complete response)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMsr1606602","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/","field":"links","label":"IARC: body fatness and cancer (NEJM 2016)"}]},{"url":"https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"access.source (UK)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"access.source (UK)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"access.source (UK)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"access.source (UK)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"access.source (UK)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"access.source (UK)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"access.source (UK)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"access.source (UK)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"access.source (UK)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"access.source (UK)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"access.source (UK)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"access.source (UK)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"access.source (UK)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"access.source (UK)"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"access.source (UK)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"access.source (UK)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"access.source (UK)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"access.source (UK)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"access.source (UK)"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"access.source (UK)"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"access.source (UK)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"access.source (UK)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"access.source (UK)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"access.source (UK)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"access.source (UK)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"access.source (UK)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"access.source (UK)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"access.source (UK)"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"access.source (UK)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"access.source (UK)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"access.source (UK)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"access.source (UK)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"access.source (UK)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"access.source (UK)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"access.source (UK)"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"access.source (UK)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"access.source (UK)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"access.source (UK)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"access.source (UK)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"access.source (UK)"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"access.source (UK)"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"access.source (UK)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"access.source (UK)"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"access.source (UK)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"access.source (UK)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"access.source (UK)"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"access.source (UK)"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"access.source (UK)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"access.source (UK)"},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"access.source (UK)"}]},{"url":"https://www.nice.org.uk/guidance/published?type=ta","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/","field":"links","label":"NICE technology appraisals"},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/","field":"url"}]},{"url":"https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html","status":403,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","field":"links","label":"My Medical Choice (NYT, 2013)"},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","field":"profiles","label":"My Medical Choice (NYT, 2013)"}]},{"url":"https://www.oecd-nea.org/jcms/pl_20168/medical-radioisotopes","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"OECD Nuclear Energy Agency: supply of medical radioisotopes"}]},{"url":"https://www.oecd-nea.org/jcms/pl_26262/medical-radioisotopes","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","field":"links","label":"OECD NEA medical radioisotopes"}]},{"url":"https://www.ornatx.com","status":403,"ok":false,"finalUrl":"https://www.lilly.com/science/subsidiaries","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","field":"website"}]},{"url":"https://www.ouhealth.com/stephenson-cancer-center/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","field":"links","label":"Stephenson Cancer Center"},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","field":"website"}]},{"url":"https://www.ouhealth.com/stephenson-cancer-center/research-clinical-trials/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","field":"links","label":"Clinical trials"}]},{"url":"https://www.parexel.com","status":403,"ok":false,"finalUrl":"https://www.parexel.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/","field":"links","label":"Official website"},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/","field":"website"}]},{"url":"https://www.pfizer.com","status":403,"ok":false,"finalUrl":"https://www.pfizer.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","field":"links","label":"Official website"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","field":"website"}]},{"url":"https://www.pfizer.com/about/partners/venture-investments","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","field":"links","label":"Official website"},{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","field":"website"}]},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-phase-2-results-next","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","field":"links","label":"Pfizer release"},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","field":"regulatoryEvents.source (2026-02)"}]},{"url":"https://www.pfizer.com/partners/venture-investments/our-portfolio","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://www.pieronline.jp/content/serial/0385-0684","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","route":"/journals/gan-to-kagaku-ryoho/","field":"links","label":"Homepage"},{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","route":"/journals/gan-to-kagaku-ryoho/","field":"url"}]},{"url":"https://www.pnas.org","status":403,"ok":false,"finalUrl":"https://www.pnas.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","field":"url"}]},{"url":"https://www.practicalradonc.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","route":"/journals/practical-radiation-oncology/","field":"links","label":"Homepage"},{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","route":"/journals/practical-radiation-oncology/","field":"url"}]},{"url":"https://www.rctduplicate.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-target-trial-emulation-standard","kind":"idea","name":"A pre-registered standard for emulating trials with real-world data","route":"/ideas/idea-data-target-trial-emulation-standard/","field":"links","label":"RCT-DUPLICATE"}]},{"url":"https://www.recordati.com","status":403,"ok":false,"finalUrl":"https://www.recordati.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/","field":"links","label":"Official website"},{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/","field":"website"}]},{"url":"https://www.redjournal.org","status":403,"ok":false,"finalUrl":"https://www.redjournal.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","field":"url"}]},{"url":"https://www.rijnstate.nl","status":403,"ok":false,"finalUrl":"https://www.rijnstate.nl/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rijnstate-arnhem","kind":"institution","name":"Rijnstate","route":"/institutions/rijnstate-arnhem/","field":"links","label":"Official website"},{"id":"rijnstate-arnhem","kind":"institution","name":"Rijnstate","route":"/institutions/rijnstate-arnhem/","field":"website"}]},{"url":"https://www.rijnstate.nl/over-rijnstate/organisatie/raad-van-bestuur/","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","field":"profiles","label":"Rijnstate Raad van Bestuur page"}]},{"url":"https://www.rogelcancercenter.org","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/our-care/specialty-centers-hospitals/rogel-cancer-center/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","field":"links","label":"Official website"},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","field":"website"},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"links","label":"Rogel Cancer Center"},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"profiles","label":"Rogel Cancer Center"}]},{"url":"https://www.rogelcancercenter.org/about/timeline","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/about/timeline","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"richard-rogel","kind":"person","name":"Richard Rogel","route":"/people/richard-rogel/","field":"links","label":"Rogel Cancer Center: timeline"}]},{"url":"https://www.rogelcancercenter.org/costas-lyssiotis-phd","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/costas-lyssiotis-phd","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","field":"links","label":"Michigan profile"},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","field":"profiles","label":"Michigan profile"}]},{"url":"https://www.rogelcancercenter.org/max-s-wicha-md","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/max-s-wicha-md","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","field":"links","label":"Michigan profile"},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","field":"profiles","label":"Michigan profile"}]},{"url":"https://www.rogelcancercenter.org/theodore-s-lawrence-md-phd","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/theodore-s-lawrence-md-phd","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","field":"links","label":"Michigan profile"},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","field":"profiles","label":"Michigan profile"}]},{"url":"https://www.rogelcancercenter.org/weiping-zou-md-phd","status":403,"ok":false,"finalUrl":"https://www.uofmhealth.org/weiping-zou-md-phd","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","field":"links","label":"Michigan profile"},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","field":"profiles","label":"Michigan profile"}]},{"url":"https://www.roswellpark.org/pawel-kalinski","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","field":"links","label":"Roswell Park profile"},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.ryvu.com","status":403,"ok":false,"finalUrl":"https://ryvu.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/","field":"links","label":"Official website"},{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/","field":"website"},{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/","field":"links","label":"Sponsor page"}]},{"url":"https://www.santa.lt","status":403,"ok":false,"finalUrl":"https://www.santa.lt/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","field":"links","label":"Official website"},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","field":"website"}]},{"url":"https://www.santa.lt/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"links","label":"Vilnius University Hospital Santaros Klinikos website"},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"profiles","label":"Vilnius University Hospital Santaros Klinikos website"}]},{"url":"https://www.santpaubarcelona.org","status":403,"ok":false,"finalUrl":"https://santpaubarcelona.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","field":"links","label":"Official website"},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","field":"website"}]},{"url":"https://www.science.org","status":403,"ok":false,"finalUrl":"https://www.science.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","field":"links","label":"Science journals"}]},{"url":"https://www.science.org/journal/science","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","field":"url"}]},{"url":"https://www.science.org/journal/stm","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","field":"url"}]},{"url":"https://www.science.org/topic/category/cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","field":"links","label":"Science cancer collection"}]},{"url":"https://www.sciencedirect.com/bookseries/advances-in-cancer-research","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","route":"/journals/advances-in-cancer-research/","field":"links","label":"Homepage"},{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","route":"/journals/advances-in-cancer-research/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/biochimica-et-biophysica-acta-bba-reviews-on-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","route":"/journals/bba-reviews-on-cancer/","field":"links","label":"Homepage"},{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","route":"/journals/bba-reviews-on-cancer/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/bulletin-du-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","field":"links","label":"Homepage"},{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/cancer-epidemiology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","route":"/journals/cancer-epidemiology/","field":"links","label":"Homepage"},{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","route":"/journals/cancer-epidemiology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/cancer-genetics","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","route":"/journals/cancer-genetics/","field":"links","label":"Homepage"},{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","route":"/journals/cancer-genetics/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/cancer-letters","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-letters","kind":"journal","name":"Cancer letters","route":"/journals/cancer-letters/","field":"links","label":"Homepage"},{"id":"cancer-letters","kind":"journal","name":"Cancer letters","route":"/journals/cancer-letters/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/cancer-radiotherapie","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","field":"links","label":"ScienceDirect"}]},{"url":"https://www.sciencedirect.com/journal/cancer-treatment-and-research-communications","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","field":"links","label":"Homepage"},{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/cancer-treatment-reviews","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","route":"/journals/cancer-treatment-reviews/","field":"links","label":"Homepage"},{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","route":"/journals/cancer-treatment-reviews/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","route":"/journals/critical-reviews-in-oncology-hematology/","field":"links","label":"Homepage"},{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","route":"/journals/critical-reviews-in-oncology-hematology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/current-problems-in-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","route":"/journals/current-problems-in-cancer/","field":"links","label":"Homepage"},{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","route":"/journals/current-problems-in-cancer/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/journal-of-cancer-policy","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","route":"/journals/journal-of-cancer-policy/","field":"links","label":"Homepage"},{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","route":"/journals/journal-of-cancer-policy/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/leukemia-research","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukemia-research","kind":"journal","name":"Leukemia research","route":"/journals/leukemia-research/","field":"links","label":"Homepage"},{"id":"leukemia-research","kind":"journal","name":"Leukemia research","route":"/journals/leukemia-research/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/lung-cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","field":"links","label":"Homepage"},{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/neoplasia","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","field":"links","label":"Homepage"},{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/oral-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-oncology","kind":"journal","name":"Oral oncology","route":"/journals/oral-oncology/","field":"links","label":"Homepage"},{"id":"oral-oncology","kind":"journal","name":"Oral oncology","route":"/journals/oral-oncology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/seminars-in-cancer-biology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","route":"/journals/seminars-in-cancer-biology/","field":"links","label":"Homepage"},{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","route":"/journals/seminars-in-cancer-biology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/seminars-in-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","route":"/journals/seminars-in-oncology/","field":"links","label":"Homepage"},{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","route":"/journals/seminars-in-oncology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/seminars-in-oncology-nursing","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","route":"/journals/seminars-in-oncology-nursing/","field":"links","label":"Homepage"},{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","route":"/journals/seminars-in-oncology-nursing/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/seminars-in-radiation-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","route":"/journals/seminars-in-radiation-oncology/","field":"links","label":"Homepage"},{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","route":"/journals/seminars-in-radiation-oncology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/surgical-oncology","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","route":"/journals/surgical-oncology/","field":"links","label":"Homepage"},{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","route":"/journals/surgical-oncology/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/tumour-virus-research","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","field":"links","label":"Homepage"},{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","field":"url"}]},{"url":"https://www.sciencedirect.com/science/article/abs/pii/S1470204525000270","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","field":"links","label":"Lancet Oncology 2025"},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","field":"outcomes.source (Overall survival at 2 years (non-inferiority))"}]},{"url":"https://www.sciencedirect.com/science/article/pii/S0923753422000059","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","field":"links","label":"Updated analysis, Annals of Oncology 2022"},{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.scimagoir.com/rankings.php?area=2730","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings: Oncology","route":"/collections/scimago-oncology/","field":"links","label":"SCImago Institutions Rankings: Oncology"},{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings: Oncology","route":"/collections/scimago-oncology/","field":"url"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207924000041/dgx-20231231.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","field":"links","label":"Quest Diagnostics 10-K (FY2023) describing the acquisition"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_ex99-1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/","field":"links","label":"Year-end 2025 results (8-K exhibit 99.1, March 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1121404/000112140422000002/pressreleaseq42021english.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/","field":"links","label":"Sanofi Q4 2021 results referencing the agreement (6-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312521363409/d237650dex992.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/","field":"links","label":"Official website"},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","field":"links","label":"Gyre completes acquisition (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","field":"links","label":"CareDx 8-K exhibit: agreement to acquire Naveris (Apr 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/naveris-pressrelease.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","field":"links","label":"CareDx completes acquisition (Jul 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","route":"/companies/c2i-genomics/","field":"links","label":"Veracyte 8-K exhibit announcing C2i acquisition (Jan 2024)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525153576/d82329dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","field":"links","label":"Concentra acquisition agreement (8-K exhibit 99.1, July 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525180763/d82965d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","field":"links","label":"Completion of merger (8-K, August 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","field":"links","label":"AbbVie Q3 2025 results noting completion (8-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/abbv-20250930.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","field":"links","label":"AbbVie Q3 2025 Form 10-Q describing the acquisition"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/d124753dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","field":"links","label":"Merger and $350 million private placement announced (8-K, April 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925055143/tm2516831d1_ex99-1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","field":"links","label":"Sanofi acquisition announcement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1597264/000119312525160804/d909980d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","field":"links","label":"Tender offer completion 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312520308501/d72504d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","field":"links","label":"December 2020 public offering 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","field":"links","label":"Q3 2025 results and business update (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000120/hcat-20240630.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","field":"links","label":"Health Catalyst 10-Q for Q2 2024 with deal terms"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312525003248/d874651d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","field":"links","label":"Completion of merger (8-K, January 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1661702/000166170219000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","field":"links","label":"Form D, October 2019"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","field":"links","label":"Merger closing and private placement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","field":"links","label":"IPO closing press release (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156459020052741/prld-ex991_6.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","field":"links","label":"Q3 2020 results noting IPO (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"links","label":"SEC Form D (January 2021)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1683327/000168332721000002/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"links","label":"SEC Form D (November 2021)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1688076/000168807620000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","field":"links","label":"SEC Form D (February 2020)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","field":"links","label":"Q4 2019 results noting IPO proceeds (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1708493/000119312524003927/d715256dex992.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","field":"links","label":"Merck to acquire Harpoon (8-K exhibit 99.2, January 2024)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1708493/000119312524064395/d808382d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","field":"links","label":"Completion of merger (8-K, March 2024)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1717115/000095017025064447/tem-20250331.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","field":"links","label":"Tempus AI 10-Q for Q1 2025 recording the acquisition"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1720544/000172054420000002/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"links","label":"Form D, July 2020"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","field":"links","label":"January 2026 corporate update (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516020000006/zentalisq12020earningrel.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","field":"links","label":"Q1 2020 results noting IPO proceeds (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","field":"links","label":"Sanofi transaction announcement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/tm243190d20_8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","field":"links","label":"Completion 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1741495/000174149522000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"links","label":"SEC Form D (Aug 2022)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1741495/000174149525000004/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"links","label":"SEC Form D (Oct 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","field":"links","label":"IPO closing 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047107/tsbx-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","field":"links","label":"Q4 2024 results noting TIDAL-01 discontinuation (8-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","field":"links","label":"XOMA acquisition agreement (8-K, June 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525177597/d27108d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","field":"links","label":"Completion of merger (8-K, August 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","field":"links","label":"IPO closing 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312524084736/d796750d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","field":"links","label":"IPO closing 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","field":"links","label":"Serapha Bio merger announcement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","field":"links","label":"Metagenomi Q2 2024 results describing the Affini-T milestone (8-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","field":"links","label":"Merger with Ambros Therapeutics announced (8-K exhibit 99.1, August 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/a06302026ex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","field":"links","label":"IPO closing release (8-K, February 2022)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1796280/000156459020019302/oric-ex991_68.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","field":"links","label":"IPO closing press release (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","field":"links","label":"Acquisition agreement announcement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","field":"links","label":"Completion of acquisition (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Form 8-K: merger agreement with Eli Lilly"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Lilly press release (8-K exhibit 99.4)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Form 8-K: completion of merger"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","field":"links","label":"Form D (July 2024)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","field":"links","label":"IPO prospectus (SEC 424B4)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312521191155/d177137dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","field":"links","label":"IPO closing release (8-K, June 2021)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","field":"links","label":"BCTG merger announcement (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1819934/000181993422000003/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","field":"links","label":"Form D (June 2022 amendment)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1822462/000119312520310711/d98800dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","field":"links","label":"Q3 2020 results noting IPO (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","field":"links","label":"Q2 2026 results and XTX501 IND clearance (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","field":"links","label":"Board appointment noting planned BLA (8-K exhibit 99.1, September 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_ex99-1.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","field":"links","label":"Q2 2026 results (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","field":"links","label":"Form D (September 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","field":"links","label":"IPO closing 8-K (SEC)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","field":"links","label":"Listing press release, August 2025 (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","field":"links","label":"Form D, February 2022"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","field":"links","label":"Form D, October 2025"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1925270/000192527022000002/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","field":"links","label":"Form D, April 2022"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312523294468/d25647dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","field":"links","label":"Q3 2023 results describing CRG-022 (8-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525156413/d74755dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","field":"links","label":"Concentra acquisition announcement (8-K, July 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1966494/000119312525183141/d58314d8k.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","field":"links","label":"Completion of acquisition (8-K, August 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/a2025q4exhibit991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","field":"links","label":"J&J Q4 2025 results referencing the acquisition (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/projectwaystar-2q26earning.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","field":"links","label":"Q2 2026 results and leadership transition (8-K exhibit 99.1)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","field":"links","label":"Form D, October 2024"}]},{"url":"https://www.sec.gov/Archives/edgar/data/2082715/000208271525000001/primary_doc.xml","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","field":"links","label":"Form D (August 2025)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963dex991.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","field":"links","label":"Closing of Galera transaction and private placement (8-K, August 2026)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","field":"links","label":"Lilly Q1 2025 results mentioning the acquisition (SEC exhibit)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/exhibit991earningspressrel.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","field":"links","label":"Gilead Q1 2023 results noting completed Tmunity acquisition (8-K)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/901832/000165495422015806/a9015h.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","route":"/companies/neogene-therapeutics/","field":"links","label":"Official website"},{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","route":"/companies/neogene-therapeutics/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/Archives/edgar/data/901832/000165495423000484/a7540m.htm","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","route":"/companies/neogene-therapeutics/","field":"links","label":"Acquisition completed (6-K, January 2023)"}]},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119774&type=20-F","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/","field":"links","label":"SEC filer record (CIK 0001119774)"}]},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001930014&type=D&dateb=&owner=include&count=40","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","field":"links","label":"SEC Form D filings for Deep 6 AI Inc."}]},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=gamida+cell&type=&dateb=&owner=include&count=40","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","field":"links","label":"SEC filings (CIK 0001600847), including the 2024 restructuring and deregistration"}]},{"url":"https://www.sec.gov/edgar/browse/?CIK=0001496323","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","field":"links","label":"Official website"},{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/edgar/browse/?CIK=0001661702","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","field":"links","label":"Official website"},{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/edgar/browse/?CIK=0001764974","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","field":"links","label":"Official website"},{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/edgar/browse/?CIK=0001966494","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","field":"links","label":"Official website"},{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.sec.gov/edgar/browse/?CIK=0002015437","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","field":"links","label":"Official website"},{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","field":"links","label":"SEC EDGAR filings"}]},{"url":"https://www.shebaonline.org","status":403,"ok":false,"finalUrl":"https://www.shebaonline.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","field":"links","label":"Sheba Medical Center"},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","field":"profiles","label":"Sheba Medical Center"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","field":"links","label":"Homepage"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","field":"website"}]},{"url":"https://www.shebaonline.org/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","route":"/people/yitshak-kreiss/","field":"links","label":"Institution profile"},{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","route":"/people/yitshak-kreiss/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.shebaonline.org/departments/cancer-center/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/","field":"links","label":"Ella Lemelbaum Institute, Sheba Medical Center"},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/","field":"profiles","label":"Ella Lemelbaum Institute, Sheba Medical Center"},{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/","field":"links","label":"Sheba Medical Center cancer centre"},{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/","field":"profiles","label":"Sheba Medical Center cancer centre"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","field":"links","label":"Cancer Center"}]},{"url":"https://www.shsfkyy.com","status":403,"ok":false,"finalUrl":"https://www.shsfkyy.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"links","label":"Shanghai Pulmonary Hospital"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"profiles","label":"Shanghai Pulmonary Hospital"},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","field":"links","label":"Shanghai Pulmonary Hospital"},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","field":"website"}]},{"url":"https://www.skandionkliniken.se","status":403,"ok":false,"finalUrl":"https://skandionkliniken.se/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"links","label":"Skandion Clinic"}]},{"url":"https://www.skane.se/en/skane-university-hospital","status":403,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"links","label":"Skåne University Hospital / Lund University Cancer Centre website"},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"profiles","label":"Skåne University Hospital / Lund University Cancer Centre website"},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","field":"links","label":"Skåne University Hospital"},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","field":"website"}]},{"url":"https://www.su.ac.za","status":403,"ok":false,"finalUrl":"https://www.su.ac.za/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/","field":"links","label":"Stellenbosch University"},{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/","field":"website"}]},{"url":"https://www.surgonc.theclinics.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","route":"/journals/surgical-oncology-clinics-of-north-america/","field":"links","label":"Homepage"},{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","route":"/journals/surgical-oncology-clinics-of-north-america/","field":"url"}]},{"url":"https://www.syngeneintl.com","status":403,"ok":false,"finalUrl":"https://www.syngeneintl.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"syngene","kind":"company","name":"Syngene International","route":"/companies/syngene/","field":"links","label":"Official website"},{"id":"syngene","kind":"company","name":"Syngene International","route":"/companies/syngene/","field":"website"}]},{"url":"https://www.tandfonline.com/doi/full/10.1080/14796694.2026.2667441","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","field":"links","label":"MEVPRO-1/2 protocols (Future Oncology 2026)"}]},{"url":"https://www.tandfonline.com/journals/hnuc20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","route":"/journals/nutrition-and-cancer/","field":"links","label":"Homepage"},{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","route":"/journals/nutrition-and-cancer/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/icns20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","field":"links","label":"Homepage"},{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/icnv20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","route":"/journals/cancer-investigation/","field":"links","label":"Homepage"},{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","route":"/journals/cancer-investigation/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/iery","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","route":"/journals/expert-review-of-anticancer-therapy/","field":"links","label":"Homepage"},{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","route":"/journals/expert-review-of-anticancer-therapy/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/ifon","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/","field":"links","label":"Homepage"},{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/ihyt","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","field":"links","label":"Homepage"},{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/ilal20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/","field":"links","label":"Homepage"},{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/ipho20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/","field":"links","label":"Homepage"},{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/kcbt","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","field":"links","label":"Homepage"},{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/koni","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","field":"links","label":"Homepage"},{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","field":"url"}]},{"url":"https://www.tandfonline.com/journals/wjpo20","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","route":"/journals/journal-of-psychosocial-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","route":"/journals/journal-of-psychosocial-oncology/","field":"url"}]},{"url":"https://www.tgen.org","status":403,"ok":false,"finalUrl":"https://www.tgen.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","route":"/institutions/tgen/","field":"links","label":"TGen"},{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","route":"/institutions/tgen/","field":"website"}]},{"url":"https://www.thebreastonline.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","field":"links","label":"Homepage"},{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","field":"url"}]},{"url":"https://www.thegreenjournal.com","status":403,"ok":false,"finalUrl":"https://www.thegreenjournal.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","field":"url"}]},{"url":"https://www.thelancet.com","status":403,"ok":false,"finalUrl":"https://www.thelancet.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","field":"links","label":"Lancet journals"},{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","field":"links","label":"Lancet journals"}]},{"url":"https://www.thelancet.com/clinical/diseases/cancer","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"links","label":"Oncology collection"}]},{"url":"https://www.thelancet.com/commissions/diagnostics","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-telepathology-district-network","kind":"idea","name":"Slide scanners in district hospitals wired to pathologists anywhere","route":"/ideas/idea-acc-telepathology-district-network/","field":"links","label":"Lancet Commission on diagnostics"}]},{"url":"https://www.thelancet.com/commissions/global-cancer-surgery","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgery-roadmap","kind":"roadmap","name":"Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work","route":"/roadmaps/surgery-roadmap/","field":"links","label":"Lancet Oncology Commission on global cancer surgery"}]},{"url":"https://www.thelancet.com/commissions/palliative-care","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-balanced-opioid-policy-reform","kind":"idea","name":"National opioid quota reform so morphine reaches cancer patients","route":"/ideas/idea-acc-balanced-opioid-policy-reform/","field":"links","label":"Lancet Commission on palliative care and pain relief"},{"id":"idea-acc-essential-palliative-package-in-uhc","kind":"idea","name":"Put the essential palliative care package into every universal health coverage benefit list","route":"/ideas/idea-acc-essential-palliative-package-in-uhc/","field":"links","label":"Lancet Commission on palliative care and pain relief"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61121-X/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60485-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","field":"outcomes.source (Event-free survival (median))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"links","label":"Lancet 2014"},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, docetaxel arm (M1))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maps","kind":"trial","name":"MAPS","route":"/trials/maps/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60165-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30650-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/","field":"outcomes.source (4-year disease-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","field":"links","label":"Lancet 2019"},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","field":"outcomes.source (Overall survival, CPS ≥20, pembrolizumab monotherapy)"},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","field":"outcomes.source (Overall survival, total population, pembrolizumab + chemotherapy)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30314-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","field":"links","label":"Lancet 2020"},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","field":"outcomes.source (Accuracy for pelvic nodal or distant metastases (AUC))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30932-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-hypofractionation-default-lmic","kind":"idea","name":"Make one-week radiotherapy the default in overloaded systems","route":"/ideas/idea-acc-hypofractionation-default-lmic/","field":"links","label":"FAST-Forward trial (Lancet 2020)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"outcomes.source (PSA response ≥50%)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00731-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","field":"links","label":"Lancet 2021"},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","field":"outcomes.source (Ovarian and tubal cancer mortality reduction (multimodal vs none))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01234-4/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","field":"outcomes.source (Overall survival, all patients)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01789-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-geriatric-assessment-by-default","kind":"idea","name":"Geriatric assessment by default for every patient over 70 starting cancer treatment","route":"/ideas/idea-acc-geriatric-assessment-by-default/","field":"links","label":"GAP70+ trial (Mohile et al., Lancet 2021)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, abiraterone arm (M1 subgroup))"},{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","field":"outcomes.source (Overall survival, abiraterone vs no abiraterone (with ADT + docetaxel))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00562-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"outcomes.source (Recurrence-free survival (first interim analysis))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02420-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00221-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","field":"links","label":"Lancet 2023"},{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00922-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01052-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","field":"outcomes.source (Complete response / CRi (primary analysis set))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01055-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"outcomes.source (Radiographic progression-free survival, all comers)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01366-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01613-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02241-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","field":"outcomes.source (Overall survival at 36 months)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02517-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","field":"links","label":"Lancet 2024"},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","field":"outcomes.source (Progression-free survival)"},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00054-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","field":"outcomes.source (3-year invasive disease-free survival (PET-adapted arm))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00317-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","field":"outcomes.source (Progression-free survival at 24 months)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00885-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"motion","kind":"trial","name":"MOTION","route":"/trials/motion/","field":"outcomes.source (Objective response rate at week 25)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"outcomes.source (Progression-free survival at 4 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01438-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","field":"links","label":"Lancet 2024"},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","field":"outcomes.source (Progression-free survival at 5 years)"},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01653-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"outcomes.source (Overall survival (crossover-adjusted))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01758-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tinivo-2","kind":"trial","name":"TiNivo-2","route":"/trials/tinivo-2/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02135-4/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","field":"links","label":"Lancet 2024"},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","field":"outcomes.source (Progression-free survival)"},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02551-0/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","field":"links","label":"Lancet"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","field":"links","label":"EMERALD-1 (Lancet 2025)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02565-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","field":"links","label":"Lancet"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","field":"links","label":"LEAP-012 (Lancet 2025)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02722-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","field":"outcomes.source (Progression-free survival (IRRC))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02848-4/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","field":"links","label":"Lancet 2025"},{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","field":"outcomes.source (Progression-free survival, all lines: combination vs nivolumab)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00403-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","field":"links","label":"Lancet 2025"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00629-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"links","label":"Lancet 2025"},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"outcomes.source (Recurrence-free at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01011-6/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01011-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00866-4/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","field":"links","label":"Lancet 2026"},{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","field":"outcomes.source (Progression-free survival at 2 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"url"}]},{"url":"https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00120-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","field":"links","label":"Lancet Diabetes & Endocrinology 2021"},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","field":"outcomes.source (Objective response rate, treatment-naive RET-mutant MTC)"}]},{"url":"https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00276-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"5-year follow-up"}]},{"url":"https://www.thelancet.com/journals/landig/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","field":"url"}]},{"url":"https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","field":"links","label":"Lancet Gastroenterol Hepatol 2024"}]},{"url":"https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00009-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","field":"links","label":"Single-dose evidence, Lancet Global Health 2024"}]},{"url":"https://www.thelancet.com/journals/langlo/collections","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","field":"links","label":"Cancer collection"}]},{"url":"https://www.thelancet.com/journals/langlo/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","field":"url"}]},{"url":"https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00134-4/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","field":"links","label":"5-year results (Lancet Haematology 2021)"},{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","field":"outcomes.source (5-year overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanhae/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","field":"url"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70025-7/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70420-6/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rainbow","kind":"trial","name":"RAINBOW","route":"/trials/rainbow/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30068-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","field":"links","label":"FIRES, Lancet Oncology 2017"},{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","field":"outcomes.source (FIRES: sensitivity of sentinel-node mapping for nodal metastasis)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30070-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","field":"outcomes.source (Event-free survival at 3 years (R1 conditioning))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30318-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30334-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","field":"outcomes.source (Overall survival at 46 months)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30517-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/","field":"outcomes.source (Overall survival, minimal residual disease population)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30142-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","field":"links","label":"Lancet Oncology 2018"},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30578-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","field":"outcomes.source (Event-free survival at 3 years (R2 immunotherapy))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30082-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30274-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/","field":"links","label":"ECHO-301/KEYNOTE-252 (Lancet Oncol 2019)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30395-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","field":"links","label":"Lancet Oncology 2019"},{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30689-8/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"outcomes.source (Overall survival, PD-L1+)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30168-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30737-3/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","field":"links","label":"Lancet Oncology 2021"},{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00005-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00293-5/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"outcomes.source (Progression-free survival (cohort 1))"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00108-0/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","field":"outcomes.source (Overall survival, all patients)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00147-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","field":"links","label":"Lancet Oncology 2023"},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00298-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/","field":"links","label":"MASAI trial (Lancet Oncology 2023)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-9/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"outcomes.source (Overall survival, all comers)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00525-2/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","field":"outcomes.source (Invasive disease-free survival at 5 years)"},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","field":"outcomes.source (Distant relapse-free survival at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00529-6/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00193-2/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.thelancet.com/journals/lanonc/commissions","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"links","label":"Lancet Oncology Commissions"}]},{"url":"https://www.thelancet.com/journals/lanonc/home","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"url"}]},{"url":"https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30139-0/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lume-meso","kind":"trial","name":"LUME-Meso","route":"/trials/lume-meso/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00309-5/abstract","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00119-X/fulltext","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mars-2","kind":"trial","name":"MARS 2","route":"/trials/mars-2/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.tyks.fi/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"links","label":"Turku University Hospital Cancer Centre website"},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"profiles","label":"Turku University Hospital Cancer Centre website"}]},{"url":"https://www.ukbiobank.ac.uk","status":403,"ok":false,"finalUrl":"https://www.ukbiobank.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","field":"links","label":"UK Biobank"},{"id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","field":"url"}]},{"url":"https://www.ukbiobank.ac.uk/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-trial-biospecimen-commons","kind":"idea","name":"A commons for leftover trial biospecimens with standard access for approved research","route":"/ideas/idea-fund-trial-biospecimen-commons/","field":"links","label":"UK Biobank"}]},{"url":"https://www.umcg.nl","status":403,"ok":false,"finalUrl":"https://www.umcg.nl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"links","label":"University Medical Center Groningen Comprehensive Cancer Center website"},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"profiles","label":"University Medical Center Groningen Comprehensive Cancer Center website"},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"links","label":"Official website"},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"website"}]},{"url":"https://www.urologiconcology.org/","status":403,"ok":false,"finalUrl":"https://www.sciencedirect.com/journal/urologic-oncology-seminars-and-original-investigations","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","route":"/journals/urologic-oncology/","field":"links","label":"Homepage"},{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","route":"/journals/urologic-oncology/","field":"url"}]},{"url":"https://www.urotoday.com/","status":403,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","field":"links","label":"UroToday"},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","field":"url"}]},{"url":"https://doi.org/10.1001/jama.2018.11350","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","field":"links","label":"SWOG S1200: acupuncture for aromatase inhibitor-related joint pain (JAMA 2018)"}],"archiveRequested":false},{"url":"https://doi.org/10.1002/1097-0142(196409)18:9<1111::AID-CNCR2820180903>3.0.CO;2-Z","status":404,"ok":false,"finalUrl":"https://doi.org/10.1002/1097-0142(196409)18:9%3C1111::AID-CNCR2820180903%3E3.0.CO;2-Z","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"log-kill-hypothesis","kind":"technology","name":"Log-kill hypothesis (Skipper)","route":"/technologies/log-kill-hypothesis/","field":"links","label":"Skipper, Schabel and Wilcox 1964"}],"archiveRequested":false},{"url":"https://doi.org/10.1016/j.annonc.2022.04.011","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"standardOfCare.guideline (Unresectable or inoperable)"}],"archiveRequested":false},{"url":"https://doi.org/10.1016/S1470-2045(23)00492-9","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"links","label":"Alliance A071601: BRAF/MEK inhibition in papillary craniopharyngioma (Lancet Oncology 2024)"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"standardOfCare.guideline (Papillary craniopharyngioma, BRAF V600E)"}],"archiveRequested":false},{"url":"https://doi.org/10.1016/S2214-109X(21)00347-3","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"links","label":"Bruni et al., HPV vaccination coverage estimates 2010-2019 (Lancet Global Health 2021)"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"metrics (Girls worldwide fully vaccinated against HPV by 2019)"}],"archiveRequested":false},{"url":"https://doi.org/10.1038/ng0997-95","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdgfrb","kind":"target","name":"PDGFRB","route":"/targets/pdgfrb/","field":"prevalence.source"}],"archiveRequested":false},{"url":"https://doi.org/10.1056/NEJMoa1809946","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","field":"links","label":"Omega-3 results (NEJM 2019)"},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","field":"outcomes.source (Invasive cancer of any type)"}],"archiveRequested":false},{"url":"https://doi.org/10.1056/NEJMoa2117013","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","field":"links","label":"Donor-derived CD7 CAR-T (NEJM 2022)"}],"archiveRequested":false},{"url":"https://doi.org/10.1097/01.sla.0000234786.09312.53","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"isolated-limb-perfusion","kind":"technology","name":"Isolated limb perfusion and infusion","route":"/technologies/isolated-limb-perfusion/","field":"links","label":"TNF-melphalan ILP in sarcoma (Ann Surg 2006)"}],"archiveRequested":false},{"url":"https://doi.org/10.1126/science.1651174","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"papers","label":"Identification of FAP locus genes from chromosome 5q21"}],"archiveRequested":false},{"url":"https://doi.org/10.1136/jitc-2020-002757","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","field":"links","label":"Pooled analysis, JITC 2021"},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","field":"outcomes.source (Objective response rate (pooled analysis))"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/go-25-00721","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kapoor-jco-glob-oncol","kind":"paper","name":"Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)","route":"/key-papers/paper-kapoor-jco-glob-oncol/","field":"links","label":"JCO Glob Oncol 2026"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/GO-25-00721","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/","field":"links","label":"METRO PLUS trial (JCO Glob Oncol 2026)"},{"id":"metro-plus-varanasi","kind":"trial","name":"METRO PLUS (Tata Memorial Centre, Varanasi)","route":"/trials/metro-plus-varanasi/","field":"links","label":"Kapoor et al., JCO Global Oncology 2026"},{"id":"metro-plus-varanasi","kind":"trial","name":"METRO PLUS (Tata Memorial Centre, Varanasi)","route":"/trials/metro-plus-varanasi/","field":"outcomes.source (Median overall survival)"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/JCO.18.02102","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","field":"standardOfCare.guideline (Very low risk (stage I FH, <2 years, <550 g))"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/JCO.2005.04.8270","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"Effects of CBT in severely fatigued disease-free cancer patients, randomised trial (JCO 2006)"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/JCO.23.02545","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","field":"links","label":"ASCO sleep disturbance guideline (JCO 2024)"}],"archiveRequested":false},{"url":"https://doi.org/10.1200/JCO.24.00575","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of cancer-related fatigue (JCO 2024)"},{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of cancer-related fatigue (JCO 2024)"},{"id":"tai-chi-qigong","kind":"technology","name":"Tai chi and qigong","route":"/technologies/tai-chi-qigong/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of cancer-related fatigue (JCO 2024)"},{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","field":"links","label":"SIO-ASCO guideline: integrative oncology care of cancer-related fatigue (JCO 2024)"}],"archiveRequested":true},{"url":"https://doi.org/10.1200/JCO.24.01373","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"links","label":"Journal of Clinical Oncology 2024"},{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"outcomes.source (Progression-free survival at 30 months)"}],"archiveRequested":false},{"url":"https://doi.org/10.4103/0971-5851.142040","status":404,"ok":false,"finalUrl":"https://www.ijmpo.org/text.asp?2014/35/3/226/142040","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pramesh-indian-j-med-paediatr-oncol","kind":"paper","name":"The national cancer grid of India","route":"/key-papers/paper-pramesh-indian-j-med-paediatr-oncol/","field":"links","label":"Indian J Med Paediatr Oncol 2014"},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"links","label":"The National Cancer Grid of India (2014)"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/AB_Science","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Adaptive_radiation_therapy","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adaptive-radiotherapy","kind":"technology","name":"Adaptive radiotherapy (online replanning)","route":"/technologies/adaptive-radiotherapy/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Ascentage_Pharma","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Celsion_Corporation","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Conjunctival_melanoma","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conjunctival-melanoma","kind":"cancer","name":"Conjunctival melanoma","route":"/cancers/conjunctival-melanoma/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Contrast-enhanced_spectral_mammography","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Decentralized_clinical_trial","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/","field":"links","label":"Wikipedia"},{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Dose_painting","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dose-painting","kind":"technology","name":"Dose painting and biologically guided radiotherapy","route":"/technologies/dose-painting/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Erytech_Pharma","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Follicular_Lymphoma_International_Prognostic_Index","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flipi","kind":"term","name":"FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)","route":"/terms/flipi/","field":"links","label":"Wikipedia"},{"id":"flipi","kind":"term","name":"FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)","route":"/terms/flipi/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Heidelberg_Pharma","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Human_Genome_Variation_Society","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hgvs","kind":"term","name":"HGVS variant nomenclature","route":"/terms/hgvs/","field":"links","label":"Wikipedia"},{"id":"hgvs","kind":"term","name":"HGVS variant nomenclature","route":"/terms/hgvs/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Hyperparathyroidism-jaw_tumor_syndrome","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Hypofractionated_radiation_therapy","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Linear-quadratic_model","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"linear-quadratic-model","kind":"technology","name":"The linear-quadratic model and fractionation","route":"/technologies/linear-quadratic-model/","field":"links","label":"Wikipedia"},{"id":"alpha-beta-ratio","kind":"term","name":"Alpha/beta ratio","route":"/terms/alpha-beta-ratio/","field":"links","label":"Wikipedia"},{"id":"alpha-beta-ratio","kind":"term","name":"Alpha/beta ratio","route":"/terms/alpha-beta-ratio/","field":"wikipedia"},{"id":"biologically-effective-dose","kind":"term","name":"Biologically effective dose (BED) and EQD2","route":"/terms/biologically-effective-dose/","field":"links","label":"Wikipedia"},{"id":"biologically-effective-dose","kind":"term","name":"Biologically effective dose (BED) and EQD2","route":"/terms/biologically-effective-dose/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Lip_cancer","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","field":"links","label":"Wikipedia"},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Luye_Pharma_Group","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"links","label":"Wikipedia"},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/NewLink_Genetics","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","route":"/companies/newlink-genetics/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Oligometastasis","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sabr-oligometastases","kind":"technology","name":"Stereotactic ablative radiotherapy for oligometastatic disease","route":"/technologies/sabr-oligometastases/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Oncopeptides","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","field":"links","label":"Wikipedia"}],"archiveRequested":true},{"url":"https://en.wikipedia.org/wiki/Papillary_tumor_of_the_pineal_region","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"papillary-tumour-pineal-region","kind":"cancer","name":"Papillary tumour of the pineal region","route":"/cancers/papillary-tumour-pineal-region/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/PharmaEssentia","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Premelanosome_protein","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/","field":"prevalence.source"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Radiation_necrosis","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","field":"links","label":"Wikipedia"},{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Radioprotector","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioprotectors","kind":"technology","name":"Radioprotectors and normal-tissue sparing drugs","route":"/technologies/radioprotectors/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Respiratory_gating","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"respiratory-motion-management","kind":"technology","name":"Respiratory motion management (4D-CT, gating, breath-hold, tracking)","route":"/technologies/respiratory-motion-management/","field":"links","label":"Wikipedia"},{"id":"deep-inspiration-breath-hold","kind":"term","name":"Deep inspiration breath-hold (DIBH)","route":"/terms/deep-inspiration-breath-hold/","field":"links","label":"Wikipedia"},{"id":"deep-inspiration-breath-hold","kind":"term","name":"Deep inspiration breath-hold (DIBH)","route":"/terms/deep-inspiration-breath-hold/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Soligenix","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/T-cell-prolymphocytic_leukemia","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Technetium_(99mTc)_sulfur_colloid","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"links","label":"Wikipedia"},{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/TG_Therapeutics","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Thyrotropic_pituitary_adenoma","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Veru_Inc.","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Ziopharm_Oncology","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","field":"links","label":"Wikipedia"}],"archiveRequested":false},{"url":"https://fastgrants.org/","status":404,"ok":false,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"idea-fund-fast-grants-oncology","kind":"idea","name":"Forty-eight-hour small grants for bold experiments in neglected cancers","route":"/ideas/idea-fund-fast-grants-oncology/","field":"links","label":"Fast Grants"}],"archive":"https://web.archive.org/web/20260421191704/https://fastgrants.org/"},{"url":"https://hospitals.aku.edu/karachi","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aku-karachi","kind":"institution","name":"Aga Khan University Hospital, Karachi","route":"/institutions/aku-karachi/","field":"links","label":"Official website"},{"id":"aku-karachi","kind":"institution","name":"Aga Khan University Hospital, Karachi","route":"/institutions/aku-karachi/","field":"website"}],"archiveRequested":false},{"url":"https://hospitals.aku.edu/pakistan/AboutUs/Pages/welcome-by-ceo-akuh-pakistan.aspx","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","route":"/people/farhat-abbas/","field":"links","label":"Source: AKUH Pakistan CEO welcome page"},{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","route":"/people/farhat-abbas/","field":"profiles","label":"Welcome by CEO, AKUH Pakistan"}],"archive":"https://web.archive.org/web/20260420003849/https://hospitals.aku.edu/pakistan/AboutUs/Pages/welcome-by-ceo-akuh-pakistan.aspx"},{"url":"https://mascc.org/resources/antiemetic-guidelines/","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","field":"links","label":"MASCC/ESMO antiemetic guideline"}],"archiveRequested":false},{"url":"https://mascc.org/resources/mascc-risk-index-score/","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","field":"links","label":"MASCC febrile neutropenia risk index"}],"archiveRequested":false},{"url":"https://nyulangone.org/locations/perlmutter-cancer-center","status":404,"ok":false,"finalUrl":"http://nyulangone.org/cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","field":"links","label":"Perlmutter Cancer Center"},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","field":"website"}],"archive":"https://web.archive.org/web/20260731024209/https://nyulangone.org/locations/perlmutter-cancer-center"},{"url":"https://seer.cancer.gov/statfacts/html/vagina.html","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"links","label":"SEER: vaginal cancer"}],"archiveRequested":false},{"url":"https://turbine.ai/meet-us/","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","field":"links","label":"Team and investors"}],"archive":"https://web.archive.org/web/20260607023701/https://turbine.ai/meet-us/"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220910Orig1s000ltr.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"FDA approval letter, NDA 220910"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"regulatoryEvents.source (2026-07-17)"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"regulatoryEvents.source (2026-08-26)"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20250202072748/https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911210935/https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911211022/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","field":"links","label":"FDA label"}],"archive":"https://web.archive.org/web/20250704130807/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","field":"links","label":"FDA label"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911211115/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","field":"links","label":"FDA label"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250614075918/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125409s128lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","field":"dosing.source"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022405s015lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","field":"dosing.source"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"links","label":"FDA label"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"dosing.source"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Avastin (bevacizumab) US prescribing information"}],"archive":"https://web.archive.org/web/20260819184831/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s040lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","field":"links","label":"FDA label"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206192s006lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","field":"dosing.source"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207981s012lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"links","label":"FDA label"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911203948/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207981s012lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911203450/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260911211137/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20251214184217/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","field":"links","label":"FDA label"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20251215002440/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213702s004lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","field":"dosing.source"}]},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"FDA prescribing information (label)"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-cost-subcutaneous-community","kind":"idea","name":"Give subcutaneous immunotherapy in community clinics and at home","route":"/ideas/idea-cost-subcutaneous-community/","field":"links","label":"FDA: Drugs@FDA approved labels"}],"archive":"https://web.archive.org/web/20260913050729/https://www.accessdata.fda.gov/scripts/cder/daf/"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009190","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","field":"links","label":"Drugs@FDA NDA009190"}],"archive":"https://web.archive.org/web/20251010024005/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009190"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018651","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","field":"links","label":"Drugs@FDA NDA018651"}],"archive":"https://web.archive.org/web/20260611044241/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018651"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018677","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","field":"links","label":"Drugs@FDA NDA018677"}],"archive":"https://web.archive.org/web/20260923052734/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018677"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020451","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","field":"links","label":"Drugs@FDA NDA020451"}],"archive":"https://web.archive.org/web/20260923052621/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020451"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020886","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","field":"links","label":"Drugs@FDA NDA020886"}],"archive":"https://web.archive.org/web/20260923052606/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020886"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021688","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","field":"links","label":"Drugs@FDA NDA021688"}],"archive":"https://web.archive.org/web/20260923052751/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021688"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022058","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","field":"links","label":"Drugs@FDA NDA022058"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","field":"links","label":"Drugs@FDA NDA 022291"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022555","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hexaminolevulinate","kind":"drug","name":"Hexaminolevulinate","route":"/drugs/hexaminolevulinate/","field":"links","label":"Drugs@FDA NDA022555"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050742","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Drugs@FDA NDA 050742"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103362","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","field":"links","label":"Drugs@FDA BLA103362"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125268","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","field":"links","label":"Drugs@FDA BLA 125268"}],"archive":"https://web.archive.org/web/20260923052533/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125268"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-cost-extended-interval-default","kind":"idea","name":"Make six-weekly immunotherapy the default schedule","route":"/ideas/idea-cost-extended-interval-default/","field":"links","label":"FDA: pembrolizumab label (Drugs@FDA)"}],"archive":"https://web.archive.org/web/20260323055456/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205410","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","field":"links","label":"Drugs@FDA NDA 205410"}],"archive":"https://web.archive.org/web/20250325203014/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205410"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","field":"links","label":"Drugs@FDA NDA 209299"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214200","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","field":"links","label":"Drugs@FDA NDA214200"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","field":"links","label":"Drugs@FDA NDA217159"}],"archive":"https://web.archive.org/web/20250411004526/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220910","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"access.source (US)"}],"archive":"https://web.archive.org/web/20260917125745/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220910"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761107","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","field":"links","label":"Drugs@FDA BLA 761107"}]},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","field":"links","label":"Drugs@FDA BLA 761108"}],"archive":"https://web.archive.org/web/20251115081545/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","field":"links","label":"Drugs@FDA BLA761148"}],"archive":"https://web.archive.org/web/20260923052636/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030052","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"urovysion","kind":"drug","name":"UroVysion Bladder Cancer Kit","route":"/drugs/urovysion/","field":"links","label":"FDA PMA P030052"}],"archive":"https://web.archive.org/web/20260412141129/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030052"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110030","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","field":"links","label":"FDA PMA P110030"}],"archive":"https://web.archive.org/web/20260614080707/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p110030"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","field":"links","label":"FDA PMA P130017"}],"archive":"https://web.archive.org/web/20260908230830/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p130017"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/","field":"links","label":"FDA PMA P140020"}],"archive":"https://web.archive.org/web/20260508082645/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140020"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/","field":"links","label":"FDA PMA P150013"}],"archive":"https://web.archive.org/web/20260310004431/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"FDA PMA P150044: cobas EGFR Mutation Test v2 (tissue and plasma)"},{"id":"cobas-egfr-mutation-test","kind":"drug","name":"cobas EGFR Mutation Test v2","route":"/drugs/cobas-egfr-mutation-test/","field":"links","label":"FDA PMA P150044"}],"archive":"https://web.archive.org/web/20251219073237/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/","field":"links","label":"FDA PMA P160002"}],"archive":"https://web.archive.org/web/20260516154048/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncomine-dx-target-test","kind":"drug","name":"Oncomine Dx Target Test","route":"/drugs/oncomine-dx-target-test/","field":"links","label":"FDA PMA P160045"}],"archive":"https://web.archive.org/web/20260313231918/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160046","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ventana-pd-l1-sp263","kind":"drug","name":"VENTANA PD-L1 (SP263) Assay","route":"/drugs/ventana-pd-l1-sp263/","field":"links","label":"FDA PMA P160046"}],"archive":"https://web.archive.org/web/20260207224134/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160046"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"links","label":"FDA premarket approval P170019: FoundationOne CDx"}],"archive":"https://web.archive.org/web/20260616100436/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P170019"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190014","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/","field":"links","label":"FDA PMA P190014"}],"archive":"https://web.archive.org/web/20260509135200/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190014"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"FDA PMA P190032: FoundationOne Liquid CDx, approved 26 August 2020"}],"archive":"https://web.archive.org/web/20260520010056/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190032"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"FDA PMA P200010: Guardant360 CDx, approved 7 August 2020"},{"id":"guardant360-cdx","kind":"drug","name":"Guardant360 CDx","route":"/drugs/guardant360-cdx/","field":"links","label":"FDA PMA P200010"}],"archive":"https://web.archive.org/web/20260828235648/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200010"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230009","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"links","label":"FDA premarket approval P230009: Shield blood-based colorectal cancer screening test"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"FDA PMA P230009: Shield blood-based colorectal cancer screening test, approved 26 July 2024"},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","field":"links","label":"FDA PMA P230009"}],"archive":"https://web.archive.org/web/20260617045529/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230009"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"her2-testing-assays","kind":"drug","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","route":"/drugs/her2-testing-assays/","field":"links","label":"FDA PMA P980018"}],"archive":"https://web.archive.org/web/20260308082928/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN170080","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/","field":"links","label":"FDA De Novo DEN170080"}],"archive":"https://web.archive.org/web/20260510055334/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN170080"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN200080","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paige-prostate","kind":"drug","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/","field":"links","label":"FDA De Novo DEN200080"}],"archive":"https://web.archive.org/web/20260613160223/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN200080"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K130010","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/","field":"links","label":"FDA 510(k) K130010"}],"archive":"https://web.archive.org/web/20260606232243/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K130010"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radiotherapy-equipment-manufacturing","kind":"technology","name":"Linac, proton system and brachytherapy machine manufacturing","route":"/technologies/radiotherapy-equipment-manufacturing/","field":"links","label":"FDA medical device recalls database"},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"FDA medical device recalls database"}],"archive":"https://web.archive.org/web/20260830062434/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm"},{"url":"https://www.accessdata.fda.gov/scripts/drugshortages/","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","field":"links","label":"FDA drug shortages database"}]},{"url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=c","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","field":"links","label":"FDA drug shortages: carboplatin injection"}],"archive":"https://web.archive.org/web/20260308104654/https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=c"},{"url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cisplatin%20Injection&st=c","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","field":"links","label":"FDA drug shortages: cisplatin injection"}],"archive":"https://web.archive.org/web/20260923054410/https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cisplatin%20Injection&st=c"},{"url":"https://www.are.com/venture-investments","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","field":"links","label":"Official website"},{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","field":"website"}],"archive":"https://web.archive.org/web/20260916051521/https://www.are.com/venture-investments"},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/cam-topics-pdq","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"reiki-energy-therapies","kind":"technology","name":"Reiki, healing touch and other energy therapies","route":"/technologies/reiki-energy-therapies/","field":"links","label":"NCI PDQ: Integrative, alternative and complementary therapies overview"}],"archive":"https://web.archive.org/web/20190409135759/https://www.cancer.gov/about-cancer/treatment/cam/hp/cam-topics-pdq"},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/hoxsey-pdq","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"essiac-herbal-cancer-cures","kind":"technology","name":"Essiac, Hoxsey and other 'herbal cancer cures'","route":"/technologies/essiac-herbal-cancer-cures/","field":"links","label":"NCI PDQ: Hoxsey herbal treatment"}],"archiveRequested":false},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/hydrazinesulfate-pdq","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hydrazine-sulfate","kind":"technology","name":"Hydrazine sulfate","route":"/technologies/hydrazine-sulfate/","field":"links","label":"NCI PDQ: Hydrazine sulfate"}],"archiveRequested":false},{"url":"https://www.cancer.gov/types/brain/patient/child-medulloblastoma-treatment-pdq","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","field":"links","label":"NCI PDQ: childhood medulloblastoma"}],"archiveRequested":false},{"url":"https://www.cancer.gov/types/myeloproliferative/patient/mds-mpn-treatment-pdq","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"links","label":"NCI PDQ: myelodysplastic/myeloproliferative neoplasms"}],"archiveRequested":false},{"url":"https://www.chumontreal.qc.ca/sites/default/files/2026-07/Organigramme%20exe%CC%81cutif.pdf","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","softPdf404":true,"checked":"2026-09-30","refs":[{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","route":"/people/marie-eve-desrosiers/","field":"links","label":"Source: CHUM executive organisation chart (July 2026, PDF)"}],"archiveRequested":false},{"url":"https://www.clatterbridgecc.nhs.uk/about-us/our-board","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","field":"profiles","label":"Trust board page"}],"archiveRequested":false},{"url":"https://www.elekta.com/products/oncology-informatics/mosaiq/","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncology-information-systems","kind":"technology","name":"Oncology information and record-and-verify systems (ARIA, MOSAIQ)","route":"/technologies/oncology-information-systems/","field":"links","label":"Elekta: MOSAIQ"}],"archiveRequested":false},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2021-05-05)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2025-03-19)"}],"archive":"https://web.archive.org/web/20260316052018/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer"},{"url":"https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-cooling-cap-reduce-hair-loss-during-chemotherapy","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dignitana","kind":"company","name":"Dignitana","route":"/companies/dignitana/","field":"links","label":"FDA allows marketing of cooling cap to reduce hair loss during chemotherapy (2015)"}],"archiveRequested":false},{"url":"https://www.hologic.com/hologic-products/breast-health-solutions/i-view-contrast-enhanced-imaging","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/","field":"links","label":"Hologic: I-View contrast enhanced imaging"}],"archiveRequested":false},{"url":"https://www.igeamedical.com/en/oncology","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"electrochemotherapy-devices","kind":"technology","name":"Electrochemotherapy devices (Cliniporator)","route":"/technologies/electrochemotherapy-devices/","field":"links","label":"IGEA: Cliniporator electrochemotherapy"}],"archiveRequested":false},{"url":"https://www.institutgodinot.fr/fr/","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"links","label":"Institut Godinot website"},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"profiles","label":"Institut Godinot website"}],"archive":"https://web.archive.org/web/20260120101718/https://www.institutgodinot.fr/fr/"},{"url":"https://www.ispytrials.org/i-spy-platform/i-spy1","status":404,"ok":false,"finalUrl":"https://www.quantumleaphealth.org/for-patients/i-spy-trials//i-spy-platform/i-spy1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","field":"links","label":"I-SPY Trials: I-SPY 1"}],"archiveRequested":false},{"url":"https://www.ispytrials.org/i-spy-platform/i-spy2-2","status":404,"ok":false,"finalUrl":"https://www.quantumleaphealth.org/for-patients/i-spy-trials//i-spy-platform/i-spy2-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/","field":"links","label":"I-SPY Trials: I-SPY 2.2"}],"archiveRequested":false},{"url":"https://www.kentandmedway.icb.nhs.uk/your-health/local-services/kent-and-medway-cancer-alliance","status":404,"ok":false,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","route":"/institutions/kent-medway-cancer-alliance/","field":"links","label":"Kent and Medway Cancer Alliance"},{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","route":"/institutions/kent-medway-cancer-alliance/","field":"website"}],"archive":"https://web.archive.org/web/20250206115557/https://www.kentandmedway.icb.nhs.uk/your-health/local-services/kent-and-medway-cancer-alliance"},{"url":"https://www.medicaid.gov/federal-policy-guidance/downloads/cib122921.pdf","status":404,"ok":false,"contentType":"text/html","softPdf404":true,"checked":"2026-09-30","refs":[{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","route":"/ideas/idea-cost-trial-enrolment-cost-lever/","field":"links","label":"Medicaid.gov: coverage of routine patient costs in clinical trials (Clinical Treatment Act)"}],"archiveRequested":false},{"url":"https://www.medrxiv.org/about-medrxiv","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","field":"links","label":"About medRxiv"}],"archive":"https://web.archive.org/web/20260911215803/https://www.medrxiv.org/about-medrxiv"},{"url":"https://www.mpnresearchfoundation.org/essential-thrombocythemia/","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","field":"links","label":"MPN Research Foundation"}],"archive":"https://web.archive.org/web/20210418205735/http://www.mpnresearchfoundation.org/Essential-Thrombocythemia"},{"url":"https://www.mpnresearchfoundation.org/polycythemia-vera/","status":404,"ok":false,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","field":"links","label":"MPN Research Foundation"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/american-ginseng","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","field":"links","label":"MSK About Herbs: American ginseng"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/fenbendazole","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/","field":"links","label":"MSK About Herbs: Fenbendazole"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/mistletoe","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","field":"links","label":"MSK About Herbs: Mistletoe"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/search","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"traditional-chinese-herbal-medicine","kind":"technology","name":"Traditional Chinese herbal medicine alongside treatment","route":"/technologies/traditional-chinese-herbal-medicine/","field":"links","label":"MSK About Herbs: About Herbs database home"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/st-johns-wort","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/","field":"links","label":"MSK About Herbs: St. John's wort"}],"archiveRequested":false},{"url":"https://www.shi.co.jp/english/products/medical/bnct/","status":404,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","field":"links","label":"Sumitomo Heavy Industries: BNCT system NeuCure"}],"archiveRequested":false},{"url":"https://www.siemens-healthineers.com/computed-tomography/photon-counting-ct","status":404,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/","field":"links","label":"Siemens Healthineers: NAEOTOM Alpha photon-counting CT"}],"archiveRequested":false},{"url":"https://www.uclh.nhs.uk/about-us/who-we-are/our-board","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-probert","kind":"person","name":"David Probert","route":"/people/david-probert/","field":"links","label":"Institution profile"},{"id":"david-probert","kind":"person","name":"David Probert","route":"/people/david-probert/","field":"profiles","label":"Institution profile"}],"archiveRequested":true},{"url":"https://www.uclh.nhs.uk/our-services/find-service/cancer-services/proton-beam-therapy","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","field":"links","label":"Proton beam therapy"}],"archiveRequested":false},{"url":"https://www.varian.com/products/software/information-systems/aria-ois-radiation-oncology","status":404,"ok":false,"finalUrl":"https://cancercare.siemens-healthineers.com/products/software/information-systems/aria-ois-radiation-oncology","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncology-information-systems","kind":"technology","name":"Oncology information and record-and-verify systems (ARIA, MOSAIQ)","route":"/technologies/oncology-information-systems/","field":"links","label":"Varian: ARIA oncology information system"}],"archiveRequested":false},{"url":"https://www.visionrt.com/product/alignrt/","status":404,"ok":false,"finalUrl":"https://visionrt.com/product/alignrt/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patient-positioning-surface-guidance-systems","kind":"technology","name":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","route":"/technologies/patient-positioning-surface-guidance-systems/","field":"links","label":"Vision RT: AlignRT"}],"archive":"https://web.archive.org/web/20191215113319/https://www.visionrt.com/product/alignrt/"},{"url":"https://www.weizmann.ac.il/Biological_Regulation/Yarden/","status":404,"ok":false,"finalUrl":"https://www.weizmann.ac.il/dept/irb/Yarden/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/","field":"links","label":"Yarden laboratory, Weizmann Institute"},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/","field":"profiles","label":"Yarden laboratory, Weizmann Institute"}],"archiveRequested":false},{"url":"https://www.weizmann.ac.il/mcb/oren/","status":404,"ok":false,"finalUrl":"https://www.weizmann.ac.il/mcb/oren","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/","field":"links","label":"Oren laboratory, Weizmann Institute"},{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/","field":"profiles","label":"Oren laboratory, Weizmann Institute"}],"archiveRequested":false},{"url":"https://www.weizmann.ac.il/molgen/Samuels/","status":404,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/","field":"links","label":"Samuels laboratory, Weizmann Institute"},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/","field":"profiles","label":"Samuels laboratory, Weizmann Institute"}],"archiveRequested":false},{"url":"https://doi.org/10.3310/HTNB6908","status":405,"ok":false,"finalUrl":"https://www.journalslibrary.nihr.ac.uk/eme/HTNB6908","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"links","label":"Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT, Efficacy and Mechanism Evaluation 2022"}]},{"url":"https://www.jla.nihr.ac.uk/","status":405,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-unanswered-questions-registry","kind":"idea","name":"A public registry of unanswered clinical questions linked to funding calls","route":"/ideas/idea-data-unanswered-questions-registry/","field":"links","label":"James Lind Alliance"}]},{"url":"https://www.nihr.ac.uk/","status":405,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-public-de-escalation-trial-fund","kind":"idea","name":"A public fund for trials that test less treatment","route":"/ideas/idea-tr1-public-de-escalation-trial-fund/","field":"links","label":"NIHR"}]},{"url":"https://doi.org/10.7554/elife.00747","status":406,"ok":false,"finalUrl":"https://elifesciences.org/articles/00747","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bozic-elife","kind":"paper","name":"Evolutionary dynamics of cancer in response to targeted combination therapy","route":"/key-papers/paper-bozic-elife/","field":"links","label":"Elife 2013"}]},{"url":"https://doi.org/10.7554/eLife.00747","status":406,"ok":false,"finalUrl":"https://elifesciences.org/articles/00747","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drug-resistance-dynamics","kind":"technology","name":"Evolutionary dynamics of drug resistance","route":"/technologies/drug-resistance-dynamics/","field":"links","label":"Bozic and colleagues 2013, eLife"}]},{"url":"https://doi.org/10.7554/eLife.67995","status":406,"ok":false,"finalUrl":"https://elifesciences.org/articles/67995","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/","field":"links","label":"Companion paper: challenges for assessing replicability"}]},{"url":"https://doi.org/10.7554/eLife.71601","status":406,"ok":false,"finalUrl":"https://elifesciences.org/articles/71601","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"links","label":"Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"metrics (Median reduction in effect size in replications vs original experiments (Reproducibility Project: Cancer Biology))"},{"id":"idea-tr2-replication-before-ind","kind":"idea","name":"Independent replication of the key experiment before first-in-human academic trials","route":"/ideas/idea-tr2-replication-before-ind/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-replication-bounties","kind":"idea","name":"Bounties for documented failed replications of high-impact findings","route":"/ideas/idea-tr2-replication-bounties/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-timestamped-eln","kind":"idea","name":"Time-stamped electronic lab notebooks submitted with the paper","route":"/ideas/idea-tr2-timestamped-eln/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-data-link-enforcement","kind":"idea","name":"Journals check that data links actually work, and flag papers whose data vanish","route":"/ideas/idea-tr2-data-link-enforcement/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-paid-statistical-review","kind":"idea","name":"Paid independent statistical review for preclinical papers that inform trials","route":"/ideas/idea-tr2-paid-statistical-review/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-two-lab-rule","kind":"idea","name":"Top journals require an independent lab to reproduce key findings before publication","route":"/ideas/idea-tr2-two-lab-rule/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-reagent-lot-ledger","kind":"idea","name":"Barcode every reagent lot so batch effects can be traced across experiments and labs","route":"/ideas/idea-tr2-reagent-lot-ledger/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-tr2-phd-replication-year","kind":"idea","name":"Every cancer biology PhD begins with a funded replication of a published finding","route":"/ideas/idea-tr2-phd-replication-year/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"idea-moon-independent-replication-institute","kind":"idea","name":"An independent replication institute that re-tests key preclinical cancer findings before trials","route":"/ideas/idea-moon-independent-replication-institute/","field":"links","label":"Bottleneck evidence (Preclinical results do not reproduce): Errington et al., Investigating the replicability of preclinical cancer biology (eLife 2021)"},{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/","field":"links","label":"DOI"}]},{"url":"https://elifesciences.org","status":406,"ok":false,"finalUrl":"https://elifesciences.org/","checked":"2026-09-30","refs":[{"id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","field":"url"}]},{"url":"https://elifesciences.org/about/peer-review","status":406,"ok":false,"checked":"2026-09-30","refs":[{"id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","field":"links","label":"eLife publishing model"}]},{"url":"https://www.uicc.org/what-we-do/thematic-areas/access-oncology-medicines-atom-coalition","status":406,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","field":"links","label":"UICC ATOM Coalition"}]},{"url":"https://www.uicc.org/who-we-are/our-team","status":406,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cary-adams","kind":"person","name":"Cary Adams","route":"/people/cary-adams/","field":"links","label":"Source: UICC team page"}]},{"url":"http://www.merrimackpharma.com","status":409,"ok":false,"finalUrl":"http://www.merrimackpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","field":"links","label":"Official website"},{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","field":"website"}]},{"url":"https://doi.org/10.1101/2022.05.29.493900","status":429,"ok":false,"finalUrl":"https://www.biorxiv.org/lookup/doi/10.1101/2022.05.29.493900","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","field":"links","label":"Almogy et al., Cost-efficient whole-genome sequencing using mostly natural sequencing-by-synthesis chemistry (Ultima Genomics, bioRxiv 2022)"},{"id":"paper-almogy-biorxiv","kind":"paper","name":"Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform","route":"/key-papers/paper-almogy-biorxiv/","field":"links","label":"bioRxiv 2022"}]},{"url":"https://doi.org/10.1101/gr.074492.107","status":429,"ok":false,"finalUrl":"http://genome.cshlp.org/lookup/doi/10.1101/gr.074492.107","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"papers","label":"Velvet: algorithms for de novo short read assembly using de Bruijn graphs"}]},{"url":"https://doi.org/10.1101/gr.126573.111","status":429,"ok":false,"finalUrl":"http://genome.cshlp.org/lookup/doi/10.1101/gr.126573.111","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"papers","label":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma"}]},{"url":"https://healthynv.org","status":429,"ok":false,"finalUrl":"https://www.renown.org/Health-Services/Genomic-Medicine-and-Genetics/renowns-healthy-nevada-project","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-prev-population-germline-screening-at-30","kind":"idea","name":"Offer everyone at 30 a test for the cancer genes that matter","route":"/ideas/idea-prev-population-germline-screening-at-30/","field":"links","label":"Healthy Nevada Project"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MagnetisMM-3%20elranatamab%20Lesokhin%20Nature%20Medicine%202023","status":429,"ok":false,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/37582952/","contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1%20afamitresgene%20autoleucel%20synovial%20sarcoma%20D'Angelo%20Lancet%202024","status":429,"ok":false,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/38554725/","contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRANSFORM%20lisocabtagene%20maraleucel%20second-line%20Kamdar%20Lancet%202022","status":429,"ok":false,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/35717989/","contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10676951/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alizadeh-nature","kind":"paper","name":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","route":"/key-papers/paper-alizadeh-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10888934/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11063134/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-swanson-cell-prolif","kind":"paper","name":"A quantitative model for differential motility of gliomas in grey and white matter","route":"/key-papers/paper-swanson-cell-prolif/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11342768/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hruban-panin-nomenclature-ajsp-2001","kind":"paper","name":"Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions","route":"/key-papers/paper-hruban-panin-nomenclature-ajsp-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12944571/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-swog-8710-neoadjuvant-mvac-nejm-2003","kind":"paper","name":"SWOG 8710: neoadjuvant MVAC chemotherapy before cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/13298683/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-warburg-science","kind":"paper","name":"On the origin of cancer cells","route":"/key-papers/paper-warburg-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1384374/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992","kind":"paper","name":"Klimstra 1992: acinar cell carcinoma of the pancreas, a clinicopathologic study of 28 cases","route":"/key-papers/paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14506150/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","field":"prevalence.source"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15256806/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004","kind":"paper","name":"Dhebri 2004: diagnosis, treatment and outcome of pancreatoblastoma","route":"/key-papers/paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15470214/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","kind":"paper","name":"SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","route":"/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15601557/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-xia-h101-head-neck-aizheng-2004","kind":"paper","name":"Xia 2004: the randomised trial behind China's approval of the oncolytic adenovirus H101","route":"/key-papers/paper-xia-h101-head-neck-aizheng-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15719031/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ren-nat-rev-cancer","kind":"paper","name":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","route":"/key-papers/paper-ren-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15858187/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kralovics-n-engl-j-med","kind":"paper","name":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","route":"/key-papers/paper-kralovics-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15947100/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-relat-cancer-2005","kind":"paper","name":"BRAF mutation in thyroid cancer","route":"/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16254181/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tomlins-tmprss2-ets-fusion-science-2005","kind":"paper","name":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","route":"/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16325696/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-lancet-2005","kind":"paper","name":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","route":"/key-papers/paper-jak2-polycythaemia-vera-lancet-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16369569/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet-2006","kind":"paper","name":"The epigenetic progenitor origin of human cancer","route":"/key-papers/paper-feinberg-nat-rev-genet-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16442208/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sylvester-eortc-risk-tables-eur-urol-2006","kind":"paper","name":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","route":"/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16724345/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roa-gallbladder-preneoplastic-lesions-jso-2006","kind":"paper","name":"Preneoplastic lesions in gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-preneoplastic-lesions-jso-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16804544/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006","kind":"paper","name":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","route":"/key-papers/paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16883312/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-huang-bone-marrow-transplant","kind":"paper","name":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","route":"/key-papers/paper-huang-bone-marrow-transplant/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1707140/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-catalona-psa-screening-test-nejm-1991","kind":"paper","name":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","route":"/key-papers/paper-catalona-psa-screening-test-nejm-1991/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17097848/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-goonetilleke-ca19-9-systematic-review-ejso-2007","kind":"paper","name":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","route":"/key-papers/paper-goonetilleke-ca19-9-systematic-review-ejso-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17189716/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-weaver-cancer-cell","kind":"paper","name":"Aneuploidy acts both oncogenically and as a tumor suppressor","route":"/key-papers/paper-weaver-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17299401/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kelly-russell-oncolytic-history-moltherapy-2007","kind":"paper","name":"Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping","route":"/key-papers/paper-kelly-russell-oncolytic-history-moltherapy-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17721432/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007","kind":"paper","name":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","route":"/key-papers/paper-jak2-polycythaemia-vera-nat-rev-cancer-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17846848/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007","kind":"paper","name":"Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection","route":"/key-papers/paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17875873/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"links","label":"Five-year follow-up on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17984186/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hillmen-j-clin-oncol","kind":"paper","name":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","route":"/key-papers/paper-hillmen-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18032762/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007","kind":"paper","name":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18089652/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-boveri-j-cell-sci","kind":"paper","name":"Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris","route":"/key-papers/paper-boveri-j-cell-sci/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18249033/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008","kind":"paper","name":"CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial","route":"/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1851332/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-martuza-engineered-hsv-glioma-science-1991","kind":"paper","name":"Martuza 1991: the first genetically engineered virus built to treat a cancer","route":"/key-papers/paper-martuza-engineered-hsv-glioma-science-1991/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18548043/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18656619/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008","kind":"paper","name":"Wisnoski 2008: 672 patients with acinar cell carcinoma of the pancreas, a population-based comparison to pancreatic adenocarcinoma","route":"/key-papers/paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18693158/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"mal-pdt-versus-cryotherapy-superficial-bcc","kind":"trial","name":"Photodynamic therapy against cryotherapy for superficial basal cell carcinoma","route":"/trials/mal-pdt-versus-cryotherapy-superficial-bcc/","field":"links","label":"Basset-Seguin et al., five-year randomised comparison (European Journal of Dermatology 2008; its digital object identifier 10.1684/ejd.2008.0472 does not resolve, so this is the working address)"},{"id":"mal-pdt-versus-cryotherapy-superficial-bcc","kind":"trial","name":"Photodynamic therapy against cryotherapy for superficial basal cell carcinoma","route":"/trials/mal-pdt-versus-cryotherapy-superficial-bcc/","field":"outcomes.source (Lesion recurrence at 5 years)"},{"id":"mal-pdt-versus-cryotherapy-superficial-bcc","kind":"trial","name":"Photodynamic therapy against cryotherapy for superficial basal cell carcinoma","route":"/trials/mal-pdt-versus-cryotherapy-superficial-bcc/","field":"outcomes.source (Excellent cosmetic outcome)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18772397/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jones-pancreatic-core-pathways-science-2008","kind":"paper","name":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","route":"/key-papers/paper-jones-pancreatic-core-pathways-science-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19098912/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009","kind":"paper","name":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1","route":"/key-papers/paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19165197/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009","kind":"paper","name":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","route":"/key-papers/paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19230772/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aza-001-fenaux-lancet-oncol-2009","kind":"paper","name":"AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes","route":"/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19273710/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009","kind":"paper","name":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","route":"/key-papers/paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19297566/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-schroder-erspc-screening-mortality-nejm-2009","kind":"paper","name":"ERSPC: screening and prostate cancer mortality in a randomised European study","route":"/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19460966/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009","kind":"paper","name":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","route":"/key-papers/paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19460998/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-vander-heiden-science","kind":"paper","name":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","route":"/key-papers/paper-vander-heiden-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19826129/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-heng-j-clin-oncol","kind":"paper","name":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","route":"/key-papers/paper-heng-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20023215/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sparano-blood","kind":"paper","name":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-sparano-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20026804/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-azacitidine-aml-j-clin-oncol-2010","kind":"paper","name":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","route":"/key-papers/paper-azacitidine-aml-j-clin-oncol-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20181022/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-seyfried-nutr-metab-lond","kind":"paper","name":"Cancer as a metabolic disease","route":"/key-papers/paper-seyfried-nutr-metab-lond/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20413742/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-welch-j-natl-cancer-inst","kind":"paper","name":"Overdiagnosis in cancer","route":"/key-papers/paper-welch-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20428194/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","kind":"paper","name":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","route":"/key-papers/paper-jak2-myeloproliferative-neoplasms-leukemia-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20579941/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","kind":"paper","name":"Integrative genomic profiling of human prostate cancer","route":"/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20601955/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-barretina-nat-genet","kind":"paper","name":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","route":"/key-papers/paper-barretina-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20842054/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-royal-ipilimumab-pancreatic-j-immunother-2010","kind":"paper","name":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","route":"/key-papers/paper-royal-ipilimumab-pancreatic-j-immunother-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20888992/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20981102/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010","kind":"paper","name":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","route":"/key-papers/paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21215367/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stephens-cell","kind":"paper","name":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","route":"/key-papers/paper-stephens-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21296615/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21460848/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-collisson-pancreatic-subtypes-nat-med-2011","kind":"paper","name":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","route":"/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21575859/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011","kind":"paper","name":"Reciprocal feedback regulation of PI3K and androgen receptor signalling in PTEN-deficient prostate cancer","route":"/key-papers/paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21576633/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-j-clin-oncol-2011","kind":"paper","name":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","route":"/key-papers/paper-blinatumomab-all-leukemia-j-clin-oncol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21663470/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tiacci-n-engl-j-med","kind":"paper","name":"BRAF mutations in hairy-cell leukemia","route":"/key-papers/paper-tiacci-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21696948/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011","kind":"paper","name":"Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)","route":"/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21709185/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-crane-smad4-progression-pattern-locally-advanced-jco-2011","kind":"paper","name":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression","route":"/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21775669/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wu-gnas-ipmn-sci-transl-med-2011","kind":"paper","name":"Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development","route":"/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21868284/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-senft-lancet-oncol","kind":"paper","name":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","route":"/key-papers/paper-senft-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22003072/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22033323/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22057348/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22158988/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011","kind":"paper","name":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways","route":"/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22173060/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-trappe-lancet-oncol","kind":"paper","name":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","route":"/key-papers/paper-trappe-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22179294/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-morris-j-r-soc-med","kind":"paper","name":"The answer is 17 years, what is the question: understanding time lags in translational research","route":"/key-papers/paper-morris-j-r-soc-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22226782/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kanda-panin-1-somatic-mutations-gastroenterology-2012","kind":"paper","name":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","route":"/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22389870/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-beltran-nepc-aurka-mycn-cancer-discov-2011","kind":"paper","name":"Molecular characterisation of neuroendocrine prostate cancer and identification of new drug targets","route":"/key-papers/paper-beltran-nepc-aurka-mycn-cancer-discov-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22610119/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012","kind":"paper","name":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","route":"/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22658128/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brahmer-anti-pd-l1-phase-1-nejm-2012","kind":"paper","name":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","route":"/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22722839/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22736790/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012","kind":"paper","name":"The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis","route":"/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22781695/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","kind":"paper","name":"Russell, Peng and Bell 2012: the field states its own problems","route":"/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22801674/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-moyer-uspstf-prostate-screening-ann-intern-med-2012","kind":"paper","name":"USPSTF 2012: screening for prostate cancer, recommendation statement (grade D)","route":"/key-papers/paper-moyer-uspstf-prostate-screening-ann-intern-med-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22810696/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22877848/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-malmstrom-lancet-oncol","kind":"paper","name":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","route":"/key-papers/paper-malmstrom-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22895193/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-seshagiri-rspo-fusions-colon-nature-2012","kind":"paper","name":"Recurrent R-spondin fusions in colon cancer","route":"/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22895264/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-adsay-icpn-gallbladder-ajsp-2012","kind":"paper","name":"Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are at least 1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases","route":"/key-papers/paper-adsay-icpn-gallbladder-ajsp-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22932871/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stylianopoulos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","route":"/key-papers/paper-stylianopoulos-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23026929/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012","kind":"paper","name":"La Rosa 2012: clinicopathologic study of 62 acinar cell carcinomas of the pancreas","route":"/key-papers/paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23073952/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-moreira-lynch-syndrome-identification-jama-2012","kind":"paper","name":"Identification of Lynch syndrome among patients with colorectal cancer","route":"/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23103869/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-biankin-pancreatic-exomes-axon-guidance-nature-2012","kind":"paper","name":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","route":"/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23117178/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-independent-uk-panel-on-breast-cancer-lancet","kind":"paper","name":"The benefits and harms of breast cancer screening: an independent review","route":"/key-papers/paper-independent-uk-panel-on-breast-cancer-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23153379/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sun-bmc-cancer","kind":"paper","name":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials","route":"/key-papers/paper-sun-bmc-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23192950/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hesseling-pediatr-blood-cancer","kind":"paper","name":"Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting","route":"/key-papers/paper-hesseling-pediatr-blood-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23263490/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-palles-germline-pole-pold1-proofreading-nat-genet-2013","kind":"paper","name":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","route":"/key-papers/paper-palles-germline-pole-pold1-proofreading-nat-genet-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23433739/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rummel-lancet","kind":"paper","name":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","route":"/key-papers/paper-rummel-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23550669/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013","kind":"paper","name":"SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer","route":"/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23569316/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-castro-germline-brca-prostate-outcomes-jco-2013","kind":"paper","name":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer","route":"/key-papers/paper-castro-germline-brca-prostate-outcomes-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23622249/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-baca-punctuated-evolution-chromoplexy-cell-2013","kind":"paper","name":"Punctuated evolution of prostate cancer genomes","route":"/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23690483/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-besser-til-melanoma-intent-to-treat-ccr-2013","kind":"paper","name":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","route":"/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23841729/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-apl0406-lo-coco-nejm-2013","kind":"paper","name":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia","route":"/key-papers/paper-apl0406-lo-coco-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24180494/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pace-ponatinib-nejm-2013","kind":"paper","name":"PACE: ponatinib in Philadelphia chromosome-positive leukaemias resistant to earlier tyrosine kinase inhibitors","route":"/key-papers/paper-pace-ponatinib-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24277834/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","kind":"paper","name":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","route":"/key-papers/paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24332516/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"links","label":"Three-year results on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24413733/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brastianos-nat-genet","kind":"paper","name":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","route":"/key-papers/paper-brastianos-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2442609/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stamey-psa-serum-marker-nejm-1987","kind":"paper","name":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","route":"/key-papers/paper-stamey-psa-serum-marker-nejm-1987/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24439788/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014","kind":"paper","name":"Overdiagnosis and overtreatment of prostate cancer","route":"/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24443733/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yang-j-oncol-pract","kind":"paper","name":"Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage","route":"/key-papers/paper-yang-j-oncol-pract/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24553142/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mack-nature","kind":"paper","name":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy","route":"/key-papers/paper-mack-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24553177/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-treon-blood","kind":"paper","name":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","route":"/key-papers/paper-treon-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24563518/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-shastri-j-natl-cancer-inst","kind":"paper","name":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","route":"/key-papers/paper-shastri-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24705311/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014","kind":"paper","name":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","route":"/key-papers/paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24714131/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-golfier-mol-cancer-ther","kind":"paper","name":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","route":"/key-papers/paper-golfier-mol-cancer-ther/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24799970/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roa-her2-overexpression-gallbladder-gcr-2014","kind":"paper","name":"Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","route":"/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24835528/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-russell-mv-nis-myeloma-mayo-2014","kind":"paper","name":"Russell 2014: a measles virus given into the vein put one patient's myeloma into complete remission","route":"/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24856585/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014","kind":"paper","name":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","route":"/key-papers/paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24881730/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24997986/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25072261/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25075216/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pantziarka-ecancermedicalscience","kind":"paper","name":"The Repurposing Drugs in Oncology (ReDO) Project","route":"/key-papers/paper-pantziarka-ecancermedicalscience/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2513569/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gross-eshhar-chimeric-receptor-pnas-1989","kind":"paper","name":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","route":"/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25139339/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014","kind":"paper","name":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies","route":"/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25184630/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25192939/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gabai-kapara-population-brca-screening-pnas-2014","kind":"paper","name":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","route":"/key-papers/paper-gabai-kapara-population-brca-screening-pnas-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25255306/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014","kind":"paper","name":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","route":"/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25262378/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"links","label":"Ten-year results on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25385737/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25454616/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015","kind":"paper","name":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","route":"/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25482145/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015","kind":"paper","name":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25524800/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-lancet-oncol-2015","kind":"paper","name":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-blinatumomab-all-leukemia-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25601342/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25624439/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-di-maio-j-clin-oncol","kind":"paper","name":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","route":"/key-papers/paper-di-maio-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25760355/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-anderson-n-engl-j-med","kind":"paper","name":"Compliance with results reporting at ClinicalTrials.gov","route":"/key-papers/paper-anderson-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25830880/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015","kind":"paper","name":"The evolutionary history of lethal metastatic prostate cancer","route":"/key-papers/paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25855536/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","kind":"paper","name":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","route":"/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25964250/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-swog-s0809-adjuvant-chemoradiation-jco-2015","kind":"paper","name":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","route":"/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25965575/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pajtler-cancer-cell","kind":"paper","name":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups","route":"/key-papers/paper-pajtler-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25987659/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25999455/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26000489/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26014293/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-andtbacka-optim-talimogene-jco-2015","kind":"paper","name":"OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus","route":"/key-papers/paper-andtbacka-optim-talimogene-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26028255/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26028364/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015","kind":"paper","name":"Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma","route":"/key-papers/paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26130744/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2015","kind":"paper","name":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26154128/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sausen-ctdna-pancreatic-resection-nat-commun-2015","kind":"paper","name":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","route":"/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26195720/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015","kind":"paper","name":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26195756/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rozhok-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations","route":"/key-papers/paper-rozhok-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26211824/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet","kind":"paper","name":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26253305/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015","kind":"paper","name":"A combination of molecular markers and clinical features improve the classification of pancreatic cysts","route":"/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26258846/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nakamura-biliary-genomic-spectra-nat-genet-2015","kind":"paper","name":"Genomic spectra of biliary tract cancer","route":"/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26376137/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dohner-n-engl-j-med","kind":"paper","name":"Acute Myeloid Leukemia","route":"/key-papers/paper-dohner-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26419354/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-atun-lancet-oncol","kind":"paper","name":"Expanding global access to radiotherapy","route":"/key-papers/paper-atun-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26427363/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26510020/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26544944/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26546118/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016","kind":"paper","name":"Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers","route":"/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26559377/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015","kind":"paper","name":"A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas","route":"/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26641137/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-n-engl-j-med-2016","kind":"paper","name":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","route":"/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26652797/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet-oncol","kind":"paper","name":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","route":"/key-papers/paper-sankaranarayanan-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26658419/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016","kind":"paper","name":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","route":"/key-papers/paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26719232/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stampede-lancet-2016","kind":"paper","name":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","route":"/key-papers/paper-stampede-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26755709/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-viardot-blood","kind":"paper","name":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-viardot-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26761625/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-armstrong-n-engl-j-med","kind":"paper","name":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer","route":"/key-papers/paper-armstrong-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26771115/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pavlova-cell-metab","kind":"paper","name":"The Emerging Hallmarks of Cancer Metabolism","route":"/key-papers/paper-pavlova-cell-metab/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26791720/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-massague-nature","kind":"paper","name":"Metastatic colonization by circulating tumour cells","route":"/key-papers/paper-massague-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26906526/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26928463/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","kind":"paper","name":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","route":"/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26972587/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet","kind":"paper","name":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","route":"/key-papers/paper-feinberg-nat-rev-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27010960/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016","kind":"paper","name":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","route":"/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27111235/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27149842/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","kind":"paper","name":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","route":"/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27158978/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27188790/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-weller-nat-rev-dis-primers","kind":"paper","name":"Glioma","route":"/key-papers/paper-weller-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27240885/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27310651/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brown-jama-oncol","kind":"paper","name":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","route":"/key-papers/paper-brown-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27433846/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","kind":"paper","name":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","route":"/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27451390/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27492215/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-altman-nat-rev-cancer","kind":"paper","name":"From Krebs to clinic: glutamine metabolism to cancer therapy","route":"/key-papers/paper-altman-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27622582/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-javle-biliary-ngs-cancer-2016","kind":"paper","name":"Biliary cancer: utility of next-generation sequencing for clinical management","route":"/key-papers/paper-javle-biliary-ngs-cancer-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27686946/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27705267/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016","kind":"paper","name":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27717299/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-niraparib-ovarian-n-engl-j-med-2016","kind":"paper","name":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","route":"/key-papers/paper-niraparib-ovarian-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27732578/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-notta-punctuated-evolution-pancreatic-nature-2016","kind":"paper","name":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","route":"/key-papers/paper-notta-punctuated-evolution-pancreatic-nature-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27768182/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017","kind":"paper","name":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27784058/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","kind":"paper","name":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium","route":"/key-papers/paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27913228/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hirsch-j-thorac-oncol","kind":"paper","name":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","route":"/key-papers/paper-hirsch-j-thorac-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27993964/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017","kind":"paper","name":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","route":"/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28029927/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brown-n-engl-j-med","kind":"paper","name":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","route":"/key-papers/paper-brown-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28052061/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cancer-genome-atlas-research-nature","kind":"paper","name":"Integrated genomic characterization of oesophageal carcinoma","route":"/key-papers/paper-cancer-genome-atlas-research-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28059767/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","kind":"paper","name":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","route":"/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28059768/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28067867/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","kind":"paper","name":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","route":"/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28092682/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017","kind":"paper","name":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","route":"/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28102259/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chen-nature","kind":"paper","name":"Elements of cancer immunity and the cancer-immune set point","route":"/key-papers/paper-chen-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28110982/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ahmed-promis-multiparametric-mri-lancet-2017","kind":"paper","name":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","route":"/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28146658/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rtog-9601-n-engl-j-med-2017","kind":"paper","name":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","route":"/key-papers/paper-rtog-9601-n-engl-j-med-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28209992/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bcl-2-cll-nat-rev-drug-discov-2017","kind":"paper","name":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","route":"/key-papers/paper-bcl-2-cll-nat-rev-drug-discov-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28212060/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-n-engl-j-med-2017","kind":"paper","name":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","route":"/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28232471/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","kind":"paper","name":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","route":"/key-papers/paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28249141/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","kind":"paper","name":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","route":"/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28276433/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28290490/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28302823/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lord-science","kind":"paper","name":"PARP inhibitors: Synthetic lethality in the clinic","route":"/key-papers/paper-lord-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28328302/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","kind":"paper","name":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","route":"/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28343976/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-takahashi-lancet-oncol","kind":"paper","name":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-takahashi-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28436999/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-greenlee-ca-cancer-j-clin","kind":"paper","name":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","route":"/key-papers/paper-greenlee-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28445112/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28450426/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017","kind":"paper","name":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","route":"/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28475456/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28476735/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017","kind":"paper","name":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28492898/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28588020/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-enasidenib-idh2-stein-blood-2017","kind":"paper","name":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-enasidenib-idh2-stein-blood-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28596308/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28642008/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28643779/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dang-nat-rev-cancer","kind":"paper","name":"Drugging the 'undruggable' cancer targets","route":"/key-papers/paper-dang-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28644114/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ratify-midostaurin-nejm-2017","kind":"paper","name":"RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation","route":"/key-papers/paper-ratify-midostaurin-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28700844/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","kind":"paper","name":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","route":"/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28729483/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-flavahan-science","kind":"paper","name":"Epigenetic plasticity and the hallmarks of cancer","route":"/key-papers/paper-flavahan-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28767289/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-shindo-germline-sporadic-pancreatic-jco-2017","kind":"paper","name":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","route":"/key-papers/paper-shindo-germline-sporadic-pancreatic-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28790115/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-guedes-msh2-loss-primary-prostate-ccr-2017","kind":"paper","name":"MSH2 loss in primary prostate cancer","route":"/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28810144/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","kind":"paper","name":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28820644/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-childers-j-clin-oncol","kind":"paper","name":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","route":"/key-papers/paper-childers-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28874546/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017","kind":"paper","name":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","route":"/key-papers/paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28885612/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28886379/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kastenhuber-cell","kind":"paper","name":"Putting p53 in Context","route":"/key-papers/paper-kastenhuber-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28923526/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lichtman-j-pain-symptom-manage","kind":"paper","name":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain","route":"/key-papers/paper-lichtman-j-pain-symptom-manage/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28927585/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","kind":"paper","name":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","route":"/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28967485/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-lancet-oncol-2017","kind":"paper","name":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-pembrolizumab-urothelial-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28978555/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-davis-bmj","kind":"paper","name":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","route":"/key-papers/paper-davis-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29017058/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017","kind":"paper","name":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signalling","route":"/key-papers/paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29032993/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-knaul-lancet","kind":"paper","name":"Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report","route":"/key-papers/paper-knaul-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29045820/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"links","label":"Five-year results on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29098284/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018","kind":"paper","name":"Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma","route":"/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29132146/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","kind":"paper","name":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","route":"/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29160902/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29180633/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-zhang-nat-commun","kind":"paper","name":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","route":"/key-papers/paper-zhang-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29206995/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","kind":"paper","name":"Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer","route":"/key-papers/paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29229594/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","kind":"paper","name":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29245013/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29288237/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aung-compass-early-results-ccr-2018","kind":"paper","name":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","route":"/key-papers/paper-aung-compass-early-results-ccr-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29298865/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018","kind":"paper","name":"Bourgeois-Daigneault 2018: giving the virus before surgery, not after everything else has failed","route":"/key-papers/paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29316426/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","kind":"paper","name":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","route":"/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29348365/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","kind":"paper","name":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","route":"/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29360550/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wardell-biliary-drivers-germline-j-hepatol-2018","kind":"paper","name":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","route":"/key-papers/paper-wardell-biliary-drivers-germline-j-hepatol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29367197/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","kind":"paper","name":"Circulating tumour DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","route":"/key-papers/paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29368341/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018","kind":"paper","name":"Intraductal and ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","route":"/key-papers/paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29394327/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wong-biostatistics","kind":"paper","name":"Estimation of clinical trial success rates and related parameters","route":"/key-papers/paper-wong-biostatistics/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29500184/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018","kind":"paper","name":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives","route":"/key-papers/paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29506128/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","kind":"paper","name":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","route":"/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29510987/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-grasso-immune-evasion-colorectal-cancer-discov-2018","kind":"paper","name":"Genetic mechanisms of immune evasion in colorectal cancer","route":"/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29511601/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-juarez-ivermectin-repositioned-cancer-drug-2018","kind":"paper","name":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","route":"/key-papers/paper-juarez-ivermectin-repositioned-cancer-drug-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29533787/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018","kind":"paper","name":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","route":"/key-papers/paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29537906/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","field":"links","label":"Primary report on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29574408/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018","kind":"paper","name":"European evidence-based guidelines on pancreatic cystic neoplasms (2018)","route":"/key-papers/paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29610475/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","kind":"paper","name":"The long tail of oncogenic drivers in prostate cancer","route":"/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29658845/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-n-engl-j-med-2018","kind":"paper","name":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","route":"/key-papers/paper-checkmate-227-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29710129/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29799911/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-patel-jama-surg","kind":"paper","name":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules","route":"/key-papers/paper-patel-jama-surg/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29801017/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-uspstf-prostate-screening-jama-2018","kind":"paper","name":"USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)","route":"/key-papers/paper-uspstf-prostate-screening-jama-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29802158/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","kind":"paper","name":"Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer","route":"/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29853643/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tiriac-cancer-discov","kind":"paper","name":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","route":"/key-papers/paper-tiriac-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29860938/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ivosidenib-idh1-dinardo-nejm-2018","kind":"paper","name":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-ivosidenib-idh1-dinardo-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29882997/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-neyaz-pdl1-gallbladder-histopathology-2018","kind":"paper","name":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","route":"/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29903880/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","kind":"paper","name":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","route":"/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29924955/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brock-n-engl-j-med","kind":"paper","name":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","route":"/key-papers/paper-brock-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29955787/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018","kind":"paper","name":"Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer","route":"/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29961768/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","kind":"paper","name":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","route":"/key-papers/paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30033370/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-quigley-structural-variation-mcrpc-cell-2018","kind":"paper","name":"Genomic hallmarks and structural variation in metastatic prostate cancer","route":"/key-papers/paper-quigley-structural-variation-mcrpc-cell-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30098152/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alter-0303-jama-oncol-2018","kind":"paper","name":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-alter-0303-jama-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30165049/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018","kind":"paper","name":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","route":"/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30177826/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-makohon-moore-precursor-cells-ductal-system-nature-2018","kind":"paper","name":"Precancerous neoplastic cells can move through the pancreatic ductal system","route":"/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30193109/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bakhoum-cell","kind":"paper","name":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","route":"/key-papers/paper-bakhoum-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30240661/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019","kind":"paper","name":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","route":"/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30280635/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-407-n-engl-j-med-2018","kind":"paper","name":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-407-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30280641/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-impower133-n-engl-j-med-2018","kind":"paper","name":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","route":"/key-papers/paper-impower133-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30280657/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alta-1l-n-engl-j-med-2018","kind":"paper","name":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-alta-1l-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30280658/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pacific-n-engl-j-med-2018-update","kind":"paper","name":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","route":"/key-papers/paper-pacific-n-engl-j-med-2018-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30342036/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-omori-ipmn-progression-pathways-gastroenterology-2019","kind":"paper","name":"Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features","route":"/key-papers/paper-omori-ipmn-progression-pathways-gastroenterology-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30377340/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019","kind":"paper","name":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","route":"/key-papers/paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30427539/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30509763/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-johnson-mpmri-individual-foci-eur-urol-2019","kind":"paper","name":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","route":"/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30522922/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30562839/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kim-t1b-gallbladder-cancer-international-jhbps-2018","kind":"paper","name":"Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study","route":"/key-papers/paper-kim-t1b-gallbladder-cancer-international-jhbps-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30575473/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bill-axelson-spcg-4-29-year-nejm-2018","kind":"paper","name":"SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up","route":"/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30578357/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dudley-cancer-discov","kind":"paper","name":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","route":"/key-papers/paper-dudley-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30582640/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-soreide-incidental-gallbladder-cancer-review-bjs-2019","kind":"paper","name":"Systematic review of management of incidental gallbladder cancer after cholecystectomy","route":"/key-papers/paper-soreide-incidental-gallbladder-cancer-review-bjs-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30589920/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","kind":"paper","name":"Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","route":"/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30629194/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hu-j-natl-cancer-inst","kind":"paper","name":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening","route":"/key-papers/paper-hu-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30730552/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019","kind":"paper","name":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","route":"/key-papers/paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30770291/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30803991/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","route":"/key-papers/paper-eln-apl-sanz-blood-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30836094/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","kind":"paper","name":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","route":"/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30865549/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-prophecy-arv7-validation-jco-2019","kind":"paper","name":"PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer","route":"/key-papers/paper-prophecy-arv7-validation-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30920593/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","kind":"paper","name":"Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial","route":"/key-papers/paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30943124/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-158-j-clin-oncol-2019","kind":"paper","name":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","route":"/key-papers/paper-keynote-158-j-clin-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30955977/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-lancet-2019","kind":"paper","name":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","route":"/key-papers/paper-keynote-042-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30969847/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bohlius-j-clin-oncol","kind":"paper","name":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","route":"/key-papers/paper-bohlius-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30982687/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sabr-comet-lancet-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","route":"/key-papers/paper-sabr-comet-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30987939/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30998813/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gap-phase2-mdacc-jama-oncol-2019","kind":"paper","name":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","route":"/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31018069/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pemmaraju-n-engl-j-med","kind":"paper","name":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","route":"/key-papers/paper-pemmaraju-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31050774/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-haslam-jama-netw-open","kind":"paper","name":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","route":"/key-papers/paper-haslam-jama-netw-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31061129/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","kind":"paper","name":"Genomic correlates of clinical outcome in advanced prostate cancer","route":"/key-papers/paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31120534/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dess-black-race-prostate-mortality-jama-oncol-2019","kind":"paper","name":"Association of Black race with prostate cancer-specific and other-cause mortality","route":"/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31135808/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31142500/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","kind":"paper","name":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","route":"/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31150574/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02489318-n-engl-j-med-2019","kind":"paper","name":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","route":"/key-papers/paper-nct02489318-n-engl-j-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31157964/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-enzamet-n-engl-j-med-2019","kind":"paper","name":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","route":"/key-papers/paper-enzamet-n-engl-j-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31197017/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019","kind":"paper","name":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","route":"/key-papers/paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31218271/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31229240/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tap-lancet","kind":"paper","name":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","route":"/key-papers/paper-tap-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31250894/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","kind":"paper","name":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","route":"/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31253621/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-polcagb-protocol-bmj-open-2019","kind":"paper","name":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol","route":"/key-papers/paper-polcagb-protocol-bmj-open-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31286228/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-zadik-support-care-cancer","kind":"paper","name":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","route":"/key-papers/paper-zadik-support-care-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31302234/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31318392/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","kind":"paper","name":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","route":"/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31329516/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-arches-j-clin-oncol-2019","kind":"paper","name":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","route":"/key-papers/paper-arches-j-clin-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31361600/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-labrecque-mcrpc-phenotypes-jci-2019","kind":"paper","name":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-labrecque-mcrpc-phenotypes-jci-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31378662/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31392046/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-weinberg-biliary-profiling-jgo-2019","kind":"paper","name":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","route":"/key-papers/paper-weinberg-biliary-profiling-jgo-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31397113/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31415071/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-loree-jama-oncol","kind":"paper","name":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","route":"/key-papers/paper-loree-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31519967/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019","kind":"paper","name":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","route":"/key-papers/paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31540791/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31591063/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31605106/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019","kind":"paper","name":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","route":"/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31666715/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roumenina-nat-rev-cancer","kind":"paper","name":"Context-dependent roles of complement in cancer","route":"/key-papers/paper-roumenina-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31672865/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jaiswal-science","kind":"paper","name":"Clonal hematopoiesis in human aging and disease","route":"/key-papers/paper-jaiswal-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31741109/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020","kind":"paper","name":"Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease","route":"/key-papers/paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31754050/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020","kind":"paper","name":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","route":"/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31774688/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-antonarakis-keynote-199-pembrolizumab-jco-2020","kind":"paper","name":"KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31812554/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31874108/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020","kind":"paper","name":"Genomics of lethal prostate cancer at diagnosis and castration resistance","route":"/key-papers/paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31932696/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020","kind":"paper","name":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","route":"/key-papers/paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31976786/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020","kind":"paper","name":"O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation","route":"/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31996850/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yoshida-nature","kind":"paper","name":"Tobacco smoking and somatic mutations in human bronchial epithelium","route":"/key-papers/paper-yoshida-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32014447/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-cytotherapy-2020","kind":"paper","name":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","route":"/key-papers/paper-cd19-dlbcl-cytotherapy-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32025003/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cortes-ciriano-nat-genet","kind":"paper","name":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","route":"/key-papers/paper-cortes-ciriano-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32027343/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-molinaro-jama-oncol","kind":"paper","name":"Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma","route":"/key-papers/paper-molinaro-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32042067/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-laconi-br-j-cancer","kind":"paper","name":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","route":"/key-papers/paper-laconi-br-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32055000/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32059704/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gain-trial-protocol-bmc-cancer-2020","kind":"paper","name":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial","route":"/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32127639/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-eln-2020-cml-hochhaus-leukemia-2020","kind":"paper","name":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","route":"/key-papers/paper-eln-2020-cml-hochhaus-leukemia-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32156747/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-okane-gata6-basal-like-compass-ccr-2020","kind":"paper","name":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","route":"/key-papers/paper-okane-gata6-basal-like-compass-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32213105/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hassan-j-clin-oncol","kind":"paper","name":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","route":"/key-papers/paper-hassan-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32220891/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020","kind":"paper","name":"Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32350089/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021","kind":"paper","name":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","route":"/key-papers/paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32359489/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32376951/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yamamoto-nature","kind":"paper","name":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","route":"/key-papers/paper-yamamoto-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32398706/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020","kind":"paper","name":"The tumour microenvironment in pancreatic cancer: clinical challenges and opportunities","route":"/key-papers/paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32400117/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-patil-mebendazole-glioma-phase-1-cancer-med-2020","kind":"paper","name":"Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma","route":"/key-papers/paper-patil-mebendazole-glioma-phase-1-cancer-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32418886/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alex-ann-oncol-2020-update","kind":"paper","name":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","route":"/key-papers/paper-alex-ann-oncol-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32423156/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020","kind":"paper","name":"Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis","route":"/key-papers/paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32437507/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-reardon-jama-oncol","kind":"paper","name":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-reardon-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32444418/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-park-hrd-pancreatic-platinum-ccr-2020","kind":"paper","name":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","route":"/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32534647/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32580883/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-murray-brunt-lancet","kind":"paper","name":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-murray-brunt-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32582924/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32701411/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32731259/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tam-blood","kind":"paper","name":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study","route":"/key-papers/paper-tam-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32738955/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fitzgerald-lancet","kind":"paper","name":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial","route":"/key-papers/paper-fitzgerald-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32781263/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32786044/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-elad-cancer","kind":"paper","name":"MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","route":"/key-papers/paper-elad-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32795228/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32796935/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-noe-cyst-malignant-progression-genomics-nat-commun-2020","kind":"paper","name":"Genomic characterization of malignant progression in neoplastic pancreatic cysts","route":"/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32818466/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32839463/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pandey-gallbladder-elf3-nat-commun-2020","kind":"paper","name":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","route":"/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32891647/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hiraoka-her2-status-biliary-hum-pathol-2020","kind":"paper","name":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","route":"/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32945632/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-javelin-bladder-100-nejm-2020","kind":"paper","name":"JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer","route":"/key-papers/paper-javelin-bladder-100-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32946773/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020","kind":"paper","name":"Challenges and opportunities for pancreatic cancer immunotherapy","route":"/key-papers/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32971268/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021","kind":"paper","name":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","route":"/key-papers/paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33001135/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nivolumab-hcc-jama-oncol-2020","kind":"paper","name":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","route":"/key-papers/paper-nivolumab-hcc-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33051307/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-topham-subtype-discordant-pancreatic-ccr-2021","kind":"paper","name":"Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics","route":"/key-papers/paper-topham-subtype-discordant-pancreatic-ccr-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33106634/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bolton-nat-genet","kind":"paper","name":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","route":"/key-papers/paper-bolton-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33119048/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33148535/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hanna-bmj","kind":"paper","name":"Mortality due to cancer treatment delay: systematic review and meta-analysis","route":"/key-papers/paper-hanna-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33151258/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021","kind":"paper","name":"Association of clonal haematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","route":"/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33194700/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02152631-front-oncol-2020","kind":"paper","name":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER","route":"/key-papers/paper-nct02152631-front-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33199490/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2021","kind":"paper","name":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33253641/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nadofaragene-firadenovec-lancet-oncol-2021","kind":"paper","name":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33259690/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021","kind":"paper","name":"Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition","route":"/key-papers/paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33264544/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33276026/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021","kind":"paper","name":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","route":"/key-papers/paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33285097/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33347829/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33398198/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021","kind":"paper","name":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","route":"/key-papers/paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33443338/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","route":"/institutions/israel-national-cancer-registry/","field":"links","label":"Moore et al., An assessment of the completeness and timeliness of the Israel National Cancer Registry (IMAJ 2021)"},{"id":"paper-moore-israel-cancer-registry-completeness-imaj-2021","kind":"paper","name":"An assessment of the completeness and timeliness of the Israel National Cancer Registry","route":"/key-papers/paper-moore-israel-cancer-registry-completeness-imaj-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33507256/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-danchev-jama-netw-open","kind":"paper","name":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement","route":"/key-papers/paper-danchev-jama-netw-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33542131/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-davar-science","kind":"paper","name":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","route":"/key-papers/paper-davar-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33558422/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021","kind":"paper","name":"Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","route":"/key-papers/paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33581798/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33581821/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-2021","kind":"paper","name":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","route":"/key-papers/paper-empower-lung-1-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33627798/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kakiuchi-nat-rev-cancer","kind":"paper","name":"Clonal expansion in non-cancer tissues","route":"/key-papers/paper-kakiuchi-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33654071/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33710123/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-patil-gallbladder-immune-microenvironment-aimm-2021","kind":"paper","name":"Immune microenvironment in gallbladder adenocarcinomas","route":"/key-papers/paper-patil-gallbladder-immune-microenvironment-aimm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33798493/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-abc-06-folfox-second-line-lancet-oncol-2021","kind":"paper","name":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","route":"/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33820998/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33872070/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-024-189-j-clin-oncol-2021-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50","route":"/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33877688/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-shah-br-j-haematol","kind":"paper","name":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline","route":"/key-papers/paper-shah-br-j-haematol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33903692/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021","kind":"paper","name":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer","route":"/key-papers/paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33918309/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-albrecht-pdl1-western-gallbladder-cancers-2021","kind":"paper","name":"Programmed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancer","route":"/key-papers/paper-albrecht-pdl1-western-gallbladder-cancers-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33946039/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-muscaritoli-clin-nutr","kind":"paper","name":"ESPEN practical guideline: Clinical Nutrition in cancer","route":"/key-papers/paper-muscaritoli-clin-nutr/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33970687/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021","kind":"paper","name":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","route":"/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34051177/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-057-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ","route":"/key-papers/paper-keynote-057-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34103352/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-j-immunother-cancer-2021","kind":"paper","name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","route":"/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34143971/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ren-lancet-oncol","kind":"paper","name":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","route":"/key-papers/paper-ren-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34174157/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bien-pediatr-blood-cancer","kind":"paper","name":"Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations","route":"/key-papers/paper-bien-pediatr-blood-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34174189/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021","kind":"paper","name":"CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34176681/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-klein-ccga3-mced-validation-ann-oncol-2021","kind":"paper","name":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","route":"/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34237031/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-navigate-j-clin-invest-2021","kind":"paper","name":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","route":"/key-papers/paper-navigate-j-clin-invest-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34246347/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021","kind":"paper","name":"IPATential150: ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34264316/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lung-map-s1400i-jama-oncol-2021","kind":"paper","name":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-lung-map-s1400i-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34291289/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-johnson-j-natl-cancer-inst","kind":"paper","name":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report","route":"/key-papers/paper-johnson-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34294911/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34310172/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-j-clin-oncol-2021","kind":"paper","name":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","route":"/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34310745/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-am-j-hematol-2021","kind":"paper","name":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","route":"/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34339623/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-javle-mypathway-her2-biliary-lancet-oncol-2021","kind":"paper","name":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34362903/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021","kind":"paper","name":"Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer","route":"/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34454916/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gonda-precede-consortium-recommendations-gastroenterology-2021","kind":"paper","name":"Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium","route":"/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34508258/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dhanasekaran-nat-rev-clin-oncol","kind":"paper","name":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","route":"/key-papers/paper-dhanasekaran-nat-rev-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34511303/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-eau-nmibc-guideline-eur-urol-2022","kind":"paper","name":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","route":"/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34600602/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34635570/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kornauth-cancer-discov","kind":"paper","name":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","route":"/key-papers/paper-kornauth-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34644529/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-grunwald-subtme-pancreatic-cell-2021","kind":"paper","name":"Spatially confined sub-tumor microenvironments in pancreatic cancer","route":"/key-papers/paper-grunwald-subtme-pancreatic-cell-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34656226/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nifty-liposomal-irinotecan-lancet-oncol-2021","kind":"paper","name":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","route":"/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34667026/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stopsack-prostate-genomes-by-race-ccr-2022","kind":"paper","name":"Differences in prostate cancer genomes by self-reported race","route":"/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34724563/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34826411/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-haematol-2021","kind":"paper","name":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34902530/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-atezolizumab-hcc-j-hepatol-2022","kind":"paper","name":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","route":"/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34907080/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","kind":"paper","name":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","route":"/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34918177/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gallbladder-polyp-joint-guideline-eur-radiol-2022","kind":"paper","name":"Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE","route":"/key-papers/paper-gallbladder-polyp-joint-guideline-eur-radiol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35026411/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roar-ann-oncol-2022-update","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","route":"/key-papers/paper-roar-ann-oncol-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35038432/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35100741/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mody-biliary-ctdna-profiling-jco-po-2019","kind":"paper","name":"Circulating tumor DNA profiling of advanced biliary tract cancers","route":"/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35113160/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fernandez-jama-oncol","kind":"paper","name":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","route":"/key-papers/paper-fernandez-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35118421/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020","kind":"paper","name":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35145263/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35245446/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wang-cancer-cell","kind":"paper","name":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","route":"/key-papers/paper-wang-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35265417/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ishiguro-dichloroacetate-ivermectin-cureus-2022","kind":"paper","name":"Synergistic anti-tumor effect of dichloroacetate and ivermectin","route":"/key-papers/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35287967/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-gynecol-oncol-2022","kind":"paper","name":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","route":"/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35297944/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-alchemist-jama-oncol-2022","kind":"paper","name":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","route":"/key-papers/paper-alchemist-jama-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35298272/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-crosby-science","kind":"paper","name":"Early detection of cancer","route":"/key-papers/paper-crosby-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35302596/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35336934/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hietanen-rigvir-echovirus-viruses-2022","kind":"paper","name":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","route":"/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35358455/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kindler-lancet-oncol","kind":"paper","name":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","route":"/key-papers/paper-kindler-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35397864/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35397952/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35405085/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-peace-1-lancet-2022","kind":"paper","name":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design","route":"/key-papers/paper-peace-1-lancet-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35442766/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-shen-j-clin-oncol","kind":"paper","name":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","route":"/key-papers/paper-shen-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35562406/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ferreri-leukemia","kind":"paper","name":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","route":"/key-papers/paper-ferreri-leukemia/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35576956/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35580297/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35657320/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35662408/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35671327/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-stampede-plos-med-2022-update","kind":"paper","name":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","route":"/key-papers/paper-stampede-plos-med-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35680043/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-158-ann-oncol-2022-update","kind":"paper","name":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","route":"/key-papers/paper-keynote-158-ann-oncol-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35717045/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022","kind":"paper","name":"Lutetium-177 DOTATATE: A Practical Review","route":"/key-papers/paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35732831/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-who-2022-myeloid-khoury-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","route":"/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35767897/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","route":"/key-papers/paper-icc-2022-arber-blood-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35797463/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35810754/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35864254/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-todo-g47delta-glioblastoma-natmed-2022","kind":"paper","name":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","route":"/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35917647/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-orient-11-lung-cancer-2022-update","kind":"paper","name":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","route":"/key-papers/paper-orient-11-lung-cancer-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36113498/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36119032/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022","kind":"paper","name":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36122322/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol","kind":"paper","name":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-mao-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36166026/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-astrum-005-jama-2022","kind":"paper","name":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","route":"/key-papers/paper-astrum-005-jama-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36214590/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36228155/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36252599/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-atlantis-lancet-respir-med-2023","kind":"paper","name":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-atlantis-lancet-respir-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36269898/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023","kind":"paper","name":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36306479/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-j-clin-oncol-2023-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study","route":"/key-papers/paper-keynote-042-j-clin-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36372281/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36374218/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hoang-ivermectin-toxicity-clin-toxicol-2022","kind":"paper","name":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19","route":"/key-papers/paper-hoang-ivermectin-toxicity-clin-toxicol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36477032/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-goteborg-2-n-engl-j-med-2022","kind":"paper","name":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","route":"/key-papers/paper-goteborg-2-n-engl-j-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36511784/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-n-engl-j-med-2023","kind":"paper","name":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","route":"/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36535300/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-crown-lancet-respir-med-2023-update","kind":"paper","name":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","route":"/key-papers/paper-crown-lancet-respir-med-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36631681/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023","kind":"paper","name":"Shalhout 2023: what the approved oncolytic viruses actually do in practice","route":"/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36646210/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36646802/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36735893/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-407-j-clin-oncol-2023-update","kind":"paper","name":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","route":"/key-papers/paper-keynote-407-j-clin-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36746507/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rodolakis-int-j-gynecol-cancer","kind":"paper","name":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","route":"/key-papers/paper-rodolakis-int-j-gynecol-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36764316/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36780674/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-calgb-140503-n-engl-j-med-2023","kind":"paper","name":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","route":"/key-papers/paper-calgb-140503-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36795891/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36952634/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-magnitude-j-clin-oncol-2023","kind":"paper","name":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-magnitude-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36976682/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-jimenez-gaona-ivermectin-loja-ecuador-2023","kind":"paper","name":"Outcome of ivermectin in cancer treatment: an experience in Loja, Ecuador","route":"/key-papers/paper-jimenez-gaona-ivermectin-loja-ecuador-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36988937/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-molenaar-jama-surg","kind":"paper","name":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial","route":"/key-papers/paper-molenaar-jama-surg/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37142373/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-sonabend-lancet-oncol","kind":"paper","name":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","route":"/key-papers/paper-sonabend-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37272513/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-671-n-engl-j-med-2023","kind":"paper","name":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-671-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37285865/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2023","kind":"paper","name":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","route":"/key-papers/paper-talapro-2-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37322367/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37548831/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-int-j-clin-oncol-2023-update","kind":"paper","name":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","route":"/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37564196/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-b7-h3-glioblastoma-int-j-biol-sci-2023","kind":"paper","name":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy","route":"/key-papers/paper-b7-h3-glioblastoma-int-j-biol-sci-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37582238/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-carlson-j-clin-oncol","kind":"paper","name":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-carlson-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37591293/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37597091/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-drugs-2023","kind":"paper","name":"Epcoritamab: First Approval","route":"/key-papers/paper-epcoritamab-dlbcl-drugs-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37647576/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-qin-j-clin-oncol","kind":"paper","name":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer","route":"/key-papers/paper-qin-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37670148/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-petersenn-nat-rev-endocrinol","kind":"paper","name":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","route":"/key-papers/paper-petersenn-nat-rev-endocrinol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37710001/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37714168/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37770126/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bsg-cholangiocarcinoma-guideline-gut-2023","kind":"paper","name":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","route":"/key-papers/paper-bsg-cholangiocarcinoma-guideline-gut-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37824153/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-carson-jama","kind":"paper","name":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","route":"/key-papers/paper-carson-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37861218/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870968/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37905734/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-martinez-cibrian-br-j-haematol","kind":"paper","name":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-martinez-cibrian-br-j-haematol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37933467/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ghai-california-poison-control-ivermectin-2024","kind":"paper","name":"Exposures to bleach, peroxide, disinfectants, antimalarials, and ivermectin reported to the California Poison Control System before and during the COVID-19 pandemic, 2015 to 2021","route":"/key-papers/paper-ghai-california-poison-control-ivermectin-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38043558/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38051328/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-xu-jama","kind":"paper","name":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","route":"/key-papers/paper-xu-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38164586/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct05413850-j-nucl-med-2024","kind":"paper","name":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","route":"/key-papers/paper-nct05413850-j-nucl-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38182527/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024","kind":"paper","name":"International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)","route":"/key-papers/paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38301010/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-montoya-science","kind":"paper","name":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127","route":"/key-papers/paper-montoya-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38319256/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38320513/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38454126/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-brown-nat-med","kind":"paper","name":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","route":"/key-papers/paper-brown-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38504018/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-chen-nat-med","kind":"paper","name":"Towards a general-purpose foundation model for computational pathology","route":"/key-papers/paper-chen-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38521086/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38521132/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38706451/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-thakurdesai-fenbendazole-liver-injury-2024","kind":"paper","name":"Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication fenbendazole","route":"/key-papers/paper-thakurdesai-fenbendazole-liver-injury-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38713595/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","kind":"paper","name":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38756145/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024","kind":"paper","name":"PHOCUS: an oncolytic vaccinia virus before sorafenib in liver cancer did worse than sorafenib alone","route":"/key-papers/paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3880867/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-moertel-n-engl-j-med","kind":"paper","name":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","route":"/key-papers/paper-moertel-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38820549/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-harmoni-a-jama-2024","kind":"paper","name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","route":"/key-papers/paper-harmoni-a-jama-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38843488/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38870977/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-naliricc-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","route":"/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38924756/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39088774/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-philip-j-clin-oncol","kind":"paper","name":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study","route":"/key-papers/paper-philip-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39102634/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","kind":"paper","name":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","route":"/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39268857/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39293462/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39339989/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39362249/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39388662/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","kind":"paper","name":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","route":"/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39513953/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025","kind":"paper","name":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39622410/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39761483/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tropion-lung05-j-clin-oncol-2025","kind":"paper","name":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","route":"/key-papers/paper-tropion-lung05-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39792928/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39839782/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-splash-front-oncol-2024","kind":"paper","name":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","route":"/key-papers/paper-splash-front-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39878970/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"scin-trial","kind":"trial","name":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma)","route":"/trials/scin-trial/","field":"links","label":"Five-year results on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39908431/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","kind":"paper","name":"eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer","route":"/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40381735/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-topaz-1-three-year-survival-j-hepatol-2025","kind":"paper","name":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","route":"/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40450658/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454642/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-checkmate-816-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","route":"/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40466642/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-med-2025","kind":"paper","name":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study","route":"/key-papers/paper-pembrolizumab-glioblastoma-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40473449/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-imforte-lancet-2025","kind":"paper","name":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","route":"/key-papers/paper-imforte-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40480428/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40523369/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40556334/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40592848/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40605964/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-makis-fenbendazole-case-series-retracted-2025","kind":"paper","name":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","route":"/key-papers/paper-makis-fenbendazole-case-series-retracted-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40608313/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40627813/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wong-ignyte-rp1-nivolumab-jco-2025","kind":"paper","name":"IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy","route":"/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40683290/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2025-update","kind":"paper","name":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","route":"/key-papers/paper-talapro-2-lancet-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40715995/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-patel-ivermectin-cancer-curr-oncol-rep-2025","kind":"paper","name":"Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?","route":"/key-papers/paper-patel-ivermectin-cancer-curr-oncol-rep-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40749900/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40851910/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40896730/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-straughn-ivermectin-hope-versus-hype-2025","kind":"paper","name":"Ivermectin treatment for gynecologic cancers: hope versus hype","route":"/key-papers/paper-straughn-ivermectin-hope-versus-hype-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40930144/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025","kind":"paper","name":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40930709/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-pugh-self-experimentation-publication-jme-2026","kind":"paper","name":"Pugh 2026: should a journal publish a scientist's experiment on herself?","route":"/key-papers/paper-pugh-self-experimentation-publication-jme-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41057655/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41104928/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-soho-01-n-engl-j-med-2025","kind":"paper","name":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","route":"/key-papers/paper-soho-01-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41114336/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","kind":"paper","name":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","route":"/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41120017/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-capitello-281-ann-oncol-2026","kind":"paper","name":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","route":"/key-papers/paper-capitello-281-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41167216/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41187298/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hammel-j-clin-oncol","kind":"paper","name":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma","route":"/key-papers/paper-hammel-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41418080/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","kind":"paper","name":"Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population","route":"/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41436297/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026","kind":"paper","name":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis","route":"/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41574240/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-makis-fenbendazole-case-series-retracted-2025","kind":"paper","name":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","route":"/key-papers/paper-makis-fenbendazole-case-series-retracted-2025/","field":"links","label":"Retraction notice on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41633900/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41682001/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026","kind":"paper","name":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-cancers-basel-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41837342/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026","kind":"paper","name":"Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management","route":"/key-papers/paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41896701/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-protect-bju-int-2026-update","kind":"paper","name":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","route":"/key-papers/paper-protect-bju-int-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41968137/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41981308/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-mahalingam-nat-med","kind":"paper","name":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","route":"/key-papers/paper-mahalingam-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42118539/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026","kind":"paper","name":"Ivermectin-benzimidazole prescribing following celebrity endorsement","route":"/key-papers/paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42140743/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42162970/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026","kind":"paper","name":"A new CA19-9 cutoff value identifies Lewis antigen status and refines prognostic stratification in PDAC","route":"/key-papers/paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42170801/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026","kind":"paper","name":"Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report","route":"/key-papers/paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42203321/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","kind":"paper","name":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","route":"/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42223064/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42223077/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct03767244-n-engl-j-med-2026","kind":"paper","name":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","route":"/key-papers/paper-nct03767244-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42225101/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42248882/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/","field":"links","label":"Expression of concern on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42298760/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42299164/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-powderly-fenbendazole-ivermectin-liver-injury-2026","kind":"paper","name":"Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report","route":"/key-papers/paper-powderly-fenbendazole-ivermectin-liver-injury-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42300708/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","kind":"paper","name":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","route":"/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/","field":"links","label":"Expression of concern on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42360806/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42368479/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42491797/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026","kind":"paper","name":"Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients","route":"/key-papers/paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42531802/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42561994/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-psmaddition-lancet-2026","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","route":"/key-papers/paper-psmaddition-lancet-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42579833/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42593771/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026","kind":"paper","name":"c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer","route":"/key-papers/paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42595189/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","kind":"paper","name":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases","route":"/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42628840/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-keynote-671-ann-oncol-2026-update","kind":"paper","name":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","route":"/key-papers/paper-keynote-671-ann-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42727418/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42728193/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42732874/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42745627/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42745863/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026","kind":"paper","name":"Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?","route":"/key-papers/paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42773209/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/6185846/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-feinberg-nature","kind":"paper","name":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","route":"/key-papers/paper-feinberg-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7503360/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995","kind":"paper","name":"Klimstra 1995: pancreatoblastoma, a clinicopathologic study and review of the literature","route":"/key-papers/paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7707126/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-grever-j-clin-oncol","kind":"paper","name":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","route":"/key-papers/paper-grever-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7723794/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995","kind":"paper","name":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","route":"/key-papers/paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7761852/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995","kind":"paper","name":"Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability","route":"/key-papers/paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8313389/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"papers","label":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8698204/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996","kind":"paper","name":"Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression","route":"/key-papers/paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8832876/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8839839/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-wattel-blood","kind":"paper","name":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group","route":"/key-papers/paper-wattel-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9121588/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-lengauer-genetic-instability-colorectal-nature-1997","kind":"paper","name":"Genetic instability in colorectal cancers","route":"/key-papers/paper-lengauer-genetic-instability-colorectal-nature-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9218740/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"links","label":"Randomised comparison on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9321529/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-tallman-atra-apl-nejm-1997","kind":"paper","name":"North American Intergroup: all-trans retinoic acid in acute promyelocytic leukaemia","route":"/key-papers/paper-tallman-atra-apl-nejm-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9618505/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998","kind":"paper","name":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","route":"/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9811862/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-duesberg-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Genetic instability of cancer cells is proportional to their degree of aneuploidy","route":"/key-papers/paper-duesberg-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9812900/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-coffey-reovirus-ras-science-1998","kind":"paper","name":"Coffey 1998: reovirus grows in cells with an activated Ras pathway, which describes a great many cancers","route":"/key-papers/paper-coffey-reovirus-ras-science-1998/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9815541/","status":429,"ok":false,"contentType":"text/plain","checked":"2026-09-30","refs":[{"id":"paper-silver-psma-expression-normal-malignant-tissues-ccr-1997","kind":"paper","name":"Prostate-specific membrane antigen expression in normal and malignant human tissues","route":"/key-papers/paper-silver-psma-expression-normal-malignant-tissues-ccr-1997/","field":"links","label":"Silver et al., Clin Cancer Res 1997: prostate-specific membrane antigen expression across normal and malignant human tissues by immunohistochemistry"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"prevalence.source"}]},{"url":"https://www.10xgenomics.com","status":429,"ok":false,"finalUrl":"https://www.10xgenomics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","field":"links","label":"Official website"},{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","field":"website"}]},{"url":"https://www.10xgenomics.com/platforms/xenium","status":429,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"10x Genomics Xenium"}]},{"url":"https://www.10xgenomics.com/products/visium-hd-spatial-gene-expression","status":429,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"10x Genomics Visium HD"}]},{"url":"https://www.ampliatx.com/","status":429,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","route":"/companies/amplia-therapeutics/","field":"links","label":"Official website"},{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","route":"/companies/amplia-therapeutics/","field":"website"}]},{"url":"https://www.csl.com","status":429,"ok":false,"finalUrl":"https://www.csl.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","field":"links","label":"Official website"},{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","field":"website"}]},{"url":"https://www.tempus.com","status":429,"ok":false,"finalUrl":"https://www.tempus.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/","field":"links","label":"Official website"},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/","field":"website"},{"id":"tempus-multimodal","kind":"technology","name":"Tempus multimodal models","route":"/technologies/tempus-multimodal/","field":"links","label":"Tempus AI"}]},{"url":"https://www.tempus.com/oncology/genomic-profiling/xt-cdx/","status":429,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/","field":"links","label":"Tempus: xT CDx"}]},{"url":"https://www.uza.be","status":429,"ok":false,"finalUrl":"https://www.uza.be/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","route":"/institutions/antwerp-university-hospital/","field":"links","label":"UZA"},{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","route":"/institutions/antwerp-university-hospital/","field":"website"}]},{"url":"https://eqipd.org/","status":500,"ok":false,"finalUrl":"https://go-eqipd.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr2-multilab-preclinical","kind":"idea","name":"Multi-laboratory preclinical trials as the standard for go/no-go decisions","route":"/ideas/idea-tr2-multilab-preclinical/","field":"links","label":"EQIPD"}]},{"url":"https://nicrh.gov.bd/administrator/directors-message","status":500,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","field":"profiles","label":"Director's message"}]},{"url":"https://nyulangone.org/locations/perlmutter-cancer-center/clinical-trials","status":500,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","field":"links","label":"Clinical trials"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34473194/","status":500,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02767804-jama-oncol-2021","kind":"paper","name":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-nct02767804-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://web.archive.org/web/20250115091955/https://www.fda.gov/about-fda/oncology-center-excellence/project-community","status":500,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-home-infusion-trial-drugs","kind":"idea","name":"Home infusion and local blood draws for trial drugs after the first cycles","route":"/ideas/idea-tr1-home-infusion-trial-drugs/","field":"links","label":"FDA Oncology Center of Excellence: Project Community (archived copy)"}]},{"url":"https://www.usz.ch/en/","status":500,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"links","label":"University Hospital Zurich / Comprehensive Cancer Center Zurich website"},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"profiles","label":"University Hospital Zurich / Comprehensive Cancer Center Zurich website"},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"links","label":"Homepage"},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"website"}]},{"url":"https://www.usz.ch/ueber-uns/spitaldirektion/","status":500,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monika-janicke","kind":"person","name":"Monika Jänicke","route":"/people/monika-janicke/","field":"links","label":"Institution profile"},{"id":"monika-janicke","kind":"person","name":"Monika Jänicke","route":"/people/monika-janicke/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.clovisoncology.com","status":502,"ok":false,"finalUrl":"https://www.clovisoncology.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","field":"website"}]},{"url":"https://www.cclg.org.uk/research","status":503,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","route":"/companies/cclg/","field":"links","label":"Research"}]},{"url":"https://www.cms.gov/medicare-coverage-database/","status":503,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","field":"links","label":"CMS: Medicare Coverage Database"}]},{"url":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58456","status":503,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"CMS article A58456: MolDX minimal residual disease testing for solid tumour cancers (revision effective 1 January 2026)"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/","field":"links","label":"CMS article A58456: MolDX minimal residual disease testing for solid tumour cancers (lists covered tests)"}]},{"url":"https://www.ptcog.site/index.php/facilities-in-operation-public","status":503,"ok":false,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","route":"/institutions/maastricht-umc/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","route":"/institutions/clatterbridge/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"carbon-ion-synchrotrons","kind":"technology","name":"Carbon-ion synchrotrons and facilities","route":"/technologies/carbon-ion-synchrotrons/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","route":"/companies/sumitomo-heavy-industries/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","route":"/companies/toshiba-energy-systems/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"protom","kind":"company","name":"ProTom International","route":"/companies/protom/","field":"links","label":"PTCOG: particle therapy facilities in operation"}]},{"url":"https://www.clinicaltrials.jp/","status":520,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"j-alex","kind":"trial","name":"J-ALEX","route":"/trials/j-alex/","field":"links","label":"Japan Pharmaceutical Information Center (the registry that held JapicCTI-132316; its record address now redirects to the registry home page)"}]},{"url":"https://rgcc-international.com/","status":521,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rgcc-international","kind":"company","name":"RGCC International","route":"/companies/rgcc-international/","field":"links","label":"Official website"},{"id":"rgcc-international","kind":"company","name":"RGCC International","route":"/companies/rgcc-international/","field":"website"}]},{"url":"https://www.zs-hospital.sh.cn","status":521,"ok":false,"finalUrl":"https://www.zs-hospital.sh.cn/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","field":"links","label":"Zhongshan Hospital"},{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","field":"website"}]},{"url":"https://www.zs-hospital.sh.cn/","status":521,"ok":false,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","field":"links","label":"Zhongshan Hospital"},{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","field":"profiles","label":"Zhongshan Hospital"}]},{"url":"https://canprevent.com","status":522,"ok":false,"finalUrl":"https://canprevent.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","field":"links","label":"Official website"},{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","field":"website"}]},{"url":"https://www.khuh.org.bh","status":525,"ok":false,"finalUrl":"https://www.khuh.org.bh/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bahrain-oncology-centre","kind":"institution","name":"Bahrain Oncology Center, King Hamad University Hospital","route":"/institutions/bahrain-oncology-centre/","field":"links","label":"Official website"},{"id":"bahrain-oncology-centre","kind":"institution","name":"Bahrain Oncology Center, King Hamad University Hospital","route":"/institutions/bahrain-oncology-centre/","field":"website"}]},{"url":"https://www.sahmri.org/australian-bragg-centre/","status":525,"ok":false,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","field":"links","label":"Australian Bragg Centre"}]},{"url":"http://agennix.com","status":200,"ok":true,"finalUrl":"https://affigen.com/en-us","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","field":"links","label":"Official website"},{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","field":"website"}]},{"url":"http://angiocrinebioscience.com","status":200,"ok":true,"finalUrl":"https://angiocrinebioscience.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","field":"links","label":"Official website"},{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","field":"website"}]},{"url":"http://convergentrx.com/","status":200,"ok":true,"finalUrl":"https://convergentrx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","field":"links","label":"Official website"},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","field":"website"}]},{"url":"http://galenabiopharma.com","status":200,"ok":true,"finalUrl":"https://www.samsclubviajes.com/","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","field":"links","label":"Official website"},{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","field":"website"}]},{"url":"http://institutducancer-hopitauxnord-u-paris.aphp.fr/","status":200,"ok":true,"finalUrl":"https://institutducancer-hopitauxnord-u-paris.aphp.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"links","label":"Cancer Institute AP-HP Nord, Université Paris Cité website"},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"profiles","label":"Cancer Institute AP-HP Nord, Université Paris Cité website"}]},{"url":"http://oakwoodlabs.com","status":200,"ok":true,"finalUrl":"https://oakwoodlabs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","field":"links","label":"Official website"},{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","field":"website"}]},{"url":"http://onco.md","status":200,"ok":true,"finalUrl":"https://onco.md/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","route":"/institutions/oncological-institute-moldova/","field":"links","label":"Official website"},{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","route":"/institutions/oncological-institute-moldova/","field":"website"}]},{"url":"http://onco.md/","status":200,"ok":true,"finalUrl":"https://onco.md/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"links","label":"Oncological Institute of Moldova website"},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"profiles","label":"Oncological Institute of Moldova website"}]},{"url":"http://oncort.ru","status":200,"ok":true,"finalUrl":"https://oncort.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","field":"links","label":"Official website"},{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","field":"website"}]},{"url":"http://preglem.com","status":200,"ok":true,"finalUrl":"http://preglem.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","field":"links","label":"Official website"},{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","field":"website"}]},{"url":"http://sorrentotherapeutics.com","status":200,"ok":true,"finalUrl":"https://sorrentotherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","field":"links","label":"Official website"},{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","field":"website"}]},{"url":"http://timer.cistrome.org/","status":200,"ok":true,"finalUrl":"https://compbio.cn/timer3/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017","kind":"paper","name":"Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data","route":"/key-papers/paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017/","field":"links","label":"TIMER2.0"},{"id":"paper-li-timer2-nar-2020","kind":"paper","name":"Li 2020: TIMER2.0 for analysis of tumour-infiltrating immune cells","route":"/key-papers/paper-li-timer2-nar-2020/","field":"links","label":"TIMER2.0"}]},{"url":"http://www.aau.edu.et","status":200,"ok":true,"finalUrl":"https://www.aau.edu.et/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","route":"/institutions/tikur-anbessa-hospital/","field":"links","label":"Addis Ababa University"},{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","route":"/institutions/tikur-anbessa-hospital/","field":"website"}]},{"url":"http://www.acaciapharma.com","status":200,"ok":true,"finalUrl":"http://www.acaciapharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","field":"links","label":"Official website"},{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","field":"website"}]},{"url":"http://www.activebiotech.com","status":200,"ok":true,"finalUrl":"https://www.activebiotech.com/sv/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","field":"links","label":"Official website"},{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","field":"website"}]},{"url":"http://www.argostherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.argostherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","field":"links","label":"Official website"},{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","field":"website"}]},{"url":"http://www.bellicum.com","status":200,"ok":true,"finalUrl":"http://www.bellicum.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","field":"links","label":"Official website"},{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","field":"website"}]},{"url":"http://www.biomedcentrum.sav.sk/","status":200,"ok":true,"finalUrl":"https://bmc.sav.sk/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"links","label":"Biomedical Research Center of the Slovak Academy of Sciences website"},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"profiles","label":"Biomedical Research Center of the Slovak Academy of Sciences website"},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","field":"links","label":"Official website"},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","field":"website"}]},{"url":"http://www.blazebioscience.com","status":200,"ok":true,"finalUrl":"https://www.blazebioscience.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","field":"links","label":"Official website"},{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","field":"website"}]},{"url":"http://www.caca.org.cn/gyxh/index.shtml","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fan-daiming","kind":"person","name":"Fan Daiming","route":"/people/fan-daiming/","field":"links","label":"Source: China Anti-Cancer Association 'About the Association' page listing current leaders"},{"id":"fan-daiming","kind":"person","name":"Fan Daiming","route":"/people/fan-daiming/","field":"profiles","label":"CACA: About the Association (current leadership)"}]},{"url":"http://www.cellseed.com","status":200,"ok":true,"finalUrl":"https://www.cellseed.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","field":"links","label":"Official website"},{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","field":"website"}]},{"url":"http://www.christie.nhs.uk/","status":200,"ok":true,"finalUrl":"https://www.christie.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"links","label":"The Christie NHS Foundation Trust website"},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"profiles","label":"The Christie NHS Foundation Trust website"}]},{"url":"http://www.cubadebate.cu/noticias/2026/06/04/inauguran-unidad-de-tratamiento-ambulatorio-de-oncologia-en-hospital-capitalino/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","route":"/people/luis-eduardo-martin-rodriguez/","field":"links","label":"Source: Cubadebate article on the opening of INOR's outpatient treatment unit (4 June 2026)"},{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","route":"/people/luis-eduardo-martin-rodriguez/","field":"profiles","label":"Cubadebate report naming him as director (June 2026)"}]},{"url":"http://www.dhpharm.co.kr","status":200,"ok":true,"finalUrl":"http://www.dhpharm.co.kr/html/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","field":"links","label":"Official website"},{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","field":"website"}]},{"url":"http://www.grupposamed.com","status":200,"ok":true,"finalUrl":"https://www.grupposamed.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","field":"links","label":"Mediterranean Institute of Oncology (IOM) website"},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","field":"profiles","label":"Mediterranean Institute of Oncology (IOM) website"},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","route":"/institutions/mediterranean-institute-of-oncology/","field":"links","label":"Official website"},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","route":"/institutions/mediterranean-institute-of-oncology/","field":"website"}]},{"url":"http://www.gtxinc.com","status":200,"ok":true,"finalUrl":"https://www.gtxinc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","field":"links","label":"Official website"},{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","field":"website"}]},{"url":"http://www.hisunpharm.com","status":200,"ok":true,"finalUrl":"http://www.hisunpharm.com/main/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","field":"links","label":"Official website"},{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","field":"website"}]},{"url":"http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"IARC and the International Association of Cancer Registries: ICD-O-3.2 morphology and behaviour codes (actinic keratosis 8070/0; Bowen disease 8081/2; keratoacanthoma a related term under 8071/3; micronodular basal cell carcinoma shares 8097/3 with nodular, and sclerosing or morphoeic shares 8092/3 with infiltrating)"},{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"IARC and the International Association of Cancer Registries: ICD-O-3.2 morphology and behaviour codes (actinic keratosis 8070/0; Bowen disease 8081/2; keratoacanthoma a related term under 8071/3; micronodular basal cell carcinoma shares 8097/3 with nodular, and sclerosing or morphoeic shares 8092/3 with infiltrating)"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"IARC and the International Association of Cancer Registries: ICD-O-3.2 morphology and behaviour codes (actinic keratosis 8070/0; Bowen disease 8081/2; keratoacanthoma a related term under 8071/3; micronodular basal cell carcinoma shares 8097/3 with nodular, and sclerosing or morphoeic shares 8092/3 with infiltrating)"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"IARC and the International Association of Cancer Registries: ICD-O-3.2 morphology and behaviour codes (actinic keratosis 8070/0; Bowen disease 8081/2; keratoacanthoma a related term under 8071/3; micronodular basal cell carcinoma shares 8097/3 with nodular, and sclerosing or morphoeic shares 8092/3 with infiltrating)"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"IARC and the International Association of Cancer Registries: ICD-O-3.2 morphology and behaviour codes (actinic keratosis 8070/0; Bowen disease 8081/2; keratoacanthoma a related term under 8071/3; micronodular basal cell carcinoma shares 8097/3 with nodular, and sclerosing or morphoeic shares 8092/3 with infiltrating)"}]},{"url":"http://www.iderapharma.com","status":200,"ok":true,"finalUrl":"https://www.iderapharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","field":"links","label":"Official website"},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","field":"website"}]},{"url":"http://www.ieo.it/en","status":200,"ok":true,"finalUrl":"https://www.ieo.it/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","field":"links","label":"IEO (European Institute of Oncology) website"},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","field":"profiles","label":"IEO (European Institute of Oncology) website"}]},{"url":"http://www.iknl.nl/","status":200,"ok":true,"finalUrl":"https://iknl.nl/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"links","label":"Netherlands Comprehensive Cancer Organisation (IKNL) website"},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"profiles","label":"Netherlands Comprehensive Cancer Organisation (IKNL) website"}]},{"url":"http://www.imvaccine.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","field":"links","label":"Official website"},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","field":"website"}]},{"url":"http://www.infi.com","status":200,"ok":true,"finalUrl":"http://www.infi.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","field":"links","label":"Official website"},{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","field":"website"}]},{"url":"http://www.institutsalahazaiez.com","status":200,"ok":true,"finalUrl":"https://www.institutsalahazaiez.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/","field":"links","label":"Institut Salah Azaïez"},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/","field":"website"}]},{"url":"http://www.institutsalahazaiez.com/espace-administratif.php?id=1","status":200,"ok":true,"finalUrl":"https://www.institutsalahazaiez.com/espace-administratif.php?id=1","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"senda-tounsi","kind":"person","name":"Senda Tounsi","route":"/people/senda-tounsi/","field":"links","label":"Source: Institut Salah Azaïez administration page"},{"id":"senda-tounsi","kind":"person","name":"Senda Tounsi","route":"/people/senda-tounsi/","field":"profiles","label":"Institut Salah Azaïez administration page"}]},{"url":"http://www.isarna-therapeutics.com","status":200,"ok":true,"finalUrl":"https://isarna-therapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","field":"links","label":"Official website"},{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","field":"website"}]},{"url":"http://www.jw-pharma.co.kr","status":200,"ok":true,"finalUrl":"https://www.jw-pharma.co.kr/pharma/ko/main.jsp","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","field":"links","label":"Official website"},{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","field":"website"}]},{"url":"http://www.kbcsm.hr/klinike/klinika-za-tumore","status":200,"ok":true,"finalUrl":"https://www.kbcsm.hr/klinike/klinika-za-tumore/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"links","label":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre website"},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"profiles","label":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre website"},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","route":"/institutions/sestre-milosrdnice-tumors/","field":"links","label":"Official website"},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","route":"/institutions/sestre-milosrdnice-tumors/","field":"website"}]},{"url":"http://www.kissei.co.jp","status":200,"ok":true,"finalUrl":"https://www.kissei.co.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","field":"links","label":"Official website"},{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","field":"website"}]},{"url":"http://www.lungca.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","field":"links","label":"Homepage"},{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","field":"url"}]},{"url":"http://www.lyell.com/pipeline","status":200,"ok":true,"finalUrl":"https://lyell.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","field":"links","label":"Sponsor pipeline page"}]},{"url":"http://www.mnioi.nmicr.ru","status":200,"ok":true,"finalUrl":"https://new.nmicr.ru/mnioi/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","field":"links","label":"Official website"},{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","field":"website"}]},{"url":"http://www.mundipharma.de","status":200,"ok":true,"finalUrl":"https://de.mundipharma.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"links","label":"Official website"},{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"website"}]},{"url":"http://www.ohri.ca/en/node/3821","status":200,"ok":true,"finalUrl":"https://ohri.ca/en/find-researcher/rauer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","field":"profiles","label":"OHRI profile"}]},{"url":"http://www.onk.ns.ac.rs/","status":200,"ok":true,"finalUrl":"https://www.onk.ns.ac.rs/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"links","label":"Oncology Institute of Vojvodina website"},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"profiles","label":"Oncology Institute of Vojvodina website"}]},{"url":"http://www.pharmacosmos.com","status":200,"ok":true,"finalUrl":"https://pharmacosmos.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","field":"links","label":"Official website"},{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","field":"website"}]},{"url":"http://www.photonamic.de","status":200,"ok":true,"finalUrl":"https://www.photonamic.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","field":"links","label":"Official website"},{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","field":"website"}]},{"url":"http://www.phsa.ca/about/leadership/phsa-executive","status":200,"ok":true,"finalUrl":"https://www.phsa.ca/about/leadership/phsa-executive","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","route":"/people/paris-ann-ingledew/","field":"links","label":"Source: PHSA executive leadership page"},{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","route":"/people/paris-ann-ingledew/","field":"profiles","label":"PHSA executive team"}]},{"url":"http://www.ppshp.fi/","status":200,"ok":true,"finalUrl":"https://oys.fi/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"links","label":"Oulu University Hospital website"},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"profiles","label":"Oulu University Hospital website"}]},{"url":"http://www.radboudumc.nl/","status":200,"ok":true,"finalUrl":"https://www.radboudumc.nl/patientenzorg","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"links","label":"Radboudumc Centre for Oncology website"},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"profiles","label":"Radboudumc Centre for Oncology website"}]},{"url":"http://www.regionaalhaigla.ee/","status":200,"ok":true,"finalUrl":"https://www.regionaalhaigla.ee/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"links","label":"North Estonia Medical Centre website"},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"profiles","label":"North Estonia Medical Centre website"}]},{"url":"http://www.saintluc.be","status":200,"ok":true,"finalUrl":"https://www.saintluc.be/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","field":"links","label":"Cliniques universitaires Saint-Luc"}]},{"url":"http://www.sd-cancer.com/into_staff/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yu-jinming","kind":"person","name":"Yu Jinming","route":"/people/yu-jinming/","field":"links","label":"Source: Shandong Cancer Hospital leadership team page"},{"id":"yu-jinming","kind":"person","name":"Yu Jinming","route":"/people/yu-jinming/","field":"profiles","label":"Hospital leadership team page (Chinese)"}]},{"url":"http://www.stampedetrial.org/","status":200,"ok":true,"finalUrl":"https://www.stampedetrial.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/","field":"links","label":"STAMPEDE trial"}]},{"url":"http://www.stjames.ie/cancer","status":200,"ok":true,"finalUrl":"https://www.stjames.ie/cancer/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"links","label":"Trinity St James's Cancer Institute website"},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"profiles","label":"Trinity St James's Cancer Institute website"}]},{"url":"http://www.sunesis.com","status":200,"ok":true,"finalUrl":"http://www.sunesis.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","field":"links","label":"Official website"},{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","field":"website"}]},{"url":"http://www.sunho-bio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","route":"/companies/sunho-biopharmaceutical/","field":"links","label":"Official website"},{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","route":"/companies/sunho-biopharmaceutical/","field":"website"}]},{"url":"http://www.survivorshipguidelines.org","status":200,"ok":true,"finalUrl":"https://childrensoncologygroup.org/survivorship/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"links","label":"COG Long-Term Follow-Up Guidelines"},{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/","field":"links","label":"COG Long-Term Follow-Up Guidelines"}]},{"url":"http://www.survivorshipguidelines.org/","status":200,"ok":true,"finalUrl":"https://childrensoncologygroup.org/survivorship/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"links","label":"Children's Oncology Group Long-Term Follow-Up Guidelines"},{"id":"idea-acc-auto-generated-survivorship-plans","kind":"idea","name":"Survivorship care plans generated automatically from the treatment record","route":"/ideas/idea-acc-auto-generated-survivorship-plans/","field":"links","label":"Children's Oncology Group long-term follow-up guidelines"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"COG Long-Term Follow-Up Guidelines"}]},{"url":"http://www.symbiopharma.com","status":200,"ok":true,"finalUrl":"https://www.symbiopharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","field":"links","label":"Official website"},{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","field":"website"}]},{"url":"http://www.tmucih.com/index/about/leaderships.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","field":"links","label":"Source: TMUCIH leadership page"},{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","field":"profiles","label":"TMUCIH leadership page (English)"}]},{"url":"http://www.traconpharma.com","status":200,"ok":true,"finalUrl":"https://www.traconpharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","field":"links","label":"Official website"},{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","field":"website"}]},{"url":"http://www.unicar-therapy.com","status":200,"ok":true,"finalUrl":"http://www.unicar-therapy.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/","field":"links","label":"Official website"},{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/","field":"website"}]},{"url":"http://www.uzbrussel.be/","status":200,"ok":true,"finalUrl":"https://www.uzbrussel.be/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"links","label":"Brussels Cancer Centre (UZ Brussel) website"},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"profiles","label":"Brussels Cancer Centre (UZ Brussel) website"}]},{"url":"http://www.wayshinebiopharm.com","status":200,"ok":true,"finalUrl":"http://www.wayshinebiopharm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/","field":"links","label":"Official website"},{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/","field":"website"}]},{"url":"http://www.wco.pl/","status":200,"ok":true,"finalUrl":"https://wco.pl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"links","label":"Greater Poland Cancer Centre website"},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"profiles","label":"Greater Poland Cancer Centre website"},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","field":"links","label":"Official website"},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","field":"website"}]},{"url":"http://www.yzybio.com","status":200,"ok":true,"finalUrl":"https://www.yzybio.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","field":"links","label":"Official website"},{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","field":"website"}]},{"url":"http://www.zeria.co.jp","status":200,"ok":true,"finalUrl":"https://www.zeria.co.jp/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","field":"links","label":"Official website"},{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","field":"website"}]},{"url":"https://2curex.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"2curex","kind":"company","name":"2cureX","route":"/companies/2curex/","field":"links","label":"Official website"},{"id":"2curex","kind":"company","name":"2cureX","route":"/companies/2curex/","field":"website"}]},{"url":"https://5amventures.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","field":"links","label":"Official website"},{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","field":"website"}]},{"url":"https://a16z.com/bio-health/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","field":"links","label":"Official website"},{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","field":"website"}]},{"url":"https://a16z.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","field":"links","label":"Portfolio"}]},{"url":"https://aalborguh.rn.dk","status":200,"ok":true,"finalUrl":"https://aalborguh.rn.dk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","field":"links","label":"Official website"},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","field":"website"}]},{"url":"https://aalborguh.rn.dk/da/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","field":"links","label":"Aalborg University Hospital website"},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","field":"profiles","label":"Aalborg University Hospital website"}]},{"url":"https://about.zenodo.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zenodo-doi","kind":"term","name":"Zenodo DOIs for data and code","route":"/terms/zenodo-doi/","field":"links","label":"About Zenodo"}]},{"url":"https://acrivon.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","field":"links","label":"Official website"},{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","field":"website"}]},{"url":"https://acrivon.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://acsbrightedge.org","status":200,"ok":true,"finalUrl":"https://acsbrightedge.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","field":"links","label":"Official website"},{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","field":"website"}]},{"url":"https://actrec.gov.in","status":200,"ok":true,"finalUrl":"https://actrec.gov.in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","field":"links","label":"ACTREC"},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","field":"website"}]},{"url":"https://actrec.gov.in/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"links","label":"ACTREC"},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"profiles","label":"ACTREC"}]},{"url":"https://adcdb.idrblab.net","status":200,"ok":true,"finalUrl":"https://adcdb.idrblab.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","route":"/collections/adcdb/","field":"links","label":"ADCdb"}]},{"url":"https://adcendo.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","field":"links","label":"Official website"},{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","field":"website"}]},{"url":"https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","field":"links","label":"Series C press release"}]},{"url":"https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","field":"links","label":"Series B press release"}]},{"url":"https://adctherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.adctherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/","field":"links","label":"Official website"},{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/","field":"website"}]},{"url":"https://adicetbio.com/pipeline","status":200,"ok":true,"finalUrl":"https://www.adicetbio.com/pipeline/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://advenchen.com","status":200,"ok":true,"finalUrl":"https://advenchen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","field":"links","label":"Official website"},{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","field":"website"}]},{"url":"https://adventris.com","status":200,"ok":true,"finalUrl":"https://www.adventris.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/","field":"links","label":"Official website"},{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/","field":"website"}]},{"url":"https://agendia.com","status":200,"ok":true,"finalUrl":"https://agendia.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agendia","kind":"company","name":"Agendia","route":"/companies/agendia/","field":"links","label":"Official website"},{"id":"agendia","kind":"company","name":"Agendia","route":"/companies/agendia/","field":"website"}]},{"url":"https://agenusbio.com","status":200,"ok":true,"finalUrl":"https://www.agenusbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","field":"links","label":"Official website"},{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","field":"website"}]},{"url":"https://agenusbio.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.agenusbio.com/pipeline","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://agsavvas-hosp.gr/organa-dioikisis/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christos-fasianos","kind":"person","name":"Christos Fasianos","route":"/people/christos-fasianos/","field":"links","label":"Source: Saint Savvas hospital governing bodies (Organa Dioikisis) page"},{"id":"christos-fasianos","kind":"person","name":"Christos Fasianos","route":"/people/christos-fasianos/","field":"profiles","label":"Saint Savvas governing bodies page"}]},{"url":"https://alentis.ch/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","field":"links","label":"Official website"},{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","field":"website"}]},{"url":"https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","field":"links","label":"Series D press release"}]},{"url":"https://alentis.ch/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","field":"links","label":"News"}]},{"url":"https://alexanderfleming.org/quienes-somos/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bernardo-rubinstein","kind":"person","name":"Bernardo Rubinstein","route":"/people/bernardo-rubinstein/","field":"links","label":"Source: Instituto Alexander Fleming institutional page (Directorio)"},{"id":"bernardo-rubinstein","kind":"person","name":"Bernardo Rubinstein","route":"/people/bernardo-rubinstein/","field":"profiles","label":"Instituto Alexander Fleming, Quiénes somos"}]},{"url":"https://allofus.nih.gov","status":200,"ok":true,"finalUrl":"https://www.nih.gov/allofus","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","field":"links","label":"All of Us Research Program"},{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","field":"url"}]},{"url":"https://allogene.com","status":200,"ok":true,"finalUrl":"https://allogene.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/","field":"website"}]},{"url":"https://alloteratx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/","field":"links","label":"Official website"},{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/","field":"website"}]},{"url":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/","field":"links","label":"$35 million financing and rename (July 2026)"}]},{"url":"https://allsci.com/news/earnings-call-insights/gileads-q126-earnings-call-anito-cel-poised-for-december-pdufa-decision-three-acquisitions-near-inflection-points/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","field":"regulatoryEvents.source (2026-02)"}]},{"url":"https://alphafold.ebi.ac.uk","status":200,"ok":true,"finalUrl":"https://alphafold.ebi.ac.uk/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/","field":"links","label":"AlphaFold Protein Structure Database"}]},{"url":"https://alunadata.com","status":200,"ok":true,"finalUrl":"https://www.alunadata.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aluna","kind":"company","name":"Aluna","route":"/companies/aluna/","field":"links","label":"Official website"},{"id":"aluna","kind":"company","name":"Aluna","route":"/companies/aluna/","field":"website"}]},{"url":"https://alxoncology.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/","field":"links","label":"Official website"},{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/","field":"website"}]},{"url":"https://amcoperations.com","status":200,"ok":true,"finalUrl":"https://amcoperations.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aids-malignancy-consortium","kind":"company","name":"AIDS Malignancy Consortium","route":"/companies/aids-malignancy-consortium/","field":"links","label":"Official website"},{"id":"aids-malignancy-consortium","kind":"company","name":"AIDS Malignancy Consortium","route":"/companies/aids-malignancy-consortium/","field":"website"}]},{"url":"https://amcoperations.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"links","label":"AIDS Malignancy Consortium"}]},{"url":"https://ammf.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"AMMF, the UK cholangiocarcinoma charity"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"AMMF, the UK cholangiocarcinoma charity"},{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/","field":"links","label":"AMMF"},{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/","field":"website"}]},{"url":"https://ammf.org.uk/centres-with-cca-expertise/","status":200,"ok":true,"finalUrl":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/","field":"links","label":"Centres with CCA expertise"}]},{"url":"https://ammf.org.uk/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","route":"/terms/trial-or-standard-treatment-biliary/","field":"links","label":"AMMF: clinical trials"}]},{"url":"https://ammf.org.uk/molecular-profiling-booklet-and-video/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/","field":"links","label":"AMMF: molecular profiling booklet"}]},{"url":"https://ammf.org.uk/nutrition/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"weight-loss-and-fat-digestion-biliary","kind":"term","name":"Weight loss, fat digestion and enzymes with gallbladder cancer","route":"/terms/weight-loss-and-fat-digestion-biliary/","field":"links","label":"AMMF: nutrition"}]},{"url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"AMMF: UK centres with hepatobiliary expertise"},{"id":"kings-college-hospital-london","kind":"institution","name":"King's College Hospital, London","route":"/institutions/kings-college-hospital-london/","field":"links","label":"AMMF centres list"},{"id":"manchester-royal-infirmary","kind":"institution","name":"Manchester Royal Infirmary HPB Unit","route":"/institutions/manchester-royal-infirmary/","field":"links","label":"AMMF centres list"},{"id":"royal-infirmary-edinburgh","kind":"institution","name":"Royal Infirmary of Edinburgh","route":"/institutions/royal-infirmary-edinburgh/","field":"links","label":"AMMF centres list"},{"id":"university-hospital-wales-cardiff","kind":"institution","name":"University Hospital of Wales, Cardiff","route":"/institutions/university-hospital-wales-cardiff/","field":"links","label":"AMMF centres list"},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","field":"links","label":"AMMF: centres with CCA expertise"}]},{"url":"https://amphista.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","field":"links","label":"Official website"},{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","field":"website"}]},{"url":"https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","field":"links","label":"AMX-883 IND clearance (June 2026)"}]},{"url":"https://amphista.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://anbogen.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","route":"/companies/anbogen-therapeutics/","field":"links","label":"Official website"},{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","route":"/companies/anbogen-therapeutics/","field":"website"}]},{"url":"https://angleplc.com","status":200,"ok":true,"finalUrl":"https://cellbxhealth.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"parsortix-ctc-harvest","kind":"technology","name":"Parsortix label-free circulating tumour cell harvest","route":"/technologies/parsortix-ctc-harvest/","field":"links","label":"ANGLE plc: Parsortix system"},{"id":"angle-plc","kind":"company","name":"ANGLE plc","route":"/companies/angle-plc/","field":"links","label":"Official website"},{"id":"angle-plc","kind":"company","name":"ANGLE plc","route":"/companies/angle-plc/","field":"website"}]},{"url":"https://anndata.readthedocs.io/en/stable/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anndata-h5ad","kind":"term","name":"AnnData and h5ad files","route":"/terms/anndata-h5ad/","field":"links","label":"anndata documentation"}]},{"url":"https://anocca.com","status":200,"ok":true,"finalUrl":"https://www.anocca.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/","field":"links","label":"Official website"},{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/","field":"website"}]},{"url":"https://anzup.org.au","status":200,"ok":true,"finalUrl":"https://anzup.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/","field":"links","label":"ANZUP"},{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/","field":"website"}]},{"url":"https://anzup.org.au/about-us/board/","status":200,"ok":true,"finalUrl":"https://anzup.org.au/about-anzup/board-of-directors/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","field":"links","label":"Society page"},{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","field":"profiles","label":"Society page"},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","field":"links","label":"Society page"},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","field":"profiles","label":"Society page"}]},{"url":"https://anzup.org.au/trials/","status":200,"ok":true,"finalUrl":"https://anzup.org.au/presentation/trials-in-progress-p3bep-anzup-1302-an-international-randomized-phase-3-trial-of-accelerated-versus-standard-bep-chemotherapy-for-individuals-aged-11-45-years-with-intermediate-and-poor-risk-metas/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/","field":"links","label":"Trials"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ABRAXANE%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"links","label":"Abraxane label (openFDA): adenocarcinoma of the pancreas study section"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"Abraxane label (openFDA): pancreatic indication and MPACT study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BIZENGRI%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"links","label":"Bizengri label (openFDA): pancreatic indication and eNRGy study section"},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"links","label":"Bizengri label (openFDA): pancreatic adenocarcinoma study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22DATROWAY%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"links","label":"Datroway label (openFDA): TNBC indication and TROPION-Breast02 study section"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Stomatitis (any grade))"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Nausea (any grade))"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"links","label":"Datroway label (openFDA): TROPION-Breast02 study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ENHERTU%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"links","label":"Enhertu label (openFDA): DESTINY-PanTumor02 efficacy by tumour type"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"outcomes.source (Confirmed objective response by independent central review, biliary tract cancer cohort with HER2 IHC 3+ (Enhertu label))"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"links","label":"Enhertu label (openFDA): HER2-low and HER2-ultralow indications, DESTINY-Breast04 study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22IMFINZI%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"Imfinzi label (openFDA): TOPAZ-1 baseline tumour location"},{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/","field":"links","label":"Imfinzi label (openFDA): TOPAZ-1 primary tumour location ICCA 56%, ECCA 18%, GBC 25%"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22JEMPERLI%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"links","label":"Jemperli label (openFDA): dMMR solid tumour indication"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KEYTRUDA%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"links","label":"Keytruda label (openFDA): MSI-H/dMMR efficacy by tumour type"},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"outcomes.source (Objective response, MSI-H or dMMR pancreatic cancer cohort (label))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"Keytruda label (openFDA): TNBC indications and KEYNOTE-522, KEYNOTE-355 and KEYNOTE-D19 study sections"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KRAZATI%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"links","label":"Krazati label (openFDA): indications"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LUMAKRAS%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"links","label":"Lumakras label (openFDA): indications, no pancreatic cancer indication"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"links","label":"Lumakras label (openFDA): indications"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LYNPARZA%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","field":"links","label":"Lynparza label (openFDA): POLO study section"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"Lynparza label (openFDA): OlympiA and OlympiAD study sections"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"links","label":"Lynparza label (openFDA): OlympiA eligibility and results"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ONIVYDE%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","field":"links","label":"Onivyde label (openFDA): NALIRIFOX indication and NAPOLI 3 results table"},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","field":"links","label":"Onivyde label (openFDA): NAPOLI 3 results table"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"links","label":"Onivyde label (openFDA): NAPOLI-1 study section"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"Onivyde label (openFDA): NAPOLI 3 and NAPOLI-1 study sections"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22RASONQUE%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"Rasonque label (openFDA): RASolute 302 efficacy table and adverse reactions"},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"outcomes.source (Progression-free survival by blinded independent central review (overall population))"},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"outcomes.source (Objective response rate by blinded independent central review (overall population))"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"Rasonque label (openFDA): indication, RASolute 302 results and adverse reactions"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TALZENNA%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"links","label":"Talzenna label (openFDA): EMBRACA study section"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"links","label":"Talzenna label (openFDA): EMBRACA study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TECENTRIQ%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"Tecentriq label (openFDA): indications list, no breast cancer indication after the 2021 withdrawal"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2021-08)"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TIBSOVO%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","field":"links","label":"Tibsovo label (openFDA): ClarIDHy baseline characteristics"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TRODELVY%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"links","label":"Trodelvy label (openFDA): first-line and later-line TNBC indications, ASCENT-03 study section"},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"links","label":"Trodelvy label (openFDA): ASCENT-03 study section"}]},{"url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZIIHERA%22","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/","field":"links","label":"Ziihera label (openFDA): 53% gallbladder cancer in HERIZON-BTC-01"},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"links","label":"Ziihera label (openFDA)"}]},{"url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"links","label":"Nobel Prize in Chemistry 2004"},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"profiles","label":"Nobel Prize in Chemistry 2004"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"links","label":"Nobel Prize in Chemistry 2004"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"profiles","label":"Nobel Prize in Chemistry 2004"},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","field":"links","label":"Nobel Prize in Chemistry 2004 (Nobel Prize API record)"}]},{"url":"https://app.usegalen.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/","field":"links","label":"Official website"},{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/","field":"website"}]},{"url":"https://ar.iiarjournals.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anticancer-research","kind":"journal","name":"Anticancer research","route":"/journals/anticancer-research/","field":"links","label":"Homepage"},{"id":"anticancer-research","kind":"journal","name":"Anticancer research","route":"/journals/anticancer-research/","field":"url"}]},{"url":"https://arcagy.org/fr/page/50-organisation-d-arcagy.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/","field":"links","label":"Source: ARCAGY organisation page"},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/","field":"profiles","label":"Institution profile"}]},{"url":"https://arcinstitute.org","status":200,"ok":true,"finalUrl":"https://arcinstitute.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","field":"links","label":"Official website"},{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","field":"website"}]},{"url":"https://arcinstitute.org/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"links","label":"Source: Arc Institute About page"}]},{"url":"https://arcinstitute.org/labs/konermannlab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"profiles","label":"Institution profile"}]},{"url":"https://arcinstitute.org/tools/virtualcellatlas","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","route":"/collections/arc-virtual-cell-atlas/","field":"links","label":"Arc Virtual Cell Atlas"},{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","route":"/collections/arc-virtual-cell-atlas/","field":"url"}]},{"url":"https://arpa-h.gov","status":200,"ok":true,"finalUrl":"https://arpa-h.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","field":"links","label":"ARPA-H"},{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","field":"website"}]},{"url":"https://arpa-h.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"links","label":"ARPA-H"},{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/","field":"links","label":"ARPA-H"},{"id":"idea-moon-supportive-care-arpa","kind":"idea","name":"An ARPA-style programme to develop supportive-care drugs nobody else will","route":"/ideas/idea-moon-supportive-care-arpa/","field":"links","label":"ARPA-H"}]},{"url":"https://arpa-h.gov/about/people","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","route":"/people/alicia-jackson/","field":"links","label":"Source: ARPA-H Our People page"}]},{"url":"https://arpa-h.gov/about/people/alicia-jackson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","route":"/people/alicia-jackson/","field":"profiles","label":"Institution profile"}]},{"url":"https://arpa-h.gov/news-and-events/arpa-h-funds-project-revolutionize-cancer-therapy-ultrasound-based-approach","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","field":"links","label":"ARPA-H award announcement (Dec 2024)"}]},{"url":"https://arpa-h.gov/research-and-funding/programs","status":200,"ok":true,"finalUrl":"https://arpa-h.gov/explore-funding/programs","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","field":"links","label":"Programs"}]},{"url":"https://arriveguidelines.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-preclinical-preregistration","kind":"idea","name":"Pre-register animal efficacy studies like clinical trials","route":"/ideas/idea-bio1-preclinical-preregistration/","field":"links","label":"ARRIVE guidelines"},{"id":"idea-tr2-arrive-audit","kind":"idea","name":"Audit animal studies for randomisation and blinding, published by institution","route":"/ideas/idea-tr2-arrive-audit/","field":"links","label":"ARRIVE guidelines"},{"id":"idea-tr2-animal-power-mandate","kind":"idea","name":"Pre-specified sample sizes for animal studies; no more 'representative' experiments","route":"/ideas/idea-tr2-animal-power-mandate/","field":"links","label":"ARRIVE guidelines"}]},{"url":"https://arsenalbio.com","status":200,"ok":true,"finalUrl":"https://arsenalbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","field":"website"}]},{"url":"https://artbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Official website"},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"website"}]},{"url":"https://artera.ai","status":200,"ok":true,"finalUrl":"https://artera.ai/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","field":"access.source (US)"},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","field":"access.source (US)"},{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/","field":"links","label":"Official website"},{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/","field":"website"}]},{"url":"https://artera.ai/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","field":"links","label":"Artera: ArteraAI tests"},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","field":"links","label":"Artera: ArteraAI tests"}]},{"url":"https://arxiv.org/abs/1802.04712","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abmil","kind":"term","name":"Attention-based multiple-instance learning (ABMIL, CLAM)","route":"/terms/abmil/","field":"links","label":"Ilse, Tomczak and Welling, Attention-based deep multiple instance learning (arXiv 2018)"}]},{"url":"https://arxiv.org/abs/1803.09010","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"model-card","kind":"term","name":"Model cards and datasheets for datasets","route":"/terms/model-card/","field":"links","label":"Gebru et al., Datasheets for Datasets (arXiv 2018)"}]},{"url":"https://arxiv.org/abs/1810.03993","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"model-card","kind":"term","name":"Model cards and datasheets for datasets","route":"/terms/model-card/","field":"links","label":"Mitchell et al., Model Cards for Model Reporting (arXiv 2018)"}]},{"url":"https://arxiv.org/abs/2106.09685","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fine-tuning-vs-frozen","kind":"term","name":"Fine-tuning versus frozen features, and LoRA","route":"/terms/fine-tuning-vs-frozen/","field":"links","label":"Hu et al., LoRA: Low-Rank Adaptation of Large Language Models (arXiv 2021)"}]},{"url":"https://arxiv.org/abs/2107.07511","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"conformal-prediction","kind":"term","name":"Conformal prediction","route":"/terms/conformal-prediction/","field":"links","label":"Angelopoulos and Bates, A gentle introduction to conformal prediction (arXiv 2021)"}]},{"url":"https://arxiv.org/abs/2308.02463","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radfm","kind":"technology","name":"RadFM (generalist radiology foundation model)","route":"/technologies/radfm/","field":"links","label":"RadFM (arXiv 2023)"}]},{"url":"https://arxiv.org/abs/2404.18416","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"med-gemini","kind":"technology","name":"Med-Gemini and MedLM (Google)","route":"/technologies/med-gemini/","field":"links","label":"Med-Gemini (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2406.05074","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hibou","kind":"technology","name":"Hibou (HistAI)","route":"/technologies/hibou/","field":"links","label":"Hibou (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2406.06512","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"merlin-ct","kind":"technology","name":"Merlin (Stanford abdominal CT vision-language model)","route":"/technologies/merlin-ct/","field":"links","label":"Merlin (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2407.07033","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pluto","kind":"technology","name":"PLUTO (PathAI)","route":"/technologies/pluto/","field":"links","label":"PLUTO (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2408.00738","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/","field":"links","label":"Virchow2 (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2409.09173","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"phikon","kind":"technology","name":"Phikon / Phikon-v2 (Owkin)","route":"/technologies/phikon/","field":"links","label":"Phikon-v2 (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2411.19666","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","field":"links","label":"TITAN (arXiv 2024)"}]},{"url":"https://arxiv.org/abs/2501.05409","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","field":"links","label":"Atlas (arXiv 2025)"}]},{"url":"https://arxiv.org/abs/2501.09001","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ct-fm","kind":"technology","name":"CT-FM (whole-body CT foundation model)","route":"/technologies/ct-fm/","field":"links","label":"CT-FM (arXiv 2025)"}]},{"url":"https://ascopost.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","field":"links","label":"The ASCO Post"},{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","field":"url"}]},{"url":"https://ascopost.com/issues/december-10-2025-supplement-conference-highlights-esmo-2025/final-overall-survival-confirms-benefit-of-durvalumab-plus-flot-in-resectable-gastric-and-gastroesophageal-junction-adenocarcinomas/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ascopost.com/issues/december-25-2021/final-analysis-of-pallas-trial-no-benefit-of-adjuvant-palbociclib-plus-endocrine-therapy-in-early-breast-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","field":"outcomes.source (4-year invasive disease-free survival (PALLAS))"}]},{"url":"https://ascopost.com/issues/february-25-2026/fda-approves-pembrolizumab-with-paclitaxel-for-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","field":"links","label":"FDA approval, ASCO Post"}]},{"url":"https://ascopost.com/issues/july-25-2026/emerald-3-shows-benefit-with-stride-plus-tace-in-hepatocellular-carcinoma/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","field":"links","label":"ASCO Post"}]},{"url":"https://ascopost.com/news/december-2025/fda-grants-traditional-approval-to-pirtobrutinib-for-cllsll/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"regulatoryEvents.source (2025-12-03)"}]},{"url":"https://ascopost.com/news/november-2025/fda-approves-ziftomenib-for-npm1-positive-aml/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","field":"toxicity.source (Differentiation syndrome)"},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","field":"regulatoryEvents.source (2025-11-13)"},{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","field":"links","label":"FDA approval coverage (ASCO Post)"}]},{"url":"https://ascopost.com/news/september-2026/fda-approves-camizestrant-combination-regimen-for-locally-advanced-or-metastatic-breast-cancer/","status":200,"ok":true,"finalUrl":"https://ascopost.com/issues/september-25-2026/fda-approves-camizestrant-combination-regimen-for-locally-advanced-or-metastatic-breast-cancer/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","field":"links","label":"ASCO Post approval"}]},{"url":"https://aslimnica.lv/par-mums/valde/","status":200,"ok":true,"finalUrl":"https://aslimnica.lv/par-mums/padome/valde/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","field":"links","label":"Source: Riga East University Hospital board (valde) page"},{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","field":"profiles","label":"Riga East University Hospital board page"}]},{"url":"https://assets.newsweek.com/wp-content/uploads/2025/08/20250730_World%C2%B4s-Best-Specialized-Hospitals_2026_Methodology.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","route":"/collections/newsweek-hospitals/","field":"links","label":"Methodology 2026"}]},{"url":"https://asthrahealth.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asthra-health","kind":"institution","name":"Asthra Health","route":"/institutions/asthra-health/","field":"links","label":"Official website"},{"id":"asthra-health","kind":"institution","name":"Asthra Health","route":"/institutions/asthra-health/","field":"website"},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","field":"links","label":"Asthra Health"},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","field":"profiles","label":"Asthra Health"}]},{"url":"https://asu-ghi.sorbonne-universite.fr/lasu-ghi/membres/joseph-gligorov","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","field":"links","label":"Source: Alliance Sorbonne Université Global Health Institute profile naming him Directeur Exécutif of the IUC"},{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","field":"profiles","label":"ASU-GHI member profile (Sorbonne Université)"}]},{"url":"https://atlasventure.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","field":"links","label":"Official website"},{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","field":"website"}]},{"url":"https://atlasventure.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","field":"links","label":"Portfolio"}]},{"url":"https://atomicalchemy.us","status":200,"ok":true,"finalUrl":"https://oklo.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"links","label":"Official website"},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"website"}]},{"url":"https://atossatherapeutics.com","status":200,"ok":true,"finalUrl":"https://atossatherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","field":"links","label":"Official website"},{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","field":"website"}]},{"url":"https://au.int/en/","status":200,"ok":true,"finalUrl":"https://au.int/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-african-medicines-agency-oncology","kind":"idea","name":"Fund an oncology joint assessment unit inside the African Medicines Agency","route":"/ideas/idea-reg-african-medicines-agency-oncology/","field":"links","label":"African Medicines Agency (page moved; nearest live section)"}]},{"url":"https://au.movember.com/about-us/governance","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"andrew-little","kind":"person","name":"Andrew Little","route":"/people/andrew-little/","field":"links","label":"Source: Movember governance page"},{"id":"andrew-little","kind":"person","name":"Andrew Little","route":"/people/andrew-little/","field":"profiles","label":"Movember leadership and governance"}]},{"url":"https://avenzotx.com/pipeline-and-science/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://avetabiomics.com","status":200,"ok":true,"finalUrl":"https://avetabiomics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/","field":"links","label":"Official website"},{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/","field":"website"}]},{"url":"https://b-s-h.org.uk/guidelines/","status":200,"ok":true,"finalUrl":"https://b-s-h.org.uk/guidelines","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-tumour-lysis","kind":"term","name":"Tumour lysis syndrome in lymphoma: who is at risk, and rasburicase","route":"/terms/lymphoma-tx-tumour-lysis/","field":"links","label":"British Society for Haematology guidelines"},{"id":"lymphoma-tx-pjp-and-infection-prophylaxis","kind":"term","name":"Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination","route":"/terms/lymphoma-tx-pjp-and-infection-prophylaxis/","field":"links","label":"British Society for Haematology guidelines"},{"id":"lymphoma-tx-immunoglobulin-replacement","kind":"term","name":"Immunoglobulin replacement after CAR-T, bispecifics and long anti-CD20 treatment","route":"/terms/lymphoma-tx-immunoglobulin-replacement/","field":"links","label":"British Society for Haematology guidelines"},{"id":"lymphoma-tx-fertility-preservation","kind":"term","name":"Fertility before lymphoma treatment: what to ask for, and when","route":"/terms/lymphoma-tx-fertility-preservation/","field":"links","label":"British Society for Haematology guidelines"}]},{"url":"https://bbotx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","field":"links","label":"Official website"},{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","field":"website"}]},{"url":"https://bbotx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://beaumontrcsicancercentre.ie/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","field":"links","label":"Source: Beaumont RCSI Cancer Centre homepage naming the Medical Director"},{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","field":"profiles","label":"Beaumont RCSI Cancer Centre homepage (Medical Director's welcome)"},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","field":"links","label":"Beaumont RCSI Cancer Centre website"},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","field":"profiles","label":"Beaumont RCSI Cancer Centre website"}]},{"url":"https://belaydiagnostics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","route":"/companies/belay-diagnostics/","field":"links","label":"Official website"},{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","route":"/companies/belay-diagnostics/","field":"website"}]},{"url":"https://belfasttrust.hscni.net","status":200,"ok":true,"finalUrl":"https://belfasttrust.hscni.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northern-ireland-cancer-centre","kind":"institution","name":"Northern Ireland Cancer Centre, Belfast City Hospital","route":"/institutions/northern-ireland-cancer-centre/","field":"links","label":"Official website"},{"id":"northern-ireland-cancer-centre","kind":"institution","name":"Northern Ireland Cancer Centre, Belfast City Hospital","route":"/institutions/northern-ireland-cancer-centre/","field":"website"}]},{"url":"https://belfasttrust.hscni.net/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belfast-trust-hpb","kind":"institution","name":"Belfast Health and Social Care Trust HPB service","route":"/institutions/belfast-trust-hpb/","field":"links","label":"Belfast Health and Social Care Trust"},{"id":"belfast-trust-hpb","kind":"institution","name":"Belfast Health and Social Care Trust HPB service","route":"/institutions/belfast-trust-hpb/","field":"website"}]},{"url":"https://belfasttrust.hscni.net/about/corporate-info/key-people/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","route":"/people/jennifer-welsh/","field":"links","label":"Source: Belfast Trust 'Key people' page (Chief Executive)"},{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","route":"/people/jennifer-welsh/","field":"profiles","label":"Belfast Trust key people page"}]},{"url":"https://belfasttrust.hscni.net/about/corporate-info/key-people/executive-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","route":"/people/jennifer-welsh/","field":"links","label":"Source: Belfast Trust executive team page"}]},{"url":"https://belong.life","status":200,"ok":true,"finalUrl":"https://belong.life/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","field":"links","label":"Official website"},{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","field":"website"}]},{"url":"https://belong.life/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","field":"links","label":"About Belong.Life"}]},{"url":"https://belong.life/contact-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","field":"links","label":"Contact page (New York office)"}]},{"url":"https://benhvienk.vn","status":200,"ok":true,"finalUrl":"https://benhvienk.vn/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"links","label":"Vietnam National Cancer Hospital (K Hospital) website"},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"profiles","label":"Vietnam National Cancer Hospital (K Hospital) website"},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/","field":"links","label":"K Hospital"},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/","field":"website"}]},{"url":"https://benhvienungbuou.vn","status":200,"ok":true,"finalUrl":"https://benhvienungbuou.vn/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/","field":"links","label":"HCMC Oncology Hospital"},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/","field":"website"}]},{"url":"https://benhvienungbuou.vn/ban-giam-doc-qua-cac-thoi-ky/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diep-bao-tuan","kind":"person","name":"Diệp Bảo Tuấn","route":"/people/diep-bao-tuan/","field":"profiles","label":"Hospital leadership page"}]},{"url":"https://benhvienungbuou.vn/le-cong-bo-va-trao-quyet-dinh-dieu-dong-bo-nhiem-pho-giam-doc-benh-vien-ung-buou-tp-hcm/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diep-bao-tuan","kind":"person","name":"Diệp Bảo Tuấn","route":"/people/diep-bao-tuan/","field":"links","label":"Source: hospital announcement naming the Director (January 2025)"}]},{"url":"https://bepartofresearch.nihr.ac.uk/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-opt-out-research-contact-register","kind":"idea","name":"Every patient is asked once at diagnosis whether researchers may contact them","route":"/ideas/idea-tr1-opt-out-research-contact-register/","field":"links","label":"NIHR Be Part of Research"},{"id":"nihr-be-part-of-research","kind":"collection","name":"Be Part of Research (NIHR)","route":"/collections/nihr-be-part-of-research/","field":"links","label":"Be Part of Research (NIHR)"},{"id":"nihr-be-part-of-research","kind":"collection","name":"Be Part of Research (NIHR)","route":"/collections/nihr-be-part-of-research/","field":"url"}]},{"url":"https://bepartofresearch.nihr.ac.uk/results/search-results?query=SUMMIT%20lung%20health%20check","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","field":"links","label":"NIHR Be Part of Research"}]},{"url":"https://bepartofresearch.nihr.ac.uk/results/search-results?query=TRACERx%20lung","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"links","label":"NIHR Be Part of Research"}]},{"url":"https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=NCT00532727","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/","field":"links","label":"Be Part of Research record"}]},{"url":"https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=NCT03150576","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/","field":"links","label":"Be Part of Research record"}]},{"url":"https://bighatbio.com/news","status":200,"ok":true,"finalUrl":"https://www.bighatbio.com/news","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","field":"links","label":"News"}]},{"url":"https://bighatbio.com/news/bighat-biosciences-announces-first-patient-dosed-in-phase-1-trial-evaluating-bhb810","status":200,"ok":true,"finalUrl":"https://www.bighatbio.com/news/bighat-biosciences-announces-first-patient-dosed-in-phase-1-trial-evaluating-bhb810","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","field":"links","label":"First patient dosed with BHB810 (September 2026)"}]},{"url":"https://biocad.ru","status":200,"ok":true,"finalUrl":"https://biocad.ru/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcd-100","kind":"drug","name":"BCD-100","route":"/drugs/bcd-100/","field":"links","label":"Sponsor page"}]},{"url":"https://biocad.ru/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/","field":"links","label":"Official website"},{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/","field":"website"}]},{"url":"https://biocad.ru/products","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","field":"links","label":"Sponsor page"}]},{"url":"https://bioconductor.org/packages/release/bioc/html/sva.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"batch-effects","kind":"term","name":"Batch effects and harmonisation","route":"/terms/batch-effects/","field":"links","label":"sva Bioconductor package (ComBat)"}]},{"url":"https://biohub.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","field":"links","label":"Chan Zuckerberg Biohub"}]},{"url":"https://biospecimens.cancer.gov/bestpractices/","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/data-tools-biospecimens/biospecimens-biobanks/resources/best-practices","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/","field":"links","label":"NCI Best Practices for Biospecimen Resources"}]},{"url":"https://birac.nic.in","status":200,"ok":true,"finalUrl":"https://birac.nic.in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/","field":"links","label":"BIRAC"}]},{"url":"https://bjcn.bg/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"links","label":"Bulgarian Joint Cancer Network (BJCN) website"},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"profiles","label":"Bulgarian Joint Cancer Network (BJCN) website"},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","route":"/institutions/bjcn/","field":"links","label":"Official website"},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","route":"/institutions/bjcn/","field":"website"}]},{"url":"https://blackdiamondtherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","field":"links","label":"Official website"},{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","field":"website"}]},{"url":"https://blackdiamondtherapeutics.com/pipeline-programs/pipeline","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://blackdiamondtherapeutics.com/pipeline-programs/silevertinib-nsclc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://blank.bio","status":200,"ok":true,"finalUrl":"https://www.blank.bio/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/","field":"links","label":"Official website"},{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/","field":"website"}]},{"url":"https://bmccancer.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/12885","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","field":"links","label":"Homepage"},{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","field":"url"}]},{"url":"https://boltbio.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.boltbio.com/pipeline-new/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://boundlessbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","field":"links","label":"Official website"},{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","field":"website"}]},{"url":"https://boundlessbio.com/what-we-do/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","field":"links","label":"What we do (ecDNA-directed therapies)"}]},{"url":"https://bowelbabe.org","status":200,"ok":true,"finalUrl":"https://www.bowelbabe.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowelbabe-fund","kind":"institution","name":"Bowelbabe Fund for Cancer Research UK","route":"/institutions/bowelbabe-fund/","field":"website"}]},{"url":"https://bowelbabe.org/","status":200,"ok":true,"finalUrl":"https://www.bowelbabe.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"links","label":"Bowelbabe Fund for Cancer Research UK"},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"profiles","label":"Bowelbabe Fund for Cancer Research UK"},{"id":"bowelbabe-fund","kind":"institution","name":"Bowelbabe Fund for Cancer Research UK","route":"/institutions/bowelbabe-fund/","field":"links","label":"Bowelbabe Fund"}]},{"url":"https://bowelresearchuk.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowel-research-uk","kind":"institution","name":"Bowel Research UK","route":"/institutions/bowel-research-uk/","field":"links","label":"Bowel Research UK"},{"id":"bowel-research-uk","kind":"institution","name":"Bowel Research UK","route":"/institutions/bowel-research-uk/","field":"website"}]},{"url":"https://brainchildbio.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://braintumor.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","field":"links","label":"NBTS"},{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","field":"url"}]},{"url":"https://breakthroughcancer.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/","field":"links","label":"Official website"},{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/","field":"website"}]},{"url":"https://breakthroughcancer.org/fast-facts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/","field":"links","label":"Fast facts"}]},{"url":"https://breast-cancer-research.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/13058","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","field":"links","label":"Homepage"},{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","field":"url"}]},{"url":"https://breastcancernow.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/","field":"links","label":"Breast Cancer Now"},{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/","field":"website"},{"id":"breast-cancer-now-helpline","kind":"collection","name":"Breast Cancer Now helpline","route":"/collections/breast-cancer-now-helpline/","field":"links","label":"Breast Cancer Now helpline"},{"id":"breast-cancer-now-helpline","kind":"collection","name":"Breast Cancer Now helpline","route":"/collections/breast-cancer-now-helpline/","field":"url"}]},{"url":"https://breastcancernow.org/about-breast-cancer/awareness/breast-cancer-in-families/genetic-testing-for-altered-breast-cancer-genes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Breast Cancer Now: genetic testing for altered breast cancer genes"}],"archive":"https://web.archive.org/web/20260611162952/https://breastcancernow.org/about-breast-cancer/awareness/breast-cancer-in-families/genetic-testing-for-altered-breast-cancer-genes"},{"url":"https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer/triple-negative-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Breast Cancer Now: triple negative breast cancer"},{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/","field":"links","label":"Triple negative breast cancer"}],"archive":"https://web.archive.org/web/20260609120723/https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer/triple-negative-breast-cancer"},{"url":"https://breastcancernow.org/about-breast-cancer/life-after-treatment/coping-with-breast-cancer-emotionally","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"Breast Cancer Now: coping with breast cancer emotionally"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Breast Cancer Now: coping with breast cancer emotionally"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Breast Cancer Now: coping with breast cancer emotionally"}]},{"url":"https://breastcancernow.org/about-breast-cancer/secondary-breast-cancer/secondary-breast-cancer-symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Breast Cancer Now: secondary breast cancer symptoms"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Breast Cancer Now: secondary breast cancer symptoms"}]},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/lymphoedema","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"Breast Cancer Now: lymphoedema"},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"Breast Cancer Now: lymphoedema"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Breast Cancer Now: lymphoedema"}]},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/radiotherapy-for-primary-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Breast Cancer Now: radiotherapy for primary breast cancer"}],"archive":"https://web.archive.org/web/20260614134129/https://breastcancernow.org/about-breast-cancer/treatment/radiotherapy-for-primary-breast-cancer"},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/surgery-for-primary-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-margins-and-re-excision","kind":"term","name":"Margins after breast-conserving surgery, and second operations","route":"/terms/breast-margins-and-re-excision/","field":"links","label":"Breast Cancer Now: surgery for primary breast cancer"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"Breast Cancer Now: surgery for primary breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Breast Cancer Now: surgery for primary breast cancer"}]},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/olaparib-lynparza","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Breast Cancer Now: olaparib (Lynparza)"}],"archive":"https://web.archive.org/web/20260609123004/https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/olaparib-lynparza"},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/pembrolizumab-keytruda","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Breast Cancer Now: pembrolizumab (Keytruda)"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Breast Cancer Now: pembrolizumab (Keytruda)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Breast Cancer Now: pembrolizumab (Keytruda)"}],"archive":"https://web.archive.org/web/20260514132841/https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/pembrolizumab-keytruda"},{"url":"https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/sacituzumab-govitecan-trodelvy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","field":"links","label":"Breast Cancer Now: sacituzumab govitecan (Trodelvy)"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Breast Cancer Now: sacituzumab govitecan (Trodelvy)"}]},{"url":"https://breastcancernow.org/all-services/services-and-information-at-breast-cancer-now","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/","field":"links","label":"Services and information"}]},{"url":"https://broadinstitute.github.io/gistic2/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gistic","kind":"term","name":"GISTIC (copy number driver detection)","route":"/terms/gistic/","field":"links","label":"GISTIC2 documentation (Broad Institute)"}]},{"url":"https://c-rad.se/","status":200,"ok":true,"finalUrl":"https://c-rad.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patient-positioning-surface-guidance-systems","kind":"technology","name":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","route":"/technologies/patient-positioning-surface-guidance-systems/","field":"links","label":"C-RAD: Catalyst+"},{"id":"c-rad","kind":"company","name":"C-RAD","route":"/companies/c-rad/","field":"links","label":"Official website"},{"id":"c-rad","kind":"company","name":"C-RAD","route":"/companies/c-rad/","field":"website"}]},{"url":"https://c4therapeutics.com","status":200,"ok":true,"finalUrl":"https://c4therapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","field":"website"}]},{"url":"https://ca.wikipedia.org/wiki/Institut_Catal%C3%A0_d%27Oncologia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","route":"/people/ramon-salazar-soler/","field":"links","label":"Source: Catalan Wikipedia article on the ICO naming the director general"},{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","route":"/people/ramon-salazar-soler/","field":"profiles","label":"Wikipedia (Catalan): Institut Català d'Oncologia"}]},{"url":"https://calliotx.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","field":"links","label":"Official website"},{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","field":"website"}]},{"url":"https://calliotx.com/news/","status":200,"ok":true,"finalUrl":"https://calliotx.com/news","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","field":"links","label":"News and publications"}]},{"url":"https://calrx.ca.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/","field":"links","label":"CalRx"}]},{"url":"https://cancer.ca","status":200,"ok":true,"finalUrl":"https://cancer.ca/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","field":"links","label":"Canadian Cancer Society"},{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","field":"website"}]},{"url":"https://cancer.ca/en/about-us/our-people","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-seale","kind":"person","name":"Andrea Seale","route":"/people/andrea-seale/","field":"links","label":"Source: Canadian Cancer Society Our People page"},{"id":"andrea-seale","kind":"person","name":"Andrea Seale","route":"/people/andrea-seale/","field":"profiles","label":"Institution profile"}]},{"url":"https://cancer.ca/en/research","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","field":"links","label":"Research"}]},{"url":"https://cancer.dartmouth.edu","status":200,"ok":true,"finalUrl":"https://cancer.dartmouth.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","field":"links","label":"Dartmouth Cancer Center"},{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","field":"website"}]},{"url":"https://cancer.dartmouth.edu/clinical-trials","status":200,"ok":true,"finalUrl":"https://cancer.dartmouth.edu/prostate/clinical-trials","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","field":"links","label":"Clinical trials"}]},{"url":"https://cancer.illinois.edu","status":200,"ok":true,"finalUrl":"https://cancer.illinois.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","field":"links","label":"Cancer Center at Illinois"},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","field":"website"}]},{"url":"https://cancer.illinois.edu/about","status":200,"ok":true,"finalUrl":"https://cancer.illinois.edu/about/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","field":"links","label":"Source: Cancer Center at Illinois 'About' page (history)"}]},{"url":"https://cancer.illinois.edu/ccil-leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","field":"links","label":"Source: Cancer Center at Illinois leadership page"},{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","field":"profiles","label":"Cancer Center at Illinois leadership directory"}]},{"url":"https://cancer.iu.edu","status":200,"ok":true,"finalUrl":"https://cancer.iu.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","route":"/institutions/iu-simon/","field":"links","label":"IU Simon Comprehensive Cancer Center"},{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","route":"/institutions/iu-simon/","field":"website"}]},{"url":"https://cancer.iu.edu/about/leadership/executive-committee.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","field":"links","label":"Source: IU Simon Cancer Center Executive Committee page"}]},{"url":"https://cancer.iu.edu/about/members/bio/1600/index.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","field":"links","label":"Source: IU Simon Cancer Center member biography"},{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","field":"profiles","label":"IU Simon Cancer Center biography"}]},{"url":"https://cancer.jmir.org","status":200,"ok":true,"finalUrl":"https://cancer.jmir.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","field":"links","label":"Homepage"},{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","field":"url"}]},{"url":"https://cancer.osu.edu","status":200,"ok":true,"finalUrl":"https://cancer.osu.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","field":"links","label":"OSUCCC-James"},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","field":"website"}]},{"url":"https://cancer.osu.edu/for-patients-and-caregivers/clinical-trials","status":200,"ok":true,"finalUrl":"https://cancer.osu.edu/utility/error404?aspxerrorpath=/for-patients-and-caregivers/clinical-trials","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","field":"links","label":"Clinical trials"}]},{"url":"https://cancer.sanger.ac.uk/cosmic","status":200,"ok":true,"finalUrl":"https://cancer.sanger.ac.uk/cosmic/login","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","route":"/collections/cosmic/","field":"links","label":"COSMIC (Catalogue of Somatic Mutations in Cancer)"},{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","route":"/collections/cosmic/","field":"url"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","field":"links","label":"COSMIC"}]},{"url":"https://cancer.sanger.ac.uk/signatures/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/","field":"links","label":"COSMIC mutational signatures"}]},{"url":"https://cancer.stanford.edu","status":200,"ok":true,"finalUrl":"https://med.stanford.edu/cancer","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/","field":"links","label":"Official website"},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/","field":"website"}]},{"url":"https://cancer.uchicago.edu","status":200,"ok":true,"finalUrl":"https://www.uchicagomedicine.org/cancer","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","field":"links","label":"UChicago Medicine Comprehensive Cancer Center"},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","field":"website"}]},{"url":"https://cancer.uchicago.edu/clinical-trials/","status":200,"ok":true,"finalUrl":"https://www.uchicagomedicine.org/cancer/research/clinical-trials","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","field":"links","label":"Clinical trials"}]},{"url":"https://cancer.uci.edu","status":200,"ok":true,"finalUrl":"https://cancer.uci.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","route":"/institutions/uci-chao/","field":"links","label":"Chao Family Comprehensive Cancer Center"},{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","route":"/institutions/uci-chao/","field":"website"}]},{"url":"https://cancer.uci.edu/about/leadership/","status":200,"ok":true,"finalUrl":"https://cancer.uci.edu/about/leadership","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","route":"/people/richard-van-etten/","field":"links","label":"Source: Chao Family Comprehensive Cancer Center leadership page"},{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","route":"/people/richard-van-etten/","field":"profiles","label":"Chao Family Comprehensive Cancer Center leadership page"}]},{"url":"https://cancer.ucsf.edu","status":200,"ok":true,"finalUrl":"https://cancer.ucsf.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"links","label":"Official website"},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"website"}]},{"url":"https://cancer.ufl.edu","status":200,"ok":true,"finalUrl":"https://cancer.ufl.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","field":"links","label":"UF Health Cancer Center"},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","field":"website"}]},{"url":"https://cancer.ufl.edu/about/leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","field":"links","label":"Source: UF Health Cancer Institute leadership page"},{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","field":"profiles","label":"UF Health Cancer Institute leadership page"}]},{"url":"https://cancer.ufl.edu/about/welcome-overview/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","field":"profiles","label":"Interim director's welcome"}]},{"url":"https://cancer.uiowa.edu","status":200,"ok":true,"finalUrl":"https://uihc.org/cancer","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","field":"links","label":"Cancer research"}]},{"url":"https://cancer.umn.edu","status":200,"ok":true,"finalUrl":"https://cancer.umn.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/","field":"links","label":"Masonic Cancer Center"},{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/","field":"website"}]},{"url":"https://cancer.umn.edu/about/leadership","status":200,"ok":true,"finalUrl":"https://cancer.umn.edu/about/leadership-and-staff-directory","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/","field":"links","label":"Source: Masonic Cancer Center leadership directory"},{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/","field":"profiles","label":"Masonic Cancer Center leadership page"}]},{"url":"https://cancer.unm.edu","status":200,"ok":true,"finalUrl":"https://unmhealth.org/cancer/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/","field":"links","label":"UNM Comprehensive Cancer Center"},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/","field":"website"}]},{"url":"https://cancer.uthscsa.edu","status":200,"ok":true,"finalUrl":"https://cancer.uthscsa.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","field":"links","label":"Mays Cancer Center"},{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","field":"website"}]},{"url":"https://cancer.uthscsa.edu/about/about-uthealthsa-mdanderson-cancer-center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","field":"links","label":"Source: Mays Cancer Center about page"}]},{"url":"https://cancer.wisc.edu","status":200,"ok":true,"finalUrl":"https://cancer.wisc.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","field":"links","label":"UW Carbone Cancer Center"},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","field":"website"}]},{"url":"https://cancer.wisc.edu/uwccc-leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christian-capitini","kind":"person","name":"Christian Capitini","route":"/people/christian-capitini/","field":"links","label":"Source: UW Carbone Cancer Center leadership page"},{"id":"christian-capitini","kind":"person","name":"Christian Capitini","route":"/people/christian-capitini/","field":"profiles","label":"UW Carbone Cancer Center leadership page"}]},{"url":"https://canceralliance.wyhpartnership.co.uk","status":200,"ok":true,"finalUrl":"https://canceralliance.wyhpartnership.co.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/","field":"links","label":"West Yorkshire and Harrogate Cancer Alliance"},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/","field":"website"}]},{"url":"https://cancercenter.arizona.edu","status":200,"ok":true,"finalUrl":"https://cancercenter.arizona.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","field":"links","label":"University of Arizona Cancer Center"},{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","field":"website"}]},{"url":"https://cancercenter.arizona.edu/message-director/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","route":"/people/dan-theodorescu/","field":"links","label":"Source: University of Arizona Cancer Center leadership page"},{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","route":"/people/dan-theodorescu/","field":"profiles","label":"University of Arizona Cancer Center leadership page"}]},{"url":"https://cancercenter.cun.es/cancer-center/organigrama","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","field":"links","label":"Institution profile"},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","field":"profiles","label":"Institution profile"},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","field":"links","label":"Institution profile"},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","field":"profiles","label":"Institution profile"},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","field":"links","label":"Institution profile"},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","field":"profiles","label":"Institution profile"}]},{"url":"https://cancercommons.org","status":200,"ok":true,"finalUrl":"https://www.cancercommons.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/","field":"links","label":"Official website"},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/","field":"website"}]},{"url":"https://cancercontrol.cancer.gov/brp/tcrb/cessation-initiative","status":200,"ok":true,"finalUrl":"https://cancercontrol.cancer.gov/brp/tcrb/cancer-center-cessation-initiative","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","field":"links","label":"NCI Cancer Center Cessation Initiative"}]},{"url":"https://cancercontrol.cancer.gov/ocs/statistics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"links","label":"NCI Office of Cancer Survivorship statistics"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"metrics (People living in the US with a history of cancer (2022 estimate))"},{"id":"idea-acc-risk-stratified-cardio-oncology-pathway","kind":"idea","name":"A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy","route":"/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-default-fertility-preservation-referral","kind":"idea","name":"Default fertility preservation referral for every patient under 40 before treatment","route":"/ideas/idea-acc-default-fertility-preservation-referral/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-risk-stratified-follow-up","kind":"idea","name":"Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry","route":"/ideas/idea-acc-risk-stratified-follow-up/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-tailored-second-cancer-screening","kind":"idea","name":"Tailored screening for second cancers in survivors with known high-risk exposures","route":"/ideas/idea-acc-tailored-second-cancer-screening/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-return-to-work-rehabilitation","kind":"idea","name":"Vocational rehabilitation integrated into cancer care so survivors can return to work","route":"/ideas/idea-acc-return-to-work-rehabilitation/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-cognitive-rehabilitation-after-chemotherapy","kind":"idea","name":"Trials of structured cognitive rehabilitation for cancer-related cognitive impairment","route":"/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-aya-survivorship-passport","kind":"idea","name":"A survivorship passport app for adolescent and young adult survivors","route":"/ideas/idea-acc-aya-survivorship-passport/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-acc-lymphoedema-prospective-surveillance","kind":"idea","name":"Prospective arm-volume surveillance to catch and reverse lymphoedema early","route":"/ideas/idea-acc-lymphoedema-prospective-surveillance/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-moon-survivor-lifelong-care-model","kind":"idea","name":"Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care","route":"/ideas/idea-moon-survivor-lifelong-care-model/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-nl-exercise-dose-finding","kind":"idea","name":"A dose-finding trial for exercise after cancer","route":"/ideas/idea-nl-exercise-dose-finding/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"},{"id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/","field":"links","label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics"}]},{"url":"https://cancergenome.ru","status":200,"ok":true,"finalUrl":"https://cancergenome.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","route":"/institutions/russco/","field":"links","label":"National molecular diagnosis programme"}]},{"url":"https://cancergrandchallenges.org","status":200,"ok":true,"finalUrl":"https://www.cancergrandchallenges.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-rapid-autopsy-commons","kind":"idea","name":"A global rapid tissue donation network for metastatic disease","route":"/ideas/idea-bio2-rapid-autopsy-commons/","field":"links","label":"Cancer Grand Challenges"},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","field":"links","label":"Cancer Grand Challenges"},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","field":"website"}]},{"url":"https://cancergrandchallenges.org/","status":200,"ok":true,"finalUrl":"https://www.cancergrandchallenges.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"links","label":"Cancer Grand Challenges"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"links","label":"Cancer Grand Challenges"},{"id":"idea-fund-metastasis-moonshot","kind":"idea","name":"A ring-fenced metastasis programme with metastasis-specific endpoints","route":"/ideas/idea-fund-metastasis-moonshot/","field":"links","label":"Cancer Grand Challenges"},{"id":"idea-moon-cure-prizes","kind":"idea","name":"Cure-focused prizes: pay for verified long-term cures, not for drugs","route":"/ideas/idea-moon-cure-prizes/","field":"links","label":"Cancer Grand Challenges"}]},{"url":"https://cancergrandchallenges.org/teams/edynamic","status":200,"ok":true,"finalUrl":"https://www.cancergrandchallenges.org/edynamic","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","field":"links","label":"Cancer Grand Challenges eDyNAmiC team"}]},{"url":"https://cancerimagingjournal.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/40644","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"Homepage"},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"url"}]},{"url":"https://cancerletter.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","field":"links","label":"The Cancer Letter"},{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","field":"url"}]},{"url":"https://cancerletter.com/clinical-roundup/20260807_8a/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","field":"regulatoryEvents.source (2026-07-30)"}]},{"url":"https://candeltx.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","field":"links","label":"Official website"},{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","field":"website"}]},{"url":"https://canopycare.us","status":200,"ok":true,"finalUrl":"https://canopycare.us/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"canopy","kind":"company","name":"Canopy","route":"/companies/canopy/","field":"links","label":"Official website"},{"id":"canopy","kind":"company","name":"Canopy","route":"/companies/canopy/","field":"website"}]},{"url":"https://canopycare.us/about","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"canopy","kind":"company","name":"Canopy","route":"/companies/canopy/","field":"links","label":"About Canopy"}]},{"url":"https://capiostgoran.se/","status":200,"ok":true,"finalUrl":"https://www.capiostgoran.se/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","field":"links","label":"Capio S:t Göran's Hospital website"},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","field":"profiles","label":"Capio S:t Göran's Hospital website"},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/","field":"links","label":"Official website"},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/","field":"website"}]},{"url":"https://captortherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","field":"links","label":"Official website"},{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","field":"website"}]},{"url":"https://captortherapeutics.com/investor-relations/overview/about-company","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","field":"links","label":"About Captor (investor relations)"}]},{"url":"https://captortherapeutics.com/investor-relations/shares-and-related-information/shares","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","field":"links","label":"Shares and WSE listing details"}]},{"url":"https://captortherapeutics.com/pipeline-en","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://cardiacinstitute.bg/en/hospitals-and-centers/heart-and-brain-center-of-excellence-pleven/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"links","label":"Heart and Brain Hospital, Pleven website"},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"profiles","label":"Heart and Brain Hospital, Pleven website"},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","route":"/institutions/heart-and-brain-pleven/","field":"links","label":"Official website"},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","route":"/institutions/heart-and-brain-pleven/","field":"website"}]},{"url":"https://careology.health/about","status":200,"ok":true,"finalUrl":"https://www.careology.health/en-us/about","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","field":"links","label":"About Careology"}]},{"url":"https://careology.health/resources/news/careology-raises-pound1-1m-for-ambitious-growth-plans","status":200,"ok":true,"finalUrl":"https://www.careology.health/en-us/resources/news/careology-raises-pound1-1m-for-ambitious-growth-plans","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","field":"links","label":"GBP 1.1 million seed announcement (November 2019)"}]},{"url":"https://careology.health/resources/news/evolent-and-careology-join-forces-to-transform-cancer-care-in-the-us","status":200,"ok":true,"finalUrl":"https://www.careology.health/en-us/resources/news/evolent-and-careology-join-forces-to-transform-cancer-care-in-the-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","field":"links","label":"Evolent partnership (May 2024)"}]},{"url":"https://carpem.fr/gouvernance/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","field":"links","label":"Source: CARPEM governance page"},{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","field":"profiles","label":"CARPEM governance page"}]},{"url":"https://carpem.fr/linstitut/","status":200,"ok":true,"finalUrl":"https://carpem.fr/linstitut-du-cancer-paris-carpem/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","field":"links","label":"Source: Institut du Cancer Paris CARPEM presentation"}]},{"url":"https://carrumhealth.com","status":200,"ok":true,"finalUrl":"https://carrumhealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","field":"links","label":"Official website"},{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","field":"website"}]},{"url":"https://carrumhealth.com/carrum-health-first-to-launch-bundled-cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","field":"links","label":"Bundled cancer care launch with Memorial Sloan Kettering (February 2021)"}]},{"url":"https://carrumhealth.com/carrum-health-raises-40-million-to-transform-healthcare/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","field":"links","label":"Series A press release (January 2021)"}]},{"url":"https://carrumhealth.com/seriesb/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","field":"links","label":"Series B press release (May 2023)"}]},{"url":"https://carthera.eu/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carthera","kind":"company","name":"Carthera","route":"/companies/carthera/","field":"links","label":"Official website"},{"id":"carthera","kind":"company","name":"Carthera","route":"/companies/carthera/","field":"website"}]},{"url":"https://casdincapital.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","field":"links","label":"Official website"},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","field":"website"}]},{"url":"https://casdincapital.com/team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","field":"links","label":"Team"}]},{"url":"https://casdincapital.com/venture/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","field":"links","label":"Venture portfolio"}]},{"url":"https://case.edu/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","field":"links","label":"Case Comprehensive Cancer Center"},{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","field":"website"}]},{"url":"https://catalogues.ema.europa.eu/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-observational-study-registration","kind":"idea","name":"Pre-registration and results reporting for real-world cancer studies","route":"/ideas/idea-data-observational-study-registration/","field":"links","label":"EU PAS Register (HMA-EMA catalogue)"}]},{"url":"https://cavuhb.nhs.wales/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-hospital-wales-cardiff","kind":"institution","name":"University Hospital of Wales, Cardiff","route":"/institutions/university-hospital-wales-cardiff/","field":"links","label":"Cardiff and Vale University Health Board"},{"id":"university-hospital-wales-cardiff","kind":"institution","name":"University Hospital of Wales, Cardiff","route":"/institutions/university-hospital-wales-cardiff/","field":"website"}]},{"url":"https://ccc.meduniwien.ac.at/ueber-uns/die-leitung-des-comprehensive-cancer-center/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"links","label":"Institution profile"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"profiles","label":"Institution profile"},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"links","label":"Institution profile"},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"profiles","label":"Institution profile"}]},{"url":"https://cccrc.gov.om","status":200,"ok":true,"finalUrl":"https://cccrc.gov.om/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sultan-qaboos-cccrc","kind":"institution","name":"Sultan Qaboos Comprehensive Cancer Care and Research Centre","route":"/institutions/sultan-qaboos-cccrc/","field":"links","label":"Official website"},{"id":"sultan-qaboos-cccrc","kind":"institution","name":"Sultan Qaboos Comprehensive Cancer Care and Research Centre","route":"/institutions/sultan-qaboos-cccrc/","field":"website"}]},{"url":"https://cco.amegroups.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","route":"/journals/chinese-clinical-oncology/","field":"links","label":"Homepage"},{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","route":"/journals/chinese-clinical-oncology/","field":"url"}]},{"url":"https://ccr.cancer.gov","status":200,"ok":true,"finalUrl":"https://ccr.cancer.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","field":"links","label":"Center for Cancer Research"},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","field":"website"}]},{"url":"https://ccr.cancer.gov/about/office-of-the-director","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/","field":"links","label":"Source: CCR Office of the Director leadership page"}]},{"url":"https://ccr.cancer.gov/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","field":"links","label":"CCR clinical trials"}]},{"url":"https://ccr.cancer.gov/comparative-oncology-program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-comparative-oncology-dogs","kind":"idea","name":"Pet dogs with spontaneous cancer as a bridge before human trials","route":"/ideas/idea-bio1-comparative-oncology-dogs/","field":"links","label":"NCI Comparative Oncology Program"}]},{"url":"https://ccr.cancer.gov/staff-directory/brigitte-c-widemann","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"links","label":"NCI CCR profile"},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/james-l-gulley","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","field":"links","label":"NCI CCR profile"},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/louis-m-staudt","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"links","label":"NCI CCR profile"},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/nirali-n-shah","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"links","label":"NCI CCR profile"},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/raffit-hassan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","field":"links","label":"NCI CCR profile"},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/senthil-k-muthuswamy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/","field":"profiles","label":"CCR staff profile"}]},{"url":"https://ccr.cancer.gov/staff-directory/steven-a-rosenberg","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"links","label":"NCI CCR profile"},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"profiles","label":"NCI CCR profile"}]},{"url":"https://ccss.stjude.org","status":200,"ok":true,"finalUrl":"https://ccss.stjude.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"links","label":"CCSS"},{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/","field":"links","label":"Childhood Cancer Survivor Study"},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/","field":"links","label":"Childhood Cancer Survivor Study"}]},{"url":"https://ccss.stjude.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","field":"links","label":"Childhood Cancer Survivor Study"}]},{"url":"https://cdas.cancer.gov","status":200,"ok":true,"finalUrl":"https://cdas.cancer.gov/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","route":"/collections/cdas-nlst-plco/","field":"links","label":"NCI CDAS: NLST and PLCO screening trial data"},{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","route":"/collections/cdas-nlst-plco/","field":"url"}]},{"url":"https://cdmrp.health.mil/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-patient-burden-review-criterion","kind":"idea","name":"A formal patient-burden score in grant peer review","route":"/ideas/idea-fund-patient-burden-review-criterion/","field":"links","label":"CDMRP (US DoD medical research programmes)"}]},{"url":"https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","field":"links","label":"Quest collaboration and Series B initial close (Nov 2023)"}]},{"url":"https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","field":"links","label":"Series B close and FDA trial (Aug 2024)"}]},{"url":"https://cdsco.gov.in/opencms/opencms/en/About-us/who/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","route":"/people/rajeev-singh-raghuvanshi/","field":"links","label":"Source: CDSCO Who's who page"},{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","route":"/people/rajeev-singh-raghuvanshi/","field":"profiles","label":"CDSCO Who's who page"}]},{"url":"https://celldex.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/","field":"links","label":"Celldex pipeline"}]},{"url":"https://cellxgene.cziscience.com","status":200,"ok":true,"finalUrl":"https://cellxgene.cziscience.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","route":"/collections/cellxgene-hca/","field":"links","label":"CZ CELLxGENE / Human Cell Atlas"},{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","route":"/collections/cellxgene-hca/","field":"url"}]},{"url":"https://cen.acs.org/articles/96/i12/40-million-boron-neutron-capture.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","field":"links","label":"C&EN: $40 million for boron neutron capture therapy (March 2018)"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000496","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/","field":"links","label":"UMIN C000000412"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000794","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/","field":"links","label":"UMIN Clinical Trials Registry UMIN000000655"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001004","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","field":"links","label":"UMIN000000843"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001028","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","field":"links","label":"UMIN Clinical Trials Registry UMIN000000843"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002809","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jcog0802","kind":"trial","name":"JCOG0802 / WJOG4607L","route":"/trials/jcog0802/","field":"links","label":"UMIN Clinical Trials Registry UMIN000002317"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013683","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","field":"links","label":"UMIN000011688"}]},{"url":"https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031885","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/","field":"links","label":"UMIN000027887"}]},{"url":"https://cgoncology.com","status":200,"ok":true,"finalUrl":"https://cgoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/","field":"links","label":"Official website"},{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/","field":"website"}]},{"url":"https://cgoncology.com/cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-updates-2/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","field":"regulatoryEvents.source (2026)"}]},{"url":"https://cgp.iiarjournals.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","route":"/journals/cancer-genomics-and-proteomics/","field":"links","label":"Homepage"},{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","route":"/journals/cancer-genomics-and-proteomics/","field":"url"}]},{"url":"https://chanzuckerberg.com/science/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","field":"links","label":"Chan Zuckerberg Science"},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","field":"links","label":"Chan Zuckerberg Initiative Science"},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","field":"links","label":"Official website"},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","field":"website"}]},{"url":"https://childrensoncologygroup.org","status":200,"ok":true,"finalUrl":"https://childrensoncologygroup.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"links","label":"Children's Oncology Group"},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"profiles","label":"Children's Oncology Group"},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"links","label":"Children's Oncology Group"},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"profiles","label":"Children's Oncology Group"},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"links","label":"Children's Oncology Group"},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"profiles","label":"Children's Oncology Group"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"links","label":"Children's Oncology Group"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"profiles","label":"Children's Oncology Group"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"links","label":"Children's Oncology Group"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"profiles","label":"Children's Oncology Group"},{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/","field":"links","label":"Official website"},{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/","field":"website"}]},{"url":"https://childrensoncologygroup.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","field":"links","label":"Children's Oncology Group"},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","field":"links","label":"Children's Oncology Group"}]},{"url":"https://cicelysaundersinternational.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"links","label":"Cicely Saunders International"},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"profiles","label":"Cicely Saunders International"}]},{"url":"https://cima.cun.es/en","status":200,"ok":true,"finalUrl":"https://cima.cun.es/en/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","field":"links","label":"CIMA"}]},{"url":"https://circlepharma.com","status":200,"ok":true,"finalUrl":"https://circlepharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/","field":"website"}]},{"url":"https://circlepharma.com/circle-pharma-to-present-new-clinical-and-preclinical-data-at-aacr-2026","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/","field":"links","label":"AACR 2026 presentations"}]},{"url":"https://cisnet.cancer.gov","status":200,"ok":true,"finalUrl":"https://cisnet.cancer.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-prev-mced-stage-endpoint-surrogate","kind":"idea","name":"Let MCED trials read out on late-stage incidence, with mortality follow-up mandated","route":"/ideas/idea-prev-mced-stage-endpoint-surrogate/","field":"links","label":"CISNET"},{"id":"idea-prev-open-stage-shift-microsimulation","kind":"idea","name":"Open-source models that translate stage shift into lives saved, for every cancer","route":"/ideas/idea-prev-open-stage-shift-microsimulation/","field":"links","label":"CISNET"}]},{"url":"https://citation-file-format.github.io/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"citation-cff","kind":"term","name":"CITATION.cff (Citation File Format)","route":"/terms/citation-cff/","field":"links","label":"Citation File Format"}]},{"url":"https://ciusss-estmtl.gouv.qc.ca","status":200,"ok":true,"finalUrl":"https://ciusss-estmtl.gouv.qc.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","route":"/institutions/ciusss-emtl-maisonneuve-rosemont/","field":"links","label":"Official website"},{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","route":"/institutions/ciusss-emtl-maisonneuve-rosemont/","field":"website"}]},{"url":"https://ciusss-estmtl.gouv.qc.ca/ressources/documentation/organigramme","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-francois-fortin-verreault","kind":"person","name":"Jean-François Fortin Verreault","route":"/people/jean-francois-fortin-verreault/","field":"profiles","label":"CIUSSS organisation chart page"}]},{"url":"https://ciusss-estmtl.gouv.qc.ca/sites/ciusssemtl/files/media/document/PDF_organigramme_decembre2025_CIUSSS-EMTL.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"jean-francois-fortin-verreault","kind":"person","name":"Jean-François Fortin Verreault","route":"/people/jean-francois-fortin-verreault/","field":"links","label":"Source: CIUSSS de l'Est-de-l'Île-de-Montréal senior management organigramme (PDF, December 2025)"}]},{"url":"https://civicarx.org","status":200,"ok":true,"finalUrl":"https://civicarx.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","field":"links","label":"Official website"},{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","field":"website"}]},{"url":"https://civicarx.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-nonprofit-generic-chemo-manufacturer","kind":"idea","name":"A non-profit manufacturer for generic cancer drugs in chronic shortage","route":"/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/","field":"links","label":"Civica Rx"},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/","field":"links","label":"Civica Rx"},{"id":"idea-cost-nonprofit-generic-oncology","kind":"idea","name":"A non-profit manufacturer for shortage-prone generic chemotherapy","route":"/ideas/idea-cost-nonprofit-generic-oncology/","field":"links","label":"Civica Rx"}]},{"url":"https://civicdb.org","status":200,"ok":true,"finalUrl":"https://civicdb.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/","field":"links","label":"CIViC"},{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/","field":"url"}]},{"url":"https://clario.com","status":200,"ok":true,"finalUrl":"https://clario.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/","field":"links","label":"Official website"},{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/","field":"website"}]},{"url":"https://cleargene.com","status":200,"ok":true,"finalUrl":"https://cleargene.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clear-gene","kind":"company","name":"Clear Gene","route":"/companies/clear-gene/","field":"links","label":"Official website"},{"id":"clear-gene","kind":"company","name":"Clear Gene","route":"/companies/clear-gene/","field":"website"}]},{"url":"https://clinicalcenter.nih.gov","status":200,"ok":true,"finalUrl":"https://www.cc.nih.gov/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","field":"links","label":"NIH Clinical Center"}]},{"url":"https://clinicaltrials.gov","status":200,"ok":true,"finalUrl":"https://clinicaltrials.gov/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","field":"dosing.source"},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"dosing.source"},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","field":"links","label":"ClinicalTrials.gov"},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","field":"url"}]},{"url":"https://clinicaltrials.gov/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-moon-results-back-to-participants","kind":"idea","name":"Plain-language trial results returned to every participant within a year","route":"/ideas/idea-moon-results-back-to-participants/","field":"links","label":"ClinicalTrials.gov"},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"links","label":"ClinicalTrials.gov"},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","field":"links","label":"ClinicalTrials.gov"}]},{"url":"https://clinicaltrials.gov/policy/reporting-requirements","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","field":"links","label":"ClinicalTrials.gov results reporting requirements (FDAAA 801)"}]},{"url":"https://clinicaltrials.gov/search?cond=colorectal%20cancer&aggFilters=phase:2%203,studyType:int","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/","field":"links","label":"ClinicalTrials.gov search: colorectal cancer, interventional, phase 2 and 3"}]},{"url":"https://clinicaltrials.gov/search?cond=lung%20cancer&aggFilters=phase:2%203,studyType:int","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/","field":"links","label":"ClinicalTrials.gov search: lung cancer, interventional, phase 2 and 3"}]},{"url":"https://clinicaltrials.gov/search?cond=pancreatic%20cancer&aggFilters=phase:2%203,status:rec%20not%20act,studyType:int","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/","field":"links","label":"ClinicalTrials.gov search: pancreatic cancer, interventional, phase 2 and 3, recruiting"}]},{"url":"https://clinicaltrials.gov/search?cond=triple%20negative%20breast%20cancer&aggFilters=phase:2%203,status:rec%20not%20act,studyType:int","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/","field":"links","label":"ClinicalTrials.gov search: triple negative breast cancer, interventional, phase 2 and 3, recruiting"}]},{"url":"https://clinicaltrials.gov/search?intr=225Ac-PSMA-617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"links","label":"ClinicalTrials.gov: trials of Actinium-225 PSMA agents"}]},{"url":"https://clinicaltrials.gov/search?intr=A-1041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/","field":"links","label":"ClinicalTrials.gov: trials of RO7771950"}]},{"url":"https://clinicaltrials.gov/search?intr=A166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/","field":"links","label":"ClinicalTrials.gov: trials of A166"}]},{"url":"https://clinicaltrials.gov/search?intr=AAA817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","field":"links","label":"ClinicalTrials.gov: trials of AAA817"}]},{"url":"https://clinicaltrials.gov/search?intr=AB-218","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","field":"links","label":"ClinicalTrials.gov: trials of Safusidenib"}]},{"url":"https://clinicaltrials.gov/search?intr=AB154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","field":"links","label":"ClinicalTrials.gov: trials of Domvanalimab"}]},{"url":"https://clinicaltrials.gov/search?intr=ABBV-151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/","field":"links","label":"ClinicalTrials.gov: trials of Livmoniplimab"}]},{"url":"https://clinicaltrials.gov/search?intr=ABBV-181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/","field":"links","label":"ClinicalTrials.gov: trials of Budigalimab"}]},{"url":"https://clinicaltrials.gov/search?intr=ABBV-400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/","field":"links","label":"ClinicalTrials.gov: trials of Telisotuzumab adizutecan"}]},{"url":"https://clinicaltrials.gov/search?intr=ABBV-706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/","field":"links","label":"ClinicalTrials.gov: trials of ABBV-706"}]},{"url":"https://clinicaltrials.gov/search?intr=ABSK061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/","field":"links","label":"ClinicalTrials.gov: trials of ABSK061"}]},{"url":"https://clinicaltrials.gov/search?intr=ABT-301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/","field":"links","label":"ClinicalTrials.gov: trials of ABT-301"}]},{"url":"https://clinicaltrials.gov/search?intr=Adavosertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adavosertib","kind":"drug","name":"Adavosertib","route":"/drugs/adavosertib/","field":"links","label":"ClinicalTrials.gov: trials of Adavosertib"}]},{"url":"https://clinicaltrials.gov/search?intr=ADG126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/","field":"links","label":"ClinicalTrials.gov: trials of ADG126"}]},{"url":"https://clinicaltrials.gov/search?intr=ADI-270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/","field":"links","label":"ClinicalTrials.gov: trials of ADI-270"}]},{"url":"https://clinicaltrials.gov/search?intr=AGEN1181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","field":"links","label":"ClinicalTrials.gov: trials of Botensilimab"}]},{"url":"https://clinicaltrials.gov/search?intr=AI-081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","field":"links","label":"ClinicalTrials.gov: trials of AI-081"}]},{"url":"https://clinicaltrials.gov/search?intr=AK112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"links","label":"ClinicalTrials.gov: trials of Ivonescimab"}]},{"url":"https://clinicaltrials.gov/search?intr=AK117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","field":"links","label":"ClinicalTrials.gov: trials of AK117"}]},{"url":"https://clinicaltrials.gov/search?intr=AK119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ak119","kind":"drug","name":"AK119","route":"/drugs/ak119/","field":"links","label":"ClinicalTrials.gov: trials of AK119"}]},{"url":"https://clinicaltrials.gov/search?intr=AL2846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","field":"links","label":"ClinicalTrials.gov: trials of AL2846"}]},{"url":"https://clinicaltrials.gov/search?intr=AL8326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","field":"links","label":"ClinicalTrials.gov: trials of AL8326"}]},{"url":"https://clinicaltrials.gov/search?intr=Alisertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/","field":"links","label":"ClinicalTrials.gov: trials of Alisertib"}]},{"url":"https://clinicaltrials.gov/search?intr=ALLO-647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/","field":"links","label":"ClinicalTrials.gov: trials of ALLO-647"}]},{"url":"https://clinicaltrials.gov/search?intr=ALX148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/","field":"links","label":"ClinicalTrials.gov: trials of Evorpacept"}]},{"url":"https://clinicaltrials.gov/search?intr=AMO959","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amo959","kind":"drug","name":"AMO959","route":"/drugs/amo959/","field":"links","label":"ClinicalTrials.gov: trials of AMO959"}]},{"url":"https://clinicaltrials.gov/search?intr=Amrubicin","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","field":"links","label":"ClinicalTrials.gov: trials of Amrubicin"}]},{"url":"https://clinicaltrials.gov/search?intr=AMT-116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/","field":"links","label":"ClinicalTrials.gov: trials of AMT-116"}]},{"url":"https://clinicaltrials.gov/search?intr=Anvumetostat","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/","field":"links","label":"ClinicalTrials.gov: trials of Anvumetostat"}]},{"url":"https://clinicaltrials.gov/search?intr=ARD103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ard103","kind":"drug","name":"ARD103","route":"/drugs/ard103/","field":"links","label":"ClinicalTrials.gov: trials of ARD103"}]},{"url":"https://clinicaltrials.gov/search?intr=ASK120067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/","field":"links","label":"ClinicalTrials.gov: trials of Limertinib"}]},{"url":"https://clinicaltrials.gov/search?intr=ASP2138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","field":"links","label":"ClinicalTrials.gov: trials of ASP2138"}]},{"url":"https://clinicaltrials.gov/search?intr=ASP3082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/","field":"links","label":"ClinicalTrials.gov: trials of Setidegrasib"}]},{"url":"https://clinicaltrials.gov/search?intr=AT101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/","field":"links","label":"ClinicalTrials.gov: trials of AT101"}]},{"url":"https://clinicaltrials.gov/search?intr=Atebimetinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","field":"links","label":"ClinicalTrials.gov: trials of Atebimetinib"}]},{"url":"https://clinicaltrials.gov/search?intr=Atigotatug","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","field":"links","label":"ClinicalTrials.gov: trials of Atigotatug"}]},{"url":"https://clinicaltrials.gov/search?intr=AU-007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/","field":"links","label":"ClinicalTrials.gov: trials of AU-007"}]},{"url":"https://clinicaltrials.gov/search?intr=AV-299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/","field":"links","label":"ClinicalTrials.gov: trials of Ficlatuzumab"}]},{"url":"https://clinicaltrials.gov/search?intr=avasopasem","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","field":"links","label":"ClinicalTrials.gov: trials of avasopasem"}]},{"url":"https://clinicaltrials.gov/search?intr=AVZO-021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","field":"links","label":"ClinicalTrials.gov: trials of AVZO-021"}]},{"url":"https://clinicaltrials.gov/search?intr=AVZO-023","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/","field":"links","label":"ClinicalTrials.gov: trials of AVZO-023"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD0120","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/","field":"links","label":"ClinicalTrials.gov: trials of AZD0120"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD3470","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/","field":"links","label":"ClinicalTrials.gov: trials of AZD3470"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD4045","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/","field":"links","label":"ClinicalTrials.gov: trials of AZD4045"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD4360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/","field":"links","label":"ClinicalTrials.gov: trials of AZD4360"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD4512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/","field":"links","label":"ClinicalTrials.gov: trials of AZD4512"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD5305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/","field":"links","label":"ClinicalTrials.gov: trials of Saruparib"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD5335","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/","field":"links","label":"ClinicalTrials.gov: trials of AZD5335"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD5492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/","field":"links","label":"ClinicalTrials.gov: trials of AZD5492"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD5863","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/","field":"links","label":"ClinicalTrials.gov: trials of AZD5863"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD6621","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/","field":"links","label":"ClinicalTrials.gov: trials of AZD6621"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD6738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ceralasertib","kind":"drug","name":"Ceralasertib","route":"/drugs/ceralasertib/","field":"links","label":"ClinicalTrials.gov: trials of Ceralasertib"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD7789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd7789","kind":"drug","name":"AZD7789","route":"/drugs/azd7789/","field":"links","label":"ClinicalTrials.gov: trials of AZD7789"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD8205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","field":"links","label":"ClinicalTrials.gov: trials of Puxitatug samrotecan"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD8421","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd8421","kind":"drug","name":"AZD8421","route":"/drugs/azd8421/","field":"links","label":"ClinicalTrials.gov: trials of AZD8421"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD9574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/","field":"links","label":"ClinicalTrials.gov: trials of Palacaparib"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD9592","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","field":"links","label":"ClinicalTrials.gov: trials of Tilatamig samrotecan"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD9750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd9750","kind":"drug","name":"AZD9750","route":"/drugs/azd9750/","field":"links","label":"ClinicalTrials.gov: trials of AZD9750"}]},{"url":"https://clinicaltrials.gov/search?intr=AZD9793","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/","field":"links","label":"ClinicalTrials.gov: trials of AZD9793"}]},{"url":"https://clinicaltrials.gov/search?intr=Azenosertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/","field":"links","label":"ClinicalTrials.gov: trials of Azenosertib"}]},{"url":"https://clinicaltrials.gov/search?intr=BA3071","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ba3071","kind":"drug","name":"BA3071","route":"/drugs/ba3071/","field":"links","label":"ClinicalTrials.gov: trials of BA3071"}]},{"url":"https://clinicaltrials.gov/search?intr=Balstilimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/","field":"links","label":"ClinicalTrials.gov: trials of Balstilimab"}]},{"url":"https://clinicaltrials.gov/search?intr=BCB-276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","field":"links","label":"ClinicalTrials.gov: trials of BCB-276"}]},{"url":"https://clinicaltrials.gov/search?intr=BCD-100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcd-100","kind":"drug","name":"BCD-100","route":"/drugs/bcd-100/","field":"links","label":"ClinicalTrials.gov: trials of BCD-100"}]},{"url":"https://clinicaltrials.gov/search?intr=BCD-217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","field":"links","label":"ClinicalTrials.gov: trials of BCD-217"}]},{"url":"https://clinicaltrials.gov/search?intr=BDC-4182","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","field":"links","label":"ClinicalTrials.gov: trials of BDC-4182"}]},{"url":"https://clinicaltrials.gov/search?intr=BDTX-1535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/","field":"links","label":"ClinicalTrials.gov: trials of Silevertinib"}]},{"url":"https://clinicaltrials.gov/search?intr=BEBT-908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/","field":"links","label":"ClinicalTrials.gov: trials of Ifupinostat"}]},{"url":"https://clinicaltrials.gov/search?intr=Befotertinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"befotertinib","kind":"drug","name":"Befotertinib","route":"/drugs/befotertinib/","field":"links","label":"ClinicalTrials.gov: trials of Befotertinib"}]},{"url":"https://clinicaltrials.gov/search?intr=Bexmarilimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bexmarilimab","kind":"drug","name":"Bexmarilimab","route":"/drugs/bexmarilimab/","field":"links","label":"ClinicalTrials.gov: trials of Bexmarilimab"}]},{"url":"https://clinicaltrials.gov/search?intr=Bexobrutideg","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","field":"links","label":"ClinicalTrials.gov: trials of Bexobrutideg"}]},{"url":"https://clinicaltrials.gov/search?intr=Bezuclastinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","field":"links","label":"ClinicalTrials.gov: trials of Bezuclastinib"}]},{"url":"https://clinicaltrials.gov/search?intr=BGB-43395","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","field":"links","label":"ClinicalTrials.gov: trials of BGB-43395"}]},{"url":"https://clinicaltrials.gov/search?intr=BI853520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","field":"links","label":"ClinicalTrials.gov: trials of IN10018"}]},{"url":"https://clinicaltrials.gov/search?intr=BIO-106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bio-106","kind":"drug","name":"BIO-106","route":"/drugs/bio-106/","field":"links","label":"ClinicalTrials.gov: trials of BIO-106"}]},{"url":"https://clinicaltrials.gov/search?intr=BLU-263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/","field":"links","label":"ClinicalTrials.gov: trials of Elenestinib"}]},{"url":"https://clinicaltrials.gov/search?intr=BMS-986365","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/","field":"links","label":"ClinicalTrials.gov: trials of BMS-986365"}]},{"url":"https://clinicaltrials.gov/search?intr=BMS-986504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/","field":"links","label":"ClinicalTrials.gov: trials of Navlimetostat"}]},{"url":"https://clinicaltrials.gov/search?intr=BNT113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bnt113","kind":"drug","name":"BNT113","route":"/drugs/bnt113/","field":"links","label":"ClinicalTrials.gov: trials of BNT113"}]},{"url":"https://clinicaltrials.gov/search?intr=BNT122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","field":"links","label":"ClinicalTrials.gov: trials of Autogene cevumeran"}]},{"url":"https://clinicaltrials.gov/search?intr=BNT327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/","field":"links","label":"ClinicalTrials.gov: trials of PM8002"}]},{"url":"https://clinicaltrials.gov/search?intr=Boserolimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boserolimab","kind":"drug","name":"Boserolimab","route":"/drugs/boserolimab/","field":"links","label":"ClinicalTrials.gov: trials of Boserolimab"}]},{"url":"https://clinicaltrials.gov/search?intr=BT8009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","field":"links","label":"ClinicalTrials.gov: trials of Zelenectide pevedotin"}]},{"url":"https://clinicaltrials.gov/search?intr=CAM2029%20(octreotide%20subcutaneous%20depot)","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/","field":"links","label":"ClinicalTrials.gov: trials of CAM2029 (octreotide subcutaneous depot)"}]},{"url":"https://clinicaltrials.gov/search?intr=Camonsertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"camonsertib","kind":"drug","name":"Camonsertib","route":"/drugs/camonsertib/","field":"links","label":"ClinicalTrials.gov: trials of Camonsertib"}]},{"url":"https://clinicaltrials.gov/search?intr=CAN-2409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","field":"links","label":"ClinicalTrials.gov: trials of Aglatimagene besadenovec"}]},{"url":"https://clinicaltrials.gov/search?intr=CART2019","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/","field":"links","label":"ClinicalTrials.gov: trials of Zamtocabtagene autoleucel"}]},{"url":"https://clinicaltrials.gov/search?intr=CART84","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/","field":"links","label":"ClinicalTrials.gov: trials of CART84"}]},{"url":"https://clinicaltrials.gov/search?intr=CC-92480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","field":"links","label":"ClinicalTrials.gov: trials of Mezigdomide"}]},{"url":"https://clinicaltrials.gov/search?intr=CC-95266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/","field":"links","label":"ClinicalTrials.gov: trials of Arlocabtagene Autoleucel"}]},{"url":"https://clinicaltrials.gov/search?intr=CD19%20t-haNK","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","field":"links","label":"ClinicalTrials.gov: trials of CD19 t-haNK"}]},{"url":"https://clinicaltrials.gov/search?intr=Cevostamab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/","field":"links","label":"ClinicalTrials.gov: trials of Cevostamab"}]},{"url":"https://clinicaltrials.gov/search?intr=CGT4859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/","field":"links","label":"ClinicalTrials.gov: trials of CGT4859"}]},{"url":"https://clinicaltrials.gov/search?intr=CLN-081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","field":"links","label":"ClinicalTrials.gov: trials of Zipalertinib"}]},{"url":"https://clinicaltrials.gov/search?intr=CMG901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","field":"links","label":"ClinicalTrials.gov: trials of Sonesitatug vedotin"}]},{"url":"https://clinicaltrials.gov/search?intr=CN-201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/","field":"links","label":"ClinicalTrials.gov: trials of MK-1045"}]},{"url":"https://clinicaltrials.gov/search?intr=Cobolimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cobolimab","kind":"drug","name":"Cobolimab","route":"/drugs/cobolimab/","field":"links","label":"ClinicalTrials.gov: trials of Cobolimab"}]},{"url":"https://clinicaltrials.gov/search?intr=CPI-0610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","field":"links","label":"ClinicalTrials.gov: trials of Pelabresib"}]},{"url":"https://clinicaltrials.gov/search?intr=CPI-818","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","field":"links","label":"ClinicalTrials.gov: trials of Soquelitinib"}]},{"url":"https://clinicaltrials.gov/search?intr=CRB-701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","field":"links","label":"ClinicalTrials.gov: trials of CRB-701"}]},{"url":"https://clinicaltrials.gov/search?intr=CRC01","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","field":"links","label":"ClinicalTrials.gov: trials of CRC01"}]},{"url":"https://clinicaltrials.gov/search?intr=CS2164","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chiauranib","kind":"drug","name":"Chiauranib","route":"/drugs/chiauranib/","field":"links","label":"ClinicalTrials.gov: trials of Chiauranib"}]},{"url":"https://clinicaltrials.gov/search?intr=CT3001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ct3001","kind":"drug","name":"CT3001","route":"/drugs/ct3001/","field":"links","label":"ClinicalTrials.gov: trials of CT3001"}]},{"url":"https://clinicaltrials.gov/search?intr=CTL-002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/","field":"links","label":"ClinicalTrials.gov: trials of Visugromab"}]},{"url":"https://clinicaltrials.gov/search?intr=CTX112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/","field":"links","label":"ClinicalTrials.gov: trials of CTX112"}]},{"url":"https://clinicaltrials.gov/search?intr=CYH33","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/","field":"links","label":"ClinicalTrials.gov: trials of CYH33"}]},{"url":"https://clinicaltrials.gov/search?intr=D-0502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"d-0502","kind":"drug","name":"D-0502","route":"/drugs/d-0502/","field":"links","label":"ClinicalTrials.gov: trials of D-0502"}]},{"url":"https://clinicaltrials.gov/search?intr=D07001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"d07001","kind":"drug","name":"D07001","route":"/drugs/d07001/","field":"links","label":"ClinicalTrials.gov: trials of D07001"}]},{"url":"https://clinicaltrials.gov/search?intr=DB-1303","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/","field":"links","label":"ClinicalTrials.gov: trials of Trastuzumab pamirtecan"}]},{"url":"https://clinicaltrials.gov/search?intr=DB-1311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/","field":"links","label":"ClinicalTrials.gov: trials of BNT324"}]},{"url":"https://clinicaltrials.gov/search?intr=DJI136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/","field":"links","label":"ClinicalTrials.gov: trials of DJI136"}]},{"url":"https://clinicaltrials.gov/search?intr=DOC1021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/","field":"links","label":"ClinicalTrials.gov: trials of DOC1021"}]},{"url":"https://clinicaltrials.gov/search?intr=DR-01","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/","field":"links","label":"ClinicalTrials.gov: trials of DR-01"}]},{"url":"https://clinicaltrials.gov/search?intr=DZD4205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/","field":"links","label":"ClinicalTrials.gov: trials of Golidocitinib"}]},{"url":"https://clinicaltrials.gov/search?intr=DZD8586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","field":"links","label":"ClinicalTrials.gov: trials of DZD8586"}]},{"url":"https://clinicaltrials.gov/search?intr=EB-CAR30-NK","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/","field":"links","label":"ClinicalTrials.gov: trials of EB-CAR30-NK"}]},{"url":"https://clinicaltrials.gov/search?intr=EB-MF-CAR-NK-01","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/","field":"links","label":"ClinicalTrials.gov: trials of EB-MF-CAR-NK-01"}]},{"url":"https://clinicaltrials.gov/search?intr=EB-NK-301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/","field":"links","label":"ClinicalTrials.gov: trials of EB-NK-301"}]},{"url":"https://clinicaltrials.gov/search?intr=EDV-D682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/","field":"links","label":"ClinicalTrials.gov: trials of E-EDV-D682"}]},{"url":"https://clinicaltrials.gov/search?intr=EIK1001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","field":"links","label":"ClinicalTrials.gov: trials of EIK1001"}]},{"url":"https://clinicaltrials.gov/search?intr=EIK1005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/","field":"links","label":"ClinicalTrials.gov: trials of EIK1005"}]},{"url":"https://clinicaltrials.gov/search?intr=Emactuzumab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/","field":"links","label":"ClinicalTrials.gov: trials of Emactuzumab"}]},{"url":"https://clinicaltrials.gov/search?intr=Emavusertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/","field":"links","label":"ClinicalTrials.gov: trials of Emavusertib"}]},{"url":"https://clinicaltrials.gov/search?intr=ENB003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/","field":"links","label":"ClinicalTrials.gov: trials of ENB003"}]},{"url":"https://clinicaltrials.gov/search?intr=Endostar","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","field":"links","label":"ClinicalTrials.gov: trials of Endostar"}]},{"url":"https://clinicaltrials.gov/search?intr=ENV-501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/","field":"links","label":"ClinicalTrials.gov: trials of ENV-501"}]},{"url":"https://clinicaltrials.gov/search?intr=EP0031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","field":"links","label":"ClinicalTrials.gov: trials of EP0031"}]},{"url":"https://clinicaltrials.gov/search?intr=EP0062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","field":"links","label":"ClinicalTrials.gov: trials of EP0062"}]},{"url":"https://clinicaltrials.gov/search?intr=ERAS-254","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/","field":"links","label":"ClinicalTrials.gov: trials of Naporafenib"}]},{"url":"https://clinicaltrials.gov/search?intr=ESG401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","field":"links","label":"ClinicalTrials.gov: trials of ESG401"}]},{"url":"https://clinicaltrials.gov/search?intr=Evexomostat","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/","field":"links","label":"ClinicalTrials.gov: trials of Evexomostat"}]},{"url":"https://clinicaltrials.gov/search?intr=EVM14","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evm14","kind":"drug","name":"EVM14","route":"/drugs/evm14/","field":"links","label":"ClinicalTrials.gov: trials of EVM14"}]},{"url":"https://clinicaltrials.gov/search?intr=F182112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/","field":"links","label":"ClinicalTrials.gov: trials of F182112"}]},{"url":"https://clinicaltrials.gov/search?intr=FAP-2286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"links","label":"ClinicalTrials.gov: trials of FAP-2286 (177Lu / 68Ga)"}]},{"url":"https://clinicaltrials.gov/search?intr=Farletuzumab-exatecan","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/","field":"links","label":"ClinicalTrials.gov: trials of Farletuzumab-exatecan"}]},{"url":"https://clinicaltrials.gov/search?intr=Farletuzumab%20ecteribulin","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","route":"/drugs/farletuzumab-ecteribulin/","field":"links","label":"ClinicalTrials.gov: trials of Farletuzumab ecteribulin"}]},{"url":"https://clinicaltrials.gov/search?intr=FC303","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"ClinicalTrials.gov: trials of Florastamin F-18"}]},{"url":"https://clinicaltrials.gov/search?intr=FDA018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fda018-adc","kind":"drug","name":"FDA018-ADC","route":"/drugs/fda018-adc/","field":"links","label":"ClinicalTrials.gov: trials of FDA018-ADC"}]},{"url":"https://clinicaltrials.gov/search?intr=Feladilimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/","field":"links","label":"ClinicalTrials.gov: trials of Feladilimab"}]},{"url":"https://clinicaltrials.gov/search?intr=Flonoltinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flonoltinib","kind":"drug","name":"Flonoltinib","route":"/drugs/flonoltinib/","field":"links","label":"ClinicalTrials.gov: trials of Flonoltinib"}]},{"url":"https://clinicaltrials.gov/search?intr=flumatinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/","field":"links","label":"ClinicalTrials.gov: trials of flumatinib"}]},{"url":"https://clinicaltrials.gov/search?intr=Fluzoparib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/","field":"links","label":"ClinicalTrials.gov: trials of Fluzoparib"}]},{"url":"https://clinicaltrials.gov/search?intr=FPI-2265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/","field":"links","label":"ClinicalTrials.gov: trials of FPI-2265"}]},{"url":"https://clinicaltrials.gov/search?intr=FTH-001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","field":"links","label":"ClinicalTrials.gov: trials of Serabelisib"}]},{"url":"https://clinicaltrials.gov/search?intr=FTH-003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","field":"links","label":"ClinicalTrials.gov: trials of Sapanisertib"}]},{"url":"https://clinicaltrials.gov/search?intr=GB491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lerociclib","kind":"drug","name":"Lerociclib","route":"/drugs/lerociclib/","field":"links","label":"ClinicalTrials.gov: trials of Lerociclib"}]},{"url":"https://clinicaltrials.gov/search?intr=GC012F","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gc012f","kind":"drug","name":"GC012F","route":"/drugs/gc012f/","field":"links","label":"ClinicalTrials.gov: trials of GC012F"}]},{"url":"https://clinicaltrials.gov/search?intr=GC101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/","field":"links","label":"ClinicalTrials.gov: trials of GC101 TIL"}]},{"url":"https://clinicaltrials.gov/search?intr=GDC-0068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","field":"links","label":"ClinicalTrials.gov: trials of Ipatasertib"}]},{"url":"https://clinicaltrials.gov/search?intr=Gecacitinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/","field":"links","label":"ClinicalTrials.gov: trials of Gecacitinib"}]},{"url":"https://clinicaltrials.gov/search?intr=GEN1046","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acasunlimab","kind":"drug","name":"Acasunlimab","route":"/drugs/acasunlimab/","field":"links","label":"ClinicalTrials.gov: trials of Acasunlimab"}]},{"url":"https://clinicaltrials.gov/search?intr=GFH375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/","field":"links","label":"ClinicalTrials.gov: trials of GFH375"}]},{"url":"https://clinicaltrials.gov/search?intr=GLS-010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/","field":"links","label":"ClinicalTrials.gov: trials of Zimberelimab"}]},{"url":"https://clinicaltrials.gov/search?intr=GLSI-100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","field":"links","label":"ClinicalTrials.gov: trials of GLSI-100"}]},{"url":"https://clinicaltrials.gov/search?intr=GQ1005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","field":"links","label":"ClinicalTrials.gov: trials of GQ1005"}]},{"url":"https://clinicaltrials.gov/search?intr=GR1803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/","field":"links","label":"ClinicalTrials.gov: trials of GR1803"}]},{"url":"https://clinicaltrials.gov/search?intr=GRT-C901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/","field":"links","label":"ClinicalTrials.gov: trials of GRT-C901"}]},{"url":"https://clinicaltrials.gov/search?intr=GRT-R902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/","field":"links","label":"ClinicalTrials.gov: trials of GRT-R902"}]},{"url":"https://clinicaltrials.gov/search?intr=GSK6042981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/","field":"links","label":"ClinicalTrials.gov: trials of Velzatinib"}]},{"url":"https://clinicaltrials.gov/search?intr=H101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","field":"links","label":"ClinicalTrials.gov: trials of H101"}]},{"url":"https://clinicaltrials.gov/search?intr=HB0036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/","field":"links","label":"ClinicalTrials.gov: trials of HB0036"}]},{"url":"https://clinicaltrials.gov/search?intr=HB1801","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/","field":"links","label":"ClinicalTrials.gov: trials of HB1801"}]},{"url":"https://clinicaltrials.gov/search?intr=HDM2017","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/","field":"links","label":"ClinicalTrials.gov: trials of HDM2017"}]},{"url":"https://clinicaltrials.gov/search?intr=HEC73543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/","field":"links","label":"ClinicalTrials.gov: trials of Clifutinib"}]},{"url":"https://clinicaltrials.gov/search?intr=HER3-DXd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"links","label":"ClinicalTrials.gov: trials of Patritumab deruxtecan"}]},{"url":"https://clinicaltrials.gov/search?intr=HL-085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/","field":"links","label":"ClinicalTrials.gov: trials of Tunlametinib"}]},{"url":"https://clinicaltrials.gov/search?intr=HLX11","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlx11","kind":"drug","name":"HLX11","route":"/drugs/hlx11/","field":"links","label":"ClinicalTrials.gov: trials of HLX11"}]},{"url":"https://clinicaltrials.gov/search?intr=HLX22","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/","field":"links","label":"ClinicalTrials.gov: trials of HLX22"}]},{"url":"https://clinicaltrials.gov/search?intr=HLX26","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlx26","kind":"drug","name":"HLX26","route":"/drugs/hlx26/","field":"links","label":"ClinicalTrials.gov: trials of HLX26"}]},{"url":"https://clinicaltrials.gov/search?intr=HLX43","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/","field":"links","label":"ClinicalTrials.gov: trials of HLX43"}]},{"url":"https://clinicaltrials.gov/search?intr=HMBD-001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/","field":"links","label":"ClinicalTrials.gov: trials of HMBD-001"}]},{"url":"https://clinicaltrials.gov/search?intr=HMPL-306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/","field":"links","label":"ClinicalTrials.gov: trials of HMPL-306"}]},{"url":"https://clinicaltrials.gov/search?intr=HMPL-453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/","field":"links","label":"ClinicalTrials.gov: trials of HMPL-453"}]},{"url":"https://clinicaltrials.gov/search?intr=HMPL-760","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/","field":"links","label":"ClinicalTrials.gov: trials of HMPL-760"}]},{"url":"https://clinicaltrials.gov/search?intr=HQP1351","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","field":"links","label":"ClinicalTrials.gov: trials of Olverembatinib"}]},{"url":"https://clinicaltrials.gov/search?intr=HR070803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hr070803","kind":"drug","name":"HR070803","route":"/drugs/hr070803/","field":"links","label":"ClinicalTrials.gov: trials of HR070803"}]},{"url":"https://clinicaltrials.gov/search?intr=HRS-4357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","field":"links","label":"ClinicalTrials.gov: trials of HRS-4357"}]},{"url":"https://clinicaltrials.gov/search?intr=HRS-8080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/","field":"links","label":"ClinicalTrials.gov: trials of HRS-8080"}]},{"url":"https://clinicaltrials.gov/search?intr=HS-20089","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/","field":"links","label":"ClinicalTrials.gov: trials of HS-20089"}]},{"url":"https://clinicaltrials.gov/search?intr=HS-20093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/","field":"links","label":"ClinicalTrials.gov: trials of HS-20093"}]},{"url":"https://clinicaltrials.gov/search?intr=HST-1011","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/","field":"links","label":"ClinicalTrials.gov: trials of HST-1011"}]},{"url":"https://clinicaltrials.gov/search?intr=HX008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/","field":"links","label":"ClinicalTrials.gov: trials of Pucotenlimab"}]},{"url":"https://clinicaltrials.gov/search?intr=I-DXd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","field":"links","label":"ClinicalTrials.gov: trials of Ifinatamab deruxtecan"}]},{"url":"https://clinicaltrials.gov/search?intr=IAH0968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/","field":"links","label":"ClinicalTrials.gov: trials of IAH0968"}]},{"url":"https://clinicaltrials.gov/search?intr=IBI310","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/","field":"links","label":"ClinicalTrials.gov: trials of IBI310"}]},{"url":"https://clinicaltrials.gov/search?intr=IBI343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/","field":"links","label":"ClinicalTrials.gov: trials of IBI343"}]},{"url":"https://clinicaltrials.gov/search?intr=IBI354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/","field":"links","label":"ClinicalTrials.gov: trials of IBI354"}]},{"url":"https://clinicaltrials.gov/search?intr=IBI363","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/","field":"links","label":"ClinicalTrials.gov: trials of IBI363"}]},{"url":"https://clinicaltrials.gov/search?intr=ICP-248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/","field":"links","label":"ClinicalTrials.gov: trials of ICP-248"}]},{"url":"https://clinicaltrials.gov/search?intr=IDE196","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","field":"links","label":"ClinicalTrials.gov: trials of Darovasertib"}]},{"url":"https://clinicaltrials.gov/search?intr=IDRX-42","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/","field":"links","label":"ClinicalTrials.gov: trials of IDRX-42"}]},{"url":"https://clinicaltrials.gov/search?intr=IMA203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","field":"links","label":"ClinicalTrials.gov: trials of IMA203"}]},{"url":"https://clinicaltrials.gov/search?intr=IMP1734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/","field":"links","label":"ClinicalTrials.gov: trials of IMP1734"}]},{"url":"https://clinicaltrials.gov/search?intr=IMP4927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","field":"links","label":"ClinicalTrials.gov: trials of IMP4927"}]},{"url":"https://clinicaltrials.gov/search?intr=INBRX-106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","field":"links","label":"ClinicalTrials.gov: trials of INBRX-106"}]},{"url":"https://clinicaltrials.gov/search?intr=INCA33890","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inca33890","kind":"drug","name":"INCA33890","route":"/drugs/inca33890/","field":"links","label":"ClinicalTrials.gov: trials of INCA33890"}]},{"url":"https://clinicaltrials.gov/search?intr=INCB123667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/","field":"links","label":"ClinicalTrials.gov: trials of INCB123667"}]},{"url":"https://clinicaltrials.gov/search?intr=INCB161734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/","field":"links","label":"ClinicalTrials.gov: trials of INCB161734"}]},{"url":"https://clinicaltrials.gov/search?intr=inetetamab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/","field":"links","label":"ClinicalTrials.gov: trials of inetetamab"}]},{"url":"https://clinicaltrials.gov/search?intr=Inlexisertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inlexisertib","kind":"drug","name":"Inlexisertib","route":"/drugs/inlexisertib/","field":"links","label":"ClinicalTrials.gov: trials of Inlexisertib"}]},{"url":"https://clinicaltrials.gov/search?intr=INO-5401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ino-5401","kind":"drug","name":"INO-5401","route":"/drugs/ino-5401/","field":"links","label":"ClinicalTrials.gov: trials of INO-5401"}]},{"url":"https://clinicaltrials.gov/search?intr=INT230-6","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/","field":"links","label":"ClinicalTrials.gov: trials of INT230-6"}]},{"url":"https://clinicaltrials.gov/search?intr=IO102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"io102-io103","kind":"drug","name":"IO102-IO103","route":"/drugs/io102-io103/","field":"links","label":"ClinicalTrials.gov: trials of IO102-IO103"}]},{"url":"https://clinicaltrials.gov/search?intr=Iomab-B","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/","field":"links","label":"ClinicalTrials.gov: trials of Iomab-B"}]},{"url":"https://clinicaltrials.gov/search?intr=IPG1094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ipg1094","kind":"drug","name":"IPG1094","route":"/drugs/ipg1094/","field":"links","label":"ClinicalTrials.gov: trials of IPG1094"}]},{"url":"https://clinicaltrials.gov/search?intr=IPH2201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/","field":"links","label":"ClinicalTrials.gov: trials of Monalizumab"}]},{"url":"https://clinicaltrials.gov/search?intr=ITF2357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"givinostat","kind":"drug","name":"Givinostat","route":"/drugs/givinostat/","field":"links","label":"ClinicalTrials.gov: trials of Givinostat"}]},{"url":"https://clinicaltrials.gov/search?intr=Ivospemin","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivospemin","kind":"drug","name":"Ivospemin","route":"/drugs/ivospemin/","field":"links","label":"ClinicalTrials.gov: trials of Ivospemin"}]},{"url":"https://clinicaltrials.gov/search?intr=JAB-21822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/","field":"links","label":"ClinicalTrials.gov: trials of Glecirasib"}]},{"url":"https://clinicaltrials.gov/search?intr=JBI-802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jbi-802","kind":"drug","name":"JBI-802","route":"/drugs/jbi-802/","field":"links","label":"ClinicalTrials.gov: trials of JBI-802"}]},{"url":"https://clinicaltrials.gov/search?intr=JDQ443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/","field":"links","label":"ClinicalTrials.gov: trials of JDQ443"}]},{"url":"https://clinicaltrials.gov/search?intr=JK08","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jk08","kind":"drug","name":"JK08","route":"/drugs/jk08/","field":"links","label":"ClinicalTrials.gov: trials of JK08"}]},{"url":"https://clinicaltrials.gov/search?intr=JMT101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/","field":"links","label":"ClinicalTrials.gov: trials of JMT101"}]},{"url":"https://clinicaltrials.gov/search?intr=JMT203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/","field":"links","label":"ClinicalTrials.gov: trials of JMT203"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-42756493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/","field":"links","label":"ClinicalTrials.gov: trials of TAR-210"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-63723283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/","field":"links","label":"ClinicalTrials.gov: trials of Cetrelimab"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-75276617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bleximenib","kind":"drug","name":"Bleximenib","route":"/drugs/bleximenib/","field":"links","label":"ClinicalTrials.gov: trials of Bleximenib"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-78278343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","field":"links","label":"ClinicalTrials.gov: trials of Pasritamig"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-79635322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/","field":"links","label":"ClinicalTrials.gov: trials of JNJ-79635322"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-87189401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","field":"links","label":"ClinicalTrials.gov: trials of JNJ-87189401"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-90014496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/","field":"links","label":"ClinicalTrials.gov: trials of JNJ-90014496"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-90301900","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","route":"/drugs/jnj-90301900/","field":"links","label":"ClinicalTrials.gov: trials of JNJ-90301900"}]},{"url":"https://clinicaltrials.gov/search?intr=JS105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/","field":"links","label":"ClinicalTrials.gov: trials of JS105"}]},{"url":"https://clinicaltrials.gov/search?intr=JS111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/","field":"links","label":"ClinicalTrials.gov: trials of JS111"}]},{"url":"https://clinicaltrials.gov/search?intr=JSKN003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/","field":"links","label":"ClinicalTrials.gov: trials of JSKN003"}]},{"url":"https://clinicaltrials.gov/search?intr=JSKN016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/","field":"links","label":"ClinicalTrials.gov: trials of JSKN016"}]},{"url":"https://clinicaltrials.gov/search?intr=JYP0015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jyp0015","kind":"drug","name":"JYP0015","route":"/drugs/jyp0015/","field":"links","label":"ClinicalTrials.gov: trials of JYP0015"}]},{"url":"https://clinicaltrials.gov/search?intr=KC1036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kc1036","kind":"drug","name":"KC1036","route":"/drugs/kc1036/","field":"links","label":"ClinicalTrials.gov: trials of KC1036"}]},{"url":"https://clinicaltrials.gov/search?intr=KCBI-0191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/","field":"links","label":"ClinicalTrials.gov: trials of BEBT-209"}]},{"url":"https://clinicaltrials.gov/search?intr=KER-050","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/","field":"links","label":"ClinicalTrials.gov: trials of Elritercept"}]},{"url":"https://clinicaltrials.gov/search?intr=KL-A167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/","field":"links","label":"ClinicalTrials.gov: trials of KL-A167"}]},{"url":"https://clinicaltrials.gov/search?intr=KN026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/","field":"links","label":"ClinicalTrials.gov: trials of KN026"}]},{"url":"https://clinicaltrials.gov/search?intr=KRT-232","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/","field":"links","label":"ClinicalTrials.gov: trials of KRT-232"}]},{"url":"https://clinicaltrials.gov/search?intr=LAM561","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lam561","kind":"drug","name":"LAM561","route":"/drugs/lam561/","field":"links","label":"ClinicalTrials.gov: trials of LAM561"}]},{"url":"https://clinicaltrials.gov/search?intr=LB1410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lb1410","kind":"drug","name":"LB1410","route":"/drugs/lb1410/","field":"links","label":"ClinicalTrials.gov: trials of LB1410"}]},{"url":"https://clinicaltrials.gov/search?intr=LB4330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lb4330","kind":"drug","name":"LB4330","route":"/drugs/lb4330/","field":"links","label":"ClinicalTrials.gov: trials of LB4330"}]},{"url":"https://clinicaltrials.gov/search?intr=LCB02A","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","field":"links","label":"ClinicalTrials.gov: trials of LCB02A"}]},{"url":"https://clinicaltrials.gov/search?intr=LCB84","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","field":"links","label":"ClinicalTrials.gov: trials of LCB84"}]},{"url":"https://clinicaltrials.gov/search?intr=Lerotinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lerotinib","kind":"drug","name":"Lerotinib","route":"/drugs/lerotinib/","field":"links","label":"ClinicalTrials.gov: trials of Lerotinib"}]},{"url":"https://clinicaltrials.gov/search?intr=LM-108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","field":"links","label":"ClinicalTrials.gov: trials of LM-108"}]},{"url":"https://clinicaltrials.gov/search?intr=LM-302","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/","field":"links","label":"ClinicalTrials.gov: trials of LM-302"}]},{"url":"https://clinicaltrials.gov/search?intr=LNS8801","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/","field":"links","label":"ClinicalTrials.gov: trials of LNS8801"}]},{"url":"https://clinicaltrials.gov/search?intr=LP-184","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/","field":"links","label":"ClinicalTrials.gov: trials of LP-184"}]},{"url":"https://clinicaltrials.gov/search?intr=LVGN6051","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lvgn6051","kind":"drug","name":"LVGN6051","route":"/drugs/lvgn6051/","field":"links","label":"ClinicalTrials.gov: trials of LVGN6051"}]},{"url":"https://clinicaltrials.gov/search?intr=LY4170156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/","field":"links","label":"ClinicalTrials.gov: trials of Sofetabart Mipitecan"}]},{"url":"https://clinicaltrials.gov/search?intr=LYL314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","field":"links","label":"ClinicalTrials.gov: trials of Rondecabtagene autoleucel"}]},{"url":"https://clinicaltrials.gov/search?intr=M108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"m108","kind":"drug","name":"M108","route":"/drugs/m108/","field":"links","label":"ClinicalTrials.gov: trials of M108"}]},{"url":"https://clinicaltrials.gov/search?intr=M701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"m701","kind":"drug","name":"M701","route":"/drugs/m701/","field":"links","label":"ClinicalTrials.gov: trials of M701"}]},{"url":"https://clinicaltrials.gov/search?intr=MCLA-129","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/","field":"links","label":"ClinicalTrials.gov: trials of MCLA-129"}]},{"url":"https://clinicaltrials.gov/search?intr=mecapegfilgrastim","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","field":"links","label":"ClinicalTrials.gov: trials of mecapegfilgrastim"}]},{"url":"https://clinicaltrials.gov/search?intr=MEDI9447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/","field":"links","label":"ClinicalTrials.gov: trials of Oleclumab"}]},{"url":"https://clinicaltrials.gov/search?intr=Merestinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"merestinib","kind":"drug","name":"Merestinib","route":"/drugs/merestinib/","field":"links","label":"ClinicalTrials.gov: trials of Merestinib"}]},{"url":"https://clinicaltrials.gov/search?intr=MGD019","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","field":"links","label":"ClinicalTrials.gov: trials of Lorigerlimab"}]},{"url":"https://clinicaltrials.gov/search?intr=MHB036C","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/","field":"links","label":"ClinicalTrials.gov: trials of MHB036C"}]},{"url":"https://clinicaltrials.gov/search?intr=MHB039A","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/","field":"links","label":"ClinicalTrials.gov: trials of MHB039A"}]},{"url":"https://clinicaltrials.gov/search?intr=MHB088C","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/","field":"links","label":"ClinicalTrials.gov: trials of QLC5508"}]},{"url":"https://clinicaltrials.gov/search?intr=Mitazalimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/","field":"links","label":"ClinicalTrials.gov: trials of Mitazalimab"}]},{"url":"https://clinicaltrials.gov/search?intr=MK-1084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","field":"links","label":"ClinicalTrials.gov: trials of Calderasib"}]},{"url":"https://clinicaltrials.gov/search?intr=MK-2140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","field":"links","label":"ClinicalTrials.gov: trials of Zilovertamab vedotin"}]},{"url":"https://clinicaltrials.gov/search?intr=MK-3543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/","field":"links","label":"ClinicalTrials.gov: trials of Bomedemstat"}]},{"url":"https://clinicaltrials.gov/search?intr=MK-4280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/","field":"links","label":"ClinicalTrials.gov: trials of Favezelimab"}]},{"url":"https://clinicaltrials.gov/search?intr=MK-5684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/","field":"links","label":"ClinicalTrials.gov: trials of Opevesostat"}]},{"url":"https://clinicaltrials.gov/search?intr=MRG002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/","field":"links","label":"ClinicalTrials.gov: trials of MRG002"}]},{"url":"https://clinicaltrials.gov/search?intr=MRG003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/","field":"links","label":"ClinicalTrials.gov: trials of MRG003"}]},{"url":"https://clinicaltrials.gov/search?intr=Navitoclax","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"navitoclax","kind":"drug","name":"Navitoclax","route":"/drugs/navitoclax/","field":"links","label":"ClinicalTrials.gov: trials of Navitoclax"}]},{"url":"https://clinicaltrials.gov/search?intr=NB003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/","field":"links","label":"ClinicalTrials.gov: trials of NB003"}]},{"url":"https://clinicaltrials.gov/search?intr=NBTXR3","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","field":"links","label":"ClinicalTrials.gov: trials of NBTXR3"}]},{"url":"https://clinicaltrials.gov/search?intr=NDI-219216","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","field":"links","label":"ClinicalTrials.gov: trials of NDI-219216"}]},{"url":"https://clinicaltrials.gov/search?intr=nimorazole","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nimorazole","kind":"drug","name":"Nimorazole","route":"/drugs/nimorazole/","field":"links","label":"ClinicalTrials.gov: trials of nimorazole"}]},{"url":"https://clinicaltrials.gov/search?intr=NP137","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/","field":"links","label":"ClinicalTrials.gov: trials of NP137"}]},{"url":"https://clinicaltrials.gov/search?intr=NUV-1511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/","field":"links","label":"ClinicalTrials.gov: trials of NUV-1511"}]},{"url":"https://clinicaltrials.gov/search?intr=NWP-775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","field":"links","label":"ClinicalTrials.gov: trials of Rocbrutinib"}]},{"url":"https://clinicaltrials.gov/search?intr=NXC-201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","field":"links","label":"ClinicalTrials.gov: trials of NXC-201 CAR-T"}]},{"url":"https://clinicaltrials.gov/search?intr=OBI-822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adagloxad-simolenin","kind":"drug","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/","field":"links","label":"ClinicalTrials.gov: trials of Adagloxad simolenin"}]},{"url":"https://clinicaltrials.gov/search?intr=OBI-902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"obi-902","kind":"drug","name":"OBI-902","route":"/drugs/obi-902/","field":"links","label":"ClinicalTrials.gov: trials of OBI-902"}]},{"url":"https://clinicaltrials.gov/search?intr=OBI-992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"obi-992","kind":"drug","name":"OBI-992","route":"/drugs/obi-992/","field":"links","label":"ClinicalTrials.gov: trials of OBI-992"}]},{"url":"https://clinicaltrials.gov/search?intr=Olvimulogene%20nanivacirepvec","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/","field":"links","label":"ClinicalTrials.gov: trials of Olvimulogene nanivacirepvec"}]},{"url":"https://clinicaltrials.gov/search?intr=ONC-392","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/","field":"links","label":"ClinicalTrials.gov: trials of Gotistobart"}]},{"url":"https://clinicaltrials.gov/search?intr=Onvansertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/","field":"links","label":"ClinicalTrials.gov: trials of Onvansertib"}]},{"url":"https://clinicaltrials.gov/search?intr=OR502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/","field":"links","label":"ClinicalTrials.gov: trials of OR502"}]},{"url":"https://clinicaltrials.gov/search?intr=Oregovomab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/","field":"links","label":"ClinicalTrials.gov: trials of Oregovomab"}]},{"url":"https://clinicaltrials.gov/search?intr=ORIC-944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","field":"links","label":"ClinicalTrials.gov: trials of Rinzimetostat"}]},{"url":"https://clinicaltrials.gov/search?intr=OSE2101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","field":"links","label":"ClinicalTrials.gov: trials of OSE2101"}]},{"url":"https://clinicaltrials.gov/search?intr=OV-1001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","field":"links","label":"ClinicalTrials.gov: trials of Cusatuzumab"}]},{"url":"https://clinicaltrials.gov/search?intr=Pamiparib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/","field":"links","label":"ClinicalTrials.gov: trials of Pamiparib"}]},{"url":"https://clinicaltrials.gov/search?intr=Parsaclisib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parsaclisib","kind":"drug","name":"Parsaclisib","route":"/drugs/parsaclisib/","field":"links","label":"ClinicalTrials.gov: trials of Parsaclisib"}]},{"url":"https://clinicaltrials.gov/search?intr=PBP1510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/","field":"links","label":"ClinicalTrials.gov: trials of PBP1510"}]},{"url":"https://clinicaltrials.gov/search?intr=PCI-24781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/","field":"links","label":"ClinicalTrials.gov: trials of Abexinostat"}]},{"url":"https://clinicaltrials.gov/search?intr=PEG20","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","field":"links","label":"ClinicalTrials.gov: trials of ADI-PEG20"}]},{"url":"https://clinicaltrials.gov/search?intr=PF-07248144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pf-07248144","kind":"drug","name":"PF-07248144","route":"/drugs/pf-07248144/","field":"links","label":"ClinicalTrials.gov: trials of PF-07248144"}]},{"url":"https://clinicaltrials.gov/search?intr=PF-08046054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/","field":"links","label":"ClinicalTrials.gov: trials of PF-08046054"}]},{"url":"https://clinicaltrials.gov/search?intr=Pimicotinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/","field":"links","label":"ClinicalTrials.gov: trials of Pimicotinib"}]},{"url":"https://clinicaltrials.gov/search?intr=Pirarubicin","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pirarubicin","kind":"drug","name":"Pirarubicin","route":"/drugs/pirarubicin/","field":"links","label":"ClinicalTrials.gov: trials of Pirarubicin"}]},{"url":"https://clinicaltrials.gov/search?intr=PLB1001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/","field":"links","label":"ClinicalTrials.gov: trials of Vebreltinib"}]},{"url":"https://clinicaltrials.gov/search?intr=PM1080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hs-20117","kind":"drug","name":"HS-20117","route":"/drugs/hs-20117/","field":"links","label":"ClinicalTrials.gov: trials of HS-20117"}]},{"url":"https://clinicaltrials.gov/search?intr=Ponsegromab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ponsegromab","kind":"drug","name":"Ponsegromab","route":"/drugs/ponsegromab/","field":"links","label":"ClinicalTrials.gov: trials of Ponsegromab"}]},{"url":"https://clinicaltrials.gov/search?intr=Precemtabart%20tocentecan","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/","field":"links","label":"ClinicalTrials.gov: trials of Precemtabart tocentecan"}]},{"url":"https://clinicaltrials.gov/search?intr=PRS-343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/","field":"links","label":"ClinicalTrials.gov: trials of Cinrebafusp alfa"}]},{"url":"https://clinicaltrials.gov/search?intr=PRTX007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prtx007","kind":"drug","name":"PRTX007","route":"/drugs/prtx007/","field":"links","label":"ClinicalTrials.gov: trials of PRTX007"}]},{"url":"https://clinicaltrials.gov/search?intr=PSB205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","field":"links","label":"ClinicalTrials.gov: trials of QL1706"}]},{"url":"https://clinicaltrials.gov/search?intr=PSMA-1007%20F-18","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","field":"links","label":"ClinicalTrials.gov: trials of PSMA-1007 F-18"}]},{"url":"https://clinicaltrials.gov/search?intr=PT199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/","field":"links","label":"ClinicalTrials.gov: trials of Mavrostobart"}]},{"url":"https://clinicaltrials.gov/search?intr=PT217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/","field":"links","label":"ClinicalTrials.gov: trials of Peluntamig"}]},{"url":"https://clinicaltrials.gov/search?intr=PT886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/","field":"links","label":"ClinicalTrials.gov: trials of Spevatamig"}]},{"url":"https://clinicaltrials.gov/search?intr=Purinostat","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/","field":"links","label":"ClinicalTrials.gov: trials of Purinostat"}]},{"url":"https://clinicaltrials.gov/search?intr=QL1706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","field":"links","label":"ClinicalTrials.gov: trials of QL1706"}]},{"url":"https://clinicaltrials.gov/search?intr=QL2107","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/","field":"links","label":"ClinicalTrials.gov: trials of QL2107"}]},{"url":"https://clinicaltrials.gov/search?intr=QLH12016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qlh12016","kind":"drug","name":"QLH12016","route":"/drugs/qlh12016/","field":"links","label":"ClinicalTrials.gov: trials of QLH12016"}]},{"url":"https://clinicaltrials.gov/search?intr=QLS31905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","field":"links","label":"ClinicalTrials.gov: trials of QLS31905"}]},{"url":"https://clinicaltrials.gov/search?intr=QLS32015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","field":"links","label":"ClinicalTrials.gov: trials of QLS32015"}]},{"url":"https://clinicaltrials.gov/search?intr=Quemliclustat","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","field":"links","label":"ClinicalTrials.gov: trials of Quemliclustat"}]},{"url":"https://clinicaltrials.gov/search?intr=R-DXd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","field":"links","label":"ClinicalTrials.gov: trials of Raludotatug deruxtecan"}]},{"url":"https://clinicaltrials.gov/search?intr=Radotinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/","field":"links","label":"ClinicalTrials.gov: trials of Radotinib"}]},{"url":"https://clinicaltrials.gov/search?intr=RC118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","route":"/drugs/rc118-adc/","field":"links","label":"ClinicalTrials.gov: trials of RC118-ADC"}]},{"url":"https://clinicaltrials.gov/search?intr=RC148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/","field":"links","label":"ClinicalTrials.gov: trials of RC148"}]},{"url":"https://clinicaltrials.gov/search?intr=REGN7075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/","field":"links","label":"ClinicalTrials.gov: trials of REGN7075"}]},{"url":"https://clinicaltrials.gov/search?intr=REM-422","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/","field":"links","label":"ClinicalTrials.gov: trials of REM-422"}]},{"url":"https://clinicaltrials.gov/search?intr=Rilvegostomig","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/","field":"links","label":"ClinicalTrials.gov: trials of Rilvegostomig"}]},{"url":"https://clinicaltrials.gov/search?intr=RLY-4008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","field":"links","label":"ClinicalTrials.gov: trials of Lirafugratinib"}]},{"url":"https://clinicaltrials.gov/search?intr=RMC-6291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","field":"links","label":"ClinicalTrials.gov: trials of Elironrasib"}]},{"url":"https://clinicaltrials.gov/search?intr=RNK05047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnk05047","kind":"drug","name":"RNK05047","route":"/drugs/rnk05047/","field":"links","label":"ClinicalTrials.gov: trials of RNK05047"}]},{"url":"https://clinicaltrials.gov/search?intr=RO7227166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","route":"/drugs/englumafusp-alfa/","field":"links","label":"ClinicalTrials.gov: trials of Englumafusp alfa"}]},{"url":"https://clinicaltrials.gov/search?intr=roginolisib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/","field":"links","label":"ClinicalTrials.gov: trials of roginolisib"}]},{"url":"https://clinicaltrials.gov/search?intr=RPH-051","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rph-051","kind":"drug","name":"RPH-051","route":"/drugs/rph-051/","field":"links","label":"ClinicalTrials.gov: trials of RPH-051"}]},{"url":"https://clinicaltrials.gov/search?intr=RV001V","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rv001v","kind":"drug","name":"RV001V","route":"/drugs/rv001v/","field":"links","label":"ClinicalTrials.gov: trials of RV001V"}]},{"url":"https://clinicaltrials.gov/search?intr=RVU120","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rvu120","kind":"drug","name":"RVU120","route":"/drugs/rvu120/","field":"links","label":"ClinicalTrials.gov: trials of RVU120"}]},{"url":"https://clinicaltrials.gov/search?intr=RYZ101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"links","label":"ClinicalTrials.gov: trials of Actinium-225 DOTATATE"}]},{"url":"https://clinicaltrials.gov/search?intr=Sabatolimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sabatolimab","kind":"drug","name":"Sabatolimab","route":"/drugs/sabatolimab/","field":"links","label":"ClinicalTrials.gov: trials of Sabatolimab"}]},{"url":"https://clinicaltrials.gov/search?intr=Samuraciclib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samuraciclib","kind":"drug","name":"Samuraciclib","route":"/drugs/samuraciclib/","field":"links","label":"ClinicalTrials.gov: trials of Samuraciclib"}]},{"url":"https://clinicaltrials.gov/search?intr=Sasanlimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sasanlimab","kind":"drug","name":"Sasanlimab","route":"/drugs/sasanlimab/","field":"links","label":"ClinicalTrials.gov: trials of Sasanlimab"}]},{"url":"https://clinicaltrials.gov/search?intr=SCC244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/","field":"links","label":"ClinicalTrials.gov: trials of Glumetinib"}]},{"url":"https://clinicaltrials.gov/search?intr=SCTB14","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","field":"links","label":"ClinicalTrials.gov: trials of SCTB14"}]},{"url":"https://clinicaltrials.gov/search?intr=SCTB35","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","field":"links","label":"ClinicalTrials.gov: trials of SCTB35"}]},{"url":"https://clinicaltrials.gov/search?intr=SCTB41","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","field":"links","label":"ClinicalTrials.gov: trials of SCTB41"}]},{"url":"https://clinicaltrials.gov/search?intr=SCTC21C","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","field":"links","label":"ClinicalTrials.gov: trials of SCTC21C"}]},{"url":"https://clinicaltrials.gov/search?intr=SEL24","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/","field":"links","label":"ClinicalTrials.gov: trials of MEN1703"}]},{"url":"https://clinicaltrials.gov/search?intr=Selicrelumab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"selicrelumab","kind":"drug","name":"Selicrelumab","route":"/drugs/selicrelumab/","field":"links","label":"ClinicalTrials.gov: trials of Selicrelumab"}]},{"url":"https://clinicaltrials.gov/search?intr=SG301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","field":"links","label":"ClinicalTrials.gov: trials of SG301"}]},{"url":"https://clinicaltrials.gov/search?intr=SGM-101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sgm-101","kind":"drug","name":"SGM-101","route":"/drugs/sgm-101/","field":"links","label":"ClinicalTrials.gov: trials of SGM-101"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-1501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/","field":"links","label":"ClinicalTrials.gov: trials of SHR-1501"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-1701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/","field":"links","label":"ClinicalTrials.gov: trials of Retlirafusp alfa"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-8068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/","field":"links","label":"ClinicalTrials.gov: trials of SHR-8068"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-A1912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/","field":"links","label":"ClinicalTrials.gov: trials of SHR-A1912"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-A1921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/","field":"links","label":"ClinicalTrials.gov: trials of SHR-A1921"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-A2009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-a2009","kind":"drug","name":"SHR-A2009","route":"/drugs/shr-a2009/","field":"links","label":"ClinicalTrials.gov: trials of SHR-A2009"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR-A2102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/","field":"links","label":"ClinicalTrials.gov: trials of SHR-A2102"}]},{"url":"https://clinicaltrials.gov/search?intr=SHR3680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","field":"links","label":"ClinicalTrials.gov: trials of Rezvilutamide"}]},{"url":"https://clinicaltrials.gov/search?intr=SI-B001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/","field":"links","label":"ClinicalTrials.gov: trials of SI-B001"}]},{"url":"https://clinicaltrials.gov/search?intr=SIM0270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/","field":"links","label":"ClinicalTrials.gov: trials of SIM0270"}]},{"url":"https://clinicaltrials.gov/search?intr=Sitneprotafib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","field":"links","label":"ClinicalTrials.gov: trials of Sitneprotafib"}]},{"url":"https://clinicaltrials.gov/search?intr=SKB105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skb105","kind":"drug","name":"SKB105","route":"/drugs/skb105/","field":"links","label":"ClinicalTrials.gov: trials of SKB105"}]},{"url":"https://clinicaltrials.gov/search?intr=Sotevtamab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/","field":"links","label":"ClinicalTrials.gov: trials of Sotevtamab"}]},{"url":"https://clinicaltrials.gov/search?intr=Spartalizumab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spartalizumab","kind":"drug","name":"Spartalizumab","route":"/drugs/spartalizumab/","field":"links","label":"ClinicalTrials.gov: trials of Spartalizumab"}]},{"url":"https://clinicaltrials.gov/search?intr=SPH4336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sph4336","kind":"drug","name":"SPH4336","route":"/drugs/sph4336/","field":"links","label":"ClinicalTrials.gov: trials of SPH4336"}]},{"url":"https://clinicaltrials.gov/search?intr=SSGJ-612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/","field":"links","label":"ClinicalTrials.gov: trials of SSGJ-612"}]},{"url":"https://clinicaltrials.gov/search?intr=SSGJ-705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/","field":"links","label":"ClinicalTrials.gov: trials of SSGJ-705"}]},{"url":"https://clinicaltrials.gov/search?intr=SSGJ-706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","route":"/drugs/ssgj-706/","field":"links","label":"ClinicalTrials.gov: trials of SSGJ-706"}]},{"url":"https://clinicaltrials.gov/search?intr=SSGJ-707","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/","field":"links","label":"ClinicalTrials.gov: trials of PF-08634404"}]},{"url":"https://clinicaltrials.gov/search?intr=STI-6129","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sti-6129","kind":"drug","name":"STI-6129","route":"/drugs/sti-6129/","field":"links","label":"ClinicalTrials.gov: trials of STI-6129"}]},{"url":"https://clinicaltrials.gov/search?intr=STP938","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/","field":"links","label":"ClinicalTrials.gov: trials of STP938"}]},{"url":"https://clinicaltrials.gov/search?intr=STX-478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tersolisib","kind":"drug","name":"Tersolisib","route":"/drugs/tersolisib/","field":"links","label":"ClinicalTrials.gov: trials of Tersolisib"}]},{"url":"https://clinicaltrials.gov/search?intr=surufatinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/","field":"links","label":"ClinicalTrials.gov: trials of surufatinib"}]},{"url":"https://clinicaltrials.gov/search?intr=SYS6010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/","field":"links","label":"ClinicalTrials.gov: trials of SYS6010"}]},{"url":"https://clinicaltrials.gov/search?intr=SYS6023","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/","field":"links","label":"ClinicalTrials.gov: trials of SYS6023"}]},{"url":"https://clinicaltrials.gov/search?intr=T3011","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/","field":"links","label":"ClinicalTrials.gov: trials of T3011"}]},{"url":"https://clinicaltrials.gov/search?intr=Tabelecleucel","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","field":"links","label":"ClinicalTrials.gov: trials of Tabelecleucel"}]},{"url":"https://clinicaltrials.gov/search?intr=TAC01","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","field":"links","label":"ClinicalTrials.gov: trials of TAC01-CLDN18.2"}]},{"url":"https://clinicaltrials.gov/search?intr=TAK-928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/","field":"links","label":"ClinicalTrials.gov: trials of TAK-928"}]},{"url":"https://clinicaltrials.gov/search?intr=TARA-002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","field":"links","label":"ClinicalTrials.gov: trials of TARA-002"}]},{"url":"https://clinicaltrials.gov/search?intr=TBI-1301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","field":"links","label":"ClinicalTrials.gov: trials of TBI-1301"}]},{"url":"https://clinicaltrials.gov/search?intr=TBI-1501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","field":"links","label":"ClinicalTrials.gov: trials of TBI-1501"}]},{"url":"https://clinicaltrials.gov/search?intr=TC011","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tc011","kind":"drug","name":"TC011","route":"/drugs/tc011/","field":"links","label":"ClinicalTrials.gov: trials of TC011"}]},{"url":"https://clinicaltrials.gov/search?intr=Tenalisib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tenalisib","kind":"drug","name":"Tenalisib","route":"/drugs/tenalisib/","field":"links","label":"ClinicalTrials.gov: trials of Tenalisib"}]},{"url":"https://clinicaltrials.gov/search?intr=TGRX-326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/","field":"links","label":"ClinicalTrials.gov: trials of TGRX-326"}]},{"url":"https://clinicaltrials.gov/search?intr=THEO-260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/","field":"links","label":"ClinicalTrials.gov: trials of THEO-260"}]},{"url":"https://clinicaltrials.gov/search?intr=TILT-123","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/","field":"links","label":"ClinicalTrials.gov: trials of TILT-123"}]},{"url":"https://clinicaltrials.gov/search?intr=TLX250-CDx","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"girentuximab-zr89","kind":"drug","name":"Zirconium-89 girentuximab","route":"/drugs/girentuximab-zr89/","field":"links","label":"ClinicalTrials.gov: trials of Zirconium-89 girentuximab"}]},{"url":"https://clinicaltrials.gov/search?intr=TNB-486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/","field":"links","label":"ClinicalTrials.gov: trials of AZD0486"}]},{"url":"https://clinicaltrials.gov/search?intr=TNG260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/","field":"links","label":"ClinicalTrials.gov: trials of TNG260"}]},{"url":"https://clinicaltrials.gov/search?intr=TNG456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","field":"links","label":"ClinicalTrials.gov: trials of TNG456"}]},{"url":"https://clinicaltrials.gov/search?intr=TNG462","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/","field":"links","label":"ClinicalTrials.gov: trials of TNG462"}]},{"url":"https://clinicaltrials.gov/search?intr=TNO155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/","field":"links","label":"ClinicalTrials.gov: trials of TNO155"}]},{"url":"https://clinicaltrials.gov/search?intr=Tovecimig","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","field":"links","label":"ClinicalTrials.gov: trials of Tovecimig"}]},{"url":"https://clinicaltrials.gov/search?intr=TQ-B3234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/","field":"links","label":"ClinicalTrials.gov: trials of TQ-B3234"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/","field":"links","label":"ClinicalTrials.gov: trials of TQB2102"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2450","kind":"drug","name":"TQB2450","route":"/drugs/tqb2450/","field":"links","label":"ClinicalTrials.gov: trials of TQB2450"},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","field":"links","label":"ClinicalTrials.gov: trials of benmelstobart"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/","field":"links","label":"ClinicalTrials.gov: trials of TQB2825"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/","field":"links","label":"ClinicalTrials.gov: trials of TQB2868"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2922","kind":"drug","name":"TQB2922","route":"/drugs/tqb2922/","field":"links","label":"ClinicalTrials.gov: trials of TQB2922"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB2930","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/","field":"links","label":"ClinicalTrials.gov: trials of TQB2930"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB3454","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb3454","kind":"drug","name":"TQB3454","route":"/drugs/tqb3454/","field":"links","label":"ClinicalTrials.gov: trials of TQB3454"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB3616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb3616","kind":"drug","name":"TQB3616","route":"/drugs/tqb3616/","field":"links","label":"ClinicalTrials.gov: trials of TQB3616"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB3702","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/","field":"links","label":"ClinicalTrials.gov: trials of TQB3702"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB3909","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/","field":"links","label":"ClinicalTrials.gov: trials of TQB3909"}]},{"url":"https://clinicaltrials.gov/search?intr=TQB6411","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/","field":"links","label":"ClinicalTrials.gov: trials of TQB6411"}]},{"url":"https://clinicaltrials.gov/search?intr=Trabedersen","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trabedersen","kind":"drug","name":"Trabedersen","route":"/drugs/trabedersen/","field":"links","label":"ClinicalTrials.gov: trials of Trabedersen"}]},{"url":"https://clinicaltrials.gov/search?intr=TRI-611","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","field":"links","label":"ClinicalTrials.gov: trials of TRI-611"}]},{"url":"https://clinicaltrials.gov/search?intr=TRK-950","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/","field":"links","label":"ClinicalTrials.gov: trials of TRK-950"}]},{"url":"https://clinicaltrials.gov/search?intr=TST001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tst001","kind":"drug","name":"TST001","route":"/drugs/tst001/","field":"links","label":"ClinicalTrials.gov: trials of TST001"}]},{"url":"https://clinicaltrials.gov/search?intr=TST003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/","field":"links","label":"ClinicalTrials.gov: trials of TST003"}]},{"url":"https://clinicaltrials.gov/search?intr=Tuspetinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/","field":"links","label":"ClinicalTrials.gov: trials of Tuspetinib"}]},{"url":"https://clinicaltrials.gov/search?intr=TVB-2640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asc40","kind":"drug","name":"ASC40","route":"/drugs/asc40/","field":"links","label":"ClinicalTrials.gov: trials of ASC40"}]},{"url":"https://clinicaltrials.gov/search?intr=TY-9591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ty-9591","kind":"drug","name":"TY-9591","route":"/drugs/ty-9591/","field":"links","label":"ClinicalTrials.gov: trials of TY-9591"}]},{"url":"https://clinicaltrials.gov/search?intr=TYRA-300","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/","field":"links","label":"ClinicalTrials.gov: trials of TYRA-300"}]},{"url":"https://clinicaltrials.gov/search?intr=Ubamatamab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","field":"links","label":"ClinicalTrials.gov: trials of Ubamatamab"}]},{"url":"https://clinicaltrials.gov/search?intr=UCART22","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ucart22","kind":"drug","name":"UCART22","route":"/drugs/ucart22/","field":"links","label":"ClinicalTrials.gov: trials of UCART22"}]},{"url":"https://clinicaltrials.gov/search?intr=UGN-103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ugn-103","kind":"drug","name":"UGN-103","route":"/drugs/ugn-103/","field":"links","label":"ClinicalTrials.gov: trials of UGN-103"}]},{"url":"https://clinicaltrials.gov/search?intr=UGN-104","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","field":"links","label":"ClinicalTrials.gov: trials of UGN-104"}]},{"url":"https://clinicaltrials.gov/search?intr=Uliledlimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/","field":"links","label":"ClinicalTrials.gov: trials of Uliledlimab"}]},{"url":"https://clinicaltrials.gov/search?intr=Upifitamab%20rilsodotin","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/","field":"links","label":"ClinicalTrials.gov: trials of Upifitamab rilsodotin"}]},{"url":"https://clinicaltrials.gov/search?intr=utidelone","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","field":"links","label":"ClinicalTrials.gov: trials of utidelone"}]},{"url":"https://clinicaltrials.gov/search?intr=Utomilumab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/","field":"links","label":"ClinicalTrials.gov: trials of Utomilumab"}]},{"url":"https://clinicaltrials.gov/search?intr=Vactosertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/","field":"links","label":"ClinicalTrials.gov: trials of Vactosertib"}]},{"url":"https://clinicaltrials.gov/search?intr=Varegacestat","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"varegacestat","kind":"drug","name":"Varegacestat","route":"/drugs/varegacestat/","field":"links","label":"ClinicalTrials.gov: trials of Varegacestat"}]},{"url":"https://clinicaltrials.gov/search?intr=VB15010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vb15010","kind":"drug","name":"VB15010","route":"/drugs/vb15010/","field":"links","label":"ClinicalTrials.gov: trials of VB15010"}]},{"url":"https://clinicaltrials.gov/search?intr=VC004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vc004","kind":"drug","name":"VC004","route":"/drugs/vc004/","field":"links","label":"ClinicalTrials.gov: trials of VC004"}]},{"url":"https://clinicaltrials.gov/search?intr=Vepugratinib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vepugratinib","kind":"drug","name":"Vepugratinib","route":"/drugs/vepugratinib/","field":"links","label":"ClinicalTrials.gov: trials of Vepugratinib"}]},{"url":"https://clinicaltrials.gov/search?intr=Vibostolimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vibostolimab","kind":"drug","name":"Vibostolimab","route":"/drugs/vibostolimab/","field":"links","label":"ClinicalTrials.gov: trials of Vibostolimab"}]},{"url":"https://clinicaltrials.gov/search?intr=Vistusertib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/","field":"links","label":"ClinicalTrials.gov: trials of Vistusertib"}]},{"url":"https://clinicaltrials.gov/search?intr=vorolanib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","field":"links","label":"ClinicalTrials.gov: trials of vorolanib"}]},{"url":"https://clinicaltrials.gov/search?intr=VRN110755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/","field":"links","label":"ClinicalTrials.gov: trials of VRN110755"}]},{"url":"https://clinicaltrials.gov/search?intr=VS-7375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/","field":"links","label":"ClinicalTrials.gov: trials of VS-7375"}]},{"url":"https://clinicaltrials.gov/search?intr=Vudalimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/","field":"links","label":"ClinicalTrials.gov: trials of Vudalimab"}]},{"url":"https://clinicaltrials.gov/search?intr=WJB001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wjb001","kind":"drug","name":"WJB001","route":"/drugs/wjb001/","field":"links","label":"ClinicalTrials.gov: trials of WJB001"}]},{"url":"https://clinicaltrials.gov/search?intr=WX-0593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","field":"links","label":"ClinicalTrials.gov: trials of iruplinalkib"}]},{"url":"https://clinicaltrials.gov/search?intr=XL092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","field":"links","label":"ClinicalTrials.gov: trials of Zanzalintinib"}]},{"url":"https://clinicaltrials.gov/search?intr=XNW27011","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xnw27011","kind":"drug","name":"XNW27011","route":"/drugs/xnw27011/","field":"links","label":"ClinicalTrials.gov: trials of XNW27011"}]},{"url":"https://clinicaltrials.gov/search?intr=XNW5004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/","field":"links","label":"ClinicalTrials.gov: trials of XNW5004"}]},{"url":"https://clinicaltrials.gov/search?intr=XZP-3287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/","field":"links","label":"ClinicalTrials.gov: trials of XZP-3287"}]},{"url":"https://clinicaltrials.gov/search?intr=YL201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/","field":"links","label":"ClinicalTrials.gov: trials of YL201"}]},{"url":"https://clinicaltrials.gov/search?intr=YL202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/","field":"links","label":"ClinicalTrials.gov: trials of YL202"}]},{"url":"https://clinicaltrials.gov/search?intr=YY-20394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/","field":"links","label":"ClinicalTrials.gov: trials of linperlisib"}]},{"url":"https://clinicaltrials.gov/search?intr=Zalifrelimab","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zalifrelimab","kind":"drug","name":"Zalifrelimab","route":"/drugs/zalifrelimab/","field":"links","label":"ClinicalTrials.gov: trials of Zalifrelimab"}]},{"url":"https://clinicaltrials.gov/search?intr=ZG006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/","field":"links","label":"ClinicalTrials.gov: trials of ZG006"}]},{"url":"https://clinicaltrials.gov/search?intr=ZKAB001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/","field":"links","label":"ClinicalTrials.gov: trials of Socazolimab"}]},{"url":"https://clinicaltrials.gov/search?intr=ZL-1310","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/","field":"links","label":"ClinicalTrials.gov: trials of ZL-1310"}]},{"url":"https://clinicaltrials.gov/search?intr=Zovegalisib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","field":"links","label":"ClinicalTrials.gov: trials of Zovegalisib"}]},{"url":"https://clinicaltrials.gov/search?lead=3D%20Medicines","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/","field":"links","label":"ClinicalTrials.gov: trials led by 3D Medicines"}]},{"url":"https://clinicaltrials.gov/search?lead=A2%20Biotherapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by A2 Biotherapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=AB%20Science","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","field":"links","label":"ClinicalTrials.gov: trials led by AB Science"}]},{"url":"https://clinicaltrials.gov/search?lead=Abbisko%20Therapeutics%20Co%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","field":"links","label":"ClinicalTrials.gov: trials led by Abbisko Therapeutics Co, Ltd"}]},{"url":"https://clinicaltrials.gov/search?lead=ABX%20advanced%20biochemical%20compounds","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"links","label":"ClinicalTrials.gov: trials led by ABX advanced biochemical compounds"}]},{"url":"https://clinicaltrials.gov/search?lead=Acacia%20Pharma%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Acacia Pharma Ltd"}]},{"url":"https://clinicaltrials.gov/search?lead=Accuray","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","field":"links","label":"ClinicalTrials.gov: trials led by Accuray"}]},{"url":"https://clinicaltrials.gov/search?lead=Achieve%20Life%20Sciences%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","field":"links","label":"ClinicalTrials.gov: trials led by Achieve Life Sciences, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Active%20Biotech%20AB","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","field":"links","label":"ClinicalTrials.gov: trials led by Active Biotech AB"}]},{"url":"https://clinicaltrials.gov/search?lead=Acute%20Leukemia%20French%20Association","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alfa","kind":"company","name":"ALFA (Acute Leukemia French Association)","route":"/companies/alfa/","field":"links","label":"ClinicalTrials.gov: trials led by Acute Leukemia French Association"}]},{"url":"https://clinicaltrials.gov/search?lead=Advenchen%20Laboratories%2C%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","field":"links","label":"ClinicalTrials.gov: trials led by Advenchen Laboratories, LLC"}]},{"url":"https://clinicaltrials.gov/search?lead=AEterna%20Zentaris","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","field":"links","label":"ClinicalTrials.gov: trials led by AEterna Zentaris"}]},{"url":"https://clinicaltrials.gov/search?lead=Agennix%20AG","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","field":"links","label":"ClinicalTrials.gov: trials led by Agennix AG"}]},{"url":"https://clinicaltrials.gov/search?lead=Agenus","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","field":"links","label":"ClinicalTrials.gov: trials led by Agenus"}]},{"url":"https://clinicaltrials.gov/search?lead=AGO%20Research%20GmbH","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/","field":"links","label":"ClinicalTrials.gov: trials led by AGO Research GmbH"}]},{"url":"https://clinicaltrials.gov/search?lead=AGO%20Study%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/","field":"links","label":"ClinicalTrials.gov: trials led by AGO Study Group"}]},{"url":"https://clinicaltrials.gov/search?lead=AIDS%20Malignancy%20Consortium","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aids-malignancy-consortium","kind":"company","name":"AIDS Malignancy Consortium","route":"/companies/aids-malignancy-consortium/","field":"links","label":"ClinicalTrials.gov: trials led by AIDS Malignancy Consortium"}]},{"url":"https://clinicaltrials.gov/search?lead=AIO-Studien-gGmbH","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","route":"/companies/aio/","field":"links","label":"ClinicalTrials.gov: trials led by AIO-Studien-gGmbH"}]},{"url":"https://clinicaltrials.gov/search?lead=Almirall","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","field":"links","label":"ClinicalTrials.gov: trials led by Almirall"}]},{"url":"https://clinicaltrials.gov/search?lead=ALX%20Oncology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/","field":"links","label":"ClinicalTrials.gov: trials led by ALX Oncology"}]},{"url":"https://clinicaltrials.gov/search?lead=Ambrx%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","field":"links","label":"ClinicalTrials.gov: trials led by Ambrx, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Amplia%20Therapeutics%20Limited","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","route":"/companies/amplia-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Amplia Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Anbogen%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","route":"/companies/anbogen-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Anbogen Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Angiocrine%20Bioscience%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","field":"links","label":"ClinicalTrials.gov: trials led by Angiocrine Bioscience, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Antengene","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/","field":"links","label":"ClinicalTrials.gov: trials led by Antengene"}]},{"url":"https://clinicaltrials.gov/search?lead=AOP%20Orphan%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/","field":"links","label":"ClinicalTrials.gov: trials led by AOP Orphan Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=AP%20Biosciences%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/","field":"links","label":"ClinicalTrials.gov: trials led by AP Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Apollomics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/","field":"links","label":"ClinicalTrials.gov: trials led by Apollomics"}]},{"url":"https://clinicaltrials.gov/search?lead=Aprea%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Aprea Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Aptose%20Biosciences","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/","field":"links","label":"ClinicalTrials.gov: trials led by Aptose Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Arcus%20Biosciences%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/","field":"links","label":"ClinicalTrials.gov: trials led by Arcus Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=argenx","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","field":"links","label":"ClinicalTrials.gov: trials led by argenx"}]},{"url":"https://clinicaltrials.gov/search?lead=Argos%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Argos Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Arog%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Arog Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=ArriVent%20BioPharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/","field":"links","label":"ClinicalTrials.gov: trials led by ArriVent BioPharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Artios%20Pharma%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Artios Pharma Ltd"}]},{"url":"https://clinicaltrials.gov/search?lead=Ascentage%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Ascentage Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Ascentawits%20Pharmaceuticals%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Ascentawits Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Ascletis%20Pharmaceuticals%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","field":"links","label":"ClinicalTrials.gov: trials led by Ascletis Pharmaceuticals Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=AskGene%20Pharma%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by AskGene Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Atossa%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Atossa Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Aura%20Biosciences","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/","field":"links","label":"ClinicalTrials.gov: trials led by Aura Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Aveta%20Biomics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/","field":"links","label":"ClinicalTrials.gov: trials led by Aveta Biomics"}]},{"url":"https://clinicaltrials.gov/search?lead=Avistone%20Biotechnology%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/","field":"links","label":"ClinicalTrials.gov: trials led by Avistone Biotechnology"}]},{"url":"https://clinicaltrials.gov/search?lead=Basilea%20Pharmaceutica","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","field":"links","label":"ClinicalTrials.gov: trials led by Basilea Pharmaceutica"}]},{"url":"https://clinicaltrials.gov/search?lead=Bavarian%20Nordic","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","field":"links","label":"ClinicalTrials.gov: trials led by Bavarian Nordic"}]},{"url":"https://clinicaltrials.gov/search?lead=BeBetter%20Med","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/","field":"links","label":"ClinicalTrials.gov: trials led by BeBetter Med"}]},{"url":"https://clinicaltrials.gov/search?lead=Bellicum%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","field":"links","label":"ClinicalTrials.gov: trials led by Bellicum Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=BeyondSpring","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","route":"/companies/beyondspring/","field":"links","label":"ClinicalTrials.gov: trials led by BeyondSpring"}]},{"url":"https://clinicaltrials.gov/search?lead=Bio-Thera%20Solutions","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","field":"links","label":"ClinicalTrials.gov: trials led by Bio-Thera Solutions"}]},{"url":"https://clinicaltrials.gov/search?lead=Biocad","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/","field":"links","label":"ClinicalTrials.gov: trials led by Biocad"}]},{"url":"https://clinicaltrials.gov/search?lead=Biogen","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","field":"links","label":"ClinicalTrials.gov: trials led by Biogen"}]},{"url":"https://clinicaltrials.gov/search?lead=BioInvent%20International%20AB","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","field":"links","label":"ClinicalTrials.gov: trials led by BioInvent International"}]},{"url":"https://clinicaltrials.gov/search?lead=BioLineRx","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","field":"links","label":"ClinicalTrials.gov: trials led by BioLineRx"}]},{"url":"https://clinicaltrials.gov/search?lead=Blaze%20Bioscience%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","field":"links","label":"ClinicalTrials.gov: trials led by Blaze Bioscience Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Can-Fite%20BioPharma%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","field":"links","label":"ClinicalTrials.gov: trials led by Can-Fite BioPharma Ltd"}]},{"url":"https://clinicaltrials.gov/search?lead=Cancer%20Prevention%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Cancer Prevention Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Cartesian%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Cartesian Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=CatalYm%20GmbH","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/","field":"links","label":"ClinicalTrials.gov: trials led by CatalYm"}]},{"url":"https://clinicaltrials.gov/search?lead=CEBIOTEX","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/","field":"links","label":"ClinicalTrials.gov: trials led by CEBIOTEX"}]},{"url":"https://clinicaltrials.gov/search?lead=Cellectar%20Biosciences","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"links","label":"ClinicalTrials.gov: trials led by Cellectar Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Cellectis%20S.A.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/","field":"links","label":"ClinicalTrials.gov: trials led by Cellectis S.A."}]},{"url":"https://clinicaltrials.gov/search?lead=CellSeed%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","field":"links","label":"ClinicalTrials.gov: trials led by CellSeed Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=CellSight%20Technologies%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","route":"/companies/cellsight-technologies/","field":"links","label":"ClinicalTrials.gov: trials led by CellSight Technologies"}]},{"url":"https://clinicaltrials.gov/search?lead=Celltrion","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/","field":"links","label":"ClinicalTrials.gov: trials led by Celltrion"}]},{"url":"https://clinicaltrials.gov/search?lead=Changchun%20GeneScience%20Pharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/","field":"links","label":"ClinicalTrials.gov: trials led by Changchun GeneScience Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Chongqing%20Precision%20Biotech%20Co.%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/","field":"links","label":"ClinicalTrials.gov: trials led by Chongqing Precision Biotech"}]},{"url":"https://clinicaltrials.gov/search?lead=Chugai%20Pharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","field":"links","label":"ClinicalTrials.gov: trials led by Chugai Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=CivaTech%20Oncology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","route":"/companies/civatech-oncology/","field":"links","label":"ClinicalTrials.gov: trials led by CivaTech Oncology"}]},{"url":"https://clinicaltrials.gov/search?lead=Clovis%20Oncology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","field":"links","label":"ClinicalTrials.gov: trials led by Clovis Oncology"}]},{"url":"https://clinicaltrials.gov/search?lead=Corbus%20Pharmaceuticals%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Corbus Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Crinetics%20Pharmaceuticals%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Crinetics Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Criterium%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","field":"links","label":"ClinicalTrials.gov: trials led by Criterium, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=CSL%20Behring","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","field":"links","label":"ClinicalTrials.gov: trials led by CSL Behring"}]},{"url":"https://clinicaltrials.gov/search?lead=Curis%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/","field":"links","label":"ClinicalTrials.gov: trials led by Curis"}]},{"url":"https://clinicaltrials.gov/search?lead=Cyclacel%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","field":"links","label":"ClinicalTrials.gov: trials led by Cyclacel Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=D3%20Bio%20(Wuxi)%20Co.%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","field":"links","label":"ClinicalTrials.gov: trials led by D3 Bio (Wuxi)"}]},{"url":"https://clinicaltrials.gov/search?lead=Daehwa%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Daehwa Pharmaceutical Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Delta-Fly%20Pharma%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Delta-Fly Pharma, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Dendreon","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","field":"links","label":"ClinicalTrials.gov: trials led by Dendreon"}]},{"url":"https://clinicaltrials.gov/search?lead=Denovo%20Biopharma%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Denovo Biopharma LLC"}]},{"url":"https://clinicaltrials.gov/search?lead=Diffusion%20Pharmaceuticals%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Diffusion Pharmaceuticals Inc"}]},{"url":"https://clinicaltrials.gov/search?lead=Disc%20Medicine%2C%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"disc-medicine","kind":"company","name":"Disc Medicine","route":"/companies/disc-medicine/","field":"links","label":"ClinicalTrials.gov: trials led by Disc Medicine"}]},{"url":"https://clinicaltrials.gov/search?lead=Dizal","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/","field":"links","label":"ClinicalTrials.gov: trials led by Dizal"}]},{"url":"https://clinicaltrials.gov/search?lead=Dong-A%20ST%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","field":"links","label":"ClinicalTrials.gov: trials led by Dong-A ST Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Dutch%20Pancreatic%20Cancer%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","route":"/companies/dpcg/","field":"links","label":"ClinicalTrials.gov: trials led by Dutch Pancreatic Cancer Group"}]},{"url":"https://clinicaltrials.gov/search?lead=Eikon%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Eikon Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Ellipses%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Ellipses Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Elpiscience%20(Suzhou)%20Biopharma%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Elpiscience (Suzhou) Biopharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Emergent%20BioSolutions%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","field":"links","label":"ClinicalTrials.gov: trials led by Emergent BioSolutions Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Endo%20International%20plc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"links","label":"ClinicalTrials.gov: trials led by Endo International plc"}]},{"url":"https://clinicaltrials.gov/search?lead=EpicentRx%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/","field":"links","label":"ClinicalTrials.gov: trials led by EpicentRx"}]},{"url":"https://clinicaltrials.gov/search?lead=ERYtech%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","field":"links","label":"ClinicalTrials.gov: trials led by ERYtech Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Eureka%20Therapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Eureka Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Eurofarma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","field":"links","label":"ClinicalTrials.gov: trials led by Eurofarma"}]},{"url":"https://clinicaltrials.gov/search?lead=Evopoint%20Biosciences%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/","field":"links","label":"ClinicalTrials.gov: trials led by Evopoint Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Federal%20Research%20Institute%20of%20Pediatric%20Hematology%2C%20Oncology%20and%20Immunology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","route":"/institutions/rogachev-centre/","field":"links","label":"ClinicalTrials.gov: studies led by the institute"}]},{"url":"https://clinicaltrials.gov/search?lead=Fondazione%20Italiana%20Linfomi%20-%20ETS","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fondazione-italiana-linfomi","kind":"company","name":"Fondazione Italiana Linfomi","route":"/companies/fondazione-italiana-linfomi/","field":"links","label":"ClinicalTrials.gov: trials led by Fondazione Italiana Linfomi - ETS"}]},{"url":"https://clinicaltrials.gov/search?lead=Foresee%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Foresee Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Forward%20Pharmaceuticals%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Forward Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Frantz%20Viral%20Therapeutics%2C%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Frantz Viral Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=French%20Innovative%20Leukemia%20Organisation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","route":"/companies/filo/","field":"links","label":"ClinicalTrials.gov: trials led by French Innovative Leukemia Organisation"}]},{"url":"https://clinicaltrials.gov/search?lead=French%20Sarcoma%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"french-sarcoma-group","kind":"company","name":"French Sarcoma Group","route":"/companies/french-sarcoma-group/","field":"links","label":"ClinicalTrials.gov: trials led by French Sarcoma Group"}]},{"url":"https://clinicaltrials.gov/search?lead=FutureChem","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"links","label":"ClinicalTrials.gov: trials led by FutureChem"}]},{"url":"https://clinicaltrials.gov/search?lead=G1%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","route":"/companies/g1-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by G1 Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Galderma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"links","label":"ClinicalTrials.gov: trials led by Galderma"}]},{"url":"https://clinicaltrials.gov/search?lead=Galena%20Biopharma%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Galena Biopharma, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Galera%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Galera Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=GC%20Cell","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/","field":"links","label":"ClinicalTrials.gov: trials led by GC Cell"}]},{"url":"https://clinicaltrials.gov/search?lead=Genelux%20Corporation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","field":"links","label":"ClinicalTrials.gov: trials led by Genelux"}]},{"url":"https://clinicaltrials.gov/search?lead=GeneQuantum%20Healthcare%20(Suzhou)%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","field":"links","label":"ClinicalTrials.gov: trials led by GeneQuantum Healthcare (Suzhou)"}]},{"url":"https://clinicaltrials.gov/search?lead=Genprex%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/","field":"links","label":"ClinicalTrials.gov: trials led by Genprex"}]},{"url":"https://clinicaltrials.gov/search?lead=Georgiamune%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/","field":"links","label":"ClinicalTrials.gov: trials led by Georgiamune"}]},{"url":"https://clinicaltrials.gov/search?lead=GERCOR%20-%20Multidisciplinary%20Oncology%20Cooperative%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/","field":"links","label":"ClinicalTrials.gov: trials led by GERCOR - Multidisciplinary Oncology Cooperative Group"}]},{"url":"https://clinicaltrials.gov/search?lead=German%20CLL%20Study%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"german-cll-study-group","kind":"company","name":"German CLL Study Group","route":"/companies/german-cll-study-group/","field":"links","label":"ClinicalTrials.gov: trials led by German CLL Study Group"}]},{"url":"https://clinicaltrials.gov/search?lead=GI%20Innovation%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/","field":"links","label":"ClinicalTrials.gov: trials led by GI Innovation"}]},{"url":"https://clinicaltrials.gov/search?lead=Grifols%20Therapeutics%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","field":"links","label":"ClinicalTrials.gov: trials led by Grifols Therapeutics LLC"}]},{"url":"https://clinicaltrials.gov/search?lead=Grit%20Biotechnology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/","field":"links","label":"ClinicalTrials.gov: trials led by Grit Bio"}]},{"url":"https://clinicaltrials.gov/search?lead=Groupe%20Oncologie%20Radiotherapie%20Tete%20et%20Cou","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gortec","kind":"company","name":"GORTEC","route":"/companies/gortec/","field":"links","label":"ClinicalTrials.gov: trials led by Groupe Oncologie Radiotherapie Tete et Cou"}]},{"url":"https://clinicaltrials.gov/search?lead=GTx%20Incorporated","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","field":"links","label":"ClinicalTrials.gov: trials led by GTx Incorporated"}]},{"url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Lupeng%20Pharmaceutical%20Company%20LTD.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Lupeng Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Virotech%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","route":"/companies/guangzhou-virotech/","field":"links","label":"ClinicalTrials.gov: trials led by Guangzhou Virotech Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=GV20%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by GV20 Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Haihe%20Biopharma%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Haihe Biopharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Halozyme%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","field":"links","label":"ClinicalTrials.gov: trials led by Halozyme Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Hangzhou%20Hanx%20Biopharmaceuticals%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Hangzhou Hanx Biopharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Hangzhou%20Sumgen%20Biotech%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/","field":"links","label":"ClinicalTrials.gov: trials led by Hangzhou Sumgen Biotech"}]},{"url":"https://clinicaltrials.gov/search?lead=Harbour%20BioMed%20(Guangzhou)%20Co.%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","field":"links","label":"ClinicalTrials.gov: trials led by Harbour BioMed (Guangzhou) Co. Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Heidelberg%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Heidelberg Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Hellenic%20Oncology%20Research%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"horg","kind":"company","name":"Hellenic Oncology Research Group","route":"/companies/horg/","field":"links","label":"ClinicalTrials.gov: trials led by Hellenic Oncology Research Group"}]},{"url":"https://clinicaltrials.gov/search?lead=HiberCell%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","field":"links","label":"ClinicalTrials.gov: trials led by HiberCell, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Hinova%20Pharmaceuticals%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Hinova Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=HUYABIO%20International%2C%20LLC.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","field":"links","label":"ClinicalTrials.gov: trials led by HUYABIO International, LLC."}]},{"url":"https://clinicaltrials.gov/search?lead=Idera%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Idera Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Il-Yang%20Pharm.%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Il-Yang Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Immuneering%20Corporation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","field":"links","label":"ClinicalTrials.gov: trials led by Immuneering"}]},{"url":"https://clinicaltrials.gov/search?lead=ImmuneOncia%20Therapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by ImmuneOncia Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Immunitor%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","field":"links","label":"ClinicalTrials.gov: trials led by Immunitor LLC"}]},{"url":"https://clinicaltrials.gov/search?lead=Immunome","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/","field":"links","label":"ClinicalTrials.gov: trials led by Immunome"}]},{"url":"https://clinicaltrials.gov/search?lead=ImmunoVaccine%20Technologies%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","field":"links","label":"ClinicalTrials.gov: trials led by ImmunoVaccine Technologies, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Immutep","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","field":"links","label":"ClinicalTrials.gov: trials led by Immutep"}]},{"url":"https://clinicaltrials.gov/search?lead=Impact%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Impact Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Imunon","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","field":"links","label":"ClinicalTrials.gov: trials led by Imunon"}]},{"url":"https://clinicaltrials.gov/search?lead=Infinity%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Infinity Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=InnoPharmax","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"innopharmax","kind":"company","name":"InnoPharmax","route":"/companies/innopharmax/","field":"links","label":"ClinicalTrials.gov: trials led by InnoPharmax"}]},{"url":"https://clinicaltrials.gov/search?lead=Inovio%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","field":"links","label":"ClinicalTrials.gov: trials led by Inovio Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=INSYS%20Therapeutics%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by INSYS Therapeutics Inc"}]},{"url":"https://clinicaltrials.gov/search?lead=Intergroupe%20Francophone%20du%20Myelome","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","route":"/companies/ifm/","field":"links","label":"ClinicalTrials.gov: trials led by Intergroupe Francophone du Myelome"}]},{"url":"https://clinicaltrials.gov/search?lead=Intra-IMMUSG%20Pte%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/","field":"links","label":"ClinicalTrials.gov: trials led by Intra-IMMUSG"}]},{"url":"https://clinicaltrials.gov/search?lead=InxMed","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","field":"links","label":"ClinicalTrials.gov: trials led by InxMed"}]},{"url":"https://clinicaltrials.gov/search?lead=iOnctura","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/","field":"links","label":"ClinicalTrials.gov: trials led by iOnctura"}]},{"url":"https://clinicaltrials.gov/search?lead=Ionis%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","field":"links","label":"ClinicalTrials.gov: trials led by Ionis Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Isarna%20Therapeutics%20GmbH","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Isarna Therapeutics GmbH"}]},{"url":"https://clinicaltrials.gov/search?lead=Italfarmaco","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"italfarmaco","kind":"company","name":"Italfarmaco","route":"/companies/italfarmaco/","field":"links","label":"ClinicalTrials.gov: trials led by Italfarmaco"}]},{"url":"https://clinicaltrials.gov/search?lead=Italian%20Sarcoma%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"italian-sarcoma-group","kind":"company","name":"Italian Sarcoma Group","route":"/companies/italian-sarcoma-group/","field":"links","label":"ClinicalTrials.gov: trials led by Italian Sarcoma Group"}]},{"url":"https://clinicaltrials.gov/search?lead=Jiangsu%20Aosaikang%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","route":"/companies/aosaikang-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Aosaikang Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=JW%20Pharmaceutical%20Corporation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by JW Pharmaceutical Corporation"}]},{"url":"https://clinicaltrials.gov/search?lead=Kartos%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Kartos Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Kissei%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","field":"links","label":"ClinicalTrials.gov: trials led by Kissei Pharmaceutical Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Korean%20Gynecologic%20Oncology%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kgog","kind":"company","name":"Korean Gynecologic Oncology Group","route":"/companies/kgog/","field":"links","label":"ClinicalTrials.gov: trials led by Korean Gynecologic Oncology Group"}]},{"url":"https://clinicaltrials.gov/search?lead=Krystal%20Biotech%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/","field":"links","label":"ClinicalTrials.gov: trials led by Krystal Biotech"}]},{"url":"https://clinicaltrials.gov/search?lead=Laboratorios%20Farmac%C3%A9uticos%20Rovi","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","field":"links","label":"ClinicalTrials.gov: trials led by Laboratorios Farmacéuticos Rovi"}]},{"url":"https://clinicaltrials.gov/search?lead=Laminar%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Laminar Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=LaNova%20Medicines%20Limited","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","field":"links","label":"ClinicalTrials.gov: trials led by LaNova Medicines"}]},{"url":"https://clinicaltrials.gov/search?lead=Lee's%20Pharmaceutical","status":200,"ok":true,"finalUrl":"https://clinicaltrials.gov/search?lead=Lee%27s%20Pharmaceutical","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Lee's Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=LEO%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by LEO Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Lepu%20Biopharma%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Lepu Biopharma"}]},{"url":"https://clinicaltrials.gov/search?lead=LigaChem%20Biosciences%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/","field":"links","label":"ClinicalTrials.gov: trials led by LigaChem Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Lisata%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lisata","kind":"company","name":"Lisata Therapeutics","route":"/companies/lisata/","field":"links","label":"ClinicalTrials.gov: trials led by Lisata Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Luye%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Luye Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Mabion%20SA","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","field":"links","label":"ClinicalTrials.gov: trials led by Mabion SA"}]},{"url":"https://clinicaltrials.gov/search?lead=Mabwell%20(Shanghai)%20Bioscience%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/","field":"links","label":"ClinicalTrials.gov: trials led by Mabwell (Shanghai) Bioscience"}]},{"url":"https://clinicaltrials.gov/search?lead=mAbxience%20Research%20S.L.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","route":"/companies/mabxience-research-s-l/","field":"links","label":"ClinicalTrials.gov: trials led by mAbxience Research S.L."}]},{"url":"https://clinicaltrials.gov/search?lead=Maia%20Biotechnology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/","field":"links","label":"ClinicalTrials.gov: trials led by Maia Biotechnology"}]},{"url":"https://clinicaltrials.gov/search?lead=Mast%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Mast Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=MBrace%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by MBrace Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Medical%20Research%20Council","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/","field":"links","label":"ClinicalTrials.gov: trials led by Medical Research Council"}]},{"url":"https://clinicaltrials.gov/search?lead=MediGene%20AG","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","field":"links","label":"ClinicalTrials.gov: trials led by MediGene AG"}]},{"url":"https://clinicaltrials.gov/search?lead=MEI%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by MEI Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Merrimack%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Merrimack Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Miltenyi%20Biomedicine%20GmbH","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/","field":"links","label":"ClinicalTrials.gov: trials led by Miltenyi Biomedicine"}]},{"url":"https://clinicaltrials.gov/search?lead=Minghui%20Pharmaceutical%20(Hangzhou)%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"minghui-pharmaceutical","kind":"company","name":"Minghui Pharmaceutical","route":"/companies/minghui-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Minghui Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=ModeX%20Therapeutics%2C%20An%20OPKO%20Health%20Company","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by ModeX Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Molecular%20Partners%20AG","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","field":"links","label":"ClinicalTrials.gov: trials led by Molecular Partners"}]},{"url":"https://clinicaltrials.gov/search?lead=Moleculin%20Biotech%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"moleculin","kind":"company","name":"Moleculin Biotech","route":"/companies/moleculin/","field":"links","label":"ClinicalTrials.gov: trials led by Moleculin Biotech, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Monopar%20Therapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"links","label":"ClinicalTrials.gov: trials led by Monopar Therapeutics Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Multitude%20Therapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Multitude Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Mundipharma%20Research%20GmbH%20%26%20Co%20KG","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"links","label":"ClinicalTrials.gov: trials led by Mundipharma Research GmbH & Co KG"}]},{"url":"https://clinicaltrials.gov/search?lead=Mylan","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","field":"links","label":"ClinicalTrials.gov: trials led by Mylan"}]},{"url":"https://clinicaltrials.gov/search?lead=N.N.%20Petrov%20National%20Medical%20Research%20Center%20of%20Oncology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/","field":"links","label":"ClinicalTrials.gov: studies led by the centre"}]},{"url":"https://clinicaltrials.gov/search?lead=Nanjing%20Leads%20Biolabs%20Co.%2CLtd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/","field":"links","label":"ClinicalTrials.gov: trials led by Nanjing Leads Biolabs"}]},{"url":"https://clinicaltrials.gov/search?lead=Natureceuticals%20Sdn%20Bhd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","route":"/companies/natureceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by NatureCeuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Navidea%20Biopharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"links","label":"ClinicalTrials.gov: trials led by Navidea Biopharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=NEC%20Bio%20B.V","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/","field":"links","label":"ClinicalTrials.gov: trials led by NEC Bio"}]},{"url":"https://clinicaltrials.gov/search?lead=Nektar%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Nektar Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Neonc%20Technologies%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/","field":"links","label":"ClinicalTrials.gov: trials led by Neonc Technologies"}]},{"url":"https://clinicaltrials.gov/search?lead=Neovii","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/","field":"links","label":"ClinicalTrials.gov: trials led by Neovii"}]},{"url":"https://clinicaltrials.gov/search?lead=Nerviano%20Medical%20Sciences","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","field":"links","label":"ClinicalTrials.gov: trials led by Nerviano Medical Sciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Nippon%20Kayaku","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","field":"links","label":"ClinicalTrials.gov: trials led by Nippon Kayaku"}]},{"url":"https://clinicaltrials.gov/search?lead=Nobelpharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","field":"links","label":"ClinicalTrials.gov: trials led by Nobelpharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Norgine","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","field":"links","label":"ClinicalTrials.gov: trials led by Norgine"}]},{"url":"https://clinicaltrials.gov/search?lead=Norroy%20Bioscience%20Co.%2C%20LTD","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","route":"/companies/norroy-bioscience/","field":"links","label":"ClinicalTrials.gov: trials led by Norroy Bioscience"}]},{"url":"https://clinicaltrials.gov/search?lead=Nuvation%20Bio%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","field":"links","label":"ClinicalTrials.gov: trials led by Nuvation Bio"}]},{"url":"https://clinicaltrials.gov/search?lead=Oakwood%20Laboratories%2C%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","field":"links","label":"ClinicalTrials.gov: trials led by Oakwood Laboratories, LLC"}]},{"url":"https://clinicaltrials.gov/search?lead=Olema%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Olema Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=OncoC4%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","field":"links","label":"ClinicalTrials.gov: trials led by OncoC4"}]},{"url":"https://clinicaltrials.gov/search?lead=Oncolytics%20Biotech","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","field":"links","label":"ClinicalTrials.gov: trials led by Oncolytics Biotech"}]},{"url":"https://clinicaltrials.gov/search?lead=Oncopeptides","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","field":"links","label":"ClinicalTrials.gov: trials led by Oncopeptides"}]},{"url":"https://clinicaltrials.gov/search?lead=OncoVerity%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/","field":"links","label":"ClinicalTrials.gov: trials led by OncoVerity"}]},{"url":"https://clinicaltrials.gov/search?lead=Ontario%20Clinical%20Oncology%20Group%20(OCOG)","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","route":"/companies/ocog/","field":"links","label":"ClinicalTrials.gov: trials led by Ontario Clinical Oncology Group (OCOG)"}]},{"url":"https://clinicaltrials.gov/search?lead=Orca%20Biosystems%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"links","label":"ClinicalTrials.gov: trials led by Orca Biosystems"}]},{"url":"https://clinicaltrials.gov/search?lead=Organon%20and%20Co","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","field":"links","label":"ClinicalTrials.gov: trials led by Organon and Co"}]},{"url":"https://clinicaltrials.gov/search?lead=Orion%20Corporation%2C%20Orion%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Orion, Orion Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Partner%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Partner Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Peregrine%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","field":"links","label":"ClinicalTrials.gov: trials led by Peregrine Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=pharmaand","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/","field":"links","label":"ClinicalTrials.gov: trials led by pharmaand"}]},{"url":"https://clinicaltrials.gov/search?lead=Pharmacosmos%20A%2FS","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","field":"links","label":"ClinicalTrials.gov: trials led by Pharmacosmos A/S"}]},{"url":"https://clinicaltrials.gov/search?lead=PharmaEssentia","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","field":"links","label":"ClinicalTrials.gov: trials led by PharmaEssentia"}]},{"url":"https://clinicaltrials.gov/search?lead=Philogen%20S.p.A.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/","field":"links","label":"ClinicalTrials.gov: trials led by Philogen S.p.A."}]},{"url":"https://clinicaltrials.gov/search?lead=Photocure","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","field":"links","label":"ClinicalTrials.gov: trials led by Photocure"}]},{"url":"https://clinicaltrials.gov/search?lead=photonamic%20GmbH%20%26%20Co.%20KG","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","field":"links","label":"ClinicalTrials.gov: trials led by photonamic GmbH & Co. KG"}]},{"url":"https://clinicaltrials.gov/search?lead=Polaris%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/","field":"links","label":"ClinicalTrials.gov: trials led by Polaris Group"}]},{"url":"https://clinicaltrials.gov/search?lead=Precigen%2C%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/","field":"links","label":"ClinicalTrials.gov: trials led by Precigen"}]},{"url":"https://clinicaltrials.gov/search?lead=PregLem%20SA","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","field":"links","label":"ClinicalTrials.gov: trials led by PregLem SA"}]},{"url":"https://clinicaltrials.gov/search?lead=Protagonist%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Protagonist Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Protara%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Protara Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=PTC%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by PTC Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=QBiotics%20Group%20Limited","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/","field":"links","label":"ClinicalTrials.gov: trials led by QBiotics"}]},{"url":"https://clinicaltrials.gov/search?lead=Qilu%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Qilu Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Qurient%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/","field":"links","label":"ClinicalTrials.gov: trials led by Qurient Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=R-Pharm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","field":"links","label":"ClinicalTrials.gov: trials led by R-Pharm"}]},{"url":"https://clinicaltrials.gov/search?lead=Radiopharm%20Theranostics%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"links","label":"ClinicalTrials.gov: trials led by Radiopharm Theranostics"}]},{"url":"https://clinicaltrials.gov/search?lead=Rakuten%20Medical%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","route":"/companies/rakuten-medical/","field":"links","label":"ClinicalTrials.gov: trials led by Rakuten Medical"}]},{"url":"https://clinicaltrials.gov/search?lead=Ranok%20Therapeutics%20(Hangzhou)%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/","field":"links","label":"ClinicalTrials.gov: trials led by Ranok Therapeutics (Hangzhou)"}]},{"url":"https://clinicaltrials.gov/search?lead=Ryvu%20Therapeutics%20SA","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Ryvu Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Salubris%20Biotherapeutics%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Salubris Biotherapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Sarcoma%20Alliance%20for%20Research%20through%20Collaboration","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sarc","kind":"company","name":"SARC (Sarcoma Alliance for Research through Collaboration)","route":"/companies/sarc/","field":"links","label":"ClinicalTrials.gov: trials led by Sarcoma Alliance for Research through Collaboration"}]},{"url":"https://clinicaltrials.gov/search?lead=SBI%20ALApharma%20Canada%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by SBI ALApharma Canada, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Scancell%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/","field":"links","label":"ClinicalTrials.gov: trials led by Scancell"}]},{"url":"https://clinicaltrials.gov/search?lead=Scandinavian%20Sarcoma%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scandinavian-sarcoma-group","kind":"company","name":"Scandinavian Sarcoma Group","route":"/companies/scandinavian-sarcoma-group/","field":"links","label":"ClinicalTrials.gov: trials led by Scandinavian Sarcoma Group"}]},{"url":"https://clinicaltrials.gov/search?lead=SecuraBio","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"securabio","kind":"company","name":"SecuraBio","route":"/companies/securabio/","field":"links","label":"ClinicalTrials.gov: trials led by SecuraBio"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20AbelZeta%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai AbelZeta"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Bovax%20Biotechnology%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai Bovax Biotechnology"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Fosun%20Pharmaceutical%20Industrial%20Development%20Co.%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai Fosun Pharmaceutical Industrial Development"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Jiatan%20Pharmatech%20Co.%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-jiatan-pharmatech","kind":"company","name":"Shanghai Jiatan Pharmatech","route":"/companies/shanghai-jiatan-pharmatech/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai Jiatan Pharmatech"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Juncell%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai Juncell Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Kechow%20Pharma%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Shanghai Kechow Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Shanghai%20Unicar-Therapy%20Bio-medicine%20Technology%20Co.%2CLtd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/","field":"links","label":"ClinicalTrials.gov: trials led by Unicar-Therapy"}]},{"url":"https://clinicaltrials.gov/search?lead=Shenzhen%20Ionova%20Life%20Sciences%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/","field":"links","label":"ClinicalTrials.gov: trials led by Shenzhen Ionova Life Sciences"}]},{"url":"https://clinicaltrials.gov/search?lead=Shenzhen%20TargetRx%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/","field":"links","label":"ClinicalTrials.gov: trials led by Shenzhen TargetRx"}]},{"url":"https://clinicaltrials.gov/search?lead=Sichuan%20Huiyu%20Pharmaceutical%20Co.%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Sichuan Huiyu Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Simcere","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/","field":"links","label":"ClinicalTrials.gov: trials led by Jiangsu Simcere Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Sinocelltech%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/","field":"links","label":"ClinicalTrials.gov: trials led by Sinocelltech"}]},{"url":"https://clinicaltrials.gov/search?lead=Sinotau%20Pharmaceutical%20Group","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Sinotau Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Soligenix","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","field":"links","label":"ClinicalTrials.gov: trials led by Soligenix"}]},{"url":"https://clinicaltrials.gov/search?lead=Sorrento%20Therapeutics%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Sorrento Therapeutics, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=SOTIO","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/","field":"links","label":"ClinicalTrials.gov: trials led by SOTIO"}]},{"url":"https://clinicaltrials.gov/search?lead=SpectraCure%20AB","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/","field":"links","label":"ClinicalTrials.gov: trials led by SpectraCure"}]},{"url":"https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Spectrum Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=STCube%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stcube","kind":"company","name":"STCube","route":"/companies/stcube/","field":"links","label":"ClinicalTrials.gov: trials led by STCube"}]},{"url":"https://clinicaltrials.gov/search?lead=Stichting%20European%20Myeloma%20Network","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","route":"/companies/european-myeloma-network/","field":"links","label":"ClinicalTrials.gov: trials led by Stichting European Myeloma Network"}]},{"url":"https://clinicaltrials.gov/search?lead=Sunesis%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","field":"links","label":"ClinicalTrials.gov: trials led by Sunesis Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=SUNHO%EF%BC%88China%EF%BC%89BioPharmaceutical%20CO.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","route":"/companies/sunho-biopharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by SunHo Biopharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Sunshine%20Lake%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by Sunshine Lake Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Suzhou%20BlueHorse%20Therapeutics%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"suzhou-bluehorse-therapeutics","kind":"company","name":"Suzhou BlueHorse Therapeutics","route":"/companies/suzhou-bluehorse-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Suzhou BlueHorse Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Suzhou%20Forlong%20Biotechnology%20Co.%2C%20Ltd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/","field":"links","label":"ClinicalTrials.gov: trials led by Suzhou Forlong Biotechnology"}]},{"url":"https://clinicaltrials.gov/search?lead=SymBio%20Pharmaceuticals%20Limited","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by SymBio Pharmaceuticals Limited"}]},{"url":"https://clinicaltrials.gov/search?lead=TaiRx%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/","field":"links","label":"ClinicalTrials.gov: trials led by TaiRx"}]},{"url":"https://clinicaltrials.gov/search?lead=Takara%20Bio%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","field":"links","label":"ClinicalTrials.gov: trials led by Takara Bio Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Teclison%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/","field":"links","label":"ClinicalTrials.gov: trials led by Teclison"}]},{"url":"https://clinicaltrials.gov/search?lead=Telik%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","field":"links","label":"ClinicalTrials.gov: trials led by Telik, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=TG%20Therapeutics","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by TG Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Threshold%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Threshold Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=TiumBio%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/","field":"links","label":"ClinicalTrials.gov: trials led by TiumBio"}]},{"url":"https://clinicaltrials.gov/search?lead=Tolmar","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/","field":"links","label":"ClinicalTrials.gov: trials led by Tolmar"}]},{"url":"https://clinicaltrials.gov/search?lead=Tomsk%20National%20Research%20Medical%20Center%20of%20the%20Russian%20Academy%20of%20Sciences","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","route":"/institutions/tomsk-cancer-research-institute/","field":"links","label":"ClinicalTrials.gov: studies led by the centre"}]},{"url":"https://clinicaltrials.gov/search?lead=TORL%20Biotherapeutics%2C%20LLC","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by TORL BioTherapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Tracon%20Pharmaceuticals%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","field":"links","label":"ClinicalTrials.gov: trials led by Tracon Pharmaceuticals Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Treadwell%20Therapeutics%2C%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Treadwell Therapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=TYK%20Medicines%2C%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","route":"/companies/tyk-medicines/","field":"links","label":"ClinicalTrials.gov: trials led by TYK Medicines"}]},{"url":"https://clinicaltrials.gov/search?lead=UCB","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","field":"links","label":"ClinicalTrials.gov: trials led by UCB"}]},{"url":"https://clinicaltrials.gov/search?lead=United%20Therapeutics%20Corporation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by United Therapeutics Corporation"}]},{"url":"https://clinicaltrials.gov/search?lead=UroGen%20Pharma%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","field":"links","label":"ClinicalTrials.gov: trials led by UroGen Pharma"}]},{"url":"https://clinicaltrials.gov/search?lead=Vasgene%20Therapeutics%2C%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Vasgene Therapeutics, Inc"}]},{"url":"https://clinicaltrials.gov/search?lead=VelaVigo%20Bio%20Inc","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/","field":"links","label":"ClinicalTrials.gov: trials led by VelaVigo"}]},{"url":"https://clinicaltrials.gov/search?lead=Veru","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","field":"links","label":"ClinicalTrials.gov: trials led by Veru"}]},{"url":"https://clinicaltrials.gov/search?lead=Vion%20Pharmaceuticals%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Vion Pharmaceuticals, Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Vironexis%20Biotherapeutics%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/","field":"links","label":"ClinicalTrials.gov: trials led by Vironexis Biotherapeutics"}]},{"url":"https://clinicaltrials.gov/search?lead=Vor%20Biopharma%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Vor Biopharma Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Vyriad%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/","field":"links","label":"ClinicalTrials.gov: trials led by Vyriad"}]},{"url":"https://clinicaltrials.gov/search?lead=Wayshine%20Biopharm%2C%20Inc.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/","field":"links","label":"ClinicalTrials.gov: trials led by Wayshine Biopharm"}]},{"url":"https://clinicaltrials.gov/search?lead=Wigen%20Biomedicine%20Technology%20(Shanghai)%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","route":"/companies/wigen-biomedicine-technology-shanghai/","field":"links","label":"ClinicalTrials.gov: trials led by Wigen Biomedicine Technology (Shanghai)"}]},{"url":"https://clinicaltrials.gov/search?lead=Wuhan%20YZY%20Biopharma%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","field":"links","label":"ClinicalTrials.gov: trials led by Wuhan YZY Biopharma Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Xuanzhu%20Biopharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Xuanzhu Biopharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Yuhan%20Corporation","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/","field":"links","label":"ClinicalTrials.gov: trials led by Yuhan Corporation"}]},{"url":"https://clinicaltrials.gov/search?lead=Zeria%20Pharmaceutical%20Co.%2C%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","field":"links","label":"ClinicalTrials.gov: trials led by Zeria Pharmaceutical Co., Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Zhejiang%20Hisun%20Pharmaceutical%20Co.%20Ltd.","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","field":"links","label":"ClinicalTrials.gov: trials led by Zhejiang Hisun Pharmaceutical Co. Ltd."}]},{"url":"https://clinicaltrials.gov/search?lead=Ziopharm%20Oncology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","field":"links","label":"ClinicalTrials.gov: trials led by Ziopharm Oncology"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Gene%20Key%20Life%20Technology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Gene Key Life Technology"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Konruns%20Pharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Konruns Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Mabworks%20Biotech","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Mabworks Biotech"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Pearl%20Biotechnology%20Limited%20Liability%20Company","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Pearl Biotechnology Limited Liability Company"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Scitech-Mq%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Scitech-Mq Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?spons=Beijing%20Tide%20Pharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Beijing Tide Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?spons=Binhui%20Biopharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Binhui Biopharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?spons=Chengdu%20Zenitar%20Biomedical%20Technology","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Chengdu Zenitar Biomedical Technology"}]},{"url":"https://clinicaltrials.gov/search?spons=Henan%20Genuine%20Biotech","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Henan Genuine Biotech"}]},{"url":"https://clinicaltrials.gov/search?spons=ImmVira%20Pharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/","field":"links","label":"ClinicalTrials.gov: trials sponsored by ImmVira Pharma"}]},{"url":"https://clinicaltrials.gov/search?spons=Jacobio%20Pharmaceuticals","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Jacobio Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?spons=Nanjing%20Immunophage%20Biotech","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Nanjing Immunophage Biotech"}]},{"url":"https://clinicaltrials.gov/search?spons=Shandong%20New%20Time%20Pharmaceutical","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Shandong New Time Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?spons=TJ%20Biopharma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","field":"links","label":"ClinicalTrials.gov: trials sponsored by TJ Biopharma"}]},{"url":"https://clinicaltrials.gov/search?spons=Zhuhai%20Yufan%20Biotechnologies","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/","field":"links","label":"ClinicalTrials.gov: trials sponsored by Zhuhai Yufan Biotechnologies"}]},{"url":"https://clinicaltrials.gov/search?term=actinium-225","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","field":"links","label":"ClinicalTrials.gov: actinium-225"}]},{"url":"https://clinicaltrials.gov/search?term=AI-designed%20antibody%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/","field":"links","label":"ClinicalTrials.gov: AI-designed antibody cancer"}]},{"url":"https://clinicaltrials.gov/search?term=antibody%20oligonucleotide%20conjugate","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","field":"links","label":"ClinicalTrials.gov: antibody oligonucleotide conjugate"}]},{"url":"https://clinicaltrials.gov/search?term=bacteriophage%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","field":"links","label":"ClinicalTrials.gov: bacteriophage cancer"}]},{"url":"https://clinicaltrials.gov/search?term=base%20editing","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","field":"links","label":"ClinicalTrials.gov: base editing studies"}]},{"url":"https://clinicaltrials.gov/search?term=DNA%20nanostructure%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","field":"links","label":"ClinicalTrials.gov: DNA nanostructure cancer"}]},{"url":"https://clinicaltrials.gov/search?term=epigenetic%20editing","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","field":"links","label":"ClinicalTrials.gov: epigenetic editing"}]},{"url":"https://clinicaltrials.gov/search?term=FAP%20CAR-T","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","field":"links","label":"ClinicalTrials.gov: FAP CAR-T"}]},{"url":"https://clinicaltrials.gov/search?term=Fusobacterium%20colorectal%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","field":"links","label":"ClinicalTrials.gov: Fusobacterium colorectal cancer"}]},{"url":"https://clinicaltrials.gov/search?term=histotripsy","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/","field":"links","label":"ClinicalTrials.gov: histotripsy"}]},{"url":"https://clinicaltrials.gov/search?term=hypoxia-activated%20prodrug","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hypoxia-activated-therapy","kind":"technology","name":"Hypoxia-activated prodrugs","route":"/technologies/hypoxia-activated-therapy/","field":"links","label":"ClinicalTrials.gov: hypoxia-activated prodrug"}]},{"url":"https://clinicaltrials.gov/search?term=in%20situ%20vaccination%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/","field":"links","label":"ClinicalTrials.gov: in situ vaccination cancer"}]},{"url":"https://clinicaltrials.gov/search?term=logic%20gated%20CAR%20T","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/","field":"links","label":"ClinicalTrials.gov: logic-gated CAR T"}]},{"url":"https://clinicaltrials.gov/search?term=losartan%20pancreatic%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/","field":"links","label":"ClinicalTrials.gov: losartan pancreatic cancer"}]},{"url":"https://clinicaltrials.gov/search?term=lutetium%20PSMA%20olaparib","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","field":"links","label":"ClinicalTrials.gov: Lu-177 PSMA plus olaparib"}]},{"url":"https://clinicaltrials.gov/search?term=Lynch%20syndrome%20vaccine","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","field":"links","label":"ClinicalTrials.gov: Lynch syndrome vaccine"}]},{"url":"https://clinicaltrials.gov/search?term=molecular%20glue%20degrader","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/","field":"links","label":"ClinicalTrials.gov: molecular glue degrader"}]},{"url":"https://clinicaltrials.gov/search?term=molecular%20ultrasound%20imaging%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quantum-dot-imaging","kind":"technology","name":"Quantum-dot and molecular ultrasound imaging agents","route":"/technologies/quantum-dot-imaging/","field":"links","label":"ClinicalTrials.gov: molecular ultrasound imaging cancer"}]},{"url":"https://clinicaltrials.gov/search?term=NBTXR3","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/","field":"links","label":"ClinicalTrials.gov: NBTXR3"}]},{"url":"https://clinicaltrials.gov/search?term=organoid%20guided%20therapy","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/","field":"links","label":"ClinicalTrials.gov: organoid-guided therapy"}]},{"url":"https://clinicaltrials.gov/search?term=proton%20arc%20therapy","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proton-arc-therapy","kind":"technology","name":"Proton arc therapy","route":"/technologies/proton-arc-therapy/","field":"links","label":"ClinicalTrials.gov: proton arc therapy"}]},{"url":"https://clinicaltrials.gov/search?term=self-amplifying%20RNA%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/","field":"links","label":"ClinicalTrials.gov: self-amplifying RNA cancer"}]},{"url":"https://clinicaltrials.gov/search?term=senolytic","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","field":"links","label":"ClinicalTrials.gov: senolytic"}]},{"url":"https://clinicaltrials.gov/search?term=serial%20ctDNA%20monitoring","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","field":"links","label":"ClinicalTrials.gov: serial ctDNA monitoring"}]},{"url":"https://clinicaltrials.gov/search?term=spatial%20transcriptomics%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/","field":"links","label":"ClinicalTrials.gov: spatial transcriptomics cancer"}]},{"url":"https://clinicaltrials.gov/search?term=terbium-161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","field":"links","label":"ClinicalTrials.gov: terbium-161"}]},{"url":"https://clinicaltrials.gov/search?term=time%20of%20day%20immunotherapy%20infusion","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/","field":"links","label":"ClinicalTrials.gov: time-of-day immunotherapy infusion"}]},{"url":"https://clinicaltrials.gov/search?term=total-body%20PET","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","field":"links","label":"ClinicalTrials.gov: total-body PET"}]},{"url":"https://clinicaltrials.gov/search?term=trained%20immunity%20cancer","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/","field":"links","label":"ClinicalTrials.gov: trained immunity cancer"}]},{"url":"https://clinicaltrials.gov/study/ACTRN12615000381583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","field":"links","label":"ClinicalTrials.gov ACTRN12615000381583: DYNAMIC"},{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/","field":"links","label":"ClinicalTrials.gov ACTRN12615000381583"}]},{"url":"https://clinicaltrials.gov/study/ISRCTN35739639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-predimed-breast-jama-im-2015","kind":"paper","name":"PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers","route":"/key-papers/paper-predimed-breast-jama-im-2015/","field":"links","label":"ClinicalTrials.gov ISRCTN35739639"}]},{"url":"https://clinicaltrials.gov/study/ISRCTN94604465","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-goteborg-2-n-engl-j-med-2022","kind":"paper","name":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","route":"/key-papers/paper-goteborg-2-n-engl-j-med-2022/","field":"links","label":"ClinicalTrials.gov ISRCTN94604465"}]},{"url":"https://clinicaltrials.gov/study/NCT00002511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22911","kind":"trial","name":"EORTC 22911","route":"/trials/eortc-22911/","field":"links","label":"ClinicalTrials.gov NCT00002511"}]},{"url":"https://clinicaltrials.gov/study/NCT00002516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"int-0091","kind":"trial","name":"INT-0091 (Ewing sarcoma)","route":"/trials/int-0091/","field":"links","label":"ClinicalTrials.gov NCT00002516"}]},{"url":"https://clinicaltrials.gov/study/NCT00002540","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011","kind":"paper","name":"Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial","route":"/key-papers/paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011/","field":"links","label":"ClinicalTrials.gov NCT00002540"},{"id":"paper-andriole-plco-prostate-screening-nejm-2009","kind":"paper","name":"PLCO: mortality results from a randomised prostate cancer screening trial","route":"/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/","field":"links","label":"ClinicalTrials.gov NCT00002540"},{"id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","field":"links","label":"ClinicalTrials.gov NCT00002540"}]},{"url":"https://clinicaltrials.gov/study/NCT00002569","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","field":"links","label":"ClinicalTrials.gov NCT00002569"}]},{"url":"https://clinicaltrials.gov/study/NCT00002597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"links","label":"ClinicalTrials.gov NCT00002597"}]},{"url":"https://clinicaltrials.gov/study/NCT00002622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002622","kind":"trial","name":"Talc in Treating Patients With Malignant Pleural Effusion","route":"/trials/nct00002622/","field":"links","label":"ClinicalTrials.gov NCT00002622"}]},{"url":"https://clinicaltrials.gov/study/NCT00002633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/","field":"links","label":"ClinicalTrials.gov NCT00002633"}]},{"url":"https://clinicaltrials.gov/study/NCT00002651","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013","kind":"paper","name":"SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer","route":"/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/","field":"links","label":"ClinicalTrials.gov NCT00002651"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","field":"links","label":"ClinicalTrials.gov NCT00002651"}]},{"url":"https://clinicaltrials.gov/study/NCT00002658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002658","kind":"trial","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","route":"/trials/nct00002658/","field":"links","label":"ClinicalTrials.gov NCT00002658"}]},{"url":"https://clinicaltrials.gov/study/NCT00002719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002719","kind":"trial","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","route":"/trials/nct00002719/","field":"links","label":"ClinicalTrials.gov NCT00002719"}]},{"url":"https://clinicaltrials.gov/study/NCT00002851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-n-engl-j-med-2015","kind":"paper","name":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer","route":"/key-papers/paper-eortc-22922-n-engl-j-med-2015/","field":"links","label":"ClinicalTrials.gov NCT00002851"},{"id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","field":"links","label":"ClinicalTrials.gov NCT00002851"},{"id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","field":"links","label":"ClinicalTrials.gov NCT00002851"}]},{"url":"https://clinicaltrials.gov/study/NCT00002872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002872","kind":"trial","name":"Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions","route":"/trials/nct00002872/","field":"links","label":"ClinicalTrials.gov NCT00002872"}]},{"url":"https://clinicaltrials.gov/study/NCT00002874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-rtog-9601-n-engl-j-med-2017","kind":"paper","name":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","route":"/key-papers/paper-rtog-9601-n-engl-j-med-2017/","field":"links","label":"ClinicalTrials.gov NCT00002874"},{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","field":"links","label":"ClinicalTrials.gov NCT00002874"}]},{"url":"https://clinicaltrials.gov/study/NCT00002881","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002881","kind":"trial","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","route":"/trials/nct00002881/","field":"links","label":"ClinicalTrials.gov NCT00002881"}]},{"url":"https://clinicaltrials.gov/study/NCT00002893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00002893","kind":"trial","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","route":"/trials/nct00002893/","field":"links","label":"ClinicalTrials.gov NCT00002893"}]},{"url":"https://clinicaltrials.gov/study/NCT00003026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22961","kind":"trial","name":"EORTC 22961","route":"/trials/eortc-22961/","field":"links","label":"ClinicalTrials.gov NCT00003026"}]},{"url":"https://clinicaltrials.gov/study/NCT00003139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003139","kind":"trial","name":"Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer","route":"/trials/nct00003139/","field":"links","label":"ClinicalTrials.gov NCT00003139"}]},{"url":"https://clinicaltrials.gov/study/NCT00003436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003436","kind":"trial","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","route":"/trials/nct00003436/","field":"links","label":"ClinicalTrials.gov NCT00003436"}]},{"url":"https://clinicaltrials.gov/study/NCT00003456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003456","kind":"trial","name":"Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme","route":"/trials/nct00003456/","field":"links","label":"ClinicalTrials.gov NCT00003456"}]},{"url":"https://clinicaltrials.gov/study/NCT00003475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003475","kind":"trial","name":"Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors","route":"/trials/nct00003475/","field":"links","label":"ClinicalTrials.gov NCT00003475"}]},{"url":"https://clinicaltrials.gov/study/NCT00003653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003653","kind":"trial","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","route":"/trials/nct00003653/","field":"links","label":"ClinicalTrials.gov NCT00003653"}]},{"url":"https://clinicaltrials.gov/study/NCT00003787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-whel-jama-2007","kind":"paper","name":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial","route":"/key-papers/paper-whel-jama-2007/","field":"links","label":"ClinicalTrials.gov NCT00003787"},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","field":"links","label":"ClinicalTrials.gov NCT00003787"}]},{"url":"https://clinicaltrials.gov/study/NCT00003788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00003788","kind":"trial","name":"Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas","route":"/trials/nct00003788/","field":"links","label":"ClinicalTrials.gov NCT00003788"}]},{"url":"https://clinicaltrials.gov/study/NCT00003830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","field":"links","label":"ClinicalTrials.gov NCT00003830"}]},{"url":"https://clinicaltrials.gov/study/NCT00003855","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"links","label":"ClinicalTrials.gov NCT00003855"}]},{"url":"https://clinicaltrials.gov/study/NCT00003912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","field":"links","label":"ClinicalTrials.gov NCT00003912"}]},{"url":"https://clinicaltrials.gov/study/NCT00003991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"study-0201","kind":"trial","name":"Study 0201","route":"/trials/study-0201/","field":"links","label":"ClinicalTrials.gov NCT00003991"},{"id":"paper-study-0201-blood-2006","kind":"paper","name":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","route":"/key-papers/paper-study-0201-blood-2006/","field":"links","label":"ClinicalTrials.gov NCT00003991"}]},{"url":"https://clinicaltrials.gov/study/NCT00004001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","field":"links","label":"ClinicalTrials.gov NCT00004001"}]},{"url":"https://clinicaltrials.gov/study/NCT00004054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00004054","kind":"trial","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","route":"/trials/nct00004054/","field":"links","label":"ClinicalTrials.gov NCT00004054"}]},{"url":"https://clinicaltrials.gov/study/NCT00004054?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00004054","kind":"trial","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","route":"/trials/nct00004054/","field":"outcomes.source (Overall Survival (5-year Rate Reported))"}]},{"url":"https://clinicaltrials.gov/study/NCT00004157","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00004157","kind":"trial","name":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","route":"/trials/nct00004157/","field":"links","label":"ClinicalTrials.gov NCT00004157"}]},{"url":"https://clinicaltrials.gov/study/NCT00004227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","field":"links","label":"ClinicalTrials.gov NCT00004227"}]},{"url":"https://clinicaltrials.gov/study/NCT00004688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00004688","kind":"trial","name":"Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms","route":"/trials/nct00004688/","field":"links","label":"ClinicalTrials.gov NCT00004688"}]},{"url":"https://clinicaltrials.gov/study/NCT00005838","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00005838","kind":"trial","name":"Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","route":"/trials/nct00005838/","field":"links","label":"ClinicalTrials.gov NCT00005838"}]},{"url":"https://clinicaltrials.gov/study/NCT00005957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-ma-20-n-engl-j-med-2015","kind":"paper","name":"Regional Nodal Irradiation in Early-Stage Breast Cancer","route":"/key-papers/paper-ma-20-n-engl-j-med-2015/","field":"links","label":"ClinicalTrials.gov NCT00005957"},{"id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","field":"links","label":"ClinicalTrials.gov NCT00005957"}]},{"url":"https://clinicaltrials.gov/study/NCT00006343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","field":"links","label":"ClinicalTrials.gov NCT00006343"}]},{"url":"https://clinicaltrials.gov/study/NCT00006353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","field":"links","label":"ClinicalTrials.gov NCT00006353"}]},{"url":"https://clinicaltrials.gov/study/NCT00006371","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00006371","kind":"trial","name":"A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer","route":"/trials/nct00006371/","field":"links","label":"ClinicalTrials.gov NCT00006371"}]},{"url":"https://clinicaltrials.gov/study/NCT00006479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-40983","kind":"trial","name":"EORTC 40983","route":"/trials/eortc-40983/","field":"links","label":"ClinicalTrials.gov NCT00006479"}]},{"url":"https://clinicaltrials.gov/study/NCT00006734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aews0031","kind":"trial","name":"AEWS0031","route":"/trials/aews0031/","field":"links","label":"ClinicalTrials.gov NCT00006734"}]},{"url":"https://clinicaltrials.gov/study/NCT00007644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","kind":"paper","name":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","route":"/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT00007644"},{"id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","field":"links","label":"ClinicalTrials.gov NCT00007644"}]},{"url":"https://clinicaltrials.gov/study/NCT00014612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"links","label":"ClinicalTrials.gov NCT00014612"}]},{"url":"https://clinicaltrials.gov/study/NCT00016276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00016276","kind":"trial","name":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","route":"/trials/nct00016276/","field":"links","label":"ClinicalTrials.gov NCT00016276"}]},{"url":"https://clinicaltrials.gov/study/NCT00021060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","kind":"paper","name":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","route":"/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/","field":"links","label":"ClinicalTrials.gov NCT00021060"}]},{"url":"https://clinicaltrials.gov/study/NCT00021450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22991","kind":"trial","name":"EORTC 22991","route":"/trials/eortc-22991/","field":"links","label":"ClinicalTrials.gov NCT00021450"}]},{"url":"https://clinicaltrials.gov/study/NCT00022282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00022282","kind":"trial","name":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct00022282/","field":"links","label":"ClinicalTrials.gov NCT00022282"}]},{"url":"https://clinicaltrials.gov/study/NCT00024167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00024167","kind":"trial","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","route":"/trials/nct00024167/","field":"links","label":"ClinicalTrials.gov NCT00024167"}]},{"url":"https://clinicaltrials.gov/study/NCT00024167?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00024167","kind":"trial","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","route":"/trials/nct00024167/","field":"outcomes.source (Overall Survival From Randomization)"}]},{"url":"https://clinicaltrials.gov/study/NCT00026117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00026117","kind":"trial","name":"Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer","route":"/trials/nct00026117/","field":"links","label":"ClinicalTrials.gov NCT00026117"}]},{"url":"https://clinicaltrials.gov/study/NCT00026273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"petacc-3","kind":"trial","name":"PETACC-3","route":"/trials/petacc-3/","field":"links","label":"ClinicalTrials.gov NCT00026273"}]},{"url":"https://clinicaltrials.gov/study/NCT00026312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","field":"links","label":"ClinicalTrials.gov NCT00026312"}]},{"url":"https://clinicaltrials.gov/study/NCT00027846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/","field":"links","label":"ClinicalTrials.gov NCT00027846"}]},{"url":"https://clinicaltrials.gov/study/NCT00033332","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00033332","kind":"trial","name":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","route":"/trials/nct00033332/","field":"links","label":"ClinicalTrials.gov NCT00033332"}]},{"url":"https://clinicaltrials.gov/study/NCT00043004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clocc","kind":"trial","name":"CLOCC","route":"/trials/clocc/","field":"links","label":"ClinicalTrials.gov NCT00043004"}]},{"url":"https://clinicaltrials.gov/study/NCT00045032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","field":"links","label":"ClinicalTrials.gov NCT00045032"},{"id":"paper-hera-b31-n9831-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","route":"/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/","field":"links","label":"ClinicalTrials.gov NCT00045032"},{"id":"paper-hera-b31-n9831-lancet-2017-update","kind":"paper","name":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","route":"/key-papers/paper-hera-b31-n9831-lancet-2017-update/","field":"links","label":"ClinicalTrials.gov NCT00045032"}]},{"url":"https://clinicaltrials.gov/study/NCT00045968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/","field":"links","label":"ClinicalTrials.gov NCT00045968"},{"id":"nct00045968","kind":"trial","name":"Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer","route":"/trials/nct00045968/","field":"links","label":"ClinicalTrials.gov NCT00045968"}],"archive":"https://web.archive.org/web/20260517031036/https://clinicaltrials.gov/study/NCT00045968"},{"url":"https://clinicaltrials.gov/study/NCT00047008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","field":"links","label":"ClinicalTrials.gov NCT00047008"}]},{"url":"https://clinicaltrials.gov/study/NCT00047320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0122","kind":"trial","name":"ACNS0122","route":"/trials/acns0122/","field":"links","label":"ClinicalTrials.gov NCT00047320"}]},{"url":"https://clinicaltrials.gov/study/NCT00047320?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0122","kind":"trial","name":"ACNS0122","route":"/trials/acns0122/","field":"outcomes.source (Response to induction chemotherapy (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT00047385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","field":"links","label":"ClinicalTrials.gov NCT00047385"},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/","field":"links","label":"ClinicalTrials.gov NCT00047385"}],"archive":"https://web.archive.org/web/20251016164856/https://clinicaltrials.gov/study/NCT00047385"},{"url":"https://clinicaltrials.gov/study/NCT00055731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00055731","kind":"trial","name":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","route":"/trials/nct00055731/","field":"links","label":"ClinicalTrials.gov NCT00055731"}]},{"url":"https://clinicaltrials.gov/study/NCT00057811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/","field":"links","label":"ClinicalTrials.gov NCT00057811"}]},{"url":"https://clinicaltrials.gov/study/NCT00057811?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/","field":"outcomes.source (Minimal Residual Disease)"}]},{"url":"https://clinicaltrials.gov/study/NCT00058032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","field":"links","label":"ClinicalTrials.gov NCT00058032"}]},{"url":"https://clinicaltrials.gov/study/NCT00058201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/","field":"links","label":"ClinicalTrials.gov NCT00058201"}]},{"url":"https://clinicaltrials.gov/study/NCT00061984","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","field":"links","label":"ClinicalTrials.gov NCT00061984"}]},{"url":"https://clinicaltrials.gov/study/NCT00065442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","field":"links","label":"ClinicalTrials.gov NCT00065442"}]},{"url":"https://clinicaltrials.gov/study/NCT00066690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","field":"links","label":"ClinicalTrials.gov NCT00066690"},{"id":"paper-soft-text-n-engl-j-med-2015","kind":"paper","name":"Adjuvant ovarian suppression in premenopausal breast cancer","route":"/key-papers/paper-soft-text-n-engl-j-med-2015/","field":"links","label":"ClinicalTrials.gov NCT00066690"},{"id":"paper-soft-text-j-clin-oncol-2023-update","kind":"paper","name":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","route":"/key-papers/paper-soft-text-j-clin-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT00066690"}]},{"url":"https://clinicaltrials.gov/study/NCT00066703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","route":"/trials/nct00066703/","field":"links","label":"ClinicalTrials.gov NCT00066703"}]},{"url":"https://clinicaltrials.gov/study/NCT00066703?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","route":"/trials/nct00066703/","field":"outcomes.source (Disease-free Survival)"},{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","route":"/trials/nct00066703/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00066872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"links","label":"ClinicalTrials.gov NCT00066872"}]},{"url":"https://clinicaltrials.gov/study/NCT00071799","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/","field":"links","label":"ClinicalTrials.gov NCT00071799"}]},{"url":"https://clinicaltrials.gov/study/NCT00072293","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibcsg-23-01","kind":"trial","name":"IBCSG 23-01","route":"/trials/ibcsg-23-01/","field":"links","label":"ClinicalTrials.gov NCT00072293"}]},{"url":"https://clinicaltrials.gov/study/NCT00075725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall0232","kind":"trial","name":"AALL0232","route":"/trials/aall0232/","field":"links","label":"ClinicalTrials.gov NCT00075725"}]},{"url":"https://clinicaltrials.gov/study/NCT00075725?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall0232","kind":"trial","name":"AALL0232","route":"/trials/aall0232/","field":"outcomes.source (Event-free survival at 5 years, patients aged 10 and over (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT00077311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00077311","kind":"trial","name":"Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct00077311/","field":"links","label":"ClinicalTrials.gov NCT00077311"}]},{"url":"https://clinicaltrials.gov/study/NCT00077389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"links","label":"ClinicalTrials.gov NCT00077389"}]},{"url":"https://clinicaltrials.gov/study/NCT00079066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"co-17","kind":"trial","name":"NCIC CO.17","route":"/trials/co-17/","field":"links","label":"ClinicalTrials.gov NCT00079066"}]},{"url":"https://clinicaltrials.gov/study/NCT00079274","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"n0147","kind":"trial","name":"Alliance N0147","route":"/trials/n0147/","field":"links","label":"ClinicalTrials.gov NCT00079274"}]},{"url":"https://clinicaltrials.gov/study/NCT00082927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00082927","kind":"trial","name":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","route":"/trials/nct00082927/","field":"links","label":"ClinicalTrials.gov NCT00082927"}]},{"url":"https://clinicaltrials.gov/study/NCT00083382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00083382","kind":"trial","name":"Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide","route":"/trials/nct00083382/","field":"links","label":"ClinicalTrials.gov NCT00083382"}]},{"url":"https://clinicaltrials.gov/study/NCT00085735","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","field":"links","label":"ClinicalTrials.gov NCT00085735"}]},{"url":"https://clinicaltrials.gov/study/NCT00094653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/","field":"links","label":"ClinicalTrials.gov NCT00094653"}]},{"url":"https://clinicaltrials.gov/study/NCT00099437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","field":"links","label":"ClinicalTrials.gov NCT00099437"}]},{"url":"https://clinicaltrials.gov/study/NCT00099437?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","field":"outcomes.source (Time to Progression (TTP))"},{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT00100243","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00100243","kind":"trial","name":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","route":"/trials/nct00100243/","field":"links","label":"ClinicalTrials.gov NCT00100243"}]},{"url":"https://clinicaltrials.gov/study/NCT00101582","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00101582","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","route":"/trials/nct00101582/","field":"links","label":"ClinicalTrials.gov NCT00101582"}]},{"url":"https://clinicaltrials.gov/study/NCT00101582?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00101582","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","route":"/trials/nct00101582/","field":"outcomes.source (Number of Participants With Severe (Grade 3 or 4) Oral Mucositis, Yes)"}]},{"url":"https://clinicaltrials.gov/study/NCT00103181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT00103181"},{"id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","field":"links","label":"ClinicalTrials.gov NCT00103181"}]},{"url":"https://clinicaltrials.gov/study/NCT00103662","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00103662","kind":"trial","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","route":"/trials/nct00103662/","field":"links","label":"ClinicalTrials.gov NCT00103662"}]},{"url":"https://clinicaltrials.gov/study/NCT00104676","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","field":"links","label":"ClinicalTrials.gov NCT00104676"}]},{"url":"https://clinicaltrials.gov/study/NCT00104715","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/","field":"links","label":"ClinicalTrials.gov NCT00104715"},{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","field":"links","label":"ClinicalTrials.gov NCT00104715"}]},{"url":"https://clinicaltrials.gov/study/NCT00104741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00104741","kind":"trial","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","route":"/trials/nct00104741/","field":"links","label":"ClinicalTrials.gov NCT00104741"}]},{"url":"https://clinicaltrials.gov/study/NCT00105443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","field":"links","label":"ClinicalTrials.gov NCT00105443"}]},{"url":"https://clinicaltrials.gov/study/NCT00106431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00106431","kind":"trial","name":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)","route":"/trials/nct00106431/","field":"links","label":"ClinicalTrials.gov NCT00106431"}]},{"url":"https://clinicaltrials.gov/study/NCT00106431?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00106431","kind":"trial","name":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)","route":"/trials/nct00106431/","field":"outcomes.source (The Percent of Patients (Pts) With Objective Disease Response)"}]},{"url":"https://clinicaltrials.gov/study/NCT00109031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00109031","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","route":"/trials/nct00109031/","field":"links","label":"ClinicalTrials.gov NCT00109031"}]},{"url":"https://clinicaltrials.gov/study/NCT00109031?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00109031","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","route":"/trials/nct00109031/","field":"outcomes.source (Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4), Yes)"}]},{"url":"https://clinicaltrials.gov/study/NCT00110214","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","field":"links","label":"ClinicalTrials.gov NCT00110214"}]},{"url":"https://clinicaltrials.gov/study/NCT00112463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00112463","kind":"trial","name":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","route":"/trials/nct00112463/","field":"links","label":"ClinicalTrials.gov NCT00112463"}]},{"url":"https://clinicaltrials.gov/study/NCT00112463?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00112463","kind":"trial","name":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","route":"/trials/nct00112463/","field":"outcomes.source (Time to Progression)"}]},{"url":"https://clinicaltrials.gov/study/NCT00112658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","field":"links","label":"ClinicalTrials.gov NCT00112658"},{"id":"paper-conroy-folfirinox-pancreatic-nejm-2011","kind":"paper","name":"Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","route":"/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/","field":"links","label":"ClinicalTrials.gov NCT00112658"}]},{"url":"https://clinicaltrials.gov/study/NCT00116935","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","field":"links","label":"ClinicalTrials.gov NCT00116935"}]},{"url":"https://clinicaltrials.gov/study/NCT00122460","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","field":"links","label":"ClinicalTrials.gov NCT00122460"}]},{"url":"https://clinicaltrials.gov/study/NCT00122681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"links","label":"ClinicalTrials.gov NCT00122681"},{"id":"paper-patricia-paavonen-lancet-2009","kind":"paper","name":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","route":"/key-papers/paper-patricia-paavonen-lancet-2009/","field":"links","label":"ClinicalTrials.gov NCT00122681"}]},{"url":"https://clinicaltrials.gov/study/NCT00125034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"opus","kind":"trial","name":"OPUS","route":"/trials/opus/","field":"links","label":"ClinicalTrials.gov NCT00125034"}]},{"url":"https://clinicaltrials.gov/study/NCT00129142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00129142","kind":"trial","name":"Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy","route":"/trials/nct00129142/","field":"links","label":"ClinicalTrials.gov NCT00129142"}]},{"url":"https://clinicaltrials.gov/study/NCT00130533","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"geicam-ciboma","kind":"trial","name":"GEICAM/2003-11_CIBOMA/2004-01","route":"/trials/geicam-ciboma/","field":"links","label":"ClinicalTrials.gov NCT00130533"}]},{"url":"https://clinicaltrials.gov/study/NCT00133887","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","field":"links","label":"ClinicalTrials.gov NCT00133887"}]},{"url":"https://clinicaltrials.gov/study/NCT00134030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"links","label":"ClinicalTrials.gov NCT00134030"}]},{"url":"https://clinicaltrials.gov/study/NCT00134056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"links","label":"ClinicalTrials.gov NCT00134056"}]},{"url":"https://clinicaltrials.gov/study/NCT00136084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00136084","kind":"trial","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","route":"/trials/nct00136084/","field":"links","label":"ClinicalTrials.gov NCT00136084"}]},{"url":"https://clinicaltrials.gov/study/NCT00143416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00143416","kind":"trial","name":"Long Term Study With B2036-PEG","route":"/trials/nct00143416/","field":"links","label":"ClinicalTrials.gov NCT00143416"}]},{"url":"https://clinicaltrials.gov/study/NCT00154102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"links","label":"ClinicalTrials.gov NCT00154102"}]},{"url":"https://clinicaltrials.gov/study/NCT00168064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","field":"links","label":"ClinicalTrials.gov NCT00168064"},{"id":"paper-study-201-jama-dermatol-2013","kind":"paper","name":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","route":"/key-papers/paper-study-201-jama-dermatol-2013/","field":"links","label":"ClinicalTrials.gov NCT00168064"}]},{"url":"https://clinicaltrials.gov/study/NCT00168181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00168181","kind":"trial","name":"Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients","route":"/trials/nct00168181/","field":"links","label":"ClinicalTrials.gov NCT00168181"}]},{"url":"https://clinicaltrials.gov/study/NCT00171873","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","field":"links","label":"ClinicalTrials.gov NCT00171873"}]},{"url":"https://clinicaltrials.gov/study/NCT00175396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","field":"links","label":"ClinicalTrials.gov NCT00175396"}]},{"url":"https://clinicaltrials.gov/study/NCT00182819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","field":"links","label":"ClinicalTrials.gov NCT00182819"}]},{"url":"https://clinicaltrials.gov/study/NCT00186628","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00186628","kind":"trial","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","route":"/trials/nct00186628/","field":"links","label":"ClinicalTrials.gov NCT00186628"}]},{"url":"https://clinicaltrials.gov/study/NCT00186628?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00186628","kind":"trial","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","route":"/trials/nct00186628/","field":"outcomes.source (Chronic Graft-vs-Host Disease (cGvHD))"},{"id":"nct00186628","kind":"trial","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","route":"/trials/nct00186628/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00189345","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00189345","kind":"trial","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","route":"/trials/nct00189345/","field":"links","label":"ClinicalTrials.gov NCT00189345"}]},{"url":"https://clinicaltrials.gov/study/NCT00193765","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elective-neck-dissection-tmh","kind":"trial","name":"Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)","route":"/trials/elective-neck-dissection-tmh/","field":"links","label":"ClinicalTrials.gov NCT00193765"}]},{"url":"https://clinicaltrials.gov/study/NCT00193895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","field":"links","label":"ClinicalTrials.gov NCT00193895"}]},{"url":"https://clinicaltrials.gov/study/NCT00199043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00199043","kind":"trial","name":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","route":"/trials/nct00199043/","field":"links","label":"ClinicalTrials.gov NCT00199043"}]},{"url":"https://clinicaltrials.gov/study/NCT00229203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00229203","kind":"trial","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","route":"/trials/nct00229203/","field":"links","label":"ClinicalTrials.gov NCT00229203"}]},{"url":"https://clinicaltrials.gov/study/NCT00229203?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00229203","kind":"trial","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","route":"/trials/nct00229203/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00248287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","field":"links","label":"ClinicalTrials.gov NCT00248287"}]},{"url":"https://clinicaltrials.gov/study/NCT00248287?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","field":"outcomes.source (Objective Response Rates (ORR))"},{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","field":"outcomes.source (Median Overall Survival (OS))"},{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","field":"outcomes.source (Median Time of Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00254163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/","field":"links","label":"ClinicalTrials.gov NCT00254163"}]},{"url":"https://clinicaltrials.gov/study/NCT00254163?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/","field":"outcomes.source (Infection Rate)"},{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/","field":"outcomes.source (Progression-free Survival (PFS) Rate at 1-year)"},{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/","field":"outcomes.source (Objective Remission Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT00261313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00261313","kind":"trial","name":"ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer","route":"/trials/nct00261313/","field":"links","label":"ClinicalTrials.gov NCT00261313"}]},{"url":"https://clinicaltrials.gov/study/NCT00262769","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"links","label":"ClinicalTrials.gov NCT00262769"}]},{"url":"https://clinicaltrials.gov/study/NCT00262847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","field":"links","label":"ClinicalTrials.gov NCT00262847"}]},{"url":"https://clinicaltrials.gov/study/NCT00265811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"petacc-8","kind":"trial","name":"PETACC-8","route":"/trials/petacc-8/","field":"links","label":"ClinicalTrials.gov NCT00265811"}]},{"url":"https://clinicaltrials.gov/study/NCT00265850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/","field":"links","label":"ClinicalTrials.gov NCT00265850"}]},{"url":"https://clinicaltrials.gov/study/NCT00268463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00268463","kind":"trial","name":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","route":"/trials/nct00268463/","field":"links","label":"ClinicalTrials.gov NCT00268463"}]},{"url":"https://clinicaltrials.gov/study/NCT00268476","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"ClinicalTrials.gov NCT00268476"},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT00268476"},{"id":"paper-stampede-lancet-2016","kind":"paper","name":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","route":"/key-papers/paper-stampede-lancet-2016/","field":"links","label":"ClinicalTrials.gov NCT00268476"},{"id":"paper-stampede-plos-med-2022-update","kind":"paper","name":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","route":"/key-papers/paper-stampede-plos-med-2022-update/","field":"links","label":"ClinicalTrials.gov NCT00268476"}]},{"url":"https://clinicaltrials.gov/study/NCT00275210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","field":"links","label":"ClinicalTrials.gov NCT00275210"}]},{"url":"https://clinicaltrials.gov/study/NCT00276757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","field":"links","label":"ClinicalTrials.gov NCT00276757"}]},{"url":"https://clinicaltrials.gov/study/NCT00282035","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rapid","kind":"trial","name":"RAPID (accelerated partial-breast irradiation)","route":"/trials/rapid/","field":"links","label":"ClinicalTrials.gov NCT00282035"}]},{"url":"https://clinicaltrials.gov/study/NCT00287105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"links","label":"ClinicalTrials.gov NCT00287105"}]},{"url":"https://clinicaltrials.gov/study/NCT00288080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-0521","kind":"trial","name":"NRG Oncology RTOG 0521","route":"/trials/rtog-0521/","field":"links","label":"ClinicalTrials.gov NCT00288080"}]},{"url":"https://clinicaltrials.gov/study/NCT00295763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00295763","kind":"trial","name":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen","route":"/trials/nct00295763/","field":"links","label":"ClinicalTrials.gov NCT00295763"}]},{"url":"https://clinicaltrials.gov/study/NCT00297895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","field":"links","label":"ClinicalTrials.gov NCT00297895"}]},{"url":"https://clinicaltrials.gov/study/NCT00299689","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00299689","kind":"trial","name":"Phase II Trial of Ontak With Metastatic Melanoma","route":"/trials/nct00299689/","field":"links","label":"ClinicalTrials.gov NCT00299689"}]},{"url":"https://clinicaltrials.gov/study/NCT00299689?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00299689","kind":"trial","name":"Phase II Trial of Ontak With Metastatic Melanoma","route":"/trials/nct00299689/","field":"outcomes.source (Positive Response Defined as Clinical Complete Response, Partial Response or Stable Disease (Persisting for at Least 4 Weeks) as Measure by Modified RECIST Criteria)"}]},{"url":"https://clinicaltrials.gov/study/NCT00303784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"links","label":"ClinicalTrials.gov NCT00303784"}]},{"url":"https://clinicaltrials.gov/study/NCT00304759","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"profit-trial","kind":"trial","name":"PROFIT (Prostate Fractionated Irradiation Trial)","route":"/trials/profit-trial/","field":"links","label":"ClinicalTrials.gov NCT00304759"}]},{"url":"https://clinicaltrials.gov/study/NCT00309985","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"links","label":"ClinicalTrials.gov NCT00309985"}],"archive":"https://web.archive.org/web/20260207133939/https://clinicaltrials.gov/study/NCT00309985"},{"url":"https://clinicaltrials.gov/study/NCT00310167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"links","label":"ClinicalTrials.gov NCT00310167"}]},{"url":"https://clinicaltrials.gov/study/NCT00310180","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/","field":"links","label":"ClinicalTrials.gov NCT00310180"},{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","field":"links","label":"ClinicalTrials.gov NCT00310180: TAILORx"}]},{"url":"https://clinicaltrials.gov/study/NCT00316927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00316927","kind":"trial","name":"Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer","route":"/trials/nct00316927/","field":"links","label":"ClinicalTrials.gov NCT00316927"}]},{"url":"https://clinicaltrials.gov/study/NCT00322452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","field":"links","label":"ClinicalTrials.gov NCT00322452"}]},{"url":"https://clinicaltrials.gov/study/NCT00326820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00326820","kind":"trial","name":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","route":"/trials/nct00326820/","field":"links","label":"ClinicalTrials.gov NCT00326820"}]},{"url":"https://clinicaltrials.gov/study/NCT00327678","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","field":"links","label":"ClinicalTrials.gov NCT00327678"}]},{"url":"https://clinicaltrials.gov/study/NCT00331773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","field":"links","label":"ClinicalTrials.gov NCT00331773"}]},{"url":"https://clinicaltrials.gov/study/NCT00343382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00343382","kind":"trial","name":"Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer","route":"/trials/nct00343382/","field":"links","label":"ClinicalTrials.gov NCT00343382"}]},{"url":"https://clinicaltrials.gov/study/NCT00343382?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00343382","kind":"trial","name":"Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer","route":"/trials/nct00343382/","field":"outcomes.source (Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics)"}]},{"url":"https://clinicaltrials.gov/study/NCT00352534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/","field":"links","label":"ClinicalTrials.gov NCT00352534"}]},{"url":"https://clinicaltrials.gov/study/NCT00352534?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/","field":"outcomes.source (Event-free survival at 4 years by risk group (registry results))"},{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/","field":"outcomes.source (Overall survival at 4 years by risk group (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT00353496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","field":"links","label":"ClinicalTrials.gov NCT00353496"}]},{"url":"https://clinicaltrials.gov/study/NCT00358501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"links","label":"ClinicalTrials.gov NCT00358501"},{"id":"paper-defibrotide-2005-01-blood-2016","kind":"paper","name":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","route":"/key-papers/paper-defibrotide-2005-01-blood-2016/","field":"links","label":"ClinicalTrials.gov NCT00358501"}]},{"url":"https://clinicaltrials.gov/study/NCT00358501?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"outcomes.source (Survival at day 180 after transplant)"}]},{"url":"https://clinicaltrials.gov/study/NCT00363584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"links","label":"ClinicalTrials.gov NCT00363584"}]},{"url":"https://clinicaltrials.gov/study/NCT00364013","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","field":"links","label":"ClinicalTrials.gov NCT00364013"}]},{"url":"https://clinicaltrials.gov/study/NCT00372593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aaml0531","kind":"trial","name":"COG AAML0531","route":"/trials/aaml0531/","field":"links","label":"ClinicalTrials.gov NCT00372593"}]},{"url":"https://clinicaltrials.gov/study/NCT00376844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","field":"links","label":"ClinicalTrials.gov NCT00376844"}]},{"url":"https://clinicaltrials.gov/study/NCT00376883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00376883","kind":"trial","name":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month","route":"/trials/nct00376883/","field":"links","label":"ClinicalTrials.gov NCT00376883"}]},{"url":"https://clinicaltrials.gov/study/NCT00377156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","field":"links","label":"ClinicalTrials.gov NCT00377156"}]},{"url":"https://clinicaltrials.gov/study/NCT00377429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/","field":"links","label":"ClinicalTrials.gov NCT00377429"}]},{"url":"https://clinicaltrials.gov/study/NCT00377429?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/","field":"outcomes.source (Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions (Defined as 10-20-50-150 Micrograms) Within 21 Days)"},{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/","field":"outcomes.source (Median Time of Progression-free Survival in Weeks (Post-study for 24 Months))"}]},{"url":"https://clinicaltrials.gov/study/NCT00379340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","field":"links","label":"ClinicalTrials.gov NCT00379340"}]},{"url":"https://clinicaltrials.gov/study/NCT00383708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00383708","kind":"trial","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","route":"/trials/nct00383708/","field":"links","label":"ClinicalTrials.gov NCT00383708"}]},{"url":"https://clinicaltrials.gov/study/NCT00383708?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00383708","kind":"trial","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","route":"/trials/nct00383708/","field":"outcomes.source (Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period)"}]},{"url":"https://clinicaltrials.gov/study/NCT00390234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/","field":"links","label":"ClinicalTrials.gov NCT00390234"}]},{"url":"https://clinicaltrials.gov/study/NCT00390234?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/","field":"outcomes.source (Objective Response Rate, Evaluated According to the RECIST Criteria)"},{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/","field":"outcomes.source (Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group))"},{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/","field":"outcomes.source (Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Carcinosarcoma Group))"}]},{"url":"https://clinicaltrials.gov/study/NCT00392327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","field":"links","label":"ClinicalTrials.gov NCT00392327"}]},{"url":"https://clinicaltrials.gov/study/NCT00399035","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/","field":"links","label":"ClinicalTrials.gov NCT00399035"}]},{"url":"https://clinicaltrials.gov/study/NCT00399035?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/","field":"outcomes.source (Progression-free Survival)"},{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/","field":"outcomes.source (Overall Survival)"},{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/","field":"outcomes.source (Overall Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT00402038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"links","label":"ClinicalTrials.gov NCT00402038"},{"id":"paper-mntx-302-thomas-nejm-2008","kind":"paper","name":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","route":"/key-papers/paper-mntx-302-thomas-nejm-2008/","field":"links","label":"ClinicalTrials.gov NCT00402038"}]},{"url":"https://clinicaltrials.gov/study/NCT00408005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","field":"links","label":"ClinicalTrials.gov NCT00408005"}]},{"url":"https://clinicaltrials.gov/study/NCT00410683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lung-art","kind":"trial","name":"Lung ART","route":"/trials/lung-art/","field":"links","label":"ClinicalTrials.gov NCT00410683"}]},{"url":"https://clinicaltrials.gov/study/NCT00410761","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","field":"links","label":"ClinicalTrials.gov NCT00410761"}]},{"url":"https://clinicaltrials.gov/study/NCT00411138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","field":"links","label":"ClinicalTrials.gov NCT00411138"},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/","field":"links","label":"ClinicalTrials.gov NCT00411138: PORTEC-3"}]},{"url":"https://clinicaltrials.gov/study/NCT00411229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","field":"links","label":"ClinicalTrials.gov NCT00411229"}]},{"url":"https://clinicaltrials.gov/study/NCT00412022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00412022","kind":"trial","name":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer","route":"/trials/nct00412022/","field":"links","label":"ClinicalTrials.gov NCT00412022"}]},{"url":"https://clinicaltrials.gov/study/NCT00415233","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"links","label":"ClinicalTrials.gov NCT00415233"}]},{"url":"https://clinicaltrials.gov/study/NCT00417079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/","field":"links","label":"ClinicalTrials.gov NCT00417079"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"links","label":"ClinicalTrials.gov NCT00417079"}]},{"url":"https://clinicaltrials.gov/study/NCT00423475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"getug-afu-16","kind":"trial","name":"GETUG-AFU 16","route":"/trials/getug-afu-16/","field":"links","label":"ClinicalTrials.gov NCT00423475"}]},{"url":"https://clinicaltrials.gov/study/NCT00426257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","field":"links","label":"ClinicalTrials.gov NCT00426257"},{"id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","field":"links","label":"ClinicalTrials.gov NCT00426257: OVHIPEC-1"}]},{"url":"https://clinicaltrials.gov/study/NCT00431080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00431080","kind":"trial","name":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","route":"/trials/nct00431080/","field":"links","label":"ClinicalTrials.gov NCT00431080"}]},{"url":"https://clinicaltrials.gov/study/NCT00433563","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/","field":"links","label":"ClinicalTrials.gov NCT00433563"},{"id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","field":"links","label":"ClinicalTrials.gov NCT00433563"},{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","field":"links","label":"ClinicalTrials.gov NCT00433563"}]},{"url":"https://clinicaltrials.gov/study/NCT00433589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","route":"/key-papers/paper-mindact-ann-oncol-2014/","field":"links","label":"ClinicalTrials.gov NCT00433589"},{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","field":"links","label":"ClinicalTrials.gov NCT00433589"}]},{"url":"https://clinicaltrials.gov/study/NCT00433927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"links","label":"ClinicalTrials.gov NCT00433927"}]},{"url":"https://clinicaltrials.gov/study/NCT00434148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00434148","kind":"trial","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","route":"/trials/nct00434148/","field":"links","label":"ClinicalTrials.gov NCT00434148"}]},{"url":"https://clinicaltrials.gov/study/NCT00434148?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00434148","kind":"trial","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","route":"/trials/nct00434148/","field":"outcomes.source (Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group)"}]},{"url":"https://clinicaltrials.gov/study/NCT00434161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/","field":"links","label":"ClinicalTrials.gov NCT00434161"}]},{"url":"https://clinicaltrials.gov/study/NCT00434161?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/","field":"outcomes.source (Incidence of Cataract Development or Progression at Month 12., Yes)"},{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/","field":"outcomes.source (Overall Survival)"},{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/","field":"outcomes.source (Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00442637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cairo3","kind":"trial","name":"CAIRO3","route":"/trials/cairo3/","field":"links","label":"ClinicalTrials.gov NCT00442637"}]},{"url":"https://clinicaltrials.gov/study/NCT00450619","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00450619","kind":"trial","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","route":"/trials/nct00450619/","field":"links","label":"ClinicalTrials.gov NCT00450619"}]},{"url":"https://clinicaltrials.gov/study/NCT00450619?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00450619","kind":"trial","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","route":"/trials/nct00450619/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct00450619","kind":"trial","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","route":"/trials/nct00450619/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00452751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klass-01","kind":"trial","name":"KLASS-01","route":"/trials/klass-01/","field":"links","label":"ClinicalTrials.gov NCT00452751"}]},{"url":"https://clinicaltrials.gov/study/NCT00481247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","field":"links","label":"ClinicalTrials.gov NCT00481247"}]},{"url":"https://clinicaltrials.gov/study/NCT00482677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","field":"links","label":"ClinicalTrials.gov NCT00482677"}]},{"url":"https://clinicaltrials.gov/study/NCT00482833","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/","field":"links","label":"ClinicalTrials.gov NCT00482833"}]},{"url":"https://clinicaltrials.gov/study/NCT00493181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00493181","kind":"trial","name":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct00493181/","field":"links","label":"ClinicalTrials.gov NCT00493181"}]},{"url":"https://clinicaltrials.gov/study/NCT00493181?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00493181","kind":"trial","name":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct00493181/","field":"outcomes.source (Number of Participants With Complete Response)"}]},{"url":"https://clinicaltrials.gov/study/NCT00499330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-calgb-140503-n-engl-j-med-2023","kind":"paper","name":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","route":"/key-papers/paper-calgb-140503-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT00499330"},{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","field":"links","label":"ClinicalTrials.gov NCT00499330"}]},{"url":"https://clinicaltrials.gov/study/NCT00499616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","field":"links","label":"ClinicalTrials.gov NCT00499616"}]},{"url":"https://clinicaltrials.gov/study/NCT00499616?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","field":"outcomes.source (Overall survival at 3 years by treatment group (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT00510068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"links","label":"ClinicalTrials.gov NCT00510068"}]},{"url":"https://clinicaltrials.gov/study/NCT00513539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00513539","kind":"trial","name":"Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery","route":"/trials/nct00513539/","field":"links","label":"ClinicalTrials.gov NCT00513539"}]},{"url":"https://clinicaltrials.gov/study/NCT00515762","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00515762","kind":"trial","name":"Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling","route":"/trials/nct00515762/","field":"links","label":"ClinicalTrials.gov NCT00515762"}]},{"url":"https://clinicaltrials.gov/study/NCT00532194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00532194","kind":"trial","name":"An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer","route":"/trials/nct00532194/","field":"links","label":"ClinicalTrials.gov NCT00532194"}]},{"url":"https://clinicaltrials.gov/study/NCT00533949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","field":"links","label":"ClinicalTrials.gov NCT00533949"},{"id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","field":"links","label":"ClinicalTrials.gov NCT00533949"}]},{"url":"https://clinicaltrials.gov/study/NCT00539591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00539591","kind":"trial","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","route":"/trials/nct00539591/","field":"links","label":"ClinicalTrials.gov NCT00539591"}]},{"url":"https://clinicaltrials.gov/study/NCT00539591?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00539591","kind":"trial","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","route":"/trials/nct00539591/","field":"outcomes.source (Probability of Event-free Survival (EFS) of Stratum A Participants)"}]},{"url":"https://clinicaltrials.gov/study/NCT00541047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","field":"links","label":"ClinicalTrials.gov NCT00541047"},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","field":"links","label":"ClinicalTrials.gov NCT00541047"}]},{"url":"https://clinicaltrials.gov/study/NCT00541125","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00541125","kind":"trial","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","route":"/trials/nct00541125/","field":"links","label":"ClinicalTrials.gov NCT00541125"}]},{"url":"https://clinicaltrials.gov/study/NCT00542451","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/","field":"links","label":"ClinicalTrials.gov NCT00542451"},{"id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT00542451"}]},{"url":"https://clinicaltrials.gov/study/NCT00542542","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00542542","kind":"trial","name":"Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery","route":"/trials/nct00542542/","field":"links","label":"ClinicalTrials.gov NCT00542542"}]},{"url":"https://clinicaltrials.gov/study/NCT00545688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","field":"links","label":"ClinicalTrials.gov NCT00545688"},{"id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","field":"links","label":"ClinicalTrials.gov NCT00545688"},{"id":"neosphere","kind":"trial","name":"NeoSphere","route":"/trials/neosphere/","field":"links","label":"ClinicalTrials.gov NCT00545688"}]},{"url":"https://clinicaltrials.gov/study/NCT00550992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"interfant-06","kind":"trial","name":"Interfant-06","route":"/trials/interfant-06/","field":"links","label":"ClinicalTrials.gov NCT00550992"}]},{"url":"https://clinicaltrials.gov/study/NCT00551525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00551525","kind":"trial","name":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer","route":"/trials/nct00551525/","field":"links","label":"ClinicalTrials.gov NCT00551525"}]},{"url":"https://clinicaltrials.gov/study/NCT00551525?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00551525","kind":"trial","name":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer","route":"/trials/nct00551525/","field":"outcomes.source (Proportion of Patients With PSA Response (pt) Within 12 Weeks of Samarium 153 Administration)"}]},{"url":"https://clinicaltrials.gov/study/NCT00554229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"links","label":"ClinicalTrials.gov NCT00554229"}]},{"url":"https://clinicaltrials.gov/study/NCT00557193","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/","field":"links","label":"ClinicalTrials.gov NCT00557193"}]},{"url":"https://clinicaltrials.gov/study/NCT00557193?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/","field":"outcomes.source (Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2))"}]},{"url":"https://clinicaltrials.gov/study/NCT00561470","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","field":"links","label":"ClinicalTrials.gov NCT00561470"}]},{"url":"https://clinicaltrials.gov/study/NCT00563836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00563836","kind":"trial","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","route":"/trials/nct00563836/","field":"links","label":"ClinicalTrials.gov NCT00563836"}]},{"url":"https://clinicaltrials.gov/study/NCT00567190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","field":"links","label":"ClinicalTrials.gov NCT00567190"},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","field":"links","label":"ClinicalTrials.gov NCT00567190: CLEOPATRA"},{"id":"paper-cleopatra-n-engl-j-med-2012","kind":"paper","name":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","route":"/key-papers/paper-cleopatra-n-engl-j-med-2012/","field":"links","label":"ClinicalTrials.gov NCT00567190"},{"id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","field":"links","label":"ClinicalTrials.gov NCT00567190"}]},{"url":"https://clinicaltrials.gov/study/NCT00567567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","field":"links","label":"ClinicalTrials.gov NCT00567567: COG ANBL0532"},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/","field":"links","label":"ClinicalTrials.gov NCT00567567"}]},{"url":"https://clinicaltrials.gov/study/NCT00567580","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/","field":"links","label":"ClinicalTrials.gov NCT00567580"}]},{"url":"https://clinicaltrials.gov/study/NCT00569127","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00569127","kind":"trial","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","route":"/trials/nct00569127/","field":"links","label":"ClinicalTrials.gov NCT00569127"}]},{"url":"https://clinicaltrials.gov/study/NCT00569127?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00569127","kind":"trial","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","route":"/trials/nct00569127/","field":"outcomes.source (Central Review-based Progression-Free Survival)"},{"id":"nct00569127","kind":"trial","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","route":"/trials/nct00569127/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00576914","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00576914","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","route":"/trials/nct00576914/","field":"links","label":"ClinicalTrials.gov NCT00576914"}]},{"url":"https://clinicaltrials.gov/study/NCT00578006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","field":"links","label":"ClinicalTrials.gov NCT00578006"}]},{"url":"https://clinicaltrials.gov/study/NCT00582075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00582075","kind":"trial","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","route":"/trials/nct00582075/","field":"links","label":"ClinicalTrials.gov NCT00582075"}]},{"url":"https://clinicaltrials.gov/study/NCT00582075?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00582075","kind":"trial","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","route":"/trials/nct00582075/","field":"outcomes.source (Percentage of Participants With Distant Brain Failure (DBF) at One Year)"},{"id":"nct00582075","kind":"trial","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","route":"/trials/nct00582075/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00582166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","route":"/trials/nct00582166/","field":"links","label":"ClinicalTrials.gov NCT00582166"}]},{"url":"https://clinicaltrials.gov/study/NCT00582166?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","route":"/trials/nct00582166/","field":"outcomes.source (Median Progression Free Survival (PFS))"},{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","route":"/trials/nct00582166/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00585195","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","kind":"paper","name":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","route":"/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/","field":"links","label":"ClinicalTrials.gov NCT00585195"},{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","field":"links","label":"ClinicalTrials.gov NCT00585195"}]},{"url":"https://clinicaltrials.gov/study/NCT00590447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","field":"links","label":"ClinicalTrials.gov NCT00590447"}]},{"url":"https://clinicaltrials.gov/study/NCT00600886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","route":"/trials/nct00600886/","field":"links","label":"ClinicalTrials.gov NCT00600886"}]},{"url":"https://clinicaltrials.gov/study/NCT00600886?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","route":"/trials/nct00600886/","field":"outcomes.source (Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1, Overall)"}]},{"url":"https://clinicaltrials.gov/study/NCT00602082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00602082","kind":"trial","name":"Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors","route":"/trials/nct00602082/","field":"links","label":"ClinicalTrials.gov NCT00602082"}]},{"url":"https://clinicaltrials.gov/study/NCT00614211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","field":"links","label":"ClinicalTrials.gov NCT00614211"},{"id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","field":"links","label":"ClinicalTrials.gov NCT00614211: LACC (Laparoscopic Approach to Cervical Cancer)"}]},{"url":"https://clinicaltrials.gov/study/NCT00615602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00615602","kind":"trial","name":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","route":"/trials/nct00615602/","field":"links","label":"ClinicalTrials.gov NCT00615602"}]},{"url":"https://clinicaltrials.gov/study/NCT00626444","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00626444","kind":"trial","name":"Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct00626444/","field":"links","label":"ClinicalTrials.gov NCT00626444"}]},{"url":"https://clinicaltrials.gov/study/NCT00626990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","route":"/trials/catnon/","field":"links","label":"ClinicalTrials.gov NCT00626990"}]},{"url":"https://clinicaltrials.gov/study/NCT00628810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00628810","kind":"trial","name":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","route":"/trials/nct00628810/","field":"links","label":"ClinicalTrials.gov NCT00628810"}]},{"url":"https://clinicaltrials.gov/study/NCT00630032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/","field":"links","label":"ClinicalTrials.gov NCT00630032"}]},{"url":"https://clinicaltrials.gov/study/NCT00630032?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/","field":"outcomes.source (Percentage of Participants With Disease-free Survival (DFS))"},{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00634322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00634322","kind":"trial","name":"High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma","route":"/trials/nct00634322/","field":"links","label":"ClinicalTrials.gov NCT00634322"}]},{"url":"https://clinicaltrials.gov/study/NCT00634725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/","field":"links","label":"ClinicalTrials.gov NCT00634725"}]},{"url":"https://clinicaltrials.gov/study/NCT00638690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","field":"links","label":"ClinicalTrials.gov NCT00638690"}]},{"url":"https://clinicaltrials.gov/study/NCT00646607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","field":"links","label":"ClinicalTrials.gov NCT00646607"}]},{"url":"https://clinicaltrials.gov/study/NCT00651261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","field":"links","label":"ClinicalTrials.gov NCT00651261"},{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","field":"links","label":"ClinicalTrials.gov NCT00651261: RATIFY (CALGB 10603)"}]},{"url":"https://clinicaltrials.gov/study/NCT00651456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maps","kind":"trial","name":"MAPS","route":"/trials/maps/","field":"links","label":"ClinicalTrials.gov NCT00651456"}]},{"url":"https://clinicaltrials.gov/study/NCT00652132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00652132","kind":"trial","name":"Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer","route":"/trials/nct00652132/","field":"links","label":"ClinicalTrials.gov NCT00652132"}]},{"url":"https://clinicaltrials.gov/study/NCT00653068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","field":"links","label":"ClinicalTrials.gov NCT00653068"}]},{"url":"https://clinicaltrials.gov/study/NCT00660894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00660894","kind":"trial","name":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","route":"/trials/nct00660894/","field":"links","label":"ClinicalTrials.gov NCT00660894"}]},{"url":"https://clinicaltrials.gov/study/NCT00667069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/","field":"links","label":"ClinicalTrials.gov NCT00667069"}]},{"url":"https://clinicaltrials.gov/study/NCT00671918","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00671918","kind":"trial","name":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","route":"/trials/nct00671918/","field":"links","label":"ClinicalTrials.gov NCT00671918"}]},{"url":"https://clinicaltrials.gov/study/NCT00671918?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00671918","kind":"trial","name":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","route":"/trials/nct00671918/","field":"outcomes.source (Concordance of Blue Dye and Lymphoseek)"}]},{"url":"https://clinicaltrials.gov/study/NCT00678327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","field":"links","label":"ClinicalTrials.gov NCT00678327"},{"id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","field":"links","label":"ClinicalTrials.gov NCT00678327: RATHL"}]},{"url":"https://clinicaltrials.gov/study/NCT00687986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stars-rosel","kind":"trial","name":"STARS and ROSEL pooled analysis","route":"/trials/stars-rosel/","field":"links","label":"ClinicalTrials.gov NCT00687986"}]},{"url":"https://clinicaltrials.gov/study/NCT00699751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","field":"links","label":"ClinicalTrials.gov NCT00699751"}],"archive":"https://web.archive.org/web/20260907201215/https://clinicaltrials.gov/study/NCT00699751"},{"url":"https://clinicaltrials.gov/study/NCT00703820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00703820","kind":"trial","name":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct00703820/","field":"links","label":"ClinicalTrials.gov NCT00703820"}]},{"url":"https://clinicaltrials.gov/study/NCT00704730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","field":"links","label":"ClinicalTrials.gov NCT00704730"}]},{"url":"https://clinicaltrials.gov/study/NCT00712140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/","field":"links","label":"ClinicalTrials.gov NCT00712140"},{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","field":"links","label":"ClinicalTrials.gov NCT00712140: PERSEPHONE"},{"id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT00712140"}]},{"url":"https://clinicaltrials.gov/study/NCT00716976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/","field":"links","label":"ClinicalTrials.gov NCT00716976"}]},{"url":"https://clinicaltrials.gov/study/NCT00716976?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/","field":"outcomes.source (Incidence of Hearing Loss)"},{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00718549","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00718549","kind":"trial","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct00718549/","field":"links","label":"ClinicalTrials.gov NCT00718549"}]},{"url":"https://clinicaltrials.gov/study/NCT00718549?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00718549","kind":"trial","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct00718549/","field":"outcomes.source (Progression-Fee Survival (PFS) Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLL)"}]},{"url":"https://clinicaltrials.gov/study/NCT00719797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"links","label":"ClinicalTrials.gov NCT00719797"}]},{"url":"https://clinicaltrials.gov/study/NCT00722228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00722228","kind":"trial","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/","field":"links","label":"ClinicalTrials.gov NCT00722228"}]},{"url":"https://clinicaltrials.gov/study/NCT00742027","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","route":"/trials/nct00742027/","field":"links","label":"ClinicalTrials.gov NCT00742027"}]},{"url":"https://clinicaltrials.gov/study/NCT00742027?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","route":"/trials/nct00742027/","field":"outcomes.source (The Overall Survival (OS))"},{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","route":"/trials/nct00742027/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00744497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","field":"links","label":"ClinicalTrials.gov NCT00744497"}]},{"url":"https://clinicaltrials.gov/study/NCT00744653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00744653","kind":"trial","name":"Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects","route":"/trials/nct00744653/","field":"links","label":"ClinicalTrials.gov NCT00744653"}]},{"url":"https://clinicaltrials.gov/study/NCT00744653?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00744653","kind":"trial","name":"Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects","route":"/trials/nct00744653/","field":"outcomes.source (Clinical Measure of Lesion Size.)"},{"id":"nct00744653","kind":"trial","name":"Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects","route":"/trials/nct00744653/","field":"outcomes.source (Participants With Objective Response Evaluated With PET/CT)"}]},{"url":"https://clinicaltrials.gov/study/NCT00769379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00769379","kind":"trial","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","route":"/trials/nct00769379/","field":"links","label":"ClinicalTrials.gov NCT00769379"}]},{"url":"https://clinicaltrials.gov/study/NCT00769379?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00769379","kind":"trial","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","route":"/trials/nct00769379/","field":"outcomes.source (Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival)"},{"id":"nct00769379","kind":"trial","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","route":"/trials/nct00769379/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT00769405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prodige-7","kind":"trial","name":"PRODIGE 7","route":"/trials/prodige-7/","field":"links","label":"ClinicalTrials.gov NCT00769405"}]},{"url":"https://clinicaltrials.gov/study/NCT00769704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00769704","kind":"trial","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","route":"/trials/nct00769704/","field":"links","label":"ClinicalTrials.gov NCT00769704"}]},{"url":"https://clinicaltrials.gov/study/NCT00769704?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00769704","kind":"trial","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","route":"/trials/nct00769704/","field":"outcomes.source (Durable Response Rate)"},{"id":"nct00769704","kind":"trial","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","route":"/trials/nct00769704/","field":"outcomes.source (Overall Survival)"},{"id":"nct00769704","kind":"trial","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","route":"/trials/nct00769704/","field":"outcomes.source (Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT00777153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","route":"/trials/nct00777153/","field":"links","label":"ClinicalTrials.gov NCT00777153"}]},{"url":"https://clinicaltrials.gov/study/NCT00777153?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","route":"/trials/nct00777153/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","route":"/trials/nct00777153/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT00777244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adiuvo","kind":"trial","name":"ADIUVO","route":"/trials/adiuvo/","field":"links","label":"ClinicalTrials.gov NCT00777244"}]},{"url":"https://clinicaltrials.gov/study/NCT00781612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00781612","kind":"trial","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","route":"/trials/nct00781612/","field":"links","label":"ClinicalTrials.gov NCT00781612"}]},{"url":"https://clinicaltrials.gov/study/NCT00786058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/","field":"links","label":"ClinicalTrials.gov NCT00786058"}]},{"url":"https://clinicaltrials.gov/study/NCT00789958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","field":"links","label":"ClinicalTrials.gov NCT00789958"},{"id":"paper-swog-s0809-adjuvant-chemoradiation-jco-2015","kind":"paper","name":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","route":"/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/","field":"links","label":"ClinicalTrials.gov NCT00789958"}]},{"url":"https://clinicaltrials.gov/study/NCT00805194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lume-lung-1","kind":"trial","name":"LUME-Lung 1","route":"/trials/lume-lung-1/","field":"links","label":"ClinicalTrials.gov NCT00805194"}]},{"url":"https://clinicaltrials.gov/study/NCT00819208","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT00819208"},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","field":"links","label":"ClinicalTrials.gov NCT00819208"}]},{"url":"https://clinicaltrials.gov/study/NCT00821860","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00821860","kind":"trial","name":"Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma","route":"/trials/nct00821860/","field":"links","label":"ClinicalTrials.gov NCT00821860"}]},{"url":"https://clinicaltrials.gov/study/NCT00822393","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00822393","kind":"trial","name":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","route":"/trials/nct00822393/","field":"links","label":"ClinicalTrials.gov NCT00822393"}]},{"url":"https://clinicaltrials.gov/study/NCT00833248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00833248","kind":"trial","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","route":"/trials/nct00833248/","field":"links","label":"ClinicalTrials.gov NCT00833248"}]},{"url":"https://clinicaltrials.gov/study/NCT00833248?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00833248","kind":"trial","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","route":"/trials/nct00833248/","field":"outcomes.source (Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set))"}]},{"url":"https://clinicaltrials.gov/study/NCT00833417","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-erivance-bmc-cancer-2017-update","kind":"paper","name":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","route":"/key-papers/paper-erivance-bmc-cancer-2017-update/","field":"links","label":"ClinicalTrials.gov NCT00833417"},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","field":"links","label":"ClinicalTrials.gov NCT00833417"}]},{"url":"https://clinicaltrials.gov/study/NCT00840749","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stars-rosel","kind":"trial","name":"STARS and ROSEL pooled analysis","route":"/trials/stars-rosel/","field":"links","label":"ClinicalTrials.gov NCT00840749"}]},{"url":"https://clinicaltrials.gov/study/NCT00841113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00841113","kind":"trial","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","route":"/trials/nct00841113/","field":"links","label":"ClinicalTrials.gov NCT00841113"}]},{"url":"https://clinicaltrials.gov/study/NCT00844649","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","field":"links","label":"ClinicalTrials.gov NCT00844649"},{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/","field":"links","label":"ClinicalTrials.gov NCT00844649"}]},{"url":"https://clinicaltrials.gov/study/NCT00849082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","field":"links","label":"ClinicalTrials.gov NCT00849082"}]},{"url":"https://clinicaltrials.gov/study/NCT00858429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00858429","kind":"trial","name":"Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases","route":"/trials/nct00858429/","field":"links","label":"ClinicalTrials.gov NCT00858429"}]},{"url":"https://clinicaltrials.gov/study/NCT00860652","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raves","kind":"trial","name":"RAVES (TROG 08.03/ANZUP)","route":"/trials/raves/","field":"links","label":"ClinicalTrials.gov NCT00860652"}]},{"url":"https://clinicaltrials.gov/study/NCT00861614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"links","label":"ClinicalTrials.gov NCT00861614"}]},{"url":"https://clinicaltrials.gov/study/NCT00861705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015","kind":"paper","name":"Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","route":"/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/","field":"links","label":"ClinicalTrials.gov NCT00861705"},{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/","field":"links","label":"ClinicalTrials.gov NCT00861705"}]},{"url":"https://clinicaltrials.gov/study/NCT00863655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-bolero-2-n-engl-j-med-2012","kind":"paper","name":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","route":"/key-papers/paper-bolero-2-n-engl-j-med-2012/","field":"links","label":"ClinicalTrials.gov NCT00863655"},{"id":"paper-bolero-2-ann-oncol-2014-update","kind":"paper","name":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†","route":"/key-papers/paper-bolero-2-ann-oncol-2014-update/","field":"links","label":"ClinicalTrials.gov NCT00863655"},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","field":"links","label":"ClinicalTrials.gov NCT00863655"}]},{"url":"https://clinicaltrials.gov/study/NCT00880269","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00880269","kind":"trial","name":"Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","route":"/trials/nct00880269/","field":"links","label":"ClinicalTrials.gov NCT00880269"}]},{"url":"https://clinicaltrials.gov/study/NCT00880360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00880360","kind":"trial","name":"A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer","route":"/trials/nct00880360/","field":"links","label":"ClinicalTrials.gov NCT00880360"}]},{"url":"https://clinicaltrials.gov/study/NCT00880360?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00880360","kind":"trial","name":"A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer","route":"/trials/nct00880360/","field":"outcomes.source (Number of Participants Demonstrating Clinical Response)"}]},{"url":"https://clinicaltrials.gov/study/NCT00881361","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acosog-z1071","kind":"trial","name":"ACOSOG Z1071 (Alliance)","route":"/trials/acosog-z1071/","field":"links","label":"ClinicalTrials.gov NCT00881361"}]},{"url":"https://clinicaltrials.gov/study/NCT00883116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/","field":"links","label":"ClinicalTrials.gov NCT00883116"}]},{"url":"https://clinicaltrials.gov/study/NCT00883116?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/","field":"outcomes.source (Progression-free Survival)"},{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/","field":"outcomes.source (Best Overall Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT00883792","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-crc-screening-uptake-and-age-extension","kind":"idea","name":"Treat screening uptake, not test sensitivity, as the thing to optimise, and settle the age extension with a trial rather than a model","route":"/ideas/idea-crc-screening-uptake-and-age-extension/","field":"links","label":"ClinicalTrials.gov NCT00883792"},{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT00883792"},{"id":"paper-nordicc-lancet-2026-update","kind":"paper","name":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","route":"/key-papers/paper-nordicc-lancet-2026-update/","field":"links","label":"ClinicalTrials.gov NCT00883792"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"links","label":"ClinicalTrials.gov NCT00883792"}]},{"url":"https://clinicaltrials.gov/study/NCT00884273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00884273","kind":"trial","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","route":"/trials/nct00884273/","field":"links","label":"ClinicalTrials.gov NCT00884273"}]},{"url":"https://clinicaltrials.gov/study/NCT00884273?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00884273","kind":"trial","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","route":"/trials/nct00884273/","field":"outcomes.source (Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set))"}]},{"url":"https://clinicaltrials.gov/study/NCT00887146","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"codel","kind":"trial","name":"CODEL","route":"/trials/codel/","field":"links","label":"ClinicalTrials.gov NCT00887146"}]},{"url":"https://clinicaltrials.gov/study/NCT00887198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","field":"links","label":"ClinicalTrials.gov NCT00887198"}]},{"url":"https://clinicaltrials.gov/study/NCT00889525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00889525","kind":"trial","name":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","route":"/trials/nct00889525/","field":"links","label":"ClinicalTrials.gov NCT00889525"}]},{"url":"https://clinicaltrials.gov/study/NCT00904813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stockholm-iii","kind":"trial","name":"Stockholm III","route":"/trials/stockholm-iii/","field":"links","label":"ClinicalTrials.gov NCT00904813"}]},{"url":"https://clinicaltrials.gov/study/NCT00911326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00911326","kind":"trial","name":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","route":"/trials/nct00911326/","field":"links","label":"ClinicalTrials.gov NCT00911326"}]},{"url":"https://clinicaltrials.gov/study/NCT00911326?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00911326","kind":"trial","name":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","route":"/trials/nct00911326/","field":"outcomes.source (False Negative Rate (FNR))"}]},{"url":"https://clinicaltrials.gov/study/NCT00916409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","field":"links","label":"ClinicalTrials.gov NCT00916409"}],"archive":"https://web.archive.org/web/20260506152519/https://clinicaltrials.gov/study/NCT00916409"},{"url":"https://clinicaltrials.gov/study/NCT00923481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00923481","kind":"trial","name":"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H..","route":"/trials/nct00923481/","field":"links","label":"ClinicalTrials.gov NCT00923481"}]},{"url":"https://clinicaltrials.gov/study/NCT00927498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","field":"links","label":"ClinicalTrials.gov NCT00927498"}]},{"url":"https://clinicaltrials.gov/study/NCT00930033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"carmena","kind":"trial","name":"CARMENA","route":"/trials/carmena/","field":"links","label":"ClinicalTrials.gov NCT00930033"}]},{"url":"https://clinicaltrials.gov/study/NCT00934544","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"comfort-ii","kind":"trial","name":"COMFORT-II","route":"/trials/comfort-ii/","field":"links","label":"ClinicalTrials.gov NCT00934544"}]},{"url":"https://clinicaltrials.gov/study/NCT00934544?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"comfort-ii","kind":"trial","name":"COMFORT-II","route":"/trials/comfort-ii/","field":"outcomes.source (Spleen volume reduction of 35% or more at week 48 (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT00936390","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/","field":"links","label":"ClinicalTrials.gov NCT00936390"}]},{"url":"https://clinicaltrials.gov/study/NCT00936390?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/","field":"outcomes.source (Percentage of Participants Alive (Overall Survival))"}]},{"url":"https://clinicaltrials.gov/study/NCT00938652","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00938652","kind":"trial","name":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","route":"/trials/nct00938652/","field":"links","label":"ClinicalTrials.gov NCT00938652"}]},{"url":"https://clinicaltrials.gov/study/NCT00940602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"telesto","kind":"trial","name":"TELESTO","route":"/trials/telesto/","field":"links","label":"ClinicalTrials.gov NCT00940602"}]},{"url":"https://clinicaltrials.gov/study/NCT00940602?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"telesto","kind":"trial","name":"TELESTO","route":"/trials/telesto/","field":"links","label":"ClinicalTrials.gov results"},{"id":"telesto","kind":"trial","name":"TELESTO","route":"/trials/telesto/","field":"outcomes.source (Event-free survival (non-fatal cardiac or hepatic event, progression to acute myeloid leukaemia, or death))"}]},{"url":"https://clinicaltrials.gov/study/NCT00943449","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00943449","kind":"trial","name":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","route":"/trials/nct00943449/","field":"links","label":"ClinicalTrials.gov NCT00943449"}]},{"url":"https://clinicaltrials.gov/study/NCT00943826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","field":"links","label":"ClinicalTrials.gov NCT00943826"}]},{"url":"https://clinicaltrials.gov/study/NCT00949650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/","field":"links","label":"ClinicalTrials.gov NCT00949650"}]},{"url":"https://clinicaltrials.gov/study/NCT00952289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/","field":"links","label":"ClinicalTrials.gov NCT00952289"},{"id":"comfort-i","kind":"trial","name":"COMFORT-I","route":"/trials/comfort-i/","field":"links","label":"ClinicalTrials.gov NCT00952289"}]},{"url":"https://clinicaltrials.gov/study/NCT00952289?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"comfort-i","kind":"trial","name":"COMFORT-I","route":"/trials/comfort-i/","field":"outcomes.source (Participants with a spleen volume reduction of 35% or more at week 24 (registry count))"}]},{"url":"https://clinicaltrials.gov/study/NCT00967057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ukallr3","kind":"trial","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","field":"links","label":"ClinicalTrials.gov NCT00967057"}]},{"url":"https://clinicaltrials.gov/study/NCT00974311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/","field":"links","label":"ClinicalTrials.gov NCT00974311"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"links","label":"ClinicalTrials.gov NCT00974311"}]},{"url":"https://clinicaltrials.gov/study/NCT00976911","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"links","label":"ClinicalTrials.gov NCT00976911"}]},{"url":"https://clinicaltrials.gov/study/NCT00976911?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","field":"outcomes.source (Progression-free survival (registry results, November 2011 cut-off))"}]},{"url":"https://clinicaltrials.gov/study/NCT00981058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"squire","kind":"trial","name":"SQUIRE","route":"/trials/squire/","field":"links","label":"ClinicalTrials.gov NCT00981058"}]},{"url":"https://clinicaltrials.gov/study/NCT00983684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"links","label":"ClinicalTrials.gov NCT00983684"}]},{"url":"https://clinicaltrials.gov/study/NCT00984282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"links","label":"ClinicalTrials.gov NCT00984282"},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","field":"links","label":"ClinicalTrials.gov NCT00984282: DECISION"}]},{"url":"https://clinicaltrials.gov/study/NCT00987636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"euro-ewing-2012","kind":"trial","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","field":"links","label":"ClinicalTrials.gov NCT00987636"}]},{"url":"https://clinicaltrials.gov/study/NCT00998738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct00998738","kind":"trial","name":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","route":"/trials/nct00998738/","field":"links","label":"ClinicalTrials.gov NCT00998738"}]},{"url":"https://clinicaltrials.gov/study/NCT01011231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01011231","kind":"trial","name":"Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma","route":"/trials/nct01011231/","field":"links","label":"ClinicalTrials.gov NCT01011231"}]},{"url":"https://clinicaltrials.gov/study/NCT01011920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/","field":"links","label":"ClinicalTrials.gov NCT01011920"}]},{"url":"https://clinicaltrials.gov/study/NCT01014130","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT01014130"},{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","route":"/trials/chisel/","field":"links","label":"ClinicalTrials.gov NCT01014130"}]},{"url":"https://clinicaltrials.gov/study/NCT01020448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01020448","kind":"trial","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","route":"/trials/nct01020448/","field":"links","label":"ClinicalTrials.gov NCT01020448"}]},{"url":"https://clinicaltrials.gov/study/NCT01032057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"links","label":"ClinicalTrials.gov NCT01032057"}]},{"url":"https://clinicaltrials.gov/study/NCT01037478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01037478","kind":"trial","name":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","route":"/trials/nct01037478/","field":"links","label":"ClinicalTrials.gov NCT01037478"}]},{"url":"https://clinicaltrials.gov/study/NCT01038271","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-temel-early-palliative-care-nejm-2010","kind":"paper","name":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","route":"/key-papers/paper-temel-early-palliative-care-nejm-2010/","field":"links","label":"ClinicalTrials.gov NCT01038271"}]},{"url":"https://clinicaltrials.gov/study/NCT01038583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","field":"links","label":"ClinicalTrials.gov NCT01038583"}]},{"url":"https://clinicaltrials.gov/study/NCT01041404","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","field":"links","label":"ClinicalTrials.gov NCT01041404"},{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/","field":"links","label":"ClinicalTrials.gov NCT01041404"}]},{"url":"https://clinicaltrials.gov/study/NCT01042379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-i-spy-2-jama-oncol-2020","kind":"paper","name":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","route":"/key-papers/paper-i-spy-2-jama-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT01042379"},{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","field":"links","label":"ClinicalTrials.gov NCT01042379"},{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/","field":"links","label":"ClinicalTrials.gov NCT01042379"}]},{"url":"https://clinicaltrials.gov/study/NCT01045304","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01045304","kind":"trial","name":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct01045304/","field":"links","label":"ClinicalTrials.gov NCT01045304"}]},{"url":"https://clinicaltrials.gov/study/NCT01053676","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","field":"links","label":"ClinicalTrials.gov NCT01053676"}]},{"url":"https://clinicaltrials.gov/study/NCT01054079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01054079","kind":"trial","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","route":"/trials/nct01054079/","field":"links","label":"ClinicalTrials.gov NCT01054079"}]},{"url":"https://clinicaltrials.gov/study/NCT01054079?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01054079","kind":"trial","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","route":"/trials/nct01054079/","field":"outcomes.source (Rate of Rise of Serum PSA)"}]},{"url":"https://clinicaltrials.gov/study/NCT01057069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","route":"/trials/nct01057069/","field":"links","label":"ClinicalTrials.gov NCT01057069"}]},{"url":"https://clinicaltrials.gov/study/NCT01059786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01059786","kind":"trial","name":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","route":"/trials/nct01059786/","field":"links","label":"ClinicalTrials.gov NCT01059786"}]},{"url":"https://clinicaltrials.gov/study/NCT01064466","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01064466","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","route":"/trials/nct01064466/","field":"links","label":"ClinicalTrials.gov NCT01064466"}]},{"url":"https://clinicaltrials.gov/study/NCT01072981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/","field":"links","label":"ClinicalTrials.gov NCT01072981"},{"id":"impress-trial","kind":"trial","name":"IMPRESS (algenpantucel-L)","route":"/trials/impress-trial/","field":"links","label":"ClinicalTrials.gov NCT01072981"}]},{"url":"https://clinicaltrials.gov/study/NCT01081951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/","field":"links","label":"ClinicalTrials.gov NCT01081951"}]},{"url":"https://clinicaltrials.gov/study/NCT01081951?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT01086488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01086488","kind":"trial","name":"Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma","route":"/trials/nct01086488/","field":"links","label":"ClinicalTrials.gov NCT01086488"}]},{"url":"https://clinicaltrials.gov/study/NCT01086605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/","field":"links","label":"ClinicalTrials.gov NCT01086605"}]},{"url":"https://clinicaltrials.gov/study/NCT01086605?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/","field":"outcomes.source (Proportion of Confirmed Tumor Responses (Complete or Partial Response))"},{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/","field":"outcomes.source (Overall Survival Time)"},{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/","field":"outcomes.source (6-month Progression-free Survival Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT01091974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01091974","kind":"trial","name":"Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy","route":"/trials/nct01091974/","field":"links","label":"ClinicalTrials.gov NCT01091974"}]},{"url":"https://clinicaltrials.gov/study/NCT01091974?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01091974","kind":"trial","name":"Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy","route":"/trials/nct01091974/","field":"outcomes.source (Change in Insomnia Severity Index From Baseline to Post-intervention)"}]},{"url":"https://clinicaltrials.gov/study/NCT01100502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/","field":"links","label":"ClinicalTrials.gov NCT01100502"}]},{"url":"https://clinicaltrials.gov/study/NCT01101438","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","field":"links","label":"MA.32 adjuvant metformin (NCT01101438)"}]},{"url":"https://clinicaltrials.gov/study/NCT01102426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","field":"links","label":"ClinicalTrials.gov NCT01102426"}]},{"url":"https://clinicaltrials.gov/study/NCT01102426?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","field":"outcomes.source (Progression Free Survival (PFS) as Per Intention-to-treat (ITT))"},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","field":"outcomes.source (Percentage of Participants With Progression Free Survival (PFS) as Per Intention-to-treat (ITT) at 6 Months)"},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","field":"outcomes.source (Overall Survival)"},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","field":"outcomes.source (Overall Response Rate (Independent Review Committee))"}]},{"url":"https://clinicaltrials.gov/study/NCT01103323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","field":"links","label":"ClinicalTrials.gov NCT01103323"}]},{"url":"https://clinicaltrials.gov/study/NCT01106040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01106040","kind":"trial","name":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","route":"/trials/nct01106040/","field":"links","label":"ClinicalTrials.gov NCT01106040"}]},{"url":"https://clinicaltrials.gov/study/NCT01106040?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01106040","kind":"trial","name":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","route":"/trials/nct01106040/","field":"outcomes.source (Concordance of Blue Dye and Lymphoseek)"}]},{"url":"https://clinicaltrials.gov/study/NCT01112826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"links","label":"ClinicalTrials.gov NCT01112826"}]},{"url":"https://clinicaltrials.gov/study/NCT01117441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01117441","kind":"trial","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","route":"/trials/nct01117441/","field":"links","label":"ClinicalTrials.gov NCT01117441"}]},{"url":"https://clinicaltrials.gov/study/NCT01120353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/","field":"links","label":"ClinicalTrials.gov NCT01120353: Childhood Cancer Survivor Study (CCSS)"},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","field":"links","label":"ClinicalTrials.gov NCT01120353"}]},{"url":"https://clinicaltrials.gov/study/NCT01124253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01124253","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct01124253/","field":"links","label":"ClinicalTrials.gov NCT01124253"}]},{"url":"https://clinicaltrials.gov/study/NCT01127451","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01127451","kind":"trial","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","route":"/trials/nct01127451/","field":"links","label":"ClinicalTrials.gov NCT01127451"}]},{"url":"https://clinicaltrials.gov/study/NCT01127451?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01127451","kind":"trial","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","route":"/trials/nct01127451/","field":"outcomes.source (Percentage of Participants With Immune-related Overall Response Rate (irORR))"},{"id":"nct01127451","kind":"trial","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","route":"/trials/nct01127451/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct01127451","kind":"trial","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","route":"/trials/nct01127451/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT01137682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01137682","kind":"trial","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","route":"/trials/nct01137682/","field":"links","label":"ClinicalTrials.gov NCT01137682"}]},{"url":"https://clinicaltrials.gov/study/NCT01137682?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01137682","kind":"trial","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","route":"/trials/nct01137682/","field":"outcomes.source (Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.)"}]},{"url":"https://clinicaltrials.gov/study/NCT01141712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","field":"links","label":"ClinicalTrials.gov NCT01141712"}]},{"url":"https://clinicaltrials.gov/study/NCT01154140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"profile-1014","kind":"trial","name":"PROFILE 1014","route":"/trials/profile-1014/","field":"links","label":"ClinicalTrials.gov NCT01154140"}]},{"url":"https://clinicaltrials.gov/study/NCT01166737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","field":"links","label":"ClinicalTrials.gov NCT01166737"}]},{"url":"https://clinicaltrials.gov/study/NCT01168973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","field":"links","label":"ClinicalTrials.gov NCT01168973"}]},{"url":"https://clinicaltrials.gov/study/NCT01169259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","field":"links","label":"ClinicalTrials.gov NCT01169259"}]},{"url":"https://clinicaltrials.gov/study/NCT01170663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rainbow","kind":"trial","name":"RAINBOW","route":"/trials/rainbow/","field":"links","label":"ClinicalTrials.gov NCT01170663"}]},{"url":"https://clinicaltrials.gov/study/NCT01174121","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01174121","kind":"trial","name":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","route":"/trials/nct01174121/","field":"links","label":"ClinicalTrials.gov NCT01174121"}]},{"url":"https://clinicaltrials.gov/study/NCT01183780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raise","kind":"trial","name":"RAISE","route":"/trials/raise/","field":"links","label":"ClinicalTrials.gov NCT01183780"}]},{"url":"https://clinicaltrials.gov/study/NCT01188187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"synergy-custirsen","kind":"trial","name":"SYNERGY","route":"/trials/synergy-custirsen/","field":"links","label":"ClinicalTrials.gov NCT01188187"}]},{"url":"https://clinicaltrials.gov/study/NCT01188798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01188798","kind":"trial","name":"Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies","route":"/trials/nct01188798/","field":"links","label":"ClinicalTrials.gov NCT01188798"}]},{"url":"https://clinicaltrials.gov/study/NCT01191060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","field":"links","label":"ClinicalTrials.gov NCT01191060"}]},{"url":"https://clinicaltrials.gov/study/NCT01193244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/","field":"links","label":"ClinicalTrials.gov NCT01193244"}]},{"url":"https://clinicaltrials.gov/study/NCT01200485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01200485","kind":"trial","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","route":"/trials/nct01200485/","field":"links","label":"ClinicalTrials.gov NCT01200485"}]},{"url":"https://clinicaltrials.gov/study/NCT01200485?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01200485","kind":"trial","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","route":"/trials/nct01200485/","field":"outcomes.source (Number of Participants (Incidence) of LTLS (Laboratory Tumor Lysis Syndrome))"}]},{"url":"https://clinicaltrials.gov/study/NCT01204125","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01204125","kind":"trial","name":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","route":"/trials/nct01204125/","field":"links","label":"ClinicalTrials.gov NCT01204125"}]},{"url":"https://clinicaltrials.gov/study/NCT01208662","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","field":"links","label":"ClinicalTrials.gov NCT01208662"}]},{"url":"https://clinicaltrials.gov/study/NCT01212991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/","field":"links","label":"ClinicalTrials.gov NCT01212991"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"links","label":"ClinicalTrials.gov NCT01212991"}]},{"url":"https://clinicaltrials.gov/study/NCT01216644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","field":"links","label":"ClinicalTrials.gov NCT01216644"}]},{"url":"https://clinicaltrials.gov/study/NCT01226394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prophylochip","kind":"trial","name":"PROPHYLOCHIP-PRODIGE 15","route":"/trials/prophylochip/","field":"links","label":"ClinicalTrials.gov NCT01226394"}]},{"url":"https://clinicaltrials.gov/study/NCT01234311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","route":"/trials/tasquinimod-10tasq10/","field":"links","label":"ClinicalTrials.gov NCT01234311"}]},{"url":"https://clinicaltrials.gov/study/NCT01243944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","field":"links","label":"ClinicalTrials.gov NCT01243944"}]},{"url":"https://clinicaltrials.gov/study/NCT01271712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/","field":"links","label":"ClinicalTrials.gov NCT01271712"}]},{"url":"https://clinicaltrials.gov/study/NCT01272037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","field":"links","label":"ClinicalTrials.gov NCT01272037"},{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","field":"links","label":"ClinicalTrials.gov NCT01272037: RxPONDER (SWOG S1007)"},{"id":"paper-rxponder-n-engl-j-med-2021","kind":"paper","name":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","route":"/key-papers/paper-rxponder-n-engl-j-med-2021/","field":"links","label":"ClinicalTrials.gov NCT01272037"}]},{"url":"https://clinicaltrials.gov/study/NCT01275677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/","field":"links","label":"ClinicalTrials.gov NCT01275677"}]},{"url":"https://clinicaltrials.gov/study/NCT01275677?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/","field":"outcomes.source (Percentage of Patients Alive and Free From Invasive Disease (IDFS))"},{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/","field":"outcomes.source (Percentage of Patients Alive (Overall Survival))"}]},{"url":"https://clinicaltrials.gov/study/NCT01276054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01276054","kind":"trial","name":"Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients","route":"/trials/nct01276054/","field":"links","label":"ClinicalTrials.gov NCT01276054"}]},{"url":"https://clinicaltrials.gov/study/NCT01292291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-ahmed-promis-multiparametric-mri-lancet-2017","kind":"paper","name":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","route":"/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/","field":"links","label":"ClinicalTrials.gov NCT01292291"}]},{"url":"https://clinicaltrials.gov/study/NCT01295827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-keynote-001-pembrolizumab-nsclc-nejm-2015","kind":"paper","name":"KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off","route":"/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01295827"}]},{"url":"https://clinicaltrials.gov/study/NCT01301963","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01301963","kind":"trial","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","route":"/trials/nct01301963/","field":"links","label":"ClinicalTrials.gov NCT01301963"}]},{"url":"https://clinicaltrials.gov/study/NCT01302834","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","field":"links","label":"ClinicalTrials.gov NCT01302834"}]},{"url":"https://clinicaltrials.gov/study/NCT01305655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01305655","kind":"trial","name":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","route":"/trials/nct01305655/","field":"links","label":"ClinicalTrials.gov NCT01305655"}]},{"url":"https://clinicaltrials.gov/study/NCT01305655?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01305655","kind":"trial","name":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","route":"/trials/nct01305655/","field":"outcomes.source (Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.)"}]},{"url":"https://clinicaltrials.gov/study/NCT01308567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/","field":"links","label":"ClinicalTrials.gov NCT01308567"}]},{"url":"https://clinicaltrials.gov/study/NCT01308580","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","field":"links","label":"ClinicalTrials.gov NCT01308580"}]},{"url":"https://clinicaltrials.gov/study/NCT01310803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01310803","kind":"trial","name":"Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder","route":"/trials/nct01310803/","field":"links","label":"ClinicalTrials.gov NCT01310803"}]},{"url":"https://clinicaltrials.gov/study/NCT01310894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","field":"links","label":"ClinicalTrials.gov NCT01310894"}]},{"url":"https://clinicaltrials.gov/study/NCT01321554","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"links","label":"ClinicalTrials.gov NCT01321554"},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","field":"links","label":"ClinicalTrials.gov NCT01321554: SELECT"}]},{"url":"https://clinicaltrials.gov/study/NCT01322490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prostvac","kind":"drug","name":"PROSTVAC","route":"/drugs/prostvac/","field":"links","label":"ClinicalTrials.gov NCT01322490"},{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/","field":"links","label":"ClinicalTrials.gov NCT01322490"}]},{"url":"https://clinicaltrials.gov/study/NCT01327053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","kind":"paper","name":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","route":"/key-papers/paper-bolt-j-eur-acad-dermatol-venereol-2018-update/","field":"links","label":"ClinicalTrials.gov NCT01327053"},{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/","field":"links","label":"ClinicalTrials.gov NCT01327053"}]},{"url":"https://clinicaltrials.gov/study/NCT01331239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01331239","kind":"trial","name":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","route":"/trials/nct01331239/","field":"links","label":"ClinicalTrials.gov NCT01331239"}]},{"url":"https://clinicaltrials.gov/study/NCT01331239?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01331239","kind":"trial","name":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","route":"/trials/nct01331239/","field":"outcomes.source (Percentage of Responders to LCI699 Based on the Change in Mean Urinary Free Cortisol (UFC) From Baseline to Week 10)"}]},{"url":"https://clinicaltrials.gov/study/NCT01332968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"links","label":"ClinicalTrials.gov NCT01332968"}]},{"url":"https://clinicaltrials.gov/study/NCT01332968?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","field":"outcomes.source (Patients with a progression-free survival event, follicular lymphoma (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT01336634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","field":"links","label":"ClinicalTrials.gov NCT01336634"}]},{"url":"https://clinicaltrials.gov/study/NCT01344018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"links","label":"ClinicalTrials.gov NCT01344018"}]},{"url":"https://clinicaltrials.gov/study/NCT01349881","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01349881","kind":"trial","name":"S0820, Adenoma and Second Primary Prevention Trial","route":"/trials/nct01349881/","field":"links","label":"ClinicalTrials.gov NCT01349881"}]},{"url":"https://clinicaltrials.gov/study/NCT01357772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tam-01","kind":"trial","name":"TAM-01","route":"/trials/tam-01/","field":"links","label":"ClinicalTrials.gov NCT01357772"}]},{"url":"https://clinicaltrials.gov/study/NCT01358877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","field":"links","label":"ClinicalTrials.gov NCT01358877"},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","field":"links","label":"ClinicalTrials.gov NCT01358877: APHINITY"},{"id":"paper-aphinity-j-clin-oncol-2024-update","kind":"paper","name":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update","route":"/key-papers/paper-aphinity-j-clin-oncol-2024-update/","field":"links","label":"ClinicalTrials.gov NCT01358877"}]},{"url":"https://clinicaltrials.gov/study/NCT01360554","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","route":"/trials/nct01360554/","field":"links","label":"ClinicalTrials.gov NCT01360554"}]},{"url":"https://clinicaltrials.gov/study/NCT01360554?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","route":"/trials/nct01360554/","field":"outcomes.source (Progression-Free Survival (PFS) Per Independent Radiologic Review.)"},{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","route":"/trials/nct01360554/","field":"outcomes.source (Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.)"},{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","route":"/trials/nct01360554/","field":"outcomes.source (Overall Survival (OS).)"}]},{"url":"https://clinicaltrials.gov/study/NCT01367665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"links","label":"ClinicalTrials.gov NCT01367665"}]},{"url":"https://clinicaltrials.gov/study/NCT01368276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01368276","kind":"trial","name":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma","route":"/trials/nct01368276/","field":"links","label":"ClinicalTrials.gov NCT01368276"}]},{"url":"https://clinicaltrials.gov/study/NCT01368276?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01368276","kind":"trial","name":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma","route":"/trials/nct01368276/","field":"outcomes.source (Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT01371201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"firstmappp","kind":"trial","name":"FIRSTMAPPP","route":"/trials/firstmappp/","field":"links","label":"ClinicalTrials.gov NCT01371201"}]},{"url":"https://clinicaltrials.gov/study/NCT01371981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"links","label":"ClinicalTrials.gov NCT01371981"}]},{"url":"https://clinicaltrials.gov/study/NCT01377220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01377220","kind":"trial","name":"Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma","route":"/trials/nct01377220/","field":"links","label":"ClinicalTrials.gov NCT01377220"}]},{"url":"https://clinicaltrials.gov/study/NCT01377753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01377753","kind":"trial","name":"MR Image Guided Therapy in Prostate Cancer","route":"/trials/nct01377753/","field":"links","label":"ClinicalTrials.gov NCT01377753"}]},{"url":"https://clinicaltrials.gov/study/NCT01387269","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","field":"links","label":"ClinicalTrials.gov NCT01387269"},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","field":"links","label":"ClinicalTrials.gov NCT01387269"}]},{"url":"https://clinicaltrials.gov/study/NCT01387282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","field":"links","label":"ClinicalTrials.gov NCT01387282"}]},{"url":"https://clinicaltrials.gov/study/NCT01387763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01387763","kind":"trial","name":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","route":"/trials/nct01387763/","field":"links","label":"ClinicalTrials.gov NCT01387763"}]},{"url":"https://clinicaltrials.gov/study/NCT01390948","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","field":"links","label":"ClinicalTrials.gov NCT01390948"}]},{"url":"https://clinicaltrials.gov/study/NCT01394263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01394263","kind":"trial","name":"Study of Histrelin Subdermal Implant in Patients With Prostate Cancer","route":"/trials/nct01394263/","field":"links","label":"ClinicalTrials.gov NCT01394263"}]},{"url":"https://clinicaltrials.gov/study/NCT01394679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01394679","kind":"trial","name":"A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer","route":"/trials/nct01394679/","field":"links","label":"ClinicalTrials.gov NCT01394679"}]},{"url":"https://clinicaltrials.gov/study/NCT01397747","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","field":"links","label":"ClinicalTrials.gov NCT01397747"},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","field":"links","label":"ClinicalTrials.gov NCT01397747"}]},{"url":"https://clinicaltrials.gov/study/NCT01398085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"links","label":"ClinicalTrials.gov NCT01398085"}]},{"url":"https://clinicaltrials.gov/study/NCT01414608","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","field":"links","label":"ClinicalTrials.gov NCT01414608"},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","field":"links","label":"ClinicalTrials.gov NCT01414608: OUTBACK / ANZGOG 0902 / GOG-0274"}]},{"url":"https://clinicaltrials.gov/study/NCT01415986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01415986","kind":"trial","name":"Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers","route":"/trials/nct01415986/","field":"links","label":"ClinicalTrials.gov NCT01415986"}]},{"url":"https://clinicaltrials.gov/study/NCT01423500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01423500","kind":"trial","name":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","route":"/trials/nct01423500/","field":"links","label":"ClinicalTrials.gov NCT01423500"}]},{"url":"https://clinicaltrials.gov/study/NCT01426880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/","field":"links","label":"ClinicalTrials.gov NCT01426880"},{"id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","field":"links","label":"ClinicalTrials.gov NCT01426880"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"links","label":"ClinicalTrials.gov NCT01426880"}]},{"url":"https://clinicaltrials.gov/study/NCT01432301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","field":"links","label":"ClinicalTrials.gov NCT01432301"},{"id":"paper-vistogard-cancer-2017","kind":"paper","name":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","route":"/key-papers/paper-vistogard-cancer-2017/","field":"links","label":"ClinicalTrials.gov NCT01432301"}]},{"url":"https://clinicaltrials.gov/study/NCT01435018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","field":"links","label":"ClinicalTrials.gov NCT01435018"}]},{"url":"https://clinicaltrials.gov/study/NCT01436968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT01436968"},{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","route":"/trials/nct01436968/","field":"links","label":"ClinicalTrials.gov NCT01436968"}]},{"url":"https://clinicaltrials.gov/study/NCT01446744","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sabr-comet-lancet-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","route":"/key-papers/paper-sabr-comet-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT01446744"},{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","field":"links","label":"ClinicalTrials.gov NCT01446744"}]},{"url":"https://clinicaltrials.gov/study/NCT01460589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01460589","kind":"trial","name":"Early Commencement of Adjuvant Chemotherapy for Colon Cancer","route":"/trials/nct01460589/","field":"links","label":"ClinicalTrials.gov NCT01460589"}]},{"url":"https://clinicaltrials.gov/study/NCT01476787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"links","label":"ClinicalTrials.gov NCT01476787"}]},{"url":"https://clinicaltrials.gov/study/NCT01476787?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","field":"outcomes.source (Progression-free survival, final (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT01480479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","field":"links","label":"ClinicalTrials.gov NCT01480479 (ACT IV)"},{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/","field":"links","label":"ClinicalTrials.gov NCT01480479"}],"archive":"https://web.archive.org/web/20260209031605/https://clinicaltrials.gov/study/NCT01480479"},{"url":"https://clinicaltrials.gov/study/NCT01482442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","field":"links","label":"ClinicalTrials.gov NCT01482442"}]},{"url":"https://clinicaltrials.gov/study/NCT01494506","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","kind":"paper","name":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","route":"/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/","field":"links","label":"ClinicalTrials.gov NCT01494506"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"links","label":"ClinicalTrials.gov NCT01494506"}]},{"url":"https://clinicaltrials.gov/study/NCT01497275","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/","field":"links","label":"ClinicalTrials.gov NCT01497275"}]},{"url":"https://clinicaltrials.gov/study/NCT01497275?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/","field":"outcomes.source (Response Rate (Complete Response + Partial Response))"},{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/","field":"outcomes.source (Overall Survival at 1 Year)"},{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/","field":"outcomes.source (Number of Participants With Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT01499303","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01499303","kind":"trial","name":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","route":"/trials/nct01499303/","field":"links","label":"ClinicalTrials.gov NCT01499303"}]},{"url":"https://clinicaltrials.gov/study/NCT01499303?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01499303","kind":"trial","name":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","route":"/trials/nct01499303/","field":"outcomes.source (Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT01500226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/","field":"links","label":"ClinicalTrials.gov NCT01500226"},{"id":"paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015","kind":"paper","name":"Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a randomised, active-controlled, double-blind, phase 3 trial","route":"/key-papers/paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015/","field":"links","label":"ClinicalTrials.gov NCT01500226"}]},{"url":"https://clinicaltrials.gov/study/NCT01502241","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"links","label":"ClinicalTrials.gov NCT01502241"}]},{"url":"https://clinicaltrials.gov/study/NCT01503502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01503502","kind":"trial","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","route":"/trials/nct01503502/","field":"links","label":"ClinicalTrials.gov NCT01503502"}]},{"url":"https://clinicaltrials.gov/study/NCT01515787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","field":"links","label":"ClinicalTrials.gov NCT01515787"}]},{"url":"https://clinicaltrials.gov/study/NCT01516580","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/","field":"links","label":"ClinicalTrials.gov NCT01516580"}]},{"url":"https://clinicaltrials.gov/study/NCT01517802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01517802","kind":"trial","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","route":"/trials/nct01517802/","field":"links","label":"ClinicalTrials.gov NCT01517802"}]},{"url":"https://clinicaltrials.gov/study/NCT01517802?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01517802","kind":"trial","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","route":"/trials/nct01517802/","field":"outcomes.source (Number of Participants With Serious Adverse Events (SAEs))"}]},{"url":"https://clinicaltrials.gov/study/NCT01526135","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","field":"links","label":"ClinicalTrials.gov NCT01526135"},{"id":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","kind":"paper","name":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT01526135"}],"archive":"https://web.archive.org/web/20260520080547/https://clinicaltrials.gov/study/NCT01526135"},{"url":"https://clinicaltrials.gov/study/NCT01558427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stomp-oligorecurrence","kind":"trial","name":"STOMP","route":"/trials/stomp-oligorecurrence/","field":"links","label":"ClinicalTrials.gov NCT01558427"}]},{"url":"https://clinicaltrials.gov/study/NCT01558921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","field":"links","label":"ClinicalTrials.gov NCT01558921"}]},{"url":"https://clinicaltrials.gov/study/NCT01564784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","field":"links","label":"ClinicalTrials.gov NCT01564784"},{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/","field":"links","label":"ClinicalTrials.gov NCT01564784"}]},{"url":"https://clinicaltrials.gov/study/NCT01566240","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","field":"links","label":"ClinicalTrials.gov NCT01566240"},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","field":"links","label":"ClinicalTrials.gov NCT01566240: INTERLACE"}]},{"url":"https://clinicaltrials.gov/study/NCT01578239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"links","label":"ClinicalTrials.gov NCT01578239"}]},{"url":"https://clinicaltrials.gov/study/NCT01578499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/","field":"links","label":"ClinicalTrials.gov NCT01578499"}]},{"url":"https://clinicaltrials.gov/study/NCT01578655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"links","label":"ClinicalTrials.gov NCT01578655"}]},{"url":"https://clinicaltrials.gov/study/NCT01578707","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","field":"links","label":"ClinicalTrials.gov NCT01578707"}]},{"url":"https://clinicaltrials.gov/study/NCT01584258","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT01584258"},{"id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","field":"links","label":"ClinicalTrials.gov NCT01584258"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"links","label":"ClinicalTrials.gov NCT01584258"}]},{"url":"https://clinicaltrials.gov/study/NCT01584648","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-combi-d-n-engl-j-med-2014","kind":"paper","name":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","route":"/key-papers/paper-combi-d-n-engl-j-med-2014/","field":"links","label":"ClinicalTrials.gov NCT01584648"},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"links","label":"ClinicalTrials.gov NCT01584648"}]},{"url":"https://clinicaltrials.gov/study/NCT01584830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"concur","kind":"trial","name":"CONCUR","route":"/trials/concur/","field":"links","label":"ClinicalTrials.gov NCT01584830"}]},{"url":"https://clinicaltrials.gov/study/NCT01590355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","field":"links","label":"ClinicalTrials.gov NCT01590355"}]},{"url":"https://clinicaltrials.gov/study/NCT01594723","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01594723","kind":"trial","name":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","route":"/trials/nct01594723/","field":"links","label":"ClinicalTrials.gov NCT01594723"}]},{"url":"https://clinicaltrials.gov/study/NCT01594879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01594879","kind":"trial","name":"Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer","route":"/trials/nct01594879/","field":"links","label":"ClinicalTrials.gov NCT01594879"}]},{"url":"https://clinicaltrials.gov/study/NCT01599559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"links","label":"ClinicalTrials.gov NCT01599559"}]},{"url":"https://clinicaltrials.gov/study/NCT01602666","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","field":"links","label":"ClinicalTrials.gov NCT01602666"}]},{"url":"https://clinicaltrials.gov/study/NCT01602666?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","field":"outcomes.source (Progression-free survival at 3 years, localised germinoma given reduced-dose radiotherapy (registry results))"},{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","field":"outcomes.source (Progression-free survival at 3 years, non-germinomatous stratum (registry results, all treated))"}]},{"url":"https://clinicaltrials.gov/study/NCT01605227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","field":"links","label":"ClinicalTrials.gov NCT01605227"}]},{"url":"https://clinicaltrials.gov/study/NCT01607957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","field":"links","label":"ClinicalTrials.gov NCT01607957"}]},{"url":"https://clinicaltrials.gov/study/NCT01617161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/","field":"links","label":"PARTIQoL (NCT01617161)"},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/","field":"links","label":"PARTIQoL (NCT01617161)"},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/","field":"links","label":"PARTIQoL (NCT01617161)"},{"id":"paper-partiqol-astro-2024","kind":"paper","name":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","route":"/key-papers/paper-partiqol-astro-2024/","field":"links","label":"ClinicalTrials.gov NCT01617161"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"links","label":"ClinicalTrials.gov NCT01617161"}]},{"url":"https://clinicaltrials.gov/study/NCT01624090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01624090","kind":"trial","name":"Mithramycin for Lung, Esophagus, and Other Chest Cancers","route":"/trials/nct01624090/","field":"links","label":"ClinicalTrials.gov NCT01624090"}]},{"url":"https://clinicaltrials.gov/study/NCT01626495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","field":"links","label":"ClinicalTrials.gov NCT01626495"}]},{"url":"https://clinicaltrials.gov/study/NCT01639508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01639508","kind":"trial","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","route":"/trials/nct01639508/","field":"links","label":"ClinicalTrials.gov NCT01639508"}]},{"url":"https://clinicaltrials.gov/study/NCT01641939","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/","field":"links","label":"ClinicalTrials.gov NCT01641939"}]},{"url":"https://clinicaltrials.gov/study/NCT01642004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-017","kind":"trial","name":"CheckMate 017","route":"/trials/checkmate-017/","field":"links","label":"ClinicalTrials.gov NCT01642004"},{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01642004"}]},{"url":"https://clinicaltrials.gov/study/NCT01645124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","field":"links","label":"ClinicalTrials.gov NCT01645124"}]},{"url":"https://clinicaltrials.gov/study/NCT01658930","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","field":"links","label":"ClinicalTrials.gov NCT01658930"}]},{"url":"https://clinicaltrials.gov/study/NCT01668784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","field":"links","label":"ClinicalTrials.gov NCT01668784"}]},{"url":"https://clinicaltrials.gov/study/NCT01673022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","field":"links","label":"ClinicalTrials.gov NCT01673022"}]},{"url":"https://clinicaltrials.gov/study/NCT01673867","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","field":"links","label":"ClinicalTrials.gov NCT01673867"},{"id":"paper-checkmate-057-nejm-2015","kind":"paper","name":"CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer","route":"/key-papers/paper-checkmate-057-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01673867"}]},{"url":"https://clinicaltrials.gov/study/NCT01682083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","field":"links","label":"ClinicalTrials.gov NCT01682083"},{"id":"paper-combi-ad-n-engl-j-med-2020-update","kind":"paper","name":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","route":"/key-papers/paper-combi-ad-n-engl-j-med-2020-update/","field":"links","label":"ClinicalTrials.gov NCT01682083"}]},{"url":"https://clinicaltrials.gov/study/NCT01682772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01682772"}]},{"url":"https://clinicaltrials.gov/study/NCT01686594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01686594","kind":"trial","name":"PUVA Maintenance Therapy in Mycosis Fungoides","route":"/trials/nct01686594/","field":"links","label":"ClinicalTrials.gov NCT01686594"}]},{"url":"https://clinicaltrials.gov/study/NCT01689519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-cobrim-n-engl-j-med-2014","kind":"paper","name":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","route":"/key-papers/paper-cobrim-n-engl-j-med-2014/","field":"links","label":"ClinicalTrials.gov NCT01689519"},{"id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","field":"links","label":"ClinicalTrials.gov NCT01689519"},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","field":"links","label":"ClinicalTrials.gov NCT01689519"}]},{"url":"https://clinicaltrials.gov/study/NCT01696084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","field":"links","label":"ClinicalTrials.gov NCT01696084"}]},{"url":"https://clinicaltrials.gov/study/NCT01697384","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01697384","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer","route":"/trials/nct01697384/","field":"links","label":"ClinicalTrials.gov NCT01697384"}]},{"url":"https://clinicaltrials.gov/study/NCT01700946","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/","field":"links","label":"ClinicalTrials.gov NCT01700946"}]},{"url":"https://clinicaltrials.gov/study/NCT01700946?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/","field":"outcomes.source (3-year Overall Survival Rate of Patients With Relapsed ALL)"},{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/","field":"outcomes.source (3-year Event-free Survival Rates in Patients With Relapsed ALL)"}]},{"url":"https://clinicaltrials.gov/study/NCT01704716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","field":"links","label":"ClinicalTrials.gov NCT01704716"},{"id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","field":"links","label":"ClinicalTrials.gov NCT01704716: SIOPEN HR-NBL1"}]},{"url":"https://clinicaltrials.gov/study/NCT01710176","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","field":"links","label":"ClinicalTrials.gov NCT01710176"}]},{"url":"https://clinicaltrials.gov/study/NCT01712490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","field":"links","label":"ClinicalTrials.gov NCT01712490"},{"id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","field":"links","label":"ClinicalTrials.gov NCT01712490: ECHELON-1"},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT01712490"}]},{"url":"https://clinicaltrials.gov/study/NCT01715285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","field":"links","label":"ClinicalTrials.gov NCT01715285"},{"id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","field":"links","label":"ClinicalTrials.gov NCT01715285"}],"archive":"https://web.archive.org/web/20260117002502/https://clinicaltrials.gov/study/NCT01715285"},{"url":"https://clinicaltrials.gov/study/NCT01722487","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","field":"links","label":"ClinicalTrials.gov NCT01722487"}]},{"url":"https://clinicaltrials.gov/study/NCT01728805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/","field":"links","label":"ClinicalTrials.gov NCT01728805"}]},{"url":"https://clinicaltrials.gov/study/NCT01740427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","field":"links","label":"ClinicalTrials.gov NCT01740427"},{"id":"paper-paloma-2-n-engl-j-med-2016","kind":"paper","name":"Palbociclib and Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-paloma-2-n-engl-j-med-2016/","field":"links","label":"ClinicalTrials.gov NCT01740427"},{"id":"paper-paloma-2-breast-cancer-res-treat-2019-update","kind":"paper","name":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","route":"/key-papers/paper-paloma-2-breast-cancer-res-treat-2019-update/","field":"links","label":"ClinicalTrials.gov NCT01740427"}],"archive":"https://web.archive.org/web/20251221191610/https://clinicaltrials.gov/study/NCT01740427"},{"url":"https://clinicaltrials.gov/study/NCT01744223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01744223","kind":"trial","name":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","route":"/trials/nct01744223/","field":"links","label":"ClinicalTrials.gov NCT01744223"}]},{"url":"https://clinicaltrials.gov/study/NCT01754350","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","field":"links","label":"ClinicalTrials.gov NCT01754350"}]},{"url":"https://clinicaltrials.gov/study/NCT01757535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quazar-aml-001","kind":"trial","name":"QUAZAR AML-001","route":"/trials/quazar-aml-001/","field":"links","label":"ClinicalTrials.gov NCT01757535"}]},{"url":"https://clinicaltrials.gov/study/NCT01757535?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quazar-aml-001","kind":"trial","name":"QUAZAR AML-001","route":"/trials/quazar-aml-001/","field":"outcomes.source (Relapse-free survival (registry, August 2024 cut-off))"}]},{"url":"https://clinicaltrials.gov/study/NCT01761266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","field":"links","label":"ClinicalTrials.gov NCT01761266"}]},{"url":"https://clinicaltrials.gov/study/NCT01761968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01761968","kind":"trial","name":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","route":"/trials/nct01761968/","field":"links","label":"ClinicalTrials.gov NCT01761968"}]},{"url":"https://clinicaltrials.gov/study/NCT01767194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","field":"links","label":"ClinicalTrials.gov NCT01767194"}]},{"url":"https://clinicaltrials.gov/study/NCT01767714","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01767714","kind":"trial","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","route":"/trials/nct01767714/","field":"links","label":"ClinicalTrials.gov NCT01767714"}]},{"url":"https://clinicaltrials.gov/study/NCT01772420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01772420","kind":"trial","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","route":"/trials/nct01772420/","field":"links","label":"ClinicalTrials.gov NCT01772420"}]},{"url":"https://clinicaltrials.gov/study/NCT01772420?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01772420","kind":"trial","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","route":"/trials/nct01772420/","field":"outcomes.source (Number of Patients Demonstrating Overall Hematologic Improvement (HI))"}]},{"url":"https://clinicaltrials.gov/study/NCT01772472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","field":"links","label":"ClinicalTrials.gov NCT01772472"},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT01772472"}]},{"url":"https://clinicaltrials.gov/study/NCT01774344","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","field":"links","label":"ClinicalTrials.gov NCT01774344"}]},{"url":"https://clinicaltrials.gov/study/NCT01774721","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"ClinicalTrials.gov NCT01774721"},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/","field":"links","label":"ClinicalTrials.gov NCT01774721"},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/","field":"links","label":"ClinicalTrials.gov NCT01774721"}]},{"url":"https://clinicaltrials.gov/study/NCT01774721?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"outcomes.source (Objective response rate (independent radiologic review))"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"outcomes.source (Duration of response (independent radiologic review))"}]},{"url":"https://clinicaltrials.gov/study/NCT01777152","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","field":"links","label":"ClinicalTrials.gov NCT01777152"}]},{"url":"https://clinicaltrials.gov/study/NCT01791829","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT01791829"},{"id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","field":"links","label":"ClinicalTrials.gov NCT01791829"}]},{"url":"https://clinicaltrials.gov/study/NCT01802814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intreall-sr-2010","kind":"trial","name":"IntReALL SR 2010","route":"/trials/intreall-sr-2010/","field":"links","label":"ClinicalTrials.gov NCT01802814"}]},{"url":"https://clinicaltrials.gov/study/NCT01804686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","field":"links","label":"ClinicalTrials.gov NCT01804686"}]},{"url":"https://clinicaltrials.gov/study/NCT01804790","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","field":"links","label":"ClinicalTrials.gov NCT01804790"}]},{"url":"https://clinicaltrials.gov/study/NCT01808573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT01808573"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","field":"links","label":"ClinicalTrials.gov NCT01808573"}]},{"url":"https://clinicaltrials.gov/study/NCT01824875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","field":"links","label":"ClinicalTrials.gov NCT01824875: ECOG-ACRIN E2211, temozolomide with or without capecitabine in advanced pancreatic neuroendocrine tumours (phase 2)"}]},{"url":"https://clinicaltrials.gov/study/NCT01827553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","field":"links","label":"ClinicalTrials.gov NCT01827553"}]},{"url":"https://clinicaltrials.gov/study/NCT01827605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01827605","kind":"trial","name":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","route":"/trials/nct01827605/","field":"links","label":"ClinicalTrials.gov NCT01827605"}]},{"url":"https://clinicaltrials.gov/study/NCT01828099","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"links","label":"ClinicalTrials.gov NCT01828099"},{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/","field":"links","label":"ClinicalTrials.gov NCT01828099"}]},{"url":"https://clinicaltrials.gov/study/NCT01828099?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"outcomes.source (Objective response rate (blinded independent review))"},{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"outcomes.source (Duration of response (blinded independent review))"}]},{"url":"https://clinicaltrials.gov/study/NCT01828112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01828112","kind":"trial","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","route":"/trials/nct01828112/","field":"links","label":"ClinicalTrials.gov NCT01828112"}]},{"url":"https://clinicaltrials.gov/study/NCT01828112?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01828112","kind":"trial","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","route":"/trials/nct01828112/","field":"outcomes.source (Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC))"},{"id":"nct01828112","kind":"trial","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","route":"/trials/nct01828112/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct01828112","kind":"trial","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","route":"/trials/nct01828112/","field":"outcomes.source (Overall Response Rate (ORR) Per BIRC)"}]},{"url":"https://clinicaltrials.gov/study/NCT01829711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01829711","kind":"trial","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","route":"/trials/nct01829711/","field":"links","label":"ClinicalTrials.gov NCT01829711"}]},{"url":"https://clinicaltrials.gov/study/NCT01829711?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01829711","kind":"trial","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","route":"/trials/nct01829711/","field":"outcomes.source (Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review)"},{"id":"nct01829711","kind":"trial","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","route":"/trials/nct01829711/","field":"outcomes.source (Percentage of Participants With Durable CR by Investigator's Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT01837745","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"ClinicalTrials.gov NCT01837745"}]},{"url":"https://clinicaltrials.gov/study/NCT01843062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"links","label":"ClinicalTrials.gov NCT01843062"},{"id":"redifferentiation-rai","kind":"pairing","name":"MAPK inhibitor redifferentiation → radioiodine","route":"/pairings/redifferentiation-rai/","field":"links","label":"ClinicalTrials.gov NCT01843062: ASTRA"}]},{"url":"https://clinicaltrials.gov/study/NCT01843374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01843374","kind":"trial","name":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","route":"/trials/nct01843374/","field":"links","label":"ClinicalTrials.gov NCT01843374"}]},{"url":"https://clinicaltrials.gov/study/NCT01844505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","field":"links","label":"ClinicalTrials.gov NCT01844505"},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT01844505"},{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/","field":"links","label":"ClinicalTrials.gov NCT01844505"}]},{"url":"https://clinicaltrials.gov/study/NCT01844986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"links","label":"ClinicalTrials.gov NCT01844986"},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","field":"links","label":"ClinicalTrials.gov NCT01844986: SOLO-1"},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT01844986"}]},{"url":"https://clinicaltrials.gov/study/NCT01853748","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atempt","kind":"trial","name":"ATEMPT","route":"/trials/atempt/","field":"links","label":"ClinicalTrials.gov NCT01853748"}]},{"url":"https://clinicaltrials.gov/study/NCT01853748?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atempt","kind":"trial","name":"ATEMPT","route":"/trials/atempt/","field":"outcomes.source (Disease-free survival at 3 years (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT01856296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","field":"links","label":"ClinicalTrials.gov NCT01856296"}]},{"url":"https://clinicaltrials.gov/study/NCT01864746","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-penelope-b-j-clin-oncol-2021","kind":"paper","name":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","route":"/key-papers/paper-penelope-b-j-clin-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT01864746"},{"id":"penelope-b","kind":"trial","name":"PENELOPE-B","route":"/trials/penelope-b/","field":"links","label":"ClinicalTrials.gov NCT01864746"}]},{"url":"https://clinicaltrials.gov/study/NCT01866319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","field":"links","label":"ClinicalTrials.gov NCT01866319"},{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01866319"}]},{"url":"https://clinicaltrials.gov/study/NCT01872260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","field":"links","label":"ClinicalTrials.gov NCT01872260"}]},{"url":"https://clinicaltrials.gov/study/NCT01872975","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsabp-b51","kind":"trial","name":"NSABP B-51 / RTOG 1304","route":"/trials/nsabp-b51/","field":"links","label":"ClinicalTrials.gov NCT01872975"}]},{"url":"https://clinicaltrials.gov/study/NCT01874171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","field":"links","label":"ClinicalTrials.gov NCT01874171"}]},{"url":"https://clinicaltrials.gov/study/NCT01874353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/","field":"links","label":"ClinicalTrials.gov NCT01874353"}]},{"url":"https://clinicaltrials.gov/study/NCT01874353?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/","field":"outcomes.source (Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1))"}]},{"url":"https://clinicaltrials.gov/study/NCT01875393","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01875393","kind":"trial","name":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","route":"/trials/nct01875393/","field":"links","label":"ClinicalTrials.gov NCT01875393"}]},{"url":"https://clinicaltrials.gov/study/NCT01876043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01876043","kind":"trial","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","route":"/trials/nct01876043/","field":"links","label":"ClinicalTrials.gov NCT01876043"}]},{"url":"https://clinicaltrials.gov/study/NCT01876043?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01876043","kind":"trial","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","route":"/trials/nct01876043/","field":"outcomes.source (1-year Overall Survival (OS) Rate)"},{"id":"nct01876043","kind":"trial","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","route":"/trials/nct01876043/","field":"outcomes.source (Progression-free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT01876511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","field":"links","label":"ClinicalTrials.gov NCT01876511"},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","field":"links","label":"ClinicalTrials.gov NCT01876511"}]},{"url":"https://clinicaltrials.gov/study/NCT01878617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/","field":"links","label":"ClinicalTrials.gov NCT01878617"}]},{"url":"https://clinicaltrials.gov/study/NCT01882868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/","field":"links","label":"ClinicalTrials.gov NCT01882868"}]},{"url":"https://clinicaltrials.gov/study/NCT01882868?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/","field":"outcomes.source (Percentage of Participants With Overall Response)"},{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT01883128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01883128","kind":"trial","name":"FOcal RECurrent Assessment and Salvage Treatment","route":"/trials/nct01883128/","field":"links","label":"ClinicalTrials.gov NCT01883128"}]},{"url":"https://clinicaltrials.gov/study/NCT01886105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01886105","kind":"trial","name":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","route":"/trials/nct01886105/","field":"links","label":"ClinicalTrials.gov NCT01886105"}]},{"url":"https://clinicaltrials.gov/study/NCT01886105?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01886105","kind":"trial","name":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","route":"/trials/nct01886105/","field":"outcomes.source (Percentage of Treated Participants With 6-month Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT01888601","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017","kind":"paper","name":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","route":"/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/","field":"links","label":"ClinicalTrials.gov NCT01888601"},{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","field":"links","label":"ClinicalTrials.gov NCT01888601"},{"id":"idea-bio1-multiregion-blocks-default","kind":"idea","name":"Bank three spatially separate tumour blocks from every resection","route":"/ideas/idea-bio1-multiregion-blocks-default/","field":"links","label":"TRACERx (NCT01888601)"},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT01888601"}]},{"url":"https://clinicaltrials.gov/study/NCT01890746","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01890746","kind":"trial","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","route":"/trials/nct01890746/","field":"links","label":"ClinicalTrials.gov NCT01890746"}]},{"url":"https://clinicaltrials.gov/study/NCT01890746?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01890746","kind":"trial","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","route":"/trials/nct01890746/","field":"outcomes.source (Number of Participants With Liver Events.)"},{"id":"nct01890746","kind":"trial","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","route":"/trials/nct01890746/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT01898494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ecog-e3311","kind":"trial","name":"ECOG-ACRIN E3311","route":"/trials/ecog-e3311/","field":"links","label":"ClinicalTrials.gov NCT01898494"}]},{"url":"https://clinicaltrials.gov/study/NCT01905657","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","field":"links","label":"ClinicalTrials.gov NCT01905657"},{"id":"paper-keynote-010-lancet-2016","kind":"paper","name":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","route":"/key-papers/paper-keynote-010-lancet-2016/","field":"links","label":"ClinicalTrials.gov NCT01905657"}]},{"url":"https://clinicaltrials.gov/study/NCT01906385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01906385","kind":"trial","name":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","route":"/trials/nct01906385/","field":"links","label":"ClinicalTrials.gov NCT01906385"}]},{"url":"https://clinicaltrials.gov/study/NCT01907100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lume-meso","kind":"trial","name":"LUME-Meso","route":"/trials/lume-meso/","field":"links","label":"ClinicalTrials.gov NCT01907100"}]},{"url":"https://clinicaltrials.gov/study/NCT01908426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","field":"links","label":"ClinicalTrials.gov NCT01908426"}]},{"url":"https://clinicaltrials.gov/study/NCT01909453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","field":"links","label":"ClinicalTrials.gov NCT01909453"},{"id":"braf-plus-mek","kind":"pairing","name":"BRAF inhibitor + MEK inhibitor","route":"/pairings/braf-plus-mek/","field":"links","label":"ClinicalTrials.gov NCT01909453: COLUMBUS"},{"id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","field":"links","label":"ClinicalTrials.gov NCT01909453"}]},{"url":"https://clinicaltrials.gov/study/NCT01926236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-abc-06-folfox-second-line-lancet-oncol-2021","kind":"paper","name":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","route":"/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT01926236"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"links","label":"ClinicalTrials.gov NCT01926236"}]},{"url":"https://clinicaltrials.gov/study/NCT01933932","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/","field":"links","label":"ClinicalTrials.gov NCT01933932"},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","field":"links","label":"ClinicalTrials.gov NCT01933932"}]},{"url":"https://clinicaltrials.gov/study/NCT01933932?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","field":"outcomes.source (Progression-Free Survival (PFS))"},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT01938001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/","field":"links","label":"ClinicalTrials.gov NCT01938001"}]},{"url":"https://clinicaltrials.gov/study/NCT01939665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"panfire-2","kind":"trial","name":"PANFIRE-2","route":"/trials/panfire-2/","field":"links","label":"ClinicalTrials.gov NCT01939665"}]},{"url":"https://clinicaltrials.gov/study/NCT01945775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-embraca-n-engl-j-med-2018","kind":"paper","name":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","route":"/key-papers/paper-embraca-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT01945775"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"links","label":"ClinicalTrials.gov NCT01945775"}]},{"url":"https://clinicaltrials.gov/study/NCT01946204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"links","label":"ClinicalTrials.gov NCT01946204"}]},{"url":"https://clinicaltrials.gov/study/NCT01949805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"links","label":"ClinicalTrials.gov NCT01949805"}]},{"url":"https://clinicaltrials.gov/study/NCT01952223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","field":"links","label":"ClinicalTrials.gov NCT01952223"}]},{"url":"https://clinicaltrials.gov/study/NCT01954992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01954992","kind":"trial","name":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","route":"/trials/nct01954992/","field":"links","label":"ClinicalTrials.gov NCT01954992"}]},{"url":"https://clinicaltrials.gov/study/NCT01957436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","field":"links","label":"ClinicalTrials.gov NCT01957436"},{"id":"paper-peace-1-lancet-2022","kind":"paper","name":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design","route":"/key-papers/paper-peace-1-lancet-2022/","field":"links","label":"ClinicalTrials.gov NCT01957436"}],"archive":"https://web.archive.org/web/20260420073855/https://clinicaltrials.gov/study/NCT01957436"},{"url":"https://clinicaltrials.gov/study/NCT01958021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","field":"links","label":"ClinicalTrials.gov NCT01958021"},{"id":"paper-monaleesa-2-n-engl-j-med-2016","kind":"paper","name":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2016/","field":"links","label":"ClinicalTrials.gov NCT01958021"},{"id":"paper-monaleesa-2-n-engl-j-med-2022-update","kind":"paper","name":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/","field":"links","label":"ClinicalTrials.gov NCT01958021"}],"archive":"https://web.archive.org/web/20260514223354/https://clinicaltrials.gov/study/NCT01958021"},{"url":"https://clinicaltrials.gov/study/NCT01964430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/","field":"links","label":"ClinicalTrials.gov NCT01964430"}]},{"url":"https://clinicaltrials.gov/study/NCT01975701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","route":"/trials/nct01975701/","field":"links","label":"ClinicalTrials.gov NCT01975701"}]},{"url":"https://clinicaltrials.gov/study/NCT01975701?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","route":"/trials/nct01975701/","field":"outcomes.source (Progression Free Survival)"},{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","route":"/trials/nct01975701/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT01985724","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01985724","kind":"trial","name":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","route":"/trials/nct01985724/","field":"links","label":"ClinicalTrials.gov NCT01985724"}]},{"url":"https://clinicaltrials.gov/study/NCT01986569","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01986569","kind":"trial","name":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer","route":"/trials/nct01986569/","field":"links","label":"ClinicalTrials.gov NCT01986569"}]},{"url":"https://clinicaltrials.gov/study/NCT01993810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct01993810","kind":"trial","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","route":"/trials/nct01993810/","field":"links","label":"ClinicalTrials.gov NCT01993810"}]},{"url":"https://clinicaltrials.gov/study/NCT01996267","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","field":"links","label":"ClinicalTrials.gov NCT01996267"}]},{"url":"https://clinicaltrials.gov/study/NCT02000089","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02000089","kind":"trial","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","route":"/trials/nct02000089/","field":"links","label":"ClinicalTrials.gov NCT02000089"}]},{"url":"https://clinicaltrials.gov/study/NCT02000622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-olympiad-ann-oncol-2019-update","kind":"paper","name":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","route":"/key-papers/paper-olympiad-ann-oncol-2019-update/","field":"links","label":"ClinicalTrials.gov NCT02000622"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"links","label":"ClinicalTrials.gov NCT02000622"}]},{"url":"https://clinicaltrials.gov/study/NCT02003209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02003209","kind":"trial","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","route":"/trials/nct02003209/","field":"links","label":"ClinicalTrials.gov NCT02003209"}]},{"url":"https://clinicaltrials.gov/study/NCT02003209?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02003209","kind":"trial","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","route":"/trials/nct02003209/","field":"outcomes.source (Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes)"}]},{"url":"https://clinicaltrials.gov/study/NCT02003222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","field":"links","label":"ClinicalTrials.gov NCT02003222"},{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","field":"links","label":"ClinicalTrials.gov NCT02003222: ECOG-ACRIN E1910"},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT02003222"}]},{"url":"https://clinicaltrials.gov/study/NCT02003924","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"links","label":"ClinicalTrials.gov NCT02003924"}]},{"url":"https://clinicaltrials.gov/study/NCT02004262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/","field":"links","label":"ClinicalTrials.gov NCT02004262"}]},{"url":"https://clinicaltrials.gov/study/NCT02005471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT02005471"},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","field":"links","label":"ClinicalTrials.gov NCT02005471"}]},{"url":"https://clinicaltrials.gov/study/NCT02008227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oak","kind":"trial","name":"OAK","route":"/trials/oak/","field":"links","label":"ClinicalTrials.gov NCT02008227"}]},{"url":"https://clinicaltrials.gov/study/NCT02008656","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-opra-j-clin-oncol-2024","kind":"paper","name":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","route":"/key-papers/paper-opra-j-clin-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT02008656"},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","field":"links","label":"ClinicalTrials.gov NCT02008656"}]},{"url":"https://clinicaltrials.gov/study/NCT02013167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","field":"links","label":"ClinicalTrials.gov NCT02013167"},{"id":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","kind":"paper","name":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","route":"/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/","field":"links","label":"ClinicalTrials.gov NCT02013167"}]},{"url":"https://clinicaltrials.gov/study/NCT02016781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmt-ctn-1102","kind":"trial","name":"BMT CTN 1102","route":"/trials/bmt-ctn-1102/","field":"links","label":"ClinicalTrials.gov NCT02016781"}]},{"url":"https://clinicaltrials.gov/study/NCT02017717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","field":"links","label":"ClinicalTrials.gov NCT02017717"},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","field":"links","label":"ClinicalTrials.gov NCT02017717: CheckMate 143"}],"archive":"https://web.archive.org/web/20260124022409/https://www.clinicaltrials.gov/study/NCT02017717"},{"url":"https://clinicaltrials.gov/study/NCT02022358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02022358","kind":"trial","name":"Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?","route":"/trials/nct02022358/","field":"links","label":"ClinicalTrials.gov NCT02022358"}]},{"url":"https://clinicaltrials.gov/study/NCT02024009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scalop-2","kind":"trial","name":"SCALOP-2","route":"/trials/scalop-2/","field":"links","label":"ClinicalTrials.gov NCT02024009"}]},{"url":"https://clinicaltrials.gov/study/NCT02029443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-acalabrutinib-cll-n-engl-j-med-2016","kind":"paper","name":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","route":"/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/","field":"links","label":"ClinicalTrials.gov NCT02029443"},{"id":"nct02029443","kind":"trial","name":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","route":"/trials/nct02029443/","field":"links","label":"ClinicalTrials.gov NCT02029443"}]},{"url":"https://clinicaltrials.gov/study/NCT02029443?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02029443","kind":"trial","name":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","route":"/trials/nct02029443/","field":"outcomes.source (Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT02032277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","kind":"paper","name":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","route":"/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT02032277"},{"id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","field":"links","label":"ClinicalTrials.gov NCT02032277"},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/","field":"links","label":"ClinicalTrials.gov NCT02032277"}]},{"url":"https://clinicaltrials.gov/study/NCT02032823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT02032823"},{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT02032823"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT02032823"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"links","label":"ClinicalTrials.gov NCT02032823"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"outcomes.source (Overall survival at 6 years)"},{"id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","field":"links","label":"ClinicalTrials.gov NCT02032823: OlympiA"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT02032823"}]},{"url":"https://clinicaltrials.gov/study/NCT02034110","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","field":"links","label":"ClinicalTrials.gov NCT02034110"},{"id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","field":"links","label":"ClinicalTrials.gov NCT02034110: ROAR (anaplastic thyroid cancer cohort)"},{"id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","field":"links","label":"ClinicalTrials.gov NCT02034110: ROAR (anaplastic thyroid cancer cohort)"},{"id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","field":"links","label":"ClinicalTrials.gov NCT02034110"},{"id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02034110"},{"id":"paper-roar-ann-oncol-2022-update","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","route":"/key-papers/paper-roar-ann-oncol-2022-update/","field":"links","label":"ClinicalTrials.gov NCT02034110"}]},{"url":"https://clinicaltrials.gov/study/NCT02038036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"response-2","kind":"trial","name":"RESPONSE-2","route":"/trials/response-2/","field":"links","label":"ClinicalTrials.gov NCT02038036"}]},{"url":"https://clinicaltrials.gov/study/NCT02040272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mars-2","kind":"trial","name":"MARS 2","route":"/trials/mars-2/","field":"links","label":"ClinicalTrials.gov NCT02040272"}]},{"url":"https://clinicaltrials.gov/study/NCT02041533","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-026","kind":"trial","name":"CheckMate 026","route":"/trials/checkmate-026/","field":"links","label":"ClinicalTrials.gov NCT02041533"}]},{"url":"https://clinicaltrials.gov/study/NCT02043678","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/","field":"links","label":"ClinicalTrials.gov NCT02043678"}]},{"url":"https://clinicaltrials.gov/study/NCT02044172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"links","label":"ClinicalTrials.gov NCT02044172"},{"id":"paper-protect-bju-int-2026-update","kind":"paper","name":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","route":"/key-papers/paper-protect-bju-int-2026-update/","field":"links","label":"ClinicalTrials.gov NCT02044172"}]},{"url":"https://clinicaltrials.gov/study/NCT02047513","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/","field":"links","label":"ClinicalTrials.gov NCT02047513"}]},{"url":"https://clinicaltrials.gov/study/NCT02049905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","field":"links","label":"Phase 3 trial NCT02049905 on ClinicalTrials.gov"},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/","field":"links","label":"ClinicalTrials.gov NCT02049905"},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02050321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02050321","kind":"trial","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","route":"/trials/nct02050321/","field":"links","label":"ClinicalTrials.gov NCT02050321"}]},{"url":"https://clinicaltrials.gov/study/NCT02051868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"links","label":"ClinicalTrials.gov NCT02051868"}]},{"url":"https://clinicaltrials.gov/study/NCT02052778","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","field":"links","label":"ClinicalTrials.gov NCT02052778"},{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","field":"links","label":"ClinicalTrials.gov NCT02052778: FOENIX-CCA2"}]},{"url":"https://clinicaltrials.gov/study/NCT02054741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-gap70-geriatric-assessment-lancet-2021","kind":"paper","name":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth","route":"/key-papers/paper-gap70-geriatric-assessment-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT02054741"}]},{"url":"https://clinicaltrials.gov/study/NCT02060188","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","field":"links","label":"ClinicalTrials.gov NCT02060188"}]},{"url":"https://clinicaltrials.gov/study/NCT02072811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02072811","kind":"trial","name":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","route":"/trials/nct02072811/","field":"links","label":"ClinicalTrials.gov NCT02072811"}]},{"url":"https://clinicaltrials.gov/study/NCT02075840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT02075840"},{"id":"paper-alex-ann-oncol-2020-update","kind":"paper","name":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","route":"/key-papers/paper-alex-ann-oncol-2020-update/","field":"links","label":"ClinicalTrials.gov NCT02075840"},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","field":"links","label":"ClinicalTrials.gov NCT02075840"}]},{"url":"https://clinicaltrials.gov/study/NCT02090114","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","kind":"paper","name":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/","field":"links","label":"ClinicalTrials.gov NCT02090114"}]},{"url":"https://clinicaltrials.gov/study/NCT02091141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-javle-mypathway-her2-biliary-lancet-oncol-2021","kind":"paper","name":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02091141"},{"id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02091141"},{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"links","label":"ClinicalTrials.gov NCT02091141"}]},{"url":"https://clinicaltrials.gov/study/NCT02094573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","field":"links","label":"ClinicalTrials.gov NCT02094573"},{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/","field":"links","label":"ClinicalTrials.gov NCT02094573"}]},{"url":"https://clinicaltrials.gov/study/NCT02101385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020","kind":"paper","name":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","route":"/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02101385"},{"id":"bre12-158","kind":"trial","name":"BRE12-158 (Hoosier Oncology Group)","route":"/trials/bre12-158/","field":"links","label":"ClinicalTrials.gov NCT02101385"}]},{"url":"https://clinicaltrials.gov/study/NCT02101853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","field":"links","label":"ClinicalTrials.gov NCT02101853"}]},{"url":"https://clinicaltrials.gov/study/NCT02105636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","field":"links","label":"ClinicalTrials.gov NCT02105636"}]},{"url":"https://clinicaltrials.gov/study/NCT02107703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02107703-j-clin-oncol-2017","kind":"paper","name":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","route":"/key-papers/paper-nct02107703-j-clin-oncol-2017/","field":"links","label":"ClinicalTrials.gov NCT02107703"},{"id":"paper-nct02107703-jama-oncol-2020-update","kind":"paper","name":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","route":"/key-papers/paper-nct02107703-jama-oncol-2020-update/","field":"links","label":"ClinicalTrials.gov NCT02107703"},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","field":"links","label":"ClinicalTrials.gov NCT02107703"}]},{"url":"https://clinicaltrials.gov/study/NCT02107703?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","field":"outcomes.source (Progression-Free Survival (PFS))"},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","field":"outcomes.source (Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]))"}]},{"url":"https://clinicaltrials.gov/study/NCT02112916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"links","label":"ClinicalTrials.gov NCT02112916"}]},{"url":"https://clinicaltrials.gov/study/NCT02112916?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","field":"outcomes.source (Event-free survival at 3 years, all randomised patients (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT02125136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/","field":"links","label":"ClinicalTrials.gov NCT02125136"}]},{"url":"https://clinicaltrials.gov/study/NCT02125461","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","field":"links","label":"ClinicalTrials.gov NCT02125461"},{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/","field":"links","label":"ClinicalTrials.gov NCT02125461"},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT02125461"},{"id":"paper-pacific-n-engl-j-med-2018-update","kind":"paper","name":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","route":"/key-papers/paper-pacific-n-engl-j-med-2018-update/","field":"links","label":"ClinicalTrials.gov NCT02125461"}],"archive":"https://web.archive.org/web/20260517190229/https://clinicaltrials.gov/study/NCT02125461"},{"url":"https://clinicaltrials.gov/study/NCT02131064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","field":"links","label":"ClinicalTrials.gov NCT02131064"},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/","field":"links","label":"ClinicalTrials.gov NCT02131064"}]},{"url":"https://clinicaltrials.gov/study/NCT02132390","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02132390","kind":"trial","name":"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea","route":"/trials/nct02132390/","field":"links","label":"ClinicalTrials.gov NCT02132390"}]},{"url":"https://clinicaltrials.gov/study/NCT02135419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anchor","kind":"trial","name":"ANCHOR","route":"/trials/anchor/","field":"links","label":"ClinicalTrials.gov NCT02135419"}]},{"url":"https://clinicaltrials.gov/study/NCT02138734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02138734","kind":"trial","name":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","route":"/trials/nct02138734/","field":"links","label":"ClinicalTrials.gov NCT02138734"}]},{"url":"https://clinicaltrials.gov/study/NCT02142738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","field":"links","label":"ClinicalTrials.gov NCT02142738"},{"id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","field":"links","label":"ClinicalTrials.gov NCT02142738: KEYNOTE-024 & KEYNOTE-189"},{"id":"paper-keynote-024-nejm-2016","kind":"paper","name":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","route":"/key-papers/paper-keynote-024-nejm-2016/","field":"links","label":"ClinicalTrials.gov NCT02142738"},{"id":"paper-keynote-024-189-j-clin-oncol-2021-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50","route":"/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/","field":"links","label":"ClinicalTrials.gov NCT02142738"}],"archive":"https://web.archive.org/web/20260508120001/https://clinicaltrials.gov/study/NCT02142738"},{"url":"https://clinicaltrials.gov/study/NCT02144077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02144077","kind":"trial","name":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy","route":"/trials/nct02144077/","field":"links","label":"ClinicalTrials.gov NCT02144077"}]},{"url":"https://clinicaltrials.gov/study/NCT02144077?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02144077","kind":"trial","name":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy","route":"/trials/nct02144077/","field":"outcomes.source (Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT)"}]},{"url":"https://clinicaltrials.gov/study/NCT02151084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02151084","kind":"trial","name":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","route":"/trials/nct02151084/","field":"links","label":"ClinicalTrials.gov NCT02151084"}]},{"url":"https://clinicaltrials.gov/study/NCT02151981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"links","label":"ClinicalTrials.gov NCT02151981"}]},{"url":"https://clinicaltrials.gov/study/NCT02152631","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02152631-front-oncol-2020","kind":"paper","name":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER","route":"/key-papers/paper-nct02152631-front-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02152631"},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","field":"links","label":"ClinicalTrials.gov NCT02152631"}]},{"url":"https://clinicaltrials.gov/study/NCT02152631?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","field":"outcomes.source (Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]))"}]},{"url":"https://clinicaltrials.gov/study/NCT02154490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02154490"},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"links","label":"ClinicalTrials.gov NCT02154490"}]},{"url":"https://clinicaltrials.gov/study/NCT02154490?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"outcomes.source (Screen Success Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT02155647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","field":"links","label":"ClinicalTrials.gov NCT02155647"},{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/","field":"links","label":"ClinicalTrials.gov NCT02155647"},{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","field":"links","label":"ClinicalTrials.gov NCT02155647"}]},{"url":"https://clinicaltrials.gov/study/NCT02159066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/","field":"links","label":"ClinicalTrials.gov NCT02159066"}]},{"url":"https://clinicaltrials.gov/study/NCT02159066?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/","field":"outcomes.source (Overall Response Rate (ORR): Part II)"},{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/","field":"outcomes.source (Overall Survival (OS): Part II)"},{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/","field":"outcomes.source (Progression-Free Survival (PFS): Part I)"}]},{"url":"https://clinicaltrials.gov/study/NCT02162563","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/","field":"links","label":"ClinicalTrials.gov NCT02162563"}]},{"url":"https://clinicaltrials.gov/study/NCT02162719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lotus","kind":"trial","name":"LOTUS","route":"/trials/lotus/","field":"links","label":"ClinicalTrials.gov NCT02162719"}]},{"url":"https://clinicaltrials.gov/study/NCT02163694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","field":"links","label":"ClinicalTrials.gov NCT02163694"}]},{"url":"https://clinicaltrials.gov/study/NCT02164916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/","field":"links","label":"ClinicalTrials.gov NCT02164916"}]},{"url":"https://clinicaltrials.gov/study/NCT02166463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/","field":"links","label":"ClinicalTrials.gov NCT02166463"}]},{"url":"https://clinicaltrials.gov/study/NCT02167490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sound","kind":"trial","name":"SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound)","route":"/trials/sound/","field":"links","label":"ClinicalTrials.gov NCT02167490"}]},{"url":"https://clinicaltrials.gov/study/NCT02170090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acticca-1","kind":"trial","name":"ACTICCA-1","route":"/trials/acticca-1/","field":"links","label":"ClinicalTrials.gov NCT02170090"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT02170090"}]},{"url":"https://clinicaltrials.gov/study/NCT02174549","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","route":"/trials/nct02174549/","field":"links","label":"ClinicalTrials.gov NCT02174549"}]},{"url":"https://clinicaltrials.gov/study/NCT02175212","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"links","label":"ClinicalTrials.gov NCT02175212"}]},{"url":"https://clinicaltrials.gov/study/NCT02180711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","route":"/trials/nct02180711/","field":"links","label":"ClinicalTrials.gov NCT02180711"}]},{"url":"https://clinicaltrials.gov/study/NCT02180711?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","route":"/trials/nct02180711/","field":"outcomes.source (Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).)"}]},{"url":"https://clinicaltrials.gov/study/NCT02180724","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","route":"/trials/nct02180724/","field":"links","label":"ClinicalTrials.gov NCT02180724"}]},{"url":"https://clinicaltrials.gov/study/NCT02180724?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","route":"/trials/nct02180724/","field":"outcomes.source (Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria, ORR 6th IWWM criteria (CR+VGPR+PR+MR))"},{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","route":"/trials/nct02180724/","field":"outcomes.source (Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria, ORR 3rd IWWM criteria (CR+VGPR+PR+MR))"}]},{"url":"https://clinicaltrials.gov/study/NCT02181738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","field":"links","label":"ClinicalTrials.gov NCT02181738"},{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","field":"links","label":"ClinicalTrials.gov NCT02181738: CheckMate 205"},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","field":"links","label":"ClinicalTrials.gov NCT02181738"}]},{"url":"https://clinicaltrials.gov/study/NCT02184195","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","field":"links","label":"ClinicalTrials.gov NCT02184195"}]},{"url":"https://clinicaltrials.gov/study/NCT02185443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02185443","kind":"trial","name":"Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases","route":"/trials/nct02185443/","field":"links","label":"ClinicalTrials.gov NCT02185443"}]},{"url":"https://clinicaltrials.gov/study/NCT02193282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","field":"links","label":"ClinicalTrials.gov NCT02193282: A081105, adjuvant erlotinib"}]},{"url":"https://clinicaltrials.gov/study/NCT02194738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-alchemist-jama-oncol-2022","kind":"paper","name":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","route":"/key-papers/paper-alchemist-jama-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT02194738"},{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","field":"links","label":"ClinicalTrials.gov NCT02194738"}]},{"url":"https://clinicaltrials.gov/study/NCT02194842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"links","label":"ClinicalTrials.gov NCT02194842"}]},{"url":"https://clinicaltrials.gov/study/NCT02196181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-intermittent-dosing-to-delay-resistance","kind":"idea","name":"Test intermittent dosing of targeted drugs to delay resistance, with honest priors","route":"/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/","field":"links","label":"SWOG S1320 (intermittent vs continuous dabrafenib and trametinib) on ClinicalTrials.gov"}]},{"url":"https://clinicaltrials.gov/study/NCT02196961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"links","label":"ClinicalTrials.gov NCT02196961"}]},{"url":"https://clinicaltrials.gov/study/NCT02200614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","field":"links","label":"ClinicalTrials.gov NCT02200614"}]},{"url":"https://clinicaltrials.gov/study/NCT02201992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","field":"links","label":"ClinicalTrials.gov NCT02201992: E4512, adjuvant crizotinib"}]},{"url":"https://clinicaltrials.gov/study/NCT02205762","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02205762","kind":"trial","name":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","route":"/trials/nct02205762/","field":"links","label":"ClinicalTrials.gov NCT02205762"}]},{"url":"https://clinicaltrials.gov/study/NCT02213926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02213926","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","route":"/trials/nct02213926/","field":"links","label":"ClinicalTrials.gov NCT02213926"}]},{"url":"https://clinicaltrials.gov/study/NCT02213991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02213991","kind":"trial","name":"Intraoperative Radiotherapy for Korean Patients With Breast Cancer","route":"/trials/nct02213991/","field":"links","label":"ClinicalTrials.gov NCT02213991"}]},{"url":"https://clinicaltrials.gov/study/NCT02215265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pathos","kind":"trial","name":"PATHOS","route":"/trials/pathos/","field":"links","label":"ClinicalTrials.gov NCT02215265"}]},{"url":"https://clinicaltrials.gov/study/NCT02215889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02215889","kind":"trial","name":"Partial Liver Segment 2/3 Transplantation Study","route":"/trials/nct02215889/","field":"links","label":"ClinicalTrials.gov NCT02215889"}]},{"url":"https://clinicaltrials.gov/study/NCT02218047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"links","label":"ClinicalTrials.gov NCT02218047"}]},{"url":"https://clinicaltrials.gov/study/NCT02219529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02219529","kind":"trial","name":"Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases","route":"/trials/nct02219529/","field":"links","label":"ClinicalTrials.gov NCT02219529"}]},{"url":"https://clinicaltrials.gov/study/NCT02220894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-lancet-2019","kind":"paper","name":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","route":"/key-papers/paper-keynote-042-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT02220894"},{"id":"paper-keynote-042-j-clin-oncol-2023-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study","route":"/key-papers/paper-keynote-042-j-clin-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02220894"},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","field":"links","label":"ClinicalTrials.gov NCT02220894"}]},{"url":"https://clinicaltrials.gov/study/NCT02224781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","field":"links","label":"ClinicalTrials.gov NCT02224781"},{"id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","field":"links","label":"ClinicalTrials.gov NCT02224781: DREAMseq (ECOG-ACRIN EA6134)"}]},{"url":"https://clinicaltrials.gov/study/NCT02227251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02227251","kind":"trial","name":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","route":"/trials/nct02227251/","field":"links","label":"ClinicalTrials.gov NCT02227251"}]},{"url":"https://clinicaltrials.gov/study/NCT02231086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"colopec","kind":"trial","name":"COLOPEC","route":"/trials/colopec/","field":"links","label":"ClinicalTrials.gov NCT02231086"}]},{"url":"https://clinicaltrials.gov/study/NCT02231749","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","field":"links","label":"ClinicalTrials.gov NCT02231749"},{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/","field":"links","label":"ClinicalTrials.gov NCT02231749: CheckMate 214"}]},{"url":"https://clinicaltrials.gov/study/NCT02240472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"senomac","kind":"trial","name":"SENOMAC","route":"/trials/senomac/","field":"links","label":"ClinicalTrials.gov NCT02240472"}]},{"url":"https://clinicaltrials.gov/study/NCT02242929","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scin-trial","kind":"trial","name":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma)","route":"/trials/scin-trial/","field":"links","label":"ClinicalTrials.gov NCT02242929"}]},{"url":"https://clinicaltrials.gov/study/NCT02242942","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","field":"links","label":"ClinicalTrials.gov NCT02242942"},{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","field":"links","label":"ClinicalTrials.gov NCT02242942: CLL14"},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT02242942"}]},{"url":"https://clinicaltrials.gov/study/NCT02243605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","field":"links","label":"ClinicalTrials.gov NCT02243605"}]},{"url":"https://clinicaltrials.gov/study/NCT02246621","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","field":"links","label":"ClinicalTrials.gov NCT02246621"}],"archive":"https://web.archive.org/web/20260416211113/https://clinicaltrials.gov/study/NCT02246621"},{"url":"https://clinicaltrials.gov/study/NCT02252172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT02252172"},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","field":"links","label":"ClinicalTrials.gov NCT02252172"}]},{"url":"https://clinicaltrials.gov/study/NCT02257736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02257736"},{"id":"nct02257736","kind":"trial","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/nct02257736/","field":"links","label":"ClinicalTrials.gov NCT02257736"}]},{"url":"https://clinicaltrials.gov/study/NCT02257736?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02257736","kind":"trial","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/nct02257736/","field":"outcomes.source (Radiographic Progression-free Survival (rPFS))"},{"id":"nct02257736","kind":"trial","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/nct02257736/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02260817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02260817","kind":"trial","name":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","route":"/trials/nct02260817/","field":"links","label":"ClinicalTrials.gov NCT02260817"}]},{"url":"https://clinicaltrials.gov/study/NCT02260817?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02260817","kind":"trial","name":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","route":"/trials/nct02260817/","field":"outcomes.source (Sensitivity of 11C Choline PET Imaging Scans)"}]},{"url":"https://clinicaltrials.gov/study/NCT02263508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02263508","kind":"trial","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","route":"/trials/nct02263508/","field":"links","label":"ClinicalTrials.gov NCT02263508"}]},{"url":"https://clinicaltrials.gov/study/NCT02263508?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02263508","kind":"trial","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","route":"/trials/nct02263508/","field":"outcomes.source (Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1)"},{"id":"nct02263508","kind":"trial","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","route":"/trials/nct02263508/","field":"outcomes.source (Phase 1b: Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT02267343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","field":"links","label":"ClinicalTrials.gov NCT02267343"}]},{"url":"https://clinicaltrials.gov/study/NCT02267603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/","field":"links","label":"ClinicalTrials.gov NCT02267603"},{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/","field":"links","label":"ClinicalTrials.gov NCT02267603"},{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","field":"links","label":"ClinicalTrials.gov NCT02267603"}]},{"url":"https://clinicaltrials.gov/study/NCT02268695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/","field":"links","label":"ClinicalTrials.gov NCT02268695"}]},{"url":"https://clinicaltrials.gov/study/NCT02269982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ar-v7-splice-variant","kind":"biomarker","name":"AR-V7 splice variant","route":"/biomarkers/ar-v7-splice-variant/","field":"links","label":"PROPHECY (NCT02269982)"}]},{"url":"https://clinicaltrials.gov/study/NCT02278887","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT02278887"}]},{"url":"https://clinicaltrials.gov/study/NCT02286921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","kind":"paper","name":"TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer","route":"/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/","field":"links","label":"ClinicalTrials.gov NCT02286921"}]},{"url":"https://clinicaltrials.gov/study/NCT02295033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","field":"links","label":"ClinicalTrials.gov NCT02295033"}]},{"url":"https://clinicaltrials.gov/study/NCT02296125","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT02296125"},{"id":"paper-osimertinib-nsclc-n-engl-j-med-2020","kind":"paper","name":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/","field":"links","label":"ClinicalTrials.gov NCT02296125"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"links","label":"ClinicalTrials.gov NCT02296125"}]},{"url":"https://clinicaltrials.gov/study/NCT02301039","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","field":"links","label":"ClinicalTrials.gov NCT02301039"}]},{"url":"https://clinicaltrials.gov/study/NCT02301286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02301286","kind":"trial","name":"A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients","route":"/trials/nct02301286/","field":"links","label":"ClinicalTrials.gov NCT02301286"}]},{"url":"https://clinicaltrials.gov/study/NCT02304367","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"links","label":"ClinicalTrials.gov NCT02304367"},{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/","field":"links","label":"ClinicalTrials.gov NCT02304367"}]},{"url":"https://clinicaltrials.gov/study/NCT02305654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"links","label":"InPACT (NCT02305654)"},{"id":"inpact","kind":"trial","name":"InPACT","route":"/trials/inpact/","field":"links","label":"ClinicalTrials.gov NCT02305654"}]},{"url":"https://clinicaltrials.gov/study/NCT02306096","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scan-b","kind":"trial","name":"SCAN-B (Sweden Cancerome Analysis Network - Breast)","route":"/trials/scan-b/","field":"links","label":"ClinicalTrials.gov NCT02306096"}]},{"url":"https://clinicaltrials.gov/study/NCT02314169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"links","label":"ClinicalTrials.gov NCT02314169"}]},{"url":"https://clinicaltrials.gov/study/NCT02314819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","field":"links","label":"ClinicalTrials.gov NCT02314819"}]},{"url":"https://clinicaltrials.gov/study/NCT02319837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","field":"links","label":"ClinicalTrials.gov NCT02319837"}],"archive":"https://web.archive.org/web/20260611201231/https://clinicaltrials.gov/study/NCT02319837"},{"url":"https://clinicaltrials.gov/study/NCT02320058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-n-engl-j-med-2018","kind":"paper","name":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","route":"/key-papers/paper-checkmate-204-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02320058"},{"id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","field":"links","label":"ClinicalTrials.gov NCT02320058"},{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","field":"links","label":"ClinicalTrials.gov NCT02320058"}]},{"url":"https://clinicaltrials.gov/study/NCT02320435","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02320435","kind":"trial","name":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","route":"/trials/nct02320435/","field":"links","label":"ClinicalTrials.gov NCT02320435"}]},{"url":"https://clinicaltrials.gov/study/NCT02332668","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02332668"},{"id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","route":"/trials/nct02332668/","field":"links","label":"ClinicalTrials.gov NCT02332668"}]},{"url":"https://clinicaltrials.gov/study/NCT02336230","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"links","label":"ClinicalTrials.gov NCT02336230"},{"id":"paper-msb-gvhd001-bbmt-2020","kind":"paper","name":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","route":"/key-papers/paper-msb-gvhd001-bbmt-2020/","field":"links","label":"ClinicalTrials.gov NCT02336230"}]},{"url":"https://clinicaltrials.gov/study/NCT02338050","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02338050","kind":"trial","name":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","route":"/trials/nct02338050/","field":"links","label":"ClinicalTrials.gov NCT02338050"}]},{"url":"https://clinicaltrials.gov/study/NCT02339116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tribe2","kind":"trial","name":"TRIBE2","route":"/trials/tribe2/","field":"links","label":"ClinicalTrials.gov NCT02339116"}]},{"url":"https://clinicaltrials.gov/study/NCT02340117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02340117","kind":"trial","name":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct02340117/","field":"links","label":"ClinicalTrials.gov NCT02340117"}]},{"url":"https://clinicaltrials.gov/study/NCT02343042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/","field":"links","label":"ClinicalTrials.gov NCT02343042"}]},{"url":"https://clinicaltrials.gov/study/NCT02346747","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","field":"links","label":"ClinicalTrials.gov NCT02346747"}]},{"url":"https://clinicaltrials.gov/study/NCT02348216","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/","field":"links","label":"ClinicalTrials.gov NCT02348216"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","field":"links","label":"ClinicalTrials.gov NCT02348216"}]},{"url":"https://clinicaltrials.gov/study/NCT02352337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/","field":"links","label":"ClinicalTrials.gov NCT02352337"}]},{"url":"https://clinicaltrials.gov/study/NCT02358031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","field":"links","label":"ClinicalTrials.gov NCT02358031"},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT02358031"}]},{"url":"https://clinicaltrials.gov/study/NCT02360215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","field":"links","label":"ClinicalTrials.gov NCT02360215"}]},{"url":"https://clinicaltrials.gov/study/NCT02360579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","field":"links","label":"ClinicalTrials.gov NCT02360579"},{"id":"io-then-til","kind":"pairing","name":"PD-1 failure → TIL therapy","route":"/pairings/io-then-til/","field":"links","label":"ClinicalTrials.gov NCT02360579: C-144-01"},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/","field":"links","label":"ClinicalTrials.gov NCT02360579"}]},{"url":"https://clinicaltrials.gov/study/NCT02362594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","field":"links","label":"ClinicalTrials.gov NCT02362594"},{"id":"nct02362594","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","route":"/trials/nct02362594/","field":"links","label":"ClinicalTrials.gov NCT02362594"}]},{"url":"https://clinicaltrials.gov/study/NCT02362594?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02362594","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","route":"/trials/nct02362594/","field":"outcomes.source (Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants)"},{"id":"nct02362594","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","route":"/trials/nct02362594/","field":"outcomes.source (Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression)"}]},{"url":"https://clinicaltrials.gov/study/NCT02363374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cao-aro-aio-12","kind":"trial","name":"CAO/ARO/AIO-12","route":"/trials/cao-aro-aio-12/","field":"links","label":"ClinicalTrials.gov NCT02363374"}]},{"url":"https://clinicaltrials.gov/study/NCT02365597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","field":"links","label":"ClinicalTrials.gov NCT02365597"}]},{"url":"https://clinicaltrials.gov/study/NCT02365597?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","field":"outcomes.source (Main Study: Percentage of Participants With Best (Overall) Objective Response)"},{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","field":"outcomes.source (Main Study: Overall Survival)"},{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","field":"outcomes.source (Main Study: Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02366143","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impower150","kind":"trial","name":"IMpower150","route":"/trials/impower150/","field":"links","label":"ClinicalTrials.gov NCT02366143"}]},{"url":"https://clinicaltrials.gov/study/NCT02366884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"ClinicalTrials.gov NCT02366884"},{"id":"nct02366884","kind":"trial","name":"Atavistic chemotherapy: combinations of antibacterial, antifungal and antiprotozoal drugs in advanced cancer (Arguello clinic, status unknown)","route":"/trials/nct02366884/","field":"links","label":"ClinicalTrials.gov NCT02366884"}]},{"url":"https://clinicaltrials.gov/study/NCT02371369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enliven","kind":"trial","name":"ENLIVEN","route":"/trials/enliven/","field":"links","label":"ClinicalTrials.gov NCT02371369"}]},{"url":"https://clinicaltrials.gov/study/NCT02375204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tiger-trial","kind":"trial","name":"TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours","route":"/trials/tiger-trial/","field":"links","label":"ClinicalTrials.gov NCT02375204"}]},{"url":"https://clinicaltrials.gov/study/NCT02379845","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"act-in-sarc","kind":"trial","name":"Act.In.Sarc","route":"/trials/act-in-sarc/","field":"links","label":"ClinicalTrials.gov NCT02379845"},{"id":"paper-act-in-sarc-lancet-oncol-2019","kind":"paper","name":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","route":"/key-papers/paper-act-in-sarc-lancet-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02379845"}]},{"url":"https://clinicaltrials.gov/study/NCT02380027","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/","field":"links","label":"ClinicalTrials.gov NCT02380027"}],"archive":"https://web.archive.org/web/20260615015327/https://clinicaltrials.gov/study/NCT02380027"},{"url":"https://clinicaltrials.gov/study/NCT02388906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","field":"links","label":"ClinicalTrials.gov NCT02388906"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","field":"links","label":"ClinicalTrials.gov NCT02388906"}]},{"url":"https://clinicaltrials.gov/study/NCT02388919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-alter-0303-jama-oncol-2018","kind":"paper","name":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-alter-0303-jama-oncol-2018/","field":"links","label":"ClinicalTrials.gov NCT02388919"},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","field":"links","label":"ClinicalTrials.gov NCT02388919"}]},{"url":"https://clinicaltrials.gov/study/NCT02389244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/","field":"links","label":"ClinicalTrials.gov NCT02389244"}]},{"url":"https://clinicaltrials.gov/study/NCT02392637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gap-phase2-mdacc","kind":"trial","name":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)","route":"/trials/gap-phase2-mdacc/","field":"links","label":"ClinicalTrials.gov NCT02392637"},{"id":"paper-gap-phase2-mdacc-jama-oncol-2019","kind":"paper","name":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","route":"/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02392637"}]},{"url":"https://clinicaltrials.gov/study/NCT02394795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","field":"links","label":"ClinicalTrials.gov NCT02394795"},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","field":"links","label":"ClinicalTrials.gov NCT02394795: PARADIGM"},{"id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","field":"links","label":"ClinicalTrials.gov NCT02394795: PARADIGM"},{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/","field":"links","label":"ClinicalTrials.gov NCT02394795"}]},{"url":"https://clinicaltrials.gov/study/NCT02395016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","field":"links","label":"ClinicalTrials.gov NCT02395016"}]},{"url":"https://clinicaltrials.gov/study/NCT02395666","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","field":"links","label":"ClinicalTrials.gov NCT02395666"}]},{"url":"https://clinicaltrials.gov/study/NCT02397928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","field":"links","label":"ClinicalTrials.gov NCT02397928"}]},{"url":"https://clinicaltrials.gov/study/NCT02398773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02398773","kind":"trial","name":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","route":"/trials/nct02398773/","field":"links","label":"ClinicalTrials.gov NCT02398773"}]},{"url":"https://clinicaltrials.gov/study/NCT02399085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","field":"links","label":"ClinicalTrials.gov NCT02399085"}]},{"url":"https://clinicaltrials.gov/study/NCT02401685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"posnoc","kind":"trial","name":"POSNOC","route":"/trials/posnoc/","field":"links","label":"ClinicalTrials.gov NCT02401685"}]},{"url":"https://clinicaltrials.gov/study/NCT02409342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02409342"},{"id":"impower110","kind":"trial","name":"IMpower110","route":"/trials/impower110/","field":"links","label":"ClinicalTrials.gov NCT02409342"}]},{"url":"https://clinicaltrials.gov/study/NCT02411448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02411448"},{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/","field":"links","label":"ClinicalTrials.gov NCT02411448"},{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/","field":"links","label":"ClinicalTrials.gov NCT02411448"}]},{"url":"https://clinicaltrials.gov/study/NCT02411448?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/","field":"outcomes.source (Part B: Progression Free Survival (PFS))"},{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/","field":"outcomes.source (Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]))"}]},{"url":"https://clinicaltrials.gov/study/NCT02414139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-wolf-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02414139"},{"id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","field":"links","label":"ClinicalTrials.gov NCT02414139"},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/","field":"links","label":"ClinicalTrials.gov NCT02414139"}]},{"url":"https://clinicaltrials.gov/study/NCT02414165","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02414165"}]},{"url":"https://clinicaltrials.gov/study/NCT02421939","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","field":"links","label":"ClinicalTrials.gov NCT02421939"},{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT02421939"}]},{"url":"https://clinicaltrials.gov/study/NCT02423603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"links","label":"ClinicalTrials.gov NCT02423603"}]},{"url":"https://clinicaltrials.gov/study/NCT02425891","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/","field":"links","label":"ClinicalTrials.gov NCT02425891"},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"links","label":"ClinicalTrials.gov NCT02425891"},{"id":"paper-impassion130-n-engl-j-med-2018","kind":"paper","name":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-impassion130-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02425891"},{"id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","field":"links","label":"ClinicalTrials.gov NCT02425891"}]},{"url":"https://clinicaltrials.gov/study/NCT02435433","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","field":"links","label":"ClinicalTrials.gov NCT02435433"}]},{"url":"https://clinicaltrials.gov/study/NCT02435849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"links","label":"ClinicalTrials.gov NCT02435849"},{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT02435849"}]},{"url":"https://clinicaltrials.gov/study/NCT02436668","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/","field":"links","label":"ClinicalTrials.gov NCT02436668"}]},{"url":"https://clinicaltrials.gov/study/NCT02437318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","field":"links","label":"ClinicalTrials.gov NCT02437318"},{"id":"paper-solar-1-ann-oncol-2021-update","kind":"paper","name":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","route":"/key-papers/paper-solar-1-ann-oncol-2021-update/","field":"links","label":"ClinicalTrials.gov NCT02437318"}],"archive":"https://web.archive.org/web/20260610182735/https://clinicaltrials.gov/study/NCT02437318"},{"url":"https://clinicaltrials.gov/study/NCT02438007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galeterone","kind":"drug","name":"Galeterone","route":"/drugs/galeterone/","field":"links","label":"ClinicalTrials.gov NCT02438007"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"links","label":"ClinicalTrials.gov NCT02438007"}]},{"url":"https://clinicaltrials.gov/study/NCT02441309","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02441309","kind":"trial","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","route":"/trials/nct02441309/","field":"links","label":"ClinicalTrials.gov NCT02441309"}]},{"url":"https://clinicaltrials.gov/study/NCT02441309?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02441309","kind":"trial","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","route":"/trials/nct02441309/","field":"outcomes.source (Disease Specific Overall Survival)"},{"id":"nct02441309","kind":"trial","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","route":"/trials/nct02441309/","field":"outcomes.source (Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02444819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02444819","kind":"trial","name":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","route":"/trials/nct02444819/","field":"links","label":"ClinicalTrials.gov NCT02444819"}]},{"url":"https://clinicaltrials.gov/study/NCT02445248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT02445248"}]},{"url":"https://clinicaltrials.gov/study/NCT02445391","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","field":"links","label":"ClinicalTrials.gov NCT02445391"}]},{"url":"https://clinicaltrials.gov/study/NCT02445391?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","field":"outcomes.source (3-year Invasive Disease-Free Survival (IDFS) Rate in Basal-Subtype Patients)"},{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","field":"outcomes.source (3-year Overall Survival (OS) Rate in Basal-Subtype Patients)"}]},{"url":"https://clinicaltrials.gov/study/NCT02446405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-enzamet-n-engl-j-med-2019","kind":"paper","name":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","route":"/key-papers/paper-enzamet-n-engl-j-med-2019/","field":"links","label":"ClinicalTrials.gov NCT02446405"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"links","label":"ClinicalTrials.gov NCT02446405"}]},{"url":"https://clinicaltrials.gov/study/NCT02448173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02448173","kind":"trial","name":"A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","route":"/trials/nct02448173/","field":"links","label":"ClinicalTrials.gov NCT02448173"}]},{"url":"https://clinicaltrials.gov/study/NCT02448381","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02448381","kind":"trial","name":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","route":"/trials/nct02448381/","field":"links","label":"ClinicalTrials.gov NCT02448381"}]},{"url":"https://clinicaltrials.gov/study/NCT02448381?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02448381","kind":"trial","name":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","route":"/trials/nct02448381/","field":"outcomes.source (Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo, Responder)"}]},{"url":"https://clinicaltrials.gov/study/NCT02448992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02448992","kind":"trial","name":"Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer","route":"/trials/nct02448992/","field":"links","label":"ClinicalTrials.gov NCT02448992"}]},{"url":"https://clinicaltrials.gov/study/NCT02451943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"announce","kind":"trial","name":"ANNOUNCE","route":"/trials/announce/","field":"links","label":"ClinicalTrials.gov NCT02451943"}]},{"url":"https://clinicaltrials.gov/study/NCT02453282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02453282-jama-oncol-2020","kind":"paper","name":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct02453282-jama-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02453282"},{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","field":"links","label":"ClinicalTrials.gov NCT02453282"}]},{"url":"https://clinicaltrials.gov/study/NCT02453282?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","field":"outcomes.source (Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy)"},{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","field":"outcomes.source (Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy)"},{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","field":"outcomes.source (Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population)"}]},{"url":"https://clinicaltrials.gov/study/NCT02454972","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","field":"links","label":"ClinicalTrials.gov NCT02454972"}]},{"url":"https://clinicaltrials.gov/study/NCT02455141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/","field":"links","label":"ClinicalTrials.gov NCT02455141"}]},{"url":"https://clinicaltrials.gov/study/NCT02465060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"ClinicalTrials.gov NCT02465060"}]},{"url":"https://clinicaltrials.gov/study/NCT02466737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"links","label":"ClinicalTrials.gov NCT02466737"}]},{"url":"https://clinicaltrials.gov/study/NCT02468024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02468024","kind":"trial","name":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","route":"/trials/nct02468024/","field":"links","label":"ClinicalTrials.gov NCT02468024"}]},{"url":"https://clinicaltrials.gov/study/NCT02475097","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","field":"links","label":"ClinicalTrials.gov NCT02475097"}]},{"url":"https://clinicaltrials.gov/study/NCT02475681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT02475681"}]},{"url":"https://clinicaltrials.gov/study/NCT02477644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","field":"links","label":"ClinicalTrials.gov NCT02477644"},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","field":"links","label":"ClinicalTrials.gov NCT02477644: PAOLA-1 / ENGOT-ov25"},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/","field":"links","label":"ClinicalTrials.gov NCT02477644"}]},{"url":"https://clinicaltrials.gov/study/NCT02477696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02477696","kind":"trial","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct02477696/","field":"links","label":"ClinicalTrials.gov NCT02477696"}]},{"url":"https://clinicaltrials.gov/study/NCT02477696?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02477696","kind":"trial","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct02477696/","field":"outcomes.source (Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT02477826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-n-engl-j-med-2018","kind":"paper","name":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","route":"/key-papers/paper-checkmate-227-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02477826"},{"id":"paper-checkmate-227-int-j-clin-oncol-2023-update","kind":"paper","name":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","route":"/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02477826"},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","field":"links","label":"ClinicalTrials.gov NCT02477826"}]},{"url":"https://clinicaltrials.gov/study/NCT02485652","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02485652","kind":"trial","name":"Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung","route":"/trials/nct02485652/","field":"links","label":"ClinicalTrials.gov NCT02485652"}]},{"url":"https://clinicaltrials.gov/study/NCT02485691","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"links","label":"ClinicalTrials.gov NCT02485691"}]},{"url":"https://clinicaltrials.gov/study/NCT02486718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT02486718"},{"id":"paper-nct02486718-ann-oncol-2023-update","kind":"paper","name":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","route":"/key-papers/paper-nct02486718-ann-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02486718"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"links","label":"ClinicalTrials.gov NCT02486718"}]},{"url":"https://clinicaltrials.gov/study/NCT02486718?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"outcomes.source (Disease-free survival, stage II to IIIA with PD-L1 on 1% or more of tumour cells)"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"outcomes.source (Disease-free survival, all randomised stage II to IIIA)"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"outcomes.source (Disease-free survival, intention-to-treat population (stage IB to IIIA))"}]},{"url":"https://clinicaltrials.gov/study/NCT02488759","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-checkmate-358-j-clin-oncol-2019","kind":"paper","name":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","route":"/key-papers/paper-checkmate-358-j-clin-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02488759"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","field":"links","label":"ClinicalTrials.gov NCT02488759"}]},{"url":"https://clinicaltrials.gov/study/NCT02488967","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02488967","kind":"trial","name":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","route":"/trials/nct02488967/","field":"links","label":"ClinicalTrials.gov NCT02488967"}]},{"url":"https://clinicaltrials.gov/study/NCT02489318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02489318-n-engl-j-med-2019","kind":"paper","name":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","route":"/key-papers/paper-nct02489318-n-engl-j-med-2019/","field":"links","label":"ClinicalTrials.gov NCT02489318"},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"links","label":"ClinicalTrials.gov NCT02489318"}]},{"url":"https://clinicaltrials.gov/study/NCT02492607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"LORD trial (NCT02492607)"}]},{"url":"https://clinicaltrials.gov/study/NCT02492711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02492711","kind":"trial","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","route":"/trials/nct02492711/","field":"links","label":"ClinicalTrials.gov NCT02492711"}]},{"url":"https://clinicaltrials.gov/study/NCT02492711?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02492711","kind":"trial","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","route":"/trials/nct02492711/","field":"outcomes.source (Progression-free Survival (PFS) as Determined by Independent Radiological Review.)"},{"id":"nct02492711","kind":"trial","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","route":"/trials/nct02492711/","field":"outcomes.source (Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).)"}]},{"url":"https://clinicaltrials.gov/study/NCT02494570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ampect","kind":"trial","name":"AMPECT","route":"/trials/ampect/","field":"links","label":"ClinicalTrials.gov NCT02494570"}]},{"url":"https://clinicaltrials.gov/study/NCT02494583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","field":"links","label":"ClinicalTrials.gov NCT02494583"}]},{"url":"https://clinicaltrials.gov/study/NCT02497820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02497820","kind":"trial","name":"Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers","route":"/trials/nct02497820/","field":"links","label":"ClinicalTrials.gov NCT02497820"}]},{"url":"https://clinicaltrials.gov/study/NCT02502370","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"links","label":"BALLAD trial (NCT02502370)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"links","label":"BALLAD (NCT02502370)"},{"id":"ballad","kind":"trial","name":"BALLAD","route":"/trials/ballad/","field":"links","label":"ClinicalTrials.gov NCT02502370"}]},{"url":"https://clinicaltrials.gov/study/NCT02503423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02503423","kind":"trial","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","route":"/trials/nct02503423/","field":"links","label":"ClinicalTrials.gov NCT02503423"}]},{"url":"https://clinicaltrials.gov/study/NCT02504372","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-091","kind":"trial","name":"KEYNOTE-091 (PEARLS)","route":"/trials/keynote-091/","field":"links","label":"ClinicalTrials.gov NCT02504372"}]},{"url":"https://clinicaltrials.gov/study/NCT02505750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02505750","kind":"trial","name":"Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma","route":"/trials/nct02505750/","field":"links","label":"ClinicalTrials.gov NCT02505750"}]},{"url":"https://clinicaltrials.gov/study/NCT02506959","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02506959","kind":"trial","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","route":"/trials/nct02506959/","field":"links","label":"ClinicalTrials.gov NCT02506959"}]},{"url":"https://clinicaltrials.gov/study/NCT02506959?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02506959","kind":"trial","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","route":"/trials/nct02506959/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct02506959","kind":"trial","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","route":"/trials/nct02506959/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02508532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","field":"links","label":"ClinicalTrials.gov NCT02508532"}]},{"url":"https://clinicaltrials.gov/study/NCT02509286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","field":"links","label":"ClinicalTrials.gov NCT02509286"}]},{"url":"https://clinicaltrials.gov/study/NCT02511106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"links","label":"ClinicalTrials.gov NCT02511106"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02511106"},{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/","field":"links","label":"ClinicalTrials.gov NCT02511106"}]},{"url":"https://clinicaltrials.gov/study/NCT02513394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","field":"links","label":"ClinicalTrials.gov NCT02513394"},{"id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02513394"}]},{"url":"https://clinicaltrials.gov/study/NCT02516241","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","field":"links","label":"ClinicalTrials.gov NCT02516241"}]},{"url":"https://clinicaltrials.gov/study/NCT02516241?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","field":"outcomes.source (To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set)"},{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","field":"outcomes.source (To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set)"},{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","field":"outcomes.source (PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC)"},{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","field":"outcomes.source (Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC)"}]},{"url":"https://clinicaltrials.gov/study/NCT02519348","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02519348","kind":"trial","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct02519348/","field":"links","label":"ClinicalTrials.gov NCT02519348"}]},{"url":"https://clinicaltrials.gov/study/NCT02519348?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02519348","kind":"trial","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct02519348/","field":"outcomes.source (Number of Participants With Dose Limiting Toxicities (DLTs))"},{"id":"nct02519348","kind":"trial","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct02519348/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02521493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02521493","kind":"trial","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","route":"/trials/nct02521493/","field":"links","label":"ClinicalTrials.gov NCT02521493"}]},{"url":"https://clinicaltrials.gov/study/NCT02521493?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02521493","kind":"trial","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","route":"/trials/nct02521493/","field":"outcomes.source (Event-free Survival (EFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02523014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","field":"links","label":"ClinicalTrials.gov NCT02523014"},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","field":"links","label":"ClinicalTrials.gov NCT02523014"},{"id":"paper-a071401-brastianos-jco-2023","kind":"paper","name":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","route":"/key-papers/paper-a071401-brastianos-jco-2023/","field":"links","label":"ClinicalTrials.gov NCT02523014"}]},{"url":"https://clinicaltrials.gov/study/NCT02531516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","field":"links","label":"ClinicalTrials.gov NCT02531516"}]},{"url":"https://clinicaltrials.gov/study/NCT02531841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/","field":"links","label":"ClinicalTrials.gov NCT02531841"}]},{"url":"https://clinicaltrials.gov/study/NCT02533271","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stellar-rectal","kind":"trial","name":"STELLAR (rectal cancer)","route":"/trials/stellar-rectal/","field":"links","label":"ClinicalTrials.gov NCT02533271"}]},{"url":"https://clinicaltrials.gov/study/NCT02534675","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","field":"links","label":"ClinicalTrials.gov NCT02534675"}]},{"url":"https://clinicaltrials.gov/study/NCT02541383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","field":"links","label":"ClinicalTrials.gov NCT02541383"}]},{"url":"https://clinicaltrials.gov/study/NCT02542293","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","route":"/trials/nct02542293/","field":"links","label":"ClinicalTrials.gov NCT02542293"}]},{"url":"https://clinicaltrials.gov/study/NCT02542293?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","route":"/trials/nct02542293/","field":"outcomes.source (Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set)"},{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","route":"/trials/nct02542293/","field":"outcomes.source (OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set)"}]},{"url":"https://clinicaltrials.gov/study/NCT02555657","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","field":"links","label":"ClinicalTrials.gov NCT02555657"}]},{"url":"https://clinicaltrials.gov/study/NCT02560298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","field":"links","label":"ClinicalTrials.gov NCT02560298"}]},{"url":"https://clinicaltrials.gov/study/NCT02561988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"links","label":"ClinicalTrials.gov NCT02561988"}]},{"url":"https://clinicaltrials.gov/study/NCT02562716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/","field":"links","label":"ClinicalTrials.gov NCT02562716"}]},{"url":"https://clinicaltrials.gov/study/NCT02563002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","field":"links","label":"ClinicalTrials.gov NCT02563002"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02563002"},{"id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","field":"links","label":"ClinicalTrials.gov NCT02563002"}]},{"url":"https://clinicaltrials.gov/study/NCT02566993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/","field":"links","label":"ClinicalTrials.gov NCT02566993"},{"id":"paper-atlantis-lancet-respir-med-2023","kind":"paper","name":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-atlantis-lancet-respir-med-2023/","field":"links","label":"ClinicalTrials.gov NCT02566993"}]},{"url":"https://clinicaltrials.gov/study/NCT02568267","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","field":"links","label":"ClinicalTrials.gov NCT02568267"}]},{"url":"https://clinicaltrials.gov/study/NCT02572141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02572141","kind":"trial","name":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","route":"/trials/nct02572141/","field":"links","label":"ClinicalTrials.gov NCT02572141"}]},{"url":"https://clinicaltrials.gov/study/NCT02573324","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/","field":"links","label":"ClinicalTrials.gov NCT02573324"}]},{"url":"https://clinicaltrials.gov/study/NCT02573324?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/","field":"outcomes.source (Overall survival (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT02574455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"links","label":"ClinicalTrials.gov NCT02574455"},{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT02574455"}]},{"url":"https://clinicaltrials.gov/study/NCT02576431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","field":"links","label":"ClinicalTrials.gov NCT02576431"},{"id":"paper-navigate-j-clin-invest-2021","kind":"paper","name":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","route":"/key-papers/paper-navigate-j-clin-invest-2021/","field":"links","label":"ClinicalTrials.gov NCT02576431"}]},{"url":"https://clinicaltrials.gov/study/NCT02576990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"links","label":"ClinicalTrials.gov NCT02576990"}]},{"url":"https://clinicaltrials.gov/study/NCT02578680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","field":"links","label":"ClinicalTrials.gov NCT02578680"},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/","field":"links","label":"ClinicalTrials.gov NCT02578680"}],"archive":"https://web.archive.org/web/20260616213031/https://clinicaltrials.gov/study/NCT02578680"},{"url":"https://clinicaltrials.gov/study/NCT02579564","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02579564","kind":"trial","name":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","route":"/trials/nct02579564/","field":"links","label":"ClinicalTrials.gov NCT02579564"}]},{"url":"https://clinicaltrials.gov/study/NCT02584244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02584244","kind":"trial","name":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","route":"/trials/nct02584244/","field":"links","label":"ClinicalTrials.gov NCT02584244"}]},{"url":"https://clinicaltrials.gov/study/NCT02586857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02586857","kind":"trial","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","route":"/trials/nct02586857/","field":"links","label":"ClinicalTrials.gov NCT02586857"}]},{"url":"https://clinicaltrials.gov/study/NCT02586857?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02586857","kind":"trial","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","route":"/trials/nct02586857/","field":"outcomes.source (Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.)"}]},{"url":"https://clinicaltrials.gov/study/NCT02588170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","field":"links","label":"ClinicalTrials.gov NCT02588170"}]},{"url":"https://clinicaltrials.gov/study/NCT02595944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","field":"links","label":"ClinicalTrials.gov NCT02595944: ANVIL (EA5142), adjuvant nivolumab"}]},{"url":"https://clinicaltrials.gov/study/NCT02598349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02598349","kind":"trial","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","route":"/trials/nct02598349/","field":"links","label":"ClinicalTrials.gov NCT02598349"}]},{"url":"https://clinicaltrials.gov/study/NCT02598661","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT02598661"},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","field":"links","label":"ClinicalTrials.gov NCT02598661"}]},{"url":"https://clinicaltrials.gov/study/NCT02598960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/","field":"links","label":"ClinicalTrials.gov NCT02598960"}]},{"url":"https://clinicaltrials.gov/study/NCT02599649","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kir2dl1","kind":"target","name":"KIR2DL1 (inhibitory KIR)","route":"/targets/kir2dl1/","field":"links","label":"ClinicalTrials.gov NCT02599649"}]},{"url":"https://clinicaltrials.gov/study/NCT02601313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02601313"},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","field":"links","label":"ClinicalTrials.gov NCT02601313"}]},{"url":"https://clinicaltrials.gov/study/NCT02603341","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/","field":"links","label":"RADCOMP (NCT02603341)"},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/","field":"links","label":"RADCOMP (NCT02603341)"},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/","field":"links","label":"RADCOMP (NCT02603341)"},{"id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/","field":"links","label":"ClinicalTrials.gov NCT02603341"}]},{"url":"https://clinicaltrials.gov/study/NCT02603432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/","field":"links","label":"ClinicalTrials.gov NCT02603432"}]},{"url":"https://clinicaltrials.gov/study/NCT02609776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/","field":"links","label":"ClinicalTrials.gov NCT02609776"},{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","field":"links","label":"ClinicalTrials.gov NCT02609776"}]},{"url":"https://clinicaltrials.gov/study/NCT02610140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/","field":"links","label":"ClinicalTrials.gov NCT02610140"}]},{"url":"https://clinicaltrials.gov/study/NCT02611882","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"links","label":"ClinicalTrials.gov NCT02611882"}]},{"url":"https://clinicaltrials.gov/study/NCT02614794","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","field":"links","label":"ClinicalTrials.gov NCT02614794"},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","field":"links","label":"ClinicalTrials.gov NCT02614794: HER2CLIMB"},{"id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","field":"links","label":"ClinicalTrials.gov NCT02614794: HER2CLIMB"},{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","field":"links","label":"ClinicalTrials.gov NCT02614794: HER2CLIMB"}]},{"url":"https://clinicaltrials.gov/study/NCT02617589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/","field":"links","label":"ClinicalTrials.gov NCT02617589"},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","field":"links","label":"ClinicalTrials.gov NCT02617589: CheckMate 498"}],"archive":"https://web.archive.org/web/20260418203310/https://clinicaltrials.gov/study/NCT02617589"},{"url":"https://clinicaltrials.gov/study/NCT02620280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neotrip","kind":"trial","name":"NeoTRIP (NeoTRIPaPDL1)","route":"/trials/neotrip/","field":"links","label":"ClinicalTrials.gov NCT02620280"}]},{"url":"https://clinicaltrials.gov/study/NCT02620852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-wisdom-trial-jama-2026","kind":"paper","name":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","route":"/key-papers/paper-wisdom-trial-jama-2026/","field":"links","label":"ClinicalTrials.gov NCT02620852"},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/","field":"links","label":"ClinicalTrials.gov NCT02620852"},{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/","field":"links","label":"ClinicalTrials.gov NCT02620852"}]},{"url":"https://clinicaltrials.gov/study/NCT02625961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/","field":"links","label":"ClinicalTrials.gov NCT02625961"}]},{"url":"https://clinicaltrials.gov/study/NCT02628067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","field":"links","label":"ClinicalTrials.gov NCT02628067"},{"id":"paper-keynote-158-j-clin-oncol-2019","kind":"paper","name":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","route":"/key-papers/paper-keynote-158-j-clin-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02628067"},{"id":"paper-keynote-158-ann-oncol-2022-update","kind":"paper","name":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","route":"/key-papers/paper-keynote-158-ann-oncol-2022-update/","field":"links","label":"ClinicalTrials.gov NCT02628067"}]},{"url":"https://clinicaltrials.gov/study/NCT02628665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02628665","kind":"trial","name":"Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer","route":"/trials/nct02628665/","field":"links","label":"ClinicalTrials.gov NCT02628665"}]},{"url":"https://clinicaltrials.gov/study/NCT02631070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","field":"links","label":"ClinicalTrials.gov NCT02631070"}]},{"url":"https://clinicaltrials.gov/study/NCT02632305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02632305","kind":"trial","name":"A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","route":"/trials/nct02632305/","field":"links","label":"ClinicalTrials.gov NCT02632305"}]},{"url":"https://clinicaltrials.gov/study/NCT02632409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","field":"links","label":"ClinicalTrials.gov NCT02632409"}]},{"url":"https://clinicaltrials.gov/study/NCT02637687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02637687","kind":"trial","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","route":"/trials/nct02637687/","field":"links","label":"ClinicalTrials.gov NCT02637687"}]},{"url":"https://clinicaltrials.gov/study/NCT02641847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02641847","kind":"trial","name":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","route":"/trials/nct02641847/","field":"links","label":"ClinicalTrials.gov NCT02641847"}]},{"url":"https://clinicaltrials.gov/study/NCT02645981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","field":"links","label":"ClinicalTrials.gov NCT02645981"}]},{"url":"https://clinicaltrials.gov/study/NCT02647099","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT02647099"},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","field":"links","label":"ClinicalTrials.gov NCT02647099"}]},{"url":"https://clinicaltrials.gov/study/NCT02650401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02650401","kind":"trial","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","route":"/trials/nct02650401/","field":"links","label":"ClinicalTrials.gov NCT02650401"}]},{"url":"https://clinicaltrials.gov/study/NCT02653755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02653755","kind":"trial","name":"The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer","route":"/trials/nct02653755/","field":"links","label":"ClinicalTrials.gov NCT02653755"}]},{"url":"https://clinicaltrials.gov/study/NCT02655016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","field":"links","label":"ClinicalTrials.gov NCT02655016"},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","field":"links","label":"ClinicalTrials.gov NCT02655016: PRIMA / ENGOT-OV26"}]},{"url":"https://clinicaltrials.gov/study/NCT02659514","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","route":"/trials/nct02659514/","field":"links","label":"ClinicalTrials.gov NCT02659514"}]},{"url":"https://clinicaltrials.gov/study/NCT02659514?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","route":"/trials/nct02659514/","field":"outcomes.source (Objective Response Rate (ORR))"},{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","route":"/trials/nct02659514/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02661503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","field":"links","label":"ClinicalTrials.gov NCT02661503: GHSG HD21"},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"links","label":"ClinicalTrials.gov NCT02661503"}]},{"url":"https://clinicaltrials.gov/study/NCT02663908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02663908","kind":"trial","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","route":"/trials/nct02663908/","field":"links","label":"ClinicalTrials.gov NCT02663908"}]},{"url":"https://clinicaltrials.gov/study/NCT02663908?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02663908","kind":"trial","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","route":"/trials/nct02663908/","field":"outcomes.source (Time From Randomization to the First Confirmed (Adjudicated) Occurrence of the Composite Major Adverse Cardiovascular Event (MACE) Endpoint; Percentage of Observed Subjects With Outcome Measure Events During the Trial)"},{"id":"nct02663908","kind":"trial","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","route":"/trials/nct02663908/","field":"outcomes.source (Time From Randomization to Failure in Progression-free Survival (PFS); Percentage of Observed Subjects With Outcome Measure Events During the Trial)"}]},{"url":"https://clinicaltrials.gov/study/NCT02664935","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","field":"links","label":"ClinicalTrials.gov NCT02664935"}]},{"url":"https://clinicaltrials.gov/study/NCT02665065","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/","field":"links","label":"ClinicalTrials.gov NCT02665065"}]},{"url":"https://clinicaltrials.gov/study/NCT02667574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"links","label":"ClinicalTrials.gov NCT02667574"}]},{"url":"https://clinicaltrials.gov/study/NCT02667587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/","field":"links","label":"ClinicalTrials.gov NCT02667587"},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","field":"links","label":"ClinicalTrials.gov NCT02667587: CheckMate 548"}]},{"url":"https://clinicaltrials.gov/study/NCT02668653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","field":"links","label":"ClinicalTrials.gov NCT02668653"},{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","field":"links","label":"ClinicalTrials.gov NCT02668653: QuANTUM-First"},{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT02668653"}]},{"url":"https://clinicaltrials.gov/study/NCT02671435","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","field":"links","label":"ClinicalTrials.gov NCT02671435"}]},{"url":"https://clinicaltrials.gov/study/NCT02671435?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","field":"outcomes.source (Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1B)"},{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","field":"outcomes.source (Overall Survival)"},{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","field":"outcomes.source (Progression-Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02674568","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02674568","kind":"trial","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","route":"/trials/nct02674568/","field":"links","label":"ClinicalTrials.gov NCT02674568"}]},{"url":"https://clinicaltrials.gov/study/NCT02674568?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02674568","kind":"trial","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","route":"/trials/nct02674568/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02677896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","field":"links","label":"ClinicalTrials.gov NCT02677896"},{"id":"paper-arches-j-clin-oncol-2019","kind":"paper","name":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","route":"/key-papers/paper-arches-j-clin-oncol-2019/","field":"links","label":"ClinicalTrials.gov NCT02677896"},{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT02677896"}],"archive":"https://web.archive.org/web/20260309210240/https://clinicaltrials.gov/study/NCT02677896"},{"url":"https://clinicaltrials.gov/study/NCT02677922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02677922","kind":"trial","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","route":"/trials/nct02677922/","field":"links","label":"ClinicalTrials.gov NCT02677922"}]},{"url":"https://clinicaltrials.gov/study/NCT02677922?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02677922","kind":"trial","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","route":"/trials/nct02677922/","field":"outcomes.source (Overall Response Rate: Phase 2 (Randomized Stage))"},{"id":"nct02677922","kind":"trial","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","route":"/trials/nct02677922/","field":"outcomes.source (Overall Survival: Phase 2 (Randomized Stage))"}]},{"url":"https://clinicaltrials.gov/study/NCT02678572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"links","label":"ClinicalTrials.gov NCT02678572"}]},{"url":"https://clinicaltrials.gov/study/NCT02678572?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"outcomes.source (Disease control rate (independent central review, treated population))"}]},{"url":"https://clinicaltrials.gov/study/NCT02680535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"photothermal-nanoparticles","kind":"technology","name":"Photothermal (plasmonic) nanoparticle ablation","route":"/technologies/photothermal-nanoparticles/","field":"links","label":"AuroLase prostate study (NCT02680535)"}]},{"url":"https://clinicaltrials.gov/study/NCT02680587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"links","label":"ClinicalTrials.gov NCT02680587"}]},{"url":"https://clinicaltrials.gov/study/NCT02683941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","field":"links","label":"ClinicalTrials.gov NCT02683941"}]},{"url":"https://clinicaltrials.gov/study/NCT02684058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","field":"links","label":"ClinicalTrials.gov NCT02684058"}]},{"url":"https://clinicaltrials.gov/study/NCT02684292","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/","field":"links","label":"ClinicalTrials.gov NCT02684292"}]},{"url":"https://clinicaltrials.gov/study/NCT02684708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"euronet-phl-c2","kind":"trial","name":"EuroNet-PHL-C2","route":"/trials/euronet-phl-c2/","field":"links","label":"ClinicalTrials.gov NCT02684708"}]},{"url":"https://clinicaltrials.gov/study/NCT02685605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02685605","kind":"trial","name":"Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","route":"/trials/nct02685605/","field":"links","label":"ClinicalTrials.gov NCT02685605"}]},{"url":"https://clinicaltrials.gov/study/NCT02693535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","field":"links","label":"ClinicalTrials.gov NCT02693535"}]},{"url":"https://clinicaltrials.gov/study/NCT02697734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02697734","kind":"trial","name":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","route":"/trials/nct02697734/","field":"links","label":"ClinicalTrials.gov NCT02697734"}]},{"url":"https://clinicaltrials.gov/study/NCT02697734?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02697734","kind":"trial","name":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","route":"/trials/nct02697734/","field":"outcomes.source (Percentage of Randomized Participants With a Complete Response)"}]},{"url":"https://clinicaltrials.gov/study/NCT02704858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02704858","kind":"trial","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","route":"/trials/nct02704858/","field":"links","label":"ClinicalTrials.gov NCT02704858"}]},{"url":"https://clinicaltrials.gov/study/NCT02706691","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02706691","kind":"trial","name":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","route":"/trials/nct02706691/","field":"links","label":"ClinicalTrials.gov NCT02706691"}]},{"url":"https://clinicaltrials.gov/study/NCT02709512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","field":"links","label":"ATOMIC-Meso phase 2/3 (NCT02709512)"}]},{"url":"https://clinicaltrials.gov/study/NCT02711553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","field":"links","label":"ClinicalTrials.gov NCT02711553"}]},{"url":"https://clinicaltrials.gov/study/NCT02711553?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","field":"outcomes.source (Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT02715284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","field":"links","label":"ClinicalTrials.gov NCT02715284"}]},{"url":"https://clinicaltrials.gov/study/NCT02715804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"ClinicalTrials.gov NCT02715804"},{"id":"pegvorhyaluronidase-alfa","kind":"drug","name":"Pegvorhyaluronidase alfa","route":"/drugs/pegvorhyaluronidase-alfa/","field":"links","label":"ClinicalTrials.gov NCT02715804"},{"id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/","field":"links","label":"ClinicalTrials.gov NCT02715804"}]},{"url":"https://clinicaltrials.gov/study/NCT02716116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02716116"},{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct02716116/","field":"links","label":"ClinicalTrials.gov NCT02716116"}]},{"url":"https://clinicaltrials.gov/study/NCT02717611","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02717611","kind":"trial","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","route":"/trials/nct02717611/","field":"links","label":"ClinicalTrials.gov NCT02717611"}]},{"url":"https://clinicaltrials.gov/study/NCT02717611?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02717611","kind":"trial","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","route":"/trials/nct02717611/","field":"outcomes.source (The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib))"}]},{"url":"https://clinicaltrials.gov/study/NCT02723994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall1521","kind":"trial","name":"AALL1521","route":"/trials/aall1521/","field":"links","label":"ClinicalTrials.gov NCT02723994"}]},{"url":"https://clinicaltrials.gov/study/NCT02724579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acns1422","kind":"trial","name":"ACNS1422","route":"/trials/acns1422/","field":"links","label":"ClinicalTrials.gov NCT02724579"}]},{"url":"https://clinicaltrials.gov/study/NCT02730299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02730299","kind":"trial","name":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","route":"/trials/nct02730299/","field":"links","label":"ClinicalTrials.gov NCT02730299"}]},{"url":"https://clinicaltrials.gov/study/NCT02730299?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02730299","kind":"trial","name":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","route":"/trials/nct02730299/","field":"outcomes.source (Time to Neutrophil Engraftment)"}]},{"url":"https://clinicaltrials.gov/study/NCT02734004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02734004"},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","field":"links","label":"ClinicalTrials.gov NCT02734004"}]},{"url":"https://clinicaltrials.gov/study/NCT02734004?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","field":"outcomes.source (Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12)"},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","field":"outcomes.source (Second Stage Cohort: Objective Response Rate (ORR))"},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","field":"outcomes.source (Second Stage Cohorts: DCR at Week 24)"}]},{"url":"https://clinicaltrials.gov/study/NCT02737501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-alta-1l-n-engl-j-med-2018","kind":"paper","name":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-alta-1l-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02737501"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","field":"links","label":"ClinicalTrials.gov NCT02737501"}]},{"url":"https://clinicaltrials.gov/study/NCT02739594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","route":"/trials/nct02739594/","field":"links","label":"ClinicalTrials.gov NCT02739594"}]},{"url":"https://clinicaltrials.gov/study/NCT02739594?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","route":"/trials/nct02739594/","field":"outcomes.source (Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44)"}]},{"url":"https://clinicaltrials.gov/study/NCT02743494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","field":"links","label":"ClinicalTrials.gov NCT02743494"},{"id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","field":"links","label":"ClinicalTrials.gov NCT02743494: CheckMate 577"},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/","field":"links","label":"ClinicalTrials.gov NCT02743494: CheckMate 577"}]},{"url":"https://clinicaltrials.gov/study/NCT02744768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","field":"links","label":"ClinicalTrials.gov NCT02744768: D-ALBA (GIMEMA LAL2116)"},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","field":"links","label":"ClinicalTrials.gov NCT02744768"},{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","field":"links","label":"ClinicalTrials.gov NCT02744768: D-ALBA (GIMEMA LAL2116)"},{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","field":"links","label":"ClinicalTrials.gov NCT02744768: D-ALBA (GIMEMA LAL2116)"}]},{"url":"https://clinicaltrials.gov/study/NCT02746952","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT02746952"}]},{"url":"https://clinicaltrials.gov/study/NCT02747004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02747004","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","route":"/trials/nct02747004/","field":"links","label":"ClinicalTrials.gov NCT02747004"}]},{"url":"https://clinicaltrials.gov/study/NCT02747004?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02747004","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","route":"/trials/nct02747004/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct02747004","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","route":"/trials/nct02747004/","field":"outcomes.source (Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR))"}]},{"url":"https://clinicaltrials.gov/study/NCT02750826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","field":"links","label":"ClinicalTrials.gov NCT02750826: BWEL (Breast Cancer Weight Loss, Alliance A011401)"},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","field":"links","label":"ClinicalTrials.gov NCT02750826"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"links","label":"ClinicalTrials.gov NCT02750826"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"outcomes.source (Invasive disease-free survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02755311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02755311","kind":"trial","name":"Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","route":"/trials/nct02755311/","field":"links","label":"ClinicalTrials.gov NCT02755311"}]},{"url":"https://clinicaltrials.gov/study/NCT02758951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02758951","kind":"trial","name":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","route":"/trials/nct02758951/","field":"links","label":"ClinicalTrials.gov NCT02758951"}]},{"url":"https://clinicaltrials.gov/study/NCT02760498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT02760498"},{"id":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","kind":"paper","name":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","route":"/key-papers/paper-empower-cscc-1-j-am-acad-dermatol-2025-update/","field":"links","label":"ClinicalTrials.gov NCT02760498"},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","field":"links","label":"ClinicalTrials.gov NCT02760498"}]},{"url":"https://clinicaltrials.gov/study/NCT02761057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/","field":"links","label":"ClinicalTrials.gov NCT02761057"}]},{"url":"https://clinicaltrials.gov/study/NCT02762084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/","field":"links","label":"ClinicalTrials.gov NCT02762084"}]},{"url":"https://clinicaltrials.gov/study/NCT02762266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02762266","kind":"trial","name":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","route":"/trials/nct02762266/","field":"links","label":"ClinicalTrials.gov NCT02762266"}]},{"url":"https://clinicaltrials.gov/study/NCT02762266?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02762266","kind":"trial","name":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","route":"/trials/nct02762266/","field":"outcomes.source (Number of Participants With a Local Progression Event)"}]},{"url":"https://clinicaltrials.gov/study/NCT02763566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02763566","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","route":"/trials/nct02763566/","field":"links","label":"ClinicalTrials.gov NCT02763566"}]},{"url":"https://clinicaltrials.gov/study/NCT02763566?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02763566","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","route":"/trials/nct02763566/","field":"outcomes.source (Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI))"},{"id":"nct02763566","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","route":"/trials/nct02763566/","field":"outcomes.source (Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)])"}]},{"url":"https://clinicaltrials.gov/study/NCT02763579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"links","label":"ClinicalTrials.gov NCT02763579"},{"id":"paper-impower133-n-engl-j-med-2018","kind":"paper","name":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","route":"/key-papers/paper-impower133-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02763579"}]},{"url":"https://clinicaltrials.gov/study/NCT02767804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02767804-jama-oncol-2021","kind":"paper","name":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-nct02767804-jama-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02767804"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"links","label":"ClinicalTrials.gov NCT02767804"}]},{"url":"https://clinicaltrials.gov/study/NCT02768363","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","route":"/trials/nct02768363/","field":"links","label":"ClinicalTrials.gov NCT02768363"}]},{"url":"https://clinicaltrials.gov/study/NCT02773030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/","field":"links","label":"ClinicalTrials.gov NCT02773030"}]},{"url":"https://clinicaltrials.gov/study/NCT02773030?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/","field":"outcomes.source (Overall Response Rate (ORR) in Cohort D and Cohort H2)"},{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/","field":"outcomes.source (Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02775435","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-keynote-407-n-engl-j-med-2018","kind":"paper","name":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-407-n-engl-j-med-2018/","field":"links","label":"ClinicalTrials.gov NCT02775435"},{"id":"paper-keynote-407-j-clin-oncol-2023-update","kind":"paper","name":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","route":"/key-papers/paper-keynote-407-j-clin-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02775435"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","field":"links","label":"ClinicalTrials.gov NCT02775435"}]},{"url":"https://clinicaltrials.gov/study/NCT02781883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","route":"/trials/nct02781883/","field":"links","label":"ClinicalTrials.gov NCT02781883"}]},{"url":"https://clinicaltrials.gov/study/NCT02784171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","field":"links","label":"ClinicalTrials.gov NCT02784171"},{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","field":"links","label":"ClinicalTrials.gov NCT02784171: IND.227 / KEYNOTE-483"}]},{"url":"https://clinicaltrials.gov/study/NCT02785952","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-lung-map-s1400i-jama-oncol-2021","kind":"paper","name":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-lung-map-s1400i-jama-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT02785952"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","field":"links","label":"ClinicalTrials.gov NCT02785952"}]},{"url":"https://clinicaltrials.gov/study/NCT02787005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-antonarakis-keynote-199-pembrolizumab-jco-2020","kind":"paper","name":"KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/","field":"links","label":"ClinicalTrials.gov NCT02787005"}]},{"url":"https://clinicaltrials.gov/study/NCT02788279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imblaze370","kind":"trial","name":"IMblaze370","route":"/trials/imblaze370/","field":"links","label":"ClinicalTrials.gov NCT02788279"}]},{"url":"https://clinicaltrials.gov/study/NCT02788981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02788981","kind":"trial","name":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","route":"/trials/nct02788981/","field":"links","label":"ClinicalTrials.gov NCT02788981"}]},{"url":"https://clinicaltrials.gov/study/NCT02788981?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02788981","kind":"trial","name":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","route":"/trials/nct02788981/","field":"outcomes.source (Progression-free Survival (PFS))"},{"id":"nct02788981","kind":"trial","name":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","route":"/trials/nct02788981/","field":"outcomes.source (Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT02791503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","field":"links","label":"ClinicalTrials.gov NCT02791503"}]},{"url":"https://clinicaltrials.gov/study/NCT02793583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02793583","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","route":"/trials/nct02793583/","field":"links","label":"ClinicalTrials.gov NCT02793583"}]},{"url":"https://clinicaltrials.gov/study/NCT02799602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","field":"links","label":"ClinicalTrials.gov NCT02799602"}],"archive":"https://web.archive.org/web/20260614013038/https://clinicaltrials.gov/study/NCT02799602"},{"url":"https://clinicaltrials.gov/study/NCT02802423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","route":"/trials/nct02802423/","field":"links","label":"ClinicalTrials.gov NCT02802423"}]},{"url":"https://clinicaltrials.gov/study/NCT02802540","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02802540","kind":"trial","name":"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients","route":"/trials/nct02802540/","field":"links","label":"ClinicalTrials.gov NCT02802540"}]},{"url":"https://clinicaltrials.gov/study/NCT02804815","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","field":"links","label":"Add-Aspirin (NCT02804815)"},{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","route":"/trials/add-aspirin/","field":"links","label":"ClinicalTrials.gov NCT02804815"}]},{"url":"https://clinicaltrials.gov/study/NCT02808442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT02808442"}]},{"url":"https://clinicaltrials.gov/study/NCT02811861","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","field":"links","label":"ClinicalTrials.gov NCT02811861"},{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT02811861"}]},{"url":"https://clinicaltrials.gov/study/NCT02813824","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02813824","kind":"trial","name":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","route":"/trials/nct02813824/","field":"links","label":"ClinicalTrials.gov NCT02813824"}]},{"url":"https://clinicaltrials.gov/study/NCT02814968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02814968","kind":"trial","name":"PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide","route":"/trials/nct02814968/","field":"links","label":"ClinicalTrials.gov NCT02814968"}]},{"url":"https://clinicaltrials.gov/study/NCT02815033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02815033","kind":"trial","name":"Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide","route":"/trials/nct02815033/","field":"links","label":"ClinicalTrials.gov NCT02815033"}]},{"url":"https://clinicaltrials.gov/study/NCT02819518","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"links","label":"ClinicalTrials.gov NCT02819518"},{"id":"paper-keynote-355-lancet-2020","kind":"paper","name":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","route":"/key-papers/paper-keynote-355-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT02819518"}]},{"url":"https://clinicaltrials.gov/study/NCT02823405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02823405","kind":"trial","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","route":"/trials/nct02823405/","field":"links","label":"ClinicalTrials.gov NCT02823405"}]},{"url":"https://clinicaltrials.gov/study/NCT02830724","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","route":"/trials/nct02830724/","field":"links","label":"ClinicalTrials.gov NCT02830724"}]},{"url":"https://clinicaltrials.gov/study/NCT02834013","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/","field":"links","label":"ClinicalTrials.gov NCT02834013"}]},{"url":"https://clinicaltrials.gov/study/NCT02838420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alesia","kind":"trial","name":"ALESIA","route":"/trials/alesia/","field":"links","label":"ClinicalTrials.gov NCT02838420"}]},{"url":"https://clinicaltrials.gov/study/NCT02839343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alliance-a021501","kind":"trial","name":"Alliance A021501","route":"/trials/alliance-a021501/","field":"links","label":"ClinicalTrials.gov NCT02839343"}]},{"url":"https://clinicaltrials.gov/study/NCT02843191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02843191","kind":"trial","name":"Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy","route":"/trials/nct02843191/","field":"links","label":"ClinicalTrials.gov NCT02843191"}]},{"url":"https://clinicaltrials.gov/study/NCT02843945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02843945","kind":"trial","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","route":"/trials/nct02843945/","field":"links","label":"ClinicalTrials.gov NCT02843945"}]},{"url":"https://clinicaltrials.gov/study/NCT02853331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","field":"links","label":"ClinicalTrials.gov NCT02853331"}]},{"url":"https://clinicaltrials.gov/study/NCT02858258","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","field":"links","label":"ClinicalTrials.gov NCT02858258"}]},{"url":"https://clinicaltrials.gov/study/NCT02861573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/","field":"links","label":"ClinicalTrials.gov NCT02861573"},{"id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/","field":"links","label":"ClinicalTrials.gov NCT02861573"}]},{"url":"https://clinicaltrials.gov/study/NCT02863718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cll12","kind":"trial","name":"CLL12","route":"/trials/cll12/","field":"links","label":"ClinicalTrials.gov NCT02863718"}]},{"url":"https://clinicaltrials.gov/study/NCT02864992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02864992-jama-oncol-2023-update","kind":"paper","name":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02864992-jama-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02864992"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","field":"links","label":"ClinicalTrials.gov NCT02864992"}]},{"url":"https://clinicaltrials.gov/study/NCT02867865","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polcagb","kind":"trial","name":"POLCAGB","route":"/trials/polcagb/","field":"links","label":"ClinicalTrials.gov NCT02867865"},{"id":"paper-polcagb-protocol-bmj-open-2019","kind":"paper","name":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol","route":"/key-papers/paper-polcagb-protocol-bmj-open-2019/","field":"links","label":"ClinicalTrials.gov NCT02867865"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT02867865"}]},{"url":"https://clinicaltrials.gov/study/NCT02872103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02872103","kind":"trial","name":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct02872103/","field":"links","label":"ClinicalTrials.gov NCT02872103"}]},{"url":"https://clinicaltrials.gov/study/NCT02872103?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02872103","kind":"trial","name":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct02872103/","field":"outcomes.source (The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo)"}]},{"url":"https://clinicaltrials.gov/study/NCT02872116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"links","label":"ClinicalTrials.gov NCT02872116"},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","field":"links","label":"ClinicalTrials.gov NCT02872116: CheckMate 649"},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT02872116"}]},{"url":"https://clinicaltrials.gov/study/NCT02883049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/","field":"links","label":"ClinicalTrials.gov NCT02883049"}]},{"url":"https://clinicaltrials.gov/study/NCT02883049?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/","field":"outcomes.source (DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) Interim Maintenance High-dose Methotrexate Backbone)"},{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/","field":"outcomes.source (DFS of Non-DS VHR Post-Induction Patients Who Receive a Modified MBFM-IMHDM Regimen That Contains a Second IM (Control Arm) Compared to Patients Receive the Cyclophosphamide + Etoposide Containing Regimen (Experimental Arm 1))"}]},{"url":"https://clinicaltrials.gov/study/NCT02885753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02885753","kind":"trial","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","route":"/trials/nct02885753/","field":"links","label":"ClinicalTrials.gov NCT02885753"}]},{"url":"https://clinicaltrials.gov/study/NCT02887040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02887040","kind":"trial","name":"Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma","route":"/trials/nct02887040/","field":"links","label":"ClinicalTrials.gov NCT02887040"}]},{"url":"https://clinicaltrials.gov/study/NCT02890602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02890602","kind":"trial","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","route":"/trials/nct02890602/","field":"links","label":"ClinicalTrials.gov NCT02890602"}]},{"url":"https://clinicaltrials.gov/study/NCT02899052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/","field":"links","label":"ClinicalTrials.gov NCT02899052"}]},{"url":"https://clinicaltrials.gov/study/NCT02899299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","field":"links","label":"ClinicalTrials.gov NCT02899299"},{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","field":"links","label":"ClinicalTrials.gov NCT02899299: CheckMate 743"}]},{"url":"https://clinicaltrials.gov/study/NCT02908672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-2020","kind":"paper","name":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-imspire150-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT02908672"},{"id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT02908672"},{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/","field":"links","label":"ClinicalTrials.gov NCT02908672"}]},{"url":"https://clinicaltrials.gov/study/NCT02908906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02908906","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","route":"/trials/nct02908906/","field":"links","label":"ClinicalTrials.gov NCT02908906"}]},{"url":"https://clinicaltrials.gov/study/NCT02910583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","field":"links","label":"ClinicalTrials.gov NCT02910583"},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","field":"links","label":"ClinicalTrials.gov NCT02910583: CAPTIVATE"}]},{"url":"https://clinicaltrials.gov/study/NCT02912559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","field":"links","label":"ClinicalTrials.gov NCT02912559"},{"id":"paper-atomic-n-engl-j-med-2026","kind":"paper","name":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","route":"/key-papers/paper-atomic-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT02912559"}]},{"url":"https://clinicaltrials.gov/study/NCT02912949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","field":"links","label":"ClinicalTrials.gov NCT02912949"}]},{"url":"https://clinicaltrials.gov/study/NCT02919111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"links","label":"ClinicalTrials.gov NCT02919111"}]},{"url":"https://clinicaltrials.gov/study/NCT02919644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02919644","kind":"trial","name":"Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.","route":"/trials/nct02919644/","field":"links","label":"ClinicalTrials.gov NCT02919644"}]},{"url":"https://clinicaltrials.gov/study/NCT02919787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"links","label":"ClinicalTrials.gov NCT02919787"}]},{"url":"https://clinicaltrials.gov/study/NCT02923921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"links","label":"ClinicalTrials.gov NCT02923921"},{"id":"pegilodecakin","kind":"drug","name":"Pegilodecakin","route":"/drugs/pegilodecakin/","field":"links","label":"ClinicalTrials.gov NCT02923921"}]},{"url":"https://clinicaltrials.gov/study/NCT02924376","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","field":"links","label":"ClinicalTrials.gov NCT02924376"},{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","field":"links","label":"ClinicalTrials.gov NCT02924376: FIGHT-202"}]},{"url":"https://clinicaltrials.gov/study/NCT02925234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-bio1-mechanism-matched-access","kind":"idea","name":"A fast route to the matched drug when it is licensed for another cancer","route":"/ideas/idea-bio1-mechanism-matched-access/","field":"links","label":"DRUP trial (NCT02925234)"}]},{"url":"https://clinicaltrials.gov/study/NCT02926196","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/","field":"links","label":"ClinicalTrials.gov NCT02926196"}]},{"url":"https://clinicaltrials.gov/study/NCT02926911","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-comet-dcis-jama-2025","kind":"paper","name":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","route":"/key-papers/paper-comet-dcis-jama-2025/","field":"links","label":"ClinicalTrials.gov NCT02926911"},{"id":"comet-dcis","kind":"trial","name":"COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)","route":"/trials/comet-dcis/","field":"links","label":"ClinicalTrials.gov NCT02926911"}]},{"url":"https://clinicaltrials.gov/study/NCT02928224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"links","label":"ClinicalTrials.gov NCT02928224"}]},{"url":"https://clinicaltrials.gov/study/NCT02934568","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","route":"/trials/nct02934568/","field":"links","label":"ClinicalTrials.gov NCT02934568"}]},{"url":"https://clinicaltrials.gov/study/NCT02938299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT02938299"},{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT02938299"},{"id":"nct02938299","kind":"trial","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","route":"/trials/nct02938299/","field":"links","label":"ClinicalTrials.gov NCT02938299"}]},{"url":"https://clinicaltrials.gov/study/NCT02945033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02945033","kind":"trial","name":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","route":"/trials/nct02945033/","field":"links","label":"ClinicalTrials.gov NCT02945033"}]},{"url":"https://clinicaltrials.gov/study/NCT02945566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02945566","kind":"trial","name":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","route":"/trials/nct02945566/","field":"links","label":"ClinicalTrials.gov NCT02945566"}]},{"url":"https://clinicaltrials.gov/study/NCT02947685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-patina-n-engl-j-med-2026","kind":"paper","name":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","route":"/key-papers/paper-patina-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT02947685"},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","field":"links","label":"ClinicalTrials.gov NCT02947685"}]},{"url":"https://clinicaltrials.gov/study/NCT02950051","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","field":"links","label":"ClinicalTrials.gov NCT02950051"},{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","field":"links","label":"ClinicalTrials.gov NCT02950051: CLL13 / GAIA"}]},{"url":"https://clinicaltrials.gov/study/NCT02952508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/","field":"links","label":"ClinicalTrials.gov NCT02952508"}]},{"url":"https://clinicaltrials.gov/study/NCT02952534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","field":"links","label":"ClinicalTrials.gov NCT02952534"}]},{"url":"https://clinicaltrials.gov/study/NCT02952586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","field":"links","label":"ClinicalTrials.gov NCT02952586"},{"id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","field":"links","label":"ClinicalTrials.gov NCT02952586: JAVELIN Head and Neck 100"}]},{"url":"https://clinicaltrials.gov/study/NCT02952885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02952885","kind":"trial","name":"Strict IGF-1 Control in Acromegaly","route":"/trials/nct02952885/","field":"links","label":"ClinicalTrials.gov NCT02952885"}]},{"url":"https://clinicaltrials.gov/study/NCT02953301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02953301","kind":"trial","name":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","route":"/trials/nct02953301/","field":"links","label":"ClinicalTrials.gov NCT02953301"}]},{"url":"https://clinicaltrials.gov/study/NCT02954874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1418","kind":"trial","name":"SWOG S1418 / NRG BR006","route":"/trials/swog-s1418/","field":"links","label":"ClinicalTrials.gov NCT02954874"}]},{"url":"https://clinicaltrials.gov/study/NCT02955940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02955940","kind":"trial","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","route":"/trials/nct02955940/","field":"links","label":"ClinicalTrials.gov NCT02955940"}]},{"url":"https://clinicaltrials.gov/study/NCT02960022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/","field":"links","label":"ClinicalTrials.gov NCT02960022"}]},{"url":"https://clinicaltrials.gov/study/NCT02963493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/","field":"links","label":"ClinicalTrials.gov NCT02963493"}]},{"url":"https://clinicaltrials.gov/study/NCT02963493?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/","field":"outcomes.source (Overall Response Rate (ORR))"},{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/","field":"outcomes.source (Overall Survival)"},{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/","field":"outcomes.source (Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT02966756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct02966756/","field":"links","label":"ClinicalTrials.gov NCT02966756"}]},{"url":"https://clinicaltrials.gov/study/NCT02970318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02970318","kind":"trial","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","route":"/trials/nct02970318/","field":"links","label":"ClinicalTrials.gov NCT02970318"}]},{"url":"https://clinicaltrials.gov/study/NCT02970318?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02970318","kind":"trial","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","route":"/trials/nct02970318/","field":"outcomes.source (Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment)"},{"id":"nct02970318","kind":"trial","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","route":"/trials/nct02970318/","field":"outcomes.source (IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis)"}]},{"url":"https://clinicaltrials.gov/study/NCT02971345","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02971345","kind":"trial","name":"Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus","route":"/trials/nct02971345/","field":"links","label":"ClinicalTrials.gov NCT02971345"}]},{"url":"https://clinicaltrials.gov/study/NCT02972840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/","field":"links","label":"ClinicalTrials.gov NCT02972840"}]},{"url":"https://clinicaltrials.gov/study/NCT02975934","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT02975934"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"links","label":"ClinicalTrials.gov NCT02975934"}]},{"url":"https://clinicaltrials.gov/study/NCT02979522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/","field":"links","label":"ClinicalTrials.gov NCT02979522"}]},{"url":"https://clinicaltrials.gov/study/NCT02979522?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/","field":"outcomes.source (Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit)"},{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/","field":"outcomes.source (Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit)"}]},{"url":"https://clinicaltrials.gov/study/NCT02979899","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","field":"links","label":"ClinicalTrials.gov NCT02979899"}]},{"url":"https://clinicaltrials.gov/study/NCT02981368","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02981368","kind":"trial","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","route":"/trials/nct02981368/","field":"links","label":"ClinicalTrials.gov NCT02981368"}]},{"url":"https://clinicaltrials.gov/study/NCT02987543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","field":"links","label":"ClinicalTrials.gov NCT02987543"}]},{"url":"https://clinicaltrials.gov/study/NCT02989857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","field":"links","label":"ClinicalTrials.gov NCT02989857"}]},{"url":"https://clinicaltrials.gov/study/NCT02990728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02990728","kind":"trial","name":"Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer","route":"/trials/nct02990728/","field":"links","label":"ClinicalTrials.gov NCT02990728"}]},{"url":"https://clinicaltrials.gov/study/NCT02993523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","field":"links","label":"ClinicalTrials.gov NCT02993523"},{"id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","field":"links","label":"ClinicalTrials.gov NCT02993523: VIALE-A"},{"id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","field":"links","label":"ClinicalTrials.gov NCT02993523: VIALE-A"},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT02993523"}]},{"url":"https://clinicaltrials.gov/study/NCT02993731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"napabucasin","kind":"drug","name":"Napabucasin","route":"/drugs/napabucasin/","field":"links","label":"ClinicalTrials.gov NCT02993731"},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/","field":"links","label":"ClinicalTrials.gov NCT02993731"}]},{"url":"https://clinicaltrials.gov/study/NCT02997202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/","field":"links","label":"ClinicalTrials.gov NCT02997202"}]},{"url":"https://clinicaltrials.gov/study/NCT02997228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct02997228","kind":"trial","name":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","route":"/trials/nct02997228/","field":"links","label":"ClinicalTrials.gov NCT02997228"}]},{"url":"https://clinicaltrials.gov/study/NCT02997358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"french-sarcoma-group","kind":"company","name":"French Sarcoma Group","route":"/companies/french-sarcoma-group/","field":"links","label":"ClinicalTrials.gov: LMS-04 (NCT02997358)"},{"id":"lms-04","kind":"trial","name":"LMS-04","route":"/trials/lms-04/","field":"links","label":"ClinicalTrials.gov NCT02997358"}]},{"url":"https://clinicaltrials.gov/study/NCT02998528","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"links","label":"ClinicalTrials.gov NCT02998528"},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT02998528"},{"id":"paper-checkmate-816-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","route":"/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/","field":"links","label":"ClinicalTrials.gov NCT02998528"}],"archive":"https://web.archive.org/web/20260727231436/https://clinicaltrials.gov/study/NCT02998528"},{"url":"https://clinicaltrials.gov/study/NCT03003065","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03003065","kind":"trial","name":"Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers","route":"/trials/nct03003065/","field":"links","label":"ClinicalTrials.gov NCT03003065"}]},{"url":"https://clinicaltrials.gov/study/NCT03003325","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"low-pv","kind":"trial","name":"Low-PV","route":"/trials/low-pv/","field":"links","label":"ClinicalTrials.gov NCT03003325"}]},{"url":"https://clinicaltrials.gov/study/NCT03003962","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03003962"},{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","field":"links","label":"ClinicalTrials.gov NCT03003962"}]},{"url":"https://clinicaltrials.gov/study/NCT03003962?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","field":"outcomes.source (OS in Participants With LREM)"},{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","field":"outcomes.source (Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT03004755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-bio1-rapid-autopsy-network","kind":"idea","name":"A national rapid research autopsy network for end-stage cancer","route":"/ideas/idea-bio1-rapid-autopsy-network/","field":"links","label":"PEACE study (NCT03004755)"}]},{"url":"https://clinicaltrials.gov/study/NCT03013998","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/","field":"links","label":"ClinicalTrials.gov NCT03013998"}]},{"url":"https://clinicaltrials.gov/study/NCT03016312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imbassador250","kind":"trial","name":"IMbassador250","route":"/trials/imbassador250/","field":"links","label":"ClinicalTrials.gov NCT03016312"}]},{"url":"https://clinicaltrials.gov/study/NCT03016819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/","field":"links","label":"ClinicalTrials.gov NCT03016819"}]},{"url":"https://clinicaltrials.gov/study/NCT03017326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","field":"links","label":"PHITT trial"}]},{"url":"https://clinicaltrials.gov/study/NCT03022825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","field":"links","label":"ClinicalTrials.gov NCT03022825"}]},{"url":"https://clinicaltrials.gov/study/NCT03026140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","field":"links","label":"ClinicalTrials.gov NCT03026140"},{"id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","field":"links","label":"ClinicalTrials.gov NCT03026140: NICHE-2"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03026140"},{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/","field":"links","label":"ClinicalTrials.gov NCT03026140"}]},{"url":"https://clinicaltrials.gov/study/NCT03033511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03033511","kind":"trial","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","route":"/trials/nct03033511/","field":"links","label":"ClinicalTrials.gov NCT03033511"}]},{"url":"https://clinicaltrials.gov/study/NCT03033511?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03033511","kind":"trial","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","route":"/trials/nct03033511/","field":"outcomes.source (Overall Survival (OS) in Participants With Extensive-Stage Small Cell Lung Cancer With Delta-Like Protein 3 High Expression in Tumor (DLL3high))"}]},{"url":"https://clinicaltrials.gov/study/NCT03036098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","field":"links","label":"ClinicalTrials.gov NCT03036098"}]},{"url":"https://clinicaltrials.gov/study/NCT03036098?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","field":"outcomes.source (Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study)"},{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","field":"outcomes.source (Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study)"},{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","field":"outcomes.source (Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study)"}]},{"url":"https://clinicaltrials.gov/study/NCT03036488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT03036488"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","field":"links","label":"ClinicalTrials.gov NCT03036488: KEYNOTE-522"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"ClinicalTrials.gov NCT03036488"},{"id":"idea-post-neoadjuvant-adc","kind":"idea","name":"ADC for residual disease after KEYNOTE-522","route":"/ideas/idea-post-neoadjuvant-adc/","field":"links","label":"ClinicalTrials.gov NCT03036488: KEYNOTE-522"},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","field":"links","label":"ClinicalTrials.gov NCT03036488: KEYNOTE-522"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03036488"},{"id":"paper-keynote-522-n-engl-j-med-2020","kind":"paper","name":"Pembrolizumab for Early Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2020/","field":"links","label":"ClinicalTrials.gov NCT03036488"},{"id":"paper-keynote-522-n-engl-j-med-2024-update","kind":"paper","name":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2024-update/","field":"links","label":"ClinicalTrials.gov NCT03036488"},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/","field":"links","label":"ClinicalTrials.gov NCT03036488: KEYNOTE-522"}]},{"url":"https://clinicaltrials.gov/study/NCT03037385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","field":"links","label":"ClinicalTrials.gov NCT03037385"}]},{"url":"https://clinicaltrials.gov/study/NCT03038672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/","field":"links","label":"ClinicalTrials.gov NCT03038672"}]},{"url":"https://clinicaltrials.gov/study/NCT03040973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/","field":"links","label":"ClinicalTrials.gov NCT03040973"}]},{"url":"https://clinicaltrials.gov/study/NCT03040999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","field":"links","label":"ClinicalTrials.gov NCT03040999"}]},{"url":"https://clinicaltrials.gov/study/NCT03043313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","field":"links","label":"ClinicalTrials.gov NCT03043313"},{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/","field":"links","label":"ClinicalTrials.gov NCT03043313"}]},{"url":"https://clinicaltrials.gov/study/NCT03043547","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-naliricc-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","route":"/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/","field":"links","label":"ClinicalTrials.gov NCT03043547"}]},{"url":"https://clinicaltrials.gov/study/NCT03043872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","field":"links","label":"ClinicalTrials.gov NCT03043872"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","field":"links","label":"ClinicalTrials.gov NCT03043872"},{"id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","field":"links","label":"ClinicalTrials.gov NCT03043872"}]},{"url":"https://clinicaltrials.gov/study/NCT03044587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nife","kind":"trial","name":"NIFE (AIO-YMO HEP-0315)","route":"/trials/nife/","field":"links","label":"ClinicalTrials.gov NCT03044587"}]},{"url":"https://clinicaltrials.gov/study/NCT03049189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"links","label":"ClinicalTrials.gov NCT03049189 (COMPETE)"},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"links","label":"ClinicalTrials.gov NCT03049189"},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","field":"links","label":"ClinicalTrials.gov NCT03049189: COMPETE"},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","field":"links","label":"ClinicalTrials.gov NCT03049189: COMPETE"}]},{"url":"https://clinicaltrials.gov/study/NCT03051464","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03051464","kind":"trial","name":"Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","route":"/trials/nct03051464/","field":"links","label":"ClinicalTrials.gov NCT03051464"}]},{"url":"https://clinicaltrials.gov/study/NCT03052608","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","field":"links","label":"ClinicalTrials.gov NCT03052608"},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","field":"links","label":"ClinicalTrials.gov NCT03052608: CROWN"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT03052608"},{"id":"paper-crown-lancet-respir-med-2023-update","kind":"paper","name":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","route":"/key-papers/paper-crown-lancet-respir-med-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03052608"}],"archive":"https://web.archive.org/web/20260904180619/https://clinicaltrials.gov/study/NCT03052608"},{"url":"https://clinicaltrials.gov/study/NCT03053440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspen-wm","kind":"trial","name":"ASPEN (Waldenström macroglobulinaemia)","route":"/trials/aspen-wm/","field":"links","label":"ClinicalTrials.gov NCT03053440"}]},{"url":"https://clinicaltrials.gov/study/NCT03053440?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspen-wm","kind":"trial","name":"ASPEN (Waldenström macroglobulinaemia)","route":"/trials/aspen-wm/","field":"outcomes.source (Complete response or very good partial response by independent review, MYD88-mutated cohort (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT03061812","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/","field":"links","label":"ClinicalTrials.gov NCT03061812"}]},{"url":"https://clinicaltrials.gov/study/NCT03061812?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03067051","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","route":"/trials/nct03067051/","field":"links","label":"ClinicalTrials.gov NCT03067051"}]},{"url":"https://clinicaltrials.gov/study/NCT03067181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"links","label":"AGCT1531 (NCT03067181)"},{"id":"agct1531","kind":"trial","name":"AGCT1531","route":"/trials/agct1531/","field":"links","label":"ClinicalTrials.gov NCT03067181"}]},{"url":"https://clinicaltrials.gov/study/NCT03068455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","field":"links","label":"ClinicalTrials.gov NCT03068455"},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/","field":"links","label":"ClinicalTrials.gov NCT03068455"}]},{"url":"https://clinicaltrials.gov/study/NCT03068455?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/","field":"outcomes.source (Recurrence-free survival, all randomised participants (registry results))"},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/","field":"outcomes.source (Recurrence-free survival, PD-L1 expression below 1% (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT03069469","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03069469","kind":"trial","name":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","route":"/trials/nct03069469/","field":"links","label":"ClinicalTrials.gov NCT03069469"}]},{"url":"https://clinicaltrials.gov/study/NCT03070392","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","field":"links","label":"ClinicalTrials.gov NCT03070392"},{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/","field":"links","label":"ClinicalTrials.gov NCT03070392"},{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03070392"}]},{"url":"https://clinicaltrials.gov/study/NCT03075696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/","field":"links","label":"ClinicalTrials.gov NCT03075696"},{"id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","route":"/trials/nct03075696/","field":"links","label":"ClinicalTrials.gov NCT03075696"}]},{"url":"https://clinicaltrials.gov/study/NCT03085095","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"links","label":"ClinicalTrials.gov NCT03085095"}]},{"url":"https://clinicaltrials.gov/study/NCT03088540","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-2021","kind":"paper","name":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","route":"/key-papers/paper-empower-lung-1-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT03088540"},{"id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03088540"},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","field":"links","label":"ClinicalTrials.gov NCT03088540"}]},{"url":"https://clinicaltrials.gov/study/NCT03090659","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","field":"links","label":"ClinicalTrials.gov NCT03090659"}]},{"url":"https://clinicaltrials.gov/study/NCT03091192","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/","field":"links","label":"ClinicalTrials.gov NCT03091192"}]},{"url":"https://clinicaltrials.gov/study/NCT03091192?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/","field":"outcomes.source (Progression Free Survival (PFS) by Blinded Independent Central Review (BICR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03093116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","field":"links","label":"ClinicalTrials.gov NCT03093116"}]},{"url":"https://clinicaltrials.gov/study/NCT03093688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03093688","kind":"trial","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","route":"/trials/nct03093688/","field":"links","label":"ClinicalTrials.gov NCT03093688"}]},{"url":"https://clinicaltrials.gov/study/NCT03093870","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"varlitinib","kind":"drug","name":"Varlitinib","route":"/drugs/varlitinib/","field":"links","label":"ClinicalTrials.gov NCT03093870"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"links","label":"ClinicalTrials.gov NCT03093870"}]},{"url":"https://clinicaltrials.gov/study/NCT03096093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","route":"/trials/nct03096093/","field":"links","label":"ClinicalTrials.gov NCT03096093"}]},{"url":"https://clinicaltrials.gov/study/NCT03105336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","field":"links","label":"ClinicalTrials.gov NCT03105336"}]},{"url":"https://clinicaltrials.gov/study/NCT03112174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","field":"links","label":"ClinicalTrials.gov NCT03112174"}]},{"url":"https://clinicaltrials.gov/study/NCT03112174?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","field":"links","label":"ClinicalTrials.gov results"},{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","field":"outcomes.source (Progression-free survival, randomised phase (registry results))"},{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","field":"outcomes.source (Complete response rate, treatment-naive TP53-mutated arm (registry results))"},{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","field":"outcomes.source (Tumour lysis syndrome events in the safety run-in (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT03125902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","field":"links","label":"ClinicalTrials.gov NCT03125902"},{"id":"paper-impassion131-ann-oncol-2021","kind":"paper","name":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","route":"/key-papers/paper-impassion131-ann-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT03125902"}]},{"url":"https://clinicaltrials.gov/study/NCT03125980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03125980","kind":"trial","name":"Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer","route":"/trials/nct03125980/","field":"links","label":"ClinicalTrials.gov NCT03125980"}]},{"url":"https://clinicaltrials.gov/study/NCT03126630","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/","field":"links","label":"Pembrolizumab with or without anetumab ravtansine, NCT03126630"},{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","field":"links","label":"ClinicalTrials.gov NCT03126630"}]},{"url":"https://clinicaltrials.gov/study/NCT03126630?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","field":"outcomes.source (Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab)"},{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","field":"outcomes.source (Phase 2 Overall Survival)"},{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","field":"outcomes.source (Phase 2 Progression Free Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT03126916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","field":"links","label":"ClinicalTrials.gov NCT03126916"}]},{"url":"https://clinicaltrials.gov/study/NCT03132636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","field":"links","label":"ClinicalTrials.gov NCT03132636"}]},{"url":"https://clinicaltrials.gov/study/NCT03134872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/","field":"links","label":"ClinicalTrials.gov NCT03134872"},{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03134872"},{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","field":"links","label":"ClinicalTrials.gov NCT03134872"}]},{"url":"https://clinicaltrials.gov/study/NCT03135769","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/","field":"links","label":"ClinicalTrials.gov NCT03135769"}]},{"url":"https://clinicaltrials.gov/study/NCT03141177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","field":"links","label":"ClinicalTrials.gov NCT03141177"}]},{"url":"https://clinicaltrials.gov/study/NCT03142334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","field":"links","label":"ClinicalTrials.gov NCT03142334"},{"id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","field":"links","label":"ClinicalTrials.gov NCT03142334: KEYNOTE-564"},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT03142334"}]},{"url":"https://clinicaltrials.gov/study/NCT03143153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","field":"links","label":"ClinicalTrials.gov NCT03143153"}]},{"url":"https://clinicaltrials.gov/study/NCT03145961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03145961"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/","field":"links","label":"ClinicalTrials.gov NCT03145961"}]},{"url":"https://clinicaltrials.gov/study/NCT03148418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03148418","kind":"trial","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","route":"/trials/nct03148418/","field":"links","label":"ClinicalTrials.gov NCT03148418"}]},{"url":"https://clinicaltrials.gov/study/NCT03150576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/","field":"links","label":"ClinicalTrials.gov NCT03150576"}]},{"url":"https://clinicaltrials.gov/study/NCT03150693","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","route":"/trials/nct03150693/","field":"links","label":"ClinicalTrials.gov NCT03150693"}]},{"url":"https://clinicaltrials.gov/study/NCT03151811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/","field":"links","label":"ClinicalTrials.gov NCT03151811"}]},{"url":"https://clinicaltrials.gov/study/NCT03151811?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03155191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/","field":"links","label":"ClinicalTrials.gov NCT03155191"}]},{"url":"https://clinicaltrials.gov/study/NCT03155620","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/","field":"links","label":"ClinicalTrials.gov NCT03155620: NCI-COG Pediatric MATCH (APEC1621)"},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"links","label":"ClinicalTrials.gov NCT03155620"}]},{"url":"https://clinicaltrials.gov/study/NCT03155997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","field":"links","label":"ClinicalTrials.gov NCT03155997"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/","field":"links","label":"ClinicalTrials.gov NCT03155997"},{"id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03155997"},{"id":"paper-monarche-ann-oncol-2026-update","kind":"paper","name":"Overall survival with abemaciclib in early breast cancer","route":"/key-papers/paper-monarche-ann-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT03155997"}]},{"url":"https://clinicaltrials.gov/study/NCT03157128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03157128-j-clin-oncol-2024-update","kind":"paper","name":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","route":"/key-papers/paper-nct03157128-j-clin-oncol-2024-update/","field":"links","label":"ClinicalTrials.gov NCT03157128"},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","field":"links","label":"ClinicalTrials.gov NCT03157128"}]},{"url":"https://clinicaltrials.gov/study/NCT03157128?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","field":"outcomes.source (Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT03161353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","field":"links","label":"ClinicalTrials.gov NCT03161353"},{"id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","field":"links","label":"ClinicalTrials.gov NCT03161353: PHERGain"},{"id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT03161353"},{"id":"paper-phergain-lancet-2024-update","kind":"paper","name":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-phergain-lancet-2024-update/","field":"links","label":"ClinicalTrials.gov NCT03161353"}]},{"url":"https://clinicaltrials.gov/study/NCT03162536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03162536","kind":"trial","name":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","route":"/trials/nct03162536/","field":"links","label":"ClinicalTrials.gov NCT03162536"}]},{"url":"https://clinicaltrials.gov/study/NCT03164616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","field":"links","label":"ClinicalTrials.gov NCT03164616"}]},{"url":"https://clinicaltrials.gov/study/NCT03164616?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","field":"outcomes.source (Progression-Free Survival (PFS); D + SoC Compared With SoC Alone)"},{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","field":"outcomes.source (Overall Survival (OS); D + SoC Compared With SoC Alone)"},{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03168880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03168880","kind":"trial","name":"A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced","route":"/trials/nct03168880/","field":"links","label":"ClinicalTrials.gov NCT03168880"}]},{"url":"https://clinicaltrials.gov/study/NCT03172299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03172299","kind":"trial","name":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","route":"/trials/nct03172299/","field":"links","label":"ClinicalTrials.gov NCT03172299"}]},{"url":"https://clinicaltrials.gov/study/NCT03173248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","field":"links","label":"ClinicalTrials.gov NCT03173248"},{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03173248"}]},{"url":"https://clinicaltrials.gov/study/NCT03175224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","route":"/trials/nct03175224/","field":"links","label":"ClinicalTrials.gov NCT03175224"}]},{"url":"https://clinicaltrials.gov/study/NCT03178552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/","field":"links","label":"ClinicalTrials.gov NCT03178552"},{"id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/","field":"links","label":"ClinicalTrials.gov NCT03178552"}]},{"url":"https://clinicaltrials.gov/study/NCT03182244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03182244","kind":"trial","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","route":"/trials/nct03182244/","field":"links","label":"ClinicalTrials.gov NCT03182244"}]},{"url":"https://clinicaltrials.gov/study/NCT03182244?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03182244","kind":"trial","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","route":"/trials/nct03182244/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03182634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT03182634"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"links","label":"ClinicalTrials.gov NCT03182634"}]},{"url":"https://clinicaltrials.gov/study/NCT03189719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","field":"links","label":"ClinicalTrials.gov NCT03189719"}]},{"url":"https://clinicaltrials.gov/study/NCT03190941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03190941","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","route":"/trials/nct03190941/","field":"links","label":"ClinicalTrials.gov NCT03190941"}]},{"url":"https://clinicaltrials.gov/study/NCT03197935","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-impassion031-lancet-2020","kind":"paper","name":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-impassion031-lancet-2020/","field":"links","label":"ClinicalTrials.gov NCT03197935"},{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/","field":"links","label":"ClinicalTrials.gov NCT03197935"},{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/","field":"links","label":"ClinicalTrials.gov NCT03197935"}]},{"url":"https://clinicaltrials.gov/study/NCT03206671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03206671","kind":"trial","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","route":"/trials/nct03206671/","field":"links","label":"ClinicalTrials.gov NCT03206671"}]},{"url":"https://clinicaltrials.gov/study/NCT03212404","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"links","label":"ClinicalTrials.gov NCT03212404"},{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/","field":"links","label":"ClinicalTrials.gov NCT03212404"}]},{"url":"https://clinicaltrials.gov/study/NCT03213665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03213665","kind":"trial","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","route":"/trials/nct03213665/","field":"links","label":"ClinicalTrials.gov NCT03213665"}]},{"url":"https://clinicaltrials.gov/study/NCT03213665?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03213665","kind":"trial","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","route":"/trials/nct03213665/","field":"outcomes.source (Objective Response Rate (ORR))"},{"id":"nct03213665","kind":"trial","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","route":"/trials/nct03213665/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03215706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-9la","kind":"trial","name":"CheckMate 9LA","route":"/trials/checkmate-9la/","field":"links","label":"ClinicalTrials.gov NCT03215706"}]},{"url":"https://clinicaltrials.gov/study/NCT03223662","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03223662","kind":"trial","name":"Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy","route":"/trials/nct03223662/","field":"links","label":"ClinicalTrials.gov NCT03223662"}]},{"url":"https://clinicaltrials.gov/study/NCT03225937","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","field":"links","label":"ClinicalTrials.gov NCT03225937"}]},{"url":"https://clinicaltrials.gov/study/NCT03227926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","field":"links","label":"ClinicalTrials.gov NCT03227926"}]},{"url":"https://clinicaltrials.gov/study/NCT03228277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03228277","kind":"trial","name":"Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA","route":"/trials/nct03228277/","field":"links","label":"ClinicalTrials.gov NCT03228277"}]},{"url":"https://clinicaltrials.gov/study/NCT03228667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/","field":"links","label":"ClinicalTrials.gov NCT03228667"}]},{"url":"https://clinicaltrials.gov/study/NCT03233191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmist","kind":"trial","name":"TMIST (Tomosynthesis Mammographic Imaging Screening Trial)","route":"/trials/tmist/","field":"links","label":"ClinicalTrials.gov NCT03233191"}]},{"url":"https://clinicaltrials.gov/study/NCT03246529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03246529","kind":"trial","name":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl","route":"/trials/nct03246529/","field":"links","label":"ClinicalTrials.gov NCT03246529"}]},{"url":"https://clinicaltrials.gov/study/NCT03252431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03252431","kind":"trial","name":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct03252431/","field":"links","label":"ClinicalTrials.gov NCT03252431"}]},{"url":"https://clinicaltrials.gov/study/NCT03252431?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03252431","kind":"trial","name":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct03252431/","field":"outcomes.source (Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT03257033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","field":"links","label":"ClinicalTrials.gov NCT03257033"}]},{"url":"https://clinicaltrials.gov/study/NCT03257267","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","field":"links","label":"ClinicalTrials.gov NCT03257267"}]},{"url":"https://clinicaltrials.gov/study/NCT03259867","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03259867","kind":"trial","name":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","route":"/trials/nct03259867/","field":"links","label":"ClinicalTrials.gov NCT03259867"}]},{"url":"https://clinicaltrials.gov/study/NCT03260023","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","field":"links","label":"ClinicalTrials.gov NCT03260023"}]},{"url":"https://clinicaltrials.gov/study/NCT03260023?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","field":"outcomes.source (Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1, Overall Response Rate)"},{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","field":"outcomes.source (Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1)"},{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","field":"outcomes.source (Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification)"}]},{"url":"https://clinicaltrials.gov/study/NCT03260712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eortc-1607-pembro-cisgem","kind":"trial","name":"EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer","route":"/trials/eortc-1607-pembro-cisgem/","field":"links","label":"ClinicalTrials.gov NCT03260712"}]},{"url":"https://clinicaltrials.gov/study/NCT03260894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03260894","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","route":"/trials/nct03260894/","field":"links","label":"ClinicalTrials.gov NCT03260894"}]},{"url":"https://clinicaltrials.gov/study/NCT03260894?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03260894","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","route":"/trials/nct03260894/","field":"outcomes.source (Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC), Objective Response (CR+PR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03262935","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/","field":"links","label":"ClinicalTrials.gov NCT03262935"}]},{"url":"https://clinicaltrials.gov/study/NCT03262935?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/","field":"outcomes.source (Progression Free Survival)"},{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/","field":"outcomes.source (Overall Survival)"},{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/","field":"outcomes.source (Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT03268382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03268382","kind":"trial","name":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","route":"/trials/nct03268382/","field":"links","label":"ClinicalTrials.gov NCT03268382"}]},{"url":"https://clinicaltrials.gov/study/NCT03268954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03268954","kind":"trial","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","route":"/trials/nct03268954/","field":"links","label":"ClinicalTrials.gov NCT03268954"}]},{"url":"https://clinicaltrials.gov/study/NCT03268954?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03268954","kind":"trial","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","route":"/trials/nct03268954/","field":"outcomes.source (Event-Free Survival (EFS))"},{"id":"nct03268954","kind":"trial","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","route":"/trials/nct03268954/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03269565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/","field":"links","label":"ClinicalTrials.gov NCT03269565"}]},{"url":"https://clinicaltrials.gov/study/NCT03271918","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03271918","kind":"trial","name":"Cabergoline in Nonfunctioning Pituitary Adenomas","route":"/trials/nct03271918/","field":"links","label":"ClinicalTrials.gov NCT03271918"}]},{"url":"https://clinicaltrials.gov/study/NCT03274414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03274414","kind":"trial","name":"A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages","route":"/trials/nct03274414/","field":"links","label":"ClinicalTrials.gov NCT03274414"}]},{"url":"https://clinicaltrials.gov/study/NCT03274492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"links","label":"ClinicalTrials.gov NCT03274492"},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03274492"}]},{"url":"https://clinicaltrials.gov/study/NCT03280511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03280511","kind":"trial","name":"Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients","route":"/trials/nct03280511/","field":"links","label":"ClinicalTrials.gov NCT03280511"}]},{"url":"https://clinicaltrials.gov/study/NCT03281954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/","field":"links","label":"ClinicalTrials.gov NCT03281954"}]},{"url":"https://clinicaltrials.gov/study/NCT03284424","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","field":"links","label":"ClinicalTrials.gov NCT03284424"}]},{"url":"https://clinicaltrials.gov/study/NCT03290534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03290534","kind":"trial","name":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","route":"/trials/nct03290534/","field":"links","label":"ClinicalTrials.gov NCT03290534"}]},{"url":"https://clinicaltrials.gov/study/NCT03298451","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"links","label":"ClinicalTrials.gov NCT03298451"},{"id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","field":"links","label":"ClinicalTrials.gov NCT03298451: HIMALAYA"}]},{"url":"https://clinicaltrials.gov/study/NCT03301168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03301168","kind":"trial","name":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","route":"/trials/nct03301168/","field":"links","label":"ClinicalTrials.gov NCT03301168"}]},{"url":"https://clinicaltrials.gov/study/NCT03301220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/","field":"links","label":"ClinicalTrials.gov NCT03301220"}]},{"url":"https://clinicaltrials.gov/study/NCT03301805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03301805","kind":"trial","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","route":"/trials/nct03301805/","field":"links","label":"ClinicalTrials.gov NCT03301805"}]},{"url":"https://clinicaltrials.gov/study/NCT03303495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03303495","kind":"trial","name":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","route":"/trials/nct03303495/","field":"links","label":"ClinicalTrials.gov NCT03303495"}]},{"url":"https://clinicaltrials.gov/study/NCT03314181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/","field":"links","label":"ClinicalTrials.gov NCT03314181"}]},{"url":"https://clinicaltrials.gov/study/NCT03315026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03315026","kind":"trial","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","route":"/trials/nct03315026/","field":"links","label":"ClinicalTrials.gov NCT03315026"}]},{"url":"https://clinicaltrials.gov/study/NCT03315364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03315364","kind":"trial","name":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","route":"/trials/nct03315364/","field":"links","label":"ClinicalTrials.gov NCT03315364"}]},{"url":"https://clinicaltrials.gov/study/NCT03315754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03315754","kind":"trial","name":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer","route":"/trials/nct03315754/","field":"links","label":"ClinicalTrials.gov NCT03315754"}]},{"url":"https://clinicaltrials.gov/study/NCT03315754?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03315754","kind":"trial","name":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer","route":"/trials/nct03315754/","field":"outcomes.source (Participants With Negative Biopsy for Gleason Score 7 (Gleason Grade 4 or 5) Prostate Cancer on 12-month Post-treatment)"}]},{"url":"https://clinicaltrials.gov/study/NCT03319628","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","route":"/trials/nct03319628/","field":"links","label":"ClinicalTrials.gov NCT03319628"}]},{"url":"https://clinicaltrials.gov/study/NCT03319667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/","field":"links","label":"ClinicalTrials.gov NCT03319667"}]},{"url":"https://clinicaltrials.gov/study/NCT03322995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03322995","kind":"trial","name":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","route":"/trials/nct03322995/","field":"links","label":"ClinicalTrials.gov NCT03322995"}]},{"url":"https://clinicaltrials.gov/study/NCT03326791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03326791","kind":"trial","name":"Aspirin in Colorectal Cancer Liver Metastases","route":"/trials/nct03326791/","field":"links","label":"ClinicalTrials.gov NCT03326791"}]},{"url":"https://clinicaltrials.gov/study/NCT03327597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","field":"links","label":"ClinicalTrials.gov NCT03327597"}]},{"url":"https://clinicaltrials.gov/study/NCT03328078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03328078","kind":"trial","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","route":"/trials/nct03328078/","field":"links","label":"ClinicalTrials.gov NCT03328078"}]},{"url":"https://clinicaltrials.gov/study/NCT03329183","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03329183","kind":"trial","name":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","route":"/trials/nct03329183/","field":"links","label":"ClinicalTrials.gov NCT03329183"}]},{"url":"https://clinicaltrials.gov/study/NCT03329690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/","field":"links","label":"ClinicalTrials.gov NCT03329690"}]},{"url":"https://clinicaltrials.gov/study/NCT03330847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03330847-clin-cancer-res-2026","kind":"paper","name":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","route":"/key-papers/paper-nct03330847-clin-cancer-res-2026/","field":"links","label":"ClinicalTrials.gov NCT03330847"},{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/","field":"links","label":"ClinicalTrials.gov NCT03330847"}]},{"url":"https://clinicaltrials.gov/study/NCT03330847?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/","field":"outcomes.source (Progression-free Survival (Per BICR), All patients per BICR)"},{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/","field":"outcomes.source (Number of Patients With Objective Response (Per BICR and Per Sensitivity Analysis), All patients per BICR)"}]},{"url":"https://clinicaltrials.gov/study/NCT03331198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","field":"links","label":"ClinicalTrials.gov NCT03331198"}]},{"url":"https://clinicaltrials.gov/study/NCT03334617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/","field":"links","label":"ClinicalTrials.gov NCT03334617"},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","field":"links","label":"ClinicalTrials.gov NCT03334617"}]},{"url":"https://clinicaltrials.gov/study/NCT03334617?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","field":"outcomes.source (Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1))"},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","field":"outcomes.source (Progression-Free Survival (PFS) Per RECIST v1.1)"}]},{"url":"https://clinicaltrials.gov/study/NCT03336333","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","field":"links","label":"ClinicalTrials.gov NCT03336333: SEQUOIA"},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","field":"links","label":"ClinicalTrials.gov NCT03336333"},{"id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/","field":"links","label":"ClinicalTrials.gov NCT03336333: SEQUOIA"},{"id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT03336333"}]},{"url":"https://clinicaltrials.gov/study/NCT03337724","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"links","label":"ClinicalTrials.gov NCT03337724"}]},{"url":"https://clinicaltrials.gov/study/NCT03341143","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","field":"links","label":"ClinicalTrials.gov NCT03341143"}]},{"url":"https://clinicaltrials.gov/study/NCT03348670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03348670","kind":"trial","name":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","route":"/trials/nct03348670/","field":"links","label":"ClinicalTrials.gov NCT03348670"}]},{"url":"https://clinicaltrials.gov/study/NCT03348904","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03348904","kind":"trial","name":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","route":"/trials/nct03348904/","field":"links","label":"ClinicalTrials.gov NCT03348904"}]},{"url":"https://clinicaltrials.gov/study/NCT03351062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03351062","kind":"trial","name":"Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer","route":"/trials/nct03351062/","field":"links","label":"ClinicalTrials.gov NCT03351062"}]},{"url":"https://clinicaltrials.gov/study/NCT03353753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","field":"links","label":"ClinicalTrials.gov NCT03353753"}]},{"url":"https://clinicaltrials.gov/study/NCT03358472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03358472","kind":"trial","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","route":"/trials/nct03358472/","field":"links","label":"ClinicalTrials.gov NCT03358472"}]},{"url":"https://clinicaltrials.gov/study/NCT03358472?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03358472","kind":"trial","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","route":"/trials/nct03358472/","field":"outcomes.source (Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen)"}]},{"url":"https://clinicaltrials.gov/study/NCT03363373","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","field":"links","label":"ClinicalTrials.gov NCT03363373"}]},{"url":"https://clinicaltrials.gov/study/NCT03364530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03364530","kind":"trial","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","route":"/trials/nct03364530/","field":"links","label":"ClinicalTrials.gov NCT03364530"}]},{"url":"https://clinicaltrials.gov/study/NCT03367572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03367572","kind":"trial","name":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","route":"/trials/nct03367572/","field":"links","label":"ClinicalTrials.gov NCT03367572"}]},{"url":"https://clinicaltrials.gov/study/NCT03368547","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"links","label":"ClinicalTrials.gov NCT03368547"},{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT03368547"}]},{"url":"https://clinicaltrials.gov/study/NCT03373097","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","field":"links","label":"ClinicalTrials.gov NCT03373097"},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","field":"links","label":"ClinicalTrials.gov NCT03373097: GD2-CART01 (Bambino Gesù phase 1/2)"},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","field":"links","label":"ClinicalTrials.gov NCT03373097: GD2-CART01 (Bambino Gesù phase 1/2)"}]},{"url":"https://clinicaltrials.gov/study/NCT03375320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"links","label":"ClinicalTrials.gov NCT03375320"}]},{"url":"https://clinicaltrials.gov/study/NCT03377491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","field":"links","label":"ClinicalTrials.gov NCT03377491"},{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","field":"links","label":"ClinicalTrials.gov NCT03377491"}],"archive":"https://web.archive.org/web/20260727200732/https://clinicaltrials.gov/study/NCT03377491"},{"url":"https://clinicaltrials.gov/study/NCT03379428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03379428","kind":"trial","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","route":"/trials/nct03379428/","field":"links","label":"ClinicalTrials.gov NCT03379428"}]},{"url":"https://clinicaltrials.gov/study/NCT03381274","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03381274"},{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","field":"links","label":"ClinicalTrials.gov NCT03381274"}]},{"url":"https://clinicaltrials.gov/study/NCT03381274?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","field":"outcomes.source (Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2)"},{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","field":"outcomes.source (Overall Survival (OS) for Parts 1 and 2)"},{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","field":"outcomes.source (Progression Free Survival (PFS) for Parts 1 and 2)"}]},{"url":"https://clinicaltrials.gov/study/NCT03382899","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","field":"links","label":"ClinicalTrials.gov NCT03382899"}]},{"url":"https://clinicaltrials.gov/study/NCT03383458","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03383458","kind":"trial","name":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","route":"/trials/nct03383458/","field":"links","label":"ClinicalTrials.gov NCT03383458"}]},{"url":"https://clinicaltrials.gov/study/NCT03384238","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03384238","kind":"trial","name":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","route":"/trials/nct03384238/","field":"links","label":"ClinicalTrials.gov NCT03384238"}]},{"url":"https://clinicaltrials.gov/study/NCT03384940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/","field":"links","label":"ClinicalTrials.gov NCT03384940"}]},{"url":"https://clinicaltrials.gov/study/NCT03386513","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","route":"/trials/nct03386513/","field":"links","label":"ClinicalTrials.gov NCT03386513"}]},{"url":"https://clinicaltrials.gov/study/NCT03386513?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","route":"/trials/nct03386513/","field":"outcomes.source (Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants)"},{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","route":"/trials/nct03386513/","field":"outcomes.source (Overall Survival in Total R/R BPDCN Participants)"}]},{"url":"https://clinicaltrials.gov/study/NCT03386617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03386617","kind":"trial","name":"AKY15-HK-301_NEPA Study","route":"/trials/nct03386617/","field":"links","label":"ClinicalTrials.gov NCT03386617"}]},{"url":"https://clinicaltrials.gov/study/NCT03386734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","field":"links","label":"ClinicalTrials.gov NCT03386734"}]},{"url":"https://clinicaltrials.gov/study/NCT03390504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","field":"links","label":"ClinicalTrials.gov NCT03390504"},{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","field":"links","label":"ClinicalTrials.gov NCT03390504: THOR"}]},{"url":"https://clinicaltrials.gov/study/NCT03390686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03390686","kind":"trial","name":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ","route":"/trials/nct03390686/","field":"links","label":"ClinicalTrials.gov NCT03390686"}]},{"url":"https://clinicaltrials.gov/study/NCT03391466","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","field":"links","label":"ClinicalTrials.gov NCT03391466"},{"id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","field":"links","label":"ClinicalTrials.gov NCT03391466: ZUMA-7"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03391466"}]},{"url":"https://clinicaltrials.gov/study/NCT03391869","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03391869","kind":"trial","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct03391869/","field":"links","label":"ClinicalTrials.gov NCT03391869"}]},{"url":"https://clinicaltrials.gov/study/NCT03392428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"links","label":"ClinicalTrials.gov NCT03392428"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","field":"links","label":"ClinicalTrials.gov NCT03392428: TheraP (ANZUP 1603)"},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","field":"links","label":"ClinicalTrials.gov NCT03392428: TheraP (ANZUP 1603)"},{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT03392428"},{"id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","field":"links","label":"ClinicalTrials.gov NCT03392428"}]},{"url":"https://clinicaltrials.gov/study/NCT03393884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","route":"/trials/nct03393884/","field":"links","label":"ClinicalTrials.gov NCT03393884"}]},{"url":"https://clinicaltrials.gov/study/NCT03394365","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03394365","kind":"trial","name":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu","route":"/trials/nct03394365/","field":"links","label":"ClinicalTrials.gov NCT03394365"}]},{"url":"https://clinicaltrials.gov/study/NCT03395197","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"links","label":"ClinicalTrials.gov NCT03395197"},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"outcomes.source (Overall survival, all comers (final))"},{"id":"paper-talapro-2-lancet-2023","kind":"paper","name":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","route":"/key-papers/paper-talapro-2-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT03395197"},{"id":"paper-talapro-2-lancet-2025-update","kind":"paper","name":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","route":"/key-papers/paper-talapro-2-lancet-2025-update/","field":"links","label":"ClinicalTrials.gov NCT03395197"}],"archive":"https://web.archive.org/web/20260215150011/https://clinicaltrials.gov/study/NCT03395197"},{"url":"https://clinicaltrials.gov/study/NCT03401294","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03401294","kind":"trial","name":"Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","route":"/trials/nct03401294/","field":"links","label":"ClinicalTrials.gov NCT03401294"}]},{"url":"https://clinicaltrials.gov/study/NCT03407144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/","field":"links","label":"ClinicalTrials.gov NCT03407144"}]},{"url":"https://clinicaltrials.gov/study/NCT03413254","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03413254","kind":"trial","name":"Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases","route":"/trials/nct03413254/","field":"links","label":"ClinicalTrials.gov NCT03413254"}]},{"url":"https://clinicaltrials.gov/study/NCT03416179","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03416179","kind":"trial","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","route":"/trials/nct03416179/","field":"links","label":"ClinicalTrials.gov NCT03416179"}]},{"url":"https://clinicaltrials.gov/study/NCT03416179?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03416179","kind":"trial","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","route":"/trials/nct03416179/","field":"outcomes.source (Intensive Study: Overall Survival (OS))"},{"id":"nct03416179","kind":"trial","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","route":"/trials/nct03416179/","field":"outcomes.source (Non-intensive Study: Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03424005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/","field":"links","label":"ClinicalTrials.gov NCT03424005"}]},{"url":"https://clinicaltrials.gov/study/NCT03425643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","field":"links","label":"ClinicalTrials.gov NCT03425643"},{"id":"paper-keynote-671-n-engl-j-med-2023","kind":"paper","name":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-671-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT03425643"},{"id":"paper-keynote-671-ann-oncol-2026-update","kind":"paper","name":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","route":"/key-papers/paper-keynote-671-ann-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT03425643"}],"archive":"https://web.archive.org/web/20260514170635/https://clinicaltrials.gov/study/NCT03425643"},{"url":"https://clinicaltrials.gov/study/NCT03426904","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03426904","kind":"trial","name":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","route":"/trials/nct03426904/","field":"links","label":"ClinicalTrials.gov NCT03426904"}]},{"url":"https://clinicaltrials.gov/study/NCT03428477","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03428477","kind":"trial","name":"EPA for Metastasis Trial 2","route":"/trials/nct03428477/","field":"links","label":"ClinicalTrials.gov NCT03428477"}]},{"url":"https://clinicaltrials.gov/study/NCT03430843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","field":"links","label":"ClinicalTrials.gov NCT03430843"}]},{"url":"https://clinicaltrials.gov/study/NCT03431350","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03431350","kind":"trial","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct03431350/","field":"links","label":"ClinicalTrials.gov NCT03431350"}]},{"url":"https://clinicaltrials.gov/study/NCT03431350?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03431350","kind":"trial","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct03431350/","field":"outcomes.source (Combination 1: Part 2: Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03434379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"links","label":"ClinicalTrials.gov NCT03434379"},{"id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","field":"links","label":"ClinicalTrials.gov NCT03434379: IMbrave150"},{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/","field":"links","label":"ClinicalTrials.gov NCT03434379"},{"id":"paper-atezolizumab-hcc-j-hepatol-2022","kind":"paper","name":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","route":"/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/","field":"links","label":"ClinicalTrials.gov NCT03434379"}]},{"url":"https://clinicaltrials.gov/study/NCT03435796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","route":"/trials/nct03435796/","field":"links","label":"ClinicalTrials.gov NCT03435796"}]},{"url":"https://clinicaltrials.gov/study/NCT03436485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/","field":"links","label":"ClinicalTrials.gov NCT03436485"},{"id":"nct03436485","kind":"trial","name":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct03436485/","field":"links","label":"ClinicalTrials.gov NCT03436485"}]},{"url":"https://clinicaltrials.gov/study/NCT03439709","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03439709","kind":"trial","name":"Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma","route":"/trials/nct03439709/","field":"links","label":"ClinicalTrials.gov NCT03439709"}]},{"url":"https://clinicaltrials.gov/study/NCT03441113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03441113","kind":"trial","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","route":"/trials/nct03441113/","field":"links","label":"ClinicalTrials.gov NCT03441113"}]},{"url":"https://clinicaltrials.gov/study/NCT03444844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03444844","kind":"trial","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","route":"/trials/nct03444844/","field":"links","label":"ClinicalTrials.gov NCT03444844"}]},{"url":"https://clinicaltrials.gov/study/NCT03448549","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03448549","kind":"trial","name":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","route":"/trials/nct03448549/","field":"links","label":"ClinicalTrials.gov NCT03448549"}]},{"url":"https://clinicaltrials.gov/study/NCT03456076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/","field":"links","label":"ClinicalTrials.gov NCT03456076"},{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03456076"}],"archive":"https://web.archive.org/web/20260416174313/https://clinicaltrials.gov/study/NCT03456076"},{"url":"https://clinicaltrials.gov/study/NCT03458260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03458260","kind":"trial","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","route":"/trials/nct03458260/","field":"links","label":"ClinicalTrials.gov NCT03458260"}]},{"url":"https://clinicaltrials.gov/study/NCT03459534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/","field":"links","label":"ClinicalTrials.gov NCT03459534"}]},{"url":"https://clinicaltrials.gov/study/NCT03459846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03459846","kind":"trial","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","route":"/trials/nct03459846/","field":"links","label":"ClinicalTrials.gov NCT03459846"}]},{"url":"https://clinicaltrials.gov/study/NCT03459846?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03459846","kind":"trial","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","route":"/trials/nct03459846/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03462719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","field":"links","label":"ClinicalTrials.gov NCT03462719"},{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","field":"links","label":"ClinicalTrials.gov NCT03462719: GLOW"}]},{"url":"https://clinicaltrials.gov/study/NCT03463252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03463252","kind":"trial","name":"Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","route":"/trials/nct03463252/","field":"links","label":"ClinicalTrials.gov NCT03463252"}]},{"url":"https://clinicaltrials.gov/study/NCT03464305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03464305","kind":"trial","name":"ASPIRIN Trial Belgium","route":"/trials/nct03464305/","field":"links","label":"ClinicalTrials.gov NCT03464305"}]},{"url":"https://clinicaltrials.gov/study/NCT03465722","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/","field":"links","label":"ClinicalTrials.gov NCT03465722"}]},{"url":"https://clinicaltrials.gov/study/NCT03470922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","field":"links","label":"ClinicalTrials.gov NCT03470922"},{"id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","field":"links","label":"ClinicalTrials.gov NCT03470922: RELATIVITY-047"},{"id":"paper-relativity-047-nejm-2022","kind":"paper","name":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","route":"/key-papers/paper-relativity-047-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03470922"},{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03470922"}]},{"url":"https://clinicaltrials.gov/study/NCT03473743","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03473743","kind":"trial","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","route":"/trials/nct03473743/","field":"links","label":"ClinicalTrials.gov NCT03473743"}]},{"url":"https://clinicaltrials.gov/study/NCT03473743?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03473743","kind":"trial","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","route":"/trials/nct03473743/","field":"outcomes.source (Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT03476681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/","field":"links","label":"ClinicalTrials.gov NCT03476681"},{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","route":"/trials/nct03476681/","field":"links","label":"ClinicalTrials.gov NCT03476681"}]},{"url":"https://clinicaltrials.gov/study/NCT03478488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","field":"links","label":"ClinicalTrials.gov NCT03478488"}]},{"url":"https://clinicaltrials.gov/study/NCT03482102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03482102","kind":"trial","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","route":"/trials/nct03482102/","field":"links","label":"ClinicalTrials.gov NCT03482102"}]},{"url":"https://clinicaltrials.gov/study/NCT03485209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03485209","kind":"trial","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","route":"/trials/nct03485209/","field":"links","label":"ClinicalTrials.gov NCT03485209"}]},{"url":"https://clinicaltrials.gov/study/NCT03486873","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03486873","kind":"trial","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","route":"/trials/nct03486873/","field":"links","label":"ClinicalTrials.gov NCT03486873"}]},{"url":"https://clinicaltrials.gov/study/NCT03491683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03491683","kind":"trial","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","route":"/trials/nct03491683/","field":"links","label":"ClinicalTrials.gov NCT03491683"}]},{"url":"https://clinicaltrials.gov/study/NCT03492671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03492671","kind":"trial","name":"Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","route":"/trials/nct03492671/","field":"links","label":"ClinicalTrials.gov NCT03492671"}]},{"url":"https://clinicaltrials.gov/study/NCT03498326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03498326","kind":"trial","name":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","route":"/trials/nct03498326/","field":"links","label":"ClinicalTrials.gov NCT03498326"}]},{"url":"https://clinicaltrials.gov/study/NCT03498521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/","field":"links","label":"ClinicalTrials.gov NCT03498521"}]},{"url":"https://clinicaltrials.gov/study/NCT03498716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/","field":"links","label":"ClinicalTrials.gov NCT03498716"}]},{"url":"https://clinicaltrials.gov/study/NCT03504397","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","field":"links","label":"ClinicalTrials.gov NCT03504397"},{"id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","field":"links","label":"ClinicalTrials.gov NCT03504397: SPOTLIGHT & GLOW"},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","field":"links","label":"ClinicalTrials.gov NCT03504397: SPOTLIGHT & GLOW"},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT03504397"}]},{"url":"https://clinicaltrials.gov/study/NCT03504423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"devimistat","kind":"drug","name":"Devimistat","route":"/drugs/devimistat/","field":"links","label":"ClinicalTrials.gov NCT03504423"},{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","field":"links","label":"ClinicalTrials.gov NCT03504423"}]},{"url":"https://clinicaltrials.gov/study/NCT03505320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/","field":"links","label":"ClinicalTrials.gov NCT03505320"}]},{"url":"https://clinicaltrials.gov/study/NCT03505710","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","field":"links","label":"ClinicalTrials.gov NCT03505710"}]},{"url":"https://clinicaltrials.gov/study/NCT03511664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"links","label":"ClinicalTrials.gov NCT03511664"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT03511664"}]},{"url":"https://clinicaltrials.gov/study/NCT03516708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03516708","kind":"trial","name":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct03516708/","field":"links","label":"ClinicalTrials.gov NCT03516708"}]},{"url":"https://clinicaltrials.gov/study/NCT03517449","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","field":"links","label":"ClinicalTrials.gov NCT03517449"},{"id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","field":"links","label":"ClinicalTrials.gov NCT03517449: KEYNOTE-775 / Study 309"}]},{"url":"https://clinicaltrials.gov/study/NCT03519230","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","route":"/trials/nct03519230/","field":"links","label":"ClinicalTrials.gov NCT03519230"}]},{"url":"https://clinicaltrials.gov/study/NCT03519971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","route":"/trials/pacific-2/","field":"links","label":"ClinicalTrials.gov NCT03519971"}]},{"url":"https://clinicaltrials.gov/study/NCT03519971?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","route":"/trials/pacific-2/","field":"outcomes.source (Progression-free survival (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT03521154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/","field":"links","label":"ClinicalTrials.gov NCT03521154"},{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03521154"}],"archive":"https://web.archive.org/web/20251211052424/https://clinicaltrials.gov/study/NCT03521154"},{"url":"https://clinicaltrials.gov/study/NCT03522246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","field":"links","label":"ClinicalTrials.gov NCT03522246"}]},{"url":"https://clinicaltrials.gov/study/NCT03524508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","field":"links","label":"ClinicalTrials.gov NCT03524508"},{"id":"paper-nifty-liposomal-irinotecan-lancet-oncol-2021","kind":"paper","name":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","route":"/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/","field":"links","label":"ClinicalTrials.gov NCT03524508"}]},{"url":"https://clinicaltrials.gov/study/NCT03526835","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03526835","kind":"trial","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","route":"/trials/nct03526835/","field":"links","label":"ClinicalTrials.gov NCT03526835"}]},{"url":"https://clinicaltrials.gov/study/NCT03528694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"potomac","kind":"trial","name":"POTOMAC","route":"/trials/potomac/","field":"links","label":"ClinicalTrials.gov NCT03528694"},{"id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","field":"links","label":"ClinicalTrials.gov NCT03528694: POTOMAC"}]},{"url":"https://clinicaltrials.gov/study/NCT03529110","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","field":"links","label":"ClinicalTrials.gov NCT03529110"},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","field":"outcomes.source (Overall survival)"},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03529110"},{"id":"paper-destiny-breast03-lancet-2023-update","kind":"paper","name":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","route":"/key-papers/paper-destiny-breast03-lancet-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03529110"}]},{"url":"https://clinicaltrials.gov/study/NCT03533283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","field":"links","label":"ClinicalTrials.gov NCT03533283"}]},{"url":"https://clinicaltrials.gov/study/NCT03539536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"luminosity","kind":"trial","name":"LUMINOSITY","route":"/trials/luminosity/","field":"links","label":"ClinicalTrials.gov NCT03539536"},{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT03539536"},{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/","field":"links","label":"ClinicalTrials.gov NCT03539536"}]},{"url":"https://clinicaltrials.gov/study/NCT03539744","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03539744","kind":"trial","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","route":"/trials/nct03539744/","field":"links","label":"ClinicalTrials.gov NCT03539744"}]},{"url":"https://clinicaltrials.gov/study/NCT03539822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03539822","kind":"trial","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","route":"/trials/nct03539822/","field":"links","label":"ClinicalTrials.gov NCT03539822"}]},{"url":"https://clinicaltrials.gov/study/NCT03547973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/","field":"links","label":"ClinicalTrials.gov NCT03547973"}]},{"url":"https://clinicaltrials.gov/study/NCT03548207","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","field":"links","label":"ClinicalTrials.gov NCT03548207"},{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/","field":"links","label":"ClinicalTrials.gov NCT03548207"},{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","kind":"paper","name":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/","field":"links","label":"ClinicalTrials.gov NCT03548207"}]},{"url":"https://clinicaltrials.gov/study/NCT03553836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"links","label":"ClinicalTrials.gov NCT03553836"},{"id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","field":"links","label":"ClinicalTrials.gov NCT03553836: KEYNOTE-716"},{"id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","field":"links","label":"ClinicalTrials.gov NCT03553836"}]},{"url":"https://clinicaltrials.gov/study/NCT03556228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/","field":"links","label":"ClinicalTrials.gov NCT03556228"}]},{"url":"https://clinicaltrials.gov/study/NCT03556839","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","field":"links","label":"ClinicalTrials.gov NCT03556839"}]},{"url":"https://clinicaltrials.gov/study/NCT03562637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","route":"/trials/nct03562637/","field":"links","label":"ClinicalTrials.gov NCT03562637"}]},{"url":"https://clinicaltrials.gov/study/NCT03564340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","field":"links","label":"ClinicalTrials.gov NCT03564340"},{"id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/","field":"links","label":"ClinicalTrials.gov NCT03564340"}]},{"url":"https://clinicaltrials.gov/study/NCT03567889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/","field":"links","label":"ClinicalTrials.gov NCT03567889"}]},{"url":"https://clinicaltrials.gov/study/NCT03570892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/","field":"links","label":"ClinicalTrials.gov NCT03570892"}]},{"url":"https://clinicaltrials.gov/study/NCT03575351","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","field":"links","label":"ClinicalTrials.gov NCT03575351"},{"id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","field":"links","label":"ClinicalTrials.gov NCT03575351: TRANSFORM"},{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/","field":"links","label":"ClinicalTrials.gov NCT03575351"}]},{"url":"https://clinicaltrials.gov/study/NCT03576417","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/","field":"links","label":"ClinicalTrials.gov NCT03576417"}]},{"url":"https://clinicaltrials.gov/study/NCT03579836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03579836","kind":"trial","name":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","route":"/trials/nct03579836/","field":"links","label":"ClinicalTrials.gov NCT03579836"}]},{"url":"https://clinicaltrials.gov/study/NCT03581786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","field":"links","label":"ClinicalTrials.gov NCT03581786"}]},{"url":"https://clinicaltrials.gov/study/NCT03583710","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adiuvo-2","kind":"trial","name":"ADIUVO-2","route":"/trials/adiuvo-2/","field":"links","label":"ClinicalTrials.gov NCT03583710"}]},{"url":"https://clinicaltrials.gov/study/NCT03589326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","field":"links","label":"ClinicalTrials.gov NCT03589326: PhALLCON"},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/","field":"links","label":"ClinicalTrials.gov NCT03589326"},{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","field":"links","label":"ClinicalTrials.gov NCT03589326: PhALLCON"}]},{"url":"https://clinicaltrials.gov/study/NCT03589469","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","field":"links","label":"ClinicalTrials.gov NCT03589469"}]},{"url":"https://clinicaltrials.gov/study/NCT03591510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03591510","kind":"trial","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","route":"/trials/nct03591510/","field":"links","label":"ClinicalTrials.gov NCT03591510"}]},{"url":"https://clinicaltrials.gov/study/NCT03592472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"renaviv","kind":"trial","name":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","route":"/trials/renaviv/","field":"links","label":"ClinicalTrials.gov NCT03592472"}]},{"url":"https://clinicaltrials.gov/study/NCT03599713","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"links","label":"ClinicalTrials.gov NCT03599713"}]},{"url":"https://clinicaltrials.gov/study/NCT03600233","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03600233","kind":"trial","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","route":"/trials/nct03600233/","field":"links","label":"ClinicalTrials.gov NCT03600233"}]},{"url":"https://clinicaltrials.gov/study/NCT03600441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/","field":"links","label":"ClinicalTrials.gov NCT03600441"}]},{"url":"https://clinicaltrials.gov/study/NCT03600883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"links","label":"ClinicalTrials.gov NCT03600883"}]},{"url":"https://clinicaltrials.gov/study/NCT03602859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","field":"links","label":"ClinicalTrials.gov NCT03602859"}]},{"url":"https://clinicaltrials.gov/study/NCT03602859?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03603795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03603795","kind":"trial","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","route":"/trials/nct03603795/","field":"links","label":"ClinicalTrials.gov NCT03603795"}]},{"url":"https://clinicaltrials.gov/study/NCT03606967","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03606967","kind":"trial","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03606967/","field":"links","label":"ClinicalTrials.gov NCT03606967"}]},{"url":"https://clinicaltrials.gov/study/NCT03607539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/","field":"links","label":"ClinicalTrials.gov NCT03607539"},{"id":"paper-orient-11-lung-cancer-2022-update","kind":"paper","name":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","route":"/key-papers/paper-orient-11-lung-cancer-2022-update/","field":"links","label":"ClinicalTrials.gov NCT03607539"},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","field":"links","label":"ClinicalTrials.gov NCT03607539"}]},{"url":"https://clinicaltrials.gov/study/NCT03608631","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03608631","kind":"trial","name":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","route":"/trials/nct03608631/","field":"links","label":"ClinicalTrials.gov NCT03608631"},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/","field":"links","label":"iExosomes phase 1 (NCT03608631)"}]},{"url":"https://clinicaltrials.gov/study/NCT03611868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03611868","kind":"trial","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","route":"/trials/nct03611868/","field":"links","label":"ClinicalTrials.gov NCT03611868"}]},{"url":"https://clinicaltrials.gov/study/NCT03615326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","field":"links","label":"ClinicalTrials.gov NCT03615326"}]},{"url":"https://clinicaltrials.gov/study/NCT03625037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","field":"links","label":"ClinicalTrials.gov NCT03625037"},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","field":"links","label":"ClinicalTrials.gov NCT03625037"}]},{"url":"https://clinicaltrials.gov/study/NCT03634540","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03634540","kind":"trial","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","route":"/trials/nct03634540/","field":"links","label":"ClinicalTrials.gov NCT03634540"}]},{"url":"https://clinicaltrials.gov/study/NCT03635021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03635021","kind":"trial","name":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu","route":"/trials/nct03635021/","field":"links","label":"ClinicalTrials.gov NCT03635021"}]},{"url":"https://clinicaltrials.gov/study/NCT03635567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","field":"links","label":"ClinicalTrials.gov NCT03635567"}]},{"url":"https://clinicaltrials.gov/study/NCT03635983","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03635983","kind":"trial","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","route":"/trials/nct03635983/","field":"links","label":"ClinicalTrials.gov NCT03635983"}]},{"url":"https://clinicaltrials.gov/study/NCT03635983?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03635983","kind":"trial","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","route":"/trials/nct03635983/","field":"outcomes.source (Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR))"},{"id":"nct03635983","kind":"trial","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","route":"/trials/nct03635983/","field":"outcomes.source (Progression-free Survival (PFS) Per Blinded Independent Central Review (BICR))"},{"id":"nct03635983","kind":"trial","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","route":"/trials/nct03635983/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03637816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03637816","kind":"trial","name":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","route":"/trials/nct03637816/","field":"links","label":"ClinicalTrials.gov NCT03637816"}]},{"url":"https://clinicaltrials.gov/study/NCT03639948","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/","field":"links","label":"ClinicalTrials.gov NCT03639948"}]},{"url":"https://clinicaltrials.gov/study/NCT03640481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"links","label":"ClinicalTrials.gov NCT03640481"},{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/","field":"links","label":"ClinicalTrials.gov NCT03640481"}]},{"url":"https://clinicaltrials.gov/study/NCT03643133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03643133","kind":"trial","name":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","route":"/trials/nct03643133/","field":"links","label":"ClinicalTrials.gov NCT03643133"}]},{"url":"https://clinicaltrials.gov/study/NCT03647163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03647163","kind":"trial","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","route":"/trials/nct03647163/","field":"links","label":"ClinicalTrials.gov NCT03647163"}]},{"url":"https://clinicaltrials.gov/study/NCT03651128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/","field":"links","label":"ClinicalTrials.gov NCT03651128"},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT03651128"}]},{"url":"https://clinicaltrials.gov/study/NCT03652064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","field":"links","label":"ClinicalTrials.gov NCT03652064"},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","field":"links","label":"ClinicalTrials.gov NCT03652064: CEPHEUS"},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/","field":"links","label":"ClinicalTrials.gov NCT03652064"}]},{"url":"https://clinicaltrials.gov/study/NCT03653507","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","field":"links","label":"GLOW NCT03653507"}]},{"url":"https://clinicaltrials.gov/study/NCT03656536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","field":"links","label":"ClinicalTrials.gov NCT03656536"}]},{"url":"https://clinicaltrials.gov/study/NCT03659448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03659448","kind":"trial","name":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","route":"/trials/nct03659448/","field":"links","label":"ClinicalTrials.gov NCT03659448"}]},{"url":"https://clinicaltrials.gov/study/NCT03665441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/","field":"links","label":"ClinicalTrials.gov NCT03665441"},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","field":"links","label":"ClinicalTrials.gov NCT03665441"}]},{"url":"https://clinicaltrials.gov/study/NCT03667170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","route":"/trials/nct03667170/","field":"links","label":"ClinicalTrials.gov NCT03667170"}]},{"url":"https://clinicaltrials.gov/study/NCT03668639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03668639","kind":"trial","name":"Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin","route":"/trials/nct03668639/","field":"links","label":"ClinicalTrials.gov NCT03668639"}]},{"url":"https://clinicaltrials.gov/study/NCT03669965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","route":"/trials/nct03669965/","field":"links","label":"ClinicalTrials.gov NCT03669965"}]},{"url":"https://clinicaltrials.gov/study/NCT03671018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03671018","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct03671018/","field":"links","label":"ClinicalTrials.gov NCT03671018"}]},{"url":"https://clinicaltrials.gov/study/NCT03671044","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03671044","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients","route":"/trials/nct03671044/","field":"links","label":"ClinicalTrials.gov NCT03671044"}]},{"url":"https://clinicaltrials.gov/study/NCT03671252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03671252","kind":"trial","name":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co","route":"/trials/nct03671252/","field":"links","label":"ClinicalTrials.gov NCT03671252"}]},{"url":"https://clinicaltrials.gov/study/NCT03673072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gain-igbc","kind":"trial","name":"GAIN (AIO/CALGP/ACO)","route":"/trials/gain-igbc/","field":"links","label":"ClinicalTrials.gov NCT03673072"},{"id":"paper-gain-trial-protocol-bmc-cancer-2020","kind":"paper","name":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial","route":"/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/","field":"links","label":"ClinicalTrials.gov NCT03673072"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT03673072"},{"id":"idea-gbc-neoadjuvant-for-high-risk-incidental-cancer","kind":"idea","name":"Chemotherapy before the second operation for high-risk incidental gallbladder cancer","route":"/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/","field":"links","label":"ClinicalTrials.gov NCT03673072"}]},{"url":"https://clinicaltrials.gov/study/NCT03673501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","field":"links","label":"ClinicalTrials.gov NCT03673501"}]},{"url":"https://clinicaltrials.gov/study/NCT03673501?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","field":"outcomes.source (Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population)"},{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","field":"outcomes.source (Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population)"},{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","field":"outcomes.source (Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population)"},{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","field":"outcomes.source (Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population)"}]},{"url":"https://clinicaltrials.gov/study/NCT03673943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03673943","kind":"trial","name":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","route":"/trials/nct03673943/","field":"links","label":"ClinicalTrials.gov NCT03673943"}]},{"url":"https://clinicaltrials.gov/study/NCT03675256","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","field":"links","label":"ClinicalTrials.gov NCT03675256"},{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","field":"links","label":"ClinicalTrials.gov NCT03675256: KEN SHE (single-dose HPV vaccine)"}]},{"url":"https://clinicaltrials.gov/study/NCT03675737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","field":"links","label":"ClinicalTrials.gov NCT03675737"}]},{"url":"https://clinicaltrials.gov/study/NCT03678025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/","field":"links","label":"ClinicalTrials.gov NCT03678025"}]},{"url":"https://clinicaltrials.gov/study/NCT03678428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03678428","kind":"trial","name":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","route":"/trials/nct03678428/","field":"links","label":"ClinicalTrials.gov NCT03678428"}]},{"url":"https://clinicaltrials.gov/study/NCT03678883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","field":"links","label":"ClinicalTrials.gov NCT03678883"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"links","label":"ClinicalTrials.gov NCT03678883"}]},{"url":"https://clinicaltrials.gov/study/NCT03682068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03682068","kind":"trial","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","route":"/trials/nct03682068/","field":"links","label":"ClinicalTrials.gov NCT03682068"}]},{"url":"https://clinicaltrials.gov/study/NCT03682536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT03682536"},{"id":"commands","kind":"trial","name":"COMMANDS","route":"/trials/commands/","field":"links","label":"ClinicalTrials.gov NCT03682536"}]},{"url":"https://clinicaltrials.gov/study/NCT03686124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct03686124/","field":"links","label":"ClinicalTrials.gov NCT03686124"}]},{"url":"https://clinicaltrials.gov/study/NCT03686215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","field":"links","label":"ClinicalTrials.gov NCT03686215"},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","field":"links","label":"ClinicalTrials.gov NCT03686215"}]},{"url":"https://clinicaltrials.gov/study/NCT03689712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","field":"links","label":"ClinicalTrials.gov NCT03689712"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"links","label":"ClinicalTrials.gov NCT03689712"},{"id":"paper-roman-anderson-eclinicalmedicine-2025","kind":"paper","name":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)","route":"/key-papers/paper-roman-anderson-eclinicalmedicine-2025/","field":"links","label":"ClinicalTrials.gov NCT03689712"}]},{"url":"https://clinicaltrials.gov/study/NCT03690388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","field":"links","label":"ClinicalTrials.gov NCT03690388"}]},{"url":"https://clinicaltrials.gov/study/NCT03690388?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03691090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","field":"links","label":"ClinicalTrials.gov NCT03691090"}]},{"url":"https://clinicaltrials.gov/study/NCT03698019","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","field":"links","label":"ClinicalTrials.gov NCT03698019"},{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","field":"links","label":"ClinicalTrials.gov NCT03698019: SWOG S1801"},{"id":"paper-swog-s1801-n-engl-j-med-2023","kind":"paper","name":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","route":"/key-papers/paper-swog-s1801-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT03698019"}]},{"url":"https://clinicaltrials.gov/study/NCT03700476","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/","field":"links","label":"ClinicalTrials.gov NCT03700476"}]},{"url":"https://clinicaltrials.gov/study/NCT03701334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","field":"links","label":"ClinicalTrials.gov NCT03701334"},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","field":"outcomes.source (Invasive disease-free survival at 4 years)"},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03701334"},{"id":"paper-natalee-jama-oncol-2025-update","kind":"paper","name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","route":"/key-papers/paper-natalee-jama-oncol-2025-update/","field":"links","label":"ClinicalTrials.gov NCT03701334"}]},{"url":"https://clinicaltrials.gov/study/NCT03703297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","field":"links","label":"ClinicalTrials.gov NCT03703297"},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03703297"}]},{"url":"https://clinicaltrials.gov/study/NCT03706365","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03706365"},{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","field":"links","label":"ClinicalTrials.gov NCT03706365"}]},{"url":"https://clinicaltrials.gov/study/NCT03706365?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","field":"outcomes.source (Radiographic Progression Free Survival (rPFS))"},{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","field":"outcomes.source (Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR))"}]},{"url":"https://clinicaltrials.gov/study/NCT03706690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03706690"},{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","field":"links","label":"ClinicalTrials.gov NCT03706690"}]},{"url":"https://clinicaltrials.gov/study/NCT03706690?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","field":"outcomes.source (Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set))"},{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","field":"outcomes.source (Overall Survival (OS), ITT set)"},{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","field":"outcomes.source (Objective Response Rate (ORR), ITT set)"}]},{"url":"https://clinicaltrials.gov/study/NCT03707509","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/","field":"links","label":"ClinicalTrials.gov NCT03707509"}]},{"url":"https://clinicaltrials.gov/study/NCT03709680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03709680","kind":"trial","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","route":"/trials/nct03709680/","field":"links","label":"ClinicalTrials.gov NCT03709680"}]},{"url":"https://clinicaltrials.gov/study/NCT03710603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","field":"links","label":"ClinicalTrials.gov NCT03710603"},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","field":"links","label":"ClinicalTrials.gov NCT03710603: PERSEUS"},{"id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/","field":"links","label":"ClinicalTrials.gov NCT03710603: PERSEUS"},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03710603"}]},{"url":"https://clinicaltrials.gov/study/NCT03711032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03711032","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","route":"/trials/nct03711032/","field":"links","label":"ClinicalTrials.gov NCT03711032"}]},{"url":"https://clinicaltrials.gov/study/NCT03711305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT03711305"},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","field":"links","label":"ClinicalTrials.gov NCT03711305"}]},{"url":"https://clinicaltrials.gov/study/NCT03711877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03711877","kind":"trial","name":"Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)","route":"/trials/nct03711877/","field":"links","label":"ClinicalTrials.gov NCT03711877"}]},{"url":"https://clinicaltrials.gov/study/NCT03712605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stamp-merkel","kind":"trial","name":"STAMP (EA6174)","route":"/trials/stamp-merkel/","field":"links","label":"ClinicalTrials.gov NCT03712605"}]},{"url":"https://clinicaltrials.gov/study/NCT03713593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","field":"links","label":"ClinicalTrials.gov NCT03713593"}]},{"url":"https://clinicaltrials.gov/study/NCT03722420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","route":"/trials/nct03722420/","field":"links","label":"ClinicalTrials.gov NCT03722420"}]},{"url":"https://clinicaltrials.gov/study/NCT03725059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT03725059"},{"id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/","field":"links","label":"ClinicalTrials.gov NCT03725059"}]},{"url":"https://clinicaltrials.gov/study/NCT03728556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gemstone-301","kind":"trial","name":"GEMSTONE-301","route":"/trials/gemstone-301/","field":"links","label":"ClinicalTrials.gov NCT03728556"}]},{"url":"https://clinicaltrials.gov/study/NCT03729245","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03729245","kind":"trial","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","route":"/trials/nct03729245/","field":"links","label":"ClinicalTrials.gov NCT03729245"}]},{"url":"https://clinicaltrials.gov/study/NCT03731260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/","field":"links","label":"ClinicalTrials.gov NCT03731260"}]},{"url":"https://clinicaltrials.gov/study/NCT03732677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","field":"links","label":"ClinicalTrials.gov NCT03732677"},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","field":"links","label":"ClinicalTrials.gov NCT03732677: NIAGARA"},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03732677"}]},{"url":"https://clinicaltrials.gov/study/NCT03732820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"links","label":"ClinicalTrials.gov NCT03732820"},{"id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03732820"}],"archive":"https://web.archive.org/web/20260416174141/https://clinicaltrials.gov/study/NCT03732820"},{"url":"https://clinicaltrials.gov/study/NCT03734016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","field":"links","label":"ClinicalTrials.gov NCT03734016"},{"id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","field":"links","label":"ClinicalTrials.gov NCT03734016: ALPINE"},{"id":"paper-zanubrutinib-cll-n-engl-j-med-2023","kind":"paper","name":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","route":"/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT03734016"}]},{"url":"https://clinicaltrials.gov/study/NCT03734029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"links","label":"ClinicalTrials.gov NCT03734029"},{"id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","field":"links","label":"ClinicalTrials.gov NCT03734029: DESTINY-Breast04"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT03734029"},{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/","field":"links","label":"ClinicalTrials.gov NCT03734029"}]},{"url":"https://clinicaltrials.gov/study/NCT03736889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03736889","kind":"trial","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","route":"/trials/nct03736889/","field":"links","label":"ClinicalTrials.gov NCT03736889"}]},{"url":"https://clinicaltrials.gov/study/NCT03737643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","field":"links","label":"ClinicalTrials.gov NCT03737643"},{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","field":"links","label":"ClinicalTrials.gov NCT03737643: DUO-O / ENGOT-ov46"}]},{"url":"https://clinicaltrials.gov/study/NCT03739684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03739684","kind":"trial","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct03739684/","field":"links","label":"ClinicalTrials.gov NCT03739684"}]},{"url":"https://clinicaltrials.gov/study/NCT03740893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/","field":"links","label":"ClinicalTrials.gov NCT03740893"}]},{"url":"https://clinicaltrials.gov/study/NCT03742102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03742102-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study","route":"/key-papers/paper-nct03742102-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT03742102"},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","field":"links","label":"ClinicalTrials.gov NCT03742102"}]},{"url":"https://clinicaltrials.gov/study/NCT03742102?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","field":"outcomes.source (Dose Limiting Toxicity (DLT) Events)"},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","field":"outcomes.source (Overall Survival (Duration))"},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03742895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","route":"/trials/nct03742895/","field":"links","label":"ClinicalTrials.gov NCT03742895"}]},{"url":"https://clinicaltrials.gov/study/NCT03742895?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","route":"/trials/nct03742895/","field":"outcomes.source (Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1)"}]},{"url":"https://clinicaltrials.gov/study/NCT03744715","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03744715","kind":"trial","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","route":"/trials/nct03744715/","field":"links","label":"ClinicalTrials.gov NCT03744715"}]},{"url":"https://clinicaltrials.gov/study/NCT03744715?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03744715","kind":"trial","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","route":"/trials/nct03744715/","field":"outcomes.source (Number of Participants With Adverse Events (AEs))"}]},{"url":"https://clinicaltrials.gov/study/NCT03745170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","field":"links","label":"ClinicalTrials.gov NCT03745170"}]},{"url":"https://clinicaltrials.gov/study/NCT03748641","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","field":"links","label":"ClinicalTrials.gov NCT03748641"},{"id":"paper-magnitude-j-clin-oncol-2023","kind":"paper","name":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-magnitude-j-clin-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03748641"}],"archive":"https://web.archive.org/web/20260417020438/https://clinicaltrials.gov/study/NCT03748641"},{"url":"https://clinicaltrials.gov/study/NCT03755739","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03755739","kind":"trial","name":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","route":"/trials/nct03755739/","field":"links","label":"ClinicalTrials.gov NCT03755739"}]},{"url":"https://clinicaltrials.gov/study/NCT03755791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03755791","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","route":"/trials/nct03755791/","field":"links","label":"ClinicalTrials.gov NCT03755791"}]},{"url":"https://clinicaltrials.gov/study/NCT03755791?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03755791","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","route":"/trials/nct03755791/","field":"outcomes.source (Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population)"},{"id":"nct03755791","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","route":"/trials/nct03755791/","field":"outcomes.source (Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population)"}]},{"url":"https://clinicaltrials.gov/study/NCT03761108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","field":"links","label":"ClinicalTrials.gov NCT03761108"}]},{"url":"https://clinicaltrials.gov/study/NCT03762018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","field":"links","label":"ClinicalTrials.gov NCT03762018"}]},{"url":"https://clinicaltrials.gov/study/NCT03764293","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","field":"links","label":"ClinicalTrials.gov NCT03764293 (CARES-310)"},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","field":"links","label":"ClinicalTrials.gov NCT03764293"}]},{"url":"https://clinicaltrials.gov/study/NCT03765918","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","field":"links","label":"ClinicalTrials.gov NCT03765918"},{"id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","field":"links","label":"ClinicalTrials.gov NCT03765918: KEYNOTE-689"}]},{"url":"https://clinicaltrials.gov/study/NCT03767244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03767244-n-engl-j-med-2026","kind":"paper","name":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","route":"/key-papers/paper-nct03767244-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT03767244"},{"id":"nct03767244","kind":"trial","name":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","route":"/trials/nct03767244/","field":"links","label":"ClinicalTrials.gov NCT03767244"}]},{"url":"https://clinicaltrials.gov/study/NCT03767348","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/","field":"links","label":"ClinicalTrials.gov NCT03767348"}]},{"url":"https://clinicaltrials.gov/study/NCT03768063","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/","field":"links","label":"ClinicalTrials.gov NCT03768063"}]},{"url":"https://clinicaltrials.gov/study/NCT03768414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/","field":"links","label":"ClinicalTrials.gov NCT03768414"}]},{"url":"https://clinicaltrials.gov/study/NCT03769506","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03769506","kind":"trial","name":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","route":"/trials/nct03769506/","field":"links","label":"ClinicalTrials.gov NCT03769506"}]},{"url":"https://clinicaltrials.gov/study/NCT03772899","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/","field":"links","label":"ClinicalTrials.gov NCT03772899"},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","field":"links","label":"ClinicalTrials.gov NCT03772899"}]},{"url":"https://clinicaltrials.gov/study/NCT03774732","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03774732","kind":"trial","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","route":"/trials/nct03774732/","field":"links","label":"ClinicalTrials.gov NCT03774732"}]},{"url":"https://clinicaltrials.gov/study/NCT03775486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT03775486"},{"id":"nct03775486","kind":"trial","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","route":"/trials/nct03775486/","field":"links","label":"ClinicalTrials.gov NCT03775486"}]},{"url":"https://clinicaltrials.gov/study/NCT03777982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03777982","kind":"trial","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","route":"/trials/nct03777982/","field":"links","label":"ClinicalTrials.gov NCT03777982"}]},{"url":"https://clinicaltrials.gov/study/NCT03778229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03778229"},{"id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/","field":"links","label":"SAVANNAH (NCT03778229)"},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","field":"links","label":"ClinicalTrials.gov NCT03778229"}]},{"url":"https://clinicaltrials.gov/study/NCT03778229?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","field":"outcomes.source (Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set)"},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","field":"outcomes.source (Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set)"},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","field":"outcomes.source (Overall Survival (OS); Target Population Analysis Set)"}]},{"url":"https://clinicaltrials.gov/study/NCT03778931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","field":"links","label":"ClinicalTrials.gov NCT03778931"}],"archive":"https://web.archive.org/web/20260802122900/https://clinicaltrials.gov/study/NCT03778931"},{"url":"https://clinicaltrials.gov/study/NCT03778957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","field":"links","label":"ClinicalTrials.gov NCT03778957"},{"id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","field":"links","label":"ClinicalTrials.gov NCT03778957: EMERALD-1"}]},{"url":"https://clinicaltrials.gov/study/NCT03780049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03780049","kind":"trial","name":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","route":"/trials/nct03780049/","field":"links","label":"ClinicalTrials.gov NCT03780049"}]},{"url":"https://clinicaltrials.gov/study/NCT03783442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","field":"links","label":"ClinicalTrials.gov NCT03783442"}]},{"url":"https://clinicaltrials.gov/study/NCT03784014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03784014","kind":"trial","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","route":"/trials/nct03784014/","field":"links","label":"ClinicalTrials.gov NCT03784014"}]},{"url":"https://clinicaltrials.gov/study/NCT03785249","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03785249-n-engl-j-med-2022","kind":"paper","name":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","route":"/key-papers/paper-nct03785249-n-engl-j-med-2022/","field":"links","label":"ClinicalTrials.gov NCT03785249"},{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","route":"/trials/nct03785249/","field":"links","label":"ClinicalTrials.gov NCT03785249"}]},{"url":"https://clinicaltrials.gov/study/NCT03785964","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","field":"links","label":"ClinicalTrials.gov NCT03785964"},{"id":"idea-desmoid-intermittent-dosing","kind":"idea","name":"Intermittent or stop-and-restart nirogacestat in desmoid tumours","route":"/ideas/idea-desmoid-intermittent-dosing/","field":"links","label":"ClinicalTrials.gov NCT03785964: DeFi"}]},{"url":"https://clinicaltrials.gov/study/NCT03786783","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/","field":"links","label":"ClinicalTrials.gov NCT03786783"}]},{"url":"https://clinicaltrials.gov/study/NCT03786783?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/","field":"links","label":"ClinicalTrials.gov results"},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/","field":"outcomes.source (Unacceptable toxicity over the first 5 cycles (registry results))"},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/","field":"outcomes.source (Feasibility failure over the first 5 cycles (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT03787992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/","field":"links","label":"ClinicalTrials.gov NCT03787992"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","field":"links","label":"ClinicalTrials.gov NCT03787992"}]},{"url":"https://clinicaltrials.gov/study/NCT03789604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT03789604"},{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/","field":"links","label":"ClinicalTrials.gov NCT03789604"},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","field":"links","label":"ClinicalTrials.gov NCT03789604"}]},{"url":"https://clinicaltrials.gov/study/NCT03790111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03790111","kind":"trial","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct03790111/","field":"links","label":"ClinicalTrials.gov NCT03790111"}]},{"url":"https://clinicaltrials.gov/study/NCT03790111?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03790111","kind":"trial","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct03790111/","field":"outcomes.source (Project Overall Survival Rate at Month 6)"},{"id":"nct03790111","kind":"trial","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct03790111/","field":"outcomes.source (Median Progression Free Survival)"},{"id":"nct03790111","kind":"trial","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct03790111/","field":"outcomes.source (Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT03793179","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03793179","kind":"trial","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","route":"/trials/nct03793179/","field":"links","label":"ClinicalTrials.gov NCT03793179"}]},{"url":"https://clinicaltrials.gov/study/NCT03793478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03793478","kind":"trial","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","route":"/trials/nct03793478/","field":"links","label":"ClinicalTrials.gov NCT03793478"}]},{"url":"https://clinicaltrials.gov/study/NCT03794440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","field":"links","label":"ClinicalTrials.gov NCT03794440"}]},{"url":"https://clinicaltrials.gov/study/NCT03800134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT03800134"},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/","field":"links","label":"ClinicalTrials.gov NCT03800134"}]},{"url":"https://clinicaltrials.gov/study/NCT03801083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03801083","kind":"trial","name":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers","route":"/trials/nct03801083/","field":"links","label":"ClinicalTrials.gov NCT03801083"}]},{"url":"https://clinicaltrials.gov/study/NCT03801525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03801525","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","route":"/trials/nct03801525/","field":"links","label":"ClinicalTrials.gov NCT03801525"}]},{"url":"https://clinicaltrials.gov/study/NCT03801525?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03801525","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","route":"/trials/nct03801525/","field":"outcomes.source (Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria)"},{"id":"nct03801525","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","route":"/trials/nct03801525/","field":"outcomes.source (Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria)"}]},{"url":"https://clinicaltrials.gov/study/NCT03803553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03803553","kind":"trial","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","route":"/trials/nct03803553/","field":"links","label":"ClinicalTrials.gov NCT03803553"}]},{"url":"https://clinicaltrials.gov/study/NCT03808337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03808337","kind":"trial","name":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina","route":"/trials/nct03808337/","field":"links","label":"ClinicalTrials.gov NCT03808337"}]},{"url":"https://clinicaltrials.gov/study/NCT03811002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03811002","kind":"trial","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","route":"/trials/nct03811002/","field":"links","label":"ClinicalTrials.gov NCT03811002"}]},{"url":"https://clinicaltrials.gov/study/NCT03812874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03812874","kind":"trial","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","route":"/trials/nct03812874/","field":"links","label":"ClinicalTrials.gov NCT03812874"}]},{"url":"https://clinicaltrials.gov/study/NCT03815643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03815643","kind":"trial","name":"Avelumab Program Rollover Study","route":"/trials/nct03815643/","field":"links","label":"ClinicalTrials.gov NCT03815643"}]},{"url":"https://clinicaltrials.gov/study/NCT03816163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03816163","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","route":"/trials/nct03816163/","field":"links","label":"ClinicalTrials.gov NCT03816163"}]},{"url":"https://clinicaltrials.gov/study/NCT03821233","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/","field":"links","label":"ClinicalTrials.gov NCT03821233 (phase 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT03828227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03828227","kind":"trial","name":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","route":"/trials/nct03828227/","field":"links","label":"ClinicalTrials.gov NCT03828227"}]},{"url":"https://clinicaltrials.gov/study/NCT03829462","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03829462","kind":"trial","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","route":"/trials/nct03829462/","field":"links","label":"ClinicalTrials.gov NCT03829462"}]},{"url":"https://clinicaltrials.gov/study/NCT03829462?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03829462","kind":"trial","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","route":"/trials/nct03829462/","field":"outcomes.source (Overall Survival)"},{"id":"nct03829462","kind":"trial","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","route":"/trials/nct03829462/","field":"outcomes.source (Progression-free Survival (PFS))"},{"id":"nct03829462","kind":"trial","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","route":"/trials/nct03829462/","field":"outcomes.source (Number of Patients With an Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT03829969","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","field":"links","label":"ClinicalTrials.gov NCT03829969"}]},{"url":"https://clinicaltrials.gov/study/NCT03830866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","field":"links","label":"ClinicalTrials.gov NCT03830866"}]},{"url":"https://clinicaltrials.gov/study/NCT03833154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03833154","kind":"trial","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","route":"/trials/nct03833154/","field":"links","label":"ClinicalTrials.gov NCT03833154"}]},{"url":"https://clinicaltrials.gov/study/NCT03834493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-641","kind":"trial","name":"KEYNOTE-641","route":"/trials/keynote-641/","field":"links","label":"ClinicalTrials.gov NCT03834493"}]},{"url":"https://clinicaltrials.gov/study/NCT03834506","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","field":"links","label":"ClinicalTrials.gov NCT03834506"}]},{"url":"https://clinicaltrials.gov/study/NCT03836261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","field":"links","label":"ClinicalTrials.gov NCT03836261: AMPLIFY"},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"links","label":"ClinicalTrials.gov NCT03836261"},{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","field":"links","label":"ClinicalTrials.gov NCT03836261: AMPLIFY"},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT03836261"}]},{"url":"https://clinicaltrials.gov/study/NCT03836352","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/","field":"links","label":"ClinicalTrials.gov NCT03836352"}]},{"url":"https://clinicaltrials.gov/study/NCT03837899","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","field":"links","label":"ClinicalTrials.gov NCT03837899"}]},{"url":"https://clinicaltrials.gov/study/NCT03837899?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","field":"outcomes.source (Dose-Expansion Phase Only: Objective Response Rate (ORR))"},{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","field":"outcomes.source (Dose-Expansion Phase Only: Duration of Response (DOR))"},{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","field":"outcomes.source (Dose-Expansion Phase Only: PFS)"}]},{"url":"https://clinicaltrials.gov/study/NCT03838159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","kind":"paper","name":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT03838159"}]},{"url":"https://clinicaltrials.gov/study/NCT03844048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/","field":"links","label":"ClinicalTrials.gov NCT03844048"}]},{"url":"https://clinicaltrials.gov/study/NCT03847428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03847428","kind":"trial","name":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","route":"/trials/nct03847428/","field":"links","label":"ClinicalTrials.gov NCT03847428"}]},{"url":"https://clinicaltrials.gov/study/NCT03849118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03849118","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study","route":"/trials/nct03849118/","field":"links","label":"ClinicalTrials.gov NCT03849118"}]},{"url":"https://clinicaltrials.gov/study/NCT03849768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/","field":"links","label":"ClinicalTrials.gov NCT03849768"},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","field":"links","label":"ClinicalTrials.gov NCT03849768"}]},{"url":"https://clinicaltrials.gov/study/NCT03850574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct03850574/","field":"links","label":"ClinicalTrials.gov NCT03850574"}]},{"url":"https://clinicaltrials.gov/study/NCT03851445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"links","label":"ClinicalTrials.gov NCT03851445"}]},{"url":"https://clinicaltrials.gov/study/NCT03851640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/","field":"links","label":"ClinicalTrials.gov NCT03851640"},{"id":"nct03851640","kind":"trial","name":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","route":"/trials/nct03851640/","field":"links","label":"ClinicalTrials.gov NCT03851640"}]},{"url":"https://clinicaltrials.gov/study/NCT03862430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","field":"links","label":"ClinicalTrials.gov NCT03862430"}]},{"url":"https://clinicaltrials.gov/study/NCT03865082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03865082","kind":"trial","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","route":"/trials/nct03865082/","field":"links","label":"ClinicalTrials.gov NCT03865082"}]},{"url":"https://clinicaltrials.gov/study/NCT03866525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03866525","kind":"trial","name":"OH2 Oncolytic Viral Therapy in Solid Tumors","route":"/trials/nct03866525/","field":"links","label":"ClinicalTrials.gov NCT03866525"}]},{"url":"https://clinicaltrials.gov/study/NCT03869892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03869892","kind":"trial","name":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","route":"/trials/nct03869892/","field":"links","label":"ClinicalTrials.gov NCT03869892"}]},{"url":"https://clinicaltrials.gov/study/NCT03873402","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","route":"/trials/nct03873402/","field":"links","label":"ClinicalTrials.gov NCT03873402"}]},{"url":"https://clinicaltrials.gov/study/NCT03874026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03874026","kind":"trial","name":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","route":"/trials/nct03874026/","field":"links","label":"ClinicalTrials.gov NCT03874026"}]},{"url":"https://clinicaltrials.gov/study/NCT03875235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"ClinicalTrials.gov NCT03875235"},{"id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","field":"links","label":"ClinicalTrials.gov NCT03875235: TOPAZ-1"},{"id":"paper-topaz-1-three-year-survival-j-hepatol-2025","kind":"paper","name":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","route":"/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/","field":"links","label":"ClinicalTrials.gov NCT03875235"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT03875235"},{"id":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","kind":"paper","name":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","route":"/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/","field":"links","label":"ClinicalTrials.gov NCT03875235"}]},{"url":"https://clinicaltrials.gov/study/NCT03875781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03875781","kind":"trial","name":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","route":"/trials/nct03875781/","field":"links","label":"ClinicalTrials.gov NCT03875781"}]},{"url":"https://clinicaltrials.gov/study/NCT03876769","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","route":"/trials/nct03876769/","field":"links","label":"ClinicalTrials.gov NCT03876769"}]},{"url":"https://clinicaltrials.gov/study/NCT03878849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","field":"links","label":"ClinicalTrials.gov NCT03878849"}]},{"url":"https://clinicaltrials.gov/study/NCT03888105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03888105","kind":"trial","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","route":"/trials/nct03888105/","field":"links","label":"ClinicalTrials.gov NCT03888105"}]},{"url":"https://clinicaltrials.gov/study/NCT03897543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","field":"links","label":"ClinicalTrials.gov NCT03897543"}]},{"url":"https://clinicaltrials.gov/study/NCT03897881","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT03897881"},{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT03897881"},{"id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","route":"/trials/nct03897881/","field":"links","label":"ClinicalTrials.gov NCT03897881"}]},{"url":"https://clinicaltrials.gov/study/NCT03899155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/","field":"links","label":"ClinicalTrials.gov NCT03899155"}]},{"url":"https://clinicaltrials.gov/study/NCT03899636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03899636","kind":"trial","name":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","route":"/trials/nct03899636/","field":"links","label":"ClinicalTrials.gov NCT03899636"}]},{"url":"https://clinicaltrials.gov/study/NCT03899792","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","route":"/trials/nct03899792/","field":"links","label":"ClinicalTrials.gov NCT03899792"}]},{"url":"https://clinicaltrials.gov/study/NCT03899792?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","route":"/trials/nct03899792/","field":"outcomes.source (Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study)"}]},{"url":"https://clinicaltrials.gov/study/NCT03901339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","field":"links","label":"ClinicalTrials.gov NCT03901339"},{"id":"paper-tropics-02-lancet-2023","kind":"paper","name":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-tropics-02-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT03901339"}]},{"url":"https://clinicaltrials.gov/study/NCT03907488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","field":"links","label":"ClinicalTrials.gov NCT03907488"},{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","field":"links","label":"ClinicalTrials.gov NCT03907488: SWOG S1826"},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT03907488"}]},{"url":"https://clinicaltrials.gov/study/NCT03907852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/","field":"links","label":"ClinicalTrials.gov NCT03907852"},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/","field":"links","label":"ClinicalTrials.gov NCT03907852"}]},{"url":"https://clinicaltrials.gov/study/NCT03912389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/","field":"links","label":"ClinicalTrials.gov NCT03912389"}]},{"url":"https://clinicaltrials.gov/study/NCT03914612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","field":"links","label":"ClinicalTrials.gov NCT03914612"},{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","field":"links","label":"ClinicalTrials.gov NCT03914612: NRG-GY018 / KEYNOTE-868"}]},{"url":"https://clinicaltrials.gov/study/NCT03914625","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","field":"links","label":"ClinicalTrials.gov NCT03914625"},{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","field":"links","label":"ClinicalTrials.gov NCT03914625: COG AALL1731"},{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT03914625"}]},{"url":"https://clinicaltrials.gov/study/NCT03915184","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/","field":"links","label":"ClinicalTrials.gov NCT03915184"}]},{"url":"https://clinicaltrials.gov/study/NCT03915951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03915951"},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/","field":"links","label":"ClinicalTrials.gov NCT03915951"}]},{"url":"https://clinicaltrials.gov/study/NCT03916627","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","kind":"paper","name":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","route":"/key-papers/paper-nct03916627-lancet-gastroenterol-hepatol-2022/","field":"links","label":"ClinicalTrials.gov NCT03916627"},{"id":"nct03916627","kind":"trial","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","route":"/trials/nct03916627/","field":"links","label":"ClinicalTrials.gov NCT03916627"}]},{"url":"https://clinicaltrials.gov/study/NCT03919461","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03919461","kind":"trial","name":"Colorectal Metastasis Prevention International Trial 2","route":"/trials/nct03919461/","field":"links","label":"ClinicalTrials.gov NCT03919461"}]},{"url":"https://clinicaltrials.gov/study/NCT03924895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","field":"links","label":"ClinicalTrials.gov NCT03924895"},{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","field":"links","label":"ClinicalTrials.gov NCT03924895: EV-303 / KEYNOTE-905"},{"id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","field":"links","label":"ClinicalTrials.gov NCT03924895: EV-303 / KEYNOTE-905"}]},{"url":"https://clinicaltrials.gov/study/NCT03925662","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03925662","kind":"trial","name":"Mebendazole as Adjuvant Treatment for Colon Cancer","route":"/trials/nct03925662/","field":"links","label":"ClinicalTrials.gov NCT03925662"}]},{"url":"https://clinicaltrials.gov/study/NCT03926338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03926338","kind":"trial","name":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","route":"/trials/nct03926338/","field":"links","label":"ClinicalTrials.gov NCT03926338"}]},{"url":"https://clinicaltrials.gov/study/NCT03927456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/","field":"links","label":"ClinicalTrials.gov NCT03927456"},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","field":"links","label":"ClinicalTrials.gov NCT03927456"}]},{"url":"https://clinicaltrials.gov/study/NCT03930953","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","route":"/trials/nct03930953/","field":"links","label":"ClinicalTrials.gov NCT03930953"}]},{"url":"https://clinicaltrials.gov/study/NCT03932331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03932331","kind":"trial","name":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign","route":"/trials/nct03932331/","field":"links","label":"ClinicalTrials.gov NCT03932331"}]},{"url":"https://clinicaltrials.gov/study/NCT03932331?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03932331","kind":"trial","name":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign","route":"/trials/nct03932331/","field":"outcomes.source (Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR))"},{"id":"nct03932331","kind":"trial","name":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign","route":"/trials/nct03932331/","field":"outcomes.source (Phase II: Percentage of Participants With Overall Survival (OS) at Month 6)"}]},{"url":"https://clinicaltrials.gov/study/NCT03933735","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03933735","kind":"trial","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct03933735/","field":"links","label":"ClinicalTrials.gov NCT03933735"}]},{"url":"https://clinicaltrials.gov/study/NCT03934372","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03934372","kind":"trial","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","route":"/trials/nct03934372/","field":"links","label":"ClinicalTrials.gov NCT03934372"}]},{"url":"https://clinicaltrials.gov/study/NCT03934567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03934567","kind":"trial","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03934567/","field":"links","label":"ClinicalTrials.gov NCT03934567"}]},{"url":"https://clinicaltrials.gov/study/NCT03934866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","field":"links","label":"ClinicalTrials.gov NCT03934866"}]},{"url":"https://clinicaltrials.gov/study/NCT03936153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct03936153/","field":"links","label":"ClinicalTrials.gov NCT03936153"}]},{"url":"https://clinicaltrials.gov/study/NCT03937141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03937141","kind":"trial","name":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","route":"/trials/nct03937141/","field":"links","label":"ClinicalTrials.gov NCT03937141"}]},{"url":"https://clinicaltrials.gov/study/NCT03937154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03937154","kind":"trial","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","route":"/trials/nct03937154/","field":"links","label":"ClinicalTrials.gov NCT03937154"}]},{"url":"https://clinicaltrials.gov/study/NCT03937219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","field":"links","label":"ClinicalTrials.gov NCT03937219"}]},{"url":"https://clinicaltrials.gov/study/NCT03937830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03937830","kind":"trial","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","route":"/trials/nct03937830/","field":"links","label":"ClinicalTrials.gov NCT03937830"}]},{"url":"https://clinicaltrials.gov/study/NCT03941093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pamrevlumab","kind":"drug","name":"Pamrevlumab","route":"/drugs/pamrevlumab/","field":"links","label":"ClinicalTrials.gov NCT03941093"},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/","field":"links","label":"ClinicalTrials.gov NCT03941093"},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/","field":"outcomes.source (Overall survival)"},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/","field":"outcomes.source (Progression-free survival (RECIST 1.1))"}]},{"url":"https://clinicaltrials.gov/study/NCT03944772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03944772"},{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","route":"/trials/nct03944772/","field":"links","label":"ClinicalTrials.gov NCT03944772"}]},{"url":"https://clinicaltrials.gov/study/NCT03945162","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03945162","kind":"trial","name":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","route":"/trials/nct03945162/","field":"links","label":"ClinicalTrials.gov NCT03945162"}]},{"url":"https://clinicaltrials.gov/study/NCT03947385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/","field":"links","label":"ClinicalTrials.gov NCT03947385"}]},{"url":"https://clinicaltrials.gov/study/NCT03949283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03949283","kind":"trial","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","route":"/trials/nct03949283/","field":"links","label":"ClinicalTrials.gov NCT03949283"}]},{"url":"https://clinicaltrials.gov/study/NCT03952585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","field":"links","label":"ClinicalTrials.gov NCT03952585"},{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","field":"outcomes.source (HN005: progression-free survival at 2 years (phase II non-inferiority))"},{"id":"hpv-deescalation-caution","kind":"pairing","name":"Caution: de-escalating radiation on HPV status alone","route":"/pairings/hpv-deescalation-caution/","field":"links","label":"ClinicalTrials.gov NCT03952585: NRG-HN002 & NRG-HN005 (HPV+ de-escalation)"},{"id":"idea-cthpv-adapted-deescalation","kind":"idea","name":"ctHPV-DNA-adapted de-escalation of chemoradiation","route":"/ideas/idea-cthpv-adapted-deescalation/","field":"links","label":"ClinicalTrials.gov NCT03952585: NRG-HN002 & NRG-HN005 (HPV+ de-escalation)"}]},{"url":"https://clinicaltrials.gov/study/NCT03957902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03957902","kind":"trial","name":"Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer","route":"/trials/nct03957902/","field":"links","label":"ClinicalTrials.gov NCT03957902"}]},{"url":"https://clinicaltrials.gov/study/NCT03960840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","route":"/trials/nct03960840/","field":"links","label":"ClinicalTrials.gov NCT03960840"}]},{"url":"https://clinicaltrials.gov/study/NCT03964727","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","route":"/trials/nct03964727/","field":"links","label":"ClinicalTrials.gov NCT03964727"}]},{"url":"https://clinicaltrials.gov/study/NCT03964727?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","route":"/trials/nct03964727/","field":"outcomes.source (Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment)"},{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","route":"/trials/nct03964727/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT03965234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03965234","kind":"trial","name":"Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","route":"/trials/nct03965234/","field":"links","label":"ClinicalTrials.gov NCT03965234"}]},{"url":"https://clinicaltrials.gov/study/NCT03967223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","field":"links","label":"ClinicalTrials.gov NCT03967223 (IGNYTE-ESO)"},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","field":"links","label":"ClinicalTrials.gov NCT03967223"},{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","field":"links","label":"ClinicalTrials.gov NCT03967223: IGNYTE-ESO"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","field":"links","label":"ClinicalTrials.gov NCT03967223: IGNYTE-ESO"}]},{"url":"https://clinicaltrials.gov/study/NCT03967977","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","route":"/trials/nct03967977/","field":"links","label":"ClinicalTrials.gov NCT03967977"}]},{"url":"https://clinicaltrials.gov/study/NCT03969004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"links","label":"ClinicalTrials.gov NCT03969004"}]},{"url":"https://clinicaltrials.gov/study/NCT03970447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","field":"links","label":"ClinicalTrials.gov NCT03970447"}]},{"url":"https://clinicaltrials.gov/study/NCT03970746","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03970746","kind":"trial","name":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","route":"/trials/nct03970746/","field":"links","label":"ClinicalTrials.gov NCT03970746"}]},{"url":"https://clinicaltrials.gov/study/NCT03971474","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/","field":"links","label":"ClinicalTrials.gov NCT03971474"}]},{"url":"https://clinicaltrials.gov/study/NCT03972488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT03972488"},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","field":"links","label":"ClinicalTrials.gov NCT03972488"}]},{"url":"https://clinicaltrials.gov/study/NCT03972488?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","field":"outcomes.source (Progression Free Survival (PFS) Per Central Assessment)"},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","field":"outcomes.source (Overall Response Rate (ORR) Per Central Assessment (Key Secondary))"}]},{"url":"https://clinicaltrials.gov/study/NCT03972657","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","field":"links","label":"ClinicalTrials.gov NCT03972657"}]},{"url":"https://clinicaltrials.gov/study/NCT03974022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct03974022-j-clin-oncol-2025","kind":"paper","name":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","route":"/key-papers/paper-nct03974022-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT03974022"},{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/","field":"links","label":"ClinicalTrials.gov NCT03974022"}]},{"url":"https://clinicaltrials.gov/study/NCT03974022?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/","field":"outcomes.source (Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).)"}]},{"url":"https://clinicaltrials.gov/study/NCT03975049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03975049","kind":"trial","name":"Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct03975049/","field":"links","label":"ClinicalTrials.gov NCT03975049"}]},{"url":"https://clinicaltrials.gov/study/NCT03975647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/","field":"links","label":"ClinicalTrials.gov NCT03975647"},{"id":"paper-her2climb-02-ann-oncol-2026","kind":"paper","name":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","route":"/key-papers/paper-her2climb-02-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT03975647"}]},{"url":"https://clinicaltrials.gov/study/NCT03975907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"links","label":"ClinicalTrials.gov NCT03975907"}]},{"url":"https://clinicaltrials.gov/study/NCT03977194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03977194","kind":"trial","name":"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy","route":"/trials/nct03977194/","field":"links","label":"ClinicalTrials.gov NCT03977194"}]},{"url":"https://clinicaltrials.gov/study/NCT03977233","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03977233","kind":"trial","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","route":"/trials/nct03977233/","field":"links","label":"ClinicalTrials.gov NCT03977233"}]},{"url":"https://clinicaltrials.gov/study/NCT03980054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","route":"/trials/nct03980054/","field":"links","label":"ClinicalTrials.gov NCT03980054"}]},{"url":"https://clinicaltrials.gov/study/NCT03981796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","field":"links","label":"ClinicalTrials.gov NCT03981796"},{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","field":"links","label":"ClinicalTrials.gov NCT03981796: RUBY / ENGOT-EN6 / GOG-3031"},{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT03981796"}]},{"url":"https://clinicaltrials.gov/study/NCT03989414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct03989414","kind":"trial","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","route":"/trials/nct03989414/","field":"links","label":"ClinicalTrials.gov NCT03989414"}]},{"url":"https://clinicaltrials.gov/study/NCT03997123","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT03997123"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT03997123"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","field":"links","label":"ClinicalTrials.gov NCT03997123"}]},{"url":"https://clinicaltrials.gov/study/NCT04002297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04002297","kind":"trial","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","route":"/trials/nct04002297/","field":"links","label":"ClinicalTrials.gov NCT04002297"}]},{"url":"https://clinicaltrials.gov/study/NCT04003636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","field":"links","label":"ClinicalTrials.gov NCT04003636"},{"id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","field":"links","label":"ClinicalTrials.gov NCT04003636: KEYNOTE-966"}]},{"url":"https://clinicaltrials.gov/study/NCT04005339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04005339","kind":"trial","name":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","route":"/trials/nct04005339/","field":"links","label":"ClinicalTrials.gov NCT04005339"}]},{"url":"https://clinicaltrials.gov/study/NCT04008030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","field":"links","label":"ClinicalTrials.gov NCT04008030"},{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT04008030"}]},{"url":"https://clinicaltrials.gov/study/NCT04008797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","route":"/trials/nct04008797/","field":"links","label":"ClinicalTrials.gov NCT04008797"}]},{"url":"https://clinicaltrials.gov/study/NCT04014075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-gastric02","kind":"trial","name":"DESTINY-Gastric02","route":"/trials/destiny-gastric02/","field":"links","label":"ClinicalTrials.gov NCT04014075"}]},{"url":"https://clinicaltrials.gov/study/NCT04014075?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-gastric02","kind":"trial","name":"DESTINY-Gastric02","route":"/trials/destiny-gastric02/","field":"outcomes.source (Confirmed objective response by independent central review (registry results, primary analysis))"},{"id":"destiny-gastric02","kind":"trial","name":"DESTINY-Gastric02","route":"/trials/destiny-gastric02/","field":"outcomes.source (Confirmed objective response by independent central review (registry results, later analysis))"}]},{"url":"https://clinicaltrials.gov/study/NCT04014205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04014205","kind":"trial","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","route":"/trials/nct04014205/","field":"links","label":"ClinicalTrials.gov NCT04014205"}]},{"url":"https://clinicaltrials.gov/study/NCT04014530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04014530","kind":"trial","name":"Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","route":"/trials/nct04014530/","field":"links","label":"ClinicalTrials.gov NCT04014530"}]},{"url":"https://clinicaltrials.gov/study/NCT04023526","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/","field":"links","label":"ClinicalTrials.gov NCT04023526"}]},{"url":"https://clinicaltrials.gov/study/NCT04023526?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/","field":"outcomes.source (Percentage of Participants With Complete Remission (CR))"},{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04024696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","route":"/trials/nct04024696/","field":"links","label":"ClinicalTrials.gov NCT04024696"}]},{"url":"https://clinicaltrials.gov/study/NCT04025879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04025879-n-engl-j-med-2024","kind":"paper","name":"Perioperative Nivolumab in Resectable Lung Cancer","route":"/key-papers/paper-nct04025879-n-engl-j-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04025879"},{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","field":"links","label":"ClinicalTrials.gov NCT04025879"}]},{"url":"https://clinicaltrials.gov/study/NCT04025879?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","field":"outcomes.source (Event-Free Survival (EFS) by BICR)"}]},{"url":"https://clinicaltrials.gov/study/NCT04035486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT04035486"},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","field":"links","label":"ClinicalTrials.gov NCT04035486"},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","field":"outcomes.source (Overall survival)"},{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/","field":"links","label":"ClinicalTrials.gov NCT04035486"}]},{"url":"https://clinicaltrials.gov/study/NCT04036682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04036682"},{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","route":"/trials/nct04036682/","field":"links","label":"ClinicalTrials.gov NCT04036682"}]},{"url":"https://clinicaltrials.gov/study/NCT04039607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","field":"links","label":"ClinicalTrials.gov NCT04039607"}]},{"url":"https://clinicaltrials.gov/study/NCT04041310","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04041310","kind":"trial","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","route":"/trials/nct04041310/","field":"links","label":"ClinicalTrials.gov NCT04041310"}]},{"url":"https://clinicaltrials.gov/study/NCT04042831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/","field":"links","label":"ClinicalTrials.gov NCT04042831"}]},{"url":"https://clinicaltrials.gov/study/NCT04042831?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/","field":"outcomes.source (Number of Patients Alive and Progression-free at First Scan)"},{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04044768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT04044768"},{"id":"nct04044768","kind":"trial","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","route":"/trials/nct04044768/","field":"links","label":"ClinicalTrials.gov NCT04044768"}]},{"url":"https://clinicaltrials.gov/study/NCT04044768?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04044768","kind":"trial","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","route":"/trials/nct04044768/","field":"outcomes.source (Overall Response Rate (ORR) (Cohort 1))"}]},{"url":"https://clinicaltrials.gov/study/NCT04050345","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-tracc-clin-cancer-res-2024","kind":"paper","name":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","route":"/key-papers/paper-tracc-clin-cancer-res-2024/","field":"links","label":"ClinicalTrials.gov NCT04050345"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ClinicalTrials.gov NCT04050345"},{"id":"tracc","kind":"trial","name":"TRACC","route":"/trials/tracc/","field":"links","label":"ClinicalTrials.gov NCT04050345"}]},{"url":"https://clinicaltrials.gov/study/NCT04050436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04050436","kind":"trial","name":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","route":"/trials/nct04050436/","field":"links","label":"ClinicalTrials.gov NCT04050436"}]},{"url":"https://clinicaltrials.gov/study/NCT04063163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/","field":"links","label":"ClinicalTrials.gov NCT04063163"},{"id":"paper-astrum-005-jama-2022","kind":"paper","name":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","route":"/key-papers/paper-astrum-005-jama-2022/","field":"links","label":"ClinicalTrials.gov NCT04063163"}]},{"url":"https://clinicaltrials.gov/study/NCT04064060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/","field":"links","label":"ClinicalTrials.gov NCT04064060"}]},{"url":"https://clinicaltrials.gov/study/NCT04065399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","field":"links","label":"ClinicalTrials.gov NCT04065399"},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/","field":"links","label":"ClinicalTrials.gov NCT04065399"}]},{"url":"https://clinicaltrials.gov/study/NCT04067336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","field":"links","label":"ClinicalTrials.gov NCT04067336"}]},{"url":"https://clinicaltrials.gov/study/NCT04068103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04068103","kind":"trial","name":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","route":"/trials/nct04068103/","field":"links","label":"ClinicalTrials.gov NCT04068103"}]},{"url":"https://clinicaltrials.gov/study/NCT04068194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04068194","kind":"trial","name":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","route":"/trials/nct04068194/","field":"links","label":"ClinicalTrials.gov NCT04068194"}]},{"url":"https://clinicaltrials.gov/study/NCT04068597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/","field":"links","label":"ClinicalTrials.gov NCT04068597"}]},{"url":"https://clinicaltrials.gov/study/NCT04068610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04068610-br-j-cancer-2024","kind":"paper","name":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","route":"/key-papers/paper-nct04068610-br-j-cancer-2024/","field":"links","label":"ClinicalTrials.gov NCT04068610"},{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","field":"links","label":"ClinicalTrials.gov NCT04068610"}]},{"url":"https://clinicaltrials.gov/study/NCT04068610?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","field":"outcomes.source (Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2)"},{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","field":"outcomes.source (Overall Survival (OS) Per RECIST v1.1 in Part 1)"},{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","field":"outcomes.source (Progression-Free Survival (PFS) Per RECIST v1.1 in Part 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT04071457","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drammatic","kind":"trial","name":"DRAMMATIC","route":"/trials/drammatic/","field":"links","label":"ClinicalTrials.gov NCT04071457"}]},{"url":"https://clinicaltrials.gov/study/NCT04075292","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04075292","kind":"trial","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct04075292/","field":"links","label":"ClinicalTrials.gov NCT04075292"}]},{"url":"https://clinicaltrials.gov/study/NCT04075292?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04075292","kind":"trial","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct04075292/","field":"outcomes.source (Progression Free Survival (PFS) Assessed by BICR)"}]},{"url":"https://clinicaltrials.gov/study/NCT04076059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","field":"links","label":"ClinicalTrials.gov NCT04076059"}]},{"url":"https://clinicaltrials.gov/study/NCT04076059?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","field":"outcomes.source (Time to Prostrate Specific Antigen (PSA) Progression)"},{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","field":"outcomes.source (Radiographic Progression-Free Survival (rPFS))"},{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04077099","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","route":"/trials/nct04077099/","field":"links","label":"ClinicalTrials.gov NCT04077099"}]},{"url":"https://clinicaltrials.gov/study/NCT04077723","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/","field":"links","label":"ClinicalTrials.gov NCT04077723"}]},{"url":"https://clinicaltrials.gov/study/NCT04078295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","route":"/trials/nct04078295/","field":"links","label":"ClinicalTrials.gov NCT04078295"}]},{"url":"https://clinicaltrials.gov/study/NCT04079166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/","field":"links","label":"ClinicalTrials.gov NCT04079166"}]},{"url":"https://clinicaltrials.gov/study/NCT04082364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04082364","kind":"trial","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","route":"/trials/nct04082364/","field":"links","label":"ClinicalTrials.gov NCT04082364"}]},{"url":"https://clinicaltrials.gov/study/NCT04082364?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04082364","kind":"trial","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","route":"/trials/nct04082364/","field":"outcomes.source (Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviews)"}]},{"url":"https://clinicaltrials.gov/study/NCT04083235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","field":"links","label":"ClinicalTrials.gov NCT04083235"},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT04083235"}],"archive":"https://web.archive.org/web/20260424094411/https://clinicaltrials.gov/study/NCT04083235"},{"url":"https://clinicaltrials.gov/study/NCT04083599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04083599","kind":"trial","name":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","route":"/trials/nct04083599/","field":"links","label":"ClinicalTrials.gov NCT04083599"}]},{"url":"https://clinicaltrials.gov/study/NCT04084496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/","field":"links","label":"ClinicalTrials.gov NCT04084496"}]},{"url":"https://clinicaltrials.gov/study/NCT04086264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","route":"/trials/nct04086264/","field":"links","label":"ClinicalTrials.gov NCT04086264"}]},{"url":"https://clinicaltrials.gov/study/NCT04087421","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04087421","kind":"trial","name":"Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome","route":"/trials/nct04087421/","field":"links","label":"ClinicalTrials.gov NCT04087421"}]},{"url":"https://clinicaltrials.gov/study/NCT04090736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04090736","kind":"trial","name":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","route":"/trials/nct04090736/","field":"links","label":"ClinicalTrials.gov NCT04090736"}]},{"url":"https://clinicaltrials.gov/study/NCT04092283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04092283","kind":"trial","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","route":"/trials/nct04092283/","field":"links","label":"ClinicalTrials.gov NCT04092283"}]},{"url":"https://clinicaltrials.gov/study/NCT04093167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04093167","kind":"trial","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","route":"/trials/nct04093167/","field":"links","label":"ClinicalTrials.gov NCT04093167"}]},{"url":"https://clinicaltrials.gov/study/NCT04093505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04093505","kind":"trial","name":"Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","route":"/trials/nct04093505/","field":"links","label":"ClinicalTrials.gov NCT04093505"}]},{"url":"https://clinicaltrials.gov/study/NCT04094311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/","field":"links","label":"ClinicalTrials.gov NCT04094311"}]},{"url":"https://clinicaltrials.gov/study/NCT04094610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04094610","kind":"trial","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","route":"/trials/nct04094610/","field":"links","label":"ClinicalTrials.gov NCT04094610"}]},{"url":"https://clinicaltrials.gov/study/NCT04094688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04094688","kind":"trial","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct04094688/","field":"links","label":"ClinicalTrials.gov NCT04094688"}]},{"url":"https://clinicaltrials.gov/study/NCT04094688?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04094688","kind":"trial","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct04094688/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04095299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04095299","kind":"trial","name":"Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients","route":"/trials/nct04095299/","field":"links","label":"ClinicalTrials.gov NCT04095299"}]},{"url":"https://clinicaltrials.gov/study/NCT04098744","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04098744","kind":"trial","name":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","route":"/trials/nct04098744/","field":"links","label":"ClinicalTrials.gov NCT04098744"}]},{"url":"https://clinicaltrials.gov/study/NCT04099251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04099251","kind":"trial","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","route":"/trials/nct04099251/","field":"links","label":"ClinicalTrials.gov NCT04099251"}]},{"url":"https://clinicaltrials.gov/study/NCT04102098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","field":"links","label":"ClinicalTrials.gov NCT04102098"}]},{"url":"https://clinicaltrials.gov/study/NCT04104776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04104776","kind":"trial","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","route":"/trials/nct04104776/","field":"links","label":"ClinicalTrials.gov NCT04104776"}]},{"url":"https://clinicaltrials.gov/study/NCT04109079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atnec","kind":"trial","name":"ATNEC","route":"/trials/atnec/","field":"links","label":"ClinicalTrials.gov NCT04109079"}]},{"url":"https://clinicaltrials.gov/study/NCT04109755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04109755","kind":"trial","name":"Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer","route":"/trials/nct04109755/","field":"links","label":"ClinicalTrials.gov NCT04109755"}]},{"url":"https://clinicaltrials.gov/study/NCT04110301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","field":"links","label":"ClinicalTrials.gov NCT04110301"}]},{"url":"https://clinicaltrials.gov/study/NCT04114825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04114825","kind":"trial","name":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","route":"/trials/nct04114825/","field":"links","label":"ClinicalTrials.gov NCT04114825"}]},{"url":"https://clinicaltrials.gov/study/NCT04115306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04115306","kind":"trial","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","route":"/trials/nct04115306/","field":"links","label":"ClinicalTrials.gov NCT04115306"}]},{"url":"https://clinicaltrials.gov/study/NCT04120701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-crc-ctdna-de-escalation-beyond-stage-ii","kind":"idea","name":"Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps","route":"/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/","field":"links","label":"ClinicalTrials.gov NCT04120701"},{"id":"nct04120701","kind":"trial","name":"CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II","route":"/trials/nct04120701/","field":"links","label":"ClinicalTrials.gov NCT04120701"}]},{"url":"https://clinicaltrials.gov/study/NCT04121455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","route":"/trials/nct04121455/","field":"links","label":"ClinicalTrials.gov NCT04121455"}]},{"url":"https://clinicaltrials.gov/study/NCT04126200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04126200","kind":"trial","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04126200/","field":"links","label":"ClinicalTrials.gov NCT04126200"}]},{"url":"https://clinicaltrials.gov/study/NCT04129502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04129502-j-clin-oncol-2025","kind":"paper","name":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial","route":"/key-papers/paper-nct04129502-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04129502"},{"id":"nct04129502","kind":"trial","name":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct04129502/","field":"links","label":"ClinicalTrials.gov NCT04129502"}]},{"url":"https://clinicaltrials.gov/study/NCT04130516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04130516","kind":"trial","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","route":"/trials/nct04130516/","field":"links","label":"ClinicalTrials.gov NCT04130516"}]},{"url":"https://clinicaltrials.gov/study/NCT04133636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/","field":"links","label":"ClinicalTrials.gov NCT04133636"}]},{"url":"https://clinicaltrials.gov/study/NCT04136002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-eclipse-shield-n-engl-j-med-2024","kind":"paper","name":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","route":"/key-papers/paper-eclipse-shield-n-engl-j-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04136002"},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","field":"links","label":"ClinicalTrials.gov NCT04136002"}]},{"url":"https://clinicaltrials.gov/study/NCT04137107","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04137107","kind":"trial","name":"Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer","route":"/trials/nct04137107/","field":"links","label":"ClinicalTrials.gov NCT04137107"}]},{"url":"https://clinicaltrials.gov/study/NCT04137653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04137653","kind":"trial","name":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","route":"/trials/nct04137653/","field":"links","label":"ClinicalTrials.gov NCT04137653"}]},{"url":"https://clinicaltrials.gov/study/NCT04138719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04138719","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","route":"/trials/nct04138719/","field":"links","label":"ClinicalTrials.gov NCT04138719"}]},{"url":"https://clinicaltrials.gov/study/NCT04140500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","route":"/trials/nct04140500/","field":"links","label":"ClinicalTrials.gov NCT04140500"}]},{"url":"https://clinicaltrials.gov/study/NCT04140526","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","route":"/trials/nct04140526/","field":"links","label":"ClinicalTrials.gov NCT04140526"}]},{"url":"https://clinicaltrials.gov/study/NCT04143607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04143607-lancet-respir-med-2025","kind":"paper","name":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","route":"/key-papers/paper-nct04143607-lancet-respir-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04143607"},{"id":"nct04143607","kind":"trial","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","route":"/trials/nct04143607/","field":"links","label":"ClinicalTrials.gov NCT04143607"}]},{"url":"https://clinicaltrials.gov/study/NCT04144738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-blue-c-n-engl-j-med-2024","kind":"paper","name":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","route":"/key-papers/paper-blue-c-n-engl-j-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04144738"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"links","label":"ClinicalTrials.gov NCT04144738"}]},{"url":"https://clinicaltrials.gov/study/NCT04145622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","field":"links","label":"ClinicalTrials.gov NCT04145622"}]},{"url":"https://clinicaltrials.gov/study/NCT04146298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04146298","kind":"trial","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","route":"/trials/nct04146298/","field":"links","label":"ClinicalTrials.gov NCT04146298"}]},{"url":"https://clinicaltrials.gov/study/NCT04150497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04150497","kind":"trial","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","route":"/trials/nct04150497/","field":"links","label":"ClinicalTrials.gov NCT04150497"}]},{"url":"https://clinicaltrials.gov/study/NCT04151277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"primus-001","kind":"trial","name":"PRIMUS 001","route":"/trials/primus-001/","field":"links","label":"ClinicalTrials.gov NCT04151277"}]},{"url":"https://clinicaltrials.gov/study/NCT04152499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04152499-j-hematol-oncol-2025","kind":"paper","name":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","route":"/key-papers/paper-nct04152499-j-hematol-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04152499"},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/","field":"links","label":"ClinicalTrials.gov NCT04152499"}]},{"url":"https://clinicaltrials.gov/study/NCT04153734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04153734","kind":"trial","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","route":"/trials/nct04153734/","field":"links","label":"ClinicalTrials.gov NCT04153734"}]},{"url":"https://clinicaltrials.gov/study/NCT04154943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"links","label":"ClinicalTrials.gov NCT04154943"}]},{"url":"https://clinicaltrials.gov/study/NCT04154956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/","field":"links","label":"ClinicalTrials.gov NCT04154956"},{"id":"ceacam5-expression","kind":"biomarker","name":"CEACAM5 expression","route":"/biomarkers/ceacam5-expression/","field":"links","label":"ClinicalTrials.gov NCT04154956 (CARMEN-LC03)"}]},{"url":"https://clinicaltrials.gov/study/NCT04154956?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/","field":"outcomes.source (Progression-free Survival (PFS))"},{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04155034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04155034","kind":"trial","name":"S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel","route":"/trials/nct04155034/","field":"links","label":"ClinicalTrials.gov NCT04155034"}]},{"url":"https://clinicaltrials.gov/study/NCT04158440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/","field":"links","label":"ClinicalTrials.gov NCT04158440"}]},{"url":"https://clinicaltrials.gov/study/NCT04159142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04159142","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","route":"/trials/nct04159142/","field":"links","label":"ClinicalTrials.gov NCT04159142"}]},{"url":"https://clinicaltrials.gov/study/NCT04159818","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04159818","kind":"trial","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","route":"/trials/nct04159818/","field":"links","label":"ClinicalTrials.gov NCT04159818"}]},{"url":"https://clinicaltrials.gov/study/NCT04161755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/","field":"links","label":"ClinicalTrials.gov NCT04161755"},{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/","field":"links","label":"ClinicalTrials.gov NCT04161755"},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/","field":"links","label":"ClinicalTrials.gov NCT04161755"}]},{"url":"https://clinicaltrials.gov/study/NCT04162210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","field":"links","label":"ClinicalTrials.gov NCT04162210"}]},{"url":"https://clinicaltrials.gov/study/NCT04162210?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","field":"outcomes.source (Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG))"},{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04164602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","kind":"paper","name":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes","route":"/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/","field":"links","label":"ClinicalTrials.gov NCT04164602"},{"id":"idea-pdac-new-onset-diabetes-risk-score-pathway","kind":"idea","name":"Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers","route":"/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/","field":"links","label":"ClinicalTrials.gov NCT04164602"}]},{"url":"https://clinicaltrials.gov/study/NCT04164901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/","field":"links","label":"ClinicalTrials.gov NCT04164901"},{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT04164901"}],"archive":"https://web.archive.org/web/20260123141142/https://www.clinicaltrials.gov/study/NCT04164901"},{"url":"https://clinicaltrials.gov/study/NCT04165070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04165070","kind":"trial","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","route":"/trials/nct04165070/","field":"links","label":"ClinicalTrials.gov NCT04165070"}]},{"url":"https://clinicaltrials.gov/study/NCT04165317","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04165317","kind":"trial","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","route":"/trials/nct04165317/","field":"links","label":"ClinicalTrials.gov NCT04165317"}]},{"url":"https://clinicaltrials.gov/study/NCT04165590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","route":"/trials/nct04165590/","field":"links","label":"ClinicalTrials.gov NCT04165590"}]},{"url":"https://clinicaltrials.gov/study/NCT04165772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT04165772"}]},{"url":"https://clinicaltrials.gov/study/NCT04169997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/","field":"links","label":"ClinicalTrials.gov NCT04169997"}]},{"url":"https://clinicaltrials.gov/study/NCT04170283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04170283","kind":"trial","name":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","route":"/trials/nct04170283/","field":"links","label":"ClinicalTrials.gov NCT04170283"}]},{"url":"https://clinicaltrials.gov/study/NCT04172532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04172532","kind":"trial","name":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04172532/","field":"links","label":"ClinicalTrials.gov NCT04172532"}]},{"url":"https://clinicaltrials.gov/study/NCT04172597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04172597","kind":"trial","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","route":"/trials/nct04172597/","field":"links","label":"ClinicalTrials.gov NCT04172597"}]},{"url":"https://clinicaltrials.gov/study/NCT04172597?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04172597","kind":"trial","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","route":"/trials/nct04172597/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04173494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT04173494"},{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","field":"links","label":"ClinicalTrials.gov NCT04173494"}]},{"url":"https://clinicaltrials.gov/study/NCT04174599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04174599","kind":"trial","name":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","route":"/trials/nct04174599/","field":"links","label":"ClinicalTrials.gov NCT04174599"}]},{"url":"https://clinicaltrials.gov/study/NCT04174599?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04174599","kind":"trial","name":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","route":"/trials/nct04174599/","field":"outcomes.source (Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT04180371","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/","field":"links","label":"ClinicalTrials.gov NCT04180371"}]},{"url":"https://clinicaltrials.gov/study/NCT04181060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04181060","kind":"trial","name":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","route":"/trials/nct04181060/","field":"links","label":"ClinicalTrials.gov NCT04181060"}]},{"url":"https://clinicaltrials.gov/study/NCT04181827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","field":"links","label":"ClinicalTrials.gov NCT04181827"},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","field":"links","label":"ClinicalTrials.gov NCT04181827: CARTITUDE-4"},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT04181827"}]},{"url":"https://clinicaltrials.gov/study/NCT04183166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/","field":"links","label":"ClinicalTrials.gov NCT04183166"}]},{"url":"https://clinicaltrials.gov/study/NCT04183712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04183712","kind":"trial","name":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","route":"/trials/nct04183712/","field":"links","label":"ClinicalTrials.gov NCT04183712"}]},{"url":"https://clinicaltrials.gov/study/NCT04188145","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04188145","kind":"trial","name":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta","route":"/trials/nct04188145/","field":"links","label":"ClinicalTrials.gov NCT04188145"}]},{"url":"https://clinicaltrials.gov/study/NCT04191096","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-991","kind":"trial","name":"KEYNOTE-991","route":"/trials/keynote-991/","field":"links","label":"ClinicalTrials.gov NCT04191096"}]},{"url":"https://clinicaltrials.gov/study/NCT04191499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","field":"links","label":"ClinicalTrials.gov NCT04191499"},{"id":"paper-inavo120-n-engl-j-med-2024","kind":"paper","name":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04191499"},{"id":"paper-inavo120-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2025-update/","field":"links","label":"ClinicalTrials.gov NCT04191499"}],"archive":"https://web.archive.org/web/20260208112742/https://clinicaltrials.gov/study/NCT04191499"},{"url":"https://clinicaltrials.gov/study/NCT04194775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04194775","kind":"trial","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","route":"/trials/nct04194775/","field":"links","label":"ClinicalTrials.gov NCT04194775"}]},{"url":"https://clinicaltrials.gov/study/NCT04194775?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04194775","kind":"trial","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","route":"/trials/nct04194775/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04194944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"libretto-431","kind":"trial","name":"LIBRETTO-431","route":"/trials/libretto-431/","field":"links","label":"ClinicalTrials.gov NCT04194944"},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","field":"links","label":"ClinicalTrials.gov NCT04194944: LIBRETTO-431"}],"archive":"https://web.archive.org/web/20251028072136/https://clinicaltrials.gov/study/NCT04194944"},{"url":"https://clinicaltrials.gov/study/NCT04195347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04195347","kind":"trial","name":"Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","route":"/trials/nct04195347/","field":"links","label":"ClinicalTrials.gov NCT04195347"}]},{"url":"https://clinicaltrials.gov/study/NCT04195750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","field":"links","label":"ClinicalTrials.gov NCT04195750"}]},{"url":"https://clinicaltrials.gov/study/NCT04198766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/","field":"links","label":"ClinicalTrials.gov NCT04198766"}]},{"url":"https://clinicaltrials.gov/study/NCT04204941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"EZH-301 on ClinicalTrials.gov"},{"id":"tazemetostat-doxorubicin-es","kind":"trial","name":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)","route":"/trials/tazemetostat-doxorubicin-es/","field":"links","label":"ClinicalTrials.gov NCT04204941"}]},{"url":"https://clinicaltrials.gov/study/NCT04205227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04205227","kind":"trial","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","route":"/trials/nct04205227/","field":"links","label":"ClinicalTrials.gov NCT04205227"}]},{"url":"https://clinicaltrials.gov/study/NCT04205630","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","route":"/trials/nct04205630/","field":"links","label":"ClinicalTrials.gov NCT04205630"}]},{"url":"https://clinicaltrials.gov/study/NCT04205630?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","route":"/trials/nct04205630/","field":"outcomes.source (Objective Response Rate (ORR))"},{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","route":"/trials/nct04205630/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","route":"/trials/nct04205630/","field":"outcomes.source (Progression-Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04208178","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04208178","kind":"trial","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","route":"/trials/nct04208178/","field":"links","label":"ClinicalTrials.gov NCT04208178"}]},{"url":"https://clinicaltrials.gov/study/NCT04209855","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","field":"links","label":"ClinicalTrials.gov NCT04209855"},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/","field":"links","label":"ClinicalTrials.gov NCT04209855: MIRASOL / GOG-3045"}]},{"url":"https://clinicaltrials.gov/study/NCT04211337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","field":"links","label":"ClinicalTrials.gov NCT04211337"}]},{"url":"https://clinicaltrials.gov/study/NCT04214262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","route":"/trials/nct04214262/","field":"links","label":"ClinicalTrials.gov NCT04214262"}]},{"url":"https://clinicaltrials.gov/study/NCT04214288","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04214288"},{"id":"nct04214288","kind":"trial","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","route":"/trials/nct04214288/","field":"links","label":"ClinicalTrials.gov NCT04214288"}]},{"url":"https://clinicaltrials.gov/study/NCT04214288?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04214288","kind":"trial","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","route":"/trials/nct04214288/","field":"outcomes.source (Progression-free Survival (PFS))"},{"id":"nct04214288","kind":"trial","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","route":"/trials/nct04214288/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04215731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04215731","kind":"trial","name":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","route":"/trials/nct04215731/","field":"links","label":"ClinicalTrials.gov NCT04215731"}]},{"url":"https://clinicaltrials.gov/study/NCT04219254","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/","field":"links","label":"ClinicalTrials.gov NCT04219254"}]},{"url":"https://clinicaltrials.gov/study/NCT04221035","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04221035","kind":"trial","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","route":"/trials/nct04221035/","field":"links","label":"ClinicalTrials.gov NCT04221035"}]},{"url":"https://clinicaltrials.gov/study/NCT04221945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","field":"links","label":"ClinicalTrials.gov NCT04221945"},{"id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","field":"links","label":"ClinicalTrials.gov NCT04221945: KEYNOTE-A18 / ENGOT-cx11 / GOG-3047"},{"id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/","field":"links","label":"ClinicalTrials.gov NCT04221945: KEYNOTE-A18 / ENGOT-cx11 / GOG-3047"},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT04221945"},{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT04221945"}]},{"url":"https://clinicaltrials.gov/study/NCT04223856","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","field":"links","label":"ClinicalTrials.gov NCT04223856: EV-302 / KEYNOTE-A39"},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","field":"links","label":"ClinicalTrials.gov NCT04223856"},{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","field":"links","label":"ClinicalTrials.gov NCT04223856: EV-302 / KEYNOTE-A39"},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT04223856"}]},{"url":"https://clinicaltrials.gov/study/NCT04224493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04224493","kind":"trial","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","route":"/trials/nct04224493/","field":"links","label":"ClinicalTrials.gov NCT04224493"}]},{"url":"https://clinicaltrials.gov/study/NCT04225117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/","field":"links","label":"ClinicalTrials.gov NCT04225117"}]},{"url":"https://clinicaltrials.gov/study/NCT04225117?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/","field":"outcomes.source (Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment)"},{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/","field":"outcomes.source (Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment)"}]},{"url":"https://clinicaltrials.gov/study/NCT04229004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/","field":"links","label":"ClinicalTrials.gov NCT04229004"}]},{"url":"https://clinicaltrials.gov/study/NCT04229979","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04229979","kind":"trial","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","route":"/trials/nct04229979/","field":"links","label":"ClinicalTrials.gov NCT04229979"}]},{"url":"https://clinicaltrials.gov/study/NCT04230109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/","field":"links","label":"ClinicalTrials.gov NCT04230109"}]},{"url":"https://clinicaltrials.gov/study/NCT04230187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04230187","kind":"trial","name":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","route":"/trials/nct04230187/","field":"links","label":"ClinicalTrials.gov NCT04230187"}]},{"url":"https://clinicaltrials.gov/study/NCT04233346","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04233346","kind":"trial","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","route":"/trials/nct04233346/","field":"links","label":"ClinicalTrials.gov NCT04233346"}]},{"url":"https://clinicaltrials.gov/study/NCT04235114","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04235114","kind":"trial","name":"Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","route":"/trials/nct04235114/","field":"links","label":"ClinicalTrials.gov NCT04235114"}]},{"url":"https://clinicaltrials.gov/study/NCT04238637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04238637","kind":"trial","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","route":"/trials/nct04238637/","field":"links","label":"ClinicalTrials.gov NCT04238637"}]},{"url":"https://clinicaltrials.gov/study/NCT04241185","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04241185","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","route":"/trials/nct04241185/","field":"links","label":"ClinicalTrials.gov NCT04241185"}]},{"url":"https://clinicaltrials.gov/study/NCT04241276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/","field":"links","label":"ClinicalTrials.gov NCT04241276"}]},{"url":"https://clinicaltrials.gov/study/NCT04241315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04241315","kind":"trial","name":"ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting","route":"/trials/nct04241315/","field":"links","label":"ClinicalTrials.gov NCT04241315"}]},{"url":"https://clinicaltrials.gov/study/NCT04241796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT04241796"}]},{"url":"https://clinicaltrials.gov/study/NCT04243499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","route":"/trials/nct04243499/","field":"links","label":"ClinicalTrials.gov NCT04243499"}]},{"url":"https://clinicaltrials.gov/study/NCT04245839","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/","field":"links","label":"ClinicalTrials.gov NCT04245839"}]},{"url":"https://clinicaltrials.gov/study/NCT04246047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","field":"links","label":"ClinicalTrials.gov NCT04246047"}]},{"url":"https://clinicaltrials.gov/study/NCT04246086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04246086","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","route":"/trials/nct04246086/","field":"links","label":"ClinicalTrials.gov NCT04246086"}]},{"url":"https://clinicaltrials.gov/study/NCT04246177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","field":"links","label":"ClinicalTrials.gov NCT04246177"},{"id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","field":"links","label":"ClinicalTrials.gov NCT04246177: LEAP-012"}]},{"url":"https://clinicaltrials.gov/study/NCT04246684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04246684","kind":"trial","name":"Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients","route":"/trials/nct04246684/","field":"links","label":"ClinicalTrials.gov NCT04246684"}]},{"url":"https://clinicaltrials.gov/study/NCT04250922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04250922","kind":"trial","name":"LAM561 With RT and TMZ for Adults With Glioblastoma","route":"/trials/nct04250922/","field":"links","label":"ClinicalTrials.gov NCT04250922"}]},{"url":"https://clinicaltrials.gov/study/NCT04252859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04252859","kind":"trial","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","route":"/trials/nct04252859/","field":"links","label":"ClinicalTrials.gov NCT04252859"}]},{"url":"https://clinicaltrials.gov/study/NCT04252859?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04252859","kind":"trial","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","route":"/trials/nct04252859/","field":"outcomes.source (Positive Detection Rate of Invasive Lobular Carcinoma (ILC))"},{"id":"nct04252859","kind":"trial","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","route":"/trials/nct04252859/","field":"outcomes.source (Relationship Between Presence of Heterogeneous FES-PET/CT Uptake at Baseline and Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT04256317","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/","field":"links","label":"ClinicalTrials.gov NCT04256317"}]},{"url":"https://clinicaltrials.gov/study/NCT04262466","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04262466","kind":"trial","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","route":"/trials/nct04262466/","field":"links","label":"ClinicalTrials.gov NCT04262466"}]},{"url":"https://clinicaltrials.gov/study/NCT04264702","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bespoke-crc","kind":"trial","name":"BESPOKE CRC","route":"/trials/bespoke-crc/","field":"links","label":"ClinicalTrials.gov NCT04264702"}]},{"url":"https://clinicaltrials.gov/study/NCT04267848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04267848","kind":"trial","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","route":"/trials/nct04267848/","field":"links","label":"ClinicalTrials.gov NCT04267848"}]},{"url":"https://clinicaltrials.gov/study/NCT04268706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04268706","kind":"trial","name":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","route":"/trials/nct04268706/","field":"links","label":"ClinicalTrials.gov NCT04268706"}]},{"url":"https://clinicaltrials.gov/study/NCT04269200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","field":"links","label":"ClinicalTrials.gov NCT04269200"}]},{"url":"https://clinicaltrials.gov/study/NCT04270409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/","field":"links","label":"ClinicalTrials.gov NCT04270409"}]},{"url":"https://clinicaltrials.gov/study/NCT04270591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/","field":"links","label":"ClinicalTrials.gov NCT04270591"},{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/","field":"links","label":"ClinicalTrials.gov NCT04270591"},{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","route":"/trials/nct04270591/","field":"links","label":"ClinicalTrials.gov NCT04270591"}]},{"url":"https://clinicaltrials.gov/study/NCT04271644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04271644/","field":"links","label":"ClinicalTrials.gov NCT04271644"}]},{"url":"https://clinicaltrials.gov/study/NCT04273061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04273061","kind":"trial","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","route":"/trials/nct04273061/","field":"links","label":"ClinicalTrials.gov NCT04273061"}]},{"url":"https://clinicaltrials.gov/study/NCT04274426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04274426","kind":"trial","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","route":"/trials/nct04274426/","field":"links","label":"ClinicalTrials.gov NCT04274426"}]},{"url":"https://clinicaltrials.gov/study/NCT04274738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04274738","kind":"trial","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","route":"/trials/nct04274738/","field":"links","label":"ClinicalTrials.gov NCT04274738"}]},{"url":"https://clinicaltrials.gov/study/NCT04275986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04275986","kind":"trial","name":"Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma","route":"/trials/nct04275986/","field":"links","label":"ClinicalTrials.gov NCT04275986"}]},{"url":"https://clinicaltrials.gov/study/NCT04280081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","route":"/trials/nct04280081/","field":"links","label":"ClinicalTrials.gov NCT04280081"}]},{"url":"https://clinicaltrials.gov/study/NCT04280081?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","route":"/trials/nct04280081/","field":"outcomes.source (Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC), Overall Response (CR/PR))"},{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","route":"/trials/nct04280081/","field":"outcomes.source (Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC, Overall Response (CR/PR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04285086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04285086","kind":"trial","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","route":"/trials/nct04285086/","field":"links","label":"ClinicalTrials.gov NCT04285086"}]},{"url":"https://clinicaltrials.gov/study/NCT04288999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04288999","kind":"trial","name":"Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer","route":"/trials/nct04288999/","field":"links","label":"ClinicalTrials.gov NCT04288999"}]},{"url":"https://clinicaltrials.gov/study/NCT04291105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04291105","kind":"trial","name":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","route":"/trials/nct04291105/","field":"links","label":"ClinicalTrials.gov NCT04291105"}]},{"url":"https://clinicaltrials.gov/study/NCT04293562","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04293562","kind":"trial","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","route":"/trials/nct04293562/","field":"links","label":"ClinicalTrials.gov NCT04293562"}]},{"url":"https://clinicaltrials.gov/study/NCT04296175","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04296175","kind":"trial","name":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","route":"/trials/nct04296175/","field":"links","label":"ClinicalTrials.gov NCT04296175"}]},{"url":"https://clinicaltrials.gov/study/NCT04296890","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/","field":"links","label":"ClinicalTrials.gov NCT04296890"}]},{"url":"https://clinicaltrials.gov/study/NCT04299191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04299191","kind":"trial","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","route":"/trials/nct04299191/","field":"links","label":"ClinicalTrials.gov NCT04299191"}]},{"url":"https://clinicaltrials.gov/study/NCT04300556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/","field":"links","label":"ClinicalTrials.gov NCT04300556"}]},{"url":"https://clinicaltrials.gov/study/NCT04301739","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04301739","kind":"trial","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","route":"/trials/nct04301739/","field":"links","label":"ClinicalTrials.gov NCT04301739"}]},{"url":"https://clinicaltrials.gov/study/NCT04302025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04302025","kind":"trial","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04302025/","field":"links","label":"ClinicalTrials.gov NCT04302025"}]},{"url":"https://clinicaltrials.gov/study/NCT04303780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","field":"links","label":"ClinicalTrials.gov NCT04303780"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT04303780"}],"archive":"https://web.archive.org/web/20260113223155/https://www.clinicaltrials.gov/study/NCT04303780"},{"url":"https://clinicaltrials.gov/study/NCT04305496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","field":"links","label":"ClinicalTrials.gov NCT04305496"}],"archive":"https://web.archive.org/web/20260604192415/https://clinicaltrials.gov/study/NCT04305496"},{"url":"https://clinicaltrials.gov/study/NCT04305795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04305795","kind":"trial","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","route":"/trials/nct04305795/","field":"links","label":"ClinicalTrials.gov NCT04305795"}]},{"url":"https://clinicaltrials.gov/study/NCT04308174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"debate","kind":"trial","name":"DEBATE","route":"/trials/debate/","field":"links","label":"ClinicalTrials.gov NCT04308174"}]},{"url":"https://clinicaltrials.gov/study/NCT04313881","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","field":"links","label":"ClinicalTrials.gov NCT04313881"}]},{"url":"https://clinicaltrials.gov/study/NCT04313881?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","field":"outcomes.source (Percentage of Participants With Complete Remission (CR))"},{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04316364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04316364","kind":"trial","name":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","route":"/trials/nct04316364/","field":"links","label":"ClinicalTrials.gov NCT04316364"}]},{"url":"https://clinicaltrials.gov/study/NCT04317534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04317534","kind":"trial","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","route":"/trials/nct04317534/","field":"links","label":"ClinicalTrials.gov NCT04317534"}]},{"url":"https://clinicaltrials.gov/study/NCT04322539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/","field":"links","label":"ClinicalTrials.gov NCT04322539"},{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","field":"links","label":"ClinicalTrials.gov NCT04322539"}]},{"url":"https://clinicaltrials.gov/study/NCT04322617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04322617","kind":"trial","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","route":"/trials/nct04322617/","field":"links","label":"ClinicalTrials.gov NCT04322617"}]},{"url":"https://clinicaltrials.gov/study/NCT04325828","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04325828","kind":"trial","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","route":"/trials/nct04325828/","field":"links","label":"ClinicalTrials.gov NCT04325828"}]},{"url":"https://clinicaltrials.gov/study/NCT04325828?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04325828","kind":"trial","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","route":"/trials/nct04325828/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04329728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/","field":"links","label":"ClinicalTrials.gov NCT04329728"}]},{"url":"https://clinicaltrials.gov/study/NCT04333537","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04333537","kind":"trial","name":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","route":"/trials/nct04333537/","field":"links","label":"ClinicalTrials.gov NCT04333537"}]},{"url":"https://clinicaltrials.gov/study/NCT04333706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04333706","kind":"trial","name":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S","route":"/trials/nct04333706/","field":"links","label":"ClinicalTrials.gov NCT04333706"}]},{"url":"https://clinicaltrials.gov/study/NCT04334759","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","field":"links","label":"ClinicalTrials.gov NCT04334759"},{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","field":"outcomes.source (Overall survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT04335292","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04335292","kind":"trial","name":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge","route":"/trials/nct04335292/","field":"links","label":"ClinicalTrials.gov NCT04335292"}]},{"url":"https://clinicaltrials.gov/study/NCT04335669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/","field":"links","label":"ClinicalTrials.gov NCT04335669"}]},{"url":"https://clinicaltrials.gov/study/NCT04338269","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/","field":"links","label":"ClinicalTrials.gov NCT04338269"},{"id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","field":"links","label":"ClinicalTrials.gov NCT04338269: CONTACT-03"}]},{"url":"https://clinicaltrials.gov/study/NCT04339062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"links","label":"ClinicalTrials.gov NCT04339062"}]},{"url":"https://clinicaltrials.gov/study/NCT04339218","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04339218","kind":"trial","name":"Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","route":"/trials/nct04339218/","field":"links","label":"ClinicalTrials.gov NCT04339218"}]},{"url":"https://clinicaltrials.gov/study/NCT04340141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"ClinicalTrials.gov NCT04340141: Alliance A021806 (active, not recruiting; 358 enrolled; primary completion December 2028; no results posted, read 24 Sept 2026)"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"ClinicalTrials.gov NCT04340141"},{"id":"idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease","kind":"idea","name":"Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed","route":"/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/","field":"links","label":"ClinicalTrials.gov NCT04340141"},{"id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/","field":"links","label":"ClinicalTrials.gov NCT04340141"}]},{"url":"https://clinicaltrials.gov/study/NCT04342910","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04342910","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","route":"/trials/nct04342910/","field":"links","label":"ClinicalTrials.gov NCT04342910"}]},{"url":"https://clinicaltrials.gov/study/NCT04349436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04349436","kind":"trial","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","route":"/trials/nct04349436/","field":"links","label":"ClinicalTrials.gov NCT04349436"}]},{"url":"https://clinicaltrials.gov/study/NCT04351555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04351555","kind":"trial","name":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S","route":"/trials/nct04351555/","field":"links","label":"ClinicalTrials.gov NCT04351555"}]},{"url":"https://clinicaltrials.gov/study/NCT04351555?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04351555","kind":"trial","name":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S","route":"/trials/nct04351555/","field":"outcomes.source (Major Pathological Response (MPR) - IASLC Method)"}]},{"url":"https://clinicaltrials.gov/study/NCT04353375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/","field":"links","label":"ClinicalTrials.gov NCT04353375"}]},{"url":"https://clinicaltrials.gov/study/NCT04365374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/","field":"links","label":"ClinicalTrials.gov NCT04365374"}]},{"url":"https://clinicaltrials.gov/study/NCT04369053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","field":"links","label":"ClinicalTrials.gov NCT04369053"},{"id":"paper-preempt-crc-shaukat-jama-2025","kind":"paper","name":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","route":"/key-papers/paper-preempt-crc-shaukat-jama-2025/","field":"links","label":"ClinicalTrials.gov NCT04369053"}]},{"url":"https://clinicaltrials.gov/study/NCT04370587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04370587","kind":"trial","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","route":"/trials/nct04370587/","field":"links","label":"ClinicalTrials.gov NCT04370587"}]},{"url":"https://clinicaltrials.gov/study/NCT04373369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04373369","kind":"trial","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04373369/","field":"links","label":"ClinicalTrials.gov NCT04373369"}]},{"url":"https://clinicaltrials.gov/study/NCT04373369?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04373369","kind":"trial","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04373369/","field":"outcomes.source (Kaplan Meier Estimate of Progression-free Survival (PFS) at 6 Months)"},{"id":"nct04373369","kind":"trial","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04373369/","field":"outcomes.source (Median Overall Survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT04374305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/","field":"links","label":"ClinicalTrials.gov NCT04374305"}]},{"url":"https://clinicaltrials.gov/study/NCT04375683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04375683","kind":"trial","name":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL","route":"/trials/nct04375683/","field":"links","label":"ClinicalTrials.gov NCT04375683"}]},{"url":"https://clinicaltrials.gov/study/NCT04379167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04379167","kind":"trial","name":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct04379167/","field":"links","label":"ClinicalTrials.gov NCT04379167"}]},{"url":"https://clinicaltrials.gov/study/NCT04379596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04379596","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","route":"/trials/nct04379596/","field":"links","label":"ClinicalTrials.gov NCT04379596"}]},{"url":"https://clinicaltrials.gov/study/NCT04379635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04379635-lancet-respir-med-2025","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","route":"/key-papers/paper-nct04379635-lancet-respir-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04379635"},{"id":"paper-nct04379635-ann-oncol-2026-update","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","route":"/key-papers/paper-nct04379635-ann-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT04379635"},{"id":"nct04379635","kind":"trial","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04379635/","field":"links","label":"ClinicalTrials.gov NCT04379635"}]},{"url":"https://clinicaltrials.gov/study/NCT04380636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/","field":"links","label":"ClinicalTrials.gov NCT04380636"}]},{"url":"https://clinicaltrials.gov/study/NCT04381130","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04381130","kind":"trial","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","route":"/trials/nct04381130/","field":"links","label":"ClinicalTrials.gov NCT04381130"}]},{"url":"https://clinicaltrials.gov/study/NCT04384484","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04384484","kind":"trial","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","route":"/trials/nct04384484/","field":"links","label":"ClinicalTrials.gov NCT04384484"}]},{"url":"https://clinicaltrials.gov/study/NCT04385368","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mermaid-1","kind":"trial","name":"MERMAID-1","route":"/trials/mermaid-1/","field":"links","label":"ClinicalTrials.gov NCT04385368"}]},{"url":"https://clinicaltrials.gov/study/NCT04389086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04389086","kind":"trial","name":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","route":"/trials/nct04389086/","field":"links","label":"ClinicalTrials.gov NCT04389086"}]},{"url":"https://clinicaltrials.gov/study/NCT04390399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04390399","kind":"trial","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct04390399/","field":"links","label":"ClinicalTrials.gov NCT04390399"}]},{"url":"https://clinicaltrials.gov/study/NCT04390737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/","field":"links","label":"ClinicalTrials.gov NCT04390737"}]},{"url":"https://clinicaltrials.gov/study/NCT04395677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04395677"},{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","field":"links","label":"ClinicalTrials.gov NCT04395677"},{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","route":"/trials/nct04395677/","field":"links","label":"ClinicalTrials.gov NCT04395677"}]},{"url":"https://clinicaltrials.gov/study/NCT04396821","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04396821","kind":"trial","name":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04396821/","field":"links","label":"ClinicalTrials.gov NCT04396821"}]},{"url":"https://clinicaltrials.gov/study/NCT04401748","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"verona","kind":"trial","name":"VERONA","route":"/trials/verona/","field":"links","label":"ClinicalTrials.gov NCT04401748"}]},{"url":"https://clinicaltrials.gov/study/NCT04404283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","route":"/trials/nct04404283/","field":"links","label":"ClinicalTrials.gov NCT04404283"}]},{"url":"https://clinicaltrials.gov/study/NCT04404595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04404595","kind":"trial","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","route":"/trials/nct04404595/","field":"links","label":"ClinicalTrials.gov NCT04404595"}]},{"url":"https://clinicaltrials.gov/study/NCT04404660","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","field":"links","label":"ClinicalTrials.gov NCT04404660"}]},{"url":"https://clinicaltrials.gov/study/NCT04408638","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","field":"links","label":"ClinicalTrials.gov NCT04408638"},{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT04408638"}]},{"url":"https://clinicaltrials.gov/study/NCT04410133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04410133","kind":"trial","name":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","route":"/trials/nct04410133/","field":"links","label":"ClinicalTrials.gov NCT04410133"}]},{"url":"https://clinicaltrials.gov/study/NCT04410133?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04410133","kind":"trial","name":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","route":"/trials/nct04410133/","field":"outcomes.source (Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level)"}]},{"url":"https://clinicaltrials.gov/study/NCT04410445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04410445","kind":"trial","name":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","route":"/trials/nct04410445/","field":"links","label":"ClinicalTrials.gov NCT04410445"}]},{"url":"https://clinicaltrials.gov/study/NCT04410796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04410796","kind":"trial","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","route":"/trials/nct04410796/","field":"links","label":"ClinicalTrials.gov NCT04410796"}]},{"url":"https://clinicaltrials.gov/study/NCT04414163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/","field":"links","label":"ClinicalTrials.gov NCT04414163"}]},{"url":"https://clinicaltrials.gov/study/NCT04414475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/","field":"links","label":"ClinicalTrials.gov NCT04414475"}]},{"url":"https://clinicaltrials.gov/study/NCT04415853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04415853","kind":"trial","name":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","route":"/trials/nct04415853/","field":"links","label":"ClinicalTrials.gov NCT04415853"}]},{"url":"https://clinicaltrials.gov/study/NCT04416984","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/","field":"links","label":"ClinicalTrials.gov NCT04416984"}]},{"url":"https://clinicaltrials.gov/study/NCT04417621","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/","field":"links","label":"ClinicalTrials.gov NCT04417621"}]},{"url":"https://clinicaltrials.gov/study/NCT04421820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04421820","kind":"trial","name":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","route":"/trials/nct04421820/","field":"links","label":"ClinicalTrials.gov NCT04421820"}]},{"url":"https://clinicaltrials.gov/study/NCT04421963","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/","field":"links","label":"ClinicalTrials.gov NCT04421963"}]},{"url":"https://clinicaltrials.gov/study/NCT04422366","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/","field":"links","label":"ClinicalTrials.gov NCT04422366"}]},{"url":"https://clinicaltrials.gov/study/NCT04423211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04423211","kind":"trial","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","route":"/trials/nct04423211/","field":"links","label":"ClinicalTrials.gov NCT04423211"}]},{"url":"https://clinicaltrials.gov/study/NCT04425018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04425018","kind":"trial","name":"MARGetuximab Or Trastuzumab (MARGOT)","route":"/trials/nct04425018/","field":"links","label":"ClinicalTrials.gov NCT04425018"}]},{"url":"https://clinicaltrials.gov/study/NCT04428905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04428905","kind":"trial","name":"Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer","route":"/trials/nct04428905/","field":"links","label":"ClinicalTrials.gov NCT04428905"}]},{"url":"https://clinicaltrials.gov/study/NCT04430738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04430738","kind":"trial","name":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","route":"/trials/nct04430738/","field":"links","label":"ClinicalTrials.gov NCT04430738"}]},{"url":"https://clinicaltrials.gov/study/NCT04430738?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04430738","kind":"trial","name":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","route":"/trials/nct04430738/","field":"outcomes.source (Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B))"}]},{"url":"https://clinicaltrials.gov/study/NCT04434040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/","field":"links","label":"ClinicalTrials.gov NCT04434040"}]},{"url":"https://clinicaltrials.gov/study/NCT04437160","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","route":"/trials/nct04437160/","field":"links","label":"ClinicalTrials.gov NCT04437160"}]},{"url":"https://clinicaltrials.gov/study/NCT04440735","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04440735","kind":"trial","name":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","route":"/trials/nct04440735/","field":"links","label":"ClinicalTrials.gov NCT04440735"}]},{"url":"https://clinicaltrials.gov/study/NCT04442022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04442022","kind":"trial","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","route":"/trials/nct04442022/","field":"links","label":"ClinicalTrials.gov NCT04442022"}]},{"url":"https://clinicaltrials.gov/study/NCT04443010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04443010","kind":"trial","name":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct04443010/","field":"links","label":"ClinicalTrials.gov NCT04443010"}]},{"url":"https://clinicaltrials.gov/study/NCT04443543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04443543","kind":"trial","name":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04443543/","field":"links","label":"ClinicalTrials.gov NCT04443543"}]},{"url":"https://clinicaltrials.gov/study/NCT04446117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04446117"},{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","route":"/trials/nct04446117/","field":"links","label":"ClinicalTrials.gov NCT04446117"}]},{"url":"https://clinicaltrials.gov/study/NCT04446117?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","route":"/trials/nct04446117/","field":"outcomes.source (Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC))"},{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","route":"/trials/nct04446117/","field":"outcomes.source (Duration of Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04447235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"ClinicalTrials.gov NCT04447235"},{"id":"nct04447235","kind":"trial","name":"Ivermectin plus losartan for COVID-19 in cancer patients (ICESP phase 2, terminated)","route":"/trials/nct04447235/","field":"links","label":"ClinicalTrials.gov NCT04447235"}]},{"url":"https://clinicaltrials.gov/study/NCT04452591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","field":"links","label":"ClinicalTrials.gov NCT04452591"},{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","field":"links","label":"ClinicalTrials.gov NCT04452591 (BOND-003)"}]},{"url":"https://clinicaltrials.gov/study/NCT04452955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04452955","kind":"trial","name":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","route":"/trials/nct04452955/","field":"links","label":"ClinicalTrials.gov NCT04452955"}]},{"url":"https://clinicaltrials.gov/study/NCT04454437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/","field":"links","label":"ClinicalTrials.gov NCT04454437"},{"id":"nct04454437","kind":"trial","name":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","route":"/trials/nct04454437/","field":"links","label":"ClinicalTrials.gov NCT04454437"}]},{"url":"https://clinicaltrials.gov/study/NCT04457245","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04457245","kind":"trial","name":"Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer","route":"/trials/nct04457245/","field":"links","label":"ClinicalTrials.gov NCT04457245"}]},{"url":"https://clinicaltrials.gov/study/NCT04457297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/","field":"links","label":"ClinicalTrials.gov NCT04457297"}]},{"url":"https://clinicaltrials.gov/study/NCT04458272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04458272","kind":"trial","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","route":"/trials/nct04458272/","field":"links","label":"ClinicalTrials.gov NCT04458272"}]},{"url":"https://clinicaltrials.gov/study/NCT04459715","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","field":"links","label":"ClinicalTrials.gov NCT04459715"}]},{"url":"https://clinicaltrials.gov/study/NCT04464226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/","field":"links","label":"ClinicalTrials.gov NCT04464226"}]},{"url":"https://clinicaltrials.gov/study/NCT04465968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04465968","kind":"trial","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","route":"/trials/nct04465968/","field":"links","label":"ClinicalTrials.gov NCT04465968"}]},{"url":"https://clinicaltrials.gov/study/NCT04466891","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"links","label":"ClinicalTrials.gov NCT04466891"}]},{"url":"https://clinicaltrials.gov/study/NCT04468061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","route":"/trials/nct04468061/","field":"links","label":"ClinicalTrials.gov NCT04468061"}]},{"url":"https://clinicaltrials.gov/study/NCT04468984","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04468984","kind":"trial","name":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","route":"/trials/nct04468984/","field":"links","label":"ClinicalTrials.gov NCT04468984"}]},{"url":"https://clinicaltrials.gov/study/NCT04471727","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/","field":"links","label":"ClinicalTrials.gov NCT04471727"}]},{"url":"https://clinicaltrials.gov/study/NCT04472429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pod1um-303","kind":"trial","name":"POD1UM-303/InterAACT-2","route":"/trials/pod1um-303/","field":"links","label":"ClinicalTrials.gov NCT04472429"}]},{"url":"https://clinicaltrials.gov/study/NCT04478279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04478279","kind":"trial","name":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","route":"/trials/nct04478279/","field":"links","label":"ClinicalTrials.gov NCT04478279"}]},{"url":"https://clinicaltrials.gov/study/NCT04481763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04481763","kind":"trial","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","route":"/trials/nct04481763/","field":"links","label":"ClinicalTrials.gov NCT04481763"}]},{"url":"https://clinicaltrials.gov/study/NCT04482309","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"links","label":"ClinicalTrials.gov NCT04482309"},{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","field":"links","label":"ClinicalTrials.gov NCT04482309: DESTINY-PanTumor02"},{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/","field":"links","label":"ClinicalTrials.gov NCT04482309"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT04482309"}]},{"url":"https://clinicaltrials.gov/study/NCT04484142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/","field":"links","label":"ClinicalTrials.gov NCT04484142"},{"id":"paper-tropion-lung05-j-clin-oncol-2025","kind":"paper","name":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","route":"/key-papers/paper-tropion-lung05-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04484142"}],"archive":"https://web.archive.org/web/20260315211711/https://clinicaltrials.gov/study/NCT04484142"},{"url":"https://clinicaltrials.gov/study/NCT04484623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/","field":"links","label":"ClinicalTrials.gov NCT04484623"}]},{"url":"https://clinicaltrials.gov/study/NCT04485286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04485286","kind":"trial","name":"Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury","route":"/trials/nct04485286/","field":"links","label":"ClinicalTrials.gov NCT04485286"}]},{"url":"https://clinicaltrials.gov/study/NCT04485949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","route":"/trials/nct04485949/","field":"links","label":"ClinicalTrials.gov NCT04485949"}]},{"url":"https://clinicaltrials.gov/study/NCT04486378","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04486378","kind":"trial","name":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","route":"/trials/nct04486378/","field":"links","label":"ClinicalTrials.gov NCT04486378"}]},{"url":"https://clinicaltrials.gov/study/NCT04486833","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04486833","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","route":"/trials/nct04486833/","field":"links","label":"ClinicalTrials.gov NCT04486833"}]},{"url":"https://clinicaltrials.gov/study/NCT04487080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","field":"links","label":"ClinicalTrials.gov NCT04487080: MARIPOSA"},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","field":"links","label":"ClinicalTrials.gov NCT04487080"},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","field":"outcomes.source (Overall survival)"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT04487080"}],"archive":"https://web.archive.org/web/20260810222649/https://clinicaltrials.gov/study/NCT04487080"},{"url":"https://clinicaltrials.gov/study/NCT04488822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04488822","kind":"trial","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","route":"/trials/nct04488822/","field":"links","label":"ClinicalTrials.gov NCT04488822"}]},{"url":"https://clinicaltrials.gov/study/NCT04488822?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04488822","kind":"trial","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","route":"/trials/nct04488822/","field":"outcomes.source (Overall Response Rate (ORR) of Pexidartinib Based on RECIST 1.1 of Asian Participants With Symptomatic Tenosynovial Giant Cell Tumor (TGCT) at Week 25, ORR)"}]},{"url":"https://clinicaltrials.gov/study/NCT04489771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","route":"/trials/nct04489771/","field":"links","label":"ClinicalTrials.gov NCT04489771"}]},{"url":"https://clinicaltrials.gov/study/NCT04489771?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","route":"/trials/nct04489771/","field":"outcomes.source (Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04492488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04492488","kind":"trial","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","route":"/trials/nct04492488/","field":"links","label":"ClinicalTrials.gov NCT04492488"}]},{"url":"https://clinicaltrials.gov/study/NCT04493853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","field":"links","label":"ClinicalTrials.gov NCT04493853"},{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","field":"outcomes.source (Radiographic progression-free survival, PTEN-deficient mHSPC)"},{"id":"paper-capitello-281-ann-oncol-2026","kind":"paper","name":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","route":"/key-papers/paper-capitello-281-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT04493853"}],"archive":"https://web.archive.org/web/20250422102432/https://clinicaltrials.gov/study/NCT04493853"},{"url":"https://clinicaltrials.gov/study/NCT04494425","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","field":"links","label":"ClinicalTrials.gov NCT04494425"},{"id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","field":"links","label":"ClinicalTrials.gov NCT04494425: DESTINY-Breast06"},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT04494425"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","field":"links","label":"DESTINY-Breast06 on ClinicalTrials.gov"}]},{"url":"https://clinicaltrials.gov/study/NCT04494503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","field":"links","label":"ClinicalTrials.gov NCT04494503"}]},{"url":"https://clinicaltrials.gov/study/NCT04495088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","field":"links","label":"ClinicalTrials.gov NCT04495088"}]},{"url":"https://clinicaltrials.gov/study/NCT04495153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/","field":"links","label":"ClinicalTrials.gov NCT04495153"}]},{"url":"https://clinicaltrials.gov/study/NCT04495296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04495296","kind":"trial","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04495296/","field":"links","label":"ClinicalTrials.gov NCT04495296"}]},{"url":"https://clinicaltrials.gov/study/NCT04496349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04496349","kind":"trial","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","route":"/trials/nct04496349/","field":"links","label":"ClinicalTrials.gov NCT04496349"}]},{"url":"https://clinicaltrials.gov/study/NCT04497844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04497844"},{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","field":"links","label":"ClinicalTrials.gov NCT04497844"}]},{"url":"https://clinicaltrials.gov/study/NCT04497844?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","field":"outcomes.source (Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator)"},{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","field":"outcomes.source (HRR Effector Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator)"},{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","field":"outcomes.source (All HRR: Radiographic Progression-free Survival (rPFS) Assessed by Investigator)"}]},{"url":"https://clinicaltrials.gov/study/NCT04498117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","route":"/trials/nct04498117/","field":"links","label":"ClinicalTrials.gov NCT04498117"}]},{"url":"https://clinicaltrials.gov/study/NCT04499053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04499053","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","route":"/trials/nct04499053/","field":"links","label":"ClinicalTrials.gov NCT04499053"}]},{"url":"https://clinicaltrials.gov/study/NCT04501120","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/","field":"links","label":"ClinicalTrials.gov NCT04501120"}]},{"url":"https://clinicaltrials.gov/study/NCT04501523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/","field":"links","label":"ClinicalTrials.gov NCT04501523"}]},{"url":"https://clinicaltrials.gov/study/NCT04502394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","route":"/trials/nct04502394/","field":"links","label":"ClinicalTrials.gov NCT04502394"}]},{"url":"https://clinicaltrials.gov/study/NCT04503265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04503265","kind":"trial","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","route":"/trials/nct04503265/","field":"links","label":"ClinicalTrials.gov NCT04503265"}]},{"url":"https://clinicaltrials.gov/study/NCT04509700","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04509700","kind":"trial","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","route":"/trials/nct04509700/","field":"links","label":"ClinicalTrials.gov NCT04509700"}]},{"url":"https://clinicaltrials.gov/study/NCT04513717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/","field":"links","label":"ClinicalTrials.gov NCT04513717"}]},{"url":"https://clinicaltrials.gov/study/NCT04514419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04514419","kind":"trial","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","route":"/trials/nct04514419/","field":"links","label":"ClinicalTrials.gov NCT04514419"}]},{"url":"https://clinicaltrials.gov/study/NCT04516681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04516681","kind":"trial","name":"Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer","route":"/trials/nct04516681/","field":"links","label":"ClinicalTrials.gov NCT04516681"}]},{"url":"https://clinicaltrials.gov/study/NCT04521231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","route":"/trials/nct04521231/","field":"links","label":"ClinicalTrials.gov NCT04521231"}]},{"url":"https://clinicaltrials.gov/study/NCT04521413","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04521413","kind":"trial","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","route":"/trials/nct04521413/","field":"links","label":"ClinicalTrials.gov NCT04521413"}]},{"url":"https://clinicaltrials.gov/study/NCT04523272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04523272","kind":"trial","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","route":"/trials/nct04523272/","field":"links","label":"ClinicalTrials.gov NCT04523272"}]},{"url":"https://clinicaltrials.gov/study/NCT04524000","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04524000","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04524000/","field":"links","label":"ClinicalTrials.gov NCT04524000"}]},{"url":"https://clinicaltrials.gov/study/NCT04524689","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","route":"/trials/nct04524689/","field":"links","label":"ClinicalTrials.gov NCT04524689"}]},{"url":"https://clinicaltrials.gov/study/NCT04524689?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","route":"/trials/nct04524689/","field":"outcomes.source (Doublet Cohort: Objective Response Rate (ORR))"},{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","route":"/trials/nct04524689/","field":"outcomes.source (Quadruplet Cohort: Objective Response Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT04524871","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/","field":"links","label":"ClinicalTrials.gov NCT04524871"}]},{"url":"https://clinicaltrials.gov/study/NCT04526730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/","field":"links","label":"Neoadjuvant Tavo plus nivolumab (NCT04526730)"}]},{"url":"https://clinicaltrials.gov/study/NCT04529772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/","field":"links","label":"ClinicalTrials.gov NCT04529772"}]},{"url":"https://clinicaltrials.gov/study/NCT04534205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04534205","kind":"trial","name":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","route":"/trials/nct04534205/","field":"links","label":"ClinicalTrials.gov NCT04534205"}]},{"url":"https://clinicaltrials.gov/study/NCT04536675","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04536675","kind":"trial","name":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","route":"/trials/nct04536675/","field":"links","label":"ClinicalTrials.gov NCT04536675"}]},{"url":"https://clinicaltrials.gov/study/NCT04538664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04538664-n-engl-j-med-2023","kind":"paper","name":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","route":"/key-papers/paper-nct04538664-n-engl-j-med-2023/","field":"links","label":"ClinicalTrials.gov NCT04538664"},{"id":"nct04538664","kind":"trial","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","route":"/trials/nct04538664/","field":"links","label":"ClinicalTrials.gov NCT04538664"}]},{"url":"https://clinicaltrials.gov/study/NCT04538664?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04538664","kind":"trial","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","route":"/trials/nct04538664/","field":"outcomes.source (Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04538742","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04538742","kind":"trial","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","route":"/trials/nct04538742/","field":"links","label":"ClinicalTrials.gov NCT04538742"}]},{"url":"https://clinicaltrials.gov/study/NCT04539496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04539496","kind":"trial","name":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","route":"/trials/nct04539496/","field":"links","label":"ClinicalTrials.gov NCT04539496"}]},{"url":"https://clinicaltrials.gov/study/NCT04542824","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/","field":"links","label":"ClinicalTrials.gov NCT04542824"}]},{"url":"https://clinicaltrials.gov/study/NCT04543279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04543279","kind":"trial","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","route":"/trials/nct04543279/","field":"links","label":"ClinicalTrials.gov NCT04543279"}]},{"url":"https://clinicaltrials.gov/study/NCT04543279?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04543279","kind":"trial","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","route":"/trials/nct04543279/","field":"outcomes.source (Number of Participants With a Platelet Response (Part A))"}]},{"url":"https://clinicaltrials.gov/study/NCT04543955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04543955","kind":"trial","name":"Telotristat With Lutathera in Neuroendocrine Tumors","route":"/trials/nct04543955/","field":"links","label":"ClinicalTrials.gov NCT04543955"}]},{"url":"https://clinicaltrials.gov/study/NCT04544189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04544189","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04544189/","field":"links","label":"ClinicalTrials.gov NCT04544189"}]},{"url":"https://clinicaltrials.gov/study/NCT04546009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","field":"links","label":"ClinicalTrials.gov NCT04546009"}],"archive":"https://web.archive.org/web/20260409180513/https://clinicaltrials.gov/study/NCT04546009"},{"url":"https://clinicaltrials.gov/study/NCT04547166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04547166"},{"id":"nct04547166","kind":"trial","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","route":"/trials/nct04547166/","field":"links","label":"ClinicalTrials.gov NCT04547166"}]},{"url":"https://clinicaltrials.gov/study/NCT04547504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04547504","kind":"trial","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","route":"/trials/nct04547504/","field":"links","label":"ClinicalTrials.gov NCT04547504"}]},{"url":"https://clinicaltrials.gov/study/NCT04550260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","route":"/trials/nct04550260/","field":"links","label":"ClinicalTrials.gov NCT04550260"}]},{"url":"https://clinicaltrials.gov/study/NCT04553133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04553133","kind":"trial","name":"PF-07104091 as a Single Agent and in Combination Therapy","route":"/trials/nct04553133/","field":"links","label":"ClinicalTrials.gov NCT04553133"}]},{"url":"https://clinicaltrials.gov/study/NCT04554914","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","route":"/trials/nct04554914/","field":"links","label":"ClinicalTrials.gov NCT04554914"}]},{"url":"https://clinicaltrials.gov/study/NCT04557059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","field":"links","label":"ClinicalTrials.gov NCT04557059"}]},{"url":"https://clinicaltrials.gov/study/NCT04557098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"links","label":"ClinicalTrials.gov NCT04557098"},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/","field":"links","label":"ClinicalTrials.gov NCT04557098"}]},{"url":"https://clinicaltrials.gov/study/NCT04557449","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04557449","kind":"trial","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","route":"/trials/nct04557449/","field":"links","label":"ClinicalTrials.gov NCT04557449"}]},{"url":"https://clinicaltrials.gov/study/NCT04559139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"opt-in","kind":"trial","name":"OPT-IN (EA2197)","route":"/trials/opt-in/","field":"links","label":"ClinicalTrials.gov NCT04559139"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT04559139"},{"id":"idea-gbc-neoadjuvant-for-high-risk-incidental-cancer","kind":"idea","name":"Chemotherapy before the second operation for high-risk incidental gallbladder cancer","route":"/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/","field":"links","label":"ClinicalTrials.gov NCT04559139"}]},{"url":"https://clinicaltrials.gov/study/NCT04561336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","field":"links","label":"ClinicalTrials.gov NCT04561336"}]},{"url":"https://clinicaltrials.gov/study/NCT04561362","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04561362-j-clin-oncol-2025","kind":"paper","name":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation","route":"/key-papers/paper-nct04561362-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04561362"},{"id":"nct04561362","kind":"trial","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","route":"/trials/nct04561362/","field":"links","label":"ClinicalTrials.gov NCT04561362"}]},{"url":"https://clinicaltrials.gov/study/NCT04562389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04562389","kind":"trial","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","route":"/trials/nct04562389/","field":"links","label":"ClinicalTrials.gov NCT04562389"}]},{"url":"https://clinicaltrials.gov/study/NCT04564157","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04564157","kind":"trial","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","route":"/trials/nct04564157/","field":"links","label":"ClinicalTrials.gov NCT04564157"}]},{"url":"https://clinicaltrials.gov/study/NCT04567420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/","field":"links","label":"ClinicalTrials.gov NCT04567420"}]},{"url":"https://clinicaltrials.gov/study/NCT04570423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/","field":"links","label":"ClinicalTrials.gov NCT04570423"}]},{"url":"https://clinicaltrials.gov/study/NCT04570943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04570943","kind":"trial","name":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04570943/","field":"links","label":"ClinicalTrials.gov NCT04570943"}]},{"url":"https://clinicaltrials.gov/study/NCT04576156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impactmf","kind":"trial","name":"IMpactMF","route":"/trials/impactmf/","field":"links","label":"ClinicalTrials.gov NCT04576156"}]},{"url":"https://clinicaltrials.gov/study/NCT04576455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04576455-j-clin-oncol-2024","kind":"paper","name":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","route":"/key-papers/paper-nct04576455-j-clin-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04576455"},{"id":"nct04576455","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","route":"/trials/nct04576455/","field":"links","label":"ClinicalTrials.gov NCT04576455"}]},{"url":"https://clinicaltrials.gov/study/NCT04576455?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04576455","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","route":"/trials/nct04576455/","field":"outcomes.source (Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1))"},{"id":"nct04576455","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","route":"/trials/nct04576455/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04579380","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04579380-j-clin-oncol-2023","kind":"paper","name":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","route":"/key-papers/paper-nct04579380-j-clin-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT04579380"},{"id":"nct04579380","kind":"trial","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","route":"/trials/nct04579380/","field":"links","label":"ClinicalTrials.gov NCT04579380"}]},{"url":"https://clinicaltrials.gov/study/NCT04579380?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04579380","kind":"trial","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","route":"/trials/nct04579380/","field":"outcomes.source (Confirmed Objective Response Rate (cORR) as Assessed by Investigator)"}]},{"url":"https://clinicaltrials.gov/study/NCT04581473","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/","field":"links","label":"ClinicalTrials.gov NCT04581473"},{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/","field":"links","label":"ClinicalTrials.gov NCT04581473"}]},{"url":"https://clinicaltrials.gov/study/NCT04581512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/","field":"links","label":"ClinicalTrials.gov NCT04581512"}]},{"url":"https://clinicaltrials.gov/study/NCT04585035","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/","field":"links","label":"ClinicalTrials.gov NCT04585035"},{"id":"nct04585035","kind":"trial","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","route":"/trials/nct04585035/","field":"links","label":"ClinicalTrials.gov NCT04585035"}]},{"url":"https://clinicaltrials.gov/study/NCT04585490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04585490","kind":"trial","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","route":"/trials/nct04585490/","field":"links","label":"ClinicalTrials.gov NCT04585490"}]},{"url":"https://clinicaltrials.gov/study/NCT04585750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT04585750"},{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","route":"/trials/nct04585750/","field":"links","label":"ClinicalTrials.gov NCT04585750"}]},{"url":"https://clinicaltrials.gov/study/NCT04586231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"links","label":"ClinicalTrials.gov NCT04586231"},{"id":"paper-litespark-011-motzer-lancet-2026","kind":"paper","name":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-litespark-011-motzer-lancet-2026/","field":"links","label":"ClinicalTrials.gov NCT04586231"}]},{"url":"https://clinicaltrials.gov/study/NCT04586426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04586426","kind":"trial","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct04586426/","field":"links","label":"ClinicalTrials.gov NCT04586426"}]},{"url":"https://clinicaltrials.gov/study/NCT04586478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","field":"links","label":"ClinicalTrials.gov NCT04586478"}]},{"url":"https://clinicaltrials.gov/study/NCT04587830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","route":"/trials/nct04587830/","field":"links","label":"ClinicalTrials.gov NCT04587830"}]},{"url":"https://clinicaltrials.gov/study/NCT04588922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04588922","kind":"trial","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","route":"/trials/nct04588922/","field":"links","label":"ClinicalTrials.gov NCT04588922"}]},{"url":"https://clinicaltrials.gov/study/NCT04589234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","field":"links","label":"Saltikva phase 2 (NCT04589234)"},{"id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/","field":"links","label":"ClinicalTrials.gov NCT04589234"}]},{"url":"https://clinicaltrials.gov/study/NCT04589845","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/","field":"links","label":"ClinicalTrials.gov NCT04589845"}]},{"url":"https://clinicaltrials.gov/study/NCT04590326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/","field":"links","label":"ClinicalTrials.gov NCT04590326"}]},{"url":"https://clinicaltrials.gov/study/NCT04590963","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04590963","kind":"trial","name":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","route":"/trials/nct04590963/","field":"links","label":"ClinicalTrials.gov NCT04590963"}]},{"url":"https://clinicaltrials.gov/study/NCT04590963?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04590963","kind":"trial","name":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","route":"/trials/nct04590963/","field":"outcomes.source (Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set)"},{"id":"nct04590963","kind":"trial","name":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","route":"/trials/nct04590963/","field":"outcomes.source (Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set)"}]},{"url":"https://clinicaltrials.gov/study/NCT04592653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04592653","kind":"trial","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","route":"/trials/nct04592653/","field":"links","label":"ClinicalTrials.gov NCT04592653"}]},{"url":"https://clinicaltrials.gov/study/NCT04592887","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","route":"/ideas/idea-fund-flash-evidence-programme/","field":"links","label":"FAST-01 (NCT04592887)"}]},{"url":"https://clinicaltrials.gov/study/NCT04592913","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","field":"links","label":"ClinicalTrials.gov NCT04592913"},{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://clinicaltrials.gov/study/NCT04595565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/","field":"links","label":"ClinicalTrials.gov NCT04595565"}]},{"url":"https://clinicaltrials.gov/study/NCT04597671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04597671","kind":"trial","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","route":"/trials/nct04597671/","field":"links","label":"ClinicalTrials.gov NCT04597671"}]},{"url":"https://clinicaltrials.gov/study/NCT04603495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"links","label":"ClinicalTrials.gov NCT04603495"}]},{"url":"https://clinicaltrials.gov/study/NCT04603807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04603807","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","route":"/trials/nct04603807/","field":"links","label":"ClinicalTrials.gov NCT04603807"}]},{"url":"https://clinicaltrials.gov/study/NCT04605913","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04605913","kind":"trial","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","route":"/trials/nct04605913/","field":"links","label":"ClinicalTrials.gov NCT04605913"}]},{"url":"https://clinicaltrials.gov/study/NCT04606446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04606446"},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/","field":"links","label":"ClinicalTrials.gov NCT04606446"}]},{"url":"https://clinicaltrials.gov/study/NCT04606771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","field":"links","label":"ClinicalTrials.gov NCT04606771"}]},{"url":"https://clinicaltrials.gov/study/NCT04606771?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","field":"outcomes.source (Objective Response Rate (ORR))"},{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04607421","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","field":"links","label":"ClinicalTrials.gov NCT04607421"},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT04607421"},{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04607421"}]},{"url":"https://clinicaltrials.gov/study/NCT04613596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/","field":"links","label":"ClinicalTrials.gov NCT04613596"}]},{"url":"https://clinicaltrials.gov/study/NCT04614103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/","field":"links","label":"ClinicalTrials.gov NCT04614103"}]},{"url":"https://clinicaltrials.gov/study/NCT04616209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","field":"links","label":"ClinicalTrials.gov NCT04616209"}]},{"url":"https://clinicaltrials.gov/study/NCT04616443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04616443","kind":"trial","name":"OH2 Injection in Combination With HX008 for Melanoma.","route":"/trials/nct04616443/","field":"links","label":"ClinicalTrials.gov NCT04616443"}]},{"url":"https://clinicaltrials.gov/study/NCT04619004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"dosing.source"},{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT04619004"},{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","route":"/trials/nct04619004/","field":"links","label":"ClinicalTrials.gov NCT04619004"}]},{"url":"https://clinicaltrials.gov/study/NCT04619004?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","route":"/trials/nct04619004/","field":"outcomes.source (Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04622319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","field":"links","label":"ClinicalTrials.gov NCT04622319"},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","field":"links","label":"ClinicalTrials.gov NCT04622319 (DESTINY-Breast05)"},{"id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","field":"links","label":"ClinicalTrials.gov NCT04622319: DESTINY-Breast05"},{"id":"paper-destiny-breast05-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","route":"/key-papers/paper-destiny-breast05-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT04622319"}]},{"url":"https://clinicaltrials.gov/study/NCT04623541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/","field":"links","label":"ClinicalTrials.gov NCT04623541"}]},{"url":"https://clinicaltrials.gov/study/NCT04624204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/","field":"links","label":"ClinicalTrials.gov NCT04624204"}]},{"url":"https://clinicaltrials.gov/study/NCT04624633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04624633","kind":"trial","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","route":"/trials/nct04624633/","field":"links","label":"ClinicalTrials.gov NCT04624633"}]},{"url":"https://clinicaltrials.gov/study/NCT04624633?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04624633","kind":"trial","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","route":"/trials/nct04624633/","field":"outcomes.source (Complete Remission (CR) Rate After 24 Cycles)"}]},{"url":"https://clinicaltrials.gov/study/NCT04625270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","field":"links","label":"ClinicalTrials.gov NCT04625270"}]},{"url":"https://clinicaltrials.gov/study/NCT04625907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","field":"links","label":"FaR-RMS trial"}]},{"url":"https://clinicaltrials.gov/study/NCT04626479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","field":"links","label":"ClinicalTrials.gov NCT04626479"}]},{"url":"https://clinicaltrials.gov/study/NCT04626518","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","field":"links","label":"ClinicalTrials.gov NCT04626518"}]},{"url":"https://clinicaltrials.gov/study/NCT04626635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04626635","kind":"trial","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","route":"/trials/nct04626635/","field":"links","label":"ClinicalTrials.gov NCT04626635"}]},{"url":"https://clinicaltrials.gov/study/NCT04628494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","field":"links","label":"ClinicalTrials.gov NCT04628494"}]},{"url":"https://clinicaltrials.gov/study/NCT04632108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04632108","kind":"trial","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04632108/","field":"links","label":"ClinicalTrials.gov NCT04632108"}]},{"url":"https://clinicaltrials.gov/study/NCT04632758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04632758","kind":"trial","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04632758/","field":"links","label":"ClinicalTrials.gov NCT04632758"}]},{"url":"https://clinicaltrials.gov/study/NCT04634058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04634058","kind":"trial","name":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","route":"/trials/nct04634058/","field":"links","label":"ClinicalTrials.gov NCT04634058"}]},{"url":"https://clinicaltrials.gov/study/NCT04634357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","route":"/trials/nct04634357/","field":"links","label":"ClinicalTrials.gov NCT04634357"}]},{"url":"https://clinicaltrials.gov/study/NCT04634552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","field":"links","label":"ClinicalTrials.gov NCT04634552"},{"id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","field":"links","label":"ClinicalTrials.gov NCT04634552: MonumenTAL-1"}]},{"url":"https://clinicaltrials.gov/study/NCT04634877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04634877","kind":"trial","name":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","route":"/trials/nct04634877/","field":"links","label":"ClinicalTrials.gov NCT04634877"}]},{"url":"https://clinicaltrials.gov/study/NCT04639180","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04639180","kind":"trial","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","route":"/trials/nct04639180/","field":"links","label":"ClinicalTrials.gov NCT04639180"}]},{"url":"https://clinicaltrials.gov/study/NCT04639219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04639219"},{"id":"nct04639219","kind":"trial","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","route":"/trials/nct04639219/","field":"links","label":"ClinicalTrials.gov NCT04639219"}]},{"url":"https://clinicaltrials.gov/study/NCT04639219?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04639219","kind":"trial","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","route":"/trials/nct04639219/","field":"outcomes.source (Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR))"},{"id":"nct04639219","kind":"trial","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","route":"/trials/nct04639219/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04639986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","route":"/trials/nct04639986/","field":"links","label":"ClinicalTrials.gov NCT04639986"}]},{"url":"https://clinicaltrials.gov/study/NCT04640623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","field":"links","label":"ClinicalTrials.gov NCT04640623"},{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","field":"links","label":"ClinicalTrials.gov NCT04640623 (SunRISe-1)"},{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/","field":"links","label":"ClinicalTrials.gov NCT04640623"}]},{"url":"https://clinicaltrials.gov/study/NCT04641247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","route":"/trials/nct04641247/","field":"links","label":"ClinicalTrials.gov NCT04641247"}]},{"url":"https://clinicaltrials.gov/study/NCT04641754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04641754","kind":"trial","name":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct04641754/","field":"links","label":"ClinicalTrials.gov NCT04641754"}]},{"url":"https://clinicaltrials.gov/study/NCT04642469","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","route":"/trials/mermaid-2/","field":"links","label":"ClinicalTrials.gov NCT04642469"}]},{"url":"https://clinicaltrials.gov/study/NCT04642469?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","route":"/trials/mermaid-2/","field":"outcomes.source (Disease-free Survival (DFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04643366","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04643366","kind":"trial","name":"Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","route":"/trials/nct04643366/","field":"links","label":"ClinicalTrials.gov NCT04643366"}]},{"url":"https://clinicaltrials.gov/study/NCT04643418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","field":"links","label":"ClinicalTrials.gov NCT04643418"}]},{"url":"https://clinicaltrials.gov/study/NCT04644068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/","field":"links","label":"ClinicalTrials.gov NCT04644068"}]},{"url":"https://clinicaltrials.gov/study/NCT04644237","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04644237"},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/","field":"links","label":"ClinicalTrials.gov NCT04644237"}]},{"url":"https://clinicaltrials.gov/study/NCT04644289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/","field":"links","label":"ClinicalTrials.gov NCT04644289"}]},{"url":"https://clinicaltrials.gov/study/NCT04645160","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04645160","kind":"trial","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","route":"/trials/nct04645160/","field":"links","label":"ClinicalTrials.gov NCT04645160"}]},{"url":"https://clinicaltrials.gov/study/NCT04647526","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"links","label":"ClinicalTrials.gov NCT04647526"},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"outcomes.source (Overall survival (interim))"},{"id":"paper-splash-front-oncol-2024","kind":"paper","name":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","route":"/key-papers/paper-splash-front-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04647526"}],"archive":"https://web.archive.org/web/20260724082433/https://clinicaltrials.gov/study/NCT04647526"},{"url":"https://clinicaltrials.gov/study/NCT04649060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/","field":"links","label":"ClinicalTrials.gov NCT04649060"}]},{"url":"https://clinicaltrials.gov/study/NCT04649060?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04649359","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","field":"links","label":"ClinicalTrials.gov NCT04649359"},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/","field":"links","label":"ClinicalTrials.gov NCT04649359"}]},{"url":"https://clinicaltrials.gov/study/NCT04651634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","route":"/trials/nct04651634/","field":"links","label":"ClinicalTrials.gov NCT04651634"}]},{"url":"https://clinicaltrials.gov/study/NCT04652076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04652076","kind":"trial","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","route":"/trials/nct04652076/","field":"links","label":"ClinicalTrials.gov NCT04652076"}]},{"url":"https://clinicaltrials.gov/study/NCT04655092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04655092","kind":"trial","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","route":"/trials/nct04655092/","field":"links","label":"ClinicalTrials.gov NCT04655092"}]},{"url":"https://clinicaltrials.gov/study/NCT04655976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","field":"links","label":"ClinicalTrials.gov NCT04655976"}]},{"url":"https://clinicaltrials.gov/study/NCT04655976?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","field":"outcomes.source (Overall Survival (OS) (Arm A Versus Arm C))"},{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","field":"outcomes.source (Overall Survival (OS) (Arm B Versus Arm C))"},{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04656652","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","field":"links","label":"ClinicalTrials.gov NCT04656652"}]},{"url":"https://clinicaltrials.gov/study/NCT04657068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/","field":"links","label":"ClinicalTrials.gov NCT04657068"}]},{"url":"https://clinicaltrials.gov/study/NCT04657081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/","field":"links","label":"ClinicalTrials.gov NCT04657081"},{"id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","field":"links","label":"ClinicalTrials.gov NCT04657081: ASCERTAIN-V"}]},{"url":"https://clinicaltrials.gov/study/NCT04657991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/","field":"links","label":"ClinicalTrials.gov NCT04657991"},{"id":"nct04657991","kind":"trial","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","route":"/trials/nct04657991/","field":"links","label":"ClinicalTrials.gov NCT04657991"}]},{"url":"https://clinicaltrials.gov/study/NCT04658862","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04658862","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","route":"/trials/nct04658862/","field":"links","label":"ClinicalTrials.gov NCT04658862"}]},{"url":"https://clinicaltrials.gov/study/NCT04659603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04659603","kind":"trial","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","route":"/trials/nct04659603/","field":"links","label":"ClinicalTrials.gov NCT04659603"}]},{"url":"https://clinicaltrials.gov/study/NCT04659603?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04659603","kind":"trial","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","route":"/trials/nct04659603/","field":"outcomes.source (Objective Response Rate (ORR))"},{"id":"nct04659603","kind":"trial","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","route":"/trials/nct04659603/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04660344","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","field":"links","label":"ClinicalTrials.gov NCT04660344: IMvigor011"},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","field":"links","label":"ClinicalTrials.gov NCT04660344: IMvigor011"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"links","label":"ClinicalTrials.gov NCT04660344 (IMvigor011)"},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","field":"links","label":"ClinicalTrials.gov NCT04660344"},{"id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","field":"links","label":"ClinicalTrials.gov NCT04660344: IMvigor011"},{"id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","field":"links","label":"ClinicalTrials.gov NCT04660344: IMvigor011"},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","field":"papers","label":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery"},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/","field":"links","label":"ClinicalTrials.gov NCT04660344"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ClinicalTrials.gov NCT04660344"}]},{"url":"https://clinicaltrials.gov/study/NCT04661007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04661007","kind":"trial","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","route":"/trials/nct04661007/","field":"links","label":"ClinicalTrials.gov NCT04661007"}]},{"url":"https://clinicaltrials.gov/study/NCT04662255","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04662255","kind":"trial","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","route":"/trials/nct04662255/","field":"links","label":"ClinicalTrials.gov NCT04662255"}]},{"url":"https://clinicaltrials.gov/study/NCT04663347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/","field":"links","label":"ClinicalTrials.gov NCT04663347"},{"id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/","field":"links","label":"ClinicalTrials.gov NCT04663347"}]},{"url":"https://clinicaltrials.gov/study/NCT04665206","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/","field":"links","label":"ClinicalTrials.gov NCT04665206"}]},{"url":"https://clinicaltrials.gov/study/NCT04665609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04665609","kind":"trial","name":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","route":"/trials/nct04665609/","field":"links","label":"ClinicalTrials.gov NCT04665609"}]},{"url":"https://clinicaltrials.gov/study/NCT04665856","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT04665856"},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","field":"links","label":"ClinicalTrials.gov NCT04665856"}]},{"url":"https://clinicaltrials.gov/study/NCT04665856?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","field":"outcomes.source (Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS))"},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","field":"outcomes.source (Overall Survival (OS) in the PAS)"},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","field":"outcomes.source (Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS)"}]},{"url":"https://clinicaltrials.gov/study/NCT04666038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/","field":"links","label":"ClinicalTrials.gov NCT04666038"}]},{"url":"https://clinicaltrials.gov/study/NCT04668690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/","field":"links","label":"ClinicalTrials.gov NCT04668690"}]},{"url":"https://clinicaltrials.gov/study/NCT04669171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04669171","kind":"trial","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","route":"/trials/nct04669171/","field":"links","label":"ClinicalTrials.gov NCT04669171"}]},{"url":"https://clinicaltrials.gov/study/NCT04673942","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04673942","kind":"trial","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","route":"/trials/nct04673942/","field":"links","label":"ClinicalTrials.gov NCT04673942"}]},{"url":"https://clinicaltrials.gov/study/NCT04674683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04674683","kind":"trial","name":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","route":"/trials/nct04674683/","field":"links","label":"ClinicalTrials.gov NCT04674683"}]},{"url":"https://clinicaltrials.gov/study/NCT04675294","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/","field":"links","label":"ClinicalTrials.gov NCT04675294"}]},{"url":"https://clinicaltrials.gov/study/NCT04675333","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/","field":"links","label":"ClinicalTrials.gov NCT04675333"}]},{"url":"https://clinicaltrials.gov/study/NCT04677816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04677816","kind":"trial","name":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","route":"/trials/nct04677816/","field":"links","label":"ClinicalTrials.gov NCT04677816"}]},{"url":"https://clinicaltrials.gov/study/NCT04680052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/","field":"links","label":"ClinicalTrials.gov NCT04680052"}]},{"url":"https://clinicaltrials.gov/study/NCT04680052?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/","field":"outcomes.source (FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First)"}]},{"url":"https://clinicaltrials.gov/study/NCT04680260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04680260","kind":"trial","name":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","route":"/trials/nct04680260/","field":"links","label":"ClinicalTrials.gov NCT04680260"}]},{"url":"https://clinicaltrials.gov/study/NCT04683250","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/","field":"links","label":"ClinicalTrials.gov NCT04683250"}]},{"url":"https://clinicaltrials.gov/study/NCT04683315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04683315","kind":"trial","name":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","route":"/trials/nct04683315/","field":"links","label":"ClinicalTrials.gov NCT04683315"}]},{"url":"https://clinicaltrials.gov/study/NCT04683679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/","field":"links","label":"ClinicalTrials.gov NCT04683679"}]},{"url":"https://clinicaltrials.gov/study/NCT04684147","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04684147","kind":"trial","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","field":"links","label":"ClinicalTrials.gov NCT04684147"}]},{"url":"https://clinicaltrials.gov/study/NCT04685135","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/","field":"links","label":"ClinicalTrials.gov NCT04685135"},{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT04685135"}],"archive":"https://web.archive.org/web/20260609145219/https://clinicaltrials.gov/study/NCT04685135"},{"url":"https://clinicaltrials.gov/study/NCT04685226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/","field":"links","label":"ClinicalTrials.gov NCT04685226"}]},{"url":"https://clinicaltrials.gov/study/NCT04686682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/","field":"links","label":"ClinicalTrials.gov NCT04686682"}]},{"url":"https://clinicaltrials.gov/study/NCT04687241","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT04687241"},{"id":"nct04687241","kind":"trial","name":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","route":"/trials/nct04687241/","field":"links","label":"ClinicalTrials.gov NCT04687241"}]},{"url":"https://clinicaltrials.gov/study/NCT04687631","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04687631","kind":"trial","name":"Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases","route":"/trials/nct04687631/","field":"links","label":"ClinicalTrials.gov NCT04687631"}]},{"url":"https://clinicaltrials.gov/study/NCT04689347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04689347","kind":"trial","name":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","route":"/trials/nct04689347/","field":"links","label":"ClinicalTrials.gov NCT04689347"}]},{"url":"https://clinicaltrials.gov/study/NCT04689828","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"links","label":"ClinicalTrials.gov NCT04689828"},{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT04689828"}]},{"url":"https://clinicaltrials.gov/study/NCT04691804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04691804","kind":"trial","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","route":"/trials/nct04691804/","field":"links","label":"ClinicalTrials.gov NCT04691804"}]},{"url":"https://clinicaltrials.gov/study/NCT04691817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04691817","kind":"trial","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","route":"/trials/nct04691817/","field":"links","label":"ClinicalTrials.gov NCT04691817"}]},{"url":"https://clinicaltrials.gov/study/NCT04692103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04692103","kind":"trial","name":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","route":"/trials/nct04692103/","field":"links","label":"ClinicalTrials.gov NCT04692103"}]},{"url":"https://clinicaltrials.gov/study/NCT04692103?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04692103","kind":"trial","name":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","route":"/trials/nct04692103/","field":"outcomes.source (Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmax)"}]},{"url":"https://clinicaltrials.gov/study/NCT04695782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04695782","kind":"trial","name":"Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy","route":"/trials/nct04695782/","field":"links","label":"ClinicalTrials.gov NCT04695782"}]},{"url":"https://clinicaltrials.gov/study/NCT04695925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04695925","kind":"trial","name":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","route":"/trials/nct04695925/","field":"links","label":"ClinicalTrials.gov NCT04695925"}]},{"url":"https://clinicaltrials.gov/study/NCT04697628","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","field":"links","label":"ClinicalTrials.gov NCT04697628"}]},{"url":"https://clinicaltrials.gov/study/NCT04699188","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04699188","kind":"trial","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct04699188/","field":"links","label":"ClinicalTrials.gov NCT04699188"}]},{"url":"https://clinicaltrials.gov/study/NCT04700124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","field":"links","label":"ClinicalTrials.gov NCT04700124"},{"id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","field":"links","label":"ClinicalTrials.gov NCT04700124: EV-304 / KEYNOTE-B15"}]},{"url":"https://clinicaltrials.gov/study/NCT04701476","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04701476","kind":"trial","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","route":"/trials/nct04701476/","field":"links","label":"ClinicalTrials.gov NCT04701476"}]},{"url":"https://clinicaltrials.gov/study/NCT04703192","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04703192","kind":"trial","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","route":"/trials/nct04703192/","field":"links","label":"ClinicalTrials.gov NCT04703192"}]},{"url":"https://clinicaltrials.gov/study/NCT04703192?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04703192","kind":"trial","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","route":"/trials/nct04703192/","field":"outcomes.source (Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1))"}]},{"url":"https://clinicaltrials.gov/study/NCT04704934","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/","field":"links","label":"ClinicalTrials.gov NCT04704934"},{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","field":"links","label":"ClinicalTrials.gov NCT04704934: DESTINY-Gastric04"}]},{"url":"https://clinicaltrials.gov/study/NCT04711135","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","field":"links","label":"ClinicalTrials.gov NCT04711135"}]},{"url":"https://clinicaltrials.gov/study/NCT04711135?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","field":"outcomes.source (Absorbed Radiation Doses in Target Organ, Total Body)"}]},{"url":"https://clinicaltrials.gov/study/NCT04711252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04711252","kind":"trial","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","route":"/trials/nct04711252/","field":"links","label":"ClinicalTrials.gov NCT04711252"}]},{"url":"https://clinicaltrials.gov/study/NCT04712097","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04712097","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","route":"/trials/nct04712097/","field":"links","label":"ClinicalTrials.gov NCT04712097"}]},{"url":"https://clinicaltrials.gov/study/NCT04712643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04712643","kind":"trial","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","route":"/trials/nct04712643/","field":"links","label":"ClinicalTrials.gov NCT04712643"}]},{"url":"https://clinicaltrials.gov/study/NCT04717414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04717414","kind":"trial","name":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi","route":"/trials/nct04717414/","field":"links","label":"ClinicalTrials.gov NCT04717414"}]},{"url":"https://clinicaltrials.gov/study/NCT04717414?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04717414","kind":"trial","name":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi","route":"/trials/nct04717414/","field":"outcomes.source (Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12))"}]},{"url":"https://clinicaltrials.gov/study/NCT04718883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04718883","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","route":"/trials/nct04718883/","field":"links","label":"ClinicalTrials.gov NCT04718883"}]},{"url":"https://clinicaltrials.gov/study/NCT04720157","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"ClinicalTrials.gov NCT04720157"},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","field":"links","label":"ClinicalTrials.gov NCT04720157: PSMAddition"},{"id":"paper-psmaddition-lancet-2026","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","route":"/key-papers/paper-psmaddition-lancet-2026/","field":"links","label":"ClinicalTrials.gov NCT04720157"}]},{"url":"https://clinicaltrials.gov/study/NCT04720313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","field":"links","label":"ClinicalTrials.gov NCT04720313"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"links","label":"ClinicalTrials.gov NCT04720313"},{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/","field":"links","label":"ClinicalTrials.gov NCT04720313"}]},{"url":"https://clinicaltrials.gov/study/NCT04721977","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04721977","kind":"trial","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","route":"/trials/nct04721977/","field":"links","label":"ClinicalTrials.gov NCT04721977"}]},{"url":"https://clinicaltrials.gov/study/NCT04721977?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04721977","kind":"trial","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","route":"/trials/nct04721977/","field":"outcomes.source (Confirmed Objective Response Rate(cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Determined by Independent Central Review (ICR): Japanese Participants)"}]},{"url":"https://clinicaltrials.gov/study/NCT04722978","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04722978","kind":"trial","name":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","route":"/trials/nct04722978/","field":"links","label":"ClinicalTrials.gov NCT04722978"}]},{"url":"https://clinicaltrials.gov/study/NCT04723316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/","field":"links","label":"ClinicalTrials.gov NCT04723316"}]},{"url":"https://clinicaltrials.gov/study/NCT04724369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/","field":"links","label":"ClinicalTrials.gov NCT04724369"}]},{"url":"https://clinicaltrials.gov/study/NCT04724980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04724980","kind":"trial","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","route":"/trials/nct04724980/","field":"links","label":"ClinicalTrials.gov NCT04724980"}]},{"url":"https://clinicaltrials.gov/study/NCT04725474","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/","field":"links","label":"ClinicalTrials.gov NCT04725474"}]},{"url":"https://clinicaltrials.gov/study/NCT04725994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04725994","kind":"trial","name":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","route":"/trials/nct04725994/","field":"links","label":"ClinicalTrials.gov NCT04725994"}]},{"url":"https://clinicaltrials.gov/study/NCT04728893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","route":"/trials/nct04728893/","field":"links","label":"ClinicalTrials.gov NCT04728893"}]},{"url":"https://clinicaltrials.gov/study/NCT04730258","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04730258","kind":"trial","name":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","route":"/trials/nct04730258/","field":"links","label":"ClinicalTrials.gov NCT04730258"}]},{"url":"https://clinicaltrials.gov/study/NCT04733183","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04733183","kind":"trial","name":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","route":"/trials/nct04733183/","field":"links","label":"ClinicalTrials.gov NCT04733183"}]},{"url":"https://clinicaltrials.gov/study/NCT04736173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/","field":"links","label":"ClinicalTrials.gov NCT04736173"}]},{"url":"https://clinicaltrials.gov/study/NCT04736199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/","field":"links","label":"ClinicalTrials.gov NCT04736199"},{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/","field":"links","label":"ClinicalTrials.gov NCT04736199"}]},{"url":"https://clinicaltrials.gov/study/NCT04736199?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/","field":"outcomes.source (Radiological progression-free survival by central review (registry results))"}]},{"url":"https://clinicaltrials.gov/study/NCT04736589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04736589","kind":"trial","name":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","route":"/trials/nct04736589/","field":"links","label":"ClinicalTrials.gov NCT04736589"}]},{"url":"https://clinicaltrials.gov/study/NCT04736706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","field":"links","label":"ClinicalTrials.gov NCT04736706"}]},{"url":"https://clinicaltrials.gov/study/NCT04737187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/","field":"links","label":"ClinicalTrials.gov NCT04737187"}]},{"url":"https://clinicaltrials.gov/study/NCT04739761","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/","field":"links","label":"ClinicalTrials.gov NCT04739761"},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","field":"links","label":"ClinicalTrials.gov NCT04739761: DESTINY-Breast12"},{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","field":"links","label":"ClinicalTrials.gov NCT04739761: DESTINY-Breast12"},{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/","field":"links","label":"ClinicalTrials.gov NCT04739761"}]},{"url":"https://clinicaltrials.gov/study/NCT04744831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/","field":"links","label":"ClinicalTrials.gov NCT04744831"},{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT04744831"}]},{"url":"https://clinicaltrials.gov/study/NCT04745689","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","route":"/trials/nct04745689/","field":"links","label":"ClinicalTrials.gov NCT04745689"}]},{"url":"https://clinicaltrials.gov/study/NCT04745689?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","route":"/trials/nct04745689/","field":"outcomes.source (Overall Survival (OS) in Maintenance Participants)"}]},{"url":"https://clinicaltrials.gov/study/NCT04747236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04747236","kind":"trial","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","route":"/trials/nct04747236/","field":"links","label":"ClinicalTrials.gov NCT04747236"}]},{"url":"https://clinicaltrials.gov/study/NCT04749108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04749108","kind":"trial","name":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","route":"/trials/nct04749108/","field":"links","label":"ClinicalTrials.gov NCT04749108"}]},{"url":"https://clinicaltrials.gov/study/NCT04752059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","field":"links","label":"ClinicalTrials.gov NCT04752059"}]},{"url":"https://clinicaltrials.gov/study/NCT04752722","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","route":"/trials/nct04752722/","field":"links","label":"ClinicalTrials.gov NCT04752722"}]},{"url":"https://clinicaltrials.gov/study/NCT04752813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04752813","kind":"trial","name":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","route":"/trials/nct04752813/","field":"links","label":"ClinicalTrials.gov NCT04752813"}]},{"url":"https://clinicaltrials.gov/study/NCT04752826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/","field":"links","label":"ClinicalTrials.gov NCT04752826"}]},{"url":"https://clinicaltrials.gov/study/NCT04762069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04762069","kind":"trial","name":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","route":"/trials/nct04762069/","field":"links","label":"ClinicalTrials.gov NCT04762069"}]},{"url":"https://clinicaltrials.gov/study/NCT04762459","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04762459","kind":"trial","name":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com","route":"/trials/nct04762459/","field":"links","label":"ClinicalTrials.gov NCT04762459"}]},{"url":"https://clinicaltrials.gov/study/NCT04765059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/","field":"links","label":"ClinicalTrials.gov NCT04765059"},{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/","field":"links","label":"ClinicalTrials.gov NCT04765059"}]},{"url":"https://clinicaltrials.gov/study/NCT04765059?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04768426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04768426","kind":"trial","name":"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer","route":"/trials/nct04768426/","field":"links","label":"ClinicalTrials.gov NCT04768426"}]},{"url":"https://clinicaltrials.gov/study/NCT04771130","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","route":"/trials/nct04771130/","field":"links","label":"ClinicalTrials.gov NCT04771130"}]},{"url":"https://clinicaltrials.gov/study/NCT04771520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04771520","kind":"trial","name":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","route":"/trials/nct04771520/","field":"links","label":"ClinicalTrials.gov NCT04771520"}]},{"url":"https://clinicaltrials.gov/study/NCT04771871","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/","field":"links","label":"ClinicalTrials.gov NCT04771871"}]},{"url":"https://clinicaltrials.gov/study/NCT04772287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04772287","kind":"trial","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","route":"/trials/nct04772287/","field":"links","label":"ClinicalTrials.gov NCT04772287"}]},{"url":"https://clinicaltrials.gov/study/NCT04774718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","route":"/trials/nct04774718/","field":"links","label":"ClinicalTrials.gov NCT04774718"}]},{"url":"https://clinicaltrials.gov/study/NCT04775485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","field":"links","label":"ClinicalTrials.gov NCT04775485"}]},{"url":"https://clinicaltrials.gov/study/NCT04776330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04776330","kind":"trial","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04776330/","field":"links","label":"ClinicalTrials.gov NCT04776330"}]},{"url":"https://clinicaltrials.gov/study/NCT04776655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04776655","kind":"trial","name":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","route":"/trials/nct04776655/","field":"links","label":"ClinicalTrials.gov NCT04776655"}]},{"url":"https://clinicaltrials.gov/study/NCT04778397","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04778397","kind":"trial","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","route":"/trials/nct04778397/","field":"links","label":"ClinicalTrials.gov NCT04778397"}]},{"url":"https://clinicaltrials.gov/study/NCT04778397?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04778397","kind":"trial","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","route":"/trials/nct04778397/","field":"outcomes.source (Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy)"}]},{"url":"https://clinicaltrials.gov/study/NCT04778670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"links","label":"ClinicalTrials.gov NCT04778670"},{"id":"paper-screentrustcad-dembrower-lancet-digit-health-2023","kind":"paper","name":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)","route":"/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/","field":"links","label":"ClinicalTrials.gov NCT04778670"}]},{"url":"https://clinicaltrials.gov/study/NCT04781192","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04781192","kind":"trial","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","route":"/trials/nct04781192/","field":"links","label":"ClinicalTrials.gov NCT04781192"}]},{"url":"https://clinicaltrials.gov/study/NCT04782687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","route":"/trials/nct04782687/","field":"links","label":"ClinicalTrials.gov NCT04782687"}]},{"url":"https://clinicaltrials.gov/study/NCT04784715","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","field":"links","label":"ClinicalTrials.gov NCT04784715"},{"id":"paper-destiny-breast09-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","route":"/key-papers/paper-destiny-breast09-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT04784715"}]},{"url":"https://clinicaltrials.gov/study/NCT04785196","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04785196","kind":"trial","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","route":"/trials/nct04785196/","field":"links","label":"ClinicalTrials.gov NCT04785196"}]},{"url":"https://clinicaltrials.gov/study/NCT04786964","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04786964","kind":"trial","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","route":"/trials/nct04786964/","field":"links","label":"ClinicalTrials.gov NCT04786964"}]},{"url":"https://clinicaltrials.gov/study/NCT04787042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04787042","kind":"trial","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","route":"/trials/nct04787042/","field":"links","label":"ClinicalTrials.gov NCT04787042"}]},{"url":"https://clinicaltrials.gov/study/NCT04789486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04789486","kind":"trial","name":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","route":"/trials/nct04789486/","field":"links","label":"ClinicalTrials.gov NCT04789486"}]},{"url":"https://clinicaltrials.gov/study/NCT04792489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/","field":"links","label":"ClinicalTrials.gov NCT04792489"}]},{"url":"https://clinicaltrials.gov/study/NCT04793958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04793958","kind":"trial","name":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","route":"/trials/nct04793958/","field":"links","label":"ClinicalTrials.gov NCT04793958"}]},{"url":"https://clinicaltrials.gov/study/NCT04801511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04801511","kind":"trial","name":"Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer","route":"/trials/nct04801511/","field":"links","label":"ClinicalTrials.gov NCT04801511"}]},{"url":"https://clinicaltrials.gov/study/NCT04802759","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/","field":"links","label":"ClinicalTrials.gov NCT04802759"}]},{"url":"https://clinicaltrials.gov/study/NCT04804644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04804644","kind":"trial","name":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M","route":"/trials/nct04804644/","field":"links","label":"ClinicalTrials.gov NCT04804644"}]},{"url":"https://clinicaltrials.gov/study/NCT04807257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","field":"links","label":"ClinicalTrials.gov NCT04807257"}]},{"url":"https://clinicaltrials.gov/study/NCT04810078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","route":"/trials/nct04810078/","field":"links","label":"ClinicalTrials.gov NCT04810078"}]},{"url":"https://clinicaltrials.gov/study/NCT04810078?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","route":"/trials/nct04810078/","field":"outcomes.source (Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale)"},{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","route":"/trials/nct04810078/","field":"outcomes.source (Objective Response Rate (ORR) Per BICR)"}]},{"url":"https://clinicaltrials.gov/study/NCT04817007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","route":"/trials/nct04817007/","field":"links","label":"ClinicalTrials.gov NCT04817007"}]},{"url":"https://clinicaltrials.gov/study/NCT04819100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT04819100"},{"id":"nct04819100","kind":"trial","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04819100/","field":"links","label":"ClinicalTrials.gov NCT04819100"}]},{"url":"https://clinicaltrials.gov/study/NCT04821622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT04821622"},{"id":"nct04821622","kind":"trial","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","route":"/trials/nct04821622/","field":"links","label":"ClinicalTrials.gov NCT04821622"}]},{"url":"https://clinicaltrials.gov/study/NCT04824092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","field":"links","label":"ClinicalTrials.gov NCT04824092"}]},{"url":"https://clinicaltrials.gov/study/NCT04827953","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04827953","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C","route":"/trials/nct04827953/","field":"links","label":"ClinicalTrials.gov NCT04827953"}]},{"url":"https://clinicaltrials.gov/study/NCT04829604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","field":"links","label":"ClinicalTrials.gov NCT04829604 (ACE-Breast-02)"},{"id":"nct04829604","kind":"trial","name":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","route":"/trials/nct04829604/","field":"links","label":"ClinicalTrials.gov NCT04829604"}]},{"url":"https://clinicaltrials.gov/study/NCT04829708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04829708","kind":"trial","name":"Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission Aft","route":"/trials/nct04829708/","field":"links","label":"ClinicalTrials.gov NCT04829708"}]},{"url":"https://clinicaltrials.gov/study/NCT04834024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04834024","kind":"trial","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","route":"/trials/nct04834024/","field":"links","label":"ClinicalTrials.gov NCT04834024"}]},{"url":"https://clinicaltrials.gov/study/NCT04836507","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/","field":"links","label":"ClinicalTrials.gov NCT04836507"}]},{"url":"https://clinicaltrials.gov/study/NCT04838756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-masai-lancet-oncol-2023","kind":"paper","name":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","route":"/key-papers/paper-masai-lancet-oncol-2023/","field":"links","label":"ClinicalTrials.gov NCT04838756"},{"id":"paper-masai-lancet-digit-health-2025","kind":"paper","name":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study","route":"/key-papers/paper-masai-lancet-digit-health-2025/","field":"links","label":"ClinicalTrials.gov NCT04838756"},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","field":"links","label":"ClinicalTrials.gov NCT04838756"}]},{"url":"https://clinicaltrials.gov/study/NCT04841811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04841811","kind":"trial","name":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)","route":"/trials/nct04841811/","field":"links","label":"ClinicalTrials.gov NCT04841811"}]},{"url":"https://clinicaltrials.gov/study/NCT04842604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04842604","kind":"trial","name":"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","route":"/trials/nct04842604/","field":"links","label":"ClinicalTrials.gov NCT04842604"}]},{"url":"https://clinicaltrials.gov/study/NCT04842617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04842617","kind":"trial","name":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne","route":"/trials/nct04842617/","field":"links","label":"ClinicalTrials.gov NCT04842617"}]},{"url":"https://clinicaltrials.gov/study/NCT04843098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04843098","kind":"trial","name":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct04843098/","field":"links","label":"ClinicalTrials.gov NCT04843098"}]},{"url":"https://clinicaltrials.gov/study/NCT04844866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","field":"links","label":"ClinicalTrials.gov NCT04844866"}]},{"url":"https://clinicaltrials.gov/study/NCT04845919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","field":"links","label":"ExAblate SDT phase 2 (NCT04845919)"}]},{"url":"https://clinicaltrials.gov/study/NCT04846634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04846634","kind":"trial","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","route":"/trials/nct04846634/","field":"links","label":"ClinicalTrials.gov NCT04846634"}]},{"url":"https://clinicaltrials.gov/study/NCT04847505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04847505","kind":"trial","name":"68Ga-DOTA-TATE PET/CT Imaging in NETs","route":"/trials/nct04847505/","field":"links","label":"ClinicalTrials.gov NCT04847505"}]},{"url":"https://clinicaltrials.gov/study/NCT04851119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04851119","kind":"trial","name":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","route":"/trials/nct04851119/","field":"links","label":"ClinicalTrials.gov NCT04851119"}]},{"url":"https://clinicaltrials.gov/study/NCT04851613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04851613","kind":"trial","name":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct04851613/","field":"links","label":"ClinicalTrials.gov NCT04851613"}]},{"url":"https://clinicaltrials.gov/study/NCT04851717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","route":"/trials/nct04851717/","field":"links","label":"ClinicalTrials.gov NCT04851717"}]},{"url":"https://clinicaltrials.gov/study/NCT04853342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04853342","kind":"trial","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","route":"/trials/nct04853342/","field":"links","label":"ClinicalTrials.gov NCT04853342"}]},{"url":"https://clinicaltrials.gov/study/NCT04854668","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/","field":"links","label":"ClinicalTrials.gov NCT04854668"},{"id":"nct04854668","kind":"trial","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","route":"/trials/nct04854668/","field":"links","label":"ClinicalTrials.gov NCT04854668"}]},{"url":"https://clinicaltrials.gov/study/NCT04858009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04858009","kind":"trial","name":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","route":"/trials/nct04858009/","field":"links","label":"ClinicalTrials.gov NCT04858009"}]},{"url":"https://clinicaltrials.gov/study/NCT04858334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04858334","kind":"trial","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","route":"/trials/nct04858334/","field":"links","label":"ClinicalTrials.gov NCT04858334"}]},{"url":"https://clinicaltrials.gov/study/NCT04861558","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04861558","kind":"trial","name":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","route":"/trials/nct04861558/","field":"links","label":"ClinicalTrials.gov NCT04861558"}]},{"url":"https://clinicaltrials.gov/study/NCT04862663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/","field":"links","label":"ClinicalTrials.gov NCT04862663"}]},{"url":"https://clinicaltrials.gov/study/NCT04864054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","route":"/trials/nct04864054/","field":"links","label":"ClinicalTrials.gov NCT04864054"}]},{"url":"https://clinicaltrials.gov/study/NCT04868604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/","field":"links","label":"ClinicalTrials.gov NCT04868604"}]},{"url":"https://clinicaltrials.gov/study/NCT04868877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04868877","kind":"trial","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","route":"/trials/nct04868877/","field":"links","label":"ClinicalTrials.gov NCT04868877"}]},{"url":"https://clinicaltrials.gov/study/NCT04871282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04871282","kind":"trial","name":"A Study of AL102 in Patients With Progressing Desmoid Tumors","route":"/trials/nct04871282/","field":"links","label":"ClinicalTrials.gov NCT04871282"}]},{"url":"https://clinicaltrials.gov/study/NCT04871412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04871412","kind":"trial","name":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","route":"/trials/nct04871412/","field":"links","label":"ClinicalTrials.gov NCT04871412"}]},{"url":"https://clinicaltrials.gov/study/NCT04873362","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","route":"/trials/nct04873362/","field":"links","label":"ClinicalTrials.gov NCT04873362"}]},{"url":"https://clinicaltrials.gov/study/NCT04875585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04875585","kind":"trial","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","route":"/trials/nct04875585/","field":"links","label":"ClinicalTrials.gov NCT04875585"}]},{"url":"https://clinicaltrials.gov/study/NCT04879043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/","field":"links","label":"ClinicalTrials.gov NCT04879043"}]},{"url":"https://clinicaltrials.gov/study/NCT04879329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04879329","kind":"trial","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","route":"/trials/nct04879329/","field":"links","label":"ClinicalTrials.gov NCT04879329"}]},{"url":"https://clinicaltrials.gov/study/NCT04883814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04883814","kind":"trial","name":"18F-fluoroestradiol (FES) PET/CT for Breast Cancer","route":"/trials/nct04883814/","field":"links","label":"ClinicalTrials.gov NCT04883814"}]},{"url":"https://clinicaltrials.gov/study/NCT04884360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","route":"/trials/nct04884360/","field":"links","label":"ClinicalTrials.gov NCT04884360"}]},{"url":"https://clinicaltrials.gov/study/NCT04886804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","field":"links","label":"ClinicalTrials.gov NCT04886804"}]},{"url":"https://clinicaltrials.gov/study/NCT04888312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","route":"/trials/nct04888312/","field":"links","label":"ClinicalTrials.gov NCT04888312"}]},{"url":"https://clinicaltrials.gov/study/NCT04889742","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04889742","kind":"trial","name":"Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors","route":"/trials/nct04889742/","field":"links","label":"ClinicalTrials.gov NCT04889742"}]},{"url":"https://clinicaltrials.gov/study/NCT04891198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/","field":"links","label":"ClinicalTrials.gov NCT04891198"}]},{"url":"https://clinicaltrials.gov/study/NCT04892173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/","field":"links","label":"ClinicalTrials.gov NCT04892173"}]},{"url":"https://clinicaltrials.gov/study/NCT04895358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04895358","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","route":"/trials/nct04895358/","field":"links","label":"ClinicalTrials.gov NCT04895358"}]},{"url":"https://clinicaltrials.gov/study/NCT04895436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04895436","kind":"trial","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct04895436/","field":"links","label":"ClinicalTrials.gov NCT04895436"}]},{"url":"https://clinicaltrials.gov/study/NCT04895709","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/","field":"links","label":"ClinicalTrials.gov NCT04895709"}]},{"url":"https://clinicaltrials.gov/study/NCT04895722","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/","field":"links","label":"ClinicalTrials.gov NCT04895722"}]},{"url":"https://clinicaltrials.gov/study/NCT04895722?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/","field":"outcomes.source (Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR))"},{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04899908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04899908","kind":"trial","name":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","route":"/trials/nct04899908/","field":"links","label":"ClinicalTrials.gov NCT04899908"}]},{"url":"https://clinicaltrials.gov/study/NCT04901741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","route":"/trials/nct04901741/","field":"links","label":"ClinicalTrials.gov NCT04901741"}]},{"url":"https://clinicaltrials.gov/study/NCT04906395","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04906395","kind":"trial","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","route":"/trials/nct04906395/","field":"links","label":"ClinicalTrials.gov NCT04906395"}]},{"url":"https://clinicaltrials.gov/study/NCT04906993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04906993","kind":"trial","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","route":"/trials/nct04906993/","field":"links","label":"ClinicalTrials.gov NCT04906993"}]},{"url":"https://clinicaltrials.gov/study/NCT04910022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/","field":"links","label":"ClinicalTrials.gov NCT04910022"}]},{"url":"https://clinicaltrials.gov/study/NCT04910386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04910386","kind":"trial","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","route":"/trials/nct04910386/","field":"links","label":"ClinicalTrials.gov NCT04910386"}]},{"url":"https://clinicaltrials.gov/study/NCT04910685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/","field":"links","label":"ClinicalTrials.gov NCT04910685"}]},{"url":"https://clinicaltrials.gov/study/NCT04912765","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04912765","kind":"trial","name":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","route":"/trials/nct04912765/","field":"links","label":"ClinicalTrials.gov NCT04912765"}]},{"url":"https://clinicaltrials.gov/study/NCT04913337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/","field":"links","label":"ClinicalTrials.gov NCT04913337"}]},{"url":"https://clinicaltrials.gov/study/NCT04914598","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04914598","kind":"trial","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","route":"/trials/nct04914598/","field":"links","label":"ClinicalTrials.gov NCT04914598"}]},{"url":"https://clinicaltrials.gov/study/NCT04915755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04915755","kind":"trial","name":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","route":"/trials/nct04915755/","field":"links","label":"ClinicalTrials.gov NCT04915755"}]},{"url":"https://clinicaltrials.gov/study/NCT04915755?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04915755","kind":"trial","name":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","route":"/trials/nct04915755/","field":"outcomes.source (Number of Participants With TEAEs Leading to Death)"}]},{"url":"https://clinicaltrials.gov/study/NCT04919226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","field":"links","label":"ClinicalTrials.gov NCT04919226"}]},{"url":"https://clinicaltrials.gov/study/NCT04919382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04919382","kind":"trial","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","route":"/trials/nct04919382/","field":"links","label":"ClinicalTrials.gov NCT04919382"}]},{"url":"https://clinicaltrials.gov/study/NCT04919811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","route":"/trials/nct04919811/","field":"links","label":"ClinicalTrials.gov NCT04919811"}]},{"url":"https://clinicaltrials.gov/study/NCT04920149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04920149","kind":"trial","name":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","route":"/trials/nct04920149/","field":"links","label":"ClinicalTrials.gov NCT04920149"}]},{"url":"https://clinicaltrials.gov/study/NCT04920617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","route":"/trials/nct04920617/","field":"links","label":"ClinicalTrials.gov NCT04920617"}]},{"url":"https://clinicaltrials.gov/study/NCT04921527","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04921527","kind":"trial","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","route":"/trials/nct04921527/","field":"links","label":"ClinicalTrials.gov NCT04921527"}]},{"url":"https://clinicaltrials.gov/study/NCT04922853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04922853","kind":"trial","name":"Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer","route":"/trials/nct04922853/","field":"links","label":"ClinicalTrials.gov NCT04922853"}]},{"url":"https://clinicaltrials.gov/study/NCT04923893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cartitude-5","kind":"trial","name":"CARTITUDE-5","route":"/trials/cartitude-5/","field":"links","label":"ClinicalTrials.gov NCT04923893"},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","field":"links","label":"ClinicalTrials.gov NCT04923893: CARTITUDE-5"}]},{"url":"https://clinicaltrials.gov/study/NCT04923906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT04923906"},{"id":"nct04923906","kind":"trial","name":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut","route":"/trials/nct04923906/","field":"links","label":"ClinicalTrials.gov NCT04923906"}]},{"url":"https://clinicaltrials.gov/study/NCT04924075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04924075","kind":"trial","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","route":"/trials/nct04924075/","field":"links","label":"ClinicalTrials.gov NCT04924075"}]},{"url":"https://clinicaltrials.gov/study/NCT04925479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04925479","kind":"trial","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","route":"/trials/nct04925479/","field":"links","label":"ClinicalTrials.gov NCT04925479"}]},{"url":"https://clinicaltrials.gov/study/NCT04927780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"ClinicalTrials.gov NCT04927780"},{"id":"idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease","kind":"idea","name":"Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed","route":"/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/","field":"links","label":"ClinicalTrials.gov NCT04927780"},{"id":"preopanc-3","kind":"trial","name":"PREOPANC-3","route":"/trials/preopanc-3/","field":"links","label":"ClinicalTrials.gov NCT04927780"}]},{"url":"https://clinicaltrials.gov/study/NCT04928222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04928222","kind":"trial","name":"Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)","route":"/trials/nct04928222/","field":"links","label":"ClinicalTrials.gov NCT04928222"}]},{"url":"https://clinicaltrials.gov/study/NCT04928807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04928807","kind":"trial","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","route":"/trials/nct04928807/","field":"links","label":"ClinicalTrials.gov NCT04928807"}]},{"url":"https://clinicaltrials.gov/study/NCT04928846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"telimet-nsclc-01","kind":"trial","name":"TeliMET NSCLC-01","route":"/trials/telimet-nsclc-01/","field":"links","label":"ClinicalTrials.gov NCT04928846"}],"archive":"https://web.archive.org/web/20260615045826/https://clinicaltrials.gov/study/NCT04928846"},{"url":"https://clinicaltrials.gov/study/NCT04929041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04929041","kind":"trial","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","route":"/trials/nct04929041/","field":"links","label":"ClinicalTrials.gov NCT04929041"}]},{"url":"https://clinicaltrials.gov/study/NCT04930432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/","field":"links","label":"ClinicalTrials.gov NCT04930432"}]},{"url":"https://clinicaltrials.gov/study/NCT04930653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","route":"/trials/nct04930653/","field":"links","label":"ClinicalTrials.gov NCT04930653"}]},{"url":"https://clinicaltrials.gov/study/NCT04931342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/","field":"links","label":"ClinicalTrials.gov NCT04931342"}]},{"url":"https://clinicaltrials.gov/study/NCT04931654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04931654","kind":"trial","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","route":"/trials/nct04931654/","field":"links","label":"ClinicalTrials.gov NCT04931654"}]},{"url":"https://clinicaltrials.gov/study/NCT04933903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04933903","kind":"trial","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","route":"/trials/nct04933903/","field":"links","label":"ClinicalTrials.gov NCT04933903"}]},{"url":"https://clinicaltrials.gov/study/NCT04938583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct04938583/","field":"links","label":"ClinicalTrials.gov NCT04938583"}]},{"url":"https://clinicaltrials.gov/study/NCT04938817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/","field":"links","label":"ClinicalTrials.gov NCT04938817"}]},{"url":"https://clinicaltrials.gov/study/NCT04939610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"dosing.source"},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","field":"links","label":"ClinicalTrials.gov NCT04939610"}]},{"url":"https://clinicaltrials.gov/study/NCT04940052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04940052","kind":"trial","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","route":"/trials/nct04940052/","field":"links","label":"ClinicalTrials.gov NCT04940052"}]},{"url":"https://clinicaltrials.gov/study/NCT04940052?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04940052","kind":"trial","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","route":"/trials/nct04940052/","field":"outcomes.source (Progression Free Survival (PFS))"},{"id":"nct04940052","kind":"trial","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","route":"/trials/nct04940052/","field":"outcomes.source (Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04941287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04941287","kind":"trial","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","route":"/trials/nct04941287/","field":"links","label":"ClinicalTrials.gov NCT04941287"}]},{"url":"https://clinicaltrials.gov/study/NCT04941287?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04941287","kind":"trial","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","route":"/trials/nct04941287/","field":"outcomes.source (Duration of Progression Free Survival (PFS))"},{"id":"nct04941287","kind":"trial","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","route":"/trials/nct04941287/","field":"outcomes.source (Duration of Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT04947189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04947189","kind":"trial","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","route":"/trials/nct04947189/","field":"links","label":"ClinicalTrials.gov NCT04947189"}]},{"url":"https://clinicaltrials.gov/study/NCT04949113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","field":"links","label":"ClinicalTrials.gov NCT04949113"},{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","field":"links","label":"ClinicalTrials.gov NCT04949113: NADINA"},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT04949113"}]},{"url":"https://clinicaltrials.gov/study/NCT04950322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04950322","kind":"trial","name":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","route":"/trials/nct04950322/","field":"links","label":"ClinicalTrials.gov NCT04950322"}]},{"url":"https://clinicaltrials.gov/study/NCT04951635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04951635","kind":"trial","name":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","route":"/trials/nct04951635/","field":"links","label":"ClinicalTrials.gov NCT04951635"}]},{"url":"https://clinicaltrials.gov/study/NCT04954001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04954001","kind":"trial","name":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","route":"/trials/nct04954001/","field":"links","label":"ClinicalTrials.gov NCT04954001"}]},{"url":"https://clinicaltrials.gov/study/NCT04956640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/","field":"links","label":"ClinicalTrials.gov NCT04956640"},{"id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/","field":"links","label":"ClinicalTrials.gov NCT04956640"}]},{"url":"https://clinicaltrials.gov/study/NCT04956692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04956692","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","route":"/trials/nct04956692/","field":"links","label":"ClinicalTrials.gov NCT04956692"}]},{"url":"https://clinicaltrials.gov/study/NCT04956692?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04956692","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","route":"/trials/nct04956692/","field":"outcomes.source (Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab)"}]},{"url":"https://clinicaltrials.gov/study/NCT04959903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","route":"/trials/nct04959903/","field":"links","label":"ClinicalTrials.gov NCT04959903"}]},{"url":"https://clinicaltrials.gov/study/NCT04960709","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04960709","kind":"trial","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","route":"/trials/nct04960709/","field":"links","label":"ClinicalTrials.gov NCT04960709"}]},{"url":"https://clinicaltrials.gov/study/NCT04961996","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","field":"links","label":"ClinicalTrials.gov NCT04961996"}]},{"url":"https://clinicaltrials.gov/study/NCT04963595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04963595","kind":"trial","name":"Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","route":"/trials/nct04963595/","field":"links","label":"ClinicalTrials.gov NCT04963595"}]},{"url":"https://clinicaltrials.gov/study/NCT04964284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04964284","kind":"trial","name":"rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)","route":"/trials/nct04964284/","field":"links","label":"ClinicalTrials.gov NCT04964284"}]},{"url":"https://clinicaltrials.gov/study/NCT04964934","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","field":"links","label":"ClinicalTrials.gov NCT04964934"},{"id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","field":"links","label":"ClinicalTrials.gov NCT04964934: SERENA-6"},{"id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/","field":"links","label":"ClinicalTrials.gov NCT04964934: SERENA-6"},{"id":"paper-serena-6-n-engl-j-med-2025","kind":"paper","name":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","route":"/key-papers/paper-serena-6-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04964934"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","field":"links","label":"SERENA-6 on ClinicalTrials.gov"}]},{"url":"https://clinicaltrials.gov/study/NCT04965493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04965493","kind":"trial","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","route":"/trials/nct04965493/","field":"links","label":"ClinicalTrials.gov NCT04965493"}]},{"url":"https://clinicaltrials.gov/study/NCT04966663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04966663","kind":"trial","name":"Using ctDNA to Determine Therapies for Lung Cancer","route":"/trials/nct04966663/","field":"links","label":"ClinicalTrials.gov NCT04966663"}]},{"url":"https://clinicaltrials.gov/study/NCT04969315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","route":"/trials/nct04969315/","field":"links","label":"ClinicalTrials.gov NCT04969315"}]},{"url":"https://clinicaltrials.gov/study/NCT04969731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04969731","kind":"trial","name":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","route":"/trials/nct04969731/","field":"links","label":"ClinicalTrials.gov NCT04969731"}]},{"url":"https://clinicaltrials.gov/study/NCT04969887","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04969887","kind":"trial","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","route":"/trials/nct04969887/","field":"links","label":"ClinicalTrials.gov NCT04969887"},{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT04969887"}]},{"url":"https://clinicaltrials.gov/study/NCT04970056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-pdac-surveillance-for-every-germline-carrier","kind":"idea","name":"Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception","route":"/ideas/idea-pdac-surveillance-for-every-germline-carrier/","field":"links","label":"ClinicalTrials.gov NCT04970056"},{"id":"precede","kind":"trial","name":"PRECEDE","route":"/trials/precede/","field":"links","label":"ClinicalTrials.gov NCT04970056"}]},{"url":"https://clinicaltrials.gov/study/NCT04971226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04971226","kind":"trial","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","route":"/trials/nct04971226/","field":"links","label":"ClinicalTrials.gov NCT04971226"}]},{"url":"https://clinicaltrials.gov/study/NCT04971226?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04971226","kind":"trial","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","route":"/trials/nct04971226/","field":"outcomes.source (Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI)"}]},{"url":"https://clinicaltrials.gov/study/NCT04971473","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04971473","kind":"trial","name":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","route":"/trials/nct04971473/","field":"links","label":"ClinicalTrials.gov NCT04971473"}]},{"url":"https://clinicaltrials.gov/study/NCT04973605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04973605","kind":"trial","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","route":"/trials/nct04973605/","field":"links","label":"ClinicalTrials.gov NCT04973605"}]},{"url":"https://clinicaltrials.gov/study/NCT04974008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04974008","kind":"trial","name":"Osteosarcoma Maintenance Therapy With OST31-164","route":"/trials/nct04974008/","field":"links","label":"ClinicalTrials.gov NCT04974008"}]},{"url":"https://clinicaltrials.gov/study/NCT04974398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04974398","kind":"trial","name":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct04974398/","field":"links","label":"ClinicalTrials.gov NCT04974398"}]},{"url":"https://clinicaltrials.gov/study/NCT04975308","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","field":"links","label":"ClinicalTrials.gov NCT04975308"},{"id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","field":"links","label":"ClinicalTrials.gov NCT04975308: EMBER-3"},{"id":"paper-ember-3-n-engl-j-med-2025","kind":"paper","name":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","route":"/key-papers/paper-ember-3-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT04975308"}],"archive":"https://web.archive.org/web/20251028081203/https://clinicaltrials.gov/study/NCT04975308"},{"url":"https://clinicaltrials.gov/study/NCT04975997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/","field":"links","label":"ClinicalTrials.gov NCT04975997"}]},{"url":"https://clinicaltrials.gov/study/NCT04976634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04976634","kind":"trial","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","route":"/trials/nct04976634/","field":"links","label":"ClinicalTrials.gov NCT04976634"}]},{"url":"https://clinicaltrials.gov/study/NCT04977024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04977024","kind":"trial","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","route":"/trials/nct04977024/","field":"links","label":"ClinicalTrials.gov NCT04977024"}]},{"url":"https://clinicaltrials.gov/study/NCT04977453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/","field":"links","label":"ClinicalTrials.gov NCT04977453"}]},{"url":"https://clinicaltrials.gov/study/NCT04980222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","route":"/trials/nct04980222/","field":"links","label":"ClinicalTrials.gov NCT04980222"}]},{"url":"https://clinicaltrials.gov/study/NCT04980222?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","route":"/trials/nct04980222/","field":"outcomes.source (End of Treatment Complete Response (EOT CR) Rate)"}]},{"url":"https://clinicaltrials.gov/study/NCT04980716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04980716","kind":"trial","name":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","route":"/trials/nct04980716/","field":"links","label":"ClinicalTrials.gov NCT04980716"}]},{"url":"https://clinicaltrials.gov/study/NCT04980885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","field":"links","label":"ClinicalTrials.gov NCT04980885"},{"id":"nct04980885","kind":"trial","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","route":"/trials/nct04980885/","field":"links","label":"ClinicalTrials.gov NCT04980885"}]},{"url":"https://clinicaltrials.gov/study/NCT04982237","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","field":"links","label":"ClinicalTrials.gov NCT04982237"}]},{"url":"https://clinicaltrials.gov/study/NCT04986423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04986423","kind":"trial","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct04986423/","field":"links","label":"ClinicalTrials.gov NCT04986423"}]},{"url":"https://clinicaltrials.gov/study/NCT04986579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04986579","kind":"trial","name":"Scalp Cooling in MBC","route":"/trials/nct04986579/","field":"links","label":"ClinicalTrials.gov NCT04986579"}]},{"url":"https://clinicaltrials.gov/study/NCT04987203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tinivo-2","kind":"trial","name":"TiNivo-2","route":"/trials/tinivo-2/","field":"links","label":"ClinicalTrials.gov NCT04987203"},{"id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","field":"links","label":"ClinicalTrials.gov NCT04987203: TiNivo-2"}]},{"url":"https://clinicaltrials.gov/study/NCT04988295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04988295","kind":"trial","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","route":"/trials/nct04988295/","field":"links","label":"ClinicalTrials.gov NCT04988295"}]},{"url":"https://clinicaltrials.gov/study/NCT04988295?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04988295","kind":"trial","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","route":"/trials/nct04988295/","field":"outcomes.source (Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR))"}]},{"url":"https://clinicaltrials.gov/study/NCT04988555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/","field":"links","label":"ClinicalTrials.gov NCT04988555"}]},{"url":"https://clinicaltrials.gov/study/NCT04990609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04990609","kind":"trial","name":"EUS-RFA PANCARDINAL-1 Trial","route":"/trials/nct04990609/","field":"links","label":"ClinicalTrials.gov NCT04990609"}]},{"url":"https://clinicaltrials.gov/study/NCT04995523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04995523","kind":"trial","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","route":"/trials/nct04995523/","field":"links","label":"ClinicalTrials.gov NCT04995523"}]},{"url":"https://clinicaltrials.gov/study/NCT04996121","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04996121","kind":"trial","name":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04996121/","field":"links","label":"ClinicalTrials.gov NCT04996121"}]},{"url":"https://clinicaltrials.gov/study/NCT04996875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","field":"links","label":"ClinicalTrials.gov NCT04996875"}]},{"url":"https://clinicaltrials.gov/study/NCT04999969","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","field":"links","label":"ClinicalTrials.gov NCT04999969"}]},{"url":"https://clinicaltrials.gov/study/NCT04999969?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","field":"outcomes.source (Overall Survival at 12 Months (OS-12))"},{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","field":"outcomes.source (Median Progression Free Survival (PFS))"},{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT05000294","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05000294","kind":"trial","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","route":"/trials/nct05000294/","field":"links","label":"ClinicalTrials.gov NCT05000294"}]},{"url":"https://clinicaltrials.gov/study/NCT05002127","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/","field":"links","label":"ClinicalTrials.gov NCT05002127"}]},{"url":"https://clinicaltrials.gov/study/NCT05002569","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","field":"links","label":"ClinicalTrials.gov NCT05002569"},{"id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","field":"links","label":"ClinicalTrials.gov NCT05002569: RELATIVITY-098"},{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05002569"}]},{"url":"https://clinicaltrials.gov/study/NCT05004285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/","field":"links","label":"ClinicalTrials.gov NCT05004285"}]},{"url":"https://clinicaltrials.gov/study/NCT05006716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05006716","kind":"trial","name":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","route":"/trials/nct05006716/","field":"links","label":"ClinicalTrials.gov NCT05006716"}]},{"url":"https://clinicaltrials.gov/study/NCT05007132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05007132","kind":"trial","name":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct05007132/","field":"links","label":"ClinicalTrials.gov NCT05007132"}]},{"url":"https://clinicaltrials.gov/study/NCT05008809","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05008809","kind":"trial","name":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","route":"/trials/nct05008809/","field":"links","label":"ClinicalTrials.gov NCT05008809"}]},{"url":"https://clinicaltrials.gov/study/NCT05009069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05009069","kind":"trial","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","route":"/trials/nct05009069/","field":"links","label":"ClinicalTrials.gov NCT05009069"}]},{"url":"https://clinicaltrials.gov/study/NCT05009329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05009329"},{"id":"nct05009329","kind":"trial","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","route":"/trials/nct05009329/","field":"links","label":"ClinicalTrials.gov NCT05009329"}]},{"url":"https://clinicaltrials.gov/study/NCT05009836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/","field":"links","label":"ClinicalTrials.gov NCT05009836"}]},{"url":"https://clinicaltrials.gov/study/NCT05016349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05016349","kind":"trial","name":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer","route":"/trials/nct05016349/","field":"links","label":"ClinicalTrials.gov NCT05016349"}]},{"url":"https://clinicaltrials.gov/study/NCT05019690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","route":"/trials/nct05019690/","field":"links","label":"ClinicalTrials.gov NCT05019690"}]},{"url":"https://clinicaltrials.gov/study/NCT05019716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/","field":"links","label":"NCI trial with platinum chemotherapy, NCT05019716"},{"id":"zen-3694-platinum-nut","kind":"trial","name":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)","route":"/trials/zen-3694-platinum-nut/","field":"links","label":"ClinicalTrials.gov NCT05019716"}]},{"url":"https://clinicaltrials.gov/study/NCT05020015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","field":"links","label":"ClinicalTrials.gov NCT05020015"}]},{"url":"https://clinicaltrials.gov/study/NCT05020015?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","field":"outcomes.source (Number of Participants With Treatment Emergent Adverse Events (TEAEs))"},{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","field":"outcomes.source (Progression-free Survival (PFS) Per Investigator)"}]},{"url":"https://clinicaltrials.gov/study/NCT05020236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","field":"links","label":"ClinicalTrials.gov NCT05020236"}]},{"url":"https://clinicaltrials.gov/study/NCT05020457","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05020457","kind":"trial","name":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","route":"/trials/nct05020457/","field":"links","label":"ClinicalTrials.gov NCT05020457"}]},{"url":"https://clinicaltrials.gov/study/NCT05020769","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05020769","kind":"trial","name":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05020769/","field":"links","label":"ClinicalTrials.gov NCT05020769"}]},{"url":"https://clinicaltrials.gov/study/NCT05022901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05022901","kind":"trial","name":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","route":"/trials/nct05022901/","field":"links","label":"ClinicalTrials.gov NCT05022901"}]},{"url":"https://clinicaltrials.gov/study/NCT05023486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05023486","kind":"trial","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","route":"/trials/nct05023486/","field":"links","label":"ClinicalTrials.gov NCT05023486"}]},{"url":"https://clinicaltrials.gov/study/NCT05023980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","field":"links","label":"ClinicalTrials.gov NCT05023980"}]},{"url":"https://clinicaltrials.gov/study/NCT05024097","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05024097","kind":"trial","name":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for","route":"/trials/nct05024097/","field":"links","label":"ClinicalTrials.gov NCT05024097"}]},{"url":"https://clinicaltrials.gov/study/NCT05024214","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05024214","kind":"trial","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","route":"/trials/nct05024214/","field":"links","label":"ClinicalTrials.gov NCT05024214"}]},{"url":"https://clinicaltrials.gov/study/NCT05027776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","field":"links","label":"ClinicalTrials.gov NCT05027776"}]},{"url":"https://clinicaltrials.gov/study/NCT05032040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/","field":"links","label":"ClinicalTrials.gov NCT05032040"}]},{"url":"https://clinicaltrials.gov/study/NCT05035745","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","route":"/trials/nct05035745/","field":"links","label":"ClinicalTrials.gov NCT05035745"}]},{"url":"https://clinicaltrials.gov/study/NCT05037279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","route":"/trials/nct05037279/","field":"links","label":"ClinicalTrials.gov NCT05037279"}]},{"url":"https://clinicaltrials.gov/study/NCT05038150","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","field":"links","label":"SGN1 phase 1/2 (NCT05038150)"}]},{"url":"https://clinicaltrials.gov/study/NCT05038735","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05038735","kind":"trial","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","route":"/trials/nct05038735/","field":"links","label":"ClinicalTrials.gov NCT05038735"}]},{"url":"https://clinicaltrials.gov/study/NCT05043090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05043090","kind":"trial","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","route":"/trials/nct05043090/","field":"links","label":"ClinicalTrials.gov NCT05043090"}]},{"url":"https://clinicaltrials.gov/study/NCT05043922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/","field":"links","label":"ClinicalTrials.gov NCT05043922"}]},{"url":"https://clinicaltrials.gov/study/NCT05044897","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05044897","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05044897/","field":"links","label":"ClinicalTrials.gov NCT05044897"}]},{"url":"https://clinicaltrials.gov/study/NCT05047250","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05047250","kind":"trial","name":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05047250/","field":"links","label":"ClinicalTrials.gov NCT05047250"}]},{"url":"https://clinicaltrials.gov/study/NCT05048797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05048797","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N","route":"/trials/nct05048797/","field":"links","label":"ClinicalTrials.gov NCT05048797"}]},{"url":"https://clinicaltrials.gov/study/NCT05050942","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05050942","kind":"trial","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","route":"/trials/nct05050942/","field":"links","label":"ClinicalTrials.gov NCT05050942"}]},{"url":"https://clinicaltrials.gov/study/NCT05052801","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","field":"links","label":"ClinicalTrials.gov NCT05052801"}]},{"url":"https://clinicaltrials.gov/study/NCT05053880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05053880","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","route":"/trials/nct05053880/","field":"links","label":"ClinicalTrials.gov NCT05053880"}]},{"url":"https://clinicaltrials.gov/study/NCT05053971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05053971","kind":"trial","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","route":"/trials/nct05053971/","field":"links","label":"ClinicalTrials.gov NCT05053971"}]},{"url":"https://clinicaltrials.gov/study/NCT05054439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05054439","kind":"trial","name":"A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05054439/","field":"links","label":"ClinicalTrials.gov NCT05054439"}]},{"url":"https://clinicaltrials.gov/study/NCT05055908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05055908","kind":"trial","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","route":"/trials/nct05055908/","field":"links","label":"ClinicalTrials.gov NCT05055908"}]},{"url":"https://clinicaltrials.gov/study/NCT05057052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05057052","kind":"trial","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","route":"/trials/nct05057052/","field":"links","label":"ClinicalTrials.gov NCT05057052"}]},{"url":"https://clinicaltrials.gov/study/NCT05057494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05057494/","field":"links","label":"ClinicalTrials.gov NCT05057494"}]},{"url":"https://clinicaltrials.gov/study/NCT05059262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"motion","kind":"trial","name":"MOTION","route":"/trials/motion/","field":"links","label":"ClinicalTrials.gov NCT05059262"}]},{"url":"https://clinicaltrials.gov/study/NCT05059522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05059522","kind":"trial","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","route":"/trials/nct05059522/","field":"links","label":"ClinicalTrials.gov NCT05059522"}]},{"url":"https://clinicaltrials.gov/study/NCT05060016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT05060016"},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","field":"links","label":"ClinicalTrials.gov NCT05060016"}]},{"url":"https://clinicaltrials.gov/study/NCT05061134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","field":"links","label":"ClinicalTrials.gov NCT05061134"}]},{"url":"https://clinicaltrials.gov/study/NCT05061134?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","field":"outcomes.source (Main Study: Objective Response Rate (ORR))"},{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","field":"outcomes.source (Main Study and Biopsy Study: Overall Survival (OS))"},{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","field":"outcomes.source (Main Study and Biopsy Study: Progression Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05061550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05061550"},{"id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/","field":"links","label":"ClinicalTrials.gov NCT05061550"}]},{"url":"https://clinicaltrials.gov/study/NCT05063565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","field":"links","label":"ClinicalTrials.gov NCT05063565"}]},{"url":"https://clinicaltrials.gov/study/NCT05065801","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05065801","kind":"trial","name":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","route":"/trials/nct05065801/","field":"links","label":"ClinicalTrials.gov NCT05065801"}]},{"url":"https://clinicaltrials.gov/study/NCT05065957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05065957","kind":"trial","name":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","route":"/trials/nct05065957/","field":"links","label":"ClinicalTrials.gov NCT05065957"}]},{"url":"https://clinicaltrials.gov/study/NCT05066646","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","field":"links","label":"ClinicalTrials.gov NCT05066646"}]},{"url":"https://clinicaltrials.gov/study/NCT05067140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","route":"/trials/nct05067140/","field":"links","label":"ClinicalTrials.gov NCT05067140"}]},{"url":"https://clinicaltrials.gov/study/NCT05067530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05067530","kind":"trial","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","route":"/trials/nct05067530/","field":"links","label":"ClinicalTrials.gov NCT05067530"}]},{"url":"https://clinicaltrials.gov/study/NCT05074810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","route":"/trials/nct05074810/","field":"links","label":"ClinicalTrials.gov NCT05074810"}]},{"url":"https://clinicaltrials.gov/study/NCT05076682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05076682","kind":"trial","name":"Reverse Triple Negative Immune Resistant Breast Cancer","route":"/trials/nct05076682/","field":"links","label":"ClinicalTrials.gov NCT05076682"}]},{"url":"https://clinicaltrials.gov/study/NCT05077449","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/","field":"links","label":"ClinicalTrials.gov NCT05077449"},{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","route":"/trials/nct05077449/","field":"links","label":"ClinicalTrials.gov NCT05077449"}]},{"url":"https://clinicaltrials.gov/study/NCT05078047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05078047","kind":"trial","name":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","route":"/trials/nct05078047/","field":"links","label":"ClinicalTrials.gov NCT05078047"}]},{"url":"https://clinicaltrials.gov/study/NCT05078866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/","field":"links","label":"ClinicalTrials.gov NCT05078866"}]},{"url":"https://clinicaltrials.gov/study/NCT05079230","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05079230","kind":"trial","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","route":"/trials/nct05079230/","field":"links","label":"ClinicalTrials.gov NCT05079230"}]},{"url":"https://clinicaltrials.gov/study/NCT05079230?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05079230","kind":"trial","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","route":"/trials/nct05079230/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05081609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/","field":"links","label":"ClinicalTrials.gov NCT05081609"},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/","field":"links","label":"ClinicalTrials.gov NCT05081609"}]},{"url":"https://clinicaltrials.gov/study/NCT05083169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","field":"links","label":"ClinicalTrials.gov NCT05083169"}]},{"url":"https://clinicaltrials.gov/study/NCT05083247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05083247","kind":"trial","name":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05083247/","field":"links","label":"ClinicalTrials.gov NCT05083247"}]},{"url":"https://clinicaltrials.gov/study/NCT05085028","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05085028","kind":"trial","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","route":"/trials/nct05085028/","field":"links","label":"ClinicalTrials.gov NCT05085028"}]},{"url":"https://clinicaltrials.gov/study/NCT05086614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05086614","kind":"trial","name":"Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer","route":"/trials/nct05086614/","field":"links","label":"ClinicalTrials.gov NCT05086614"}]},{"url":"https://clinicaltrials.gov/study/NCT05086692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/","field":"links","label":"ClinicalTrials.gov NCT05086692"}]},{"url":"https://clinicaltrials.gov/study/NCT05089734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05089734/","field":"links","label":"ClinicalTrials.gov NCT05089734"}]},{"url":"https://clinicaltrials.gov/study/NCT05089734?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05089734/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05091567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"links","label":"ClinicalTrials.gov NCT05091567"},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","field":"links","label":"ClinicalTrials.gov NCT05091567: IMforte"},{"id":"paper-imforte-lancet-2025","kind":"paper","name":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","route":"/key-papers/paper-imforte-lancet-2025/","field":"links","label":"ClinicalTrials.gov NCT05091567"}]},{"url":"https://clinicaltrials.gov/study/NCT05093231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","route":"/trials/nct05093231/","field":"links","label":"ClinicalTrials.gov NCT05093231"}]},{"url":"https://clinicaltrials.gov/study/NCT05093907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05093907","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","route":"/trials/nct05093907/","field":"links","label":"ClinicalTrials.gov NCT05093907"}]},{"url":"https://clinicaltrials.gov/study/NCT05094336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","route":"/trials/nct05094336/","field":"links","label":"ClinicalTrials.gov NCT05094336"}]},{"url":"https://clinicaltrials.gov/study/NCT05096663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05096663","kind":"trial","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","route":"/trials/nct05096663/","field":"links","label":"ClinicalTrials.gov NCT05096663"}]},{"url":"https://clinicaltrials.gov/study/NCT05098132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/","field":"links","label":"ClinicalTrials.gov NCT05098132"}]},{"url":"https://clinicaltrials.gov/study/NCT05099172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","field":"links","label":"ClinicalTrials.gov NCT05099172"},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","field":"outcomes.source (Objective response rate, HER2-mutant NSCLC after platinum (Cohort D))"},{"id":"paper-soho-01-n-engl-j-med-2025","kind":"paper","name":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","route":"/key-papers/paper-soho-01-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05099172"}],"archive":"https://web.archive.org/web/20260312224630/https://clinicaltrials.gov/study/NCT05099172"},{"url":"https://clinicaltrials.gov/study/NCT05100862","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05100862","kind":"trial","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","route":"/trials/nct05100862/","field":"links","label":"ClinicalTrials.gov NCT05100862"}]},{"url":"https://clinicaltrials.gov/study/NCT05101070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","route":"/trials/nct05101070/","field":"links","label":"ClinicalTrials.gov NCT05101070"}]},{"url":"https://clinicaltrials.gov/study/NCT05101096","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/","field":"links","label":"ClinicalTrials.gov NCT05101096"},{"id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","route":"/trials/nct05101096/","field":"links","label":"ClinicalTrials.gov NCT05101096"}]},{"url":"https://clinicaltrials.gov/study/NCT05103358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05103358","kind":"trial","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","route":"/trials/nct05103358/","field":"links","label":"ClinicalTrials.gov NCT05103358"}]},{"url":"https://clinicaltrials.gov/study/NCT05104866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","field":"links","label":"ClinicalTrials.gov NCT05104866"},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","field":"outcomes.source (Overall survival)"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/","field":"links","label":"ClinicalTrials.gov NCT05104866"},{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/","field":"links","label":"ClinicalTrials.gov NCT05104866"}]},{"url":"https://clinicaltrials.gov/study/NCT05112965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05112965","kind":"trial","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","route":"/trials/nct05112965/","field":"links","label":"ClinicalTrials.gov NCT05112965"}]},{"url":"https://clinicaltrials.gov/study/NCT05112991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05112991","kind":"trial","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","route":"/trials/nct05112991/","field":"links","label":"ClinicalTrials.gov NCT05112991"}]},{"url":"https://clinicaltrials.gov/study/NCT05113251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","field":"links","label":"ClinicalTrials.gov NCT05113251: DESTINY-Breast11"},{"id":"destiny-breast11","kind":"trial","name":"DESTINY-Breast11","route":"/trials/destiny-breast11/","field":"links","label":"ClinicalTrials.gov NCT05113251"}]},{"url":"https://clinicaltrials.gov/study/NCT05116072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05116072","kind":"trial","name":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","route":"/trials/nct05116072/","field":"links","label":"ClinicalTrials.gov NCT05116072"}]},{"url":"https://clinicaltrials.gov/study/NCT05116189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","field":"links","label":"ClinicalTrials.gov NCT05116189"},{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","field":"links","label":"ClinicalTrials.gov NCT05116189: KEYNOTE-B96 / ENGOT-ov65"}]},{"url":"https://clinicaltrials.gov/study/NCT05116462","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05116462","kind":"trial","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","route":"/trials/nct05116462/","field":"links","label":"ClinicalTrials.gov NCT05116462"}]},{"url":"https://clinicaltrials.gov/study/NCT05117242","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05117242","kind":"trial","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","route":"/trials/nct05117242/","field":"links","label":"ClinicalTrials.gov NCT05117242"}]},{"url":"https://clinicaltrials.gov/study/NCT05118776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05118776","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","route":"/trials/nct05118776/","field":"links","label":"ClinicalTrials.gov NCT05118776"}]},{"url":"https://clinicaltrials.gov/study/NCT05118789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/","field":"links","label":"ClinicalTrials.gov NCT05118789"}]},{"url":"https://clinicaltrials.gov/study/NCT05119907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05119907","kind":"trial","name":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","route":"/trials/nct05119907/","field":"links","label":"ClinicalTrials.gov NCT05119907"}]},{"url":"https://clinicaltrials.gov/study/NCT05120271","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05120271","kind":"trial","name":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","route":"/trials/nct05120271/","field":"links","label":"ClinicalTrials.gov NCT05120271"}]},{"url":"https://clinicaltrials.gov/study/NCT05120349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/","field":"links","label":"ClinicalTrials.gov NCT05120349"}]},{"url":"https://clinicaltrials.gov/study/NCT05120596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","route":"/trials/nct05120596/","field":"links","label":"ClinicalTrials.gov NCT05120596"}]},{"url":"https://clinicaltrials.gov/study/NCT05123482","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","field":"dosing.source"},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/","field":"links","label":"ClinicalTrials.gov NCT05123482"}]},{"url":"https://clinicaltrials.gov/study/NCT05125016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","route":"/trials/nct05125016/","field":"links","label":"ClinicalTrials.gov NCT05125016"}]},{"url":"https://clinicaltrials.gov/study/NCT05126719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05126719","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05126719/","field":"links","label":"ClinicalTrials.gov NCT05126719"}]},{"url":"https://clinicaltrials.gov/study/NCT05128487","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05128487"},{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","route":"/trials/nct05128487/","field":"links","label":"ClinicalTrials.gov NCT05128487"}]},{"url":"https://clinicaltrials.gov/study/NCT05128734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/","field":"links","label":"ClinicalTrials.gov NCT05128734"}]},{"url":"https://clinicaltrials.gov/study/NCT05128825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05128825/","field":"links","label":"ClinicalTrials.gov NCT05128825"}]},{"url":"https://clinicaltrials.gov/study/NCT05132075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05132075","kind":"trial","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","route":"/trials/nct05132075/","field":"links","label":"ClinicalTrials.gov NCT05132075"}]},{"url":"https://clinicaltrials.gov/study/NCT05132504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05132504","kind":"trial","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05132504/","field":"links","label":"ClinicalTrials.gov NCT05132504"}]},{"url":"https://clinicaltrials.gov/study/NCT05132582","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","field":"links","label":"ClinicalTrials.gov NCT05132582"},{"id":"paper-her2climb-05-j-clin-oncol-2026","kind":"paper","name":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","route":"/key-papers/paper-her2climb-05-j-clin-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05132582"}]},{"url":"https://clinicaltrials.gov/study/NCT05133882","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/","field":"links","label":"ClinicalTrials.gov NCT05133882"}]},{"url":"https://clinicaltrials.gov/study/NCT05136326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05136326","kind":"trial","name":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer","route":"/trials/nct05136326/","field":"links","label":"ClinicalTrials.gov NCT05136326"}]},{"url":"https://clinicaltrials.gov/study/NCT05139017","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"waveline-003","kind":"trial","name":"waveLINE-003","route":"/trials/waveline-003/","field":"links","label":"ClinicalTrials.gov NCT05139017"},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","field":"dosing.source"}]},{"url":"https://clinicaltrials.gov/study/NCT05141149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","route":"/trials/nct05141149/","field":"links","label":"ClinicalTrials.gov NCT05141149"}]},{"url":"https://clinicaltrials.gov/study/NCT05141721","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05141721","kind":"trial","name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05141721/","field":"links","label":"ClinicalTrials.gov NCT05141721"}]},{"url":"https://clinicaltrials.gov/study/NCT05142423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","route":"/trials/nct05142423/","field":"links","label":"ClinicalTrials.gov NCT05142423"}]},{"url":"https://clinicaltrials.gov/study/NCT05142696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","field":"links","label":"ClinicalTrials.gov NCT05142696"}]},{"url":"https://clinicaltrials.gov/study/NCT05144698","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05144698","kind":"trial","name":"RAPA-201 Therapy of Solid Tumors","route":"/trials/nct05144698/","field":"links","label":"ClinicalTrials.gov NCT05144698"}]},{"url":"https://clinicaltrials.gov/study/NCT05144854","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05144854","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct05144854/","field":"links","label":"ClinicalTrials.gov NCT05144854"}]},{"url":"https://clinicaltrials.gov/study/NCT05147467","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05147467","kind":"trial","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct05147467/","field":"links","label":"ClinicalTrials.gov NCT05147467"}]},{"url":"https://clinicaltrials.gov/study/NCT05150691","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/","field":"links","label":"ClinicalTrials.gov NCT05150691"}]},{"url":"https://clinicaltrials.gov/study/NCT05152147","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","field":"links","label":"ClinicalTrials.gov NCT05152147"},{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","field":"links","label":"ClinicalTrials.gov NCT05152147: HERIZON-GEA-01"}]},{"url":"https://clinicaltrials.gov/study/NCT05153772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"links","label":"ClinicalTrials.gov NCT05153772"},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","field":"links","label":"ClinicalTrials.gov NCT05153772: ALPHAMEDIX-02"}]},{"url":"https://clinicaltrials.gov/study/NCT05155254","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05155254","kind":"trial","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","route":"/trials/nct05155254/","field":"links","label":"ClinicalTrials.gov NCT05155254"}]},{"url":"https://clinicaltrials.gov/study/NCT05155605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","field":"links","label":"ClinicalTrials.gov NCT05155605"},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","field":"outcomes.source (Cancer signal detected)"},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","field":"outcomes.source (Positive predictive value)"},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","field":"outcomes.source (Specificity)"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ClinicalTrials.gov NCT05155605"}]},{"url":"https://clinicaltrials.gov/study/NCT05163041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05163041","kind":"trial","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","route":"/trials/nct05163041/","field":"links","label":"ClinicalTrials.gov NCT05163041"}]},{"url":"https://clinicaltrials.gov/study/NCT05168566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05168566"},{"id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/","field":"links","label":"ClinicalTrials.gov NCT05168566"}]},{"url":"https://clinicaltrials.gov/study/NCT05168839","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05168839","kind":"trial","name":"Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage","route":"/trials/nct05168839/","field":"links","label":"ClinicalTrials.gov NCT05168839"}]},{"url":"https://clinicaltrials.gov/study/NCT05169567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","field":"links","label":"ClinicalTrials.gov NCT05169567"}]},{"url":"https://clinicaltrials.gov/study/NCT05170204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/","field":"links","label":"ClinicalTrials.gov NCT05170204"}]},{"url":"https://clinicaltrials.gov/study/NCT05170438","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05170438","kind":"trial","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","route":"/trials/nct05170438/","field":"links","label":"ClinicalTrials.gov NCT05170438"}]},{"url":"https://clinicaltrials.gov/study/NCT05170958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05170958","kind":"trial","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","route":"/trials/nct05170958/","field":"links","label":"ClinicalTrials.gov NCT05170958"}]},{"url":"https://clinicaltrials.gov/study/NCT05171647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","field":"links","label":"ClinicalTrials.gov NCT05171647"},{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/","field":"links","label":"ClinicalTrials.gov NCT05171647: SUNMO"}]},{"url":"https://clinicaltrials.gov/study/NCT05171660","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05171660","kind":"trial","name":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","route":"/trials/nct05171660/","field":"links","label":"ClinicalTrials.gov NCT05171660"}]},{"url":"https://clinicaltrials.gov/study/NCT05171816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/","field":"links","label":"ClinicalTrials.gov NCT05171816"}]},{"url":"https://clinicaltrials.gov/study/NCT05171816?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/","field":"outcomes.source (Radiological Progression Free Survival (rPFS))"},{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05173987","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05173987","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","route":"/trials/nct05173987/","field":"links","label":"ClinicalTrials.gov NCT05173987"}]},{"url":"https://clinicaltrials.gov/study/NCT05174169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05174169"},{"id":"idea-crc-ctdna-de-escalation-beyond-stage-ii","kind":"idea","name":"Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps","route":"/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/","field":"links","label":"ClinicalTrials.gov NCT05174169"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ClinicalTrials.gov NCT05174169"},{"id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/","field":"links","label":"ClinicalTrials.gov NCT05174169"}]},{"url":"https://clinicaltrials.gov/study/NCT05179889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05179889","kind":"trial","name":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","route":"/trials/nct05179889/","field":"links","label":"ClinicalTrials.gov NCT05179889"}]},{"url":"https://clinicaltrials.gov/study/NCT05180799","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05180799","kind":"trial","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","route":"/trials/nct05180799/","field":"links","label":"ClinicalTrials.gov NCT05180799"}]},{"url":"https://clinicaltrials.gov/study/NCT05184712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-harmoni-a-jama-2024","kind":"paper","name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","route":"/key-papers/paper-harmoni-a-jama-2024/","field":"links","label":"ClinicalTrials.gov NCT05184712"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","field":"links","label":"ClinicalTrials.gov NCT05184712"}]},{"url":"https://clinicaltrials.gov/study/NCT05186506","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05186506","kind":"trial","name":"A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","route":"/trials/nct05186506/","field":"links","label":"ClinicalTrials.gov NCT05186506"}]},{"url":"https://clinicaltrials.gov/study/NCT05186753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05186753","kind":"trial","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","route":"/trials/nct05186753/","field":"links","label":"ClinicalTrials.gov NCT05186753"}]},{"url":"https://clinicaltrials.gov/study/NCT05186974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05186974"},{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/","field":"links","label":"ClinicalTrials.gov NCT05186974"}]},{"url":"https://clinicaltrials.gov/study/NCT05187338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05187338","kind":"trial","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","route":"/trials/nct05187338/","field":"links","label":"ClinicalTrials.gov NCT05187338"}]},{"url":"https://clinicaltrials.gov/study/NCT05190445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05190445","kind":"trial","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","route":"/trials/nct05190445/","field":"links","label":"ClinicalTrials.gov NCT05190445"}]},{"url":"https://clinicaltrials.gov/study/NCT05192486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05192486","kind":"trial","name":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct05192486/","field":"links","label":"ClinicalTrials.gov NCT05192486"}]},{"url":"https://clinicaltrials.gov/study/NCT05192798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/","field":"links","label":"ClinicalTrials.gov NCT05192798"}]},{"url":"https://clinicaltrials.gov/study/NCT05194878","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05194878","kind":"trial","name":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","route":"/trials/nct05194878/","field":"links","label":"ClinicalTrials.gov NCT05194878"}]},{"url":"https://clinicaltrials.gov/study/NCT05194995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05194995","kind":"trial","name":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","route":"/trials/nct05194995/","field":"links","label":"ClinicalTrials.gov NCT05194995"}]},{"url":"https://clinicaltrials.gov/study/NCT05195632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/","field":"links","label":"ClinicalTrials.gov NCT05195632"},{"id":"nct05195632","kind":"trial","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","route":"/trials/nct05195632/","field":"links","label":"ClinicalTrials.gov NCT05195632"}]},{"url":"https://clinicaltrials.gov/study/NCT05197426","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05197426","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","route":"/trials/nct05197426/","field":"links","label":"ClinicalTrials.gov NCT05197426"}]},{"url":"https://clinicaltrials.gov/study/NCT05197426?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05197426","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","route":"/trials/nct05197426/","field":"outcomes.source (Recurrence Free Survival (RFS))"},{"id":"nct05197426","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","route":"/trials/nct05197426/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05198934","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","field":"links","label":"ClinicalTrials.gov NCT05198934"},{"id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","field":"links","label":"ClinicalTrials.gov NCT05198934: CodeBreaK 300"},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","field":"links","label":"ClinicalTrials.gov NCT05198934"}]},{"url":"https://clinicaltrials.gov/study/NCT05199272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","field":"links","label":"ClinicalTrials.gov NCT05199272"},{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/","field":"links","label":"ClinicalTrials.gov NCT05199272"}]},{"url":"https://clinicaltrials.gov/study/NCT05201066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","route":"/trials/nct05201066/","field":"links","label":"ClinicalTrials.gov NCT05201066"}]},{"url":"https://clinicaltrials.gov/study/NCT05201248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05201248","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","route":"/trials/nct05201248/","field":"links","label":"ClinicalTrials.gov NCT05201248"}]},{"url":"https://clinicaltrials.gov/study/NCT05201404","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05201404","kind":"trial","name":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","route":"/trials/nct05201404/","field":"links","label":"ClinicalTrials.gov NCT05201404"}]},{"url":"https://clinicaltrials.gov/study/NCT05201430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05201430","kind":"trial","name":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","route":"/trials/nct05201430/","field":"links","label":"ClinicalTrials.gov NCT05201430"}]},{"url":"https://clinicaltrials.gov/study/NCT05204862","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05204862","kind":"trial","name":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","route":"/trials/nct05204862/","field":"links","label":"ClinicalTrials.gov NCT05204862"}]},{"url":"https://clinicaltrials.gov/study/NCT05204927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","field":"links","label":"ClinicalTrials.gov NCT05204927"},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","field":"outcomes.source (Radiographic progression-free survival)"}],"archive":"https://web.archive.org/web/20260623190237/https://clinicaltrials.gov/study/NCT05204927"},{"url":"https://clinicaltrials.gov/study/NCT05205330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05205330","kind":"trial","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","route":"/trials/nct05205330/","field":"links","label":"ClinicalTrials.gov NCT05205330"}]},{"url":"https://clinicaltrials.gov/study/NCT05205850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05205850","kind":"trial","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct05205850/","field":"links","label":"ClinicalTrials.gov NCT05205850"}]},{"url":"https://clinicaltrials.gov/study/NCT05207670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05207670","kind":"trial","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","route":"/trials/nct05207670/","field":"links","label":"ClinicalTrials.gov NCT05207670"}]},{"url":"https://clinicaltrials.gov/study/NCT05208047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","field":"links","label":"ClinicalTrials.gov NCT05208047"}]},{"url":"https://clinicaltrials.gov/study/NCT05208944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/","field":"links","label":"ClinicalTrials.gov NCT05208944"}]},{"url":"https://clinicaltrials.gov/study/NCT05210790","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/","field":"links","label":"ClinicalTrials.gov NCT05210790"}]},{"url":"https://clinicaltrials.gov/study/NCT05211570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05211570","kind":"trial","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","route":"/trials/nct05211570/","field":"links","label":"ClinicalTrials.gov NCT05211570"}]},{"url":"https://clinicaltrials.gov/study/NCT05211895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05211895","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","route":"/trials/nct05211895/","field":"links","label":"ClinicalTrials.gov NCT05211895"}]},{"url":"https://clinicaltrials.gov/study/NCT05215340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/","field":"links","label":"ClinicalTrials.gov NCT05215340"}]},{"url":"https://clinicaltrials.gov/study/NCT05217446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05217446","kind":"trial","name":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic","route":"/trials/nct05217446/","field":"links","label":"ClinicalTrials.gov NCT05217446"}]},{"url":"https://clinicaltrials.gov/study/NCT05218889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/","field":"links","label":"ClinicalTrials.gov NCT05218889"}]},{"url":"https://clinicaltrials.gov/study/NCT05219500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05219500","kind":"trial","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","route":"/trials/nct05219500/","field":"links","label":"ClinicalTrials.gov NCT05219500"}]},{"url":"https://clinicaltrials.gov/study/NCT05220800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05220800","kind":"trial","name":"Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer","route":"/trials/nct05220800/","field":"links","label":"ClinicalTrials.gov NCT05220800"}]},{"url":"https://clinicaltrials.gov/study/NCT05221840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05221840","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct05221840/","field":"links","label":"ClinicalTrials.gov NCT05221840"},{"id":"klrc1","kind":"target","name":"NKG2A (KLRC1)","route":"/targets/klrc1/","field":"links","label":"ClinicalTrials.gov NCT05221840"}]},{"url":"https://clinicaltrials.gov/study/NCT05222555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05222555","kind":"trial","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","route":"/trials/nct05222555/","field":"links","label":"ClinicalTrials.gov NCT05222555"}]},{"url":"https://clinicaltrials.gov/study/NCT05222555?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05222555","kind":"trial","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","route":"/trials/nct05222555/","field":"outcomes.source (Number of Participants With Any Treatment-emergent Adverse Event (TEAE))"}]},{"url":"https://clinicaltrials.gov/study/NCT05222971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05222971","kind":"trial","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","route":"/trials/nct05222971/","field":"links","label":"ClinicalTrials.gov NCT05222971"}]},{"url":"https://clinicaltrials.gov/study/NCT05224141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","field":"links","label":"ClinicalTrials.gov NCT05224141"}]},{"url":"https://clinicaltrials.gov/study/NCT05224141?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","field":"outcomes.source (Overall Survival (OS))"},{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","field":"outcomes.source (Progression-Free Survival (PFS))"},{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT05226871","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/","field":"links","label":"ClinicalTrials.gov NCT05226871"}]},{"url":"https://clinicaltrials.gov/study/NCT05227664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05227664"},{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05227664/","field":"links","label":"ClinicalTrials.gov NCT05227664"}]},{"url":"https://clinicaltrials.gov/study/NCT05228431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05228431","kind":"trial","name":"Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer","route":"/trials/nct05228431/","field":"links","label":"ClinicalTrials.gov NCT05228431"}]},{"url":"https://clinicaltrials.gov/study/NCT05229497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05229497","kind":"trial","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","route":"/trials/nct05229497/","field":"links","label":"ClinicalTrials.gov NCT05229497"}]},{"url":"https://clinicaltrials.gov/study/NCT05230810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05230810","kind":"trial","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","route":"/trials/nct05230810/","field":"links","label":"ClinicalTrials.gov NCT05230810"}]},{"url":"https://clinicaltrials.gov/study/NCT05231850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05231850","kind":"trial","name":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.","route":"/trials/nct05231850/","field":"links","label":"ClinicalTrials.gov NCT05231850"}]},{"url":"https://clinicaltrials.gov/study/NCT05232916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/","field":"links","label":"ClinicalTrials.gov NCT05232916"}]},{"url":"https://clinicaltrials.gov/study/NCT05235516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05235516","kind":"trial","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","route":"/trials/nct05235516/","field":"links","label":"ClinicalTrials.gov NCT05235516"}]},{"url":"https://clinicaltrials.gov/study/NCT05236946","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05236946","kind":"trial","name":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","route":"/trials/nct05236946/","field":"links","label":"ClinicalTrials.gov NCT05236946"}]},{"url":"https://clinicaltrials.gov/study/NCT05236972","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05236972","kind":"trial","name":"PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer","route":"/trials/nct05236972/","field":"links","label":"ClinicalTrials.gov NCT05236972"}]},{"url":"https://clinicaltrials.gov/study/NCT05239546","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05239546","kind":"trial","name":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","route":"/trials/nct05239546/","field":"links","label":"ClinicalTrials.gov NCT05239546"}]},{"url":"https://clinicaltrials.gov/study/NCT05239650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05239650","kind":"trial","name":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","route":"/trials/nct05239650/","field":"links","label":"ClinicalTrials.gov NCT05239650"}]},{"url":"https://clinicaltrials.gov/study/NCT05239728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","field":"links","label":"ClinicalTrials.gov NCT05239728"},{"id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","field":"links","label":"ClinicalTrials.gov NCT05239728: LITESPARK-022"}]},{"url":"https://clinicaltrials.gov/study/NCT05239741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05239741","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","route":"/trials/nct05239741/","field":"links","label":"ClinicalTrials.gov NCT05239741"}]},{"url":"https://clinicaltrials.gov/study/NCT05241249","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05241249","kind":"trial","name":"Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma","route":"/trials/nct05241249/","field":"links","label":"ClinicalTrials.gov NCT05241249"}]},{"url":"https://clinicaltrials.gov/study/NCT05243550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05243550","kind":"trial","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct05243550/","field":"links","label":"ClinicalTrials.gov NCT05243550"}]},{"url":"https://clinicaltrials.gov/study/NCT05243550?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05243550","kind":"trial","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct05243550/","field":"outcomes.source (Complete Response Rate (CRR))"}]},{"url":"https://clinicaltrials.gov/study/NCT05245474","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05245474","kind":"trial","name":"Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer","route":"/trials/nct05245474/","field":"links","label":"ClinicalTrials.gov NCT05245474"}]},{"url":"https://clinicaltrials.gov/study/NCT05246514","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/","field":"links","label":"ClinicalTrials.gov NCT05246514"},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","field":"links","label":"ClinicalTrials.gov NCT05246514"}]},{"url":"https://clinicaltrials.gov/study/NCT05246514?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","field":"outcomes.source (ICR-assessed ORR (Objective Response Rate))"},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","field":"outcomes.source (OS (Overall Survival))"},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","field":"outcomes.source (ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival))"}]},{"url":"https://clinicaltrials.gov/study/NCT05247684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05247684","kind":"trial","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","route":"/trials/nct05247684/","field":"links","label":"ClinicalTrials.gov NCT05247684"}]},{"url":"https://clinicaltrials.gov/study/NCT05251714","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05251714","kind":"trial","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","route":"/trials/nct05251714/","field":"links","label":"ClinicalTrials.gov NCT05251714"},{"id":"ttk","kind":"target","name":"MPS1 (TTK)","route":"/targets/ttk/","field":"links","label":"ClinicalTrials.gov NCT05251714"}]},{"url":"https://clinicaltrials.gov/study/NCT05253053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","field":"links","label":"ClinicalTrials.gov NCT05253053: TT-00420 (tinengotinib) monotherapy and combinations (phase 1/2)"}]},{"url":"https://clinicaltrials.gov/study/NCT05253651","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","field":"links","label":"MOUNTAINEER-03 NCT05253651"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05253651"},{"id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/","field":"links","label":"ClinicalTrials.gov NCT05253651"}]},{"url":"https://clinicaltrials.gov/study/NCT05254171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05254171","kind":"trial","name":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","route":"/trials/nct05254171/","field":"links","label":"ClinicalTrials.gov NCT05254171"}]},{"url":"https://clinicaltrials.gov/study/NCT05254327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05254327","kind":"trial","name":"Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001","route":"/trials/nct05254327/","field":"links","label":"ClinicalTrials.gov NCT05254327"}]},{"url":"https://clinicaltrials.gov/study/NCT05254743","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05254743/","field":"links","label":"ClinicalTrials.gov NCT05254743"}]},{"url":"https://clinicaltrials.gov/study/NCT05255302","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05255302","kind":"trial","name":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","route":"/trials/nct05255302/","field":"links","label":"ClinicalTrials.gov NCT05255302"}]},{"url":"https://clinicaltrials.gov/study/NCT05255653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rainbo","kind":"trial","name":"RAINBO","route":"/trials/rainbo/","field":"links","label":"ClinicalTrials.gov NCT05255653"}]},{"url":"https://clinicaltrials.gov/study/NCT05256290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05256290","kind":"trial","name":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05256290/","field":"links","label":"ClinicalTrials.gov NCT05256290"}]},{"url":"https://clinicaltrials.gov/study/NCT05257083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cartitude-6","kind":"trial","name":"CARTITUDE-6","route":"/trials/cartitude-6/","field":"links","label":"ClinicalTrials.gov NCT05257083"}]},{"url":"https://clinicaltrials.gov/study/NCT05257395","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05257395","kind":"trial","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","route":"/trials/nct05257395/","field":"links","label":"ClinicalTrials.gov NCT05257395"}]},{"url":"https://clinicaltrials.gov/study/NCT05257408","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","field":"links","label":"ClinicalTrials.gov NCT05257408"}]},{"url":"https://clinicaltrials.gov/study/NCT05257590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05257590","kind":"trial","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","route":"/trials/nct05257590/","field":"links","label":"ClinicalTrials.gov NCT05257590"}]},{"url":"https://clinicaltrials.gov/study/NCT05257993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/","field":"links","label":"ClinicalTrials.gov NCT05257993"}]},{"url":"https://clinicaltrials.gov/study/NCT05261399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05261399","kind":"trial","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","route":"/trials/nct05261399/","field":"links","label":"ClinicalTrials.gov NCT05261399"}]},{"url":"https://clinicaltrials.gov/study/NCT05261750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","route":"/trials/nct05261750/","field":"links","label":"ClinicalTrials.gov NCT05261750"}]},{"url":"https://clinicaltrials.gov/study/NCT05262010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","route":"/trials/nct05262010/","field":"links","label":"ClinicalTrials.gov NCT05262010"}]},{"url":"https://clinicaltrials.gov/study/NCT05262400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05262400","kind":"trial","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","route":"/trials/nct05262400/","field":"links","label":"ClinicalTrials.gov NCT05262400"}]},{"url":"https://clinicaltrials.gov/study/NCT05263583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05263583","kind":"trial","name":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","route":"/trials/nct05263583/","field":"links","label":"ClinicalTrials.gov NCT05263583"}]},{"url":"https://clinicaltrials.gov/study/NCT05263960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","route":"/trials/nct05263960/","field":"links","label":"ClinicalTrials.gov NCT05263960"}]},{"url":"https://clinicaltrials.gov/study/NCT05265091","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05265091","kind":"trial","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","route":"/trials/nct05265091/","field":"links","label":"ClinicalTrials.gov NCT05265091"}]},{"url":"https://clinicaltrials.gov/study/NCT05267626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/","field":"links","label":"ClinicalTrials.gov NCT05267626"}]},{"url":"https://clinicaltrials.gov/study/NCT05268692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05268692","kind":"trial","name":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","route":"/trials/nct05268692/","field":"links","label":"ClinicalTrials.gov NCT05268692"}]},{"url":"https://clinicaltrials.gov/study/NCT05269316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05269316","kind":"trial","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","route":"/trials/nct05269316/","field":"links","label":"ClinicalTrials.gov NCT05269316"}]},{"url":"https://clinicaltrials.gov/study/NCT05269381","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/","field":"links","label":"ClinicalTrials.gov NCT05269381"}]},{"url":"https://clinicaltrials.gov/study/NCT05270044","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","route":"/trials/nct05270044/","field":"links","label":"ClinicalTrials.gov NCT05270044"}]},{"url":"https://clinicaltrials.gov/study/NCT05271318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/","field":"links","label":"ClinicalTrials.gov NCT05271318"}]},{"url":"https://clinicaltrials.gov/study/NCT05275374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05275374","kind":"trial","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","route":"/trials/nct05275374/","field":"links","label":"ClinicalTrials.gov NCT05275374"}]},{"url":"https://clinicaltrials.gov/study/NCT05276726","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/","field":"links","label":"ClinicalTrials.gov NCT05276726"}]},{"url":"https://clinicaltrials.gov/study/NCT05277168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05277168","kind":"trial","name":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","route":"/trials/nct05277168/","field":"links","label":"ClinicalTrials.gov NCT05277168"}]},{"url":"https://clinicaltrials.gov/study/NCT05278052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05278052","kind":"trial","name":"Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","route":"/trials/nct05278052/","field":"links","label":"ClinicalTrials.gov NCT05278052"}]},{"url":"https://clinicaltrials.gov/study/NCT05280314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","route":"/trials/nct05280314/","field":"links","label":"ClinicalTrials.gov NCT05280314"}]},{"url":"https://clinicaltrials.gov/study/NCT05280470","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","field":"dosing.source"},{"id":"nct05280470","kind":"trial","name":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05280470/","field":"links","label":"ClinicalTrials.gov NCT05280470"}]},{"url":"https://clinicaltrials.gov/study/NCT05281471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05281471","kind":"trial","name":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","route":"/trials/nct05281471/","field":"links","label":"ClinicalTrials.gov NCT05281471"}]},{"url":"https://clinicaltrials.gov/study/NCT05283226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05283226","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck","route":"/trials/nct05283226/","field":"links","label":"ClinicalTrials.gov NCT05283226"}]},{"url":"https://clinicaltrials.gov/study/NCT05283720","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/","field":"links","label":"ClinicalTrials.gov NCT05283720"}]},{"url":"https://clinicaltrials.gov/study/NCT05286294","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","field":"links","label":"Oslo FMT phase 2 (NCT05286294)"}]},{"url":"https://clinicaltrials.gov/study/NCT05286814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05286814","kind":"trial","name":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc","route":"/trials/nct05286814/","field":"links","label":"ClinicalTrials.gov NCT05286814"}]},{"url":"https://clinicaltrials.gov/study/NCT05286957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05286957","kind":"trial","name":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","route":"/trials/nct05286957/","field":"links","label":"ClinicalTrials.gov NCT05286957"}]},{"url":"https://clinicaltrials.gov/study/NCT05287113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05287113","kind":"trial","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","route":"/trials/nct05287113/","field":"links","label":"ClinicalTrials.gov NCT05287113"}]},{"url":"https://clinicaltrials.gov/study/NCT05287113?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05287113","kind":"trial","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","route":"/trials/nct05287113/","field":"outcomes.source (Progeression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05287945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","route":"/trials/nct05287945/","field":"links","label":"ClinicalTrials.gov NCT05287945"}]},{"url":"https://clinicaltrials.gov/study/NCT05288166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05288166","kind":"trial","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","route":"/trials/nct05288166/","field":"links","label":"ClinicalTrials.gov NCT05288166"}]},{"url":"https://clinicaltrials.gov/study/NCT05288205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05288205"},{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/","field":"links","label":"ClinicalTrials.gov NCT05288205"}]},{"url":"https://clinicaltrials.gov/study/NCT05294172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/","field":"links","label":"ClinicalTrials.gov NCT05294172"}]},{"url":"https://clinicaltrials.gov/study/NCT05294731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05294731","kind":"trial","name":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","route":"/trials/nct05294731/","field":"links","label":"ClinicalTrials.gov NCT05294731"}]},{"url":"https://clinicaltrials.gov/study/NCT05296564","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/","field":"links","label":"ClinicalTrials.gov NCT05296564"}]},{"url":"https://clinicaltrials.gov/study/NCT05296681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05296681","kind":"trial","name":"Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery","route":"/trials/nct05296681/","field":"links","label":"ClinicalTrials.gov NCT05296681"}]},{"url":"https://clinicaltrials.gov/study/NCT05296798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/","field":"links","label":"ClinicalTrials.gov NCT05296798"}]},{"url":"https://clinicaltrials.gov/study/NCT05297890","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05297890","kind":"trial","name":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","route":"/trials/nct05297890/","field":"links","label":"ClinicalTrials.gov NCT05297890"}]},{"url":"https://clinicaltrials.gov/study/NCT05299424","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05299424","kind":"trial","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05299424/","field":"links","label":"ClinicalTrials.gov NCT05299424"}]},{"url":"https://clinicaltrials.gov/study/NCT05300269","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/","field":"links","label":"ClinicalTrials.gov NCT05300269"},{"id":"nct05300269","kind":"trial","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","route":"/trials/nct05300269/","field":"links","label":"ClinicalTrials.gov NCT05300269"}]},{"url":"https://clinicaltrials.gov/study/NCT05301842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","field":"links","label":"ClinicalTrials.gov NCT05301842"}]},{"url":"https://clinicaltrials.gov/study/NCT05302284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05302284","kind":"trial","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","route":"/trials/nct05302284/","field":"links","label":"ClinicalTrials.gov NCT05302284"}]},{"url":"https://clinicaltrials.gov/study/NCT05303519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/","field":"links","label":"ClinicalTrials.gov NCT05303519"}]},{"url":"https://clinicaltrials.gov/study/NCT05304481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","field":"links","label":"ClinicalTrials.gov NCT05304481"}]},{"url":"https://clinicaltrials.gov/study/NCT05306340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","field":"links","label":"ClinicalTrials.gov NCT05306340"},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","field":"links","label":"ClinicalTrials.gov NCT05306340 (evERA)"}],"archive":"https://web.archive.org/web/20260424132630/https://clinicaltrials.gov/study/NCT05306340"},{"url":"https://clinicaltrials.gov/study/NCT05308264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","route":"/trials/nct05308264/","field":"links","label":"ClinicalTrials.gov NCT05308264"}]},{"url":"https://clinicaltrials.gov/study/NCT05309421","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05309421","kind":"trial","name":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","route":"/trials/nct05309421/","field":"links","label":"ClinicalTrials.gov NCT05309421"}]},{"url":"https://clinicaltrials.gov/study/NCT05310643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05310643","kind":"trial","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","route":"/trials/nct05310643/","field":"links","label":"ClinicalTrials.gov NCT05310643"}]},{"url":"https://clinicaltrials.gov/study/NCT05312710","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05312710","kind":"trial","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","route":"/trials/nct05312710/","field":"links","label":"ClinicalTrials.gov NCT05312710"}]},{"url":"https://clinicaltrials.gov/study/NCT05315167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","route":"/trials/nct05315167/","field":"links","label":"ClinicalTrials.gov NCT05315167"}]},{"url":"https://clinicaltrials.gov/study/NCT05315700","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","route":"/trials/nct05315700/","field":"links","label":"ClinicalTrials.gov NCT05315700"}]},{"url":"https://clinicaltrials.gov/study/NCT05316155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","route":"/trials/nct05316155/","field":"links","label":"ClinicalTrials.gov NCT05316155"}]},{"url":"https://clinicaltrials.gov/study/NCT05316701","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","field":"links","label":"ClinicalTrials.gov NCT05316701 (Precision-T)"},{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","route":"/trials/nct05316701/","field":"links","label":"ClinicalTrials.gov NCT05316701"}]},{"url":"https://clinicaltrials.gov/study/NCT05316701?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","route":"/trials/nct05316701/","field":"outcomes.source (Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC))"},{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","route":"/trials/nct05316701/","field":"outcomes.source (Event-free at 12 Months for Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05317416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/","field":"links","label":"ClinicalTrials.gov NCT05317416"}]},{"url":"https://clinicaltrials.gov/study/NCT05317819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05317819","kind":"trial","name":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05317819/","field":"links","label":"ClinicalTrials.gov NCT05317819"}]},{"url":"https://clinicaltrials.gov/study/NCT05317858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/","field":"links","label":"ClinicalTrials.gov NCT05317858"}]},{"url":"https://clinicaltrials.gov/study/NCT05318469","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"ClinicalTrials.gov NCT05318469"},{"id":"nct05318469","kind":"trial","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","route":"/trials/nct05318469/","field":"links","label":"ClinicalTrials.gov NCT05318469"}]},{"url":"https://clinicaltrials.gov/study/NCT05318573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/","field":"links","label":"ClinicalTrials.gov NCT05318573"}]},{"url":"https://clinicaltrials.gov/study/NCT05319314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/","field":"links","label":"ClinicalTrials.gov NCT05319314"}]},{"url":"https://clinicaltrials.gov/study/NCT05319730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","route":"/trials/nct05319730/","field":"links","label":"ClinicalTrials.gov NCT05319730"}]},{"url":"https://clinicaltrials.gov/study/NCT05320198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/","field":"links","label":"ClinicalTrials.gov NCT05320198"}]},{"url":"https://clinicaltrials.gov/study/NCT05320588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05320588","kind":"trial","name":"A Study in Patients With Advanced Cancers","route":"/trials/nct05320588/","field":"links","label":"ClinicalTrials.gov NCT05320588"}]},{"url":"https://clinicaltrials.gov/study/NCT05320692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05320692","kind":"trial","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","route":"/trials/nct05320692/","field":"links","label":"ClinicalTrials.gov NCT05320692"}]},{"url":"https://clinicaltrials.gov/study/NCT05322590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05322590","kind":"trial","name":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","route":"/trials/nct05322590/","field":"links","label":"ClinicalTrials.gov NCT05322590"}]},{"url":"https://clinicaltrials.gov/study/NCT05326243","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05326243","kind":"trial","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","route":"/trials/nct05326243/","field":"links","label":"ClinicalTrials.gov NCT05326243"}]},{"url":"https://clinicaltrials.gov/study/NCT05327530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","field":"links","label":"ClinicalTrials.gov NCT05327530"}]},{"url":"https://clinicaltrials.gov/study/NCT05327530?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","field":"outcomes.source (Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control]))"},{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","field":"outcomes.source (Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + M6223 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control]))"},{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","field":"outcomes.source (Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + NKTR-255 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control]))"},{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","field":"outcomes.source (Overall Survival (OS) -Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control]))"}]},{"url":"https://clinicaltrials.gov/study/NCT05329532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","route":"/trials/nct05329532/","field":"links","label":"ClinicalTrials.gov NCT05329532"}]},{"url":"https://clinicaltrials.gov/study/NCT05329766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/","field":"links","label":"ClinicalTrials.gov NCT05329766"}]},{"url":"https://clinicaltrials.gov/study/NCT05334277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05334277","kind":"trial","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","route":"/trials/nct05334277/","field":"links","label":"ClinicalTrials.gov NCT05334277"}]},{"url":"https://clinicaltrials.gov/study/NCT05334823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/","field":"links","label":"ClinicalTrials.gov NCT05334823"}]},{"url":"https://clinicaltrials.gov/study/NCT05335993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","route":"/trials/nct05335993/","field":"links","label":"ClinicalTrials.gov NCT05335993"}]},{"url":"https://clinicaltrials.gov/study/NCT05338931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/","field":"links","label":"ClinicalTrials.gov NCT05338931"}]},{"url":"https://clinicaltrials.gov/study/NCT05338970","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","field":"links","label":"ClinicalTrials.gov NCT05338970"},{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","field":"outcomes.source (Overall survival)"},{"id":"her3-expression","kind":"biomarker","name":"HER3 expression","route":"/biomarkers/her3-expression/","field":"links","label":"ClinicalTrials.gov NCT05338970 (HERTHENA-Lung02)"}],"archive":"https://web.archive.org/web/20260610061017/https://clinicaltrials.gov/study/NCT05338970"},{"url":"https://clinicaltrials.gov/study/NCT05343013","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","field":"links","label":"ClinicalTrials.gov NCT05343013"}]},{"url":"https://clinicaltrials.gov/study/NCT05346224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05346224","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","route":"/trials/nct05346224/","field":"links","label":"ClinicalTrials.gov NCT05346224"}]},{"url":"https://clinicaltrials.gov/study/NCT05347134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05347134"},{"id":"nct05347134","kind":"trial","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct05347134/","field":"links","label":"ClinicalTrials.gov NCT05347134"}]},{"url":"https://clinicaltrials.gov/study/NCT05348577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05348577","kind":"trial","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct05348577/","field":"links","label":"ClinicalTrials.gov NCT05348577"}]},{"url":"https://clinicaltrials.gov/study/NCT05351788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05351788"},{"id":"nct05351788","kind":"trial","name":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","route":"/trials/nct05351788/","field":"links","label":"ClinicalTrials.gov NCT05351788"}]},{"url":"https://clinicaltrials.gov/study/NCT05352672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","field":"links","label":"ClinicalTrials.gov NCT05352672"}]},{"url":"https://clinicaltrials.gov/study/NCT05353257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05353257","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage","route":"/trials/nct05353257/","field":"links","label":"ClinicalTrials.gov NCT05353257"}]},{"url":"https://clinicaltrials.gov/study/NCT05355298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","route":"/trials/nct05355298/","field":"links","label":"ClinicalTrials.gov NCT05355298"}]},{"url":"https://clinicaltrials.gov/study/NCT05358249","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05358249","kind":"trial","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct05358249/","field":"links","label":"ClinicalTrials.gov NCT05358249"}]},{"url":"https://clinicaltrials.gov/study/NCT05359393","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05359393","kind":"trial","name":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","route":"/trials/nct05359393/","field":"links","label":"ClinicalTrials.gov NCT05359393"}]},{"url":"https://clinicaltrials.gov/study/NCT05360277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05360277","kind":"trial","name":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer","route":"/trials/nct05360277/","field":"links","label":"ClinicalTrials.gov NCT05360277"}]},{"url":"https://clinicaltrials.gov/study/NCT05361174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/","field":"links","label":"ClinicalTrials.gov NCT05361174"}]},{"url":"https://clinicaltrials.gov/study/NCT05363280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/","field":"links","label":"ClinicalTrials.gov NCT05363280"}]},{"url":"https://clinicaltrials.gov/study/NCT05364489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05364489","kind":"trial","name":"Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer","route":"/trials/nct05364489/","field":"links","label":"ClinicalTrials.gov NCT05364489"}]},{"url":"https://clinicaltrials.gov/study/NCT05365178","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05365178","kind":"trial","name":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","route":"/trials/nct05365178/","field":"links","label":"ClinicalTrials.gov NCT05365178"}]},{"url":"https://clinicaltrials.gov/study/NCT05367440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","route":"/trials/nct05367440/","field":"links","label":"ClinicalTrials.gov NCT05367440"}]},{"url":"https://clinicaltrials.gov/study/NCT05367778","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05367778","kind":"trial","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","route":"/trials/nct05367778/","field":"links","label":"ClinicalTrials.gov NCT05367778"}]},{"url":"https://clinicaltrials.gov/study/NCT05371093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/","field":"links","label":"ClinicalTrials.gov NCT05371093"}]},{"url":"https://clinicaltrials.gov/study/NCT05372354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05372354","kind":"trial","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","route":"/trials/nct05372354/","field":"links","label":"ClinicalTrials.gov NCT05372354"}]},{"url":"https://clinicaltrials.gov/study/NCT05372640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/","field":"links","label":"NCI trial with abemaciclib, NCT05372640"},{"id":"zen-3694-abemaciclib-nut","kind":"trial","name":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)","route":"/trials/zen-3694-abemaciclib-nut/","field":"links","label":"ClinicalTrials.gov NCT05372640"}]},{"url":"https://clinicaltrials.gov/study/NCT05374512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05374512"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05374512"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"links","label":"ClinicalTrials.gov NCT05374512"}]},{"url":"https://clinicaltrials.gov/study/NCT05374603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/","field":"links","label":"ClinicalTrials.gov NCT05374603"}]},{"url":"https://clinicaltrials.gov/study/NCT05374915","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","route":"/trials/nct05374915/","field":"links","label":"ClinicalTrials.gov NCT05374915"}]},{"url":"https://clinicaltrials.gov/study/NCT05377996","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/","field":"links","label":"ClinicalTrials.gov NCT05377996"}]},{"url":"https://clinicaltrials.gov/study/NCT05378919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05378919","kind":"trial","name":"Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","route":"/trials/nct05378919/","field":"links","label":"ClinicalTrials.gov NCT05378919"}]},{"url":"https://clinicaltrials.gov/study/NCT05379595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05379595-j-clin-oncol-2026","kind":"paper","name":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","route":"/key-papers/paper-nct05379595-j-clin-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05379595"},{"id":"nct05379595","kind":"trial","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct05379595/","field":"links","label":"ClinicalTrials.gov NCT05379595"}]},{"url":"https://clinicaltrials.gov/study/NCT05379946","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/","field":"links","label":"ClinicalTrials.gov NCT05379946"}]},{"url":"https://clinicaltrials.gov/study/NCT05379985","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05379985-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","route":"/key-papers/paper-nct05379985-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05379985"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","field":"links","label":"ClinicalTrials.gov NCT05379985"}]},{"url":"https://clinicaltrials.gov/study/NCT05381103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","field":"links","label":"ClinicalTrials.gov NCT05381103"}]},{"url":"https://clinicaltrials.gov/study/NCT05382286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","field":"links","label":"ClinicalTrials.gov NCT05382286"},{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","field":"links","label":"ClinicalTrials.gov NCT05382286: ASCENT-04 / KEYNOTE-D19"},{"id":"paper-ascent-04-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-04-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05382286"}]},{"url":"https://clinicaltrials.gov/study/NCT05382299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"links","label":"ClinicalTrials.gov NCT05382299"},{"id":"paper-ascent-03-n-engl-j-med-2025","kind":"paper","name":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-03-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05382299"}]},{"url":"https://clinicaltrials.gov/study/NCT05382338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05382338","kind":"trial","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","route":"/trials/nct05382338/","field":"links","label":"ClinicalTrials.gov NCT05382338"}]},{"url":"https://clinicaltrials.gov/study/NCT05382442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05382442","kind":"trial","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","route":"/trials/nct05382442/","field":"links","label":"ClinicalTrials.gov NCT05382442"}]},{"url":"https://clinicaltrials.gov/study/NCT05382728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fleteo","kind":"trial","name":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","route":"/trials/fleteo/","field":"links","label":"ClinicalTrials.gov NCT05382728"}]},{"url":"https://clinicaltrials.gov/study/NCT05384587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05384587","kind":"trial","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","route":"/trials/nct05384587/","field":"links","label":"ClinicalTrials.gov NCT05384587"}]},{"url":"https://clinicaltrials.gov/study/NCT05384626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","field":"links","label":"ClinicalTrials.gov NCT05384626"},{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","field":"outcomes.source (Objective response rate, TKI-pretreated ALK+ NSCLC (pivotal cohort))"}],"archive":"https://web.archive.org/web/20260826015645/https://clinicaltrials.gov/study/NCT05384626"},{"url":"https://clinicaltrials.gov/study/NCT05386108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05386108","kind":"trial","name":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","route":"/trials/nct05386108/","field":"links","label":"ClinicalTrials.gov NCT05386108"}]},{"url":"https://clinicaltrials.gov/study/NCT05388669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05388669","kind":"trial","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)","route":"/trials/nct05388669/","field":"links","label":"ClinicalTrials.gov NCT05388669"}]},{"url":"https://clinicaltrials.gov/study/NCT05388669?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05388669","kind":"trial","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)","route":"/trials/nct05388669/","field":"outcomes.source (For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State)"}]},{"url":"https://clinicaltrials.gov/study/NCT05393466","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05393466","kind":"trial","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05393466/","field":"links","label":"ClinicalTrials.gov NCT05393466"}]},{"url":"https://clinicaltrials.gov/study/NCT05394103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","route":"/trials/nct05394103/","field":"links","label":"ClinicalTrials.gov NCT05394103"}]},{"url":"https://clinicaltrials.gov/study/NCT05394831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05394831","kind":"trial","name":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","route":"/trials/nct05394831/","field":"links","label":"ClinicalTrials.gov NCT05394831"}]},{"url":"https://clinicaltrials.gov/study/NCT05395962","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05395962","kind":"trial","name":"Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer","route":"/trials/nct05395962/","field":"links","label":"ClinicalTrials.gov NCT05395962"}]},{"url":"https://clinicaltrials.gov/study/NCT05396885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","field":"links","label":"ClinicalTrials.gov NCT05396885 (iMMagine-1)"},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","field":"links","label":"ClinicalTrials.gov NCT05396885"}]},{"url":"https://clinicaltrials.gov/study/NCT05403385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05403385","kind":"trial","name":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct05403385/","field":"links","label":"ClinicalTrials.gov NCT05403385"}]},{"url":"https://clinicaltrials.gov/study/NCT05405595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05405595","kind":"trial","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct05405595/","field":"links","label":"ClinicalTrials.gov NCT05405595"}]},{"url":"https://clinicaltrials.gov/study/NCT05406401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/","field":"links","label":"ClinicalTrials.gov NCT05406401"}]},{"url":"https://clinicaltrials.gov/study/NCT05409066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","field":"links","label":"ClinicalTrials.gov NCT05409066"}]},{"url":"https://clinicaltrials.gov/study/NCT05410145","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/","field":"links","label":"ClinicalTrials.gov NCT05410145"}]},{"url":"https://clinicaltrials.gov/study/NCT05411718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05411718","kind":"trial","name":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","route":"/trials/nct05411718/","field":"links","label":"ClinicalTrials.gov NCT05411718"}]},{"url":"https://clinicaltrials.gov/study/NCT05413018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05413018","kind":"trial","name":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","route":"/trials/nct05413018/","field":"links","label":"ClinicalTrials.gov NCT05413018"}]},{"url":"https://clinicaltrials.gov/study/NCT05413850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05413850-j-nucl-med-2024","kind":"paper","name":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","route":"/key-papers/paper-nct05413850-j-nucl-med-2024/","field":"links","label":"ClinicalTrials.gov NCT05413850"},{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/","field":"links","label":"ClinicalTrials.gov NCT05413850"}]},{"url":"https://clinicaltrials.gov/study/NCT05415072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05415072"},{"id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/","field":"links","label":"ClinicalTrials.gov NCT05415072"}]},{"url":"https://clinicaltrials.gov/study/NCT05417321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","route":"/trials/nct05417321/","field":"links","label":"ClinicalTrials.gov NCT05417321"}]},{"url":"https://clinicaltrials.gov/study/NCT05417594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/","field":"links","label":"ClinicalTrials.gov NCT05417594"}]},{"url":"https://clinicaltrials.gov/study/NCT05417789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05417789","kind":"trial","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","route":"/trials/nct05417789/","field":"links","label":"ClinicalTrials.gov NCT05417789"}]},{"url":"https://clinicaltrials.gov/study/NCT05421663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/","field":"links","label":"ClinicalTrials.gov NCT05421663"}]},{"url":"https://clinicaltrials.gov/study/NCT05422690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05422690","kind":"trial","name":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","route":"/trials/nct05422690/","field":"links","label":"ClinicalTrials.gov NCT05422690"}]},{"url":"https://clinicaltrials.gov/study/NCT05422911","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05422911","kind":"trial","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","route":"/trials/nct05422911/","field":"links","label":"ClinicalTrials.gov NCT05422911"}]},{"url":"https://clinicaltrials.gov/study/NCT05423262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/","field":"links","label":"ClinicalTrials.gov NCT05423262"}]},{"url":"https://clinicaltrials.gov/study/NCT05424835","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/","field":"links","label":"ClinicalTrials.gov NCT05424835"},{"id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05424835"}]},{"url":"https://clinicaltrials.gov/study/NCT05425940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05425940-lancet-2025","kind":"paper","name":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct05425940-lancet-2025/","field":"links","label":"ClinicalTrials.gov NCT05425940"},{"id":"nct05425940","kind":"trial","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","route":"/trials/nct05425940/","field":"links","label":"ClinicalTrials.gov NCT05425940"}]},{"url":"https://clinicaltrials.gov/study/NCT05427383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05427383","kind":"trial","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","route":"/trials/nct05427383/","field":"links","label":"ClinicalTrials.gov NCT05427383"}]},{"url":"https://clinicaltrials.gov/study/NCT05427669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05427669","kind":"trial","name":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","route":"/trials/nct05427669/","field":"links","label":"ClinicalTrials.gov NCT05427669"}]},{"url":"https://clinicaltrials.gov/study/NCT05428969","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05428969","kind":"trial","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","route":"/trials/nct05428969/","field":"links","label":"ClinicalTrials.gov NCT05428969"}]},{"url":"https://clinicaltrials.gov/study/NCT05429268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05429268","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (","route":"/trials/nct05429268/","field":"links","label":"ClinicalTrials.gov NCT05429268"}]},{"url":"https://clinicaltrials.gov/study/NCT05429463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05429463","kind":"trial","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","route":"/trials/nct05429463/","field":"links","label":"ClinicalTrials.gov NCT05429463"}]},{"url":"https://clinicaltrials.gov/study/NCT05429632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","route":"/trials/nct05429632/","field":"links","label":"ClinicalTrials.gov NCT05429632"}]},{"url":"https://clinicaltrials.gov/study/NCT05431270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/","field":"links","label":"ClinicalTrials.gov NCT05431270"}]},{"url":"https://clinicaltrials.gov/study/NCT05433532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05433532","kind":"trial","name":"Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients","route":"/trials/nct05433532/","field":"links","label":"ClinicalTrials.gov NCT05433532"}]},{"url":"https://clinicaltrials.gov/study/NCT05434234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/","field":"links","label":"ClinicalTrials.gov NCT05434234"}]},{"url":"https://clinicaltrials.gov/study/NCT05435248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05435248"},{"id":"nct05435248","kind":"trial","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","route":"/trials/nct05435248/","field":"links","label":"ClinicalTrials.gov NCT05435248"}]},{"url":"https://clinicaltrials.gov/study/NCT05438043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/","field":"links","label":"ClinicalTrials.gov NCT05438043"}]},{"url":"https://clinicaltrials.gov/study/NCT05438329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/","field":"links","label":"ClinicalTrials.gov NCT05438329"}]},{"url":"https://clinicaltrials.gov/study/NCT05438420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/","field":"links","label":"ClinicalTrials.gov NCT05438420"}]},{"url":"https://clinicaltrials.gov/study/NCT05438459","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05438459","kind":"trial","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","route":"/trials/nct05438459/","field":"links","label":"ClinicalTrials.gov NCT05438459"}]},{"url":"https://clinicaltrials.gov/study/NCT05440708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05440708","kind":"trial","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05440708/","field":"links","label":"ClinicalTrials.gov NCT05440708"}]},{"url":"https://clinicaltrials.gov/study/NCT05440786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","route":"/trials/nct05440786/","field":"links","label":"ClinicalTrials.gov NCT05440786"}]},{"url":"https://clinicaltrials.gov/study/NCT05440786?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","route":"/trials/nct05440786/","field":"outcomes.source (PFS Assessed by BIRC by Frequentist Analysis)"},{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","route":"/trials/nct05440786/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05442060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05442060","kind":"trial","name":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N","route":"/trials/nct05442060/","field":"links","label":"ClinicalTrials.gov NCT05442060"}]},{"url":"https://clinicaltrials.gov/study/NCT05443126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/","field":"links","label":"ClinicalTrials.gov NCT05443126"}]},{"url":"https://clinicaltrials.gov/study/NCT05445778","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/","field":"links","label":"ClinicalTrials.gov NCT05445778"}]},{"url":"https://clinicaltrials.gov/study/NCT05445791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05445791","kind":"trial","name":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05445791/","field":"links","label":"ClinicalTrials.gov NCT05445791"}]},{"url":"https://clinicaltrials.gov/study/NCT05445843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05445843","kind":"trial","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","route":"/trials/nct05445843/","field":"links","label":"ClinicalTrials.gov NCT05445843"}]},{"url":"https://clinicaltrials.gov/study/NCT05445843?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05445843","kind":"trial","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","route":"/trials/nct05445843/","field":"outcomes.source (Overall Response Rate (ORR) as Determined by the Investigator in Cohort A)"}]},{"url":"https://clinicaltrials.gov/study/NCT05446298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","route":"/trials/nct05446298/","field":"links","label":"ClinicalTrials.gov NCT05446298"}]},{"url":"https://clinicaltrials.gov/study/NCT05446870","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","field":"links","label":"ClinicalTrials.gov NCT05446870"}]},{"url":"https://clinicaltrials.gov/study/NCT05447702","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/","field":"links","label":"ClinicalTrials.gov NCT05447702"}]},{"url":"https://clinicaltrials.gov/study/NCT05450029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05450029","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer","route":"/trials/nct05450029/","field":"links","label":"ClinicalTrials.gov NCT05450029"}]},{"url":"https://clinicaltrials.gov/study/NCT05450692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05450692","kind":"trial","name":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","route":"/trials/nct05450692/","field":"links","label":"ClinicalTrials.gov NCT05450692"}]},{"url":"https://clinicaltrials.gov/study/NCT05450965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05450965","kind":"trial","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","route":"/trials/nct05450965/","field":"links","label":"ClinicalTrials.gov NCT05450965"}]},{"url":"https://clinicaltrials.gov/study/NCT05451043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05451043","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","route":"/trials/nct05451043/","field":"links","label":"ClinicalTrials.gov NCT05451043"}]},{"url":"https://clinicaltrials.gov/study/NCT05451290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05451290","kind":"trial","name":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","route":"/trials/nct05451290/","field":"links","label":"ClinicalTrials.gov NCT05451290"}]},{"url":"https://clinicaltrials.gov/study/NCT05451602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","route":"/trials/nct05451602/","field":"links","label":"ClinicalTrials.gov NCT05451602"}]},{"url":"https://clinicaltrials.gov/study/NCT05451784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05451784","kind":"trial","name":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","route":"/trials/nct05451784/","field":"links","label":"ClinicalTrials.gov NCT05451784"}]},{"url":"https://clinicaltrials.gov/study/NCT05451810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05451810","kind":"trial","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","route":"/trials/nct05451810/","field":"links","label":"ClinicalTrials.gov NCT05451810"}]},{"url":"https://clinicaltrials.gov/study/NCT05455320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/","field":"links","label":"ClinicalTrials.gov NCT05455320"}]},{"url":"https://clinicaltrials.gov/study/NCT05455619","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05455619","kind":"trial","name":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","route":"/trials/nct05455619/","field":"links","label":"ClinicalTrials.gov NCT05455619"}]},{"url":"https://clinicaltrials.gov/study/NCT05456191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05456191","kind":"trial","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","route":"/trials/nct05456191/","field":"links","label":"ClinicalTrials.gov NCT05456191"}]},{"url":"https://clinicaltrials.gov/study/NCT05456191?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05456191","kind":"trial","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","route":"/trials/nct05456191/","field":"outcomes.source (Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis))"}]},{"url":"https://clinicaltrials.gov/study/NCT05456256","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05456256","kind":"trial","name":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","route":"/trials/nct05456256/","field":"links","label":"ClinicalTrials.gov NCT05456256"}]},{"url":"https://clinicaltrials.gov/study/NCT05456685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05456685","kind":"trial","name":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov","route":"/trials/nct05456685/","field":"links","label":"ClinicalTrials.gov NCT05456685"}]},{"url":"https://clinicaltrials.gov/study/NCT05458297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","route":"/trials/nct05458297/","field":"links","label":"ClinicalTrials.gov NCT05458297"}]},{"url":"https://clinicaltrials.gov/study/NCT05458674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/","field":"links","label":"ClinicalTrials.gov NCT05458674"}]},{"url":"https://clinicaltrials.gov/study/NCT05459844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/","field":"links","label":"ClinicalTrials.gov NCT05459844"}]},{"url":"https://clinicaltrials.gov/study/NCT05460273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","route":"/trials/nct05460273/","field":"links","label":"ClinicalTrials.gov NCT05460273"}]},{"url":"https://clinicaltrials.gov/study/NCT05460273?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","route":"/trials/nct05460273/","field":"outcomes.source (Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR))"},{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","route":"/trials/nct05460273/","field":"outcomes.source (Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05462236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05462236","kind":"trial","name":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","route":"/trials/nct05462236/","field":"links","label":"ClinicalTrials.gov NCT05462236"}]},{"url":"https://clinicaltrials.gov/study/NCT05462496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05462496","kind":"trial","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","route":"/trials/nct05462496/","field":"links","label":"ClinicalTrials.gov NCT05462496"}]},{"url":"https://clinicaltrials.gov/study/NCT05462613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05462613","kind":"trial","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","route":"/trials/nct05462613/","field":"links","label":"ClinicalTrials.gov NCT05462613"}]},{"url":"https://clinicaltrials.gov/study/NCT05463263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05463263","kind":"trial","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","route":"/trials/nct05463263/","field":"links","label":"ClinicalTrials.gov NCT05463263"}]},{"url":"https://clinicaltrials.gov/study/NCT05463601","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05463601","kind":"trial","name":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","route":"/trials/nct05463601/","field":"links","label":"ClinicalTrials.gov NCT05463601"}]},{"url":"https://clinicaltrials.gov/study/NCT05466149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05466149","kind":"trial","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","route":"/trials/nct05466149/","field":"links","label":"ClinicalTrials.gov NCT05466149"}]},{"url":"https://clinicaltrials.gov/study/NCT05466799","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05466799","kind":"trial","name":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","route":"/trials/nct05466799/","field":"links","label":"ClinicalTrials.gov NCT05466799"}]},{"url":"https://clinicaltrials.gov/study/NCT05468489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05468489","kind":"trial","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","route":"/trials/nct05468489/","field":"links","label":"ClinicalTrials.gov NCT05468489"}]},{"url":"https://clinicaltrials.gov/study/NCT05468697","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05468697","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6","route":"/trials/nct05468697/","field":"links","label":"ClinicalTrials.gov NCT05468697"}]},{"url":"https://clinicaltrials.gov/study/NCT05469022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05469022","kind":"trial","name":"Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","route":"/trials/nct05469022/","field":"links","label":"ClinicalTrials.gov NCT05469022"}]},{"url":"https://clinicaltrials.gov/study/NCT05471843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct05471843/","field":"links","label":"ClinicalTrials.gov NCT05471843"}]},{"url":"https://clinicaltrials.gov/study/NCT05471843?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct05471843/","field":"outcomes.source (Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC))"},{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct05471843/","field":"outcomes.source (Part 1: Overall Survival (OS))"}]},{"url":"https://clinicaltrials.gov/study/NCT05473156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05473156","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","route":"/trials/nct05473156/","field":"links","label":"ClinicalTrials.gov NCT05473156"}]},{"url":"https://clinicaltrials.gov/study/NCT05475678","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05475678","kind":"trial","name":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","route":"/trials/nct05475678/","field":"links","label":"ClinicalTrials.gov NCT05475678"}]},{"url":"https://clinicaltrials.gov/study/NCT05475925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05475925","kind":"trial","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","route":"/trials/nct05475925/","field":"links","label":"ClinicalTrials.gov NCT05475925"}]},{"url":"https://clinicaltrials.gov/study/NCT05477576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","field":"links","label":"ClinicalTrials.gov NCT05477576"},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","field":"links","label":"ClinicalTrials.gov NCT05477576: ACTION-1"},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"dosing.source"}]},{"url":"https://clinicaltrials.gov/study/NCT05479136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05479136","kind":"trial","name":"18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy","route":"/trials/nct05479136/","field":"links","label":"ClinicalTrials.gov NCT05479136"}]},{"url":"https://clinicaltrials.gov/study/NCT05479240","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05479240","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct05479240/","field":"links","label":"ClinicalTrials.gov NCT05479240"}]},{"url":"https://clinicaltrials.gov/study/NCT05479994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05479994","kind":"trial","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05479994/","field":"links","label":"ClinicalTrials.gov NCT05479994"}]},{"url":"https://clinicaltrials.gov/study/NCT05481151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05481151","kind":"trial","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","route":"/trials/nct05481151/","field":"links","label":"ClinicalTrials.gov NCT05481151"}]},{"url":"https://clinicaltrials.gov/study/NCT05482516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05482516","kind":"trial","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","route":"/trials/nct05482516/","field":"links","label":"ClinicalTrials.gov NCT05482516"}]},{"url":"https://clinicaltrials.gov/study/NCT05482568","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05482568","kind":"trial","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct05482568/","field":"links","label":"ClinicalTrials.gov NCT05482568"}]},{"url":"https://clinicaltrials.gov/study/NCT05482893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/","field":"links","label":"ClinicalTrials.gov NCT05482893"}]},{"url":"https://clinicaltrials.gov/study/NCT05482971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05482971","kind":"trial","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","route":"/trials/nct05482971/","field":"links","label":"ClinicalTrials.gov NCT05482971"}]},{"url":"https://clinicaltrials.gov/study/NCT05484024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05484024","kind":"trial","name":"Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer","route":"/trials/nct05484024/","field":"links","label":"ClinicalTrials.gov NCT05484024"}]},{"url":"https://clinicaltrials.gov/study/NCT05485766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/","field":"links","label":"ClinicalTrials.gov NCT05485766"}]},{"url":"https://clinicaltrials.gov/study/NCT05485948","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05485948","kind":"trial","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","route":"/trials/nct05485948/","field":"links","label":"ClinicalTrials.gov NCT05485948"}]},{"url":"https://clinicaltrials.gov/study/NCT05487170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05487170","kind":"trial","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","route":"/trials/nct05487170/","field":"links","label":"ClinicalTrials.gov NCT05487170"}]},{"url":"https://clinicaltrials.gov/study/NCT05487391","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/","field":"links","label":"ClinicalTrials.gov NCT05487391"}]},{"url":"https://clinicaltrials.gov/study/NCT05488314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/","field":"links","label":"ClinicalTrials.gov NCT05488314"}]},{"url":"https://clinicaltrials.gov/study/NCT05489211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/","field":"links","label":"ClinicalTrials.gov NCT05489211"}]},{"url":"https://clinicaltrials.gov/study/NCT05489289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05489289","kind":"trial","name":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","route":"/trials/nct05489289/","field":"links","label":"ClinicalTrials.gov NCT05489289"}]},{"url":"https://clinicaltrials.gov/study/NCT05490472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","route":"/trials/nct05490472/","field":"links","label":"ClinicalTrials.gov NCT05490472"}]},{"url":"https://clinicaltrials.gov/study/NCT05491083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05491083","kind":"trial","name":"Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","route":"/trials/nct05491083/","field":"links","label":"ClinicalTrials.gov NCT05491083"}]},{"url":"https://clinicaltrials.gov/study/NCT05491226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05491226","kind":"trial","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","route":"/trials/nct05491226/","field":"links","label":"ClinicalTrials.gov NCT05491226"}]},{"url":"https://clinicaltrials.gov/study/NCT05491525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/","field":"links","label":"ClinicalTrials.gov NCT05491525"}]},{"url":"https://clinicaltrials.gov/study/NCT05496166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05496166","kind":"trial","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","route":"/trials/nct05496166/","field":"links","label":"ClinicalTrials.gov NCT05496166"}]},{"url":"https://clinicaltrials.gov/study/NCT05498155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05498155","kind":"trial","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","route":"/trials/nct05498155/","field":"links","label":"ClinicalTrials.gov NCT05498155"}]},{"url":"https://clinicaltrials.gov/study/NCT05498311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05498311","kind":"trial","name":"Breast Cancer With Intraoperative Radiotherapy Followed by Hypofractionated External Beam Radiotherapy","route":"/trials/nct05498311/","field":"links","label":"ClinicalTrials.gov NCT05498311"}]},{"url":"https://clinicaltrials.gov/study/NCT05498428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct05498428/","field":"links","label":"ClinicalTrials.gov NCT05498428"}]},{"url":"https://clinicaltrials.gov/study/NCT05498896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"barbican","kind":"trial","name":"BARBICAN","route":"/trials/barbican/","field":"links","label":"ClinicalTrials.gov NCT05498896"}]},{"url":"https://clinicaltrials.gov/study/NCT05499013","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","route":"/trials/nct05499013/","field":"links","label":"ClinicalTrials.gov NCT05499013"}]},{"url":"https://clinicaltrials.gov/study/NCT05499390","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","field":"links","label":"ClinicalTrials.gov NCT05499390"},{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","field":"links","label":"ClinicalTrials.gov NCT05499390: HARMONi-2"},{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/","field":"links","label":"ClinicalTrials.gov NCT05499390"}],"archive":"https://web.archive.org/web/20251122113308/https://clinicaltrials.gov/study/NCT05499390"},{"url":"https://clinicaltrials.gov/study/NCT05501665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05501665","kind":"trial","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","route":"/trials/nct05501665/","field":"links","label":"ClinicalTrials.gov NCT05501665"}]},{"url":"https://clinicaltrials.gov/study/NCT05501886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05501886","kind":"trial","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","route":"/trials/nct05501886/","field":"links","label":"ClinicalTrials.gov NCT05501886"}]},{"url":"https://clinicaltrials.gov/study/NCT05502237","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct05502237/","field":"links","label":"ClinicalTrials.gov NCT05502237"}]},{"url":"https://clinicaltrials.gov/study/NCT05502913","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05502913","kind":"trial","name":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","route":"/trials/nct05502913/","field":"links","label":"ClinicalTrials.gov NCT05502913"}]},{"url":"https://clinicaltrials.gov/study/NCT05503797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/","field":"links","label":"ClinicalTrials.gov NCT05503797"}]},{"url":"https://clinicaltrials.gov/study/NCT05503888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05503888","kind":"trial","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","route":"/trials/nct05503888/","field":"links","label":"ClinicalTrials.gov NCT05503888"}]},{"url":"https://clinicaltrials.gov/study/NCT05506943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/","field":"links","label":"ClinicalTrials.gov NCT05506943"}]},{"url":"https://clinicaltrials.gov/study/NCT05514054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/","field":"links","label":"ClinicalTrials.gov NCT05514054"}]},{"url":"https://clinicaltrials.gov/study/NCT05518045","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","route":"/trials/nct05518045/","field":"links","label":"ClinicalTrials.gov NCT05518045"}]},{"url":"https://clinicaltrials.gov/study/NCT05518903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05518903","kind":"trial","name":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","route":"/trials/nct05518903/","field":"links","label":"ClinicalTrials.gov NCT05518903"}]},{"url":"https://clinicaltrials.gov/study/NCT05519085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/","field":"links","label":"ClinicalTrials.gov NCT05519085"}]},{"url":"https://clinicaltrials.gov/study/NCT05520567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/","field":"links","label":"ClinicalTrials.gov NCT05520567"}]},{"url":"https://clinicaltrials.gov/study/NCT05521802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05521802","kind":"trial","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05521802/","field":"links","label":"ClinicalTrials.gov NCT05521802"}]},{"url":"https://clinicaltrials.gov/study/NCT05522491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/","field":"links","label":"ClinicalTrials.gov NCT05522491"}]},{"url":"https://clinicaltrials.gov/study/NCT05522660","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05522660","kind":"trial","name":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","route":"/trials/nct05522660/","field":"links","label":"ClinicalTrials.gov NCT05522660"}]},{"url":"https://clinicaltrials.gov/study/NCT05523947","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/","field":"links","label":"ClinicalTrials.gov NCT05523947"}]},{"url":"https://clinicaltrials.gov/study/NCT05526755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","route":"/trials/nct05526755/","field":"links","label":"ClinicalTrials.gov NCT05526755"}]},{"url":"https://clinicaltrials.gov/study/NCT05528133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","route":"/trials/nct05528133/","field":"links","label":"ClinicalTrials.gov NCT05528133"}]},{"url":"https://clinicaltrials.gov/study/NCT05529940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05529940","kind":"trial","name":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","route":"/trials/nct05529940/","field":"links","label":"ClinicalTrials.gov NCT05529940"}]},{"url":"https://clinicaltrials.gov/study/NCT05532696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","route":"/trials/nct05532696/","field":"links","label":"ClinicalTrials.gov NCT05532696"}]},{"url":"https://clinicaltrials.gov/study/NCT05533697","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","route":"/trials/nct05533697/","field":"links","label":"ClinicalTrials.gov NCT05533697"}]},{"url":"https://clinicaltrials.gov/study/NCT05533775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05533775","kind":"trial","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","route":"/trials/nct05533775/","field":"links","label":"ClinicalTrials.gov NCT05533775"}]},{"url":"https://clinicaltrials.gov/study/NCT05534087","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05534087","kind":"trial","name":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","route":"/trials/nct05534087/","field":"links","label":"ClinicalTrials.gov NCT05534087"}]},{"url":"https://clinicaltrials.gov/study/NCT05535244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcrh5-expression","kind":"biomarker","name":"FcRH5 expression","route":"/biomarkers/fcrh5-expression/","field":"links","label":"ClinicalTrials.gov NCT05535244 (CAMMA 2)"},{"id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/","field":"links","label":"ClinicalTrials.gov NCT05535244"}]},{"url":"https://clinicaltrials.gov/study/NCT05541822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","route":"/trials/nct05541822/","field":"links","label":"ClinicalTrials.gov NCT05541822"}]},{"url":"https://clinicaltrials.gov/study/NCT05543330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05543330","kind":"trial","name":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","route":"/trials/nct05543330/","field":"links","label":"ClinicalTrials.gov NCT05543330"}]},{"url":"https://clinicaltrials.gov/study/NCT05544552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","route":"/trials/nct05544552/","field":"links","label":"ClinicalTrials.gov NCT05544552"}]},{"url":"https://clinicaltrials.gov/study/NCT05546268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/","field":"links","label":"ClinicalTrials.gov NCT05546268"}]},{"url":"https://clinicaltrials.gov/study/NCT05546476","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","field":"links","label":"ClinicalTrials.gov NCT05546476"},{"id":"idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials","kind":"idea","name":"Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints","route":"/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/","field":"links","label":"ClinicalTrials.gov NCT05546476"},{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","field":"links","label":"Phase 2 (NCT05546476)"},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","field":"links","label":"ClinicalTrials.gov NCT05546476"}]},{"url":"https://clinicaltrials.gov/study/NCT05546866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/","field":"links","label":"ClinicalTrials.gov NCT05546866"}]},{"url":"https://clinicaltrials.gov/study/NCT05547061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/","field":"links","label":"ClinicalTrials.gov NCT05547061"}]},{"url":"https://clinicaltrials.gov/study/NCT05548127","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","field":"links","label":"ClinicalTrials.gov NCT05548127"}]},{"url":"https://clinicaltrials.gov/study/NCT05548296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/","field":"links","label":"ClinicalTrials.gov NCT05548296"}]},{"url":"https://clinicaltrials.gov/study/NCT05549297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/","field":"links","label":"ClinicalTrials.gov NCT05549297"}]},{"url":"https://clinicaltrials.gov/study/NCT05550415","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05550415","kind":"trial","name":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","route":"/trials/nct05550415/","field":"links","label":"ClinicalTrials.gov NCT05550415"}]},{"url":"https://clinicaltrials.gov/study/NCT05551507","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","route":"/trials/nct05551507/","field":"links","label":"ClinicalTrials.gov NCT05551507"}]},{"url":"https://clinicaltrials.gov/study/NCT05552001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05552001","kind":"trial","name":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","route":"/trials/nct05552001/","field":"links","label":"ClinicalTrials.gov NCT05552001"}]},{"url":"https://clinicaltrials.gov/study/NCT05552222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/","field":"links","label":"ClinicalTrials.gov NCT05552222"}]},{"url":"https://clinicaltrials.gov/study/NCT05552976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05552976","kind":"trial","name":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","route":"/trials/nct05552976/","field":"links","label":"ClinicalTrials.gov NCT05552976"}]},{"url":"https://clinicaltrials.gov/study/NCT05555732","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/","field":"links","label":"ClinicalTrials.gov NCT05555732"}]},{"url":"https://clinicaltrials.gov/study/NCT05555888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05555888","kind":"trial","name":"The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","route":"/trials/nct05555888/","field":"links","label":"ClinicalTrials.gov NCT05555888"}]},{"url":"https://clinicaltrials.gov/study/NCT05557591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/","field":"links","label":"ClinicalTrials.gov NCT05557591"}]},{"url":"https://clinicaltrials.gov/study/NCT05557838","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05557838","kind":"trial","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","route":"/trials/nct05557838/","field":"links","label":"ClinicalTrials.gov NCT05557838"}]},{"url":"https://clinicaltrials.gov/study/NCT05558007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","route":"/trials/nct05558007/","field":"links","label":"ClinicalTrials.gov NCT05558007"}]},{"url":"https://clinicaltrials.gov/study/NCT05562297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05562297","kind":"trial","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct05562297/","field":"links","label":"ClinicalTrials.gov NCT05562297"}]},{"url":"https://clinicaltrials.gov/study/NCT05562830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05562830","kind":"trial","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","route":"/trials/nct05562830/","field":"links","label":"ClinicalTrials.gov NCT05562830"}]},{"url":"https://clinicaltrials.gov/study/NCT05563220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05563220","kind":"trial","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","route":"/trials/nct05563220/","field":"links","label":"ClinicalTrials.gov NCT05563220"}]},{"url":"https://clinicaltrials.gov/study/NCT05563844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05563844","kind":"trial","name":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","route":"/trials/nct05563844/","field":"links","label":"ClinicalTrials.gov NCT05563844"}]},{"url":"https://clinicaltrials.gov/study/NCT05563922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05563922","kind":"trial","name":"Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma","route":"/trials/nct05563922/","field":"links","label":"ClinicalTrials.gov NCT05563922"}]},{"url":"https://clinicaltrials.gov/study/NCT05564377","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"combomatch","kind":"trial","name":"ComboMATCH (EAY191)","route":"/trials/combomatch/","field":"links","label":"ClinicalTrials.gov NCT05564377"}]},{"url":"https://clinicaltrials.gov/study/NCT05564390","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myelomatch","kind":"trial","name":"myeloMATCH","route":"/trials/myelomatch/","field":"links","label":"ClinicalTrials.gov NCT05564390"},{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/","field":"links","label":"ClinicalTrials.gov NCT05564390: myeloMATCH"}]},{"url":"https://clinicaltrials.gov/study/NCT05564403","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"combomatch-binimetinib-folfox","kind":"trial","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","route":"/trials/combomatch-binimetinib-folfox/","field":"links","label":"ClinicalTrials.gov NCT05564403"}]},{"url":"https://clinicaltrials.gov/study/NCT05565378","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05565378","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct05565378/","field":"links","label":"ClinicalTrials.gov NCT05565378"},{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/","field":"links","label":"ClinicalTrials.gov NCT05565378"}]},{"url":"https://clinicaltrials.gov/study/NCT05565417","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05565417","kind":"trial","name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05565417/","field":"links","label":"ClinicalTrials.gov NCT05565417"}]},{"url":"https://clinicaltrials.gov/study/NCT05565807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05565807/","field":"links","label":"ClinicalTrials.gov NCT05565807"}]},{"url":"https://clinicaltrials.gov/study/NCT05566041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","route":"/trials/nct05566041/","field":"links","label":"ClinicalTrials.gov NCT05566041"}]},{"url":"https://clinicaltrials.gov/study/NCT05566795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","route":"/trials/nct05566795/","field":"links","label":"ClinicalTrials.gov NCT05566795"}]},{"url":"https://clinicaltrials.gov/study/NCT05570253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/","field":"links","label":"ClinicalTrials.gov NCT05570253"}]},{"url":"https://clinicaltrials.gov/study/NCT05570825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/","field":"links","label":"ClinicalTrials.gov NCT05570825"}]},{"url":"https://clinicaltrials.gov/study/NCT05571644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05571644","kind":"trial","name":"Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer","route":"/trials/nct05571644/","field":"links","label":"ClinicalTrials.gov NCT05571644"}]},{"url":"https://clinicaltrials.gov/study/NCT05572515","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05572515","kind":"trial","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","route":"/trials/nct05572515/","field":"links","label":"ClinicalTrials.gov NCT05572515"}]},{"url":"https://clinicaltrials.gov/study/NCT05573126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/","field":"links","label":"ClinicalTrials.gov NCT05573126"}]},{"url":"https://clinicaltrials.gov/study/NCT05573555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/","field":"links","label":"ClinicalTrials.gov NCT05573555"}]},{"url":"https://clinicaltrials.gov/study/NCT05576480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05576480","kind":"trial","name":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","route":"/trials/nct05576480/","field":"links","label":"ClinicalTrials.gov NCT05576480"}]},{"url":"https://clinicaltrials.gov/study/NCT05578326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05578326","kind":"trial","name":"Study of Trilaciclib and Lurbinectidin","route":"/trials/nct05578326/","field":"links","label":"ClinicalTrials.gov NCT05578326"}]},{"url":"https://clinicaltrials.gov/study/NCT05578976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epcore-dlbcl-2","kind":"trial","name":"EPCORE DLBCL-2","route":"/trials/epcore-dlbcl-2/","field":"links","label":"ClinicalTrials.gov NCT05578976"}]},{"url":"https://clinicaltrials.gov/study/NCT05579132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/","field":"links","label":"ClinicalTrials.gov NCT05579132"}]},{"url":"https://clinicaltrials.gov/study/NCT05579366","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/","field":"links","label":"Rinatabart sesutecan in advanced solid tumours, NCT05579366"},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","field":"links","label":"ClinicalTrials.gov NCT05579366"},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","field":"links","label":"ClinicalTrials.gov NCT05579366 (RAINFOL-01 (Rina-S))"}]},{"url":"https://clinicaltrials.gov/study/NCT05580562","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"links","label":"ACTION phase 3 (NCT05580562)"},{"id":"action-dmg","kind":"trial","name":"ACTION","route":"/trials/action-dmg/","field":"links","label":"ClinicalTrials.gov NCT05580562"}]},{"url":"https://clinicaltrials.gov/study/NCT05582538","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05582538","kind":"trial","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","route":"/trials/nct05582538/","field":"links","label":"ClinicalTrials.gov NCT05582538"}]},{"url":"https://clinicaltrials.gov/study/NCT05583552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","route":"/trials/nct05583552/","field":"links","label":"ClinicalTrials.gov NCT05583552"}]},{"url":"https://clinicaltrials.gov/study/NCT05583552?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","route":"/trials/nct05583552/","field":"outcomes.source (Overall Hematological Response Rate of Participants After Treatment With Imetelstat)"}]},{"url":"https://clinicaltrials.gov/study/NCT05583617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/","field":"links","label":"ClinicalTrials.gov NCT05583617"}]},{"url":"https://clinicaltrials.gov/study/NCT05584670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/","field":"links","label":"ClinicalTrials.gov NCT05584670"}]},{"url":"https://clinicaltrials.gov/study/NCT05584800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05584800","kind":"trial","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","route":"/trials/nct05584800/","field":"links","label":"ClinicalTrials.gov NCT05584800"}]},{"url":"https://clinicaltrials.gov/study/NCT05585320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct05585320/","field":"links","label":"ClinicalTrials.gov NCT05585320"}]},{"url":"https://clinicaltrials.gov/study/NCT05586074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/","field":"links","label":"ClinicalTrials.gov NCT05586074"}]},{"url":"https://clinicaltrials.gov/study/NCT05587296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05587296-n-engl-j-med-2025","kind":"paper","name":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","route":"/key-papers/paper-nct05587296-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05587296"},{"id":"nct05587296","kind":"trial","name":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","route":"/trials/nct05587296/","field":"links","label":"ClinicalTrials.gov NCT05587296"}]},{"url":"https://clinicaltrials.gov/study/NCT05588388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05588388","kind":"trial","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","route":"/trials/nct05588388/","field":"links","label":"ClinicalTrials.gov NCT05588388"}]},{"url":"https://clinicaltrials.gov/study/NCT05588648","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05588648","kind":"trial","name":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","route":"/trials/nct05588648/","field":"links","label":"ClinicalTrials.gov NCT05588648"}]},{"url":"https://clinicaltrials.gov/study/NCT05589896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05589896","kind":"trial","name":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","route":"/trials/nct05589896/","field":"links","label":"ClinicalTrials.gov NCT05589896"}]},{"url":"https://clinicaltrials.gov/study/NCT05592626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/","field":"links","label":"ClinicalTrials.gov NCT05592626"}]},{"url":"https://clinicaltrials.gov/study/NCT05593094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/","field":"links","label":"ClinicalTrials.gov NCT05593094"}]},{"url":"https://clinicaltrials.gov/study/NCT05594797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05594797","kind":"trial","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","route":"/trials/nct05594797/","field":"links","label":"ClinicalTrials.gov NCT05594797"}]},{"url":"https://clinicaltrials.gov/study/NCT05596409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05596409","kind":"trial","name":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","route":"/trials/nct05596409/","field":"links","label":"ClinicalTrials.gov NCT05596409"}]},{"url":"https://clinicaltrials.gov/study/NCT05601505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05601505","kind":"trial","name":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","route":"/trials/nct05601505/","field":"links","label":"ClinicalTrials.gov NCT05601505"}]},{"url":"https://clinicaltrials.gov/study/NCT05601726","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05601726","kind":"trial","name":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","route":"/trials/nct05601726/","field":"links","label":"ClinicalTrials.gov NCT05601726"}]},{"url":"https://clinicaltrials.gov/study/NCT05601752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","route":"/trials/nct05601752/","field":"links","label":"ClinicalTrials.gov NCT05601752"}]},{"url":"https://clinicaltrials.gov/study/NCT05605535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05605535","kind":"trial","name":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","route":"/trials/nct05605535/","field":"links","label":"ClinicalTrials.gov NCT05605535"}]},{"url":"https://clinicaltrials.gov/study/NCT05607004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05607004","kind":"trial","name":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","route":"/trials/nct05607004/","field":"links","label":"ClinicalTrials.gov NCT05607004"}]},{"url":"https://clinicaltrials.gov/study/NCT05607108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05607108","kind":"trial","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","route":"/trials/nct05607108/","field":"links","label":"ClinicalTrials.gov NCT05607108"}]},{"url":"https://clinicaltrials.gov/study/NCT05607420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05607420/","field":"links","label":"ClinicalTrials.gov NCT05607420"}]},{"url":"https://clinicaltrials.gov/study/NCT05607550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","route":"/trials/nct05607550/","field":"links","label":"ClinicalTrials.gov NCT05607550"}]},{"url":"https://clinicaltrials.gov/study/NCT05608044","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/","field":"links","label":"ClinicalTrials.gov NCT05608044"},{"id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","field":"links","label":"ClinicalTrials.gov NCT05608044"}]},{"url":"https://clinicaltrials.gov/study/NCT05608291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05608291","kind":"trial","name":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af","route":"/trials/nct05608291/","field":"links","label":"ClinicalTrials.gov NCT05608291"}]},{"url":"https://clinicaltrials.gov/study/NCT05608876","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05608876","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","route":"/trials/nct05608876/","field":"links","label":"ClinicalTrials.gov NCT05608876"}]},{"url":"https://clinicaltrials.gov/study/NCT05609370","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","route":"/trials/nct05609370/","field":"links","label":"ClinicalTrials.gov NCT05609370"}]},{"url":"https://clinicaltrials.gov/study/NCT05609370?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","route":"/trials/nct05609370/","field":"outcomes.source (Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C)"}]},{"url":"https://clinicaltrials.gov/study/NCT05609578","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05609578","kind":"trial","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","route":"/trials/nct05609578/","field":"links","label":"ClinicalTrials.gov NCT05609578"}]},{"url":"https://clinicaltrials.gov/study/NCT05609968","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/","field":"links","label":"ClinicalTrials.gov NCT05609968"}]},{"url":"https://clinicaltrials.gov/study/NCT05610163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-crc-organ-preservation-randomised-in-pmmr-rectal","kind":"idea","name":"Randomise organ preservation against surgery in mismatch repair-proficient rectal cancer, with bowel function as a co-primary endpoint","route":"/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/","field":"links","label":"ClinicalTrials.gov NCT05610163"},{"id":"nct05610163","kind":"trial","name":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage","route":"/trials/nct05610163/","field":"links","label":"ClinicalTrials.gov NCT05610163"}]},{"url":"https://clinicaltrials.gov/study/NCT05611632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"links","label":"ClinicalTrials.gov NCT05611632"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05611632"}]},{"url":"https://clinicaltrials.gov/study/NCT05611931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","field":"links","label":"ClinicalTrials.gov NCT05611931"}]},{"url":"https://clinicaltrials.gov/study/NCT05615623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05615623","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","route":"/trials/nct05615623/","field":"links","label":"ClinicalTrials.gov NCT05615623"}]},{"url":"https://clinicaltrials.gov/study/NCT05615818","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/","field":"links","label":"ClinicalTrials.gov NCT05615818"}]},{"url":"https://clinicaltrials.gov/study/NCT05615974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/","field":"links","label":"ClinicalTrials.gov NCT05615974"}]},{"url":"https://clinicaltrials.gov/study/NCT05619016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05619016","kind":"trial","name":"[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors","route":"/trials/nct05619016/","field":"links","label":"ClinicalTrials.gov NCT05619016"}]},{"url":"https://clinicaltrials.gov/study/NCT05620134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jk08","kind":"drug","name":"JK08","route":"/drugs/jk08/","field":"links","label":"ClinicalTrials.gov NCT05620134"},{"id":"nct05620134","kind":"trial","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct05620134/","field":"links","label":"ClinicalTrials.gov NCT05620134"}]},{"url":"https://clinicaltrials.gov/study/NCT05623020","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/","field":"links","label":"ClinicalTrials.gov NCT05623020"}]},{"url":"https://clinicaltrials.gov/study/NCT05623267","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05623267","kind":"trial","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","route":"/trials/nct05623267/","field":"links","label":"ClinicalTrials.gov NCT05623267"}]},{"url":"https://clinicaltrials.gov/study/NCT05623319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05623319","kind":"trial","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05623319/","field":"links","label":"ClinicalTrials.gov NCT05623319"}]},{"url":"https://clinicaltrials.gov/study/NCT05623982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05623982","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05623982/","field":"links","label":"ClinicalTrials.gov NCT05623982"}]},{"url":"https://clinicaltrials.gov/study/NCT05624138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05624138","kind":"trial","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","route":"/trials/nct05624138/","field":"links","label":"ClinicalTrials.gov NCT05624138"}]},{"url":"https://clinicaltrials.gov/study/NCT05624554","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/","field":"links","label":"ClinicalTrials.gov NCT05624554"}]},{"url":"https://clinicaltrials.gov/study/NCT05624918","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05624918","kind":"trial","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05624918/","field":"links","label":"ClinicalTrials.gov NCT05624918"}]},{"url":"https://clinicaltrials.gov/study/NCT05624996","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05624996","kind":"trial","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","route":"/trials/nct05624996/","field":"links","label":"ClinicalTrials.gov NCT05624996"}]},{"url":"https://clinicaltrials.gov/study/NCT05625399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","field":"links","label":"ClinicalTrials.gov NCT05625399"}]},{"url":"https://clinicaltrials.gov/study/NCT05625399?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","field":"outcomes.source (Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale)"},{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","field":"outcomes.source (Progression Free Survival Per BICR)"},{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","field":"outcomes.source (Disease Control Rate (ORR) Per BICR)"}]},{"url":"https://clinicaltrials.gov/study/NCT05627856","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05627856","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","route":"/trials/nct05627856/","field":"links","label":"ClinicalTrials.gov NCT05627856"}]},{"url":"https://clinicaltrials.gov/study/NCT05628038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05628038","kind":"trial","name":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct05628038/","field":"links","label":"ClinicalTrials.gov NCT05628038"}]},{"url":"https://clinicaltrials.gov/study/NCT05629234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","route":"/trials/nct05629234/","field":"links","label":"ClinicalTrials.gov NCT05629234"}]},{"url":"https://clinicaltrials.gov/study/NCT05629585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05629585"},{"id":"idea-tnbc-ctdna-guided-adjuvant-decisions","kind":"idea","name":"ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative","route":"/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/","field":"links","label":"ClinicalTrials.gov NCT05629585"},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","field":"links","label":"ClinicalTrials.gov NCT05629585"}]},{"url":"https://clinicaltrials.gov/study/NCT05630209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05630209","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)","route":"/trials/nct05630209/","field":"links","label":"ClinicalTrials.gov NCT05630209"}]},{"url":"https://clinicaltrials.gov/study/NCT05631262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05631262","kind":"trial","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","route":"/trials/nct05631262/","field":"links","label":"ClinicalTrials.gov NCT05631262"}]},{"url":"https://clinicaltrials.gov/study/NCT05632809","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","route":"/trials/nct05632809/","field":"links","label":"ClinicalTrials.gov NCT05632809"}]},{"url":"https://clinicaltrials.gov/study/NCT05632939","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05632939","kind":"trial","name":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","route":"/trials/nct05632939/","field":"links","label":"ClinicalTrials.gov NCT05632939"}]},{"url":"https://clinicaltrials.gov/study/NCT05633602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-post-approval-pragmatic-trial-in-excluded","kind":"idea","name":"After approval, a pragmatic trial in the patients the pivotal trial excluded","route":"/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/","field":"links","label":"Pragmatica-Lung (S2302) on ClinicalTrials.gov"}]},{"url":"https://clinicaltrials.gov/study/NCT05633654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05633654"},{"id":"idea-tnbc-ctdna-guided-adjuvant-decisions","kind":"idea","name":"ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative","route":"/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/","field":"links","label":"ClinicalTrials.gov NCT05633654"},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","field":"links","label":"ClinicalTrials.gov NCT05633654"}]},{"url":"https://clinicaltrials.gov/study/NCT05633667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/","field":"links","label":"ClinicalTrials.gov NCT05633667"}]},{"url":"https://clinicaltrials.gov/study/NCT05635708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05635708","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","route":"/trials/nct05635708/","field":"links","label":"ClinicalTrials.gov NCT05635708"}]},{"url":"https://clinicaltrials.gov/study/NCT05636215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05636215","kind":"trial","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct05636215/","field":"links","label":"ClinicalTrials.gov NCT05636215"}]},{"url":"https://clinicaltrials.gov/study/NCT05636618","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","field":"links","label":"ClinicalTrials.gov NCT05636618"}]},{"url":"https://clinicaltrials.gov/study/NCT05637567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05637567","kind":"trial","name":"Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","route":"/trials/nct05637567/","field":"links","label":"ClinicalTrials.gov NCT05637567"}]},{"url":"https://clinicaltrials.gov/study/NCT05640791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05640791","kind":"trial","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","route":"/trials/nct05640791/","field":"links","label":"ClinicalTrials.gov NCT05640791"}]},{"url":"https://clinicaltrials.gov/study/NCT05642455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05642455","kind":"trial","name":"SPEARHEAD-3 Pediatric Study","route":"/trials/nct05642455/","field":"links","label":"ClinicalTrials.gov NCT05642455"}]},{"url":"https://clinicaltrials.gov/study/NCT05642780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/","field":"links","label":"ClinicalTrials.gov NCT05642780"}]},{"url":"https://clinicaltrials.gov/study/NCT05643742","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/","field":"links","label":"ClinicalTrials.gov NCT05643742"}]},{"url":"https://clinicaltrials.gov/study/NCT05645107","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05645107","kind":"trial","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","route":"/trials/nct05645107/","field":"links","label":"ClinicalTrials.gov NCT05645107"}]},{"url":"https://clinicaltrials.gov/study/NCT05645692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05645692","kind":"trial","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","route":"/trials/nct05645692/","field":"links","label":"ClinicalTrials.gov NCT05645692"}]},{"url":"https://clinicaltrials.gov/study/NCT05646511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05646511","kind":"trial","name":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","route":"/trials/nct05646511/","field":"links","label":"ClinicalTrials.gov NCT05646511"}]},{"url":"https://clinicaltrials.gov/study/NCT05646862","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05646862","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","route":"/trials/nct05646862/","field":"links","label":"ClinicalTrials.gov NCT05646862"}]},{"url":"https://clinicaltrials.gov/study/NCT05647122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","field":"dosing.source"},{"id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","field":"links","label":"ClinicalTrials.gov NCT05647122"}]},{"url":"https://clinicaltrials.gov/study/NCT05651022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/","field":"links","label":"ClinicalTrials.gov NCT05651022"}]},{"url":"https://clinicaltrials.gov/study/NCT05652686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/","field":"links","label":"ClinicalTrials.gov NCT05652686"}]},{"url":"https://clinicaltrials.gov/study/NCT05652894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05652894","kind":"trial","name":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","route":"/trials/nct05652894/","field":"links","label":"ClinicalTrials.gov NCT05652894"}]},{"url":"https://clinicaltrials.gov/study/NCT05652920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05652920","kind":"trial","name":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","route":"/trials/nct05652920/","field":"links","label":"ClinicalTrials.gov NCT05652920"}]},{"url":"https://clinicaltrials.gov/study/NCT05653453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05653453","kind":"trial","name":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct05653453/","field":"links","label":"ClinicalTrials.gov NCT05653453"}]},{"url":"https://clinicaltrials.gov/study/NCT05654454","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05654454","kind":"trial","name":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","route":"/trials/nct05654454/","field":"links","label":"ClinicalTrials.gov NCT05654454"}]},{"url":"https://clinicaltrials.gov/study/NCT05654623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","field":"links","label":"ClinicalTrials.gov NCT05654623"}]},{"url":"https://clinicaltrials.gov/study/NCT05655078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ucl-proton-hemithoracic-mpm","kind":"trial","name":"Hemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)","route":"/trials/ucl-proton-hemithoracic-mpm/","field":"links","label":"ClinicalTrials.gov NCT05655078"}]},{"url":"https://clinicaltrials.gov/study/NCT05655312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","field":"links","label":"ClinicalTrials.gov NCT05655312"}]},{"url":"https://clinicaltrials.gov/study/NCT05658003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/","field":"links","label":"ClinicalTrials.gov NCT05658003"}]},{"url":"https://clinicaltrials.gov/study/NCT05658562","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","route":"/trials/nct05658562/","field":"links","label":"ClinicalTrials.gov NCT05658562"}]},{"url":"https://clinicaltrials.gov/study/NCT05660083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05660083","kind":"trial","name":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","route":"/trials/nct05660083/","field":"links","label":"ClinicalTrials.gov NCT05660083"}]},{"url":"https://clinicaltrials.gov/study/NCT05661955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05661955","kind":"trial","name":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants","route":"/trials/nct05661955/","field":"links","label":"ClinicalTrials.gov NCT05661955"}]},{"url":"https://clinicaltrials.gov/study/NCT05662397","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05662397","kind":"trial","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","route":"/trials/nct05662397/","field":"links","label":"ClinicalTrials.gov NCT05662397"}]},{"url":"https://clinicaltrials.gov/study/NCT05663775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05663775","kind":"trial","name":"Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)","route":"/trials/nct05663775/","field":"links","label":"ClinicalTrials.gov NCT05663775"}]},{"url":"https://clinicaltrials.gov/study/NCT05663866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT05663866"},{"id":"nct05663866","kind":"trial","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","route":"/trials/nct05663866/","field":"links","label":"ClinicalTrials.gov NCT05663866"}]},{"url":"https://clinicaltrials.gov/study/NCT05663866?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05663866","kind":"trial","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","route":"/trials/nct05663866/","field":"outcomes.source (Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT05664243","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05664243","kind":"trial","name":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","route":"/trials/nct05664243/","field":"links","label":"ClinicalTrials.gov NCT05664243"}]},{"url":"https://clinicaltrials.gov/study/NCT05667506","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","field":"links","label":"ClinicalTrials.gov NCT05667506"}]},{"url":"https://clinicaltrials.gov/study/NCT05668858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05668858","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct05668858/","field":"links","label":"ClinicalTrials.gov NCT05668858"}]},{"url":"https://clinicaltrials.gov/study/NCT05668988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05668988-n-engl-j-med-2026","kind":"paper","name":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","route":"/key-papers/paper-nct05668988-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05668988"},{"id":"nct05668988","kind":"trial","name":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","route":"/trials/nct05668988/","field":"links","label":"ClinicalTrials.gov NCT05668988"}]},{"url":"https://clinicaltrials.gov/study/NCT05669430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05669430","kind":"trial","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","route":"/trials/nct05669430/","field":"links","label":"ClinicalTrials.gov NCT05669430"}]},{"url":"https://clinicaltrials.gov/study/NCT05669482","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05669482","kind":"trial","name":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","route":"/trials/nct05669482/","field":"links","label":"ClinicalTrials.gov NCT05669482"}]},{"url":"https://clinicaltrials.gov/study/NCT05671510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05671510"},{"id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/","field":"links","label":"ClinicalTrials.gov NCT05671510"}]},{"url":"https://clinicaltrials.gov/study/NCT05671822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/","field":"links","label":"ClinicalTrials.gov NCT05671822"}]},{"url":"https://clinicaltrials.gov/study/NCT05672108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05672108","kind":"trial","name":"Phase II Trial of Lung Chemoemobolization","route":"/trials/nct05672108/","field":"links","label":"ClinicalTrials.gov NCT05672108"}]},{"url":"https://clinicaltrials.gov/study/NCT05672524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05672524","kind":"trial","name":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","route":"/trials/nct05672524/","field":"links","label":"ClinicalTrials.gov NCT05672524"}]},{"url":"https://clinicaltrials.gov/study/NCT05673057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","field":"links","label":"ClinicalTrials.gov NCT05673057"}]},{"url":"https://clinicaltrials.gov/study/NCT05673148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05673148","kind":"trial","name":"Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial","route":"/trials/nct05673148/","field":"links","label":"ClinicalTrials.gov NCT05673148"}]},{"url":"https://clinicaltrials.gov/study/NCT05673785","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/","field":"links","label":"ClinicalTrials.gov NCT05673785"}]},{"url":"https://clinicaltrials.gov/study/NCT05673785?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/","field":"outcomes.source (Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma)"}]},{"url":"https://clinicaltrials.gov/study/NCT05675410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","field":"links","label":"ClinicalTrials.gov NCT05675410: AHOD2131 (COG / NCTN)"},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","field":"links","label":"ClinicalTrials.gov NCT05675410"},{"id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","field":"links","label":"ClinicalTrials.gov NCT05675410: AHOD2131 (COG / NCTN)"}]},{"url":"https://clinicaltrials.gov/study/NCT05676931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/","field":"links","label":"ClinicalTrials.gov NCT05676931"}]},{"url":"https://clinicaltrials.gov/study/NCT05678270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05678270","kind":"trial","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct05678270/","field":"links","label":"ClinicalTrials.gov NCT05678270"}]},{"url":"https://clinicaltrials.gov/study/NCT05679583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05679583","kind":"trial","name":"Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer","route":"/trials/nct05679583/","field":"links","label":"ClinicalTrials.gov NCT05679583"}]},{"url":"https://clinicaltrials.gov/study/NCT05682443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/","field":"links","label":"ClinicalTrials.gov NCT05682443"}]},{"url":"https://clinicaltrials.gov/study/NCT05683886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05683886","kind":"trial","name":"A Study of KC1036 in Patients with Advanced Thymic Tumors","route":"/trials/nct05683886/","field":"links","label":"ClinicalTrials.gov NCT05683886"}]},{"url":"https://clinicaltrials.gov/study/NCT05684965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","route":"/trials/nct05684965/","field":"links","label":"ClinicalTrials.gov NCT05684965"}]},{"url":"https://clinicaltrials.gov/study/NCT05687266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/","field":"links","label":"ClinicalTrials.gov NCT05687266"}]},{"url":"https://clinicaltrials.gov/study/NCT05688280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05688280","kind":"trial","name":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","route":"/trials/nct05688280/","field":"links","label":"ClinicalTrials.gov NCT05688280"}]},{"url":"https://clinicaltrials.gov/study/NCT05688605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","route":"/trials/nct05688605/","field":"links","label":"ClinicalTrials.gov NCT05688605"}]},{"url":"https://clinicaltrials.gov/study/NCT05689853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05689853","kind":"trial","name":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05689853/","field":"links","label":"ClinicalTrials.gov NCT05689853"}]},{"url":"https://clinicaltrials.gov/study/NCT05690945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/","field":"links","label":"ClinicalTrials.gov NCT05690945"}]},{"url":"https://clinicaltrials.gov/study/NCT05691491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05691491","kind":"trial","name":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","route":"/trials/nct05691491/","field":"links","label":"ClinicalTrials.gov NCT05691491"}]},{"url":"https://clinicaltrials.gov/study/NCT05692024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05692024","kind":"trial","name":"COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","route":"/trials/nct05692024/","field":"links","label":"ClinicalTrials.gov NCT05692024"}]},{"url":"https://clinicaltrials.gov/study/NCT05692999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05692999","kind":"trial","name":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","route":"/trials/nct05692999/","field":"links","label":"ClinicalTrials.gov NCT05692999"}]},{"url":"https://clinicaltrials.gov/study/NCT05696626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05696626","kind":"trial","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","route":"/trials/nct05696626/","field":"links","label":"ClinicalTrials.gov NCT05696626"}]},{"url":"https://clinicaltrials.gov/study/NCT05699746","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05699746","kind":"trial","name":"CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD","route":"/trials/nct05699746/","field":"links","label":"ClinicalTrials.gov NCT05699746"}]},{"url":"https://clinicaltrials.gov/study/NCT05700084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05700084","kind":"trial","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","route":"/trials/nct05700084/","field":"links","label":"ClinicalTrials.gov NCT05700084"}]},{"url":"https://clinicaltrials.gov/study/NCT05701306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/","field":"links","label":"ClinicalTrials.gov NCT05701306"}]},{"url":"https://clinicaltrials.gov/study/NCT05701436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05701436","kind":"trial","name":"Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial","route":"/trials/nct05701436/","field":"links","label":"ClinicalTrials.gov NCT05701436"}]},{"url":"https://clinicaltrials.gov/study/NCT05702229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/","field":"links","label":"ClinicalTrials.gov NCT05702229"}]},{"url":"https://clinicaltrials.gov/study/NCT05703971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/","field":"links","label":"ClinicalTrials.gov NCT05703971"}]},{"url":"https://clinicaltrials.gov/study/NCT05704049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05704049","kind":"trial","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","route":"/trials/nct05704049/","field":"links","label":"ClinicalTrials.gov NCT05704049"}]},{"url":"https://clinicaltrials.gov/study/NCT05704244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","route":"/trials/nct05704244/","field":"links","label":"ClinicalTrials.gov NCT05704244"}]},{"url":"https://clinicaltrials.gov/study/NCT05705492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05705492","kind":"trial","name":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","route":"/trials/nct05705492/","field":"links","label":"ClinicalTrials.gov NCT05705492"}]},{"url":"https://clinicaltrials.gov/study/NCT05706129","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","field":"links","label":"ClinicalTrials.gov NCT05706129"}]},{"url":"https://clinicaltrials.gov/study/NCT05706779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05706779","kind":"trial","name":"Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer","route":"/trials/nct05706779/","field":"links","label":"ClinicalTrials.gov NCT05706779"}]},{"url":"https://clinicaltrials.gov/study/NCT05709171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05709171","kind":"trial","name":"Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms","route":"/trials/nct05709171/","field":"links","label":"ClinicalTrials.gov NCT05709171"}]},{"url":"https://clinicaltrials.gov/study/NCT05709249","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","route":"/trials/nct05709249/","field":"links","label":"ClinicalTrials.gov NCT05709249"}]},{"url":"https://clinicaltrials.gov/study/NCT05710406","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05710406","kind":"trial","name":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","route":"/trials/nct05710406/","field":"links","label":"ClinicalTrials.gov NCT05710406"}]},{"url":"https://clinicaltrials.gov/study/NCT05710848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","route":"/trials/nct05710848/","field":"links","label":"ClinicalTrials.gov NCT05710848"}]},{"url":"https://clinicaltrials.gov/study/NCT05712694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","field":"links","label":"ARGSARC phase 3, terminated (NCT05712694)"}]},{"url":"https://clinicaltrials.gov/study/NCT05712902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/","field":"links","label":"ClinicalTrials.gov NCT05712902"},{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","route":"/trials/nct05712902/","field":"links","label":"ClinicalTrials.gov NCT05712902"}]},{"url":"https://clinicaltrials.gov/study/NCT05714202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hr-nmibc","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","route":"/trials/hr-nmibc/","field":"links","label":"ClinicalTrials.gov NCT05714202"}]},{"url":"https://clinicaltrials.gov/study/NCT05714839","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/","field":"links","label":"ClinicalTrials.gov NCT05714839"}]},{"url":"https://clinicaltrials.gov/study/NCT05716087","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","route":"/trials/nct05716087/","field":"links","label":"ClinicalTrials.gov NCT05716087"}]},{"url":"https://clinicaltrials.gov/study/NCT05717803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05717803","kind":"trial","name":"Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","route":"/trials/nct05717803/","field":"links","label":"ClinicalTrials.gov NCT05717803"}]},{"url":"https://clinicaltrials.gov/study/NCT05718323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05718323","kind":"trial","name":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","route":"/trials/nct05718323/","field":"links","label":"ClinicalTrials.gov NCT05718323"}]},{"url":"https://clinicaltrials.gov/study/NCT05720130","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","field":"links","label":"ClinicalTrials.gov NCT05720130"}]},{"url":"https://clinicaltrials.gov/study/NCT05720338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05720338","kind":"trial","name":"Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?","route":"/trials/nct05720338/","field":"links","label":"ClinicalTrials.gov NCT05720338"}]},{"url":"https://clinicaltrials.gov/study/NCT05722015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT05722015"},{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","route":"/trials/nct05722015/","field":"links","label":"ClinicalTrials.gov NCT05722015"}]},{"url":"https://clinicaltrials.gov/study/NCT05722015?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","route":"/trials/nct05722015/","field":"outcomes.source (Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose)"}]},{"url":"https://clinicaltrials.gov/study/NCT05722886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"determine-trial","kind":"trial","name":"DETERMINE","route":"/trials/determine-trial/","field":"links","label":"ClinicalTrials.gov NCT05722886"}]},{"url":"https://clinicaltrials.gov/study/NCT05723562","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","field":"links","label":"ClinicalTrials.gov NCT05723562"},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","field":"links","label":"ClinicalTrials.gov NCT05723562: AZUR-1"},{"id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","field":"links","label":"ClinicalTrials.gov NCT05723562: AZUR-1"}]},{"url":"https://clinicaltrials.gov/study/NCT05724563","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05724563","kind":"trial","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","route":"/trials/nct05724563/","field":"links","label":"ClinicalTrials.gov NCT05724563"},{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/","field":"links","label":"ClinicalTrials.gov NCT05724563"}]},{"url":"https://clinicaltrials.gov/study/NCT05725200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05725200","kind":"trial","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","route":"/trials/nct05725200/","field":"links","label":"ClinicalTrials.gov NCT05725200"}]},{"url":"https://clinicaltrials.gov/study/NCT05726864","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","field":"links","label":"ClinicalTrials.gov NCT05726864"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","field":"links","label":"ClinicalTrials.gov NCT05726864: AMPLIFY-7P"}]},{"url":"https://clinicaltrials.gov/study/NCT05727163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05727163","kind":"trial","name":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat","route":"/trials/nct05727163/","field":"links","label":"ClinicalTrials.gov NCT05727163"}]},{"url":"https://clinicaltrials.gov/study/NCT05727176","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05727176","kind":"trial","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","route":"/trials/nct05727176/","field":"links","label":"ClinicalTrials.gov NCT05727176"}]},{"url":"https://clinicaltrials.gov/study/NCT05727904","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/","field":"links","label":"ClinicalTrials.gov NCT05727904"}]},{"url":"https://clinicaltrials.gov/study/NCT05730036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/","field":"links","label":"ClinicalTrials.gov NCT05730036"}]},{"url":"https://clinicaltrials.gov/study/NCT05731271","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/","field":"links","label":"ClinicalTrials.gov NCT05731271"},{"id":"nct05731271","kind":"trial","name":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","route":"/trials/nct05731271/","field":"links","label":"ClinicalTrials.gov NCT05731271"}]},{"url":"https://clinicaltrials.gov/study/NCT05731726","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05731726","kind":"trial","name":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","route":"/trials/nct05731726/","field":"links","label":"ClinicalTrials.gov NCT05731726"}]},{"url":"https://clinicaltrials.gov/study/NCT05732103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05732103","kind":"trial","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","route":"/trials/nct05732103/","field":"links","label":"ClinicalTrials.gov NCT05732103"}]},{"url":"https://clinicaltrials.gov/study/NCT05732389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05732389","kind":"trial","name":"Immunotherapy in Patients With Early dMMR Rectal Cancer","route":"/trials/nct05732389/","field":"links","label":"ClinicalTrials.gov NCT05732389"}]},{"url":"https://clinicaltrials.gov/study/NCT05732805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/","field":"links","label":"ClinicalTrials.gov NCT05732805"},{"id":"nct05732805","kind":"trial","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","route":"/trials/nct05732805/","field":"links","label":"ClinicalTrials.gov NCT05732805"}]},{"url":"https://clinicaltrials.gov/study/NCT05732831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/","field":"links","label":"ClinicalTrials.gov NCT05732831"}]},{"url":"https://clinicaltrials.gov/study/NCT05733000","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05733000","kind":"trial","name":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","route":"/trials/nct05733000/","field":"links","label":"ClinicalTrials.gov NCT05733000"}]},{"url":"https://clinicaltrials.gov/study/NCT05733598","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","route":"/trials/nct05733598/","field":"links","label":"ClinicalTrials.gov NCT05733598"}]},{"url":"https://clinicaltrials.gov/study/NCT05734066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05734066","kind":"trial","name":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","route":"/trials/nct05734066/","field":"links","label":"ClinicalTrials.gov NCT05734066"}]},{"url":"https://clinicaltrials.gov/study/NCT05734105","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","field":"links","label":"ClinicalTrials.gov NCT05734105"},{"id":"ctdna-genotype-gist-tki","kind":"pairing","name":"ctDNA KIT genotyping → TKI selection in GIST","route":"/pairings/ctdna-genotype-gist-tki/","field":"links","label":"ClinicalTrials.gov NCT05734105: INSIGHT"}]},{"url":"https://clinicaltrials.gov/study/NCT05735080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/","field":"links","label":"ClinicalTrials.gov NCT05735080"}]},{"url":"https://clinicaltrials.gov/study/NCT05736406","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05736406","kind":"trial","name":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","route":"/trials/nct05736406/","field":"links","label":"ClinicalTrials.gov NCT05736406"}]},{"url":"https://clinicaltrials.gov/study/NCT05736731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","route":"/trials/nct05736731/","field":"links","label":"ClinicalTrials.gov NCT05736731"}]},{"url":"https://clinicaltrials.gov/study/NCT05737706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/","field":"links","label":"ClinicalTrials.gov NCT05737706: MRTX1133 in KRAS G12D-mutant advanced solid tumours (phase 1)"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"ClinicalTrials.gov NCT05737706"},{"id":"nct05737706","kind":"trial","name":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","route":"/trials/nct05737706/","field":"links","label":"ClinicalTrials.gov NCT05737706"}]},{"url":"https://clinicaltrials.gov/study/NCT05739981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/","field":"links","label":"ClinicalTrials.gov NCT05739981"}]},{"url":"https://clinicaltrials.gov/study/NCT05740566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","field":"links","label":"ClinicalTrials.gov NCT05740566: DeLLphi-304"},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","field":"links","label":"ClinicalTrials.gov NCT05740566"},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","field":"outcomes.source (Overall survival)"},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-tarlatamab-sclc-n-engl-j-med-2025","kind":"paper","name":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","route":"/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/","field":"links","label":"ClinicalTrials.gov NCT05740566"}]},{"url":"https://clinicaltrials.gov/study/NCT05741164","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05741164","kind":"trial","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","route":"/trials/nct05741164/","field":"links","label":"ClinicalTrials.gov NCT05741164"}]},{"url":"https://clinicaltrials.gov/study/NCT05742425","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05742425","kind":"trial","name":"Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases","route":"/trials/nct05742425/","field":"links","label":"ClinicalTrials.gov NCT05742425"}]},{"url":"https://clinicaltrials.gov/study/NCT05742607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/","field":"links","label":"ClinicalTrials.gov NCT05742607"}]},{"url":"https://clinicaltrials.gov/study/NCT05744219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05744219","kind":"trial","name":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","route":"/trials/nct05744219/","field":"links","label":"ClinicalTrials.gov NCT05744219"}]},{"url":"https://clinicaltrials.gov/study/NCT05744427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","route":"/trials/nct05744427/","field":"links","label":"ClinicalTrials.gov NCT05744427"}]},{"url":"https://clinicaltrials.gov/study/NCT05744687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05744687","kind":"trial","name":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","route":"/trials/nct05744687/","field":"links","label":"ClinicalTrials.gov NCT05744687"}]},{"url":"https://clinicaltrials.gov/study/NCT05745623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/","field":"links","label":"ClinicalTrials.gov NCT05745623"}]},{"url":"https://clinicaltrials.gov/study/NCT05745740","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05745740","kind":"trial","name":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","route":"/trials/nct05745740/","field":"links","label":"ClinicalTrials.gov NCT05745740"}]},{"url":"https://clinicaltrials.gov/study/NCT05747716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05747716","kind":"trial","name":"SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC","route":"/trials/nct05747716/","field":"links","label":"ClinicalTrials.gov NCT05747716"}]},{"url":"https://clinicaltrials.gov/study/NCT05748145","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05748145","kind":"trial","name":"Metronidazole as Preoperative Therapy in CRC / FusoMetro-001","route":"/trials/nct05748145/","field":"links","label":"ClinicalTrials.gov NCT05748145"}]},{"url":"https://clinicaltrials.gov/study/NCT05748171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05748171","kind":"trial","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","route":"/trials/nct05748171/","field":"links","label":"ClinicalTrials.gov NCT05748171"}]},{"url":"https://clinicaltrials.gov/study/NCT05749588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","route":"/trials/nct05749588/","field":"links","label":"ClinicalTrials.gov NCT05749588"}]},{"url":"https://clinicaltrials.gov/study/NCT05749900","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05749900","kind":"trial","name":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","route":"/trials/nct05749900/","field":"links","label":"ClinicalTrials.gov NCT05749900"}]},{"url":"https://clinicaltrials.gov/study/NCT05751512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","route":"/trials/nct05751512/","field":"links","label":"ClinicalTrials.gov NCT05751512"}]},{"url":"https://clinicaltrials.gov/study/NCT05751798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/","field":"links","label":"ClinicalTrials.gov NCT05751798"},{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/","field":"links","label":"ClinicalTrials.gov NCT05751798"}]},{"url":"https://clinicaltrials.gov/study/NCT05751928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/","field":"links","label":"ClinicalTrials.gov NCT05751928"}]},{"url":"https://clinicaltrials.gov/study/NCT05752136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05752136","kind":"trial","name":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","route":"/trials/nct05752136/","field":"links","label":"ClinicalTrials.gov NCT05752136"}]},{"url":"https://clinicaltrials.gov/study/NCT05754853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05754853","kind":"trial","name":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","route":"/trials/nct05754853/","field":"links","label":"ClinicalTrials.gov NCT05754853"}]},{"url":"https://clinicaltrials.gov/study/NCT05755113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","route":"/trials/nct05755113/","field":"links","label":"ClinicalTrials.gov NCT05755113"}]},{"url":"https://clinicaltrials.gov/study/NCT05757336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05757336","kind":"trial","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","route":"/trials/nct05757336/","field":"links","label":"ClinicalTrials.gov NCT05757336"}]},{"url":"https://clinicaltrials.gov/study/NCT05759728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/","field":"links","label":"ClinicalTrials.gov NCT05759728"}]},{"url":"https://clinicaltrials.gov/study/NCT05760378","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","route":"/trials/nct05760378/","field":"links","label":"ClinicalTrials.gov NCT05760378"}]},{"url":"https://clinicaltrials.gov/study/NCT05761223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05761223","kind":"trial","name":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","route":"/trials/nct05761223/","field":"links","label":"ClinicalTrials.gov NCT05761223"}]},{"url":"https://clinicaltrials.gov/study/NCT05764928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05764928","kind":"trial","name":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","route":"/trials/nct05764928/","field":"links","label":"ClinicalTrials.gov NCT05764928"}]},{"url":"https://clinicaltrials.gov/study/NCT05765032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05765032","kind":"trial","name":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","route":"/trials/nct05765032/","field":"links","label":"ClinicalTrials.gov NCT05765032"}]},{"url":"https://clinicaltrials.gov/study/NCT05765812","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05765812","kind":"trial","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","route":"/trials/nct05765812/","field":"links","label":"ClinicalTrials.gov NCT05765812"}]},{"url":"https://clinicaltrials.gov/study/NCT05765877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05765877","kind":"trial","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct05765877/","field":"links","label":"ClinicalTrials.gov NCT05765877"}]},{"url":"https://clinicaltrials.gov/study/NCT05766605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05766605","kind":"trial","name":"Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial","route":"/trials/nct05766605/","field":"links","label":"ClinicalTrials.gov NCT05766605"}]},{"url":"https://clinicaltrials.gov/study/NCT05767892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05767892","kind":"trial","name":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct05767892/","field":"links","label":"ClinicalTrials.gov NCT05767892"}]},{"url":"https://clinicaltrials.gov/study/NCT05768139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/","field":"links","label":"ClinicalTrials.gov NCT05768139"}]},{"url":"https://clinicaltrials.gov/study/NCT05768178","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05768178","kind":"trial","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","route":"/trials/nct05768178/","field":"links","label":"ClinicalTrials.gov NCT05768178"}]},{"url":"https://clinicaltrials.gov/study/NCT05768503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05768503","kind":"trial","name":"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC","route":"/trials/nct05768503/","field":"links","label":"ClinicalTrials.gov NCT05768503"}]},{"url":"https://clinicaltrials.gov/study/NCT05768529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05768529","kind":"trial","name":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05768529/","field":"links","label":"ClinicalTrials.gov NCT05768529"}]},{"url":"https://clinicaltrials.gov/study/NCT05768919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05768919","kind":"trial","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","route":"/trials/nct05768919/","field":"links","label":"ClinicalTrials.gov NCT05768919"}]},{"url":"https://clinicaltrials.gov/study/NCT05770102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05770102","kind":"trial","name":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi","route":"/trials/nct05770102/","field":"links","label":"ClinicalTrials.gov NCT05770102"}]},{"url":"https://clinicaltrials.gov/study/NCT05770531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","route":"/trials/nct05770531/","field":"links","label":"ClinicalTrials.gov NCT05770531"}]},{"url":"https://clinicaltrials.gov/study/NCT05771181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05771181","kind":"trial","name":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","route":"/trials/nct05771181/","field":"links","label":"ClinicalTrials.gov NCT05771181"}]},{"url":"https://clinicaltrials.gov/study/NCT05771480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05771480","kind":"trial","name":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","route":"/trials/nct05771480/","field":"links","label":"ClinicalTrials.gov NCT05771480"}]},{"url":"https://clinicaltrials.gov/study/NCT05771584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/","field":"links","label":"ClinicalTrials.gov NCT05771584"}]},{"url":"https://clinicaltrials.gov/study/NCT05773820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05773820","kind":"trial","name":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","route":"/trials/nct05773820/","field":"links","label":"ClinicalTrials.gov NCT05773820"}]},{"url":"https://clinicaltrials.gov/study/NCT05774756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"links","label":"ClinicalTrials.gov NCT05774756"},{"id":"paper-transcend-miller-nejm-2026","kind":"paper","name":"Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)","route":"/key-papers/paper-transcend-miller-nejm-2026/","field":"links","label":"ClinicalTrials.gov NCT05774756"}]},{"url":"https://clinicaltrials.gov/study/NCT05774951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","route":"/trials/nct05774951/","field":"links","label":"ClinicalTrials.gov NCT05774951"}]},{"url":"https://clinicaltrials.gov/study/NCT05775146","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05775146","kind":"trial","name":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","route":"/trials/nct05775146/","field":"links","label":"ClinicalTrials.gov NCT05775146"}]},{"url":"https://clinicaltrials.gov/study/NCT05775159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05775159","kind":"trial","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","route":"/trials/nct05775159/","field":"links","label":"ClinicalTrials.gov NCT05775159"}]},{"url":"https://clinicaltrials.gov/study/NCT05776381","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05776381","kind":"trial","name":"The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp","route":"/trials/nct05776381/","field":"links","label":"ClinicalTrials.gov NCT05776381"}]},{"url":"https://clinicaltrials.gov/study/NCT05776524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05776524","kind":"trial","name":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","route":"/trials/nct05776524/","field":"links","label":"ClinicalTrials.gov NCT05776524"}]},{"url":"https://clinicaltrials.gov/study/NCT05780567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05780567","kind":"trial","name":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","route":"/trials/nct05780567/","field":"links","label":"ClinicalTrials.gov NCT05780567"}]},{"url":"https://clinicaltrials.gov/study/NCT05784688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05784688","kind":"trial","name":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","route":"/trials/nct05784688/","field":"links","label":"ClinicalTrials.gov NCT05784688"}]},{"url":"https://clinicaltrials.gov/study/NCT05785039","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05785039","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","route":"/trials/nct05785039/","field":"links","label":"ClinicalTrials.gov NCT05785039"}]},{"url":"https://clinicaltrials.gov/study/NCT05785741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/","field":"links","label":"ClinicalTrials.gov NCT05785741"}]},{"url":"https://clinicaltrials.gov/study/NCT05785767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/","field":"links","label":"ClinicalTrials.gov NCT05785767"}]},{"url":"https://clinicaltrials.gov/study/NCT05786716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"determine-arm04","kind":"trial","name":"DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers","route":"/trials/determine-arm04/","field":"links","label":"ClinicalTrials.gov NCT05786716"}]},{"url":"https://clinicaltrials.gov/study/NCT05786924","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05786924","kind":"trial","name":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","route":"/trials/nct05786924/","field":"links","label":"ClinicalTrials.gov NCT05786924"}]},{"url":"https://clinicaltrials.gov/study/NCT05787613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05787613","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","route":"/trials/nct05787613/","field":"links","label":"ClinicalTrials.gov NCT05787613"}]},{"url":"https://clinicaltrials.gov/study/NCT05789082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/","field":"links","label":"ClinicalTrials.gov NCT05789082"}]},{"url":"https://clinicaltrials.gov/study/NCT05794750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05794750","kind":"trial","name":"Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）","route":"/trials/nct05794750/","field":"links","label":"ClinicalTrials.gov NCT05794750"}]},{"url":"https://clinicaltrials.gov/study/NCT05794906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/","field":"links","label":"ClinicalTrials.gov NCT05794906"}]},{"url":"https://clinicaltrials.gov/study/NCT05794971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05794971","kind":"trial","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","route":"/trials/nct05794971/","field":"links","label":"ClinicalTrials.gov NCT05794971"}]},{"url":"https://clinicaltrials.gov/study/NCT05796375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05796375","kind":"trial","name":"Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance","route":"/trials/nct05796375/","field":"links","label":"ClinicalTrials.gov NCT05796375"}]},{"url":"https://clinicaltrials.gov/study/NCT05797077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05797077","kind":"trial","name":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","route":"/trials/nct05797077/","field":"links","label":"ClinicalTrials.gov NCT05797077"}]},{"url":"https://clinicaltrials.gov/study/NCT05797168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/","field":"links","label":"ClinicalTrials.gov NCT05797168"}]},{"url":"https://clinicaltrials.gov/study/NCT05797467","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05797467","kind":"trial","name":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","route":"/trials/nct05797467/","field":"links","label":"ClinicalTrials.gov NCT05797467"}]},{"url":"https://clinicaltrials.gov/study/NCT05797831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","route":"/trials/nct05797831/","field":"links","label":"ClinicalTrials.gov NCT05797831"}]},{"url":"https://clinicaltrials.gov/study/NCT05798819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","route":"/trials/nct05798819/","field":"links","label":"ClinicalTrials.gov NCT05798819"}]},{"url":"https://clinicaltrials.gov/study/NCT05800015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/","field":"links","label":"ClinicalTrials.gov NCT05800015"}]},{"url":"https://clinicaltrials.gov/study/NCT05800223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05800223","kind":"trial","name":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","route":"/trials/nct05800223/","field":"links","label":"ClinicalTrials.gov NCT05800223"}]},{"url":"https://clinicaltrials.gov/study/NCT05801029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/","field":"links","label":"ClinicalTrials.gov NCT05801029"}]},{"url":"https://clinicaltrials.gov/study/NCT05801237","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","route":"/trials/nct05801237/","field":"links","label":"ClinicalTrials.gov NCT05801237"}]},{"url":"https://clinicaltrials.gov/study/NCT05802225","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05802225","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","route":"/trials/nct05802225/","field":"links","label":"ClinicalTrials.gov NCT05802225"}]},{"url":"https://clinicaltrials.gov/study/NCT05803018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05803018","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","route":"/trials/nct05803018/","field":"links","label":"ClinicalTrials.gov NCT05803018"}]},{"url":"https://clinicaltrials.gov/study/NCT05804045","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","route":"/trials/nct05804045/","field":"links","label":"ClinicalTrials.gov NCT05804045"}]},{"url":"https://clinicaltrials.gov/study/NCT05804045?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","route":"/trials/nct05804045/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT05804370","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/","field":"links","label":"ClinicalTrials.gov NCT05804370"}]},{"url":"https://clinicaltrials.gov/study/NCT05804669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05804669","kind":"trial","name":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","route":"/trials/nct05804669/","field":"links","label":"ClinicalTrials.gov NCT05804669"}]},{"url":"https://clinicaltrials.gov/study/NCT05805501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05805501","kind":"trial","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","route":"/trials/nct05805501/","field":"links","label":"ClinicalTrials.gov NCT05805501"}]},{"url":"https://clinicaltrials.gov/study/NCT05806060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05806060","kind":"trial","name":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05806060/","field":"links","label":"ClinicalTrials.gov NCT05806060"}]},{"url":"https://clinicaltrials.gov/study/NCT05806099","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05806099","kind":"trial","name":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","route":"/trials/nct05806099/","field":"links","label":"ClinicalTrials.gov NCT05806099"}]},{"url":"https://clinicaltrials.gov/study/NCT05806385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","route":"/trials/nct05806385/","field":"links","label":"ClinicalTrials.gov NCT05806385"}]},{"url":"https://clinicaltrials.gov/study/NCT05806931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05806931","kind":"trial","name":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","route":"/trials/nct05806931/","field":"links","label":"ClinicalTrials.gov NCT05806931"}]},{"url":"https://clinicaltrials.gov/study/NCT05807984","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05807984","kind":"trial","name":"Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion","route":"/trials/nct05807984/","field":"links","label":"ClinicalTrials.gov NCT05807984"}]},{"url":"https://clinicaltrials.gov/study/NCT05810792","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05810792","kind":"trial","name":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","route":"/trials/nct05810792/","field":"links","label":"ClinicalTrials.gov NCT05810792"}]},{"url":"https://clinicaltrials.gov/study/NCT05812807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05812807"},{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/","field":"links","label":"ClinicalTrials.gov NCT05812807"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","field":"links","label":"ClinicalTrials.gov NCT05812807: OptimICE-pCR (A012103)"},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/","field":"links","label":"ClinicalTrials.gov NCT05812807"},{"id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","field":"links","label":"ClinicalTrials.gov NCT05812807: OptimICE-pCR (A012103)"}]},{"url":"https://clinicaltrials.gov/study/NCT05814354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05814354","kind":"trial","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","route":"/trials/nct05814354/","field":"links","label":"ClinicalTrials.gov NCT05814354"}]},{"url":"https://clinicaltrials.gov/study/NCT05815082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05815082","kind":"trial","name":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","route":"/trials/nct05815082/","field":"links","label":"ClinicalTrials.gov NCT05815082"}]},{"url":"https://clinicaltrials.gov/study/NCT05816252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05816252","kind":"trial","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","route":"/trials/nct05816252/","field":"links","label":"ClinicalTrials.gov NCT05816252"}]},{"url":"https://clinicaltrials.gov/study/NCT05821556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05821556","kind":"trial","name":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","route":"/trials/nct05821556/","field":"links","label":"ClinicalTrials.gov NCT05821556"}]},{"url":"https://clinicaltrials.gov/study/NCT05821686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","route":"/trials/nct05821686/","field":"links","label":"ClinicalTrials.gov NCT05821686"}]},{"url":"https://clinicaltrials.gov/study/NCT05822752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05822752","kind":"trial","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","route":"/trials/nct05822752/","field":"links","label":"ClinicalTrials.gov NCT05822752"}]},{"url":"https://clinicaltrials.gov/study/NCT05824975","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/","field":"links","label":"ClinicalTrials.gov NCT05824975"}]},{"url":"https://clinicaltrials.gov/study/NCT05825443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05825443","kind":"trial","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","route":"/trials/nct05825443/","field":"links","label":"ClinicalTrials.gov NCT05825443"}]},{"url":"https://clinicaltrials.gov/study/NCT05826535","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/","field":"links","label":"ClinicalTrials.gov NCT05826535"}]},{"url":"https://clinicaltrials.gov/study/NCT05827016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/","field":"links","label":"ClinicalTrials.gov NCT05827016"}]},{"url":"https://clinicaltrials.gov/study/NCT05827081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","field":"links","label":"ClinicalTrials.gov NCT05827081"}]},{"url":"https://clinicaltrials.gov/study/NCT05827796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05827796","kind":"trial","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct05827796/","field":"links","label":"ClinicalTrials.gov NCT05827796"}]},{"url":"https://clinicaltrials.gov/study/NCT05828511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/","field":"links","label":"ClinicalTrials.gov NCT05828511"}]},{"url":"https://clinicaltrials.gov/study/NCT05830123","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05830123","kind":"trial","name":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","route":"/trials/nct05830123/","field":"links","label":"ClinicalTrials.gov NCT05830123"}]},{"url":"https://clinicaltrials.gov/study/NCT05833724","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/","field":"links","label":"ClinicalTrials.gov NCT05833724"}]},{"url":"https://clinicaltrials.gov/study/NCT05836870","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05836870","kind":"trial","name":"Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05836870/","field":"links","label":"ClinicalTrials.gov NCT05836870"}]},{"url":"https://clinicaltrials.gov/study/NCT05837767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","field":"links","label":"MSK spatially fractionated RT (NCT05837767)"}]},{"url":"https://clinicaltrials.gov/study/NCT05838066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05838066","kind":"trial","name":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct05838066/","field":"links","label":"ClinicalTrials.gov NCT05838066"}]},{"url":"https://clinicaltrials.gov/study/NCT05838729","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05838729","kind":"trial","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","route":"/trials/nct05838729/","field":"links","label":"ClinicalTrials.gov NCT05838729"}]},{"url":"https://clinicaltrials.gov/study/NCT05840016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2025","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct05840016-lancet-2025/","field":"links","label":"ClinicalTrials.gov NCT05840016"},{"id":"paper-nct05840016-lancet-2026-update","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","route":"/key-papers/paper-nct05840016-lancet-2026-update/","field":"links","label":"ClinicalTrials.gov NCT05840016"},{"id":"nct05840016","kind":"trial","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05840016/","field":"links","label":"ClinicalTrials.gov NCT05840016"}]},{"url":"https://clinicaltrials.gov/study/NCT05840211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/","field":"links","label":"ClinicalTrials.gov NCT05840211"}]},{"url":"https://clinicaltrials.gov/study/NCT05841134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05841134","kind":"trial","name":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","route":"/trials/nct05841134/","field":"links","label":"ClinicalTrials.gov NCT05841134"}]},{"url":"https://clinicaltrials.gov/study/NCT05841420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05841420","kind":"trial","name":"Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","route":"/trials/nct05841420/","field":"links","label":"ClinicalTrials.gov NCT05841420"}]},{"url":"https://clinicaltrials.gov/study/NCT05841472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05841472","kind":"trial","name":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas","route":"/trials/nct05841472/","field":"links","label":"ClinicalTrials.gov NCT05841472"}]},{"url":"https://clinicaltrials.gov/study/NCT05844150","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05844150","kind":"trial","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","route":"/trials/nct05844150/","field":"links","label":"ClinicalTrials.gov NCT05844150"}]},{"url":"https://clinicaltrials.gov/study/NCT05844514","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","field":"links","label":"COBRA2 (NCT05844514)"}]},{"url":"https://clinicaltrials.gov/study/NCT05845450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05845450","kind":"trial","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","route":"/trials/nct05845450/","field":"links","label":"ClinicalTrials.gov NCT05845450"}]},{"url":"https://clinicaltrials.gov/study/NCT05845814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/","field":"links","label":"ClinicalTrials.gov NCT05845814"}]},{"url":"https://clinicaltrials.gov/study/NCT05846789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05846789","kind":"trial","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","route":"/trials/nct05846789/","field":"links","label":"ClinicalTrials.gov NCT05846789"}]},{"url":"https://clinicaltrials.gov/study/NCT05846867","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05846867","kind":"trial","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","route":"/trials/nct05846867/","field":"links","label":"ClinicalTrials.gov NCT05846867"}]},{"url":"https://clinicaltrials.gov/study/NCT05849298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05849298","kind":"trial","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","route":"/trials/nct05849298/","field":"links","label":"ClinicalTrials.gov NCT05849298"}]},{"url":"https://clinicaltrials.gov/study/NCT05849480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05849480","kind":"trial","name":"A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)","route":"/trials/nct05849480/","field":"links","label":"ClinicalTrials.gov NCT05849480"}]},{"url":"https://clinicaltrials.gov/study/NCT05850234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/","field":"links","label":"ClinicalTrials.gov NCT05850234"}]},{"url":"https://clinicaltrials.gov/study/NCT05851014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05851014","kind":"trial","name":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","route":"/trials/nct05851014/","field":"links","label":"ClinicalTrials.gov NCT05851014"}]},{"url":"https://clinicaltrials.gov/study/NCT05852691","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05852691","kind":"trial","name":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05852691/","field":"links","label":"ClinicalTrials.gov NCT05852691"}]},{"url":"https://clinicaltrials.gov/study/NCT05852990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05852990","kind":"trial","name":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","route":"/trials/nct05852990/","field":"links","label":"ClinicalTrials.gov NCT05852990"}]},{"url":"https://clinicaltrials.gov/study/NCT05853575","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05853575","kind":"trial","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","route":"/trials/nct05853575/","field":"links","label":"ClinicalTrials.gov NCT05853575"}]},{"url":"https://clinicaltrials.gov/study/NCT05854498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05854498","kind":"trial","name":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05854498/","field":"links","label":"ClinicalTrials.gov NCT05854498"}]},{"url":"https://clinicaltrials.gov/study/NCT05855200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct05855200/","field":"links","label":"ClinicalTrials.gov NCT05855200"}]},{"url":"https://clinicaltrials.gov/study/NCT05859217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05859217","kind":"trial","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","route":"/trials/nct05859217/","field":"links","label":"ClinicalTrials.gov NCT05859217"}]},{"url":"https://clinicaltrials.gov/study/NCT05859750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05859750","kind":"trial","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","route":"/trials/nct05859750/","field":"links","label":"ClinicalTrials.gov NCT05859750"}]},{"url":"https://clinicaltrials.gov/study/NCT05860465","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05860465","kind":"trial","name":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05860465/","field":"links","label":"ClinicalTrials.gov NCT05860465"}]},{"url":"https://clinicaltrials.gov/study/NCT05861505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05861505","kind":"trial","name":"COLLISION RELAPSE Trial","route":"/trials/nct05861505/","field":"links","label":"ClinicalTrials.gov NCT05861505"}]},{"url":"https://clinicaltrials.gov/study/NCT05862012","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862012","kind":"trial","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","route":"/trials/nct05862012/","field":"links","label":"ClinicalTrials.gov NCT05862012"}]},{"url":"https://clinicaltrials.gov/study/NCT05862064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862064","kind":"trial","name":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem","route":"/trials/nct05862064/","field":"links","label":"ClinicalTrials.gov NCT05862064"}]},{"url":"https://clinicaltrials.gov/study/NCT05862272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/","field":"links","label":"ClinicalTrials.gov NCT05862272"}]},{"url":"https://clinicaltrials.gov/study/NCT05862285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862285","kind":"trial","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","route":"/trials/nct05862285/","field":"links","label":"ClinicalTrials.gov NCT05862285"}]},{"url":"https://clinicaltrials.gov/study/NCT05862324","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/","field":"links","label":"ClinicalTrials.gov NCT05862324"}]},{"url":"https://clinicaltrials.gov/study/NCT05862337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862337","kind":"trial","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","route":"/trials/nct05862337/","field":"links","label":"ClinicalTrials.gov NCT05862337"}]},{"url":"https://clinicaltrials.gov/study/NCT05862610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05862610","kind":"trial","name":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","route":"/trials/nct05862610/","field":"links","label":"ClinicalTrials.gov NCT05862610"}]},{"url":"https://clinicaltrials.gov/study/NCT05863195","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05863195","kind":"trial","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","route":"/trials/nct05863195/","field":"links","label":"ClinicalTrials.gov NCT05863195"}]},{"url":"https://clinicaltrials.gov/study/NCT05864014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05864014","kind":"trial","name":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","route":"/trials/nct05864014/","field":"links","label":"ClinicalTrials.gov NCT05864014"}]},{"url":"https://clinicaltrials.gov/study/NCT05864534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05864534","kind":"trial","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","route":"/trials/nct05864534/","field":"links","label":"ClinicalTrials.gov NCT05864534"}]},{"url":"https://clinicaltrials.gov/study/NCT05866432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05866432","kind":"trial","name":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","route":"/trials/nct05866432/","field":"links","label":"ClinicalTrials.gov NCT05866432"}]},{"url":"https://clinicaltrials.gov/study/NCT05867251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/","field":"links","label":"ClinicalTrials.gov NCT05867251"}]},{"url":"https://clinicaltrials.gov/study/NCT05867420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05867420","kind":"trial","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","route":"/trials/nct05867420/","field":"links","label":"ClinicalTrials.gov NCT05867420"}]},{"url":"https://clinicaltrials.gov/study/NCT05868226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05868226","kind":"trial","name":"PRE-ISPY Phase I/II Oncology Platform Program","route":"/trials/nct05868226/","field":"links","label":"ClinicalTrials.gov NCT05868226"}]},{"url":"https://clinicaltrials.gov/study/NCT05868707","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05868707","kind":"trial","name":"OH2 Injection in Melanoma","route":"/trials/nct05868707/","field":"links","label":"ClinicalTrials.gov NCT05868707"}]},{"url":"https://clinicaltrials.gov/study/NCT05870319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT05870319"},{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","route":"/trials/nct05870319/","field":"links","label":"ClinicalTrials.gov NCT05870319"}]},{"url":"https://clinicaltrials.gov/study/NCT05870748","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/","field":"links","label":"REFRαME-O1"},{"id":"nct05870748","kind":"trial","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","route":"/trials/nct05870748/","field":"links","label":"ClinicalTrials.gov NCT05870748"}]},{"url":"https://clinicaltrials.gov/study/NCT05870800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05870800","kind":"trial","name":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","route":"/trials/nct05870800/","field":"links","label":"ClinicalTrials.gov NCT05870800"}]},{"url":"https://clinicaltrials.gov/study/NCT05872347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05872347","kind":"trial","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","route":"/trials/nct05872347/","field":"links","label":"ClinicalTrials.gov NCT05872347"}]},{"url":"https://clinicaltrials.gov/study/NCT05874414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","route":"/trials/nct05874414/","field":"links","label":"ClinicalTrials.gov NCT05874414"}]},{"url":"https://clinicaltrials.gov/study/NCT05875168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05875168","kind":"trial","name":"First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors","route":"/trials/nct05875168/","field":"links","label":"ClinicalTrials.gov NCT05875168"}]},{"url":"https://clinicaltrials.gov/study/NCT05876754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05876754","kind":"trial","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","route":"/trials/nct05876754/","field":"links","label":"ClinicalTrials.gov NCT05876754"}]},{"url":"https://clinicaltrials.gov/study/NCT05877430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/","field":"links","label":"ClinicalTrials.gov NCT05877430"},{"id":"nct05877430","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","route":"/trials/nct05877430/","field":"links","label":"ClinicalTrials.gov NCT05877430"}]},{"url":"https://clinicaltrials.gov/study/NCT05879055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","route":"/trials/nct05879055/","field":"links","label":"ClinicalTrials.gov NCT05879055"}]},{"url":"https://clinicaltrials.gov/study/NCT05879068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05879068","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","route":"/trials/nct05879068/","field":"links","label":"ClinicalTrials.gov NCT05879068"}]},{"url":"https://clinicaltrials.gov/study/NCT05879822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05879822","kind":"trial","name":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","route":"/trials/nct05879822/","field":"links","label":"ClinicalTrials.gov NCT05879822"}]},{"url":"https://clinicaltrials.gov/study/NCT05880394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05880394","kind":"trial","name":"Study of Dotatate Imaging in Breast Cancer","route":"/trials/nct05880394/","field":"links","label":"ClinicalTrials.gov NCT05880394"}]},{"url":"https://clinicaltrials.gov/study/NCT05880706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/","field":"links","label":"ClinicalTrials.gov NCT05880706"}]},{"url":"https://clinicaltrials.gov/study/NCT05882058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/","field":"links","label":"ClinicalTrials.gov NCT05882058"}]},{"url":"https://clinicaltrials.gov/study/NCT05883644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05883644","kind":"trial","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct05883644/","field":"links","label":"ClinicalTrials.gov NCT05883644"}]},{"url":"https://clinicaltrials.gov/study/NCT05883956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05883956","kind":"trial","name":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","route":"/trials/nct05883956/","field":"links","label":"ClinicalTrials.gov NCT05883956"}]},{"url":"https://clinicaltrials.gov/study/NCT05884255","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/","field":"links","label":"ClinicalTrials.gov NCT05884255"}]},{"url":"https://clinicaltrials.gov/study/NCT05884398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05884398","kind":"trial","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","route":"/trials/nct05884398/","field":"links","label":"ClinicalTrials.gov NCT05884398"}]},{"url":"https://clinicaltrials.gov/study/NCT05885464","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05885464","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","route":"/trials/nct05885464/","field":"links","label":"ClinicalTrials.gov NCT05885464"}]},{"url":"https://clinicaltrials.gov/study/NCT05886920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/","field":"links","label":"ClinicalTrials.gov NCT05886920"}]},{"url":"https://clinicaltrials.gov/study/NCT05887492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/","field":"links","label":"ClinicalTrials.gov NCT05887492"}]},{"url":"https://clinicaltrials.gov/study/NCT05888493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/","field":"links","label":"ClinicalTrials.gov NCT05888493"}]},{"url":"https://clinicaltrials.gov/study/NCT05888831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05888831","kind":"trial","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","route":"/trials/nct05888831/","field":"links","label":"ClinicalTrials.gov NCT05888831"}]},{"url":"https://clinicaltrials.gov/study/NCT05890742","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/","field":"links","label":"ClinicalTrials.gov NCT05890742"},{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/","field":"links","label":"ClinicalTrials.gov NCT05890742"}]},{"url":"https://clinicaltrials.gov/study/NCT05893888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05893888","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","route":"/trials/nct05893888/","field":"links","label":"ClinicalTrials.gov NCT05893888"}]},{"url":"https://clinicaltrials.gov/study/NCT05894239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/","field":"links","label":"ClinicalTrials.gov NCT05894239"}]},{"url":"https://clinicaltrials.gov/study/NCT05898399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/","field":"links","label":"ClinicalTrials.gov NCT05898399"}]},{"url":"https://clinicaltrials.gov/study/NCT05899049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05899049","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","route":"/trials/nct05899049/","field":"links","label":"ClinicalTrials.gov NCT05899049"}]},{"url":"https://clinicaltrials.gov/study/NCT05899608","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","field":"links","label":"ClinicalTrials.gov NCT05899608"},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","field":"outcomes.source (Progression-free survival (interim analysis, May 2026))"}],"archive":"https://web.archive.org/web/20260811042107/https://clinicaltrials.gov/study/NCT05899608"},{"url":"https://clinicaltrials.gov/study/NCT05902169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05902169","kind":"trial","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","route":"/trials/nct05902169/","field":"links","label":"ClinicalTrials.gov NCT05902169"}]},{"url":"https://clinicaltrials.gov/study/NCT05902988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05902988","kind":"trial","name":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","route":"/trials/nct05902988/","field":"links","label":"ClinicalTrials.gov NCT05902988"}]},{"url":"https://clinicaltrials.gov/study/NCT05903092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05903092","kind":"trial","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","route":"/trials/nct05903092/","field":"links","label":"ClinicalTrials.gov NCT05903092"}]},{"url":"https://clinicaltrials.gov/study/NCT05903833","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","route":"/trials/nct05903833/","field":"links","label":"ClinicalTrials.gov NCT05903833"}]},{"url":"https://clinicaltrials.gov/study/NCT05904379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05904379","kind":"trial","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","route":"/trials/nct05904379/","field":"links","label":"ClinicalTrials.gov NCT05904379"}]},{"url":"https://clinicaltrials.gov/study/NCT05904886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05904886","kind":"trial","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","route":"/trials/nct05904886/","field":"links","label":"ClinicalTrials.gov NCT05904886"}]},{"url":"https://clinicaltrials.gov/study/NCT05907057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05907057","kind":"trial","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","route":"/trials/nct05907057/","field":"links","label":"ClinicalTrials.gov NCT05907057"}]},{"url":"https://clinicaltrials.gov/study/NCT05907954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/","field":"links","label":"ClinicalTrials.gov NCT05907954"}]},{"url":"https://clinicaltrials.gov/study/NCT05908409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05908409","kind":"trial","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","route":"/trials/nct05908409/","field":"links","label":"ClinicalTrials.gov NCT05908409"}]},{"url":"https://clinicaltrials.gov/study/NCT05908643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","field":"links","label":"ClinicalTrials.gov NCT05908643"}]},{"url":"https://clinicaltrials.gov/study/NCT05908734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05908734/","field":"links","label":"ClinicalTrials.gov NCT05908734"}]},{"url":"https://clinicaltrials.gov/study/NCT05909332","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05909332","kind":"trial","name":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","route":"/trials/nct05909332/","field":"links","label":"ClinicalTrials.gov NCT05909332"}]},{"url":"https://clinicaltrials.gov/study/NCT05909397","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05909397","kind":"trial","name":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","route":"/trials/nct05909397/","field":"links","label":"ClinicalTrials.gov NCT05909397"}]},{"url":"https://clinicaltrials.gov/study/NCT05909423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05909423","kind":"trial","name":"Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer","route":"/trials/nct05909423/","field":"links","label":"ClinicalTrials.gov NCT05909423"}]},{"url":"https://clinicaltrials.gov/study/NCT05909436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05909436","kind":"trial","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","route":"/trials/nct05909436/","field":"links","label":"ClinicalTrials.gov NCT05909436"}]},{"url":"https://clinicaltrials.gov/study/NCT05910827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/","field":"links","label":"ClinicalTrials.gov NCT05910827"}]},{"url":"https://clinicaltrials.gov/study/NCT05911295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05911295","kind":"trial","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","route":"/trials/nct05911295/","field":"links","label":"ClinicalTrials.gov NCT05911295"}]},{"url":"https://clinicaltrials.gov/study/NCT05913089","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/","field":"links","label":"ClinicalTrials.gov NCT05913089"}]},{"url":"https://clinicaltrials.gov/study/NCT05913674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05913674","kind":"trial","name":"Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)","route":"/trials/nct05913674/","field":"links","label":"ClinicalTrials.gov NCT05913674"}]},{"url":"https://clinicaltrials.gov/study/NCT05914116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/","field":"links","label":"ClinicalTrials.gov NCT05914116"}]},{"url":"https://clinicaltrials.gov/study/NCT05914389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05914389","kind":"trial","name":"Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","route":"/trials/nct05914389/","field":"links","label":"ClinicalTrials.gov NCT05914389"}]},{"url":"https://clinicaltrials.gov/study/NCT05917405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05917405","kind":"trial","name":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","route":"/trials/nct05917405/","field":"links","label":"ClinicalTrials.gov NCT05917405"}]},{"url":"https://clinicaltrials.gov/study/NCT05918133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05918133","kind":"trial","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct05918133/","field":"links","label":"ClinicalTrials.gov NCT05918133"}]},{"url":"https://clinicaltrials.gov/study/NCT05918302","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05918302","kind":"trial","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","route":"/trials/nct05918302/","field":"links","label":"ClinicalTrials.gov NCT05918302"}]},{"url":"https://clinicaltrials.gov/study/NCT05918445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05918445","kind":"trial","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct05918445/","field":"links","label":"ClinicalTrials.gov NCT05918445"}]},{"url":"https://clinicaltrials.gov/study/NCT05919264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05919264","kind":"trial","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05919264/","field":"links","label":"ClinicalTrials.gov NCT05919264"}]},{"url":"https://clinicaltrials.gov/study/NCT05920135","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05920135","kind":"trial","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","route":"/trials/nct05920135/","field":"links","label":"ClinicalTrials.gov NCT05920135"}]},{"url":"https://clinicaltrials.gov/study/NCT05920356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/","field":"links","label":"ClinicalTrials.gov NCT05920356"}]},{"url":"https://clinicaltrials.gov/study/NCT05923008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/","field":"links","label":"ClinicalTrials.gov NCT05923008"}]},{"url":"https://clinicaltrials.gov/study/NCT05924841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05924841","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct05924841/","field":"links","label":"ClinicalTrials.gov NCT05924841"}]},{"url":"https://clinicaltrials.gov/study/NCT05925530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05925530","kind":"trial","name":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,","route":"/trials/nct05925530/","field":"links","label":"ClinicalTrials.gov NCT05925530"}]},{"url":"https://clinicaltrials.gov/study/NCT05927142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05927142","kind":"trial","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","route":"/trials/nct05927142/","field":"links","label":"ClinicalTrials.gov NCT05927142"}]},{"url":"https://clinicaltrials.gov/study/NCT05929768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT05929768"},{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/","field":"links","label":"ClinicalTrials.gov NCT05929768"},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/","field":"links","label":"ClinicalTrials.gov NCT05929768"},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","field":"links","label":"ClinicalTrials.gov NCT05929768: SCARLET (SWOG S2212)"}]},{"url":"https://clinicaltrials.gov/study/NCT05929885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05929885","kind":"trial","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","route":"/trials/nct05929885/","field":"links","label":"ClinicalTrials.gov NCT05929885"}]},{"url":"https://clinicaltrials.gov/study/NCT05932212","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05932212","kind":"trial","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","route":"/trials/nct05932212/","field":"links","label":"ClinicalTrials.gov NCT05932212"}]},{"url":"https://clinicaltrials.gov/study/NCT05933265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/","field":"links","label":"ClinicalTrials.gov NCT05933265"},{"id":"nct05933265","kind":"trial","name":"Study of LP-184 in Patients With Advanced Solid Tumors","route":"/trials/nct05933265/","field":"links","label":"ClinicalTrials.gov NCT05933265"}]},{"url":"https://clinicaltrials.gov/study/NCT05933577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","field":"dosing.source"},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","field":"links","label":"ClinicalTrials.gov NCT05933577"},{"id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","field":"links","label":"ClinicalTrials.gov NCT05933577: INTerpath-001 (V940-001)"}]},{"url":"https://clinicaltrials.gov/study/NCT05934331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/","field":"links","label":"ClinicalTrials.gov NCT05934331"}]},{"url":"https://clinicaltrials.gov/study/NCT05934513","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","route":"/trials/nct05934513/","field":"links","label":"ClinicalTrials.gov NCT05934513"}]},{"url":"https://clinicaltrials.gov/study/NCT05936658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/","field":"links","label":"ClinicalTrials.gov NCT05936658"}]},{"url":"https://clinicaltrials.gov/study/NCT05939414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","field":"links","label":"ClinicalTrials.gov NCT05939414"}]},{"url":"https://clinicaltrials.gov/study/NCT05939661","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05939661","kind":"trial","name":"A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer","route":"/trials/nct05939661/","field":"links","label":"ClinicalTrials.gov NCT05939661"}]},{"url":"https://clinicaltrials.gov/study/NCT05939687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05939687","kind":"trial","name":"Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection","route":"/trials/nct05939687/","field":"links","label":"ClinicalTrials.gov NCT05939687"}]},{"url":"https://clinicaltrials.gov/study/NCT05941507","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/","field":"links","label":"ClinicalTrials.gov NCT05941507"}]},{"url":"https://clinicaltrials.gov/study/NCT05941897","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05941897","kind":"trial","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","route":"/trials/nct05941897/","field":"links","label":"ClinicalTrials.gov NCT05941897"}]},{"url":"https://clinicaltrials.gov/study/NCT05943106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05943106","kind":"trial","name":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","route":"/trials/nct05943106/","field":"links","label":"ClinicalTrials.gov NCT05943106"}]},{"url":"https://clinicaltrials.gov/study/NCT05943795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05943795","kind":"trial","name":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","route":"/trials/nct05943795/","field":"links","label":"ClinicalTrials.gov NCT05943795"}]},{"url":"https://clinicaltrials.gov/study/NCT05944224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05944224","kind":"trial","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","route":"/trials/nct05944224/","field":"links","label":"ClinicalTrials.gov NCT05944224"}]},{"url":"https://clinicaltrials.gov/study/NCT05944237","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05944237","kind":"trial","name":"HTL0039732 in Participants With Advanced Solid Tumours","route":"/trials/nct05944237/","field":"links","label":"ClinicalTrials.gov NCT05944237"}]},{"url":"https://clinicaltrials.gov/study/NCT05944978","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05944978","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","route":"/trials/nct05944978/","field":"links","label":"ClinicalTrials.gov NCT05944978"}]},{"url":"https://clinicaltrials.gov/study/NCT05945823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05945823","kind":"trial","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","route":"/trials/nct05945823/","field":"links","label":"ClinicalTrials.gov NCT05945823"}]},{"url":"https://clinicaltrials.gov/study/NCT05945901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05945901","kind":"trial","name":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","route":"/trials/nct05945901/","field":"links","label":"ClinicalTrials.gov NCT05945901"}]},{"url":"https://clinicaltrials.gov/study/NCT05946603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05946603","kind":"trial","name":"IS-002 Phase 2 Prostate Cancer Study","route":"/trials/nct05946603/","field":"links","label":"ClinicalTrials.gov NCT05946603"}]},{"url":"https://clinicaltrials.gov/study/NCT05947851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05947851","kind":"trial","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","route":"/trials/nct05947851/","field":"links","label":"ClinicalTrials.gov NCT05947851"}]},{"url":"https://clinicaltrials.gov/study/NCT05948475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","field":"links","label":"ClinicalTrials.gov NCT05948475: tinengotinib versus physician's choice in FGFR-altered cholangiocarcinoma (phase 3)"},{"id":"nct05948475","kind":"trial","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","route":"/trials/nct05948475/","field":"links","label":"ClinicalTrials.gov NCT05948475"}]},{"url":"https://clinicaltrials.gov/study/NCT05948813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","field":"links","label":"ClinicalTrials.gov NCT05948813"}]},{"url":"https://clinicaltrials.gov/study/NCT05948943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","route":"/trials/nct05948943/","field":"links","label":"ClinicalTrials.gov NCT05948943"}]},{"url":"https://clinicaltrials.gov/study/NCT05949606","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05949606","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05949606/","field":"links","label":"ClinicalTrials.gov NCT05949606"}]},{"url":"https://clinicaltrials.gov/study/NCT05949619","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05949619","kind":"trial","name":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","route":"/trials/nct05949619/","field":"links","label":"ClinicalTrials.gov NCT05949619"}]},{"url":"https://clinicaltrials.gov/study/NCT05950139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05950139","kind":"trial","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","route":"/trials/nct05950139/","field":"links","label":"ClinicalTrials.gov NCT05950139"}]},{"url":"https://clinicaltrials.gov/study/NCT05950165","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05950165","kind":"trial","name":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly","route":"/trials/nct05950165/","field":"links","label":"ClinicalTrials.gov NCT05950165"}]},{"url":"https://clinicaltrials.gov/study/NCT05950945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05950945","kind":"trial","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","route":"/trials/nct05950945/","field":"links","label":"ClinicalTrials.gov NCT05950945"}]},{"url":"https://clinicaltrials.gov/study/NCT05951179","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/","field":"links","label":"ClinicalTrials.gov NCT05951179"}]},{"url":"https://clinicaltrials.gov/study/NCT05951608","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05951608","kind":"trial","name":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05951608/","field":"links","label":"ClinicalTrials.gov NCT05951608"}]},{"url":"https://clinicaltrials.gov/study/NCT05951959","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","route":"/trials/nct05951959/","field":"links","label":"ClinicalTrials.gov NCT05951959"}]},{"url":"https://clinicaltrials.gov/study/NCT05952024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","route":"/trials/nct05952024/","field":"links","label":"ClinicalTrials.gov NCT05952024"}]},{"url":"https://clinicaltrials.gov/study/NCT05952037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05952037","kind":"trial","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","route":"/trials/nct05952037/","field":"links","label":"ClinicalTrials.gov NCT05952037"}]},{"url":"https://clinicaltrials.gov/study/NCT05952557","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","field":"links","label":"ClinicalTrials.gov NCT05952557"}]},{"url":"https://clinicaltrials.gov/study/NCT05953181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","field":"links","label":"ClinicalTrials.gov NCT05953181: SANO"},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","field":"links","label":"ClinicalTrials.gov NCT05953181"},{"id":"idea-organ-preservation-esophageal","kind":"idea","name":"Organ preservation as the default after complete response in oesophageal cancer","route":"/ideas/idea-organ-preservation-esophageal/","field":"links","label":"ClinicalTrials.gov NCT05953181: SANO"}]},{"url":"https://clinicaltrials.gov/study/NCT05954078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05954078","kind":"trial","name":"Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer","route":"/trials/nct05954078/","field":"links","label":"ClinicalTrials.gov NCT05954078"}]},{"url":"https://clinicaltrials.gov/study/NCT05954429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05954429","kind":"trial","name":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente","route":"/trials/nct05954429/","field":"links","label":"ClinicalTrials.gov NCT05954429"}]},{"url":"https://clinicaltrials.gov/study/NCT05955391","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT05955391"},{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/","field":"links","label":"ClinicalTrials.gov NCT05955391"}]},{"url":"https://clinicaltrials.gov/study/NCT05955508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/","field":"links","label":"ClinicalTrials.gov NCT05955508"}]},{"url":"https://clinicaltrials.gov/study/NCT05956587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05956587","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","route":"/trials/nct05956587/","field":"links","label":"ClinicalTrials.gov NCT05956587"}]},{"url":"https://clinicaltrials.gov/study/NCT05957367","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","field":"links","label":"ClinicalTrials.gov NCT05957367"}]},{"url":"https://clinicaltrials.gov/study/NCT05958121","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct05958121/","field":"links","label":"ClinicalTrials.gov NCT05958121"}]},{"url":"https://clinicaltrials.gov/study/NCT05959356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05959356","kind":"trial","name":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","route":"/trials/nct05959356/","field":"links","label":"ClinicalTrials.gov NCT05959356"}]},{"url":"https://clinicaltrials.gov/study/NCT05962502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05962502","kind":"trial","name":"Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy","route":"/trials/nct05962502/","field":"links","label":"ClinicalTrials.gov NCT05962502"}]},{"url":"https://clinicaltrials.gov/study/NCT05963074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct05963074/","field":"links","label":"ClinicalTrials.gov NCT05963074"}]},{"url":"https://clinicaltrials.gov/study/NCT05963490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05963490","kind":"trial","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","route":"/trials/nct05963490/","field":"links","label":"ClinicalTrials.gov NCT05963490"}]},{"url":"https://clinicaltrials.gov/study/NCT05965531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05965531","kind":"trial","name":"Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy","route":"/trials/nct05965531/","field":"links","label":"ClinicalTrials.gov NCT05965531"}]},{"url":"https://clinicaltrials.gov/study/NCT05965856","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05965856","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","route":"/trials/nct05965856/","field":"links","label":"ClinicalTrials.gov NCT05965856"}]},{"url":"https://clinicaltrials.gov/study/NCT05966194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/","field":"links","label":"ClinicalTrials.gov NCT05966194"}]},{"url":"https://clinicaltrials.gov/study/NCT05967689","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/","field":"links","label":"ClinicalTrials.gov NCT05967689"}]},{"url":"https://clinicaltrials.gov/study/NCT05968326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/","field":"links","label":"ClinicalTrials.gov NCT05968326"},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","field":"dosing.source"},{"id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/","field":"links","label":"ClinicalTrials.gov NCT05968326"}]},{"url":"https://clinicaltrials.gov/study/NCT05969171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05969171","kind":"trial","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","route":"/trials/nct05969171/","field":"links","label":"ClinicalTrials.gov NCT05969171"}]},{"url":"https://clinicaltrials.gov/study/NCT05969847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05969847","kind":"trial","name":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","route":"/trials/nct05969847/","field":"links","label":"ClinicalTrials.gov NCT05969847"}]},{"url":"https://clinicaltrials.gov/study/NCT05969860","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05969860","kind":"trial","name":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","route":"/trials/nct05969860/","field":"links","label":"ClinicalTrials.gov NCT05969860"}]},{"url":"https://clinicaltrials.gov/study/NCT05970016","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05970016","kind":"trial","name":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","route":"/trials/nct05970016/","field":"links","label":"ClinicalTrials.gov NCT05970016"}]},{"url":"https://clinicaltrials.gov/study/NCT05970497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05970497/","field":"links","label":"ClinicalTrials.gov NCT05970497"}]},{"url":"https://clinicaltrials.gov/study/NCT05972655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05972655","kind":"trial","name":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","route":"/trials/nct05972655/","field":"links","label":"ClinicalTrials.gov NCT05972655"}]},{"url":"https://clinicaltrials.gov/study/NCT05973773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","route":"/trials/nct05973773/","field":"links","label":"ClinicalTrials.gov NCT05973773"}]},{"url":"https://clinicaltrials.gov/study/NCT05973864","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05973864","kind":"trial","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","route":"/trials/nct05973864/","field":"links","label":"ClinicalTrials.gov NCT05973864"}]},{"url":"https://clinicaltrials.gov/study/NCT05978284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct05978284/","field":"links","label":"ClinicalTrials.gov NCT05978284"}]},{"url":"https://clinicaltrials.gov/study/NCT05980481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05980481","kind":"trial","name":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","route":"/trials/nct05980481/","field":"links","label":"ClinicalTrials.gov NCT05980481"}]},{"url":"https://clinicaltrials.gov/study/NCT05984277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/","field":"links","label":"ClinicalTrials.gov NCT05984277"}]},{"url":"https://clinicaltrials.gov/study/NCT05984485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05984485","kind":"trial","name":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca","route":"/trials/nct05984485/","field":"links","label":"ClinicalTrials.gov NCT05984485"}]},{"url":"https://clinicaltrials.gov/study/NCT05984810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05984810","kind":"trial","name":"NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101","route":"/trials/nct05984810/","field":"links","label":"ClinicalTrials.gov NCT05984810"}]},{"url":"https://clinicaltrials.gov/study/NCT05985109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05985109","kind":"trial","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","route":"/trials/nct05985109/","field":"links","label":"ClinicalTrials.gov NCT05985109"}]},{"url":"https://clinicaltrials.gov/study/NCT05985655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/","field":"links","label":"ClinicalTrials.gov NCT05985655"}]},{"url":"https://clinicaltrials.gov/study/NCT05985707","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05985707","kind":"trial","name":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","route":"/trials/nct05985707/","field":"links","label":"ClinicalTrials.gov NCT05985707"}]},{"url":"https://clinicaltrials.gov/study/NCT05986851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05986851","kind":"trial","name":"Azeliragon in MGMT Unmethylated Glioblastoma","route":"/trials/nct05986851/","field":"links","label":"ClinicalTrials.gov NCT05986851"}]},{"url":"https://clinicaltrials.gov/study/NCT05987332","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/","field":"links","label":"ClinicalTrials.gov NCT05987332"}]},{"url":"https://clinicaltrials.gov/study/NCT05987358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05987358","kind":"trial","name":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma","route":"/trials/nct05987358/","field":"links","label":"ClinicalTrials.gov NCT05987358"}]},{"url":"https://clinicaltrials.gov/study/NCT05987644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05987644","kind":"trial","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","route":"/trials/nct05987644/","field":"links","label":"ClinicalTrials.gov NCT05987644"}]},{"url":"https://clinicaltrials.gov/study/NCT05987956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05987956","kind":"trial","name":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","route":"/trials/nct05987956/","field":"links","label":"ClinicalTrials.gov NCT05987956"}]},{"url":"https://clinicaltrials.gov/study/NCT05988372","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05988372","kind":"trial","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","route":"/trials/nct05988372/","field":"links","label":"ClinicalTrials.gov NCT05988372"}]},{"url":"https://clinicaltrials.gov/study/NCT05988814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05988814","kind":"trial","name":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Li","route":"/trials/nct05988814/","field":"links","label":"ClinicalTrials.gov NCT05988814"}]},{"url":"https://clinicaltrials.gov/study/NCT05989542","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05989542","kind":"trial","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","route":"/trials/nct05989542/","field":"links","label":"ClinicalTrials.gov NCT05989542"}]},{"url":"https://clinicaltrials.gov/study/NCT05990127","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05990127","kind":"trial","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","route":"/trials/nct05990127/","field":"links","label":"ClinicalTrials.gov NCT05990127"}]},{"url":"https://clinicaltrials.gov/study/NCT05990452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","route":"/trials/nct05990452/","field":"links","label":"ClinicalTrials.gov NCT05990452"}]},{"url":"https://clinicaltrials.gov/study/NCT05990803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05990803","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","route":"/trials/nct05990803/","field":"links","label":"ClinicalTrials.gov NCT05990803"}]},{"url":"https://clinicaltrials.gov/study/NCT05991583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05991583","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","route":"/trials/nct05991583/","field":"links","label":"ClinicalTrials.gov NCT05991583"}]},{"url":"https://clinicaltrials.gov/study/NCT05994001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05994001","kind":"trial","name":"Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody","route":"/trials/nct05994001/","field":"links","label":"ClinicalTrials.gov NCT05994001"}]},{"url":"https://clinicaltrials.gov/study/NCT05994131","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","route":"/trials/nct05994131/","field":"links","label":"ClinicalTrials.gov NCT05994131"}]},{"url":"https://clinicaltrials.gov/study/NCT05997017","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05997017","kind":"trial","name":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","route":"/trials/nct05997017/","field":"links","label":"ClinicalTrials.gov NCT05997017"}]},{"url":"https://clinicaltrials.gov/study/NCT05998122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05998122","kind":"trial","name":"Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A","route":"/trials/nct05998122/","field":"links","label":"ClinicalTrials.gov NCT05998122"}]},{"url":"https://clinicaltrials.gov/study/NCT05999149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05999149","kind":"trial","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC","route":"/trials/nct05999149/","field":"links","label":"ClinicalTrials.gov NCT05999149"}]},{"url":"https://clinicaltrials.gov/study/NCT05999994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/","field":"links","label":"ClinicalTrials.gov NCT05999994"}]},{"url":"https://clinicaltrials.gov/study/NCT06001658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06001658","kind":"trial","name":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","route":"/trials/nct06001658/","field":"links","label":"ClinicalTrials.gov NCT06001658"}]},{"url":"https://clinicaltrials.gov/study/NCT06002789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06002789","kind":"trial","name":"Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC","route":"/trials/nct06002789/","field":"links","label":"ClinicalTrials.gov NCT06002789"}]},{"url":"https://clinicaltrials.gov/study/NCT06003231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06003231","kind":"trial","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","route":"/trials/nct06003231/","field":"links","label":"ClinicalTrials.gov NCT06003231"}]},{"url":"https://clinicaltrials.gov/study/NCT06004661","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/","field":"links","label":"ClinicalTrials.gov NCT06004661"}]},{"url":"https://clinicaltrials.gov/study/NCT06005493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","field":"links","label":"ClinicalTrials.gov NCT06005493"}]},{"url":"https://clinicaltrials.gov/study/NCT06006169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06006169","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor","route":"/trials/nct06006169/","field":"links","label":"ClinicalTrials.gov NCT06006169"}]},{"url":"https://clinicaltrials.gov/study/NCT06007690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/","field":"links","label":"ClinicalTrials.gov NCT06007690"}]},{"url":"https://clinicaltrials.gov/study/NCT06007729","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06007729","kind":"trial","name":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06007729/","field":"links","label":"ClinicalTrials.gov NCT06007729"}]},{"url":"https://clinicaltrials.gov/study/NCT06008054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06008054","kind":"trial","name":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ","route":"/trials/nct06008054/","field":"links","label":"ClinicalTrials.gov NCT06008054"}]},{"url":"https://clinicaltrials.gov/study/NCT06008093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06008093","kind":"trial","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","route":"/trials/nct06008093/","field":"links","label":"ClinicalTrials.gov NCT06008093"}]},{"url":"https://clinicaltrials.gov/study/NCT06008106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","route":"/trials/nct06008106/","field":"links","label":"ClinicalTrials.gov NCT06008106"}]},{"url":"https://clinicaltrials.gov/study/NCT06008119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06008119","kind":"trial","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","route":"/trials/nct06008119/","field":"links","label":"ClinicalTrials.gov NCT06008119"}]},{"url":"https://clinicaltrials.gov/study/NCT06008288","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06008288","kind":"trial","name":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","route":"/trials/nct06008288/","field":"links","label":"ClinicalTrials.gov NCT06008288"}]},{"url":"https://clinicaltrials.gov/study/NCT06009029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06009029","kind":"trial","name":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","route":"/trials/nct06009029/","field":"links","label":"ClinicalTrials.gov NCT06009029"}]},{"url":"https://clinicaltrials.gov/study/NCT06010329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/","field":"links","label":"ClinicalTrials.gov NCT06010329"}]},{"url":"https://clinicaltrials.gov/study/NCT06010342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06010342","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","route":"/trials/nct06010342/","field":"links","label":"ClinicalTrials.gov NCT06010342"}]},{"url":"https://clinicaltrials.gov/study/NCT06011109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","route":"/trials/nct06011109/","field":"links","label":"ClinicalTrials.gov NCT06011109"}]},{"url":"https://clinicaltrials.gov/study/NCT06012435","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06012435","kind":"trial","name":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","route":"/trials/nct06012435/","field":"links","label":"ClinicalTrials.gov NCT06012435"}]},{"url":"https://clinicaltrials.gov/study/NCT06012695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","route":"/trials/nct06012695/","field":"links","label":"ClinicalTrials.gov NCT06012695"}]},{"url":"https://clinicaltrials.gov/study/NCT06014190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/","field":"links","label":"ClinicalTrials.gov NCT06014190"}]},{"url":"https://clinicaltrials.gov/study/NCT06014528","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","route":"/trials/nct06014528/","field":"links","label":"ClinicalTrials.gov NCT06014528"}]},{"url":"https://clinicaltrials.gov/study/NCT06014658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06014658","kind":"trial","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","route":"/trials/nct06014658/","field":"links","label":"ClinicalTrials.gov NCT06014658"}]},{"url":"https://clinicaltrials.gov/study/NCT06014944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06014944","kind":"trial","name":"Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody","route":"/trials/nct06014944/","field":"links","label":"ClinicalTrials.gov NCT06014944"}]},{"url":"https://clinicaltrials.gov/study/NCT06015048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06015048","kind":"trial","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","route":"/trials/nct06015048/","field":"links","label":"ClinicalTrials.gov NCT06015048"}]},{"url":"https://clinicaltrials.gov/study/NCT06015503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT06015503"},{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct06015503/","field":"links","label":"ClinicalTrials.gov NCT06015503"}]},{"url":"https://clinicaltrials.gov/study/NCT06016062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06016062","kind":"trial","name":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct06016062/","field":"links","label":"ClinicalTrials.gov NCT06016062"}]},{"url":"https://clinicaltrials.gov/study/NCT06016738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06016738","kind":"trial","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct06016738/","field":"links","label":"ClinicalTrials.gov NCT06016738"}]},{"url":"https://clinicaltrials.gov/study/NCT06016920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06016920","kind":"trial","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","route":"/trials/nct06016920/","field":"links","label":"ClinicalTrials.gov NCT06016920"}]},{"url":"https://clinicaltrials.gov/study/NCT06017284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06017284","kind":"trial","name":"Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer","route":"/trials/nct06017284/","field":"links","label":"ClinicalTrials.gov NCT06017284"}]},{"url":"https://clinicaltrials.gov/study/NCT06018337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06018337","kind":"trial","name":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre","route":"/trials/nct06018337/","field":"links","label":"ClinicalTrials.gov NCT06018337"}]},{"url":"https://clinicaltrials.gov/study/NCT06022861","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06022861","kind":"trial","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct06022861/","field":"links","label":"ClinicalTrials.gov NCT06022861"}]},{"url":"https://clinicaltrials.gov/study/NCT06028074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06028074","kind":"trial","name":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","route":"/trials/nct06028074/","field":"links","label":"ClinicalTrials.gov NCT06028074"}]},{"url":"https://clinicaltrials.gov/study/NCT06028633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06028633","kind":"trial","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","route":"/trials/nct06028633/","field":"links","label":"ClinicalTrials.gov NCT06028633"}]},{"url":"https://clinicaltrials.gov/study/NCT06030258","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06030258","kind":"trial","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","route":"/trials/nct06030258/","field":"links","label":"ClinicalTrials.gov NCT06030258"}]},{"url":"https://clinicaltrials.gov/study/NCT06030622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06030622","kind":"trial","name":"Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer","route":"/trials/nct06030622/","field":"links","label":"ClinicalTrials.gov NCT06030622"}]},{"url":"https://clinicaltrials.gov/study/NCT06031181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06031181","kind":"trial","name":"Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)","route":"/trials/nct06031181/","field":"links","label":"ClinicalTrials.gov NCT06031181"}]},{"url":"https://clinicaltrials.gov/study/NCT06031246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06031246","kind":"trial","name":"Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","route":"/trials/nct06031246/","field":"links","label":"ClinicalTrials.gov NCT06031246"}]},{"url":"https://clinicaltrials.gov/study/NCT06031558","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06031558","kind":"trial","name":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","route":"/trials/nct06031558/","field":"links","label":"ClinicalTrials.gov NCT06031558"}]},{"url":"https://clinicaltrials.gov/study/NCT06031584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06031584","kind":"trial","name":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","route":"/trials/nct06031584/","field":"links","label":"ClinicalTrials.gov NCT06031584"}]},{"url":"https://clinicaltrials.gov/study/NCT06033586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06033586","kind":"trial","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","route":"/trials/nct06033586/","field":"links","label":"ClinicalTrials.gov NCT06033586"}]},{"url":"https://clinicaltrials.gov/study/NCT06035497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/","field":"links","label":"ClinicalTrials.gov NCT06035497"}]},{"url":"https://clinicaltrials.gov/study/NCT06037655","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06037655","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC","route":"/trials/nct06037655/","field":"links","label":"ClinicalTrials.gov NCT06037655"}]},{"url":"https://clinicaltrials.gov/study/NCT06037941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","field":"links","label":"MSK e-nose study (NCT06037941)"}]},{"url":"https://clinicaltrials.gov/study/NCT06037980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06037980","kind":"trial","name":"CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence","route":"/trials/nct06037980/","field":"links","label":"ClinicalTrials.gov NCT06037980"}]},{"url":"https://clinicaltrials.gov/study/NCT06038396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct06038396/","field":"links","label":"ClinicalTrials.gov NCT06038396"}]},{"url":"https://clinicaltrials.gov/study/NCT06038578","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06038578","kind":"trial","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","route":"/trials/nct06038578/","field":"links","label":"ClinicalTrials.gov NCT06038578"}]},{"url":"https://clinicaltrials.gov/study/NCT06040099","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06040099","kind":"trial","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","route":"/trials/nct06040099/","field":"links","label":"ClinicalTrials.gov NCT06040099"}]},{"url":"https://clinicaltrials.gov/study/NCT06040541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","field":"links","label":"ClinicalTrials.gov NCT06040541 (RMC-9805-001)"},{"id":"nct06040541","kind":"trial","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","route":"/trials/nct06040541/","field":"links","label":"ClinicalTrials.gov NCT06040541"}],"archive":"https://web.archive.org/web/20260710112447/https://clinicaltrials.gov/study/NCT06040541"},{"url":"https://clinicaltrials.gov/study/NCT06041061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06041061","kind":"trial","name":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","route":"/trials/nct06041061/","field":"links","label":"ClinicalTrials.gov NCT06041061"}]},{"url":"https://clinicaltrials.gov/study/NCT06041776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/","field":"links","label":"ClinicalTrials.gov NCT06041776"}]},{"url":"https://clinicaltrials.gov/study/NCT06041802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","route":"/trials/nct06041802/","field":"links","label":"ClinicalTrials.gov NCT06041802"}]},{"url":"https://clinicaltrials.gov/study/NCT06042894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06042894","kind":"trial","name":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","route":"/trials/nct06042894/","field":"links","label":"ClinicalTrials.gov NCT06042894"}]},{"url":"https://clinicaltrials.gov/study/NCT06043817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/","field":"links","label":"ClinicalTrials.gov NCT06043817"}]},{"url":"https://clinicaltrials.gov/study/NCT06043973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06043973","kind":"trial","name":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","route":"/trials/nct06043973/","field":"links","label":"ClinicalTrials.gov NCT06043973"}]},{"url":"https://clinicaltrials.gov/study/NCT06044623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06044623","kind":"trial","name":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","route":"/trials/nct06044623/","field":"links","label":"ClinicalTrials.gov NCT06044623"}]},{"url":"https://clinicaltrials.gov/study/NCT06045767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06045767","kind":"trial","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","route":"/trials/nct06045767/","field":"links","label":"ClinicalTrials.gov NCT06045767"}]},{"url":"https://clinicaltrials.gov/study/NCT06045806","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06045806","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","route":"/trials/nct06045806/","field":"links","label":"ClinicalTrials.gov NCT06045806"}]},{"url":"https://clinicaltrials.gov/study/NCT06047015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06047015","kind":"trial","name":"Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","route":"/trials/nct06047015/","field":"links","label":"ClinicalTrials.gov NCT06047015"}]},{"url":"https://clinicaltrials.gov/study/NCT06047379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/","field":"links","label":"ClinicalTrials.gov NCT06047379"}]},{"url":"https://clinicaltrials.gov/study/NCT06048133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06048133","kind":"trial","name":"Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)","route":"/trials/nct06048133/","field":"links","label":"ClinicalTrials.gov NCT06048133"}]},{"url":"https://clinicaltrials.gov/study/NCT06048315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06048315","kind":"trial","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","route":"/trials/nct06048315/","field":"links","label":"ClinicalTrials.gov NCT06048315"}]},{"url":"https://clinicaltrials.gov/study/NCT06049290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct06049290/","field":"links","label":"ClinicalTrials.gov NCT06049290"}]},{"url":"https://clinicaltrials.gov/study/NCT06050122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","field":"links","label":"ClinicalTrials.gov NCT06050122"}]},{"url":"https://clinicaltrials.gov/study/NCT06050317","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06050317","kind":"trial","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/","field":"links","label":"ClinicalTrials.gov NCT06050317"}]},{"url":"https://clinicaltrials.gov/study/NCT06051409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06051409","kind":"trial","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","route":"/trials/nct06051409/","field":"links","label":"ClinicalTrials.gov NCT06051409"}]},{"url":"https://clinicaltrials.gov/study/NCT06051695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/","field":"links","label":"ClinicalTrials.gov NCT06051695"}]},{"url":"https://clinicaltrials.gov/study/NCT06052826","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06052826","kind":"trial","name":"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study","route":"/trials/nct06052826/","field":"links","label":"ClinicalTrials.gov NCT06052826"}]},{"url":"https://clinicaltrials.gov/study/NCT06054555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","route":"/trials/nct06054555/","field":"links","label":"ClinicalTrials.gov NCT06054555"}]},{"url":"https://clinicaltrials.gov/study/NCT06055439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06055439","kind":"trial","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","route":"/trials/nct06055439/","field":"links","label":"ClinicalTrials.gov NCT06055439"}]},{"url":"https://clinicaltrials.gov/study/NCT06055959","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06055959","kind":"trial","name":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","route":"/trials/nct06055959/","field":"links","label":"ClinicalTrials.gov NCT06055959"}]},{"url":"https://clinicaltrials.gov/study/NCT06056830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06056830","kind":"trial","name":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","route":"/trials/nct06056830/","field":"links","label":"ClinicalTrials.gov NCT06056830"}]},{"url":"https://clinicaltrials.gov/study/NCT06057610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06057610","kind":"trial","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct06057610/","field":"links","label":"ClinicalTrials.gov NCT06057610"}]},{"url":"https://clinicaltrials.gov/study/NCT06057831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06057831","kind":"trial","name":"PET/MRI in Rectal Cancer","route":"/trials/nct06057831/","field":"links","label":"ClinicalTrials.gov NCT06057831"}]},{"url":"https://clinicaltrials.gov/study/NCT06057922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06057922","kind":"trial","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","route":"/trials/nct06057922/","field":"links","label":"ClinicalTrials.gov NCT06057922"}]},{"url":"https://clinicaltrials.gov/study/NCT06060613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","route":"/trials/nct06060613/","field":"links","label":"ClinicalTrials.gov NCT06060613"}]},{"url":"https://clinicaltrials.gov/study/NCT06061809","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","route":"/trials/nct06061809/","field":"links","label":"ClinicalTrials.gov NCT06061809"}]},{"url":"https://clinicaltrials.gov/study/NCT06062420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06062420","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","route":"/trials/nct06062420/","field":"links","label":"ClinicalTrials.gov NCT06062420"}]},{"url":"https://clinicaltrials.gov/study/NCT06062810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06062810","kind":"trial","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","route":"/trials/nct06062810/","field":"links","label":"ClinicalTrials.gov NCT06062810"}]},{"url":"https://clinicaltrials.gov/study/NCT06064812","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06064812","kind":"trial","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","route":"/trials/nct06064812/","field":"links","label":"ClinicalTrials.gov NCT06064812"}]},{"url":"https://clinicaltrials.gov/study/NCT06064877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/","field":"links","label":"ClinicalTrials.gov NCT06064877"}]},{"url":"https://clinicaltrials.gov/study/NCT06065748","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06065748","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","route":"/trials/nct06065748/","field":"links","label":"ClinicalTrials.gov NCT06065748"}]},{"url":"https://clinicaltrials.gov/study/NCT06066203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06066203","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","route":"/trials/nct06066203/","field":"links","label":"ClinicalTrials.gov NCT06066203"}]},{"url":"https://clinicaltrials.gov/study/NCT06072131","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/","field":"links","label":"ClinicalTrials.gov NCT06072131"}]},{"url":"https://clinicaltrials.gov/study/NCT06072612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/","field":"links","label":"ClinicalTrials.gov NCT06072612"}]},{"url":"https://clinicaltrials.gov/study/NCT06072781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/","field":"links","label":"ClinicalTrials.gov NCT06072781"}]},{"url":"https://clinicaltrials.gov/study/NCT06073821","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","route":"/trials/celestial-tncll/","field":"links","label":"ClinicalTrials.gov NCT06073821"},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","field":"links","label":"ClinicalTrials.gov NCT06073821: CELESTIAL-TNCLL"}]},{"url":"https://clinicaltrials.gov/study/NCT06074588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/","field":"links","label":"ClinicalTrials.gov NCT06074588"}]},{"url":"https://clinicaltrials.gov/study/NCT06075264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06075264","kind":"trial","name":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","route":"/trials/nct06075264/","field":"links","label":"ClinicalTrials.gov NCT06075264"}]},{"url":"https://clinicaltrials.gov/study/NCT06077760","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/","field":"links","label":"ClinicalTrials.gov NCT06077760"}]},{"url":"https://clinicaltrials.gov/study/NCT06077877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06077877","kind":"trial","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","route":"/trials/nct06077877/","field":"links","label":"ClinicalTrials.gov NCT06077877"}]},{"url":"https://clinicaltrials.gov/study/NCT06078384","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06078384","kind":"trial","name":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","route":"/trials/nct06078384/","field":"links","label":"ClinicalTrials.gov NCT06078384"}]},{"url":"https://clinicaltrials.gov/study/NCT06079112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06079112","kind":"trial","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06079112/","field":"links","label":"ClinicalTrials.gov NCT06079112"}]},{"url":"https://clinicaltrials.gov/study/NCT06079346","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06079346","kind":"trial","name":"A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct06079346/","field":"links","label":"ClinicalTrials.gov NCT06079346"}]},{"url":"https://clinicaltrials.gov/study/NCT06079671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","field":"links","label":"ClinicalTrials.gov NCT06079671"}]},{"url":"https://clinicaltrials.gov/study/NCT06079983","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","route":"/trials/nct06079983/","field":"links","label":"ClinicalTrials.gov NCT06079983"}]},{"url":"https://clinicaltrials.gov/study/NCT06080776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/","field":"links","label":"ClinicalTrials.gov NCT06080776"}]},{"url":"https://clinicaltrials.gov/study/NCT06081244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/","field":"links","label":"ClinicalTrials.gov NCT06081244"}]},{"url":"https://clinicaltrials.gov/study/NCT06081920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/","field":"links","label":"ClinicalTrials.gov NCT06081920"}]},{"url":"https://clinicaltrials.gov/study/NCT06081959","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06081959","kind":"trial","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06081959/","field":"links","label":"ClinicalTrials.gov NCT06081959"}]},{"url":"https://clinicaltrials.gov/study/NCT06082102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/","field":"links","label":"ClinicalTrials.gov NCT06082102"}]},{"url":"https://clinicaltrials.gov/study/NCT06082167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/","field":"links","label":"ClinicalTrials.gov NCT06082167"}]},{"url":"https://clinicaltrials.gov/study/NCT06082635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsclc-3","kind":"trial","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-3/","field":"links","label":"ClinicalTrials.gov NCT06082635"}]},{"url":"https://clinicaltrials.gov/study/NCT06083207","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06083207/","field":"links","label":"ClinicalTrials.gov NCT06083207"}]},{"url":"https://clinicaltrials.gov/study/NCT06084806","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","route":"/trials/nct06084806/","field":"links","label":"ClinicalTrials.gov NCT06084806"}]},{"url":"https://clinicaltrials.gov/study/NCT06084884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","route":"/trials/nct06084884/","field":"links","label":"ClinicalTrials.gov NCT06084884"}]},{"url":"https://clinicaltrials.gov/study/NCT06084936","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06084936","kind":"trial","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct06084936/","field":"links","label":"ClinicalTrials.gov NCT06084936"}]},{"url":"https://clinicaltrials.gov/study/NCT06087653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/","field":"links","label":"ClinicalTrials.gov NCT06087653"}]},{"url":"https://clinicaltrials.gov/study/NCT06088004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06088004","kind":"trial","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","route":"/trials/nct06088004/","field":"links","label":"ClinicalTrials.gov NCT06088004"}]},{"url":"https://clinicaltrials.gov/study/NCT06088290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/","field":"links","label":"ClinicalTrials.gov NCT06088290"}]},{"url":"https://clinicaltrials.gov/study/NCT06090266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06090266","kind":"trial","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","route":"/trials/nct06090266/","field":"links","label":"ClinicalTrials.gov NCT06090266"}]},{"url":"https://clinicaltrials.gov/study/NCT06090539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06090539","kind":"trial","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","route":"/trials/nct06090539/","field":"links","label":"ClinicalTrials.gov NCT06090539"}]},{"url":"https://clinicaltrials.gov/study/NCT06091254","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/","field":"links","label":"ClinicalTrials.gov NCT06091254"}]},{"url":"https://clinicaltrials.gov/study/NCT06091865","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/","field":"links","label":"ClinicalTrials.gov NCT06091865"}]},{"url":"https://clinicaltrials.gov/study/NCT06092242","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06092242","kind":"trial","name":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer","route":"/trials/nct06092242/","field":"links","label":"ClinicalTrials.gov NCT06092242"}]},{"url":"https://clinicaltrials.gov/study/NCT06093672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06093672","kind":"trial","name":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","route":"/trials/nct06093672/","field":"links","label":"ClinicalTrials.gov NCT06093672"}]},{"url":"https://clinicaltrials.gov/study/NCT06093841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/","field":"links","label":"ClinicalTrials.gov NCT06093841"}]},{"url":"https://clinicaltrials.gov/study/NCT06095141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06095141","kind":"trial","name":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","route":"/trials/nct06095141/","field":"links","label":"ClinicalTrials.gov NCT06095141"}]},{"url":"https://clinicaltrials.gov/study/NCT06095505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/","field":"links","label":"ClinicalTrials.gov NCT06095505"}]},{"url":"https://clinicaltrials.gov/study/NCT06095583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/","field":"links","label":"ClinicalTrials.gov NCT06095583"}]},{"url":"https://clinicaltrials.gov/study/NCT06096779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","route":"/trials/nct06096779/","field":"links","label":"ClinicalTrials.gov NCT06096779"}]},{"url":"https://clinicaltrials.gov/study/NCT06096844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06096844","kind":"trial","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","route":"/trials/nct06096844/","field":"links","label":"ClinicalTrials.gov NCT06096844"}]},{"url":"https://clinicaltrials.gov/study/NCT06097364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/","field":"links","label":"ClinicalTrials.gov NCT06097364"}]},{"url":"https://clinicaltrials.gov/study/NCT06097416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06097416","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer","route":"/trials/nct06097416/","field":"links","label":"ClinicalTrials.gov NCT06097416"}]},{"url":"https://clinicaltrials.gov/study/NCT06097728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06097728","kind":"trial","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","route":"/trials/nct06097728/","field":"links","label":"ClinicalTrials.gov NCT06097728"}]},{"url":"https://clinicaltrials.gov/study/NCT06099769","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06099769","kind":"trial","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","route":"/trials/nct06099769/","field":"links","label":"ClinicalTrials.gov NCT06099769"}]},{"url":"https://clinicaltrials.gov/study/NCT06099782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06099782-jco-oncol-pract-2026","kind":"paper","name":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","route":"/key-papers/paper-nct06099782-jco-oncol-pract-2026/","field":"links","label":"ClinicalTrials.gov NCT06099782"},{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","route":"/trials/nct06099782/","field":"links","label":"ClinicalTrials.gov NCT06099782"}]},{"url":"https://clinicaltrials.gov/study/NCT06099782?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","route":"/trials/nct06099782/","field":"outcomes.source (Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT06099951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06099951","kind":"trial","name":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","route":"/trials/nct06099951/","field":"links","label":"ClinicalTrials.gov NCT06099951"}]},{"url":"https://clinicaltrials.gov/study/NCT06101134","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06101134","kind":"trial","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","route":"/trials/nct06101134/","field":"links","label":"ClinicalTrials.gov NCT06101134"}]},{"url":"https://clinicaltrials.gov/study/NCT06101134?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06101134","kind":"trial","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","route":"/trials/nct06101134/","field":"outcomes.source (Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose)"}]},{"url":"https://clinicaltrials.gov/study/NCT06102057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06102057","kind":"trial","name":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","route":"/trials/nct06102057/","field":"links","label":"ClinicalTrials.gov NCT06102057"}]},{"url":"https://clinicaltrials.gov/study/NCT06102161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06102161","kind":"trial","name":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","route":"/trials/nct06102161/","field":"links","label":"ClinicalTrials.gov NCT06102161"}]},{"url":"https://clinicaltrials.gov/study/NCT06103864","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06103864"},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","field":"links","label":"ClinicalTrials.gov NCT06103864"}]},{"url":"https://clinicaltrials.gov/study/NCT06105021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06105021","kind":"trial","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","route":"/trials/nct06105021/","field":"links","label":"ClinicalTrials.gov NCT06105021"}]},{"url":"https://clinicaltrials.gov/study/NCT06105619","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06105619","kind":"trial","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","route":"/trials/nct06105619/","field":"links","label":"ClinicalTrials.gov NCT06105619"}]},{"url":"https://clinicaltrials.gov/study/NCT06105632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","field":"links","label":"ClinicalTrials.gov NCT06105632"},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","field":"links","label":"ClinicalTrials.gov NCT06105632 (FOURLIGHT-1)"},{"id":"idea-cdk4-selective-first-line","kind":"idea","name":"CDK4-selective inhibitors as the new first-line backbone","route":"/ideas/idea-cdk4-selective-first-line/","field":"links","label":"ClinicalTrials.gov NCT06105632: FOURLIGHT-1"}]},{"url":"https://clinicaltrials.gov/study/NCT06106308","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06106308-j-clin-oncol-2025","kind":"paper","name":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","route":"/key-papers/paper-nct06106308-j-clin-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT06106308"},{"id":"nct06106308","kind":"trial","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","route":"/trials/nct06106308/","field":"links","label":"ClinicalTrials.gov NCT06106308"}]},{"url":"https://clinicaltrials.gov/study/NCT06106945","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/","field":"links","label":"ClinicalTrials.gov NCT06106945"}]},{"url":"https://clinicaltrials.gov/study/NCT06107374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06107374","kind":"trial","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","route":"/trials/nct06107374/","field":"links","label":"ClinicalTrials.gov NCT06107374"}]},{"url":"https://clinicaltrials.gov/study/NCT06107413","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06107413","kind":"trial","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","route":"/trials/nct06107413/","field":"links","label":"ClinicalTrials.gov NCT06107413"}]},{"url":"https://clinicaltrials.gov/study/NCT06107686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06107686","kind":"trial","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","route":"/trials/nct06107686/","field":"links","label":"ClinicalTrials.gov NCT06107686"}]},{"url":"https://clinicaltrials.gov/study/NCT06107920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06107920","kind":"trial","name":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","route":"/trials/nct06107920/","field":"links","label":"ClinicalTrials.gov NCT06107920"}]},{"url":"https://clinicaltrials.gov/study/NCT06109272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","field":"links","label":"ClinicalTrials.gov NCT06109272"}]},{"url":"https://clinicaltrials.gov/study/NCT06109779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06109779"},{"id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/","field":"links","label":"ClinicalTrials.gov NCT06109779"}]},{"url":"https://clinicaltrials.gov/study/NCT06110572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06110572","kind":"trial","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","route":"/trials/nct06110572/","field":"links","label":"ClinicalTrials.gov NCT06110572"}]},{"url":"https://clinicaltrials.gov/study/NCT06111235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06111235","kind":"trial","name":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","route":"/trials/nct06111235/","field":"links","label":"ClinicalTrials.gov NCT06111235"}]},{"url":"https://clinicaltrials.gov/study/NCT06111274","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06111274","kind":"trial","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06111274/","field":"links","label":"ClinicalTrials.gov NCT06111274"}]},{"url":"https://clinicaltrials.gov/study/NCT06112314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/","field":"links","label":"ClinicalTrials.gov NCT06112314"},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/","field":"dosing.source"}]},{"url":"https://clinicaltrials.gov/study/NCT06112379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","field":"links","label":"ClinicalTrials.gov NCT06112379"}]},{"url":"https://clinicaltrials.gov/study/NCT06112704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06112704","kind":"trial","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","route":"/trials/nct06112704/","field":"links","label":"ClinicalTrials.gov NCT06112704"}]},{"url":"https://clinicaltrials.gov/study/NCT06114511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06114511","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","route":"/trials/nct06114511/","field":"links","label":"ClinicalTrials.gov NCT06114511"}]},{"url":"https://clinicaltrials.gov/study/NCT06115135","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06115135","kind":"trial","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06115135/","field":"links","label":"ClinicalTrials.gov NCT06115135"}]},{"url":"https://clinicaltrials.gov/study/NCT06115499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06115499","kind":"trial","name":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","route":"/trials/nct06115499/","field":"links","label":"ClinicalTrials.gov NCT06115499"}]},{"url":"https://clinicaltrials.gov/study/NCT06116136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","route":"/trials/nct06116136/","field":"links","label":"ClinicalTrials.gov NCT06116136"}]},{"url":"https://clinicaltrials.gov/study/NCT06117540","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06117540","kind":"trial","name":"A Study of WX390 in Patients With Advanced Solid Tumors","route":"/trials/nct06117540/","field":"links","label":"ClinicalTrials.gov NCT06117540"}]},{"url":"https://clinicaltrials.gov/study/NCT06117566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06117566","kind":"trial","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","route":"/trials/nct06117566/","field":"links","label":"ClinicalTrials.gov NCT06117566"}]},{"url":"https://clinicaltrials.gov/study/NCT06117774","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/","field":"links","label":"ClinicalTrials.gov NCT06117774"}]},{"url":"https://clinicaltrials.gov/study/NCT06118086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/","field":"links","label":"ClinicalTrials.gov NCT06118086"}]},{"url":"https://clinicaltrials.gov/study/NCT06118333","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06118333","kind":"trial","name":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","route":"/trials/nct06118333/","field":"links","label":"ClinicalTrials.gov NCT06118333"}]},{"url":"https://clinicaltrials.gov/study/NCT06118788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","field":"links","label":"ClinicalTrials.gov NCT06118788"}]},{"url":"https://clinicaltrials.gov/study/NCT06119217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/","field":"links","label":"ClinicalTrials.gov NCT06119217"}]},{"url":"https://clinicaltrials.gov/study/NCT06119581","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06119581","kind":"trial","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","route":"/trials/nct06119581/","field":"links","label":"ClinicalTrials.gov NCT06119581"}]},{"url":"https://clinicaltrials.gov/study/NCT06119685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/","field":"links","label":"ClinicalTrials.gov NCT06119685"}]},{"url":"https://clinicaltrials.gov/study/NCT06119867","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06119867","kind":"trial","name":"CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)","route":"/trials/nct06119867/","field":"links","label":"ClinicalTrials.gov NCT06119867"}]},{"url":"https://clinicaltrials.gov/study/NCT06120140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/","field":"links","label":"ClinicalTrials.gov NCT06120140"},{"id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","route":"/trials/nct06120140/","field":"links","label":"ClinicalTrials.gov NCT06120140"}]},{"url":"https://clinicaltrials.gov/study/NCT06120491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","route":"/trials/nct06120491/","field":"links","label":"ClinicalTrials.gov NCT06120491"}]},{"url":"https://clinicaltrials.gov/study/NCT06121505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06121505","kind":"trial","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","route":"/trials/nct06121505/","field":"links","label":"ClinicalTrials.gov NCT06121505"}]},{"url":"https://clinicaltrials.gov/study/NCT06122584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/","field":"links","label":"ClinicalTrials.gov NCT06122584"}]},{"url":"https://clinicaltrials.gov/study/NCT06123156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06123156","kind":"trial","name":"Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer","route":"/trials/nct06123156/","field":"links","label":"ClinicalTrials.gov NCT06123156"}]},{"url":"https://clinicaltrials.gov/study/NCT06123494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/","field":"links","label":"ClinicalTrials.gov NCT06123494"}]},{"url":"https://clinicaltrials.gov/study/NCT06123754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/","field":"links","label":"ClinicalTrials.gov NCT06123754"}]},{"url":"https://clinicaltrials.gov/study/NCT06123884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06123884","kind":"trial","name":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","route":"/trials/nct06123884/","field":"links","label":"ClinicalTrials.gov NCT06123884"}]},{"url":"https://clinicaltrials.gov/study/NCT06125080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06125080","kind":"trial","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","route":"/trials/nct06125080/","field":"links","label":"ClinicalTrials.gov NCT06125080"}]},{"url":"https://clinicaltrials.gov/study/NCT06125522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06125522","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","route":"/trials/nct06125522/","field":"links","label":"ClinicalTrials.gov NCT06125522"}]},{"url":"https://clinicaltrials.gov/study/NCT06126510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","route":"/trials/nct06126510/","field":"links","label":"ClinicalTrials.gov NCT06126510"}]},{"url":"https://clinicaltrials.gov/study/NCT06126640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/","field":"links","label":"ClinicalTrials.gov NCT06126640"}]},{"url":"https://clinicaltrials.gov/study/NCT06127238","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06127238","kind":"trial","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","route":"/trials/nct06127238/","field":"links","label":"ClinicalTrials.gov NCT06127238"}]},{"url":"https://clinicaltrials.gov/study/NCT06127407","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","route":"/trials/nct06127407/","field":"links","label":"ClinicalTrials.gov NCT06127407"}]},{"url":"https://clinicaltrials.gov/study/NCT06127654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06127654","kind":"trial","name":"Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy","route":"/trials/nct06127654/","field":"links","label":"ClinicalTrials.gov NCT06127654"}]},{"url":"https://clinicaltrials.gov/study/NCT06128551","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/","field":"links","label":"ClinicalTrials.gov NCT06128551"}]},{"url":"https://clinicaltrials.gov/study/NCT06128837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/","field":"links","label":"ClinicalTrials.gov NCT06128837"}]},{"url":"https://clinicaltrials.gov/study/NCT06130280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06130280","kind":"trial","name":"A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal","route":"/trials/nct06130280/","field":"links","label":"ClinicalTrials.gov NCT06130280"}]},{"url":"https://clinicaltrials.gov/study/NCT06130553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/","field":"links","label":"ClinicalTrials.gov NCT06130553"}]},{"url":"https://clinicaltrials.gov/study/NCT06131450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06131450","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","route":"/trials/nct06131450/","field":"links","label":"ClinicalTrials.gov NCT06131450"}]},{"url":"https://clinicaltrials.gov/study/NCT06132958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06132958","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","route":"/trials/nct06132958/","field":"links","label":"ClinicalTrials.gov NCT06132958"}]},{"url":"https://clinicaltrials.gov/study/NCT06134232","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/","field":"links","label":"ClinicalTrials.gov NCT06134232"}]},{"url":"https://clinicaltrials.gov/study/NCT06134375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","route":"/trials/nct06134375/","field":"links","label":"ClinicalTrials.gov NCT06134375"}]},{"url":"https://clinicaltrials.gov/study/NCT06134388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06134388","kind":"trial","name":"Sulfasalazine in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06134388/","field":"links","label":"ClinicalTrials.gov NCT06134388"}]},{"url":"https://clinicaltrials.gov/study/NCT06135896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06135896","kind":"trial","name":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","route":"/trials/nct06135896/","field":"links","label":"ClinicalTrials.gov NCT06135896"}]},{"url":"https://clinicaltrials.gov/study/NCT06136559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","field":"links","label":"ClinicalTrials.gov NCT06136559 (BELLWAVE-011)"},{"id":"bellwave-011","kind":"trial","name":"BELLWAVE-011","route":"/trials/bellwave-011/","field":"links","label":"ClinicalTrials.gov NCT06136559"}]},{"url":"https://clinicaltrials.gov/study/NCT06136624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","route":"/trials/nct06136624/","field":"links","label":"ClinicalTrials.gov NCT06136624"}]},{"url":"https://clinicaltrials.gov/study/NCT06136650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06136650","kind":"trial","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","route":"/trials/nct06136650/","field":"links","label":"ClinicalTrials.gov NCT06136650"}]},{"url":"https://clinicaltrials.gov/study/NCT06137118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","route":"/trials/nct06137118/","field":"links","label":"ClinicalTrials.gov NCT06137118"}]},{"url":"https://clinicaltrials.gov/study/NCT06137144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/","field":"links","label":"ClinicalTrials.gov NCT06137144"}]},{"url":"https://clinicaltrials.gov/study/NCT06139575","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","field":"links","label":"ClinicalTrials.gov NCT06139575"}]},{"url":"https://clinicaltrials.gov/study/NCT06140524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/","field":"links","label":"ClinicalTrials.gov NCT06140524"}]},{"url":"https://clinicaltrials.gov/study/NCT06140576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06140576","kind":"trial","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","route":"/trials/nct06140576/","field":"links","label":"ClinicalTrials.gov NCT06140576"}]},{"url":"https://clinicaltrials.gov/study/NCT06140836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06140836","kind":"trial","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","route":"/trials/nct06140836/","field":"links","label":"ClinicalTrials.gov NCT06140836"}]},{"url":"https://clinicaltrials.gov/study/NCT06141070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06141070","kind":"trial","name":"Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease","route":"/trials/nct06141070/","field":"links","label":"ClinicalTrials.gov NCT06141070"}]},{"url":"https://clinicaltrials.gov/study/NCT06144671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/","field":"links","label":"ClinicalTrials.gov NCT06144671"}]},{"url":"https://clinicaltrials.gov/study/NCT06145074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06145074","kind":"trial","name":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.","route":"/trials/nct06145074/","field":"links","label":"ClinicalTrials.gov NCT06145074"},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","field":"links","label":"Perioperative propranolol in PDAC (NCT06145074)"}]},{"url":"https://clinicaltrials.gov/study/NCT06147570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/","field":"links","label":"ClinicalTrials.gov NCT06147570"}]},{"url":"https://clinicaltrials.gov/study/NCT06149247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149247","kind":"trial","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","route":"/trials/nct06149247/","field":"links","label":"ClinicalTrials.gov NCT06149247"}]},{"url":"https://clinicaltrials.gov/study/NCT06149247?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149247","kind":"trial","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","route":"/trials/nct06149247/","field":"outcomes.source (Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score)"}]},{"url":"https://clinicaltrials.gov/study/NCT06149286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149286","kind":"trial","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","route":"/trials/nct06149286/","field":"links","label":"ClinicalTrials.gov NCT06149286"}]},{"url":"https://clinicaltrials.gov/study/NCT06149481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/","field":"links","label":"ClinicalTrials.gov NCT06149481"}]},{"url":"https://clinicaltrials.gov/study/NCT06149559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149559","kind":"trial","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","route":"/trials/nct06149559/","field":"links","label":"ClinicalTrials.gov NCT06149559"}]},{"url":"https://clinicaltrials.gov/study/NCT06149689","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06149689","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","route":"/trials/nct06149689/","field":"links","label":"ClinicalTrials.gov NCT06149689"}]},{"url":"https://clinicaltrials.gov/study/NCT06150885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","field":"links","label":"ClinicalTrials.gov NCT06150885"}]},{"url":"https://clinicaltrials.gov/study/NCT06151262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06151262","kind":"trial","name":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct06151262/","field":"links","label":"ClinicalTrials.gov NCT06151262"}]},{"url":"https://clinicaltrials.gov/study/NCT06151574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06151574","kind":"trial","name":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","route":"/trials/nct06151574/","field":"links","label":"ClinicalTrials.gov NCT06151574"}]},{"url":"https://clinicaltrials.gov/study/NCT06152575","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06152575","kind":"trial","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","route":"/trials/nct06152575/","field":"links","label":"ClinicalTrials.gov NCT06152575"}]},{"url":"https://clinicaltrials.gov/study/NCT06153173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06153173","kind":"trial","name":"Mirdametinib in Histiocytic Disorders","route":"/trials/nct06153173/","field":"links","label":"ClinicalTrials.gov NCT06153173"}]},{"url":"https://clinicaltrials.gov/study/NCT06154291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06154291/","field":"links","label":"ClinicalTrials.gov NCT06154291"}]},{"url":"https://clinicaltrials.gov/study/NCT06154538","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06154538","kind":"trial","name":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","route":"/trials/nct06154538/","field":"links","label":"ClinicalTrials.gov NCT06154538"}]},{"url":"https://clinicaltrials.gov/study/NCT06155084","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06155084","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","route":"/trials/nct06155084/","field":"links","label":"ClinicalTrials.gov NCT06155084"}]},{"url":"https://clinicaltrials.gov/study/NCT06155383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06155383","kind":"trial","name":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct06155383/","field":"links","label":"ClinicalTrials.gov NCT06155383"}]},{"url":"https://clinicaltrials.gov/study/NCT06155396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/","field":"links","label":"ClinicalTrials.gov NCT06155396"}]},{"url":"https://clinicaltrials.gov/study/NCT06157151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06157151/","field":"links","label":"ClinicalTrials.gov NCT06157151"}]},{"url":"https://clinicaltrials.gov/study/NCT06157892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/","field":"links","label":"ClinicalTrials.gov NCT06157892"}]},{"url":"https://clinicaltrials.gov/study/NCT06158841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/","field":"links","label":"ClinicalTrials.gov NCT06158841"}]},{"url":"https://clinicaltrials.gov/study/NCT06159478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06159478","kind":"trial","name":"Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)","route":"/trials/nct06159478/","field":"links","label":"ClinicalTrials.gov NCT06159478"}]},{"url":"https://clinicaltrials.gov/study/NCT06161025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","field":"links","label":"ClinicalTrials.gov NCT06161025"},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","field":"dosing.source"}]},{"url":"https://clinicaltrials.gov/study/NCT06161441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06161441","kind":"trial","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","route":"/trials/nct06161441/","field":"links","label":"ClinicalTrials.gov NCT06161441"}]},{"url":"https://clinicaltrials.gov/study/NCT06161974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/","field":"links","label":"ClinicalTrials.gov NCT06161974"}]},{"url":"https://clinicaltrials.gov/study/NCT06162221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/","field":"links","label":"ClinicalTrials.gov NCT06162221"}]},{"url":"https://clinicaltrials.gov/study/NCT06162572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/","field":"links","label":"ClinicalTrials.gov NCT06162572"}]},{"url":"https://clinicaltrials.gov/study/NCT06162650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06162650","kind":"trial","name":"Total Neoadjuvant Therapy in Rectal Cancer","route":"/trials/nct06162650/","field":"links","label":"ClinicalTrials.gov NCT06162650"}]},{"url":"https://clinicaltrials.gov/study/NCT06163430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","route":"/trials/nct06163430/","field":"links","label":"ClinicalTrials.gov NCT06163430"}]},{"url":"https://clinicaltrials.gov/study/NCT06165900","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06165900","kind":"trial","name":"Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC","route":"/trials/nct06165900/","field":"links","label":"ClinicalTrials.gov NCT06165900"}]},{"url":"https://clinicaltrials.gov/study/NCT06166589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06166589","kind":"trial","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","route":"/trials/nct06166589/","field":"links","label":"ClinicalTrials.gov NCT06166589"}]},{"url":"https://clinicaltrials.gov/study/NCT06166836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/","field":"links","label":"ClinicalTrials.gov NCT06166836"}]},{"url":"https://clinicaltrials.gov/study/NCT06167694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06167694","kind":"trial","name":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06167694/","field":"links","label":"ClinicalTrials.gov NCT06167694"}]},{"url":"https://clinicaltrials.gov/study/NCT06168786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06168786","kind":"trial","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","route":"/trials/nct06168786/","field":"links","label":"ClinicalTrials.gov NCT06168786"}]},{"url":"https://clinicaltrials.gov/study/NCT06170788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/","field":"links","label":"ClinicalTrials.gov NCT06170788"}]},{"url":"https://clinicaltrials.gov/study/NCT06172036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06172036","kind":"trial","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","route":"/trials/nct06172036/","field":"links","label":"ClinicalTrials.gov NCT06172036"}]},{"url":"https://clinicaltrials.gov/study/NCT06172478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/","field":"links","label":"ClinicalTrials.gov NCT06172478"}]},{"url":"https://clinicaltrials.gov/study/NCT06174987","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06174987","kind":"trial","name":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","route":"/trials/nct06174987/","field":"links","label":"ClinicalTrials.gov NCT06174987"}]},{"url":"https://clinicaltrials.gov/study/NCT06176261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","route":"/trials/nct06176261/","field":"links","label":"ClinicalTrials.gov NCT06176261"}]},{"url":"https://clinicaltrials.gov/study/NCT06176885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06176885","kind":"trial","name":"Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite","route":"/trials/nct06176885/","field":"links","label":"ClinicalTrials.gov NCT06176885"}]},{"url":"https://clinicaltrials.gov/study/NCT06177041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06177041","kind":"trial","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","route":"/trials/nct06177041/","field":"links","label":"ClinicalTrials.gov NCT06177041"}]},{"url":"https://clinicaltrials.gov/study/NCT06177522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06177522","kind":"trial","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","route":"/trials/nct06177522/","field":"links","label":"ClinicalTrials.gov NCT06177522"}]},{"url":"https://clinicaltrials.gov/study/NCT06177925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06177925","kind":"trial","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","route":"/trials/nct06177925/","field":"links","label":"ClinicalTrials.gov NCT06177925"}]},{"url":"https://clinicaltrials.gov/study/NCT06178159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06178159","kind":"trial","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","route":"/trials/nct06178159/","field":"links","label":"ClinicalTrials.gov NCT06178159"}]},{"url":"https://clinicaltrials.gov/study/NCT06178445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trap-btc","kind":"trial","name":"TRAP-BTC","route":"/trials/trap-btc/","field":"links","label":"ClinicalTrials.gov NCT06178445"}]},{"url":"https://clinicaltrials.gov/study/NCT06179524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06179524","kind":"trial","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","route":"/trials/nct06179524/","field":"links","label":"ClinicalTrials.gov NCT06179524"}]},{"url":"https://clinicaltrials.gov/study/NCT06184035","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","field":"links","label":"ClinicalTrials.gov NCT06184035"}]},{"url":"https://clinicaltrials.gov/study/NCT06184698","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06184698","kind":"trial","name":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","route":"/trials/nct06184698/","field":"links","label":"ClinicalTrials.gov NCT06184698"}]},{"url":"https://clinicaltrials.gov/study/NCT06185556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06185556","kind":"trial","name":"COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases","route":"/trials/nct06185556/","field":"links","label":"ClinicalTrials.gov NCT06185556"}]},{"url":"https://clinicaltrials.gov/study/NCT06187402","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06187402","kind":"trial","name":"A Study of LM-24C5 For Advanced Solid Tumors","route":"/trials/nct06187402/","field":"links","label":"ClinicalTrials.gov NCT06187402"}]},{"url":"https://clinicaltrials.gov/study/NCT06188520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","field":"links","label":"ClinicalTrials.gov NCT06188520"}]},{"url":"https://clinicaltrials.gov/study/NCT06188702","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","field":"links","label":"ClinicalTrials.gov NCT06188702"}]},{"url":"https://clinicaltrials.gov/study/NCT06189209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06189209","kind":"trial","name":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","route":"/trials/nct06189209/","field":"links","label":"ClinicalTrials.gov NCT06189209"}]},{"url":"https://clinicaltrials.gov/study/NCT06190899","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/","field":"links","label":"ClinicalTrials.gov NCT06190899"}]},{"url":"https://clinicaltrials.gov/study/NCT06190951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06190951","kind":"trial","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","route":"/trials/nct06190951/","field":"links","label":"ClinicalTrials.gov NCT06190951"}]},{"url":"https://clinicaltrials.gov/study/NCT06191263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/","field":"links","label":"ClinicalTrials.gov NCT06191263"}]},{"url":"https://clinicaltrials.gov/study/NCT06191744","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","field":"links","label":"ClinicalTrials.gov NCT06191744"}]},{"url":"https://clinicaltrials.gov/study/NCT06192680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06192680","kind":"trial","name":"Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct06192680/","field":"links","label":"ClinicalTrials.gov NCT06192680"}]},{"url":"https://clinicaltrials.gov/study/NCT06193902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","field":"links","label":"ClinicalTrials.gov NCT06193902"}]},{"url":"https://clinicaltrials.gov/study/NCT06194448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06194448","kind":"trial","name":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","route":"/trials/nct06194448/","field":"links","label":"ClinicalTrials.gov NCT06194448"}]},{"url":"https://clinicaltrials.gov/study/NCT06194656","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06194656","kind":"trial","name":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06194656/","field":"links","label":"ClinicalTrials.gov NCT06194656"}]},{"url":"https://clinicaltrials.gov/study/NCT06194734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06194734","kind":"trial","name":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","route":"/trials/nct06194734/","field":"links","label":"ClinicalTrials.gov NCT06194734"}]},{"url":"https://clinicaltrials.gov/study/NCT06195670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06195670","kind":"trial","name":"Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC","route":"/trials/nct06195670/","field":"links","label":"ClinicalTrials.gov NCT06195670"}]},{"url":"https://clinicaltrials.gov/study/NCT06196671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06196671","kind":"trial","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196671/","field":"links","label":"ClinicalTrials.gov NCT06196671"}]},{"url":"https://clinicaltrials.gov/study/NCT06196736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06196736","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06196736/","field":"links","label":"ClinicalTrials.gov NCT06196736"}]},{"url":"https://clinicaltrials.gov/study/NCT06196788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06196788","kind":"trial","name":"Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196788/","field":"links","label":"ClinicalTrials.gov NCT06196788"}]},{"url":"https://clinicaltrials.gov/study/NCT06197425","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06197425","kind":"trial","name":"Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer","route":"/trials/nct06197425/","field":"links","label":"ClinicalTrials.gov NCT06197425"}]},{"url":"https://clinicaltrials.gov/study/NCT06198751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT06198751"},{"id":"nct06198751","kind":"trial","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct06198751/","field":"links","label":"ClinicalTrials.gov NCT06198751"}]},{"url":"https://clinicaltrials.gov/study/NCT06198907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06198907","kind":"trial","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","route":"/trials/nct06198907/","field":"links","label":"ClinicalTrials.gov NCT06198907"}]},{"url":"https://clinicaltrials.gov/study/NCT06199895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06199895","kind":"trial","name":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholan","route":"/trials/nct06199895/","field":"links","label":"ClinicalTrials.gov NCT06199895"}]},{"url":"https://clinicaltrials.gov/study/NCT06199973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06199973","kind":"trial","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","route":"/trials/nct06199973/","field":"links","label":"ClinicalTrials.gov NCT06199973"}]},{"url":"https://clinicaltrials.gov/study/NCT06202001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06202001","kind":"trial","name":"Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients","route":"/trials/nct06202001/","field":"links","label":"ClinicalTrials.gov NCT06202001"}]},{"url":"https://clinicaltrials.gov/study/NCT06202261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06202261","kind":"trial","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","route":"/trials/nct06202261/","field":"links","label":"ClinicalTrials.gov NCT06202261"}]},{"url":"https://clinicaltrials.gov/study/NCT06202313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06202313/","field":"links","label":"ClinicalTrials.gov NCT06202313"}]},{"url":"https://clinicaltrials.gov/study/NCT06203210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/","field":"links","label":"ClinicalTrials.gov NCT06203210"},{"id":"b7-h3-expression","kind":"biomarker","name":"B7-H3 (CD276) expression","route":"/biomarkers/b7-h3-expression/","field":"links","label":"ClinicalTrials.gov NCT06203210 (IDeate-Lung02)"}]},{"url":"https://clinicaltrials.gov/study/NCT06204094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06204094","kind":"trial","name":"Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer","route":"/trials/nct06204094/","field":"links","label":"ClinicalTrials.gov NCT06204094"}]},{"url":"https://clinicaltrials.gov/study/NCT06205485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06205485","kind":"trial","name":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","route":"/trials/nct06205485/","field":"links","label":"ClinicalTrials.gov NCT06205485"}]},{"url":"https://clinicaltrials.gov/study/NCT06205706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/","field":"links","label":"ClinicalTrials.gov NCT06205706"}]},{"url":"https://clinicaltrials.gov/study/NCT06205836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06205836","kind":"trial","name":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","route":"/trials/nct06205836/","field":"links","label":"ClinicalTrials.gov NCT06205836"}]},{"url":"https://clinicaltrials.gov/study/NCT06206174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06206174","kind":"trial","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","route":"/trials/nct06206174/","field":"links","label":"ClinicalTrials.gov NCT06206174"}]},{"url":"https://clinicaltrials.gov/study/NCT06206837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06206837","kind":"trial","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","route":"/trials/nct06206837/","field":"links","label":"ClinicalTrials.gov NCT06206837"}]},{"url":"https://clinicaltrials.gov/study/NCT06207656","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06207656","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial","route":"/trials/nct06207656/","field":"links","label":"ClinicalTrials.gov NCT06207656"}]},{"url":"https://clinicaltrials.gov/study/NCT06208150","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","route":"/trials/nct06208150/","field":"links","label":"ClinicalTrials.gov NCT06208150"}]},{"url":"https://clinicaltrials.gov/study/NCT06208371","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06208371","kind":"trial","name":"Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","route":"/trials/nct06208371/","field":"links","label":"ClinicalTrials.gov NCT06208371"}]},{"url":"https://clinicaltrials.gov/study/NCT06208410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/","field":"links","label":"ClinicalTrials.gov NCT06208410"}]},{"url":"https://clinicaltrials.gov/study/NCT06209580","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06209580","kind":"trial","name":"AMT-253 in Patients With Advanced Solid Tumours","route":"/trials/nct06209580/","field":"links","label":"ClinicalTrials.gov NCT06209580"}]},{"url":"https://clinicaltrials.gov/study/NCT06210360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06210360","kind":"trial","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","route":"/trials/nct06210360/","field":"links","label":"ClinicalTrials.gov NCT06210360"}]},{"url":"https://clinicaltrials.gov/study/NCT06211036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"links","label":"ClinicalTrials.gov NCT06211036"},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","field":"links","label":"ClinicalTrials.gov NCT06211036: DeLLphi-305"}]},{"url":"https://clinicaltrials.gov/study/NCT06211764","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06211764","kind":"trial","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","route":"/trials/nct06211764/","field":"links","label":"ClinicalTrials.gov NCT06211764"}]},{"url":"https://clinicaltrials.gov/study/NCT06212076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/","field":"links","label":"ClinicalTrials.gov NCT06212076"}]},{"url":"https://clinicaltrials.gov/study/NCT06212752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","route":"/trials/nct06212752/","field":"links","label":"ClinicalTrials.gov NCT06212752"}]},{"url":"https://clinicaltrials.gov/study/NCT06212752?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","route":"/trials/nct06212752/","field":"outcomes.source (Objective Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT06214143","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06214143","kind":"trial","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","route":"/trials/nct06214143/","field":"links","label":"ClinicalTrials.gov NCT06214143"}]},{"url":"https://clinicaltrials.gov/study/NCT06214572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rugb","kind":"trial","name":"RUGB","route":"/trials/rugb/","field":"links","label":"ClinicalTrials.gov NCT06214572"}]},{"url":"https://clinicaltrials.gov/study/NCT06216301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/","field":"links","label":"ClinicalTrials.gov NCT06216301"}]},{"url":"https://clinicaltrials.gov/study/NCT06217042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06217042","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06217042/","field":"links","label":"ClinicalTrials.gov NCT06217042"}]},{"url":"https://clinicaltrials.gov/study/NCT06218810","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06218810","kind":"trial","name":"Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal","route":"/trials/nct06218810/","field":"links","label":"ClinicalTrials.gov NCT06218810"}]},{"url":"https://clinicaltrials.gov/study/NCT06218888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06218888","kind":"trial","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro","route":"/trials/nct06218888/","field":"links","label":"ClinicalTrials.gov NCT06218888"}]},{"url":"https://clinicaltrials.gov/study/NCT06219941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06219941","kind":"trial","name":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","route":"/trials/nct06219941/","field":"links","label":"ClinicalTrials.gov NCT06219941"}]},{"url":"https://clinicaltrials.gov/study/NCT06220032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06220032","kind":"trial","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","route":"/trials/nct06220032/","field":"links","label":"ClinicalTrials.gov NCT06220032"}]},{"url":"https://clinicaltrials.gov/study/NCT06220318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06220318","kind":"trial","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","route":"/trials/nct06220318/","field":"links","label":"ClinicalTrials.gov NCT06220318"}]},{"url":"https://clinicaltrials.gov/study/NCT06221748","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06221748","kind":"trial","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","route":"/trials/nct06221748/","field":"links","label":"ClinicalTrials.gov NCT06221748"}]},{"url":"https://clinicaltrials.gov/study/NCT06222489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06222489","kind":"trial","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","route":"/trials/nct06222489/","field":"links","label":"ClinicalTrials.gov NCT06222489"}]},{"url":"https://clinicaltrials.gov/study/NCT06222879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06222879","kind":"trial","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06222879/","field":"links","label":"ClinicalTrials.gov NCT06222879"}]},{"url":"https://clinicaltrials.gov/study/NCT06223841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06223841","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06223841/","field":"links","label":"ClinicalTrials.gov NCT06223841"}]},{"url":"https://clinicaltrials.gov/study/NCT06224257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06224257","kind":"trial","name":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia","route":"/trials/nct06224257/","field":"links","label":"ClinicalTrials.gov NCT06224257"}]},{"url":"https://clinicaltrials.gov/study/NCT06225284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06225284","kind":"trial","name":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","route":"/trials/nct06225284/","field":"links","label":"ClinicalTrials.gov NCT06225284"}]},{"url":"https://clinicaltrials.gov/study/NCT06225596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/","field":"links","label":"ClinicalTrials.gov NCT06225596"}]},{"url":"https://clinicaltrials.gov/study/NCT06225843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/","field":"links","label":"ClinicalTrials.gov NCT06225843"},{"id":"nct06225843","kind":"trial","name":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","route":"/trials/nct06225843/","field":"links","label":"ClinicalTrials.gov NCT06225843"}]},{"url":"https://clinicaltrials.gov/study/NCT06226857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06226857","kind":"trial","name":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","route":"/trials/nct06226857/","field":"links","label":"ClinicalTrials.gov NCT06226857"}]},{"url":"https://clinicaltrials.gov/study/NCT06227065","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06227065","kind":"trial","name":"Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids","route":"/trials/nct06227065/","field":"links","label":"ClinicalTrials.gov NCT06227065"}]},{"url":"https://clinicaltrials.gov/study/NCT06227117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06227117","kind":"trial","name":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","route":"/trials/nct06227117/","field":"links","label":"ClinicalTrials.gov NCT06227117"}]},{"url":"https://clinicaltrials.gov/study/NCT06228053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/","field":"links","label":"ClinicalTrials.gov NCT06228053"}]},{"url":"https://clinicaltrials.gov/study/NCT06228326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","route":"/trials/nct06228326/","field":"links","label":"ClinicalTrials.gov NCT06228326"}]},{"url":"https://clinicaltrials.gov/study/NCT06229041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06229041","kind":"trial","name":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","route":"/trials/nct06229041/","field":"links","label":"ClinicalTrials.gov NCT06229041"}]},{"url":"https://clinicaltrials.gov/study/NCT06229067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06229067","kind":"trial","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","route":"/trials/nct06229067/","field":"links","label":"ClinicalTrials.gov NCT06229067"}]},{"url":"https://clinicaltrials.gov/study/NCT06229340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06229340","kind":"trial","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","route":"/trials/nct06229340/","field":"links","label":"ClinicalTrials.gov NCT06229340"}]},{"url":"https://clinicaltrials.gov/study/NCT06230224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06230224","kind":"trial","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","route":"/trials/nct06230224/","field":"links","label":"ClinicalTrials.gov NCT06230224"}]},{"url":"https://clinicaltrials.gov/study/NCT06230445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06230445","kind":"trial","name":"Effects of Digital Therapeutic in Whole Process Management of Lung Cancer","route":"/trials/nct06230445/","field":"links","label":"ClinicalTrials.gov NCT06230445"}]},{"url":"https://clinicaltrials.gov/study/NCT06230471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06230471","kind":"trial","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06230471/","field":"links","label":"ClinicalTrials.gov NCT06230471"}]},{"url":"https://clinicaltrials.gov/study/NCT06232096","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","route":"/trials/nct06232096/","field":"links","label":"ClinicalTrials.gov NCT06232096"}]},{"url":"https://clinicaltrials.gov/study/NCT06233877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06233877","kind":"trial","name":"Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer","route":"/trials/nct06233877/","field":"links","label":"ClinicalTrials.gov NCT06233877"}]},{"url":"https://clinicaltrials.gov/study/NCT06234007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06234007","kind":"trial","name":"Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Mult","route":"/trials/nct06234007/","field":"links","label":"ClinicalTrials.gov NCT06234007"}]},{"url":"https://clinicaltrials.gov/study/NCT06234072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06234072","kind":"trial","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","route":"/trials/nct06234072/","field":"links","label":"ClinicalTrials.gov NCT06234072"}]},{"url":"https://clinicaltrials.gov/study/NCT06234098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/","field":"links","label":"ClinicalTrials.gov NCT06234098"}]},{"url":"https://clinicaltrials.gov/study/NCT06235151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/","field":"links","label":"ClinicalTrials.gov NCT06235151"}]},{"url":"https://clinicaltrials.gov/study/NCT06235229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06235229/","field":"links","label":"ClinicalTrials.gov NCT06235229"}]},{"url":"https://clinicaltrials.gov/study/NCT06236438","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","field":"links","label":"ClinicalTrials.gov NCT06236438"}]},{"url":"https://clinicaltrials.gov/study/NCT06238921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/","field":"links","label":"ClinicalTrials.gov NCT06238921"}]},{"url":"https://clinicaltrials.gov/study/NCT06239155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06239155","kind":"trial","name":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","route":"/trials/nct06239155/","field":"links","label":"ClinicalTrials.gov NCT06239155"}]},{"url":"https://clinicaltrials.gov/study/NCT06239194","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/","field":"links","label":"ClinicalTrials.gov NCT06239194"}]},{"url":"https://clinicaltrials.gov/study/NCT06241781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/","field":"links","label":"ClinicalTrials.gov NCT06241781"}]},{"url":"https://clinicaltrials.gov/study/NCT06241846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/","field":"links","label":"ClinicalTrials.gov NCT06241846"}]},{"url":"https://clinicaltrials.gov/study/NCT06242067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06242067","kind":"trial","name":"Second-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct06242067/","field":"links","label":"ClinicalTrials.gov NCT06242067"}]},{"url":"https://clinicaltrials.gov/study/NCT06242418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06242418","kind":"trial","name":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","route":"/trials/nct06242418/","field":"links","label":"ClinicalTrials.gov NCT06242418"}]},{"url":"https://clinicaltrials.gov/study/NCT06243354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06243354","kind":"trial","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","route":"/trials/nct06243354/","field":"links","label":"ClinicalTrials.gov NCT06243354"}]},{"url":"https://clinicaltrials.gov/study/NCT06243393","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06243393","kind":"trial","name":"Sacituzumab Govitecan in Metastatic Colorectal Cancer","route":"/trials/nct06243393/","field":"links","label":"ClinicalTrials.gov NCT06243393"}]},{"url":"https://clinicaltrials.gov/study/NCT06243458","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","route":"/trials/nct06243458/","field":"links","label":"ClinicalTrials.gov NCT06243458"}]},{"url":"https://clinicaltrials.gov/study/NCT06244771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","field":"links","label":"PROSPER trial"},{"id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/","field":"links","label":"ClinicalTrials.gov NCT06244771"}]},{"url":"https://clinicaltrials.gov/study/NCT06244992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06244992/","field":"links","label":"ClinicalTrials.gov NCT06244992"}]},{"url":"https://clinicaltrials.gov/study/NCT06245330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06245330","kind":"trial","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","route":"/trials/nct06245330/","field":"links","label":"ClinicalTrials.gov NCT06245330"}]},{"url":"https://clinicaltrials.gov/study/NCT06245356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06245356","kind":"trial","name":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","route":"/trials/nct06245356/","field":"links","label":"ClinicalTrials.gov NCT06245356"}]},{"url":"https://clinicaltrials.gov/study/NCT06245889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/","field":"links","label":"ClinicalTrials.gov NCT06245889"}]},{"url":"https://clinicaltrials.gov/study/NCT06245915","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","field":"links","label":"AB-2100 trial"},{"id":"nct06245915","kind":"trial","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","route":"/trials/nct06245915/","field":"links","label":"ClinicalTrials.gov NCT06245915"}]},{"url":"https://clinicaltrials.gov/study/NCT06246110","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06246110","kind":"trial","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","route":"/trials/nct06246110/","field":"links","label":"ClinicalTrials.gov NCT06246110"}]},{"url":"https://clinicaltrials.gov/study/NCT06246344","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06246344","kind":"trial","name":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct06246344/","field":"links","label":"ClinicalTrials.gov NCT06246344"}]},{"url":"https://clinicaltrials.gov/study/NCT06246643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/","field":"links","label":"ClinicalTrials.gov NCT06246643"}]},{"url":"https://clinicaltrials.gov/study/NCT06246916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06246916","kind":"trial","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","route":"/trials/nct06246916/","field":"links","label":"ClinicalTrials.gov NCT06246916"}]},{"url":"https://clinicaltrials.gov/study/NCT06247605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/","field":"links","label":"ClinicalTrials.gov NCT06247605"}]},{"url":"https://clinicaltrials.gov/study/NCT06247956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06247956","kind":"trial","name":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","route":"/trials/nct06247956/","field":"links","label":"ClinicalTrials.gov NCT06247956"}]},{"url":"https://clinicaltrials.gov/study/NCT06247995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","field":"links","label":"ClinicalTrials.gov NCT06247995"}]},{"url":"https://clinicaltrials.gov/study/NCT06248606","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06248606","kind":"trial","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","route":"/trials/nct06248606/","field":"links","label":"ClinicalTrials.gov NCT06248606"}]},{"url":"https://clinicaltrials.gov/study/NCT06249048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/","field":"links","label":"ClinicalTrials.gov NCT06249048"}]},{"url":"https://clinicaltrials.gov/study/NCT06249321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06249321","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","route":"/trials/nct06249321/","field":"links","label":"ClinicalTrials.gov NCT06249321"}]},{"url":"https://clinicaltrials.gov/study/NCT06250972","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06250972","kind":"trial","name":"Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer","route":"/trials/nct06250972/","field":"links","label":"ClinicalTrials.gov NCT06250972"}]},{"url":"https://clinicaltrials.gov/study/NCT06252649","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","route":"/trials/nct06252649/","field":"links","label":"ClinicalTrials.gov NCT06252649"}]},{"url":"https://clinicaltrials.gov/study/NCT06252675","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06252675","kind":"trial","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct06252675/","field":"links","label":"ClinicalTrials.gov NCT06252675"}]},{"url":"https://clinicaltrials.gov/study/NCT06253130","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/","field":"links","label":"ClinicalTrials.gov NCT06253130"}]},{"url":"https://clinicaltrials.gov/study/NCT06253663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/","field":"links","label":"ClinicalTrials.gov NCT06253663"}]},{"url":"https://clinicaltrials.gov/study/NCT06254521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06254521","kind":"trial","name":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","route":"/trials/nct06254521/","field":"links","label":"ClinicalTrials.gov NCT06254521"}]},{"url":"https://clinicaltrials.gov/study/NCT06254599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06254599","kind":"trial","name":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","route":"/trials/nct06254599/","field":"links","label":"ClinicalTrials.gov NCT06254599"}]},{"url":"https://clinicaltrials.gov/study/NCT06255379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06255379","kind":"trial","name":"Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06255379/","field":"links","label":"ClinicalTrials.gov NCT06255379"}]},{"url":"https://clinicaltrials.gov/study/NCT06255912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06255912","kind":"trial","name":"Clinical Trial for Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06255912/","field":"links","label":"ClinicalTrials.gov NCT06255912"}]},{"url":"https://clinicaltrials.gov/study/NCT06256328","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06256328","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct06256328/","field":"links","label":"ClinicalTrials.gov NCT06256328"}]},{"url":"https://clinicaltrials.gov/study/NCT06256588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06256588","kind":"trial","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06256588/","field":"links","label":"ClinicalTrials.gov NCT06256588"}]},{"url":"https://clinicaltrials.gov/study/NCT06258525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06258525","kind":"trial","name":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","route":"/trials/nct06258525/","field":"links","label":"ClinicalTrials.gov NCT06258525"}]},{"url":"https://clinicaltrials.gov/study/NCT06259058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06259058","kind":"trial","name":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06259058/","field":"links","label":"ClinicalTrials.gov NCT06259058"}]},{"url":"https://clinicaltrials.gov/study/NCT06260033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06260033","kind":"trial","name":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","route":"/trials/nct06260033/","field":"links","label":"ClinicalTrials.gov NCT06260033"}]},{"url":"https://clinicaltrials.gov/study/NCT06260774","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","route":"/trials/nct06260774/","field":"links","label":"ClinicalTrials.gov NCT06260774"}]},{"url":"https://clinicaltrials.gov/study/NCT06262139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","route":"/trials/nct06262139/","field":"links","label":"ClinicalTrials.gov NCT06262139"}]},{"url":"https://clinicaltrials.gov/study/NCT06263231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"invincible-3","kind":"trial","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","route":"/trials/invincible-3/","field":"links","label":"ClinicalTrials.gov NCT06263231"}]},{"url":"https://clinicaltrials.gov/study/NCT06264180","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06264180","kind":"trial","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","route":"/trials/nct06264180/","field":"links","label":"ClinicalTrials.gov NCT06264180"}]},{"url":"https://clinicaltrials.gov/study/NCT06265025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","route":"/trials/nct06265025/","field":"links","label":"ClinicalTrials.gov NCT06265025"}]},{"url":"https://clinicaltrials.gov/study/NCT06265285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06265285","kind":"trial","name":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW)","route":"/trials/nct06265285/","field":"links","label":"ClinicalTrials.gov NCT06265285"}]},{"url":"https://clinicaltrials.gov/study/NCT06265428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06265428","kind":"trial","name":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","route":"/trials/nct06265428/","field":"links","label":"ClinicalTrials.gov NCT06265428"}]},{"url":"https://clinicaltrials.gov/study/NCT06265727","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","route":"/trials/nct06265727/","field":"links","label":"ClinicalTrials.gov NCT06265727"}]},{"url":"https://clinicaltrials.gov/study/NCT06266832","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06266832","kind":"trial","name":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra","route":"/trials/nct06266832/","field":"links","label":"ClinicalTrials.gov NCT06266832"}]},{"url":"https://clinicaltrials.gov/study/NCT06267729","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06267729","kind":"trial","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","route":"/trials/nct06267729/","field":"links","label":"ClinicalTrials.gov NCT06267729"}]},{"url":"https://clinicaltrials.gov/study/NCT06268327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06268327","kind":"trial","name":"Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy","route":"/trials/nct06268327/","field":"links","label":"ClinicalTrials.gov NCT06268327"}]},{"url":"https://clinicaltrials.gov/study/NCT06270017","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06270017","kind":"trial","name":"Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars","route":"/trials/nct06270017/","field":"links","label":"ClinicalTrials.gov NCT06270017"}]},{"url":"https://clinicaltrials.gov/study/NCT06271421","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","route":"/technologies/magnetic-nanoparticle-hyperthermia/","field":"links","label":"NanoTherm adjuvant GBM phase 2 (NCT06271421)"}]},{"url":"https://clinicaltrials.gov/study/NCT06271837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","route":"/trials/nct06271837/","field":"links","label":"ClinicalTrials.gov NCT06271837"}]},{"url":"https://clinicaltrials.gov/study/NCT06274879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06274879","kind":"trial","name":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","route":"/trials/nct06274879/","field":"links","label":"ClinicalTrials.gov NCT06274879"}]},{"url":"https://clinicaltrials.gov/study/NCT06275958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06275958","kind":"trial","name":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","route":"/trials/nct06275958/","field":"links","label":"ClinicalTrials.gov NCT06275958"}]},{"url":"https://clinicaltrials.gov/study/NCT06276283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06276283","kind":"trial","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","route":"/trials/nct06276283/","field":"links","label":"ClinicalTrials.gov NCT06276283"}]},{"url":"https://clinicaltrials.gov/study/NCT06277154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06277154","kind":"trial","name":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","route":"/trials/nct06277154/","field":"links","label":"ClinicalTrials.gov NCT06277154"}]},{"url":"https://clinicaltrials.gov/study/NCT06277219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","route":"/trials/nct06277219/","field":"links","label":"ClinicalTrials.gov NCT06277219"}]},{"url":"https://clinicaltrials.gov/study/NCT06279351","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06279351","kind":"trial","name":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","route":"/trials/nct06279351/","field":"links","label":"ClinicalTrials.gov NCT06279351"}]},{"url":"https://clinicaltrials.gov/study/NCT06279364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/","field":"links","label":"ClinicalTrials.gov NCT06279364"}]},{"url":"https://clinicaltrials.gov/study/NCT06280495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06280495","kind":"trial","name":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","route":"/trials/nct06280495/","field":"links","label":"ClinicalTrials.gov NCT06280495"}]},{"url":"https://clinicaltrials.gov/study/NCT06280508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06280508","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","route":"/trials/nct06280508/","field":"links","label":"ClinicalTrials.gov NCT06280508"}]},{"url":"https://clinicaltrials.gov/study/NCT06281405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06281405","kind":"trial","name":"CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer","route":"/trials/nct06281405/","field":"links","label":"ClinicalTrials.gov NCT06281405"}]},{"url":"https://clinicaltrials.gov/study/NCT06281678","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","route":"/trials/nct06281678/","field":"links","label":"ClinicalTrials.gov NCT06281678"}]},{"url":"https://clinicaltrials.gov/study/NCT06281964","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/","field":"links","label":"ClinicalTrials.gov NCT06281964"}]},{"url":"https://clinicaltrials.gov/study/NCT06282445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06282445","kind":"trial","name":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate","route":"/trials/nct06282445/","field":"links","label":"ClinicalTrials.gov NCT06282445"}]},{"url":"https://clinicaltrials.gov/study/NCT06282575","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","field":"links","label":"ClinicalTrials.gov NCT06282575"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06282575"}]},{"url":"https://clinicaltrials.gov/study/NCT06283719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","route":"/trials/nct06283719/","field":"links","label":"ClinicalTrials.gov NCT06283719"}]},{"url":"https://clinicaltrials.gov/study/NCT06284317","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06284317","kind":"trial","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","route":"/trials/nct06284317/","field":"links","label":"ClinicalTrials.gov NCT06284317"}]},{"url":"https://clinicaltrials.gov/study/NCT06284590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/","field":"links","label":"ClinicalTrials.gov NCT06284590"}]},{"url":"https://clinicaltrials.gov/study/NCT06290869","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06290869","kind":"trial","name":"Tobacco Education and Lung Health Study (TEAL)","route":"/trials/nct06290869/","field":"links","label":"ClinicalTrials.gov NCT06290869"}]},{"url":"https://clinicaltrials.gov/study/NCT06291064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/","field":"links","label":"ClinicalTrials.gov NCT06291064"}]},{"url":"https://clinicaltrials.gov/study/NCT06292208","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","route":"/trials/nct06292208/","field":"links","label":"ClinicalTrials.gov NCT06292208"}]},{"url":"https://clinicaltrials.gov/study/NCT06293014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06293014","kind":"trial","name":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","route":"/trials/nct06293014/","field":"links","label":"ClinicalTrials.gov NCT06293014"}]},{"url":"https://clinicaltrials.gov/study/NCT06293625","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06293625","kind":"trial","name":"Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More","route":"/trials/nct06293625/","field":"links","label":"ClinicalTrials.gov NCT06293625"}]},{"url":"https://clinicaltrials.gov/study/NCT06293651","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06293651","kind":"trial","name":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06293651/","field":"links","label":"ClinicalTrials.gov NCT06293651"}]},{"url":"https://clinicaltrials.gov/study/NCT06295432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/","field":"links","label":"ClinicalTrials.gov NCT06295432"}]},{"url":"https://clinicaltrials.gov/study/NCT06295731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/","field":"links","label":"ClinicalTrials.gov NCT06295731"}]},{"url":"https://clinicaltrials.gov/study/NCT06296706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06296706","kind":"trial","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","route":"/trials/nct06296706/","field":"links","label":"ClinicalTrials.gov NCT06296706"}]},{"url":"https://clinicaltrials.gov/study/NCT06297226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","field":"links","label":"ClinicalTrials.gov NCT06297226"}]},{"url":"https://clinicaltrials.gov/study/NCT06298916","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06298916","kind":"trial","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","route":"/trials/nct06298916/","field":"links","label":"ClinicalTrials.gov NCT06298916"}]},{"url":"https://clinicaltrials.gov/study/NCT06300177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06300177","kind":"trial","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","route":"/trials/nct06300177/","field":"links","label":"ClinicalTrials.gov NCT06300177"}]},{"url":"https://clinicaltrials.gov/study/NCT06300463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06300463","kind":"trial","name":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","route":"/trials/nct06300463/","field":"links","label":"ClinicalTrials.gov NCT06300463"}]},{"url":"https://clinicaltrials.gov/study/NCT06301386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06301386","kind":"trial","name":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients","route":"/trials/nct06301386/","field":"links","label":"ClinicalTrials.gov NCT06301386"}]},{"url":"https://clinicaltrials.gov/study/NCT06303505","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/","field":"links","label":"ClinicalTrials.gov NCT06303505"}]},{"url":"https://clinicaltrials.gov/study/NCT06304545","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06304545","kind":"trial","name":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","route":"/trials/nct06304545/","field":"links","label":"ClinicalTrials.gov NCT06304545"}]},{"url":"https://clinicaltrials.gov/study/NCT06304974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","field":"links","label":"ClinicalTrials.gov NCT06304974"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","field":"links","label":"ClinicalTrials.gov NCT06304974: PANKU-Esophagus01 (BL-B01D1-305)"}]},{"url":"https://clinicaltrials.gov/study/NCT06305247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06305247/","field":"links","label":"ClinicalTrials.gov NCT06305247"}]},{"url":"https://clinicaltrials.gov/study/NCT06305754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/","field":"links","label":"ClinicalTrials.gov NCT06305754"}]},{"url":"https://clinicaltrials.gov/study/NCT06305767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","route":"/trials/nct06305767/","field":"links","label":"ClinicalTrials.gov NCT06305767"}]},{"url":"https://clinicaltrials.gov/study/NCT06307431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","route":"/trials/nct06307431/","field":"links","label":"ClinicalTrials.gov NCT06307431"}]},{"url":"https://clinicaltrials.gov/study/NCT06307548","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06307548","kind":"trial","name":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurre","route":"/trials/nct06307548/","field":"links","label":"ClinicalTrials.gov NCT06307548"}]},{"url":"https://clinicaltrials.gov/study/NCT06311695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06311695","kind":"trial","name":"Contrast-Enhanced Spectral Mammography (CESM)","route":"/trials/nct06311695/","field":"links","label":"ClinicalTrials.gov NCT06311695"}]},{"url":"https://clinicaltrials.gov/study/NCT06311721","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/","field":"links","label":"ClinicalTrials.gov NCT06311721"}]},{"url":"https://clinicaltrials.gov/study/NCT06312137","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/","field":"links","label":"ClinicalTrials.gov NCT06312137"}]},{"url":"https://clinicaltrials.gov/study/NCT06312176","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/","field":"links","label":"ClinicalTrials.gov NCT06312176"}]},{"url":"https://clinicaltrials.gov/study/NCT06312670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06312670","kind":"trial","name":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct06312670/","field":"links","label":"ClinicalTrials.gov NCT06312670"}]},{"url":"https://clinicaltrials.gov/study/NCT06312982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06312982","kind":"trial","name":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct06312982/","field":"links","label":"ClinicalTrials.gov NCT06312982"}]},{"url":"https://clinicaltrials.gov/study/NCT06313086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06313086","kind":"trial","name":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","route":"/trials/nct06313086/","field":"links","label":"ClinicalTrials.gov NCT06313086"}]},{"url":"https://clinicaltrials.gov/study/NCT06313463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06313463","kind":"trial","name":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","route":"/trials/nct06313463/","field":"links","label":"ClinicalTrials.gov NCT06313463"}]},{"url":"https://clinicaltrials.gov/study/NCT06313983","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06313983","kind":"trial","name":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","route":"/trials/nct06313983/","field":"links","label":"ClinicalTrials.gov NCT06313983"}]},{"url":"https://clinicaltrials.gov/study/NCT06314373","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","field":"links","label":"ClinicalTrials.gov NCT06314373"}]},{"url":"https://clinicaltrials.gov/study/NCT06315010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06315010","kind":"trial","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","route":"/trials/nct06315010/","field":"links","label":"ClinicalTrials.gov NCT06315010"}]},{"url":"https://clinicaltrials.gov/study/NCT06316531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06316531","kind":"trial","name":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","route":"/trials/nct06316531/","field":"links","label":"ClinicalTrials.gov NCT06316531"}]},{"url":"https://clinicaltrials.gov/study/NCT06317311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06317311","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","route":"/trials/nct06317311/","field":"links","label":"ClinicalTrials.gov NCT06317311"}]},{"url":"https://clinicaltrials.gov/study/NCT06318897","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/","field":"links","label":"ClinicalTrials.gov NCT06318897"}]},{"url":"https://clinicaltrials.gov/study/NCT06319313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06319313","kind":"trial","name":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","route":"/trials/nct06319313/","field":"links","label":"ClinicalTrials.gov NCT06319313"}]},{"url":"https://clinicaltrials.gov/study/NCT06319820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/","field":"links","label":"ClinicalTrials.gov NCT06319820"}]},{"url":"https://clinicaltrials.gov/study/NCT06319963","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06319963","kind":"trial","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","route":"/trials/nct06319963/","field":"links","label":"ClinicalTrials.gov NCT06319963"}]},{"url":"https://clinicaltrials.gov/study/NCT06320067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06320067"}]},{"url":"https://clinicaltrials.gov/study/NCT06321081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06321081","kind":"trial","name":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","route":"/trials/nct06321081/","field":"links","label":"ClinicalTrials.gov NCT06321081"}]},{"url":"https://clinicaltrials.gov/study/NCT06323148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06323148","kind":"trial","name":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","route":"/trials/nct06323148/","field":"links","label":"ClinicalTrials.gov NCT06323148"}]},{"url":"https://clinicaltrials.gov/study/NCT06324357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06324357","kind":"trial","name":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit","route":"/trials/nct06324357/","field":"links","label":"ClinicalTrials.gov NCT06324357"}]},{"url":"https://clinicaltrials.gov/study/NCT06326411","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","field":"links","label":"NST-628 phase 1 trial"}]},{"url":"https://clinicaltrials.gov/study/NCT06329947","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06329947","kind":"trial","name":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","route":"/trials/nct06329947/","field":"links","label":"ClinicalTrials.gov NCT06329947"}]},{"url":"https://clinicaltrials.gov/study/NCT06330064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06330064","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","route":"/trials/nct06330064/","field":"links","label":"ClinicalTrials.gov NCT06330064"}]},{"url":"https://clinicaltrials.gov/study/NCT06331299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06331299","kind":"trial","name":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","route":"/trials/nct06331299/","field":"links","label":"ClinicalTrials.gov NCT06331299"}]},{"url":"https://clinicaltrials.gov/study/NCT06332092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06332092","kind":"trial","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06332092/","field":"links","label":"ClinicalTrials.gov NCT06332092"}]},{"url":"https://clinicaltrials.gov/study/NCT06332274","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06332274","kind":"trial","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","route":"/trials/nct06332274/","field":"links","label":"ClinicalTrials.gov NCT06332274"}]},{"url":"https://clinicaltrials.gov/study/NCT06333314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06333314","kind":"trial","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","route":"/trials/nct06333314/","field":"links","label":"ClinicalTrials.gov NCT06333314"}]},{"url":"https://clinicaltrials.gov/study/NCT06334432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/","field":"links","label":"ClinicalTrials.gov NCT06334432"}]},{"url":"https://clinicaltrials.gov/study/NCT06335355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06335355","kind":"trial","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","route":"/trials/nct06335355/","field":"links","label":"ClinicalTrials.gov NCT06335355"}]},{"url":"https://clinicaltrials.gov/study/NCT06336291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06336291","kind":"trial","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","route":"/trials/nct06336291/","field":"links","label":"ClinicalTrials.gov NCT06336291"}]},{"url":"https://clinicaltrials.gov/study/NCT06338683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06338683","kind":"trial","name":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","route":"/trials/nct06338683/","field":"links","label":"ClinicalTrials.gov NCT06338683"}]},{"url":"https://clinicaltrials.gov/study/NCT06340568","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06340568","kind":"trial","name":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","route":"/trials/nct06340568/","field":"links","label":"ClinicalTrials.gov NCT06340568"}]},{"url":"https://clinicaltrials.gov/study/NCT06341114","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06341114","kind":"trial","name":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","route":"/trials/nct06341114/","field":"links","label":"ClinicalTrials.gov NCT06341114"}]},{"url":"https://clinicaltrials.gov/study/NCT06341296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06341296","kind":"trial","name":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct06341296/","field":"links","label":"ClinicalTrials.gov NCT06341296"}]},{"url":"https://clinicaltrials.gov/study/NCT06342037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06342037","kind":"trial","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","route":"/trials/nct06342037/","field":"links","label":"ClinicalTrials.gov NCT06342037"}]},{"url":"https://clinicaltrials.gov/study/NCT06343064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/","field":"links","label":"ClinicalTrials.gov NCT06343064"}]},{"url":"https://clinicaltrials.gov/study/NCT06343116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06343116","kind":"trial","name":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","route":"/trials/nct06343116/","field":"links","label":"ClinicalTrials.gov NCT06343116"}]},{"url":"https://clinicaltrials.gov/study/NCT06343311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06343311","kind":"trial","name":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","route":"/trials/nct06343311/","field":"links","label":"ClinicalTrials.gov NCT06343311"}]},{"url":"https://clinicaltrials.gov/study/NCT06343948","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06343948","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","route":"/trials/nct06343948/","field":"links","label":"ClinicalTrials.gov NCT06343948"}]},{"url":"https://clinicaltrials.gov/study/NCT06344052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06344052","kind":"trial","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","route":"/trials/nct06344052/","field":"links","label":"ClinicalTrials.gov NCT06344052"}]},{"url":"https://clinicaltrials.gov/study/NCT06345287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06345287","kind":"trial","name":"Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC","route":"/trials/nct06345287/","field":"links","label":"ClinicalTrials.gov NCT06345287"}]},{"url":"https://clinicaltrials.gov/study/NCT06345482","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06345482","kind":"trial","name":"A Study of MHB039A for Advanced Solid Tumor","route":"/trials/nct06345482/","field":"links","label":"ClinicalTrials.gov NCT06345482"}]},{"url":"https://clinicaltrials.gov/study/NCT06345729","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06345729","kind":"trial","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","route":"/trials/nct06345729/","field":"links","label":"ClinicalTrials.gov NCT06345729"}]},{"url":"https://clinicaltrials.gov/study/NCT06346067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/","field":"links","label":"ClinicalTrials.gov NCT06346067"}]},{"url":"https://clinicaltrials.gov/study/NCT06346392","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","field":"links","label":"ClinicalTrials.gov NCT06346392"},{"id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","field":"links","label":"ClinicalTrials.gov NCT06346392: CLARITY-Gastric 01"},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","field":"dosing.source"}]},{"url":"https://clinicaltrials.gov/study/NCT06348199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06348199","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s","route":"/trials/nct06348199/","field":"links","label":"ClinicalTrials.gov NCT06348199"}]},{"url":"https://clinicaltrials.gov/study/NCT06349590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06349590","kind":"trial","name":"Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery","route":"/trials/nct06349590/","field":"links","label":"ClinicalTrials.gov NCT06349590"}]},{"url":"https://clinicaltrials.gov/study/NCT06349980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06349980","kind":"trial","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","route":"/trials/nct06349980/","field":"links","label":"ClinicalTrials.gov NCT06349980"}]},{"url":"https://clinicaltrials.gov/study/NCT06350097","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/","field":"links","label":"ClinicalTrials.gov NCT06350097"}]},{"url":"https://clinicaltrials.gov/study/NCT06351631","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/","field":"links","label":"ClinicalTrials.gov NCT06351631"}]},{"url":"https://clinicaltrials.gov/study/NCT06353386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/","field":"links","label":"ClinicalTrials.gov NCT06353386"}]},{"url":"https://clinicaltrials.gov/study/NCT06353997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/","field":"links","label":"ClinicalTrials.gov NCT06353997"}]},{"url":"https://clinicaltrials.gov/study/NCT06355427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06355427","kind":"trial","name":"The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma","route":"/trials/nct06355427/","field":"links","label":"ClinicalTrials.gov NCT06355427"}]},{"url":"https://clinicaltrials.gov/study/NCT06356129","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","field":"links","label":"ClinicalTrials.gov NCT06356129 (GOLSEEK-1)"},{"id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","field":"links","label":"ClinicalTrials.gov NCT06356129"}]},{"url":"https://clinicaltrials.gov/study/NCT06356311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","field":"links","label":"ClinicalTrials.gov NCT06356311"}]},{"url":"https://clinicaltrials.gov/study/NCT06356584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06356584","kind":"trial","name":"Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases","route":"/trials/nct06356584/","field":"links","label":"ClinicalTrials.gov NCT06356584"}]},{"url":"https://clinicaltrials.gov/study/NCT06356714","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06356714","kind":"trial","name":"Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Statu","route":"/trials/nct06356714/","field":"links","label":"ClinicalTrials.gov NCT06356714"}]},{"url":"https://clinicaltrials.gov/study/NCT06357533","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/","field":"links","label":"ClinicalTrials.gov NCT06357533"}]},{"url":"https://clinicaltrials.gov/study/NCT06358573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","route":"/trials/nct06358573/","field":"links","label":"ClinicalTrials.gov NCT06358573"}]},{"url":"https://clinicaltrials.gov/study/NCT06359275","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06359275","kind":"trial","name":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","route":"/trials/nct06359275/","field":"links","label":"ClinicalTrials.gov NCT06359275"}]},{"url":"https://clinicaltrials.gov/study/NCT06359847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","field":"links","label":"ClinicalTrials.gov NCT06359847"}]},{"url":"https://clinicaltrials.gov/study/NCT06359860","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06359860","kind":"trial","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","route":"/trials/nct06359860/","field":"links","label":"ClinicalTrials.gov NCT06359860"}]},{"url":"https://clinicaltrials.gov/study/NCT06361030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06361030","kind":"trial","name":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","route":"/trials/nct06361030/","field":"links","label":"ClinicalTrials.gov NCT06361030"}]},{"url":"https://clinicaltrials.gov/study/NCT06361888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/","field":"links","label":"ClinicalTrials.gov NCT06361888"}]},{"url":"https://clinicaltrials.gov/study/NCT06362252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06362252","kind":"trial","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","route":"/trials/nct06362252/","field":"links","label":"ClinicalTrials.gov NCT06362252"}]},{"url":"https://clinicaltrials.gov/study/NCT06362369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06362369","kind":"trial","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","route":"/trials/nct06362369/","field":"links","label":"ClinicalTrials.gov NCT06362369"}]},{"url":"https://clinicaltrials.gov/study/NCT06363994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/","field":"links","label":"ClinicalTrials.gov NCT06363994"}]},{"url":"https://clinicaltrials.gov/study/NCT06365788","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06365788","kind":"trial","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","route":"/trials/nct06365788/","field":"links","label":"ClinicalTrials.gov NCT06365788"}]},{"url":"https://clinicaltrials.gov/study/NCT06365840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/","field":"links","label":"ClinicalTrials.gov NCT06365840"}]},{"url":"https://clinicaltrials.gov/study/NCT06365853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/","field":"links","label":"ClinicalTrials.gov NCT06365853"}]},{"url":"https://clinicaltrials.gov/study/NCT06367088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06367088","kind":"trial","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","route":"/trials/nct06367088/","field":"links","label":"ClinicalTrials.gov NCT06367088"}]},{"url":"https://clinicaltrials.gov/study/NCT06368141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06368141","kind":"trial","name":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","route":"/trials/nct06368141/","field":"links","label":"ClinicalTrials.gov NCT06368141"}]},{"url":"https://clinicaltrials.gov/study/NCT06369259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06369259","kind":"trial","name":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R","route":"/trials/nct06369259/","field":"links","label":"ClinicalTrials.gov NCT06369259"}]},{"url":"https://clinicaltrials.gov/study/NCT06369285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/","field":"links","label":"ClinicalTrials.gov NCT06369285"}]},{"url":"https://clinicaltrials.gov/study/NCT06369831","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/","field":"links","label":"ClinicalTrials.gov NCT06369831"}]},{"url":"https://clinicaltrials.gov/study/NCT06370416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06370416","kind":"trial","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","route":"/trials/nct06370416/","field":"links","label":"ClinicalTrials.gov NCT06370416"}]},{"url":"https://clinicaltrials.gov/study/NCT06370754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06370754","kind":"trial","name":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","route":"/trials/nct06370754/","field":"links","label":"ClinicalTrials.gov NCT06370754"}]},{"url":"https://clinicaltrials.gov/study/NCT06371157","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06371157","kind":"trial","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","route":"/trials/nct06371157/","field":"links","label":"ClinicalTrials.gov NCT06371157"}]},{"url":"https://clinicaltrials.gov/study/NCT06371807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06371807","kind":"trial","name":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","route":"/trials/nct06371807/","field":"links","label":"ClinicalTrials.gov NCT06371807"}]},{"url":"https://clinicaltrials.gov/study/NCT06373133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06373133","kind":"trial","name":"SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer","route":"/trials/nct06373133/","field":"links","label":"ClinicalTrials.gov NCT06373133"}]},{"url":"https://clinicaltrials.gov/study/NCT06373406","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06373406","kind":"trial","name":"A Study of MHB036C for Advanced Solid Tumor","route":"/trials/nct06373406/","field":"links","label":"ClinicalTrials.gov NCT06373406"}]},{"url":"https://clinicaltrials.gov/study/NCT06375733","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06375733","kind":"trial","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","route":"/trials/nct06375733/","field":"links","label":"ClinicalTrials.gov NCT06375733"}]},{"url":"https://clinicaltrials.gov/study/NCT06376136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06376136","kind":"trial","name":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","route":"/trials/nct06376136/","field":"links","label":"ClinicalTrials.gov NCT06376136"}]},{"url":"https://clinicaltrials.gov/study/NCT06378138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/","field":"links","label":"ClinicalTrials.gov NCT06378138"}]},{"url":"https://clinicaltrials.gov/study/NCT06378177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/","field":"links","label":"ClinicalTrials.gov NCT06378177"}]},{"url":"https://clinicaltrials.gov/study/NCT06378242","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06378242","kind":"trial","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","route":"/trials/nct06378242/","field":"links","label":"ClinicalTrials.gov NCT06378242"}]},{"url":"https://clinicaltrials.gov/study/NCT06378593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","route":"/trials/nct06378593/","field":"links","label":"ClinicalTrials.gov NCT06378593"}]},{"url":"https://clinicaltrials.gov/study/NCT06380348","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06380348","kind":"trial","name":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara","route":"/trials/nct06380348/","field":"links","label":"ClinicalTrials.gov NCT06380348"}]},{"url":"https://clinicaltrials.gov/study/NCT06380660","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/","field":"links","label":"ClinicalTrials.gov NCT06380660"}]},{"url":"https://clinicaltrials.gov/study/NCT06380751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","route":"/trials/nct06380751/","field":"links","label":"ClinicalTrials.gov NCT06380751"}]},{"url":"https://clinicaltrials.gov/study/NCT06380816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06380816","kind":"trial","name":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","route":"/trials/nct06380816/","field":"links","label":"ClinicalTrials.gov NCT06380816"}]},{"url":"https://clinicaltrials.gov/study/NCT06382116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06382116","kind":"trial","name":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","route":"/trials/nct06382116/","field":"links","label":"ClinicalTrials.gov NCT06382116"}]},{"url":"https://clinicaltrials.gov/study/NCT06382129","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06382129","kind":"trial","name":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU","route":"/trials/nct06382129/","field":"links","label":"ClinicalTrials.gov NCT06382129"}]},{"url":"https://clinicaltrials.gov/study/NCT06382142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06382142"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","field":"links","label":"ClinicalTrials.gov NCT06382142: BL-B01D1-307"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","field":"dosing.source"},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","field":"links","label":"ClinicalTrials.gov NCT06382142"}]},{"url":"https://clinicaltrials.gov/study/NCT06382168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06382168","kind":"trial","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06382168/","field":"links","label":"ClinicalTrials.gov NCT06382168"}]},{"url":"https://clinicaltrials.gov/study/NCT06383052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/","field":"links","label":"ClinicalTrials.gov NCT06383052"}]},{"url":"https://clinicaltrials.gov/study/NCT06383078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06383078/","field":"links","label":"ClinicalTrials.gov NCT06383078"}]},{"url":"https://clinicaltrials.gov/study/NCT06383767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/","field":"links","label":"ClinicalTrials.gov NCT06383767"}]},{"url":"https://clinicaltrials.gov/study/NCT06384560","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06384560","kind":"trial","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","route":"/trials/nct06384560/","field":"links","label":"ClinicalTrials.gov NCT06384560"}]},{"url":"https://clinicaltrials.gov/study/NCT06384807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/","field":"links","label":"ClinicalTrials.gov NCT06384807"}]},{"url":"https://clinicaltrials.gov/study/NCT06385080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","route":"/trials/nct06385080/","field":"links","label":"ClinicalTrials.gov NCT06385080"}]},{"url":"https://clinicaltrials.gov/study/NCT06385418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06385418","kind":"trial","name":"Fluorouracil Treatment Via Colon for Colorectal Cancer","route":"/trials/nct06385418/","field":"links","label":"ClinicalTrials.gov NCT06385418"}]},{"url":"https://clinicaltrials.gov/study/NCT06385678","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06385678","kind":"trial","name":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385678/","field":"links","label":"ClinicalTrials.gov NCT06385678"}]},{"url":"https://clinicaltrials.gov/study/NCT06385925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06385925","kind":"trial","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385925/","field":"links","label":"ClinicalTrials.gov NCT06385925"}]},{"url":"https://clinicaltrials.gov/study/NCT06385990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06385990","kind":"trial","name":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","route":"/trials/nct06385990/","field":"links","label":"ClinicalTrials.gov NCT06385990"}]},{"url":"https://clinicaltrials.gov/study/NCT06386146","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/","field":"links","label":"ClinicalTrials.gov NCT06386146"}]},{"url":"https://clinicaltrials.gov/study/NCT06387069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/","field":"links","label":"ClinicalTrials.gov NCT06387069"}]},{"url":"https://clinicaltrials.gov/study/NCT06387342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06387342","kind":"trial","name":"Namodenoson Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06387342/","field":"links","label":"ClinicalTrials.gov NCT06387342"}]},{"url":"https://clinicaltrials.gov/study/NCT06387628","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/","field":"links","label":"ClinicalTrials.gov NCT06387628"}]},{"url":"https://clinicaltrials.gov/study/NCT06389006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06389006","kind":"trial","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","route":"/trials/nct06389006/","field":"links","label":"ClinicalTrials.gov NCT06389006"}]},{"url":"https://clinicaltrials.gov/study/NCT06389292","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/","field":"links","label":"ClinicalTrials.gov NCT06389292"}]},{"url":"https://clinicaltrials.gov/study/NCT06389500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06389500","kind":"trial","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","route":"/trials/nct06389500/","field":"links","label":"ClinicalTrials.gov NCT06389500"}]},{"url":"https://clinicaltrials.gov/study/NCT06389760","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06389760","kind":"trial","name":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06389760/","field":"links","label":"ClinicalTrials.gov NCT06389760"}]},{"url":"https://clinicaltrials.gov/study/NCT06390982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06390982","kind":"trial","name":"Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study","route":"/trials/nct06390982/","field":"links","label":"ClinicalTrials.gov NCT06390982"}]},{"url":"https://clinicaltrials.gov/study/NCT06390995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/","field":"links","label":"ClinicalTrials.gov NCT06390995"}]},{"url":"https://clinicaltrials.gov/study/NCT06390995?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/","field":"outcomes.source (Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1))"}]},{"url":"https://clinicaltrials.gov/study/NCT06391892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06391892","kind":"trial","name":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","route":"/trials/nct06391892/","field":"links","label":"ClinicalTrials.gov NCT06391892"}]},{"url":"https://clinicaltrials.gov/study/NCT06391905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06391905","kind":"trial","name":"PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS","route":"/trials/nct06391905/","field":"links","label":"ClinicalTrials.gov NCT06391905"}]},{"url":"https://clinicaltrials.gov/study/NCT06391944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06391944","kind":"trial","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","route":"/trials/nct06391944/","field":"links","label":"ClinicalTrials.gov NCT06391944"}]},{"url":"https://clinicaltrials.gov/study/NCT06393374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/","field":"links","label":"ClinicalTrials.gov NCT06393374"}]},{"url":"https://clinicaltrials.gov/study/NCT06394492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06394492","kind":"trial","name":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06394492/","field":"links","label":"ClinicalTrials.gov NCT06394492"}]},{"url":"https://clinicaltrials.gov/study/NCT06395103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","route":"/trials/nct06395103/","field":"links","label":"ClinicalTrials.gov NCT06395103"}]},{"url":"https://clinicaltrials.gov/study/NCT06395519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","route":"/trials/nct06395519/","field":"links","label":"ClinicalTrials.gov NCT06395519"}]},{"url":"https://clinicaltrials.gov/study/NCT06396065","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT06396065"},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/","field":"links","label":"ClinicalTrials.gov NCT06396065"}]},{"url":"https://clinicaltrials.gov/study/NCT06398444","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","field":"links","label":"ClinicalTrials.gov NCT06398444"}]},{"url":"https://clinicaltrials.gov/study/NCT06399757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","field":"links","label":"ClinicalTrials.gov NCT06399757"}]},{"url":"https://clinicaltrials.gov/study/NCT06400160","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06400160","kind":"trial","name":"Clinical Trial of TB511 in Advanced Solid Tumors","route":"/trials/nct06400160/","field":"links","label":"ClinicalTrials.gov NCT06400160"}]},{"url":"https://clinicaltrials.gov/study/NCT06401005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06401005","kind":"trial","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","route":"/trials/nct06401005/","field":"links","label":"ClinicalTrials.gov NCT06401005"}]},{"url":"https://clinicaltrials.gov/study/NCT06401356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/","field":"links","label":"ClinicalTrials.gov NCT06401356"}]},{"url":"https://clinicaltrials.gov/study/NCT06401824","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06401824","kind":"trial","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","route":"/trials/nct06401824/","field":"links","label":"ClinicalTrials.gov NCT06401824"}]},{"url":"https://clinicaltrials.gov/study/NCT06402331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","field":"links","label":"ClinicalTrials.gov NCT06402331"},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","field":"links","label":"ClinicalTrials.gov NCT06402331: AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)"}]},{"url":"https://clinicaltrials.gov/study/NCT06404736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06404736","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","route":"/trials/nct06404736/","field":"links","label":"ClinicalTrials.gov NCT06404736"}]},{"url":"https://clinicaltrials.gov/study/NCT06405139","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06405139","kind":"trial","name":"Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer","route":"/trials/nct06405139/","field":"links","label":"ClinicalTrials.gov NCT06405139"}]},{"url":"https://clinicaltrials.gov/study/NCT06405425","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06405425","kind":"trial","name":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06405425/","field":"links","label":"ClinicalTrials.gov NCT06405425"}]},{"url":"https://clinicaltrials.gov/study/NCT06405490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06405490","kind":"trial","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","route":"/trials/nct06405490/","field":"links","label":"ClinicalTrials.gov NCT06405490"}]},{"url":"https://clinicaltrials.gov/study/NCT06407310","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06407310","kind":"trial","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","route":"/trials/nct06407310/","field":"links","label":"ClinicalTrials.gov NCT06407310"}]},{"url":"https://clinicaltrials.gov/study/NCT06409429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06409429","kind":"trial","name":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06409429/","field":"links","label":"ClinicalTrials.gov NCT06409429"}]},{"url":"https://clinicaltrials.gov/study/NCT06411600","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06411600","kind":"trial","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","route":"/trials/nct06411600/","field":"links","label":"ClinicalTrials.gov NCT06411600"}]},{"url":"https://clinicaltrials.gov/study/NCT06411795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06411795","kind":"trial","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","route":"/trials/nct06411795/","field":"links","label":"ClinicalTrials.gov NCT06411795"}]},{"url":"https://clinicaltrials.gov/study/NCT06412198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06412198","kind":"trial","name":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","route":"/trials/nct06412198/","field":"links","label":"ClinicalTrials.gov NCT06412198"}]},{"url":"https://clinicaltrials.gov/study/NCT06413498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/","field":"links","label":"ClinicalTrials.gov NCT06413498"}]},{"url":"https://clinicaltrials.gov/study/NCT06413680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06413680","kind":"trial","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","route":"/trials/nct06413680/","field":"links","label":"ClinicalTrials.gov NCT06413680"}]},{"url":"https://clinicaltrials.gov/study/NCT06413706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06413706","kind":"trial","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","route":"/trials/nct06413706/","field":"links","label":"ClinicalTrials.gov NCT06413706"}]},{"url":"https://clinicaltrials.gov/study/NCT06413745","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06413745","kind":"trial","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","route":"/trials/nct06413745/","field":"links","label":"ClinicalTrials.gov NCT06413745"}]},{"url":"https://clinicaltrials.gov/study/NCT06414460","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/","field":"links","label":"ClinicalTrials.gov NCT06414460"}]},{"url":"https://clinicaltrials.gov/study/NCT06416410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/","field":"links","label":"ClinicalTrials.gov NCT06416410"}]},{"url":"https://clinicaltrials.gov/study/NCT06416852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06416852","kind":"trial","name":"Clinical Study of 18F-Alfatide Injection PET/CT","route":"/trials/nct06416852/","field":"links","label":"ClinicalTrials.gov NCT06416852"}]},{"url":"https://clinicaltrials.gov/study/NCT06417008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06417008","kind":"trial","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct06417008/","field":"links","label":"ClinicalTrials.gov NCT06417008"}]},{"url":"https://clinicaltrials.gov/study/NCT06417554","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","route":"/trials/nct06417554/","field":"links","label":"ClinicalTrials.gov NCT06417554"}]},{"url":"https://clinicaltrials.gov/study/NCT06417814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/","field":"links","label":"ClinicalTrials.gov NCT06417814"}]},{"url":"https://clinicaltrials.gov/study/NCT06419179","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","route":"/trials/nct06419179/","field":"links","label":"ClinicalTrials.gov NCT06419179"}]},{"url":"https://clinicaltrials.gov/study/NCT06419621","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06419621"},{"id":"nct06419621","kind":"trial","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","route":"/trials/nct06419621/","field":"links","label":"ClinicalTrials.gov NCT06419621"}]},{"url":"https://clinicaltrials.gov/study/NCT06422143","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/","field":"links","label":"ClinicalTrials.gov NCT06422143"}]},{"url":"https://clinicaltrials.gov/study/NCT06422936","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","field":"links","label":"ClinicalTrials.gov NCT06422936"}]},{"url":"https://clinicaltrials.gov/study/NCT06423170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06423170","kind":"trial","name":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","route":"/trials/nct06423170/","field":"links","label":"ClinicalTrials.gov NCT06423170"}]},{"url":"https://clinicaltrials.gov/study/NCT06423326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06423326","kind":"trial","name":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","route":"/trials/nct06423326/","field":"links","label":"ClinicalTrials.gov NCT06423326"}]},{"url":"https://clinicaltrials.gov/study/NCT06423911","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","route":"/trials/nct06423911/","field":"links","label":"ClinicalTrials.gov NCT06423911"}]},{"url":"https://clinicaltrials.gov/study/NCT06423937","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06423937","kind":"trial","name":"Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer","route":"/trials/nct06423937/","field":"links","label":"ClinicalTrials.gov NCT06423937"}]},{"url":"https://clinicaltrials.gov/study/NCT06425133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06425133","kind":"trial","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","route":"/trials/nct06425133/","field":"links","label":"ClinicalTrials.gov NCT06425133"}]},{"url":"https://clinicaltrials.gov/study/NCT06425302","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","route":"/trials/nct06425302/","field":"links","label":"ClinicalTrials.gov NCT06425302"}]},{"url":"https://clinicaltrials.gov/study/NCT06425926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06425926","kind":"trial","name":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","route":"/trials/nct06425926/","field":"links","label":"ClinicalTrials.gov NCT06425926"}]},{"url":"https://clinicaltrials.gov/study/NCT06427239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06427239","kind":"trial","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06427239/","field":"links","label":"ClinicalTrials.gov NCT06427239"}]},{"url":"https://clinicaltrials.gov/study/NCT06427447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06427447","kind":"trial","name":"Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)","route":"/trials/nct06427447/","field":"links","label":"ClinicalTrials.gov NCT06427447"}]},{"url":"https://clinicaltrials.gov/study/NCT06427460","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06427460","kind":"trial","name":"Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)","route":"/trials/nct06427460/","field":"links","label":"ClinicalTrials.gov NCT06427460"}]},{"url":"https://clinicaltrials.gov/study/NCT06427941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/","field":"links","label":"ClinicalTrials.gov NCT06427941"}]},{"url":"https://clinicaltrials.gov/study/NCT06428019","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06428019","kind":"trial","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct06428019/","field":"links","label":"ClinicalTrials.gov NCT06428019"}]},{"url":"https://clinicaltrials.gov/study/NCT06428396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06428396","kind":"trial","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","route":"/trials/nct06428396/","field":"links","label":"ClinicalTrials.gov NCT06428396"}]},{"url":"https://clinicaltrials.gov/study/NCT06428409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06428409","kind":"trial","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","route":"/trials/nct06428409/","field":"links","label":"ClinicalTrials.gov NCT06428409"}]},{"url":"https://clinicaltrials.gov/study/NCT06430437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06430437","kind":"trial","name":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","route":"/trials/nct06430437/","field":"links","label":"ClinicalTrials.gov NCT06430437"}]},{"url":"https://clinicaltrials.gov/study/NCT06430866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06430866","kind":"trial","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","route":"/trials/nct06430866/","field":"links","label":"ClinicalTrials.gov NCT06430866"}]},{"url":"https://clinicaltrials.gov/study/NCT06431243","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06431243","kind":"trial","name":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06431243/","field":"links","label":"ClinicalTrials.gov NCT06431243"}]},{"url":"https://clinicaltrials.gov/study/NCT06431490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/","field":"links","label":"ClinicalTrials.gov NCT06431490"}]},{"url":"https://clinicaltrials.gov/study/NCT06431633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06431633","kind":"trial","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","route":"/trials/nct06431633/","field":"links","label":"ClinicalTrials.gov NCT06431633"}]},{"url":"https://clinicaltrials.gov/study/NCT06432296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06432296","kind":"trial","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","route":"/trials/nct06432296/","field":"links","label":"ClinicalTrials.gov NCT06432296"}]},{"url":"https://clinicaltrials.gov/study/NCT06434064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06434064","kind":"trial","name":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","route":"/trials/nct06434064/","field":"links","label":"ClinicalTrials.gov NCT06434064"}]},{"url":"https://clinicaltrials.gov/study/NCT06434597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06434597","kind":"trial","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","route":"/trials/nct06434597/","field":"links","label":"ClinicalTrials.gov NCT06434597"}]},{"url":"https://clinicaltrials.gov/study/NCT06434610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06434610","kind":"trial","name":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","route":"/trials/nct06434610/","field":"links","label":"ClinicalTrials.gov NCT06434610"}]},{"url":"https://clinicaltrials.gov/study/NCT06434909","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06434909","kind":"trial","name":"CYTALUX™for the Intraoperative Imaging of Prostate Cancer","route":"/trials/nct06434909/","field":"links","label":"ClinicalTrials.gov NCT06434909"}]},{"url":"https://clinicaltrials.gov/study/NCT06435260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06435260","kind":"trial","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/","field":"links","label":"ClinicalTrials.gov NCT06435260"}]},{"url":"https://clinicaltrials.gov/study/NCT06435429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/","field":"links","label":"ClinicalTrials.gov NCT06435429"}]},{"url":"https://clinicaltrials.gov/study/NCT06437509","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06437509","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct06437509/","field":"links","label":"ClinicalTrials.gov NCT06437509"}]},{"url":"https://clinicaltrials.gov/study/NCT06437522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06437522","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06437522/","field":"links","label":"ClinicalTrials.gov NCT06437522"}]},{"url":"https://clinicaltrials.gov/study/NCT06437977","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06437977","kind":"trial","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","route":"/trials/nct06437977/","field":"links","label":"ClinicalTrials.gov NCT06437977"}]},{"url":"https://clinicaltrials.gov/study/NCT06438822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06438822","kind":"trial","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","route":"/trials/nct06438822/","field":"links","label":"ClinicalTrials.gov NCT06438822"}]},{"url":"https://clinicaltrials.gov/study/NCT06439771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/","field":"links","label":"ClinicalTrials.gov NCT06439771"}]},{"url":"https://clinicaltrials.gov/study/NCT06440057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06440057","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","route":"/trials/nct06440057/","field":"links","label":"ClinicalTrials.gov NCT06440057"}]},{"url":"https://clinicaltrials.gov/study/NCT06440902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06440902","kind":"trial","name":"Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA","route":"/trials/nct06440902/","field":"links","label":"ClinicalTrials.gov NCT06440902"}]},{"url":"https://clinicaltrials.gov/study/NCT06441344","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06441344","kind":"trial","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","route":"/trials/nct06441344/","field":"links","label":"ClinicalTrials.gov NCT06441344"}]},{"url":"https://clinicaltrials.gov/study/NCT06441565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06441565","kind":"trial","name":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","route":"/trials/nct06441565/","field":"links","label":"ClinicalTrials.gov NCT06441565"}]},{"url":"https://clinicaltrials.gov/study/NCT06443671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06443671","kind":"trial","name":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct06443671/","field":"links","label":"ClinicalTrials.gov NCT06443671"}]},{"url":"https://clinicaltrials.gov/study/NCT06445062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/","field":"links","label":"ClinicalTrials.gov NCT06445062"}]},{"url":"https://clinicaltrials.gov/study/NCT06445400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06445400","kind":"trial","name":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ","route":"/trials/nct06445400/","field":"links","label":"ClinicalTrials.gov NCT06445400"}]},{"url":"https://clinicaltrials.gov/study/NCT06445972","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","route":"/trials/nct06445972/","field":"links","label":"ClinicalTrials.gov NCT06445972"}]},{"url":"https://clinicaltrials.gov/study/NCT06446557","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06446557","kind":"trial","name":"De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unrese","route":"/trials/nct06446557/","field":"links","label":"ClinicalTrials.gov NCT06446557"}]},{"url":"https://clinicaltrials.gov/study/NCT06447103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06447103","kind":"trial","name":"An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","route":"/trials/nct06447103/","field":"links","label":"ClinicalTrials.gov NCT06447103"}]},{"url":"https://clinicaltrials.gov/study/NCT06448312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06448312-lancet-2026","kind":"paper","name":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct06448312-lancet-2026/","field":"links","label":"ClinicalTrials.gov NCT06448312"},{"id":"nct06448312","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06448312/","field":"links","label":"ClinicalTrials.gov NCT06448312"}]},{"url":"https://clinicaltrials.gov/study/NCT06448572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06448572","kind":"trial","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","route":"/trials/nct06448572/","field":"links","label":"ClinicalTrials.gov NCT06448572"}]},{"url":"https://clinicaltrials.gov/study/NCT06448754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/","field":"links","label":"ClinicalTrials.gov NCT06448754"}]},{"url":"https://clinicaltrials.gov/study/NCT06449209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/","field":"links","label":"ClinicalTrials.gov NCT06449209"}]},{"url":"https://clinicaltrials.gov/study/NCT06449222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/","field":"links","label":"ClinicalTrials.gov NCT06449222"}]},{"url":"https://clinicaltrials.gov/study/NCT06449313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06449313","kind":"trial","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","route":"/trials/nct06449313/","field":"links","label":"ClinicalTrials.gov NCT06449313"}]},{"url":"https://clinicaltrials.gov/study/NCT06450574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06450574","kind":"trial","name":"Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)","route":"/trials/nct06450574/","field":"links","label":"ClinicalTrials.gov NCT06450574"}]},{"url":"https://clinicaltrials.gov/study/NCT06452277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/","field":"links","label":"ClinicalTrials.gov NCT06452277"}]},{"url":"https://clinicaltrials.gov/study/NCT06452706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06452706","kind":"trial","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","route":"/trials/nct06452706/","field":"links","label":"ClinicalTrials.gov NCT06452706"}]},{"url":"https://clinicaltrials.gov/study/NCT06453486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06453486","kind":"trial","name":"A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","route":"/trials/nct06453486/","field":"links","label":"ClinicalTrials.gov NCT06453486"}]},{"url":"https://clinicaltrials.gov/study/NCT06453902","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06453902","kind":"trial","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct06453902/","field":"links","label":"ClinicalTrials.gov NCT06453902"}]},{"url":"https://clinicaltrials.gov/study/NCT06454448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06454448","kind":"trial","name":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P","route":"/trials/nct06454448/","field":"links","label":"ClinicalTrials.gov NCT06454448"}]},{"url":"https://clinicaltrials.gov/study/NCT06455124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06455124","kind":"trial","name":"Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)","route":"/trials/nct06455124/","field":"links","label":"ClinicalTrials.gov NCT06455124"}]},{"url":"https://clinicaltrials.gov/study/NCT06456138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06456138","kind":"trial","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","route":"/trials/nct06456138/","field":"links","label":"ClinicalTrials.gov NCT06456138"}]},{"url":"https://clinicaltrials.gov/study/NCT06456463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","route":"/trials/nct06456463/","field":"links","label":"ClinicalTrials.gov NCT06456463"}]},{"url":"https://clinicaltrials.gov/study/NCT06457906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/","field":"links","label":"ClinicalTrials.gov NCT06457906"}]},{"url":"https://clinicaltrials.gov/study/NCT06459180","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/","field":"links","label":"ClinicalTrials.gov NCT06459180"}]},{"url":"https://clinicaltrials.gov/study/NCT06459687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","route":"/trials/nct06459687/","field":"links","label":"ClinicalTrials.gov NCT06459687"}]},{"url":"https://clinicaltrials.gov/study/NCT06459973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/","field":"links","label":"ClinicalTrials.gov NCT06459973"}]},{"url":"https://clinicaltrials.gov/study/NCT06460298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/","field":"links","label":"ClinicalTrials.gov NCT06460298"}]},{"url":"https://clinicaltrials.gov/study/NCT06462053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06462053","kind":"trial","name":"Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer","route":"/trials/nct06462053/","field":"links","label":"ClinicalTrials.gov NCT06462053"}]},{"url":"https://clinicaltrials.gov/study/NCT06463028","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06463028","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","route":"/trials/nct06463028/","field":"links","label":"ClinicalTrials.gov NCT06463028"}]},{"url":"https://clinicaltrials.gov/study/NCT06463665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/","field":"links","label":"ClinicalTrials.gov NCT06463665"}]},{"url":"https://clinicaltrials.gov/study/NCT06464055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/","field":"links","label":"ClinicalTrials.gov NCT06464055"}]},{"url":"https://clinicaltrials.gov/study/NCT06464991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/","field":"links","label":"ClinicalTrials.gov NCT06464991"}]},{"url":"https://clinicaltrials.gov/study/NCT06465329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/","field":"links","label":"ClinicalTrials.gov NCT06465329"}]},{"url":"https://clinicaltrials.gov/study/NCT06465433","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06465433","kind":"trial","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","route":"/trials/nct06465433/","field":"links","label":"ClinicalTrials.gov NCT06465433"}]},{"url":"https://clinicaltrials.gov/study/NCT06465563","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06465563","kind":"trial","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06465563/","field":"links","label":"ClinicalTrials.gov NCT06465563"}]},{"url":"https://clinicaltrials.gov/study/NCT06465914","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/","field":"links","label":"ClinicalTrials.gov NCT06465914"}]},{"url":"https://clinicaltrials.gov/study/NCT06467357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/","field":"links","label":"ClinicalTrials.gov NCT06467357"}]},{"url":"https://clinicaltrials.gov/study/NCT06468033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","route":"/trials/nct06468033/","field":"links","label":"ClinicalTrials.gov NCT06468033"}]},{"url":"https://clinicaltrials.gov/study/NCT06468358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct06468358/","field":"links","label":"ClinicalTrials.gov NCT06468358"}]},{"url":"https://clinicaltrials.gov/study/NCT06469879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","route":"/trials/nct06469879/","field":"links","label":"ClinicalTrials.gov NCT06469879"}]},{"url":"https://clinicaltrials.gov/study/NCT06469944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","route":"/trials/nct06469944/","field":"links","label":"ClinicalTrials.gov NCT06469944"}]},{"url":"https://clinicaltrials.gov/study/NCT06470451","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06470451","kind":"trial","name":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","route":"/trials/nct06470451/","field":"links","label":"ClinicalTrials.gov NCT06470451"}]},{"url":"https://clinicaltrials.gov/study/NCT06471205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06471205","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","route":"/trials/nct06471205/","field":"links","label":"ClinicalTrials.gov NCT06471205"}]},{"url":"https://clinicaltrials.gov/study/NCT06472076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06472076","kind":"trial","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","route":"/trials/nct06472076/","field":"links","label":"ClinicalTrials.gov NCT06472076"}]},{"url":"https://clinicaltrials.gov/study/NCT06472245","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/","field":"links","label":"ClinicalTrials.gov NCT06472245"}]},{"url":"https://clinicaltrials.gov/study/NCT06474455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06474455","kind":"trial","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct06474455/","field":"links","label":"ClinicalTrials.gov NCT06474455"}]},{"url":"https://clinicaltrials.gov/study/NCT06474468","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06474468","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","route":"/trials/nct06474468/","field":"links","label":"ClinicalTrials.gov NCT06474468"}]},{"url":"https://clinicaltrials.gov/study/NCT06474806","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","field":"links","label":"ClinicalTrials.gov NCT06474806"}]},{"url":"https://clinicaltrials.gov/study/NCT06475209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06475209","kind":"trial","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","route":"/trials/nct06475209/","field":"links","label":"ClinicalTrials.gov NCT06475209"}]},{"url":"https://clinicaltrials.gov/study/NCT06475300","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/","field":"links","label":"ClinicalTrials.gov NCT06475300"}]},{"url":"https://clinicaltrials.gov/study/NCT06475352","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06475352","kind":"trial","name":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","route":"/trials/nct06475352/","field":"links","label":"ClinicalTrials.gov NCT06475352"}]},{"url":"https://clinicaltrials.gov/study/NCT06478108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06478108","kind":"trial","name":"Interventional Software for Multi-immunotherapy of Solid Tumors","route":"/trials/nct06478108/","field":"links","label":"ClinicalTrials.gov NCT06478108"}]},{"url":"https://clinicaltrials.gov/study/NCT06478719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","route":"/trials/nct06478719/","field":"links","label":"ClinicalTrials.gov NCT06478719"}]},{"url":"https://clinicaltrials.gov/study/NCT06479239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06479239","kind":"trial","name":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","route":"/trials/nct06479239/","field":"links","label":"ClinicalTrials.gov NCT06479239"}]},{"url":"https://clinicaltrials.gov/study/NCT06479356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","route":"/trials/nct06479356/","field":"links","label":"ClinicalTrials.gov NCT06479356"}]},{"url":"https://clinicaltrials.gov/study/NCT06480240","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","route":"/trials/nct06480240/","field":"links","label":"ClinicalTrials.gov NCT06480240"}]},{"url":"https://clinicaltrials.gov/study/NCT06480565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","route":"/trials/nct06480565/","field":"links","label":"ClinicalTrials.gov NCT06480565"}]},{"url":"https://clinicaltrials.gov/study/NCT06481592","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/","field":"links","label":"ClinicalTrials.gov NCT06481592"}]},{"url":"https://clinicaltrials.gov/study/NCT06483100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06483100","kind":"trial","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","route":"/trials/nct06483100/","field":"links","label":"ClinicalTrials.gov NCT06483100"}]},{"url":"https://clinicaltrials.gov/study/NCT06483334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","route":"/trials/nct06483334/","field":"links","label":"ClinicalTrials.gov NCT06483334"}]},{"url":"https://clinicaltrials.gov/study/NCT06483555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06483555","kind":"trial","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","route":"/trials/nct06483555/","field":"links","label":"ClinicalTrials.gov NCT06483555"}]},{"url":"https://clinicaltrials.gov/study/NCT06484153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06484153","kind":"trial","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","route":"/trials/nct06484153/","field":"links","label":"ClinicalTrials.gov NCT06484153"}]},{"url":"https://clinicaltrials.gov/study/NCT06484829","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06484829","kind":"trial","name":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06484829/","field":"links","label":"ClinicalTrials.gov NCT06484829"}]},{"url":"https://clinicaltrials.gov/study/NCT06485219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06485219","kind":"trial","name":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","route":"/trials/nct06485219/","field":"links","label":"ClinicalTrials.gov NCT06485219"}]},{"url":"https://clinicaltrials.gov/study/NCT06486142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06486142","kind":"trial","name":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","route":"/trials/nct06486142/","field":"links","label":"ClinicalTrials.gov NCT06486142"}]},{"url":"https://clinicaltrials.gov/study/NCT06486441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06486441","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im","route":"/trials/nct06486441/","field":"links","label":"ClinicalTrials.gov NCT06486441"}]},{"url":"https://clinicaltrials.gov/study/NCT06490107","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06490107","kind":"trial","name":"Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC","route":"/trials/nct06490107/","field":"links","label":"ClinicalTrials.gov NCT06490107"}]},{"url":"https://clinicaltrials.gov/study/NCT06490536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06490536","kind":"trial","name":"The Sagittarius Trial","route":"/trials/nct06490536/","field":"links","label":"ClinicalTrials.gov NCT06490536"}]},{"url":"https://clinicaltrials.gov/study/NCT06491472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06491472","kind":"trial","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","route":"/trials/nct06491472/","field":"links","label":"ClinicalTrials.gov NCT06491472"}]},{"url":"https://clinicaltrials.gov/study/NCT06492005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06492005","kind":"trial","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06492005/","field":"links","label":"ClinicalTrials.gov NCT06492005"}]},{"url":"https://clinicaltrials.gov/study/NCT06492616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/","field":"links","label":"ClinicalTrials.gov NCT06492616"}]},{"url":"https://clinicaltrials.gov/study/NCT06492759","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06492759","kind":"trial","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","route":"/trials/nct06492759/","field":"links","label":"ClinicalTrials.gov NCT06492759"}]},{"url":"https://clinicaltrials.gov/study/NCT06492941","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06492941","kind":"trial","name":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06492941/","field":"links","label":"ClinicalTrials.gov NCT06492941"}]},{"url":"https://clinicaltrials.gov/study/NCT06493552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","route":"/trials/nct06493552/","field":"links","label":"ClinicalTrials.gov NCT06493552"}]},{"url":"https://clinicaltrials.gov/study/NCT06493760","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06493760","kind":"trial","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","route":"/trials/nct06493760/","field":"links","label":"ClinicalTrials.gov NCT06493760"}]},{"url":"https://clinicaltrials.gov/study/NCT06496048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/","field":"links","label":"ClinicalTrials.gov NCT06496048"}]},{"url":"https://clinicaltrials.gov/study/NCT06496178","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06496178","kind":"trial","name":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P","route":"/trials/nct06496178/","field":"links","label":"ClinicalTrials.gov NCT06496178"}]},{"url":"https://clinicaltrials.gov/study/NCT06496490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06496490","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","route":"/trials/nct06496490/","field":"links","label":"ClinicalTrials.gov NCT06496490"}]},{"url":"https://clinicaltrials.gov/study/NCT06496971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06496971","kind":"trial","name":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","route":"/trials/nct06496971/","field":"links","label":"ClinicalTrials.gov NCT06496971"}]},{"url":"https://clinicaltrials.gov/study/NCT06497556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","field":"links","label":"ClinicalTrials.gov NCT06497556"},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","field":"outcomes.source (Overall survival (interim))"}],"archive":"https://web.archive.org/web/20260826003324/https://clinicaltrials.gov/study/NCT06497556"},{"url":"https://clinicaltrials.gov/study/NCT06497985","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06497985","kind":"trial","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","route":"/trials/nct06497985/","field":"links","label":"ClinicalTrials.gov NCT06497985"}]},{"url":"https://clinicaltrials.gov/study/NCT06498479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06498479","kind":"trial","name":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06498479/","field":"links","label":"ClinicalTrials.gov NCT06498479"}]},{"url":"https://clinicaltrials.gov/study/NCT06498635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06498635","kind":"trial","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","route":"/trials/nct06498635/","field":"links","label":"ClinicalTrials.gov NCT06498635"}]},{"url":"https://clinicaltrials.gov/study/NCT06498986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","field":"links","label":"ClinicalTrials.gov NCT06498986"}]},{"url":"https://clinicaltrials.gov/study/NCT06499285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/","field":"links","label":"ClinicalTrials.gov NCT06499285"}]},{"url":"https://clinicaltrials.gov/study/NCT06499350","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06499350","kind":"trial","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct06499350/","field":"links","label":"ClinicalTrials.gov NCT06499350"}]},{"url":"https://clinicaltrials.gov/study/NCT06500026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500026","kind":"trial","name":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","route":"/trials/nct06500026/","field":"links","label":"ClinicalTrials.gov NCT06500026"}]},{"url":"https://clinicaltrials.gov/study/NCT06500273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/","field":"links","label":"ClinicalTrials.gov NCT06500273"}]},{"url":"https://clinicaltrials.gov/study/NCT06500455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500455","kind":"trial","name":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","route":"/trials/nct06500455/","field":"links","label":"ClinicalTrials.gov NCT06500455"}]},{"url":"https://clinicaltrials.gov/study/NCT06500481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500481","kind":"trial","name":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","route":"/trials/nct06500481/","field":"links","label":"ClinicalTrials.gov NCT06500481"}]},{"url":"https://clinicaltrials.gov/study/NCT06500676","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/","field":"links","label":"ClinicalTrials.gov NCT06500676"}]},{"url":"https://clinicaltrials.gov/study/NCT06500884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/","field":"links","label":"ClinicalTrials.gov NCT06500884"}]},{"url":"https://clinicaltrials.gov/study/NCT06501482","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06501482","kind":"trial","name":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","route":"/trials/nct06501482/","field":"links","label":"ClinicalTrials.gov NCT06501482"}]},{"url":"https://clinicaltrials.gov/study/NCT06502080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06502080","kind":"trial","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","route":"/trials/nct06502080/","field":"links","label":"ClinicalTrials.gov NCT06502080"}]},{"url":"https://clinicaltrials.gov/study/NCT06502977","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","route":"/trials/nct06502977/","field":"links","label":"ClinicalTrials.gov NCT06502977"}]},{"url":"https://clinicaltrials.gov/study/NCT06502977?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","route":"/trials/nct06502977/","field":"outcomes.source (Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1))"}]},{"url":"https://clinicaltrials.gov/study/NCT06503146","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06503146","kind":"trial","name":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","route":"/trials/nct06503146/","field":"links","label":"ClinicalTrials.gov NCT06503146"}]},{"url":"https://clinicaltrials.gov/study/NCT06504147","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","field":"links","label":"ClinicalTrials.gov NCT06504147"}]},{"url":"https://clinicaltrials.gov/study/NCT06504732","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/","field":"links","label":"ClinicalTrials.gov NCT06504732"}]},{"url":"https://clinicaltrials.gov/study/NCT06505395","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","field":"links","label":"ClinicalTrials.gov NCT06505395"}]},{"url":"https://clinicaltrials.gov/study/NCT06505837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06505837","kind":"trial","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","route":"/trials/nct06505837/","field":"links","label":"ClinicalTrials.gov NCT06505837"}]},{"url":"https://clinicaltrials.gov/study/NCT06506643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","field":"links","label":"ClinicalTrials.gov NCT06506643"}]},{"url":"https://clinicaltrials.gov/study/NCT06506955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","route":"/trials/nct06506955/","field":"links","label":"ClinicalTrials.gov NCT06506955"}]},{"url":"https://clinicaltrials.gov/study/NCT06507371","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06507371","kind":"trial","name":"Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer","route":"/trials/nct06507371/","field":"links","label":"ClinicalTrials.gov NCT06507371"}]},{"url":"https://clinicaltrials.gov/study/NCT06508216","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06508216","kind":"trial","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","route":"/trials/nct06508216/","field":"links","label":"ClinicalTrials.gov NCT06508216"}]},{"url":"https://clinicaltrials.gov/study/NCT06508658","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06508658","kind":"trial","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","route":"/trials/nct06508658/","field":"links","label":"ClinicalTrials.gov NCT06508658"}]},{"url":"https://clinicaltrials.gov/study/NCT06508931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/","field":"links","label":"ClinicalTrials.gov NCT06508931"}]},{"url":"https://clinicaltrials.gov/study/NCT06508983","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/","field":"links","label":"ClinicalTrials.gov NCT06508983"}]},{"url":"https://clinicaltrials.gov/study/NCT06509126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06509126","kind":"trial","name":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct06509126/","field":"links","label":"ClinicalTrials.gov NCT06509126"}]},{"url":"https://clinicaltrials.gov/study/NCT06510374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06510374/","field":"links","label":"ClinicalTrials.gov NCT06510374"}]},{"url":"https://clinicaltrials.gov/study/NCT06512051","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06512051","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06512051/","field":"links","label":"ClinicalTrials.gov NCT06512051"}]},{"url":"https://clinicaltrials.gov/study/NCT06513221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06513221","kind":"trial","name":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","route":"/trials/nct06513221/","field":"links","label":"ClinicalTrials.gov NCT06513221"}]},{"url":"https://clinicaltrials.gov/study/NCT06513455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06513455","kind":"trial","name":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","route":"/trials/nct06513455/","field":"links","label":"ClinicalTrials.gov NCT06513455"}]},{"url":"https://clinicaltrials.gov/study/NCT06514027","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/","field":"links","label":"ClinicalTrials.gov NCT06514027"}]},{"url":"https://clinicaltrials.gov/study/NCT06514508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","field":"links","label":"ClinicalTrials.gov NCT06514508"}]},{"url":"https://clinicaltrials.gov/study/NCT06514534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06514534","kind":"trial","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","route":"/trials/nct06514534/","field":"links","label":"ClinicalTrials.gov NCT06514534"}]},{"url":"https://clinicaltrials.gov/study/NCT06514794","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06514794","kind":"trial","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","route":"/trials/nct06514794/","field":"links","label":"ClinicalTrials.gov NCT06514794"}]},{"url":"https://clinicaltrials.gov/study/NCT06515990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06515990","kind":"trial","name":"A Study of DM005 in Patients With Advanced Solid Tumors","route":"/trials/nct06515990/","field":"links","label":"ClinicalTrials.gov NCT06515990"}]},{"url":"https://clinicaltrials.gov/study/NCT06519266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06519266","kind":"trial","name":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","route":"/trials/nct06519266/","field":"links","label":"ClinicalTrials.gov NCT06519266"}]},{"url":"https://clinicaltrials.gov/study/NCT06519370","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06519370","kind":"trial","name":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06519370/","field":"links","label":"ClinicalTrials.gov NCT06519370"}]},{"url":"https://clinicaltrials.gov/study/NCT06520345","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","field":"links","label":"ClinicalTrials.gov NCT06520345"}]},{"url":"https://clinicaltrials.gov/study/NCT06520488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","route":"/trials/nct06520488/","field":"links","label":"ClinicalTrials.gov NCT06520488"}]},{"url":"https://clinicaltrials.gov/study/NCT06520683","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06520683","kind":"trial","name":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","route":"/trials/nct06520683/","field":"links","label":"ClinicalTrials.gov NCT06520683"}]},{"url":"https://clinicaltrials.gov/study/NCT06521567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06521567","kind":"trial","name":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","route":"/trials/nct06521567/","field":"links","label":"ClinicalTrials.gov NCT06521567"}]},{"url":"https://clinicaltrials.gov/study/NCT06521866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06521866","kind":"trial","name":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","route":"/trials/nct06521866/","field":"links","label":"ClinicalTrials.gov NCT06521866"}]},{"url":"https://clinicaltrials.gov/study/NCT06522737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06522737","kind":"trial","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","route":"/trials/nct06522737/","field":"links","label":"ClinicalTrials.gov NCT06522737"}]},{"url":"https://clinicaltrials.gov/study/NCT06522828","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06522828","kind":"trial","name":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","route":"/trials/nct06522828/","field":"links","label":"ClinicalTrials.gov NCT06522828"}]},{"url":"https://clinicaltrials.gov/study/NCT06522919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06522919","kind":"trial","name":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mi","route":"/trials/nct06522919/","field":"links","label":"ClinicalTrials.gov NCT06522919"}]},{"url":"https://clinicaltrials.gov/study/NCT06523049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06523049","kind":"trial","name":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","route":"/trials/nct06523049/","field":"links","label":"ClinicalTrials.gov NCT06523049"}]},{"url":"https://clinicaltrials.gov/study/NCT06523673","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06523673","kind":"trial","name":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06523673/","field":"links","label":"ClinicalTrials.gov NCT06523673"}]},{"url":"https://clinicaltrials.gov/study/NCT06524375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06524375","kind":"trial","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","route":"/trials/nct06524375/","field":"links","label":"ClinicalTrials.gov NCT06524375"}]},{"url":"https://clinicaltrials.gov/study/NCT06525220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/","field":"links","label":"ClinicalTrials.gov NCT06525220"},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","field":"links","label":"ClinicalTrials.gov NCT06525220"},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","field":"dosing.source"},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","field":"links","label":"ClinicalTrials.gov NCT06525220: LiGeR-HN1"}]},{"url":"https://clinicaltrials.gov/study/NCT06525298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/","field":"links","label":"ClinicalTrials.gov NCT06525298"}]},{"url":"https://clinicaltrials.gov/study/NCT06525350","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06525350","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed","route":"/trials/nct06525350/","field":"links","label":"ClinicalTrials.gov NCT06525350"}]},{"url":"https://clinicaltrials.gov/study/NCT06525428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06525428","kind":"trial","name":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","route":"/trials/nct06525428/","field":"links","label":"ClinicalTrials.gov NCT06525428"}]},{"url":"https://clinicaltrials.gov/study/NCT06526624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06526624","kind":"trial","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","route":"/trials/nct06526624/","field":"links","label":"ClinicalTrials.gov NCT06526624"}]},{"url":"https://clinicaltrials.gov/study/NCT06526793","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/","field":"links","label":"ClinicalTrials.gov NCT06526793"}]},{"url":"https://clinicaltrials.gov/study/NCT06526819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/","field":"links","label":"ClinicalTrials.gov NCT06526819"}]},{"url":"https://clinicaltrials.gov/study/NCT06528990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06528990","kind":"trial","name":"Telehealth Intervention for Ostomy Self-Management","route":"/trials/nct06528990/","field":"links","label":"ClinicalTrials.gov NCT06528990"}]},{"url":"https://clinicaltrials.gov/study/NCT06529523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06529523","kind":"trial","name":"Tislelizumab in People With Colorectal Cancer","route":"/trials/nct06529523/","field":"links","label":"ClinicalTrials.gov NCT06529523"}]},{"url":"https://clinicaltrials.gov/study/NCT06529718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sevilla","kind":"trial","name":"SEVILLA","route":"/trials/sevilla/","field":"links","label":"ClinicalTrials.gov NCT06529718"}]},{"url":"https://clinicaltrials.gov/study/NCT06530251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06530251","kind":"trial","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct06530251/","field":"links","label":"ClinicalTrials.gov NCT06530251"}]},{"url":"https://clinicaltrials.gov/study/NCT06530303","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06530303","kind":"trial","name":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","route":"/trials/nct06530303/","field":"links","label":"ClinicalTrials.gov NCT06530303"}]},{"url":"https://clinicaltrials.gov/study/NCT06530823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06530823","kind":"trial","name":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma","route":"/trials/nct06530823/","field":"links","label":"ClinicalTrials.gov NCT06530823"}]},{"url":"https://clinicaltrials.gov/study/NCT06531278","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06531278","kind":"trial","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","route":"/trials/nct06531278/","field":"links","label":"ClinicalTrials.gov NCT06531278"}]},{"url":"https://clinicaltrials.gov/study/NCT06531291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06531291","kind":"trial","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","route":"/trials/nct06531291/","field":"links","label":"ClinicalTrials.gov NCT06531291"}]},{"url":"https://clinicaltrials.gov/study/NCT06532006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06532006","kind":"trial","name":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","route":"/trials/nct06532006/","field":"links","label":"ClinicalTrials.gov NCT06532006"}]},{"url":"https://clinicaltrials.gov/study/NCT06532617","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06532617","kind":"trial","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06532617/","field":"links","label":"ClinicalTrials.gov NCT06532617"}]},{"url":"https://clinicaltrials.gov/study/NCT06532812","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06532812","kind":"trial","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","route":"/trials/nct06532812/","field":"links","label":"ClinicalTrials.gov NCT06532812"}]},{"url":"https://clinicaltrials.gov/study/NCT06533384","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06533384","kind":"trial","name":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","route":"/trials/nct06533384/","field":"links","label":"ClinicalTrials.gov NCT06533384"}]},{"url":"https://clinicaltrials.gov/study/NCT06533579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/","field":"links","label":"ClinicalTrials.gov NCT06533579"}]},{"url":"https://clinicaltrials.gov/study/NCT06533644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/","field":"links","label":"ClinicalTrials.gov NCT06533644"}]},{"url":"https://clinicaltrials.gov/study/NCT06534060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/","field":"links","label":"ClinicalTrials.gov NCT06534060"}]},{"url":"https://clinicaltrials.gov/study/NCT06534437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","route":"/trials/nct06534437/","field":"links","label":"ClinicalTrials.gov NCT06534437"}]},{"url":"https://clinicaltrials.gov/study/NCT06534762","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06534762","kind":"trial","name":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","route":"/trials/nct06534762/","field":"links","label":"ClinicalTrials.gov NCT06534762"}]},{"url":"https://clinicaltrials.gov/study/NCT06535607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/","field":"links","label":"ClinicalTrials.gov NCT06535607"}]},{"url":"https://clinicaltrials.gov/study/NCT06538857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","route":"/trials/nct06538857/","field":"links","label":"ClinicalTrials.gov NCT06538857"}]},{"url":"https://clinicaltrials.gov/study/NCT06538896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06538896","kind":"trial","name":"Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu","route":"/trials/nct06538896/","field":"links","label":"ClinicalTrials.gov NCT06538896"}]},{"url":"https://clinicaltrials.gov/study/NCT06539182","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/","field":"links","label":"ClinicalTrials.gov NCT06539182"}]},{"url":"https://clinicaltrials.gov/study/NCT06540326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06540326","kind":"trial","name":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","route":"/trials/nct06540326/","field":"links","label":"ClinicalTrials.gov NCT06540326"}]},{"url":"https://clinicaltrials.gov/study/NCT06542250","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/","field":"links","label":"ClinicalTrials.gov NCT06542250"}]},{"url":"https://clinicaltrials.gov/study/NCT06542588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06542588","kind":"trial","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","route":"/trials/nct06542588/","field":"links","label":"ClinicalTrials.gov NCT06542588"}]},{"url":"https://clinicaltrials.gov/study/NCT06545747","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06545747","kind":"trial","name":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","route":"/trials/nct06545747/","field":"links","label":"ClinicalTrials.gov NCT06545747"}]},{"url":"https://clinicaltrials.gov/study/NCT06545955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06545955","kind":"trial","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","route":"/trials/nct06545955/","field":"links","label":"ClinicalTrials.gov NCT06545955"}]},{"url":"https://clinicaltrials.gov/study/NCT06547203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06547203","kind":"trial","name":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","route":"/trials/nct06547203/","field":"links","label":"ClinicalTrials.gov NCT06547203"}]},{"url":"https://clinicaltrials.gov/study/NCT06547736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","route":"/trials/nct06547736/","field":"links","label":"ClinicalTrials.gov NCT06547736"}]},{"url":"https://clinicaltrials.gov/study/NCT06548412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06548412","kind":"trial","name":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","route":"/trials/nct06548412/","field":"links","label":"ClinicalTrials.gov NCT06548412"}]},{"url":"https://clinicaltrials.gov/study/NCT06549439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","field":"links","label":"eFLASH skin melanoma study (NCT06549439)"}]},{"url":"https://clinicaltrials.gov/study/NCT06549465","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","field":"links","label":"ClinicalTrials.gov NCT06549465"}]},{"url":"https://clinicaltrials.gov/study/NCT06549595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/","field":"links","label":"ClinicalTrials.gov NCT06549595"}]},{"url":"https://clinicaltrials.gov/study/NCT06549946","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/","field":"links","label":"ClinicalTrials.gov NCT06549946"}]},{"url":"https://clinicaltrials.gov/study/NCT06550141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06550141","kind":"trial","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","route":"/trials/nct06550141/","field":"links","label":"ClinicalTrials.gov NCT06550141"}]},{"url":"https://clinicaltrials.gov/study/NCT06550895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/","field":"links","label":"ClinicalTrials.gov NCT06550895"}]},{"url":"https://clinicaltrials.gov/study/NCT06551324","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","field":"links","label":"ClinicalTrials.gov NCT06551324"}],"archive":"https://web.archive.org/web/20260910073350/https://clinicaltrials.gov/study/NCT06551324"},{"url":"https://clinicaltrials.gov/study/NCT06553885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06553885","kind":"trial","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","route":"/trials/nct06553885/","field":"links","label":"ClinicalTrials.gov NCT06553885"}]},{"url":"https://clinicaltrials.gov/study/NCT06554795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/","field":"links","label":"ClinicalTrials.gov NCT06554795"}]},{"url":"https://clinicaltrials.gov/study/NCT06555003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06555003","kind":"trial","name":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","route":"/trials/nct06555003/","field":"links","label":"ClinicalTrials.gov NCT06555003"}]},{"url":"https://clinicaltrials.gov/study/NCT06555068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06555068","kind":"trial","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","route":"/trials/nct06555068/","field":"links","label":"ClinicalTrials.gov NCT06555068"}]},{"url":"https://clinicaltrials.gov/study/NCT06555133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06555133","kind":"trial","name":"Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC","route":"/trials/nct06555133/","field":"links","label":"ClinicalTrials.gov NCT06555133"}]},{"url":"https://clinicaltrials.gov/study/NCT06556563","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06556563","kind":"trial","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","route":"/trials/nct06556563/","field":"links","label":"ClinicalTrials.gov NCT06556563"}]},{"url":"https://clinicaltrials.gov/study/NCT06557733","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06557733","kind":"trial","name":"An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis","route":"/trials/nct06557733/","field":"links","label":"ClinicalTrials.gov NCT06557733"}]},{"url":"https://clinicaltrials.gov/study/NCT06558214","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06558214","kind":"trial","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","route":"/trials/nct06558214/","field":"links","label":"ClinicalTrials.gov NCT06558214"}]},{"url":"https://clinicaltrials.gov/study/NCT06558227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06558227","kind":"trial","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct06558227/","field":"links","label":"ClinicalTrials.gov NCT06558227"}]},{"url":"https://clinicaltrials.gov/study/NCT06558773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06558773","kind":"trial","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","route":"/trials/nct06558773/","field":"links","label":"ClinicalTrials.gov NCT06558773"}]},{"url":"https://clinicaltrials.gov/study/NCT06560112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06560112","kind":"trial","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","route":"/trials/nct06560112/","field":"links","label":"ClinicalTrials.gov NCT06560112"}]},{"url":"https://clinicaltrials.gov/study/NCT06561048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/","field":"links","label":"ClinicalTrials.gov NCT06561048"}]},{"url":"https://clinicaltrials.gov/study/NCT06561386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/","field":"links","label":"ClinicalTrials.gov NCT06561386"}]},{"url":"https://clinicaltrials.gov/study/NCT06561607","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/","field":"links","label":"ClinicalTrials.gov NCT06561607"}]},{"url":"https://clinicaltrials.gov/study/NCT06563388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06563388","kind":"trial","name":"Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial","route":"/trials/nct06563388/","field":"links","label":"ClinicalTrials.gov NCT06563388"}]},{"url":"https://clinicaltrials.gov/study/NCT06563986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06563986","kind":"trial","name":"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","route":"/trials/nct06563986/","field":"links","label":"ClinicalTrials.gov NCT06563986"}]},{"url":"https://clinicaltrials.gov/study/NCT06564038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/","field":"links","label":"ClinicalTrials.gov NCT06564038"}]},{"url":"https://clinicaltrials.gov/study/NCT06564272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06564272","kind":"trial","name":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","route":"/trials/nct06564272/","field":"links","label":"ClinicalTrials.gov NCT06564272"}]},{"url":"https://clinicaltrials.gov/study/NCT06564324","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/","field":"links","label":"ClinicalTrials.gov NCT06564324"}]},{"url":"https://clinicaltrials.gov/study/NCT06564844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/","field":"links","label":"ClinicalTrials.gov NCT06564844"}]},{"url":"https://clinicaltrials.gov/study/NCT06566079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/","field":"links","label":"ClinicalTrials.gov NCT06566079"}]},{"url":"https://clinicaltrials.gov/study/NCT06566547","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/","field":"links","label":"ClinicalTrials.gov NCT06566547"}]},{"url":"https://clinicaltrials.gov/study/NCT06566586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06566586","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","route":"/trials/nct06566586/","field":"links","label":"ClinicalTrials.gov NCT06566586"}]},{"url":"https://clinicaltrials.gov/study/NCT06566755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06566755","kind":"trial","name":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","route":"/trials/nct06566755/","field":"links","label":"ClinicalTrials.gov NCT06566755"}]},{"url":"https://clinicaltrials.gov/study/NCT06567015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/","field":"links","label":"ClinicalTrials.gov NCT06567015"}]},{"url":"https://clinicaltrials.gov/study/NCT06567743","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06567743","kind":"trial","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","route":"/trials/nct06567743/","field":"links","label":"ClinicalTrials.gov NCT06567743"}]},{"url":"https://clinicaltrials.gov/study/NCT06567782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06567782","kind":"trial","name":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","route":"/trials/nct06567782/","field":"links","label":"ClinicalTrials.gov NCT06567782"}]},{"url":"https://clinicaltrials.gov/study/NCT06568094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06568094","kind":"trial","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","route":"/trials/nct06568094/","field":"links","label":"ClinicalTrials.gov NCT06568094"}]},{"url":"https://clinicaltrials.gov/study/NCT06568692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","field":"links","label":"ClinicalTrials.gov NCT06568692"}]},{"url":"https://clinicaltrials.gov/study/NCT06568939","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/","field":"links","label":"ClinicalTrials.gov NCT06568939"}]},{"url":"https://clinicaltrials.gov/study/NCT06569368","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06569368","kind":"trial","name":"Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy","route":"/trials/nct06569368/","field":"links","label":"ClinicalTrials.gov NCT06569368"}]},{"url":"https://clinicaltrials.gov/study/NCT06569420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","field":"links","label":"ClinicalTrials.gov NCT06569420"}]},{"url":"https://clinicaltrials.gov/study/NCT06571461","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","route":"/trials/nct06571461/","field":"links","label":"ClinicalTrials.gov NCT06571461"}]},{"url":"https://clinicaltrials.gov/study/NCT06572813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06572813","kind":"trial","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","route":"/trials/nct06572813/","field":"links","label":"ClinicalTrials.gov NCT06572813"}]},{"url":"https://clinicaltrials.gov/study/NCT06573398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06573398","kind":"trial","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","route":"/trials/nct06573398/","field":"links","label":"ClinicalTrials.gov NCT06573398"}]},{"url":"https://clinicaltrials.gov/study/NCT06574347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/","field":"links","label":"ClinicalTrials.gov NCT06574347"}]},{"url":"https://clinicaltrials.gov/study/NCT06576115","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06576115","kind":"trial","name":"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","route":"/trials/nct06576115/","field":"links","label":"ClinicalTrials.gov NCT06576115"}]},{"url":"https://clinicaltrials.gov/study/NCT06577025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/","field":"links","label":"ClinicalTrials.gov NCT06577025"}]},{"url":"https://clinicaltrials.gov/study/NCT06578624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06578624","kind":"trial","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06578624/","field":"links","label":"ClinicalTrials.gov NCT06578624"}]},{"url":"https://clinicaltrials.gov/study/NCT06580002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06580002","kind":"trial","name":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","route":"/trials/nct06580002/","field":"links","label":"ClinicalTrials.gov NCT06580002"}]},{"url":"https://clinicaltrials.gov/study/NCT06580301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","route":"/trials/nct06580301/","field":"links","label":"ClinicalTrials.gov NCT06580301"}]},{"url":"https://clinicaltrials.gov/study/NCT06580574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06580574","kind":"trial","name":"Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers","route":"/trials/nct06580574/","field":"links","label":"ClinicalTrials.gov NCT06580574"}]},{"url":"https://clinicaltrials.gov/study/NCT06581380","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06581380","kind":"trial","name":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06581380/","field":"links","label":"ClinicalTrials.gov NCT06581380"}]},{"url":"https://clinicaltrials.gov/study/NCT06581406","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","route":"/trials/nct06581406/","field":"links","label":"ClinicalTrials.gov NCT06581406"}]},{"url":"https://clinicaltrials.gov/study/NCT06581419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","field":"links","label":"ClinicalTrials.gov NCT06581419"}]},{"url":"https://clinicaltrials.gov/study/NCT06581432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","route":"/trials/nct06581432/","field":"links","label":"ClinicalTrials.gov NCT06581432"}]},{"url":"https://clinicaltrials.gov/study/NCT06584032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/","field":"links","label":"ClinicalTrials.gov NCT06584032"}]},{"url":"https://clinicaltrials.gov/study/NCT06584227","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06584227","kind":"trial","name":"Adebrelimab and Chidamide for Pancreatic Cancer","route":"/trials/nct06584227/","field":"links","label":"ClinicalTrials.gov NCT06584227"}]},{"url":"https://clinicaltrials.gov/study/NCT06585410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","route":"/trials/nct06585410/","field":"links","label":"ClinicalTrials.gov NCT06585410"}]},{"url":"https://clinicaltrials.gov/study/NCT06586866","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06586866","kind":"trial","name":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","route":"/trials/nct06586866/","field":"links","label":"ClinicalTrials.gov NCT06586866"}]},{"url":"https://clinicaltrials.gov/study/NCT06587061","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06587061","kind":"trial","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct06587061/","field":"links","label":"ClinicalTrials.gov NCT06587061"}]},{"url":"https://clinicaltrials.gov/study/NCT06588478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06588478","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct06588478/","field":"links","label":"ClinicalTrials.gov NCT06588478"}]},{"url":"https://clinicaltrials.gov/study/NCT06589440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/","field":"links","label":"ClinicalTrials.gov NCT06589440"}]},{"url":"https://clinicaltrials.gov/study/NCT06589778","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06589778","kind":"trial","name":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06589778/","field":"links","label":"ClinicalTrials.gov NCT06589778"}]},{"url":"https://clinicaltrials.gov/study/NCT06589830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06589830","kind":"trial","name":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","route":"/trials/nct06589830/","field":"links","label":"ClinicalTrials.gov NCT06589830"}]},{"url":"https://clinicaltrials.gov/study/NCT06590246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/","field":"links","label":"ClinicalTrials.gov NCT06590246"}]},{"url":"https://clinicaltrials.gov/study/NCT06590259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06590259","kind":"trial","name":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","route":"/trials/nct06590259/","field":"links","label":"ClinicalTrials.gov NCT06590259"}]},{"url":"https://clinicaltrials.gov/study/NCT06590857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","field":"links","label":"ClinicalTrials.gov NCT06590857"}]},{"url":"https://clinicaltrials.gov/study/NCT06591520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06591520","kind":"trial","name":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct06591520/","field":"links","label":"ClinicalTrials.gov NCT06591520"}]},{"url":"https://clinicaltrials.gov/study/NCT06591650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06591650","kind":"trial","name":"Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer","route":"/trials/nct06591650/","field":"links","label":"ClinicalTrials.gov NCT06591650"}]},{"url":"https://clinicaltrials.gov/study/NCT06592326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06592326/","field":"links","label":"ClinicalTrials.gov NCT06592326"}]},{"url":"https://clinicaltrials.gov/study/NCT06593431","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06593431","kind":"trial","name":"Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","route":"/trials/nct06593431/","field":"links","label":"ClinicalTrials.gov NCT06593431"}]},{"url":"https://clinicaltrials.gov/study/NCT06593522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06593522","kind":"trial","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","route":"/trials/nct06593522/","field":"links","label":"ClinicalTrials.gov NCT06593522"}]},{"url":"https://clinicaltrials.gov/study/NCT06593548","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06593548","kind":"trial","name":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","route":"/trials/nct06593548/","field":"links","label":"ClinicalTrials.gov NCT06593548"}]},{"url":"https://clinicaltrials.gov/study/NCT06594692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06594692","kind":"trial","name":"Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study","route":"/trials/nct06594692/","field":"links","label":"ClinicalTrials.gov NCT06594692"}]},{"url":"https://clinicaltrials.gov/study/NCT06595186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06595186","kind":"trial","name":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","route":"/trials/nct06595186/","field":"links","label":"ClinicalTrials.gov NCT06595186"}]},{"url":"https://clinicaltrials.gov/study/NCT06596343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06596343","kind":"trial","name":"Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer","route":"/trials/nct06596343/","field":"links","label":"ClinicalTrials.gov NCT06596343"}]},{"url":"https://clinicaltrials.gov/study/NCT06596694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","field":"links","label":"ClinicalTrials.gov NCT06596694"}]},{"url":"https://clinicaltrials.gov/study/NCT06598007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ct3001","kind":"drug","name":"CT3001","route":"/drugs/ct3001/","field":"links","label":"ClinicalTrials.gov NCT06598007"},{"id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/","field":"links","label":"ClinicalTrials.gov NCT06598007"}]},{"url":"https://clinicaltrials.gov/study/NCT06598033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06598033","kind":"trial","name":"Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer","route":"/trials/nct06598033/","field":"links","label":"ClinicalTrials.gov NCT06598033"}]},{"url":"https://clinicaltrials.gov/study/NCT06598527","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06598527","kind":"trial","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","route":"/trials/nct06598527/","field":"links","label":"ClinicalTrials.gov NCT06598527"}]},{"url":"https://clinicaltrials.gov/study/NCT06598787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06598787","kind":"trial","name":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","route":"/trials/nct06598787/","field":"links","label":"ClinicalTrials.gov NCT06598787"}]},{"url":"https://clinicaltrials.gov/study/NCT06599775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06599775","kind":"trial","name":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","route":"/trials/nct06599775/","field":"links","label":"ClinicalTrials.gov NCT06599775"}]},{"url":"https://clinicaltrials.gov/study/NCT06599827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06599827","kind":"trial","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC","route":"/trials/nct06599827/","field":"links","label":"ClinicalTrials.gov NCT06599827"}]},{"url":"https://clinicaltrials.gov/study/NCT06600022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","route":"/trials/nct06600022/","field":"links","label":"ClinicalTrials.gov NCT06600022"}]},{"url":"https://clinicaltrials.gov/study/NCT06600789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","field":"links","label":"ClinicalTrials.gov NCT06600789"}]},{"url":"https://clinicaltrials.gov/study/NCT06601283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06601283","kind":"trial","name":"Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer","route":"/trials/nct06601283/","field":"links","label":"ClinicalTrials.gov NCT06601283"}]},{"url":"https://clinicaltrials.gov/study/NCT06601335","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/","field":"links","label":"ClinicalTrials.gov NCT06601335"}]},{"url":"https://clinicaltrials.gov/study/NCT06601504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06601504","kind":"trial","name":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct06601504/","field":"links","label":"ClinicalTrials.gov NCT06601504"}]},{"url":"https://clinicaltrials.gov/study/NCT06603376","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06603376","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated","route":"/trials/nct06603376/","field":"links","label":"ClinicalTrials.gov NCT06603376"}]},{"url":"https://clinicaltrials.gov/study/NCT06603844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06603844","kind":"trial","name":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","route":"/trials/nct06603844/","field":"links","label":"ClinicalTrials.gov NCT06603844"}]},{"url":"https://clinicaltrials.gov/study/NCT06605222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06605222","kind":"trial","name":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06605222/","field":"links","label":"ClinicalTrials.gov NCT06605222"}]},{"url":"https://clinicaltrials.gov/study/NCT06605430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06605430","kind":"trial","name":"Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","route":"/trials/nct06605430/","field":"links","label":"ClinicalTrials.gov NCT06605430"}]},{"url":"https://clinicaltrials.gov/study/NCT06606730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06606730","kind":"trial","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","route":"/trials/nct06606730/","field":"links","label":"ClinicalTrials.gov NCT06606730"}]},{"url":"https://clinicaltrials.gov/study/NCT06606847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06606847","kind":"trial","name":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ","route":"/trials/nct06606847/","field":"links","label":"ClinicalTrials.gov NCT06606847"}]},{"url":"https://clinicaltrials.gov/study/NCT06607458","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06607458","kind":"trial","name":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme","route":"/trials/nct06607458/","field":"links","label":"ClinicalTrials.gov NCT06607458"}]},{"url":"https://clinicaltrials.gov/study/NCT06607796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06607796","kind":"trial","name":"Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy","route":"/trials/nct06607796/","field":"links","label":"ClinicalTrials.gov NCT06607796"}]},{"url":"https://clinicaltrials.gov/study/NCT06608927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/","field":"links","label":"ClinicalTrials.gov NCT06608927"}]},{"url":"https://clinicaltrials.gov/study/NCT06609005","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/","field":"links","label":"ClinicalTrials.gov NCT06609005"}]},{"url":"https://clinicaltrials.gov/study/NCT06609551","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06609551","kind":"trial","name":"ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study","route":"/trials/nct06609551/","field":"links","label":"ClinicalTrials.gov NCT06609551"}]},{"url":"https://clinicaltrials.gov/study/NCT06610734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06610734","kind":"trial","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","route":"/trials/nct06610734/","field":"links","label":"ClinicalTrials.gov NCT06610734"}]},{"url":"https://clinicaltrials.gov/study/NCT06612151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT06612151"},{"id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/","field":"links","label":"ClinicalTrials.gov NCT06612151"}]},{"url":"https://clinicaltrials.gov/study/NCT06612281","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","route":"/trials/nct06612281/","field":"links","label":"ClinicalTrials.gov NCT06612281"}]},{"url":"https://clinicaltrials.gov/study/NCT06614192","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","field":"links","label":"ClinicalTrials.gov NCT06614192"}]},{"url":"https://clinicaltrials.gov/study/NCT06615479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/","field":"links","label":"ClinicalTrials.gov NCT06615479"}]},{"url":"https://clinicaltrials.gov/study/NCT06616259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616259","kind":"trial","name":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Contro","route":"/trials/nct06616259/","field":"links","label":"ClinicalTrials.gov NCT06616259"}]},{"url":"https://clinicaltrials.gov/study/NCT06616389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/","field":"links","label":"ClinicalTrials.gov NCT06616389"}]},{"url":"https://clinicaltrials.gov/study/NCT06616532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/","field":"links","label":"ClinicalTrials.gov NCT06616532"}]},{"url":"https://clinicaltrials.gov/study/NCT06616584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616584","kind":"trial","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","route":"/trials/nct06616584/","field":"links","label":"ClinicalTrials.gov NCT06616584"}]},{"url":"https://clinicaltrials.gov/study/NCT06616766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/","field":"links","label":"ClinicalTrials.gov NCT06616766"}]},{"url":"https://clinicaltrials.gov/study/NCT06616987","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06616987","kind":"trial","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06616987/","field":"links","label":"ClinicalTrials.gov NCT06616987"}]},{"url":"https://clinicaltrials.gov/study/NCT06617416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06617416","kind":"trial","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","route":"/trials/nct06617416/","field":"links","label":"ClinicalTrials.gov NCT06617416"}]},{"url":"https://clinicaltrials.gov/study/NCT06617481","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06617481","kind":"trial","name":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","route":"/trials/nct06617481/","field":"links","label":"ClinicalTrials.gov NCT06617481"}]},{"url":"https://clinicaltrials.gov/study/NCT06617858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06617858","kind":"trial","name":"Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment","route":"/trials/nct06617858/","field":"links","label":"ClinicalTrials.gov NCT06617858"}]},{"url":"https://clinicaltrials.gov/study/NCT06618235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/","field":"links","label":"ClinicalTrials.gov NCT06618235"}]},{"url":"https://clinicaltrials.gov/study/NCT06618287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","route":"/trials/nct06618287/","field":"links","label":"ClinicalTrials.gov NCT06618287"}]},{"url":"https://clinicaltrials.gov/study/NCT06619236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","field":"links","label":"ClinicalTrials.gov NCT06619236"}]},{"url":"https://clinicaltrials.gov/study/NCT06619509","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","route":"/trials/nct06619509/","field":"links","label":"ClinicalTrials.gov NCT06619509"}]},{"url":"https://clinicaltrials.gov/study/NCT06620848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06620848","kind":"trial","name":"A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.","route":"/trials/nct06620848/","field":"links","label":"ClinicalTrials.gov NCT06620848"}]},{"url":"https://clinicaltrials.gov/study/NCT06621095","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06621095","kind":"trial","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","route":"/trials/nct06621095/","field":"links","label":"ClinicalTrials.gov NCT06621095"}]},{"url":"https://clinicaltrials.gov/study/NCT06622057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06622057","kind":"trial","name":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06622057/","field":"links","label":"ClinicalTrials.gov NCT06622057"}]},{"url":"https://clinicaltrials.gov/study/NCT06622486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","field":"links","label":"ClinicalTrials.gov NCT06622486"}]},{"url":"https://clinicaltrials.gov/study/NCT06623136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","field":"links","label":"ClinicalTrials.gov NCT06623136"}]},{"url":"https://clinicaltrials.gov/study/NCT06623422","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06623422","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","route":"/trials/nct06623422/","field":"links","label":"ClinicalTrials.gov NCT06623422"}]},{"url":"https://clinicaltrials.gov/study/NCT06623461","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","field":"links","label":"LND101 + ICB phase 2 (NCT06623461)"},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","field":"links","label":"ClinicalTrials.gov NCT06623461"}]},{"url":"https://clinicaltrials.gov/study/NCT06623656","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06623656","kind":"trial","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","route":"/trials/nct06623656/","field":"links","label":"ClinicalTrials.gov NCT06623656"}]},{"url":"https://clinicaltrials.gov/study/NCT06624644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/","field":"links","label":"ClinicalTrials.gov NCT06624644"}]},{"url":"https://clinicaltrials.gov/study/NCT06625320","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"ClinicalTrials.gov NCT06625320"},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"outcomes.source (Overall survival)"},{"id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","field":"links","label":"ClinicalTrials.gov NCT06625320: RASolute 302"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"dosing.source"},{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/","field":"links","label":"ClinicalTrials.gov NCT06625320"}],"archive":"https://web.archive.org/web/20260909211326/https://clinicaltrials.gov/study/NCT06625320"},{"url":"https://clinicaltrials.gov/study/NCT06627647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/","field":"links","label":"ClinicalTrials.gov NCT06627647"}]},{"url":"https://clinicaltrials.gov/study/NCT06627712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","route":"/trials/nct06627712/","field":"links","label":"ClinicalTrials.gov NCT06627712"}]},{"url":"https://clinicaltrials.gov/study/NCT06629597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/","field":"links","label":"ClinicalTrials.gov NCT06629597"}]},{"url":"https://clinicaltrials.gov/study/NCT06629779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06629779","kind":"trial","name":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","route":"/trials/nct06629779/","field":"links","label":"ClinicalTrials.gov NCT06629779"}]},{"url":"https://clinicaltrials.gov/study/NCT06630234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06630234","kind":"trial","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","route":"/trials/nct06630234/","field":"links","label":"ClinicalTrials.gov NCT06630234"}]},{"url":"https://clinicaltrials.gov/study/NCT06630624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06630624","kind":"trial","name":"Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM","route":"/trials/nct06630624/","field":"links","label":"ClinicalTrials.gov NCT06630624"}]},{"url":"https://clinicaltrials.gov/study/NCT06631079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06631079","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","route":"/trials/nct06631079/","field":"links","label":"ClinicalTrials.gov NCT06631079"}]},{"url":"https://clinicaltrials.gov/study/NCT06631092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/","field":"links","label":"ClinicalTrials.gov NCT06631092"}]},{"url":"https://clinicaltrials.gov/study/NCT06631989","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/","field":"links","label":"ClinicalTrials.gov NCT06631989"}]},{"url":"https://clinicaltrials.gov/study/NCT06632262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/","field":"links","label":"ClinicalTrials.gov NCT06632262"}]},{"url":"https://clinicaltrials.gov/study/NCT06632327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06632327","kind":"trial","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","route":"/trials/nct06632327/","field":"links","label":"ClinicalTrials.gov NCT06632327"}]},{"url":"https://clinicaltrials.gov/study/NCT06632405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06632405","kind":"trial","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","route":"/trials/nct06632405/","field":"links","label":"ClinicalTrials.gov NCT06632405"}]},{"url":"https://clinicaltrials.gov/study/NCT06632912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06632912","kind":"trial","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","route":"/trials/nct06632912/","field":"links","label":"ClinicalTrials.gov NCT06632912"}]},{"url":"https://clinicaltrials.gov/study/NCT06632951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06632951","kind":"trial","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","route":"/trials/nct06632951/","field":"links","label":"ClinicalTrials.gov NCT06632951"}]},{"url":"https://clinicaltrials.gov/study/NCT06634056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06634056","kind":"trial","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","route":"/trials/nct06634056/","field":"links","label":"ClinicalTrials.gov NCT06634056"}]},{"url":"https://clinicaltrials.gov/study/NCT06634589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06634589","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct06634589/","field":"links","label":"ClinicalTrials.gov NCT06634589"}]},{"url":"https://clinicaltrials.gov/study/NCT06634849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","field":"links","label":"ClinicalTrials.gov NCT06634849"}]},{"url":"https://clinicaltrials.gov/study/NCT06634875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06634875","kind":"trial","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","route":"/trials/nct06634875/","field":"links","label":"ClinicalTrials.gov NCT06634875"}]},{"url":"https://clinicaltrials.gov/study/NCT06634966","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06634966","kind":"trial","name":"Segmentectomy for Solid-dominant Lung Cancer","route":"/trials/nct06634966/","field":"links","label":"ClinicalTrials.gov NCT06634966"}]},{"url":"https://clinicaltrials.gov/study/NCT06635447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06635447","kind":"trial","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","route":"/trials/nct06635447/","field":"links","label":"ClinicalTrials.gov NCT06635447"}]},{"url":"https://clinicaltrials.gov/study/NCT06635785","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/","field":"links","label":"ClinicalTrials.gov NCT06635785"}]},{"url":"https://clinicaltrials.gov/study/NCT06635824","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/","field":"links","label":"ClinicalTrials.gov NCT06635824"}]},{"url":"https://clinicaltrials.gov/study/NCT06635980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06635980","kind":"trial","name":"Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer","route":"/trials/nct06635980/","field":"links","label":"ClinicalTrials.gov NCT06635980"}]},{"url":"https://clinicaltrials.gov/study/NCT06636682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","route":"/trials/nct06636682/","field":"links","label":"ClinicalTrials.gov NCT06636682"}]},{"url":"https://clinicaltrials.gov/study/NCT06636981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06636981","kind":"trial","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","route":"/trials/nct06636981/","field":"links","label":"ClinicalTrials.gov NCT06636981"}]},{"url":"https://clinicaltrials.gov/study/NCT06637423","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","route":"/trials/nct06637423/","field":"links","label":"ClinicalTrials.gov NCT06637423"}]},{"url":"https://clinicaltrials.gov/study/NCT06637501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06637501","kind":"trial","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct06637501/","field":"links","label":"ClinicalTrials.gov NCT06637501"}]},{"url":"https://clinicaltrials.gov/study/NCT06638502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06638502","kind":"trial","name":"Safety of HRX215 in Patients After Minor and Major Liver Resection","route":"/trials/nct06638502/","field":"links","label":"ClinicalTrials.gov NCT06638502"}]},{"url":"https://clinicaltrials.gov/study/NCT06638931","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06638931","kind":"trial","name":"Agnostic Therapy in Rare Solid Tumors","route":"/trials/nct06638931/","field":"links","label":"ClinicalTrials.gov NCT06638931"}]},{"url":"https://clinicaltrials.gov/study/NCT06639256","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06639256","kind":"trial","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","route":"/trials/nct06639256/","field":"links","label":"ClinicalTrials.gov NCT06639256"}]},{"url":"https://clinicaltrials.gov/study/NCT06639347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","route":"/trials/nct06639347/","field":"links","label":"ClinicalTrials.gov NCT06639347"}]},{"url":"https://clinicaltrials.gov/study/NCT06640049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","route":"/trials/nct06640049/","field":"links","label":"ClinicalTrials.gov NCT06640049"}]},{"url":"https://clinicaltrials.gov/study/NCT06640166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06640166","kind":"trial","name":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen","route":"/trials/nct06640166/","field":"links","label":"ClinicalTrials.gov NCT06640166"}]},{"url":"https://clinicaltrials.gov/study/NCT06640361","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06640361","kind":"trial","name":"A Study of Olverembatinib in SDH-deficient GIST.","route":"/trials/nct06640361/","field":"links","label":"ClinicalTrials.gov NCT06640361"}]},{"url":"https://clinicaltrials.gov/study/NCT06640530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06640530","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","route":"/trials/nct06640530/","field":"links","label":"ClinicalTrials.gov NCT06640530"}]},{"url":"https://clinicaltrials.gov/study/NCT06641635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06641635","kind":"trial","name":"Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer","route":"/trials/nct06641635/","field":"links","label":"ClinicalTrials.gov NCT06641635"}]},{"url":"https://clinicaltrials.gov/study/NCT06642545","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06642545","kind":"trial","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","route":"/trials/nct06642545/","field":"links","label":"ClinicalTrials.gov NCT06642545"}]},{"url":"https://clinicaltrials.gov/study/NCT06642844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06642844","kind":"trial","name":"Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment","route":"/trials/nct06642844/","field":"links","label":"ClinicalTrials.gov NCT06642844"}]},{"url":"https://clinicaltrials.gov/study/NCT06643754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct06643754/","field":"links","label":"ClinicalTrials.gov NCT06643754"}]},{"url":"https://clinicaltrials.gov/study/NCT06643793","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06643793","kind":"trial","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","route":"/trials/nct06643793/","field":"links","label":"ClinicalTrials.gov NCT06643793"}]},{"url":"https://clinicaltrials.gov/study/NCT06643884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06643884","kind":"trial","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","route":"/trials/nct06643884/","field":"links","label":"ClinicalTrials.gov NCT06643884"}]},{"url":"https://clinicaltrials.gov/study/NCT06644768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/","field":"links","label":"ClinicalTrials.gov NCT06644768"}]},{"url":"https://clinicaltrials.gov/study/NCT06644781","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","route":"/trials/nct06644781/","field":"links","label":"ClinicalTrials.gov NCT06644781"}]},{"url":"https://clinicaltrials.gov/study/NCT06646055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06646055","kind":"trial","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct06646055/","field":"links","label":"ClinicalTrials.gov NCT06646055"}]},{"url":"https://clinicaltrials.gov/study/NCT06646276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/","field":"links","label":"ClinicalTrials.gov NCT06646276"}]},{"url":"https://clinicaltrials.gov/study/NCT06646445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06646445","kind":"trial","name":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","route":"/trials/nct06646445/","field":"links","label":"ClinicalTrials.gov NCT06646445"}]},{"url":"https://clinicaltrials.gov/study/NCT06647680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06647680","kind":"trial","name":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","route":"/trials/nct06647680/","field":"links","label":"ClinicalTrials.gov NCT06647680"}]},{"url":"https://clinicaltrials.gov/study/NCT06649708","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06649708","kind":"trial","name":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","route":"/trials/nct06649708/","field":"links","label":"ClinicalTrials.gov NCT06649708"}]},{"url":"https://clinicaltrials.gov/study/NCT06650566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","route":"/trials/nct06650566/","field":"links","label":"ClinicalTrials.gov NCT06650566"}]},{"url":"https://clinicaltrials.gov/study/NCT06652412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06652412","kind":"trial","name":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","route":"/trials/nct06652412/","field":"links","label":"ClinicalTrials.gov NCT06652412"}]},{"url":"https://clinicaltrials.gov/study/NCT06652633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","route":"/trials/nct06652633/","field":"links","label":"ClinicalTrials.gov NCT06652633"}]},{"url":"https://clinicaltrials.gov/study/NCT06654440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06654440","kind":"trial","name":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","route":"/trials/nct06654440/","field":"links","label":"ClinicalTrials.gov NCT06654440"}]},{"url":"https://clinicaltrials.gov/study/NCT06654947","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06654947","kind":"trial","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","route":"/trials/nct06654947/","field":"links","label":"ClinicalTrials.gov NCT06654947"}]},{"url":"https://clinicaltrials.gov/study/NCT06656390","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","field":"links","label":"ClinicalTrials.gov NCT06656390"}]},{"url":"https://clinicaltrials.gov/study/NCT06657222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/","field":"links","label":"ClinicalTrials.gov NCT06657222"}]},{"url":"https://clinicaltrials.gov/study/NCT06658353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06658353","kind":"trial","name":"Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors","route":"/trials/nct06658353/","field":"links","label":"ClinicalTrials.gov NCT06658353"}]},{"url":"https://clinicaltrials.gov/study/NCT06659705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06659705","kind":"trial","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","route":"/trials/nct06659705/","field":"links","label":"ClinicalTrials.gov NCT06659705"}]},{"url":"https://clinicaltrials.gov/study/NCT06660654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","field":"links","label":"ClinicalTrials.gov NCT06660654"}]},{"url":"https://clinicaltrials.gov/study/NCT06662006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06662006","kind":"trial","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic","route":"/trials/nct06662006/","field":"links","label":"ClinicalTrials.gov NCT06662006"}]},{"url":"https://clinicaltrials.gov/study/NCT06662669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","route":"/trials/nct06662669/","field":"links","label":"ClinicalTrials.gov NCT06662669"}]},{"url":"https://clinicaltrials.gov/study/NCT06662786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/","field":"links","label":"ClinicalTrials.gov NCT06662786"}]},{"url":"https://clinicaltrials.gov/study/NCT06662877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06662877","kind":"trial","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","route":"/trials/nct06662877/","field":"links","label":"ClinicalTrials.gov NCT06662877"}]},{"url":"https://clinicaltrials.gov/study/NCT06663098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06663098","kind":"trial","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","route":"/trials/nct06663098/","field":"links","label":"ClinicalTrials.gov NCT06663098"}]},{"url":"https://clinicaltrials.gov/study/NCT06663137","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","route":"/trials/nct06663137/","field":"links","label":"ClinicalTrials.gov NCT06663137"}]},{"url":"https://clinicaltrials.gov/study/NCT06665087","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06665087","kind":"trial","name":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","route":"/trials/nct06665087/","field":"links","label":"ClinicalTrials.gov NCT06665087"}]},{"url":"https://clinicaltrials.gov/study/NCT06665100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","field":"links","label":"ClinicalTrials.gov NCT06665100"}]},{"url":"https://clinicaltrials.gov/study/NCT06666166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06666166","kind":"trial","name":"SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","route":"/trials/nct06666166/","field":"links","label":"ClinicalTrials.gov NCT06666166"}]},{"url":"https://clinicaltrials.gov/study/NCT06667076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06667076","kind":"trial","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667076/","field":"links","label":"ClinicalTrials.gov NCT06667076"}]},{"url":"https://clinicaltrials.gov/study/NCT06667544","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06667544","kind":"trial","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","route":"/trials/nct06667544/","field":"links","label":"ClinicalTrials.gov NCT06667544"}]},{"url":"https://clinicaltrials.gov/study/NCT06667908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/","field":"links","label":"ClinicalTrials.gov NCT06667908"}]},{"url":"https://clinicaltrials.gov/study/NCT06667960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct06667960/","field":"links","label":"ClinicalTrials.gov NCT06667960"}]},{"url":"https://clinicaltrials.gov/study/NCT06668103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/","field":"links","label":"ClinicalTrials.gov NCT06668103"}]},{"url":"https://clinicaltrials.gov/study/NCT06668792","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06668792/","field":"links","label":"ClinicalTrials.gov NCT06668792"}]},{"url":"https://clinicaltrials.gov/study/NCT06668961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06668961","kind":"trial","name":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq","route":"/trials/nct06668961/","field":"links","label":"ClinicalTrials.gov NCT06668961"}]},{"url":"https://clinicaltrials.gov/study/NCT06669078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06669078","kind":"trial","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","route":"/trials/nct06669078/","field":"links","label":"ClinicalTrials.gov NCT06669078"}]},{"url":"https://clinicaltrials.gov/study/NCT06669117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","route":"/trials/nct06669117/","field":"links","label":"ClinicalTrials.gov NCT06669117"}]},{"url":"https://clinicaltrials.gov/study/NCT06669247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/","field":"links","label":"ClinicalTrials.gov NCT06669247"}]},{"url":"https://clinicaltrials.gov/study/NCT06669975","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06669975","kind":"trial","name":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","route":"/trials/nct06669975/","field":"links","label":"ClinicalTrials.gov NCT06669975"}]},{"url":"https://clinicaltrials.gov/study/NCT06670196","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/","field":"links","label":"ClinicalTrials.gov NCT06670196"}]},{"url":"https://clinicaltrials.gov/study/NCT06671379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06671379","kind":"trial","name":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct06671379/","field":"links","label":"ClinicalTrials.gov NCT06671379"}]},{"url":"https://clinicaltrials.gov/study/NCT06671418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"biliary-drainage-routes","kind":"term","name":"Biliary drainage routes: ERCP stent, percutaneous (PTC) and EUS-guided","route":"/terms/biliary-drainage-routes/","field":"links","label":"ClinicalTrials.gov NCT06671418"},{"id":"tesla-rct","kind":"trial","name":"TESLA RCT","route":"/trials/tesla-rct/","field":"links","label":"ClinicalTrials.gov NCT06671418"}]},{"url":"https://clinicaltrials.gov/study/NCT06672068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06672068","kind":"trial","name":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","route":"/trials/nct06672068/","field":"links","label":"ClinicalTrials.gov NCT06672068"}]},{"url":"https://clinicaltrials.gov/study/NCT06672133","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06672133","kind":"trial","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","route":"/trials/nct06672133/","field":"links","label":"ClinicalTrials.gov NCT06672133"}]},{"url":"https://clinicaltrials.gov/study/NCT06674343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06674343","kind":"trial","name":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations","route":"/trials/nct06674343/","field":"links","label":"ClinicalTrials.gov NCT06674343"}]},{"url":"https://clinicaltrials.gov/study/NCT06678048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06678048","kind":"trial","name":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","route":"/trials/nct06678048/","field":"links","label":"ClinicalTrials.gov NCT06678048"}]},{"url":"https://clinicaltrials.gov/study/NCT06678659","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/","field":"links","label":"ClinicalTrials.gov NCT06678659"}]},{"url":"https://clinicaltrials.gov/study/NCT06679036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679036","kind":"trial","name":"A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","route":"/trials/nct06679036/","field":"links","label":"ClinicalTrials.gov NCT06679036"}]},{"url":"https://clinicaltrials.gov/study/NCT06679101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/","field":"links","label":"ClinicalTrials.gov NCT06679101"}]},{"url":"https://clinicaltrials.gov/study/NCT06679634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","route":"/trials/nct06679634/","field":"links","label":"ClinicalTrials.gov NCT06679634"}]},{"url":"https://clinicaltrials.gov/study/NCT06679673","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679673","kind":"trial","name":"SHR-1701 Combined with SHR2554 and BP102 for MCRC","route":"/trials/nct06679673/","field":"links","label":"ClinicalTrials.gov NCT06679673"}]},{"url":"https://clinicaltrials.gov/study/NCT06679829","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679829","kind":"trial","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","route":"/trials/nct06679829/","field":"links","label":"ClinicalTrials.gov NCT06679829"}]},{"url":"https://clinicaltrials.gov/study/NCT06679985","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/","field":"links","label":"ClinicalTrials.gov NCT06679985"}]},{"url":"https://clinicaltrials.gov/study/NCT06680739","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06680739","kind":"trial","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","route":"/trials/nct06680739/","field":"links","label":"ClinicalTrials.gov NCT06680739"}]},{"url":"https://clinicaltrials.gov/study/NCT06680752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/","field":"links","label":"ClinicalTrials.gov NCT06680752"}]},{"url":"https://clinicaltrials.gov/study/NCT06680921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/","field":"links","label":"ClinicalTrials.gov NCT06680921"}]},{"url":"https://clinicaltrials.gov/study/NCT06681038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06681038","kind":"trial","name":"Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","route":"/trials/nct06681038/","field":"links","label":"ClinicalTrials.gov NCT06681038"}]},{"url":"https://clinicaltrials.gov/study/NCT06682195","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06682195","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","route":"/trials/nct06682195/","field":"links","label":"ClinicalTrials.gov NCT06682195"}]},{"url":"https://clinicaltrials.gov/study/NCT06682572","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06682572","kind":"trial","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","route":"/trials/nct06682572/","field":"links","label":"ClinicalTrials.gov NCT06682572"}]},{"url":"https://clinicaltrials.gov/study/NCT06682780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/","field":"links","label":"ClinicalTrials.gov NCT06682780"}]},{"url":"https://clinicaltrials.gov/study/NCT06682793","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/","field":"links","label":"ClinicalTrials.gov NCT06682793"}]},{"url":"https://clinicaltrials.gov/study/NCT06682988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06682988","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","route":"/trials/nct06682988/","field":"links","label":"ClinicalTrials.gov NCT06682988"}]},{"url":"https://clinicaltrials.gov/study/NCT06683703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06683703","kind":"trial","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","route":"/trials/nct06683703/","field":"links","label":"ClinicalTrials.gov NCT06683703"}]},{"url":"https://clinicaltrials.gov/study/NCT06685276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06685276","kind":"trial","name":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct06685276/","field":"links","label":"ClinicalTrials.gov NCT06685276"}]},{"url":"https://clinicaltrials.gov/study/NCT06686030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/","field":"links","label":"ClinicalTrials.gov NCT06686030"}]},{"url":"https://clinicaltrials.gov/study/NCT06686394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06686394","kind":"trial","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","route":"/trials/nct06686394/","field":"links","label":"ClinicalTrials.gov NCT06686394"}]},{"url":"https://clinicaltrials.gov/study/NCT06686576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/","field":"links","label":"ClinicalTrials.gov NCT06686576"}]},{"url":"https://clinicaltrials.gov/study/NCT06686771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06686771","kind":"trial","name":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct06686771/","field":"links","label":"ClinicalTrials.gov NCT06686771"}]},{"url":"https://clinicaltrials.gov/study/NCT06687369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06687369","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L","route":"/trials/nct06687369/","field":"links","label":"ClinicalTrials.gov NCT06687369"}]},{"url":"https://clinicaltrials.gov/study/NCT06687681","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","route":"/trials/nct06687681/","field":"links","label":"ClinicalTrials.gov NCT06687681"}]},{"url":"https://clinicaltrials.gov/study/NCT06689163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06689163","kind":"trial","name":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","route":"/trials/nct06689163/","field":"links","label":"ClinicalTrials.gov NCT06689163"}]},{"url":"https://clinicaltrials.gov/study/NCT06690528","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06690528","kind":"trial","name":"Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","route":"/trials/nct06690528/","field":"links","label":"ClinicalTrials.gov NCT06690528"}]},{"url":"https://clinicaltrials.gov/study/NCT06690775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/","field":"links","label":"ClinicalTrials.gov NCT06690775"}]},{"url":"https://clinicaltrials.gov/study/NCT06690840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","route":"/trials/nct06690840/","field":"links","label":"ClinicalTrials.gov NCT06690840"}]},{"url":"https://clinicaltrials.gov/study/NCT06691594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06691594","kind":"trial","name":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","route":"/trials/nct06691594/","field":"links","label":"ClinicalTrials.gov NCT06691594"}]},{"url":"https://clinicaltrials.gov/study/NCT06691984","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xaluritamig","kind":"drug","name":"Xaluritamig","route":"/drugs/xaluritamig/","field":"links","label":"ClinicalTrials.gov NCT06691984"},{"id":"xalute","kind":"trial","name":"XALute","route":"/trials/xalute/","field":"links","label":"ClinicalTrials.gov NCT06691984"}],"archive":"https://web.archive.org/web/20260826004540/https://clinicaltrials.gov/study/NCT06691984"},{"url":"https://clinicaltrials.gov/study/NCT06692166","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/","field":"links","label":"ClinicalTrials.gov NCT06692166"}]},{"url":"https://clinicaltrials.gov/study/NCT06692738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/","field":"links","label":"ClinicalTrials.gov NCT06692738"}]},{"url":"https://clinicaltrials.gov/study/NCT06693336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06693336","kind":"trial","name":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","route":"/trials/nct06693336/","field":"links","label":"ClinicalTrials.gov NCT06693336"}]},{"url":"https://clinicaltrials.gov/study/NCT06693375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06693375","kind":"trial","name":"To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.","route":"/trials/nct06693375/","field":"links","label":"ClinicalTrials.gov NCT06693375"}]},{"url":"https://clinicaltrials.gov/study/NCT06695845","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06695845","kind":"trial","name":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","route":"/trials/nct06695845/","field":"links","label":"ClinicalTrials.gov NCT06695845"}]},{"url":"https://clinicaltrials.gov/study/NCT06697184","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","route":"/trials/nct06697184/","field":"links","label":"ClinicalTrials.gov NCT06697184"}]},{"url":"https://clinicaltrials.gov/study/NCT06697197","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct06697197/","field":"links","label":"ClinicalTrials.gov NCT06697197"}]},{"url":"https://clinicaltrials.gov/study/NCT06697301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/","field":"links","label":"ClinicalTrials.gov NCT06697301"}]},{"url":"https://clinicaltrials.gov/study/NCT06698042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06698042","kind":"trial","name":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","route":"/trials/nct06698042/","field":"links","label":"ClinicalTrials.gov NCT06698042"}]},{"url":"https://clinicaltrials.gov/study/NCT06698757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06698757","kind":"trial","name":"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer","route":"/trials/nct06698757/","field":"links","label":"ClinicalTrials.gov NCT06698757"}]},{"url":"https://clinicaltrials.gov/study/NCT06698965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","route":"/trials/nct06698965/","field":"links","label":"ClinicalTrials.gov NCT06698965"}]},{"url":"https://clinicaltrials.gov/study/NCT06699212","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/","field":"links","label":"ClinicalTrials.gov NCT06699212"}]},{"url":"https://clinicaltrials.gov/study/NCT06699836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","route":"/trials/nct06699836/","field":"links","label":"ClinicalTrials.gov NCT06699836"}]},{"url":"https://clinicaltrials.gov/study/NCT06700603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06700603","kind":"trial","name":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","route":"/trials/nct06700603/","field":"links","label":"ClinicalTrials.gov NCT06700603"}]},{"url":"https://clinicaltrials.gov/study/NCT06702618","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06702618","kind":"trial","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","route":"/trials/nct06702618/","field":"links","label":"ClinicalTrials.gov NCT06702618"}]},{"url":"https://clinicaltrials.gov/study/NCT06702995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06702995","kind":"trial","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06702995/","field":"links","label":"ClinicalTrials.gov NCT06702995"}]},{"url":"https://clinicaltrials.gov/study/NCT06703177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06703177","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","route":"/trials/nct06703177/","field":"links","label":"ClinicalTrials.gov NCT06703177"}]},{"url":"https://clinicaltrials.gov/study/NCT06703255","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06703255","kind":"trial","name":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","route":"/trials/nct06703255/","field":"links","label":"ClinicalTrials.gov NCT06703255"}]},{"url":"https://clinicaltrials.gov/study/NCT06703398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","field":"links","label":"ClinicalTrials.gov NCT06703398"}]},{"url":"https://clinicaltrials.gov/study/NCT06704620","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06704620","kind":"trial","name":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can","route":"/trials/nct06704620/","field":"links","label":"ClinicalTrials.gov NCT06704620"}]},{"url":"https://clinicaltrials.gov/study/NCT06706076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/","field":"links","label":"ClinicalTrials.gov NCT06706076"}]},{"url":"https://clinicaltrials.gov/study/NCT06706713","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06706713","kind":"trial","name":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","route":"/trials/nct06706713/","field":"links","label":"ClinicalTrials.gov NCT06706713"}]},{"url":"https://clinicaltrials.gov/study/NCT06708663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","route":"/trials/nct06708663/","field":"links","label":"ClinicalTrials.gov NCT06708663"}]},{"url":"https://clinicaltrials.gov/study/NCT06708858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06708858","kind":"trial","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06708858/","field":"links","label":"ClinicalTrials.gov NCT06708858"}]},{"url":"https://clinicaltrials.gov/study/NCT06709144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06709144","kind":"trial","name":"Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer","route":"/trials/nct06709144/","field":"links","label":"ClinicalTrials.gov NCT06709144"}]},{"url":"https://clinicaltrials.gov/study/NCT06709885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06709885","kind":"trial","name":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer","route":"/trials/nct06709885/","field":"links","label":"ClinicalTrials.gov NCT06709885"}]},{"url":"https://clinicaltrials.gov/study/NCT06710132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/","field":"links","label":"ClinicalTrials.gov NCT06710132"}]},{"url":"https://clinicaltrials.gov/study/NCT06710288","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/","field":"links","label":"ClinicalTrials.gov NCT06710288"}]},{"url":"https://clinicaltrials.gov/study/NCT06710756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","field":"links","label":"ClinicalTrials.gov NCT06710756"}]},{"url":"https://clinicaltrials.gov/study/NCT06710847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06710847","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct06710847/","field":"links","label":"ClinicalTrials.gov NCT06710847"}]},{"url":"https://clinicaltrials.gov/study/NCT06711900","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06711900","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","route":"/trials/nct06711900/","field":"links","label":"ClinicalTrials.gov NCT06711900"}]},{"url":"https://clinicaltrials.gov/study/NCT06712316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/","field":"links","label":"ClinicalTrials.gov NCT06712316"}]},{"url":"https://clinicaltrials.gov/study/NCT06712355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/","field":"links","label":"ClinicalTrials.gov NCT06712355"}]},{"url":"https://clinicaltrials.gov/study/NCT06712420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neogb","kind":"trial","name":"NEOGB","route":"/trials/neogb/","field":"links","label":"ClinicalTrials.gov NCT06712420"}]},{"url":"https://clinicaltrials.gov/study/NCT06712680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/","field":"links","label":"ClinicalTrials.gov NCT06712680"}]},{"url":"https://clinicaltrials.gov/study/NCT06714357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06714357","kind":"trial","name":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","route":"/trials/nct06714357/","field":"links","label":"ClinicalTrials.gov NCT06714357"}]},{"url":"https://clinicaltrials.gov/study/NCT06714604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06714604","kind":"trial","name":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","route":"/trials/nct06714604/","field":"links","label":"ClinicalTrials.gov NCT06714604"}]},{"url":"https://clinicaltrials.gov/study/NCT06717126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/","field":"links","label":"ClinicalTrials.gov NCT06717126"}]},{"url":"https://clinicaltrials.gov/study/NCT06717347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/","field":"links","label":"ClinicalTrials.gov NCT06717347"}]},{"url":"https://clinicaltrials.gov/study/NCT06717464","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06717464","kind":"trial","name":"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer","route":"/trials/nct06717464/","field":"links","label":"ClinicalTrials.gov NCT06717464"}]},{"url":"https://clinicaltrials.gov/study/NCT06718543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06718543","kind":"trial","name":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","route":"/trials/nct06718543/","field":"links","label":"ClinicalTrials.gov NCT06718543"}]},{"url":"https://clinicaltrials.gov/study/NCT06719336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06719336","kind":"trial","name":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","route":"/trials/nct06719336/","field":"links","label":"ClinicalTrials.gov NCT06719336"}]},{"url":"https://clinicaltrials.gov/study/NCT06722183","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06722183","kind":"trial","name":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","route":"/trials/nct06722183/","field":"links","label":"ClinicalTrials.gov NCT06722183"}]},{"url":"https://clinicaltrials.gov/study/NCT06722911","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06722911","kind":"trial","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","route":"/trials/nct06722911/","field":"links","label":"ClinicalTrials.gov NCT06722911"}]},{"url":"https://clinicaltrials.gov/study/NCT06724263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06724263","kind":"trial","name":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","route":"/trials/nct06724263/","field":"links","label":"ClinicalTrials.gov NCT06724263"}]},{"url":"https://clinicaltrials.gov/study/NCT06725758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","route":"/trials/nct06725758/","field":"links","label":"ClinicalTrials.gov NCT06725758"}]},{"url":"https://clinicaltrials.gov/study/NCT06726148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/","field":"links","label":"ClinicalTrials.gov NCT06726148"}]},{"url":"https://clinicaltrials.gov/study/NCT06726161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","field":"links","label":"ClinicalTrials.gov NCT06726161"}]},{"url":"https://clinicaltrials.gov/study/NCT06726265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/","field":"links","label":"ClinicalTrials.gov NCT06726265"}]},{"url":"https://clinicaltrials.gov/study/NCT06727565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/","field":"links","label":"ClinicalTrials.gov NCT06727565"}]},{"url":"https://clinicaltrials.gov/study/NCT06727630","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06727630","kind":"trial","name":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","route":"/trials/nct06727630/","field":"links","label":"ClinicalTrials.gov NCT06727630"}]},{"url":"https://clinicaltrials.gov/study/NCT06728072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06728072","kind":"trial","name":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","route":"/trials/nct06728072/","field":"links","label":"ClinicalTrials.gov NCT06728072"}]},{"url":"https://clinicaltrials.gov/study/NCT06728410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06728410","kind":"trial","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","route":"/trials/nct06728410/","field":"links","label":"ClinicalTrials.gov NCT06728410"}]},{"url":"https://clinicaltrials.gov/study/NCT06730009","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","route":"/trials/nct06730009/","field":"links","label":"ClinicalTrials.gov NCT06730009"}]},{"url":"https://clinicaltrials.gov/study/NCT06730347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/","field":"links","label":"ClinicalTrials.gov NCT06730347"}]},{"url":"https://clinicaltrials.gov/study/NCT06730750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06730750","kind":"trial","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","route":"/trials/nct06730750/","field":"links","label":"ClinicalTrials.gov NCT06730750"}]},{"url":"https://clinicaltrials.gov/study/NCT06731153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/","field":"links","label":"ClinicalTrials.gov NCT06731153"}]},{"url":"https://clinicaltrials.gov/study/NCT06731478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06731478","kind":"trial","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct06731478/","field":"links","label":"ClinicalTrials.gov NCT06731478"}]},{"url":"https://clinicaltrials.gov/study/NCT06731894","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06731894","kind":"trial","name":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","route":"/trials/nct06731894/","field":"links","label":"ClinicalTrials.gov NCT06731894"}]},{"url":"https://clinicaltrials.gov/study/NCT06731907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/","field":"links","label":"ClinicalTrials.gov NCT06731907"}]},{"url":"https://clinicaltrials.gov/study/NCT06732323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/","field":"links","label":"ClinicalTrials.gov NCT06732323"}]},{"url":"https://clinicaltrials.gov/study/NCT06732401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06732401","kind":"trial","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","route":"/trials/nct06732401/","field":"links","label":"ClinicalTrials.gov NCT06732401"}]},{"url":"https://clinicaltrials.gov/study/NCT06732531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06732531","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06732531/","field":"links","label":"ClinicalTrials.gov NCT06732531"}]},{"url":"https://clinicaltrials.gov/study/NCT06733038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06733038","kind":"trial","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","route":"/trials/nct06733038/","field":"links","label":"ClinicalTrials.gov NCT06733038"}]},{"url":"https://clinicaltrials.gov/study/NCT06734702","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06734702","kind":"trial","name":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca","route":"/trials/nct06734702/","field":"links","label":"ClinicalTrials.gov NCT06734702"}]},{"url":"https://clinicaltrials.gov/study/NCT06735131","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06735131","kind":"trial","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","route":"/trials/nct06735131/","field":"links","label":"ClinicalTrials.gov NCT06735131"}]},{"url":"https://clinicaltrials.gov/study/NCT06735144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","field":"links","label":"ClinicalTrials.gov NCT06735144"}]},{"url":"https://clinicaltrials.gov/study/NCT06735391","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06735391","kind":"trial","name":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","route":"/trials/nct06735391/","field":"links","label":"ClinicalTrials.gov NCT06735391"}]},{"url":"https://clinicaltrials.gov/study/NCT06736704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/","field":"links","label":"ClinicalTrials.gov NCT06736704"}]},{"url":"https://clinicaltrials.gov/study/NCT06736717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","field":"links","label":"ClinicalTrials.gov NCT06736717"}]},{"url":"https://clinicaltrials.gov/study/NCT06737081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","route":"/trials/nct06737081/","field":"links","label":"ClinicalTrials.gov NCT06737081"}]},{"url":"https://clinicaltrials.gov/study/NCT06737731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06737731","kind":"trial","name":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06737731/","field":"links","label":"ClinicalTrials.gov NCT06737731"}]},{"url":"https://clinicaltrials.gov/study/NCT06741644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06741644","kind":"trial","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","route":"/trials/nct06741644/","field":"links","label":"ClinicalTrials.gov NCT06741644"}]},{"url":"https://clinicaltrials.gov/study/NCT06742892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06742892","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06742892/","field":"links","label":"ClinicalTrials.gov NCT06742892"}]},{"url":"https://clinicaltrials.gov/study/NCT06742996","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06742996","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","route":"/trials/nct06742996/","field":"links","label":"ClinicalTrials.gov NCT06742996"}]},{"url":"https://clinicaltrials.gov/study/NCT06743126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/","field":"links","label":"ClinicalTrials.gov NCT06743126"}]},{"url":"https://clinicaltrials.gov/study/NCT06745323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/","field":"links","label":"ClinicalTrials.gov NCT06745323"}]},{"url":"https://clinicaltrials.gov/study/NCT06745882","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06745882","kind":"trial","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","route":"/trials/nct06745882/","field":"links","label":"ClinicalTrials.gov NCT06745882"}]},{"url":"https://clinicaltrials.gov/study/NCT06745908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","route":"/trials/nct06745908/","field":"links","label":"ClinicalTrials.gov NCT06745908"}]},{"url":"https://clinicaltrials.gov/study/NCT06746116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06746116","kind":"trial","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","route":"/trials/nct06746116/","field":"links","label":"ClinicalTrials.gov NCT06746116"}]},{"url":"https://clinicaltrials.gov/study/NCT06746545","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06746545","kind":"trial","name":"A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.","route":"/trials/nct06746545/","field":"links","label":"ClinicalTrials.gov NCT06746545"}]},{"url":"https://clinicaltrials.gov/study/NCT06746870","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06746870","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr","route":"/trials/nct06746870/","field":"links","label":"ClinicalTrials.gov NCT06746870"}]},{"url":"https://clinicaltrials.gov/study/NCT06747338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT06747338"},{"id":"nct06747338","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","route":"/trials/nct06747338/","field":"links","label":"ClinicalTrials.gov NCT06747338"}]},{"url":"https://clinicaltrials.gov/study/NCT06747585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/","field":"links","label":"ClinicalTrials.gov NCT06747585"}]},{"url":"https://clinicaltrials.gov/study/NCT06747845","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06747845","kind":"trial","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","route":"/trials/nct06747845/","field":"links","label":"ClinicalTrials.gov NCT06747845"}]},{"url":"https://clinicaltrials.gov/study/NCT06750094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/","field":"links","label":"ClinicalTrials.gov NCT06750094"}]},{"url":"https://clinicaltrials.gov/study/NCT06750185","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","route":"/trials/nct06750185/","field":"links","label":"ClinicalTrials.gov NCT06750185"}]},{"url":"https://clinicaltrials.gov/study/NCT06750419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06750419","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","route":"/trials/nct06750419/","field":"links","label":"ClinicalTrials.gov NCT06750419"}]},{"url":"https://clinicaltrials.gov/study/NCT06750861","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06750861","kind":"trial","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","route":"/trials/nct06750861/","field":"links","label":"ClinicalTrials.gov NCT06750861"}]},{"url":"https://clinicaltrials.gov/study/NCT06751329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/","field":"links","label":"ClinicalTrials.gov NCT06751329"}]},{"url":"https://clinicaltrials.gov/study/NCT06751394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06751394","kind":"trial","name":"Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer","route":"/trials/nct06751394/","field":"links","label":"ClinicalTrials.gov NCT06751394"}]},{"url":"https://clinicaltrials.gov/study/NCT06752811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct06752811/","field":"links","label":"ClinicalTrials.gov NCT06752811"}]},{"url":"https://clinicaltrials.gov/study/NCT06754085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","field":"links","label":"ClinicalTrials.gov NCT06754085"}]},{"url":"https://clinicaltrials.gov/study/NCT06754644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06754644","kind":"trial","name":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","route":"/trials/nct06754644/","field":"links","label":"ClinicalTrials.gov NCT06754644"}]},{"url":"https://clinicaltrials.gov/study/NCT06754930","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/","field":"links","label":"ClinicalTrials.gov NCT06754930"}]},{"url":"https://clinicaltrials.gov/study/NCT06756074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06756074","kind":"trial","name":"Reinforced Pancreaticojejunostomy With or Without glubran2","route":"/trials/nct06756074/","field":"links","label":"ClinicalTrials.gov NCT06756074"}]},{"url":"https://clinicaltrials.gov/study/NCT06756269","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","field":"links","label":"ClinicalTrials.gov NCT06756269"}]},{"url":"https://clinicaltrials.gov/study/NCT06757244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06757244","kind":"trial","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","route":"/trials/nct06757244/","field":"links","label":"ClinicalTrials.gov NCT06757244"}]},{"url":"https://clinicaltrials.gov/study/NCT06757634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/","field":"links","label":"ClinicalTrials.gov NCT06757634"}]},{"url":"https://clinicaltrials.gov/study/NCT06758401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/","field":"links","label":"ClinicalTrials.gov NCT06758401"}]},{"url":"https://clinicaltrials.gov/study/NCT06758544","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06758544","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer","route":"/trials/nct06758544/","field":"links","label":"ClinicalTrials.gov NCT06758544"}]},{"url":"https://clinicaltrials.gov/study/NCT06758557","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06758557","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","route":"/trials/nct06758557/","field":"links","label":"ClinicalTrials.gov NCT06758557"}]},{"url":"https://clinicaltrials.gov/study/NCT06758830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06758830","kind":"trial","name":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","route":"/trials/nct06758830/","field":"links","label":"ClinicalTrials.gov NCT06758830"}]},{"url":"https://clinicaltrials.gov/study/NCT06759090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06759090","kind":"trial","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06759090/","field":"links","label":"ClinicalTrials.gov NCT06759090"}]},{"url":"https://clinicaltrials.gov/study/NCT06759857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06759857","kind":"trial","name":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","route":"/trials/nct06759857/","field":"links","label":"ClinicalTrials.gov NCT06759857"}]},{"url":"https://clinicaltrials.gov/study/NCT06760520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06760520","kind":"trial","name":"Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer","route":"/trials/nct06760520/","field":"links","label":"ClinicalTrials.gov NCT06760520"}]},{"url":"https://clinicaltrials.gov/study/NCT06760637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/","field":"links","label":"ClinicalTrials.gov NCT06760637"}]},{"url":"https://clinicaltrials.gov/study/NCT06760819","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/","field":"links","label":"ClinicalTrials.gov NCT06760819"}]},{"url":"https://clinicaltrials.gov/study/NCT06761027","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06761027","kind":"trial","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","route":"/trials/nct06761027/","field":"links","label":"ClinicalTrials.gov NCT06761027"}]},{"url":"https://clinicaltrials.gov/study/NCT06762405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06762405","kind":"trial","name":"PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-defi","route":"/trials/nct06762405/","field":"links","label":"ClinicalTrials.gov NCT06762405"}]},{"url":"https://clinicaltrials.gov/study/NCT06763029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06763029","kind":"trial","name":"Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer","route":"/trials/nct06763029/","field":"links","label":"ClinicalTrials.gov NCT06763029"}]},{"url":"https://clinicaltrials.gov/study/NCT06764186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764186","kind":"trial","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","route":"/trials/nct06764186/","field":"links","label":"ClinicalTrials.gov NCT06764186"}]},{"url":"https://clinicaltrials.gov/study/NCT06764485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct06764485/","field":"links","label":"ClinicalTrials.gov NCT06764485"}]},{"url":"https://clinicaltrials.gov/study/NCT06764628","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","route":"/trials/nct06764628/","field":"links","label":"ClinicalTrials.gov NCT06764628"}]},{"url":"https://clinicaltrials.gov/study/NCT06764680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764680","kind":"trial","name":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","route":"/trials/nct06764680/","field":"links","label":"ClinicalTrials.gov NCT06764680"}]},{"url":"https://clinicaltrials.gov/study/NCT06764875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/","field":"links","label":"ClinicalTrials.gov NCT06764875"}]},{"url":"https://clinicaltrials.gov/study/NCT06764940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","route":"/trials/nct06764940/","field":"links","label":"ClinicalTrials.gov NCT06764940"}]},{"url":"https://clinicaltrials.gov/study/NCT06765109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/","field":"links","label":"ClinicalTrials.gov NCT06765109"}]},{"url":"https://clinicaltrials.gov/study/NCT06765616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06765616","kind":"trial","name":"Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer","route":"/trials/nct06765616/","field":"links","label":"ClinicalTrials.gov NCT06765616"}]},{"url":"https://clinicaltrials.gov/study/NCT06767007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06767007","kind":"trial","name":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","route":"/trials/nct06767007/","field":"links","label":"ClinicalTrials.gov NCT06767007"}]},{"url":"https://clinicaltrials.gov/study/NCT06767514","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/","field":"links","label":"ClinicalTrials.gov NCT06767514"}]},{"url":"https://clinicaltrials.gov/study/NCT06767527","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06767527","kind":"trial","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","route":"/trials/nct06767527/","field":"links","label":"ClinicalTrials.gov NCT06767527"}]},{"url":"https://clinicaltrials.gov/study/NCT06767813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06767813","kind":"trial","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","route":"/trials/nct06767813/","field":"links","label":"ClinicalTrials.gov NCT06767813"}]},{"url":"https://clinicaltrials.gov/study/NCT06769113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06769113","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06769113/","field":"links","label":"ClinicalTrials.gov NCT06769113"}]},{"url":"https://clinicaltrials.gov/study/NCT06769152","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct06769152/","field":"links","label":"ClinicalTrials.gov NCT06769152"}]},{"url":"https://clinicaltrials.gov/study/NCT06769698","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06769698","kind":"trial","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","route":"/trials/nct06769698/","field":"links","label":"ClinicalTrials.gov NCT06769698"}]},{"url":"https://clinicaltrials.gov/study/NCT06770270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06770270","kind":"trial","name":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","route":"/trials/nct06770270/","field":"links","label":"ClinicalTrials.gov NCT06770270"}]},{"url":"https://clinicaltrials.gov/study/NCT06770439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06770439","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct06770439/","field":"links","label":"ClinicalTrials.gov NCT06770439"}]},{"url":"https://clinicaltrials.gov/study/NCT06770452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","route":"/trials/nct06770452/","field":"links","label":"ClinicalTrials.gov NCT06770452"}]},{"url":"https://clinicaltrials.gov/study/NCT06771609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","route":"/trials/nct06771609/","field":"links","label":"ClinicalTrials.gov NCT06771609"}]},{"url":"https://clinicaltrials.gov/study/NCT06771622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06771622","kind":"trial","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","route":"/trials/nct06771622/","field":"links","label":"ClinicalTrials.gov NCT06771622"}]},{"url":"https://clinicaltrials.gov/study/NCT06772623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","route":"/trials/nct06772623/","field":"links","label":"ClinicalTrials.gov NCT06772623"}]},{"url":"https://clinicaltrials.gov/study/NCT06774131","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/","field":"links","label":"ClinicalTrials.gov NCT06774131"}]},{"url":"https://clinicaltrials.gov/study/NCT06775483","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","route":"/trials/nct06775483/","field":"links","label":"ClinicalTrials.gov NCT06775483"}]},{"url":"https://clinicaltrials.gov/study/NCT06776757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06776757","kind":"trial","name":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct06776757/","field":"links","label":"ClinicalTrials.gov NCT06776757"}]},{"url":"https://clinicaltrials.gov/study/NCT06776952","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/","field":"links","label":"ClinicalTrials.gov NCT06776952"}]},{"url":"https://clinicaltrials.gov/study/NCT06777316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/","field":"links","label":"ClinicalTrials.gov NCT06777316"}]},{"url":"https://clinicaltrials.gov/study/NCT06777433","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/","field":"links","label":"ClinicalTrials.gov NCT06777433"}]},{"url":"https://clinicaltrials.gov/study/NCT06778031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/","field":"links","label":"ClinicalTrials.gov NCT06778031"}]},{"url":"https://clinicaltrials.gov/study/NCT06778382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06778382","kind":"trial","name":"Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","route":"/trials/nct06778382/","field":"links","label":"ClinicalTrials.gov NCT06778382"}]},{"url":"https://clinicaltrials.gov/study/NCT06780085","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780085","kind":"trial","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","route":"/trials/nct06780085/","field":"links","label":"ClinicalTrials.gov NCT06780085"}]},{"url":"https://clinicaltrials.gov/study/NCT06780098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780098","kind":"trial","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","route":"/trials/nct06780098/","field":"links","label":"ClinicalTrials.gov NCT06780098"}]},{"url":"https://clinicaltrials.gov/study/NCT06780111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780111","kind":"trial","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","route":"/trials/nct06780111/","field":"links","label":"ClinicalTrials.gov NCT06780111"}]},{"url":"https://clinicaltrials.gov/study/NCT06780137","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/","field":"links","label":"ClinicalTrials.gov NCT06780137"}]},{"url":"https://clinicaltrials.gov/study/NCT06780670","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","field":"links","label":"ClinicalTrials.gov NCT06780670"}]},{"url":"https://clinicaltrials.gov/study/NCT06780787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780787","kind":"trial","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","route":"/trials/nct06780787/","field":"links","label":"ClinicalTrials.gov NCT06780787"}]},{"url":"https://clinicaltrials.gov/study/NCT06780839","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06780839","kind":"trial","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","route":"/trials/nct06780839/","field":"links","label":"ClinicalTrials.gov NCT06780839"}]},{"url":"https://clinicaltrials.gov/study/NCT06781567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06781567","kind":"trial","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","route":"/trials/nct06781567/","field":"links","label":"ClinicalTrials.gov NCT06781567"}]},{"url":"https://clinicaltrials.gov/study/NCT06782334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06782334","kind":"trial","name":"AMT-116 in Patients with Solid Tumors","route":"/trials/nct06782334/","field":"links","label":"ClinicalTrials.gov NCT06782334"}]},{"url":"https://clinicaltrials.gov/study/NCT06782412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06782412","kind":"trial","name":"Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif","route":"/trials/nct06782412/","field":"links","label":"ClinicalTrials.gov NCT06782412"}]},{"url":"https://clinicaltrials.gov/study/NCT06782555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/","field":"links","label":"ClinicalTrials.gov NCT06782555"}]},{"url":"https://clinicaltrials.gov/study/NCT06782685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06782685","kind":"trial","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","route":"/trials/nct06782685/","field":"links","label":"ClinicalTrials.gov NCT06782685"}]},{"url":"https://clinicaltrials.gov/study/NCT06782932","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/","field":"links","label":"ClinicalTrials.gov NCT06782932"}]},{"url":"https://clinicaltrials.gov/study/NCT06783140","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06783140","kind":"trial","name":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","route":"/trials/nct06783140/","field":"links","label":"ClinicalTrials.gov NCT06783140"}]},{"url":"https://clinicaltrials.gov/study/NCT06783491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06783491","kind":"trial","name":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","route":"/trials/nct06783491/","field":"links","label":"ClinicalTrials.gov NCT06783491"}]},{"url":"https://clinicaltrials.gov/study/NCT06783647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06783647","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","route":"/trials/nct06783647/","field":"links","label":"ClinicalTrials.gov NCT06783647"}]},{"url":"https://clinicaltrials.gov/study/NCT06784648","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","route":"/trials/nct06784648/","field":"links","label":"ClinicalTrials.gov NCT06784648"}]},{"url":"https://clinicaltrials.gov/study/NCT06784752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","field":"links","label":"ClinicalTrials.gov NCT06784752"}]},{"url":"https://clinicaltrials.gov/study/NCT06784791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06784791","kind":"trial","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut","route":"/trials/nct06784791/","field":"links","label":"ClinicalTrials.gov NCT06784791"}]},{"url":"https://clinicaltrials.gov/study/NCT06785636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/","field":"links","label":"ClinicalTrials.gov NCT06785636"}]},{"url":"https://clinicaltrials.gov/study/NCT06786026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","route":"/trials/nct06786026/","field":"links","label":"ClinicalTrials.gov NCT06786026"}]},{"url":"https://clinicaltrials.gov/study/NCT06787183","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06787183","kind":"trial","name":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases","route":"/trials/nct06787183/","field":"links","label":"ClinicalTrials.gov NCT06787183"}]},{"url":"https://clinicaltrials.gov/study/NCT06787339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/","field":"links","label":"ClinicalTrials.gov NCT06787339"}]},{"url":"https://clinicaltrials.gov/study/NCT06787612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","field":"links","label":"ClinicalTrials.gov NCT06787612"},{"id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/","field":"links","label":"ClinicalTrials.gov NCT06787612"}]},{"url":"https://clinicaltrials.gov/study/NCT06787664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","route":"/trials/nct06787664/","field":"links","label":"ClinicalTrials.gov NCT06787664"}]},{"url":"https://clinicaltrials.gov/study/NCT06788171","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06788171","kind":"trial","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","route":"/trials/nct06788171/","field":"links","label":"ClinicalTrials.gov NCT06788171"}]},{"url":"https://clinicaltrials.gov/study/NCT06788756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06788756","kind":"trial","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","route":"/trials/nct06788756/","field":"links","label":"ClinicalTrials.gov NCT06788756"}]},{"url":"https://clinicaltrials.gov/study/NCT06788912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","field":"links","label":"ClinicalTrials.gov NCT06788912"}]},{"url":"https://clinicaltrials.gov/study/NCT06788990","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","field":"links","label":"ClinicalTrials.gov NCT06788990"},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","field":"dosing.source"},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","field":"links","label":"ClinicalTrials.gov NCT06788990: FORTIFI-HN01"}]},{"url":"https://clinicaltrials.gov/study/NCT06789679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06789679","kind":"trial","name":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06789679/","field":"links","label":"ClinicalTrials.gov NCT06789679"}]},{"url":"https://clinicaltrials.gov/study/NCT06789796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/","field":"links","label":"ClinicalTrials.gov NCT06789796"}]},{"url":"https://clinicaltrials.gov/study/NCT06789848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06789848","kind":"trial","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","route":"/trials/nct06789848/","field":"links","label":"ClinicalTrials.gov NCT06789848"}]},{"url":"https://clinicaltrials.gov/study/NCT06790212","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06790212","kind":"trial","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","route":"/trials/nct06790212/","field":"links","label":"ClinicalTrials.gov NCT06790212"}]},{"url":"https://clinicaltrials.gov/study/NCT06790602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06790602","kind":"trial","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct06790602/","field":"links","label":"ClinicalTrials.gov NCT06790602"}]},{"url":"https://clinicaltrials.gov/study/NCT06790693","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06790693","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","route":"/trials/nct06790693/","field":"links","label":"ClinicalTrials.gov NCT06790693"}]},{"url":"https://clinicaltrials.gov/study/NCT06791512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06791512","kind":"trial","name":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","route":"/trials/nct06791512/","field":"links","label":"ClinicalTrials.gov NCT06791512"}]},{"url":"https://clinicaltrials.gov/study/NCT06792253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/","field":"links","label":"ClinicalTrials.gov NCT06792253"}]},{"url":"https://clinicaltrials.gov/study/NCT06792435","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/","field":"links","label":"ClinicalTrials.gov NCT06792435"}]},{"url":"https://clinicaltrials.gov/study/NCT06792695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","field":"links","label":"ClinicalTrials.gov NCT06792695"}]},{"url":"https://clinicaltrials.gov/study/NCT06793137","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06793137","kind":"trial","name":"Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct06793137/","field":"links","label":"ClinicalTrials.gov NCT06793137"}]},{"url":"https://clinicaltrials.gov/study/NCT06793215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/","field":"links","label":"ClinicalTrials.gov NCT06793215"}]},{"url":"https://clinicaltrials.gov/study/NCT06793332","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06793332","kind":"trial","name":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","route":"/trials/nct06793332/","field":"links","label":"ClinicalTrials.gov NCT06793332"}]},{"url":"https://clinicaltrials.gov/study/NCT06793553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06793553","kind":"trial","name":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","route":"/trials/nct06793553/","field":"links","label":"ClinicalTrials.gov NCT06793553"}]},{"url":"https://clinicaltrials.gov/study/NCT06794086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06794086","kind":"trial","name":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","route":"/trials/nct06794086/","field":"links","label":"ClinicalTrials.gov NCT06794086"}]},{"url":"https://clinicaltrials.gov/study/NCT06795022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/","field":"links","label":"ClinicalTrials.gov NCT06795022"}]},{"url":"https://clinicaltrials.gov/study/NCT06795412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/","field":"links","label":"ClinicalTrials.gov NCT06795412"}]},{"url":"https://clinicaltrials.gov/study/NCT06795503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/","field":"links","label":"ClinicalTrials.gov NCT06795503"}]},{"url":"https://clinicaltrials.gov/study/NCT06796907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","route":"/trials/nct06796907/","field":"links","label":"ClinicalTrials.gov NCT06796907"}]},{"url":"https://clinicaltrials.gov/study/NCT06797297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06797297","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","route":"/trials/nct06797297/","field":"links","label":"ClinicalTrials.gov NCT06797297"}]},{"url":"https://clinicaltrials.gov/study/NCT06797635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/","field":"links","label":"ClinicalTrials.gov NCT06797635"}]},{"url":"https://clinicaltrials.gov/study/NCT06797986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","route":"/trials/nct06797986/","field":"links","label":"ClinicalTrials.gov NCT06797986"}]},{"url":"https://clinicaltrials.gov/study/NCT06797999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/","field":"links","label":"ClinicalTrials.gov NCT06797999"}]},{"url":"https://clinicaltrials.gov/study/NCT06799637","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/","field":"links","label":"ClinicalTrials.gov NCT06799637"}]},{"url":"https://clinicaltrials.gov/study/NCT06800313","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/","field":"links","label":"ClinicalTrials.gov NCT06800313"}]},{"url":"https://clinicaltrials.gov/study/NCT06801665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06801665","kind":"trial","name":"FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis","route":"/trials/nct06801665/","field":"links","label":"ClinicalTrials.gov NCT06801665"}]},{"url":"https://clinicaltrials.gov/study/NCT06801834","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/","field":"links","label":"ClinicalTrials.gov NCT06801834"}]},{"url":"https://clinicaltrials.gov/study/NCT06802666","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06802666","kind":"trial","name":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct06802666/","field":"links","label":"ClinicalTrials.gov NCT06802666"}]},{"url":"https://clinicaltrials.gov/study/NCT06802757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","route":"/trials/nct06802757/","field":"links","label":"ClinicalTrials.gov NCT06802757"}]},{"url":"https://clinicaltrials.gov/study/NCT06805305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/","field":"links","label":"ClinicalTrials.gov NCT06805305"}]},{"url":"https://clinicaltrials.gov/study/NCT06806033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06806033","kind":"trial","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","route":"/trials/nct06806033/","field":"links","label":"ClinicalTrials.gov NCT06806033"}]},{"url":"https://clinicaltrials.gov/study/NCT06807359","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06807359","kind":"trial","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","route":"/trials/nct06807359/","field":"links","label":"ClinicalTrials.gov NCT06807359"}]},{"url":"https://clinicaltrials.gov/study/NCT06807437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/","field":"links","label":"ClinicalTrials.gov NCT06807437"}]},{"url":"https://clinicaltrials.gov/study/NCT06808412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06808412","kind":"trial","name":"To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer","route":"/trials/nct06808412/","field":"links","label":"ClinicalTrials.gov NCT06808412"}]},{"url":"https://clinicaltrials.gov/study/NCT06810375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06810375","kind":"trial","name":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","route":"/trials/nct06810375/","field":"links","label":"ClinicalTrials.gov NCT06810375"}]},{"url":"https://clinicaltrials.gov/study/NCT06810544","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/","field":"links","label":"ClinicalTrials.gov NCT06810544"}]},{"url":"https://clinicaltrials.gov/study/NCT06810804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06810804","kind":"trial","name":"A Phase IIa Study to Evaluate NBQ72S","route":"/trials/nct06810804/","field":"links","label":"ClinicalTrials.gov NCT06810804"}]},{"url":"https://clinicaltrials.gov/study/NCT06812260","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06812260","kind":"trial","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","route":"/trials/nct06812260/","field":"links","label":"ClinicalTrials.gov NCT06812260"}]},{"url":"https://clinicaltrials.gov/study/NCT06812728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06812728","kind":"trial","name":"Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients","route":"/trials/nct06812728/","field":"links","label":"ClinicalTrials.gov NCT06812728"}]},{"url":"https://clinicaltrials.gov/study/NCT06813079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06813079","kind":"trial","name":"Using Tumor Models to Determine Treatments","route":"/trials/nct06813079/","field":"links","label":"ClinicalTrials.gov NCT06813079"}]},{"url":"https://clinicaltrials.gov/study/NCT06814496","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06814496","kind":"trial","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","route":"/trials/nct06814496/","field":"links","label":"ClinicalTrials.gov NCT06814496"}]},{"url":"https://clinicaltrials.gov/study/NCT06817525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06817525","kind":"trial","name":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","route":"/trials/nct06817525/","field":"links","label":"ClinicalTrials.gov NCT06817525"}]},{"url":"https://clinicaltrials.gov/study/NCT06818643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","route":"/trials/nct06818643/","field":"links","label":"ClinicalTrials.gov NCT06818643"}]},{"url":"https://clinicaltrials.gov/study/NCT06819007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/","field":"links","label":"ClinicalTrials.gov NCT06819007"}]},{"url":"https://clinicaltrials.gov/study/NCT06819215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06819215","kind":"trial","name":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06819215/","field":"links","label":"ClinicalTrials.gov NCT06819215"}]},{"url":"https://clinicaltrials.gov/study/NCT06819319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06819319","kind":"trial","name":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","route":"/trials/nct06819319/","field":"links","label":"ClinicalTrials.gov NCT06819319"}]},{"url":"https://clinicaltrials.gov/study/NCT06819735","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","field":"links","label":"ClinicalTrials.gov NCT06819735"}]},{"url":"https://clinicaltrials.gov/study/NCT06820463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","route":"/trials/nct06820463/","field":"links","label":"ClinicalTrials.gov NCT06820463"}]},{"url":"https://clinicaltrials.gov/study/NCT06821503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/","field":"links","label":"ClinicalTrials.gov NCT06821503"}]},{"url":"https://clinicaltrials.gov/study/NCT06822543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06822543","kind":"trial","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","route":"/trials/nct06822543/","field":"links","label":"ClinicalTrials.gov NCT06822543"}]},{"url":"https://clinicaltrials.gov/study/NCT06823427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06823427","kind":"trial","name":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06823427/","field":"links","label":"ClinicalTrials.gov NCT06823427"}]},{"url":"https://clinicaltrials.gov/study/NCT06824064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","field":"links","label":"ClinicalTrials.gov NCT06824064"}]},{"url":"https://clinicaltrials.gov/study/NCT06824168","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","route":"/trials/nct06824168/","field":"links","label":"ClinicalTrials.gov NCT06824168"}]},{"url":"https://clinicaltrials.gov/study/NCT06824467","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/","field":"links","label":"ClinicalTrials.gov NCT06824467"}]},{"url":"https://clinicaltrials.gov/study/NCT06825494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06825494","kind":"trial","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","route":"/trials/nct06825494/","field":"links","label":"ClinicalTrials.gov NCT06825494"}]},{"url":"https://clinicaltrials.gov/study/NCT06826092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06826092","kind":"trial","name":"Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy","route":"/trials/nct06826092/","field":"links","label":"ClinicalTrials.gov NCT06826092"}]},{"url":"https://clinicaltrials.gov/study/NCT06827236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/","field":"links","label":"ClinicalTrials.gov NCT06827236"}]},{"url":"https://clinicaltrials.gov/study/NCT06827613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/","field":"links","label":"ClinicalTrials.gov NCT06827613"}]},{"url":"https://clinicaltrials.gov/study/NCT06828354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/","field":"links","label":"ClinicalTrials.gov NCT06828354"}]},{"url":"https://clinicaltrials.gov/study/NCT06828757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06828757","kind":"trial","name":"Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer","route":"/trials/nct06828757/","field":"links","label":"ClinicalTrials.gov NCT06828757"}]},{"url":"https://clinicaltrials.gov/study/NCT06828991","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06828991","kind":"trial","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","route":"/trials/nct06828991/","field":"links","label":"ClinicalTrials.gov NCT06828991"}]},{"url":"https://clinicaltrials.gov/study/NCT06829355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06829355","kind":"trial","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","route":"/trials/nct06829355/","field":"links","label":"ClinicalTrials.gov NCT06829355"}]},{"url":"https://clinicaltrials.gov/study/NCT06829459","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/","field":"links","label":"ClinicalTrials.gov NCT06829459"}]},{"url":"https://clinicaltrials.gov/study/NCT06829771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06829771","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","route":"/trials/nct06829771/","field":"links","label":"ClinicalTrials.gov NCT06829771"}]},{"url":"https://clinicaltrials.gov/study/NCT06830239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06830239","kind":"trial","name":"Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer","route":"/trials/nct06830239/","field":"links","label":"ClinicalTrials.gov NCT06830239"}]},{"url":"https://clinicaltrials.gov/study/NCT06830889","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","field":"regulatoryEvents.source (2025-02)"},{"id":"nct06830889","kind":"trial","name":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","route":"/trials/nct06830889/","field":"links","label":"ClinicalTrials.gov NCT06830889"}]},{"url":"https://clinicaltrials.gov/study/NCT06831136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06831136","kind":"trial","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","route":"/trials/nct06831136/","field":"links","label":"ClinicalTrials.gov NCT06831136"}]},{"url":"https://clinicaltrials.gov/study/NCT06831955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06831955","kind":"trial","name":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","route":"/trials/nct06831955/","field":"links","label":"ClinicalTrials.gov NCT06831955"}]},{"url":"https://clinicaltrials.gov/study/NCT06832202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06832202","kind":"trial","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","route":"/trials/nct06832202/","field":"links","label":"ClinicalTrials.gov NCT06832202"}]},{"url":"https://clinicaltrials.gov/study/NCT06832917","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06832917","kind":"trial","name":"Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC):","route":"/trials/nct06832917/","field":"links","label":"ClinicalTrials.gov NCT06832917"}]},{"url":"https://clinicaltrials.gov/study/NCT06833008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","field":"links","label":"ClinicalTrials.gov NCT06833008"}]},{"url":"https://clinicaltrials.gov/study/NCT06833073","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","route":"/trials/nct06833073/","field":"links","label":"ClinicalTrials.gov NCT06833073"}]},{"url":"https://clinicaltrials.gov/study/NCT06834672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/","field":"links","label":"ClinicalTrials.gov NCT06834672"}]},{"url":"https://clinicaltrials.gov/study/NCT06835179","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06835179","kind":"trial","name":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","route":"/trials/nct06835179/","field":"links","label":"ClinicalTrials.gov NCT06835179"}]},{"url":"https://clinicaltrials.gov/study/NCT06835530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06835530","kind":"trial","name":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","route":"/trials/nct06835530/","field":"links","label":"ClinicalTrials.gov NCT06835530"}]},{"url":"https://clinicaltrials.gov/study/NCT06838273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/","field":"links","label":"ClinicalTrials.gov NCT06838273"}]},{"url":"https://clinicaltrials.gov/study/NCT06838546","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06838546","kind":"trial","name":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","route":"/trials/nct06838546/","field":"links","label":"ClinicalTrials.gov NCT06838546"}]},{"url":"https://clinicaltrials.gov/study/NCT06839066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06839066","kind":"trial","name":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","route":"/trials/nct06839066/","field":"links","label":"ClinicalTrials.gov NCT06839066"}]},{"url":"https://clinicaltrials.gov/study/NCT06839092","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06839092","kind":"trial","name":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","route":"/trials/nct06839092/","field":"links","label":"ClinicalTrials.gov NCT06839092"}]},{"url":"https://clinicaltrials.gov/study/NCT06839144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","field":"links","label":"Beta-blockade in ovarian cancer (NCT06839144)"}]},{"url":"https://clinicaltrials.gov/study/NCT06840002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840002","kind":"trial","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct06840002/","field":"links","label":"ClinicalTrials.gov NCT06840002"}]},{"url":"https://clinicaltrials.gov/study/NCT06840119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840119","kind":"trial","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","route":"/trials/nct06840119/","field":"links","label":"ClinicalTrials.gov NCT06840119"}]},{"url":"https://clinicaltrials.gov/study/NCT06840483","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/","field":"links","label":"ClinicalTrials.gov NCT06840483"}]},{"url":"https://clinicaltrials.gov/study/NCT06840665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840665","kind":"trial","name":"MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer","route":"/trials/nct06840665/","field":"links","label":"ClinicalTrials.gov NCT06840665"}]},{"url":"https://clinicaltrials.gov/study/NCT06840704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840704","kind":"trial","name":"Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer","route":"/trials/nct06840704/","field":"links","label":"ClinicalTrials.gov NCT06840704"}]},{"url":"https://clinicaltrials.gov/study/NCT06840782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840782","kind":"trial","name":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","route":"/trials/nct06840782/","field":"links","label":"ClinicalTrials.gov NCT06840782"}]},{"url":"https://clinicaltrials.gov/study/NCT06840821","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06840821","kind":"trial","name":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor","route":"/trials/nct06840821/","field":"links","label":"ClinicalTrials.gov NCT06840821"}]},{"url":"https://clinicaltrials.gov/study/NCT06841055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/","field":"links","label":"ClinicalTrials.gov NCT06841055"}]},{"url":"https://clinicaltrials.gov/study/NCT06841159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06841159","kind":"trial","name":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can","route":"/trials/nct06841159/","field":"links","label":"ClinicalTrials.gov NCT06841159"}]},{"url":"https://clinicaltrials.gov/study/NCT06841354","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/","field":"links","label":"ClinicalTrials.gov NCT06841354"}]},{"url":"https://clinicaltrials.gov/study/NCT06842498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06842498/","field":"links","label":"ClinicalTrials.gov NCT06842498"}]},{"url":"https://clinicaltrials.gov/study/NCT06843434","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06843434","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","route":"/trials/nct06843434/","field":"links","label":"ClinicalTrials.gov NCT06843434"}]},{"url":"https://clinicaltrials.gov/study/NCT06843447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/","field":"links","label":"ClinicalTrials.gov NCT06843447"}]},{"url":"https://clinicaltrials.gov/study/NCT06843551","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06843551","kind":"trial","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","route":"/trials/nct06843551/","field":"links","label":"ClinicalTrials.gov NCT06843551"}]},{"url":"https://clinicaltrials.gov/study/NCT06844357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","route":"/trials/nct06844357/","field":"links","label":"ClinicalTrials.gov NCT06844357"}]},{"url":"https://clinicaltrials.gov/study/NCT06844422","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","route":"/trials/nct06844422/","field":"links","label":"ClinicalTrials.gov NCT06844422"}]},{"url":"https://clinicaltrials.gov/study/NCT06845306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06845306","kind":"trial","name":"The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surger","route":"/trials/nct06845306/","field":"links","label":"ClinicalTrials.gov NCT06845306"}]},{"url":"https://clinicaltrials.gov/study/NCT06845319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06845319","kind":"trial","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","route":"/trials/nct06845319/","field":"links","label":"ClinicalTrials.gov NCT06845319"}]},{"url":"https://clinicaltrials.gov/study/NCT06846268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06846268","kind":"trial","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","route":"/trials/nct06846268/","field":"links","label":"ClinicalTrials.gov NCT06846268"}]},{"url":"https://clinicaltrials.gov/study/NCT06846437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","route":"/trials/nct06846437/","field":"links","label":"ClinicalTrials.gov NCT06846437"}]},{"url":"https://clinicaltrials.gov/study/NCT06846671","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06846671","kind":"trial","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","route":"/trials/nct06846671/","field":"links","label":"ClinicalTrials.gov NCT06846671"}]},{"url":"https://clinicaltrials.gov/study/NCT06847334","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06847334","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous","route":"/trials/nct06847334/","field":"links","label":"ClinicalTrials.gov NCT06847334"}]},{"url":"https://clinicaltrials.gov/study/NCT06848699","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06848699","kind":"trial","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06848699/","field":"links","label":"ClinicalTrials.gov NCT06848699"}]},{"url":"https://clinicaltrials.gov/study/NCT06848842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06848842","kind":"trial","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","route":"/trials/nct06848842/","field":"links","label":"ClinicalTrials.gov NCT06848842"}]},{"url":"https://clinicaltrials.gov/study/NCT06849492","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","route":"/trials/nct06849492/","field":"links","label":"ClinicalTrials.gov NCT06849492"}]},{"url":"https://clinicaltrials.gov/study/NCT06850090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06850090","kind":"trial","name":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","route":"/trials/nct06850090/","field":"links","label":"ClinicalTrials.gov NCT06850090"}]},{"url":"https://clinicaltrials.gov/study/NCT06850103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06850103","kind":"trial","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","route":"/trials/nct06850103/","field":"links","label":"ClinicalTrials.gov NCT06850103"}]},{"url":"https://clinicaltrials.gov/study/NCT06850623","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06850623","kind":"trial","name":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct06850623/","field":"links","label":"ClinicalTrials.gov NCT06850623"}]},{"url":"https://clinicaltrials.gov/study/NCT06851299","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06851299","kind":"trial","name":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast","route":"/trials/nct06851299/","field":"links","label":"ClinicalTrials.gov NCT06851299"}]},{"url":"https://clinicaltrials.gov/study/NCT06851663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06851663","kind":"trial","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","route":"/trials/nct06851663/","field":"links","label":"ClinicalTrials.gov NCT06851663"}]},{"url":"https://clinicaltrials.gov/study/NCT06852222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06852222","kind":"trial","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","route":"/trials/nct06852222/","field":"links","label":"ClinicalTrials.gov NCT06852222"}]},{"url":"https://clinicaltrials.gov/study/NCT06852287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06852287","kind":"trial","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","route":"/trials/nct06852287/","field":"links","label":"ClinicalTrials.gov NCT06852287"}]},{"url":"https://clinicaltrials.gov/study/NCT06854445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06854445","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","route":"/trials/nct06854445/","field":"links","label":"ClinicalTrials.gov NCT06854445"}]},{"url":"https://clinicaltrials.gov/study/NCT06855069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/","field":"links","label":"ClinicalTrials.gov NCT06855069"}]},{"url":"https://clinicaltrials.gov/study/NCT06855277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","field":"links","label":"ClinicalTrials.gov NCT06855277"}]},{"url":"https://clinicaltrials.gov/study/NCT06855771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06855771","kind":"trial","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","field":"links","label":"ClinicalTrials.gov NCT06855771"}]},{"url":"https://clinicaltrials.gov/study/NCT06855849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06855849","kind":"trial","name":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients","route":"/trials/nct06855849/","field":"links","label":"ClinicalTrials.gov NCT06855849"}]},{"url":"https://clinicaltrials.gov/study/NCT06856187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06856187","kind":"trial","name":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","route":"/trials/nct06856187/","field":"links","label":"ClinicalTrials.gov NCT06856187"}]},{"url":"https://clinicaltrials.gov/study/NCT06856837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06856837","kind":"trial","name":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec","route":"/trials/nct06856837/","field":"links","label":"ClinicalTrials.gov NCT06856837"}]},{"url":"https://clinicaltrials.gov/study/NCT06857175","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","field":"links","label":"ClinicalTrials.gov NCT06857175"}]},{"url":"https://clinicaltrials.gov/study/NCT06857773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06857773","kind":"trial","name":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","route":"/trials/nct06857773/","field":"links","label":"ClinicalTrials.gov NCT06857773"}]},{"url":"https://clinicaltrials.gov/study/NCT06858410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06858410","kind":"trial","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","route":"/trials/nct06858410/","field":"links","label":"ClinicalTrials.gov NCT06858410"}]},{"url":"https://clinicaltrials.gov/study/NCT06858618","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06858618","kind":"trial","name":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","route":"/trials/nct06858618/","field":"links","label":"ClinicalTrials.gov NCT06858618"}]},{"url":"https://clinicaltrials.gov/study/NCT06858969","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06858969","kind":"trial","name":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","route":"/trials/nct06858969/","field":"links","label":"ClinicalTrials.gov NCT06858969"}]},{"url":"https://clinicaltrials.gov/study/NCT06859775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06859775","kind":"trial","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06859775/","field":"links","label":"ClinicalTrials.gov NCT06859775"}]},{"url":"https://clinicaltrials.gov/study/NCT06860685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06860685","kind":"trial","name":"Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery","route":"/trials/nct06860685/","field":"links","label":"ClinicalTrials.gov NCT06860685"}]},{"url":"https://clinicaltrials.gov/study/NCT06860971","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","field":"links","label":"ClinicalTrials.gov NCT06860971"}]},{"url":"https://clinicaltrials.gov/study/NCT06861088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","route":"/trials/nct06861088/","field":"links","label":"ClinicalTrials.gov NCT06861088"}]},{"url":"https://clinicaltrials.gov/study/NCT06861452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06861452","kind":"trial","name":"Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","route":"/trials/nct06861452/","field":"links","label":"ClinicalTrials.gov NCT06861452"}]},{"url":"https://clinicaltrials.gov/study/NCT06863272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","route":"/trials/nct06863272/","field":"links","label":"ClinicalTrials.gov NCT06863272"}]},{"url":"https://clinicaltrials.gov/study/NCT06864013","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06864013","kind":"trial","name":"SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer","route":"/trials/nct06864013/","field":"links","label":"ClinicalTrials.gov NCT06864013"}]},{"url":"https://clinicaltrials.gov/study/NCT06864169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06864169","kind":"trial","name":"A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)","route":"/trials/nct06864169/","field":"links","label":"ClinicalTrials.gov NCT06864169"}]},{"url":"https://clinicaltrials.gov/study/NCT06864624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06864624","kind":"trial","name":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC","route":"/trials/nct06864624/","field":"links","label":"ClinicalTrials.gov NCT06864624"}]},{"url":"https://clinicaltrials.gov/study/NCT06865339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06865339","kind":"trial","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06865339/","field":"links","label":"ClinicalTrials.gov NCT06865339"}]},{"url":"https://clinicaltrials.gov/study/NCT06866977","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06866977","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","route":"/trials/nct06866977/","field":"links","label":"ClinicalTrials.gov NCT06866977"}]},{"url":"https://clinicaltrials.gov/study/NCT06867705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06867705","kind":"trial","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","route":"/trials/nct06867705/","field":"links","label":"ClinicalTrials.gov NCT06867705"}]},{"url":"https://clinicaltrials.gov/study/NCT06868199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/","field":"links","label":"ClinicalTrials.gov NCT06868199"}]},{"url":"https://clinicaltrials.gov/study/NCT06868277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/","field":"links","label":"ClinicalTrials.gov NCT06868277"}]},{"url":"https://clinicaltrials.gov/study/NCT06868485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/","field":"links","label":"ClinicalTrials.gov NCT06868485"}]},{"url":"https://clinicaltrials.gov/study/NCT06868654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","route":"/trials/nct06868654/","field":"links","label":"ClinicalTrials.gov NCT06868654"}]},{"url":"https://clinicaltrials.gov/study/NCT06868654?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","route":"/trials/nct06868654/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT06868667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868667","kind":"trial","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","route":"/trials/nct06868667/","field":"links","label":"ClinicalTrials.gov NCT06868667"}]},{"url":"https://clinicaltrials.gov/study/NCT06868667?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06868667","kind":"trial","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","route":"/trials/nct06868667/","field":"outcomes.source (Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT06868849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/","field":"links","label":"ClinicalTrials.gov NCT06868849"},{"id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/","field":"links","label":"ClinicalTrials.gov NCT06868849"}]},{"url":"https://clinicaltrials.gov/study/NCT06872541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06872541","kind":"trial","name":"Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas","route":"/trials/nct06872541/","field":"links","label":"ClinicalTrials.gov NCT06872541"}]},{"url":"https://clinicaltrials.gov/study/NCT06872606","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06872606","kind":"trial","name":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for","route":"/trials/nct06872606/","field":"links","label":"ClinicalTrials.gov NCT06872606"}]},{"url":"https://clinicaltrials.gov/study/NCT06873555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/","field":"links","label":"ClinicalTrials.gov NCT06873555"}]},{"url":"https://clinicaltrials.gov/study/NCT06873763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06873763","kind":"trial","name":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","route":"/trials/nct06873763/","field":"links","label":"ClinicalTrials.gov NCT06873763"}]},{"url":"https://clinicaltrials.gov/study/NCT06875310","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06875310","kind":"trial","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","route":"/trials/nct06875310/","field":"links","label":"ClinicalTrials.gov NCT06875310"}]},{"url":"https://clinicaltrials.gov/study/NCT06877650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/","field":"links","label":"ClinicalTrials.gov NCT06877650"}]},{"url":"https://clinicaltrials.gov/study/NCT06878625","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","route":"/trials/nct06878625/","field":"links","label":"ClinicalTrials.gov NCT06878625"}]},{"url":"https://clinicaltrials.gov/study/NCT06879145","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","route":"/trials/nct06879145/","field":"links","label":"ClinicalTrials.gov NCT06879145"}]},{"url":"https://clinicaltrials.gov/study/NCT06879717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/","field":"links","label":"ClinicalTrials.gov NCT06879717"}]},{"url":"https://clinicaltrials.gov/study/NCT06881537","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06881537","kind":"trial","name":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","route":"/trials/nct06881537/","field":"links","label":"ClinicalTrials.gov NCT06881537"}]},{"url":"https://clinicaltrials.gov/study/NCT06881784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/","field":"links","label":"ClinicalTrials.gov NCT06881784"}]},{"url":"https://clinicaltrials.gov/study/NCT06883526","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/","field":"links","label":"ClinicalTrials.gov NCT06883526"}]},{"url":"https://clinicaltrials.gov/study/NCT06885034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06885034","kind":"trial","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","route":"/trials/nct06885034/","field":"links","label":"ClinicalTrials.gov NCT06885034"}]},{"url":"https://clinicaltrials.gov/study/NCT06885281","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/","field":"links","label":"ClinicalTrials.gov NCT06885281"}]},{"url":"https://clinicaltrials.gov/study/NCT06885385","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06885385","kind":"trial","name":"A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer","route":"/trials/nct06885385/","field":"links","label":"ClinicalTrials.gov NCT06885385"}]},{"url":"https://clinicaltrials.gov/study/NCT06885840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","route":"/trials/nct06885840/","field":"links","label":"ClinicalTrials.gov NCT06885840"}]},{"url":"https://clinicaltrials.gov/study/NCT06887218","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06887218","kind":"trial","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06887218/","field":"links","label":"ClinicalTrials.gov NCT06887218"}]},{"url":"https://clinicaltrials.gov/study/NCT06888648","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06888648","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","route":"/trials/nct06888648/","field":"links","label":"ClinicalTrials.gov NCT06888648"}]},{"url":"https://clinicaltrials.gov/study/NCT06888674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06888674","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","route":"/trials/nct06888674/","field":"links","label":"ClinicalTrials.gov NCT06888674"}]},{"url":"https://clinicaltrials.gov/study/NCT06888843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06888843","kind":"trial","name":"Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced C","route":"/trials/nct06888843/","field":"links","label":"ClinicalTrials.gov NCT06888843"}]},{"url":"https://clinicaltrials.gov/study/NCT06888921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","field":"links","label":"ClinicalTrials.gov NCT06888921"},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","field":"links","label":"ClinicalTrials.gov NCT06888921"}]},{"url":"https://clinicaltrials.gov/study/NCT06889610","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06889610","kind":"trial","name":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","route":"/trials/nct06889610/","field":"links","label":"ClinicalTrials.gov NCT06889610"}]},{"url":"https://clinicaltrials.gov/study/NCT06889688","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/","field":"links","label":"ClinicalTrials.gov NCT06889688"}]},{"url":"https://clinicaltrials.gov/study/NCT06890338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/","field":"links","label":"ClinicalTrials.gov NCT06890338"}]},{"url":"https://clinicaltrials.gov/study/NCT06890598","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06890598","kind":"trial","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","route":"/trials/nct06890598/","field":"links","label":"ClinicalTrials.gov NCT06890598"}]},{"url":"https://clinicaltrials.gov/study/NCT06890624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06890624","kind":"trial","name":"mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer","route":"/trials/nct06890624/","field":"links","label":"ClinicalTrials.gov NCT06890624"}]},{"url":"https://clinicaltrials.gov/study/NCT06890884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/","field":"links","label":"ClinicalTrials.gov NCT06890884"}]},{"url":"https://clinicaltrials.gov/study/NCT06891833","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06891833","kind":"trial","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","route":"/trials/nct06891833/","field":"links","label":"ClinicalTrials.gov NCT06891833"}]},{"url":"https://clinicaltrials.gov/study/NCT06892522","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/","field":"links","label":"ClinicalTrials.gov NCT06892522"}]},{"url":"https://clinicaltrials.gov/study/NCT06892548","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/","field":"links","label":"ClinicalTrials.gov NCT06892548"}]},{"url":"https://clinicaltrials.gov/study/NCT06892925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06892925","kind":"trial","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","route":"/trials/nct06892925/","field":"links","label":"ClinicalTrials.gov NCT06892925"}]},{"url":"https://clinicaltrials.gov/study/NCT06894511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/","field":"links","label":"ClinicalTrials.gov NCT06894511"}]},{"url":"https://clinicaltrials.gov/study/NCT06895031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06895031","kind":"trial","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct06895031/","field":"links","label":"ClinicalTrials.gov NCT06895031"}]},{"url":"https://clinicaltrials.gov/study/NCT06895928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","route":"/trials/nct06895928/","field":"links","label":"ClinicalTrials.gov NCT06895928"}]},{"url":"https://clinicaltrials.gov/study/NCT06896890","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06896890","kind":"trial","name":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct06896890/","field":"links","label":"ClinicalTrials.gov NCT06896890"}]},{"url":"https://clinicaltrials.gov/study/NCT06897644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06897644","kind":"trial","name":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C","route":"/trials/nct06897644/","field":"links","label":"ClinicalTrials.gov NCT06897644"}]},{"url":"https://clinicaltrials.gov/study/NCT06898450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/","field":"links","label":"ClinicalTrials.gov NCT06898450"}]},{"url":"https://clinicaltrials.gov/study/NCT06898970","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06898970","kind":"trial","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","route":"/trials/nct06898970/","field":"links","label":"ClinicalTrials.gov NCT06898970"}]},{"url":"https://clinicaltrials.gov/study/NCT06899126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/","field":"links","label":"ClinicalTrials.gov NCT06899126"}]},{"url":"https://clinicaltrials.gov/study/NCT06899477","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06899477","kind":"trial","name":"Pre-Operative Treatment in REseCTable COlon CanceR","route":"/trials/nct06899477/","field":"links","label":"ClinicalTrials.gov NCT06899477"}]},{"url":"https://clinicaltrials.gov/study/NCT06901531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/","field":"links","label":"ClinicalTrials.gov NCT06901531"}]},{"url":"https://clinicaltrials.gov/study/NCT06901622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06901622","kind":"trial","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","route":"/trials/nct06901622/","field":"links","label":"ClinicalTrials.gov NCT06901622"}]},{"url":"https://clinicaltrials.gov/study/NCT06903273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06903273","kind":"trial","name":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","route":"/trials/nct06903273/","field":"links","label":"ClinicalTrials.gov NCT06903273"}]},{"url":"https://clinicaltrials.gov/study/NCT06903377","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/","field":"links","label":"ClinicalTrials.gov NCT06903377"}]},{"url":"https://clinicaltrials.gov/study/NCT06903858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06903858","kind":"trial","name":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","route":"/trials/nct06903858/","field":"links","label":"ClinicalTrials.gov NCT06903858"}]},{"url":"https://clinicaltrials.gov/study/NCT06904235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06904235","kind":"trial","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","route":"/trials/nct06904235/","field":"links","label":"ClinicalTrials.gov NCT06904235"}]},{"url":"https://clinicaltrials.gov/study/NCT06904378","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06904378","kind":"trial","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06904378/","field":"links","label":"ClinicalTrials.gov NCT06904378"}]},{"url":"https://clinicaltrials.gov/study/NCT06906341","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","route":"/trials/nct06906341/","field":"links","label":"ClinicalTrials.gov NCT06906341"}]},{"url":"https://clinicaltrials.gov/study/NCT06906471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","field":"links","label":"ClinicalTrials.gov NCT06906471"}]},{"url":"https://clinicaltrials.gov/study/NCT06906562","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06906562","kind":"trial","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","route":"/trials/nct06906562/","field":"links","label":"ClinicalTrials.gov NCT06906562"}]},{"url":"https://clinicaltrials.gov/study/NCT06907043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/","field":"links","label":"ClinicalTrials.gov NCT06907043"}]},{"url":"https://clinicaltrials.gov/study/NCT06907342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06907342","kind":"trial","name":"Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)","route":"/trials/nct06907342/","field":"links","label":"ClinicalTrials.gov NCT06907342"}]},{"url":"https://clinicaltrials.gov/study/NCT06907615","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06907615","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06907615/","field":"links","label":"ClinicalTrials.gov NCT06907615"}]},{"url":"https://clinicaltrials.gov/study/NCT06908304","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/","field":"links","label":"ClinicalTrials.gov NCT06908304"}]},{"url":"https://clinicaltrials.gov/study/NCT06908772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06908772","kind":"trial","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","route":"/trials/nct06908772/","field":"links","label":"ClinicalTrials.gov NCT06908772"}]},{"url":"https://clinicaltrials.gov/study/NCT06908993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06908993","kind":"trial","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","route":"/trials/nct06908993/","field":"links","label":"ClinicalTrials.gov NCT06908993"}]},{"url":"https://clinicaltrials.gov/study/NCT06909825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","field":"links","label":"ClinicalTrials.gov NCT06909825"}]},{"url":"https://clinicaltrials.gov/study/NCT06909877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","field":"links","label":"ClinicalTrials.gov NCT06909877"}]},{"url":"https://clinicaltrials.gov/study/NCT06910072","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06910072","kind":"trial","name":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN","route":"/trials/nct06910072/","field":"links","label":"ClinicalTrials.gov NCT06910072"}]},{"url":"https://clinicaltrials.gov/study/NCT06911333","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","field":"links","label":"ClinicalTrials.gov NCT06911333"}]},{"url":"https://clinicaltrials.gov/study/NCT06911502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/","field":"links","label":"ClinicalTrials.gov NCT06911502"}]},{"url":"https://clinicaltrials.gov/study/NCT06911684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06911684","kind":"trial","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","route":"/trials/nct06911684/","field":"links","label":"ClinicalTrials.gov NCT06911684"}]},{"url":"https://clinicaltrials.gov/study/NCT06911827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/","field":"links","label":"ClinicalTrials.gov NCT06911827"}]},{"url":"https://clinicaltrials.gov/study/NCT06914128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/","field":"links","label":"ClinicalTrials.gov NCT06914128"}]},{"url":"https://clinicaltrials.gov/study/NCT06914674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06914674","kind":"trial","name":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","route":"/trials/nct06914674/","field":"links","label":"ClinicalTrials.gov NCT06914674"}]},{"url":"https://clinicaltrials.gov/study/NCT06915025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/","field":"links","label":"ClinicalTrials.gov NCT06915025"}]},{"url":"https://clinicaltrials.gov/study/NCT06915142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06915142","kind":"trial","name":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","route":"/trials/nct06915142/","field":"links","label":"ClinicalTrials.gov NCT06915142"}]},{"url":"https://clinicaltrials.gov/study/NCT06915246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06915246","kind":"trial","name":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","route":"/trials/nct06915246/","field":"links","label":"ClinicalTrials.gov NCT06915246"}]},{"url":"https://clinicaltrials.gov/study/NCT06916975","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06916975","kind":"trial","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06916975/","field":"links","label":"ClinicalTrials.gov NCT06916975"}]},{"url":"https://clinicaltrials.gov/study/NCT06919510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06919510","kind":"trial","name":"A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct06919510/","field":"links","label":"ClinicalTrials.gov NCT06919510"}]},{"url":"https://clinicaltrials.gov/study/NCT06919848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06919848","kind":"trial","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","route":"/trials/nct06919848/","field":"links","label":"ClinicalTrials.gov NCT06919848"}]},{"url":"https://clinicaltrials.gov/study/NCT06919965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/","field":"links","label":"ClinicalTrials.gov NCT06919965"}]},{"url":"https://clinicaltrials.gov/study/NCT06921785","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/","field":"links","label":"ClinicalTrials.gov NCT06921785"}]},{"url":"https://clinicaltrials.gov/study/NCT06921837","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/","field":"links","label":"ClinicalTrials.gov NCT06921837"}]},{"url":"https://clinicaltrials.gov/study/NCT06921928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/","field":"links","label":"ClinicalTrials.gov NCT06921928"}]},{"url":"https://clinicaltrials.gov/study/NCT06922357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06922357/","field":"links","label":"ClinicalTrials.gov NCT06922357"}]},{"url":"https://clinicaltrials.gov/study/NCT06922383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06922383","kind":"trial","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","route":"/trials/nct06922383/","field":"links","label":"ClinicalTrials.gov NCT06922383"}]},{"url":"https://clinicaltrials.gov/study/NCT06922591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/","field":"links","label":"ClinicalTrials.gov NCT06922591"}]},{"url":"https://clinicaltrials.gov/study/NCT06923345","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06923345","kind":"trial","name":"Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)","route":"/trials/nct06923345/","field":"links","label":"ClinicalTrials.gov NCT06923345"}]},{"url":"https://clinicaltrials.gov/study/NCT06923787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06923787","kind":"trial","name":"Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer -","route":"/trials/nct06923787/","field":"links","label":"ClinicalTrials.gov NCT06923787"}]},{"url":"https://clinicaltrials.gov/study/NCT06925581","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","field":"links","label":"ClinicalTrials.gov NCT06925581"}]},{"url":"https://clinicaltrials.gov/study/NCT06925737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","route":"/trials/nct06925737/","field":"links","label":"ClinicalTrials.gov NCT06925737"}]},{"url":"https://clinicaltrials.gov/study/NCT06926075","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/","field":"links","label":"ClinicalTrials.gov NCT06926075"}]},{"url":"https://clinicaltrials.gov/study/NCT06926868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","field":"links","label":"ClinicalTrials.gov NCT06926868"},{"id":"izabright-breast01","kind":"trial","name":"IZABRIGHT-Breast01","route":"/trials/izabright-breast01/","field":"links","label":"ClinicalTrials.gov NCT06926868"}]},{"url":"https://clinicaltrials.gov/study/NCT06926920","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06926920","kind":"trial","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","route":"/trials/nct06926920/","field":"links","label":"ClinicalTrials.gov NCT06926920"}]},{"url":"https://clinicaltrials.gov/study/NCT06927687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/","field":"links","label":"ClinicalTrials.gov NCT06927687"}]},{"url":"https://clinicaltrials.gov/study/NCT06927986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06927986","kind":"trial","name":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","route":"/trials/nct06927986/","field":"links","label":"ClinicalTrials.gov NCT06927986"}]},{"url":"https://clinicaltrials.gov/study/NCT06928389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/","field":"links","label":"ClinicalTrials.gov NCT06928389"}]},{"url":"https://clinicaltrials.gov/study/NCT06928584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06928584","kind":"trial","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct06928584/","field":"links","label":"ClinicalTrials.gov NCT06928584"}]},{"url":"https://clinicaltrials.gov/study/NCT06929624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","field":"links","label":"ClinicalTrials.gov NCT06929624"}]},{"url":"https://clinicaltrials.gov/study/NCT06929663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","field":"links","label":"ClinicalTrials.gov NCT06929663: AK146D1 in advanced solid tumours (phase 1)"}]},{"url":"https://clinicaltrials.gov/study/NCT06930118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06930118","kind":"trial","name":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advan","route":"/trials/nct06930118/","field":"links","label":"ClinicalTrials.gov NCT06930118"}]},{"url":"https://clinicaltrials.gov/study/NCT06930794","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/","field":"links","label":"ClinicalTrials.gov NCT06930794"}]},{"url":"https://clinicaltrials.gov/study/NCT06931717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06931717","kind":"trial","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","route":"/trials/nct06931717/","field":"links","label":"ClinicalTrials.gov NCT06931717"}]},{"url":"https://clinicaltrials.gov/study/NCT06933329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/","field":"links","label":"ClinicalTrials.gov NCT06933329"}]},{"url":"https://clinicaltrials.gov/study/NCT06934538","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","field":"links","label":"ClinicalTrials.gov NCT06934538"}]},{"url":"https://clinicaltrials.gov/study/NCT06935409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06935409","kind":"trial","name":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","route":"/trials/nct06935409/","field":"links","label":"ClinicalTrials.gov NCT06935409"}]},{"url":"https://clinicaltrials.gov/study/NCT06936527","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06936527","kind":"trial","name":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct06936527/","field":"links","label":"ClinicalTrials.gov NCT06936527"}]},{"url":"https://clinicaltrials.gov/study/NCT06936644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06936644","kind":"trial","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","route":"/trials/nct06936644/","field":"links","label":"ClinicalTrials.gov NCT06936644"}]},{"url":"https://clinicaltrials.gov/study/NCT06936774","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06936774","kind":"trial","name":"Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance","route":"/trials/nct06936774/","field":"links","label":"ClinicalTrials.gov NCT06936774"}]},{"url":"https://clinicaltrials.gov/study/NCT06937177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","field":"links","label":"ClinicalTrials.gov NCT06937177"}]},{"url":"https://clinicaltrials.gov/study/NCT06938282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06938282","kind":"trial","name":"An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer","route":"/trials/nct06938282/","field":"links","label":"ClinicalTrials.gov NCT06938282"}]},{"url":"https://clinicaltrials.gov/study/NCT06938321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06938321/","field":"links","label":"ClinicalTrials.gov NCT06938321"}]},{"url":"https://clinicaltrials.gov/study/NCT06938503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","route":"/trials/nct06938503/","field":"links","label":"ClinicalTrials.gov NCT06938503"}]},{"url":"https://clinicaltrials.gov/study/NCT06938867","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06938867","kind":"trial","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","route":"/trials/nct06938867/","field":"links","label":"ClinicalTrials.gov NCT06938867"}]},{"url":"https://clinicaltrials.gov/study/NCT06938880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/","field":"links","label":"ClinicalTrials.gov NCT06938880"}]},{"url":"https://clinicaltrials.gov/study/NCT06939283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","field":"links","label":"ClinicalTrials.gov NCT06939283"}]},{"url":"https://clinicaltrials.gov/study/NCT06939595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","route":"/trials/nct06939595/","field":"links","label":"ClinicalTrials.gov NCT06939595"}]},{"url":"https://clinicaltrials.gov/study/NCT06940388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06940388","kind":"trial","name":"Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.","route":"/trials/nct06940388/","field":"links","label":"ClinicalTrials.gov NCT06940388"}]},{"url":"https://clinicaltrials.gov/study/NCT06940401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/","field":"links","label":"ClinicalTrials.gov NCT06940401"}]},{"url":"https://clinicaltrials.gov/study/NCT06940739","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/","field":"links","label":"ClinicalTrials.gov NCT06940739"}]},{"url":"https://clinicaltrials.gov/study/NCT06940947","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06940947","kind":"trial","name":"Endoscopic Therapy Or Surgery for Early Colon Cancer","route":"/trials/nct06940947/","field":"links","label":"ClinicalTrials.gov NCT06940947"}]},{"url":"https://clinicaltrials.gov/study/NCT06941272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","route":"/trials/nct06941272/","field":"links","label":"ClinicalTrials.gov NCT06941272"}]},{"url":"https://clinicaltrials.gov/study/NCT06941857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","route":"/trials/nct06941857/","field":"links","label":"ClinicalTrials.gov NCT06941857"}]},{"url":"https://clinicaltrials.gov/study/NCT06942234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/","field":"links","label":"ClinicalTrials.gov NCT06942234"}]},{"url":"https://clinicaltrials.gov/study/NCT06943521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06943521","kind":"trial","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","route":"/trials/nct06943521/","field":"links","label":"ClinicalTrials.gov NCT06943521"}]},{"url":"https://clinicaltrials.gov/study/NCT06943755","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/","field":"links","label":"ClinicalTrials.gov NCT06943755"}]},{"url":"https://clinicaltrials.gov/study/NCT06943820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06943820","kind":"trial","name":"AK129 Combination Therapy for Advanced Solid Tumors","route":"/trials/nct06943820/","field":"links","label":"ClinicalTrials.gov NCT06943820"}]},{"url":"https://clinicaltrials.gov/study/NCT06943833","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/","field":"links","label":"ClinicalTrials.gov NCT06943833"}]},{"url":"https://clinicaltrials.gov/study/NCT06943872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06943872","kind":"trial","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","route":"/trials/nct06943872/","field":"links","label":"ClinicalTrials.gov NCT06943872"}]},{"url":"https://clinicaltrials.gov/study/NCT06944106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06944106","kind":"trial","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06944106/","field":"links","label":"ClinicalTrials.gov NCT06944106"}]},{"url":"https://clinicaltrials.gov/study/NCT06944548","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06944548","kind":"trial","name":"Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer","route":"/trials/nct06944548/","field":"links","label":"ClinicalTrials.gov NCT06944548"}]},{"url":"https://clinicaltrials.gov/study/NCT06946420","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06946420","kind":"trial","name":"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy","route":"/trials/nct06946420/","field":"links","label":"ClinicalTrials.gov NCT06946420"}]},{"url":"https://clinicaltrials.gov/study/NCT06946797","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/","field":"links","label":"ClinicalTrials.gov NCT06946797"}]},{"url":"https://clinicaltrials.gov/study/NCT06946901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06946901","kind":"trial","name":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a","route":"/trials/nct06946901/","field":"links","label":"ClinicalTrials.gov NCT06946901"}]},{"url":"https://clinicaltrials.gov/study/NCT06947291","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/","field":"links","label":"ClinicalTrials.gov NCT06947291"}]},{"url":"https://clinicaltrials.gov/study/NCT06947928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","route":"/trials/nct06947928/","field":"links","label":"ClinicalTrials.gov NCT06947928"}]},{"url":"https://clinicaltrials.gov/study/NCT06947967","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/","field":"links","label":"ClinicalTrials.gov NCT06947967"}]},{"url":"https://clinicaltrials.gov/study/NCT06948448","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","route":"/trials/nct06948448/","field":"links","label":"ClinicalTrials.gov NCT06948448"}]},{"url":"https://clinicaltrials.gov/study/NCT06948981","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/","field":"links","label":"ClinicalTrials.gov NCT06948981"}]},{"url":"https://clinicaltrials.gov/study/NCT06949098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06949098","kind":"trial","name":"Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer","route":"/trials/nct06949098/","field":"links","label":"ClinicalTrials.gov NCT06949098"}]},{"url":"https://clinicaltrials.gov/study/NCT06949111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06949111","kind":"trial","name":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）","route":"/trials/nct06949111/","field":"links","label":"ClinicalTrials.gov NCT06949111"}]},{"url":"https://clinicaltrials.gov/study/NCT06949982","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06949982","kind":"trial","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","route":"/trials/nct06949982/","field":"links","label":"ClinicalTrials.gov NCT06949982"}]},{"url":"https://clinicaltrials.gov/study/NCT06950086","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06950086","kind":"trial","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06950086/","field":"links","label":"ClinicalTrials.gov NCT06950086"}]},{"url":"https://clinicaltrials.gov/study/NCT06951399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06951399","kind":"trial","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06951399/","field":"links","label":"ClinicalTrials.gov NCT06951399"}]},{"url":"https://clinicaltrials.gov/study/NCT06951503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","route":"/trials/nct06951503/","field":"links","label":"ClinicalTrials.gov NCT06951503"}]},{"url":"https://clinicaltrials.gov/study/NCT06951646","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06951646","kind":"trial","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","route":"/trials/nct06951646/","field":"links","label":"ClinicalTrials.gov NCT06951646"}]},{"url":"https://clinicaltrials.gov/study/NCT06951997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06951997","kind":"trial","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","route":"/trials/nct06951997/","field":"links","label":"ClinicalTrials.gov NCT06951997"}]},{"url":"https://clinicaltrials.gov/study/NCT06952478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","field":"links","label":"ClinicalTrials.gov NCT06952478"}]},{"url":"https://clinicaltrials.gov/study/NCT06952504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","route":"/trials/nct06952504/","field":"links","label":"ClinicalTrials.gov NCT06952504"}]},{"url":"https://clinicaltrials.gov/study/NCT06952803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","route":"/trials/nct06952803/","field":"links","label":"ClinicalTrials.gov NCT06952803"}]},{"url":"https://clinicaltrials.gov/study/NCT06953089","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/","field":"links","label":"ClinicalTrials.gov NCT06953089"}]},{"url":"https://clinicaltrials.gov/study/NCT06953323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06953323","kind":"trial","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","route":"/trials/nct06953323/","field":"links","label":"ClinicalTrials.gov NCT06953323"}]},{"url":"https://clinicaltrials.gov/study/NCT06953960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/","field":"links","label":"ClinicalTrials.gov NCT06953960"}]},{"url":"https://clinicaltrials.gov/study/NCT06953999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/","field":"links","label":"ClinicalTrials.gov NCT06953999"}]},{"url":"https://clinicaltrials.gov/study/NCT06954246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/","field":"links","label":"ClinicalTrials.gov NCT06954246"}]},{"url":"https://clinicaltrials.gov/study/NCT06954480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/","field":"links","label":"ClinicalTrials.gov NCT06954480"}]},{"url":"https://clinicaltrials.gov/study/NCT06954961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06954961","kind":"trial","name":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct06954961/","field":"links","label":"ClinicalTrials.gov NCT06954961"}]},{"url":"https://clinicaltrials.gov/study/NCT06955325","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","route":"/trials/nct06955325/","field":"links","label":"ClinicalTrials.gov NCT06955325"}]},{"url":"https://clinicaltrials.gov/study/NCT06956001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/","field":"links","label":"ClinicalTrials.gov NCT06956001"}]},{"url":"https://clinicaltrials.gov/study/NCT06956170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","route":"/trials/nct06956170/","field":"links","label":"ClinicalTrials.gov NCT06956170"}]},{"url":"https://clinicaltrials.gov/study/NCT06956170?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","route":"/trials/nct06956170/","field":"outcomes.source (Progression-Free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT06956690","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/","field":"links","label":"ClinicalTrials.gov NCT06956690"}]},{"url":"https://clinicaltrials.gov/study/NCT06957379","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06957379","kind":"trial","name":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","route":"/trials/nct06957379/","field":"links","label":"ClinicalTrials.gov NCT06957379"}]},{"url":"https://clinicaltrials.gov/study/NCT06957886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/","field":"links","label":"ClinicalTrials.gov NCT06957886"}]},{"url":"https://clinicaltrials.gov/study/NCT06958328","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct06958328/","field":"links","label":"ClinicalTrials.gov NCT06958328"}]},{"url":"https://clinicaltrials.gov/study/NCT06958419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06958419","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","route":"/trials/nct06958419/","field":"links","label":"ClinicalTrials.gov NCT06958419"}]},{"url":"https://clinicaltrials.gov/study/NCT06958432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06958432","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)","route":"/trials/nct06958432/","field":"links","label":"ClinicalTrials.gov NCT06958432"}]},{"url":"https://clinicaltrials.gov/study/NCT06959082","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","route":"/trials/nct06959082/","field":"links","label":"ClinicalTrials.gov NCT06959082"}]},{"url":"https://clinicaltrials.gov/study/NCT06959550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","route":"/trials/nct06959550/","field":"links","label":"ClinicalTrials.gov NCT06959550"}]},{"url":"https://clinicaltrials.gov/study/NCT06959589","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06959589","kind":"trial","name":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met","route":"/trials/nct06959589/","field":"links","label":"ClinicalTrials.gov NCT06959589"}]},{"url":"https://clinicaltrials.gov/study/NCT06959615","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06959615","kind":"trial","name":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","route":"/trials/nct06959615/","field":"links","label":"ClinicalTrials.gov NCT06959615"}]},{"url":"https://clinicaltrials.gov/study/NCT06959693","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06959693","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col","route":"/trials/nct06959693/","field":"links","label":"ClinicalTrials.gov NCT06959693"}]},{"url":"https://clinicaltrials.gov/study/NCT06960577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","field":"links","label":"ClinicalTrials.gov NCT06960577"}]},{"url":"https://clinicaltrials.gov/study/NCT06961006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06961006","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","route":"/trials/nct06961006/","field":"links","label":"ClinicalTrials.gov NCT06961006"}]},{"url":"https://clinicaltrials.gov/study/NCT06961188","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06961188","kind":"trial","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","route":"/trials/nct06961188/","field":"links","label":"ClinicalTrials.gov NCT06961188"}]},{"url":"https://clinicaltrials.gov/study/NCT06961201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06961201","kind":"trial","name":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache","route":"/trials/nct06961201/","field":"links","label":"ClinicalTrials.gov NCT06961201"}]},{"url":"https://clinicaltrials.gov/study/NCT06962267","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/","field":"links","label":"ClinicalTrials.gov NCT06962267"}]},{"url":"https://clinicaltrials.gov/study/NCT06962787","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06962787","kind":"trial","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","route":"/trials/nct06962787/","field":"links","label":"ClinicalTrials.gov NCT06962787"}]},{"url":"https://clinicaltrials.gov/study/NCT06962865","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06962865","kind":"trial","name":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv","route":"/trials/nct06962865/","field":"links","label":"ClinicalTrials.gov NCT06962865"}]},{"url":"https://clinicaltrials.gov/study/NCT06963060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06963060","kind":"trial","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","route":"/trials/nct06963060/","field":"links","label":"ClinicalTrials.gov NCT06963060"}]},{"url":"https://clinicaltrials.gov/study/NCT06963905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","route":"/trials/nct06963905/","field":"links","label":"ClinicalTrials.gov NCT06963905"}]},{"url":"https://clinicaltrials.gov/study/NCT06966453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","route":"/trials/nct06966453/","field":"links","label":"ClinicalTrials.gov NCT06966453"}]},{"url":"https://clinicaltrials.gov/study/NCT06966700","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/","field":"links","label":"ClinicalTrials.gov NCT06966700"}]},{"url":"https://clinicaltrials.gov/study/NCT06968221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06968221","kind":"trial","name":"Bovine Reinforcement in Stomach, Colorectal and Lung Operation","route":"/trials/nct06968221/","field":"links","label":"ClinicalTrials.gov NCT06968221"}]},{"url":"https://clinicaltrials.gov/study/NCT06968585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/","field":"links","label":"ClinicalTrials.gov NCT06968585"},{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","route":"/trials/nct06968585/","field":"links","label":"ClinicalTrials.gov NCT06968585"}]},{"url":"https://clinicaltrials.gov/study/NCT06969430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct06969430/","field":"links","label":"ClinicalTrials.gov NCT06969430"}]},{"url":"https://clinicaltrials.gov/study/NCT06970639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/","field":"links","label":"ClinicalTrials.gov NCT06970639"}]},{"url":"https://clinicaltrials.gov/study/NCT06970743","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06970743","kind":"trial","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","route":"/trials/nct06970743/","field":"links","label":"ClinicalTrials.gov NCT06970743"}]},{"url":"https://clinicaltrials.gov/study/NCT06970782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/","field":"links","label":"ClinicalTrials.gov NCT06970782"}]},{"url":"https://clinicaltrials.gov/study/NCT06970847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06970847","kind":"trial","name":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","route":"/trials/nct06970847/","field":"links","label":"ClinicalTrials.gov NCT06970847"}]},{"url":"https://clinicaltrials.gov/study/NCT06971523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","field":"links","label":"ClinicalTrials.gov NCT06971523"}]},{"url":"https://clinicaltrials.gov/study/NCT06971614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/","field":"links","label":"ClinicalTrials.gov NCT06971614"}]},{"url":"https://clinicaltrials.gov/study/NCT06972498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06972498","kind":"trial","name":"A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets","route":"/trials/nct06972498/","field":"links","label":"ClinicalTrials.gov NCT06972498"}]},{"url":"https://clinicaltrials.gov/study/NCT06973187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct06973187/","field":"links","label":"ClinicalTrials.gov NCT06973187"}]},{"url":"https://clinicaltrials.gov/study/NCT06973343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06973343","kind":"trial","name":"Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis","route":"/trials/nct06973343/","field":"links","label":"ClinicalTrials.gov NCT06973343"}]},{"url":"https://clinicaltrials.gov/study/NCT06973564","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/","field":"links","label":"ClinicalTrials.gov NCT06973564"}]},{"url":"https://clinicaltrials.gov/study/NCT06974812","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/","field":"links","label":"ClinicalTrials.gov NCT06974812"}]},{"url":"https://clinicaltrials.gov/study/NCT06974929","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06974929","kind":"trial","name":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","route":"/trials/nct06974929/","field":"links","label":"ClinicalTrials.gov NCT06974929"}]},{"url":"https://clinicaltrials.gov/study/NCT06975293","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/","field":"links","label":"ClinicalTrials.gov NCT06975293"}]},{"url":"https://clinicaltrials.gov/study/NCT06975410","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/","field":"links","label":"ClinicalTrials.gov NCT06975410"}]},{"url":"https://clinicaltrials.gov/study/NCT06976190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","route":"/trials/nct06976190/","field":"links","label":"ClinicalTrials.gov NCT06976190"}]},{"url":"https://clinicaltrials.gov/study/NCT06976944","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","route":"/trials/nct06976944/","field":"links","label":"ClinicalTrials.gov NCT06976944"}]},{"url":"https://clinicaltrials.gov/study/NCT06977542","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/","field":"links","label":"ClinicalTrials.gov NCT06977542"}]},{"url":"https://clinicaltrials.gov/study/NCT06977737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","field":"links","label":"ClinicalTrials.gov NCT06977737"}]},{"url":"https://clinicaltrials.gov/study/NCT06978114","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06978114","kind":"trial","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06978114/","field":"links","label":"ClinicalTrials.gov NCT06978114"}]},{"url":"https://clinicaltrials.gov/study/NCT06978400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06978400","kind":"trial","name":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","route":"/trials/nct06978400/","field":"links","label":"ClinicalTrials.gov NCT06978400"}]},{"url":"https://clinicaltrials.gov/study/NCT06979596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06979596","kind":"trial","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","route":"/trials/nct06979596/","field":"links","label":"ClinicalTrials.gov NCT06979596"}]},{"url":"https://clinicaltrials.gov/study/NCT06979908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06979908","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C","route":"/trials/nct06979908/","field":"links","label":"ClinicalTrials.gov NCT06979908"}]},{"url":"https://clinicaltrials.gov/study/NCT06980259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","field":"links","label":"Randomised SFRT vs conventional RT (NCT06980259)"}]},{"url":"https://clinicaltrials.gov/study/NCT06980272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06980272","kind":"trial","name":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06980272/","field":"links","label":"ClinicalTrials.gov NCT06980272"}]},{"url":"https://clinicaltrials.gov/study/NCT06980480","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/","field":"links","label":"ClinicalTrials.gov NCT06980480"}]},{"url":"https://clinicaltrials.gov/study/NCT06980532","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06980532","kind":"trial","name":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer","route":"/trials/nct06980532/","field":"links","label":"ClinicalTrials.gov NCT06980532"}]},{"url":"https://clinicaltrials.gov/study/NCT06982521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/","field":"links","label":"ClinicalTrials.gov NCT06982521"}]},{"url":"https://clinicaltrials.gov/study/NCT06982924","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06982924","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","route":"/trials/nct06982924/","field":"links","label":"ClinicalTrials.gov NCT06982924"}]},{"url":"https://clinicaltrials.gov/study/NCT06984588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","route":"/trials/nct06984588/","field":"links","label":"ClinicalTrials.gov NCT06984588"}]},{"url":"https://clinicaltrials.gov/study/NCT06985147","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06985147","kind":"trial","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","route":"/trials/nct06985147/","field":"links","label":"ClinicalTrials.gov NCT06985147"}]},{"url":"https://clinicaltrials.gov/study/NCT06985355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06985355","kind":"trial","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06985355/","field":"links","label":"ClinicalTrials.gov NCT06985355"}]},{"url":"https://clinicaltrials.gov/study/NCT06986811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","route":"/trials/nct06986811/","field":"links","label":"ClinicalTrials.gov NCT06986811"}]},{"url":"https://clinicaltrials.gov/study/NCT06987500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/","field":"links","label":"ClinicalTrials.gov NCT06987500"}]},{"url":"https://clinicaltrials.gov/study/NCT06987734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06987734","kind":"trial","name":"Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients","route":"/trials/nct06987734/","field":"links","label":"ClinicalTrials.gov NCT06987734"}]},{"url":"https://clinicaltrials.gov/study/NCT06988488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/","field":"links","label":"ClinicalTrials.gov NCT06988488"}]},{"url":"https://clinicaltrials.gov/study/NCT06989112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/","field":"links","label":"ClinicalTrials.gov NCT06989112"}]},{"url":"https://clinicaltrials.gov/study/NCT06989437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","field":"links","label":"Ponsegromab phase 2/3 in PDAC cachexia (NCT06989437)"},{"id":"nct06989437","kind":"trial","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","route":"/trials/nct06989437/","field":"links","label":"ClinicalTrials.gov NCT06989437"}]},{"url":"https://clinicaltrials.gov/study/NCT06990880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","field":"links","label":"ClinicalTrials.gov NCT06990880"}]},{"url":"https://clinicaltrials.gov/study/NCT06991465","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06991465","kind":"trial","name":"Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)","route":"/trials/nct06991465/","field":"links","label":"ClinicalTrials.gov NCT06991465"}]},{"url":"https://clinicaltrials.gov/study/NCT06991491","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06991491","kind":"trial","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","route":"/trials/nct06991491/","field":"links","label":"ClinicalTrials.gov NCT06991491"}]},{"url":"https://clinicaltrials.gov/study/NCT06991556","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","route":"/trials/nct06991556/","field":"links","label":"ClinicalTrials.gov NCT06991556"}]},{"url":"https://clinicaltrials.gov/study/NCT06992258","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/","field":"links","label":"ClinicalTrials.gov NCT06992258"}]},{"url":"https://clinicaltrials.gov/study/NCT06992336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/","field":"links","label":"ClinicalTrials.gov NCT06992336"}]},{"url":"https://clinicaltrials.gov/study/NCT06992609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/","field":"links","label":"ClinicalTrials.gov NCT06992609"}]},{"url":"https://clinicaltrials.gov/study/NCT06992648","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06992648","kind":"trial","name":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","route":"/trials/nct06992648/","field":"links","label":"ClinicalTrials.gov NCT06992648"}]},{"url":"https://clinicaltrials.gov/study/NCT06993025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06993025","kind":"trial","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","route":"/trials/nct06993025/","field":"links","label":"ClinicalTrials.gov NCT06993025"}]},{"url":"https://clinicaltrials.gov/study/NCT06993844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/","field":"links","label":"ClinicalTrials.gov NCT06993844"}]},{"url":"https://clinicaltrials.gov/study/NCT06994195","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/","field":"links","label":"ClinicalTrials.gov NCT06994195"}]},{"url":"https://clinicaltrials.gov/study/NCT06994507","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06994507","kind":"trial","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","route":"/trials/nct06994507/","field":"links","label":"ClinicalTrials.gov NCT06994507"}]},{"url":"https://clinicaltrials.gov/study/NCT06995677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/","field":"links","label":"ClinicalTrials.gov NCT06995677"}]},{"url":"https://clinicaltrials.gov/study/NCT06995898","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"ClinicalTrials.gov NCT06995898"},{"id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/","field":"links","label":"ClinicalTrials.gov NCT06995898"}]},{"url":"https://clinicaltrials.gov/study/NCT06996782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/","field":"links","label":"ClinicalTrials.gov NCT06996782"}]},{"url":"https://clinicaltrials.gov/study/NCT06997497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","route":"/trials/nct06997497/","field":"links","label":"ClinicalTrials.gov NCT06997497"}]},{"url":"https://clinicaltrials.gov/study/NCT06998108","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06998108","kind":"trial","name":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","route":"/trials/nct06998108/","field":"links","label":"ClinicalTrials.gov NCT06998108"}]},{"url":"https://clinicaltrials.gov/study/NCT06998407","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/","field":"links","label":"ClinicalTrials.gov NCT06998407"}]},{"url":"https://clinicaltrials.gov/study/NCT06998758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06998758","kind":"trial","name":"Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC","route":"/trials/nct06998758/","field":"links","label":"ClinicalTrials.gov NCT06998758"}]},{"url":"https://clinicaltrials.gov/study/NCT06998940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","route":"/trials/nct06998940/","field":"links","label":"ClinicalTrials.gov NCT06998940"}]},{"url":"https://clinicaltrials.gov/study/NCT06999252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06999252","kind":"trial","name":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients","route":"/trials/nct06999252/","field":"links","label":"ClinicalTrials.gov NCT06999252"}]},{"url":"https://clinicaltrials.gov/study/NCT06999512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct06999512","kind":"trial","name":"Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for C","route":"/trials/nct06999512/","field":"links","label":"ClinicalTrials.gov NCT06999512"}]},{"url":"https://clinicaltrials.gov/study/NCT07000305","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07000305","kind":"trial","name":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07000305/","field":"links","label":"ClinicalTrials.gov NCT07000305"}]},{"url":"https://clinicaltrials.gov/study/NCT07001618","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","route":"/trials/nct07001618/","field":"links","label":"ClinicalTrials.gov NCT07001618"}]},{"url":"https://clinicaltrials.gov/study/NCT07002177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/","field":"links","label":"ClinicalTrials.gov NCT07002177"}]},{"url":"https://clinicaltrials.gov/study/NCT07002203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","field":"links","label":"ClinicalTrials.gov NCT07002203"}]},{"url":"https://clinicaltrials.gov/study/NCT07003022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07003022","kind":"trial","name":"Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","route":"/trials/nct07003022/","field":"links","label":"ClinicalTrials.gov NCT07003022"}]},{"url":"https://clinicaltrials.gov/study/NCT07003074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/","field":"links","label":"ClinicalTrials.gov NCT07003074"}]},{"url":"https://clinicaltrials.gov/study/NCT07003321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07003321","kind":"trial","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07003321/","field":"links","label":"ClinicalTrials.gov NCT07003321"}]},{"url":"https://clinicaltrials.gov/study/NCT07003815","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07003815","kind":"trial","name":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","route":"/trials/nct07003815/","field":"links","label":"ClinicalTrials.gov NCT07003815"}]},{"url":"https://clinicaltrials.gov/study/NCT07004413","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07004413","kind":"trial","name":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","route":"/trials/nct07004413/","field":"links","label":"ClinicalTrials.gov NCT07004413"}]},{"url":"https://clinicaltrials.gov/study/NCT07005102","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005102","kind":"trial","name":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07005102/","field":"links","label":"ClinicalTrials.gov NCT07005102"}]},{"url":"https://clinicaltrials.gov/study/NCT07005128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/","field":"links","label":"ClinicalTrials.gov NCT07005128"}]},{"url":"https://clinicaltrials.gov/study/NCT07005154","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/","field":"links","label":"ClinicalTrials.gov NCT07005154"}]},{"url":"https://clinicaltrials.gov/study/NCT07005336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005336","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr","route":"/trials/nct07005336/","field":"links","label":"ClinicalTrials.gov NCT07005336"}]},{"url":"https://clinicaltrials.gov/study/NCT07005570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005570","kind":"trial","name":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS","route":"/trials/nct07005570/","field":"links","label":"ClinicalTrials.gov NCT07005570"}]},{"url":"https://clinicaltrials.gov/study/NCT07005583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/","field":"links","label":"ClinicalTrials.gov NCT07005583"}]},{"url":"https://clinicaltrials.gov/study/NCT07006077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","field":"links","label":"ClinicalTrials.gov NCT07006077"}]},{"url":"https://clinicaltrials.gov/study/NCT07007312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07007312","kind":"trial","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","route":"/trials/nct07007312/","field":"links","label":"ClinicalTrials.gov NCT07007312"}]},{"url":"https://clinicaltrials.gov/study/NCT07007559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/","field":"links","label":"ClinicalTrials.gov NCT07007559"}]},{"url":"https://clinicaltrials.gov/study/NCT07007728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07007728","kind":"trial","name":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","route":"/trials/nct07007728/","field":"links","label":"ClinicalTrials.gov NCT07007728"}]},{"url":"https://clinicaltrials.gov/study/NCT07007767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07007767","kind":"trial","name":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","route":"/trials/nct07007767/","field":"links","label":"ClinicalTrials.gov NCT07007767"}]},{"url":"https://clinicaltrials.gov/study/NCT07007780","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07007780","kind":"trial","name":"Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC","route":"/trials/nct07007780/","field":"links","label":"ClinicalTrials.gov NCT07007780"}]},{"url":"https://clinicaltrials.gov/study/NCT07008703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07008703","kind":"trial","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","route":"/trials/nct07008703/","field":"links","label":"ClinicalTrials.gov NCT07008703"}]},{"url":"https://clinicaltrials.gov/study/NCT07008716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07008716","kind":"trial","name":"Omitting CTV for Primary Tumor in LS-SCLC","route":"/trials/nct07008716/","field":"links","label":"ClinicalTrials.gov NCT07008716"}]},{"url":"https://clinicaltrials.gov/study/NCT07008976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/","field":"links","label":"ClinicalTrials.gov NCT07008976"}]},{"url":"https://clinicaltrials.gov/study/NCT07009145","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07009145","kind":"trial","name":"QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC","route":"/trials/nct07009145/","field":"links","label":"ClinicalTrials.gov NCT07009145"}]},{"url":"https://clinicaltrials.gov/study/NCT07010263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/","field":"links","label":"ClinicalTrials.gov NCT07010263"}]},{"url":"https://clinicaltrials.gov/study/NCT07011056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","route":"/trials/nct07011056/","field":"links","label":"ClinicalTrials.gov NCT07011056"}]},{"url":"https://clinicaltrials.gov/study/NCT07011186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","route":"/trials/nct07011186/","field":"links","label":"ClinicalTrials.gov NCT07011186"}]},{"url":"https://clinicaltrials.gov/study/NCT07011576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011576","kind":"trial","name":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","route":"/trials/nct07011576/","field":"links","label":"ClinicalTrials.gov NCT07011576"}]},{"url":"https://clinicaltrials.gov/study/NCT07011654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","route":"/trials/nct07011654/","field":"links","label":"ClinicalTrials.gov NCT07011654"}]},{"url":"https://clinicaltrials.gov/study/NCT07011719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/","field":"links","label":"ClinicalTrials.gov NCT07011719"}]},{"url":"https://clinicaltrials.gov/study/NCT07011823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","route":"/trials/nct07011823/","field":"links","label":"ClinicalTrials.gov NCT07011823"}]},{"url":"https://clinicaltrials.gov/study/NCT07012954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07012954","kind":"trial","name":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","route":"/trials/nct07012954/","field":"links","label":"ClinicalTrials.gov NCT07012954"}]},{"url":"https://clinicaltrials.gov/study/NCT07015190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/","field":"links","label":"ClinicalTrials.gov NCT07015190"}]},{"url":"https://clinicaltrials.gov/study/NCT07015242","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","route":"/trials/nct07015242/","field":"links","label":"ClinicalTrials.gov NCT07015242"}]},{"url":"https://clinicaltrials.gov/study/NCT07015853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","route":"/trials/nct07015853/","field":"links","label":"ClinicalTrials.gov NCT07015853"}]},{"url":"https://clinicaltrials.gov/study/NCT07015892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07015892","kind":"trial","name":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","route":"/trials/nct07015892/","field":"links","label":"ClinicalTrials.gov NCT07015892"}]},{"url":"https://clinicaltrials.gov/study/NCT07016126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07016126","kind":"trial","name":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","route":"/trials/nct07016126/","field":"links","label":"ClinicalTrials.gov NCT07016126"}]},{"url":"https://clinicaltrials.gov/study/NCT07016230","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07016230","kind":"trial","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","route":"/trials/nct07016230/","field":"links","label":"ClinicalTrials.gov NCT07016230"}]},{"url":"https://clinicaltrials.gov/study/NCT07016399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/","field":"links","label":"ClinicalTrials.gov NCT07016399"}]},{"url":"https://clinicaltrials.gov/study/NCT07017673","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/","field":"links","label":"ClinicalTrials.gov NCT07017673"}]},{"url":"https://clinicaltrials.gov/study/NCT07018050","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/","field":"links","label":"ClinicalTrials.gov NCT07018050"}]},{"url":"https://clinicaltrials.gov/study/NCT07018869","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07018869","kind":"trial","name":"Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors","route":"/trials/nct07018869/","field":"links","label":"ClinicalTrials.gov NCT07018869"}]},{"url":"https://clinicaltrials.gov/study/NCT07019675","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/","field":"links","label":"ClinicalTrials.gov NCT07019675"}]},{"url":"https://clinicaltrials.gov/study/NCT07019779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07019779","kind":"trial","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","route":"/trials/nct07019779/","field":"links","label":"ClinicalTrials.gov NCT07019779"}]},{"url":"https://clinicaltrials.gov/study/NCT07020221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/","field":"links","label":"ClinicalTrials.gov NCT07020221"}]},{"url":"https://clinicaltrials.gov/study/NCT07020247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07020247","kind":"trial","name":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","route":"/trials/nct07020247/","field":"links","label":"ClinicalTrials.gov NCT07020247"}]},{"url":"https://clinicaltrials.gov/study/NCT07021261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","route":"/trials/nct07021261/","field":"links","label":"ClinicalTrials.gov NCT07021261"}]},{"url":"https://clinicaltrials.gov/study/NCT07021950","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07021950","kind":"trial","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct07021950/","field":"links","label":"ClinicalTrials.gov NCT07021950"}]},{"url":"https://clinicaltrials.gov/study/NCT07022002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07022002/","field":"links","label":"ClinicalTrials.gov NCT07022002"}]},{"url":"https://clinicaltrials.gov/study/NCT07022483","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07022483","kind":"trial","name":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","route":"/trials/nct07022483/","field":"links","label":"ClinicalTrials.gov NCT07022483"}]},{"url":"https://clinicaltrials.gov/study/NCT07023289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07023289","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o","route":"/trials/nct07023289/","field":"links","label":"ClinicalTrials.gov NCT07023289"}]},{"url":"https://clinicaltrials.gov/study/NCT07023315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07023315","kind":"trial","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","route":"/trials/nct07023315/","field":"links","label":"ClinicalTrials.gov NCT07023315"}]},{"url":"https://clinicaltrials.gov/study/NCT07023627","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/","field":"links","label":"ClinicalTrials.gov NCT07023627"}]},{"url":"https://clinicaltrials.gov/study/NCT07023731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07023731","kind":"trial","name":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","route":"/trials/nct07023731/","field":"links","label":"ClinicalTrials.gov NCT07023731"}]},{"url":"https://clinicaltrials.gov/study/NCT07024173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07024173","kind":"trial","name":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","route":"/trials/nct07024173/","field":"links","label":"ClinicalTrials.gov NCT07024173"}]},{"url":"https://clinicaltrials.gov/study/NCT07024706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","route":"/trials/nct07024706/","field":"links","label":"ClinicalTrials.gov NCT07024706"}]},{"url":"https://clinicaltrials.gov/study/NCT07024784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/","field":"links","label":"ClinicalTrials.gov NCT07024784"}]},{"url":"https://clinicaltrials.gov/study/NCT07025174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07025174","kind":"trial","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct07025174/","field":"links","label":"ClinicalTrials.gov NCT07025174"}]},{"url":"https://clinicaltrials.gov/study/NCT07025239","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07025239","kind":"trial","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","route":"/trials/nct07025239/","field":"links","label":"ClinicalTrials.gov NCT07025239"}]},{"url":"https://clinicaltrials.gov/study/NCT07025850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07025850","kind":"trial","name":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","route":"/trials/nct07025850/","field":"links","label":"ClinicalTrials.gov NCT07025850"}]},{"url":"https://clinicaltrials.gov/study/NCT07026279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07026279/","field":"links","label":"ClinicalTrials.gov NCT07026279"}]},{"url":"https://clinicaltrials.gov/study/NCT07026422","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07026422","kind":"trial","name":"Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)","route":"/trials/nct07026422/","field":"links","label":"ClinicalTrials.gov NCT07026422"}]},{"url":"https://clinicaltrials.gov/study/NCT07028268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07028268","kind":"trial","name":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","route":"/trials/nct07028268/","field":"links","label":"ClinicalTrials.gov NCT07028268"}]},{"url":"https://clinicaltrials.gov/study/NCT07028281","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/","field":"links","label":"ClinicalTrials.gov NCT07028281"}]},{"url":"https://clinicaltrials.gov/study/NCT07028424","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","route":"/trials/nct07028424/","field":"links","label":"ClinicalTrials.gov NCT07028424"}]},{"url":"https://clinicaltrials.gov/study/NCT07028853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07028853","kind":"trial","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","route":"/trials/nct07028853/","field":"links","label":"ClinicalTrials.gov NCT07028853"}]},{"url":"https://clinicaltrials.gov/study/NCT07029737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","route":"/trials/nct07029737/","field":"links","label":"ClinicalTrials.gov NCT07029737"}]},{"url":"https://clinicaltrials.gov/study/NCT07030257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/","field":"links","label":"ClinicalTrials.gov NCT07030257"}]},{"url":"https://clinicaltrials.gov/study/NCT07032077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","route":"/trials/nct07032077/","field":"links","label":"ClinicalTrials.gov NCT07032077"}]},{"url":"https://clinicaltrials.gov/study/NCT07033026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","field":"links","label":"ClinicalTrials.gov NCT07033026"}]},{"url":"https://clinicaltrials.gov/study/NCT07033598","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/","field":"links","label":"ClinicalTrials.gov NCT07033598"}]},{"url":"https://clinicaltrials.gov/study/NCT07034326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07034326","kind":"trial","name":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","route":"/trials/nct07034326/","field":"links","label":"ClinicalTrials.gov NCT07034326"}]},{"url":"https://clinicaltrials.gov/study/NCT07036250","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","route":"/trials/nct07036250/","field":"links","label":"ClinicalTrials.gov NCT07036250"}]},{"url":"https://clinicaltrials.gov/study/NCT07036380","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07036380","kind":"trial","name":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","route":"/trials/nct07036380/","field":"links","label":"ClinicalTrials.gov NCT07036380"}]},{"url":"https://clinicaltrials.gov/study/NCT07038096","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/","field":"links","label":"ClinicalTrials.gov NCT07038096"}]},{"url":"https://clinicaltrials.gov/study/NCT07038343","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/","field":"links","label":"ClinicalTrials.gov NCT07038343"}]},{"url":"https://clinicaltrials.gov/study/NCT07039526","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07039526","kind":"trial","name":"Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer","route":"/trials/nct07039526/","field":"links","label":"ClinicalTrials.gov NCT07039526"}]},{"url":"https://clinicaltrials.gov/study/NCT07040098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07040098","kind":"trial","name":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07040098/","field":"links","label":"ClinicalTrials.gov NCT07040098"}]},{"url":"https://clinicaltrials.gov/study/NCT07040228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07040228","kind":"trial","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07040228/","field":"links","label":"ClinicalTrials.gov NCT07040228"}]},{"url":"https://clinicaltrials.gov/study/NCT07040644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07040644","kind":"trial","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","route":"/trials/nct07040644/","field":"links","label":"ClinicalTrials.gov NCT07040644"}]},{"url":"https://clinicaltrials.gov/study/NCT07042685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07042685","kind":"trial","name":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07042685/","field":"links","label":"ClinicalTrials.gov NCT07042685"}]},{"url":"https://clinicaltrials.gov/study/NCT07042802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/","field":"links","label":"ClinicalTrials.gov NCT07042802"}]},{"url":"https://clinicaltrials.gov/study/NCT07043270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","route":"/trials/nct07043270/","field":"links","label":"ClinicalTrials.gov NCT07043270"}]},{"url":"https://clinicaltrials.gov/study/NCT07043725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/","field":"links","label":"ClinicalTrials.gov NCT07043725"}]},{"url":"https://clinicaltrials.gov/study/NCT07043907","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07043907","kind":"trial","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","route":"/trials/nct07043907/","field":"links","label":"ClinicalTrials.gov NCT07043907"}]},{"url":"https://clinicaltrials.gov/study/NCT07044336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07044336","kind":"trial","name":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","route":"/trials/nct07044336/","field":"links","label":"ClinicalTrials.gov NCT07044336"}]},{"url":"https://clinicaltrials.gov/study/NCT07044453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07044453","kind":"trial","name":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","route":"/trials/nct07044453/","field":"links","label":"ClinicalTrials.gov NCT07044453"}]},{"url":"https://clinicaltrials.gov/study/NCT07044908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07044908","kind":"trial","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct07044908/","field":"links","label":"ClinicalTrials.gov NCT07044908"}]},{"url":"https://clinicaltrials.gov/study/NCT07044921","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07044921","kind":"trial","name":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","route":"/trials/nct07044921/","field":"links","label":"ClinicalTrials.gov NCT07044921"}]},{"url":"https://clinicaltrials.gov/study/NCT07045311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/","field":"links","label":"ClinicalTrials.gov NCT07045311"}]},{"url":"https://clinicaltrials.gov/study/NCT07047001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07047001","kind":"trial","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","route":"/trials/nct07047001/","field":"links","label":"ClinicalTrials.gov NCT07047001"}]},{"url":"https://clinicaltrials.gov/study/NCT07047118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","field":"links","label":"ClinicalTrials.gov NCT07047118"}]},{"url":"https://clinicaltrials.gov/study/NCT07047365","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/","field":"links","label":"ClinicalTrials.gov NCT07047365"}]},{"url":"https://clinicaltrials.gov/study/NCT07047560","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07047560","kind":"trial","name":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Si","route":"/trials/nct07047560/","field":"links","label":"ClinicalTrials.gov NCT07047560"}]},{"url":"https://clinicaltrials.gov/study/NCT07049055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/","field":"links","label":"ClinicalTrials.gov NCT07049055"}]},{"url":"https://clinicaltrials.gov/study/NCT07049926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/","field":"links","label":"ClinicalTrials.gov NCT07049926"}]},{"url":"https://clinicaltrials.gov/study/NCT07050043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07050043","kind":"trial","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","route":"/trials/nct07050043/","field":"links","label":"ClinicalTrials.gov NCT07050043"}]},{"url":"https://clinicaltrials.gov/study/NCT07050186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cemiplimab-nut","kind":"trial","name":"Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)","route":"/trials/cemiplimab-nut/","field":"links","label":"ClinicalTrials.gov NCT07050186"}]},{"url":"https://clinicaltrials.gov/study/NCT07050641","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07050641","kind":"trial","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","route":"/trials/nct07050641/","field":"links","label":"ClinicalTrials.gov NCT07050641"}]},{"url":"https://clinicaltrials.gov/study/NCT07051486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","route":"/trials/nct07051486/","field":"links","label":"ClinicalTrials.gov NCT07051486"}]},{"url":"https://clinicaltrials.gov/study/NCT07051785","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07051785","kind":"trial","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07051785/","field":"links","label":"ClinicalTrials.gov NCT07051785"}]},{"url":"https://clinicaltrials.gov/study/NCT07052214","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","field":"links","label":"ClinicalTrials.gov NCT07052214"}]},{"url":"https://clinicaltrials.gov/study/NCT07052253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/","field":"links","label":"ClinicalTrials.gov NCT07052253"}]},{"url":"https://clinicaltrials.gov/study/NCT07052669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07052669","kind":"trial","name":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","route":"/trials/nct07052669/","field":"links","label":"ClinicalTrials.gov NCT07052669"}]},{"url":"https://clinicaltrials.gov/study/NCT07054190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07054190","kind":"trial","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","route":"/trials/nct07054190/","field":"links","label":"ClinicalTrials.gov NCT07054190"}]},{"url":"https://clinicaltrials.gov/study/NCT07054242","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07054242","kind":"trial","name":"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca","route":"/trials/nct07054242/","field":"links","label":"ClinicalTrials.gov NCT07054242"}]},{"url":"https://clinicaltrials.gov/study/NCT07054567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/","field":"links","label":"ClinicalTrials.gov NCT07054567"}]},{"url":"https://clinicaltrials.gov/study/NCT07055594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","field":"links","label":"ClinicalTrials.gov NCT07055594"}]},{"url":"https://clinicaltrials.gov/study/NCT07056777","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/","field":"links","label":"ClinicalTrials.gov NCT07056777"}]},{"url":"https://clinicaltrials.gov/study/NCT07057791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07057791","kind":"trial","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07057791/","field":"links","label":"ClinicalTrials.gov NCT07057791"}]},{"url":"https://clinicaltrials.gov/study/NCT07058012","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07058012","kind":"trial","name":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal","route":"/trials/nct07058012/","field":"links","label":"ClinicalTrials.gov NCT07058012"}]},{"url":"https://clinicaltrials.gov/study/NCT07058519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07058519","kind":"trial","name":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","route":"/trials/nct07058519/","field":"links","label":"ClinicalTrials.gov NCT07058519"}]},{"url":"https://clinicaltrials.gov/study/NCT07059221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07059221","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","route":"/trials/nct07059221/","field":"links","label":"ClinicalTrials.gov NCT07059221"}]},{"url":"https://clinicaltrials.gov/study/NCT07059338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07059338","kind":"trial","name":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer","route":"/trials/nct07059338/","field":"links","label":"ClinicalTrials.gov NCT07059338"}]},{"url":"https://clinicaltrials.gov/study/NCT07059650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/","field":"links","label":"ClinicalTrials.gov NCT07059650"}]},{"url":"https://clinicaltrials.gov/study/NCT07059845","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/","field":"links","label":"ClinicalTrials.gov NCT07059845"}]},{"url":"https://clinicaltrials.gov/study/NCT07059949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07059949","kind":"trial","name":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","route":"/trials/nct07059949/","field":"links","label":"ClinicalTrials.gov NCT07059949"}]},{"url":"https://clinicaltrials.gov/study/NCT07060443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07060443","kind":"trial","name":"Fluorescence Lymph Node Mapping for Colon Cancer Surgery","route":"/trials/nct07060443/","field":"links","label":"ClinicalTrials.gov NCT07060443"}]},{"url":"https://clinicaltrials.gov/study/NCT07060807","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07060807","kind":"trial","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","route":"/trials/nct07060807/","field":"links","label":"ClinicalTrials.gov NCT07060807"}]},{"url":"https://clinicaltrials.gov/study/NCT07060989","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","route":"/trials/nct07060989/","field":"links","label":"ClinicalTrials.gov NCT07060989"}]},{"url":"https://clinicaltrials.gov/study/NCT07061210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07061210","kind":"trial","name":"An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer","route":"/trials/nct07061210/","field":"links","label":"ClinicalTrials.gov NCT07061210"}]},{"url":"https://clinicaltrials.gov/study/NCT07061951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07061951","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","route":"/trials/nct07061951/","field":"links","label":"ClinicalTrials.gov NCT07061951"}]},{"url":"https://clinicaltrials.gov/study/NCT07062263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07062263","kind":"trial","name":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","route":"/trials/nct07062263/","field":"links","label":"ClinicalTrials.gov NCT07062263"}]},{"url":"https://clinicaltrials.gov/study/NCT07062536","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07062536","kind":"trial","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","route":"/trials/nct07062536/","field":"links","label":"ClinicalTrials.gov NCT07062536"}]},{"url":"https://clinicaltrials.gov/study/NCT07062965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/","field":"links","label":"ClinicalTrials.gov NCT07062965"}]},{"url":"https://clinicaltrials.gov/study/NCT07063329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/","field":"links","label":"ClinicalTrials.gov NCT07063329"}]},{"url":"https://clinicaltrials.gov/study/NCT07063745","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/","field":"links","label":"ClinicalTrials.gov NCT07063745"}]},{"url":"https://clinicaltrials.gov/study/NCT07064018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07064018","kind":"trial","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","route":"/trials/nct07064018/","field":"links","label":"ClinicalTrials.gov NCT07064018"}]},{"url":"https://clinicaltrials.gov/study/NCT07066098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/","field":"links","label":"ClinicalTrials.gov NCT07066098"}]},{"url":"https://clinicaltrials.gov/study/NCT07066995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07066995","kind":"trial","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07066995/","field":"links","label":"ClinicalTrials.gov NCT07066995"}]},{"url":"https://clinicaltrials.gov/study/NCT07068763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07068763","kind":"trial","name":"Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer","route":"/trials/nct07068763/","field":"links","label":"ClinicalTrials.gov NCT07068763"}]},{"url":"https://clinicaltrials.gov/study/NCT07069062","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/","field":"links","label":"ClinicalTrials.gov NCT07069062"}]},{"url":"https://clinicaltrials.gov/study/NCT07069595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/","field":"links","label":"ClinicalTrials.gov NCT07069595"}]},{"url":"https://clinicaltrials.gov/study/NCT07069712","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/","field":"links","label":"ClinicalTrials.gov NCT07069712"}]},{"url":"https://clinicaltrials.gov/study/NCT07070219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","route":"/trials/nct07070219/","field":"links","label":"ClinicalTrials.gov NCT07070219"}]},{"url":"https://clinicaltrials.gov/study/NCT07070232","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070232","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","route":"/trials/nct07070232/","field":"links","label":"ClinicalTrials.gov NCT07070232"}]},{"url":"https://clinicaltrials.gov/study/NCT07070349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","field":"links","label":"ClinicalTrials.gov NCT07070349"}]},{"url":"https://clinicaltrials.gov/study/NCT07070440","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/","field":"links","label":"ClinicalTrials.gov NCT07070440"}]},{"url":"https://clinicaltrials.gov/study/NCT07070518","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/","field":"links","label":"ClinicalTrials.gov NCT07070518"}]},{"url":"https://clinicaltrials.gov/study/NCT07070622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070622","kind":"trial","name":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","route":"/trials/nct07070622/","field":"links","label":"ClinicalTrials.gov NCT07070622"}]},{"url":"https://clinicaltrials.gov/study/NCT07070713","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07070713","kind":"trial","name":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","route":"/trials/nct07070713/","field":"links","label":"ClinicalTrials.gov NCT07070713"}]},{"url":"https://clinicaltrials.gov/study/NCT07071337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/","field":"links","label":"ClinicalTrials.gov NCT07071337"}]},{"url":"https://clinicaltrials.gov/study/NCT07071714","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","route":"/trials/nct07071714/","field":"links","label":"ClinicalTrials.gov NCT07071714"}]},{"url":"https://clinicaltrials.gov/study/NCT07071844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07071844","kind":"trial","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","route":"/trials/nct07071844/","field":"links","label":"ClinicalTrials.gov NCT07071844"}]},{"url":"https://clinicaltrials.gov/study/NCT07071961","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","route":"/trials/nct07071961/","field":"links","label":"ClinicalTrials.gov NCT07071961"}]},{"url":"https://clinicaltrials.gov/study/NCT07072728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07072728","kind":"trial","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","route":"/trials/nct07072728/","field":"links","label":"ClinicalTrials.gov NCT07072728"}]},{"url":"https://clinicaltrials.gov/study/NCT07073534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","route":"/trials/nct07073534/","field":"links","label":"ClinicalTrials.gov NCT07073534"}]},{"url":"https://clinicaltrials.gov/study/NCT07074106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07074106","kind":"trial","name":"TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC","route":"/trials/nct07074106/","field":"links","label":"ClinicalTrials.gov NCT07074106"}]},{"url":"https://clinicaltrials.gov/study/NCT07074353","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07074353","kind":"trial","name":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","route":"/trials/nct07074353/","field":"links","label":"ClinicalTrials.gov NCT07074353"}]},{"url":"https://clinicaltrials.gov/study/NCT07075328","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07075328","kind":"trial","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","route":"/trials/nct07075328/","field":"links","label":"ClinicalTrials.gov NCT07075328"}]},{"url":"https://clinicaltrials.gov/study/NCT07076095","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07076095","kind":"trial","name":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","route":"/trials/nct07076095/","field":"links","label":"ClinicalTrials.gov NCT07076095"}]},{"url":"https://clinicaltrials.gov/study/NCT07076121","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/","field":"links","label":"ClinicalTrials.gov NCT07076121"}]},{"url":"https://clinicaltrials.gov/study/NCT07076693","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07076693","kind":"trial","name":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","route":"/trials/nct07076693/","field":"links","label":"ClinicalTrials.gov NCT07076693"}]},{"url":"https://clinicaltrials.gov/study/NCT07078604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07078604","kind":"trial","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07078604/","field":"links","label":"ClinicalTrials.gov NCT07078604"}]},{"url":"https://clinicaltrials.gov/study/NCT07079228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/","field":"links","label":"ClinicalTrials.gov NCT07079228"}]},{"url":"https://clinicaltrials.gov/study/NCT07079475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/","field":"links","label":"ClinicalTrials.gov NCT07079475"}]},{"url":"https://clinicaltrials.gov/study/NCT07079631","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07079631","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","route":"/trials/nct07079631/","field":"links","label":"ClinicalTrials.gov NCT07079631"}]},{"url":"https://clinicaltrials.gov/study/NCT07080216","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/","field":"links","label":"ClinicalTrials.gov NCT07080216"}]},{"url":"https://clinicaltrials.gov/study/NCT07081360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07081360","kind":"trial","name":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","route":"/trials/nct07081360/","field":"links","label":"ClinicalTrials.gov NCT07081360"}]},{"url":"https://clinicaltrials.gov/study/NCT07081633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07081633","kind":"trial","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07081633/","field":"links","label":"ClinicalTrials.gov NCT07081633"}]},{"url":"https://clinicaltrials.gov/study/NCT07082686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/","field":"links","label":"ClinicalTrials.gov NCT07082686"}]},{"url":"https://clinicaltrials.gov/study/NCT07083323","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/","field":"links","label":"ClinicalTrials.gov NCT07083323"}]},{"url":"https://clinicaltrials.gov/study/NCT07084896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/","field":"links","label":"ClinicalTrials.gov NCT07084896"}]},{"url":"https://clinicaltrials.gov/study/NCT07084896?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/","field":"outcomes.source (CE Phase: Overall Response Rate (ORR))"},{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/","field":"outcomes.source (CE Phase: Progression-free Survival (PFS))"}]},{"url":"https://clinicaltrials.gov/study/NCT07085169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07085169","kind":"trial","name":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","route":"/trials/nct07085169/","field":"links","label":"ClinicalTrials.gov NCT07085169"}]},{"url":"https://clinicaltrials.gov/study/NCT07085767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/","field":"links","label":"ClinicalTrials.gov NCT07085767"}]},{"url":"https://clinicaltrials.gov/study/NCT07087054","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/","field":"links","label":"ClinicalTrials.gov NCT07087054"}]},{"url":"https://clinicaltrials.gov/study/NCT07087158","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","route":"/trials/nct07087158/","field":"links","label":"ClinicalTrials.gov NCT07087158"}]},{"url":"https://clinicaltrials.gov/study/NCT07093814","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/","field":"links","label":"ClinicalTrials.gov NCT07093814"}]},{"url":"https://clinicaltrials.gov/study/NCT07093970","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct07093970/","field":"links","label":"ClinicalTrials.gov NCT07093970"}]},{"url":"https://clinicaltrials.gov/study/NCT07095309","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07095309","kind":"trial","name":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","route":"/trials/nct07095309/","field":"links","label":"ClinicalTrials.gov NCT07095309"}]},{"url":"https://clinicaltrials.gov/study/NCT07095439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07095439","kind":"trial","name":"Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients","route":"/trials/nct07095439/","field":"links","label":"ClinicalTrials.gov NCT07095439"}]},{"url":"https://clinicaltrials.gov/study/NCT07095452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/","field":"links","label":"ClinicalTrials.gov NCT07095452"}]},{"url":"https://clinicaltrials.gov/study/NCT07095868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","route":"/trials/nct07095868/","field":"links","label":"ClinicalTrials.gov NCT07095868"}]},{"url":"https://clinicaltrials.gov/study/NCT07097064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07097064","kind":"trial","name":"Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","route":"/trials/nct07097064/","field":"links","label":"ClinicalTrials.gov NCT07097064"}]},{"url":"https://clinicaltrials.gov/study/NCT07098338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/","field":"links","label":"ClinicalTrials.gov NCT07098338"}]},{"url":"https://clinicaltrials.gov/study/NCT07098598","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07098598","kind":"trial","name":"Pancreatic Cancer Diagnosis With FAPI-PET Imaging","route":"/trials/nct07098598/","field":"links","label":"ClinicalTrials.gov NCT07098598"}]},{"url":"https://clinicaltrials.gov/study/NCT07098988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/","field":"links","label":"ClinicalTrials.gov NCT07098988"}]},{"url":"https://clinicaltrials.gov/study/NCT07099794","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07099794","kind":"trial","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","route":"/trials/nct07099794/","field":"links","label":"ClinicalTrials.gov NCT07099794"}]},{"url":"https://clinicaltrials.gov/study/NCT07099898","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/","field":"links","label":"ClinicalTrials.gov NCT07099898"}]},{"url":"https://clinicaltrials.gov/study/NCT07100080","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/","field":"links","label":"ClinicalTrials.gov NCT07100080"}]},{"url":"https://clinicaltrials.gov/study/NCT07100106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/","field":"links","label":"ClinicalTrials.gov NCT07100106"}]},{"url":"https://clinicaltrials.gov/study/NCT07100730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","route":"/trials/nct07100730/","field":"links","label":"ClinicalTrials.gov NCT07100730"}]},{"url":"https://clinicaltrials.gov/study/NCT07101614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","route":"/trials/nct07101614/","field":"links","label":"ClinicalTrials.gov NCT07101614"}]},{"url":"https://clinicaltrials.gov/study/NCT07101627","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07101627","kind":"trial","name":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","route":"/trials/nct07101627/","field":"links","label":"ClinicalTrials.gov NCT07101627"}]},{"url":"https://clinicaltrials.gov/study/NCT07101679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07101679","kind":"trial","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","route":"/trials/nct07101679/","field":"links","label":"ClinicalTrials.gov NCT07101679"}]},{"url":"https://clinicaltrials.gov/study/NCT07102004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07102004","kind":"trial","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","route":"/trials/nct07102004/","field":"links","label":"ClinicalTrials.gov NCT07102004"}]},{"url":"https://clinicaltrials.gov/study/NCT07102381","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07102381","kind":"trial","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","route":"/trials/nct07102381/","field":"links","label":"ClinicalTrials.gov NCT07102381"}]},{"url":"https://clinicaltrials.gov/study/NCT07102901","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/","field":"links","label":"ClinicalTrials.gov NCT07102901"}]},{"url":"https://clinicaltrials.gov/study/NCT07103447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/","field":"links","label":"ClinicalTrials.gov NCT07103447"}]},{"url":"https://clinicaltrials.gov/study/NCT07103668","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","route":"/trials/nct07103668/","field":"links","label":"ClinicalTrials.gov NCT07103668"}]},{"url":"https://clinicaltrials.gov/study/NCT07104266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","route":"/trials/nct07104266/","field":"links","label":"ClinicalTrials.gov NCT07104266"}]},{"url":"https://clinicaltrials.gov/study/NCT07104604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07104604","kind":"trial","name":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally","route":"/trials/nct07104604/","field":"links","label":"ClinicalTrials.gov NCT07104604"}]},{"url":"https://clinicaltrials.gov/study/NCT07105215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","route":"/trials/nct07105215/","field":"links","label":"ClinicalTrials.gov NCT07105215"}]},{"url":"https://clinicaltrials.gov/study/NCT07105852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07105852","kind":"trial","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","route":"/trials/nct07105852/","field":"links","label":"ClinicalTrials.gov NCT07105852"}]},{"url":"https://clinicaltrials.gov/study/NCT07106034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07106034","kind":"trial","name":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","route":"/trials/nct07106034/","field":"links","label":"ClinicalTrials.gov NCT07106034"}]},{"url":"https://clinicaltrials.gov/study/NCT07106528","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07106528","kind":"trial","name":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07106528/","field":"links","label":"ClinicalTrials.gov NCT07106528"}]},{"url":"https://clinicaltrials.gov/study/NCT07106762","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","route":"/trials/nct07106762/","field":"links","label":"ClinicalTrials.gov NCT07106762"}]},{"url":"https://clinicaltrials.gov/study/NCT07106892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07106892","kind":"trial","name":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07106892/","field":"links","label":"ClinicalTrials.gov NCT07106892"}]},{"url":"https://clinicaltrials.gov/study/NCT07107217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07107217","kind":"trial","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","route":"/trials/nct07107217/","field":"links","label":"ClinicalTrials.gov NCT07107217"}]},{"url":"https://clinicaltrials.gov/study/NCT07108127","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07108127","kind":"trial","name":"Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced","route":"/trials/nct07108127/","field":"links","label":"ClinicalTrials.gov NCT07108127"}]},{"url":"https://clinicaltrials.gov/study/NCT07108270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07108270","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","route":"/trials/nct07108270/","field":"links","label":"ClinicalTrials.gov NCT07108270"}]},{"url":"https://clinicaltrials.gov/study/NCT07108309","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07108309","kind":"trial","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07108309/","field":"links","label":"ClinicalTrials.gov NCT07108309"}]},{"url":"https://clinicaltrials.gov/study/NCT07108504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07108504","kind":"trial","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07108504/","field":"links","label":"ClinicalTrials.gov NCT07108504"}]},{"url":"https://clinicaltrials.gov/study/NCT07109167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07109167","kind":"trial","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","route":"/trials/nct07109167/","field":"links","label":"ClinicalTrials.gov NCT07109167"}]},{"url":"https://clinicaltrials.gov/study/NCT07109219","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/","field":"links","label":"ClinicalTrials.gov NCT07109219"}]},{"url":"https://clinicaltrials.gov/study/NCT07109414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/","field":"links","label":"ClinicalTrials.gov NCT07109414"}]},{"url":"https://clinicaltrials.gov/study/NCT07109531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/","field":"links","label":"ClinicalTrials.gov NCT07109531"}]},{"url":"https://clinicaltrials.gov/study/NCT07109726","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/","field":"links","label":"ClinicalTrials.gov NCT07109726"}]},{"url":"https://clinicaltrials.gov/study/NCT07110064","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/","field":"links","label":"ClinicalTrials.gov NCT07110064"}]},{"url":"https://clinicaltrials.gov/study/NCT07110103","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","route":"/trials/nct07110103/","field":"links","label":"ClinicalTrials.gov NCT07110103"}]},{"url":"https://clinicaltrials.gov/study/NCT07110571","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07110571","kind":"trial","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","route":"/trials/nct07110571/","field":"links","label":"ClinicalTrials.gov NCT07110571"}]},{"url":"https://clinicaltrials.gov/study/NCT07111520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/","field":"links","label":"ClinicalTrials.gov NCT07111520"}]},{"url":"https://clinicaltrials.gov/study/NCT07111546","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/","field":"links","label":"ClinicalTrials.gov NCT07111546"}]},{"url":"https://clinicaltrials.gov/study/NCT07111832","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/","field":"links","label":"ClinicalTrials.gov NCT07111832"}]},{"url":"https://clinicaltrials.gov/study/NCT07112196","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07112196","kind":"trial","name":"Visugromab in Cachexia International Trial","route":"/trials/nct07112196/","field":"links","label":"ClinicalTrials.gov NCT07112196"}]},{"url":"https://clinicaltrials.gov/study/NCT07112222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/","field":"links","label":"ClinicalTrials.gov NCT07112222"}]},{"url":"https://clinicaltrials.gov/study/NCT07113275","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07113275","kind":"trial","name":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R","route":"/trials/nct07113275/","field":"links","label":"ClinicalTrials.gov NCT07113275"}]},{"url":"https://clinicaltrials.gov/study/NCT07114315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07114315","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07114315/","field":"links","label":"ClinicalTrials.gov NCT07114315"}]},{"url":"https://clinicaltrials.gov/study/NCT07114861","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","field":"links","label":"ClinicalTrials.gov NCT07114861"}]},{"url":"https://clinicaltrials.gov/study/NCT07115043","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/","field":"links","label":"ClinicalTrials.gov NCT07115043"}]},{"url":"https://clinicaltrials.gov/study/NCT07116577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07116577","kind":"trial","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","route":"/trials/nct07116577/","field":"links","label":"ClinicalTrials.gov NCT07116577"}]},{"url":"https://clinicaltrials.gov/study/NCT07116616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/","field":"links","label":"ClinicalTrials.gov NCT07116616"}]},{"url":"https://clinicaltrials.gov/study/NCT07118800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07118800","kind":"trial","name":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","route":"/trials/nct07118800/","field":"links","label":"ClinicalTrials.gov NCT07118800"}]},{"url":"https://clinicaltrials.gov/study/NCT07121595","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07121595","kind":"trial","name":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","route":"/trials/nct07121595/","field":"links","label":"ClinicalTrials.gov NCT07121595"}]},{"url":"https://clinicaltrials.gov/study/NCT07122063","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/","field":"links","label":"ClinicalTrials.gov NCT07122063"}]},{"url":"https://clinicaltrials.gov/study/NCT07122414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/","field":"links","label":"ClinicalTrials.gov NCT07122414"}]},{"url":"https://clinicaltrials.gov/study/NCT07122687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07122687","kind":"trial","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","route":"/trials/nct07122687/","field":"links","label":"ClinicalTrials.gov NCT07122687"}]},{"url":"https://clinicaltrials.gov/study/NCT07123441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07123441","kind":"trial","name":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","route":"/trials/nct07123441/","field":"links","label":"ClinicalTrials.gov NCT07123441"}]},{"url":"https://clinicaltrials.gov/study/NCT07123454","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/","field":"links","label":"ClinicalTrials.gov NCT07123454"}]},{"url":"https://clinicaltrials.gov/study/NCT07124117","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","route":"/trials/nct07124117/","field":"links","label":"ClinicalTrials.gov NCT07124117"}]},{"url":"https://clinicaltrials.gov/study/NCT07124884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07124884","kind":"trial","name":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemother","route":"/trials/nct07124884/","field":"links","label":"ClinicalTrials.gov NCT07124884"}]},{"url":"https://clinicaltrials.gov/study/NCT07124936","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/","field":"links","label":"ClinicalTrials.gov NCT07124936"}]},{"url":"https://clinicaltrials.gov/study/NCT07125391","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07125391","kind":"trial","name":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","route":"/trials/nct07125391/","field":"links","label":"ClinicalTrials.gov NCT07125391"}]},{"url":"https://clinicaltrials.gov/study/NCT07125872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/","field":"links","label":"ClinicalTrials.gov NCT07125872"}]},{"url":"https://clinicaltrials.gov/study/NCT07126158","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07126158","kind":"trial","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","route":"/trials/nct07126158/","field":"links","label":"ClinicalTrials.gov NCT07126158"}]},{"url":"https://clinicaltrials.gov/study/NCT07126665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07126665/","field":"links","label":"ClinicalTrials.gov NCT07126665"}]},{"url":"https://clinicaltrials.gov/study/NCT07128199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","route":"/trials/nct07128199/","field":"links","label":"ClinicalTrials.gov NCT07128199"}]},{"url":"https://clinicaltrials.gov/study/NCT07129018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07129018","kind":"trial","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","route":"/trials/nct07129018/","field":"links","label":"ClinicalTrials.gov NCT07129018"}]},{"url":"https://clinicaltrials.gov/study/NCT07129252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","field":"links","label":"ClinicalTrials.gov NCT07129252"}]},{"url":"https://clinicaltrials.gov/study/NCT07129993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07129993","kind":"trial","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07129993/","field":"links","label":"ClinicalTrials.gov NCT07129993"}]},{"url":"https://clinicaltrials.gov/study/NCT07130383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","route":"/trials/nct07130383/","field":"links","label":"ClinicalTrials.gov NCT07130383"}]},{"url":"https://clinicaltrials.gov/study/NCT07130903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07130903","kind":"trial","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","route":"/trials/nct07130903/","field":"links","label":"ClinicalTrials.gov NCT07130903"}]},{"url":"https://clinicaltrials.gov/study/NCT07131202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07131202","kind":"trial","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","route":"/trials/nct07131202/","field":"links","label":"ClinicalTrials.gov NCT07131202"}]},{"url":"https://clinicaltrials.gov/study/NCT07131319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07131319","kind":"trial","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","route":"/trials/nct07131319/","field":"links","label":"ClinicalTrials.gov NCT07131319"}]},{"url":"https://clinicaltrials.gov/study/NCT07131514","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07131514","kind":"trial","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct07131514/","field":"links","label":"ClinicalTrials.gov NCT07131514"}]},{"url":"https://clinicaltrials.gov/study/NCT07132008","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07132008","kind":"trial","name":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","route":"/trials/nct07132008/","field":"links","label":"ClinicalTrials.gov NCT07132008"}]},{"url":"https://clinicaltrials.gov/study/NCT07132190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07132190","kind":"trial","name":"Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","route":"/trials/nct07132190/","field":"links","label":"ClinicalTrials.gov NCT07132190"}]},{"url":"https://clinicaltrials.gov/study/NCT07132463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07132463","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","route":"/trials/nct07132463/","field":"links","label":"ClinicalTrials.gov NCT07132463"}]},{"url":"https://clinicaltrials.gov/study/NCT07133425","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07133425","kind":"trial","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","route":"/trials/nct07133425/","field":"links","label":"ClinicalTrials.gov NCT07133425"}]},{"url":"https://clinicaltrials.gov/study/NCT07133750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07133750","kind":"trial","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07133750/","field":"links","label":"ClinicalTrials.gov NCT07133750"}]},{"url":"https://clinicaltrials.gov/study/NCT07134088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","route":"/trials/nct07134088/","field":"links","label":"ClinicalTrials.gov NCT07134088"}]},{"url":"https://clinicaltrials.gov/study/NCT07134101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07134101","kind":"trial","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","route":"/trials/nct07134101/","field":"links","label":"ClinicalTrials.gov NCT07134101"}]},{"url":"https://clinicaltrials.gov/study/NCT07134205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07134205","kind":"trial","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","route":"/trials/nct07134205/","field":"links","label":"ClinicalTrials.gov NCT07134205"}]},{"url":"https://clinicaltrials.gov/study/NCT07134218","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07134218","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","route":"/trials/nct07134218/","field":"links","label":"ClinicalTrials.gov NCT07134218"}]},{"url":"https://clinicaltrials.gov/study/NCT07135544","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07135544","kind":"trial","name":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","route":"/trials/nct07135544/","field":"links","label":"ClinicalTrials.gov NCT07135544"}]},{"url":"https://clinicaltrials.gov/study/NCT07135882","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07135882","kind":"trial","name":"Primary Radiotherapy In MEtastatic Lung Cancer","route":"/trials/nct07135882/","field":"links","label":"ClinicalTrials.gov NCT07135882"}]},{"url":"https://clinicaltrials.gov/study/NCT07136142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07136142","kind":"trial","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07136142/","field":"links","label":"ClinicalTrials.gov NCT07136142"}]},{"url":"https://clinicaltrials.gov/study/NCT07136181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","field":"links","label":"ClinicalTrials.gov NCT07136181"}]},{"url":"https://clinicaltrials.gov/study/NCT07136779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/","field":"links","label":"ClinicalTrials.gov NCT07136779"}]},{"url":"https://clinicaltrials.gov/study/NCT07138209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/","field":"links","label":"ClinicalTrials.gov NCT07138209"}]},{"url":"https://clinicaltrials.gov/study/NCT07138846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07138846","kind":"trial","name":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct07138846/","field":"links","label":"ClinicalTrials.gov NCT07138846"}]},{"url":"https://clinicaltrials.gov/study/NCT07139470","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","route":"/trials/nct07139470/","field":"links","label":"ClinicalTrials.gov NCT07139470"}]},{"url":"https://clinicaltrials.gov/study/NCT07139873","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/","field":"links","label":"ClinicalTrials.gov NCT07139873"}]},{"url":"https://clinicaltrials.gov/study/NCT07140393","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/","field":"links","label":"ClinicalTrials.gov NCT07140393"}]},{"url":"https://clinicaltrials.gov/study/NCT07140679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07140679","kind":"trial","name":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","route":"/trials/nct07140679/","field":"links","label":"ClinicalTrials.gov NCT07140679"}]},{"url":"https://clinicaltrials.gov/study/NCT07143604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07143604","kind":"trial","name":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","route":"/trials/nct07143604/","field":"links","label":"ClinicalTrials.gov NCT07143604"}]},{"url":"https://clinicaltrials.gov/study/NCT07144280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-4/","field":"links","label":"ClinicalTrials.gov NCT07144280"}]},{"url":"https://clinicaltrials.gov/study/NCT07145255","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/","field":"links","label":"ClinicalTrials.gov NCT07145255"}]},{"url":"https://clinicaltrials.gov/study/NCT07145333","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07145333","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","route":"/trials/nct07145333/","field":"links","label":"ClinicalTrials.gov NCT07145333"}]},{"url":"https://clinicaltrials.gov/study/NCT07146230","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07146230","kind":"trial","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","route":"/trials/nct07146230/","field":"links","label":"ClinicalTrials.gov NCT07146230"}]},{"url":"https://clinicaltrials.gov/study/NCT07146646","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07146646","kind":"trial","name":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct07146646/","field":"links","label":"ClinicalTrials.gov NCT07146646"}]},{"url":"https://clinicaltrials.gov/study/NCT07146672","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07146672","kind":"trial","name":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","route":"/trials/nct07146672/","field":"links","label":"ClinicalTrials.gov NCT07146672"}]},{"url":"https://clinicaltrials.gov/study/NCT07147231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07147231","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refracto","route":"/trials/nct07147231/","field":"links","label":"ClinicalTrials.gov NCT07147231"}]},{"url":"https://clinicaltrials.gov/study/NCT07147348","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07147348","kind":"trial","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","route":"/trials/nct07147348/","field":"links","label":"ClinicalTrials.gov NCT07147348"}]},{"url":"https://clinicaltrials.gov/study/NCT07148128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07148128","kind":"trial","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","route":"/trials/nct07148128/","field":"links","label":"ClinicalTrials.gov NCT07148128"}]},{"url":"https://clinicaltrials.gov/study/NCT07149363","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07149363","kind":"trial","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","route":"/trials/nct07149363/","field":"links","label":"ClinicalTrials.gov NCT07149363"}]},{"url":"https://clinicaltrials.gov/study/NCT07149649","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07149649","kind":"trial","name":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07149649/","field":"links","label":"ClinicalTrials.gov NCT07149649"}]},{"url":"https://clinicaltrials.gov/study/NCT07149857","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/","field":"links","label":"ClinicalTrials.gov NCT07149857"}]},{"url":"https://clinicaltrials.gov/study/NCT07150091","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/","field":"links","label":"ClinicalTrials.gov NCT07150091"}]},{"url":"https://clinicaltrials.gov/study/NCT07150091?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/","field":"outcomes.source (DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs))"},{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/","field":"outcomes.source (DE Phase: Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT07150104","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/","field":"links","label":"ClinicalTrials.gov NCT07150104"}]},{"url":"https://clinicaltrials.gov/study/NCT07150104?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/","field":"outcomes.source (DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs))"},{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/","field":"outcomes.source (DE Phase: Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT07150247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150247","kind":"trial","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07150247/","field":"links","label":"ClinicalTrials.gov NCT07150247"}]},{"url":"https://clinicaltrials.gov/study/NCT07150403","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150403","kind":"trial","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","route":"/trials/nct07150403/","field":"links","label":"ClinicalTrials.gov NCT07150403"}]},{"url":"https://clinicaltrials.gov/study/NCT07150416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150416","kind":"trial","name":"Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","route":"/trials/nct07150416/","field":"links","label":"ClinicalTrials.gov NCT07150416"}]},{"url":"https://clinicaltrials.gov/study/NCT07150663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150663","kind":"trial","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07150663/","field":"links","label":"ClinicalTrials.gov NCT07150663"}]},{"url":"https://clinicaltrials.gov/study/NCT07150949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07150949","kind":"trial","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","route":"/trials/nct07150949/","field":"links","label":"ClinicalTrials.gov NCT07150949"}]},{"url":"https://clinicaltrials.gov/study/NCT07151040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07151040","kind":"trial","name":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","route":"/trials/nct07151040/","field":"links","label":"ClinicalTrials.gov NCT07151040"}]},{"url":"https://clinicaltrials.gov/study/NCT07151586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07151586","kind":"trial","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo","route":"/trials/nct07151586/","field":"links","label":"ClinicalTrials.gov NCT07151586"}]},{"url":"https://clinicaltrials.gov/study/NCT07151872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07151872","kind":"trial","name":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07151872/","field":"links","label":"ClinicalTrials.gov NCT07151872"}]},{"url":"https://clinicaltrials.gov/study/NCT07153055","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07153055","kind":"trial","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","route":"/trials/nct07153055/","field":"links","label":"ClinicalTrials.gov NCT07153055"}]},{"url":"https://clinicaltrials.gov/study/NCT07153289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07153289","kind":"trial","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","route":"/trials/nct07153289/","field":"links","label":"ClinicalTrials.gov NCT07153289"}]},{"url":"https://clinicaltrials.gov/study/NCT07153965","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07153965","kind":"trial","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07153965/","field":"links","label":"ClinicalTrials.gov NCT07153965"}]},{"url":"https://clinicaltrials.gov/study/NCT07154264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/","field":"links","label":"ClinicalTrials.gov NCT07154264"}]},{"url":"https://clinicaltrials.gov/study/NCT07154290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/","field":"links","label":"ClinicalTrials.gov NCT07154290"}]},{"url":"https://clinicaltrials.gov/study/NCT07154316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07154316","kind":"trial","name":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","route":"/trials/nct07154316/","field":"links","label":"ClinicalTrials.gov NCT07154316"}]},{"url":"https://clinicaltrials.gov/study/NCT07154368","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07154368","kind":"trial","name":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","route":"/trials/nct07154368/","field":"links","label":"ClinicalTrials.gov NCT07154368"}]},{"url":"https://clinicaltrials.gov/study/NCT07154706","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/","field":"links","label":"ClinicalTrials.gov NCT07154706"}]},{"url":"https://clinicaltrials.gov/study/NCT07155174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/","field":"links","label":"ClinicalTrials.gov NCT07155174"}]},{"url":"https://clinicaltrials.gov/study/NCT07155187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155187","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07155187/","field":"links","label":"ClinicalTrials.gov NCT07155187"}]},{"url":"https://clinicaltrials.gov/study/NCT07155200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155200","kind":"trial","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","route":"/trials/nct07155200/","field":"links","label":"ClinicalTrials.gov NCT07155200"}]},{"url":"https://clinicaltrials.gov/study/NCT07155226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155226","kind":"trial","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","route":"/trials/nct07155226/","field":"links","label":"ClinicalTrials.gov NCT07155226"}]},{"url":"https://clinicaltrials.gov/study/NCT07155525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155525","kind":"trial","name":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","route":"/trials/nct07155525/","field":"links","label":"ClinicalTrials.gov NCT07155525"}]},{"url":"https://clinicaltrials.gov/study/NCT07155629","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07155629","kind":"trial","name":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","route":"/trials/nct07155629/","field":"links","label":"ClinicalTrials.gov NCT07155629"}]},{"url":"https://clinicaltrials.gov/study/NCT07156682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07156682","kind":"trial","name":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","route":"/trials/nct07156682/","field":"links","label":"ClinicalTrials.gov NCT07156682"}]},{"url":"https://clinicaltrials.gov/study/NCT07157033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/","field":"links","label":"ClinicalTrials.gov NCT07157033"}]},{"url":"https://clinicaltrials.gov/study/NCT07158840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07158840","kind":"trial","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","route":"/trials/nct07158840/","field":"links","label":"ClinicalTrials.gov NCT07158840"}]},{"url":"https://clinicaltrials.gov/study/NCT07158918","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","route":"/trials/nct07158918/","field":"links","label":"ClinicalTrials.gov NCT07158918"}]},{"url":"https://clinicaltrials.gov/study/NCT07159204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07159204","kind":"trial","name":"Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer","route":"/trials/nct07159204/","field":"links","label":"ClinicalTrials.gov NCT07159204"}]},{"url":"https://clinicaltrials.gov/study/NCT07159217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07159217","kind":"trial","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07159217/","field":"links","label":"ClinicalTrials.gov NCT07159217"}]},{"url":"https://clinicaltrials.gov/study/NCT07160283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07160283","kind":"trial","name":"The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer","route":"/trials/nct07160283/","field":"links","label":"ClinicalTrials.gov NCT07160283"}]},{"url":"https://clinicaltrials.gov/study/NCT07160686","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07160686","kind":"trial","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","route":"/trials/nct07160686/","field":"links","label":"ClinicalTrials.gov NCT07160686"}]},{"url":"https://clinicaltrials.gov/study/NCT07160725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","route":"/trials/nct07160725/","field":"links","label":"ClinicalTrials.gov NCT07160725"}]},{"url":"https://clinicaltrials.gov/study/NCT07161115","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07161115","kind":"trial","name":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","route":"/trials/nct07161115/","field":"links","label":"ClinicalTrials.gov NCT07161115"}]},{"url":"https://clinicaltrials.gov/study/NCT07161791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07161791","kind":"trial","name":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","route":"/trials/nct07161791/","field":"links","label":"ClinicalTrials.gov NCT07161791"}]},{"url":"https://clinicaltrials.gov/study/NCT07162181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","route":"/trials/nct07162181/","field":"links","label":"ClinicalTrials.gov NCT07162181"}]},{"url":"https://clinicaltrials.gov/study/NCT07162714","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07162714","kind":"trial","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","route":"/trials/nct07162714/","field":"links","label":"ClinicalTrials.gov NCT07162714"}]},{"url":"https://clinicaltrials.gov/study/NCT07162883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07162883/","field":"links","label":"ClinicalTrials.gov NCT07162883"}]},{"url":"https://clinicaltrials.gov/study/NCT07164170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/","field":"links","label":"ClinicalTrials.gov NCT07164170"}]},{"url":"https://clinicaltrials.gov/study/NCT07164443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","field":"links","label":"ClinicalTrials.gov NCT07164443"}]},{"url":"https://clinicaltrials.gov/study/NCT07165886","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/","field":"links","label":"ClinicalTrials.gov NCT07165886"}]},{"url":"https://clinicaltrials.gov/study/NCT07166094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07166094","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","route":"/trials/nct07166094/","field":"links","label":"ClinicalTrials.gov NCT07166094"}]},{"url":"https://clinicaltrials.gov/study/NCT07168200","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/","field":"links","label":"ClinicalTrials.gov NCT07168200"}]},{"url":"https://clinicaltrials.gov/study/NCT07168226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","field":"links","label":"ClinicalTrials.gov NCT07168226"}]},{"url":"https://clinicaltrials.gov/study/NCT07169552","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07169552","kind":"trial","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","route":"/trials/nct07169552/","field":"links","label":"ClinicalTrials.gov NCT07169552"}]},{"url":"https://clinicaltrials.gov/study/NCT07169734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/","field":"links","label":"ClinicalTrials.gov NCT07169734"}]},{"url":"https://clinicaltrials.gov/study/NCT07169851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07169851","kind":"trial","name":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","route":"/trials/nct07169851/","field":"links","label":"ClinicalTrials.gov NCT07169851"}]},{"url":"https://clinicaltrials.gov/study/NCT07169903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07169903","kind":"trial","name":"Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","route":"/trials/nct07169903/","field":"links","label":"ClinicalTrials.gov NCT07169903"}]},{"url":"https://clinicaltrials.gov/study/NCT07169994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/","field":"links","label":"ClinicalTrials.gov NCT07169994"}]},{"url":"https://clinicaltrials.gov/study/NCT07170644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07170644","kind":"trial","name":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","route":"/trials/nct07170644/","field":"links","label":"ClinicalTrials.gov NCT07170644"}]},{"url":"https://clinicaltrials.gov/study/NCT07170995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/","field":"links","label":"ClinicalTrials.gov NCT07170995"}]},{"url":"https://clinicaltrials.gov/study/NCT07171606","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07171606","kind":"trial","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","route":"/trials/nct07171606/","field":"links","label":"ClinicalTrials.gov NCT07171606"}]},{"url":"https://clinicaltrials.gov/study/NCT07172802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","field":"links","label":"ClinicalTrials.gov NCT07172802"}]},{"url":"https://clinicaltrials.gov/study/NCT07172919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07172919","kind":"trial","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","route":"/trials/nct07172919/","field":"links","label":"ClinicalTrials.gov NCT07172919"}]},{"url":"https://clinicaltrials.gov/study/NCT07173751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/","field":"links","label":"ClinicalTrials.gov NCT07173751"}]},{"url":"https://clinicaltrials.gov/study/NCT07174336","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/","field":"links","label":"ClinicalTrials.gov NCT07174336"}]},{"url":"https://clinicaltrials.gov/study/NCT07174427","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/","field":"links","label":"ClinicalTrials.gov NCT07174427"}]},{"url":"https://clinicaltrials.gov/study/NCT07174583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/","field":"links","label":"ClinicalTrials.gov NCT07174583"}]},{"url":"https://clinicaltrials.gov/study/NCT07174908","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/","field":"links","label":"ClinicalTrials.gov NCT07174908"}]},{"url":"https://clinicaltrials.gov/study/NCT07175220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/","field":"links","label":"ClinicalTrials.gov NCT07175220"}]},{"url":"https://clinicaltrials.gov/study/NCT07175389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07175389","kind":"trial","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","route":"/trials/nct07175389/","field":"links","label":"ClinicalTrials.gov NCT07175389"}]},{"url":"https://clinicaltrials.gov/study/NCT07175636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07175636","kind":"trial","name":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","route":"/trials/nct07175636/","field":"links","label":"ClinicalTrials.gov NCT07175636"}]},{"url":"https://clinicaltrials.gov/study/NCT07176182","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07176182","kind":"trial","name":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","route":"/trials/nct07176182/","field":"links","label":"ClinicalTrials.gov NCT07176182"}]},{"url":"https://clinicaltrials.gov/study/NCT07178717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07178717","kind":"trial","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","route":"/trials/nct07178717/","field":"links","label":"ClinicalTrials.gov NCT07178717"}]},{"url":"https://clinicaltrials.gov/study/NCT07178730","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/","field":"links","label":"ClinicalTrials.gov NCT07178730"}]},{"url":"https://clinicaltrials.gov/study/NCT07178795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/","field":"links","label":"ClinicalTrials.gov NCT07178795"}]},{"url":"https://clinicaltrials.gov/study/NCT07181161","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/","field":"links","label":"ClinicalTrials.gov NCT07181161"}]},{"url":"https://clinicaltrials.gov/study/NCT07181499","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/","field":"links","label":"ClinicalTrials.gov NCT07181499"}]},{"url":"https://clinicaltrials.gov/study/NCT07182682","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/","field":"links","label":"ClinicalTrials.gov NCT07182682"}]},{"url":"https://clinicaltrials.gov/study/NCT07183189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","field":"links","label":"ClinicalTrials.gov NCT07183189"}]},{"url":"https://clinicaltrials.gov/study/NCT07183865","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07183865","kind":"trial","name":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","route":"/trials/nct07183865/","field":"links","label":"ClinicalTrials.gov NCT07183865"}]},{"url":"https://clinicaltrials.gov/study/NCT07185880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/","field":"links","label":"ClinicalTrials.gov NCT07185880"}]},{"url":"https://clinicaltrials.gov/study/NCT07185997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/","field":"links","label":"ClinicalTrials.gov NCT07185997"}]},{"url":"https://clinicaltrials.gov/study/NCT07186842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","route":"/trials/nct07186842/","field":"links","label":"ClinicalTrials.gov NCT07186842"}]},{"url":"https://clinicaltrials.gov/study/NCT07188025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07188025","kind":"trial","name":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","route":"/trials/nct07188025/","field":"links","label":"ClinicalTrials.gov NCT07188025"}]},{"url":"https://clinicaltrials.gov/study/NCT07188246","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","route":"/trials/nct07188246/","field":"links","label":"ClinicalTrials.gov NCT07188246"}]},{"url":"https://clinicaltrials.gov/study/NCT07188441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07188441","kind":"trial","name":"Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin","route":"/trials/nct07188441/","field":"links","label":"ClinicalTrials.gov NCT07188441"}]},{"url":"https://clinicaltrials.gov/study/NCT07188558","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/","field":"links","label":"ClinicalTrials.gov NCT07188558"}]},{"url":"https://clinicaltrials.gov/study/NCT07189065","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/","field":"links","label":"ClinicalTrials.gov NCT07189065"}]},{"url":"https://clinicaltrials.gov/study/NCT07189455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/","field":"links","label":"ClinicalTrials.gov NCT07189455"}]},{"url":"https://clinicaltrials.gov/study/NCT07189871","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","field":"links","label":"ClinicalTrials.gov NCT07189871"}]},{"url":"https://clinicaltrials.gov/study/NCT07190248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07190248","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","route":"/trials/nct07190248/","field":"links","label":"ClinicalTrials.gov NCT07190248"}]},{"url":"https://clinicaltrials.gov/study/NCT07190300","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07190300","kind":"trial","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","route":"/trials/nct07190300/","field":"links","label":"ClinicalTrials.gov NCT07190300"}]},{"url":"https://clinicaltrials.gov/study/NCT07192068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192068","kind":"trial","name":"Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.","route":"/trials/nct07192068/","field":"links","label":"ClinicalTrials.gov NCT07192068"}]},{"url":"https://clinicaltrials.gov/study/NCT07192107","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","route":"/trials/nct07192107/","field":"links","label":"ClinicalTrials.gov NCT07192107"}]},{"url":"https://clinicaltrials.gov/study/NCT07192120","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192120","kind":"trial","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","route":"/trials/nct07192120/","field":"links","label":"ClinicalTrials.gov NCT07192120"}]},{"url":"https://clinicaltrials.gov/study/NCT07192432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/","field":"links","label":"ClinicalTrials.gov NCT07192432"}]},{"url":"https://clinicaltrials.gov/study/NCT07192588","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","route":"/trials/nct07192588/","field":"links","label":"ClinicalTrials.gov NCT07192588"}]},{"url":"https://clinicaltrials.gov/study/NCT07192614","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/","field":"links","label":"ClinicalTrials.gov NCT07192614"}]},{"url":"https://clinicaltrials.gov/study/NCT07193511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/","field":"links","label":"ClinicalTrials.gov NCT07193511"}]},{"url":"https://clinicaltrials.gov/study/NCT07195591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/","field":"links","label":"ClinicalTrials.gov NCT07195591"}]},{"url":"https://clinicaltrials.gov/study/NCT07195695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/","field":"links","label":"ClinicalTrials.gov NCT07195695"}]},{"url":"https://clinicaltrials.gov/study/NCT07196644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07196644","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","route":"/trials/nct07196644/","field":"links","label":"ClinicalTrials.gov NCT07196644"}]},{"url":"https://clinicaltrials.gov/study/NCT07196774","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/","field":"links","label":"ClinicalTrials.gov NCT07196774"}]},{"url":"https://clinicaltrials.gov/study/NCT07197580","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","field":"links","label":"ClinicalTrials.gov NCT07197580"}]},{"url":"https://clinicaltrials.gov/study/NCT07197827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/","field":"links","label":"ClinicalTrials.gov NCT07197827"}]},{"url":"https://clinicaltrials.gov/study/NCT07197853","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07197853","kind":"trial","name":"Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,","route":"/trials/nct07197853/","field":"links","label":"ClinicalTrials.gov NCT07197853"}]},{"url":"https://clinicaltrials.gov/study/NCT07198165","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07198165","kind":"trial","name":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","route":"/trials/nct07198165/","field":"links","label":"ClinicalTrials.gov NCT07198165"}]},{"url":"https://clinicaltrials.gov/study/NCT07198321","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07198321","kind":"trial","name":"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","route":"/trials/nct07198321/","field":"links","label":"ClinicalTrials.gov NCT07198321"}]},{"url":"https://clinicaltrials.gov/study/NCT07198633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07198633","kind":"trial","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","route":"/trials/nct07198633/","field":"links","label":"ClinicalTrials.gov NCT07198633"}]},{"url":"https://clinicaltrials.gov/study/NCT07198841","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07198841","kind":"trial","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07198841/","field":"links","label":"ClinicalTrials.gov NCT07198841"}]},{"url":"https://clinicaltrials.gov/study/NCT07199764","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","route":"/trials/nct07199764/","field":"links","label":"ClinicalTrials.gov NCT07199764"}]},{"url":"https://clinicaltrials.gov/study/NCT07200141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07200141","kind":"trial","name":"Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer","route":"/trials/nct07200141/","field":"links","label":"ClinicalTrials.gov NCT07200141"}]},{"url":"https://clinicaltrials.gov/study/NCT07201519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07201519","kind":"trial","name":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","route":"/trials/nct07201519/","field":"links","label":"ClinicalTrials.gov NCT07201519"}]},{"url":"https://clinicaltrials.gov/study/NCT07202364","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/","field":"links","label":"ClinicalTrials.gov NCT07202364"}]},{"url":"https://clinicaltrials.gov/study/NCT07203053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07203053","kind":"trial","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","route":"/trials/nct07203053/","field":"links","label":"ClinicalTrials.gov NCT07203053"}]},{"url":"https://clinicaltrials.gov/study/NCT07204574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07204574","kind":"trial","name":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi","route":"/trials/nct07204574/","field":"links","label":"ClinicalTrials.gov NCT07204574"}]},{"url":"https://clinicaltrials.gov/study/NCT07205718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/","field":"links","label":"ClinicalTrials.gov NCT07205718"}]},{"url":"https://clinicaltrials.gov/study/NCT07205822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07205822","kind":"trial","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","route":"/trials/nct07205822/","field":"links","label":"ClinicalTrials.gov NCT07205822"}]},{"url":"https://clinicaltrials.gov/study/NCT07206056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07206056","kind":"trial","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","route":"/trials/nct07206056/","field":"links","label":"ClinicalTrials.gov NCT07206056"}]},{"url":"https://clinicaltrials.gov/study/NCT07206498","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/","field":"links","label":"ClinicalTrials.gov NCT07206498"}]},{"url":"https://clinicaltrials.gov/study/NCT07207070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/","field":"links","label":"ClinicalTrials.gov NCT07207070"}]},{"url":"https://clinicaltrials.gov/study/NCT07208149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/","field":"links","label":"ClinicalTrials.gov NCT07208149"}]},{"url":"https://clinicaltrials.gov/study/NCT07208539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07208539","kind":"trial","name":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","route":"/trials/nct07208539/","field":"links","label":"ClinicalTrials.gov NCT07208539"}]},{"url":"https://clinicaltrials.gov/study/NCT07208773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/","field":"links","label":"ClinicalTrials.gov NCT07208773"}]},{"url":"https://clinicaltrials.gov/study/NCT07209111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","route":"/trials/nct07209111/","field":"links","label":"ClinicalTrials.gov NCT07209111"}]},{"url":"https://clinicaltrials.gov/study/NCT07209215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07209215","kind":"trial","name":"ctDNA-Informed Management of Early-Stage Rectal Cancer","route":"/trials/nct07209215/","field":"links","label":"ClinicalTrials.gov NCT07209215"}]},{"url":"https://clinicaltrials.gov/study/NCT07209384","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07209384","kind":"trial","name":"Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer","route":"/trials/nct07209384/","field":"links","label":"ClinicalTrials.gov NCT07209384"}]},{"url":"https://clinicaltrials.gov/study/NCT07209813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/","field":"links","label":"ClinicalTrials.gov NCT07209813"}]},{"url":"https://clinicaltrials.gov/study/NCT07211958","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","route":"/trials/nct07211958/","field":"links","label":"ClinicalTrials.gov NCT07211958"}]},{"url":"https://clinicaltrials.gov/study/NCT07213375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213375","kind":"trial","name":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","route":"/trials/nct07213375/","field":"links","label":"ClinicalTrials.gov NCT07213375"}]},{"url":"https://clinicaltrials.gov/study/NCT07213570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213570","kind":"trial","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","route":"/trials/nct07213570/","field":"links","label":"ClinicalTrials.gov NCT07213570"}]},{"url":"https://clinicaltrials.gov/study/NCT07213609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct07213609/","field":"links","label":"ClinicalTrials.gov NCT07213609"}]},{"url":"https://clinicaltrials.gov/study/NCT07213674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/","field":"links","label":"ClinicalTrials.gov NCT07213674"}]},{"url":"https://clinicaltrials.gov/study/NCT07213804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/","field":"links","label":"ClinicalTrials.gov NCT07213804"}]},{"url":"https://clinicaltrials.gov/study/NCT07213817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213817","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct07213817/","field":"links","label":"ClinicalTrials.gov NCT07213817"}]},{"url":"https://clinicaltrials.gov/study/NCT07213830","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07213830","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","route":"/trials/nct07213830/","field":"links","label":"ClinicalTrials.gov NCT07213830"}]},{"url":"https://clinicaltrials.gov/study/NCT07214142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07214142","kind":"trial","name":"Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer","route":"/trials/nct07214142/","field":"links","label":"ClinicalTrials.gov NCT07214142"}]},{"url":"https://clinicaltrials.gov/study/NCT07214298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07214298","kind":"trial","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07214298/","field":"links","label":"ClinicalTrials.gov NCT07214298"}]},{"url":"https://clinicaltrials.gov/study/NCT07214779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/","field":"links","label":"ClinicalTrials.gov NCT07214779"}]},{"url":"https://clinicaltrials.gov/study/NCT07215585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/","field":"links","label":"ClinicalTrials.gov NCT07215585"}]},{"url":"https://clinicaltrials.gov/study/NCT07216443","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct07216443/","field":"links","label":"ClinicalTrials.gov NCT07216443"}]},{"url":"https://clinicaltrials.gov/study/NCT07216560","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07216560","kind":"trial","name":"First-in-human Study of 7MW4911 in GI Cancer","route":"/trials/nct07216560/","field":"links","label":"ClinicalTrials.gov NCT07216560"}]},{"url":"https://clinicaltrials.gov/study/NCT07216703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/","field":"links","label":"ClinicalTrials.gov NCT07216703"}]},{"url":"https://clinicaltrials.gov/study/NCT07217119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/","field":"links","label":"ClinicalTrials.gov NCT07217119"}]},{"url":"https://clinicaltrials.gov/study/NCT07217119?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/","field":"outcomes.source (Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs))"},{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/","field":"outcomes.source (DE Phase: Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT07217184","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/","field":"links","label":"ClinicalTrials.gov NCT07217184"}]},{"url":"https://clinicaltrials.gov/study/NCT07217184?tab=results","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/","field":"outcomes.source (Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT))"},{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/","field":"outcomes.source (DE Phase: Overall Response Rate (ORR))"}]},{"url":"https://clinicaltrials.gov/study/NCT07217301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/","field":"links","label":"ClinicalTrials.gov NCT07217301"}]},{"url":"https://clinicaltrials.gov/study/NCT07217704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","field":"links","label":"ClinicalTrials.gov NCT07217704"}]},{"url":"https://clinicaltrials.gov/study/NCT07218146","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/","field":"links","label":"ClinicalTrials.gov NCT07218146"}]},{"url":"https://clinicaltrials.gov/study/NCT07218380","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/","field":"links","label":"ClinicalTrials.gov NCT07218380"}]},{"url":"https://clinicaltrials.gov/study/NCT07218809","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/","field":"links","label":"ClinicalTrials.gov NCT07218809"}]},{"url":"https://clinicaltrials.gov/study/NCT07218926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/","field":"links","label":"ClinicalTrials.gov NCT07218926"}]},{"url":"https://clinicaltrials.gov/study/NCT07219238","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","field":"links","label":"ClinicalTrials.gov NCT07219238"}]},{"url":"https://clinicaltrials.gov/study/NCT07219459","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/","field":"links","label":"ClinicalTrials.gov NCT07219459"}]},{"url":"https://clinicaltrials.gov/study/NCT07219576","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07219576","kind":"trial","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","route":"/trials/nct07219576/","field":"links","label":"ClinicalTrials.gov NCT07219576"}]},{"url":"https://clinicaltrials.gov/study/NCT07220616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","route":"/trials/nct07220616/","field":"links","label":"ClinicalTrials.gov NCT07220616"}]},{"url":"https://clinicaltrials.gov/study/NCT07221149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221149","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","route":"/trials/nct07221149/","field":"links","label":"ClinicalTrials.gov NCT07221149"}]},{"url":"https://clinicaltrials.gov/study/NCT07221253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/","field":"links","label":"ClinicalTrials.gov NCT07221253"}]},{"url":"https://clinicaltrials.gov/study/NCT07221357","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","route":"/trials/nct07221357/","field":"links","label":"ClinicalTrials.gov NCT07221357"}]},{"url":"https://clinicaltrials.gov/study/NCT07221474","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/","field":"links","label":"ClinicalTrials.gov NCT07221474"}]},{"url":"https://clinicaltrials.gov/study/NCT07221500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/","field":"links","label":"ClinicalTrials.gov NCT07221500"}]},{"url":"https://clinicaltrials.gov/study/NCT07221734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/","field":"links","label":"ClinicalTrials.gov NCT07221734"}]},{"url":"https://clinicaltrials.gov/study/NCT07222488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","route":"/trials/nct07222488/","field":"links","label":"ClinicalTrials.gov NCT07222488"}]},{"url":"https://clinicaltrials.gov/study/NCT07222566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/symbiotic-lung-01/","field":"links","label":"ClinicalTrials.gov NCT07222566"}]},{"url":"https://clinicaltrials.gov/study/NCT07222800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","route":"/trials/symbiotic-gi-03/","field":"links","label":"ClinicalTrials.gov NCT07222800"}]},{"url":"https://clinicaltrials.gov/study/NCT07222969","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","field":"links","label":"ClinicalTrials.gov NCT07222969"}]},{"url":"https://clinicaltrials.gov/study/NCT07223047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/","field":"links","label":"ClinicalTrials.gov NCT07223047"}]},{"url":"https://clinicaltrials.gov/study/NCT07223424","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07223424","kind":"trial","name":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","route":"/trials/nct07223424/","field":"links","label":"ClinicalTrials.gov NCT07223424"}]},{"url":"https://clinicaltrials.gov/study/NCT07224022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07224022","kind":"trial","name":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","route":"/trials/nct07224022/","field":"links","label":"ClinicalTrials.gov NCT07224022"}]},{"url":"https://clinicaltrials.gov/study/NCT07224152","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07224152","kind":"trial","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","route":"/trials/nct07224152/","field":"links","label":"ClinicalTrials.gov NCT07224152"}]},{"url":"https://clinicaltrials.gov/study/NCT07225270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/","field":"links","label":"ClinicalTrials.gov NCT07225270"}]},{"url":"https://clinicaltrials.gov/study/NCT07225621","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","field":"links","label":"Alpheus phase 2 in GBM (NCT07225621)"},{"id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/","field":"links","label":"ClinicalTrials.gov NCT07225621"}]},{"url":"https://clinicaltrials.gov/study/NCT07225946","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/","field":"links","label":"ClinicalTrials.gov NCT07225946"}]},{"url":"https://clinicaltrials.gov/study/NCT07226752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07226752","kind":"trial","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","route":"/trials/nct07226752/","field":"links","label":"ClinicalTrials.gov NCT07226752"}]},{"url":"https://clinicaltrials.gov/study/NCT07226856","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07226856","kind":"trial","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","route":"/trials/nct07226856/","field":"links","label":"ClinicalTrials.gov NCT07226856"}]},{"url":"https://clinicaltrials.gov/study/NCT07226986","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","field":"links","label":"ClinicalTrials.gov NCT07226986"}]},{"url":"https://clinicaltrials.gov/study/NCT07226999","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"symbiotic-lung-04","kind":"trial","name":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","route":"/trials/symbiotic-lung-04/","field":"links","label":"ClinicalTrials.gov NCT07226999"}]},{"url":"https://clinicaltrials.gov/study/NCT07227012","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227012","kind":"trial","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","route":"/trials/nct07227012/","field":"links","label":"ClinicalTrials.gov NCT07227012"}]},{"url":"https://clinicaltrials.gov/study/NCT07227025","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07227025/","field":"links","label":"ClinicalTrials.gov NCT07227025"}]},{"url":"https://clinicaltrials.gov/study/NCT07227298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/","field":"links","label":"ClinicalTrials.gov NCT07227298"}]},{"url":"https://clinicaltrials.gov/study/NCT07227311","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/","field":"links","label":"ClinicalTrials.gov NCT07227311"}]},{"url":"https://clinicaltrials.gov/study/NCT07227350","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/","field":"links","label":"ClinicalTrials.gov NCT07227350"}]},{"url":"https://clinicaltrials.gov/study/NCT07227402","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/","field":"links","label":"ClinicalTrials.gov NCT07227402"}]},{"url":"https://clinicaltrials.gov/study/NCT07227415","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227415","kind":"trial","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","route":"/trials/nct07227415/","field":"links","label":"ClinicalTrials.gov NCT07227415"}]},{"url":"https://clinicaltrials.gov/study/NCT07227597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/","field":"links","label":"ClinicalTrials.gov NCT07227597"}]},{"url":"https://clinicaltrials.gov/study/NCT07227636","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227636","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","route":"/trials/nct07227636/","field":"links","label":"ClinicalTrials.gov NCT07227636"}]},{"url":"https://clinicaltrials.gov/study/NCT07227870","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/","field":"links","label":"ClinicalTrials.gov NCT07227870"}]},{"url":"https://clinicaltrials.gov/study/NCT07228247","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/","field":"links","label":"ClinicalTrials.gov NCT07228247"}]},{"url":"https://clinicaltrials.gov/study/NCT07228832","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/","field":"links","label":"ClinicalTrials.gov NCT07228832"}]},{"url":"https://clinicaltrials.gov/study/NCT07229339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229339","kind":"trial","name":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","route":"/trials/nct07229339/","field":"links","label":"ClinicalTrials.gov NCT07229339"}]},{"url":"https://clinicaltrials.gov/study/NCT07229586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","route":"/trials/nct07229586/","field":"links","label":"ClinicalTrials.gov NCT07229586"}]},{"url":"https://clinicaltrials.gov/study/NCT07229599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/","field":"links","label":"ClinicalTrials.gov NCT07229599"}]},{"url":"https://clinicaltrials.gov/study/NCT07229612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07229612/","field":"links","label":"ClinicalTrials.gov NCT07229612"}]},{"url":"https://clinicaltrials.gov/study/NCT07229625","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07229625/","field":"links","label":"ClinicalTrials.gov NCT07229625"}]},{"url":"https://clinicaltrials.gov/study/NCT07229638","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","route":"/trials/nct07229638/","field":"links","label":"ClinicalTrials.gov NCT07229638"}]},{"url":"https://clinicaltrials.gov/study/NCT07229729","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229729","kind":"trial","name":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07229729/","field":"links","label":"ClinicalTrials.gov NCT07229729"}]},{"url":"https://clinicaltrials.gov/study/NCT07229846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229846","kind":"trial","name":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme","route":"/trials/nct07229846/","field":"links","label":"ClinicalTrials.gov NCT07229846"}]},{"url":"https://clinicaltrials.gov/study/NCT07229872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07229872","kind":"trial","name":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer","route":"/trials/nct07229872/","field":"links","label":"ClinicalTrials.gov NCT07229872"}]},{"url":"https://clinicaltrials.gov/study/NCT07230106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/","field":"links","label":"ClinicalTrials.gov NCT07230106"}]},{"url":"https://clinicaltrials.gov/study/NCT07230301","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07230301","kind":"trial","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","route":"/trials/nct07230301/","field":"links","label":"ClinicalTrials.gov NCT07230301"}]},{"url":"https://clinicaltrials.gov/study/NCT07230405","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/","field":"links","label":"ClinicalTrials.gov NCT07230405"}]},{"url":"https://clinicaltrials.gov/study/NCT07230509","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07230509","kind":"trial","name":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","route":"/trials/nct07230509/","field":"links","label":"ClinicalTrials.gov NCT07230509"}]},{"url":"https://clinicaltrials.gov/study/NCT07230639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07230639","kind":"trial","name":"Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized,","route":"/trials/nct07230639/","field":"links","label":"ClinicalTrials.gov NCT07230639"}]},{"url":"https://clinicaltrials.gov/study/NCT07231068","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/","field":"links","label":"ClinicalTrials.gov NCT07231068"}]},{"url":"https://clinicaltrials.gov/study/NCT07231211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07231211","kind":"trial","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct07231211/","field":"links","label":"ClinicalTrials.gov NCT07231211"}]},{"url":"https://clinicaltrials.gov/study/NCT07232290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/","field":"links","label":"ClinicalTrials.gov NCT07232290"}]},{"url":"https://clinicaltrials.gov/study/NCT07232602","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07232602","kind":"trial","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","route":"/trials/nct07232602/","field":"links","label":"ClinicalTrials.gov NCT07232602"}]},{"url":"https://clinicaltrials.gov/study/NCT07232849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07232849/","field":"links","label":"ClinicalTrials.gov NCT07232849"}]},{"url":"https://clinicaltrials.gov/study/NCT07232875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07232875/","field":"links","label":"ClinicalTrials.gov NCT07232875"}]},{"url":"https://clinicaltrials.gov/study/NCT07233850","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","route":"/trials/nct07233850/","field":"links","label":"ClinicalTrials.gov NCT07233850"}]},{"url":"https://clinicaltrials.gov/study/NCT07234162","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/","field":"links","label":"ClinicalTrials.gov NCT07234162"}]},{"url":"https://clinicaltrials.gov/study/NCT07234877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/","field":"links","label":"ClinicalTrials.gov NCT07234877"}]},{"url":"https://clinicaltrials.gov/study/NCT07235176","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/","field":"links","label":"ClinicalTrials.gov NCT07235176"}]},{"url":"https://clinicaltrials.gov/study/NCT07235293","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07235293","kind":"trial","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","route":"/trials/nct07235293/","field":"links","label":"ClinicalTrials.gov NCT07235293"}]},{"url":"https://clinicaltrials.gov/study/NCT07235930","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07235930/","field":"links","label":"ClinicalTrials.gov NCT07235930"}]},{"url":"https://clinicaltrials.gov/study/NCT07237100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07237100","kind":"trial","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","route":"/trials/nct07237100/","field":"links","label":"ClinicalTrials.gov NCT07237100"}]},{"url":"https://clinicaltrials.gov/study/NCT07238283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/","field":"links","label":"ClinicalTrials.gov NCT07238283"}]},{"url":"https://clinicaltrials.gov/study/NCT07239466","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07239466","kind":"trial","name":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T","route":"/trials/nct07239466/","field":"links","label":"ClinicalTrials.gov NCT07239466"}]},{"url":"https://clinicaltrials.gov/study/NCT07239596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","route":"/trials/nct07239596/","field":"links","label":"ClinicalTrials.gov NCT07239596"}]},{"url":"https://clinicaltrials.gov/study/NCT07240766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07240766","kind":"trial","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","route":"/trials/nct07240766/","field":"links","label":"ClinicalTrials.gov NCT07240766"}]},{"url":"https://clinicaltrials.gov/study/NCT07241416","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07241416","kind":"trial","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct07241416/","field":"links","label":"ClinicalTrials.gov NCT07241416"}]},{"url":"https://clinicaltrials.gov/study/NCT07241767","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07241767","kind":"trial","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","route":"/trials/nct07241767/","field":"links","label":"ClinicalTrials.gov NCT07241767"}]},{"url":"https://clinicaltrials.gov/study/NCT07241936","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/","field":"links","label":"ClinicalTrials.gov NCT07241936"}]},{"url":"https://clinicaltrials.gov/study/NCT07242274","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07242274","kind":"trial","name":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","route":"/trials/nct07242274/","field":"links","label":"ClinicalTrials.gov NCT07242274"}]},{"url":"https://clinicaltrials.gov/study/NCT07243340","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/","field":"links","label":"ClinicalTrials.gov NCT07243340"}]},{"url":"https://clinicaltrials.gov/study/NCT07243938","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07243938","kind":"trial","name":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","route":"/trials/nct07243938/","field":"links","label":"ClinicalTrials.gov NCT07243938"}]},{"url":"https://clinicaltrials.gov/study/NCT07244705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/","field":"links","label":"ClinicalTrials.gov NCT07244705"}]},{"url":"https://clinicaltrials.gov/study/NCT07244874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","route":"/trials/nct07244874/","field":"links","label":"ClinicalTrials.gov NCT07244874"}]},{"url":"https://clinicaltrials.gov/study/NCT07245446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/","field":"links","label":"ClinicalTrials.gov NCT07245446"}]},{"url":"https://clinicaltrials.gov/study/NCT07246863","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/","field":"links","label":"ClinicalTrials.gov NCT07246863"}]},{"url":"https://clinicaltrials.gov/study/NCT07248020","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07248020","kind":"trial","name":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational","route":"/trials/nct07248020/","field":"links","label":"ClinicalTrials.gov NCT07248020"}]},{"url":"https://clinicaltrials.gov/study/NCT07249905","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/","field":"links","label":"ClinicalTrials.gov NCT07249905"}]},{"url":"https://clinicaltrials.gov/study/NCT07251582","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07251582","kind":"trial","name":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","route":"/trials/nct07251582/","field":"links","label":"ClinicalTrials.gov NCT07251582"}]},{"url":"https://clinicaltrials.gov/study/NCT07252232","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","field":"links","label":"ClinicalTrials.gov NCT07252232"},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/","field":"links","label":"ClinicalTrials.gov NCT07252232"}]},{"url":"https://clinicaltrials.gov/study/NCT07252739","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07252739","kind":"trial","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","route":"/trials/nct07252739/","field":"links","label":"ClinicalTrials.gov NCT07252739"}]},{"url":"https://clinicaltrials.gov/study/NCT07253116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","field":"links","label":"ClinicalTrials.gov NCT07253116"}]},{"url":"https://clinicaltrials.gov/study/NCT07253142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/","field":"links","label":"ClinicalTrials.gov NCT07253142"}]},{"url":"https://clinicaltrials.gov/study/NCT07253896","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07253896","kind":"trial","name":"Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab","route":"/trials/nct07253896/","field":"links","label":"ClinicalTrials.gov NCT07253896"}]},{"url":"https://clinicaltrials.gov/study/NCT07254585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07254585","kind":"trial","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","route":"/trials/nct07254585/","field":"links","label":"ClinicalTrials.gov NCT07254585"}]},{"url":"https://clinicaltrials.gov/study/NCT07255404","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07255404","kind":"trial","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","route":"/trials/nct07255404/","field":"links","label":"ClinicalTrials.gov NCT07255404"}]},{"url":"https://clinicaltrials.gov/study/NCT07255612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07255612","kind":"trial","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","route":"/trials/nct07255612/","field":"links","label":"ClinicalTrials.gov NCT07255612"}]},{"url":"https://clinicaltrials.gov/study/NCT07255664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/","field":"links","label":"ClinicalTrials.gov NCT07255664"}]},{"url":"https://clinicaltrials.gov/study/NCT07255872","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07255872","kind":"trial","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","route":"/trials/nct07255872/","field":"links","label":"ClinicalTrials.gov NCT07255872"}]},{"url":"https://clinicaltrials.gov/study/NCT07256509","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07256509","kind":"trial","name":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No","route":"/trials/nct07256509/","field":"links","label":"ClinicalTrials.gov NCT07256509"}]},{"url":"https://clinicaltrials.gov/study/NCT07256782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07256782","kind":"trial","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","route":"/trials/nct07256782/","field":"links","label":"ClinicalTrials.gov NCT07256782"}]},{"url":"https://clinicaltrials.gov/study/NCT07256964","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07256964","kind":"trial","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","route":"/trials/nct07256964/","field":"links","label":"ClinicalTrials.gov NCT07256964"}]},{"url":"https://clinicaltrials.gov/study/NCT07257523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07257523","kind":"trial","name":"Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","route":"/trials/nct07257523/","field":"links","label":"ClinicalTrials.gov NCT07257523"}]},{"url":"https://clinicaltrials.gov/study/NCT07257653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07257653","kind":"trial","name":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresect","route":"/trials/nct07257653/","field":"links","label":"ClinicalTrials.gov NCT07257653"}]},{"url":"https://clinicaltrials.gov/study/NCT07258121","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/","field":"links","label":"ClinicalTrials.gov NCT07258121"}]},{"url":"https://clinicaltrials.gov/study/NCT07258407","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","field":"links","label":"ClinicalTrials.gov NCT07258407"}]},{"url":"https://clinicaltrials.gov/study/NCT07258511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/","field":"links","label":"ClinicalTrials.gov NCT07258511"}]},{"url":"https://clinicaltrials.gov/study/NCT07258979","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/","field":"links","label":"ClinicalTrials.gov NCT07258979"}]},{"url":"https://clinicaltrials.gov/study/NCT07259213","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","field":"links","label":"ClinicalTrials.gov NCT07259213"}]},{"url":"https://clinicaltrials.gov/study/NCT07259317","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/","field":"links","label":"ClinicalTrials.gov NCT07259317"}]},{"url":"https://clinicaltrials.gov/study/NCT07259590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/","field":"links","label":"ClinicalTrials.gov NCT07259590"}]},{"url":"https://clinicaltrials.gov/study/NCT07260058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07260058","kind":"trial","name":"Immune Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07260058/","field":"links","label":"ClinicalTrials.gov NCT07260058"}]},{"url":"https://clinicaltrials.gov/study/NCT07261709","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07261709","kind":"trial","name":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-","route":"/trials/nct07261709/","field":"links","label":"ClinicalTrials.gov NCT07261709"}]},{"url":"https://clinicaltrials.gov/study/NCT07262567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/","field":"links","label":"ClinicalTrials.gov NCT07262567"}]},{"url":"https://clinicaltrials.gov/study/NCT07262619","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/","field":"links","label":"ClinicalTrials.gov NCT07262619"},{"id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/","field":"links","label":"ClinicalTrials.gov NCT07262619"}]},{"url":"https://clinicaltrials.gov/study/NCT07263360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07263360","kind":"trial","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","route":"/trials/nct07263360/","field":"links","label":"ClinicalTrials.gov NCT07263360"}]},{"url":"https://clinicaltrials.gov/study/NCT07263594","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/","field":"links","label":"ClinicalTrials.gov NCT07263594"}]},{"url":"https://clinicaltrials.gov/study/NCT07264816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/","field":"links","label":"ClinicalTrials.gov NCT07264816"}]},{"url":"https://clinicaltrials.gov/study/NCT07265622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","route":"/trials/nct07265622/","field":"links","label":"ClinicalTrials.gov NCT07265622"}]},{"url":"https://clinicaltrials.gov/study/NCT07265674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","route":"/trials/nct07265674/","field":"links","label":"ClinicalTrials.gov NCT07265674"}]},{"url":"https://clinicaltrials.gov/study/NCT07266428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/","field":"links","label":"ClinicalTrials.gov NCT07266428"}]},{"url":"https://clinicaltrials.gov/study/NCT07266441","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","field":"links","label":"ClinicalTrials.gov NCT07266441"}]},{"url":"https://clinicaltrials.gov/study/NCT07267078","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07267078","kind":"trial","name":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","route":"/trials/nct07267078/","field":"links","label":"ClinicalTrials.gov NCT07267078"}]},{"url":"https://clinicaltrials.gov/study/NCT07268040","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/","field":"links","label":"ClinicalTrials.gov NCT07268040"}]},{"url":"https://clinicaltrials.gov/study/NCT07268677","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07268677","kind":"trial","name":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peri","route":"/trials/nct07268677/","field":"links","label":"ClinicalTrials.gov NCT07268677"}]},{"url":"https://clinicaltrials.gov/study/NCT07269158","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07269158","kind":"trial","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07269158/","field":"links","label":"ClinicalTrials.gov NCT07269158"}]},{"url":"https://clinicaltrials.gov/study/NCT07269626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07269626","kind":"trial","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","route":"/trials/nct07269626/","field":"links","label":"ClinicalTrials.gov NCT07269626"}]},{"url":"https://clinicaltrials.gov/study/NCT07269782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07269782","kind":"trial","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","route":"/trials/nct07269782/","field":"links","label":"ClinicalTrials.gov NCT07269782"}]},{"url":"https://clinicaltrials.gov/study/NCT07271355","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/","field":"links","label":"ClinicalTrials.gov NCT07271355"}]},{"url":"https://clinicaltrials.gov/study/NCT07271667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/","field":"links","label":"ClinicalTrials.gov NCT07271667"}]},{"url":"https://clinicaltrials.gov/study/NCT07271992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07271992","kind":"trial","name":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","route":"/trials/nct07271992/","field":"links","label":"ClinicalTrials.gov NCT07271992"}]},{"url":"https://clinicaltrials.gov/study/NCT07272109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07272109","kind":"trial","name":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","route":"/trials/nct07272109/","field":"links","label":"ClinicalTrials.gov NCT07272109"}]},{"url":"https://clinicaltrials.gov/study/NCT07272772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07272772","kind":"trial","name":"Colon Cancer Diagnosis With FAPI-PET Imaging","route":"/trials/nct07272772/","field":"links","label":"ClinicalTrials.gov NCT07272772"}]},{"url":"https://clinicaltrials.gov/study/NCT07276373","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07276373","kind":"trial","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","route":"/trials/nct07276373/","field":"links","label":"ClinicalTrials.gov NCT07276373"}]},{"url":"https://clinicaltrials.gov/study/NCT07276399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/","field":"links","label":"ClinicalTrials.gov NCT07276399"}]},{"url":"https://clinicaltrials.gov/study/NCT07276789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","field":"links","label":"ClinicalTrials.gov NCT07276789"}]},{"url":"https://clinicaltrials.gov/study/NCT07276880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07276880","kind":"trial","name":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","route":"/trials/nct07276880/","field":"links","label":"ClinicalTrials.gov NCT07276880"}]},{"url":"https://clinicaltrials.gov/study/NCT07277231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07277231","kind":"trial","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct07277231/","field":"links","label":"ClinicalTrials.gov NCT07277231"}]},{"url":"https://clinicaltrials.gov/study/NCT07277322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07277322","kind":"trial","name":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","route":"/trials/nct07277322/","field":"links","label":"ClinicalTrials.gov NCT07277322"}]},{"url":"https://clinicaltrials.gov/study/NCT07277452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07277452","kind":"trial","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct07277452/","field":"links","label":"ClinicalTrials.gov NCT07277452"}]},{"url":"https://clinicaltrials.gov/study/NCT07277842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07277842","kind":"trial","name":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","route":"/trials/nct07277842/","field":"links","label":"ClinicalTrials.gov NCT07277842"}]},{"url":"https://clinicaltrials.gov/study/NCT07278479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","field":"links","label":"ClinicalTrials.gov NCT07278479"}]},{"url":"https://clinicaltrials.gov/study/NCT07279077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07279077","kind":"trial","name":"Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Ar","route":"/trials/nct07279077/","field":"links","label":"ClinicalTrials.gov NCT07279077"}]},{"url":"https://clinicaltrials.gov/study/NCT07280377","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/","field":"links","label":"ClinicalTrials.gov NCT07280377"}]},{"url":"https://clinicaltrials.gov/study/NCT07280832","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07280832","kind":"trial","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","route":"/trials/nct07280832/","field":"links","label":"ClinicalTrials.gov NCT07280832"}]},{"url":"https://clinicaltrials.gov/study/NCT07281157","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07281157","kind":"trial","name":"Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07281157/","field":"links","label":"ClinicalTrials.gov NCT07281157"}]},{"url":"https://clinicaltrials.gov/study/NCT07281716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07281716","kind":"trial","name":"Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC","route":"/trials/nct07281716/","field":"links","label":"ClinicalTrials.gov NCT07281716"}]},{"url":"https://clinicaltrials.gov/study/NCT07281768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07281768","kind":"trial","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","route":"/trials/nct07281768/","field":"links","label":"ClinicalTrials.gov NCT07281768"}]},{"url":"https://clinicaltrials.gov/study/NCT07281976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/","field":"links","label":"ClinicalTrials.gov NCT07281976"}]},{"url":"https://clinicaltrials.gov/study/NCT07282262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07282262","kind":"trial","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","route":"/trials/nct07282262/","field":"links","label":"ClinicalTrials.gov NCT07282262"}]},{"url":"https://clinicaltrials.gov/study/NCT07282587","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07282587","kind":"trial","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","route":"/trials/nct07282587/","field":"links","label":"ClinicalTrials.gov NCT07282587"}]},{"url":"https://clinicaltrials.gov/study/NCT07282912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07282912","kind":"trial","name":"Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","route":"/trials/nct07282912/","field":"links","label":"ClinicalTrials.gov NCT07282912"}]},{"url":"https://clinicaltrials.gov/study/NCT07283198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07283198","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07283198/","field":"links","label":"ClinicalTrials.gov NCT07283198"}]},{"url":"https://clinicaltrials.gov/study/NCT07283367","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/","field":"links","label":"ClinicalTrials.gov NCT07283367"}]},{"url":"https://clinicaltrials.gov/study/NCT07283692","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07283692","kind":"trial","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","route":"/trials/nct07283692/","field":"links","label":"ClinicalTrials.gov NCT07283692"}]},{"url":"https://clinicaltrials.gov/study/NCT07283705","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07283705","kind":"trial","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","route":"/trials/nct07283705/","field":"links","label":"ClinicalTrials.gov NCT07283705"}]},{"url":"https://clinicaltrials.gov/study/NCT07283835","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","route":"/trials/nct07283835/","field":"links","label":"ClinicalTrials.gov NCT07283835"}]},{"url":"https://clinicaltrials.gov/study/NCT07284277","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284277","kind":"trial","name":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","route":"/trials/nct07284277/","field":"links","label":"ClinicalTrials.gov NCT07284277"}]},{"url":"https://clinicaltrials.gov/study/NCT07284394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284394","kind":"trial","name":"Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease","route":"/trials/nct07284394/","field":"links","label":"ClinicalTrials.gov NCT07284394"}]},{"url":"https://clinicaltrials.gov/study/NCT07284433","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/","field":"links","label":"ClinicalTrials.gov NCT07284433"}]},{"url":"https://clinicaltrials.gov/study/NCT07284758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/","field":"links","label":"ClinicalTrials.gov NCT07284758"}]},{"url":"https://clinicaltrials.gov/study/NCT07284849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284849","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","route":"/trials/nct07284849/","field":"links","label":"ClinicalTrials.gov NCT07284849"}]},{"url":"https://clinicaltrials.gov/study/NCT07284992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07284992","kind":"trial","name":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","route":"/trials/nct07284992/","field":"links","label":"ClinicalTrials.gov NCT07284992"}]},{"url":"https://clinicaltrials.gov/study/NCT07285044","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07285044","kind":"trial","name":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients","route":"/trials/nct07285044/","field":"links","label":"ClinicalTrials.gov NCT07285044"}]},{"url":"https://clinicaltrials.gov/study/NCT07285057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07285057","kind":"trial","name":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","route":"/trials/nct07285057/","field":"links","label":"ClinicalTrials.gov NCT07285057"}]},{"url":"https://clinicaltrials.gov/study/NCT07285148","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/","field":"links","label":"ClinicalTrials.gov NCT07285148"}]},{"url":"https://clinicaltrials.gov/study/NCT07285694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/","field":"links","label":"ClinicalTrials.gov NCT07285694"}]},{"url":"https://clinicaltrials.gov/study/NCT07286149","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07286149","kind":"trial","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","route":"/trials/nct07286149/","field":"links","label":"ClinicalTrials.gov NCT07286149"}]},{"url":"https://clinicaltrials.gov/study/NCT07286266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/","field":"links","label":"ClinicalTrials.gov NCT07286266"}]},{"url":"https://clinicaltrials.gov/study/NCT07286331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","route":"/trials/nct07286331/","field":"links","label":"ClinicalTrials.gov NCT07286331"}]},{"url":"https://clinicaltrials.gov/study/NCT07286695","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07286695","kind":"trial","name":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07286695/","field":"links","label":"ClinicalTrials.gov NCT07286695"}]},{"url":"https://clinicaltrials.gov/study/NCT07287098","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07287098","kind":"trial","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","route":"/trials/nct07287098/","field":"links","label":"ClinicalTrials.gov NCT07287098"}]},{"url":"https://clinicaltrials.gov/study/NCT07287150","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07287150","kind":"trial","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07287150/","field":"links","label":"ClinicalTrials.gov NCT07287150"}]},{"url":"https://clinicaltrials.gov/study/NCT07287917","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/","field":"links","label":"ClinicalTrials.gov NCT07287917"}]},{"url":"https://clinicaltrials.gov/study/NCT07287995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/","field":"links","label":"ClinicalTrials.gov NCT07287995"}]},{"url":"https://clinicaltrials.gov/study/NCT07288112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/","field":"links","label":"ClinicalTrials.gov NCT07288112"}]},{"url":"https://clinicaltrials.gov/study/NCT07288177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/","field":"links","label":"ClinicalTrials.gov NCT07288177"}]},{"url":"https://clinicaltrials.gov/study/NCT07288203","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/","field":"links","label":"ClinicalTrials.gov NCT07288203"}]},{"url":"https://clinicaltrials.gov/study/NCT07288359","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07288359","kind":"trial","name":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","route":"/trials/nct07288359/","field":"links","label":"ClinicalTrials.gov NCT07288359"}]},{"url":"https://clinicaltrials.gov/study/NCT07288879","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/","field":"links","label":"ClinicalTrials.gov NCT07288879"}]},{"url":"https://clinicaltrials.gov/study/NCT07289646","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07289646","kind":"trial","name":"Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy","route":"/trials/nct07289646/","field":"links","label":"ClinicalTrials.gov NCT07289646"}]},{"url":"https://clinicaltrials.gov/study/NCT07290088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07290088","kind":"trial","name":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","route":"/trials/nct07290088/","field":"links","label":"ClinicalTrials.gov NCT07290088"}]},{"url":"https://clinicaltrials.gov/study/NCT07291037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/","field":"links","label":"ClinicalTrials.gov NCT07291037"}]},{"url":"https://clinicaltrials.gov/study/NCT07291076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07291076","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","route":"/trials/nct07291076/","field":"links","label":"ClinicalTrials.gov NCT07291076"}]},{"url":"https://clinicaltrials.gov/study/NCT07291401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07291401","kind":"trial","name":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","route":"/trials/nct07291401/","field":"links","label":"ClinicalTrials.gov NCT07291401"}]},{"url":"https://clinicaltrials.gov/study/NCT07292142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07292142","kind":"trial","name":"FMT in Triple Negative Breast Cancer Guided by ctDNA","route":"/trials/nct07292142/","field":"links","label":"ClinicalTrials.gov NCT07292142"}]},{"url":"https://clinicaltrials.gov/study/NCT07292298","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07292298","kind":"trial","name":"Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation","route":"/trials/nct07292298/","field":"links","label":"ClinicalTrials.gov NCT07292298"}]},{"url":"https://clinicaltrials.gov/study/NCT07293351","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07293351","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","route":"/trials/nct07293351/","field":"links","label":"ClinicalTrials.gov NCT07293351"}]},{"url":"https://clinicaltrials.gov/study/NCT07293754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/","field":"links","label":"ClinicalTrials.gov NCT07293754"}]},{"url":"https://clinicaltrials.gov/study/NCT07294261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07294261","kind":"trial","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","route":"/trials/nct07294261/","field":"links","label":"ClinicalTrials.gov NCT07294261"}]},{"url":"https://clinicaltrials.gov/study/NCT07294508","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07294508/","field":"links","label":"ClinicalTrials.gov NCT07294508"}]},{"url":"https://clinicaltrials.gov/study/NCT07295821","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","route":"/trials/nct07295821/","field":"links","label":"ClinicalTrials.gov NCT07295821"}]},{"url":"https://clinicaltrials.gov/study/NCT07296341","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07296341/","field":"links","label":"ClinicalTrials.gov NCT07296341"}]},{"url":"https://clinicaltrials.gov/study/NCT07296666","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07296666","kind":"trial","name":"Adjuvant Chemotherapy for BTC Based on 3D-PTA","route":"/trials/nct07296666/","field":"links","label":"ClinicalTrials.gov NCT07296666"}]},{"url":"https://clinicaltrials.gov/study/NCT07296809","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/","field":"links","label":"ClinicalTrials.gov NCT07296809"}]},{"url":"https://clinicaltrials.gov/study/NCT07297004","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07297004","kind":"trial","name":"Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer","route":"/trials/nct07297004/","field":"links","label":"ClinicalTrials.gov NCT07297004"}]},{"url":"https://clinicaltrials.gov/study/NCT07297030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07297030","kind":"trial","name":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","route":"/trials/nct07297030/","field":"links","label":"ClinicalTrials.gov NCT07297030"}]},{"url":"https://clinicaltrials.gov/study/NCT07297212","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","route":"/trials/nct07297212/","field":"links","label":"ClinicalTrials.gov NCT07297212"}]},{"url":"https://clinicaltrials.gov/study/NCT07297329","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/","field":"links","label":"ClinicalTrials.gov NCT07297329"}]},{"url":"https://clinicaltrials.gov/study/NCT07298772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07298772/","field":"links","label":"ClinicalTrials.gov NCT07298772"}]},{"url":"https://clinicaltrials.gov/study/NCT07299409","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/","field":"links","label":"ClinicalTrials.gov NCT07299409"}]},{"url":"https://clinicaltrials.gov/study/NCT07299747","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/","field":"links","label":"ClinicalTrials.gov NCT07299747"}]},{"url":"https://clinicaltrials.gov/study/NCT07299825","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/","field":"links","label":"ClinicalTrials.gov NCT07299825"}]},{"url":"https://clinicaltrials.gov/study/NCT07300943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/","field":"links","label":"ClinicalTrials.gov NCT07300943"}]},{"url":"https://clinicaltrials.gov/study/NCT07301229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07301229","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct07301229/","field":"links","label":"ClinicalTrials.gov NCT07301229"}]},{"url":"https://clinicaltrials.gov/study/NCT07302126","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07302126","kind":"trial","name":"Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy","route":"/trials/nct07302126/","field":"links","label":"ClinicalTrials.gov NCT07302126"}]},{"url":"https://clinicaltrials.gov/study/NCT07302347","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07302347","kind":"trial","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","route":"/trials/nct07302347/","field":"links","label":"ClinicalTrials.gov NCT07302347"}]},{"url":"https://clinicaltrials.gov/study/NCT07306273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07306273","kind":"trial","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306273/","field":"links","label":"ClinicalTrials.gov NCT07306273"}]},{"url":"https://clinicaltrials.gov/study/NCT07306286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07306286","kind":"trial","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306286/","field":"links","label":"ClinicalTrials.gov NCT07306286"}]},{"url":"https://clinicaltrials.gov/study/NCT07306624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/","field":"links","label":"ClinicalTrials.gov NCT07306624"}]},{"url":"https://clinicaltrials.gov/study/NCT07308106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/","field":"links","label":"ClinicalTrials.gov NCT07308106"}]},{"url":"https://clinicaltrials.gov/study/NCT07309289","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07309289","kind":"trial","name":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","route":"/trials/nct07309289/","field":"links","label":"ClinicalTrials.gov NCT07309289"}]},{"url":"https://clinicaltrials.gov/study/NCT07310069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07310069","kind":"trial","name":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","route":"/trials/nct07310069/","field":"links","label":"ClinicalTrials.gov NCT07310069"}]},{"url":"https://clinicaltrials.gov/study/NCT07310173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","route":"/trials/nct07310173/","field":"links","label":"ClinicalTrials.gov NCT07310173"}]},{"url":"https://clinicaltrials.gov/study/NCT07310784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/","field":"links","label":"ClinicalTrials.gov NCT07310784"}]},{"url":"https://clinicaltrials.gov/study/NCT07311694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","field":"links","label":"ClinicalTrials.gov NCT07311694"}]},{"url":"https://clinicaltrials.gov/study/NCT07312188","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/","field":"links","label":"ClinicalTrials.gov NCT07312188"}]},{"url":"https://clinicaltrials.gov/study/NCT07312422","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07312422","kind":"trial","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","route":"/trials/nct07312422/","field":"links","label":"ClinicalTrials.gov NCT07312422"}]},{"url":"https://clinicaltrials.gov/study/NCT07314294","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","field":"links","label":"ClinicalTrials.gov NCT07314294"}]},{"url":"https://clinicaltrials.gov/study/NCT07314528","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07314528","kind":"trial","name":"Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","route":"/trials/nct07314528/","field":"links","label":"ClinicalTrials.gov NCT07314528"}]},{"url":"https://clinicaltrials.gov/study/NCT07314723","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","route":"/trials/nct07314723/","field":"links","label":"ClinicalTrials.gov NCT07314723"}]},{"url":"https://clinicaltrials.gov/study/NCT07315750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07315750","kind":"trial","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct07315750/","field":"links","label":"ClinicalTrials.gov NCT07315750"}]},{"url":"https://clinicaltrials.gov/study/NCT07318558","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/","field":"links","label":"ClinicalTrials.gov NCT07318558"}]},{"url":"https://clinicaltrials.gov/study/NCT07318883","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07318883","kind":"trial","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","route":"/trials/nct07318883/","field":"links","label":"ClinicalTrials.gov NCT07318883"}]},{"url":"https://clinicaltrials.gov/study/NCT07321015","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","route":"/trials/nct07321015/","field":"links","label":"ClinicalTrials.gov NCT07321015"}]},{"url":"https://clinicaltrials.gov/study/NCT07321574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","field":"links","label":"ClinicalTrials.gov NCT07321574"}]},{"url":"https://clinicaltrials.gov/study/NCT07321847","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07321847","kind":"trial","name":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","route":"/trials/nct07321847/","field":"links","label":"ClinicalTrials.gov NCT07321847"}]},{"url":"https://clinicaltrials.gov/study/NCT07322094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/","field":"links","label":"ClinicalTrials.gov NCT07322094"}]},{"url":"https://clinicaltrials.gov/study/NCT07322341","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/","field":"links","label":"ClinicalTrials.gov NCT07322341"}]},{"url":"https://clinicaltrials.gov/study/NCT07323641","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07323641","kind":"trial","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","route":"/trials/nct07323641/","field":"links","label":"ClinicalTrials.gov NCT07323641"}]},{"url":"https://clinicaltrials.gov/study/NCT07324304","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","route":"/trials/nct07324304/","field":"links","label":"ClinicalTrials.gov NCT07324304"}]},{"url":"https://clinicaltrials.gov/study/NCT07324629","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/","field":"links","label":"ClinicalTrials.gov NCT07324629"}]},{"url":"https://clinicaltrials.gov/study/NCT07325136","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/","field":"links","label":"ClinicalTrials.gov NCT07325136"}]},{"url":"https://clinicaltrials.gov/study/NCT07326488","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","route":"/trials/nct07326488/","field":"links","label":"ClinicalTrials.gov NCT07326488"}]},{"url":"https://clinicaltrials.gov/study/NCT07326566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/","field":"links","label":"ClinicalTrials.gov NCT07326566"}]},{"url":"https://clinicaltrials.gov/study/NCT07327034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/","field":"links","label":"ClinicalTrials.gov NCT07327034"}]},{"url":"https://clinicaltrials.gov/study/NCT07328217","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/","field":"links","label":"ClinicalTrials.gov NCT07328217"}]},{"url":"https://clinicaltrials.gov/study/NCT07329322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/","field":"links","label":"ClinicalTrials.gov NCT07329322"}]},{"url":"https://clinicaltrials.gov/study/NCT07331155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/","field":"links","label":"ClinicalTrials.gov NCT07331155"}]},{"url":"https://clinicaltrials.gov/study/NCT07332000","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/","field":"links","label":"ClinicalTrials.gov NCT07332000"}]},{"url":"https://clinicaltrials.gov/study/NCT07332455","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","route":"/trials/nct07332455/","field":"links","label":"ClinicalTrials.gov NCT07332455"}]},{"url":"https://clinicaltrials.gov/study/NCT07333287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07333287","kind":"trial","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","route":"/trials/nct07333287/","field":"links","label":"ClinicalTrials.gov NCT07333287"}]},{"url":"https://clinicaltrials.gov/study/NCT07333651","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07333651","kind":"trial","name":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","route":"/trials/nct07333651/","field":"links","label":"ClinicalTrials.gov NCT07333651"}]},{"url":"https://clinicaltrials.gov/study/NCT07335497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","field":"links","label":"ClinicalTrials.gov NCT07335497"}]},{"url":"https://clinicaltrials.gov/study/NCT07336446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07336446","kind":"trial","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","route":"/trials/nct07336446/","field":"links","label":"ClinicalTrials.gov NCT07336446"}]},{"url":"https://clinicaltrials.gov/study/NCT07336732","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07336732","kind":"trial","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","route":"/trials/nct07336732/","field":"links","label":"ClinicalTrials.gov NCT07336732"}]},{"url":"https://clinicaltrials.gov/study/NCT07336953","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07336953","kind":"trial","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","route":"/trials/nct07336953/","field":"links","label":"ClinicalTrials.gov NCT07336953"}]},{"url":"https://clinicaltrials.gov/study/NCT07337551","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07337551","kind":"trial","name":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","route":"/trials/nct07337551/","field":"links","label":"ClinicalTrials.gov NCT07337551"}]},{"url":"https://clinicaltrials.gov/study/NCT07337876","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07337876","kind":"trial","name":"Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy","route":"/trials/nct07337876/","field":"links","label":"ClinicalTrials.gov NCT07337876"}]},{"url":"https://clinicaltrials.gov/study/NCT07339059","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07339059","kind":"trial","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07339059/","field":"links","label":"ClinicalTrials.gov NCT07339059"}]},{"url":"https://clinicaltrials.gov/study/NCT07339176","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/","field":"links","label":"ClinicalTrials.gov NCT07339176"}]},{"url":"https://clinicaltrials.gov/study/NCT07340541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","route":"/trials/nct07340541/","field":"links","label":"ClinicalTrials.gov NCT07340541"}]},{"url":"https://clinicaltrials.gov/study/NCT07340567","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07340567","kind":"trial","name":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","route":"/trials/nct07340567/","field":"links","label":"ClinicalTrials.gov NCT07340567"}]},{"url":"https://clinicaltrials.gov/study/NCT07341100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/","field":"links","label":"ClinicalTrials.gov NCT07341100"}]},{"url":"https://clinicaltrials.gov/study/NCT07341737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07341737","kind":"trial","name":"SL-28 for Advanced Solid Tumours","route":"/trials/nct07341737/","field":"links","label":"ClinicalTrials.gov NCT07341737"}]},{"url":"https://clinicaltrials.gov/study/NCT07342283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","route":"/trials/nct07342283/","field":"links","label":"ClinicalTrials.gov NCT07342283"}]},{"url":"https://clinicaltrials.gov/study/NCT07342478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07342478","kind":"trial","name":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","route":"/trials/nct07342478/","field":"links","label":"ClinicalTrials.gov NCT07342478"}]},{"url":"https://clinicaltrials.gov/study/NCT07342725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07342725","kind":"trial","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","route":"/trials/nct07342725/","field":"links","label":"ClinicalTrials.gov NCT07342725"}]},{"url":"https://clinicaltrials.gov/study/NCT07343479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07343479","kind":"trial","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","route":"/trials/nct07343479/","field":"links","label":"ClinicalTrials.gov NCT07343479"}]},{"url":"https://clinicaltrials.gov/study/NCT07344220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07344220","kind":"trial","name":"Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","route":"/trials/nct07344220/","field":"links","label":"ClinicalTrials.gov NCT07344220"}]},{"url":"https://clinicaltrials.gov/study/NCT07346144","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07346144","kind":"trial","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","route":"/trials/nct07346144/","field":"links","label":"ClinicalTrials.gov NCT07346144"}]},{"url":"https://clinicaltrials.gov/study/NCT07347951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07347951","kind":"trial","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","route":"/trials/nct07347951/","field":"links","label":"ClinicalTrials.gov NCT07347951"}]},{"url":"https://clinicaltrials.gov/study/NCT07349069","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","route":"/trials/nct07349069/","field":"links","label":"ClinicalTrials.gov NCT07349069"}]},{"url":"https://clinicaltrials.gov/study/NCT07351487","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07351487","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","route":"/trials/nct07351487/","field":"links","label":"ClinicalTrials.gov NCT07351487"}]},{"url":"https://clinicaltrials.gov/study/NCT07351591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07351591","kind":"trial","name":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","route":"/trials/nct07351591/","field":"links","label":"ClinicalTrials.gov NCT07351591"}]},{"url":"https://clinicaltrials.gov/study/NCT07353268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07353268","kind":"trial","name":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil","route":"/trials/nct07353268/","field":"links","label":"ClinicalTrials.gov NCT07353268"}]},{"url":"https://clinicaltrials.gov/study/NCT07353645","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07353645","kind":"trial","name":"KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer","route":"/trials/nct07353645/","field":"links","label":"ClinicalTrials.gov NCT07353645"}]},{"url":"https://clinicaltrials.gov/study/NCT07354022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07354022","kind":"trial","name":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy","route":"/trials/nct07354022/","field":"links","label":"ClinicalTrials.gov NCT07354022"}]},{"url":"https://clinicaltrials.gov/study/NCT07354074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","route":"/trials/nct07354074/","field":"links","label":"ClinicalTrials.gov NCT07354074"}]},{"url":"https://clinicaltrials.gov/study/NCT07354711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","route":"/trials/nct07354711/","field":"links","label":"ClinicalTrials.gov NCT07354711"}]},{"url":"https://clinicaltrials.gov/study/NCT07354919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07354919","kind":"trial","name":"Axelopran for Advanced Cancer in Patients Receiving Opioids","route":"/trials/nct07354919/","field":"links","label":"ClinicalTrials.gov NCT07354919"}]},{"url":"https://clinicaltrials.gov/study/NCT07355205","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07355205","kind":"trial","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","route":"/trials/nct07355205/","field":"links","label":"ClinicalTrials.gov NCT07355205"}]},{"url":"https://clinicaltrials.gov/study/NCT07355231","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07355231","kind":"trial","name":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","route":"/trials/nct07355231/","field":"links","label":"ClinicalTrials.gov NCT07355231"}]},{"url":"https://clinicaltrials.gov/study/NCT07356973","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","route":"/trials/nct07356973/","field":"links","label":"ClinicalTrials.gov NCT07356973"}]},{"url":"https://clinicaltrials.gov/study/NCT07357220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07357220","kind":"trial","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","route":"/trials/nct07357220/","field":"links","label":"ClinicalTrials.gov NCT07357220"}]},{"url":"https://clinicaltrials.gov/study/NCT07357519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","field":"links","label":"ClinicalTrials.gov NCT07357519"}]},{"url":"https://clinicaltrials.gov/study/NCT07358585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07358585","kind":"trial","name":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct07358585/","field":"links","label":"ClinicalTrials.gov NCT07358585"}]},{"url":"https://clinicaltrials.gov/study/NCT07359066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","field":"links","label":"ClinicalTrials.gov NCT07359066"}]},{"url":"https://clinicaltrials.gov/study/NCT07359404","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07359404","kind":"trial","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","route":"/trials/nct07359404/","field":"links","label":"ClinicalTrials.gov NCT07359404"}]},{"url":"https://clinicaltrials.gov/study/NCT07359456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07359456","kind":"trial","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","route":"/trials/nct07359456/","field":"links","label":"ClinicalTrials.gov NCT07359456"}]},{"url":"https://clinicaltrials.gov/study/NCT07359820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","route":"/trials/nct07359820/","field":"links","label":"ClinicalTrials.gov NCT07359820"}]},{"url":"https://clinicaltrials.gov/study/NCT07360132","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07360132","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","route":"/trials/nct07360132/","field":"links","label":"ClinicalTrials.gov NCT07360132"}]},{"url":"https://clinicaltrials.gov/study/NCT07361003","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/","field":"links","label":"ClinicalTrials.gov NCT07361003"}]},{"url":"https://clinicaltrials.gov/study/NCT07361484","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07361484","kind":"trial","name":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","route":"/trials/nct07361484/","field":"links","label":"ClinicalTrials.gov NCT07361484"}]},{"url":"https://clinicaltrials.gov/study/NCT07361497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/","field":"links","label":"ClinicalTrials.gov NCT07361497"}]},{"url":"https://clinicaltrials.gov/study/NCT07361510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/","field":"links","label":"ClinicalTrials.gov NCT07361510"}]},{"url":"https://clinicaltrials.gov/study/NCT07362186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/","field":"links","label":"ClinicalTrials.gov NCT07362186"}]},{"url":"https://clinicaltrials.gov/study/NCT07362459","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07362459","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer","route":"/trials/nct07362459/","field":"links","label":"ClinicalTrials.gov NCT07362459"}]},{"url":"https://clinicaltrials.gov/study/NCT07362836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07362836","kind":"trial","name":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","route":"/trials/nct07362836/","field":"links","label":"ClinicalTrials.gov NCT07362836"}]},{"url":"https://clinicaltrials.gov/study/NCT07362940","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/","field":"links","label":"ClinicalTrials.gov NCT07362940"}]},{"url":"https://clinicaltrials.gov/study/NCT07365241","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/","field":"links","label":"ClinicalTrials.gov NCT07365241"}]},{"url":"https://clinicaltrials.gov/study/NCT07365319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/","field":"links","label":"ClinicalTrials.gov NCT07365319"}]},{"url":"https://clinicaltrials.gov/study/NCT07365592","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07365592","kind":"trial","name":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","route":"/trials/nct07365592/","field":"links","label":"ClinicalTrials.gov NCT07365592"}]},{"url":"https://clinicaltrials.gov/study/NCT07365995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07365995/","field":"links","label":"ClinicalTrials.gov NCT07365995"}]},{"url":"https://clinicaltrials.gov/study/NCT07366840","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07366840","kind":"trial","name":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","route":"/trials/nct07366840/","field":"links","label":"ClinicalTrials.gov NCT07366840"}]},{"url":"https://clinicaltrials.gov/study/NCT07367516","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/","field":"links","label":"ClinicalTrials.gov NCT07367516"}]},{"url":"https://clinicaltrials.gov/study/NCT07367529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/","field":"links","label":"ClinicalTrials.gov NCT07367529"}]},{"url":"https://clinicaltrials.gov/study/NCT07368998","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","route":"/trials/nct07368998/","field":"links","label":"ClinicalTrials.gov NCT07368998"}]},{"url":"https://clinicaltrials.gov/study/NCT07371208","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","route":"/trials/nct07371208/","field":"links","label":"ClinicalTrials.gov NCT07371208"}]},{"url":"https://clinicaltrials.gov/study/NCT07371273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07371273","kind":"trial","name":"Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR","route":"/trials/nct07371273/","field":"links","label":"ClinicalTrials.gov NCT07371273"}]},{"url":"https://clinicaltrials.gov/study/NCT07371663","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/","field":"links","label":"ClinicalTrials.gov NCT07371663"}]},{"url":"https://clinicaltrials.gov/study/NCT07372079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07372079","kind":"trial","name":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth","route":"/trials/nct07372079/","field":"links","label":"ClinicalTrials.gov NCT07372079"}]},{"url":"https://clinicaltrials.gov/study/NCT07372300","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07372300","kind":"trial","name":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07372300/","field":"links","label":"ClinicalTrials.gov NCT07372300"}]},{"url":"https://clinicaltrials.gov/study/NCT07374419","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","field":"links","label":"ClinicalTrials.gov NCT07374419"}]},{"url":"https://clinicaltrials.gov/study/NCT07376382","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07376382","kind":"trial","name":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","route":"/trials/nct07376382/","field":"links","label":"ClinicalTrials.gov NCT07376382"}]},{"url":"https://clinicaltrials.gov/study/NCT07376629","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/","field":"links","label":"ClinicalTrials.gov NCT07376629"}]},{"url":"https://clinicaltrials.gov/study/NCT07377578","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07377578","kind":"trial","name":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct07377578/","field":"links","label":"ClinicalTrials.gov NCT07377578"}]},{"url":"https://clinicaltrials.gov/study/NCT07377643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/","field":"links","label":"ClinicalTrials.gov NCT07377643"}]},{"url":"https://clinicaltrials.gov/study/NCT07378306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07378306","kind":"trial","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","route":"/trials/nct07378306/","field":"links","label":"ClinicalTrials.gov NCT07378306"}]},{"url":"https://clinicaltrials.gov/study/NCT07379047","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","route":"/trials/nct07379047/","field":"links","label":"ClinicalTrials.gov NCT07379047"}]},{"url":"https://clinicaltrials.gov/study/NCT07380386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/","field":"links","label":"ClinicalTrials.gov NCT07380386"}]},{"url":"https://clinicaltrials.gov/study/NCT07381309","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07381309","kind":"trial","name":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","route":"/trials/nct07381309/","field":"links","label":"ClinicalTrials.gov NCT07381309"}]},{"url":"https://clinicaltrials.gov/study/NCT07381400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07381400","kind":"trial","name":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","route":"/trials/nct07381400/","field":"links","label":"ClinicalTrials.gov NCT07381400"}]},{"url":"https://clinicaltrials.gov/study/NCT07381764","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07381764","kind":"trial","name":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","route":"/trials/nct07381764/","field":"links","label":"ClinicalTrials.gov NCT07381764"}]},{"url":"https://clinicaltrials.gov/study/NCT07381777","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07381777","kind":"trial","name":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)","route":"/trials/nct07381777/","field":"links","label":"ClinicalTrials.gov NCT07381777"}]},{"url":"https://clinicaltrials.gov/study/NCT07382531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","route":"/trials/nct07382531/","field":"links","label":"ClinicalTrials.gov NCT07382531"}]},{"url":"https://clinicaltrials.gov/study/NCT07383116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","route":"/trials/nct07383116/","field":"links","label":"ClinicalTrials.gov NCT07383116"}]},{"url":"https://clinicaltrials.gov/study/NCT07383285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07383285","kind":"trial","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","route":"/trials/nct07383285/","field":"links","label":"ClinicalTrials.gov NCT07383285"}]},{"url":"https://clinicaltrials.gov/study/NCT07383922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07383922","kind":"trial","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","route":"/trials/nct07383922/","field":"links","label":"ClinicalTrials.gov NCT07383922"}]},{"url":"https://clinicaltrials.gov/study/NCT07384377","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07384377","kind":"trial","name":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri","route":"/trials/nct07384377/","field":"links","label":"ClinicalTrials.gov NCT07384377"}]},{"url":"https://clinicaltrials.gov/study/NCT07385703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/","field":"links","label":"ClinicalTrials.gov NCT07385703"}]},{"url":"https://clinicaltrials.gov/study/NCT07386704","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07386704","kind":"trial","name":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","route":"/trials/nct07386704/","field":"links","label":"ClinicalTrials.gov NCT07386704"}]},{"url":"https://clinicaltrials.gov/study/NCT07386938","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07386938","kind":"trial","name":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","route":"/trials/nct07386938/","field":"links","label":"ClinicalTrials.gov NCT07386938"}]},{"url":"https://clinicaltrials.gov/study/NCT07387081","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/","field":"links","label":"ClinicalTrials.gov NCT07387081"}]},{"url":"https://clinicaltrials.gov/study/NCT07387471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","route":"/trials/nct07387471/","field":"links","label":"ClinicalTrials.gov NCT07387471"}]},{"url":"https://clinicaltrials.gov/study/NCT07387926","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/","field":"links","label":"ClinicalTrials.gov NCT07387926"}]},{"url":"https://clinicaltrials.gov/study/NCT07388524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07388524","kind":"trial","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","route":"/trials/nct07388524/","field":"links","label":"ClinicalTrials.gov NCT07388524"}]},{"url":"https://clinicaltrials.gov/study/NCT07389265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07389265","kind":"trial","name":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","route":"/trials/nct07389265/","field":"links","label":"ClinicalTrials.gov NCT07389265"}]},{"url":"https://clinicaltrials.gov/study/NCT07389733","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07389733","kind":"trial","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","route":"/trials/nct07389733/","field":"links","label":"ClinicalTrials.gov NCT07389733"}]},{"url":"https://clinicaltrials.gov/study/NCT07390383","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/","field":"links","label":"ClinicalTrials.gov NCT07390383"}]},{"url":"https://clinicaltrials.gov/study/NCT07391566","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07391566","kind":"trial","name":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct07391566/","field":"links","label":"ClinicalTrials.gov NCT07391566"}]},{"url":"https://clinicaltrials.gov/study/NCT07391618","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07391618","kind":"trial","name":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","route":"/trials/nct07391618/","field":"links","label":"ClinicalTrials.gov NCT07391618"}]},{"url":"https://clinicaltrials.gov/study/NCT07391657","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/","field":"links","label":"ClinicalTrials.gov NCT07391657"}]},{"url":"https://clinicaltrials.gov/study/NCT07391813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/","field":"links","label":"ClinicalTrials.gov NCT07391813"}]},{"url":"https://clinicaltrials.gov/study/NCT07392541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07392541","kind":"trial","name":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","route":"/trials/nct07392541/","field":"links","label":"ClinicalTrials.gov NCT07392541"}]},{"url":"https://clinicaltrials.gov/study/NCT07392736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/","field":"links","label":"ClinicalTrials.gov NCT07392736"}]},{"url":"https://clinicaltrials.gov/study/NCT07392892","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"symbiotic-gi-16","kind":"trial","name":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","route":"/trials/symbiotic-gi-16/","field":"links","label":"ClinicalTrials.gov NCT07392892"}]},{"url":"https://clinicaltrials.gov/study/NCT07393282","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/","field":"links","label":"ClinicalTrials.gov NCT07393282"}]},{"url":"https://clinicaltrials.gov/study/NCT07393542","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07393542","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07393542/","field":"links","label":"ClinicalTrials.gov NCT07393542"}]},{"url":"https://clinicaltrials.gov/study/NCT07394192","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07394192","kind":"trial","name":"Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer","route":"/trials/nct07394192/","field":"links","label":"ClinicalTrials.gov NCT07394192"}]},{"url":"https://clinicaltrials.gov/study/NCT07394387","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07394387","kind":"trial","name":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","route":"/trials/nct07394387/","field":"links","label":"ClinicalTrials.gov NCT07394387"}]},{"url":"https://clinicaltrials.gov/study/NCT07395063","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07395063","kind":"trial","name":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","route":"/trials/nct07395063/","field":"links","label":"ClinicalTrials.gov NCT07395063"}]},{"url":"https://clinicaltrials.gov/study/NCT07396584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/","field":"links","label":"ClinicalTrials.gov NCT07396584"}]},{"url":"https://clinicaltrials.gov/study/NCT07397338","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/","field":"links","label":"ClinicalTrials.gov NCT07397338"}]},{"url":"https://clinicaltrials.gov/study/NCT07397442","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07397442","kind":"trial","name":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","route":"/trials/nct07397442/","field":"links","label":"ClinicalTrials.gov NCT07397442"}]},{"url":"https://clinicaltrials.gov/study/NCT07398326","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07398326","kind":"trial","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","route":"/trials/nct07398326/","field":"links","label":"ClinicalTrials.gov NCT07398326"}]},{"url":"https://clinicaltrials.gov/study/NCT07398339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07398339","kind":"trial","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","route":"/trials/nct07398339/","field":"links","label":"ClinicalTrials.gov NCT07398339"}]},{"url":"https://clinicaltrials.gov/study/NCT07398664","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07398664","kind":"trial","name":"H101 Plus TACE for r/m HNSCC","route":"/trials/nct07398664/","field":"links","label":"ClinicalTrials.gov NCT07398664"}]},{"url":"https://clinicaltrials.gov/study/NCT07401537","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07401537","kind":"trial","name":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","route":"/trials/nct07401537/","field":"links","label":"ClinicalTrials.gov NCT07401537"}]},{"url":"https://clinicaltrials.gov/study/NCT07402070","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07402070","kind":"trial","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","route":"/trials/nct07402070/","field":"links","label":"ClinicalTrials.gov NCT07402070"}]},{"url":"https://clinicaltrials.gov/study/NCT07402486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07402486","kind":"trial","name":"A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer","route":"/trials/nct07402486/","field":"links","label":"ClinicalTrials.gov NCT07402486"}]},{"url":"https://clinicaltrials.gov/study/NCT07403877","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07403877","kind":"trial","name":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","route":"/trials/nct07403877/","field":"links","label":"ClinicalTrials.gov NCT07403877"}]},{"url":"https://clinicaltrials.gov/study/NCT07405151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","route":"/trials/nct07405151/","field":"links","label":"ClinicalTrials.gov NCT07405151"}]},{"url":"https://clinicaltrials.gov/study/NCT07405164","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","route":"/trials/nct07405164/","field":"links","label":"ClinicalTrials.gov NCT07405164"}]},{"url":"https://clinicaltrials.gov/study/NCT07405190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/","field":"links","label":"ClinicalTrials.gov NCT07405190"}]},{"url":"https://clinicaltrials.gov/study/NCT07405476","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405476","kind":"trial","name":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","route":"/trials/nct07405476/","field":"links","label":"ClinicalTrials.gov NCT07405476"}]},{"url":"https://clinicaltrials.gov/study/NCT07405736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405736","kind":"trial","name":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","route":"/trials/nct07405736/","field":"links","label":"ClinicalTrials.gov NCT07405736"}]},{"url":"https://clinicaltrials.gov/study/NCT07405801","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07405801","kind":"trial","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","route":"/trials/nct07405801/","field":"links","label":"ClinicalTrials.gov NCT07405801"}]},{"url":"https://clinicaltrials.gov/study/NCT07406633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/","field":"links","label":"ClinicalTrials.gov NCT07406633"}]},{"url":"https://clinicaltrials.gov/study/NCT07407283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/","field":"links","label":"ClinicalTrials.gov NCT07407283"}]},{"url":"https://clinicaltrials.gov/study/NCT07407465","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407465","kind":"trial","name":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","route":"/trials/nct07407465/","field":"links","label":"ClinicalTrials.gov NCT07407465"}]},{"url":"https://clinicaltrials.gov/study/NCT07407517","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","route":"/trials/nct07407517/","field":"links","label":"ClinicalTrials.gov NCT07407517"}]},{"url":"https://clinicaltrials.gov/study/NCT07407647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407647","kind":"trial","name":"Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer","route":"/trials/nct07407647/","field":"links","label":"ClinicalTrials.gov NCT07407647"}]},{"url":"https://clinicaltrials.gov/study/NCT07407803","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/","field":"links","label":"ClinicalTrials.gov NCT07407803"}]},{"url":"https://clinicaltrials.gov/study/NCT07407933","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/","field":"links","label":"ClinicalTrials.gov NCT07407933"}]},{"url":"https://clinicaltrials.gov/study/NCT07409272","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/","field":"links","label":"ClinicalTrials.gov NCT07409272"}]},{"url":"https://clinicaltrials.gov/study/NCT07409428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/","field":"links","label":"ClinicalTrials.gov NCT07409428"}]},{"url":"https://clinicaltrials.gov/study/NCT07409844","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07409844","kind":"trial","name":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","route":"/trials/nct07409844/","field":"links","label":"ClinicalTrials.gov NCT07409844"}]},{"url":"https://clinicaltrials.gov/study/NCT07410494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07410494","kind":"trial","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07410494/","field":"links","label":"ClinicalTrials.gov NCT07410494"}]},{"url":"https://clinicaltrials.gov/study/NCT07410676","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07410676","kind":"trial","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct07410676/","field":"links","label":"ClinicalTrials.gov NCT07410676"}]},{"url":"https://clinicaltrials.gov/study/NCT07411599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07411599","kind":"trial","name":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela","route":"/trials/nct07411599/","field":"links","label":"ClinicalTrials.gov NCT07411599"}]},{"url":"https://clinicaltrials.gov/study/NCT07412262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07412262","kind":"trial","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","route":"/trials/nct07412262/","field":"links","label":"ClinicalTrials.gov NCT07412262"}]},{"url":"https://clinicaltrials.gov/study/NCT07412613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/","field":"links","label":"ClinicalTrials.gov NCT07412613"}]},{"url":"https://clinicaltrials.gov/study/NCT07413601","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/","field":"links","label":"ClinicalTrials.gov NCT07413601"}]},{"url":"https://clinicaltrials.gov/study/NCT07413939","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/","field":"links","label":"ClinicalTrials.gov NCT07413939"}]},{"url":"https://clinicaltrials.gov/study/NCT07414927","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07414927","kind":"trial","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","route":"/trials/nct07414927/","field":"links","label":"ClinicalTrials.gov NCT07414927"}]},{"url":"https://clinicaltrials.gov/study/NCT07415031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","route":"/trials/nct07415031/","field":"links","label":"ClinicalTrials.gov NCT07415031"}]},{"url":"https://clinicaltrials.gov/study/NCT07415525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07415525","kind":"trial","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","route":"/trials/nct07415525/","field":"links","label":"ClinicalTrials.gov NCT07415525"}]},{"url":"https://clinicaltrials.gov/study/NCT07415863","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/","field":"links","label":"ClinicalTrials.gov NCT07415863"}]},{"url":"https://clinicaltrials.gov/study/NCT07416058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/","field":"links","label":"ClinicalTrials.gov NCT07416058"}]},{"url":"https://clinicaltrials.gov/study/NCT07416474","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/","field":"links","label":"ClinicalTrials.gov NCT07416474"}]},{"url":"https://clinicaltrials.gov/study/NCT07416994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/","field":"links","label":"ClinicalTrials.gov NCT07416994"}]},{"url":"https://clinicaltrials.gov/study/NCT07417189","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/","field":"links","label":"ClinicalTrials.gov NCT07417189"}]},{"url":"https://clinicaltrials.gov/study/NCT07418749","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/","field":"links","label":"ClinicalTrials.gov NCT07418749"}]},{"url":"https://clinicaltrials.gov/study/NCT07419295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","route":"/trials/nct07419295/","field":"links","label":"ClinicalTrials.gov NCT07419295"}]},{"url":"https://clinicaltrials.gov/study/NCT07419880","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07419880","kind":"trial","name":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","route":"/trials/nct07419880/","field":"links","label":"ClinicalTrials.gov NCT07419880"}]},{"url":"https://clinicaltrials.gov/study/NCT07421700","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/","field":"links","label":"ClinicalTrials.gov NCT07421700"}]},{"url":"https://clinicaltrials.gov/study/NCT07423585","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07423585","kind":"trial","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","route":"/trials/nct07423585/","field":"links","label":"ClinicalTrials.gov NCT07423585"}]},{"url":"https://clinicaltrials.gov/study/NCT07424287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07424287","kind":"trial","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","route":"/trials/nct07424287/","field":"links","label":"ClinicalTrials.gov NCT07424287"}]},{"url":"https://clinicaltrials.gov/study/NCT07427394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","route":"/trials/nct07427394/","field":"links","label":"ClinicalTrials.gov NCT07427394"}]},{"url":"https://clinicaltrials.gov/study/NCT07428044","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","route":"/trials/nct07428044/","field":"links","label":"ClinicalTrials.gov NCT07428044"}]},{"url":"https://clinicaltrials.gov/study/NCT07429266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","route":"/trials/nct07429266/","field":"links","label":"ClinicalTrials.gov NCT07429266"}]},{"url":"https://clinicaltrials.gov/study/NCT07429643","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07429643","kind":"trial","name":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","route":"/trials/nct07429643/","field":"links","label":"ClinicalTrials.gov NCT07429643"}]},{"url":"https://clinicaltrials.gov/study/NCT07430696","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07430696","kind":"trial","name":"INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY","route":"/trials/nct07430696/","field":"links","label":"ClinicalTrials.gov NCT07430696"}]},{"url":"https://clinicaltrials.gov/study/NCT07431281","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/","field":"links","label":"ClinicalTrials.gov NCT07431281"}]},{"url":"https://clinicaltrials.gov/study/NCT07431827","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","route":"/trials/nct07431827/","field":"links","label":"ClinicalTrials.gov NCT07431827"}]},{"url":"https://clinicaltrials.gov/study/NCT07432295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07432295","kind":"trial","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","route":"/trials/nct07432295/","field":"links","label":"ClinicalTrials.gov NCT07432295"}]},{"url":"https://clinicaltrials.gov/study/NCT07432399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07432399","kind":"trial","name":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","route":"/trials/nct07432399/","field":"links","label":"ClinicalTrials.gov NCT07432399"}]},{"url":"https://clinicaltrials.gov/study/NCT07432633","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","field":"links","label":"ClinicalTrials.gov NCT07432633"}]},{"url":"https://clinicaltrials.gov/study/NCT07433283","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07433283","kind":"trial","name":"Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor","route":"/trials/nct07433283/","field":"links","label":"ClinicalTrials.gov NCT07433283"}]},{"url":"https://clinicaltrials.gov/study/NCT07433673","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07433673","kind":"trial","name":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07433673/","field":"links","label":"ClinicalTrials.gov NCT07433673"}]},{"url":"https://clinicaltrials.gov/study/NCT07435038","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07435038","kind":"trial","name":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct07435038/","field":"links","label":"ClinicalTrials.gov NCT07435038"}]},{"url":"https://clinicaltrials.gov/study/NCT07435584","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07435584","kind":"trial","name":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","route":"/trials/nct07435584/","field":"links","label":"ClinicalTrials.gov NCT07435584"}]},{"url":"https://clinicaltrials.gov/study/NCT07436728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/","field":"links","label":"ClinicalTrials.gov NCT07436728"}]},{"url":"https://clinicaltrials.gov/study/NCT07436741","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07436741","kind":"trial","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","route":"/trials/nct07436741/","field":"links","label":"ClinicalTrials.gov NCT07436741"}]},{"url":"https://clinicaltrials.gov/study/NCT07437287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07437287","kind":"trial","name":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","route":"/trials/nct07437287/","field":"links","label":"ClinicalTrials.gov NCT07437287"}]},{"url":"https://clinicaltrials.gov/study/NCT07438106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07438106","kind":"trial","name":"A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct07438106/","field":"links","label":"ClinicalTrials.gov NCT07438106"}]},{"url":"https://clinicaltrials.gov/study/NCT07439094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","route":"/trials/nct07439094/","field":"links","label":"ClinicalTrials.gov NCT07439094"}]},{"url":"https://clinicaltrials.gov/study/NCT07439653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/","field":"links","label":"ClinicalTrials.gov NCT07439653"}]},{"url":"https://clinicaltrials.gov/study/NCT07440290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07440290","kind":"trial","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","route":"/trials/nct07440290/","field":"links","label":"ClinicalTrials.gov NCT07440290"}]},{"url":"https://clinicaltrials.gov/study/NCT07441174","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07441174/","field":"links","label":"ClinicalTrials.gov NCT07441174"}]},{"url":"https://clinicaltrials.gov/study/NCT07441369","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07441369","kind":"trial","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","route":"/trials/nct07441369/","field":"links","label":"ClinicalTrials.gov NCT07441369"}]},{"url":"https://clinicaltrials.gov/study/NCT07441460","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/","field":"links","label":"ClinicalTrials.gov NCT07441460"}]},{"url":"https://clinicaltrials.gov/study/NCT07441512","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/","field":"links","label":"ClinicalTrials.gov NCT07441512"}]},{"url":"https://clinicaltrials.gov/study/NCT07442565","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","route":"/trials/nct07442565/","field":"links","label":"ClinicalTrials.gov NCT07442565"}]},{"url":"https://clinicaltrials.gov/study/NCT07443397","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","route":"/trials/nct07443397/","field":"links","label":"ClinicalTrials.gov NCT07443397"}]},{"url":"https://clinicaltrials.gov/study/NCT07443475","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07443475","kind":"trial","name":"Electrochemotherapy for Recurrent Vulvar Cancer","route":"/trials/nct07443475/","field":"links","label":"ClinicalTrials.gov NCT07443475"}]},{"url":"https://clinicaltrials.gov/study/NCT07444437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/","field":"links","label":"ClinicalTrials.gov NCT07444437"}]},{"url":"https://clinicaltrials.gov/study/NCT07444541","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct07444541/","field":"links","label":"ClinicalTrials.gov NCT07444541"}]},{"url":"https://clinicaltrials.gov/study/NCT07446153","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07446153","kind":"trial","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","route":"/trials/nct07446153/","field":"links","label":"ClinicalTrials.gov NCT07446153"}]},{"url":"https://clinicaltrials.gov/study/NCT07446270","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07446270","kind":"trial","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","route":"/trials/nct07446270/","field":"links","label":"ClinicalTrials.gov NCT07446270"}]},{"url":"https://clinicaltrials.gov/study/NCT07446322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/","field":"links","label":"ClinicalTrials.gov NCT07446322"}]},{"url":"https://clinicaltrials.gov/study/NCT07446387","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07446387","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","route":"/trials/nct07446387/","field":"links","label":"ClinicalTrials.gov NCT07446387"}]},{"url":"https://clinicaltrials.gov/study/NCT07446855","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","route":"/trials/nct07446855/","field":"links","label":"ClinicalTrials.gov NCT07446855"}]},{"url":"https://clinicaltrials.gov/study/NCT07447050","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07447050","kind":"trial","name":"Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","route":"/trials/nct07447050/","field":"links","label":"ClinicalTrials.gov NCT07447050"}]},{"url":"https://clinicaltrials.gov/study/NCT07447570","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07447570","kind":"trial","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","route":"/trials/nct07447570/","field":"links","label":"ClinicalTrials.gov NCT07447570"}]},{"url":"https://clinicaltrials.gov/study/NCT07448077","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07448077","kind":"trial","name":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","route":"/trials/nct07448077/","field":"links","label":"ClinicalTrials.gov NCT07448077"}]},{"url":"https://clinicaltrials.gov/study/NCT07448116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/","field":"links","label":"ClinicalTrials.gov NCT07448116"}]},{"url":"https://clinicaltrials.gov/study/NCT07448142","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07448142","kind":"trial","name":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07448142/","field":"links","label":"ClinicalTrials.gov NCT07448142"}]},{"url":"https://clinicaltrials.gov/study/NCT07448922","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/","field":"links","label":"ClinicalTrials.gov NCT07448922"}]},{"url":"https://clinicaltrials.gov/study/NCT07449754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/","field":"links","label":"ClinicalTrials.gov NCT07449754"}]},{"url":"https://clinicaltrials.gov/study/NCT07450183","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07450183","kind":"trial","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","route":"/trials/nct07450183/","field":"links","label":"ClinicalTrials.gov NCT07450183"}]},{"url":"https://clinicaltrials.gov/study/NCT07450599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/","field":"links","label":"ClinicalTrials.gov NCT07450599"}]},{"url":"https://clinicaltrials.gov/study/NCT07450859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/","field":"links","label":"ClinicalTrials.gov NCT07450859"}]},{"url":"https://clinicaltrials.gov/study/NCT07450976","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/","field":"links","label":"ClinicalTrials.gov NCT07450976"}]},{"url":"https://clinicaltrials.gov/study/NCT07452198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/","field":"links","label":"ClinicalTrials.gov NCT07452198"}]},{"url":"https://clinicaltrials.gov/study/NCT07452224","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/","field":"links","label":"ClinicalTrials.gov NCT07452224"}]},{"url":"https://clinicaltrials.gov/study/NCT07453394","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/","field":"links","label":"ClinicalTrials.gov NCT07453394"}]},{"url":"https://clinicaltrials.gov/study/NCT07454187","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/","field":"links","label":"ClinicalTrials.gov NCT07454187"}]},{"url":"https://clinicaltrials.gov/study/NCT07454720","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07454720","kind":"trial","name":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07454720/","field":"links","label":"ClinicalTrials.gov NCT07454720"}]},{"url":"https://clinicaltrials.gov/study/NCT07455331","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07455331","kind":"trial","name":"Flash Radiotherapy for Skin Cancer","route":"/trials/nct07455331/","field":"links","label":"ClinicalTrials.gov NCT07455331"}]},{"url":"https://clinicaltrials.gov/study/NCT07455734","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07455734","kind":"trial","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","route":"/trials/nct07455734/","field":"links","label":"ClinicalTrials.gov NCT07455734"}]},{"url":"https://clinicaltrials.gov/study/NCT07455851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/","field":"links","label":"ClinicalTrials.gov NCT07455851"}]},{"url":"https://clinicaltrials.gov/study/NCT07455903","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07455903","kind":"trial","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","route":"/trials/nct07455903/","field":"links","label":"ClinicalTrials.gov NCT07455903"}]},{"url":"https://clinicaltrials.gov/study/NCT07457359","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07457359","kind":"trial","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","route":"/trials/nct07457359/","field":"links","label":"ClinicalTrials.gov NCT07457359"}]},{"url":"https://clinicaltrials.gov/study/NCT07458113","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07458113","kind":"trial","name":"Sac-TMT for Active TNBC Brain Metastases","route":"/trials/nct07458113/","field":"links","label":"ClinicalTrials.gov NCT07458113"}]},{"url":"https://clinicaltrials.gov/study/NCT07458204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","route":"/trials/nct07458204/","field":"links","label":"ClinicalTrials.gov NCT07458204"}]},{"url":"https://clinicaltrials.gov/study/NCT07458529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07458529","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07458529/","field":"links","label":"ClinicalTrials.gov NCT07458529"}]},{"url":"https://clinicaltrials.gov/study/NCT07459634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/","field":"links","label":"ClinicalTrials.gov NCT07459634"}]},{"url":"https://clinicaltrials.gov/study/NCT07459751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07459751","kind":"trial","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07459751/","field":"links","label":"ClinicalTrials.gov NCT07459751"}]},{"url":"https://clinicaltrials.gov/study/NCT07459998","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/","field":"links","label":"ClinicalTrials.gov NCT07459998"}]},{"url":"https://clinicaltrials.gov/study/NCT07460375","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/","field":"links","label":"ClinicalTrials.gov NCT07460375"}]},{"url":"https://clinicaltrials.gov/study/NCT07461454","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/","field":"links","label":"ClinicalTrials.gov NCT07461454"}]},{"url":"https://clinicaltrials.gov/study/NCT07462143","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/","field":"links","label":"ClinicalTrials.gov NCT07462143"}]},{"url":"https://clinicaltrials.gov/study/NCT07462650","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/","field":"links","label":"ClinicalTrials.gov NCT07462650"}]},{"url":"https://clinicaltrials.gov/study/NCT07463235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07463235","kind":"trial","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","route":"/trials/nct07463235/","field":"links","label":"ClinicalTrials.gov NCT07463235"}]},{"url":"https://clinicaltrials.gov/study/NCT07463573","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/","field":"links","label":"ClinicalTrials.gov NCT07463573"}]},{"url":"https://clinicaltrials.gov/study/NCT07463599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07463599","kind":"trial","name":"Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07463599/","field":"links","label":"ClinicalTrials.gov NCT07463599"}]},{"url":"https://clinicaltrials.gov/study/NCT07464327","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","route":"/trials/nct07464327/","field":"links","label":"ClinicalTrials.gov NCT07464327"}]},{"url":"https://clinicaltrials.gov/study/NCT07465757","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/","field":"links","label":"ClinicalTrials.gov NCT07465757"}]},{"url":"https://clinicaltrials.gov/study/NCT07466160","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07466160","kind":"trial","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","route":"/trials/nct07466160/","field":"links","label":"ClinicalTrials.gov NCT07466160"}]},{"url":"https://clinicaltrials.gov/study/NCT07467590","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07467590","kind":"trial","name":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","route":"/trials/nct07467590/","field":"links","label":"ClinicalTrials.gov NCT07467590"}]},{"url":"https://clinicaltrials.gov/study/NCT07467863","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/","field":"links","label":"ClinicalTrials.gov NCT07467863"}]},{"url":"https://clinicaltrials.gov/study/NCT07468071","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","field":"links","label":"ClinicalTrials.gov NCT07468071"}]},{"url":"https://clinicaltrials.gov/study/NCT07468630","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07468630","kind":"trial","name":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","route":"/trials/nct07468630/","field":"links","label":"ClinicalTrials.gov NCT07468630"}]},{"url":"https://clinicaltrials.gov/study/NCT07468851","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/","field":"links","label":"ClinicalTrials.gov NCT07468851"}]},{"url":"https://clinicaltrials.gov/study/NCT07469306","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07469306","kind":"trial","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","route":"/trials/nct07469306/","field":"links","label":"ClinicalTrials.gov NCT07469306"}]},{"url":"https://clinicaltrials.gov/study/NCT07469774","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07469774/","field":"links","label":"ClinicalTrials.gov NCT07469774"}]},{"url":"https://clinicaltrials.gov/study/NCT07469956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07469956","kind":"trial","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","route":"/trials/nct07469956/","field":"links","label":"ClinicalTrials.gov NCT07469956"}]},{"url":"https://clinicaltrials.gov/study/NCT07471165","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07471165","kind":"trial","name":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","route":"/trials/nct07471165/","field":"links","label":"ClinicalTrials.gov NCT07471165"}]},{"url":"https://clinicaltrials.gov/study/NCT07471776","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07471776","kind":"trial","name":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","route":"/trials/nct07471776/","field":"links","label":"ClinicalTrials.gov NCT07471776"}]},{"url":"https://clinicaltrials.gov/study/NCT07471789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/","field":"links","label":"ClinicalTrials.gov NCT07471789"}]},{"url":"https://clinicaltrials.gov/study/NCT07472517","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/","field":"links","label":"ClinicalTrials.gov NCT07472517"}]},{"url":"https://clinicaltrials.gov/study/NCT07472647","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","route":"/trials/nct07472647/","field":"links","label":"ClinicalTrials.gov NCT07472647"}]},{"url":"https://clinicaltrials.gov/study/NCT07472868","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07472868","kind":"trial","name":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","route":"/trials/nct07472868/","field":"links","label":"ClinicalTrials.gov NCT07472868"}]},{"url":"https://clinicaltrials.gov/study/NCT07472933","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07472933","kind":"trial","name":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","route":"/trials/nct07472933/","field":"links","label":"ClinicalTrials.gov NCT07472933"}]},{"url":"https://clinicaltrials.gov/study/NCT07473128","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/","field":"links","label":"ClinicalTrials.gov NCT07473128"}]},{"url":"https://clinicaltrials.gov/study/NCT07473167","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/","field":"links","label":"ClinicalTrials.gov NCT07473167"}]},{"url":"https://clinicaltrials.gov/study/NCT07474727","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/","field":"links","label":"ClinicalTrials.gov NCT07474727"}]},{"url":"https://clinicaltrials.gov/study/NCT07475806","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/","field":"links","label":"ClinicalTrials.gov NCT07475806"}]},{"url":"https://clinicaltrials.gov/study/NCT07476287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/","field":"links","label":"ClinicalTrials.gov NCT07476287"}]},{"url":"https://clinicaltrials.gov/study/NCT07477418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07477418","kind":"trial","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","route":"/trials/nct07477418/","field":"links","label":"ClinicalTrials.gov NCT07477418"}]},{"url":"https://clinicaltrials.gov/study/NCT07477808","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07477808","kind":"trial","name":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","route":"/trials/nct07477808/","field":"links","label":"ClinicalTrials.gov NCT07477808"}]},{"url":"https://clinicaltrials.gov/study/NCT07478523","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07478523","kind":"trial","name":"FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers","route":"/trials/nct07478523/","field":"links","label":"ClinicalTrials.gov NCT07478523"}]},{"url":"https://clinicaltrials.gov/study/NCT07478731","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07478731","kind":"trial","name":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07478731/","field":"links","label":"ClinicalTrials.gov NCT07478731"}]},{"url":"https://clinicaltrials.gov/study/NCT07479485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","route":"/trials/nct07479485/","field":"links","label":"ClinicalTrials.gov NCT07479485"}]},{"url":"https://clinicaltrials.gov/study/NCT07480213","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","field":"links","label":"ClinicalTrials.gov NCT07480213"}]},{"url":"https://clinicaltrials.gov/study/NCT07480356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/","field":"links","label":"ClinicalTrials.gov NCT07480356"}]},{"url":"https://clinicaltrials.gov/study/NCT07480928","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/","field":"links","label":"ClinicalTrials.gov NCT07480928"}]},{"url":"https://clinicaltrials.gov/study/NCT07480954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/","field":"links","label":"ClinicalTrials.gov NCT07480954"}]},{"url":"https://clinicaltrials.gov/study/NCT07481058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07481058","kind":"trial","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","route":"/trials/nct07481058/","field":"links","label":"ClinicalTrials.gov NCT07481058"}]},{"url":"https://clinicaltrials.gov/study/NCT07481786","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07481786","kind":"trial","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","route":"/trials/nct07481786/","field":"links","label":"ClinicalTrials.gov NCT07481786"}]},{"url":"https://clinicaltrials.gov/study/NCT07483554","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/","field":"links","label":"ClinicalTrials.gov NCT07483554"}]},{"url":"https://clinicaltrials.gov/study/NCT07483684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07483684","kind":"trial","name":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal","route":"/trials/nct07483684/","field":"links","label":"ClinicalTrials.gov NCT07483684"}]},{"url":"https://clinicaltrials.gov/study/NCT07483983","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07483983","kind":"trial","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","route":"/trials/nct07483983/","field":"links","label":"ClinicalTrials.gov NCT07483983"}]},{"url":"https://clinicaltrials.gov/study/NCT07483996","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07483996","kind":"trial","name":"Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer","route":"/trials/nct07483996/","field":"links","label":"ClinicalTrials.gov NCT07483996"}]},{"url":"https://clinicaltrials.gov/study/NCT07485452","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07485452","kind":"trial","name":"Boosting Osimertinib Blood Brain Barrier Penetration","route":"/trials/nct07485452/","field":"links","label":"ClinicalTrials.gov NCT07485452"}]},{"url":"https://clinicaltrials.gov/study/NCT07486089","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","route":"/trials/nct07486089/","field":"links","label":"ClinicalTrials.gov NCT07486089"}]},{"url":"https://clinicaltrials.gov/study/NCT07486687","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/","field":"links","label":"ClinicalTrials.gov NCT07486687"}]},{"url":"https://clinicaltrials.gov/study/NCT07486817","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07486817","kind":"trial","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","route":"/trials/nct07486817/","field":"links","label":"ClinicalTrials.gov NCT07486817"}]},{"url":"https://clinicaltrials.gov/study/NCT07487519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07487519","kind":"trial","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","route":"/trials/nct07487519/","field":"links","label":"ClinicalTrials.gov NCT07487519"}]},{"url":"https://clinicaltrials.gov/study/NCT07487805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"ClinicalTrials.gov NCT07487805"},{"id":"nct05318469","kind":"trial","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","route":"/trials/nct05318469/","field":"links","label":"ClinicalTrials.gov NCT07487805"},{"id":"nct07487805","kind":"trial","name":"ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2)","route":"/trials/nct07487805/","field":"links","label":"ClinicalTrials.gov NCT07487805"},{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/","field":"links","label":"ClinicalTrials.gov NCT07487805"}]},{"url":"https://clinicaltrials.gov/study/NCT07488676","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/","field":"links","label":"ClinicalTrials.gov NCT07488676"}]},{"url":"https://clinicaltrials.gov/study/NCT07489066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/","field":"links","label":"ClinicalTrials.gov NCT07489066"}]},{"url":"https://clinicaltrials.gov/study/NCT07489495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/","field":"links","label":"ClinicalTrials.gov NCT07489495"}]},{"url":"https://clinicaltrials.gov/study/NCT07489716","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","route":"/trials/nct07489716/","field":"links","label":"ClinicalTrials.gov NCT07489716"}]},{"url":"https://clinicaltrials.gov/study/NCT07490119","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07490119","kind":"trial","name":"Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer","route":"/trials/nct07490119/","field":"links","label":"ClinicalTrials.gov NCT07490119"}]},{"url":"https://clinicaltrials.gov/study/NCT07490262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/","field":"links","label":"ClinicalTrials.gov NCT07490262"}]},{"url":"https://clinicaltrials.gov/study/NCT07491445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","field":"links","label":"ClinicalTrials.gov NCT07491445"},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/","field":"links","label":"ClinicalTrials.gov NCT07491445"}]},{"url":"https://clinicaltrials.gov/study/NCT07491497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/","field":"links","label":"ClinicalTrials.gov NCT07491497"}]},{"url":"https://clinicaltrials.gov/study/NCT07492342","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","route":"/trials/nct07492342/","field":"links","label":"ClinicalTrials.gov NCT07492342"}]},{"url":"https://clinicaltrials.gov/study/NCT07492641","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07492641","kind":"trial","name":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","route":"/trials/nct07492641/","field":"links","label":"ClinicalTrials.gov NCT07492641"}]},{"url":"https://clinicaltrials.gov/study/NCT07492680","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07492680","kind":"trial","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","route":"/trials/nct07492680/","field":"links","label":"ClinicalTrials.gov NCT07492680"}]},{"url":"https://clinicaltrials.gov/study/NCT07496229","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/","field":"links","label":"ClinicalTrials.gov NCT07496229"}]},{"url":"https://clinicaltrials.gov/study/NCT07497386","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/","field":"links","label":"ClinicalTrials.gov NCT07497386"}]},{"url":"https://clinicaltrials.gov/study/NCT07498478","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/","field":"links","label":"ClinicalTrials.gov NCT07498478"}]},{"url":"https://clinicaltrials.gov/study/NCT07498725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/","field":"links","label":"ClinicalTrials.gov NCT07498725"}]},{"url":"https://clinicaltrials.gov/study/NCT07499362","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","route":"/trials/nct07499362/","field":"links","label":"ClinicalTrials.gov NCT07499362"}]},{"url":"https://clinicaltrials.gov/study/NCT07499674","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07499674","kind":"trial","name":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","route":"/trials/nct07499674/","field":"links","label":"ClinicalTrials.gov NCT07499674"}]},{"url":"https://clinicaltrials.gov/study/NCT07500220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/","field":"links","label":"ClinicalTrials.gov NCT07500220"}]},{"url":"https://clinicaltrials.gov/study/NCT07501169","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/","field":"links","label":"ClinicalTrials.gov NCT07501169"}]},{"url":"https://clinicaltrials.gov/study/NCT07501559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","field":"links","label":"ClinicalTrials.gov NCT07501559"}]},{"url":"https://clinicaltrials.gov/study/NCT07502014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07502014","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","route":"/trials/nct07502014/","field":"links","label":"ClinicalTrials.gov NCT07502014"}]},{"url":"https://clinicaltrials.gov/study/NCT07502287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/","field":"links","label":"ClinicalTrials.gov NCT07502287"}]},{"url":"https://clinicaltrials.gov/study/NCT07502300","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/","field":"links","label":"ClinicalTrials.gov NCT07502300"}]},{"url":"https://clinicaltrials.gov/study/NCT07503639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07503639","kind":"trial","name":"Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07503639/","field":"links","label":"ClinicalTrials.gov NCT07503639"}]},{"url":"https://clinicaltrials.gov/study/NCT07503756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07503756","kind":"trial","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","route":"/trials/nct07503756/","field":"links","label":"ClinicalTrials.gov NCT07503756"}]},{"url":"https://clinicaltrials.gov/study/NCT07504198","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07504198","kind":"trial","name":"Neuroprotection of Memantine and Rosuvastatin","route":"/trials/nct07504198/","field":"links","label":"ClinicalTrials.gov NCT07504198"}]},{"url":"https://clinicaltrials.gov/study/NCT07504263","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07504263","kind":"trial","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","route":"/trials/nct07504263/","field":"links","label":"ClinicalTrials.gov NCT07504263"}]},{"url":"https://clinicaltrials.gov/study/NCT07504471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07504471","kind":"trial","name":"Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metast","route":"/trials/nct07504471/","field":"links","label":"ClinicalTrials.gov NCT07504471"}]},{"url":"https://clinicaltrials.gov/study/NCT07505472","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07505472","kind":"trial","name":"Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuva","route":"/trials/nct07505472/","field":"links","label":"ClinicalTrials.gov NCT07505472"}]},{"url":"https://clinicaltrials.gov/study/NCT07506057","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07506057","kind":"trial","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","route":"/trials/nct07506057/","field":"links","label":"ClinicalTrials.gov NCT07506057"}]},{"url":"https://clinicaltrials.gov/study/NCT07506109","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07506109","kind":"trial","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo","route":"/trials/nct07506109/","field":"links","label":"ClinicalTrials.gov NCT07506109"}]},{"url":"https://clinicaltrials.gov/study/NCT07508761","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/","field":"links","label":"ClinicalTrials.gov NCT07508761"}]},{"url":"https://clinicaltrials.gov/study/NCT07509151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/","field":"links","label":"ClinicalTrials.gov NCT07509151"}]},{"url":"https://clinicaltrials.gov/study/NCT07509398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07509398","kind":"trial","name":"FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer","route":"/trials/nct07509398/","field":"links","label":"ClinicalTrials.gov NCT07509398"}]},{"url":"https://clinicaltrials.gov/study/NCT07509424","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07509424","kind":"trial","name":"Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Ca","route":"/trials/nct07509424/","field":"links","label":"ClinicalTrials.gov NCT07509424"}]},{"url":"https://clinicaltrials.gov/study/NCT07509515","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/","field":"links","label":"ClinicalTrials.gov NCT07509515"}]},{"url":"https://clinicaltrials.gov/study/NCT07510802","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/","field":"links","label":"ClinicalTrials.gov NCT07510802"}]},{"url":"https://clinicaltrials.gov/study/NCT07510815","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/","field":"links","label":"ClinicalTrials.gov NCT07510815"}]},{"url":"https://clinicaltrials.gov/study/NCT07510828","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","route":"/trials/nct07510828/","field":"links","label":"ClinicalTrials.gov NCT07510828"}]},{"url":"https://clinicaltrials.gov/study/NCT07510932","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07510932","kind":"trial","name":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","route":"/trials/nct07510932/","field":"links","label":"ClinicalTrials.gov NCT07510932"}]},{"url":"https://clinicaltrials.gov/study/NCT07512583","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/","field":"links","label":"ClinicalTrials.gov NCT07512583"}]},{"url":"https://clinicaltrials.gov/study/NCT07513376","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/","field":"links","label":"ClinicalTrials.gov NCT07513376"}]},{"url":"https://clinicaltrials.gov/study/NCT07514533","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07514533","kind":"trial","name":"The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma","route":"/trials/nct07514533/","field":"links","label":"ClinicalTrials.gov NCT07514533"}]},{"url":"https://clinicaltrials.gov/study/NCT07515820","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07515820","kind":"trial","name":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07515820/","field":"links","label":"ClinicalTrials.gov NCT07515820"}]},{"url":"https://clinicaltrials.gov/study/NCT07515963","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07515963","kind":"trial","name":"FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.","route":"/trials/nct07515963/","field":"links","label":"ClinicalTrials.gov NCT07515963"}]},{"url":"https://clinicaltrials.gov/study/NCT07516093","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/","field":"links","label":"ClinicalTrials.gov NCT07516093"}]},{"url":"https://clinicaltrials.gov/study/NCT07516210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07516210","kind":"trial","name":"Adaptive Radiotherapy for Safe Hypofractionation","route":"/trials/nct07516210/","field":"links","label":"ClinicalTrials.gov NCT07516210"}]},{"url":"https://clinicaltrials.gov/study/NCT07518147","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07518147","kind":"trial","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","route":"/trials/nct07518147/","field":"links","label":"ClinicalTrials.gov NCT07518147"}]},{"url":"https://clinicaltrials.gov/study/NCT07518173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07518173","kind":"trial","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","route":"/trials/nct07518173/","field":"links","label":"ClinicalTrials.gov NCT07518173"}]},{"url":"https://clinicaltrials.gov/study/NCT07518186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/","field":"links","label":"ClinicalTrials.gov NCT07518186"}]},{"url":"https://clinicaltrials.gov/study/NCT07519772","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/","field":"links","label":"ClinicalTrials.gov NCT07519772"}]},{"url":"https://clinicaltrials.gov/study/NCT07520006","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/","field":"links","label":"ClinicalTrials.gov NCT07520006"}]},{"url":"https://clinicaltrials.gov/study/NCT07520578","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07520578","kind":"trial","name":"EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENIN","route":"/trials/nct07520578/","field":"links","label":"ClinicalTrials.gov NCT07520578"}]},{"url":"https://clinicaltrials.gov/study/NCT07521605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07521605","kind":"trial","name":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer","route":"/trials/nct07521605/","field":"links","label":"ClinicalTrials.gov NCT07521605"}]},{"url":"https://clinicaltrials.gov/study/NCT07521852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/","field":"links","label":"ClinicalTrials.gov NCT07521852"}]},{"url":"https://clinicaltrials.gov/study/NCT07522073","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","field":"links","label":"ClinicalTrials.gov NCT07522073"},{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/","field":"links","label":"ClinicalTrials.gov NCT07522073"}]},{"url":"https://clinicaltrials.gov/study/NCT07522151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","route":"/trials/nct07522151/","field":"links","label":"ClinicalTrials.gov NCT07522151"}]},{"url":"https://clinicaltrials.gov/study/NCT07523529","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/","field":"links","label":"ClinicalTrials.gov NCT07523529"}]},{"url":"https://clinicaltrials.gov/study/NCT07523555","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/","field":"links","label":"ClinicalTrials.gov NCT07523555"}]},{"url":"https://clinicaltrials.gov/study/NCT07525206","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07525206","kind":"trial","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","field":"links","label":"ClinicalTrials.gov NCT07525206"}]},{"url":"https://clinicaltrials.gov/study/NCT07527026","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07527026","kind":"trial","name":"A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS","route":"/trials/nct07527026/","field":"links","label":"ClinicalTrials.gov NCT07527026"}]},{"url":"https://clinicaltrials.gov/study/NCT07527520","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07527520","kind":"trial","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp","route":"/trials/nct07527520/","field":"links","label":"ClinicalTrials.gov NCT07527520"}]},{"url":"https://clinicaltrials.gov/study/NCT07527806","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07527806","kind":"trial","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","route":"/trials/nct07527806/","field":"links","label":"ClinicalTrials.gov NCT07527806"}]},{"url":"https://clinicaltrials.gov/study/NCT07527858","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","route":"/trials/nct07527858/","field":"links","label":"ClinicalTrials.gov NCT07527858"}]},{"url":"https://clinicaltrials.gov/study/NCT07528209","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07528209","kind":"trial","name":"Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07528209/","field":"links","label":"ClinicalTrials.gov NCT07528209"}]},{"url":"https://clinicaltrials.gov/study/NCT07528768","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","route":"/trials/nct07528768/","field":"links","label":"ClinicalTrials.gov NCT07528768"}]},{"url":"https://clinicaltrials.gov/study/NCT07529717","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","route":"/trials/nct07529717/","field":"links","label":"ClinicalTrials.gov NCT07529717"}]},{"url":"https://clinicaltrials.gov/study/NCT07529808","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/","field":"links","label":"ClinicalTrials.gov NCT07529808"}]},{"url":"https://clinicaltrials.gov/study/NCT07530445","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07530445","kind":"trial","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","route":"/trials/nct07530445/","field":"links","label":"ClinicalTrials.gov NCT07530445"}]},{"url":"https://clinicaltrials.gov/study/NCT07533123","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/","field":"links","label":"ClinicalTrials.gov NCT07533123"}]},{"url":"https://clinicaltrials.gov/study/NCT07535437","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/","field":"links","label":"ClinicalTrials.gov NCT07535437"}]},{"url":"https://clinicaltrials.gov/study/NCT07535463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/","field":"links","label":"ClinicalTrials.gov NCT07535463"}]},{"url":"https://clinicaltrials.gov/study/NCT07535632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07535632","kind":"trial","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","route":"/trials/nct07535632/","field":"links","label":"ClinicalTrials.gov NCT07535632"}]},{"url":"https://clinicaltrials.gov/study/NCT07537660","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07537660","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel","route":"/trials/nct07537660/","field":"links","label":"ClinicalTrials.gov NCT07537660"}]},{"url":"https://clinicaltrials.gov/study/NCT07537998","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07537998","kind":"trial","name":"Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co","route":"/trials/nct07537998/","field":"links","label":"ClinicalTrials.gov NCT07537998"}]},{"url":"https://clinicaltrials.gov/study/NCT07538271","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/","field":"links","label":"ClinicalTrials.gov NCT07538271"}]},{"url":"https://clinicaltrials.gov/study/NCT07538804","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/","field":"links","label":"ClinicalTrials.gov NCT07538804"}]},{"url":"https://clinicaltrials.gov/study/NCT07539155","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07539155","kind":"trial","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","route":"/trials/nct07539155/","field":"links","label":"ClinicalTrials.gov NCT07539155"}]},{"url":"https://clinicaltrials.gov/study/NCT07541001","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07541001","kind":"trial","name":"PRL3-Zumab in Patients With Advanced Solid Tumors","route":"/trials/nct07541001/","field":"links","label":"ClinicalTrials.gov NCT07541001"}]},{"url":"https://clinicaltrials.gov/study/NCT07541079","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","route":"/trials/nct07541079/","field":"links","label":"ClinicalTrials.gov NCT07541079"}]},{"url":"https://clinicaltrials.gov/study/NCT07541170","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/","field":"links","label":"ClinicalTrials.gov NCT07541170"}]},{"url":"https://clinicaltrials.gov/study/NCT07541430","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07541430","kind":"trial","name":"A Study in Adults With Desmoid Tumors","route":"/trials/nct07541430/","field":"links","label":"ClinicalTrials.gov NCT07541430"}]},{"url":"https://clinicaltrials.gov/study/NCT07542002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07542002","kind":"trial","name":"Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan","route":"/trials/nct07542002/","field":"links","label":"ClinicalTrials.gov NCT07542002"}]},{"url":"https://clinicaltrials.gov/study/NCT07542262","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07542262","kind":"trial","name":"Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers","route":"/trials/nct07542262/","field":"links","label":"ClinicalTrials.gov NCT07542262"}]},{"url":"https://clinicaltrials.gov/study/NCT07543848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07543848","kind":"trial","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot","route":"/trials/nct07543848/","field":"links","label":"ClinicalTrials.gov NCT07543848"}]},{"url":"https://clinicaltrials.gov/study/NCT07544056","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/","field":"links","label":"ClinicalTrials.gov NCT07544056"}]},{"url":"https://clinicaltrials.gov/study/NCT07544654","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07544654","kind":"trial","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","route":"/trials/nct07544654/","field":"links","label":"ClinicalTrials.gov NCT07544654"}]},{"url":"https://clinicaltrials.gov/study/NCT07544784","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07544784","kind":"trial","name":"AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)","route":"/trials/nct07544784/","field":"links","label":"ClinicalTrials.gov NCT07544784"}]},{"url":"https://clinicaltrials.gov/study/NCT07545213","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07545213","kind":"trial","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","route":"/trials/nct07545213/","field":"links","label":"ClinicalTrials.gov NCT07545213"}]},{"url":"https://clinicaltrials.gov/study/NCT07545265","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/","field":"links","label":"ClinicalTrials.gov NCT07545265"}]},{"url":"https://clinicaltrials.gov/study/NCT07545603","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/","field":"links","label":"ClinicalTrials.gov NCT07545603"}]},{"url":"https://clinicaltrials.gov/study/NCT07546500","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/","field":"links","label":"ClinicalTrials.gov NCT07546500"}]},{"url":"https://clinicaltrials.gov/study/NCT07547553","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/","field":"links","label":"ClinicalTrials.gov NCT07547553"}]},{"url":"https://clinicaltrials.gov/study/NCT07548177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/","field":"links","label":"ClinicalTrials.gov NCT07548177"}]},{"url":"https://clinicaltrials.gov/study/NCT07548736","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07548736","kind":"trial","name":"Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury","route":"/trials/nct07548736/","field":"links","label":"ClinicalTrials.gov NCT07548736"}]},{"url":"https://clinicaltrials.gov/study/NCT07549399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07549399","kind":"trial","name":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC","route":"/trials/nct07549399/","field":"links","label":"ClinicalTrials.gov NCT07549399"}]},{"url":"https://clinicaltrials.gov/study/NCT07549412","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/","field":"links","label":"ClinicalTrials.gov NCT07549412"}]},{"url":"https://clinicaltrials.gov/study/NCT07549906","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07549906","kind":"trial","name":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti","route":"/trials/nct07549906/","field":"links","label":"ClinicalTrials.gov NCT07549906"}]},{"url":"https://clinicaltrials.gov/study/NCT07550088","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07550088","kind":"trial","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","route":"/trials/nct07550088/","field":"links","label":"ClinicalTrials.gov NCT07550088"}]},{"url":"https://clinicaltrials.gov/study/NCT07551349","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07551349/","field":"links","label":"ClinicalTrials.gov NCT07551349"}]},{"url":"https://clinicaltrials.gov/study/NCT07551362","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/","field":"links","label":"ClinicalTrials.gov NCT07551362"}]},{"url":"https://clinicaltrials.gov/study/NCT07551414","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551414","kind":"trial","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","route":"/trials/nct07551414/","field":"links","label":"ClinicalTrials.gov NCT07551414"}]},{"url":"https://clinicaltrials.gov/study/NCT07551479","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551479","kind":"trial","name":"SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer","route":"/trials/nct07551479/","field":"links","label":"ClinicalTrials.gov NCT07551479"}]},{"url":"https://clinicaltrials.gov/study/NCT07551596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551596","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","route":"/trials/nct07551596/","field":"links","label":"ClinicalTrials.gov NCT07551596"}]},{"url":"https://clinicaltrials.gov/study/NCT07551635","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","route":"/trials/nct07551635/","field":"links","label":"ClinicalTrials.gov NCT07551635"}]},{"url":"https://clinicaltrials.gov/study/NCT07551778","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07551778","kind":"trial","name":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","route":"/trials/nct07551778/","field":"links","label":"ClinicalTrials.gov NCT07551778"}]},{"url":"https://clinicaltrials.gov/study/NCT07552181","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07552181","kind":"trial","name":"Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer","route":"/trials/nct07552181/","field":"links","label":"ClinicalTrials.gov NCT07552181"}]},{"url":"https://clinicaltrials.gov/study/NCT07553988","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07553988","kind":"trial","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07553988/","field":"links","label":"ClinicalTrials.gov NCT07553988"}]},{"url":"https://clinicaltrials.gov/study/NCT07554339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07554339","kind":"trial","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","route":"/trials/nct07554339/","field":"links","label":"ClinicalTrials.gov NCT07554339"}]},{"url":"https://clinicaltrials.gov/study/NCT07554456","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07554456","kind":"trial","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","route":"/trials/nct07554456/","field":"links","label":"ClinicalTrials.gov NCT07554456"}]},{"url":"https://clinicaltrials.gov/study/NCT07554521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","route":"/trials/nct07554521/","field":"links","label":"ClinicalTrials.gov NCT07554521"}]},{"url":"https://clinicaltrials.gov/study/NCT07554846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07554846","kind":"trial","name":"Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC","route":"/trials/nct07554846/","field":"links","label":"ClinicalTrials.gov NCT07554846"}]},{"url":"https://clinicaltrials.gov/study/NCT07554859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07554859","kind":"trial","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07554859/","field":"links","label":"ClinicalTrials.gov NCT07554859"}]},{"url":"https://clinicaltrials.gov/study/NCT07555938","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/","field":"links","label":"ClinicalTrials.gov NCT07555938"}]},{"url":"https://clinicaltrials.gov/study/NCT07556848","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07556848","kind":"trial","name":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07556848/","field":"links","label":"ClinicalTrials.gov NCT07556848"}]},{"url":"https://clinicaltrials.gov/study/NCT07558083","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07558083","kind":"trial","name":"FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","route":"/trials/nct07558083/","field":"links","label":"ClinicalTrials.gov NCT07558083"}]},{"url":"https://clinicaltrials.gov/study/NCT07558733","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","route":"/trials/nct07558733/","field":"links","label":"ClinicalTrials.gov NCT07558733"}]},{"url":"https://clinicaltrials.gov/study/NCT07559760","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07559760","kind":"trial","name":"New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer","route":"/trials/nct07559760/","field":"links","label":"ClinicalTrials.gov NCT07559760"}]},{"url":"https://clinicaltrials.gov/study/NCT07559929","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","route":"/trials/nct07559929/","field":"links","label":"ClinicalTrials.gov NCT07559929"}]},{"url":"https://clinicaltrials.gov/study/NCT07560111","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/","field":"links","label":"ClinicalTrials.gov NCT07560111"}]},{"url":"https://clinicaltrials.gov/study/NCT07560358","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07560358","kind":"trial","name":"Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct07560358/","field":"links","label":"ClinicalTrials.gov NCT07560358"}]},{"url":"https://clinicaltrials.gov/study/NCT07561060","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07561060","kind":"trial","name":"Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","route":"/trials/nct07561060/","field":"links","label":"ClinicalTrials.gov NCT07561060"}]},{"url":"https://clinicaltrials.gov/study/NCT07561463","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07561463","kind":"trial","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","route":"/trials/nct07561463/","field":"links","label":"ClinicalTrials.gov NCT07561463"}]},{"url":"https://clinicaltrials.gov/study/NCT07561775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07561775","kind":"trial","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","route":"/trials/nct07561775/","field":"links","label":"ClinicalTrials.gov NCT07561775"}]},{"url":"https://clinicaltrials.gov/study/NCT07562022","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562022","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct07562022/","field":"links","label":"ClinicalTrials.gov NCT07562022"}]},{"url":"https://clinicaltrials.gov/study/NCT07562152","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/","field":"links","label":"ClinicalTrials.gov NCT07562152"}]},{"url":"https://clinicaltrials.gov/study/NCT07562490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562490","kind":"trial","name":"A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","route":"/trials/nct07562490/","field":"links","label":"ClinicalTrials.gov NCT07562490"}]},{"url":"https://clinicaltrials.gov/study/NCT07562503","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562503","kind":"trial","name":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","route":"/trials/nct07562503/","field":"links","label":"ClinicalTrials.gov NCT07562503"}]},{"url":"https://clinicaltrials.gov/study/NCT07562581","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/","field":"links","label":"ClinicalTrials.gov NCT07562581"}]},{"url":"https://clinicaltrials.gov/study/NCT07562659","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562659","kind":"trial","name":"Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer","route":"/trials/nct07562659/","field":"links","label":"ClinicalTrials.gov NCT07562659"}]},{"url":"https://clinicaltrials.gov/study/NCT07562711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07562711","kind":"trial","name":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","route":"/trials/nct07562711/","field":"links","label":"ClinicalTrials.gov NCT07562711"}]},{"url":"https://clinicaltrials.gov/study/NCT07563738","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/","field":"links","label":"ClinicalTrials.gov NCT07563738"}]},{"url":"https://clinicaltrials.gov/study/NCT07564141","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/","field":"links","label":"ClinicalTrials.gov NCT07564141"}]},{"url":"https://clinicaltrials.gov/study/NCT07564401","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/","field":"links","label":"ClinicalTrials.gov NCT07564401"}]},{"url":"https://clinicaltrials.gov/study/NCT07565285","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/","field":"links","label":"ClinicalTrials.gov NCT07565285"}]},{"url":"https://clinicaltrials.gov/study/NCT07566052","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/","field":"links","label":"ClinicalTrials.gov NCT07566052"}]},{"url":"https://clinicaltrials.gov/study/NCT07566156","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/","field":"links","label":"ClinicalTrials.gov NCT07566156"}]},{"url":"https://clinicaltrials.gov/study/NCT07567014","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07567014","kind":"trial","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","route":"/trials/nct07567014/","field":"links","label":"ClinicalTrials.gov NCT07567014"}]},{"url":"https://clinicaltrials.gov/study/NCT07567521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","field":"links","label":"ClinicalTrials.gov NCT07567521"}]},{"url":"https://clinicaltrials.gov/study/NCT07567846","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","route":"/trials/nct07567846/","field":"links","label":"ClinicalTrials.gov NCT07567846"}]},{"url":"https://clinicaltrials.gov/study/NCT07569042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07569042","kind":"trial","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct07569042/","field":"links","label":"ClinicalTrials.gov NCT07569042"}]},{"url":"https://clinicaltrials.gov/study/NCT07569679","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07569679","kind":"trial","name":"Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer","route":"/trials/nct07569679/","field":"links","label":"ClinicalTrials.gov NCT07569679"}]},{"url":"https://clinicaltrials.gov/study/NCT07570173","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/","field":"links","label":"ClinicalTrials.gov NCT07570173"}]},{"url":"https://clinicaltrials.gov/study/NCT07570823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07570823","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct07570823/","field":"links","label":"ClinicalTrials.gov NCT07570823"}]},{"url":"https://clinicaltrials.gov/study/NCT07570849","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07570849","kind":"trial","name":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct07570849/","field":"links","label":"ClinicalTrials.gov NCT07570849"}]},{"url":"https://clinicaltrials.gov/study/NCT07570914","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07570914","kind":"trial","name":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases","route":"/trials/nct07570914/","field":"links","label":"ClinicalTrials.gov NCT07570914"}]},{"url":"https://clinicaltrials.gov/study/NCT07572396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07572396","kind":"trial","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","route":"/trials/nct07572396/","field":"links","label":"ClinicalTrials.gov NCT07572396"}]},{"url":"https://clinicaltrials.gov/study/NCT07575191","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07575191","kind":"trial","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","route":"/trials/nct07575191/","field":"links","label":"ClinicalTrials.gov NCT07575191"}]},{"url":"https://clinicaltrials.gov/study/NCT07576725","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07576725","kind":"trial","name":"Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial","route":"/trials/nct07576725/","field":"links","label":"ClinicalTrials.gov NCT07576725"}]},{"url":"https://clinicaltrials.gov/study/NCT07578337","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07578337","kind":"trial","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","route":"/trials/nct07578337/","field":"links","label":"ClinicalTrials.gov NCT07578337"}]},{"url":"https://clinicaltrials.gov/study/NCT07579234","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/","field":"links","label":"ClinicalTrials.gov NCT07579234"}]},{"url":"https://clinicaltrials.gov/study/NCT07580339","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07580339","kind":"trial","name":"Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07580339/","field":"links","label":"ClinicalTrials.gov NCT07580339"}]},{"url":"https://clinicaltrials.gov/study/NCT07581002","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07581002","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct07581002/","field":"links","label":"ClinicalTrials.gov NCT07581002"}]},{"url":"https://clinicaltrials.gov/study/NCT07581314","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07581314","kind":"trial","name":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07581314/","field":"links","label":"ClinicalTrials.gov NCT07581314"}]},{"url":"https://clinicaltrials.gov/study/NCT07581626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07581626","kind":"trial","name":"Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced","route":"/trials/nct07581626/","field":"links","label":"ClinicalTrials.gov NCT07581626"}]},{"url":"https://clinicaltrials.gov/study/NCT07581912","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07581912","kind":"trial","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","route":"/trials/nct07581912/","field":"links","label":"ClinicalTrials.gov NCT07581912"}]},{"url":"https://clinicaltrials.gov/study/NCT07582315","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07582315","kind":"trial","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","route":"/trials/nct07582315/","field":"links","label":"ClinicalTrials.gov NCT07582315"}]},{"url":"https://clinicaltrials.gov/study/NCT07582432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","route":"/trials/nct07582432/","field":"links","label":"ClinicalTrials.gov NCT07582432"}]},{"url":"https://clinicaltrials.gov/study/NCT07583511","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07583511","kind":"trial","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","route":"/trials/nct07583511/","field":"links","label":"ClinicalTrials.gov NCT07583511"}]},{"url":"https://clinicaltrials.gov/study/NCT07585266","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07585266","kind":"trial","name":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","route":"/trials/nct07585266/","field":"links","label":"ClinicalTrials.gov NCT07585266"}]},{"url":"https://clinicaltrials.gov/study/NCT07585279","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07585279","kind":"trial","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct07585279/","field":"links","label":"ClinicalTrials.gov NCT07585279"}]},{"url":"https://clinicaltrials.gov/study/NCT07586124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07586124","kind":"trial","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","route":"/trials/nct07586124/","field":"links","label":"ClinicalTrials.gov NCT07586124"}]},{"url":"https://clinicaltrials.gov/study/NCT07586202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","route":"/trials/nct07586202/","field":"links","label":"ClinicalTrials.gov NCT07586202"}]},{"url":"https://clinicaltrials.gov/study/NCT07586813","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07586813","kind":"trial","name":"Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors","route":"/trials/nct07586813/","field":"links","label":"ClinicalTrials.gov NCT07586813"}]},{"url":"https://clinicaltrials.gov/study/NCT07586943","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/","field":"links","label":"ClinicalTrials.gov NCT07586943"}]},{"url":"https://clinicaltrials.gov/study/NCT07589257","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/","field":"links","label":"ClinicalTrials.gov NCT07589257"}]},{"url":"https://clinicaltrials.gov/study/NCT07589517","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/","field":"links","label":"ClinicalTrials.gov NCT07589517"}]},{"url":"https://clinicaltrials.gov/study/NCT07589530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/","field":"links","label":"ClinicalTrials.gov NCT07589530"}]},{"url":"https://clinicaltrials.gov/study/NCT07589543","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/","field":"links","label":"ClinicalTrials.gov NCT07589543"}]},{"url":"https://clinicaltrials.gov/study/NCT07589569","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","route":"/trials/nct07589569/","field":"links","label":"ClinicalTrials.gov NCT07589569"}]},{"url":"https://clinicaltrials.gov/study/NCT07589634","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/","field":"links","label":"ClinicalTrials.gov NCT07589634"}]},{"url":"https://clinicaltrials.gov/study/NCT07590531","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/","field":"links","label":"ClinicalTrials.gov NCT07590531"}]},{"url":"https://clinicaltrials.gov/study/NCT07590934","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","field":"links","label":"ClinicalTrials.gov NCT07590934"}]},{"url":"https://clinicaltrials.gov/study/NCT07591090","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07591090","kind":"trial","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","route":"/trials/nct07591090/","field":"links","label":"ClinicalTrials.gov NCT07591090"}]},{"url":"https://clinicaltrials.gov/study/NCT07591597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07591597","kind":"trial","name":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F","route":"/trials/nct07591597/","field":"links","label":"ClinicalTrials.gov NCT07591597"}]},{"url":"https://clinicaltrials.gov/study/NCT07594106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07594106","kind":"trial","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","route":"/trials/nct07594106/","field":"links","label":"ClinicalTrials.gov NCT07594106"}]},{"url":"https://clinicaltrials.gov/study/NCT07594626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07594626","kind":"trial","name":"BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion","route":"/trials/nct07594626/","field":"links","label":"ClinicalTrials.gov NCT07594626"}]},{"url":"https://clinicaltrials.gov/study/NCT07594925","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07594925","kind":"trial","name":"Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz","route":"/trials/nct07594925/","field":"links","label":"ClinicalTrials.gov NCT07594925"}]},{"url":"https://clinicaltrials.gov/study/NCT07595172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07595172","kind":"trial","name":"NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","route":"/trials/nct07595172/","field":"links","label":"ClinicalTrials.gov NCT07595172"}]},{"url":"https://clinicaltrials.gov/study/NCT07595276","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07595276","kind":"trial","name":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat","route":"/trials/nct07595276/","field":"links","label":"ClinicalTrials.gov NCT07595276"}]},{"url":"https://clinicaltrials.gov/study/NCT07595835","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07595835","kind":"trial","name":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer","route":"/trials/nct07595835/","field":"links","label":"ClinicalTrials.gov NCT07595835"}]},{"url":"https://clinicaltrials.gov/study/NCT07595874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07595874","kind":"trial","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","route":"/trials/nct07595874/","field":"links","label":"ClinicalTrials.gov NCT07595874"}]},{"url":"https://clinicaltrials.gov/study/NCT07596290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07596290","kind":"trial","name":"Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC","route":"/trials/nct07596290/","field":"links","label":"ClinicalTrials.gov NCT07596290"}]},{"url":"https://clinicaltrials.gov/study/NCT07597629","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/","field":"links","label":"ClinicalTrials.gov NCT07597629"}]},{"url":"https://clinicaltrials.gov/study/NCT07598318","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07598318","kind":"trial","name":"Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations","route":"/trials/nct07598318/","field":"links","label":"ClinicalTrials.gov NCT07598318"}]},{"url":"https://clinicaltrials.gov/study/NCT07598955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/","field":"links","label":"ClinicalTrials.gov NCT07598955"}]},{"url":"https://clinicaltrials.gov/study/NCT07599995","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07599995","kind":"trial","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","route":"/trials/nct07599995/","field":"links","label":"ClinicalTrials.gov NCT07599995"}]},{"url":"https://clinicaltrials.gov/study/NCT07600268","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07600268","kind":"trial","name":"Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07600268/","field":"links","label":"ClinicalTrials.gov NCT07600268"}]},{"url":"https://clinicaltrials.gov/study/NCT07601048","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07601048","kind":"trial","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","route":"/trials/nct07601048/","field":"links","label":"ClinicalTrials.gov NCT07601048"}]},{"url":"https://clinicaltrials.gov/study/NCT07601178","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","route":"/trials/nct07601178/","field":"links","label":"ClinicalTrials.gov NCT07601178"}]},{"url":"https://clinicaltrials.gov/study/NCT07602777","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","route":"/trials/nct07602777/","field":"links","label":"ClinicalTrials.gov NCT07602777"}]},{"url":"https://clinicaltrials.gov/study/NCT07602842","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/","field":"links","label":"ClinicalTrials.gov NCT07602842"}]},{"url":"https://clinicaltrials.gov/study/NCT07602855","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","route":"/trials/nct07602855/","field":"links","label":"ClinicalTrials.gov NCT07602855"}]},{"url":"https://clinicaltrials.gov/study/NCT07603791","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07603791","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC","route":"/trials/nct07603791/","field":"links","label":"ClinicalTrials.gov NCT07603791"}]},{"url":"https://clinicaltrials.gov/study/NCT07604766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/","field":"links","label":"ClinicalTrials.gov NCT07604766"}]},{"url":"https://clinicaltrials.gov/study/NCT07604909","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07604909","kind":"trial","name":"A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy","route":"/trials/nct07604909/","field":"links","label":"ClinicalTrials.gov NCT07604909"}]},{"url":"https://clinicaltrials.gov/study/NCT07605728","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07605728","kind":"trial","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","route":"/trials/nct07605728/","field":"links","label":"ClinicalTrials.gov NCT07605728"}]},{"url":"https://clinicaltrials.gov/study/NCT07605962","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","route":"/trials/nct07605962/","field":"links","label":"ClinicalTrials.gov NCT07605962"}]},{"url":"https://clinicaltrials.gov/study/NCT07606599","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07606599","kind":"trial","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","route":"/trials/nct07606599/","field":"links","label":"ClinicalTrials.gov NCT07606599"}]},{"url":"https://clinicaltrials.gov/study/NCT07608159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07608159","kind":"trial","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","route":"/trials/nct07608159/","field":"links","label":"ClinicalTrials.gov NCT07608159"}]},{"url":"https://clinicaltrials.gov/study/NCT07609251","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07609251","kind":"trial","name":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study","route":"/trials/nct07609251/","field":"links","label":"ClinicalTrials.gov NCT07609251"}]},{"url":"https://clinicaltrials.gov/study/NCT07609823","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/","field":"links","label":"ClinicalTrials.gov NCT07609823"}]},{"url":"https://clinicaltrials.gov/study/NCT07609862","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/","field":"links","label":"ClinicalTrials.gov NCT07609862"}]},{"url":"https://clinicaltrials.gov/study/NCT07610525","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","route":"/trials/nct07610525/","field":"links","label":"ClinicalTrials.gov NCT07610525"}]},{"url":"https://clinicaltrials.gov/study/NCT07610798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/","field":"links","label":"ClinicalTrials.gov NCT07610798"}]},{"url":"https://clinicaltrials.gov/study/NCT07611110","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","field":"links","label":"ClinicalTrials.gov NCT07611110"}]},{"url":"https://clinicaltrials.gov/study/NCT07612007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07612007","kind":"trial","name":"HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization","route":"/trials/nct07612007/","field":"links","label":"ClinicalTrials.gov NCT07612007"}]},{"url":"https://clinicaltrials.gov/study/NCT07612280","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07612280","kind":"trial","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","route":"/trials/nct07612280/","field":"links","label":"ClinicalTrials.gov NCT07612280"}]},{"url":"https://clinicaltrials.gov/study/NCT07612891","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/","field":"links","label":"ClinicalTrials.gov NCT07612891"}]},{"url":"https://clinicaltrials.gov/study/NCT07615101","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","field":"links","label":"ClinicalTrials.gov NCT07615101"}]},{"url":"https://clinicaltrials.gov/study/NCT07617389","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07617389","kind":"trial","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","route":"/trials/nct07617389/","field":"links","label":"ClinicalTrials.gov NCT07617389"}]},{"url":"https://clinicaltrials.gov/study/NCT07617493","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/","field":"links","label":"ClinicalTrials.gov NCT07617493"}]},{"url":"https://clinicaltrials.gov/study/NCT07617753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/","field":"links","label":"ClinicalTrials.gov NCT07617753"}]},{"url":"https://clinicaltrials.gov/study/NCT07617805","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/","field":"links","label":"ClinicalTrials.gov NCT07617805"}]},{"url":"https://clinicaltrials.gov/study/NCT07619521","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07619521","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07619521/","field":"links","label":"ClinicalTrials.gov NCT07619521"}]},{"url":"https://clinicaltrials.gov/study/NCT07619898","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07619898","kind":"trial","name":"PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","route":"/trials/nct07619898/","field":"links","label":"ClinicalTrials.gov NCT07619898"}]},{"url":"https://clinicaltrials.gov/study/NCT07620548","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07620548","kind":"trial","name":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","route":"/trials/nct07620548/","field":"links","label":"ClinicalTrials.gov NCT07620548"}]},{"url":"https://clinicaltrials.gov/study/NCT07620574","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07620574","kind":"trial","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","route":"/trials/nct07620574/","field":"links","label":"ClinicalTrials.gov NCT07620574"}]},{"url":"https://clinicaltrials.gov/study/NCT07621159","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07621159","kind":"trial","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","route":"/trials/nct07621159/","field":"links","label":"ClinicalTrials.gov NCT07621159"}]},{"url":"https://clinicaltrials.gov/study/NCT07621497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07621497","kind":"trial","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","route":"/trials/nct07621497/","field":"links","label":"ClinicalTrials.gov NCT07621497"}]},{"url":"https://clinicaltrials.gov/study/NCT07621718","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/","field":"links","label":"ClinicalTrials.gov NCT07621718"}]},{"url":"https://clinicaltrials.gov/study/NCT07622017","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07622017","kind":"trial","name":"KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer","route":"/trials/nct07622017/","field":"links","label":"ClinicalTrials.gov NCT07622017"}]},{"url":"https://clinicaltrials.gov/study/NCT07622186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/","field":"links","label":"ClinicalTrials.gov NCT07622186"}]},{"url":"https://clinicaltrials.gov/study/NCT07622550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07622550","kind":"trial","name":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated A","route":"/trials/nct07622550/","field":"links","label":"ClinicalTrials.gov NCT07622550"}]},{"url":"https://clinicaltrials.gov/study/NCT07622771","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07622771","kind":"trial","name":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","route":"/trials/nct07622771/","field":"links","label":"ClinicalTrials.gov NCT07622771"}]},{"url":"https://clinicaltrials.gov/study/NCT07623356","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/","field":"links","label":"ClinicalTrials.gov NCT07623356"}]},{"url":"https://clinicaltrials.gov/study/NCT07623577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","route":"/trials/nct07623577/","field":"links","label":"ClinicalTrials.gov NCT07623577"}]},{"url":"https://clinicaltrials.gov/study/NCT07623616","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/","field":"links","label":"ClinicalTrials.gov NCT07623616"}]},{"url":"https://clinicaltrials.gov/study/NCT07623642","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07623642","kind":"trial","name":"A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.","route":"/trials/nct07623642/","field":"links","label":"ClinicalTrials.gov NCT07623642"}]},{"url":"https://clinicaltrials.gov/study/NCT07625644","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/","field":"links","label":"ClinicalTrials.gov NCT07625644"}]},{"url":"https://clinicaltrials.gov/study/NCT07627698","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/","field":"links","label":"ClinicalTrials.gov NCT07627698"}]},{"url":"https://clinicaltrials.gov/study/NCT07627711","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/","field":"links","label":"ClinicalTrials.gov NCT07627711"}]},{"url":"https://clinicaltrials.gov/study/NCT07628504","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/","field":"links","label":"ClinicalTrials.gov NCT07628504"}]},{"url":"https://clinicaltrials.gov/study/NCT07629609","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07629609","kind":"trial","name":"BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer","route":"/trials/nct07629609/","field":"links","label":"ClinicalTrials.gov NCT07629609"}]},{"url":"https://clinicaltrials.gov/study/NCT07629726","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/","field":"links","label":"ClinicalTrials.gov NCT07629726"}]},{"url":"https://clinicaltrials.gov/study/NCT07629960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/","field":"links","label":"ClinicalTrials.gov NCT07629960"}]},{"url":"https://clinicaltrials.gov/study/NCT07630974","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07630974","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","route":"/trials/nct07630974/","field":"links","label":"ClinicalTrials.gov NCT07630974"}]},{"url":"https://clinicaltrials.gov/study/NCT07631871","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07631871","kind":"trial","name":"An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","route":"/trials/nct07631871/","field":"links","label":"ClinicalTrials.gov NCT07631871"}]},{"url":"https://clinicaltrials.gov/study/NCT07631884","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07631884","kind":"trial","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","route":"/trials/nct07631884/","field":"links","label":"ClinicalTrials.gov NCT07631884"}]},{"url":"https://clinicaltrials.gov/study/NCT07632118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07632118","kind":"trial","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","route":"/trials/nct07632118/","field":"links","label":"ClinicalTrials.gov NCT07632118"}]},{"url":"https://clinicaltrials.gov/study/NCT07632235","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07632235","kind":"trial","name":"A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct07632235/","field":"links","label":"ClinicalTrials.gov NCT07632235"}]},{"url":"https://clinicaltrials.gov/study/NCT07633873","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","route":"/trials/nct07633873/","field":"links","label":"ClinicalTrials.gov NCT07633873"}]},{"url":"https://clinicaltrials.gov/study/NCT07634471","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/","field":"links","label":"ClinicalTrials.gov NCT07634471"}]},{"url":"https://clinicaltrials.gov/study/NCT07635290","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07635290","kind":"trial","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","route":"/trials/nct07635290/","field":"links","label":"ClinicalTrials.gov NCT07635290"}]},{"url":"https://clinicaltrials.gov/study/NCT07636226","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/","field":"links","label":"ClinicalTrials.gov NCT07636226"}]},{"url":"https://clinicaltrials.gov/study/NCT07636785","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07636785","kind":"trial","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","route":"/trials/nct07636785/","field":"links","label":"ClinicalTrials.gov NCT07636785"}]},{"url":"https://clinicaltrials.gov/study/NCT07636798","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07636798","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","route":"/trials/nct07636798/","field":"links","label":"ClinicalTrials.gov NCT07636798"}]},{"url":"https://clinicaltrials.gov/study/NCT07636824","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07636824","kind":"trial","name":"Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study","route":"/trials/nct07636824/","field":"links","label":"ClinicalTrials.gov NCT07636824"}]},{"url":"https://clinicaltrials.gov/study/NCT07637513","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07637513","kind":"trial","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","route":"/trials/nct07637513/","field":"links","label":"ClinicalTrials.gov NCT07637513"}]},{"url":"https://clinicaltrials.gov/study/NCT07638501","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07638501","kind":"trial","name":"Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer","route":"/trials/nct07638501/","field":"links","label":"ClinicalTrials.gov NCT07638501"}]},{"url":"https://clinicaltrials.gov/study/NCT07638852","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07638852","kind":"trial","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","route":"/trials/nct07638852/","field":"links","label":"ClinicalTrials.gov NCT07638852"}]},{"url":"https://clinicaltrials.gov/study/NCT07639450","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","route":"/trials/nct07639450/","field":"links","label":"ClinicalTrials.gov NCT07639450"}]},{"url":"https://clinicaltrials.gov/study/NCT07640295","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/","field":"links","label":"ClinicalTrials.gov NCT07640295"}]},{"url":"https://clinicaltrials.gov/study/NCT07640789","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/","field":"links","label":"ClinicalTrials.gov NCT07640789"}]},{"url":"https://clinicaltrials.gov/study/NCT07641023","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/","field":"links","label":"ClinicalTrials.gov NCT07641023"}]},{"url":"https://clinicaltrials.gov/study/NCT07641036","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/","field":"links","label":"ClinicalTrials.gov NCT07641036"}]},{"url":"https://clinicaltrials.gov/study/NCT07642024","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/","field":"links","label":"ClinicalTrials.gov NCT07642024"}]},{"url":"https://clinicaltrials.gov/study/NCT07644039","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/","field":"links","label":"ClinicalTrials.gov NCT07644039"}]},{"url":"https://clinicaltrials.gov/study/NCT07644286","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07644286","kind":"trial","name":"A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer","route":"/trials/nct07644286/","field":"links","label":"ClinicalTrials.gov NCT07644286"}]},{"url":"https://clinicaltrials.gov/study/NCT07644559","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/","field":"links","label":"ClinicalTrials.gov NCT07644559"}]},{"url":"https://clinicaltrials.gov/study/NCT07645118","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07645118","kind":"trial","name":"Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer","route":"/trials/nct07645118/","field":"links","label":"ClinicalTrials.gov NCT07645118"}]},{"url":"https://clinicaltrials.gov/study/NCT07646626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/","field":"links","label":"ClinicalTrials.gov NCT07646626"}]},{"url":"https://clinicaltrials.gov/study/NCT07646639","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07646639","kind":"trial","name":"Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC","route":"/trials/nct07646639/","field":"links","label":"ClinicalTrials.gov NCT07646639"}]},{"url":"https://clinicaltrials.gov/study/NCT07647328","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","route":"/trials/nct07647328/","field":"links","label":"ClinicalTrials.gov NCT07647328"}]},{"url":"https://clinicaltrials.gov/study/NCT07648030","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/","field":"links","label":"ClinicalTrials.gov NCT07648030"}]},{"url":"https://clinicaltrials.gov/study/NCT07648264","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","route":"/trials/nct07648264/","field":"links","label":"ClinicalTrials.gov NCT07648264"}]},{"url":"https://clinicaltrials.gov/study/NCT07648914","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07648914","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","route":"/trials/nct07648914/","field":"links","label":"ClinicalTrials.gov NCT07648914"}]},{"url":"https://clinicaltrials.gov/study/NCT07649122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","field":"links","label":"ClinicalTrials.gov NCT07649122"}]},{"url":"https://clinicaltrials.gov/study/NCT07649473","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07649473","kind":"trial","name":"QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","route":"/trials/nct07649473/","field":"links","label":"ClinicalTrials.gov NCT07649473"}]},{"url":"https://clinicaltrials.gov/study/NCT07649980","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07649980","kind":"trial","name":"Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II","route":"/trials/nct07649980/","field":"links","label":"ClinicalTrials.gov NCT07649980"}]},{"url":"https://clinicaltrials.gov/study/NCT07651007","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07651007","kind":"trial","name":"Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR","route":"/trials/nct07651007/","field":"links","label":"ClinicalTrials.gov NCT07651007"}]},{"url":"https://clinicaltrials.gov/study/NCT07653685","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07653685","kind":"trial","name":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan","route":"/trials/nct07653685/","field":"links","label":"ClinicalTrials.gov NCT07653685"}]},{"url":"https://clinicaltrials.gov/study/NCT07654400","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/","field":"links","label":"ClinicalTrials.gov NCT07654400"}]},{"url":"https://clinicaltrials.gov/study/NCT07654530","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07654530","kind":"trial","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","route":"/trials/nct07654530/","field":"links","label":"ClinicalTrials.gov NCT07654530"}]},{"url":"https://clinicaltrials.gov/study/NCT07655622","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07655622","kind":"trial","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","route":"/trials/nct07655622/","field":"links","label":"ClinicalTrials.gov NCT07655622"}]},{"url":"https://clinicaltrials.gov/study/NCT07656376","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07656376","kind":"trial","name":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07656376/","field":"links","label":"ClinicalTrials.gov NCT07656376"}]},{"url":"https://clinicaltrials.gov/study/NCT07656766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07656766","kind":"trial","name":"Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer","route":"/trials/nct07656766/","field":"links","label":"ClinicalTrials.gov NCT07656766"}]},{"url":"https://clinicaltrials.gov/study/NCT07659782","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/","field":"links","label":"ClinicalTrials.gov NCT07659782"}]},{"url":"https://clinicaltrials.gov/study/NCT07659795","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/","field":"links","label":"ClinicalTrials.gov NCT07659795"}]},{"url":"https://clinicaltrials.gov/study/NCT07660094","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/","field":"links","label":"ClinicalTrials.gov NCT07660094"}]},{"url":"https://clinicaltrials.gov/study/NCT07662031","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","route":"/trials/nct07662031/","field":"links","label":"ClinicalTrials.gov NCT07662031"}]},{"url":"https://clinicaltrials.gov/study/NCT07662278","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07662278","kind":"trial","name":"rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer","route":"/trials/nct07662278/","field":"links","label":"ClinicalTrials.gov NCT07662278"}]},{"url":"https://clinicaltrials.gov/study/NCT07662395","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07662395","kind":"trial","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662395/","field":"links","label":"ClinicalTrials.gov NCT07662395"}]},{"url":"https://clinicaltrials.gov/study/NCT07662811","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07662811","kind":"trial","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662811/","field":"links","label":"ClinicalTrials.gov NCT07662811"}]},{"url":"https://clinicaltrials.gov/study/NCT07664150","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","field":"links","label":"ClinicalTrials.gov NCT07664150"}]},{"url":"https://clinicaltrials.gov/study/NCT07665684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07665684","kind":"trial","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","route":"/trials/nct07665684/","field":"links","label":"ClinicalTrials.gov NCT07665684"}]},{"url":"https://clinicaltrials.gov/study/NCT07668453","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07668453","kind":"trial","name":"An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies","route":"/trials/nct07668453/","field":"links","label":"ClinicalTrials.gov NCT07668453"}]},{"url":"https://clinicaltrials.gov/study/NCT07668752","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/","field":"links","label":"ClinicalTrials.gov NCT07668752"}]},{"url":"https://clinicaltrials.gov/study/NCT07669220","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669220","kind":"trial","name":"A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours","route":"/trials/nct07669220/","field":"links","label":"ClinicalTrials.gov NCT07669220"}]},{"url":"https://clinicaltrials.gov/study/NCT07669415","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/","field":"links","label":"ClinicalTrials.gov NCT07669415"}]},{"url":"https://clinicaltrials.gov/study/NCT07669454","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669454","kind":"trial","name":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","route":"/trials/nct07669454/","field":"links","label":"ClinicalTrials.gov NCT07669454"}]},{"url":"https://clinicaltrials.gov/study/NCT07669467","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669467","kind":"trial","name":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","route":"/trials/nct07669467/","field":"links","label":"ClinicalTrials.gov NCT07669467"}]},{"url":"https://clinicaltrials.gov/study/NCT07669519","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","route":"/trials/nct07669519/","field":"links","label":"ClinicalTrials.gov NCT07669519"}]},{"url":"https://clinicaltrials.gov/study/NCT07669779","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/","field":"links","label":"ClinicalTrials.gov NCT07669779"}]},{"url":"https://clinicaltrials.gov/study/NCT07670273","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07670273","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","route":"/trials/nct07670273/","field":"links","label":"ClinicalTrials.gov NCT07670273"}]},{"url":"https://clinicaltrials.gov/study/NCT07670312","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07670312","kind":"trial","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/","field":"links","label":"ClinicalTrials.gov NCT07670312"}]},{"url":"https://clinicaltrials.gov/study/NCT07672223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07672223/","field":"links","label":"ClinicalTrials.gov NCT07672223"}]},{"url":"https://clinicaltrials.gov/study/NCT07672236","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07672236","kind":"trial","name":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","route":"/trials/nct07672236/","field":"links","label":"ClinicalTrials.gov NCT07672236"}]},{"url":"https://clinicaltrials.gov/study/NCT07673029","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/","field":"links","label":"ClinicalTrials.gov NCT07673029"}]},{"url":"https://clinicaltrials.gov/study/NCT07673887","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/","field":"links","label":"ClinicalTrials.gov NCT07673887"}]},{"url":"https://clinicaltrials.gov/study/NCT07674732","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07674732","kind":"trial","name":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07674732/","field":"links","label":"ClinicalTrials.gov NCT07674732"}]},{"url":"https://clinicaltrials.gov/study/NCT07676162","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/","field":"links","label":"ClinicalTrials.gov NCT07676162"}]},{"url":"https://clinicaltrials.gov/study/NCT07677579","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07677579","kind":"trial","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","route":"/trials/nct07677579/","field":"links","label":"ClinicalTrials.gov NCT07677579"}]},{"url":"https://clinicaltrials.gov/study/NCT07678593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/","field":"links","label":"ClinicalTrials.gov NCT07678593"}]},{"url":"https://clinicaltrials.gov/study/NCT07678684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","field":"links","label":"ClinicalTrials.gov NCT07678684"}]},{"url":"https://clinicaltrials.gov/study/NCT07678957","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct07678957/","field":"links","label":"ClinicalTrials.gov NCT07678957"}]},{"url":"https://clinicaltrials.gov/study/NCT07679360","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/","field":"links","label":"ClinicalTrials.gov NCT07679360"}]},{"url":"https://clinicaltrials.gov/study/NCT07679399","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07679399","kind":"trial","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","route":"/trials/nct07679399/","field":"links","label":"ClinicalTrials.gov NCT07679399"}]},{"url":"https://clinicaltrials.gov/study/NCT07680439","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/","field":"links","label":"ClinicalTrials.gov NCT07680439"}]},{"url":"https://clinicaltrials.gov/study/NCT07680764","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/","field":"links","label":"ClinicalTrials.gov NCT07680764"}]},{"url":"https://clinicaltrials.gov/study/NCT07680790","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07680790","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","route":"/trials/nct07680790/","field":"links","label":"ClinicalTrials.gov NCT07680790"}]},{"url":"https://clinicaltrials.gov/study/NCT07681297","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","route":"/trials/nct07681297/","field":"links","label":"ClinicalTrials.gov NCT07681297"}]},{"url":"https://clinicaltrials.gov/study/NCT07681596","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/","field":"links","label":"ClinicalTrials.gov NCT07681596"}]},{"url":"https://clinicaltrials.gov/study/NCT07683221","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07683221","kind":"trial","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","route":"/trials/nct07683221/","field":"links","label":"ClinicalTrials.gov NCT07683221"}]},{"url":"https://clinicaltrials.gov/study/NCT07683403","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07683403","kind":"trial","name":"Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct07683403/","field":"links","label":"ClinicalTrials.gov NCT07683403"}]},{"url":"https://clinicaltrials.gov/study/NCT07683949","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07683949","kind":"trial","name":"Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl","route":"/trials/nct07683949/","field":"links","label":"ClinicalTrials.gov NCT07683949"}]},{"url":"https://clinicaltrials.gov/study/NCT07686640","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07686640","kind":"trial","name":"Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07686640/","field":"links","label":"ClinicalTrials.gov NCT07686640"}]},{"url":"https://clinicaltrials.gov/study/NCT07686796","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07686796","kind":"trial","name":"Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P","route":"/trials/nct07686796/","field":"links","label":"ClinicalTrials.gov NCT07686796"}]},{"url":"https://clinicaltrials.gov/study/NCT07688577","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07688577","kind":"trial","name":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","route":"/trials/nct07688577/","field":"links","label":"ClinicalTrials.gov NCT07688577"}]},{"url":"https://clinicaltrials.gov/study/NCT07689201","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","route":"/trials/nct07689201/","field":"links","label":"ClinicalTrials.gov NCT07689201"}]},{"url":"https://clinicaltrials.gov/study/NCT07689539","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07689539","kind":"trial","name":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07689539/","field":"links","label":"ClinicalTrials.gov NCT07689539"}]},{"url":"https://clinicaltrials.gov/study/NCT07689955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07689955","kind":"trial","name":"A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer","route":"/trials/nct07689955/","field":"links","label":"ClinicalTrials.gov NCT07689955"}]},{"url":"https://clinicaltrials.gov/study/NCT07691489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07691489","kind":"trial","name":"A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer","route":"/trials/nct07691489/","field":"links","label":"ClinicalTrials.gov NCT07691489"}]},{"url":"https://clinicaltrials.gov/study/NCT07691593","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07691593","kind":"trial","name":"Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","route":"/trials/nct07691593/","field":"links","label":"ClinicalTrials.gov NCT07691593"}]},{"url":"https://clinicaltrials.gov/study/NCT07691632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07691632","kind":"trial","name":"Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer","route":"/trials/nct07691632/","field":"links","label":"ClinicalTrials.gov NCT07691632"}]},{"url":"https://clinicaltrials.gov/study/NCT07691775","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/","field":"links","label":"ClinicalTrials.gov NCT07691775"}]},{"url":"https://clinicaltrials.gov/study/NCT07692204","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/","field":"links","label":"ClinicalTrials.gov NCT07692204"}]},{"url":"https://clinicaltrials.gov/study/NCT07692750","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct07692750/","field":"links","label":"ClinicalTrials.gov NCT07692750"}]},{"url":"https://clinicaltrials.gov/study/NCT07693751","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07693751","kind":"trial","name":"A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07693751/","field":"links","label":"ClinicalTrials.gov NCT07693751"}]},{"url":"https://clinicaltrials.gov/study/NCT07697586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/","field":"links","label":"ClinicalTrials.gov NCT07697586"}]},{"url":"https://clinicaltrials.gov/study/NCT07698106","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07698106","kind":"trial","name":"Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","route":"/trials/nct07698106/","field":"links","label":"ClinicalTrials.gov NCT07698106"}]},{"url":"https://clinicaltrials.gov/study/NCT07698613","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07698613","kind":"trial","name":"EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","route":"/trials/nct07698613/","field":"links","label":"ClinicalTrials.gov NCT07698613"}]},{"url":"https://clinicaltrials.gov/study/NCT07699328","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/","field":"links","label":"ClinicalTrials.gov NCT07699328"}]},{"url":"https://clinicaltrials.gov/study/NCT07700160","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/","field":"links","label":"ClinicalTrials.gov NCT07700160"}]},{"url":"https://clinicaltrials.gov/study/NCT07700667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/","field":"links","label":"ClinicalTrials.gov NCT07700667"}]},{"url":"https://clinicaltrials.gov/study/NCT07700719","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07700719","kind":"trial","name":"SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07700719/","field":"links","label":"ClinicalTrials.gov NCT07700719"}]},{"url":"https://clinicaltrials.gov/study/NCT07701122","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07701122","kind":"trial","name":"Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer","route":"/trials/nct07701122/","field":"links","label":"ClinicalTrials.gov NCT07701122"}]},{"url":"https://clinicaltrials.gov/study/NCT07701486","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07701486","kind":"trial","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","route":"/trials/nct07701486/","field":"links","label":"ClinicalTrials.gov NCT07701486"}]},{"url":"https://clinicaltrials.gov/study/NCT07702032","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07702032","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta","route":"/trials/nct07702032/","field":"links","label":"ClinicalTrials.gov NCT07702032"}]},{"url":"https://clinicaltrials.gov/study/NCT07702292","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","field":"links","label":"ClinicalTrials.gov NCT07702292"}]},{"url":"https://clinicaltrials.gov/study/NCT07704177","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07704177","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","route":"/trials/nct07704177/","field":"links","label":"ClinicalTrials.gov NCT07704177"}]},{"url":"https://clinicaltrials.gov/study/NCT07704645","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07704645","kind":"trial","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07704645/","field":"links","label":"ClinicalTrials.gov NCT07704645"}]},{"url":"https://clinicaltrials.gov/study/NCT07705074","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07705074","kind":"trial","name":"FAPI PET Imaging - An Exploratory Study","route":"/trials/nct07705074/","field":"links","label":"ClinicalTrials.gov NCT07705074"}]},{"url":"https://clinicaltrials.gov/study/NCT07705919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/","field":"links","label":"ClinicalTrials.gov NCT07705919"}]},{"url":"https://clinicaltrials.gov/study/NCT07707895","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/","field":"links","label":"ClinicalTrials.gov NCT07707895"}]},{"url":"https://clinicaltrials.gov/study/NCT07710612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","route":"/trials/nct07710612/","field":"links","label":"ClinicalTrials.gov NCT07710612"}]},{"url":"https://clinicaltrials.gov/study/NCT07710885","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/","field":"links","label":"ClinicalTrials.gov NCT07710885"}]},{"url":"https://clinicaltrials.gov/study/NCT07711067","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07711067","kind":"trial","name":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","route":"/trials/nct07711067/","field":"links","label":"ClinicalTrials.gov NCT07711067"}]},{"url":"https://clinicaltrials.gov/study/NCT07714447","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07714447","kind":"trial","name":"Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer","route":"/trials/nct07714447/","field":"links","label":"ClinicalTrials.gov NCT07714447"}]},{"url":"https://clinicaltrials.gov/study/NCT07714668","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/","field":"links","label":"ClinicalTrials.gov NCT07714668"}]},{"url":"https://clinicaltrials.gov/study/NCT07715396","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07715396","kind":"trial","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","route":"/trials/nct07715396/","field":"links","label":"ClinicalTrials.gov NCT07715396"}]},{"url":"https://clinicaltrials.gov/study/NCT07716228","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07716228","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","route":"/trials/nct07716228/","field":"links","label":"ClinicalTrials.gov NCT07716228"}]},{"url":"https://clinicaltrials.gov/study/NCT07718243","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07718243","kind":"trial","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","route":"/trials/nct07718243/","field":"links","label":"ClinicalTrials.gov NCT07718243"}]},{"url":"https://clinicaltrials.gov/study/NCT07718490","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07718490","kind":"trial","name":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer","route":"/trials/nct07718490/","field":"links","label":"ClinicalTrials.gov NCT07718490"}]},{"url":"https://clinicaltrials.gov/study/NCT07718737","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","route":"/trials/nct07718737/","field":"links","label":"ClinicalTrials.gov NCT07718737"}]},{"url":"https://clinicaltrials.gov/study/NCT07720284","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/","field":"links","label":"ClinicalTrials.gov NCT07720284"}]},{"url":"https://clinicaltrials.gov/study/NCT07721259","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","route":"/trials/nct07721259/","field":"links","label":"ClinicalTrials.gov NCT07721259"}]},{"url":"https://clinicaltrials.gov/study/NCT07722494","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/","field":"links","label":"ClinicalTrials.gov NCT07722494"}]},{"url":"https://clinicaltrials.gov/study/NCT07722754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07722754","kind":"trial","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","route":"/trials/nct07722754/","field":"links","label":"ClinicalTrials.gov NCT07722754"}]},{"url":"https://clinicaltrials.gov/study/NCT07723248","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/","field":"links","label":"ClinicalTrials.gov NCT07723248"}]},{"url":"https://clinicaltrials.gov/study/NCT07723469","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07723469","kind":"trial","name":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","route":"/trials/nct07723469/","field":"links","label":"ClinicalTrials.gov NCT07723469"}]},{"url":"https://clinicaltrials.gov/study/NCT07723482","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","route":"/trials/nct07723482/","field":"links","label":"ClinicalTrials.gov NCT07723482"}]},{"url":"https://clinicaltrials.gov/study/NCT07723534","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07723534","kind":"trial","name":"Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers","route":"/trials/nct07723534/","field":"links","label":"ClinicalTrials.gov NCT07723534"}]},{"url":"https://clinicaltrials.gov/study/NCT07724223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07724223","kind":"trial","name":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC","route":"/trials/nct07724223/","field":"links","label":"ClinicalTrials.gov NCT07724223"}]},{"url":"https://clinicaltrials.gov/study/NCT07724756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/","field":"links","label":"ClinicalTrials.gov NCT07724756"}]},{"url":"https://clinicaltrials.gov/study/NCT07726446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07726446","kind":"trial","name":"Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors","route":"/trials/nct07726446/","field":"links","label":"ClinicalTrials.gov NCT07726446"}]},{"url":"https://clinicaltrials.gov/study/NCT07726992","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07726992","kind":"trial","name":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","route":"/trials/nct07726992/","field":"links","label":"ClinicalTrials.gov NCT07726992"}]},{"url":"https://clinicaltrials.gov/study/NCT07728019","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07728019","kind":"trial","name":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","route":"/trials/nct07728019/","field":"links","label":"ClinicalTrials.gov NCT07728019"}]},{"url":"https://clinicaltrials.gov/study/NCT07728955","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07728955","kind":"trial","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","route":"/trials/nct07728955/","field":"links","label":"ClinicalTrials.gov NCT07728955"}]},{"url":"https://clinicaltrials.gov/study/NCT07729033","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07729033","kind":"trial","name":"A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.","route":"/trials/nct07729033/","field":"links","label":"ClinicalTrials.gov NCT07729033"}]},{"url":"https://clinicaltrials.gov/study/NCT07729605","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07729605","kind":"trial","name":"FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC","route":"/trials/nct07729605/","field":"links","label":"ClinicalTrials.gov NCT07729605"}]},{"url":"https://clinicaltrials.gov/study/NCT07729917","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07729917","kind":"trial","name":"Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","route":"/trials/nct07729917/","field":"links","label":"ClinicalTrials.gov NCT07729917"}]},{"url":"https://clinicaltrials.gov/study/NCT07729956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/","field":"links","label":"ClinicalTrials.gov NCT07729956"}]},{"url":"https://clinicaltrials.gov/study/NCT07730021","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/","field":"links","label":"ClinicalTrials.gov NCT07730021"}]},{"url":"https://clinicaltrials.gov/study/NCT07730125","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/","field":"links","label":"ClinicalTrials.gov NCT07730125"}]},{"url":"https://clinicaltrials.gov/study/NCT07730489","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07730489","kind":"trial","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","route":"/trials/nct07730489/","field":"links","label":"ClinicalTrials.gov NCT07730489"}]},{"url":"https://clinicaltrials.gov/study/NCT07730515","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/","field":"links","label":"ClinicalTrials.gov NCT07730515"}]},{"url":"https://clinicaltrials.gov/study/NCT07733115","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07733115","kind":"trial","name":"QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","route":"/trials/nct07733115/","field":"links","label":"ClinicalTrials.gov NCT07733115"}]},{"url":"https://clinicaltrials.gov/study/NCT07734116","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07734116","kind":"trial","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","route":"/trials/nct07734116/","field":"links","label":"ClinicalTrials.gov NCT07734116"}]},{"url":"https://clinicaltrials.gov/study/NCT07735624","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07735624","kind":"trial","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","route":"/trials/nct07735624/","field":"links","label":"ClinicalTrials.gov NCT07735624"}]},{"url":"https://clinicaltrials.gov/study/NCT07736495","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07736495","kind":"trial","name":"Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis","route":"/trials/nct07736495/","field":"links","label":"ClinicalTrials.gov NCT07736495"}]},{"url":"https://clinicaltrials.gov/study/NCT07736612","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07736612","kind":"trial","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","route":"/trials/nct07736612/","field":"links","label":"ClinicalTrials.gov NCT07736612"}]},{"url":"https://clinicaltrials.gov/study/NCT07736937","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/","field":"links","label":"ClinicalTrials.gov NCT07736937"}]},{"url":"https://clinicaltrials.gov/study/NCT07737600","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07737600","kind":"trial","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","route":"/trials/nct07737600/","field":"links","label":"ClinicalTrials.gov NCT07737600"}]},{"url":"https://clinicaltrials.gov/study/NCT07738172","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07738172","kind":"trial","name":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","route":"/trials/nct07738172/","field":"links","label":"ClinicalTrials.gov NCT07738172"}]},{"url":"https://clinicaltrials.gov/study/NCT07739186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07739186","kind":"trial","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","route":"/trials/nct07739186/","field":"links","label":"ClinicalTrials.gov NCT07739186"}]},{"url":"https://clinicaltrials.gov/study/NCT07739199","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07739199","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","route":"/trials/nct07739199/","field":"links","label":"ClinicalTrials.gov NCT07739199"}]},{"url":"https://clinicaltrials.gov/study/NCT07739485","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07739485","kind":"trial","name":"Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study","route":"/trials/nct07739485/","field":"links","label":"ClinicalTrials.gov NCT07739485"}]},{"url":"https://clinicaltrials.gov/study/NCT07739758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/","field":"links","label":"ClinicalTrials.gov NCT07739758"}]},{"url":"https://clinicaltrials.gov/study/NCT07739966","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07739966","kind":"trial","name":"A Study of DS-3939a in Participants With Solid Tumors","route":"/trials/nct07739966/","field":"links","label":"ClinicalTrials.gov NCT07739966"}]},{"url":"https://clinicaltrials.gov/study/NCT07740720","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07740720","kind":"trial","name":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","route":"/trials/nct07740720/","field":"links","label":"ClinicalTrials.gov NCT07740720"}]},{"url":"https://clinicaltrials.gov/study/NCT07742215","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/","field":"links","label":"ClinicalTrials.gov NCT07742215"}]},{"url":"https://clinicaltrials.gov/study/NCT07742956","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07742956","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","route":"/trials/nct07742956/","field":"links","label":"ClinicalTrials.gov NCT07742956"}]},{"url":"https://clinicaltrials.gov/study/NCT07743112","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct07743112/","field":"links","label":"ClinicalTrials.gov NCT07743112"}]},{"url":"https://clinicaltrials.gov/study/NCT07743190","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07743190","kind":"trial","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","route":"/trials/nct07743190/","field":"links","label":"ClinicalTrials.gov NCT07743190"}]},{"url":"https://clinicaltrials.gov/study/NCT07743632","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/","field":"links","label":"ClinicalTrials.gov NCT07743632"}]},{"url":"https://clinicaltrials.gov/study/NCT07743723","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/","field":"links","label":"ClinicalTrials.gov NCT07743723"}]},{"url":"https://clinicaltrials.gov/study/NCT07744256","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","field":"links","label":"ClinicalTrials.gov NCT07744256"}]},{"url":"https://clinicaltrials.gov/study/NCT07744763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/","field":"links","label":"ClinicalTrials.gov NCT07744763"}]},{"url":"https://clinicaltrials.gov/study/NCT07745296","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07745296","kind":"trial","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","route":"/trials/nct07745296/","field":"links","label":"ClinicalTrials.gov NCT07745296"}]},{"url":"https://clinicaltrials.gov/study/NCT07745361","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/","field":"links","label":"ClinicalTrials.gov NCT07745361"}]},{"url":"https://clinicaltrials.gov/study/NCT07745790","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07745790","kind":"trial","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07745790/","field":"links","label":"ClinicalTrials.gov NCT07745790"}]},{"url":"https://clinicaltrials.gov/study/NCT07746388","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07746388","kind":"trial","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","route":"/trials/nct07746388/","field":"links","label":"ClinicalTrials.gov NCT07746388"}]},{"url":"https://clinicaltrials.gov/study/NCT07748611","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07748611","kind":"trial","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","route":"/trials/nct07748611/","field":"links","label":"ClinicalTrials.gov NCT07748611"}]},{"url":"https://clinicaltrials.gov/study/NCT07749586","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07749586","kind":"trial","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","route":"/trials/nct07749586/","field":"links","label":"ClinicalTrials.gov NCT07749586"}]},{"url":"https://clinicaltrials.gov/study/NCT07750041","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07750041","kind":"trial","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07750041/","field":"links","label":"ClinicalTrials.gov NCT07750041"}]},{"url":"https://clinicaltrials.gov/study/NCT07750158","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07750158","kind":"trial","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","route":"/trials/nct07750158/","field":"links","label":"ClinicalTrials.gov NCT07750158"}]},{"url":"https://clinicaltrials.gov/study/NCT07750951","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07750951","kind":"trial","name":"Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A","route":"/trials/nct07750951/","field":"links","label":"ClinicalTrials.gov NCT07750951"}]},{"url":"https://clinicaltrials.gov/study/NCT07751042","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/","field":"links","label":"ClinicalTrials.gov NCT07751042"}]},{"url":"https://clinicaltrials.gov/study/NCT07752550","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","route":"/trials/nct07752550/","field":"links","label":"ClinicalTrials.gov NCT07752550"}]},{"url":"https://clinicaltrials.gov/study/NCT07752875","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07752875","kind":"trial","name":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","route":"/trials/nct07752875/","field":"links","label":"ClinicalTrials.gov NCT07752875"}]},{"url":"https://clinicaltrials.gov/study/NCT07754123","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07754123","kind":"trial","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","route":"/trials/nct07754123/","field":"links","label":"ClinicalTrials.gov NCT07754123"}]},{"url":"https://clinicaltrials.gov/study/NCT07755124","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07755124","kind":"trial","name":"Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial","route":"/trials/nct07755124/","field":"links","label":"ClinicalTrials.gov NCT07755124"}]},{"url":"https://clinicaltrials.gov/study/NCT07756645","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07756645","kind":"trial","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","route":"/trials/nct07756645/","field":"links","label":"ClinicalTrials.gov NCT07756645"}]},{"url":"https://clinicaltrials.gov/study/NCT07761429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/","field":"links","label":"ClinicalTrials.gov NCT07761429"}]},{"url":"https://clinicaltrials.gov/study/NCT07761533","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","route":"/trials/nct07761533/","field":"links","label":"ClinicalTrials.gov NCT07761533"}]},{"url":"https://clinicaltrials.gov/study/NCT07762703","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07762703","kind":"trial","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","route":"/trials/nct07762703/","field":"links","label":"ClinicalTrials.gov NCT07762703"}]},{"url":"https://clinicaltrials.gov/study/NCT07764497","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07764497","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis","route":"/trials/nct07764497/","field":"links","label":"ClinicalTrials.gov NCT07764497"}]},{"url":"https://clinicaltrials.gov/study/NCT07764653","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07764653","kind":"trial","name":"Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer","route":"/trials/nct07764653/","field":"links","label":"ClinicalTrials.gov NCT07764653"}]},{"url":"https://clinicaltrials.gov/study/NCT07764978","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/","field":"links","label":"ClinicalTrials.gov NCT07764978"}]},{"url":"https://clinicaltrials.gov/study/NCT07765433","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ea2197-ivonescimab","kind":"trial","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","route":"/trials/ea2197-ivonescimab/","field":"links","label":"ClinicalTrials.gov NCT07765433"}]},{"url":"https://clinicaltrials.gov/study/NCT07765446","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","field":"links","label":"ClinicalTrials.gov NCT07765446"}]},{"url":"https://clinicaltrials.gov/study/NCT07765667","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07765667","kind":"trial","name":"NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC","route":"/trials/nct07765667/","field":"links","label":"ClinicalTrials.gov NCT07765667"}]},{"url":"https://clinicaltrials.gov/study/NCT07765836","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07765836","kind":"trial","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","route":"/trials/nct07765836/","field":"links","label":"ClinicalTrials.gov NCT07765836"}]},{"url":"https://clinicaltrials.gov/study/NCT07766018","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07766018","kind":"trial","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","route":"/trials/nct07766018/","field":"links","label":"ClinicalTrials.gov NCT07766018"}]},{"url":"https://clinicaltrials.gov/study/NCT07767994","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07767994","kind":"trial","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","route":"/trials/nct07767994/","field":"links","label":"ClinicalTrials.gov NCT07767994"}]},{"url":"https://clinicaltrials.gov/study/NCT07768436","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07768436","kind":"trial","name":"A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","route":"/trials/nct07768436/","field":"links","label":"ClinicalTrials.gov NCT07768436"}]},{"url":"https://clinicaltrials.gov/study/NCT07769502","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07769502","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","route":"/trials/nct07769502/","field":"links","label":"ClinicalTrials.gov NCT07769502"}]},{"url":"https://clinicaltrials.gov/study/NCT07773363","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07773363","kind":"trial","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","route":"/trials/nct07773363/","field":"links","label":"ClinicalTrials.gov NCT07773363"}]},{"url":"https://clinicaltrials.gov/study/NCT07774754","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07774754","kind":"trial","name":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","route":"/trials/nct07774754/","field":"links","label":"ClinicalTrials.gov NCT07774754"}]},{"url":"https://clinicaltrials.gov/study/NCT07775287","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/","field":"links","label":"ClinicalTrials.gov NCT07775287"}]},{"url":"https://clinicaltrials.gov/study/NCT07777211","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/","field":"links","label":"ClinicalTrials.gov NCT07777211"}]},{"url":"https://clinicaltrials.gov/study/NCT07777822","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/","field":"links","label":"ClinicalTrials.gov NCT07777822"}]},{"url":"https://clinicaltrials.gov/study/NCT07778316","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/","field":"links","label":"ClinicalTrials.gov NCT07778316"}]},{"url":"https://clinicaltrials.gov/study/NCT07779694","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07779694","kind":"trial","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","route":"/trials/nct07779694/","field":"links","label":"ClinicalTrials.gov NCT07779694"}]},{"url":"https://clinicaltrials.gov/study/NCT07780838","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07780838","kind":"trial","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","route":"/trials/nct07780838/","field":"links","label":"ClinicalTrials.gov NCT07780838"}]},{"url":"https://clinicaltrials.gov/study/NCT07784374","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07784374","kind":"trial","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","route":"/trials/nct07784374/","field":"links","label":"ClinicalTrials.gov NCT07784374"}]},{"url":"https://clinicaltrials.gov/study/NCT07786428","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07786428","kind":"trial","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","route":"/trials/nct07786428/","field":"links","label":"ClinicalTrials.gov NCT07786428"}]},{"url":"https://clinicaltrials.gov/study/NCT07786766","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07786766","kind":"trial","name":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma","route":"/trials/nct07786766/","field":"links","label":"ClinicalTrials.gov NCT07786766"}]},{"url":"https://clinicaltrials.gov/study/NCT07787429","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07787429","kind":"trial","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","route":"/trials/nct07787429/","field":"links","label":"ClinicalTrials.gov NCT07787429"}]},{"url":"https://clinicaltrials.gov/study/NCT07788222","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/","field":"links","label":"ClinicalTrials.gov NCT07788222"}]},{"url":"https://clinicaltrials.gov/study/NCT07789210","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07789210","kind":"trial","name":"A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan","route":"/trials/nct07789210/","field":"links","label":"ClinicalTrials.gov NCT07789210"}]},{"url":"https://clinicaltrials.gov/study/NCT07790510","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07790510","kind":"trial","name":"HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07790510/","field":"links","label":"ClinicalTrials.gov NCT07790510"}]},{"url":"https://clinicaltrials.gov/study/NCT07791758","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07791758","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07791758/","field":"links","label":"ClinicalTrials.gov NCT07791758"}]},{"url":"https://clinicaltrials.gov/study/NCT07793253","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07793253","kind":"trial","name":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer","route":"/trials/nct07793253/","field":"links","label":"ClinicalTrials.gov NCT07793253"}]},{"url":"https://clinicaltrials.gov/study/NCT07795034","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07795034","kind":"trial","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","route":"/trials/nct07795034/","field":"links","label":"ClinicalTrials.gov NCT07795034"}]},{"url":"https://clinicaltrials.gov/study/NCT07795749","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07795749","kind":"trial","name":"Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)","route":"/trials/nct07795749/","field":"links","label":"ClinicalTrials.gov NCT07795749"}]},{"url":"https://clinicaltrials.gov/study/NCT07796100","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","route":"/trials/nct07796100/","field":"links","label":"ClinicalTrials.gov NCT07796100"}]},{"url":"https://clinicaltrials.gov/study/NCT07796763","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07796763","kind":"trial","name":"A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta","route":"/trials/nct07796763/","field":"links","label":"ClinicalTrials.gov NCT07796763"}]},{"url":"https://clinicaltrials.gov/study/NCT07797244","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07797244","kind":"trial","name":"A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cance","route":"/trials/nct07797244/","field":"links","label":"ClinicalTrials.gov NCT07797244"}]},{"url":"https://clinicaltrials.gov/study/NCT07797816","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07797816","kind":"trial","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","route":"/trials/nct07797816/","field":"links","label":"ClinicalTrials.gov NCT07797816"}]},{"url":"https://clinicaltrials.gov/study/NCT07798947","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07798947","kind":"trial","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","route":"/trials/nct07798947/","field":"links","label":"ClinicalTrials.gov NCT07798947"}]},{"url":"https://clinicaltrials.gov/study/NCT07802184","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","route":"/trials/nct07802184/","field":"links","label":"ClinicalTrials.gov NCT07802184"}]},{"url":"https://clinicaltrials.gov/study/NCT07802418","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07802418","kind":"trial","name":"Molecularly Tailored Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07802418/","field":"links","label":"ClinicalTrials.gov NCT07802418"}]},{"url":"https://clinicaltrials.gov/study/NCT07802626","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","route":"/trials/nct07802626/","field":"links","label":"ClinicalTrials.gov NCT07802626"}]},{"url":"https://clinicaltrials.gov/study/NCT07802821","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07802821","kind":"trial","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","route":"/trials/nct07802821/","field":"links","label":"ClinicalTrials.gov NCT07802821"}]},{"url":"https://clinicaltrials.gov/study/NCT07802834","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07802834","kind":"trial","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","route":"/trials/nct07802834/","field":"links","label":"ClinicalTrials.gov NCT07802834"}]},{"url":"https://clinicaltrials.gov/study/NCT07803783","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","route":"/trials/nct07803783/","field":"links","label":"ClinicalTrials.gov NCT07803783"}]},{"url":"https://clinicaltrials.gov/study/NCT07804186","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/","field":"links","label":"ClinicalTrials.gov NCT07804186"}]},{"url":"https://clinicaltrials.gov/study/NCT07805252","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","route":"/trials/nct07805252/","field":"links","label":"ClinicalTrials.gov NCT07805252"}]},{"url":"https://clinicaltrials.gov/study/NCT07805551","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07805551/","field":"links","label":"ClinicalTrials.gov NCT07805551"}]},{"url":"https://clinicaltrials.gov/study/NCT07805954","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","field":"links","label":"ClinicalTrials.gov NCT07805954"},{"id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/","field":"links","label":"ClinicalTrials.gov NCT07805954"}]},{"url":"https://clinicaltrials.gov/study/NCT07806058","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07806058","kind":"trial","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","route":"/trials/nct07806058/","field":"links","label":"ClinicalTrials.gov NCT07806058"}]},{"url":"https://clinicaltrials.gov/study/NCT07806773","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/","field":"links","label":"ClinicalTrials.gov NCT07806773"}]},{"url":"https://clinicaltrials.gov/study/NCT07807163","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07807163","kind":"trial","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","route":"/trials/nct07807163/","field":"links","label":"ClinicalTrials.gov NCT07807163"}]},{"url":"https://clinicaltrials.gov/study/NCT07807800","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07807800","kind":"trial","name":"A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)","route":"/trials/nct07807800/","field":"links","label":"ClinicalTrials.gov NCT07807800"}]},{"url":"https://clinicaltrials.gov/study/NCT07808138","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07808138","kind":"trial","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","route":"/trials/nct07808138/","field":"links","label":"ClinicalTrials.gov NCT07808138"}]},{"url":"https://clinicaltrials.gov/study/NCT07808151","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07808151","kind":"trial","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","route":"/trials/nct07808151/","field":"links","label":"ClinicalTrials.gov NCT07808151"}]},{"url":"https://clinicaltrials.gov/study/NCT07809256","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07809256","kind":"trial","name":"A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati","route":"/trials/nct07809256/","field":"links","label":"ClinicalTrials.gov NCT07809256"}]},{"url":"https://clinicaltrials.gov/study/NCT07809893","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07809893","kind":"trial","name":"Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients","route":"/trials/nct07809893/","field":"links","label":"ClinicalTrials.gov NCT07809893"}]},{"url":"https://clinicaltrials.gov/study/NCT07810114","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07810114","kind":"trial","name":"Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc","route":"/trials/nct07810114/","field":"links","label":"ClinicalTrials.gov NCT07810114"}]},{"url":"https://clinicaltrials.gov/study/NCT07811037","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","field":"links","label":"ClinicalTrials.gov NCT07811037"}]},{"url":"https://clinicaltrials.gov/study/NCT07811076","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07811076","kind":"trial","name":"Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer","route":"/trials/nct07811076/","field":"links","label":"ClinicalTrials.gov NCT07811076"}]},{"url":"https://clinicaltrials.gov/study/NCT07811193","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/","field":"links","label":"ClinicalTrials.gov NCT07811193"}]},{"url":"https://clinicaltrials.gov/study/NCT07814066","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07814066","kind":"trial","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","route":"/trials/nct07814066/","field":"links","label":"ClinicalTrials.gov NCT07814066"}]},{"url":"https://clinicaltrials.gov/study/NCT07814417","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07814417","kind":"trial","name":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","route":"/trials/nct07814417/","field":"links","label":"ClinicalTrials.gov NCT07814417"}]},{"url":"https://clinicaltrials.gov/study/NCT07814859","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07814859","kind":"trial","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","route":"/trials/nct07814859/","field":"links","label":"ClinicalTrials.gov NCT07814859"}]},{"url":"https://clinicaltrials.gov/study/NCT07815223","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07815223","kind":"trial","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","route":"/trials/nct07815223/","field":"links","label":"ClinicalTrials.gov NCT07815223"}]},{"url":"https://clinicaltrials.gov/study/NCT07815288","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07815288","kind":"trial","name":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases","route":"/trials/nct07815288/","field":"links","label":"ClinicalTrials.gov NCT07815288"}]},{"url":"https://clinicaltrials.gov/study/NCT07815665","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/","field":"links","label":"ClinicalTrials.gov NCT07815665"}]},{"url":"https://clinicaltrials.gov/study/NCT07815834","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07815834","kind":"trial","name":"FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)","route":"/trials/nct07815834/","field":"links","label":"ClinicalTrials.gov NCT07815834"}]},{"url":"https://clinicaltrials.gov/study/NCT07816380","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07816380","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07816380/","field":"links","label":"ClinicalTrials.gov NCT07816380"}]},{"url":"https://clinicaltrials.gov/study/NCT07817888","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07817888","kind":"trial","name":"mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer","route":"/trials/nct07817888/","field":"links","label":"ClinicalTrials.gov NCT07817888"}]},{"url":"https://clinicaltrials.gov/study/NCT07819578","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","route":"/trials/nct07819578/","field":"links","label":"ClinicalTrials.gov NCT07819578"}]},{"url":"https://clinicaltrials.gov/study/NCT07819591","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/","field":"links","label":"ClinicalTrials.gov NCT07819591"}]},{"url":"https://clinicaltrials.gov/study/NCT07819604","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07819604","kind":"trial","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07819604/","field":"links","label":"ClinicalTrials.gov NCT07819604"}]},{"url":"https://clinicaltrials.gov/study/NCT07821684","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07821684","kind":"trial","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","route":"/trials/nct07821684/","field":"links","label":"ClinicalTrials.gov NCT07821684"}]},{"url":"https://clinicaltrials.gov/study/NCT07822542","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","route":"/trials/nct07822542/","field":"links","label":"ClinicalTrials.gov NCT07822542"}]},{"url":"https://clinicaltrials.gov/study/NCT07823049","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/","field":"links","label":"ClinicalTrials.gov NCT07823049"}]},{"url":"https://clinicaltrials.gov/study/NCT07823322","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07823322","kind":"trial","name":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection a","route":"/trials/nct07823322/","field":"links","label":"ClinicalTrials.gov NCT07823322"}]},{"url":"https://clinicaltrials.gov/study/NCT07824882","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07824882","kind":"trial","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","route":"/trials/nct07824882/","field":"links","label":"ClinicalTrials.gov NCT07824882"}]},{"url":"https://clinicaltrials.gov/study/NCT07824960","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07824960","kind":"trial","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","route":"/trials/nct07824960/","field":"links","label":"ClinicalTrials.gov NCT07824960"}]},{"url":"https://clinicaltrials.gov/study/NCT07825753","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07825753","kind":"trial","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","route":"/trials/nct07825753/","field":"links","label":"ClinicalTrials.gov NCT07825753"}]},{"url":"https://clinicaltrials.gov/study/NCT07827053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07827053","kind":"trial","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","route":"/trials/nct07827053/","field":"links","label":"ClinicalTrials.gov NCT07827053"}]},{"url":"https://clinicaltrials.gov/study/NCT07827261","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07827261","kind":"trial","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07827261/","field":"links","label":"ClinicalTrials.gov NCT07827261"}]},{"url":"https://clinicaltrials.gov/study/NCT07828756","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07828756","kind":"trial","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","route":"/trials/nct07828756/","field":"links","label":"ClinicalTrials.gov NCT07828756"}]},{"url":"https://clinicaltrials.gov/study/NCT07829549","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07829549","kind":"trial","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","route":"/trials/nct07829549/","field":"links","label":"ClinicalTrials.gov NCT07829549"}]},{"url":"https://clinicaltrials.gov/study/NCT07829874","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07829874","kind":"trial","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","route":"/trials/nct07829874/","field":"links","label":"ClinicalTrials.gov NCT07829874"}]},{"url":"https://clinicaltrials.gov/study/NCT07831330","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07831330","kind":"trial","name":"Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer","route":"/trials/nct07831330/","field":"links","label":"ClinicalTrials.gov NCT07831330"}]},{"url":"https://clinicaltrials.gov/study/NCT07831863","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07831863","kind":"trial","name":"A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy","route":"/trials/nct07831863/","field":"links","label":"ClinicalTrials.gov NCT07831863"}]},{"url":"https://clinicaltrials.gov/study/NCT07831993","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07831993","kind":"trial","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","route":"/trials/nct07831993/","field":"links","label":"ClinicalTrials.gov NCT07831993"}]},{"url":"https://clinicaltrials.gov/study/NCT07833202","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07833202","kind":"trial","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","route":"/trials/nct07833202/","field":"links","label":"ClinicalTrials.gov NCT07833202"}]},{"url":"https://clinicaltrials.gov/study/NCT07833241","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","route":"/trials/nct07833241/","field":"links","label":"ClinicalTrials.gov NCT07833241"}]},{"url":"https://clinicaltrials.gov/study/NCT07833319","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07833319","kind":"trial","name":"Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer","route":"/trials/nct07833319/","field":"links","label":"ClinicalTrials.gov NCT07833319"}]},{"url":"https://clinicaltrials.gov/study/NCT07837362","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nct07837362","kind":"trial","name":"SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer","route":"/trials/nct07837362/","field":"links","label":"ClinicalTrials.gov NCT07837362"}]},{"url":"https://clinicaltrials.ucsd.edu","status":200,"ok":true,"finalUrl":"https://clinicaltrials.ucsd.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","field":"links","label":"Clinical trials"}]},{"url":"https://clinicomalvarrosa.san.gva.es","status":200,"ok":true,"finalUrl":"https://clinicomalvarrosa.san.gva.es/va/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","field":"links","label":"Hospital Clínico Universitario de Valencia"}]},{"url":"https://cllsociety.org/2026/03/btk-degrader-shows-promise-for-relapsed-cll/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/","field":"toxicity.source (Fatigue)"}]},{"url":"https://cllsociety.org/2026/07/an-update-on-sonrotoclax-plus-zanubrutinib-for-cll/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","route":"/trials/celestial-tncll/","field":"links","label":"CLL Society update (July 2026)"}]},{"url":"https://cmhs.uaeu.ac.ae","status":200,"ok":true,"finalUrl":"https://www.uaeu.ac.ae/en/cmhs/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","field":"links","label":"UAE University College of Medicine"}]},{"url":"https://cmo.health","status":200,"ok":true,"finalUrl":"https://cmo.health/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","field":"links","label":"Official website"},{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","field":"website"}]},{"url":"https://cmrsurgical.com","status":200,"ok":true,"finalUrl":"https://us.cmrsurgical.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-robot-platforms","kind":"technology","name":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","route":"/technologies/surgical-robot-platforms/","field":"links","label":"CMR Surgical: Versius"},{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","route":"/companies/cmr-surgical/","field":"links","label":"Official website"},{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","route":"/companies/cmr-surgical/","field":"website"}]},{"url":"https://cnsidediagnostics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","route":"/companies/cnside-diagnostics/","field":"links","label":"Official website"},{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","route":"/companies/cnside-diagnostics/","field":"website"}]},{"url":"https://cofactorgenomics.com","status":200,"ok":true,"finalUrl":"https://cofactorgenomics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","field":"links","label":"Official website"},{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","field":"website"}]},{"url":"https://colorectalcancer.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","field":"links","label":"Colorectal Cancer Alliance"},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","field":"profiles","label":"Colorectal Cancer Alliance"},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","field":"links","label":"Colorectal Cancer Alliance"},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","field":"url"}]},{"url":"https://commonfund.nih.gov/idg","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-white-space-map","kind":"idea","name":"An annual map of high-burden questions that nobody is funding","route":"/ideas/idea-fund-white-space-map/","field":"links","label":"Illuminating the Druggable Genome"}]},{"url":"https://compare-trials.org/","status":200,"ok":true,"finalUrl":"https://www.compare-trials.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-outcome-switching-monitor","kind":"idea","name":"Automatically detect when a trial changes its outcomes after the fact","route":"/ideas/idea-tr2-outcome-switching-monitor/","field":"links","label":"COMPare trials project"}]},{"url":"https://consensosalud.com.ar/el-hospital-italiano-entre-los-mejores-5-de-america-latina/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","field":"links","label":"Source: Consenso Salud news report naming the Director Médico (September 2025)"},{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","field":"profiles","label":"Consenso Salud report quoting the Director Médico (September 2025)"}]},{"url":"https://convention.bio.org/participating-companies/bulsara-bioworks","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","route":"/companies/bulsara-bioworks/","field":"links","label":"BIO 2026 participant profile"}]},{"url":"https://coppafeel.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","field":"links","label":"CoppaFeel!"},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","field":"profiles","label":"CoppaFeel!"}]},{"url":"https://cormorantcapital.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","field":"links","label":"Official website"},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","field":"website"}]},{"url":"https://corvuspharma.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.corvuspharma.com/our-science/our-pipeline/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://cotahealthcare.com","status":200,"ok":true,"finalUrl":"https://veranahealth.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cota-healthcare","kind":"company","name":"COTA","route":"/companies/cota-healthcare/","field":"links","label":"Official website"},{"id":"cota-healthcare","kind":"company","name":"COTA","route":"/companies/cota-healthcare/","field":"website"}]},{"url":"https://covid-nma.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-funded-living-systematic-reviews","kind":"idea","name":"Funded living systematic reviews for every major cancer indication","route":"/ideas/idea-data-funded-living-systematic-reviews/","field":"links","label":"COVID-NMA living evidence"}]},{"url":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","status":200,"ok":true,"finalUrl":"https://www.clinpgx.org/guideline/PA166251462","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr1-ancestry-aware-pharmacology-programme","kind":"idea","name":"Ancestry-aware pharmacology: drug-level sub-studies across populations before approval","route":"/ideas/idea-tr1-ancestry-aware-pharmacology-programme/","field":"links","label":"CPIC guideline: fluoropyrimidines and DPYD"},{"id":"idea-tr1-pre-emptive-pharmacogenomic-testing","kind":"idea","name":"Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere","route":"/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/","field":"links","label":"CPIC guideline: fluoropyrimidines and DPYD"},{"id":"dpyd-genotyping","kind":"technology","name":"DPYD genotyping and DPD phenotyping before fluoropyrimidines","route":"/technologies/dpyd-genotyping/","field":"links","label":"CPIC guideline for fluoropyrimidines and DPYD"}]},{"url":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","status":200,"ok":true,"finalUrl":"https://www.clinpgx.org/guideline/PA166251442","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tpmt-nudt15-genotyping","kind":"technology","name":"TPMT and NUDT15 genotyping before thiopurines","route":"/technologies/tpmt-nudt15-genotyping/","field":"links","label":"CPIC guideline for thiopurines and TPMT and NUDT15"}]},{"url":"https://ct.catapult.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/","field":"links","label":"Cell and Gene Therapy Catapult"}]},{"url":"https://ctep.cancer.gov/","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/programs/ctep","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr2-combination-template-agreement","kind":"idea","name":"A standard cross-company combination agreement that takes weeks, not years, to sign","route":"/ideas/idea-tr2-combination-template-agreement/","field":"links","label":"NCI CTEP"},{"id":"idea-tr2-public-combination-formulary","kind":"idea","name":"A publicly held library of investigational drugs available for academic combination trials","route":"/ideas/idea-tr2-public-combination-formulary/","field":"links","label":"NCI CTEP"}]},{"url":"https://ctti-clinicaltrials.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-national-master-trial-agreement","kind":"idea","name":"One national master contract and budget template for all cancer trials","route":"/ideas/idea-tr1-national-master-trial-agreement/","field":"links","label":"Clinical Trials Transformation Initiative"},{"id":"idea-tr1-public-trial-cost-benchmarks","kind":"idea","name":"Publish per-patient trial cost benchmarks and target halving them","route":"/ideas/idea-tr1-public-trial-cost-benchmarks/","field":"links","label":"Clinical Trials Transformation Initiative"},{"id":"idea-moon-global-open-trials-os","kind":"idea","name":"A global open trials operating system any hospital can plug into","route":"/ideas/idea-moon-global-open-trials-os/","field":"links","label":"Clinical Trials Transformation Initiative"}]},{"url":"https://cullinantherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","field":"links","label":"Official website"},{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","field":"website"}]},{"url":"https://cure-first.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cure-first","kind":"company","name":"Cure-First","route":"/companies/cure-first/","field":"links","label":"Official website"},{"id":"cure-first","kind":"company","name":"Cure-First","route":"/companies/cure-first/","field":"website"}]},{"url":"https://curie.fr","status":200,"ok":true,"finalUrl":"https://curie.fr/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","field":"links","label":"Official website"},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","field":"website"}]},{"url":"https://cytekbio.com","status":200,"ok":true,"finalUrl":"https://cytekbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cytek-biosciences","kind":"company","name":"Cytek Biosciences","route":"/companies/cytek-biosciences/","field":"links","label":"Official website"},{"id":"cytek-biosciences","kind":"company","name":"Cytek Biosciences","route":"/companies/cytek-biosciences/","field":"website"}]},{"url":"https://cytomx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/","field":"links","label":"Official website"},{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/","field":"website"}]},{"url":"https://cytomx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://d2mp61vkno2eva.cloudfront.net/pdfs/2026-08/a9eb4639f5fd45f32da9363b.pdf","status":200,"ok":true,"contentType":"application/octet-stream","checked":"2026-09-30","refs":[{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","route":"/institutions/israel-cancer-association/","field":"links","label":"Israel Cancer Association annual report 2025 (English PDF)"}]},{"url":"https://da.wikipedia.org/wiki/Sygehus_Lilleb%C3%A6lt","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christian-sauvr","kind":"person","name":"Christian Sauvr","route":"/people/christian-sauvr/","field":"links","label":"Source: Danish Wikipedia article on Sygehus Lillebælt naming the chief executive"},{"id":"christian-sauvr","kind":"person","name":"Christian Sauvr","route":"/people/christian-sauvr/","field":"profiles","label":"Wikipedia: Sygehus Lillebælt (Danish)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=004f93d7-a1cd-4b67-9207-31cdcb5c5976","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alk-fusion","kind":"biomarker","name":"ALK fusion (ALK-positive)","route":"/biomarkers/alk-fusion/","field":"links","label":"Lorbrena prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"dosing.source"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (AST increased)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Fatigue)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Blurred vision)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (ALT increased)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Keratopathy)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Peripheral neuropathy)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Abdominal pain)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Dry eye)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Diarrhoea)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"toxicity.source (Nausea)"},{"id":"folr1-expression","kind":"biomarker","name":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)","route":"/biomarkers/folr1-expression/","field":"links","label":"ELAHERE prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","field":"links","label":"RUBRACA prescribing information (DailyMed)"},{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","field":"links","label":"RUBRACA prescribing information (DailyMed)"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","field":"links","label":"Rubraca prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=046a9011-3911-4d3f-a15f-fbb56d5aad56","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/","field":"links","label":"TEMODAR prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bdadd5-d2db-406f-a3f8-de47f48a52e3","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","field":"links","label":"Unloxcyt label (DailyMed)"},{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"links","label":"Unloxcyt label (DailyMed)"},{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"outcomes.source (Objective response rate, independent central review (locally advanced cohort, US label))"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dmmr-ihc","kind":"biomarker","name":"dMMR (mismatch repair deficiency by IHC)","route":"/biomarkers/dmmr-ihc/","field":"links","label":"Jemperli prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1332a1-0581-4707-9bf6-1eccfa39bef4","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgfr2-fusion-rearrangement","kind":"biomarker","name":"FGFR2 fusion or rearrangement","route":"/biomarkers/fgfr2-fusion-rearrangement/","field":"links","label":"LYTGOBI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"dosing.source"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Diarrhoea)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Nausea)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Fatigue)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Vomiting)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Hepatotoxicity)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Renal impairment)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Dyspnoea)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (Oedema)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"toxicity.source (QT prolongation)"},{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/","field":"links","label":"KRAZATI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c8ca614-58b2-4aa4-83d3-0387a8f782fd","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ntrk-fusion","kind":"biomarker","name":"NTRK1/2/3 gene fusion","route":"/biomarkers/ntrk-fusion/","field":"links","label":"VITRAKVI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102e4ef4-7f84-4e34-8df1-479c24d1575d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","field":"links","label":"Rezurock label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102f96a0-6e3a-4fc1-b204-34d604683af6","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/","field":"links","label":"US label (DailyMed)"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"links","label":"Crysvita label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flt3-itd","kind":"biomarker","name":"FLT3-ITD (internal tandem duplication)","route":"/biomarkers/flt3-itd/","field":"links","label":"RYDAPT prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13839d4f-6acf-4ffb-a128-79df59319273","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/","field":"links","label":"Talzenna prescribing information (DailyMed)"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","field":"links","label":"Talzenna prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"dosing.source"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Rash)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Nail toxicity)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Infusion-related reaction)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Oedema)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Stomatitis)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Venous thromboembolism)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"toxicity.source (Paraesthesia)"},{"id":"egfr-exon-19-deletion","kind":"biomarker","name":"EGFR exon 19 deletion","route":"/biomarkers/egfr-exon-19-deletion/","field":"links","label":"Rybrevant prescribing information (DailyMed)"},{"id":"egfr-exon-20-insertion","kind":"biomarker","name":"EGFR exon 20 insertion","route":"/biomarkers/egfr-exon-20-insertion/","field":"links","label":"Rybrevant prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"dosing.source"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Lymphocytes decreased)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Haemoglobin decreased)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Fatigue)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Dry mouth)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Nausea)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Decreased appetite)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Platelets decreased)"},{"id":"psma-pet-expression","kind":"biomarker","name":"PSMA expression by PET (PSMA-positive)","route":"/biomarkers/psma-pet-expression/","field":"links","label":"PLUVICTO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcr-abl1-t315i","kind":"biomarker","name":"BCR::ABL1 T315I","route":"/biomarkers/bcr-abl1-t315i/","field":"links","label":"Iclusig prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16edd46e-28b8-f06d-e063-6394a90ae31b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ret-fusion","kind":"biomarker","name":"RET fusion and RET mutation","route":"/biomarkers/ret-fusion/","field":"links","label":"Gavreto prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"links","label":"Ensacove label (DailyMed)"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","field":"outcomes.source (Objective response rate (blinded independent central review, US label))"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"dosing.source"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Cytokine release syndrome)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Haemoglobin decreased)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Fatigue)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Dysgeusia)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Pyrexia)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Decreased appetite)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Constipation)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Nausea)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"toxicity.source (Neurologic toxicity incl. ICANS)"},{"id":"dll3-expression","kind":"biomarker","name":"DLL3 expression","route":"/biomarkers/dll3-expression/","field":"links","label":"IMDELLTRA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=203daea4-fc87-40a4-a92f-ba2351b16de1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/","field":"links","label":"BIZENGRI (zenocutuzumab) prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcr-abl1-transcript","kind":"biomarker","name":"BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)","route":"/biomarkers/bcr-abl1-transcript/","field":"links","label":"Gleevec prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"braf-v600e","kind":"biomarker","name":"BRAF V600E (and V600K)","route":"/biomarkers/braf-v600e/","field":"links","label":"BRAFTOVI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"dosing.source"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Fatigue)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Nausea)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Transaminases increased)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Haemorrhage)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Thrombocytopenia)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Headache)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Peripheral neuropathy)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"toxicity.source (Left ventricular dysfunction)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a49f57-d2fc-4ffe-9eb1-fe0460c6b067","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-a-02-01","kind":"biomarker","name":"HLA-A*02:01 (HLA typing for TCR therapies)","route":"/biomarkers/hla-a-02-01/","field":"links","label":"KIMMTRAK prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=269f7363-63ed-444e-85f1-f0009e44818b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","field":"links","label":"Vistogard label (DailyMed)"},{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","field":"outcomes.source (Survival at 30 days or until chemotherapy resumed (US label, Studies 1 and 2 combined))"},{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"dosing.source"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Stomatitis)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Nausea)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Fatigue)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Alopecia)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Constipation)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Dry eye)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Keratitis)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"toxicity.source (Vomiting)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flt3-itd","kind":"biomarker","name":"FLT3-ITD (internal tandem duplication)","route":"/biomarkers/flt3-itd/","field":"links","label":"VANFLYTA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgfr3-alteration","kind":"biomarker","name":"FGFR3 alteration (mutation or fusion)","route":"/biomarkers/fgfr3-alteration/","field":"links","label":"BALVERSA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c3db989-d7ad-41ed-9ebf-698dcf6c24ec","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","field":"links","label":"Defitelio label (DailyMed)"},{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idh1-r132","kind":"biomarker","name":"IDH1 R132 mutation","route":"/biomarkers/idh1-r132/","field":"links","label":"VORANIGO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd33-expression","kind":"biomarker","name":"CD33 expression (CD33-positive)","route":"/biomarkers/cd33-expression/","field":"links","label":"Mylotarg prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-960b-4591-9857-5031ecb830aa","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"dosing.source"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Neurological toxicities)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Pyrexia)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Febrile neutropenia)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Infections)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Cytokine release syndrome)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Infusion-related reactions)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"toxicity.source (Headache)"},{"id":"cd19-expression","kind":"biomarker","name":"CD19 expression (CD19-positive)","route":"/biomarkers/cd19-expression/","field":"links","label":"BLINCYTO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"dosing.source"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Neutropenia)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Peripheral sensory neuropathy)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Constipation)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Nausea)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Vomiting)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"toxicity.source (Febrile neutropenia)"},{"id":"cd30-expression","kind":"biomarker","name":"CD30 expression (CD30-positive)","route":"/biomarkers/cd30-expression/","field":"links","label":"ADCETRIS prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alk-fusion","kind":"biomarker","name":"ALK fusion (ALK-positive)","route":"/biomarkers/alk-fusion/","field":"links","label":"ALECENSA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/","field":"links","label":"LIBTAYO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/","field":"links","label":"TABRECTA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/","field":"links","label":"Herceptin prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab27d2f-e385-4e9c-b324-fa69c10b855a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"Vizimpro label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f83c8f7-4cc0-4219-88d5-7cfddce91198","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hepzato","kind":"drug","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","field":"links","label":"Hepzato Kit label (DailyMed)"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"links","label":"Hepzato Kit label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51ac8e52-3269-4102-8dc8-dba22d82128c","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ros1-fusion","kind":"biomarker","name":"ROS1 fusion (ROS1-positive)","route":"/biomarkers/ros1-fusion/","field":"links","label":"IBTROZI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54e0f974-ccee-44ea-9254-40e9883cee1e","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"dosing.source"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Pyrexia)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Cytokine release syndrome)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Neutrophils decreased)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Injection site reaction)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Fatigue)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Pneumonia)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Neurologic toxicity)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"toxicity.source (Serious infections)"},{"id":"bcma-expression","kind":"biomarker","name":"BCMA expression","route":"/biomarkers/bcma-expression/","field":"links","label":"TECVAYLI prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"dosing.source"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Neutropenia)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Anaemia)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Fatigue)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Diarrhoea)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Nausea)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Alopecia)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Constipation)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Vomiting)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Decreased appetite)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"toxicity.source (Rash)"},{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","route":"/biomarkers/trop2-expression/","field":"links","label":"TRODELVY prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","field":"links","label":"Inluriyo prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3ca-hotspot-mutation","kind":"biomarker","name":"PIK3CA mutation","route":"/biomarkers/pik3ca-hotspot-mutation/","field":"links","label":"Itovebi prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"dosing.source"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Diarrhoea)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Rash)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Dry skin)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Nail toxicity)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Stomatitis)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Fatigue)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Decreased appetite)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Interstitial lung disease)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (Cardiomyopathy)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"toxicity.source (QTc >500 ms)"},{"id":"egfr-exon-19-deletion","kind":"biomarker","name":"EGFR exon 19 deletion","route":"/biomarkers/egfr-exon-19-deletion/","field":"links","label":"TAGRISSO prescribing information (DailyMed)"},{"id":"egfr-l858r","kind":"biomarker","name":"EGFR L858R","route":"/biomarkers/egfr-l858r/","field":"links","label":"TAGRISSO prescribing information (DailyMed)"},{"id":"egfr-t790m","kind":"biomarker","name":"EGFR T790M","route":"/biomarkers/egfr-t790m/","field":"links","label":"TAGRISSO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kit-d816v","kind":"biomarker","name":"KIT D816V","route":"/biomarkers/kit-d816v/","field":"links","label":"AYVAKIT prescribing information (DailyMed)"},{"id":"pdgfra-exon-18-d842v","kind":"biomarker","name":"PDGFRA exon 18 mutation (D842V)","route":"/biomarkers/pdgfra-exon-18-d842v/","field":"links","label":"AYVAKIT prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idh1-r132","kind":"biomarker","name":"IDH1 R132 mutation","route":"/biomarkers/idh1-r132/","field":"links","label":"TIBSOVO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Stromectol label on DailyMed"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"dosing.source"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Pruritus (itching))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Skin oedema, papular, pustular or urticarial rash)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Fever)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Headache (regardless of cause))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Myalgia (regardless of cause))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Arthralgia or synovitis)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Tachycardia (arrhythmia: fast heart rate))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Peripheral oedema)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Facial oedema)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Orthostatic hypotension)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Decrease in white cell count)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Dizziness (neurological, per label))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (ALT or AST elevation)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Diarrhoea)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Nausea)"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Somnolence, vertigo or tremor (neurological, per label))"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"toxicity.source (Neurotoxicity: altered consciousness, stupor, coma, confusion, seizures, death)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a52e4c2-6a9f-4ebb-bc77-046b4f8bcd57","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","field":"links","label":"Valchlor label (DailyMed)"},{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"npm1-mutation","kind":"biomarker","name":"NPM1 mutation","route":"/biomarkers/npm1-mutation/","field":"links","label":"Revuforj prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"dosing.source"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Fatigue/asthenia)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Decreased appetite)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Nausea)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Cough)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Dyspnoea)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Hypothyroidism (immune-mediated))"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Pneumonitis (immune-mediated))"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Hepatitis (immune-mediated))"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"toxicity.source (Colitis (immune-mediated))"},{"id":"pd-l1-ic-score","kind":"biomarker","name":"PD-L1 IC score (immune-cell score, SP142)","route":"/biomarkers/pd-l1-ic-score/","field":"links","label":"TECENTRIQ prescribing information (DailyMed)"},{"id":"pd-l1-tc-score","kind":"biomarker","name":"PD-L1 TC score (tumour-cell score, SP263 and 28-8)","route":"/biomarkers/pd-l1-tc-score/","field":"links","label":"TECENTRIQ prescribing information (DailyMed)"},{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/","field":"links","label":"TECENTRIQ prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","field":"links","label":"Imcivree label (DailyMed)"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"links","label":"Imcivree label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"dosing.source"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Lymphopenia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (GGT increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Vomiting)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Nausea)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (AST increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (ALT increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Hyperglycaemia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Hypokalaemia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Myelodysplastic syndrome)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Acute leukaemia)"},{"id":"sstr-pet-expression","kind":"biomarker","name":"Somatostatin receptor expression by PET (SSTR-positive)","route":"/biomarkers/sstr-pet-expression/","field":"links","label":"Lutathera prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","field":"links","label":"LYNPARZA prescribing information (DailyMed)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"dosing.source"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Nausea)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Fatigue)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Anaemia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Vomiting)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Diarrhoea)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Leukopenia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Neutropenia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (MDS/AML)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Pneumonitis)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Venous thromboembolism (prostate))"},{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/","field":"links","label":"Lynparza prescribing information (DailyMed)"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","field":"links","label":"Lynparza prescribing information (DailyMed)"},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/","field":"links","label":"Lynparza prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d040b91-3fb8-41db-ba7f-60a36f06e2c2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"dosing.source"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Cytokine release syndrome)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Neutropenia (grade 3+))"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Hypogammaglobulinaemia)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Infections (grade 3+))"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (ICANS)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Parkinsonism / movement disorders)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"toxicity.source (Secondary haematological malignancies)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"dosing.source"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Nausea)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Fatigue)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Neutropenia)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Anaemia)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Interstitial lung disease / pneumonitis)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Vomiting)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Alopecia)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Constipation)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"toxicity.source (Decreased appetite)"},{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-ihc-2-plus","kind":"biomarker","name":"HER2 IHC 2+ (equivocal, reflex to ISH)","route":"/biomarkers/her2-ihc-2-plus/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-ihc-1-plus","kind":"biomarker","name":"HER2 IHC 1+","route":"/biomarkers/her2-ihc-1-plus/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-ihc-0","kind":"biomarker","name":"HER2 IHC 0 (HER2-negative, including ultralow)","route":"/biomarkers/her2-ihc-0/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-low-ihc","kind":"biomarker","name":"HER2-low (IHC 1+ or IHC 2+/ISH-negative)","route":"/biomarkers/her2-low-ihc/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-ultralow","kind":"biomarker","name":"HER2-ultralow (IHC 0 with membrane staining)","route":"/biomarkers/her2-ultralow/","field":"links","label":"ENHERTU prescribing information (DailyMed)"},{"id":"her2-mutation","kind":"biomarker","name":"HER2 (ERBB2) activating mutation","route":"/biomarkers/her2-mutation/","field":"links","label":"ENHERTU prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ret-fusion","kind":"biomarker","name":"RET fusion and RET mutation","route":"/biomarkers/ret-fusion/","field":"links","label":"Retevmo prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80a0f1b9-071a-47f5-9e67-32d638a669dc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/","field":"links","label":"TEPMETKO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8245a990-3268-4613-b5c5-9537858a1eb9","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","field":"links","label":"AKEEGA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8670c3cf-82d9-466d-be49-de33d8c8742b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","field":"links","label":"US label (DailyMed)"},{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/","field":"links","label":"Varubi label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"dosing.source"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Pneumonitis (any cause, PACIFIC))"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Cough)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Fatigue)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Radiation pneumonitis)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Upper respiratory infection)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Dyspnoea)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Rash)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9001355e-003d-4d4e-b4ce-337e0fd14952","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gprc5d-expression","kind":"biomarker","name":"GPRC5D expression","route":"/biomarkers/gprc5d-expression/","field":"links","label":"TALVEY prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"dosing.source"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Hypothyroidism (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Pneumonitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Colitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Hepatitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Fatigue)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Rash)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Diarrhoea)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Pyrexia)"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","field":"links","label":"KEYTRUDA prescribing information (DailyMed)"},{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/","field":"links","label":"KEYTRUDA prescribing information (DailyMed)"},{"id":"dmmr-ihc","kind":"biomarker","name":"dMMR (mismatch repair deficiency by IHC)","route":"/biomarkers/dmmr-ihc/","field":"links","label":"KEYTRUDA prescribing information (DailyMed)"},{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/","field":"links","label":"KEYTRUDA prescribing information (DailyMed)"},{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/","field":"links","label":"KEYTRUDA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgfr2-fusion-rearrangement","kind":"biomarker","name":"FGFR2 fusion or rearrangement","route":"/biomarkers/fgfr2-fusion-rearrangement/","field":"links","label":"PEMAZYRE prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd38-expression","kind":"biomarker","name":"CD38 expression","route":"/biomarkers/cd38-expression/","field":"links","label":"DARZALEX prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"remestemcel-l","kind":"drug","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","field":"links","label":"Ryoncil label (DailyMed)"},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"links","label":"Ryoncil label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idh2-mutation","kind":"biomarker","name":"IDH2 mutation (R140 and R172)","route":"/biomarkers/idh2-mutation/","field":"links","label":"Idhifa prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","field":"links","label":"ORSERDU prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"dosing.source"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Neutrophils decreased)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Leukocytes decreased)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Lymphocytes decreased)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Infections)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (ALT/AST increased (grade 3-4))"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Nausea)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Fatigue)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (Diarrhoea)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"toxicity.source (QT prolongation)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab24631f-3364-46e1-8074-7244863bcbab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-a-02-01","kind":"biomarker","name":"HLA-A*02:01 (HLA typing for TCR therapies)","route":"/biomarkers/hla-a-02-01/","field":"links","label":"TECELRA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad45b43e-fdef-47ad-9c34-055b41bdc576","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h3-k27m","kind":"biomarker","name":"H3 K27M mutation","route":"/biomarkers/h3-k27m/","field":"links","label":"MODEYSO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/","field":"links","label":"Venclexta prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd20-expression","kind":"biomarker","name":"CD20 expression (CD20-positive)","route":"/biomarkers/cd20-expression/","field":"links","label":"Rituxan prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3ca-hotspot-mutation","kind":"biomarker","name":"PIK3CA mutation","route":"/biomarkers/pik3ca-hotspot-mutation/","field":"links","label":"PIQRAY prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"dosing.source"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Rash)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Peripheral neuropathy)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Fatigue)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Pruritus)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Diarrhoea)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Alopecia)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Decreased appetite)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Weight decrease)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Dry eye)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"toxicity.source (Hyperglycaemia (grade 3-4 glucose elevation))"},{"id":"nectin-4-expression","kind":"biomarker","name":"Nectin-4 expression","route":"/biomarkers/nectin-4-expression/","field":"links","label":"PADCEV prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flt3-tkd","kind":"biomarker","name":"FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)","route":"/biomarkers/flt3-tkd/","field":"links","label":"XOSPATA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"npm1-mutation","kind":"biomarker","name":"NPM1 mutation","route":"/biomarkers/npm1-mutation/","field":"links","label":"Komzifti prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"dosing.source"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (Thrombocytopenia)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (Anaemia)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (Nausea)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (Fatigue)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (Neutropenia)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"toxicity.source (MDS/AML)"},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/","field":"links","label":"ZEJULA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"met-overexpression","kind":"biomarker","name":"c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)","route":"/biomarkers/met-overexpression/","field":"links","label":"EMRELIS prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"dosing.source"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Diarrhoea)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Neutropenia)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Infections)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Venous thromboembolism)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Interstitial lung disease)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Fatigue)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Nausea)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (Anaemia)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"toxicity.source (ALT increased)"},{"id":"ki-67-index","kind":"biomarker","name":"Ki-67 index (proliferation by IHC)","route":"/biomarkers/ki-67-index/","field":"links","label":"Verzenio prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","field":"links","label":"US label (DailyMed)"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"links","label":"Relistor label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fd147f-a77e-4a0b-9280-e82ecc41b4be","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","field":"links","label":"TALZENNA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ros1-fusion","kind":"biomarker","name":"ROS1 fusion (ROS1-positive)","route":"/biomarkers/ros1-fusion/","field":"links","label":"Rozlytrek prescribing information (DailyMed)"},{"id":"ntrk-fusion","kind":"biomarker","name":"NTRK1/2/3 gene fusion","route":"/biomarkers/ntrk-fusion/","field":"links","label":"Rozlytrek prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"dosing.source"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Diarrhoea)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Nausea)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Fatigue)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Hepatotoxicity)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Cough)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Vomiting)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"toxicity.source (Interstitial lung disease)"},{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/","field":"links","label":"LUMAKRAS prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8b58efa-1820-48a4-b70d-62918fc4abfc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"dosing.source"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Peripheral neuropathy)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Conjunctival disorders)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Nausea)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Fatigue)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Epistaxis)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Alopecia)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Decreased appetite)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Haemorrhage)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Dry eye)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"toxicity.source (Corneal complications)"},{"id":"tissue-factor-expression","kind":"biomarker","name":"Tissue factor expression","route":"/biomarkers/tissue-factor-expression/","field":"links","label":"TIVDAK prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd22-expression","kind":"biomarker","name":"CD22 expression (CD22-positive)","route":"/biomarkers/cd22-expression/","field":"links","label":"Besponsa prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3fabf12-354e-4e5c-b5de-20fdb579b783","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"her2-mutation","kind":"biomarker","name":"HER2 (ERBB2) activating mutation","route":"/biomarkers/her2-mutation/","field":"links","label":"HERNEXEOS prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4643b31-9b4f-673f-e053-2a95a90a559d","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","field":"links","label":"FDA label (DailyMed)"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"links","label":"Illuccix label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d66bdf0d-9d65-45de-ae5b-a58617c27492","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/","field":"links","label":"Unituxin prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"dosing.source"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Diarrhoea)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Cutaneous adverse reactions)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Fatigue)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Nausea)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Stomatitis)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Vomiting)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"toxicity.source (Hyperglycaemia)"},{"id":"pik3ca-hotspot-mutation","kind":"biomarker","name":"PIK3CA mutation","route":"/biomarkers/pik3ca-hotspot-mutation/","field":"links","label":"TRUQAP prescribing information (DailyMed)"},{"id":"akt1-e17k","kind":"biomarker","name":"AKT1 E17K mutation","route":"/biomarkers/akt1-e17k/","field":"links","label":"TRUQAP prescribing information (DailyMed)"},{"id":"pten-alteration","kind":"biomarker","name":"PTEN alteration (sequencing) and PTEN loss (IHC)","route":"/biomarkers/pten-alteration/","field":"links","label":"TRUQAP prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcr-abl1-t315i","kind":"biomarker","name":"BCR::ABL1 T315I","route":"/biomarkers/bcr-abl1-t315i/","field":"links","label":"SCEMBLIX prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7695a21-abb6-47ac-93f8-0ece5a9c4409","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cldn18-2-expression","kind":"biomarker","name":"Claudin 18.2 expression (>= 75% of tumour cells, moderate to strong)","route":"/biomarkers/cldn18-2-expression/","field":"links","label":"VYLOY prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"braf-class-ii-iii","kind":"biomarker","name":"BRAF class II and class III mutations (non-V600)","route":"/biomarkers/braf-class-ii-iii/","field":"links","label":"OJEMDA prescribing information (DailyMed)"},{"id":"braf-fusion","kind":"biomarker","name":"BRAF fusion or rearrangement","route":"/biomarkers/braf-fusion/","field":"links","label":"OJEMDA prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"dosing.source"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Immune-mediated rash)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Hypothyroidism)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Pneumonitis)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Colitis)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Hepatitis)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Nephritis)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Adrenal insufficiency)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Colitis with ipilimumab (1+3 mg/kg))"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"toxicity.source (Hepatitis with ipilimumab)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"dosing.source"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Colitis (with nivolumab 1+3))"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Hepatitis (with nivolumab))"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Hypothyroidism (with nivolumab))"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Rash (with nivolumab))"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Adrenal insufficiency (with nivolumab))"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"toxicity.source (Hyperthyroidism (with nivolumab))"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","field":"links","label":"OPDIVO prescribing information (DailyMed)"},{"id":"pd-l1-tc-score","kind":"biomarker","name":"PD-L1 TC score (tumour-cell score, SP263 and 28-8)","route":"/biomarkers/pd-l1-tc-score/","field":"links","label":"OPDIVO prescribing information (DailyMed)"},{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/","field":"links","label":"OPDIVO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"dosing.source"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Neutropenia)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Infections)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Leukopenia)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Fatigue)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Nausea)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Alopecia)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Stomatitis)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Diarrhoea)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Anaemia)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"toxicity.source (Rash)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"braf-v600e","kind":"biomarker","name":"BRAF V600E (and V600K)","route":"/biomarkers/braf-v600e/","field":"links","label":"Tafinlar prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"links","label":"Zykadia label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Adcetris","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Adcetris)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=afatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aldesleukin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=alemtuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=alitretinoin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=amifostine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a17563f2-d231-4385-bc94-0217be78b89d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aminolevulinic%20acid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=anagrelide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aprepitant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=arsenic%20trioxide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aucatzyl","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fef6986-b988-45e4-8c20-b14f0ef1f538","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","field":"dosing.source"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Axumin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=389a502e-a7d5-43dd-b6bf-f022ff23f3b9","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=azacitidine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","field":"dosing.source"},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","field":"toxicity.source (Neutropenia)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=belinostat","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e8ef36b-71fa-4492-a16f-577d5f7d111d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=belumosudil","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102e4ef4-7f84-4e34-8df1-479c24d1575d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bendamustine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Besponsa","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","field":"dosing.source"},{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","field":"toxicity.source (Hepatic veno-occlusive disease)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bexarotene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bicalutamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bleomycin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/","field":"links","label":"Label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: bleomycin)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bosutinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Breyanzi","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"dosing.source"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"toxicity.source (Cytokine release syndrome)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=brigatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Brukinsa","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"dosing.source"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"toxicity.source (Atrial fibrillation/flutter)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=busulfan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Calquence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","field":"dosing.source"},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","field":"toxicity.source (Headache)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capecitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capmatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=carmustine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Carvykti","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d040b91-3fb8-41db-ba7f-60a36f06e2c2","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Carvykti)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cerianna","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2c2a2df-cf3e-4a29-a033-231ed5a94b58","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ceritinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cervarix","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=chlorambucil","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=choline%20c%2011","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cinacalcet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cisplatin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: cisplatin)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cladribine%20injection","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cladribine","kind":"drug","name":"Cladribine","route":"/drugs/cladribine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=clofarabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=crizotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cyclophosphamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/","field":"links","label":"Label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: cyclophosphamide)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cytarabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","field":"dosing.source"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dabrafenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dacarbazine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dacomitinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab27d2f-e385-4e9c-b324-fa69c10b855a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dactinomycin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=darbepoetin%20alfa","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Datroway","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Datroway)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=daunorubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=decitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=degarelix","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=denileukin%20diftitox","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac3613d7-4304-40e7-a3f5-adb8a8adca5d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=denosumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Detectnet","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f898c8a7-beb7-4318-a8ea-6f058d69342b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","field":"links","label":"Label: Detectnet (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dexamethasone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dexrazoxane","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dolasetron","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=201b0eb8-4a1e-4e22-ab4b-addb642710d6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: doxorubicin)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dronabinol","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=duvelisib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=efbemalenograstim","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=290ed754-758c-9cae-e063-6294a90ae68b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eflapegrastim","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=elotuzumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80686b7e-f6f4-4154-b5c0-c846425e2d91","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eltrombopag","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Elzonris","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80eb1080-fe20-4af0-b2a5-a67999923fa8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","field":"dosing.source"},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","field":"toxicity.source (Capillary leak syndrome)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=emapalumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a865e0ef-8685-4f69-8838-648c4f3bab47","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Enhertu","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Enhertu)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ensartinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=entrectinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=epirubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=epoetin%20alfa","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eribulin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=erlotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=estramustine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=etoposide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fedratinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=filgrastim","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=floxuridine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fludarabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fluorouracil%20injection","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","field":"links","label":"Label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: fluorouracil injection)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=flutamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fostamatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21149cc3-049b-43e2-b141-c9499160556c","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gardasil","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gazyva","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","field":"dosing.source"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","field":"toxicity.source (Infusion-related reactions)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=gefitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=gemcitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=glasdegib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=204a6f7e-c9a4-472b-abd2-9527bda64d17","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"glasdegib","kind":"drug","name":"Glasdegib","route":"/drugs/glasdegib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gleolan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdeded66-0017-42cf-9471-13f231014323","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=glucarpidase","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acaef5a6-b740-40e3-8ffe-74a75c74745c","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=granisetron","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Hepzato","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f83c8f7-4cc0-4219-88d5-7cfddce91198","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","field":"links","label":"Label: Hepzato Kit (DailyMed)"},{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","field":"links","label":"Hepzato Kit label"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=hydroxyurea","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ibrance","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Ibrance)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibritumomab%20tiuxetan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25d367dc-da65-44c9-a844-1bf15339c285","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Iclusig","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","field":"dosing.source"},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","field":"toxicity.source (Arterial occlusive events)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=idarubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=idelalisib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Idhifa","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","field":"dosing.source"},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","field":"toxicity.source (Differentiation syndrome)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Idhifa)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imbruvica","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","field":"dosing.source"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","field":"toxicity.source (Atrial fibrillation)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Imbruvica)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=imetelstat","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0fab7ca-e578-43c5-9df6-bdaff4182257","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=imiquimod","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Inqovi","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91a0f80b-f865-4d06-a40d-4d148d99ee71","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","field":"toxicity.source (Neutropenia and febrile neutropenia)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=iobenguane","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=irinotecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ixabepilone","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ixazomib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038f2461-834b-4488-9ebd-863c83eef5a7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Jaypirca","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"dosing.source"},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"toxicity.source (Fatigue)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Jelmyto","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d3d5053-5427-4a68-a40b-edb60699521e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","field":"links","label":"Label: Jelmyto (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Kisqali","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Kisqali)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Kymriah","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","field":"dosing.source"},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","field":"toxicity.source (Cytokine release syndrome)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Kyprolis","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Kyprolis)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=lapatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: lapatinib)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=larotrectinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=leucovorin%20calcium","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=leuprolide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=luspatercept","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f4d266-3f52-41eb-86ba-0abf3cf468e8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lutathera","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Lutathera)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lymphoseek","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72f31b09-4d7b-475c-b37a-9daf2ad80240","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lynparza","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Lynparza)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=megestrol","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=melphalan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mercaptopurine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mesna","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=methotrexate%20injection","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mirdametinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c41bf90-5fa7-4935-a95c-e047ea6bbf8e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mitomycin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mitotane","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mitoxantrone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mogamulizumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e53960ab-42a1-40d1-9c7d-eb013fe7f18f","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=momelotinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a672fd1-eb7b-4aa9-9b23-845e4b5dc400","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=motixafortide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nabilone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=necitumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nelarabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=neratinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: neratinib)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Netspot","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b3be70-17d8-4093-896c-f1c54a2cf242","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","field":"links","label":"Label: Netspot (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=netupitant","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nilotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nilutamide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5740b8f-fbb3-4023-9133-9e359a9ab980","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ofatumumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ofatumumab","kind":"drug","name":"Ofatumumab","route":"/drugs/ofatumumab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=omacetaxine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ondansetron","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=osimertinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: osimertinib)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=oxaliplatin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","field":"links","label":"Label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: oxaliplatin)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pacritinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Padcev","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Padcev)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pafolacianine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d21952b9-7c4e-3a56-e053-2a95a90a0ab0","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=palifermin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=426f6e64-2c20-4a61-6d65-7320426f6e64","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=palonosetron","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pamidronate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pedmark","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f98c7076-2a7b-4fd7-ab90-eed5e9137bae","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pegfilgrastim","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=peginterferon%20alfa-2b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pentostatin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=674e0e6d-46ed-4868-9196-04019d667716","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pentostatin","kind":"drug","name":"Pentostatin","route":"/drugs/pentostatin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pexidartinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=plerixafor","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pluvicto","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Pluvicto)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pomalidomide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=porfimer","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4841b4-fbc0-4163-8ee1-cb28629cbfbf","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pralatrexate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=prednisone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=procarbazine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=propranolol%20hydrochloride%20oral%20solution","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=raloxifene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RAPAMUNE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/","field":"links","label":"DailyMed: Rapamune (sirolimus) prescribing information"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=rasburicase","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ae10bc4-6b65-402f-9db5-2d7753054922","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ravulizumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a590d9-0217-43c7-908d-e62a71279791","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=retifanlimab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=109648d0-d30a-42fc-8273-39cb1540a751","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Revlimid","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Revlimid)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rezlidhia","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a0c7c8b-b95f-455d-9600-b7351e4397fe","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","field":"dosing.source"},{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","field":"toxicity.source (Differentiation syndrome)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ribociclib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: ribociclib)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rituxan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"dosing.source"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"toxicity.source (Infusion-related reactions (first infusion))"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=romidepsin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=romiplostim","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c45f9a58-37c1-4f76-8e36-97d38c577037","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ropeginterferon","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9583405d-53a0-49dc-88eb-5e6384ebabcb","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ruxolitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rydapt","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","field":"dosing.source"},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","field":"toxicity.source (Febrile neutropenia)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rylaze","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=857e53aa-1098-4dad-b654-0276cdd43e03","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/","field":"links","label":"Label: Rylaze (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=samarium","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sargramostim","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb9a3820-f31a-4dd9-bef4-97094c01a398","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Scemblix","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","field":"dosing.source"},{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","field":"toxicity.source (Thrombocytopenia)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=selumetinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d042c61-f28f-4ab5-ab10-d7558c0d49ff","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=siltuximab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d663642-f52e-49c0-a023-2da083fdfc0b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sipuleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8309b497-5d4e-4408-ac0c-2452c11c8a35","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sirolimus%20protein-bound","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sonidegib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028312dc-d155-4fd5-8abd-6bb9f011d3cc","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sprycel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","field":"dosing.source"},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","field":"toxicity.source (Pleural effusion)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=streptozocin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f31d3bff-6fc6-c35f-e053-2995a90a596b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=talc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Talvey","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9001355e-003d-4d4e-b4ce-337e0fd14952","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Talvey)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tamoxifen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: tamoxifen)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tecartus","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=technetium%20tc%2099m%20sulfur%20colloid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tecvayli","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54e0f974-ccee-44ea-9254-40e9883cee1e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Tecvayli)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=telotristat","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=temsirolimus","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","route":"/drugs/temsirolimus/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tepotinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80a0f1b9-071a-47f5-9e67-32d638a669dc","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=thioguanine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44b0c461-47fb-4106-ba11-6ed85530235c","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=thiotepa","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=thyrotropin%20alfa","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tibsovo","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","field":"dosing.source"},{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","field":"toxicity.source (Differentiation syndrome)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Tibsovo)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tivdak","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Tivdak)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tocilizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=toremifene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=trametinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","field":"links","label":"US label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: trametinib)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tretinoin%20capsules","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tretinoin-atra","kind":"drug","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=trilaciclib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=triptorelin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trodelvy","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Trodelvy)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=uvadex","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ad333bd-845f-43f8-9ecf-43491f26c7c7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=valrubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valrubicin","kind":"drug","name":"Valrubicin","route":"/drugs/valrubicin/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vanflyta","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","field":"dosing.source"},{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","field":"toxicity.source (QT prolongation)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Velcade","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Velcade)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Venclexta","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Venclexta)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Verzenio","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Verzenio)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vinblastine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vincristine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/","field":"links","label":"Label (DailyMed)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: vincristine)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vinorelbine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vismodegib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vorinostat","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vorinostat","kind":"drug","name":"Vorinostat","route":"/drugs/vorinostat/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vyxeos","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","field":"dosing.source"},{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","field":"toxicity.source (Prolonged cytopenias)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xofigo","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a398400e-bd31-41a9-9696-4f7c06569ede","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Xofigo)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xospata","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","field":"dosing.source"},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","field":"toxicity.source (Differentiation syndrome)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Xtandi","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Xtandi)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Yescarta","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Yescarta)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zejula","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Zejula)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ziv-aflibercept","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=zoledronic%20acid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zytiga","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"US prescribing information (DailyMed: Zytiga)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Abemaciclib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Abiraterone%20acetate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Acalabrutinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Adagrasib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Afamitresgene%20autoleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab24631f-3364-46e1-8074-7244863bcbab","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Alectinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Alpelisib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Amivantamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Apalutamide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Asciminib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Atezolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avapritinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avelumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avutometinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65889527-1406-45df-8a85-e2690dcf427d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Axicabtagene%20ciloleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Axitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Azacitidine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Belantamab%20mafodotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aef7c34c-fef8-407c-99c0-a68aded53c60","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Belzutifan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13e15ee0-d679-4fa9-9430-e2e2170474da","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bevacizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20220529064241/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bevacizumab"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Binimetinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Blinatumomab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-960b-4591-9857-5031ecb830aa","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bortezomib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brentuximab%20vedotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabazitaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabozantinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cadonilimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Camizestrant","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c54223d3-f3c7-4186-afa0-429d84805826","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capivasertib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capmatinib%20%26%20tepotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Carboplatin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Carfilzomib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cemiplimab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ciltacabtagene%20autoleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d040b91-3fb8-41db-ba7f-60a36f06e2c2","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cisplatin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cobimetinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dabrafenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Daratumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Darolutamide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dasatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Datopotamab%20deruxtecan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Decitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dinutuximab/%20dinutuximab%20beta","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Disitamab%20vedotin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Docetaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20240615025115/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=docetaxel"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dostarlimab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Eflornithine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Elacestrant","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Elranatamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enasidenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Encorafenib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enfortumab%20vedotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enzalutamide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20210510050236/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enzalutamide"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Epcoritamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Erdafitinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Everolimus","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Exemestane","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Flotufolastat%20F-18","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=907ac4a4-a088-4826-ab50-cfc31985c9d4","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fludeoxyglucose%20F%2018","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fulvestrant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gallium-68%20gozetotide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gedatolisib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=959d73ef-831f-4005-956c-210702270bda","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gemtuzumab%20ozogamicin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gilteritinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Glofitamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3516e753-f064-4d30-9bd5-e3f2e143f75d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Goserelin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Iberdomide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3663d9cb-3f66-48ae-bf0a-6958bc0888de","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ibrutinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Idecabtagene%20vicleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ifosfamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Imatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Imlunestrant","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Inavolisib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Inotuzumab%20ozogamicin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ipilimumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Isatuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ivosidenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lapatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lazertinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c417f9ee-2027-4ed5-92ad-3c19266de16c","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lenalidomide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lenvatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Letrozole","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lifileucel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Linvoseltamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9fd0739-1b3f-4b8b-824a-1f0a902384d3","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lisocabtagene%20maraleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Locametz","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8683b06e-4901-4526-89ad-23a8fe2d1331","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Loncastuximab%20tesirine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af54af12-3edf-4301-8bc5-0446bc813c1d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lorlatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lurbinectedin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=632bb50c-3bcb-4c85-9056-fc33410550ae","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lutetium-177%20dotatate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lutetium-177%20vipivotide%20tetraxetan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Margetuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Midostaurin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mirvetuximab%20soravtansine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mosunetuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nadofaragene%20firadenovec","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Naxitamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Neratinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Niraparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nirogacestat","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f172e6ff-3190-41b0-b95a-58a7ef9e9e1e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nogapendekin%20alfa%20inbakicept","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nonavalent%20HPV%20vaccine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Obecabtagene%20autoleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fef6986-b988-45e4-8c20-b14f0ef1f538","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Obinutuzumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Odronextamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olutasidenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a0c7c8b-b95f-455d-9600-b7351e4397fe","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Osimertinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Paclitaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Palbociclib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pazopanib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pegylated%20liposomal%20doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pemetrexed","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pemigatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pertuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Piflufolastat%20F-18","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pirtobrutinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Polatuzumab%20vedotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ponatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pralsetinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Progestins","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pyrotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Quizartinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radioactive%20iodine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radium-223%20dichloride","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a398400e-bd31-41a9-9696-4f7c06569ede","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relacorilant","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fcebfb5-19d6-4f63-b852-999d68a13729","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relatlimab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relugolix","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20220625172521/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=RELUGOLIX"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Repotrectinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb526827-40ba-4462-94cf-179ae3b0cb8a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Revumenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ribociclib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ripretinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f18e462-03dd-4296-a02a-a0577e3ee78d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Rituximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Rucaparib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sacituzumab%20govitecan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selinexor","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selpercatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Serplulimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Somatostatin%20analogues","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sonrotoclax","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff684558-e9cb-46de-a8bf-f4d79093df7a","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sorafenib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sotorasib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sunitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tafasitamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tagraxofusp","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80eb1080-fe20-4af0-b2a5-a67999923fa8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talazoparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talimogene%20laherparepvec","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ffb680-ea8c-42fc-9649-9e8c0eb77ddb","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talquetamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9001355e-003d-4d4e-b4ce-337e0fd14952","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tamoxifen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tarlatamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tebentafusp","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a49f57-d2fc-4ffe-9eb1-fe0460c6b067","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Teclistamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54e0f974-ccee-44ea-9254-40e9883cee1e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Telisotuzumab%20vedotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tisagenlecleucel","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tisotumab%20vedotin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tivozanib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de77155c-ecf2-4f15-9758-21d271449d83","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Topotecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trabectedin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20biosimilars","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20deruxtecan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20emtansine","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20rezetecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tremelimumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6690679c-be2f-4588-a2e4-89fff74dd6be","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tucatinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vandetanib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Venetoclax","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vepdegestrant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vimseltinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f73c7a62-9601-4df0-810f-100f515d79ea","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vorasidenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vusolimogene%20oderparepvec","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26627b8d-91ac-4f76-a213-7e25efd024d1","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zanidatamab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zanubrutinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zenocutuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zidesamtinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3760e421-b523-4d9b-e063-6394a90ab94b","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ziftomenib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","field":"links","label":"FDA label (DailyMed)"},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","field":"dosing.source"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zongertinib","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3fabf12-354e-4e5c-b5de-20fdb579b783","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailynews.co.tz/orci-set-to-begin-major-cancer-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diwani-msemo","kind":"person","name":"Diwani Msemo","route":"/people/diwani-msemo/","field":"links","label":"Source: Daily News Tanzania, ORCI set to begin major cancer surgery (August 2026)"},{"id":"diwani-msemo","kind":"person","name":"Diwani Msemo","route":"/people/diwani-msemo/","field":"profiles","label":"Daily News (Tanzania) report"}]},{"url":"https://dailyreporter.esmo.org/esmo-congress-2025/breast-cancer/survival-improvements-observed-with-first-line-antibody-drug-conjugates-in-triple-negative-breast-cancer","status":200,"ok":true,"finalUrl":"https://www.esmo.org/insights-by-esmo","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://data-vault.health","status":200,"ok":true,"finalUrl":"https://data-vault.health/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/","field":"website"}]},{"url":"https://data-vault.health/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/","field":"links","label":"About"}]},{"url":"https://datacommons.cancer.gov/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/","field":"links","label":"NCI Cancer Research Data Commons"}]},{"url":"https://datadrivenbioscience.com","status":200,"ok":true,"finalUrl":"https://www.duoseq.com/","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","route":"/companies/data-driven-bioscience/","field":"links","label":"Official website"},{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","route":"/companies/data-driven-bioscience/","field":"website"}]},{"url":"https://dceg.cancer.gov/research/cancer-types/lung/sherlock-lung-study","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/","field":"links","label":"Sherlock-Lung study (NCI)"}]},{"url":"https://deephealth.com/kheiron-medical-technologies/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kheiron-mia","kind":"drug","name":"Mia (Mammography Intelligent Assessment)","route":"/drugs/kheiron-mia/","field":"links","label":"DeepHealth: Kheiron Medical Technologies"},{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","route":"/companies/kheiron-medical-technologies/","field":"links","label":"Official website"},{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","route":"/companies/kheiron-medical-technologies/","field":"website"}]},{"url":"https://deephealth.com/press-releases/deephealth-expands-its-ai-powered-cancer-diagnostic-and-screening-portfolio-with-the-acquisition-of-kheiron","status":200,"ok":true,"finalUrl":"https://deephealth.com/press-releases/deephealth-expands-its-ai-powered-cancer-diagnostic-and-screening-portfolio-with-the-acquisition-of-kheiron/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","route":"/companies/kheiron-medical-technologies/","field":"links","label":"DeepHealth acquisition release (Oct 2024)"}]},{"url":"https://deepmind.google","status":200,"ok":true,"finalUrl":"https://deepmind.google/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/","field":"links","label":"Official website"},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/","field":"website"}]},{"url":"https://deepmind.google/discover/blog/alphagenome-ai-for-better-understanding-the-genome/","status":200,"ok":true,"finalUrl":"https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alphagenome","kind":"technology","name":"AlphaGenome","route":"/technologies/alphagenome/","field":"links","label":"DeepMind AlphaGenome"}]},{"url":"https://deerfield.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","field":"links","label":"Official website"},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","field":"website"}]},{"url":"https://deerfield.com/what-we-do/investment/portfolio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","field":"links","label":"Portfolio"}]},{"url":"https://delfidiagnostics.com","status":200,"ok":true,"finalUrl":"https://delfidiagnostics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","route":"/companies/delfi-diagnostics/","field":"website"}]},{"url":"https://denovobiopharma.com","status":200,"ok":true,"finalUrl":"https://denovobiopharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","field":"links","label":"Official website"},{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","field":"website"}]},{"url":"https://depmap.org","status":200,"ok":true,"finalUrl":"https://depmap.org/portal/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/","field":"links","label":"DepMap (Cancer Dependency Map)"},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/","field":"url"},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","field":"links","label":"DepMap"},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","field":"profiles","label":"DepMap"},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","field":"links","label":"DepMap portal"}]},{"url":"https://depmap.org/portal/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-model-patient-matching","kind":"idea","name":"Pick the laboratory model that matches the patient, not the one to hand","route":"/ideas/idea-bio1-model-patient-matching/","field":"links","label":"DepMap portal"},{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","field":"links","label":"DepMap portal"},{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/","field":"links","label":"DepMap"},{"id":"idea-moon-synthetic-lethality-map-every-driver","kind":"idea","name":"A synthetic lethality map for every cancer driver in every tissue context","route":"/ideas/idea-moon-synthetic-lethality-map-every-driver/","field":"links","label":"DepMap"},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/","field":"links","label":"DepMap portal (Broad Institute)"},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/","field":"links","label":"DepMap portal"}]},{"url":"https://deprescribing.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-structured-deprescribing-at-diagnosis","kind":"idea","name":"Structured deprescribing review at cancer diagnosis and again at transition to palliative care","route":"/ideas/idea-acc-structured-deprescribing-at-diagnosis/","field":"links","label":"Deprescribing.org algorithms"}]},{"url":"https://dharmais.co.id","status":200,"ok":true,"finalUrl":"https://dharmais.co.id/cgi-sys/suspendedpage.cgi","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/","field":"links","label":"Dharmais National Cancer Center"},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/","field":"website"}]},{"url":"https://digistain.co.uk","status":200,"ok":true,"finalUrl":"https://digistain.co.uk/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/","field":"links","label":"Official website"},{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/","field":"website"}]},{"url":"https://digitalhealth.tu-dresden.de","status":200,"ok":true,"finalUrl":"https://digitalhealth.tu-dresden.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"EKFZ for Digital Health"}]},{"url":"https://dinglab.wustl.edu","status":200,"ok":true,"finalUrl":"https://dinglab.wustl.edu/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","field":"links","label":"Ding lab"},{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","field":"profiles","label":"Ding lab"}]},{"url":"https://dirac.iaea.org/","status":200,"ok":true,"finalUrl":"https://nucleus.iaea.org/Pages/Others/Unauthorised.aspx","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-acc-open-hardware-linac","kind":"idea","name":"An open-hardware radiotherapy machine built for unreliable power and dust","route":"/ideas/idea-acc-open-hardware-linac/","field":"links","label":"IAEA DIRAC directory of radiotherapy centres"},{"id":"radiotherapy-access-gap","kind":"technology","name":"Radiotherapy access and the global machine gap","route":"/technologies/radiotherapy-access-gap/","field":"links","label":"IAEA DIRAC directory of radiotherapy centres"},{"id":"radiotherapy-equipment-manufacturing","kind":"technology","name":"Linac, proton system and brachytherapy machine manufacturing","route":"/technologies/radiotherapy-equipment-manufacturing/","field":"links","label":"IAEA DIRAC: directory of radiotherapy centres"}]},{"url":"https://divisionofresearch.kaiserpermanente.org","status":200,"ok":true,"finalUrl":"https://divisionofresearch.kaiserpermanente.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","field":"links","label":"Kaiser Permanente Division of Research"},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","field":"website"}]},{"url":"https://divisionofresearch.kaiserpermanente.org/our-team/leadership-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","field":"links","label":"Institution profile"},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","field":"profiles","label":"Institution profile"},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","field":"links","label":"Institution profile"},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","field":"profiles","label":"Institution profile"}]},{"url":"https://dktk.dkfz.de","status":200,"ok":true,"finalUrl":"https://dktk.dkfz.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","route":"/institutions/dktk/","field":"website"}]},{"url":"https://dktk.dkfz.de/en","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","route":"/institutions/dktk/","field":"links","label":"DKTK: about"}]},{"url":"https://dktk.dkfz.de/en/sites/overview","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","route":"/institutions/dktk/","field":"links","label":"DKTK: partner sites"}]},{"url":"https://dndi.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/","field":"links","label":"Drugs for Neglected Diseases initiative"}]},{"url":"https://dnpm.de","status":200,"ok":true,"finalUrl":"https://dnpm.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","route":"/institutions/dnpm/","field":"links","label":"DNPM"},{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","route":"/institutions/dnpm/","field":"website"}]},{"url":"https://dnpm.de/de/zentren-des-dnpm","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","route":"/institutions/dnpm/","field":"links","label":"The DNPM centres"}]},{"url":"https://docrates.mehilainen.fi/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","field":"links","label":"Official website"},{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","field":"website"}]},{"url":"https://docs.gdc.cancer.gov/Encyclopedia/pages/TCGA_Barcode/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tcga-barcode","kind":"term","name":"TCGA barcode","route":"/terms/tcga-barcode/","field":"links","label":"GDC documentation: TCGA barcode"}]},{"url":"https://doctorpeset.san.gva.es","status":200,"ok":true,"finalUrl":"https://doctorpeset.san.gva.es/va/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","route":"/institutions/doctor-peset-valencia/","field":"links","label":"Official website"},{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","route":"/institutions/doctor-peset-valencia/","field":"website"}]},{"url":"https://doctorpeset.san.gva.es/es/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","field":"links","label":"Hospital Universitario Doctor Peset website"},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","field":"profiles","label":"Hospital Universitario Doctor Peset website"}]},{"url":"https://doctors.intermountainhealth.org/provider/derrick-s-haslem/2556921","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","route":"/people/derrick-haslem/","field":"links","label":"Source: Intermountain Health provider profile"},{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","route":"/people/derrick-haslem/","field":"profiles","label":"Institution profile"}]},{"url":"https://doi.org/10.1002/j.1460-2075.1992.tb05481.x","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1002/j.1460-2075.1992.tb05481.x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/","field":"links","label":"Discovery of PD-1 (Ishida 1992)"}]},{"url":"https://doi.org/10.1007/978-1-4613-1247-5_23","status":200,"ok":true,"finalUrl":"https://link.springer.com/chapter/10.1007/978-1-4613-1247-5_23","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peritoneal-carcinomatosis-index","kind":"term","name":"Peritoneal cancer index","route":"/terms/peritoneal-carcinomatosis-index/","field":"links","label":"Jacquet and Sugarbaker, Cancer Treat Res 1996: clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis (the peritoneal cancer index)"}]},{"url":"https://doi.org/10.1007/bf01840834","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/BF01840834","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nottingham-prognostic-index","kind":"term","name":"Nottingham Prognostic Index (NPI), and PREDICT","route":"/terms/nottingham-prognostic-index/","field":"links","label":"Galea, Blamey, Elston and Ellis, Breast Cancer Research and Treatment 1992;22:207 to 219: the Nottingham Prognostic Index in primary breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Galea, Blamey, Elston and Ellis, Breast Cancer Research and Treatment 1992;22:207 to 219: the Nottingham Prognostic Index in primary breast cancer"}]},{"url":"https://doi.org/10.1007/bf02460644","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/BF02460644","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kuznetsov-bull-math-biol","kind":"paper","name":"Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis","route":"/key-papers/paper-kuznetsov-bull-math-biol/","field":"links","label":"Bull Math Biol 1994"}]},{"url":"https://doi.org/10.1007/BF02460644","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/BF02460644","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immune-tumour-dynamics-models","kind":"technology","name":"Tumour-immune dynamics models","route":"/technologies/immune-tumour-dynamics-models/","field":"links","label":"Kuznetsov and colleagues 1994, Bulletin of Mathematical Biology"}]},{"url":"https://doi.org/10.1007/PL00011720","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/PL00011720","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000","kind":"paper","name":"Incidence of lymph node metastasis from early gastric cancer: estimation from 5,265 patients at two large centres","route":"/key-papers/paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000/","field":"links","label":"Gastric Cancer 2000"}]},{"url":"https://doi.org/10.1007/s00125-017-4372-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00125-017-4372-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","field":"papers","label":"Repurposing metformin for the prevention of cancer and cancer recurrence"},{"id":"paper-andrea-decensi-diabetologia-2017","kind":"paper","name":"Repurposing metformin for the prevention of cancer and cancer recurrence","route":"/key-papers/paper-andrea-decensi-diabetologia-2017/","field":"links","label":"Diabetologia 2017"}]},{"url":"https://doi.org/10.1007/s00204-010-0595-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00204-010-0595-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"papers","label":"Selenium: a double-edged sword for defense and offence in cancer"}]},{"url":"https://doi.org/10.1007/s00259-004-1687-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00259-004-1687-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"papers","label":"[18F]FLT-PET in oncology: current status and opportunities"}]},{"url":"https://doi.org/10.1007/s00259-009-1297-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00259-009-1297-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0"}]},{"url":"https://doi.org/10.1007/s00262-005-0054-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00262-005-0054-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sakamoto-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials","route":"/key-papers/paper-sakamoto-cancer-immunol-immunother/","field":"links","label":"Cancer Immunol Immunother 2006"},{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","field":"links","label":"PSK adjuvant immunochemotherapy in curatively resected colorectal cancer: meta-analysis (Cancer Immunol Immunother 2006)"}]},{"url":"https://doi.org/10.1007/s00262-006-0248-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00262-006-0248-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oba-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer","route":"/key-papers/paper-oba-cancer-immunol-immunother/","field":"links","label":"Cancer Immunol Immunother 2007"},{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","field":"links","label":"Efficacy of adjuvant immunochemotherapy with PSK for curatively resected gastric cancer: meta-analysis of 8,009 patients (Cancer Immunol Immunother 2007)"}]},{"url":"https://doi.org/10.1007/s00266-024-03956-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00266-024-03956-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bia-alcl","kind":"term","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/terms/bia-alcl/","field":"links","label":"Risk of BIA-ALCL, systematic review and meta-analysis (Aesthetic Plastic Surgery 2024)"}]},{"url":"https://doi.org/10.1007/s00277-014-2298-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00277-014-2298-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"Annals of Hematology 2015: antibiotics as sole management of H. pylori-negative gastric MALT lymphoma"}]},{"url":"https://doi.org/10.1007/s00280-014-2635-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00280-014-2635-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"papers","label":"Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells"}]},{"url":"https://doi.org/10.1007/s00292-019-0605-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00292-019-0605-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","field":"links","label":"Büttner 2019, the Cologne model (Der Pathologe)"}]},{"url":"https://doi.org/10.1007/s00330-021-08384-w","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00330-021-08384-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"ESGAR, EAES, EFISDS and ESGE joint guideline on gallbladder polyps (Foley, Eur Radiol 2022)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Polyps and precursors (prevention))"},{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"links","label":"ESGAR, EAES, EFISDS and ESGE joint guideline on gallbladder polyps (Foley, Eur Radiol 2022)"},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"links","label":"ESGAR, EAES, EFISDS and ESGE joint guideline on gallbladder polyps (Foley, Eur Radiol 2022)"},{"id":"paper-gallbladder-polyp-joint-guideline-eur-radiol-2022","kind":"paper","name":"Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE","route":"/key-papers/paper-gallbladder-polyp-joint-guideline-eur-radiol-2022/","field":"links","label":"Eur Radiol 2022"}]},{"url":"https://doi.org/10.1007/s00345-012-0882-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00345-012-0882-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"links","label":"Derksen 2013, World J Urol: primary urethral carcinoma in females, Netherlands registry"}]},{"url":"https://doi.org/10.1007/s00345-015-1583-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00345-015-1583-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"links","label":"Gakis 2016, World J Urol: international collaboration on primary urethral carcinoma, 154 patients"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"links","label":"Gakis 2016, World J Urol: international collaboration on primary urethral carcinoma, 154 patients"},{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"links","label":"Gakis 2016, World J Urol: international collaboration on primary urethral carcinoma, 154 patients"}]},{"url":"https://doi.org/10.1007/s00401-011-0922-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00401-011-0922-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","field":"links","label":"Taylor 2012 consensus subgroups"},{"id":"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012","kind":"paper","name":"Molecular subgroups of medulloblastoma: the current consensus","route":"/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/","field":"links","label":"Acta Neuropathol 2012"}]},{"url":"https://doi.org/10.1007/s00401-015-1478-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00401-015-1478-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","field":"papers","label":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes"},{"id":"paper-jacques-grill-acta-neuropathol-2015","kind":"paper","name":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","route":"/key-papers/paper-jacques-grill-acta-neuropathol-2015/","field":"links","label":"Acta Neuropathol 2015"}]},{"url":"https://doi.org/10.1007/s00401-016-1574-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00401-016-1574-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","field":"links","label":"Acta Neuropathologica 2016: poorly differentiated chordoma with SMARCB1/INI1 loss, a distinct entity with dismal prognosis"}]},{"url":"https://doi.org/10.1007/s00401-019-01990-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00401-019-01990-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pineal-parenchymal-tumours","kind":"cancer","name":"Pineocytoma and pineal parenchymal tumour of intermediate differentiation","route":"/cancers/pineal-parenchymal-tumours/","field":"links","label":"Acta Neuropathologica 2019: KBTBD4 insertions differentiate PPTID from pineoblastoma"}]},{"url":"https://doi.org/10.1007/s00401-019-02111-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00401-019-02111-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/","field":"links","label":"Acta Neuropathologica 2020: pineoblastoma molecular subgroups, Rare Brain Tumor Consortium registry"}]},{"url":"https://doi.org/10.1007/s00404-019-05063-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00404-019-05063-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"papers","label":"Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method"}]},{"url":"https://doi.org/10.1007/s00405-016-4248-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00405-016-4248-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","field":"papers","label":"A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma"}]},{"url":"https://doi.org/10.1007/s00405-020-05823-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00405-020-05823-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","field":"papers","label":"Post-traumatic brain injury olfactory dysfunction: factors influencing quality of life"}]},{"url":"https://doi.org/10.1007/s00405-020-05998-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00405-020-05998-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acinic-cell-carcinoma-salivary","kind":"cancer","name":"Acinic cell carcinoma of the salivary glands","route":"/cancers/acinic-cell-carcinoma-salivary/","field":"links","label":"Eur Arch Otorhinolaryngol 2020: acinic cell carcinoma of the parotid gland, from pathogenesis to management (review)"}]},{"url":"https://doi.org/10.1007/s00423-020-02075-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00423-020-02075-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Chaudhary, Langenbecks Arch Surg 2021: resection in gallbladder cancer with jaundice"}]},{"url":"https://doi.org/10.1007/s00428-013-1478-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00428-013-1478-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Roa, Virchows Arch 2013: early gallbladder carcinoma and Rokitansky-Aschoff sinus involvement"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"Roa, Virchows Arch 2013: early gallbladder carcinoma and Rokitansky-Aschoff sinus involvement"},{"id":"rokitansky-aschoff-sinus","kind":"term","name":"Rokitansky-Aschoff sinus","route":"/terms/rokitansky-aschoff-sinus/","field":"links","label":"Roa, Virchows Arch 2013: early gallbladder carcinoma and Rokitansky-Aschoff sinus involvement"}]},{"url":"https://doi.org/10.1007/s00428-013-1501-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00428-013-1501-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","field":"links","label":"Pelosi 2014, Virchows Archiv: large cell carcinoma of the lung reclassified by immunohistochemistry and molecular biology"},{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","field":"links","label":"Pelosi 2014, Virchows Archiv: large cell carcinoma of the lung reclassified by immunohistochemistry and molecular biology"}]},{"url":"https://doi.org/10.1007/s00428-021-03021-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00428-021-03021-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"links","label":"Luchini, Virchows Arch 2021: undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, a review"}]},{"url":"https://doi.org/10.1007/s00428-026-04425-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00428-026-04425-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","kind":"paper","name":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-null to HER2-low, including HER2-ultralow status","route":"/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/","field":"links","label":"Boissiere-Michot et al., Virchows Arch 2026: HER2-null, ultralow and low in 367 chemotherapy-naive non-metastatic TNBCs"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1007/s00432-016-2224-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00432-016-2224-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"links","label":"J Cancer Res Clin Oncol 2016: mucinous and signet ring cell colorectal cancer in 28,056 Munich registry patients"},{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","field":"links","label":"J Cancer Res Clin Oncol 2016: mucinous and signet ring cell colorectal cancer in 28,056 Munich registry patients"},{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","field":"links","label":"J Cancer Res Clin Oncol 2016: mucinous and signet ring cell colorectal cancer in 28,056 Munich registry patients"}]},{"url":"https://doi.org/10.1007/s00432-017-2490-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00432-017-2490-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","field":"links","label":"J Cancer Res Clin Oncol 2017: serum microRNA-371a-3p in 27 patients with germ cell neoplasia in situ"}]},{"url":"https://doi.org/10.1007/s00432-023-04588-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00432-023-04588-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"papers","label":"Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial"}]},{"url":"https://doi.org/10.1007/s00464-018-6444-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00464-018-6444-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019","kind":"paper","name":"Polyp size of 1 cm is insufficient to discriminate neoplastic and non-neoplastic gallbladder polyps","route":"/key-papers/paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019/","field":"links","label":"Surg Endosc 2019"}]},{"url":"https://doi.org/10.1007/s00520-011-1236-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00520-011-1236-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ryan-support-care-cancer","kind":"paper","name":"Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients","route":"/key-papers/paper-ryan-support-care-cancer/","field":"links","label":"Support Care Cancer 2012"},{"id":"ginger-nausea","kind":"technology","name":"Ginger for chemotherapy nausea","route":"/technologies/ginger-nausea/","field":"links","label":"Ginger for chemotherapy-related nausea in cancer patients, randomised trial of 576 patients (Support Care Cancer 2012)"}]},{"url":"https://doi.org/10.1007/s00520-019-04890-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s00520-019-04890-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zadik-support-care-cancer","kind":"paper","name":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","route":"/key-papers/paper-zadik-support-care-cancer/","field":"links","label":"Support Care Cancer 2019"},{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/","field":"links","label":"MASCC/ISOO systematic review of photobiomodulation for the management of oral mucositis (Support Care Cancer 2019)"}]},{"url":"https://doi.org/10.1007/s10120-022-01331-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10120-022-01331-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","field":"links","label":"JGCA guidelines 2021 (Gastric Cancer)"},{"id":"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023","kind":"paper","name":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","route":"/key-papers/paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023/","field":"links","label":"Gastric Cancer 2023"}]},{"url":"https://doi.org/10.1007/s10147-023-02390-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10147-023-02390-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-227-int-j-clin-oncol-2023-update","kind":"paper","name":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","route":"/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/","field":"links","label":"Int J Clin Oncol 2023"}]},{"url":"https://doi.org/10.1007/s10147-024-02589-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10147-024-02589-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/","field":"links","label":"Int J Clin Oncol 2024"}]},{"url":"https://doi.org/10.1007/s10549-010-0894-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-010-0894-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"papers","label":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy"}]},{"url":"https://doi.org/10.1007/s10549-010-1156-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-010-1156-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-donenberg-bahamas-brca1-founder-bcrt-2011","kind":"paper","name":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas","route":"/key-papers/paper-donenberg-bahamas-brca1-founder-bcrt-2011/","field":"links","label":"Donenberg et al., Breast Cancer Res Treat 2011: BRCA1 founder mutations in 214 Bahamian breast cancer patients"}]},{"url":"https://doi.org/10.1007/s10549-010-1217-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-010-1217-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"links","label":"Laitman et al., No predominant recurring germline mutations among ethnically diverse Israeli high-risk families (Breast Cancer Res Treat 2011)"}]},{"url":"https://doi.org/10.1007/s10549-011-1837-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10549-011-1837-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"papers","label":"Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review"}]},{"url":"https://doi.org/10.1007/s10549-012-2339-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-012-2339-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Pierobon, Breast Cancer Res Treat 2013: obesity as a risk factor for triple-negative breast cancer, meta-analysis"}]},{"url":"https://doi.org/10.1007/s10549-014-2980-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-014-2980-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Sharma, Breast Cancer Res Treat 2014: germline BRCA mutations in a prospective triple-negative breast cancer registry"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Sharma, Breast Cancer Res Treat 2014: germline BRCA mutations in a prospective triple-negative breast cancer registry"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"Sharma, Breast Cancer Res Treat 2014: germline BRCA mutations in a prospective triple-negative breast cancer registry"},{"id":"paper-sharma-tnbc-registry-germline-brca-bcrt-2014","kind":"paper","name":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing","route":"/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/","field":"links","label":"Sharma et al., Breast Cancer Res Treat 2014: germline BRCA in a prospective registry of 207 TNBC patients"}]},{"url":"https://doi.org/10.1007/s10549-015-3312-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-015-3312-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015","kind":"paper","name":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer","route":"/key-papers/paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015/","field":"links","label":"Villarreal-Garza et al., Breast Cancer Res Treat 2015: BRCA mutations in 190 young Mexican TNBC patients"}]},{"url":"https://doi.org/10.1007/s10549-017-4185-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-017-4185-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Scalp cooling and scalp metastases: systematic review and meta-analysis (Breast Cancer Res Treat 2017)"},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/","field":"links","label":"Scalp cooling and the risk of scalp metastases: systematic review (Breast Cancer Res Treat 2017)"}]},{"url":"https://doi.org/10.1007/s10549-018-05125-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10549-018-05125-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paloma-2-breast-cancer-res-treat-2019-update","kind":"paper","name":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","route":"/key-papers/paper-paloma-2-breast-cancer-res-treat-2019-update/","field":"links","label":"Breast Cancer Res Treat 2019"}]},{"url":"https://doi.org/10.1007/s10549-021-06336-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10549-021-06336-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1007/s10552-009-9331-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10552-009-9331-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Trivers, Cancer Causes Control 2009: the epidemiology of triple-negative breast cancer, including race"}]},{"url":"https://doi.org/10.1007/s10552-025-01967-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10552-025-01967-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"Louis, Cancer Causes Control 2025: gallbladder adenocarcinoma and neuroendocrine carcinoma in the National Cancer Database"},{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"links","label":"Louis, Cancer Causes Control 2025: gallbladder adenocarcinoma and neuroendocrine carcinoma in the National Cancer Database"}]},{"url":"https://doi.org/10.1007/s10555-016-9645-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s10555-016-9645-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","kind":"paper","name":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","route":"/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/","field":"links","label":"Cancer Metastasis Rev 2017"}]},{"url":"https://doi.org/10.1007/s10637-024-01442-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10637-024-01442-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hr070803","kind":"drug","name":"HR070803","route":"/drugs/hr070803/","field":"links","label":"Liposomal irinotecan (HR070803) with fluorouracil and leucovorin in advanced solid tumours: phase 1b (Investigational New Drugs 2024)"}]},{"url":"https://doi.org/10.1007/s10637-026-01626-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10637-026-01626-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/","field":"links","label":"Invest New Drugs 2026"}]},{"url":"https://doi.org/10.1007/s10689-021-00247-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s10689-021-00247-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"Foulkes, Kamihara, Evans et al., Familial Cancer 2021;20(4):317 to 325: current recommendations for cancer surveillance in Gorlin syndrome, a report from the SIOPE host genome working group"}]},{"url":"https://doi.org/10.1007/s11136-016-1367-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s11136-016-1367-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"papers","label":"Quality of life in patients with a permanent stoma after rectal cancer surgery"}]},{"url":"https://doi.org/10.1007/s11154-020-09588-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s11154-020-09588-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","field":"links","label":"Giustina 2020, Rev Endocr Metab Disord: multidisciplinary management of acromegaly, a consensus"}]},{"url":"https://doi.org/10.1007/s11605-007-0309-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1091255X23049119","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Pawlik et al., J Gastrointest Surg 2007: residual disease at re-resection by T stage (115 patients, 6 centres)"},{"id":"paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007","kind":"paper","name":"Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection","route":"/key-papers/paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007/","field":"links","label":"J Gastrointest Surg 2007"}]},{"url":"https://doi.org/10.1007/s11605-008-0505-z","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1091255X23087371","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Bachmann, J Gastrointest Surg 2008: cachexia worsens prognosis in resectable pancreatic cancer (227 patients)"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Bachmann, J Gastrointest Surg 2008: cachexia worsens prognosis in resectable pancreatic cancer (227 patients)"}]},{"url":"https://doi.org/10.1007/s11605-013-2170-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1091255X23070701","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Schnelldorfer, J Gastrointest Surg 2013: porcelain gallbladder, benign process or concern for malignancy"},{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","field":"links","label":"Schnelldorfer, J Gastrointest Surg 2013: porcelain gallbladder, benign process or concern for malignancy"}]},{"url":"https://doi.org/10.1007/s11605-020-04729-w","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1091255X23011447","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"links","label":"Murimwa, J Gastrointest Surg 2021: adenosquamous carcinoma of the gallbladder in the National Cancer Database"}]},{"url":"https://doi.org/10.1007/s11912-014-0430-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s11912-014-0430-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","field":"links","label":"Current Oncology Reports 2015: testicular choriocarcinoma, a rare variant needing a unique treatment approach"}]},{"url":"https://doi.org/10.1007/s11912-025-01704-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s11912-025-01704-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Patel review 2025"},{"id":"paper-patel-ivermectin-cancer-curr-oncol-rep-2025","kind":"paper","name":"Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?","route":"/key-papers/paper-patel-ivermectin-cancer-curr-oncol-rep-2025/","field":"links","label":"Patel review 2025"}]},{"url":"https://doi.org/10.1007/s12012-019-09556-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s12012-019-09556-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"papers","label":"Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients"}]},{"url":"https://doi.org/10.1007/s12012-020-09595-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s12012-020-09595-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"papers","label":"HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity"}]},{"url":"https://doi.org/10.1007/s12022-022-09703-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s12022-022-09703-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lactotroph-pitnet","kind":"cancer","name":"Lactotroph pituitary neuroendocrine tumour (prolactinoma)","route":"/cancers/lactotroph-pitnet/","field":"links","label":"Asa 2022, Endocrine Pathology: overview of the 2022 WHO classification of pituitary tumours"},{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","field":"links","label":"Asa 2022, Endocrine Pathology: overview of the 2022 WHO classification of pituitary tumours"},{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","field":"links","label":"Asa 2022, Endocrine Pathology: overview of the 2022 WHO classification of pituitary tumours"},{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","field":"links","label":"Asa 2022, Endocrine Pathology: overview of the 2022 WHO classification of pituitary tumours"},{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","field":"links","label":"Asa 2022, Endocrine Pathology: overview of the 2022 WHO classification of pituitary tumours"}]},{"url":"https://doi.org/10.1007/s12029-025-01372-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s12029-025-01372-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"links","label":"J Gastrointest Cancer 2026: colorectal micropapillary adenocarcinoma, molecular mechanisms and clinical implications (review)"}]},{"url":"https://doi.org/10.1007/s12105-011-0281-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s12105-011-0281-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carcinoma-ex-pleomorphic-adenoma","kind":"cancer","name":"Carcinoma ex pleomorphic adenoma","route":"/cancers/carcinoma-ex-pleomorphic-adenoma/","field":"links","label":"Head and Neck Pathology 2012: carcinoma ex pleomorphic adenoma, comprehensive review"}]},{"url":"https://doi.org/10.1007/s12282-019-01043-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s12282-019-01043-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kurata-japanese-tnbc-msi-breast-cancer-2020","kind":"paper","name":"Microsatellite instability in Japanese female patients with triple-negative breast cancer","route":"/key-papers/paper-kurata-japanese-tnbc-msi-breast-cancer-2020/","field":"links","label":"Kurata et al., Breast Cancer 2020: MSI in 228 Japanese TNBC patients"}]},{"url":"https://doi.org/10.1007/s12672-021-00398-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s12672-021-00398-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","field":"links","label":"Discover Oncology 2021: signet ring cell and mucinous carcinoma versus adenocarcinoma, meta-analysis of 1,087,055 patients"},{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","field":"links","label":"Discover Oncology 2021: signet ring cell and mucinous carcinoma versus adenocarcinoma, meta-analysis of 1,087,055 patients"}]},{"url":"https://doi.org/10.1007/s13300-017-0273-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1007/s13300-017-0273-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"papers","label":"Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis"}]},{"url":"https://doi.org/10.1007/s13304-021-01150-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s13304-021-01150-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021","kind":"paper","name":"Tumor location and concurrent liver resection, impact survival in T2 gallbladder cancer: a meta-analysis of the literature","route":"/key-papers/paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021/","field":"links","label":"Updates Surg 2021"}]},{"url":"https://doi.org/10.1007/s40265-023-01930-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40265-023-01930-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-epcoritamab-dlbcl-drugs-2023","kind":"paper","name":"Epcoritamab: First Approval","route":"/key-papers/paper-epcoritamab-dlbcl-drugs-2023/","field":"links","label":"Drugs 2023"}]},{"url":"https://doi.org/10.1007/s40265-024-01998-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40265-024-01998-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-drugs-2024","kind":"paper","name":"Capivasertib: First Approval","route":"/key-papers/paper-capivasertib-breast-hr-positive-drugs-2024/","field":"links","label":"Drugs 2024"}]},{"url":"https://doi.org/10.1007/s40291-023-00673-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40291-023-00673-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keam-mol-diagn-ther","kind":"paper","name":"Equecabtagene Autoleucel: First Approval","route":"/key-papers/paper-keam-mol-diagn-ther/","field":"links","label":"Mol Diagn Ther 2023"},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","field":"links","label":"Equecabtagene autoleucel: first approval (Mol Diagn Ther 2023)"}]},{"url":"https://doi.org/10.1007/s40291-024-00723-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40291-024-00723-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","route":"/key-papers/paper-dhillon-mol-diagn-ther/","field":"links","label":"Mol Diagn Ther 2024"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","field":"links","label":"Zevorcabtagene autoleucel: first approval (Mol Diagn Ther 2024)"}]},{"url":"https://doi.org/10.1007/s40487-025-00377-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40487-025-00377-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025","kind":"paper","name":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025/","field":"links","label":"Oncol Ther 2025"}]},{"url":"https://doi.org/10.1007/s40615-026-02959-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s40615-026-02959-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Kosuru, J Racial Ethn Health Disparities 2026: gallbladder cancer incidence in Native American people, 1962 to 2021"}]},{"url":"https://doi.org/10.1016/0016-5085(94)90246-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/0016508594902461","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/0022-3468(95)90046-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/0022346895900462","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","field":"papers","label":"Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model"}]},{"url":"https://doi.org/10.1016/0046-8177(90)90235-w","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/004681779090235W","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","field":"links","label":"Venable 1990, Human Pathology: infiltrating cribriform carcinoma of the breast, a distinctive entity"}]},{"url":"https://doi.org/10.1016/0092-8674(84)90438-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/0092867484904380","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"papers","label":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity"}]},{"url":"https://doi.org/10.1016/0092-8674(88)90175-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/0092867488901754","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"papers","label":"Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement"}]},{"url":"https://doi.org/10.1016/0092-8674(88)90571-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/0092867488905715","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-almoguera-kras-codon-12-pancreatic-cell-1988","kind":"paper","name":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","route":"/key-papers/paper-almoguera-kras-codon-12-pancreatic-cell-1988/","field":"links","label":"Cell 1988"}]},{"url":"https://doi.org/10.1016/0092-8674(90)90186-i","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/009286749090186I","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Fearon and Vogelstein, Cell 1990: a genetic model for colorectal tumorigenesis"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"links","label":"Fearon and Vogelstein, Cell 1990: a genetic model for colorectal tumorigenesis"},{"id":"paper-fearon-cell","kind":"paper","name":"A genetic model for colorectal tumorigenesis","route":"/key-papers/paper-fearon-cell/","field":"links","label":"Cell 1990"}]},{"url":"https://doi.org/10.1016/0092-8674(90)90186-I","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/009286749090186I","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","kind":"paper","name":"Genetic alterations during colorectal-tumor development","route":"/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/","field":"links","label":"Fearon and Vogelstein: a genetic model for colorectal tumorigenesis (Cell 1990)"},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"papers","label":"A genetic model for colorectal tumorigenesis"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Fearon and Vogelstein, A genetic model for colorectal tumorigenesis (Cell 1990)"}]},{"url":"https://doi.org/10.1016/0092-8674(93)90500-P","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/009286749390500P","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"El-Deiry 1993: WAF1, the gene through which p53 stops cell division"},{"id":"paper-el-deiry-waf1-p21-cell-1993","kind":"paper","name":"El-Deiry 1993: WAF1, the gene through which p53 stops cell division","route":"/key-papers/paper-el-deiry-waf1-p21-cell-1993/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/0140-6736(93)90939-e","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/014067369390939E","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"papers","label":"Glutamine and the preservation of gut integrity"}]},{"url":"https://doi.org/10.1016/0140-6736(93)91409-F","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/014067369391409F","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-h-pylori-eradication","kind":"term","name":"Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma","route":"/terms/lymphoma-tx-h-pylori-eradication/","field":"links","label":"Wotherspoon et al., regression of gastric MALT lymphoma after Helicobacter pylori eradication, Lancet 1993"},{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/","field":"links","label":"Lancet 1993"}]},{"url":"https://doi.org/10.1016/0190-9622(92)70178-I","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/019096229270178I","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"surgical-margins-keratinocyte-cancer","kind":"term","name":"The margin in skin cancer surgery","route":"/terms/surgical-margins-keratinocyte-cancer/","field":"links","label":"Surgical margins for cutaneous squamous cell carcinoma (Journal of the American Academy of Dermatology 1992, PubMed 1430364)"}]},{"url":"https://doi.org/10.1016/j.ajhg.2010.04.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002929710002089","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"papers","label":"Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies"}]},{"url":"https://doi.org/10.1016/j.ajhg.2018.11.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002929718304051","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mavaddat-am-j-hum-genet","kind":"paper","name":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","route":"/key-papers/paper-mavaddat-am-j-hum-genet/","field":"links","label":"Am J Hum Genet 2019"},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/","field":"links","label":"Mavaddat et al., 313-SNP breast cancer PRS (AJHG 2019)"}]},{"url":"https://doi.org/10.1016/j.ajhg.2019.01.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002929719300126","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"papers","label":"Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease"}]},{"url":"https://doi.org/10.1016/j.ajog.2010.04.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002937810004321","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","field":"links","label":"Am J Obstet Gynecol 2010: small cell carcinoma of the cervix, treatment and survival of 188 patients"}]},{"url":"https://doi.org/10.1016/j.amjmed.2018.05.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002934318305096","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","field":"links","label":"Gilligan 2018 (Am J Med)"},{"id":"paper-gilligan-am-j-med","kind":"paper","name":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer","route":"/key-papers/paper-gilligan-am-j-med/","field":"links","label":"Am J Med 2018"}]},{"url":"https://doi.org/10.1016/j.amjoto.2019.102279","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0196070919306416","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carcinoma-ex-pleomorphic-adenoma","kind":"cancer","name":"Carcinoma ex pleomorphic adenoma","route":"/cancers/carcinoma-ex-pleomorphic-adenoma/","field":"links","label":"American Journal of Otolaryngology 2019: carcinoma ex pleomorphic adenoma in SEER 1973 to 2015, 619 patients"}]},{"url":"https://doi.org/10.1016/j.amjsurg.2021.05.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002961021003305","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"American Journal of Surgery 2022: positive margins after mastectomy in 357 patients with invasive lobular carcinoma"}]},{"url":"https://doi.org/10.1016/j.annonc.2019.10.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419354651","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-h-pylori-eradication","kind":"term","name":"Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma","route":"/terms/lymphoma-tx-h-pylori-eradication/","field":"links","label":"Zucca et al., marginal zone lymphomas: ESMO clinical practice guidelines, Annals of Oncology 2020"},{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/","field":"links","label":"Ann Oncol 2020"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"Zucca 2020, Annals of Oncology: marginal zone lymphomas, ESMO clinical practice guidelines"},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"links","label":"Zucca 2020, Annals of Oncology: marginal zone lymphomas, ESMO clinical practice guidelines"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"links","label":"Zucca 2020, Annals of Oncology: marginal zone lymphomas, ESMO clinical practice guidelines"},{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","field":"links","label":"Zucca 2020, Annals of Oncology: marginal zone lymphomas, ESMO clinical practice guidelines"}]},{"url":"https://doi.org/10.1016/j.annonc.2019.11.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419406984","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020","kind":"paper","name":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","route":"/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/","field":"links","label":"Barroso-Sousa et al., Ann Oncol 2020: prevalence of high tumour mutation burden in 3,969 breast cancers"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.02.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420360774","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Fabi et al., cancer-related fatigue, ESMO clinical practice guidelines (Annals of Oncology 2020)"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.04.478","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420397969","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alex-ann-oncol-2020-update","kind":"paper","name":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","route":"/key-papers/paper-alex-ann-oncol-2020-update/","field":"links","label":"Ann Oncol 2020"},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","field":"links","label":"Annals of Oncology 2020 (five-year survival)"},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","field":"outcomes.source (Progression-free survival (investigator, updated))"},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.05.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420398732","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020","kind":"paper","name":"Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients","route":"/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/","field":"links","label":"Ann Oncol 2020"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"links","label":"Anti-PD-1 in 193 Japanese patients with acral melanoma (Annals of Oncology 2020)"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.06.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420399324","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020","kind":"paper","name":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/","field":"links","label":"Ann Oncol 2020"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.07.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342039949X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","field":"papers","label":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},{"id":"paper-jean-pascal-machiels-ann-oncol-2020","kind":"paper","name":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/","field":"links","label":"Ann Oncol 2020"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.08.2098","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420421064","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.10.477","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420429795","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","field":"links","label":"TOSCA: overall survival with 3 or 6 months of adjuvant chemotherapy (Annals of Oncology 2021)"},{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","field":"outcomes.source (Relapse-free survival)"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.11.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342043162X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021","kind":"paper","name":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","route":"/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/","field":"links","label":"Magbanua et al., Ann Oncol 2021: ctDNA during neoadjuvant therapy in 84 I-SPY 2 patients"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.11.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420431667","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-solar-1-ann-oncol-2021-update","kind":"paper","name":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","route":"/key-papers/paper-solar-1-ann-oncol-2021-update/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2020.12.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420432107","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","field":"papers","label":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †"},{"id":"paper-jean-pascal-machiels-ann-oncol-2021","kind":"paper","name":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.01.070","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421000983","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","field":"links","label":"Tempero et al., RESOLVE (Annals of Oncology 2021)"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Tempero et al., RESOLVE (Annals of Oncology 2021)"},{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/","field":"links","label":"Tempero et al., RESOLVE (Annals of Oncology 2021)"},{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/","field":"outcomes.source (Overall survival)"},{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/","field":"outcomes.source (Progression-free survival (investigator))"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.02.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421001575","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021","kind":"paper","name":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.05.355","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421015556","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"links","label":"IMpassion130 final overall survival (Annals of Oncology 2021)"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.05.801","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421020263","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","field":"links","label":"IMpassion131 primary results (Annals of Oncology 2021)"},{"id":"paper-impassion131-ann-oncol-2021","kind":"paper","name":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","route":"/key-papers/paper-impassion131-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.05.806","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421020469","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-klein-ccga3-mced-validation-ann-oncol-2021","kind":"paper","name":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","route":"/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/","field":"links","label":"Klein et al., Ann Oncol 2021: CCGA3 validation of the Galleri methylation test in 4,077 participants"},{"id":"ccga-study","kind":"term","name":"CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test","route":"/terms/ccga-study/","field":"links","label":"Klein et al., Ann Oncol 2021: CCGA3 validation of the Galleri methylation test in 4,077 participants"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.06.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421020470","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/","field":"links","label":"Bardia et al., Ann Oncol 2021: Trop-2 and germline BRCA biomarker analyses in ASCENT"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.06.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421020640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-anal-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.07.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421021840","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","field":"papers","label":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline"},{"id":"paper-esmo-sts-guideline-gronchi-ann-oncol-2021","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","route":"/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"standardOfCare.guideline (Localised)"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.08.1995","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421042800","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021","kind":"paper","name":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline","route":"/key-papers/paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.09.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342104480X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","field":"links","label":"ESMO-EURACAN GIST guideline (2022)"},{"id":"paper-casali-ann-oncol","kind":"paper","name":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-casali-ann-oncol/","field":"links","label":"Ann Oncol 2022"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.09.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421044987","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Palliation of symptoms: bone, pleura, skin and end of life)"},{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/","field":"links","label":"Ann Oncol 2021"},{"id":"tnbc-symptom-control-palliation","kind":"term","name":"Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life","route":"/terms/tnbc-symptom-control-palliation/","field":"links","label":"ESMO metastatic breast cancer guideline (Annals of Oncology 2021)"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.11.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753421048286","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"papers","label":"European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer"}]},{"url":"https://doi.org/10.1016/j.annonc.2021.12.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roar-ann-oncol-2022-update","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","route":"/key-papers/paper-roar-ann-oncol-2022-update/","field":"links","label":"Ann Oncol 2022"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.01.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422000187","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","kind":"paper","name":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","route":"/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/","field":"links","label":"Ann Oncol 2022"},{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"links","label":"BrighTNess 4-year follow-up (Annals of Oncology 2022)"},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/","field":"links","label":"BrighTNess 4-year follow-up (Annals of Oncology 2022)"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.02.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422001132","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neotrip","kind":"trial","name":"NeoTRIP (NeoTRIPaPDL1)","route":"/trials/neotrip/","field":"links","label":"Gianni et al., Annals of Oncology 2022: NeoTRIP pathological complete response"},{"id":"neotrip","kind":"trial","name":"NeoTRIP (NeoTRIPaPDL1)","route":"/trials/neotrip/","field":"outcomes.source (Pathological complete response (breast and nodes))"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.05.519","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422017203","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-158-ann-oncol-2022-update","kind":"paper","name":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","route":"/key-papers/paper-keynote-158-ann-oncol-2022-update/","field":"links","label":"Ann Oncol 2022"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.07.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422018592","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"papers","label":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.09.159","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422041655","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Geyer et al., overall survival in OlympiA (Annals of Oncology 2022)"},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/","field":"links","label":"Ann Oncol 2022"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"links","label":"OlympiA overall survival (Annals of Oncology 2022)"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"papers","label":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.09.161","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422041849","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/","field":"links","label":"Seufferlein et al., NEONAX (Annals of Oncology 2023)"},{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/","field":"outcomes.source (Disease-free survival at 18 months (modified intention to treat))"},{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/","field":"outcomes.source (Overall survival (intention to treat))"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.10.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422041874","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Haanen et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline (Annals of Oncology 2022)"},{"id":"paper-haanen-ann-oncol","kind":"paper","name":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-haanen-ann-oncol/","field":"links","label":"Ann Oncol 2022"},{"id":"immune-endocrinopathy","kind":"term","name":"Immune-related endocrinopathies (thyroiditis, hypophysitis)","route":"/terms/immune-endocrinopathy/","field":"links","label":"Haanen et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline (Annals of Oncology 2022)"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.10.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422041928","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.10.506","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422046993","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"ESMO Clinical Practice Guideline: biliary tract cancer (Ann Oncol 2023)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Palliation of obstruction and symptoms)"},{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.11.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753422047354","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/","field":"links","label":"Turner et al., Annals of Oncology 2023: results of the c-TRAK TN trial"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/","field":"outcomes.source (ctDNA detection by 12 months)"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/","field":"outcomes.source (Sustained ctDNA clearance on pembrolizumab)"}]},{"url":"https://doi.org/10.1016/j.annonc.2022.11.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342204769X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"links","label":"ESMO CUP guideline 2023"},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"standardOfCare.guideline (Favourable subsets)"},{"id":"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023","kind":"paper","name":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"links","label":"ESMO CUP guideline 2023"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Work-up)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Axillary node adenocarcinoma in a woman)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Peritoneal serous carcinoma in a woman)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Cervical node squamous carcinoma)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Midline poorly differentiated carcinoma in a young man)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Neuroendocrine carcinoma of unknown primary)"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"standardOfCare.guideline (Single metastasis)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"links","label":"ESMO CUP guideline 2023"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"standardOfCare.guideline (Work-up)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"standardOfCare.guideline (First line, fit patients)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"standardOfCare.guideline (Actionable alterations)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"standardOfCare.guideline (Second line)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"standardOfCare.guideline (Poor performance status)"}]},{"url":"https://doi.org/10.1016/j.annonc.2023.01.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753423000492","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-042-tmb-mutations-ann-oncol-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042","route":"/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/","field":"links","label":"Mok et al., Ann Oncol 2023: tissue tumour mutational burden and mutation status in KEYNOTE-042 (793 patients)"}]},{"url":"https://doi.org/10.1016/j.annonc.2023.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753423007640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02486718-ann-oncol-2023-update","kind":"paper","name":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","route":"/key-papers/paper-nct02486718-ann-oncol-2023-update/","field":"links","label":"Ann Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.annonc.2023.08.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753423008244","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.annonc.2023.08.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753423008359","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-st-gallen-2023-consensus-ann-oncol-2023","kind":"paper","name":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","route":"/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/","field":"links","label":"Ann Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.annonc.2023.11.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753423051049","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Choice of neoadjuvant backbone: the platinum debate)"},{"id":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","kind":"paper","name":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/","field":"links","label":"Ann Oncol 2024"}]},{"url":"https://doi.org/10.1016/j.annonc.2024.02.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753424000462","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/","field":"links","label":"KEYNOTE-522: event-free survival by residual cancer burden (Annals of Oncology 2024)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"KEYNOTE-522 event-free survival by residual cancer burden (Annals of Oncology 2024)"}]},{"url":"https://doi.org/10.1016/j.annonc.2024.04.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342400111X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"papers","label":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group"}]},{"url":"https://doi.org/10.1016/j.annonc.2024.04.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342400139X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"papers","label":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3"},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"papers","label":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3"}]},{"url":"https://doi.org/10.1016/j.annonc.2024.08.2239","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753424037591","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-bispecific-step-up","kind":"term","name":"CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one","route":"/terms/lymphoma-tx-bispecific-step-up/","field":"links","label":"Odronextamab in relapsed or refractory follicular lymphoma, ELM-2, Annals of Oncology 2024"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Relapsed follicular lymphoma after two or more lines: bispecific antibodies, CAR-T and R-squared)"}]},{"url":"https://doi.org/10.1016/j.annonc.2024.12.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425000031","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","field":"outcomes.source (Overall survival)"},{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","field":"outcomes.source (Progression-free survival)"},{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","field":"outcomes.source (Overall survival, non-epithelioid histology)"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.03.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425001231","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/","field":"links","label":"Ann Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.04.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425001577","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/","field":"links","label":"Ann Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.05.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425001991","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-641","kind":"trial","name":"KEYNOTE-641","route":"/trials/keynote-641/","field":"links","label":"KEYNOTE-641 (Annals of Oncology 2025)"},{"id":"keynote-641","kind":"trial","name":"KEYNOTE-641","route":"/trials/keynote-641/","field":"outcomes.source (Overall survival (median))"},{"id":"keynote-641","kind":"trial","name":"KEYNOTE-641","route":"/trials/keynote-641/","field":"outcomes.source (Grade 3 or higher treatment-related adverse events)"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.05.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425002005","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-991","kind":"trial","name":"KEYNOTE-991","route":"/trials/keynote-991/","field":"links","label":"KEYNOTE-991 (Annals of Oncology 2025)"},{"id":"keynote-991","kind":"trial","name":"KEYNOTE-991","route":"/trials/keynote-991/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"keynote-991","kind":"trial","name":"KEYNOTE-991","route":"/trials/keynote-991/","field":"outcomes.source (Grade 3 or higher adverse events)"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.06.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425008294","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/","field":"links","label":"Ann Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.07.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425009147","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","kind":"paper","name":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","route":"/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/","field":"links","label":"Ann Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.09.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425047180","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-st-gallen-2025-consensus-ann-oncol-2025","kind":"paper","name":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","route":"/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/","field":"links","label":"Ann Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.10.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425049361","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capitello-281-ann-oncol-2026","kind":"paper","name":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","route":"/key-papers/paper-capitello-281-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.10.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425049488","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-monarche-ann-oncol-2026-update","kind":"paper","name":"Overall survival with abemaciclib in early breast cancer","route":"/key-papers/paper-monarche-ann-oncol-2026-update/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.10.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425049683","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026","kind":"paper","name":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.11.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425062635","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-her2climb-02-ann-oncol-2026","kind":"paper","name":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","route":"/key-papers/paper-her2climb-02-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.11.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753425062878","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04379635-ann-oncol-2026-update","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","route":"/key-papers/paper-nct04379635-ann-oncol-2026-update/","field":"links","label":"Ann Oncol 2026"},{"id":"nct04379635","kind":"trial","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04379635/","field":"links","label":"RATIONALE-315 final analysis (Annals of Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.annonc.2025.12.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342506332X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"links","label":"CAPItello-290 (Annals of Oncology 2026)"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","field":"links","label":"CAPItello-290 (Annals of Oncology 2026)"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","field":"outcomes.source (Overall survival, all patients)"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","field":"outcomes.source (Overall survival, PIK3CA/AKT1/PTEN-altered tumours)"},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","field":"outcomes.source (Progression-free survival (investigator), all patients)"}]},{"url":"https://doi.org/10.1016/j.annonc.2026.02.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753426000657","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"links","label":"PEACE-3 final overall survival (Annals of Oncology 2026)"},{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/","field":"links","label":"PEACE-3 final overall survival (Annals of Oncology 2026)"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"links","label":"PEACE-3 final overall survival (Annals of Oncology 2026)"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"outcomes.source (Overall survival (median))"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"outcomes.source (Radiological progression-free survival)"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"outcomes.source (Grade 3 or worse treatment-emergent adverse events)"}]},{"url":"https://doi.org/10.1016/j.annonc.2026.03.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753426001304","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"links","label":"TROPION-Breast02 (Annals of Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.annonc.2026.05.693","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S092375342600877X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03742102-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study","route":"/key-papers/paper-nct03742102-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","field":"links","label":"BEGONIA arms 7 and 8 (Annals of Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.annonc.2026.08.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753426014560","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.annonc.2026.08.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753426014626","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-671-ann-oncol-2026-update","kind":"paper","name":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","route":"/key-papers/paper-keynote-671-ann-oncol-2026-update/","field":"links","label":"Ann Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.athoracsur.2007.09.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0003497507019650","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"Kesler 2008, Ann Thorac Surg: 25 years of surgery for primary mediastinal non-seminomatous germ cell tumours"}]},{"url":"https://doi.org/10.1016/j.bbmt.2018.12.758","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1083879118316914","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"standardOfCare.guideline (Supportive care that belongs to lymphoma specifically)"},{"id":"lymphoma-tx-crs-icans","kind":"term","name":"Cytokine release syndrome and ICANS: grading and management","route":"/terms/lymphoma-tx-crs-icans/","field":"links","label":"Lee et al., ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biology of Blood and Marrow Transplantation 2019"},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","field":"links","label":"ASTCT consensus grading for CRS and ICANS (Lee et al., Biol Blood Marrow Transplant 2019)"},{"id":"paper-lee-biol-blood-marrow-transplant","kind":"paper","name":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","route":"/key-papers/paper-lee-biol-blood-marrow-transplant/","field":"links","label":"Biol Blood Marrow Transplant 2019"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"ASTCT consensus grading for CRS and ICANS (2019)"}]},{"url":"https://doi.org/10.1016/j.bbmt.2020.01.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1083879120300513","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"remestemcel-l","kind":"drug","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","field":"links","label":"MSB-GVHD001 (Biol Blood Marrow Transplant 2020)"},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"links","label":"Biology of Blood and Marrow Transplantation 2020"},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"outcomes.source (Overall response rate at day 28 (complete plus partial))"},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"outcomes.source (Overall survival at day 100)"},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","field":"outcomes.source (Overall survival at day 180)"},{"id":"paper-msb-gvhd001-bbmt-2020","kind":"paper","name":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","route":"/key-papers/paper-msb-gvhd001-bbmt-2020/","field":"links","label":"Biology of Blood and Marrow Transplantation 2020"}]},{"url":"https://doi.org/10.1016/j.bcp.2023.115727","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0006295223003180","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-biochem-pharmacol-2023","kind":"paper","name":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","route":"/key-papers/paper-ezh2-sarcoma-biochem-pharmacol-2023/","field":"links","label":"Biochem Pharmacol 2023"}]},{"url":"https://doi.org/10.1016/j.biopha.2020.110668","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0753332220308611","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"papers","label":"Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2"}]},{"url":"https://doi.org/10.1016/j.bjhh.2016.09.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1516848416301311","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"links","label":"Rev Bras Hematol Hemoter 2017: splenic marginal zone lymphoma, review of diagnostic and therapeutic challenges"}]},{"url":"https://doi.org/10.1016/j.bpg.2022.101793","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1521691822000099","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"Best Pract Res Clin Gastroenterol 2022: management of familial adenomatous polyposis and MUTYH-associated polyposis, new insights"}]},{"url":"https://doi.org/10.1016/j.breast.2022.03.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0960977622000728","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-breast-2022","kind":"paper","name":"\"The emerging role of capivasertib in breast cancer\"","route":"/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/","field":"links","label":"Breast 2022"}]},{"url":"https://doi.org/10.1016/j.canep.2021.102014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1877782121001314","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"papers","label":"Thyroid cancer overdiagnosis revisited"}]},{"url":"https://doi.org/10.1016/j.canep.2023.102354","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1877782123000346","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Cancer Epidemiol 2023: the value of blood-based measures of liver function and urate in lung cancer risk prediction (388,199 UK Biobank participants; the 1.51 percent six-year threshold)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"Cancer Epidemiol 2023: the value of blood-based measures of liver function and urate in lung cancer risk prediction (388,199 UK Biobank participants; the 1.51 percent six-year threshold)"},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","field":"links","label":"Cancer Epidemiol 2023: the value of blood-based measures of liver function and urate in lung cancer risk prediction (388,199 UK Biobank participants; the 1.51 percent six-year threshold)"}]},{"url":"https://doi.org/10.1016/j.canep.2025.102958","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1877782125002188","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Patkar, Cancer Epidemiol 2025: hospital-based gallbladder cancer registry, Tata Memorial, India"},{"id":"paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025","kind":"paper","name":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care","route":"/key-papers/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025/","field":"links","label":"Cancer Epidemiol 2025"}]},{"url":"https://doi.org/10.1016/j.canlet.2005.01.038","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0304383505001126","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"papers","label":"Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells"}]},{"url":"https://doi.org/10.1016/j.canlet.2025.218006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0304383525005762","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/","field":"links","label":"Cancer Lett 2026"}]},{"url":"https://doi.org/10.1016/j.ccell.2014.09.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610814003699","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","field":"papers","label":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells"},{"id":"paper-shelley-hwang-cancer-cell-2014","kind":"paper","name":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","route":"/key-papers/paper-shelley-hwang-cancer-cell-2014/","field":"links","label":"Cancer Cell 2014"}]},{"url":"https://doi.org/10.1016/j.ccell.2014.10.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610814004103","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jain-cancer-cell","kind":"paper","name":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","route":"/key-papers/paper-jain-cancer-cell/","field":"links","label":"Cancer Cell 2014"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Jain, Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia (Cancer Cell 2014)"}]},{"url":"https://doi.org/10.1016/j.ccell.2015.04.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S153561081500135X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pajtler-cancer-cell","kind":"paper","name":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups","route":"/key-papers/paper-pajtler-cancer-cell/","field":"links","label":"Cancer Cell 2015"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"links","label":"Pajtler 2015: molecular classification of ependymal tumours (Cancer Cell)"}]},{"url":"https://doi.org/10.1016/j.ccell.2015.07.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S153561081500269X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"papers","label":"Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia"}]},{"url":"https://doi.org/10.1016/j.ccell.2015.09.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610815003499","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"papers","label":"RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics"}]},{"url":"https://doi.org/10.1016/j.ccell.2017.05.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610817302015","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017","kind":"paper","name":"Intertumoural heterogeneity within medulloblastoma subgroups","route":"/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/","field":"links","label":"Cancer Cell 2017"}]},{"url":"https://doi.org/10.1016/j.ccell.2017.07.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610817302994","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","kind":"paper","name":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/","field":"links","label":"Cancer Genome Atlas Research Network, Cancer Cell 2017: integrated characterisation of 150 pancreatic ductal adenocarcinomas"}]},{"url":"https://doi.org/10.1016/j.ccell.2017.08.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610817303628","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","field":"papers","label":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas"},{"id":"paper-mackay-paediatric-hgg-cancer-cell-2017","kind":"paper","name":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","route":"/key-papers/paper-mackay-paediatric-hgg-cancer-cell-2017/","field":"links","label":"Cancer Cell 2017"}]},{"url":"https://doi.org/10.1016/j.ccell.2017.09.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610817304075","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017","kind":"paper","name":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signalling","route":"/key-papers/paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017/","field":"links","label":"Bluemn et al., Cancer Cell 2017: androgen receptor pathway-independent, neuroendocrine-null metastatic prostate cancer sustained by FGF and MAPK signalling"}]},{"url":"https://doi.org/10.1016/j.ccell.2017.12.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610817305561","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","kind":"paper","name":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","route":"/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/","field":"links","label":"Yaeger et al., Cancer Cell 2018: prospective targeted sequencing of 1,134 colorectal cancers (MSK)"}]},{"url":"https://doi.org/10.1016/j.ccell.2018.02.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610818300564","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018","kind":"paper","name":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","route":"/key-papers/paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018/","field":"links","label":"Andricovich et al., Cancer Cell 2018: KDM6A loss induces squamous-like pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.ccell.2018.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610818303064","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","field":"links","label":"Kahles et al., Comprehensive analysis of alternative splicing across tumours from 8,705 patients (Cancer Cell 2018)"},{"id":"paper-kahles-cancer-cell","kind":"paper","name":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","route":"/key-papers/paper-kahles-cancer-cell/","field":"links","label":"Cancer Cell 2018"}]},{"url":"https://doi.org/10.1016/j.ccell.2019.02.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/","field":"links","label":"Jiang et al., Cancer Cell 2019: genomic and transcriptomic landscape of 465 Chinese TNBCs (FUSCC)"}]},{"url":"https://doi.org/10.1016/j.ccell.2019.02.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610819301047","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","field":"papers","label":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets"},{"id":"paper-shelley-hwang-cancer-cell-2019","kind":"paper","name":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","route":"/key-papers/paper-shelley-hwang-cancer-cell-2019/","field":"links","label":"Cancer Cell 2019"}]},{"url":"https://doi.org/10.1016/j.ccell.2019.10.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610819304763","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","field":"papers","label":"A selective small-molecule STAT3 degrader achieves complete tumor regression in vivo"}]},{"url":"https://doi.org/10.1016/j.ccell.2019.12.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610819305793","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"papers","label":"Sticking it to KRAS: Covalent Inhibitors Enter the Clinic"}]},{"url":"https://doi.org/10.1016/j.ccell.2020.08.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610820304153","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020","kind":"paper","name":"Challenges and opportunities for pancreatic cancer immunotherapy","route":"/key-papers/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020/","field":"links","label":"Bear, Vonderheide and O'Hara, Cancer Cell 2020: challenges and opportunities for pancreatic cancer immunotherapy"}]},{"url":"https://doi.org/10.1016/j.ccell.2020.10.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610820305468","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exceptional-responder","kind":"term","name":"Exceptional responder","route":"/terms/exceptional-responder/","field":"links","label":"Wheeler, Cancer Cell 2021: molecular features of cancers exhibiting exceptional responses to treatment"}]},{"url":"https://doi.org/10.1016/j.ccell.2020.12.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610820306620","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","kind":"paper","name":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","route":"/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/","field":"links","label":"Gay et al., Cancer Cell 2021: four transcriptional subtypes of small-cell lung cancer with distinct vulnerabilities, including the inflamed subtype"}]},{"url":"https://doi.org/10.1016/j.ccell.2022.02.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610822000599","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wang-cancer-cell","kind":"paper","name":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","route":"/key-papers/paper-wang-cancer-cell/","field":"links","label":"Cancer Cell 2022"},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","field":"links","label":"Cancer Cell 2022"},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/j.ccell.2022.07.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610822003178","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"multimodal-fusion","kind":"term","name":"Multimodal fusion (early, late, modality dropout)","route":"/terms/multimodal-fusion/","field":"links","label":"Chen et al., PORPOISE: pan-cancer integrative histology-genomic analysis via multimodal deep learning (Cancer Cell 2022)"}]},{"url":"https://doi.org/10.1016/j.ccell.2023.02.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610823000442","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","field":"links","label":"de Visser & Joyce, The evolving tumor microenvironment (Cancer Cell 2023)"},{"id":"paper-de-visser-cancer-cell","kind":"paper","name":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","route":"/key-papers/paper-de-visser-cancer-cell/","field":"links","label":"Cancer Cell 2023"}]},{"url":"https://doi.org/10.1016/j.ccell.2023.11.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610823003665","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"papers","label":"Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies"}]},{"url":"https://doi.org/10.1016/j.ccell.2025.09.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610825003964","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/","field":"links","label":"Cancer Cell 2025"}]},{"url":"https://doi.org/10.1016/j.ccr.2004.11.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S153561080400337X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/","field":"links","label":"O'Shea 2004, the correction to the mechanism (Cancer Cell)"}]},{"url":"https://doi.org/10.1016/j.ccr.2005.03.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610805000942","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","field":"papers","label":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis"}]},{"url":"https://doi.org/10.1016/j.ccr.2005.08.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610805002680","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paszek-cancer-cell","kind":"paper","name":"Tensional homeostasis and the malignant phenotype","route":"/key-papers/paper-paszek-cancer-cell/","field":"links","label":"Cancer Cell 2005"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Paszek et al., Tensional homeostasis and the malignant phenotype (Cancer Cell 2005)"}]},{"url":"https://doi.org/10.1016/j.ccr.2006.12.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610806003680","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weaver-cancer-cell","kind":"paper","name":"Aneuploidy acts both oncogenically and as a tumor suppressor","route":"/key-papers/paper-weaver-cancer-cell/","field":"links","label":"Cancer Cell 2007"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Weaver et al., Aneuploidy acts both oncogenically and as a tumor suppressor (Cancer Cell 2007)"}]},{"url":"https://doi.org/10.1016/j.ccr.2010.05.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610810002382","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","kind":"paper","name":"Integrative genomic profiling of human prostate cancer","route":"/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/","field":"links","label":"Cancer Cell 2010"}]},{"url":"https://doi.org/10.1016/j.ccr.2011.04.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610811001553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011","kind":"paper","name":"Reciprocal feedback regulation of PI3K and androgen receptor signalling in PTEN-deficient prostate cancer","route":"/key-papers/paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011/","field":"links","label":"Carver et al., Cancer Cell 2011: reciprocal feedback between PI3K and androgen receptor signalling in PTEN-deficient prostate cancer"}]},{"url":"https://doi.org/10.1016/j.ccr.2011.10.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610811003989","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","field":"papers","label":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia"}]},{"url":"https://doi.org/10.1016/j.ccr.2012.02.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610812000827","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hanahan-cancer-cell","kind":"paper","name":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","route":"/key-papers/paper-hanahan-cancer-cell/","field":"links","label":"Cancer Cell 2012"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Hanahan and Coussens, Accessories to the crime: functions of cells recruited to the tumor microenvironment (Cancer Cell 2012)"}]},{"url":"https://doi.org/10.1016/j.ccr.2014.04.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610814001755","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014","kind":"paper","name":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","route":"/key-papers/paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014/","field":"links","label":"Cancer Cell 2014"}]},{"url":"https://doi.org/10.1016/j.ccr.2014.04.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610814001846","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014","kind":"paper","name":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","route":"/key-papers/paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014/","field":"links","label":"Rhim et al., Cancer Cell 2014: stromal elements restrain pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.ccr.2014.07.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610814003043","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-chromophobe-davis-cancer-cell-2014","kind":"paper","name":"The somatic genomic landscape of chromophobe renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-chromophobe-davis-cancer-cell-2014/","field":"links","label":"Cancer Cell 2014"}]},{"url":"https://doi.org/10.1016/j.cell.2007.01.037","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867407001961","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","field":"papers","label":"Programmed anuclear cell death delimits platelet life span"}]},{"url":"https://doi.org/10.1016/j.cell.2008.03.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867408004443","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mani-emt-stem-cell-properties-cell-2008","kind":"paper","name":"Mani 2008: the epithelial-mesenchymal transition generates cells with properties of stem cells","route":"/key-papers/paper-mani-emt-stem-cell-properties-cell-2008/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/j.cell.2009.05.046","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867409006515","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"papers","label":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis"}]},{"url":"https://doi.org/10.1016/j.cell.2009.10.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867409013531","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-levental-cell","kind":"paper","name":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","route":"/key-papers/paper-levental-cell/","field":"links","label":"Cell 2009"},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"links","label":"Levental et al., Matrix crosslinking forces tumor progression by enhancing integrin signaling (Cell 2009)"}]},{"url":"https://doi.org/10.1016/j.cell.2010.01.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867410000607","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"papers","label":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer"},{"id":"paper-grivennikov-immunity-inflammation-cancer-cell-2010","kind":"paper","name":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer","route":"/key-papers/paper-grivennikov-immunity-inflammation-cancer-cell-2010/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/j.cell.2010.02.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867410001807","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sharma-cell","kind":"paper","name":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","route":"/key-papers/paper-sharma-cell/","field":"links","label":"Cell 2010"},{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/","field":"links","label":"Sharma et al., A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations (Cell 2010)"}]},{"url":"https://doi.org/10.1016/j.cell.2010.06.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867410006653","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","kind":"paper","name":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","route":"/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/","field":"links","label":"Full text (DOI)"},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/","field":"links","label":"Lemmon & Schlessinger, Cell signaling by receptor tyrosine kinases (Cell 2010)"}]},{"url":"https://doi.org/10.1016/j.cell.2010.11.055","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867410013772","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stephens-cell","kind":"paper","name":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","route":"/key-papers/paper-stephens-cell/","field":"links","label":"Cell 2011"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Stephens et al., Massive genomic rearrangement acquired in a single catastrophic event during cancer development (Cell 2011)"}]},{"url":"https://doi.org/10.1016/j.cell.2011.02.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867411001279","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","field":"links","label":"Hanahan & Weinberg, Hallmarks of Cancer: The Next Generation (Cell 2011)"},{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/","field":"links","label":"Hallmarks of Cancer: The Next Generation (2011)"},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","field":"links","label":"Hanahan and Weinberg, Hallmarks of cancer: the next generation (Cell 2011)"}]},{"url":"https://doi.org/10.1016/j.cell.2011.11.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867411013547","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-friedl-cell","kind":"paper","name":"Cancer invasion and the microenvironment: plasticity and reciprocity","route":"/key-papers/paper-friedl-cell/","field":"links","label":"Cell 2011"},{"id":"invasion-ecm-degradation","kind":"pathway","name":"Invasion: proteases, adhesion & the invasive front","route":"/pathways/invasion-ecm-degradation/","field":"links","label":"Friedl & Alexander, Cancer invasion and the microenvironment: plasticity and reciprocity (Cell 2011)"}]},{"url":"https://doi.org/10.1016/j.cell.2012.08.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867412010227","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","field":"papers","label":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers"}]},{"url":"https://doi.org/10.1016/j.cell.2013.03.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867413003437","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-baca-punctuated-evolution-chromoplexy-cell-2013","kind":"paper","name":"Punctuated evolution of prostate cancer genomes","route":"/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/","field":"links","label":"Cell 2013"},{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/","field":"links","label":"Baca et al., Cell 2013: punctuated evolution of prostate cancer genomes"}]},{"url":"https://doi.org/10.1016/j.cell.2013.08.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867413010155","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"papers","label":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity"}]},{"url":"https://doi.org/10.1016/j.cell.2014.07.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867414009271","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aceto-cell","kind":"paper","name":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","route":"/key-papers/paper-aceto-cell/","field":"links","label":"Cell 2014"},{"id":"intravasation-ctc-survival","kind":"pathway","name":"Intravasation & circulating tumour cells","route":"/pathways/intravasation-ctc-survival/","field":"links","label":"Aceto et al., Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis (Cell 2014)"}]},{"url":"https://doi.org/10.1016/j.cell.2014.11.036","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S009286741401513X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","field":"papers","label":"Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production"}]},{"url":"https://doi.org/10.1016/j.cell.2014.12.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S009286741401592X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"papers","label":"Organoid models of human and mouse ductal pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.cell.2015.03.030","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867415003177","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"papers","label":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential"}]},{"url":"https://doi.org/10.1016/j.cell.2015.05.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867415005486","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/","field":"links","label":"Cell 2015"},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"papers","label":"Integrative clinical genomics of advanced prostate cancer"}]},{"url":"https://doi.org/10.1016/j.cell.2015.08.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867415010296","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chang-cell","kind":"paper","name":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","route":"/key-papers/paper-chang-cell/","field":"links","label":"Cell 2015"},{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/","field":"links","label":"Chang et al., Metabolic competition in the tumor microenvironment is a driver of cancer progression (Cell 2015)"}]},{"url":"https://doi.org/10.1016/j.cell.2015.09.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867415011952","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"Ciriello 2015, Cell: comprehensive molecular portraits of invasive lobular breast cancer (TCGA)"},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"Ciriello 2015, Cell: comprehensive molecular portraits of invasive lobular breast cancer (TCGA)"}]},{"url":"https://doi.org/10.1016/j.cell.2015.10.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867415013392","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","field":"links","label":"Cell 2015"}]},{"url":"https://doi.org/10.1016/j.cell.2016.01.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867416000556","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","field":"papers","label":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs"},{"id":"paper-jacques-grill-cell-2016","kind":"paper","name":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","route":"/key-papers/paper-jacques-grill-cell-2016/","field":"links","label":"Cell 2016"}]},{"url":"https://doi.org/10.1016/j.cell.2016.12.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867416317275","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bradner-cell","kind":"paper","name":"Transcriptional Addiction in Cancer","route":"/key-papers/paper-bradner-cell/","field":"links","label":"Cell 2017"},{"id":"transcription-addiction","kind":"pathway","name":"Transcriptional machinery & addiction","route":"/pathways/transcription-addiction/","field":"links","label":"Bradner, Hnisz & Young, Transcriptional addiction in cancer (Cell 2017)"}]},{"url":"https://doi.org/10.1016/j.cell.2017.01.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S009286741730065X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"papers","label":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy"}]},{"url":"https://doi.org/10.1016/j.cell.2017.01.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417300661","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"links","label":"McGranahan & Swanton, Clonal heterogeneity and tumor evolution (Cell 2017)"},{"id":"paper-mcgranahan-cell","kind":"paper","name":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","route":"/key-papers/paper-mcgranahan-cell/","field":"links","label":"Cell 2017"}]},{"url":"https://doi.org/10.1016/j.cell.2017.04.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417304270","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","field":"papers","label":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses"}]},{"url":"https://doi.org/10.1016/j.cell.2017.06.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417306517","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","field":"links","label":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without (Cell 2017)"},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/","field":"links","label":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without (Cell 2017)"},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","field":"papers","label":"Defining a cancer dependency map"},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","field":"links","label":"DOI"},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/","field":"links","label":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without (Cell 2017)"}]},{"url":"https://doi.org/10.1016/j.cell.2017.08.028","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417309534","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kastenhuber-cell","kind":"paper","name":"Putting p53 in Context","route":"/key-papers/paper-kastenhuber-cell/","field":"links","label":"Cell 2017"},{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/","field":"links","label":"Kastenhuber & Lowe, Putting p53 in context (Cell 2017)"}]},{"url":"https://doi.org/10.1016/j.cell.2017.09.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417310681","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/","field":"links","label":"Faubert et al., Lactate metabolism in human lung tumours (Cell 2017)"},{"id":"paper-faubert-cell","kind":"paper","name":"Lactate Metabolism in Human Lung Tumors","route":"/key-papers/paper-faubert-cell/","field":"links","label":"Cell 2017"}]},{"url":"https://doi.org/10.1016/j.cell.2017.09.028","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417311224","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","field":"papers","label":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab"},{"id":"paper-shailender-bhatia-cell-2017","kind":"paper","name":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","route":"/key-papers/paper-shailender-bhatia-cell-2017/","field":"links","label":"Cell 2017"}]},{"url":"https://doi.org/10.1016/j.cell.2017.09.042","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417311364","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-martincorena-cell","kind":"paper","name":"Universal Patterns of Selection in Cancer and Somatic Tissues","route":"/key-papers/paper-martincorena-cell/","field":"links","label":"Cell 2017"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"links","label":"Martincorena et al., Universal patterns of selection in cancer and somatic tissues (Cell 2017)"}]},{"url":"https://doi.org/10.1016/j.cell.2017.11.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867417313181","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","field":"links","label":"Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","field":"metrics (Approved combination therapies whose clinical benefit is explained by independent drug action (patient-to-patient variability) without synergy)"},{"id":"idea-tr2-smart-sequencing-adc","kind":"idea","name":"Sequential multiple-assignment randomised trials to find the best order of ADCs","route":"/ideas/idea-tr2-smart-sequencing-adc/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-alternating-vs-concurrent","kind":"idea","name":"Test alternating drug schedules against giving both drugs at once","route":"/ideas/idea-tr2-alternating-vs-concurrent/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-ctdna-futility-gates","kind":"idea","name":"Kill combination arms early using circulating tumour DNA, before waiting for scans","route":"/ideas/idea-tr2-ctdna-futility-gates/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-resistance-mechanism-baskets","kind":"idea","name":"Combination baskets defined by resistance mechanism rather than by cancer type","route":"/ideas/idea-tr2-resistance-mechanism-baskets/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-combination-patent-pool","kind":"idea","name":"A patent pool for combination method-of-use claims","route":"/ideas/idea-tr2-combination-patent-pool/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-sequence-registry","kind":"idea","name":"A registry of every treatment sequence patients actually receive, with outcomes","route":"/ideas/idea-tr2-sequence-registry/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-bandit-allocation","kind":"idea","name":"Let the trial learn: response-adaptive allocation across many combination arms","route":"/ideas/idea-tr2-bandit-allocation/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-combo-readiness-dossier","kind":"idea","name":"Every approved cancer drug ships with a public combination-readiness data pack","route":"/ideas/idea-tr2-combo-readiness-dossier/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","route":"/ideas/idea-tr2-payer-combo-cwe/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-combination-forecast-tournament","kind":"idea","name":"An open forecasting tournament on which combination trials will succeed","route":"/ideas/idea-tr2-combination-forecast-tournament/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-contribution-of-components-mandate","kind":"idea","name":"No accelerated approval for a combination without proof each part contributes","route":"/ideas/idea-tr2-contribution-of-components-mandate/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-tr2-window-of-opportunity-triplets","kind":"idea","name":"Two-week pre-operative windows to compare combination biology head to head","route":"/ideas/idea-tr2-window-of-opportunity-triplets/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"idea-moon-automated-combination-discovery","kind":"idea","name":"Automated combination discovery: patient-sample screens feeding Bayesian platform trials","route":"/ideas/idea-moon-automated-combination-discovery/","field":"links","label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)"},{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/","field":"links","label":"Cell 2017"}]},{"url":"https://doi.org/10.1016/j.cell.2018.02.060","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S009286741830237X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","field":"papers","label":"Comprehensive characterization of cancer driver genes and mutations"},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","field":"links","label":"Driver genes (Bailey 2018)"}]},{"url":"https://doi.org/10.1016/j.cell.2018.03.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418303027","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"papers","label":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features"},{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/","field":"papers","label":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features"},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","field":"papers","label":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features"},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/","field":"papers","label":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features"},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","field":"links","label":"DOI"},{"id":"organ-of-origin-signal","kind":"term","name":"Tissue-of-origin signal in tumour data","route":"/terms/organ-of-origin-signal/","field":"links","label":"Hoadley et al., Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer (Cell 2018)"}]},{"url":"https://doi.org/10.1016/j.cell.2018.03.043","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418303751","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"papers","label":"Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal"}]},{"url":"https://doi.org/10.1016/j.cell.2018.03.057","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418303891","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"papers","label":"Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal"}]},{"url":"https://doi.org/10.1016/j.cell.2018.06.039","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418308420","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quigley-structural-variation-mcrpc-cell-2018","kind":"paper","name":"Genomic hallmarks and structural variation in metastatic prostate cancer","route":"/key-papers/paper-quigley-structural-variation-mcrpc-cell-2018/","field":"links","label":"Quigley et al., Cell 2018: genomic hallmarks and structural variation in 101 metastatic castration-resistant prostate cancers (deep whole genomes)"},{"id":"ar-amplification","kind":"biomarker","name":"AR amplification (gene and upstream enhancer)","route":"/biomarkers/ar-amplification/","field":"links","label":"Quigley et al., Cell 2018: genomic hallmarks and structural variation in 101 metastatic castration-resistant prostate cancers (deep whole genomes)"},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"papers","label":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer"}]},{"url":"https://doi.org/10.1016/j.cell.2018.07.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418309048","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"Goltsev et al., CODEX multiplexed imaging (Cell 2018)"}]},{"url":"https://doi.org/10.1016/j.cell.2018.08.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867418310432","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bakhoum-cell","kind":"paper","name":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","route":"/key-papers/paper-bakhoum-cell/","field":"links","label":"Cell 2018"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Bakhoum and Cantley, The multifaceted role of chromosomal instability in cancer and its microenvironment (Cell 2018)"}]},{"url":"https://doi.org/10.1016/j.cell.2020.03.034","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867420303275","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/","field":"links","label":"Monje et al., Roadmap for the emerging field of cancer neuroscience (Cell 2020)"},{"id":"paper-monje-cell","kind":"paper","name":"Roadmap for the Emerging Field of Cancer Neuroscience","route":"/key-papers/paper-monje-cell/","field":"links","label":"Cell 2020"}]},{"url":"https://doi.org/10.1016/j.cell.2020.09.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867420311569","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","field":"links","label":"Wells et al., Key parameters of tumour epitope immunogenicity revealed through a consortium approach (Cell 2020)"},{"id":"paper-wells-cell","kind":"paper","name":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","route":"/key-papers/paper-wells-cell/","field":"links","label":"Cell 2020"}]},{"url":"https://doi.org/10.1016/j.cell.2020.10.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S009286742031391X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shen-cell","kind":"paper","name":"Persistent Cancer Cells: The Deadly Survivors","route":"/key-papers/paper-shen-cell/","field":"links","label":"Cell 2020"},{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/","field":"links","label":"Shen, Vagner & Robert, Persistent cancer cells: the deadly survivors (Cell 2020)"}]},{"url":"https://doi.org/10.1016/j.cell.2021.02.034","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867421002233","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-levin-cell","kind":"paper","name":"Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer","route":"/key-papers/paper-levin-cell/","field":"links","label":"Cell 2021"},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"links","label":"Levin, Bioelectric signaling: reprogrammable circuits underlying embryogenesis, regeneration, and cancer (Cell 2021)"}]},{"url":"https://doi.org/10.1016/j.cell.2021.09.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867421011053","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-grunwald-subtme-pancreatic-cell-2021","kind":"paper","name":"Spatially confined sub-tumor microenvironments in pancreatic cancer","route":"/key-papers/paper-grunwald-subtme-pancreatic-cell-2021/","field":"links","label":"Grunwald et al., Cell 2021: spatially confined sub-tumour microenvironments"},{"id":"caf-subtypes-pancreatic","kind":"term","name":"Fibroblast subtypes in the pancreatic cancer stroma (myCAF, iCAF and apCAF)","route":"/terms/caf-subtypes-pancreatic/","field":"links","label":"Grunwald et al., Cell 2021: spatially confined sub-tumour microenvironments"}]},{"url":"https://doi.org/10.1016/j.cell.2022.06.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867422007085","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","field":"links","label":"Stockwell, Ferroptosis turns 10 (Cell 2022)"},{"id":"paper-stockwell-cell","kind":"paper","name":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","route":"/key-papers/paper-stockwell-cell/","field":"links","label":"Cell 2022"}]},{"url":"https://doi.org/10.1016/j.cell.2023.03.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867423002210","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","field":"links","label":"Gerstberger, Jiang & Ganesh, Metastasis (Cell 2023)"},{"id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","field":"links","label":"Cell 2023"}]},{"url":"https://doi.org/10.1016/j.celrep.2013.07.029","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2211124713003914","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"papers","label":"Conserved regulation of the Jak/STAT pathway by the endosomal protein asrij maintains stem cell potency"}]},{"url":"https://doi.org/10.1016/j.celrep.2016.03.075","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2211124716303643","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","kind":"paper","name":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","route":"/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/","field":"links","label":"Giannakis et al., Cell Reports 2016: exomes of 619 incident colorectal cancers with immune, pathology and survival data"}]},{"url":"https://doi.org/10.1016/j.cels.2026.101657","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2405471226001390","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","field":"links","label":"Kang et al., BulkFormer: a large-scale foundation model for bulk transcriptomes (Cell Systems 2026)"}]},{"url":"https://doi.org/10.1016/j.cgh.2010.09.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1542356510009079","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","field":"links","label":"Clin Gastroenterol Hepatol 2011: factors contributing to hepatosplenic T-cell lymphoma in inflammatory bowel disease"}]},{"url":"https://doi.org/10.1016/j.cgh.2020.05.035","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1542356520306960","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"biliary-drainage-routes","kind":"term","name":"Biliary drainage routes: ERCP stent, percutaneous (PTC) and EUS-guided","route":"/terms/biliary-drainage-routes/","field":"links","label":"INTERCPT: an unsuccessful randomised trial of percutaneous versus endoscopic drainage of malignant hilar obstruction (Clin Gastroenterol Hepatol 2021)"}]},{"url":"https://doi.org/10.1016/j.cgh.2021.08.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1542356521008661","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","field":"links","label":"Chalasani et al., Validation of a novel multitarget blood test shows high sensitivity to detect early-stage hepatocellular carcinoma (Clinical Gastroenterology and Hepatology 2022)"},{"id":"paper-chalasani-clin-gastroenterol-hepatol","kind":"paper","name":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","route":"/key-papers/paper-chalasani-clin-gastroenterol-hepatol/","field":"links","label":"Clin Gastroenterol Hepatol 2022"}]},{"url":"https://doi.org/10.1016/j.chom.2014.02.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1931312814000699","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mesri-cell-host-microbe","kind":"paper","name":"Human viral oncogenesis: a cancer hallmarks analysis","route":"/key-papers/paper-mesri-cell-host-microbe/","field":"links","label":"Cell Host Microbe 2014"},{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/","field":"links","label":"Mesri, Feitelson & Munger, Human viral oncogenesis: a cancer hallmarks analysis (Cell Host Microbe 2014)"}]},{"url":"https://doi.org/10.1016/j.chom.2015.05.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1931312815002061","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"salmonella-typhi-gallbladder-cancer","kind":"term","name":"Salmonella Typhi carriage and gallbladder cancer","route":"/terms/salmonella-typhi-gallbladder-cancer/","field":"links","label":"Scanu et al., Cell Host Microbe 2015: Salmonella infection transforms predisposed gallbladder cells"},{"id":"paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015","kind":"paper","name":"Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma","route":"/key-papers/paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015/","field":"links","label":"Scanu et al., Cell Host Microbe 2015: Salmonella infection transforms predisposed gallbladder cells"}]},{"url":"https://doi.org/10.1016/j.clbc.2026.07.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1526820926001333","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","kind":"paper","name":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","route":"/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/","field":"links","label":"Hudson-Phillips et al., Clin Breast Cancer 2026: expanded germline high-penetrance testing in 576 newly diagnosed patients"}]},{"url":"https://doi.org/10.1016/j.clcc.2012.07.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1533002812001077","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"links","label":"Clinical Colorectal Cancer 2013: two adjuvant trials reveal differences between colon and rectal cancer"}]},{"url":"https://doi.org/10.1016/j.clcc.2020.04.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1533002820300670","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020","kind":"paper","name":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","route":"/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/","field":"links","label":"Schirripa et al., Clin Colorectal Cancer 2020: KRAS G12C metastatic colorectal cancer in 839 KRAS-mutant patients"}]},{"url":"https://doi.org/10.1016/j.clinimag.2012.05.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0899707112001751","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Li, Clin Imaging 2013: CT for assessing resectability of gallbladder carcinoma, meta-analysis"}]},{"url":"https://doi.org/10.1016/j.cllc.2016.03.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1525730416300304","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"links","label":"Vieira 2016, Clinical Lung Cancer: characteristics and outcomes of 93 sarcomatoid carcinomas of the lung"}]},{"url":"https://doi.org/10.1016/j.cllc.2026.06.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1525730426000835","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/","field":"links","label":"Clin Lung Cancer 2026"}]},{"url":"https://doi.org/10.1016/j.clml.2019.10.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2152265019320336","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"Clin Lymphoma Myeloma Leuk 2020: FDG PET in MALT lymphoma, critical review of 32 studies"}]},{"url":"https://doi.org/10.1016/j.clnu.2016.07.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0261561416301819","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-arends-clin-nutr","kind":"paper","name":"ESPEN guidelines on nutrition in cancer patients","route":"/key-papers/paper-arends-clin-nutr/","field":"links","label":"Clin Nutr 2017"},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","field":"links","label":"ESPEN guideline on clinical nutrition in cancer 2017"}]},{"url":"https://doi.org/10.1016/j.clnu.2021.02.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0261561421000790","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"ESPEN practical guideline 2021"},{"id":"paper-muscaritoli-clin-nutr","kind":"paper","name":"ESPEN practical guideline: Clinical Nutrition in cancer","route":"/key-papers/paper-muscaritoli-clin-nutr/","field":"links","label":"Clin Nutr 2021"},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","field":"links","label":"ESPEN practical guideline 2021"},{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","field":"links","label":"ESPEN practical guideline 2021"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Muscaritoli et al., ESPEN practical guideline: clinical nutrition in cancer (Clinical Nutrition 2021)"},{"id":"immunonutrition","kind":"term","name":"Immunonutrition","route":"/terms/immunonutrition/","field":"links","label":"Muscaritoli et al., ESPEN practical guideline: clinical nutrition in cancer (Clinical Nutrition 2021)"},{"id":"malnutrition-screening","kind":"term","name":"Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)","route":"/terms/malnutrition-screening/","field":"links","label":"Muscaritoli et al., ESPEN practical guideline: clinical nutrition in cancer (Clinical Nutrition 2021)"}]},{"url":"https://doi.org/10.1016/j.clon.2019.05.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0936655519302018","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"links","label":"CHHiP radiotherapy quality assurance (Clinical Oncology 2019)"}]},{"url":"https://doi.org/10.1016/j.clon.2023.10.054","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0936655523003953","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"links","label":"PATCH and STAMPEDE repurposing programme (Clinical Oncology 2024)"}]},{"url":"https://doi.org/10.1016/j.clon.2025.103993","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0936655525002481","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"abc-07","kind":"trial","name":"ABC-07","route":"/trials/abc-07/","field":"links","label":"Radiotherapy plan quality assurance in the ABC-07 trial (Clinical Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.cmet.2012.06.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1550413112002483","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","field":"papers","label":"Cancer cachexia: mediators, signaling, and metabolic pathways"}]},{"url":"https://doi.org/10.1016/j.cmet.2015.12.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155041311500621X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pavlova-cell-metab","kind":"paper","name":"The Emerging Hallmarks of Cancer Metabolism","route":"/key-papers/paper-pavlova-cell-metab/","field":"links","label":"Cell Metab 2016"},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","field":"links","label":"Pavlova and Thompson, The emerging hallmarks of cancer metabolism (Cell Metabolism 2016)"}]},{"url":"https://doi.org/10.1016/j.cmet.2022.01.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1550413122000225","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/","field":"links","label":"Pavlova, Zhu & Thompson, The hallmarks of cancer metabolism (Cell Metabolism 2022)"},{"id":"paper-pavlova-cell-metab-2022","kind":"paper","name":"The hallmarks of cancer metabolism: Still emerging","route":"/key-papers/paper-pavlova-cell-metab-2022/","field":"links","label":"Cell Metab 2022"}]},{"url":"https://doi.org/10.1016/j.coviro.2015.09.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1879625715001352","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"papers","label":"Human papillomaviruses: shared and distinct pathways for pathogenesis"}]},{"url":"https://doi.org/10.1016/j.critrevonc.2017.06.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1040842816302645","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bartholin-gland-carcinoma","kind":"cancer","name":"Bartholin gland carcinoma","route":"/cancers/bartholin-gland-carcinoma/","field":"links","label":"Critical Reviews in Oncology/Hematology 2017: Bartholin gland cancer, 275 reported cases"}]},{"url":"https://doi.org/10.1016/j.critrevonc.2023.104217","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1040842823003050","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"papers","label":"Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group"}]},{"url":"https://doi.org/10.1016/j.ctro.2019.10.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2405630819301041","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"papers","label":"Spatially fractionated radiation therapy: History, present and the future"}]},{"url":"https://doi.org/10.1016/j.ctrv.2020.102017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0305737220300554","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","field":"papers","label":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook"},{"id":"paper-olivier-chinot-cancer-treat-rev-2020","kind":"paper","name":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","route":"/key-papers/paper-olivier-chinot-cancer-treat-rev-2020/","field":"links","label":"Cancer Treat Rev 2020"}]},{"url":"https://doi.org/10.1016/j.ctrv.2022.102491","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0305737222001608","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"standardOfCare.guideline (Localised TGCT)"}]},{"url":"https://doi.org/10.1016/j.ebiom.2026.106305","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352396426001878","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026","kind":"paper","name":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis","route":"/key-papers/paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026/","field":"links","label":"EBioMedicine 2026"}]},{"url":"https://doi.org/10.1016/j.eclinm.2021.100844","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589537021001243","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"links","label":"First results (EClinicalMedicine 2021)"},{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"outcomes.source (Surgical downstaging after neoadjuvant vismodegib)"},{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"outcomes.source (Objective response rate)"},{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"outcomes.source (Recurrence at 3 years among downstaged patients)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Shrinking a tumour before the operation)"}]},{"url":"https://doi.org/10.1016/j.eclinm.2023.101897","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589537023000743","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","field":"links","label":"Bekaii-Saab et al., CanStem111P (eClinicalMedicine 2023)"},{"id":"napabucasin","kind":"drug","name":"Napabucasin","route":"/drugs/napabucasin/","field":"links","label":"Bekaii-Saab et al., CanStem111P (eClinicalMedicine 2023)"},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/","field":"links","label":"Bekaii-Saab et al., CanStem111P (eClinicalMedicine 2023)"},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/j.eclinm.2023.101952","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589537023001293","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/","field":"links","label":"EClinicalMedicine 2023"}]},{"url":"https://doi.org/10.1016/j.eclinm.2025.103539","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589537025004729","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","field":"links","label":"ROMAN (eClinicalMedicine 2025)"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"links","label":"eClinicalMedicine 2025"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"outcomes.source (Severe oral mucositis (WHO grade 3 or 4) incidence through the end of radiotherapy)"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"outcomes.source (Median duration of severe oral mucositis)"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"outcomes.source (Median time to onset of severe oral mucositis)"},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"paper-roman-anderson-eclinicalmedicine-2025","kind":"paper","name":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)","route":"/key-papers/paper-roman-anderson-eclinicalmedicine-2025/","field":"links","label":"eClinicalMedicine 2025"}]},{"url":"https://doi.org/10.1016/j.ejca.2008.10.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804908008733","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/","field":"links","label":"RECIST 1.1 (Eisenhauer 2009)"},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","field":"links","label":"European Journal of Cancer 2009: New response evaluation criteria in solid tumours, revised RECIST guideline (version 1.1)"}]},{"url":"https://doi.org/10.1016/j.ejca.2010.02.039","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804910001668","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"metrics (Estimated share of cancer research funding directed at metastasis)"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"metrics (Estimated share of cancer research funding directed at metastasis, which causes most deaths)"}]},{"url":"https://doi.org/10.1016/j.ejca.2010.11.035","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804910011615","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"papers","label":"Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial"}]},{"url":"https://doi.org/10.1016/j.ejca.2011.03.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S095980491100147X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Ben, Eur J Cancer 2011: diabetes mellitus and pancreatic cancer risk, meta-analysis of 35 cohorts"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Ben, Eur J Cancer 2011: diabetes mellitus and pancreatic cancer risk, meta-analysis of 35 cohorts"}]},{"url":"https://doi.org/10.1016/j.ejca.2011.05.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804911003674","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011","kind":"paper","name":"Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)","route":"/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/","field":"links","label":"Eur J Cancer 2011"}]},{"url":"https://doi.org/10.1016/j.ejca.2011.06.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804911003960","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","field":"papers","label":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)"},{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/","field":"links","label":"Eur J Cancer 2011"}]},{"url":"https://doi.org/10.1016/j.ejca.2011.08.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804911006083","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"links","label":"Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"metrics (Share of all cancer diagnoses in Europe that are rare cancers (RARECARE))"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"metrics (Five-year relative survival for rare vs common cancers in Europe (RARECARE))"},{"id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-moon-rare-cancer-global-network","kind":"idea","name":"One global rare cancer network with n-of-1 and Bayesian trial frameworks","route":"/ideas/idea-moon-rare-cancer-global-network/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/","field":"links","label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)"},{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/","field":"links","label":"Eur J Cancer 2011"}]},{"url":"https://doi.org/10.1016/j.ejca.2011.10.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804911008665","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"links","label":"Visser 2012, Eur J Cancer: incidence and survival of rare urogenital cancers in Europe (RARECARE)"}]},{"url":"https://doi.org/10.1016/j.ejca.2014.08.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804914009137","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"van Loo et al., surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: randomised clinical trial with 10-year follow-up (Eur J Cancer 2014)"},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"links","label":"Ten-year results (European Journal of Cancer 2014)"},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"outcomes.source (Cumulative recurrence at 10 years, primary facial basal cell carcinoma)"},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"outcomes.source (Cumulative recurrence at 10 years, recurrent facial basal cell carcinoma)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"van Loo et al., surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: randomised clinical trial with 10-year follow-up (Eur J Cancer 2014)"},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"links","label":"van Loo et al., surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: randomised clinical trial with 10-year follow-up (Eur J Cancer 2014)"}]},{"url":"https://doi.org/10.1016/j.ejca.2015.07.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804915007029","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"papers","label":"Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study"}]},{"url":"https://doi.org/10.1016/j.ejca.2017.02.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804917307931","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"links","label":"EORTC consensus recommendations for mycosis fungoides and Sezary syndrome, update 2017 (Eur J Cancer)"}]},{"url":"https://doi.org/10.1016/j.ejca.2017.04.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804917309218","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","kind":"paper","name":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report","route":"/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/","field":"links","label":"Eur J Cancer 2017"}]},{"url":"https://doi.org/10.1016/j.ejca.2017.08.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804917312479","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hedgehog-inhibitor-tolerability","kind":"term","name":"Why people stop taking hedgehog inhibitors","route":"/terms/hedgehog-inhibitor-tolerability/","field":"links","label":"STEVIE primary analysis (European Journal of Cancer 2017)"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"links","label":"Primary analysis (European Journal of Cancer 2017)"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"outcomes.source (Objective response rate, locally advanced basal cell carcinoma (investigator assessed))"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"outcomes.source (Objective response rate, metastatic basal cell carcinoma (investigator assessed))"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"outcomes.source (Serious treatment-emergent adverse events)"},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"outcomes.source (Median duration of treatment)"}]},{"url":"https://doi.org/10.1016/j.ejca.2018.08.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804918313406","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"links","label":"European Journal of Cancer 2018: left-sided colon and rectal cancer in 2,879 ARCAD trial patients"}]},{"url":"https://doi.org/10.1016/j.ejca.2018.09.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804918313832","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"papers","label":"Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries"}]},{"url":"https://doi.org/10.1016/j.ejca.2020.01.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804920300265","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"metrics (Total cost of cancer in Europe in 2018, including health expenditure, informal care and productivity loss)"}]},{"url":"https://doi.org/10.1016/j.ejca.2020.05.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804920302811","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"papers","label":"A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries"},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"papers","label":"A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries"}]},{"url":"https://doi.org/10.1016/j.ejca.2020.06.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804920303531","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","field":"links","label":"InspECT registry (Eur J Cancer 2020)"},{"id":"paper-clover-eur-j-cancer","kind":"paper","name":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)","route":"/key-papers/paper-clover-eur-j-cancer/","field":"links","label":"Eur J Cancer 2020"}]},{"url":"https://doi.org/10.1016/j.ejca.2020.06.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804920303555","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","route":"/key-papers/paper-timbergen-eur-j-cancer/","field":"links","label":"Eur J Cancer 2020"},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"links","label":"Desmoid Tumor Working Group consensus (Eur J Cancer 2020)"},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"standardOfCare.guideline (Newly diagnosed, asymptomatic or minimally symptomatic)"}]},{"url":"https://doi.org/10.1016/j.ejca.2021.02.030","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804921001362","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/","field":"links","label":"Eur J Cancer 2021"}]},{"url":"https://doi.org/10.1016/j.ejca.2021.10.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804921011813","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"van Dam, Eur J Cancer 2022: neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer, meta-analysis of 7 trials"},{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"van Dam, Eur J Cancer 2022: neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer, meta-analysis of 7 trials"}]},{"url":"https://doi.org/10.1016/j.ejca.2023.113343","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804923006457","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"links","label":"EORTC consensus recommendations for mycosis fungoides and Sezary syndrome, update 2023 (Eur J Cancer)"}]},{"url":"https://doi.org/10.1016/j.ejca.2024.113580","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S095980492400056X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"links","label":"BROCADE3 final overall survival (European Journal of Cancer 2024)"},{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","field":"links","label":"BROCADE3 final overall survival (European Journal of Cancer 2024)"},{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","field":"outcomes.source (Overall survival (final))"}]},{"url":"https://doi.org/10.1016/j.ejca.2024.115070","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804924012012","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/","field":"links","label":"Eur J Cancer 2024"}]},{"url":"https://doi.org/10.1016/j.ejca.2025.115255","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S095980492500036X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/","field":"links","label":"Eur J Cancer 2025"}]},{"url":"https://doi.org/10.1016/j.ejca.2025.115381","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804925001625","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","field":"outcomes.source (Recurrence-free survival at 48 months)"}]},{"url":"https://doi.org/10.1016/j.ejca.2025.115674","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804925004563","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/","field":"links","label":"Eur J Cancer 2025"}]},{"url":"https://doi.org/10.1016/j.ejca.2026.116729","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804926005095","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/","field":"links","label":"Eur J Cancer 2026"}]},{"url":"https://doi.org/10.1016/j.ejcsup.2006.08.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S135963490600187X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","field":"links","label":"ESOPE standard operating procedures"}]},{"url":"https://doi.org/10.1016/j.ejrad.2018.11.034","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0720048X18304297","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"de Savornin Lohman, Eur J Radiol 2019: CT and MRI for lymph node metastases in gallbladder cancer"}]},{"url":"https://doi.org/10.1016/j.ejso.2006.10.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0748798306003763","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-goonetilleke-ca19-9-systematic-review-ejso-2007","kind":"paper","name":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","route":"/key-papers/paper-goonetilleke-ca19-9-systematic-review-ejso-2007/","field":"links","label":"Goonetilleke and Siriwardena, Eur J Surg Oncol 2007: systematic review of CA 19-9 in 2,283 patients"}]},{"url":"https://doi.org/10.1016/j.ejvs.2018.09.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1078588418306981","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"papers","label":"Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms"}]},{"url":"https://doi.org/10.1016/j.esmogo.2026.100334","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2949819826000348","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","field":"links","label":"CheckMate 142: nivolumab, ipilimumab and cobimetinib in MSS metastatic colorectal cancer (ESMO Gastrointestinal Oncology 2026)"},{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","field":"outcomes.source (Objective response rate (MSS, nivolumab, ipilimumab and cobimetinib))"}]},{"url":"https://doi.org/10.1016/j.esmogo.2026.100344","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2949819826000440","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026","kind":"paper","name":"Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer","route":"/key-papers/paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026/","field":"links","label":"ESMO Gastrointest Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.esmogo.2026.100398","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2949819826000981","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","field":"links","label":"CAVE pooled analysis of clinical factors and outcomes (ESMO Gastrointestinal Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2021.100134","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702921000934","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"papers","label":"Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France"}]},{"url":"https://doi.org/10.1016/j.esmoop.2021.100170","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702921001307","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ehe-consensus-stacchiotti-esmo-open-2021","kind":"paper","name":"Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","route":"/key-papers/paper-ehe-consensus-stacchiotti-esmo-open-2021/","field":"links","label":"ESMO Open 2021"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"links","label":"EHE consensus (ESMO Open 2021)"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"standardOfCare.guideline (Epithelioid haemangioendothelioma)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2021.100204","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702921001654","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021","kind":"paper","name":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021/","field":"links","label":"ESMO Open 2021"}]},{"url":"https://doi.org/10.1016/j.esmoop.2021.100314","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702921002763","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/","field":"links","label":"TreeTopp (ESMO Open 2022): gallbladder subgroup"},{"id":"varlitinib","kind":"drug","name":"Varlitinib","route":"/drugs/varlitinib/","field":"links","label":"TreeTopp, ESMO Open 2022"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"links","label":"Javle et al., ESMO Open 2022: TreeTopp"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"outcomes.source (Objective response rate (independent central review))"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"outcomes.source (Progression-free survival)"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"outcomes.source (Overall survival)"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","field":"outcomes.source (Progression-free survival, gallbladder cancer subgroup)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2022.100554","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S205970292200182X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","field":"links","label":"Powell et al., pooled analysis of interstitial lung disease in nine trastuzumab deruxtecan studies (ESMO Open 2022)"},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","field":"links","label":"Powell et al., pooled analysis of interstitial lung disease in nine trastuzumab deruxtecan studies (ESMO Open 2022)"},{"id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","field":"links","label":"Powell et al., Pooled analysis of drug-related interstitial lung disease and pneumonitis in trastuzumab deruxtecan trials (ESMO Open 2022)"},{"id":"paper-powell-esmo-open","kind":"paper","name":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","route":"/key-papers/paper-powell-esmo-open/","field":"links","label":"ESMO Open 2022"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Powell et al., pooled analysis of interstitial lung disease in nine trastuzumab deruxtecan studies (ESMO Open 2022)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2022.100602","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702922002320","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","field":"links","label":"ESMO-EURACAN salivary gland guideline (2022)"},{"id":"paper-van-herpen-esmo-open","kind":"paper","name":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-van-herpen-esmo-open/","field":"links","label":"ESMO Open 2022"}]},{"url":"https://doi.org/10.1016/j.esmoop.2024.102995","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702924007634","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-symptom-control-palliation","kind":"term","name":"Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life","route":"/terms/tnbc-symptom-control-palliation/","field":"links","label":"Sacituzumab govitecan and trastuzumab deruxtecan in stable and active brain metastases: multicentre real-world analysis (ESMO Open 2024)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2025.105122","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702925009913","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","field":"links","label":"Mahalingam et al., single-arm phase 2 (ESMO Open 2025)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2025.105807","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S205970292501676X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/","field":"links","label":"ESMO Open 2025"}]},{"url":"https://doi.org/10.1016/j.esmoop.2026.107734","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702926016765","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/","field":"links","label":"TRIUMPH: prior anti-EGFR therapy and ctDNA resistance alterations predict failure (ESMO Open 2026)"}]},{"url":"https://doi.org/10.1016/j.esmoop.2026.108344","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2059702926022866","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/","field":"links","label":"Oh et al., ESMO Open 2026: trastuzumab deruxtecan in the biliary and pancreatic cohorts of DESTINY-PanTumor02"}]},{"url":"https://doi.org/10.1016/j.esmoop.2026.108538","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S205970292602483X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/","field":"links","label":"ESMO Open 2026"}]},{"url":"https://doi.org/10.1016/j.euo.2018.03.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2588931118300191","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"papers","label":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer"}]},{"url":"https://doi.org/10.1016/j.euo.2020.08.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2588931120301279","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"whole-mount-pathology","kind":"term","name":"Whole-mount pathology","route":"/terms/whole-mount-pathology/","field":"links","label":"Cimadamore et al., European Urology Oncology 2021: added clinical value of whole-mount histopathology of radical prostatectomy specimens, a collaborative review"}]},{"url":"https://doi.org/10.1016/j.euo.2025.02.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2588931125000501","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","field":"links","label":"KEYNOTE-921 patient-reported outcomes (European Urology Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.euo.2025.12.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2588931125003396","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"links","label":"Sud, McNeill and Vickers, European Urology Oncology 2026: comparison of results from the BARCODE1 study and contemporary prostate cancer screening trials"}]},{"url":"https://doi.org/10.1016/j.eururo.2005.12.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283805008523","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sylvester-eortc-risk-tables-eur-urol-2006","kind":"paper","name":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","route":"/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/","field":"links","label":"Eur Urol 2006"}]},{"url":"https://doi.org/10.1016/j.eururo.2013.03.044","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283813002984","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"links","label":"Gakis 2013, European Urology: EAU guidelines on primary urethral carcinoma"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"links","label":"Gakis 2013, European Urology: EAU guidelines on primary urethral carcinoma"}]},{"url":"https://doi.org/10.1016/j.eururo.2013.12.062","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283813014905","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014","kind":"paper","name":"Overdiagnosis and overtreatment of prostate cancer","route":"/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/","field":"links","label":"Eur Urol 2014"},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"links","label":"Loeb et al., European Urology 2014: overdiagnosis and overtreatment of prostate cancer"}]},{"url":"https://doi.org/10.1016/j.eururo.2014.10.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283814011002","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015","kind":"paper","name":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","route":"/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/","field":"links","label":"Ferraldeschi et al., Eur Urol 2015: PTEN protein loss by immunohistochemistry and outcome on abiraterone in 144 men"}]},{"url":"https://doi.org/10.1016/j.eururo.2016.02.029","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283816002062","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"embryonal-carcinoma-testis","kind":"cancer","name":"Embryonal carcinoma of the testis","route":"/cancers/embryonal-carcinoma-testis/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"},{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","field":"links","label":"Moch 2016, European Urology: the 2016 WHO classification of urinary and male genital tumours, part A"}]},{"url":"https://doi.org/10.1016/j.eururo.2016.05.041","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283816302494","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"papers","label":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016"}]},{"url":"https://doi.org/10.1016/j.eururo.2017.08.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283817307200","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","kind":"paper","name":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","route":"/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/","field":"links","label":"Ren et al., Eur Urol 2018: whole-genome and transcriptome sequencing of 65 treatment-naive Chinese prostate cancers with a 145-tumour targeted validation cohort"}]},{"url":"https://doi.org/10.1016/j.eururo.2018.09.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283818306584","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-boeve-eur-urol","kind":"paper","name":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","route":"/key-papers/paper-boeve-eur-urol/","field":"links","label":"Eur Urol 2019"},{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","field":"links","label":"European Urology 2019"},{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","field":"outcomes.source (Overall survival)"},{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","field":"outcomes.source (Time to PSA progression)"}]},{"url":"https://doi.org/10.1016/j.eururo.2018.11.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283818309308","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-johnson-mpmri-individual-foci-eur-urol-2019","kind":"paper","name":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","route":"/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/","field":"links","label":"Eur Urol 2019"},{"id":"whole-mount-pathology","kind":"term","name":"Whole-mount pathology","route":"/terms/whole-mount-pathology/","field":"links","label":"Johnson et al., European Urology 2019: detection of individual prostate cancer foci via multiparametric magnetic resonance imaging"},{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"links","label":"Johnson et al., European Urology 2019: detection of individual prostate cancer foci via multiparametric magnetic resonance imaging"}]},{"url":"https://doi.org/10.1016/j.eururo.2019.02.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283819301502","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"links","label":"ERSPC at 16 years (European Urology 2019)"},{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"outcomes.source (Death from prostate cancer, core age group, 16 years)"},{"id":"number-needed-to-screen","kind":"term","name":"Number needed to screen (and number needed to diagnose)","route":"/terms/number-needed-to-screen/","field":"links","label":"Hugosson et al., European Urology 2019: a 16-year follow-up of the European Randomized study of Screening for Prostate Cancer"},{"id":"paper-hugosson-eur-urol","kind":"paper","name":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","route":"/key-papers/paper-hugosson-eur-urol/","field":"links","label":"Eur Urol 2019"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","field":"links","label":"ERSPC 16-year follow-up (Eur Urol 2019)"}]},{"url":"https://doi.org/10.1016/j.eururo.2019.02.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283819301800","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"links","label":"Turkbey et al., European Urology 2019: Prostate Imaging Reporting and Data System version 2.1, the 2019 update of PI-RADS version 2"}]},{"url":"https://doi.org/10.1016/j.eururo.2019.08.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283819306608","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"papers","label":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update"}]},{"url":"https://doi.org/10.1016/j.eururo.2019.08.034","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283819306840","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"galeterone","kind":"drug","name":"Galeterone","route":"/drugs/galeterone/","field":"links","label":"ARMOR3-SV (European Urology 2019)"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"links","label":"ARMOR3-SV (European Urology 2019)"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"outcomes.source (AR-V7 prevalence in first-line metastatic castration-resistant prostate cancer)"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"outcomes.source (PSA50 response)"}]},{"url":"https://doi.org/10.1016/j.eururo.2021.08.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283821019783","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"papers","label":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)"},{"id":"paper-eau-nmibc-guideline-eur-urol-2022","kind":"paper","name":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","route":"/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/","field":"links","label":"Eur Urol 2022"}]},{"url":"https://doi.org/10.1016/j.eururo.2022.02.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283822016657","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/","field":"links","label":"Eur Urol 2022"}]},{"url":"https://doi.org/10.1016/j.eururo.2022.06.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283822024678","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-who-2022-gu-moch-eur-urol-2022","kind":"paper","name":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","route":"/key-papers/paper-who-2022-gu-moch-eur-urol-2022/","field":"links","label":"Eur Urol 2022"},{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"mucinous-tubular-spindle-cell-carcinoma","kind":"cancer","name":"Mucinous tubular and spindle cell carcinoma of the kidney","route":"/cancers/mucinous-tubular-spindle-cell-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"eosinophilic-solid-cystic-renal-cell-carcinoma","kind":"cancer","name":"Eosinophilic solid and cystic renal cell carcinoma","route":"/cancers/eosinophilic-solid-cystic-renal-cell-carcinoma/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"},{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"links","label":"Moch 2022, European Urology: the 2022 WHO classification of urinary and male genital tumours, part A (renal, penile, testicular)"}]},{"url":"https://doi.org/10.1016/j.eururo.2023.02.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283823026386","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","kind":"paper","name":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","route":"/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/","field":"links","label":"Eur Urol 2023"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"links","label":"EAU-ASCO collaborative guideline (Eur Urol 2023)"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"standardOfCare.guideline (Primary tumour)"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"links","label":"EAU-ASCO penile cancer guideline 2023"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"standardOfCare.guideline (Penile intraepithelial neoplasia)"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"standardOfCare.guideline (T1 to T2 tumours)"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"standardOfCare.guideline (Clinically negative groins)"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"standardOfCare.guideline (Prevention)"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"standardOfCare.guideline (Positive sentinel node or resectable palpable nodes)"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"standardOfCare.guideline (Bulky or fixed inguinal nodes)"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"standardOfCare.guideline (After lymphadenectomy with pelvic nodes or extranodal extension)"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"standardOfCare.guideline (Metastatic disease)"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"standardOfCare.guideline (HPV 16-positive recurrent disease)"}]},{"url":"https://doi.org/10.1016/j.eururo.2023.03.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283823026520","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"papers","label":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update"}]},{"url":"https://doi.org/10.1016/j.eururo.2025.07.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283825003975","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-radiotherapy-fractionation","kind":"term","name":"How many radiotherapy visits: the prostate fractionation trials","route":"/terms/prostate-radiotherapy-fractionation/","field":"links","label":"PACE-B late urinary toxicity factors (European Urology 2026)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"links","label":"PACE-B late urinary toxicity factors (European Urology 2026)"}]},{"url":"https://doi.org/10.1016/j.eururo.2025.12.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283825048766","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/","field":"links","label":"Eur Urol 2026"}]},{"url":"https://doi.org/10.1016/j.eururo.2026.05.034","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283826022128","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-treatment-choice-localised","kind":"term","name":"Choosing treatment for localised prostate cancer: what each option costs","route":"/terms/prostate-treatment-choice-localised/","field":"links","label":"PACE-B 5-year patient-reported outcomes (European Urology 2026)"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","field":"links","label":"PACE-B 5-year patient-reported outcomes (European Urology 2026)"}]},{"url":"https://doi.org/10.1016/j.eururo.2026.07.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0302283826023134","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/","field":"links","label":"Eur Urol 2026"}]},{"url":"https://doi.org/10.1016/j.gastro.2005.05.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508505008772","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005","kind":"paper","name":"Probability of pancreatic cancer following diabetes: a population-based study","route":"/key-papers/paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005/","field":"links","label":"Gastroenterology 2005"}]},{"url":"https://doi.org/10.1016/j.gie.2009.09.042","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016510709025590","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Jeurnink et al., SUSTENT randomised trial (Gastrointest Endosc 2010)"},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"SUSTENT: surgical gastrojejunostomy or endoscopic stent placement for malignant gastric outlet obstruction, multicentre randomised trial (GIE 2010)"}]},{"url":"https://doi.org/10.1016/j.giec.2021.08.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1052515721000891","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Gastrointest Endosc Clin N Am 2022: endoscopic management and surgical considerations for familial adenomatous polyposis"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"Gastrointest Endosc Clin N Am 2022: endoscopic management and surgical considerations for familial adenomatous polyposis"}]},{"url":"https://doi.org/10.1016/j.gimo.2023.100849","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2949774423008580","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"Evans, Genet Med Open 2024: population-based germline testing of BRCA1, BRCA2 and PALB2 in UK breast cancer patients"}]},{"url":"https://doi.org/10.1016/j.gore.2025.101803","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352578925001286","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Mujumdar review 2025"},{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/","field":"links","label":"Mujumdar review 2025"}]},{"url":"https://doi.org/10.1016/j.gore.2025.101920","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352578925001456","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Straughn editorial 2025"},{"id":"paper-straughn-ivermectin-hope-versus-hype-2025","kind":"paper","name":"Ivermectin treatment for gynecologic cancers: hope versus hype","route":"/key-papers/paper-straughn-ivermectin-hope-versus-hype-2025/","field":"links","label":"Straughn editorial 2025"}]},{"url":"https://doi.org/10.1016/j.hoc.2015.09.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0889858815001379","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors"}]},{"url":"https://doi.org/10.1016/j.hpb.2021.12.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X21017457","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Alrawashdeh, HPB 2022: meta-analysis of T2a and T2b gallbladder cancer"},{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","field":"links","label":"Alrawashdeh, HPB 2022: meta-analysis of T2a and T2b gallbladder cancer"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"links","label":"Alrawashdeh, HPB 2022: meta-analysis of T2a and T2b gallbladder cancer"}]},{"url":"https://doi.org/10.1016/j.hpb.2024.01.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X24000145","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Rhodin, HPB 2024: simple versus radical cholecystectomy for T1b in the National Cancer Database"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Rhodin, HPB 2024: simple versus radical cholecystectomy for T1b in the National Cancer Database"},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","field":"links","label":"Rhodin, HPB 2024: simple versus radical cholecystectomy for T1b in the National Cancer Database"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Rhodin, HPB 2024: simple versus radical cholecystectomy for T1b in the National Cancer Database"}]},{"url":"https://doi.org/10.1016/j.hpb.2025.12.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X25017319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026","kind":"paper","name":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis","route":"/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/","field":"links","label":"HPB 2026"}]},{"url":"https://doi.org/10.1016/j.hpb.2026.06.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X26006805","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026","kind":"paper","name":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026/","field":"links","label":"HPB 2026"}]},{"url":"https://doi.org/10.1016/j.humpath.2003.08.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817703005021","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/j.humpath.2013.08.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817713003377","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"links","label":"Human Pathology 2014: clear cell papillary RCC is the fourth most common type in 290 nephrectomies"}]},{"url":"https://doi.org/10.1016/j.humpath.2018.02.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817718301163","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"links","label":"Hum Pathol 2018: the clinicopathological significance of micropapillary pattern in colorectal cancers (266 tumours)"}]},{"url":"https://doi.org/10.1016/j.humpath.2020.08.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817720301684","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/","field":"links","label":"Hiraoka et al., Hum Pathol 2020: HER2 status in 454 biliary tract cancers"},{"id":"paper-hiraoka-her2-status-biliary-hum-pathol-2020","kind":"paper","name":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","route":"/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/","field":"links","label":"Hiraoka et al., Hum Pathol 2020: HER2 status in 454 biliary tract cancers"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/j.humpath.2020.09.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817720301805","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"links","label":"Hum Pathol 2021: adenoma-like adenocarcinoma, clinicopathological characterisation of a newly recognised subtype (91 cases against 251 controls)"}]},{"url":"https://doi.org/10.1016/j.humpath.2020.09.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817720301957","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","field":"links","label":"Human Pathology 2020: molecular landscape of primary cutaneous follicle centre lymphoma"}]},{"url":"https://doi.org/10.1016/j.humpath.2026.106234","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0046817726002030","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/","field":"links","label":"Angerilli et al., Hum Pathol 2026: HER2 IHC and chromogenic ISH concordance in 140 biliary cancers"},{"id":"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","kind":"paper","name":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases","route":"/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/","field":"links","label":"Angerilli et al., Hum Pathol 2026: HER2 IHC and chromogenic ISH concordance in 140 biliary cancers"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2003.10.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301603021102","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dutch-bone-metastasis-study","kind":"trial","name":"Dutch Bone Metastasis Study","route":"/trials/dutch-bone-metastasis-study/","field":"links","label":"Dutch Bone Metastasis Study reanalysis (International Journal of Radiation Oncology, Biology, Physics 2004)"},{"id":"dutch-bone-metastasis-study","kind":"trial","name":"Dutch Bone Metastasis Study","route":"/trials/dutch-bone-metastasis-study/","field":"outcomes.source (Pain response to initial treatment)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2003.11.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301603022946","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"papers","label":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2005.07.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301605011533","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"papers","label":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2009.09.040","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301609033008","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bentzen-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","route":"/key-papers/paper-bentzen-int-j-radiat-oncol-biol-phys/","field":"links","label":"Int J Radiat Oncol Biol Phys 2010"},{"id":"tumour-control-probability-models","kind":"technology","name":"Tumour control and normal tissue complication probability (TCP and NTCP)","route":"/technologies/tumour-control-probability-models/","field":"links","label":"QUANTEC introduction 2010"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2010.02.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301610002373","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/","field":"links","label":"Int J Radiat Oncol Biol Phys 2011: outcome of adenocarcinoma and adenosquamous carcinoma of the cervix after definitive radiotherapy, 148 patients"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2014.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301614034683","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","field":"links","label":"Paganetti, RBE values for proton beam therapy (IJROBP 2014)"},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/","field":"links","label":"Paganetti, RBE values for proton beam therapy (IJROBP 2014)"},{"id":"paper-paganetti-proton-rbe-ijrobp-2014","kind":"paper","name":"Paganetti 2014: proton RBE is not a fixed 1.1","route":"/key-papers/paper-paganetti-proton-rbe-ijrobp-2014/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2015.07.2278","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301615030692","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nagata-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403","route":"/key-papers/paper-nagata-int-j-radiat-oncol-biol-phys/","field":"links","label":"Int J Radiat Oncol Biol Phys 2015"},{"id":"jcog0403","kind":"trial","name":"JCOG0403","route":"/trials/jcog0403/","field":"links","label":"IJROBP 2015"},{"id":"jcog0403","kind":"trial","name":"JCOG0403","route":"/trials/jcog0403/","field":"outcomes.source (Overall survival at 3 years)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2016.11.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301616334848","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","field":"links","label":"ASCENDE-RT survival endpoints (International Journal of Radiation Oncology Biology Physics 2017)"},{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","field":"outcomes.source (Biochemical progression-free survival at 9 years)"},{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2020.06.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301620313080","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-voss-int-j-radiat-oncol-biol-phys","kind":"paper","name":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma","route":"/key-papers/paper-voss-int-j-radiat-oncol-biol-phys/","field":"links","label":"Int J Radiat Oncol Biol Phys 2020"},{"id":"ketogenic-diet-glioblastoma","kind":"technology","name":"Ketogenic diets in glioblastoma","route":"/technologies/ketogenic-diet-glioblastoma/","field":"links","label":"ERGO2 (Int J Radiat Oncol Biol Phys 2020)"},{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","field":"links","label":"Voss et al. (Int J Radiat Oncol Biol Phys 2020)"},{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","field":"outcomes.source (Progression-free survival at 6 months)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2022.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301622007209","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"act-in-sarc","kind":"trial","name":"Act.In.Sarc","route":"/trials/act-in-sarc/","field":"links","label":"International Journal of Radiation Oncology, Biology, Physics 2022 (final safety and quality of life)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2024.02.063","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301624003821","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","field":"links","label":"Int J Radiat Oncol Biol Phys 2024"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2024.08.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301624032371","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-partiqol-astro-2024","kind":"paper","name":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","route":"/key-papers/paper-partiqol-astro-2024/","field":"links","label":"IJROBP 2024 supplement (LBA01)"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"links","label":"ASTRO 2024 late-breaking abstract (IJROBP)"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"outcomes.source (EPIC bowel quality of life at 24 months)"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"outcomes.source (Progression-free survival at 5 years)"}]},{"url":"https://doi.org/10.1016/j.ijrobp.2024.09.043","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301624034448","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"links","label":"PARTIQoL feasibility and baseline characteristics (International Journal of Radiation Oncology Biology Physics 2025)"}]},{"url":"https://doi.org/10.1016/j.ijsu.2016.07.061","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1743919116302709","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Elmasry, Int J Surg 2016: risk of malignancy in ultrasound-detected gallbladder polyps"},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"links","label":"Elmasry, Int J Surg 2016: risk of malignancy in ultrasound-detected gallbladder polyps"},{"id":"paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016","kind":"paper","name":"The risk of malignancy in ultrasound detected gallbladder polyps: A systematic review","route":"/key-papers/paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016/","field":"links","label":"Int J Surg 2016"}]},{"url":"https://doi.org/10.1016/j.immuni.2005.06.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1074761305002116","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","field":"papers","label":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA"}]},{"url":"https://doi.org/10.1016/j.immuni.2013.07.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1074761313002963","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-mellman-cancer-immunity-cycle-immunity-2013","kind":"paper","name":"Chen and Mellman 2013: the cancer-immunity cycle","route":"/key-papers/paper-chen-mellman-cancer-immunity-cycle-immunity-2013/","field":"links","label":"Full text (DOI)"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/","field":"links","label":"Chen & Mellman, Oncology meets immunology: the cancer-immunity cycle (Immunity 2013)"}]},{"url":"https://doi.org/10.1016/j.immuni.2016.02.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1074761316300644","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mlecnik-immunoscore-msi-colorectal-immunity-2016","kind":"paper","name":"Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability","route":"/key-papers/paper-mlecnik-immunoscore-msi-colorectal-immunity-2016/","field":"links","label":"Mlecnik et al., Immunity 2016: Immunoscore is a stronger predictor of survival than microsatellite instability"}]},{"url":"https://doi.org/10.1016/j.immuni.2018.03.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1074761318301213","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-thorsson-immune-landscape-of-cancer-immunity-2018","kind":"paper","name":"Thorsson 2018: the immune landscape of cancer across 10,000 tumours","route":"/key-papers/paper-thorsson-immune-landscape-of-cancer-immunity-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/j.immuni.2019.06.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S107476131930295X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"papers","label":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences"},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/","field":"links","label":"Greten & Grivennikov, Inflammation and cancer: triggers, mechanisms, and consequences (Immunity 2019)"},{"id":"paper-greten-immunity","kind":"paper","name":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","route":"/key-papers/paper-greten-immunity/","field":"links","label":"Immunity 2019"}]},{"url":"https://doi.org/10.1016/j.jaad.2013.04.047","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S019096221300515X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","field":"links","label":"J Am Acad Dermatol 2013: primary cutaneous marginal zone B-cell lymphoma, 137 patients"}]},{"url":"https://doi.org/10.1016/j.jaad.2018.03.056","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0190962218305309","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-j-am-acad-dermatol","kind":"paper","name":"Hair disorders in cancer survivors","route":"/key-papers/paper-freites-martinez-j-am-acad-dermatol/","field":"links","label":"J Am Acad Dermatol 2019"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","field":"links","label":"Hair disorders in cancer survivors (J Am Acad Dermatol 2019)"}]},{"url":"https://doi.org/10.1016/j.jaad.2021.04.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S019096222100757X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","field":"outcomes.source (Objective response rate (locally advanced cohort))"}]},{"url":"https://doi.org/10.1016/j.jaad.2024.06.108","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0190962224027701","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","kind":"paper","name":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","route":"/key-papers/paper-empower-cscc-1-j-am-acad-dermatol-2025-update/","field":"links","label":"J Am Acad Dermatol 2025"}]},{"url":"https://doi.org/10.1016/j.jaad.2025.09.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0190962225027914","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","field":"links","label":"Journal of the American Academy of Dermatology 2026 (longer follow-up)"}]},{"url":"https://doi.org/10.1016/j.jacc.2014.05.050","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0735109714043046","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","field":"papers","label":"Electrocardiographic changes improve risk prediction in asymptomatic persons age 65 years or above without cardiovascular disease"}]},{"url":"https://doi.org/10.1016/j.jacc.2020.04.031","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0735109720350087","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"papers","label":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review"}]},{"url":"https://doi.org/10.1016/j.jacep.2021.04.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2405500X21003285","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","field":"papers","label":"A Randomized Trial of His Pacing Versus Biventricular Pacing in Symptomatic HF Patients With Left Bundle Branch Block (His-Alternative)"}]},{"url":"https://doi.org/10.1016/j.jcmg.2023.09.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1936878X2300431X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"papers","label":"Carotid Plaque-RADS"}]},{"url":"https://doi.org/10.1016/j.jcms.2016.07.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1010518216301305","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"papers","label":"Increase of prevalence of craniosynostosis"}]},{"url":"https://doi.org/10.1016/j.jconrel.2012.03.020","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168365912002301","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","field":"links","label":"Barenholz, Doxil, the first FDA-approved nano-drug: lessons learned (J Control Release 2012)"},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","field":"links","label":"Barenholz, Doxil, the first FDA-approved nano-drug: lessons learned (J Control Release 2012)"}]},{"url":"https://doi.org/10.1016/j.jcpo.2018.01.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213538317300577","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"papers","label":"Access to cancer care in Colombia, a middle-income country with universal health coverage"}]},{"url":"https://doi.org/10.1016/j.jcyt.2019.12.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1465324919309181","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-dlbcl-cytotherapy-2020","kind":"paper","name":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","route":"/key-papers/paper-cd19-dlbcl-cytotherapy-2020/","field":"links","label":"Cytotherapy 2020"}]},{"url":"https://doi.org/10.1016/j.jhep.2018.01.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168827818300217","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wardell-biliary-drivers-germline-j-hepatol-2018","kind":"paper","name":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","route":"/key-papers/paper-wardell-biliary-drivers-germline-j-hepatol-2018/","field":"links","label":"Wardell et al., J Hepatol 2018: genomic characterisation of 412 biliary tract cancers"}]},{"url":"https://doi.org/10.1016/j.jhep.2020.11.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168827820338204","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021","kind":"paper","name":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","route":"/key-papers/paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021/","field":"links","label":"Nepal et al., J Hepatol 2021: integrative molecular characterisation of 190 gallbladder cancers"}]},{"url":"https://doi.org/10.1016/j.jhep.2021.11.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bclc-staging","kind":"term","name":"BCLC staging","route":"/terms/bclc-staging/","field":"links","label":"Reig et al., BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update (Journal of Hepatology 2022)"},{"id":"paper-bclc-2022-reig-j-hepatol-2022","kind":"paper","name":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","route":"/key-papers/paper-bclc-2022-reig-j-hepatol-2022/","field":"links","label":"J Hepatol 2022"}]},{"url":"https://doi.org/10.1016/j.jhep.2021.11.030","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168827821022418","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atezolizumab-hcc-j-hepatol-2022","kind":"paper","name":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","route":"/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/","field":"links","label":"J Hepatol 2022"}]},{"url":"https://doi.org/10.1016/j.jhep.2025.05.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168827825022019","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"TOPAZ-1 3-year overall survival update, J Hepatol 2025"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"outcomes.source (36-month overall survival (3-year update, median follow-up 41.3 months))"},{"id":"paper-topaz-1-three-year-survival-j-hepatol-2025","kind":"paper","name":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","route":"/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/","field":"links","label":"J Hepatol 2025"}]},{"url":"https://doi.org/10.1016/j.jid.2016.10.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0022202X16325386","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Williams et al., surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma, 5-year results of the SINS randomised controlled trial (J Invest Dermatol 2017)"},{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"links","label":"Five-year results (Journal of Investigative Dermatology 2017)"},{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"outcomes.source (Clinical success at 5 years)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Williams et al., surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma, 5-year results of the SINS randomised controlled trial (J Invest Dermatol 2017)"},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"links","label":"Williams et al., surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma, 5-year results of the SINS randomised controlled trial (J Invest Dermatol 2017)"},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"Williams et al., surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma, 5-year results of the SINS randomised controlled trial (J Invest Dermatol 2017)"}]},{"url":"https://doi.org/10.1016/j.jid.2017.09.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0022202X17330452","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"},{"id":"topical-and-destructive-treatment-bcc","kind":"term","name":"Creams, light and cold for basal cell carcinoma","route":"/terms/topical-and-destructive-treatment-bcc/","field":"links","label":"Five-year three-arm comparison (Journal of Investigative Dermatology 2018)"},{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"links","label":"Five-year results (Journal of Investigative Dermatology 2018)"},{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"outcomes.source (Tumour-free survival at 5 years)"},{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"outcomes.source (Hazard ratio for treatment failure at 5 years against photodynamic therapy)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"},{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"links","label":"Jansen et al., five-year results of a randomised controlled trial comparing photodynamic therapy, topical imiquimod and topical 5-fluorouracil in superficial basal cell carcinoma (J Invest Dermatol 2018)"}]},{"url":"https://doi.org/10.1016/j.jmoldx.2016.10.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1525157816302239","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","field":"links","label":"Li et al., Standards and guidelines for the interpretation and reporting of sequence variants in cancer: AMP, ASCO and CAP joint consensus (Journal of Molecular Diagnostics 2017)"},{"id":"paper-li-j-mol-diagn","kind":"paper","name":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","route":"/key-papers/paper-li-j-mol-diagn/","field":"links","label":"J Mol Diagn 2017"}]},{"url":"https://doi.org/10.1016/j.jncc.2024.01.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2667005424000061","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-han-j-natl-cancer-cent","kind":"paper","name":"Cancer incidence and mortality in China, 2022","route":"/key-papers/paper-han-j-natl-cancer-cent/","field":"links","label":"J Natl Cancer Cent 2024"},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","field":"links","label":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024"}]},{"url":"https://doi.org/10.1016/j.joms.2008.09.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0278239108014985","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"papers","label":"Patient Benefit From Endoscopically Assisted Fixation of Condylar Neck Fractures—A Randomized Controlled Trial"}]},{"url":"https://doi.org/10.1016/j.joms.2014.09.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0278239114014852","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"Kelly 2015, J Oral Maxillofac Surg: HPT-JT case report and genetic review"}]},{"url":"https://doi.org/10.1016/j.jpainsymman.2017.09.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0885392417304657","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lichtman-j-pain-symptom-manage","kind":"paper","name":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain","route":"/key-papers/paper-lichtman-j-pain-symptom-manage/","field":"links","label":"J Pain Symptom Manage 2018"},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","field":"links","label":"Nabiximols for opioid-treated cancer patients with poorly controlled chronic pain, randomised trial (J Pain Symptom Manage 2018)"}]},{"url":"https://doi.org/10.1016/j.jss.2011.06.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0022480411005415","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"links","label":"Boyd, J Surg Res 2012: 415 patients with adenosquamous carcinoma of the pancreas, SEER analysis"}]},{"url":"https://doi.org/10.1016/j.jtho.2016.11.2228","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086416335365","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","field":"links","label":"Hirsch et al., Blueprint PD-L1 IHC assay comparison project (JTO 2017)"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","field":"links","label":"Hirsch et al., Blueprint PD-L1 IHC assay comparison project (JTO 2017)"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","field":"metrics (PD-L1 assays in the Blueprint comparison project whose tumour-cell staining was interchangeable (22C3, 28-8, SP263) vs discordant (SP142))"},{"id":"paper-hirsch-j-thorac-oncol","kind":"paper","name":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","route":"/key-papers/paper-hirsch-j-thorac-oncol/","field":"links","label":"J Thorac Oncol 2017"}]},{"url":"https://doi.org/10.1016/j.jtho.2017.12.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155608641733071X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/","field":"links","label":"Lindeman et al., J Thorac Oncol 2018: the CAP, IASLC and AMP molecular testing guideline for lung cancer"}]},{"url":"https://doi.org/10.1016/j.jtho.2018.05.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086418306269","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blueprint-phase-2-pd-l1-assays-jto-2018","kind":"paper","name":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","route":"/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/","field":"links","label":"Tsao et al., J Thorac Oncol 2018: Blueprint phase 2, five PD-L1 assays on 81 real-world lung cancer specimens"}]},{"url":"https://doi.org/10.1016/j.jtho.2019.06.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086419304666","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/","field":"links","label":"Offin et al., J Thorac Oncol 2019: concurrent RB1 and TP53 alterations and the risk of histological transformation in EGFR-mutant lung cancer"}]},{"url":"https://doi.org/10.1016/j.jtho.2019.06.027","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155608641930557X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/","field":"links","label":"J Thorac Oncol 2019"}]},{"url":"https://doi.org/10.1016/j.jtho.2020.07.014","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086420305955","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/","field":"links","label":"J Thorac Oncol 2020"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"links","label":"ORIENT-11 (J Thorac Oncol 2020)"},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","field":"links","label":"J Thorac Oncol 2020"},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/j.jtho.2020.09.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086420307553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/","field":"links","label":"Baine et al., J Thorac Oncol 2020: immunohistochemical characterisation of the small-cell subtypes in 174 patient samples"}]},{"url":"https://doi.org/10.1016/j.jtho.2021.04.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086421021249","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","field":"links","label":"Yotsukura 2021, JTO: long-term prognosis of 524 resected adenocarcinoma in situ and minimally invasive adenocarcinoma"}]},{"url":"https://doi.org/10.1016/j.jtho.2021.07.035","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086421023984","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-camidge-j-thorac-oncol","kind":"paper","name":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","route":"/key-papers/paper-camidge-j-thorac-oncol/","field":"links","label":"J Thorac Oncol 2021"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","field":"links","label":"Journal of Thoracic Oncology 2021 (final analysis)"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","field":"outcomes.source (Progression-free survival (blinded independent review, final))"}]},{"url":"https://doi.org/10.1016/j.jtho.2021.10.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086421032585","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","kind":"paper","name":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","route":"/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/","field":"links","label":"J Thorac Oncol 2022"},{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"WHO Classification of Tumours of the thymus and mediastinum, 5th edition (Marx 2022, JTO summary)"}]},{"url":"https://doi.org/10.1016/j.jtho.2021.10.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086421032846","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/","field":"links","label":"Ricciuti et al., J Thorac Oncol 2022: STK11 and KEAP1 mutations and PD-(L)1 inhibition in 1,261 lung adenocarcinomas, by KRAS status"},{"id":"stk11-keap1-loss","kind":"biomarker","name":"STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma","route":"/biomarkers/stk11-keap1-loss/","field":"links","label":"Ricciuti et al., J Thorac Oncol 2022: STK11 and KEAP1 mutations and PD-(L)1 inhibition in 1,261 lung adenocarcinomas, by KRAS status"}]},{"url":"https://doi.org/10.1016/j.jtho.2021.11.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086421033165","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"spread-through-air-spaces","kind":"term","name":"Spread through air spaces (STAS)","route":"/terms/spread-through-air-spaces/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015"},{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"lymphoepithelial-carcinoma-lung","kind":"cancer","name":"Lymphoepithelial carcinoma of the lung","route":"/cancers/lymphoepithelial-carcinoma-lung/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"},{"id":"pulmonary-blastoma","kind":"cancer","name":"Pulmonary blastoma (adult)","route":"/cancers/pulmonary-blastoma/","field":"links","label":"Nicholson 2022, JTO: the 2021 WHO classification of lung tumours"}]},{"url":"https://doi.org/10.1016/j.jtho.2022.12.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086422019931","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/","field":"links","label":"J Thorac Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.jtho.2022.12.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086422019979","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/","field":"links","label":"J Thorac Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.jtho.2023.01.088","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086423000977","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"J Thorac Oncol 2023: IASLC lung cancer staging project, the new database to inform revisions in the ninth edition of the TNM classification"},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","field":"links","label":"J Thorac Oncol 2023: IASLC lung cancer staging project, the new database to inform revisions in the ninth edition of the TNM classification"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"J Thorac Oncol 2023: IASLC lung cancer staging project, the new database to inform revisions in the ninth edition of the TNM classification"}]},{"url":"https://doi.org/10.1016/j.jtho.2023.03.015","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155608642300196X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-j-thorac-oncol","kind":"paper","name":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","route":"/key-papers/paper-li-j-thorac-oncol/","field":"links","label":"J Thorac Oncol 2023"},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","field":"links","label":"D-1553 phase 1 (J Thorac Oncol 2023)"}]},{"url":"https://doi.org/10.1016/j.jtho.2023.06.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086423006366","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/","field":"links","label":"J Thorac Oncol 2023"}]},{"url":"https://doi.org/10.1016/j.jtho.2023.12.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086423024115","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for the revisions of the T descriptors in the forthcoming ninth edition (no change recommended)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for the revisions of the T descriptors in the forthcoming ninth edition (no change recommended)"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.01.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086424000601","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"J Thorac Oncol 2024: IASLC staging project for lung cancer, proposals for the revision of the M descriptors in the forthcoming ninth edition (M1c split into M1c1 and M1c2)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"J Thorac Oncol 2024: IASLC staging project for lung cancer, proposals for the revision of the M descriptors in the forthcoming ninth edition (M1c split into M1c1 and M1c2)"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.02.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086424000790","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"},{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"},{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"},{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered)"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.07.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086424007512","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kozono-j-thorac-oncol","kind":"paper","name":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","route":"/key-papers/paper-kozono-j-thorac-oncol/","field":"links","label":"J Thorac Oncol 2024"},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"links","label":"Lung-MAP next-generation sequencing analysis of advanced squamous cell lung cancers, Journal of Thoracic Oncology 2024"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.08.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086424007627","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhou-j-thorac-oncol","kind":"paper","name":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","route":"/key-papers/paper-zhou-j-thorac-oncol/","field":"links","label":"J Thorac Oncol 2024"},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","field":"links","label":"IBI351 pivotal phase 2 (J Thorac Oncol 2024)"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.10.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155608642402433X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2024.11.032","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S155608642402495X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.01.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425000516","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.05.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425007531","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.07.117","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425009396","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.07.129","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425009815","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/","field":"links","label":"J Thorac Oncol 2025"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.10.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425028904","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtho.2025.11.008","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086425029028","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtho.2026.103713","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426001668","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtho.2026.103737","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426001905","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtho.2026.104165","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426006180","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtho.2026.104179","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426006325","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"links","label":"ADAURA 8-year overall survival landmark update (Journal of Thoracic Oncology 2026)"},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"outcomes.source (8-year overall survival, stage II to IIIA)"},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"outcomes.source (8-year overall survival, stage IB to IIIA)"},{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/","field":"links","label":"J Thorac Oncol 2026"}]},{"url":"https://doi.org/10.1016/j.jtocrr.2022.100431","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666364322001552","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-189-407-tmb-jtocrr-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer","route":"/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/","field":"links","label":"Garassino et al., JTO Clin Res Rep 2023: tissue tumour mutational burden with pembrolizumab plus chemotherapy in KEYNOTE-189 and KEYNOTE-407"}]},{"url":"https://doi.org/10.1016/j.jtocrr.2026.100988","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666364326000391","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/","field":"links","label":"JTO Clin Res Rep 2026"}]},{"url":"https://doi.org/10.1016/j.juro.2007.03.024","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/auajuro/abstract/00076734-200707000-00030~population-based-incidence-and-age-distribution-of?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","field":"links","label":"Journal of Urology 2007: population-based incidence and age distribution of spermatocytic seminoma"}]},{"url":"https://doi.org/10.1016/j.jvs.2019.02.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0741521419303210","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"papers","label":"Global vascular guidelines on the management of chronic limb-threatening ischemia"}]},{"url":"https://doi.org/10.1016/j.kint.2020.10.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0085253820312692","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"papers","label":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease"}]},{"url":"https://doi.org/10.1016/j.kint.2020.10.047","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0085253820314198","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"papers","label":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease"}]},{"url":"https://doi.org/10.1016/j.lanepe.2023.100673","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666776223000923","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"links","label":"Korrel, Lancet Reg Health Eur 2023: DIPLOMA, minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer"},{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/","field":"links","label":"Korrel, Lancet Reg Health Eur 2023: DIPLOMA, minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Korrel, Lancet Reg Health Eur 2023: DIPLOMA, minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.lanepe.2023.100788","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666776223002077","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","field":"links","label":"Kästner 2024, outcomes (Lancet Reg Health Eur)"}]},{"url":"https://doi.org/10.1016/j.lanepe.2024.100886","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666776224000528","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Acs, Lancet Reg Health Eur 2024: ER-zero and ER-low HER2-negative breast cancer treated as triple-negative, Swedish cohort"},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"links","label":"Acs, Lancet Reg Health Eur 2024: ER-zero and ER-low HER2-negative breast cancer treated as triple-negative, Swedish cohort"},{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/","field":"links","label":"Acs, Lancet Reg Health Eur 2024: ER-zero and ER-low HER2-negative breast cancer treated as triple-negative, Swedish cohort"}]},{"url":"https://doi.org/10.1016/j.lansea.2024.100514","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2772368224001641","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-halder-lancet-reg-health-southeast-asia","kind":"paper","name":"Access to timely cancer treatment initiation in India: extent, determinants and trends","route":"/key-papers/paper-halder-lancet-reg-health-southeast-asia/","field":"links","label":"Lancet Reg Health Southeast Asia 2025"},{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","route":"/institutions/nha-pmjay/","field":"links","label":"Timely cancer treatment initiation and PM-JAY (Lancet Reg Health SE Asia 2025)"}]},{"url":"https://doi.org/10.1016/j.lungcan.2011.03.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500211002108","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-blastoma","kind":"cancer","name":"Pulmonary blastoma (adult)","route":"/cancers/pulmonary-blastoma/","field":"links","label":"Lung Cancer 2011: classic biphasic pulmonary blastoma, case report and review"}]},{"url":"https://doi.org/10.1016/j.lungcan.2015.03.017","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500215001695","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoepithelial-carcinoma-lung","kind":"cancer","name":"Lymphoepithelial carcinoma of the lung","route":"/cancers/lymphoepithelial-carcinoma-lung/","field":"links","label":"Chang 2015, Lung Cancer: PD-L1 is highly expressed in 66 lung lymphoepithelioma-like carcinomas"}]},{"url":"https://doi.org/10.1016/j.lungcan.2022.01.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500222000368","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"metrics (Patients with metastatic non-squamous NSCLC in a US community network tested for all five guideline-recommended biomarkers before first-line therapy (2018-2020))"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"metrics (Patients with metastatic non-squamous NSCLC in a US community network tested for all five guideline-recommended biomarkers before first-line therapy (2018-2020))"}]},{"url":"https://doi.org/10.1016/j.lungcan.2022.07.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500222005530","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-orient-11-lung-cancer-2022-update","kind":"paper","name":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","route":"/key-papers/paper-orient-11-lung-cancer-2022-update/","field":"links","label":"Lung Cancer 2022"}]},{"url":"https://doi.org/10.1016/j.lungcan.2026.109580","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500226006410","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/","field":"links","label":"Lung Cancer 2026"}]},{"url":"https://doi.org/10.1016/j.lungcan.2026.109588","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0169500226006495","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/","field":"links","label":"Lung Cancer 2026"}]},{"url":"https://doi.org/10.1016/j.mayocp.2014.04.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0025619614003322","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-russell-mv-nis-myeloma-mayo-2014","kind":"paper","name":"Russell 2014: a measles virus given into the vein put one patient's myeloma into complete remission","route":"/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/","field":"links","label":"Mayo Clin Proc 2014"}]},{"url":"https://doi.org/10.1016/j.media.2022.102559","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1361841522002043","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"Wang et al., CTransPath: transformer-based unsupervised contrastive learning for histopathological image classification (Medical Image Analysis 2022)"}]},{"url":"https://doi.org/10.1016/j.medj.2024.05.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666634024002137","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/","field":"links","label":"Med 2024"}]},{"url":"https://doi.org/10.1016/j.medj.2024.08.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S266663402400312X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-symptom-control-palliation","kind":"term","name":"Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life","route":"/terms/tnbc-symptom-control-palliation/","field":"links","label":"DEBBRAH cohort 5: trastuzumab deruxtecan in leptomeningeal disease (Med 2025)"}]},{"url":"https://doi.org/10.1016/j.medj.2025.100708","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666634025001357","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-glioblastoma-med-2025","kind":"paper","name":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study","route":"/key-papers/paper-pembrolizumab-glioblastoma-med-2025/","field":"links","label":"Med 2025"}]},{"url":"https://doi.org/10.1016/j.modpat.2025.100824","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395225001218","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","kind":"paper","name":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance","route":"/key-papers/paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025/","field":"links","label":"Mod Pathol 2025"}]},{"url":"https://doi.org/10.1016/j.molcel.2020.10.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1097276520307401","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","field":"links","label":"Rubin, Bristow, Thienger et al., Impact of lineage plasticity to and from a neuroendocrine phenotype (Molecular Cell 2020)"},{"id":"paper-rubin-mol-cell","kind":"paper","name":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","route":"/key-papers/paper-rubin-mol-cell/","field":"links","label":"Mol Cell 2020"}]},{"url":"https://doi.org/10.1016/j.molcel.2022.05.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1097276522004385","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/","field":"links","label":"Saxena & Zou, Hallmarks of DNA replication stress (Molecular Cell 2022)"},{"id":"paper-saxena-mol-cell","kind":"paper","name":"Hallmarks of DNA replication stress","route":"/key-papers/paper-saxena-mol-cell/","field":"links","label":"Mol Cell 2022"}]},{"url":"https://doi.org/10.1016/j.molmed.2014.10.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147149141400183X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-trends-mol-med-2015","kind":"paper","name":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","route":"/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/","field":"links","label":"Trends Mol Med 2015"}]},{"url":"https://doi.org/10.1016/j.mrrev.2003.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1383574203000711","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"papers","label":"DNA double-strand break repair by homologous recombination"}]},{"url":"https://doi.org/10.1016/j.omtm.2016.12.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2329050116302029","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","field":"papers","label":"Global manufacturing of CAR T cell therapy"}]},{"url":"https://doi.org/10.1016/j.omto.2021.02.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S237277052100022X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"papers","label":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications"}]},{"url":"https://doi.org/10.1016/j.ophtha.2010.06.021","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0161642010006512","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"conjunctival-melanoma","kind":"cancer","name":"Conjunctival melanoma","route":"/cancers/conjunctival-melanoma/","field":"links","label":"Shields 2011, Ophthalmology: conjunctival melanoma outcomes by tumour origin in 382 consecutive cases"}]},{"url":"https://doi.org/10.1016/j.oraloncology.2012.11.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1368837512003521","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kerala-oral-screening","kind":"trial","name":"Kerala oral cancer visual screening trial (Trivandrum)","route":"/trials/kerala-oral-screening/","field":"links","label":"15-year follow-up, Oral Oncology 2013"},{"id":"paper-sankaranarayanan-oral-screening-lancet-2005","kind":"paper","name":"Effect of screening on oral cancer mortality in Kerala, India","route":"/key-papers/paper-sankaranarayanan-oral-screening-lancet-2005/","field":"links","label":"15-year follow-up (Oral Oncology 2013)"}]},{"url":"https://doi.org/10.1016/j.oraloncology.2018.05.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1368837518301866","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acinic-cell-carcinoma-salivary","kind":"cancer","name":"Acinic cell carcinoma of the salivary glands","route":"/cancers/acinic-cell-carcinoma-salivary/","field":"links","label":"Oral Oncology 2018: parotid acinic cell carcinoma, National Cancer Database study of 2,362 cases"}]},{"url":"https://doi.org/10.1016/j.pan.2012.02.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S142439031200035X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Aggarwal, Pancreatology 2012: new-onset diabetes in pancreatic cancer in primary care"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Aggarwal, Pancreatology 2012: new-onset diabetes in pancreatic cancer in primary care"}]},{"url":"https://doi.org/10.1016/j.pan.2017.07.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390317305161","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017","kind":"paper","name":"Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)","route":"/key-papers/paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017/","field":"links","label":"Pancreatology 2017"}]},{"url":"https://doi.org/10.1016/j.pan.2017.11.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390317308864","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Isaji, Pancreatology 2018: international consensus on the definition and criteria of borderline resectable pancreatic cancer"},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","field":"links","label":"Isaji, Pancreatology 2018: international consensus on the definition and criteria of borderline resectable pancreatic cancer"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"Isaji, Pancreatology 2018: international consensus on the definition and criteria of borderline resectable pancreatic cancer"},{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","field":"links","label":"Isaji, Pancreatology 2018: international consensus on the definition and criteria of borderline resectable pancreatic cancer"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"Isaji, Pancreatology 2018: international consensus on the definition and criteria of borderline resectable pancreatic cancer"}]},{"url":"https://doi.org/10.1016/j.pan.2018.08.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390318306410","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Luo, Pancreatology 2018: CA19-9 in Lewis-negative patients with pancreatic cancer (1,482 patients)"},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","field":"links","label":"Luo, Pancreatology 2018: CA19-9 in Lewis-negative patients with pancreatic cancer (1,482 patients)"},{"id":"lewis-negative","kind":"term","name":"Lewis-negative (Lewis antigen-negative, CA 19-9 non-secretor) status","route":"/terms/lewis-negative/","field":"links","label":"Luo, Pancreatology 2018: CA19-9 in Lewis-negative patients with pancreatic cancer (1,482 patients)"}]},{"url":"https://doi.org/10.1016/j.pan.2018.10.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S142439031830704X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Roberts et al., enzyme replacement improves survival among patients with pancreatic cancer, population-based study (Pancreatology 2019)"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Roberts, Pancreatology 2019: enzyme replacement and survival in pancreatic cancer, UK CPRD population study"},{"id":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","kind":"paper","name":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","route":"/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/","field":"links","label":"Pancreatology 2019"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Roberts et al., enzyme replacement improves survival among patients with pancreatic cancer, population-based study (Pancreatology 2019)"}]},{"url":"https://doi.org/10.1016/j.pan.2020.12.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390320308760","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Koulouris et al., EUS-CPN meta-analysis (Pancreatology 2021)"}]},{"url":"https://doi.org/10.1016/j.pan.2021.08.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S142439032100524X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vipoma","kind":"cancer","name":"VIPoma","route":"/cancers/vipoma/","field":"links","label":"Pancreatology 2021: efficacy of treatments for VIPoma, French GTE multicentre series of 22 patients"}]},{"url":"https://doi.org/10.1016/j.pan.2023.12.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390323018835","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024","kind":"paper","name":"International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)","route":"/key-papers/paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024/","field":"links","label":"Pancreatology 2024"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"links","label":"Kyoto guidelines for IPMN (Pancreatology 2024)"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"standardOfCare.guideline (Incidental cyst)"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"standardOfCare.guideline (High-risk stigmata)"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"standardOfCare.guideline (Worrisome features)"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"standardOfCare.guideline (Surveillance)"}]},{"url":"https://doi.org/10.1016/j.pcd.2011.03.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S175199181100026X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","field":"papers","label":"Mortality in an elderly type 2 diabetic patients’ cohort who attended a self-management educational workshop"}]},{"url":"https://doi.org/10.1016/j.pdpdt.2025.104702","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1572100025002340","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","field":"links","label":"Ten-year three-arm replication (Photodiagnosis and Photodynamic Therapy 2025)"}]},{"url":"https://doi.org/10.1016/j.phrs.2020.105207","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1043661820315152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021","kind":"paper","name":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","route":"/key-papers/paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021/","field":"links","label":"Tang review 2021"}]},{"url":"https://doi.org/10.1016/j.phrs.2022.106264","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1043661822002092","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd47-pancreatic-pharmacol-res-2022","kind":"paper","name":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade","route":"/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/","field":"links","label":"Pharmacol Res 2022"}]},{"url":"https://doi.org/10.1016/j.prp.2026.156477","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0344033826001305","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gpc3-gastric-pathol-res-pract-2026","kind":"paper","name":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","route":"/key-papers/paper-gpc3-gastric-pathol-res-pract-2026/","field":"links","label":"Pathol Res Pract 2026"}]},{"url":"https://doi.org/10.1016/j.prro.2016.08.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1879850016301229","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","field":"links","label":"ASTRO bone metastases guideline 2017"},{"id":"paper-lutz-pract-radiat-oncol","kind":"paper","name":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","route":"/key-papers/paper-lutz-pract-radiat-oncol/","field":"links","label":"Pract Radiat Oncol 2017"}]},{"url":"https://doi.org/10.1016/j.prro.2022.02.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1879850022000534","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022","kind":"paper","name":"Lutetium-177 DOTATATE: A Practical Review","route":"/key-papers/paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022/","field":"links","label":"Pract Radiat Oncol 2022"}]},{"url":"https://doi.org/10.1016/j.radonc.2013.08.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814013003988","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"papers","label":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer"}]},{"url":"https://doi.org/10.1016/j.radonc.2014.03.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814014001698","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"links","label":"Barton et al., Estimating the demand for radiotherapy from the evidence (Radiotherapy and Oncology 2014)"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"metrics (Evidence-based optimal radiotherapy utilisation rate across all cancers (proportion of patients who should receive radiotherapy at least once))"},{"id":"paper-barton-radiother-oncol","kind":"paper","name":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012","route":"/key-papers/paper-barton-radiother-oncol/","field":"links","label":"Radiother Oncol 2014"}]},{"url":"https://doi.org/10.1016/j.radonc.2014.08.029","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814014003594","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"papers","label":"Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey"}]},{"url":"https://doi.org/10.1016/j.radonc.2015.04.018","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814015002091","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"papers","label":"The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis"}]},{"url":"https://doi.org/10.1016/j.radonc.2016.10.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814016343778","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pineal-parenchymal-tumours","kind":"cancer","name":"Pineocytoma and pineal parenchymal tumour of intermediate differentiation","route":"/cancers/pineal-parenchymal-tumours/","field":"links","label":"Radiotherapy and Oncology 2016: pineal parenchymal tumour of intermediate differentiation, individual patient data of 127 cases"}]},{"url":"https://doi.org/10.1016/j.radonc.2017.05.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814017303766","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"papers","label":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer"}]},{"url":"https://doi.org/10.1016/j.radonc.2017.09.038","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814017326245","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"papers","label":"High dose rate brachytherapy as monotherapy for localised prostate cancer"}]},{"url":"https://doi.org/10.1016/j.radonc.2019.06.019","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814019329597","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bourhis-radiother-oncol","kind":"paper","name":"Treatment of a first patient with FLASH-radiotherapy","route":"/key-papers/paper-bourhis-radiother-oncol/","field":"links","label":"Radiother Oncol 2019"},{"id":"flash-research-accelerators","kind":"technology","name":"FLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)","route":"/technologies/flash-research-accelerators/","field":"links","label":"Bourhis et al., Treatment of a first patient with FLASH-radiotherapy (Radiotherapy and Oncology 2019)"}]},{"url":"https://doi.org/10.1016/j.radonc.2020.04.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814020301845","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","field":"links","label":"Lievens et al., Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus (Radiotherapy and Oncology 2020)"},{"id":"paper-lievens-radiother-oncol","kind":"paper","name":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","route":"/key-papers/paper-lievens-radiother-oncol/","field":"links","label":"Radiother Oncol 2020"}]},{"url":"https://doi.org/10.1016/j.radonc.2020.11.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814020308902","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hirose-radiother-oncol","kind":"paper","name":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ( 10 B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial","route":"/key-papers/paper-hirose-radiother-oncol/","field":"links","label":"Radiother Oncol 2021"},{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","field":"links","label":"Hirose et al., Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan for recurrent or locally advanced head and neck cancer (Radiotherapy and Oncology 2021)"}]},{"url":"https://doi.org/10.1016/j.radonc.2021.01.013","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S016781402100013X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"papers","label":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group"}]},{"url":"https://doi.org/10.1016/j.radonc.2023.109590","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814023001287","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-karius-radiother-oncol","kind":"paper","name":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy","route":"/key-papers/paper-karius-radiother-oncol/","field":"links","label":"Radiother Oncol 2023"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"links","label":"ESGO / ESTRO / ESP rare gynaecological cancers (vaginal cancer) guidance"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"standardOfCare.guideline (Stage I to IVA, most patients)"}]},{"url":"https://doi.org/10.1016/j.radonc.2026.111416","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S016781402600054X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"links","label":"Reconsidering postmastectomy radiotherapy after SUPREMO (Radiotherapy and Oncology 2026)"}]},{"url":"https://doi.org/10.1016/j.semcancer.2008.03.012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1044579X08000333","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sonnenschein-semin-cancer-biol","kind":"paper","name":"Theories of carcinogenesis: an emerging perspective","route":"/key-papers/paper-sonnenschein-semin-cancer-biol/","field":"links","label":"Semin Cancer Biol 2008"},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","field":"links","label":"Sonnenschein and Soto, Theories of carcinogenesis: an emerging perspective (Seminars in Cancer Biology 2008)"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"links","label":"Sonnenschein and Soto, Theories of carcinogenesis: an emerging perspective (Seminars in Cancer Biology 2008)"}]},{"url":"https://doi.org/10.1016/j.semradonc.2019.02.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1053429619300104","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"auto-contouring-ai","kind":"technology","name":"AI auto-contouring and adaptive planning","route":"/technologies/auto-contouring-ai/","field":"links","label":"Cardenas et al., Advances in auto-segmentation (Seminars in Radiation Oncology 2019)"},{"id":"paper-cardenas-semin-radiat-oncol","kind":"paper","name":"Advances in Auto-Segmentation","route":"/key-papers/paper-cardenas-semin-radiat-oncol/","field":"links","label":"Semin Radiat Oncol 2019"}]},{"url":"https://doi.org/10.1016/j.smrv.2015.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1087079215000921","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-johnson-sleep-med-rev","kind":"paper","name":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors","route":"/key-papers/paper-johnson-sleep-med-rev/","field":"links","label":"Sleep Med Rev 2016"},{"id":"cbt-insomnia-cancer","kind":"technology","name":"Cognitive behavioural therapy for insomnia (CBT-I)","route":"/technologies/cbt-insomnia-cancer/","field":"links","label":"Systematic review and meta-analysis of CBT-I in cancer survivors (Sleep Med Rev 2016)"}]},{"url":"https://doi.org/10.1016/j.stem.2012.10.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1934590912005863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"papers","label":"Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal"}]},{"url":"https://doi.org/10.1016/j.stemcr.2023.08.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213671123003028","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"papers","label":"ISSCR standards for the use of human stem cells in basic research"}]},{"url":"https://doi.org/10.1016/j.surg.2007.05.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0039606007003017","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Wente et al., delayed gastric emptying after pancreatic surgery, the ISGPS definition (Surgery 2007)"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Wente et al., delayed gastric emptying after pancreatic surgery, the ISGPS definition (Surgery 2007)"}]},{"url":"https://doi.org/10.1016/j.surg.2008.03.006","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0039606008001748","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008","kind":"paper","name":"Wisnoski 2008: 672 patients with acinar cell carcinoma of the pancreas, a population-based comparison to pancreatic adenocarcinoma","route":"/key-papers/paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008/","field":"links","label":"Surgery 2008"}]},{"url":"https://doi.org/10.1016/j.surg.2012.05.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0039606012002152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"links","label":"Yendamuri 2012, Surgery: outcomes of sarcomatoid carcinoma of the lung, SEER analysis"}]},{"url":"https://doi.org/10.1016/j.surg.2016.08.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S003960601630424X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Berger-Richardson, Surgery 2017: trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Berger-Richardson, Surgery 2017: trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer"},{"id":"port-site-metastasis","kind":"term","name":"Port-site metastasis","route":"/terms/port-site-metastasis/","field":"links","label":"Berger-Richardson, Surgery 2017: trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer"},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Berger-Richardson et al., Surgery 2017: systematic review of port-site metastasis (27 studies)"}]},{"url":"https://doi.org/10.1016/j.surg.2017.05.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0039606017303227","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Lee et al., Surgery 2017: hepatic-sided versus peritoneal-sided T2 tumours (192 patients, 6 centres)"}]},{"url":"https://doi.org/10.1016/j.surg.2018.01.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0039606018300813","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Scholten et al., new-onset diabetes after pancreatoduodenectomy, systematic review and meta-analysis (Surgery 2018)"},{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"links","label":"Scholten et al., new-onset diabetes after pancreatoduodenectomy, systematic review and meta-analysis (Surgery 2018)"}]},{"url":"https://doi.org/10.1016/j.surge.2016.06.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1479666X16300269","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Routine extrahepatic bile duct resection without duct infiltration: systematic review (The Surgeon 2016)"}]},{"url":"https://doi.org/10.1016/j.tig.2020.07.011","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0168952520301967","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/","field":"links","label":"Centore, Sandoval, Soares, Kadoch & Chan, Mammalian SWI/SNF chromatin remodeling complexes (Trends in Genetics 2020)"},{"id":"paper-centore-trends-genet","kind":"paper","name":"Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","route":"/key-papers/paper-centore-trends-genet/","field":"links","label":"Trends Genet 2020"}]},{"url":"https://doi.org/10.1016/j.tranon.2020.100868","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1936523320303600","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"links","label":"Translational Oncology 2020: MET exon 14 skipping, amplification and overexpression in 124 pulmonary sarcomatoid carcinomas"}]},{"url":"https://doi.org/10.1016/j.trecan.2015.07.009","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2405803315000102","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-obenauf-trends-cancer","kind":"paper","name":"Surviving at a Distance: Organ-Specific Metastasis","route":"/key-papers/paper-obenauf-trends-cancer/","field":"links","label":"Trends Cancer 2015"},{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/","field":"links","label":"Obenauf & Massagué, Surviving at a distance: organ-specific metastasis (Trends Cancer 2015)"}]},{"url":"https://doi.org/10.1016/j.urology.2023.09.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0090429523008063","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-focal-therapy","kind":"term","name":"Focal and tissue-preserving treatment of prostate cancer","route":"/terms/prostate-focal-therapy/","field":"links","label":"Biopsy and erectile outcomes after partial prostate ablation, systematic review and meta-analysis (Urology 2023)"}]},{"url":"https://doi.org/10.1016/j.urolonc.2017.07.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1078143917303782","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Nead et al., androgen deprivation therapy and depression, systematic review and meta-analysis (Urologic Oncology 2017)"}]},{"url":"https://doi.org/10.1016/j.xcrm.2026.102789","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2666379126002065","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/","field":"links","label":"Cell Rep Med 2026"}]},{"url":"https://doi.org/10.1016/j.ygyno.2011.03.024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0090825811002320","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/","field":"links","label":"Gynecologic Oncology 2011: ovarian sex cord-stromal tumours, pleuropulmonary blastoma and DICER1, International PPB Registry"}]},{"url":"https://doi.org/10.1016/j.ygyno.2022.02.025","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0090825822001457","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-durvalumab-endometrial-gynecol-oncol-2022","kind":"paper","name":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","route":"/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/","field":"links","label":"Gynecol Oncol 2022"}]},{"url":"https://doi.org/10.1016/j.ymthe.2018.10.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1525001618304908","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/s0002-9343(03)00013-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002934303000135","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-contopoulos-ioannidis-am-j-med","kind":"paper","name":"Translation of highly promising basic science research into clinical applications","route":"/key-papers/paper-contopoulos-ioannidis-am-j-med/","field":"links","label":"Am J Med 2003"}]},{"url":"https://doi.org/10.1016/S0002-9343(03)00013-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002934303000135","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"links","label":"Contopoulos-Ioannidis et al., Translation of highly promising basic research into clinical applications (Am J Med 2003)"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"metrics (Highly promising basic science findings (101 claims in top journals, 1979-1983) that led to a licensed clinical use within about 20 years)"}]},{"url":"https://doi.org/10.1016/s0002-9440(10)62563-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002944010625631","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"links","label":"Abraham, Am J Pathol 2002: solid-pseudopapillary tumours are genetically distinct and almost always carry beta-catenin mutations"}]},{"url":"https://doi.org/10.1016/s0065-2776(08)60778-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0065277608607786","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"papers","label":"Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells"}]},{"url":"https://doi.org/10.1016/s0090-4295(00)01122-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0090429500011225","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/S0092-8674(00)81683-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867400816839","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/","field":"links","label":"DOI"},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","field":"links","label":"Hanahan and Weinberg, The hallmarks of cancer (Cell 2000)"}]},{"url":"https://doi.org/10.1016/S0092-8674(00)81871-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0092867400818711","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-levine-p53-gatekeeper-cell-1997","kind":"paper","name":"Levine 1997: p53, the cellular gatekeeper for growth and division","route":"/key-papers/paper-levine-p53-gatekeeper-cell-1997/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/s0140-6736(00)02059-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673600020596","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-van-der-zee-lancet","kind":"paper","name":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group","route":"/key-papers/paper-van-der-zee-lancet/","field":"links","label":"Lancet 2000"}]},{"url":"https://doi.org/10.1016/S0140-6736(00)02059-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673600020596","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","field":"links","label":"van der Zee et al., Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective randomised multicentre trial (Lancet 2000)"}]},{"url":"https://doi.org/10.1016/S0140-6736(00)04046-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673600040460","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-balkwill-mantovani-inflammation-virchow-lancet-2001","kind":"paper","name":"Balkwill and Mantovani 2001: inflammation and cancer, back to Virchow?","route":"/key-papers/paper-balkwill-mantovani-inflammation-virchow-lancet-2001/","field":"links","label":"Full text (DOI)"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Balkwill and Mantovani, Inflammation and cancer: back to Virchow? (Lancet 2001)"}]},{"url":"https://doi.org/10.1016/s0140-6736(00)49915-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673600499150","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paget-cancer-metastasis-rev","kind":"paper","name":"The distribution of secondary growths in cancer of the breast. 1889","route":"/key-papers/paper-paget-cancer-metastasis-rev/","field":"links","label":"Cancer Metastasis Rev 1989"}]},{"url":"https://doi.org/10.1016/S0140-6736(00)49915-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673600499150","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Paget, The distribution of secondary growths in cancer of the breast (Lancet 1889, reprinted)"}]},{"url":"https://doi.org/10.1016/S0140-6736(02)08649-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067360208649X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-llovet-tace-lancet-2002","kind":"paper","name":"Arterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma","route":"/key-papers/paper-llovet-tace-lancet-2002/","field":"links","label":"Lancet 2002"}]},{"url":"https://doi.org/10.1016/S0140-6736(02)09292-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673602092929","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002","kind":"paper","name":"NCIC SR2: preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs","route":"/key-papers/paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002/","field":"links","label":"Lancet 2002"}]},{"url":"https://doi.org/10.1016/s0140-6736(05)66481-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673605664811","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Leach, Lancet 2005: MRI and mammography screening of a UK population at high familial risk (MARIBS)"},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"links","label":"Leach, Lancet 2005: MRI and mammography screening of a UK population at high familial risk (MARIBS)"}]},{"url":"https://doi.org/10.1016/S0140-6736(05)66658-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673605666585","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oral-visual-screening","kind":"technology","name":"Oral cancer visual screening","route":"/technologies/oral-visual-screening/","field":"links","label":"Kerala oral cancer screening trial (Lancet 2005)"},{"id":"kerala-oral-screening","kind":"trial","name":"Kerala oral cancer visual screening trial (Trivandrum)","route":"/trials/kerala-oral-screening/","field":"links","label":"Sankaranarayanan et al., Lancet 2005"},{"id":"kerala-oral-screening","kind":"trial","name":"Kerala oral cancer visual screening trial (Trivandrum)","route":"/trials/kerala-oral-screening/","field":"outcomes.source (Oral cancer mortality, tobacco or alcohol users (rate ratio, 3 rounds))"},{"id":"paper-sankaranarayanan-oral-screening-lancet-2005","kind":"paper","name":"Effect of screening on oral cancer mortality in Kerala, India","route":"/key-papers/paper-sankaranarayanan-oral-screening-lancet-2005/","field":"links","label":"Lancet 2005"},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","field":"standardOfCare.guideline (Screening in high-risk populations)"}]},{"url":"https://doi.org/10.1016/S0140-6736(05)66984-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067360566984X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005","kind":"paper","name":"MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma","route":"/key-papers/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005/","field":"links","label":"Lancet 2005"}]},{"url":"https://doi.org/10.1016/s0140-6736(05)67785-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673605677859","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-lancet-2005","kind":"paper","name":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","route":"/key-papers/paper-jak2-polycythaemia-vera-lancet-2005/","field":"links","label":"Lancet 2005"}]},{"url":"https://doi.org/10.1016/S0140-6736(06)69446-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673606694464","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-demetri-sunitinib-gist-lancet-2006","kind":"paper","name":"Sunitinib in advanced gastrointestinal stromal tumour after failure of imatinib","route":"/key-papers/paper-demetri-sunitinib-gist-lancet-2006/","field":"links","label":"Lancet 2006"}]},{"url":"https://doi.org/10.1016/S0140-6736(07)61126-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067360761126X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","field":"papers","label":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia"},{"id":"paper-interfant-99-lancet-2007","kind":"paper","name":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-99-lancet-2007/","field":"links","label":"Lancet 2007"}]},{"url":"https://doi.org/10.1016/s0140-6736(07)61195-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673607611957","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet","kind":"paper","name":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","route":"/key-papers/paper-sankaranarayanan-lancet/","field":"links","label":"Lancet 2007"}]},{"url":"https://doi.org/10.1016/S0140-6736(07)61195-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673607611957","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/","field":"links","label":"Lancet 2007: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India, a cluster-randomised trial"}]},{"url":"https://doi.org/10.1016/S0140-6736(07)61866-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673607618662","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","kind":"paper","name":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","route":"/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/","field":"links","label":"Lancet 2007"}]},{"url":"https://doi.org/10.1016/s0140-6736(08)60455-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673608604559","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Nordlinger, Lancet 2008: EORTC 40983, perioperative FOLFOX4 and surgery versus surgery alone for resectable colorectal liver metastases (364 patients)"},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","field":"links","label":"Nordlinger, Lancet 2008: EORTC 40983, perioperative FOLFOX4 and surgery versus surgery alone for resectable colorectal liver metastases (364 patients)"},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/","field":"links","label":"Nordlinger, Lancet 2008: EORTC 40983, perioperative FOLFOX4 and surgery versus surgery alone for resectable colorectal liver metastases (364 patients)"}]},{"url":"https://doi.org/10.1016/s0140-6736(08)60661-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673608606613","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"papers","label":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study"}]},{"url":"https://doi.org/10.1016/S0140-6736(08)61815-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673608618152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/","field":"links","label":"SPCG-7/SFUO-3 (Lancet 2009)"},{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/","field":"outcomes.source (Prostate cancer mortality at 10 years)"},{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/","field":"outcomes.source (Overall mortality at 10 years)"}]},{"url":"https://doi.org/10.1016/S0140-6736(09)60484-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609604840","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009","kind":"paper","name":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)","route":"/key-papers/paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009/","field":"links","label":"Lancet 2009"}]},{"url":"https://doi.org/10.1016/S0140-6736(09)60618-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609606188","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009","kind":"paper","name":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","route":"/key-papers/paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009/","field":"links","label":"Lancet 2009"}]},{"url":"https://doi.org/10.1016/s0140-6736(09)61116-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609611168","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mcculloch-lancet","kind":"paper","name":"No surgical innovation without evaluation: the IDEAL recommendations","route":"/key-papers/paper-mcculloch-lancet/","field":"links","label":"Lancet 2009"}]},{"url":"https://doi.org/10.1016/S0140-6736(09)61116-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609611168","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"links","label":"McCulloch et al., No surgical innovation without evaluation: the IDEAL recommendations (Lancet 2009)"}]},{"url":"https://doi.org/10.1016/S0140-6736(09)61248-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609612484","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","field":"links","label":"PATRICIA (Lancet 2009)"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"links","label":"Lancet 2009"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"outcomes.source (Vaccine efficacy against CIN2+ associated with HPV-16 or HPV-18 (according-to-protocol cohort for efficacy, primary analysis))"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"outcomes.source (Vaccine efficacy against CIN2+ irrespective of HPV type (total vaccinated cohort, no evidence of oncogenic HPV at baseline))"},{"id":"paper-patricia-paavonen-lancet-2009","kind":"paper","name":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","route":"/key-papers/paper-patricia-paavonen-lancet-2009/","field":"links","label":"Lancet 2009"}]},{"url":"https://doi.org/10.1016/s0140-6736(09)61638-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067360961638X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"papers","label":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis"}]},{"url":"https://doi.org/10.1016/S0140-6736(09)62163-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673609621632","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","field":"papers","label":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer"},{"id":"paper-portec-2-lancet-2010","kind":"paper","name":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","route":"/key-papers/paper-portec-2-lancet-2010/","field":"links","label":"Lancet 2010"},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","field":"outcomes.source (Vaginal recurrence at 5 years)"},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","field":"outcomes.source (Locoregional relapse at 5 years)"},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","field":"outcomes.source (Acute grade 1-2 gastrointestinal toxicity at completion of radiotherapy)"}]},{"url":"https://doi.org/10.1016/s0140-6736(10)60206-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610602061","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"papers","label":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)60551-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361060551X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010","kind":"paper","name":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial","route":"/key-papers/paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010/","field":"links","label":"Lancet 2010"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)61121-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/s0140-6736(10)61268-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610612688","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rustin-lancet","kind":"paper","name":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial","route":"/key-papers/paper-rustin-lancet/","field":"links","label":"Lancet 2010"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)61268-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610612688","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/","field":"links","label":"Lancet 2010: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955), a randomised trial of CA-125-triggered treatment"}]},{"url":"https://doi.org/10.1016/s0140-6736(10)61389-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361061389X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/","field":"links","label":"Lancet 2010"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)61389-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361061389X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"links","label":"TROPIC (Lancet 2010)"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"outcomes.source (Overall survival (median))"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"outcomes.source (Progression-free survival (median))"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"outcomes.source (Grade 3 or higher neutropenia)"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)62002-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610620028","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ukallr3","kind":"trial","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","field":"outcomes.source (Progression-free survival at 3 years)"},{"id":"ukallr3","kind":"trial","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"ukallr3","kind":"trial","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","field":"outcomes.source (Disease events (progression, second relapse, disease-related death), hazard for mitoxantrone against idarubicin)"},{"id":"paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010","kind":"paper","name":"ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia","route":"/key-papers/paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010/","field":"links","label":"Lancet 2010"}]},{"url":"https://doi.org/10.1016/s0140-6736(10)62110-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610621101","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rothwell-lancet","kind":"paper","name":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","route":"/key-papers/paper-rothwell-lancet/","field":"links","label":"Lancet 2011"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)62110-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610621101","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Rothwell et al., Effect of daily aspirin on long-term risk of death due to cancer (Lancet 2011)"}]},{"url":"https://doi.org/10.1016/S0140-6736(10)62175-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673610621757","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-maintenance","kind":"term","name":"Maintenance and consolidation in lymphoma: where it works and where it does not","route":"/terms/lymphoma-tx-maintenance/","field":"links","label":"PRIMA: two years of rituximab maintenance in follicular lymphoma, Lancet 2011"}]},{"url":"https://doi.org/10.1016/s0140-6736(11)60070-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673611600706","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cortes-lancet","kind":"paper","name":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","route":"/key-papers/paper-cortes-lancet/","field":"links","label":"Lancet 2011"}]},{"url":"https://doi.org/10.1016/S0140-6736(11)60070-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673611600706","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","field":"links","label":"EMBRACE (Lancet 2011)"}]},{"url":"https://doi.org/10.1016/S0140-6736(11)61625-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673611616255","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/","field":"links","label":"Lancet 2012"}]},{"url":"https://doi.org/10.1016/S0140-6736(11)61629-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673611616292","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiotherapy-omission-early-breast-cancer","kind":"term","name":"Leaving radiotherapy out","route":"/terms/radiotherapy-omission-early-breast-cancer/","field":"links","label":"EBCTCG: radiotherapy after breast-conserving surgery, 10,801 women in 17 trials (The Lancet 2011)"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"EBCTCG, radiotherapy after breast-conserving surgery: meta-analysis of 10,801 women in 17 randomised trials (Lancet 2011)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"EBCTCG, radiotherapy after breast-conserving surgery: meta-analysis of 10,801 women in 17 randomised trials (Lancet 2011)"}]},{"url":"https://doi.org/10.1016/S0140-6736(11)61873-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","field":"outcomes.source (Disease-free survival at 3 years)"},{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","field":"outcomes.source (Grade 3 or 4 adverse events)"},{"id":"paper-classic-adjuvant-capox-gastric-bang-lancet-2012","kind":"paper","name":"CLASSIC: adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-adjuvant-capox-gastric-bang-lancet-2012/","field":"links","label":"Lancet 2012"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)60485-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612604851","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)61253-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612612537","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-22911","kind":"trial","name":"EORTC 22911","route":"/trials/eortc-22911/","field":"links","label":"EORTC 22911 long-term results (Lancet 2012)"},{"id":"eortc-22911","kind":"trial","name":"EORTC 22911","route":"/trials/eortc-22911/","field":"outcomes.source (Biochemical or clinical progression or death)"},{"id":"eortc-22911","kind":"trial","name":"EORTC 22911","route":"/trials/eortc-22911/","field":"outcomes.source (Late adverse effects of any grade at 10 years)"}]},{"url":"https://doi.org/10.1016/s0140-6736(12)61611-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612616110","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-independent-uk-panel-on-breast-cancer-lancet","kind":"paper","name":"The benefits and harms of breast cancer screening: an independent review","route":"/key-papers/paper-independent-uk-panel-on-breast-cancer-lancet/","field":"links","label":"Lancet 2012"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)61611-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612616110","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"links","label":"Independent UK Panel on Breast Cancer Screening (Lancet 2012)"},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","field":"metrics (Estimated breast cancers overdiagnosed for each breast cancer death prevented by UK mammography screening)"},{"id":"overdiagnosis","kind":"term","name":"Overdiagnosis","route":"/terms/overdiagnosis/","field":"links","label":"Independent UK Panel on Breast Cancer Screening (Lancet 2012)"}]},{"url":"https://doi.org/10.1016/s0140-6736(12)61763-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612617632","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rummel-lancet","kind":"paper","name":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","route":"/key-papers/paper-rummel-lancet/","field":"links","label":"Lancet 2013"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)61763-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612617632","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","field":"links","label":"StiL NHL1 (Lancet 2013)"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)61857-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673612618571","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","field":"papers","label":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib"},{"id":"paper-grid-regorafenib-gist-lancet-2013","kind":"paper","name":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","route":"/key-papers/paper-grid-regorafenib-gist-lancet-2013/","field":"links","label":"Lancet 2013"},{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/","field":"outcomes.source (Progression-free survival (independent blinded central review))"}]},{"url":"https://doi.org/10.1016/S0140-6736(12)61900-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361261900X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-grothey-correct-regorafenib-lancet-2013","kind":"paper","name":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)","route":"/key-papers/paper-grothey-correct-regorafenib-lancet-2013/","field":"links","label":"Lancet 2013"},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","field":"links","label":"CORRECT: regorafenib monotherapy for previously treated metastatic colorectal cancer (Lancet 2013)"},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(13)62422-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","field":"links","label":"Cortazar, Lancet 2014: pathological complete response and long-term benefit, the CTNeoBC pooled analysis"}]},{"url":"https://doi.org/10.1016/S0140-6736(13)62422-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014","kind":"paper","name":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","route":"/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/","field":"links","label":"Lancet 2014"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)60421-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614604219","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-decision-sorafenib-lancet-2014","kind":"paper","name":"DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-decision-sorafenib-lancet-2014/","field":"links","label":"Lancet 2014"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)60488-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614604888","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"post-mastectomy-radiotherapy","kind":"term","name":"Radiotherapy after mastectomy","route":"/terms/post-mastectomy-radiotherapy/","field":"links","label":"EBCTCG: radiotherapy after mastectomy, 8,135 women in 22 trials (The Lancet 2014)"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)60493-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614604931","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"papers","label":"Multiple myeloma"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)60845-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361460845X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","field":"links","label":"REVEL (Lancet 2014)"},{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","field":"outcomes.source (Overall survival)"},{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)61085-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614610850","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"crest-thoracic-rt","kind":"trial","name":"CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer","route":"/trials/crest-thoracic-rt/","field":"links","label":"CREST (Lancet 2015)"},{"id":"crest-thoracic-rt","kind":"trial","name":"CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer","route":"/trials/crest-thoracic-rt/","field":"outcomes.source (Overall survival at 1 year)"},{"id":"crest-thoracic-rt","kind":"trial","name":"CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer","route":"/trials/crest-thoracic-rt/","field":"outcomes.source (Overall survival at 2 years)"}]},{"url":"https://doi.org/10.1016/s0140-6736(14)61231-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614612319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sharpe-lancet","kind":"paper","name":"Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial","route":"/key-papers/paper-sharpe-lancet/","field":"links","label":"Lancet 2014"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)61231-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614612319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"SMaRT Oncology-2 (Lancet 2014)"}]},{"url":"https://doi.org/10.1016/S0140-6736(14)62004-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673614620043","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cairo3","kind":"trial","name":"CAIRO3","route":"/trials/cairo3/","field":"links","label":"CAIRO3: maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (Lancet 2015)"},{"id":"cairo3","kind":"trial","name":"CAIRO3","route":"/trials/cairo3/","field":"outcomes.source (Progression-free survival 2)"}]},{"url":"https://doi.org/10.1016/s0140-6736(15)00758-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615007588","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"papers","label":"Providing incentives to share data early in health emergencies: the role of journal editors"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)00817-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361500817X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"outcomes.source (Progression-free survival (RADIANT-4))"},{"id":"paper-radiant-4-everolimus-lancet-2016","kind":"paper","name":"RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract","route":"/key-papers/paper-radiant-4-everolimus-lancet-2016/","field":"links","label":"Lancet 2016"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"links","label":"RADIANT-4 (Lancet 2016)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)00986-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615009861","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","kind":"paper","name":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","route":"/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/","field":"links","label":"Lancet 2016"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"links","label":"Wang-Gillam et al., NAPOLI-1 (Lancet 2016)"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(15)01037-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615010375","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stampede-lancet-2016","kind":"paper","name":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","route":"/key-papers/paper-stampede-lancet-2016/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)01037-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615010375","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"James et al., Lancet 2016: addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)01168-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361501168X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"standardOfCare.guideline (ER-positive DCIS after breast conservation)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)01281-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615012817","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","field":"links","label":"KEYNOTE-010 (Lancet 2016)"},{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","field":"outcomes.source (Overall survival)"},{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","field":"outcomes.source (Overall survival, higher dose)"},{"id":"paper-keynote-010-lancet-2016","kind":"paper","name":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","route":"/key-papers/paper-keynote-010-lancet-2016/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)01283-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615012830","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","field":"papers","label":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma"},{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)60165-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615601659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","kind":"paper","name":"AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse","route":"/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/","field":"links","label":"Lancet 2015"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"links","label":"AETHERA (Lancet 2015)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)60898-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615608984","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-combi-d-long-lancet-2015","kind":"paper","name":"COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma","route":"/key-papers/paper-combi-d-long-lancet-2015/","field":"links","label":"Lancet 2015"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"links","label":"COMBI-d final analysis (Lancet 2015)"},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"links","label":"Final analysis, Lancet 2015"},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"outcomes.source (Progression-free survival)"},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(15)60908-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet","kind":"paper","name":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet/","field":"links","label":"Lancet 2015"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)60908-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","field":"links","label":"EBCTCG adjuvant bisphosphonates (Lancet 2015)"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Early Breast Cancer Trialists' Collaborative Group, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data (Lancet 2015)"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)00587-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616005870","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","field":"papers","label":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial"},{"id":"paper-keunchil-park-lancet-2016","kind":"paper","name":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2016/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)30172-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616301726","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)30172-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616301726","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","field":"links","label":"Review: Thyroid cancer (Lancet seminar)"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)30583-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616305839","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/","field":"links","label":"Uesaka et al., JASPAC 01 (Lancet 2016)"},{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/","field":"outcomes.source (Overall survival (per-protocol population))"},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","field":"links","label":"Uesaka et al., JASPAC 01 (Lancet 2016)"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)30587-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616305876","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","field":"papers","label":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial"},{"id":"paper-robin-jones-lancet-2016","kind":"paper","name":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","route":"/key-papers/paper-robin-jones-lancet-2016/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)30825-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361630825X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quartz-lancet-2016","kind":"paper","name":"QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer","route":"/key-papers/paper-quartz-lancet-2016/","field":"links","label":"Lancet 2016"},{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","field":"links","label":"Lancet 2016"},{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","field":"outcomes.source (Quality-adjusted life-years)"},{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","field":"outcomes.source (Overall survival)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"links","label":"QUARTZ (Lancet 2016)"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)31388-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616313885","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016","kind":"paper","name":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016/","field":"links","label":"Lancet 2016"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)32401-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616324011","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ahmed-promis-multiparametric-mri-lancet-2017","kind":"paper","name":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","route":"/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/","field":"links","label":"Lancet 2017"},{"id":"whole-mount-pathology","kind":"term","name":"Whole-mount pathology","route":"/terms/whole-mount-pathology/","field":"links","label":"Ahmed et al., The Lancet 2017 (PROMIS): diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer"},{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"links","label":"Ahmed et al., The Lancet 2017 (PROMIS): diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer"},{"id":"template-mapping-biopsy","kind":"term","name":"Template mapping biopsy (transperineal template prostate mapping)","route":"/terms/template-mapping-biopsy/","field":"links","label":"Ahmed et al., The Lancet 2017 (PROMIS): diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)32409-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616324096","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Neoptolemos et al., adjuvant gemcitabine and capecitabine versus gemcitabine alone, ESPAC-4 (Lancet 2017)"},{"id":"paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017","kind":"paper","name":"ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer","route":"/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/","field":"links","label":"Lancet 2017"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"outcomes.source (Overall survival)"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"outcomes.source (Patients with grade 3 to 4 adverse events)"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)32453-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616324539","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)32517-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361632517X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","field":"papers","label":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial"},{"id":"paper-keunchil-park-lancet-2017","kind":"paper","name":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2017/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(16)32517-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361632517X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oak","kind":"trial","name":"OAK","route":"/trials/oak/","field":"links","label":"OAK (Lancet 2017)"},{"id":"oak","kind":"trial","name":"OAK","route":"/trials/oak/","field":"outcomes.source (Overall survival (intention to treat))"}]},{"url":"https://doi.org/10.1016/s0140-6736(16)32616-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673616326162","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-lancet-2017-update","kind":"paper","name":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","route":"/key-papers/paper-hera-b31-n9831-lancet-2017-update/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)30123-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361730123X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","field":"papers","label":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study"},{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","field":"links","label":"ASCEND-4 (Lancet 2017)"},{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"links","label":"The Lancet 2017"},{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","field":"outcomes.source (Progression-free survival (blinded independent review))"},{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/","field":"links","label":"The Lancet 2017"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)30131-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617301319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"papers","label":"CEPI-a new global R&D organisation for epidemic preparedness and response"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)30396-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617303963","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Atkin, Lancet 2017: UK Flexible Sigmoidoscopy Screening Trial, 17 years of follow-up (170,034 people)"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"Atkin, Lancet 2017: UK Flexible Sigmoidoscopy Screening Trial, 17 years of follow-up (170,034 people)"},{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","field":"links","label":"Atkin, Lancet 2017: UK Flexible Sigmoidoscopy Screening Trial, 17 years of follow-up (170,034 people)"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)30396-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617303963","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","kind":"paper","name":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","route":"/key-papers/paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)30565-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617305652","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"j-alex","kind":"trial","name":"J-ALEX","route":"/trials/j-alex/","field":"links","label":"J-ALEX (Lancet 2017)"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)30938-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617309388","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"papers","label":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)31145-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617311455","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-coles-lancet","kind":"paper","name":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","route":"/key-papers/paper-coles-lancet/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)31145-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617311455","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Coles et al., partial-breast radiotherapy after breast conservation, IMPORT LOW (Lancet 2017)"},{"id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)31266-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617312667","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","field":"papers","label":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma"},{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/","field":"links","label":"Lancet 2017"},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/","field":"outcomes.source (Objective global response lasting at least 4 months (independent review))"},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/","field":"outcomes.source (Grade 3-4 adverse events)"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)31442-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617314423","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-catnon-lancet-2017","kind":"paper","name":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","route":"/key-papers/paper-catnon-lancet-2017/","field":"links","label":"Lancet 2017"},{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","route":"/trials/catnon/","field":"links","label":"Lancet 2017"},{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","route":"/trials/catnon/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)31827-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","field":"outcomes.source (Overall survival)"},{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","field":"outcomes.source (Overall survival at 12 months)"},{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","field":"outcomes.source (Grade 3-4 treatment-related adverse events)"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)32134-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617321347","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Advanced Hodgkin lymphoma in Germany and much of Europe: PET-guided BrECADD)"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)32247-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361732247X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ridker-lancet","kind":"paper","name":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-ridker-lancet/","field":"links","label":"Lancet 2017"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)32247-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361732247X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Ridker et al., Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer (CANTOS, Lancet 2017)"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)32513-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617325138","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-knaul-lancet","kind":"paper","name":"Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report","route":"/key-papers/paper-knaul-lancet/","field":"links","label":"Lancet 2018"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)32513-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617325138","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"links","label":"Knaul et al., Alleviating the access abyss in palliative care and pain relief (Lancet Commission 2018)"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"metrics (People who die each year with serious health-related suffering, most in low- and middle-income countries)"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Lancet Commission on Palliative Care 2017"}]},{"url":"https://doi.org/10.1016/s0140-6736(17)33326-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617333263","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"papers","label":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries"}]},{"url":"https://doi.org/10.1016/S0140-6736(17)33326-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673617333263","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-allemani-concord-3-lancet-2018","kind":"paper","name":"Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014","route":"/key-papers/paper-allemani-concord-3-lancet-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)30207-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618302071","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","field":"outcomes.source (Overall survival)"},{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-reflect-lenvatinib-lancet-2018","kind":"paper","name":"REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma","route":"/key-papers/paper-reflect-lenvatinib-lancet-2018/","field":"links","label":"Lancet 2018"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)30458-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618304586","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wilson-lancet","kind":"paper","name":"Access to pathology and laboratory medicine services: a crucial gap","route":"/key-papers/paper-wilson-lancet/","field":"links","label":"Lancet 2018"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)30458-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618304586","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","field":"links","label":"Lancet Oncology Commission: pathology and lab medicine (2018)"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)30789-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361830789X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immunoscore","kind":"term","name":"Immunoscore","route":"/terms/immunoscore/","field":"links","label":"Pages, Lancet 2018: international validation of the consensus Immunoscore for the classification of colon cancer (2,681 patients)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)30789-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361830789X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pages-immunoscore-international-validation-lancet-2018","kind":"paper","name":"International validation of the consensus Immunoscore for the classification of colon cancer","route":"/key-papers/paper-pages-immunoscore-international-validation-lancet-2018/","field":"links","label":"Pages et al., Lancet 2018: international validation of the consensus Immunoscore in 2,681 stage I-III colon cancers"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)31078-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361831078X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"van der Valk, Lancet 2018: long-term outcomes of clinical complete responders in the International Watch and Wait Database (880 patients)"},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","field":"links","label":"van der Valk, Lancet 2018: long-term outcomes of clinical complete responders in the International Watch and Wait Database (880 patients)"},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","field":"links","label":"van der Valk, Lancet 2018: long-term outcomes of clinical complete responders in the International Watch and Wait Database (880 patients)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)31078-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361831078X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iwwd","kind":"trial","name":"International Watch & Wait Database","route":"/trials/iwwd/","field":"links","label":"IWWD: long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer (Lancet 2018)"},{"id":"iwwd","kind":"trial","name":"International Watch & Wait Database","route":"/trials/iwwd/","field":"outcomes.source (Cumulative local regrowth at 2 years)"},{"id":"iwwd","kind":"trial","name":"International Watch & Wait Database","route":"/trials/iwwd/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)31559-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618315599","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"papers","label":"Melanoma"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)31999-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618319998","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","field":"papers","label":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study"},{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)32409-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324097","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-042-lancet-2019","kind":"paper","name":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","route":"/key-papers/paper-keynote-042-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32409-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324097","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","field":"links","label":"The Lancet 2019"},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","field":"outcomes.source (Overall survival, PD-L1 tumour proportion score 50% or more)"},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","field":"outcomes.source (Overall survival, PD-L1 tumour proportion score 1% or more)"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)32486-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-parker-lancet","kind":"paper","name":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","route":"/key-papers/paper-parker-lancet/","field":"links","label":"Lancet 2018"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32486-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Parker et al., Lancet 2018: radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE)"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, prostate radiotherapy comparison)"},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","field":"links","label":"STAMPEDE prostate radiotherapy (Lancet 2018)"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)32487-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324875","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sabr-comet-lancet-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","route":"/key-papers/paper-sabr-comet-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32487-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324875","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","field":"links","label":"Palma et al., SABR-COMET (Lancet 2019)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32557-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","field":"papers","label":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma"},{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","field":"papers","label":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma"},{"id":"paper-flot4-lancet-2019","kind":"paper","name":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-flot4-lancet-2019/","field":"links","label":"Lancet 2019"},{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","field":"outcomes.source (Overall survival)"},{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","field":"outcomes.source (Related serious adverse events)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32752-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618327521","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-de-escalate-lancet-2019","kind":"paper","name":"De-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer","route":"/key-papers/paper-de-escalate-lancet-2019/","field":"links","label":"Lancet 2019"},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","field":"links","label":"Lancet 2019"},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","field":"outcomes.source (Severe (grade 3-5) toxicity events per patient at 24 months)"},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","field":"outcomes.source (Overall survival at 2 years)"},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","field":"outcomes.source (Recurrence at 2 years)"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)32776-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618327764","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schuetz-lancet","kind":"paper","name":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","route":"/key-papers/paper-schuetz-lancet/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32776-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618327764","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","field":"links","label":"EFFORT trial (Lancet 2019)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32779-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361832779X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-1016-lancet-2019","kind":"paper","name":"NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer","route":"/key-papers/paper-rtog-1016-lancet-2019/","field":"links","label":"Lancet 2019"},{"id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)32984-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618329842","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/","field":"links","label":"Lancet 2019"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","field":"outcomes.source (Progression-free survival (blinded independent central review))"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","field":"outcomes.source (Febrile neutropenia)"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","field":"outcomes.source (Peripheral neuropathy)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32984-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618329842","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"links","label":"ECHELON-2 (Lancet 2019)"}]},{"url":"https://doi.org/10.1016/s0140-6736(18)33137-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019","kind":"paper","name":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)33137-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"norton-simon-hypothesis","kind":"technology","name":"Norton-Simon hypothesis and dose-dense chemotherapy","route":"/technologies/norton-simon-hypothesis/","field":"links","label":"EBCTCG 2019 meta-analysis"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)30650-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619306506","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)30650-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619306506","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"Earl et al., 6 versus 12 months of adjuvant trastuzumab (PERSEPHONE, Lancet 2019)"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"metrics (Six vs twelve months of adjuvant trastuzumab in HER2-positive breast cancer (PERSEPHONE): 4-year disease-free survival)"},{"id":"idea-cost-shorter-course-trials","kind":"idea","name":"Fund trials that test shorter courses of the most expensive adjuvant drugs","route":"/ideas/idea-cost-shorter-course-trials/","field":"links","label":"Earl et al., Lancet 2019: PERSEPHONE"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)30653-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619306531","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"papers","label":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)30764-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619307640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tap-lancet","kind":"paper","name":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","route":"/key-papers/paper-tap-lancet/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)30764-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619307640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","field":"links","label":"ENLIVEN (Lancet 2019)"},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","field":"links","label":"ENLIVEN (Lancet 2019)"},{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"links","label":"ENLIVEN (Lancet 2019)"},{"id":"enliven","kind":"trial","name":"ENLIVEN","route":"/trials/enliven/","field":"links","label":"Lancet 2019"},{"id":"enliven","kind":"trial","name":"ENLIVEN","route":"/trials/enliven/","field":"outcomes.source (Objective response at week 25 (RECIST))"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)31131-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619311316","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-widmark-lancet","kind":"paper","name":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","route":"/key-papers/paper-widmark-lancet/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)31131-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619311316","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-radiotherapy-fractionation","kind":"term","name":"How many radiotherapy visits: the prostate fractionation trials","route":"/terms/prostate-radiotherapy-fractionation/","field":"links","label":"HYPO-RT-PC 5-year outcomes (Lancet 2019)"},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"links","label":"Lancet 2019"},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"links","label":"HYPO-RT-PC 5-year outcomes (Lancet 2019)"},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"outcomes.source (Failure-free survival at 5 years)"},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"outcomes.source (RTOG grade 2 or worse urinary toxicity at 1 year)"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)31240-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619312401","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cassiopeia-lancet-2019","kind":"paper","name":"CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma","route":"/key-papers/paper-cassiopeia-lancet-2019/","field":"links","label":"Lancet 2019"},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","field":"outcomes.source (Stringent complete response at day 100 after transplantation (part 1))"},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","field":"outcomes.source (Minimal residual disease negativity (10^-5, flow cytometry))"},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","field":"outcomes.source (Progression-free survival from first randomisation)"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)32222-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)32222-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","field":"outcomes.source (3-year overall survival rate)"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)32319-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619323190","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)32319-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619323190","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","field":"links","label":"Review: Colorectal cancer (Lancet seminar)"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)32514-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619325140","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)32514-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619325140","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","field":"links","label":"Lancet 2019"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)32515-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619325152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"partial-breast-irradiation","kind":"term","name":"Partial-breast irradiation","route":"/terms/partial-breast-irradiation/","field":"links","label":"RAPID (The Lancet 2019)"},{"id":"rapid","kind":"trial","name":"RAPID (accelerated partial-breast irradiation)","route":"/trials/rapid/","field":"links","label":"RAPID (The Lancet 2019)"},{"id":"rapid","kind":"trial","name":"RAPID (accelerated partial-breast irradiation)","route":"/trials/rapid/","field":"outcomes.source (Ipsilateral breast tumour recurrence at 8 years)"},{"id":"rapid","kind":"trial","name":"RAPID (accelerated partial-breast irradiation)","route":"/trials/rapid/","field":"outcomes.source (Late radiation toxicity, grade 2 or worse)"}]},{"url":"https://doi.org/10.1016/s0140-6736(19)32955-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619329551","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cuzick, Lancet 2020: anastrozole for breast cancer prevention (IBIS-II), long-term results"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"Cuzick, Lancet 2020: anastrozole for breast cancer prevention (IBIS-II), long-term results"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)32955-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619329551","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/","field":"links","label":"Lancet 2020 (DOI)"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)33008-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619330089","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Limited stage (I to II), non-bulky, low risk: four cycles, and often no radiotherapy)"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)33222-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619332222","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","field":"links","label":"ACTG A5263 (Lancet 2020)"},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","field":"outcomes.source (Progression-free survival at week 48, paclitaxel against etoposide (non-inferiority))"},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","field":"outcomes.source (Progression-free survival at week 48, paclitaxel against bleomycin plus vincristine (non-inferiority))"},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","field":"outcomes.source (Absolute difference in week-48 progression-free survival, etoposide minus paclitaxel)"},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","field":"outcomes.source (Absolute difference in week-48 progression-free survival, bleomycin-vincristine minus paclitaxel)"},{"id":"paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020","kind":"paper","name":"ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings","route":"/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30230-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620302300","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","field":"papers","label":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130)"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30262-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620302622","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","field":"outcomes.source (Overall survival (A+O vs O+Clb))"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30314-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620303147","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)30366-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620303664","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Burn, Lancet 2020: CAPP2, cancer prevention with aspirin in Lynch syndrome, 10-year follow-up (861 patients randomised)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"Burn, Lancet 2020: CAPP2, cancer prevention with aspirin in Lynch syndrome, 10-year follow-up (861 patients randomised)"},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"Burn, Lancet 2020: CAPP2, cancer prevention with aspirin in Lynch syndrome, 10-year follow-up (861 patients randomised)"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30366-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620303664","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/","field":"links","label":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years (The Lancet 2020)"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"metrics (Reduction in colorectal cancer with daily aspirin in Lynch syndrome carriers at 10 years (CAPP2, per-protocol))"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"links","label":"Burn et al., Cancer prevention with aspirin in hereditary colorectal cancer (CAPP2, Lancet 2020)"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"metrics (Colorectal cancer reduction with aspirin in Lynch syndrome carriers at 10-year follow-up (CAPP2, per-protocol))"},{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","field":"links","label":"DOI"},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"CAPP2 10-year follow-up (Lancet 2020)"},{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","field":"links","label":"CAPP2 long-term follow-up, Lancet 2020"},{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/","field":"outcomes.source (Colorectal cancer over a mean of 10 years of follow-up (intention to treat))"},{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/","field":"outcomes.source (Colorectal cancer, per protocol (at least 2 years of treatment))"},{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/","field":"outcomes.source (Incidence rate ratio for colorectal cancer accounting for multiple primaries (intention to treat))"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30417-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620304177","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"papers","label":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma (IMMUNED)"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)30932-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620309326","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-murray-brunt-lancet","kind":"paper","name":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-murray-brunt-lancet/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30932-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620309326","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Murray Brunt et al., FAST-Forward: 1 week versus 3 weeks of breast radiotherapy, 5-year results (Lancet 2020)"},{"id":"idea-cost-hypofractionation-payment","kind":"idea","name":"Pay for a course of radiotherapy, not for each fraction","route":"/ideas/idea-cost-hypofractionation-payment/","field":"links","label":"Brunt et al., Lancet 2020: FAST-Forward"},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/","field":"links","label":"FAST-Forward: five-fraction breast radiotherapy (Lancet 2020)"},{"id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)30934-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362030934X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-2020","kind":"paper","name":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-imspire150-lancet-2020/","field":"links","label":"Lancet 2020"},{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/","field":"outcomes.source (Progression-free survival (investigator-assessed))"},{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/","field":"outcomes.source (Stopped all treatment for adverse events)"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)31042-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620310424","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"papers","label":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)31099-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620310990","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fitzgerald-lancet","kind":"paper","name":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial","route":"/key-papers/paper-fitzgerald-lancet/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31099-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620310990","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","route":"/ideas/idea-non-endoscopic-barretts-screening/","field":"links","label":"BEST3: Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus (Lancet 2020)"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)31288-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620312885","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31288-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620312885","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","field":"links","label":"Review: Gastric cancer (Lancet seminar)"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31553-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620315531","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","field":"links","label":"RADICALS-RT (Lancet 2020)"},{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","field":"outcomes.source (Biochemical progression-free survival at 5 years)"},{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","field":"outcomes.source (Grade 3 to 4 urethral stricture within 2 years)"},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"papers","label":"RADICALS-RT: timing of radiotherapy after radical prostatectomy"},{"id":"paper-radicals-rt-lancet-2020","kind":"paper","name":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","route":"/key-papers/paper-radicals-rt-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31952-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620319528","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"artistic-meta-analysis","kind":"trial","name":"ARTISTIC meta-analysis","route":"/trials/artistic-meta-analysis/","field":"links","label":"ARTISTIC prospectively planned meta-analysis (Lancet 2020)"},{"id":"artistic-meta-analysis","kind":"trial","name":"ARTISTIC meta-analysis","route":"/trials/artistic-meta-analysis/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)31953-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-impassion031-lancet-2020","kind":"paper","name":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-impassion031-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31953-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/","field":"links","label":"Mittendorf et al., IMpassion031 (Lancet 2020)"},{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/","field":"outcomes.source (Pathological complete response (all patients))"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)32531-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620325319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"Cortes, Lancet 2020: KEYNOTE-355, pembrolizumab plus chemotherapy in untreated metastatic triple-negative breast cancer"},{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","field":"links","label":"Cortes, Lancet 2020: KEYNOTE-355, pembrolizumab plus chemotherapy in untreated metastatic triple-negative breast cancer"},{"id":"paper-keynote-355-lancet-2020","kind":"paper","name":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","route":"/key-papers/paper-keynote-355-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)32531-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620325319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"links","label":"KEYNOTE-355 progression-free survival (Lancet 2020)"}]},{"url":"https://doi.org/10.1016/s0140-6736(20)32661-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620326611","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"papers","label":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)32714-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620327148","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","route":"/key-papers/paper-checkmate-743-lancet-2021/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00085-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621000854","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","field":"papers","label":"The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00100-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621001008","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-langley-lancet","kind":"paper","name":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","route":"/key-papers/paper-langley-lancet/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00100-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621001008","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Langley et al., Lancet 2021: transdermal oestradiol for androgen suppression in prostate cancer, long-term cardiovascular outcomes from PATCH"},{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","field":"links","label":"PATCH cardiovascular outcomes (Lancet 2021)"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"links","label":"PATCH long-term cardiovascular outcomes (Lancet 2021)"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"outcomes.source (Time to first cardiovascular event)"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"outcomes.source (Hot flushes, any grade)"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"outcomes.source (Gynaecomastia, any grade)"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00152-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621001525","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"papers","label":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial"},{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/","field":"links","label":"Lancet 2021"},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/","field":"outcomes.source (Progression-free survival)"},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/","field":"outcomes.source (Response rate)"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00228-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-2021","kind":"paper","name":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","route":"/key-papers/paper-empower-lung-1-lancet-2021/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00228-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","field":"links","label":"The Lancet 2021"},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","field":"outcomes.source (Progression-free survival, PD-L1 50% or more)"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00237-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621002373","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00580-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621005808","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021","kind":"paper","name":"IPATential150: ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/","field":"links","label":"Sweeney et al., Lancet 2021: IPATential150, ipatasertib with abiraterone in 1,101 men with metastatic castration-resistant prostate cancer split by PTEN loss"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00731-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621007315","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-menon-lancet","kind":"paper","name":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","route":"/key-papers/paper-menon-lancet/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00731-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621007315","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"links","label":"Menon et al., UKCTOCS ovarian screening mortality results (Lancet 2021)"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"metrics (Ovarian cancer deaths prevented by annual multimodal screening over 16 years of follow-up (UKCTOCS))"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00797-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621007972","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"papers","label":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00933-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621009338","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)00950-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621009508","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"papers","label":"Prostate cancer"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)01234-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621012344","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","field":"papers","label":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer"},{"id":"paper-keynote-590-lancet-2021","kind":"paper","name":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","route":"/key-papers/paper-keynote-590-lancet-2021/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)01789-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362101789X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","field":"links","label":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth (The Lancet 2021)"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"links","label":"Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"metrics (Grade 3-5 toxicity with geriatric assessment-guided management vs usual care in patients aged 70 or older starting chemotherapy (GAP70+))"},{"id":"idea-acc-broad-eligibility-as-regulatory-default","kind":"idea","name":"Make sponsors justify every trial exclusion of older and multimorbid patients","route":"/ideas/idea-acc-broad-eligibility-as-regulatory-default/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-pragmatic-trials-over-75-function-endpoints","kind":"idea","name":"Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint","route":"/ideas/idea-acc-pragmatic-trials-over-75-function-endpoints/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-home-chemotherapy-older-patients","kind":"idea","name":"Home administration of selected chemotherapy and immunotherapy for older and frail patients","route":"/ideas/idea-acc-home-chemotherapy-older-patients/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-hospital-at-home-oncology","kind":"idea","name":"Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home","route":"/ideas/idea-acc-hospital-at-home-oncology/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-upfront-reduced-dose-trials-frail","kind":"idea","name":"Upfront reduced-dose regimens tested head-to-head in frail older patients","route":"/ideas/idea-acc-upfront-reduced-dose-trials-frail/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-electronic-frailty-index-oncology","kind":"idea","name":"An automatic electronic frailty index inside the oncology record","route":"/ideas/idea-acc-electronic-frailty-index-oncology/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-geriatric-co-management-surgery","kind":"idea","name":"Geriatrician co-management for older patients having cancer surgery","route":"/ideas/idea-acc-geriatric-co-management-surgery/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-post-approval-evidence-over-75","kind":"idea","name":"Require post-approval evidence in patients over 75 and update labels accordingly","route":"/ideas/idea-acc-post-approval-evidence-over-75/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-caregiver-training-as-covered-service","kind":"idea","name":"Caregiver training and respite as a covered service in cancer care for older patients","route":"/ideas/idea-acc-caregiver-training-as-covered-service/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days spent in healthcare, as a standard outcome for older patients","route":"/ideas/idea-acc-time-toxicity-reporting/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-prehabilitation-older-surgery","kind":"idea","name":"Multimodal prehabilitation for older patients before major cancer surgery","route":"/ideas/idea-acc-prehabilitation-older-surgery/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-acc-dementia-and-cancer-pathway","kind":"idea","name":"A defined pathway for patients with both dementia and cancer","route":"/ideas/idea-acc-dementia-and-cancer-pathway/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"idea-moon-geriatric-assessment-default","kind":"idea","name":"Geriatric assessment by default for every older patient, and trials that admit them","route":"/ideas/idea-moon-geriatric-assessment-default/","field":"links","label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)"},{"id":"paper-gap70-geriatric-assessment-lancet-2021","kind":"paper","name":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth","route":"/key-papers/paper-gap70-geriatric-assessment-lancet-2021/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)01790-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621017906","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/","field":"links","label":"SPPORT / NRG Oncology RTOG 0534 (Lancet 2022)"},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/","field":"outcomes.source (Freedom from progression at 5 years)"},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/","field":"outcomes.source (Acute grade 2 or worse adverse events within 3 months)"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)02098-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621020985","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","field":"links","label":"Lancet 2021"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)02098-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621020985","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","field":"links","label":"Lancet 2021"},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"papers","label":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"links","label":"IMpower010 (Lancet 2021)"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"outcomes.source (Disease-free survival at the primary analysis (Lancet 2021), stage II to IIIA with PD-L1 on 1% or more of tumour cells)"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"outcomes.source (Atezolizumab-related grade 3 to 4 adverse events)"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)02175-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621021759","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","field":"links","label":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer (Lancet 2022)"},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","field":"papers","label":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer"},{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/","field":"links","label":"Lancet 2022"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)02178-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621021784","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1016/s0140-6736(21)02333-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621023333","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sublobar-resection","kind":"term","name":"Sublobar resection (segmentectomy and wedge)","route":"/terms/sublobar-resection/","field":"links","label":"Saji, Lancet 2022: JCOG0802/WJOG4607L, segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (1,106 patients)"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)02437-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621024375","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Attard et al., Lancet 2022: abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer (STAMPEDE)"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Metastasis-free survival at 6 years, high-risk non-metastatic comparison)"},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","field":"links","label":"STAMPEDE abiraterone with or without enzalutamide in non-metastatic disease (Lancet 2022)"},{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","field":"papers","label":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer"},{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/","field":"links","label":"Lancet 2022"}]},{"url":"https://doi.org/10.1016/s0140-6736(22)00323-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622003233","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","field":"links","label":"Lancet 2022"}]},{"url":"https://doi.org/10.1016/S0140-6736(22)00323-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622003233","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","field":"links","label":"Review: Endometrial cancer (Lancet 2022)"}]},{"url":"https://doi.org/10.1016/s0140-6736(22)00367-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622003671","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peace-1-lancet-2022","kind":"paper","name":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design","route":"/key-papers/paper-peace-1-lancet-2022/","field":"links","label":"Lancet 2022"}]},{"url":"https://doi.org/10.1016/S0140-6736(22)00562-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622005621","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"papers","label":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)"},{"id":"paper-keynote-716-lancet-2022","kind":"paper","name":"KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma","route":"/key-papers/paper-keynote-716-lancet-2022/","field":"links","label":"Lancet 2022"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"links","label":"KEYNOTE-716 (Lancet 2022)"}]},{"url":"https://doi.org/10.1016/s0140-6736(22)02036-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622020360","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","field":"outcomes.source (Total symptom score response (>=50% reduction) at week 24)"},{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","field":"outcomes.source (Grade 3 or higher anaemia (laboratory))"},{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","field":"outcomes.source (Grade 3 or higher thrombocytopenia (laboratory))"}]},{"url":"https://doi.org/10.1016/S0140-6736(22)02036-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622020360","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","field":"links","label":"MOMENTUM (Lancet 2023)"}]},{"url":"https://doi.org/10.1016/S0140-6736(22)02038-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622020384","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","field":"links","label":"Nakachi et al., Lancet 2023: adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT)"},{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","field":"outcomes.source (3-year overall survival)"},{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","field":"outcomes.source (3-year relapse-free survival)"}]},{"url":"https://doi.org/10.1016/s0140-6736(22)02420-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622024205","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-breast03-lancet-2023-update","kind":"paper","name":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","route":"/key-papers/paper-destiny-breast03-lancet-2023-update/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(22)02420-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673622024205","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"papers","label":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00221-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623002210","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","field":"outcomes.source (Overall survival)"},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","field":"metrics (Median progression-free survival with sotorasib vs docetaxel in previously treated KRAS G12C NSCLC (CodeBreaK 200))"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00727-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623007274","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","field":"outcomes.source (Overall survival)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"KEYNOTE-966 (Lancet 2023)"},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","field":"papers","label":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer"},{"id":"paper-keynote-966-lancet-2023","kind":"paper","name":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","route":"/key-papers/paper-keynote-966-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)00769-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623007699","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"outcomes.source (Disease-free survival at 24 months)"},{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"outcomes.source (Disease-free survival at 12 months)"},{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"outcomes.source (Grade 3 or 4 adverse events)"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"standardOfCare.guideline (After complete resection: what the adjuvant evidence does and does not show)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00769-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623007699","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"links","label":"Interim analysis (The Lancet 2023)"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)00772-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623007729","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00772-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623007729","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)00874-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623008747","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"commands","kind":"trial","name":"COMMANDS","route":"/trials/commands/","field":"outcomes.source (Transfusion independence >=12 weeks with haemoglobin rise >=1.5 g/dL, weeks 1-24 (interim analysis))"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00874-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623008747","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","field":"papers","label":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions"},{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","field":"links","label":"COMMANDS (Lancet 2023)"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)00961-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623009613","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-qin-lancet","kind":"paper","name":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","route":"/key-papers/paper-qin-lancet/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)00961-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623009613","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","field":"outcomes.source (Overall survival)"},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","field":"outcomes.source (Progression-free survival)"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","field":"links","label":"CARES-310 (Lancet 2023)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01041-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623010413","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"links","label":"Accompanying comment (The Lancet 2023)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01052-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623010528","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","field":"outcomes.source (Overall response rate)"},{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","field":"outcomes.source (Undetectable MRD in blood)"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)01055-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623010553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2023","kind":"paper","name":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","route":"/key-papers/paper-talapro-2-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01055-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623010553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","field":"links","label":"TALAPRO-2: talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer (Lancet 2023)"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"papers","label":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)01245-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362301245X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tropics-02-lancet-2023","kind":"paper","name":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-tropics-02-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01366-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623013661","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Wainberg et al., NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive metastatic pancreatic cancer, NAPOLI 3 (Lancet 2023)"},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","field":"links","label":"Wainberg et al., NAPOLI 3 (Lancet 2023)"},{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Wainberg et al., NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive metastatic pancreatic cancer, NAPOLI 3 (Lancet 2023)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01613-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623016136","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","field":"papers","label":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma"},{"id":"paper-keynote-483-lancet-2023","kind":"paper","name":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","route":"/key-papers/paper-keynote-483-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01700-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623017002","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","field":"links","label":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms (The Lancet 2023)"},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","field":"links","label":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms (The Lancet 2023)"},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","field":"links","label":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms (The Lancet 2023)"},{"id":"eric-klein","kind":"person","name":"Eric A. Klein","route":"/people/eric-klein/","field":"papers","label":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms"},{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1016/s0140-6736(23)01724-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623017245","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","field":"outcomes.source (Red blood cell transfusion independence >=8 weeks)"},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","field":"outcomes.source (Grade 3-4 neutropenia)"},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","field":"outcomes.source (Grade 3-4 thrombocytopenia)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01724-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623017245","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","field":"links","label":"IMerge (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01796-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623017968","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","field":"outcomes.source (Recurrence-free survival (interim))"},{"id":"paper-imbrave050-lancet-2023","kind":"paper","name":"IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma","route":"/key-papers/paper-imbrave050-lancet-2023/","field":"links","label":"Lancet 2023"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01883-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623018834","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)02033-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623020330","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"papers","label":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma"},{"id":"paper-keynote-811-janjigian-lancet-2023","kind":"paper","name":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-keynote-811-janjigian-lancet-2023/","field":"links","label":"Lancet 2023"},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","field":"outcomes.source (Progression-free survival (second interim analysis))"},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","field":"outcomes.source (Overall survival (second interim analysis))"},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","field":"outcomes.source (Progression-free survival (third interim analysis))"},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","field":"outcomes.source (Overall survival (third interim analysis))"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)02554-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623025540","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"links","label":"FIRSTMAPPP (Lancet 2024)"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"links","label":"FIRSTMAPPP (Lancet 2024)"},{"id":"firstmappp","kind":"trial","name":"FIRSTMAPPP","route":"/trials/firstmappp/","field":"outcomes.source (Progression-free survival at 12 months)"},{"id":"firstmappp","kind":"trial","name":"FIRSTMAPPP","route":"/trials/firstmappp/","field":"outcomes.source (Grade 3 or 4 asthenia)"},{"id":"firstmappp","kind":"trial","name":"FIRSTMAPPP","route":"/trials/firstmappp/","field":"outcomes.source (Grade 3 or 4 hypertension)"},{"id":"paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024","kind":"paper","name":"FIRSTMAPPP: sunitinib for metastatic progressive phaeochromocytomas and paragangliomas","route":"/key-papers/paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/s0140-6736(24)00054-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624000540","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-2024-update","kind":"paper","name":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-phergain-lancet-2024-update/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00184-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624001843","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"links","label":"TRIANGLE (Lancet 2024)"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","field":"outcomes.source (Failure-free survival at 3 years, arm A+I against arm A)"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","field":"outcomes.source (Failure-free survival at 3 years, arm A against arm I (superiority of transplant not shown))"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","field":"outcomes.source (Grade 3 to 5 haematological adverse events during maintenance or follow-up)"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","field":"outcomes.source (Grade 3 to 5 infections during maintenance or follow-up)"},{"id":"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","kind":"paper","name":"TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma","route":"/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00317-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624003179","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","field":"links","label":"PFS, Lancet 2024"},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/","field":"links","label":"Lancet 2024 (PFS)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00549-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067362400549X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","field":"links","label":"RADICALS-HD (Lancet 2024)"},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","field":"links","label":"RADICALS-HD (Lancet 2024)"},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","field":"outcomes.source (Metastasis-free survival at 10 years)"},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","field":"outcomes.source (Grade 3 or higher toxicity)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00594-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624005944","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/","field":"outcomes.source (Event-free survival at 3 years)"},{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/","field":"outcomes.source (Grade 3 to 4 adverse events)"},{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/","field":"outcomes.source (Grade 3 to 4 immune-related adverse events)"},{"id":"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024","kind":"paper","name":"CONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma","route":"/key-papers/paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00701-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624007013","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"links","label":"NETTER-2 (Lancet 2024)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"links","label":"NETTER-2 (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00814-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624008146","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"standardOfCare.guideline (Molecularly directed)"},{"id":"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024","kind":"paper","name":"CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary","route":"/key-papers/paper-cupisco-molecularly-guided-therapy-cup-lancet-2024/","field":"links","label":"Lancet 2024"},{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/","field":"links","label":"Krämer et al., Lancet 2024: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO)"},{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/","field":"outcomes.source (Progression-free survival)"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"links","label":"CUPISCO (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/s0140-6736(24)00885-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624008857","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gelderblom-lancet","kind":"paper","name":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-gelderblom-lancet/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00885-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624008857","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"links","label":"MOTION (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01315-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624013151","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"outcomes.source (Treatment-related morbidity)"},{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/","field":"links","label":"Lancet 2024"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"links","label":"HD21 (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01438-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624014387","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-interlace-lancet-2024","kind":"paper","name":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-interlace-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/s0140-6736(24)01653-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624016532","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01653-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624016532","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"papers","label":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)"}]},{"url":"https://doi.org/10.1016/s0140-6736(24)01774-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624017744","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/","field":"links","label":"Lancet 2024"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01808-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624018087","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","field":"links","label":"OS, Lancet 2024"},{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/","field":"links","label":"Lancet 2024 (OS)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)02551-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624025510","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-emerald-1-lancet-2025","kind":"paper","name":"EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma","route":"/key-papers/paper-emerald-1-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)02575-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624025753","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-leap-012-lancet-2025","kind":"paper","name":"LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma","route":"/key-papers/paper-leap-012-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)02848-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624028484","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-8hw-lancet-2025","kind":"paper","name":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","route":"/key-papers/paper-checkmate-8hw-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)00403-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625004039","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","field":"outcomes.source (Overall survival)"},{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)00631-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625006312","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","field":"links","label":"POD1UM-303 (Lancet 2025)"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"links","label":"POD1UM-303 (Lancet 2025)"},{"id":"pod1um-303","kind":"trial","name":"POD1UM-303/InterAACT-2","route":"/trials/pod1um-303/","field":"outcomes.source (Progression-free survival (blinded independent central review))"},{"id":"pod1um-303","kind":"trial","name":"POD1UM-303/InterAACT-2","route":"/trials/pod1um-303/","field":"outcomes.source (Grade 3 or worse adverse events)"},{"id":"pod1um-303","kind":"trial","name":"POD1UM-303/InterAACT-2","route":"/trials/pod1um-303/","field":"outcomes.source (Serious adverse events)"},{"id":"paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025","kind":"paper","name":"POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma","route":"/key-papers/paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/s0140-6736(25)00684-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625006841","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-talapro-2-lancet-2025-update","kind":"paper","name":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","route":"/key-papers/paper-talapro-2-lancet-2025-update/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)00860-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625008608","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","field":"links","label":"CT041-ST-01 (Lancet 2025)"},{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/","field":"links","label":"The Lancet 2025"},{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/","field":"outcomes.source (Progression-free survival (independent review, intention-to-treat))"},{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/","field":"links","label":"The Lancet 2025"}]},{"url":"https://doi.org/10.1016/s0140-6736(25)01011-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625010116","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imforte-lancet-2025","kind":"paper","name":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","route":"/key-papers/paper-imforte-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)01011-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625010116","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"outcomes.source (Progression-free survival (IRF))"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)01040-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625010402","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/S0140-6736(25)01432-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625014321","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"standardOfCare.guideline (Where British and American practice differ)"},{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/","field":"links","label":"ENRICH: ibrutinib with rituximab against immunochemotherapy in untreated mantle cell lymphoma aged 60 and over, Lancet 2025"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (First-line mantle cell lymphoma in older patients: the British answer and the international one)"}]},{"url":"https://doi.org/10.1016/s0140-6736(25)01848-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625018483","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2025","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct05840016-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/s0140-6736(25)02025-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625020252","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05425940-lancet-2025","kind":"paper","name":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct05425940-lancet-2025/","field":"links","label":"Lancet 2025"}]},{"url":"https://doi.org/10.1016/s0140-6736(26)00508-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626005088","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nordicc-lancet-2026-update","kind":"paper","name":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","route":"/key-papers/paper-nordicc-lancet-2026-update/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/S0140-6736(26)00604-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626006045","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"outcomes.source (Progression-free survival)"},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"outcomes.source (Overall survival (interim))"}]},{"url":"https://doi.org/10.1016/S0140-6736(26)00917-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626009177","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/","field":"outcomes.source (Progression-free survival at 3 years)"},{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/","field":"outcomes.source (Mean adverse events per patient)"},{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/","field":"outcomes.source (Fatal serious adverse events after consolidation)"},{"id":"paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026","kind":"paper","name":"MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma","route":"/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/s0140-6736(26)00966-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626009669","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2026-update","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","route":"/key-papers/paper-nct05840016-lancet-2026-update/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/s0140-6736(26)00968-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626009682","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06448312-lancet-2026","kind":"paper","name":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct06448312-lancet-2026/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/S0140-6736(26)01089-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626010895","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"links","label":"Lancet 2026"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Progression-free survival by masked independent central review (final analysis at the second interim analysis, data cutoff 9 April 2025))"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Overall survival (interim analysis at the second interim analysis, data cutoff 9 April 2025))"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Grade 3 or worse treatment-emergent adverse events (treated participants))"},{"id":"paper-litespark-011-motzer-lancet-2026","kind":"paper","name":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-litespark-011-motzer-lancet-2026/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/s0140-6736(26)01092-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626010925","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-psmaddition-lancet-2026","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","route":"/key-papers/paper-psmaddition-lancet-2026/","field":"links","label":"Lancet 2026"}]},{"url":"https://doi.org/10.1016/s0140-6736(86)92612-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673686926127","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Quirke, Lancet 1986: local recurrence of rectal adenocarcinoma due to inadequate surgical resection (52 specimens sliced transversely)"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"Quirke, Lancet 1986: local recurrence of rectal adenocarcinoma due to inadequate surgical resection (52 specimens sliced transversely)"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Quirke, Lancet 1986: local recurrence of rectal adenocarcinoma due to inadequate surgical resection (52 specimens sliced transversely)"}]},{"url":"https://doi.org/10.1016/s0140-6736(96)03386-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673696033867","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"links","label":"Hardcastle, Lancet 1996: randomised controlled trial of faecal occult blood screening for colorectal cancer (Nottingham, 152,850 people)"},{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","field":"links","label":"Hardcastle, Lancet 1996: randomised controlled trial of faecal occult blood screening for colorectal cancer (Nottingham, 152,850 people)"}]},{"url":"https://doi.org/10.1016/S0140-6736(96)03386-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673696033867","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised controlled trial of faecal-occult-blood screening for colorectal cancer (Nottingham)","route":"/key-papers/paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996/","field":"links","label":"Lancet 1996"}]},{"url":"https://doi.org/10.1016/S0140-6736(96)03430-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673696034307","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kronborg-funen-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised study of screening for colorectal cancer with faecal-occult-blood test (Funen)","route":"/key-papers/paper-kronborg-funen-faecal-occult-blood-lancet-1996/","field":"links","label":"Lancet 1996"},{"id":"funen-fob","kind":"trial","name":"Funen faecal occult blood screening trial","route":"/trials/funen-fob/","field":"links","label":"Funen: randomised study of screening for colorectal cancer with faecal-occult-blood test (Lancet 1996)"},{"id":"funen-fob","kind":"trial","name":"Funen faecal occult blood screening trial","route":"/trials/funen-fob/","field":"outcomes.source (Colorectal cancer mortality)"}]},{"url":"https://doi.org/10.1016/s0167-8140(97)00220-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S016781409700220X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-overgaard-radiother-oncol","kind":"paper","name":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","route":"/key-papers/paper-overgaard-radiother-oncol/","field":"links","label":"Radiother Oncol 1998"}]},{"url":"https://doi.org/10.1016/S0167-8140(97)00220-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S016781409700220X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","field":"papers","label":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85"},{"id":"dahanca-5","kind":"trial","name":"DAHANCA 5","route":"/trials/dahanca-5/","field":"links","label":"Radiotherapy and Oncology 1998"}]},{"url":"https://doi.org/10.1016/s0190-9622(96)90500-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0190962296905009","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-duvic-j-am-acad-dermatol","kind":"paper","name":"A randomized trial of minoxidil in chemotherapy-induced alopecia","route":"/key-papers/paper-duvic-j-am-acad-dermatol/","field":"links","label":"J Am Acad Dermatol 1996"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","field":"links","label":"A randomised trial of minoxidil in chemotherapy-induced alopecia (J Am Acad Dermatol 1996)"}]},{"url":"https://doi.org/10.1016/s0211-139x(06)72977-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0211139X06729778","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"papers","label":"Estrategias para un control eficaz de la hipertensión arterial en España. Documento de consenso"}]},{"url":"https://doi.org/10.1016/s0268-960x(03)00004-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0268960X03000043","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"papers","label":"Primary cutaneous lymphomas: a review with current treatment options"}]},{"url":"https://doi.org/10.1016/s0360-3016(02)02884-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301602028845","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jaffray-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Flat-panel cone-beam computed tomography for image-guided radiation therapy","route":"/key-papers/paper-jaffray-int-j-radiat-oncol-biol-phys/","field":"links","label":"Int J Radiat Oncol Biol Phys 2002"}]},{"url":"https://doi.org/10.1016/S0360-3016(02)02884-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0360301602028845","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"in-room-imaging-systems","kind":"technology","name":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","route":"/technologies/in-room-imaging-systems/","field":"links","label":"Jaffray et al., Flat-panel cone-beam computed tomography for image-guided radiation therapy (IJROBP 2002)"}]},{"url":"https://doi.org/10.1016/s0959-8049(01)00231-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804901002313","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-egfr-gastric-eur-j-cancer-2001","kind":"paper","name":"EGFR and cancer prognosis","route":"/key-papers/paper-egfr-gastric-eur-j-cancer-2001/","field":"links","label":"Eur J Cancer 2001"}]},{"url":"https://doi.org/10.1016/s1134-2072(09)71973-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1134207209719735","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"papers","label":"Tratamiento combinado con antagonistas del calcio e inhibidores de la enzima de conversión de angiotensina (IECA) como terapia inicial preferible a diuréticos e IECA en hipertensos de riesgo alto"}]},{"url":"https://doi.org/10.1016/S1470-2045(01)00558-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204501005587","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001","kind":"paper","name":"Esthesioneuroblastoma: a meta-analysis and review","route":"/key-papers/paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001/","field":"links","label":"Lancet Oncol 2001"}]},{"url":"https://doi.org/10.1016/s1470-2045(06)70665-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204506706659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stummer-lancet-oncol","kind":"paper","name":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","route":"/key-papers/paper-stummer-lancet-oncol/","field":"links","label":"Lancet Oncol 2006"}]},{"url":"https://doi.org/10.1016/S1470-2045(06)70665-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204506706659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","field":"links","label":"Stummer et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial (Lancet Oncology 2006)"},{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","field":"links","label":"Stummer 2006 (Lancet Oncol)"}]},{"url":"https://doi.org/10.1016/S1470-2045(06)70804-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020450670804X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anita","kind":"trial","name":"ANITA (Adjuvant Navelbine International Trialist Association)","route":"/trials/anita/","field":"links","label":"ANITA (Lancet Oncology 2006)"},{"id":"anita","kind":"trial","name":"ANITA (Adjuvant Navelbine International Trialist Association)","route":"/trials/anita/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(08)70001-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508700019","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008","kind":"paper","name":"CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial","route":"/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/","field":"links","label":"Hess et al., Lancet Oncol 2008: CA 19-9 response to chemotherapy in a randomised trial"}]},{"url":"https://doi.org/10.1016/s1470-2045(08)70153-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508701530","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-prado-lancet-oncol","kind":"paper","name":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","route":"/key-papers/paper-prado-lancet-oncol/","field":"links","label":"Lancet Oncol 2008"}]},{"url":"https://doi.org/10.1016/S1470-2045(08)70153-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508701530","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ct-body-composition-sarcopenia","kind":"technology","name":"CT body composition and sarcopenia measurement","route":"/technologies/ct-body-composition-sarcopenia/","field":"links","label":"Lancet Oncology 2008: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts"}]},{"url":"https://doi.org/10.1016/S1470-2045(08)70178-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508701785","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Brantsch et al., analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: prospective study of 615 patients (Lancet Oncology 2008)"},{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"Brantsch et al., analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: prospective study of 615 patients (Lancet Oncology 2008)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Brantsch et al., analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: prospective study of 615 patients (Lancet Oncology 2008)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (Which squamous cell carcinomas are the dangerous ones)"}]},{"url":"https://doi.org/10.1016/s1470-2045(08)70260-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508702602","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"outcomes.source (Recurrence at 5 years, primary facial basal cell carcinoma)"},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"outcomes.source (Recurrence at 5 years, recurrent facial basal cell carcinoma)"},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"outcomes.source (Treatment cost, primary facial basal cell carcinoma)"}]},{"url":"https://doi.org/10.1016/S1470-2045(08)70260-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508702602","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"links","label":"Five-year results (Lancet Oncology 2008)"}]},{"url":"https://doi.org/10.1016/S1470-2045(08)70339-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204508703395","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009","kind":"paper","name":"A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)","route":"/key-papers/paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009/","field":"links","label":"Lancet Oncol 2009"}]},{"url":"https://doi.org/10.1016/S1470-2045(09)70003-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509700038","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aza-001-fenaux-lancet-oncol-2009","kind":"paper","name":"AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes","route":"/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/","field":"links","label":"Lancet Oncol 2009"},{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/","field":"outcomes.source (Overall survival)"},{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/","field":"outcomes.source (Overall survival at 2 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(09)70159-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509701597","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sjostrom-lancet-oncol","kind":"paper","name":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","route":"/key-papers/paper-sjostrom-lancet-oncol/","field":"links","label":"Lancet Oncol 2009"}]},{"url":"https://doi.org/10.1016/S1470-2045(09)70159-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509701597","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","field":"links","label":"SOS study cancer (Lancet Oncol 2009)"}]},{"url":"https://doi.org/10.1016/S1470-2045(09)70284-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509702840","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"papers","label":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(09)70314-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509703146","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"papers","label":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial"}]},{"url":"https://doi.org/10.1016/s1470-2045(09)70330-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509703304","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Folprecht, Lancet Oncol 2010: CELIM, tumour response and secondary resectability of colorectal liver metastases with cetuximab (111 patients)"},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/","field":"links","label":"Folprecht, Lancet Oncol 2010: CELIM, tumour response and secondary resectability of colorectal liver metastases with cetuximab (111 patients)"}]},{"url":"https://doi.org/10.1016/S1470-2045(09)70338-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204509703389","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Irani et al., venlafaxine, medroxyprogesterone acetate and cyproterone acetate for vasomotor hot flushes (Lancet Oncology 2010)"},{"id":"hot-flushes-on-hormone-therapy","kind":"term","name":"Hot flushes on hormone therapy","route":"/terms/hot-flushes-on-hormone-therapy/","field":"links","label":"Irani et al., venlafaxine, medroxyprogesterone acetate and cyproterone acetate for vasomotor hot flushes (Lancet Oncology 2010)"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70023-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510700231","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","field":"links","label":"Lancet Oncol 2010"}]},{"url":"https://doi.org/10.1016/s1470-2045(10)70071-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510700711","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-issels-lancet-oncol","kind":"paper","name":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","route":"/key-papers/paper-issels-lancet-oncol/","field":"links","label":"Lancet Oncol 2010"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70071-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510700711","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","field":"links","label":"Issels et al., Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma (Lancet Oncology 2010)"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70132-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510701327","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"papers","label":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70207-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510702072","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","field":"links","label":"NSABP B-32 overall survival (Lancet Oncology 2010)"},{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","field":"outcomes.source (Overall survival at 8 years (sentinel node-negative patients))"},{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","field":"outcomes.source (Disease-free survival at 8 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(10)70209-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510702096","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-lancet-oncol-2011","kind":"paper","name":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-lancet-oncol-2011/","field":"links","label":"Lancet Oncol 2011"}]},{"url":"https://doi.org/10.1016/s1470-2045(10)70218-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510702187","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/","field":"links","label":"Lancet Oncol 2011"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70218-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510702187","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"links","label":"Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-prehabilitation-standard","kind":"idea","name":"Four weeks of training and nutrition before major cancer surgery, as standard","route":"/ideas/idea-bio2-prehabilitation-standard/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-exercise-reimbursement","kind":"idea","name":"Pay for supervised exercise the way we pay for drugs","route":"/ideas/idea-bio2-exercise-reimbursement/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-low-dose-olanzapine-appetite","kind":"idea","name":"A cheap old tablet to restore appetite","route":"/ideas/idea-bio2-low-dose-olanzapine-appetite/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-cachexia-pathway-code","kind":"idea","name":"Treat wasting like sepsis: a trigger, a bundle, an audit","route":"/ideas/idea-bio2-cachexia-pathway-code/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-protein-plus-training-during-io","kind":"idea","name":"Test protein and resistance training during immunotherapy","route":"/ideas/idea-bio2-protein-plus-training-during-io/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-bio2-remote-weight-step-monitoring","kind":"idea","name":"Catch wasting early with a smart scale and a step counter","route":"/ideas/idea-bio2-remote-weight-step-monitoring/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"idea-moon-cachexia-as-treatable-disease","kind":"idea","name":"Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles","route":"/ideas/idea-moon-cachexia-as-treatable-disease/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Fearon consensus (Lancet Oncol 2011)"},{"id":"idea-nl-dietitian-in-every-mdt","kind":"idea","name":"A dietitian in every gastrointestinal and head and neck tumour board","route":"/ideas/idea-nl-dietitian-in-every-mdt/","field":"links","label":"Bottleneck evidence (Cachexia, toxicity and the limits of the patient): Fearon et al., Definition and classification of cancer cachexia (Lancet Oncology 2011)"}]},{"url":"https://doi.org/10.1016/S1470-2045(10)70223-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204510702230","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","field":"links","label":"EORTC 22863 at 10 years (Lancet Oncology 2010)"},{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","field":"outcomes.source (Clinical disease-free survival at 10 years)"},{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","field":"outcomes.source (Overall survival at 10 years)"},{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","field":"outcomes.source (Prostate cancer mortality at 10 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(11)70196-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204511701966","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-senft-lancet-oncol","kind":"paper","name":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","route":"/key-papers/paper-senft-lancet-oncol/","field":"links","label":"Lancet Oncol 2011"}]},{"url":"https://doi.org/10.1016/S1470-2045(11)70196-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204511701966","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intraoperative-mri-ct","kind":"technology","name":"Intraoperative MRI and CT","route":"/technologies/intraoperative-mri-ct/","field":"links","label":"Senft et al., Intraoperative MRI guidance and extent of resection in glioma surgery (Lancet Oncology 2011)"}]},{"url":"https://doi.org/10.1016/s1470-2045(11)70300-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451170300X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-trappe-lancet-oncol","kind":"paper","name":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","route":"/key-papers/paper-trappe-lancet-oncol/","field":"links","label":"Lancet Oncol 2012"}]},{"url":"https://doi.org/10.1016/S1470-2045(11)70300-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451170300X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"links","label":"PTLD-1 sequential treatment (Lancet Oncol 2012)"}]},{"url":"https://doi.org/10.1016/s1470-2045(11)70336-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","field":"links","label":"Lancet Oncol 2012"},{"id":"neosphere","kind":"trial","name":"NeoSphere","route":"/trials/neosphere/","field":"outcomes.source (Pathological complete response in the breast)"}]},{"url":"https://doi.org/10.1016/s1470-2045(11)70393-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451170393X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-lancet-oncol-2012","kind":"paper","name":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","route":"/key-papers/paper-egfr-nsclc-lancet-oncol-2012/","field":"links","label":"Lancet Oncol 2012"}]},{"url":"https://doi.org/10.1016/S1470-2045(12)70042-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512700426","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-10801","kind":"trial","name":"EORTC 10801","route":"/trials/eortc-10801/","field":"links","label":"EORTC 10801 twenty-year follow-up (Lancet Oncology 2012)"},{"id":"eortc-10801","kind":"trial","name":"EORTC 10801","route":"/trials/eortc-10801/","field":"outcomes.source (Time to distant metastasis)"},{"id":"eortc-10801","kind":"trial","name":"EORTC 10801","route":"/trials/eortc-10801/","field":"outcomes.source (Overall survival at 20 years)"}]},{"url":"https://doi.org/10.1016/S1470-2045(12)70164-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451270164X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","field":"links","label":"Wick et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (Lancet Oncology 2012)"},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"outcomes.source (Overall survival (non-inferiority))"},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"outcomes.source (Event-free survival)"},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"outcomes.source (Event-free survival, MGMT promoter methylated)"},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"outcomes.source (Event-free survival, MGMT promoter unmethylated)"},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","field":"outcomes.source (Overall survival by MGMT status (both arms))"},{"id":"paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012","kind":"paper","name":"NOA-08: temozolomide alone versus radiotherapy alone for malignant astrocytoma in the elderly","route":"/key-papers/paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012/","field":"links","label":"Lancet Oncol 2012"}]},{"url":"https://doi.org/10.1016/s1470-2045(12)70265-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512702656","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-malmstrom-lancet-oncol","kind":"paper","name":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","route":"/key-papers/paper-malmstrom-lancet-oncol/","field":"links","label":"Lancet Oncol 2012"}]},{"url":"https://doi.org/10.1016/S1470-2045(12)70265-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512702656","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","field":"links","label":"Malmström et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (Lancet Oncology 2012)"}]},{"url":"https://doi.org/10.1016/S1470-2045(12)70377-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512703777","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esphall-imatinib-biondi-lancet-oncol-2012","kind":"paper","name":"EsPhALL: imatinib after induction for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukaemia","route":"/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/","field":"links","label":"Lancet Oncol 2012"},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"outcomes.source (Disease-free survival at 4 years, good-risk patients (EsPhALL2004))"},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"outcomes.source (Event-free survival at 4 years, poor-risk patients (EsPhALL2004, all given imatinib))"}]},{"url":"https://doi.org/10.1016/s1470-2045(12)70379-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512703790","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2012","kind":"paper","name":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/","field":"links","label":"Lancet Oncol 2012"}]},{"url":"https://doi.org/10.1016/s1470-2045(12)70560-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512705600","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/","field":"links","label":"Lancet Oncol 2013"}]},{"url":"https://doi.org/10.1016/S1470-2045(12)70560-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204512705600","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","field":"links","label":"GETUG-AFU 15 (Lancet Oncology 2013)"},{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","field":"outcomes.source (Overall survival (median))"},{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","field":"outcomes.source (Grade 3 or worse neutropenia)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70021-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513700214","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"links","label":"Mukherjee et al., SCALOP (Lancet Oncology 2013)"},{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"outcomes.source (Progression-free survival at 9 months)"},{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"outcomes.source (Overall survival (primary report))"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70076-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513700767","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"DiSipio et al., incidence of unilateral arm lymphoedema after breast cancer: systematic review and meta-analysis (Lancet Oncology 2013)"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"DiSipio et al., incidence of unilateral arm lymphoedema after breast cancer: systematic review and meta-analysis (Lancet Oncology 2013)"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"DiSipio et al., incidence of unilateral arm lymphoedema after breast cancer: systematic review and meta-analysis (Lancet Oncology 2013)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"DiSipio et al., incidence of unilateral arm lymphoedema after breast cancer: systematic review and meta-analysis (Lancet Oncology 2013)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70086-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451370086X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013","kind":"paper","name":"ACT II: mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for squamous cell carcinoma of the anus","route":"/key-papers/paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013/","field":"links","label":"Lancet Oncol 2013"},{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","field":"links","label":"Lancet Oncology 2013"},{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","field":"outcomes.source (Complete response at 26 weeks)"},{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","field":"outcomes.source (Progression-free survival at 3 years)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"links","label":"ACT II (Lancet Oncology 2013)"}]},{"url":"https://doi.org/10.1016/s1470-2045(13)70130-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451370130X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","field":"links","label":"Lancet Oncol 2013"}]},{"url":"https://doi.org/10.1016/s1470-2045(13)70143-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513701438","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"outcomes.source (Free of tumour at both 3 and 12 months)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70143-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513701438","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Arits et al., photodynamic therapy versus topical imiquimod versus topical fluorouracil for superficial basal-cell carcinoma, randomised trial of 601 patients (Lancet Oncology 2013)"},{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"links","label":"One-year results (Lancet Oncology 2013)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Arits et al., photodynamic therapy versus topical imiquimod versus topical fluorouracil for superficial basal-cell carcinoma, randomised trial of 601 patients (Lancet Oncology 2013)"},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"Arits et al., photodynamic therapy versus topical imiquimod versus topical fluorouracil for superficial basal-cell carcinoma, randomised trial of 601 patients (Lancet Oncology 2013)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70272-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513702729","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Complete remission at the end of treatment)"},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Partial response to pre-operative chemotherapy)"},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Complete resection of all tumour lesions)"},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Event-free survival at 3 years)"},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Overall survival at 3 years)"},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","field":"outcomes.source (Febrile neutropenia (at least one episode))"},{"id":"paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013","kind":"paper","name":"SIOPEL-4: dose-dense cisplatin-based chemotherapy and surgery for high-risk hepatoblastoma","route":"/key-papers/paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013/","field":"links","label":"Lancet Oncol 2013"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70294-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513702948","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"atrasentan","kind":"drug","name":"Atrasentan","route":"/drugs/atrasentan/","field":"links","label":"SWOG S0421 (Lancet Oncology 2013)"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"links","label":"SWOG S0421 (Lancet Oncology 2013)"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"outcomes.source (Overall survival (median))"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(13)70355-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513703553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shi-lancet-oncol","kind":"paper","name":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","route":"/key-papers/paper-shi-lancet-oncol/","field":"links","label":"Lancet Oncol 2013"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70355-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513703553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","field":"links","label":"ICOGEN (Lancet Oncol 2013)"}]},{"url":"https://doi.org/10.1016/s1470-2045(13)70386-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513703863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-haviland-lancet-oncol","kind":"paper","name":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","route":"/key-papers/paper-haviland-lancet-oncol/","field":"links","label":"Lancet Oncol 2013"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70386-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513703863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Haviland et al., START trials of breast radiotherapy hypofractionation, 10-year results (Lancet Oncology 2013)"},{"id":"start-a","kind":"trial","name":"START-A (UK Standardisation of Breast Radiotherapy, trial A)","route":"/trials/start-a/","field":"links","label":"START ten-year results (Lancet Oncology 2013)"},{"id":"start-a","kind":"trial","name":"START-A (UK Standardisation of Breast Radiotherapy, trial A)","route":"/trials/start-a/","field":"outcomes.source (Local-regional relapse at 10 years)"},{"id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","field":"links","label":"Lancet Oncology 2013"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70447-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513704479","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-40983","kind":"trial","name":"EORTC 40983","route":"/trials/eortc-40983/","field":"links","label":"EORTC 40983: perioperative FOLFOX4 and surgery versus surgery alone for resectable liver metastases, long-term results (Lancet Oncology 2013)"},{"id":"eortc-40983","kind":"trial","name":"EORTC 40983","route":"/trials/eortc-40983/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70479-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513704790","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","field":"links","label":"READY (Lancet Oncology 2013)"},{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(13)70530-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513705308","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"outcomes.source (Clinical success at 3 years)"},{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"outcomes.source (Withdrawal because of adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70530-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513705308","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Bath-Hextall et al., surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma, SINS (Lancet Oncology 2014)"},{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"links","label":"Three-year results (Lancet Oncology 2014)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Bath-Hextall et al., surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma, SINS (Lancet Oncology 2014)"},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"Bath-Hextall et al., surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma, SINS (Lancet Oncology 2014)"}]},{"url":"https://doi.org/10.1016/S1470-2045(13)70586-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204513705862","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lume-lung-1","kind":"trial","name":"LUME-Lung 1","route":"/trials/lume-lung-1/","field":"links","label":"LUME-Lung 1 (Lancet Oncology 2014)"},{"id":"lume-lung-1","kind":"trial","name":"LUME-Lung 1","route":"/trials/lume-lung-1/","field":"outcomes.source (Progression-free survival (independent central review))"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70027-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514700270","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-watch-and-wait","kind":"term","name":"Watch and wait in lymphoma: when the right treatment is none yet","route":"/terms/lymphoma-tx-watch-and-wait/","field":"links","label":"Ardeshna et al., rituximab against watch and wait in asymptomatic advanced follicular lymphoma, Lancet Oncology 2014 (379 patients)"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Advanced follicular lymphoma with no symptoms: watch and wait, or rituximab alone)"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70036-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514700361","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"outcomes.source (Time to local progression, first analysis (hazard for 4 Gy against 24 Gy))"},{"id":"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014","kind":"paper","name":"FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70063-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514700634","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014","kind":"paper","name":"EORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma","route":"/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"},{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","field":"links","label":"Lancet Oncology 2014"},{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","field":"outcomes.source (Overall survival (median))"},{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)70117-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514701172","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pramesh-lancet-oncol","kind":"paper","name":"Delivery of affordable and equitable cancer care in India","route":"/key-papers/paper-pramesh-lancet-oncol/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70117-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514701172","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","field":"links","label":"Lancet Oncology Commission: cancer care in India (Pramesh et al.)"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)70160-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514701603","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"outcomes.source (Pathological complete response (ypT0 ypN0), all patients)"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"outcomes.source (Pathological complete response, triple-negative breast cancer)"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"outcomes.source (Pathological complete response, HER2-positive breast cancer)"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"outcomes.source (Grade 3-4 neutropenia)"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70189-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514701895","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"links","label":"CA184-043 (Lancet Oncology 2014)"},{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"outcomes.source (Overall survival (median))"},{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"outcomes.source (Grade 3 to 4 immune-related adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70227-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451470227X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"petacc-8","kind":"trial","name":"PETACC-8","route":"/trials/petacc-8/","field":"links","label":"PETACC-8: FOLFOX4 with or without cetuximab in resected stage III colon cancer (Lancet Oncology 2014)"},{"id":"petacc-8","kind":"trial","name":"PETACC-8","route":"/trials/petacc-8/","field":"outcomes.source (Disease-free survival (KRAS exon 2 wild-type))"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70330-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514703304","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"links","label":"FIRE-3: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment (Lancet Oncology 2014)"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"outcomes.source (FIRE-3: overall survival (KRAS exon 2 wild-type))"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"outcomes.source (FIRE-3: objective response (primary endpoint))"},{"id":"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","kind":"paper","name":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","route":"/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70420-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514704206","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","field":"papers","label":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer"},{"id":"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014","kind":"paper","name":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer","route":"/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70442-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514704425","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"papers","label":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma"},{"id":"paper-imwg-criteria-rajkumar-lancet-oncol-2014","kind":"paper","name":"IMWG updated criteria for the diagnosis of multiple myeloma (2014)","route":"/key-papers/paper-imwg-criteria-rajkumar-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70473-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514704735","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","field":"outcomes.source (Disease-free survival at 5 years)"},{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"paper-classic-5-year-follow-up-noh-lancet-oncol-2014","kind":"paper","name":"CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)70490-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514704905","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","field":"outcomes.source (Progression-free survival at 3 years, unfavourable marker decline)"},{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","field":"outcomes.source (Progression-free survival at 3 years, favourable marker decline (continued BEP, not randomised))"},{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","field":"outcomes.source (Salvage high-dose chemotherapy with stem cell transplant required)"},{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","field":"outcomes.source (Grade 3 to 4 neurotoxicity)"},{"id":"paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014","kind":"paper","name":"GETUG 13: personalised chemotherapy based on tumour marker decline in poor-prognosis germ cell tumours","route":"/key-papers/paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014/","field":"links","label":"Lancet Oncol 2014"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)71135-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711350","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"papers","label":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)71156-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711568","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumour-bed-boost","kind":"term","name":"Tumour bed boost","route":"/terms/tumour-bed-boost/","field":"links","label":"EORTC boost trial at twenty years (Lancet Oncology 2015)"},{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","field":"links","label":"EORTC boost trial twenty-year follow-up (Lancet Oncology 2015)"},{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","field":"outcomes.source (Overall survival at 20 years)"},{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","field":"outcomes.source (Cumulative incidence of ipsilateral breast tumour recurrence at 20 years)"},{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","field":"outcomes.source (Cumulative incidence of severe fibrosis at 20 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71159-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711593","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-palbociclib-breast-hr-positive-lancet-oncol-2015","kind":"paper","name":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study","route":"/key-papers/paper-palbociclib-breast-hr-positive-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71170-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711702","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-all-leukemia-lancet-oncol-2015","kind":"paper","name":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-blinatumomab-all-leukemia-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71171-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711714","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cuzick, Lancet Oncol 2015: IBIS-I tamoxifen prevention trial, extended long-term follow-up"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"Cuzick, Lancet Oncol 2015: IBIS-I tamoxifen prevention trial, extended long-term follow-up"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)71171-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711714","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/","field":"links","label":"Lancet Oncology 2015 (DOI)"},{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71190-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711908","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stacchiotti-lancet-oncol","kind":"paper","name":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","route":"/key-papers/paper-stacchiotti-lancet-oncol/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)71190-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514711908","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","field":"links","label":"Chordoma Global Consensus Group recommendations (Lancet Oncol 2015)"},{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","field":"standardOfCare.guideline (Resectable, any site)"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71205-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514712057","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2015","kind":"paper","name":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(14)71207-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514712070","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(14)71207-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204514712070","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","field":"links","label":"RTOG 0617 (Lancet Oncology 2015)"},{"id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","field":"links","label":"Lancet Oncology 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00021-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515000212","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"SQUIRE (Thatcher 2015, Lancet Oncology): necitumumab with gemcitabine and cisplatin in squamous NSCLC"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00021-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515000212","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"squire","kind":"trial","name":"SQUIRE","route":"/trials/squire/","field":"links","label":"SQUIRE (Lancet Oncology 2015)"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00034-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515000340","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","field":"links","label":"Study 3 (Lancet Oncology 2015)"},{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/","field":"links","label":"Lancet Oncology 2015"},{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/","field":"outcomes.source (Complete response in the delayed phase (no emesis and no rescue medication, more than 24 to 120 hours), cycle 1)"},{"id":"paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015","kind":"paper","name":"Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a randomised, active-controlled, double-blind, phase 3 trial","route":"/key-papers/paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015/","field":"links","label":"Lancet Oncology 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00040-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515000406","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"papers","label":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00122-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515001229","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","kind":"paper","name":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE","route":"/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00198-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515001989","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","field":"papers","label":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma"},{"id":"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015","kind":"paper","name":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma","route":"/key-papers/paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00222-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515002223","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atun-lancet-oncol","kind":"paper","name":"Expanding global access to radiotherapy","route":"/key-papers/paper-atun-lancet-oncol/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00222-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515002223","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"links","label":"Atun et al., Expanding global access to radiotherapy (Lancet Oncology Commission 2015)"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"metrics (Patients in low-income countries with access to radiotherapy relative to need (2015 estimate))"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"links","label":"Atun et al., Expanding global access to radiotherapy (Lancet Oncology Commission 2015)"},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","field":"links","label":"Lancet Oncology Commission: radiotherapy (2015)"},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/","field":"links","label":"Lancet Oncology Commission: expanding global access to radiotherapy (2015)"},{"id":"radiotherapy-access-gap","kind":"technology","name":"Radiotherapy access and the global machine gap","route":"/technologies/radiotherapy-access-gap/","field":"links","label":"Lancet Oncology Commission 2015"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00223-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515002235","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00223-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515002235","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"links","label":"Sullivan et al., Global cancer surgery: delivering safe, affordable, and timely cancer surgery (Lancet Oncology Commission 2015)"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"metrics (Patients needing cancer surgery in low-income countries with access to safe, affordable, timely surgery)"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"links","label":"Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","field":"metrics (Patients with cancer who will need surgery at some point in their disease (global estimate, 2015))"},{"id":"idea-fund-surgical-ai-robotics-evaluation","kind":"idea","name":"An independent evaluation unit for surgical robots and AI, paid on evidence","route":"/ideas/idea-fund-surgical-ai-robotics-evaluation/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","route":"/ideas/idea-fund-intraoperative-imaging-trials/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-rt-planning-ai-capacity","kind":"idea","name":"Validate and reimburse AI contouring and planning to expand radiotherapy capacity","route":"/ideas/idea-fund-rt-planning-ai-capacity/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-ablation-versus-surgery-trials","kind":"idea","name":"Device-agnostic public trials of ablation technologies against surgery","route":"/ideas/idea-fund-ablation-versus-surgery-trials/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"},{"id":"idea-moon-compact-flash-proton","kind":"idea","name":"Compact FLASH and proton systems at the price of a conventional linac","route":"/ideas/idea-moon-compact-flash-proton/","field":"links","label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00414-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515004143","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet-oncol","kind":"paper","name":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","route":"/key-papers/paper-sankaranarayanan-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00414-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515004143","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/","field":"links","label":"Sankaranarayanan et al., Lancet Oncology 2016"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00444-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515004441","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bouvard-lancet-oncol","kind":"paper","name":"Carcinogenicity of consumption of red and processed meat","route":"/key-papers/paper-bouvard-lancet-oncol/","field":"links","label":"Lancet Oncol 2015"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00444-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515004441","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"red-processed-meat-reduction","kind":"technology","name":"Red and processed meat reduction","route":"/technologies/red-processed-meat-reduction/","field":"links","label":"IARC Monograph 114: red and processed meat (Lancet Oncol 2015)"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00489-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515004891","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","kind":"paper","name":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","route":"/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00515-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451500515X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-aspen-armstrong-lancet-oncol-2016","kind":"paper","name":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","route":"/key-papers/paper-aspen-armstrong-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)00558-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515005586","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)00558-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515005586","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","field":"links","label":"ROMANA 1 and 2 (Lancet Oncol 2016)"},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","field":"links","label":"Temel et al. (Lancet Oncol 2016)"},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","field":"outcomes.source (Change in lean body mass over 12 weeks (ROMANA 1))"},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","field":"outcomes.source (Change in lean body mass over 12 weeks (ROMANA 2))"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70027-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515700276","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/","field":"links","label":"ELM-PC 4 (Lancet Oncology 2015)"},{"id":"orteronel","kind":"drug","name":"Orteronel","route":"/drugs/orteronel/","field":"links","label":"ELM-PC 4 (Lancet Oncology 2015)"},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/","field":"links","label":"ELM-PC 4 (Lancet Oncology 2015)"},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/","field":"outcomes.source (Radiographic progression-free survival (median))"},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70045-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515700458","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"links","label":"DART 01/05 GICOR (Lancet Oncology 2015)"},{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"outcomes.source (Biochemical disease-free survival at 5 years)"},{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"outcomes.source (Overall survival at 5 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(15)70054-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515700549","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"papers","label":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70100-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515701002","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","field":"papers","label":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma"},{"id":"paper-bolt-sonidegib-migden-lancet-oncol-2015","kind":"paper","name":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma","route":"/key-papers/paper-bolt-sonidegib-migden-lancet-oncol-2015/","field":"links","label":"Lancet Oncol 2015"},{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/","field":"links","label":"Lancet Oncology 2015"},{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/","field":"outcomes.source (Objective response rate, 200 mg (locally advanced))"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70127-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515701270","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"raise","kind":"trial","name":"RAISE","route":"/trials/raise/","field":"links","label":"RAISE: ramucirumab with second-line FOLFIRI in metastatic colorectal carcinoma (Lancet Oncology 2015)"},{"id":"raise","kind":"trial","name":"RAISE","route":"/trials/raise/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70156-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515701567","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"concur","kind":"trial","name":"CONCUR","route":"/trials/concur/","field":"links","label":"CONCUR: regorafenib in Asian patients with previously treated metastatic colorectal cancer (Lancet Oncology 2015)"},{"id":"concur","kind":"trial","name":"CONCUR","route":"/trials/concur/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(15)70168-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204515701683","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stars-rosel","kind":"trial","name":"STARS and ROSEL pooled analysis","route":"/trials/stars-rosel/","field":"links","label":"STARS and ROSEL pooled analysis (Lancet Oncology 2015)"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)00150-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516001509","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","field":"papers","label":"HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer"},{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","field":"outcomes.source (Objective response (independent central review))"},{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","field":"outcomes.source (Stable disease)"},{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","field":"outcomes.source (Grade 3 adverse events)"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)00163-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516001637","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30102-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516301024","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-radiotherapy-fractionation","kind":"term","name":"How many radiotherapy visits: the prostate fractionation trials","route":"/terms/prostate-radiotherapy-fractionation/","field":"links","label":"CHHiP 5-year outcomes (Lancet Oncology 2016)"},{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","field":"papers","label":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer"},{"id":"paper-chhip-lancet-oncol-2016","kind":"paper","name":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","route":"/key-papers/paper-chhip-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"links","label":"Lancet Oncology 2016"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"links","label":"CHHiP 5-year outcomes (Lancet Oncology 2016)"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"outcomes.source (Freedom from biochemical or clinical failure at 5 years)"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"outcomes.source (Cumulative RTOG grade 2 or worse bowel adverse events at 5 years)"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"outcomes.source (Cumulative RTOG grade 2 or worse bladder adverse events at 5 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30122-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451630122X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30122-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451630122X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","field":"links","label":"Updated analysis, Lancet Oncology 2016"},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","field":"outcomes.source (Progression-free survival)"},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30146-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516301462","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30167-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451630167X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30206-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302066","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kumar-lancet-oncol","kind":"paper","name":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","route":"/key-papers/paper-kumar-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30206-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302066","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","field":"links","label":"IMWG consensus criteria for response and MRD assessment (Kumar et al., Lancet Oncology 2016)"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"papers","label":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30214-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302145","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-marina-lancet-oncol","kind":"paper","name":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","route":"/key-papers/paper-marina-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30214-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302145","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","field":"links","label":"EURAMOS-1 (Lancet Oncol 2016)"},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"links","label":"Marina et al., Lancet Oncology 2016 (poor responders)"},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"outcomes.source (Event-free survival, poor responders (MAPIE vs MAP))"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30239-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451630239X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-loomis-lancet-oncol","kind":"paper","name":"Carcinogenicity of drinking coffee, mate, and very hot beverages","route":"/key-papers/paper-loomis-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30239-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451630239X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","field":"links","label":"IARC Monograph 116: coffee, mate and very hot beverages (Lancet Oncol 2016)"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30249-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302492","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-villani-lancet-oncol","kind":"paper","name":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","route":"/key-papers/paper-villani-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30249-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302492","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","field":"links","label":"Toronto protocol (Lancet Oncol 2016)"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30313-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516303138","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30313-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516303138","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","field":"links","label":"Lancet Oncology 2016"},{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30364-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516303643","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","field":"links","label":"Lancet Oncol 2016"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30364-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516303643","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","field":"links","label":"Lancet Oncology 2016"},{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","field":"outcomes.source (Objective response rate (part A, after chemotherapy))"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30559-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516305599","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"links","label":"Swisher et al., Lancet Oncology 2017 (ARIEL2 part 1): rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma"}]},{"url":"https://doi.org/10.1016/s1470-2045(16)30560-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516305605","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"papers","label":"Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30661-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516306611","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-focal-therapy","kind":"term","name":"Focal and tissue-preserving treatment of prostate cancer","route":"/terms/prostate-focal-therapy/","field":"links","label":"PCM301 padeliporfin against active surveillance (Lancet Oncology 2017)"},{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","field":"links","label":"PCM301 padeliporfin against active surveillance (Lancet Oncology 2017)"},{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","field":"outcomes.source (Disease progression at 24 months)"},{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","field":"outcomes.source (Negative prostate biopsy at 24 months)"},{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","field":"links","label":"PCM301 (Lancet Oncology 2017)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30070-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517300700","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017","kind":"paper","name":"HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma","route":"/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30086-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517300864","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stockholm-iii","kind":"trial","name":"Stockholm III","route":"/trials/stockholm-iii/","field":"links","label":"Stockholm III: optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Lancet Oncology 2017)"},{"id":"stockholm-iii","kind":"trial","name":"Stockholm III","route":"/trials/stockholm-iii/","field":"outcomes.source (Local recurrence)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30104-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517301043","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","field":"outcomes.source (Objective response rate, part A)"},{"id":"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017","kind":"paper","name":"NCI9673: nivolumab for previously treated unresectable metastatic anal cancer","route":"/key-papers/paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30111-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517301110","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/","field":"outcomes.source (Overall survival (final analysis))"},{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/","field":"outcomes.source (Grade 3 or worse adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30155-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517301559","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sahm-meningioma-methylation-lancet-oncol-2017","kind":"paper","name":"DNA methylation-based classification and grading system for meningioma","route":"/key-papers/paper-sahm-meningioma-methylation-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30167-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517301675","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Mhatre, Lancet Oncol 2017: genome-wide association study of gallbladder cancer in India (ABCB1 and ABCB4)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30168-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517301687","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"custirsen","kind":"drug","name":"Custirsen","route":"/drugs/custirsen/","field":"links","label":"SYNERGY (Lancet Oncology 2017)"},{"id":"synergy-custirsen","kind":"trial","name":"SYNERGY","route":"/trials/synergy-custirsen/","field":"links","label":"SYNERGY (Lancet Oncology 2017)"},{"id":"synergy-custirsen","kind":"trial","name":"SYNERGY","route":"/trials/synergy-custirsen/","field":"outcomes.source (Overall survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30230-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517302309","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-takahashi-lancet-oncol","kind":"paper","name":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-takahashi-lancet-oncol/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30230-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517302309","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/","field":"links","label":"Takahashi et al., Prophylactic cranial irradiation versus MRI observation in extensive-stage small-cell lung cancer (Lancet Oncology 2017)"},{"id":"takahashi-pci","kind":"trial","name":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer","route":"/trials/takahashi-pci/","field":"links","label":"Lancet Oncology 2017"},{"id":"takahashi-pci","kind":"trial","name":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer","route":"/trials/takahashi-pci/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30243-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517302437","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"papers","label":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30318-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517303182","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30334-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517303340","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","field":"links","label":"Gronchi et al., ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft-tissue sarcoma (Lancet Oncology 2017)"},{"id":"paper-isg-sts-1001-gronchi-lancet-oncol-2017","kind":"paper","name":"ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma","route":"/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30355-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517303558","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","field":"links","label":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (Lancet Oncology 2017)"},{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","field":"outcomes.source (Objective response over the first 6 cycles, randomised patients)"},{"id":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","kind":"paper","name":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","route":"/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30381-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517303819","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"papers","label":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30422-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517304229","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","kind":"paper","name":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)","route":"/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/","field":"links","label":"Overman et al., Lancet Oncol 2017: CheckMate 142, nivolumab in 74 patients with dMMR/MSI-high metastatic colorectal cancer"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30441-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517304412","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","field":"papers","label":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis"},{"id":"paper-n107c-brown-lancet-oncol-2017","kind":"paper","name":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","route":"/key-papers/paper-n107c-brown-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30445-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451730445X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"papers","label":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30450-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517304503","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","kind":"paper","name":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/","field":"links","label":"Kim et al., Lancet Oncol 2017: LOTUS, ipatasertib plus paclitaxel in 124 metastatic TNBC patients"},{"id":"lotus","kind":"trial","name":"LOTUS","route":"/trials/lotus/","field":"links","label":"Kim et al., Lancet Oncology 2017: ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic TNBC (LOTUS)"},{"id":"lotus","kind":"trial","name":"LOTUS","route":"/trials/lotus/","field":"outcomes.source (Progression-free survival, intention to treat)"},{"id":"lotus","kind":"trial","name":"LOTUS","route":"/trials/lotus/","field":"outcomes.source (Progression-free survival, PTEN-low tumours)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30605-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306058","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"custirsen","kind":"drug","name":"Custirsen","route":"/drugs/custirsen/","field":"links","label":"AFFINITY (Lancet Oncology 2017)"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"links","label":"AFFINITY (Lancet Oncology 2017)"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"outcomes.source (Overall survival, all randomised (median))"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"outcomes.source (Overall survival, poor-prognosis subgroup (median))"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30608-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306083","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","field":"links","label":"ARCHER 1050 (Lancet Oncol 2017)"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"The Lancet Oncology 2017"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"ARCHER 1050 (Lancet Oncology 2017)"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"outcomes.source (Progression-free survival (masked independent review))"},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/","field":"links","label":"The Lancet Oncology 2017"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30616-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306162","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pembrolizumab-urothelial-lancet-oncol-2017","kind":"paper","name":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-pembrolizumab-urothelial-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30622-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306228","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-seddon-lancet-oncol","kind":"paper","name":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","route":"/key-papers/paper-seddon-lancet-oncol/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30622-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306228","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"links","label":"GeDDiS (Lancet Oncol 2017)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30624-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306241","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","field":"papers","label":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma"},{"id":"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017","kind":"paper","name":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","route":"/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","field":"outcomes.source (Objective response (investigator-assessed), soft-tissue sarcoma cohort)"},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","field":"outcomes.source (Objective response (investigator-assessed), bone sarcoma cohort)"},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","field":"outcomes.source (Objective response, undifferentiated pleomorphic sarcoma)"},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","field":"outcomes.source (Objective response, liposarcoma)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30679-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306794","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","field":"links","label":"BRF113928 cohort C (Lancet Oncology 2017)"},{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","field":"outcomes.source (Objective response rate (investigator assessed, untreated cohort))"},{"id":"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017","kind":"paper","name":"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017/","field":"links","label":"Lancet Oncol 2017"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30683-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","field":"outcomes.source (Overall survival (SARAH))"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30716-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30716-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517307167","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"papers","label":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial"},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/","field":"links","label":"Hurvitz et al., KRISTINE (Lancet Oncology 2018)"},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/","field":"outcomes.source (Pathological complete response (breast and axilla))"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30729-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517307295","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"papers","label":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30777-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517307775","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neoadjuvant-versus-adjuvant-breast","kind":"term","name":"Drugs before or after the operation","route":"/terms/neoadjuvant-versus-adjuvant-breast/","field":"links","label":"EBCTCG: chemotherapy before or after surgery, 4,756 women in ten trials (Lancet Oncology 2018)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Drugs before or after surgery)"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30891-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517308914","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Copson, Lancet Oncol 2018: germline BRCA mutation and outcome in young-onset breast cancer (POSH)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"Copson, Lancet Oncol 2018: germline BRCA mutation and outcome in young-onset breast cancer (POSH)"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"Copson, Lancet Oncol 2018: germline BRCA mutation and outcome in young-onset breast cancer (POSH)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30904-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451730904X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018","kind":"paper","name":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","route":"/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/","field":"links","label":"Denkert et al., Lancet Oncol 2018: TILs in 3,771 neoadjuvant patients from six German Breast Group trials"}]},{"url":"https://doi.org/10.1016/s1470-2045(17)30906-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517309063","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","kind":"paper","name":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"},{"id":"bipolar-androgen-therapy","kind":"term","name":"Bipolar androgen therapy (BAT)","route":"/terms/bipolar-androgen-therapy/","field":"links","label":"Teply et al., Lancet Oncology 2018 (RESTORE): bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30062-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518300627","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018","kind":"paper","name":"Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study","route":"/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"links","label":"Pembrolizumab in thymic carcinoma (Lancet Oncology 2018)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30079-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518300792","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","route":"/key-papers/paper-portec-3-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30111-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518301116","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/","field":"outcomes.source (Pathological complete response (breast and lymph nodes))"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30111-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518301116","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"links","label":"BrighTNess primary results (Lancet Oncology 2018)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30142-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518301426","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-columbus-lancet-oncol-2018","kind":"paper","name":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","route":"/key-papers/paper-columbus-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30192-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451830192X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"standardOfCare.guideline (Sustained deep molecular response)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30292-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518302924","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"papers","label":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30379-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518303796","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","field":"papers","label":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","field":"links","label":"MAVORIC (Lancet Oncol 2018)"},{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","field":"links","label":"MAVORIC (Lancet Oncol 2018)"},{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/","field":"outcomes.source (Progression-free survival (investigator-assessed))"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/","field":"outcomes.source (Grade 3-4 adverse events (any cause))"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30380-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518303802","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ibcsg-23-01","kind":"trial","name":"IBCSG 23-01","route":"/trials/ibcsg-23-01/","field":"links","label":"IBCSG 23-01 ten-year follow-up (Lancet Oncology 2018)"},{"id":"ibcsg-23-01","kind":"trial","name":"IBCSG 23-01","route":"/trials/ibcsg-23-01/","field":"outcomes.source (Disease-free survival at 10 years)"},{"id":"ibcsg-23-01","kind":"trial","name":"IBCSG 23-01","route":"/trials/ibcsg-23-01/","field":"outcomes.source (Lymphoedema of any grade)"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30497-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518304972","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","field":"links","label":"Lancet Oncol 2018"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30532-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518305321","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"papers","label":"Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30570-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518305709","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-train-2-lancet-oncol-2018","kind":"paper","name":"TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade","route":"/key-papers/paper-train-2-lancet-oncol-2018/","field":"links","label":"Lancet Oncol 2018"},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","field":"links","label":"TRAIN-2 (Lancet Oncology 2018)"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","field":"links","label":"van Ramshorst et al., TRAIN-2 (Lancet Oncology 2018)"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","field":"outcomes.source (Pathological complete response (breast and axilla))"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30608-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518306089","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"papers","label":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30686-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518306867","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-henricks-lancet-oncol","kind":"paper","name":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","route":"/key-papers/paper-henricks-lancet-oncol/","field":"links","label":"Lancet Oncol 2018"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30686-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518306867","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dpyd-genotyping","kind":"technology","name":"DPYD genotyping and DPD phenotyping before fluoropyrimidines","route":"/technologies/dpyd-genotyping/","field":"links","label":"Lancet Oncology 2018: DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer, a prospective safety analysis"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30742-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518307423","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","field":"papers","label":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study"},{"id":"paper-florence-duffaud-lancet-oncol-2019","kind":"paper","name":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"},{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/","field":"outcomes.source (Non-progression at 8 weeks, osteosarcoma cohort)"},{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/","field":"outcomes.source (Treatment-related serious adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30781-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518307812","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"iBRA (Lancet Oncology 2019)"},{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","field":"links","label":"iBRA short-term safety outcomes (Lancet Oncology 2019)"},{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","field":"outcomes.source (Implant loss within 3 months)"},{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","field":"outcomes.source (Infection needing antibiotics or surgery within 3 months)"},{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","field":"outcomes.source (Unplanned return to theatre within 3 months)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30860-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451830860X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/","field":"links","label":"ERA 223 (Lancet Oncology 2019)"},{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/","field":"links","label":"ERA 223 (Lancet Oncology 2019)"},{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/","field":"outcomes.source (Symptomatic skeletal event-free survival (median))"},{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/","field":"outcomes.source (Fracture, any grade)"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30896-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518308969","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30896-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518308969","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","route":"/trials/chisel/","field":"links","label":"Lancet Oncology 2019"},{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","route":"/trials/chisel/","field":"outcomes.source (Local treatment failure (freedom from local failure was the primary endpoint))"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30904-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518309045","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30904-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518309045","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"links","label":"Meric-Bernstam et al., Lancet Oncology 2019: pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway)"},{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"outcomes.source (Objective response, trastuzumab plus pertuzumab in HER2-amplified colorectal cancer)"}]},{"url":"https://doi.org/10.1016/S1470-2045(18)30915-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020451830915X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"links","label":"Primrose et al., Lancet Oncology 2019"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Overall survival (ITT))"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Overall survival (per protocol))"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Overall survival (ITT, sensitivity analysis adjusted for minimisation factors, nodal status, grade and sex))"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Recurrence-free survival (ITT))"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"outcomes.source (Grade 3 toxicity, capecitabine arm (at least one event))"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"BILCAP: adjuvant capecitabine (Lancet Oncology 2019)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (After resection)"},{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","field":"papers","label":"BILCAP: capecitabine compared with observation in resected biliary tract cancer"},{"id":"paper-bilcap-lancet-oncol-2019","kind":"paper","name":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","route":"/key-papers/paper-bilcap-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/s1470-2045(18)30937-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204518309379","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","field":"outcomes.source (Overall survival)"},{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","field":"outcomes.source (Progression-free survival)"},{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","field":"outcomes.source (Objective response)"},{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","field":"outcomes.source (Grade 3 or worse hypertension)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30027-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519300270","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019","kind":"paper","name":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)","route":"/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/","field":"links","label":"Eng et al., Lancet Oncol 2019: IMblaze370, atezolizumab with or without cobimetinib versus regorafenib (363 patients)"},{"id":"imblaze370","kind":"trial","name":"IMblaze370","route":"/trials/imblaze370/","field":"links","label":"IMblaze370: atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (Lancet Oncology 2019)"},{"id":"imblaze370","kind":"trial","name":"IMblaze370","route":"/trials/imblaze370/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30082-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519300828","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30164-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519301640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jiang-lancet-oncol","kind":"paper","name":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-jiang-lancet-oncol/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30164-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519301640","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","field":"links","label":"ACE trial (Lancet Oncol 2019)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30272-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519302724","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"papers","label":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30277-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519302773","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","field":"links","label":"Fangusaro 2019, Lancet Oncology: selumetinib in paediatric BRAF-aberrant or NF1-associated low-grade glioma, phase 2"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30318-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519303183","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alyami-lancet-oncol","kind":"paper","name":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","route":"/key-papers/paper-alyami-lancet-oncol/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30318-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519303183","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hipec-pipac-devices","kind":"technology","name":"HIPEC perfusion pumps and PIPAC nebulisers","route":"/technologies/hipec-pipac-devices/","field":"links","label":"Alyami et al., Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications (Lancet Oncology 2019)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30326-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519303262","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"act-in-sarc","kind":"trial","name":"Act.In.Sarc","route":"/trials/act-in-sarc/","field":"links","label":"The Lancet Oncology 2019"},{"id":"act-in-sarc","kind":"trial","name":"Act.In.Sarc","route":"/trials/act-in-sarc/","field":"outcomes.source (Pathological complete response (central review, EORTC guidelines))"},{"id":"paper-act-in-sarc-lancet-oncol-2019","kind":"paper","name":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","route":"/key-papers/paper-act-in-sarc-lancet-oncol-2019/","field":"links","label":"The Lancet Oncology 2019"},{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","field":"links","label":"Act.In.Sarc (Lancet Oncology 2019)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30410-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304103","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","field":"papers","label":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial"},{"id":"paper-anthony-nichols-lancet-oncol-2019","kind":"paper","name":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","route":"/key-papers/paper-anthony-nichols-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","field":"outcomes.source (MD Anderson Dysphagia Inventory total score at 1 year (mean))"},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","field":"outcomes.source (Neutropenia)"},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","field":"outcomes.source (Hearing loss)"},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","field":"outcomes.source (Trismus)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30415-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"papers","label":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30455-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-iarc-monographs-vol-124-group-lancet-oncol","kind":"paper","name":"Carcinogenicity of night shift work","route":"/key-papers/paper-iarc-monographs-vol-124-group-lancet-oncol/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30455-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304553","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","field":"links","label":"IARC Monograph 124: night shift work (Lancet Oncol 2019)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30486-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"getug-afu-16","kind":"trial","name":"GETUG-AFU 16","route":"/trials/getug-afu-16/","field":"links","label":"GETUG-AFU 16 at 112 months (Lancet Oncology 2019)"},{"id":"getug-afu-16","kind":"trial","name":"GETUG-AFU 16","route":"/trials/getug-afu-16/","field":"outcomes.source (Progression-free survival at 120 months)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30532-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519305327","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","field":"outcomes.source (Overall survival (single arm vs historical))"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30569-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519305698","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30617-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306175","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bisogno-lancet-oncol","kind":"paper","name":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-bisogno-lancet-oncol/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30617-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306175","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","field":"links","label":"EpSSG RMS 2005 maintenance (Lancet Oncol 2019)"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","field":"standardOfCare.guideline (Low risk (embryonal, favourable site, complete resection))"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30634-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306345","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","field":"links","label":"Lancet Oncol 2019"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30669-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306692","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"papers","label":"EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30671-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306710","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30689-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306898","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30690-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306904","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-drilon-entrectinib-ros1-lancet-oncol-2020","kind":"paper","name":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials","route":"/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30691-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519306916","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","field":"papers","label":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials"},{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"papers","label":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials"},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","field":"links","label":"Entrectinib integrated analysis (Lancet Oncology 2020)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30718-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519307181","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30718-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519307181","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oligoprogression","kind":"term","name":"Oligoprogression","route":"/terms/oligoprogression/","field":"links","label":"Guckenberger et al., Characterisation and classification of oligometastatic disease: ESTRO and EORTC consensus (Lancet Oncology 2020)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30728-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519307284","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30798-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519307983","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/","field":"links","label":"New EPOC: systemic chemotherapy with or without cetuximab in resectable colorectal liver metastasis, long-term results (Lancet Oncology 2020)"},{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/","field":"outcomes.source (Overall survival)"},{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30825-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519308253","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","field":"papers","label":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial"},{"id":"paper-florence-duffaud-lancet-oncol-2020","kind":"paper","name":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"},{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","field":"outcomes.source (Objective response within 6 months, Ewing sarcoma cohort)"},{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","field":"outcomes.source (Objective response within 6 months, osteosarcoma cohort)"},{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","field":"outcomes.source (Non-progression at 6 months, osteosarcoma cohort)"}]},{"url":"https://doi.org/10.1016/S1470-2045(19)30862-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519308629","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","field":"links","label":"TRIBE2 (Lancet Oncology 2020)"},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","field":"toxicity.source (Neutropenia (grade 3-4))"},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","field":"toxicity.source (Diarrhoea (grade 3-4))"},{"id":"tribe2","kind":"trial","name":"TRIBE2","route":"/trials/tribe2/","field":"links","label":"TRIBE2: upfront FOLFOXIRI plus bevacizumab and reintroduction after progression (Lancet Oncology 2020)"},{"id":"tribe2","kind":"trial","name":"TRIBE2","route":"/trials/tribe2/","field":"outcomes.source (Progression-free survival 2)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30059-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520300590","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","field":"links","label":"PRIMEUR-IVL (Shimada 2020, Lancet Oncology): R-CHOP with high-dose methotrexate and intrathecal chemotherapy in intravascular large B-cell lymphoma"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30068-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520300681","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","field":"links","label":"Lurbinectedin SCLC basket cohort (Lancet Oncology 2020)"},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","field":"outcomes.source (Objective response rate (investigator assessed))"},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"papers","label":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30074-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520300747","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30074-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520300747","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","field":"links","label":"Know Your Tumor outcomes (Lancet Oncol 2020)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30109-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520301091","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","field":"links","label":"FIGHT-202: pemigatinib for previously treated FGFR2-rearranged cholangiocarcinoma (Lancet Oncology 2020)"},{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","field":"outcomes.source (Objective response rate)"},{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","field":"outcomes.source (Progression-free survival)"},{"id":"paper-fight-202-pemigatinib-lancet-oncol-2020","kind":"paper","name":"FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements","route":"/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30139-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452030139X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30139-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452030139X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"links","label":"Vokinger et al., Prices and clinical benefit of cancer drugs in the USA and Europe (Lancet Oncology 2020)"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"metrics (Correlation between monthly treatment cost and ESMO-MCBS or ASCO clinical benefit grade for cancer drugs in the US and four European countries)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"links","label":"Vokinger et al., Prices and clinical benefit of cancer drugs (Lancet Oncology 2020)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"metrics (Correlation between cancer drug prices and clinical benefit (ESMO-MCBS, ASCO framework) in the US and Europe)"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","field":"links","label":"Vokinger 2020 price vs benefit (Lancet Oncol)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30157-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520301571","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"papers","label":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30157-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520301571","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","field":"outcomes.source (Progression-free survival)"},{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","field":"outcomes.source (Overall survival (crossover-adjusted))"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30162-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520301625","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020","kind":"paper","name":"REMORA: lenvatinib in advanced or metastatic thymic carcinoma","route":"/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"links","label":"REMORA lenvatinib (Lancet Oncology 2020)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30168-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520301686","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","field":"outcomes.source (Overall survival (median))"},{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30225-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520302254","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30269-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520302692","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","field":"papers","label":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour"},{"id":"paper-navigator-avapritinib-heinrich-lancet-oncol-2020","kind":"paper","name":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","route":"/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","field":"outcomes.source (Overall response, PDGFRA D842V-mutant GIST (dose-expansion primary endpoint))"},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","field":"outcomes.source (Complete response, PDGFRA D842V-mutant GIST)"},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","field":"outcomes.source (Treatment-related grade 3-4 adverse events)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30321-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303211","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30321-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303211","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","field":"links","label":"Subbiah et al., Lancet Oncology 2020: dabrafenib plus trametinib in BRAF V600E biliary tract cancer (ROAR)"},{"id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","field":"outcomes.source (Overall response rate, biliary tract cancer cohort (investigator-assessed))"},{"id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","field":"outcomes.source (Overall response rate, biliary tract cancer cohort (independent review))"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30322-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303223","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prophylochip","kind":"trial","name":"PROPHYLOCHIP-PRODIGE 15","route":"/trials/prophylochip/","field":"links","label":"PROPHYLOCHIP-PRODIGE 15: second-look surgery plus HIPEC versus surveillance (Lancet Oncology 2020)"},{"id":"prophylochip","kind":"trial","name":"PROPHYLOCHIP-PRODIGE 15","route":"/trials/prophylochip/","field":"outcomes.source (Disease-free survival at 3 years)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30324-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303247","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30324-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303247","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"papers","label":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30398-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520303983","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"agex","kind":"trial","name":"AgeX","route":"/trials/agex/","field":"links","label":"UK Age trial final results, Lancet Oncology 2020 (DOI)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30444-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304447","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30444-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304447","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"links","label":"Turner et al., Lancet Oncology 2020: circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH)"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"outcomes.source (Confirmed objective response rate by cohort)"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","field":"outcomes.source (Sensitivity of digital PCR ctDNA testing for mutations found in tissue sequencing)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30446-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304460","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","field":"papers","label":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma"},{"id":"paper-strass-lancet-oncol-2020","kind":"paper","name":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma","route":"/key-papers/paper-strass-lancet-oncol-2020/","field":"links","label":"Lancet Oncol 2020"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"links","label":"Lancet Oncology 2020"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Abdominal recurrence-free survival (median))"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Completed allocated treatment)"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Grade 3-4 lymphopenia)"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Grade 3-4 anaemia)"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Grade 3-4 hypoalbuminaemia)"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Serious adverse events)"},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","field":"outcomes.source (Treatment-related deaths)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30447-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304472","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"links","label":"BROCADE3 primary results (Lancet Oncology 2020)"},{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"toxicity.source (Neutropenia (grade 3 or worse), with carboplatin and paclitaxel)"},{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"toxicity.source (Thrombocytopenia (grade 3 or worse))"},{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","field":"links","label":"Dieras et al., Lancet Oncology 2020: veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3)"},{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","field":"outcomes.source (Progression-free survival (investigator))"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30451-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304514","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gounder-lancet-oncol","kind":"paper","name":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","route":"/key-papers/paper-gounder-lancet-oncol/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30451-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304514","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"EZH-202 (Lancet Oncol 2020)"},{"id":"tazemetostat-doxorubicin-es","kind":"trial","name":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)","route":"/trials/tazemetostat-doxorubicin-es/","field":"links","label":"Gounder et al., tazemetostat in advanced epithelioid sarcoma (Lancet Oncology 2020)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30454-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452030454X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/","field":"links","label":"GETUG-AFU 17 (Lancet Oncology 2020)"},{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/","field":"outcomes.source (Event-free survival at 5 years)"},{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/","field":"outcomes.source (Late grade 2 or worse erectile dysfunction)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30456-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304563","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"raves","kind":"trial","name":"RAVES (TROG 08.03/ANZUP)","route":"/trials/raves/","field":"links","label":"RAVES (Lancet Oncology 2020)"},{"id":"raves","kind":"trial","name":"RAVES (TROG 08.03/ANZUP)","route":"/trials/raves/","field":"outcomes.source (Freedom from biochemical progression at 5 years)"},{"id":"raves","kind":"trial","name":"RAVES (TROG 08.03/ANZUP)","route":"/trials/raves/","field":"outcomes.source (Grade 2 or worse genitourinary toxicity)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30472-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304721","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30475-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304757","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-redman-lancet-oncol","kind":"paper","name":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","route":"/key-papers/paper-redman-lancet-oncol/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30475-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304757","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","field":"links","label":"Redman et al., Lancet Oncology 2020: biomarker-driven therapies for previously treated squamous NSCLC (Lung-MAP SWOG S1400)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30493-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304939","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","field":"outcomes.source (Progression-free survival (SANET-p))"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30494-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304940","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","field":"links","label":"Lancet Oncol 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30494-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304940","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","field":"links","label":"4-year follow-up, Lancet Oncology 2020"},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","field":"outcomes.source (Recurrence-free survival at 4 years)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30496-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520304964","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","field":"outcomes.source (Progression-free survival (SANET-ep))"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30525-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305258","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"papers","label":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30539-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305398","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"papers","label":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial"},{"id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30540-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305404","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","field":"papers","label":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer"},{"id":"paper-nadofaragene-firadenovec-lancet-oncol-2021","kind":"paper","name":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30555-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305556","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021","kind":"paper","name":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy in locally advanced rectal cancer (RAPIDO)","route":"/key-papers/paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","field":"links","label":"Lancet Oncology 2020"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30581-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305817","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"links","label":"HYPO-RT-PC patient-reported quality of life (Lancet Oncology 2021)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30599-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305994","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Quenet, Lancet Oncol 2021: PRODIGE 7, cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases (265 patients)"},{"id":"colorectal-peritoneal-metastases","kind":"term","name":"Peritoneal metastases from bowel cancer","route":"/terms/colorectal-peritoneal-metastases/","field":"links","label":"Quenet, Lancet Oncol 2021: PRODIGE 7, cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases (265 patients)"},{"id":"cytoreductive-surgery","kind":"term","name":"Cytoreductive surgery","route":"/terms/cytoreductive-surgery/","field":"links","label":"Quenet, Lancet Oncol 2021: PRODIGE 7, cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases (265 patients)"},{"id":"peritoneal-carcinomatosis-index","kind":"term","name":"Peritoneal cancer index","route":"/terms/peritoneal-carcinomatosis-index/","field":"links","label":"Quenet, Lancet Oncol 2021: PRODIGE 7, cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases (265 patients)"},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","field":"links","label":"Quenet, Lancet Oncol 2021: PRODIGE 7, cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases (265 patients)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30599-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520305994","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021","kind":"paper","name":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)","route":"/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"prodige-7","kind":"trial","name":"PRODIGE 7","route":"/trials/prodige-7/","field":"links","label":"PRODIGE 7: cytoreductive surgery plus HIPEC versus cytoreductive surgery alone for colorectal peritoneal metastases (Lancet Oncology 2021)"},{"id":"prodige-7","kind":"trial","name":"PRODIGE 7","route":"/trials/prodige-7/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30641-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-9la","kind":"trial","name":"CheckMate 9LA","route":"/trials/checkmate-9la/","field":"links","label":"CheckMate 9LA (Lancet Oncology 2021)"},{"id":"checkmate-9la","kind":"trial","name":"CheckMate 9LA","route":"/trials/checkmate-9la/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(20)30642-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520306422","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30686-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520306860","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"outcomes.source (Local progression-free rate at 5 years in the irradiated site)"},{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"outcomes.source (Local progression-free rate at 2 years in the irradiated site)"},{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30754-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520307543","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","field":"links","label":"Winer et al., Lancet Oncology 2021: pembrolizumab versus investigator-choice chemotherapy for metastatic TNBC (KEYNOTE-119)"},{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","field":"outcomes.source (Overall survival, PD-L1 CPS 10 or more)"},{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","field":"outcomes.source (Overall survival, PD-L1 CPS 1 or more)"},{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","field":"outcomes.source (Overall survival, all patients)"},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"papers","label":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(20)30755-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204520307555","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","field":"papers","label":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer"},{"id":"paper-tpextreme-lancet-oncol-2021","kind":"paper","name":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-tpextreme-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/","field":"outcomes.source (Overall survival)"},{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/","field":"outcomes.source (Grade 3 or worse adverse events during chemotherapy)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00005-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452100005X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma","route":"/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"links","label":"KEYNOTE-204 (Lancet Oncology 2021)"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00007-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000073","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-piccart-lancet-oncol","kind":"paper","name":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","route":"/key-papers/paper-piccart-lancet-oncol/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00007-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000073","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","field":"links","label":"8-year update (Lancet Oncol 2021)"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00027-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"outcomes.source (Overall survival)"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"outcomes.source (Overall survival at 12 months)"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"outcomes.source (Overall survival at 6 months)"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"outcomes.source (Grade 3-5 adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00027-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Second line, no actionable target)"},{"id":"paper-abc-06-folfox-second-line-lancet-oncol-2021","kind":"paper","name":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","route":"/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","field":"links","label":"Lamarca et al., Lancet Oncology 2021: ABC-06"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00065-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000656","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00077-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000772","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","route":"/key-papers/paper-ranganathan-lancet-oncol/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00077-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000772","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"links","label":"CReDO workshops (Lancet Oncol 2021)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00079-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000796","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021","kind":"paper","name":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)","route":"/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","field":"links","label":"Lancet Oncology 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00080-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000802","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-orecchia-lancet-oncol","kind":"paper","name":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","route":"/key-papers/paper-orecchia-lancet-oncol/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00080-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000802","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","field":"links","label":"ELIOT long-term (Lancet Oncol 2021)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00086-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521000863","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/","field":"links","label":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer (Lancet Oncology 2021)"},{"id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/","field":"outcomes.source (Confirmed objective response rate (cohort A, HER2-positive))"},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","field":"papers","label":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00122-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521001224","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00126-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521001261","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","field":"outcomes.source (Objective response by independent central review)"},{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","field":"outcomes.source (Grade 3 or 4 treatment-emergent adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00126-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521001261","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","field":"links","label":"Primary analysis (Lancet Oncology 2021)"},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","field":"papers","label":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy"},{"id":"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021","kind":"paper","name":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy","route":"/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"links","label":"Cemiplimab after hedgehog inhibitors (Lancet Oncology 2021)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00139-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452100139X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00147-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521001479","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-057-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ","route":"/key-papers/paper-keynote-057-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"},{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/","field":"outcomes.source (Complete response at 3 months, cohort A (BCG-unresponsive carcinoma in situ))"},{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/","field":"outcomes.source (Grade 3-4 treatment-related adverse events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00247-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521002473","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","field":"links","label":"ARROW lung cohort (Lancet Oncology 2021)"},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"papers","label":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW)"},{"id":"paper-arrow-pralsetinib-gainor-lancet-oncol-2021","kind":"paper","name":"ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00252-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521002527","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ren-lancet-oncol","kind":"paper","name":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","route":"/key-papers/paper-ren-lancet-oncol/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00252-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521002527","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"links","label":"ORIENT-32 (Lancet Oncol 2021)"},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","field":"links","label":"Lancet Oncol 2021"},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00279-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521002795","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alcohol-cancer-burden-lancet-oncol-2021","kind":"paper","name":"Alcohol caused an estimated 741,000 cancers worldwide in 2020","route":"/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/","field":"links","label":"DOI"},{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","field":"links","label":"Global burden of alcohol-attributable cancer 2020 (Lancet Oncol 2021)"},{"id":"alcohol-attributable-cancer","kind":"term","name":"Alcohol-attributable cancer","route":"/terms/alcohol-attributable-cancer/","field":"links","label":"Rumgay et al. (Lancet Oncol 2021)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00301-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521003016","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","kind":"paper","name":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","route":"/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/","field":"links","label":"Denkert et al., Lancet Oncol 2021: HER2-low-positive disease in 2,310 patients from four neoadjuvant trials"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00302-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521003028","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021","kind":"paper","name":"CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00336-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521003363","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-javle-mypathway-her2-biliary-lancet-oncol-2021","kind":"paper","name":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/","field":"links","label":"Javle et al., Lancet Oncol 2021: pertuzumab and trastuzumab in HER2-positive biliary tract cancer (MyPathway)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00336-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521003363","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","field":"outcomes.source (Objective response, trastuzumab plus pertuzumab in HER2-amplified or overexpressing metastatic biliary tract cancer (investigator-assessed))"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00402-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521004022","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00453-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521004538","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","field":"papers","label":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","field":"papers","label":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India"},{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/","field":"links","label":"Basu et al., Lancet Oncology 2021"},{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/","field":"outcomes.source (Vaccine efficacy against persistent HPV 16/18 infection)"},{"id":"paper-basu-single-dose-hpv-lancet-oncol-2021","kind":"paper","name":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","route":"/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/","field":"links","label":"Lancet Oncology 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00486-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521004861","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"NIFTY, Lancet Oncology 2021"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"toxicity.source (Neutropenia (grade 3-4))"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"toxicity.source (Fatigue or asthenia (grade 3-4))"},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","field":"links","label":"Yoo et al., Lancet Oncology 2021: NIFTY"},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","field":"outcomes.source (Grade 3-4 neutropenia)"},{"id":"paper-nifty-liposomal-irinotecan-lancet-oncol-2021","kind":"paper","name":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","route":"/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00545-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521005453","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00545-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521005453","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","field":"links","label":"3-year follow-up, Lancet Oncology 2021"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00546-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521005465","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/","field":"links","label":"Lancet Oncol 2021"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00546-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521005465","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/","field":"links","label":"Qian et al., Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (Lancet Oncology 2021)"},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/","field":"links","label":"Qian et al., Effect of immunotherapy time-of-day infusion on overall survival in advanced melanoma (Lancet Oncology 2021)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00589-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521005891","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Yau et al., residual cancer burden and long-term survival, pooled analysis of 5,161 patients (Lancet Oncology 2022)"},{"id":"paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022","kind":"paper","name":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","route":"/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/","field":"links","label":"Residual cancer burden and long-term survival: pooled analysis of 5,161 patients (Lancet Oncology 2022)"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00591-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452100591X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","field":"outcomes.source (Overall response rate (independent review, primary analysis))"},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","field":"outcomes.source (Complete response (primary analysis))"},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","field":"outcomes.source (Grade 3 or worse cytokine release syndrome)"},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","field":"outcomes.source (Grade 3-4 neurological events)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00606-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521006069","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","field":"links","label":"Lung ART (Lancet Oncology 2022)"},{"id":"lung-art","kind":"trial","name":"Lung ART","route":"/trials/lung-art/","field":"links","label":"Lung ART (Lancet Oncology 2022)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00630-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521006306","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gemstone-301","kind":"trial","name":"GEMSTONE-301","route":"/trials/gemstone-301/","field":"links","label":"GEMSTONE-301 (Lancet Oncology 2022)"},{"id":"gemstone-301","kind":"trial","name":"GEMSTONE-301","route":"/trials/gemstone-301/","field":"outcomes.source (Progression-free survival (blinded independent central review))"}]},{"url":"https://doi.org/10.1016/s1470-2045(21)00650-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00650-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","field":"links","label":"GEMSTONE-302 (Lancet Oncol 2022)"},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","field":"links","label":"Lancet Oncol 2022"},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/S1470-2045(21)00705-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204521007051","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"papers","label":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00061-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522000614","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kindler-lancet-oncol","kind":"paper","name":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","route":"/key-papers/paper-kindler-lancet-oncol/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00061-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522000614","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/","field":"links","label":"Kindler et al., anetumab ravtansine versus vinorelbine (Lancet Oncology 2022)"},{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","field":"links","label":"Kindler et al., anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive mesothelioma, randomised phase 2 (Lancet Oncology 2022)"},{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/","field":"links","label":"Lancet Oncology 2022"},{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00197-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522001978","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00224-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002248","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00224-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002248","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","field":"links","label":"CAPSTONE-1 (Lancet Oncol 2022)"},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","field":"links","label":"Lancet Oncol 2022"},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00226-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cho-lancet-oncol","kind":"paper","name":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","route":"/key-papers/paper-cho-lancet-oncol/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00226-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","field":"links","label":"CITYSCAPE: tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC, phase 2 (Lancet Oncology 2022)"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00284-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002844","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","kind":"paper","name":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","route":"/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00293-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522002935","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00335-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522003357","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-bispecific-step-up","kind":"term","name":"CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one","route":"/terms/lymphoma-tx-bispecific-step-up/","field":"links","label":"Mosunetuzumab in relapsed or refractory follicular lymphoma, Lancet Oncology 2022 (complete response 60.0 per cent)"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00380-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522003801","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","field":"papers","label":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma"},{"id":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","kind":"paper","name":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","route":"/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/","field":"links","label":"Lancet Oncol 2022"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"links","label":"LMS-04 (Lancet Oncol 2022)"},{"id":"lms-04","kind":"trial","name":"LMS-04","route":"/trials/lms-04/","field":"links","label":"Lancet Oncology 2022"},{"id":"lms-04","kind":"trial","name":"LMS-04","route":"/trials/lms-04/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00517-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522005174","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/S1470-2045(22)00518-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522005186","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-091","kind":"trial","name":"KEYNOTE-091 (PEARLS)","route":"/trials/keynote-091/","field":"links","label":"PEARLS/KEYNOTE-091 interim analysis (Lancet Oncology 2022)"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00559-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522005599","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","field":"links","label":"Lancet Oncol 2022"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00687-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522006878","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(22)00694-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204522006945","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00051-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523000517","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00112-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523001122","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sonabend-lancet-oncol","kind":"paper","name":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","route":"/key-papers/paper-sonabend-lancet-oncol/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00112-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523001122","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/","field":"links","label":"Sonabend et al., Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in glioblastoma (Lancet Oncology 2023)"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00147-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452300147X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-outback-lancet-oncol-2023","kind":"paper","name":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-outback-lancet-oncol-2023/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00148-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523001481","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-attard-lancet-oncol","kind":"paper","name":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","route":"/key-papers/paper-attard-lancet-oncol/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00148-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523001481","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Attard et al., Lancet Oncology 2023: abiraterone plus prednisolone with or without enzalutamide for metastatic prostate cancer starting ADT (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00150-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452300150X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","field":"links","label":"MOUNTAINEER: tucatinib plus trastuzumab for chemotherapy-refractory HER2-positive RAS wild-type metastatic colorectal cancer (Lancet Oncology 2023)"},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/","field":"links","label":"Lancet Oncol 2023"},{"id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/","field":"links","label":"MOUNTAINEER: tucatinib plus trastuzumab for chemotherapy-refractory HER2-positive RAS wild-type metastatic colorectal cancer (Lancet Oncology 2023)"},{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","field":"papers","label":"MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00219-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452300219X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/","field":"links","label":"CAIRO5: first-line systemic treatment strategies in initially unresectable colorectal cancer liver metastases (Lancet Oncology 2023)"},{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/","field":"outcomes.source (Progression-free survival (right-sided or RAS/BRAF mutant))"},{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/","field":"outcomes.source (Progression-free survival (left-sided, RAS and BRAF wild-type))"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00242-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523002425","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/","field":"links","label":"Harding et al., Lancet Oncol 2023: HERIZON-BTC-01, zanidatamab in HER2-amplified biliary tract cancer"},{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00242-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523002425","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"HERIZON-BTC-01 (Lancet Oncol 2023)"},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"links","label":"Harding et al., Lancet Oncology 2023: HERIZON-BTC-01"},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"outcomes.source (Grade 3 treatment-related adverse events)"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00246-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523002462","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00282-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523002826","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-blay-lancet-oncol","kind":"paper","name":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","route":"/key-papers/paper-blay-lancet-oncol/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00282-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523002826","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"AcSe pembrolizumab in rare sarcomas (Lancet Oncol 2023)"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00298-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S147020452300298X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"links","label":"Lång et al., AI-supported mammography screening (MASAI, Lancet Oncology 2023)"},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"metrics (Screen-reading workload reduction with AI-supported mammography screening at equal or higher cancer detection (MASAI, randomised, 80,033 women))"},{"id":"paper-masai-lancet-oncol-2023","kind":"paper","name":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","route":"/key-papers/paper-masai-lancet-oncol-2023/","field":"links","label":"DOI"},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/","field":"links","label":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload (Lancet Oncology 2023)"},{"id":"transpara","kind":"drug","name":"Transpara","route":"/drugs/transpara/","field":"links","label":"MASAI interim analysis (Lancet Oncol 2023)"},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","field":"links","label":"MASAI interim analysis (Lancet Oncol 2023)"},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","field":"outcomes.source (Cancer detection rate (interim analysis))"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00329-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523003297","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00329-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523003297","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","field":"links","label":"Lancet Oncology 2023 (three-year update)"},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","field":"outcomes.source (Overall survival, PD-L1 50% or more (three-year update))"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00382-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523003820","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00469-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523004692","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00479-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523004795","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","field":"outcomes.source (Progression-free survival (investigator-assessed))"},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","field":"outcomes.source (Progression-free survival at 12 months)"},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","field":"outcomes.source (Serious adverse events)"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00515-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"papers","label":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00515-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-keynote-859-lancet-oncol-2023","kind":"paper","name":"KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer","route":"/key-papers/paper-keynote-859-lancet-oncol-2023/","field":"links","label":"Lancet Oncol 2023"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00529-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523005296","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/s1470-2045(23)00629-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523006290","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"papers","label":"Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00100-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524001001","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","field":"outcomes.source (Event-free survival)"},{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","field":"outcomes.source (Grade 3 or worse adverse events)"},{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","field":"outcomes.source (Serious adverse events)"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00140-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524001402","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/S1470-2045(24)00373-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524003735","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"papers","label":"Capivasertib and fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291)"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00380-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524003802","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00387-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524003875","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/S1470-2045(24)00387-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524003875","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"papers","label":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2)"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00402-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524004029","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shuch-lancet-oncol","kind":"paper","name":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-shuch-lancet-oncol/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/S1470-2045(24)00402-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524004029","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","field":"links","label":"Shuch et al., ZIRCON: 89Zr-girentuximab PET-CT imaging of clear-cell renal cell carcinoma (Lancet Oncology 2024)"},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","field":"links","label":"Shuch et al., ZIRCON: 89Zr-girentuximab PET-CT imaging of clear-cell renal cell carcinoma (Lancet Oncology 2024)"}]},{"url":"https://doi.org/10.1016/s1470-2045(24)00441-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524004418","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","field":"links","label":"Lancet Oncol 2024"}]},{"url":"https://doi.org/10.1016/S1470-2045(25)00167-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525001676","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"papers","label":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025"}]},{"url":"https://doi.org/10.1016/s1470-2045(25)00209-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525002098","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","field":"links","label":"Lancet Oncol 2025"}]},{"url":"https://doi.org/10.1016/S1470-2045(25)00231-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525002311","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"STAMPEDE metformin (Lancet Oncology 2025)"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival (median), metformin comparison)"},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","field":"links","label":"STAMPEDE metformin (Lancet Oncology 2025)"}]},{"url":"https://doi.org/10.1016/S1470-2045(25)00363-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525003638","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/","field":"links","label":"Lancet Oncol 2025"},{"id":"preopanc-2","kind":"trial","name":"PREOPANC-2","route":"/trials/preopanc-2/","field":"links","label":"Janssen et al., PREOPANC-2 (Lancet Oncology 2025)"},{"id":"preopanc-2","kind":"trial","name":"PREOPANC-2","route":"/trials/preopanc-2/","field":"outcomes.source (Overall survival (modified intention to treat))"}]},{"url":"https://doi.org/10.1016/s1470-2045(25)00475-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525004759","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","field":"links","label":"Lancet Oncol 2025"}]},{"url":"https://doi.org/10.1016/S1470-2045(25)00545-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525005455","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"links","label":"SYSUCC-001 ten-year outcomes and FOXC1 analysis (Lancet Oncology 2025)"},{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"outcomes.source (Disease-free survival at 10 years)"},{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","field":"outcomes.source (Overall survival at 10 years)"}]},{"url":"https://doi.org/10.1016/S1470-2045(25)00601-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525006011","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/","field":"links","label":"Letter: Neoptolemos and colleagues (Lancet Oncol 2026)"}]},{"url":"https://doi.org/10.1016/s1470-2045(25)00643-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204525006436","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","field":"links","label":"Lancet Oncol 2026"}]},{"url":"https://doi.org/10.1016/s1470-2045(26)00071-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204526000719","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","field":"links","label":"Lancet Oncol 2026"}]},{"url":"https://doi.org/10.1016/s1470-2045(26)00090-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204526000902","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","field":"links","label":"Lancet Oncol 2026"}]},{"url":"https://doi.org/10.1016/s1470-2045(26)00193-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204526001932","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","field":"links","label":"Lancet Oncol 2026"}]},{"url":"https://doi.org/10.1016/S1470-2045(26)00194-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204526001944","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","field":"outcomes.source (Complete response at 24 months)"}]},{"url":"https://doi.org/10.1016/s1470-2045(26)00282-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204526002822","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","field":"links","label":"Lancet Oncol 2026"}]},{"url":"https://doi.org/10.1016/s1535-6108(02)00180-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1535610802001800","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"secretory-carcinoma-breast","kind":"cancer","name":"Secretory carcinoma of the breast","route":"/cancers/secretory-carcinoma-breast/","field":"links","label":"Tognon, Cancer Cell 2002: the ETV6-NTRK3 gene fusion as a primary event in secretory breast carcinoma"}]},{"url":"https://doi.org/10.1016/s2213-2600(14)70041-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260014700414","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"papers","label":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data"}]},{"url":"https://doi.org/10.1016/s2213-2600(14)70290-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260014702905","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","field":"papers","label":"Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study"}]},{"url":"https://doi.org/10.1016/s2213-2600(18)30116-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260018301164","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schoffski-lancet-respir-med","kind":"paper","name":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","route":"/key-papers/paper-schoffski-lancet-respir-med/","field":"links","label":"Lancet Respir Med 2018"}]},{"url":"https://doi.org/10.1016/S2213-2600(18)30116-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260018301164","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","field":"links","label":"EORTC 90101 CREATE (Lancet Respir Med 2018)"}]},{"url":"https://doi.org/10.1016/S2213-2600(19)30053-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260019300530","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alesia","kind":"trial","name":"ALESIA","route":"/trials/alesia/","field":"links","label":"ALESIA (Lancet Respiratory Medicine 2019)"}]},{"url":"https://doi.org/10.1016/s2213-2600(20)30365-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/","field":"links","label":"Lancet Respir Med 2021"}]},{"url":"https://doi.org/10.1016/S2213-2600(20)30365-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","field":"links","label":"Lancet Respir Med 2021"},{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/s2213-2600(22)00168-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260022001680","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/","field":"links","label":"Lancet Respir Med 2022"}]},{"url":"https://doi.org/10.1016/S2213-2600(22)00168-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260022001680","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","field":"links","label":"FURLONG (Lancet Respir Med 2022)"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","field":"links","label":"Lancet Respir Med 2022"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1016/s2213-2600(22)00309-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260022003095","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-atlantis-lancet-respir-med-2023","kind":"paper","name":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-atlantis-lancet-respir-med-2023/","field":"links","label":"Lancet Respir Med 2023"}]},{"url":"https://doi.org/10.1016/s2213-2600(22)00437-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260022004374","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-crown-lancet-respir-med-2023-update","kind":"paper","name":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","route":"/key-papers/paper-crown-lancet-respir-med-2023-update/","field":"links","label":"Lancet Respir Med 2023"}]},{"url":"https://doi.org/10.1016/s2213-2600(23)00379-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S221326002300379X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/","field":"links","label":"Lancet Respir Med 2024"}]},{"url":"https://doi.org/10.1016/S2213-2600(23)00382-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S221326002300382X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jcog0802","kind":"trial","name":"JCOG0802 / WJOG4607L","route":"/trials/jcog0802/","field":"links","label":"JCOG0802/WJOG4607L pure-solid supplemental analysis (Lancet Respiratory Medicine 2024)"},{"id":"jcog0802","kind":"trial","name":"JCOG0802 / WJOG4607L","route":"/trials/jcog0802/","field":"outcomes.source (Overall survival at 5 years (radiologically pure-solid subgroup))"}]},{"url":"https://doi.org/10.1016/S2213-2600(24)00119-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S221326002400119X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mars-2-lancet-respir-med-2024","kind":"paper","name":"MARS 2: extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma","route":"/key-papers/paper-mars-2-lancet-respir-med-2024/","field":"links","label":"Lancet Respir Med 2024"}]},{"url":"https://doi.org/10.1016/s2213-2600(24)00269-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260024002698","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04379635-lancet-respir-med-2025","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","route":"/key-papers/paper-nct04379635-lancet-respir-med-2025/","field":"links","label":"Lancet Respir Med 2025"}]},{"url":"https://doi.org/10.1016/s2213-2600(24)00428-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260024004284","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"},{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents)"}]},{"url":"https://doi.org/10.1016/s2213-2600(25)00121-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260025001213","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04143607-lancet-respir-med-2025","kind":"paper","name":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","route":"/key-papers/paper-nct04143607-lancet-respir-med-2025/","field":"links","label":"Lancet Respir Med 2025"}]},{"url":"https://doi.org/10.1016/s2213-2600(25)00258-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213260025002589","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/","field":"links","label":"Lancet Respir Med 2026"}]},{"url":"https://doi.org/10.1016/s2213-8587(23)00119-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213858723001195","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","field":"papers","label":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study"}]},{"url":"https://doi.org/10.1016/S2213-8587(23)00193-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2213858723001936","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"links","label":"ADIUVO (Lancet Diabetes and Endocrinology 2023)"},{"id":"adiuvo","kind":"trial","name":"ADIUVO","route":"/trials/adiuvo/","field":"outcomes.source (Recurrence-free survival at 5 years)"},{"id":"adiuvo","kind":"trial","name":"ADIUVO","route":"/trials/adiuvo/","field":"outcomes.source (Overall survival at 5 years)"},{"id":"adiuvo","kind":"trial","name":"ADIUVO","route":"/trials/adiuvo/","field":"outcomes.source (Discontinuation of mitotane for adverse events)"},{"id":"paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023","kind":"paper","name":"ADIUVO: adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma","route":"/key-papers/paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023/","field":"links","label":"Lancet Diabetes Endocrinol 2023"}]},{"url":"https://doi.org/10.1016/s2214-109x(20)30275-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2214109X20302758","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-patil-lancet-glob-health","kind":"paper","name":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-patil-lancet-glob-health/","field":"links","label":"Lancet Glob Health 2020"}]},{"url":"https://doi.org/10.1016/S2214-109X(20)30275-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2214109X20302758","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metronomic-vs-cisplatin-tmh","kind":"trial","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","route":"/trials/metronomic-vs-cisplatin-tmh/","field":"links","label":"Patil et al., Lancet Global Health 2020"},{"id":"metronomic-vs-cisplatin-tmh","kind":"trial","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","route":"/trials/metronomic-vs-cisplatin-tmh/","field":"outcomes.source (Median overall survival)"}]},{"url":"https://doi.org/10.1016/s2214-109x(22)00545-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2214109X22005459","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"papers","label":"Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study"}]},{"url":"https://doi.org/10.1016/S2352-3026(16)00036-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302616000363","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/","field":"outcomes.source (Complete remission after induction chemotherapy)"},{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/","field":"outcomes.source (Deaths from toxicity during induction)"},{"id":"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016","kind":"paper","name":"IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/","field":"links","label":"Lancet Haematol 2016"}]},{"url":"https://doi.org/10.1016/S2352-3026(16)30050-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302616300503","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"papers","label":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial"}]},{"url":"https://doi.org/10.1016/S2352-3026(17)30174-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302617301746","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/","field":"outcomes.source (Failure-free survival at 2 years after the second randomisation)"},{"id":"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017","kind":"paper","name":"IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/","field":"links","label":"Lancet Haematol 2017"}]},{"url":"https://doi.org/10.1016/S2352-3026(18)30173-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S235230261830173X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"outcomes.source (Event-free survival at 5 years (EsPhALL2010, continuous imatinib))"},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"outcomes.source (Overall survival at 5 years (EsPhALL2010, continuous imatinib))"},{"id":"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018","kind":"paper","name":"EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL","route":"/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/","field":"links","label":"Lancet Haematol 2018"}]},{"url":"https://doi.org/10.1016/s2352-3026(19)30115-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302619301152","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/","field":"links","label":"Lancet Haematol 2019"}]},{"url":"https://doi.org/10.1016/s2352-3026(19)30236-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302619302364","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gisslinger-lancet-haematol","kind":"paper","name":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","route":"/key-papers/paper-gisslinger-lancet-haematol/","field":"links","label":"Lancet Haematol 2020"}]},{"url":"https://doi.org/10.1016/S2352-3026(19)30236-4","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302619302364","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"links","label":"Lancet Haematology 2020"},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"outcomes.source (Complete haematological response with normal spleen size at 12 months (PROUD-PV))"},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"outcomes.source (Complete haematological response with improved disease burden at 36 months (CONTINUATION-PV))"},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","field":"outcomes.source (Complete haematological response at 36 months (without the spleen criterion))"}]},{"url":"https://doi.org/10.1016/s2352-3026(21)00307-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302621003070","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zanubrutinib-cll-lancet-haematol-2021","kind":"paper","name":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/","field":"links","label":"Lancet Haematol 2021"}]},{"url":"https://doi.org/10.1016/s2352-3026(23)00333-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302623003332","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zeidan-lancet-haematol","kind":"paper","name":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-zeidan-lancet-haematol/","field":"links","label":"Lancet Haematol 2024"}]},{"url":"https://doi.org/10.1016/S2352-3026(23)00333-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302623003332","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/","field":"links","label":"STIMULUS-MDS2 (Lancet Haematol 2024)"}]},{"url":"https://doi.org/10.1016/S2352-3026(23)00371-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S235230262300371X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"papers","label":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial"}]},{"url":"https://doi.org/10.1016/S2352-3026(24)00065-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302624000656","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"papers","label":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP)"}]},{"url":"https://doi.org/10.1016/S2352-3026(24)00377-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302624003776","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","field":"papers","label":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study"},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/","field":"links","label":"Phase 1/2 results (Lancet Haematol 2025)"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"links","label":"Phase 1/2 study (Lancet Haematol 2025)"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"dosing.source"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"toxicity.source (Neutropenia (grade 3 or worse))"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"toxicity.source (Thrombocytopenia (grade 3 or worse))"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"toxicity.source (Anaemia (grade 3 or worse))"},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/","field":"links","label":"Jain et al., Lancet Haematology 2025"},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/","field":"outcomes.source (Overall response rate)"},{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/","field":"links","label":"Lancet Haematology 2025"}]},{"url":"https://doi.org/10.1016/S2352-3026(25)00040-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2352302625000407","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"links","label":"Commentary: CAR T-cell therapy in LMICs (Lancet Haematol 2025)"},{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/","field":"links","label":"Commentary: CAR T-cell therapy in LMICs"}]},{"url":"https://doi.org/10.1016/S2468-1253(16)30014-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125316300140","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016","kind":"paper","name":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer","route":"/key-papers/paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016/","field":"links","label":"Domingo et al., Lancet Gastroenterol Hepatol 2016: somatic POLE proofreading mutation, immune response and prognosis in 6,517 colorectal cancers"},{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1016/s2468-1253(16)30079-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125316300796","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Walter, Lancet Gastroenterol Hepatol 2016: symptoms and diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study)"},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"links","label":"Walter, Lancet Gastroenterol Hepatol 2016: symptoms and diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study)"}]},{"url":"https://doi.org/10.1016/s2468-1253(16)30082-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125316300826","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"papers","label":"Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study"}]},{"url":"https://doi.org/10.1016/S2468-1253(19)30239-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125319302390","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colopec","kind":"trial","name":"COLOPEC","route":"/trials/colopec/","field":"links","label":"COLOPEC: adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (Lancet Gastroenterology and Hepatology 2019)"},{"id":"colopec","kind":"trial","name":"COLOPEC","route":"/trials/colopec/","field":"outcomes.source (Peritoneal metastasis-free survival at 18 months)"}]},{"url":"https://doi.org/10.1016/S2468-1253(19)30332-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125319303322","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","field":"papers","label":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer"},{"id":"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020","kind":"paper","name":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer","route":"/key-papers/paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020/","field":"links","label":"Lancet Gastroenterol Hepatol 2020"}]},{"url":"https://doi.org/10.1016/s2468-1253(19)30416-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125319304169","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pereira, Lancet Gastroenterol Hepatol 2020: early detection of pancreatic cancer, a review"}]},{"url":"https://doi.org/10.1016/S2468-1253(20)30330-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125320303307","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/","field":"links","label":"Kunzmann et al., NEOLAP (Lancet Gastroenterology and Hepatology 2021)"},{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/","field":"outcomes.source (Surgical conversion rate (complete macroscopic resection))"},{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1016/s2468-1253(21)00385-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S246812532100385X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","kind":"paper","name":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","route":"/key-papers/paper-nct03916627-lancet-gastroenterol-hepatol-2022/","field":"links","label":"Lancet Gastroenterol Hepatol 2022"}]},{"url":"https://doi.org/10.1016/S2468-1253(21)00385-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S246812532100385X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","field":"papers","label":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial"}]},{"url":"https://doi.org/10.1016/S2468-1253(22)00348-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S246812532200348X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023","kind":"paper","name":"ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/","field":"links","label":"Lancet Gastroenterol Hepatol 2023"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"links","label":"Lancet Gastroenterol Hepatol 2023"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"outcomes.source (Resection rate)"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"outcomes.source (Overall survival at 1 year)"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"outcomes.source (Disease-free survival at 1 year from surgery)"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"outcomes.source (R0 resection among resected patients)"}]},{"url":"https://doi.org/10.1016/S2468-1253(23)00405-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125323004053","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"outcomes.source (Alive at 18 months (intention to treat))"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"outcomes.source (Overall survival (intention to treat))"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"outcomes.source (Resection rate)"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"outcomes.source (Patients with at least one grade 3 or worse adverse event (safety population))"},{"id":"paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer","route":"/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/","field":"links","label":"Lancet Gastroenterol Hepatol 2024"}]},{"url":"https://doi.org/10.1016/S2468-1253(24)00017-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125324000177","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","field":"links","label":"Timmer et al., CROSSFIRE (Lancet Gastroenterology and Hepatology 2024)"},{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","field":"outcomes.source (Overall survival from randomisation)"}]},{"url":"https://doi.org/10.1016/s2468-1253(24)00095-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125324000955","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","kind":"paper","name":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","route":"/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/","field":"links","label":"Lancet Gastroenterol Hepatol 2024"}]},{"url":"https://doi.org/10.1016/s2468-1253(24)00119-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2468125324001195","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-naliricc-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","route":"/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/","field":"links","label":"Lancet Gastroenterol Hepatol 2024"}]},{"url":"https://doi.org/10.1016/S2589-7500(23)00153-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S258975002300153X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lunit-insight-mmg","kind":"drug","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/","field":"links","label":"ScreenTrustCAD (Lancet Digital Health 2023)"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"links","label":"Lancet Digital Health 2023"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"outcomes.source (Screen-detected breast cancers (primary comparison: one radiologist plus AI versus two radiologists))"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"outcomes.source (Screen-detected breast cancers, AI alone versus two radiologists)"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"outcomes.source (Screen-detected breast cancers, two radiologists plus AI versus two radiologists)"},{"id":"paper-screentrustcad-dembrower-lancet-digit-health-2023","kind":"paper","name":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)","route":"/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/","field":"links","label":"Lancet Digital Health 2023"}]},{"url":"https://doi.org/10.1016/s2589-7500(24)00025-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589750024000256","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kraljevic-lancet-digit-health","kind":"paper","name":"Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study","route":"/key-papers/paper-kraljevic-lancet-digit-health/","field":"links","label":"Lancet Digit Health 2024"}]},{"url":"https://doi.org/10.1016/S2589-7500(24)00025-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2589750024000256","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"foresight-ehr","kind":"technology","name":"Foresight (generative EHR model)","route":"/technologies/foresight-ehr/","field":"links","label":"Lancet Digital Health 2024"}]},{"url":"https://doi.org/10.1016/s2589-7500(24)00267-x","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S258975002400267X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-masai-lancet-digit-health-2025","kind":"paper","name":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study","route":"/key-papers/paper-masai-lancet-digit-health-2025/","field":"links","label":"Lancet Digit Health 2025"}]},{"url":"https://doi.org/10.1016/S2589-7500(24)00267-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S258975002400267X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/","field":"links","label":"MASAI randomised trial of AI-supported mammography screening (Lancet Digital Health 2025)"}]},{"url":"https://doi.org/10.1038/301089a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/301089a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-feinberg-nature","kind":"paper","name":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","route":"/key-papers/paper-feinberg-nature/","field":"links","label":"Nature 1983"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"links","label":"Feinberg and Vogelstein, Hypomethylation distinguishes genes of some human cancers from their normal counterparts (Nature 1983)"}]},{"url":"https://doi.org/10.1038/336738a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/336738a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"papers","label":"Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate"}]},{"url":"https://doi.org/10.1038/35000501","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35000501","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","field":"links","label":"Distinct types of DLBCL by gene expression profiling (Alizadeh et al., Nature 2000)"},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"papers","label":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling"},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"papers","label":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling"},{"id":"paper-alizadeh-nature","kind":"paper","name":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","route":"/key-papers/paper-alizadeh-nature/","field":"links","label":"Nature 2000"}]},{"url":"https://doi.org/10.1038/35021093","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35021093","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"links","label":"Perou, Nature 2000: molecular portraits of human breast tumours"},{"id":"paper-perou-molecular-portraits-breast-tumours-nature-2000","kind":"paper","name":"Molecular portraits of human breast tumours","route":"/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/","field":"links","label":"Nature 2000"}]},{"url":"https://doi.org/10.1038/35030148","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35030148","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"papers","label":"A chemical switch for inhibitor-sensitive alleles of any protein kinase"}]},{"url":"https://doi.org/10.1038/35042675","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35042675","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"papers","label":"Vogelstein, Lane and Levine 2000: surfing the p53 network"},{"id":"paper-vogelstein-surfing-p53-network-nature-2000","kind":"paper","name":"Vogelstein, Lane and Levine 2000: surfing the p53 network","route":"/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/35052073","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35052073","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/35074122","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35074122","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shankaran-nature","kind":"paper","name":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","route":"/key-papers/paper-shankaran-nature/","field":"links","label":"Nature 2001"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Shankaran et al., IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity (Nature 2001)"}]},{"url":"https://doi.org/10.1038/35102167","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/35102167","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"papers","label":"Reya 2001: stem cells, cancer and cancer stem cells"},{"id":"paper-reya-cancer-stem-cells-nature-2001","kind":"paper","name":"Reya 2001: stem cells, cancer and cancer stem cells","route":"/key-papers/paper-reya-cancer-stem-cells-nature-2001/","field":"links","label":"Full text (DOI)"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Reya, Morrison, Clarke and Weissman, Stem cells, cancer, and cancer stem cells (Nature 2001)"}]},{"url":"https://doi.org/10.1038/357128a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/357128a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","field":"papers","label":"ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex"}]},{"url":"https://doi.org/10.1038/359162a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/359162a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","field":"links","label":"Delattre 1992 (Nature)"},{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","field":"prevalence.source"},{"id":"paper-delattre-nature","kind":"paper","name":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","route":"/key-papers/paper-delattre-nature/","field":"links","label":"Nature 1992"}]},{"url":"https://doi.org/10.1038/367645a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/367645a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lapidot-nature","kind":"paper","name":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","route":"/key-papers/paper-lapidot-nature/","field":"links","label":"Nature 1994"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Lapidot et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice (Nature 1994)"}]},{"url":"https://doi.org/10.1038/386623a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/386623a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lengauer-genetic-instability-colorectal-nature-1997","kind":"paper","name":"Genetic instability in colorectal cancers","route":"/key-papers/paper-lengauer-genetic-instability-colorectal-nature-1997/","field":"links","label":"Lengauer, Kinzler and Vogelstein, Nature 1997: two distinct forms of genetic instability in colorectal cancer"}]},{"url":"https://doi.org/10.1038/386761a0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/386761a0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kinzler-nature","kind":"paper","name":"Cancer-susceptibility genes. Gatekeepers and caretakers","route":"/key-papers/paper-kinzler-nature/","field":"links","label":"Nature 1997"},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/","field":"links","label":"Kinzler & Vogelstein, Gatekeepers and caretakers (Nature 1997)"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"links","label":"Kinzler and Vogelstein, Gatekeepers and caretakers (Nature 1997)"}]},{"url":"https://doi.org/10.1038/453840a","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/453840a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"links","label":"Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"idea-moon-public-phase1-factory","kind":"idea","name":"A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials","route":"/ideas/idea-moon-public-phase1-factory/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"},{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/","field":"links","label":"Nature 2008"}]},{"url":"https://doi.org/10.1038/483531a","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/483531a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"links","label":"Begley & Ellis, Raise standards for preclinical cancer research (Nature 2012)"},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"metrics (Landmark preclinical cancer papers whose findings Amgen scientists could reproduce)"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"links","label":"Begley & Ellis, Raise standards for preclinical cancer research (Nature 2012)"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"metrics (Landmark preclinical cancer findings reproduced by Amgen)"},{"id":"paper-begley-nature","kind":"paper","name":"Drug development: Raise standards for preclinical cancer research","route":"/key-papers/paper-begley-nature/","field":"links","label":"Nature 2012"}]},{"url":"https://doi.org/10.1038/538161a","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/538161a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"metrics (Share of participants in genome-wide association studies of European ancestry (2016))"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"metrics (Share of genome-wide association study participants of European ancestry (2016))"}]},{"url":"https://doi.org/10.1038/77558","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm0700_821","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/","field":"links","label":"Nat Med 2000"}]},{"url":"https://doi.org/10.1038/ajg.2016.345","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajg/abstract/10.1038/ajg.2016.345~gallstones-and-the-risk-of-gallbladder-cancer-mortality-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Ryu, Am J Gastroenterol 2016: gallstones and gallbladder cancer mortality in 396,720 Koreans"}]},{"url":"https://doi.org/10.1038/ajg.2016.512","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajg/abstract/10.1038/ajg.2016.512~plastic-vs-self-expandable-metal-stents-for-palliation-in?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"links","label":"Almadi et al., plastic versus self-expandable metal stents for palliation in malignant biliary obstruction, meta-analyses (Am J Gastroenterol 2017)"},{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Almadi et al., plastic versus self-expandable metal stents for malignant biliary obstruction, meta-analyses (Am J Gastroenterol 2017)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Jaundice from a blocked bile duct: stent or bypass)"},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"Almadi et al., plastic versus self-expandable metal stents for palliation in malignant biliary obstruction, meta-analyses (Am J Gastroenterol 2017)"},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","field":"links","label":"Almadi et al., plastic versus self-expandable metal stents for palliation in malignant biliary obstruction, meta-analyses (Am J Gastroenterol 2017)"}]},{"url":"https://doi.org/10.1038/ajg.2017.218","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajg/abstract/10.1038/ajg.2017.218~chronic-pancreatitis-and-pancreatic-cancer-risk-a-systematic?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Kirkegard, Am J Gastroenterol 2017: chronic pancreatitis and pancreatic cancer risk, meta-analysis"}]},{"url":"https://doi.org/10.1038/aps.2014.18","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/aps201418","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-acta-pharmacol-sin-2015","kind":"paper","name":"Androgen receptor: structure, role in prostate cancer and drug discovery","route":"/key-papers/paper-androgen-receptor-prostate-acta-pharmacol-sin-2015/","field":"links","label":"Acta Pharmacol Sin 2015"}]},{"url":"https://doi.org/10.1038/bcj.2017.85","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bcj201785","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/","field":"links","label":"Blood Cancer J 2017"}]},{"url":"https://doi.org/10.1038/bjc.1954.1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc19541","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-armitage-br-j-cancer","kind":"paper","name":"The age distribution of cancer and a multi-stage theory of carcinogenesis","route":"/key-papers/paper-armitage-br-j-cancer/","field":"links","label":"Br J Cancer 1954"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"links","label":"Armitage and Doll, The age distribution of cancer and a multi-stage theory of carcinogenesis (British Journal of Cancer 1954)"}]},{"url":"https://doi.org/10.1038/bjc.1964.55","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fbjc196455&code=138b832a-5b98-4d30-951f-b61bd60d3f03","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-laird-br-j-cancer","kind":"paper","name":"DYNAMICS OF TUMOR GROWTH","route":"/key-papers/paper-laird-br-j-cancer/","field":"links","label":"Br J Cancer 1964"},{"id":"gompertzian-growth-model","kind":"technology","name":"Gompertzian tumour growth","route":"/technologies/gompertzian-growth-model/","field":"links","label":"Laird 1964, British Journal of Cancer"}]},{"url":"https://doi.org/10.1038/bjc.1997.343","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc1997343","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiotherapy-for-skin-cancer","kind":"term","name":"Radiotherapy for skin cancer","route":"/terms/radiotherapy-for-skin-cancer/","field":"links","label":"Surgery against radiotherapy in facial basal cell carcinoma (British Journal of Cancer 1997)"},{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"links","label":"Randomised comparison (British Journal of Cancer 1997)"},{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"outcomes.source (Actuarial failure rate at 4 years)"},{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"outcomes.source (Good cosmetic result, patient's assessment at 4 years)"}]},{"url":"https://doi.org/10.1038/bjc.2012.408","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc2012408","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Elliss-Brookes, Br J Cancer 2012: routes to diagnosis for cancer in England"},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"links","label":"Elliss-Brookes, Br J Cancer 2012: routes to diagnosis for cancer in England"}]},{"url":"https://doi.org/10.1038/bjc.2012.557","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc2012557","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"papers","label":"Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas"}]},{"url":"https://doi.org/10.1038/bjc.2013.650","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc2013650","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Copson, Br J Cancer 2014: ethnicity and outcome of young breast cancer patients in the UK (POSH)"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Copson, Br J Cancer 2014: ethnicity and outcome of young breast cancer patients in the UK (POSH)"},{"id":"paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014","kind":"paper","name":"Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study","route":"/key-papers/paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014/","field":"links","label":"Br J Cancer 2014"}]},{"url":"https://doi.org/10.1038/bjc.2014.418","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc2014418","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/","field":"links","label":"Golan et al., Br J Cancer 2014: 71 BRCA carriers with pancreatic cancer, platinum and survival"}]},{"url":"https://doi.org/10.1038/bjc.2015.308","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc2015308","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"papers","label":"Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma"}]},{"url":"https://doi.org/10.1038/bjc.2017.95","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/bjc201795","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"links","label":"Hurt et al., SCALOP long-term results (British Journal of Cancer 2017)"}]},{"url":"https://doi.org/10.1038/ctg.2016.18","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ctg/abstract/10.1038/ctg.2016.18~krasg12d-mutation-subtype-is-a-prognostic-factor-for?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016","kind":"paper","name":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","route":"/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/","field":"links","label":"Bournet et al., Clin Transl Gastroenterol 2016: KRAS G12D and prognosis in 219 advanced patients"}]},{"url":"https://doi.org/10.1038/d41573-022-00030-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/d41573-022-00030-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","field":"links","label":"Upadhaya et al., Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","field":"metrics (Clinical trials of PD-1/PD-L1 inhibitors registered by 2021, the large majority as combinations)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"links","label":"Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","field":"metrics (Clinical trials of PD-1/PD-L1 inhibitors registered by 2021)"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"metrics (Clinical trials of PD-1/PD-L1 inhibitors registered by 2021, mostly combinations and mostly within single-sponsor portfolios)"},{"id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","field":"links","label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)"},{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/","field":"links","label":"Nat Rev Drug Discov 2022"}]},{"url":"https://doi.org/10.1038/ejhg.2012.124","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ejhg2012124","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"links","label":"Laitman et al., The spectrum of BRCA1 c.68_69delAG haplotypes (Eur J Hum Genet 2013)"}]},{"url":"https://doi.org/10.1038/gim.2017.119","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1098360021018578","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"papers","label":"Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test"}]},{"url":"https://doi.org/10.1038/gt.2010.47","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/gt201047","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"papers","label":"Large animal models of hematopoietic stem cell gene therapy"}]},{"url":"https://doi.org/10.1038/ki.2012.169","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0085253815555701","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"papers","label":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C"}]},{"url":"https://doi.org/10.1038/leu.2010.69","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/leu201069","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","kind":"paper","name":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","route":"/key-papers/paper-jak2-myeloproliferative-neoplasms-leukemia-2010/","field":"links","label":"Leukemia 2010"}]},{"url":"https://doi.org/10.1038/modpathol.2012.204","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222022451","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"links","label":"Modern Pathology 2013: clear cell papillary renal cell carcinoma, 55 tumours, differential diagnosis and immunoprofile"}]},{"url":"https://doi.org/10.1038/modpathol.2013.106","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S089339522203006X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","field":"links","label":"Modern Pathology 2013: IgG4 expression in primary cutaneous marginal zone lymphomas"}]},{"url":"https://doi.org/10.1038/modpathol.2014.86","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222035025","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","field":"links","label":"Modern Pathology 2015: succinate dehydrogenase-deficient renal cell carcinoma, 11 tumours"}]},{"url":"https://doi.org/10.1038/modpathol.2015.98","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222013576","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/","field":"links","label":"Valtorta et al., Mod Pathol 2015: the HERACLES HER2 scoring criteria for colorectal cancer (256 plus 830 samples)"},{"id":"heracles-criteria","kind":"term","name":"HERACLES criteria (HER2 in bowel cancer)","route":"/terms/heracles-criteria/","field":"links","label":"Valtorta, Mod Pathol 2015: assessment of a HER2 scoring system for colorectal cancer, the HERACLES diagnostic criteria (256 and 830 tumours)"}]},{"url":"https://doi.org/10.1038/modpathol.2016.149","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222023365","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","field":"links","label":"Modern Pathology 2016: PD-L1 expression in 56 basaloid squamous cell lung carcinomas"}]},{"url":"https://doi.org/10.1038/modpathol.2016.239","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222022256","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","kind":"paper","name":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017/","field":"links","label":"Mod Pathol 2017"}]},{"url":"https://doi.org/10.1038/modpathol.2016.54","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222021329","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","field":"links","label":"Modern Pathology 2016: medullary carcinoma of the colon, immunoregulatory microenvironment in 105 cases"}]},{"url":"https://doi.org/10.1038/nature01322","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature01322","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-coussens-werb-inflammation-cancer-nature-2002","kind":"paper","name":"Coussens and Werb 2002: inflammation and cancer","route":"/key-papers/paper-coussens-werb-inflammation-cancer-nature-2002/","field":"links","label":"Full text (DOI)"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Coussens and Werb, Inflammation and cancer (Nature 2002)"}]},{"url":"https://doi.org/10.1038/nature01552","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature01552","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"papers","label":"Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis"}]},{"url":"https://doi.org/10.1038/nature02026","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature02026&code=6e13de06-1dbb-4285-9558-9acc2165eb99","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","field":"papers","label":"Global analysis of protein localization in budding yeast"}]},{"url":"https://doi.org/10.1038/nature02046","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature02046","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","field":"papers","label":"Global analysis of protein expression in yeast"}]},{"url":"https://doi.org/10.1038/nature02384","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature02384","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"papers","label":"Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria"}]},{"url":"https://doi.org/10.1038/nature03128","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature03128","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-singh-brain-tumour-initiating-cells-nature-2004","kind":"paper","name":"Singh 2004: identification of human brain tumour initiating cells","route":"/key-papers/paper-singh-brain-tumour-initiating-cells-nature-2004/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nature03445","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature03445","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"papers","label":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy"}]},{"url":"https://doi.org/10.1038/nature03669","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature03669","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-michor-nature","kind":"paper","name":"Dynamics of chronic myeloid leukaemia","route":"/key-papers/paper-michor-nature/","field":"links","label":"Nature 2005"},{"id":"mrd-kinetics-models","kind":"technology","name":"Residual disease kinetics (BCR-ABL halving and ctDNA slopes)","route":"/technologies/mrd-kinetics-models/","field":"links","label":"Michor and colleagues 2005, Nature"}]},{"url":"https://doi.org/10.1038/nature03799","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature03799&code=7b46b28d-8605-41dd-be9f-401e0cb27af2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-minn-nature","kind":"paper","name":"Genes that mediate breast cancer metastasis to lung","route":"/key-papers/paper-minn-nature/","field":"links","label":"Nature 2005"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Minn et al., Genes that mediate breast cancer metastasis to lung (Nature 2005)"}]},{"url":"https://doi.org/10.1038/nature03889","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature03889","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"papers","label":"Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism"}]},{"url":"https://doi.org/10.1038/nature04186","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature04186","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kaplan-nature","kind":"paper","name":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","route":"/key-papers/paper-kaplan-nature/","field":"links","label":"Nature 2005"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Kaplan et al., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche (Nature 2005)"}]},{"url":"https://doi.org/10.1038/nature04784","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature04784","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"papers","label":"Platensimycin is a selective FabF inhibitor with potent antibiotic properties"}]},{"url":"https://doi.org/10.1038/nature05236","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature05236","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bao-glioma-stem-cells-radioresistance-nature-2006","kind":"paper","name":"Bao 2006: glioma stem cells resist radiotherapy by activating the DNA damage response","route":"/key-papers/paper-bao-glioma-stem-cells-radioresistance-nature-2006/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nature05329","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature05329","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"papers","label":"Global variation in copy number in the human genome"}]},{"url":"https://doi.org/10.1038/nature05887","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature05887","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"papers","label":"Genome-wide association study identifies novel breast cancer susceptibility loci"}]},{"url":"https://doi.org/10.1038/nature05945","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature05945","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/","field":"links","label":"Nature 2007"},{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/","field":"links","label":"Soda et al., Nature 2007: identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer"}]},{"url":"https://doi.org/10.1038/nature06385","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature06385","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"papers","label":"Isolation of rare circulating tumour cells in cancer patients by microchip technology"}]},{"url":"https://doi.org/10.1038/nature07336","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature07336&code=082b599a-4c6f-4be1-ad41-3c6b276d4b69","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"papers","label":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes"}]},{"url":"https://doi.org/10.1038/nature07485","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature07485","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","field":"papers","label":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome"}]},{"url":"https://doi.org/10.1038/nature07567","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature07567","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-quintana-nature","kind":"paper","name":"Efficient tumour formation by single human melanoma cells","route":"/key-papers/paper-quintana-nature/","field":"links","label":"Nature 2008"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Quintana et al., Efficient tumour formation by single human melanoma cells (Nature 2008)"}]},{"url":"https://doi.org/10.1038/nature07935","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature07935","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sato-lgr5-organoids-nature-2009","kind":"paper","name":"Sato 2009: single Lgr5 stem cells build crypt-villus organoids","route":"/key-papers/paper-sato-lgr5-organoids-nature-2009/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nature07943","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature07943&code=5122c0b9-5394-4ce7-b35b-63038ef7c55a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stratton-nature","kind":"paper","name":"The cancer genome","route":"/key-papers/paper-stratton-nature/","field":"links","label":"Nature 2009"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"links","label":"Stratton, Campbell and Futreal, The cancer genome (Nature 2009)"}]},{"url":"https://doi.org/10.1038/nature08162","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature08162&code=d94ee1a0-4930-4720-a368-0fe3c9781945","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","field":"papers","label":"Distinctive chromatin in human sperm packages genes for embryo development"}]},{"url":"https://doi.org/10.1038/nature08460","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature08460","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","field":"links","label":"Barbie et al., ssGSEA introduced in Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 (Nature 2009)"}]},{"url":"https://doi.org/10.1038/nature09504","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature09504","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-filippakopoulos-nature","kind":"paper","name":"Selective inhibition of BET bromodomains","route":"/key-papers/paper-filippakopoulos-nature/","field":"links","label":"Nature 2010"},{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","field":"links","label":"Filippakopoulos 2010: BET inhibition in NUT carcinoma (Nature)"}]},{"url":"https://doi.org/10.1038/nature09515","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature09515","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010","kind":"paper","name":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","route":"/key-papers/paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010/","field":"links","label":"Yachida et al., Nature 2010: distant metastasis occurs late in the genetic evolution"}]},{"url":"https://doi.org/10.1038/nature10166","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature10166","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-ovarian-nature-2011","kind":"paper","name":"Integrated genomic analyses of ovarian carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-ovarian-nature-2011/","field":"links","label":"Nature 2011"}]},{"url":"https://doi.org/10.1038/nature10334","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature10334","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","field":"papers","label":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia"}]},{"url":"https://doi.org/10.1038/nature10730","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature10730","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","field":"papers","label":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer"}]},{"url":"https://doi.org/10.1038/nature10762","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature10762&code=c912d93b-7f72-4fad-90a2-ba8f1aad0a3a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-greaves-nature","kind":"paper","name":"Clonal evolution in cancer","route":"/key-papers/paper-greaves-nature/","field":"links","label":"Nature 2012"},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","field":"links","label":"Greaves and Maley, Clonal evolution in cancer (Nature 2012)"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Greaves and Maley, Clonal evolution in cancer (Nature 2012)"}]},{"url":"https://doi.org/10.1038/nature10933","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature10933","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shah-tnbc-clonal-evolution-nature-2012","kind":"paper","name":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","route":"/key-papers/paper-shah-tnbc-clonal-evolution-nature-2012/","field":"links","label":"Shah et al., Nature 2012: clonal and mutational evolution spectrum of 104 primary TNBCs"}]},{"url":"https://doi.org/10.1038/nature10983","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature10983","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"microarray-expression","kind":"term","name":"Microarray expression data","route":"/terms/microarray-expression/","field":"links","label":"Curtis et al., METABRIC: the genomic and transcriptomic architecture of 2,000 breast tumours (Nature 2012)"}]},{"url":"https://doi.org/10.1038/nature11003","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11003","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/","field":"links","label":"Barretina et al., The Cancer Cell Line Encyclopedia (Nature 2012)"}]},{"url":"https://doi.org/10.1038/nature11125","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11125","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/","field":"links","label":"Nature 2012"},{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/","field":"links","label":"Grasso et al., Nature 2012: the mutational landscape of lethal castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1038/nature11156","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11156","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/","field":"links","label":"Misale et al., Nature 2012: emergence of KRAS mutations and acquired resistance to anti-EGFR therapy"}]},{"url":"https://doi.org/10.1038/nature11219","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11219","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","kind":"paper","name":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","route":"/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/","field":"links","label":"Diaz et al., Nature 2012: the molecular evolution of acquired resistance to EGFR blockade (28 panitumumab patients)"}]},{"url":"https://doi.org/10.1038/nature11252","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11252","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","field":"links","label":"Cancer Genome Atlas Network, Nature 2012: comprehensive molecular characterisation of 276 colon and rectal cancers"},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/nature11282","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11282","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-seshagiri-rspo-fusions-colon-nature-2012","kind":"paper","name":"Recurrent R-spondin fusions in colon cancer","route":"/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/","field":"links","label":"Seshagiri et al., Nature 2012: recurrent R-spondin fusions in colon cancer (more than 70 tumour pairs)"},{"id":"rspo-fusion","kind":"term","name":"R-spondin fusion","route":"/terms/rspo-fusion/","field":"links","label":"Seshagiri, Nature 2012: recurrent R-spondin fusions in colon cancer"},{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/nature11404","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11404","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-squamous-nature-2012","kind":"paper","name":"Comprehensive genomic characterization of squamous cell lung cancers","route":"/key-papers/paper-tcga-lung-squamous-nature-2012/","field":"links","label":"Cancer Genome Atlas Research Network, Nature 2012: comprehensive genomic characterisation of 178 squamous cell lung cancers"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"TCGA 2012, Nature: comprehensive genomic characterisation of squamous cell lung cancers"}]},{"url":"https://doi.org/10.1038/nature11412","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11412","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cancer Genome Atlas Network, Nature 2012: comprehensive molecular portraits of human breast tumours"},{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"links","label":"Cancer Genome Atlas Network, Nature 2012: comprehensive molecular portraits of human breast tumours"},{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/","field":"links","label":"Cancer Genome Atlas Network, Nature 2012: comprehensive molecular portraits of human breast tumours"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"prevalence.source"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/nature11547","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature11547","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-biankin-pancreatic-exomes-axon-guidance-nature-2012","kind":"paper","name":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","route":"/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/","field":"links","label":"Biankin et al., Nature 2012: exomes of 99 early pancreatic cancers (APGI/ICGC)"}]},{"url":"https://doi.org/10.1038/nature12113","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature12113","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-endometrial-nature-2013","kind":"paper","name":"Integrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-endometrial-nature-2013/","field":"links","label":"Nature 2013"}]},{"url":"https://doi.org/10.1038/nature12213","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature12213","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"papers","label":"Mutational heterogeneity in cancer and the search for new cancer-associated genes"},{"id":"variant-calling","kind":"term","name":"Variant calling","route":"/terms/variant-calling/","field":"links","label":"Lawrence et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes (MutSigCV, Nature 2013)"},{"id":"mutsig","kind":"term","name":"MutSig (significantly mutated gene detection)","route":"/terms/mutsig/","field":"links","label":"Lawrence et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes (Nature 2013)"}]},{"url":"https://doi.org/10.1038/nature12634","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature12634","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","field":"metrics (TP53 mutation frequency across 12 major tumour types (TCGA pan-cancer))"}]},{"url":"https://doi.org/10.1038/nature12796","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature12796","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","field":"links","label":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable (Nature 2013)"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"papers","label":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions"},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","field":"papers","label":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable"},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1038/nature13038","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13038","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"papers","label":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia"}]},{"url":"https://doi.org/10.1038/nature13108","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13108","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mack-nature","kind":"paper","name":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy","route":"/key-papers/paper-mack-nature/","field":"links","label":"Nature 2014"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"links","label":"Mack et al., Epigenomic alterations define lethal CIMP-positive ependymomas of infancy (Nature 2014)"}]},{"url":"https://doi.org/10.1038/nature13385","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13385","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/","field":"links","label":"Cancer Genome Atlas Research Network, Nature 2014: comprehensive molecular profiling of 230 resected lung adenocarcinomas"}]},{"url":"https://doi.org/10.1038/nature13480","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13480","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tcga-gastric-nature-2014","kind":"paper","name":"Comprehensive molecular characterisation of gastric adenocarcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-gastric-nature-2014/","field":"links","label":"Nature 2014"}]},{"url":"https://doi.org/10.1038/nature13772","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13772","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"papers","label":"Synaptic, transcriptional and chromatin genes disrupted in autism"}]},{"url":"https://doi.org/10.1038/nature13954","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13954","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"papers","label":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge"},{"id":"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","kind":"paper","name":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","route":"/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nature13988","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature13988","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","field":"papers","label":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens"}]},{"url":"https://doi.org/10.1038/nature14129","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14129","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","field":"papers","label":"Comprehensive genomic characterization of head and neck squamous cell carcinomas"}]},{"url":"https://doi.org/10.1038/nature14136","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14136","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"papers","label":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex"}]},{"url":"https://doi.org/10.1038/nature14169","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14169","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-waddell-whole-genomes-pancreatic-nature-2015","kind":"paper","name":"Whole genomes redefine the mutational landscape of pancreatic cancer","route":"/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/","field":"links","label":"Nature 2015"}]},{"url":"https://doi.org/10.1038/nature14347","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14347","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015","kind":"paper","name":"The evolutionary history of lethal metastatic prostate cancer","route":"/key-papers/paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015/","field":"links","label":"Nature 2015"}]},{"url":"https://doi.org/10.1038/nature14404","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14404","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-spranger-nature","kind":"paper","name":"Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity","route":"/key-papers/paper-spranger-nature/","field":"links","label":"Nature 2015"},{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/","field":"links","label":"Spranger, Bao & Gajewski, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity (Nature 2015)"}]},{"url":"https://doi.org/10.1038/nature14664","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature14664","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/","field":"links","label":"Nature 2015"}]},{"url":"https://doi.org/10.1038/nature16965","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature16965","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"Bailey, Nature 2016: genomic analyses of 456 pancreatic cancers identify squamous, pancreatic progenitor, immunogenic and ADEX subtypes"},{"id":"paper-bailey-molecular-subtypes-pancreatic-nature-2016","kind":"paper","name":"Genomic analyses identify molecular subtypes of pancreatic cancer","route":"/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/","field":"links","label":"Nature 2016"}]},{"url":"https://doi.org/10.1038/nature17038","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature17038","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","field":"links","label":"Massagué & Obenauf, Metastatic colonization by circulating tumour cells (Nature 2016)"},{"id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/","field":"links","label":"Massague and Obenauf, Metastatic colonisation by circulating tumour cells (Nature 2016)"},{"id":"paper-massague-nature","kind":"paper","name":"Metastatic colonization by circulating tumour cells","route":"/key-papers/paper-massague-nature/","field":"links","label":"Nature 2016"},{"id":"intravasation-ctc-survival","kind":"pathway","name":"Intravasation & circulating tumour cells","route":"/pathways/intravasation-ctc-survival/","field":"links","label":"Massagué & Obenauf, Metastatic colonization by circulating tumour cells (Nature 2016)"}]},{"url":"https://doi.org/10.1038/nature17173","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature17173","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","field":"papers","label":"High-fat diet enhances stemness and tumorigenicity of intestinal progenitors"}]},{"url":"https://doi.org/10.1038/nature18268","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature18268","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-nature-2016","kind":"paper","name":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","route":"/key-papers/paper-chen-nature-2016/","field":"links","label":"Nature 2016"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/","field":"links","label":"Chen et al., Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer (Nature 2016)"}]},{"url":"https://doi.org/10.1038/nature18642","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature18642","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","field":"papers","label":"The genetic architecture of type 2 diabetes"}]},{"url":"https://doi.org/10.1038/nature19084","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature19084","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","field":"papers","label":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion"}]},{"url":"https://doi.org/10.1038/nature19823","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature19823","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-notta-punctuated-evolution-pancreatic-nature-2016","kind":"paper","name":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","route":"/key-papers/paper-notta-punctuated-evolution-pancreatic-nature-2016/","field":"links","label":"Notta et al., Nature 2016: a renewed, punctuated model of pancreatic cancer evolution"},{"id":"kras-allelic-imbalance","kind":"term","name":"KRAS allelic imbalance and mutant KRAS dosage in pancreatic cancer","route":"/terms/kras-allelic-imbalance/","field":"links","label":"Notta et al., Nature 2016: a renewed, punctuated model of pancreatic cancer evolution"}]},{"url":"https://doi.org/10.1038/nature20805","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature20805","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","field":"links","label":"The Cancer Genome Atlas: integrated genomic characterization of oesophageal carcinoma (Nature 2017)"},{"id":"paper-cancer-genome-atlas-research-nature","kind":"paper","name":"Integrated genomic characterization of oesophageal carcinoma","route":"/key-papers/paper-cancer-genome-atlas-research-nature/","field":"links","label":"Nature 2017"}]},{"url":"https://doi.org/10.1038/nature21056","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature21056","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dermoscopy-ai","kind":"technology","name":"Dermoscopy, total-body photography & AI skin analysis","route":"/technologies/dermoscopy-ai/","field":"links","label":"Esteva et al., Dermatologist-level classification of skin cancer with deep neural networks (Nature 2017)"},{"id":"paper-esteva-skin-cancer-deep-learning-nature-2017","kind":"paper","name":"Esteva 2017: a deep neural network classifies skin cancer at dermatologist level","route":"/key-papers/paper-esteva-skin-cancer-deep-learning-nature-2017/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nature21349","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature21349","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"links","label":"Chen & Mellman, Elements of cancer immunity and the cancer-immunity set point (Nature 2017)"},{"id":"paper-chen-nature","kind":"paper","name":"Elements of cancer immunity and the cancer-immune set point","route":"/key-papers/paper-chen-nature/","field":"links","label":"Nature 2017"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/","field":"links","label":"Chen & Mellman, Elements of cancer immunity and the cancer-immune set point (Nature 2017)"},{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/","field":"links","label":"Chen & Mellman, Elements of cancer immunity and the cancer-immune set point (Nature 2017)"}]},{"url":"https://doi.org/10.1038/nature21356","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature21356","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/","field":"links","label":"Turner et al., Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity (Nature 2017)"},{"id":"paper-turner-nature","kind":"paper","name":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","route":"/key-papers/paper-turner-nature/","field":"links","label":"Nature 2017"}]},{"url":"https://doi.org/10.1038/nature22071","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature22071&code=9c531f3b-b91a-4514-92cf-b4483a9a8554","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hayward-melanoma-whole-genome-nature-2017","kind":"paper","name":"Whole-genome landscapes of major melanoma subtypes","route":"/key-papers/paper-hayward-melanoma-whole-genome-nature-2017/","field":"links","label":"Nature 2017"}]},{"url":"https://doi.org/10.1038/nature22364","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature22364&code=aa6e4f8c-1e39-46f8-bde9-b4a84afbefcc","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017","kind":"paper","name":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","route":"/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/","field":"links","label":"Nature 2017"},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","field":"links","label":"Phylogenetic ctDNA analysis (Abbosh 2017)"}]},{"url":"https://doi.org/10.1038/nature23007","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature23007","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","field":"links","label":"Viswanathan et al., Dependency of a therapy-resistant state on a lipid peroxidase pathway (Nature 2017)"},{"id":"paper-viswanathan-nature","kind":"paper","name":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","route":"/key-papers/paper-viswanathan-nature/","field":"links","label":"Nature 2017"}]},{"url":"https://doi.org/10.1038/nature24297","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature24297","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/","field":"links","label":"Hangauer et al., Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition (Nature 2017)"},{"id":"paper-hangauer-nature","kind":"paper","name":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","route":"/key-papers/paper-hangauer-nature/","field":"links","label":"Nature 2017"}]},{"url":"https://doi.org/10.1038/nature24462","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature24462&code=55c4a413-e41c-4126-86b2-838e37167145","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","kind":"paper","name":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","route":"/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/","field":"links","label":"Balachandran et al., Nature 2017: neoantigen quality in long-term survivors"}]},{"url":"https://doi.org/10.1038/nature25183","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature25183","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herbst-nature","kind":"paper","name":"The biology and management of non-small cell lung cancer","route":"/key-papers/paper-herbst-nature/","field":"links","label":"Nature 2018"},{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","field":"links","label":"Review: The biology and management of non-small cell lung cancer"}]},{"url":"https://doi.org/10.1038/nature25432","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature25432","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","field":"links","label":"Bakhoum et al., Chromosomal instability drives metastasis through a cytosolic DNA response (Nature 2018)"},{"id":"paper-bakhoum-nature","kind":"paper","name":"Chromosomal instability drives metastasis through a cytosolic DNA response","route":"/key-papers/paper-bakhoum-nature/","field":"links","label":"Nature 2018"}]},{"url":"https://doi.org/10.1038/nature25492","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature25492","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","kind":"paper","name":"TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis","route":"/key-papers/paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018/","field":"links","label":"Tauriello et al., Nature 2018: TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis"},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/","field":"links","label":"Tauriello et al., TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis (Nature 2018)"}]},{"url":"https://doi.org/10.1038/nature25501","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nature25501","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/","field":"links","label":"Mariathasan et al., TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells (Nature 2018)"},{"id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/","field":"links","label":"Mariathasan et al., TGF-beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells (Nature 2018)"},{"id":"paper-mariathasan-nature","kind":"paper","name":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","route":"/key-papers/paper-mariathasan-nature/","field":"links","label":"Nature 2018"}]},{"url":"https://doi.org/10.1038/nbt.2287","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nbt.2287","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","kind":"paper","name":"Russell, Peng and Bell 2012: the field states its own problems","route":"/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/","field":"links","label":"Nat Biotechnol 2012"}]},{"url":"https://doi.org/10.1038/nbt.2647","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nbt.2647","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"papers","label":"DNA targeting specificity of RNA-guided Cas9 nucleases"}]},{"url":"https://doi.org/10.1038/nbt.2786","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nbt.2786","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"metrics (Oncology likelihood of approval from phase 1 (industry data 2003-2011), lowest of all disease areas)"}]},{"url":"https://doi.org/10.1038/nbt832","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nbt832","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-doronina-nat-biotechnol","kind":"paper","name":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","route":"/key-papers/paper-doronina-nat-biotechnol/","field":"links","label":"Nat Biotechnol 2003"},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","field":"links","label":"Monoclonal antibody auristatin (vc-MMAE) conjugates (Doronina et al., Nature Biotechnology 2003)"}]},{"url":"https://doi.org/10.1038/ncb3346","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ncb3346","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"papers","label":"Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal"}]},{"url":"https://doi.org/10.1038/nchembio.1548","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nchembio.1548","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"papers","label":"Multifaceted pathways protect human skin from UV radiation"}]},{"url":"https://doi.org/10.1038/ncomms13671","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ncomms13671","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","kind":"paper","name":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","route":"/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/","field":"links","label":"Taylor et al., Nat Commun 2017: genomes and methylomes of localised prostate cancer from 14 germline BRCA2 carriers, with microdissection of intraductal carcinoma"}]},{"url":"https://doi.org/10.1038/ncomms5988","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ncomms5988","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014","kind":"paper","name":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","route":"/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/","field":"links","label":"Pritchard et al., Nat Commun 2014: complex MSH2 and MSH6 rearrangements in hypermutated microsatellite-unstable advanced prostate cancer (60 cancers)"}]},{"url":"https://doi.org/10.1038/ncomms7744","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ncomms7744","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","kind":"paper","name":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","route":"/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/","field":"links","label":"Witkiewicz et al., Nat Commun 2015: exomes of 109 microdissected pancreatic cancers (UTSW)"}]},{"url":"https://doi.org/10.1038/ncomms8686","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ncomms8686","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sausen-ctdna-pancreatic-resection-nat-commun-2015","kind":"paper","name":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","route":"/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/","field":"links","label":"Sausen et al., Nat Commun 2015: tumour and circulating alterations in 101 patients"}]},{"url":"https://doi.org/10.1038/ncomms9971","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fncomms9971&code=ba3b3fad-3fa3-4762-963b-b7fe666705f0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tumour-purity","kind":"term","name":"Tumour purity","route":"/terms/tumour-purity/","field":"links","label":"Aran, Sirota and Butte, Systematic pan-cancer analysis of tumour purity (Nature Communications 2015)"}]},{"url":"https://doi.org/10.1038/ng.2279","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fng.2279&code=0b922e73-7b71-48c4-9ebd-6532f084023f","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012","kind":"paper","name":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","route":"/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/","field":"links","label":"Barbieri et al., Nat Genet 2012: exome sequencing of 112 prostate tumour and normal pairs identifies recurrent SPOP, FOXA1 and MED12 mutations"},{"id":"spop-mutation","kind":"biomarker","name":"SPOP mutation","route":"/biomarkers/spop-mutation/","field":"links","label":"Barbieri et al., Nat Genet 2012: exome sequencing of 112 prostate tumour and normal pairs identifies recurrent SPOP, FOXA1 and MED12 mutations"}]},{"url":"https://doi.org/10.1038/ng.2330","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.2330","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/ng.2503","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.2503","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-palles-germline-pole-pold1-proofreading-nat-genet-2013","kind":"paper","name":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","route":"/key-papers/paper-palles-germline-pole-pold1-proofreading-nat-genet-2013/","field":"links","label":"Palles et al., Nat Genet 2013: germline POLE and POLD1 proofreading-domain mutations predispose to colorectal adenomas and carcinomas"}]},{"url":"https://doi.org/10.1038/ng.2529","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.2529","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","field":"papers","label":"The genetic landscape of high-risk neuroblastoma"}]},{"url":"https://doi.org/10.1038/ng.283","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.283","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009","kind":"paper","name":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1","route":"/key-papers/paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009/","field":"links","label":"Ligtenberg et al., Nat Genet 2009: EPCAM (TACSTD1) 3' deletions silence MSH2 in Lynch syndrome"}]},{"url":"https://doi.org/10.1038/ng.2868","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.2868","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-brastianos-nat-genet","kind":"paper","name":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","route":"/key-papers/paper-brastianos-nat-genet/","field":"links","label":"Nat Genet 2014"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"links","label":"Brastianos 2014: exome sequencing of craniopharyngioma (Nature Genetics)"}]},{"url":"https://doi.org/10.1038/ng.3030","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fng.3030&code=3c460120-b40a-46da-a3f1-c2ae1c67dac1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/","field":"links","label":"Li et al., Nat Genet 2014: exome and targeted sequencing of 57 gallbladder carcinomas"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/ng.3095","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3095","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lee-prc2-mpnst-nat-genet-2014","kind":"paper","name":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumours","route":"/key-papers/paper-lee-prc2-mpnst-nat-genet-2014/","field":"links","label":"Nat Genet 2014"}]},{"url":"https://doi.org/10.1038/ng.3096","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3096","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","field":"papers","label":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands"},{"id":"paper-anthony-nichols-nat-genet-2014","kind":"paper","name":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","route":"/key-papers/paper-anthony-nichols-nat-genet-2014/","field":"links","label":"Nat Genet 2014"}]},{"url":"https://doi.org/10.1038/ng.3214","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3214","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sottoriva-nat-genet","kind":"paper","name":"A Big Bang model of human colorectal tumor growth","route":"/key-papers/paper-sottoriva-nat-genet/","field":"links","label":"Nat Genet 2015"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Sottoriva et al., A Big Bang model of human colorectal tumor growth (Nature Genetics 2015)"}]},{"url":"https://doi.org/10.1038/ng.3224","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3224","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015","kind":"paper","name":"Stromal contribution to the colorectal cancer transcriptome","route":"/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/","field":"links","label":"Isella et al., Nat Genet 2015: the stromal contribution to the colorectal cancer transcriptome"}]},{"url":"https://doi.org/10.1038/ng.3225","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3225","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015","kind":"paper","name":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","route":"/key-papers/paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015/","field":"links","label":"Calon et al., Nat Genet 2015: stromal gene expression defines the poor-prognosis subtypes of colorectal cancer"}]},{"url":"https://doi.org/10.1038/ng.3375","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3375","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nakamura-biliary-genomic-spectra-nat-genet-2015","kind":"paper","name":"Genomic spectra of biliary tract cancer","route":"/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/","field":"links","label":"Nakamura et al., Nat Genet 2015: genomic spectra of 260 biliary tract cancers"}]},{"url":"https://doi.org/10.1038/ng.3398","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3398","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"Moffitt, Nat Genet 2015: virtual microdissection identifies tumour-specific classical and basal-like subtypes and stromal subtypes"},{"id":"paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015","kind":"paper","name":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/","field":"links","label":"Nat Genet 2015"}]},{"url":"https://doi.org/10.1038/ng.3525","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fng.3525&code=ceeeb65b-16da-40b1-9395-218a1b0f0048","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","field":"links","label":"BCC genomics (Nat Genet 2016)"},{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","field":"prevalence.source"},{"id":"paper-bonilla-nat-genet","kind":"paper","name":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","route":"/key-papers/paper-bonilla-nat-genet/","field":"links","label":"Nat Genet 2016"}]},{"url":"https://doi.org/10.1038/ng.3564","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3564","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/","field":"links","label":"Campbell et al., Nat Genet 2016: distinct patterns of somatic genome alteration in 660 lung adenocarcinomas and 484 squamous cell carcinomas"}]},{"url":"https://doi.org/10.1038/ng.3757","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3757","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","field":"papers","label":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas"},{"id":"paper-anthony-nichols-nat-genet-2017","kind":"paper","name":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","route":"/key-papers/paper-anthony-nichols-nat-genet-2017/","field":"links","label":"Nat Genet 2017"}]},{"url":"https://doi.org/10.1038/ng.3764","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3764","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017","kind":"paper","name":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","route":"/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/","field":"links","label":"Makohon-Moore et al., Nat Genet 2017: limited driver heterogeneity among 26 metastases from four patients"}]},{"url":"https://doi.org/10.1038/ng.3774","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3774","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","field":"papers","label":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer"},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","field":"papers","label":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer"},{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","field":"links","label":"Griffith et al., CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer (Nature Genetics 2017)"},{"id":"paper-griffith-nat-genet","kind":"paper","name":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","route":"/key-papers/paper-griffith-nat-genet/","field":"links","label":"Nat Genet 2017"}]},{"url":"https://doi.org/10.1038/ng.3984","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.3984","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","field":"links","label":"CRISPR-based DepMap (Meyers 2017)"}]},{"url":"https://doi.org/10.1038/ng.438","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.438","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"erbb4","kind":"target","name":"HER4 (ERBB4)","route":"/targets/erbb4/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/ng.619","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.619","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","field":"links","label":"Liposarcoma genomics (Nat Genet 2010)"},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","field":"prevalence.source"},{"id":"paper-barretina-nat-genet","kind":"paper","name":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","route":"/key-papers/paper-barretina-nat-genet/","field":"links","label":"Nat Genet 2010"}]},{"url":"https://doi.org/10.1038/ng.763","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng.763","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"papers","label":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia"}]},{"url":"https://doi.org/10.1038/ng0197-95","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng0197-95","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997","kind":"paper","name":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with COL1A1 in dermatofibrosarcoma protuberans","route":"/key-papers/paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997/","field":"links","label":"Nat Genet 1997"}]},{"url":"https://doi.org/10.1038/ng0495-401","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng0495-401","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-visakorpi-androgen-receptor-amplification-nat-genet-1995","kind":"paper","name":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","route":"/key-papers/paper-visakorpi-androgen-receptor-amplification-nat-genet-1995/","field":"links","label":"Nat Genet 1995"},{"id":"ar-amplification","kind":"biomarker","name":"AR amplification (gene and upstream enhancer)","route":"/biomarkers/ar-amplification/","field":"links","label":"Visakorpi et al., Nat Genet 1995: in vivo amplification of the androgen receptor gene in tumours recurring on androgen deprivation (23 recurrent tumours)"}]},{"url":"https://doi.org/10.1038/ng0894-502","status":200,"ok":true,"finalUrl":"https://idp.nature.com/authorize?response_type=cookie&client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fng0894-502","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994","kind":"paper","name":"Identification of SYT and SSX, the genes fused by the t(X;18) translocation in synovial sarcoma","route":"/key-papers/paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994/","field":"links","label":"Nat Genet 1994"}]},{"url":"https://doi.org/10.1038/ng1048","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng1048z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"Carpten 2002, Nature Genetics: HRPT2 (CDC73), encoding parafibromin, is mutated in HPT-JT"}]},{"url":"https://doi.org/10.1038/ng1083","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng1083z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-tonon-crtc1-maml2-nat-genet-2003","kind":"paper","name":"The t(11;19) translocation in mucoepidermoid carcinoma creates a CRTC1-MAML2 fusion","route":"/key-papers/paper-tonon-crtc1-maml2-nat-genet-2003/","field":"links","label":"Nat Genet 2003"}]},{"url":"https://doi.org/10.1038/ng1096-185","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng1096-185","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"links","label":"Roa, Nat Genet 1996: Ashkenazi Jewish population frequencies for the common BRCA1 and BRCA2 mutations"}]},{"url":"https://doi.org/10.1038/ng1834","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ng1834","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006","kind":"paper","name":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","route":"/key-papers/paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006/","field":"links","label":"Weisenberger et al., Nat Genet 2006: CIMP underlies sporadic microsatellite instability and tracks BRAF mutation (295 tumours)"},{"id":"cimp","kind":"term","name":"CpG island methylator phenotype (CIMP)","route":"/terms/cimp/","field":"links","label":"Weisenberger, Nat Genet 2006: the CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation (295 tumours)"}]},{"url":"https://doi.org/10.1038/ni.1774","status":200,"ok":true,"finalUrl":"https://idp.nature.com/authorize?response_type=cookie&client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fni.1774","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"papers","label":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo"}]},{"url":"https://doi.org/10.1038/ni1102-991","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/ni1102-991","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dunn-nat-immunol","kind":"paper","name":"Cancer immunoediting: from immunosurveillance to tumor escape","route":"/key-papers/paper-dunn-nat-immunol/","field":"links","label":"Nat Immunol 2002"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"links","label":"Dunn et al., Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology 2002)"}]},{"url":"https://doi.org/10.1038/nm.1944","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.1944","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"papers","label":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer"}]},{"url":"https://doi.org/10.1038/nm.2328","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.2328","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bissell-nat-med","kind":"paper","name":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression","route":"/key-papers/paper-bissell-nat-med/","field":"links","label":"Nat Med 2011"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"links","label":"Bissell and Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression (Nature Medicine 2011)"}]},{"url":"https://doi.org/10.1038/nm.2344","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.2344","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"Collisson, Nat Med 2011: subtypes of pancreatic ductal adenocarcinoma (classical, quasimesenchymal, exocrine-like) and their responses to therapy"},{"id":"paper-collisson-pancreatic-subtypes-nat-med-2011","kind":"paper","name":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","route":"/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/","field":"links","label":"Collisson et al., Nat Med 2011: classical, quasi-mesenchymal and exocrine-like subtypes"}]},{"url":"https://doi.org/10.1038/nm.2554","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.2554","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","route":"/ideas/idea-photoimmunotherapy-plus-pd1/","field":"links","label":"Mitsunaga et al., Cancer cell-selective in vivo near-infrared photoimmunotherapy (Nature Medicine 2011)"},{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/","field":"links","label":"Nat Med 2011"}]},{"url":"https://doi.org/10.1038/nm.3394","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.3394","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","field":"papers","label":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis"},{"id":"paper-quail-joyce-microenvironment-metastasis-natmed-2013","kind":"paper","name":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis","route":"/key-papers/paper-quail-joyce-microenvironment-metastasis-natmed-2013/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nm.3519","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.3519","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"papers","label":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage"}]},{"url":"https://doi.org/10.1038/nm.3854","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnm.3854&code=0f181659-b7c3-426d-b5f8-1564ce423582","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","field":"links","label":"Thress et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 (Nature Medicine 2015)"},{"id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","field":"links","label":"Thress et al., Nat Med 2015: acquired EGFR C797S mediates resistance to osimertinib in T790M-positive lung cancer"},{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/","field":"links","label":"Nat Med 2015"}]},{"url":"https://doi.org/10.1038/nm.3967","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.3967","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","field":"links","label":"The consensus molecular subtypes of colorectal cancer (Guinney et al., Nature Medicine 2015)"},{"id":"immunoscore","kind":"term","name":"Immunoscore","route":"/terms/immunoscore/","field":"links","label":"Guinney, Nat Med 2015: the consensus molecular subtypes of colorectal cancer"},{"id":"rspo-fusion","kind":"term","name":"R-spondin fusion","route":"/terms/rspo-fusion/","field":"links","label":"Guinney, Nat Med 2015: the consensus molecular subtypes of colorectal cancer"},{"id":"paper-cms-guinney-nat-med-2015","kind":"paper","name":"The consensus molecular subtypes of colorectal cancer","route":"/key-papers/paper-cms-guinney-nat-med-2015/","field":"links","label":"Nat Med 2015"}]},{"url":"https://doi.org/10.1038/nm.4045","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4045","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nepc-transformation","kind":"biomarker","name":"Treatment-emergent neuroendocrine transformation (recognising it)","route":"/biomarkers/nepc-transformation/","field":"links","label":"Beltran et al., Nat Med 2016: divergent clonal evolution of castration-resistant neuroendocrine prostate cancer (114 samples)"},{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/","field":"links","label":"Nat Med 2016"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"links","label":"Beltran et al., Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer (Nat Med 2016)"}]},{"url":"https://doi.org/10.1038/nm.4053","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4053","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","kind":"paper","name":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","route":"/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/","field":"links","label":"Kumar et al., Nat Med 2016: multiple metastases per man show limited within-patient and substantial between-patient genomic diversity in disseminated prostate cancer"}]},{"url":"https://doi.org/10.1038/nm.4292","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4292","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-davies-nat-med","kind":"paper","name":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","route":"/key-papers/paper-davies-nat-med/","field":"links","label":"Nat Med 2017"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","field":"links","label":"Nature Medicine 2017: HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures"}]},{"url":"https://doi.org/10.1038/nm.4333","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4333","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","field":"papers","label":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients"}]},{"url":"https://doi.org/10.1038/nm.4407","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4407","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1-NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/","field":"links","label":"Romero et al., Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis (Nature Medicine 2017)"},{"id":"paper-romero-nat-med","kind":"paper","name":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","route":"/key-papers/paper-romero-nat-med/","field":"links","label":"Nat Med 2017"}]},{"url":"https://doi.org/10.1038/nm.4409","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4409","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-batlle-nat-med","kind":"paper","name":"Cancer stem cells revisited","route":"/key-papers/paper-batlle-nat-med/","field":"links","label":"Nat Med 2017"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Batlle and Clevers, Cancer stem cells revisited (Nature Medicine 2017)"}]},{"url":"https://doi.org/10.1038/nm.4439","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4439","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","kind":"paper","name":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","route":"/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/","field":"links","label":"Nat Med 2018"}]},{"url":"https://doi.org/10.1038/nm.4441","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4441","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"papers","label":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy"}]},{"url":"https://doi.org/10.1038/nm0797-730","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm0797-730","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"papers","label":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell"},{"id":"paper-bonnet-nat-med","kind":"paper","name":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","route":"/key-papers/paper-bonnet-nat-med/","field":"links","label":"Nat Med 1997"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Bonnet and Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell (Nature Medicine 1997)"}]},{"url":"https://doi.org/10.1038/nm0909-1010","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm0909-1010","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gupta-nat-med","kind":"paper","name":"Cancer stem cells: mirage or reality?","route":"/key-papers/paper-gupta-nat-med/","field":"links","label":"Nat Med 2009"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"links","label":"Gupta, Chaffer and Weinberg, Cancer stem cells: mirage or reality? (Nature Medicine 2009)"}]},{"url":"https://doi.org/10.1038/nm972","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm972","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","kind":"paper","name":"Molecular determinants of resistance to antiandrogen therapy","route":"/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/","field":"links","label":"Nat Med 2004"}]},{"url":"https://doi.org/10.1038/nmeth.2329","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nmeth.2329","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/","field":"links","label":"Method of the Year 2012: targeted proteomics (Nature Methods 2013)"},{"id":"paper-authors-nat-methods","kind":"paper","name":"Method of the Year 2012","route":"/key-papers/paper-authors-nat-methods/","field":"links","label":"Nat Methods 2013"}]},{"url":"https://doi.org/10.1038/nmeth.4197","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nmeth.4197","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tpm-fpkm-counts","kind":"term","name":"TPM, FPKM and raw counts (expression units)","route":"/terms/tpm-fpkm-counts/","field":"links","label":"Salmon: fast and bias-aware quantification of transcript expression (Nature Methods 2017)"},{"id":"star-salmon","kind":"term","name":"STAR and Salmon (RNA-seq alignment and quantification)","route":"/terms/star-salmon/","field":"links","label":"Patro et al., Salmon (Nature Methods 2017)"}]},{"url":"https://doi.org/10.1038/npjgenmed.2015.12","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/npjgenmed201512","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"papers","label":"Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine"}]},{"url":"https://doi.org/10.1038/nprot.2009.97","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nprot.2009.97","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"papers","label":"Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt"}]},{"url":"https://doi.org/10.1038/nrc.2015.5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2015.5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-morvan-nat-rev-cancer","kind":"paper","name":"NK cells and cancer: you can teach innate cells new tricks","route":"/key-papers/paper-morvan-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/","field":"links","label":"Morvan & Lanier, NK cells and cancer: you can teach innate cells new tricks (Nat Rev Cancer 2016)"}]},{"url":"https://doi.org/10.1038/nrc.2016.25","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2016.25","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"links","label":"Steeg, Targeting metastasis (Nature Reviews Cancer 2016)"},{"id":"paper-steeg-nat-rev-cancer","kind":"paper","name":"Targeting metastasis","route":"/key-papers/paper-steeg-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"}]},{"url":"https://doi.org/10.1038/nrc.2016.37","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2016.37","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shain-nat-rev-cancer","kind":"paper","name":"From melanocytes to melanomas","route":"/key-papers/paper-shain-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"},{"id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","field":"links","label":"Review: From melanocytes to melanomas"}]},{"url":"https://doi.org/10.1038/nrc.2016.71","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2016.71","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-altman-nat-rev-cancer","kind":"paper","name":"From Krebs to clinic: glutamine metabolism to cancer therapy","route":"/key-papers/paper-altman-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"},{"id":"glutamine-metabolism","kind":"pathway","name":"Glutamine addiction","route":"/pathways/glutamine-metabolism/","field":"links","label":"Altman, Stine & Dang, From Krebs to clinic: glutamine metabolism to cancer therapy (Nat Rev Cancer 2016)"}]},{"url":"https://doi.org/10.1038/nrc.2016.73","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2016.73","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kalluri-nat-rev-cancer","kind":"paper","name":"The biology and function of fibroblasts in cancer","route":"/key-papers/paper-kalluri-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"},{"id":"caf-activation-desmoplasia","kind":"pathway","name":"Fibroblast activation, desmoplasia & matrix stiffness","route":"/pathways/caf-activation-desmoplasia/","field":"links","label":"Kalluri, The biology and function of fibroblasts in cancer (Nat Rev Cancer 2016)"}]},{"url":"https://doi.org/10.1038/nrc.2016.89","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2016.89","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rohrig-nat-rev-cancer","kind":"paper","name":"The multifaceted roles of fatty acid synthesis in cancer","route":"/key-papers/paper-rohrig-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2016"},{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/","field":"links","label":"Röhrig & Schulze, The multifaceted roles of fatty acid synthesis in cancer (Nat Rev Cancer 2016)"}]},{"url":"https://doi.org/10.1038/nrc.2017.36","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2017.36","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","field":"links","label":"Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-mutant-p53-degrader","kind":"idea","name":"Degrade the damaged p53 protein rather than trying to repair it","route":"/ideas/idea-bio1-mutant-p53-degrader/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-covalent-ligandability-atlas","kind":"idea","name":"An open map of which cancer proteins any drug can stick to","route":"/ideas/idea-bio1-covalent-ligandability-atlas/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-condensate-disruptors","kind":"idea","name":"Break up the liquid droplets where oncogenic transcription happens","route":"/ideas/idea-bio1-condensate-disruptors/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-lytac-surface-degraders","kind":"idea","name":"Drag cancer's surface and secreted proteins to the cell's recycling bin","route":"/ideas/idea-bio1-lytac-surface-degraders/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-rna-targeting-small-molecules","kind":"idea","name":"Small molecules that cut the RNA message of an undruggable oncogene","route":"/ideas/idea-bio1-rna-targeting-small-molecules/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-paralog-synthetic-lethality","kind":"idea","name":"Attack the backup copy when a tumour has lost the original gene","route":"/ideas/idea-bio1-paralog-synthetic-lethality/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-pp2a-activators","kind":"idea","name":"Turn a brake back on: drugs that reactivate the PP2A phosphatase","route":"/ideas/idea-bio1-pp2a-activators/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-wrn-msi-programme","kind":"idea","name":"WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers","route":"/ideas/idea-bio1-wrn-msi-programme/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-mrna-intrabodies","kind":"idea","name":"Instruct tumour cells to make antibodies against their own oncoprotein","route":"/ideas/idea-bio1-mrna-intrabodies/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"idea-bio1-undruggable-market-commitment","kind":"idea","name":"A guaranteed purchase prize for the first drug against a named hard target","route":"/ideas/idea-bio1-undruggable-market-commitment/","field":"links","label":"Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017)"},{"id":"paper-dang-nat-rev-cancer","kind":"paper","name":"Drugging the 'undruggable' cancer targets","route":"/key-papers/paper-dang-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2017"}]},{"url":"https://doi.org/10.1038/nrc.2017.6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc.2017.6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-peinado-nat-rev-cancer","kind":"paper","name":"Pre-metastatic niches: organ-specific homes for metastases","route":"/key-papers/paper-peinado-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2017"},{"id":"pre-metastatic-niche","kind":"pathway","name":"The pre-metastatic niche","route":"/pathways/pre-metastatic-niche/","field":"links","label":"Peinado et al., Pre-metastatic niches: organ-specific homes for metastases (Nat Rev Cancer 2017)"}]},{"url":"https://doi.org/10.1038/nrc1093","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc1093","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bergers-nat-rev-cancer","kind":"paper","name":"Tumorigenesis and the angiogenic switch","route":"/key-papers/paper-bergers-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2003"},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/","field":"links","label":"Bergers & Benjamin, Tumorigenesis and the angiogenic switch (Nat Rev Cancer 2003)"}]},{"url":"https://doi.org/10.1038/nrc1098","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc1098","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fidler-nat-rev-cancer","kind":"paper","name":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited","route":"/key-papers/paper-fidler-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2003"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"links","label":"Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited (Nature Reviews Cancer 2003)"}]},{"url":"https://doi.org/10.1038/nrc1429","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc1429","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004","kind":"paper","name":"Gallbladder cancer: lessons from a rare tumour","route":"/key-papers/paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004/","field":"links","label":"Nat Rev Cancer 2004"}]},{"url":"https://doi.org/10.1038/nrc1567","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc1567","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ren-nat-rev-cancer","kind":"paper","name":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","route":"/key-papers/paper-ren-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2005"},{"id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","field":"links","label":"Review: Mechanisms of BCR-ABL in the pathogenesis of CML"}]},{"url":"https://doi.org/10.1038/nrc1997","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc1997","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-calin-nat-rev-cancer","kind":"paper","name":"MicroRNA signatures in human cancers","route":"/key-papers/paper-calin-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2006"},{"id":"micrornas-in-cancer","kind":"pathway","name":"MicroRNAs in cancer","route":"/pathways/micrornas-in-cancer/","field":"links","label":"Review: MicroRNA signatures in human cancers"}]},{"url":"https://doi.org/10.1038/nrc2013","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2013","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-merlo-nat-rev-cancer","kind":"paper","name":"Cancer as an evolutionary and ecological process","route":"/key-papers/paper-merlo-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2006"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Merlo, Pepper, Reid and Maley, Cancer as an evolutionary and ecological process (Nature Reviews Cancer 2006)"}]},{"url":"https://doi.org/10.1038/nrc2210","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2210","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007","kind":"paper","name":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","route":"/key-papers/paper-jak2-polycythaemia-vera-nat-rev-cancer-2007/","field":"links","label":"Nat Rev Cancer 2007"}]},{"url":"https://doi.org/10.1038/nrc2503","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2503","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-epstein-nat-rev-cancer","kind":"paper","name":"Basal cell carcinomas: attack of the hedgehog","route":"/key-papers/paper-epstein-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2008"},{"id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","field":"links","label":"Review: Basal cell carcinomas, attack of the hedgehog"}]},{"url":"https://doi.org/10.1038/nrc2602","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2602","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-malumbres-nat-rev-cancer","kind":"paper","name":"Cell cycle, CDKs and cancer: a changing paradigm","route":"/key-papers/paper-malumbres-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2009"},{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/","field":"links","label":"Malumbres & Barbacid, Cell cycle, CDKs and cancer: a changing paradigm (Nat Rev Cancer 2009)"}]},{"url":"https://doi.org/10.1038/nrc2827","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2827","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lazebnik-nat-rev-cancer","kind":"paper","name":"What are the hallmarks of cancer?","route":"/key-papers/paper-lazebnik-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2010"},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","field":"links","label":"Lazebnik, What are the hallmarks of cancer? (Nature Reviews Cancer 2010)"}]},{"url":"https://doi.org/10.1038/nrc2943","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc2943","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rara","kind":"target","name":"Retinoic acid receptor alpha (RARA)","route":"/targets/rara/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/nrc3130","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3130","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"papers","label":"A decade of exploring the cancer epigenome — biological and translational implications"}]},{"url":"https://doi.org/10.1038/nrc3162","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3162","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-glunde-nat-rev-cancer","kind":"paper","name":"Choline metabolism in malignant transformation","route":"/key-papers/paper-glunde-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2011"},{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","field":"links","label":"Review: Choline metabolism in malignant transformation"}]},{"url":"https://doi.org/10.1038/nrc3239","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3239","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"papers","label":"The blockade of immune checkpoints in cancer immunotherapy"},{"id":"paper-pardoll-immune-checkpoint-blockade-nrc-2012","kind":"paper","name":"Pardoll 2012: the blockade of immune checkpoints in cancer immunotherapy","route":"/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nrc3712","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3712","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-korolev-nat-rev-cancer","kind":"paper","name":"Turning ecology and evolution against cancer","route":"/key-papers/paper-korolev-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2014"},{"id":"evolutionary-game-theory-cancer","kind":"technology","name":"Evolutionary game theory in cancer","route":"/technologies/evolutionary-game-theory-cancer/","field":"links","label":"Korolev, Xavier and Gore 2014, Nature Reviews Cancer"}]},{"url":"https://doi.org/10.1038/nrc3793","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3793","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-dormancy-maintenance-therapy","kind":"idea","name":"Keep them asleep: dormancy maintenance as adjuvant therapy","route":"/ideas/idea-dormancy-maintenance-therapy/","field":"links","label":"Sosa, Bragado and Aguirre-Ghiso, Mechanisms of disseminated cancer cell dormancy: an awakening field (Nature Reviews Cancer 2014)"},{"id":"paper-sosa-nat-rev-cancer","kind":"paper","name":"Mechanisms of disseminated cancer cell dormancy: an awakening field","route":"/key-papers/paper-sosa-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2014"}]},{"url":"https://doi.org/10.1038/nrc3817","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3817","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-knowles-nat-rev-cancer","kind":"paper","name":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","route":"/key-papers/paper-knowles-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2015"},{"id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/","field":"links","label":"Review: Molecular biology of bladder cancer"}]},{"url":"https://doi.org/10.1038/nrc3829","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3829","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","field":"metrics (Share of cancer deaths in which cachexia is the immediate cause (estimate))"}]},{"url":"https://doi.org/10.1038/nrc3846","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3846","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-murray-nat-rev-cancer","kind":"paper","name":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","route":"/key-papers/paper-murray-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2014"},{"id":"chemical-carcinogenesis-receptor-activation","kind":"pathway","name":"Chemical carcinogenesis - receptor activation","route":"/pathways/chemical-carcinogenesis-receptor-activation/","field":"links","label":"Review: Aryl hydrocarbon receptor ligands in cancer, friend and foe"}]},{"url":"https://doi.org/10.1038/nrc3896","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc3896","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Dietze, Nat Rev Cancer 2015: triple-negative breast cancer in African-American women, disparities versus biology"}]},{"url":"https://doi.org/10.1038/nrc4016","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc4016","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-nat-rev-cancer-2015","kind":"paper","name":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-nat-rev-cancer-2015/","field":"links","label":"Nat Rev Cancer 2015"},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","field":"links","label":"Review: Emerging mechanisms of resistance to AR inhibitors in prostate cancer"}]},{"url":"https://doi.org/10.1038/nrc822","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc822","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-thiery-emt-tumour-progression-nrc-2002","kind":"paper","name":"Thiery 2002: epithelial-mesenchymal transitions in tumour progression","route":"/key-papers/paper-thiery-emt-tumour-progression-nrc-2002/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nrclinonc.2017.31","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrclinonc.2017.31","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"links","label":"Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-io-subscription-national","kind":"idea","name":"Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use","route":"/ideas/idea-reg-io-subscription-national/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-public-deescalation-trials-for-cost","kind":"idea","name":"Publicly funded trials of lower and less frequent doses of expensive cancer drugs","route":"/ideas/idea-reg-public-deescalation-trials-for-cost/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-net-price-transparency-registry","kind":"idea","name":"An international registry of real (net) cancer drug prices paid by public payers","route":"/ideas/idea-reg-net-price-transparency-registry/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-rd-cost-disclosure-condition","kind":"idea","name":"Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage","route":"/ideas/idea-reg-rd-cost-disclosure-condition/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-provisional-price-until-os","kind":"idea","name":"Provisional prices for surrogate-endpoint approvals, reset when survival data arrive","route":"/ideas/idea-reg-provisional-price-until-os/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-patent-buyout-prize","kind":"idea","name":"Buy out the patent on a curative cancer drug and sell it at generic prices","route":"/ideas/idea-reg-patent-buyout-prize/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-secondary-patent-thicket-limits","kind":"idea","name":"Limit secondary patents and pay-for-delay so cancer generics arrive on time","route":"/ideas/idea-reg-secondary-patent-thicket-limits/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-middle-income-negotiation-bloc","kind":"idea","name":"A joint price negotiation bloc for middle-income countries, modelled on Beneluxa","route":"/ideas/idea-reg-middle-income-negotiation-bloc/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-tiered-pricing-for-exclusivity","kind":"idea","name":"Grant extra exclusivity only in exchange for binding low prices in poorer countries","route":"/ideas/idea-reg-tiered-pricing-for-exclusivity/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","route":"/ideas/idea-reg-biosimilar-first-default-switching/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-annuity-payment-durable-therapies","kind":"idea","name":"Pay for one-time curative therapies as an annuity that stops at relapse","route":"/ideas/idea-reg-annuity-payment-durable-therapies/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-social-impact-bond-switching","kind":"idea","name":"Social impact bonds that fund biosimilar switching, repaid from payer savings","route":"/ideas/idea-reg-social-impact-bond-switching/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-reg-market-expansion-repricing","kind":"idea","name":"Automatic price cuts when a cancer drug's approved indications and volumes expand","route":"/ideas/idea-reg-market-expansion-repricing/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-moon-pay-for-cure-contracts","kind":"idea","name":"Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission","route":"/ideas/idea-moon-pay-for-cure-contracts/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","field":"links","label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)"},{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/","field":"links","label":"Nat Rev Clin Oncol 2017"}]},{"url":"https://doi.org/10.1038/nrd.2016.213","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrd.2016.213","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","field":"links","label":"Goodnow et al., DNA-encoded chemistry: enabling the deeper sampling of chemical space (Nature Reviews Drug Discovery 2016)"},{"id":"paper-goodnow-nat-rev-drug-discov","kind":"paper","name":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","route":"/key-papers/paper-goodnow-nat-rev-drug-discov/","field":"links","label":"Nat Rev Drug Discov 2017"}]},{"url":"https://doi.org/10.1038/nrd.2016.253","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnrd.2016.253&code=20d32d51-7e65-4790-87e1-fb297b5f75fe","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bcl-2-cll-nat-rev-drug-discov-2017","kind":"paper","name":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","route":"/key-papers/paper-bcl-2-cll-nat-rev-drug-discov-2017/","field":"links","label":"Nat Rev Drug Discov 2017"}]},{"url":"https://doi.org/10.1038/nrdp.2015.17","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrdp201517","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weller-nat-rev-dis-primers","kind":"paper","name":"Glioma","route":"/key-papers/paper-weller-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2015"},{"id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/","field":"links","label":"Review: Glioma (Nature Reviews Disease Primers)"}]},{"url":"https://doi.org/10.1038/nrdp.2016.18","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrdp201618","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","field":"papers","label":"Hepatocellular carcinoma"}]},{"url":"https://doi.org/10.1038/nrdp.2016.22","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrdp201622","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2016"},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","field":"links","label":"Review: Pancreatic cancer (Nature Reviews Disease Primers)"}]},{"url":"https://doi.org/10.1038/nrdp.2017.9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrdp20179","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2017"},{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","field":"links","label":"Review: Renal cell carcinoma (Nat Rev Dis Primers 2017)"}]},{"url":"https://doi.org/10.1038/nrendo.2014.21","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrendo.2014.21","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","field":"links","label":"Giustina 2014, Nature Reviews Endocrinology: consensus on the medical treatment of acromegaly"}]},{"url":"https://doi.org/10.1038/nrg.2016.13","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrg.2016.13","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet","kind":"paper","name":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","route":"/key-papers/paper-feinberg-nat-rev-genet/","field":"links","label":"Nat Rev Genet 2016"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"links","label":"Feinberg, Koldobskiy and Göndör, Epigenetic modulators, modifiers and mediators in cancer aetiology and progression (Nature Reviews Genetics 2016)"}]},{"url":"https://doi.org/10.1038/nrg1748","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrg1748","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-feinberg-nat-rev-genet-2006","kind":"paper","name":"The epigenetic progenitor origin of human cancer","route":"/key-papers/paper-feinberg-nat-rev-genet-2006/","field":"links","label":"Nat Rev Genet 2006"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"links","label":"Feinberg, Ohlsson and Henikoff, The epigenetic progenitor origin of human cancer (Nature Reviews Genetics 2006)"}]},{"url":"https://doi.org/10.1038/nrg2380","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrg2380","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-caldecott-nat-rev-genet","kind":"paper","name":"Single-strand break repair and genetic disease","route":"/key-papers/paper-caldecott-nat-rev-genet/","field":"links","label":"Nat Rev Genet 2008"},{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/","field":"links","label":"Caldecott, Single-strand break repair and genetic disease (Nat Rev Genet 2008)"}]},{"url":"https://doi.org/10.1038/nri3660","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnri3660&code=1b29ddb3-c5b6-4cbf-a015-71ae906c7f6b","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"papers","label":"Emergency granulopoiesis"}]},{"url":"https://doi.org/10.1038/nri3862","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nri3862","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wherry-nat-rev-immunol","kind":"paper","name":"Molecular and cellular insights into T cell exhaustion","route":"/key-papers/paper-wherry-nat-rev-immunol/","field":"links","label":"Nat Rev Immunol 2015"},{"id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","field":"links","label":"Wherry & Kurachi, Molecular and cellular insights into T cell exhaustion (Nat Rev Immunol 2015)"}]},{"url":"https://doi.org/10.1038/nrm.2017.26","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnrm.2017.26&code=d0942f1f-05af-4f01-b88b-5ba59f629b92","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","field":"papers","label":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes"}]},{"url":"https://doi.org/10.1038/nrm.2017.48","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrm.2017.48","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chang-nat-rev-mol-cell-biol","kind":"paper","name":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","route":"/key-papers/paper-chang-nat-rev-mol-cell-biol/","field":"links","label":"Nat Rev Mol Cell Biol 2017"},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/","field":"links","label":"Chang, Pannunzio, Adachi & Lieber, Non-homologous DNA end joining and alternative pathways to double-strand break repair (Nat Rev Mol Cell Biol 2017)"}]},{"url":"https://doi.org/10.1038/nrm2163","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrm2163","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-musacchio-nat-rev-mol-cell-biol","kind":"paper","name":"The spindle-assembly checkpoint in space and time","route":"/key-papers/paper-musacchio-nat-rev-mol-cell-biol/","field":"links","label":"Nat Rev Mol Cell Biol 2007"},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/","field":"links","label":"Musacchio & Salmon, The spindle-assembly checkpoint in space and time (Nat Rev Mol Cell Biol 2007)"}]},{"url":"https://doi.org/10.1038/nrm2455","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrm2455","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schafer-nat-rev-mol-cell-biol","kind":"paper","name":"Cancer as an overhealing wound: an old hypothesis revisited","route":"/key-papers/paper-schafer-nat-rev-mol-cell-biol/","field":"links","label":"Nat Rev Mol Cell Biol 2008"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"links","label":"Schäfer and Werner, Cancer as an overhealing wound: an old hypothesis revisited (Nature Reviews Molecular Cell Biology 2008)"}]},{"url":"https://doi.org/10.1038/nrm3758","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrm3758","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014","kind":"paper","name":"Lamouille 2014: molecular mechanisms of epithelial-mesenchymal transition","route":"/key-papers/paper-lamouille-emt-molecular-mechanisms-nrmcb-2014/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/nrurol.2017.163","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrurol.2017.163","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","field":"links","label":"SIOP-RTSG UMBRELLA protocol (Nat Rev Urol 2017)"},{"id":"paper-van-den-heuvel-eibrink-nat-rev-urol","kind":"paper","name":"Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","route":"/key-papers/paper-van-den-heuvel-eibrink-nat-rev-urol/","field":"links","label":"Nat Rev Urol 2017"}]},{"url":"https://doi.org/10.1038/s41375-018-0058-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41375-018-0058-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","field":"links","label":"Maruffi 2018, Leukemia: therapy for mixed-phenotype acute leukaemia, systematic review and meta-analysis"}]},{"url":"https://doi.org/10.1038/s41375-020-0734-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41375-020-0734-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/","field":"links","label":"Leukemia 2020"}]},{"url":"https://doi.org/10.1038/s41375-020-0776-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41375-020-0776-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-eln-2020-cml-hochhaus-leukemia-2020","kind":"paper","name":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","route":"/key-papers/paper-eln-2020-cml-hochhaus-leukemia-2020/","field":"links","label":"Leukemia 2020"}]},{"url":"https://doi.org/10.1038/s41375-022-01582-5","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41375-022-01582-5&code=973d7df2-ac98-4801-9391-579ac00e3062","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-transplant-role","kind":"term","name":"Stem cell transplant in lymphoma: what it is still for","route":"/terms/lymphoma-tx-transplant-role/","field":"links","label":"IELSG32 seven-year results: MATRix then autologous transplant or whole-brain radiotherapy in primary CNS lymphoma, Leukemia 2022"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"links","label":"IELSG32 long-term (Leukemia 2022)"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"standardOfCare.guideline (Consolidation after methotrexate-based induction: transplant against whole-brain radiotherapy)"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"standardOfCare.guideline (Primary CNS lymphoma in older or less fit patients, and at relapse)"},{"id":"paper-ferreri-leukemia","kind":"paper","name":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","route":"/key-papers/paper-ferreri-leukemia/","field":"links","label":"Leukemia 2022"}]},{"url":"https://doi.org/10.1038/s41375-022-01613-1","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41375-022-01613-1&code=b2adf8c7-58d0-471a-aa74-353f19e7c52b","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-who-2022-myeloid-khoury-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","route":"/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/","field":"links","label":"Leukemia 2022"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"links","label":"WHO 5th edition haematolymphoid tumours (Leukemia 2022)"},{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","field":"links","label":"Khoury 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, myeloid and histiocytic neoplasms"},{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","field":"links","label":"Khoury 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, myeloid and histiocytic neoplasms"}]},{"url":"https://doi.org/10.1038/s41375-022-01620-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41375-022-01620-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/","field":"links","label":"Leukemia 2022"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"links","label":"Alaggio 2022, Leukemia: the 5th edition WHO classification of haematolymphoid tumours, lymphoid neoplasms"}]},{"url":"https://doi.org/10.1038/s41379-018-0002-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222011656","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","field":"links","label":"Modern Pathology 2018: clinicopathologic characteristics of poorly differentiated chordoma, 19 patients"}]},{"url":"https://doi.org/10.1038/s41379-018-0047-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222011474","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"papillary-carcinoma-breast","kind":"cancer","name":"Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)","route":"/cancers/papillary-carcinoma-breast/","field":"links","label":"Modern Pathology 2018: solid papillary carcinoma with reverse polarity, nine cases"}]},{"url":"https://doi.org/10.1038/s41379-018-0110-y","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222011322","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rindi-common-classification-framework-mod-pathol-2018","kind":"paper","name":"A common classification framework for neuroendocrine neoplasms (IARC and WHO expert consensus)","route":"/key-papers/paper-rindi-common-classification-framework-mod-pathol-2018/","field":"links","label":"Mod Pathol 2018"}]},{"url":"https://doi.org/10.1038/s41379-019-0364-z","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222009358","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/s41379-019-0391-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222008882","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoepithelial-carcinoma-lung","kind":"cancer","name":"Lymphoepithelial carcinoma of the lung","route":"/cancers/lymphoepithelial-carcinoma-lung/","field":"links","label":"Modern Pathology 2020: genomic profiles and PD-L1 expression of 29 primary lymphoepithelioma-like carcinomas of the lung"}]},{"url":"https://doi.org/10.1038/s41392-021-00791-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41392-021-00791-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/","field":"links","label":"Hu et al., The JAK/STAT signaling pathway: from bench to clinic (Signal Transduction and Targeted Therapy 2021)"},{"id":"paper-hu-signal-transduct-target-ther","kind":"paper","name":"The JAK/STAT signaling pathway: from bench to clinic","route":"/key-papers/paper-hu-signal-transduct-target-ther/","field":"links","label":"Signal Transduct Target Ther 2021"}]},{"url":"https://doi.org/10.1038/s41392-025-02274-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41392-025-02274-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/","field":"links","label":"Signal Transduct Target Ther 2025"}]},{"url":"https://doi.org/10.1038/s41392-026-02618-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41392-026-02618-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/","field":"links","label":"Signal Transduct Target Ther 2026"}]},{"url":"https://doi.org/10.1038/s41392-026-02938-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41392-026-02938-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/","field":"links","label":"Signal Transduct Target Ther 2026"}]},{"url":"https://doi.org/10.1038/s41395-018-0122-8","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajg/fulltext/10.1038/s41395-018-0122-8~eus-guided-biliary-drainage-versus-ercp-for-the-primary","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Paik et al., EUS-guided biliary drainage versus ERCP, randomised (Am J Gastroenterol 2018)"},{"id":"biliary-drainage-routes","kind":"term","name":"Biliary drainage routes: ERCP stent, percutaneous (PTC) and EUS-guided","route":"/terms/biliary-drainage-routes/","field":"links","label":"Paik et al., Am J Gastroenterol 2018: EUS-guided biliary drainage versus ERCP, multicentre randomised trial (125 patients)"}]},{"url":"https://doi.org/10.1038/s41395-018-0395-y","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajg/fulltext/10.1038/s41395-018-0395-y~identification-of-cystic-lesions-by-secondary-screening-of","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Sheel, Am J Gastroenterol 2019: cystic lesions found by EUROPAC secondary screening of familial pancreatic cancer kindreds"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Sheel, Am J Gastroenterol 2019: cystic lesions found by EUROPAC secondary screening of familial pancreatic cancer kindreds"}]},{"url":"https://doi.org/10.1038/s41408-020-00366-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41408-020-00366-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mateos-20-2-20-smouldering-bcj-2020","kind":"paper","name":"IMWG 20/2/20 risk stratification model for smouldering multiple myeloma","route":"/key-papers/paper-mateos-20-2-20-smouldering-bcj-2020/","field":"links","label":"Blood Cancer J 2020"}]},{"url":"https://doi.org/10.1038/s41408-021-00587-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41408-021-00587-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021","kind":"paper","name":"IMWG consensus definition of primary plasma cell leukaemia at 5 percent circulating plasma cells","route":"/key-papers/paper-imwg-plasma-cell-leukaemia-definition-bcj-2021/","field":"links","label":"Blood Cancer J 2021"}]},{"url":"https://doi.org/10.1038/s41416-018-0199-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-018-0199-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019","kind":"paper","name":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","route":"/key-papers/paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019/","field":"links","label":"Goeppert et al., Br J Cancer 2019: mismatch repair deficiency in 308 Western cholangiocarcinomas"}]},{"url":"https://doi.org/10.1038/s41416-019-0402-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-019-0402-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","kind":"paper","name":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","route":"/key-papers/paper-froeling-pstt-ett-intensified-therapy-bjc-2019/","field":"links","label":"Br J Cancer 2019"}]},{"url":"https://doi.org/10.1038/s41416-019-0721-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-019-0721-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-laconi-br-j-cancer","kind":"paper","name":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","route":"/key-papers/paper-laconi-br-j-cancer/","field":"links","label":"Br J Cancer 2020"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Laconi, Marongiu and DeGregori, Cancer as a disease of old age: changing mutational and microenvironmental landscapes (British Journal of Cancer 2020)"}]},{"url":"https://doi.org/10.1038/s41416-021-01278-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-021-01278-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Br J Cancer 2021: comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom (273,789 people in three cohorts)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"Br J Cancer 2021: comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom (273,789 people in three cohorts)"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","field":"links","label":"Br J Cancer 2021: comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom (273,789 people in three cohorts)"}]},{"url":"https://doi.org/10.1038/s41416-021-01409-7","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-021-01409-7&code=edfd8666-c087-4cf1-a07a-3143f4c823fb","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Gathani, Br J Cancer 2021: ethnicity and tumour characteristics of invasive breast cancer in 116,500 women in England"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"Gathani, Br J Cancer 2021: ethnicity and tumour characteristics of invasive breast cancer in 116,500 women in England"}]},{"url":"https://doi.org/10.1038/s41416-022-01919-y","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-022-01919-y&code=0e784013-1126-4cef-a2d6-7b518176de40","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Br J Cancer 2022: interscreening interval and faecal immunochemical test threshold in the English bowel cancer screening programme (FIT pilot)"},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","field":"links","label":"Br J Cancer 2022: interscreening interval and faecal immunochemical test threshold in the English bowel cancer screening programme (FIT pilot)"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"Br J Cancer 2022: interscreening interval and faecal immunochemical test threshold in the English bowel cancer screening programme (FIT pilot)"}]},{"url":"https://doi.org/10.1038/s41416-024-02796-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-024-02796-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04068610-br-j-cancer-2024","kind":"paper","name":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","route":"/key-papers/paper-nct04068610-br-j-cancer-2024/","field":"links","label":"Br J Cancer 2024"}]},{"url":"https://doi.org/10.1038/s41416-026-03343-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41416-026-03343-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Br J Cancer 2026: a digital quality measure for emergency presentation of pancreatic cancer (US Veterans Affairs)"},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"links","label":"Br J Cancer 2026: a digital quality measure for emergency presentation of pancreatic cancer (US Veterans Affairs)"}]},{"url":"https://doi.org/10.1038/s41422-024-01034-y","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41422-024-01034-y&code=fa8d2556-8043-4bf7-a239-d7673c992c5c","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","field":"links","label":"Yang et al., GeneCompass (Cell Research 2024)"}]},{"url":"https://doi.org/10.1038/s41436-018-0009-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1098360021000769","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","kind":"paper","name":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","route":"/key-papers/paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019/","field":"links","label":"Yurgelun et al., Genet Med 2019: germline variants and somatic second hits in 289 resected cancers"}]},{"url":"https://doi.org/10.1038/s41467-017-01968-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-017-01968-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","field":"papers","label":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer"},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","field":"links","label":"Zhang et al., Integrating evolutionary dynamics into treatment of mCRPC (Nature Communications 2017)"},{"id":"paper-zhang-nat-commun","kind":"paper","name":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","route":"/key-papers/paper-zhang-nat-commun/","field":"links","label":"Nat Commun 2017"},{"id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/","field":"links","label":"Zhang and colleagues 2017, Nature Communications"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"links","label":"Zhang et al., Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (Nature Communications 2017)"}]},{"url":"https://doi.org/10.1038/s41467-019-09799-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-019-09799-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","field":"links","label":"Menden et al., Community assessment to advance computational prediction of cancer drug combinations (Nature Communications 2019)"},{"id":"paper-menden-nat-commun","kind":"paper","name":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","route":"/key-papers/paper-menden-nat-commun/","field":"links","label":"Nat Commun 2019"}]},{"url":"https://doi.org/10.1038/s41467-019-11862-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-019-11862-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","kind":"paper","name":"The molecular origin and taxonomy of mucinous ovarian carcinoma","route":"/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/","field":"links","label":"Nat Commun 2019"}]},{"url":"https://doi.org/10.1038/s41467-020-15574-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-15574-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"links","label":"Fougner, Nat Commun 2020: re-definition of claudin-low as a breast cancer phenotype"},{"id":"tnbc-mesenchymal-stem-like","kind":"cancer","name":"Mesenchymal stem-like triple-negative breast cancer (MSL)","route":"/cancers/tnbc-mesenchymal-stem-like/","field":"links","label":"Fougner, Nat Commun 2020: re-definition of claudin-low as a breast cancer phenotype"},{"id":"claudin-low","kind":"term","name":"Claudin-low breast cancer","route":"/terms/claudin-low/","field":"links","label":"Fougner, Nat Commun 2020: re-definition of claudin-low as a breast cancer phenotype"}]},{"url":"https://doi.org/10.1038/s41467-020-16138-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-16138-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-de-groot-nat-commun","kind":"paper","name":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial","route":"/key-papers/paper-de-groot-nat-commun/","field":"links","label":"Nat Commun 2020"},{"id":"fasting-mimicking-diet","kind":"technology","name":"Fasting and fasting-mimicking diets around chemotherapy","route":"/technologies/fasting-mimicking-diet/","field":"links","label":"DIRECT trial (Nat Commun 2020)"}]},{"url":"https://doi.org/10.1038/s41467-020-16814-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-16814-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"papers","label":"Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery"}]},{"url":"https://doi.org/10.1038/s41467-020-17880-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-17880-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pandey-gallbladder-elf3-nat-commun-2020","kind":"paper","name":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","route":"/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/","field":"links","label":"Pandey et al., Nat Commun 2020: integrated genomics of 167 gallbladder cancers from Korea, India and Chile"}]},{"url":"https://doi.org/10.1038/s41467-020-17917-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-17917-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-noe-cyst-malignant-progression-genomics-nat-commun-2020","kind":"paper","name":"Genomic characterization of malignant progression in neoplastic pancreatic cysts","route":"/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/","field":"links","label":"Noe et al., Nat Commun 2020: genomic progression in 148 samples from IPMNs, MCNs and associated cancers"}]},{"url":"https://doi.org/10.1038/s41467-020-20603-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-020-20603-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-koelsche-nat-commun","kind":"paper","name":"Sarcoma classification by DNA methylation profiling","route":"/key-papers/paper-koelsche-nat-commun/","field":"links","label":"Nat Commun 2021"},{"id":"sarcoma-methylation-classifier","kind":"technology","name":"Methylation classifier for sarcomas","route":"/technologies/sarcoma-methylation-classifier/","field":"links","label":"Nature Communications 2021: Sarcoma classification by DNA methylation profiling"}]},{"url":"https://doi.org/10.1038/s41467-021-23793-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-021-23793-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","field":"links","label":"Yamazaki et al., Antibody-drug conjugates with dual payloads for combating breast tumour heterogeneity and drug resistance (Nature Communications 2021)"},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/","field":"links","label":"Yamazaki et al., Antibody-drug conjugates with dual payloads for combating breast tumour heterogeneity and drug resistance (Nature Communications 2021)"},{"id":"paper-yamazaki-nat-commun","kind":"paper","name":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","route":"/key-papers/paper-yamazaki-nat-commun/","field":"links","label":"Nat Commun 2021"}]},{"url":"https://doi.org/10.1038/s41467-021-25012-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-021-25012-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplasia-dysplasia-carcinoma-sequence","kind":"term","name":"Metaplasia, dysplasia, carcinoma in situ: the flat route to gallbladder cancer","route":"/terms/metaplasia-dysplasia-carcinoma-sequence/","field":"links","label":"Lin et al., Nat Commun 2021: co-existing neoplasia and carcinoma lesions of the gallbladder"},{"id":"paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021","kind":"paper","name":"Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer","route":"/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/","field":"links","label":"Lin et al., Nat Commun 2021: co-existing neoplasia and carcinoma lesions of the gallbladder"}]},{"url":"https://doi.org/10.1038/s41467-021-25618-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-021-25618-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","field":"links","label":"Nature Communications 2021: integrated exome and RNA sequencing of 63 TFE3-translocation renal cell carcinomas"}]},{"url":"https://doi.org/10.1038/s41467-021-26502-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-021-26502-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","kind":"paper","name":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","route":"/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/","field":"links","label":"Lehmann et al., Nat Commun 2021: multi-omics vulnerabilities of TNBC subtypes"}]},{"url":"https://doi.org/10.1038/s41467-023-42458-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-023-42458-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"papers","label":"Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth"}]},{"url":"https://doi.org/10.1038/s41467-024-44824-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-024-44824-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ma-nat-commun","kind":"paper","name":"Segment anything in medical images","route":"/key-papers/paper-ma-nat-commun/","field":"links","label":"Nat Commun 2024"},{"id":"medsam","kind":"technology","name":"MedSAM / SAM-Med3D (segment anything for medicine)","route":"/technologies/medsam/","field":"links","label":"MedSAM, Nature Communications 2024"}]},{"url":"https://doi.org/10.1038/s41467-025-58647-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-025-58647-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/","field":"links","label":"Nat Commun 2025"}]},{"url":"https://doi.org/10.1038/s41467-025-60757-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-025-60757-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/","field":"links","label":"Nat Commun 2025"}]},{"url":"https://doi.org/10.1038/s41467-025-67783-5","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41467-025-67783-5&code=6fc08253-fa58-4dc7-bf99-403b31ad648a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","route":"/key-papers/paper-santosh-kesari-nat-commun-2026/","field":"links","label":"Nat Commun 2026"},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","field":"papers","label":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations"}]},{"url":"https://doi.org/10.1038/s41467-025-67824-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-025-67824-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/","field":"links","label":"Nat Commun 2026"}]},{"url":"https://doi.org/10.1038/s41467-026-69943-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-026-69943-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/","field":"links","label":"Nat Commun 2026"}]},{"url":"https://doi.org/10.1038/s41467-026-72903-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41467-026-72903-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drug-response-splits","kind":"term","name":"Drug-response data splits: leave-cell-line-out, leave-drug-out, leave-tissue-out","route":"/terms/drug-response-splits/","field":"links","label":"Bernett et al., Critical evaluation of drug response prediction models with DrEval (Nature Communications 2026)"},{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","field":"links","label":"Bernett et al., DrEval (Nature Communications 2026)"}]},{"url":"https://doi.org/10.1038/s41523-017-0014-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-017-0014-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Houssami and Hunter, NPJ Breast Cancer 2017: interval breast cancers in population mammography screening"},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"links","label":"Houssami and Hunter, NPJ Breast Cancer 2017: interval breast cancers in population mammography screening"}]},{"url":"https://doi.org/10.1038/s41523-017-0040-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-017-0040-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ligibel-npj-breast-cancer","kind":"paper","name":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design","route":"/key-papers/paper-ligibel-npj-breast-cancer/","field":"links","label":"NPJ Breast Cancer 2017"},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","field":"links","label":"BWEL design paper (npj Breast Cancer 2017)"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"links","label":"BWEL design paper (npj Breast Cancer 2017)"}]},{"url":"https://doi.org/10.1038/s41523-020-00208-2","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41523-020-00208-2&code=34fbd3cb-e6f6-407c-a305-82030c0aac79","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/","field":"links","label":"NPJ Breast Cancer 2021"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/s41523-021-00229-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-021-00229-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Draganov mouse study 2021"},{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/","field":"links","label":"Draganov mouse study 2021"}]},{"url":"https://doi.org/10.1038/s41523-021-00308-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-021-00308-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Dieci, NPJ Breast Cancer 2021: ER levels and outcome in non-metastatic triple-negative breast cancer"},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"links","label":"Dieci, NPJ Breast Cancer 2021: ER levels and outcome in non-metastatic triple-negative breast cancer"}]},{"url":"https://doi.org/10.1038/s41523-022-00448-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-022-00448-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Yoder, NPJ Breast Cancer 2022: low versus negative ER/PR in HER2-negative breast cancer"},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"links","label":"Yoder, NPJ Breast Cancer 2022: low versus negative ER/PR in HER2-negative breast cancer"}]},{"url":"https://doi.org/10.1038/s41523-023-00512-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-023-00512-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","kind":"paper","name":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","route":"/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/","field":"links","label":"Stecklein et al., npj Breast Cancer 2023: ctDNA and residual cancer burden in 80 TNBC patients with residual disease"}]},{"url":"https://doi.org/10.1038/s41523-023-00554-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-023-00554-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Thomas, NPJ Breast Cancer 2023: rare subtypes of triple-negative breast cancer"},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Thomas, NPJ Breast Cancer 2023: rare subtypes of triple-negative breast cancer"},{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","field":"links","label":"Thomas, NPJ Breast Cancer 2023: rare subtypes of triple-negative breast cancer"},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","field":"links","label":"Thomas, NPJ Breast Cancer 2023: rare subtypes of triple-negative breast cancer"},{"id":"secretory-carcinoma-breast","kind":"cancer","name":"Secretory carcinoma of the breast","route":"/cancers/secretory-carcinoma-breast/","field":"links","label":"Thomas, NPJ Breast Cancer 2023: rare subtypes of triple-negative breast cancer"}]},{"url":"https://doi.org/10.1038/s41523-024-00635-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-024-00635-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"links","label":"ASCENT subgroup analyses (npj Breast Cancer 2024)"}]},{"url":"https://doi.org/10.1038/s41523-025-00744-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-025-00744-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"axillary-surgery-de-escalation","kind":"term","name":"Doing less to the armpit","route":"/terms/axillary-surgery-de-escalation/","field":"links","label":"Locoregional de-escalation trials mapped (npj Breast Cancer 2025)"}]},{"url":"https://doi.org/10.1038/s41523-026-00988-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41523-026-00988-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Expression of concern 2026"},{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/","field":"links","label":"Expression of concern 2026"}]},{"url":"https://doi.org/10.1038/s41551-020-00682-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41551-020-00682-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tile-patch-encoding","kind":"term","name":"Tile and patch encoding of slides","route":"/terms/tile-patch-encoding/","field":"links","label":"Lu et al., CLAM: data-efficient and weakly supervised computational pathology on whole-slide images (Nature Biomedical Engineering 2021)"},{"id":"abmil","kind":"term","name":"Attention-based multiple-instance learning (ABMIL, CLAM)","route":"/terms/abmil/","field":"links","label":"Lu et al., CLAM (Nature Biomedical Engineering 2021)"}]},{"url":"https://doi.org/10.1038/s41568-018-0005-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-018-0005-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-robey-nat-rev-cancer","kind":"paper","name":"Revisiting the role of ABC transporters in multidrug-resistant cancer","route":"/key-papers/paper-robey-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2018"},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","field":"links","label":"Robey et al., Revisiting the role of ABC transporters in multidrug-resistant cancer (Nat Rev Cancer 2018)"}]},{"url":"https://doi.org/10.1038/s41568-019-0133-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-019-0133-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","field":"links","label":"Nat Rev Cancer 2019"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","field":"links","label":"Rudin et al., Nat Rev Cancer 2019: the molecular subtypes of small-cell lung cancer, a synthesis of human and mouse data"}]},{"url":"https://doi.org/10.1038/s41568-019-0144-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-019-0144-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tertiary-lymphoid-structures","kind":"term","name":"Tertiary lymphoid structures (TLS)","route":"/terms/tertiary-lymphoid-structures/","field":"links","label":"Sautès-Fridman et al., Tertiary lymphoid structures in the era of cancer immunotherapy (Nature Reviews Cancer 2019)"}]},{"url":"https://doi.org/10.1038/s41568-019-0205-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-019-0205-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"links","label":"Arvanitis, Ferraro & Jain, The blood-brain barrier and blood-tumour barrier in brain tumours and metastases (Nature Reviews Cancer 2020)"},{"id":"paper-arvanitis-nat-rev-cancer","kind":"paper","name":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","route":"/key-papers/paper-arvanitis-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2020"}]},{"url":"https://doi.org/10.1038/s41568-019-0210-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-019-0210-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roumenina-nat-rev-cancer","kind":"paper","name":"Context-dependent roles of complement in cancer","route":"/key-papers/paper-roumenina-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2019"},{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/","field":"links","label":"Roumenina et al., Context-dependent roles of complement in cancer (Nat Rev Cancer 2019)"}]},{"url":"https://doi.org/10.1038/s41568-019-0238-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-019-0238-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sahai-nat-rev-cancer","kind":"paper","name":"A framework for advancing our understanding of cancer-associated fibroblasts","route":"/key-papers/paper-sahai-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2020"},{"id":"caf-activation-desmoplasia","kind":"pathway","name":"Fibroblast activation, desmoplasia & matrix stiffness","route":"/pathways/caf-activation-desmoplasia/","field":"links","label":"Sahai et al., A framework for advancing our understanding of cancer-associated fibroblasts (Nat Rev Cancer 2020)"}]},{"url":"https://doi.org/10.1038/s41568-020-0263-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-020-0263-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","field":"links","label":"Phan & Croucher, The dormant cancer cell life cycle (Nature Reviews Cancer 2020)"},{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/","field":"links","label":"Phan & Croucher, The dormant cancer cell life cycle (Nature Reviews Cancer 2020)"},{"id":"paper-phan-nat-rev-cancer","kind":"paper","name":"The dormant cancer cell life cycle","route":"/key-papers/paper-phan-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2020"}]},{"url":"https://doi.org/10.1038/s41568-021-00335-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-021-00335-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kakiuchi-nat-rev-cancer","kind":"paper","name":"Clonal expansion in non-cancer tissues","route":"/key-papers/paper-kakiuchi-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2021"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Kakiuchi and Ogawa, Clonal expansion in non-cancer tissues (Nature Reviews Cancer 2021)"}]},{"url":"https://doi.org/10.1038/s41568-021-00380-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-021-00380-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/","field":"links","label":"Fabbri, Chakraborty, Robert & Vagner, The plasticity of mRNA translation during cancer progression and therapy resistance (Nature Reviews Cancer 2021)"},{"id":"paper-fabbri-nat-rev-cancer","kind":"paper","name":"The plasticity of mRNA translation during cancer progression and therapy resistance","route":"/key-papers/paper-fabbri-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2021"}]},{"url":"https://doi.org/10.1038/s41568-022-00541-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-022-00541-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/","field":"links","label":"Bradley & Anczuków, RNA splicing dysregulation and the hallmarks of cancer (Nature Reviews Cancer 2023)"},{"id":"paper-bradley-nat-rev-cancer","kind":"paper","name":"RNA splicing dysregulation and the hallmarks of cancer","route":"/key-papers/paper-bradley-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2023"}]},{"url":"https://doi.org/10.1038/s41568-023-00579-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41568-023-00579-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/","field":"links","label":"Franklin, Wu & Guan, Insights into recent findings and clinical application of YAP and TAZ in cancer (Nature Reviews Cancer 2023)"},{"id":"paper-franklin-nat-rev-cancer","kind":"paper","name":"Insights into recent findings and clinical application of YAP and TAZ in cancer","route":"/key-papers/paper-franklin-nat-rev-cancer/","field":"links","label":"Nat Rev Cancer 2023"}]},{"url":"https://doi.org/10.1038/s41571-018-0055-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-018-0055-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"papers","label":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?"}]},{"url":"https://doi.org/10.1038/s41571-020-00447-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-020-00447-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","field":"papers","label":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood"},{"id":"paper-olivier-chinot-nat-rev-clin-oncol-2021","kind":"paper","name":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","route":"/key-papers/paper-olivier-chinot-nat-rev-clin-oncol-2021/","field":"links","label":"Nat Rev Clin Oncol 2021"}]},{"url":"https://doi.org/10.1038/s41571-020-0363-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-020-0363-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020","kind":"paper","name":"The tumour microenvironment in pancreatic cancer: clinical challenges and opportunities","route":"/key-papers/paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020/","field":"links","label":"Ho, Jaffee and Zheng, Nat Rev Clin Oncol 2020: the tumour microenvironment in pancreatic cancer"}]},{"url":"https://doi.org/10.1038/s41571-021-00549-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-021-00549-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","field":"links","label":"Dhanasekaran et al., The MYC oncogene: the grand orchestrator of cancer growth and immune evasion (Nature Reviews Clinical Oncology 2022)"},{"id":"paper-dhanasekaran-nat-rev-clin-oncol","kind":"paper","name":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","route":"/key-papers/paper-dhanasekaran-nat-rev-clin-oncol/","field":"links","label":"Nat Rev Clin Oncol 2022"}]},{"url":"https://doi.org/10.1038/s41571-022-00668-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-022-00668-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/","field":"links","label":"Schmitt, Wang & Demaria, Senescence and cancer: role and therapeutic opportunities (Nature Reviews Clinical Oncology 2022)"},{"id":"paper-schmitt-nat-rev-clin-oncol","kind":"paper","name":"Senescence and cancer - role and therapeutic opportunities","route":"/key-papers/paper-schmitt-nat-rev-clin-oncol/","field":"links","label":"Nat Rev Clin Oncol 2022"}]},{"url":"https://doi.org/10.1038/s41571-022-00719-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41571-022-00719-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023","kind":"paper","name":"Shalhout 2023: what the approved oncolytic viruses actually do in practice","route":"/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/","field":"links","label":"Nat Rev Clin Oncol 2023"}]},{"url":"https://doi.org/10.1038/s41572-018-0055-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41572-018-0055-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","field":"metrics (Adults with cancer who develop brain metastases)"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"links","label":"Achrol et al., Brain metastases (Nature Reviews Disease Primers 2019)"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","field":"metrics (Adults with cancer who develop brain metastases)"},{"id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2019"}]},{"url":"https://doi.org/10.1038/s41572-019-0111-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41572-019-0111-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2019"},{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","field":"links","label":"Review: Breast cancer (Nat Rev Dis Primers 2019)"}]},{"url":"https://doi.org/10.1038/s41572-020-00235-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41572-020-00235-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2021"},{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","field":"links","label":"Review: Small-cell lung cancer (Nat Rev Dis Primers 2021)"}]},{"url":"https://doi.org/10.1038/s41572-020-00240-3","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41572-020-00240-3&code=a5ef2560-3448-41bd-a810-9d6abbd055cf","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","field":"links","label":"Nat Rev Dis Primers 2021"},{"id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","field":"links","label":"Review: Hepatocellular carcinoma (Nature Reviews Disease Primers)"}]},{"url":"https://doi.org/10.1038/s41572-020-00243-0","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41572-020-00243-0&code=1aee4027-24a4-4469-a58a-6e34bc671626","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"papers","label":"Prostate cancer"},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"papers","label":"Prostate cancer"}]},{"url":"https://doi.org/10.1038/s41572-022-00398-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41572-022-00398-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Roa, Nature Reviews Disease Primers 2022: gallbladder cancer"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"Roa, Nature Reviews Disease Primers 2022: gallbladder cancer"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Roa, Nature Reviews Disease Primers 2022: gallbladder cancer"},{"id":"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022","kind":"paper","name":"Gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/","field":"links","label":"Nat Rev Dis Primers 2022"}]},{"url":"https://doi.org/10.1038/s41573-019-0051-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41573-019-0051-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/","field":"links","label":"Depil et al., 'Off-the-shelf' allogeneic CAR T cells: development and challenges (Nature Reviews Drug Discovery 2020)"},{"id":"paper-depil-nat-rev-drug-discov","kind":"paper","name":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","route":"/key-papers/paper-depil-nat-rev-drug-discov/","field":"links","label":"Nat Rev Drug Discov 2020"}]},{"url":"https://doi.org/10.1038/s41573-021-00371-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41573-021-00371-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bekes-nat-rev-drug-discov","kind":"paper","name":"PROTAC targeted protein degraders: the past is prologue","route":"/key-papers/paper-bekes-nat-rev-drug-discov/","field":"links","label":"Nat Rev Drug Discov 2022"},{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/","field":"links","label":"Békés, Langley & Crews, PROTAC targeted protein degraders: the past is prologue (Nat Rev Drug Discov 2022)"}]},{"url":"https://doi.org/10.1038/s41574-023-00886-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41574-023-00886-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-petersenn-nat-rev-endocrinol","kind":"paper","name":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","route":"/key-papers/paper-petersenn-nat-rev-endocrinol/","field":"links","label":"Nat Rev Endocrinol 2023"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"links","label":"Pituitary Society prolactinoma consensus (2023)"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"standardOfCare.guideline (Prolactinoma)"},{"id":"lactotroph-pitnet","kind":"cancer","name":"Lactotroph pituitary neuroendocrine tumour (prolactinoma)","route":"/cancers/lactotroph-pitnet/","field":"links","label":"Petersenn 2023, Nature Reviews Endocrinology: Pituitary Society international consensus on prolactin-secreting pituitary adenomas"}]},{"url":"https://doi.org/10.1038/s41575-021-00457-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41575-021-00457-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Klein, Nat Rev Gastroenterol Hepatol 2021: pancreatic cancer epidemiology, lifestyle and inherited risk"}]},{"url":"https://doi.org/10.1038/s41576-019-0099-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41576-019-0099-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/","field":"links","label":"Shay & Wright, Telomeres and telomerase: three decades of progress (Nature Reviews Genetics 2019)"},{"id":"paper-shay-nat-rev-genet","kind":"paper","name":"Telomeres and telomerase: three decades of progress","route":"/key-papers/paper-shay-nat-rev-genet/","field":"links","label":"Nat Rev Genet 2019"}]},{"url":"https://doi.org/10.1038/s41576-019-0171-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41576-019-0171-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/","field":"links","label":"Ben-David and Amon, Context is everything: aneuploidy in cancer (Nature Reviews Genetics 2019)"},{"id":"paper-ben-david-nat-rev-genet","kind":"paper","name":"Context is everything: aneuploidy in cancer","route":"/key-papers/paper-ben-david-nat-rev-genet/","field":"links","label":"Nat Rev Genet 2020"}]},{"url":"https://doi.org/10.1038/s41576-020-0236-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41576-020-0236-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/","field":"links","label":"Logsdon et al., Long-read human genome sequencing and its applications (Nature Reviews Genetics 2020)"},{"id":"paper-logsdon-nat-rev-genet","kind":"paper","name":"Long-read human genome sequencing and its applications","route":"/key-papers/paper-logsdon-nat-rev-genet/","field":"links","label":"Nat Rev Genet 2020"}]},{"url":"https://doi.org/10.1038/s41577-019-0127-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41577-019-0127-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-denardo-nat-rev-immunol","kind":"paper","name":"Macrophages as regulators of tumour immunity and immunotherapy","route":"/key-papers/paper-denardo-nat-rev-immunol/","field":"links","label":"Nat Rev Immunol 2019"},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/","field":"links","label":"DeNardo & Ruffell, Macrophages as regulators of tumour immunity and immunotherapy (Nat Rev Immunol 2019)"}]},{"url":"https://doi.org/10.1038/s41580-020-0234-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41580-020-0234-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"papers","label":"Regulation of human telomerase in homeostasis and disease"}]},{"url":"https://doi.org/10.1038/s41586-018-0481-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-018-0481-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-makohon-moore-precursor-cells-ductal-system-nature-2018","kind":"paper","name":"Precancerous neoplastic cells can move through the pancreatic ductal system","route":"/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/","field":"links","label":"Makohon-Moore et al., Nature 2018: precancerous cells move through the ductal system"}]},{"url":"https://doi.org/10.1038/s41586-019-1012-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1012-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-diamond-nature","kind":"paper","name":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","route":"/key-papers/paper-diamond-nature/","field":"links","label":"Nature 2019"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"links","label":"Cobimetinib in histiocytosis (Nature 2019)"}]},{"url":"https://doi.org/10.1038/s41586-019-1056-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1056-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bertucci-metastatic-breast-genomics-nature-2019","kind":"paper","name":"Genomic characterization of metastatic breast cancers","route":"/key-papers/paper-bertucci-metastatic-breast-genomics-nature-2019/","field":"links","label":"Bertucci et al., Nature 2019: genomic characterisation of 617 metastatic breast cancers"}]},{"url":"https://doi.org/10.1038/s41586-019-1102-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1102-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/","field":"links","label":"WRN dependency (Nature 2019)"},{"id":"paper-chan-nature","kind":"paper","name":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","route":"/key-papers/paper-chan-nature/","field":"links","label":"Nature 2019"}]},{"url":"https://doi.org/10.1038/s41586-019-1170-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1170-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","field":"papers","label":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy"}]},{"url":"https://doi.org/10.1038/s41586-019-1563-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1563-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/","field":"links","label":"Venkatesh et al., Electrical and synaptic integration of glioma into neural circuits (Nature 2019)"},{"id":"paper-venkatesh-nature","kind":"paper","name":"Electrical and synaptic integration of glioma into neural circuits","route":"/key-papers/paper-venkatesh-nature/","field":"links","label":"Nature 2019"},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"links","label":"Venkatesh et al., Electrical and synaptic integration of glioma into neural circuits (Nature 2019)"}]},{"url":"https://doi.org/10.1038/s41586-019-1564-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1564-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-venkataramani-nature","kind":"paper","name":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","route":"/key-papers/paper-venkataramani-nature/","field":"links","label":"Nature 2019"},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"links","label":"Venkataramani et al., Glutamatergic synaptic input to glioma cells drives brain tumour progression (Nature 2019)"}]},{"url":"https://doi.org/10.1038/s41586-019-1672-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1672-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019","kind":"paper","name":"The landscape of somatic mutation in normal colorectal epithelial cells","route":"/key-papers/paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019/","field":"links","label":"Lee-Six et al., Nature 2019: whole genomes of hundreds of normal colorectal crypts from 42 people"}]},{"url":"https://doi.org/10.1038/s41586-019-1674-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1674-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/","field":"links","label":"pH-selective VISTA (Nature 2019)"},{"id":"paper-johnston-nature","kind":"paper","name":"VISTA is an acidic pH-selective ligand for PSGL-1","route":"/key-papers/paper-johnston-nature/","field":"links","label":"Nature 2019"}]},{"url":"https://doi.org/10.1038/s41586-019-1730-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1730-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","field":"links","label":"Vasan, Baselga & Hyman, A view on drug resistance in cancer (Nature 2019)"},{"id":"paper-vasan-nature","kind":"paper","name":"A view on drug resistance in cancer","route":"/key-papers/paper-vasan-nature/","field":"links","label":"Nature 2019"},{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/","field":"links","label":"Vasan, Baselga & Hyman, A view on drug resistance in cancer (Nature 2019)"}]},{"url":"https://doi.org/10.1038/s41586-019-1805-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1805-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"papers","label":"c-Jun overexpression in CAR T cells induces exhaustion resistance"}]},{"url":"https://doi.org/10.1038/s41586-019-1906-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-019-1906-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","field":"papers","label":"B cells are associated with survival and immunotherapy response in sarcoma"},{"id":"paper-antoine-italiano-nature-2020","kind":"paper","name":"B cells are associated with survival and immunotherapy response in sarcoma","route":"/key-papers/paper-antoine-italiano-nature-2020/","field":"links","label":"Nature 2020"}]},{"url":"https://doi.org/10.1038/s41586-020-1943-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-1943-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-alexandrov-nature","kind":"paper","name":"The repertoire of mutational signatures in human cancer","route":"/key-papers/paper-alexandrov-nature/","field":"links","label":"Nature 2020"},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/","field":"links","label":"Alexandrov et al., The repertoire of mutational signatures in human cancer (Nature 2020)"}]},{"url":"https://doi.org/10.1038/s41586-020-1961-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-1961-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-yoshida-nature","kind":"paper","name":"Tobacco smoking and somatic mutations in human bronchial epithelium","route":"/key-papers/paper-yoshida-nature/","field":"links","label":"Nature 2020"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"links","label":"Yoshida et al., Tobacco smoking and somatic mutations in human bronchial epithelium (Nature 2020)"}]},{"url":"https://doi.org/10.1038/s41586-020-2080-8","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-020-2080-8&code=e7525cb2-d9a5-4e5c-8927-b13bd1032e5e","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colibactin","kind":"term","name":"Colibactin","route":"/terms/colibactin/","field":"links","label":"Pleguezuelos-Manzano, Nature 2020: a mutational signature in colorectal cancer caused by genotoxic pks-positive Escherichia coli"}]},{"url":"https://doi.org/10.1038/s41586-020-2140-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-2140-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"papers","label":"Integrating genomic features for non-invasive early lung cancer detection"}]},{"url":"https://doi.org/10.1038/s41586-020-2229-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-2229-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"autophagy","kind":"pathway","name":"Autophagy","route":"/pathways/autophagy/","field":"links","label":"Yamamoto et al., Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I (Nature 2020)"},{"id":"paper-yamamoto-nature","kind":"paper","name":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","route":"/key-papers/paper-yamamoto-nature/","field":"links","label":"Nature 2020"}]},{"url":"https://doi.org/10.1038/s41586-020-2308-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-2308-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"papers","label":"The mutational constraint spectrum quantified from variation in 141,456 humans"}]},{"url":"https://doi.org/10.1038/s41586-020-2481-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-020-2481-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-middleton-nature","kind":"paper","name":"The National Lung Matrix Trial of personalized therapy in lung cancer","route":"/key-papers/paper-middleton-nature/","field":"links","label":"Nature 2020"},{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","field":"links","label":"Middleton et al., Nature 2020: the National Lung Matrix Trial of personalized therapy in lung cancer"},{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","field":"outcomes.source (Median progression-free survival, palbociclib in KRAS-mutant NSCLC (cohort C6; PFS is the primary outcome for the palbociclib arm))"},{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","field":"outcomes.source (Screening funnel)"}]},{"url":"https://doi.org/10.1038/s41586-020-2864-x","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-020-2864-x&code=6ac330b8-a18e-478a-8981-c7f00b4cb0fb","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","field":"papers","label":"Single-cell mutation analysis of clonal evolution in myeloid malignancies"},{"id":"paper-raajit-rampal-nature-2020","kind":"paper","name":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","route":"/key-papers/paper-raajit-rampal-nature-2020/","field":"links","label":"Nature 2020"}]},{"url":"https://doi.org/10.1038/s41586-021-03819-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-021-03819-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/","field":"papers","label":"AlphaFold 2: predicting protein structures to near-experimental accuracy"},{"id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/","field":"links","label":"AlphaFold 2: predicting protein structures to near-experimental accuracy (Nature 2021)"},{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1038/s41586-021-04161-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-021-04161-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"papers","label":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer"}]},{"url":"https://doi.org/10.1038/s41586-021-04390-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-021-04390-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"papers","label":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells"}]},{"url":"https://doi.org/10.1038/s41586-022-04489-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-022-04489-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","field":"links","label":"Majzner et al., GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas (Nature 2022)"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"papers","label":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas"},{"id":"paper-majzner-nature","kind":"paper","name":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","route":"/key-papers/paper-majzner-nature/","field":"links","label":"Nature 2022"},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"links","label":"GD2 CAR-T in H3 K27M diffuse midline glioma (Nature 2022)"}]},{"url":"https://doi.org/10.1038/s41586-022-05473-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-022-05473-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"papers","label":"FinnGen provides genetic insights from a well-phenotyped isolated population"}]},{"url":"https://doi.org/10.1038/s41586-023-05783-5","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-023-05783-5&code=bb0b47dd-994f-41cd-9c8c-084ac1a0d1b1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"papers","label":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"links","label":"TRACERx lung cancer evolution (Nature 2023)"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","field":"metrics (Patients and tumour regions in the TRACERx evolutionary cohort)"},{"id":"paper-tracerx-evolution-nature-2023","kind":"paper","name":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","route":"/key-papers/paper-tracerx-evolution-nature-2023/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1038/s41586-023-05812-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-05812-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","field":"links","label":"Issa et al., The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia (Nature 2023)"},{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/","field":"links","label":"AUGMENT-101: revumenib (Nature 2023)"}]},{"url":"https://doi.org/10.1038/s41586-023-05874-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-05874-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","kind":"paper","name":"Lung adenocarcinoma promotion by air pollutants","route":"/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/","field":"links","label":"Nature 2023"}]},{"url":"https://doi.org/10.1038/s41586-023-06063-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-06063-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/","field":"links","label":"Rojas et al., personalised RNA neoantigen vaccines stimulate T cells in pancreatic cancer (Nature 2023)"}]},{"url":"https://doi.org/10.1038/s41586-023-06139-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-06139-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-theodoris-nature","kind":"paper","name":"Transfer learning enables predictions in network biology","route":"/key-papers/paper-theodoris-nature/","field":"links","label":"Nature 2023"},{"id":"geneformer","kind":"technology","name":"Geneformer","route":"/technologies/geneformer/","field":"links","label":"Nature 2023"}]},{"url":"https://doi.org/10.1038/s41586-023-06367-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-06367-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","field":"papers","label":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer"},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","field":"papers","label":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer"}]},{"url":"https://doi.org/10.1038/s41586-023-06415-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-023-06415-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-watson-nature","kind":"paper","name":"De novo design of protein structure and function with RFdiffusion","route":"/key-papers/paper-watson-nature/","field":"links","label":"Nature 2023"},{"id":"rfdiffusion","kind":"technology","name":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","route":"/technologies/rfdiffusion/","field":"links","label":"Nature 2023"}]},{"url":"https://doi.org/10.1038/s41586-024-07205-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-07205-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","kind":"paper","name":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","route":"/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/","field":"links","label":"Nature 2024"}]},{"url":"https://doi.org/10.1038/s41586-024-07384-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-07384-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/","field":"links","label":"Nature 2024 (DOI)"}]},{"url":"https://doi.org/10.1038/s41586-024-07441-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-07441-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-xu-nature","kind":"paper","name":"A whole-slide foundation model for digital pathology from real-world data","route":"/key-papers/paper-xu-nature/","field":"links","label":"Nature 2024"},{"id":"prov-gigapath","kind":"technology","name":"Prov-GigaPath (Microsoft, Providence)","route":"/technologies/prov-gigapath/","field":"links","label":"Nature 2024"}]},{"url":"https://doi.org/10.1038/s41586-024-07487-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-07487-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-abramson-nature","kind":"paper","name":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","route":"/key-papers/paper-abramson-nature/","field":"links","label":"Nature 2024"},{"id":"alphafold3","kind":"technology","name":"AlphaFold 3","route":"/technologies/alphafold3/","field":"links","label":"Nature 2024"},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/","field":"links","label":"AlphaFold 3 (Nature 2024)"}]},{"url":"https://doi.org/10.1038/s41586-024-07894-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-07894-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-wang-nature","kind":"paper","name":"A pathology foundation model for cancer diagnosis and prognosis prediction","route":"/key-papers/paper-wang-nature/","field":"links","label":"Nature 2024"},{"id":"chief","kind":"technology","name":"CHIEF (Harvard, Yu Lab)","route":"/technologies/chief/","field":"links","label":"Nature 2024"}]},{"url":"https://doi.org/10.1038/s41586-024-08378-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-08378-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-xiang-nature","kind":"paper","name":"A vision-language foundation model for precision oncology","route":"/key-papers/paper-xiang-nature/","field":"links","label":"Nature 2025"},{"id":"musk","kind":"technology","name":"MUSK (Stanford, vision-language pathology)","route":"/technologies/musk/","field":"links","label":"Nature 2025"}]},{"url":"https://doi.org/10.1038/s41586-024-08508-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-024-08508-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/","field":"links","label":"Nature 2025"},{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/","field":"links","label":"Sethna et al., RNA neoantigen vaccines prime long-lived CD8 T cells in pancreatic cancer (Nature 2025)"},{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/","field":"outcomes.source (Recurrence-free survival by vaccine response (exploratory))"},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","field":"links","label":"Sethna et al., Nature 2025"}]},{"url":"https://doi.org/10.1038/s41586-025-09025-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41586-025-09025-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025","kind":"paper","name":"Geographic and age variations in mutational processes in colorectal cancer","route":"/key-papers/paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025/","field":"links","label":"Nature 2025"},{"id":"colibactin","kind":"term","name":"Colibactin","route":"/terms/colibactin/","field":"links","label":"Nature 2025: geographic and age variations in mutational processes in colorectal cancer (981 genomes from 11 countries)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"links","label":"Nature 2025: geographic and age variations in mutational processes in colorectal cancer (981 genomes from 11 countries)"}]},{"url":"https://doi.org/10.1038/s41587-020-0462-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41587-020-0462-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","field":"links","label":"Klichinsky et al., Human chimeric antigen receptor macrophages for cancer immunotherapy (Nature Biotechnology 2020)"},{"id":"paper-klichinsky-nat-biotechnol","kind":"paper","name":"Human chimeric antigen receptor macrophages for cancer immunotherapy","route":"/key-papers/paper-klichinsky-nat-biotechnol/","field":"links","label":"Nat Biotechnol 2020"}]},{"url":"https://doi.org/10.1038/s41587-021-00981-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41587-021-00981-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","field":"links","label":"Kurtz et al., Enhanced detection of minimal residual disease by targeted sequencing of phased variants (Nature Biotechnology 2021)"},{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/","field":"links","label":"Nat Biotechnol 2021"}]},{"url":"https://doi.org/10.1038/s41587-022-01483-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41587-022-01483-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"He et al., CosMx spatial molecular imager (Nature Biotechnology 2022)"}]},{"url":"https://doi.org/10.1038/s41587-023-01905-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41587-023-01905-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-roohani-nat-biotechnol","kind":"paper","name":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","route":"/key-papers/paper-roohani-nat-biotechnol/","field":"links","label":"Nat Biotechnol 2024"},{"id":"gears","kind":"technology","name":"GEARS and perturbation prediction benchmarks","route":"/technologies/gears/","field":"links","label":"Nature Biotechnology 2023"}]},{"url":"https://doi.org/10.1038/s41588-018-0078-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-018-0078-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","kind":"paper","name":"The long tail of oncogenic drivers in prostate cancer","route":"/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/","field":"links","label":"Armenia et al., Nat Genet 2018: the long tail of oncogenic drivers across 1,013 uniformly analysed prostate cancer exomes"}]},{"url":"https://doi.org/10.1038/s41588-018-0165-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-018-0165-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"whole-genome-doubling","kind":"term","name":"Whole-genome doubling (WGD)","route":"/terms/whole-genome-doubling/","field":"links","label":"Bielski et al., Genome doubling shapes the evolution and prognosis of advanced cancers (Nature Genetics 2018)"},{"id":"paper-bielski-nat-genet","kind":"paper","name":"Genome doubling shapes the evolution and prognosis of advanced cancers","route":"/key-papers/paper-bielski-nat-genet/","field":"links","label":"Nat Genet 2018"}]},{"url":"https://doi.org/10.1038/s41588-018-0318-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-018-0318-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"papers","label":"Molecular landmarks of tumor hypoxia across cancer types"}]},{"url":"https://doi.org/10.1038/s41588-019-0566-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-019-0566-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"links","label":"Chan-Seng-Yue, Nat Genet 2020: transcription phenotypes of pancreatic cancer are a continuum driven by genomic events"},{"id":"paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020","kind":"paper","name":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","route":"/key-papers/paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020/","field":"links","label":"Chan-Seng-Yue et al., Nat Genet 2020: transcription phenotypes driven by genomic events (purified whole genomes)"},{"id":"gata6-classical-basal-marker","kind":"term","name":"GATA6 as the marker of classical versus basal-like pancreatic cancer","route":"/terms/gata6-classical-basal-marker/","field":"links","label":"Chan-Seng-Yue et al., Nat Genet 2020: transcription phenotypes driven by genomic events (purified whole genomes)"},{"id":"kras-allelic-imbalance","kind":"term","name":"KRAS allelic imbalance and mutant KRAS dosage in pancreatic cancer","route":"/terms/kras-allelic-imbalance/","field":"links","label":"Chan-Seng-Yue et al., Nat Genet 2020: transcription phenotypes driven by genomic events (purified whole genomes)"},{"id":"compass-study-pancreatic","kind":"term","name":"COMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection","route":"/terms/compass-study-pancreatic/","field":"links","label":"Chan-Seng-Yue et al., Nat Genet 2020: transcription phenotypes driven by genomic events (purified whole genomes)"}]},{"url":"https://doi.org/10.1038/s41588-019-0569-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-019-0569-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/","field":"links","label":"Chen et al., Nat Genet 2020: the genomic landscape of lung adenocarcinoma in 305 East Asians (OncoSG)"}]},{"url":"https://doi.org/10.1038/s41588-019-0576-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-019-0576-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cortes-ciriano-nat-genet","kind":"paper","name":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","route":"/key-papers/paper-cortes-ciriano-nat-genet/","field":"links","label":"Nat Genet 2020"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"links","label":"Cortés-Ciriano et al., Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (Nature Genetics 2020)"}]},{"url":"https://doi.org/10.1038/s41588-020-00710-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-020-00710-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","field":"links","label":"Bolton et al., Cancer therapy shapes the fitness landscape of clonal hematopoiesis (Nature Genetics 2020)"},{"id":"paper-bolton-nat-genet","kind":"paper","name":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","route":"/key-papers/paper-bolton-nat-genet/","field":"links","label":"Nat Genet 2020"}]},{"url":"https://doi.org/10.1038/s41588-020-00748-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-020-00748-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021","kind":"paper","name":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","route":"/key-papers/paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021/","field":"links","label":"Nat Genet 2021"},{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"links","label":"Conti et al., Nature Genetics 2021: trans-ancestry genome-wide association meta-analysis of prostate cancer"}]},{"url":"https://doi.org/10.1038/s41588-020-0628-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-020-0628-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hu-nat-genet","kind":"paper","name":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","route":"/key-papers/paper-hu-nat-genet/","field":"links","label":"Nat Genet 2020"},{"id":"metastasis-seeding-models","kind":"technology","name":"Metastatic seeding and dormancy models","route":"/technologies/metastasis-seeding-models/","field":"links","label":"Hu and colleagues 2020, Nature Genetics: timing of metastasis"}]},{"url":"https://doi.org/10.1038/s41588-021-00920-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-021-00920-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/","field":"links","label":"Nat Genet 2021"}]},{"url":"https://doi.org/10.1038/s41588-022-01024-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-022-01024-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"papers","label":"New insights into the genetic etiology of Alzheimer's disease and related dementias"}]},{"url":"https://doi.org/10.1038/s41588-024-02053-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41588-024-02053-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-linder-nat-genet","kind":"paper","name":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation","route":"/key-papers/paper-linder-nat-genet/","field":"links","label":"Nat Genet 2025"},{"id":"enformer-borzoi","kind":"technology","name":"Enformer and Borzoi (DeepMind, Calico)","route":"/technologies/enformer-borzoi/","field":"links","label":"Borzoi, Nature Genetics 2025"}]},{"url":"https://doi.org/10.1038/s41591-018-0009-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-018-0009-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/","field":"links","label":"Nature Medicine 2018 (DOI)"},{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/","field":"links","label":"Tutt et al., Nature Medicine 2018: carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups, the TNT trial"},{"id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/","field":"links","label":"TNT trial: carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups (Nature Medicine 2018)"},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"papers","label":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial"},{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/","field":"links","label":"Nat Med 2018"}]},{"url":"https://doi.org/10.1038/s41591-018-0014-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-018-0014-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","field":"links","label":"Binnewies et al., Understanding the tumor immune microenvironment (Nature Medicine 2018)"},{"id":"paper-binnewies-tumor-immune-microenvironment-natmed-2018","kind":"paper","name":"Binnewies 2018: understanding the tumour immune microenvironment for effective therapy","route":"/key-papers/paper-binnewies-tumor-immune-microenvironment-natmed-2018/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1038/s41591-018-0134-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-018-0134-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gandara-blood-tmb-atezolizumab-nat-med-2018","kind":"paper","name":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","route":"/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/","field":"links","label":"Gandara et al., Nat Med 2018: blood-based tumour mutational burden as a predictor of atezolizumab benefit"}]},{"url":"https://doi.org/10.1038/s41591-018-0255-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-018-0255-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","field":"links","label":"Bensch et al., 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade (Nature Medicine 2018)"},{"id":"paper-bensch-nat-med","kind":"paper","name":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","route":"/key-papers/paper-bensch-nat-med/","field":"links","label":"Nat Med 2018"}]},{"url":"https://doi.org/10.1038/s41591-019-0380-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0380-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rothwell-nat-med","kind":"paper","name":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","route":"/key-papers/paper-rothwell-nat-med/","field":"links","label":"Nat Med 2019"},{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/","field":"links","label":"Rothwell et al., Nature Medicine 2019: utility of ctDNA to support patient selection for early phase clinical trials, the TARGET study"}]},{"url":"https://doi.org/10.1038/s41591-019-0407-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0407-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sicklick-nat-med","kind":"paper","name":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","route":"/key-papers/paper-sicklick-nat-med/","field":"links","label":"Nat Med 2019"},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","field":"links","label":"Sicklick et al., Nature Medicine 2019: molecular profiling of cancer patients enables personalized combination therapy, the I-PREDICT study"},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","field":"outcomes.source (Consented patients who received molecularly matched personalised treatment)"},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","field":"outcomes.source (Disease control (stable disease 6 months or longer, or response) by matching score)"},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","field":"outcomes.source (Progression-free survival by matching score)"}]},{"url":"https://doi.org/10.1038/s41591-019-0410-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0410-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","field":"papers","label":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination"}]},{"url":"https://doi.org/10.1038/s41591-019-0424-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0424-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rodon-nat-med","kind":"paper","name":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","route":"/key-papers/paper-rodon-nat-med/","field":"links","label":"Nat Med 2019"},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","field":"links","label":"Rodon et al., Nature Medicine 2019: genomic and transcriptomic profiling expands precision cancer medicine, the WINTHER trial"},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","field":"outcomes.source (Progression-free survival ratio above 1.5 against the prior line of therapy)"},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","field":"outcomes.source (Stable disease 6 months or longer, or partial or complete response)"}]},{"url":"https://doi.org/10.1038/s41591-019-0472-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0472-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"papers","label":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant"}]},{"url":"https://doi.org/10.1038/s41591-019-0582-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0582-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","kind":"paper","name":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","route":"/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/","field":"links","label":"Staaf et al., Nat Med 2019: whole-genome sequencing of 254 population-based TNBCs (SCAN-B)"}]},{"url":"https://doi.org/10.1038/s41591-019-0653-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-019-0653-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-durham-nat-med","kind":"paper","name":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","route":"/key-papers/paper-durham-nat-med/","field":"links","label":"Nat Med 2019"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"links","label":"Cobimetinib in histiocytic neoplasms (Nature Medicine 2019)"}]},{"url":"https://doi.org/10.1038/s41591-020-0805-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-020-0805-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/","field":"links","label":"Nat Med 2020"}]},{"url":"https://doi.org/10.1038/s41591-020-0910-8","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-020-0910-8&code=e7f8fe35-106f-4d10-abad-d0ec817bca50","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","field":"papers","label":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents"}]},{"url":"https://doi.org/10.1038/s41591-020-0968-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-020-0968-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"papers","label":"Extrapulmonary manifestations of COVID-19"}]},{"url":"https://doi.org/10.1038/s41591-020-1089-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-020-1089-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","field":"links","label":"Beat AML (Nat Med 2020)"},{"id":"paper-burd-nat-med","kind":"paper","name":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","route":"/key-papers/paper-burd-nat-med/","field":"links","label":"Nat Med 2020"},{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/","field":"links","label":"Burd et al., Nature Medicine 2020: precision medicine treatment in acute myeloid leukemia using prospective genomic profiling, feasibility and preliminary efficacy of the Beat AML Master Trial"},{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/","field":"outcomes.source (Overall survival (non-randomised comparison))"}]},{"url":"https://doi.org/10.1038/s41591-021-01312-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01312-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"links","label":"Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"metrics (FDA-approved AI medical devices (to 2020) evaluated only retrospectively)"},{"id":"idea-data-ai-post-market-performance-reporting","kind":"idea","name":"Mandatory post-market performance reporting for cancer AI","route":"/ideas/idea-data-ai-post-market-performance-reporting/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-drift-monitoring-standard","kind":"idea","name":"A standard for monitoring AI performance drift with pause thresholds","route":"/ideas/idea-data-drift-monitoring-standard/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-neutral-ai-evaluator","kind":"idea","name":"A neutral public evaluator for cancer AI, on the model of NIST","route":"/ideas/idea-data-neutral-ai-evaluator/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-liability-safe-harbour","kind":"idea","name":"A liability framework for clinical AI: safe harbour for clinicians, liability for makers","route":"/ideas/idea-data-ai-liability-safe-harbour/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-silent-trial-before-deployment","kind":"idea","name":"A mandatory silent (shadow) trial before any cancer AI goes live","route":"/ideas/idea-data-silent-trial-before-deployment/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-subgroup-performance-reporting-mandate","kind":"idea","name":"Mandatory subgroup performance reporting for cancer AI","route":"/ideas/idea-data-subgroup-performance-reporting-mandate/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-open-weights-for-public-funded-ai","kind":"idea","name":"Publicly funded cancer AI must release open weights and model cards","route":"/ideas/idea-data-open-weights-for-public-funded-ai/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-digital-twin-predict-then-observe","kind":"idea","name":"Digital twins for treatment selection, validated by predicting before observing","route":"/ideas/idea-data-digital-twin-predict-then-observe/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-in-silico-trials-calibrated","kind":"idea","name":"In silico trials to prioritise combinations, scored against later real trials","route":"/ideas/idea-data-in-silico-trials-calibrated/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-screening-endpoints","kind":"idea","name":"Require stage-shift or interval-cancer endpoints for AI in cancer screening","route":"/ideas/idea-data-ai-screening-endpoints/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-multisite-validation-precondition","kind":"idea","name":"External validation at five or more sites in two countries before clearance","route":"/ideas/idea-data-multisite-validation-precondition/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-patient-facing-model-cards","kind":"idea","name":"Patients told which AI is used in their care, in plain language","route":"/ideas/idea-data-patient-facing-model-cards/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-red-team-programme","kind":"idea","name":"Red-team programmes that attack cancer AI before patients do","route":"/ideas/idea-data-ai-red-team-programme/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-audit-trail-in-ehr","kind":"idea","name":"Every AI output logged in the record with input hash, version and clinician response","route":"/ideas/idea-data-ai-audit-trail-in-ehr/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-decommissioning-rules","kind":"idea","name":"Rules for retiring cancer AI when performance drops or the standard of care moves","route":"/ideas/idea-data-ai-decommissioning-rules/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-llm-documentation-rct-oncology","kind":"idea","name":"A randomised trial of AI scribes in oncology clinics measuring errors and time","route":"/ideas/idea-data-llm-documentation-rct-oncology/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-data-ai-vs-tumour-board-rct","kind":"idea","name":"A randomised trial of AI-generated treatment recommendations versus tumour boards","route":"/ideas/idea-data-ai-vs-tumour-board-rct/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/","field":"links","label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)"},{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/","field":"links","label":"Nat Med 2021"}]},{"url":"https://doi.org/10.1038/s41591-021-01444-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01444-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021","kind":"paper","name":"JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma","route":"/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/","field":"links","label":"Nat Med 2021"}]},{"url":"https://doi.org/10.1038/s41591-021-01538-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01538-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)","route":"/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","field":"links","label":"Nat Med 2021"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"outcomes.source (Overall response rate (response-evaluable advanced systemic mastocytosis))"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"outcomes.source (Complete remission rate (response-evaluable advanced systemic mastocytosis))"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"outcomes.source (Reduction of 50% or more in serum tryptase)"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"outcomes.source (Intracranial bleeding)"},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","field":"outcomes.source (Periorbital oedema (any grade))"}]},{"url":"https://doi.org/10.1038/s41591-021-01539-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01539-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)","route":"/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","field":"links","label":"Nat Med 2021"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"links","label":"PATHFINDER: avapritinib in advanced SM (Nature Medicine 2021)"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"standardOfCare.guideline (Advanced SM, first line)"}]},{"url":"https://doi.org/10.1038/s41591-021-01553-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01553-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021","kind":"paper","name":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)","route":"/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/","field":"links","label":"Nakamura et al., Nat Med 2021: TRIUMPH, ctDNA-guided pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer"},{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/","field":"links","label":"TRIUMPH: circulating tumour DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (Nature Medicine 2021)"},{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/","field":"outcomes.source (Confirmed objective response rate)"}]},{"url":"https://doi.org/10.1038/s41591-021-01562-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01562-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/","field":"links","label":"Nat Med 2021"},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","field":"links","label":"DAWNA-1 (Nat Med 2021)"},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","field":"links","label":"Nat Med 2021"},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://doi.org/10.1038/s41591-021-01600-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01600-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/","field":"links","label":"IMbassador250 (Nature Medicine 2022)"},{"id":"imbassador250","kind":"trial","name":"IMbassador250","route":"/trials/imbassador250/","field":"links","label":"IMbassador250 (Nature Medicine 2022)"},{"id":"imbassador250","kind":"trial","name":"IMbassador250","route":"/trials/imbassador250/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1038/s41591-021-01622-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-021-01622-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphoma-tx-pod24","kind":"term","name":"POD24: progression of follicular lymphoma within two years, and why it changes the plan","route":"/terms/lymphoma-tx-pod24/","field":"links","label":"ELARA: tisagenlecleucel in relapsed or refractory follicular lymphoma, Nature Medicine 2022"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Progression within two years of first chemotherapy (POD24): biopsy first, then a different class of treatment)"}]},{"url":"https://doi.org/10.1038/s41591-022-01694-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-01694-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dizman-nat-med","kind":"paper","name":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","route":"/key-papers/paper-dizman-nat-med/","field":"links","label":"Nat Med 2022"},{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/","field":"links","label":"CBM588 + nivolumab/ipilimumab RCT (Nat Med 2022)"}]},{"url":"https://doi.org/10.1038/s41591-022-01886-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-01886-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","field":"links","label":"CHRONOS: ctDNA-guided anti-EGFR rechallenge with panitumumab in metastatic colorectal cancer (Nature Medicine 2022)"},{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","field":"outcomes.source (Objective response rate)"},{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/","field":"links","label":"Sartore-Bianchi, Nat Med 2022: CHRONOS, circulating tumour DNA to guide rechallenge with panitumumab in metastatic colorectal cancer (27 patients treated)"}]},{"url":"https://doi.org/10.1038/s41591-022-01897-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-01897-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-todo-g47delta-glioblastoma-natmed-2022","kind":"paper","name":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","route":"/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/","field":"links","label":"Nat Med 2022"}]},{"url":"https://doi.org/10.1038/s41591-022-01933-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-01933-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/","field":"links","label":"Nat Med 2022"}]},{"url":"https://doi.org/10.1038/s41591-022-01935-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-01935-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","field":"papers","label":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases"},{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/","field":"links","label":"Nat Med 2022"},{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","field":"outcomes.source (Best overall intracranial response rate (RANO-BM))"},{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","field":"outcomes.source (Complete intracranial response)"},{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","field":"outcomes.source (Partial intracranial response)"}]},{"url":"https://doi.org/10.1038/s41591-022-02115-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-02115-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-late-recurrence-interception","kind":"idea","name":"Intercepting late recurrence with ctDNA surveillance and oral SERDs","route":"/ideas/idea-late-recurrence-interception/","field":"links","label":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold (Nature Medicine 2023)"},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","field":"outcomes.source (GALAXY (observational): recurrence risk by post-operative ctDNA status (4 weeks after surgery))"},{"id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","field":"links","label":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold (Nature Medicine 2023)"},{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","field":"papers","label":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold"},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1038/s41591-022-02183-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-022-02183-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","field":"outcomes.source (Prevalence of smouldering multiple myeloma among screened residents aged 40 or older)"}]},{"url":"https://doi.org/10.1038/s41591-023-02379-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02379-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-o-dwyer-nat-med","kind":"paper","name":"The NCI-MATCH trial: lessons for precision oncology","route":"/key-papers/paper-o-dwyer-nat-med/","field":"links","label":"Nat Med 2023"},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"O'Dwyer et al., Nature Medicine 2023: the NCI-MATCH trial, lessons for precision oncology"}]},{"url":"https://doi.org/10.1038/s41591-023-02452-y","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-023-02452-y&code=e1771992-ba3e-41ed-a584-c4dea5a1ac85","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/","field":"links","label":"Nat Med 2023"}]},{"url":"https://doi.org/10.1038/s41591-023-02453-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02453-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/","field":"links","label":"Nat Med 2023"},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","field":"links","label":"Routy et al. MIMic-01 (Nat Med 2023)"},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","field":"links","label":"Routy et al. (Nat Med 2023)"},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1038/s41591-023-02465-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02465-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","field":"papers","label":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma"},{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/","field":"links","label":"Nat Med 2023"}]},{"url":"https://doi.org/10.1038/s41591-023-02528-9","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02528-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1038/s41591-023-02554-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02554-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/","field":"links","label":"Nat Med 2023"}]},{"url":"https://doi.org/10.1038/s41591-023-02583-2","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02583-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","field":"papers","label":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma"},{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/","field":"links","label":"Nat Med 2023"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"links","label":"CheckMate 76K (Nature Medicine 2023)"}]},{"url":"https://doi.org/10.1038/s41591-023-02612-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02612-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/","field":"links","label":"BNT211 CARVac (Nat Med 2023)"},{"id":"paper-mackensen-nat-med","kind":"paper","name":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","route":"/key-papers/paper-mackensen-nat-med/","field":"links","label":"Nat Med 2023"}]},{"url":"https://doi.org/10.1038/s41591-023-02668-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02668-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kilburn-nat-med","kind":"paper","name":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","route":"/key-papers/paper-kilburn-nat-med/","field":"links","label":"Nat Med 2024"},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","field":"links","label":"FIREFLY-1: tovorafenib in relapsed BRAF-altered pLGG (Nature Medicine 2024)"},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","field":"links","label":"Kilburn et al., Nature Medicine 2024"},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","field":"outcomes.source (Overall response rate (RANO-HGG, independent review))"},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","field":"outcomes.source (Overall response rate (RAPNO-LGG, including minor responses))"},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","field":"outcomes.source (Median duration of response)"}]},{"url":"https://doi.org/10.1038/s41591-023-02760-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-023-02760-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","field":"links","label":"Pant et al., AMPLIFY-201: lymph-node-targeted mutant KRAS amphiphile vaccine in pancreatic and colorectal cancer (Nature Medicine 2024)"},{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-02805-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-02805-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/","field":"links","label":"Garralda et al., MYC targeting by OMO-103 in solid tumours: a phase 1 trial (Nature Medicine 2024)"},{"id":"paper-garralda-nat-med","kind":"paper","name":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","route":"/key-papers/paper-garralda-nat-med/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-02808-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-02808-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-02856-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-02856-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lu-nat-med","kind":"paper","name":"A visual-language foundation model for computational pathology","route":"/key-papers/paper-lu-nat-med/","field":"links","label":"Nat Med 2024"},{"id":"uni-conch","kind":"technology","name":"UNI and CONCH (Harvard, Mahmood Lab)","route":"/technologies/uni-conch/","field":"links","label":"CONCH, Nature Medicine 2024"},{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"Lu et al., CONCH: a visual-language foundation model for computational pathology (Nature Medicine 2024)"}]},{"url":"https://doi.org/10.1038/s41591-024-02857-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-02857-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","field":"links","label":"Chen et al., Towards a general-purpose foundation model for computational pathology (Nature Medicine 2024)"},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/","field":"links","label":"Chen et al., Towards a general-purpose foundation model for computational pathology (Nature Medicine 2024)"},{"id":"paper-chen-nat-med","kind":"paper","name":"Towards a general-purpose foundation model for computational pathology","route":"/key-papers/paper-chen-nat-med/","field":"links","label":"Nat Med 2024"},{"id":"uni-conch","kind":"technology","name":"UNI and CONCH (Harvard, Mahmood Lab)","route":"/technologies/uni-conch/","field":"links","label":"UNI, Nature Medicine 2024"},{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"Chen et al., UNI: towards a general-purpose foundation model for computational pathology (Nature Medicine 2024)"}]},{"url":"https://doi.org/10.1038/s41591-024-02875-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-02875-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"papers","label":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial"},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","field":"links","label":"OMO-103 first-in-human (Nature Medicine 2024)"},{"id":"paper-brown-nat-med","kind":"paper","name":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","route":"/key-papers/paper-brown-nat-med/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-03060-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03060-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-03083-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03083-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","field":"links","label":"Bullock et al., Botensilimab plus balstilimab in relapsed or refractory microsatellite-stable colorectal cancer (Nature Medicine 2024)"},{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-03141-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03141-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","field":"links","label":"Vorontsov et al., A foundation model for clinical-grade computational pathology (Nature Medicine 2024)"},{"id":"paper-vorontsov-nat-med","kind":"paper","name":"A foundation model for clinical-grade computational pathology and rare cancers detection","route":"/key-papers/paper-vorontsov-nat-med/","field":"links","label":"Nat Med 2024"},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/","field":"links","label":"Virchow, Nature Medicine 2024"},{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"Vorontsov et al., Virchow: a foundation model for clinical-grade computational pathology (Nature Medicine 2024)"}]},{"url":"https://doi.org/10.1038/s41591-024-03261-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03261-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/","field":"links","label":"Nat Med 2024"}]},{"url":"https://doi.org/10.1038/s41591-024-03401-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03401-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-024-03415-7","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-024-03415-7&code=a3df6adc-c3af-46a9-bbc9-54a3aaf6b2b4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-024-03443-3","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03443-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-024-03485-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-024-03485-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","field":"outcomes.source (MRD negativity (10⁻⁵))"},{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","field":"outcomes.source (Progression-free survival at 54 months)"}]},{"url":"https://doi.org/10.1038/s41591-025-03572-3","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-03572-3&code=6a7bf6e0-eeef-4a4a-916f-d660560622c1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"outcomes.source (Spleen volume reduction >=35% at week 24)"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"outcomes.source (Total symptom score reduction >=50% at week 24 (TSS50))"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"outcomes.source (Absolute change in total symptom score at week 24)"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"outcomes.source (Grade 3 or higher anaemia)"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","field":"outcomes.source (Grade 3 or higher thrombocytopenia)"}]},{"url":"https://doi.org/10.1038/s41591-025-03579-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03579-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03630-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03630-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03725-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03725-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03746-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03746-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03883-5","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03883-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03961-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03961-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-03981-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-03981-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"links","label":"DESTINY-Breast04 long-term survival analysis (Nature Medicine 2025)"},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"links","label":"DESTINY-Breast04 long-term survival (Nature Medicine 2025)"},{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-025-04030-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-025-04030-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dynamic-iii","kind":"trial","name":"DYNAMIC-III","route":"/trials/dynamic-iii/","field":"links","label":"DYNAMIC-III: circulating tumour DNA-guided adjuvant therapy in locally advanced colon cancer (Nature Medicine 2025)"},{"id":"dynamic-iii","kind":"trial","name":"DYNAMIC-III","route":"/trials/dynamic-iii/","field":"outcomes.source (Recurrence-free survival at 3 years by ctDNA status)"}]},{"url":"https://doi.org/10.1038/s41591-025-04032-8","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-04032-8&code=d818f3d3-8634-43dc-a98b-159a7a73a21d","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","field":"outcomes.source (Recurrence-free survival)"},{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/","field":"links","label":"Nat Med 2025"}]},{"url":"https://doi.org/10.1038/s41591-026-04292-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04292-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Nature Medicine 2026: implementation of the NHS England Lung Cancer Screening Programme over 5 years (over two million invited, 7,193 cancers to March 2025)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"Nature Medicine 2026: implementation of the NHS England Lung Cancer Screening Programme over 5 years (over two million invited, 7,193 cancers to March 2025)"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","field":"links","label":"Nature Medicine 2026: implementation of the NHS England Lung Cancer Screening Programme over 5 years (over two million invited, 7,193 cancers to March 2025)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Nature Medicine 2026: implementation of the NHS England Lung Cancer Screening Programme over 5 years (over two million invited, 7,193 cancers to March 2025)"}]},{"url":"https://doi.org/10.1038/s41591-026-04323-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04323-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/","field":"links","label":"Nat Med 2026"}]},{"url":"https://doi.org/10.1038/s41591-026-04327-4","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04327-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mahalingam-nat-med","kind":"paper","name":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","route":"/key-papers/paper-mahalingam-nat-med/","field":"links","label":"Nat Med 2026"},{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","field":"links","label":"Mahalingam et al., elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma, randomised phase 2 (Nature Medicine 2026)"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"links","label":"Mahalingam et al., Nature Medicine 2026: elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma, randomised phase 2"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"links","label":"Mahalingam et al., elraglusib randomised phase 2 (Nature Medicine 2026)"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"outcomes.source (Overall survival)"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"outcomes.source (Overall survival at 1 year)"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"outcomes.source (Overall survival (modified intention to treat))"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","field":"outcomes.source (Overall survival at 1 year)"}]},{"url":"https://doi.org/10.1038/s41591-026-04428-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04428-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","field":"links","label":"ALTAIR: post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer (Nature Medicine 2026)"},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","field":"outcomes.source (ALTAIR (randomised phase 3): disease-free survival in post-adjuvant ctDNA-positive patients)"},{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/","field":"links","label":"ALTAIR: post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer (Nature Medicine 2026)"},{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/","field":"outcomes.source (Disease-free survival)"}]},{"url":"https://doi.org/10.1038/s41591-026-04518-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04518-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/","field":"links","label":"Nat Med 2026"}]},{"url":"https://doi.org/10.1038/s41591-026-04564-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04564-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/","field":"links","label":"Nat Med 2026"}]},{"url":"https://doi.org/10.1038/s41591-026-04565-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04565-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/","field":"links","label":"Geyer, Loibl et al., Nature Medicine 2026: atezolizumab in early triple-negative breast cancer, NSABP B-59/GeparDouze"},{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/","field":"outcomes.source (Event-free survival (four-year difference 3.3 points))"},{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/","field":"outcomes.source (Overall survival (four-year difference 0.7 points))"}]},{"url":"https://doi.org/10.1038/s41591-026-04652-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41591-026-04652-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","field":"links","label":"NHS-Galleri: test performance across three annual rounds (Nature Medicine 2026)"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"links","label":"NHS-Galleri test performance (Nature Medicine 2026)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"links","label":"Nature Medicine 2026: test performance across three rounds"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Stage III to IV incidence, 12 prespecified cancers (primary))"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Positive test results by screening round)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Cancer detection rate by screening round)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Positive predictive value by screening round)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Negative predictive value by screening round)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Specificity, range across rounds)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Episode sensitivity, all cancers, range across rounds)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Episode sensitivity, 12 prespecified cancer types, range across rounds)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Cancer signal origin accuracy, range across rounds)"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/","field":"links","label":"Nature Medicine 2026"}]},{"url":"https://doi.org/10.1038/s41592-020-01042-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-020-01042-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/","field":"links","label":"Method of the Year 2020: spatially resolved transcriptomics (Nature Methods 2021)"},{"id":"paper-authors-nat-methods-2021","kind":"paper","name":"Method of the Year 2020: spatially resolved transcriptomics","route":"/key-papers/paper-authors-nat-methods-2021/","field":"links","label":"Nat Methods 2021"}]},{"url":"https://doi.org/10.1038/s41592-021-01252-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-021-01252-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-avsec-z-nat-methods","kind":"paper","name":"Effective gene expression prediction from sequence by integrating long-range interactions","route":"/key-papers/paper-avsec-z-nat-methods/","field":"links","label":"Nat Methods 2021"},{"id":"enformer-borzoi","kind":"technology","name":"Enformer and Borzoi (DeepMind, Calico)","route":"/technologies/enformer-borzoi/","field":"links","label":"Enformer, Nature Methods 2021"},{"id":"genomic-and-protein-language-models","kind":"term","name":"Genomic and protein language models: Evo 2, Enformer, ESM","route":"/terms/genomic-and-protein-language-models/","field":"links","label":"Avsec et al., Enformer: effective gene expression prediction from sequence by integrating long-range interactions (Nature Methods 2021)"}]},{"url":"https://doi.org/10.1038/s41592-021-01255-8","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-021-01255-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"spagcn","kind":"term","name":"Spatially aware clustering (SpaGCN, KNN smoothing)","route":"/terms/spagcn/","field":"links","label":"Hu et al., SpaGCN: integrating gene expression, spatial location and histology to identify spatial domains (Nature Methods 2021)"}]},{"url":"https://doi.org/10.1038/s41592-024-02201-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-024-02201-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cui-nat-methods","kind":"paper","name":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","route":"/key-papers/paper-cui-nat-methods/","field":"links","label":"Nat Methods 2024"},{"id":"scgpt","kind":"technology","name":"scGPT","route":"/technologies/scgpt/","field":"links","label":"Nature Methods 2024"}]},{"url":"https://doi.org/10.1038/s41592-024-02305-7","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-024-02305-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hao-nat-methods","kind":"paper","name":"Large-scale foundation model on single-cell transcriptomics","route":"/key-papers/paper-hao-nat-methods/","field":"links","label":"Nat Methods 2024"},{"id":"scfoundation","kind":"technology","name":"scFoundation (BioMap)","route":"/technologies/scfoundation/","field":"links","label":"Nature Methods 2024"}]},{"url":"https://doi.org/10.1038/s41592-024-02523-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41592-024-02523-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dalla-torre-nat-methods","kind":"paper","name":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics","route":"/key-papers/paper-dalla-torre-nat-methods/","field":"links","label":"Nat Methods 2025"},{"id":"nucleotide-transformer","kind":"technology","name":"Nucleotide Transformer (InstaDeep)","route":"/technologies/nucleotide-transformer/","field":"links","label":"Nature Methods 2024"}]},{"url":"https://doi.org/10.1038/s41598-018-36340-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-018-36340-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"bbb-focused-ultrasound","kind":"technology","name":"Focused-ultrasound blood-brain barrier opening","route":"/technologies/bbb-focused-ultrasound/","field":"links","label":"Mainprize et al., Blood-brain barrier opening in primary brain tumours with non-invasive MR-guided focused ultrasound (Scientific Reports 2019)"},{"id":"paper-mainprize-sci-rep","kind":"paper","name":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study","route":"/key-papers/paper-mainprize-sci-rep/","field":"links","label":"Sci Rep 2019"},{"id":"transcranial-focused-ultrasound-systems","kind":"technology","name":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","route":"/technologies/transcranial-focused-ultrasound-systems/","field":"links","label":"Mainprize et al., Blood-brain barrier opening in primary brain tumours with non-invasive MR-guided focused ultrasound (Scientific Reports 2019)"}]},{"url":"https://doi.org/10.1038/s41598-019-46906-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-019-46906-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"links","label":"Scientific Reports 2019: systematic review of somatic mutations in splenic marginal zone lymphoma, 475 cases"}]},{"url":"https://doi.org/10.1038/s41598-019-49860-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-019-49860-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019","kind":"paper","name":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","route":"/key-papers/paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019/","field":"links","label":"Ettrich et al., Sci Rep 2019: ctDNA genotyping in cholangiocarcinoma"}]},{"url":"https://doi.org/10.1038/s41598-020-71236-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-020-71236-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020","kind":"paper","name":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","route":"/key-papers/paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020/","field":"links","label":"Cavallone et al., Sci Rep 2020: ctDNA during neoadjuvant chemotherapy in 26 TNBC patients"}]},{"url":"https://doi.org/10.1038/s41598-021-88433-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-021-88433-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","field":"links","label":"Mebendazole phase 2a 2021"},{"id":"paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021","kind":"paper","name":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer","route":"/key-papers/paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021/","field":"links","label":"Mebendazole phase 2a 2021"}]},{"url":"https://doi.org/10.1038/s41598-022-07138-y","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-022-07138-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"papers","label":"Development and validation of a population-based risk stratification model for severe COVID-19 in the general population"}]},{"url":"https://doi.org/10.1038/s41598-024-67740-0","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41598-024-67740-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Van Coile et al., the impact of basal cell carcinoma on the quality of life in older patients, 400 patients scored on the BaSQoL questionnaire (Scientific Reports 2024)"}]},{"url":"https://doi.org/10.1038/s41698-023-00458-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41698-023-00458-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"papers","label":"NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology"}]},{"url":"https://doi.org/10.1038/s41746-020-00323-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41746-020-00323-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"federated-learning-medical-ai","kind":"technology","name":"Federated learning and privacy-preserving AI","route":"/technologies/federated-learning-medical-ai/","field":"links","label":"Rieke et al., The future of digital health with federated learning (npj Digital Medicine 2020)"},{"id":"paper-rieke-npj-digit-med","kind":"paper","name":"The future of digital health with federated learning","route":"/key-papers/paper-rieke-npj-digit-med/","field":"links","label":"NPJ Digit Med 2020"}]},{"url":"https://doi.org/10.1038/s41746-022-00613-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s41746-022-00613-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/","field":"links","label":"Esteva et al., Prostate cancer therapy personalisation via multimodal deep learning on randomised phase 3 trials (npj Digital Medicine 2022)"},{"id":"paper-esteva-npj-digit-med","kind":"paper","name":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","route":"/key-papers/paper-esteva-npj-digit-med/","field":"links","label":"NPJ Digit Med 2022"}]},{"url":"https://doi.org/10.1038/s43018-019-0010-1","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s43018-019-0010-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020","kind":"paper","name":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/","field":"links","label":"Hayashi et al., Nat Cancer 2020: squamous features are the histological correlate of basal-like expression"}]},{"url":"https://doi.org/10.1038/s43018-019-0018-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s43018-019-0018-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"papers","label":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling"}]},{"url":"https://doi.org/10.1038/s43018-020-00136-x","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s43018-020-00136-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","field":"links","label":"Ackerman et al., Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumour immunity (Nature Cancer 2020)"},{"id":"paper-ackerman-nat-cancer","kind":"paper","name":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","route":"/key-papers/paper-ackerman-nat-cancer/","field":"links","label":"Nat Cancer 2021"}]},{"url":"https://doi.org/10.1038/s43018-021-00232-6","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s43018-021-00232-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","field":"papers","label":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression"},{"id":"paper-antoine-italiano-nat-cancer-2021","kind":"paper","name":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","route":"/key-papers/paper-antoine-italiano-nat-cancer-2021/","field":"links","label":"Nat Cancer 2021"}]},{"url":"https://doi.org/10.1038/s43018-023-00578-z","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s43018-023-00578-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/","field":"links","label":"Nat Cancer 2023"}]},{"url":"https://doi.org/10.1038/s44276-023-00006-w","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/s44276-023-00006-w","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"BJC Reports 2023: lung cancer in never smokers, development of a UK national research strategy (127 surveys, 190 attendees)"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"BJC Reports 2023: lung cancer in never smokers, development of a UK national research strategy (127 surveys, 190 attendees)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"BJC Reports 2023: lung cancer in never smokers, development of a UK national research strategy (127 surveys, 190 attendees)"}]},{"url":"https://doi.org/10.1038/sj.bjc.6600678","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/6600678","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"papers","label":"NF-kappaB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase"}]},{"url":"https://doi.org/10.1038/sj.bjc.6602619","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/6602619","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Huxley, Br J Cancer 2005: type 2 diabetes and pancreatic cancer, meta-analysis of 36 studies"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Huxley, Br J Cancer 2005: type 2 diabetes and pancreatic cancer, meta-analysis of 36 studies"}]},{"url":"https://doi.org/10.1038/sj.bjc.6602924","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/6602924","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","field":"prevalence.source"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1038/sj.bjc.6604867","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/6604867","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009","kind":"paper","name":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","route":"/key-papers/paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009/","field":"links","label":"Koopman et al., Br J Cancer 2009: deficient mismatch repair in 515 patients with sporadic advanced colorectal cancer"}]},{"url":"https://doi.org/10.1038/sj.bjc.6605333","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/6605333","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ezh2-colorectal-br-j-cancer-2009","kind":"paper","name":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis","route":"/key-papers/paper-ezh2-colorectal-br-j-cancer-2009/","field":"links","label":"Br J Cancer 2009"}]},{"url":"https://doi.org/10.1038/sj.bmt.1705445","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/1705445","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-huang-bone-marrow-transplant","kind":"paper","name":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","route":"/key-papers/paper-huang-bone-marrow-transplant/","field":"links","label":"Bone Marrow Transplant 2006"},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","field":"links","label":"Huang XJ et al. Bone Marrow Transplant 2006"}]},{"url":"https://doi.org/10.1038/sj.mt.6300108","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1525001616313314","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kelly-russell-oncolytic-history-moltherapy-2007","kind":"paper","name":"Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping","route":"/key-papers/paper-kelly-russell-oncolytic-history-moltherapy-2007/","field":"links","label":"Mol Ther 2007"}]},{"url":"https://doi.org/10.1038/sj.onc.1204074","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/1204074","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ladanyi-aspl-tfe3-oncogene-2001","kind":"paper","name":"The der(17)t(X;17) of alveolar soft part sarcoma fuses TFE3 to ASPL","route":"/key-papers/paper-ladanyi-aspl-tfe3-oncogene-2001/","field":"links","label":"Oncogene 2001"}]},{"url":"https://doi.org/10.1038/srep11874","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/srep11874","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"papers","label":"IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells"}]},{"url":"https://doi.org/10.1038/srep30173","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/srep30173","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"papers","label":"Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial"}]},{"url":"https://doi.org/10.1053/gast.1996.v111.pm8698204","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508596003228","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplasia-dysplasia-carcinoma-sequence","kind":"term","name":"Metaplasia, dysplasia, carcinoma in situ: the flat route to gallbladder cancer","route":"/terms/metaplasia-dysplasia-carcinoma-sequence/","field":"links","label":"Roa et al., Gastroenterology 1996: time from dysplasia to gallbladder carcinoma"},{"id":"paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996","kind":"paper","name":"Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression","route":"/key-papers/paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996/","field":"links","label":"Roa et al., Gastroenterology 1996: time from dysplasia to gallbladder carcinoma"}]},{"url":"https://doi.org/10.1053/j.gastro.2005.05.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508505008772","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Chari, Gastroenterology 2005: probability of pancreatic cancer following diabetes, Rochester population"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Chari, Gastroenterology 2005: probability of pancreatic cancer following diabetes, Rochester population"}]},{"url":"https://doi.org/10.1053/j.gastro.2008.01.039","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508508001133","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pannala, Gastroenterology 2008: prevalence and profile of pancreatic cancer-associated diabetes"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Pannala, Gastroenterology 2008: prevalence and profile of pancreatic cancer-associated diabetes"}]},{"url":"https://doi.org/10.1053/j.gastro.2011.12.042","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508512000078","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kanda-panin-1-somatic-mutations-gastroenterology-2012","kind":"paper","name":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","route":"/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/","field":"links","label":"Kanda et al., Gastroenterology 2012: somatic mutations in more than 99% of PanIN-1 lesions"}]},{"url":"https://doi.org/10.1053/j.gastro.2015.07.041","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508515010677","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015","kind":"paper","name":"A combination of molecular markers and clinical features improve the classification of pancreatic cysts","route":"/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/","field":"links","label":"Springer et al., Gastroenterology 2015: molecular markers plus clinical features classify 130 resected cysts"}]},{"url":"https://doi.org/10.1053/j.gastro.2017.01.029","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508517300896","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jun-gastroenterology","kind":"paper","name":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality","route":"/key-papers/paper-jun-gastroenterology/","field":"links","label":"Gastroenterology 2017"},{"id":"gastric-endoscopic-screening","kind":"technology","name":"Gastric cancer endoscopic screening (East Asia)","route":"/technologies/gastric-endoscopic-screening/","field":"links","label":"Korean endoscopic screening and gastric cancer mortality (Gastroenterology 2017)"}]},{"url":"https://doi.org/10.1053/j.gastro.2017.04.005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508517354409","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Koshiol, Gastroenterology 2017: aflatoxin and gallbladder cancer (Shanghai case-control)"}]},{"url":"https://doi.org/10.1053/j.gastro.2017.05.004","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508517355580","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"papers","label":"Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing"}]},{"url":"https://doi.org/10.1053/j.gastro.2018.05.023","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508518345438","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Sharma, Gastroenterology 2018: the ENDPAC model for pancreatic cancer risk in new-onset diabetes"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"Sharma, Gastroenterology 2018: the ENDPAC model for pancreatic cancer risk in new-onset diabetes"},{"id":"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","kind":"paper","name":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes","route":"/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/","field":"links","label":"Gastroenterology 2018"}]},{"url":"https://doi.org/10.1053/j.gastro.2018.05.035","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508518345682","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Canto, Gastroenterology 2018: neoplastic progression in 354 high-risk individuals under long-term CAPS surveillance"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"Canto, Gastroenterology 2018: neoplastic progression in 354 high-risk individuals under long-term CAPS surveillance"},{"id":"paper-canto-caps-long-term-surveillance-gastroenterology-2018","kind":"paper","name":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","route":"/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/","field":"links","label":"Gastroenterology 2018"},{"id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","route":"/terms/caps-consortium-pancreatic-screening/","field":"links","label":"Canto et al., Gastroenterology 2018: 16 years of CAPS surveillance in 354 high-risk individuals"}]},{"url":"https://doi.org/10.1053/j.gastro.2018.08.033","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508518349199","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018","kind":"paper","name":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","route":"/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/","field":"links","label":"Puleo et al., Gastroenterology 2018: five tumour and microenvironment subtypes in 309 resected cancers"}]},{"url":"https://doi.org/10.1053/j.gastro.2018.09.022","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508518350066","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019","kind":"paper","name":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","route":"/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/","field":"links","label":"Bernard et al., Gastroenterology 2019: ctDNA and exosome DNA in 194 patients"}]},{"url":"https://doi.org/10.1053/j.gastro.2018.10.029","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508518351606","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-omori-ipmn-progression-pathways-gastroenterology-2019","kind":"paper","name":"Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features","route":"/key-papers/paper-omori-ipmn-progression-pathways-gastroenterology-2019/","field":"links","label":"Omori et al., Gastroenterology 2019: sequential, branch-off and de novo pathways from IPMN to cancer"}]},{"url":"https://doi.org/10.1053/j.gastro.2019.01.259","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508519303580","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"papers","label":"Early Detection of Pancreatic Cancer: Opportunities and Challenges"}]},{"url":"https://doi.org/10.1053/j.gastro.2019.02.037","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508519325053","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","kind":"paper","name":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","route":"/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/","field":"links","label":"Singhi et al., Gastroenterology 2019: targeted profiling of 3,594 pancreatic ductal adenocarcinomas"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1053/j.gastro.2019.06.041","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508519411153","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","kind":"paper","name":"Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia","route":"/key-papers/paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019/","field":"links","label":"Crockett and Nagtegaal, Gastroenterology 2019: terminology, molecular features, epidemiology and management of serrated colorectal neoplasia"}]},{"url":"https://doi.org/10.1053/j.gastro.2020.10.007","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508520352446","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Huang, Gastroenterology 2021: worldwide burden of, risk factors for, and trends in pancreatic cancer"}]},{"url":"https://doi.org/10.1053/j.gastro.2020.11.052","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508520355463","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fahrmann-ca19-9-lead-time-gastroenterology-2021","kind":"paper","name":"Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection","route":"/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/","field":"links","label":"Gastroenterology 2021"}]},{"url":"https://doi.org/10.1053/j.gastro.2021.08.036","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508521034168","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Gonda, Gastroenterology 2021: PRECEDE consortium recommendations for a more organised approach to early detection"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"Gonda, Gastroenterology 2021: PRECEDE consortium recommendations for a more organised approach to early detection"},{"id":"paper-gonda-precede-consortium-recommendations-gastroenterology-2021","kind":"paper","name":"Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium","route":"/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/","field":"links","label":"Gonda et al., Gastroenterology 2021: PRECEDE consortium recommendations for early detection"}]},{"url":"https://doi.org/10.1053/j.gastro.2023.04.016","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0016508523006303","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"Teoh et al., DRA-MBO randomised trial (Gastroenterology 2023)"}]},{"url":"https://doi.org/10.1053/j.seminoncol.2019.04.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0093775418300071","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"Rosti 2019, Seminars in Oncology: primary mediastinal germ cell tumours (review)"}]},{"url":"https://doi.org/10.1053/jpsu.2003.50110","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0022346802631185","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","field":"papers","label":"The diagnosis of acute appendicitis in a pediatric population: to CT or not to CT"}]},{"url":"https://doi.org/10.1054/bjoc.2000.1719","status":200,"ok":true,"finalUrl":"https://www.nature.com/doifinder/10.1054/bjoc.2000.1719","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"papers","label":"Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase"}]},{"url":"https://doi.org/10.1055/a-1185-3109","status":200,"ok":true,"finalUrl":"https://www.thieme-connect.de/DOI/DOI?10.1055/a-1185-3109","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"ESGE Guideline update 2020: post-polypectomy colonoscopy surveillance"},{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","field":"links","label":"ESGE Guideline update 2020: post-polypectomy colonoscopy surveillance"},{"id":"colonoscopy-surveillance-intervals","kind":"term","name":"Surveillance intervals after polypectomy","route":"/terms/colonoscopy-surveillance-intervals/","field":"links","label":"ESGE Guideline update 2020: post-polypectomy colonoscopy surveillance"}]},{"url":"https://doi.org/10.1055/s-0040-1709458","status":200,"ok":true,"finalUrl":"https://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1709458","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"papers","label":"Newborn Infant Parasympathetic Evaluation Index for the Assessment of Procedural Pain in Nonanesthetized Infants: A Multicenter Pilot Study"}]},{"url":"https://doi.org/10.1055/s-0043-101695","status":200,"ok":true,"finalUrl":"https://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-101695","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"EUS-guided gastroenterostomy versus surgical gastrojejunostomy: international multicentre comparison (Endoscopy 2017)"}]},{"url":"https://doi.org/10.1080/0284186x.2016.1189094","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actaoncologica/article/view/25621","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"papers","label":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research"}]},{"url":"https://doi.org/10.1080/0284186x.2018.1454602","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actaoncologica/article/view/25268","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gehl-acta-oncol","kind":"paper","name":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","route":"/key-papers/paper-gehl-acta-oncol/","field":"links","label":"Acta Oncol 2018"}]},{"url":"https://doi.org/10.1080/0284186X.2018.1454602","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actaoncologica/article/view/25268","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"electrochemotherapy-devices","kind":"technology","name":"Electrochemotherapy devices (Cliniporator)","route":"/technologies/electrochemotherapy-devices/","field":"links","label":"Gehl et al., Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases (Acta Oncologica 2018)"}]},{"url":"https://doi.org/10.1080/0284186X.2021.1967443","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actaoncologica/article/view/23886","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-validity-acta-oncol-2021","kind":"paper","name":"Comparability and validity of cancer registry data in the north-west of Russia","route":"/key-papers/paper-barchuk-registry-validity-acta-oncol-2021/","field":"links","label":"Acta Oncologica 2021"}]},{"url":"https://doi.org/10.1080/13651820510028873","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X15308571","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","field":"links","label":"Yamaguchi, HPB 2005: frozen section of the bile duct margin in gallbladder and bile duct cancer"}]},{"url":"https://doi.org/10.1086/302922","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002929707635484","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gorski-brca1-founder-mutations-poland-ajhg-2000","kind":"paper","name":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","route":"/key-papers/paper-gorski-brca1-founder-mutations-poland-ajhg-2000/","field":"links","label":"Am J Hum Genet 2000"}]},{"url":"https://doi.org/10.1086/663206","status":200,"ok":true,"finalUrl":"https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/randomized-doubleblind-placebocontrolled-trial-of-selective-digestive-decontamination-using-oral-gentamicin-and-oral-polymyxin-e-for-eradication-of-carbapenemresistant-klebsiella-pneumoniae-carriage/26498EA3C6A54666B4553FD696DCF3EC","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"papers","label":"A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage"}]},{"url":"https://doi.org/10.1088/0031-9155/59/22/r419","status":200,"ok":true,"finalUrl":"https://iopscience.iop.org/article/10.1088/0031-9155/59/22/R419","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-paganetti-phys-med-biol","kind":"paper","name":"Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer","route":"/key-papers/paper-paganetti-phys-med-biol/","field":"links","label":"Phys Med Biol 2014"}]},{"url":"https://doi.org/10.1088/0031-9155/59/22/R419","status":200,"ok":true,"finalUrl":"https://iopscience.iop.org/article/10.1088/0031-9155/59/22/R419","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","field":"links","label":"Paganetti, RBE values for proton beam therapy (Physics in Medicine and Biology 2014)"},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","field":"links","label":"Paganetti, RBE values for proton beam therapy (Physics in Medicine and Biology 2014)"}]},{"url":"https://doi.org/10.1088/1478-3975/8/1/015001","status":200,"ok":true,"finalUrl":"https://iopscience.iop.org/article/10.1088/1478-3975/8/1/015001","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-davies-phys-biol","kind":"paper","name":"Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors","route":"/key-papers/paper-davies-phys-biol/","field":"links","label":"Phys Biol 2011"},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"links","label":"Davies and Lineweaver, Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors (Physical Biology 2011)"}]},{"url":"https://doi.org/10.1093/ajcn/72.2.472","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002916523067217","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","field":"papers","label":"Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi"}]},{"url":"https://doi.org/10.1093/annonc/mdf003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419627602","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"links","label":"Scholz 2002, Annals of Oncology: retroperitoneal germ cell tumour, evidence of origin in the testis"}]},{"url":"https://doi.org/10.1093/annonc/mdq338","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419377907","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011","kind":"paper","name":"First-line chemotherapy for malignant peripheral nerve sheath tumour versus other soft tissue sarcomas (EORTC pooled analysis)","route":"/key-papers/paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011/","field":"links","label":"Ann Oncol 2011"}]},{"url":"https://doi.org/10.1093/annonc/mdq345","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419385965","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011","kind":"paper","name":"International expert panel consensus on the diagnosis and treatment of inflammatory breast cancer","route":"/key-papers/paper-dawood-inflammatory-breast-consensus-ann-oncol-2011/","field":"links","label":"Ann Oncol 2011"},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","field":"links","label":"International expert panel consensus (Annals of Oncology 2011)"}]},{"url":"https://doi.org/10.1093/annonc/mdq632","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419384352","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"opus","kind":"trial","name":"OPUS","route":"/trials/opus/","field":"links","label":"OPUS: efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment (Annals of Oncology 2011)"},{"id":"opus","kind":"trial","name":"OPUS","route":"/trials/opus/","field":"outcomes.source (Progression-free survival (KRAS wild-type))"}]},{"url":"https://doi.org/10.1093/annonc/mdr541","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419380007","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Bosetti, Ann Oncol 2012: cigarette smoking and pancreatic cancer, PanC4 pooled analysis of 6,507 cases"}]},{"url":"https://doi.org/10.1093/annonc/mdr587","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419381025","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bellera-ann-oncol","kind":"paper","name":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","route":"/key-papers/paper-bellera-ann-oncol/","field":"links","label":"Ann Oncol 2012"},{"id":"g8-geriatric-screening","kind":"technology","name":"G8 geriatric screening tool","route":"/technologies/g8-geriatric-screening/","field":"links","label":"Annals of Oncology 2012: Screening older cancer patients, first evaluation of the G-8 geriatric screening tool"}]},{"url":"https://doi.org/10.1093/annonc/mds105","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419375088","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Huober, Ann Oncol 2012: prognosis of medullary breast cancer in 13 IBCSG trials"}]},{"url":"https://doi.org/10.1093/annonc/mds276","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419370486","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nordic-nec-sorbye-ann-oncol-2013","kind":"paper","name":"NORDIC NEC: predictive and prognostic factors in 305 patients with advanced gastrointestinal neuroendocrine carcinoma","route":"/key-papers/paper-nordic-nec-sorbye-ann-oncol-2013/","field":"links","label":"Ann Oncol 2013"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"links","label":"NORDIC NEC (Annals of Oncology 2013)"}]},{"url":"https://doi.org/10.1093/annonc/mdt199","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419315492","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","field":"links","label":"ESMO cancer in pregnancy guideline"},{"id":"paper-peccatori-ann-oncol","kind":"paper","name":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-peccatori-ann-oncol/","field":"links","label":"Ann Oncol 2013"}]},{"url":"https://doi.org/10.1093/annonc/mdu026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419365081","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","route":"/key-papers/paper-mindact-ann-oncol-2014/","field":"links","label":"Ann Oncol 2014"}]},{"url":"https://doi.org/10.1093/annonc/mdu275","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419366177","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","kind":"paper","name":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","route":"/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/","field":"links","label":"Missiaglia et al., Ann Oncol 2014: distal and proximal colon cancers differ molecularly and clinically (PETACC-3, 3,045 patients)"}]},{"url":"https://doi.org/10.1093/annonc/mdu456","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419369054","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bolero-2-ann-oncol-2014-update","kind":"paper","name":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†","route":"/key-papers/paper-bolero-2-ann-oncol-2014-update/","field":"links","label":"Ann Oncol 2014"}]},{"url":"https://doi.org/10.1093/annonc/mdv041","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419318319","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-enets-lung-net-consensus-caplin-ann-oncol-2015","kind":"paper","name":"ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours","route":"/key-papers/paper-enets-lung-net-consensus-caplin-ann-oncol-2015/","field":"links","label":"Ann Oncol 2015"}]},{"url":"https://doi.org/10.1093/annonc/mdv277","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419471779","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015","kind":"paper","name":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/","field":"links","label":"Ann Oncol 2015"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"links","label":"ESMO thymic epithelial tumours guideline 2015"}]},{"url":"https://doi.org/10.1093/annonc/mdv577","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419357424","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","field":"links","label":"Gebhart et al., ZEPHIR: molecular imaging of heterogeneity in advanced HER2-positive breast cancer with 89Zr-trastuzumab PET (Annals of Oncology 2016)"},{"id":"paper-gebhart-ann-oncol","kind":"paper","name":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","route":"/key-papers/paper-gebhart-ann-oncol/","field":"links","label":"Ann Oncol 2016"}]},{"url":"https://doi.org/10.1093/annonc/mdx163","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419322604","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"links","label":"Annals of Oncology 2017: characteristics, outcomes and treatment of 119 patients with T-PLL"}]},{"url":"https://doi.org/10.1093/annonc/mdx175","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419321350","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","field":"links","label":"Arnold, Ann Oncol 2017: prognostic and predictive value of primary tumour side in RAS wild-type metastatic colorectal cancer, pooled analysis of six randomised trials (2,159 patients)"},{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/","field":"links","label":"Ann Oncol 2017"},{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/","field":"links","label":"Arnold, Ann Oncol 2017: prognostic and predictive value of primary tumour side in RAS wild-type metastatic colorectal cancer, pooled analysis of six randomised trials (2,159 patients)"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"papers","label":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials"}]},{"url":"https://doi.org/10.1093/annonc/mdx224","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419421522","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-rectal-cancer-guideline-ann-oncol-2017","kind":"paper","name":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-rectal-cancer-guideline-ann-oncol-2017/","field":"links","label":"Ann Oncol 2017"}]},{"url":"https://doi.org/10.1093/annonc/mdx484","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419346046","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","field":"papers","label":"Improved survival using specialized multidisciplinary board in sarcoma patients"},{"id":"paper-florence-duffaud-ann-oncol-2017","kind":"paper","name":"Improved survival using specialized multidisciplinary board in sarcoma patients","route":"/key-papers/paper-florence-duffaud-ann-oncol-2017/","field":"links","label":"Ann Oncol 2017"}]},{"url":"https://doi.org/10.1093/annonc/mdx651","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419350379","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cardoso-ann-oncol","kind":"paper","name":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","route":"/key-papers/paper-cardoso-ann-oncol/","field":"links","label":"Ann Oncol 2018"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"links","label":"International Male Breast Cancer Program (Ann Oncol 2018)"}]},{"url":"https://doi.org/10.1093/annonc/mdx771","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419454525","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018","kind":"paper","name":"Combined androgen blockade in androgen receptor-positive salivary gland carcinoma","route":"/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/","field":"links","label":"Ann Oncol 2018"}]},{"url":"https://doi.org/10.1093/annonc/mdy001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419316898","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018","kind":"paper","name":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018/","field":"links","label":"Ann Oncol 2018"}]},{"url":"https://doi.org/10.1093/annonc/mdy024","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419454707","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/","field":"links","label":"Bareche et al., Ann Oncol 2018: integrative multiomic analysis of 550 TNBCs from METABRIC and TCGA"}]},{"url":"https://doi.org/10.1093/annonc/mdy096","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419316928","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","field":"papers","label":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up"},{"id":"paper-robin-jones-ann-oncol-2018","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-robin-jones-ann-oncol-2018/","field":"links","label":"Ann Oncol 2018"}]},{"url":"https://doi.org/10.1093/annonc/mdy226","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419341407","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","field":"links","label":"INMC pathological assessment after neoadjuvant therapy for melanoma (Tetzlaff et al., Ann Oncol 2018)"},{"id":"paper-tetzlaff-ann-oncol","kind":"paper","name":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","route":"/key-papers/paper-tetzlaff-ann-oncol/","field":"links","label":"Ann Oncol 2018"}]},{"url":"https://doi.org/10.1093/annonc/mdy460","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419342462","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"links","label":"Loibl, Ann Oncol 2018: GeparSixto survival and HRD score as predictor of response"},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"links","label":"Loibl, Ann Oncol 2018: GeparSixto survival and HRD score as predictor of response"},{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/","field":"links","label":"Ann Oncol 2018"},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","field":"links","label":"GeparSixto survival and HRD analysis (Annals of Oncology 2018)"}]},{"url":"https://doi.org/10.1093/annonc/mdz012","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419311111","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-olympiad-ann-oncol-2019-update","kind":"paper","name":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","route":"/key-papers/paper-olympiad-ann-oncol-2019-update/","field":"links","label":"Ann Oncol 2019"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"links","label":"OlympiAD final overall survival (Annals of Oncology 2019)"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"outcomes.source (Overall survival)"}]},{"url":"https://doi.org/10.1093/annonc/mdz167","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419312840","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"papers","label":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry"}]},{"url":"https://doi.org/10.1093/annonc/mdz199","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419459905","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","field":"papers","label":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study"},{"id":"paper-peter-thuss-patience-ann-oncol-2019","kind":"paper","name":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","route":"/key-papers/paper-peter-thuss-patience-ann-oncol-2019/","field":"links","label":"Ann Oncol 2019"}]},{"url":"https://doi.org/10.1093/annonc/mdz200","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419459917","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","kind":"paper","name":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","route":"/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/","field":"links","label":"Lee et al., Ann Oncol 2019: ctDNA before and after resection in 42 patients (Australian cohort)"}]},{"url":"https://doi.org/10.1093/annonc/mdz385","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419551195","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019","kind":"paper","name":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","route":"/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/","field":"links","label":"O'Reilly and Hechtman, Ann Oncol 2019: CTRC-NTRK1 fusion pancreatic cancer treated with larotrectinib"}]},{"url":"https://doi.org/10.1093/annonc/mdz395","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420325515","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/","field":"links","label":"Park et al., Ann Oncol 2019: TILs in 476 early TNBC patients who received no chemotherapy"}]},{"url":"https://doi.org/10.1093/annonc/mdz397","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753420326016","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"papers","label":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1093/neuros/nyy375","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/neurosurgery/fulltext/10.1093/neuros/nyy375~glioblastoma-treated-with-magnetic-resonance-imaging-guided","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"litt","kind":"technology","name":"Laser interstitial thermal therapy (LITT)","route":"/technologies/litt/","field":"links","label":"Kamath et al., Glioblastoma treated with MRI-guided laser interstitial thermal therapy: safety, efficacy and outcomes (Neurosurgery 2018)"},{"id":"paper-kamath-neurosurgery","kind":"paper","name":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes","route":"/key-papers/paper-kamath-neurosurgery/","field":"links","label":"Neurosurgery 2019"}]},{"url":"https://doi.org/10.1093/neuros/nyz062","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/neurosurgery/abstract/10.1093/neuros/nyz062~papillary-tumor-of-the-pineal-region-systematic-review-and?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"papillary-tumour-pineal-region","kind":"cancer","name":"Papillary tumour of the pineal region","route":"/cancers/papillary-tumour-pineal-region/","field":"links","label":"Neurosurgery 2019: papillary tumour of the pineal region, systematic review of 177 patients"}]},{"url":"https://doi.org/10.1093/neuros/nyz141","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/neurosurgery/fulltext/10.1093/neuros/nyz141~laser-ablation-of-abnormal-neurological-tissue-using-robotic","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-rennert-neurosurgery","kind":"paper","name":"Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization","route":"/key-papers/paper-rennert-neurosurgery/","field":"links","label":"Neurosurgery 2020"},{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/","field":"links","label":"Kim et al., Laser ablation of abnormal neurological tissue using robotic NeuroBlate system (LAANTERN) registry (Neurosurgery 2020)"}]},{"url":"https://doi.org/10.1097/00000478-198511000-00005","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-198511000-00005~clear-cell-adenocarcinoma-of-the-bladder-and-urethra-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"links","label":"Young and Scully 1985, Am J Surg Pathol: clear cell adenocarcinoma of the bladder and urethra"}]},{"url":"https://doi.org/10.1097/00000478-199209000-00001","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-199209000-00001~acinar-cell-carcinoma-of-the-pancreas-a-clinicopathologic?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992","kind":"paper","name":"Klimstra 1992: acinar cell carcinoma of the pancreas, a clinicopathologic study of 28 cases","route":"/key-papers/paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992/","field":"links","label":"Am J Surg Pathol 1992"}]},{"url":"https://doi.org/10.1097/00000478-199512000-00005","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-199512000-00005~pancreatoblastoma-a-clinicopathologic-study-and-review-of?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995","kind":"paper","name":"Klimstra 1995: pancreatoblastoma, a clinicopathologic study and review of the literature","route":"/key-papers/paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995/","field":"links","label":"Am J Surg Pathol 1995"}]},{"url":"https://doi.org/10.1097/00000478-199604000-00001","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-199604000-00001~myxofibrosarcoma-clinicopathologic-analysis-of-75-cases-with?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-myxofibrosarcoma-mentzel-ajsp-1996","kind":"paper","name":"Myxofibrosarcoma: clinicopathological analysis of 75 cases with emphasis on the low-grade variant","route":"/key-papers/paper-myxofibrosarcoma-mentzel-ajsp-1996/","field":"links","label":"Am J Surg Pathol 1996"}]},{"url":"https://doi.org/10.1097/00000478-199806000-00008","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-199806000-00008~sertoli-cell-tumors-of-the-testis-not-otherwise-specified-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"links","label":"Young 1998, Am J Surg Pathol: Sertoli cell tumours of the testis, not otherwise specified, 60 cases"}]},{"url":"https://doi.org/10.1097/00000478-200006000-00003","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-200006000-00003~primary-malignant-melanoma-of-the-urethra-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","field":"links","label":"Oliva 2000, Am J Surg Pathol: primary malignant melanoma of the urethra, 15 cases"}]},{"url":"https://doi.org/10.1097/00000478-200101000-00003","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-200101000-00003~colloid-mucinous-noncystic-carcinoma-of-the-pancreas?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"links","label":"Adsay, Am J Surg Pathol 2001: colloid (mucinous non-cystic) carcinoma of the pancreas"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"links","label":"Adsay, Am J Surg Pathol 2001: colloid (mucinous non-cystic) carcinoma of the pancreas"}]},{"url":"https://doi.org/10.1097/00000478-200105000-00003","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-200105000-00003~pancreatic-intraepithelial-neoplasia-a-new-nomenclature-and?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Hruban, Am J Surg Pathol 2001: pancreatic intraepithelial neoplasia, a new nomenclature (PanIN)"},{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/","field":"links","label":"Hruban, Am J Surg Pathol 2001: pancreatic intraepithelial neoplasia, a new nomenclature (PanIN)"},{"id":"paper-hruban-panin-nomenclature-ajsp-2001","kind":"paper","name":"Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions","route":"/key-papers/paper-hruban-panin-nomenclature-ajsp-2001/","field":"links","label":"Hruban et al., Am J Surg Pathol 2001: the PanIN nomenclature"}]},{"url":"https://doi.org/10.1097/00000478-200110000-00003","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-200110000-00003~sertoli-cell-proliferations-of-the-infantile-testis-an?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"links","label":"Am J Surg Pathol 2001: intratubular Sertoli cell proliferations of the infantile testis in Peutz-Jeghers syndrome"}]},{"url":"https://doi.org/10.1097/00000478-200407000-00014","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/00000478-200407000-00014~oct4-staining-in-testicular-tumors-a-sensitive-and-specific?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"embryonal-carcinoma-testis","kind":"cancer","name":"Embryonal carcinoma of the testis","route":"/cancers/embryonal-carcinoma-testis/","field":"links","label":"Am J Surg Pathol 2004: OCT4 staining in testicular tumours, a marker for seminoma and embryonal carcinoma"},{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"links","label":"Am J Surg Pathol 2004: OCT4 staining in testicular tumours, a marker for seminoma and embryonal carcinoma"}]},{"url":"https://doi.org/10.1097/00000658-193510000-00023","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/00000658-193510000-00023~teeatment-of-carcinoma-of-the-ampulla-of-vater?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935","kind":"paper","name":"Treatment of carcinoma of the ampulla of Vater","route":"/key-papers/paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935/","field":"links","label":"Ann Surg 1935"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Whipple, Parsons and Mullins, Ann Surg 1935: treatment of carcinoma of the ampulla of Vater"}]},{"url":"https://doi.org/10.1097/00000658-198009000-00005","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/00000658-198009000-00005~preservation-of-the-pylorus-in-pancreaticoduodenectomy-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978","kind":"paper","name":"Preservation of the pylorus in pancreaticoduodenectomy","route":"/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/","field":"links","label":"Follow-up evaluation, 18 patients (Ann Surg 1980)"}]},{"url":"https://doi.org/10.1097/00000658-199610000-00002","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/00000658-199610000-00002~prenatal-glucocorticoid-therapy-reverses-pulmonary?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","field":"papers","label":"Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep"}]},{"url":"https://doi.org/10.1097/00006534-200006000-00039","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/plasreconsurg/abstract/00006534-200006000-00039~evaluation-of-cosmetic-results-of-a-randomized-trial?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"links","label":"Cosmetic analysis (Plastic and Reconstructive Surgery 2000)"},{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","field":"outcomes.source (Good cosmetic result, dermatologist's assessment at 4 years)"}]},{"url":"https://doi.org/10.1097/01.ccm.0000126262.23422.f0","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ccmjournal/abstract/10.1097/01.ccm.0000126262.23422.f0~differentiated-and-dose-related-cardiovascular-effects-of-a?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"papers","label":"Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock"}]},{"url":"https://doi.org/10.1097/01.ccm.0000215830.48977.29","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ccmjournal/abstract/10.1097/01.ccm.0000215830.48977.29~comparison-of-a-single-indicator-and-gravimetric-technique?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"papers","label":"Comparison of a single indicator and gravimetric technique for estimation of extravascular lung water in endotoxemic pigs"}]},{"url":"https://doi.org/10.1097/01.MP.0000086072.56290.FB","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0893395222047305","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"papers","label":"Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray"}]},{"url":"https://doi.org/10.1097/01.pas.0000209827.39477.4f","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/01.pas.0000209827.39477.4f~loss-of-nuclear-expression-of-parafibromin-distinguishes?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"Gill 2006, Am J Surg Pathol: loss of parafibromin distinguishes parathyroid carcinoma and HPT-JT adenomas"}]},{"url":"https://doi.org/10.1097/01.pas.0000213435.99492.8a","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/01.pas.0000213435.99492.8a~prevalence-and-risk-factors-for-gallbladder-neoplasia-in?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Lewis, Am J Surg Pathol 2007: gallbladder neoplasia in primary sclerosing cholangitis explants"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"Lewis, Am J Surg Pathol 2007: gallbladder neoplasia in primary sclerosing cholangitis explants"}]},{"url":"https://doi.org/10.1097/01.prs.0000227738.42077.2d","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/plasreconsurg/abstract/10.1097/01.prs.0000227738.42077.2d~frontal-sinus-fractures-a-treatment-algorithm-and-assessment?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"papers","label":"Frontal Sinus Fractures: A Treatment Algorithm and Assessment of Outcomes Based on 78 Clinical Cases"}]},{"url":"https://doi.org/10.1097/01.prs.0000260595.85557.41","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/plasreconsurg/abstract/10.1097/01.prs.0000260595.85557.41~free-functioning-muscle-transfer-for-lower-extremity?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"papers","label":"Free Functioning Muscle Transfer for Lower Extremity Posttraumatic Composite Structure and Functional Defect"}]},{"url":"https://doi.org/10.1097/01.sla.0000141194.27992.32","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/10.1097/01.sla.0000141194.27992.32~operative-versus-nonoperative-treatment-for-stage-0-distal?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004","kind":"paper","name":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","route":"/key-papers/paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004/","field":"links","label":"Ann Surg 2004"}]},{"url":"https://doi.org/10.1097/CJI.0b013e3181eec14c","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/immunotherapy-journal/abstract/10.1097/cji.0b013e3181eec14c~phase-2-trial-of-single-agent-ipilimumab-anti-ctla-4-for?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-royal-ipilimumab-pancreatic-j-immunother-2010","kind":"paper","name":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","route":"/key-papers/paper-royal-ipilimumab-pancreatic-j-immunother-2010/","field":"links","label":"Royal et al., J Immunother 2010: ipilimumab in 27 patients, no RECIST response"}]},{"url":"https://doi.org/10.1097/cmr.0b013e32833684e8","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/melanomaresearch/abstract/10.1097/cmr.0b013e32833684e8~population-based-incidence-of-vulvar-and-vaginal-melanoma-in?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"links","label":"Melanoma Research 2010: population-based incidence of vulvar and vaginal melanoma by race and ethnicity, SEER 1992 to 2005"},{"id":"vaginal-melanoma","kind":"cancer","name":"Vaginal melanoma","route":"/cancers/vaginal-melanoma/","field":"links","label":"Melanoma Research 2010: population-based incidence of vulvar and vaginal melanoma by race and ethnicity, SEER 1992 to 2005"}]},{"url":"https://doi.org/10.1097/eja.0b013e32834a0255","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ejanaesthesiology/fulltext/10.1097/eja.0b013e32834992a1~how-to-write-a-good-title","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"papers","label":"Pain treatment after craniotomy:  where is the (procedure-specific) evidence? A qualitative systematic review"}]},{"url":"https://doi.org/10.1097/igc.0000000000000262","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1048891X24198428","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","field":"links","label":"Int J Gynecol Cancer 2014: GCIG consensus review for small cell carcinoma of the cervix"}]},{"url":"https://doi.org/10.1097/jto.0000000000000154","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415302756","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","field":"links","label":"Marx 2014, JTO: ITMIG consensus on the use of the WHO histological classification of thymoma and thymic carcinoma"},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/","field":"links","label":"Marx 2014, JTO: ITMIG consensus on the use of the WHO histological classification of thymoma and thymic carcinoma"},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/","field":"links","label":"Marx 2014, JTO: ITMIG consensus on the use of the WHO histological classification of thymoma and thymic carcinoma"}]},{"url":"https://doi.org/10.1097/jto.0000000000000393","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415323418","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","field":"links","label":"Weis 2015, JTO: the impact of thymoma histotype on prognosis in the ITMIG worldwide database, 4,221 thymomas"},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/","field":"links","label":"Weis 2015, JTO: the impact of thymoma histotype on prognosis in the ITMIG worldwide database, 4,221 thymomas"},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/","field":"links","label":"Weis 2015, JTO: the impact of thymoma histotype on prognosis in the ITMIG worldwide database, 4,221 thymomas"}]},{"url":"https://doi.org/10.1097/jto.0000000000000422","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415316518","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"papers","label":"EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey"}]},{"url":"https://doi.org/10.1097/jto.0000000000000481","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415323984","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","field":"papers","label":"Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)"}]},{"url":"https://doi.org/10.1097/jto.0000000000000579","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415335425","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","field":"links","label":"Shim 2015, JTO: unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung"}]},{"url":"https://doi.org/10.1097/jto.0000000000000630","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415335711","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","field":"links","label":"Travis 2015, JTO: the 2015 WHO classification of lung tumours"},{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","field":"links","label":"Travis 2015, JTO: the 2015 WHO classification of lung tumours"}]},{"url":"https://doi.org/10.1097/jto.0b013e318206a221","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1556086415319304","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"Travis 2011, JTO: IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma"},{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","field":"links","label":"Travis 2011, JTO: IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma"},{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","field":"links","label":"Travis 2011, JTO: IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma"}]},{"url":"https://doi.org/10.1097/mpa.0b013e3181f749d3","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/pancreasjournal/abstract/10.1097/mpa.0b013e3181f749d3~clinicopathological-features-and-prognosis-of-mucinous?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"links","label":"Yamao, Pancreas 2011: mucinous cystic neoplasm with ovarian-type stroma, Japan Pancreas Society multi-institutional study"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"Yamao, Pancreas 2011: mucinous cystic neoplasm with ovarian-type stroma, Japan Pancreas Society multi-institutional study"}]},{"url":"https://doi.org/10.1097/pas.0000000000002580","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/pas.0000000000002580~neuroendocrine-carcinoma-of-the-gallbladder?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"links","label":"Reid, Am J Surg Pathol 2026: neuroendocrine carcinoma of the gallbladder, 31 cases"}]},{"url":"https://doi.org/10.1097/PAS.0b013e31802b86f8","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/pas.0b013e31802b86f8~translocation-and-expression-of-csf1-in-pigmented?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1097/pas.0b013e3181fd8781","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/pas.0b013e3181fd8781~lymphomatoid-granulomatosis-insights-gained-over-4-decades?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","field":"links","label":"Katzenstein 2010, Am J Surg Pathol: lymphomatoid granulomatosis, insights over four decades"}]},{"url":"https://doi.org/10.1097/pas.0b013e31821b3f65","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/ajsp/abstract/10.1097/pas.0b013e31821b3f65~encapsulated-papillary-carcinoma-of-the-breast-an-invasive?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"papillary-carcinoma-breast","kind":"cancer","name":"Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)","route":"/cancers/papillary-carcinoma-breast/","field":"links","label":"Rakha 2011, Am J Surg Pathol: encapsulated papillary carcinoma of the breast, 302 papillary carcinomas"}]},{"url":"https://doi.org/10.1097/sla.0b013e31823ac299","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/10.1097/sla.0b013e31823ac299~arterial-resection-during-pancreatectomy-for-pancreatic?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","field":"links","label":"Mollberg, Ann Surg 2011: arterial resection during pancreatectomy, systematic review and meta-analysis"}]},{"url":"https://doi.org/10.1097/SLA.0b013e31824f1c21","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/annalsofsurgery/abstract/10.1097/sla.0b013e31824f1c21~low-anterior-resection-syndrome-score-development-and?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"links","label":"Emmertsen and Laurberg, low anterior resection syndrome score: a simple tool to identify bowel dysfunction after rectal cancer surgery (Annals of Surgery 2012)"}]},{"url":"https://doi.org/10.1101/2023.11.28.568918","status":200,"ok":true,"finalUrl":"https://www.biorxiv.org/content/10.1101/2023.11.28.568918v3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","field":"links","label":"Rosen et al., Universal Cell Embeddings: a foundation model for cell biology (bioRxiv 2023)"}]},{"url":"https://doi.org/10.1101/2024.06.18.599483","status":200,"ok":true,"finalUrl":"https://www.biorxiv.org/content/10.1101/2024.06.18.599483v4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","field":"links","label":"Gélard et al., BulkRNABert: cancer prognosis from bulk RNA-seq based language models (bioRxiv 2024)"}]},{"url":"https://doi.org/10.1111/ajt.16448","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S160061352208563X","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-hcc-io-before-transplant","kind":"idea","name":"Immunotherapy downstaging to transplant with a safe washout","route":"/ideas/idea-hcc-io-before-transplant/","field":"links","label":"Tabrizian et al., PD-1 inhibitor as bridge therapy to liver transplantation? (American Journal of Transplantation 2021)"},{"id":"paper-tabrizian-am-j-transplant","kind":"paper","name":"PD-1 inhibitor as bridge therapy to liver transplantation?","route":"/key-papers/paper-tabrizian-am-j-transplant/","field":"links","label":"Am J Transplant 2021"}]},{"url":"https://doi.org/10.1111/hpb.12444","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1365182X15312521","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (T1b, T2 or T3 (incidental or suspected before surgery))"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"port-site-metastasis","kind":"term","name":"Port-site metastasis","route":"/terms/port-site-metastasis/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"},{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","field":"links","label":"AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015)"}]},{"url":"https://doi.org/10.1136/annrheumdis-2015-207726","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0003496724017175","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"papers","label":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)"}]},{"url":"https://doi.org/10.1136/ijgc-2020-002230","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1048891X24026021","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"papers","label":"ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma"},{"id":"paper-esgo-estro-esp-endometrial-concin-ijgc-2021","kind":"paper","name":"ESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)","route":"/key-papers/paper-esgo-estro-esp-endometrial-concin-ijgc-2021/","field":"links","label":"Int J Gynecol Cancer 2021"}]},{"url":"https://doi.org/10.1136/ijgc-2022-004047","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1048891X24009137","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","field":"links","label":"Rodolakis et al., ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma (International Journal of Gynecological Cancer 2023)"},{"id":"paper-rodolakis-int-j-gynecol-cancer","kind":"paper","name":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","route":"/key-papers/paper-rodolakis-int-j-gynecol-cancer/","field":"links","label":"Int J Gynecol Cancer 2023"}]},{"url":"https://doi.org/10.1159/000079823","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1424390304800565","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004","kind":"paper","name":"Dhebri 2004: diagnosis, treatment and outcome of pancreatoblastoma","route":"/key-papers/paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004/","field":"links","label":"Pancreatology 2004"}]},{"url":"https://doi.org/10.1172/JCI114392","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/114392","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1172/JCI128212","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/128212","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-labrecque-mcrpc-phenotypes-jci-2019","kind":"paper","name":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-labrecque-mcrpc-phenotypes-jci-2019/","field":"links","label":"Labrecque et al., J Clin Invest 2019: five phenotypes of treatment-refractory metastatic castration-resistant prostate cancer defined by androgen receptor and neuroendocrine gene expression"}]},{"url":"https://doi.org/10.1172/JCI132031","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/132031","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020","kind":"paper","name":"Genomics of lethal prostate cancer at diagnosis and castration resistance","route":"/key-papers/paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020/","field":"links","label":"Mateo et al., J Clin Invest 2020: genomics of 470 diagnostic biopsies from men who went on to develop metastatic castration-resistant disease, with 61 matched later biopsies"}]},{"url":"https://doi.org/10.1172/jci144847","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/144847","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-navigate-j-clin-invest-2021","kind":"paper","name":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","route":"/key-papers/paper-navigate-j-clin-invest-2021/","field":"links","label":"J Clin Invest 2021"}]},{"url":"https://doi.org/10.1172/jci15888","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/15888","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","field":"papers","label":"Adenoviral transfer of HSP-70 into pulmonary epithelium ameliorates experimental acute respiratory distress syndrome"}]},{"url":"https://doi.org/10.1172/JCI39104","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/39104","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-kalluri-weinberg-emt-basics-jci-2009","kind":"paper","name":"Kalluri and Weinberg 2009: the basics of epithelial-mesenchymal transition","route":"/key-papers/paper-kalluri-weinberg-emt-basics-jci-2009/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.1172/jci45014","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/45014","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-mesenchymal-stem-like","kind":"cancer","name":"Mesenchymal stem-like triple-negative breast cancer (MSL)","route":"/cancers/tnbc-mesenchymal-stem-like/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"claudin-low","kind":"term","name":"Claudin-low breast cancer","route":"/terms/claudin-low/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","field":"links","label":"Lehmann, J Clin Invest 2011: identification of human triple-negative breast cancer subtypes (BL1, BL2, IM, M, MSL, LAR)"}]},{"url":"https://doi.org/10.1172/JCI45014","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/45014","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/","field":"links","label":"J Clin Invest 2011"}]},{"url":"https://doi.org/10.1172/JCI76739","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/76739","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"papers","label":"Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients"}]},{"url":"https://doi.org/10.1172/jci80420","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/80420","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ashkenazi-j-clin-invest","kind":"paper","name":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions","route":"/key-papers/paper-ashkenazi-j-clin-invest/","field":"links","label":"J Clin Invest 2015"}]},{"url":"https://doi.org/10.1172/JCI80420","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/80420","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"extrinsic-apoptosis-death-receptors","kind":"pathway","name":"Extrinsic apoptosis (death receptors)","route":"/pathways/extrinsic-apoptosis-death-receptors/","field":"links","label":"Ashkenazi, Targeting the extrinsic apoptotic pathway in cancer (J Clin Invest 2015)"}]},{"url":"https://doi.org/10.1172/jci85309","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/85309","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/","field":"links","label":"J Clin Invest 2016"}]},{"url":"https://doi.org/10.1172/JCI85309","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/85309","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"papers","label":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients"}]},{"url":"https://doi.org/10.1172/JCI96313","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/96313","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","kind":"paper","name":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","route":"/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/","field":"links","label":"Gruosso et al., J Clin Invest 2019: spatially distinct immune microenvironments stratify TNBC"}]},{"url":"https://doi.org/10.1172/jci97992","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/97992","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-makvandi-j-clin-invest","kind":"paper","name":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","route":"/key-papers/paper-makvandi-j-clin-invest/","field":"links","label":"J Clin Invest 2018"}]},{"url":"https://doi.org/10.1172/JCI97992","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/97992","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","field":"links","label":"Makvandi et al., A PET imaging agent for evaluating PARP-1 expression in ovarian cancer (Journal of Clinical Investigation 2018)"}]},{"url":"https://doi.org/10.1177/2284240319880534","status":200,"ok":true,"finalUrl":"https://journals.aboutscience.eu/index.php/grhta/article/view/452","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"papers","label":"Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis"}]},{"url":"https://doi.org/10.1186/1471-2407-12-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1471-2407-12-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-micropapillary-carcinoma-breast","kind":"cancer","name":"Invasive micropapillary carcinoma of the breast","route":"/cancers/invasive-micropapillary-carcinoma-breast/","field":"links","label":"BMC Cancer 2012: a spheroid model of the chemoresistance of invasive micropapillary carcinoma"}]},{"url":"https://doi.org/10.1186/1471-2407-12-526","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1471-2407-12-526","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"links","label":"Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"metrics (Cancers under-funded relative to incidence, mortality and years of life lost in an analysis of NCI, charity and industry funding)"},{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-programme-officer-incentives","kind":"idea","name":"Judge funding programme officers on burden alignment and trials completed","route":"/ideas/idea-fund-programme-officer-incentives/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-cachexia-programme","kind":"idea","name":"A dedicated programme for cachexia and treatment toxicity research","route":"/ideas/idea-fund-cachexia-programme/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/","field":"links","label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)"},{"id":"paper-sun-bmc-cancer","kind":"paper","name":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials","route":"/key-papers/paper-sun-bmc-cancer/","field":"links","label":"BMC Cancer 2012"}]},{"url":"https://doi.org/10.1186/1471-2407-13-386","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1471-2407-13-386","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","field":"links","label":"XM22-03 (BMC Cancer 2013)"},{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/","field":"links","label":"BMC Cancer 2013"},{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/","field":"outcomes.source (Duration of severe neutropenia in cycle 1)"},{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/","field":"links","label":"BMC Cancer 2013"}]},{"url":"https://doi.org/10.1186/1475-4924-2-28","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1475-4924-2-28","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","field":"papers","label":"Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade"}]},{"url":"https://doi.org/10.1186/1477-7819-10-87","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1477-7819-10-87","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Shirai, World J Surg Oncol 2012: number of positive nodes (0, 1 to 3, 4 or more) in gallbladder cancer"},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Lymph node status in gallbladder cancer: location, number or ratio (World J Surg Oncol 2012, 135 patients)"}]},{"url":"https://doi.org/10.1186/1477-7819-11-139","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1477-7819-11-139","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mucinous-carcinoma-breast","kind":"cancer","name":"Mucinous carcinoma of the breast","route":"/cancers/mucinous-carcinoma-breast/","field":"links","label":"World J Surg Oncol 2013: pure mucinous carcinoma of the breast, 93 cases against 2,674 ductal carcinomas"}]},{"url":"https://doi.org/10.1186/1741-7015-9-63","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1741-7015-9-63","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-bmc-med-2011","kind":"paper","name":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications","route":"/key-papers/paper-ezh2-sarcoma-bmc-med-2011/","field":"links","label":"BMC Med 2011"}]},{"url":"https://doi.org/10.1186/1743-7075-7-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1743-7075-7-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-seyfried-nutr-metab-lond","kind":"paper","name":"Cancer as a metabolic disease","route":"/key-papers/paper-seyfried-nutr-metab-lond/","field":"links","label":"Nutr Metab (Lond) 2010"},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","field":"links","label":"Seyfried and Shelton, Cancer as a metabolic disease (Nutrition and Metabolism 2010)"}]},{"url":"https://doi.org/10.1186/1748-717x-5-39","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1748-717X-5-39","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"papers","label":"Concurrent radiochemotherapy in advanced hypopharyngeal cancer"}]},{"url":"https://doi.org/10.1186/1750-1172-6-70","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/1750-1172-6-70","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"Lehmann, McGibbon and Stefanini, Orphanet Journal of Rare Diseases 2011;6:70: xeroderma pigmentosum"}]},{"url":"https://doi.org/10.1186/bcr2142","status":200,"ok":true,"finalUrl":"https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2142","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-herschkowitz-rb1-loss-basal-like-bcr-2008","kind":"paper","name":"The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas","route":"/key-papers/paper-herschkowitz-rb1-loss-basal-like-bcr-2008/","field":"links","label":"Herschkowitz et al., Breast Cancer Res 2008: RB1 loss in basal-like and luminal B carcinomas"}]},{"url":"https://doi.org/10.1186/bcr2613","status":200,"ok":true,"finalUrl":"https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2613","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","field":"links","label":"Ghabach, Breast Cancer Res 2010: adenoid cystic carcinoma of the breast in the United States 1977 to 2006 (SEER)"},{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"links","label":"Ghabach, Breast Cancer Res 2010: adenoid cystic carcinoma of the breast in the United States 1977 to 2006 (SEER)"}]},{"url":"https://doi.org/10.1186/bcr2635","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/bcr2635","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"links","label":"Prat, Breast Cancer Res 2010: phenotypic and molecular characterisation of the claudin-low intrinsic subtype"},{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Prat, Breast Cancer Res 2010: phenotypic and molecular characterisation of the claudin-low intrinsic subtype"},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Prat, Breast Cancer Res 2010: phenotypic and molecular characterisation of the claudin-low intrinsic subtype"},{"id":"claudin-low","kind":"term","name":"Claudin-low breast cancer","route":"/terms/claudin-low/","field":"links","label":"Prat, Breast Cancer Res 2010: phenotypic and molecular characterisation of the claudin-low intrinsic subtype"}]},{"url":"https://doi.org/10.1186/bcr2834","status":200,"ok":true,"finalUrl":"https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2834","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/","field":"links","label":"Keam, Breast Cancer Res 2011: Ki-67 classifies triple-negative breast cancer into two groups with different response and prognosis"}]},{"url":"https://doi.org/10.1186/bcr3421","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/bcr3421","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Lehmann-Che, Breast Cancer Res 2013: molecular apocrine breast cancers overexpress HER2 or GCDFP15"},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","field":"links","label":"Lehmann-Che, Breast Cancer Res 2013: molecular apocrine breast cancers overexpress HER2 or GCDFP15"}]},{"url":"https://doi.org/10.1186/cc12571","status":200,"ok":true,"finalUrl":"https://ccforum.biomedcentral.com/articles/10.1186/cc12571","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"papers","label":"Palmar skin conductance variability and the relation to stimulation, pain and the motor activity assessment scale in intensive care unit patients"}]},{"url":"https://doi.org/10.1186/cc3731","status":200,"ok":true,"finalUrl":"https://ccforum.biomedcentral.com/articles/10.1186/cc3731","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"papers","label":"The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study"}]},{"url":"https://doi.org/10.1186/gb-2011-12-4-r41","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/gb-2011-12-4-r41","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"copy-number-variation-term","kind":"term","name":"Copy number alteration (CNA)","route":"/terms/copy-number-variation-term/","field":"links","label":"Mermel et al., GISTIC2.0 (Genome Biology 2011)"},{"id":"gistic","kind":"term","name":"GISTIC (copy number driver detection)","route":"/terms/gistic/","field":"links","label":"Mermel et al., GISTIC2.0 (Genome Biology 2011)"}]},{"url":"https://doi.org/10.1186/s12885-015-1498-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12885-015-1498-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"acticca-1","kind":"trial","name":"ACTICCA-1","route":"/trials/acticca-1/","field":"links","label":"Stein et al., BMC Cancer 2015: ACTICCA-1 protocol"}]},{"url":"https://doi.org/10.1186/s12885-017-3286-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12885-017-3286-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-erivance-bmc-cancer-2017-update","kind":"paper","name":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","route":"/key-papers/paper-erivance-bmc-cancer-2017-update/","field":"links","label":"BMC Cancer 2017"}]},{"url":"https://doi.org/10.1186/s12885-018-4371-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12885-018-4371-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc-symptom-control-palliation","kind":"term","name":"Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life","route":"/terms/tnbc-symptom-control-palliation/","field":"links","label":"Incidence, pattern and prognosis of brain metastases in metastatic TNBC (BMC Cancer 2018, 433 patients)"}]},{"url":"https://doi.org/10.1186/s12885-019-6142-y","status":200,"ok":true,"finalUrl":"https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6142-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nife","kind":"trial","name":"NIFE (AIO-YMO HEP-0315)","route":"/trials/nife/","field":"links","label":"Perkhofer et al., BMC Cancer 2019: NIFE protocol"}]},{"url":"https://doi.org/10.1186/s12885-020-6610-4","status":200,"ok":true,"finalUrl":"https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-6610-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gain-igbc","kind":"trial","name":"GAIN (AIO/CALGP/ACO)","route":"/trials/gain-igbc/","field":"links","label":"Goetze et al., BMC Cancer 2020: GAIN protocol"},{"id":"paper-gain-trial-protocol-bmc-cancer-2020","kind":"paper","name":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial","route":"/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/","field":"links","label":"BMC Cancer 2020"}]},{"url":"https://doi.org/10.1186/s12885-021-08031-z","status":200,"ok":true,"finalUrl":"https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08031-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/","field":"links","label":"Protocol (BMC Cancer 2021)"}]},{"url":"https://doi.org/10.1186/s12885-023-11141-5","status":200,"ok":true,"finalUrl":"https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11141-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"preopanc-3","kind":"trial","name":"PREOPANC-3","route":"/trials/preopanc-3/","field":"links","label":"PREOPANC-3 protocol (BMC Cancer 2023)"}]},{"url":"https://doi.org/10.1186/s12885-023-11492-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12885-023-11492-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-completeness-bmc-cancer-2023","kind":"paper","name":"Completeness of regional cancer registry data in north-west Russia, 2008 to 2017","route":"/key-papers/paper-barchuk-registry-completeness-bmc-cancer-2023/","field":"links","label":"BMC Cancer 2023"}]},{"url":"https://doi.org/10.1186/s12893-019-0647-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12893-019-0647-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cystic-duct-carcinoma","kind":"cancer","name":"Cystic duct carcinoma","route":"/cancers/cystic-duct-carcinoma/","field":"links","label":"Prasoon, BMC Surg 2019: remnant cystic duct adenocarcinoma, with the AJCC history of cystic duct staging"}]},{"url":"https://doi.org/10.1186/s12915-020-00775-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12915-020-00775-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"papers","label":"Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions"}]},{"url":"https://doi.org/10.1186/s12967-025-06613-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s12967-025-06613-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/","field":"links","label":"J Transl Med 2025"}]},{"url":"https://doi.org/10.1186/s13045-018-0681-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13045-018-0681-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-zhao-j-hematol-oncol","kind":"paper","name":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","route":"/key-papers/paper-zhao-j-hematol-oncol/","field":"links","label":"J Hematol Oncol 2018"},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","field":"links","label":"J Hematol Oncol 2018"},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://doi.org/10.1186/s13045-020-00984-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13045-020-00984-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"papers","label":"The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands"}]},{"url":"https://doi.org/10.1186/s13045-025-01705-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13045-025-01705-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04152499-j-hematol-oncol-2025","kind":"paper","name":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","route":"/key-papers/paper-nct04152499-j-hematol-oncol-2025/","field":"links","label":"J Hematol Oncol 2025"}]},{"url":"https://doi.org/10.1186/s13045-025-01768-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13045-025-01768-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/","field":"links","label":"J Hematol Oncol 2025"}]},{"url":"https://doi.org/10.1186/s13046-019-1259-z","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13046-019-1259-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019","kind":"paper","name":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","route":"/key-papers/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019/","field":"links","label":"J Exp Clin Cancer Res 2019"}]},{"url":"https://doi.org/10.1186/s13046-019-1302-0","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13046-019-1302-0","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"papers","label":"Targeting mutant p53 in cancer: the latest insights"}]},{"url":"https://doi.org/10.1186/s13046-023-02649-6","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13046-023-02649-6","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/","field":"links","label":"J Exp Clin Cancer Res 2023"}]},{"url":"https://doi.org/10.1186/s13053-023-00256-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13053-023-00256-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"links","label":"Ahmad et al., Founder variants and population genomes (Hereditary Cancer in Clinical Practice 2023)"}]},{"url":"https://doi.org/10.1186/s13054-015-0873-1","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13054-015-0873-1","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","field":"papers","label":"Gender differences in outcome and use of resources do exist in Swedish intensive care, but to no advantage for women of premenopausal age"}]},{"url":"https://doi.org/10.1186/s13054-017-1676-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13054-017-1676-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"papers","label":"Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography"}]},{"url":"https://doi.org/10.1186/s13054-020-03101-3","status":200,"ok":true,"finalUrl":"https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03101-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"papers","label":"Brain tight junction protein expression in sepsis in an autopsy series"}]},{"url":"https://doi.org/10.1186/s13058-019-1115-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13058-019-1115-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"papers","label":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial"}]},{"url":"https://doi.org/10.1186/s13058-020-01353-z","status":200,"ok":true,"finalUrl":"https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01353-z","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Reddy, Breast Cancer Res 2020: a comprehensive overview of metaplastic breast cancer"}]},{"url":"https://doi.org/10.1186/s13058-023-01724-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13058-023-01724-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","kind":"paper","name":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","route":"/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/","field":"links","label":"Sigurjonsdottir et al., Breast Cancer Res 2023: SP142 versus 22C3 in 232 population-based early TNBCs (SCAN-B)"}]},{"url":"https://doi.org/10.1186/s13098-017-0290-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13098-017-0290-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"papers","label":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis"}]},{"url":"https://doi.org/10.1186/s40164-025-00710-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s40164-025-00710-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chen-exp-hematol-oncol","kind":"paper","name":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","route":"/key-papers/paper-chen-exp-hematol-oncol/","field":"links","label":"Exp Hematol Oncol 2025"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","field":"links","label":"Phase 2 study of zevorcabtagene autoleucel (Exp Hematol Oncol 2025)"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"links","label":"Exp Hematol Oncol 2025"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"outcomes.source (Objective response rate (independent review committee))"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"outcomes.source (Stringent complete response)"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"outcomes.source (Cytokine release syndrome, any grade)"}]},{"url":"https://doi.org/10.1186/s41687-018-0054-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s41687-018-0054-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"atrasentan","kind":"drug","name":"Atrasentan","route":"/drugs/atrasentan/","field":"links","label":"SWOG S0421 patient-reported outcomes (Journal of Patient-Reported Outcomes 2017)"}]},{"url":"https://doi.org/10.1188/08.ONF.E45-E52","status":200,"ok":true,"finalUrl":"https://www.ons.org/publications-research/onf/35/3/symptom-concerns-and-quality-life-hepatobiliary-cancers","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"papers","label":"Symptom concerns and quality of life in hepatobiliary cancers"}]},{"url":"https://doi.org/10.1245/s10434-008-9839-8","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-008-9839-8","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Esposito, Ann Surg Oncol 2008: most pancreatic cancer resections are R1 resections"},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"links","label":"Esposito, Ann Surg Oncol 2008: most pancreatic cancer resections are R1 resections"}]},{"url":"https://doi.org/10.1245/s10434-009-0489-2","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-009-0489-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009","kind":"paper","name":"Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours","route":"/key-papers/paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009/","field":"links","label":"Ann Surg Oncol 2009"}]},{"url":"https://doi.org/10.1245/s10434-011-1850-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-011-1850-9","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Maker et al., Ann Surg Oncol 2012: is port site resection necessary? (113 patients)"}]},{"url":"https://doi.org/10.1245/s10434-014-4300-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-014-4300-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015","kind":"paper","name":"Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location","route":"/key-papers/paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015/","field":"links","label":"Ann Surg Oncol 2015"}]},{"url":"https://doi.org/10.1245/s10434-015-4552-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-015-4552-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"links","label":"Annals of Surgical Oncology 2015: pleomorphic lobular carcinoma in situ, features and management"}]},{"url":"https://doi.org/10.1245/s10434-017-5810-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-017-5810-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Kamarajah, Ann Surg Oncol 2017: validation of the AJCC 8th edition for pancreatic adenocarcinoma in SEER"}]},{"url":"https://doi.org/10.1245/s10434-017-6025-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-017-6025-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018","kind":"paper","name":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers","route":"/key-papers/paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018/","field":"links","label":"Ann Surg Oncol 2018"}]},{"url":"https://doi.org/10.1245/s10434-018-6533-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-018-6533-3","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Ong, Ann Surg Oncol 2018: metaplastic breast cancer treatment and outcomes in 2,500 patients (National Cancer Data Base)"}]},{"url":"https://doi.org/10.1245/s10434-019-08074-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1245/s10434-019-08074-4","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020","kind":"paper","name":"Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease","route":"/key-papers/paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020/","field":"links","label":"Ann Surg Oncol 2020"}]},{"url":"https://doi.org/10.1245/s10434-021-10277-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1245/s10434-021-10277-7","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"opt-in","kind":"trial","name":"OPT-IN (EA2197)","route":"/trials/opt-in/","field":"links","label":"Trial in progress, Ann Surg Oncol 2022"}]},{"url":"https://doi.org/10.1245/s10434-024-15117-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1245/s10434-024-15117-y","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","field":"links","label":"Adjuvant chemoradiation in resected biliary adenocarcinoma: evaluation of SWOG S0809 with a large national database (Ann Surg Oncol 2024)"}]},{"url":"https://doi.org/10.1245/s10434-024-15293-x","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1245/s10434-024-15293-x","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"hepzato","kind":"drug","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","field":"links","label":"FOCUS (Ann Surg Oncol 2024)"},{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","field":"links","label":"FOCUS trial (Ann Surg Oncol 2024)"},{"id":"paper-zager-ann-surg-oncol","kind":"paper","name":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","route":"/key-papers/paper-zager-ann-surg-oncol/","field":"links","label":"Ann Surg Oncol 2024"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"links","label":"Annals of Surgical Oncology 2024"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"outcomes.source (Objective response rate (independent central review, treated population))"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"outcomes.source (Duration of response (independent central review))"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"outcomes.source (Progression-free survival (treated population))"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","field":"outcomes.source (Overall survival (treated population))"}]},{"url":"https://doi.org/10.1245/s10434-024-15817-5","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1245/s10434-024-15817-5","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"Ann Surg Oncol 2024: Alliance A021806, phase III perioperative versus adjuvant chemotherapy for resectable pancreatic cancer (design)"},{"id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/","field":"links","label":"Eade et al., ALLIANCE A021806 design (Annals of Surgical Oncology 2024)"}]},{"url":"https://doi.org/10.1249/mss.0000000000002116","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/acsm-msse/abstract/10.1249/mss.0000000000002116~exercise-guidelines-for-cancer-survivors-consensus-statement?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-campbell-med-sci-sports-exerc","kind":"paper","name":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","route":"/key-papers/paper-campbell-med-sci-sports-exerc/","field":"links","label":"Med Sci Sports Exerc 2019"}]},{"url":"https://doi.org/10.1249/MSS.0000000000002116","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/acsm-msse/abstract/10.1249/mss.0000000000002116~exercise-guidelines-for-cancer-survivors-consensus-statement?redirectionsource=fulltextview","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","field":"links","label":"ACSM roundtable 2019 (Med Sci Sports Exerc)"}]},{"url":"https://doi.org/10.12659/msmbr.901651","status":200,"ok":true,"finalUrl":"https://basic.medscimonit.com/abstract/full/idArt/901651","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Liu, Med Sci Monit Basic Res 2016: body mass index and gallbladder cancer, meta-analysis of 14 cohorts"}]},{"url":"https://doi.org/10.1302/0301-620x.90b5.20365","status":200,"ok":true,"finalUrl":"https://boneandjoint.org.uk/Article/10.1302/0301-620X.90B5.20365","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dedifferentiated-chordoma","kind":"cancer","name":"Dedifferentiated chordoma","route":"/cancers/dedifferentiated-chordoma/","field":"links","label":"JBJS British 2008: dedifferentiated chordoma, four cases arising de novo"}]},{"url":"https://doi.org/10.1371/journal.pbio.1002165","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"links","label":"Freedman, Cockburn & Simcoe, The economics of reproducibility in preclinical research (PLOS Biology 2015)"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"metrics (Estimated annual US spend on irreproducible preclinical research)"},{"id":"paper-freedman-plos-biol","kind":"paper","name":"The Economics of Reproducibility in Preclinical Research","route":"/key-papers/paper-freedman-plos-biol/","field":"links","label":"PLoS Biol 2015"}]},{"url":"https://doi.org/10.1371/journal.pcbi.1005991","status":200,"ok":true,"finalUrl":"https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1005991","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ghaffarizadeh-plos-comput-biol","kind":"paper","name":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems","route":"/key-papers/paper-ghaffarizadeh-plos-comput-biol/","field":"links","label":"PLoS Comput Biol 2018"},{"id":"agent-based-tumour-models","kind":"technology","name":"Agent-based and multicellular simulations","route":"/technologies/agent-based-tumour-models/","field":"links","label":"Ghaffarizadeh and colleagues 2018, PhysiCell, PLOS Computational Biology"}]},{"url":"https://doi.org/10.1371/journal.pgen.1006756","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006756","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Lorenzo Bermejo, PLoS Genet 2017: Mapuche ancestry and gallbladder cancer risk in Chile"}]},{"url":"https://doi.org/10.1371/journal.pmed.0020073","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020073","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","kind":"paper","name":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","route":"/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/","field":"links","label":"Pao et al., PLoS Med 2005: a second EGFR kinase-domain mutation in lung adenocarcinomas with acquired resistance to gefitinib or erlotinib"}]},{"url":"https://doi.org/10.1371/journal.pmed.1000113","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000113","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"papers","label":"Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice"}]},{"url":"https://doi.org/10.1371/journal.pmed.1001376","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001376","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","kind":"paper","name":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","route":"/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/","field":"links","label":"PLoS Med 2013"}]},{"url":"https://doi.org/10.1371/journal.pmed.1003998","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003998","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-stampede-plos-med-2022-update","kind":"paper","name":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","route":"/key-papers/paper-stampede-plos-med-2022-update/","field":"links","label":"PLoS Med 2022"}]},{"url":"https://doi.org/10.1371/journal.pone.0089778","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089778","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"PLoS One 2014: sentinel node dissection alone versus axillary dissection in early invasive lobular carcinoma, SEER"}]},{"url":"https://doi.org/10.1371/journal.pone.0108498","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108498","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Keane, PLoS One 2014: incidence of pancreatic and biliary tract cancer in UK primary care 2000 to 2010"}]},{"url":"https://doi.org/10.1371/journal.pone.0157368","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157368","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-mesenchymal-stem-like","kind":"cancer","name":"Mesenchymal stem-like triple-negative breast cancer (MSL)","route":"/cancers/tnbc-mesenchymal-stem-like/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","field":"links","label":"Lehmann, PLoS One 2016: refinement of triple-negative breast cancer molecular subtypes to four (TNBCtype-4)"},{"id":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","kind":"paper","name":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","route":"/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/","field":"links","label":"PLoS One 2016"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"prevalence.source"}]},{"url":"https://doi.org/10.1371/journal.pone.0186281","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186281","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"metrics (Published articles using misidentified or contaminated cell lines)"}]},{"url":"https://doi.org/10.1371/journal.pone.0272205","status":200,"ok":true,"finalUrl":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272205","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"papers","label":"Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America"}]},{"url":"https://doi.org/10.14309/crj.0000000000001354","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/acgcr/fulltext/10.14309/crj.0000000000001354~severe-drug-induced-liver-injury-due-to-self-administration","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"links","label":"Thakurdesai case report 2024"},{"id":"paper-thakurdesai-fenbendazole-liver-injury-2024","kind":"paper","name":"Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication fenbendazole","route":"/key-papers/paper-thakurdesai-fenbendazole-liver-injury-2024/","field":"links","label":"Thakurdesai case report 2024"}]},{"url":"https://doi.org/10.14670/hh-28.1393","status":200,"ok":true,"finalUrl":"https://www.hh.um.es/Abstracts/Vol_28/28_11/28_11_1393.htm","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","field":"links","label":"Vranic, Histol Histopathol 2013: apocrine carcinoma of the breast, a comprehensive review"}]},{"url":"https://doi.org/10.14701/ahbps.24-223","status":200,"ok":true,"finalUrl":"http://www.ahbps.org/journal/view.html?doi=10.14701/ahbps.24-223","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025","kind":"paper","name":"Neoadjuvant treatment for incidental gallbladder cancer: A systematic review","route":"/key-papers/paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025/","field":"links","label":"Ann Hepatobiliary Pancreat Surg 2025"}]},{"url":"https://doi.org/10.14701/ahbps.26-091","status":200,"ok":true,"finalUrl":"http://www.ahbps.org/journal/view.html?doi=10.14701/ahbps.26-091","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cho, Ann Hepatobiliary Pancreat Surg 2026: extended versus simple cholecystectomy for T1b, meta-analysis"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Cho, Ann Hepatobiliary Pancreat Surg 2026: extended versus simple cholecystectomy for T1b, meta-analysis"},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","field":"links","label":"Cho, Ann Hepatobiliary Pancreat Surg 2026: extended versus simple cholecystectomy for T1b, meta-analysis"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"links","label":"Cho, Ann Hepatobiliary Pancreat Surg 2026: extended versus simple cholecystectomy for T1b, meta-analysis"},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Extended versus simple cholecystectomy for pT1b gallbladder cancer: meta-analysis of 26 cohorts (Ann Hepatobiliary Pancreat Surg 2026)"}]},{"url":"https://doi.org/10.1515/raon-2016-0002","status":200,"ok":true,"finalUrl":"https://reference-global.com/article/10.1515/raon-2016-0002","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-symptom-control","kind":"term","name":"Symptom control in advanced gallbladder cancer: pain, ascites and nutrition","route":"/terms/gallbladder-cancer-symptom-control/","field":"links","label":"Tenckhoff tunnelled peritoneal catheter for malignant ascites: technical and clinical outcome (Radiol Oncol 2016, 94 patients)"}]},{"url":"https://doi.org/10.15252/embj.201694054","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.15252/embj.201694054","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"papers","label":"UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells"}]},{"url":"https://doi.org/10.15252/emmm.201606711","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.15252/emmm.201606711","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","field":"links","label":"EMBO Molecular Medicine 2017: gene signature driving invasive mucinous adenocarcinoma of the lung"}]},{"url":"https://doi.org/10.15252/emmm.201809158","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.15252/emmm.201809158","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","field":"links","label":"Pfeiffer et al., In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome (EMBO Molecular Medicine 2018)"},{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/","field":"links","label":"Pfeiffer et al., In vivo generation of human CD19-CAR T cells (EMBO Molecular Medicine 2018)"},{"id":"paper-pfeiffer-embo-mol-med","kind":"paper","name":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","route":"/key-papers/paper-pfeiffer-embo-mol-med/","field":"links","label":"EMBO Mol Med 2018"}]},{"url":"https://doi.org/10.15252/emmm.201809172","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.15252/emmm.201809172","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-castroviejo-bermejo-embo-mol-med","kind":"paper","name":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","route":"/key-papers/paper-castroviejo-bermejo-embo-mol-med/","field":"links","label":"EMBO Mol Med 2018"},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/","field":"links","label":"EMBO Molecular Medicine 2018: A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation"}]},{"url":"https://doi.org/10.1615/critrevoncog.v16.i1-2.40","status":200,"ok":true,"finalUrl":"https://www.dl.begellhouse.com/journals/439f422d0783386a,049e8a5e62fb019e,3e98dc741286f62b.html","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","field":"links","label":"Critical Reviews in Oncogenesis 2011: myeloid leukaemia in Down syndrome"}]},{"url":"https://doi.org/10.1701/3761.37486","status":200,"ok":true,"finalUrl":"https://www.recentiprogressi.it/archivio/3761/articoli/37486/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"papers","label":"Chronic treatment of COPD: state of the art and real-world analysis of healthcare costs based on medication adherence data"}]},{"url":"https://doi.org/10.20471/acc.2020.59.01.12","status":200,"ok":true,"finalUrl":"https://hrcak.srce.hr/clanak/351936","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"papers","label":"CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY"}]},{"url":"https://doi.org/10.20471/acc.2021.60.01.08","status":200,"ok":true,"finalUrl":"https://hrcak.srce.hr/clanak/377948","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"papers","label":"THE ROLE OF SALIVARY AND SERUM CA125 AND ROUTINE BLOOD TESTS IN PATIENTS WITH OVARIAN MALIGNANCIES"}]},{"url":"https://doi.org/10.21037/atm.2020.01.52","status":200,"ok":true,"finalUrl":"https://atm.amegroups.org/article/view/37527/html","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","field":"links","label":"Annals of Translational Medicine 2020: colorectal mucinous adenocarcinoma in SEER, 9,494 against 107,735 patients"}]},{"url":"https://doi.org/10.21037/cco.2019.08.03","status":200,"ok":true,"finalUrl":"https://cco.amegroups.org/article/view/28518/25067","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019","kind":"paper","name":"Epidemiology of gallbladder cancer in India","route":"/key-papers/paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019/","field":"links","label":"Chin Clin Oncol 2019"}]},{"url":"https://doi.org/10.21037/jgo-22-1292","status":200,"ok":true,"finalUrl":"https://jgo.amegroups.org/article/view/72553/html","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"links","label":"Fang, J Gastrointest Oncol 2023: adenosquamous gallbladder carcinoma in SEER"}]},{"url":"https://doi.org/10.21037/jgo.2018.08.18","status":200,"ok":true,"finalUrl":"https://jgo.amegroups.org/article/view/24186/21575","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-weinberg-biliary-profiling-jgo-2019","kind":"paper","name":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","route":"/key-papers/paper-weinberg-biliary-profiling-jgo-2019/","field":"links","label":"Weinberg et al., J Gastrointest Oncol 2019: molecular profiling of 1,502 biliary cancers"}]},{"url":"https://doi.org/10.21037/jtd.2017.07.95","status":200,"ok":true,"finalUrl":"https://jtd.amegroups.org/article/view/15337/12781","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","field":"links","label":"Journal of Thoracic Disease 2017: AB thymoma with atypical type A component and delayed lung and brain metastases"}]},{"url":"https://doi.org/10.21037/tlcr-2025-638","status":200,"ok":true,"finalUrl":"https://tlcr.amegroups.org/article/view/106043/html","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/","field":"links","label":"Transl Lung Cancer Res 2025"}]},{"url":"https://doi.org/10.2147/bctt.s126341","status":200,"ok":true,"finalUrl":"https://www.dovepress.com/invasive-lobular-carcinoma-of-the-male-breast-a-systematic-review-with-peer-reviewed-fulltext-article-BCTT","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"Breast Cancer (Dove) 2017: invasive lobular carcinoma of the male breast, systematic review"}]},{"url":"https://doi.org/10.2147/clep.s37357","status":200,"ok":true,"finalUrl":"https://www.dovepress.com/gallbladder-cancer-epidemiology-and-outcome-peer-reviewed-fulltext-article-CLEP","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Hundal and Shaffer, Clin Epidemiol 2014: gallbladder cancer epidemiology and outcome"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"Hundal and Shaffer, Clin Epidemiol 2014: gallbladder cancer epidemiology and outcome"}]},{"url":"https://doi.org/10.2147/cmar.s267825","status":200,"ok":true,"finalUrl":"https://www.dovepress.com/prognosis-of-intravascular-large-b-cell-lymphoma-ivlbcl-analysis-of-18-peer-reviewed-fulltext-article-CMAR","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","field":"links","label":"Cancer Management and Research 2020: prognosis of intravascular large B-cell lymphoma, 182 published cases"}]},{"url":"https://doi.org/10.2147/ott.s105862","status":200,"ok":true,"finalUrl":"https://www.dovepress.com/pd-l1-expression-in-human-cancers-and-its-association-with-clinical-ou-peer-reviewed-fulltext-article-OTT","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-onco-targets-ther-2016","kind":"paper","name":"PD-L1 expression in human cancers and its association with clinical outcomes","route":"/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/","field":"links","label":"Onco Targets Ther 2016"}]},{"url":"https://doi.org/10.2147/ott.s164574","status":200,"ok":true,"finalUrl":"https://www.dovepress.com/adenosquamous-carcinoma-of-the-lung-peer-reviewed-fulltext-article-OTT","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/","field":"links","label":"Li 2018, OncoTargets and Therapy: adenosquamous carcinoma of the lung (review)"}]},{"url":"https://doi.org/10.2222/jsv.55.267","status":200,"ok":true,"finalUrl":"https://www.jstage.jst.go.jp/article/jsv/55/2/55_2_267/_article/-char/ja/","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"papers","label":"Antiviral defense by APOBEC3 Family Proteins"}]},{"url":"https://doi.org/10.2340/actadv.v104.40601","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actadv/article/view/40601","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Philipp-Dormston et al., Acta Dermato-Venereologica 2024;104:adv40601: a European consensus on the consistent use of the term 'keratinocyte cancer'"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"links","label":"Philipp-Dormston et al., Acta Dermato-Venereologica 2024;104:adv40601: a European consensus on the consistent use of the term 'keratinocyte cancer'"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Philipp-Dormston et al., Acta Dermato-Venereologica 2024;104:adv40601: a European consensus on the consistent use of the term 'keratinocyte cancer'"}]},{"url":"https://doi.org/10.2340/actadv.v106.adv-2025-0079","status":200,"ok":true,"finalUrl":"https://medicaljournalssweden.se/actadv/article/view/46241","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"links","label":"Nationwide cohort of 47,358 tumours (Acta Dermato-Venereologica 2026)"}]},{"url":"https://doi.org/10.2353/ajpath.2008.080475","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002944010615374","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gamma-secretase","kind":"target","name":"Gamma-secretase (PSEN1)","route":"/targets/gamma-secretase/","field":"prevalence.source"}]},{"url":"https://doi.org/10.2478/raon-2013-0057","status":200,"ok":true,"finalUrl":"https://reference-global.com/article/10.2478/raon-2013-0057","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"papers","label":"Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature"}]},{"url":"https://doi.org/10.2967/jnumed.116.183194","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/58/1/85","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients"}]},{"url":"https://doi.org/10.2967/jnumed.117.193169","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/59/1/147","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","field":"links","label":"Pandit-Taskar et al., Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET study (Journal of Nuclear Medicine 2017)"},{"id":"paper-pandit-taskar-j-nucl-med","kind":"paper","name":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","route":"/key-papers/paper-pandit-taskar-j-nucl-med/","field":"links","label":"J Nucl Med 2018"}]},{"url":"https://doi.org/10.2967/jnumed.118.217463","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/5/623","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","field":"links","label":"J Nucl Med 2019"}]},{"url":"https://doi.org/10.2967/jnumed.119.226498","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/3/299","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","field":"links","label":"Badawi et al., First human imaging studies with the EXPLORER total-body PET scanner (Journal of Nuclear Medicine 2019)"},{"id":"paper-badawi-j-nucl-med","kind":"paper","name":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner","route":"/key-papers/paper-badawi-j-nucl-med/","field":"links","label":"J Nucl Med 2019"}]},{"url":"https://doi.org/10.2967/jnumed.119.227967","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/6/801","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","field":"links","label":"Kratochwil et al., 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer (Journal of Nuclear Medicine 2019)"},{"id":"paper-kratochwil-j-nucl-med","kind":"paper","name":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer","route":"/key-papers/paper-kratochwil-j-nucl-med/","field":"links","label":"J Nucl Med 2019"}]},{"url":"https://doi.org/10.2967/jnumed.121.261982","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/62/10/1440","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"papers","label":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort"}]},{"url":"https://doi.org/10.2967/jnumed.121.262485","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/63/5/720","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","field":"links","label":"Farwell et al., CD8-targeted PET imaging of tumour-infiltrating T cells in patients with cancer: a phase 1 first-in-human study of 89Zr-Df-IAB22M2C (Journal of Nuclear Medicine 2021)"},{"id":"paper-farwell-j-nucl-med","kind":"paper","name":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","route":"/key-papers/paper-farwell-j-nucl-med/","field":"links","label":"J Nucl Med 2022"}]},{"url":"https://doi.org/10.2967/jnumed.123.266741","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/65/3/432","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct05413850-j-nucl-med-2024","kind":"paper","name":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","route":"/key-papers/paper-nct05413850-j-nucl-med-2024/","field":"links","label":"J Nucl Med 2024"}]},{"url":"https://doi.org/10.31083/bjhm53142","status":200,"ok":true,"finalUrl":"https://www.imrpress.com/journal/BJHM/87/4/10.31083/BJHM53142","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Br J Hosp Med 2026: how to translate quality standards into good lung cancer screening programmes, the UK experience"},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","field":"links","label":"Br J Hosp Med 2026: how to translate quality standards into good lung cancer screening programmes, the UK experience"}]},{"url":"https://doi.org/10.32074/1591-951x-1-20","status":200,"ok":true,"finalUrl":"https://old.pathologica.it/article/view/96","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"links","label":"Cserni, Pathologica 2020: histological type and typing of breast carcinomas and WHO classification changes"},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"links","label":"Cserni, Pathologica 2020: histological type and typing of breast carcinomas and WHO classification changes"},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","field":"links","label":"Cserni, Pathologica 2020: histological type and typing of breast carcinomas and WHO classification changes"}]},{"url":"https://doi.org/10.3238/arztebl.m2023.0169","status":200,"ok":true,"finalUrl":"https://di.aerzteblatt.de/int/archive/article/233578","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"WiZen (Dtsch Arztebl Int 2023)"}]},{"url":"https://doi.org/10.3322/caac.20006","status":200,"ok":true,"finalUrl":"https://chooser.crossref.org/?doi=10.3322%2Fcaac.20006","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jemal-cancer-statistics-2009-cacancer-2009","kind":"paper","name":"Jemal 2009: Cancer statistics, 2009","route":"/key-papers/paper-jemal-cancer-statistics-2009-cacancer-2009/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.20073","status":200,"ok":true,"finalUrl":"https://chooser.crossref.org/?doi=10.3322%2Fcaac.20073","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-jemal-cancer-statistics-2010-cacancer-2010","kind":"paper","name":"Jemal 2010: Cancer statistics, 2010","route":"/key-papers/paper-jemal-cancer-statistics-2010-cacancer-2010/","field":"links","label":"Full text (DOI)"}]},{"url":"https://doi.org/10.3322/caac.20087","status":200,"ok":true,"finalUrl":"https://chooser.crossref.org/?doi=10.3322%2Fcaac.20087","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"papers","label":"Improving outcomes for patients with diffuse large B-cell lymphoma"}]},{"url":"https://doi.org/10.3324/haematol.2016.144428","status":200,"ok":true,"finalUrl":"https://haematologica.org/article/view/7766","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"standardOfCare.guideline (After allogeneic HSCT, high risk)"}]},{"url":"https://doi.org/10.3324/haematol.2019.220962","status":200,"ok":true,"finalUrl":"https://haematologica.org/article/view/9939","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"outcomes.source (Event-free survival at 3 years, bortezomib randomisation)"},{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"outcomes.source (Overall survival at 3 years, bortezomib randomisation)"},{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","field":"outcomes.source (Complete remission after induction, bortezomib randomisation)"},{"id":"paper-aaml1031-bortezomib-aplenc-haematologica-2020","kind":"paper","name":"AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes","route":"/key-papers/paper-aaml1031-bortezomib-aplenc-haematologica-2020/","field":"links","label":"Haematologica 2020"}]},{"url":"https://doi.org/10.3324/haematol.2022.281628","status":200,"ok":true,"finalUrl":"https://haematologica.org/article/view/haematol.2022.281628","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","field":"links","label":"HBI0101 phase 1 (Haematologica 2023)"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"links","label":"Haematologica 2023"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"outcomes.source (Overall response rate)"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"outcomes.source ((Stringent) complete response rate)"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"outcomes.source (Median progression-free survival)"},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","field":"outcomes.source (Grade 1 to 2 cytokine release syndrome)"},{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/","field":"links","label":"Haematologica 2023"}]},{"url":"https://doi.org/10.3332/ecancer.2014.442","status":200,"ok":true,"finalUrl":"https://ecancer.org/en/journal/article/442-the-repurposing-drugs-in-oncology-redo-project","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"links","label":"Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-repurposing-prize","kind":"idea","name":"A $50 million prize for the first off-patent drug proven to extend cancer survival","route":"/ideas/idea-reg-repurposing-prize/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-repurposing-social-impact-bond","kind":"idea","name":"A social impact bond: investors fund a repurposing trial, payers repay from savings","route":"/ideas/idea-reg-repurposing-social-impact-bond/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-perioperative-propranolol-etodolac","kind":"idea","name":"Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery","route":"/ideas/idea-reg-perioperative-propranolol-etodolac/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-statin-hcc-prevention-trial","kind":"idea","name":"A pragmatic trial of statins to prevent liver cancer in people with cirrhosis","route":"/ideas/idea-reg-statin-hcc-prevention-trial/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-evidence-gate-before-repurposing-phase3","kind":"idea","name":"Require genetic and target-trial evidence before funding any repurposing phase 3","route":"/ideas/idea-reg-evidence-gate-before-repurposing-phase3/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-target-trial-emulation-pipeline","kind":"idea","name":"An automated pipeline emulating trials of every common drug against every cancer","route":"/ideas/idea-reg-target-trial-emulation-pipeline/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-new-indication-exclusivity-off-patent","kind":"idea","name":"Three years of indication-specific exclusivity for proving a new cancer use of an old drug","route":"/ideas/idea-reg-new-indication-exclusivity-off-patent/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-antihistamine-plus-io-trial","kind":"idea","name":"Randomise a cheap antihistamine alongside immunotherapy","route":"/ideas/idea-reg-antihistamine-plus-io-trial/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-vitamin-d-digestive-cancer-biomarker-trial","kind":"idea","name":"A biomarker-directed trial of vitamin D after surgery for digestive tract cancers","route":"/ideas/idea-reg-vitamin-d-digestive-cancer-biomarker-trial/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-losartan-pancreatic-stroma","kind":"idea","name":"Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3","route":"/ideas/idea-reg-losartan-pancreatic-stroma/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-payer-coverage-off-label-generic-commitment","kind":"idea","name":"Payers pre-commit to cover off-label generics when a definitive trial is positive","route":"/ideas/idea-reg-payer-coverage-off-label-generic-commitment/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-nonprofit-marketing-authorisation-holder","kind":"idea","name":"A non-profit company to hold marketing authorisations for repurposed cancer drugs","route":"/ideas/idea-reg-nonprofit-marketing-authorisation-holder/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-generic-chemo-strategic-reserve","kind":"idea","name":"A strategic reserve of essential generic cancer drugs to end recurring shortages","route":"/ideas/idea-reg-generic-chemo-strategic-reserve/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-factorial-addon-arms-cooperative-trials","kind":"idea","name":"Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial","route":"/ideas/idea-reg-factorial-addon-arms-cooperative-trials/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-olanzapine-cachexia-global-confirmation","kind":"idea","name":"Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide","route":"/ideas/idea-reg-olanzapine-cachexia-global-confirmation/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-reg-preregistered-ai-repurposing-scoring","kind":"idea","name":"Pre-registered, publicly scored AI ranking of repurposing candidates for cancer","route":"/ideas/idea-reg-preregistered-ai-repurposing-scoring/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"idea-moon-generics-for-cancer-fund","kind":"idea","name":"A public fund and label pathway to trial generic drugs against cancer","route":"/ideas/idea-moon-generics-for-cancer-fund/","field":"links","label":"Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014)"},{"id":"paper-pantziarka-ecancermedicalscience","kind":"paper","name":"The Repurposing Drugs in Oncology (ReDO) Project","route":"/key-papers/paper-pantziarka-ecancermedicalscience/","field":"links","label":"Ecancermedicalscience 2014"}]},{"url":"https://doi.org/10.3332/ecancer.2018.886","status":200,"ok":true,"finalUrl":"https://ecancer.org/en/journal/article/886-redo-db-the-repurposing-drugs-in-oncology-database","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"metrics (Licensed non-cancer drugs with published evidence of anticancer activity catalogued in ReDO_DB)"}]},{"url":"https://doi.org/10.3389/fimmu.2022.991092","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.991092/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022","kind":"paper","name":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022/","field":"links","label":"Front Immunol 2022"}]},{"url":"https://doi.org/10.3389/fneur.2015.00216","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2015.00216/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"papers","label":"The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases"}]},{"url":"https://doi.org/10.3389/fonc.2020.00082","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00082/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"carbon-ion","kind":"technology","name":"Carbon-ion therapy","route":"/technologies/carbon-ion/","field":"links","label":"Malouff et al., Carbon ion therapy: a modern review of an emerging technology (Frontiers in Oncology 2020)"},{"id":"paper-malouff-front-oncol","kind":"paper","name":"Carbon Ion Therapy: A Modern Review of an Emerging Technology","route":"/key-papers/paper-malouff-front-oncol/","field":"links","label":"Front Oncol 2020"},{"id":"carbon-ion-synchrotrons","kind":"technology","name":"Carbon-ion synchrotrons and facilities","route":"/technologies/carbon-ion-synchrotrons/","field":"links","label":"Malouff et al., Carbon ion therapy: a modern review of an emerging technology (Frontiers in Oncology 2020)"}]},{"url":"https://doi.org/10.3389/fonc.2020.01214","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01214/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cldn18-gastric-front-oncol-2020","kind":"paper","name":"The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-cldn18-gastric-front-oncol-2020/","field":"links","label":"Front Oncol 2020"}]},{"url":"https://doi.org/10.3389/fonc.2020.578756","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.578756/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nct02152631-front-oncol-2020","kind":"paper","name":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER","route":"/key-papers/paper-nct02152631-front-oncol-2020/","field":"links","label":"Front Oncol 2020"}]},{"url":"https://doi.org/10.3389/fonc.2021.570623","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.570623/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-ren-tnbc-mmr-msi-440-front-oncol-2021","kind":"paper","name":"Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients","route":"/key-papers/paper-ren-tnbc-mmr-msi-440-front-oncol-2021/","field":"links","label":"Ren et al., Front Oncol 2021: mismatch repair and MSI in 440 Chinese TNBC patients"},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"prevalence.source"}]},{"url":"https://doi.org/10.3389/fonc.2021.727222","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.727222/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"Frontiers in Oncology 2021: collecting duct carcinoma of the kidney, 286 SEER patients 2004 to 2018"}]},{"url":"https://doi.org/10.3389/fonc.2022.800920","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.800920/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"papers","label":"Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors"}]},{"url":"https://doi.org/10.3389/fonc.2023.1186378","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1186378/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Chen, Front Oncol 2023: wedge resection versus segment IVb and V resection for T2, meta-analysis"},{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","field":"links","label":"Chen, Front Oncol 2023: wedge resection versus segment IVb and V resection for T2, meta-analysis"}]},{"url":"https://doi.org/10.3389/fonc.2024.1483953","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1483953/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-splash-front-oncol-2024","kind":"paper","name":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","route":"/key-papers/paper-splash-front-oncol-2024/","field":"links","label":"Front Oncol 2024"}]},{"url":"https://doi.org/10.3389/fonc.2025.1658528","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1658528/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","kind":"paper","name":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","route":"/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/","field":"links","label":"Erices et al., Front Oncol 2025: mutational landscape of Chilean gallbladder cancer"}]},{"url":"https://doi.org/10.3389/fonc.2026.1907192","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1907192/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026","kind":"paper","name":"Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?","route":"/key-papers/paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026/","field":"links","label":"Cheng melanoma case report 2026"}]},{"url":"https://doi.org/10.3389/fped.2021.746504","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.746504/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"papers","label":"Procedural Pain Assessment in Infants Without Analgosedation: Comparison of Newborn Infant Parasympathetic Evaluation and Skin Conductance Activity - A Pilot Study"}]},{"url":"https://doi.org/10.3389/fsurg.2025.1477301","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2025.1477301/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Simple versus extended cholecystectomy for T1b gallbladder cancer: meta-analysis of 8 studies (Front Surg 2025)"}]},{"url":"https://doi.org/10.3389/pore.2021.1609859","status":200,"ok":true,"finalUrl":"https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2021.1609859/full","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","field":"links","label":"Pathology Oncology Research 2021: clinicopathological and molecular characteristics of colorectal signet ring cell carcinoma (review)"}]},{"url":"https://doi.org/10.3892/etm.2020.8965","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/10.3892/etm.2020.8965","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"somatostatinoma","kind":"cancer","name":"Somatostatinoma","route":"/cancers/somatostatinoma/","field":"links","label":"Experimental and Therapeutic Medicine 2020: somatostatinoma beyond neurofibromatosis type 1 (review)"}]},{"url":"https://doi.org/10.3892/ijmm.2014.1659","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/10.3892/ijmm.2014.1659","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"links","label":"Int J Mol Med 2014: clinicopathological review of 33 vulvar melanomas, c-KIT as a prognostic marker"}]},{"url":"https://doi.org/10.3892/ijo_00000741","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/ijo/37/4/901","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","field":"links","label":"International Journal of Oncology 2010: medullary carcinoma of the large intestine, SEER population analysis"}]},{"url":"https://doi.org/10.3892/ijo.2013.2063","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/10.3892/ijo.2013.2063","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"papers","label":"Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin"}]},{"url":"https://doi.org/10.3892/ijo.2020.4989","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/10.3892/ijo.2020.4989","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lewis-negative","kind":"term","name":"Lewis-negative (Lewis antigen-negative, CA 19-9 non-secretor) status","route":"/terms/lewis-negative/","field":"links","label":"Int J Oncol 2020: Lewis antigen-negative pancreatic cancer, an aggressive subgroup (853 patients)"}]},{"url":"https://doi.org/10.3892/ol.2020.12333","status":200,"ok":true,"finalUrl":"https://www.spandidos-publications.com/10.3892/ol.2020.12333","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"links","label":"Oncol Lett 2021: villin as a biomarker for reverse polarity in colorectal micropapillary carcinoma (453 tumours)"}]},{"url":"https://doi.org/10.3945/ajcn.112.035972","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0002916523028666","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-nechuta-am-j-clin-nutr","kind":"paper","name":"Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women","route":"/key-papers/paper-nechuta-am-j-clin-nutr/","field":"links","label":"Am J Clin Nutr 2012"},{"id":"soy-breast-cancer","kind":"technology","name":"Soy foods and breast cancer","route":"/technologies/soy-breast-cancer/","field":"links","label":"Soy intake and breast cancer recurrence, pooled analysis (Am J Clin Nutr 2012)"}]},{"url":"https://doi.org/10.3978/j.issn.2078-6891.2011.021","status":200,"ok":true,"finalUrl":"https://jgo.amegroups.org/article/view/181","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Ballehaninna and Chamberlain, J Gastrointest Oncol 2012: clinical utility of serum CA 19-9 in pancreatic adenocarcinoma"},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","field":"links","label":"Ballehaninna and Chamberlain, J Gastrointest Oncol 2012: clinical utility of serum CA 19-9 in pancreatic adenocarcinoma"},{"id":"lewis-negative","kind":"term","name":"Lewis-negative (Lewis antigen-negative, CA 19-9 non-secretor) status","route":"/terms/lewis-negative/","field":"links","label":"Ballehaninna and Chamberlain, J Gastrointest Oncol 2012: clinical utility of serum CA 19-9 in pancreatic adenocarcinoma"}]},{"url":"https://doi.org/10.4103/1319-3767.65184","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/sjga/fulltext/10.4103/1319-3767.65184~systematic-review-should-routine-resection-of-the","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"links","label":"Systematic review: routine extrahepatic bile duct resection in gallbladder cancer (Saudi J Gastroenterol 2010)"}]},{"url":"https://doi.org/10.4103/2153-3539.119005","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2153353922006484","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"digital-pathology-wsi","kind":"term","name":"Digital pathology and whole-slide images (WSI)","route":"/terms/digital-pathology-wsi/","field":"links","label":"Goode et al., OpenSlide: a vendor-neutral software foundation for digital pathology (J Pathol Inform 2013)"}]},{"url":"https://doi.org/10.4103/2231-0770.112789","status":200,"ok":true,"finalUrl":"https://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.112789","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","field":"links","label":"Avicenna Journal of Medicine 2013: testicular adrenal rest tumour or Leydig cell tumour, case and review"}]},{"url":"https://doi.org/10.4103/ijc.ijc_822_19","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/indianjcancer/fulltext/10.4103/ijc.ijc_822_19~predictors-of-toxicity-after-neoadjuvant-chemoradiotherapy","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"polcagb","kind":"trial","name":"POLCAGB","route":"/trials/polcagb/","field":"links","label":"Predictors of toxicity after neoadjuvant chemoradiotherapy for locally advanced gall bladder cancer (Indian J Cancer 2022)"}]},{"url":"https://doi.org/10.4103/ijmr.ijmr_1821_22","status":200,"ok":true,"finalUrl":"https://ijmr.org.in/cancer-incidence-estimates-for-2022-projection-for-2025-result-from-national-cancer-registry-programme-india/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","field":"links","label":"Cancer incidence estimates 2022 and projection 2025 (IJMR)"},{"id":"paper-mathur-ncrp-cancer-statistics-2020","kind":"paper","name":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India","route":"/key-papers/paper-mathur-ncrp-cancer-statistics-2020/","field":"links","label":"2022 estimates and 2025 projection (IJMR)"}]},{"url":"https://doi.org/10.4103/jcrt.jcrt_1931_22","status":200,"ok":true,"finalUrl":"https://www.ovid.com/jnls/cancerjournal/fulltext/10.4103/jcrt.jcrt_1931_22~splenic-b-cell-lymphomaleukemia-with-prominent-nucleoli-a","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"links","label":"J Cancer Res Ther 2024: splenic B-cell lymphoma/leukaemia with prominent nucleoli, three cases and review"}]},{"url":"https://doi.org/10.4143/crt.2019.271","status":200,"ok":true,"finalUrl":"https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2019.271","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Sung, Cancer Res Treat 2020: validation of the AJCC 8th edition for gallbladder cancer"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"links","label":"Sung, Cancer Res Treat 2020: validation of the AJCC 8th edition for gallbladder cancer"}]},{"url":"https://doi.org/10.4143/crt.2024.660","status":200,"ok":true,"finalUrl":"https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2024.660","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cystic-duct-carcinoma","kind":"cancer","name":"Cystic duct carcinoma","route":"/cancers/cystic-duct-carcinoma/","field":"links","label":"Kim, Cancer Res Treat 2025: stage evaluation of cystic duct cancer"},{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","field":"links","label":"Kim, Cancer Res Treat 2025: stage evaluation of cystic duct cancer"}]},{"url":"https://doi.org/10.4178/epih.e2021011","status":200,"ok":true,"finalUrl":"https://www.e-epih.org/journal/view.php?doi=10.4178/epih.e2021011","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Huang, Epidemiol Health 2021: gallstones and biliary tract cancer risk, meta-analysis"}]},{"url":"https://doi.org/10.4321/s0212-71992005000400003","status":200,"ok":true,"finalUrl":"https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992005000400003&lng=en&nrm=iso&tlng=en","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","field":"papers","label":"Prevención de eventos cardiovasculares en hipertensos mayores de 65 años bajo el cuidado de un programa de control: Estudio de cohorte"}]},{"url":"https://doi.org/10.4321/s1135-57272013000400004","status":200,"ok":true,"finalUrl":"https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1135-57272013000400004&lng=en&nrm=iso&tlng=en","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"papers","label":"Dabigatrón versus acenocumarol para la prevención del ictus en la fibrilación atrial: análisis de impacto presupuestario en un departamento sanitario"}]},{"url":"https://doi.org/10.5114/pm.2019.85785","status":200,"ok":true,"finalUrl":"https://www.termedia.pl/Non-obstetric-complications-in-preeclampsia,4,36874,0,1.html","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"papers","label":"Non-obstetric complications in preeclampsia"}]},{"url":"https://doi.org/10.5664/jcsm.6514","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.5664/jcsm.6514","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"papers","label":"Validation of Contact-Free Sleep Monitoring Device with Comparison to Polysomnography"}]},{"url":"https://doi.org/10.61409/a11240787","status":200,"ok":true,"finalUrl":"https://ugeskriftet.dk/dmj/incidence-and-clinicopathological-features-incidental-gallbladder-cancer","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Lerche-Jorgensen, Dan Med J 2025: incidental gallbladder cancer in 9,698 cholecystectomies"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"Lerche-Jorgensen, Dan Med J 2025: incidental gallbladder cancer in 9,698 cholecystectomies"},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","field":"links","label":"Lerche-Jorgensen, Dan Med J 2025: incidental gallbladder cancer in 9,698 cholecystectomies"}]},{"url":"https://doi.org/10.61679/1503035044","status":200,"ok":true,"finalUrl":"https://economiadelasalud.com/wp-content/uploads/2020/07/RevEspEconSalud2020.V15N3.35-44_emicizumab.pdf","contentType":"application/pdf","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"papers","label":"Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis of haemophilia a patients without inhibitors in Spain by multi-criteria decision analysis (MCDA)"}]},{"url":"https://doi.org/10.7150/ijbs.85813","status":200,"ok":true,"finalUrl":"https://www.ijbs.com/v19p3762.htm","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-b7-h3-glioblastoma-int-j-biol-sci-2023","kind":"paper","name":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy","route":"/key-papers/paper-b7-h3-glioblastoma-int-j-biol-sci-2023/","field":"links","label":"Int J Biol Sci 2023"}]},{"url":"https://dreamchallenges.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","field":"links","label":"DREAM Challenges"}]},{"url":"https://dtp.cancer.gov/","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/programs/dtp","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","field":"links","label":"NCI Developmental Therapeutics Program"}]},{"url":"https://dtp.cancer.gov/ncialmanac","status":200,"ok":true,"finalUrl":"https://dtp.cancer.gov/ncialmanac/initializePage.do","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","field":"links","label":"NCI ALMANAC"}]},{"url":"https://dukecancerinstitute.org","status":200,"ok":true,"finalUrl":"https://www.dukecancerinstitute.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","field":"links","label":"Duke Cancer Institute"},{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","field":"website"}]},{"url":"https://dukecancerinstitute.org/clinical-trials","status":200,"ok":true,"finalUrl":"https://www.dukecancerinstitute.org/clinical-trials","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","field":"links","label":"Clinical trials"}]},{"url":"https://eanm.org/the-eanm-community/organisation/board/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"links","label":"Society page"},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"profiles","label":"Society page"}]},{"url":"https://ecog-acrin.org","status":200,"ok":true,"finalUrl":"https://ecog-acrin.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"links","label":"ECOG-ACRIN"},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"profiles","label":"ECOG-ACRIN"},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"links","label":"ECOG-ACRIN"},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"profiles","label":"ECOG-ACRIN"},{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/","field":"links","label":"Official website"},{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/","field":"website"}]},{"url":"https://ecog-acrin.org/clinical-trials/tmist-breast-cancer-screening-trial/","status":200,"ok":true,"finalUrl":"https://www.msn.com/en-us/health/other/large-scale-breast-cancer-screening-trial-achieves-enrollment-goal-paving-the-way-for-precision-approach-to-screening/ar-AA1xfBWg?ocid=BingNewsVerp","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tmist","kind":"trial","name":"TMIST (Tomosynthesis Mammographic Imaging Screening Trial)","route":"/trials/tmist/","field":"links","label":"ECOG-ACRIN: TMIST"}]},{"url":"https://ehaweb.org","status":200,"ok":true,"finalUrl":"https://ehaweb.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","field":"links","label":"European Hematology Association"},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/","field":"links","label":"EHA"},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/","field":"website"}]},{"url":"https://ehaweb.org/about-eha/organization/eha-board","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","field":"links","label":"Society page"},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","field":"profiles","label":"Society page"},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","field":"links","label":"Society page"},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","field":"profiles","label":"Society page"}]},{"url":"https://ehs-clccblida.dz","status":200,"ok":true,"finalUrl":"https://ehs-clccblida.dz/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"links","label":"Anti-Cancer Center of Blida website"},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"profiles","label":"Anti-Cancer Center of Blida website"},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","route":"/institutions/blida-anti-cancer-center/","field":"links","label":"Official website"},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","route":"/institutions/blida-anti-cancer-center/","field":"website"}]},{"url":"https://eit.org","status":200,"ok":true,"finalUrl":"https://eit.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","field":"website"}]},{"url":"https://eit.org/about/","status":200,"ok":true,"finalUrl":"https://eit.org/about","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","field":"links","label":"Ellison Institute of Technology: about"},{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","field":"links","label":"About EIT"}]},{"url":"https://ejgo.org","status":200,"ok":true,"finalUrl":"https://ejgo.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","field":"url"}]},{"url":"https://elht.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-blackburn-elht","kind":"institution","name":"Royal Blackburn Hospital (East Lancashire HPB MDT)","route":"/institutions/royal-blackburn-elht/","field":"website"}]},{"url":"https://elicio.com","status":200,"ok":true,"finalUrl":"https://elicio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/","field":"links","label":"Official website"},{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260909073617/https://elicio.com/"},{"url":"https://elicio.com/press_releases/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-refined-phase-3-development-strategy-for-eli-002-7p-in-adjuvant-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","field":"links","label":"Elicio AMPLIFY-7P results (June 2026)"},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","field":"outcomes.source (Disease-free survival (ITT))"},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","field":"outcomes.source (Disease-free survival at 3 months (landmark))"},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","field":"outcomes.source (Disease-free survival, R0-resected subgroup (post hoc))"}]},{"url":"https://ellisonmedicalinstitute.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","field":"links","label":"Ellison Medical Institute"},{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","field":"links","label":"Ellison Medical Institute"}]},{"url":"https://elucidatebio.com","status":200,"ok":true,"finalUrl":"https://elucidatebio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/","field":"website"}]},{"url":"https://elucidatebio.com/products-and-services/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/","field":"links","label":"Products and services"}]},{"url":"https://emilywhiteheadfoundation.org/","status":200,"ok":true,"finalUrl":"https://www.emilywhiteheadfoundation.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","field":"links","label":"Emily Whitehead Foundation"},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","field":"profiles","label":"Emily Whitehead Foundation"}]},{"url":"https://empyreanmed.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","field":"links","label":"Official website"},{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","field":"website"}]},{"url":"https://empyreanmed.com/vektra/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","field":"links","label":"Vektra product page"}]},{"url":"https://en.cancer.org.il/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","route":"/institutions/israel-cancer-association/","field":"links","label":"Israel Cancer Association (English)"},{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","route":"/institutions/israel-cancer-association/","field":"website"}]},{"url":"https://en.globes.co.il/en/article-xact-robotics-shuts-down-lays-off-65-1001456845","status":200,"ok":true,"contentType":"text/html; charset=windows-1255","checked":"2026-09-30","refs":[{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","field":"links","label":"Globes: XACT Robotics shuts down, lays off 65 (3 September 2023)"}]},{"url":"https://en.huji.ac.il","status":200,"ok":true,"finalUrl":"https://en.huji.ac.il/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","field":"links","label":"Hebrew University of Jerusalem"},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","field":"website"}]},{"url":"https://en.mgi-tech.com","status":200,"ok":true,"finalUrl":"https://global-mgitech.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mgi-tech","kind":"company","name":"MGI Tech","route":"/companies/mgi-tech/","field":"links","label":"Official website"},{"id":"mgi-tech","kind":"company","name":"MGI Tech","route":"/companies/mgi-tech/","field":"website"}]},{"url":"https://en.ouh.dk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","field":"links","label":"Odense University Hospital website"},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","field":"profiles","label":"Odense University Hospital website"}]},{"url":"https://en.uoa.gr","status":200,"ok":true,"finalUrl":"https://en.uoa.gr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","route":"/institutions/nkua-athens/","field":"links","label":"NKUA"},{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","route":"/institutions/nkua-athens/","field":"website"}]},{"url":"https://en.wikipedia.org/wiki/%C3%96rebro_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/10x_Genomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/21st_Century_Cures_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","field":"links","label":"Wikipedia"},{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/340B_Drug_Pricing_Program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/5-HT3_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"htr3a","kind":"target","name":"5-HT3 receptor (HTR3A)","route":"/targets/htr3a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/5%27-nucleotidase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aalborg_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","field":"links","label":"Wikipedia"},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aarhus_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aaron_Ciechanover","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abarelix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/","field":"links","label":"Wikipedia"},{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abbott_Laboratories","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abdominoperineal_resection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abdominoperineal-resection","kind":"term","name":"Abdominoperineal resection","route":"/terms/abdominoperineal-resection/","field":"links","label":"Wikipedia"},{"id":"abdominoperineal-resection","kind":"term","name":"Abdominoperineal resection","route":"/terms/abdominoperineal-resection/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abemaciclib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abigail_Alliance_for_Better_Access_to_Developmental_Drugs_v._von_Eschenbach","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abigail-alliance","kind":"term","name":"Abigail Alliance v. von Eschenbach (2007)","route":"/terms/abigail-alliance/","field":"links","label":"Wikipedia"},{"id":"abigail-alliance","kind":"term","name":"Abigail Alliance v. von Eschenbach (2007)","route":"/terms/abigail-alliance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abiraterone_acetate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ablation_(artificial_intelligence)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ablation-study","kind":"term","name":"Ablation study and multi-task heads","route":"/terms/ablation-study/","field":"links","label":"Wikipedia"},{"id":"ablation-study","kind":"term","name":"Ablation study and multi-task heads","route":"/terms/ablation-study/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Abscopal_effect","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/","field":"links","label":"Wikipedia"},{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ABVD","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/","field":"links","label":"Wikipedia"},{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acalabrutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Accelerated_approval_(FDA)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","field":"links","label":"Wikipedia"},{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","field":"wikipedia"},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/","field":"links","label":"Wikipedia"},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Accuracy_and_precision","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accuracy-f1","kind":"term","name":"Accuracy, macro-F1 and confusion matrices","route":"/terms/accuracy-f1/","field":"links","label":"Wikipedia: accuracy and precision"}]},{"url":"https://en.wikipedia.org/wiki/Accuray","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acinar_cell_carcinoma_of_the_pancreas","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"links","label":"Wikipedia"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acinic_cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acinic-cell-carcinoma-salivary","kind":"cancer","name":"Acinic cell carcinoma of the salivary glands","route":"/cancers/acinic-cell-carcinoma-salivary/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acitretin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acitretin","kind":"drug","name":"Acitretin","route":"/drugs/acitretin/","field":"links","label":"Wikipedia"},{"id":"acitretin","kind":"drug","name":"Acitretin","route":"/drugs/acitretin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acral_lentiginous_melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"links","label":"Wikipedia"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acromegaly","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Actinic_keratosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Actinium-225","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Active_ingredient","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","field":"links","label":"Wikipedia"},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","field":"wikipedia"},{"id":"active-surveillance-term","kind":"term","name":"Active surveillance and observation","route":"/terms/active-surveillance-term/","field":"links","label":"Wikipedia"},{"id":"active-surveillance-term","kind":"term","name":"Active surveillance and observation","route":"/terms/active-surveillance-term/","field":"wikipedia"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"links","label":"Wikipedia"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260324033606/https://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/Acupuncture","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","field":"wikipedia"},{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","field":"wikipedia"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"links","label":"Wikipedia: Acute lymphoblastic leukaemia"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"wikipedia"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"links","label":"Wikipedia: Acute lymphoblastic leukaemia"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"wikipedia"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"links","label":"Wikipedia: Acute lymphoblastic leukaemia"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"wikipedia"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"links","label":"Wikipedia: Acute lymphoblastic leukaemia"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260823030608/https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia"},{"url":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"wikipedia"},{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","route":"/terms/eln-risk/","field":"wikipedia"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"links","label":"Wikipedia: Acute myeloid leukaemia"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"wikipedia"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"links","label":"Wikipedia"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"wikipedia"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"links","label":"Wikipedia: Acute myeloid leukaemia"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260906144309/https://en.wikipedia.org/wiki/Acute_myeloid_leukemia"},{"url":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia#Treatment","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","field":"links","label":"Wikipedia"},{"id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Acute_promyelocytic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"links","label":"Wikipedia"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adagrasib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adamantinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adamantinoma","kind":"cancer","name":"Adamantinoma of bone","route":"/cancers/adamantinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adaptive_design_(medicine)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/","field":"links","label":"Wikipedia"},{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/","field":"wikipedia"},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/","field":"links","label":"Wikipedia"},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/","field":"wikipedia"},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/","field":"links","label":"Wikipedia"},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adenocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adenocarcinoma_of_the_lung","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spread-through-air-spaces","kind":"term","name":"Spread through air spaces (STAS)","route":"/terms/spread-through-air-spaces/","field":"wikipedia"},{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"wikipedia"},{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","field":"wikipedia"},{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adenoid_cystic_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","field":"wikipedia"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"links","label":"Wikipedia"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adenosine_deaminase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ada","kind":"target","name":"Adenosine deaminase (ADA)","route":"/targets/ada/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adenosquamous_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"wikipedia"},{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"wikipedia"},{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adolescent_and_young_adult_oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","field":"wikipedia"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"links","label":"Wikipedia: Adolescent and young adult oncology"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adrenalectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adrenalectomy","kind":"term","name":"Adrenalectomy","route":"/terms/adrenalectomy/","field":"links","label":"Wikipedia"},{"id":"adrenalectomy","kind":"term","name":"Adrenalectomy","route":"/terms/adrenalectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adrenocortical_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"wikipedia"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"links","label":"Wikipedia"},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","field":"wikipedia"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"links","label":"Wikipedia"},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Adverse_event","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"side-effect-vs-adverse-event","kind":"term","name":"Side effect versus adverse event","route":"/terms/side-effect-vs-adverse-event/","field":"links","label":"Wikipedia"},{"id":"side-effect-vs-adverse-event","kind":"term","name":"Side effect versus adverse event","route":"/terms/side-effect-vs-adverse-event/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Afamitresgene_autoleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Afatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aflibercept","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aga_Khan_University_Hospital,_Nairobi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","route":"/people/rashid-khalani/","field":"links","label":"Source: Wikipedia article on the hospital (names the CEO)"},{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","route":"/people/rashid-khalani/","field":"profiles","label":"Wikipedia: Aga Khan University Hospital, Nairobi"},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Agenus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","field":"links","label":"Wikipedia"},{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aggressive_fibromatosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Agonist","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/","field":"links","label":"Wikipedia"},{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aidoc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/AIDS-related_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Akershus_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","field":"links","label":"Wikipedia"},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Akeso","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alan_Venook","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Albert_Einstein_Israelite_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Albert_Lasker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"albert-lasker","kind":"person","name":"Albert Lasker","route":"/people/albert-lasker/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alberto_Bardelli","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alcohol_and_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","field":"wikipedia"},{"id":"alcohol-attributable-cancer","kind":"term","name":"Alcohol-attributable cancer","route":"/terms/alcohol-attributable-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aldesleukin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aldoxorubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alectinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260727003105/https://en.wikipedia.org/wiki/Alectinib"},{"url":"https://en.wikipedia.org/wiki/Alemtuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alex%27s_Lemonade_Stand_Foundation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","field":"links","label":"Wikipedia"},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","field":"wikipedia"},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alexandria_Real_Estate_Equities","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","field":"links","label":"Wikipedia (Alexandria Real Estate Equities)"}]},{"url":"https://en.wikipedia.org/wiki/Alfred_P._Sloan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","route":"/people/alfred-sloan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ali_T._Taher","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alitretinoin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","field":"links","label":"Wikipedia"},{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alkaline_diet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"unproven-diet-claims","kind":"term","name":"Unproven diet claims (alkaline, juice, 'anti-cancer' diets)","route":"/terms/unproven-diet-claims/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alkylating_antineoplastic_agent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/","field":"links","label":"Wikipedia"},{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/All_India_Institute_of_Medical_Sciences,_Delhi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Allele_frequency","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alliance_for_Clinical_Trials_in_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Almirall","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","field":"links","label":"Wikipedia"},{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Almonertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alpelisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alpha-fetoprotein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"afp","kind":"term","name":"Alpha-fetoprotein (AFP)","route":"/terms/afp/","field":"links","label":"Wikipedia"},{"id":"afp","kind":"term","name":"Alpha-fetoprotein (AFP)","route":"/terms/afp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alternative_cancer_treatments","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alternative-medicine-instead-of-treatment","kind":"technology","name":"Alternative medicine used instead of standard treatment","route":"/technologies/alternative-medicine-instead-of-treatment/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Altretamine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","field":"links","label":"Wikipedia"},{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Alveolar_soft_part_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/","field":"links","label":"Wikipedia"},{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/American_ginseng","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/American_Society_of_Hematology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amgen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amifostine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aminoglutethimide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","field":"links","label":"Wikipedia"},{"id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aminolevulinic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","field":"wikipedia"},{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aminopterin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aminopterin","kind":"drug","name":"Aminopterin","route":"/drugs/aminopterin/","field":"links","label":"Wikipedia"},{"id":"aminopterin","kind":"drug","name":"Aminopterin","route":"/drugs/aminopterin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amivantamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amneal_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","route":"/companies/amneal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/AMNOG","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"links","label":"Wikipedia"},{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ampullary_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amrubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amsacrine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","field":"links","label":"Wikipedia"},{"id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Amygdalin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laetrile-amygdalin","kind":"technology","name":"Laetrile (amygdalin, 'vitamin B17')","route":"/technologies/laetrile-amygdalin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anadolu_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","route":"/institutions/anadolu-medical-center/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anagrelide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"wikipedia"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"links","label":"Wikipedia"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"wikipedia"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"links","label":"Wikipedia"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"wikipedia"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"links","label":"Wikipedia"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"links","label":"Wikipedia"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"wikipedia"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"prevalence.source"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"links","label":"Wikipedia"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anaplastic_thyroid_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/","field":"links","label":"Wikipedia"},{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anastrozole","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/","field":"links","label":"Wikipedia"},{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Andreessen_Horowitz","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Androgen_deprivation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","field":"links","label":"Wikipedia"},{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","field":"wikipedia"},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","field":"links","label":"Wikipedia"},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Androgen_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","field":"wikipedia"},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","field":"wikipedia"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","field":"wikipedia"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"links","label":"Wikipedia"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"wikipedia"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"prevalence.source"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"prevalence.source"},{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/","field":"links","label":"Wikipedia"},{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Androgen_receptor#Splice_variants","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Androgen_receptor","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","field":"links","label":"Wikipedia"},{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902160421/https://en.wikipedia.org/wiki/Androgen_receptor"},{"url":"https://en.wikipedia.org/wiki/Anemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"links","label":"Wikipedia"},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anetumab_ravtansine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Angelina_Jolie","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","field":"links","label":"Wikipedia"},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","field":"wikipedia"},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Angiogenesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/","field":"links","label":"Wikipedia"},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/","field":"wikipedia"},{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/","field":"links","label":"Wikipedia"},{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/","field":"wikipedia"},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Angiogenesis_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/","field":"links","label":"Wikipedia"},{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Angioimmunoblastic_T-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Angiosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"wikipedia"},{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","field":"links","label":"Wikipedia"},{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anlotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ann_Arbor_staging","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/","field":"links","label":"Wikipedia"},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ann_Lurie","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ann-lurie","kind":"person","name":"Ann Lurie","route":"/people/ann-lurie/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ann_Partridge","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anomaly_detection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ood-detection","kind":"term","name":"Out-of-distribution detection (Mahalanobis guard)","route":"/terms/ood-detection/","field":"links","label":"Wikipedia"},{"id":"ood-detection","kind":"term","name":"Out-of-distribution detection (Mahalanobis guard)","route":"/terms/ood-detection/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anthony_Lawler","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","route":"/people/anthony-lawler/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anthony_Letai","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Anthracycline","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthracycline","kind":"term","name":"Anthracyclines (doxorubicin, epirubicin)","route":"/terms/anthracycline/","field":"links","label":"Wikipedia"},{"id":"anthracycline","kind":"term","name":"Anthracyclines (doxorubicin, epirubicin)","route":"/terms/anthracycline/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antiandrogen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","field":"links","label":"Wikipedia"},{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antibody","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/","field":"links","label":"Wikipedia"},{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/","field":"links","label":"Wikipedia"},{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antibody-drug_conjugate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/","field":"links","label":"Wikipedia"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/","field":"wikipedia"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","field":"links","label":"Wikipedia"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","field":"wikipedia"},{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/","field":"links","label":"Wikipedia"},{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/","field":"wikipedia"},{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","field":"links","label":"Wikipedia"},{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","field":"wikipedia"},{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","field":"wikipedia"},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","field":"links","label":"Wikipedia"},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","field":"wikipedia"},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","field":"links","label":"Wikipedia"},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antineoplaston","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antineoplastons","kind":"technology","name":"Antineoplastons (Burzynski clinic)","route":"/technologies/antineoplastons/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antisense_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","field":"links","label":"Wikipedia"},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Antoni_Ribas_(professor)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Apache_License","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"open-licences","kind":"term","name":"Open licences: Apache-2.0, MIT and CC BY 4.0","route":"/terms/open-licences/","field":"links","label":"Wikipedia"},{"id":"open-licences","kind":"term","name":"Open licences: Apache-2.0, MIT and CC BY 4.0","route":"/terms/open-licences/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Apache_Parquet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","field":"links","label":"Wikipedia: Apache Parquet"}]},{"url":"https://en.wikipedia.org/wiki/Apalutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260729000651/https://en.wikipedia.org/wiki/Apalutamide"},{"url":"https://en.wikipedia.org/wiki/Apatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Apheresis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/","field":"links","label":"Wikipedia"},{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Apoptosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apoptosis","kind":"term","name":"Apoptosis","route":"/terms/apoptosis/","field":"links","label":"Wikipedia"},{"id":"apoptosis","kind":"term","name":"Apoptosis","route":"/terms/apoptosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Appendix_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aprepitant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aquagenic_pruritus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aquagenic-pruritus","kind":"term","name":"Aquagenic pruritus","route":"/terms/aquagenic-pruritus/","field":"links","label":"Wikipedia"},{"id":"aquagenic-pruritus","kind":"term","name":"Aquagenic pruritus","route":"/terms/aquagenic-pruritus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Arc_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ARCH_Venture_Partners","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Argenx","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","field":"links","label":"Wikipedia"},{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Armando_E._Giuliano","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aromatase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aromatase","kind":"target","name":"Aromatase (CYP19A1)","route":"/targets/aromatase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aromatase_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/","field":"links","label":"Wikipedia"},{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aromatherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aromatherapy-cancer","kind":"technology","name":"Aromatherapy","route":"/technologies/aromatherapy-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Arsenic_trioxide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Artificial_intelligence_in_healthcare","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/","field":"links","label":"Wikipedia"},{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Asan_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Asbestos","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asbestos","kind":"term","name":"Asbestos","route":"/terms/asbestos/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Asciminib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ash_Alizadeh","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ashya_King_case","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","field":"links","label":"Wikipedia"},{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","field":"wikipedia"},{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Asparaginase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aspirin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Aspirin#Cancer_prevention","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Aspirin","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/","field":"links","label":"Wikipedia"},{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Astatine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","field":"links","label":"Wikipedia"},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Astellas_Pharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/AstraZeneca","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Astrocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"links","label":"Wikipedia"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Atavism","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ataxia_telangiectasia_and_Rad3_related","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atr-chk1-inhibitors","kind":"technology","name":"ATR and CHK1 inhibitors","route":"/technologies/atr-chk1-inhibitors/","field":"links","label":"Wikipedia"},{"id":"atr-chk1-inhibitors","kind":"technology","name":"ATR and CHK1 inhibitors","route":"/technologies/atr-chk1-inhibitors/","field":"wikipedia"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","field":"links","label":"Wikipedia"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","field":"wikipedia"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Atezolizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Atlas_Venture","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Attention_(machine_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transformer-architecture","kind":"term","name":"Transformer and attention","route":"/terms/transformer-architecture/","field":"links","label":"Wikipedia: attention (machine learning)"}]},{"url":"https://en.wikipedia.org/wiki/Atypical_teratoid_rhabdoid_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Audre_Lorde","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","field":"links","label":"Wikipedia"},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","field":"wikipedia"},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Autoencoder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"masked-modelling","kind":"term","name":"Masked autoencoders and masked gene modelling","route":"/terms/masked-modelling/","field":"links","label":"Wikipedia"},{"id":"masked-modelling","kind":"term","name":"Masked autoencoders and masked gene modelling","route":"/terms/masked-modelling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Autophagy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"autophagy","kind":"pathway","name":"Autophagy","route":"/pathways/autophagy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Autoregressive_model","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"autoregressive-modelling","kind":"term","name":"Autoregressive (next-token) modelling","route":"/terms/autoregressive-modelling/","field":"links","label":"Wikipedia"},{"id":"autoregressive-modelling","kind":"term","name":"Autoregressive (next-token) modelling","route":"/terms/autoregressive-modelling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Avapritinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","field":"wikipedia"},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","field":"links","label":"Wikipedia"},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Avelumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Avram_Hershko","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Axitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/AXL_receptor_tyrosine_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ayurveda","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ayurvedic-medicine-cancer","kind":"technology","name":"Ayurvedic medicine and cancer","route":"/technologies/ayurvedic-medicine-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Azacitidine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","field":"wikipedia"},{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/","field":"links","label":"Wikipedia"},{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/B_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/","field":"links","label":"Wikipedia"},{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/B-cell_maturation_antigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","field":"links","label":"Wikipedia"},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","field":"wikipedia"},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/B-cell_prolymphocytic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/B-cell_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/","field":"links","label":"Wikipedia"},{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/B._Braun","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BAP1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bap1-loss","kind":"term","name":"BAP1 loss","route":"/terms/bap1-loss/","field":"links","label":"Wikipedia"},{"id":"bap1-loss","kind":"term","name":"BAP1 loss","route":"/terms/bap1-loss/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Barbara_Ann_Karmanos_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","field":"links","label":"Source: Wikipedia article on the institute (names President and CEO)"},{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","field":"profiles","label":"Wikipedia: Barbara Ann Karmanos Cancer Institute"}]},{"url":"https://en.wikipedia.org/wiki/Barbara_Burtness","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bariatric_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Barrett%27s_esophagus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/","field":"links","label":"Wikipedia"},{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bartholin_gland_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bartholin-gland-carcinoma","kind":"cancer","name":"Bartholin gland carcinoma","route":"/cancers/bartholin-gland-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Basal-cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"wikipedia"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"wikipedia"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"links","label":"Wikipedia"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Basal-like_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Base_excision_repair","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Basement_membrane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"basement-membrane-tissue-barriers","kind":"pathway","name":"Basement membrane & tissue barriers","route":"/pathways/basement-membrane-tissue-barriers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Basilea_Pharmaceutica","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","field":"links","label":"Wikipedia"},{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Basket_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/","field":"links","label":"Wikipedia"},{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/","field":"wikipedia"},{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/","field":"links","label":"Wikipedia"},{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/","field":"wikipedia"},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/","field":"links","label":"Wikipedia: basket trial"},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Batch_effect","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"batch-effects","kind":"term","name":"Batch effects and harmonisation","route":"/terms/batch-effects/","field":"links","label":"Wikipedia"},{"id":"batch-effects","kind":"term","name":"Batch effects and harmonisation","route":"/terms/batch-effects/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bausch_Health","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bausch-health","kind":"company","name":"Bausch Health","route":"/companies/bausch-health/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bavarian_Nordic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","field":"links","label":"Wikipedia"},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Baxter_International","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bayer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bayesian_statistics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","field":"links","label":"Wikipedia"},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BCG_vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","field":"links","label":"Wikipedia"},{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","field":"wikipedia"},{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BCG_vaccine#Cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/BCG_vaccine","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","field":"links","label":"Wikipedia"},{"id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bcl-2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","field":"links","label":"Wikipedia"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","field":"wikipedia"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","field":"prevalence.source"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","field":"prevalence.source"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Bcl-2_family","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/","field":"links","label":"Wikipedia"},{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/","field":"wikipedia"},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/","field":"links","label":"Wikipedia"},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Belantamab_mafodotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Belinostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Belotecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","field":"links","label":"Wikipedia"},{"id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Belumosudil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Belzutifan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bempegaldesleukin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Benchmark_(computing)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leaderboard-benchmark","kind":"term","name":"Benchmarks, leaderboards and contamination","route":"/terms/leaderboard-benchmark/","field":"links","label":"Wikipedia"},{"id":"leaderboard-benchmark","kind":"term","name":"Benchmarks, leaderboards and contamination","route":"/terms/leaderboard-benchmark/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bendamustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","field":"wikipedia"},{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"links","label":"Wikipedia: bendamustine"}]},{"url":"https://en.wikipedia.org/wiki/Benign_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"benign-vs-malignant","kind":"term","name":"Benign versus malignant","route":"/terms/benign-vs-malignant/","field":"links","label":"Wikipedia"},{"id":"benign-vs-malignant","kind":"term","name":"Benign versus malignant","route":"/terms/benign-vs-malignant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Benjamin_L._Ebert","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bernard_Fisher_(scientist)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","field":"links","label":"Wikipedia"},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","field":"wikipedia"},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bert_Vogelstein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Best_Pharmaceuticals_for_Children_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","field":"links","label":"Wikipedia"},{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BET_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bethesda_System_for_Reporting_Thyroid_Cytopathology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Betty_Ford","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","field":"links","label":"Wikipedia"},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","field":"wikipedia"},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bevacizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","field":"wikipedia"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260813101312/https://en.wikipedia.org/wiki/Bevacizumab"},{"url":"https://en.wikipedia.org/wiki/Bevacizumab#Adverse_effects","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Bevacizumab","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antiangiogenic-toxicities","kind":"term","name":"Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)","route":"/terms/antiangiogenic-toxicities/","field":"links","label":"Wikipedia"},{"id":"antiangiogenic-toxicities","kind":"term","name":"Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)","route":"/terms/antiangiogenic-toxicities/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bexarotene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/","field":"links","label":"Wikipedia"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bicalutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biliary_stent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"links","label":"Wikipedia"},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biliary_tract_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","field":"links","label":"Wikipedia"},{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bill_Gates","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bimatoprost","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bimatoprost-eyelash-regrowth","kind":"technology","name":"Bimatoprost for eyelash and eyebrow regrowth","route":"/technologies/bimatoprost-eyelash-regrowth/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Binimetinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biochemical_recurrence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","field":"links","label":"Wikipedia"},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","field":"wikipedia"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"links","label":"Wikipedia"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260207092109/https://en.wikipedia.org/wiki/Biochemical_recurrence"},{"url":"https://en.wikipedia.org/wiki/Biocon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bioconjugation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","field":"links","label":"Wikipedia"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bioelectricity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biogen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bioinvent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BioLineRx","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","field":"links","label":"Wikipedia"},{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biological_half-life","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","field":"links","label":"Wikipedia"},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biologics_Price_Competition_and_Innovation_Act_of_2009","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","field":"links","label":"Wikipedia"},{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biomarker_(medicine)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/","field":"links","label":"Wikipedia"},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/","field":"wikipedia"},{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/","field":"links","label":"Wikipedia"},{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BioNTech","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biopsy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/","field":"links","label":"Wikipedia"},{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biosecure_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","field":"links","label":"Wikipedia"},{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Biosimilar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","field":"wikipedia"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/","field":"links","label":"Wikipedia"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/","field":"wikipedia"},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bispecific_monoclonal_antibody","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/","field":"links","label":"Wikipedia"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/","field":"wikipedia"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/","field":"links","label":"Wikipedia"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bispecific_T-cell_engager","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/","field":"links","label":"Wikipedia"},{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bisphosphonate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Black_salve","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"black-salve-escharotics","kind":"technology","name":"Black salve and other escharotic pastes","route":"/technologies/black-salve-escharotics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bladder_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"wikipedia"},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","field":"wikipedia"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","field":"links","label":"Wikipedia"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","field":"wikipedia"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","field":"links","label":"Wikipedia"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260829104401/https://en.wikipedia.org/wiki/Bladder_cancer"},{"url":"https://en.wikipedia.org/wiki/Blast_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blasts","kind":"term","name":"Blasts (leukaemic blast cells)","route":"/terms/blasts/","field":"links","label":"Wikipedia"},{"id":"blasts","kind":"term","name":"Blasts (leukaemic blast cells)","route":"/terms/blasts/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blastic_plasmacytoid_dendritic_cell_neoplasm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bleomycin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blinatumomab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blinded_experiment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","field":"links","label":"Wikipedia"},{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","field":"wikipedia"},{"id":"blinding","kind":"term","name":"Blinded trial","route":"/terms/blinding/","field":"links","label":"Wikipedia"},{"id":"blinding","kind":"term","name":"Blinded trial","route":"/terms/blinding/","field":"wikipedia"},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/","field":"links","label":"Wikipedia"},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blood_(journal)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blood_transfusion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Blood–brain_barrier","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/","field":"links","label":"Wikipedia"},{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/","field":"wikipedia"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260911113838/https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier"},{"url":"https://en.wikipedia.org/wiki/Blood%E2%80%93brain_barrier","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cns-penetration","kind":"term","name":"CNS penetration (brain-penetrant drugs)","route":"/terms/cns-penetration/","field":"links","label":"Wikipedia"},{"id":"cns-penetration","kind":"term","name":"CNS penetration (brain-penetrant drugs)","route":"/terms/cns-penetration/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bloodletting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phlebotomy","kind":"term","name":"Phlebotomy (venesection)","route":"/terms/phlebotomy/","field":"links","label":"Wikipedia"},{"id":"phlebotomy","kind":"term","name":"Phlebotomy (venesection)","route":"/terms/phlebotomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Body_composition","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/","field":"links","label":"Wikipedia"},{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Body_surface_area","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"body-surface-area-dosing","kind":"technology","name":"Body-surface-area dosing","route":"/technologies/body-surface-area-dosing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Boehringer_Ingelheim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bone_marrow","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","field":"links","label":"Wikipedia"},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bone_metastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"Wikipedia"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bootstrapping_(statistics)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bootstrap","kind":"term","name":"Bootstrap resampling","route":"/terms/bootstrap/","field":"links","label":"Wikipedia"},{"id":"bootstrap","kind":"term","name":"Bootstrap resampling","route":"/terms/bootstrap/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bortezomib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Boston_Scientific","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bosutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bowel_obstruction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bowen%27s_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brachytherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","field":"links","label":"Wikipedia"},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","field":"wikipedia"},{"id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","field":"links","label":"Wikipedia"},{"id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","field":"wikipedia"},{"id":"hdr-brachytherapy","kind":"technology","name":"High-dose-rate brachytherapy","route":"/technologies/hdr-brachytherapy/","field":"links","label":"Wikipedia"},{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/","field":"links","label":"Wikipedia"},{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brachytherapy#Prostate_cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Brachytherapy","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ldr-seed-brachytherapy","kind":"technology","name":"Low-dose-rate seed brachytherapy","route":"/technologies/ldr-seed-brachytherapy/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bradley_J._Monk","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BRAF_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"links","label":"Wikipedia"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"wikipedia"},{"id":"braf-v600-mutation","kind":"term","name":"BRAF V600E mutation","route":"/terms/braf-v600-mutation/","field":"links","label":"Wikipedia"},{"id":"braf-v600-mutation","kind":"term","name":"BRAF V600E mutation","route":"/terms/braf-v600-mutation/","field":"wikipedia"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"links","label":"Wikipedia"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"wikipedia"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"links","label":"Wikipedia"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"wikipedia"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"links","label":"Wikipedia"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bragg_peak","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bragg-peak","kind":"term","name":"Bragg peak","route":"/terms/bragg-peak/","field":"links","label":"Wikipedia"},{"id":"bragg-peak","kind":"term","name":"Bragg peak","route":"/terms/bragg-peak/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brain_metastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","field":"wikipedia"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"links","label":"Wikipedia"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"wikipedia"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"links","label":"Wikipedia"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"wikipedia"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brain_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260909225146/https://en.wikipedia.org/wiki/Brain_tumor"},{"url":"https://en.wikipedia.org/wiki/Brainlab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/BRCA_mutation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"wikipedia"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"wikipedia"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"links","label":"Wikipedia"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"wikipedia"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","field":"links","label":"Wikipedia"},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","field":"wikipedia"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"links","label":"Wikipedia"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Breakthrough_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","field":"links","label":"Wikipedia"},{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Breast_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"Wikipedia"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"wikipedia"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Wikipedia"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"wikipedia"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","field":"links","label":"Wikipedia"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","field":"wikipedia"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260903013003/https://en.wikipedia.org/wiki/Breast_cancer"},{"url":"https://en.wikipedia.org/wiki/Breast_cancer_classification","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","field":"wikipedia"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"wikipedia"},{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/","field":"wikipedia"},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","field":"wikipedia"},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","field":"wikipedia"},{"id":"papillary-carcinoma-breast","kind":"cancer","name":"Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)","route":"/cancers/papillary-carcinoma-breast/","field":"wikipedia"},{"id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","field":"wikipedia"},{"id":"invasive-micropapillary-carcinoma-breast","kind":"cancer","name":"Invasive micropapillary carcinoma of the breast","route":"/cancers/invasive-micropapillary-carcinoma-breast/","field":"wikipedia"},{"id":"neuroendocrine-neoplasms-breast","kind":"cancer","name":"Neuroendocrine neoplasms of the breast","route":"/cancers/neuroendocrine-neoplasms-breast/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Breast_cancer_screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brentuximab_vedotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"wikipedia"},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Breslow%27s_depth","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breslow-thickness","kind":"term","name":"Breslow thickness","route":"/terms/breslow-thickness/","field":"links","label":"Wikipedia"},{"id":"breslow-thickness","kind":"term","name":"Breslow thickness","route":"/terms/breslow-thickness/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brexucabtagene_autoleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brian_Druker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","field":"links","label":"Wikipedia"},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","field":"wikipedia"},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brier_score","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"calibration","kind":"term","name":"Calibration: reliability diagrams and the Brier score","route":"/terms/calibration/","field":"links","label":"Wikipedia: Brier score"}]},{"url":"https://en.wikipedia.org/wiki/Brigatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Brigitte_C._Widemann","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bristol_Myers_Squibb","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Broad_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bromocriptine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bromocriptine","kind":"drug","name":"Bromocriptine","route":"/drugs/bromocriptine/","field":"links","label":"Wikipedia"},{"id":"bromocriptine","kind":"drug","name":"Bromocriptine","route":"/drugs/bromocriptine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bronchoscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robotic-bronchoscopy","kind":"technology","name":"Robotic and navigational bronchoscopy","route":"/technologies/robotic-bronchoscopy/","field":"links","label":"Wikipedia"},{"id":"robotic-bronchoscopy","kind":"technology","name":"Robotic and navigational bronchoscopy","route":"/technologies/robotic-bronchoscopy/","field":"wikipedia"},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"links","label":"Wikipedia"},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907011619/https://en.wikipedia.org/wiki/Bronchoscopy"},{"url":"https://en.wikipedia.org/wiki/Bruce_Power","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bruce-power","kind":"company","name":"Bruce Power","route":"/companies/bruce-power/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/","field":"links","label":"Wikipedia"},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Burkitt_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"wikipedia"},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Buserelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/","field":"links","label":"Wikipedia"},{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Busulfan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Byte-pair_encoding","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tokenisation","kind":"term","name":"Tokenisation (genes, tiles and sequence as tokens)","route":"/terms/tokenisation/","field":"links","label":"Wikipedia: byte-pair encoding"}]},{"url":"https://en.wikipedia.org/wiki/C-Met","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","field":"wikipedia"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"links","label":"Wikipedia"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"wikipedia"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"links","label":"Wikipedia"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260112080723/https://en.wikipedia.org/wiki/C-Met"},{"url":"https://en.wikipedia.org/wiki/C-Raf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CA-125","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/","field":"links","label":"Wikipedia"},{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/","field":"wikipedia"},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CA19-9","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","field":"links","label":"Wikipedia"},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","field":"wikipedia"},{"id":"lewis-negative","kind":"term","name":"Lewis-negative (Lewis antigen-negative, CA 19-9 non-secretor) status","route":"/terms/lewis-negative/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cabazitaxel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cabergoline","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cabergoline","kind":"drug","name":"Cabergoline","route":"/drugs/cabergoline/","field":"links","label":"Wikipedia"},{"id":"cabergoline","kind":"drug","name":"Cabergoline","route":"/drugs/cabergoline/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cabozantinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cachexia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-gdf15-plus-exercise","kind":"idea","name":"Combine the new anti-wasting antibody with exercise and protein","route":"/ideas/idea-bio2-gdf15-plus-exercise/","field":"links","label":"Cachexia (overview)"},{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","field":"wikipedia"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"wikipedia"},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","field":"wikipedia"},{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","field":"wikipedia"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Calibration_(statistics)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"calibration","kind":"term","name":"Calibration: reliability diagrams and the Brier score","route":"/terms/calibration/","field":"links","label":"Wikipedia"},{"id":"calibration","kind":"term","name":"Calibration: reliability diagrams and the Brier score","route":"/terms/calibration/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Calicheamicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"calicheamicin","kind":"term","name":"Calicheamicin","route":"/terms/calicheamicin/","field":"links","label":"Wikipedia"},{"id":"calicheamicin","kind":"term","name":"Calicheamicin","route":"/terms/calicheamicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Camptothecin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","field":"links","label":"Wikipedia"},{"id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Camrelizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Camurus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"camurus","kind":"company","name":"Camurus","route":"/companies/camurus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Canadian_Cancer_Society","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_Drugs_Fund","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","field":"links","label":"Wikipedia"},{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_epigenetics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","field":"wikipedia"},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_genome_sequencing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/","field":"links","label":"Wikipedia"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/","field":"wikipedia"},{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/","field":"links","label":"Wikipedia"},{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_immunoediting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_immunology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","field":"links","label":"Wikipedia"},{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","field":"wikipedia"},{"id":"immunotherapy-response","kind":"term","name":"Immunotherapy response and its prediction","route":"/terms/immunotherapy-response/","field":"links","label":"Wikipedia"},{"id":"immunotherapy-response","kind":"term","name":"Immunotherapy response and its prediction","route":"/terms/immunotherapy-response/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"wikipedia"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"links","label":"Wikipedia"},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","field":"wikipedia"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"links","label":"Wikipedia"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","field":"wikipedia"},{"id":"organ-of-origin-signal","kind":"term","name":"Tissue-of-origin signal in tumour data","route":"/terms/organ-of-origin-signal/","field":"links","label":"Wikipedia"},{"id":"organ-of-origin-signal","kind":"term","name":"Tissue-of-origin signal in tumour data","route":"/terms/organ-of-origin-signal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_pain","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_Prevention_and_Research_Institute_of_Texas","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wayne-roberts","kind":"person","name":"Wayne Roberts","route":"/people/wayne-roberts/","field":"links","label":"Source: Wikipedia article on CPRIT (infobox names the CEO)"},{"id":"wayne-roberts","kind":"person","name":"Wayne Roberts","route":"/people/wayne-roberts/","field":"profiles","label":"Wikipedia: Cancer Prevention and Research Institute of Texas"},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_registry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","field":"wikipedia"},{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"wikipedia"},{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/","field":"links","label":"Wikipedia"},{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_screening#Early_detection","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Cancer_screening","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"early-detection-term","kind":"term","name":"Early detection","route":"/terms/early-detection-term/","field":"links","label":"Wikipedia"},{"id":"early-detection-term","kind":"term","name":"Early detection","route":"/terms/early-detection-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_staging","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","field":"links","label":"Wikipedia"},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","field":"wikipedia"},{"id":"cancer-stage","kind":"term","name":"Stage","route":"/terms/cancer-stage/","field":"links","label":"Wikipedia"},{"id":"cancer-stage","kind":"term","name":"Stage","route":"/terms/cancer-stage/","field":"wikipedia"},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","field":"links","label":"Wikipedia"},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","field":"wikipedia"},{"id":"locally-advanced","kind":"term","name":"Locally advanced and locoregional disease","route":"/terms/locally-advanced/","field":"links","label":"Wikipedia"},{"id":"locally-advanced","kind":"term","name":"Locally advanced and locoregional disease","route":"/terms/locally-advanced/","field":"wikipedia"},{"id":"grade-vs-stage","kind":"term","name":"Grade versus stage","route":"/terms/grade-vs-stage/","field":"links","label":"Wikipedia: cancer staging"},{"id":"ajcc-stage","kind":"term","name":"AJCC stage (TNM staging manual)","route":"/terms/ajcc-stage/","field":"links","label":"Wikipedia: cancer staging"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_stem_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","field":"wikipedia"},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_survivor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer_vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/","field":"links","label":"Wikipedia"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/","field":"wikipedia"},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/","field":"links","label":"Wikipedia"},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/","field":"wikipedia"},{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/","field":"links","label":"Wikipedia"},{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer-associated_fibroblast","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/","field":"links","label":"Wikipedia"},{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/","field":"wikipedia"},{"id":"caf-activation-desmoplasia","kind":"pathway","name":"Fibroblast activation, desmoplasia & matrix stiffness","route":"/pathways/caf-activation-desmoplasia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer-related_fatigue","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cancer#Invasion_and_metastasis","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invasive-cancer","kind":"term","name":"Invasive","route":"/terms/invasive-cancer/","field":"links","label":"Wikipedia"},{"id":"invasive-cancer","kind":"term","name":"Invasive","route":"/terms/invasive-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cannabinoid_receptor_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Canon_Medical_Systems_Corporation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Capecitabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Capivasertib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Capmatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","field":"wikipedia"},{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251009035731/https://en.wikipedia.org/wiki/Capmatinib"},{"url":"https://en.wikipedia.org/wiki/Capsule_endoscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capsule-endoscopy-systems","kind":"technology","name":"Capsule endoscopy (PillCam, EndoCapsule, CapsoCam)","route":"/technologies/capsule-endoscopy-systems/","field":"links","label":"Wikipedia: capsule endoscopy"},{"id":"capsule-endoscopy-systems","kind":"technology","name":"Capsule endoscopy (PillCam, EndoCapsule, CapsoCam)","route":"/technologies/capsule-endoscopy-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carboplatin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"links","label":"Wikipedia"},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"wikipedia"},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"prevalence.source"},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"prevalence.source"},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Carcinogenesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","field":"links","label":"Wikipedia: Carcinogenesis"},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","field":"wikipedia"},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinogenesis#Driver_and_passenger_mutations","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Carcinogenesis","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/","field":"links","label":"Wikipedia"},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/","field":"wikipedia"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinoid_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/","field":"links","label":"Wikipedia"},{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/","field":"links","label":"Wikipedia"},{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinoma_ex_pleomorphic_adenoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carcinoma-ex-pleomorphic-adenoma","kind":"cancer","name":"Carcinoma ex pleomorphic adenoma","route":"/cancers/carcinoma-ex-pleomorphic-adenoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carcinoma_in_situ","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"wikipedia"},{"id":"in-situ","kind":"term","name":"In situ","route":"/terms/in-situ/","field":"links","label":"Wikipedia"},{"id":"in-situ","kind":"term","name":"In situ","route":"/terms/in-situ/","field":"wikipedia"},{"id":"carcinoma-in-situ","kind":"term","name":"Carcinoma in situ (CIS)","route":"/terms/carcinoma-in-situ/","field":"links","label":"Wikipedia"},{"id":"carcinoma-in-situ","kind":"term","name":"Carcinoma in situ (CIS)","route":"/terms/carcinoma-in-situ/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cardiotoxicity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/","field":"links","label":"Wikipedia"},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carfilzomib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carl_H._June","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carl_Zeiss_Meditec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","route":"/companies/carl-zeiss-meditec/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carlos_Caldas","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Carmustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Case_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","field":"links","label":"Wikipedia"},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","field":"wikipedia"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"links","label":"Wikipedia"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"wikipedia"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"links","label":"Wikipedia"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260501200928/https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/Catumaxomab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CCR4_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD117","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","field":"links","label":"Wikipedia"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","field":"wikipedia"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD135","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","field":"wikipedia"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","field":"links","label":"Wikipedia"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","field":"wikipedia"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"links","label":"Wikipedia: FLT3"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD19","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","field":"links","label":"Wikipedia"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","field":"wikipedia"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","field":"prevalence.source"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","field":"prevalence.source"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD20","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"links","label":"Wikipedia"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"wikipedia"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"prevalence.source"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD22","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/","field":"links","label":"Wikipedia"},{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD276","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"links","label":"Wikipedia"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"wikipedia"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"prevalence.source"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD3_(immunology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","field":"links","label":"Wikipedia"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD30","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","field":"links","label":"Wikipedia"},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD33","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","field":"links","label":"Wikipedia"},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","field":"wikipedia"},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD38","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","field":"links","label":"Wikipedia"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","field":"wikipedia"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","field":"prevalence.source"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD40_(protein)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd40-agonists","kind":"technology","name":"CD40 agonist antibodies","route":"/technologies/cd40-agonists/","field":"links","label":"Wikipedia"},{"id":"cd40-agonists","kind":"technology","name":"CD40 agonist antibodies","route":"/technologies/cd40-agonists/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD47","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/","field":"links","label":"Wikipedia"},{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/","field":"wikipedia"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","field":"links","label":"Wikipedia"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","field":"wikipedia"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","field":"prevalence.source"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","field":"prevalence.source"},{"id":"cd47-sirpa","kind":"pathway","name":"CD47 / SIRPα (the 'don't eat me' signal)","route":"/pathways/cd47-sirpa/","field":"links","label":"Wikipedia"},{"id":"cd47-sirpa","kind":"pathway","name":"CD47 / SIRPα (the 'don't eat me' signal)","route":"/pathways/cd47-sirpa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD52","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD7","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CD70","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","field":"links","label":"Wikipedia"},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","field":"wikipedia"},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","field":"prevalence.source"},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CD79B","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CDH6","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","field":"links","label":"Wikipedia"},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","field":"wikipedia"},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","field":"prevalence.source"},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CDK_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","field":"links","label":"Wikipedia"},{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CDKN2A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdkn2a-homozygous-deletion","kind":"term","name":"CDKN2A/B homozygous deletion","route":"/terms/cdkn2a-homozygous-deletion/","field":"links","label":"Wikipedia"},{"id":"cdkn2a-homozygous-deletion","kind":"term","name":"CDKN2A/B homozygous deletion","route":"/terms/cdkn2a-homozygous-deletion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cediranib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/","field":"links","label":"Wikipedia"},{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Celecoxib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/","field":"links","label":"Wikipedia"},{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_(biology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","field":"links","label":"Wikipedia"},{"id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_(journal)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_cycle","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-cycle","kind":"term","name":"Cell cycle","route":"/terms/cell-cycle/","field":"links","label":"Wikipedia"},{"id":"cell-cycle","kind":"term","name":"Cell cycle","route":"/terms/cell-cycle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_cycle_checkpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/","field":"links","label":"Wikipedia"},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_division","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-division","kind":"term","name":"Cell division","route":"/terms/cell-division/","field":"links","label":"Wikipedia"},{"id":"cell-division","kind":"term","name":"Cell division","route":"/terms/cell-division/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_membrane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-membrane","kind":"term","name":"Cell membrane","route":"/terms/cell-membrane/","field":"links","label":"Wikipedia"},{"id":"cell-membrane","kind":"term","name":"Cell membrane","route":"/terms/cell-membrane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_nucleus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleus","kind":"term","name":"Nucleus","route":"/terms/nucleus/","field":"links","label":"Wikipedia"},{"id":"nucleus","kind":"term","name":"Nucleus","route":"/terms/nucleus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_Ontology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","field":"links","label":"Wikipedia: Cell Ontology"}]},{"url":"https://en.wikipedia.org/wiki/Cell_proliferation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proliferation","kind":"term","name":"Proliferation","route":"/terms/proliferation/","field":"links","label":"Wikipedia"},{"id":"proliferation","kind":"term","name":"Proliferation","route":"/terms/proliferation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell_signaling","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/","field":"links","label":"Wikipedia"},{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell-free_DNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cell-free_fetal_DNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/","field":"links","label":"Wikipedia"},{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/","field":"wikipedia"},{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/","field":"links","label":"Wikipedia"},{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cellular_differentiation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/","field":"links","label":"Wikipedia"},{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cellular_model","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"links","label":"Wikipedia"},{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cellular_senescence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/","field":"wikipedia"},{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cemiplimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Censoring_(statistics)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"data-maturity","kind":"term","name":"Data maturity (immature vs mature survival data)","route":"/terms/data-maturity/","field":"links","label":"Wikipedia"},{"id":"data-maturity","kind":"term","name":"Data maturity (immature vs mature survival data)","route":"/terms/data-maturity/","field":"wikipedia"},{"id":"censoring-and-events","kind":"term","name":"Censoring and events in survival data","route":"/terms/censoring-and-events/","field":"links","label":"Wikipedia"},{"id":"censoring-and-events","kind":"term","name":"Censoring and events in survival data","route":"/terms/censoring-and-events/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Central_Drugs_Standard_Control_Organisation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"india-new-drugs-rules-2019","kind":"term","name":"India New Drugs and Clinical Trials Rules 2019","route":"/terms/india-new-drugs-rules-2019/","field":"links","label":"Wikipedia"},{"id":"india-new-drugs-rules-2019","kind":"term","name":"India New Drugs and Clinical Trials Rules 2019","route":"/terms/india-new-drugs-rules-2019/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Centre_hospitalier_de_l'Universit%C3%A9_de_Montr%C3%A9al","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cereblon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","field":"links","label":"Wikipedia"},{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","field":"wikipedia"},{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ceritinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cervarix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cervical_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"links","label":"Wikipedia"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"wikipedia"},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/","field":"links","label":"Wikipedia"},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/","field":"wikipedia"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","field":"links","label":"Wikipedia"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","field":"wikipedia"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","field":"links","label":"Wikipedia"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","field":"wikipedia"},{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/","field":"wikipedia"},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260915061055/https://en.wikipedia.org/wiki/Cervical_cancer"},{"url":"https://en.wikipedia.org/wiki/Cervical_intraepithelial_neoplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/","field":"links","label":"Wikipedia"},{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cetuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","field":"wikipedia"},{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chadwick_Boseman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","field":"links","label":"Wikipedia"},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","field":"wikipedia"},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Champions_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Charles_F._Kettering","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","route":"/people/charles-kettering/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Charles_River_Laboratories","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Charles_Sawyers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Charles_Swanton","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Charlotte_Coles","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Checkpoint_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"links","label":"Wikipedia"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemoprophylaxis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","field":"links","label":"Wikipedia"},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemoradiotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/","field":"links","label":"Wikipedia"},{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/","field":"wikipedia"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"links","label":"Wikipedia"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/","field":"links","label":"Wikipedia"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/","field":"wikipedia"},{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","field":"links","label":"Wikipedia"},{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemotherapy_regimen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-regimen","kind":"term","name":"Regimen and cycles","route":"/terms/chemotherapy-regimen/","field":"links","label":"Wikipedia"},{"id":"chemotherapy-regimen","kind":"term","name":"Regimen and cycles","route":"/terms/chemotherapy-regimen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemotherapy-induced_acral_erythema","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Wikipedia"},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemotherapy-induced_nausea_and_vomiting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chemotherapy-induced_peripheral_neuropathy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Wikipedia"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"wikipedia"},{"id":"acupuncture-chemotherapy-neuropathy","kind":"technology","name":"Acupuncture for chemotherapy-induced neuropathy","route":"/technologies/acupuncture-chemotherapy-neuropathy/","field":"wikipedia"},{"id":"frozen-gloves-compression-taxane","kind":"technology","name":"Frozen gloves, socks and compression for taxane nail and nerve damage","route":"/technologies/frozen-gloves-compression-taxane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chidamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Child–Pugh_score","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Child%E2%80%93Pugh_score","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"child-pugh-albi","kind":"term","name":"Child-Pugh and ALBI liver-function scores","route":"/terms/child-pugh-albi/","field":"links","label":"Wikipedia"},{"id":"child-pugh-albi","kind":"term","name":"Child-Pugh and ALBI liver-function scores","route":"/terms/child-pugh-albi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Child%E2%80%93Pugh_score","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"child-pugh","kind":"term","name":"Child-Pugh score","route":"/terms/child-pugh/","field":"links","label":"Wikipedia"},{"id":"child-pugh","kind":"term","name":"Child-Pugh score","route":"/terms/child-pugh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Childhood_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","field":"wikipedia"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260917203013/https://en.wikipedia.org/wiki/Childhood_cancer"},{"url":"https://en.wikipedia.org/wiki/Children's_Hospital_of_Philadelphia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Children's_National_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","route":"/institutions/childrens-national-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Children%27s_Cancer_Hospital_Egypt","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","field":"links","label":"Source: Wikipedia article on Children's Cancer Hospital Egypt"}]},{"url":"https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","field":"links","label":"Wikipedia"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","field":"wikipedia"},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/","field":"links","label":"Wikipedia"},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/","field":"wikipedia"},{"id":"bridging-therapy","kind":"term","name":"Bridging therapy","route":"/terms/bridging-therapy/","field":"links","label":"Wikipedia"},{"id":"bridging-therapy","kind":"term","name":"Bridging therapy","route":"/terms/bridging-therapy/","field":"wikipedia"},{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/","field":"links","label":"Wikipedia"},{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/","field":"wikipedia"},{"id":"antigen-escape","kind":"term","name":"Antigen escape (antigen loss, lineage switch)","route":"/terms/antigen-escape/","field":"links","label":"Wikipedia"},{"id":"antigen-escape","kind":"term","name":"Antigen escape (antigen loss, lineage switch)","route":"/terms/antigen-escape/","field":"wikipedia"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell#Allogeneic_CAR_T_cells","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chlorambucil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chlormethine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cholangiocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","field":"links","label":"Wikipedia"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","field":"wikipedia"},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/","field":"links","label":"Wikipedia"},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/","field":"wikipedia"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","field":"links","label":"Wikipedia"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260913015919/https://en.wikipedia.org/wiki/Cholangiocarcinoma"},{"url":"https://en.wikipedia.org/wiki/Cholecystectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"wikipedia"},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","field":"wikipedia"},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","field":"wikipedia"},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cholesterol_side-chain_cleavage_enzyme","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Choline_C-11","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"links","label":"Wikipedia"},{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chondrosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chondrosarcoma","kind":"cancer","name":"Chondrosarcoma","route":"/cancers/chondrosarcoma/","field":"links","label":"Wikipedia"},{"id":"chondrosarcoma","kind":"cancer","name":"Chondrosarcoma","route":"/cancers/chondrosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chordoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","field":"wikipedia"},{"id":"dedifferentiated-chordoma","kind":"cancer","name":"Dedifferentiated chordoma","route":"/cancers/dedifferentiated-chordoma/","field":"wikipedia"},{"id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Choriocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"links","label":"Wikipedia"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"wikipedia"},{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Choroid_plexus_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chris_Hoy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","route":"/people/chris-hoy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromogranin_A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromogranin-a","kind":"term","name":"Chromogranin A","route":"/terms/chromogranin-a/","field":"links","label":"Wikipedia"},{"id":"chromogranin-a","kind":"term","name":"Chromogranin A","route":"/terms/chromogranin-a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromophobe_renal_cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/","field":"links","label":"Wikipedia"},{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromoplexy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromosome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromosome","kind":"term","name":"Chromosome","route":"/terms/chromosome/","field":"links","label":"Wikipedia"},{"id":"chromosome","kind":"term","name":"Chromosome","route":"/terms/chromosome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromosome_17","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"co-amplification","kind":"term","name":"Co-amplification and the 17q12 HER2 amplicon","route":"/terms/co-amplification/","field":"links","label":"Wikipedia: chromosome 17"}]},{"url":"https://en.wikipedia.org/wiki/Chromosome_5q_deletion_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"del5q","kind":"term","name":"del(5q) (5q- syndrome and lenalidomide response)","route":"/terms/del5q/","field":"links","label":"Wikipedia"},{"id":"del5q","kind":"term","name":"del(5q) (5q- syndrome and lenalidomide response)","route":"/terms/del5q/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chromosome_instability","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","field":"wikipedia"},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"wikipedia"},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/","field":"links","label":"Wikipedia"},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/","field":"wikipedia"},{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","field":"wikipedia"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"links","label":"Wikipedia"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"wikipedia"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"links","label":"Wikipedia"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260831094823/https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia"},{"url":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia#Treatment","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/","field":"links","label":"Wikipedia"},{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"wikipedia"},{"id":"molecular-response","kind":"term","name":"Molecular response (MMR, MR4, treatment-free remission)","route":"/terms/molecular-response/","field":"links","label":"Wikipedia"},{"id":"molecular-response","kind":"term","name":"Molecular response (MMR, MR4, treatment-free remission)","route":"/terms/molecular-response/","field":"wikipedia"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"links","label":"Wikipedia"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"wikipedia"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"links","label":"Wikipedia"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chronic_myelomonocytic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chronotherapy_(treatment_scheduling)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/","field":"wikipedia"},{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chugai","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Chugai_Pharmaceutical_Co.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cicely_Saunders","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"links","label":"Wikipedia"},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"wikipedia"},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ciltacabtagene_autoleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cinacalcet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","field":"links","label":"Wikipedia"},{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cipla","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cipla","kind":"company","name":"Cipla","route":"/companies/cipla/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Circulating_tumor_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/","field":"links","label":"Wikipedia"},{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/","field":"wikipedia"},{"id":"intravasation-ctc-survival","kind":"pathway","name":"Intravasation & circulating tumour cells","route":"/pathways/intravasation-ctc-survival/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Circulating_tumor_DNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/","field":"links","label":"Wikipedia"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cirrhosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cirrhosis","kind":"term","name":"Cirrhosis","route":"/terms/cirrhosis/","field":"links","label":"Wikipedia"},{"id":"cirrhosis","kind":"term","name":"Cirrhosis","route":"/terms/cirrhosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cisplatin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Civica_Rx","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cladribine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cladribine","kind":"drug","name":"Cladribine","route":"/drugs/cladribine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clatterbridge_Cancer_Centre_NHS_Foundation_Trust","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","field":"links","label":"Source: Wikipedia article on the trust"}]},{"url":"https://en.wikipedia.org/wiki/Claudin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"claudin-low","kind":"term","name":"Claudin-low breast cancer","route":"/terms/claudin-low/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CLDN18","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","field":"links","label":"Wikipedia"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","field":"wikipedia"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/CLDN6","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clear-cell_ovarian_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clear-cell_renal_cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/","field":"links","label":"Wikipedia"},{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cleveland_Clinic_Abu_Dhabi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_decision_support_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"local-llm-reasoning-layer","kind":"term","name":"Local-only language models over patient data (privacy by architecture)","route":"/terms/local-llm-reasoning-layer/","field":"links","label":"Wikipedia: clinical decision support system"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_endpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exceptional-responder","kind":"term","name":"Exceptional responder","route":"/terms/exceptional-responder/","field":"wikipedia"},{"id":"endpoint","kind":"term","name":"Endpoint","route":"/terms/endpoint/","field":"links","label":"Wikipedia"},{"id":"endpoint","kind":"term","name":"Endpoint","route":"/terms/endpoint/","field":"wikipedia"},{"id":"primary-endpoint","kind":"term","name":"Primary, secondary and co-primary endpoints","route":"/terms/primary-endpoint/","field":"links","label":"Wikipedia"},{"id":"primary-endpoint","kind":"term","name":"Primary, secondary and co-primary endpoints","route":"/terms/primary-endpoint/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_equipoise","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/","field":"links","label":"Wikipedia"},{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/","field":"links","label":"Wikipedia"},{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/","field":"wikipedia"},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","field":"links","label":"Wikipedia"},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_trial_protocol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","field":"links","label":"Wikipedia"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_trial_registration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"links","label":"Wikipedia"},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clinical_trial#Participants","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Clinical_trial","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/","field":"links","label":"Wikipedia"},{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clofarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Clonal_hematopoiesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","field":"wikipedia"},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Closed_system_drug_transfer_device","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"closed-system-transfer-devices","kind":"technology","name":"Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)","route":"/technologies/closed-system-transfer-devices/","field":"links","label":"Wikipedia: closed system drug transfer device"}]},{"url":"https://en.wikipedia.org/wiki/Clovis_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","field":"links","label":"Wikipedia"},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cluster_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zero-shot","kind":"term","name":"Zero-shot prediction","route":"/terms/zero-shot/","field":"links","label":"Wikipedia: cluster analysis"}]},{"url":"https://en.wikipedia.org/wiki/Cluster_randomised_controlled_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/","field":"links","label":"Wikipedia"},{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CMR_Surgical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","route":"/companies/cmr-surgical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cobalt_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cobalt-60-teletherapy","kind":"technology","name":"Cobalt-60 teletherapy","route":"/technologies/cobalt-60-teletherapy/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cobimetinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cofactor_Genomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cognitive_behavioral_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cognitive_behavioral_therapy_for_insomnia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cbt-insomnia-cancer","kind":"technology","name":"Cognitive behavioural therapy for insomnia (CBT-I)","route":"/technologies/cbt-insomnia-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cold_Spring_Harbor_Laboratory","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"links","label":"Wikipedia"},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colibactin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colibactin","kind":"term","name":"Colibactin","route":"/terms/colibactin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colitis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","field":"links","label":"Wikipedia"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Collecting_duct_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cologuard","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colonoscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colonoscopy-surveillance-intervals","kind":"term","name":"Surveillance intervals after polypectomy","route":"/terms/colonoscopy-surveillance-intervals/","field":"wikipedia"},{"id":"adenoma-detection-rate","kind":"term","name":"Adenoma detection rate","route":"/terms/adenoma-detection-rate/","field":"wikipedia"},{"id":"ai-endoscopy-detection","kind":"technology","name":"AI polyp detection in colonoscopy","route":"/technologies/ai-endoscopy-detection/","field":"links","label":"Wikipedia"},{"id":"ai-endoscopy-detection","kind":"technology","name":"AI polyp detection in colonoscopy","route":"/technologies/ai-endoscopy-detection/","field":"wikipedia"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"Wikipedia"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colony_stimulating_factor_1_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colorectal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"wikipedia"},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","field":"wikipedia"},{"id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","field":"wikipedia"},{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"wikipedia"},{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"wikipedia"},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","field":"wikipedia"},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","field":"wikipedia"},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/","field":"wikipedia"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"links","label":"Wikipedia"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"wikipedia"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"links","label":"Wikipedia"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"wikipedia"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"wikipedia"},{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908072955/https://en.wikipedia.org/wiki/Colorectal_cancer"},{"url":"https://en.wikipedia.org/wiki/Colorectal_cancer_screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"Wikipedia"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"wikipedia"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colorectal_cancer#Rectal_cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Colorectal_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","field":"links","label":"Wikipedia"},{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colorectal_polyp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colposcopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Combination_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"doublet-triplet","kind":"term","name":"Doublet, triplet and quadruplet regimens","route":"/terms/doublet-triplet/","field":"links","label":"Wikipedia"},{"id":"doublet-triplet","kind":"term","name":"Doublet, triplet and quadruplet regimens","route":"/terms/doublet-triplet/","field":"wikipedia"},{"id":"backbone-add-on","kind":"term","name":"Backbone, add-on and monotherapy","route":"/terms/backbone-add-on/","field":"links","label":"Wikipedia"},{"id":"backbone-add-on","kind":"term","name":"Backbone, add-on and monotherapy","route":"/terms/backbone-add-on/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Common_Rule","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","field":"links","label":"Wikipedia"},{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Common_Terminology_Criteria_for_Adverse_Events","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toxicity-grade","kind":"term","name":"Toxicity grade","route":"/terms/toxicity-grade/","field":"links","label":"Wikipedia"},{"id":"toxicity-grade","kind":"term","name":"Toxicity grade","route":"/terms/toxicity-grade/","field":"wikipedia"},{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/","field":"links","label":"Wikipedia"},{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Companion_diagnostic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/","field":"links","label":"Wikipedia"},{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/","field":"wikipedia"},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","field":"links","label":"Wikipedia"},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Complement_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Complication_(medicine)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-morbidity","kind":"term","name":"Surgical morbidity and postoperative complications","route":"/terms/surgical-morbidity/","field":"links","label":"Wikipedia"},{"id":"surgical-morbidity","kind":"term","name":"Surgical morbidity and postoperative complications","route":"/terms/surgical-morbidity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Compugen_(company)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Compulsory_license","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/","field":"links","label":"Wikipedia"},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Confidence_interval","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"confidence-interval","kind":"term","name":"Confidence interval","route":"/terms/confidence-interval/","field":"links","label":"Wikipedia"},{"id":"confidence-interval","kind":"term","name":"Confidence interval","route":"/terms/confidence-interval/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Conformal_prediction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conformal-prediction","kind":"term","name":"Conformal prediction","route":"/terms/conformal-prediction/","field":"links","label":"Wikipedia"},{"id":"conformal-prediction","kind":"term","name":"Conformal prediction","route":"/terms/conformal-prediction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Consolidation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/","field":"links","label":"Wikipedia"},{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Content-addressable_storage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"provenance-fields","kind":"term","name":"Provenance fields for research data","route":"/terms/provenance-fields/","field":"links","label":"Wikipedia: content-addressable storage"}]},{"url":"https://en.wikipedia.org/wiki/Contract_development_and_manufacturing_organization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","field":"links","label":"Wikipedia"},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Contrast-enhanced_ultrasound","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/","field":"links","label":"Wikipedia: contrast-enhanced ultrasound"}]},{"url":"https://en.wikipedia.org/wiki/Copanlisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/","field":"links","label":"Wikipedia"},{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Copy_number_variation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"copy-number-variation-term","kind":"term","name":"Copy number alteration (CNA)","route":"/terms/copy-number-variation-term/","field":"links","label":"Wikipedia"},{"id":"copy-number-variation-term","kind":"term","name":"Copy number alteration (CNA)","route":"/terms/copy-number-variation-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Corcept_Therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cord_blood","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dorocubicel","kind":"drug","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cosibelimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CpG_site","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cimp","kind":"term","name":"CpG island methylator phenotype (CIMP)","route":"/terms/cimp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Craniopharyngioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Creative_Commons_license","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"open-licences","kind":"term","name":"Open licences: Apache-2.0, MIT and CC BY 4.0","route":"/terms/open-licences/","field":"links","label":"Wikipedia: Creative Commons license"}]},{"url":"https://en.wikipedia.org/wiki/Crinetics_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CRISPR_Therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Crizotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cross-entropy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross-entropy-mse","kind":"term","name":"Loss functions: cross-entropy and mean squared error","route":"/terms/cross-entropy-mse/","field":"links","label":"Wikipedia"},{"id":"cross-entropy-mse","kind":"term","name":"Loss functions: cross-entropy and mean squared error","route":"/terms/cross-entropy-mse/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cross-resistance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross-resistance","kind":"term","name":"Cross-resistance","route":"/terms/cross-resistance/","field":"links","label":"Wikipedia"},{"id":"cross-resistance","kind":"term","name":"Cross-resistance","route":"/terms/cross-resistance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cross-validation_(statistics)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross-validation","kind":"term","name":"Cross-validation and stratified k-fold","route":"/terms/cross-validation/","field":"links","label":"Wikipedia"},{"id":"cross-validation","kind":"term","name":"Cross-validation and stratified k-fold","route":"/terms/cross-validation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Crossover_study","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","field":"links","label":"Wikipedia"},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cryoablation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cryoablation","kind":"term","name":"Cryoablation","route":"/terms/cryoablation/","field":"links","label":"Wikipedia"},{"id":"cryoablation","kind":"term","name":"Cryoablation","route":"/terms/cryoablation/","field":"wikipedia"},{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/","field":"links","label":"Wikipedia"},{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CSL_Limited","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CSPC_Pharmaceutical_Group","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CT_scan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreas-protocol-ct","kind":"term","name":"Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)","route":"/terms/pancreas-protocol-ct/","field":"wikipedia"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","field":"links","label":"Wikipedia"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","field":"wikipedia"},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CTLA-4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","field":"links","label":"Wikipedia"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","field":"wikipedia"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Curcumin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CureVac","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cushing%27s_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CXCR4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CyberKnife","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/","field":"links","label":"Wikipedia"},{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cyclacel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cyclin_D1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","route":"/terms/cyclin-d1-t11-14/","field":"links","label":"Wikipedia"},{"id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","route":"/terms/cyclin-d1-t11-14/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","field":"links","label":"Wikipedia"},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","field":"wikipedia"},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Cyclophosphamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/CYP17A1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cystectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cystectomy","kind":"term","name":"Radical cystectomy","route":"/terms/cystectomy/","field":"links","label":"Wikipedia"},{"id":"cystectomy","kind":"term","name":"Radical cystectomy","route":"/terms/cystectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cystic_duct","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cystic-duct-carcinoma","kind":"cancer","name":"Cystic duct carcinoma","route":"/cancers/cystic-duct-carcinoma/","field":"wikipedia"},{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cytarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","field":"links","label":"Wikipedia"},{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","field":"wikipedia"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cytogenetics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/","field":"links","label":"Wikipedia"},{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cytokine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/","field":"links","label":"Wikipedia"},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/","field":"wikipedia"},{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/","field":"links","label":"Wikipedia"},{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/","field":"wikipedia"},{"id":"cytokine","kind":"term","name":"Cytokine","route":"/terms/cytokine/","field":"links","label":"Wikipedia"},{"id":"cytokine","kind":"term","name":"Cytokine","route":"/terms/cytokine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Cytokine_release_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","field":"links","label":"Wikipedia"},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","field":"wikipedia"},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dabrafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","field":"wikipedia"},{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260415033851/https://en.wikipedia.org/wiki/Dabrafenib"},{"url":"https://en.wikipedia.org/wiki/Dacarbazine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dacomitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dactinomycin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daiichi_Sankyo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dalpiciclib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Danazol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"danazol","kind":"drug","name":"Danazol","route":"/drugs/danazol/","field":"links","label":"Wikipedia"},{"id":"danazol","kind":"drug","name":"Danazol","route":"/drugs/danazol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dance_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dance-movement-therapy","kind":"technology","name":"Dance and movement therapy","route":"/technologies/dance-movement-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daniel_K._Ludwig","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daniel_Von_Hoff","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daratumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Darbepoetin_alfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Darolutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260811034552/https://en.wikipedia.org/wiki/Darolutamide"},{"url":"https://en.wikipedia.org/wiki/Dasatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Data_lineage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"provenance-fields","kind":"term","name":"Provenance fields for research data","route":"/terms/provenance-fields/","field":"links","label":"Wikipedia"},{"id":"provenance-fields","kind":"term","name":"Provenance fields for research data","route":"/terms/provenance-fields/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Data_monitoring_committee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/","field":"links","label":"Wikipedia"},{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Data_Protection_Act_2018","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","field":"links","label":"Wikipedia"},{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Data_sharing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"data-use-agreements","kind":"term","name":"Data use agreements and consent for research use","route":"/terms/data-use-agreements/","field":"links","label":"Wikipedia: data sharing"}]},{"url":"https://en.wikipedia.org/wiki/Datopotamab_deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daunorubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Daunorubicin/cytarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/David_Koch","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dawn_L._Hershman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Death_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extrinsic-apoptosis-death-receptors","kind":"pathway","name":"Extrinsic apoptosis (death receptors)","route":"/pathways/extrinsic-apoptosis-death-receptors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deauville_Criteria","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","field":"wikipedia"},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Debiopharm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deborah_James_(journalist)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"links","label":"Wikipedia"},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"wikipedia"},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deborah_Schrag","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Debra_Black","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"debra-black","kind":"person","name":"Debra Black","route":"/people/debra-black/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Debulking","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytoreductive-surgery","kind":"term","name":"Cytoreductive surgery","route":"/terms/cytoreductive-surgery/","field":"wikipedia"},{"id":"debulking","kind":"term","name":"Debulking (cytoreductive surgery)","route":"/terms/debulking/","field":"links","label":"Wikipedia"},{"id":"debulking","kind":"term","name":"Debulking (cytoreductive surgery)","route":"/terms/debulking/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Decitabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Decitabine/cedazuridine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Declaration_of_Helsinki","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"declaration-of-helsinki","kind":"term","name":"Declaration of Helsinki","route":"/terms/declaration-of-helsinki/","field":"links","label":"Wikipedia"},{"id":"declaration-of-helsinki","kind":"term","name":"Declaration of Helsinki","route":"/terms/declaration-of-helsinki/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deep_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mixed-precision-gpu","kind":"term","name":"GPU training and mixed precision","route":"/terms/mixed-precision-gpu/","field":"links","label":"Wikipedia: deep learning"}]},{"url":"https://en.wikipedia.org/wiki/Deerfield_Management","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Defibrotide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Degarelix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Delcath_Systems","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deletion_(genetics)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","field":"links","label":"Wikipedia"},{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dendreon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","field":"links","label":"Wikipedia"},{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Denileukin_diftitox","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Denise_Aberle","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dennis_Slamon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"wikipedia"},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","field":"links","label":"Dennis Slamon (Wikipedia)"},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","field":"profiles","label":"Dennis Slamon (Wikipedia)"}]},{"url":"https://en.wikipedia.org/wiki/Denosumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Department_of_Biotechnology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"links","label":"Source: Wikipedia article on the Department of Biotechnology (Secretary field)"}]},{"url":"https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"depatuxizumab-mafodotin","kind":"drug","name":"Depatuxizumab mafodotin","route":"/drugs/depatuxizumab-mafodotin/","field":"links","label":"Wikipedia"},{"id":"depatuxizumab-mafodotin","kind":"drug","name":"Depatuxizumab mafodotin","route":"/drugs/depatuxizumab-mafodotin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dermatofibrosarcoma_protuberans","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/","field":"links","label":"Wikipedia"},{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","field":"links","label":"Wikipedia"},{"id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Desmoplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/","field":"links","label":"Wikipedia"},{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Desmoplastic_small-round-cell_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Devi_Shetty","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","field":"links","label":"Wikipedia"},{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dexamethasone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dexrazoxane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Diazoxide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diazoxide","kind":"drug","name":"Diazoxide","route":"/drugs/diazoxide/","field":"links","label":"Wikipedia"},{"id":"diazoxide","kind":"drug","name":"Diazoxide","route":"/drugs/diazoxide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dietary_fiber","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dietary_supplement","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Diethylstilbestrol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diethylstilbestrol","kind":"drug","name":"Diethylstilbestrol","route":"/drugs/diethylstilbestrol/","field":"links","label":"Wikipedia"},{"id":"diethylstilbestrol","kind":"drug","name":"Diethylstilbestrol","route":"/drugs/diethylstilbestrol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Differentiation_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"differentiation-syndrome","kind":"term","name":"Differentiation syndrome","route":"/terms/differentiation-syndrome/","field":"links","label":"Wikipedia"},{"id":"differentiation-syndrome","kind":"term","name":"Differentiation syndrome","route":"/terms/differentiation-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Diffuse_intrinsic_pontine_glioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"links","label":"Wikipedia"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"wikipedia"},{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","field":"wikipedia"},{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260904150511/https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma"},{"url":"https://en.wikipedia.org/wiki/Diffuse_midline_glioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"h3k27m","kind":"term","name":"H3 K27M (diffuse midline glioma)","route":"/terms/h3k27m/","field":"links","label":"Wikipedia"},{"id":"h3k27m","kind":"term","name":"H3 K27M (diffuse midline glioma)","route":"/terms/h3k27m/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260627223820/https://en.wikipedia.org/wiki/Diffuse_midline_glioma"},{"url":"https://en.wikipedia.org/wiki/Diffusion_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Digital_object_identifier","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zenodo-doi","kind":"term","name":"Zenodo DOIs for data and code","route":"/terms/zenodo-doi/","field":"links","label":"Wikipedia: digital object identifier"}]},{"url":"https://en.wikipedia.org/wiki/Digital_pathology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/","field":"links","label":"Wikipedia"},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/","field":"wikipedia"},{"id":"ai-pathology-scoring","kind":"technology","name":"AI scoring of biomarkers and grade on pathology slides","route":"/technologies/ai-pathology-scoring/","field":"links","label":"Wikipedia"},{"id":"ai-pathology-scoring","kind":"technology","name":"AI scoring of biomarkers and grade on pathology slides","route":"/technologies/ai-pathology-scoring/","field":"wikipedia"},{"id":"digital-pathology-wsi","kind":"term","name":"Digital pathology and whole-slide images (WSI)","route":"/terms/digital-pathology-wsi/","field":"links","label":"Wikipedia"},{"id":"digital-pathology-wsi","kind":"term","name":"Digital pathology and whole-slide images (WSI)","route":"/terms/digital-pathology-wsi/","field":"wikipedia"},{"id":"magnification","kind":"term","name":"Magnification (20x, 40x) and microns per pixel","route":"/terms/magnification/","field":"links","label":"Wikipedia"},{"id":"magnification","kind":"term","name":"Magnification (20x, 40x) and microns per pixel","route":"/terms/magnification/","field":"wikipedia"},{"id":"radiology-imaging-modality","kind":"term","name":"Radiology imaging as a data modality (CT, MRI, TCIA)","route":"/terms/radiology-imaging-modality/","field":"links","label":"Wikipedia"},{"id":"radiology-imaging-modality","kind":"term","name":"Radiology imaging as a data modality (CT, MRI, TCIA)","route":"/terms/radiology-imaging-modality/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dihydrofolate_reductase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dhfr","kind":"target","name":"Dihydrofolate reductase (DHFR)","route":"/targets/dhfr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dinutuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Discoidin_domain-containing_receptor_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Disease-free_survival","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","field":"links","label":"Wikipedia"},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DLL3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"links","label":"Wikipedia"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"wikipedia"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"prevalence.source"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/DNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dna-term","kind":"term","name":"DNA","route":"/terms/dna-term/","field":"links","label":"Wikipedia"},{"id":"dna-term","kind":"term","name":"DNA","route":"/terms/dna-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNA_methylation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/","field":"links","label":"Wikipedia"},{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/","field":"wikipedia"},{"id":"cns-tumour-methylation-classifier","kind":"technology","name":"Methylation classifier for brain tumours","route":"/technologies/cns-tumour-methylation-classifier/","field":"links","label":"Wikipedia"},{"id":"cns-tumour-methylation-classifier","kind":"technology","name":"Methylation classifier for brain tumours","route":"/technologies/cns-tumour-methylation-classifier/","field":"wikipedia"},{"id":"methylation-arrays","kind":"term","name":"DNA methylation arrays and beta values (450k, EPIC)","route":"/terms/methylation-arrays/","field":"links","label":"Wikipedia: DNA methylation"}]},{"url":"https://en.wikipedia.org/wiki/DNA_microarray","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microarray-expression","kind":"term","name":"Microarray expression data","route":"/terms/microarray-expression/","field":"links","label":"Wikipedia"},{"id":"microarray-expression","kind":"term","name":"Microarray expression data","route":"/terms/microarray-expression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNA_mismatch_repair","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mismatch-repair-msi","kind":"pathway","name":"Mismatch repair & microsatellite instability","route":"/pathways/mismatch-repair-msi/","field":"wikipedia"},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNA_polymerase_alpha","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNA_repair","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/","field":"links","label":"Wikipedia"},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNA_sequencing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","field":"links","label":"Wikipedia"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNMT1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dnmt1","kind":"target","name":"DNMT1 (DNA methyltransferase 1)","route":"/targets/dnmt1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DNMT3A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Docetaxel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902123220/https://en.wikipedia.org/wiki/Docetaxel"},{"url":"https://en.wikipedia.org/wiki/Docrates_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Doha_Declaration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","field":"links","label":"Wikipedia: Doha Declaration"}]},{"url":"https://en.wikipedia.org/wiki/Dolasetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","field":"links","label":"Wikipedia"},{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Domain_adaptation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","field":"links","label":"Wikipedia"},{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Donafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Donald_Pinkel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","field":"links","label":"Wikipedia"},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","field":"wikipedia"},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dopamine_receptor_D2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dorabji_Tata","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dorabji-tata","kind":"person","name":"Sir Dorabji Tata","route":"/people/dorabji-tata/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dose_(biochemistry)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","field":"links","label":"Wikipedia"},{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","field":"wikipedia"},{"id":"dose-modification","kind":"term","name":"Dose reduction, interruption and discontinuation","route":"/terms/dose-modification/","field":"links","label":"Wikipedia"},{"id":"dose-modification","kind":"term","name":"Dose reduction, interruption and discontinuation","route":"/terms/dose-modification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dosimetry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","field":"links","label":"Wikipedia"},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","field":"wikipedia"},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","field":"links","label":"Wikipedia"},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","field":"wikipedia"},{"id":"in-vivo-dosimetry","kind":"technology","name":"In vivo dosimetry and patient-specific quality assurance","route":"/technologies/in-vivo-dosimetry/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dostarlimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DOTA-TATE","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","field":"links","label":"Wikipedia"},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Douglas_R._Lowy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Doxifluridine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"doxifluridine","kind":"drug","name":"Doxifluridine","route":"/drugs/doxifluridine/","field":"links","label":"Wikipedia"},{"id":"doxifluridine","kind":"drug","name":"Doxifluridine","route":"/drugs/doxifluridine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dr._Reddy's_Laboratories","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","route":"/companies/dr-reddys/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dronabinol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","field":"links","label":"Wikipedia"},{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dropout_(neural_networks)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multimodal-fusion","kind":"term","name":"Multimodal fusion (early, late, modality dropout)","route":"/terms/multimodal-fusion/","field":"links","label":"Wikipedia: dropout"}]},{"url":"https://en.wikipedia.org/wiki/Drug_design","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","field":"links","label":"Wikipedia"},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_eruption","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","field":"links","label":"Wikipedia"},{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_holiday","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rechallenge","kind":"term","name":"Rechallenge and retreatment","route":"/terms/rechallenge/","field":"links","label":"Wikipedia"},{"id":"rechallenge","kind":"term","name":"Rechallenge and retreatment","route":"/terms/rechallenge/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_labelling","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/","field":"links","label":"Wikipedia"},{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_Price_Competition_and_Patent_Term_Restoration_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","field":"links","label":"Wikipedia"},{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_resistance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/","field":"links","label":"Wikipedia"},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/","field":"wikipedia"},{"id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/","field":"links","label":"Wikipedia"},{"id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/","field":"wikipedia"},{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Drug_withdrawal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"approval-withdrawal","kind":"term","name":"Indication withdrawal","route":"/terms/approval-withdrawal/","field":"links","label":"Wikipedia"},{"id":"approval-withdrawal","kind":"term","name":"Indication withdrawal","route":"/terms/approval-withdrawal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/DuckDB","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duckdb-catalog","kind":"term","name":"Analytical databases as a data catalogue (DuckDB, PostgreSQL)","route":"/terms/duckdb-catalog/","field":"links","label":"Wikipedia"},{"id":"duckdb-catalog","kind":"term","name":"Analytical databases as a data catalogue (DuckDB, PostgreSQL)","route":"/terms/duckdb-catalog/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ductal_carcinoma_in_situ","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","field":"links","label":"Wikipedia"},{"id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","field":"wikipedia"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Duke_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Duocarmycin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/","field":"links","label":"Wikipedia"},{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/","field":"wikipedia"},{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","field":"links","label":"Wikipedia"},{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Durvalumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Duvelisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dysgeusia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-impact-symptoms","kind":"term","name":"Nutrition impact symptoms","route":"/terms/nutrition-impact-symptoms/","field":"links","label":"Wikipedia"},{"id":"nutrition-impact-symptoms","kind":"term","name":"Nutrition impact symptoms","route":"/terms/nutrition-impact-symptoms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dysphagia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","field":"links","label":"Wikipedia"},{"id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Dysplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/","field":"links","label":"Wikipedia"},{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/East_Tallinn_Central_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","field":"links","label":"Wikipedia"},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EEF2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Efbemalenograstim_alfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eflapegrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","field":"links","label":"Wikipedia"},{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eflornithine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EGFRvIII","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/","field":"links","label":"Wikipedia"},{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250626024710/https://en.wikipedia.org/wiki/EGFRvIII"},{"url":"https://en.wikipedia.org/wiki/Eicosapentaenoic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omega3-epa-cachexia","kind":"technology","name":"Fish oil (EPA) for cancer weight loss","route":"/technologies/omega3-epa-cachexia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EIF4E","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Einar_Gustafson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","field":"links","label":"Wikipedia"},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","field":"wikipedia"},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eisai_(company)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elacestrant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elastography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/","field":"links","label":"Wikipedia: elastography"},{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Electrochemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Electrodesiccation_and_curettage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Electron_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"electron-beam-therapy-systems","kind":"technology","name":"Electron beam therapy systems (linac electrons, total skin electron units, mobile electron IORT)","route":"/technologies/electron-beam-therapy-systems/","field":"links","label":"Wikipedia: electron therapy"}]},{"url":"https://en.wikipedia.org/wiki/Electronic_health_record","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ehr-text-pathology-reports","kind":"term","name":"Clinical text: EHR notes and pathology reports","route":"/terms/ehr-text-pathology-reports/","field":"links","label":"Wikipedia"},{"id":"ehr-text-pathology-reports","kind":"term","name":"Clinical text: EHR notes and pathology reports","route":"/terms/ehr-text-pathology-reports/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elekta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eli_Broad","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eli-broad","kind":"person","name":"Eli Broad","route":"/people/eli-broad/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eli_Sprecher","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elisabeth_K%C3%BCbler-Ross","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","field":"links","label":"Wikipedia"},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","field":"wikipedia"},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elizabeth_Jaffee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elotuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Elranatamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eltrombopag","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emapalumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Embedding_(machine_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embedding","kind":"term","name":"Embedding (learned representation)","route":"/terms/embedding/","field":"links","label":"Wikipedia"},{"id":"embedding","kind":"term","name":"Embedding (learned representation)","route":"/terms/embedding/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Embryonal_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embryonal-carcinoma-testis","kind":"cancer","name":"Embryonal carcinoma of the testis","route":"/cancers/embryonal-carcinoma-testis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emergency_department","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emergent_BioSolutions","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emil_Frei","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","field":"links","label":"Wikipedia"},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","field":"wikipedia"},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emil_J._Freireich","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","field":"links","label":"Wikipedia"},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","field":"wikipedia"},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Emily_Whitehead","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","field":"links","label":"Wikipedia"},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","field":"wikipedia"},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Enasidenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Encorafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endo_International","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endobronchial_ultrasound","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endodermal_sinus_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endometrial_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","field":"links","label":"Wikipedia"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","field":"wikipedia"},{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/","field":"wikipedia"},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/","field":"links","label":"Wikipedia"},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/","field":"wikipedia"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/","field":"links","label":"Wikipedia"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/","field":"wikipedia"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","field":"links","label":"Wikipedia"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","field":"wikipedia"},{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","field":"links","label":"Wikipedia"},{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260724151648/https://en.wikipedia.org/wiki/Endometrial_cancer"},{"url":"https://en.wikipedia.org/wiki/Endoscopic_mucosal_resection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endoscopic-resection-term","kind":"term","name":"EMR and ESD (endoscopic mucosal resection, endoscopic submucosal dissection)","route":"/terms/endoscopic-resection-term/","field":"links","label":"Wikipedia"},{"id":"endoscopic-resection-term","kind":"term","name":"EMR and ESD (endoscopic mucosal resection, endoscopic submucosal dissection)","route":"/terms/endoscopic-resection-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endoscopic_submucosal_dissection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/","field":"links","label":"Wikipedia"},{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endoscopic_ultrasound","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Endoscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endoscopy","kind":"term","name":"Endoscopy (EGD, EUS, ERCP)","route":"/terms/endoscopy/","field":"links","label":"Wikipedia"},{"id":"endoscopy","kind":"term","name":"Endoscopy (EGD, EUS, ERCP)","route":"/terms/endoscopy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Enediyne","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","field":"links","label":"Wikipedia"},{"id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Energy_homeostasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/","field":"links","label":"Wikipedia"},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Energy_medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reiki-energy-therapies","kind":"technology","name":"Reiki, healing touch and other energy therapies","route":"/technologies/reiki-energy-therapies/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Enfortumab_vedotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ensartinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ensembl_genome_database_project","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ensembl-gene-id","kind":"term","name":"Ensembl gene ID","route":"/terms/ensembl-gene-id/","field":"links","label":"Wikipedia"},{"id":"ensembl-gene-id","kind":"term","name":"Ensembl gene ID","route":"/terms/ensembl-gene-id/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Entrectinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Envafolimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Enzalutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260731221112/https://en.wikipedia.org/wiki/Enzalutamide"},{"url":"https://en.wikipedia.org/wiki/Enzyme","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enzyme","kind":"term","name":"Enzyme","route":"/terms/enzyme/","field":"links","label":"Wikipedia"},{"id":"enzyme","kind":"term","name":"Enzyme","route":"/terms/enzyme/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Enzyme_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/","field":"links","label":"Wikipedia"},{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epacadostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EPAS1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","field":"links","label":"Wikipedia"},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epcoritamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ependymoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EPH_receptor_A2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epic_Systems","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","field":"wikipedia"},{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","field":"wikipedia"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"links","label":"Wikipedia"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"wikipedia"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/","field":"links","label":"Wikipedia"},{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/","field":"wikipedia"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"links","label":"Wikipedia"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908043701/https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"},{"url":"https://en.wikipedia.org/wiki/Epigallocatechin_gallate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"green-tea-egcg","kind":"technology","name":"Green tea and EGCG extracts","route":"/technologies/green-tea-egcg/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epigenetic_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/","field":"links","label":"Wikipedia"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epirubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epithelial_cell_adhesion_molecule","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epithelial–mesenchymal_transition","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Epithelial%E2%80%93mesenchymal_transition","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/","field":"links","label":"Wikipedia"},{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epithelioid_hemangioendothelioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epithelioid-haemangioendothelioma","kind":"cancer","name":"Epithelioid haemangioendothelioma","route":"/cancers/epithelioid-haemangioendothelioma/","field":"links","label":"Wikipedia"},{"id":"epithelioid-haemangioendothelioma","kind":"cancer","name":"Epithelioid haemangioendothelioma","route":"/cancers/epithelioid-haemangioendothelioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epithelioid_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epitope","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/","field":"links","label":"Wikipedia"},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epoetin_alfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eprenetapopt","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epstein-Barr_virus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Epstein%E2%80%93Barr_virus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ebv-term","kind":"term","name":"Epstein-Barr virus (EBV) in cancer","route":"/terms/ebv-term/","field":"links","label":"Wikipedia"},{"id":"ebv-term","kind":"term","name":"Epstein-Barr virus (EBV) in cancer","route":"/terms/ebv-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EQT_AB","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","field":"links","label":"Wikipedia (EQT AB)"}]},{"url":"https://en.wikipedia.org/wiki/Erasto_Gaertner_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","route":"/institutions/erasto-gaertner/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ERBB3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"links","label":"Wikipedia"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"wikipedia"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"prevalence.source"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"prevalence.source"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/ERBB4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erbb4","kind":"target","name":"HER4 (ERBB4)","route":"/targets/erbb4/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Erdafitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Erdheim%E2%80%93Chester_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"wikipedia"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"links","label":"Wikipedia"},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eribulin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eric_Fearon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eric_Winer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eric._J._Small","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Erlotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Erythromelalgia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erythromelalgia","kind":"term","name":"Erythromelalgia","route":"/terms/erythromelalgia/","field":"links","label":"Wikipedia"},{"id":"erythromelalgia","kind":"term","name":"Erythromelalgia","route":"/terms/erythromelalgia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Erythropoietin_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epor","kind":"target","name":"Erythropoietin receptor (EPOR)","route":"/targets/epor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Esophageal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"wikipedia"},{"id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","field":"wikipedia"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/","field":"links","label":"Wikipedia"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/","field":"wikipedia"},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907232947/https://en.wikipedia.org/wiki/Esophageal_cancer"},{"url":"https://en.wikipedia.org/wiki/Esophagectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oesophagectomy","kind":"term","name":"Oesophagectomy","route":"/terms/oesophagectomy/","field":"links","label":"Wikipedia"},{"id":"oesophagectomy","kind":"term","name":"Oesophagectomy","route":"/terms/oesophagectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Essential_thrombocythemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","field":"links","label":"Wikipedia"},{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Essiac","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"essiac-herbal-cancer-cures","kind":"technology","name":"Essiac, Hoxsey and other 'herbal cancer cures'","route":"/technologies/essiac-herbal-cancer-cures/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Esthesioneuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"wikipedia"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"links","label":"Wikipedia"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Estimand","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"links","label":"Wikipedia"},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Estramustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","field":"links","label":"Wikipedia"},{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Estrogen_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"er-signaling","kind":"pathway","name":"Oestrogen receptor signalling","route":"/pathways/er-signaling/","field":"links","label":"Wikipedia"},{"id":"er-signaling","kind":"pathway","name":"Oestrogen receptor signalling","route":"/pathways/er-signaling/","field":"wikipedia"},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","field":"links","label":"Wikipedia"},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Estrogen_receptor_alpha","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","field":"links","label":"Wikipedia"},{"id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","field":"wikipedia"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","field":"links","label":"Wikipedia"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","field":"wikipedia"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","field":"prevalence.source"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Estrogen_receptor_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ethiodized_oil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","field":"links","label":"Wikipedia"},{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Etoposide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","field":"links","label":"Wikipedia"},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","field":"wikipedia"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eukaryotic_DNA_replication","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Eurofarma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/European_Bioinformatics_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/European_Genome-phenome_Archive","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"controlled-access-data","kind":"term","name":"Controlled-access genomic data (dbGaP, EGA)","route":"/terms/controlled-access-data/","field":"links","label":"Wikipedia"},{"id":"controlled-access-data","kind":"term","name":"Controlled-access genomic data (dbGaP, EGA)","route":"/terms/controlled-access-data/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/European_Health_Data_Space","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","field":"links","label":"Wikipedia"},{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/European_Medicines_Agency","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","field":"links","label":"Wikipedia"},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/European_Union_Clinical_Trials_Regulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","field":"links","label":"Wikipedia"},{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Evelyn_Lauder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","field":"links","label":"Wikipedia"},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","field":"wikipedia"},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Everett_E._Vokes","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Everolimus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Evofosfamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evofosfamide","kind":"drug","name":"Evofosfamide","route":"/drugs/evofosfamide/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ewing_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EWS/FLI","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Exatecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exatecan","kind":"term","name":"Exatecan (and derivatives)","route":"/terms/exatecan/","field":"links","label":"Wikipedia"},{"id":"exatecan","kind":"term","name":"Exatecan (and derivatives)","route":"/terms/exatecan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Exelixis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Exemestane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Exome_sequencing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"somatic-mutations-wxs-wgs","kind":"term","name":"Somatic mutations from exome and genome sequencing (WXS, WGS)","route":"/terms/somatic-mutations-wxs-wgs/","field":"links","label":"Wikipedia"},{"id":"somatic-mutations-wxs-wgs","kind":"term","name":"Somatic mutations from exome and genome sequencing (WXS, WGS)","route":"/terms/somatic-mutations-wxs-wgs/","field":"wikipedia"},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/","field":"links","label":"Wikipedia"},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Expanded_access","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","field":"links","label":"Wikipedia"},{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/External_validity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"external-validation","kind":"term","name":"External validation","route":"/terms/external-validation/","field":"links","label":"Wikipedia"},{"id":"external-validation","kind":"term","name":"External validation","route":"/terms/external-validation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Extracorporeal_photopheresis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","field":"links","label":"Wikipedia"},{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/EZH2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","field":"wikipedia"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","field":"prevalence.source"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/F-score","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accuracy-f1","kind":"term","name":"Accuracy, macro-F1 and confusion matrices","route":"/terms/accuracy-f1/","field":"links","label":"Wikipedia"},{"id":"accuracy-f1","kind":"term","name":"Accuracy, macro-F1 and confusion matrices","route":"/terms/accuracy-f1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fabrice_Andr%C3%A9","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Familial_adenomatous_polyposis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Family_Smoking_Prevention_and_Tobacco_Control_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","field":"links","label":"Wikipedia"},{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Faron_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fast_track_(FDA)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/","field":"links","label":"Wikipedia"},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fatty_acid_synthesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FCRL5","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Febrile_neutropenia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","field":"links","label":"Wikipedia"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fecal_immunochemical_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","field":"links","label":"Wikipedia"},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fecal_microbiota_transplant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fecal_occult_blood","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Federal_Food,_Drug,_and_Cosmetic_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","field":"links","label":"Wikipedia"},{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fedratinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fenbendazole","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"wikipedia"},{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ferroptosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fibroblast_activation_protein,_alpha","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","field":"links","label":"Wikipedia"},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","field":"wikipedia"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"links","label":"Wikipedia"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"wikipedia"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"prevalence.source"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"prevalence.source"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"prevalence.source"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/","field":"links","label":"Wikipedia"},{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","field":"wikipedia"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"links","label":"Wikipedia"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","field":"wikipedia"},{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FibroGen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fiducial_marker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fiducial-markers","kind":"term","name":"Fiducial markers","route":"/terms/fiducial-markers/","field":"links","label":"Wikipedia"},{"id":"fiducial-markers","kind":"term","name":"Fiducial markers","route":"/terms/fiducial-markers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Field_cancerization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Filgrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","field":"wikipedia"},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Financial_toxicity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","field":"wikipedia"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fine-tuning_(deep_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fine-tuning-vs-frozen","kind":"term","name":"Fine-tuning versus frozen features, and LoRA","route":"/terms/fine-tuning-vs-frozen/","field":"links","label":"Wikipedia"},{"id":"fine-tuning-vs-frozen","kind":"term","name":"Fine-tuning versus frozen features, and LoRA","route":"/terms/fine-tuning-vs-frozen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/First_Affiliated_Hospital_of_Sun_Yat-sen_University","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FKBP1A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Flagship_Pioneering","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FLASH_radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","field":"links","label":"Wikipedia"},{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FLOT","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","field":"links","label":"Wikipedia"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Flow_cytometry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/","field":"links","label":"Wikipedia"},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/","field":"wikipedia"},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/","field":"links","label":"Wikipedia"},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/","field":"wikipedia"},{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/","field":"links","label":"Wikipedia"},{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Floxuridine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","field":"links","label":"Wikipedia"},{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fluciclovine_(18F)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fludarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fludeoxyglucose_(18F)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","field":"links","label":"Wikipedia"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","field":"wikipedia"},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fluorescence_image-guided_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/","field":"links","label":"Wikipedia"},{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/","field":"wikipedia"},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/","field":"links","label":"Wikipedia"},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/","field":"wikipedia"},{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/","field":"links","label":"Wikipedia: fluorescence image-guided surgery"}]},{"url":"https://en.wikipedia.org/wiki/Fluorescence_in_situ_hybridization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/","field":"links","label":"Wikipedia"},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/","field":"wikipedia"},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/","field":"links","label":"Wikipedia"},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fluorine-18","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fluoroestradiol_F-18","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","field":"wikipedia"},{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/","field":"links","label":"Wikipedia: Fluoroestradiol F-18"}]},{"url":"https://en.wikipedia.org/wiki/Fluoroscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/","field":"links","label":"Wikipedia: fluoroscopy"}]},{"url":"https://en.wikipedia.org/wiki/Fluorouracil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fluoxymesterone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fluoxymesterone","kind":"drug","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","field":"links","label":"Wikipedia"},{"id":"fluoxymesterone","kind":"drug","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Flutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Folate_receptor_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"links","label":"Wikipedia"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"wikipedia"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"prevalence.source"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"prevalence.source"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/FOLFIRI","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","field":"links","label":"Wikipedia"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FOLFIRINOX","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","field":"links","label":"Wikipedia"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260804032415/https://en.wikipedia.org/wiki/FOLFIRINOX"},{"url":"https://en.wikipedia.org/wiki/FOLFOX","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","field":"links","label":"Wikipedia"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","field":"wikipedia"},{"id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","field":"links","label":"Wikipedia"},{"id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Folinic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Follicular_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Follicular_thyroid_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"follicular-thyroid-cancer","kind":"cancer","name":"Follicular thyroid cancer","route":"/cancers/follicular-thyroid-cancer/","field":"links","label":"Wikipedia"},{"id":"follicular-thyroid-cancer","kind":"cancer","name":"Follicular thyroid cancer","route":"/cancers/follicular-thyroid-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Food_and_Drug_Administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"complete-response-letter","kind":"term","name":"Complete response letter (CRL)","route":"/terms/complete-response-letter/","field":"links","label":"Wikipedia"},{"id":"complete-response-letter","kind":"term","name":"Complete response letter (CRL)","route":"/terms/complete-response-letter/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Food_and_Drug_Administration_Safety_and_Innovation_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","field":"links","label":"Wikipedia"},{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Foresite_Capital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Formestane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"formestane","kind":"drug","name":"Formestane","route":"/drugs/formestane/","field":"links","label":"Wikipedia"},{"id":"formestane","kind":"drug","name":"Formestane","route":"/drugs/formestane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fostamatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Foundation_model","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foundation-model","kind":"term","name":"Foundation model","route":"/terms/foundation-model/","field":"links","label":"Wikipedia"},{"id":"foundation-model","kind":"term","name":"Foundation model","route":"/terms/foundation-model/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Founder_effect","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"wikipedia"},{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Founders_Fund","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fox_Chase_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fragment_crystallizable_region","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","field":"links","label":"Wikipedia"},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Frazier_Healthcare_Partners","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","field":"links","label":"Wikipedia (Frazier Healthcare Partners)"}]},{"url":"https://en.wikipedia.org/wiki/Fred_Hutchinson_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Frederick_National_Laboratory_for_Cancer_Research","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/FRK_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fruquintinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fujifilm_Diosynth_Biotechnologies","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fujirebio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fulvestrant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Furmonertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Fusion_gene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/","field":"links","label":"Wikipedia"},{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Futibatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/G1_Therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","route":"/companies/g1-therapeutics/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Galderma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"links","label":"Wikipedia"},{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Galena_Biopharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gallbladder_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"wikipedia"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"wikipedia"},{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"wikipedia"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gallbladder_polyp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gamma_delta_T_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/","field":"links","label":"Wikipedia"},{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gamma_secretase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/","field":"links","label":"Wikipedia"},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/","field":"wikipedia"},{"id":"gamma-secretase","kind":"target","name":"Gamma-secretase (PSEN1)","route":"/targets/gamma-secretase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gardasil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","field":"wikipedia"},{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastrectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastrectomy","kind":"term","name":"Gastrectomy","route":"/terms/gastrectomy/","field":"links","label":"Wikipedia"},{"id":"gastrectomy","kind":"term","name":"Gastrectomy","route":"/terms/gastrectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastric_cancer#Classification","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Gastric_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lauren-classification","kind":"term","name":"Lauren classification (intestinal vs diffuse)","route":"/terms/lauren-classification/","field":"links","label":"Wikipedia"},{"id":"lauren-classification","kind":"term","name":"Lauren classification (intestinal vs diffuse)","route":"/terms/lauren-classification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastric_cancer#Treatment","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Gastric_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","field":"links","label":"Wikipedia"},{"id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastrin-releasing_peptide_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"links","label":"Wikipedia"},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastroesophageal_junction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gej","kind":"term","name":"Gastro-oesophageal junction (GEJ)","route":"/terms/gej/","field":"links","label":"Wikipedia"},{"id":"gej","kind":"term","name":"Gastro-oesophageal junction (GEJ)","route":"/terms/gej/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gastrointestinal_stromal_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","field":"wikipedia"},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","field":"links","label":"Wikipedia"},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GD2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","field":"links","label":"Wikipedia"},{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GDF15","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-gdf15-stratified-enrolment","kind":"idea","name":"Select cachexia trial patients by the hormone driving their wasting","route":"/ideas/idea-bio2-gdf15-stratified-enrolment/","field":"links","label":"GDF15"}]},{"url":"https://en.wikipedia.org/wiki/GE_HealthCare","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gefitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gemcitabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","field":"links","label":"Wikipedia"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","field":"wikipedia"},{"id":"clinical-benefit-response","kind":"term","name":"Clinical benefit response (the gemcitabine trial endpoint)","route":"/terms/clinical-benefit-response/","field":"wikipedia"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","field":"links","label":"Wikipedia"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","field":"wikipedia"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260811223511/https://en.wikipedia.org/wiki/Gemcitabine"},{"url":"https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","field":"links","label":"Wikipedia"},{"id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_amplification","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"co-amplification","kind":"term","name":"Co-amplification and the 17q12 HER2 amplicon","route":"/terms/co-amplification/","field":"links","label":"Wikipedia"},{"id":"co-amplification","kind":"term","name":"Co-amplification and the 17q12 HER2 amplicon","route":"/terms/co-amplification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_co-expression_network","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gene-co-expression","kind":"term","name":"Gene co-expression structure","route":"/terms/gene-co-expression/","field":"links","label":"Wikipedia"},{"id":"gene-co-expression","kind":"term","name":"Gene co-expression structure","route":"/terms/gene-co-expression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_duplication","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/","field":"links","label":"Wikipedia"},{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/","field":"wikipedia"},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/","field":"links","label":"Wikipedia"},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_expression","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gene-expression","kind":"term","name":"Gene expression","route":"/terms/gene-expression/","field":"links","label":"Wikipedia"},{"id":"gene-expression","kind":"term","name":"Gene expression","route":"/terms/gene-expression/","field":"wikipedia"},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/","field":"links","label":"Wikipedia"},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_expression_profiling_in_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/","field":"links","label":"Wikipedia"},{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gene_set_enrichment_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","field":"links","label":"Wikipedia"},{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Genelux_Corporation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/General_Catalyst","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/General_Data_Protection_Regulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gdpr","kind":"term","name":"GDPR and health data (Regulation (EU) 2016/679)","route":"/terms/gdpr/","field":"links","label":"Wikipedia"},{"id":"gdpr","kind":"term","name":"GDPR and health data (Regulation (EU) 2016/679)","route":"/terms/gdpr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Genetic_Information_Nondiscrimination_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","field":"links","label":"Wikipedia"},{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Genetic_testing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Wikipedia"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Genetically_modified_mouse","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genetically-engineered-mouse-models","kind":"technology","name":"Genetically engineered mouse models","route":"/technologies/genetically-engineered-mouse-models/","field":"links","label":"Wikipedia"},{"id":"genetically-engineered-mouse-models","kind":"technology","name":"Genetically engineered mouse models","route":"/technologies/genetically-engineered-mouse-models/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Genmab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/George_D._Demetri","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Georgina_Long","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Germ_cell_neoplasia_in_situ","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Germ_cell_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extragonadal-germ-cell-tumour","kind":"cancer","name":"Extragonadal germ cell tumour","route":"/cancers/extragonadal-germ-cell-tumour/","field":"wikipedia"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"wikipedia"},{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"wikipedia"},{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908171755/https://en.wikipedia.org/wiki/Germ_cell_tumor"},{"url":"https://en.wikipedia.org/wiki/Germinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"links","label":"Wikipedia"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Germline_mutation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/","field":"links","label":"Wikipedia"},{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Geron_Corporation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gerson_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gerson-therapy-detox-regimens","kind":"technology","name":"Gerson therapy, coffee enemas and 'detox' regimens","route":"/technologies/gerson-therapy-detox-regimens/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gert_Boyle","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gert-boyle","kind":"person","name":"Gert Boyle","route":"/people/gert-boyle/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gertrude_B._Elion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","field":"links","label":"Wikipedia"},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","field":"wikipedia"},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gestational_trophoblastic_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","field":"wikipedia"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"links","label":"Wikipedia"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Giant-cell_tumor_of_bone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Giant-cell_tumor_of_the_tendon_sheath","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gilda_Radner","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","field":"links","label":"Wikipedia"},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","field":"wikipedia"},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gilles_Salles","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gilteritinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ginger","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ginger-nausea","kind":"technology","name":"Ginger for chemotherapy nausea","route":"/technologies/ginger-nausea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glasdegib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glasdegib","kind":"drug","name":"Glasdegib","route":"/drugs/glasdegib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gleason_grading_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","field":"links","label":"Wikipedia"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260909055510/https://en.wikipedia.org/wiki/Gleason_grading_system"},{"url":"https://en.wikipedia.org/wiki/Glioblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","field":"links","label":"Wikipedia"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260820074333/https://en.wikipedia.org/wiki/Glioblastoma"},{"url":"https://en.wikipedia.org/wiki/Glioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","field":"links","label":"Wikipedia"},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Global_health","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glofitamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GLP-1_receptor_agonist","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glucagonoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucagonoma","kind":"cancer","name":"Glucagonoma","route":"/cancers/glucagonoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glucarpidase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glucocorticoid_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glutamate_carboxypeptidase_II","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"links","label":"Wikipedia"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glutamine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glutamine-mucositis-neuropathy","kind":"technology","name":"Glutamine for mucositis and neuropathy","route":"/technologies/glutamine-mucositis-neuropathy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glutaminolysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glutamine-metabolism","kind":"pathway","name":"Glutamine addiction","route":"/pathways/glutamine-metabolism/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glutathione_reductase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glycemic_index","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glycaemic-index","kind":"term","name":"Glycaemic index and glycaemic load","route":"/terms/glycaemic-index/","field":"links","label":"Wikipedia"},{"id":"glycaemic-index","kind":"term","name":"Glycaemic index and glycaemic load","route":"/terms/glycaemic-index/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Glypican_3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"links","label":"Wikipedia"},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"wikipedia"},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/GM-CSF_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Goblet_cell_carcinoid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Goh_Cheng_Liang","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"goh-cheng-liang","kind":"person","name":"Goh Cheng Liang","route":"/people/goh-cheng-liang/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gompertz_function","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gompertzian-growth-model","kind":"technology","name":"Gompertzian tumour growth","route":"/technologies/gompertzian-growth-model/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gnrhr","kind":"target","name":"GnRH receptor (GNRHR)","route":"/targets/gnrhr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Good_clinical_practice","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ich-gcp","kind":"term","name":"ICH good clinical practice (E6)","route":"/terms/ich-gcp/","field":"links","label":"Wikipedia"},{"id":"ich-gcp","kind":"term","name":"ICH good clinical practice (E6)","route":"/terms/ich-gcp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gordon_J._Freeman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Goserelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GPRC5D","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","field":"links","label":"Wikipedia"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","field":"wikipedia"},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Gr%C3%BCnenthal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Grading_(tumors)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","field":"wikipedia"},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","field":"links","label":"Wikipedia"},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","field":"wikipedia"},{"id":"tumour-differentiation","kind":"term","name":"Tumour differentiation (well / moderately / poorly differentiated)","route":"/terms/tumour-differentiation/","field":"links","label":"Wikipedia"},{"id":"tumour-differentiation","kind":"term","name":"Tumour differentiation (well / moderately / poorly differentiated)","route":"/terms/tumour-differentiation/","field":"wikipedia"},{"id":"grade-vs-stage","kind":"term","name":"Grade versus stage","route":"/terms/grade-vs-stage/","field":"links","label":"Wikipedia"},{"id":"grade-vs-stage","kind":"term","name":"Grade versus stage","route":"/terms/grade-vs-stage/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Graft-versus-host_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/","field":"links","label":"Wikipedia"},{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Granisetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Granulocyte_colony-stimulating_factor_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","route":"/targets/csf3r/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Granulosa_cell_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"granulosa-cell-tumour","kind":"cancer","name":"Adult granulosa cell tumour of the ovary","route":"/cancers/granulosa-cell-tumour/","field":"links","label":"Wikipedia"},{"id":"granulosa-cell-tumour","kind":"cancer","name":"Adult granulosa cell tumour of the ovary","route":"/cancers/granulosa-cell-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gray_(unit)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","field":"links","label":"Wikipedia"},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Grifols","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gritstone_bio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Growth_factor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","field":"links","label":"Wikipedia"},{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GSK_plc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/GTx,_Inc.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","field":"links","label":"Wikipedia: GTx, Inc."}]},{"url":"https://en.wikipedia.org/wiki/Guangdong_Provincial_People's_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Guardant_Health","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Guided_imagery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relaxation-guided-imagery","kind":"technology","name":"Relaxation training and guided imagery","route":"/technologies/relaxation-guided-imagery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Gut_microbiota","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gut-microbiome-diversity","kind":"term","name":"Gut microbiome diversity and composition","route":"/terms/gut-microbiome-diversity/","field":"links","label":"Wikipedia"},{"id":"gut-microbiome-diversity","kind":"term","name":"Gut microbiome diversity and composition","route":"/terms/gut-microbiome-diversity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/H._Lee_Moffitt_Cancer_Center_%26_Research_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/H%26E_stain","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"h-and-e-staining","kind":"term","name":"H&E staining (haematoxylin and eosin)","route":"/terms/h-and-e-staining/","field":"links","label":"Wikipedia"},{"id":"h-and-e-staining","kind":"term","name":"H&E staining (haematoxylin and eosin)","route":"/terms/h-and-e-staining/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/H3F3A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"h3-3a","kind":"target","name":"Histone H3.3 (H3-3A)","route":"/targets/h3-3a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hadassah_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hagop_Kantarjian","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hairy_cell_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hamamatsu_Photonics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hanmi_Pharm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hansoh_Pharmaceutical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Harald_zur_Hausen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","field":"links","label":"Wikipedia"},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","field":"wikipedia"},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Haukeland_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","field":"links","label":"Wikipedia"},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HAVCR2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/","field":"links","label":"Wikipedia"},{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/","field":"wikipedia"},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hazard_ratio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/","field":"links","label":"Wikipedia"},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/","field":"wikipedia"},{"id":"hazard-ratio-basics","kind":"term","name":"Reading a hazard ratio","route":"/terms/hazard-ratio-basics/","field":"links","label":"Wikipedia"},{"id":"hazard-ratio-basics","kind":"term","name":"Reading a hazard ratio","route":"/terms/hazard-ratio-basics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HCK","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Head_and_neck_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","field":"links","label":"Wikipedia"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","field":"wikipedia"},{"id":"head-neck-subsites","kind":"term","name":"Head and neck subsites (oral cavity, oropharynx, larynx)","route":"/terms/head-neck-subsites/","field":"links","label":"Wikipedia"},{"id":"head-neck-subsites","kind":"term","name":"Head and neck subsites (oral cavity, oropharynx, larynx)","route":"/terms/head-neck-subsites/","field":"wikipedia"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"links","label":"Wikipedia"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"wikipedia"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"links","label":"Wikipedia"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260909140154/https://en.wikipedia.org/wiki/Head_and_neck_cancer"},{"url":"https://en.wikipedia.org/wiki/Health_effects_of_coffee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Health_equity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"wikipedia"},{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Health_Insurance_Portability_and_Accountability_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","field":"links","label":"Wikipedia"},{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Health_technology_assessment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","field":"wikipedia"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","field":"links","label":"Wikipedia"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Heather_Wakelee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hebrew_University_of_Jerusalem","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hedgehog_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hedgehog-inhibitors","kind":"technology","name":"Hedgehog pathway inhibitors","route":"/technologies/hedgehog-inhibitors/","field":"links","label":"Wikipedia"},{"id":"hedgehog-inhibitors","kind":"technology","name":"Hedgehog pathway inhibitors","route":"/technologies/hedgehog-inhibitors/","field":"wikipedia"},{"id":"hedgehog","kind":"pathway","name":"Hedgehog signalling","route":"/pathways/hedgehog/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hematocrit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haematocrit","kind":"term","name":"Haematocrit","route":"/terms/haematocrit/","field":"links","label":"Wikipedia"},{"id":"haematocrit","kind":"term","name":"Haematocrit","route":"/terms/haematocrit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","field":"links","label":"Wikipedia"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","field":"wikipedia"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","field":"links","label":"Wikipedia"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","field":"wikipedia"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","field":"links","label":"Wikipedia"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","field":"wikipedia"},{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","field":"links","label":"Wikipedia"},{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/","field":"links","label":"Wikipedia"},{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hemoptysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haemoptysis","kind":"term","name":"Haemoptysis (coughing up blood)","route":"/terms/haemoptysis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Henrietta_Lacks","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"links","label":"Wikipedia"},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"wikipedia"},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","field":"links","label":"Wikipedia"},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatic_arterial_infusion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatitis_B","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/","field":"links","label":"Wikipedia"},{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatoblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatocellular_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","field":"links","label":"Wikipedia"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","field":"wikipedia"},{"id":"hcc-surveillance","kind":"technology","name":"HCC surveillance in cirrhosis (ultrasound + AFP)","route":"/technologies/hcc-surveillance/","field":"links","label":"Wikipedia"},{"id":"hcc-surveillance","kind":"technology","name":"HCC surveillance in cirrhosis (ultrasound + AFP)","route":"/technologies/hcc-surveillance/","field":"wikipedia"},{"id":"bclc-staging","kind":"term","name":"BCLC staging","route":"/terms/bclc-staging/","field":"wikipedia"},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","field":"links","label":"Wikipedia"},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","field":"wikipedia"},{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","field":"links","label":"Wikipedia"},{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260817163643/https://en.wikipedia.org/wiki/Hepatocellular_carcinoma"},{"url":"https://en.wikipedia.org/wiki/Hepatosplenic_T-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepatotoxicity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepatotoxicity","kind":"term","name":"Hepatotoxicity (liver enzyme elevation)","route":"/terms/hepatotoxicity/","field":"links","label":"Wikipedia"},{"id":"hepatotoxicity","kind":"term","name":"Hepatotoxicity (liver enzyme elevation)","route":"/terms/hepatotoxicity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hepcidin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepcidin","kind":"term","name":"Hepcidin","route":"/terms/hepcidin/","field":"links","label":"Wikipedia"},{"id":"hepcidin","kind":"term","name":"Hepcidin","route":"/terms/hepcidin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HER2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","field":"wikipedia"},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","field":"links","label":"Wikipedia"},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","field":"wikipedia"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"links","label":"Wikipedia"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HER2-positive_breast_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"links","label":"Wikipedia"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"wikipedia"},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","field":"links","label":"Wikipedia"},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260814041608/https://en.wikipedia.org/wiki/HER2-positive_breast_cancer"},{"url":"https://en.wikipedia.org/wiki/HER2/neu","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"heracles-criteria","kind":"term","name":"HERACLES criteria (HER2 in bowel cancer)","route":"/terms/heracles-criteria/","field":"wikipedia"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"links","label":"Wikipedia"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"wikipedia"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"links","label":"Wikipedia"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Herbert_Irving","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"herbert-irving","kind":"person","name":"Herbert Irving","route":"/people/herbert-irving/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hereditary_cancer_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hereditary_leiomyomatosis_and_renal_cell_cancer_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hetero_Drugs","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hetero","kind":"company","name":"Hetero Drugs","route":"/companies/hetero/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hexaminolevulinate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hexaminolevulinate","kind":"drug","name":"Hexaminolevulinate","route":"/drugs/hexaminolevulinate/","field":"links","label":"Wikipedia"},{"id":"hexaminolevulinate","kind":"drug","name":"Hexaminolevulinate","route":"/drugs/hexaminolevulinate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hierarchical_Data_Format","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anndata-h5ad","kind":"term","name":"AnnData and h5ad files","route":"/terms/anndata-h5ad/","field":"links","label":"Wikipedia: Hierarchical Data Format"},{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","field":"links","label":"Wikipedia"},{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/High-grade_serous_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","field":"links","label":"Wikipedia"},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/High-intensity_focused_ultrasound","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hifu-histotripsy","kind":"technology","name":"Focused ultrasound & histotripsy","route":"/technologies/hifu-histotripsy/","field":"links","label":"Wikipedia"},{"id":"hifu-histotripsy","kind":"technology","name":"Focused ultrasound & histotripsy","route":"/technologies/hifu-histotripsy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hikma_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","route":"/companies/hikma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hippo_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hisham_Mehanna","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Histamine_dihydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histamine-dihydrochloride","kind":"drug","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Histone_deacetylase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Histopathology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/","field":"links","label":"Wikipedia"},{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Histrelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","field":"links","label":"Wikipedia"},{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HLA-A*02","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","field":"links","label":"Wikipedia"},{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hodgkin_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","field":"links","label":"Wikipedia"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","field":"wikipedia"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"links","label":"Wikipedia"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"wikipedia"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"links","label":"Wikipedia"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"wikipedia"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"links","label":"Wikipedia"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260906171656/https://en.wikipedia.org/wiki/Hodgkin_lymphoma"},{"url":"https://en.wikipedia.org/wiki/Hologic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Homeopathy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"homeopathy-cancer","kind":"technology","name":"Homeopathy","route":"/technologies/homeopathy-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Homologous_recombination","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"wikipedia"},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/","field":"links","label":"Wikipedia"},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/","field":"wikipedia"},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Honey","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"honey-radiation-mucositis","kind":"technology","name":"Honey for radiation mucositis","route":"/technologies/honey-radiation-mucositis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hope_Rugo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hormonal_therapy_(oncology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","field":"links","label":"Wikipedia"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","field":"wikipedia"},{"id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","field":"links","label":"Wikipedia"},{"id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","field":"wikipedia"},{"id":"endocrine-therapy-resistance","kind":"term","name":"Endocrine therapy and endocrine resistance","route":"/terms/endocrine-therapy-resistance/","field":"links","label":"Wikipedia"},{"id":"endocrine-therapy-resistance","kind":"term","name":"Endocrine therapy and endocrine resistance","route":"/terms/endocrine-therapy-resistance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hormone_therapy_(oncology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","field":"links","label":"Wikipedia"},{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospice","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Cl%C3%ADnico_San_Carlos","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_de_Cl%C3%ADnicas_de_Porto_Alegre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_de_Sant_Pau","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","field":"links","label":"Wikipedia"},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_General_Universitario_Gregorio_Mara%C3%B1%C3%B3n","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Italiano_de_Buenos_Aires","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","route":"/institutions/hospital-italiano-buenos-aires/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_S%C3%ADrio-Liban%C3%AAs","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Universitario_12_de_Octubre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Universitario_de_la_Princesa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Universitario_La_Paz","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hospital_Universitario_Ram%C3%B3n_y_Cajal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hot_flash","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Howard_Scher","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HPV_DNA_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/","field":"links","label":"Wikipedia"},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HPV_vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/","field":"links","label":"Wikipedia"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HPV-positive_oropharyngeal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","field":"links","label":"Wikipedia"},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","field":"wikipedia"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"links","label":"Wikipedia"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hugging_Face","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hugging-face-hub","kind":"term","name":"Hugging Face Hub","route":"/terms/hugging-face-hub/","field":"links","label":"Wikipedia"},{"id":"hugging-face-hub","kind":"term","name":"Hugging Face Hub","route":"/terms/hugging-face-hub/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/HUGO_Gene_Nomenclature_Committee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hgnc-symbol","kind":"term","name":"HGNC gene symbol","route":"/terms/hgnc-symbol/","field":"links","label":"Wikipedia"},{"id":"hgnc-symbol","kind":"term","name":"HGNC gene symbol","route":"/terms/hgnc-symbol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Human_papillomavirus_infection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/","field":"links","label":"Wikipedia"},{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Human_Phenotype_Ontology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpo","kind":"term","name":"Human Phenotype Ontology (HPO)","route":"/terms/hpo/","field":"links","label":"Wikipedia"},{"id":"hpo","kind":"term","name":"Human Phenotype Ontology (HPO)","route":"/terms/hpo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Humanized_mouse","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"humanised-mouse-models","kind":"technology","name":"Humanised mouse models","route":"/technologies/humanised-mouse-models/","field":"links","label":"Wikipedia"},{"id":"humanised-mouse-models","kind":"technology","name":"Humanised mouse models","route":"/technologies/humanised-mouse-models/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hydrazine_sulfate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hydrazine-sulfate","kind":"technology","name":"Hydrazine sulfate","route":"/technologies/hydrazine-sulfate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hydrazone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","field":"links","label":"Wikipedia"},{"id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hydroxycarbamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hyperbaric_medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperbaric-oxygen-radiation-injury","kind":"technology","name":"Hyperbaric oxygen for late radiation injury","route":"/technologies/hyperbaric-oxygen-radiation-injury/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hyperglycemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/","field":"links","label":"Wikipedia"},{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypericin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","route":"/drugs/hypericin-sgx301/","field":"links","label":"Wikipedia"},{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","route":"/drugs/hypericin-sgx301/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypericum_perforatum","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hyperthermia_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/","field":"links","label":"Wikipedia"},{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/","field":"wikipedia"},{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hyperthermic_intraperitoneal_chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","field":"links","label":"Wikipedia"},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","field":"wikipedia"},{"id":"hipec-procedure","kind":"term","name":"HIPEC (hyperthermic intraperitoneal chemotherapy)","route":"/terms/hipec-procedure/","field":"links","label":"Wikipedia"},{"id":"hipec-procedure","kind":"term","name":"HIPEC (hyperthermic intraperitoneal chemotherapy)","route":"/terms/hipec-procedure/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypnotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypofractionation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypofractionation","kind":"term","name":"Hypofractionation (fewer, larger radiotherapy doses)","route":"/terms/hypofractionation/","field":"links","label":"Wikipedia"},{"id":"hypofractionation","kind":"term","name":"Hypofractionation (fewer, larger radiotherapy doses)","route":"/terms/hypofractionation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypogammaglobulinemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/","field":"links","label":"Wikipedia"},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypopharyngeal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"links","label":"Wikipedia"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypophysitis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immune-endocrinopathy","kind":"term","name":"Immune-related endocrinopathies (thyroiditis, hypophysitis)","route":"/terms/immune-endocrinopathy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hypoxia-inducible_factor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","field":"links","label":"Wikipedia"},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Hysterectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hysterectomy","kind":"term","name":"Hysterectomy","route":"/terms/hysterectomy/","field":"links","label":"Wikipedia"},{"id":"hysterectomy","kind":"term","name":"Hysterectomy","route":"/terms/hysterectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ian_Frazer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","field":"links","label":"Wikipedia"},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","field":"wikipedia"},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ibandronic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ibrutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/IC50","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/","field":"links","label":"Wikipedia"},{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ICON_PLC","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Icotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ICU_Medical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icu-medical","kind":"company","name":"ICU Medical","route":"/companies/icu-medical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Idarubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Idecabtagene_vicleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Idelalisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/IFNAR1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ifnar1","kind":"target","name":"Interferon alpha receptor (IFNAR1)","route":"/targets/ifnar1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ifosfamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/IIT_Bombay","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/IL2RA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Illumina_Methylation_Assay","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methylation-arrays","kind":"term","name":"DNA methylation arrays and beta values (450k, EPIC)","route":"/terms/methylation-arrays/","field":"links","label":"Wikipedia"},{"id":"methylation-arrays","kind":"term","name":"DNA methylation arrays and beta values (450k, EPIC)","route":"/terms/methylation-arrays/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Illumina,_Inc.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Image-guided_radiation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surface-guided-radiotherapy","kind":"technology","name":"Surface-guided radiotherapy (SGRT)","route":"/technologies/surface-guided-radiotherapy/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Imatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"wikipedia"},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","field":"links","label":"Imatinib (Wikipedia)"},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","field":"profiles","label":"Imatinib (Wikipedia)"}]},{"url":"https://en.wikipedia.org/wiki/Imetelstat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Imiquimod","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immortalised_cell_line","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-cell-line-encyclopedias","kind":"technology","name":"Cancer cell line encyclopedias and dependency maps","route":"/technologies/cancer-cell-line-encyclopedias/","field":"links","label":"Wikipedia"},{"id":"cancer-cell-line-encyclopedias","kind":"technology","name":"Cancer cell line encyclopedias and dependency maps","route":"/technologies/cancer-cell-line-encyclopedias/","field":"wikipedia"},{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/","field":"links","label":"Wikipedia"},{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/","field":"wikipedia"},{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/","field":"links","label":"Wikipedia"},{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immune_checkpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/","field":"links","label":"Wikipedia"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/","field":"wikipedia"},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/","field":"links","label":"Wikipedia"},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immune_checkpoint_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","field":"links","label":"Wikipedia"},{"id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immune_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immune-system","kind":"term","name":"Immune system","route":"/terms/immune-system/","field":"links","label":"Wikipedia"},{"id":"immune-system","kind":"term","name":"Immune system","route":"/terms/immune-system/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunocore","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunoediting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunofluorescence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multiplex-immunofluorescence","kind":"technology","name":"Multiplex immunofluorescence","route":"/technologies/multiplex-immunofluorescence/","field":"links","label":"Wikipedia"},{"id":"multiplex-immunofluorescence","kind":"technology","name":"Multiplex immunofluorescence","route":"/technologies/multiplex-immunofluorescence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunogenic_cell_death","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/","field":"links","label":"Wikipedia"},{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunohistochemistry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/","field":"links","label":"Wikipedia"},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/","field":"wikipedia"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/","field":"links","label":"Wikipedia"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunomodulatory_imide_drug","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","field":"links","label":"Wikipedia"},{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immunoscore","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunoscore","kind":"term","name":"Immunoscore","route":"/terms/immunoscore/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Immutep","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","field":"links","label":"Wikipedia"},{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/IMP_dehydrogenase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Imugene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/In_silico","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"links","label":"Wikipedia: in silico"}]},{"url":"https://en.wikipedia.org/wiki/In_vitro","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","field":"links","label":"Wikipedia"},{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/In_Vitro_Diagnostic_Medical_Devices_Regulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inavolisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Incidence_(epidemiology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incidence-vs-prevalence","kind":"term","name":"Incidence versus prevalence","route":"/terms/incidence-vs-prevalence/","field":"links","label":"Wikipedia"},{"id":"incidence-vs-prevalence","kind":"term","name":"Incidence versus prevalence","route":"/terms/incidence-vs-prevalence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Incyte","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Indian_Council_of_Medical_Research","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Indian_Institute_of_Science","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Induction_chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/","field":"links","label":"Wikipedia"},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Infigratinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","field":"links","label":"Wikipedia"},{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inflammation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammation","kind":"term","name":"Inflammation","route":"/terms/inflammation/","field":"links","label":"Wikipedia"},{"id":"inflammation","kind":"term","name":"Inflammation","route":"/terms/inflammation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inflammatory_breast_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","field":"links","label":"Wikipedia"},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inflammatory_myofibroblastic_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inflation_Reduction_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","field":"links","label":"Wikipedia"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Informed_consent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","field":"links","label":"Wikipedia"},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","field":"wikipedia"},{"id":"data-use-agreements","kind":"term","name":"Data use agreements and consent for research use","route":"/terms/data-use-agreements/","field":"links","label":"Wikipedia"},{"id":"data-use-agreements","kind":"term","name":"Data use agreements and consent for research use","route":"/terms/data-use-agreements/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Infusion-related_reaction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extravasation-infusion-reaction","kind":"term","name":"Infusion reactions, hypersensitivity and extravasation","route":"/terms/extravasation-infusion-reaction/","field":"links","label":"Wikipedia"},{"id":"extravasation-infusion-reaction","kind":"term","name":"Infusion reactions, hypersensitivity and extravasation","route":"/terms/extravasation-infusion-reaction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Iniparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Innovent_Biologics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inotuzumab_ozogamicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Inovio_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","field":"links","label":"Wikipedia"},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Insightec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Insilico_Medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Institut_Gustave_Roussy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Institut_Jules_Bordet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Institute_of_Cancer_Research","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Institutional_review_board","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","field":"links","label":"Wikipedia"},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Instituto_Nacional_de_Cancerolog%C3%ADa_(Mexico)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Insys_Therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intention-to-treat_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intention-to-treat","kind":"term","name":"Intention-to-treat (ITT) and per-protocol analysis","route":"/terms/intention-to-treat/","field":"links","label":"Wikipedia"},{"id":"intention-to-treat","kind":"term","name":"Intention-to-treat (ITT) and per-protocol analysis","route":"/terms/intention-to-treat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interferon_type_I","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","field":"links","label":"Wikipedia"},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interim_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"futility","kind":"term","name":"Futility analysis (stopped for futility)","route":"/terms/futility/","field":"links","label":"Wikipedia"},{"id":"futility","kind":"term","name":"Futility analysis (stopped for futility)","route":"/terms/futility/","field":"wikipedia"},{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/","field":"links","label":"Wikipedia"},{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interleukin_11_receptor_alpha_subunit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interleukin_6","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interleukin-3_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","field":"links","label":"Wikipedia"},{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","field":"wikipedia"},{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Intermittent_fasting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"time-restricted-eating","kind":"technology","name":"Time-restricted eating in cancer prevention and survivorship","route":"/technologies/time-restricted-eating/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/International_Classification_of_Diseases_for_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icd-o-3","kind":"term","name":"ICD-O-3 (International Classification of Diseases for Oncology)","route":"/terms/icd-o-3/","field":"links","label":"Wikipedia"},{"id":"icd-o-3","kind":"term","name":"ICD-O-3 (International Classification of Diseases for Oncology)","route":"/terms/icd-o-3/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/International_Prognostic_Index","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/","field":"links","label":"Wikipedia"},{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/International_Prognostic_Scoring_System","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipss-m-ipss-r","kind":"term","name":"IPSS-R and IPSS-M (myelodysplastic syndrome risk scores)","route":"/terms/ipss-m-ipss-r/","field":"links","label":"Wikipedia"},{"id":"ipss-m-ipss-r","kind":"term","name":"IPSS-R and IPSS-M (myelodysplastic syndrome risk scores)","route":"/terms/ipss-m-ipss-r/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Interstitial_lung_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","field":"links","label":"Wikipedia"},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"wikipedia"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"wikipedia"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"links","label":"Wikipedia"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intraoperative_MRI","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraoperative-mri-ct","kind":"technology","name":"Intraoperative MRI and CT","route":"/technologies/intraoperative-mri-ct/","field":"links","label":"Wikipedia"},{"id":"intraoperative-mri-ct","kind":"technology","name":"Intraoperative MRI and CT","route":"/technologies/intraoperative-mri-ct/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intraoperative_radiation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intraperitoneal_chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraperitoneal-chemotherapy","kind":"term","name":"Intraperitoneal (IP) chemotherapy","route":"/terms/intraperitoneal-chemotherapy/","field":"links","label":"Wikipedia"},{"id":"intraperitoneal-chemotherapy","kind":"term","name":"Intraperitoneal (IP) chemotherapy","route":"/terms/intraperitoneal-chemotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intrathecal_administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intrathecal-therapy","kind":"term","name":"Intrathecal therapy (lumbar puncture, Ommaya reservoir)","route":"/terms/intrathecal-therapy/","field":"links","label":"Wikipedia"},{"id":"intrathecal-therapy","kind":"term","name":"Intrathecal therapy (lumbar puncture, Ommaya reservoir)","route":"/terms/intrathecal-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intravascular_lymphomas","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intravenous_ascorbic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Intuitive_Surgical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Invadopodia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invasion-ecm-degradation","kind":"pathway","name":"Invasion: proteases, adhesion & the invasive front","route":"/pathways/invasion-ecm-degradation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Invasive_carcinoma_of_no_special_type","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Invasive_lobular_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Iobenguane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","field":"links","label":"Wikipedia"},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","field":"wikipedia"},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"links","label":"Wikipedia"},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Iodine-131","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"wikipedia"},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","field":"links","label":"Wikipedia"},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ionis_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Iovance_Biotherapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ipilimumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ipsen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260821113525/https://en.wikipedia.org/wiki/Ipsen"},{"url":"https://en.wikipedia.org/wiki/Irinotecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"wikipedia"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Irreversible_electroporation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/","field":"links","label":"Wikipedia"},{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isatuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isocitrate_dehydrogenase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idh-inhibitors","kind":"technology","name":"IDH inhibitors","route":"/technologies/idh-inhibitors/","field":"links","label":"Wikipedia"},{"id":"idh-inhibitors","kind":"technology","name":"IDH inhibitors","route":"/technologies/idh-inhibitors/","field":"wikipedia"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"links","label":"Wikipedia"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"wikipedia"},{"id":"idh-2hg","kind":"pathway","name":"Mutant IDH / 2-hydroxyglutarate","route":"/pathways/idh-2hg/","field":"links","label":"Wikipedia"},{"id":"idh-2hg","kind":"pathway","name":"Mutant IDH / 2-hydroxyglutarate","route":"/pathways/idh-2hg/","field":"wikipedia"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"links","label":"Wikipedia: Isocitrate dehydrogenase"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isolated_limb_perfusion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isolated-limb-perfusion","kind":"technology","name":"Isolated limb perfusion and infusion","route":"/technologies/isolated-limb-perfusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isomorphic_Labs","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isotopes_of_iodine#Iodine-131","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Isotopes_of_iodine","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","field":"links","label":"Wikipedia"},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Isotretinoin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/","field":"links","label":"Wikipedia"},{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Istituto_Nazionale_dei_Tumori","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ivermectin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"Wikipedia"},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ivosidenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ixabepilone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ixazomib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jackson_Orem","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jade_Goody","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","field":"links","label":"Wikipedia"},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","field":"wikipedia"},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/JAK-STAT_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jalid_Sehouli","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/JAMA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/James_D._Brenton","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/James_L._Gulley","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/James_P._Allison","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"wikipedia"},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","field":"links","label":"James P. Allison (Wikipedia)"},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","field":"profiles","label":"James P. Allison (Wikipedia)"}]},{"url":"https://en.wikipedia.org/wiki/James_R._Downing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jane_Cooke_Wright","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","field":"links","label":"Wikipedia"},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","field":"wikipedia"},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Janet_Dancey","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Janet_Rowley","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","field":"links","label":"Wikipedia"},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","field":"wikipedia"},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Janus_kinase_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","field":"wikipedia"},{"id":"jak2-v617f","kind":"term","name":"JAK2 V617F","route":"/terms/jak2-v617f/","field":"links","label":"Wikipedia"},{"id":"jak2-v617f","kind":"term","name":"JAK2 V617F","route":"/terms/jak2-v617f/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jaundice","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","field":"links","label":"Wikipedia"},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jazz_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jian_Zhou","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","field":"links","label":"Wikipedia"},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","field":"wikipedia"},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jim_Valvano","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","field":"links","label":"Wikipedia"},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","field":"wikipedia"},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jimmie_Holland","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","field":"links","label":"Wikipedia"},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","field":"wikipedia"},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Johanna_Joyce","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/John_D._Rockefeller_Jr.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","route":"/people/john-d-rockefeller-jr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/John_Jacob_Astor_III","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","route":"/people/john-jacob-astor-iii/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/John_M._Maris","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/John_V._Heymach","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson_Innovation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","field":"links","label":"Wikipedia (Johnson & Johnson Innovation)"}]},{"url":"https://en.wikipedia.org/wiki/Jon_Huntsman_Sr.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","route":"/people/jon-huntsman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Jos%C3%A9_Baselga","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Journal_of_Clinical_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Judah_Folkman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","field":"links","label":"Wikipedia"},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","field":"wikipedia"},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Julie_Brahmer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/K-means_clustering","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spagcn","kind":"term","name":"Spatially aware clustering (SpaGCN, KNN smoothing)","route":"/terms/spagcn/","field":"links","label":"Wikipedia: k-means clustering"}]},{"url":"https://en.wikipedia.org/wiki/K-nearest_neighbors_algorithm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spagcn","kind":"term","name":"Spatially aware clustering (SpaGCN, KNN smoothing)","route":"/terms/spagcn/","field":"links","label":"Wikipedia: k-nearest neighbours"}]},{"url":"https://en.wikipedia.org/wiki/Kaplan-Meier_estimator","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/","field":"links","label":"Wikipedia"},{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kaplan%E2%80%93Meier_estimator","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"median-survival","kind":"term","name":"Median survival","route":"/terms/median-survival/","field":"links","label":"Wikipedia"},{"id":"median-survival","kind":"term","name":"Median survival","route":"/terms/median-survival/","field":"wikipedia"},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/","field":"links","label":"Wikipedia"},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kaposi%27s_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kaposi%27s_sarcoma-associated_herpesvirus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hhv8-kshv","kind":"term","name":"HHV-8 (KSHV) status and LANA-1 immunohistochemistry","route":"/terms/hhv8-kshv/","field":"links","label":"Wikipedia"},{"id":"hhv8-kshv","kind":"term","name":"HHV-8 (KSHV) status and LANA-1 immunohistochemistry","route":"/terms/hhv8-kshv/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Karmanos_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Karolinska_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/KAT6A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kat6-inhibitors","kind":"technology","name":"KAT6 inhibitors","route":"/technologies/kat6-inhibitors/","field":"links","label":"Wikipedia"},{"id":"kat6-inhibitors","kind":"technology","name":"KAT6 inhibitors","route":"/technologies/kat6-inhibitors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kate_Granger","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","field":"links","label":"Wikipedia"},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","field":"wikipedia"},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Katie_Couric","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","field":"links","label":"Wikipedia"},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","field":"wikipedia"},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/KDM1A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/","field":"links","label":"Wikipedia"},{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kefauver%E2%80%93Harris_Amendment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","field":"links","label":"Wikipedia: Kefauver-Harris Amendment"}]},{"url":"https://en.wikipedia.org/wiki/Keio_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kenneth_C._Anderson_(physician)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kenneth_W._Kinzler","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kenyatta_National_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Keratoacanthoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Keratopathy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/","field":"links","label":"Wikipedia"},{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ketogenic_diet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ketogenic-diet-glioblastoma","kind":"technology","name":"Ketogenic diets in glioblastoma","route":"/technologies/ketogenic-diet-glioblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Khosla_Ventures","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ki-67_(protein)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/","field":"wikipedia"},{"id":"mki67","kind":"target","name":"Ki-67 (MKI67)","route":"/targets/mki67/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kidwai_Memorial_Institute_of_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/","field":"links","label":"Wikipedia"},{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/King_Faisal_Specialist_Hospital_and_Research_Centre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/King_Hussein_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kiran_Mazumdar-Shaw","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","field":"links","label":"Wikipedia"},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","field":"wikipedia"},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kissei","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Klatskin_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","field":"links","label":"Wikipedia"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/KLK2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","field":"links","label":"Wikipedia"},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260730112942/https://en.wikipedia.org/wiki/KLK2"},{"url":"https://en.wikipedia.org/wiki/KMT2A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/","field":"links","label":"Wikipedia"},{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/","field":"wikipedia"},{"id":"menin-kmt2a","kind":"pathway","name":"Menin / KMT2A (HOXA9-MEIS1 axis)","route":"/pathways/menin-kmt2a/","field":"links","label":"Wikipedia"},{"id":"menin-kmt2a","kind":"pathway","name":"Menin / KMT2A (HOXA9-MEIS1 axis)","route":"/pathways/menin-kmt2a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Knight_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Knudson_hypothesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Komfo_Anokye_Teaching_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Korle-Bu_Teaching_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/KRAS","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/","field":"wikipedia"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/","field":"links","label":"Wikipedia"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/","field":"wikipedia"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"links","label":"Wikipedia"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"wikipedia"},{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/","field":"links","label":"Wikipedia"},{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/","field":"wikipedia"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"links","label":"Wikipedia"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"wikipedia"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"links","label":"Wikipedia"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"wikipedia"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"links","label":"Wikipedia"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kris_Hallenga","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","field":"links","label":"Wikipedia"},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","field":"wikipedia"},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kunle_Odunsi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kyntra_Bio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Kyowa_Kirin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Labcorp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Laboratory-developed_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fda-ldt-rule","kind":"term","name":"FDA laboratory-developed test (LDT) rule","route":"/terms/fda-ldt-rule/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LAG3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/","field":"links","label":"Wikipedia"},{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/","field":"wikipedia"},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","field":"links","label":"Wikipedia"},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","field":"wikipedia"},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Lance_Armstrong","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","field":"links","label":"Wikipedia"},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","field":"wikipedia"},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Landspítali","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Landsp%C3%ADtali","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"wikipedia"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"links","label":"Wikipedia"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"wikipedia"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"links","label":"Wikipedia"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Laparoscopy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"port-site-metastasis","kind":"term","name":"Port-site metastasis","route":"/terms/port-site-metastasis/","field":"wikipedia"},{"id":"staging-laparoscopy","kind":"term","name":"Laparoscopy (keyhole surgery)","route":"/terms/staging-laparoscopy/","field":"links","label":"Wikipedia"},{"id":"staging-laparoscopy","kind":"term","name":"Laparoscopy (keyhole surgery)","route":"/terms/staging-laparoscopy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lapatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Large_granular_lymphocytic_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Large_language_model","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"autoregressive-modelling","kind":"term","name":"Autoregressive (next-token) modelling","route":"/terms/autoregressive-modelling/","field":"links","label":"Wikipedia: large language model"},{"id":"local-llm-reasoning-layer","kind":"term","name":"Local-only language models over patient data (privacy by architecture)","route":"/terms/local-llm-reasoning-layer/","field":"links","label":"Wikipedia"},{"id":"local-llm-reasoning-layer","kind":"term","name":"Local-only language models over patient data (privacy by architecture)","route":"/terms/local-llm-reasoning-layer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Large-cell_lung_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","field":"wikipedia"},{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Larotrectinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Larry_Ellison","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Laryngeal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laryngeal-cancer","kind":"cancer","name":"Laryngeal and hypopharyngeal cancer","route":"/cancers/laryngeal-cancer/","field":"links","label":"Wikipedia"},{"id":"laryngeal-cancer","kind":"cancer","name":"Laryngeal and hypopharyngeal cancer","route":"/cancers/laryngeal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Late_effect","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","field":"links","label":"Wikipedia"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Laura_J._Esserman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Laurence_Zitvogel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lazertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251212165157/https://en.wikipedia.org/wiki/Lazertinib"},{"url":"https://en.wikipedia.org/wiki/Lead_time_bias","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leakage_(machine_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"data-leakage","kind":"term","name":"Data leakage in model evaluation","route":"/terms/data-leakage/","field":"links","label":"Wikipedia"},{"id":"data-leakage","kind":"term","name":"Data leakage in model evaluation","route":"/terms/data-leakage/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leiden_University_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leiomyosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/","field":"links","label":"Wikipedia"},{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lenalidomide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lenograstim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/","field":"links","label":"Wikipedia"},{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lenvatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lenzilumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lenzilumab","kind":"drug","name":"Lenzilumab","route":"/drugs/lenzilumab/","field":"links","label":"Wikipedia"},{"id":"lenzilumab","kind":"drug","name":"Lenzilumab","route":"/drugs/lenzilumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leo_Pharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LEO_Pharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leon_Black","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leon-black","kind":"person","name":"Leon Black","route":"/people/leon-black/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leonard_Abramson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leonard-abramson","kind":"person","name":"Leonard Abramson","route":"/people/leonard-abramson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leptomeningeal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leptomeningeal-disease","kind":"term","name":"Leptomeningeal disease","route":"/terms/leptomeningeal-disease/","field":"links","label":"Wikipedia"},{"id":"leptomeningeal-disease","kind":"term","name":"Leptomeningeal disease","route":"/terms/leptomeningeal-disease/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lesion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lesion","kind":"term","name":"Lesion","route":"/terms/lesion/","field":"links","label":"Wikipedia"},{"id":"lesion","kind":"term","name":"Lesion","route":"/terms/lesion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Letrozole","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","field":"links","label":"Wikipedia"},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","field":"wikipedia"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","field":"links","label":"Wikipedia"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leukemia_and_Lymphoma_Society","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/","field":"links","label":"Wikipedia (Blood Cancer United)"}]},{"url":"https://en.wikipedia.org/wiki/Leuprorelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lexical_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tokenisation","kind":"term","name":"Tokenisation (genes, tiles and sequence as tokens)","route":"/terms/tokenisation/","field":"links","label":"Wikipedia"},{"id":"tokenisation","kind":"term","name":"Tokenisation (genes, tiles and sequence as tokens)","route":"/terms/tokenisation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Leydig_cell_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LGR5","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","field":"links","label":"Wikipedia"},{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Li_Ka-shing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LI-RADS","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-rads","kind":"term","name":"LI-RADS (Liver Imaging Reporting and Data System)","route":"/terms/li-rads/","field":"links","label":"Wikipedia"},{"id":"li-rads","kind":"term","name":"LI-RADS (Liver Imaging Reporting and Data System)","route":"/terms/li-rads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Li–Fraumeni_syndrome","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Li%E2%80%93Fraumeni_syndrome","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lifileucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ligand_(biochemistry)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","field":"links","label":"Wikipedia"},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LightGBM","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","field":"links","label":"Wikipedia"},{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lillian_Siu","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Limb-sparing_techniques","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"limb-salvage-surgery","kind":"technology","name":"Limb-salvage surgery and endoprosthetic reconstruction","route":"/technologies/limb-salvage-surgery/","field":"links","label":"Wikipedia"},{"id":"limb-salvage-surgery","kind":"technology","name":"Limb-salvage surgery and endoprosthetic reconstruction","route":"/technologies/limb-salvage-surgery/","field":"wikipedia"},{"id":"limb-salvage-term","kind":"term","name":"Limb-salvage surgery","route":"/terms/limb-salvage-term/","field":"links","label":"Wikipedia"},{"id":"limb-salvage-term","kind":"term","name":"Limb-salvage surgery","route":"/terms/limb-salvage-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Linear_energy_transfer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","field":"links","label":"Wikipedia"},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Linear_particle_accelerator","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Linear_particle_accelerator#Medical_linacs","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Linear_particle_accelerator","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiotherapy-equipment-manufacturing","kind":"technology","name":"Linac, proton system and brachytherapy machine manufacturing","route":"/technologies/radiotherapy-equipment-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Linkou_Chang_Gung_Memorial_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lipegfilgrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Liposarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/","field":"links","label":"Wikipedia"},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Liposomal_doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Liquid_biopsy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","field":"links","label":"Wikipedia"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lisocabtagene_maraleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Liver_cancer#Treatment","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Liver_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liver-directed-therapy","kind":"term","name":"Liver-directed therapy (TACE, TARE, HAI, ablation)","route":"/terms/liver-directed-therapy/","field":"links","label":"Wikipedia"},{"id":"liver-directed-therapy","kind":"term","name":"Liver-directed therapy (TACE, TARE, HAI, ablation)","route":"/terms/liver-directed-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Liver_segment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Living_Proof_(2008_film)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","field":"links","label":"Living Proof (2008 film)"},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","field":"profiles","label":"Living Proof (2008 film)"}]},{"url":"https://en.wikipedia.org/wiki/Lobectomy_(lung)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","field":"links","label":"Wikipedia"},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lobular_carcinoma_in_situ","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Logistic_regression","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"linear-probe","kind":"term","name":"Linear probe","route":"/terms/linear-probe/","field":"links","label":"Wikipedia"},{"id":"linear-probe","kind":"term","name":"Linear probe","route":"/terms/linear-probe/","field":"wikipedia"},{"id":"logistic-regression-term","kind":"term","name":"Logistic regression and nearest-centroid classifiers","route":"/terms/logistic-regression-term/","field":"links","label":"Wikipedia"},{"id":"logistic-regression-term","kind":"term","name":"Logistic regression and nearest-centroid classifiers","route":"/terms/logistic-regression-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lomustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/","field":"links","label":"Wikipedia"},{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Loncastuximab_tesirine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"wikipedia"},{"id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Long_QT_syndrome#Drug-induced","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Long_QT_syndrome","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"qt-prolongation","kind":"term","name":"QT prolongation","route":"/terms/qt-prolongation/","field":"links","label":"Wikipedia"},{"id":"qt-prolongation","kind":"term","name":"QT prolongation","route":"/terms/qt-prolongation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lonza_Group","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Loop_electrical_excision_procedure","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/","field":"links","label":"Wikipedia"},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LoRA_(machine_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fine-tuning-vs-frozen","kind":"term","name":"Fine-tuning versus frozen features, and LoRA","route":"/terms/fine-tuning-vs-frozen/","field":"links","label":"Wikipedia: LoRA"}]},{"url":"https://en.wikipedia.org/wiki/Lori_J._Pierce","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lorlatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Loss_of_heterozygosity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Low_anterior_resection_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Low-level_laser_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lucille_P._Markey","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucille-markey","kind":"person","name":"Lucille P. Markey","route":"/people/lucille-markey/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lumpectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"Wikipedia"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lung_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"wikipedia"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Wikipedia"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lung_cancer_screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"Wikipedia"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"wikipedia"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"wikipedia"},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260705002052/https://en.wikipedia.org/wiki/Lung_cancer_screening"},{"url":"https://en.wikipedia.org/wiki/Lung_cancer_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","field":"wikipedia"},{"id":"sublobar-resection","kind":"term","name":"Sublobar resection (segmentectomy and wedge)","route":"/terms/sublobar-resection/","field":"wikipedia"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"links","label":"Wikipedia"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lung_nodule","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lurbinectedin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Luspatercept","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivotide_tetraxetan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lutetium-177","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","field":"links","label":"Wikipedia"},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lux_Capital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lyell_Immunopharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymph_node","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymph-node","kind":"term","name":"Lymph node","route":"/terms/lymph-node/","field":"links","label":"Wikipedia"},{"id":"lymph-node","kind":"term","name":"Lymph node","route":"/terms/lymph-node/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymph_node_metastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymph-node-status","kind":"term","name":"Lymph node status (node-positive / node-negative)","route":"/terms/lymph-node-status/","field":"links","label":"Wikipedia"},{"id":"lymph-node-status","kind":"term","name":"Lymph node status (node-positive / node-negative)","route":"/terms/lymph-node-status/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphadenectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"Wikipedia"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphedema","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphoepithelioma-like_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoepithelial-carcinoma-lung","kind":"cancer","name":"Lymphoepithelial carcinoma of the lung","route":"/cancers/lymphoepithelial-carcinoma-lung/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","field":"links","label":"Wikipedia"},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphomatoid_granulomatosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lymphovascular_invasion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphovascular-invasion","kind":"term","name":"Lymphovascular invasion (LVI)","route":"/terms/lymphovascular-invasion/","field":"links","label":"Wikipedia"},{"id":"lymphovascular-invasion","kind":"term","name":"Lymphovascular invasion (LVI)","route":"/terms/lymphovascular-invasion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/LYN_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Lynch_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","field":"links","label":"Wikipedia"},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","field":"wikipedia"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Macrophage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/","field":"links","label":"Wikipedia"},{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MAGEA4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","field":"links","label":"Wikipedia"},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","field":"wikipedia"},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","field":"prevalence.source"},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Magnetic_resonance_imaging","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/","field":"links","label":"Wikipedia"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/","field":"wikipedia"},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/","field":"links","label":"Wikipedia: magnetic resonance imaging"},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Maha_H._Hussain","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mahalanobis_distance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ood-detection","kind":"term","name":"Out-of-distribution detection (Mahalanobis guard)","route":"/terms/ood-detection/","field":"links","label":"Wikipedia: Mahalanobis distance"}]},{"url":"https://en.wikipedia.org/wiki/Maintenance_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/","field":"links","label":"Wikipedia"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Male_breast_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"malignant-peripheral-nerve-sheath-tumour","kind":"cancer","name":"Malignant peripheral nerve sheath tumour (MPNST)","route":"/cancers/malignant-peripheral-nerve-sheath-tumour/","field":"links","label":"Wikipedia"},{"id":"malignant-peripheral-nerve-sheath-tumour","kind":"cancer","name":"Malignant peripheral nerve sheath tumour (MPNST)","route":"/cancers/malignant-peripheral-nerve-sheath-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Malignant_pleural_effusion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","field":"links","label":"Wikipedia"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Malnutrition","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MALT_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MammaPrint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","field":"links","label":"Wikipedia"},{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mammography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/","field":"links","label":"Wikipedia"},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/","field":"wikipedia"},{"id":"ai-mammography-screening","kind":"technology","name":"AI-assisted mammography screening","route":"/technologies/ai-mammography-screening/","field":"links","label":"Wikipedia"},{"id":"ai-mammography-screening","kind":"technology","name":"AI-assisted mammography screening","route":"/technologies/ai-mammography-screening/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mann%E2%80%93Whitney_U_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"permutation-test","kind":"term","name":"Permutation test and the Mann-Whitney U test","route":"/terms/permutation-test/","field":"links","label":"Wikipedia: Mann-Whitney U test"}]},{"url":"https://en.wikipedia.org/wiki/Mantle_cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MAP2K1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MAPK/ERK_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/","field":"links","label":"Wikipedia"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Margetuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Marginal_zone_B-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","field":"links","label":"Wikipedia"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","field":"wikipedia"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Maria_Sk%C5%82odowska-Curie_National_Research_Institute_of_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mark_Emberton","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mark-emberton","kind":"person","name":"Mark Emberton","route":"/people/mark-emberton/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Martha_Rivers_Ingram","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","route":"/people/martha-ingram/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Martine_Piccart","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mary_Lasker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","field":"links","label":"Wikipedia"},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","field":"wikipedia"},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mary-Claire_King","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","field":"links","label":"Wikipedia"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","field":"wikipedia"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mass_cytometry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imaging-mass-cytometry","kind":"technology","name":"Imaging mass cytometry","route":"/technologies/imaging-mass-cytometry/","field":"links","label":"Wikipedia"},{"id":"imaging-mass-cytometry","kind":"technology","name":"Imaging mass cytometry","route":"/technologies/imaging-mass-cytometry/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mass_spectrometry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mass-spec-proteome","kind":"term","name":"Deep mass-spectrometry proteome (CPTAC)","route":"/terms/mass-spec-proteome/","field":"links","label":"Wikipedia"},{"id":"mass-spec-proteome","kind":"term","name":"Deep mass-spectrometry proteome (CPTAC)","route":"/terms/mass-spec-proteome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Massage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"massage-therapy-cancer","kind":"technology","name":"Massage therapy in cancer care","route":"/technologies/massage-therapy-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mastectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"links","label":"Wikipedia"},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mastocytosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"wikipedia"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"links","label":"Wikipedia"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"wikipedia"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"links","label":"Wikipedia"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mater_Misericordiae_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","field":"links","label":"Wikipedia"},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mathematical_oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Maura_L._Gillison","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mavorixafor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mavorixafor","kind":"drug","name":"Mavorixafor","route":"/drugs/mavorixafor/","field":"links","label":"Wikipedia"},{"id":"mavorixafor","kind":"drug","name":"Mavorixafor","route":"/drugs/mavorixafor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Max_Delbr%C3%BCck_Center_for_Molecular_Medicine_in_the_Helmholtz_Association","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Max_Healthcare","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abhay-soi","kind":"person","name":"Abhay Soi","route":"/people/abhay-soi/","field":"links","label":"Source: Wikipedia article on Max Healthcare (leadership infobox)"},{"id":"abhay-soi","kind":"person","name":"Abhay Soi","route":"/people/abhay-soi/","field":"profiles","label":"Wikipedia: Max Healthcare"}]},{"url":"https://en.wikipedia.org/wiki/Maximilian_Diehn","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Maximum_tolerated_dose","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mtd","kind":"term","name":"Maximum tolerated dose (MTD)","route":"/terms/mtd/","field":"links","label":"Wikipedia"},{"id":"mtd","kind":"term","name":"Maximum tolerated dose (MTD)","route":"/terms/mtd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mayo_Clinic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MD_Anderson_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mdm2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdm2-inhibitors","kind":"technology","name":"MDM2 inhibitors","route":"/technologies/mdm2-inhibitors/","field":"links","label":"Wikipedia"},{"id":"mdm2-inhibitors","kind":"technology","name":"MDM2 inhibitors","route":"/technologies/mdm2-inhibitors/","field":"wikipedia"},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mean_squared_error","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross-entropy-mse","kind":"term","name":"Loss functions: cross-entropy and mean squared error","route":"/terms/cross-entropy-mse/","field":"links","label":"Wikipedia: mean squared error"}]},{"url":"https://en.wikipedia.org/wiki/Mebendazole","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mechanism_of_action","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mechanism-of-action-recovery","kind":"term","name":"Mechanism-of-action recovery and known-biology probes","route":"/terms/mechanism-of-action-recovery/","field":"links","label":"Wikipedia"},{"id":"mechanism-of-action-recovery","kind":"term","name":"Mechanism-of-action recovery and known-biology probes","route":"/terms/mechanism-of-action-recovery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mechanobiology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medac","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mediastinal_lymph_node","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mediastinum","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediastinum","kind":"term","name":"Mediastinum","route":"/terms/mediastinum/","field":"links","label":"Wikipedia"},{"id":"mediastinum","kind":"term","name":"Mediastinum","route":"/terms/mediastinum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medical_cannabis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medical_software","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samd","kind":"term","name":"Software as a medical device (SaMD)","route":"/terms/samd/","field":"links","label":"Wikipedia: medical software"}]},{"url":"https://en.wikipedia.org/wiki/Medical_ultrasound","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/","field":"links","label":"Wikipedia"},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medicinal_fungi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medicinal-mushrooms-reishi-turkey-tail","kind":"technology","name":"Medicinal mushrooms: reishi, turkey tail, shiitake and others","route":"/technologies/medicinal-mushrooms-reishi-turkey-tail/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MediGene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mediso","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mediterranean_diet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediterranean-plant-forward-diet","kind":"technology","name":"Mediterranean and plant-forward dietary patterns","route":"/technologies/mediterranean-plant-forward-diet/","field":"wikipedia"},{"id":"dietary-pattern-scores","kind":"term","name":"Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)","route":"/terms/dietary-pattern-scores/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medpace","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medtronic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medtronic","kind":"company","name":"Medtronic","route":"/companies/medtronic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medullary_breast_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medullary_thyroid_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/","field":"links","label":"Wikipedia"},{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Medulloblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","field":"wikipedia"},{"id":"medulloblastoma-molecular-groups","kind":"term","name":"Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)","route":"/terms/medulloblastoma-molecular-groups/","field":"links","label":"Wikipedia"},{"id":"medulloblastoma-molecular-groups","kind":"term","name":"Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)","route":"/terms/medulloblastoma-molecular-groups/","field":"wikipedia"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"links","label":"Wikipedia: Medulloblastoma"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"wikipedia"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"links","label":"Wikipedia: Medulloblastoma"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"wikipedia"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"links","label":"Wikipedia: Medulloblastoma"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Megestrol_acetate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","field":"wikipedia"},{"id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"links","label":"Wikipedia"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"wikipedia"},{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","field":"wikipedia"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"links","label":"Wikipedia"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"wikipedia"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"links","label":"Wikipedia"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"wikipedia"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"links","label":"Wikipedia"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907132415/https://en.wikipedia.org/wiki/Melanoma"},{"url":"https://en.wikipedia.org/wiki/Melanoma_Institute_Australia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Melatonin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melatonin-cancer","kind":"technology","name":"Melatonin as a cancer adjunct","route":"/technologies/melatonin-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Melphalan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Melphalan_flufenamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Memantine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"memantine","kind":"drug","name":"Memantine","route":"/drugs/memantine/","field":"links","label":"Wikipedia"},{"id":"memantine","kind":"drug","name":"Memantine","route":"/drugs/memantine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Menin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"menin-inhibitors","kind":"technology","name":"Menin inhibitors","route":"/technologies/menin-inhibitors/","field":"links","label":"Wikipedia"},{"id":"menin-inhibitors","kind":"technology","name":"Menin inhibitors","route":"/technologies/menin-inhibitors/","field":"wikipedia"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","field":"links","label":"Wikipedia"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","field":"wikipedia"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Meningioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"links","label":"Wikipedia"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mercaptopurine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Merck_Group","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Merkel_cell_polyomavirus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mcpyv-status","kind":"term","name":"Merkel cell polyomavirus (MCPyV) status","route":"/terms/mcpyv-status/","field":"links","label":"Wikipedia"},{"id":"mcpyv-status","kind":"term","name":"Merkel cell polyomavirus (MCPyV) status","route":"/terms/mcpyv-status/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Merkel-cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Merrimack_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mertansine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dm1","kind":"term","name":"DM1","route":"/terms/dm1/","field":"links","label":"Wikipedia"},{"id":"dm1","kind":"term","name":"DM1","route":"/terms/dm1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mesna","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mesoblast","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesoblast","kind":"company","name":"Mesoblast","route":"/companies/mesoblast/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mesothelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","field":"links","label":"Wikipedia"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","field":"wikipedia"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","field":"prevalence.source"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","field":"prevalence.source"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Mesothelioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","field":"wikipedia"},{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","field":"links","label":"Wikipedia"},{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","field":"wikipedia"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/","field":"links","label":"Wikipedia"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260915074921/https://en.wikipedia.org/wiki/Mesothelioma"},{"url":"https://en.wikipedia.org/wiki/Metabolic_equivalent_of_task","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"met-hours","kind":"term","name":"MET-hours per week","route":"/terms/met-hours/","field":"links","label":"Wikipedia"},{"id":"met-hours","kind":"term","name":"MET-hours per week","route":"/terms/met-hours/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Metabolic_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/","field":"links","label":"Wikipedia"},{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Metaplastic_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Metastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/","field":"wikipedia"},{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","field":"wikipedia"},{"id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","field":"links","label":"Wikipedia"},{"id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","field":"wikipedia"},{"id":"pre-metastatic-niche","kind":"pathway","name":"The pre-metastatic niche","route":"/pathways/pre-metastatic-niche/","field":"wikipedia"},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260912231737/https://en.wikipedia.org/wiki/Metastasis"},{"url":"https://en.wikipedia.org/wiki/Methotrexate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Methyl_aminolevulinate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"Wikipedia"},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"wikipedia"},{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"links","label":"Wikipedia: methyl aminolevulinate (Galderma holds the Metvix rights)"}]},{"url":"https://en.wikipedia.org/wiki/Methylnaltrexone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Metronomic_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dose-dense-chemotherapy","kind":"term","name":"Dose-dense and metronomic chemotherapy","route":"/terms/dose-dense-chemotherapy/","field":"links","label":"Wikipedia"},{"id":"dose-dense-chemotherapy","kind":"term","name":"Dose-dense and metronomic chemotherapy","route":"/terms/dose-dense-chemotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Metyrapone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","field":"links","label":"Wikipedia"},{"id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Michael_A._Caligiuri","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Michael_Bloomberg","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Michael_Milken","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-milken","kind":"person","name":"Michael Milken","route":"/people/michael-milken/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Michelle_Monje","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Microbiome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Micrometastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"disseminated-tumor-cells","kind":"term","name":"Disseminated tumour cells (DTCs)","route":"/terms/disseminated-tumor-cells/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Microsatellite_instability","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/","field":"links","label":"Wikipedia"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/","field":"wikipedia"},{"id":"mss-pmmr","kind":"term","name":"Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)","route":"/terms/mss-pmmr/","field":"links","label":"Wikipedia"},{"id":"mss-pmmr","kind":"term","name":"Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)","route":"/terms/mss-pmmr/","field":"wikipedia"},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","field":"wikipedia"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"links","label":"Wikipedia"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"wikipedia"},{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","field":"links","label":"Wikipedia"},{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","field":"wikipedia"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"links","label":"Wikipedia"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Microwave_ablation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microwave-ablation","kind":"term","name":"Microwave ablation (MWA)","route":"/terms/microwave-ablation/","field":"links","label":"Wikipedia"},{"id":"microwave-ablation","kind":"term","name":"Microwave ablation (MWA)","route":"/terms/microwave-ablation/","field":"wikipedia"},{"id":"microwave-rf-ablation","kind":"technology","name":"Microwave and radiofrequency ablation systems","route":"/technologies/microwave-rf-ablation/","field":"links","label":"Wikipedia: microwave ablation"},{"id":"microwave-rf-ablation","kind":"technology","name":"Microwave and radiofrequency ablation systems","route":"/technologies/microwave-rf-ablation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Midostaurin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mifamurtide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mifepristone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mifepristone","kind":"drug","name":"Mifepristone","route":"/drugs/mifepristone/","field":"links","label":"Wikipedia"},{"id":"mifepristone","kind":"drug","name":"Mifepristone","route":"/drugs/mifepristone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Milan_criteria","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liver-transplant-oncology","kind":"technology","name":"Liver transplantation for cancer (Milan criteria and beyond)","route":"/technologies/liver-transplant-oncology/","field":"links","label":"Wikipedia"},{"id":"liver-transplant-oncology","kind":"technology","name":"Liver transplantation for cancer (Milan criteria and beyond)","route":"/technologies/liver-transplant-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Miltenyi_Biotec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mindfulness-based_stress_reduction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mindfulness-based-interventions","kind":"technology","name":"Mindfulness-based stress reduction and cognitive therapy","route":"/technologies/mindfulness-based-interventions/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mindray","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mindray","kind":"company","name":"Mindray","route":"/companies/mindray/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Minimal_residual_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/","field":"links","label":"Wikipedia"},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/","field":"wikipedia"},{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","field":"wikipedia"},{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","field":"wikipedia"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/","field":"links","label":"Wikipedia"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/","field":"wikipedia"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/","field":"links","label":"Wikipedia"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/","field":"wikipedia"},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/","field":"links","label":"Wikipedia"},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Minimally_invasive_procedure","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"minimally-invasive-surgery","kind":"term","name":"Minimally invasive surgery (laparoscopic, robotic, VATS)","route":"/terms/minimally-invasive-surgery/","field":"links","label":"Wikipedia"},{"id":"minimally-invasive-surgery","kind":"term","name":"Minimally invasive surgery (laparoscopic, robotic, VATS)","route":"/terms/minimally-invasive-surgery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Minoxidil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mirdametinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mirvetuximab_soravtansine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"wikipedia"},{"id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MIT_License","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"open-licences","kind":"term","name":"Open licences: Apache-2.0, MIT and CC BY 4.0","route":"/terms/open-licences/","field":"links","label":"Wikipedia: MIT License"}]},{"url":"https://en.wikipedia.org/wiki/Mitobronitol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitobronitol","kind":"drug","name":"Mitobronitol","route":"/drugs/mitobronitol/","field":"links","label":"Wikipedia"},{"id":"mitobronitol","kind":"drug","name":"Mitobronitol","route":"/drugs/mitobronitol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mitomycin_C","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mitotane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mitotic_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","field":"links","label":"Wikipedia"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mitoxantrone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mixed-phenotype_acute_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mixed-precision_arithmetic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mixed-precision-gpu","kind":"term","name":"GPU training and mixed precision","route":"/terms/mixed-precision-gpu/","field":"links","label":"Wikipedia"},{"id":"mixed-precision-gpu","kind":"term","name":"GPU training and mixed precision","route":"/terms/mixed-precision-gpu/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mobocertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/","field":"links","label":"Wikipedia"},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Model_organism","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"model-organism","kind":"term","name":"Model organism","route":"/terms/model-organism/","field":"links","label":"Wikipedia"},{"id":"model-organism","kind":"term","name":"Model organism","route":"/terms/model-organism/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Moderna","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mogamulizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mohs_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"links","label":"Wikipedia"},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Molecular_Partners","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Momelotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monoclonal_antibody","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monoclonal","kind":"term","name":"Monoclonal","route":"/terms/monoclonal/","field":"links","label":"Wikipedia"},{"id":"monoclonal","kind":"term","name":"Monoclonal","route":"/terms/monoclonal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monoclonal_antibody_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/","field":"links","label":"Wikipedia"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monoclonal_gammopathy_of_undetermined_significance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/","field":"links","label":"Wikipedia"},{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monomethyl_auristatin_E","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/","field":"links","label":"Wikipedia"},{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monomethyl_auristatin_F","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/","field":"links","label":"Wikipedia"},{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Monroe_Dunaway_Anderson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monroe-anderson","kind":"person","name":"Monroe Dunaway Anderson","route":"/people/monroe-anderson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Moran's_I","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spatial-autocorrelation","kind":"term","name":"Spatial autocorrelation (Moran's I)","route":"/terms/spatial-autocorrelation/","field":"links","label":"Wikipedia"},{"id":"spatial-autocorrelation","kind":"term","name":"Spatial autocorrelation (Moran's I)","route":"/terms/spatial-autocorrelation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mortality_rate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/","field":"links","label":"Wikipedia"},{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mortimer_Zuckerman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","route":"/people/mortimer-zuckerman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mosunetuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Motixafortide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","field":"links","label":"Wikipedia"},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Motol_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","field":"links","label":"Wikipedia"},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Moxetumomab_pasudotox","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","field":"links","label":"Wikipedia"},{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MRNA_vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MST1R","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MTOR","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mucinous_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"wikipedia"},{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","field":"wikipedia"},{"id":"mucinous-carcinoma-breast","kind":"cancer","name":"Mucinous carcinoma of the breast","route":"/cancers/mucinous-carcinoma-breast/","field":"wikipedia"},{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mucoepidermoid_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","field":"links","label":"Wikipedia"},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mucosal_melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"links","label":"Wikipedia"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"wikipedia"},{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mucositis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"links","label":"Wikipedia"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multi-task_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ablation-study","kind":"term","name":"Ablation study and multi-task heads","route":"/terms/ablation-study/","field":"links","label":"Wikipedia: multi-task learning"}]},{"url":"https://en.wikipedia.org/wiki/Multilayer_perceptron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ridge-regression","kind":"term","name":"Ridge regression and the multilayer perceptron","route":"/terms/ridge-regression/","field":"links","label":"Wikipedia: multilayer perceptron"}]},{"url":"https://en.wikipedia.org/wiki/Multimodal_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multimodal-fusion","kind":"term","name":"Multimodal fusion (early, late, modality dropout)","route":"/terms/multimodal-fusion/","field":"links","label":"Wikipedia"},{"id":"multimodal-fusion","kind":"term","name":"Multimodal fusion (early, late, modality dropout)","route":"/terms/multimodal-fusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia_type_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"men1-hereditary-net","kind":"term","name":"MEN1 and hereditary neuroendocrine syndromes","route":"/terms/men1-hereditary-net/","field":"links","label":"Wikipedia"},{"id":"men1-hereditary-net","kind":"term","name":"MEN1 and hereditary neuroendocrine syndromes","route":"/terms/men1-hereditary-net/","field":"wikipedia"},{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia_type_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_instance_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tile-patch-encoding","kind":"term","name":"Tile and patch encoding of slides","route":"/terms/tile-patch-encoding/","field":"links","label":"Wikipedia"},{"id":"tile-patch-encoding","kind":"term","name":"Tile and patch encoding of slides","route":"/terms/tile-patch-encoding/","field":"wikipedia"},{"id":"abmil","kind":"term","name":"Attention-based multiple-instance learning (ABMIL, CLAM)","route":"/terms/abmil/","field":"links","label":"Wikipedia"},{"id":"abmil","kind":"term","name":"Attention-based multiple-instance learning (ABMIL, CLAM)","route":"/terms/abmil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_myeloma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","field":"links","label":"Wikipedia"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","field":"wikipedia"},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","field":"wikipedia"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"links","label":"Wikipedia"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"wikipedia"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"links","label":"Wikipedia"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"wikipedia"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"links","label":"Wikipedia"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260913124307/https://en.wikipedia.org/wiki/Multiple_myeloma"},{"url":"https://en.wikipedia.org/wiki/Multiple_Myeloma_Research_Foundation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_myeloma#Staging","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Multiple_myeloma","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","field":"links","label":"Wikipedia"},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Multiple_myeloma","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/","field":"links","label":"Wikipedia"},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mundipharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Music_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"music-therapy-cancer","kind":"technology","name":"Music therapy and music medicine","route":"/technologies/music-therapy-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mutation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mutation","kind":"term","name":"Mutation","route":"/terms/mutation/","field":"links","label":"Wikipedia"},{"id":"mutation","kind":"term","name":"Mutation","route":"/terms/mutation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mutational_signatures","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/","field":"links","label":"Wikipedia"},{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/","field":"wikipedia"},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Mycosis_fungoides","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"links","label":"Wikipedia"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MYD88","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/","field":"links","label":"Wikipedia"},{"id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myelodysplastic_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","field":"wikipedia"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"links","label":"Wikipedia"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"wikipedia"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"links","label":"Wikipedia"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myelofibrosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"post-pv-myelofibrosis","kind":"term","name":"Post-PV myelofibrosis (spent phase)","route":"/terms/post-pv-myelofibrosis/","field":"links","label":"Wikipedia"},{"id":"post-pv-myelofibrosis","kind":"term","name":"Post-PV myelofibrosis (spent phase)","route":"/terms/post-pv-myelofibrosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myeloid-derived_suppressor_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","route":"/terms/myeloid-derived-suppressor-cells/","field":"links","label":"Wikipedia"},{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","route":"/terms/myeloid-derived-suppressor-cells/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myeloma_protein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/","field":"links","label":"Wikipedia"},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myeloproliferative_neoplasm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myelosuppression","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","field":"links","label":"Wikipedia"},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myocarditis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myocarditis","kind":"term","name":"Immune-related myocarditis","route":"/terms/myocarditis/","field":"links","label":"Wikipedia"},{"id":"myocarditis","kind":"term","name":"Immune-related myocarditis","route":"/terms/myocarditis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myriad_Genetics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/MyTomorrows","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Myxofibrosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myxofibrosarcoma","kind":"cancer","name":"Myxofibrosarcoma","route":"/cancers/myxofibrosarcoma/","field":"links","label":"Wikipedia"},{"id":"myxofibrosarcoma","kind":"cancer","name":"Myxofibrosarcoma","route":"/cancers/myxofibrosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/N_of_1_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"n-of-1-trial","kind":"term","name":"N-of-1 trial","route":"/terms/n-of-1-trial/","field":"links","label":"Wikipedia"},{"id":"n-of-1-trial","kind":"term","name":"N-of-1 trial","route":"/terms/n-of-1-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/N-Myc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","field":"links","label":"Wikipedia"},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","field":"wikipedia"},{"id":"mycn","kind":"target","name":"MYCN (N-myc)","route":"/targets/mycn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nabilone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","field":"links","label":"Wikipedia"},{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","field":"wikipedia"},{"id":"cannabinoids-nausea","kind":"technology","name":"Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)","route":"/technologies/cannabinoids-nausea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nadofaragene_firadenovec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nancy_Brinker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","field":"links","label":"Wikipedia"},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","field":"wikipedia"},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nancy_Lin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Naoto_Ueno","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","field":"wikipedia"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"links","label":"Wikipedia"},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","field":"wikipedia"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"links","label":"Wikipedia"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Natco_Pharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Natera","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Breast_Cancer_Coalition","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","field":"links","label":"National Breast Cancer Coalition (Wikipedia)"},{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","field":"profiles","label":"National Breast Cancer Coalition (Wikipedia)"}]},{"url":"https://en.wikipedia.org/wiki/National_Cancer_Centre_Singapore","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ncit","kind":"term","name":"NCI Thesaurus (NCIt)","route":"/terms/ncit/","field":"links","label":"Wikipedia: National Cancer Institute"}]},{"url":"https://en.wikipedia.org/wiki/National_Centre_for_Biological_Sciences","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Comprehensive_Cancer_Network","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nccn-compendium","kind":"term","name":"NCCN Compendium and drug compendia","route":"/terms/nccn-compendium/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Health_Authority","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunil-kumar-barnwal","kind":"person","name":"Sunil Kumar Barnwal","route":"/people/sunil-kumar-barnwal/","field":"links","label":"Source: Wikipedia article naming the CEO"},{"id":"sunil-kumar-barnwal","kind":"person","name":"Sunil Kumar Barnwal","route":"/people/sunil-kumar-barnwal/","field":"profiles","label":"Wikipedia article on the National Health Authority"}]},{"url":"https://en.wikipedia.org/wiki/National_Healthcare_Security_Administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","route":"/terms/china-vbp-nrdl/","field":"links","label":"Wikipedia"},{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","route":"/terms/china-vbp-nrdl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Institute_of_Neoplastic_Diseases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Medical_Products_Administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/","field":"links","label":"Wikipedia"},{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/National_Taiwan_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nationwide_Children's_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Natural_killer_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/","field":"links","label":"Wikipedia"},{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/","field":"wikipedia"},{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/","field":"links","label":"Wikipedia"},{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/","field":"wikipedia"},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/","field":"links","label":"Wikipedia"},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/","field":"wikipedia"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nature_(journal)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Naxitamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nearest_centroid_classifier","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"logistic-regression-term","kind":"term","name":"Logistic regression and nearest-centroid classifiers","route":"/terms/logistic-regression-term/","field":"links","label":"Wikipedia: nearest centroid classifier"}]},{"url":"https://en.wikipedia.org/wiki/Necitumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Necrosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"necrosis","kind":"term","name":"Necrosis","route":"/terms/necrosis/","field":"links","label":"Wikipedia"},{"id":"necrosis","kind":"term","name":"Necrosis","route":"/terms/necrosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nectin-4","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"links","label":"Wikipedia"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"wikipedia"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"prevalence.source"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Nedaplatin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/","field":"links","label":"Wikipedia"},{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Needle_aspiration_biopsy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"core-needle-biopsy","kind":"term","name":"Core needle biopsy and fine-needle aspiration (FNA)","route":"/terms/core-needle-biopsy/","field":"links","label":"Wikipedia"},{"id":"core-needle-biopsy","kind":"term","name":"Core needle biopsy and fine-needle aspiration (FNA)","route":"/terms/core-needle-biopsy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nektar_Therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","field":"links","label":"Wikipedia"},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nelarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neoadjuvant_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"wikipedia"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/","field":"links","label":"Wikipedia"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/","field":"wikipedia"},{"id":"downstaging","kind":"term","name":"Downstaging and conversion therapy","route":"/terms/downstaging/","field":"links","label":"Wikipedia"},{"id":"downstaging","kind":"term","name":"Downstaging and conversion therapy","route":"/terms/downstaging/","field":"wikipedia"},{"id":"window-of-opportunity-trial","kind":"term","name":"Window-of-opportunity trial","route":"/terms/window-of-opportunity-trial/","field":"links","label":"Wikipedia"},{"id":"window-of-opportunity-trial","kind":"term","name":"Window-of-opportunity trial","route":"/terms/window-of-opportunity-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neoantigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/","field":"links","label":"Wikipedia"},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/NeoGenomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nephrectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"partial-nephrectomy-active-surveillance","kind":"technology","name":"Partial nephrectomy, ablation & active surveillance of small renal masses","route":"/technologies/partial-nephrectomy-active-surveillance/","field":"links","label":"Wikipedia"},{"id":"partial-nephrectomy-active-surveillance","kind":"technology","name":"Partial nephrectomy, ablation & active surveillance of small renal masses","route":"/technologies/partial-nephrectomy-active-surveillance/","field":"wikipedia"},{"id":"nephrectomy","kind":"term","name":"Nephrectomy","route":"/terms/nephrectomy/","field":"links","label":"Wikipedia"},{"id":"nephrectomy","kind":"term","name":"Nephrectomy","route":"/terms/nephrectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neratinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Netupitant/palonosetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neuro-oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","field":"links","label":"Wikipedia"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","field":"wikipedia"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"links","label":"Wikipedia: Neuroblastoma"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"wikipedia"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"links","label":"Wikipedia: Neuroblastoma"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"wikipedia"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"links","label":"Wikipedia: Neuroblastoma"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260826065856/https://en.wikipedia.org/wiki/Neuroblastoma"},{"url":"https://en.wikipedia.org/wiki/Neuroblastoma#Staging","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Neuroblastoma","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/","field":"links","label":"Wikipedia"},{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neuroendocrine_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","field":"links","label":"Wikipedia"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","field":"wikipedia"},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","field":"links","label":"Wikipedia"},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","field":"wikipedia"},{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"wikipedia"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"wikipedia"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"links","label":"Wikipedia"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"wikipedia"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"links","label":"Wikipedia"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"wikipedia"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"links","label":"Wikipedia"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"wikipedia"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"links","label":"Wikipedia"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260822015219/https://en.wikipedia.org/wiki/Neuroendocrine_tumor"},{"url":"https://en.wikipedia.org/wiki/Neutron_capture_therapy_of_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bnct","kind":"technology","name":"Boron neutron capture therapy","route":"/technologies/bnct/","field":"links","label":"Wikipedia"},{"id":"bnct","kind":"technology","name":"Boron neutron capture therapy","route":"/technologies/bnct/","field":"wikipedia"},{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","field":"links","label":"Wikipedia: neutron capture therapy"},{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Neutropenia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Wikipedia"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nevoid_basal_cell_carcinoma_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/New_Drug_Application","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/","field":"links","label":"Wikipedia"},{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/NF-κB","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/NF-%CE%BAB","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/NFE2L2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1-NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nicotinamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicotinamide","kind":"drug","name":"Nicotinamide","route":"/drugs/nicotinamide/","field":"links","label":"Wikipedia"},{"id":"nicotinamide","kind":"drug","name":"Nicotinamide","route":"/drugs/nicotinamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nilotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nilutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nimorazole","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nimorazole","kind":"drug","name":"Nimorazole","route":"/drugs/nimorazole/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nimotuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/","field":"links","label":"Wikipedia"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nintedanib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","field":"links","label":"Wikipedia"},{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nippon_Kayaku","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","field":"links","label":"Wikipedia"},{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nirali_N._Shah","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Niraparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nirogacestat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nivolumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nivolumab/relatlimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nodular_lymphocyte_predominant_Hodgkin_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"links","label":"Wikipedia"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nogapendekin_alfa_inbakicept","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907114535/https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma"},{"url":"https://en.wikipedia.org/wiki/Non-inferiority_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","field":"links","label":"Wikipedia"},{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","field":"wikipedia"},{"id":"non-inferiority","kind":"term","name":"Non-inferiority trial","route":"/terms/non-inferiority/","field":"links","label":"Wikipedia"},{"id":"non-inferiority","kind":"term","name":"Non-inferiority trial","route":"/terms/non-inferiority/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Wikipedia"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260911160703/https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer"},{"url":"https://en.wikipedia.org/wiki/North_Estonia_Medical_Centre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","field":"links","label":"Wikipedia"},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Northwest_Biotherapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260106074252/https://en.wikipedia.org/wiki/Northwest_Biotherapeutics"},{"url":"https://en.wikipedia.org/wiki/Notch_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nottingham_Prognostic_Index","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nottingham-prognostic-index","kind":"term","name":"Nottingham Prognostic Index (NPI), and PREDICT","route":"/terms/nottingham-prognostic-index/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Novartis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/","field":"links","label":"Wikipedia"},{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/","field":"wikipedia"},{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","field":"links","label":"Novartis v Union of India (2013)"}]},{"url":"https://en.wikipedia.org/wiki/Nucleophosmin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","field":"links","label":"Wikipedia"},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","field":"wikipedia"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"links","label":"Wikipedia: Nucleophosmin"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Null_result","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reproducibility","kind":"term","name":"Reproducibility and negative results","route":"/terms/reproducibility/","field":"links","label":"Wikipedia: null result"}]},{"url":"https://en.wikipedia.org/wiki/Number_needed_to_treat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/","field":"links","label":"Wikipedia"},{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/NUT_midline_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Nvidia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/O-6-methylguanine-DNA_methyltransferase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","field":"links","label":"Wikipedia"},{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","field":"wikipedia"},{"id":"mgmt-protein","kind":"target","name":"MGMT (O6-methylguanine-DNA methyltransferase)","route":"/targets/mgmt-protein/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260823124443/https://en.wikipedia.org/wiki/O-6-methylguanine-DNA_methyltransferase"},{"url":"https://en.wikipedia.org/wiki/Obesity_and_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/OBI_Pharma,_Inc.","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Obinutuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Observational_Health_Data_Sciences_and_Informatics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omop-ohdsi","kind":"term","name":"OMOP common data model and OHDSI","route":"/terms/omop-ohdsi/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Octreotide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Odense_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","field":"links","label":"Wikipedia"},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ofatumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ofatumumab","kind":"drug","name":"Ofatumumab","route":"/drugs/ofatumumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Off-label_use","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/","field":"links","label":"Wikipedia"},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olaparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olaratumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olaratumab","kind":"drug","name":"Olaratumab","route":"/drugs/olaratumab/","field":"links","label":"Wikipedia"},{"id":"olaratumab","kind":"drug","name":"Olaratumab","route":"/drugs/olaratumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oligodendroglioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"links","label":"Wikipedia"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oliver_Sartor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olmutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/","field":"links","label":"Wikipedia"},{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olutasidenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olverembatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Olympus_Corporation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olympus","kind":"company","name":"Olympus","route":"/companies/olympus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Omnicell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/OncoDNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncofertility","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncogene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","field":"links","label":"Wikipedia"},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncogene_addiction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/","field":"links","label":"Wikipedia"},{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncology_Drug_Advisory_Committee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"odac","kind":"term","name":"ODAC (Oncologic Drugs Advisory Committee)","route":"/terms/odac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncology_nursing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncolytic_virus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","field":"links","label":"Wikipedia"},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncolytics_Biotech","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncotherm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oncovirus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ondansetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ontario_Institute_for_Cancer_Research","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ontology_(information_science)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mondo","kind":"term","name":"Mondo disease ontology","route":"/terms/mondo/","field":"links","label":"Wikipedia: ontology (information science)"},{"id":"units-ontology","kind":"term","name":"Units of measurement ontology (UO)","route":"/terms/units-ontology/","field":"links","label":"Wikipedia: ontology (information science)"}]},{"url":"https://en.wikipedia.org/wiki/Open-source_artificial_intelligence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"open-weights","kind":"term","name":"Open weights, open code and gated models","route":"/terms/open-weights/","field":"links","label":"Wikipedia"},{"id":"open-weights","kind":"term","name":"Open weights, open code and gated models","route":"/terms/open-weights/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oprelvekin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/","field":"links","label":"Wikipedia"},{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Optic_nerve_glioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oral_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-cavity-cancer","kind":"cancer","name":"Oral cavity cancer (mouth and tongue)","route":"/cancers/oral-cavity-cancer/","field":"links","label":"Wikipedia"},{"id":"oral-cavity-cancer","kind":"cancer","name":"Oral cavity cancer (mouth and tongue)","route":"/cancers/oral-cavity-cancer/","field":"wikipedia"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"links","label":"Wikipedia"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"wikipedia"},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","field":"links","label":"Wikipedia"},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oral_mucositis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-cryotherapy-mucositis","kind":"technology","name":"Oral cryotherapy (ice chips) to prevent mucositis","route":"/technologies/oral-cryotherapy-mucositis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/OrbiMed","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Orchiectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orchiectomy","kind":"term","name":"Orchiectomy","route":"/terms/orchiectomy/","field":"links","label":"Wikipedia"},{"id":"orchiectomy","kind":"term","name":"Orchiectomy","route":"/terms/orchiectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Örebro_University_Hospital","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/%C3%96rebro_University_Hospital","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Orelabrutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Organ-on-a-chip","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-on-chip","kind":"technology","name":"Tumour-on-a-chip","route":"/technologies/tumour-on-chip/","field":"links","label":"Wikipedia"},{"id":"tumour-on-chip","kind":"technology","name":"Tumour-on-a-chip","route":"/technologies/tumour-on-chip/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Organoid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/","field":"links","label":"Wikipedia"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/","field":"wikipedia"},{"id":"organoid","kind":"term","name":"Organoid","route":"/terms/organoid/","field":"links","label":"Wikipedia"},{"id":"organoid","kind":"term","name":"Organoid","route":"/terms/organoid/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oropharyngeal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","field":"links","label":"Wikipedia"},{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Orphan_drug","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orphan-drug","kind":"term","name":"Orphan drug","route":"/terms/orphan-drug/","field":"links","label":"Wikipedia"},{"id":"orphan-drug","kind":"term","name":"Orphan drug","route":"/terms/orphan-drug/","field":"wikipedia"},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/","field":"links","label":"Wikipedia"},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Orphan_Drug_Act_of_1983","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","field":"links","label":"Wikipedia"},{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Orthovoltage_X-rays","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"superficial-radiotherapy","kind":"technology","name":"Superficial and orthovoltage radiotherapy for skin cancer","route":"/technologies/superficial-radiotherapy/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Osaka_International_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Osilodrostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/","field":"links","label":"Wikipedia"},{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Osimertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","field":"wikipedia"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Osteosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ostomy_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oulu_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","field":"links","label":"Wikipedia"},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ovarian_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"links","label":"Wikipedia"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"wikipedia"},{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","field":"wikipedia"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/","field":"wikipedia"},{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","field":"wikipedia"},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/","field":"wikipedia"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","field":"wikipedia"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","field":"links","label":"Wikipedia"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907063646/https://en.wikipedia.org/wiki/Ovarian_cancer"},{"url":"https://en.wikipedia.org/wiki/Overdiagnosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"overdiagnosis","kind":"term","name":"Overdiagnosis","route":"/terms/overdiagnosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oxaliplatin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Oxygen_enhancement_ratio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oxygen-enhancement-ratio","kind":"term","name":"Oxygen enhancement ratio","route":"/terms/oxygen-enhancement-ratio/","field":"links","label":"Wikipedia"},{"id":"oxygen-enhancement-ratio","kind":"term","name":"Oxygen enhancement ratio","route":"/terms/oxygen-enhancement-ratio/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/P-glycoprotein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","field":"links","label":"Wikipedia"},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","field":"wikipedia"},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/P-value","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p-value","kind":"term","name":"P-value","route":"/terms/p-value/","field":"links","label":"Wikipedia"},{"id":"p-value","kind":"term","name":"P-value","route":"/terms/p-value/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/P110α","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/P110%CE%B1","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"links","label":"Wikipedia"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/P53","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"links","label":"Wikipedia"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"wikipedia"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"tp53-mutated","kind":"term","name":"TP53-mutated (p53-abnormal)","route":"/terms/tp53-mutated/","field":"links","label":"Wikipedia"},{"id":"tp53-mutated","kind":"term","name":"TP53-mutated (p53-abnormal)","route":"/terms/tp53-mutated/","field":"wikipedia"},{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pack-year","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Paclitaxel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pacritinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Padeliporfin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Padmanee_Sharma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pafolacianine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Paget%27s_disease_of_the_breast","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paget-disease-of-the-nipple","kind":"cancer","name":"Paget disease of the nipple","route":"/cancers/paget-disease-of-the-nipple/","field":"links","label":"Wikipedia"},{"id":"paget-disease-of-the-nipple","kind":"cancer","name":"Paget disease of the nipple","route":"/cancers/paget-disease-of-the-nipple/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Palbociclib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Palifermin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Palliative_care","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"wikipedia"},{"id":"palliative-treatment","kind":"term","name":"Palliative","route":"/terms/palliative-treatment/","field":"links","label":"Wikipedia"},{"id":"palliative-treatment","kind":"term","name":"Palliative","route":"/terms/palliative-treatment/","field":"wikipedia"},{"id":"curative-intent","kind":"term","name":"Curative intent vs palliative intent","route":"/terms/curative-intent/","field":"links","label":"Wikipedia"},{"id":"curative-intent","kind":"term","name":"Curative intent vs palliative intent","route":"/terms/curative-intent/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Palonosetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pamidronic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancoast_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancoast-tumour","kind":"term","name":"Pancoast (superior sulcus) tumour","route":"/terms/pancoast-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatic_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Wikipedia"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"wikipedia"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"wikipedia"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"wikipedia"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"wikipedia"},{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","field":"wikipedia"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"links","label":"Wikipedia"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"wikipedia"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"links","label":"Wikipedia"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"wikipedia"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"links","label":"Wikipedia"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"wikipedia"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"links","label":"Wikipedia"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"wikipedia"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"links","label":"Wikipedia"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260909034509/https://en.wikipedia.org/wiki/Pancreatic_cancer"},{"url":"https://en.wikipedia.org/wiki/Pancreatic_enzymes_(medication)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatic_intraepithelial_neoplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatic_mucinous_cystic_neoplasm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatic_neuroendocrine_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"links","label":"Wikipedia"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreaticoduodenectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","field":"wikipedia"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Wikipedia"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancreatoblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"links","label":"Wikipedia"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pancrelipase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Panitumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Panobinostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/","field":"links","label":"Wikipedia"},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Papillary_renal_cell_carcinomas","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/","field":"links","label":"Wikipedia"},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Papillary_thyroid_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"papillary-thyroid-cancer","kind":"cancer","name":"Papillary thyroid cancer","route":"/cancers/papillary-thyroid-cancer/","field":"links","label":"Wikipedia"},{"id":"papillary-thyroid-cancer","kind":"cancer","name":"Papillary thyroid cancer","route":"/cancers/papillary-thyroid-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Paraganglioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"links","label":"Wikipedia"},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Parathyroid_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Parenteral_nutrition","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Parker_Institute_for_Cancer_Immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PARP_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/","field":"links","label":"Wikipedia"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/","field":"wikipedia"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"links","label":"Wikipedia"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"wikipedia"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"prevalence.source"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Particle_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carbon-ion-synchrotrons","kind":"technology","name":"Carbon-ion synchrotrons and facilities","route":"/technologies/carbon-ion-synchrotrons/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pasireotide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","field":"links","label":"Wikipedia"},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pasteur_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","route":"/people/yasmine-belkaid/","field":"links","label":"Source: Wikipedia, Pasteur Institute (director-general listing)"},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Patient_derived_xenograft","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/","field":"links","label":"Wikipedia"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Patient-reported_outcome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","field":"wikipedia"},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/","field":"links","label":"Wikipedia"},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Patrick_Sch%C3%B6ffski","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Paul_Workman_(pharmacologist)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pauls_Stradi%C5%86%C5%A1_Clinical_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pauls_Stradiņš_Clinical_University_Hospital","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Pauls_Stradi%C5%86%C5%A1_Clinical_University_Hospital","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pazopanib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PD-L1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","field":"wikipedia"},{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"wikipedia"},{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","field":"wikipedia"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"links","label":"Wikipedia"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"wikipedia"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","field":"prevalence.source"},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","field":"links","label":"Wikipedia"},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","field":"wikipedia"},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/","field":"links","label":"Wikipedia"},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/","field":"wikipedia"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"links","label":"Wikipedia"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260906011039/https://en.wikipedia.org/wiki/PD-L1"},{"url":"https://en.wikipedia.org/wiki/PDGFRA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PDGFRB","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pdgfrb","kind":"target","name":"PDGFRB","route":"/targets/pdgfrb/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pegfilgrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peginterferon_alfa-2b","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","field":"links","label":"Wikipedia"},{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pegulicianine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pegvisomant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/","field":"links","label":"Wikipedia"},{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peking_Union_Medical_College_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peking_University_People's_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pemetrexed","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pemigatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Penile_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"wikipedia"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"links","label":"Wikipedia"},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","field":"wikipedia"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"links","label":"Wikipedia"},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Penpulimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pentostatin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pentostatin","kind":"drug","name":"Pentostatin","route":"/drugs/pentostatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/People's_Liberation_Army_General_Hospital_and_Medical_School","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","field":"links","label":"Wikipedia"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","field":"wikipedia"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","field":"links","label":"Wikipedia"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Perceiver","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transformer-architecture","kind":"term","name":"Transformer and attention","route":"/terms/transformer-architecture/","field":"links","label":"Wikipedia: Perceiver"}]},{"url":"https://en.wikipedia.org/wiki/Perceptive_Advisors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Percutaneous_endoscopic_gastrostomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"feeding-tube","kind":"term","name":"Feeding tube (gastrostomy, PEG, jejunostomy)","route":"/terms/feeding-tube/","field":"links","label":"Wikipedia"},{"id":"feeding-tube","kind":"term","name":"Feeding tube (gastrostomy, PEG, jejunostomy)","route":"/terms/feeding-tube/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Performance_status","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","field":"links","label":"Wikipedia"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Perineural_invasion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","field":"links","label":"Wikipedia"},{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peritoneal_carcinomatosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","field":"links","label":"Wikipedia"},{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","field":"wikipedia"},{"id":"colorectal-peritoneal-metastases","kind":"term","name":"Peritoneal metastases from bowel cancer","route":"/terms/colorectal-peritoneal-metastases/","field":"wikipedia"},{"id":"peritoneal-carcinomatosis-index","kind":"term","name":"Peritoneal cancer index","route":"/terms/peritoneal-carcinomatosis-index/","field":"wikipedia"},{"id":"peritoneum","kind":"term","name":"Peritoneum and peritoneal metastases","route":"/terms/peritoneum/","field":"links","label":"Wikipedia"},{"id":"peritoneum","kind":"term","name":"Peritoneum and peritoneal metastases","route":"/terms/peritoneum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peritoneal_mesothelioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/","field":"links","label":"Wikipedia"},{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Perivascular_epithelioid_cell_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/","field":"links","label":"Wikipedia"},{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Permutation_test","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"permutation-test","kind":"term","name":"Permutation test and the Mann-Whitney U test","route":"/terms/permutation-test/","field":"links","label":"Wikipedia"},{"id":"permutation-test","kind":"term","name":"Permutation test and the Mann-Whitney U test","route":"/terms/permutation-test/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Persister_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Personal_Information_Protection_Law_of_the_People%27s_Republic_of_China","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pipl","kind":"term","name":"PIPL (China Personal Information Protection Law 2021)","route":"/terms/pipl/","field":"links","label":"Wikipedia"},{"id":"pipl","kind":"term","name":"PIPL (China Personal Information Protection Law 2021)","route":"/terms/pipl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Personalized_medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","route":"/terms/cancer-drivers-vs-actionable/","field":"links","label":"Wikipedia"},{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","route":"/terms/cancer-drivers-vs-actionable/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pertuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","field":"wikipedia"},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PET-CT","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","field":"links","label":"Wikipedia"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PET-MRI","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","field":"links","label":"Wikipedia"},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Peter_MacCallum_Cancer_Centre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pevonedistat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pevonedistat","kind":"drug","name":"Pevonedistat","route":"/drugs/pevonedistat/","field":"links","label":"Wikipedia"},{"id":"pevonedistat","kind":"drug","name":"Pevonedistat","route":"/drugs/pevonedistat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pexidartinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pharmacogenomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-pharmacogenomics","kind":"technology","name":"Pharmacogenomic testing before chemotherapy","route":"/technologies/oncology-pharmacogenomics/","field":"links","label":"Wikipedia"},{"id":"oncology-pharmacogenomics","kind":"technology","name":"Pharmacogenomic testing before chemotherapy","route":"/technologies/oncology-pharmacogenomics/","field":"wikipedia"},{"id":"pharmacogenomics-term","kind":"term","name":"Pharmacogenomics","route":"/terms/pharmacogenomics-term/","field":"links","label":"Wikipedia"},{"id":"pharmacogenomics-term","kind":"term","name":"Pharmacogenomics","route":"/terms/pharmacogenomics-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pharmacokinetics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","field":"links","label":"Wikipedia"},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","field":"wikipedia"},{"id":"pkpd-modelling","kind":"technology","name":"Pharmacokinetic and pharmacodynamic modelling","route":"/technologies/pkpd-modelling/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phase_I_clinical_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/","field":"links","label":"Wikipedia"},{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/","field":"wikipedia"},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/","field":"links","label":"Wikipedia"},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phase_I_clinical_trial#Dose_escalation","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Phase_I_clinical_trial","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/","field":"links","label":"Wikipedia"},{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phases_of_clinical_research","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/","field":"links","label":"Wikipedia"},{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/","field":"wikipedia"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/","field":"links","label":"Wikipedia"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pheochromocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"wikipedia"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"links","label":"Wikipedia"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phil_Knight","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phil-knight","kind":"person","name":"Phil Knight","route":"/people/phil-knight/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Philadelphia_chromosome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","field":"links","label":"Wikipedia"},{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","field":"wikipedia"},{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","field":"wikipedia"},{"id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","field":"links","label":"Wikipedia"},{"id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","field":"wikipedia"},{"id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","field":"links","label":"Wikipedia"},{"id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","field":"wikipedia"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"links","label":"Wikipedia: Philadelphia chromosome"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Philippine_General_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phosphoproteomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pathway-activation-state","kind":"term","name":"Pathway activation state (phosphosignalling)","route":"/terms/pathway-activation-state/","field":"links","label":"Wikipedia"},{"id":"pathway-activation-state","kind":"term","name":"Pathway activation state (phosphosignalling)","route":"/terms/pathway-activation-state/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phosphorus-32","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","field":"links","label":"Wikipedia"},{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Photocure","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Photodynamic_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Photoimmunotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/","field":"links","label":"Wikipedia"},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Photon-counting_computed_tomography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/","field":"links","label":"Wikipedia"},{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Phyllodes_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phyllodes-tumour","kind":"cancer","name":"Phyllodes tumour of the breast","route":"/cancers/phyllodes-tumour/","field":"links","label":"Wikipedia"},{"id":"phyllodes-tumour","kind":"cancer","name":"Phyllodes tumour of the breast","route":"/cancers/phyllodes-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Physics_of_magnetic_resonance_imaging","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/","field":"links","label":"Wikipedia: physics of MRI"},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PI-RADS","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","route":"/technologies/mp-mri/","field":"links","label":"Wikipedia"},{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","route":"/technologies/mp-mri/","field":"wikipedia"},{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260101100042/https://en.wikipedia.org/wiki/PI-RADS"},{"url":"https://en.wikipedia.org/wiki/PI3K/AKT/mTOR_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/","field":"links","label":"Wikipedia"},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/","field":"wikipedia"},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/","field":"links","label":"Wikipedia"},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Piflufolastat_F-18","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PIK3CD","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pilocarpine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pilocarpine","kind":"drug","name":"Pilocarpine","route":"/drugs/pilocarpine/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pilocytic_astrocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pineoblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pineocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pineal-parenchymal-tumours","kind":"cancer","name":"Pineocytoma and pineal parenchymal tumour of intermediate differentiation","route":"/cancers/pineal-parenchymal-tumours/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pipobroman","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","field":"links","label":"Wikipedia"},{"id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pirarubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pirarubicin","kind":"drug","name":"Pirarubicin","route":"/drugs/pirarubicin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pirtobrutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pituitary_adenoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"wikipedia"},{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pivekimab_sunirine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pixantrone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","field":"links","label":"Wikipedia"},{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Placebo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/","field":"links","label":"Wikipedia"},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Placental_site_trophoblastic_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"links","label":"Wikipedia"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Plasma_cell_leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"links","label":"Wikipedia"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Platinum-based_antineoplastic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/","field":"links","label":"Wikipedia"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/","field":"wikipedia"},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","field":"links","label":"Wikipedia"},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Plerixafor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pleural_effusion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"malignant-pleural-effusion","kind":"term","name":"Malignant pleural effusion","route":"/terms/malignant-pleural-effusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pleurectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleurectomy-decortication","kind":"technology","name":"Extended pleurectomy/decortication & radical mesothelioma surgery","route":"/technologies/pleurectomy-decortication/","field":"links","label":"Wikipedia"},{"id":"pleurectomy-decortication","kind":"technology","name":"Extended pleurectomy/decortication & radical mesothelioma surgery","route":"/technologies/pleurectomy-decortication/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pleurodesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","field":"links","label":"Wikipedia"},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","field":"wikipedia"},{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pleuropulmonary_blastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"wikipedia"},{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Plicamycin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","field":"links","label":"Wikipedia"},{"id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Plitidepsin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/","field":"links","label":"Wikipedia"},{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pneumonectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pneumonectomy","kind":"term","name":"Pneumonectomy","route":"/terms/pneumonectomy/","field":"links","label":"Wikipedia"},{"id":"pneumonectomy","kind":"term","name":"Pneumonectomy","route":"/terms/pneumonectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pneumonitis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polaris_Partners","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polatuzumab_vedotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/POLE_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pole-ultramutation","kind":"term","name":"POLE ultramutation (POLEmut)","route":"/terms/pole-ultramutation/","field":"links","label":"Wikipedia"},{"id":"pole-ultramutation","kind":"term","name":"POLE ultramutation (POLEmut)","route":"/terms/pole-ultramutation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Policlinico_San_Matteo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","field":"links","label":"Wikipedia"},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polycythemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erythrocytosis","kind":"term","name":"Erythrocytosis (primary vs secondary)","route":"/terms/erythrocytosis/","field":"links","label":"Wikipedia"},{"id":"erythrocytosis","kind":"term","name":"Erythrocytosis (primary vs secondary)","route":"/terms/erythrocytosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polycythemia_vera","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","field":"links","label":"Wikipedia"},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polygenic_score","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","field":"wikipedia"},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polyploidy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"whole-genome-doubling","kind":"term","name":"Whole-genome doubling (WGD)","route":"/terms/whole-genome-doubling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Polysaccharide-K","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pomalidomide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ponatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pooling_layer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embedding","kind":"term","name":"Embedding (learned representation)","route":"/terms/embedding/","field":"links","label":"Wikipedia: pooling layer"}]},{"url":"https://en.wikipedia.org/wiki/Porcelain_gallbladder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Porfimer_sodium","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","field":"links","label":"Wikipedia"},{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Port_(medical)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/","field":"links","label":"Wikipedia"},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Portal_vein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"portal-vein-tumour-thrombus","kind":"term","name":"Portal vein tumour thrombus (macrovascular invasion)","route":"/terms/portal-vein-tumour-thrombus/","field":"links","label":"Wikipedia"},{"id":"portal-vein-tumour-thrombus","kind":"term","name":"Portal vein tumour thrombus (macrovascular invasion)","route":"/terms/portal-vein-tumour-thrombus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Positive_and_negative_predictive_values","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/","field":"links","label":"Wikipedia"},{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Positron_emission_tomography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","field":"links","label":"Wikipedia"},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Post-transcriptional_regulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"post-transcriptional-regulation-term","kind":"term","name":"Post-transcriptional and post-translational regulation","route":"/terms/post-transcriptional-regulation-term/","field":"links","label":"Wikipedia"},{"id":"post-transcriptional-regulation-term","kind":"term","name":"Post-transcriptional and post-translational regulation","route":"/terms/post-transcriptional-regulation-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PostgreSQL","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duckdb-catalog","kind":"term","name":"Analytical databases as a data catalogue (DuckDB, PostgreSQL)","route":"/terms/duckdb-catalog/","field":"links","label":"Wikipedia: PostgreSQL"}]},{"url":"https://en.wikipedia.org/wiki/Poziotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/","field":"links","label":"Wikipedia"},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pragmatic_clinical_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/","field":"links","label":"Wikipedia"},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pralatrexate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pralsetinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251222061727/https://en.wikipedia.org/wiki/Pralsetinib"},{"url":"https://en.wikipedia.org/wiki/PRAME","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","field":"links","label":"Wikipedia"},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pre-clinical_development","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/","field":"links","label":"Wikipedia"},{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Precision_and_recall","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roc-auc","kind":"term","name":"ROC-AUC, PR-AUC and time-dependent AUC","route":"/terms/roc-auc/","field":"links","label":"Wikipedia: precision and recall"}]},{"url":"https://en.wikipedia.org/wiki/Precision_medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/","field":"links","label":"Wikipedia"},{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prednisone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prehabilitation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"wikipedia"},{"id":"prehabilitation-term","kind":"term","name":"Prehabilitation (the pre-treatment window)","route":"/terms/prehabilitation-term/","field":"links","label":"Wikipedia"},{"id":"prehabilitation-term","kind":"term","name":"Prehabilitation (the pre-treatment window)","route":"/terms/prehabilitation-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Preregistration_(science)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prespecified-vs-post-hoc","kind":"term","name":"Pre-specified vs post-hoc analysis","route":"/terms/prespecified-vs-post-hoc/","field":"links","label":"Wikipedia"},{"id":"prespecified-vs-post-hoc","kind":"term","name":"Pre-specified vs post-hoc analysis","route":"/terms/prespecified-vs-post-hoc/","field":"wikipedia"},{"id":"pre-registered-experiment","kind":"term","name":"Pre-registered experiment","route":"/terms/pre-registered-experiment/","field":"links","label":"Wikipedia"},{"id":"pre-registered-experiment","kind":"term","name":"Pre-registered experiment","route":"/terms/pre-registered-experiment/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prescription_drug_prices_in_the_United_States","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/","field":"links","label":"Wikipedia"},{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_central_nervous_system_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_cutaneous_follicle_center_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_cutaneous_marginal_zone_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_mediastinal_B-cell_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"links","label":"Wikipedia"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_myelofibrosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"links","label":"Wikipedia"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Primary_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","field":"links","label":"Wikipedia"},{"id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Princess_Chulabhorn","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","route":"/people/princess-chulabhorn/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Princess_Margaret_Cancer_Centre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Principal_component_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pca","kind":"term","name":"Principal component analysis (PCA) as a feature compressor","route":"/terms/pca/","field":"links","label":"Wikipedia"},{"id":"pca","kind":"term","name":"Principal component analysis (PCA) as a feature compressor","route":"/terms/pca/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Priscilla_Chan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PRMT5","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Probiotic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/","field":"wikipedia"},{"id":"probiotics-treatment-diarrhoea","kind":"technology","name":"Probiotics for chemotherapy and radiotherapy diarrhoea","route":"/technologies/probiotics-treatment-diarrhoea/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Procarbazine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prodrug","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prodrug","kind":"term","name":"Prodrug","route":"/terms/prodrug/","field":"links","label":"Wikipedia"},{"id":"prodrug","kind":"term","name":"Prodrug","route":"/terms/prodrug/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Progesterone_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prognosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prognosis","kind":"term","name":"Prognosis","route":"/terms/prognosis/","field":"links","label":"Wikipedia"},{"id":"prognosis","kind":"term","name":"Prognosis","route":"/terms/prognosis/","field":"wikipedia"},{"id":"prognosis-risk-percentile","kind":"term","name":"Risk score and risk percentile","route":"/terms/prognosis-risk-percentile/","field":"links","label":"Wikipedia"},{"id":"prognosis-risk-percentile","kind":"term","name":"Risk score and risk percentile","route":"/terms/prognosis-risk-percentile/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Programmed_cell_death_protein_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","field":"links","label":"Wikipedia"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","field":"wikipedia"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","field":"prevalence.source"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Progression-free_survival","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/","field":"links","label":"Wikipedia"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/","field":"wikipedia"},{"id":"ttp","kind":"term","name":"Time to progression (TTP) and time to next treatment (TTNT)","route":"/terms/ttp/","field":"links","label":"Wikipedia"},{"id":"ttp","kind":"term","name":"Time to progression (TTP) and time to next treatment (TTNT)","route":"/terms/ttp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Progressive_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/","field":"links","label":"Wikipedia"},{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prolactinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lactotroph-pitnet","kind":"cancer","name":"Lactotroph pituitary neuroendocrine tumour (prolactinoma)","route":"/cancers/lactotroph-pitnet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prophylactic_cranial_irradiation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/","field":"links","label":"Wikipedia"},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/","field":"wikipedia"},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/","field":"links","label":"Wikipedia"},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prophylactic_mastectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proportional_hazards_model","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-covariates","kind":"term","name":"Clinical covariates (age, stage, nodes, treatment flags)","route":"/terms/clinical-covariates/","field":"links","label":"Wikipedia"},{"id":"clinical-covariates","kind":"term","name":"Clinical covariates (age, stage, nodes, treatment flags)","route":"/terms/clinical-covariates/","field":"wikipedia"},{"id":"time-dependent-auc","kind":"term","name":"Univariate Cox scores and time-dependent metrics","route":"/terms/time-dependent-auc/","field":"links","label":"Wikipedia"},{"id":"time-dependent-auc","kind":"term","name":"Univariate Cox scores and time-dependent metrics","route":"/terms/time-dependent-auc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Propranolol","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostaglandin-endoperoxide_synthase_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate_biopsy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"template-mapping-biopsy","kind":"term","name":"Template mapping biopsy (transperineal template prostate mapping)","route":"/terms/template-mapping-biopsy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Wikipedia"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"wikipedia"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"wikipedia"},{"id":"prostate-acinar-adenocarcinoma","kind":"term","name":"Acinar adenocarcinoma of the prostate","route":"/terms/prostate-acinar-adenocarcinoma/","field":"wikipedia"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"links","label":"Wikipedia"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"links","label":"Wikipedia"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902174526/https://en.wikipedia.org/wiki/Prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer_screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer_staging","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cambridge-prognostic-group","kind":"term","name":"Cambridge Prognostic Group (CPG 1 to 5)","route":"/terms/cambridge-prognostic-group/","field":"wikipedia"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","field":"wikipedia"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"links","label":"Wikipedia"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"wikipedia"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"links","label":"Wikipedia"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Prostate_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","field":"links","label":"Wikipedia"},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer#Metastatic_disease","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Prostate_cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostate-specific_antigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","field":"links","label":"Wikipedia"},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","field":"wikipedia"},{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260904181656/https://en.wikipedia.org/wiki/Prostate-specific_antigen"},{"url":"https://en.wikipedia.org/wiki/Prostatectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","field":"links","label":"Wikipedia"},{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Prostatic_acid_phosphatase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proteasome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/","field":"wikipedia"},{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proteasome_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/","field":"links","label":"Wikipedia"},{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"protein","kind":"term","name":"Protein","route":"/terms/protein/","field":"links","label":"Wikipedia"},{"id":"protein","kind":"term","name":"Protein","route":"/terms/protein/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein_A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein_kinase_B","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","field":"links","label":"Wikipedia"},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein_kinase_C","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein_phosphorylation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phosphorylation","kind":"term","name":"Phosphorylation","route":"/terms/phosphorylation/","field":"links","label":"Wikipedia"},{"id":"phosphorylation","kind":"term","name":"Phosphorylation","route":"/terms/phosphorylation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Protein-bound_paclitaxel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proteogenomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mrna-protein-concordance","kind":"term","name":"mRNA to protein concordance","route":"/terms/mrna-protein-concordance/","field":"links","label":"Wikipedia"},{"id":"mrna-protein-concordance","kind":"term","name":"mRNA to protein concordance","route":"/terms/mrna-protein-concordance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proteolysis_targeting_chimera","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","field":"links","label":"Wikipedia"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proteomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/","field":"links","label":"Wikipedia"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proto-oncogene_tyrosine-protein_kinase_Src","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src","kind":"target","name":"SRC family kinases","route":"/targets/src/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Proton_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","field":"links","label":"Wikipedia"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","field":"wikipedia"},{"id":"intensity-modulated-proton-therapy","kind":"technology","name":"Pencil-beam scanning and intensity-modulated proton therapy","route":"/technologies/intensity-modulated-proton-therapy/","field":"links","label":"Wikipedia"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/","field":"links","label":"Wikipedia"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Providence_Health_%26_Services","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pseudomyxoma_peritonei","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","field":"wikipedia"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"links","label":"Wikipedia"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Psycho-oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PTEN_(gene)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pten-loss","kind":"term","name":"PTEN loss","route":"/terms/pten-loss/","field":"links","label":"Wikipedia"},{"id":"pten-loss","kind":"term","name":"PTEN loss","route":"/terms/pten-loss/","field":"wikipedia"},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/PTK6","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Publication_bias","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","field":"links","label":"Wikipedia"},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pulmonary_blastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pulmonary-blastoma","kind":"cancer","name":"Pulmonary blastoma (adult)","route":"/cancers/pulmonary-blastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pulmonary_pleurae","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleura","kind":"term","name":"Pleura","route":"/terms/pleura/","field":"links","label":"Wikipedia"},{"id":"pleura","kind":"term","name":"Pleura","route":"/terms/pleura/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Pyrrolobenzodiazepine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pbd-sg3199","kind":"term","name":"PBD dimer (SG3199 / tesirine)","route":"/terms/pbd-sg3199/","field":"links","label":"Wikipedia"},{"id":"pbd-sg3199","kind":"term","name":"PBD dimer (SG3199 / tesirine)","route":"/terms/pbd-sg3199/","field":"wikipedia"},{"id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","field":"links","label":"Wikipedia"},{"id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/QIMR_Berghofer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Quality_of_life_(healthcare)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","field":"links","label":"Wikipedia"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Quality-adjusted_life_year","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quality-adjusted-survival","kind":"term","name":"Quality-adjusted survival (QALYs and Q-TWiST)","route":"/terms/quality-adjusted-survival/","field":"links","label":"Wikipedia"},{"id":"quality-adjusted-survival","kind":"term","name":"Quality-adjusted survival (QALYs and Q-TWiST)","route":"/terms/quality-adjusted-survival/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Quantile_normalization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quantile-normalisation","kind":"term","name":"Quantile normalisation, rank transforms and z-scores","route":"/terms/quantile-normalisation/","field":"links","label":"Wikipedia"},{"id":"quantile-normalisation","kind":"term","name":"Quantile normalisation, rank transforms and z-scores","route":"/terms/quantile-normalisation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Quizartinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Quynh-Thu_Le","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","route":"/people/quynh-thu-le/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/R-CHOP","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/","field":"links","label":"Wikipedia"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/R-Pharm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/R-spondin_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rspo-fusion","kind":"term","name":"R-spondin fusion","route":"/terms/rspo-fusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RA_Capital_Management","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_burn","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-dermatitis","kind":"term","name":"Radiation dermatitis (skin reaction)","route":"/terms/radiation-dermatitis/","field":"links","label":"Wikipedia"},{"id":"radiation-dermatitis","kind":"term","name":"Radiation dermatitis (skin reaction)","route":"/terms/radiation-dermatitis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_pneumonitis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","field":"links","label":"Wikipedia"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","field":"wikipedia"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","field":"links","label":"Wikipedia"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","field":"wikipedia"},{"id":"re-irradiation","kind":"term","name":"Re-irradiation","route":"/terms/re-irradiation/","field":"links","label":"Wikipedia"},{"id":"re-irradiation","kind":"term","name":"Re-irradiation","route":"/terms/re-irradiation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_therapy#Intensity-modulated_radiation_therapy_(IMRT)","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Radiation_therapy","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imrt-term","kind":"term","name":"IMRT / IGRT / VMAT (modern external beam radiotherapy)","route":"/terms/imrt-term/","field":"links","label":"Wikipedia"},{"id":"imrt-term","kind":"term","name":"IMRT / IGRT / VMAT (modern external beam radiotherapy)","route":"/terms/imrt-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_therapy#Volumetric_modulated_arc_therapy","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Radiation_therapy","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vmat","kind":"technology","name":"Volumetric modulated arc therapy (VMAT)","route":"/technologies/vmat/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation_treatment_planning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"knowledge-based-planning","kind":"technology","name":"Knowledge-based and automated treatment planning","route":"/technologies/knowledge-based-planning/","field":"links","label":"Wikipedia"},{"id":"planning-target-volume","kind":"term","name":"GTV, CTV and PTV (target volumes)","route":"/terms/planning-target-volume/","field":"links","label":"Wikipedia"},{"id":"planning-target-volume","kind":"term","name":"GTV, CTV and PTV (target volumes)","route":"/terms/planning-target-volume/","field":"wikipedia"},{"id":"organs-at-risk","kind":"term","name":"Organs at risk and dose constraints","route":"/terms/organs-at-risk/","field":"links","label":"Wikipedia"},{"id":"organs-at-risk","kind":"term","name":"Organs at risk and dose constraints","route":"/terms/organs-at-risk/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiation-induced_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"second-cancers-after-radiotherapy","kind":"term","name":"Second cancers after radiotherapy","route":"/terms/second-cancers-after-radiotherapy/","field":"links","label":"Wikipedia"},{"id":"second-cancers-after-radiotherapy","kind":"term","name":"Second cancers after radiotherapy","route":"/terms/second-cancers-after-radiotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiobiology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-control-probability-models","kind":"technology","name":"Tumour control and normal tissue complication probability (TCP and NTCP)","route":"/technologies/tumour-control-probability-models/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiofrequency_ablation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","field":"links","label":"Wikipedia"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","field":"wikipedia"},{"id":"radiofrequency-ablation","kind":"term","name":"Radiofrequency ablation (RFA)","route":"/terms/radiofrequency-ablation/","field":"links","label":"Wikipedia"},{"id":"radiofrequency-ablation","kind":"term","name":"Radiofrequency ablation (RFA)","route":"/terms/radiofrequency-ablation/","field":"wikipedia"},{"id":"microwave-rf-ablation","kind":"technology","name":"Microwave and radiofrequency ablation systems","route":"/technologies/microwave-rf-ablation/","field":"links","label":"Wikipedia: radiofrequency ablation"}]},{"url":"https://en.wikipedia.org/wiki/Radiogenomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiogenomics","kind":"technology","name":"Radiogenomics: predicting radiation sensitivity from genes","route":"/technologies/radiogenomics/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/","field":"links","label":"Wikipedia: radiography"},{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radioimmunotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","field":"links","label":"Wikipedia"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radioligand_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","field":"links","label":"Wikipedia"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","field":"links","label":"Wikipedia"},{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiopharmaceutical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiosensitizer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radiosurgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","field":"links","label":"Wikipedia"},{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","field":"wikipedia"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/","field":"links","label":"Wikipedia"},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/","field":"links","label":"Wikipedia: radiosurgery"},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radium-223","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Radon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radon","kind":"term","name":"Radon","route":"/terms/radon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rajesh_Sudhir_Gokhale","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"links","label":"Source: Wikipedia article on Rajesh Sudhir Gokhale"},{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Raloxifene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ralph_Weichselbaum","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Raltitrexed","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","field":"links","label":"Wikipedia"},{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rambam_Health_Care_Campus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ramucirumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Randomized_controlled_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","field":"links","label":"Wikipedia"},{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Randy_Pausch","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","field":"links","label":"Wikipedia"},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","field":"wikipedia"},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RANKL","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rare_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rasburicase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ratan_Tata","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ratan-tata","kind":"person","name":"Ratan Tata","route":"/people/ratan-tata/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ravtansine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ravulizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Real_world_evidence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","field":"links","label":"Wikipedia"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rebecca_Fitzgerald","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Receiver_operating_characteristic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roc-auc","kind":"term","name":"ROC-AUC, PR-AUC and time-dependent AUC","route":"/terms/roc-auc/","field":"links","label":"Wikipedia"},{"id":"roc-auc","kind":"term","name":"ROC-AUC, PR-AUC and time-dependent AUC","route":"/terms/roc-auc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Receptor_(biochemistry)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/","field":"links","label":"Wikipedia"},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Receptor_tyrosine_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Red_meat#Health_effects","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Red_meat","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"red-processed-meat-reduction","kind":"technology","name":"Red and processed meat reduction","route":"/technologies/red-processed-meat-reduction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Reed–Sternberg_cell","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Reed%E2%80%93Sternberg_cell","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/","field":"links","label":"Wikipedia"},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Reference_genome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genome-builds","kind":"term","name":"Genome builds: GRCh38 versus hg19 (GRCh37)","route":"/terms/genome-builds/","field":"links","label":"Wikipedia"},{"id":"genome-builds","kind":"term","name":"Genome builds: GRCh38 versus hg19 (GRCh37)","route":"/terms/genome-builds/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Reflexology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reflexology-cancer","kind":"technology","name":"Reflexology","route":"/technologies/reflexology-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Regorafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","field":"links","label":"Wikipedia"},{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Relapse","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","field":"wikipedia"},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/","field":"links","label":"Wikipedia"},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/","field":"wikipedia"},{"id":"relapsed-refractory","kind":"term","name":"Relapsed / refractory (R/R)","route":"/terms/relapsed-refractory/","field":"links","label":"Wikipedia"},{"id":"relapsed-refractory","kind":"term","name":"Relapsed / refractory (R/R)","route":"/terms/relapsed-refractory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Relative_biological_effectiveness","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","field":"links","label":"Wikipedia"},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Relugolix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Remission_(medicine)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/","field":"links","label":"Wikipedia"},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ren%C3%A9_Bernards","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Renal_cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","field":"wikipedia"},{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","field":"wikipedia"},{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","field":"wikipedia"},{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","field":"wikipedia"},{"id":"mucinous-tubular-spindle-cell-carcinoma","kind":"cancer","name":"Mucinous tubular and spindle cell carcinoma of the kidney","route":"/cancers/mucinous-tubular-spindle-cell-carcinoma/","field":"wikipedia"},{"id":"eosinophilic-solid-cystic-renal-cell-carcinoma","kind":"cancer","name":"Eosinophilic solid and cystic renal cell carcinoma","route":"/cancers/eosinophilic-solid-cystic-renal-cell-carcinoma/","field":"wikipedia"},{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908030938/https://en.wikipedia.org/wiki/Renal_cell_carcinoma"},{"url":"https://en.wikipedia.org/wiki/Renal_medullary_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Replication_stress","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Repotrectinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251228063606/https://en.wikipedia.org/wiki/Repotrectinib"},{"url":"https://en.wikipedia.org/wiki/Reproducibility","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reproducibility","kind":"term","name":"Reproducibility and negative results","route":"/terms/reproducibility/","field":"links","label":"Wikipedia"},{"id":"reproducibility","kind":"term","name":"Reproducibility and negative results","route":"/terms/reproducibility/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Resection_margin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","field":"wikipedia"},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","field":"links","label":"Wikipedia"},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Resistant_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/","field":"links","label":"Wikipedia"},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/","field":"wikipedia"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/","field":"links","label":"Wikipedia"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/","field":"wikipedia"},{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/","field":"links","label":"Wikipedia"},{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/","field":"wikipedia"},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/","field":"links","label":"Wikipedia"},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/","field":"wikipedia"},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/","field":"links","label":"Wikipedia"},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/","field":"wikipedia"},{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/","field":"links","label":"Wikipedia"},{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","field":"links","label":"Wikipedia"},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","field":"wikipedia"},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/","field":"links","label":"Wikipedia"},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/","field":"wikipedia"},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/","field":"links","label":"Wikipedia"},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RET_proto-oncogene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"links","label":"Wikipedia"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"wikipedia"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"prevalence.source"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","field":"links","label":"Wikipedia"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Retifanlimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Retinoblastoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Retinoic_acid_receptor_alpha","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rara","kind":"target","name":"Retinoic acid receptor alpha (RARA)","route":"/targets/rara/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Retinoid_X_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rxr","kind":"target","name":"Retinoid X receptor (RXR)","route":"/targets/rxr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Retroperitoneal_space","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","field":"links","label":"Wikipedia"},{"id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Reverse_phase_protein_lysate_microarray","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rppa","kind":"term","name":"Reverse-phase protein array (RPPA)","route":"/terms/rppa/","field":"links","label":"Wikipedia"},{"id":"rppa","kind":"term","name":"Reverse-phase protein array (RPPA)","route":"/terms/rppa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Revumenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rhabdomyosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ribociclib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Richter%27s_transformation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richter-transformation","kind":"term","name":"Richter transformation","route":"/terms/richter-transformation/","field":"links","label":"Wikipedia"},{"id":"richter-transformation","kind":"term","name":"Richter transformation","route":"/terms/richter-transformation/","field":"wikipedia"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"links","label":"Wikipedia"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ridge_regression","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ridge-regression","kind":"term","name":"Ridge regression and the multilayer perceptron","route":"/terms/ridge-regression/","field":"links","label":"Wikipedia"},{"id":"ridge-regression","kind":"term","name":"Ridge regression and the multilayer perceptron","route":"/terms/ridge-regression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Right-to-try_law","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","field":"links","label":"Wikipedia"},{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ripretinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","field":"wikipedia"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","field":"links","label":"Wikipedia"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Risk_factor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"risk-factor","kind":"term","name":"Risk factor","route":"/terms/risk-factor/","field":"links","label":"Wikipedia"},{"id":"risk-factor","kind":"term","name":"Risk factor","route":"/terms/risk-factor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rituximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RNA","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rna","kind":"term","name":"RNA","route":"/terms/rna/","field":"links","label":"Wikipedia"},{"id":"rna","kind":"term","name":"RNA","route":"/terms/rna/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RNA_splicing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RNA-Seq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/","field":"links","label":"Wikipedia"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/","field":"wikipedia"},{"id":"bulk-rna-seq","kind":"term","name":"Bulk RNA sequencing (RNA-seq) and the full transcriptome","route":"/terms/bulk-rna-seq/","field":"links","label":"Wikipedia"},{"id":"bulk-rna-seq","kind":"term","name":"Bulk RNA sequencing (RNA-seq) and the full transcriptome","route":"/terms/bulk-rna-seq/","field":"wikipedia"},{"id":"tpm-fpkm-counts","kind":"term","name":"TPM, FPKM and raw counts (expression units)","route":"/terms/tpm-fpkm-counts/","field":"links","label":"Wikipedia"},{"id":"tpm-fpkm-counts","kind":"term","name":"TPM, FPKM and raw counts (expression units)","route":"/terms/tpm-fpkm-counts/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Robert_A._Winn","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Robert_W._Woodruff","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-woodruff","kind":"person","name":"Robert W. Woodruff","route":"/people/robert-woodruff/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Robot-assisted_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","field":"links","label":"Wikipedia"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","field":"wikipedia"},{"id":"surgical-robot-platforms","kind":"technology","name":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","route":"/technologies/surgical-robot-platforms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rokitansky%E2%80%93Aschoff_sinuses","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rokitansky-aschoff-sinus","kind":"term","name":"Rokitansky-Aschoff sinus","route":"/terms/rokitansky-aschoff-sinus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rolapitant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Romidepsin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Romiplostim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ronald_Levy_(scientist)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ropeginterferon_alfa-2b","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/ROR1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","field":"links","label":"Wikipedia"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","field":"wikipedia"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","field":"prevalence.source"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","field":"prevalence.source"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/ROS1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","field":"links","label":"Wikipedia"},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","field":"wikipedia"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"links","label":"Wikipedia"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260728033411/https://en.wikipedia.org/wiki/ROS1"},{"url":"https://en.wikipedia.org/wiki/Rosai%E2%80%93Dorfman_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"links","label":"Wikipedia"},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rose_Kushner","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","field":"links","label":"Wikipedia"},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","field":"wikipedia"},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Roswell_Park_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rovalpituzumab_tesirine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Roy_S._Herbst","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Royal_Adelaide_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RRM1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rrm1","kind":"target","name":"Ribonucleotide reductase (RRM1)","route":"/targets/rrm1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rucaparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rusfertide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Rutgers_Cancer_Institute_of_New_Jersey","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ruth_Plummer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ruxolitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/RxNorm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rxnorm","kind":"term","name":"RxNorm drug nomenclature","route":"/terms/rxnorm/","field":"links","label":"Wikipedia"},{"id":"rxnorm","kind":"term","name":"RxNorm drug nomenclature","route":"/terms/rxnorm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/S%C3%A9zary_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sacituzumab_govitecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"wikipedia"},{"id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sakigake","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","field":"links","label":"Wikipedia"},{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salivary_duct_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"links","label":"Wikipedia"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salivary_gland_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salpingectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/","field":"links","label":"Wikipedia"},{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salpingoophorectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salpingo-oophorectomy","kind":"term","name":"Salpingo-oophorectomy","route":"/terms/salpingo-oophorectomy/","field":"links","label":"Wikipedia"},{"id":"salpingo-oophorectomy","kind":"term","name":"Salpingo-oophorectomy","route":"/terms/salpingo-oophorectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salvage_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salvage-therapy","kind":"term","name":"Salvage therapy","route":"/terms/salvage-therapy/","field":"links","label":"Wikipedia"},{"id":"salvage-therapy","kind":"term","name":"Salvage therapy","route":"/terms/salvage-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Salvatore_Siena","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Samarium_(153Sm)_lexidronam","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Samsung_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/San_Raffaele_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sandra_M._Swain","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sanford_Burnham_Prebys","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sanford_Diller","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helen-diller","kind":"person","name":"Helen Diller","route":"/people/helen-diller/","field":"links","label":"Sanford Diller (Wikipedia)"}]},{"url":"https://en.wikipedia.org/wiki/Sanford_I._Weill","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","route":"/people/sanford-weill/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sarah-Jane_Dawson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","field":"links","label":"Wikipedia"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","field":"wikipedia"},{"id":"sarcoma-type","kind":"term","name":"Sarcoma (tissue type)","route":"/terms/sarcoma-type/","field":"links","label":"Wikipedia"},{"id":"sarcoma-type","kind":"term","name":"Sarcoma (tissue type)","route":"/terms/sarcoma-type/","field":"wikipedia"},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260913141244/https://en.wikipedia.org/wiki/Sarcoma"},{"url":"https://en.wikipedia.org/wiki/Sarcomatoid_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","field":"links","label":"Wikipedia"},{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","field":"wikipedia"},{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sarcopenia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/","field":"links","label":"Wikipedia"},{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sargramostim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","field":"links","label":"Wikipedia"},{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Savolitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Scalp_cooling","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Scar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"facial-scar-after-skin-cancer","kind":"term","name":"The scar on the face after skin cancer surgery","route":"/terms/facial-scar-after-skin-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Science_(journal)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Scientific_control","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"control-arm","kind":"term","name":"Control arm and comparator (investigator's choice)","route":"/terms/control-arm/","field":"links","label":"Wikipedia"},{"id":"control-arm","kind":"term","name":"Control arm and comparator (investigator's choice)","route":"/terms/control-arm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sean_Parker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Seattle_Children's","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","route":"/institutions/seattle-childrens/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Secondary_malignant_neoplasm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Secretory_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"secretory-carcinoma-breast","kind":"cancer","name":"Secretory carcinoma of the breast","route":"/cancers/secretory-carcinoma-breast/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Seed_and_soil_hypothesis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/","field":"wikipedia"},{"id":"metastasis-seeding-models","kind":"technology","name":"Metastatic seeding and dormancy models","route":"/technologies/metastasis-seeding-models/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Segmental_resection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"segmentectomy","kind":"term","name":"Segmentectomy (sublobar resection)","route":"/terms/segmentectomy/","field":"links","label":"Wikipedia"},{"id":"segmentectomy","kind":"term","name":"Segmentectomy (sublobar resection)","route":"/terms/segmentectomy/","field":"wikipedia"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"Wikipedia"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","field":"links","label":"Wikipedia"},{"id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","field":"wikipedia"},{"id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","field":"links","label":"Wikipedia"},{"id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","field":"wikipedia"},{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","field":"links","label":"Wikipedia"},{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","field":"links","label":"Wikipedia"},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","field":"wikipedia"},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","field":"links","label":"Wikipedia"},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Self-supervised_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"self-supervised-pretraining","kind":"term","name":"Self-supervised pretraining (SSL)","route":"/terms/self-supervised-pretraining/","field":"links","label":"Wikipedia"},{"id":"self-supervised-pretraining","kind":"term","name":"Self-supervised pretraining (SSL)","route":"/terms/self-supervised-pretraining/","field":"wikipedia"},{"id":"contrastive-learning","kind":"term","name":"Contrastive learning (InfoNCE)","route":"/terms/contrastive-learning/","field":"links","label":"Wikipedia"},{"id":"contrastive-learning","kind":"term","name":"Contrastive learning (InfoNCE)","route":"/terms/contrastive-learning/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selinexor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selpercatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selumetinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Selwyn_M._Vickers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Seminoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminoma","kind":"cancer","name":"Seminoma","route":"/cancers/seminoma/","field":"links","label":"Wikipedia"},{"id":"seminoma","kind":"cancer","name":"Seminoma","route":"/cancers/seminoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sensitivity_and_specificity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sensitivity-specificity","kind":"term","name":"Sensitivity and specificity","route":"/terms/sensitivity-specificity/","field":"links","label":"Wikipedia"},{"id":"sensitivity-specificity","kind":"term","name":"Sensitivity and specificity","route":"/terms/sensitivity-specificity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sentinel_lymph_node","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/","field":"links","label":"Wikipedia"},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/","field":"wikipedia"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"Wikipedia"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"wikipedia"},{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"Wikipedia: sentinel lymph node"}]},{"url":"https://en.wikipedia.org/wiki/Seoul_National_University_Bundang_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","route":"/institutions/snu-bundang-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Seoul_National_University_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sequential_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","field":"links","label":"Wikipedia"},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sertoli_cell_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sessile_serrated_lesion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","field":"wikipedia"},{"id":"colorectal-serrated-adenocarcinoma","kind":"cancer","name":"Serrated adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-serrated-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Setmelanotide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","field":"links","label":"Wikipedia"},{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SF3B1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/","field":"links","label":"Wikipedia"},{"id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shaare_Zedek_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shanghai_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shanghai_Chest_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shanghai_Pulmonary_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shark_cartilage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sheba_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sheffield_Teaching_Hospitals_NHS_Foundation_Trust","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kirsten-major","kind":"person","name":"Kirsten Major","route":"/people/kirsten-major/","field":"links","label":"Source: Wikipedia article on Sheffield Teaching Hospitals naming the chief executive"},{"id":"kirsten-major","kind":"person","name":"Kirsten Major","route":"/people/kirsten-major/","field":"profiles","label":"Wikipedia: Sheffield Teaching Hospitals NHS Foundation Trust"}]},{"url":"https://en.wikipedia.org/wiki/Sherene_Loi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sherry_Lansing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","route":"/people/sherry-lansing/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shivaani_Kummar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Shlomi_Codish","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"links","label":"Source: Wikipedia biography of Shlomi Codish"},{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"profiles","label":"Wikipedia (Shlomi Codish)"}]},{"url":"https://en.wikipedia.org/wiki/Sidney_Farber","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","field":"links","label":"Sidney Farber (Wikipedia)"},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","field":"profiles","label":"Sidney Farber (Wikipedia)"},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","field":"links","label":"Wikipedia"},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","field":"wikipedia"},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sidney_Kimmel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Siewert_classification","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"siewert-classification","kind":"term","name":"Siewert classification (GEJ tumours)","route":"/terms/siewert-classification/","field":"links","label":"Wikipedia"},{"id":"siewert-classification","kind":"term","name":"Siewert classification (GEJ tumours)","route":"/terms/siewert-classification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Signal_transduction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/","field":"links","label":"Wikipedia"},{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/","field":"wikipedia"},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/","field":"links","label":"Wikipedia"},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Signet_ring_cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Siltuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Single-arm_study_design","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"single-arm","kind":"term","name":"Single-arm trial","route":"/terms/single-arm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Single-cell_transcriptomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"single-cell-rna-seq","kind":"term","name":"Single-cell RNA sequencing (scRNA-seq, 10x Chromium)","route":"/terms/single-cell-rna-seq/","field":"links","label":"Wikipedia"},{"id":"single-cell-rna-seq","kind":"term","name":"Single-cell RNA sequencing (scRNA-seq, 10x Chromium)","route":"/terms/single-cell-rna-seq/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","field":"links","label":"Wikipedia"},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","field":"wikipedia"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"links","label":"Wikipedia: SPECT"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Single-use_bioreactor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sino_Biopharmaceutical_Limited","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sinonasal_undifferentiated_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"links","label":"Wikipedia"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sintilimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sipuleucel-T","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/","field":"links","label":"Wikipedia"},{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/","field":"wikipedia"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sirolimus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/","field":"links","label":"Wikipedia"},{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/","field":"wikipedia"},{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Skin_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"wikipedia"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"wikipedia"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260830015314/https://en.wikipedia.org/wiki/Skin_cancer"},{"url":"https://en.wikipedia.org/wiki/Skin_grafting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-graft-and-flap-reconstruction","kind":"term","name":"Skin grafts and flaps after skin cancer surgery","route":"/terms/skin-graft-and-flap-reconstruction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SLAMF7","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SLC39A6","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Small_intestine_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"wikipedia"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"wikipedia"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Small_molecule","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-molecule","kind":"term","name":"Small molecule drug","route":"/terms/small-molecule/","field":"links","label":"Wikipedia"},{"id":"small-molecule","kind":"term","name":"Small molecule drug","route":"/terms/small-molecule/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Small-cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"wikipedia"},{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/","field":"links","label":"Wikipedia"},{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/","field":"wikipedia"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"links","label":"Wikipedia"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"wikipedia"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"links","label":"Wikipedia"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260913133139/https://en.wikipedia.org/wiki/Small-cell_carcinoma"},{"url":"https://en.wikipedia.org/wiki/Smoking_cessation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","field":"wikipedia"},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Smoothened","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Smouldering_myeloma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","field":"links","label":"Wikipedia"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SN-38","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sn-38","kind":"term","name":"SN-38","route":"/terms/sn-38/","field":"links","label":"Wikipedia"},{"id":"sn-38","kind":"term","name":"SN-38","route":"/terms/sn-38/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SNV_calling_from_NGS_data","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"variant-calling","kind":"term","name":"Variant calling","route":"/terms/variant-calling/","field":"links","label":"Wikipedia"},{"id":"variant-calling","kind":"term","name":"Variant calling","route":"/terms/variant-calling/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sodium_thiosulfate_(medical_use)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Soft-tissue_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","field":"wikipedia"},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/","field":"links","label":"Wikipedia"},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Solid_pseudopapillary_tumour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Somatic_evolution_in_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clonal-evolution-tracking","kind":"technology","name":"Tumour clonal evolution tracking","route":"/technologies/clonal-evolution-tracking/","field":"links","label":"Wikipedia"},{"id":"clonal-evolution-tracking","kind":"technology","name":"Tumour clonal evolution tracking","route":"/technologies/clonal-evolution-tracking/","field":"wikipedia"},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","field":"wikipedia"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","field":"wikipedia"},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","field":"wikipedia"},{"id":"tumour-evolution","kind":"term","name":"Tumour evolution (somatic evolution)","route":"/terms/tumour-evolution/","field":"links","label":"Wikipedia"},{"id":"tumour-evolution","kind":"term","name":"Tumour evolution (somatic evolution)","route":"/terms/tumour-evolution/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Somatostatin_receptor_2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"links","label":"Wikipedia"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"wikipedia"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"prevalence.source"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Somatostatinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"somatostatinoma","kind":"cancer","name":"Somatostatinoma","route":"/cancers/somatostatinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sonidegib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sorafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","field":"wikipedia"},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/","field":"links","label":"Wikipedia: sorafenib (Nexavar)"}]},{"url":"https://en.wikipedia.org/wiki/Soroka_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"links","label":"Source: Wikipedia article on Soroka Medical Center naming the director general"},{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"profiles","label":"Wikipedia (Soroka Medical Center)"}]},{"url":"https://en.wikipedia.org/wiki/Sotorasib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Soybean#Health_effects","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Soybean","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"soy-breast-cancer","kind":"technology","name":"Soy foods and breast cancer","route":"/technologies/soy-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spatial_transcriptomics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/","field":"links","label":"Wikipedia"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/","field":"wikipedia"},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/","field":"links","label":"Wikipedia"},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/","field":"wikipedia"},{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"links","label":"Wikipedia"},{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spearman's_rank_correlation_coefficient","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spearman-correlation","kind":"term","name":"Spearman rank correlation","route":"/terms/spearman-correlation/","field":"links","label":"Wikipedia"},{"id":"spearman-correlation","kind":"term","name":"Spearman rank correlation","route":"/terms/spearman-correlation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"links","label":"Wikipedia"},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spermatocytic_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spinal_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"links","label":"Wikipedia"},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Spindle_checkpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Splenic_marginal_zone_lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Squamous-cell_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","field":"links","label":"Wikipedia"},{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_lung","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"wikipedia"},{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_skin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"wikipedia"},{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"wikipedia"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"wikipedia"},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"links","label":"Wikipedia"},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SRD5A2","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/St._Jude_Children's_Research_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Standard_of_care","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/","field":"links","label":"Wikipedia"},{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Standard_score","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quantile-normalisation","kind":"term","name":"Quantile normalisation, rank transforms and z-scores","route":"/terms/quantile-normalisation/","field":"links","label":"Wikipedia: standard score"}]},{"url":"https://en.wikipedia.org/wiki/Standardized_uptake_value","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","field":"links","label":"Wikipedia"},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Statistical_power","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","field":"links","label":"Wikipedia"},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Statistical_significance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"statistical-significance","kind":"term","name":"Statistical significance (P values, alpha, multiplicity)","route":"/terms/statistical-significance/","field":"links","label":"Wikipedia"},{"id":"statistical-significance","kind":"term","name":"Statistical significance (P values, alpha, multiplicity)","route":"/terms/statistical-significance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/STEAP1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","field":"links","label":"Wikipedia"},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250801005040/https://en.wikipedia.org/wiki/STEAP1"},{"url":"https://en.wikipedia.org/wiki/Stefan_Pfister","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stem_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/","field":"links","label":"Wikipedia"},{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biliary-stent","kind":"term","name":"Stenting (biliary, oesophageal, airway)","route":"/terms/biliary-stent/","field":"links","label":"Wikipedia"},{"id":"biliary-stent","kind":"term","name":"Stenting (biliary, oesophageal, airway)","route":"/terms/biliary-stent/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stephan_Grupp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stephen_B._Baylin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stephen_P._Hunger","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stephen_Sutton","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","field":"links","label":"Wikipedia"},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","field":"wikipedia"},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stepped-wedge_trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stepped-wedge-design","kind":"term","name":"Stepped-wedge design","route":"/terms/stepped-wedge-design/","field":"links","label":"Wikipedia"},{"id":"stepped-wedge-design","kind":"term","name":"Stepped-wedge design","route":"/terms/stepped-wedge-design/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stereotactic_body_radiation_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sbrt-term","kind":"term","name":"Stereotactic body radiotherapy (SBRT / SABR)","route":"/terms/sbrt-term/","field":"links","label":"Wikipedia"},{"id":"sbrt-term","kind":"term","name":"Stereotactic body radiotherapy (SBRT / SABR)","route":"/terms/sbrt-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stereotactic_radiosurgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","field":"links","label":"Wikipedia"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Steve_Biko_Academic_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","route":"/people/lehlohonolo-majake/","field":"links","label":"Source: Wikipedia article on Steve Biko Academic Hospital"}]},{"url":"https://en.wikipedia.org/wiki/Steve_Jobs","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","field":"links","label":"Wikipedia"},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","field":"wikipedia"},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Steven_Libutti","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Steven_T._Rosen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stimulator_of_interferon_genes","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","field":"links","label":"Wikipedia"},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","field":"wikipedia"},{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/","field":"links","label":"Wikipedia"},{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/STK11","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/","field":"links","label":"Wikipedia"},{"id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stoma_(medicine)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"Wikipedia"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stomach_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"wikipedia"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","field":"links","label":"Wikipedia"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","field":"wikipedia"},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","field":"links","label":"Wikipedia"},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","field":"wikipedia"},{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","field":"links","label":"Wikipedia"},{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260913105240/https://en.wikipedia.org/wiki/Stomach_cancer"},{"url":"https://en.wikipedia.org/wiki/Stratification_(clinical_trials)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","field":"links","label":"Wikipedia"},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Stratified_sampling","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cross-validation","kind":"term","name":"Cross-validation and stratified k-fold","route":"/terms/cross-validation/","field":"links","label":"Wikipedia: stratified sampling"}]},{"url":"https://en.wikipedia.org/wiki/Streptozotocin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","field":"links","label":"Wikipedia"},{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Subgroup_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"subgroup-analysis","kind":"term","name":"Subgroup analysis (forest plots)","route":"/terms/subgroup-analysis/","field":"links","label":"Wikipedia"},{"id":"subgroup-analysis","kind":"term","name":"Subgroup analysis (forest plots)","route":"/terms/subgroup-analysis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Succinimidyl_4-(N-maleimidomethyl)cyclohexane-1-carboxylate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","field":"links","label":"Wikipedia"},{"id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sudeep_Gupta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sugemalimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sun_Yat-sen_University_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sunitinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Sunvozertinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Super-enhancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transcription-addiction","kind":"pathway","name":"Transcriptional machinery & addiction","route":"/pathways/transcription-addiction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Superior_vena_cava_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"superior-vena-cava-obstruction","kind":"term","name":"Superior vena cava obstruction","route":"/terms/superior-vena-cava-obstruction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Supplementary_protection_certificate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","field":"links","label":"Wikipedia"},{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Support_group","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Surrogate_endpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/","field":"links","label":"Wikipedia"},{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/","field":"wikipedia"},{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","field":"links","label":"Wikipedia"},{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Survival_analysis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"os-pfs-time-event","kind":"term","name":"Survival outcomes as time plus event (OS, PFS)","route":"/terms/os-pfs-time-event/","field":"links","label":"Wikipedia"},{"id":"os-pfs-time-event","kind":"term","name":"Survival outcomes as time plus event (OS, PFS)","route":"/terms/os-pfs-time-event/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Survival_rate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/","field":"wikipedia"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/","field":"links","label":"Wikipedia"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Susan_Domchek","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Susan_L._Cohn","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Susan_Love","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","field":"links","label":"Wikipedia"},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","field":"wikipedia"},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Susana_Banerjee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Suzanne_L._Topalian","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/SWI/SNF","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Syncona","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Synovial_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/","field":"links","label":"Wikipedia"},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Synthetic_control_method","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"external-control-arm","kind":"term","name":"External and synthetic control arms","route":"/terms/external-control-arm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Synthetic_lethality","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/","field":"links","label":"Wikipedia"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/","field":"wikipedia"},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/","field":"links","label":"Wikipedia"},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/","field":"wikipedia"},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Systemic_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"systemic-vs-local-therapy","kind":"term","name":"Systemic versus local therapy","route":"/terms/systemic-vs-local-therapy/","field":"links","label":"Wikipedia"},{"id":"systemic-vs-local-therapy","kind":"term","name":"Systemic versus local therapy","route":"/terms/systemic-vs-local-therapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/T_cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","field":"links","label":"Wikipedia"},{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/T_cell_exhaustion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/","field":"links","label":"Wikipedia"},{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/","field":"wikipedia"},{"id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tabelecleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/","field":"links","label":"Wikipedia"},{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/","field":"wikipedia"},{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tablet_(pharmacy)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tachykinin_receptor_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tacr1","kind":"target","name":"NK1 receptor (TACR1)","route":"/targets/tacr1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tafasitamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tagraxofusp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tai_chi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tai-chi-qigong","kind":"technology","name":"Tai chi and qigong","route":"/technologies/tai-chi-qigong/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Taipei_Veterans_General_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Talazoparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Taletrectinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Talimogene_laherparepvec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Talquetamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tamoxifen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","field":"wikipedia"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Taofeek_Owonikoko","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Targeted_alpha-particle_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","field":"links","label":"Wikipedia"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","field":"wikipedia"},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","field":"links","label":"Wikipedia"},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Targeted_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","field":"links","label":"Wikipedia"},{"id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tarlatamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tasonermin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tasonermin","kind":"drug","name":"Tasonermin","route":"/drugs/tasonermin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tasuku_Honjo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","field":"links","label":"Wikipedia"},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","field":"wikipedia"},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tata_Memorial_Centre","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Taxane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","field":"links","label":"Wikipedia"},{"id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tazemetostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","field":"links","label":"Wikipedia"},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Te_Whatu_Ora","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","field":"links","label":"Source: Wikipedia article on Te Whatu Ora (appointment date)"}]},{"url":"https://en.wikipedia.org/wiki/Tebentafusp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Technetium-99m#Shortages","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Technetium-99m","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"Wikipedia: technetium-99m and the Mo-99 supply crisis"}]},{"url":"https://en.wikipedia.org/wiki/Technion_%E2%80%93_Israel_Institute_of_Technology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Teclistamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ted_Williams","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ted-williams","kind":"person","name":"Ted Williams","route":"/people/ted-williams/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tegafur/gimeracil/oteracil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TEK_tyrosine_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tel_Aviv_Sourasky_Medical_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tel_Aviv_University","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Telehealth","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Telomerase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Telomerase_reverse_transcriptase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Telotristat_ethyl","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Temoporfin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"temoporfin","kind":"drug","name":"Temoporfin","route":"/drugs/temoporfin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Temozolomide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","field":"links","label":"Wikipedia"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Temsirolimus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","route":"/drugs/temsirolimus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Teniposide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","field":"links","label":"Wikipedia"},{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tepotinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Terminal_duct_lobular_unit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"terminal-duct-lobular-unit","kind":"term","name":"Ducts, lobules and the terminal duct lobular unit","route":"/terms/terminal-duct-lobular-unit/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Terry_Fox","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","field":"links","label":"Wikipedia"},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","field":"wikipedia"},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Test_data_exclusivity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","route":"/terms/us-regulatory-exclusivity/","field":"links","label":"Wikipedia"},{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","route":"/terms/us-regulatory-exclusivity/","field":"wikipedia"},{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/","field":"links","label":"Wikipedia"},{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Testicular_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","field":"wikipedia"},{"id":"non-seminoma","kind":"cancer","name":"Non-seminomatous germ cell tumour","route":"/cancers/non-seminoma/","field":"links","label":"Wikipedia"},{"id":"non-seminoma","kind":"cancer","name":"Non-seminomatous germ cell tumour","route":"/cancers/non-seminoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TGF_beta_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thalidomide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/","field":"links","label":"Wikipedia"},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_BMJ","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_Hallmarks_of_Cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","field":"wikipedia"},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/","field":"wikipedia"},{"id":"evading-growth-suppressors","kind":"term","name":"Hallmark: evading growth suppressors","route":"/terms/evading-growth-suppressors/","field":"wikipedia"},{"id":"resisting-cell-death","kind":"term","name":"Hallmark: resisting cell death","route":"/terms/resisting-cell-death/","field":"wikipedia"},{"id":"enabling-replicative-immortality","kind":"term","name":"Hallmark: enabling replicative immortality","route":"/terms/enabling-replicative-immortality/","field":"wikipedia"},{"id":"inducing-angiogenesis","kind":"term","name":"Hallmark: inducing or accessing vasculature","route":"/terms/inducing-angiogenesis/","field":"wikipedia"},{"id":"activating-invasion-metastasis","kind":"term","name":"Hallmark: activating invasion and metastasis","route":"/terms/activating-invasion-metastasis/","field":"wikipedia"},{"id":"deregulating-cellular-energetics","kind":"term","name":"Hallmark: reprogramming cellular metabolism","route":"/terms/deregulating-cellular-energetics/","field":"wikipedia"},{"id":"avoiding-immune-destruction","kind":"term","name":"Hallmark: avoiding immune destruction","route":"/terms/avoiding-immune-destruction/","field":"wikipedia"},{"id":"genome-instability-mutation","kind":"term","name":"Enabling characteristic: genome instability and mutation","route":"/terms/genome-instability-mutation/","field":"wikipedia"},{"id":"tumor-promoting-inflammation","kind":"term","name":"Enabling characteristic: tumour-promoting inflammation","route":"/terms/tumor-promoting-inflammation/","field":"wikipedia"},{"id":"unlocking-phenotypic-plasticity","kind":"term","name":"Hallmark (2022): unlocking phenotypic plasticity","route":"/terms/unlocking-phenotypic-plasticity/","field":"wikipedia"},{"id":"nonmutational-epigenetic-reprogramming","kind":"term","name":"Hallmark (2022): non-mutational epigenetic reprogramming","route":"/terms/nonmutational-epigenetic-reprogramming/","field":"wikipedia"},{"id":"polymorphic-microbiomes","kind":"term","name":"Hallmark (2022): polymorphic microbiomes","route":"/terms/polymorphic-microbiomes/","field":"wikipedia"},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_Lancet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_Lancet_Oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Theodore_Lawrence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Theranostics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","field":"links","label":"Wikipedia"},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Therapeutic_Goods_Administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","route":"/people/anthony-lawler/","field":"links","label":"Source: Wikipedia, Therapeutic Goods Administration"}]},{"url":"https://en.wikipedia.org/wiki/Therapeutic_index","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therapeutic-index","kind":"term","name":"Therapeutic index (therapeutic window)","route":"/terms/therapeutic-index/","field":"links","label":"Wikipedia"},{"id":"therapeutic-index","kind":"term","name":"Therapeutic index (therapeutic window)","route":"/terms/therapeutic-index/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Therapy#Lines_of_therapy","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Therapy","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thioredoxin_reductase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thiotepa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thrombocytopenia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","field":"links","label":"Wikipedia"},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thymic_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"links","label":"Wikipedia"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thymidylate_synthase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tyms","kind":"target","name":"Thymidylate synthase (TYMS)","route":"/targets/tyms/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thymoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","field":"wikipedia"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"links","label":"Wikipedia"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"wikipedia"},{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","field":"wikipedia"},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/","field":"wikipedia"},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/","field":"wikipedia"},{"id":"micronodular-thymoma","kind":"cancer","name":"Micronodular thymoma with lymphoid stroma","route":"/cancers/micronodular-thymoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thyroid_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","field":"links","label":"Wikipedia"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","field":"wikipedia"},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","field":"wikipedia"},{"id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260910105221/https://en.wikipedia.org/wiki/Thyroid_cancer"},{"url":"https://en.wikipedia.org/wiki/Thyroid_transcription_factor_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thyroid-stimulating_hormone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thyroidectomy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyroidectomy","kind":"term","name":"Thyroidectomy","route":"/terms/thyroidectomy/","field":"links","label":"Wikipedia"},{"id":"thyroidectomy","kind":"term","name":"Thyroidectomy","route":"/terms/thyroidectomy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thyrotropin_alfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Thyrotropin_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tianjin_Medical_University_Cancer_Institute_and_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","field":"links","label":"Source: Wikipedia article on TMUCIH"},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TIGIT","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/","field":"links","label":"Wikipedia"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/","field":"wikipedia"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","field":"links","label":"Wikipedia"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","field":"wikipedia"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Tilmanocept","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tioguanine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tisagenlecleucel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","field":"wikipedia"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"links","label":"Wikipedia: Tisagenlecleucel"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tislelizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tisotumab_vedotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tissue_factor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","field":"links","label":"Wikipedia"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","field":"wikipedia"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","field":"prevalence.source"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Tissue-agnostic_drug","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/","field":"links","label":"Wikipedia"},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tivozanib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TLR7","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TNM_staging_system","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"wikipedia"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"wikipedia"},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/","field":"links","label":"Wikipedia"},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tobacco_21","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","field":"links","label":"Wikipedia"},{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tocilizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tomotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tomotherapy","kind":"technology","name":"TomoTherapy and Radixact (helical radiotherapy)","route":"/technologies/tomotherapy/","field":"links","label":"Wikipedia"},{"id":"tomotherapy","kind":"technology","name":"TomoTherapy and Radixact (helical radiotherapy)","route":"/technologies/tomotherapy/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tongji_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","field":"links","label":"Source: Wikipedia article on Tongji Hospital"}]},{"url":"https://en.wikipedia.org/wiki/Toni_Choueiri","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TOP1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/TOP2A","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Topoisomerase_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/","field":"links","label":"Wikipedia"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Topotecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Toremifene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Toripalimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Total_body_irradiation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"total-body-irradiation","kind":"technology","name":"Total body and total marrow irradiation","route":"/technologies/total-body-irradiation/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Total_mesorectal_excision","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"wikipedia"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Wikipedia"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Total_skin_electron_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"total-skin-electron-therapy","kind":"technology","name":"Total skin electron beam therapy","route":"/technologies/total-skin-electron-therapy/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trabectedin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Traditional_Chinese_medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"traditional-chinese-herbal-medicine","kind":"technology","name":"Traditional Chinese herbal medicine alongside treatment","route":"/technologies/traditional-chinese-herbal-medicine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Training,_validation,_and_test_data_sets","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"train-test-discipline","kind":"term","name":"Train, validation and test split discipline","route":"/terms/train-test-discipline/","field":"links","label":"Wikipedia"},{"id":"train-test-discipline","kind":"term","name":"Train, validation and test split discipline","route":"/terms/train-test-discipline/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trametinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transarterial_chemoembolization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/","field":"links","label":"Wikipedia"},{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tace-term","kind":"term","name":"TACE (transarterial chemoembolisation)","route":"/terms/tace-term/","field":"links","label":"Wikipedia"},{"id":"tace-term","kind":"term","name":"TACE (transarterial chemoembolisation)","route":"/terms/tace-term/","field":"wikipedia"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","field":"links","label":"Wikipedia"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transcriptome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bulk-rna-seq","kind":"term","name":"Bulk RNA sequencing (RNA-seq) and the full transcriptome","route":"/terms/bulk-rna-seq/","field":"links","label":"Wikipedia: transcriptome"}]},{"url":"https://en.wikipedia.org/wiki/Transdifferentiation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907110729/https://en.wikipedia.org/wiki/Transdifferentiation"},{"url":"https://en.wikipedia.org/wiki/Transfer_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transfer-learning","kind":"term","name":"Transfer learning and the low-label regime","route":"/terms/transfer-learning/","field":"links","label":"Wikipedia"},{"id":"transfer-learning","kind":"term","name":"Transfer learning and the low-label regime","route":"/terms/transfer-learning/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transformer_(deep_learning)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transformer-architecture","kind":"term","name":"Transformer and attention","route":"/terms/transformer-architecture/","field":"links","label":"Wikipedia"},{"id":"transformer-architecture","kind":"term","name":"Transformer and attention","route":"/terms/transformer-architecture/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transient_myeloproliferative_disease","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transoral_robotic_surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tors","kind":"technology","name":"Transoral robotic surgery (TORS)","route":"/technologies/tors/","field":"links","label":"Wikipedia"},{"id":"tors","kind":"technology","name":"Transoral robotic surgery (TORS)","route":"/technologies/tors/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transurethral_resection_of_bladder_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cystoscopy-turbt","kind":"technology","name":"Cystoscopy, blue-light imaging & TURBT","route":"/technologies/cystoscopy-turbt/","field":"links","label":"Wikipedia"},{"id":"cystoscopy-turbt","kind":"technology","name":"Cystoscopy, blue-light imaging & TURBT","route":"/technologies/cystoscopy-turbt/","field":"wikipedia"},{"id":"turbt","kind":"term","name":"Transurethral resection of bladder tumour (TURBT)","route":"/terms/turbt/","field":"links","label":"Wikipedia"},{"id":"turbt","kind":"term","name":"Transurethral resection of bladder tumour (TURBT)","route":"/terms/turbt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","field":"wikipedia"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"wikipedia"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"wikipedia"},{"id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","field":"wikipedia"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","field":"links","label":"Wikipedia"},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trastuzumab_emtansine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"wikipedia"},{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tremelimumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260412095100/https://en.wikipedia.org/wiki/Tremelimumab"},{"url":"https://en.wikipedia.org/wiki/Treosulfan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tretinoin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tretinoin-atra","kind":"drug","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trifluridine/tipiracil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trifunctional_purine_biosynthetic_protein_adenosine-3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trilaciclib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","field":"links","label":"Wikipedia"},{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Triple-negative_breast_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Wikipedia"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"wikipedia"},{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","field":"wikipedia"},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/","field":"wikipedia"},{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","field":"wikipedia"},{"id":"tnbc-mesenchymal-stem-like","kind":"cancer","name":"Mesenchymal stem-like triple-negative breast cancer (MSL)","route":"/cancers/tnbc-mesenchymal-stem-like/","field":"wikipedia"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","field":"wikipedia"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907132422/https://en.wikipedia.org/wiki/Triple-negative_breast_cancer"},{"url":"https://en.wikipedia.org/wiki/TRIPS_Agreement","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","field":"links","label":"Wikipedia"},{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Triptorelin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trk_receptor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"links","label":"Wikipedia"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"wikipedia"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","field":"links","label":"Wikipedia"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Trousseau_sign_of_malignancy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tryptophan_hydroxylase_1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tubular_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tubulin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tucatinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/","field":"links","label":"Wikipedia"},{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/","field":"wikipedia"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_board","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_board_review","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-board","kind":"term","name":"Tumour board (multidisciplinary team meeting)","route":"/terms/tumour-board/","field":"links","label":"Wikipedia"},{"id":"tumour-board","kind":"term","name":"Tumour board (multidisciplinary team meeting)","route":"/terms/tumour-board/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_hypoxia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/","field":"links","label":"Wikipedia"},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","field":"links","label":"Wikipedia"},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_lysis_syndrome","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/","field":"links","label":"Wikipedia"},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_marker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","field":"links","label":"Wikipedia"},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","field":"wikipedia"},{"id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/","field":"links","label":"Wikipedia"},{"id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_microenvironment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","field":"wikipedia"},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","field":"wikipedia"},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/","field":"wikipedia"},{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/","field":"wikipedia"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","field":"wikipedia"},{"id":"cell-composition-confound","kind":"term","name":"Cell composition confound (tumour versus stroma and immune cells)","route":"/terms/cell-composition-confound/","field":"links","label":"Wikipedia"},{"id":"cell-composition-confound","kind":"term","name":"Cell composition confound (tumour versus stroma and immune cells)","route":"/terms/cell-composition-confound/","field":"wikipedia"},{"id":"desmoplastic-stroma-rich","kind":"term","name":"Stroma-rich and desmoplastic tumours in molecular data","route":"/terms/desmoplastic-stroma-rich/","field":"links","label":"Wikipedia"},{"id":"desmoplastic-stroma-rich","kind":"term","name":"Stroma-rich and desmoplastic tumours in molecular data","route":"/terms/desmoplastic-stroma-rich/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_mutational_burden","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/","field":"links","label":"Wikipedia"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_suppressor_gene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-suppressor-gene","kind":"term","name":"Tumour suppressor gene","route":"/terms/tumour-suppressor-gene/","field":"links","label":"Wikipedia"},{"id":"tumour-suppressor-gene","kind":"term","name":"Tumour suppressor gene","route":"/terms/tumour-suppressor-gene/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor_treating_fields","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/","field":"links","label":"Wikipedia"},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/","field":"wikipedia"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"links","label":"Wikipedia"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor-associated_macrophage","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/","field":"links","label":"Wikipedia"},{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/","field":"wikipedia"},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumor-infiltrating_lymphocytes","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","field":"wikipedia"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","field":"links","label":"Wikipedia"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","field":"wikipedia"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/","field":"links","label":"Wikipedia"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/","field":"wikipedia"},{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tumour_heterogeneity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intra-tumour-heterogeneity","kind":"term","name":"Intra-tumour heterogeneity","route":"/terms/intra-tumour-heterogeneity/","field":"links","label":"Wikipedia"},{"id":"intra-tumour-heterogeneity","kind":"term","name":"Intra-tumour heterogeneity","route":"/terms/intra-tumour-heterogeneity/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Type_3c_diabetes","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/","field":"links","label":"Wikipedia"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/","field":"wikipedia"},{"id":"tki-term","kind":"term","name":"Tyrosine kinase inhibitor (TKI)","route":"/terms/tki-term/","field":"links","label":"Wikipedia"},{"id":"tki-term","kind":"term","name":"Tyrosine kinase inhibitor (TKI)","route":"/terms/tki-term/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/U%C4%9Fur_%C5%9Eahin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uberon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","field":"links","label":"Wikipedia"},{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/UC_Davis_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/UCB_(company)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uganda_Cancer_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Ultra-processed_food","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","field":"wikipedia"},{"id":"ultra-processed-food","kind":"term","name":"Ultra-processed food (NOVA group 4)","route":"/terms/ultra-processed-food/","field":"links","label":"Wikipedia"},{"id":"ultra-processed-food","kind":"term","name":"Ultra-processed food (NOVA group 4)","route":"/terms/ultra-processed-food/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Umbralisib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/","field":"links","label":"Wikipedia"},{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/UNC_Lineberger_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uncertainty_quantification","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uncertainty-quantification","kind":"term","name":"Uncertainty quantification and confidence gates","route":"/terms/uncertainty-quantification/","field":"links","label":"Wikipedia"},{"id":"uncertainty-quantification","kind":"term","name":"Uncertainty quantification and confidence gates","route":"/terms/uncertainty-quantification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Undifferentiated_pleomorphic_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/","field":"links","label":"Wikipedia"},{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_Clinical_Centre,_Gdańsk","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/University_Clinical_Centre,_Gda%C5%84sk","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_College_Hospital,_Ibadan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","route":"/institutions/uch-ibadan/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_Medical_Center_Hamburg-Eppendorf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Alberta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","route":"/institutions/university-of-alberta/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Arizona_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Maryland_Marlene_and_Stewart_Greenebaum_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Michigan_Rogel_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Virginia_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/","field":"links","label":"Source: Wikipedia article on UVA Cancer Center naming the director"},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/","field":"profiles","label":"Wikipedia: University of Virginia Cancer Center"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Western_Australia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/University_of_Wisconsin_Carbone_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Unnecessary_health_care","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uramustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","field":"links","label":"Wikipedia"},{"id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Urethral_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","field":"wikipedia"},{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"wikipedia"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"wikipedia"},{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uridine_triacetate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/UroVysion","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urovysion","kind":"drug","name":"UroVysion Bladder Cancer Kit","route":"/drugs/urovysion/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/USC_Norris_Comprehensive_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uterine_carcinosarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/","field":"links","label":"Wikipedia"},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uterine_sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uterine_serous_carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/","field":"links","label":"Wikipedia"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Uveal_melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/V._Shanta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vaginal_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"wikipedia"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"links","label":"Wikipedia"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"wikipedia"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"links","label":"Wikipedia"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"wikipedia"},{"id":"vaginal-melanoma","kind":"cancer","name":"Vaginal melanoma","route":"/cancers/vaginal-melanoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Valrubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valrubicin","kind":"drug","name":"Valrubicin","route":"/drugs/valrubicin/","field":"wikipedia"},{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"links","label":"Wikipedia: valrubicin (Valstar)"}]},{"url":"https://en.wikipedia.org/wiki/Vanderbilt-Ingram_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vandetanib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vanillylmandelic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/","field":"links","label":"Wikipedia"},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Variant_calling","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"variant-effect-prediction","kind":"term","name":"Variant effect prediction","route":"/terms/variant-effect-prediction/","field":"links","label":"Wikipedia"},{"id":"variant-effect-prediction","kind":"term","name":"Variant effect prediction","route":"/terms/variant-effect-prediction/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Variant_of_uncertain_significance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vus","kind":"term","name":"Variant of uncertain significance (VUS)","route":"/terms/vus/","field":"links","label":"Wikipedia"},{"id":"vus","kind":"term","name":"Variant of uncertain significance (VUS)","route":"/terms/vus/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","field":"links","label":"Wikipedia"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","field":"wikipedia"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","field":"prevalence.source"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/VCU_Massey_Cancer_Center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","field":"links","label":"Source: Wikipedia article on VCU Massey Cancer Center naming the director"},{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","field":"profiles","label":"Wikipedia: VCU Massey Cancer Center"}]},{"url":"https://en.wikipedia.org/wiki/Veliparib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vemurafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Venetoclax","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/","field":"links","label":"Wikipedia"},{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/","field":"wikipedia"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Venous_thrombosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","field":"links","label":"Wikipedia"},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Venrock","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Versant_Ventures","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vestibular_schwannoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"links","label":"Wikipedia"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vilnius_University_Hospital_Santaros_Clinics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","field":"links","label":"Wikipedia"},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vinblastine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vincristine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vindesine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/","field":"links","label":"Wikipedia"},{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vinflunine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vinod_P._Balachandran","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vinorelbine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/VIPoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vipoma","kind":"cancer","name":"VIPoma","route":"/cancers/vipoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Viscum_album","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vismodegib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vitamin_D","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Von_Hippel–Lindau_disease","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Von_Hippel%E2%80%93Lindau_disease","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vorasidenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vorinostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vorinostat","kind":"drug","name":"Vorinostat","route":"/drugs/vorinostat/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vorolanib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","field":"links","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Vulvar_cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","field":"wikipedia"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"links","label":"Wikipedia"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"wikipedia"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"links","label":"Wikipedia"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"wikipedia"},{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Waldenstr%C3%B6m_macroglobulinemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Walter_Winchell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"walter-winchell","kind":"person","name":"Walter Winchell","route":"/people/walter-winchell/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Warburg_effect_(oncology)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/","field":"wikipedia"},{"id":"warburg-effect","kind":"term","name":"Warburg effect","route":"/terms/warburg-effect/","field":"links","label":"Wikipedia"},{"id":"warburg-effect","kind":"term","name":"Warburg effect","route":"/terms/warburg-effect/","field":"wikipedia"},{"id":"warburg-effect-diet-claims","kind":"term","name":"Warburg-effect diet claims ('sugar feeds cancer')","route":"/terms/warburg-effect-diet-claims/","field":"links","label":"Wikipedia"},{"id":"warburg-effect-diet-claims","kind":"term","name":"Warburg-effect diet claims ('sugar feeds cancer')","route":"/terms/warburg-effect-diet-claims/","field":"wikipedia"},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Watchful_waiting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","field":"wikipedia"},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","field":"wikipedia"},{"id":"watchful-waiting","kind":"term","name":"Watchful waiting, and how it differs from active surveillance","route":"/terms/watchful-waiting/","field":"wikipedia"},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wee1-like_protein_kinase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","field":"links","label":"Wikipedia"},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","field":"wikipedia"},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","field":"prevalence.source"}]},{"url":"https://en.wikipedia.org/wiki/Weight_loss","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wellcome_Sanger_Institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Werner_syndrome_ATP-dependent_helicase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/West_China_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/WHO_Blue_Books","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"who-breast-classification","kind":"term","name":"The WHO classification of breast tumours, and what the 6th edition changed","route":"/terms/who-breast-classification/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Whole_brain_radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wbrt","kind":"term","name":"Whole-brain radiotherapy (WBRT)","route":"/terms/wbrt/","field":"links","label":"Wikipedia"},{"id":"wbrt","kind":"term","name":"Whole-brain radiotherapy (WBRT)","route":"/terms/wbrt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Whole_genome_sequencing","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/","field":"links","label":"Wikipedia"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/","field":"wikipedia"},{"id":"somatic-mutations-wxs-wgs","kind":"term","name":"Somatic mutations from exome and genome sequencing (WXS, WGS)","route":"/terms/somatic-mutations-wxs-wgs/","field":"links","label":"Wikipedia: whole genome sequencing"}]},{"url":"https://en.wikipedia.org/wiki/Wide_local_excision","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"links","label":"Wikipedia"},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wig","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wikipedia:WikiProject_Medicine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-wikipedia-oncology-editors","kind":"idea","name":"Fund expert editors for the cancer pages of Wikipedia and Wikidata","route":"/ideas/idea-data-wikipedia-oncology-editors/","field":"links","label":"WikiProject Medicine"},{"id":"idea-moon-wikipedia-oncology-fellowships","kind":"idea","name":"Fund oncologists to maintain cancer articles on Wikipedia in many languages","route":"/ideas/idea-moon-wikipedia-oncology-fellowships/","field":"links","label":"WikiProject Medicine"}]},{"url":"https://en.wikipedia.org/wiki/Wild_type","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wild-type","kind":"term","name":"Wild-type (WT)","route":"/terms/wild-type/","field":"links","label":"Wikipedia"},{"id":"wild-type","kind":"term","name":"Wild-type (WT)","route":"/terms/wild-type/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/William_G._Nelson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wilms%27_tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Wnt_signaling_pathway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/","field":"links","label":"Wikipedia"},{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Xanthine_oxidase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Xavier_Pivot","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/XELOX","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","field":"links","label":"Wikipedia"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Xerostomia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acupuncture-xerostomia","kind":"technology","name":"Acupuncture for dry mouth after head and neck radiotherapy","route":"/technologies/acupuncture-xerostomia/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Xevinapant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xevinapant","kind":"drug","name":"Xevinapant","route":"/drugs/xevinapant/","field":"links","label":"Wikipedia"},{"id":"xevinapant","kind":"drug","name":"Xevinapant","route":"/drugs/xevinapant/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/XPO1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Yasmine_Belkaid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","route":"/people/yasmine-belkaid/","field":"profiles","label":"Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Yoga_as_therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Yuman_Fong","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yuman-fong","kind":"person","name":"Yuman Fong","route":"/people/yuman-fong/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zanidatamab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zanubrutinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zarr_(data_format)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","field":"links","label":"Wikipedia: Zarr"}]},{"url":"https://en.wikipedia.org/wiki/Zenocutuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zenodo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zenodo-doi","kind":"term","name":"Zenodo DOIs for data and code","route":"/terms/zenodo-doi/","field":"links","label":"Wikipedia"},{"id":"zenodo-doi","kind":"term","name":"Zenodo DOIs for data and code","route":"/terms/zenodo-doi/","field":"wikipedia"},{"id":"citation-cff","kind":"term","name":"CITATION.cff (Citation File Format)","route":"/terms/citation-cff/","field":"links","label":"Wikipedia: Zenodo"}]},{"url":"https://en.wikipedia.org/wiki/Zero-shot_learning","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zero-shot","kind":"term","name":"Zero-shot prediction","route":"/terms/zero-shot/","field":"links","label":"Wikipedia"},{"id":"zero-shot","kind":"term","name":"Zero-shot prediction","route":"/terms/zero-shot/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zhejiang_Cancer_Hospital","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zolbetuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","field":"wikipedia"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","field":"prevalence.source"},{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","field":"links","label":"Wikipedia"},{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Zoledronic_acid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Μ-opioid_receptor","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/%CE%9C-opioid_receptor","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","field":"wikipedia"}]},{"url":"https://endpoints.news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","field":"links","label":"Endpoints News"},{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","field":"url"}]},{"url":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"links","label":"Endpoints News: Abdera raises $110M Series B"}]},{"url":"https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Endpoints News: Artbio attracts $132M"}]},{"url":"https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Endpoints News: Artbio raises $90M"}]},{"url":"https://endpoints.news/boehringer-merges-cancer-vaccine-and-oncolytic-virus-teams-dantari-sells-off-assets/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","field":"links","label":"Endpoints News: Dantari sells off assets"}]},{"url":"https://eng.amc.seoul.kr","status":200,"ok":true,"finalUrl":"https://eng.amc.seoul.kr/gb/lang/main.do","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","field":"links","label":"Official website"},{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","field":"website"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","field":"links","label":"Asan Medical Center"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","field":"profiles","label":"Asan Medical Center"},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","field":"links","label":"Asan Medical Center"},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","field":"profiles","label":"Asan Medical Center"},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","field":"links","label":"Asan Medical Center"},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","field":"profiles","label":"Asan Medical Center"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"links","label":"Asan Medical Center"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"profiles","label":"Asan Medical Center"},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","field":"links","label":"Asan Medical Center"},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","field":"profiles","label":"Asan Medical Center"},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","field":"links","label":"Asan Medical Center"},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","field":"profiles","label":"Asan Medical Center"},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","field":"links","label":"Asan Medical Center"},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","field":"profiles","label":"Asan Medical Center"}]},{"url":"https://english.nmpa.gov.cn/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/","field":"links","label":"NMPA (English)"}]},{"url":"https://english.nmpa.gov.cn/leadership.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","field":"links","label":"Source: NMPA English leadership page"},{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","field":"profiles","label":"NMPA leadership page (English)"}]},{"url":"https://english.tau.ac.il","status":200,"ok":true,"finalUrl":"https://english.tau.ac.il/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","field":"links","label":"Tel Aviv University"},{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","field":"website"}]},{"url":"https://enlazatx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","field":"links","label":"Official website"},{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","field":"website"}]},{"url":"https://enlazatx.com/press_release/enlaza-therapeutics-launches-with-61-million-financing-to-advance-the-first-covalent-biologic-therapeutic-platform/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","field":"links","label":"Seed financing release"}]},{"url":"https://enlazatx.com/press_release/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","field":"links","label":"Series A press release"}]},{"url":"https://epistamaibio.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","route":"/companies/epistamai-biotech/","field":"links","label":"Official website"},{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","route":"/companies/epistamai-biotech/","field":"website"}]},{"url":"https://eqtgroup.com/private-capital/eqt-life-sciences","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","field":"links","label":"Official website"},{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","field":"website"}]},{"url":"https://erassociety.org/guidelines/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","field":"links","label":"ERAS Society guidelines"}]},{"url":"https://erastogaertner.com.br","status":200,"ok":true,"finalUrl":"https://erastogaertner.com.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","route":"/institutions/erasto-gaertner/","field":"links","label":"Official website"},{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","route":"/institutions/erasto-gaertner/","field":"website"}]},{"url":"https://erastogaertner.com.br/pagina/conselho-de-administracao","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","field":"links","label":"Source: Hospital Erasto Gaertner 'Conselho de Administração' page"},{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","field":"profiles","label":"Hospital Erasto Gaertner board page"}]},{"url":"https://erastogaertner.com.br/pagina/diretoria-e-gerencias","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","field":"links","label":"Source: Hospital Erasto Gaertner 'Diretoria e Gerências' page"}]},{"url":"https://es.wikipedia.org/wiki/Instituto_Nacional_del_C%C3%A1ncer_(Uruguay)","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","field":"links","label":"Source: Wikipedia (Spanish) article on the institute"},{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","field":"profiles","label":"Wikipedia (Spanish), Instituto Nacional del Cáncer (Uruguay)"}]},{"url":"https://es.wikipedia.org/wiki/Zo%C3%A9_Robledo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zoe-robledo","kind":"person","name":"Zoé Robledo","route":"/people/zoe-robledo/","field":"links","label":"Source: Spanish Wikipedia article on Zoé Robledo (IMSS Director General since 2019)"},{"id":"zoe-robledo","kind":"person","name":"Zoé Robledo","route":"/people/zoe-robledo/","field":"profiles","label":"Wikipedia (Spanish)"}]},{"url":"https://etj.bioscientifica.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","field":"links","label":"Homepage"},{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","field":"url"}]},{"url":"https://eu.trialstracker.net/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-trial-completion-bonus","kind":"idea","name":"Pay investigators for finishing and publishing trials, not for enrolling patients","route":"/ideas/idea-fund-trial-completion-bonus/","field":"links","label":"EU Trials Tracker"}]},{"url":"https://euclinicaltrials.eu","status":200,"ok":true,"finalUrl":"https://euclinicaltrials.eu/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","route":"/collections/eudract-ctis/","field":"links","label":"EU Clinical Trials Register / CTIS"},{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","route":"/collections/eudract-ctis/","field":"url"}]},{"url":"https://euclinicaltrials.eu/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/","field":"links","label":"EU Clinical Trials Information System"},{"id":"idea-tr2-platform-single-ethics","kind":"idea","name":"One ethics approval and one consent form for a platform trial across countries","route":"/ideas/idea-tr2-platform-single-ethics/","field":"links","label":"EU Clinical Trials Information System"},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"links","label":"EU Clinical Trials Information System (CTIS) public portal"},{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","field":"links","label":"CTIS public portal"}]},{"url":"https://euracan.eu","status":200,"ok":true,"finalUrl":"https://www.euracan.eu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","field":"links","label":"EURACAN"}]},{"url":"https://euracan.eu/","status":200,"ok":true,"finalUrl":"https://www.euracan.eu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-cross-border-rare-cancer-pool","kind":"idea","name":"One legal framework for pooling rare cancer data across borders","route":"/ideas/idea-data-cross-border-rare-cancer-pool/","field":"links","label":"EURACAN"}]},{"url":"https://evaxion.ai/news-resources/?press_release_id=11281","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","field":"links","label":"EVX-05 glioblastoma vaccine programme announcement"}]},{"url":"https://evaxion.ai/news-resources/?press_release_id=11296","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","field":"links","label":"Q2 2026 business update"}]},{"url":"https://evenone.ventures","status":200,"ok":true,"finalUrl":"https://evenone.ventures/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/","field":"links","label":"Official website"},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/","field":"website"}]},{"url":"https://evenone.ventures/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","field":"links","label":"Even One Ventures portfolio"},{"id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"echo-immune","kind":"company","name":"Echo Immune","route":"/companies/echo-immune/","field":"links","label":"Even One Ventures portfolio"},{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"invocata","kind":"company","name":"Invocata","route":"/companies/invocata/","field":"links","label":"Even One Ventures portfolio"},{"id":"kernis-health","kind":"company","name":"Kernis Health","route":"/companies/kernis-health/","field":"links","label":"Even One Ventures portfolio"},{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","route":"/companies/minuteman-therapeutics/","field":"links","label":"Even One Ventures portfolio"},{"id":"palitra-bio","kind":"company","name":"Palitra Bio","route":"/companies/palitra-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","route":"/companies/ranata-therapeutics/","field":"links","label":"Even One Ventures portfolio"},{"id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","field":"links","label":"Even One Ventures portfolio"},{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","route":"/companies/relit-biosciences/","field":"links","label":"Even One Ventures portfolio"},{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","route":"/companies/stitchpoint-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/","field":"links","label":"Even One Ventures portfolio"},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://exceldiagnostics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"links","label":"Official website"},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"website"}]},{"url":"https://exp-oncology.com.ua/","status":200,"ok":true,"finalUrl":"https://exp-oncology.com.ua/index.php/Exp","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","route":"/journals/experimental-oncology/","field":"links","label":"Homepage"},{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","route":"/journals/experimental-oncology/","field":"url"}]},{"url":"https://experts-recherche-lymphome.org/lysa_redirect/en/","status":200,"ok":true,"finalUrl":"https://experts-recherche-lymphome.org/lysa/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","field":"links","label":"Society page"},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","field":"profiles","label":"Society page"}]},{"url":"https://extranet.who.int/fctcapps/sites/default/files/2026-04/NCTOH2026_Panel_Discussion_Summary_%21.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","field":"links","label":"Source: WHO FCTC summary of NCTOH 2026 panel discussion listing her as Director ICMR-NICPR"}]},{"url":"https://fatetherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.fatetherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/","field":"website"}]},{"url":"https://fchampalimaud.org/champalimaud-foundation/team","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leonor-beleza","kind":"person","name":"Leonor Beleza","route":"/people/leonor-beleza/","field":"links","label":"Institution profile"},{"id":"leonor-beleza","kind":"person","name":"Leonor Beleza","route":"/people/leonor-beleza/","field":"profiles","label":"Institution profile"},{"id":"teresa-cotta-dias","kind":"person","name":"Teresa Cotta-Dias","route":"/people/teresa-cotta-dias/","field":"links","label":"Institution profile"},{"id":"teresa-cotta-dias","kind":"person","name":"Teresa Cotta-Dias","route":"/people/teresa-cotta-dias/","field":"profiles","label":"Institution profile"}]},{"url":"https://fci.health","status":200,"ok":true,"finalUrl":"https://fci.health/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","field":"links","label":"Frankfurt Cancer Institute"}]},{"url":"https://fctc.who.int/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"links","label":"WHO Framework Convention on Tobacco Control"}]},{"url":"https://fdaaa.trialstracker.net/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-fdaaa-enforcement","kind":"idea","name":"Actually fine sponsors who do not post trial results","route":"/ideas/idea-tr2-fdaaa-enforcement/","field":"links","label":"FDAAA TrialsTracker"},{"id":"idea-tr2-sponsor-transparency-score","kind":"idea","name":"A public transparency score for every trial sponsor, used by sites and patients","route":"/ideas/idea-tr2-sponsor-transparency-score/","field":"links","label":"FDAAA TrialsTracker"}],"archive":"https://web.archive.org/web/20260615151842/https://fdaaa.trialstracker.net/"},{"url":"https://feinstein.northwell.edu","status":200,"ok":true,"finalUrl":"https://feinstein.northwell.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","field":"links","label":"Feinstein Institutes"}]},{"url":"https://fican.fi/itainen-syopakeskus/tietoa-meista2/organisaatio-ja-johtoryhma/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","field":"links","label":"Source: FICAN East organisation and board page"}]},{"url":"https://fican.fi/itainen-syopakeskus/yhteystiedot/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","field":"links","label":"Source: Itäinen syöpäkeskus (FICAN East) contact and staff page"},{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","field":"profiles","label":"FICAN East contact page"}]},{"url":"https://fican.fi/lantinen-syopakeskus/tietoa-meista/organisaatio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","route":"/people/pia-vihinen/","field":"links","label":"Source: FICAN West organisation page naming the director"},{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","route":"/people/pia-vihinen/","field":"profiles","label":"FICAN West organisation page (Finnish)"}]},{"url":"https://fightcolorectalcancer.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","field":"links","label":"Fight Colorectal Cancer"}]},{"url":"https://findata.fi/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-national-cancer-data-space","kind":"idea","name":"A national cancer data space with one legal front door","route":"/ideas/idea-data-national-cancer-data-space/","field":"links","label":"Findata"}]},{"url":"https://firstascentbiomedical.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","route":"/companies/first-ascent-biomedical/","field":"links","label":"Official website"},{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","route":"/companies/first-ascent-biomedical/","field":"website"}]},{"url":"https://firstdescents.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"first-descents","kind":"collection","name":"First Descents","route":"/collections/first-descents/","field":"links","label":"First Descents"},{"id":"first-descents","kind":"collection","name":"First Descents","route":"/collections/first-descents/","field":"url"}]},{"url":"https://flatiron.com","status":200,"ok":true,"finalUrl":"https://flatiron.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","field":"links","label":"Official website"},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","field":"website"}]},{"url":"https://flatiron.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/","field":"links","label":"Flatiron Health and Foundation Medicine Clinico-Genomic Database (page moved; nearest live section)"},{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/","field":"url"}]},{"url":"https://flcancer.com","status":200,"ok":true,"finalUrl":"https://www.flcancer.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/","field":"links","label":"Official website"},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/","field":"website"}]},{"url":"https://forbion.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","field":"links","label":"Official website"},{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","field":"website"}]},{"url":"https://forbion.com/about-us/history/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","field":"links","label":"History"}]},{"url":"https://forbion.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","field":"links","label":"Portfolio"}]},{"url":"https://foresight-dx.com","status":200,"ok":true,"finalUrl":"https://foresight-dx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","route":"/companies/foresight-diagnostics/","field":"website"}]},{"url":"https://foresight-dx.com/foresight-products-services/foresight-clarity/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","route":"/companies/foresight-diagnostics/","field":"links","label":"CLARITY platform"}]},{"url":"https://foundersfund.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","field":"links","label":"Official website"},{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","field":"website"}]},{"url":"https://foundersfund.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","field":"links","label":"Portfolio"}]},{"url":"https://fprimecapital.com","status":200,"ok":true,"finalUrl":"https://fprimecapital.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","field":"links","label":"Official website"},{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","field":"website"}]},{"url":"https://fr.wikipedia.org/wiki/Hôpital_Bicêtre","status":200,"ok":true,"finalUrl":"https://fr.wikipedia.org/wiki/H%C3%B4pital_Bic%C3%AAtre","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","field":"links","label":"Wikipedia (French): Hôpital de Bicêtre"}]},{"url":"https://fr.wikipedia.org/wiki/Institut_de_canc%C3%A9rologie_de_l%27Ouest","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","field":"links","label":"Source: Wikipedia (French), Institut de cancérologie de l'Ouest"}]},{"url":"https://fr.wikipedia.org/wiki/Institut_national_d%27oncologie_Sidi_Mohamed_ben_Abdellah","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","route":"/people/brahim-lakhal/","field":"links","label":"Source: Wikipedia (French), Institut national d'oncologie Sidi Mohamed ben Abdellah"}]},{"url":"https://frantzviraltherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/","field":"links","label":"Official website"},{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/","field":"website"}]},{"url":"https://frazierls.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","field":"links","label":"Official website"},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","field":"website"}]},{"url":"https://frederick.cancer.gov","status":200,"ok":true,"finalUrl":"https://frederick.cancer.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","field":"links","label":"Frederick National Laboratory"},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","field":"website"}]},{"url":"https://frederick.cancer.gov/about/leadership","status":200,"ok":true,"finalUrl":"https://frederick.cancer.gov/about/people","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","field":"links","label":"Institution profile"},{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","field":"profiles","label":"Institution profile"}]},{"url":"https://friendsofcancerresearch.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-justify-every-exclusion","kind":"idea","name":"Default-inclusive eligibility: sponsors must justify every exclusion criterion","route":"/ideas/idea-tr1-justify-every-exclusion/","field":"links","label":"Friends of Cancer Research"}]},{"url":"https://friendsofcancerresearch.org/tmb/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/","field":"links","label":"Friends of Cancer Research TMB Harmonization"}]},{"url":"https://fujifilmdiosynth.com","status":200,"ok":true,"finalUrl":"https://fujifilmbiotechnologies.fujifilm.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","field":"links","label":"Official website"},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","field":"website"}]},{"url":"https://fundedresearch.cancer.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"links","label":"NCI Funded Research Portfolio"}]},{"url":"https://gamgee.io","status":200,"ok":true,"finalUrl":"https://www.gamgee.io/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/","field":"links","label":"Official website"},{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/","field":"website"}]},{"url":"https://gammatile.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","field":"links","label":"Official website"},{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","field":"website"}]},{"url":"https://gammatile.com/about-gt-medical-technologies/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","field":"links","label":"About GT Medical Technologies"}]},{"url":"https://ganjoho.jp/reg_stat/statistics/stat/cancer/9_gallbladder.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"National Cancer Center Japan: gallbladder and bile duct cancer statistics"}]},{"url":"https://gastro.org","status":200,"ok":true,"finalUrl":"https://gastro.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastroenterology","kind":"journal","name":"Gastroenterology","route":"/journals/gastroenterology/","field":"links","label":"American Gastroenterological Association"}]},{"url":"https://gco.iarc.fr/","status":200,"ok":true,"finalUrl":"https://gco.iarc.who.int/","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-acc-registries-as-aid-condition","kind":"idea","name":"Make a population cancer registry a condition of every cancer aid programme","route":"/ideas/idea-acc-registries-as-aid-condition/","field":"links","label":"Global Cancer Observatory (IARC)"},{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","field":"links","label":"GLOBOCAN (IARC Global Cancer Observatory)"}]},{"url":"https://gco.iarc.who.int","status":200,"ok":true,"finalUrl":"https://gco.iarc.who.int/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/","field":"links","label":"GLOBOCAN / Global Cancer Observatory"},{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/","field":"url"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/12-gallbladder-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"GLOBOCAN gallbladder fact sheet (IARC Global Cancer Observatory)"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/13-pancreas-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"GLOBOCAN pancreas fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"GLOBOCAN trachea, bronchus and lung fact sheet (IARC Global Cancer Observatory, 2024 estimates)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"GLOBOCAN trachea, bronchus and lung fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}],"archive":"https://web.archive.org/web/20260929021931/https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf"},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"GLOBOCAN breast fact sheet (IARC Global Cancer Observatory, 2024 estimates)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"GLOBOCAN breast fact sheet (IARC Global Cancer Observatory, 2024 estimates)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"GLOBOCAN breast fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}],"archive":"https://web.archive.org/web/20260924210618/https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf"},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/27-prostate-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"GLOBOCAN prostate fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"GLOBOCAN colon fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/9-rectum-fact-sheet.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"GLOBOCAN rectum fact sheet (IARC Global Cancer Observatory, 2024 estimates)"}]},{"url":"https://gco.iarc.who.int/today","status":200,"ok":true,"finalUrl":"https://gco.iarc.who.int/today/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"IARC Cancer Today: GLOBOCAN 2022 (gallbladder, C23) by country and sex"},{"id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-bray-globocan-2018-cacancer-2018","kind":"paper","name":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","route":"/key-papers/paper-bray-globocan-2018-cacancer-2018/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-jemal-global-cancer-statistics-2011-cacancer","kind":"paper","name":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)","route":"/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-parkin-global-cancer-statistics-2002-cacancer-2005","kind":"paper","name":"Parkin 2005: Global cancer statistics, 2002","route":"/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-ferlay-globocan-2012-methods-ijc-2015","kind":"paper","name":"Ferlay 2015: sources, methods and major patterns in GLOBOCAN 2012","route":"/key-papers/paper-ferlay-globocan-2012-methods-ijc-2015/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-ferlay-globocan-2018-methods-ijc-2019","kind":"paper","name":"Ferlay 2019: GLOBOCAN 2018 sources and methods","route":"/key-papers/paper-ferlay-globocan-2018-methods-ijc-2019/","field":"links","label":"IARC Global Cancer Observatory"},{"id":"paper-ferlay-cancer-statistics-2020-overview-ijc-2021","kind":"paper","name":"Ferlay 2021: cancer statistics for the year 2020, an overview","route":"/key-papers/paper-ferlay-cancer-statistics-2020-overview-ijc-2021/","field":"links","label":"IARC Global Cancer Observatory"}]},{"url":"https://gdc.cancer.gov/access-data/obtaining-access-controlled-data","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"controlled-access-data","kind":"term","name":"Controlled-access genomic data (dbGaP, EGA)","route":"/terms/controlled-access-data/","field":"links","label":"GDC: obtaining access to controlled data"},{"id":"tcga-tiers","kind":"term","name":"TCGA open versus controlled data tiers","route":"/terms/tcga-tiers/","field":"links","label":"GDC: obtaining access to controlled data"}]},{"url":"https://gdc.cancer.gov/developers/gdc-application-programming-interface-api","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcga-tiers","kind":"term","name":"TCGA open versus controlled data tiers","route":"/terms/tcga-tiers/","field":"links","label":"NCI Genomic Data Commons API (data-sources)"}]},{"url":"https://generatebiomedicines.com","status":200,"ok":true,"finalUrl":"https://generatebiomedicines.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","field":"website"}]},{"url":"https://genuine-bio.com","status":200,"ok":true,"finalUrl":"https://genuine-bio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","field":"website"}]},{"url":"https://gicr.iarc.fr/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-registry-in-a-box","kind":"idea","name":"Open-source cancer registry-in-a-box for low-resource settings","route":"/ideas/idea-data-registry-in-a-box/","field":"links","label":"Global Initiative for Cancer Registry Development (IARC)"}]},{"url":"https://gildehealthcare.com","status":200,"ok":true,"finalUrl":"https://gildehealthcare.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","field":"links","label":"Official website"},{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","field":"website"}]},{"url":"https://github.com/alexdobin/STAR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"star-salmon","kind":"term","name":"STAR and Salmon (RNA-seq alignment and quantification)","route":"/terms/star-salmon/","field":"links","label":"STAR on GitHub (alexdobin/STAR)"}]},{"url":"https://github.com/facebookresearch/esm","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genomic-and-protein-language-models","kind":"term","name":"Genomic and protein language models: Evo 2, Enformer, ESM","route":"/terms/genomic-and-protein-language-models/","field":"links","label":"ESM on GitHub (facebookresearch/esm)"}]},{"url":"https://github.com/instadeepai/multiomics-open-research","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","field":"links","label":"BulkRNABert code (InstaDeep)"}]},{"url":"https://github.com/JDACS4C-IMPROVE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","field":"links","label":"IMPROVE project (Argonne and NCI) on GitHub"}]},{"url":"https://github.com/jianhuupenn/SpaGCN","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spagcn","kind":"term","name":"Spatially aware clustering (SpaGCN, KNN smoothing)","route":"/terms/spagcn/","field":"links","label":"SpaGCN on GitHub"}]},{"url":"https://github.com/MicheleNuijten/statcheck","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-automated-stats-check","kind":"idea","name":"Run automated statistics and image checks on every cancer manuscript before review","route":"/ideas/idea-tr2-automated-stats-check/","field":"links","label":"statcheck"}]},{"url":"https://github.com/seandavi/awesome-cancer-variant-resources","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","route":"/collections/awesome-cancer-variant-resources/","field":"links","label":"awesome-cancer-variant-resources"},{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","route":"/collections/awesome-cancer-variant-resources/","field":"url"}]},{"url":"https://github.com/yc-oss/api","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","field":"links","label":"Open YC directory dataset (yc-oss/api)"}]},{"url":"https://gliwice.nio.gov.pl/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","field":"links","label":"Official website"},{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","field":"website"}]},{"url":"https://global.medical.canon","status":200,"ok":true,"finalUrl":"https://global.medical.canon/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"links","label":"Official website"},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"website"}]},{"url":"https://globalsurg.org/","status":200,"ok":true,"finalUrl":"https://www.globalsurgeryunit.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/","field":"links","label":"GlobalSurg Collaborative"}]},{"url":"https://gmcancer.org.uk","status":200,"ok":true,"finalUrl":"https://gmcancer.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","route":"/institutions/greater-manchester-cancer-alliance/","field":"links","label":"Greater Manchester Cancer Alliance"},{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","route":"/institutions/greater-manchester-cancer-alliance/","field":"website"}]},{"url":"https://go2.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","field":"links","label":"GO2 for Lung Cancer"}]},{"url":"https://grail.com","status":200,"ok":true,"finalUrl":"https://grail.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/","field":"links","label":"Official website"},{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/","field":"website"}]},{"url":"https://grail.com/press-releases/grail-announces-fda-advisory-committee-meeting-to-review-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"GRAIL: FDA advisory committee meeting on the Galleri PMA set for 23 September 2026"}]},{"url":"https://grail.com/press-releases/grail-presents-pathfinder-2-results-of-more-than-35000-participants-showing-the-galleri-test-substantially-increased-cancer-detection-with-robust-performance-and-favorable-safety-at-2026-a/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"GRAIL: PATHFINDER 2 results in more than 35,000 participants, 31 May 2026"}]},{"url":"https://grail.com/press-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Relative reduction in stage IV diagnoses, rounds 2 and 3)"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"outcomes.source (Relative reduction in diagnosis through emergency presentation)"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"GRAIL: full results from the NHS-Galleri trial, 30 May 2026"}]},{"url":"https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"links","label":"GRAIL PMA announcement"}]},{"url":"https://grants.nih.gov/policy-and-compliance/policy-topics/reproducibility","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","field":"links","label":"NIH Rigor and Reproducibility"}]},{"url":"https://greenwichlifesciences.com/gp2/","status":200,"ok":true,"finalUrl":"https://greenwichlifesciences.com/technology/gp2-cancer-immunotherapy/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://griffithlab.org","status":200,"ok":true,"finalUrl":"https://griffithlab.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","field":"links","label":"Griffith lab"},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","field":"profiles","label":"Griffith lab"},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","field":"links","label":"Griffith lab"},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","field":"profiles","label":"Griffith lab"}]},{"url":"https://grit-bio.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/","field":"links","label":"Official website"},{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/","field":"website"}]},{"url":"https://guardanthealth.com","status":200,"ok":true,"finalUrl":"https://guardanthealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","field":"links","label":"Official website"},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","field":"website"}]},{"url":"https://guardanthealth.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guardant-reveal","kind":"drug","name":"Guardant Reveal","route":"/drugs/guardant-reveal/","field":"links","label":"Guardant Reveal (page moved; nearest live section)"}]},{"url":"https://guardanthealth.com/shield","status":200,"ok":true,"finalUrl":"https://guardanthealth.com/clinical-studies/shield/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"access.source (US)"}]},{"url":"https://guidelines.esgo.org","status":200,"ok":true,"finalUrl":"https://guidelines.esgo.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","field":"links","label":"Guidelines"}]},{"url":"https://gv20tx.com","status":200,"ok":true,"finalUrl":"https://gv20tx.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/","field":"links","label":"Official website"},{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/","field":"website"}]},{"url":"https://haematologica.org","status":200,"ok":true,"finalUrl":"https://haematologica.org/index","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","field":"url"}]},{"url":"https://harmonicdiscovery.com","status":200,"ok":true,"finalUrl":"https://harmonicdiscovery.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/","field":"links","label":"Official website"},{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/","field":"website"}]},{"url":"https://haystackmrd.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","field":"links","label":"Official website"},{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","field":"website"}]},{"url":"https://haystackmrd.com/fda-grants-breakthrough-device-designation-for-haystack-mrd-circulating-tumor-dna-test-from-quest-diagnostics/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","field":"links","label":"FDA Breakthrough Device Designation release (Aug 2025)"}]},{"url":"https://haystackmrd.com/haystack-mrd-receives-new-york-state-approval/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","field":"links","label":"New York State approval (June 2026)"}]},{"url":"https://hcgoncology.com","status":200,"ok":true,"finalUrl":"https://www.hcgoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","field":"links","label":"HCG"},{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","field":"profiles","label":"HCG"},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/","field":"links","label":"HCG"},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/","field":"website"}]},{"url":"https://he.wikipedia.org/wiki/ארז_ברנבוים","status":200,"ok":true,"finalUrl":"https://he.wikipedia.org/wiki/%D7%90%D7%A8%D7%96_%D7%91%D7%A8%D7%A0%D7%91%D7%95%D7%99%D7%9D","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","field":"links","label":"Source: Hebrew Wikipedia article on Erez Barenboim"},{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","field":"profiles","label":"Wikipedia (Hebrew)"}]},{"url":"https://he.wikipedia.org/wiki/מרכז_רפואי_רבין","status":200,"ok":true,"finalUrl":"https://he.wikipedia.org/wiki/%D7%9E%D7%A8%D7%9B%D7%96_%D7%A8%D7%A4%D7%95%D7%90%D7%99_%D7%A8%D7%91%D7%99%D7%9F","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","field":"links","label":"Source: Hebrew Wikipedia article on Rabin Medical Center (director field)"}]},{"url":"https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en","status":200,"ok":true,"finalUrl":"https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space-regulation-ehds_en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"links","label":"European Health Data Space"},{"id":"idea-data-national-cancer-data-space","kind":"idea","name":"A national cancer data space with one legal front door","route":"/ideas/idea-data-national-cancer-data-space/","field":"links","label":"European Health Data Space"}]},{"url":"https://health.ec.europa.eu/health-technology-assessment_en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","field":"links","label":"European Commission: health technology assessment"}]},{"url":"https://health.ec.europa.eu/medical-devices-sector/new-regulations_en","status":200,"ok":true,"finalUrl":"https://health.ec.europa.eu/medical-devices-new-regulations_en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","field":"links","label":"European Commission: in vitro diagnostic medical devices"}]},{"url":"https://health.ec.europa.eu/medicinal-products/clinical-trials/clinical-trials-regulation-eu-no-5362014_en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-plain-language-summary-mandate","kind":"idea","name":"A plain-language summary of every cancer trial result within a year","route":"/ideas/idea-data-plain-language-summary-mandate/","field":"links","label":"EU CTR lay summary guidance"}]},{"url":"https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","field":"links","label":"EudraLex Volume 4: EU guidelines for good manufacturing practice"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"EU GMP Annex 3: manufacture of radiopharmaceuticals"}]},{"url":"https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_en","status":200,"ok":true,"finalUrl":"https://health.ec.europa.eu/medicinal-products/reform-eu-pharmaceutical-legislation_en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-third-party-label-update","kind":"idea","name":"Let non-profits and academics add a cancer indication to an off-patent drug's label","route":"/ideas/idea-reg-third-party-label-update/","field":"links","label":"EU pharmaceutical legislation reform"}]},{"url":"https://health.ec.europa.eu/medicinal-products/reform-eu-pharmaceutical-legislation_en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eu-pharma-package","kind":"term","name":"EU pharmaceutical package reform (2023 proposal)","route":"/terms/eu-pharma-package/","field":"links","label":"European Commission: reform of the EU pharmaceutical legislation"}]},{"url":"https://health.google","status":200,"ok":true,"finalUrl":"https://health.google/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/","field":"links","label":"Official website"},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/","field":"website"}]},{"url":"https://health.ucdavis.edu/cancer/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","field":"links","label":"UC Davis Comprehensive Cancer Center"},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","field":"website"}]},{"url":"https://health.ucdavis.edu/cancer/clinical-trials/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","field":"links","label":"Clinical trials"}]},{"url":"https://health.uct.ac.za","status":200,"ok":true,"finalUrl":"https://health.uct.ac.za/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","field":"links","label":"UCT Faculty of Health Sciences"}]},{"url":"https://healthcare.utah.edu/huntsmancancerinstitute","status":200,"ok":true,"finalUrl":"https://healthcare.utah.edu/huntsmancancerinstitute/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","field":"links","label":"Huntsman Cancer Institute"},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","field":"website"}]},{"url":"https://healthcare.utah.edu/huntsmancancerinstitute/about-us","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","route":"/people/jon-huntsman/","field":"links","label":"Huntsman Cancer Institute: about us"}]},{"url":"https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","field":"links","label":"Clinical trials"}]},{"url":"https://healthcare.utah.edu/huntsmancancerinstitute/foundation/about-us","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","route":"/people/jon-huntsman/","field":"links","label":"Huntsman Cancer Foundation: about us"}]},{"url":"https://healthcaredelivery.cancer.gov/pro-ctcae/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"links","label":"NCI PRO-CTCAE"},{"id":"idea-tr1-tolerability-estimands","kind":"idea","name":"Define tolerability endpoints as rigorously as efficacy endpoints","route":"/ideas/idea-tr1-tolerability-estimands/","field":"links","label":"PRO-CTCAE (NCI)"},{"id":"idea-tr1-patient-reported-toxicity-dose-algorithms","kind":"idea","name":"Dose adjustments driven by patients' own symptom reports, tested against clinician judgement","route":"/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/","field":"links","label":"PRO-CTCAE (NCI)"},{"id":"idea-moon-pro-monitoring-standard","kind":"idea","name":"Weekly symptom check-ins with automatic alerts as standard of care on treatment","route":"/ideas/idea-moon-pro-monitoring-standard/","field":"links","label":"NCI PRO-CTCAE"},{"id":"idea-moon-pro-ctcae-in-every-pivotal-trial","kind":"idea","name":"Patient-reported side-effects (PRO-CTCAE) collected and published in every registrational trial","route":"/ideas/idea-moon-pro-ctcae-in-every-pivotal-trial/","field":"links","label":"NCI PRO-CTCAE"}]},{"url":"https://healthimpactfund.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-fund-health-impact-fund-oncology","kind":"idea","name":"A Health Impact Fund pilot that pays for measured health gain instead of price","route":"/ideas/idea-fund-health-impact-fund-oncology/","field":"links","label":"Health Impact Fund"}]},{"url":"https://heavy-ion.showa.gunma-u.ac.jp","status":200,"ok":true,"finalUrl":"https://heavy-ion.showa.gunma-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","field":"links","label":"Gunma University Heavy Ion Medical Center"},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","field":"website"}]},{"url":"https://heavy-ion.showa.gunma-u.ac.jp/page.php?id=15","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","route":"/people/tatsuya-ohno/","field":"links","label":"Source: GHMC director's greeting"},{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","route":"/people/tatsuya-ohno/","field":"profiles","label":"Institution profile"}]},{"url":"https://heidelberg-pharma.com","status":200,"ok":true,"finalUrl":"https://heidelberg-pharma.com/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","field":"links","label":"Official website"},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","field":"website"}]},{"url":"https://helse-bergen.no","status":200,"ok":true,"finalUrl":"https://www.helse-bergen.no/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"links","label":"Haukeland University Hospital website"},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"profiles","label":"Haukeland University Hospital website"},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","field":"links","label":"Official website"},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","field":"website"}]},{"url":"https://henriettalacksfoundation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"links","label":"Henrietta Lacks Foundation"},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","field":"profiles","label":"Henrietta Lacks Foundation"}]},{"url":"https://hetero.com","status":200,"ok":true,"finalUrl":"https://hetero.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hetero","kind":"company","name":"Hetero Drugs","route":"/companies/hetero/","field":"website"}]},{"url":"https://hgvs-nomenclature.org/stable/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"variant-effect-prediction","kind":"term","name":"Variant effect prediction","route":"/terms/variant-effect-prediction/","field":"links","label":"HGVS nomenclature"},{"id":"hgvs","kind":"term","name":"HGVS variant nomenclature","route":"/terms/hgvs/","field":"links","label":"HGVS nomenclature"}]},{"url":"https://hibercell.com","status":200,"ok":true,"finalUrl":"https://hibercell.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","field":"links","label":"Official website"},{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","field":"website"}]},{"url":"https://hillman.upmc.com","status":200,"ok":true,"finalUrl":"https://hillman.upmc.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","field":"links","label":"UPMC Hillman Cancer Center"},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","field":"website"}]},{"url":"https://hillman.upmc.com/research/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","field":"links","label":"Clinical trials"}]},{"url":"https://hist.ai","status":200,"ok":true,"finalUrl":"https://hist.ai/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"histai","kind":"company","name":"HistAI","route":"/companies/histai/","field":"links","label":"Official website"},{"id":"histai","kind":"company","name":"HistAI","route":"/companies/histai/","field":"website"}]},{"url":"https://histiocytesociety.org","status":200,"ok":true,"finalUrl":"https://histiocytesociety.org/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histiocyte-society","kind":"institution","name":"Histiocyte Society","route":"/institutions/histiocyte-society/","field":"links","label":"Histiocyte Society"},{"id":"histiocyte-society","kind":"institution","name":"Histiocyte Society","route":"/institutions/histiocyte-society/","field":"website"}]},{"url":"https://histiocytesociety.org/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"links","label":"Histiocyte Society"}]},{"url":"https://histiocytesociety.org/executive-board/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","field":"links","label":"Source: Histiocyte Society executive board page"},{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","field":"profiles","label":"Histiocyte Society executive board"}]},{"url":"https://histiocytesociety.org/LCH-IV","status":200,"ok":true,"finalUrl":"https://histiocytesociety.org/i4a/notfound.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","field":"links","label":"Histiocyte Society: LCH-IV"}]},{"url":"https://histosonics.com","status":200,"ok":true,"finalUrl":"https://histosonics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","field":"links","label":"Official website"},{"id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","field":"website"}]},{"url":"https://histowiz.com","status":200,"ok":true,"finalUrl":"https://home.histowiz.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/","field":"links","label":"Official website"},{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/","field":"website"}]},{"url":"https://hl7.org/fhir/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","field":"links","label":"HL7 FHIR"}]},{"url":"https://hl7.org/fhir/us/mcode/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-mcode-payment-condition","kind":"idea","name":"No mCODE, no payment: tie oncology reimbursement to a minimal structured record","route":"/ideas/idea-data-mcode-payment-condition/","field":"links","label":"mCODE implementation guide (HL7)"},{"id":"mcode","kind":"term","name":"mCODE (minimal Common Oncology Data Elements)","route":"/terms/mcode/","field":"links","label":"mCODE"},{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","field":"links","label":"mCODE"}]},{"url":"https://hl7.org/fhir/uv/bulkdata/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-oncology-api-certification","kind":"idea","name":"Certify every oncology software product for a standard bulk data export","route":"/ideas/idea-data-oncology-api-certification/","field":"links","label":"FHIR Bulk Data Access"}]},{"url":"https://hl7.org/fhir/uv/cpg/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/","field":"links","label":"HL7 CPG-on-FHIR"}]},{"url":"https://hl7.org/fhir/uv/genomics-reporting/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/","field":"links","label":"HL7 Genomics Reporting IG"}]},{"url":"https://hl7.org/fhir/uv/ips/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-patient-held-cancer-record","kind":"idea","name":"A patient-held cancer record that travels across providers and borders","route":"/ideas/idea-data-patient-held-cancer-record/","field":"links","label":"International Patient Summary (HL7)"}]},{"url":"https://hl7europe.org/hl7-international-appoints-professor-rachel-dunscombe-as-ceo-to-lead-next-phase-of-global-interoperability/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rachel-dunscombe","kind":"person","name":"Rachel Dunscombe","route":"/people/rachel-dunscombe/","field":"links","label":"Source: HL7 Europe news release on the HL7 International CEO appointment (January 2026)"},{"id":"rachel-dunscombe","kind":"person","name":"Rachel Dunscombe","route":"/people/rachel-dunscombe/","field":"profiles","label":"HL7 Europe announcement of her appointment as CEO"}]},{"url":"https://holden.uihealthcare.org/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","route":"/people/mark-burkard/","field":"links","label":"Source: Holden Comprehensive Cancer Center leadership page"},{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","route":"/people/mark-burkard/","field":"profiles","label":"Holden leadership page"}]},{"url":"https://hollingscancercenter.musc.edu","status":200,"ok":true,"finalUrl":"https://hollingscancercenter.musc.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","field":"links","label":"MUSC Hollings Cancer Center"},{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","field":"website"}]},{"url":"https://hollingscancercenter.musc.edu/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","route":"/people/raymond-dubois/","field":"links","label":"Source: MUSC Hollings Cancer Center leadership page"},{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","route":"/people/raymond-dubois/","field":"profiles","label":"Hollings Cancer Center leadership page"}]},{"url":"https://hollingscancercenter.musc.edu/research/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","field":"links","label":"Clinical trials"}]},{"url":"https://hospitaldeamor.com.br","status":200,"ok":true,"finalUrl":"https://hospitaldeamor.com.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/","field":"links","label":"Hospital de Amor"},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/","field":"website"}]},{"url":"https://hospitaldeamor.com.br/henrique-prata-lanca-seu-novo-livro-o-parque-dos-lobos/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henrique-prata","kind":"person","name":"Henrique Prata","route":"/people/henrique-prata/","field":"links","label":"Source: Hospital de Amor news article (president of HA)"},{"id":"henrique-prata","kind":"person","name":"Henrique Prata","route":"/people/henrique-prata/","field":"profiles","label":"Hospital de Amor article naming him as president"}]},{"url":"https://hospitals.aku.edu/nairobi","status":200,"ok":true,"finalUrl":"https://hospitals.aku.edu/kenya/home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/","field":"links","label":"Official website"},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/","field":"website"}]},{"url":"https://hospitals.aku.edu/nairobi/AboutUs/Pages/OurProfile.aspx","status":200,"ok":true,"finalUrl":"https://hospitals.aku.edu/kenya/about-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","route":"/people/rashid-khalani/","field":"profiles","label":"Hospital profile page"}]},{"url":"https://hovon.nl","status":200,"ok":true,"finalUrl":"https://hovon.nl/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/","field":"links","label":"HOVON"},{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/","field":"website"}]},{"url":"https://hovon.nl/en/about-hovon","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","field":"links","label":"Society page"},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","field":"profiles","label":"Society page"},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","field":"links","label":"Society page"},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","field":"profiles","label":"Society page"}]},{"url":"https://hovon.nl/en/trials","status":200,"ok":true,"finalUrl":"https://hovon.nl/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/","field":"links","label":"Trials"}]},{"url":"https://hpo.jax.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hpo","kind":"term","name":"Human Phenotype Ontology (HPO)","route":"/terms/hpo/","field":"links","label":"HPO (Jackson Laboratory)"}]},{"url":"https://hsc.unm.edu/echo/","status":200,"ok":true,"finalUrl":"https://projectecho.unm.edu/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-acc-echo-tele-mentoring-oncology","kind":"idea","name":"Project ECHO tele-mentoring for district clinicians managing cancer","route":"/ideas/idea-acc-echo-tele-mentoring-oncology/","field":"links","label":"Project ECHO"}]},{"url":"https://huggingface.co/bioptimus/H-optimus-0","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h-optimus","kind":"technology","name":"H-optimus (Bioptimus)","route":"/technologies/h-optimus/","field":"links","label":"Hugging Face model card"}]},{"url":"https://huggingface.co/docs/hub/index","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"model-card","kind":"term","name":"Model cards and datasheets for datasets","route":"/terms/model-card/","field":"links","label":"Hugging Face Hub documentation"},{"id":"hugging-face-hub","kind":"term","name":"Hugging Face Hub","route":"/terms/hugging-face-hub/","field":"links","label":"Hugging Face Hub documentation"}]},{"url":"https://huggingface.co/MahmoodLab/UNI2-h","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"UNI2-h on Hugging Face (MahmoodLab)"}]},{"url":"https://huggingface.co/paige-ai/Virchow2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","field":"links","label":"Virchow2 on Hugging Face (Paige)"}]},{"url":"https://humanegenomics.com","status":200,"ok":true,"finalUrl":"https://humanegenomics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/","field":"links","label":"Official website"},{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/","field":"website"}]},{"url":"https://humantumoratlas.org","status":200,"ok":true,"finalUrl":"https://humantumoratlas.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","field":"links","label":"Human Tumor Atlas Network"}]},{"url":"https://humantumoratlas.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-moon-open-cancer-cell-state-model","kind":"idea","name":"An open model of every cancer cell state, built from perturbation atlases","route":"/ideas/idea-moon-open-cancer-cell-state-model/","field":"links","label":"Human Tumor Atlas Network"}]},{"url":"https://huon.hu","status":200,"ok":true,"finalUrl":"https://huon.hu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","route":"/journals/magyar-onkologia/","field":"links","label":"Homepage"},{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","route":"/journals/magyar-onkologia/","field":"url"}]},{"url":"https://huyabio.com","status":200,"ok":true,"finalUrl":"https://huyabio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","field":"links","label":"Official website"},{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","field":"website"}]},{"url":"https://iba.med.muni.cz/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"links","label":"Institute of Biostatistics and Analyses, Masaryk University website"},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"profiles","label":"Institute of Biostatistics and Analyses, Masaryk University website"},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","route":"/institutions/iba-masaryk/","field":"links","label":"Official website"},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","route":"/institutions/iba-masaryk/","field":"website"}]},{"url":"https://icd.who.int/browse10/2019/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"WHO ICD-10 (2019): C43 to C44 melanoma and other malignant neoplasms of skin; D04 carcinoma in situ of skin; L57.0 actinic keratosis, under skin changes due to chronic exposure to nonionizing radiation"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"links","label":"WHO ICD-10 (2019): C43 to C44 melanoma and other malignant neoplasms of skin; D04 carcinoma in situ of skin; L57.0 actinic keratosis, under skin changes due to chronic exposure to nonionizing radiation"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"WHO ICD-10 (2019): C43 to C44 melanoma and other malignant neoplasms of skin; D04 carcinoma in situ of skin; L57.0 actinic keratosis, under skin changes due to chronic exposure to nonionizing radiation"}]},{"url":"https://icer.org","status":200,"ok":true,"finalUrl":"https://icer.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","field":"links","label":"ICER"}]},{"url":"https://icer.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-value-scale-in-coverage","kind":"idea","name":"Tie coverage and copays to the ESMO benefit scale","route":"/ideas/idea-cost-value-scale-in-coverage/","field":"links","label":"ICER"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","field":"links","label":"ICER"}]},{"url":"https://icesp.org.br/conselho-diretor-e-diretorias/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","route":"/people/arthur-violante-sapia/","field":"links","label":"Source: ICESP Conselho Diretor e Diretorias page"},{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","route":"/people/arthur-violante-sapia/","field":"profiles","label":"ICESP board and directorates page"}]},{"url":"https://icesp.org.br/o-icesp/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","route":"/people/arthur-violante-sapia/","field":"links","label":"Source: ICESP institutional overview"}]},{"url":"https://iclac.org/databases/cross-contaminations/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-model-authentication-mandate","kind":"idea","name":"Prove the cell line is what you say it is, or the paper does not run","route":"/ideas/idea-bio1-model-authentication-mandate/","field":"links","label":"ICLAC register of misidentified cell lines"},{"id":"idea-tr2-cell-line-authentication-mandate","kind":"idea","name":"Prove your cell lines are what you say they are, or the paper is not published","route":"/ideas/idea-tr2-cell-line-authentication-mandate/","field":"links","label":"ICLAC register of misidentified cell lines"}]},{"url":"https://icmrnine.org","status":200,"ok":true,"finalUrl":"https://icmrnine.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","field":"links","label":"ICMR-NINE"},{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","field":"profiles","label":"ICMR-NINE"},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","field":"links","label":"ICMR-NINE (formerly NCDIR)"},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","field":"website"}]},{"url":"https://ico.gencat.cat","status":200,"ok":true,"finalUrl":"https://ico.gencat.cat/ca/inici","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","field":"links","label":"Catalan Institute of Oncology (ICO) website"},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","field":"profiles","label":"Catalan Institute of Oncology (ICO) website"},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","route":"/institutions/ico-catalonia/","field":"links","label":"Official website"},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","route":"/institutions/ico-catalonia/","field":"website"}]},{"url":"https://ico.gencat.cat/ca/linstitut/","status":200,"ok":true,"finalUrl":"https://ico.gencat.cat/ca/linstitut","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","route":"/people/ramon-salazar-soler/","field":"profiles","label":"ICO institutional pages"}]},{"url":"https://ideayabio.com/pipeline/","status":200,"ok":true,"finalUrl":"https://ideayabio.com/pipeline","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://idrblab.org/ttd/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","field":"links","label":"Therapeutic Target Database (TTD)"},{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","field":"url"}]},{"url":"https://ignitus.bio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","field":"links","label":"Official website"},{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","field":"website"}]},{"url":"https://iisc.ac.in","status":200,"ok":true,"finalUrl":"https://www.iisc.ac.in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/","field":"links","label":"Indian Institute of Science"},{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/","field":"website"}]},{"url":"https://iknl.nl","status":200,"ok":true,"finalUrl":"https://iknl.nl/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/","field":"links","label":"Official website"},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/","field":"website"}]},{"url":"https://iktos.ai","status":200,"ok":true,"finalUrl":"https://iktos.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/","field":"links","label":"Official website"},{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/","field":"website"}]},{"url":"https://illinois.edu","status":200,"ok":true,"finalUrl":"https://illinois.edu/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","field":"links","label":"University of Illinois Urbana-Champaign"}]},{"url":"https://imagene-ai.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","field":"links","label":"Official website"},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","field":"website"}]},{"url":"https://imagene-ai.com/newsroom/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","field":"links","label":"Newsroom"}]},{"url":"https://imas12.es","status":200,"ok":true,"finalUrl":"https://imas12.es/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","field":"links","label":"i+12"}]},{"url":"https://imdxinc.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","field":"links","label":"Official website"},{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","field":"website"}]},{"url":"https://imermanangels.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imerman-angels","kind":"collection","name":"Imerman Angels","route":"/collections/imerman-angels/","field":"links","label":"Imerman Angels"},{"id":"imerman-angels","kind":"collection","name":"Imerman Angels","route":"/collections/imerman-angels/","field":"url"}]},{"url":"https://imid.med.pl/pl/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"links","label":"Institute of Mother and Child, Warsaw website"},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"profiles","label":"Institute of Mother and Child, Warsaw website"},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","field":"links","label":"Official website"},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","field":"website"}]},{"url":"https://immatics.com","status":200,"ok":true,"finalUrl":"https://www.immatics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","field":"website"}]},{"url":"https://immunitybio.com","status":200,"ok":true,"finalUrl":"https://immunitybio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/","field":"links","label":"Official website"},{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/","field":"website"}]},{"url":"https://immunoact.com","status":200,"ok":true,"finalUrl":"https://immunoact.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"links","label":"ImmunoACT"},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"profiles","label":"ImmunoACT"},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","field":"links","label":"ImmunoACT (spin-off)"},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/","field":"links","label":"Official website"},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/","field":"website"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"links","label":"ImmunoACT: NexCAR19"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"access.source (IN)"},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","field":"regulatoryEvents.source (2023)"}]},{"url":"https://immunocine.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunocine","kind":"institution","name":"Immunocine","route":"/institutions/immunocine/","field":"links","label":"Official website"},{"id":"immunocine","kind":"institution","name":"Immunocine","route":"/institutions/immunocine/","field":"website"}]},{"url":"https://imugene.com/pipeline/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","field":"links","label":"Clinical trials"}]},{"url":"https://indapta.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","field":"links","label":"Official website"},{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","field":"website"}]},{"url":"https://indicalab.com","status":200,"ok":true,"finalUrl":"https://indicalab.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/","field":"links","label":"Official website"},{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/","field":"website"}]},{"url":"https://inhibrx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","field":"links","label":"Official website"},{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","field":"website"}]},{"url":"https://inhibrx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","field":"links","label":"Pipeline"},{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://inoc.it/it/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","field":"links","label":"Istituto di Candiolo IRCCS (FPO) website"},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","field":"profiles","label":"Istituto di Candiolo IRCCS (FPO) website"}]},{"url":"https://inoc.it/it/direzione-scientifica/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","field":"links","label":"Institution profile"},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","field":"profiles","label":"Institution profile"}]},{"url":"https://insight.jci.org","status":200,"ok":true,"finalUrl":"https://insight.jci.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","field":"links","label":"JCI Insight"}]},{"url":"https://insightec.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transcranial-focused-ultrasound-systems","kind":"technology","name":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","route":"/technologies/transcranial-focused-ultrasound-systems/","field":"links","label":"Insightec: Exablate Neuro"}]},{"url":"https://insilico.com","status":200,"ok":true,"finalUrl":"https://insilico.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","field":"website"},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/","field":"links","label":"Insilico Medicine"}]},{"url":"https://instem.res.in/directors-message/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"links","label":"Source: inStem Director's note"},{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"profiles","label":"inStem Director's note"}]},{"url":"https://instituciones.sld.cu/inor","status":200,"ok":true,"finalUrl":"https://instituciones.sld.cu/inor/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/","field":"links","label":"Official website"},{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/","field":"website"}]},{"url":"https://instituciones.sld.cu/inor/quienes-somos-2/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","route":"/people/luis-eduardo-martin-rodriguez/","field":"links","label":"Source: INOR 'Quiénes somos' page (institution description)"}]},{"url":"https://institutducancer-hopitaux-universiteparissaclay.aphp.fr/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"links","label":"AP-HP Paris-Saclay University Hospitals Cancer Institute website"},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"profiles","label":"AP-HP Paris-Saclay University Hospitals Cancer Institute website"},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","field":"links","label":"Official website"},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","field":"website"}]},{"url":"https://institutnationalducancer.lu/","status":200,"ok":true,"finalUrl":"https://institutcancer.lu/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"links","label":"Institut National du Cancer, Luxembourg website"},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"profiles","label":"Institut National du Cancer, Luxembourg website"},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","route":"/institutions/inc-luxembourg/","field":"links","label":"Official website"},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","route":"/institutions/inc-luxembourg/","field":"website"}]},{"url":"https://institutoroffo.uba.ar/autoridades/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roxana-del-aguila","kind":"person","name":"Roxana del Águila","route":"/people/roxana-del-aguila/","field":"links","label":"Source: Instituto Roffo autoridades page"},{"id":"roxana-del-aguila","kind":"person","name":"Roxana del Águila","route":"/people/roxana-del-aguila/","field":"profiles","label":"Instituto Roffo authorities page"}]},{"url":"https://intermountainhealthcare.org/services/cancer-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","field":"links","label":"Intermountain cancer care"},{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","field":"website"}]},{"url":"https://intermountainhealthcare.org/services/cancer-care/precision-genomics","status":200,"ok":true,"finalUrl":"https://intermountainhealthcare.org/services/genetic-counseling","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","field":"links","label":"Intermountain Precision Genomics"}]},{"url":"https://intodna.com","status":200,"ok":true,"finalUrl":"https://intodna.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","route":"/technologies/stride-dna-break-detection/","field":"links","label":"intoDNA: STRIDE technology"},{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/","field":"links","label":"Official website"},{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/","field":"website"}]},{"url":"https://intraop.com","status":200,"ok":true,"finalUrl":"https://intraop.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","field":"links","label":"Official website"},{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","field":"website"}]},{"url":"https://intraop.com/intraop/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","field":"links","label":"About IntraOp"}]},{"url":"https://intraop.com/intraop/news-and-events-2/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","field":"links","label":"News and events"}]},{"url":"https://intraop.com/mobetron/","status":200,"ok":true,"finalUrl":"https://intraop.com/mobetron-iort/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"electron-beam-therapy-systems","kind":"technology","name":"Electron beam therapy systems (linac electrons, total skin electron units, mobile electron IORT)","route":"/technologies/electron-beam-therapy-systems/","field":"links","label":"IntraOp: Mobetron mobile electron IORT"}]},{"url":"https://intraop.com/news-events/intraop-medical-announces-completion-of-pioneering-human-flash-radiotherapy-trial-and-publication-of-landmark-clinical-physics-results-with-lausanne-university-hospital-chuv/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","field":"links","label":"IMPulse FLASH trial completion with CHUV (March 2026)"}]},{"url":"https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/","field":"links","label":"ANTLER data"}]},{"url":"https://investor.fibrogen.com/news-releases","status":200,"ok":true,"finalUrl":"https://investor.kyntrabio.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"pamrevlumab","kind":"drug","name":"Pamrevlumab","route":"/drugs/pamrevlumab/","field":"links","label":"FibroGen announcement, LAPIS topline results (2024)"}]},{"url":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","field":"links","label":"Lilly acquisition"}]},{"url":"https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-adults-er-her2-esr1","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","field":"links","label":"Lilly approval release"},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","field":"regulatoryEvents.source (2025-09-25)"}],"archive":"https://web.archive.org/web/20260107144315/https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-adults-er-her2-esr1"},{"url":"https://investor.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","field":"regulatoryEvents.source (2025-07-02)"}]},{"url":"https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-phase-3-trial-fianlimab-lag-3","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","field":"links","label":"Regeneron update"},{"id":"fianlimab","kind":"drug","name":"Fianlimab","route":"/drugs/fianlimab/","field":"links","label":"Regeneron update"}]},{"url":"https://investor.verastem.com/news-releases/news-release-details/fda-approves-avmapkitm-fakzynjatm-combination-therapy-first-ever","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/","field":"links","label":"FDA approval"}]},{"url":"https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-pricing-initial-public-offering","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","field":"links","label":"IPO pricing release (Oct 2020)"}]},{"url":"https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-second-quarter-2026-results-and-highlights","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","field":"links","label":"Q2 2026 results"}]},{"url":"https://investors.coherus.com/news-releases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","field":"links","label":"Coherus licence (February 2021)"}]},{"url":"https://investors.imdxinc.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","field":"links","label":"Investor relations"}]},{"url":"https://investors.imdxinc.com/news-releases/2026/08-10-2026-210715920","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","field":"links","label":"Q2 2026 results release (Nashville dateline, former name)"}]},{"url":"https://investors.karyopharm.com/2026-07-30-Karyopharm-Announces-Topline-Results-from-Phase-3-XPORT-EC-042-Trial-in-Endometrial-Cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","field":"links","label":"Karyopharm topline"},{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","field":"outcomes.source (Progression-free survival (mITT))"}]},{"url":"https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","field":"links","label":"Nuvalent NDA submission"}],"archive":"https://web.archive.org/web/20260522083704/https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC"},{"url":"https://investors.tempus.com/news-releases/news-release-details/tempus-acquire-personalis-more-tightly-integrating-molecular","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","field":"links","label":"Tempus acquisition"}]},{"url":"https://investors.xencor.com/news-releases/news-release-details/xencor-highlights-corporate-priorities-and-2026-pipeline","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","field":"links","label":"2026 milestones"}]},{"url":"https://invocata.bio/","status":200,"ok":true,"finalUrl":"https://www.invocata.bio/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"invocata","kind":"company","name":"Invocata","route":"/companies/invocata/","field":"links","label":"Official website"},{"id":"invocata","kind":"company","name":"Invocata","route":"/companies/invocata/","field":"website"}]},{"url":"https://invoke.bio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"invoke-bio","kind":"company","name":"Invoke Bio","route":"/companies/invoke-bio/","field":"links","label":"Official website"},{"id":"invoke-bio","kind":"company","name":"Invoke Bio","route":"/companies/invoke-bio/","field":"website"}]},{"url":"https://ipindia.gov.in/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-voluntary-licensing-oncology","kind":"idea","name":"Voluntary licences and price caps for patented cancer drugs in low-income countries","route":"/ideas/idea-cost-voluntary-licensing-oncology/","field":"links","label":"Intellectual Property India"}]},{"url":"https://ipos-society.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","field":"links","label":"International Psycho-Oncology Society"},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","field":"profiles","label":"International Psycho-Oncology Society"}]},{"url":"https://ir.actiniumpharma.com/press-releases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"Press releases"}]},{"url":"https://ir.actiniumpharma.com/press-releases/detail/525/actinium-pharmaceuticals-announces-actimab-a-intellectual","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"August 2026 Actimab-A and listing update"}]},{"url":"https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-receives-fda-regenerative-medicine-0","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/","field":"links","label":"Cema-cel RMAT"}]},{"url":"https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-presentations-2026-asco-and-eular","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/","field":"links","label":"ASCO/EULAR 2026"}]},{"url":"https://ir.genmab.com/news-releases/news-release-details/genmab-announces-topline-results-epcoritamab-duobodyr-cd3xcd20/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","field":"outcomes.source (Overall survival)"}]},{"url":"https://ir.ideayabio.com/news-releases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","field":"links","label":"Investor news releases"}]},{"url":"https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/","field":"links","label":"FDA approval of Komzifti (Kura, 13 Nov 2025)"}]},{"url":"https://ir.neogenomics.com/news-events/press-releases/detail/176/neogenomics-to-acquire-inivata---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","field":"links","label":"NeoGenomics to acquire Inivata (May 2021)"}]},{"url":"https://ir.neogenomics.com/news-events/press-releases/detail/180/neogenomics-completes-inivata-acquisition---combining-best-in-class-liquid-biopsy-technology-with-leading-community-oncology-platform","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","field":"links","label":"NeoGenomics completes Inivata acquisition (June 2021)"}]},{"url":"https://ir.perimetermed.com/news-events/press-releases/detail/200/perimeter-medical-imaging-ai-claire-becomes-first","status":200,"ok":true,"finalUrl":"https://ir.perimetermed.com/news-events/press-releases/detail/200/perimeter-medical-imaging-ais-claire-becomes-first","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"links","label":"Claire FDA PMA approval (March 2026)"}]},{"url":"https://ir.perimetermed.com/news-events/press-releases/detail/207/perimeter-medical-imaging-ai-closes-life-offering","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"links","label":"LIFE offering closing (May 2026)"}]},{"url":"https://ir.perimetermed.com/news-events/press-releases/detail/210/perimeter-medical-imaging-ai-closes-final-tranche-of","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"links","label":"Convertible debenture final tranche (June 2026)"}]},{"url":"https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/","field":"links","label":"Q1 2026 update"}]},{"url":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"Revolution Medicines announcement"}]},{"url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","field":"links","label":"Revolution Medicines, ESMO GI 2026"}]},{"url":"https://ir.volition.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","field":"links","label":"Investor relations"}]},{"url":"https://isabl.io","status":200,"ok":true,"finalUrl":"https://www.isabl.io/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isabl","kind":"company","name":"Isabl","route":"/companies/isabl/","field":"links","label":"Official website"},{"id":"isabl","kind":"company","name":"Isabl","route":"/companies/isabl/","field":"website"}]},{"url":"https://isanidad.com/330649/el-dr-urruticoechea-tomas-las-riendas-de-geicam-con-el-reto-de-sostener-la-investigacion-academica-en-cancer-de-mama-sin-apoyo-publico/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","route":"/people/ander-urruticoechea/","field":"links","label":"Source: iSanidad interview naming him GEICAM president (May 2025)"},{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","route":"/people/ander-urruticoechea/","field":"profiles","label":"iSanidad interview on taking over the GEICAM presidency (May 2025)"}]},{"url":"https://it.wikipedia.org/wiki/Arcispedale_Santa_Maria_Nuova","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"davide-fornaciari","kind":"person","name":"Davide Fornaciari","route":"/people/davide-fornaciari/","field":"links","label":"Source: Italian Wikipedia article naming the Direttore Generale"},{"id":"davide-fornaciari","kind":"person","name":"Davide Fornaciari","route":"/people/davide-fornaciari/","field":"profiles","label":"Wikipedia (Italian): Arcispedale Santa Maria Nuova"}]},{"url":"https://itm-radiopharma.com","status":200,"ok":true,"finalUrl":"https://www.itm-radiopharma.com/home/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","field":"links","label":"Official website"},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","field":"website"}]},{"url":"https://itmig.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","field":"links","label":"ITMIG"}]},{"url":"https://iuc-aphp-sorbonneuniversite.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"links","label":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université website"},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"profiles","label":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université website"}]},{"url":"https://iuc-hopitaux-u-mondor.aphp.fr/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"links","label":"AP-HP Henri-Mondor University Hospitals Cancer Institute website"},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"profiles","label":"AP-HP Henri-Mondor University Hospitals Cancer Institute website"},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","field":"links","label":"Official website"},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","field":"website"}]},{"url":"https://iv.iiarjournals.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","field":"links","label":"Homepage"},{"id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","field":"url"}]},{"url":"https://ivl24.it/il-vescovo-fanelli-al-fianco-della-ricerca-oncologica-la-conferma-del-carattere-scientifico-del-crob-e-una-vittoria-della-vita/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","route":"/people/massimo-de-fino/","field":"links","label":"Source: ivl24 report naming him as director of CROB (August 2026)"}]},{"url":"https://ivl24.it/massimo-de-fino-nuovo-direttore-generale-del-crob/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","route":"/people/massimo-de-fino/","field":"links","label":"Source: ivl24 appointment report (November 2023)"},{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","route":"/people/massimo-de-fino/","field":"profiles","label":"ivl24 report of his appointment as Direttore Generale (November 2023)"}],"archive":"https://web.archive.org/web/20250518033720/https://ivl24.it/massimo-de-fino-nuovo-direttore-generale-del-crob/"},{"url":"https://iwmf.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"links","label":"IWMF (patient foundation)"}]},{"url":"https://ja.wikipedia.org/wiki/%E6%84%9B%E7%9F%A5%E7%9C%8C%E3%81%8C%E3%82%93%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yasumasa-niwa","kind":"person","name":"Yasumasa Niwa","route":"/people/yasumasa-niwa/","field":"links","label":"Source: Japanese Wikipedia article on Aichi Cancer Center"},{"id":"yasumasa-niwa","kind":"person","name":"Yasumasa Niwa","route":"/people/yasumasa-niwa/","field":"profiles","label":"Wikipedia (Japanese)"}]},{"url":"https://jaimeleandrofoundation.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","route":"/companies/jaime-leandro-foundation/","field":"links","label":"Official website"},{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","route":"/companies/jaime-leandro-foundation/","field":"website"}]},{"url":"https://jeccr.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/13046","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","field":"links","label":"Homepage"},{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","field":"url"}]},{"url":"https://jenci.springeropen.com","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/43046","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","field":"links","label":"Homepage"},{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","field":"url"}]},{"url":"https://jgc-online.org","status":200,"ok":true,"finalUrl":"https://jgc-online.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","route":"/journals/journal-of-gastric-cancer/","field":"links","label":"Homepage"},{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","route":"/journals/journal-of-gastric-cancer/","field":"url"}]},{"url":"https://jhoonline.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/13045","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","field":"url"}]},{"url":"https://jnjinnovation.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","field":"links","label":"Official website"}]},{"url":"https://jnjinnovation.com/venture-investing-jjdc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","field":"links","label":"Official website"},{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","field":"website"}]},{"url":"https://jnm.snmjournals.org","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","field":"url"}]},{"url":"https://jnm.snmjournals.org/content/67/8/1239","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","field":"links","label":"ACTION-1 dosimetry (JNM 2026)"}]},{"url":"https://joincountmein.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-donor-card","kind":"idea","name":"A cancer data donor card: patient-controlled donation of records for research","route":"/ideas/idea-data-donor-card/","field":"links","label":"Count Me In"},{"id":"idea-fund-portable-patient-consent","kind":"idea","name":"Patient-held portable consent for reusing samples and data across studies","route":"/ideas/idea-fund-portable-patient-consent/","field":"links","label":"Count Me In"}]},{"url":"https://journal.waocp.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","field":"links","label":"Homepage"},{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","field":"url"}]},{"url":"https://journals.plos.org/plosmedicine/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","field":"links","label":"PLOS Medicine cancer (page moved; nearest live section)"},{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","field":"url"}]},{"url":"https://kanser.hacettepe.edu.tr/?sayfa=yonetim-mudur","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","route":"/people/kadir-mutlu-hayran/","field":"links","label":"Source: Hacettepe Cancer Institute director page"}]},{"url":"https://kath.gov.gh","status":200,"ok":true,"finalUrl":"https://kath.gov.gh/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/","field":"links","label":"Official website"},{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/","field":"website"}]},{"url":"https://kath.gov.gh/management/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paa-kwesi-baidoo","kind":"person","name":"Paa Kwesi Baidoo","route":"/people/paa-kwesi-baidoo/","field":"links","label":"Source: Komfo Anokye Teaching Hospital management page"},{"id":"paa-kwesi-baidoo","kind":"person","name":"Paa Kwesi Baidoo","route":"/people/paa-kwesi-baidoo/","field":"profiles","label":"KATH management page"}]},{"url":"https://kbth.gov.gh","status":200,"ok":true,"finalUrl":"https://kbth.gov.gh/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","field":"links","label":"Korle Bu Teaching Hospital"},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","field":"website"}]},{"url":"https://kechowpharma.com","status":200,"ok":true,"finalUrl":"https://www.kechowpharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/","field":"links","label":"Official website"},{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/","field":"website"}]},{"url":"https://keloniatx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","field":"links","label":"Official website"},{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","field":"website"}]},{"url":"https://keloniatx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","field":"links","label":"Pipeline and inMMyCAR trial"}]},{"url":"https://kernis.health/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kernis-health","kind":"company","name":"Kernis Health","route":"/companies/kernis-health/","field":"links","label":"Official website"},{"id":"kernis-health","kind":"company","name":"Kernis Health","route":"/companies/kernis-health/","field":"website"}]},{"url":"https://ki.mit.edu","status":200,"ok":true,"finalUrl":"https://ki.mit.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/","field":"links","label":"Koch Institute"},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/","field":"website"}]},{"url":"https://ki.mit.edu/about/history","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/","field":"links","label":"MIT Koch Institute: history"}]},{"url":"https://ki.mit.edu/people/faculty/langer","status":200,"ok":true,"finalUrl":"https://ki.mit.edu/people/faculty/robert-langer","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","field":"links","label":"Institution profile"},{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","field":"profiles","label":"Institution profile"}]},{"url":"https://ki.mit.edu/people/institute-directorship","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","field":"links","label":"Institution profile"},{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","field":"profiles","label":"Institution profile"}]},{"url":"https://ki.se/en/collaboration/healthcare-services/karolinska-comprehensive-cancer-centre","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"links","label":"Karolinska University Hospital website"},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"profiles","label":"Karolinska University Hospital website"}]},{"url":"https://kiyatec.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/","field":"links","label":"Official website"},{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/","field":"website"}]},{"url":"https://knh.or.ke","status":200,"ok":true,"finalUrl":"https://knh.or.ke/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","field":"links","label":"Kenyatta National Hospital"},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","field":"website"}]},{"url":"https://knh.or.ke/index.php/organizational-management/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richard-lesiyampe","kind":"person","name":"Richard Lesiyampe","route":"/people/richard-lesiyampe/","field":"links","label":"Institution profile"},{"id":"richard-lesiyampe","kind":"person","name":"Richard Lesiyampe","route":"/people/richard-lesiyampe/","field":"profiles","label":"Institution profile"}]},{"url":"https://knownmed.com","status":200,"ok":true,"finalUrl":"https://www.knownmed.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/","field":"links","label":"Official website"},{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/","field":"website"}]},{"url":"https://kopra.bio","status":200,"ok":true,"finalUrl":"https://www.kopra.bio/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/","field":"links","label":"Official website"},{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/","field":"website"}]},{"url":"https://kumquatbiosciences.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","field":"links","label":"Official website"},{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","field":"website"}]},{"url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-enter-global-exclusive-license-and-collaboration-in-precision-oncology/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","field":"links","label":"Bayer licence and collaboration (August 2025)"}]},{"url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-initiate-phase-i-study-with-kras-g12d-inhibitor-in-patients-with-kras-mutated-tumors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","field":"links","label":"Phase 1 start with Bayer (October 2025)"}]},{"url":"https://kumquatbiosciences.com/news/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","field":"links","label":"Takeda collaboration"}]},{"url":"https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","field":"links","label":"SPLASH primary analysis (Lantheus, ESMO 2024)"}]},{"url":"https://laskerfoundation.org","status":200,"ok":true,"finalUrl":"https://laskerfoundation.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lasker-foundation","kind":"institution","name":"Lasker Foundation","route":"/institutions/lasker-foundation/","field":"website"}]},{"url":"https://laskerfoundation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","field":"links","label":"Lasker Foundation"},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","field":"profiles","label":"Lasker Foundation"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","field":"links","label":"Lasker Foundation"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","field":"profiles","label":"Lasker Foundation"}]},{"url":"https://laskerfoundation.org/about/","status":200,"ok":true,"finalUrl":"https://laskerfoundation.org/about-us/mission/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"albert-lasker","kind":"person","name":"Albert Lasker","route":"/people/albert-lasker/","field":"links","label":"Lasker Foundation: about"},{"id":"lasker-foundation","kind":"institution","name":"Lasker Foundation","route":"/institutions/lasker-foundation/","field":"links","label":"About the Lasker Foundation"}]},{"url":"https://lazarex.org/","status":200,"ok":true,"finalUrl":"https://uscnorriscancer.usc.edu/patient-services/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr1-travel-lodging-in-every-budget","kind":"idea","name":"Travel, lodging and meals reimbursed as a standard line in every trial budget","route":"/ideas/idea-tr1-travel-lodging-in-every-budget/","field":"links","label":"Lazarex Cancer Foundation"},{"id":"lazarex-cancer-foundation","kind":"collection","name":"Lazarex Cancer Foundation","route":"/collections/lazarex-cancer-foundation/","field":"links","label":"Lazarex Cancer Foundation"},{"id":"lazarex-cancer-foundation","kind":"collection","name":"Lazarex Cancer Foundation","route":"/collections/lazarex-cancer-foundation/","field":"url"}]},{"url":"https://leocancercare.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","field":"links","label":"Official website"},{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","field":"website"}]},{"url":"https://leocancercare.com/contact/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","field":"links","label":"Contact page listing UK and US offices"}]},{"url":"https://liferaftgroup.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","field":"links","label":"Life Raft Group (patient organisation)"}]},{"url":"https://limbus.ai","status":200,"ok":true,"finalUrl":"https://limbus.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"limbus-ai","kind":"company","name":"Limbus AI","route":"/companies/limbus-ai/","field":"links","label":"Official website"},{"id":"limbus-ai","kind":"company","name":"Limbus AI","route":"/companies/limbus-ai/","field":"website"}]},{"url":"https://link.springer.com/bookseries/392","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","route":"/journals/recent-results-in-cancer-research/","field":"links","label":"Homepage"},{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","route":"/journals/recent-results-in-cancer-research/","field":"url"}]},{"url":"https://link.springer.com/bookseries/5808","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","route":"/journals/cancer-treatment-and-research/","field":"links","label":"Homepage"},{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","route":"/journals/cancer-treatment-and-research/","field":"url"}]},{"url":"https://link.springer.com/journal/10014","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","route":"/journals/brain-tumor-pathology/","field":"links","label":"Homepage"},{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","route":"/journals/brain-tumor-pathology/","field":"url"}]},{"url":"https://link.springer.com/journal/10120","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","field":"links","label":"Homepage"},{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","field":"url"}]},{"url":"https://link.springer.com/journal/10147","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","route":"/journals/international-journal-of-clinical-oncology/","field":"links","label":"Homepage"},{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","route":"/journals/international-journal-of-clinical-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/10280","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","route":"/journals/cancer-chemotherapy-and-pharmacology/","field":"links","label":"Homepage"},{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","route":"/journals/cancer-chemotherapy-and-pharmacology/","field":"url"}]},{"url":"https://link.springer.com/journal/10388","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esophagus-journal","kind":"journal","name":"Esophagus","route":"/journals/esophagus-journal/","field":"links","label":"Homepage"},{"id":"esophagus-journal","kind":"journal","name":"Esophagus","route":"/journals/esophagus-journal/","field":"url"}]},{"url":"https://link.springer.com/journal/10434","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","route":"/journals/annals-of-surgical-oncology/","field":"links","label":"Homepage"},{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","route":"/journals/annals-of-surgical-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/10549","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/","field":"links","label":"Homepage"},{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/","field":"url"}]},{"url":"https://link.springer.com/journal/10552","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","route":"/journals/cancer-causes-and-control/","field":"links","label":"Homepage"},{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","route":"/journals/cancer-causes-and-control/","field":"url"}]},{"url":"https://link.springer.com/journal/10555","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","route":"/journals/cancer-metastasis-reviews/","field":"links","label":"Homepage"},{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","route":"/journals/cancer-metastasis-reviews/","field":"url"}]},{"url":"https://link.springer.com/journal/10585","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","route":"/journals/clinical-and-experimental-metastasis/","field":"links","label":"Homepage"},{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","route":"/journals/clinical-and-experimental-metastasis/","field":"url"}]},{"url":"https://link.springer.com/journal/10689","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"familial-cancer","kind":"journal","name":"Familial cancer","route":"/journals/familial-cancer/","field":"links","label":"Homepage"},{"id":"familial-cancer","kind":"journal","name":"Familial cancer","route":"/journals/familial-cancer/","field":"url"}]},{"url":"https://link.springer.com/journal/10911","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","route":"/journals/journal-of-mammary-gland-biology-and-neoplasia/","field":"links","label":"Homepage"},{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","route":"/journals/journal-of-mammary-gland-biology-and-neoplasia/","field":"url"}]},{"url":"https://link.springer.com/journal/11060","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","route":"/journals/journal-of-neuro-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","route":"/journals/journal-of-neuro-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/11523","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","field":"links","label":"Homepage"},{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/11764","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","field":"links","label":"Homepage"},{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","field":"url"}]},{"url":"https://link.springer.com/journal/11864","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","route":"/journals/current-treatment-options-in-oncology/","field":"links","label":"Homepage"},{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","route":"/journals/current-treatment-options-in-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/11899","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/","field":"links","label":"Homepage"},{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/","field":"url"}]},{"url":"https://link.springer.com/journal/11912","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","route":"/journals/current-oncology-reports/","field":"links","label":"Homepage"},{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","route":"/journals/current-oncology-reports/","field":"url"}]},{"url":"https://link.springer.com/journal/12029","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","route":"/journals/journal-of-gastrointestinal-cancer/","field":"links","label":"Homepage"},{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","route":"/journals/journal-of-gastrointestinal-cancer/","field":"url"}]},{"url":"https://link.springer.com/journal/12032","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medical-oncology","kind":"journal","name":"Medical oncology","route":"/journals/medical-oncology/","field":"links","label":"Homepage"},{"id":"medical-oncology","kind":"journal","name":"Medical oncology","route":"/journals/medical-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/12094","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","route":"/journals/clinical-and-translational-oncology/","field":"links","label":"Homepage"},{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","route":"/journals/clinical-and-translational-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/12105","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","route":"/journals/head-and-neck-pathology/","field":"links","label":"Homepage"},{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","route":"/journals/head-and-neck-pathology/","field":"url"}]},{"url":"https://link.springer.com/journal/12282","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","field":"links","label":"Homepage"},{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","field":"url"}]},{"url":"https://link.springer.com/journal/13187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","route":"/journals/journal-of-cancer-education/","field":"links","label":"Homepage"},{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","route":"/journals/journal-of-cancer-education/","field":"url"}]},{"url":"https://link.springer.com/journal/13402","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","route":"/journals/cellular-oncology/","field":"links","label":"Homepage"},{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","route":"/journals/cellular-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/262","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","field":"links","label":"Homepage"},{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","field":"url"}]},{"url":"https://link.springer.com/journal/411","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","route":"/journals/radiation-and-environmental-biophysics/","field":"links","label":"Homepage"},{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","route":"/journals/radiation-and-environmental-biophysics/","field":"url"}]},{"url":"https://link.springer.com/journal/432","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","field":"url"}]},{"url":"https://link.springer.com/journal/520","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","route":"/journals/supportive-care-in-cancer/","field":"links","label":"Homepage"},{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","route":"/journals/supportive-care-in-cancer/","field":"url"}]},{"url":"https://link.springer.com/journal/66","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","route":"/journals/strahlentherapie-und-onkologie/","field":"links","label":"Homepage"},{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","route":"/journals/strahlentherapie-und-onkologie/","field":"url"}]},{"url":"https://list.essentialmeds.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-moon-olanzapine-antiemetic-everywhere","kind":"idea","name":"Low-dose olanzapine and generic antiemetic bundles in every guideline and formulary","route":"/ideas/idea-moon-olanzapine-antiemetic-everywhere/","field":"links","label":"WHO Model List of Essential Medicines"},{"id":"idea-moon-pooled-procurement-licensing-pool","kind":"idea","name":"Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries","route":"/ideas/idea-moon-pooled-procurement-licensing-pool/","field":"links","label":"WHO Model List of Essential Medicines"}]},{"url":"https://list.essentialmeds.org/medicines/58","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"WHO Model List of Essential Medicines"}]},{"url":"https://lombardi.georgetown.edu","status":200,"ok":true,"finalUrl":"https://lombardi.georgetown.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","field":"links","label":"Georgetown Lombardi"},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","field":"website"}]},{"url":"https://longitudeprize.org/","status":200,"ok":true,"finalUrl":"https://challengeworks.org/longitude-prize/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/","field":"links","label":"Longitude Prize"}]},{"url":"https://lookgoodfeelbetter.co.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","route":"/collections/look-good-feel-better/","field":"links","label":"Look Good Feel Better UK"}]},{"url":"https://lookgoodfeelbetter.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","field":"links","label":"Look Good Feel Better"},{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","route":"/collections/look-good-feel-better/","field":"links","label":"Look Good Feel Better"},{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","route":"/collections/look-good-feel-better/","field":"url"}]},{"url":"https://lsvp.com","status":200,"ok":true,"finalUrl":"https://lsvp.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","field":"links","label":"Official website"},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","field":"website"}]},{"url":"https://lt.wikipedia.org/wiki/Nacionalinis_vėžio_institutas","status":200,"ok":true,"finalUrl":"https://lt.wikipedia.org/wiki/Nacionalinis_v%C4%97%C5%BEio_institutas","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","field":"links","label":"Source: Lithuanian Wikipedia article naming the director"},{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","field":"profiles","label":"Wikipedia (Lithuanian) article on the institute"}]},{"url":"https://lustgarten.org","status":200,"ok":true,"finalUrl":"https://lustgarten.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","field":"links","label":"Lustgarten Foundation"},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","field":"website"}]},{"url":"https://lustgarten.org/leadership/story/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marc-lustgarten","kind":"person","name":"Marc Lustgarten","route":"/people/marc-lustgarten/","field":"links","label":"Lustgarten Foundation: the Lustgarten story"}]},{"url":"https://lustgarten.org/research/","status":200,"ok":true,"finalUrl":"https://lustgarten.org/the-science/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","field":"links","label":"Research"}]},{"url":"https://lustgarten.org/who-we-are/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"linda-tantawi","kind":"person","name":"Linda Tantawi","route":"/people/linda-tantawi/","field":"links","label":"Institution profile"},{"id":"linda-tantawi","kind":"person","name":"Linda Tantawi","route":"/people/linda-tantawi/","field":"profiles","label":"Institution profile"}]},{"url":"https://luth.gov.ng","status":200,"ok":true,"finalUrl":"https://luth.gov.ng/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","field":"links","label":"LUTH"},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","field":"website"}]},{"url":"https://lv.wikipedia.org/wiki/Rīgas_Austrumu_klīniskā_universitātes_slimnīca","status":200,"ok":true,"finalUrl":"https://lv.wikipedia.org/wiki/R%C4%ABgas_Austrumu_kl%C4%ABnisk%C4%81_universit%C4%81tes_slimn%C4%ABca","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","field":"links","label":"Wikipedia (Latvian) article on the hospital"}]},{"url":"https://lymphoma.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/","field":"links","label":"LRF"},{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/","field":"url"}]},{"url":"https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/","status":200,"ok":true,"finalUrl":"https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"links","label":"Lymphoma Research Foundation: FL"}]},{"url":"https://macrogenics.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.macrogenics.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://magicevidence.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/","field":"links","label":"MAGICapp"}]},{"url":"https://marengotx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","field":"links","label":"Official website"},{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","field":"website"}]},{"url":"https://marengotx.com/news-investors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","field":"links","label":"News and investors"}]},{"url":"https://marengotx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://marianaoncology.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Official website"},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"website"}]},{"url":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Series B press release"}]},{"url":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Novartis acquisition announcement"}]},{"url":"https://markertherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/","field":"links","label":"Official website"},{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/","field":"website"}]},{"url":"https://mascc.org","status":200,"ok":true,"finalUrl":"https://mascc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/","field":"links","label":"MASCC"},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/","field":"website"}]},{"url":"https://mascc.org/about-mascc/leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","field":"links","label":"Society page"},{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","field":"profiles","label":"Society page"}]},{"url":"https://massivebio.com","status":200,"ok":true,"finalUrl":"https://massivebio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","field":"links","label":"Official website"},{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","field":"website"}]},{"url":"https://massivebio.com/about-us/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","field":"links","label":"About Massive Bio"}]},{"url":"https://massivebio.com/mb-raises-9-million-to-scale-growth/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","field":"links","label":"USD 9 million financing announcement (May 2020)"}]},{"url":"https://mdxhealth.com","status":200,"ok":true,"finalUrl":"https://mdxhealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdxhealth","kind":"company","name":"MDxHealth","route":"/companies/mdxhealth/","field":"links","label":"Official website"},{"id":"mdxhealth","kind":"company","name":"MDxHealth","route":"/companies/mdxhealth/","field":"website"}]},{"url":"https://mdxhealth.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotype-dx-gps","kind":"drug","name":"Oncotype DX Genomic Prostate Score","route":"/drugs/oncotype-dx-gps/","field":"links","label":"MDxHealth: Oncotype DX GPS (page moved; nearest live section)"}]},{"url":"https://medicaldialogues.in/news/health/hospital-diagnostics/kidwai-memorial-institute-of-oncology-plans-450-bed-expansion-156647","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"t-naveen","kind":"person","name":"T. Naveen","route":"/people/t-naveen/","field":"links","label":"Source: Medical Dialogues report on the 450-bed expansion naming the Director (October 2025)"},{"id":"t-naveen","kind":"person","name":"T. Naveen","route":"/people/t-naveen/","field":"profiles","label":"Medical Dialogues report naming the KMIO director (October 2025)"}]},{"url":"https://medicaljournalssweden.se/actaoncologica","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","field":"links","label":"Homepage"},{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","field":"url"}],"archive":"https://web.archive.org/web/20260912173450/https://medicaljournalssweden.se/actaoncologica"},{"url":"https://medicinasa.com.br/programa-princess-margaret/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/","field":"links","label":"Source: Medicina S/A article quoting him as CEO of A.C.Camargo (May 2026)"}]},{"url":"https://medicinasa.com.br/victor-piana-de-andrade/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/","field":"links","label":"Source: Medicina S/A appointment news (June 2021)"},{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/","field":"profiles","label":"Medicina S/A: appointment as diretor-geral (June 2021)"}]},{"url":"https://medicine.ekmd.huji.ac.il/en/research/yechezkelb/Pages/default.aspx","status":200,"ok":true,"finalUrl":"https://en.huca.huji.ac.il/update-regarding-sharepoint-sites","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/","field":"links","label":"Laboratory of Membrane and Liposome Research, Hebrew University"},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/","field":"profiles","label":"Laboratory of Membrane and Liposome Research, Hebrew University"}]},{"url":"https://medicine.nus.edu.sg","status":200,"ok":true,"finalUrl":"https://medicine.nus.edu.sg/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","field":"links","label":"NUS Medicine"}]},{"url":"https://medicine.yale.edu","status":200,"ok":true,"finalUrl":"https://medicine.yale.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","route":"/institutions/yale-school-of-medicine/","field":"links","label":"Official website"},{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","route":"/institutions/yale-school-of-medicine/","field":"website"}]},{"url":"https://medicine.yale.edu/cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","field":"links","label":"Official website"},{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","field":"website"}]},{"url":"https://medicine.yale.edu/cancer/about/history/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","field":"links","label":"History"}]},{"url":"https://medicine.yale.edu/cancer/about/ncidesignation/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","field":"links","label":"NCI designation"}]},{"url":"https://medicine.yale.edu/cancer/about/people/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"links","label":"Yale Cancer Center leadership"},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"profiles","label":"Yale Cancer Center leadership"}]},{"url":"https://medicine.yale.edu/profile/eric-winer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"links","label":"Yale School of Medicine profile"},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"profiles","label":"Yale School of Medicine profile"}]},{"url":"https://medicinehealth.leeds.ac.uk/medicine/staff/3085/professor-matt-seymour","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matt-seymour","kind":"person","name":"Matt Seymour","route":"/people/matt-seymour/","field":"links","label":"University of Leeds staff page"},{"id":"matt-seymour","kind":"person","name":"Matt Seymour","route":"/people/matt-seymour/","field":"profiles","label":"University of Leeds staff page"}]},{"url":"https://medicinehealth.leeds.ac.uk/medicine/staff/745/professor-david-sebag-montefiore","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-sebag-montefiore","kind":"person","name":"David Sebag-Montefiore","route":"/people/david-sebag-montefiore/","field":"links","label":"University of Leeds staff page"},{"id":"david-sebag-montefiore","kind":"person","name":"David Sebag-Montefiore","route":"/people/david-sebag-montefiore/","field":"profiles","label":"University of Leeds staff page"}]},{"url":"https://medicinespatentpool.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-patent-pool-oncology-eml","kind":"idea","name":"Medicines Patent Pool licences for every patented cancer drug on the WHO list","route":"/ideas/idea-reg-patent-pool-oncology-eml/","field":"links","label":"Medicines Patent Pool"},{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","route":"/ideas/idea-fund-conditional-transferable-voucher/","field":"links","label":"Medicines Patent Pool"},{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/","field":"links","label":"Medicines Patent Pool"},{"id":"idea-fund-combination-patent-pool","kind":"idea","name":"An oncology patent pool for combination trials across companies","route":"/ideas/idea-fund-combination-patent-pool/","field":"links","label":"Medicines Patent Pool"},{"id":"idea-moon-pooled-procurement-licensing-pool","kind":"idea","name":"Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries","route":"/ideas/idea-moon-pooled-procurement-licensing-pool/","field":"links","label":"Medicines Patent Pool"},{"id":"idea-cost-voluntary-licensing-oncology","kind":"idea","name":"Voluntary licences and price caps for patented cancer drugs in low-income countries","route":"/ideas/idea-cost-voluntary-licensing-oncology/","field":"links","label":"Medicines Patent Pool"}]},{"url":"https://mediso.com","status":200,"ok":true,"finalUrl":"https://mediso.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"links","label":"Official website"},{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"website"}]},{"url":"https://medschool.cuanschutz.edu/colorado-cancer-center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","field":"links","label":"University of Colorado Cancer Center"},{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","field":"website"}]},{"url":"https://medschool.cuanschutz.edu/colorado-cancer-center/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","field":"links","label":"Clinical trials"}]},{"url":"https://meetings.asco.org/meetings","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","route":"/collections/src-asco-meeting-library/","field":"links","label":"ASCO Meeting Library"},{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","route":"/collections/src-asco-meeting-library/","field":"url"}]},{"url":"https://merkelcell.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"links","label":"Merkelcell.org (UW/Fred Hutch)"}]},{"url":"https://merus.nl","status":200,"ok":true,"finalUrl":"https://www.genmab.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/","field":"links","label":"Official website"},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/","field":"website"}]},{"url":"https://mesowatch.org/news/2026/03/mesothelioma-clinical-trial-results-compared/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","field":"links","label":"2026 trial landscape (MesoWatch)"}]},{"url":"https://meyercancer.weill.cornell.edu","status":200,"ok":true,"finalUrl":"https://meyercancer.weill.cornell.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/","field":"links","label":"Meyer Cancer Center"},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/","field":"website"}]},{"url":"https://mft.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"manchester-royal-infirmary","kind":"institution","name":"Manchester Royal Infirmary HPB Unit","route":"/institutions/manchester-royal-infirmary/","field":"website"}]},{"url":"https://mft.nhs.uk/mri/services/hepato-pancreato-biliary-hpb-unit/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"manchester-royal-infirmary","kind":"institution","name":"Manchester Royal Infirmary HPB Unit","route":"/institutions/manchester-royal-infirmary/","field":"links","label":"HPB Unit"}]},{"url":"https://microbiotica.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","field":"links","label":"About (funding and origins)"}]},{"url":"https://microbiotica.com/press-releases/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","field":"links","label":"Press releases"}]},{"url":"https://minuteman.bio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","route":"/companies/minuteman-therapeutics/","field":"links","label":"Official website"},{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","route":"/companies/minuteman-therapeutics/","field":"website"}]},{"url":"https://missionbio.com","status":200,"ok":true,"finalUrl":"https://www.missionbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","field":"links","label":"Official website"},{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","field":"website"}]},{"url":"https://missionbio.com/company/newsroom","status":200,"ok":true,"finalUrl":"https://www.missionbio.com/company/newsroom","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","field":"links","label":"Newsroom"}]},{"url":"https://modularit.bio","status":200,"ok":true,"finalUrl":"https://modularit.bio/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/","field":"links","label":"Official website"},{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/","field":"website"}]},{"url":"https://molecular-cancer.biomedcentral.com","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/12943","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","field":"links","label":"Homepage"},{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","field":"url"}]},{"url":"https://mondo.monarchinitiative.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mondo","kind":"term","name":"Mondo disease ontology","route":"/terms/mondo/","field":"links","label":"Mondo Disease Ontology (Monarch Initiative)"}]},{"url":"https://montefioreeinstein.org/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","field":"links","label":"Montefiore Einstein Comprehensive Cancer Center"},{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","field":"website"}]},{"url":"https://montefioreeinstein.org/cancer/about/team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/","field":"links","label":"Source: Montefiore Einstein Comprehensive Cancer Center team page"},{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/","field":"profiles","label":"Montefiore Einstein cancer centre team page"}]},{"url":"https://montefioreeinstein.org/cancer/research/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","field":"links","label":"Clinical trials"}]},{"url":"https://moorescancercenter.ucsd.edu","status":200,"ok":true,"finalUrl":"https://moorescancercenter.ucsd.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","field":"links","label":"Moores Cancer Center"},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","field":"website"}]},{"url":"https://moorescancercenter.ucsd.edu/about/leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","field":"links","label":"Institution profile"},{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","field":"profiles","label":"Institution profile"},{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","field":"links","label":"Institution profile"},{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","field":"profiles","label":"Institution profile"},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","field":"links","label":"Institution profile"},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","field":"profiles","label":"Institution profile"}]},{"url":"https://movember.com","status":200,"ok":true,"finalUrl":"https://movember.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/","field":"links","label":"Movember"},{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/","field":"website"}]},{"url":"https://mpmbioimpact.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","field":"links","label":"Official website"},{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","field":"website"}]},{"url":"https://mpmbioimpact.com/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","field":"links","label":"News"}]},{"url":"https://mpmbioimpact.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","field":"links","label":"Portfolio"}]},{"url":"https://muhc.ca","status":200,"ok":true,"finalUrl":"https://muhc.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"muhc-cedars-cancer-centre","kind":"institution","name":"McGill University Health Centre / Cedars Cancer Centre","route":"/institutions/muhc-cedars-cancer-centre/","field":"links","label":"Official website"},{"id":"muhc-cedars-cancer-centre","kind":"institution","name":"McGill University Health Centre / Cedars Cancer Centre","route":"/institutions/muhc-cedars-cancer-centre/","field":"website"}]},{"url":"https://muhc.ca/corporate-leadership/senior-management-profiles","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","route":"/people/lucie-opatrny/","field":"links","label":"Source: MUHC senior management profiles page"},{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","route":"/people/lucie-opatrny/","field":"profiles","label":"MUHC senior management profiles"}]},{"url":"https://mvision.ai","status":200,"ok":true,"finalUrl":"https://mvision.ai/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mvision-ai","kind":"company","name":"MVision AI","route":"/companies/mvision-ai/","field":"links","label":"Official website"},{"id":"mvision-ai","kind":"company","name":"MVision AI","route":"/companies/mvision-ai/","field":"website"}]},{"url":"https://mvz-tuebingen.de/en/oncology/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","route":"/institutions/cecurio/","field":"links","label":"Official website"},{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","route":"/institutions/cecurio/","field":"website"}]},{"url":"https://my.clevelandclinic.org/departments/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","field":"links","label":"Official website"},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","field":"website"}]},{"url":"https://my.clevelandclinic.org/staff/17181-jame-abraham","status":200,"ok":true,"finalUrl":"https://providers.clevelandclinic.org/provider/toms-augustin/4269482","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","field":"links","label":"Cleveland Clinic profile"},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","field":"profiles","label":"Cleveland Clinic profile"}]},{"url":"https://myelomainvestmentfund.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","field":"links","label":"Myeloma Investment Fund"}]},{"url":"https://myelomainvestmentfund.org/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","field":"links","label":"MIF portfolio"}]},{"url":"https://myriad.com","status":200,"ok":true,"finalUrl":"https://myriad.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/","field":"links","label":"Official website"},{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/","field":"website"}]},{"url":"https://myriad.com/oncology/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prolaris","kind":"drug","name":"Prolaris","route":"/drugs/prolaris/","field":"links","label":"Myriad: Prolaris (page moved; nearest live section)"}]},{"url":"https://myriad.com/oncology/endopredict/","status":200,"ok":true,"finalUrl":"https://myriad.com/oncology/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endopredict","kind":"drug","name":"EndoPredict","route":"/drugs/endopredict/","field":"links","label":"Myriad: EndoPredict"}]},{"url":"https://myricxbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/","field":"links","label":"Official website"},{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/","field":"website"}]},{"url":"https://mythictherapeutics.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","field":"links","label":"Official website"},{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","field":"website"}]},{"url":"https://mytomorrows.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","field":"links","label":"Official website"},{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","field":"website"}]},{"url":"https://nanoporetech.com","status":200,"ok":true,"finalUrl":"https://nanoporetech.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","route":"/companies/oxford-nanopore/","field":"links","label":"Official website"},{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","route":"/companies/oxford-nanopore/","field":"website"}]},{"url":"https://nap.nationalacademies.org/catalog/26894","status":200,"ok":true,"finalUrl":"https://www.nationalacademies.org/projects/DEPS-BMSA-21-03/publication/26894","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"digital-twin-patient-models","kind":"technology","name":"Patient digital twins","route":"/technologies/digital-twin-patient-models/","field":"links","label":"National Academies 2023: Foundational research gaps and future directions for digital twins"}]},{"url":"https://naveris.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","field":"links","label":"Official website"},{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","field":"website"}]},{"url":"https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","field":"links","label":"$51 million financing (Sep 2022)"}]},{"url":"https://navexio.com","status":200,"ok":true,"finalUrl":"https://navexio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/","field":"website"}]},{"url":"https://navexio.com/clinical-trial-navigation","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/","field":"links","label":"Clinical trial navigation"}]},{"url":"https://nbe-therapeutics.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","route":"/companies/nbe-therapeutics/","field":"links","label":"Official website"},{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","route":"/companies/nbe-therapeutics/","field":"website"}]},{"url":"https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","route":"/companies/nbe-therapeutics/","field":"links","label":"Boehringer Ingelheim opens NBE R&D centre (states 2020 acquisition)"}]},{"url":"https://ncats.nih.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"links","label":"NCATS"},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/","field":"links","label":"NCATS"}]},{"url":"https://ncats.nih.gov/research/research-activities/ntu","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-shelved-asset-commons","kind":"idea","name":"A commons of shelved cancer drugs with their full data, open to new hypotheses","route":"/ideas/idea-tr2-shelved-asset-commons/","field":"links","label":"NCATS New Therapeutic Uses"}]},{"url":"https://ncc.re.kr/main.ncc?uri=english/sub01_Greetings","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"links","label":"Institution profile"},{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"profiles","label":"Institution profile"}]},{"url":"https://ncc.re.kr/main.ncc?uri=english/sub04_ControlPrograms","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","field":"links","label":"Korea Central Cancer Registry"}]},{"url":"https://ncdirindia.org/All_Reports/Report_2020/resources/Chapter5ComparisonofcancerincidenceandpatternsofallPopulationBasedCancerRegistries.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"ICMR-NCDIR: National Cancer Registry Programme report 2020, gall bladder (C23-C24) by registry"},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","field":"links","label":"ICMR-NCDIR, Report of National Cancer Registry Programme 2020 (2012-2016), Chapter 5, Fig. 5.12: gall bladder (C23-C24), comparison of age-adjusted incidence rates of 28 PBCRs"}]},{"url":"https://nces.ed.gov/pubs2006/2006483.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"metrics (US adults with basic or below-basic health literacy (National Assessment of Adult Literacy 2003))"}]},{"url":"https://nci.cu.edu.eg","status":200,"ok":true,"finalUrl":"https://nci.cu.edu.eg/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","field":"links","label":"NCI Cairo University"},{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","field":"website"}]},{"url":"https://nci.cu.edu.eg/%D8%A7%D9%84%D8%A5%D8%AF%D8%A7%D8%B1%D8%A9-%D8%A7%D9%84%D8%B9%D9%84%D9%8A%D8%A7/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","route":"/people/mohamed-abdel-moaty-samra/","field":"links","label":"Source: NCI Cairo senior administration page"},{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","route":"/people/mohamed-abdel-moaty-samra/","field":"profiles","label":"NCI Cairo senior administration"}]},{"url":"https://ncithesaurus.nci.nih.gov/ncitbrowser/","status":200,"ok":true,"finalUrl":"https://evsexplore.semantics.cancer.gov/evsexplore/welcome","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ncit","kind":"term","name":"NCI Thesaurus (NCIt)","route":"/terms/ncit/","field":"links","label":"NCI Thesaurus browser"}]},{"url":"https://ncorp.cancer.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","field":"links","label":"NCI Community Oncology Research Program"},{"id":"idea-tr1-community-site-quota","kind":"idea","name":"At least a third of pivotal-trial sites in community and rural settings","route":"/ideas/idea-tr1-community-site-quota/","field":"links","label":"NCI Community Oncology Research Program"}]},{"url":"https://nearwave.co","status":200,"ok":true,"finalUrl":"https://nearwave.co/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nearwave","kind":"company","name":"NearWave","route":"/companies/nearwave/","field":"links","label":"Official website"},{"id":"nearwave","kind":"company","name":"NearWave","route":"/companies/nearwave/","field":"website"}]},{"url":"https://neogenomics.com","status":200,"ok":true,"finalUrl":"https://www.neogenomics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","field":"links","label":"Official website"},{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","field":"website"}]},{"url":"https://neogenomics.com/","status":200,"ok":true,"finalUrl":"https://www.neogenomics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","field":"links","label":"Official website"},{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","field":"website"}]},{"url":"https://neogenomics.com/test-menu/","status":200,"ok":true,"finalUrl":"https://www.neogenomics.com/providers/test-search","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radar-mrd","kind":"drug","name":"RaDaR","route":"/drugs/radar-mrd/","field":"links","label":"NeoGenomics: RaDaR (page moved; nearest live section)"}]},{"url":"https://neomorph.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","field":"links","label":"Official website"},{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","field":"website"}]},{"url":"https://neomorph.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","field":"links","label":"Pipeline"}]},{"url":"https://neomorph.com/press-release/abbvie-and-neomorph-announce-collaboration-to-develop-molecularglue-degraders-for-oncology-and-immunology/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","field":"links","label":"AbbVie collaboration"}]},{"url":"https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","field":"links","label":"Series B press release"}]},{"url":"https://nestedtx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","field":"links","label":"Official website"},{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","field":"website"}]},{"url":"https://nestedtx.com/wp-content/uploads/2022/09/Nested-Launches-With-125-Million-Financing.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","field":"links","label":"Launch and Series A press release (PDF)"}]},{"url":"https://neutrontherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"links","label":"Official website"},{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"website"}]},{"url":"https://neutrontherapeutics.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"links","label":"About Neutron Therapeutics"}]},{"url":"https://neutrontherapeutics.com/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"links","label":"News page (Helsinki, Shonan Kamakura, Aviko partnership)"}]},{"url":"https://neutrontherapeutics.com/news/pr_121323/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"links","label":"Birmingham accelerator final acceptance (Dec 2023)"}]},{"url":"https://neutrontherapeutics.com/news/pr-071619/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","field":"links","label":"Shonan Kamakura nuBeam agreement (July 2019)"}]},{"url":"https://news.abbvie.com/2026-01-16-AbbVie-Announces-Topline-Results-for-Epcoritamab-DuoBody-R-CD3xCD20-from-Phase-3-EPCORE-R-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"regulatoryEvents.source (2026-01-16)"}]},{"url":"https://news.uthscsa.edu/ut-health-san-antonio-names-nih-expert-inaugural-director-of-stem-cell-transplant-and-cellular-therapy-program/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","field":"links","label":"Source: UT Health San Antonio news release naming Lei Zheng as Executive Director"},{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","field":"profiles","label":"UT Health San Antonio news (August 2026) quoting the Executive Director"}]},{"url":"https://newsroom.astellas.com/2026-08-25-astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://next.cancer.gov/","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/drug-discovery-development/services/next","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","field":"links","label":"NCI Experimental Therapeutics (NExT) Program"},{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/","field":"links","label":"NCI Experimental Therapeutics (NExT) Program"},{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/","field":"links","label":"NCI NExT Program"}]},{"url":"https://ngff.openmicroscopy.org/latest/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","field":"links","label":"OME-NGFF (OME-Zarr) specification"}]},{"url":"https://nicrh.gov.bd","status":200,"ok":true,"finalUrl":"https://nicrh.gov.bd/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicrh-dhaka","kind":"institution","name":"National Institute of Cancer Research and Hospital","route":"/institutions/nicrh-dhaka/","field":"links","label":"Official website"},{"id":"nicrh-dhaka","kind":"institution","name":"National Institute of Cancer Research and Hospital","route":"/institutions/nicrh-dhaka/","field":"website"}]},{"url":"https://nicrh.gov.bd/administrator/director","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","field":"links","label":"Source: NICRH Director page"},{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","field":"profiles","label":"NICRH Director page"}]},{"url":"https://nimbustx.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.nimbustx.com/pipeline-targets/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://nio.gov.pl/dyrekcja-instytutu","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","field":"links","label":"Institution profile"},{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","field":"profiles","label":"Institution profile"},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","field":"links","label":"Institution profile"},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","field":"profiles","label":"Institution profile"},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","field":"links","label":"Institution profile"},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","field":"profiles","label":"Institution profile"}]},{"url":"https://nl.wikipedia.org/wiki/Universitair_Medisch_Centrum_Groningen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","route":"/people/ate-van-der-zee/","field":"links","label":"Source: Dutch Wikipedia article on UMCG naming the board chair"},{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","route":"/people/ate-van-der-zee/","field":"profiles","label":"Wikipedia: Universitair Medisch Centrum Groningen (Dutch)"}]},{"url":"https://nlcc.ng","status":200,"ok":true,"finalUrl":"https://nlcc.ng/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","field":"links","label":"NSIA-LUTH Cancer Centre"}]},{"url":"https://nngm.de/ueber-das-nngm/kooperationskrankenkassen/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","field":"links","label":"Cooperating sickness funds"}]},{"url":"https://novoholdings.dk/","status":200,"ok":true,"finalUrl":"https://novoholdings.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","field":"links","label":"Official website"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","field":"website"}]},{"url":"https://novoholdings.dk/investments/venture-investments","status":200,"ok":true,"finalUrl":"https://novoholdings.com/investments/venture-investments","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","field":"links","label":"Venture Investments"}]},{"url":"https://nucleai.ai/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","field":"links","label":"Official website"},{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","field":"website"}]},{"url":"https://nucleai.ai/news","status":200,"ok":true,"finalUrl":"https://nucleai.ai/news/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","field":"links","label":"News page"}]},{"url":"https://nucleai.ai/nucleai-advances-ai-powered-tissue-intelligence-through-large-scale-oncology-adc-collaboration/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","field":"links","label":"Gilead ADC collaboration (Aug 2026)"}]},{"url":"https://nucleix.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","field":"links","label":"Official website"},{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","field":"website"}]},{"url":"https://nucleix.com/blog/news_and_events/nucleix-secures-55-million-funding-led-by-ra-capital-management-and-additional-prominent-life-science-investors-to-advance-lung-epicheck-for-early-detection-of-lung-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","field":"links","label":"$55 million financing (April 2021)"}]},{"url":"https://nucleix.com/wp-content/uploads/2023/05/PR_Nucleix_Bladder-EpiCheck-FDA-Clearance.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","field":"links","label":"FDA 510(k) clearance for Bladder EpiCheck (May 2023)"}]},{"url":"https://nucleoresearch.com","status":200,"ok":true,"finalUrl":"https://nucleoresearch.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nucleo-research","kind":"company","name":"Nucleo","route":"/companies/nucleo-research/","field":"links","label":"Official website"},{"id":"nucleo-research","kind":"company","name":"Nucleo","route":"/companies/nucleo-research/","field":"website"}]},{"url":"https://nucleusrad.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"Official website"},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"website"}]},{"url":"https://nucleusrad.com/news-events/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"News and events"}]},{"url":"https://nucleusrad.com/wp-content/uploads/Nucleus-RadioPharma-Secures-50-Million-Financing-from-OrbiMed-to-Expand-Radiopharmaceutical-Manufacturing-Capacity.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"OrbiMed financing release (PDF)"}]},{"url":"https://nvi.lt","status":200,"ok":true,"finalUrl":"https://nvi.lt/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","route":"/institutions/nci-vilnius/","field":"links","label":"Official website"},{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","route":"/institutions/nci-vilnius/","field":"website"}]},{"url":"https://nvi.lt/apie-mus/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","field":"links","label":"Institute about page"}]},{"url":"https://nwbio.com","status":200,"ok":true,"finalUrl":"https://nwbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","field":"links","label":"Official website"},{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","field":"website"}]},{"url":"https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","field":"links","label":"Private placement completed (August 2026)"}]},{"url":"https://obofoundry.org/ontology/cl.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","field":"links","label":"OBO Foundry: Cell Ontology"}]},{"url":"https://obofoundry.org/ontology/uberon.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","field":"links","label":"OBO Foundry: Uberon"}]},{"url":"https://obofoundry.org/ontology/uo.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"units-ontology","kind":"term","name":"Units of measurement ontology (UO)","route":"/terms/units-ontology/","field":"links","label":"OBO Foundry: Units of measurement ontology"}]},{"url":"https://obsidiantx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","field":"links","label":"Official website"},{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","field":"website"}]},{"url":"https://ocrahope.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/","field":"links","label":"OCRA"},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/","field":"url"}]},{"url":"https://ocularmelanoma.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","field":"links","label":"Ocular Melanoma Foundation"}]},{"url":"https://ohdsi.github.io/OncologyWG/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-federated-analytics-network","kind":"idea","name":"Send the code to the data: a federated analytics network of cancer centres","route":"/ideas/idea-data-federated-analytics-network/","field":"links","label":"OMOP Oncology working group"}]},{"url":"https://oici.jp","status":200,"ok":true,"finalUrl":"https://oici.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","field":"links","label":"Osaka International Cancer Institute"},{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","field":"website"}]},{"url":"https://oici.jp/center/outline/overview/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","field":"links","label":"Source: Osaka International Cancer Institute centre overview page"},{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","field":"profiles","label":"Institute overview and president's greeting (Japanese)"}]},{"url":"https://oicr.on.ca","status":200,"ok":true,"finalUrl":"https://oicr.on.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","field":"links","label":"OICR"},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","field":"website"}]},{"url":"https://oicr.on.ca/about-us/leadership/","status":200,"ok":true,"finalUrl":"https://oicr.on.ca/about/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","field":"links","label":"OICR leadership"}]},{"url":"https://omanta.com","status":200,"ok":true,"finalUrl":"https://omanta.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"omanta","kind":"company","name":"Omanta","route":"/companies/omanta/","field":"links","label":"Official website"},{"id":"omanta","kind":"company","name":"Omanta","route":"/companies/omanta/","field":"website"}]},{"url":"https://omegafunds.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/","field":"links","label":"Official website"},{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/","field":"website"}]},{"url":"https://omegafunds.com/impact/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/","field":"links","label":"Impact"}]},{"url":"https://onc.ai","status":200,"ok":true,"finalUrl":"https://onc.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","field":"links","label":"Official website"},{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","field":"website"}]},{"url":"https://onc.ai/25mm-series-a-financing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","field":"links","label":"Series A announcement page"}]},{"url":"https://onc.ai/6mm-series-seed-financing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","field":"links","label":"Seed announcement page"}]},{"url":"https://onc.ai/category/press-releases/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","field":"links","label":"Press releases index"}]},{"url":"https://onco-umber.vercel.app/assistance/","status":200,"ok":true,"finalUrl":"https://onco.cc/assistance/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cost-financial-toxicity-screening","kind":"idea","name":"Screen every patient for money trouble the way we screen for pain","route":"/ideas/idea-cost-financial-toxicity-screening/","field":"links","label":"OnCo financial help browser"}]},{"url":"https://onco-umber.vercel.app/coverage/uk/","status":200,"ok":true,"finalUrl":"https://onco.cc/coverage/uk/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/","field":"links","label":"OnCo: What the NHS offers"}]},{"url":"https://onco.cc/costs/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","field":"links","label":"OnCo: getting the cost of cancer care down"}]},{"url":"https://onco.cc/models/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/","field":"links","label":"OnCo models table"}]},{"url":"https://onco.cc/virotherapy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","field":"links","label":"Oncolytic virotherapy on OnCo: history, approvals, engineering and failures"}]},{"url":"https://oncobox.com","status":200,"ok":true,"finalUrl":"https://oncobox.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncobox","kind":"company","name":"Oncobox","route":"/companies/oncobox/","field":"links","label":"Official website"},{"id":"oncobox","kind":"company","name":"Oncobox","route":"/companies/oncobox/","field":"website"}]},{"url":"https://oncodaily.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","field":"links","label":"OncoDaily"},{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","field":"url"}]},{"url":"https://oncodaily.com/techology/majestec-3468305","status":200,"ok":true,"finalUrl":"https://oncodaily.com/technology/majestec-3468305","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","field":"outcomes.source (Progression-free survival at 36 months)"}]},{"url":"https://oncodna.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","field":"links","label":"Official website"},{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","field":"website"}]},{"url":"https://oncofertility.msu.edu/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Oncofertility Consortium"}]},{"url":"https://oncohealth.us","status":200,"ok":true,"finalUrl":"https://oncohealth.us/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","field":"links","label":"Official website"},{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","field":"website"}]},{"url":"https://oncohealth.us/about-oncohealth/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","field":"links","label":"About OncoHealth"}]},{"url":"https://oncohealth.us/seriesc/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","field":"links","label":"Series C press release (May 2020)"}]},{"url":"https://oncology-association.ru/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","route":"/institutions/russco/","field":"links","label":"Association of Oncologists of Russia (Russian)"}]},{"url":"https://oncology.wustl.edu/people/ramaswamy-govindan-md/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","field":"links","label":"WashU profile"},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","field":"profiles","label":"WashU profile"}]},{"url":"https://oncologynewstoday.co.uk/the-clatterbridge-cancer-centre-announces-new-chief-executive-from-march-2025/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","field":"links","label":"Source: Oncology News Today report of the trust's announcement (26 November 2024)"}]},{"url":"https://oncopeptides.com","status":200,"ok":true,"finalUrl":"https://oncopeptides.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","field":"links","label":"Official website"},{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","field":"website"}]},{"url":"https://oncosalud.pe","status":200,"ok":true,"finalUrl":"https://oncosalud.pe/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","route":"/institutions/oncosalud-auna/","field":"links","label":"Official website"},{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","route":"/institutions/oncosalud-auna/","field":"website"}]},{"url":"https://oncosalud.pe/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","field":"links","label":"Oncosalud (AUNA) website"},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","field":"profiles","label":"Oncosalud (AUNA) website"}]},{"url":"https://oncotree.mskcc.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncotree-term","kind":"term","name":"OncoTree cancer classification","route":"/terms/oncotree-term/","field":"links","label":"OncoTree (Memorial Sloan Kettering)"}]},{"url":"https://onderzoekmetmensen.nl/en/trial/21669","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crest-thoracic-rt","kind":"trial","name":"CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer","route":"/trials/crest-thoracic-rt/","field":"links","label":"Netherlands Trial Register NTR1527"}]},{"url":"https://onkol.hu/igazgatok/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/","field":"links","label":"Source: National Institute of Oncology directors page"},{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/","field":"profiles","label":"Institute directors page"}]},{"url":"https://onkoloji.deu.edu.tr","status":200,"ok":true,"finalUrl":"https://onkoloji.deu.edu.tr/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","route":"/institutions/dokuz-eylul-institute-of-oncology/","field":"links","label":"Official website"},{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","route":"/institutions/dokuz-eylul-institute-of-oncology/","field":"website"}]},{"url":"https://onkoloji.deu.edu.tr/tr/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"links","label":"Dokuz Eylül University Institute of Oncology website"},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"profiles","label":"Dokuz Eylül University Institute of Oncology website"}]},{"url":"https://onkoloji.istanbul.edu.tr/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","field":"links","label":"Homepage"},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","field":"website"}]},{"url":"https://ontargetlabs.com","status":200,"ok":true,"finalUrl":"https://ontargetlabs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","route":"/companies/on-target-laboratories/","field":"links","label":"Official website"},{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","route":"/companies/on-target-laboratories/","field":"website"}]},{"url":"https://opencancer.ai/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/","field":"links","label":"Official website"},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/","field":"website"}]},{"url":"https://openmta.org/","status":200,"ok":true,"finalUrl":"https://www.openplant.org/openmta/","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fund-universal-mta-fast-lane","kind":"idea","name":"A universal material transfer agreement with a thirty-day default","route":"/ideas/idea-fund-universal-mta-fast-lane/","field":"links","label":"OpenMTA"}]},{"url":"https://optellum.com","status":200,"ok":true,"finalUrl":"https://optellum.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"optellum-virtual-nodule-clinic","kind":"drug","name":"Optellum Virtual Nodule Clinic","route":"/drugs/optellum-virtual-nodule-clinic/","field":"links","label":"Optellum"},{"id":"optellum","kind":"company","name":"Optellum","route":"/companies/optellum/","field":"links","label":"Official website"},{"id":"optellum","kind":"company","name":"Optellum","route":"/companies/optellum/","field":"website"}]},{"url":"https://orcabio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"links","label":"Official website"},{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"website"}]},{"url":"https://orcabio.com/newsroom/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"links","label":"Newsroom"}]},{"url":"https://orcabio.com/orca-bios-tregzi-receives-u-s-fda-approval-as-first-and-only-precision-engineered-cell-therapy-for-allogeneic-transplant-in-adults-with-hematological-malignanciesorca-bio-adds-east/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","field":"links","label":"TREGZI FDA approval (June 2026)"}]},{"url":"https://orcid.org/0000-0001-7370-0997","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"links","label":"ORCID"},{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"profiles","label":"ORCID"}]},{"url":"https://orcid.org/0000-0002-0362-5597","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/","field":"links","label":"ORCID"},{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/","field":"profiles","label":"ORCID"}]},{"url":"https://orcid.org/0000-0002-0799-6432","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"links","label":"ORCID"},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"profiles","label":"ORCID"}]},{"url":"https://orcid.org/0000-0003-0523-8010","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"links","label":"ORCID"},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"profiles","label":"ORCID"}]},{"url":"https://oricpharma.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","field":"links","label":"Official website"},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","field":"website"}]},{"url":"https://oricpharma.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","field":"links","label":"Pipeline"},{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://origin.bio","status":200,"ok":true,"finalUrl":"https://origin.bio/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/","field":"links","label":"Official website"},{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/","field":"website"}]},{"url":"https://osarahealth.com","status":200,"ok":true,"finalUrl":"https://osarahealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","field":"links","label":"Official website"},{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","field":"website"}]},{"url":"https://osarahealth.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","field":"links","label":"About Osara Health"}]},{"url":"https://oslocancercluster.no","status":200,"ok":true,"finalUrl":"https://oslocancercluster.no/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Oslo Cancer Cluster"}]},{"url":"https://ouh.dk","status":200,"ok":true,"finalUrl":"https://ouh.dk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","field":"links","label":"Official website"},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","field":"website"}]},{"url":"https://ourfuturehealth.org.uk","status":200,"ok":true,"finalUrl":"https://ourfuturehealth.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-prev-population-germline-screening-at-30","kind":"idea","name":"Offer everyone at 30 a test for the cancer genes that matter","route":"/ideas/idea-prev-population-germline-screening-at-30/","field":"links","label":"Our Future Health"}]},{"url":"https://outcomes4me.com","status":200,"ok":true,"finalUrl":"https://outcomes4me.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","field":"links","label":"Official website"},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","field":"website"}]},{"url":"https://outcomes4me.com/press-release/breast-cancer-blog-seriesa/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","field":"links","label":"Series A press release (April 2021)"}]},{"url":"https://outcomes4me.com/press-release/outcomes4me-secures-21m-in-funding-to-accelerate-ai-driven-innovation-and-drive-global-expansion-to-transform-cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","field":"links","label":"USD 21 million funding press release (May 2025)"}]},{"url":"https://oys.fi","status":200,"ok":true,"finalUrl":"https://oys.fi/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","field":"links","label":"Official website"},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","field":"website"}]},{"url":"https://paige.ai","status":200,"ok":true,"finalUrl":"https://www.paige.ai/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/","field":"links","label":"Official website"},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/","field":"website"}]},{"url":"https://palitra.bio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palitra-bio","kind":"company","name":"Palitra Bio","route":"/companies/palitra-bio/","field":"links","label":"Official website"},{"id":"palitra-bio","kind":"company","name":"Palitra Bio","route":"/companies/palitra-bio/","field":"website"}]},{"url":"https://pancan.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","field":"links","label":"PanCAN"},{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","field":"url"}]},{"url":"https://pancan.org/facing-pancreatic-cancer/patient-services/know-your-tumor/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","route":"/collections/pancan-know-your-tumor/","field":"links","label":"PanCAN Know Your Tumor"},{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","route":"/collections/pancan-know-your-tumor/","field":"url"}]},{"url":"https://pancan.org/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","field":"links","label":"PanCAN news"}]},{"url":"https://pancan.org/research/precision-promise/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/","field":"links","label":"Pancreatic Cancer Action Network: Precision Promise"}]},{"url":"https://pancreaticcanceraction.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-action","kind":"institution","name":"Pancreatic Cancer Action","route":"/institutions/pancreatic-cancer-action/","field":"website"}]},{"url":"https://pancreaticcanceraction.org/about-us/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-action","kind":"institution","name":"Pancreatic Cancer Action","route":"/institutions/pancreatic-cancer-action/","field":"links","label":"Pancreatic Cancer Action: about us"}]},{"url":"https://panda.grand-challenge.org","status":200,"ok":true,"finalUrl":"https://panda.grand-challenge.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","field":"links","label":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)"},{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","field":"url"}]},{"url":"https://pathfinderoncology.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","route":"/companies/pathfinder-oncology/","field":"links","label":"Official website"},{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","route":"/companies/pathfinder-oncology/","field":"website"}]},{"url":"https://paxmanscalpcooling.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Paxman Scalp Cooling"},{"id":"paxman","kind":"company","name":"Paxman","route":"/companies/paxman/","field":"links","label":"Official website"},{"id":"paxman","kind":"company","name":"Paxman","route":"/companies/paxman/","field":"website"}]},{"url":"https://pdmr.cancer.gov/","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/drug-discovery-development/reagents-materials/pdmr","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-fund-organoid-translation-gate","kind":"idea","name":"A funded organoid and PDX panel as the go/no-go gate before IND-enabling money","route":"/ideas/idea-fund-organoid-translation-gate/","field":"links","label":"NCI Patient-Derived Models Repository"}]},{"url":"https://percihealth.com","status":200,"ok":true,"finalUrl":"https://percihealth.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"perci-health","kind":"company","name":"Perci Health","route":"/companies/perci-health/","field":"links","label":"Official website"},{"id":"perci-health","kind":"company","name":"Perci Health","route":"/companies/perci-health/","field":"website"}]},{"url":"https://percihealth.com/about","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"perci-health","kind":"company","name":"Perci Health","route":"/companies/perci-health/","field":"links","label":"About Perci Health"}]},{"url":"https://perimetermed.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"links","label":"Official website"},{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"website"}]},{"url":"https://perimetermed.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","field":"links","label":"About Perimeter"}]},{"url":"https://perita.bio/","status":200,"ok":true,"finalUrl":"https://www.perita.bio/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","field":"links","label":"Official website"},{"id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","field":"website"}]},{"url":"https://persephonebiosciences.com","status":200,"ok":true,"finalUrl":"https://persephone.bio/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/","field":"links","label":"Official website"},{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/","field":"website"}]},{"url":"https://perspectivetherapeutics.com","status":200,"ok":true,"finalUrl":"https://perspectivetherapeutics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","field":"website"}]},{"url":"https://pheontx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","route":"/companies/pheon-therapeutics/","field":"links","label":"Official website"},{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","route":"/companies/pheon-therapeutics/","field":"website"}]},{"url":"https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","route":"/companies/pheon-therapeutics/","field":"links","label":"Series B press release"}]},{"url":"https://phw.nhs.wales/reports/non-melanoma-skin-cancer-incidence-in-wales/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Public Health Wales: non-melanoma skin cancer incidence in Wales, published 30 May 2024 (first per person per annum counting; non-melanoma skin cancer was 40 percent of all cancer cases in Wales in 2020)"}]},{"url":"https://physicell.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agent-based-tumour-models","kind":"technology","name":"Agent-based and multicellular simulations","route":"/technologies/agent-based-tumour-models/","field":"links","label":"PhysiCell"}]},{"url":"https://picnichealth.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/","field":"links","label":"Official website"},{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/","field":"website"}]},{"url":"https://picscheme.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","field":"links","label":"PIC/S"}]},{"url":"https://pihrwanda.org/about-us/our-team","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nadine-karema","kind":"person","name":"Nadine Karema","route":"/people/nadine-karema/","field":"links","label":"Source: PIH Rwanda team page"},{"id":"nadine-karema","kind":"person","name":"Nadine Karema","route":"/people/nadine-karema/","field":"profiles","label":"Institution profile"}]},{"url":"https://platform.opentargets.org","status":200,"ok":true,"finalUrl":"https://platform.opentargets.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","field":"links","label":"Open Targets Platform"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","field":"url"}]},{"url":"https://platform.opentargets.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr2-target-failure-index","kind":"idea","name":"A target de-risking index that counts failures as well as successes","route":"/ideas/idea-tr2-target-failure-index/","field":"links","label":"Open Targets"}]},{"url":"https://plexium.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","field":"links","label":"Official website"},{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","field":"website"}]},{"url":"https://plexium.com/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","field":"links","label":"Clinical trials"}]},{"url":"https://plexium.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","field":"links","label":"Pipeline"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Ding et al., BMJ Open 2024: applying the ESMO Magnitude of Clinical Benefit Scale to antibody-drug conjugates in solid cancers, a systematic analysis of phase 3 and pivotal phase 2 trials"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Later lines)"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"standardOfCare.guideline (Metastatic)"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"standardOfCare.guideline (Platinum-resistant)"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"standardOfCare.guideline (Recurrent/metastatic)"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","field":"standardOfCare.guideline (Recurrent/metastatic)"}],"archive":"https://web.archive.org/web/20250304143952/https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11520537/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","field":"links","label":"OptimICE-RD design (Future Oncology 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12796145/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"prevalence.source"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"prevalence.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13059868/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"prevalence.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13114725/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Stage II-III)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Metastatic, later lines)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"NCCN Guidelines for Patients and the NCCN breast cancer guideline summary (PMC)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"links","label":"NCCN Guidelines for Patients and the NCCN breast cancer guideline summary (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13377776/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026","kind":"paper","name":"Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients","route":"/key-papers/paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026/","field":"links","label":"Guilford case series 2026"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5835698/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-juarez-ivermectin-repositioned-cancer-drug-2018","kind":"paper","name":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","route":"/key-papers/paper-juarez-ivermectin-repositioned-cancer-drug-2018/","field":"links","label":"Juarez review 2018"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8818899/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","route":"/institutions/iscort/","field":"links","label":"Shapira-Frommer et al., ranking new cancer drugs for the Israeli national basket (ESMO Open 2022)"}]},{"url":"https://polarispartners.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","field":"links","label":"Official website"},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","field":"website"}]},{"url":"https://polarispartners.com/companies-list/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","field":"links","label":"Companies list"}]},{"url":"https://portal.gdc.cancer.gov","status":200,"ok":true,"finalUrl":"https://portal.gdc.cancer.gov/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","route":"/collections/tcga-gdc/","field":"links","label":"TCGA / NCI Genomic Data Commons"},{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","route":"/collections/tcga-gdc/","field":"url"},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","field":"links","label":"NCI Genomic Data Commons"}]},{"url":"https://portal.gdc.cancer.gov/projects/TCGA-PRAD","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","field":"links","label":"TCGA PRAD at the NCI Genomic Data Commons"}]},{"url":"https://portal.imaging.datacommons.cancer.gov","status":200,"ok":true,"finalUrl":"https://portal.imaging.datacommons.cancer.gov/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"links","label":"NCI Imaging Data Commons (IDC)"},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"url"}]},{"url":"https://portal.imaging.datacommons.cancer.gov/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiology-imaging-modality","kind":"term","name":"Radiology imaging as a data modality (CT, MRI, TCIA)","route":"/terms/radiology-imaging-modality/","field":"links","label":"NCI Imaging Data Commons"}]},{"url":"https://portal.inen.sld.pe","status":200,"ok":true,"finalUrl":"https://www.gob.pe/inen","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","field":"links","label":"INEN"},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","field":"website"}]},{"url":"https://portal.inen.sld.pe/jefatura-institucional/","status":200,"ok":true,"finalUrl":"https://www.gob.pe/inen","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","route":"/people/francisco-berrospi-espinoza/","field":"links","label":"Source: INEN Jefatura Institucional page"},{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","route":"/people/francisco-berrospi-espinoza/","field":"profiles","label":"Institution profile"}]},{"url":"https://precedestudy.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/","field":"links","label":"PRECEDE consortium"}]},{"url":"https://precigen.com","status":200,"ok":true,"finalUrl":"https://precigen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/","field":"links","label":"Official website"},{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/","field":"website"}]},{"url":"https://preludetx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","field":"links","label":"Official website"},{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","field":"website"}]},{"url":"https://preludetx.com/science/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://privatehealth.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"private-health-management","kind":"company","name":"Private Health Management","route":"/companies/private-health-management/","field":"links","label":"Official website"},{"id":"private-health-management","kind":"company","name":"Private Health Management","route":"/companies/private-health-management/","field":"website"}]},{"url":"https://privatemedical.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"private-medical","kind":"company","name":"Private Medical","route":"/companies/private-medical/","field":"links","label":"Official website"},{"id":"private-medical","kind":"company","name":"Private Medical","route":"/companies/private-medical/","field":"website"}]},{"url":"https://profiles.imperial.ac.uk/r.heer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rakesh-heer","kind":"person","name":"Rakesh Heer","route":"/people/rakesh-heer/","field":"links","label":"Imperial College London profiles"},{"id":"rakesh-heer","kind":"person","name":"Rakesh Heer","route":"/people/rakesh-heer/","field":"profiles","label":"Imperial College London profiles"}]},{"url":"https://profiles.imperial.ac.uk/shahid.khan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","route":"/people/shahid-khan/","field":"links","label":"Imperial College London profile"},{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","route":"/people/shahid-khan/","field":"profiles","label":"Imperial College London profile"}]},{"url":"https://profiles.mountsinai.org/miriam-merad","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","field":"links","label":"Mount Sinai profile"},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","field":"profiles","label":"Mount Sinai profile"}]},{"url":"https://profiles.mountsinai.org/nina-bhardwaj","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","field":"links","label":"Mount Sinai profile"},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","field":"profiles","label":"Mount Sinai profile"}]},{"url":"https://profiles.mountsinai.org/sundar-jagannath","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","field":"links","label":"Mount Sinai profile"},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","field":"profiles","label":"Mount Sinai profile"}]},{"url":"https://profiles.mountsinai.org/thomas-u-marron","status":200,"ok":true,"finalUrl":"https://profiles.mountsinai.org/thomas-marron","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","field":"links","label":"Mount Sinai profile"},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","field":"profiles","label":"Mount Sinai profile"}]},{"url":"https://profiles.stanford.edu/robert-negrin","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"links","label":"Stanford profile"},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Crystal%20L.%20Mackall","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"links","label":"Stanford profile"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Heather%20A.%20Wakelee","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"links","label":"Stanford profile"},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Irving%20L.%20Weissman","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"links","label":"Stanford profile"},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Maximilian%20Diehn","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"links","label":"Stanford profile"},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Ronald%20Levy","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"links","label":"Stanford profile"},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.stanford.edu/search?q=Steven%20E.%20Artandi","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"links","label":"Stanford profile"},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"profiles","label":"Stanford profile"}]},{"url":"https://profiles.ucl.ac.uk/4911-caroline-moore","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"caroline-moore","kind":"person","name":"Caroline Moore","route":"/people/caroline-moore/","field":"links","label":"UCL profiles"},{"id":"caroline-moore","kind":"person","name":"Caroline Moore","route":"/people/caroline-moore/","field":"profiles","label":"UCL profiles"}]},{"url":"https://profiles.ucl.ac.uk/824-john-bridgewater","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","route":"/people/john-bridgewater/","field":"links","label":"UCL profile"},{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","route":"/people/john-bridgewater/","field":"profiles","label":"UCL profile"}]},{"url":"https://profiles.ucsf.edu/jeffrey.bluestone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"links","label":"UCSF profile"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20Ashworth","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"links","label":"UCSF profile"},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"links","label":"UCSF profile"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"UCSF profile"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Eric%20J.%20Small","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"links","label":"UCSF profile"},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Frank%20McCormick","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"links","label":"UCSF profile"},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"UCSF profile"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Kevan%20M.%20Shokat","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"links","label":"UCSF profile"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Laura%20J.%20Esserman","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"links","label":"UCSF profile"},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"UCSF profile"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"UCSF profile"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profoundmedical.com","status":200,"ok":true,"finalUrl":"https://profoundmedical.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"profound-medical","kind":"company","name":"Profound Medical","route":"/companies/profound-medical/","field":"links","label":"Official website"},{"id":"profound-medical","kind":"company","name":"Profound Medical","route":"/companies/profound-medical/","field":"website"}]},{"url":"https://proscia.com","status":200,"ok":true,"finalUrl":"https://proscia.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/","field":"links","label":"Official website"},{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/","field":"website"}]},{"url":"https://prostatecanceruk.org","status":200,"ok":true,"finalUrl":"https://prostatecanceruk.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-prev-mri-first-prostate-screening-prs","kind":"idea","name":"MRI-first prostate screening with genetic pre-selection","route":"/ideas/idea-prev-mri-first-prostate-screening-prs/","field":"links","label":"Prostate Cancer UK (TRANSFORM)"}]},{"url":"https://prostatecanceruk.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK"},{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"links","label":"Prostate Cancer UK"},{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"website"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/advanced-prostate-cancer/metastatic-spinal-cord-compression-mscc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: metastatic spinal cord compression (MSCC)"},{"id":"metastatic-spinal-cord-compression","kind":"term","name":"Metastatic spinal cord compression (MSCC)","route":"/terms/metastatic-spinal-cord-compression/","field":"links","label":"Prostate Cancer UK: metastatic spinal cord compression (MSCC)"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"Prostate Cancer UK: metastatic spinal cord compression (MSCC)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Prostate Cancer UK: metastatic spinal cord compression (MSCC)"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/get-support","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"links","label":"Get support"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/get-support/our-specialist-nurses","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: our specialist nurses"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: just diagnosed"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/dealing-with-my-diagnosis","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: dealing with my diagnosis"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/localised-prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: localised prostate cancer"},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","field":"links","label":"Prostate Cancer UK: localised prostate cancer"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/fatigue","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: fatigue"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Prostate Cancer UK: fatigue"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: how hormone therapy affects you"},{"id":"treatment-induced-bone-loss","kind":"term","name":"Treatment-induced bone loss","route":"/terms/treatment-induced-bone-loss/","field":"links","label":"Prostate Cancer UK: how hormone therapy affects you"},{"id":"gynaecomastia","kind":"term","name":"Gynaecomastia","route":"/terms/gynaecomastia/","field":"links","label":"Prostate Cancer UK: how hormone therapy affects you"},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","field":"links","label":"Prostate Cancer UK: how hormone therapy affects you"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Prostate Cancer UK: how hormone therapy affects you"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you/hot-flushes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: hot flushes"},{"id":"hot-flushes-on-hormone-therapy","kind":"term","name":"Hot flushes on hormone therapy","route":"/terms/hot-flushes-on-hormone-therapy/","field":"links","label":"Prostate Cancer UK: hot flushes"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/pelvic-floor-muscle-exercises","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: pelvic floor muscle exercises"},{"id":"pelvic-floor-muscle-exercises","kind":"term","name":"Pelvic floor muscle exercises","route":"/terms/pelvic-floor-muscle-exercises/","field":"links","label":"Prostate Cancer UK: pelvic floor muscle exercises"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/physical-activity-and-prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: physical activity and prostate cancer"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/sex-and-relationships","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: sex and relationships"},{"id":"erectile-dysfunction-after-prostate-cancer","kind":"term","name":"Erectile dysfunction after prostate cancer treatment","route":"/terms/erectile-dysfunction-after-prostate-cancer/","field":"links","label":"Prostate Cancer UK: sex and relationships"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/sex-and-relationships/treatments-for-erection-problems","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: treatments for erection problems"},{"id":"erectile-dysfunction-after-prostate-cancer","kind":"term","name":"Erectile dysfunction after prostate cancer treatment","route":"/terms/erectile-dysfunction-after-prostate-cancer/","field":"links","label":"Prostate Cancer UK: treatments for erection problems"},{"id":"priapism","kind":"term","name":"Priapism","route":"/terms/priapism/","field":"links","label":"Prostate Cancer UK: treatments for erection problems"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Prostate Cancer UK: treatments for erection problems"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/the-emotional-impact","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: the emotional impact"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/urinary-problems","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"},{"id":"acute-urinary-retention","kind":"term","name":"Acute urinary retention","route":"/terms/acute-urinary-retention/","field":"links","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"},{"id":"stress-urinary-incontinence","kind":"term","name":"Stress urinary incontinence","route":"/terms/stress-urinary-incontinence/","field":"links","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"},{"id":"artificial-urinary-sphincter","kind":"term","name":"Artificial urinary sphincter","route":"/terms/artificial-urinary-sphincter/","field":"links","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","field":"links","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Prostate Cancer UK: urinary problems after prostate cancer treatment"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/risk-and-symptoms/black-men-and-prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"links","label":"Black men and prostate cancer"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/treatments/choosing-a-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: choosing a treatment"}]},{"url":"https://prostatecanceruk.org/prostate-information-and-support/treatments/follow-up-after-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Prostate Cancer UK: follow-up after treatment"},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","field":"links","label":"Prostate Cancer UK: follow-up after treatment"}]},{"url":"https://prostatecanceruk.org/research/transform-trial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"links","label":"The TRANSFORM trial"},{"id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","field":"links","label":"Prostate Cancer UK: the TRANSFORM trial"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","field":"links","label":"Prostate Cancer UK: TRANSFORM trial"}]},{"url":"https://prostatecanceruk.org/risk-checker","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","field":"links","label":"The risk checker"}]},{"url":"https://proteanbiodx.com/","status":200,"ok":true,"finalUrl":"https://www.proteanbiodx.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","route":"/companies/protean-biodiagnostics/","field":"links","label":"Official website"},{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","route":"/companies/protean-biodiagnostics/","field":"website"}]},{"url":"https://proteomics.cancer.gov","status":200,"ok":true,"finalUrl":"https://dctd.cancer.gov/programs/occpr","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","route":"/collections/cptac/","field":"links","label":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)"},{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","route":"/collections/cptac/","field":"url"},{"id":"mass-spec-proteome","kind":"term","name":"Deep mass-spectrometry proteome (CPTAC)","route":"/terms/mass-spec-proteome/","field":"links","label":"CPTAC (NCI Office of Cancer Clinical Proteomics Research)"}]},{"url":"https://proxygen.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","field":"links","label":"Official website"},{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","field":"website"}]},{"url":"https://proxygen.com/chronicle?post=532","status":200,"ok":true,"finalUrl":"https://proxygen.com/chronicle/?post=532","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","field":"links","label":"Platform expansion announcement (April 2026)"}]},{"url":"https://proxygen.com/pipeline-beyond","status":200,"ok":true,"finalUrl":"https://proxygen.com/pipeline-beyond/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","field":"links","label":"Pipeline and beyond"}]},{"url":"https://pt.wikipedia.org/wiki/Henrique_Prata","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henrique-prata","kind":"person","name":"Henrique Prata","route":"/people/henrique-prata/","field":"profiles","label":"Wikipedia (Portuguese)"}]},{"url":"https://publications.iarc.fr/119","status":200,"ok":true,"finalUrl":"https://publications.iarc.who.int/119","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/","field":"links","label":"IARC Monographs, biological agents (volume 100B)"}]},{"url":"https://publications.iarc.who.int/122","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-alcohol-cancer-burden-lancet-oncol-2021","kind":"paper","name":"Alcohol caused an estimated 741,000 cancers worldwide in 2020","route":"/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/","field":"links","label":"IARC Monographs Volume 100E"}]},{"url":"https://publications.iarc.who.int/570","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/","field":"links","label":"IARC Handbooks Volume 16"}]},{"url":"https://publications.iarc.who.int/579","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"links","label":"WHO Classification of Tumours: Digestive System (2019)"}]},{"url":"https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Skin-Tumours-2025","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"},{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"},{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"WHO Classification of Tumours Editorial Board: Skin tumours, 5th edition, volume 12 (IARC, Lyon, 2025), ISBN 978-92-832-4535-3"}]},{"url":"https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Skin-Tumours-2018","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"Elder, Massi, Scolyer and Willemze (eds): WHO Classification of Skin Tumours, 4th edition, volume 11 (IARC, Lyon, 2018)"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"Elder, Massi, Scolyer and Willemze (eds): WHO Classification of Skin Tumours, 4th edition, volume 11 (IARC, Lyon, 2018)"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Elder, Massi, Scolyer and Willemze (eds): WHO Classification of Skin Tumours, 4th edition, volume 11 (IARC, Lyon, 2018)"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"Elder, Massi, Scolyer and Willemze (eds): WHO Classification of Skin Tumours, 4th edition, volume 11 (IARC, Lyon, 2018)"},{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","field":"links","label":"Elder, Massi, Scolyer and Willemze (eds): WHO Classification of Skin Tumours, 4th edition, volume 11 (IARC, Lyon, 2018)"}]},{"url":"https://publichealthscotland.scot/publications/cancer-incidence-in-scotland/cancer-incidence-in-scotland-to-december-2023/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Public Health Scotland: cancer incidence in Scotland to December 2023, published 30 September 2025 (only the first occurrence of a basal cell carcinoma is collected in Scotland)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/","field":"links","label":"PubMed & Europe PMC"},{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/","field":"url"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"papers","label":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL"},{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","field":"papers","label":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL"},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","field":"papers","label":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL"},{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abbas+F%5BAuthor%5D+AND+Aga+Khan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","route":"/people/farhat-abbas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aberle%20DR%5BAuthor%5D%20lung%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/","field":"links","label":"PubMed"},{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abou-Alfa%20GK%5BAuthor%5D%20hepatocellular%20OR%20cholangiocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","field":"links","label":"PubMed"},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abouelnaga+S%5BAuthor%5D+OR+Abou+El+Naga+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abraham%20J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","field":"links","label":"PubMed"},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adalsteinsson%20VA%5BAuthor%5D%20cell-free%20DNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/","field":"links","label":"PubMed"},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adams+J%5BAuthor%5D+AND+proteasome","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","field":"links","label":"PubMed"},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Addeo+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","field":"links","label":"PubMed"},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adeyemo+WL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wasiu-lanre-adeyemo","kind":"person","name":"Wasiu Lanre Adeyemo","route":"/people/wasiu-lanre-adeyemo/","field":"links","label":"PubMed"},{"id":"wasiu-lanre-adeyemo","kind":"person","name":"Wasiu Lanre Adeyemo","route":"/people/wasiu-lanre-adeyemo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aebersold+DM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","field":"links","label":"PubMed"},{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Agarwal%20N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"links","label":"PubMed"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20C%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","field":"links","label":"PubMed"},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"PubMed"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aguirre%20AJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","field":"links","label":"PubMed"},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahmed%20HU%5BAuthor%5D%20prostate%20PROMIS%20OR%20focal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hashim-ahmed","kind":"person","name":"Hashim U. Ahmed","route":"/people/hashim-ahmed/","field":"links","label":"PubMed"},{"id":"hashim-ahmed","kind":"person","name":"Hashim U. Ahmed","route":"/people/hashim-ahmed/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn%20MJ%5BAuthor%5D%20Samsung%20Medical%20Center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","field":"links","label":"PubMed author search"},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn+JS%5BAuthor%5D+Samsung+lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","field":"links","label":"PubMed"},{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajaikumar%20BS%5BAuthor%5D%20HCG","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","field":"links","label":"PubMed author search"},{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajani%20JA%5BAuthor%5D%20gastric%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","field":"links","label":"PubMed"},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Al-Batran%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"links","label":"PubMed"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","field":"links","label":"PubMed"},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alexandrov%20LB%5BAuthor%5D%20mutational%20signatures","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","field":"links","label":"PubMed"},{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alfayyadh+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"majid-alfayyadh","kind":"person","name":"Majid Ibrahim Alfayyadh","route":"/people/majid-alfayyadh/","field":"links","label":"PubMed"},{"id":"majid-alfayyadh","kind":"person","name":"Majid Ibrahim Alfayyadh","route":"/people/majid-alfayyadh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"links","label":"PubMed"},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Allison%20JP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"links","label":"PubMed"},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Altieri+DC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPLIFY%20acalabrutinib%20venetoclax%20obinutuzumab%20Brown%20NEJM%202025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","field":"papers","label":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients"},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20KC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"links","label":"PubMed"},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20F%5BAuthor%5D%20breast%20alpelisib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","field":"links","label":"PubMed"},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","field":"links","label":"PubMed"},{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Antonia%20SJ%5BAuthor%5D%20durvalumab%20PACIFIC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/","field":"links","label":"PubMed"},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armand%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","route":"/people/andrew-armstrong/","field":"links","label":"PubMed"},{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","route":"/people/andrew-armstrong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Arribas%20J%5BAuthor%5D%20p95HER2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","field":"links","label":"PubMed"},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Arrieta+O%5BAuthor%5D+AND+Cancerologia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Artandi%20SE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"links","label":"PubMed"},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ascierto%20PA%5BAuthor%5D%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","field":"links","label":"PubMed"},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ashworth%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"links","label":"PubMed"},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Atkins%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Attal%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Attard%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Auer+RC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AUGMENT-101%20revumenib%20menin%20inhibitor%20KMT2A%20NPM1%20Issa%20Nature%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","field":"papers","label":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation"},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","field":"papers","label":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation"},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Auranen+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"annika-auranen","kind":"person","name":"Annika Auranen","route":"/people/annika-auranen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/","field":"links","label":"PubMed"},{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bachelot%20T%5BAuthor%5D%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","field":"links","label":"PubMed"},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badie%20B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"links","label":"PubMed"},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badwe%20RA%5BAuthor%5D%20Tata%20Memorial%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","field":"links","label":"PubMed author search"},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","field":"links","label":"PubMed"},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baker+D%5BAuthor%5D+AND+protein+design","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-baker","kind":"person","name":"David Baker","route":"/people/david-baker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balachandran%20VP%5BAuthor%5D%20pancreatic%20vaccine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","field":"links","label":"PubMed"},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","field":"links","label":"PubMed"},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Banerjee%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bang%20YJ%5BAuthor%5D%20gastric%20cancer%20Seoul%20National%20University","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","field":"links","label":"PubMed author search"},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barakat+RR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-barakat","kind":"person","name":"Richard Barakat","route":"/people/richard-barakat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardelli%20A%5BAuthor%5D%20colorectal%20ctDNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","field":"links","label":"PubMed"},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardia%20A%5BAuthor%5D%20sacituzumab%20OR%20elacestrant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","field":"links","label":"PubMed"},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barenholz%20Y%5BAuthor%5D%20liposome","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/","field":"links","label":"PubMed author search"},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bargou+RC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barlesi%20F%5BAuthor%5D%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","field":"links","label":"PubMed"},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barranger+E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"links","label":"PubMed author search"},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","field":"links","label":"PubMed"},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartsch%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barzilay%20R%5BAuthor%5D%20deep%20learning%20cancer%20risk","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"regina-barzilay","kind":"person","name":"Regina Barzilay","route":"/people/regina-barzilay/","field":"links","label":"PubMed"},{"id":"regina-barzilay","kind":"person","name":"Regina Barzilay","route":"/people/regina-barzilay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basch%20E%5BAuthor%5D%20patient-reported%20outcomes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/","field":"links","label":"PubMed"},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baselga%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basu%20P%5BAuthor%5D%20IARC%20cervical%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","field":"links","label":"PubMed author search"},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bauer%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"links","label":"PubMed"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baylin%20SB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"links","label":"PubMed"},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beets+GL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","field":"links","label":"PubMed"},{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Behrens+A%5BAuthor%5D+AND+cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bekaii-Saab%20T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"links","label":"PubMed"},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Belka%20C%5BAuthor%5D%20MR-guided%20radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","field":"links","label":"PubMed"},{"id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Belkaid+Y%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","route":"/people/yasmine-belkaid/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bell%20JC%5BAuthor%5D%20oncolytic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-bell","kind":"person","name":"John C. Bell","route":"/people/john-bell/","field":"links","label":"PubMed"},{"id":"john-bell","kind":"person","name":"John C. Bell","route":"/people/john-bell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","field":"links","label":"PubMed"},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Benger+JR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","field":"links","label":"PubMed"},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/","field":"links","label":"PubMed"},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MS%5BAuthor%5D%20glioma%20resection","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/","field":"links","label":"PubMed"},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergerot+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","route":"/people/philippe-bergerot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergh%20J%5BAuthor%5D%20breast%20cancer%20adjuvant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","field":"links","label":"PubMed"},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"PubMed"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernards%20R%5BAuthor%5D%20BRAF%20colorectal%20EGFR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","field":"links","label":"PubMed"},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernstein%20BE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","field":"links","label":"PubMed"},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berrospi+F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","route":"/people/francisco-berrospi-espinoza/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besse%20B%5BAuthor%5D%20lung%20deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","field":"links","label":"PubMed"},{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besselink%20MG%5BAuthor%5D%20pancreatic%20PREOPANC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","route":"/people/marc-besselink/","field":"links","label":"PubMed"},{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","route":"/people/marc-besselink/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besser%20MJ%5BAuthor%5D%20tumor-infiltrating%20lymphocytes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/","field":"links","label":"PubMed author search"},{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beyaz%20S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","field":"links","label":"PubMed"},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhardwaj%20N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","field":"links","label":"PubMed"},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhargava+R%5BAuthor%5D+AND+Illinois","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhatia%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bible%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bidard%20FC%5BAuthor%5D%20ESR1%20ctDNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","field":"links","label":"PubMed"},{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bielack%20SS%5BAuthor%5D%20osteosarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stefan-bielack","kind":"person","name":"Stefan S. Bielack","route":"/people/stefan-bielack/","field":"links","label":"PubMed"},{"id":"stefan-bielack","kind":"person","name":"Stefan S. Bielack","route":"/people/stefan-bielack/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Birney+E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"links","label":"PubMed"},{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blackhall%20F%5BAuthor%5D%20small%20cell%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","field":"links","label":"PubMed"},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blandino+G%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"links","label":"PubMed"},{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blank%20CU%5BAuthor%5D%20neoadjuvant%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","field":"links","label":"PubMed"},{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blanke%20CD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"links","label":"PubMed"},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blay%20JY%5BAuthor%5D%20sarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","field":"links","label":"PubMed"},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bliss%20JM%5BAuthor%5D%20breast%20radiotherapy%20trial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"judith-bliss","kind":"person","name":"Judith M. Bliss","route":"/people/judith-bliss/","field":"links","label":"PubMed"},{"id":"judith-bliss","kind":"person","name":"Judith M. Bliss","route":"/people/judith-bliss/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bluestone+JA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"links","label":"PubMed"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bokemeyer%20C%5BAuthor%5D%20cetuximab%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","field":"links","label":"PubMed"},{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bonvalot%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boorjian%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Booth%20CM%5BAuthor%5D%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","field":"links","label":"PubMed"},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","field":"links","label":"PubMed"},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borja-Aburto+VH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bornhauser+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"links","label":"PubMed"},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bourhis%20J%5BAuthor%5D%20head%20neck%20meta-analysis%20OR%20FLASH","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-bourhis","kind":"person","name":"Jean Bourhis","route":"/people/jean-bourhis/","field":"links","label":"PubMed"},{"id":"jean-bourhis","kind":"person","name":"Jean Bourhis","route":"/people/jean-bourhis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boutros+PC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-boutros","kind":"person","name":"Paul Boutros","route":"/people/paul-boutros/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boyer+MJ%5BAuthor%5D+lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bradley%20JD%5BAuthor%5D%20RTOG%200617","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/","field":"links","label":"PubMed"},{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"links","label":"PubMed"},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bramley+D%5BAuthor%5D+AND+New+Zealand","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brandts+CH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","field":"links","label":"PubMed"},{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bray%20F%5BAuthor%5D%20global%20cancer%20statistics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"links","label":"PubMed author search"},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","field":"papers","label":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer"},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/","field":"links","label":"PubMed search: BREAKWATER encorafenib NEJM 2025"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenner%20H%5BAuthor%5D%20colorectal%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","field":"links","label":"PubMed"},{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brentjens%20RJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","field":"links","label":"PubMed"},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenton+JD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","field":"links","label":"PubMed"},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bretthauer%20M%5BAuthor%5D%20colonoscopy%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-bretthauer","kind":"person","name":"Michael Bretthauer","route":"/people/michael-bretthauer/","field":"links","label":"PubMed"},{"id":"michael-bretthauer","kind":"person","name":"Michael Bretthauer","route":"/people/michael-bretthauer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brody%20JD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","field":"links","label":"PubMed"},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","field":"links","label":"PubMed"},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20CE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"links","label":"PubMed"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","field":"links","label":"PubMed"},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brucker+SY%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","field":"links","label":"PubMed"},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bruix%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bruner%20DW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"links","label":"PubMed"},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brunt%20AM%5BAuthor%5D%20FAST-Forward","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"murray-brunt","kind":"person","name":"A. Murray Brunt","route":"/people/murray-brunt/","field":"links","label":"PubMed"},{"id":"murray-brunt","kind":"person","name":"A. Murray Brunt","route":"/people/murray-brunt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Buckner%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bullinger%20L%5BAuthor%5D%20AML","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","field":"links","label":"PubMed"},{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burger%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burkard+ME%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","route":"/people/mark-burkard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burtness%20B%5BAuthor%5D%20head%20neck%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","field":"links","label":"PubMed"},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Buttner%20R%5BAuthor%5D%20lung%20cancer%20genome","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","field":"links","label":"PubMed"},{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","field":"links","label":"PubMed"},{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=C-144-01%20lifileucel%20tumor-infiltrating%20lymphocyte%20melanoma%20Sarnaik%20JCO%202021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"papers","label":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed"},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"papers","label":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed"},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cabanillas%20ME%5BAuthor%5D%20anaplastic%20thyroid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","route":"/people/maria-cabanillas/","field":"links","label":"PubMed"},{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","route":"/people/maria-cabanillas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cairns+BR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","field":"links","label":"PubMed"},{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"PubMed"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caldas%20C%5BAuthor%5D%20breast%20genomic%20METABRIC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/","field":"links","label":"PubMed"},{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caligiuri%20MA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"links","label":"PubMed"},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cameron%20D%5BAuthor%5D%20HERA%20trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","field":"links","label":"PubMed"},{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","field":"links","label":"PubMed"},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Campone+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Capitini+CM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christian-capitini","kind":"person","name":"Christian Capitini","route":"/people/christian-capitini/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caplin%20ME%5BAuthor%5D%20neuroendocrine%20lanreotide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","field":"links","label":"PubMed"},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carroll+JS%5BAuthor%5D+Cambridge","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","field":"links","label":"PubMed"},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARTITUDE-1%20ciltacabtagene%20autoleucel%20Berdeja%20Lancet%202021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"papers","label":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma"},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","field":"papers","label":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma"},{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","route":"/people/richard-carvajal/","field":"links","label":"PubMed"},{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","route":"/people/richard-carvajal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","field":"links","label":"PubMed"},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Castelo%20B%5BAuthor%5D%20head%20and%20neck","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","field":"links","label":"PubMed"},{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cavalli+F%5BAuthor%5D+AND+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHEUS%20daratumumab%20bortezomib%20lenalidomide%20transplant-ineligible%20Usmani%20Nature%20Medicine%202025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"papers","label":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint"},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cercek%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","field":"links","label":"PubMed"},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cervantes%20A%5BAuthor%5D%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","field":"links","label":"PubMed"},{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chalabi%20M%5BAuthor%5D%20NICHE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","field":"links","label":"PubMed"},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%20TA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"links","label":"PubMed"},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+A%5BAuthor%5D+supportive+care+cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","field":"links","label":"PubMed"},{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+AT%5BAuthor%5D+nasopharyngeal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","field":"links","label":"PubMed"},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chang%20JY%5BAuthor%5D%20stereotactic%20ablative%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joe-chang","kind":"person","name":"Joe Y. Chang","route":"/people/joe-chang/","field":"links","label":"PubMed"},{"id":"joe-chang","kind":"person","name":"Joe Y. Chang","route":"/people/joe-chang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chapman%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/","field":"links","label":"PubMed"},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chaturvedi%20P%5BAuthor%5D%20Tata%20Memorial%20oral%20cancer%20tobacco","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"links","label":"PubMed author search"},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chavez-MacGregor%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"links","label":"PubMed"},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chawla+SP%5BAuthor%5D+sarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"links","label":"PubMed"},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","field":"papers","label":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"papers","label":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"papers","label":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later"},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"papers","label":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma"},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"papers","label":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma"},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"papers","label":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma"},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","field":"papers","label":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma"},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/","field":"links","label":"PubMed search: CheckMate 649 Lancet 2021"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chee+CE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","field":"links","label":"PubMed"},{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20L%5BAuthor%5D%20B7-H1%20PD-L1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","field":"links","label":"PubMed"},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20SJ%5BAuthor%5D%20acute%20promyelocytic%20leukemia%20Shanghai%20Institute%20of%20Hematology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","field":"links","label":"PubMed author search"},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20Z%5BAuthor%5D%20arsenic%20trioxide%20PML-RARA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","field":"links","label":"PubMed author search"},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen+A%5BAuthor%5D+Weizmann+stress","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alon-chen","kind":"person","name":"Alon Chen","route":"/people/alon-chen/","field":"links","label":"PubMed"},{"id":"alon-chen","kind":"person","name":"Alon Chen","route":"/people/alon-chen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen+CT%5BAuthor%5D+AND+Chang+Gung+AND+plastic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","field":"links","label":"PubMed"},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20Y%5BAuthor%5D%20small%20cell%20lung%20cancer%20Jilin%20Cancer%20Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","field":"links","label":"PubMed author search"},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+T%5BAuthor%5D+AND+Tianjin+hematology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cherny%20NI%5BAuthor%5D%20ESMO-MCBS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","field":"links","label":"PubMed"},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chesler+L%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","field":"links","label":"PubMed"},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/","field":"links","label":"PubMed"},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","field":"links","label":"PubMed"},{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiang%20AC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"links","label":"PubMed"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chinnaiyan%20AM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"links","label":"PubMed"},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chinot%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiu+PW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","field":"links","label":"PubMed"},{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cho%20BC%5BAuthor%5D%20Yonsei%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"links","label":"PubMed author search"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choudhury%20A%5BAuthor%5D%20bladder%20radiotherapy%20hypoxia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","field":"links","label":"PubMed"},{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"links","label":"PubMed"},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chu%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chu+NM%5BAuthor%5D+AND+Taiwan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chung%20CH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","field":"links","label":"PubMed"},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciechanover%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"links","label":"PubMed author search"},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciruelos+E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","field":"links","label":"PubMed"},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clapp+DW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clark+SJ%5BAuthor%5D+methylation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-clark","kind":"person","name":"Susan Clark","route":"/people/susan-clark/","field":"links","label":"PubMed"},{"id":"susan-clark","kind":"person","name":"Susan Clark","route":"/people/susan-clark/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clifford+SC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"links","label":"PubMed"},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","field":"links","label":"PubMed"},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CodeBreaK+200+sotorasib+docetaxel+de+Langen+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","field":"papers","label":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","field":"links","label":"PubMed search: CodeBreaK 200 Lancet 2023"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Codish+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohen%20EEW%5BAuthor%5D%20head%20neck%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/","field":"links","label":"PubMed"},{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn%20SL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"links","label":"PubMed"},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn+RD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"links","label":"PubMed"},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","field":"links","label":"PubMed"},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coles%20CE%5BAuthor%5D%20breast%20radiotherapy%20IMPORT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/","field":"links","label":"PubMed"},{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Collet+L%5BAuthor%5D+Lyon","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lionel-collet","kind":"person","name":"Lionel Collet","route":"/people/lionel-collet/","field":"links","label":"PubMed"},{"id":"lionel-collet","kind":"person","name":"Lionel Collet","route":"/people/lionel-collet/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Collins+DC%5BAuthor%5D+AND+Cork","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Colombo%20N%5BAuthor%5D%20cervical%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","field":"links","label":"PubMed"},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COMMANDS%20luspatercept%20epoetin%20alfa%20lower-risk%20MDS%20Platzbecker%20Lancet%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","field":"papers","label":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions"},{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Concin+N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"links","label":"PubMed"},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","field":"links","label":"PubMed"},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Conroy%20T%5BAuthor%5D%20FOLFIRINOX","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","field":"links","label":"PubMed"},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Corcoran%20RB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","field":"links","label":"PubMed"},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","field":"links","label":"PubMed"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortot+AB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","field":"links","label":"PubMed"},{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Courneya%20KS%5BAuthor%5D%20exercise%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","route":"/people/kerry-courneya/","field":"links","label":"PubMed"},{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","route":"/people/kerry-courneya/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cree%20IA%5BAuthor%5D%20WHO%20classification%20of%20tumours","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","field":"links","label":"PubMed author search"},{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Creutzberg%20CL%5BAuthor%5D%20PORTEC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/","field":"links","label":"PubMed"},{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cristofanilli%20M%5BAuthor%5D%20breast%20circulating","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"massimo-cristofanilli","kind":"person","name":"Massimo Cristofanilli","route":"/people/massimo-cristofanilli/","field":"links","label":"PubMed"},{"id":"massimo-cristofanilli","kind":"person","name":"Massimo Cristofanilli","route":"/people/massimo-cristofanilli/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuneo+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","field":"links","label":"PubMed"},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cunningham%20D%5BAuthor%5D%20gastric%20perioperative","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","field":"links","label":"PubMed"},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curigliano%20G%5BAuthor%5D%20breast%20deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","field":"links","label":"PubMed"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curtis%20C%5BAuthor%5D%20tumor%20evolution","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christina-curtis","kind":"person","name":"Christina Curtis","route":"/people/christina-curtis/","field":"links","label":"PubMed"},{"id":"christina-curtis","kind":"person","name":"Christina Curtis","route":"/people/christina-curtis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","route":"/people/jack-cuzick/","field":"links","label":"PubMed"},{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","route":"/people/jack-cuzick/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"PubMed"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Amico%20AV%5BAuthor%5D%20prostate%20risk","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=D%27Amico%20AV%5BAuthor%5D%20prostate%20risk","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-damico","kind":"person","name":"Anthony V. D'Amico","route":"/people/anthony-damico/","field":"links","label":"PubMed"},{"id":"anthony-damico","kind":"person","name":"Anthony V. D'Amico","route":"/people/anthony-damico/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=D%27Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","field":"links","label":"PubMed"},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=D%27Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","field":"links","label":"PubMed"},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Cruz%20AK%5BAuthor%5D%20Tata%20Memorial%20head%20and%20neck","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=D%27Cruz%20AK%5BAuthor%5D%20Tata%20Memorial%20head%20and%20neck","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"links","label":"PubMed author search"},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dancey%20J%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"links","label":"PubMed author search"},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dank+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Davis+ID%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","field":"links","label":"PubMed"},{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dawson%20SJ%5BAuthor%5D%20circulating%20tumor%20DNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","field":"links","label":"PubMed author search"},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","field":"links","label":"PubMed"},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Bono%20JS%5BAuthor%5D%20prostate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"links","label":"PubMed"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Braud%20F%5BAuthor%5D%20phase%20I","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","field":"links","label":"PubMed"},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Gramont%20A%5BAuthor%5D%20oxaliplatin%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","route":"/people/aimery-de-gramont/","field":"links","label":"PubMed"},{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","route":"/people/aimery-de-gramont/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Koning%20HJ%5BAuthor%5D%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","route":"/people/harry-de-koning/","field":"links","label":"PubMed"},{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","route":"/people/harry-de-koning/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Claro+RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","route":"/people/r-angelo-de-claro/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Crevoisier+R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","route":"/people/renaud-de-crevoisier/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Laat+W%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","field":"links","label":"PubMed"},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dearnaley%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Debus%20J%5BAuthor%5D%20carbon%20ion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","field":"links","label":"PubMed"},{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeCensi%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delaloge+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","field":"links","label":"PubMed"},{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delattre%20O%5BAuthor%5D%20Ewing","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","field":"links","label":"PubMed"},{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delord+JP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","field":"links","label":"PubMed"},{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"links","label":"PubMed"},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demaria+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","field":"links","label":"PubMed"},{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demetri%20GD%5BAuthor%5D%20GIST%20imatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","field":"links","label":"PubMed"},{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","field":"links","label":"PubMed"},{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","field":"links","label":"PubMed"},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","field":"links","label":"PubMed"},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","field":"papers","label":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer"},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/","field":"links","label":"PubMed search: DESTINY-Breast06"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Devine+EB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","field":"links","label":"PubMed"},{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diaz%20LA%20Jr%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"links","label":"PubMed"},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dick%20JE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"links","label":"PubMed"},{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/","field":"links","label":"PubMed"},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diehn%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"links","label":"PubMed"},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dietrich+S%5BAuthor%5D+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","field":"links","label":"PubMed"},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dimopoulos%20MA%5BAuthor%5D%20myeloma%20daratumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","field":"links","label":"PubMed"},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiNardo%20CD%5BAuthor%5D%20venetoclax%20azacitidine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","field":"links","label":"PubMed"},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ding%20L%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","field":"links","label":"PubMed"},{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiPersio%20JF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","field":"links","label":"PubMed"},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dirksen+U%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","field":"links","label":"PubMed"},{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dive%20C%5BAuthor%5D%20circulating%20tumour%20cells%20small%20cell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","field":"links","label":"PubMed"},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doebele%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner%20H%5BAuthor%5D%20acute%20myeloid%20leukemia%20ELN","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","field":"links","label":"PubMed"},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","field":"links","label":"PubMed"},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"links","label":"PubMed author search"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doki%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dombret%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Domchek%20SM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"links","label":"PubMed"},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dome%20JS%5BAuthor%5D%20Wilms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-dome","kind":"person","name":"Jeffrey S. Dome","route":"/people/jeffrey-dome/","field":"links","label":"PubMed"},{"id":"jeffrey-dome","kind":"person","name":"Jeffrey S. Dome","route":"/people/jeffrey-dome/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Downing+JR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/","field":"links","label":"PubMed"},{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dowsett%20M%5BAuthor%5D%20Ki67%20endocrine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","route":"/people/mitch-dowsett/","field":"links","label":"PubMed"},{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","route":"/people/mitch-dowsett/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Draetta%20G%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"links","label":"PubMed"},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/","field":"links","label":"PubMed"},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Drilon%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"links","label":"PubMed"},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=du%20Bois%20A%5BAuthor%5D%20ovarian%20DESKTOP","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/","field":"links","label":"PubMed"},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DuBois+RN%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","route":"/people/raymond-dubois/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Duffaud%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","field":"links","label":"PubMed"},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dunsmore%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/","field":"links","label":"PubMed"},{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eberlein%20TJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","field":"links","label":"PubMed"},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ebert%20BL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"links","label":"PubMed"},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","field":"links","label":"PubMed"},{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggert%20A%5BAuthor%5D%20neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","field":"links","label":"PubMed"},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","field":"links","label":"PubMed"},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=El-Ashry+D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","field":"links","label":"PubMed"},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELEVATE-TN%20acalabrutinib%20obinutuzumab%20chlorambucil%20Sharman%20Lancet%202020","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","field":"papers","label":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL"},{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elez%20E%5BAuthor%5D%20colorectal%20BRAF","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","field":"links","label":"PubMed"},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elisei%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ellisen%20LW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","field":"links","label":"PubMed"},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emberton%20M%5BAuthor%5D%20prostate%20MRI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-emberton","kind":"person","name":"Mark Emberton","route":"/people/mark-emberton/","field":"links","label":"PubMed"},{"id":"mark-emberton","kind":"person","name":"Mark Emberton","route":"/people/mark-emberton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","field":"links","label":"PubMed"},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Engert%20A%5BAuthor%5D%20Hodgkin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/","field":"links","label":"PubMed"},{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Enver+T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORE%20NHL-1%20epcoritamab%20large%20B-cell%20lymphoma%20Thieblemont%20JCO%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","field":"papers","label":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T"},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"links","label":"PubMed"},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eriksson+AG%5BAuthor%5D+gynecologic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","field":"links","label":"PubMed"},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eshhar%20Z%5BAuthor%5D%20chimeric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/","field":"links","label":"PubMed author search"},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","field":"links","label":"PubMed"},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Espinosa%20E%5BAuthor%5D%20melanoma%20gene%20expression","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","field":"links","label":"PubMed"},{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Esserman%20LJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"links","label":"PubMed"},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","field":"links","label":"PubMed"},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fader%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fagotti%20A%5BAuthor%5D%20ovarian%20laparoscopy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","field":"links","label":"PubMed"},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faivre-Finn%20C%5BAuthor%5D%20small-cell%20radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/","field":"links","label":"PubMed"},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fan%20J%5BAuthor%5D%20hepatocellular%20carcinoma%20Zhongshan%20Hospital%20Fudan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","field":"links","label":"PubMed author search"},{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fan+D%5BAuthor%5D+AND+integrative+oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fan-daiming","kind":"person","name":"Fan Daiming","route":"/people/fan-daiming/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fang%20W%5BAuthor%5D%20Sun%20Yat-sen%20ivonescimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","field":"links","label":"PubMed author search"},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faries%20MB%5BAuthor%5D%20melanoma%20sentinel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/","field":"links","label":"PubMed"},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fearon%20ER%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"links","label":"PubMed"},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"links","label":"PubMed"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Feliu%20J%5BAuthor%5D%20geriatric%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","field":"links","label":"PubMed"},{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenaux%20P%5BAuthor%5D%20azacitidine%20myelodysplastic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","field":"links","label":"PubMed"},{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fennell%20DA%5BAuthor%5D%20mesothelioma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","field":"links","label":"PubMed"},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fennelly+D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenstermaker%20RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","field":"links","label":"PubMed"},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/","field":"links","label":"PubMed"},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferris%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Figlin+RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","field":"links","label":"PubMed"},{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","field":"links","label":"PubMed"},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fitzgerald%20RC%5BAuthor%5D%20Cytosponge%20Barrett","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","field":"links","label":"PubMed"},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"links","label":"PubMed"},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flaherty%20KT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"links","label":"PubMed"},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flowers%20CR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"links","label":"PubMed"},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fong%20Y%5BAuthor%5D%20hepatic%20metastases","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yuman-fong","kind":"person","name":"Yuman Fong","route":"/people/yuman-fong/","field":"links","label":"PubMed"},{"id":"yuman-fong","kind":"person","name":"Yuman Fong","route":"/people/yuman-fong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forcic%20D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","route":"/people/dubravko-forcic/","field":"links","label":"PubMed"},{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","route":"/people/dubravko-forcic/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"links","label":"PubMed"},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forman%20SJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"links","label":"PubMed"},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Foti%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"links","label":"PubMed"},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Francis%20PA%5BAuthor%5D%20SOFT%20TEXT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","route":"/people/prudence-francis/","field":"links","label":"PubMed"},{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","route":"/people/prudence-francis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Freedland%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Freeman%20GJ%5BAuthor%5D%20PD-L1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","field":"links","label":"PubMed"},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Friedman%20E%5BAuthor%5D%20BRCA%20Sheba","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","field":"links","label":"PubMed author search"},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Frohling%20S%5BAuthor%5D%20MASTER%20precision%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","field":"links","label":"PubMed"},{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fuchs%20TJ%5BAuthor%5D%20computational%20pathology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","route":"/people/thomas-fuchs/","field":"links","label":"PubMed"},{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","route":"/people/thomas-fuchs/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fujiwara+Y%5BAuthor%5D+regulatory","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","field":"links","label":"PubMed"},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukuda%20H%5BAuthor%5D%20JCOG","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","field":"links","label":"PubMed author search"},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukunaga+K%5BAuthor%5D+Keio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","field":"links","label":"PubMed"},{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Furth+SL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"links","label":"PubMed"},{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabizon%20A%5BAuthor%5D%20liposomal%20doxorubicin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"links","label":"PubMed author search"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gainor%20JF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"links","label":"PubMed"},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajewski%20TF%5BAuthor%5D%20tumor%20immunity","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","route":"/people/thomas-gajewski/","field":"links","label":"PubMed"},{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","route":"/people/thomas-gajewski/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajjar%20A%5BAuthor%5D%20medulloblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","route":"/people/amar-gajjar/","field":"links","label":"PubMed"},{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","route":"/people/amar-gajjar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galanis%20E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"links","label":"PubMed"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galloway%20DA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"links","label":"PubMed"},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","field":"links","label":"PubMed"},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","field":"links","label":"PubMed"},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garcia-Aguilar%20J%5BAuthor%5D%20rectal%20organ%20preservation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/","field":"links","label":"PubMed"},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garralda%20E%5BAuthor%5D%20phase%20I","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","field":"links","label":"PubMed"},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garrido%20P%5BAuthor%5D%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","field":"links","label":"PubMed"},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gatenby%20RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","field":"links","label":"PubMed"},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=George+B%5BAuthor%5D+AND+Vellore","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=George+TJ%5BAuthor%5D+AND+Florida","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gershenson%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gershenwald%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Getz%20G%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"links","label":"PubMed"},{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Geyer%20CE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"links","label":"PubMed"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gianni%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","field":"links","label":"PubMed"},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gil+RA%5BAuthor%5D+INCA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"links","label":"PubMed"},{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","field":"links","label":"PubMed"},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillison%20ML%5BAuthor%5D%20HPV%20oropharyngeal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/","field":"links","label":"PubMed"},{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giuliano%20AE%5BAuthor%5D%20sentinel%20Z0011","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/","field":"links","label":"PubMed"},{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gligorov+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Glimm+H%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"links","label":"PubMed"},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gnant+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","field":"links","label":"PubMed"},{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goetz%20MP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"links","label":"PubMed"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goh+BC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","field":"links","label":"PubMed"},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","route":"/people/nicola-gokbuget/","field":"links","label":"PubMed"},{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","route":"/people/nicola-gokbuget/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokhale+RS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","field":"links","label":"PubMed"},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golub%20TR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"links","label":"PubMed"},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goncalves%20A%5BAuthor%5D%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","field":"links","label":"PubMed"},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gonzalez-Martin+A%5BAuthor%5D+ovarian","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","field":"links","label":"PubMed"},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goto%20K%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","field":"links","label":"PubMed author search"},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gourley+C%5BAuthor%5D+ovarian","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","field":"links","label":"PubMed"},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Govindan%20R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","field":"links","label":"PubMed"},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","field":"links","label":"PubMed"},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Graefen%20M%5BAuthor%5D%20prostatectomy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","field":"links","label":"PubMed"},{"id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20R%5BAuthor%5D%20EBCTCG%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-gray","kind":"person","name":"Richard Gray","route":"/people/richard-gray/","field":"links","label":"PubMed"},{"id":"richard-gray","kind":"person","name":"Richard Gray","route":"/people/richard-gray/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greaves%20M%5BAuthor%5D%20leukaemia%20evolution","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","field":"links","label":"PubMed"},{"id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greenberg%20PD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"links","label":"PubMed"},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greten+FR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"links","label":"PubMed"},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","field":"links","label":"PubMed"},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20OL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","field":"links","label":"PubMed"},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grill%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grob%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gronchi%20A%5BAuthor%5D%20sarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","field":"links","label":"PubMed"},{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gross%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grupp%20SA%5BAuthor%5D%20tisagenlecleucel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","field":"links","label":"PubMed"},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guckenberger+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","field":"links","label":"PubMed"},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guigay%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gulley%20JL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","field":"links","label":"PubMed"},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","field":"links","label":"PubMed author search"},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","field":"links","label":"PubMed"},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","field":"links","label":"PubMed"},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20Tata%20Memorial%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","field":"links","label":"PubMed author search"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutkind+JS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","field":"links","label":"PubMed"},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutzmer%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guzzo%20M%5BAuthor%5D%20salivary","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","field":"links","label":"PubMed"},{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=H%C3%B6ppner%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haanen%20JB%5BAuthor%5D%20tumor-infiltrating%20lymphocytes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","field":"links","label":"PubMed"},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber%20DA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"links","label":"PubMed"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber+GP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","field":"links","label":"PubMed"},{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","field":"links","label":"PubMed"},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Habr-Gama%20A%5BAuthor%5D%20rectal%20watch%20and%20wait","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","route":"/people/angelita-habr-gama/","field":"links","label":"PubMed"},{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","route":"/people/angelita-habr-gama/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hadoux%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Halassy%20B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"links","label":"PubMed"},{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hall%20P%5BAuthor%5D%20mammographic%20density%20risk","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","field":"links","label":"PubMed"},{"id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hallek%20M%5BAuthor%5D%20CLL","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","field":"links","label":"PubMed"},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hamdy%20FC%5BAuthor%5D%20ProtecT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"freddie-hamdy","kind":"person","name":"Freddie C. Hamdy","route":"/people/freddie-hamdy/","field":"links","label":"PubMed"},{"id":"freddie-hamdy","kind":"person","name":"Freddie C. Hamdy","route":"/people/freddie-hamdy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hao+J%5BAuthor%5D+AND+Tianjin+Medical+University+Cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harbeck%20N%5BAuthor%5D%20breast%20ADAPT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","route":"/people/nadia-harbeck/","field":"links","label":"PubMed"},{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","route":"/people/nadia-harbeck/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hargrave%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HARMONi-2+ivonescimab+pembrolizumab+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"papers","label":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer"},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","field":"papers","label":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer"},{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/","field":"links","label":"PubMed search: HARMONi-2 ivonescimab Lancet"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D%20oncolytic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","field":"links","label":"PubMed"},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","field":"links","label":"PubMed"},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haslem+DS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","route":"/people/derrick-haslem/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hassan%20R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","field":"links","label":"PubMed"},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haugen%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haura%20EB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","field":"links","label":"PubMed"},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hawkins%20DS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"links","label":"PubMed"},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hayashi+H%5BAuthor%5D+Kindai+lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","field":"links","label":"PubMed"},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hayran+KM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","route":"/people/kadir-mutlu-hayran/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=He%20J%5BAuthor%5D%20National%20Cancer%20Center%20China%20cancer%20statistics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","field":"links","label":"PubMed author search"},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","field":"links","label":"PubMed"},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinemann%20V%5BAuthor%5D%20FIRE-3","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","field":"links","label":"PubMed"},{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinrich%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helin%20K%5BAuthor%5D%20epigenetic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","field":"links","label":"PubMed"},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helleday%20T%5BAuthor%5D%20PARP%20synthetic%20lethality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/","field":"links","label":"PubMed"},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hellmann%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","field":"links","label":"PubMed"},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herold+MJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrera%20AF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"links","label":"PubMed"},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","field":"links","label":"PubMed"},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershko%20A%5BAuthor%5D%20ubiquitin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"links","label":"PubMed author search"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershman%20DL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"links","label":"PubMed"},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herzog+TJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","field":"links","label":"PubMed"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heymach%20JV%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"links","label":"PubMed"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillis+C%5BAuthor%5D+AND+hematology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-hillis","kind":"person","name":"Chris Hillis","route":"/people/chris-hillis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillmen%20P%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20FLAIR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","field":"links","label":"PubMed"},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"links","label":"PubMed"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hoff%20PM%5BAuthor%5D%20colorectal%20capecitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","field":"links","label":"PubMed author search"},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"links","label":"PubMed author search"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hong%20TS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","field":"links","label":"PubMed"},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"PubMed"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","field":"links","label":"PubMed"},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","field":"links","label":"PubMed"},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hu%20X%5BAuthor%5D%20Fudan%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","field":"links","label":"PubMed author search"},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hu+J%5BAuthor%5D+AND+Tongji+Hospital+Wuhan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20J%5BAuthor%5D%20camrelizumab%20esophageal%20ESCORT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","field":"links","label":"PubMed author search"},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20XJ%5BAuthor%5D%20haploidentical%20Peking%20University","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","field":"links","label":"PubMed author search"},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hudis%20CA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"links","label":"PubMed"},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","field":"links","label":"PubMed"},{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hunger%20SP%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20children","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","field":"links","label":"PubMed"},{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huntly+BJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","field":"links","label":"PubMed"},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurles+ME%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","field":"links","label":"PubMed"},{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurvitz%20SA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"links","label":"PubMed"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","field":"links","label":"PubMed"},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hwang%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hwu%20P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","field":"links","label":"PubMed"},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ilbawi%20AM%5BAuthor%5D%20WHO%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","field":"links","label":"PubMed author search"},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"links","label":"PubMed author search"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMerge%20imetelstat%20lower-risk%20MDS%20Platzbecker%20Lancet%202024","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","field":"papers","label":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed"},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMvigor011%20atezolizumab%20ctDNA%20Powles","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Inamdar+MS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ingledew+PA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","route":"/people/paris-ann-ingledew/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ingsathit+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","route":"/people/atiporn-ingsathit/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Irish+JC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Irwin+MS%5BAuthor%5D+neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","field":"links","label":"PubMed"},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","field":"links","label":"PubMed"},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Italiano%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","route":"/people/elias-jabbour/","field":"links","label":"PubMed"},{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","route":"/people/elias-jabbour/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","field":"links","label":"PubMed"},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jacobson%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jaffee%20EM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"links","label":"PubMed"},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagannath%20S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","field":"links","label":"PubMed"},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagielska+B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","field":"links","label":"PubMed"},{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jain%20H%5BAuthor%5D%20Tata%20Memorial%20lymphoma%20CAR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","field":"links","label":"PubMed author search"},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=James%20ND%5BAuthor%5D%20STAMPEDE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","field":"links","label":"PubMed"},{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janjigian%20YY%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"links","label":"PubMed"},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"links","label":"PubMed"},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janowitz%20T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","field":"links","label":"PubMed"},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jereczek-Fossa+BA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","field":"links","label":"PubMed"},{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/","field":"links","label":"PubMed"},{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jiang%20YZ%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","field":"links","label":"PubMed author search"},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Joensuu%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson%20CS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","field":"links","label":"PubMed"},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+PW%5BAuthor%5D+AND+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","field":"links","label":"PubMed"},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnston%20SRD%5BAuthor%5D%20abemaciclib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","field":"links","label":"PubMed"},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jonasch%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jones%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Joyce+JA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jr.%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=June%20CH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"links","label":"PubMed"},{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaelin%20WG%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","field":"links","label":"PubMed"},{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaiser+T%5BAuthor%5D+IQWiG","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","field":"links","label":"PubMed"},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaliks%20R%5BAuthor%5D%20Einstein%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","field":"links","label":"PubMed author search"},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinski%20P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","field":"links","label":"PubMed"},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","route":"/people/kevin-kalinsky/","field":"links","label":"PubMed"},{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","route":"/people/kevin-kalinsky/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kamat%20AM%5BAuthor%5D%20bladder%20BCG","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","route":"/people/ashish-kamat/","field":"links","label":"PubMed"},{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","route":"/people/ashish-kamat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20WK%5BAuthor%5D%20gastric%20cancer%20Samsung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","field":"links","label":"PubMed author search"},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","field":"links","label":"PubMed author search"},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang+TI%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","field":"links","label":"PubMed"},{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kantarjian%20HM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"links","label":"PubMed"},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kapoor%20A%5BAuthor%5D%20Varanasi%20head%20and%20neck%20metronomic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","field":"links","label":"PubMed author search"},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","field":"links","label":"PubMed"},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kasenda+B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"links","label":"PubMed"},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Katai%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kather%20JN%5BAuthor%5D%20deep%20learning%20histology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/","field":"links","label":"PubMed"},{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20K%5BAuthor%5D%20esophageal%20nivolumab%20OR%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","field":"links","label":"PubMed"},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Katz%20A%5BAuthor%5D%20Sirio-Libanes%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","field":"links","label":"PubMed author search"},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaufman%20HL%5BAuthor%5D%20talimogene%20oncolytic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","field":"links","label":"PubMed"},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kawecki+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","field":"links","label":"PubMed"},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kazda+T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","field":"links","label":"PubMed"},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kearns+PR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","route":"/people/pamela-kearns/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Keilholz%20U%5BAuthor%5D%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","field":"links","label":"PubMed"},{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelley%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20KM%5BAuthor%5D%20Hodgkin%20children","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","route":"/people/kara-kelly/","field":"links","label":"PubMed"},{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","route":"/people/kara-kelly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","field":"links","label":"PubMed"},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly+K%5BAuthor%5D+lung+cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","field":"links","label":"PubMed"},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kennecke%20HF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"links","label":"PubMed"},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kennedy+J%5BAuthor%5D+AND+St+James%27s+Dublin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kerin+MJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-kerin","kind":"person","name":"Michael Kerin","route":"/people/michael-kerin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kesari+S%5BAuthor%5D+glioblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","field":"links","label":"PubMed"},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-048+pembrolizumab+head+and+neck+Burtness+Lancet+2019","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","field":"papers","label":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer"},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","field":"papers","label":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer"},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/","field":"links","label":"PubMed search: KEYNOTE-048 Lancet 2019"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-A18+pembrolizumab+chemoradiotherapy+cervical+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","field":"papers","label":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiem%20HP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"links","label":"PubMed"},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiessling%20R%5BAuthor%5D%20natural%20killer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","field":"links","label":"PubMed"},{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kile+BT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","field":"links","label":"PubMed"},{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20DW%5BAuthor%5D%20Seoul%20National%20University%20ALK%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","field":"links","label":"PubMed author search"},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20HR%5BAuthor%5D%20Yonsei%20lung%20cancer%20immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","field":"links","label":"PubMed author search"},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","field":"links","label":"PubMed author search"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TW%5BAuthor%5D%20Asan%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"links","label":"PubMed author search"},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TY%5BAuthor%5D%20Seoul%20National%20University%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","field":"links","label":"PubMed author search"},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","field":"profiles","label":"PubMed"},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler%20HL%5BAuthor%5D%20mesothelioma%20OR%20pancreatic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/","field":"links","label":"PubMed"},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler+T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","field":"links","label":"PubMed"},{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=King+TA%5BAuthor%5D+breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","field":"links","label":"PubMed"},{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kinzler%20KW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"links","label":"PubMed"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kirkwood%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kishan%20AU%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"links","label":"PubMed"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiss+I%5BAuthor%5D+Brno","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","field":"links","label":"PubMed"},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kitagawa%20Y%5BAuthor%5D%20esophageal%20JCOG","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","field":"links","label":"PubMed author search"},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-klein","kind":"person","name":"Eric A. Klein","route":"/people/eric-klein/","field":"links","label":"PubMed"},{"id":"eric-klein","kind":"person","name":"Eric A. Klein","route":"/people/eric-klein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klek+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Knudsen+KE%5BAuthor%5D+prostate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"links","label":"PubMed"},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kohno%20T%5BAuthor%5D%20National%20Cancer%20Center%20RET%20fusion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","field":"links","label":"PubMed author search"},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Konermann+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Koong%20AC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"links","label":"PubMed"},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kopetz%20S%5BAuthor%5D%20BRAF%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","field":"links","label":"PubMed"},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krainer%20AR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","field":"links","label":"PubMed"},{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","field":"links","label":"PubMed"},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kristinsson%20SY%5BAuthor%5D%20iStopMM","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/","field":"links","label":"PubMed"},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/","field":"links","label":"PubMed"},{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krumholz+HM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"links","label":"PubMed"},{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krzyzanowska+MK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","route":"/people/monika-krzyzanowska/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kuball+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","field":"links","label":"PubMed"},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kudo%20M%5BAuthor%5D%20hepatocellular%20lenvatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","field":"links","label":"PubMed"},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kumar%20SK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"links","label":"PubMed"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kummar+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","field":"links","label":"PubMed"},{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kurzrock%20R%5BAuthor%5D%20precision%20oncology%20matched","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/","field":"links","label":"PubMed"},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ladenstein%20R%5BAuthor%5D%20neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","route":"/people/ruth-ladenstein/","field":"links","label":"PubMed"},{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","route":"/people/ruth-ladenstein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lakhani+SR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","field":"links","label":"PubMed"},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lal+V%5BAuthor%5D+PGIMER","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vivek-lal","kind":"person","name":"Vivek Lal","route":"/people/vivek-lal/","field":"links","label":"PubMed"},{"id":"vivek-lal","kind":"person","name":"Vivek Lal","route":"/people/vivek-lal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lamarca%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lancet%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","field":"links","label":"PubMed"},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lang%20K%5BAuthor%5D%20mammography%20artificial%20intelligence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kristina-lang","kind":"person","name":"Kristina Lång","route":"/people/kristina-lang/","field":"links","label":"PubMed"},{"id":"kristina-lang","kind":"person","name":"Kristina Lång","route":"/people/kristina-lang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Langer+R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","field":"links","label":"PubMed"},{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Langlois+E%5BAuthor%5D+AND+Buenos+Aires","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lara%20PN%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"links","label":"PubMed"},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","field":"links","label":"PubMed"},{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lassman%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lathia%20JD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","field":"links","label":"PubMed"},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lau+CS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Laurent-Puig+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lawrence%20TS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","field":"links","label":"PubMed"},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20DT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"links","label":"PubMed"},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Gouill%20S%5BAuthor%5D%20mantle%20cell%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","field":"links","label":"PubMed"},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20QT%5BAuthor%5D%20head%20neck%20radiotherapy%20hypoxia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","route":"/people/quynh-thu-le/","field":"links","label":"PubMed"},{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","route":"/people/quynh-thu-le/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Tourneau%20C%5BAuthor%5D%20SHIVA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","field":"links","label":"PubMed"},{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+H%5BAuthor%5D+AND+radiation+oncology+Adelaide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","field":"links","label":"PubMed"},{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+VQ%5BAuthor%5D+Vietnam","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"links","label":"PubMed"},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leary%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LeBlanc%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"links","label":"PubMed"},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","field":"links","label":"PubMed"},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20DH%5BAuthor%5D%20Asan%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","field":"links","label":"PubMed author search"},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20J%5BAuthor%5D%20Samsung%20Medical%20Center%20gastric%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","field":"links","label":"PubMed author search"},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20JL%5BAuthor%5D%20Asan%20urothelial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","field":"links","label":"PubMed author search"},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SG%5BAuthor%5D%20Asan%20living%20donor%20liver%20transplantation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","field":"links","label":"PubMed author search"},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","field":"links","label":"PubMed author search"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Legaspi+GD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","route":"/people/gerardo-legaspi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lehman%20CD%5BAuthor%5D%20mammography%20deep%20learning","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"constance-lehman","kind":"person","name":"Constance D. Lehman","route":"/people/constance-lehman/","field":"links","label":"PubMed"},{"id":"constance-lehman","kind":"person","name":"Constance D. Lehman","route":"/people/constance-lehman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leighl%20NB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","field":"links","label":"PubMed"},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lemmens+VE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","route":"/people/valery-lemmens/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lenz%20HJ%5BAuthor%5D%20colorectal%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","field":"links","label":"PubMed"},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leonard%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lepp%C3%A4+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Letai%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"links","label":"PubMed"},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levin+TR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","field":"links","label":"PubMed"},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20BL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","field":"links","label":"PubMed"},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20DA%5BAuthor%5D%20endometrial%20genomic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","field":"links","label":"PubMed"},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20RL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","field":"links","label":"PubMed"},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy-Lahad%20E%5BAuthor%5D%20BRCA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","field":"links","label":"PubMed author search"},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy%20R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"links","label":"PubMed"},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","field":"links","label":"PubMed"},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ley%20TJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","field":"links","label":"PubMed"},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","field":"links","label":"PubMed"},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20J%5BAuthor%5D%20fruquintinib%20FRESCO","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","field":"links","label":"PubMed author search"},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20W%5BAuthor%5D%20West%20China%20Hospital%20lung%20cancer%20screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","field":"links","label":"PubMed author search"},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20Z%5BAuthor%5D%20claudin18.2%20CAR-T%20gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","field":"links","label":"PubMed author search"},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li+ZY%5BAuthor%5D+gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","field":"links","label":"PubMed"},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Libutti+SK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim%20HY%5BAuthor%5D%20hepatocellular%20carcinoma%20Samsung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","field":"links","label":"PubMed author search"},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim+ST%5BAuthor%5D+Singapore+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","field":"links","label":"PubMed"},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20NU%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"links","label":"PubMed"},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lin+T%5BAuthor%5D+AND+Sichuan+Cancer+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","route":"/people/lin-tongyu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","field":"links","label":"PubMed"},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"links","label":"PubMed"},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"links","label":"PubMed"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ljunggren%20HG%5BAuthor%5D%20missing%20self","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","field":"links","label":"PubMed"},{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Llombart-Bosch+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","route":"/people/antonio-llombart-bosch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Llovet%20JM%5BAuthor%5D%20hepatocellular","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","field":"links","label":"PubMed"},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lo-Coco%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Locke%20FL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"links","label":"PubMed"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loi%20S%5BAuthor%5D%20tumor%20infiltrating%20lymphocytes%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"links","label":"PubMed author search"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loibl%20S%5BAuthor%5D%20neoadjuvant%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"links","label":"PubMed"},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","field":"links","label":"PubMed"},{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lonial%20S%5BAuthor%5D%20myeloma%20belantamab%20OR%20daratumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","field":"links","label":"PubMed"},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","field":"links","label":"PubMed"},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lord%20CJ%5BAuthor%5D%20PARP%20synthetic%20lethality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","field":"links","label":"PubMed"},{"id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lordick%20F%5BAuthor%5D%20gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"florian-lordick","kind":"person","name":"Florian Lordick","route":"/people/florian-lordick/","field":"links","label":"PubMed"},{"id":"florian-lordick","kind":"person","name":"Florian Lordick","route":"/people/florian-lordick/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","field":"links","label":"PubMed"},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loughran+TP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lowy%20DR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"links","label":"PubMed"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20S%5BAuthor%5D%20Shanghai%20Chest%20Hospital%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","field":"links","label":"PubMed author search"},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20Y%5BAuthor%5D%20West%20China%20CRISPR%20PD-1%20T%20cells","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","field":"links","label":"PubMed author search"},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu+KH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","field":"links","label":"PubMed"},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lugowska+I%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","field":"links","label":"PubMed"},{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","field":"links","label":"PubMed"},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyman%20GH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"links","label":"PubMed"},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lynch%20TJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"links","label":"PubMed"},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyssiotis%20CA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","field":"links","label":"PubMed"},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20F%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20pyrotinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","field":"links","label":"PubMed author search"},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20J%5BAuthor%5D%20nasopharyngeal%20carcinoma%20Sun%20Yat-sen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","field":"links","label":"PubMed author search"},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","field":"links","label":"PubMed"},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Machiels%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maciejewski%20JP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","field":"links","label":"PubMed"},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mackall%20CL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"links","label":"PubMed"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Madhi+SA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"links","label":"PubMed"},{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mahmood%20F%5BAuthor%5D%20computational%20pathology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/","field":"links","label":"PubMed"},{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maitra%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"links","label":"PubMed"},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Majzner%20RG%5BAuthor%5D%20CAR%20T","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/","field":"links","label":"PubMed"},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mak%20TW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","field":"links","label":"PubMed"},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Makker%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","route":"/people/eleftherios-mamounas/","field":"links","label":"PubMed"},{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","route":"/people/eleftherios-mamounas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Management%20of%20Immune-Related%20Adverse%20Events%20ASCO%20Guideline%20Update%20Schneider%20JCO%202021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","field":"papers","label":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors"},{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mannel+RS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","field":"links","label":"PubMed"},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mansour+A%5BAuthor%5D+King+Hussein+Cancer+Center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asem-mansour","kind":"person","name":"Asem Mansour","route":"/people/asem-mansour/","field":"links","label":"PubMed"},{"id":"asem-mansour","kind":"person","name":"Asem Mansour","route":"/people/asem-mansour/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","field":"links","label":"PubMed"},{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maris%20JM%5BAuthor%5D%20neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/","field":"links","label":"PubMed"},{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Markel%20G%5BAuthor%5D%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/","field":"links","label":"PubMed author search"},{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marron%20TU%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","field":"links","label":"PubMed"},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martin%20M%5BAuthor%5D%20GEICAM%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","field":"links","label":"PubMed"},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martinez-Lopez+J%5BAuthor%5D+myeloma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","field":"links","label":"PubMed"},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martino+G%5BAuthor%5D+AND+San+Raffaele","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"links","label":"PubMed"},{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martuza%20RL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","route":"/people/robert-martuza/","field":"links","label":"PubMed"},{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","route":"/people/robert-martuza/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mateos%20MV%5BAuthor%5D%20myeloma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/","field":"links","label":"PubMed"},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mathur%20P%5BAuthor%5D%20National%20Cancer%20Registry%20Programme%20India","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","field":"links","label":"PubMed author search"},{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matsuura+Nariaki%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"PubMed"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mattson+J%5BAuthor%5D+AND+Helsinki","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","route":"/people/johanna-mattson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","field":"links","label":"PubMed"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maus%20MV%5BAuthor%5D%20CAR%20T%20glioblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/","field":"links","label":"PubMed"},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","field":"links","label":"PubMed author search"},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormack%20M%5BAuthor%5D%20INTERLACE%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/","field":"links","label":"PubMed"},{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormick%20F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"links","label":"PubMed"},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=McKay+RR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","field":"links","label":"PubMed"},{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Medema+RH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehanna%20H%5BAuthor%5D%20oropharyngeal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","field":"links","label":"PubMed"},{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehlen+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","field":"links","label":"PubMed"},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mejean%20A%5BAuthor%5D%20CARMENA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/","field":"links","label":"PubMed"},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mekel+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michal-mekel","kind":"person","name":"Michal Mekel","route":"/people/michal-mekel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Melero%20I%5BAuthor%5D%20immunotherapy%20CD137","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/","field":"links","label":"PubMed"},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","field":"links","label":"PubMed"},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Menon%20U%5BAuthor%5D%20UKCTOCS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/","field":"links","label":"PubMed"},{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Merad%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","field":"links","label":"PubMed"},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meric-Bernstam%20F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"links","label":"PubMed"},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mertens+H%5BAuthor%5D+AND+Maastricht","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"helen-mertens","kind":"person","name":"Helen Mertens","route":"/people/helen-mertens/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mesa+RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mesecar+AD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","route":"/people/andrew-mesecar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"links","label":"PubMed"},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Michaelson-Cohen%20R%5BAuthor%5D%20BRCA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","field":"links","label":"PubMed author search"},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Middleton+MR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-middleton","kind":"person","name":"Mark Middleton","route":"/people/mark-middleton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Migden%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mikula+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","field":"links","label":"PubMed"},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mileshkin%20L%5BAuthor%5D%20cervical%20OUTBACK","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","route":"/people/linda-mileshkin/","field":"links","label":"PubMed"},{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","route":"/people/linda-mileshkin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Miller+JS%5BAuthor%5D+AND+Minnesota","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Miri+SR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","route":"/people/seyed-rouhollah-miri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mirza%20MR%5BAuthor%5D%20niraparib%20OR%20dostarlimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","field":"links","label":"PubMed"},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","route":"/people/elizabeth-mittendorf/","field":"links","label":"PubMed"},{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","route":"/people/elizabeth-mittendorf/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/","field":"links","label":"PubMed"},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mohile%20SG%5BAuthor%5D%20geriatric%20assessment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"supriya-mohile","kind":"person","name":"Supriya G. Mohile","route":"/people/supriya-mohile/","field":"links","label":"PubMed"},{"id":"supriya-mohile","kind":"person","name":"Supriya G. Mohile","route":"/people/supriya-mohile/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mok+TS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","field":"links","label":"PubMed"},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOMENTUM%20momelotinib%20danazol%20myelofibrosis%20anaemia%20Verstovsek%20Lancet%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","field":"papers","label":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor"},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","field":"papers","label":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor"},{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","field":"papers","label":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/","field":"links","label":"PubMed search: monarchE JCO 2020"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monje%20M%5BAuthor%5D%20glioma%20GD2%20OR%20neuroligin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","field":"links","label":"PubMed"},{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monk%20BJ%5BAuthor%5D%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","field":"links","label":"PubMed"},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","field":"links","label":"PubMed"},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moreau%20P%5BAuthor%5D%20myeloma%20teclistamab%20OR%20daratumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","field":"links","label":"PubMed"},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"links","label":"PubMed"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris+PG%5BAuthor%5D+AND+Dublin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morrow%20M%5BAuthor%5D%20breast%20margins","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"monica-morrow","kind":"person","name":"Monica Morrow","route":"/people/monica-morrow/","field":"links","label":"PubMed"},{"id":"monica-morrow","kind":"person","name":"Monica Morrow","route":"/people/monica-morrow/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morschhauser+F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","field":"links","label":"PubMed"},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mosse%20YP%5BAuthor%5D%20neuroblastoma%20ALK","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","route":"/people/yael-mosse/","field":"links","label":"PubMed"},{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","route":"/people/yael-mosse/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Motzer%20RJ%5BAuthor%5D%20renal%20cell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","field":"links","label":"PubMed"},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","field":"papers","label":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery"},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","field":"papers","label":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery"},{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/","field":"links","label":"PubMed search: KEYNOTE-942 mRNA-4157 Lancet 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Msadabwe+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","route":"/people/susan-msadabwe/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mundel+T%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"links","label":"PubMed"},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munoz%20N%5BAuthor%5D%20human%20papillomavirus%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/","field":"links","label":"PubMed"},{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","field":"links","label":"PubMed"},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","field":"links","label":"PubMed"},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murthy%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Muthuswamy+SK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nakagama%20H%5BAuthor%5D%20National%20Cancer%20Center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","field":"links","label":"PubMed author search"},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nakashima+Y%5BAuthor%5D+AND+Kyushu+orthopaedic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","route":"/people/yasuharu-nakashima/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nanduri+V%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Narula%20G%5BAuthor%5D%20Tata%20Memorial%20paediatric%20leukaemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","field":"links","label":"PubMed author search"},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nasuhara+Y%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-nathan","kind":"person","name":"Paul Nathan","route":"/people/paul-nathan/","field":"links","label":"PubMed"},{"id":"paul-nathan","kind":"person","name":"Paul Nathan","route":"/people/paul-nathan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","field":"links","label":"PubMed"},{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","field":"links","label":"PubMed"},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Negrin+RS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nelson%20WG%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"links","label":"PubMed"},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","field":"papers","label":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"papers","label":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"papers","label":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","field":"links","label":"PubMed search: NETTER-2 Lancet 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","field":"papers","label":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients"},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","field":"papers","label":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nichols%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nik-Zainal%20S%5BAuthor%5D%20mutational%20signatures","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","field":"links","label":"PubMed"},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Niyazi+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","field":"links","label":"PubMed"},{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nolte+S%5BAuthor%5D+AND+quality+of+life","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Noronha%20V%5BAuthor%5D%20Tata%20Memorial%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","field":"links","label":"PubMed author search"},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nout%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","route":"/people/anna-nowak/","field":"links","label":"PubMed"},{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","route":"/people/anna-nowak/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Dwyer%20PJ%5BAuthor%5D","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=O%27Dwyer%20PJ%5BAuthor%5D","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"links","label":"PubMed"},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Reilly%20EM%5BAuthor%5D","status":200,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/?term=O%27Reilly%20EM%5BAuthor%5D","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","field":"links","label":"PubMed"},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=O%27Shea+EK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","field":"links","label":"PubMed"},{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oakes+SR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","field":"links","label":"PubMed"},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oaknin%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ochsenbein+AF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","field":"links","label":"PubMed"},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ocvirk+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","field":"links","label":"PubMed"},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Odunsi+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","field":"links","label":"PubMed"},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oelfke%20U%5BAuthor%5D%20MR-linac","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","field":"links","label":"PubMed"},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","field":"links","label":"PubMed author search"},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohashi%20PS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","field":"links","label":"PubMed"},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","field":"links","label":"PubMed author search"},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohno%20S%5BAuthor%5D%20breast%20cancer%20Cancer%20Institute%20Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","field":"links","label":"PubMed author search"},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohno+T%5BAuthor%5D+carbon+ion+Gunma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","route":"/people/tatsuya-ohno/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oliveira+M%5BAuthor%5D+AND+SOLTI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"links","label":"PubMed"},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Opatrny+L%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","route":"/people/lucie-opatrny/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orecchia%20R%5BAuthor%5D%20intraoperative%20radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","field":"links","label":"PubMed"},{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orem+J%5BAuthor%5D+Uganda","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","field":"links","label":"PubMed"},{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oren%20M%5BAuthor%5D%20p53%20Weizmann","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/","field":"links","label":"PubMed author search"},{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Otegbayo+JA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","route":"/people/jesse-otegbayo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Overgaard+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","field":"links","label":"PubMed"},{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Owonikoko+TK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"links","label":"PubMed"},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paik%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","field":"links","label":"PubMed"},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Palma%20DA%5BAuthor%5D%20SABR-COMET","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-palma","kind":"person","name":"David A. Palma","route":"/people/david-palma/","field":"links","label":"PubMed"},{"id":"david-palma","kind":"person","name":"David A. Palma","route":"/people/david-palma/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Palucka+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","field":"links","label":"PubMed"},{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Papadopoulos%20N%5BAuthor%5D%20CancerSEEK%20OR%20liquid%20biopsy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","route":"/people/nickolas-papadopoulos/","field":"links","label":"PubMed"},{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","route":"/people/nickolas-papadopoulos/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pardoll%20DM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"links","label":"PubMed"},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","field":"links","label":"PubMed"},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"links","label":"PubMed"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20WY%5BAuthor%5D%20Samsung%20Genome%20Institute","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","field":"links","label":"PubMed author search"},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20YH%5BAuthor%5D%20Samsung%20Medical%20Center%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"links","label":"PubMed author search"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parker%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parmar%20MKB%5BAuthor%5D%20multi-arm%20multi-stage","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","route":"/people/mahesh-parmar/","field":"links","label":"PubMed"},{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","route":"/people/mahesh-parmar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parsons%20R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","field":"links","label":"PubMed"},{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Partridge%20AH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"links","label":"PubMed"},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parulekar%20WR%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","field":"links","label":"PubMed author search"},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pasche+B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patel%20SP%5BAuthor%5D%20melanoma%20neoadjuvant%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","field":"links","label":"PubMed"},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patil%20VM%5BAuthor%5D%20low-dose%20nivolumab%20head%20and%20neck","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","field":"links","label":"PubMed author search"},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pautier%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paz-Ares+L%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","field":"links","label":"PubMed"},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peceliunas+V%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelaez+F%5BAuthor%5D+CNIO","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"links","label":"PubMed"},{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelicci%20PG%5BAuthor%5D%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","field":"links","label":"PubMed"},{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Penault-Llorca+F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","route":"/people/frederique-penault-llorca/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Penel+N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pennell%20NA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","field":"links","label":"PubMed"},{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","field":"links","label":"PubMed"},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perou%20CM%5BAuthor%5D%20breast%20subtypes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/","field":"links","label":"PubMed"},{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Personalized%20RNA%20neoantigen%20vaccines%20stimulate%20T%20cells%20in%20pancreatic%20cancer%20Rojas%20Nature%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","field":"papers","label":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer"},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","field":"papers","label":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer"},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peters%20S%5BAuthor%5D%20mesothelioma%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","field":"links","label":"PubMed"},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peto%20R%5BAuthor%5D%20smoking%20mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","route":"/people/richard-peto/","field":"links","label":"PubMed"},{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","route":"/people/richard-peto/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pfister%20SM%5BAuthor%5D%20medulloblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","field":"links","label":"PubMed"},{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piaggio%20E%5BAuthor%5D%20regulatory%20T%20cells%20tumor","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","field":"links","label":"PubMed"},{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piccart%20M%5BAuthor%5D%20HERA%20trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","field":"links","label":"PubMed"},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pierce%20LJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"links","label":"PubMed"},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pieters%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pilon-Thomas%20S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","field":"links","label":"PubMed"},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pisters%20PWT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"links","label":"PubMed"},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","field":"links","label":"PubMed"},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plante%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","field":"links","label":"PubMed"},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plotkin%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plummer%20R%5BAuthor%5D%20PARP%20inhibitor%20phase%20I","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","field":"links","label":"PubMed"},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Porter%20DL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"links","label":"PubMed"},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","field":"links","label":"PubMed"},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pott+C%5BAuthor%5D+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powell+MA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","field":"links","label":"PubMed"},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","field":"links","label":"PubMed"},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prabhash%20K%5BAuthor%5D%20Tata%20Memorial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"links","label":"PubMed author search"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prager%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pramesh%20CS%5BAuthor%5D%20National%20Cancer%20Grid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"links","label":"PubMed author search"},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/","field":"links","label":"PubMed"},{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Primrose%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prince%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pugh%20TJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","field":"links","label":"PubMed"},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pui%20CH%5BAuthor%5D%20acute%20lymphoblastic%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","route":"/people/ching-hon-pui/","field":"links","label":"PubMed"},{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","route":"/people/ching-hon-pui/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puig+S%5BAuthor%5D+melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","field":"links","label":"PubMed"},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Purwar%20R%5BAuthor%5D%20CAR%20T%20India","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"links","label":"PubMed author search"},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","route":"/people/lajos-pusztai/","field":"links","label":"PubMed"},{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","route":"/people/lajos-pusztai/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","field":"links","label":"PubMed"},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qasim%20W%5BAuthor%5D%20CAR%20T%20gene-edited","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","route":"/people/waseem-qasim/","field":"links","label":"PubMed"},{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","route":"/people/waseem-qasim/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qi%20C%5BAuthor%5D%20claudin18.2%20CAR%20T","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","field":"links","label":"PubMed author search"},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/","field":"links","label":"PubMed author search"},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=QuANTUM-First%20quizartinib%20FLT3-ITD%20Erba%20Lancet%202023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","field":"papers","label":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML"},{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaijmakers+MHGP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","field":"links","label":"PubMed"},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaymakers%20BW%5BAuthor%5D%20MR-linac","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bas-raaymakers","kind":"person","name":"Bas W. Raaymakers","route":"/people/bas-raaymakers/","field":"links","label":"PubMed"},{"id":"bas-raaymakers","kind":"person","name":"Bas W. Raaymakers","route":"/people/bas-raaymakers/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raina%20V%5BAuthor%5D%20AIIMS%20medical%20oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"links","label":"PubMed author search"},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raje%20N%5BAuthor%5D%20myeloma%20BCMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","field":"links","label":"PubMed"},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajewsky+N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","field":"links","label":"PubMed"},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"links","label":"PubMed"},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","field":"links","label":"PubMed"},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramirez%20PT%5BAuthor%5D%20cervical%20LACC","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","route":"/people/pedro-ramirez/","field":"links","label":"PubMed"},{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","route":"/people/pedro-ramirez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramoni+RB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","field":"links","label":"PubMed"},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rampal%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rangarajan+G%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rastogi+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","field":"links","label":"PubMed"},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rau%20RE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"links","label":"PubMed"},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ray-Coquard%20I%5BAuthor%5D%20ovarian%20PAOLA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","field":"links","label":"PubMed"},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","field":"links","label":"PubMed"},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reddy+P%5BAuthor%5D+AND+Baylor","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Redhead+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julian-redhead","kind":"person","name":"Julian Redhead","route":"/people/julian-redhead/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reis%20e%20Sousa%20C%5BAuthor%5D%20dendritic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","field":"links","label":"PubMed"},{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rezvani%20K%5BAuthor%5D%20CAR%20NK","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","route":"/people/katy-rezvani/","field":"links","label":"PubMed"},{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","route":"/people/katy-rezvani/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rha%20SY%5BAuthor%5D%20Yonsei%20gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","field":"links","label":"PubMed author search"},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ribas%20A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"links","label":"PubMed"},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Richardson%20PG%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","field":"links","label":"PubMed"},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riddell%20SR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"links","label":"PubMed"},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riely%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","field":"links","label":"PubMed"},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rischin%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robert%20C%5BAuthor%5D%20melanoma%20pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","field":"links","label":"PubMed"},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robinson%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robson%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roman-Roman%20S%5BAuthor%5D%20uveal%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","field":"links","label":"PubMed"},{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosato+A%5BAuthor%5D+Padova","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/","field":"links","label":"PubMed"},{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosen%20ST%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"links","label":"PubMed"},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","field":"links","label":"PubMed"},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20SA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"links","label":"PubMed"},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/","field":"links","label":"PubMed"},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roser+F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","field":"links","label":"PubMed"},{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ross+JS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"links","label":"PubMed"},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rottingen+JA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-arne-rottingen","kind":"person","name":"John-Arne Røttingen","route":"/people/john-arne-rottingen/","field":"links","label":"PubMed"},{"id":"john-arne-rottingen","kind":"person","name":"John-Arne Røttingen","route":"/people/john-arne-rottingen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rouzier+R%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rubio+IT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","field":"links","label":"PubMed"},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/","field":"links","label":"PubMed"},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rugo%20HS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"links","label":"PubMed"},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rusch%20VW%5BAuthor%5D%20lung%20cancer%20staging","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/","field":"links","label":"PubMed"},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Russell%20SJ%5BAuthor%5D%20oncolytic%20OR%20measles","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"links","label":"PubMed"},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rutkowski%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ryu%20MH%5BAuthor%5D%20Asan%20gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","field":"links","label":"PubMed author search"},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saad%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sadelain%20M%5BAuthor%5D%20chimeric%20antigen%20receptor","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","field":"links","label":"PubMed"},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saez-Rodriguez+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","field":"links","label":"PubMed"},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahai%20E%5BAuthor%5D%20tumour%20microenvironment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","field":"links","label":"PubMed"},{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahin%20U%5BAuthor%5D%20mRNA%20vaccine%20neoantigen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","field":"links","label":"PubMed"},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sakaguchi%20S%5BAuthor%5D%20regulatory%20T%20cells","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","route":"/people/shimon-sakaguchi/","field":"links","label":"PubMed"},{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","route":"/people/shimon-sakaguchi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","field":"links","label":"PubMed"},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samra+MA%5BAuthor%5D+Cairo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","route":"/people/mohamed-abdel-moaty-samra/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuels%20Y%5BAuthor%5D%20melanoma%20Weizmann","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/","field":"links","label":"PubMed author search"},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuelsson+C%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","field":"links","label":"PubMed"},{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=San-Miguel+JF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","field":"links","label":"PubMed"},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sander+M%5BAuthor%5D+pancreas","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","field":"links","label":"PubMed"},{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"links","label":"PubMed author search"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sangro+B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","field":"links","label":"PubMed"},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sankaranarayanan%20R%5BAuthor%5D%20screening%20India","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","field":"links","label":"PubMed author search"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sano%20T%5BAuthor%5D%20gastric%20cancer%20surgery%20Cancer%20Institute%20Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","field":"links","label":"PubMed author search"},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sansom+OJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","field":"links","label":"PubMed"},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Santis%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Santoro+A%5BAuthor%5D+AND+Humanitas","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"links","label":"PubMed"},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sanz%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sapino+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","field":"links","label":"PubMed"},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"links","label":"PubMed"},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"links","label":"PubMed"},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartore-Bianchi%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasako%20M%5BAuthor%5D%20gastric%20D2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","route":"/people/mitsuru-sasako/","field":"links","label":"PubMed"},{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","route":"/people/mitsuru-sasako/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasieni%20P%5BAuthor%5D%20cervical%20screening%20HPV","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/","field":"links","label":"PubMed"},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saura%20C%5BAuthor%5D%20breast%20HER2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/","field":"links","label":"PubMed"},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sawyers%20CL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"links","label":"PubMed"},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scambia%20G%5BAuthor%5D%20ovarian","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","field":"links","label":"PubMed"},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sch%C3%B6ffski%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schaap+NPM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","field":"links","label":"PubMed"},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schachter%20J%5BAuthor%5D%20melanoma%20Sheba","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/","field":"links","label":"PubMed author search"},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schadendorf+D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"links","label":"PubMed"},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scher%20HI%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"links","label":"PubMed"},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scherer+SW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"links","label":"PubMed"},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schiffman%20M%5BAuthor%5D%20HPV%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/","field":"links","label":"PubMed"},{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schimmer%20AD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","field":"links","label":"PubMed"},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","route":"/people/martin-schlumberger/","field":"links","label":"PubMed"},{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","route":"/people/martin-schlumberger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","field":"links","label":"PubMed"},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmieder+K%5BAuthor%5D+neurosurgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","field":"links","label":"PubMed"},{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmutzler+RK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schnall%20MD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"links","label":"PubMed"},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schorb+E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schrag%20D%5BAuthor%5D%20PATHFINDER%20OR%20PROSPECT","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/","field":"links","label":"PubMed"},{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schreiber%20RD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","field":"links","label":"PubMed"},{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuchter%20LM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"links","label":"PubMed"},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuler+M%5BAuthor%5D+lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","field":"links","label":"PubMed"},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schulick+RD%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-schulick","kind":"person","name":"Richard Schulick","route":"/people/richard-schulick/","field":"links","label":"PubMed"},{"id":"richard-schulick","kind":"person","name":"Richard Schulick","route":"/people/richard-schulick/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schumacher%20TN%5BAuthor%5D%20neoantigen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","field":"links","label":"PubMed"},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuster%20SJ%5BAuthor%5D%20tisagenlecleucel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","field":"links","label":"PubMed"},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","field":"links","label":"PubMed"},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehouli+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"links","label":"PubMed"},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sekulic%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sequist%20LV%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"links","label":"PubMed"},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Serve+H%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","field":"links","label":"PubMed"},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","field":"links","label":"PubMed"},{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shah%20NN%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"links","label":"PubMed"},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shah%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shanta%20V%5BAuthor%5D%20Cancer%20Institute%20Adyar","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","field":"links","label":"PubMed author search"},{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shao%20ZM%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"links","label":"PubMed author search"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shariat+SF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"links","label":"PubMed"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"links","label":"PubMed"},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","field":"profiles","label":"PubMed"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"links","label":"PubMed"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shashidhara+LS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shastri%20SS%5BAuthor%5D%20visual%20inspection%20acetic%20acid%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","field":"links","label":"PubMed author search"},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shaw%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shaw+RJ%5BAuthor%5D+AND+Salk","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","route":"/people/reuben-shaw/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"links","label":"PubMed author search"},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20Y%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","field":"links","label":"PubMed author search"},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shin%20SJ%5BAuthor%5D%20Yonsei%20colorectal%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","field":"links","label":"PubMed author search"},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shitara%20K%5BAuthor%5D%20gastric%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"links","label":"PubMed author search"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shokat%20KM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"links","label":"PubMed"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siena%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Silva+Neto+B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brasil-silva-neto","kind":"person","name":"Brasil Silva Neto","route":"/people/brasil-silva-neto/","field":"links","label":"PubMed"},{"id":"brasil-silva-neto","kind":"person","name":"Brasil Silva Neto","route":"/people/brasil-silva-neto/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simeone+DM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","field":"links","label":"PubMed"},{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simone+CB%5BAuthor%5D+proton","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"links","label":"PubMed"},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singer+CF%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","field":"links","label":"PubMed"},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"links","label":"PubMed"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh+S%5BAuthor%5D+AND+NICPR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sirivatanauksorn+Y%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","route":"/people/yongyut-sirivatanauksorn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siu%20LL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"links","label":"PubMed"},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siva%20S%5BAuthor%5D%20stereotactic%20kidney","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shankar-siva","kind":"person","name":"Shankar Siva","route":"/people/shankar-siva/","field":"links","label":"PubMed"},{"id":"shankar-siva","kind":"person","name":"Shankar Siva","route":"/people/shankar-siva/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","field":"links","label":"PubMed"},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Slamon%20DJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"links","label":"PubMed"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sluis%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Small%20EJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"links","label":"PubMed"},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","field":"links","label":"PubMed"},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20MR%5BAuthor%5D%20darolutamide%20OR%20apalutamide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","route":"/people/matthew-smith/","field":"links","label":"PubMed"},{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","route":"/people/matthew-smith/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=So+JB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","field":"links","label":"PubMed"},{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"links","label":"PubMed author search"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","field":"links","label":"PubMed"},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solit%20DB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","field":"links","label":"PubMed"},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solomon%20BJ%5BAuthor%5D%20ALK%20lung%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","field":"links","label":"PubMed author search"},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Somervaille+TC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"links","label":"PubMed"},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"links","label":"PubMed author search"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song+YQ%5BAuthor%5D+lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","field":"links","label":"PubMed"},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/","field":"links","label":"PubMed"},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soria%20JC%5BAuthor%5D%20osimertinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","field":"links","label":"PubMed"},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sparano%20JA%5BAuthor%5D%20TAILORx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-sparano","kind":"person","name":"Joseph A. Sparano","route":"/people/joseph-sparano/","field":"links","label":"PubMed"},{"id":"joseph-sparano","kind":"person","name":"Joseph A. Sparano","route":"/people/joseph-sparano/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","field":"papers","label":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma"},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","field":"papers","label":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma"},{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","field":"links","label":"PubMed search: SPEARHEAD-1 afamitresgene autoleucel Lancet"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","route":"/people/jonathan-spicer/","field":"links","label":"PubMed"},{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","route":"/people/jonathan-spicer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","field":"papers","label":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer"},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","field":"papers","label":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"papers","label":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","field":"papers","label":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer"},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/","field":"links","label":"PubMed search: SPOTLIGHT zolbetuximab Lancet 2023"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spratt%20DE%5BAuthor%5D%20prostate%20artificial%20intelligence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/","field":"links","label":"PubMed"},{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sprecher+E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stacchiotti%20S%5BAuthor%5D%20sarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","route":"/people/silvia-stacchiotti/","field":"links","label":"PubMed"},{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","route":"/people/silvia-stacchiotti/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stagg+J%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stahel%20RA%5BAuthor%5D%20thoracic%20ETOP","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rolf-stahel","kind":"person","name":"Rolf A. Stahel","route":"/people/rolf-stahel/","field":"links","label":"PubMed"},{"id":"rolf-stahel","kind":"person","name":"Rolf A. Stahel","route":"/people/rolf-stahel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Staudt%20LM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"links","label":"PubMed"},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Steidl+U%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","field":"links","label":"PubMed"},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stepensky%20P%5BAuthor%5D%20CAR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/","field":"links","label":"PubMed author search"},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stewart%20AK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","field":"links","label":"PubMed"},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stillman%20B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","field":"links","label":"PubMed"},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stobart+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kent-stobart","kind":"person","name":"Kent Stobart","route":"/people/kent-stobart/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RM%5BAuthor%5D%20midostaurin%20RATIFY","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","field":"links","label":"PubMed"},{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RW%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"links","label":"PubMed"},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stratigos%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stratton+MR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-stratton","kind":"person","name":"Michael Stratton","route":"/people/michael-stratton/","field":"links","label":"PubMed"},{"id":"michael-stratton","kind":"person","name":"Michael Stratton","route":"/people/michael-stratton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strickler%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"links","label":"PubMed"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stupp%20R%5BAuthor%5D%20glioblastoma%20temozolomide","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","field":"links","label":"PubMed"},{"id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Subbiah%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","field":"links","label":"PubMed"},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sultan+F%5BAuthor%5D+AND+Shaukat+Khanum","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sumon+MA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%20V%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"links","label":"PubMed"},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sundaresan+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","field":"links","label":"PubMed"},{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SunRISe-1+TAR-200+BCG-unresponsive","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","field":"papers","label":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer"},{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/","field":"links","label":"PubMed search: SunRISe-1 TAR-200"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","route":"/people/inge-marie-svane/","field":"links","label":"PubMed"},{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","route":"/people/inge-marie-svane/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svoboda+M%5BAuthor%5D+Brno","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","field":"links","label":"PubMed"},{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","field":"links","label":"PubMed"},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swanton%20C%5BAuthor%5D%20TRACERx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"links","label":"PubMed"},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweasy+JB%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","route":"/people/joann-sweasy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweeney%20CJ%5BAuthor%5D%20prostate%20docetaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","route":"/people/christopher-sweeney/","field":"links","label":"PubMed"},{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","route":"/people/christopher-sweeney/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tabernero%20J%5BAuthor%5D%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","field":"links","label":"PubMed"},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taher+A%5BAuthor%5D+AND+Beirut","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","field":"links","label":"PubMed author search"},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takaori-Kondo+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"links","label":"PubMed"},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tam%20CS%5BAuthor%5D%20zanubrutinib%20OR%20ibrutinib%20venetoclax","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","field":"links","label":"PubMed"},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tan+W%5BAuthor%5D+AND+Hangzhou+Institute+of+Medicine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tanabe+KK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","field":"links","label":"PubMed"},{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tandon+N%5BAuthor%5D+AIIMS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","field":"links","label":"PubMed"},{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tannock%20IF%5BAuthor%5D%20prostate%20docetaxel%20OR%20clinical%20benefit","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","field":"links","label":"PubMed"},{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tap%20WD%5BAuthor%5D%20sarcoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/","field":"links","label":"PubMed"},{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tasken+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","field":"links","label":"PubMed"},{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tawbi%20HA%5BAuthor%5D%20melanoma%20relatlimab%20OR%20brain","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","field":"links","label":"PubMed"},{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taylor%20MD%5BAuthor%5D%20medulloblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-taylor","kind":"person","name":"Michael D. Taylor","route":"/people/michael-taylor/","field":"links","label":"PubMed"},{"id":"michael-taylor","kind":"person","name":"Michael D. Taylor","route":"/people/michael-taylor/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Teitell%20MA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"links","label":"PubMed"},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Temel%20JS%5BAuthor%5D%20palliative%20care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","route":"/people/jennifer-temel/","field":"links","label":"PubMed"},{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","route":"/people/jennifer-temel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tewari%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Theodorescu+D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","route":"/people/dan-theodorescu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","field":"links","label":"PubMed"},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thomas%20RK%5BAuthor%5D%20small%20cell%20lung%20cancer%20genomic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","field":"links","label":"PubMed"},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thuss-Patience%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tiainen+S%5BAuthor%5D+AND+Kuopio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tie%20J%5BAuthor%5D%20ctDNA%20colon","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","field":"links","label":"PubMed"},{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","field":"links","label":"PubMed"},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Timmerman%20RD%5BAuthor%5D%20stereotactic%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-timmerman","kind":"person","name":"Robert D. Timmerman","route":"/people/robert-timmerman/","field":"links","label":"PubMed"},{"id":"robert-timmerman","kind":"person","name":"Robert D. Timmerman","route":"/people/robert-timmerman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Todo%20T%5BAuthor%5D%20oncolytic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"links","label":"PubMed"},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tolaney%20SM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"links","label":"PubMed"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tomasich+F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Topalian%20SL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"links","label":"PubMed"},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tortora%20G%5BAuthor%5D%20pancreatic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","field":"links","label":"PubMed"},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trapani%20JA%5BAuthor%5D%20perforin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","field":"links","label":"PubMed author search"},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"steven-treon","kind":"person","name":"Steven P. Treon","route":"/people/steven-treon/","field":"links","label":"PubMed"},{"id":"steven-treon","kind":"person","name":"Steven P. Treon","route":"/people/steven-treon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tripathy%20D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"links","label":"PubMed"},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"papers","label":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival"},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","field":"papers","label":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"papers","label":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival"},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","field":"papers","label":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/","field":"links","label":"PubMed search: TROPION-Breast01"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trumpp%20A%5BAuthor%5D%20metastasis%20stem%20cells","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","field":"links","label":"PubMed"},{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tu%20D%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","field":"links","label":"PubMed author search"},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuohy%20VK%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","field":"links","label":"PubMed"},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turajlic+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"links","label":"PubMed"},{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turner%20NC%5BAuthor%5D%20breast%20ctDNA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","field":"links","label":"PubMed"},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","field":"links","label":"PubMed"},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuveson%20DA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"links","label":"PubMed"},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=UCART19%20genome-edited%20donor-derived%20allogeneic%20anti-CD19%20CAR%20T%20Benjamin%20Lancet%202020","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","route":"/people/waseem-qasim/","field":"papers","label":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL"},{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","field":"links","label":"PubMed search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ueno%20T%5BAuthor%5D%20breast%20Cancer%20Institute%20Hospital%20JFCR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","field":"links","label":"PubMed author search"},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ueno+NT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uesaka+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","route":"/people/katsuhiko-uesaka/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Unger%20JM%5BAuthor%5D%20clinical%20trial%20participation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-unger","kind":"person","name":"Joseph M. Unger","route":"/people/joseph-unger/","field":"links","label":"PubMed"},{"id":"joseph-unger","kind":"person","name":"Joseph M. Unger","route":"/people/joseph-unger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uppaluri%20R%5BAuthor%5D%20neoadjuvant%20pembrolizumab%20head%20neck","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ravindra-uppaluri","kind":"person","name":"Ravindra Uppaluri","route":"/people/ravindra-uppaluri/","field":"links","label":"PubMed"},{"id":"ravindra-uppaluri","kind":"person","name":"Ravindra Uppaluri","route":"/people/ravindra-uppaluri/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Urruticoechea+A%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","route":"/people/ander-urruticoechea/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Usmani%20SZ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"links","label":"PubMed"},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uzzo+RG%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","route":"/people/robert-uzzo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vakoc%20CR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","field":"links","label":"PubMed"},{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valentini%20V%5BAuthor%5D%20rectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","field":"links","label":"PubMed"},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","field":"links","label":"PubMed"},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Allen%20EM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","field":"links","label":"PubMed"},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Cutsem%20E%5BAuthor%5D%20colorectal%20cetuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/","field":"links","label":"PubMed"},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20de%20Velde%20CJ%5BAuthor%5D%20rectal%20TME","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cornelis-van-de-velde","kind":"person","name":"Cornelis J. H. van de Velde","route":"/people/cornelis-van-de-velde/","field":"links","label":"PubMed"},{"id":"cornelis-van-de-velde","kind":"person","name":"Cornelis J. H. van de Velde","route":"/people/cornelis-van-de-velde/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","field":"links","label":"PubMed"},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20der%20Graaf%20WT%5BAuthor%5D%20sarcoma%20pazopanib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/","field":"links","label":"PubMed"},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Driel%20WJ%5BAuthor%5D%20HIPEC%20ovarian","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/","field":"links","label":"PubMed"},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Lanschot%20JJB%5BAuthor%5D%20esophageal%20CROSS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jan-van-lanschot","kind":"person","name":"J. Jan B. van Lanschot","route":"/people/jan-van-lanschot/","field":"links","label":"PubMed"},{"id":"jan-van-lanschot","kind":"person","name":"J. Jan B. van Lanschot","route":"/people/jan-van-lanschot/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+der+Zee+AGJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","route":"/people/ate-van-der-zee/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van+Etten+RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","route":"/people/richard-van-etten/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+Gils+CH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","route":"/people/carla-van-gils/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+Goudoever%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vander+Heiden+MG%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","field":"links","label":"PubMed"},{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Varadkar+S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","field":"links","label":"PubMed"},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vassal+G%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","field":"links","label":"PubMed"},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vazquez%20F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","field":"links","label":"PubMed"},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"links","label":"PubMed"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vera+P%5BAuthor%5D+AND+Rouen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vergote%20I%5BAuthor%5D%20ovarian%20OR%20cervical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","field":"links","label":"PubMed"},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermaelen+K%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","field":"links","label":"PubMed"},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","field":"links","label":"PubMed"},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Veronesi%20P%5BAuthor%5D%20breast%20sentinel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","field":"links","label":"PubMed"},{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Verstovsek%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vey+N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"norbert-vey","kind":"person","name":"Norbert Vey","route":"/people/norbert-vey/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vickers%20SM%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","field":"links","label":"PubMed"},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vignetti+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"links","label":"PubMed"},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vihinen+P%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","route":"/people/pia-vihinen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","field":"links","label":"PubMed"},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vogelstein%20B%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"links","label":"PubMed"},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vokes%20EE%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"links","label":"PubMed"},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","field":"links","label":"PubMed"},{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Deimling%20A%5BAuthor%5D%20methylation%20classifier","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","field":"links","label":"PubMed"},{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","field":"links","label":"PubMed"},{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Kalle%20C%5BAuthor%5D%20gene%20therapy%20integration","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","field":"links","label":"PubMed"},{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Minckwitz%20G%5BAuthor%5D%20KATHERINE","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","field":"links","label":"PubMed"},{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vonderheide%20RH%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","field":"links","label":"PubMed"},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vozenin%20MC%5BAuthor%5D%20FLASH","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marie-catherine-vozenin","kind":"person","name":"Marie-Catherine Vozenin","route":"/people/marie-catherine-vozenin/","field":"links","label":"PubMed"},{"id":"marie-catherine-vozenin","kind":"person","name":"Marie-Catherine Vozenin","route":"/people/marie-catherine-vozenin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wagner%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainberg%20ZA%5BAuthor%5D%20pancreatic%20NAPOLI","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","field":"links","label":"PubMed"},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainwright+BJ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wakelee%20HA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"links","label":"PubMed"},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ES%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","field":"links","label":"PubMed"},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20F%5BAuthor%5D%20Sun%20Yat-sen%20gastric%20cancer%20immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","field":"links","label":"PubMed author search"},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","field":"links","label":"PubMed author search"},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","field":"links","label":"PubMed"},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20S%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","field":"links","label":"PubMed"},{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Y%5BAuthor%5D+AND+Chongqing+University+Cancer+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wang-ying","kind":"person","name":"Wang Ying","route":"/people/wang-ying/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ward+RL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","field":"links","label":"PubMed"},{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","route":"/people/jennifer-wargo/","field":"links","label":"PubMed"},{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","route":"/people/jennifer-wargo/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","field":"links","label":"PubMed"},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","field":"links","label":"PubMed"},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","field":"links","label":"PubMed"},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20YQ%5BAuthor%5D%20State%20Key%20Laboratory%20of%20Biotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","field":"links","label":"PubMed author search"},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weichselbaum+RR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","field":"links","label":"PubMed"},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weiderpass%20E%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","field":"links","label":"PubMed author search"},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20D%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","field":"links","label":"PubMed"},{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20IL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"links","label":"PubMed"},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weitz+J%5BAuthor%5D+AND+Dresden","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","field":"links","label":"PubMed"},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weller%20M%5BAuthor%5D%20glioblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","field":"links","label":"PubMed"},{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wen%20PY%5BAuthor%5D%20glioblastoma%20RANO","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","route":"/people/patrick-wen/","field":"links","label":"PubMed"},{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","route":"/people/patrick-wen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","field":"links","label":"PubMed"},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Whelan%20TJ%5BAuthor%5D%20breast%20radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","route":"/people/timothy-whelan/","field":"links","label":"PubMed"},{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","route":"/people/timothy-whelan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wicha%20MS%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","field":"links","label":"PubMed"},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Widemann%20BC%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"links","label":"PubMed"},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","field":"links","label":"PubMed"},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wilke%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Willman%20CL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"links","label":"PubMed"},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wilson%20WH%5BAuthor%5D%20lymphoma%20EPOCH","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","field":"links","label":"PubMed"},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Winer%20EP%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"links","label":"PubMed"},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Winn+RA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wirth%20LJ%5BAuthor%5D%20thyroid%20selpercatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","field":"links","label":"PubMed"},{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Witte%20ON%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"links","label":"PubMed"},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolchok%20JD%5BAuthor%5D%20melanoma%20ipilimumab%20nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"links","label":"PubMed"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolf%20J%5BAuthor%5D%20capmatinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","field":"links","label":"PubMed"},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolmark+N%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","field":"links","label":"PubMed"},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woodgett+JR%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Workman%20P%5BAuthor%5D%20drug%20discovery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","field":"links","label":"PubMed"},{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woyach%20JA%5BAuthor%5D%20chronic%20lymphocytic%20leukemia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","field":"links","label":"PubMed"},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","route":"/people/catherine-wu/","field":"links","label":"PubMed"},{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","route":"/people/catherine-wu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","field":"links","label":"PubMed author search"},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xia+J%5BAuthor%5D+AND+Union+Hospital+AND+Wuhan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xiang+H%5BAuthor%5D+AND+Hunan+Cancer+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xiang-hua","kind":"person","name":"Xiang Hua","route":"/people/xiang-hua/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20B%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20breast%20cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"links","label":"PubMed author search"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20J%5BAuthor%5D%20gastric%20cancer%20307%20Hospital%20PLA","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xu-jianming","kind":"person","name":"Jianming Xu","route":"/people/xu-jianming/","field":"links","label":"PubMed author search"},{"id":"xu-jianming","kind":"person","name":"Jianming Xu","route":"/people/xu-jianming/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","field":"links","label":"PubMed author search"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yaeger%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","field":"links","label":"PubMed author search"},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+N%5BAuthor%5D+lung","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","field":"links","label":"PubMed"},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yang+HK%5BAuthor%5D+AND+gastric","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"links","label":"PubMed"},{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yao%20JC%5BAuthor%5D%20neuroendocrine%20everolimus","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","field":"links","label":"PubMed"},{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yarden%20Y%5BAuthor%5D%20Weizmann%20EGFR","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/","field":"links","label":"PubMed author search"},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ychou+M%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marc-ychou","kind":"person","name":"Marc Ychou","route":"/people/marc-ychou/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","field":"links","label":"PubMed author search"},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yonemori%20K%5BAuthor%5D%20National%20Cancer%20Center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","field":"links","label":"PubMed author search"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yoshino%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20colorectal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"links","label":"PubMed author search"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20AL%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"links","label":"PubMed"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"links","label":"PubMed"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+CJ%5BAuthor%5D+National+Taiwan+University+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","field":"links","label":"PubMed"},{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+J%5BAuthor%5D+AND+Shandong+Cancer+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yu-jinming","kind":"person","name":"Yu Jinming","route":"/people/yu-jinming/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeidan%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zender+L%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","field":"links","label":"PubMed"},{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeng%20MS%5BAuthor%5D%20Epstein-Barr%20virus%20nasopharyngeal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","field":"links","label":"PubMed author search"},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20F%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","field":"links","label":"PubMed"},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20L%5BAuthor%5D%20Sun%20Yat-sen%20lung%20cancer%20camrelizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","field":"links","label":"PubMed author search"},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+S%5BAuthor%5D+AND+Peking+Union+Medical+College+Hospital","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+L%5BAuthor%5D+AND+San+Antonio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhong+WZ%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"links","label":"PubMed"},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20C%5BAuthor%5D%20Shanghai%20Pulmonary%20Hospital%20ivonescimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"links","label":"PubMed author search"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","field":"links","label":"PubMed"},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhu%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zietman%20AL%5BAuthor%5D%20prostate%20proton","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","route":"/people/anthony-zietman/","field":"links","label":"PubMed"},{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","route":"/people/anthony-zietman/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zitvogel%20L%5BAuthor%5D%20microbiome","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","field":"links","label":"PubMed"},{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zon%20RT%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"links","label":"PubMed"},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zou%20W%5BAuthor%5D","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","field":"links","label":"PubMed"},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10070977/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20250202020818/https://pubmed.ncbi.nlm.nih.gov/10070977/"},{"url":"https://pubmed.ncbi.nlm.nih.gov/10202165/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999","kind":"paper","name":"GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-rose-cisplatin-chemoradiation-cervical-nejm-1999/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10441603/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","kind":"paper","name":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","route":"/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10926586/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000","kind":"paper","name":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","route":"/key-papers/paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11784875/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002","kind":"paper","name":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","route":"/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11948273/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-birkmeyer-n-engl-j-med","kind":"paper","name":"Hospital volume and surgical mortality in the United States","route":"/key-papers/paper-birkmeyer-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12189228/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mathijssen-j-natl-cancer-inst","kind":"paper","name":"Effects of St. John's wort on irinotecan metabolism","route":"/key-papers/paper-mathijssen-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1247951/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nevin-gallbladder-carcinoma-staging-cancer-1976","kind":"paper","name":"Carcinoma of the gallbladder: staging, treatment, and prognosis","route":"/key-papers/paper-nevin-gallbladder-carcinoma-staging-cancer-1976/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12731504/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-contopoulos-ioannidis-am-j-med","kind":"paper","name":"Translation of highly promising basic science research into clinical applications","route":"/key-papers/paper-contopoulos-ioannidis-am-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12767102/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-swain-cancer","kind":"paper","name":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","route":"/key-papers/paper-swain-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12778055/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-doronina-nat-biotechnol","kind":"paper","name":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","route":"/key-papers/paper-doronina-nat-biotechnol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/13404306/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-burnet-br-med-j","kind":"paper","name":"Cancer; a biological approach. I. The processes of control","route":"/key-papers/paper-burnet-br-med-j/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15118073/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","kind":"paper","name":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15118125/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15128894/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bernier-eortc-22931-nejm-2004","kind":"paper","name":"EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer","route":"/key-papers/paper-bernier-eortc-22931-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15175436/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1522903/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-delattre-nature","kind":"paper","name":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","route":"/key-papers/paper-delattre-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15343276/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004","kind":"paper","name":"Gallbladder cancer: lessons from a rare tumour","route":"/key-papers/paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15415260/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950","kind":"paper","name":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","route":"/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15637262/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jain-science","kind":"paper","name":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","route":"/key-papers/paper-jain-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15659725/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-falini-npm1-nejm-2005","kind":"paper","name":"Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype","route":"/key-papers/paper-falini-npm1-nejm-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16417259/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-doronina-bioconjug-chem","kind":"paper","name":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","route":"/key-papers/paper-doronina-bioconjug-chem/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16556892/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-study-0201-blood-2006","kind":"paper","name":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","route":"/key-papers/paper-study-0201-blood-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16648043/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stummer-lancet-oncol","kind":"paper","name":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","route":"/key-papers/paper-stummer-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16821799/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-widdison-j-med-chem","kind":"paper","name":"Semisynthetic maytansine analogues for the targeted treatment of cancer","route":"/key-papers/paper-widdison-j-med-chem/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17167137/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","kind":"paper","name":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","route":"/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17253515/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dewey-cochrane-database-syst-rev","kind":"paper","name":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","route":"/key-papers/paper-dewey-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17625570/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18083404/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","kind":"paper","name":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","route":"/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18472276/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sonnenschein-semin-cancer-biol","kind":"paper","name":"Theories of carcinogenesis: an emerging perspective","route":"/key-papers/paper-sonnenschein-semin-cancer-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18506025/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","kind":"paper","name":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","route":"/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18506026/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008","kind":"paper","name":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","route":"/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18728265/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-saper-jama","kind":"paper","name":"Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet","route":"/key-papers/paper-saper-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19360079/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stratton-nature","kind":"paper","name":"The cancer genome","route":"/key-papers/paper-stratton-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19424757/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009","kind":"paper","name":"Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours","route":"/key-papers/paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19487300/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gatenby-cancer-res","kind":"paper","name":"Adaptive therapy","route":"/key-papers/paper-gatenby-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19556163/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sjostrom-lancet-oncol","kind":"paper","name":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","route":"/key-papers/paper-sjostrom-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19805687/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009","kind":"paper","name":"AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children","route":"/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19841262/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-persson-myb-nfib-pnas-2009","kind":"paper","name":"Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma","route":"/key-papers/paper-persson-myb-nfib-pnas-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19917862/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009","kind":"paper","name":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry","route":"/key-papers/paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19931152/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-levental-cell","kind":"paper","name":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","route":"/key-papers/paper-levental-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19955524/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-klaveren-n-engl-j-med","kind":"paper","name":"Management of lung nodules detected by volume CT scanning","route":"/key-papers/paper-van-klaveren-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20430429/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010","kind":"paper","name":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial","route":"/key-papers/paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20463339/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010","kind":"paper","name":"Quality indicators for colonoscopy and the risk of interval cancer","route":"/key-papers/paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20603440/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011","kind":"paper","name":"International expert panel consensus on the diagnosis and treatment of inflammatory breast cancer","route":"/key-papers/paper-dawood-inflammatory-breast-consensus-ann-oncol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20979469/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","kind":"paper","name":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","route":"/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21155971/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-iozzo-j-cell-mol-med","kind":"paper","name":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis","route":"/key-papers/paper-iozzo-j-cell-mol-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21417701/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sanai-j-neurosurg","kind":"paper","name":"An extent of resection threshold for newly diagnosed glioblastomas","route":"/key-papers/paper-sanai-j-neurosurg/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21425776/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kellogg-bioconjug-chem","kind":"paper","name":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","route":"/key-papers/paper-kellogg-bioconjug-chem/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21430269/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21503935/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-soto-bioessays","kind":"paper","name":"The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory","route":"/key-papers/paper-soto-bioessays/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21720365/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-ovarian-nature-2011","kind":"paper","name":"Integrated genomic analyses of ovarian carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-ovarian-nature-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21818642/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ryan-support-care-cancer","kind":"paper","name":"Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients","route":"/key-papers/paper-ryan-support-care-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22031728/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011","kind":"paper","name":"Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial","route":"/key-papers/paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22067404/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011","kind":"paper","name":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","route":"/key-papers/paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22105565/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vincent-bioessays","kind":"paper","name":"Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer","route":"/key-papers/paper-vincent-bioessays/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22149875/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cleopatra-n-engl-j-med-2012","kind":"paper","name":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","route":"/key-papers/paper-cleopatra-n-engl-j-med-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22258609/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-greaves-nature","kind":"paper","name":"Clonal evolution in cancer","route":"/key-papers/paper-greaves-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22356322/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012","kind":"paper","name":"Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths (National Polyp Study)","route":"/key-papers/paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22460880/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-begley-nature","kind":"paper","name":"Drug development: Raise standards for preclinical cancer research","route":"/key-papers/paper-begley-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22591257/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-downing-n-engl-j-med","kind":"paper","name":"Regulatory review of novel therapeutics--comparison of three regulatory agencies","route":"/key-papers/paper-downing-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22722830/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22782416/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-neoptolemos-jama","kind":"paper","name":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","route":"/key-papers/paper-neoptolemos-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22830463/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","field":"links","label":"Primary report on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2300087/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990","kind":"paper","name":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","route":"/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23069814/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-study-201-jama-dermatol-2013","kind":"paper","name":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","route":"/key-papers/paper-study-201-jama-dermatol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23182993/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-91-11-long-term-forastiere-jco-2013","kind":"paper","name":"Long-term results of RTOG 91-11: three non-surgical strategies to preserve the larynx","route":"/key-papers/paper-rtog-91-11-long-term-forastiere-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23339363/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bettington-serrated-pathway-colorectal-histopathology-2013","kind":"paper","name":"The serrated pathway to colorectal carcinoma: current concepts and challenges","route":"/key-papers/paper-bettington-serrated-pathway-colorectal-histopathology-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23388632/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcfarland-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Impact of deleterious passenger mutations on cancer progression","route":"/key-papers/paper-mcfarland-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23460321/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013","kind":"paper","name":"SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy","route":"/key-papers/paper-siop-cns-gct-96-calaminus-neuro-oncology-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23470965/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23547284/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-authors-nat-methods","kind":"paper","name":"Method of the Year 2012","route":"/key-papers/paper-authors-nat-methods/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23813932/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peccatori-ann-oncol","kind":"paper","name":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-peccatori-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23853057/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barton-j-natl-cancer-inst","kind":"paper","name":"Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2","route":"/key-papers/paper-barton-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23948351/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shi-lancet-oncol","kind":"paper","name":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","route":"/key-papers/paper-shi-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24024839/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-douillard-prime-panitumumab-ras-nejm-2013","kind":"paper","name":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)","route":"/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24612190/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014","kind":"paper","name":"Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer","route":"/key-papers/paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24731888/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-lancet-oncol","kind":"paper","name":"Delivery of affordable and equitable cancer care in India","route":"/key-papers/paper-pramesh-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24739582/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-korolev-nat-rev-cancer","kind":"paper","name":"Turning ecology and evolution against cancer","route":"/key-papers/paper-korolev-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24854451/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015","kind":"paper","name":"Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study","route":"/key-papers/paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24888808/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rueth-inflammatory-breast-trimodality-jco-2014","kind":"paper","name":"Underuse of trimodality treatment and survival in inflammatory breast cancer (National Cancer Data Base)","route":"/key-papers/paper-rueth-inflammatory-breast-trimodality-jco-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25043755/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lineweaver-bioessays","kind":"paper","name":"Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model","route":"/key-papers/paper-lineweaver-bioessays/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25057166/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","kind":"paper","name":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","route":"/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25113753/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cheson-j-clin-oncol","kind":"paper","name":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","route":"/key-papers/paper-cheson-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25171411/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aceto-cell","kind":"paper","name":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","route":"/key-papers/paper-aceto-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25175478/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sharpe-lancet","kind":"paper","name":"Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial","route":"/key-papers/paper-sharpe-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25240281/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lee-prc2-mpnst-nat-genet-2014","kind":"paper","name":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumours","route":"/key-papers/paper-lee-prc2-mpnst-nat-genet-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25251053/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-english-cancer","kind":"paper","name":"Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo","route":"/key-papers/paper-english-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25296533/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-glaser-br-j-dermatol","kind":"paper","name":"Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial","route":"/key-papers/paper-glaser-br-j-dermatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25361443/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paganetti-phys-med-biol","kind":"paper","name":"Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer","route":"/key-papers/paper-paganetti-phys-med-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25372084/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ahn-n-engl-j-med","kind":"paper","name":"Korea's thyroid-cancer \"epidemic\"--screening and overdiagnosis","route":"/key-papers/paper-ahn-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25439696/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imwg-criteria-rajkumar-lancet-oncol-2014","kind":"paper","name":"IMWG updated criteria for the diagnosis of multiple myeloma (2014)","route":"/key-papers/paper-imwg-criteria-rajkumar-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25505230/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-church-pole-endometrial-jnci-2015","kind":"paper","name":"Prognostic significance of POLE proofreading mutations in endometrial cancer","route":"/key-papers/paper-church-pole-endometrial-jnci-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25519930/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015","kind":"paper","name":"Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location","route":"/key-papers/paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25564897/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-apt-tolaney-nejm-2015","kind":"paper","name":"APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer","route":"/key-papers/paper-apt-tolaney-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25638683/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stacchiotti-lancet-oncol","kind":"paper","name":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","route":"/key-papers/paper-stacchiotti-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25680375/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-clin-cancer-res","kind":"paper","name":"Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400","route":"/key-papers/paper-herbst-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25706627/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015","kind":"paper","name":"Stromal contribution to the colorectal cancer transcriptome","route":"/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25706628/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015","kind":"paper","name":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","route":"/key-papers/paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25918920/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-milazzo-cochrane-database-syst-rev","kind":"paper","name":"Laetrile treatment for cancer","route":"/key-papers/paper-milazzo-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25939061/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25970248/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-spranger-nature","kind":"paper","name":"Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity","route":"/key-papers/paper-spranger-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26033801/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bielack-j-clin-oncol","kind":"paper","name":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","route":"/key-papers/paper-bielack-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26181265/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mailankody-jama-oncol","kind":"paper","name":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","route":"/key-papers/paper-mailankody-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26321679/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chang-cell","kind":"paper","name":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","route":"/key-papers/paper-chang-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26378637/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chawla-jama-oncol","kind":"paper","name":"First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial","route":"/key-papers/paper-chawla-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26415085/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-amant-n-engl-j-med","kind":"paper","name":"Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy","route":"/key-papers/paper-amant-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26449765/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26465987/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hunger-mullighan-all-children-nejm-2015","kind":"paper","name":"Acute lymphoblastic leukaemia in children (review)","route":"/key-papers/paper-hunger-mullighan-all-children-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26536169/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-papillary-rcc-nejm-2016","kind":"paper","name":"Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-papillary-rcc-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26695736/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-riley-cochrane-database-syst-rev","kind":"paper","name":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy","route":"/key-papers/paper-riley-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26768026/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tan-phyllodes-consensus-histopathology-2016","kind":"paper","name":"Phyllodes tumours of the breast: a consensus review","route":"/key-papers/paper-tan-phyllodes-consensus-histopathology-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26789727/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ivey-npm1-mrd-nejm-2016","kind":"paper","name":"Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)","route":"/key-papers/paper-ivey-npm1-mrd-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26825712/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-defibrotide-2005-01-blood-2016","kind":"paper","name":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","route":"/key-papers/paper-defibrotide-2005-01-blood-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27009393/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-steeg-nat-rev-cancer","kind":"paper","name":"Targeting metastasis","route":"/key-papers/paper-steeg-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27050206/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-9802-buckner-nejm-2016","kind":"paper","name":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","route":"/key-papers/paper-rtog-9802-buckner-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27114594/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27158780/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27194046/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-baylin-cold-spring-harb-perspect-biol","kind":"paper","name":"Epigenetic Determinants of Cancer","route":"/key-papers/paper-baylin-cold-spring-harb-perspect-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27258432/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shin-cochrane-database-syst-rev","kind":"paper","name":"Massage with or without aromatherapy for symptom relief in people with cancer","route":"/key-papers/paper-shin-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27458945/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alliance-n0574-brown-jama-2016","kind":"paper","name":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","route":"/key-papers/paper-alliance-n0574-brown-jama-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27465099/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016","kind":"paper","name":"The risk of malignancy in ultrasound detected gallbladder polyps: A systematic review","route":"/key-papers/paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27511158/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kumar-lancet-oncol","kind":"paper","name":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","route":"/key-papers/paper-kumar-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27569442/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-marina-lancet-oncol","kind":"paper","name":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","route":"/key-papers/paper-marina-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27604504/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-quartz-lancet-2016","kind":"paper","name":"QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer","route":"/key-papers/paper-quartz-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27622829/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vistogard-cancer-2017","kind":"paper","name":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","route":"/key-papers/paper-vistogard-cancer-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27663933/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lutz-pract-radiat-oncol","kind":"paper","name":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","route":"/key-papers/paper-lutz-pract-radiat-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27726295/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016","kind":"paper","name":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","route":"/key-papers/paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27932801/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-goodnow-nat-rev-drug-discov","kind":"paper","name":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","route":"/key-papers/paper-goodnow-nat-rev-drug-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27981460/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","kind":"paper","name":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","route":"/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27993330/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-li-j-mol-diagn","kind":"paper","name":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","route":"/key-papers/paper-li-j-mol-diagn/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28074653/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nelson-j-med-chem","kind":"paper","name":"The Essential Medicinal Chemistry of Curcumin","route":"/key-papers/paper-nelson-j-med-chem/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28076709/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28126333/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28165299/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","kind":"paper","name":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","route":"/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28236467/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","kind":"paper","name":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","route":"/key-papers/paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28278348/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rimm-pd-l1-assay-comparison-jama-oncol-2017","kind":"paper","name":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","route":"/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28296618/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-perry-n-engl-j-med","kind":"paper","name":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","route":"/key-papers/paper-perry-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28303905/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peinado-nat-rev-cancer","kind":"paper","name":"Pre-metastatic niches: organ-specific homes for metastases","route":"/key-papers/paper-peinado-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28314689/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sahm-meningioma-methylation-lancet-oncol-2017","kind":"paper","name":"DNA methylation-based classification and grading system for meningioma","route":"/key-papers/paper-sahm-meningioma-methylation-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28376186/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017","kind":"paper","name":"Colorectal cancer incidence patterns in the United States, 1974-2013","route":"/key-papers/paper-siegel-colorectal-incidence-birth-cohort-jnci-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28379796/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ifm-2009-attal-nejm-2017","kind":"paper","name":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","route":"/key-papers/paper-ifm-2009-attal-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28445469/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017","kind":"paper","name":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","route":"/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28484005/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trigos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors","route":"/key-papers/paper-trigos-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28489508/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-irwin-j-clin-oncol","kind":"paper","name":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial","route":"/key-papers/paper-irwin-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28578601/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28581356/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aphinity-nejm-2017","kind":"paper","name":"APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer","route":"/key-papers/paper-aphinity-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28584134/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bussey-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Ancestral gene regulatory networks drive cancer","route":"/key-papers/paper-bussey-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28632865/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28679092/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-woodcock-n-engl-j-med","kind":"paper","name":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","route":"/key-papers/paper-woodcock-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28687377/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-n107c-brown-lancet-oncol-2017","kind":"paper","name":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","route":"/key-papers/paper-n107c-brown-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28734759/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","kind":"paper","name":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)","route":"/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28752469/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018","kind":"paper","name":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers","route":"/key-papers/paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28792880/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chan-n-engl-j-med","kind":"paper","name":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","route":"/key-papers/paper-chan-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28801186/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-catnon-lancet-2017","kind":"paper","name":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","route":"/key-papers/paper-catnon-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28814435/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alexander-clin-cancer-res","kind":"paper","name":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","route":"/key-papers/paper-alexander-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28881920/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-rectal-cancer-guideline-ann-oncol-2017","kind":"paper","name":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-rectal-cancer-guideline-ann-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28882536/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-seddon-lancet-oncol","kind":"paper","name":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","route":"/key-papers/paper-seddon-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28948213/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ligibel-npj-breast-cancer","kind":"paper","name":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design","route":"/key-papers/paper-ligibel-npj-breast-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28958502/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28966033/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mackay-paediatric-hgg-cancer-cell-2017","kind":"paper","name":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","route":"/key-papers/paper-mackay-paediatric-hgg-cancer-cell-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28967920/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-romero-nat-med","kind":"paper","name":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","route":"/key-papers/paper-romero-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28985563/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-faubert-cell","kind":"paper","name":"Lactate Metabolism in Human Lung Tumors","route":"/key-papers/paper-faubert-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29046323/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raverot-eur-j-endocrinol","kind":"paper","name":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","route":"/key-papers/paper-raverot-eur-j-endocrinol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29073584/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","field":"links","label":"Primary analysis on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29088702/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hangauer-nature","kind":"paper","name":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","route":"/key-papers/paper-hangauer-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29089605/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-den-heuvel-eibrink-nat-rev-urol","kind":"paper","name":"Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","route":"/key-papers/paper-van-den-heuvel-eibrink-nat-rev-urol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29117498/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pan-n-engl-j-med","kind":"paper","name":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","route":"/key-papers/paper-pan-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29211833/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018","kind":"paper","name":"Combined androgen blockade in androgen receptor-positive salivary gland carcinoma","route":"/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29227476/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","kind":"paper","name":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","route":"/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29342134/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bakhoum-nature","kind":"paper","name":"Chromosomal instability drives metastasis through a cytosolic DNA response","route":"/key-papers/paper-bakhoum-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29364287/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-nature","kind":"paper","name":"The biology and management of non-small cell lung cancer","route":"/key-papers/paper-herbst-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29443390/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-miften-med-phys","kind":"paper","name":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","route":"/key-papers/paper-miften-med-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29443964/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","kind":"paper","name":"TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis","route":"/key-papers/paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29584549/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29590544/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","kind":"paper","name":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","route":"/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29669701/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schoffski-lancet-respir-med","kind":"paper","name":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","route":"/key-papers/paper-schoffski-lancet-respir-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29692342/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rossi-richter-syndrome-blood-2018","kind":"paper","name":"Biology and treatment of Richter syndrome","route":"/key-papers/paper-rossi-richter-syndrome-blood-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29697741/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018","kind":"paper","name":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29754777/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pages-immunoscore-international-validation-lancet-2018","kind":"paper","name":"International validation of the consensus Immunoscore for the classification of colon cancer","route":"/key-papers/paper-pages-immunoscore-international-validation-lancet-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29860917/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tailorx-nejm-2018","kind":"paper","name":"TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer","route":"/key-papers/paper-tailorx-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29864379/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29906429/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gilligan-am-j-med","kind":"paper","name":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer","route":"/key-papers/paper-gilligan-am-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30013179/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bielski-nat-genet","kind":"paper","name":"Genome doubling shapes the evolution and prognosis of advanced cancers","route":"/key-papers/paper-bielski-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30024784/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30137606/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kamath-neurosurgery","kind":"paper","name":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes","route":"/key-papers/paper-kamath-neurosurgery/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30140036/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rindi-common-classification-framework-mod-pathol-2018","kind":"paper","name":"A common classification framework for neuroendocrine neoplasms (IARC and WHO expert consensus)","route":"/key-papers/paper-rindi-common-classification-framework-mod-pathol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30203209/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019","kind":"paper","name":"Polyp size of 1 cm is insufficient to discriminate neoplastic and non-neoplastic gallbladder polyps","route":"/key-papers/paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30221595/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcneil-n-engl-j-med","kind":"paper","name":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","route":"/key-papers/paper-mcneil-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30224381/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pfeiffer-embo-mol-med","kind":"paper","name":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","route":"/key-papers/paper-pfeiffer-embo-mol-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30309915/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cristescu-science","kind":"paper","name":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","route":"/key-papers/paper-cristescu-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30337457/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-martincorena-science","kind":"paper","name":"Somatic mutant clones colonize the human esophagus with age","route":"/key-papers/paper-martincorena-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30345906/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-impassion130-n-engl-j-med-2018","kind":"paper","name":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-impassion130-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30415629/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-manson-n-engl-j-med","kind":"paper","name":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease","route":"/key-papers/paper-manson-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30478423/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bensch-nat-med","kind":"paper","name":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","route":"/key-papers/paper-bensch-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30572922/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhao-j-hematol-oncol","kind":"paper","name":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","route":"/key-papers/paper-zhao-j-hematol-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30592986/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lee-biol-blood-marrow-transplant","kind":"paper","name":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","route":"/key-papers/paper-lee-biol-blood-marrow-transplant/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30674905/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mainprize-sci-rep","kind":"paper","name":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study","route":"/key-papers/paper-mainprize-sci-rep/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30718830/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-denardo-nat-rev-immunol","kind":"paper","name":"Macrophages as regulators of tumour immunity and immunotherapy","route":"/key-papers/paper-denardo-nat-rev-immunol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30779529/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-426-nejm-2019","kind":"paper","name":"KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","route":"/key-papers/paper-keynote-426-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30867592/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-diamond-nature","kind":"paper","name":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","route":"/key-papers/paper-diamond-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30890548/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-idbaih-clin-cancer-res","kind":"paper","name":"Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma","route":"/key-papers/paper-idbaih-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30939095/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019","kind":"paper","name":"Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma","route":"/key-papers/paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30964527/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ng-jama","kind":"paper","name":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial","route":"/key-papers/paper-ng-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31011204/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rothwell-nat-med","kind":"paper","name":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","route":"/key-papers/paper-rothwell-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31011205/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rodon-nat-med","kind":"paper","name":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","route":"/key-papers/paper-rodon-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31030981/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schuetz-lancet","kind":"paper","name":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","route":"/key-papers/paper-schuetz-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31042420/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lenz-cms-calgb-swog-80405-jco-2019","kind":"paper","name":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","route":"/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31097539/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vuik-early-onset-colorectal-europe-gut-2019","kind":"paper","name":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","route":"/key-papers/paper-vuik-early-onset-colorectal-europe-gut-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31171419/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cassiopeia-lancet-2019","kind":"paper","name":"CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma","route":"/key-papers/paper-cassiopeia-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31209238/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-menden-nat-commun","kind":"paper","name":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","route":"/key-papers/paper-menden-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31246249/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019","kind":"paper","name":"Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers","route":"/key-papers/paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31296491/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-act-in-sarc-lancet-oncol-2019","kind":"paper","name":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","route":"/key-papers/paper-act-in-sarc-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31323292/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","kind":"paper","name":"Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia","route":"/key-papers/paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31454045/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anbl0532-tandem-transplant-park-jama-2019","kind":"paper","name":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","route":"/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31464026/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cillessen-psychooncology","kind":"paper","name":"Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials","route":"/key-papers/paper-cillessen-psychooncology/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31477716/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","kind":"paper","name":"The molecular origin and taxonomy of mucinous ovarian carcinoma","route":"/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31484488/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019","kind":"paper","name":"Epidemiology of gallbladder cancer in India","route":"/key-papers/paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31534222/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-venkatesh-nature","kind":"paper","name":"Electrical and synaptic integration of glioma into neural circuits","route":"/key-papers/paper-venkatesh-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31562043/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bisogno-lancet-oncol","kind":"paper","name":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-bisogno-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31590988/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31645730/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019","kind":"paper","name":"The landscape of somatic mutation in normal colorectal epithelial cells","route":"/key-papers/paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31652094/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020","kind":"paper","name":"E3A06: lenalidomide versus observation in smouldering multiple myeloma","route":"/key-papers/paper-e3a06-lenalidomide-smouldering-lonial-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31723286/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vasan-nature","kind":"paper","name":"A view on drug resistance in cancer","route":"/key-papers/paper-vasan-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31768065/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-durham-nat-med","kind":"paper","name":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","route":"/key-papers/paper-durham-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31794625/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hoskin-jama","kind":"paper","name":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial","route":"/key-papers/paper-hoskin-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31825569/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-nejm-2020","kind":"paper","name":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases","route":"/key-papers/paper-her2climb-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31859984/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019","kind":"paper","name":"Changes in gallbladder cancer mortality and hospital discharges due to preventive cholecystectomy in Chile","route":"/key-papers/paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31883020/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fruhwald-neuro-oncol","kind":"paper","name":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors","route":"/key-papers/paper-fruhwald-neuro-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31900462/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-depil-nat-rev-drug-discov","kind":"paper","name":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","route":"/key-papers/paper-depil-nat-rev-drug-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31969335/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020","kind":"paper","name":"DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort","route":"/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31971541/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kelly-jama-oncol","kind":"paper","name":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","route":"/key-papers/paper-kelly-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32014125/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gisslinger-lancet-haematol","kind":"paper","name":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","route":"/key-papers/paper-gisslinger-lancet-haematol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32018062/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-msb-gvhd001-bbmt-2020","kind":"paper","name":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","route":"/key-papers/paper-msb-gvhd001-bbmt-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32023374/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-liu-n-engl-j-med","kind":"paper","name":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","route":"/key-papers/paper-liu-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32105305/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-global-retinoblastoma-study-jama-oncol","kind":"paper","name":"Global Retinoblastoma Presentation and Analysis by National Income Level","route":"/key-papers/paper-global-retinoblastoma-study-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32117737/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-malouff-front-oncol","kind":"paper","name":"Carbon Ion Therapy: A Modern Review of an Emerging Technology","route":"/key-papers/paper-malouff-front-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32135080/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32209560/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prior-cancer-res","kind":"paper","name":"The Frequency of Ras Mutations in Cancer","route":"/key-papers/paper-prior-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32217756/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-merino-j-immunother-cancer","kind":"paper","name":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","route":"/key-papers/paper-merino-j-immunother-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32271377/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02453282-jama-oncol-2020","kind":"paper","name":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct02453282-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32361713/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-klichinsky-nat-biotechnol","kind":"paper","name":"Human chimeric antigen receptor macrophages for cancer immunotherapy","route":"/key-papers/paper-klichinsky-nat-biotechnol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32421183/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020","kind":"paper","name":"Outcomes of Gallbladder Polyps and Their Association With Gallbladder Cancer in a 20-Year Cohort","route":"/key-papers/paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32432946/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roeland-j-clin-oncol","kind":"paper","name":"Management of Cancer Cachexia: ASCO Guideline","route":"/key-papers/paper-roeland-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32468955/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-brain-lin-jco-2020","kind":"paper","name":"HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib","route":"/key-papers/paper-her2climb-brain-lin-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32488200/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-phan-nat-rev-cancer","kind":"paper","name":"The dormant cancer cell life cycle","route":"/key-papers/paper-phan-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32492302/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-minard-colin-n-engl-j-med","kind":"paper","name":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children","route":"/key-papers/paper-minard-colin-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32504078/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-logsdon-nat-rev-genet","kind":"paper","name":"Long-read human genome sequencing and its applications","route":"/key-papers/paper-logsdon-nat-rev-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32605718/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020","kind":"paper","name":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","route":"/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32702383/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020","kind":"paper","name":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32738571/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","route":"/key-papers/paper-timbergen-eur-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32771088/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32813610/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020","kind":"paper","name":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33001143/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33015372/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rieke-npj-digit-med","kind":"paper","name":"The future of digital health with federated learning","route":"/key-papers/paper-rieke-npj-digit-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33035459/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gounder-lancet-oncol","kind":"paper","name":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","route":"/key-papers/paper-gounder-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33038342/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wells-cell","kind":"paper","name":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","route":"/key-papers/paper-wells-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33067414/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mateos-20-2-20-smouldering-bcj-2020","kind":"paper","name":"IMWG 20/2/20 risk stratification model for smouldering multiple myeloma","route":"/key-papers/paper-mateos-20-2-20-smouldering-bcj-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33125909/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-redman-lancet-oncol","kind":"paper","name":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","route":"/key-papers/paper-redman-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33186528/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shen-cell","kind":"paper","name":"Persistent Cancer Cells: The Deadly Survivors","route":"/key-papers/paper-shen-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33197225/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gordan-j-clin-oncol","kind":"paper","name":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","route":"/key-papers/paper-gordan-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33207094/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33303685/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-baruch-science","kind":"paper","name":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","route":"/key-papers/paper-baruch-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33382529/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33397713/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esgo-estro-esp-endometrial-concin-ijgc-2021","kind":"paper","name":"ESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)","route":"/key-papers/paper-esgo-estro-esp-endometrial-concin-ijgc-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33408396/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-authors-nat-methods-2021","kind":"paper","name":"Method of the Year 2020: spatially resolved transcriptomics","route":"/key-papers/paper-authors-nat-methods-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33446664/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33479225/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-koelsche-nat-commun","kind":"paper","name":"Sarcoma classification by DNA methylation profiling","route":"/key-papers/paper-koelsche-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33482121/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","kind":"paper","name":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","route":"/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33535552/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021","kind":"paper","name":"Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors","route":"/key-papers/paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33687470/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33826821/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-carlson-link-vestibular-schwannomas-nejm-2021","kind":"paper","name":"Vestibular schwannomas (review)","route":"/key-papers/paper-carlson-link-vestibular-schwannomas-nejm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33991479/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-menon-lancet","kind":"paper","name":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","route":"/key-papers/paper-menon-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33997740/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","field":"links","label":"First results on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34003218/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-uspstf-crc-screening-45-jama-2021","kind":"paper","name":"US Preventive Services Task Force recommendation: colorectal cancer screening from age 45","route":"/key-papers/paper-uspstf-crc-screening-45-jama-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34216541/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","route":"/key-papers/paper-ranganathan-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34219000/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-impassion131-ann-oncol-2021","kind":"paper","name":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","route":"/key-papers/paper-impassion131-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34261675/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021","kind":"paper","name":"Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma","route":"/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34265047/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34266848/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-bmj-glob-health","kind":"paper","name":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China","route":"/key-papers/paper-zhang-bmj-glob-health/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34266984/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-adusumilli-cancer-discov","kind":"paper","name":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","route":"/key-papers/paper-adusumilli-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34310171/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sheikh-ann-intern-med","kind":"paper","name":"Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study","route":"/key-papers/paper-sheikh-ann-intern-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34362101/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021","kind":"paper","name":"Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34380663/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wagner-j-immunother-cancer","kind":"paper","name":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","route":"/key-papers/paper-wagner-j-immunother-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34426958/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021","kind":"paper","name":"Tumor location and concurrent liver resection, impact survival in T2 gallbladder cancer: a meta-analysis of the literature","route":"/key-papers/paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34493867/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34537440/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-camidge-j-thorac-oncol","kind":"paper","name":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","route":"/key-papers/paper-camidge-j-thorac-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34555333/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34560242/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-casali-ann-oncol","kind":"paper","name":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-casali-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34608324/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-avsec-z-nat-methods","kind":"paper","name":"Effective gene expression prediction from sequence by integrating long-range interactions","route":"/key-papers/paper-avsec-z-nat-methods/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34637527/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev-2021","kind":"paper","name":"Music interventions for improving psychological and physical outcomes in people with cancer","route":"/key-papers/paper-bradt-cochrane-database-syst-rev-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34647988/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34780711/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34818478/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-belzutifan-vhl-jonasch-nejm-2021","kind":"paper","name":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","route":"/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34857730/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021","kind":"paper","name":"IMWG consensus definition of primary plasma cell leukaemia at 5 percent circulating plasma cells","route":"/key-papers/paper-imwg-plasma-cell-leukaemia-definition-bcj-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35065058/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","kind":"paper","name":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","route":"/key-papers/paper-nct03916627-lancet-gastroenterol-hepatol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35123694/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35130560/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-majzner-nature","kind":"paper","name":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","route":"/key-papers/paper-majzner-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35139273/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cervical-1-cemiplimab-nejm-2022","kind":"paper","name":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","route":"/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35419607/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-omuro-neuro-oncol","kind":"paper","name":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","route":"/key-papers/paper-omuro-neuro-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35483010/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35511454/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lim-neuro-oncol","kind":"paper","name":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","route":"/key-papers/paper-lim-neuro-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35584336/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-emerald-elacestrant-jco-2022","kind":"paper","name":"EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor","route":"/key-papers/paper-emerald-elacestrant-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35661856/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-basch-jama","kind":"paper","name":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-basch-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35693874/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barnabas-nejm-evid","kind":"paper","name":"Efficacy of single-dose HPV vaccination among young African women","route":"/key-papers/paper-barnabas-nejm-evid/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35714587/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-saxena-mol-cell","kind":"paper","name":"Hallmarks of DNA replication stress","route":"/key-papers/paper-saxena-mol-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35732829/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35803244/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stockwell-cell","kind":"paper","name":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","route":"/key-papers/paper-stockwell-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35817480/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35857659/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-355-nejm-2022","kind":"paper","name":"KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer","route":"/key-papers/paper-keynote-355-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35941372/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35961053/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-karschnia-neuro-oncol","kind":"paper","name":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","route":"/key-papers/paper-karschnia-neuro-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35995953/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36017568/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lyon-eur-heart-j","kind":"paper","name":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","route":"/key-papers/paper-lyon-eur-heart-j/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36045302/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schmitt-nat-rev-clin-oncol","kind":"paper","name":"Senescence and cancer - role and therapeutic opportunities","route":"/key-papers/paper-schmitt-nat-rev-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36094839/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","field":"links","label":"Primary report on PubMed"},{"id":"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022","kind":"paper","name":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","route":"/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36302789/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022","kind":"paper","name":"Gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36307056/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36507686/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monumental-1-talquetamab-nejm-2022","kind":"paper","name":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","route":"/key-papers/paper-monumental-1-talquetamab-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36546659/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-krystal-1-crc-yaeger-nejm-2023","kind":"paper","name":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","route":"/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36567082/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-herpen-esmo-open","kind":"paper","name":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-van-herpen-esmo-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36641093/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36657089/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023","kind":"paper","name":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","route":"/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36856579/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siegel-colorectal-cancer-statistics-ca-2023","kind":"paper","name":"Colorectal cancer statistics, 2023","route":"/key-papers/paper-siegel-colorectal-cancer-statistics-ca-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36858202/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-karius-radiother-oncol","kind":"paper","name":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy","route":"/key-papers/paper-karius-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36884323/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gounder-n-engl-j-med","kind":"paper","name":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors","route":"/key-papers/paper-gounder-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36948246/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-li-j-thorac-oncol","kind":"paper","name":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","route":"/key-papers/paper-li-j-thorac-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36977285/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sandhya-j-clin-oncol","kind":"paper","name":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer","route":"/key-papers/paper-sandhya-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36991390/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37020004/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","kind":"paper","name":"Lung adenocarcinoma promotion by air pollutants","route":"/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37059065/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37075273/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-key-j-clin-oncol","kind":"paper","name":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-key-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37256976/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-capitello-291-nejm-2023","kind":"paper","name":"CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-capitello-291-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37258680/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-theodoris-nature","kind":"paper","name":"Transfer learning enables predictions in network biology","route":"/key-papers/paper-theodoris-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37270698/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02864992-jama-oncol-2023-update","kind":"paper","name":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02864992-jama-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37272534/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prospect-nejm-2023","kind":"paper","name":"PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer","route":"/key-papers/paper-prospect-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37276871/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/","field":"links","label":"PubMed"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","field":"links","label":"HERIZON-BTC-01 (Lancet Oncology 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37308716/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-franklin-nat-rev-cancer","kind":"paper","name":"Insights into recent findings and clinical application of YAP and TAZ in cancer","route":"/key-papers/paper-franklin-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37322121/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-o-dwyer-nat-med","kind":"paper","name":"The NCI-MATCH trial: lessons for precision oncology","route":"/key-papers/paper-o-dwyer-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37390980/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37427847/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ali-thyroid","kind":"paper","name":"The 2023 Bethesda System for Reporting Thyroid Cytopathology","route":"/key-papers/paper-ali-thyroid/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37429302/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-blay-lancet-oncol","kind":"paper","name":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","route":"/key-papers/paper-blay-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37433327/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-watson-nature","kind":"paper","name":"De novo design of protein structure and function with RFdiffusion","route":"/key-papers/paper-watson-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37451295/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"links","label":"Interim analysis on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37467930/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02486718-ann-oncol-2023-update","kind":"paper","name":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","route":"/key-papers/paper-nct02486718-ann-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37501016/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37552839/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-engstrom-cancer-discov","kind":"paper","name":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","route":"/key-papers/paper-engstrom-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37592036/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roohani-nat-biotechnol","kind":"paper","name":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","route":"/key-papers/paper-roohani-nat-biotechnol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37689979/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37694347/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-lung02-goto-jco-2023","kind":"paper","name":"DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung02-goto-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37733309/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bouffet-n-engl-j-med","kind":"paper","name":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","route":"/key-papers/paper-bouffet-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37848259/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870974/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37931632/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-483-lancet-2023","kind":"paper","name":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","route":"/key-papers/paper-keynote-483-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37937763/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37978284/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kilburn-nat-med","kind":"paper","name":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","route":"/key-papers/paper-kilburn-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38015220/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mai-jama","kind":"paper","name":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","route":"/key-papers/paper-mai-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38252908/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","field":"links","label":"Primary report on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38335473/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arrillaga-romany-j-clin-oncol","kind":"paper","name":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma","route":"/key-papers/paper-arrillaga-romany-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38351187/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38409223/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cui-nat-methods","kind":"paper","name":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","route":"/key-papers/paper-cui-nat-methods/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38478773/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-braun-j-clin-oncol","kind":"paper","name":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","route":"/key-papers/paper-braun-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38519155/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kraljevic-lancet-digit-health","kind":"paper","name":"Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study","route":"/key-papers/paper-kraljevic-lancet-digit-health/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38576158/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024","kind":"paper","name":"Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?","route":"/key-papers/paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38598794/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38718835/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abramson-nature","kind":"paper","name":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","route":"/key-papers/paper-abramson-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38740044/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mars-2-lancet-respir-med-2024","kind":"paper","name":"MARS 2: extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma","route":"/key-papers/paper-mars-2-lancet-respir-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38749033/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04025879-n-engl-j-med-2024","kind":"paper","name":"Perioperative Nivolumab in Resectable Lung Cancer","route":"/key-papers/paper-nct04025879-n-engl-j-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38822758/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38828946/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38843860/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gelderblom-lancet","kind":"paper","name":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-gelderblom-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38888762/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","route":"/key-papers/paper-dhillon-mol-diagn-ther/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3889389/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950","kind":"paper","name":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","route":"/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/","field":"links","label":"JAMA landmark reprint (1985)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39036382/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-han-j-natl-cancer-cent","kind":"paper","name":"Cancer incidence and mortality in China, 2022","route":"/key-papers/paper-han-j-natl-cancer-cent/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39094065/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03157128-j-clin-oncol-2024-update","kind":"paper","name":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","route":"/key-papers/paper-nct03157128-j-clin-oncol-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39127176/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhou-j-thorac-oncol","kind":"paper","name":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","route":"/key-papers/paper-zhou-j-thorac-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39159403/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ielsg37-pmbcl-martelli-jco-2024","kind":"paper","name":"IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan","route":"/key-papers/paper-ielsg37-pmbcl-martelli-jco-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39259563/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-greer-jama","kind":"paper","name":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial","route":"/key-papers/paper-greer-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39282906/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-522-n-engl-j-med-2024-update","kind":"paper","name":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39419054/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-interlace-lancet-2024","kind":"paper","name":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-interlace-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39521433/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39545486/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/","field":"links","label":"Phase 2A report on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39652449/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhu-clin-transl-sci","kind":"paper","name":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer","route":"/key-papers/paper-zhu-clin-transl-sci/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39652675/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aquila-daratumumab-smouldering-nejm-2025","kind":"paper","name":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","route":"/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39665585/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-comet-dcis-jama-2025","kind":"paper","name":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","route":"/key-papers/paper-comet-dcis-jama-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39772829/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025","kind":"paper","name":"Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection","route":"/key-papers/paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39802701/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-halder-lancet-reg-health-southeast-asia","kind":"paper","name":"Access to timely cancer treatment initiation in India: extent, determinants and trends","route":"/key-papers/paper-halder-lancet-reg-health-southeast-asia/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39818825/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hayes-science","kind":"paper","name":"Simulating 500 million years of evolution with a language model","route":"/key-papers/paper-hayes-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39864547/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39874977/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-8hw-lancet-2025","kind":"paper","name":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","route":"/key-papers/paper-checkmate-8hw-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39879577/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04129502-j-clin-oncol-2025","kind":"paper","name":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial","route":"/key-papers/paper-nct04129502-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40052976/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024","kind":"paper","name":"Gallbladder Cancer: Is It Time to Modify the Explicit Health Guarantees (GES) Program?","route":"/key-papers/paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40064481/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025","kind":"paper","name":"Neoadjuvant treatment for incidental gallbladder cancer: A systematic review","route":"/key-papers/paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40157574/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40267983/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025","kind":"paper","name":"Geographic and age variations in mutational processes in colorectal cancer","route":"/key-papers/paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40293180/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-beamion-lung-1-zongertinib-nejm-2025","kind":"paper","name":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40450572/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454639/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","field":"links","label":"Primary report on PubMed"},{"id":"paper-c-post-adjuvant-cemiplimab-nejm-2025","kind":"paper","name":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","route":"/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40460847/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40461383/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40466026/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40473448/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40523897/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40532178/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-689-nejm-2025","kind":"paper","name":"KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer","route":"/key-papers/paper-keynote-689-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40541865/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","kind":"paper","name":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance","route":"/key-papers/paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40796223/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"links","label":"Primary report on PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40923280/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03974022-j-clin-oncol-2025","kind":"paper","name":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","route":"/key-papers/paper-nct03974022-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41197088/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04561362-j-clin-oncol-2025","kind":"paper","name":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation","route":"/key-papers/paper-nct04561362-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41237686/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025","kind":"paper","name":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care","route":"/key-papers/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41344593/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04379635-ann-oncol-2026-update","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","route":"/key-papers/paper-nct04379635-ann-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41354932/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41539318/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41820335/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41950998/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41980234/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wen-j-clin-oncol","kind":"paper","name":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial","route":"/key-papers/paper-wen-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42013358/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","kind":"paper","name":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42013573/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42090791/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05379985-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","route":"/key-papers/paper-nct05379985-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42167123/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026","kind":"paper","name":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis","route":"/key-papers/paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42214392/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06448312-lancet-2026","kind":"paper","name":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct06448312-lancet-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42223087/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42308452/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kapoor-jco-glob-oncol","kind":"paper","name":"Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)","route":"/key-papers/paper-kapoor-jco-glob-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42399203/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026","kind":"paper","name":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42410111/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42583118/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026","kind":"paper","name":"Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer","route":"/key-papers/paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/6693192/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trojani-int-j-cancer","kind":"paper","name":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","route":"/key-papers/paper-trojani-int-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/6751457/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982","kind":"paper","name":"The mesorectum in rectal cancer surgery: the clue to pelvic recurrence?","route":"/key-papers/paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8602180/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996","kind":"paper","name":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","route":"/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8942775/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised controlled trial of faecal-occult-blood screening for colorectal cancer (Nottingham)","route":"/key-papers/paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9091798/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997","kind":"paper","name":"Improved survival with preoperative radiotherapy in resectable rectal cancer (Swedish Rectal Cancer Trial)","route":"/key-papers/paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9105051/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-weaver-j-cell-biol","kind":"paper","name":"Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies","route":"/key-papers/paper-weaver-j-cell-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9126728/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kinzler-nature","kind":"paper","name":"Cancer-susceptibility genes. Gatekeepers and caretakers","route":"/key-papers/paper-kinzler-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/959840/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nowell-science","kind":"paper","name":"The clonal evolution of tumor cell populations","route":"/key-papers/paper-nowell-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9800687/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fraass-med-phys","kind":"paper","name":"American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning","route":"/key-papers/paper-fraass-med-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9920950/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999","kind":"paper","name":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","route":"/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/","field":"links","label":"PubMed"}]},{"url":"https://pubpeer.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-replication-status-badge","kind":"idea","name":"A replication status badge on every cancer paper, visible in PubMed","route":"/ideas/idea-tr2-replication-status-badge/","field":"links","label":"PubPeer"}]},{"url":"https://pure.au.dk/portal/en/persons/jens-overgaard","status":200,"ok":true,"finalUrl":"https://pure.au.dk/portal/en/persons/jens%40oncology.au.dk/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","field":"links","label":"Institution profile"},{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","field":"profiles","label":"Institution profile"}]},{"url":"https://qol.eortc.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","field":"links","label":"EORTC Quality of Life Group"},{"id":"idea-tr1-ttf-and-qol-coprimary","kind":"idea","name":"Time to treatment failure and quality of life as co-primary endpoints in non-curative trials","route":"/ideas/idea-tr1-ttf-and-qol-coprimary/","field":"links","label":"EORTC Quality of Life Group (QLQ-C30)"},{"id":"idea-tr1-language-access-in-trials","kind":"idea","name":"Drop the 'must speak English' rule: translated consent and questionnaires as standard","route":"/ideas/idea-tr1-language-access-in-trials/","field":"links","label":"EORTC Quality of Life Group (translated instruments)"},{"id":"paper-aaronson-eortc-qlq-c30-jnci-1993","kind":"paper","name":"Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire","route":"/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/","field":"links","label":"EORTC Quality of Life Group"}]},{"url":"https://r-pharm.com","status":200,"ok":true,"finalUrl":"https://r-pharm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","field":"links","label":"Official website"},{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","field":"website"}]},{"url":"https://radionetics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Official website"},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"website"}]},{"url":"https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly","status":200,"ok":true,"finalUrl":"https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Lilly strategic agreement release"}]},{"url":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a","status":200,"ok":true,"finalUrl":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Series A press release"}]},{"url":"https://radiopharmtheranostics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"links","label":"Official website"},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"website"}]},{"url":"https://ranatatx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","route":"/companies/ranata-therapeutics/","field":"links","label":"Official website"},{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","route":"/companies/ranata-therapeutics/","field":"website"}]},{"url":"https://rankings.newsweek.com/worlds-best-specialized-hospitals-2026/oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","route":"/collections/newsweek-hospitals/","field":"url"}]},{"url":"https://rarivive.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","field":"links","label":"Official website"},{"id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","field":"website"}]},{"url":"https://ratiotx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"Official website"},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"website"}]},{"url":"https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"Series C press release"}]},{"url":"https://ratiotx.com/news1/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"News"}]},{"url":"https://reflexion.com","status":200,"ok":true,"finalUrl":"https://reflexion.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reflexion","kind":"company","name":"RefleXion Medical","route":"/companies/reflexion/","field":"links","label":"Official website"},{"id":"reflexion","kind":"company","name":"RefleXion Medical","route":"/companies/reflexion/","field":"website"},{"id":"biology-guided-radiotherapy","kind":"technology","name":"Biology-guided radiotherapy (RefleXion X1, SCINTIX)","route":"/technologies/biology-guided-radiotherapy/","field":"links","label":"RefleXion Medical"}]},{"url":"https://reimaginecare.com","status":200,"ok":true,"finalUrl":"https://reimaginecare.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","field":"links","label":"Official website"},{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","field":"website"}]},{"url":"https://reimaginecare.com/publications/cureety-acquires-reimagine-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","field":"links","label":"Cureety acquisition announcement (September 2026)"}]},{"url":"https://reimaginecare.com/publications/reimagine-care-secures-25-million-in-series-a-funding-to-drive-commercialization-of-home-centered-value-based-cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","field":"links","label":"Series A press release (January 2022)"}]},{"url":"https://relaytx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","field":"links","label":"Official website"},{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","field":"website"}]},{"url":"https://relaytx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","field":"links","label":"Pipeline"},{"id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://relit.bio/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","route":"/companies/relit-biosciences/","field":"links","label":"Official website"},{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","route":"/companies/relit-biosciences/","field":"website"}]},{"url":"https://reporter.nih.gov/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-fund-dollars-per-death-dashboard","kind":"idea","name":"A public dashboard of research money per death for every cancer","route":"/ideas/idea-fund-dollars-per-death-dashboard/","field":"links","label":"NIH RePORTER"}]},{"url":"https://research-information.bris.ac.uk/en/persons/jenny-l-donovan","status":200,"ok":true,"finalUrl":"https://research-information.bris.ac.uk/en/persons/jenny-l-donovan/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jenny-donovan","kind":"person","name":"Jenny Donovan","route":"/people/jenny-donovan/","field":"links","label":"University of Bristol research information"},{"id":"jenny-donovan","kind":"person","name":"Jenny Donovan","route":"/people/jenny-donovan/","field":"profiles","label":"University of Bristol research information"}]},{"url":"https://research.hacettepe.edu.tr/en/persons/kadir-mutlu-hayran-10/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","route":"/people/kadir-mutlu-hayran/","field":"profiles","label":"Institution profile"}]},{"url":"https://research.hsr.it","status":200,"ok":true,"finalUrl":"https://research.hsr.it/en/index.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","field":"links","label":"Research"}]},{"url":"https://research.hsr.it/en/index.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"links","label":"Institution profile"},{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","field":"profiles","label":"Institution profile"}]},{"url":"https://research.manchester.ac.uk/en/persons/mairead.mcnamara/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/","field":"links","label":"University of Manchester Research Explorer"},{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/","field":"profiles","label":"University of Manchester Research Explorer"}]},{"url":"https://research.manchester.ac.uk/en/persons/philip.crosbie","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philip-crosbie","kind":"person","name":"Philip Crosbie","route":"/people/philip-crosbie/","field":"links","label":"University of Manchester staff page"},{"id":"philip-crosbie","kind":"person","name":"Philip Crosbie","route":"/people/philip-crosbie/","field":"profiles","label":"University of Manchester staff page"}]},{"url":"https://research.pasteur.fr/en/research-area/cancer/","status":200,"ok":true,"finalUrl":"https://research.pasteur.fr/en/news/cancer-car-t-cell-function-scrutinized-to-improve-immunotherapy/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","field":"links","label":"Cancer research"}]},{"url":"https://research.prinsesmaximacentrum.nl","status":200,"ok":true,"finalUrl":"https://www.prinsesmaximacentrum.nl/nl/professionals/research","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","field":"links","label":"Research"}]},{"url":"https://research.umcutrecht.nl/strategic-programs/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","field":"links","label":"Institution profile"},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","field":"profiles","label":"Institution profile"},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","field":"links","label":"Institution profile"},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","field":"profiles","label":"Institution profile"}]},{"url":"https://retractionwatch.com/retraction-watch-database-user-guide/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-retraction-propagation","kind":"idea","name":"Alert guidelines and trials when a paper they rely on is retracted","route":"/ideas/idea-tr2-retraction-propagation/","field":"links","label":"Retraction Watch Database"},{"id":"idea-data-retraction-propagation","kind":"idea","name":"Automatic flagging of retracted or corrected evidence in guidelines and decision support","route":"/ideas/idea-data-retraction-propagation/","field":"links","label":"Retraction Watch Database"}]},{"url":"https://rmpartners.nhs.uk/wp-content/uploads/2024/09/national-optimal-lung-cancer-pathway_v4_01jan2024.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NHS England: National Optimal Lung Cancer Pathway v4.0"}]},{"url":"https://rms.bh/en/about/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","route":"/people/shaikh-fahad-bin-khalifa-al-khalifa/","field":"links","label":"Source: RMS about page naming the Commander"},{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","route":"/people/shaikh-fahad-bin-khalifa-al-khalifa/","field":"profiles","label":"Royal Medical Services: About RMS (Commander's message)"}]},{"url":"https://rms.bh/en/news/bdf-commander-in-chief-received-brig-gen-dr-shaikh-fahad-bin-khalifa/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","route":"/people/shaikh-fahad-bin-khalifa-al-khalifa/","field":"links","label":"Source: RMS news on his promotion to Major General (November 2025)"}]},{"url":"https://ro-journal.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/13014","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","field":"links","label":"Homepage"},{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","field":"url"}]},{"url":"https://royalpapworth.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-papworth","kind":"institution","name":"Royal Papworth Hospital NHS Foundation Trust","route":"/institutions/royal-papworth/","field":"links","label":"Royal Papworth Hospital"},{"id":"royal-papworth","kind":"institution","name":"Royal Papworth Hospital NHS Foundation Trust","route":"/institutions/royal-papworth/","field":"website"}]},{"url":"https://roycastle.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Roy Castle Lung Cancer Foundation"},{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"links","label":"Roy Castle Lung Cancer Foundation"},{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"website"}],"archive":"https://web.archive.org/web/20260928031157/https://roycastle.org/"},{"url":"https://roycastle.org/about-us/campaigns/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"links","label":"Campaigns"}]},{"url":"https://roycastle.org/about-us/research/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"links","label":"Research"}]},{"url":"https://roycastle.org/learn-about-lung-cancer/advanced-lung-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Roy Castle Lung Cancer Foundation: advanced lung cancer"}],"archive":"https://web.archive.org/web/20260928031145/https://roycastle.org/learn-about-lung-cancer/advanced-lung-cancer/"},{"url":"https://roycastle.org/learn-about-lung-cancer/getting-diagnosed/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"Roy Castle Lung Cancer Foundation: getting diagnosed"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Roy Castle Lung Cancer Foundation: getting diagnosed"}]},{"url":"https://roycastle.org/learn-about-lung-cancer/living-with-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Roy Castle Lung Cancer Foundation: living with lung cancer"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Roy Castle Lung Cancer Foundation: living with lung cancer"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Roy Castle Lung Cancer Foundation: living with lung cancer"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","field":"links","label":"Roy Castle Lung Cancer Foundation: living with lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Roy Castle Lung Cancer Foundation: living with lung cancer"}]},{"url":"https://roycastle.org/learn-about-lung-cancer/lung-cancer-treatments/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Roy Castle Lung Cancer Foundation: lung cancer treatments"}]},{"url":"https://roycastle.org/our-support/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Roy Castle Lung Cancer Foundation: the support available to you"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Roy Castle Lung Cancer Foundation: the support available to you"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Roy Castle Lung Cancer Foundation: the support available to you"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Roy Castle Lung Cancer Foundation: the support available to you"}],"archive":"https://web.archive.org/web/20260928031217/https://roycastle.org/our-support/"},{"url":"https://roycastle.org/our-support/stop-smoking/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Roy Castle Lung Cancer Foundation: stop smoking"}]},{"url":"https://roycastle.org/our-support/telephone-support/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"links","label":"Telephone support"}]},{"url":"https://roycastle.org/our-support/useful-contacts-and-support-organisations/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","field":"links","label":"Useful contacts and support organisations"}]},{"url":"https://ru.wikipedia.org/wiki/Национальный_медицинский_исследовательский_центр_онкологии_имени_Н._Н._Блохина","status":200,"ok":true,"finalUrl":"https://ru.wikipedia.org/wiki/%D0%9D%D0%B0%D1%86%D0%B8%D0%BE%D0%BD%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B9_%D0%BC%D0%B5%D0%B4%D0%B8%D1%86%D0%B8%D0%BD%D1%81%D0%BA%D0%B8%D0%B9_%D0%B8%D1%81%D1%81%D0%BB%D0%B5%D0%B4%D0%BE%D0%B2%D0%B0%D1%82%D0%B5%D0%BB%D1%8C%D1%81%D0%BA%D0%B8%D0%B9_%D1%86%D0%B5%D0%BD%D1%82%D1%80_%D0%BE%D0%BD%D0%BA%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D0%B8_%D0%B8%D0%BC%D0%B5%D0%BD%D0%B8_%D0%9D._%D0%9D._%D0%91%D0%BB%D0%BE%D1%85%D0%B8%D0%BD%D0%B0","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","field":"links","label":"Wikipedia (Russian)"}]},{"url":"https://salmon.readthedocs.io/en/latest/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"star-salmon","kind":"term","name":"STAR and Salmon (RNA-seq alignment and quantification)","route":"/terms/star-salmon/","field":"links","label":"Salmon documentation"}]},{"url":"https://samsungbiologics.com","status":200,"ok":true,"finalUrl":"https://samsungbiologics.com/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/","field":"links","label":"Official website"},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/","field":"website"}]},{"url":"https://sana.com","status":200,"ok":true,"finalUrl":"https://sana.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","field":"website"}]},{"url":"https://sante.com","status":200,"ok":true,"finalUrl":"https://sante.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","field":"links","label":"Official website"},{"id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","field":"website"}]},{"url":"https://sante.sorbonne-universite.fr/actualites/linstitut-universitaire-de-cancerologie-iuc-decroche-laccreditation-comprehensive-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","field":"links","label":"Source: Sorbonne Université Faculté de Santé interview with the IUC director on OECI accreditation (2023)"}]},{"url":"https://sarahcannon.com","status":200,"ok":true,"finalUrl":"https://www.hcahealthcare.com/locations/sarah-cannon","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/","field":"links","label":"Official website"},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/","field":"website"}]},{"url":"https://sarcomaoncology.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/","field":"links","label":"Official website"},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/","field":"website"}]},{"url":"https://sarctrials.org","status":200,"ok":true,"finalUrl":"https://sarctrials.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarc","kind":"company","name":"SARC (Sarcoma Alliance for Research through Collaboration)","route":"/companies/sarc/","field":"website"}]},{"url":"https://sarctrials.org/about/","status":200,"ok":true,"finalUrl":"https://sarctrials.org/about-sarc/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarc","kind":"company","name":"SARC (Sarcoma Alliance for Research through Collaboration)","route":"/companies/sarc/","field":"links","label":"SARC: about"}]},{"url":"https://savarapharma.com","status":200,"ok":true,"finalUrl":"https://savarapharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","field":"links","label":"Official website"},{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","field":"website"}]},{"url":"https://sbpdiscovery.org","status":200,"ok":true,"finalUrl":"https://sbpdiscovery.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","field":"links","label":"Sanford Burnham Prebys"},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","field":"website"}]},{"url":"https://sbpdiscovery.org/research/cancer-center/","status":200,"ok":true,"finalUrl":"https://sbpdiscovery.org/events/cancer-center-mini-symposia/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","field":"links","label":"NCI-designated Cancer Center"}]},{"url":"https://sbuhb.nhs.wales/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"morriston-swansea","kind":"institution","name":"Morriston Hospital, Swansea","route":"/institutions/morriston-swansea/","field":"links","label":"Swansea Bay University Health Board"},{"id":"morriston-swansea","kind":"institution","name":"Morriston Hospital, Swansea","route":"/institutions/morriston-swansea/","field":"website"}]},{"url":"https://scirouter.ai","status":200,"ok":true,"finalUrl":"https://scirouter.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scirouter","kind":"company","name":"SciRouter","route":"/companies/scirouter/","field":"links","label":"Official website"},{"id":"scirouter","kind":"company","name":"SciRouter","route":"/companies/scirouter/","field":"website"}]},{"url":"https://scottishmedicines.org.uk","status":200,"ok":true,"finalUrl":"https://scottishmedicines.org.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/","field":"links","label":"Scottish Medicines Consortium"},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/","field":"website"}]},{"url":"https://scottishmedicines.org.uk/about-us/who-we-are/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-peel","kind":"person","name":"Robert Peel","route":"/people/robert-peel/","field":"links","label":"Source: SMC who we are page"},{"id":"robert-peel","kind":"person","name":"Robert Peel","route":"/people/robert-peel/","field":"profiles","label":"SMC who we are"}]},{"url":"https://screenpoint-medical.com","status":200,"ok":true,"finalUrl":"https://screenpoint-medical.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","route":"/companies/screenpoint-medical/","field":"links","label":"Official website"},{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","route":"/companies/screenpoint-medical/","field":"website"}]},{"url":"https://sectra.com","status":200,"ok":true,"finalUrl":"https://sectra.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sectra","kind":"company","name":"Sectra","route":"/companies/sectra/","field":"links","label":"Official website"},{"id":"sectra","kind":"company","name":"Sectra","route":"/companies/sectra/","field":"website"}]},{"url":"https://securabio.com","status":200,"ok":true,"finalUrl":"https://securabio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"securabio","kind":"company","name":"SecuraBio","route":"/companies/securabio/","field":"website"}]},{"url":"https://seer.cancer.gov","status":200,"ok":true,"finalUrl":"https://seer.cancer.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","route":"/collections/seer/","field":"links","label":"SEER (Surveillance, Epidemiology, and End Results)"},{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","route":"/collections/seer/","field":"url"}]},{"url":"https://seer.cancer.gov/statfacts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"links","label":"NCI SEER Cancer Stat Facts"}]},{"url":"https://seer.cancer.gov/statfacts/html/breast-subtypes.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer subtypes (rates, share, survival by stage and by race)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer subtypes (share of cases and five-year relative survival by receptor subtype and stage, SEER 21)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer subtypes (share of cases and five-year relative survival by receptor subtype and stage, SEER 21)"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer subtypes (rates, share, survival by stage and by race)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer subtypes (share of cases and five-year relative survival by receptor subtype and stage, SEER 21)"}],"archive":"https://web.archive.org/web/20260927195755/https://seer.cancer.gov/statfacts/html/breast-subtypes.html"},{"url":"https://seer.cancer.gov/statfacts/html/breast.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer (incidence, stage distribution and survival)"}]},{"url":"https://seer.cancer.gov/statfacts/html/cmyl.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"links","label":"SEER: CML"}]},{"url":"https://seer.cancer.gov/statfacts/html/colorect.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"SEER Cancer Stat Facts: colorectal cancer (rates, stage distribution, survival by stage, age and race)"}]},{"url":"https://seer.cancer.gov/statfacts/html/lungb.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"SEER Cancer Stat Facts: lung and bronchus cancer (rates, stage distribution, survival by stage, age and race)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"SEER Cancer Stat Facts: lung and bronchus cancer (rates, stage distribution, survival by stage, age and race)"}],"archive":"https://web.archive.org/web/20260927122206/https://seer.cancer.gov/statfacts/html/lungb.html"},{"url":"https://seer.cancer.gov/statfacts/html/pancreas.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"SEER Cancer Stat Facts: pancreatic cancer (rates, stage distribution, survival by stage, age and race)"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","field":"metrics (Five-year relative survival for pancreatic cancer diagnosed at localised vs distant stage (SEER, US))"}]},{"url":"https://seer.cancer.gov/statfacts/html/prost.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"SEER Cancer Stat Facts: prostate cancer (US incidence, stage distribution and survival by stage)"}]},{"url":"https://seer.cancer.gov/statfacts/html/smint.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"links","label":"SEER: small intestine cancer"}]},{"url":"https://servier.com","status":200,"ok":true,"finalUrl":"https://servier.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","field":"links","label":"Official website"},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","field":"website"}]},{"url":"https://sev.severance.healthcare","status":200,"ok":true,"finalUrl":"https://sev.severance.healthcare/sev/index.do","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","field":"links","label":"Official website"},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","field":"website"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"links","label":"Yonsei Cancer Center"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","field":"profiles","label":"Yonsei Cancer Center"},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","field":"links","label":"Yonsei Cancer Center"},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","field":"profiles","label":"Yonsei Cancer Center"},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","field":"links","label":"Yonsei Cancer Center"},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","field":"profiles","label":"Yonsei Cancer Center"},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","field":"links","label":"Yonsei Cancer Center"},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","field":"profiles","label":"Yonsei Cancer Center"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"links","label":"Yonsei Cancer Center"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","field":"profiles","label":"Yonsei Cancer Center"}]},{"url":"https://sfc.asso.fr/informer/le-bulletin-du-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","field":"links","label":"Société Française du Cancer page"}]},{"url":"https://sfdora.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-tenure-replication-credit","kind":"idea","name":"Count replications and open data in hiring and promotion","route":"/ideas/idea-tr2-tenure-replication-credit/","field":"links","label":"DORA"},{"id":"idea-fund-academic-promotion-reform","kind":"idea","name":"Promote academics for trials completed, data shared and findings replicated","route":"/ideas/idea-fund-academic-promotion-reform/","field":"links","label":"San Francisco Declaration on Research Assessment"}]},{"url":"https://shaukatkhanum.org.pk","status":200,"ok":true,"finalUrl":"https://shaukatkhanum.org.pk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shaukat-khanum","kind":"institution","name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre","route":"/institutions/shaukat-khanum/","field":"links","label":"Official website"},{"id":"shaukat-khanum","kind":"institution","name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre","route":"/institutions/shaukat-khanum/","field":"website"}]},{"url":"https://shaukatkhanum.org.pk/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","field":"links","label":"Source: SKMCH&RC about us page"}]},{"url":"https://shaukatkhanum.org.pk/about-us/our-leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","field":"links","label":"Source: SKMCH&RC leadership page (Board of Governors and senior management)"},{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","field":"profiles","label":"SKMCH&RC leadership page"}]},{"url":"https://sijbrandijfoundation.org","status":200,"ok":true,"finalUrl":"https://sijbrandijfoundation.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","field":"links","label":"Official website"},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","field":"website"}]},{"url":"https://sijbrandijfoundation.org/fcct","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"poornima-parameswaran","kind":"person","name":"Poornima Parameswaran","route":"/people/poornima-parameswaran/","field":"links","label":"FCCT"},{"id":"poornima-parameswaran","kind":"person","name":"Poornima Parameswaran","route":"/people/poornima-parameswaran/","field":"profiles","label":"FCCT"},{"id":"bayli-divita-dean","kind":"person","name":"Bayli DiVita Dean","route":"/people/bayli-divita-dean/","field":"links","label":"FCCT"},{"id":"bayli-divita-dean","kind":"person","name":"Bayli DiVita Dean","route":"/people/bayli-divita-dean/","field":"profiles","label":"FCCT"},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","route":"/institutions/cecurio/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"immunocine","kind":"institution","name":"Immunocine","route":"/institutions/immunocine/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","route":"/institutions/houston-methodist-rna-therapeutics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"asthra-health","kind":"institution","name":"Asthra Health","route":"/institutions/asthra-health/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","field":"links","label":"Future of Cancer Care Today"},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","field":"links","label":"Official website"},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","field":"links","label":"FCCT page"},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","field":"website"},{"id":"specicare","kind":"company","name":"SpeciCare","route":"/companies/specicare/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"storemytumor","kind":"company","name":"StoreMyTumor","route":"/companies/storemytumor/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","route":"/companies/belay-diagnostics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","route":"/companies/cnside-diagnostics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"rgcc-international","kind":"company","name":"RGCC International","route":"/companies/rgcc-international/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"navignostics","kind":"company","name":"Navignostics","route":"/companies/navignostics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cegat","kind":"company","name":"CeGaT","route":"/companies/cegat/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","route":"/companies/hartwig-medical-foundation/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","route":"/companies/vicinity-bio/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","route":"/companies/protean-biodiagnostics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"travera","kind":"company","name":"Travera","route":"/companies/travera/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","route":"/companies/first-ascent-biomedical/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cure-first","kind":"company","name":"Cure-First","route":"/companies/cure-first/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"sagemedic","kind":"company","name":"SageMedic","route":"/companies/sagemedic/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","route":"/companies/kyan-technologies/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cancertain","kind":"company","name":"CanCertain","route":"/companies/cancertain/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"2curex","kind":"company","name":"2cureX","route":"/companies/2curex/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","route":"/companies/pathfinder-oncology/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","route":"/companies/jaime-leandro-foundation/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"invoke-bio","kind":"company","name":"Invoke Bio","route":"/companies/invoke-bio/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"ubivac","kind":"company","name":"UbiVac","route":"/companies/ubivac/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","route":"/companies/cartx-therapeutics/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"patient-advocators","kind":"company","name":"Patient Advocators","route":"/companies/patient-advocators/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"private-health-management","kind":"company","name":"Private Health Management","route":"/companies/private-health-management/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","route":"/companies/outperform-cancer/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","route":"/companies/epistamai-biotech/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"private-medical","kind":"company","name":"Private Medical","route":"/companies/private-medical/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"}]},{"url":"https://simulacrum.healthdatainsight.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-synthetic-companion-datasets","kind":"idea","name":"A synthetic twin of every restricted cancer dataset for code development","route":"/ideas/idea-data-synthetic-companion-datasets/","field":"links","label":"The Simulacrum (Health Data Insight)"}]},{"url":"https://siop-online.org","status":200,"ok":true,"finalUrl":"https://siop-online.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","field":"links","label":"SIOP"},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/","field":"links","label":"SIOP International"}]},{"url":"https://siope.eu","status":200,"ok":true,"finalUrl":"https://siope.eu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/","field":"links","label":"SIOP Europe"},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/","field":"website"}]},{"url":"https://siope.eu/about-siope/board/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","field":"links","label":"Society page"},{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","field":"profiles","label":"Society page"},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","field":"links","label":"Society page"},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","field":"profiles","label":"Society page"}]},{"url":"https://siteman.washu.edu","status":200,"ok":true,"finalUrl":"https://siteman.washu.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","field":"links","label":"Siteman Cancer Center"},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","field":"profiles","label":"Siteman Cancer Center"}]},{"url":"https://siteman.wustl.edu","status":200,"ok":true,"finalUrl":"https://siteman.washu.edu/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","field":"links","label":"Official website"},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","field":"website"}]},{"url":"https://sites.aub.edu.lb/aubmcacc/aboutus/nkbci-dean-message/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","field":"profiles","label":"NKBCI director's message"}]},{"url":"https://sites.aub.edu.lb/aubmcacc/nkbci/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","field":"links","label":"Source: NKBCI institute page naming the director"}]},{"url":"https://sjlife.stjude.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"St Jude Lifetime Cohort"}]},{"url":"https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Monotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-HARMONi-2-Study-Conducted-by-Akeso-in-China/default.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","field":"links","label":"Summit press release (2026 OS)"}],"archive":"https://web.archive.org/web/20260911202003/https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Monotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-HARMONi-2-Study-Conducted-by-Akeso-in-China/default.aspx"},{"url":"https://sofie.com","status":200,"ok":true,"finalUrl":"https://sofie.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","field":"website"}]},{"url":"https://sofie.com/2026/02/11/sofie-biosciences-announces-first-patient-dosed-in-18ffapi-74-phase-3-study-for-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","field":"links","label":"Phase 3 first patient"}]},{"url":"https://sofinnovapartners.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","field":"links","label":"Official website"},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","field":"website"}]},{"url":"https://sofinnovapartners.com/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","field":"links","label":"News"}]},{"url":"https://sofinnovapartners.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","field":"links","label":"Portfolio"}]},{"url":"https://specicare.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"specicare","kind":"company","name":"SpeciCare","route":"/companies/specicare/","field":"links","label":"Official website"},{"id":"specicare","kind":"company","name":"SpeciCare","route":"/companies/specicare/","field":"website"}]},{"url":"https://stella-pharma.co.jp/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stella-pharma","kind":"company","name":"Stella Pharma","route":"/companies/stella-pharma/","field":"links","label":"Official website"},{"id":"stella-pharma","kind":"company","name":"Stella Pharma","route":"/companies/stella-pharma/","field":"website"}]},{"url":"https://stitchpoint.bio/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","route":"/companies/stitchpoint-bio/","field":"links","label":"Official website"},{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","route":"/companies/stitchpoint-bio/","field":"website"}]},{"url":"https://storemytumor.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"storemytumor","kind":"company","name":"StoreMyTumor","route":"/companies/storemytumor/","field":"links","label":"Official website"},{"id":"storemytumor","kind":"company","name":"StoreMyTumor","route":"/companies/storemytumor/","field":"website"}]},{"url":"https://strandai.com","status":200,"ok":true,"finalUrl":"https://strandai.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","field":"links","label":"Official website"},{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","field":"website"}]},{"url":"https://sunnybrook.ca/2025/10/sunnybrooks-odette-cancer-program-launches-cancer-care-at-home/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","route":"/people/monika-krzyzanowska/","field":"links","label":"Source: Sunnybrook Cancer Care at Home news release"}]},{"url":"https://sunnybrook.ca/content/?page=odette-cancer-centre","status":200,"ok":true,"finalUrl":"https://sunnybrook.ca/programs/odette-cancer-program/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","field":"links","label":"Odette Cancer Centre"},{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","field":"website"}]},{"url":"https://sunnybrook.ca/find-a-doctor/monika-krzyzanowska/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","route":"/people/monika-krzyzanowska/","field":"profiles","label":"Sunnybrook profile"}]},{"url":"https://sunnybrook.ca/research/","status":200,"ok":true,"finalUrl":"https://research.sunnybrook.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","field":"links","label":"Sunnybrook Research Institute"}]},{"url":"https://surreyandsussexcanceralliance.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","route":"/institutions/surrey-sussex-cancer-alliance/","field":"links","label":"Surrey and Sussex Cancer Alliance"},{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","route":"/institutions/surrey-sussex-cancer-alliance/","field":"website"}]},{"url":"https://sytse.com/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","field":"links","label":"Sid Sijbrandij's cancer journey"}]},{"url":"https://taelifesciences.com","status":200,"ok":true,"finalUrl":"https://taelifesciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","field":"links","label":"Official website"},{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","field":"website"}]},{"url":"https://taelifesciences.com/company/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","field":"links","label":"Investors and news page"}]},{"url":"https://taelifesciences.com/wp-content/uploads/2026/02/TAE-Life-Sciences-to-Develop-Groundbreaking-Therapy.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","field":"links","label":"Series A launch press release (March 2018, PDF)"}]},{"url":"https://tangotx.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.tangotx.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://tarebio.com","status":200,"ok":true,"finalUrl":"https://tarebio.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/","field":"links","label":"Official website"},{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/","field":"website"}]},{"url":"https://tawam.seha.ae/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sultan-mohamed-alkaram","kind":"person","name":"Sultan Mohamed Alkaram","route":"/people/sultan-mohamed-alkaram/","field":"links","label":"Source: Tawam Hospital homepage, Message from the CEO"},{"id":"sultan-mohamed-alkaram","kind":"person","name":"Sultan Mohamed Alkaram","route":"/people/sultan-mohamed-alkaram/","field":"profiles","label":"Tawam Hospital (Message from the CEO)"}]},{"url":"https://tcgcrossover.com","status":200,"ok":true,"finalUrl":"https://tcgcrossover.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","field":"links","label":"Official website"},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","field":"website"}]},{"url":"https://telixpharma.com","status":200,"ok":true,"finalUrl":"https://telixpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Official website"},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"website"}]},{"url":"https://tempus-fujit.files.svdcdn.com/production/images/ukons_triage_toolkit_v3_final.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"UKONS Oncology/Haemato-oncology 24-hour triage toolkit (version 3)"}]},{"url":"https://terryfox.org","status":200,"ok":true,"finalUrl":"https://terryfox.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","route":"/institutions/terry-fox-foundation/","field":"website"}]},{"url":"https://terryfox.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","field":"links","label":"Terry Fox Foundation"},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","field":"profiles","label":"Terry Fox Foundation"},{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","route":"/institutions/terry-fox-foundation/","field":"links","label":"Terry Fox Foundation"}]},{"url":"https://th.wikipedia.org/wiki/%E0%B8%A3%E0%B8%B2%E0%B8%8A%E0%B8%A7%E0%B8%B4%E0%B8%97%E0%B8%A2%E0%B8%B2%E0%B8%A5%E0%B8%B1%E0%B8%A2%E0%B8%88%E0%B8%B8%E0%B8%AC%E0%B8%B2%E0%B8%A0%E0%B8%A3%E0%B8%93%E0%B9%8C","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","route":"/people/princess-chulabhorn/","field":"links","label":"Source: Thai Wikipedia article on the Chulabhorn Royal Academy"}]},{"url":"https://thamesvalleycanceralliance.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","route":"/institutions/thames-valley-cancer-alliance/","field":"links","label":"Thames Valley Cancer Alliance"},{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","route":"/institutions/thames-valley-cancer-alliance/","field":"website"}]},{"url":"https://theibsi.github.io/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-radiomics-ibsi-mandate","kind":"idea","name":"No clinical claims for imaging-derived biomarkers without phantom and standards compliance","route":"/ideas/idea-tr2-radiomics-ibsi-mandate/","field":"links","label":"Image Biomarker Standardisation Initiative"}]},{"url":"https://themarkfoundation.org","status":200,"ok":true,"finalUrl":"https://themarkfoundation.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/","field":"links","label":"Mark Foundation"},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/","field":"website"}]},{"url":"https://themarkfoundation.org/about/team/","status":200,"ok":true,"finalUrl":"https://themarkfoundation.org/the-mark-foundation-team/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","route":"/people/ryan-schoenfeld/","field":"links","label":"Source: Mark Foundation team page"},{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","route":"/people/ryan-schoenfeld/","field":"profiles","label":"Mark Foundation team page"}]},{"url":"https://themarkfoundation.org/team/ryan-schoenfeld/","status":200,"ok":true,"finalUrl":"https://themarkfoundation.org/2021/02/ryan-schoenfeld-named-chief-scientific-officer/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","route":"/people/ryan-schoenfeld/","field":"profiles","label":"Mark Foundation biography"}]},{"url":"https://themmrf.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","field":"links","label":"MMRF"},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","field":"url"},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","field":"links","label":"Official website"},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","field":"website"}]},{"url":"https://themmrf.org/finding-a-cure/our-work/the-mmrf-commpass-study/","status":200,"ok":true,"finalUrl":"https://themmrf.org/finding-a-cure/personalized-treatment-approaches","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","field":"links","label":"CoMMpass"}]},{"url":"https://theobjective.com/actualidad/2025-10-17/fundacion-jimenez-diaz-premio-gestion-hospitalaria/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"links","label":"Source: The Objective, Top 20 award report naming the Gerente (October 2025)"},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"profiles","label":"The Objective report naming the hospital Gerente (October 2025)"}]},{"url":"https://theobjective.com/actualidad/2026-06-22/fundacion-jimenez-diaz-comprehensive-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"links","label":"Source: The Objective, OECI Comprehensive Cancer Center accreditation (June 2026)"}]},{"url":"https://theros.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Royal Osteoporosis Society"},{"id":"treatment-induced-bone-loss","kind":"term","name":"Treatment-induced bone loss","route":"/terms/treatment-induced-bone-loss/","field":"links","label":"Royal Osteoporosis Society"}]},{"url":"https://thesecondopinion.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thesecondopinion","kind":"collection","name":"thesecondopinion","route":"/collections/thesecondopinion/","field":"links","label":"thesecondopinion"},{"id":"thesecondopinion","kind":"collection","name":"thesecondopinion","route":"/collections/thesecondopinion/","field":"url"}]},{"url":"https://tischbraintumorcenter.duke.edu","status":200,"ok":true,"finalUrl":"https://tischbraintumorcenter.duke.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","field":"links","label":"Tisch Brain Tumor Center"}]},{"url":"https://tmc.gov.in","status":200,"ok":true,"finalUrl":"https://tmc.gov.in/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","field":"links","label":"Official website"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","field":"website"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","field":"links","label":"Tata Memorial Centre"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","field":"profiles","label":"Tata Memorial Centre"},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","field":"links","label":"Tata Memorial Centre"},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","field":"profiles","label":"Tata Memorial Centre"},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","field":"links","label":"Tata Memorial Centre"},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","field":"profiles","label":"Tata Memorial Centre"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"links","label":"Tata Memorial Centre"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","field":"profiles","label":"Tata Memorial Centre"},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","field":"links","label":"Tata Memorial Centre"},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","field":"profiles","label":"Tata Memorial Centre"},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"links","label":"Tata Memorial Centre"},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","field":"profiles","label":"Tata Memorial Centre"},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","field":"links","label":"Tata Memorial Centre"},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","field":"profiles","label":"Tata Memorial Centre"},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"links","label":"Tata Memorial Centre"},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"profiles","label":"Tata Memorial Centre"},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","field":"links","label":"Tata Memorial Centre"},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","field":"profiles","label":"Tata Memorial Centre"},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","field":"links","label":"Tata Memorial Centre"},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","field":"profiles","label":"Tata Memorial Centre"},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","field":"links","label":"Tata Memorial Centre"},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","field":"profiles","label":"Tata Memorial Centre"},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","field":"links","label":"Tata Memorial Centre"},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/","field":"links","label":"Tata Memorial Centre (units)"},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/","field":"website"}]},{"url":"https://tmc.gov.in/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-acc-hub-spoke-national-networks","kind":"idea","name":"National hub-and-spoke cancer networks with defined referral tiers","route":"/ideas/idea-acc-hub-spoke-national-networks/","field":"links","label":"Tata Memorial Centre"}]},{"url":"https://tmckolkata.com","status":200,"ok":true,"finalUrl":"https://tmckolkata.com/in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","route":"/institutions/tata-medical-center-kolkata/","field":"links","label":"Tata Medical Center"},{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","route":"/institutions/tata-medical-center-kolkata/","field":"website"}],"archive":"https://web.archive.org/web/20210309185751/http://tmckolkata.com/"},{"url":"https://tnbcfoundation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","field":"links","label":"Triple Negative Breast Cancer Foundation"},{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","field":"url"}]},{"url":"https://tnbcfoundation.org/living-with-tnbc/caregivers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","field":"links","label":"Triple Negative Breast Cancer Foundation: caregivers"}]},{"url":"https://tnbcfoundation.org/living-with-tnbc/living-with-metastatic-tnbc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Triple Negative Breast Cancer Foundation: living with metastatic TNBC"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"links","label":"Triple Negative Breast Cancer Foundation: living with metastatic TNBC"}]},{"url":"https://tnbcfoundation.org/living-with-tnbc/newly-diagnosed","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Triple Negative Breast Cancer Foundation: newly diagnosed"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Triple Negative Breast Cancer Foundation: newly diagnosed"}],"archive":"https://web.archive.org/web/20260316015504/https://tnbcfoundation.org/living-with-tnbc/newly-diagnosed"},{"url":"https://torlbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/","field":"links","label":"Official website"},{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/","field":"website"}]},{"url":"https://travera.com/","status":200,"ok":true,"finalUrl":"https://www.travera.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"travera","kind":"company","name":"Travera","route":"/companies/travera/","field":"links","label":"Official website"},{"id":"travera","kind":"company","name":"Travera","route":"/companies/travera/","field":"website"}]},{"url":"https://treadwelltx.com","status":200,"ok":true,"finalUrl":"https://treadwelltx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","field":"links","label":"Official website"},{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","field":"website"}]},{"url":"https://treadwelltx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","field":"links","label":"Pipeline page"}]},{"url":"https://treeline.bio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","field":"links","label":"Official website"},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","field":"website"}]},{"url":"https://treeline.bio/medicines","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","field":"links","label":"Medicines (pipeline)"}]},{"url":"https://trialsearch.who.int/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"links","label":"WHO International Clinical Trials Registry Platform"}]},{"url":"https://trianabio.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","field":"links","label":"Official website"},{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","field":"website"}]},{"url":"https://trianabio.com/pipeline","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","field":"links","label":"Pipeline"}]},{"url":"https://trianabio.com/press-release-12032025-1","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","field":"links","label":"Series B press release (December 2025)"}]},{"url":"https://trianabio.com/press-release-4-6-2022","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","field":"links","label":"Launch press release (April 2022)"}]},{"url":"https://trinetx.com","status":200,"ok":true,"finalUrl":"https://trinetx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/","field":"links","label":"Official website"},{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/","field":"website"}]},{"url":"https://triomics.com","status":200,"ok":true,"finalUrl":"https://triomics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/","field":"links","label":"Official website"},{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/","field":"website"}]},{"url":"https://trog.com.au/about-us/our-board/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","field":"links","label":"Society page"},{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","field":"profiles","label":"Society page"},{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","field":"links","label":"Society page"},{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","field":"profiles","label":"Society page"}]},{"url":"https://tron-mainz.de","status":200,"ok":true,"finalUrl":"https://tron-mainz.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","field":"links","label":"TRON"}]},{"url":"https://tubulis.com","status":200,"ok":true,"finalUrl":"https://tubulis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/","field":"website"}]},{"url":"https://tumourclassification.iarc.who.int","status":200,"ok":true,"finalUrl":"https://tumourclassification.iarc.who.int/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","field":"links","label":"WHO Classification of Tumours"},{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","field":"profiles","label":"WHO Classification of Tumours"}]},{"url":"https://tumourclassification.iarc.who.int/chapters/36","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"},{"id":"prostate-acinar-adenocarcinoma","kind":"term","name":"Acinar adenocarcinoma of the prostate","route":"/terms/prostate-acinar-adenocarcinoma/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"},{"id":"intraductal-carcinoma-prostate","kind":"term","name":"Intraductal carcinoma of the prostate (IDC-P)","route":"/terms/intraductal-carcinoma-prostate/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"},{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"links","label":"WHO Classification of Tumours, 5th edition: tumours of the prostate (IARC, 2022)"}]},{"url":"https://turbine.ai","status":200,"ok":true,"finalUrl":"https://turbine.ai/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","field":"links","label":"Official website"},{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","field":"website"}]},{"url":"https://turbine.ai/press-kit/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","field":"links","label":"Press kit (company facts)"}]},{"url":"https://tyra.bio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","field":"links","label":"Official website"},{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","field":"website"}]},{"url":"https://tyra.bio/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","field":"links","label":"Pipeline"}]},{"url":"https://uch-ibadan.org.ng","status":200,"ok":true,"finalUrl":"https://uch-ibadan.org.ng/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","route":"/people/jesse-otegbayo/","field":"links","label":"Source: UCH Ibadan website naming the Chief Medical Director"},{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","route":"/institutions/uch-ibadan/","field":"links","label":"Official website"},{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","route":"/institutions/uch-ibadan/","field":"website"}]},{"url":"https://uck.pl","status":200,"ok":true,"finalUrl":"https://uck.pl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","field":"links","label":"Official website"},{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","field":"website"}]},{"url":"https://ughe.org","status":200,"ok":true,"finalUrl":"https://ughe.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","field":"links","label":"University of Global Health Equity"}]},{"url":"https://ugms.ug.edu.gh","status":200,"ok":true,"finalUrl":"https://ugms.ug.edu.gh/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","field":"links","label":"University of Ghana Medical School"}],"archive":"https://web.archive.org/web/20260513013748/https://ugms.ug.edu.gh/"},{"url":"https://uihc.org/holden-comprehensive-cancer-center","status":200,"ok":true,"finalUrl":"https://holden.uihealthcare.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","field":"links","label":"Holden Comprehensive Cancer Center"},{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","field":"website"}]},{"url":"https://ukhealthcare.uky.edu/markey-cancer-center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/","field":"links","label":"Markey Cancer Center"},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/","field":"website"}]},{"url":"https://ukhealthcare.uky.edu/markey-cancer-center/about","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucille-markey","kind":"person","name":"Lucille P. Markey","route":"/people/lucille-markey/","field":"links","label":"UK Markey Cancer Center: about"}]},{"url":"https://ukneqas.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-eqa-public-results","kind":"idea","name":"Publish each laboratory's biomarker proficiency results","route":"/ideas/idea-tr2-eqa-public-results/","field":"links","label":"UK NEQAS"}]},{"url":"https://umiamihealth.org/sylvester-comprehensive-cancer-center","status":200,"ok":true,"finalUrl":"https://umiamihealth.org/en/sylvester-comprehensive-cancer-center","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","field":"links","label":"Sylvester Comprehensive Cancer Center"},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","field":"website"}]},{"url":"https://unci.org.ua/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","field":"links","label":"National Cancer Institute of Ukraine website"},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","field":"profiles","label":"National Cancer Institute of Ukraine website"},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","route":"/institutions/nci-ukraine/","field":"links","label":"Official website"},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","route":"/institutions/nci-ukraine/","field":"website"}]},{"url":"https://unclineberger.org","status":200,"ok":true,"finalUrl":"https://unclineberger.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","field":"links","label":"UNC Lineberger"},{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","field":"website"}]},{"url":"https://unclineberger.org/patientcare/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","field":"links","label":"Clinical trials"}]},{"url":"https://uroweb.org/guidelines","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","field":"links","label":"EAU Guidelines"}]},{"url":"https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","field":"links","label":"EAU guidelines: non-muscle-invasive bladder cancer"},{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","field":"links","label":"EAU guidelines: non-muscle-invasive bladder cancer"},{"id":"urine-bladder-cancer-tests","kind":"technology","name":"Urine tests for bladder cancer (cytology, FISH, RNA and methylation)","route":"/technologies/urine-bladder-cancer-tests/","field":"links","label":"European Association of Urology guideline: non-muscle-invasive bladder cancer"}]},{"url":"https://uroweb.org/guidelines/primary-urethral-carcinoma","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","field":"links","label":"EAU Guidelines: Primary Urethral Carcinoma"},{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","field":"standardOfCare.guideline (Distal, localised)"},{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"links","label":"EAU Guidelines: primary urethral carcinoma"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"links","label":"EAU Guidelines: primary urethral carcinoma"},{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"links","label":"EAU Guidelines: primary urethral carcinoma"}]},{"url":"https://uroweb.org/guidelines/prostate-cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Combinations and strategies that were tested and abandoned)"},{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","field":"links","label":"EAU guidelines: prostate cancer"},{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/","field":"links","label":"EAU guidelines on prostate cancer"}]},{"url":"https://us.movember.com/","status":200,"ok":true,"finalUrl":"https://movember.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"Movember"}]},{"url":"https://uscnorriscancer.usc.edu","status":200,"ok":true,"finalUrl":"https://uscnorriscancer.usc.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","field":"links","label":"USC Norris Comprehensive Cancer Center"},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","field":"website"}]},{"url":"https://uscnorriscancer.usc.edu/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","field":"links","label":"Clinical trials"}]},{"url":"https://uvahealth.com/services/cancer","status":200,"ok":true,"finalUrl":"https://www.uvahealth.com/specialties/cancer","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/","field":"links","label":"UVA Comprehensive Cancer Center"},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/","field":"website"}]},{"url":"https://valledellili.org","status":200,"ok":true,"finalUrl":"https://valledellili.org/pacientes-internacionales/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fundacion-valle-del-lili","kind":"institution","name":"Fundación Valle del Lili","route":"/institutions/fundacion-valle-del-lili/","field":"links","label":"Official website"},{"id":"fundacion-valle-del-lili","kind":"institution","name":"Fundación Valle del Lili","route":"/institutions/fundacion-valle-del-lili/","field":"website"}]},{"url":"https://valledellili.org/homenaje-al-dr-vicente-borrero-director-general-de-la-fundacion-valle-del-lili-por-sus-30-anos-de-gestion-de-la-institucion/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vicente-borrero","kind":"person","name":"Vicente Borrero","route":"/people/vicente-borrero/","field":"links","label":"Source: Fundación Valle del Lili article naming the Director General"},{"id":"vicente-borrero","kind":"person","name":"Vicente Borrero","route":"/people/vicente-borrero/","field":"profiles","label":"Fundación Valle del Lili tribute article (February 2026)"}]},{"url":"https://vanallenlab.dana-farber.org","status":200,"ok":true,"finalUrl":"https://labs.dana-farber.org/vanallenlab/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","field":"links","label":"Van Allen lab"},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","field":"profiles","label":"Van Allen lab"}]},{"url":"https://velindre.nhs.wales","status":200,"ok":true,"finalUrl":"https://velindre.nhs.wales/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"links","label":"Velindre Cancer Centre website"},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"profiles","label":"Velindre Cancer Centre website"},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","field":"links","label":"Homepage"},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","field":"website"}]},{"url":"https://velindre.nhs.wales/news/latest-news/velindre-university-nhs-trust-appoints-new-executive-director-of-workforce-and-organisational-development/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carl-james","kind":"person","name":"Carl James","route":"/people/carl-james/","field":"links","label":"Source: Velindre trust announcement, 12 August 2026"},{"id":"carl-james","kind":"person","name":"Carl James","route":"/people/carl-james/","field":"profiles","label":"Velindre University NHS Trust news (quoted as Chief Executive)"}]},{"url":"https://velsera.com","status":200,"ok":true,"finalUrl":"https://velsera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","route":"/companies/velsera/","field":"links","label":"Official website"},{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","route":"/companies/velsera/","field":"website"}]},{"url":"https://ventures.mckesson.com","status":200,"ok":true,"finalUrl":"https://ventures.mckesson.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","field":"links","label":"Official website"},{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","field":"website"}]},{"url":"https://verupharma.com","status":200,"ok":true,"finalUrl":"https://verupharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","field":"links","label":"Official website"},{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","field":"website"}]},{"url":"https://vhio.net","status":200,"ok":true,"finalUrl":"https://vhio.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/","field":"links","label":"Official website"},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/","field":"website"}]},{"url":"https://vhio.net/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","field":"links","label":"VHIO"},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","field":"profiles","label":"VHIO"}]},{"url":"https://vicinitybio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","route":"/companies/vicinity-bio/","field":"links","label":"Official website"},{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","route":"/companies/vicinity-bio/","field":"website"}]},{"url":"https://vidaventures.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","field":"links","label":"Official website"},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","field":"website"}]},{"url":"https://vidaventures.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","field":"links","label":"About"}]},{"url":"https://vidaventures.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://view-health-screening-recommendations.service.gov.uk/review/prostate-cancer-screening-modelling-report-2025/download-documents/cover_sheet/","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","field":"links","label":"UK National Screening Committee coversheet, March 2026"}]},{"url":"https://viewray.com","status":200,"ok":true,"finalUrl":"http://viewraysystems.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/","field":"links","label":"Official website"},{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/","field":"website"}]},{"url":"https://vironexis.com","status":200,"ok":true,"finalUrl":"https://vironexis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/","field":"links","label":"Official website"},{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/","field":"website"}]},{"url":"https://virtualcellchallenge.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"links","label":"Arc Institute Virtual Cell Challenge"}]},{"url":"https://virtualcellmodels.cziscience.com","status":200,"ok":true,"finalUrl":"https://virtualcellmodels.cziscience.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"transcriptformer","kind":"technology","name":"TranscriptFormer and rBio (CZI virtual cell models)","route":"/technologies/transcriptformer/","field":"links","label":"CZI Virtual Cells Platform"}]},{"url":"https://virtualcellmodels.cziscience.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/","field":"links","label":"CZI virtual cell"},{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"links","label":"CZ Biohub AI-supported Virtual Cells platform"}]},{"url":"https://vivli.org","status":200,"ok":true,"finalUrl":"https://vivli.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vivli","kind":"institution","name":"Vivli","route":"/institutions/vivli/","field":"links","label":"Vivli"},{"id":"vivli","kind":"institution","name":"Vivli","route":"/institutions/vivli/","field":"website"}]},{"url":"https://vivli.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"links","label":"Vivli"},{"id":"idea-tr2-failed-trial-ipd-default","kind":"idea","name":"Patient-level data from failed trials becomes open by default after two years","route":"/ideas/idea-tr2-failed-trial-ipd-default/","field":"links","label":"Vivli"},{"id":"idea-data-ipd-deposit-enforcement","kind":"idea","name":"Enforce individual participant data sharing as a condition of publication and funding","route":"/ideas/idea-data-ipd-deposit-enforcement/","field":"links","label":"Vivli"},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","field":"links","label":"Vivli"},{"id":"idea-moon-open-pro-data-commons","kind":"idea","name":"An open commons of patient-reported outcome data from cancer trials","route":"/ideas/idea-moon-open-pro-data-commons/","field":"links","label":"Vivli"}]},{"url":"https://vivli.org/about/leadership-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rebecca-li","kind":"person","name":"Rebecca Li","route":"/people/rebecca-li/","field":"links","label":"Institution profile"},{"id":"rebecca-li","kind":"person","name":"Rebecca Li","route":"/people/rebecca-li/","field":"profiles","label":"Institution profile"}]},{"url":"https://vivosight.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"confocal-oct-skin-imaging","kind":"technology","name":"Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)","route":"/technologies/confocal-oct-skin-imaging/","field":"links","label":"Michelson Diagnostics: VivoSight OCT"},{"id":"michelson-diagnostics","kind":"company","name":"Michelson Diagnostics","route":"/companies/michelson-diagnostics/","field":"links","label":"Official website"},{"id":"michelson-diagnostics","kind":"company","name":"Michelson Diagnostics","route":"/companies/michelson-diagnostics/","field":"website"}]},{"url":"https://vizgen.com","status":200,"ok":true,"finalUrl":"https://vizgen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/","field":"links","label":"Official website"},{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/","field":"website"}]},{"url":"https://vizhub.healthdata.org/gbd-results/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017","kind":"paper","name":"Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015","route":"/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/","field":"links","label":"GBD results tool"}]},{"url":"https://volition.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","field":"links","label":"Official website"},{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","field":"website"}]},{"url":"https://volition.com/volitionrx-limited-announces-second-quarter-2026-financial-results-and-business-update","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","field":"links","label":"Q2 2026 results (Aug 2026)"}]},{"url":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","field":"regulatoryEvents.source (2020-06-22)"},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","field":"regulatoryEvents.source (2026-04-30)"}]},{"url":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","field":"regulatoryEvents.source (2026-06-22)"}]},{"url":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","field":"regulatoryEvents.source (2026-06-22)"}]},{"url":"https://wclc.iaslc.org","status":200,"ok":true,"finalUrl":"https://wclc.iaslc.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","field":"links","label":"World Conference on Lung Cancer"}]},{"url":"https://web.archive.org/web/2014/https://www.broadinstitute.org/news/5346","status":200,"ok":true,"finalUrl":"https://web.archive.org/web/20140830073434/http://www.broadinstitute.org/news/5346","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eli-broad","kind":"person","name":"Eli Broad","route":"/people/eli-broad/","field":"links","label":"Broad Institute: next decade launched with new $100M gift (2013, archived)"}]},{"url":"https://web.archive.org/web/20140517065619/http://drup.nl/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/","field":"links","label":"DRUP trial (archived copy)"}]},{"url":"https://web.archive.org/web/20180506044652/http://crchum.chumontreal.qc.ca/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","field":"links","label":"CRCHUM (archived copy)"}]},{"url":"https://web.archive.org/web/20200904070334/https://fchampalimaud.org/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","route":"/institutions/champalimaud/","field":"links","label":"Homepage (archived copy)"},{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","route":"/institutions/champalimaud/","field":"website"}]},{"url":"https://web.archive.org/web/20211020135241/https://www.geicam.org/en/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/","field":"links","label":"Clinical trials (archived copy)"}]},{"url":"https://web.archive.org/web/20211202003714/http://dualitybiotherapeutics.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/","field":"links","label":"Official website (archived copy)"}]},{"url":"https://web.archive.org/web/20211206023820/https://www.pref.aichi.jp/cancer-center/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/","field":"links","label":"Aichi Cancer Center (archived copy)"},{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/","field":"website"}]},{"url":"https://web.archive.org/web/20220505192107/https://www.heteroworld.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hetero","kind":"company","name":"Hetero Drugs","route":"/companies/hetero/","field":"links","label":"Official website"}]},{"url":"https://web.archive.org/web/20230614152013/http://www.thekinghorncancercentre.org.au/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","field":"links","label":"The Kinghorn Cancer Centre (archived copy)"}]},{"url":"https://web.archive.org/web/20230702005939/https://www.oeci.eu/Accreditation/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","field":"links","label":"Accreditation and Designation (archived copy)"}]},{"url":"https://web.archive.org/web/20231029084627/https://practice.asco.org/quality-improvement/quality-programs/quality-oncology-practice-initiative","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"links","label":"ASCO Quality Oncology Practice Initiative (archived copy)"}]},{"url":"https://web.archive.org/web/20231201043719/https://www.esmo.org/newsroom/press-releases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"destiny-breast11","kind":"trial","name":"DESTINY-Breast11","route":"/trials/destiny-breast11/","field":"outcomes.source (Pathologic complete response (ypT0/Tis ypN0))"}]},{"url":"https://web.archive.org/web/20231211122757/https://www.ipocoimbra.min-saude.pt/2021/01/27/conselho-de-administracao/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"links","label":"Source: IPO Coimbra Conselho de Administração page (archived copy)"}]},{"url":"https://web.archive.org/web/20240225223721/https://www.ipocoimbra.min-saude.pt/2024/01/22/nomeacao-do-ca-do-ipo-de-coimbra/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"links","label":"Source: IPO Coimbra notice of the board's reappointment for 2024 to 2026 (archived copy)"},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"profiles","label":"IPO Coimbra board appointment notice (archived copy)"}]},{"url":"https://web.archive.org/web/20240415200043/https://www.fda.gov/about-fda/oncology-center-excellence/project-equity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","field":"links","label":"FDA Oncology Center of Excellence, Project Equity (archived copy)"}]},{"url":"https://web.archive.org/web/20240420075523/https://cancergrandchallenges.org/teams","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","field":"links","label":"Funded teams (archived copy)"}]},{"url":"https://web.archive.org/web/20240525134719/https://www.rijnstate.nl/over-rijnstate/organisatie/raad-van-bestuur/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","field":"links","label":"Source: Rijnstate Raad van Bestuur page (archived copy, May 2024)"}]},{"url":"https://web.archive.org/web/20240909081739/https://www.westerncape.gov.za/your_gov/163/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","field":"links","label":"Groote Schuur Hospital (archived copy)"},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","field":"website"}]},{"url":"https://web.archive.org/web/20250114190714/https://www.rijnstate.nl/over-rijnstate/nieuws/2024/rijnstate-bestuursvoorzitter-geraline-leusink-benoemd-in-rvt-umc-utrecht/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","field":"links","label":"Source: Rijnstate news on her appointment to the UMC Utrecht supervisory board (archived copy)"}]},{"url":"https://web.archive.org/web/20250117063852/https://uch-ibadan.org.ng/member/professor-jesse-abiodun-otegbayo/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","route":"/people/jesse-otegbayo/","field":"profiles","label":"UCH Ibadan Chief Medical Director profile (archived copy)"}]},{"url":"https://web.archive.org/web/20250120094403/https://www.fda.gov/about-fda/oncology-center-excellence/project-silver","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-mandatory-older-adult-cohort","kind":"idea","name":"A mandatory over-70s cohort with geriatric assessment in every pivotal trial","route":"/ideas/idea-tr1-mandatory-older-adult-cohort/","field":"links","label":"FDA Oncology Center of Excellence: Project Silver (archived copy)"}]},{"url":"https://web.archive.org/web/20250121103628/https://www.dkfz.de/en/hi-tron/","status":200,"ok":true,"contentType":"text/html; charset=ISO-8859-1","checked":"2026-09-30","refs":[{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","field":"links","label":"HI-TRON Mainz (archived copy)"}]},{"url":"https://web.archive.org/web/20250201021950/https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-diversity-plans-with-consequences","kind":"idea","name":"Diversity action plans with consequences: unmet targets trigger post-approval requirements","route":"/ideas/idea-tr1-diversity-plans-with-consequences/","field":"links","label":"FDA: Clinical trial diversity (archived copy)"}]},{"url":"https://web.archive.org/web/20250302091714/https://www.fda.gov/advisory-committees/advisory-committee-calendar/february-10-2022-meeting-oncologic-drugs-advisory-committee-meeting-announcement-02102022","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"regulatoryEvents.source (2022-03)"},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","field":"links","label":"FDA ODAC 10 February 2022 (archived copy)"}]},{"url":"https://web.archive.org/web/20250427051345/https://www.fda.gov/news-events/press-announcements/fda-authorizes-software-can-help-identify-prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paige-prostate","kind":"drug","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/","field":"links","label":"FDA press release (2021) (archived copy)"}]},{"url":"https://web.archive.org/web/20250623085121/https://www.ialch.co.za/senior-management/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","route":"/people/lp-mtshali/","field":"links","label":"Source: IALCH senior management page (archived copy)"},{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","route":"/people/lp-mtshali/","field":"profiles","label":"IALCH senior management page (archived copy, June 2025)"}]},{"url":"https://web.archive.org/web/20250708090325/http://www.nppaindia.nic.in/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-voluntary-licensing-oncology","kind":"idea","name":"Voluntary licences and price caps for patented cancer drugs in low-income countries","route":"/ideas/idea-cost-voluntary-licensing-oncology/","field":"links","label":"National Pharmaceutical Pricing Authority (India) (archived copy)"}]},{"url":"https://web.archive.org/web/20250717031142/https://nicpr.org/from-the-directors-desk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","field":"links","label":"Source: ICMR-NICPR 'From the Director's Desk' page (archived copy)"},{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","field":"profiles","label":"From the Director's Desk (archived copy, July 2025)"}]},{"url":"https://web.archive.org/web/20250805173531/http://www.incancer.cl/en-cuenta-publica-2024-se-refuerza-el-compromiso-con-la-salud-oncologica-de-excelencia/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"berta-cerda-alvarez","kind":"person","name":"Berta Cerda Álvarez","route":"/people/berta-cerda-alvarez/","field":"links","label":"Source: INC article on the 2024 Cuenta Pública led by the Directora (July 2025, archived copy)"},{"id":"berta-cerda-alvarez","kind":"person","name":"Berta Cerda Álvarez","route":"/people/berta-cerda-alvarez/","field":"profiles","label":"INC news article naming the Directora (archived copy)"}]},{"url":"https://web.archive.org/web/20250905154857/https://cancer.wisc.edu/research/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","field":"links","label":"Clinical trials (archived copy)"}]},{"url":"https://web.archive.org/web/20250917092427/https://www.gauteng.gov.za/Departments/DepartmentDetails/CPM-001004","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","field":"links","label":"CMJAH (Gauteng Health) (archived copy)"}]},{"url":"https://web.archive.org/web/20251018210106/https://www.cuh.hse.ie/our-services/our-consultants-a-z/dr-dearbhaile-collins/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","field":"links","label":"Source: CUH consultant profile (archived copy, October 2025; live site under maintenance)"}]},{"url":"https://web.archive.org/web/20251207101158/https://www.57357.org/en/board-of-directors-afnci","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","field":"links","label":"Source: 57357 Board of Directors / AFNCI page (archived copy, December 2025; live site blocks automated access)"}]},{"url":"https://web.archive.org/web/20251230054709/https://www.aphp.fr/actualites/retour-sur-la-1re-journee-des-infirmiers-en-cancerologie-de-linstitut-du-cancer-ap-hp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","route":"/people/nicolas-revel/","field":"links","label":"Source: AP-HP article naming Nicolas Revel as directeur general (archived copy, December 2025)"}]},{"url":"https://web.archive.org/web/20251231165538/https://www.england.nhs.uk/cancer/faster-diagnosis/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-acc-28-day-diagnosis-standard","kind":"idea","name":"A legislated, publicly reported 28-day standard from urgent referral to diagnosis","route":"/ideas/idea-acc-28-day-diagnosis-standard/","field":"links","label":"NHS England Faster Diagnosis Standard (archived copy)"}]},{"url":"https://web.archive.org/web/20260101015106/https://cuh.hse.ie/about-us/our-structure/leadership-team/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","field":"links","label":"Source: CUH leadership team page (archived copy, January 2026)"}]},{"url":"https://web.archive.org/web/20260118064043/https://www.zchospital.com/cn/survey","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","field":"links","label":"Source: Zhejiang Cancer Hospital leadership listing (archived copy, January 2026)"}]},{"url":"https://web.archive.org/web/20260118080219/https://www.zchospital.com/cn/index","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","field":"links","label":"Source: Zhejiang Cancer Hospital homepage with June 2025 news naming the president (archived copy)"}]},{"url":"https://web.archive.org/web/20260209042353/https://dbtindia.gov.in/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/","field":"links","label":"Department of Biotechnology (archived copy)"},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/","field":"website"}]},{"url":"https://web.archive.org/web/20260213082319/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","field":"links","label":"FDA approval of crizotinib for ALK-positive IMT (archived copy)"}]},{"url":"https://web.archive.org/web/20260217063458/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ventana-mmr-rxdx","kind":"drug","name":"VENTANA MMR RxDx Panel","route":"/drugs/ventana-mmr-rxdx/","field":"links","label":"FDA: dostarlimab accelerated approval (dMMR endometrial cancer) (archived copy)"}]},{"url":"https://web.archive.org/web/20260419021737/https://www.aphp.fr/actualites/institut-du-cancer-ap-hp-nord-universite-paris-cite-des-avancees-concretes-un-apres","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","route":"/people/nicolas-revel/","field":"links","label":"Source: AP-HP article on the institute one year after the OECI label (archived copy, March 2026)"}]},{"url":"https://web.archive.org/web/20260420012135/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","field":"links","label":"FDA: pembrolizumab tissue-agnostic approval for MSI-H/dMMR tumours (2017) (archived copy)"}]},{"url":"https://web.archive.org/web/20260516224208/https://deep6.ai/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","field":"links","label":"Official website"},{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","field":"website"}]},{"url":"https://wechope.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","field":"links","label":"World Eye Cancer Hope"}]},{"url":"https://wellcome.org","status":200,"ok":true,"finalUrl":"https://wellcome.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","field":"links","label":"Wellcome"},{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","field":"website"}]},{"url":"https://wellcome.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/","field":"links","label":"Wellcome Trust"}]},{"url":"https://werewolftx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","field":"links","label":"Official website"},{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","field":"website"}]},{"url":"https://wessexcanceralliance.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","route":"/institutions/wessex-cancer-alliance/","field":"links","label":"Wessex Cancer Alliance"},{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","route":"/institutions/wessex-cancer-alliance/","field":"website"}]},{"url":"https://winshipcancer.emory.edu","status":200,"ok":true,"finalUrl":"https://winshipcancer.emory.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","field":"links","label":"Winship Cancer Institute"},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","field":"website"}]},{"url":"https://winshipcancer.emory.edu/about-us/history.php","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-woodruff","kind":"person","name":"Robert W. Woodruff","route":"/people/robert-woodruff/","field":"links","label":"Winship Cancer Institute: history"}]},{"url":"https://winshipcancer.emory.edu/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","field":"links","label":"Clinical trials"}]},{"url":"https://wistar.org","status":200,"ok":true,"finalUrl":"https://www.wistar.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","field":"links","label":"The Wistar Institute"},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","field":"website"}]},{"url":"https://wistar.org/our-scientists/research-centers/cancer-center","status":200,"ok":true,"finalUrl":"https://www.wistar.org/404-requested-page-not-found/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","field":"links","label":"Cancer Center"}]},{"url":"https://wjso.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/12957","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","field":"links","label":"Homepage"},{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","field":"url"}]},{"url":"https://wmcanceralliance.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","route":"/institutions/west-midlands-cancer-alliance/","field":"links","label":"West Midlands Cancer Alliance"},{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","route":"/institutions/west-midlands-cancer-alliance/","field":"website"}]},{"url":"https://wtz-essen.de/direktorium-wtz-essen/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"links","label":"Institution profile"},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","field":"profiles","label":"Institution profile"},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","field":"links","label":"Institution profile"},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.3d-medicines.com","status":200,"ok":true,"finalUrl":"https://www.3d-medicines.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/","field":"website"}]},{"url":"https://www.3dhistech.com","status":200,"ok":true,"finalUrl":"https://www.3dhistech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"3dhistech","kind":"company","name":"3DHISTECH","route":"/companies/3dhistech/","field":"links","label":"Official website"},{"id":"3dhistech","kind":"company","name":"3DHISTECH","route":"/companies/3dhistech/","field":"website"}]},{"url":"https://www.3sbio.com","status":200,"ok":true,"finalUrl":"https://www.3sbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/","field":"links","label":"Official website"},{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/","field":"website"}]},{"url":"https://www.4sc.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","field":"links","label":"Official website"},{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","field":"website"}]},{"url":"https://www.a2bio.com","status":200,"ok":true,"finalUrl":"https://www.a2bio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/","field":"links","label":"Official website"},{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/","field":"website"}]},{"url":"https://www.a9oncology.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"Official website"},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"website"}]},{"url":"https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"GRPR phase 1 first patient dosed"}]},{"url":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"Series C press release"}]},{"url":"https://www.aacr.org","status":200,"ok":true,"finalUrl":"https://www.aacr.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/","field":"links","label":"Official website"},{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/","field":"website"},{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","field":"links","label":"AACR"}]},{"url":"https://www.aacr.org/about-the-aacr/leadership/officers/","status":200,"ok":true,"finalUrl":"https://www.aacr.org/about-the-aacr/leadership-and-governance/officers/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"links","label":"AACR officers"},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","field":"profiles","label":"AACR officers"}]},{"url":"https://www.aacr.org/about-the-aacr/newsroom/news-releases/adding-tucatinib-to-first-line-maintenance-therapy-delayed-disease-progression-in-her2-positive-metastatic-breast-cancer-in-her2climb-05-trial/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.aacr.org/blog/2016/06/06/fda-approval-liquid-biopsy-test-lung-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"AACR: FDA approves first liquid biopsy test for lung cancer patients, 1 June 2016"}]},{"url":"https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","field":"links","label":"AACR Q1 2026 digest"}]},{"url":"https://www.aacr.org/blog/2026/07/02/fda-approvals-in-oncology-april-june-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","field":"links","label":"AACR Q2 2026 digest"}]},{"url":"https://www.aacr.org/meeting/aacr-annual-meeting-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","route":"/collections/src-aacr-annual/","field":"links","label":"AACR Annual Meeting"},{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","route":"/collections/src-aacr-annual/","field":"url"}]},{"url":"https://www.aacr.org/professionals/research/aacr-project-genie/","status":200,"ok":true,"finalUrl":"https://aacrprojectgenie.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genie","kind":"collection","name":"AACR Project GENIE","route":"/collections/genie/","field":"links","label":"AACR Project GENIE"},{"id":"genie","kind":"collection","name":"AACR Project GENIE","route":"/collections/genie/","field":"url"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","field":"links","label":"AACR Project GENIE"},{"id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/","field":"links","label":"AACR Project GENIE"},{"id":"idea-data-open-line-of-therapy-algorithms","kind":"idea","name":"Open, benchmarked algorithms for lines of therapy and progression from routine data","route":"/ideas/idea-data-open-line-of-therapy-algorithms/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-point-of-care-randomisation","kind":"idea","name":"Point-of-care randomisation built into the oncology record","route":"/ideas/idea-data-point-of-care-randomisation/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-procurement-open-api-clauses","kind":"idea","name":"Public procurement clauses banning data export fees and lock-in","route":"/ideas/idea-data-procurement-open-api-clauses/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-privacy-preserving-linkage-tokens","kind":"idea","name":"Privacy-preserving linkage tokens for every cancer data holder","route":"/ideas/idea-data-privacy-preserving-linkage-tokens/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-atlas-to-outcome-linkage","kind":"idea","name":"Link single-cell and spatial tumour atlases to clinical outcomes","route":"/ideas/idea-data-atlas-to-outcome-linkage/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-radiotherapy-dose-repository","kind":"idea","name":"A national repository of radiotherapy dose plans linked to outcomes","route":"/ideas/idea-data-radiotherapy-dose-repository/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-surgical-video-commons","kind":"idea","name":"A consented commons of surgical video linked to pathology and outcomes","route":"/ideas/idea-data-surgical-video-commons/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-quality-scorecards","kind":"idea","name":"Public data-quality scorecards for every cancer centre","route":"/ideas/idea-data-quality-scorecards/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-data-structured-radiology-response","kind":"idea","name":"Structured, coded radiology reports for cancer response instead of free text","route":"/ideas/idea-data-structured-radiology-response/","field":"links","label":"Bottleneck evidence (Data silos): AACR Project GENIE"},{"id":"idea-moon-universal-sequencing-learning-system","kind":"idea","name":"Universal tumour and germline sequencing at diagnosis feeding a shared learning system","route":"/ideas/idea-moon-universal-sequencing-learning-system/","field":"links","label":"AACR Project GENIE"},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/","field":"links","label":"AACR Project GENIE"}]},{"url":"https://www.aadibio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","route":"/companies/aadi-bioscience/","field":"links","label":"Official website"},{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","route":"/companies/aadi-bioscience/","field":"website"}]},{"url":"https://www.ab-science.com","status":200,"ok":true,"finalUrl":"https://www.ab-science.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","field":"links","label":"Official website"},{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","field":"website"}]},{"url":"https://www.abbott.com","status":200,"ok":true,"finalUrl":"https://www.abbott.com/en-us/homepage","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/","field":"links","label":"Official website"},{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/","field":"website"}]},{"url":"https://www.abclon.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/","field":"links","label":"Official website"},{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/","field":"website"}]},{"url":"https://www.abcsg.at","status":200,"ok":true,"finalUrl":"https://www.abcsg.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","field":"links","label":"ABCSG"}]},{"url":"https://www.abcsg.org","status":200,"ok":true,"finalUrl":"https://www.abcsg.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abcsg","kind":"company","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/companies/abcsg/","field":"links","label":"ABCSG"},{"id":"abcsg","kind":"company","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/companies/abcsg/","field":"website"}]},{"url":"https://www.abcsg.org/en/about-us/board/","status":200,"ok":true,"finalUrl":"https://www.abcsg.org/en/the-abcsg/organisation/board-of-directors/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","field":"links","label":"Society page"},{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","field":"profiles","label":"Society page"},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","field":"links","label":"Society page"},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","field":"profiles","label":"Society page"}]},{"url":"https://www.abcsg.org/studien/","status":200,"ok":true,"finalUrl":"https://www.abcsg.org/studien-news/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abcsg","kind":"company","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/companies/abcsg/","field":"links","label":"Trials"}]},{"url":"https://www.abelzeta.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/","field":"links","label":"Official website"},{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/","field":"website"}]},{"url":"https://www.abx.de","status":200,"ok":true,"finalUrl":"https://abx.de/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"links","label":"Official website"},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"website"}]},{"url":"https://www.abzena.com","status":200,"ok":true,"finalUrl":"https://abzena.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/","field":"links","label":"Official website"},{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/","field":"website"}]},{"url":"https://www.accelerate-platform.org","status":200,"ok":true,"finalUrl":"https://www.accelerate-platform.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/","field":"links","label":"ACCELERATE"},{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/","field":"website"}]},{"url":"https://www.accelerate-platform.org/our-leadership","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicole-scobie","kind":"person","name":"Nicole Scobie","route":"/people/nicole-scobie/","field":"links","label":"Source: ACCELERATE 'Our Leadership' page"},{"id":"nicole-scobie","kind":"person","name":"Nicole Scobie","route":"/people/nicole-scobie/","field":"profiles","label":"ACCELERATE leadership page"}]},{"url":"https://www.accelerate-platform.org/paediatric-strategy-forums/","status":200,"ok":true,"finalUrl":"https://www.accelerate-platform.org/paediatric-strategy-forums","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/","field":"links","label":"Paediatric Strategy Forums"},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/","field":"links","label":"ACCELERATE Paediatric Strategy Forums"}]},{"url":"https://www.accrf.org/","status":200,"ok":true,"finalUrl":"https://accrf.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","field":"links","label":"Adenoid Cystic Carcinoma Research Foundation"}]},{"url":"https://www.accuray.com","status":200,"ok":true,"finalUrl":"https://www.accuray.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","field":"links","label":"Official website"},{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","field":"website"}]},{"url":"https://www.accuray.com/cyberknife/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/","field":"links","label":"Accuray: CyberKnife"}]},{"url":"https://www.accuray.com/radixact/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tomotherapy","kind":"technology","name":"TomoTherapy and Radixact (helical radiotherapy)","route":"/technologies/tomotherapy/","field":"links","label":"Accuray: Radixact"}]},{"url":"https://www.accuray.com/software/synchrony/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"respiratory-gating-tumour-tracking-systems","kind":"technology","name":"Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)","route":"/technologies/respiratory-gating-tumour-tracking-systems/","field":"links","label":"Accuray: Synchrony motion tracking"}]},{"url":"https://www.achievelifesciences.com","status":200,"ok":true,"finalUrl":"https://achievelifesciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","field":"links","label":"Official website"},{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","field":"website"}]},{"url":"https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/LI-RADS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-rads","kind":"term","name":"LI-RADS (Liver Imaging Reporting and Data System)","route":"/terms/li-rads/","field":"links","label":"American College of Radiology: LI-RADS"}]},{"url":"https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/PI-RADS","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"links","label":"American College of Radiology: PI-RADS, Prostate Imaging Reporting and Data System (v2.1, a joint development of the ACR, ESUR and the Admetech Foundation)"}]},{"url":"https://www.acrotechbiopharma.com","status":200,"ok":true,"finalUrl":"https://acrotechbiopharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","field":"links","label":"Official website"},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","field":"website"}]},{"url":"https://www.actiniumpharma.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"Official website"},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"website"}]},{"url":"https://www.actuatetherapeutics.com","status":200,"ok":true,"finalUrl":"https://actuatetherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","field":"links","label":"Actuate Therapeutics: elraglusib programme"},{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","route":"/companies/actuate-therapeutics/","field":"links","label":"Official website"},{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","route":"/companies/actuate-therapeutics/","field":"website"}]},{"url":"https://www.adacap.com","status":200,"ok":true,"finalUrl":"https://www.novartis.com/research-and-development/technology-platforms/radioligand-therapy","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","field":"links","label":"Official website"},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","field":"website"}]},{"url":"https://www.adaptimmune.com","status":200,"ok":true,"finalUrl":"https://www.adaptimmune.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","field":"links","label":"Official website"},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","field":"website"}]},{"url":"https://www.adaptivebiotech.com","status":200,"ok":true,"finalUrl":"https://www.adaptivebiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/","field":"links","label":"Official website"},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/","field":"website"}]},{"url":"https://www.addaspirintrial.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-factorial-adjuvant-generics","kind":"idea","name":"Factorial trials that test several cheap generics at once in the adjuvant setting","route":"/ideas/idea-tr2-factorial-adjuvant-generics/","field":"links","label":"Add-Aspirin trial"},{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","route":"/trials/add-aspirin/","field":"links","label":"Add-Aspirin trial site"},{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","field":"links","label":"Add-Aspirin trial"}]},{"url":"https://www.addgene.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-universal-mta-fast-lane","kind":"idea","name":"A universal material transfer agreement with a thirty-day default","route":"/ideas/idea-fund-universal-mta-fast-lane/","field":"links","label":"Addgene"}]},{"url":"https://www.adelabio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","field":"links","label":"Official website"},{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","field":"website"}]},{"url":"https://www.adelabio.com/adela-news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","field":"links","label":"News page"}]},{"url":"https://www.adelabio.com/press/adela-announces-48-million-in-financing-and-leadership-addition-to-advance-tissue-agnostic-minimal-residual-disease-mrd-monitoring-product-portfolio-based-on-genome-wide-methylome-approach","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","field":"links","label":"$48 million financing (Sep 2023)"}]},{"url":"https://www.adelabio.com/press/adela-debuts-with-60m","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","field":"links","label":"Series A launch release (Jun 2021)"}]},{"url":"https://www.adhb.health.nz","status":200,"ok":true,"finalUrl":"https://www.healthnz.govt.nz/hospitals-services/hospitals/auckland/central","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/","field":"links","label":"Te Whatu Ora Auckland"},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/","field":"website"}]},{"url":"https://www.adialante.com","status":200,"ok":true,"finalUrl":"https://adialante.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adialante","kind":"company","name":"Adialante","route":"/companies/adialante/","field":"links","label":"Official website"},{"id":"adialante","kind":"company","name":"Adialante","route":"/companies/adialante/","field":"website"}]},{"url":"https://www.adicetbio.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","field":"links","label":"Official website"},{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","field":"website"}]},{"url":"https://www.adienne.com","status":200,"ok":true,"finalUrl":"https://www.adienne.com/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adienne","kind":"company","name":"Adienne Pharma & Biotech","route":"/companies/adienne/","field":"links","label":"Official website"},{"id":"adienne","kind":"company","name":"Adienne Pharma & Biotech","route":"/companies/adienne/","field":"website"}]},{"url":"https://www.advenchen.com","status":200,"ok":true,"finalUrl":"https://advenchen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","field":"links","label":"Sponsor page"}]},{"url":"https://www.affinittx.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","field":"links","label":"Official website"},{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","field":"website"}]},{"url":"https://www.afirma.com","status":200,"ok":true,"finalUrl":"https://www.veracyte.com/tests/afirma-thyroid/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"afirma","kind":"drug","name":"Afirma Genomic Sequencing Classifier","route":"/drugs/afirma/","field":"links","label":"Veracyte: Afirma"}]},{"url":"https://www.agilent.com","status":200,"ok":true,"finalUrl":"https://www.agilent.com/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/","field":"links","label":"Official website"},{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/","field":"website"}]},{"url":"https://www.agilent.com/en/product/pharmdx/pd-l1-ihc-22c3-pharmdx","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/","field":"links","label":"Agilent: PD-L1 IHC 22C3 pharmDx"}]},{"url":"https://www.ago-ovar.de","status":200,"ok":true,"finalUrl":"https://ago-ovar.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/","field":"website"}]},{"url":"https://www.ago-ovar.de/en/profile/","status":200,"ok":true,"finalUrl":"https://ago-ovar.de/en/profile/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/","field":"links","label":"AGO Study Group: profile"}]},{"url":"https://www.agora-cancer.ch","status":200,"ok":true,"finalUrl":"https://agora-cancer.ch/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","field":"links","label":"AGORA"}]},{"url":"https://www.agsavvas-hosp.gr","status":200,"ok":true,"finalUrl":"https://agsavvas-hosp.gr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","field":"links","label":"Saint Savvas General Oncology Hospital of Athens website"},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","field":"profiles","label":"Saint Savvas General Oncology Hospital of Athens website"},{"id":"saint-savvas-athens","kind":"institution","name":"Saint Savvas General Oncology Hospital of Athens","route":"/institutions/saint-savvas-athens/","field":"links","label":"Official website"},{"id":"saint-savvas-athens","kind":"institution","name":"Saint Savvas General Oncology Hospital of Athens","route":"/institutions/saint-savvas-athens/","field":"website"}]},{"url":"https://www.ahus.no","status":200,"ok":true,"finalUrl":"https://www.ahus.no/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","field":"links","label":"Akershus University Hospital website"},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","field":"profiles","label":"Akershus University Hospital website"},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","field":"links","label":"Official website"},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","field":"website"}]},{"url":"https://www.aidoc.com","status":200,"ok":true,"finalUrl":"https://www.aidoc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","field":"website"},{"id":"aidoc-care","kind":"technology","name":"Aidoc CARE (clinical radiology foundation model)","route":"/technologies/aidoc-care/","field":"links","label":"Aidoc"}]},{"url":"https://www.aidport.pl/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","field":"links","label":"AidPort Clinical Trial Hospital website"},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","field":"profiles","label":"AidPort Clinical Trial Hospital website"},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","route":"/institutions/aidport/","field":"links","label":"Official website"},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","route":"/institutions/aidport/","field":"website"}]},{"url":"https://www.aignostics.com","status":200,"ok":true,"finalUrl":"https://www.aignostics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","field":"links","label":"Official website"},{"id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","field":"website"}]},{"url":"https://www.aiims.edu","status":200,"ok":true,"finalUrl":"https://www.aiims.edu/index.php/en","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"links","label":"AIIMS New Delhi"},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"profiles","label":"AIIMS New Delhi"},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"links","label":"AIIMS New Delhi"},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"website"},{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","route":"/institutions/aiims-network/","field":"links","label":"AIIMS New Delhi"}]},{"url":"https://www.aimatmelanoma.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","field":"links","label":"AIM at Melanoma"}]},{"url":"https://www.aio-portal.de","status":200,"ok":true,"finalUrl":"https://www.aio-portal.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","route":"/companies/aio/","field":"website"}]},{"url":"https://www.aio-portal.de/die-aio.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","route":"/companies/aio/","field":"links","label":"AIO: Die AIO"}]},{"url":"https://www.aio-studien-ggmbh.de/ueber-uns.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","route":"/companies/aio/","field":"links","label":"AIO-Studien-gGmbH: Über uns"}]},{"url":"https://www.airc.it","status":200,"ok":true,"finalUrl":"https://www.airc.it/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/","field":"links","label":"AIRC"},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/","field":"website"}]},{"url":"https://www.airc.it/fondazione/chi-siamo/i-nostri-organi-di-governo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"andrea-sironi","kind":"person","name":"Andrea Sironi","route":"/people/andrea-sironi/","field":"links","label":"Source: AIRC governing bodies page"},{"id":"andrea-sironi","kind":"person","name":"Andrea Sironi","route":"/people/andrea-sironi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ajmc.com/view/fda-grants-full-approval-to-pirtobrutinib-for-cll-sll","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/","field":"outcomes.source (Progression-free survival (median))"}]},{"url":"https://www.akademiska.se","status":200,"ok":true,"finalUrl":"https://www.akademiska.se/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"links","label":"Homepage"},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"website"}]},{"url":"https://www.akademiska.se/om-oss/sjukhusets-organisation/sjukhusledningen/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marianne-van-rooijen","kind":"person","name":"Marianne van Rooijen","route":"/people/marianne-van-rooijen/","field":"links","label":"Institution profile"},{"id":"marianne-van-rooijen","kind":"person","name":"Marianne van Rooijen","route":"/people/marianne-van-rooijen/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.akdn.org/our-agencies/aga-khan-health-services","status":200,"ok":true,"finalUrl":"https://the.akdn/en/how-we-work/our-agencies/aga-khan-health-services","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"links","label":"The Aga Khan Hospital, Dar es Salaam website"},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"profiles","label":"The Aga Khan Hospital, Dar es Salaam website"},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","route":"/institutions/aga-khan-hospital-dar-es-salaam/","field":"links","label":"Official website"},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","route":"/institutions/aga-khan-hospital-dar-es-salaam/","field":"website"}]},{"url":"https://www.akesobio.com","status":200,"ok":true,"finalUrl":"https://www.akesobio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"dosing.source"},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","field":"links","label":"Official website"},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","field":"website"}]},{"url":"https://www.akesobio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/","field":"links","label":"Akeso"},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/","field":"profiles","label":"Akeso"}]},{"url":"https://www.akesobio.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","field":"links","label":"Akeso"}]},{"url":"https://www.aktisoncology.com","status":200,"ok":true,"finalUrl":"https://www.aktisoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","field":"website"}]},{"url":"https://www.alaunos.com","status":200,"ok":true,"finalUrl":"https://alaunos.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","field":"links","label":"Official website"},{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","field":"website"}]},{"url":"https://www.albertahealthservices.ca/ajecccc/ajecccc.aspx","status":200,"ok":true,"finalUrl":"https://www.albertahealthservices.ca/NotFound.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","field":"links","label":"Arthur J.E. Child Comprehensive Cancer Centre"}]},{"url":"https://www.albertahealthservices.ca/cancer/cancer.aspx","status":200,"ok":true,"finalUrl":"https://www.cancercarealberta.ca/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","field":"links","label":"Cancer Care Alberta"},{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","field":"website"}]},{"url":"https://www.albertahealthservices.ca/cci/cci.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","field":"links","label":"Cross Cancer Institute"}]},{"url":"https://www.aldevron.com","status":200,"ok":true,"finalUrl":"https://www.aldevron.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","field":"links","label":"Official website"},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","field":"website"}]},{"url":"https://www.alexanderfleming.org","status":200,"ok":true,"finalUrl":"https://alexanderfleming.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/","field":"links","label":"Instituto Alexander Fleming"},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/","field":"website"}]},{"url":"https://www.alfa-leukemia.org","status":200,"ok":true,"finalUrl":"https://www.alfa-leukemia.org/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alfa","kind":"company","name":"ALFA (Acute Leukemia French Association)","route":"/companies/alfa/","field":"links","label":"Official website"},{"id":"alfa","kind":"company","name":"ALFA (Acute Leukemia French Association)","route":"/companies/alfa/","field":"website"}]},{"url":"https://www.alfredhealth.org.au","status":200,"ok":true,"finalUrl":"https://www.alfredhealth.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alfred-health-monash","kind":"institution","name":"Alfred Health / Monash University","route":"/institutions/alfred-health-monash/","field":"links","label":"Alfred Health"},{"id":"alfred-health-monash","kind":"institution","name":"Alfred Health / Monash University","route":"/institutions/alfred-health-monash/","field":"website"}]},{"url":"https://www.algenbio.com","status":200,"ok":true,"finalUrl":"https://www.algenbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/","field":"links","label":"Official website"},{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/","field":"website"}]},{"url":"https://www.alixia.com","status":200,"ok":true,"finalUrl":"https://www.alixia.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alixia","kind":"company","name":"Alixia","route":"/companies/alixia/","field":"links","label":"Official website"},{"id":"alixia","kind":"company","name":"Alixia","route":"/companies/alixia/","field":"website"}]},{"url":"https://www.alkpositive.org/","status":200,"ok":true,"finalUrl":"https://alkpositive.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","field":"links","label":"ALK Positive"}]},{"url":"https://www.alleanzacontroilcancro.it","status":200,"ok":true,"finalUrl":"https://alleanzacontroilcancro.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","field":"links","label":"Alleanza Contro il Cancro"}]},{"url":"https://www.allianceforclinicaltrialsinoncology.org","status":200,"ok":true,"finalUrl":"https://www.allianceforclinicaltrialsinoncology.org/main/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/","field":"links","label":"Official website"},{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/","field":"website"}]},{"url":"https://www.alligatorbioscience.com/","status":200,"ok":true,"finalUrl":"https://alligatorbioscience.se/en/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","route":"/companies/alligator-bioscience/","field":"links","label":"Official website"},{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","route":"/companies/alligator-bioscience/","field":"website"}]},{"url":"https://www.allist.com.cn/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","field":"links","label":"Shanghai Allist Pharmaceuticals"},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/","field":"links","label":"Official website"},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/","field":"website"}]},{"url":"https://www.almirall.com","status":200,"ok":true,"finalUrl":"https://www.almirall.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","field":"links","label":"Official website"},{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","field":"website"}]},{"url":"https://www.alphamabonc.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","field":"links","label":"Alphamab Oncology"},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/","field":"links","label":"Official website"},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/","field":"website"}],"archive":"https://web.archive.org/web/20260513054845/https://www.alphamabonc.com/en/"},{"url":"https://www.altaytherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.altaytherapeutics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","route":"/companies/altay-therapeutics/","field":"links","label":"Official website"},{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","route":"/companies/altay-therapeutics/","field":"website"}]},{"url":"https://www.alxoncology.com","status":200,"ok":true,"finalUrl":"https://alxoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/","field":"links","label":"Sponsor page"}]},{"url":"https://www.ambagontx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","field":"links","label":"Official website"},{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","field":"website"}]},{"url":"https://www.ambagontx.com/platform-pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","field":"links","label":"Platform and pipeline"}]},{"url":"https://www.amgen.com","status":200,"ok":true,"finalUrl":"https://www.amgen.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","field":"links","label":"Official website"},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","field":"website"}]},{"url":"https://www.amgen.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/","field":"links","label":"Official website"},{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/","field":"website"}]},{"url":"https://www.amgen.com/newsroom/press-releases/2025/06/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-firstline-gastric-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","route":"/drugs/bemarituzumab/","field":"links","label":"Amgen topline announcement"}]},{"url":"https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"links","label":"Amgen topline release (8 Sep 2026)"},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"outcomes.source (Overall survival)"},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"outcomes.source (Progression-free survival)"},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.amneal.com","status":200,"ok":true,"finalUrl":"https://amneal.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","route":"/companies/amneal/","field":"links","label":"Official website"},{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","route":"/companies/amneal/","field":"website"}]},{"url":"https://www.amsterdamumc.org","status":200,"ok":true,"finalUrl":"https://www.amsterdamumc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","route":"/institutions/amsterdam-umc/","field":"links","label":"Official website"},{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","route":"/institutions/amsterdam-umc/","field":"website"}]},{"url":"https://www.amsterdamumc.org/en/organization/board-1","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","field":"profiles","label":"Amsterdam UMC Board (English)"}]},{"url":"https://www.amsterdamumc.org/nl/organisatie/raad-van-bestuur.htm","status":200,"ok":true,"finalUrl":"https://www.amsterdamumc.org/nl/organisatie/bestuur","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","field":"links","label":"Source: Amsterdam UMC executive board page"},{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","field":"profiles","label":"Amsterdam UMC Raad van Bestuur (Dutch)"}]},{"url":"https://www.anadolusaglik.org","status":200,"ok":true,"finalUrl":"https://www.anadolusaglik.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","route":"/institutions/anadolu-medical-center/","field":"links","label":"Official website"},{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","route":"/institutions/anadolu-medical-center/","field":"website"}]},{"url":"https://www.anadolusaglik.org/kurumsal/yonetim-ekibimiz","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timur-atsuren","kind":"person","name":"Timur Atsüren","route":"/people/timur-atsuren/","field":"links","label":"Source: Anadolu Sağlık Merkezi 'Yönetim Ekibimiz' page"},{"id":"timur-atsuren","kind":"person","name":"Timur Atsüren","route":"/people/timur-atsuren/","field":"profiles","label":"Anadolu Medical Center management team (Turkish)"}]},{"url":"https://www.ananya.health","status":200,"ok":true,"finalUrl":"https://www.ananya.health/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/","field":"links","label":"Official website"},{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/","field":"website"}]},{"url":"https://www.anderapartners.com/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","field":"links","label":"Official website"},{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","field":"website"}]},{"url":"https://www.anderapartners.com/en/expertise/life-sciences-biotechnologies/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","field":"links","label":"Life sciences"}]},{"url":"https://www.ansa.it/campania/notizie/2026/01/19/al-pascale-primo-prelievo-di-cornee-svolta-per-listituto-tumori-di-napoli_c083e153-1312-4491-b9c3-cd318b98edea.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maurizio-di-mauro","kind":"person","name":"Maurizio Di Mauro","route":"/people/maurizio-di-mauro/","field":"links","label":"Source: ANSA report quoting the Pascale General Director, January 2026"}]},{"url":"https://www.ansto.gov.au","status":200,"ok":true,"finalUrl":"https://www.ansto.gov.au/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","field":"links","label":"Official website"},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","field":"website"}]},{"url":"https://www.antaranews.com/berita/5594340/rs-kanker-dharmais-terapkan-ngs-untuk-dukung-diagnostik-presisi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eniarti","kind":"person","name":"Eniarti","route":"/people/eniarti/","field":"links","label":"Source: Antara news report quoting the Direktur Utama (June 2026)"},{"id":"eniarti","kind":"person","name":"Eniarti","route":"/people/eniarti/","field":"profiles","label":"Antara news report (June 2026)"}]},{"url":"https://www.antengene.com","status":200,"ok":true,"finalUrl":"https://www.antengene.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/","field":"links","label":"Official website"},{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/","field":"website"}]},{"url":"https://www.anticancerfund.org/","status":200,"ok":true,"finalUrl":"https://www.anticancerfund.org/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-public-de-escalation-trial-fund","kind":"idea","name":"A public fund for trials that test less treatment","route":"/ideas/idea-tr1-public-de-escalation-trial-fund/","field":"links","label":"The Anticancer Fund"},{"id":"idea-tr1-public-dose-reduction-trials-of-approved-drugs","kind":"idea","name":"Publicly funded dose-reduction trials of expensive approved drugs","route":"/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/","field":"links","label":"The Anticancer Fund"},{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/","field":"links","label":"Anticancer Fund"}]},{"url":"https://www.anticancerfund.org/en/","status":200,"ok":true,"finalUrl":"https://www.anticancerfund.org/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-global-repurposing-fund","kind":"idea","name":"A public fund that pays for phase 3 trials of cheap, off-patent drugs against cancer","route":"/ideas/idea-reg-global-repurposing-fund/","field":"links","label":"Anticancer Fund ReDO project (page moved; nearest live section)"},{"id":"idea-reg-regulator-ready-repurposing-dossiers","kind":"idea","name":"Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs","route":"/ideas/idea-reg-regulator-ready-repurposing-dossiers/","field":"links","label":"ReDO_DB (page moved; nearest live section)"}]},{"url":"https://www.antidote.me/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/","field":"links","label":"Official website"},{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/","field":"website"}]},{"url":"https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368271","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","field":"links","label":"ANZCTR ACTRN12615000381583"}]},{"url":"https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374135","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dynamic-iii","kind":"trial","name":"DYNAMIC-III","route":"/trials/dynamic-iii/","field":"links","label":"ANZCTR ACTRN12617001566325"}]},{"url":"https://www.aoadx.com","status":200,"ok":true,"finalUrl":"https://aoadx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/","field":"links","label":"Official website"},{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/","field":"website"}]},{"url":"https://www.aop-health.com","status":200,"ok":true,"finalUrl":"https://www.aop-health.com/global_en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/","field":"links","label":"Official website"},{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/","field":"website"}]},{"url":"https://www.aosp.bo.it","status":200,"ok":true,"finalUrl":"https://www.aosp.bo.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chiara-gibertoni","kind":"person","name":"Chiara Gibertoni","route":"/people/chiara-gibertoni/","field":"links","label":"Institution profile"},{"id":"chiara-gibertoni","kind":"person","name":"Chiara Gibertoni","route":"/people/chiara-gibertoni/","field":"profiles","label":"Institution profile"},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"links","label":"Homepage"},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"website"}]},{"url":"https://www.aosp.bo.it/content/ematologia","status":200,"ok":true,"finalUrl":"https://www.aosp.bo.it/il-policlinico/strutture/ematologia","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"links","label":"Haematology"}]},{"url":"https://www.ap-hm.fr","status":200,"ok":true,"finalUrl":"https://fr.ap-hm.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ap-hm-timone","kind":"institution","name":"Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille","route":"/institutions/ap-hm-timone/","field":"links","label":"AP-HM"},{"id":"ap-hm-timone","kind":"institution","name":"Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille","route":"/institutions/ap-hm-timone/","field":"website"}]},{"url":"https://www.apbioinc.com","status":200,"ok":true,"finalUrl":"https://www.apbioinc.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/","field":"links","label":"Official website"},{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/","field":"website"}]},{"url":"https://www.aphp.fr","status":200,"ok":true,"finalUrl":"https://www.aphp.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/","field":"links","label":"Official website"},{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/","field":"website"},{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/","field":"links","label":"Official website"},{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/","field":"website"},{"id":"carpem-aphp-centre","kind":"institution","name":"Institut du Cancer Paris CARPEM, AP-HP Centre","route":"/institutions/carpem-aphp-centre/","field":"links","label":"Official website"},{"id":"carpem-aphp-centre","kind":"institution","name":"Institut du Cancer Paris CARPEM, AP-HP Centre","route":"/institutions/carpem-aphp-centre/","field":"website"}]},{"url":"https://www.aphp.fr/actualites/retour-sur-la-1re-journee-des-infirmiers-en-cancerologie-de-linstitut-du-cancer-ap-hp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","route":"/people/nicolas-revel/","field":"profiles","label":"AP-HP news: first cancer nursing day of the Institut du Cancer AP-HP. Nord (December 2025)"}]},{"url":"https://www.apollomicsinc.com","status":200,"ok":true,"finalUrl":"https://www.apollomicsinc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/","field":"links","label":"Official website"},{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/","field":"website"}]},{"url":"https://www.appliedclinicaltrialsonline.com/view/fda-approves-komzifti-npm1-mutated-aml-positive-komet-001-trial-data","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","field":"outcomes.source (Complete remission)"}]},{"url":"https://www.aptose.com","status":200,"ok":true,"finalUrl":"https://www.aptose.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/","field":"links","label":"Official website"},{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/","field":"website"}]},{"url":"https://www.aqemia.com","status":200,"ok":true,"finalUrl":"https://aqemia.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","field":"links","label":"Official website"},{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","field":"website"}]},{"url":"https://www.aqemia.com/news","status":200,"ok":true,"finalUrl":"https://aqemia.com/news","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","field":"links","label":"News"}]},{"url":"https://www.aqemia.com/who-we-are","status":200,"ok":true,"finalUrl":"https://aqemia.com/who-we-are","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","field":"links","label":"Who we are"}]},{"url":"https://www.arcagy.org","status":200,"ok":true,"finalUrl":"https://www.arcagy.org/fr","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/","field":"links","label":"ARCAGY-GINECO"},{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/","field":"website"}]},{"url":"https://www.archventure.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","field":"links","label":"Official website"},{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","field":"website"}]},{"url":"https://www.archventure.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","field":"links","label":"Portfolio"}]},{"url":"https://www.arcusbio.com","status":200,"ok":true,"finalUrl":"https://arcusbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/","field":"links","label":"Official website"},{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/","field":"website"},{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","field":"links","label":"Sponsor page"},{"id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","field":"links","label":"Sponsor page"}]},{"url":"https://www.arden.bio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","field":"links","label":"Official website"},{"id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","field":"website"}]},{"url":"https://www.argentina.gob.ar/salud/inc","status":200,"ok":true,"finalUrl":"https://www.argentina.gob.ar/salud/dnc","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","field":"links","label":"Official website"},{"id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","field":"website"}]},{"url":"https://www.argentina.gob.ar/salud/inc/institucional/equipo-de-trabajo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susana-blanco","kind":"person","name":"Susana Blanco","route":"/people/susana-blanco/","field":"links","label":"Source: Argentina Ministry of Health, Instituto Nacional del Cáncer team page"},{"id":"susana-blanco","kind":"person","name":"Susana Blanco","route":"/people/susana-blanco/","field":"profiles","label":"Ministerio de Salud, INC team page"}]},{"url":"https://www.argenx.com","status":200,"ok":true,"finalUrl":"https://argenx.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","field":"links","label":"Official website"},{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","field":"website"}]},{"url":"https://www.arogpharma.com","status":200,"ok":true,"finalUrl":"https://www.arogpharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","field":"links","label":"Official website"},{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20250516021043/https://arogpharma.com/"},{"url":"https://www.arrivent.com","status":200,"ok":true,"finalUrl":"https://arrivent.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/","field":"links","label":"Official website"},{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/","field":"website"}]},{"url":"https://www.artios.com","status":200,"ok":true,"finalUrl":"https://www.artios.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","field":"links","label":"Official website"},{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","field":"website"}]},{"url":"https://www.arvinas.com","status":200,"ok":true,"finalUrl":"https://www.arvinas.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/","field":"links","label":"Official website"},{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/","field":"website"}]},{"url":"https://www.ascentage.com","status":200,"ok":true,"finalUrl":"https://www.ascentage.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","field":"links","label":"Official website"},{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","field":"website"}]},{"url":"https://www.ascentawits.com","status":200,"ok":true,"finalUrl":"https://www.ascentawits.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/","field":"links","label":"Official website"},{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/","field":"website"}]},{"url":"https://www.ascletis.com","status":200,"ok":true,"finalUrl":"https://www.ascletis.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","field":"links","label":"Official website"},{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","field":"website"}]},{"url":"https://www.asco.org","status":200,"ok":true,"finalUrl":"https://www.asco.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/","field":"links","label":"Official website"},{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/","field":"website"},{"id":"idea-bio2-cns-cohort-mandate","kind":"idea","name":"Stop excluding brain metastases from cancer trials","route":"/ideas/idea-bio2-cns-cohort-mandate/","field":"links","label":"ASCO-Friends eligibility criteria work"}]},{"url":"https://www.asco.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","field":"links","label":"ASCO"},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","field":"profiles","label":"ASCO"}]},{"url":"https://www.asco.org/about-asco/asco-leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"links","label":"ASCO leadership"},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","field":"profiles","label":"ASCO leadership"},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"links","label":"ASCO leadership"},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","field":"profiles","label":"ASCO leadership"},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"links","label":"ASCO leadership"},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","field":"profiles","label":"ASCO leadership"},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"links","label":"ASCO leadership"},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","field":"profiles","label":"ASCO leadership"}]},{"url":"https://www.asco.org/about-asco/press-center/news-releases/trastuzumab-deruxtecan-can-help-some-people-with-advanced-gastric-cancers-live-about-3-months-longer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.asco.org/guidelines","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/","field":"links","label":"ASCO guidelines"},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"links","label":"ASCO guideline: small bowel adenocarcinoma (JCO 2024)"},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"standardOfCare.guideline (Adjuvant (stage III; selected stage II))"}]},{"url":"https://www.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/choosing-wisely","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-early-palliative-default","kind":"idea","name":"Make early palliative care and a goals conversation part of every advanced-cancer pathway","route":"/ideas/idea-cost-early-palliative-default/","field":"links","label":"ASCO: Choosing Wisely recommendations"}]},{"url":"https://www.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/oncology-workforce-information","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","field":"links","label":"ASCO State of the Oncology Workforce"}]},{"url":"https://www.asco.org/practice-patients/guidelines","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","field":"links","label":"ASCO guidelines"},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","field":"url"},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"links","label":"ASCO guidelines"}]},{"url":"https://www.asco.org/practice-patients/quality-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","field":"links","label":"ASCO end-of-life quality measures"}]},{"url":"https://www.ascpt.org","status":200,"ok":true,"finalUrl":"https://www.ascpt.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","field":"links","label":"ASCPT"}]},{"url":"https://www.asherbio.com","status":200,"ok":true,"finalUrl":"https://asherbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/","field":"links","label":"Official website"},{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/","field":"website"}]},{"url":"https://www.ask-gene.com","status":200,"ok":true,"finalUrl":"https://ask-gene.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/","field":"links","label":"Official website"},{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/","field":"website"}]},{"url":"https://www.ask-pharm.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","route":"/companies/aosaikang-pharmaceutical/","field":"links","label":"Official website"},{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","route":"/companies/aosaikang-pharmaceutical/","field":"website"}]},{"url":"https://www.asst-spedalicivili.it","status":200,"ok":true,"finalUrl":"https://www.asst-spedalicivili.it/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spedali-civili-brescia","kind":"institution","name":"ASST Spedali Civili di Brescia","route":"/institutions/spedali-civili-brescia/","field":"links","label":"Official website"},{"id":"spedali-civili-brescia","kind":"institution","name":"ASST Spedali Civili di Brescia","route":"/institutions/spedali-civili-brescia/","field":"website"}]},{"url":"https://www.asst-spedalicivili.it/chi-siamo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","route":"/people/luigi-cajazzo/","field":"links","label":"Source: ASST Spedali Civili di Brescia direzione strategica listing"},{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","route":"/people/luigi-cajazzo/","field":"profiles","label":"ASST Spedali Civili 'Chi siamo' page"}]},{"url":"https://www.asst-spedalicivili.it/luigi-cajazzo-direttore-generale","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","route":"/people/luigi-cajazzo/","field":"profiles","label":"Direttore Generale page"}]},{"url":"https://www.astellas.com","status":200,"ok":true,"finalUrl":"https://www.astellas.com/en","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","field":"links","label":"Official website"},{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","field":"website"}]},{"url":"https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Asthma + Lung UK: breathlessness"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","field":"links","label":"Asthma + Lung UK: breathlessness"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Asthma + Lung UK: breathlessness"}]},{"url":"https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness/how-can-i-manage-my-breathlessness","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","field":"links","label":"Asthma + Lung UK: how can I manage my breathlessness?"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Asthma + Lung UK: how can I manage my breathlessness?"}]},{"url":"https://www.atarabio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","route":"/companies/atara-biotherapeutics/","field":"links","label":"Official website"},{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","route":"/companies/atara-biotherapeutics/","field":"website"}]},{"url":"https://www.ataraxis.ai/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/","field":"links","label":"Official website"},{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/","field":"website"}]},{"url":"https://www.ataraxis.ai/resources/ataraxis-ai-to-transform-precision-medicine-in-cancer-care-with-20-4-million-series-a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/","field":"links","label":"Series A announcement (Mar 2025)"}]},{"url":"https://www.aubmc.org.lb","status":200,"ok":true,"finalUrl":"https://aubmc.org.lb/pages/home.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","route":"/institutions/aubmc-basile-cancer-institute/","field":"links","label":"Official website"},{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","route":"/institutions/aubmc-basile-cancer-institute/","field":"website"}]},{"url":"https://www.aulosbio.com/","status":200,"ok":true,"finalUrl":"https://aulosbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aulos-bioscience","kind":"company","name":"Aulos Bioscience","route":"/companies/aulos-bioscience/","field":"links","label":"Official website"},{"id":"aulos-bioscience","kind":"company","name":"Aulos Bioscience","route":"/companies/aulos-bioscience/","field":"website"}]},{"url":"https://www.aurabiosciences.com","status":200,"ok":true,"finalUrl":"https://www.aurabiosciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/","field":"links","label":"Official website"},{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/","field":"website"}]},{"url":"https://www.aurigene.com","status":200,"ok":true,"finalUrl":"https://www.aurigene.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/","field":"links","label":"Official website"},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/","field":"website"}]},{"url":"https://www.autolus.com","status":200,"ok":true,"finalUrl":"https://www.autolus.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/","field":"website"}]},{"url":"https://www.avenzotx.com","status":200,"ok":true,"finalUrl":"https://avenzotx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","field":"links","label":"Official website"},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","field":"website"}]},{"url":"https://www.aveooncology.com","status":200,"ok":true,"finalUrl":"https://www.aveooncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/","field":"links","label":"Official website"},{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/","field":"website"}]},{"url":"https://www.avidbio.com","status":200,"ok":true,"finalUrl":"https://avidbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","field":"links","label":"Official website"},{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","field":"website"}]},{"url":"https://www.avistonebio.com","status":200,"ok":true,"finalUrl":"https://www.avistonebio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/","field":"links","label":"Official website"},{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/","field":"website"}]},{"url":"https://www.azgroeninge.be","status":200,"ok":true,"finalUrl":"https://www.azgroeninge.be/nl","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"az-groeninge-kortrijk","kind":"institution","name":"AZ Groeninge Kortrijk Cancer Centre","route":"/institutions/az-groeninge-kortrijk/","field":"links","label":"Official website"},{"id":"az-groeninge-kortrijk","kind":"institution","name":"AZ Groeninge Kortrijk Cancer Centre","route":"/institutions/az-groeninge-kortrijk/","field":"website"}]},{"url":"https://www.azgroeninge.be/nl/patient/bestuur-directie-comites","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inge-buyse","kind":"person","name":"Inge Buyse","route":"/people/inge-buyse/","field":"links","label":"Source: AZ Groeninge 'Bestuur - Directie - Comités' page"},{"id":"inge-buyse","kind":"person","name":"Inge Buyse","route":"/people/inge-buyse/","field":"profiles","label":"AZ Groeninge board, management and committees (Dutch)"}]},{"url":"https://www.baclesse.fr","status":200,"ok":true,"finalUrl":"https://www.baclesse.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-francois-baclesse","kind":"institution","name":"Centre François Baclesse","route":"/institutions/centre-francois-baclesse/","field":"links","label":"Official website"},{"id":"centre-francois-baclesse","kind":"institution","name":"Centre François Baclesse","route":"/institutions/centre-francois-baclesse/","field":"website"}]},{"url":"https://www.baclesse.fr/decouvrir-le-centre/organisation/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/","field":"links","label":"Source: Centre François Baclesse organisation page"},{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/","field":"profiles","label":"Centre François Baclesse organisation page"}]},{"url":"https://www.baincapitallifesciences.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","field":"links","label":"Official website"},{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","field":"website"}]},{"url":"https://www.baincapitallifesciences.com/about","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","field":"links","label":"About"}]},{"url":"https://www.baincapitallifesciences.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","field":"links","label":"Portfolio"}]},{"url":"https://www.bartshealth.nhs.uk/our-board","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shane-degaris","kind":"person","name":"Shane DeGaris","route":"/people/shane-degaris/","field":"links","label":"Institution profile"},{"id":"shane-degaris","kind":"person","name":"Shane DeGaris","route":"/people/shane-degaris/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.basilea.com","status":200,"ok":true,"finalUrl":"https://www.basilea.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","field":"links","label":"Official website"},{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","field":"website"}]},{"url":"https://www.basser.org","status":200,"ok":true,"finalUrl":"https://www.basser.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"links","label":"Basser Center"},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","field":"profiles","label":"Basser Center"}]},{"url":"https://www.bauschhealth.com","status":200,"ok":true,"finalUrl":"https://www.bauschhealth.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bausch-health","kind":"company","name":"Bausch Health","route":"/companies/bausch-health/","field":"links","label":"Official website"},{"id":"bausch-health","kind":"company","name":"Bausch Health","route":"/companies/bausch-health/","field":"website"}]},{"url":"https://www.bavarian-nordic.com","status":200,"ok":true,"finalUrl":"https://www.bavarian-nordic.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","field":"links","label":"Official website"},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","field":"website"}]},{"url":"https://www.bbraun.com","status":200,"ok":true,"finalUrl":"https://www.bbraun.com/en.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","field":"links","label":"Official website"},{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","field":"website"}]},{"url":"https://www.bccancer.bc.ca","status":200,"ok":true,"finalUrl":"https://www.bccancer.bc.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","field":"links","label":"BC Cancer"},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","field":"website"}]},{"url":"https://www.bcgsc.ca","status":200,"ok":true,"finalUrl":"https://www.bcgsc.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","field":"links","label":"Michael Smith Genome Sciences Centre"}]},{"url":"https://www.bcm.edu/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/","field":"links","label":"Dan L Duncan Comprehensive Cancer Center (page moved; nearest live section)"},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/","field":"website"}]},{"url":"https://www.bcm.edu/centers/cancer-center","status":200,"ok":true,"finalUrl":"https://www.bcm.edu/academic-centers/dan-l-duncan-comprehensive-cancer-center","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","field":"profiles","label":"Baylor College of Medicine cancer centre website"}]},{"url":"https://www.bcpm.unibe.ch","status":200,"ok":true,"finalUrl":"https://www.bcpm.unibe.ch/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"Bern Center for Precision Medicine"}]},{"url":"https://www.bcrf.org","status":200,"ok":true,"finalUrl":"https://www.bcrf.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","field":"links","label":"BCRF"},{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","field":"website"}]},{"url":"https://www.bcrf.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","field":"links","label":"Breast Cancer Research Foundation"},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","field":"profiles","label":"Breast Cancer Research Foundation"},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","field":"links","label":"Breast Cancer Research Foundation"}]},{"url":"https://www.bcrf.org/about-bcrf/","status":200,"ok":true,"finalUrl":"https://www.bcrf.org/wp-content/uploads/2026/06/About-BCRF.pdf","contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","field":"links","label":"About BCRF"}]},{"url":"https://www.bcrf.org/blog/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","field":"links","label":"Breast Cancer Research Foundation"},{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","field":"url"}]},{"url":"https://www.bcrf.org/team","status":200,"ok":true,"finalUrl":"https://www.bcrf.org/team/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"donna-mckay","kind":"person","name":"Donna McKay","route":"/people/donna-mckay/","field":"links","label":"Institution profile"},{"id":"donna-mckay","kind":"person","name":"Donna McKay","route":"/people/donna-mckay/","field":"profiles","label":"Institution profile"},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","field":"links","label":"Institution profile"},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.beatson.gla.ac.uk","status":200,"ok":true,"finalUrl":"https://www.crukscotlandinstitute.ac.uk/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","field":"links","label":"CRUK Scotland Institute"}]},{"url":"https://www.beatson.scot.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.beatson.scot.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","field":"links","label":"Beatson West of Scotland Cancer Centre"},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","field":"website"}]},{"url":"https://www.beatson.scot.nhs.uk/about-us/meet-the-management-team/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sharon-armstrong","kind":"person","name":"Sharon Armstrong","route":"/people/sharon-armstrong/","field":"links","label":"Institution profile"},{"id":"sharon-armstrong","kind":"person","name":"Sharon Armstrong","route":"/people/sharon-armstrong/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.beaumont.ie","status":200,"ok":true,"finalUrl":"https://www.beaumont.ie/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beaumont-rcsi-cancer-centre","kind":"institution","name":"Beaumont RCSI Cancer Centre","route":"/institutions/beaumont-rcsi-cancer-centre/","field":"links","label":"Official website"},{"id":"beaumont-rcsi-cancer-centre","kind":"institution","name":"Beaumont RCSI Cancer Centre","route":"/institutions/beaumont-rcsi-cancer-centre/","field":"website"}],"archive":"https://web.archive.org/web/20260802205749/https://www.beaumont.ie/"},{"url":"https://www.beaumont.ie/pages/about-pages/our-people","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","field":"links","label":"Source: Beaumont Hospital 'Our People' page (hospital executive)"}],"archive":"https://web.archive.org/web/20260725183308/https://www.beaumont.ie/pages/about-pages/our-people"},{"url":"https://www.bebettermed.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/","field":"links","label":"Official website"},{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/","field":"website"}]},{"url":"https://www.becquerel.fr","status":200,"ok":true,"finalUrl":"https://www.becquerel.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","route":"/institutions/centre-henri-becquerel/","field":"links","label":"Official website"},{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","route":"/institutions/centre-henri-becquerel/","field":"website"}]},{"url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"links","label":"Source: Centre Henri Becquerel organisation page"},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"profiles","label":"Centre Henri Becquerel organisation page"}]},{"url":"https://www.begellhouse.com/journals/critical-reviews-in-oncogenesis.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","route":"/journals/critical-reviews-in-oncogenesis/","field":"links","label":"Homepage"},{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","route":"/journals/critical-reviews-in-oncogenesis/","field":"url"}]},{"url":"https://www.belmontmedtech.com/","status":200,"ok":true,"finalUrl":"https://belmontmedtech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hipec-pipac-devices","kind":"technology","name":"HIPEC perfusion pumps and PIPAC nebulisers","route":"/technologies/hipec-pipac-devices/","field":"links","label":"Belmont Medical Technologies: Hyperthermia Pump"},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","route":"/companies/belmont-medical-technologies/","field":"links","label":"Official website"},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","route":"/companies/belmont-medical-technologies/","field":"website"}]},{"url":"https://www.beonemedicines.com","status":200,"ok":true,"finalUrl":"https://beonemedicines.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/","field":"links","label":"Official website"},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/","field":"website"}]},{"url":"https://www.beonemedicines.com/","status":200,"ok":true,"finalUrl":"https://beonemedicines.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oyler-john","kind":"person","name":"John Oyler","route":"/people/oyler-john/","field":"links","label":"BeOne Medicines"},{"id":"oyler-john","kind":"person","name":"John Oyler","route":"/people/oyler-john/","field":"profiles","label":"BeOne Medicines"}]},{"url":"https://www.beonemedicines.com/pipeline/","status":200,"ok":true,"finalUrl":"https://beonemedicines.com/science/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.bergonie.fr","status":200,"ok":true,"finalUrl":"https://www.bergonie.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","field":"links","label":"Homepage"},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","field":"website"}]},{"url":"https://www.bergonie.fr/linstitut/","status":200,"ok":true,"finalUrl":"https://www.bergonie.fr/linstitut-bergonie/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","field":"links","label":"Source: Institut Bergonié institutional page naming the direction"},{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","field":"profiles","label":"Institut Bergonié presentation page"}]},{"url":"https://www.bettapharma.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","field":"links","label":"Betta Pharmaceuticals"},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/","field":"links","label":"Official website"},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/","field":"website"}]},{"url":"https://www.beyondspringpharma.com","status":200,"ok":true,"finalUrl":"https://beyondspringpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","route":"/companies/beyondspring/","field":"links","label":"Official website"},{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","route":"/companies/beyondspring/","field":"website"}]},{"url":"https://www.bicara.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","field":"links","label":"Official website"},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","field":"website"}]},{"url":"https://www.bicycletherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.bicycletherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/","field":"links","label":"Official website"},{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/","field":"website"}]},{"url":"https://www.bighatbio.com","status":200,"ok":true,"finalUrl":"https://www.bighatbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","field":"links","label":"Official website"},{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","field":"website"}]},{"url":"https://www.billiontoone.com","status":200,"ok":true,"finalUrl":"https://www.billiontoone.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"billiontoone","kind":"company","name":"BillionToOne","route":"/companies/billiontoone/","field":"links","label":"Official website"},{"id":"billiontoone","kind":"company","name":"BillionToOne","route":"/companies/billiontoone/","field":"website"}]},{"url":"https://www.bio-thera.com","status":200,"ok":true,"finalUrl":"https://www.bio-thera.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","field":"links","label":"Official website"},{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","field":"website"}]},{"url":"https://www.bio-thera.com/col_16/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","field":"links","label":"Pipeline page"}]},{"url":"https://www.bioatla.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/","field":"links","label":"Official website"},{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/","field":"website"}]},{"url":"https://www.bioatla.com/cab-portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ba3071","kind":"drug","name":"BA3071","route":"/drugs/ba3071/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.biocentury.com/","status":200,"ok":true,"finalUrl":"https://www.biocentury.com/home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","field":"links","label":"BioCentury"},{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","field":"url"}]},{"url":"https://www.biodesix.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","field":"links","label":"Official website"},{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","field":"website"}]},{"url":"https://www.biofrontera.com","status":200,"ok":true,"finalUrl":"https://www.biofrontera-us.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"biofrontera","kind":"company","name":"Biofrontera","route":"/companies/biofrontera/","field":"links","label":"Official website"},{"id":"biofrontera","kind":"company","name":"Biofrontera","route":"/companies/biofrontera/","field":"website"}]},{"url":"https://www.biogen.com","status":200,"ok":true,"finalUrl":"https://www.biogen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","field":"links","label":"Official website"},{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","field":"website"}]},{"url":"https://www.bioinvent.com","status":200,"ok":true,"finalUrl":"https://www.bioinvent.com/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","field":"links","label":"Official website"},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","field":"website"}]},{"url":"https://www.biolifesolutions.com","status":200,"ok":true,"finalUrl":"https://biolifesolutions.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","route":"/companies/biolife-solutions/","field":"links","label":"Official website"},{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","route":"/companies/biolife-solutions/","field":"website"}],"archive":"https://web.archive.org/web/20260908114442/https://biolifesolutions.com/"},{"url":"https://www.biolinerx.com","status":200,"ok":true,"finalUrl":"https://biolinerx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","field":"links","label":"Official website"},{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","field":"website"}]},{"url":"https://www.biolitec.com","status":200,"ok":true,"finalUrl":"https://www.biolitec.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biolitec","kind":"company","name":"biolitec","route":"/companies/biolitec/","field":"links","label":"Official website"},{"id":"biolitec","kind":"company","name":"biolitec","route":"/companies/biolitec/","field":"website"}]},{"url":"https://www.biontech.com","status":200,"ok":true,"finalUrl":"https://www.biontech.com/us/en/home.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","field":"links","label":"Official website"},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","field":"website"}]},{"url":"https://www.biopharmadive.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","field":"links","label":"BioPharma Dive"},{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","field":"url"}]},{"url":"https://www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","route":"/companies/emergence-therapeutics/","field":"links","label":"BioPharma Dive: Lilly to acquire Emergence"}]},{"url":"https://www.bioptimus.com","status":200,"ok":true,"finalUrl":"https://www.bioptimus.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bioptimus","kind":"company","name":"Bioptimus","route":"/companies/bioptimus/","field":"links","label":"Official website"},{"id":"bioptimus","kind":"company","name":"Bioptimus","route":"/companies/bioptimus/","field":"website"}]},{"url":"https://www.biorxiv.org","status":200,"ok":true,"finalUrl":"https://www.biorxiv.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","field":"url"}]},{"url":"https://www.biorxiv.org/about-biorxiv","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","field":"links","label":"About bioRxiv"}]},{"url":"https://www.biorxiv.org/collection/cancer-biology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","field":"links","label":"bioRxiv cancer biology collection"}]},{"url":"https://www.biorxiv.org/content/10.1101/2023.10.16.562533v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genept","kind":"technology","name":"GenePT","route":"/technologies/genept/","field":"links","label":"bioRxiv 2023"}]},{"url":"https://www.biorxiv.org/content/10.1101/2023.11.28.568918v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"universal-cell-embedding","kind":"technology","name":"Universal Cell Embedding (UCE)","route":"/technologies/universal-cell-embedding/","field":"links","label":"bioRxiv 2023"}]},{"url":"https://www.biorxiv.org/content/10.1101/2024.04.15.589472v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicheformer","kind":"technology","name":"Nicheformer (spatial single-cell)","route":"/technologies/nicheformer/","field":"links","label":"bioRxiv 2024"}]},{"url":"https://www.biorxiv.org/content/10.1101/2024.06.04.597369v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cellfm","kind":"technology","name":"CellFM","route":"/technologies/cellfm/","field":"links","label":"bioRxiv 2024"}]},{"url":"https://www.biorxiv.org/content/10.1101/2024.11.19.624167v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/","field":"links","label":"Boltz-1 bioRxiv 2024"}]},{"url":"https://www.biorxiv.org/content/10.1101/2025.02.18.638918v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evo2","kind":"technology","name":"Evo 2 (Arc Institute, NVIDIA)","route":"/technologies/evo2/","field":"links","label":"Evo 2 bioRxiv 2025"}]},{"url":"https://www.biorxiv.org/content/10.1101/2025.02.20.639398v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","route":"/collections/tahoe-100m/","field":"links","label":"Tahoe-100M"},{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","route":"/collections/tahoe-100m/","field":"url"}]},{"url":"https://www.biorxiv.org/content/10.1101/2025.04.14.648850v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"c2s-scale","kind":"technology","name":"Cell2Sentence / C2S-Scale (Yale, Google)","route":"/technologies/c2s-scale/","field":"links","label":"C2S-Scale bioRxiv 2025"}]},{"url":"https://www.biorxiv.org/content/10.1101/2025.06.26.661135v1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"state-arc","kind":"technology","name":"State (Arc Institute perturbation model)","route":"/technologies/state-arc/","field":"links","label":"State bioRxiv 2025"}]},{"url":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"links","label":"Official website"},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"website"}]},{"url":"https://www.biospace.com/business/gilead-swallows-another-partner-paying-up-to-5-b-for-adc-specialist-tubulis","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/","field":"links","label":"Gilead acquisition"}]},{"url":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","route":"/companies/mablink-bioscience/","field":"links","label":"Acquisition announcement (BioSpace copy)"}]},{"url":"https://www.biospace.com/mythic-therapeutics-launches-with-new-approach-to-improving-antibody-drug-conjugate-performance-backed-by-103-million-in-series-b-financing","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","field":"links","label":"Series B press release (BioSpace copy)"}]},{"url":"https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","field":"links","label":"Official website"},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","field":"website"}]},{"url":"https://www.biospace.com/press-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","field":"links","label":"H1 2026 results"}]},{"url":"https://www.biospace.com/press-releases/delfi-diagnostics-to-present-first-clinical-utility-data-for-blood-based-lung-cancer-screening-at-ats-2026-international-conference","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","route":"/companies/delfi-diagnostics/","field":"links","label":"ATS 2026"},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","field":"links","label":"DELFI FIRSTLUNG at ATS 2026"}]},{"url":"https://www.biospace.com/press-releases/generate-biomedicines-inc-reports-second-quarter-2026-financial-results-and-provides-business-update","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","field":"links","label":"Q2 2026 business update"},{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/","field":"links","label":"Generate Biomedicines Q2 2026"}]},{"url":"https://www.biospace.com/press-releases/izalontamab-brengitecan-iza-bren-demonstrates-statistically-significant-and-clinically-meaningful-improvements-in-overall-survival-and-progression-free-survival-in-patients-with-triple-negative-breast-cancer-and-esophageal-squamous-cell-carcinoma","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","field":"links","label":"Announcement"}]},{"url":"https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","field":"links","label":"Assignment for benefit of creditors and IP sale notice"}]},{"url":"https://www.biospace.com/press-releases/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/","field":"links","label":"AACR 2026 pipeline data"}]},{"url":"https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","field":"links","label":"Strategic reorganisation"}]},{"url":"https://www.biospace.com/sengine-precision-medicine-receives-new-york-state-clep-approval-for-paris-test","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/","field":"links","label":"NY CLEP approval"}]},{"url":"https://www.biospace.com/transthera-announces-the-global-multicenter-phase-3-clinical-trial-completed-first-patient-dosing-in-the-us-evaluating-tinengotinib-in-fgfri-relapsed-refractory-patients-with-cholangiocarcinoma","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"first-308","kind":"trial","name":"FIRST-308","route":"/trials/first-308/","field":"links","label":"TransThera announcement"}]},{"url":"https://www.birmingham.ac.uk/research/crctu","status":200,"ok":true,"finalUrl":"https://www.birmingham.ac.uk/research/centres-institutes/cancer-research-uk-clinical-trials-unit","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","field":"links","label":"CRUK Clinical Trials Unit"}]},{"url":"https://www.birmingham.ac.uk/staff/profiles/applied-health/morton-dion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dion-morton","kind":"person","name":"Dion Morton","route":"/people/dion-morton/","field":"links","label":"University of Birmingham staff page"},{"id":"dion-morton","kind":"person","name":"Dion Morton","route":"/people/dion-morton/","field":"profiles","label":"University of Birmingham staff page"}]},{"url":"https://www.birmingham.ac.uk/staff/profiles/immunology-immunotherapy/middleton-gary","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gary-middleton","kind":"person","name":"Gary Middleton","route":"/people/gary-middleton/","field":"links","label":"University of Birmingham staff page"},{"id":"gary-middleton","kind":"person","name":"Gary Middleton","route":"/people/gary-middleton/","field":"profiles","label":"University of Birmingham staff page"}]},{"url":"https://www.blueearthdiagnostics.com","status":200,"ok":true,"finalUrl":"https://www.blueearthdiagnostics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","field":"links","label":"Official website"},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","field":"website"}],"archive":"https://web.archive.org/web/20260608173215/https://www.blueearthdiagnostics.com/"},{"url":"https://www.bms.com","status":200,"ok":true,"finalUrl":"https://www.bms.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"links","label":"Official website"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"website"}]},{"url":"https://www.bms.com/researchers-and-partners/in-the-pipeline.html","status":200,"ok":true,"finalUrl":"https://www.bms.com/research-and-development/pipeline.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.bococ.org.cy","status":200,"ok":true,"finalUrl":"https://www.bococ.org.cy/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","field":"links","label":"Bank of Cyprus Oncology Centre website"},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","field":"profiles","label":"Bank of Cyprus Oncology Centre website"},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","route":"/institutions/bank-of-cyprus-oncology-centre/","field":"links","label":"Official website"},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","route":"/institutions/bank-of-cyprus-oncology-centre/","field":"website"}]},{"url":"https://www.boehringer-ingelheim.com","status":200,"ok":true,"finalUrl":"https://www.boehringer-ingelheim.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","field":"links","label":"Official website"},{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","field":"website"}]},{"url":"https://www.boehringer-ingelheim.com/bioxcellence","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/","field":"links","label":"Official website"},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/","field":"website"}]},{"url":"https://www.boltbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","route":"/companies/bolt-biotherapeutics/","field":"links","label":"Official website"},{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","route":"/companies/bolt-biotherapeutics/","field":"website"}]},{"url":"https://www.borderline24.com/2024/03/26/istituto-tumori-bari-e-vito-campanile-il-nuovo-direttore-sanitario/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"links","label":"Source: Borderline24 report naming him Direttore Generale (March 2024)"}]},{"url":"https://www.borderline24.com/2025/11/28/listituto-tumori-giovanni-paolo-ii-di-bari-conquista-arezzo-con-lia-in-sanita/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"links","label":"Source: Borderline24 report, Commissario Straordinario (November 2025)"},{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","field":"profiles","label":"Borderline24 report naming him Commissario Straordinario (November 2025)"}]},{"url":"https://www.bordet.be","status":200,"ok":true,"finalUrl":"https://www.bordet.be/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","field":"links","label":"Institut Jules Bordet website"},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","field":"profiles","label":"Institut Jules Bordet website"},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"links","label":"Homepage"},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"website"}]},{"url":"https://www.bordet.be/fr/organisation-institut-jules-bordet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","route":"/people/renaud-witmeur/","field":"links","label":"Source: Institut Jules Bordet organisation and governance page"},{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","route":"/people/renaud-witmeur/","field":"profiles","label":"Institut Jules Bordet organisation page"}]},{"url":"https://www.bostonscientific.com","status":200,"ok":true,"finalUrl":"https://www.bostonscientific.com/en-US/home.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"links","label":"Official website"},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"website"}]},{"url":"https://www.bowelcanceruk.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK"},{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"links","label":"Bowel Cancer UK"},{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"website"}]},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/advanced-bowel-cancer/treating-advanced-bowel-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: treating advanced bowel cancer"},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","field":"links","label":"Bowel Cancer UK: treating advanced bowel cancer"}],"archive":"https://web.archive.org/web/20260510022917/https://www.bowelcanceruk.org.uk/about-bowel-cancer/advanced-bowel-cancer/treating-advanced-bowel-cancer/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/diagnosis/questions-to-ask/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: questions to ask at your hospital appointment"}],"archive":"https://web.archive.org/web/20260501084208/https://www.bowelcanceruk.org.uk/about-bowel-cancer/diagnosis/questions-to-ask/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/end-of-life-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: end of life care"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Bowel Cancer UK: end of life care"}],"archive":"https://web.archive.org/web/20260609055636/https://www.bowelcanceruk.org.uk/about-bowel-cancer/end-of-life-care/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/body-image-and-sex/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: body image and sex"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Bowel Cancer UK: body image and sex"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Bowel Cancer UK: body image and sex"}],"archive":"https://web.archive.org/web/20260520072756/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/body-image-and-sex/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/change-in-bowel-habit-after-treatment/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: change in bowel habit after treatment"},{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"links","label":"Bowel Cancer UK: change in bowel habit after treatment"}],"archive":"https://web.archive.org/web/20260501084254/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/change-in-bowel-habit-after-treatment/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/diet-after-treatment/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: diet after treatment"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Bowel Cancer UK: diet after treatment"}],"archive":"https://web.archive.org/web/20260501084124/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/diet-after-treatment/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/emotional-wellbeing/supporting-someone-with-bowel-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: supporting someone with bowel cancer"},{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"Bowel Cancer UK: supporting someone with bowel cancer"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Bowel Cancer UK: supporting someone with bowel cancer"}],"archive":"https://web.archive.org/web/20260501084305/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/emotional-wellbeing/supporting-someone-with-bowel-cancer/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/fertility/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: fertility"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Bowel Cancer UK: fertility"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Bowel Cancer UK: fertility"}],"archive":"https://web.archive.org/web/20260611064623/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/fertility/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/long-term-and-late-side-effects/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: long term and late side effects"},{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Bowel Cancer UK: long term and late side effects"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"Bowel Cancer UK: long term and late side effects"},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Bowel Cancer UK: long term and late side effects"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Bowel Cancer UK: long term and late side effects"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","field":"links","label":"Bowel Cancer UK: long term and late side effects"}],"archive":"https://web.archive.org/web/20260501084209/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/long-term-and-late-side-effects/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/sleep-and-fatigue/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: sleep and fatigue"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Bowel Cancer UK: sleep and fatigue"}],"archive":"https://web.archive.org/web/20260611075243/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/sleep-and-fatigue/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/work,-money-and-travel/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: work, money and travel"},{"id":"work-and-money-bowel-cancer-uk","kind":"term","name":"Work and money with bowel cancer (UK)","route":"/terms/work-and-money-bowel-cancer-uk/","field":"links","label":"Bowel Cancer UK: work, money and travel"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Bowel Cancer UK: work, money and travel"}],"archive":"https://web.archive.org/web/20260611070904/https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/work,-money-and-travel/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/risk-factors/family-history/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","field":"links","label":"Bowel Cancer UK: family history"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Bowel Cancer UK: family history"}]},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/screening/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"links","label":"Screening in the four nations"}]},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: clinical trials"}],"archive":"https://web.archive.org/web/20260611070704/https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/clinical-trials/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/getting-a-second-opinion/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: getting a second opinion"}],"archive":"https://web.archive.org/web/20260615044836/https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/getting-a-second-opinion/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/prehabilitation/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: prehabilitation, preparing for treatment"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Bowel Cancer UK: prehabilitation, preparing for treatment"},{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","field":"links","label":"Bowel Cancer UK: prehabilitation, preparing for treatment"},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"links","label":"Bowel Cancer UK: prehabilitation, preparing for treatment"}],"archive":"https://web.archive.org/web/20260611071944/https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/prehabilitation/"},{"url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/surgery/stomas/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: stomas"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"Bowel Cancer UK: stomas"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Bowel Cancer UK: stomas"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"Bowel Cancer UK: stomas"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Bowel Cancer UK: stomas"}],"archive":"https://web.archive.org/web/20260520080141/https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/surgery/stomas/"},{"url":"https://www.bowelcanceruk.org.uk/campaigning/never-too-young/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"links","label":"Never Too Young"}]},{"url":"https://www.bowelcanceruk.org.uk/campaigning/never-too-young/lynch-syndrome/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Bowel Cancer UK: Lynch syndrome"},{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","field":"links","label":"Bowel Cancer UK: Lynch syndrome"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Bowel Cancer UK: Lynch syndrome"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"Bowel Cancer UK: Lynch syndrome"},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","field":"links","label":"Bowel Cancer UK: Lynch syndrome"}],"archive":"https://web.archive.org/web/20260908025339/https://www.bowelcanceruk.org.uk/campaigning/never-too-young/lynch-syndrome/"},{"url":"https://www.bowelcanceruk.org.uk/campaigning/policy-reports-and-consultations/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"links","label":"Policy reports"}]},{"url":"https://www.bowelcanceruk.org.uk/how-we-can-help/ask-the-nurse/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","field":"links","label":"Ask the Nurse"}]},{"url":"https://www.bowelcanceruk.org.uk/how-we-can-help/family-friends-carers-support/taking-care-of-yourself/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"Bowel Cancer UK: taking care of yourself as a carer"}]},{"url":"https://www.boxercap.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/","field":"links","label":"Official website"},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/","field":"website"}]},{"url":"https://www.boxercap.com/venture-highlights/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/","field":"links","label":"Venture highlights"}]},{"url":"https://www.bp.org.br","status":200,"ok":true,"finalUrl":"https://www.bp.org.br/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bp-beneficencia-portuguesa","kind":"institution","name":"BP - A Beneficência Portuguesa de São Paulo","route":"/institutions/bp-beneficencia-portuguesa/","field":"links","label":"Official website"},{"id":"bp-beneficencia-portuguesa","kind":"institution","name":"BP - A Beneficência Portuguesa de São Paulo","route":"/institutions/bp-beneficencia-portuguesa/","field":"website"}],"archive":"https://web.archive.org/web/20260909175100/https://www.bp.org.br/"},{"url":"https://www.bp.org.br/institucional/governanca-corporativa/","status":200,"ok":true,"finalUrl":"https://www.bp.org.br/institucional/governanca-corporativa","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"denise-soares-dos-santos","kind":"person","name":"Denise Soares dos Santos","route":"/people/denise-soares-dos-santos/","field":"links","label":"Source: BP 'Governança corporativa' page"},{"id":"denise-soares-dos-santos","kind":"person","name":"Denise Soares dos Santos","route":"/people/denise-soares-dos-santos/","field":"profiles","label":"BP corporate governance page (Portuguese)"}]},{"url":"https://www.bpifrance.com","status":200,"ok":true,"finalUrl":"https://www.bpifrance.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","field":"links","label":"Official website"},{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","field":"website"}]},{"url":"https://www.brainlab.com","status":200,"ok":true,"finalUrl":"https://www.brainlab.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","field":"links","label":"Official website"},{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","field":"website"}]},{"url":"https://www.brainlab.com/radiosurgery-products/exactrac/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"in-room-imaging-systems","kind":"technology","name":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","route":"/technologies/in-room-imaging-systems/","field":"links","label":"Brainlab: ExacTrac Dynamic"}]},{"url":"https://www.breastcancerindex.com","status":200,"ok":true,"finalUrl":"https://www.breastcancerindex.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/","field":"links","label":"Breast Cancer Index"}]},{"url":"https://www.breastcancertrials.org.au","status":200,"ok":true,"finalUrl":"https://www.breastcancertrials.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/","field":"links","label":"Breast Cancer Trials"},{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/","field":"website"}]},{"url":"https://www.breastcancertrials.org.au/clinical-trials/","status":200,"ok":true,"finalUrl":"https://www.breastcancertrials.org.au/publications/clinical-trials-and-local-treatment-of-early-breast-cancer/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/","field":"links","label":"Clinical trials"}]},{"url":"https://www.breastcancertrials.org.au/our-people/board-of-directors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","field":"links","label":"Institution profile"},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.bristolft.nhs.uk/about-us/our-board/chief-executive-and-executive-directors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maria-kane","kind":"person","name":"Maria Kane","route":"/people/maria-kane/","field":"links","label":"Source: UHBW 'Chief executive and executive directors' page"},{"id":"maria-kane","kind":"person","name":"Maria Kane","route":"/people/maria-kane/","field":"profiles","label":"UHBW board: chief executive and executive directors"}]},{"url":"https://www.broadinstitute.org","status":200,"ok":true,"finalUrl":"https://www.broadinstitute.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","field":"links","label":"Official website"},{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","field":"website"}]},{"url":"https://www.broadinstitute.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eli-broad","kind":"person","name":"Eli Broad","route":"/people/eli-broad/","field":"links","label":"Broad Institute"}]},{"url":"https://www.broadinstitute.org/bios/bradley-e-bernstein","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","field":"links","label":"Broad bio"},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","field":"profiles","label":"Broad bio"}]},{"url":"https://www.broadinstitute.org/bios/feng-zhang","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","field":"links","label":"Broad bio"},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","field":"profiles","label":"Broad bio"}]},{"url":"https://www.broadinstitute.org/bios/gad-getz","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"links","label":"Broad bio"},{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","field":"profiles","label":"Broad bio"}]},{"url":"https://www.broadinstitute.org/bios/matthew-meyerson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"links","label":"Broad bio"},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","field":"profiles","label":"Broad bio"}]},{"url":"https://www.broadinstitute.org/bios/todd-r-golub","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"links","label":"Broad bio"},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","field":"profiles","label":"Broad bio"}]},{"url":"https://www.brucepower.com","status":200,"ok":true,"finalUrl":"https://www.brucepower.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bruce-power","kind":"company","name":"Bruce Power","route":"/companies/bruce-power/","field":"links","label":"Official website"},{"id":"bruce-power","kind":"company","name":"Bruce Power","route":"/companies/bruce-power/","field":"website"}]},{"url":"https://www.bruker.com","status":200,"ok":true,"finalUrl":"https://www.bruker.com/en.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/","field":"links","label":"Official website"},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/","field":"website"}]},{"url":"https://www.bsg.org.uk/clinical-resource","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gut","kind":"journal","name":"Gut","route":"/journals/gut/","field":"links","label":"British Society of Gastroenterology guidelines"}]},{"url":"https://www.bswhealth.com","status":200,"ok":true,"finalUrl":"https://www.bswhealth.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","route":"/institutions/baylor-sammons-dallas/","field":"links","label":"Baylor Scott & White Health"},{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","route":"/institutions/baylor-sammons-dallas/","field":"website"}]},{"url":"https://www.bulsarabio.com","status":200,"ok":true,"finalUrl":"https://www.bulsarabio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","route":"/companies/bulsara-bioworks/","field":"website"}]},{"url":"https://www.butterflynetwork.com","status":200,"ok":true,"finalUrl":"https://www.butterflynetwork.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hand-held-ultrasound","kind":"technology","name":"Hand-held and point-of-care ultrasound","route":"/technologies/hand-held-ultrasound/","field":"links","label":"Butterfly Network"},{"id":"butterfly-network","kind":"company","name":"Butterfly Network","route":"/companies/butterfly-network/","field":"links","label":"Official website"},{"id":"butterfly-network","kind":"company","name":"Butterfly Network","route":"/companies/butterfly-network/","field":"website"}]},{"url":"https://www.buzer.de/gesetz/17632/a340690.htm","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"links","label":"GKV-Beitragssatzstabilisierungsgesetz 2026: the amending text that repealed the guardrails"}]},{"url":"https://www.byondis.com/","status":200,"ok":true,"finalUrl":"https://byondis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"byondis","kind":"company","name":"Byondis","route":"/companies/byondis/","field":"links","label":"Official website"},{"id":"byondis","kind":"company","name":"Byondis","route":"/companies/byondis/","field":"website"}]},{"url":"https://www.caliberid.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"caliber-imaging-diagnostics","kind":"company","name":"Caliber Imaging and Diagnostics","route":"/companies/caliber-imaging-diagnostics/","field":"links","label":"Official website"},{"id":"caliber-imaging-diagnostics","kind":"company","name":"Caliber Imaging and Diagnostics","route":"/companies/caliber-imaging-diagnostics/","field":"website"}]},{"url":"https://www.calyx.ai","status":200,"ok":true,"finalUrl":"https://www.perceptive.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/","field":"links","label":"Official website"},{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/","field":"website"}]},{"url":"https://www.cam.ac.uk/research/news/new-approach-to-treating-aggressive-breast-cancers-shows-significant-improvement-in-survival","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/","field":"links","label":"University of Cambridge news: PARTNER results"},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/","field":"profiles","label":"University of Cambridge news: PARTNER results"},{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/","field":"links","label":"University of Cambridge news release"}]},{"url":"https://www.cambridgecancer.org.uk","status":200,"ok":true,"finalUrl":"https://www.cambridgecancer.org.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","field":"links","label":"Cambridge Cancer Research Hospital"}]},{"url":"https://www.camurus.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"camurus","kind":"company","name":"Camurus","route":"/companies/camurus/","field":"links","label":"Official website"},{"id":"camurus","kind":"company","name":"Camurus","route":"/companies/camurus/","field":"website"}]},{"url":"https://www.canada.ca/en/health-canada.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","field":"links","label":"Health Canada"},{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","field":"website"}]},{"url":"https://www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/deputy-minister.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","route":"/people/shalene-curtis-micallef/","field":"links","label":"Source: Health Canada Deputy Minister page"},{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","route":"/people/shalene-curtis-micallef/","field":"profiles","label":"Health Canada profile"}]},{"url":"https://www.canada.ca/en/health-canada/services/drugs-health-products.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","field":"links","label":"Drug and health products"}]},{"url":"https://www.canariabio.com","status":200,"ok":true,"finalUrl":"https://www.canariabio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/","field":"links","label":"Sponsor page"}]},{"url":"https://www.cancer.columbia.edu","status":200,"ok":true,"finalUrl":"https://www.cancer.columbia.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/","field":"links","label":"Herbert Irving Comprehensive Cancer Center"},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/","field":"website"}]},{"url":"https://www.cancer.columbia.edu/about-us/irving-family","status":200,"ok":true,"finalUrl":"https://www.cancer.columbia.edu/about-us/about-herbert-irving-comprehensive-cancer-center/irving-family","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"herbert-irving","kind":"person","name":"Herbert Irving","route":"/people/herbert-irving/","field":"links","label":"Herbert Irving Comprehensive Cancer Center: the Irving family"}]},{"url":"https://www.cancer.fr","status":200,"ok":true,"finalUrl":"https://www.cancer.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","field":"links","label":"Homepage"},{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","field":"website"}]},{"url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nicolas-scotte","kind":"person","name":"Nicolas Scotté","route":"/people/nicolas-scotte/","field":"links","label":"Institution profile"},{"id":"nicolas-scotte","kind":"person","name":"Nicolas Scotté","route":"/people/nicolas-scotte/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances/conseil-d-administration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","field":"links","label":"Institution profile"},{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cancer.fr/professionnels-de-la-recherche","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","field":"links","label":"Research"}]},{"url":"https://www.cancer.gov","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","field":"links","label":"Official website"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","field":"website"}]},{"url":"https://www.cancer.gov/about-cancer/causes-prevention","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/","field":"links","label":"NCI: Cancer causes and prevention"}]},{"url":"https://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/publications/pdq/information-summaries/genetics/overview-hp-pdq","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","field":"links","label":"NCI Cancer Genetics Overview (PDQ)"}]},{"url":"https://www.cancer.gov/about-cancer/coping/survivorship","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","field":"links","label":"NCI: Survivorship"}]},{"url":"https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/","field":"links","label":"NCI: Cancer diagnosis, including imaging tests"}]},{"url":"https://www.cancer.gov/about-cancer/screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/","field":"links","label":"NCI: Cancer screening"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"links","label":"NCI PDQ Integrative, Alternative, and Complementary Therapies summaries"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/acupuncture-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","field":"links","label":"NCI PDQ: Acupuncture"},{"id":"acupuncture-xerostomia","kind":"technology","name":"Acupuncture for dry mouth after head and neck radiotherapy","route":"/technologies/acupuncture-xerostomia/","field":"links","label":"NCI PDQ: Acupuncture"},{"id":"acupuncture-chemotherapy-neuropathy","kind":"technology","name":"Acupuncture for chemotherapy-induced neuropathy","route":"/technologies/acupuncture-chemotherapy-neuropathy/","field":"links","label":"NCI PDQ: Acupuncture"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/antineoplastons-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antineoplastons","kind":"technology","name":"Antineoplastons (Burzynski clinic)","route":"/technologies/antineoplastons/","field":"links","label":"NCI PDQ: Antineoplastons"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/aromatherapy-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aromatherapy-cancer","kind":"technology","name":"Aromatherapy","route":"/technologies/aromatherapy-cancer/","field":"links","label":"NCI PDQ: Aromatherapy with essential oils"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cannabinoids-nausea","kind":"technology","name":"Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)","route":"/technologies/cannabinoids-nausea/","field":"links","label":"NCI PDQ: Cannabis and cannabinoids"},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","field":"links","label":"NCI PDQ: Cannabis and cannabinoids"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/cartilage-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/","field":"links","label":"NCI PDQ: Cartilage (bovine and shark)"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","field":"links","label":"NCI PDQ: Curcumin (curcuma, turmeric) and cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"essiac-herbal-cancer-cures","kind":"technology","name":"Essiac, Hoxsey and other 'herbal cancer cures'","route":"/technologies/essiac-herbal-cancer-cures/","field":"links","label":"NCI PDQ: Essiac/Flor Essence"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/gerson-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gerson-therapy-detox-regimens","kind":"technology","name":"Gerson therapy, coffee enemas and 'detox' regimens","route":"/technologies/gerson-therapy-detox-regimens/","field":"links","label":"NCI PDQ: Gerson therapy"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laetrile-amygdalin","kind":"technology","name":"Laetrile (amygdalin, 'vitamin B17')","route":"/technologies/laetrile-amygdalin/","field":"links","label":"NCI PDQ: Laetrile/amygdalin"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","field":"links","label":"NCI PDQ: Mistletoe extracts"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/mushrooms-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","field":"links","label":"NCI PDQ: Medicinal mushrooms"},{"id":"medicinal-mushrooms-reishi-turkey-tail","kind":"technology","name":"Medicinal mushrooms: reishi, turkey tail, shiitake and others","route":"/technologies/medicinal-mushrooms-reishi-turkey-tail/","field":"links","label":"NCI PDQ: Medicinal mushrooms"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/","field":"links","label":"NCI PDQ: High-dose vitamin C"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/research/infrastructure/clinical-trials/featured/nci-match","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","field":"links","label":"NCI: NCI-MATCH trial"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pediatric-match","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/research/infrastructure/clinical-trials/featured/pediatric-match","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","field":"links","label":"NCI: Pediatric MATCH"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/alemtuzumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/amifostine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/aminolevulinicacid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/aprepitant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/bexarotene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/busulfan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/carmustine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/carmustineimplant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","field":"links","label":"NCI page (carmustine implant)"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/chlorambucil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/clofarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/cytarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/dacarbazine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/darbepoetinalfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/decitabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/defibrotide-sodium","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/denileukindiftitox-cxdl","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/denosumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/dexamethasone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/epirubicinhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/epoetinalfa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/filgrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/fludarabinephosphate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/flutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/glucarpidase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/granisetron","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/granisetronhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","field":"links","label":"NCI page (granisetron hydrochloride)"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/idarubicinhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/imiquimod","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/iobenguanei131","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ixabepilone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/mechlorethaminehydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/megestrolacetate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/mercaptopurine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/mesna","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/methylnaltrexonebromide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/mitoxantronehydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/necitumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/nelarabine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/netupitant-palonosetronhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/nilutamide","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ofatumumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ofatumumab","kind":"drug","name":"Ofatumumab","route":"/drugs/ofatumumab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/omacetaxinemepesuccinate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ondansetronhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/palifermin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/palonosetronhydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/pamidronatedisodium","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/pegfilgrastim","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/plerixafor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/prednisone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/procarbazinehydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/raloxifenehydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/rasburicase","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/recombinant-hpv-bivalent-vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/recombinant-hpv-quadrivalent-vaccine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/rolapitanthydrochloride","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/selumetinibsulfate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/siltuximab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/sirolimus-protein-bound-particles","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/talc","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/thioguanine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/thiotepa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/tocilizumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/toremifene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/trametinib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/triptorelin-pamoate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/uridinetriacetate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/valrubicin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valrubicin","kind":"drug","name":"Valrubicin","route":"/drugs/valrubicin/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/vorinostat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vorinostat","kind":"drug","name":"Vorinostat","route":"/drugs/vorinostat/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ziv-aflibercept","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/zoledronicacid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","field":"links","label":"NCI drug page"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","field":"links","label":"NCI: Side effects of cancer treatment"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"NCI PDQ: lymphedema (health professional version)"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/","field":"links","label":"NCI: Biomarker testing for cancer treatment"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","field":"links","label":"NCI: Chemotherapy to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/hormone-therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","field":"links","label":"NCI: Hormone therapy to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/hyperthermia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","field":"links","label":"NCI: Hyperthermia to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","field":"links","label":"NCI: Immunotherapy to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/","field":"links","label":"NCI: T-cell transfer therapy"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","field":"links","label":"NCI: Radiation therapy to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/","field":"links","label":"NCI: Surgery to treat cancer"}]},{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","field":"links","label":"NCI: Targeted therapy to treat cancer"}]},{"url":"https://www.cancer.gov/about-nci/leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"links","label":"NCI leadership"},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","field":"profiles","label":"NCI leadership"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"links","label":"NCI leadership"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","field":"profiles","label":"NCI leadership"}]},{"url":"https://www.cancer.gov/about-nci/organization/crchd","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","field":"links","label":"NCI Center to Reduce Cancer Health Disparities"}]},{"url":"https://www.cancer.gov/ccg/research/functional-genomics/hcmi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","route":"/ideas/idea-tr2-organoid-matrix-atlas/","field":"links","label":"Cancer Models (HCMI)"},{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/","field":"links","label":"Human Cancer Models Initiative"}]},{"url":"https://www.cancer.gov/contact","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-cancer-information-service","kind":"collection","name":"NCI Cancer Information Service","route":"/collections/nci-cancer-information-service/","field":"links","label":"NCI Cancer Information Service"},{"id":"nci-cancer-information-service","kind":"collection","name":"NCI Cancer Information Service","route":"/collections/nci-cancer-information-service/","field":"url"}]},{"url":"https://www.cancer.gov/pediatric-adult-rare-tumor","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/pediatric-adult-rare-tumor/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","field":"links","label":"NCI MyPART"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligufalimab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","field":"links","label":"NCI Drug Dictionary: ligufalimab"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oleclumab","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/","field":"links","label":"NCI Drug Dictionary: oleclumab"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/onvansertib","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/","field":"links","label":"NCI Drug Dictionary: onvansertib"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/","field":"links","label":"NCI: Dictionary of Cancer Terms: antibody-drug conjugate"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/dose-limiting","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dose-limiting-toxicity","kind":"term","name":"Dose-limiting toxicity (DLT)","route":"/terms/dose-limiting-toxicity/","field":"links","label":"NCI Dictionary of Cancer Terms: dose-limiting"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/double-hit-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","field":"links","label":"NCI Dictionary of Cancer Terms: double-hit lymphoma"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/epigenetics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/","field":"links","label":"NCI: Dictionary of Cancer Terms: epigenetics"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/first-line-therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","field":"links","label":"NCI Dictionary of Cancer Terms: first-line therapy"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2-low-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","field":"links","label":"NCI Dictionary of Cancer Terms: HER2-low breast cancer"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hot-tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","field":"links","label":"NCI Dictionary of Cancer Terms: hot tumor"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/malnutrition","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"malnutrition-screening","kind":"term","name":"Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)","route":"/terms/malnutrition-screening/","field":"links","label":"NCI Dictionary of Cancer Terms: malnutrition"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oligometastasis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","field":"links","label":"NCI Dictionary of Cancer Terms: oligometastasis"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ovarian-suppression","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ovarian-function-suppression","kind":"term","name":"Ovarian function suppression (OFS)","route":"/terms/ovarian-function-suppression/","field":"links","label":"NCI Dictionary of Cancer Terms: ovarian suppression"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/radiopharmaceutical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/","field":"links","label":"NCI: Dictionary of Cancer Terms: radiopharmaceutical"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/refractory-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/","field":"links","label":"NCI Dictionary of Cancer Terms: refractory cancer"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/secondary-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/","field":"links","label":"NCI Dictionary of Cancer Terms: secondary cancer"}]},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ulceration","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","field":"links","label":"NCI Dictionary of Cancer Terms: ulceration"}]},{"url":"https://www.cancer.gov/publications/pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","route":"/collections/cancer-gov-pdq/","field":"links","label":"NCI PDQ Cancer Information Summaries"},{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","route":"/collections/cancer-gov-pdq/","field":"url"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"links","label":"NCI PDQ Cancer Information Summaries"},{"id":"idea-moon-verified-information-layer","kind":"idea","name":"A verified information layer that labels and links cancer content across platforms","route":"/ideas/idea-moon-verified-information-layer/","field":"links","label":"NCI PDQ cancer information summaries"}]},{"url":"https://www.cancer.gov/research/areas/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","field":"links","label":"NCI: Cancer treatment research"}]},{"url":"https://www.cancer.gov/research/infrastructure/artificial-intelligence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/","field":"links","label":"NCI: Artificial intelligence in cancer research"}]},{"url":"https://www.cancer.gov/research/infrastructure/cancer-centers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/","field":"links","label":"NCI-Designated Cancer Centers"},{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/","field":"url"}]},{"url":"https://www.cancer.gov/research/infrastructure/cancer-centers/find/baylorduncan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","field":"links","label":"Source: National Cancer Institute cancer centre listing naming the Director"},{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","field":"profiles","label":"NCI cancer centre listing: Dan L Duncan Comprehensive Cancer Center"}]},{"url":"https://www.cancer.gov/research/key-initiatives/ras","status":200,"ok":true,"finalUrl":"https://frederick.cancer.gov/initiatives/ras-initiative","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","field":"links","label":"NCI RAS Initiative"},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","field":"links","label":"NCI RAS Initiative"}]},{"url":"https://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/adrenocortical/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"links","label":"NCI PDQ: adrenocortical carcinoma"}]},{"url":"https://www.cancer.gov/types/anal/patient/anal-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/anal/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"links","label":"NCI PDQ: anal cancer"}]},{"url":"https://www.cancer.gov/types/aya","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","field":"links","label":"NCI AYA cancers"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"links","label":"NCI: Adolescents and Young Adults with Cancer"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"standardOfCare.guideline (Acute lymphoblastic leukaemia, 15 to 39)"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"standardOfCare.guideline (Before any gonadotoxic treatment)"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"standardOfCare.guideline (Psychosocial and financial)"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"standardOfCare.guideline (Survivorship)"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","field":"standardOfCare.guideline (Hereditary risk)"}]},{"url":"https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"links","label":"NCI PDQ: bladder cancer treatment"}],"archive":"https://web.archive.org/web/20260818100552/https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq"},{"url":"https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/bladder/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","field":"links","label":"NCI PDQ: bladder cancer treatment"}]},{"url":"https://www.cancer.gov/types/bone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","field":"links","label":"NCI PDQ: childhood chordoma (bone cancer)"}]},{"url":"https://www.cancer.gov/types/bone/patient/ewing-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","field":"links","label":"NCI PDQ: Ewing sarcoma"}]},{"url":"https://www.cancer.gov/types/bone/patient/osteosarcoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","field":"links","label":"NCI PDQ: osteosarcoma"}]},{"url":"https://www.cancer.gov/types/brain","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/","field":"links","label":"NCI: Brain tumors"}],"archive":"https://web.archive.org/web/20260813095033/https://www.cancer.gov/types/brain"},{"url":"https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"links","label":"NCI: adult central nervous system tumours treatment (PDQ)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-astrocytoma-treament-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","field":"links","label":"NCI PDQ: childhood astrocytomas, other gliomas and glioneuronal tumours"},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","field":"standardOfCare.guideline (Resectable tumour)"},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"links","label":"NCI PDQ: childhood astrocytomas and other gliomas (includes diffuse midline glioma)"},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"standardOfCare.guideline (Newly diagnosed)"},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","field":"links","label":"NCI PDQ: childhood astrocytomas, other gliomas and glioneuronal tumours"},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","field":"standardOfCare.guideline (Newly diagnosed, child over about three years)"},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","field":"standardOfCare.guideline (Infant-type hemispheric glioma with a fusion)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-cns-atrt-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"links","label":"NCI PDQ: childhood CNS atypical teratoid/rhabdoid tumour"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","field":"standardOfCare.guideline (Germline SMARCB1 or SMARCA4 alteration)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"links","label":"NCI PDQ: Childhood Medulloblastoma Treatment"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"standardOfCare.guideline (Non-metastatic, standard therapy)"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"standardOfCare.guideline (Non-metastatic, de-escalation trials)"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"standardOfCare.guideline (Metastatic or residual disease)"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","field":"standardOfCare.guideline (Survivorship)"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"links","label":"NCI PDQ: Childhood Medulloblastoma Treatment"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"standardOfCare.guideline (Infants under three, TP53-wildtype)"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"standardOfCare.guideline (Children over three and adults, TP53-wildtype)"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"standardOfCare.guideline (TP53-mutant)"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"standardOfCare.guideline (Relapsed, skeletally mature, upstream PTCH1 or SMO lesion)"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","field":"standardOfCare.guideline (Survivorship)"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"links","label":"NCI PDQ: Childhood Medulloblastoma Treatment"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"standardOfCare.guideline (Average risk (aged 3 or over, no metastases, residual under 1.5 square centimetres))"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"standardOfCare.guideline (High risk (metastatic, residual disease or MYC amplification))"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"standardOfCare.guideline (Infants under three)"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"standardOfCare.guideline (Relapsed)"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","field":"standardOfCare.guideline (Survivorship)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-cns-germ-cell-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"links","label":"NCI PDQ: childhood CNS germ cell tumours"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"standardOfCare.guideline (CNS germinoma)"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"links","label":"NCI PDQ: childhood CNS germ cell tumours"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"standardOfCare.guideline (Localised germinoma)"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"standardOfCare.guideline (Disseminated germinoma)"},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","field":"standardOfCare.guideline (Non-germinomatous germ cell tumour)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"links","label":"NCI PDQ: childhood craniopharyngioma"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"standardOfCare.guideline (Newly diagnosed, no or limited hypothalamic involvement)"},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","field":"standardOfCare.guideline (Hypothalamic involvement)"}]},{"url":"https://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"links","label":"NCI PDQ: childhood ependymoma"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","field":"standardOfCare.guideline (Infants under one year or unresectable residual)"}]},{"url":"https://www.cancer.gov/types/brain/patient/child-cns-embryonal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/","field":"links","label":"NCI PDQ: childhood medulloblastoma and other CNS embryonal tumours treatment"}]},{"url":"https://www.cancer.gov/types/brain/patient/childhood-glioma-astrocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","field":"links","label":"NCI PDQ: childhood glioma (including astrocytoma)"}]},{"url":"https://www.cancer.gov/types/breast","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NCI PDQ"}]},{"url":"https://www.cancer.gov/types/breast/breast-cancer-types/dcis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"NCI: ductal carcinoma in situ"}]},{"url":"https://www.cancer.gov/types/breast/ibc-fact-sheet","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/breast/breast-cancer-types/inflammatory","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","field":"links","label":"NCI: inflammatory breast cancer"}]},{"url":"https://www.cancer.gov/types/breast/male-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"links","label":"NCI PDQ: male breast cancer"}]},{"url":"https://www.cancer.gov/types/breast/paget-breast-fact-sheet","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/breast/breast-cancer-types/paget-disease-breast","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paget-disease-of-the-nipple","kind":"cancer","name":"Paget disease of the nipple","route":"/cancers/paget-disease-of-the-nipple/","field":"links","label":"NCI: Paget disease of the breast"}]},{"url":"https://www.cancer.gov/types/breast/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"NCI PDQ: breast cancer treatment"}]},{"url":"https://www.cancer.gov/types/cardiac/patient-child-cardiac-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"links","label":"NCI PDQ: childhood cardiac tumours"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"standardOfCare.guideline (Cardiac rhabdomyoma with tuberous sclerosis)"}]},{"url":"https://www.cancer.gov/types/cervical/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/","field":"links","label":"NCI PDQ: cervical cancer treatment"},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","field":"links","label":"NCI PDQ: cervical cancer treatment"}]},{"url":"https://www.cancer.gov/types/childhood-cancers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","field":"links","label":"NCI: Childhood cancers"}],"archive":"https://web.archive.org/web/20260821122211/https://www.cancer.gov/types/childhood-cancers"},{"url":"https://www.cancer.gov/types/childhood-cancers/patient/rare-childhood-cancers-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"links","label":"NCI PDQ: childhood pleuropulmonary blastoma (in rare cancers of childhood)"},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"standardOfCare.guideline (Type I or Ir pleuropulmonary blastoma)"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"links","label":"NCI PDQ: rare cancers of childhood"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"standardOfCare.guideline (Recurrent respiratory papillomatosis)"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"standardOfCare.guideline (Adult-type carcinoma in a child)"},{"id":"adamantinoma","kind":"cancer","name":"Adamantinoma of bone","route":"/cancers/adamantinoma/","field":"links","label":"NCI PDQ: rare cancers of childhood"},{"id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","field":"links","label":"NCI PDQ: rare cancers of childhood"},{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","field":"links","label":"NCI PDQ: rare cancers of childhood"},{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/","field":"links","label":"NCI PDQ: rare cancers of childhood"}]},{"url":"https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NCI PDQ colon cancer treatment"}],"archive":"https://web.archive.org/web/20260914230153/https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq"},{"url":"https://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","field":"links","label":"NCI PDQ: colon cancer treatment"}]},{"url":"https://www.cancer.gov/types/esophageal/hp/esophageal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"links","label":"NCI PDQ esophageal cancer treatment"}],"archive":"https://web.archive.org/web/20260912235938/https://www.cancer.gov/types/esophageal/hp/esophageal-treatment-pdq"},{"url":"https://www.cancer.gov/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"links","label":"NCI PDQ: childhood extracranial germ cell tumours"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"standardOfCare.guideline (Low-risk malignant extracranial GCT (e.g. stage I testicular, stage I ovarian))"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","field":"standardOfCare.guideline (Standard- and high-risk malignant extracranial GCT)"}]},{"url":"https://www.cancer.gov/types/extragonadal-germ-cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"extragonadal-germ-cell-tumour","kind":"cancer","name":"Extragonadal germ cell tumour","route":"/cancers/extragonadal-germ-cell-tumour/","field":"links","label":"NCI: Extragonadal germ cell tumors"}],"archive":"https://web.archive.org/web/20260824120721/https://www.cancer.gov/types/extragonadal-germ-cell"},{"url":"https://www.cancer.gov/types/extragonadal-germ-cell/patient/extragonadal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","field":"links","label":"NCI PDQ: extragonadal germ cell tumours treatment"},{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","field":"links","label":"NCI PDQ: extragonadal germ cell tumours treatment"}]},{"url":"https://www.cancer.gov/types/eye/patient/intraocular-melanoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conjunctival-melanoma","kind":"cancer","name":"Conjunctival melanoma","route":"/cancers/conjunctival-melanoma/","field":"links","label":"NCI PDQ: intraocular (uveal) melanoma treatment"}]},{"url":"https://www.cancer.gov/types/gallbladder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NCI PDQ: gallbladder cancer"}]},{"url":"https://www.cancer.gov/types/gestational-trophoblastic/patient/gtd-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","field":"links","label":"NCI PDQ: GTD"}]},{"url":"https://www.cancer.gov/types/head-and-neck/patient/adult/nasopharyngeal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","field":"links","label":"NCI PDQ: nasopharyngeal cancer"}]},{"url":"https://www.cancer.gov/types/head-and-neck/patient/adult/paranasal-sinus-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"links","label":"NCI PDQ: paranasal sinus and nasal cavity cancer"}]},{"url":"https://www.cancer.gov/types/head-and-neck/patient/adult/salivary-gland-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acinic-cell-carcinoma-salivary","kind":"cancer","name":"Acinic cell carcinoma of the salivary glands","route":"/cancers/acinic-cell-carcinoma-salivary/","field":"links","label":"NCI PDQ: salivary gland cancer treatment"},{"id":"carcinoma-ex-pleomorphic-adenoma","kind":"cancer","name":"Carcinoma ex pleomorphic adenoma","route":"/cancers/carcinoma-ex-pleomorphic-adenoma/","field":"links","label":"NCI PDQ: salivary gland cancer treatment"}]},{"url":"https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","field":"links","label":"NCI PDQ: renal cell cancer treatment"}],"archive":"https://web.archive.org/web/20260807185602/https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq"},{"url":"https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"NCI PDQ: renal cell cancer treatment"},{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","field":"links","label":"NCI PDQ: renal cell cancer treatment"},{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","field":"links","label":"NCI PDQ: renal cell cancer treatment"},{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","field":"links","label":"NCI PDQ: renal cell cancer treatment"}]},{"url":"https://www.cancer.gov/types/kidney/patient/wilms-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","field":"links","label":"NCI PDQ: Wilms tumour"}]},{"url":"https://www.cancer.gov/types/langerhans","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"links","label":"NCI PDQ: Langerhans cell histiocytosis (histiocytic disorders)"}]},{"url":"https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"links","label":"NCI PDQ: Langerhans cell histiocytosis"},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","field":"standardOfCare.guideline (Single-system bone or skin)"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"links","label":"NCI PDQ Langerhans cell histiocytosis"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"standardOfCare.guideline (Unifocal bone disease)"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"standardOfCare.guideline (Multifocal bone or special-site disease)"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"standardOfCare.guideline (Skin-only disease)"},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","field":"standardOfCare.guideline (Adult single-system or refractory disease)"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"links","label":"NCI PDQ Langerhans cell histiocytosis"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"standardOfCare.guideline (First line)"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"standardOfCare.guideline (Non-response at week six or risk-organ progression)"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"standardOfCare.guideline (Reactivation)"},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","field":"standardOfCare.guideline (Long-term follow-up)"}]},{"url":"https://www.cancer.gov/types/leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","field":"links","label":"NCI PDQ"}]},{"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/","field":"prevalence.source"}]},{"url":"https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"standardOfCare.guideline (Induction (four weeks))"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"standardOfCare.guideline (Consolidation and interim maintenance)"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"standardOfCare.guideline (Delayed intensification and maintenance)"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","field":"standardOfCare.guideline (Relapse)"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"standardOfCare.guideline (Induction (four weeks))"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"standardOfCare.guideline (Consolidation and interim maintenance, high-risk B-ALL)"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"standardOfCare.guideline (T-cell ALL)"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"standardOfCare.guideline (Delayed intensification and maintenance)"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","field":"standardOfCare.guideline (Very high risk: induction failure, hypodiploidy, persistent residual disease)"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"standardOfCare.guideline (Newly diagnosed)"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"standardOfCare.guideline (Poor residual disease response)"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"standardOfCare.guideline (ABL-class fusions)"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"standardOfCare.guideline (CRLF2, JAK2 or EPOR lesions)"},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","field":"standardOfCare.guideline (Persistent residual disease)"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"standardOfCare.guideline (Induction)"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"standardOfCare.guideline (Post-induction, KMT2A-rearranged)"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"standardOfCare.guideline (High risk)"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"links","label":"NCI PDQ: Childhood ALL Treatment"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"standardOfCare.guideline (First relapse: reinduction)"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"standardOfCare.guideline (First relapse, high or intermediate risk: consolidation)"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"standardOfCare.guideline (Second or later relapse, or refractory disease)"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"standardOfCare.guideline (Relapsed T-cell ALL)"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","field":"standardOfCare.guideline (Relapsed KMT2A-rearranged ALL)"}]},{"url":"https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"links","label":"NCI PDQ: Childhood AML Treatment"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (Induction (two courses))"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (Consolidation (two or three courses))"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (FLT3-ITD)"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (High-risk genetics or persistent residual disease)"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","field":"standardOfCare.guideline (Supportive care and late effects)"}]},{"url":"https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/","field":"prevalence.source"}]},{"url":"https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","field":"links","label":"NCI PDQ: acute lymphoblastic leukaemia treatment"},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"links","label":"NCI PDQ: acute lymphoblastic leukaemia treatment"}]},{"url":"https://www.cancer.gov/types/leukemia/patient/child-aml-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","field":"links","label":"NCI PDQ: childhood acute myeloid leukaemia treatment"}]},{"url":"https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","field":"links","label":"NCI PDQ: chronic lymphocytic leukaemia treatment"},{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","field":"links","label":"NCI PDQ: chronic lymphocytic leukaemia treatment"},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","field":"links","label":"NCI PDQ: chronic lymphocytic leukaemia treatment"}]},{"url":"https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"links","label":"NCI PDQ: CML"}]},{"url":"https://www.cancer.gov/types/liver/patient/bile-duct-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/liver/bile-duct-cancer/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","field":"links","label":"NCI PDQ: bile duct cancer"}]},{"url":"https://www.cancer.gov/types/liver/patient/child-liver-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/liver/childhood-liver-cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","field":"links","label":"NCI PDQ: childhood liver cancer"}]},{"url":"https://www.cancer.gov/types/lung","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","field":"links","label":"NCI PDQ: lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NCI PDQ"}]},{"url":"https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"NCI PDQ (health professional): non-small cell lung cancer treatment, histological shares"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"NCI PDQ (health professional): non-small cell lung cancer treatment, histological shares"},{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","field":"links","label":"NCI PDQ (health professional): non-small cell lung cancer treatment, histological shares"}]},{"url":"https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NCI PDQ: small cell lung cancer treatment"}],"archive":"https://web.archive.org/web/20260905054553/https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq"},{"url":"https://www.cancer.gov/types/lung/research/alchemist","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","field":"links","label":"NCI: the ALCHEMIST lung cancer trials"}]},{"url":"https://www.cancer.gov/types/lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"links","label":"NCI: Lymphoma"}],"archive":"https://web.archive.org/web/20260813095341/https://www.cancer.gov/types/lymphoma"},{"url":"https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","field":"standardOfCare.guideline (Choosing treatment in Hodgkin lymphoma: stage, risk factors and the interim PET)"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","field":"standardOfCare.guideline (Survivorship after Hodgkin lymphoma: what the cure costs, and what is watched for)"},{"id":"lymphoma-tx-fertility-preservation","kind":"term","name":"Fertility before lymphoma treatment: what to ask for, and when","route":"/terms/lymphoma-tx-fertility-preservation/","field":"links","label":"NCI PDQ: adult Hodgkin lymphoma treatment (health professional)"},{"id":"lymphoma-tx-hodgkin-late-effects","kind":"term","name":"Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them","route":"/terms/lymphoma-tx-hodgkin-late-effects/","field":"links","label":"NCI PDQ: adult Hodgkin lymphoma treatment (health professional)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Advanced Hodgkin lymphoma with ABVD and brentuximab: what the earlier standards showed)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (First relapse of classical Hodgkin lymphoma: salvage to a negative PET, then autologous transplant)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Relapse after autologous transplant, or where transplant is not possible: PD-1 blockade)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (After brentuximab vedotin and PD-1 blockade have both failed)"}]},{"url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Before the first dose: the tests that change the plan)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Advanced stage, IPI 2 to 5: pola-R-CHP or R-CHOP, and where polatuzumab did and did not win)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit), and MYC with BCL6)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Older or frail patients: R-mini-CHOP and the comprehensive geriatric assessment)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Primary refractory disease or relapse within twelve months: CAR-T, not transplant)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Late relapse (after twelve months), transplant-eligible: salvage chemotherapy then autologous transplant)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Third line and beyond, including relapse after CAR-T)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Response assessment, follow-up and what a scan is for)"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","field":"standardOfCare.guideline (How the treatment of a non-Hodgkin lymphoma is decided)"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional)"},{"id":"lymphoma-tx-watch-and-wait","kind":"term","name":"Watch and wait in lymphoma: when the right treatment is none yet","route":"/terms/lymphoma-tx-watch-and-wait/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional)"},{"id":"lymphoma-tx-h-pylori-eradication","kind":"term","name":"Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma","route":"/terms/lymphoma-tx-h-pylori-eradication/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional)"},{"id":"lymphoma-tx-pjp-and-infection-prophylaxis","kind":"term","name":"Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination","route":"/terms/lymphoma-tx-pjp-and-infection-prophylaxis/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional)"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Transformation of follicular lymphoma to diffuse large B-cell lymphoma)"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (Mantle cell lymphoma: the three things to establish before choosing treatment)"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (Relapsed mantle cell lymphoma that has not yet had a BTK inhibitor)"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (Mantle cell lymphoma after a BTK inhibitor has failed: brexucabtagene autoleucel and pirtobrutinib)"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (Peripheral T-cell lymphoma: the questions that decide the regimen)"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (First-line nodal peripheral T-cell lymphoma, CD30-positive: brentuximab vedotin with CHP)"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (First-line nodal peripheral T-cell lymphoma, CD30-negative: CHOP, CHOEP and an honest account of the evidence)"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (Autologous transplant consolidation in first remission)"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (Relapsed and refractory peripheral T-cell lymphoma)"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"standardOfCare.guideline (Waldenstrom macroglobulinaemia: what to test before treatment, and why the genotype matters)"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"standardOfCare.guideline (Waldenstrom macroglobulinaemia, first treatment: BTK inhibitor or chemoimmunotherapy)"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"standardOfCare.guideline (Relapsed Waldenstrom macroglobulinaemia)"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"standardOfCare.guideline (Burkitt lymphoma that relapses)"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"standardOfCare.guideline (Primary mediastinal B-cell lymphoma: which first-line regimen, and why radiotherapy is now usually avoided)"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"standardOfCare.guideline (Primary mediastinal B-cell lymphoma that relapses or does not respond)"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"standardOfCare.guideline (Angioimmunoblastic T-cell lymphoma: treated as a nodal peripheral T-cell lymphoma, with two differences)"}]},{"url":"https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Children, adolescents and young adults with early-stage Hodgkin lymphoma)"}]},{"url":"https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"links","label":"NCI PDQ: childhood non-Hodgkin lymphoma (Burkitt)"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","field":"standardOfCare.guideline (Burkitt lymphoma with HIV, and in countries where the endemic form is common)"}]},{"url":"https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-skin-directed-therapy","kind":"term","name":"Skin-directed therapy in mycosis fungoides: creams, light and small radiotherapy fields","route":"/terms/lymphoma-tx-skin-directed-therapy/","field":"links","label":"NCI PDQ: mycosis fungoides and Sezary syndrome treatment (health professional)"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"standardOfCare.guideline (Early-stage mycosis fungoides (IA to IIA): skin-directed treatment only)"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"standardOfCare.guideline (Advanced mycosis fungoides (IIB to IVB): systemic treatment, and what to reach for first)"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","field":"standardOfCare.guideline (Living with mycosis fungoides: itch, infection and the things that make the difference day to day)"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"standardOfCare.guideline (Sezary syndrome: treatment aimed at the blood as well as the skin)"}]},{"url":"https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"standardOfCare.guideline (Primary CNS lymphoma: why R-CHOP fails, and what is given instead)"}]},{"url":"https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"links","label":"NCI PDQ: adult NHL"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"links","label":"NCI PDQ: adult NHL"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma (post-transplant lymphoproliferative disorder)"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","field":"links","label":"NCI PDQ: adult non-Hodgkin lymphoma treatment"}]},{"url":"https://www.cancer.gov/types/lymphoma/patient/aids-related-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"links","label":"NCI PDQ: AIDS-related lymphoma"}]},{"url":"https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"links","label":"NCI PDQ: mycosis fungoides"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","field":"links","label":"NCI PDQ: mycosis fungoides (including Sezary syndrome) treatment"}]},{"url":"https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"links","label":"NCI PDQ: primary CNS lymphoma"}]},{"url":"https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","field":"links","label":"NCI PDQ: malignant mesothelioma treatment"}],"archive":"https://web.archive.org/web/20260905052630/https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq"},{"url":"https://www.cancer.gov/types/metastatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/","field":"links","label":"NCI: Metastatic cancer"}],"archive":"https://web.archive.org/web/20260905075046/https://www.cancer.gov/types/metastatic-cancer"},{"url":"https://www.cancer.gov/types/midline/patient-child-midline-tract-carcinoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","field":"links","label":"NCI PDQ: childhood midline tract carcinoma with NUT gene changes"},{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","field":"standardOfCare.guideline (Localised)"}]},{"url":"https://www.cancer.gov/types/multiple-endocrine-neoplasia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"links","label":"NCI PDQ: multiple endocrine neoplasia syndromes"},{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"links","label":"NCI: multiple endocrine neoplasia (MEN) syndromes"},{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","field":"links","label":"NCI: multiple endocrine neoplasia (MEN) syndromes"}]},{"url":"https://www.cancer.gov/types/myeloproliferative","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"links","label":"NCI PDQ: mastocytosis (within myeloproliferative neoplasms)"}]},{"url":"https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","field":"links","label":"NCI PDQ: chronic MPN"},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","field":"links","label":"NCI PDQ: chronic myeloproliferative neoplasms"}]},{"url":"https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","field":"links","label":"NCI PDQ: MDS"}]},{"url":"https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","field":"standardOfCare.guideline (High-risk)"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"links","label":"NCI PDQ: Neuroblastoma Treatment"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"standardOfCare.guideline (L1 tumours and small adrenal masses in infants)"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"standardOfCare.guideline (L2 tumours in infants with favourable biology)"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"standardOfCare.guideline (Stage MS)"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","field":"standardOfCare.guideline (Follow-up)"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"links","label":"NCI PDQ: Neuroblastoma Treatment"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"standardOfCare.guideline (Chemotherapy)"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"standardOfCare.guideline (Response assessment and surgery)"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"standardOfCare.guideline (Non-responding or life-threatening disease)"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","field":"standardOfCare.guideline (Follow-up)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"links","label":"NCI PDQ: Neuroblastoma Treatment"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Induction)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Consolidation)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Local control)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Post-consolidation)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Survivorship)"}],"archive":"https://web.archive.org/web/20260914231814/https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq"},{"url":"https://www.cancer.gov/types/pancreatic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"links","label":"NCI PDQ: pancreatic cancer (ampullary cancers are covered with periampullary tumours)"}]},{"url":"https://www.cancer.gov/types/pancreatic/neuroendocrine-tumors/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glucagonoma","kind":"cancer","name":"Glucagonoma","route":"/cancers/glucagonoma/","field":"links","label":"NCI PDQ: pancreatic neuroendocrine (islet cell) tumour treatment"},{"id":"vipoma","kind":"cancer","name":"VIPoma","route":"/cancers/vipoma/","field":"links","label":"NCI PDQ: pancreatic neuroendocrine (islet cell) tumour treatment"},{"id":"somatostatinoma","kind":"cancer","name":"Somatostatinoma","route":"/cancers/somatostatinoma/","field":"links","label":"NCI PDQ: pancreatic neuroendocrine (islet cell) tumour treatment"}]},{"url":"https://www.cancer.gov/types/parathyroid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","field":"links","label":"NCI PDQ: parathyroid cancer"}]},{"url":"https://www.cancer.gov/types/parathyroid/patient/parathyroid-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"NCI PDQ: parathyroid cancer treatment"}]},{"url":"https://www.cancer.gov/types/penile","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"links","label":"NCI PDQ: penile cancer"}]},{"url":"https://www.cancer.gov/types/pheochromocytoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"links","label":"NCI PDQ: pheochromocytoma and paraganglioma"}]},{"url":"https://www.cancer.gov/types/pituitary","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","field":"links","label":"NCI PDQ: pituitary tumours"}]},{"url":"https://www.cancer.gov/types/pituitary/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lactotroph-pitnet","kind":"cancer","name":"Lactotroph pituitary neuroendocrine tumour (prolactinoma)","route":"/cancers/lactotroph-pitnet/","field":"links","label":"NCI PDQ: pituitary tumours treatment"},{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","field":"links","label":"NCI PDQ: pituitary tumours treatment"},{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","field":"links","label":"NCI PDQ: pituitary tumours treatment"},{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","field":"links","label":"NCI PDQ: pituitary tumours treatment"},{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","field":"links","label":"NCI PDQ: pituitary tumours treatment"}]},{"url":"https://www.cancer.gov/types/prostate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","field":"links","label":"NCI PDQ: prostate cancer"}]},{"url":"https://www.cancer.gov/types/prostate/hp/prostate-prevention-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","field":"prevalence.source"},{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","field":"prevalence.source"}]},{"url":"https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/","field":"prevalence.source"},{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","field":"prevalence.source"}]},{"url":"https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","field":"standardOfCare.guideline (Advanced unilateral (group E, no vision potential))"}]},{"url":"https://www.cancer.gov/types/retinoblastoma/patient/retinoblastoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","field":"links","label":"NCI PDQ: retinoblastoma"}]},{"url":"https://www.cancer.gov/types/skin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NCI: Skin cancer"}],"archive":"https://web.archive.org/web/20260910014700/https://www.cancer.gov/types/skin"},{"url":"https://www.cancer.gov/types/skin/patient/merkel-cell-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"links","label":"NCI PDQ: Merkel cell carcinoma"}]},{"url":"https://www.cancer.gov/types/skin/patient/skin-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"NCI PDQ: skin cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"NCI PDQ: skin cancer"}]},{"url":"https://www.cancer.gov/types/small-intestine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"links","label":"NCI PDQ: small intestine cancer"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"links","label":"NCI PDQ: soft tissue sarcoma"},{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"links","label":"NCI PDQ: soft tissue sarcoma"},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"NCI PDQ: soft tissue sarcoma"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"links","label":"NCI PDQ: soft tissue sarcoma"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","field":"links","label":"NCI PDQ: childhood soft tissue sarcoma (includes IMT)"},{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","field":"standardOfCare.guideline (Resectable)"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma/patient/child-soft-tissue-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/","field":"links","label":"NCI PDQ: childhood soft tissue sarcoma treatment"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma/patient/child-vascular-tumors-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"links","label":"NCI PDQ: childhood vascular tumours"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma/patient/kaposi-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","field":"links","label":"NCI PDQ: Kaposi sarcoma"}]},{"url":"https://www.cancer.gov/types/soft-tissue-sarcoma/patient/rhabdomyosarcoma-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","field":"links","label":"NCI PDQ: childhood rhabdomyosarcoma"}]},{"url":"https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"links","label":"NCI PDQ gastric cancer treatment"}],"archive":"https://web.archive.org/web/20260805075445/https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq"},{"url":"https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/testicular/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","field":"links","label":"NCI PDQ: testicular cancer"}]},{"url":"https://www.cancer.gov/types/testicular/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"embryonal-carcinoma-testis","kind":"cancer","name":"Embryonal carcinoma of the testis","route":"/cancers/embryonal-carcinoma-testis/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","field":"links","label":"NCI PDQ: testicular cancer treatment"},{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","field":"links","label":"NCI PDQ: testicular cancer treatment"}]},{"url":"https://www.cancer.gov/types/thymoma/patient/thymoma-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/thymus-cancer/thymoma-thymic-carcinoma","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","field":"links","label":"NCI PDQ: thymoma and thymic carcinoma"}]},{"url":"https://www.cancer.gov/types/thymus-cancer/thymoma-thymic-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","field":"links","label":"NCI PDQ: thymoma and thymic carcinoma treatment"},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/","field":"links","label":"NCI PDQ: thymoma and thymic carcinoma treatment"},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/","field":"links","label":"NCI PDQ: thymoma and thymic carcinoma treatment"},{"id":"micronodular-thymoma","kind":"cancer","name":"Micronodular thymoma with lymphoid stroma","route":"/cancers/micronodular-thymoma/","field":"links","label":"NCI PDQ: thymoma and thymic carcinoma treatment"}]},{"url":"https://www.cancer.gov/types/urethral","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","field":"links","label":"NCI PDQ: urethral cancer"}]},{"url":"https://www.cancer.gov/types/urethral/patient/urethral-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","field":"links","label":"NCI PDQ: urethral cancer treatment"},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","field":"links","label":"NCI PDQ: urethral cancer treatment"},{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","field":"links","label":"NCI PDQ: urethral cancer treatment"},{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","field":"links","label":"NCI PDQ: urethral cancer treatment"}]},{"url":"https://www.cancer.gov/types/uterine/patient/uterine-sarcoma-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/uterine/sarcoma/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"links","label":"NCI PDQ: uterine sarcoma"}]},{"url":"https://www.cancer.gov/types/vaginal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"links","label":"NCI PDQ: vaginal cancer"}]},{"url":"https://www.cancer.gov/types/vaginal/patient/vaginal-treatment-pdq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vaginal-melanoma","kind":"cancer","name":"Vaginal melanoma","route":"/cancers/vaginal-melanoma/","field":"links","label":"NCI PDQ: vaginal cancer treatment"}]},{"url":"https://www.cancer.gov/types/vulvar/patient/vulvar-treatment-pdq","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/types/vulvar/treatment","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","field":"links","label":"NCI PDQ: vulvar cancer"}]},{"url":"https://www.cancer.gov/types/vulvar/treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bartholin-gland-carcinoma","kind":"cancer","name":"Bartholin gland carcinoma","route":"/cancers/bartholin-gland-carcinoma/","field":"links","label":"NCI PDQ: vulvar cancer treatment"},{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","field":"links","label":"NCI PDQ: vulvar cancer treatment"}]},{"url":"https://www.cancer.ie","status":200,"ok":true,"finalUrl":"https://www.cancer.ie/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","route":"/institutions/irish-cancer-society/","field":"links","label":"Irish Cancer Society"},{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","route":"/institutions/irish-cancer-society/","field":"website"}]},{"url":"https://www.cancer.ie/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","field":"links","label":"Irish Cancer Society website"},{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","field":"profiles","label":"Irish Cancer Society website"}]},{"url":"https://www.cancer.ie/about-our-work/our-leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nikki-gallagher","kind":"person","name":"Nikki Gallagher","route":"/people/nikki-gallagher/","field":"links","label":"Source: Irish Cancer Society leadership page"},{"id":"nikki-gallagher","kind":"person","name":"Nikki Gallagher","route":"/people/nikki-gallagher/","field":"profiles","label":"Institution leadership page"}]},{"url":"https://www.cancer.northwestern.edu","status":200,"ok":true,"finalUrl":"https://www.cancer.northwestern.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","field":"links","label":"Lurie Cancer Center"},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","field":"website"}]},{"url":"https://www.cancer.northwestern.edu/about/index.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ann-lurie","kind":"person","name":"Ann Lurie","route":"/people/ann-lurie/","field":"links","label":"Lurie Cancer Center: about"}]},{"url":"https://www.cancer.org.au","status":200,"ok":true,"finalUrl":"https://www.cancer.org.au/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","field":"links","label":"Cancer Council Australia"},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","field":"website"}]},{"url":"https://www.cancer.org.au/about-us/about-cancer-council/australia/ceo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jacinta-reddan","kind":"person","name":"Jacinta Reddan","route":"/people/jacinta-reddan/","field":"links","label":"Source: Cancer Council Australia CEO page"},{"id":"jacinta-reddan","kind":"person","name":"Jacinta Reddan","route":"/people/jacinta-reddan/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cancer.org.au/clinical-guidelines","status":200,"ok":true,"finalUrl":"https://www.cancer.org.au/health-professionals/clinical-practice-guidelines","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","field":"links","label":"Clinical guidelines"}]},{"url":"https://www.cancer.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","field":"url"}]},{"url":"https://www.cancer.org/cancer/managing-cancer/side-effects/hair-skin-nails/hair-loss.html","status":200,"ok":true,"finalUrl":"https://www.cancer.org/cancer/side-effects/hair-skin-nails/hair-loss.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","field":"links","label":"American Cancer Society: hair loss"}]},{"url":"https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"aromatase","kind":"target","name":"Aromatase (CYP19A1)","route":"/targets/aromatase/","field":"prevalence.source"},{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","field":"prevalence.source"}]},{"url":"https://www.cancer.org/research/cancer-facts-statistics.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siegel-cancer-statistics-2024-cacancer-2024","kind":"paper","name":"Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report","route":"/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2019-cacancer-2019","kind":"paper","name":"Siegel 2019: Cancer statistics, 2019","route":"/key-papers/paper-siegel-cancer-statistics-2019-cacancer-2019/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2022-cacancer-2022","kind":"paper","name":"Siegel 2022: Cancer statistics, 2022","route":"/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2023-cacancer-2023","kind":"paper","name":"Siegel 2023: Cancer statistics, 2023","route":"/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2012-cacancer-2012","kind":"paper","name":"Siegel 2012: Cancer statistics, 2012","route":"/key-papers/paper-siegel-cancer-statistics-2012-cacancer-2012/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2015-cacancer-2015","kind":"paper","name":"Siegel 2015: Cancer statistics, 2015","route":"/key-papers/paper-siegel-cancer-statistics-2015-cacancer-2015/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2016-cacancer-2016","kind":"paper","name":"Siegel 2016: Cancer statistics, 2016","route":"/key-papers/paper-siegel-cancer-statistics-2016-cacancer-2016/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2017-cacancer-2017","kind":"paper","name":"Siegel 2017: Cancer statistics, 2017","route":"/key-papers/paper-siegel-cancer-statistics-2017-cacancer-2017/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2018-cacancer-2018","kind":"paper","name":"Siegel 2018: Cancer statistics, 2018","route":"/key-papers/paper-siegel-cancer-statistics-2018-cacancer-2018/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2021-cacancer-2021","kind":"paper","name":"Siegel 2021: Cancer statistics, 2021","route":"/key-papers/paper-siegel-cancer-statistics-2021-cacancer-2021/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-jemal-cancer-statistics-2007-cacancer-2007","kind":"paper","name":"Jemal 2007: Cancer statistics, 2007","route":"/key-papers/paper-jemal-cancer-statistics-2007-cacancer-2007/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-jemal-cancer-statistics-2008-cacancer-2008","kind":"paper","name":"Jemal 2008: Cancer statistics, 2008","route":"/key-papers/paper-jemal-cancer-statistics-2008-cacancer-2008/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-jemal-cancer-statistics-2009-cacancer-2009","kind":"paper","name":"Jemal 2009: Cancer statistics, 2009","route":"/key-papers/paper-jemal-cancer-statistics-2009-cacancer-2009/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-jemal-cancer-statistics-2010-cacancer-2010","kind":"paper","name":"Jemal 2010: Cancer statistics, 2010","route":"/key-papers/paper-jemal-cancer-statistics-2010-cacancer-2010/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2013-cacancer-2013","kind":"paper","name":"Siegel 2013: Cancer statistics, 2013","route":"/key-papers/paper-siegel-cancer-statistics-2013-cacancer-2013/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"paper-siegel-cancer-statistics-2014-cacancer-2014","kind":"paper","name":"Siegel 2014: Cancer statistics, 2014","route":"/key-papers/paper-siegel-cancer-statistics-2014-cacancer-2014/","field":"links","label":"ACS Cancer Facts and Figures"},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/","field":"links","label":"Cancer Facts & Figures"}]},{"url":"https://www.cancer.org/research/cancer-facts-statistics/cancer-facts-figures-for-african-americans.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","field":"links","label":"ACS Cancer Facts & Figures for African American/Black People"}]},{"url":"https://www.cancer.org/support-programs-and-services.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"acs-cancer-helpline","kind":"collection","name":"American Cancer Society helpline","route":"/collections/acs-cancer-helpline/","field":"links","label":"American Cancer Society helpline"},{"id":"acs-cancer-helpline","kind":"collection","name":"American Cancer Society helpline","route":"/collections/acs-cancer-helpline/","field":"url"}]},{"url":"https://www.cancer.org/support-programs-and-services/patient-lodging/hope-lodge.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"acs-hope-lodge","kind":"collection","name":"ACS Hope Lodge","route":"/collections/acs-hope-lodge/","field":"links","label":"ACS Hope Lodge"},{"id":"acs-hope-lodge","kind":"collection","name":"ACS Hope Lodge","route":"/collections/acs-hope-lodge/","field":"url"}]},{"url":"https://www.cancer.org/support-programs-and-services/road-to-recovery.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"acs-road-to-recovery","kind":"collection","name":"ACS Road To Recovery","route":"/collections/acs-road-to-recovery/","field":"links","label":"ACS Road To Recovery"},{"id":"acs-road-to-recovery","kind":"collection","name":"ACS Road To Recovery","route":"/collections/acs-road-to-recovery/","field":"url"}]},{"url":"https://www.cancer.ox.ac.uk","status":200,"ok":true,"finalUrl":"https://www.cancer.ox.ac.uk/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","field":"links","label":"Oxford Cancer"},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","field":"website"}]},{"url":"https://www.cancer.ox.ac.uk/about/our-team","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-middleton","kind":"person","name":"Mark Middleton","route":"/people/mark-middleton/","field":"links","label":"Source: Oxford Cancer, Our Team"}]},{"url":"https://www.canceralliance.co.uk","status":200,"ok":true,"finalUrl":"https://www.canceralliance.co.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/","field":"links","label":"East of England Cancer Alliance"},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/","field":"website"}]},{"url":"https://www.canceralliancesybnd.co.uk","status":200,"ok":true,"finalUrl":"https://canceralliancesyb.co.uk/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","route":"/institutions/south-yorkshire-bassetlaw-cancer-alliance/","field":"links","label":"South Yorkshire and Bassetlaw Cancer Alliance"},{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","route":"/institutions/south-yorkshire-bassetlaw-cancer-alliance/","field":"website"}]},{"url":"https://www.cancerbiomed.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","field":"links","label":"Homepage"},{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","field":"url"}]},{"url":"https://www.cancercare.mb.ca","status":200,"ok":true,"finalUrl":"https://www.cancercare.mb.ca/home/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","route":"/institutions/cancercare-manitoba/","field":"links","label":"Official website"},{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","route":"/institutions/cancercare-manitoba/","field":"website"}]},{"url":"https://www.cancercare.mb.ca/About-Us","status":200,"ok":true,"finalUrl":"https://www.cancercare.mb.ca/About-Us/who-we-are","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","route":"/institutions/cancercare-manitoba/","field":"links","label":"About CancerCare Manitoba"}]},{"url":"https://www.cancercare.mb.ca/About-Us/leadership-team/","status":200,"ok":true,"finalUrl":"https://www.cancercare.mb.ca/About-Us/leadership-team","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kent-stobart","kind":"person","name":"Kent Stobart","route":"/people/kent-stobart/","field":"links","label":"Source: CancerCare Manitoba executive leadership page"},{"id":"kent-stobart","kind":"person","name":"Kent Stobart","route":"/people/kent-stobart/","field":"profiles","label":"CancerCare Manitoba executive leadership page"}]},{"url":"https://www.cancercare.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancercare","kind":"collection","name":"CancerCare","route":"/collections/cancercare/","field":"links","label":"CancerCare"},{"id":"cancercare","kind":"collection","name":"CancerCare","route":"/collections/cancercare/","field":"url"}]},{"url":"https://www.cancercarealberta.ca/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brenda-hubley","kind":"person","name":"Brenda Hubley","route":"/people/brenda-hubley/","field":"links","label":"Source: Cancer Care Alberta homepage"},{"id":"brenda-hubley","kind":"person","name":"Brenda Hubley","route":"/people/brenda-hubley/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cancerfreefuture.eu/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","field":"links","label":"Cancer Free Future Association (CFFA) website"},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","field":"profiles","label":"Cancer Free Future Association (CFFA) website"},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","route":"/institutions/cancer-free-future-association/","field":"links","label":"Official website"},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","route":"/institutions/cancer-free-future-association/","field":"website"}]},{"url":"https://www.cancerinpregnancy.org/","status":200,"ok":true,"finalUrl":"https://cancerinpregnancy.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","field":"links","label":"INCIP network"}]},{"url":"https://www.cancermodels.org","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/biostudies/CancerModelsOrg/studies/","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/","field":"links","label":"Cancer Models (PDCM Finder) & HCMI"},{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/","field":"url"}]},{"url":"https://www.cancermodels.org/","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/biostudies/CancerModelsOrg/studies/","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","field":"links","label":"Cancer Models / PDCM Finder"}]},{"url":"https://www.cancernetwork.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","field":"links","label":"CancerNetwork (ONCOLOGY)"},{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","field":"url"}]},{"url":"https://www.cancernetwork.com/journals/oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","field":"links","label":"Homepage"},{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","field":"url"}]},{"url":"https://www.cancernetwork.com/view/atirmociclib-fulvestrant-improves-pfs-in-hr-her2-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","field":"outcomes.source (Progression-free survival (investigator-assessed))"}]},{"url":"https://www.cancernetwork.com/view/behind-the-matterhorn-trial-of-durvalumab-flot-in-gastric-gej-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","field":"outcomes.source (Pathologic complete response)"}]},{"url":"https://www.cancernetwork.com/view/dostarlimab-yields-sustained-complete-responses-in-dmmr-msi-h-rectal-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","field":"outcomes.source (Sustained clinical complete response at 12 months (independent central review))"}]},{"url":"https://www.cancernetwork.com/view/fda-accepts-new-drug-application-for-177lu-edotreotide-in-gep-nets","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"regulatoryEvents.source (2026-08-28)"}]},{"url":"https://www.cancernetwork.com/view/fda-approves-vimseltinib-in-tenosynovial-giant-cell-tumor","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","field":"regulatoryEvents.source (2025-02-14)"}]},{"url":"https://www.cancernetwork.com/view/fda-issues-second-camrelizumab-rivoceranib-crl-in-hepatocellular-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","field":"links","label":"FDA CRL coverage"}]},{"url":"https://www.cancernetwork.com/view/fda-odac-no-camizestrant-for-hr-her2-esr1-advanced-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","field":"links","label":"ODAC vote (CancerNetwork)"},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","field":"regulatoryEvents.source (2026-04-30)"}],"archive":"https://web.archive.org/web/20260519035558/https://www.cancernetwork.com/view/fda-odac-no-camizestrant-for-hr-her2-esr1-advanced-breast-cancer"},{"url":"https://www.cancernetwork.com/view/fda-oks-pembrolizumab-enfortumab-vedotin-in-muscle-invasive-bladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","field":"links","label":"FDA approval (Nov 2025)"}]},{"url":"https://www.cancernetwork.com/view/fianlimab-combo-does-not-significantly-improve-pfs-in-advanced-melanoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","field":"outcomes.source (Progression-free survival, fianlimab 1600 mg + cemiplimab vs pembrolizumab)"},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","field":"outcomes.source (Progression-free survival, fianlimab 400 mg + cemiplimab vs pembrolizumab)"},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","field":"outcomes.source (Progression-free survival, cemiplimab monotherapy arm)"}]},{"url":"https://www.cancernetwork.com/view/itm-11-demonstrates-superior-pfs-vs-everolimus-in-sstr-gep-nets","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"links","label":"CancerNetwork: COMPETE"}]},{"url":"https://www.cancernetwork.com/view/rina-s-earns-fda-breakthrough-therapy-designation-in-endometrial-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","field":"outcomes.source (Objective response rate, endometrial, 100 mg/m²)"},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","field":"regulatoryEvents.source (2025)"}]},{"url":"https://www.cancernetwork.com/view/rina-s-elicits-encouraging-antitumor-activity-in-advanced-ovarian-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","field":"outcomes.source (Objective response rate, ovarian, 120 mg/m²)"}]},{"url":"https://www.cancernetwork.com/view/sonesitatug-vedotin-improves-overall-survival-in-cldn18-2-gastric-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","field":"outcomes.source (Overall survival, third-line or later (dual primary))"},{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","field":"outcomes.source (Progression-free survival (BICR), second-line or later (dual primary))"}]},{"url":"https://www.cancerresearch.my","status":200,"ok":true,"finalUrl":"https://www.cancerresearch.my/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","field":"links","label":"Cancer Research Malaysia"}]},{"url":"https://www.cancerresearchhorizons.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","field":"links","label":"Official website"},{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","field":"website"}]},{"url":"https://www.cancerresearchhorizons.com/investors/our-seed-fund","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","field":"links","label":"Seed Fund"}]},{"url":"https://www.cancerresearchhorizons.com/our-portfolio/our-start-up-portfolio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","field":"links","label":"Start-up portfolio"}]},{"url":"https://www.cancerresearchuk.org","status":200,"ok":true,"finalUrl":"https://www.cancerresearchuk.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","field":"links","label":"Official website"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","field":"website"},{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","field":"links","label":"Cancer Research UK"}]},{"url":"https://www.cancerresearchuk.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","field":"links","label":"Cancer Research UK"},{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","field":"profiles","label":"Cancer Research UK"},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","field":"links","label":"Cancer Research UK"},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","field":"profiles","label":"Cancer Research UK"},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"links","label":"Cancer Research UK"},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","field":"profiles","label":"Cancer Research UK"}]},{"url":"https://www.cancerresearchuk.org/about-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","field":"links","label":"Cancer Research UK: About Cancer"},{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","field":"url"},{"id":"cruk-nurse-helpline","kind":"collection","name":"Cancer Research UK nurse helpline","route":"/collections/cruk-nurse-helpline/","field":"links","label":"Cancer Research UK nurse helpline"},{"id":"cruk-nurse-helpline","kind":"collection","name":"Cancer Research UK nurse helpline","route":"/collections/cruk-nurse-helpline/","field":"url"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bile-duct-cancer/treatment/controlling-symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"Cancer Research UK: controlling symptoms of bile duct cancer"},{"id":"pain-with-biliary-cancer","kind":"term","name":"Pain with gallbladder and bile duct cancer","route":"/terms/pain-with-biliary-cancer/","field":"links","label":"Cancer Research UK: controlling symptoms of bile duct cancer"},{"id":"weight-loss-and-fat-digestion-biliary","kind":"term","name":"Weight loss, fat digestion and enzymes with gallbladder cancer","route":"/terms/weight-loss-and-fat-digestion-biliary/","field":"links","label":"Cancer Research UK: controlling symptoms of bile duct cancer"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Cancer Research UK: controlling symptoms of bile duct cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bile-duct-cancer/treatment/stents","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"links","label":"Cancer Research UK: biliary stents"},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"Cancer Research UK: biliary stents"},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","field":"links","label":"Cancer Research UK: biliary stents"},{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"Cancer Research UK: biliary stents"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"Cancer Research UK: biliary stents"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: biliary stents"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: living with bowel cancer"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Cancer Research UK: living with bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/bowel-changes-after-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: bowel changes after treatment for bowel cancer"},{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"links","label":"Cancer Research UK: bowel changes after treatment for bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/coping","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: coping with bowel cancer"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Cancer Research UK: coping with bowel cancer"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Cancer Research UK: coping with bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/eating","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: eating and bowel cancer"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Cancer Research UK: eating and bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/having-stoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: coping with a stoma"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"Cancer Research UK: coping with a stoma"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"Cancer Research UK: coping with a stoma"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/sex-life","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Cancer Research UK: your sex life and bowel cancer"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Cancer Research UK: your sex life and bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/stages-types-and-grades/grades-and-types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: grades and types of bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/stages-types-and-grades/TNM-staging","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: TNM staging for bowel cancer"},{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","field":"links","label":"CRUK: TNM staging for bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: survival for bowel cancer (by stage, England 2016 to 2020)"},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","field":"links","label":"CRUK: survival for bowel cancer (by stage, England 2016 to 2020)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/bowel-cancer/symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: symptoms of bowel cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/getting-diagnosed/tests","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: tests to diagnose breast cancer"}],"archive":"https://web.archive.org/web/20260703043128/https://www.cancerresearchuk.org/about-cancer/breast-cancer/getting-diagnosed/tests"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/coping-support","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Cancer Research UK: coping with breast cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/life-after-surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"Cancer Research UK: life after breast cancer surgery"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: life after breast cancer surgery"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/lymphoedema-after-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"Cancer Research UK: lymphoedema after breast cancer treatment"},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"Cancer Research UK: lymphoedema after breast cancer treatment"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: lymphoedema after breast cancer treatment"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/menopausal-symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"menopause-after-chemotherapy-breast","kind":"term","name":"Menopause symptoms after chemotherapy for breast cancer","route":"/terms/menopause-after-chemotherapy-breast/","field":"links","label":"Cancer Research UK: menopausal symptoms and breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: menopausal symptoms and breast cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/preserving-fertility","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Cancer Research UK: preserving fertility with breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: preserving fertility with breast cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/risks-causes/family-history-and-inherited-genes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: family history and inherited genes in breast cancer"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"CRUK: family history and inherited genes in breast cancer"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"CRUK: family history and inherited genes in breast cancer"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"CRUK: family history and inherited genes in breast cancer"},{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"links","label":"CRUK: family history and inherited genes in breast cancer"}],"archive":"https://web.archive.org/web/20260809073845/https://www.cancerresearchuk.org/about-cancer/breast-cancer/risks-causes/family-history-and-inherited-genes"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/number-stages","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: number stages of breast cancer"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"CRUK: number stages of breast cancer"}],"archive":"https://web.archive.org/web/20260907114608/https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/number-stages"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/tnm-staging","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: TNM staging of breast cancer"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"CRUK: TNM staging of breast cancer"}],"archive":"https://web.archive.org/web/20260901230752/https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/tnm-staging"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: survival for breast cancer (England by stage, 2018 to 2022)"}],"archive":"https://web.archive.org/web/20260712073546/https://www.cancerresearchuk.org/about-cancer/breast-cancer/survival"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: symptoms of breast cancer"}],"archive":"https://web.archive.org/web/20260928021717/https://www.cancerresearchuk.org/about-cancer/breast-cancer/symptoms"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cancer Research UK: chemotherapy for breast cancer"}],"archive":"https://web.archive.org/web/20260908032235/https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/chemotherapy"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/radiotherapy/radiotherapy-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cancer Research UK: having radiotherapy for breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: having radiotherapy for breast cancer"}],"archive":"https://web.archive.org/web/20260723211710/https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/radiotherapy/radiotherapy-treatment"},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/radiotherapy/side-effects","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Cancer Research UK: side effects of breast radiotherapy"},{"id":"radiation-dermatitis","kind":"term","name":"Radiation dermatitis (skin reaction)","route":"/terms/radiation-dermatitis/","field":"links","label":"Cancer Research UK: side effects of breast radiotherapy"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/surgery/after-surgery/problems-after-mastectomy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"Cancer Research UK: possible problems after mastectomy"},{"id":"numbness-after-breast-surgery","kind":"term","name":"Numbness and nerve pain after breast surgery","route":"/terms/numbness-after-breast-surgery/","field":"links","label":"Cancer Research UK: possible problems after mastectomy"},{"id":"cording-axillary-web-syndrome","kind":"term","name":"Cording (axillary web syndrome)","route":"/terms/cording-axillary-web-syndrome/","field":"links","label":"Cancer Research UK: possible problems after mastectomy"},{"id":"seroma-after-breast-surgery","kind":"term","name":"Seroma after breast surgery","route":"/terms/seroma-after-breast-surgery/","field":"links","label":"Cancer Research UK: possible problems after mastectomy"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: possible problems after mastectomy"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: possible problems after mastectomy"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/surgery/breast-reconstruction","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"Cancer Research UK: breast reconstruction"},{"id":"numbness-after-breast-surgery","kind":"term","name":"Numbness and nerve pain after breast surgery","route":"/terms/numbness-after-breast-surgery/","field":"links","label":"Cancer Research UK: breast reconstruction"},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"links","label":"Cancer Research UK: breast reconstruction"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: breast reconstruction"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"terminal-duct-lobular-unit","kind":"term","name":"Ducts, lobules and the terminal duct lobular unit","route":"/terms/terminal-duct-lobular-unit/","field":"links","label":"Cancer Research UK: types of breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: types of breast cancer"},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"Cancer Research UK: types of breast cancer"},{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","field":"links","label":"Cancer Research UK: types of breast cancer"},{"id":"mucinous-carcinoma-breast","kind":"cancer","name":"Mucinous carcinoma of the breast","route":"/cancers/mucinous-carcinoma-breast/","field":"links","label":"Cancer Research UK: types of breast cancer"},{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"links","label":"Cancer Research UK: types of breast cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/invasive-lobular-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","field":"links","label":"Cancer Research UK: invasive lobular breast cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/triple-negative-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: triple negative breast cancer (patient page)"}],"archive":"https://web.archive.org/web/20260908062715/https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/triple-negative-breast-cancer"},{"url":"https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","field":"links","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","field":"links","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: fluid on the lungs (pleural effusion)"}],"archive":"https://web.archive.org/web/20260919075639/https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion"},{"url":"https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/treatment/oxygen-at-home","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: oxygen at home"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/coping/physically/skin-problems/itching","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"Cancer Research UK: itching"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-determine-whether-number-types-bacteria-gut-affects-how-well-treatment-works-bile-duct-cancer-abc-12","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abc-12","kind":"trial","name":"ABC-12","route":"/trials/abc-12/","field":"links","label":"Cancer Research UK trial page: ABC-12"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-chemotherapy-stereotactic-radiotherapy-people-locally-advanced-bile-duct-cancer-abc-07","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abc-07","kind":"trial","name":"ABC-07","route":"/trials/abc-07/","field":"links","label":"Cancer Research UK trial page: ABC-07"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: what is gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/advanced-gallbladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"Cancer Research UK: advanced gallbladder cancer"},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","field":"links","label":"Cancer Research UK: advanced gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/getting-diagnosed/screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: screening for gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/living-with/coping","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Cancer Research UK: coping with gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/living-with/eating-problems","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"weight-loss-and-fat-digestion-biliary","kind":"term","name":"Weight loss, fat digestion and enzymes with gallbladder cancer","route":"/terms/weight-loss-and-fat-digestion-biliary/","field":"links","label":"Cancer Research UK: eating problems and gallbladder cancer"},{"id":"eating-after-gallbladder-removal","kind":"term","name":"Eating after gallbladder removal","route":"/terms/eating-after-gallbladder-removal/","field":"links","label":"Cancer Research UK: eating problems and gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/risks-causes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: risks and causes of gallbladder cancer"},{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","field":"links","label":"CRUK: risks and causes of gallbladder cancer"},{"id":"anomalous-pancreaticobiliary-junction","kind":"term","name":"Anomalous pancreaticobiliary junction (pancreaticobiliary maljunction)","route":"/terms/anomalous-pancreaticobiliary-junction/","field":"links","label":"CRUK: risks and causes of gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/stages-and-grades","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: stages and grades of gallbladder cancer"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"CRUK: stages and grades of gallbladder cancer"},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","field":"links","label":"CRUK: stages and grades of gallbladder cancer"},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","field":"links","label":"CRUK: stages and grades of gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: survival for gallbladder cancer (England and SEER by stage)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: chemotherapy for gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/follow-up","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: follow up after gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/immunotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: immunotherapy for gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: surgery for gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/treatment/treatment-decisions","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: gallbladder cancer treatment decisions"},{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","route":"/terms/trial-or-standard-treatment-biliary/","field":"links","label":"Cancer Research UK: gallbladder cancer treatment decisions"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/gallbladder-cancer/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: types of gallbladder cancer"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","field":"links","label":"CRUK: types of gallbladder cancer"},{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","field":"links","label":"CRUK: types of gallbladder cancer"},{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","field":"links","label":"CRUK: types of gallbladder cancer"},{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","field":"links","label":"CRUK: types of gallbladder cancer"},{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","field":"links","label":"CRUK: types of gallbladder cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/kidney-cancer/stages-types-grades/types-grades","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","field":"links","label":"Cancer Research UK: types and grades of kidney cancer"},{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","field":"links","label":"Cancer Research UK: types and grades of kidney cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Cancer Research UK: living with lung cancer"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"Cancer Research UK: living with lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: living with lung cancer"}],"archive":"https://web.archive.org/web/20260607102008/https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with"},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: coping and support when you have lung cancer"}],"archive":"https://web.archive.org/web/20260519001958/https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping"},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: coping with breathlessness when you have lung cancer"}],"archive":"https://web.archive.org/web/20260918204436/https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness"},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/resources-books","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Cancer Research UK: lung cancer resources and support organisations"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: lung cancer resources and support organisations"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/metastatic/symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"links","label":"Cancer Research UK: symptoms of metastatic lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: symptoms of metastatic lung cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","field":"links","label":"Cancer Research UK: types of lung cancer"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","field":"links","label":"Cancer Research UK: types of lung cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/treatment/help-you-breathe","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"links","label":"Cancer Research UK: treatments to help you breathe when you have lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Cancer Research UK: treatments to help you breathe when you have lung cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"links","label":"Cancer Research UK: types and grades of non-Hodgkin lymphoma"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/getting-diagnosed/screening","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: screening for pancreatic cancer (no national programme; high-risk surveillance)"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"CRUK: screening for pancreatic cancer (no national programme; high-risk surveillance)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/getting-diagnosed/tests","status":200,"ok":true,"finalUrl":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/getting-diagnosed/tests-pancreatic-cancer","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: tests for pancreatic cancer"},{"id":"pancreas-protocol-ct","kind":"term","name":"Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)","route":"/terms/pancreas-protocol-ct/","field":"links","label":"CRUK: tests for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/living-with/coping","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: coping and support when you have pancreatic cancer"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Cancer Research UK: coping and support when you have pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/living-with/diet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: your diet and pancreatic cancer"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Cancer Research UK: your diet and pancreatic cancer"},{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"links","label":"Cancer Research UK: your diet and pancreatic cancer"},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"Cancer Research UK: your diet and pancreatic cancer"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Cancer Research UK: your diet and pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/risks-causes","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: risks and causes of pancreatic cancer (patient page)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: stages, types and grades of pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/tnm-staging","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: TNM staging for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: types of pancreatic cancer"},{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"links","label":"CRUK: types of pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: survival for pancreatic cancer (ICBP SURVMARK-2 by stage; England and Wales index)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: symptoms of pancreatic cancer"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"CRUK: symptoms of pancreatic cancer"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"CRUK: symptoms of pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/about-radiotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: radiotherapy for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: chemotherapy for pancreatic cancer"},{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Cancer Research UK: chemotherapy for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/controlling-symptoms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: controlling symptoms of advanced pancreatic cancer"},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","field":"links","label":"Cancer Research UK: controlling symptoms of advanced pancreatic cancer"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"Cancer Research UK: controlling symptoms of advanced pancreatic cancer"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Cancer Research UK: controlling symptoms of advanced pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/follow-up-appointment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: follow up after treatment for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: surgery for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/treatment-decisions","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Cancer Research UK: treatment options for pancreatic cancer"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"Cancer Research UK: treatment options for pancreatic cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/hormone-therapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Cancer Research UK: hormone therapy for prostate cancer"},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","field":"links","label":"Cancer Research UK: hormone therapy for prostate cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/about-skin-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: about non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/getting-diagnosed/referral-specialist","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: referral to a skin cancer specialist"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/living-with/coping","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: coping with non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/living-with/skin-care-after-skin-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: skin care after non-melanoma skin cancer"},{"id":"sun-protection-after-skin-cancer","kind":"term","name":"Sun protection after a skin cancer diagnosis","route":"/terms/sun-protection-after-skin-cancer/","field":"links","label":"Cancer Research UK: skin care after non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/stages-grades","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: stages and grades of non-melanoma skin cancer"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Cancer Research UK: stages and grades of non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: survival for non-melanoma skin cancer (net survival for skin squamous cell carcinoma, England, first tumours diagnosed 2014 to 2016, from the NDRS Get Data Out programme)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Cancer Research UK: survival for non-melanoma skin cancer (net survival for skin squamous cell carcinoma, England, first tumours diagnosed 2014 to 2016, from the NDRS Get Data Out programme)"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/chemotherapy-cream","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: chemotherapy cream for non-melanoma skin cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: chemotherapy cream for non-melanoma skin cancer"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","field":"links","label":"Cancer Research UK: chemotherapy cream for non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/follow-up-appointments","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: follow-up after non-melanoma skin cancer treatment"},{"id":"second-primary-skin-cancer","kind":"term","name":"The next skin cancer: second primaries after a keratinocyte cancer","route":"/terms/second-primary-skin-cancer/","field":"links","label":"Cancer Research UK: follow-up after non-melanoma skin cancer treatment"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Cancer Research UK: follow-up after non-melanoma skin cancer treatment"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: follow-up after non-melanoma skin cancer treatment"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: follow-up after non-melanoma skin cancer treatment"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/photodynamic-therapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: photodynamic therapy for non-melanoma skin cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: photodynamic therapy for non-melanoma skin cancer"},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"Cancer Research UK: photodynamic therapy for non-melanoma skin cancer"},{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"links","label":"Cancer Research UK: photodynamic therapy for non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/mohs-micrographic-surgery-mms","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: Mohs micrographic surgery"},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"links","label":"Cancer Research UK: Mohs micrographic surgery"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/problems-after-surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: problems after surgery for non-melanoma skin cancer"},{"id":"skin-graft-and-flap-reconstruction","kind":"term","name":"Skin grafts and flaps after skin cancer surgery","route":"/terms/skin-graft-and-flap-reconstruction/","field":"links","label":"Cancer Research UK: problems after surgery for non-melanoma skin cancer"},{"id":"facial-scar-after-skin-cancer","kind":"term","name":"The scar on the face after skin cancer surgery","route":"/terms/facial-scar-after-skin-cancer/","field":"links","label":"Cancer Research UK: problems after surgery for non-melanoma skin cancer"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: problems after surgery for non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/treatment-surgery-types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Surgery on the face: grafts, flaps, and what the scar does in the first year)"},{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"skin-graft-and-flap-reconstruction","kind":"term","name":"Skin grafts and flaps after skin cancer surgery","route":"/terms/skin-graft-and-flap-reconstruction/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"links","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Cancer Research UK: types of surgery for non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/types","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: types of non-melanoma skin cancer"},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","field":"links","label":"Cancer Research UK: types of non-melanoma skin cancer"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Cancer Research UK: types of non-melanoma skin cancer"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/types/basal-cell-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"Cancer Research UK: basal cell carcinoma"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: basal cell carcinoma"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/types/bowens-disease","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Cancer Research UK: Bowen's disease"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/skin-cancer/types/squamous-cell-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"Cancer Research UK: squamous cell carcinoma of the skin"},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","field":"links","label":"Cancer Research UK: squamous cell carcinoma of the skin"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"Cancer Research UK: squamous cell carcinoma of the skin"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Cancer Research UK: squamous cell carcinoma of the skin"}]},{"url":"https://www.cancerresearchuk.org/about-cancer/treatment/prehabilitation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Cancer Research UK: prehabilitation"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Cancer Research UK: prehabilitation"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Cancer Research UK: prehabilitation"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: prehabilitation"}],"archive":"https://web.archive.org/web/20260510032850/https://www.cancerresearchuk.org/about-cancer/treatment/prehabilitation"},{"url":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure/centres","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","field":"links","label":"CRUK: our centres"},{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","route":"/institutions/cruk-city-of-london-centre/","field":"links","label":"CRUK Centres"},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/","field":"links","label":"CRUK Centres"}]},{"url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure","status":200,"ok":true,"finalUrl":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","field":"links","label":"CRUK: our research infrastructure"}]},{"url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centres","status":200,"ok":true,"finalUrl":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure/centres","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","field":"links","label":"Source: Cancer Research UK research centres page listing the centre Director"},{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","field":"profiles","label":"Cancer Research UK: our centres (names the Director)"},{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","field":"links","label":"Source: Cancer Research UK research centres page listing the centre Director"},{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","field":"profiles","label":"Cancer Research UK: our centres (names the Director)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/all-cancers-combined/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Cancer Research UK: all cancers combined incidence statistics (UK)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: bowel cancer statistics (incidence, mortality, survival, early diagnosis, treatment)"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"CRUK: bowel cancer statistics (incidence, mortality, survival, early diagnosis, treatment)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: bowel cancer incidence statistics"},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","field":"links","label":"CRUK: bowel cancer incidence statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: bowel cancer mortality statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/risk-factors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: bowel cancer risk factors (professional)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"CRUK: bowel cancer risk factors (professional)"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"CRUK: bowel cancer risk factors (professional)"},{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","field":"links","label":"CRUK: bowel cancer risk factors (professional)"},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"CRUK: bowel cancer risk factors (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"CRUK: bowel cancer survival statistics (professional)"},{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"links","label":"CRUK: bowel cancer survival statistics (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: breast cancer statistics (stage, routes to diagnosis, treatment)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: breast cancer statistics (UK incidence, mortality, survival, stage at diagnosis and routes to diagnosis)"}],"archive":"https://web.archive.org/web/20260920132406/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: breast cancer incidence statistics (invasive)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Cancer Research UK: breast cancer incidence statistics (invasive)"}],"archive":"https://web.archive.org/web/20260920085157/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: breast cancer mortality statistics"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"CRUK: breast cancer mortality statistics"}],"archive":"https://web.archive.org/web/20260907171846/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/mortality"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/risk-factors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: breast cancer risk factors (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"CRUK: breast cancer survival statistics (professional)"},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","field":"links","label":"CRUK: breast cancer survival statistics (professional)"}],"archive":"https://web.archive.org/web/20260901225832/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: gallbladder cancer statistics (diagnosis routes, stage, treatment)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: gallbladder cancer incidence statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: gallbladder cancer mortality statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/risk-factors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: gallbladder cancer risk factors (professional)"},{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","field":"links","label":"CRUK: gallbladder cancer risk factors (professional)"},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","field":"links","label":"CRUK: gallbladder cancer risk factors (professional)"},{"id":"anomalous-pancreaticobiliary-junction","kind":"term","name":"Anomalous pancreaticobiliary junction (pancreaticobiliary maljunction)","route":"/terms/anomalous-pancreaticobiliary-junction/","field":"links","label":"CRUK: gallbladder cancer risk factors (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"CRUK: gallbladder cancer survival statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"CRUK: lung cancer statistics (incidence, mortality, survival, early diagnosis, treatment)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"CRUK: lung cancer statistics (incidence, mortality, survival, early diagnosis, treatment)"}],"archive":"https://web.archive.org/web/20260916085657/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"CRUK: lung cancer incidence statistics"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"CRUK: lung cancer incidence statistics"}],"archive":"https://web.archive.org/web/20260910034509/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"CRUK: lung cancer mortality statistics (including mortality by deprivation)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"CRUK: lung cancer mortality statistics (including mortality by deprivation)"}],"archive":"https://web.archive.org/web/20260724211530/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"radon","kind":"term","name":"Radon","route":"/terms/radon/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"asbestos","kind":"term","name":"Asbestos","route":"/terms/asbestos/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"CRUK: lung cancer risk factors (attributable fractions for the UK)"}],"archive":"https://web.archive.org/web/20260919212931/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"CRUK: lung cancer survival statistics (by age, deprivation and over time)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"CRUK: lung cancer survival statistics (by age, deprivation and over time)"}],"archive":"https://web.archive.org/web/20251208101655/https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival"},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-melanoma-skin-cancer/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Cancer Research UK: non-melanoma skin cancer incidence statistics (UK)"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Cancer Research UK: non-melanoma skin cancer incidence statistics (UK)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Cancer Research UK: non-melanoma skin cancer incidence statistics (UK)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: pancreatic cancer statistics (incidence, mortality, survival, early diagnosis and routes to diagnosis)"},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"links","label":"CRUK: pancreatic cancer statistics (incidence, mortality, survival, early diagnosis and routes to diagnosis)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/incidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: pancreatic cancer incidence statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/mortality","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: pancreatic cancer mortality statistics"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/risk-factors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: pancreatic cancer risk factors (professional)"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"CRUK: pancreatic cancer risk factors (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/survival","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"CRUK: pancreatic cancer survival statistics (professional)"}]},{"url":"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Cancer Research UK: prostate cancer statistics (UK incidence, mortality, survival, stage at diagnosis and route to diagnosis)"}]},{"url":"https://www.cancersupportcommunity.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","field":"links","label":"Cancer Support Community (Gilda's Club)"},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","field":"profiles","label":"Cancer Support Community (Gilda's Club)"},{"id":"cancer-support-community","kind":"collection","name":"Cancer Support Community","route":"/collections/cancer-support-community/","field":"links","label":"Cancer Support Community"},{"id":"cancer-support-community","kind":"collection","name":"Cancer Support Community","route":"/collections/cancer-support-community/","field":"url"}]},{"url":"https://www.cancertain.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancertain","kind":"company","name":"CanCertain","route":"/companies/cancertain/","field":"links","label":"Official website"},{"id":"cancertain","kind":"company","name":"CanCertain","route":"/companies/cancertain/","field":"website"}]},{"url":"https://www.candeltx.com/pipeline/","status":200,"ok":true,"finalUrl":"https://candeltx.com/pipeline","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.canfieldsci.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"canfield-scientific","kind":"company","name":"Canfield Scientific","route":"/companies/canfield-scientific/","field":"links","label":"Official website"},{"id":"canfield-scientific","kind":"company","name":"Canfield Scientific","route":"/companies/canfield-scientific/","field":"website"}]},{"url":"https://www.canfite.com","status":200,"ok":true,"finalUrl":"https://www.canfite.com/","contentType":"text/html; Charset=utf-8","checked":"2026-09-30","refs":[{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","field":"links","label":"Official website"},{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","field":"website"}]},{"url":"https://www.cardiffoncology.com/","status":200,"ok":true,"finalUrl":"https://cardiffoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","route":"/companies/cardiff-oncology/","field":"links","label":"Official website"},{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","route":"/companies/cardiff-oncology/","field":"website"}]},{"url":"https://www.careology.health","status":200,"ok":true,"finalUrl":"https://www.careology.health/en-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","field":"links","label":"Official website"},{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","field":"website"}]},{"url":"https://www.cariboubio.com","status":200,"ok":true,"finalUrl":"https://www.cariboubio.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/","field":"website"}]},{"url":"https://www.carilionclinic.org","status":200,"ok":true,"finalUrl":"https://www.carilionclinic.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carilion-clinic","kind":"institution","name":"Carilion Clinic / Virginia Tech Carilion School of Medicine","route":"/institutions/carilion-clinic/","field":"links","label":"Carilion Clinic"},{"id":"carilion-clinic","kind":"institution","name":"Carilion Clinic / Virginia Tech Carilion School of Medicine","route":"/institutions/carilion-clinic/","field":"website"}]},{"url":"https://www.carislifesciences.com","status":200,"ok":true,"finalUrl":"https://www.carislifesciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/","field":"links","label":"Official website"},{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/","field":"website"}]},{"url":"https://www.carislifesciences.com/products-and-services/molecular-profiling/","status":200,"ok":true,"finalUrl":"https://www.carislifesciences.com/why-order-molecular-profiling/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/","field":"links","label":"Caris: MI Cancer Seek (page moved; nearest live section)"}]},{"url":"https://www.carsgen.com","status":200,"ok":true,"finalUrl":"https://www.carsgen.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","field":"dosing.source"},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/","field":"links","label":"Official website"},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/","field":"website"}]},{"url":"https://www.carsgen.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","field":"links","label":"CARsgen Therapeutics"},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","field":"profiles","label":"CARsgen Therapeutics"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","field":"links","label":"CARsgen Therapeutics"}]},{"url":"https://www.cartesiantherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.cartesiantherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","field":"links","label":"Official website"},{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","field":"website"}]},{"url":"https://www.cartx.health/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","route":"/companies/cartx-therapeutics/","field":"links","label":"Official website"},{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","route":"/companies/cartx-therapeutics/","field":"website"}]},{"url":"https://www.catalent.com","status":200,"ok":true,"finalUrl":"https://www.catalent.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/","field":"links","label":"Official website"},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/","field":"website"}]},{"url":"https://www.catalym.com","status":200,"ok":true,"finalUrl":"https://www.catalym.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/","field":"links","label":"Official website"},{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/","field":"website"}]},{"url":"https://www.catholic.ac.kr","status":200,"ok":true,"finalUrl":"https://www.catholic.ac.kr/ko/index.do","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","field":"links","label":"Catholic University of Korea"}]},{"url":"https://www.cbioportal.org","status":200,"ok":true,"finalUrl":"https://www.cbioportal.org/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/","field":"links","label":"cBioPortal for Cancer Genomics"},{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/","field":"url"}]},{"url":"https://www.cbioportal.org/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotree-term","kind":"term","name":"OncoTree cancer classification","route":"/terms/oncotree-term/","field":"links","label":"cBioPortal"}]},{"url":"https://www.cbioportal.org/study/summary?id=biliary_tract_msk_2026","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/","field":"links","label":"cBioPortal study biliary_tract_msk_2026 (Hepatobiliary Cancer, MSK 2026)"}]},{"url":"https://www.cbioportal.org/study/summary?id=blca_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=brca_metabric","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/","field":"links","label":"cBioPortal study brca_metabric (METABRIC, Nature 2012 and Nat Commun 2016; 320 triple-negative samples, 299 on the 173-gene panel)"}]},{"url":"https://www.cbioportal.org/study/summary?id=brca_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/","field":"links","label":"cBioPortal study brca_tcga_pan_can_atlas_2018 (TCGA PanCancer Atlas; the same 123 triple-negative patients, all sequenced, 119 with copy number)"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","field":"prevalence.source"},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=brca_tcga_pub","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/","field":"links","label":"cBioPortal study brca_tcga_pub (TCGA, Nature 2012; 825 samples, 123 recorded ER-, PR- and HER2-negative, 84 of them exome-sequenced)"},{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/","field":"links","label":"cBioPortal study brca_tcga_pub (TCGA, Nature 2012; 825 samples, 123 recorded ER-, PR- and HER2-negative, 84 of them exome-sequenced)"}]},{"url":"https://www.cbioportal.org/study/summary?id=chol_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"prevalence.source"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=coadread_dfci_2016","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","kind":"paper","name":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","route":"/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/","field":"links","label":"cBioPortal study coadread_dfci_2016 (DFCI, Cell Reports 2016; 619 exomes from the Nurses' Health Study and Health Professionals Follow-up Study, no copy-number profile)"}]},{"url":"https://www.cbioportal.org/study/summary?id=coadread_genentech","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-seshagiri-rspo-fusions-colon-nature-2012","kind":"paper","name":"Recurrent R-spondin fusions in colon cancer","route":"/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/","field":"links","label":"cBioPortal study coadread_genentech (Genentech, Nature 2012; 72 sequenced colon tumours, the R-spondin fusion discovery set)"}]},{"url":"https://www.cbioportal.org/study/summary?id=coadread_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","field":"links","label":"cBioPortal study coadread_tcga_pan_can_atlas_2018 (TCGA PanCancer Atlas colorectal; 594 samples, 534 sequenced, 592 with copy number)"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=coadread_tcga_pub","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","field":"links","label":"cBioPortal study coadread_tcga_pub (TCGA, Nature 2012; 276 samples, 224 sequenced, 257 with copy number)"}]},{"url":"https://www.cbioportal.org/study/summary?id=crc_msk_2017","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","kind":"paper","name":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","route":"/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/","field":"links","label":"cBioPortal study crc_msk_2017 (MSK, Cancer Cell 2018; 1,134 MSK-IMPACT samples from patients with metastatic disease, 601 primaries and 533 metastases)"}]},{"url":"https://www.cbioportal.org/study/summary?id=crc_msk_2026","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"prevalence.source"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"prevalence.source"},{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","field":"prevalence.source"},{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"prevalence.source"},{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"prevalence.source"},{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","field":"prevalence.source"},{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"prevalence.source"},{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"prevalence.source"},{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","field":"prevalence.source"},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"prevalence.source"},{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","field":"prevalence.source"},{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","field":"prevalence.source"},{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"prevalence.source"},{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","field":"prevalence.source"},{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","field":"prevalence.source"},{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=gbc_msk_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"cBioPortal study gbc_msk_2018 (Gallbladder Cancer, MSK, Cancer 2018; 103 samples)"},{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/","field":"links","label":"cBioPortal study gbc_msk_2018 (Gallbladder Cancer, MSK, Cancer 2018; 103 samples)"}]},{"url":"https://www.cbioportal.org/study/summary?id=gbc_mskcc_2022","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"cBioPortal study gbc_mskcc_2022 (Gallbladder Cancer, MSK 2022; 244 samples from 233 patients)"},{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/","field":"links","label":"cBioPortal study gbc_mskcc_2022 (Gallbladder Cancer, MSK 2022; 244 samples from 233 patients)"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","field":"prevalence.source"},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"prevalence.source"},{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"prevalence.source"},{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"prevalence.source"},{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"prevalence.source"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"prevalence.source"},{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","field":"prevalence.source"},{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","field":"prevalence.source"},{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=gbc_shanghai_2014","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"cBioPortal study gbc_shanghai_2014 (Gallbladder Carcinoma, Shanghai, Nat Genet 2014; 32 exomes)"},{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/","field":"links","label":"cBioPortal study gbc_shanghai_2014 (Gallbladder Carcinoma, Shanghai, Nat Genet 2014; 32 exomes)"}]},{"url":"https://www.cbioportal.org/study/summary?id=gbm_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=hnsc_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=kirc_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","field":"prevalence.source"},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=kirp_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=laml_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","field":"prevalence.source"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"prevalence.source"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=lgg_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","field":"links","label":"cBioPortal study luad_mskcc_2023_met_organotropism (MSK, Cancer Cell 2023; 2,653 MSK-IMPACT lung adenocarcinoma samples, 2,422 with copy number and structural variants)"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"prevalence.source"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"prevalence.source"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/","field":"links","label":"cBioPortal study luad_mskcc_2023_met_organotropism (MSK, Cancer Cell 2023; 2,653 MSK-IMPACT lung adenocarcinoma samples, 2,422 with copy number and structural variants)"},{"id":"nf1","kind":"target","name":"NF1 (neurofibromin)","route":"/targets/nf1/","field":"prevalence.source"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"prevalence.source"},{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","field":"prevalence.source"},{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"prevalence.source"},{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","field":"prevalence.source"},{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","field":"prevalence.source"},{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=luad_oncosg_2020","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/","field":"links","label":"cBioPortal study luad_oncosg_2020 (OncoSG, Nat Genet 2020; 305 East Asian lung adenocarcinomas, 302 sequenced)"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","field":"prevalence.source"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"prevalence.source"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","field":"prevalence.source"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=luad_tcga_pub","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/","field":"links","label":"cBioPortal study luad_tcga_pub (TCGA, Nature 2014; the 230 resected lung adenocarcinomas of the landmark paper)"}]},{"url":"https://www.cbioportal.org/study/summary?id=lung_msk_2017","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","field":"prevalence.source"},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/","field":"links","label":"cBioPortal study lung_msk_2017 (MSK, Cancer Discov 2017; 915 MSK-IMPACT samples from the 860 prospectively sequenced metastatic lung adenocarcinomas)"}]},{"url":"https://www.cbioportal.org/study/summary?id=lung_nci_2022","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/","field":"links","label":"cBioPortal study lung_nci_2022 (Sherlock-Lung, NCI, Nat Genet 2021; 232 whole genomes of lung cancer in never smokers)"}]},{"url":"https://www.cbioportal.org/study/summary?id=lusc_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","field":"prevalence.source"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"prevalence.source"},{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","field":"prevalence.source"},{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=lusc_tcga_pub","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-squamous-nature-2012","kind":"paper","name":"Comprehensive genomic characterization of squamous cell lung cancers","route":"/key-papers/paper-tcga-lung-squamous-nature-2012/","field":"links","label":"cBioPortal study lusc_tcga_pub (TCGA, Nature 2012; the 178 squamous cell lung cancers of the landmark paper)"}]},{"url":"https://www.cbioportal.org/study/summary?id=nsclc_ctdx_msk_2022","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=nsclc_pd1_msk_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/","field":"links","label":"cBioPortal study nsclc_pd1_msk_2018 (MSK, J Clin Oncol 2018; 240 non-small-cell lung cancers profiled before PD-(L)1 blockade)"},{"id":"stk11-keap1-loss","kind":"biomarker","name":"STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma","route":"/biomarkers/stk11-keap1-loss/","field":"links","label":"cBioPortal study nsclc_pd1_msk_2018 (MSK, J Clin Oncol 2018; 240 non-small-cell lung cancers profiled before PD-(L)1 blockade)"}]},{"url":"https://www.cbioportal.org/study/summary?id=nsclc_tcga_broad_2016","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/","field":"links","label":"cBioPortal study nsclc_tcga_broad_2016 (Pan-Lung TCGA and Broad, Nat Genet 2016; 1,144 tumour-normal pairs, 660 adenocarcinoma and 484 squamous)"}]},{"url":"https://www.cbioportal.org/study/summary?id=ov_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=paad_icgc","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-biankin-pancreatic-exomes-axon-guidance-nature-2012","kind":"paper","name":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","route":"/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/","field":"links","label":"cBioPortal study paad_icgc (ICGC/APGI, Nature 2012; 99 exomes)"}]},{"url":"https://www.cbioportal.org/study/summary?id=paad_qcmg_uq_2016","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-bailey-molecular-subtypes-pancreatic-nature-2016","kind":"paper","name":"Genomic analyses identify molecular subtypes of pancreatic cancer","route":"/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/","field":"links","label":"cBioPortal study paad_qcmg_uq_2016 (QCMG, Nature 2016; 456 samples, 383 sequenced, no copy-number profile)"}]},{"url":"https://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","kind":"paper","name":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/","field":"links","label":"cBioPortal study paad_tcga_pan_can_atlas_2018 (TCGA PanCancer Atlas; 184 samples, 179 sequenced, 183 with copy number; the deposit keeps the low-cellularity and non-ductal samples the 2017 paper excluded)"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=paad_utsw_2015","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","kind":"paper","name":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","route":"/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/","field":"links","label":"cBioPortal study paad_utsw_2015 (UTSW, Nat Commun 2015; 109 microdissected exomes with copy number)"}]},{"url":"https://www.cbioportal.org/study/summary?id=pdac_msk_2024","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","field":"prevalence.source"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"prevalence.source"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"prevalence.source"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"prevalence.source"},{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"prevalence.source"},{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"prevalence.source"},{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","field":"prevalence.source"},{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","field":"prevalence.source"},{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_broad","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012","kind":"paper","name":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","route":"/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/","field":"links","label":"cBioPortal study prad_broad (Broad and Cornell, Nat Genet 2012; 112 sequenced primary tumour and normal pairs)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_cpcg_2017","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_eururol_2017","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","kind":"paper","name":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","route":"/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/","field":"links","label":"cBioPortal study prad_eururol_2017 (Second Military Medical University, Eur Urol 2018; 65 treatment-naive Chinese prostate cancers)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_fhcrc","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","kind":"paper","name":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","route":"/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/","field":"links","label":"cBioPortal study prad_fhcrc (Fred Hutchinson, Nat Med 2016; 141 sequenced and 149 copy-number-profiled metastases from men with disseminated prostate cancer)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_mcspc_mskcc_2020","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020","kind":"paper","name":"Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/","field":"links","label":"cBioPortal study prad_mcspc_mskcc_2020 (MSK, Clin Cancer Res 2020; 424 metastatic castration-sensitive prostate cancers)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_mich","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/","field":"links","label":"cBioPortal study prad_mich (University of Michigan, Nature 2012; 61 samples, 50 lethal castration-resistant cancers at rapid autopsy and 11 treatment-naive primaries)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_msk_stopsack_2021","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-stopsack-prostate-genomes-by-race-ccr-2022","kind":"paper","name":"Differences in prostate cancer genomes by self-reported race","route":"/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/","field":"links","label":"cBioPortal study prad_msk_stopsack_2021 (MSK-IMPACT, Clin Cancer Res 2022; 2,069 men with self-reported race recorded, 1,841 White, 165 Black, 63 Asian)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_p1000","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","kind":"paper","name":"The long tail of oncogenic drivers in prostate cancer","route":"/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/","field":"links","label":"cBioPortal study prad_p1000 (MSK and Dana-Farber, Nat Genet 2018; 1,013 uniformly reanalysed prostate cancer exomes, primary and metastatic)"},{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_su2c_2015","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/","field":"links","label":"cBioPortal: SU2C/PCF prostate (2015)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_su2c_2019","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","kind":"paper","name":"Genomic correlates of clinical outcome in advanced prostate cancer","route":"/key-papers/paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019/","field":"links","label":"cBioPortal study prad_su2c_2019 (SU2C/PCF Dream Team, PNAS 2019; 444 metastatic castration-resistant samples from 429 patients, whole exome)"},{"id":"ar-amplification","kind":"biomarker","name":"AR amplification (gene and upstream enhancer)","route":"/biomarkers/ar-amplification/","field":"links","label":"cBioPortal study prad_su2c_2019 (SU2C/PCF Dream Team, PNAS 2019; 444 metastatic castration-resistant samples from 429 patients, whole exome)"},{"id":"ar-ligand-binding-domain-mutation","kind":"biomarker","name":"AR ligand-binding-domain mutation (L702H, W742C, H875Y, T878A, F877L)","route":"/biomarkers/ar-ligand-binding-domain-mutation/","field":"links","label":"cBioPortal study prad_su2c_2019 (SU2C/PCF Dream Team, PNAS 2019; 444 metastatic castration-resistant samples from 429 patients, whole exome)"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","field":"links","label":"cBioPortal study prad_tcga_pan_can_atlas_2018 (TCGA PanCancer Atlas; 494 sequenced primary prostate adenocarcinomas, 489 with copy number, 494 with structural variants)"},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","field":"prevalence.source"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"prevalence.source"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","field":"prevalence.source"},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","field":"prevalence.source"},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"prevalence.source"},{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"prevalence.source"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"prevalence.source"},{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","field":"prevalence.source"},{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_tcga_pub","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","field":"links","label":"cBioPortal study prad_tcga_pub (TCGA, Cell 2015; the 333 primary tumours of the published molecular taxonomy)"},{"id":"tmprss2-erg-fusion","kind":"biomarker","name":"TMPRSS2-ERG fusion (and the other ETS rearrangements)","route":"/biomarkers/tmprss2-erg-fusion/","field":"links","label":"cBioPortal study prad_tcga_pub (TCGA, Cell 2015; the 333 primary tumours of the published molecular taxonomy)"},{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","field":"prevalence.source"},{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","field":"prevalence.source"},{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=prostate_msk_2024","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spop-mutation","kind":"biomarker","name":"SPOP mutation","route":"/biomarkers/spop-mutation/","field":"links","label":"cBioPortal study prostate_msk_2024 (MSK-IMPACT, Clin Cancer Res 2024; 2,260 prostate cancers, the largest panel cohort, primary and metastatic)"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"},{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"prevalence.source"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"prevalence.source"},{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","field":"prevalence.source"},{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","field":"prevalence.source"},{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","field":"prevalence.source"},{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=sclc_ucologne_2015","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/","field":"links","label":"cBioPortal study sclc_ucologne_2015 (University of Cologne, Nature 2015; 120 small-cell lung cancers, no copy-number profile deposited)"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","field":"prevalence.source"},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"prevalence.source"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=skcm_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=stad_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/","field":"prevalence.source"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=thca_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","field":"prevalence.source"}]},{"url":"https://www.cbioportal.org/study/summary?id=ucec_tcga_pan_can_atlas_2018","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","field":"prevalence.source"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","field":"prevalence.source"}]},{"url":"https://www.ccanewsonline.com/issues/2026/march-2026-vol-7-no-1/zanidatamab-improves-survival-outcomes-in-her2-positive-biliary-tract-cancer-post-hoc-herizon-btc-01-analysis","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","field":"links","label":"Post-hoc HERIZON-BTC-01 analysis"}]},{"url":"https://www.ccc-muenchen.de","status":200,"ok":true,"finalUrl":"https://www.ccc-muenchen.de/ccc-muenchen","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"CCC München"}]},{"url":"https://www.ccc.ac.at","status":200,"ok":true,"finalUrl":"https://ccc.meduniwien.ac.at/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"links","label":"CCC Vienna website"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"profiles","label":"CCC Vienna website"},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","field":"links","label":"CCC Vienna"},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","field":"website"}]},{"url":"https://www.ccdatalab.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","field":"links","label":"Childhood Cancer Data Lab"}]},{"url":"https://www.ccia.org.au","status":200,"ok":true,"finalUrl":"https://www.ccia.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","field":"links","label":"Children's Cancer Institute"}]},{"url":"https://www.ccia.org.au/about-cci/our-people","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","field":"links","label":"Institution profile"},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cclg.org.uk","status":200,"ok":true,"finalUrl":"https://www.cclg.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","route":"/companies/cclg/","field":"links","label":"CCLG"},{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","route":"/companies/cclg/","field":"website"}]},{"url":"https://www.cclg.org.uk/about-us/our-team/our-executive-members","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ashley-ball-gamble","kind":"person","name":"Ashley Ball-Gamble","route":"/people/ashley-ball-gamble/","field":"links","label":"Source: CCLG executive members page"},{"id":"ashley-ball-gamble","kind":"person","name":"Ashley Ball-Gamble","route":"/people/ashley-ball-gamble/","field":"profiles","label":"Institution executive members page"}]},{"url":"https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/03-Barnabas-HPV-508.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","field":"outcomes.source (Vaccine efficacy against persistent HPV16/18 infection)"}]},{"url":"https://www.cdc.gov/breast-cervical-cancer-screening/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","route":"/collections/cdc-nbccedp/","field":"links","label":"CDC National Breast and Cervical Cancer Early Detection Program"},{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","route":"/collections/cdc-nbccedp/","field":"url"}]},{"url":"https://www.cdc.gov/niosh/healthcare/hazardous-drugs/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"closed-system-transfer-devices","kind":"technology","name":"Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)","route":"/technologies/closed-system-transfer-devices/","field":"links","label":"NIOSH: hazardous drug exposures in healthcare, closed system drug-transfer devices"}]},{"url":"https://www.cdisc.org","status":200,"ok":true,"finalUrl":"https://www.cdisc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","field":"links","label":"CDISC"},{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","field":"website"}]},{"url":"https://www.cdisc.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/","field":"links","label":"CDISC standards"},{"id":"idea-tr1-open-protocol-and-sap-library","kind":"idea","name":"Open-source protocol and statistical analysis plan templates with runnable code","route":"/ideas/idea-tr1-open-protocol-and-sap-library/","field":"links","label":"CDISC"},{"id":"idea-data-trial-to-registry-bridge","kind":"idea","name":"Map trial case report forms to the registry standard so trial and routine data join","route":"/ideas/idea-data-trial-to-registry-bridge/","field":"links","label":"CDISC"}]},{"url":"https://www.cdisc.org/leadership-team","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chris-decker","kind":"person","name":"Chris Decker","route":"/people/chris-decker/","field":"links","label":"Institution profile"},{"id":"chris-decker","kind":"person","name":"Chris Decker","route":"/people/chris-decker/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cdisc.org/standards","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","field":"links","label":"Standards"}]},{"url":"https://www.cebiotex.com","status":200,"ok":true,"finalUrl":"https://www.cebiotex.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/","field":"links","label":"Official website"},{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/","field":"website"}]},{"url":"https://www.cedars-sinai.org/newsroom/beckers-healthcare-podcast-expanding-access-translational-research-and-the-future-of-cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/","field":"profiles","label":"Institution newsroom (March 2026)"}]},{"url":"https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-director-stepping-down/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/","field":"links","label":"Source: Cedars-Sinai newsroom, director stepping down (Feb 2025)"}]},{"url":"https://www.cedars-sinai.org/programs/cancer.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","field":"links","label":"Cedars-Sinai Cancer"},{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","field":"website"}]},{"url":"https://www.cedars-sinai.org/research/clinical-trials.html","status":200,"ok":true,"finalUrl":"https://clinicaltrials.cedars-sinai.edu/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","field":"links","label":"Clinical trials"}]},{"url":"https://www.celcuity.com","status":200,"ok":true,"finalUrl":"https://www.celcuity.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/","field":"links","label":"Official website"},{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/","field":"website"}]},{"url":"https://www.cellares.com","status":200,"ok":true,"finalUrl":"https://www.cellares.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","field":"links","label":"Official website"},{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","field":"website"}]},{"url":"https://www.celldex.com","status":200,"ok":true,"finalUrl":"https://celldex.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/","field":"website"}]},{"url":"https://www.cellectar.com","status":200,"ok":true,"finalUrl":"https://www.cellectar.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"links","label":"Official website"},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"website"}]},{"url":"https://www.cellectis.com","status":200,"ok":true,"finalUrl":"https://www.cellectis.com/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ucart22","kind":"drug","name":"UCART22","route":"/drugs/ucart22/","field":"links","label":"Sponsor page"},{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/","field":"links","label":"Official website"},{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/","field":"website"}]},{"url":"https://www.cellogentherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.cellogentherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellogen","kind":"company","name":"Cellogen Therapeutics","route":"/companies/cellogen/","field":"links","label":"Official website"},{"id":"cellogen","kind":"company","name":"Cellogen Therapeutics","route":"/companies/cellogen/","field":"website"}]},{"url":"https://www.cellosaurus.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-cell-line-authentication-mandate","kind":"idea","name":"Prove your cell lines are what you say they are, or the paper is not published","route":"/ideas/idea-tr2-cell-line-authentication-mandate/","field":"links","label":"Cellosaurus"},{"id":"idea-tr2-cell-line-passport","kind":"idea","name":"A digital passport for every cell culture: identity, contamination status, passage number","route":"/ideas/idea-tr2-cell-line-passport/","field":"links","label":"Cellosaurus"}]},{"url":"https://www.cellsearchctc.com","status":200,"ok":true,"finalUrl":"https://www.cellsearchctc.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cellsearch-ctc-count","kind":"technology","name":"CellSearch circulating tumour cell count","route":"/technologies/cellsearch-ctc-count/","field":"links","label":"CellSearch system (Menarini Silicon Biosystems)"},{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","route":"/companies/menarini-silicon-biosystems/","field":"links","label":"CellSearch"}]},{"url":"https://www.cellsighttech.com","status":200,"ok":true,"finalUrl":"https://www.cellsighttech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","route":"/companies/cellsight-technologies/","field":"links","label":"Official website"},{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","route":"/companies/cellsight-technologies/","field":"website"}]},{"url":"https://www.celltrion.com","status":200,"ok":true,"finalUrl":"https://www.celltrion.com/en-us","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/","field":"links","label":"Official website"},{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/","field":"website"}]},{"url":"https://www.centre-eugene-marquis.fr","status":200,"ok":true,"finalUrl":"https://www.centre-eugene-marquis.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","field":"links","label":"Official website"},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","field":"website"}]},{"url":"https://www.centre-eugene-marquis.fr/organigramme-de-direction/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","route":"/people/renaud-de-crevoisier/","field":"links","label":"Source: Centre Eugène Marquis organigramme de direction"},{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","route":"/people/renaud-de-crevoisier/","field":"profiles","label":"Centre Eugène Marquis direction organigramme"}]},{"url":"https://www.centreantoinelacassagne.org","status":200,"ok":true,"finalUrl":"https://www.centreantoinelacassagne.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","field":"links","label":"Homepage"},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","field":"website"}]},{"url":"https://www.centreantoinelacassagne.org/organisation-du-centre/","status":200,"ok":true,"finalUrl":"https://www.centreantoinelacassagne.org/le-centre/organisation-du-centre/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/","field":"links","label":"Source: Centre Antoine Lacassagne organisation page"},{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/","field":"profiles","label":"Institution organisation page"}]},{"url":"https://www.centreleonberard.fr","status":200,"ok":true,"finalUrl":"https://www.centreleonberard.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","field":"links","label":"Homepage"},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","field":"website"}]},{"url":"https://www.centreleonberard.fr/comment-est-organise-le-centre-leon-berard","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","field":"links","label":"Institution profile"},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.centreoscarlambret.fr","status":200,"ok":true,"finalUrl":"https://www.centreoscarlambret.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"links","label":"Centre Oscar Lambret website"},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"profiles","label":"Centre Oscar Lambret website"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","field":"links","label":"Homepage"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","field":"website"}]},{"url":"https://www.centurytx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","field":"links","label":"Official website"},{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","field":"website"}]},{"url":"https://www.certisoncology.com","status":200,"ok":true,"finalUrl":"https://www.certisoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/","field":"links","label":"Official website"},{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/","field":"website"}]},{"url":"https://www.certisoncology.com/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/","field":"links","label":"About us"}]},{"url":"https://www.cgen.com","status":200,"ok":true,"finalUrl":"https://www.cgen.com/overview/default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/","field":"links","label":"Compugen"},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/","field":"website"},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","field":"links","label":"Compugen, which predicted the target computationally and made the antibody"}]},{"url":"https://www.cgfl.fr","status":200,"ok":true,"finalUrl":"https://www.cgfl.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"links","label":"Centre Georges-François Leclerc website"},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"profiles","label":"Centre Georges-François Leclerc website"},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","route":"/institutions/centre-georges-francois-leclerc/","field":"links","label":"Official website"},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","route":"/institutions/centre-georges-francois-leclerc/","field":"website"}]},{"url":"https://www.cgmh.org.tw","status":200,"ok":true,"finalUrl":"https://www.cgmh.org.tw/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","field":"links","label":"Chang Gung Memorial Hospital"},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260831084829/https://www.cgmh.org.tw/"},{"url":"https://www.chaidiscovery.com","status":200,"ok":true,"finalUrl":"https://www.chaidiscovery.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/","field":"links","label":"Official website"},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/","field":"website"},{"id":"chai-1","kind":"technology","name":"Chai-1 / Chai-2","route":"/technologies/chai-1/","field":"links","label":"Chai Discovery"}]},{"url":"https://www.championsoncology.com","status":200,"ok":true,"finalUrl":"https://www.championsoncology.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","field":"website"}]},{"url":"https://www.championsoncology.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","field":"links","label":"Company site"}]},{"url":"https://www.changingfaces.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Changing Faces: support for people with a visible difference"},{"id":"facial-scar-after-skin-cancer","kind":"term","name":"The scar on the face after skin cancer surgery","route":"/terms/facial-scar-after-skin-cancer/","field":"links","label":"Changing Faces: support for people with a visible difference"}]},{"url":"https://www.charite.de","status":200,"ok":true,"finalUrl":"https://www.charite.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"links","label":"Official website"},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"website"}]},{"url":"https://www.checkpointtherapeutics.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/","field":"links","label":"Official website"},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20250714142442/http://checkpointtherapeutics.com/"},{"url":"https://www.childrenshospital.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","field":"links","label":"Boston Children's Hospital"},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","field":"profiles","label":"Boston Children's Hospital"}]},{"url":"https://www.childrensnational.org","status":200,"ok":true,"finalUrl":"https://www.childrensnational.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","route":"/institutions/childrens-national-hospital/","field":"links","label":"Children's National"},{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","route":"/institutions/childrens-national-hospital/","field":"website"}]},{"url":"https://www.chinablood.com.cn/","status":200,"ok":true,"finalUrl":"https://www.chinablood.com.cn/index.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-hematology/","field":"links","label":"Official website"},{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-hematology/","field":"website"}]},{"url":"https://www.chinablood.com.cn/en/IHCAMS.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","field":"links","label":"Source: IHCAMS English introduction"}]},{"url":"https://www.chinablood.com.cn/en/science/team.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","field":"profiles","label":"IHCAMS research team page (English)"}]},{"url":"https://www.chinablood.com.cn/jyb/hospitals.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","field":"links","label":"Source: IHCAMS leadership team listing (Chinese)"},{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","field":"profiles","label":"Hospital overview and leadership team (Chinese)"}]},{"url":"https://www.chop.edu","status":200,"ok":true,"finalUrl":"https://www.chop.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","field":"links","label":"Children's Hospital of Philadelphia"},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","field":"website"}]},{"url":"https://www.chop.edu/about-us/executive-leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"madeline-bell","kind":"person","name":"Madeline Bell","route":"/people/madeline-bell/","field":"links","label":"Institution profile"},{"id":"madeline-bell","kind":"person","name":"Madeline Bell","route":"/people/madeline-bell/","field":"profiles","label":"Institution profile"},{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"links","label":"Institution profile"},{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.chop.edu/centers-programs/cancer-center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","field":"links","label":"CHOP Cancer Center"}]},{"url":"https://www.chordomafoundation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","field":"links","label":"Chordoma Foundation"}]},{"url":"https://www.chrishanibaragwanathhospital.co.za","status":200,"ok":true,"finalUrl":"https://www.chrishanibaragwanathhospital.co.za/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-hani-baragwanath","kind":"institution","name":"Chris Hani Baragwanath Academic Hospital","route":"/institutions/chris-hani-baragwanath/","field":"links","label":"Official website"},{"id":"chris-hani-baragwanath","kind":"institution","name":"Chris Hani Baragwanath Academic Hospital","route":"/institutions/chris-hani-baragwanath/","field":"website"}]},{"url":"https://www.chrishanibaragwanathhospital.co.za/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandile-mfenyana","kind":"person","name":"Sandile Mfenyana","route":"/people/sandile-mfenyana/","field":"links","label":"Source: hospital website naming the CEO"},{"id":"sandile-mfenyana","kind":"person","name":"Sandile Mfenyana","route":"/people/sandile-mfenyana/","field":"profiles","label":"Chris Hani Baragwanath Academic Hospital website"}]},{"url":"https://www.christie.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.christie.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","field":"links","label":"Official website"},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","field":"website"}]},{"url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/armstrong-anne","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","route":"/people/anne-armstrong/","field":"links","label":"The Christie consultant page"},{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","route":"/people/anne-armstrong/","field":"profiles","label":"The Christie consultant page"}]},{"url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/mcnamara-mairead","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/","field":"links","label":"The Christie consultant page"},{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/","field":"profiles","label":"The Christie consultant page"}]},{"url":"https://www.christie.nhs.uk/your-treatment-and-care/services/clinical-oncology/meet-the-clinical-oncology-teams/breast","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","route":"/people/anne-armstrong/","field":"links","label":"The Christie breast clinical oncology team"},{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","route":"/people/anne-armstrong/","field":"profiles","label":"The Christie breast clinical oncology team"}]},{"url":"https://www.chu-lille.fr","status":200,"ok":true,"finalUrl":"https://www.chu-lille.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/","field":"links","label":"CHU de Lille"},{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/","field":"website"}]},{"url":"https://www.chu-nantes.fr","status":200,"ok":true,"finalUrl":"https://www.chu-nantes.fr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/","field":"links","label":"CHU de Nantes"},{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/","field":"website"}]},{"url":"https://www.chudequebec.ca","status":200,"ok":true,"finalUrl":"https://www.chudequebec.ca/accueil.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","route":"/institutions/chu-de-quebec/","field":"links","label":"Official website"},{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","route":"/institutions/chu-de-quebec/","field":"website"}]},{"url":"https://www.chudequebec.ca/a-propos-de-nous/direction-et-gouvernance/directions.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-beaumont","kind":"person","name":"Martin Beaumont","route":"/people/martin-beaumont/","field":"links","label":"Source: CHU de Québec directions page"},{"id":"martin-beaumont","kind":"person","name":"Martin Beaumont","route":"/people/martin-beaumont/","field":"profiles","label":"CHU de Québec directions page"}]},{"url":"https://www.chugai-pharm.co.jp/english/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","field":"links","label":"Official website"},{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","field":"website"}]},{"url":"https://www.chumontreal.qc.ca","status":200,"ok":true,"finalUrl":"https://www.chumontreal.qc.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","field":"links","label":"CHUM"},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","field":"website"}]},{"url":"https://www.chumontreal.qc.ca/propos-chum/leadership-organisationnel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","route":"/people/marie-eve-desrosiers/","field":"profiles","label":"Institution leadership page"}]},{"url":"https://www.chuv.ch/","status":200,"ok":true,"finalUrl":"https://www.chuv.ch/fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","field":"links","label":"CHUV Oncology (page moved; nearest live section)"},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","field":"website"}]},{"url":"https://www.cicams.ac.cn","status":200,"ok":true,"finalUrl":"https://www.cicams.ac.cn/index.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/","field":"links","label":"Official website"},{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/","field":"website"},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","field":"profiles","label":"Cancer Hospital, CAMS"},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","field":"profiles","label":"Cancer Hospital, CAMS"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","field":"profiles","label":"Cancer Hospital, CAMS"},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","field":"profiles","label":"Cancer Hospital, CAMS"},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","field":"profiles","label":"Cancer Hospital, CAMS"},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","field":"links","label":"Cancer Hospital, CAMS"},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","field":"profiles","label":"Cancer Hospital, CAMS"}]},{"url":"https://www.cinj.org","status":200,"ok":true,"finalUrl":"https://cinj.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","field":"links","label":"Rutgers Cancer Institute"},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","field":"website"}]},{"url":"https://www.cinj.org/","status":200,"ok":true,"finalUrl":"https://cinj.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","field":"links","label":"Rutgers Cancer Institute home page naming the Director"}]},{"url":"https://www.cinj.org/about-cinj/steven-k-libutti-md-facs","status":200,"ok":true,"finalUrl":"https://cinj.org/about-cinj/steven-k-libutti-md-facs","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","field":"links","label":"Source: Rutgers Cancer Institute leadership profile"},{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","field":"profiles","label":"Rutgers Cancer Institute profile"}]},{"url":"https://www.cinj.org/clinical-trials","status":200,"ok":true,"finalUrl":"https://cinj.org/clinical-trials/clinical-trials-overview","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","field":"links","label":"Clinical trials"}]},{"url":"https://www.cipla.com","status":200,"ok":true,"finalUrl":"https://www.cipla.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cipla","kind":"company","name":"Cipla","route":"/companies/cipla/","field":"links","label":"Official website"},{"id":"cipla","kind":"company","name":"Cipla","route":"/companies/cipla/","field":"website"}]},{"url":"https://www.cira.kyoto-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.cira.kyoto-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","field":"links","label":"Center for iPS Cell Research and Application"}]},{"url":"https://www.cirm.ca.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","field":"links","label":"CIRM"}],"archive":"https://web.archive.org/web/20260831123322/https://www.cirm.ca.gov/"},{"url":"https://www.citiuspharma.com","status":200,"ok":true,"finalUrl":"https://www.citiuspharma.com/home/default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"citius-pharmaceuticals","kind":"company","name":"Citius Pharmaceuticals","route":"/companies/citius-pharmaceuticals/","field":"links","label":"Official website"},{"id":"citius-pharmaceuticals","kind":"company","name":"Citius Pharmaceuticals","route":"/companies/citius-pharmaceuticals/","field":"website"}]},{"url":"https://www.civatechoncology.com","status":200,"ok":true,"finalUrl":"https://civatechoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","route":"/companies/civatech-oncology/","field":"links","label":"Official website"},{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","route":"/companies/civatech-oncology/","field":"website"}]},{"url":"https://www.cjp.fr","status":200,"ok":true,"finalUrl":"https://www.cjp.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"centre-jean-perrin","kind":"institution","name":"Centre Jean Perrin","route":"/institutions/centre-jean-perrin/","field":"links","label":"Official website"},{"id":"centre-jean-perrin","kind":"institution","name":"Centre Jean Perrin","route":"/institutions/centre-jean-perrin/","field":"website"}]},{"url":"https://www.cjp.fr/nous-connaitre/notre-organisation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","route":"/people/frederique-penault-llorca/","field":"links","label":"Source: Centre Jean Perrin organisation page"},{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","route":"/people/frederique-penault-llorca/","field":"profiles","label":"Centre Jean Perrin organisation page"}]},{"url":"https://www.claritypharmaceuticals.com","status":200,"ok":true,"finalUrl":"https://www.claritypharmaceuticals.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","field":"website"}]},{"url":"https://www.clatterbridgecc.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.clatterbridgecc.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","route":"/institutions/clatterbridge/","field":"links","label":"Official website"},{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","route":"/institutions/clatterbridge/","field":"website"}]},{"url":"https://www.clatterbridgecc.nhs.uk/about-us/news/trust-appoints-joan-spencer-chief-executive","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","field":"profiles","label":"Trust announcement of permanent appointment"}]},{"url":"https://www.clearnotehealth.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","field":"links","label":"Official website"},{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","field":"website"}]},{"url":"https://www.clearnotehealth.com/category/press-release/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","field":"links","label":"Press release archive"}]},{"url":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","field":"links","label":"Series D press release (May 2026)"}]},{"url":"https://www.clevelandclinicabudhabi.ae","status":200,"ok":true,"finalUrl":"https://www.clevelandclinicabudhabi.ae/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","field":"links","label":"Cleveland Clinic Abu Dhabi"},{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","field":"website"}]},{"url":"https://www.clevelandclinicabudhabi.ae/en/about-us/leadership-team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","field":"links","label":"Institution profile"},{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","field":"profiles","label":"Institution profile"},{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","field":"links","label":"Institution profile"},{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","field":"links","label":"Trials of AI-designed drugs"}]},{"url":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002036-17","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"preopanc-2","kind":"trial","name":"PREOPANC-2","route":"/trials/preopanc-2/","field":"links","label":"EU Clinical Trials Register 2017-002036-17"}]},{"url":"https://www.clinicbarcelona.org/en","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","field":"links","label":"Homepage"},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","field":"website"}]},{"url":"https://www.clinicbarcelona.org/en/assistance/management-board","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","route":"/people/josep-maria-campistol/","field":"links","label":"Institution profile"},{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","route":"/people/josep-maria-campistol/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.clinicbarcelona.org/en/idibaps","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","field":"links","label":"IDIBAPS"}]},{"url":"https://www.clinicbarcelona.org/en/idibaps/about-us/scientific-organizational-structure","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","field":"links","label":"Institution profile"},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","field":"profiles","label":"Institution profile"},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","field":"links","label":"Institution profile"},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.clo.cuhk.edu.hk/staff/university-staff/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","field":"links","label":"Institution profile"},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","field":"profiles","label":"Institution profile"},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","field":"links","label":"Institution profile"},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.clonoseq.com","status":200,"ok":true,"finalUrl":"https://www.clonoseq.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/","field":"links","label":"clonoSEQ"}]},{"url":"https://www.cmcanceralliance.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.cmcanceralliance.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","route":"/institutions/cheshire-merseyside-cancer-alliance/","field":"links","label":"Cheshire and Merseyside Cancer Alliance"},{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","route":"/institutions/cheshire-merseyside-cancer-alliance/","field":"website"}]},{"url":"https://www.cmch-vellore.edu","status":200,"ok":true,"finalUrl":"https://www.cmch-vellore.edu/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/","field":"links","label":"CMC Vellore"},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/","field":"website"}]},{"url":"https://www.cmch-vellore.edu/administration/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/","field":"links","label":"Source: CMC Vellore administration page"},{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/","field":"profiles","label":"CMC Vellore administration page"}]},{"url":"https://www.cmcseoul.or.kr","status":200,"ok":true,"finalUrl":"https://www.cmcseoul.or.kr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","field":"links","label":"Seoul St. Mary's Hospital"},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","field":"website"}]},{"url":"https://www.cmcseoul.or.kr/en.aboutus.greeting.sp","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","route":"/people/yoon-seung-kew/","field":"links","label":"Source: Seoul St. Mary's Hospital president's greeting"},{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","route":"/people/yoon-seung-kew/","field":"profiles","label":"President's greeting"}]},{"url":"https://www.cms.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare","status":200,"ok":true,"finalUrl":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-inflation-rebate-program","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-inflation-rebates-commercial","kind":"idea","name":"Extend Medicare's inflation rebates to employer plans","route":"/ideas/idea-cost-inflation-rebates-commercial/","field":"links","label":"CMS: Medicare Prescription Drug Inflation Rebate Program"}]},{"url":"https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation","status":200,"ok":true,"finalUrl":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","field":"links","label":"CMS Medicare Drug Price Negotiation Program"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","field":"links","label":"CMS Medicare Drug Price Negotiation"}]},{"url":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","field":"links","label":"CMS: Medicare Drug Price Negotiation Program"}]},{"url":"https://www.cms.gov/medicare/coverage/evidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","field":"links","label":"CMS: coverage with evidence development"}]},{"url":"https://www.cms.gov/medicare/payment/part-b-drugs/","status":200,"ok":true,"finalUrl":"https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-vial-sharing-dose-rounding","kind":"idea","name":"Share vials and round doses to stop throwing away expensive drug","route":"/ideas/idea-cost-vial-sharing-dose-rounding/","field":"links","label":"CMS: Discarded drug refunds (JW and JZ modifiers) (page moved; nearest live section)"}]},{"url":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"access.source (US)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"access.source (US)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"access.source (US)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"access.source (US)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"access.source (US)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"access.source (US)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"access.source (US)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"access.source (US)"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","field":"access.source (US)"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"access.source (US)"},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"access.source (US)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"access.source (US)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"access.source (US)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"access.source (US)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"access.source (US)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"access.source (US)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"access.source (US)"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"access.source (US)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"access.source (US)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"access.source (US)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"access.source (US)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"access.source (US)"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"access.source (US)"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"access.source (US)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"access.source (US)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"access.source (US)"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"access.source (US)"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"access.source (US)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"access.source (US)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"access.source (US)"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"access.source (US)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"access.source (US)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"access.source (US)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"access.source (US)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"access.source (US)"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"access.source (US)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"access.source (US)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"access.source (US)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"access.source (US)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"access.source (US)"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"access.source (US)"},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","field":"access.source (US)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"access.source (US)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"access.source (US)"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"access.source (US)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"access.source (US)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"access.source (US)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"access.source (US)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"access.source (US)"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"access.source (US)"},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","field":"access.source (US)"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"access.source (US)"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"access.source (US)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"access.source (US)"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","field":"access.source (US)"},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"access.source (US)"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"access.source (US)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"access.source (US)"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"access.source (US)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"access.source (US)"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"access.source (US)"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"access.source (US)"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"access.source (US)"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"access.source (US)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"access.source (US)"},{"id":"idea-cost-asp-flat-fee","kind":"idea","name":"Pay a flat fee for giving a Part B drug instead of 6% of its price","route":"/ideas/idea-cost-asp-flat-fee/","field":"links","label":"CMS: Part B drug payment (ASP pricing files)"}]},{"url":"https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-site-neutral-infusion","kind":"idea","name":"Pay the same for an infusion whether it is given in a hospital or a clinic","route":"/ideas/idea-cost-site-neutral-infusion/","field":"links","label":"CMS: Hospital Outpatient Prospective Payment System"}]},{"url":"https://www.cms.gov/priorities/innovation/innovation-models/","status":200,"ok":true,"finalUrl":"https://www.cms.gov/priorities/innovation/models","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-cart-outcomes-refund","kind":"idea","name":"Full refund for CAR-T if the patient has not responded at three months","route":"/ideas/idea-reg-cart-outcomes-refund/","field":"links","label":"CMS Cell and Gene Therapy Access Model (page moved; nearest live section)"}]},{"url":"https://www.cms.gov/priorities/key-initiatives/burden-reduction/interoperability/policies-and-regulations/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f","status":200,"ok":true,"finalUrl":"https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-real-time-pa-fhir","kind":"idea","name":"Answer prior authorisation requests in seconds from the medical record","route":"/ideas/idea-cost-real-time-pa-fhir/","field":"links","label":"CMS Interoperability and Prior Authorization final rule (CMS-0057-F, January 2024)"}]},{"url":"https://www.cmu.edu/randyslecture/","status":200,"ok":true,"finalUrl":"https://etc.cmu.edu/about/last-lecture","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","field":"links","label":"Carnegie Mellon: The Last Lecture"},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","field":"profiles","label":"Carnegie Mellon: The Last Lecture"}]},{"url":"https://www.cnio.es/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","field":"links","label":"Homepage"},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","field":"website"}]},{"url":"https://www.cnio.es/en/about-the-cnio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"links","label":"Institution profile"},{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cnio.es/en/research-innovation/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","field":"links","label":"Research programmes"}]},{"url":"https://www.cnio.es/en/research/research-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/","status":200,"ok":true,"finalUrl":"https://www.cnio.es/en/research-innovation/scientific-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","field":"links","label":"Institution profile"},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cnio.es/en/the-cnio/","status":200,"ok":true,"finalUrl":"https://www.cnio.es/en/news/publications/the-cnio-and-hospital-12-de-octubre-find-a-potential-new-combination-therapy-against-a-rare-disease-of-the-bone-marrow/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","field":"links","label":"Institution profile"},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cogentbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","field":"links","label":"Official website"},{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","field":"website"}]},{"url":"https://www.cogentbio.com/pipeline","status":200,"ok":true,"finalUrl":"https://www.cogentbio.com/pipeline-publications/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.cogentbio.com/pipeline-publications/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","field":"links","label":"Pipeline and publications"}]},{"url":"https://www.coherus.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/","field":"links","label":"Official website"},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/","field":"website"}]},{"url":"https://www.colcc.ac.uk","status":200,"ok":true,"finalUrl":"https://www.colcc.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","route":"/institutions/cruk-city-of-london-centre/","field":"links","label":"Official website"},{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","route":"/institutions/cruk-city-of-london-centre/","field":"website"}]},{"url":"https://www.colcc.ac.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","field":"profiles","label":"CRUK City of London Centre website"}]},{"url":"https://www.color.com","status":200,"ok":true,"finalUrl":"https://www.color.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"links","label":"Official website"},{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"website"}]},{"url":"https://www.color.com/about-us","status":200,"ok":true,"finalUrl":"https://www.color.com/about-us/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"links","label":"About Color Health"}]},{"url":"https://www.colostomyuk.org/information/diet/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Colostomy UK: diet"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Colostomy UK: diet"}]},{"url":"https://www.colostomyuk.org/information/information-for-carers/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"Colostomy UK: caring for someone with a colostomy"}]},{"url":"https://www.colostomyuk.org/information/love-and-relationships/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Colostomy UK: love, sex and relationships"}]},{"url":"https://www.colostomyuk.org/information/managing-your-colostomy/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Colostomy UK: managing your colostomy"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"Colostomy UK: managing your colostomy"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"Colostomy UK: managing your colostomy"}]},{"url":"https://www.colostomyuk.org/information/prescriptions/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Colostomy UK: obtaining stoma prescription supplies"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"Colostomy UK: obtaining stoma prescription supplies"},{"id":"work-and-money-bowel-cancer-uk","kind":"term","name":"Work and money with bowel cancer (UK)","route":"/terms/work-and-money-bowel-cancer-uk/","field":"links","label":"Colostomy UK: obtaining stoma prescription supplies"}]},{"url":"https://www.colostomyuk.org/information/returning-to-work-after-stoma-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"Colostomy UK: returning to work after stoma surgery"},{"id":"work-and-money-bowel-cancer-uk","kind":"term","name":"Work and money with bowel cancer (UK)","route":"/terms/work-and-money-bowel-cancer-uk/","field":"links","label":"Colostomy UK: returning to work after stoma surgery"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Colostomy UK: returning to work after stoma surgery"}]},{"url":"https://www.comecer.com","status":200,"ok":true,"finalUrl":"https://www.comecer.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","field":"links","label":"Official website"},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","field":"website"}]},{"url":"https://www.compasstherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","field":"links","label":"Official website"},{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","field":"website"}]},{"url":"https://www.compasstherapeutics.com/pipeline","status":200,"ok":true,"finalUrl":"https://www.compasstherapeutics.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.comunidad.madrid/hospital/12octubre/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","field":"links","label":"Hospital Universitario 12 de Octubre website"},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","field":"profiles","label":"Hospital Universitario 12 de Octubre website"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","field":"links","label":"Homepage"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","field":"website"}]},{"url":"https://www.comunidad.madrid/hospital/clinicosancarlos","status":200,"ok":true,"finalUrl":"https://www.comunidad.madrid/hospital/clinicosancarlos/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","field":"links","label":"Hospital Clínico San Carlos website"},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","field":"profiles","label":"Hospital Clínico San Carlos website"},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","field":"links","label":"Official website"},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","field":"website"}]},{"url":"https://www.comunidad.madrid/hospital/gregoriomaranon","status":200,"ok":true,"finalUrl":"https://www.comunidad.madrid/hospital/gregoriomaranon/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","field":"links","label":"Official website"},{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","field":"website"},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"links","label":"Hospital General Universitario Gregorio Marañón website"},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"profiles","label":"Hospital General Universitario Gregorio Marañón website"}]},{"url":"https://www.comunidad.madrid/hospital/lapaz","status":200,"ok":true,"finalUrl":"https://www.comunidad.madrid/hospital/lapaz/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","field":"links","label":"Official website"},{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","field":"website"},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"links","label":"Hospital Universitario La Paz website"},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"profiles","label":"Hospital Universitario La Paz website"}]},{"url":"https://www.comunidad.madrid/hospital/laprincesa/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","field":"links","label":"Hospital Universitario de La Princesa website"},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","field":"profiles","label":"Hospital Universitario de La Princesa website"},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","field":"links","label":"Official website"},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","field":"website"}]},{"url":"https://www.comunidad.madrid/hospital/puertadehierro/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","field":"links","label":"Hospital Universitario Puerta de Hierro Majadahonda website"},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","field":"profiles","label":"Hospital Universitario Puerta de Hierro Majadahonda website"},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","field":"links","label":"Official website"},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","field":"website"}]},{"url":"https://www.comunidad.madrid/hospital/ramonycajal/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","field":"links","label":"Hospital Universitario Ramón y Cajal website"},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","field":"profiles","label":"Hospital Universitario Ramón y Cajal website"},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","field":"links","label":"Official website"},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","field":"website"}]},{"url":"https://www.concertai.com","status":200,"ok":true,"finalUrl":"https://www.concertai.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"concertai","kind":"company","name":"ConcertAI","route":"/companies/concertai/","field":"links","label":"Official website"},{"id":"concertai","kind":"company","name":"ConcertAI","route":"/companies/concertai/","field":"website"}]},{"url":"https://www.consort-statement.org/","status":200,"ok":true,"finalUrl":"https://www.consort-spirit.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","field":"links","label":"CONSORT statement: reporting randomised trials"},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","field":"links","label":"CONSORT statement: reporting randomised trials"},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/","field":"links","label":"CONSORT statement: reporting randomised trials"},{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/","field":"links","label":"CONSORT extension for cluster randomised trials"},{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/","field":"links","label":"CONSORT statement: reporting randomised trials"},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","field":"links","label":"CONSORT statement: reporting randomised trials"}]},{"url":"https://www.contraelcancer.es/es","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","field":"links","label":"Spanish Association Against Cancer (AECC) website"},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","field":"profiles","label":"Spanish Association Against Cancer (AECC) website"},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","field":"links","label":"Official website"},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","field":"website"}]},{"url":"https://www.contrelecancer.ma","status":200,"ok":true,"finalUrl":"https://www.contrelecancer.ma/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","field":"links","label":"Fondation Lalla Salma"}]},{"url":"https://www.convergencesciencecentre.ac.uk","status":200,"ok":true,"finalUrl":"https://www.convergencesciencecentre.ac.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/","field":"links","label":"Official website"},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/","field":"website"}]},{"url":"https://www.convergencesciencecentre.ac.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","field":"profiles","label":"CRUK Convergence Science Centre website"}]},{"url":"https://www.cookmedical.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cook-medical","kind":"company","name":"Cook Medical","route":"/companies/cook-medical/","field":"links","label":"Official website"},{"id":"cook-medical","kind":"company","name":"Cook Medical","route":"/companies/cook-medical/","field":"website"}]},{"url":"https://www.corbuspharma.com","status":200,"ok":true,"finalUrl":"https://www.corbuspharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","field":"links","label":"Official website"},{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","field":"website"},{"id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","field":"links","label":"Sponsor page"}]},{"url":"https://www.corcept.com","status":200,"ok":true,"finalUrl":"https://www.corcept.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","field":"links","label":"Official website"},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","field":"website"}]},{"url":"https://www.cormorantcapital.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","field":"links","label":"Official website (parked at time of research)"}]},{"url":"https://www.cornerstonepharma.com","status":200,"ok":true,"finalUrl":"https://cornerstonepharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","route":"/companies/cornerstone-pharmaceuticals/","field":"links","label":"Official website"},{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","route":"/companies/cornerstone-pharmaceuticals/","field":"website"}]},{"url":"https://www.corpangelnetwork.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"corporate-angel-network","kind":"collection","name":"Corporate Angel Network","route":"/collections/corporate-angel-network/","field":"links","label":"Corporate Angel Network"},{"id":"corporate-angel-network","kind":"collection","name":"Corporate Angel Network","route":"/collections/corporate-angel-network/","field":"url"}]},{"url":"https://www.corvuspharma.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","route":"/companies/corvus-pharmaceuticals/","field":"links","label":"Official website"},{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","route":"/companies/corvus-pharmaceuticals/","field":"website"}]},{"url":"https://www.cos.io/initiatives/registered-reports","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-preclinical-registered-reports","kind":"idea","name":"Registered reports for cancer biology: the plan is peer-reviewed before the result","route":"/ideas/idea-tr2-preclinical-registered-reports/","field":"links","label":"Registered Reports (Center for Open Science)"}]},{"url":"https://www.cos.io/rpcb","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-replication-set-aside","kind":"idea","name":"Funders set aside a fixed share of budget for independent replication","route":"/ideas/idea-tr2-replication-set-aside/","field":"links","label":"Reproducibility Project: Cancer Biology"},{"id":"idea-fund-replication-set-aside","kind":"idea","name":"Set aside 3% of grant budgets to replicate findings before translation","route":"/ideas/idea-fund-replication-set-aside/","field":"links","label":"Reproducibility Project: Cancer Biology"}]},{"url":"https://www.cprit.texas.gov","status":200,"ok":true,"finalUrl":"https://www.cprit.texas.gov/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","field":"links","label":"CPRIT"},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","field":"website"}],"archive":"https://web.archive.org/web/20260831153726/https://www.cprit.texas.gov/"},{"url":"https://www.cprit.texas.gov/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","field":"links","label":"CPRIT"}]},{"url":"https://www.cprit.texas.gov/grants-funded","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","field":"links","label":"Grants"}],"archive":"https://web.archive.org/web/20260517072728/https://cprit.texas.gov/grants-funded"},{"url":"https://www.cra.ac.th","status":200,"ok":true,"finalUrl":"https://www.cra.ac.th/th/home","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","field":"links","label":"Chulabhorn Royal Academy"}]},{"url":"https://www.cradle.bio","status":200,"ok":true,"finalUrl":"https://www.cradle.bio/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","field":"links","label":"Official website"},{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","field":"website"}]},{"url":"https://www.crcl.fr","status":200,"ok":true,"finalUrl":"https://www.crcl.fr/en/home/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","field":"links","label":"Cancer Research Center of Lyon"}]},{"url":"https://www.crct-inserm.fr","status":200,"ok":true,"finalUrl":"https://www.crct-inserm.fr/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/","field":"links","label":"CRCT"}]},{"url":"https://www.crd.york.ac.uk/PROSPERO/view/132669","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"artistic-meta-analysis","kind":"trial","name":"ARTISTIC meta-analysis","route":"/trials/artistic-meta-analysis/","field":"links","label":"PROSPERO CRD42019132669"}]},{"url":"https://www.crick.ac.uk","status":200,"ok":true,"finalUrl":"https://www.crick.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","route":"/institutions/francis-crick/","field":"links","label":"Official website"},{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","route":"/institutions/francis-crick/","field":"website"}]},{"url":"https://www.crick.ac.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","field":"links","label":"Crick"},{"id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","field":"profiles","label":"Crick"}]},{"url":"https://www.crick.ac.uk/research/find-a-researcher/charles-swanton","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"links","label":"Crick profile"},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","field":"profiles","label":"Crick profile"}]},{"url":"https://www.crig.ugent.be","status":200,"ok":true,"finalUrl":"https://www.crig.ugent.be/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","field":"links","label":"CRIG"}]},{"url":"https://www.crig.ugent.be/en/management","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","field":"links","label":"Institution profile"},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.crinetics.com","status":200,"ok":true,"finalUrl":"https://crinetics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","field":"links","label":"Official website"},{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","field":"website"}]},{"url":"https://www.crisprtx.com/","status":200,"ok":true,"finalUrl":"https://crisprtx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/","field":"links","label":"Official website"},{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/","field":"website"}]},{"url":"https://www.cro.sanita.fvg.it","status":200,"ok":true,"finalUrl":"https://www.cro.sanita.fvg.it/it/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cro-aviano","kind":"institution","name":"Centro di Riferimento Oncologico di Aviano (CRO)","route":"/institutions/cro-aviano/","field":"links","label":"Official website"},{"id":"cro-aviano","kind":"institution","name":"Centro di Riferimento Oncologico di Aviano (CRO)","route":"/institutions/cro-aviano/","field":"website"}]},{"url":"https://www.cro.sanita.fvg.it/it/istituto/direzioni.html","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"giuseppe-tonutti","kind":"person","name":"Giuseppe Tonutti","route":"/people/giuseppe-tonutti/","field":"links","label":"Source: CRO Aviano direzione strategica page"},{"id":"giuseppe-tonutti","kind":"person","name":"Giuseppe Tonutti","route":"/people/giuseppe-tonutti/","field":"profiles","label":"CRO Aviano strategic direction page"}]},{"url":"https://www.cruk.cam.ac.uk","status":200,"ok":true,"finalUrl":"https://www.cruk.cam.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","field":"links","label":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute website"},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","field":"profiles","label":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute website"},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","field":"links","label":"CRUK Cambridge Centre"},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","field":"website"}]},{"url":"https://www.cruk.cam.ac.uk/about-us","status":200,"ok":true,"finalUrl":"https://www.cruk.cam.ac.uk/about-us/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","field":"links","label":"CRUK Cambridge Institute: about us"}]},{"url":"https://www.cruk.cam.ac.uk/leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","field":"links","label":"Institution profile"},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","field":"profiles","label":"Institution profile"},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","field":"links","label":"Institution profile"},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cruk.manchester.ac.uk","status":200,"ok":true,"finalUrl":"https://www.cruk.manchester.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","field":"links","label":"Homepage"},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","field":"website"}]},{"url":"https://www.cruk.manchester.ac.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"links","label":"Institution profile"},{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","field":"profiles","label":"Institution profile"},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"links","label":"Institution profile"},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.crukscotlandcentre.ac.uk/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","field":"links","label":"Institution profile"},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","field":"profiles","label":"Institution profile"},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","field":"links","label":"Institution profile"},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.cryoport.com","status":200,"ok":true,"finalUrl":"https://www.cryoport.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/","field":"links","label":"Official website"},{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/","field":"website"}]},{"url":"https://www.csco.org.cn","status":200,"ok":true,"finalUrl":"https://www.csco.org.cn/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/","field":"links","label":"CSCO"},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/","field":"website"}]},{"url":"https://www.csco.org.cn/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","field":"links","label":"CSCO (page moved; nearest live section)"},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","field":"url"}]},{"url":"https://www.cshl.edu","status":200,"ok":true,"finalUrl":"https://www.cshl.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","field":"links","label":"Official website"},{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","field":"website"}]},{"url":"https://www.cshl.edu/about-us/leadership/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","field":"links","label":"CSHL leadership"},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","field":"profiles","label":"CSHL leadership"}]},{"url":"https://www.cshl.edu/research/faculty-staff/david-tuveson/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"links","label":"CSHL profile"},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","field":"profiles","label":"CSHL profile"}]},{"url":"https://www.cshl.edu/research/faculty-staff/semir-beyaz/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","field":"links","label":"CSHL profile"},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","field":"profiles","label":"CSHL profile"}]},{"url":"https://www.cshl.edu/research/faculty-staff/tobias-janowitz/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","field":"links","label":"CSHL profile"},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","field":"profiles","label":"CSHL profile"}]},{"url":"https://www.cshlpress.com","status":200,"ok":true,"finalUrl":"https://www.cshlpress.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","field":"links","label":"Cold Spring Harbor Laboratory Press"}]},{"url":"https://www.csi.nus.edu.sg","status":200,"ok":true,"finalUrl":"https://csi.nus.edu.sg/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","field":"links","label":"Cancer Science Institute of Singapore"}]},{"url":"https://www.cspc.com.hk/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","field":"links","label":"Official website"},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","field":"website"}]},{"url":"https://www.cstonepharma.com/en/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","field":"links","label":"CStone Pharmaceuticals"},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/","field":"links","label":"Official website"},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/","field":"website"}]},{"url":"https://www.ctg.queensu.ca","status":200,"ok":true,"finalUrl":"https://www.ctg.queensu.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"links","label":"Canadian Cancer Trials Group"},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","field":"profiles","label":"Canadian Cancer Trials Group"},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","field":"links","label":"Canadian Cancer Trials Group"},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","field":"profiles","label":"Canadian Cancer Trials Group"},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","field":"links","label":"Canadian Cancer Trials Group"},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","field":"profiles","label":"Canadian Cancer Trials Group"},{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/","field":"links","label":"Official website"},{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/","field":"website"}]},{"url":"https://www.cuh.hse.ie","status":200,"ok":true,"finalUrl":"https://www2.hse.ie/website-maintenance-cuh/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cork-university-hospital","kind":"institution","name":"Cork University Hospital / UCC Cancer Centre","route":"/institutions/cork-university-hospital/","field":"links","label":"Official website"},{"id":"cork-university-hospital","kind":"institution","name":"Cork University Hospital / UCC Cancer Centre","route":"/institutions/cork-university-hospital/","field":"website"}]},{"url":"https://www.cuh.hse.ie/our-services/our-consultants-a-z/dr-dearbhaile-collins/","status":200,"ok":true,"finalUrl":"https://www2.hse.ie/website-maintenance-cuh/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","field":"profiles","label":"CUH consultant profile"}]},{"url":"https://www.cuh.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","route":"/institutions/addenbrookes-cambridge/","field":"links","label":"Cambridge University Hospitals"},{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","route":"/institutions/addenbrookes-cambridge/","field":"website"}]},{"url":"https://www.cullgen.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","field":"links","label":"Official website"},{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","field":"website"}]},{"url":"https://www.cullgen.com/s/Cullgen-Gyreagreementpressrelease-4c4h.pdf","status":200,"ok":true,"finalUrl":"https://static1.squarespace.com/static/64fa49d6dc6a8807524aa6c6/t/69a5d058064867108bc7f631/1772474456845/Cullgen-Gyreagreementpressrelease.pdf","contentType":"application/pdf","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","field":"links","label":"Gyre agreement announcement (PDF on Cullgen site)"}]},{"url":"https://www.cun.es/en","status":200,"ok":true,"finalUrl":"https://www.cun.es/en/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","field":"links","label":"Cancer Center"},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","field":"website"}]},{"url":"https://www.cupfoundjo.org/","status":200,"ok":true,"finalUrl":"https://cupfoundjo.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"links","label":"CUP Foundation (Jo's Friends)"}]},{"url":"https://www.curanosticum.de/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"links","label":"Official website"},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"website"}]},{"url":"https://www.curanosticum.de/en/","status":200,"ok":true,"finalUrl":"https://www.curanosticum.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"links","label":"Curanosticum"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"profiles","label":"Curanosticum"}]},{"url":"https://www.curemelanoma.org","status":200,"ok":true,"finalUrl":"https://www.curemelanoma.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","field":"website"}]},{"url":"https://www.curemelanoma.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","field":"links","label":"MRA"},{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","field":"url"}]},{"url":"https://www.curemelanoma.org/mra-overview/mra-overview","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leon-black","kind":"person","name":"Leon Black","route":"/people/leon-black/","field":"links","label":"Melanoma Research Alliance: overview"},{"id":"debra-black","kind":"person","name":"Debra Black","route":"/people/debra-black/","field":"links","label":"Melanoma Research Alliance: overview"},{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","field":"links","label":"MRA overview"}]},{"url":"https://www.cureswithinreach.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/","field":"links","label":"Cures Within Reach"}]},{"url":"https://www.curetoday.com/view/litespark-012-trial-falls-short-in-advanced-kidney-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","field":"links","label":"CURE report"}]},{"url":"https://www.curevac.com","status":200,"ok":true,"finalUrl":"https://www.curevac.com/curevac-is-now-part-of-the-biontech-group/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/","field":"links","label":"Official website"},{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/","field":"website"}]},{"url":"https://www.curis.com","status":200,"ok":true,"finalUrl":"https://www.curis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/","field":"links","label":"Official website"},{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/","field":"website"}]},{"url":"https://www.curiumpharma.com","status":200,"ok":true,"finalUrl":"https://www.curiumpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","field":"links","label":"Official website"},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","field":"website"}],"archive":"https://web.archive.org/web/20260725223245/https://www.curiumpharma.com/"},{"url":"https://www.cxbladder.com","status":200,"ok":true,"finalUrl":"https://www.cxbladder.com/us/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cxbladder","kind":"drug","name":"Cxbladder","route":"/drugs/cxbladder/","field":"links","label":"Pacific Edge: Cxbladder"}]},{"url":"https://www.cytedhealth.com/","status":200,"ok":true,"finalUrl":"https://www.cytedhealth.com/uk","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","field":"links","label":"Official website"},{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","field":"website"}]},{"url":"https://www.cytedhealth.com/news-awards","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","field":"links","label":"News and awards"}]},{"url":"https://www.cytedhealth.com/post/cyted-health-secures-44-million-in-series-b-financing-to-accelerate-us-expansion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","field":"links","label":"Series B press release (Aug 2025)"}]},{"url":"https://www.cytoreason.com","status":200,"ok":true,"finalUrl":"https://www.cytoreason.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","field":"links","label":"Official website"},{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","field":"website"}]},{"url":"https://www.cytoreason.com/CytoReason%20Company.dc.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","field":"links","label":"Company page"}]},{"url":"https://www.cytoreason.com/CytoReason%20Press%20Release%2080M.dc.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","field":"links","label":"USD 80 million financing (July 2024)"}]},{"url":"https://www.czbiohub.org","status":200,"ok":true,"finalUrl":"https://biohub.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","field":"links","label":"CZ Biohub"},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","field":"website"}]},{"url":"https://www.d3bio.com","status":200,"ok":true,"finalUrl":"https://www.d3bio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","field":"links","label":"Official website"},{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","field":"website"}]},{"url":"https://www.d3bio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","field":"links","label":"D3 Bio pipeline"}]},{"url":"https://www.dahanca.dk","status":200,"ok":true,"finalUrl":"https://www.dahanca.dk/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dahanca","kind":"company","name":"DAHANCA","route":"/companies/dahanca/","field":"links","label":"Official website"},{"id":"dahanca","kind":"company","name":"DAHANCA","route":"/companies/dahanca/","field":"website"}]},{"url":"https://www.daiichisankyo.com","status":200,"ok":true,"finalUrl":"https://www.daiichisankyo.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","field":"links","label":"Official website"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","field":"website"}]},{"url":"https://www.damae-medical.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"damae-medical","kind":"company","name":"DAMAE Medical","route":"/companies/damae-medical/","field":"links","label":"Official website"},{"id":"damae-medical","kind":"company","name":"DAMAE Medical","route":"/companies/damae-medical/","field":"website"}]},{"url":"https://www.damonrunyon.org","status":200,"ok":true,"finalUrl":"https://www.damonrunyon.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/","field":"links","label":"Damon Runyon"},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/","field":"website"}]},{"url":"https://www.damonrunyon.org/our-strategy/our-history","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"walter-winchell","kind":"person","name":"Walter Winchell","route":"/people/walter-winchell/","field":"links","label":"Damon Runyon Cancer Research Foundation: our history"}]},{"url":"https://www.damonrunyon.org/our-strategy/our-leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yung-s-lie","kind":"person","name":"Yung S. Lie","route":"/people/yung-s-lie/","field":"links","label":"Source: Damon Runyon leadership page"},{"id":"yung-s-lie","kind":"person","name":"Yung S. Lie","route":"/people/yung-s-lie/","field":"profiles","label":"Institution leadership page"}]},{"url":"https://www.dana-farber.org","status":200,"ok":true,"finalUrl":"https://www.dana-farber.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","field":"links","label":"Official website"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","field":"website"}]},{"url":"https://www.dana-farber.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","field":"links","label":"Dana-Farber Cancer Institute"},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","field":"profiles","label":"Dana-Farber Cancer Institute"},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","field":"links","label":"Dana-Farber Cancer Institute"},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","field":"profiles","label":"Dana-Farber Cancer Institute"}]},{"url":"https://www.dana-farber.org/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"links","label":"Dana-Farber leadership"},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","field":"profiles","label":"Dana-Farber leadership"}]},{"url":"https://www.dana-farber.org/find-a-doctor/ann-h-partridge","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"links","label":"Dana-Farber profile"},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/f-stephen-hodi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"links","label":"Dana-Farber profile"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/judy-e-garber","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","field":"links","label":"Dana-Farber profile"},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/kenneth-c-anderson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"links","label":"Dana-Farber profile"},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/nancy-u-lin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"links","label":"Dana-Farber profile"},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/pasi-a-janne","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"links","label":"Dana-Farber profile"},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/paul-g-richardson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","field":"links","label":"Dana-Farber profile"},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/sara-m-tolaney","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"links","label":"Dana-Farber profile"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","field":"links","label":"Dana-Farber profile"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","field":"profiles","label":"Dana-Farber profile"}]},{"url":"https://www.darwin-eu.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-gcp-for-real-world-data","kind":"idea","name":"Good practice standards and inspection for real-world data sources","route":"/ideas/idea-data-gcp-for-real-world-data/","field":"links","label":"EMA DARWIN EU"}]},{"url":"https://www.datavant.com","status":200,"ok":true,"finalUrl":"https://www.datavant.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"datavant","kind":"company","name":"Datavant","route":"/companies/datavant/","field":"links","label":"Official website"},{"id":"datavant","kind":"company","name":"Datavant","route":"/companies/datavant/","field":"website"}]},{"url":"https://www.dayonebio.com","status":200,"ok":true,"finalUrl":"https://www.dayonebio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/","field":"links","label":"Official website"},{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260917204338/https://www.dayonebio.com/"},{"url":"https://www.dccc.dk/english/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","field":"links","label":"Danish Comprehensive Cancer Center"}]},{"url":"https://www.dcllsg.de","status":200,"ok":true,"finalUrl":"https://www.dcllsg.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"german-cll-study-group","kind":"company","name":"German CLL Study Group","route":"/companies/german-cll-study-group/","field":"links","label":"Official website"},{"id":"german-cll-study-group","kind":"company","name":"German CLL Study Group","route":"/companies/german-cll-study-group/","field":"website"}]},{"url":"https://www.dcvc.com","status":200,"ok":true,"finalUrl":"https://www.dcvc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","field":"links","label":"Official website"},{"id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","field":"website"}]},{"url":"https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","field":"links","label":"DCVC leads USD 14 million seed"}]},{"url":"https://www.debiopharm.com","status":200,"ok":true,"finalUrl":"https://www.debiopharm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","field":"website"}]},{"url":"https://www.debiopharm.com/drug-development/press-releases/debiopharm-to-unveil-new-pre-clinical-and-clinical-research-advances-in-ddr-inhibition-dual-payload-adcs-and-ai-driven-biomarkers-at-aacr-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","field":"links","label":"Debiopharm AACR 2026"}]},{"url":"https://www.deciphera.com","status":200,"ok":true,"finalUrl":"https://www.deciphera.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","field":"links","label":"Official website"},{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","field":"website"}]},{"url":"https://www.definevc.com/insights/putting-the-patient-at-the-center-of-cancer-science-with-valius-sciences","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","field":"links","label":"Define Ventures profile"}]},{"url":"https://www.delcath.com/","status":200,"ok":true,"finalUrl":"https://delcath.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","field":"links","label":"Official website"},{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","field":"website"}]},{"url":"https://www.delta-flypharma.co.jp","status":200,"ok":true,"finalUrl":"https://www.delta-flypharma.co.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","field":"links","label":"Official website"},{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","field":"website"}]},{"url":"https://www.diakonosoncology.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/","field":"links","label":"Official website"},{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/","field":"website"}]},{"url":"https://www.dimensions.ai/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","field":"links","label":"Dimensions"},{"id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","field":"url"}]},{"url":"https://www.discmedicine.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"disc-medicine","kind":"company","name":"Disc Medicine","route":"/companies/disc-medicine/","field":"links","label":"Official website"},{"id":"disc-medicine","kind":"company","name":"Disc Medicine","route":"/companies/disc-medicine/","field":"website"}]},{"url":"https://www.dizalpharma.com","status":200,"ok":true,"finalUrl":"https://www.dizalpharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","field":"links","label":"Sponsor page"}]},{"url":"https://www.dizalpharma.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/","field":"links","label":"Official website"},{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/","field":"website"}]},{"url":"https://www.dkfz.de","status":200,"ok":true,"finalUrl":"https://www.dkfz.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/","field":"links","label":"Official website"},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/","field":"website"}]},{"url":"https://www.dkfz.de/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","field":"links","label":"DKFZ"},{"id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","field":"profiles","label":"DKFZ"}]},{"url":"https://www.dl.begellhouse.com/journals/0ff459a57a4c08d0.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","route":"/journals/journal-of-environmental-pathology-toxicology-and-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","route":"/journals/journal-of-environmental-pathology-toxicology-and-oncology/","field":"url"}]},{"url":"https://www.dls.com","status":200,"ok":true,"finalUrl":"https://dls.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/","field":"links","label":"Official website"},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/","field":"website"}]},{"url":"https://www.dnanexus.com","status":200,"ok":true,"finalUrl":"https://www.dnanexus.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dnanexus","kind":"company","name":"DNAnexus","route":"/companies/dnanexus/","field":"links","label":"Official website"},{"id":"dnanexus","kind":"company","name":"DNAnexus","route":"/companies/dnanexus/","field":"website"}]},{"url":"https://www.drenbio.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dren-bio","kind":"company","name":"Dren Bio","route":"/companies/dren-bio/","field":"links","label":"Official website"},{"id":"dren-bio","kind":"company","name":"Dren Bio","route":"/companies/dren-bio/","field":"website"}]},{"url":"https://www.drreddys.com","status":200,"ok":true,"finalUrl":"https://www.drreddys.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","route":"/companies/dr-reddys/","field":"links","label":"Official website"},{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","route":"/companies/dr-reddys/","field":"website"}]},{"url":"https://www.dualitybiologics.com","status":200,"ok":true,"finalUrl":"https://www.dualitybiologics.com/","contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/","field":"website"}]},{"url":"https://www.duke-nus.edu.sg","status":200,"ok":true,"finalUrl":"https://www.duke-nus.edu.sg/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"links","label":"Duke-NUS Medical School"}]},{"url":"https://www.dysismedical.com/","status":200,"ok":true,"finalUrl":"https://dysismedical.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","route":"/companies/dysis-medical/","field":"links","label":"Official website"},{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","route":"/companies/dysis-medical/","field":"website"}]},{"url":"https://www.e-crt.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/","field":"links","label":"Homepage"},{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/","field":"url"}]},{"url":"https://www.eacr.org","status":200,"ok":true,"finalUrl":"https://www.eacr.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","field":"links","label":"Homepage"},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","field":"website"}]},{"url":"https://www.eacr.org/governance/board","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","field":"links","label":"Source: EACR board page"}]},{"url":"https://www.eanm.org","status":200,"ok":true,"finalUrl":"https://eanm.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","field":"links","label":"EANM"},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","field":"website"}]},{"url":"https://www.eastmidlandscanceralliance.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.eastmidlandscanceralliance.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","route":"/institutions/east-midlands-cancer-alliance/","field":"links","label":"East Midlands Cancer Alliance"},{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","route":"/institutions/east-midlands-cancer-alliance/","field":"website"}]},{"url":"https://www.ebi.ac.uk","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","field":"links","label":"Homepage"},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","field":"website"}]},{"url":"https://www.ebi.ac.uk/about/leadership","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/about/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"links","label":"Institution profile"},{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","field":"profiles","label":"Institution profile"},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","field":"links","label":"Institution profile"},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ebi.ac.uk/bioimage-archive/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr2-raw-image-deposit","kind":"idea","name":"Deposit the raw blots, gels and microscopy images behind every figure","route":"/ideas/idea-tr2-raw-image-deposit/","field":"links","label":"BioImage Archive"}]},{"url":"https://www.ebi.ac.uk/chembl/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/","field":"links","label":"DrugBank & ChEMBL"},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/","field":"url"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1199","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","field":"links","label":"ChEMBL CHEMBL1199"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200538","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","field":"links","label":"ChEMBL CHEMBL1200538"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200604","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","field":"links","label":"ChEMBL CHEMBL1200604"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200645","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitobronitol","kind":"drug","name":"Mitobronitol","route":"/drugs/mitobronitol/","field":"links","label":"ChEMBL CHEMBL1200645"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200740","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL1200740","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","field":"links","label":"ChEMBL CHEMBL1200740"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200856","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","field":"links","label":"ChEMBL CHEMBL1200856"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200880","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","field":"links","label":"ChEMBL CHEMBL1200880"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200937","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/","field":"links","label":"ChEMBL CHEMBL1200937"},{"id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","field":"links","label":"ChEMBL CHEMBL1200937"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200953","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"doxifluridine","kind":"drug","name":"Doxifluridine","route":"/drugs/doxifluridine/","field":"links","label":"ChEMBL CHEMBL1200953"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201078","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","field":"links","label":"ChEMBL CHEMBL1201078"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201180","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/","field":"links","label":"ChEMBL CHEMBL1201180"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201205","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL1201205","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","field":"links","label":"ChEMBL CHEMBL1201205"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201248","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/","field":"links","label":"ChEMBL CHEMBL1201248"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","field":"links","label":"ChEMBL CHEMBL1201294"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201303","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","field":"links","label":"ChEMBL CHEMBL1201303"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201306","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL1201306","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","field":"links","label":"ChEMBL CHEMBL1201306"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201310","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL1201310","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"formestane","kind":"drug","name":"Formestane","route":"/drugs/formestane/","field":"links","label":"ChEMBL CHEMBL1201310"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201564","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/","field":"links","label":"ChEMBL CHEMBL1201564"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201567","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/","field":"links","label":"ChEMBL CHEMBL1201567"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201855","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL1201855","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","field":"links","label":"ChEMBL CHEMBL1201855"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1445","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fluoxymesterone","kind":"drug","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","field":"links","label":"ChEMBL CHEMBL1445"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1731","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","field":"links","label":"ChEMBL CHEMBL1731"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1852688","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","field":"links","label":"ChEMBL CHEMBL1852688"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2107854","status":200,"ok":true,"finalUrl":"https://www.ebi.ac.uk/chembl/id_lookup/CHEMBL2107854","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/","field":"links","label":"ChEMBL CHEMBL2107854"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2108574","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/","field":"links","label":"ChEMBL CHEMBL2108574"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2109625","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olaratumab","kind":"drug","name":"Olaratumab","route":"/drugs/olaratumab/","field":"links","label":"ChEMBL CHEMBL2109625"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL225071","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","field":"links","label":"ChEMBL CHEMBL225071"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3545110","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/","field":"links","label":"ChEMBL CHEMBL3545110"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL411","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"diethylstilbestrol","kind":"drug","name":"Diethylstilbestrol","route":"/drugs/diethylstilbestrol/","field":"links","label":"ChEMBL CHEMBL411"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL505124","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/","field":"links","label":"ChEMBL CHEMBL505124"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1795108","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","field":"links","label":"ChEMBL target CHEMBL1795108"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1856","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","field":"links","label":"ChEMBL target CHEMBL1856"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1902","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","field":"links","label":"ChEMBL target CHEMBL1902"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1906","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","field":"links","label":"ChEMBL target CHEMBL1906"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1927","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","field":"links","label":"ChEMBL target CHEMBL1927"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1929","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","field":"links","label":"ChEMBL target CHEMBL1929"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1957","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","field":"links","label":"ChEMBL target CHEMBL1957"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1963","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","field":"links","label":"ChEMBL target CHEMBL1963"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1992","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","field":"links","label":"ChEMBL target CHEMBL1992"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2033","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","field":"links","label":"ChEMBL target CHEMBL2033"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2050","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","field":"links","label":"ChEMBL target CHEMBL2050"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2068","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","field":"links","label":"ChEMBL target CHEMBL2068"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2093867","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","field":"links","label":"ChEMBL target CHEMBL2093867"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2111369","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","field":"links","label":"ChEMBL target CHEMBL2111369"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL217","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","field":"links","label":"ChEMBL target CHEMBL217"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL218","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","field":"links","label":"ChEMBL target CHEMBL218"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL230","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","field":"links","label":"ChEMBL target CHEMBL230"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL233","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","field":"links","label":"ChEMBL target CHEMBL233"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2363042","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","field":"links","label":"ChEMBL target CHEMBL2363042"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2364169","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","field":"links","label":"ChEMBL target CHEMBL2364169"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2633","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","field":"links","label":"ChEMBL target CHEMBL2633"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2689","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","field":"links","label":"ChEMBL target CHEMBL2689"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2755","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","field":"links","label":"ChEMBL target CHEMBL2755"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3234","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","field":"links","label":"ChEMBL target CHEMBL3234"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3831287","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","field":"links","label":"ChEMBL target CHEMBL3831287"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3905","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","field":"links","label":"ChEMBL target CHEMBL3905"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3972","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","field":"links","label":"ChEMBL target CHEMBL3972"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4128","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","field":"links","label":"ChEMBL target CHEMBL4128"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4223","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","field":"links","label":"ChEMBL target CHEMBL4223"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4601","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","field":"links","label":"ChEMBL target CHEMBL4601"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","field":"links","label":"ChEMBL target CHEMBL5122"}]},{"url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5936","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","field":"links","label":"ChEMBL target CHEMBL5936"}]},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","field":"links","label":"FDA: protection of human subjects, 21 CFR Part 50"}]},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"}]},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"}]},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/","field":"links","label":"21 CFR Part 1271: human cells, tissues, and cellular and tissue-based products"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/","field":"links","label":"21 CFR Part 1271: human cells, tissues and cellular products"}]},{"url":"https://www.echoimmune.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"echo-immune","kind":"company","name":"Echo Immune","route":"/companies/echo-immune/","field":"links","label":"Official website"},{"id":"echo-immune","kind":"company","name":"Echo Immune","route":"/companies/echo-immune/","field":"website"}]},{"url":"https://www.ecor1cap.com","status":200,"ok":true,"finalUrl":"https://www.ecor1cap.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","field":"links","label":"Official website"},{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","field":"website"}]},{"url":"https://www.ed.ac.uk/clinical-brain-sciences/research/camarades","status":200,"ok":true,"finalUrl":"https://clinical-brain-sciences.ed.ac.uk/camarades","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-preclinical-living-reviews","kind":"idea","name":"Living systematic reviews of animal and organoid evidence before every new trial","route":"/ideas/idea-tr2-preclinical-living-reviews/","field":"links","label":"CAMARADES"}]},{"url":"https://www.ed.ac.uk/institute-genetics-cancer","status":200,"ok":true,"finalUrl":"https://institute-genetics-cancer.ed.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","field":"links","label":"Institute of Genetics and Cancer"}]},{"url":"https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","field":"links","label":"EEOC: the Genetic Information Nondiscrimination Act of 2008"}]},{"url":"https://www.eikontx.com","status":200,"ok":true,"finalUrl":"https://www.eikontx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/","field":"links","label":"Official website"},{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/","field":"website"},{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","field":"links","label":"Sponsor page"}]},{"url":"https://www.eisaimedicalinformation.com/-/media/Files/EisaiMedicalInformation/Oncology/Congress-Materials/ASCO-GU-2026/Motzer_LS011_ASCO-GU-2026_Presented.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"links","label":"ASCO GU 2026 investigator presentation (Eisai medical information)"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Confirmed objective response rate by masked independent central review (key secondary; second interim analysis, descriptive))"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Median duration of response by masked independent central review (second interim analysis, descriptive))"},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","field":"outcomes.source (Grade 3 or worse treatment-related adverse events (as-treated population, descriptive))"}]},{"url":"https://www.ekrfoundation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","field":"links","label":"Elisabeth Kübler-Ross Foundation"},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","field":"profiles","label":"Elisabeth Kübler-Ross Foundation"}]},{"url":"https://www.elekta.com","status":200,"ok":true,"finalUrl":"https://www.elekta.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","field":"links","label":"Official website"},{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","field":"website"}]},{"url":"https://www.elekta.com/products/brachytherapy/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/","field":"links","label":"Elekta: brachytherapy"}]},{"url":"https://www.elekta.com/products/neurosurgery/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/","field":"links","label":"Elekta: neurosurgery and Gamma Knife"}]},{"url":"https://www.elekta.com/products/oncology-informatics/","status":200,"ok":true,"finalUrl":"https://www.elekta.com/products/oncology-informatics/elekta-one/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","route":"/companies/kaiku-health/","field":"links","label":"Official website"},{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","route":"/companies/kaiku-health/","field":"website"}]},{"url":"https://www.elekta.com/products/radiation-therapy/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/","field":"links","label":"Elekta: linear accelerators"}]},{"url":"https://www.elementbiosciences.com","status":200,"ok":true,"finalUrl":"https://www.elementbiosciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"element-biosciences","kind":"company","name":"Element Biosciences","route":"/companies/element-biosciences/","field":"links","label":"Official website"},{"id":"element-biosciences","kind":"company","name":"Element Biosciences","route":"/companies/element-biosciences/","field":"website"}]},{"url":"https://www.elis.sk/index.php?option=com_content&view=article&id=4:neoplasma&catid=4:journals","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neoplasma","kind":"journal","name":"Neoplasma","route":"/journals/neoplasma/","field":"links","label":"Homepage"},{"id":"neoplasma","kind":"journal","name":"Neoplasma","route":"/journals/neoplasma/","field":"url"}]},{"url":"https://www.ellipses.life","status":200,"ok":true,"finalUrl":"https://ellipses.life/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/","field":"links","label":"Official website"},{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/","field":"website"},{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","field":"links","label":"Sponsor page"},{"id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","field":"links","label":"Sponsor page"}]},{"url":"https://www.elpiscience.com","status":200,"ok":true,"finalUrl":"https://www.elpiscience.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/","field":"links","label":"Official website"},{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/","field":"website"}]},{"url":"https://www.elypta.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","field":"links","label":"Official website"},{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","field":"website"}]},{"url":"https://www.elypta.com/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","field":"links","label":"News page"}]},{"url":"https://www.elypta.com/news/elypta-raises-21-million-series-a-to-develop-metabolism-based-multi-cancer-early-detection-test","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","field":"links","label":"Series A press release (Jun 2022)"}]},{"url":"https://www.em-consulte.com/revue/CANRAD/presentation/cancer-radiotherapie","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","field":"links","label":"Homepage"},{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","field":"url"}]},{"url":"https://www.ema.europa.eu","status":200,"ok":true,"finalUrl":"https://www.ema.europa.eu/en/homepage","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"links","label":"EMA"},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"website"}]},{"url":"https://www.ema.europa.eu/en/about-us/who-we-are/executive-director","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","field":"links","label":"Institution profile"},{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"links","label":"CHMP"}]},{"url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","field":"regulatoryEvents.source (2019-12-01)"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/","field":"links","label":"EMA: biosimilar medicines"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/conditional-marketing-authorisation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-regulation-726-2004","kind":"term","name":"Regulation (EC) No 726/2004: the EU centralised procedure","route":"/terms/eu-regulation-726-2004/","field":"links","label":"EMA: conditional marketing authorisation"},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","field":"links","label":"EMA: conditional marketing authorisation"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-rare-cancer-prize-fund","kind":"idea","name":"Pay a prize for rare cancer drugs instead of hoping for a market","route":"/ideas/idea-bio2-rare-cancer-prize-fund/","field":"links","label":"EMA orphan designation"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","field":"links","label":"EMA: the Clinical Trials Regulation"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/orphan-designation-research-development","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-orphan-regulation","kind":"term","name":"Regulation (EC) No 141/2000: EU orphan medicines","route":"/terms/eu-orphan-regulation/","field":"links","label":"EMA: orphan designation"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/paediatric-medicines-research-development","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-paediatric-regulation","kind":"term","name":"Regulation (EC) No 1901/2006: EU paediatric medicines","route":"/terms/eu-paediatric-regulation/","field":"links","label":"EMA: paediatric medicines"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance/","status":200,"ok":true,"finalUrl":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-joint-scientific-advice-default","kind":"idea","name":"Joint FDA-EMA-MHRA-PMDA scientific advice by default before pivotal cancer trials","route":"/ideas/idea-reg-joint-scientific-advice-default/","field":"links","label":"EMA-FDA parallel scientific advice (page moved; nearest live section)"}]},{"url":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/multidisciplinary-guidelines/multidisciplinary-biosimilar","status":200,"ok":true,"finalUrl":"https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/multidisciplinary-guidelines/multidisciplinary-guidelines-biosimilar","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","field":"links","label":"EMA reflection paper on biosimilar clinical requirements"}]},{"url":"https://www.ema.europa.eu/en/medicines","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-public-assessment-reports-all","kind":"idea","name":"Every regulator publishes its full assessment report so others can rely on it","route":"/ideas/idea-reg-public-assessment-reports-all/","field":"links","label":"EMA medicines and EPARs"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","field":"links","label":"Abevmy EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"EMA Abraxane product page: EU indications"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/aldara","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","field":"links","label":"EPAR (Aldara)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ameluz","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","field":"links","label":"EPAR (Ameluz)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/aranesp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/atriance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","field":"links","label":"EPAR (Atriance)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/avastin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"links","label":"EMA Avastin"},{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/","field":"links","label":"EMA Avastin"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/beromun","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tasonermin","kind":"drug","name":"Tasonermin","route":"/drugs/tasonermin/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","field":"links","label":"EPAR (Binocrit)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","route":"/drugs/epoetin-theta/","field":"links","label":"EMA: Biopoin (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/bondronat","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"links","label":"EMA Braftovi"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/busilvex","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","field":"links","label":"EPAR (Busilvex)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cejemly","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","field":"links","label":"EMA: Cejemly"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"study-0201","kind":"trial","name":"Study 0201","route":"/trials/study-0201/","field":"links","label":"Ceplene EPAR (EMA)"},{"id":"histamine-dihydrochloride","kind":"drug","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","field":"links","label":"EPAR"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"links","label":"Cervarix EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/","field":"links","label":"EMA: Crysvita (EPAR)"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"links","label":"Crysvita EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/datroway","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"links","label":"EMA Datroway product page (HR-positive indication only)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","field":"links","label":"EMA: Ebvallo (tabelecleucel)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/effentora","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fentanyl","kind":"drug","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","field":"links","label":"EMA: Effentora (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/emend","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","field":"links","label":"EPAR (Emend)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"crisantaspase","kind":"drug","name":"Crisantaspase (recombinant Erwinia asparaginase)","route":"/drugs/crisantaspase/","field":"links","label":"EMA: Enrylaze (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","route":"/drugs/epoetin-theta/","field":"links","label":"EMA: Eporatio (EPAR)"},{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","field":"links","label":"Eporatio EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","field":"links","label":"EMA Erbitux"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","field":"links","label":"EPAR (Evoltra)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ezmekly","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fareston","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","field":"links","label":"EPAR (Fasturtec)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/foscan","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"temoporfin","kind":"drug","name":"Temoporfin","route":"/drugs/temoporfin/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","field":"links","label":"EMA Fruzaqla"},{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","field":"links","label":"EMA Fruzaqla"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/instanyl","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fentanyl","kind":"drug","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","field":"links","label":"EMA: Instanyl (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/javlor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"links","label":"EMA Jemperli product page"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"resminostat","kind":"drug","name":"Resminostat","route":"/drugs/resminostat/","field":"links","label":"EMA: Kinselby (EPAR)"},{"id":"resminostat","kind":"drug","name":"Resminostat","route":"/drugs/resminostat/","field":"regulatoryEvents.source (2025-05-22)"},{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","field":"links","label":"EMA: Kinselby (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kiovig","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/","field":"links","label":"EMA: Kiovig (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","field":"links","label":"EMA: Korjuny (catumaxomab)"},{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","field":"links","label":"EPAR (Ledaga)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","field":"links","label":"EPAR (EMA)"},{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/","field":"links","label":"Lonquex EPAR (EMA)"},{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/","field":"links","label":"Lonquex EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"links","label":"EMA Lonsurf"},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","field":"links","label":"EMA Lonsurf"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/mepact","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/","field":"links","label":"EMA product information"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/neofordex","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","field":"links","label":"EPAR (Neofordex)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/neulasta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","field":"links","label":"Ogivri EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"links","label":"EMA Onivyde pegylated liposomal product page (marketing authorisation 14 October 2016)"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"EMA Onivyde pegylated liposomal product page"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pecfent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fentanyl","kind":"drug","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","field":"links","label":"EMA: PecFent (EPAR)"},{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","field":"links","label":"EMA: PecFent (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","route":"/companies/intas/","field":"links","label":"Pelgraz EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","field":"links","label":"EMA product page"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/privigen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/","field":"links","label":"EMA: Privigen (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/relistor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"links","label":"EMA Rozlytrek product page"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ryzneuta","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","field":"links","label":"EPAR (Sancuso)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sepalna","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","field":"links","label":"EMA: Sepalna (senaparib), CHMP opinion 17 September 2026"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","field":"links","label":"EMA Stivarga"},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","field":"links","label":"EMA Stivarga"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tacquell","kind":"drug","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/","field":"links","label":"EMA: Tacquell (EPAR)"},{"id":"tacquell","kind":"drug","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/","field":"regulatoryEvents.source (2026-06-25)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","field":"links","label":"EMA Tarceva product page: pancreatic indication"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/targretin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"EMA Tecentriq product page: EU TNBC indication retained"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tepadina","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","field":"links","label":"EPAR (Tepadina)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tookad","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"links","label":"EMA Trodelvy product page: EU therapeutic indications"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","field":"links","label":"EMA: Vargatef (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","field":"links","label":"EMA Vectibix"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"links","label":"EMA Vitrakvi product page"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xagrid","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","field":"links","label":"EPAR (Xaluprine)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","field":"links","label":"EPAR (Xgeva)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","field":"links","label":"EMA Zaltrap"},{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","field":"links","label":"EPAR (Zarzio)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemcelpro","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dorocubicel","kind":"drug","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","field":"links","label":"EPAR (EMA)"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zometa","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","field":"links","label":"EPAR"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-pre-emptive-pharmacogenomic-testing","kind":"idea","name":"Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere","route":"/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/","field":"links","label":"EMA: fluorouracil and related substances (DPD testing)"}]},{"url":"https://www.ema.europa.eu/en/news","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","route":"/collections/src-ema-chmp/","field":"links","label":"EMA news and CHMP meeting highlights"},{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","route":"/collections/src-ema-chmp/","field":"url"}]},{"url":"https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dpyd-genotyping","kind":"technology","name":"DPYD genotyping and DPD phenotyping before fluoropyrimidines","route":"/technologies/dpyd-genotyping/","field":"links","label":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine (2020)"}]},{"url":"https://www.emergentbiosolutions.com","status":200,"ok":true,"finalUrl":"https://www.emergentbiosolutions.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","field":"links","label":"Official website"},{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","field":"website"}]},{"url":"https://www.emersoncollective.com","status":200,"ok":true,"finalUrl":"https://www.emersoncollective.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/","field":"links","label":"Emerson Collective"},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/","field":"website"}]},{"url":"https://www.emersoncollective.com/about","status":200,"ok":true,"finalUrl":"https://www.emersoncollective.com/about-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laurene-powell-jobs","kind":"person","name":"Laurene Powell Jobs","route":"/people/laurene-powell-jobs/","field":"links","label":"Source: Emerson Collective about page"},{"id":"laurene-powell-jobs","kind":"person","name":"Laurene Powell Jobs","route":"/people/laurene-powell-jobs/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.en.auh.dk","status":200,"ok":true,"finalUrl":"https://www.en.auh.dk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","field":"links","label":"Homepage"},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","field":"website"}]},{"url":"https://www.en.auh.dk/About-the-Hospital/executive-management/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-balle-kristensen","kind":"person","name":"Thomas Balle Kristensen","route":"/people/thomas-balle-kristensen/","field":"links","label":"Institution profile"},{"id":"thomas-balle-kristensen","kind":"person","name":"Thomas Balle Kristensen","route":"/people/thomas-balle-kristensen/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.endo.com","status":200,"ok":true,"finalUrl":"https://www.endo.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"links","label":"Official website"},{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"website"}]},{"url":"https://www.england.nhs.uk/wp-content/uploads/2018/04/B1350_Skin-cancer-timed-diagnostic-pathway.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS England: implementing a timed skin cancer diagnostic pathway"}]},{"url":"https://www.england.nhs.uk/wp-content/uploads/2024/09/2260-hpb-liver-service-specification.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","field":"links","label":"NHS England service specification 2260"}]},{"url":"https://www.enherts-tr.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.enherts-tr.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","route":"/institutions/mount-vernon-cancer-centre/","field":"links","label":"Official website"},{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","route":"/institutions/mount-vernon-cancer-centre/","field":"website"}]},{"url":"https://www.enherts-tr.nhs.uk/about/board/meet-the-trusts-executive-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","route":"/people/martin-armstrong/","field":"links","label":"Source: East and North Hertfordshire Teaching NHS Trust executive team page"},{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","route":"/people/martin-armstrong/","field":"profiles","label":"East and North Hertfordshire executive team page"}]},{"url":"https://www.enherts-tr.nhs.uk/hospitals/mount-vernon/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","route":"/people/martin-armstrong/","field":"links","label":"Source: Mount Vernon Cancer Centre page on the trust website"}]},{"url":"https://www.enliventherapeutics.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","field":"links","label":"Official website"},{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","field":"website"}]},{"url":"https://www.enliventherapeutics.com/pipeline/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000000938","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgr","kind":"target","name":"FGR","route":"/targets/fgr/","field":"links","label":"Ensembl ENSG00000000938"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000003400","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"casp10","kind":"target","name":"CASP10","route":"/targets/casp10/","field":"links","label":"Ensembl ENSG00000003400"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000003402","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cflar","kind":"target","name":"CFLAR","route":"/targets/cflar/","field":"links","label":"Ensembl ENSG00000003402"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005073","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxa11","kind":"target","name":"HOXA11","route":"/targets/hoxa11/","field":"links","label":"Ensembl ENSG00000005073"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005187","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acsm3","kind":"target","name":"ACSM3","route":"/targets/acsm3/","field":"links","label":"Ensembl ENSG00000005187"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005339","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/","field":"links","label":"Ensembl ENSG00000005339"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005961","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itga2b","kind":"target","name":"ITGA2B","route":"/targets/itga2b/","field":"links","label":"Ensembl ENSG00000005961"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006210","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cx3cl1","kind":"target","name":"CX3CL1","route":"/targets/cx3cl1/","field":"links","label":"Ensembl ENSG00000006210"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006283","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cacna1g","kind":"target","name":"CACNA1G","route":"/targets/cacna1g/","field":"links","label":"Ensembl ENSG00000006283"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006459","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm7a","kind":"target","name":"KDM7A","route":"/targets/kdm7a/","field":"links","label":"Ensembl ENSG00000006459"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006468","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","field":"links","label":"Ensembl ENSG00000006468"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006530","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"agk","kind":"target","name":"AGK","route":"/targets/agk/","field":"links","label":"Ensembl ENSG00000006530"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006744","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elac2","kind":"target","name":"ELAC2","route":"/targets/elac2/","field":"links","label":"Ensembl ENSG00000006744"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000007062","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prom1","kind":"target","name":"PROM1","route":"/targets/prom1/","field":"links","label":"Ensembl ENSG00000007062"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000007314","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn4a","kind":"target","name":"SCN4A","route":"/targets/scn4a/","field":"links","label":"Ensembl ENSG00000007314"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000007372","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax6","kind":"target","name":"PAX6","route":"/targets/pax6/","field":"links","label":"Ensembl ENSG00000007372"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000008018","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/","field":"links","label":"Ensembl ENSG00000008018"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000008853","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rhobtb2","kind":"target","name":"RHOBTB2","route":"/targets/rhobtb2/","field":"links","label":"Ensembl ENSG00000008853"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000009709","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax7","kind":"target","name":"PAX7","route":"/targets/pax7/","field":"links","label":"Ensembl ENSG00000009709"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000010810","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/","field":"links","label":"Ensembl ENSG00000010810"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000011021","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"clcn6","kind":"target","name":"CLCN6","route":"/targets/clcn6/","field":"links","label":"Ensembl ENSG00000011021"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012061","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/","field":"links","label":"Ensembl ENSG00000012061"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012817","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm5d","kind":"target","name":"KDM5D","route":"/targets/kdm5d/","field":"links","label":"Ensembl ENSG00000012817"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013275","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/","field":"links","label":"Ensembl ENSG00000013275"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013619","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mamld1","kind":"target","name":"MAMLD1","route":"/targets/mamld1/","field":"links","label":"Ensembl ENSG00000013619"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000014138","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/","field":"links","label":"Ensembl ENSG00000014138"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000015133","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccdc88c","kind":"target","name":"CCDC88C","route":"/targets/ccdc88c/","field":"links","label":"Ensembl ENSG00000015133"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000015285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"was","kind":"target","name":"WAS","route":"/targets/was/","field":"links","label":"Ensembl ENSG00000015285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000018408","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/","field":"links","label":"Ensembl ENSG00000018408"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000019582","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd74","kind":"target","name":"CD74","route":"/targets/cd74/","field":"links","label":"Ensembl ENSG00000019582"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000019991","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/","field":"links","label":"Ensembl ENSG00000019991"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000020922","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/","field":"links","label":"Ensembl ENSG00000020922"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000023445","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/","field":"links","label":"Ensembl ENSG00000023445"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000025708","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tymp","kind":"target","name":"TYMP","route":"/targets/tymp/","field":"links","label":"Ensembl ENSG00000025708"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000026103","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/","field":"links","label":"Ensembl ENSG00000026103"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000026297","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rnaset2","kind":"target","name":"RNASET2","route":"/targets/rnaset2/","field":"links","label":"Ensembl ENSG00000026297"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000026508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/","field":"links","label":"Ensembl ENSG00000026508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000027075","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkch","kind":"target","name":"PRKCH","route":"/targets/prkch/","field":"links","label":"Ensembl ENSG00000027075"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000027697","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ifngr1","kind":"target","name":"IFNGR1","route":"/targets/ifngr1/","field":"links","label":"Ensembl ENSG00000027697"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000028277","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pou2f2","kind":"target","name":"POU2F2","route":"/targets/pou2f2/","field":"links","label":"Ensembl ENSG00000028277"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000028839","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbpl1","kind":"target","name":"TBPL1","route":"/targets/tbpl1/","field":"links","label":"Ensembl ENSG00000028839"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000029363","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bclaf1","kind":"target","name":"BCLAF1","route":"/targets/bclaf1/","field":"links","label":"Ensembl ENSG00000029363"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000029534","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ank1","kind":"target","name":"ANK1","route":"/targets/ank1/","field":"links","label":"Ensembl ENSG00000029534"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000030110","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bak1","kind":"target","name":"BAK1","route":"/targets/bak1/","field":"links","label":"Ensembl ENSG00000030110"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033030","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zcchc8","kind":"target","name":"ZCCHC8","route":"/targets/zcchc8/","field":"links","label":"Ensembl ENSG00000033030"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033327","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gab2","kind":"target","name":"GAB2","route":"/targets/gab2/","field":"links","label":"Ensembl ENSG00000033327"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000035403","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vcl","kind":"target","name":"VCL","route":"/targets/vcl/","field":"links","label":"Ensembl ENSG00000035403"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000036257","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cul3","kind":"target","name":"CUL3","route":"/targets/cul3/","field":"links","label":"Ensembl ENSG00000036257"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000036828","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"casr","kind":"target","name":"CASR","route":"/targets/casr/","field":"links","label":"Ensembl ENSG00000036828"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000038945","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msr1","kind":"target","name":"MSR1","route":"/targets/msr1/","field":"links","label":"Ensembl ENSG00000038945"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000039068","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/","field":"links","label":"Ensembl ENSG00000039068"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000040275","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"spdl1","kind":"target","name":"SPDL1","route":"/targets/spdl1/","field":"links","label":"Ensembl ENSG00000040275"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000040731","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdh10","kind":"target","name":"CDH10","route":"/targets/cdh10/","field":"links","label":"Ensembl ENSG00000040731"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000041357","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/","field":"links","label":"Ensembl ENSG00000041357"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000041880","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/","field":"links","label":"Ensembl ENSG00000041880"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000041982","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/","field":"links","label":"Ensembl ENSG00000041982"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000042832","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tg","kind":"target","name":"TG","route":"/targets/tg/","field":"links","label":"Ensembl ENSG00000042832"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044090","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cul7","kind":"target","name":"CUL7","route":"/targets/cul7/","field":"links","label":"Ensembl ENSG00000044090"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044115","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/","field":"links","label":"Ensembl ENSG00000044115"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044524","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha3","kind":"target","name":"EPHA3","route":"/targets/epha3/","field":"links","label":"Ensembl ENSG00000044524"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044574","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hspa5","kind":"target","name":"HSPA5","route":"/targets/hspa5/","field":"links","label":"Ensembl ENSG00000044574"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000046889","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/","field":"links","label":"Ensembl ENSG00000046889"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000047410","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tpr","kind":"target","name":"TPR","route":"/targets/tpr/","field":"links","label":"Ensembl ENSG00000047410"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000047932","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gopc","kind":"target","name":"GOPC","route":"/targets/gopc/","field":"links","label":"Ensembl ENSG00000047932"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048028","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"usp28","kind":"target","name":"USP28","route":"/targets/usp28/","field":"links","label":"Ensembl ENSG00000048028"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048052","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/","field":"links","label":"Ensembl ENSG00000048052"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048392","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/","field":"links","label":"Ensembl ENSG00000048392"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048471","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"snx29","kind":"target","name":"SNX29","route":"/targets/snx29/","field":"links","label":"Ensembl ENSG00000048471"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048649","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rsf1","kind":"target","name":"RSF1","route":"/targets/rsf1/","field":"links","label":"Ensembl ENSG00000048649"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048740","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"celf2","kind":"target","name":"CELF2","route":"/targets/celf2/","field":"links","label":"Ensembl ENSG00000048740"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049130","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kitlg","kind":"target","name":"KITLG","route":"/targets/kitlg/","field":"links","label":"Ensembl ENSG00000049130"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049246","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"per3","kind":"target","name":"PER3","route":"/targets/per3/","field":"links","label":"Ensembl ENSG00000049246"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049540","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eln","kind":"target","name":"ELN","route":"/targets/eln/","field":"links","label":"Ensembl ENSG00000049540"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049618","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/","field":"links","label":"Ensembl ENSG00000049618"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049656","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"clptm1l","kind":"target","name":"CLPTM1L","route":"/targets/clptm1l/","field":"links","label":"Ensembl ENSG00000049656"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049768","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxp3","kind":"target","name":"FOXP3","route":"/targets/foxp3/","field":"links","label":"Ensembl ENSG00000049768"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000050327","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgef5","kind":"target","name":"ARHGEF5","route":"/targets/arhgef5/","field":"links","label":"Ensembl ENSG00000050327"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000050748","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mapk9","kind":"target","name":"MAPK9","route":"/targets/mapk9/","field":"links","label":"Ensembl ENSG00000050748"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000051108","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"herpud1","kind":"target","name":"HERPUD1","route":"/targets/herpud1/","field":"links","label":"Ensembl ENSG00000051108"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000051180","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad51","kind":"target","name":"RAD51","route":"/targets/rad51/","field":"links","label":"Ensembl ENSG00000051180"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000051341","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/","field":"links","label":"Ensembl ENSG00000051341"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000051382","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/","field":"links","label":"Ensembl ENSG00000051382"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000053918","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnq1","kind":"target","name":"KCNQ1","route":"/targets/kcnq1/","field":"links","label":"Ensembl ENSG00000053918"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000054118","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"thrap3","kind":"target","name":"THRAP3","route":"/targets/thrap3/","field":"links","label":"Ensembl ENSG00000054118"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000054282","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdccag8","kind":"target","name":"SDCCAG8","route":"/targets/sdccag8/","field":"links","label":"Ensembl ENSG00000054282"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000055130","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cul1","kind":"target","name":"CUL1","route":"/targets/cul1/","field":"links","label":"Ensembl ENSG00000055130"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000055147","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fam114a2","kind":"target","name":"FAM114A2","route":"/targets/fam114a2/","field":"links","label":"Ensembl ENSG00000055147"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000055609","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","field":"links","label":"Ensembl ENSG00000055609"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000057657","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/","field":"links","label":"Ensembl ENSG00000057657"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000060237","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wnk1","kind":"target","name":"WNK1","route":"/targets/wnk1/","field":"links","label":"Ensembl ENSG00000060237"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000060339","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccar1","kind":"target","name":"CCAR1","route":"/targets/ccar1/","field":"links","label":"Ensembl ENSG00000060339"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000061273","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/","field":"links","label":"Ensembl ENSG00000061273"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000062822","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","field":"links","label":"Ensembl ENSG00000062822"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000063244","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"u2af2","kind":"target","name":"U2AF2","route":"/targets/u2af2/","field":"links","label":"Ensembl ENSG00000063244"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064012","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/","field":"links","label":"Ensembl ENSG00000064012"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064651","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc12a2","kind":"target","name":"SLC12A2","route":"/targets/slc12a2/","field":"links","label":"Ensembl ENSG00000064651"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064692","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sncaip","kind":"target","name":"SNCAIP","route":"/targets/sncaip/","field":"links","label":"Ensembl ENSG00000064692"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000064933","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pms1","kind":"target","name":"PMS1","route":"/targets/pms1/","field":"links","label":"Ensembl ENSG00000064933"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065057","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nthl1","kind":"target","name":"NTHL1","route":"/targets/nthl1/","field":"links","label":"Ensembl ENSG00000065057"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065526","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","field":"links","label":"Ensembl ENSG00000065526"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065559","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"map2k4","kind":"target","name":"MAP2K4","route":"/targets/map2k4/","field":"links","label":"Ensembl ENSG00000065559"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkcq","kind":"target","name":"PRKCQ","route":"/targets/prkcq/","field":"links","label":"Ensembl ENSG00000065675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066027","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r5a","kind":"target","name":"PPP2R5A","route":"/targets/ppp2r5a/","field":"links","label":"Ensembl ENSG00000066027"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066032","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctnna2","kind":"target","name":"CTNNA2","route":"/targets/ctnna2/","field":"links","label":"Ensembl ENSG00000066032"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066117","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smarcd1","kind":"target","name":"SMARCD1","route":"/targets/smarcd1/","field":"links","label":"Ensembl ENSG00000066117"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066455","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"golga5","kind":"target","name":"GOLGA5","route":"/targets/golga5/","field":"links","label":"Ensembl ENSG00000066455"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066923","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stag3","kind":"target","name":"STAG3","route":"/targets/stag3/","field":"links","label":"Ensembl ENSG00000066923"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067082","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klf6","kind":"target","name":"KLF6","route":"/targets/klf6/","field":"links","label":"Ensembl ENSG00000067082"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067369","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tp53bp1","kind":"target","name":"TP53BP1","route":"/targets/tp53bp1/","field":"links","label":"Ensembl ENSG00000067369"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067560","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/","field":"links","label":"Ensembl ENSG00000067560"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067606","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkcz","kind":"target","name":"PRKCZ","route":"/targets/prkcz/","field":"links","label":"Ensembl ENSG00000067606"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067842","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atp2b3","kind":"target","name":"ATP2B3","route":"/targets/atp2b3/","field":"links","label":"Ensembl ENSG00000067842"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067955","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cbfb","kind":"target","name":"CBFB","route":"/targets/cbfb/","field":"links","label":"Ensembl ENSG00000067955"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000068024","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/","field":"links","label":"Ensembl ENSG00000068024"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000068323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tfe3","kind":"target","name":"TFE3","route":"/targets/tfe3/","field":"links","label":"Ensembl ENSG00000068323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000068971","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r5b","kind":"target","name":"PPP2R5B","route":"/targets/ppp2r5b/","field":"links","label":"Ensembl ENSG00000068971"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000069399","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl3","kind":"target","name":"BCL3","route":"/targets/bcl3/","field":"links","label":"Ensembl ENSG00000069399"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000069702","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfbr3","kind":"target","name":"TGFBR3","route":"/targets/tgfbr3/","field":"links","label":"Ensembl ENSG00000069702"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070061","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elp1","kind":"target","name":"ELP1","route":"/targets/elp1/","field":"links","label":"Ensembl ENSG00000070061"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070159","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn3","kind":"target","name":"PTPN3","route":"/targets/ptpn3/","field":"links","label":"Ensembl ENSG00000070159"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070193","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf10","kind":"target","name":"FGF10","route":"/targets/fgf10/","field":"links","label":"Ensembl ENSG00000070193"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070371","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cltcl1","kind":"target","name":"CLTCL1","route":"/targets/cltcl1/","field":"links","label":"Ensembl ENSG00000070371"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf22","kind":"target","name":"FGF22","route":"/targets/fgf22/","field":"links","label":"Ensembl ENSG00000070388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070669","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/","field":"links","label":"Ensembl ENSG00000070669"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070756","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/","field":"links","label":"Ensembl ENSG00000070756"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070886","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha8","kind":"target","name":"EPHA8","route":"/targets/epha8/","field":"links","label":"Ensembl ENSG00000070886"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000071564","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcf3","kind":"target","name":"TCF3","route":"/targets/tcf3/","field":"links","label":"Ensembl ENSG00000071564"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000071626","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dazap1","kind":"target","name":"DAZAP1","route":"/targets/dazap1/","field":"links","label":"Ensembl ENSG00000071626"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072062","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkaca","kind":"target","name":"PRKACA","route":"/targets/prkaca/","field":"links","label":"Ensembl ENSG00000072062"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072274","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tfrc","kind":"target","name":"TFRC","route":"/targets/tfrc/","field":"links","label":"Ensembl ENSG00000072274"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072364","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aff4","kind":"target","name":"AFF4","route":"/targets/aff4/","field":"links","label":"Ensembl ENSG00000072364"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072501","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smc1a","kind":"target","name":"SMC1A","route":"/targets/smc1a/","field":"links","label":"Ensembl ENSG00000072501"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072518","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mark2","kind":"target","name":"MARK2","route":"/targets/mark2/","field":"links","label":"Ensembl ENSG00000072518"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072694","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/","field":"links","label":"Ensembl ENSG00000072694"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072803","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fbxw11","kind":"target","name":"FBXW11","route":"/targets/fbxw11/","field":"links","label":"Ensembl ENSG00000072803"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072858","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sidt1","kind":"target","name":"SIDT1","route":"/targets/sidt1/","field":"links","label":"Ensembl ENSG00000072858"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073050","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/","field":"links","label":"Ensembl ENSG00000073050"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073282","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/","field":"links","label":"Ensembl ENSG00000073282"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073331","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"alpk1","kind":"target","name":"ALPK1","route":"/targets/alpk1/","field":"links","label":"Ensembl ENSG00000073331"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073578","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","field":"links","label":"Ensembl ENSG00000073578"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073584","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smarce1","kind":"target","name":"SMARCE1","route":"/targets/smarce1/","field":"links","label":"Ensembl ENSG00000073584"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073614","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm5a","kind":"target","name":"KDM5A","route":"/targets/kdm5a/","field":"links","label":"Ensembl ENSG00000073614"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073712","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fermt2","kind":"target","name":"FERMT2","route":"/targets/fermt2/","field":"links","label":"Ensembl ENSG00000073712"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073803","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"map3k13","kind":"target","name":"MAP3K13","route":"/targets/map3k13/","field":"links","label":"Ensembl ENSG00000073803"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073921","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"picalm","kind":"target","name":"PICALM","route":"/targets/picalm/","field":"links","label":"Ensembl ENSG00000073921"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074181","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"notch3","kind":"target","name":"NOTCH3","route":"/targets/notch3/","field":"links","label":"Ensembl ENSG00000074181"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074266","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/","field":"links","label":"Ensembl ENSG00000074266"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074964","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgef10l","kind":"target","name":"ARHGEF10L","route":"/targets/arhgef10l/","field":"links","label":"Ensembl ENSG00000074964"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf4","kind":"target","name":"FGF4","route":"/targets/fgf4/","field":"links","label":"Ensembl ENSG00000075388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075413","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mark3","kind":"target","name":"MARK3","route":"/targets/mark3/","field":"links","label":"Ensembl ENSG00000075413"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075420","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fndc3b","kind":"target","name":"FNDC3B","route":"/targets/fndc3b/","field":"links","label":"Ensembl ENSG00000075420"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075624","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"actb","kind":"target","name":"ACTB","route":"/targets/actb/","field":"links","label":"Ensembl ENSG00000075624"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076242","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","field":"links","label":"Ensembl ENSG00000076242"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nt5c2","kind":"target","name":"NT5C2","route":"/targets/nt5c2/","field":"links","label":"Ensembl ENSG00000076685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076984","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"map2k7","kind":"target","name":"MAP2K7","route":"/targets/map2k7/","field":"links","label":"Ensembl ENSG00000076984"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077092","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rarb","kind":"target","name":"RARB","route":"/targets/rarb/","field":"links","label":"Ensembl ENSG00000077092"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077097","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/","field":"links","label":"Ensembl ENSG00000077097"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077150","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfkb2","kind":"target","name":"NFKB2","route":"/targets/nfkb2/","field":"links","label":"Ensembl ENSG00000077150"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077238","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il4r","kind":"target","name":"IL4R","route":"/targets/il4r/","field":"links","label":"Ensembl ENSG00000077238"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077420","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"apbb1ip","kind":"target","name":"APBB1IP","route":"/targets/apbb1ip/","field":"links","label":"Ensembl ENSG00000077420"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077498","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/","field":"links","label":"Ensembl ENSG00000077498"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077514","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/","field":"links","label":"Ensembl ENSG00000077514"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077721","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ube2a","kind":"target","name":"UBE2A","route":"/targets/ube2a/","field":"links","label":"Ensembl ENSG00000077721"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078061","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/","field":"links","label":"Ensembl ENSG00000078061"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078177","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"n4bp2","kind":"target","name":"N4BP2","route":"/targets/n4bp2/","field":"links","label":"Ensembl ENSG00000078177"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078304","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r5c","kind":"target","name":"PPP2R5C","route":"/targets/ppp2r5c/","field":"links","label":"Ensembl ENSG00000078304"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078328","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbfox1","kind":"target","name":"RBFOX1","route":"/targets/rbfox1/","field":"links","label":"Ensembl ENSG00000078328"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078369","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gnb1","kind":"target","name":"GNB1","route":"/targets/gnb1/","field":"links","label":"Ensembl ENSG00000078369"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078403","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/","field":"links","label":"Ensembl ENSG00000078403"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078579","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf20","kind":"target","name":"FGF20","route":"/targets/fgf20/","field":"links","label":"Ensembl ENSG00000078579"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078674","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pcm1","kind":"target","name":"PCM1","route":"/targets/pcm1/","field":"links","label":"Ensembl ENSG00000078674"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079102","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"runx1t1","kind":"target","name":"RUNX1T1","route":"/targets/runx1t1/","field":"links","label":"Ensembl ENSG00000079102"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079263","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/","field":"links","label":"Ensembl ENSG00000079263"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079308","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tns1","kind":"target","name":"TNS1","route":"/targets/tns1/","field":"links","label":"Ensembl ENSG00000079308"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079385","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ceacam1","kind":"target","name":"CEACAM1","route":"/targets/ceacam1/","field":"links","label":"Ensembl ENSG00000079385"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079432","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cic","kind":"target","name":"CIC","route":"/targets/cic/","field":"links","label":"Ensembl ENSG00000079432"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079805","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dnm2","kind":"target","name":"DNM2","route":"/targets/dnm2/","field":"links","label":"Ensembl ENSG00000079805"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000079999","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","field":"links","label":"Ensembl ENSG00000079999"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080007","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx43","kind":"target","name":"DDX43","route":"/targets/ddx43/","field":"links","label":"Ensembl ENSG00000080007"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080224","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha6","kind":"target","name":"EPHA6","route":"/targets/epha6/","field":"links","label":"Ensembl ENSG00000080224"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080503","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/","field":"links","label":"Ensembl ENSG00000080503"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080644","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chrna3","kind":"target","name":"CHRNA3","route":"/targets/chrna3/","field":"links","label":"Ensembl ENSG00000080644"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080824","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","field":"links","label":"Ensembl ENSG00000080824"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000081189","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mef2c","kind":"target","name":"MEF2C","route":"/targets/mef2c/","field":"links","label":"Ensembl ENSG00000081189"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000081237","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprc","kind":"target","name":"PTPRC","route":"/targets/ptprc/","field":"links","label":"Ensembl ENSG00000081237"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000082701","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gsk3b","kind":"target","name":"GSK3B","route":"/targets/gsk3b/","field":"links","label":"Ensembl ENSG00000082701"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000082805","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"erc1","kind":"target","name":"ERC1","route":"/targets/erc1/","field":"links","label":"Ensembl ENSG00000082805"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083093","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"links","label":"Ensembl ENSG00000083093"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083168","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/","field":"links","label":"Ensembl ENSG00000083168"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083307","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grhl2","kind":"target","name":"GRHL2","route":"/targets/grhl2/","field":"links","label":"Ensembl ENSG00000083307"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083520","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/","field":"links","label":"Ensembl ENSG00000083520"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083799","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/","field":"links","label":"Ensembl ENSG00000083799"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083857","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/","field":"links","label":"Ensembl ENSG00000083857"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000084093","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rest","kind":"target","name":"REST","route":"/targets/rest/","field":"links","label":"Ensembl ENSG00000084093"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000084207","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/","field":"links","label":"Ensembl ENSG00000084207"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000084676","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncoa1","kind":"target","name":"NCOA1","route":"/targets/ncoa1/","field":"links","label":"Ensembl ENSG00000084676"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085185","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/","field":"links","label":"Ensembl ENSG00000085185"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085224","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/","field":"links","label":"Ensembl ENSG00000085224"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085276","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/","field":"links","label":"Ensembl ENSG00000085276"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085563","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/","field":"links","label":"Ensembl ENSG00000085563"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085721","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rrn3","kind":"target","name":"RRN3","route":"/targets/rrn3/","field":"links","label":"Ensembl ENSG00000085721"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085741","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wnt11","kind":"target","name":"WNT11","route":"/targets/wnt11/","field":"links","label":"Ensembl ENSG00000085741"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085832","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eps15","kind":"target","name":"EPS15","route":"/targets/eps15/","field":"links","label":"Ensembl ENSG00000085832"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085840","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"orc1","kind":"target","name":"ORC1","route":"/targets/orc1/","field":"links","label":"Ensembl ENSG00000085840"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085999","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad54l","kind":"target","name":"RAD54L","route":"/targets/rad54l/","field":"links","label":"Ensembl ENSG00000085999"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000086062","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"b4galt1","kind":"target","name":"B4GALT1","route":"/targets/b4galt1/","field":"links","label":"Ensembl ENSG00000086062"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000086570","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fat2","kind":"target","name":"FAT2","route":"/targets/fat2/","field":"links","label":"Ensembl ENSG00000086570"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000086991","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nox4","kind":"target","name":"NOX4","route":"/targets/nox4/","field":"links","label":"Ensembl ENSG00000086991"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087074","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp1r15a","kind":"target","name":"PPP1R15A","route":"/targets/ppp1r15a/","field":"links","label":"Ensembl ENSG00000087074"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087191","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/","field":"links","label":"Ensembl ENSG00000087191"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087245","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mmp2","kind":"target","name":"MMP2","route":"/targets/mmp2/","field":"links","label":"Ensembl ENSG00000087245"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087460","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","field":"links","label":"Ensembl ENSG00000087460"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087586","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","field":"links","label":"Ensembl ENSG00000087586"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000088038","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cnot3","kind":"target","name":"CNOT3","route":"/targets/cnot3/","field":"links","label":"Ensembl ENSG00000088038"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000088256","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","field":"links","label":"Ensembl ENSG00000088256"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000088305","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dnmt3b","kind":"target","name":"DNMT3B","route":"/targets/dnmt3b/","field":"links","label":"Ensembl ENSG00000088305"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089280","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fus","kind":"target","name":"FUS","route":"/targets/fus/","field":"links","label":"Ensembl ENSG00000089280"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/","field":"links","label":"Ensembl ENSG00000089685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090447","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tfap4","kind":"target","name":"TFAP4","route":"/targets/tfap4/","field":"links","label":"Ensembl ENSG00000090447"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090554","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"flt3lg","kind":"target","name":"FLT3LG","route":"/targets/flt3lg/","field":"links","label":"Ensembl ENSG00000090554"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090659","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd209","kind":"target","name":"CD209","route":"/targets/cd209/","field":"links","label":"Ensembl ENSG00000090659"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091409","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itga6","kind":"target","name":"ITGA6","route":"/targets/itga6/","field":"links","label":"Ensembl ENSG00000091409"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091483","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fh","kind":"target","name":"FH","route":"/targets/fh/","field":"links","label":"Ensembl ENSG00000091483"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091513","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tf","kind":"target","name":"TF","route":"/targets/tf/","field":"links","label":"Ensembl ENSG00000091513"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091656","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zfhx4","kind":"target","name":"ZFHX4","route":"/targets/zfhx4/","field":"links","label":"Ensembl ENSG00000091656"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091844","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rgs17","kind":"target","name":"RGS17","route":"/targets/rgs17/","field":"links","label":"Ensembl ENSG00000091844"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000091972","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd200","kind":"target","name":"CD200","route":"/targets/cd200/","field":"links","label":"Ensembl ENSG00000091972"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000092820","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ezr","kind":"target","name":"EZR","route":"/targets/ezr/","field":"links","label":"Ensembl ENSG00000092820"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000092969","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfb2","kind":"target","name":"TGFB2","route":"/targets/tgfb2/","field":"links","label":"Ensembl ENSG00000092969"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095002","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","field":"links","label":"Ensembl ENSG00000095002"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095015","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/","field":"links","label":"Ensembl ENSG00000095015"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095303","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptgs1","kind":"target","name":"PTGS1","route":"/targets/ptgs1/","field":"links","label":"Ensembl ENSG00000095303"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hsp90ab1","kind":"target","name":"HSP90AB1","route":"/targets/hsp90ab1/","field":"links","label":"Ensembl ENSG00000096384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096696","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dsp","kind":"target","name":"DSP","route":"/targets/dsp/","field":"links","label":"Ensembl ENSG00000096696"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096717","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sirt1","kind":"target","name":"SIRT1","route":"/targets/sirt1/","field":"links","label":"Ensembl ENSG00000096717"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099341","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/","field":"links","label":"Ensembl ENSG00000099341"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099942","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"crkl","kind":"target","name":"CRKL","route":"/targets/crkl/","field":"links","label":"Ensembl ENSG00000099942"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099949","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lztr1","kind":"target","name":"LZTR1","route":"/targets/lztr1/","field":"links","label":"Ensembl ENSG00000099949"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099956","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/","field":"links","label":"Ensembl ENSG00000099956"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000099994","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"susd2","kind":"target","name":"SUSD2","route":"/targets/susd2/","field":"links","label":"Ensembl ENSG00000099994"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100030","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/","field":"links","label":"Ensembl ENSG00000100030"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100105","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"patz1","kind":"target","name":"PATZ1","route":"/targets/patz1/","field":"links","label":"Ensembl ENSG00000100105"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100146","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sox10","kind":"target","name":"SOX10","route":"/targets/sox10/","field":"links","label":"Ensembl ENSG00000100146"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cyp2d6","kind":"target","name":"CYP2D6","route":"/targets/cyp2d6/","field":"links","label":"Ensembl ENSG00000100197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100290","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bik","kind":"target","name":"BIK","route":"/targets/bik/","field":"links","label":"Ensembl ENSG00000100290"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100292","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hmox1","kind":"target","name":"HMOX1","route":"/targets/hmox1/","field":"links","label":"Ensembl ENSG00000100292"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100311","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdgfb","kind":"target","name":"PDGFB","route":"/targets/pdgfb/","field":"links","label":"Ensembl ENSG00000100311"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100344","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pnpla3","kind":"target","name":"PNPLA3","route":"/targets/pnpla3/","field":"links","label":"Ensembl ENSG00000100344"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100345","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/","field":"links","label":"Ensembl ENSG00000100345"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100346","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cacna1i","kind":"target","name":"CACNA1I","route":"/targets/cacna1i/","field":"links","label":"Ensembl ENSG00000100346"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100368","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csf2rb","kind":"target","name":"CSF2RB","route":"/targets/csf2rb/","field":"links","label":"Ensembl ENSG00000100368"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100385","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/","field":"links","label":"Ensembl ENSG00000100385"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100387","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/","field":"links","label":"Ensembl ENSG00000100387"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100393","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/","field":"links","label":"Ensembl ENSG00000100393"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100429","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/","field":"links","label":"Ensembl ENSG00000100429"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100479","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/","field":"links","label":"Ensembl ENSG00000100479"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100503","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nin","kind":"target","name":"NIN","route":"/targets/nin/","field":"links","label":"Ensembl ENSG00000100503"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100519","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/","field":"links","label":"Ensembl ENSG00000100519"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100567","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/","field":"links","label":"Ensembl ENSG00000100567"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100603","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"snw1","kind":"target","name":"SNW1","route":"/targets/snw1/","field":"links","label":"Ensembl ENSG00000100603"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100697","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/","field":"links","label":"Ensembl ENSG00000100697"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100721","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcl1a","kind":"target","name":"TCL1A","route":"/targets/tcl1a/","field":"links","label":"Ensembl ENSG00000100721"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100764","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/","field":"links","label":"Ensembl ENSG00000100764"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100814","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnb1ip1","kind":"target","name":"CCNB1IP1","route":"/targets/ccnb1ip1/","field":"links","label":"Ensembl ENSG00000100814"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100815","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trip11","kind":"target","name":"TRIP11","route":"/targets/trip11/","field":"links","label":"Ensembl ENSG00000100815"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100852","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/","field":"links","label":"Ensembl ENSG00000100852"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100888","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chd8","kind":"target","name":"CHD8","route":"/targets/chd8/","field":"links","label":"Ensembl ENSG00000100888"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100902","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/","field":"links","label":"Ensembl ENSG00000100902"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100906","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/","field":"links","label":"Ensembl ENSG00000100906"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100985","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mmp9","kind":"target","name":"MMP9","route":"/targets/mmp9/","field":"links","label":"Ensembl ENSG00000100985"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101096","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfatc2","kind":"target","name":"NFATC2","route":"/targets/nfatc2/","field":"links","label":"Ensembl ENSG00000101096"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101115","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sall4","kind":"target","name":"SALL4","route":"/targets/sall4/","field":"links","label":"Ensembl ENSG00000101115"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101144","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmp7","kind":"target","name":"BMP7","route":"/targets/bmp7/","field":"links","label":"Ensembl ENSG00000101144"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101162","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/","field":"links","label":"Ensembl ENSG00000101162"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101182","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/","field":"links","label":"Ensembl ENSG00000101182"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"birc7","kind":"target","name":"BIRC7","route":"/targets/birc7/","field":"links","label":"Ensembl ENSG00000101197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101204","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chrna4","kind":"target","name":"CHRNA4","route":"/targets/chrna4/","field":"links","label":"Ensembl ENSG00000101204"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101347","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/","field":"links","label":"Ensembl ENSG00000101347"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"jag1","kind":"target","name":"JAG1","route":"/targets/jag1/","field":"links","label":"Ensembl ENSG00000101384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101665","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smad7","kind":"target","name":"SMAD7","route":"/targets/smad7/","field":"links","label":"Ensembl ENSG00000101665"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101773","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbbp8","kind":"target","name":"RBBP8","route":"/targets/rbbp8/","field":"links","label":"Ensembl ENSG00000101773"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101938","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chrdl1","kind":"target","name":"CHRDL1","route":"/targets/chrdl1/","field":"links","label":"Ensembl ENSG00000101938"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101972","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stag2","kind":"target","name":"STAG2","route":"/targets/stag2/","field":"links","label":"Ensembl ENSG00000101972"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102034","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elf4","kind":"target","name":"ELF4","route":"/targets/elf4/","field":"links","label":"Ensembl ENSG00000102034"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102054","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbbp7","kind":"target","name":"RBBP7","route":"/targets/rbbp7/","field":"links","label":"Ensembl ENSG00000102054"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102096","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pim2","kind":"target","name":"PIM2","route":"/targets/pim2/","field":"links","label":"Ensembl ENSG00000102096"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102145","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gata1","kind":"target","name":"GATA1","route":"/targets/gata1/","field":"links","label":"Ensembl ENSG00000102145"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102265","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"timp1","kind":"target","name":"TIMP1","route":"/targets/timp1/","field":"links","label":"Ensembl ENSG00000102265"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102302","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgd1","kind":"target","name":"FGD1","route":"/targets/fgd1/","field":"links","label":"Ensembl ENSG00000102302"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102554","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/","field":"links","label":"Ensembl ENSG00000102554"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102678","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf9","kind":"target","name":"FGF9","route":"/targets/fgf9/","field":"links","label":"Ensembl ENSG00000102678"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102699","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/","field":"links","label":"Ensembl ENSG00000102699"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102882","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/","field":"links","label":"Ensembl ENSG00000102882"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102974","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctcf","kind":"target","name":"CTCF","route":"/targets/ctcf/","field":"links","label":"Ensembl ENSG00000102974"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103035","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/","field":"links","label":"Ensembl ENSG00000103035"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103126","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"axin1","kind":"target","name":"AXIN1","route":"/targets/axin1/","field":"links","label":"Ensembl ENSG00000103126"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tsc2","kind":"target","name":"TSC2","route":"/targets/tsc2/","field":"links","label":"Ensembl ENSG00000103197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103222","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcc1","kind":"target","name":"ABCC1","route":"/targets/abcc1/","field":"links","label":"Ensembl ENSG00000103222"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103241","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxf1","kind":"target","name":"FOXF1","route":"/targets/foxf1/","field":"links","label":"Ensembl ENSG00000103241"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103460","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tox3","kind":"target","name":"TOX3","route":"/targets/tox3/","field":"links","label":"Ensembl ENSG00000103460"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103546","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc6a2","kind":"target","name":"SLC6A2","route":"/targets/slc6a2/","field":"links","label":"Ensembl ENSG00000103546"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103653","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csk","kind":"target","name":"CSK","route":"/targets/csk/","field":"links","label":"Ensembl ENSG00000103653"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103811","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctsh","kind":"target","name":"CTSH","route":"/targets/ctsh/","field":"links","label":"Ensembl ENSG00000103811"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104044","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"oca2","kind":"target","name":"OCA2","route":"/targets/oca2/","field":"links","label":"Ensembl ENSG00000104044"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104213","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdgfrl","kind":"target","name":"PDGFRL","route":"/targets/pdgfrl/","field":"links","label":"Ensembl ENSG00000104213"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104320","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/","field":"links","label":"Ensembl ENSG00000104320"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104365","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/","field":"links","label":"Ensembl ENSG00000104365"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104408","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/","field":"links","label":"Ensembl ENSG00000104408"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104413","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"esrp1","kind":"target","name":"ESRP1","route":"/targets/esrp1/","field":"links","label":"Ensembl ENSG00000104413"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104419","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ndrg1","kind":"target","name":"NDRG1","route":"/targets/ndrg1/","field":"links","label":"Ensembl ENSG00000104419"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104447","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trps1","kind":"target","name":"TRPS1","route":"/targets/trps1/","field":"links","label":"Ensembl ENSG00000104447"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104517","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/","field":"links","label":"Ensembl ENSG00000104517"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104695","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2cb","kind":"target","name":"PPP2CB","route":"/targets/ppp2cb/","field":"links","label":"Ensembl ENSG00000104695"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104728","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","field":"links","label":"Ensembl ENSG00000104728"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104833","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/","field":"links","label":"Ensembl ENSG00000104833"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104884","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/","field":"links","label":"Ensembl ENSG00000104884"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104885","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/","field":"links","label":"Ensembl ENSG00000104885"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104903","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lyl1","kind":"target","name":"LYL1","route":"/targets/lyl1/","field":"links","label":"Ensembl ENSG00000104903"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105173","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","field":"links","label":"Ensembl ENSG00000105173"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105287","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/","field":"links","label":"Ensembl ENSG00000105287"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105329","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfb1","kind":"target","name":"TGFB1","route":"/targets/tgfb1/","field":"links","label":"Ensembl ENSG00000105329"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105369","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd79a","kind":"target","name":"CD79A","route":"/targets/cd79a/","field":"links","label":"Ensembl ENSG00000105369"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105372","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps19","kind":"target","name":"RPS19","route":"/targets/rps19/","field":"links","label":"Ensembl ENSG00000105372"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105397","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tyk2","kind":"target","name":"TYK2","route":"/targets/tyk2/","field":"links","label":"Ensembl ENSG00000105397"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105401","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdc37","kind":"target","name":"CDC37","route":"/targets/cdc37/","field":"links","label":"Ensembl ENSG00000105401"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105568","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/","field":"links","label":"Ensembl ENSG00000105568"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105639","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/","field":"links","label":"Ensembl ENSG00000105639"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105647","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3r2","kind":"target","name":"PIK3R2","route":"/targets/pik3r2/","field":"links","label":"Ensembl ENSG00000105647"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105656","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/","field":"links","label":"Ensembl ENSG00000105656"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105662","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"crtc1","kind":"target","name":"CRTC1","route":"/targets/crtc1/","field":"links","label":"Ensembl ENSG00000105662"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atp4a","kind":"target","name":"ATP4A","route":"/targets/atp4a/","field":"links","label":"Ensembl ENSG00000105675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105851","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3cg","kind":"target","name":"PIK3CG","route":"/targets/pik3cg/","field":"links","label":"Ensembl ENSG00000105851"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105877","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dnah11","kind":"target","name":"DNAH11","route":"/targets/dnah11/","field":"links","label":"Ensembl ENSG00000105877"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105939","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zc3hav1","kind":"target","name":"ZC3HAV1","route":"/targets/zc3hav1/","field":"links","label":"Ensembl ENSG00000105939"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106031","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxa13","kind":"target","name":"HOXA13","route":"/targets/hoxa13/","field":"links","label":"Ensembl ENSG00000106031"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106066","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cpvl","kind":"target","name":"CPVL","route":"/targets/cpvl/","field":"links","label":"Ensembl ENSG00000106066"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106211","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hspb1","kind":"target","name":"HSPB1","route":"/targets/hspb1/","field":"links","label":"Ensembl ENSG00000106211"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106305","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aimp2","kind":"target","name":"AIMP2","route":"/targets/aimp2/","field":"links","label":"Ensembl ENSG00000106305"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106348","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"impdh1","kind":"target","name":"IMPDH1","route":"/targets/impdh1/","field":"links","label":"Ensembl ENSG00000106348"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106483","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sfrp4","kind":"target","name":"SFRP4","route":"/targets/sfrp4/","field":"links","label":"Ensembl ENSG00000106483"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106541","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"agr2","kind":"target","name":"AGR2","route":"/targets/agr2/","field":"links","label":"Ensembl ENSG00000106541"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106588","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/","field":"links","label":"Ensembl ENSG00000106588"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106615","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rheb","kind":"target","name":"RHEB","route":"/targets/rheb/","field":"links","label":"Ensembl ENSG00000106615"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106624","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aebp1","kind":"target","name":"AEBP1","route":"/targets/aebp1/","field":"links","label":"Ensembl ENSG00000106624"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106628","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/","field":"links","label":"Ensembl ENSG00000106628"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106772","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/","field":"links","label":"Ensembl ENSG00000106772"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106799","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfbr1","kind":"target","name":"TGFBR1","route":"/targets/tgfbr1/","field":"links","label":"Ensembl ENSG00000106799"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107099","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dock8","kind":"target","name":"DOCK8","route":"/targets/dock8/","field":"links","label":"Ensembl ENSG00000107099"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107104","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kank1","kind":"target","name":"KANK1","route":"/targets/kank1/","field":"links","label":"Ensembl ENSG00000107104"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107165","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tyrp1","kind":"target","name":"TYRP1","route":"/targets/tyrp1/","field":"links","label":"Ensembl ENSG00000107165"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107485","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gata3","kind":"target","name":"GATA3","route":"/targets/gata3/","field":"links","label":"Ensembl ENSG00000107485"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107643","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mapk8","kind":"target","name":"MAPK8","route":"/targets/mapk8/","field":"links","label":"Ensembl ENSG00000107643"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107719","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"Ensembl ENSG00000107719"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107779","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/","field":"links","label":"Ensembl ENSG00000107779"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107789","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"minpp1","kind":"target","name":"MINPP1","route":"/targets/minpp1/","field":"links","label":"Ensembl ENSG00000107789"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107796","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acta2","kind":"target","name":"ACTA2","route":"/targets/acta2/","field":"links","label":"Ensembl ENSG00000107796"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107807","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tlx1","kind":"target","name":"TLX1","route":"/targets/tlx1/","field":"links","label":"Ensembl ENSG00000107807"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107831","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf8","kind":"target","name":"FGF8","route":"/targets/fgf8/","field":"links","label":"Ensembl ENSG00000107831"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107864","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cpeb3","kind":"target","name":"CPEB3","route":"/targets/cpeb3/","field":"links","label":"Ensembl ENSG00000107864"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107882","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","field":"links","label":"Ensembl ENSG00000107882"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107960","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stn1","kind":"target","name":"STN1","route":"/targets/stn1/","field":"links","label":"Ensembl ENSG00000107960"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107984","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dkk1","kind":"target","name":"DKK1","route":"/targets/dkk1/","field":"links","label":"Ensembl ENSG00000107984"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108091","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccdc6","kind":"target","name":"CCDC6","route":"/targets/ccdc6/","field":"links","label":"Ensembl ENSG00000108091"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108175","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zmiz1","kind":"target","name":"ZMIZ1","route":"/targets/zmiz1/","field":"links","label":"Ensembl ENSG00000108175"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108187","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pbld","kind":"target","name":"PBLD","route":"/targets/pbld/","field":"links","label":"Ensembl ENSG00000108187"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108312","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ubtf","kind":"target","name":"UBTF","route":"/targets/ubtf/","field":"links","label":"Ensembl ENSG00000108312"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108344","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/","field":"links","label":"Ensembl ENSG00000108344"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108375","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"links","label":"Ensembl ENSG00000108375"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/","field":"links","label":"Ensembl ENSG00000108384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108528","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc25a11","kind":"target","name":"SLC25A11","route":"/targets/slc25a11/","field":"links","label":"Ensembl ENSG00000108528"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108576","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc6a4","kind":"target","name":"SLC6A4","route":"/targets/slc6a4/","field":"links","label":"Ensembl ENSG00000108576"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108654","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx5","kind":"target","name":"DDX5","route":"/targets/ddx5/","field":"links","label":"Ensembl ENSG00000108654"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108671","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/","field":"links","label":"Ensembl ENSG00000108671"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108773","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/","field":"links","label":"Ensembl ENSG00000108773"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108821","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/","field":"links","label":"Ensembl ENSG00000108821"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108840","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/","field":"links","label":"Ensembl ENSG00000108840"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108846","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcc3","kind":"target","name":"ABCC3","route":"/targets/abcc3/","field":"links","label":"Ensembl ENSG00000108846"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108883","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/","field":"links","label":"Ensembl ENSG00000108883"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108924","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hlf","kind":"target","name":"HLF","route":"/targets/hlf/","field":"links","label":"Ensembl ENSG00000108924"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108946","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkar1a","kind":"target","name":"PRKAR1A","route":"/targets/prkar1a/","field":"links","label":"Ensembl ENSG00000108946"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108953","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ywhae","kind":"target","name":"YWHAE","route":"/targets/ywhae/","field":"links","label":"Ensembl ENSG00000108953"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109132","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/","field":"links","label":"Ensembl ENSG00000109132"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109321","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"areg","kind":"target","name":"AREG","route":"/targets/areg/","field":"links","label":"Ensembl ENSG00000109321"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109458","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gab1","kind":"target","name":"GAB1","route":"/targets/gab1/","field":"links","label":"Ensembl ENSG00000109458"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109670","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","field":"links","label":"Ensembl ENSG00000109670"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/","field":"links","label":"Ensembl ENSG00000109685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109906","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","field":"links","label":"Ensembl ENSG00000109906"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109911","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elp4","kind":"target","name":"ELP4","route":"/targets/elp4/","field":"links","label":"Ensembl ENSG00000109911"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110092","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","field":"links","label":"Ensembl ENSG00000110092"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110367","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx6","kind":"target","name":"DDX6","route":"/targets/ddx6/","field":"links","label":"Ensembl ENSG00000110367"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110395","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/","field":"links","label":"Ensembl ENSG00000110395"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110619","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cars1","kind":"target","name":"CARS1","route":"/targets/cars1/","field":"links","label":"Ensembl ENSG00000110619"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110628","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc67a1","kind":"target","name":"SLC67A1","route":"/targets/slc67a1/","field":"links","label":"Ensembl ENSG00000110628"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110713","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/","field":"links","label":"Ensembl ENSG00000110713"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110777","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pou2af1","kind":"target","name":"POU2AF1","route":"/targets/pou2af1/","field":"links","label":"Ensembl ENSG00000110777"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110799","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vwf","kind":"target","name":"VWF","route":"/targets/vwf/","field":"links","label":"Ensembl ENSG00000110799"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110841","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppfibp1","kind":"target","name":"PPFIBP1","route":"/targets/ppfibp1/","field":"links","label":"Ensembl ENSG00000110841"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110987","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/","field":"links","label":"Ensembl ENSG00000110987"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111057","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"krt18","kind":"target","name":"KRT18","route":"/targets/krt18/","field":"links","label":"Ensembl ENSG00000111057"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111087","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gli1","kind":"target","name":"GLI1","route":"/targets/gli1/","field":"links","label":"Ensembl ENSG00000111087"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111241","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf6","kind":"target","name":"FGF6","route":"/targets/fgf6/","field":"links","label":"Ensembl ENSG00000111241"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111252","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sh2b3","kind":"target","name":"SH2B3","route":"/targets/sh2b3/","field":"links","label":"Ensembl ENSG00000111252"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111266","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dusp16","kind":"target","name":"DUSP16","route":"/targets/dusp16/","field":"links","label":"Ensembl ENSG00000111266"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111275","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aldh2","kind":"target","name":"ALDH2","route":"/targets/aldh2/","field":"links","label":"Ensembl ENSG00000111275"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111276","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","field":"links","label":"Ensembl ENSG00000111276"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111424","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vdr","kind":"target","name":"VDR","route":"/targets/vdr/","field":"links","label":"Ensembl ENSG00000111424"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111605","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cpsf6","kind":"target","name":"CPSF6","route":"/targets/cpsf6/","field":"links","label":"Ensembl ENSG00000111605"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111642","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chd4","kind":"target","name":"CHD4","route":"/targets/chd4/","field":"links","label":"Ensembl ENSG00000111642"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111679","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn6","kind":"target","name":"PTPN6","route":"/targets/ptpn6/","field":"links","label":"Ensembl ENSG00000111679"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111790","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgfr1op2","kind":"target","name":"FGFR1OP2","route":"/targets/fgfr1op2/","field":"links","label":"Ensembl ENSG00000111790"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111859","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nedd9","kind":"target","name":"NEDD9","route":"/targets/nedd9/","field":"links","label":"Ensembl ENSG00000111859"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112039","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fance","kind":"target","name":"FANCE","route":"/targets/fance/","field":"links","label":"Ensembl ENSG00000112039"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112081","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srsf3","kind":"target","name":"SRSF3","route":"/targets/srsf3/","field":"links","label":"Ensembl ENSG00000112081"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112149","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd83","kind":"target","name":"CD83","route":"/targets/cd83/","field":"links","label":"Ensembl ENSG00000112149"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112175","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmp5","kind":"target","name":"BMP5","route":"/targets/bmp5/","field":"links","label":"Ensembl ENSG00000112175"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112182","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bach2","kind":"target","name":"BACH2","route":"/targets/bach2/","field":"links","label":"Ensembl ENSG00000112182"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112282","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"med23","kind":"target","name":"MED23","route":"/targets/med23/","field":"links","label":"Ensembl ENSG00000112282"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112531","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"qki","kind":"target","name":"QKI","route":"/targets/qki/","field":"links","label":"Ensembl ENSG00000112531"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112561","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tfeb","kind":"target","name":"TFEB","route":"/targets/tfeb/","field":"links","label":"Ensembl ENSG00000112561"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112576","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnd3","kind":"target","name":"CCND3","route":"/targets/ccnd3/","field":"links","label":"Ensembl ENSG00000112576"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112640","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r5d","kind":"target","name":"PPP2R5D","route":"/targets/ppp2r5d/","field":"links","label":"Ensembl ENSG00000112640"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112697","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdc50a","kind":"target","name":"CDC50A","route":"/targets/cdc50a/","field":"links","label":"Ensembl ENSG00000112697"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112759","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc29a1","kind":"target","name":"SLC29A1","route":"/targets/slc29a1/","field":"links","label":"Ensembl ENSG00000112759"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112851","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"erbin","kind":"target","name":"ERBIN","route":"/targets/erbin/","field":"links","label":"Ensembl ENSG00000112851"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112941","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tent4a","kind":"target","name":"TENT4A","route":"/targets/tent4a/","field":"links","label":"Ensembl ENSG00000112941"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113070","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hbegf","kind":"target","name":"HBEGF","route":"/targets/hbegf/","field":"links","label":"Ensembl ENSG00000113070"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113161","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hmgcr","kind":"target","name":"HMGCR","route":"/targets/hmgcr/","field":"links","label":"Ensembl ENSG00000113161"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113263","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/","field":"links","label":"Ensembl ENSG00000113263"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113318","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msh3","kind":"target","name":"MSH3","route":"/targets/msh3/","field":"links","label":"Ensembl ENSG00000113318"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113360","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/","field":"links","label":"Ensembl ENSG00000113360"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113430","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irx4","kind":"target","name":"IRX4","route":"/targets/irx4/","field":"links","label":"Ensembl ENSG00000113430"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113522","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/","field":"links","label":"Ensembl ENSG00000113522"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113558","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"skp1","kind":"target","name":"SKP1","route":"/targets/skp1/","field":"links","label":"Ensembl ENSG00000113558"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2ca","kind":"target","name":"PPP2CA","route":"/targets/ppp2ca/","field":"links","label":"Ensembl ENSG00000113575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113578","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf1","kind":"target","name":"FGF1","route":"/targets/fgf1/","field":"links","label":"Ensembl ENSG00000113578"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113594","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/","field":"links","label":"Ensembl ENSG00000113594"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113712","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/","field":"links","label":"Ensembl ENSG00000113712"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113916","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/","field":"links","label":"Ensembl ENSG00000113916"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114026","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ogg1","kind":"target","name":"OGG1","route":"/targets/ogg1/","field":"links","label":"Ensembl ENSG00000114026"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114166","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/","field":"links","label":"Ensembl ENSG00000114166"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114353","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gnai2","kind":"target","name":"GNAI2","route":"/targets/gnai2/","field":"links","label":"Ensembl ENSG00000114353"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114354","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tfg","kind":"target","name":"TFG","route":"/targets/tfg/","field":"links","label":"Ensembl ENSG00000114354"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nprl2","kind":"target","name":"NPRL2","route":"/targets/nprl2/","field":"links","label":"Ensembl ENSG00000114388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114416","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fxr1","kind":"target","name":"FXR1","route":"/targets/fxr1/","field":"links","label":"Ensembl ENSG00000114416"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114423","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cblb","kind":"target","name":"CBLB","route":"/targets/cblb/","field":"links","label":"Ensembl ENSG00000114423"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114857","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nktr","kind":"target","name":"NKTR","route":"/targets/nktr/","field":"links","label":"Ensembl ENSG00000114857"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000114861","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/","field":"links","label":"Ensembl ENSG00000114861"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115233","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/","field":"links","label":"Ensembl ENSG00000115233"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115306","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sptbn1","kind":"target","name":"SPTBN1","route":"/targets/sptbn1/","field":"links","label":"Ensembl ENSG00000115306"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115350","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pole4","kind":"target","name":"POLE4","route":"/targets/pole4/","field":"links","label":"Ensembl ENSG00000115350"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115392","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancl","kind":"target","name":"FANCL","route":"/targets/fancl/","field":"links","label":"Ensembl ENSG00000115392"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115414","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/","field":"links","label":"Ensembl ENSG00000115414"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115415","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/","field":"links","label":"Ensembl ENSG00000115415"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115504","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ehbp1","kind":"target","name":"EHBP1","route":"/targets/ehbp1/","field":"links","label":"Ensembl ENSG00000115504"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115507","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"otx1","kind":"target","name":"OTX1","route":"/targets/otx1/","field":"links","label":"Ensembl ENSG00000115507"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115524","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","field":"links","label":"Ensembl ENSG00000115524"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115596","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wnt6","kind":"target","name":"WNT6","route":"/targets/wnt6/","field":"links","label":"Ensembl ENSG00000115596"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115648","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mlph","kind":"target","name":"MLPH","route":"/targets/mlph/","field":"links","label":"Ensembl ENSG00000115648"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115760","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"birc6","kind":"target","name":"BIRC6","route":"/targets/birc6/","field":"links","label":"Ensembl ENSG00000115760"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115808","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"strn","kind":"target","name":"STRN","route":"/targets/strn/","field":"links","label":"Ensembl ENSG00000115808"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115825","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkd3","kind":"target","name":"PRKD3","route":"/targets/prkd3/","field":"links","label":"Ensembl ENSG00000115825"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115904","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sos1","kind":"target","name":"SOS1","route":"/targets/sos1/","field":"links","label":"Ensembl ENSG00000115904"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116044","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","field":"links","label":"Ensembl ENSG00000116044"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116062","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/","field":"links","label":"Ensembl ENSG00000116062"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116106","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha4","kind":"target","name":"EPHA4","route":"/targets/epha4/","field":"links","label":"Ensembl ENSG00000116106"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116128","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl9","kind":"target","name":"BCL9","route":"/targets/bcl9/","field":"links","label":"Ensembl ENSG00000116128"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116183","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pappa2","kind":"target","name":"PAPPA2","route":"/targets/pappa2/","field":"links","label":"Ensembl ENSG00000116183"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116251","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rpl22","kind":"target","name":"RPL22","route":"/targets/rpl22/","field":"links","label":"Ensembl ENSG00000116251"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"errfi1","kind":"target","name":"ERRFI1","route":"/targets/errfi1/","field":"links","label":"Ensembl ENSG00000116285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116473","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rap1a","kind":"target","name":"RAP1A","route":"/targets/rap1a/","field":"links","label":"Ensembl ENSG00000116473"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116560","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sfpq","kind":"target","name":"SFPQ","route":"/targets/sfpq/","field":"links","label":"Ensembl ENSG00000116560"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116604","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mef2d","kind":"target","name":"MEF2D","route":"/targets/mef2d/","field":"links","label":"Ensembl ENSG00000116604"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116678","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lepr","kind":"target","name":"LEPR","route":"/targets/lepr/","field":"links","label":"Ensembl ENSG00000116678"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116717","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/","field":"links","label":"Ensembl ENSG00000116717"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116731","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/","field":"links","label":"Ensembl ENSG00000116731"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116815","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd58","kind":"target","name":"CD58","route":"/targets/cd58/","field":"links","label":"Ensembl ENSG00000116815"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116833","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nr5a2","kind":"target","name":"NR5A2","route":"/targets/nr5a2/","field":"links","label":"Ensembl ENSG00000116833"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116954","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rragc","kind":"target","name":"RRAGC","route":"/targets/rragc/","field":"links","label":"Ensembl ENSG00000116954"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116990","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/","field":"links","label":"Ensembl ENSG00000116990"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117118","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdhb","kind":"target","name":"SDHB","route":"/targets/sdhb/","field":"links","label":"Ensembl ENSG00000117118"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117318","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"id3","kind":"target","name":"ID3","route":"/targets/id3/","field":"links","label":"Ensembl ENSG00000117318"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117362","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aph1a","kind":"target","name":"APH1A","route":"/targets/aph1a/","field":"links","label":"Ensembl ENSG00000117362"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117461","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3r3","kind":"target","name":"PIK3R3","route":"/targets/pik3r3/","field":"links","label":"Ensembl ENSG00000117461"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117632","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stmn1","kind":"target","name":"STMN1","route":"/targets/stmn1/","field":"links","label":"Ensembl ENSG00000117632"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117713","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"links","label":"Ensembl ENSG00000117713"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118046","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"links","label":"Ensembl ENSG00000118046"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118260","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"creb1","kind":"target","name":"CREB1","route":"/targets/creb1/","field":"links","label":"Ensembl ENSG00000118260"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118503","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/","field":"links","label":"Ensembl ENSG00000118503"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118513","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/","field":"links","label":"Ensembl ENSG00000118513"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118515","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sgk1","kind":"target","name":"SGK1","route":"/targets/sgk1/","field":"links","label":"Ensembl ENSG00000118515"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118523","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccn2","kind":"target","name":"CCN2","route":"/targets/ccn2/","field":"links","label":"Ensembl ENSG00000118523"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118655","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","field":"links","label":"Ensembl ENSG00000118655"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118689","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxo3","kind":"target","name":"FOXO3","route":"/targets/foxo3/","field":"links","label":"Ensembl ENSG00000118689"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118777","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/","field":"links","label":"Ensembl ENSG00000118777"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118971","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnd2","kind":"target","name":"CCND2","route":"/targets/ccnd2/","field":"links","label":"Ensembl ENSG00000118971"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118972","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf23","kind":"target","name":"FGF23","route":"/targets/fgf23/","field":"links","label":"Ensembl ENSG00000118972"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119318","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad23b","kind":"target","name":"RAD23B","route":"/targets/rad23b/","field":"links","label":"Ensembl ENSG00000119318"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119335","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"set","kind":"target","name":"SET","route":"/targets/set/","field":"links","label":"Ensembl ENSG00000119335"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119397","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cntrl","kind":"target","name":"CNTRL","route":"/targets/cntrl/","field":"links","label":"Ensembl ENSG00000119397"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119414","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp6c","kind":"target","name":"PPP6C","route":"/targets/ppp6c/","field":"links","label":"Ensembl ENSG00000119414"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nr4a3","kind":"target","name":"NR4A3","route":"/targets/nr4a3/","field":"links","label":"Ensembl ENSG00000119508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119684","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mlh3","kind":"target","name":"MLH3","route":"/targets/mlh3/","field":"links","label":"Ensembl ENSG00000119684"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119689","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dlst","kind":"target","name":"DLST","route":"/targets/dlst/","field":"links","label":"Ensembl ENSG00000119689"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119699","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfb3","kind":"target","name":"TGFB3","route":"/targets/tgfb3/","field":"links","label":"Ensembl ENSG00000119699"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119866","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl11a","kind":"target","name":"BCL11A","route":"/targets/bcl11a/","field":"links","label":"Ensembl ENSG00000119866"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119950","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mxi1","kind":"target","name":"MXI1","route":"/targets/mxi1/","field":"links","label":"Ensembl ENSG00000119950"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120063","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gna13","kind":"target","name":"GNA13","route":"/targets/gna13/","field":"links","label":"Ensembl ENSG00000120063"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120262","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccdc170","kind":"target","name":"CCDC170","route":"/targets/ccdc170/","field":"links","label":"Ensembl ENSG00000120262"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120694","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hsph1","kind":"target","name":"HSPH1","route":"/targets/hsph1/","field":"links","label":"Ensembl ENSG00000120694"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120733","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm3b","kind":"target","name":"KDM3B","route":"/targets/kdm3b/","field":"links","label":"Ensembl ENSG00000120733"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120889","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnfrsf10b","kind":"target","name":"TNFRSF10B","route":"/targets/tnfrsf10b/","field":"links","label":"Ensembl ENSG00000120889"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120907","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra1a","kind":"target","name":"ADRA1A","route":"/targets/adra1a/","field":"links","label":"Ensembl ENSG00000120907"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121067","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","field":"links","label":"Ensembl ENSG00000121067"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121152","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncaph","kind":"target","name":"NCAPH","route":"/targets/ncaph/","field":"links","label":"Ensembl ENSG00000121152"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121289","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cep89","kind":"target","name":"CEP89","route":"/targets/cep89/","field":"links","label":"Ensembl ENSG00000121289"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121390","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pspc1","kind":"target","name":"PSPC1","route":"/targets/pspc1/","field":"links","label":"Ensembl ENSG00000121390"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121741","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zmym2","kind":"target","name":"ZMYM2","route":"/targets/zmym2/","field":"links","label":"Ensembl ENSG00000121741"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121853","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ghsr","kind":"target","name":"GHSR","route":"/targets/ghsr/","field":"links","label":"Ensembl ENSG00000121853"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121858","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnfsf10","kind":"target","name":"TNFSF10","route":"/targets/tnfsf10/","field":"links","label":"Ensembl ENSG00000121858"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121989","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acvr2a","kind":"target","name":"ACVR2A","route":"/targets/acvr2a/","field":"links","label":"Ensembl ENSG00000121989"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122008","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"polk","kind":"target","name":"POLK","route":"/targets/polk/","field":"links","label":"Ensembl ENSG00000122008"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122406","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rpl5","kind":"target","name":"RPL5","route":"/targets/rpl5/","field":"links","label":"Ensembl ENSG00000122406"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122512","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/","field":"links","label":"Ensembl ENSG00000122512"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122566","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnrnpa2b1","kind":"target","name":"HNRNPA2B1","route":"/targets/hnrnpa2b1/","field":"links","label":"Ensembl ENSG00000122566"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122643","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nt5c3a","kind":"target","name":"NT5C3A","route":"/targets/nt5c3a/","field":"links","label":"Ensembl ENSG00000122643"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122728","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"taf1l","kind":"target","name":"TAF1L","route":"/targets/taf1l/","field":"links","label":"Ensembl ENSG00000122728"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122778","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kiaa1549","kind":"target","name":"KIAA1549","route":"/targets/kiaa1549/","field":"links","label":"Ensembl ENSG00000122778"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122779","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/","field":"links","label":"Ensembl ENSG00000122779"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122877","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"egr2","kind":"target","name":"EGR2","route":"/targets/egr2/","field":"links","label":"Ensembl ENSG00000122877"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122986","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hvcn1","kind":"target","name":"HVCN1","route":"/targets/hvcn1/","field":"links","label":"Ensembl ENSG00000122986"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123080","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkn2c","kind":"target","name":"CDKN2C","route":"/targets/cdkn2c/","field":"links","label":"Ensembl ENSG00000123080"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123191","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/","field":"links","label":"Ensembl ENSG00000123191"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123268","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atf1","kind":"target","name":"ATF1","route":"/targets/atf1/","field":"links","label":"Ensembl ENSG00000123268"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123364","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxc13","kind":"target","name":"HOXC13","route":"/targets/hoxc13/","field":"links","label":"Ensembl ENSG00000123364"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123374","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/","field":"links","label":"Ensembl ENSG00000123374"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxc11","kind":"target","name":"HOXC11","route":"/targets/hoxc11/","field":"links","label":"Ensembl ENSG00000123388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123416","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/","field":"links","label":"Ensembl ENSG00000123416"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123473","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stil","kind":"target","name":"STIL","route":"/targets/stil/","field":"links","label":"Ensembl ENSG00000123473"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123572","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrk","kind":"target","name":"NRK","route":"/targets/nrk/","field":"links","label":"Ensembl ENSG00000123572"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123983","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acsl3","kind":"target","name":"ACSL3","route":"/targets/acsl3/","field":"links","label":"Ensembl ENSG00000123983"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124145","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdc4","kind":"target","name":"SDC4","route":"/targets/sdc4/","field":"links","label":"Ensembl ENSG00000124145"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124151","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/","field":"links","label":"Ensembl ENSG00000124151"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124181","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/","field":"links","label":"Ensembl ENSG00000124181"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124486","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"usp9x","kind":"target","name":"USP9X","route":"/targets/usp9x/","field":"links","label":"Ensembl ENSG00000124486"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124574","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcc10","kind":"target","name":"ABCC10","route":"/targets/abcc10/","field":"links","label":"Ensembl ENSG00000124574"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h1-3","kind":"target","name":"H1-3","route":"/targets/h1-3/","field":"links","label":"Ensembl ENSG00000124575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124762","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkn1a","kind":"target","name":"CDKN1A","route":"/targets/cdkn1a/","field":"links","label":"Ensembl ENSG00000124762"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124795","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dek","kind":"target","name":"DEK","route":"/targets/dek/","field":"links","label":"Ensembl ENSG00000124795"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124831","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lrrfip1","kind":"target","name":"LRRFIP1","route":"/targets/lrrfip1/","field":"links","label":"Ensembl ENSG00000124831"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124882","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ereg","kind":"target","name":"EREG","route":"/targets/ereg/","field":"links","label":"Ensembl ENSG00000124882"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125084","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wnt1","kind":"target","name":"WNT1","route":"/targets/wnt1/","field":"links","label":"Ensembl ENSG00000125084"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125257","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abcc4","kind":"target","name":"ABCC4","route":"/targets/abcc4/","field":"links","label":"Ensembl ENSG00000125257"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sox21","kind":"target","name":"SOX21","route":"/targets/sox21/","field":"links","label":"Ensembl ENSG00000125285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125347","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/","field":"links","label":"Ensembl ENSG00000125347"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125378","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmp4","kind":"target","name":"BMP4","route":"/targets/bmp4/","field":"links","label":"Ensembl ENSG00000125378"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125398","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","field":"links","label":"Ensembl ENSG00000125398"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125482","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","field":"links","label":"Ensembl ENSG00000125482"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srms","kind":"target","name":"SRMS","route":"/targets/srms/","field":"links","label":"Ensembl ENSG00000125508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125618","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax8","kind":"target","name":"PAX8","route":"/targets/pax8/","field":"links","label":"Ensembl ENSG00000125618"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125740","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fosb","kind":"target","name":"FOSB","route":"/targets/fosb/","field":"links","label":"Ensembl ENSG00000125740"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125780","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgm3","kind":"target","name":"TGM3","route":"/targets/tgm3/","field":"links","label":"Ensembl ENSG00000125780"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125798","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxa2","kind":"target","name":"FOXA2","route":"/targets/foxa2/","field":"links","label":"Ensembl ENSG00000125798"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125845","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmp2","kind":"target","name":"BMP2","route":"/targets/bmp2/","field":"links","label":"Ensembl ENSG00000125845"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125850","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ovol2","kind":"target","name":"OVOL2","route":"/targets/ovol2/","field":"links","label":"Ensembl ENSG00000125850"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125885","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mcm8","kind":"target","name":"MCM8","route":"/targets/mcm8/","field":"links","label":"Ensembl ENSG00000125885"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125952","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"max","kind":"target","name":"MAX","route":"/targets/max/","field":"links","label":"Ensembl ENSG00000125952"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126012","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/","field":"links","label":"Ensembl ENSG00000126012"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126067","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/","field":"links","label":"Ensembl ENSG00000126067"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126214","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klc1","kind":"target","name":"KLC1","route":"/targets/klc1/","field":"links","label":"Ensembl ENSG00000126214"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126215","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"xrcc3","kind":"target","name":"XRCC3","route":"/targets/xrcc3/","field":"links","label":"Ensembl ENSG00000126215"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126351","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"thra","kind":"target","name":"THRA","route":"/targets/thra/","field":"links","label":"Ensembl ENSG00000126351"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126353","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccr7","kind":"target","name":"CCR7","route":"/targets/ccr7/","field":"links","label":"Ensembl ENSG00000126353"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126524","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sbds","kind":"target","name":"SBDS","route":"/targets/sbds/","field":"links","label":"Ensembl ENSG00000126524"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126583","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkcg","kind":"target","name":"PRKCG","route":"/targets/prkcg/","field":"links","label":"Ensembl ENSG00000126583"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126752","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ssx1","kind":"target","name":"SSX1","route":"/targets/ssx1/","field":"links","label":"Ensembl ENSG00000126752"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126777","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ktn1","kind":"target","name":"KTN1","route":"/targets/ktn1/","field":"links","label":"Ensembl ENSG00000126777"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126778","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"six1","kind":"target","name":"SIX1","route":"/targets/six1/","field":"links","label":"Ensembl ENSG00000126778"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126883","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nup214","kind":"target","name":"NUP214","route":"/targets/nup214/","field":"links","label":"Ensembl ENSG00000126883"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126890","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","field":"links","label":"Ensembl ENSG00000126890"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127152","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl11b","kind":"target","name":"BCL11B","route":"/targets/bcl11b/","field":"links","label":"Ensembl ENSG00000127152"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127314","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rap1b","kind":"target","name":"RAP1B","route":"/targets/rap1b/","field":"links","label":"Ensembl ENSG00000127314"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127329","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/","field":"links","label":"Ensembl ENSG00000127329"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127528","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/","field":"links","label":"Ensembl ENSG00000127528"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127616","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","field":"links","label":"Ensembl ENSG00000127616"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127824","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/","field":"links","label":"Ensembl ENSG00000127824"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127870","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rnf6","kind":"target","name":"RNF6","route":"/targets/rnf6/","field":"links","label":"Ensembl ENSG00000127870"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127914","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"akap9","kind":"target","name":"AKAP9","route":"/targets/akap9/","field":"links","label":"Ensembl ENSG00000127914"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127922","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/","field":"links","label":"Ensembl ENSG00000127922"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127946","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hip1","kind":"target","name":"HIP1","route":"/targets/hip1/","field":"links","label":"Ensembl ENSG00000127946"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127947","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn12","kind":"target","name":"PTPN12","route":"/targets/ptpn12/","field":"links","label":"Ensembl ENSG00000127947"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128039","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srd5a3","kind":"target","name":"SRD5A3","route":"/targets/srd5a3/","field":"links","label":"Ensembl ENSG00000128039"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128059","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppat","kind":"target","name":"PPAT","route":"/targets/ppat/","field":"links","label":"Ensembl ENSG00000128059"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128191","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dgcr8","kind":"target","name":"DGCR8","route":"/targets/dgcr8/","field":"links","label":"Ensembl ENSG00000128191"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128513","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pot1","kind":"target","name":"POT1","route":"/targets/pot1/","field":"links","label":"Ensembl ENSG00000128513"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128604","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irf5","kind":"target","name":"IRF5","route":"/targets/irf5/","field":"links","label":"Ensembl ENSG00000128604"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128713","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxd11","kind":"target","name":"HOXD11","route":"/targets/hoxd11/","field":"links","label":"Ensembl ENSG00000128713"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128714","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxd13","kind":"target","name":"HOXD13","route":"/targets/hoxd13/","field":"links","label":"Ensembl ENSG00000128714"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128917","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/","field":"links","label":"Ensembl ENSG00000128917"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128918","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aldh1a2","kind":"target","name":"ALDH1A2","route":"/targets/aldh1a2/","field":"links","label":"Ensembl ENSG00000128918"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128944","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"knstrn","kind":"target","name":"KNSTRN","route":"/targets/knstrn/","field":"links","label":"Ensembl ENSG00000128944"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129071","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mbd4","kind":"target","name":"MBD4","route":"/targets/mbd4/","field":"links","label":"Ensembl ENSG00000129071"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129084","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/","field":"links","label":"Ensembl ENSG00000129084"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129152","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myod1","kind":"target","name":"MYOD1","route":"/targets/myod1/","field":"links","label":"Ensembl ENSG00000129152"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129204","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"usp6","kind":"target","name":"USP6","route":"/targets/usp6/","field":"links","label":"Ensembl ENSG00000129204"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129315","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnt1","kind":"target","name":"CCNT1","route":"/targets/ccnt1/","field":"links","label":"Ensembl ENSG00000129315"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129474","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ajuba","kind":"target","name":"AJUBA","route":"/targets/ajuba/","field":"links","label":"Ensembl ENSG00000129474"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129484","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/","field":"links","label":"Ensembl ENSG00000129484"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129514","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","field":"links","label":"Ensembl ENSG00000129514"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129682","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf13","kind":"target","name":"FGF13","route":"/targets/fgf13/","field":"links","label":"Ensembl ENSG00000129682"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129993","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cbfa2t3","kind":"target","name":"CBFA2T3","route":"/targets/cbfa2t3/","field":"links","label":"Ensembl ENSG00000129993"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130203","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"apoe","kind":"target","name":"APOE","route":"/targets/apoe/","field":"links","label":"Ensembl ENSG00000130203"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130382","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mllt1","kind":"target","name":"MLLT1","route":"/targets/mllt1/","field":"links","label":"Ensembl ENSG00000130382"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130396","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"afdn","kind":"target","name":"AFDN","route":"/targets/afdn/","field":"links","label":"Ensembl ENSG00000130396"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130592","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lsp1","kind":"target","name":"LSP1","route":"/targets/lsp1/","field":"links","label":"Ensembl ENSG00000130592"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130702","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lama5","kind":"target","name":"LAMA5","route":"/targets/lama5/","field":"links","label":"Ensembl ENSG00000130702"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130706","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/","field":"links","label":"Ensembl ENSG00000130706"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130707","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/","field":"links","label":"Ensembl ENSG00000130707"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130726","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trim28","kind":"target","name":"TRIM28","route":"/targets/trim28/","field":"links","label":"Ensembl ENSG00000130726"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130779","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/","field":"links","label":"Ensembl ENSG00000130779"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130844","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf331","kind":"target","name":"ZNF331","route":"/targets/znf331/","field":"links","label":"Ensembl ENSG00000130844"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130940","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"casz1","kind":"target","name":"CASZ1","route":"/targets/casz1/","field":"links","label":"Ensembl ENSG00000130940"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131023","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/","field":"links","label":"Ensembl ENSG00000131023"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131051","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/","field":"links","label":"Ensembl ENSG00000131051"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/","field":"links","label":"Ensembl ENSG00000131323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131653","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"traf7","kind":"target","name":"TRAF7","route":"/targets/traf7/","field":"links","label":"Ensembl ENSG00000131653"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131941","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rhpn2","kind":"target","name":"RHPN2","route":"/targets/rhpn2/","field":"links","label":"Ensembl ENSG00000131941"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132002","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dnajb1","kind":"target","name":"DNAJB1","route":"/targets/dnajb1/","field":"links","label":"Ensembl ENSG00000132002"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132170","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/","field":"links","label":"Ensembl ENSG00000132170"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132475","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h3-3b","kind":"target","name":"H3-3B","route":"/targets/h3-3b/","field":"links","label":"Ensembl ENSG00000132475"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132639","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"snap25","kind":"target","name":"SNAP25","route":"/targets/snap25/","field":"links","label":"Ensembl ENSG00000132639"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132646","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/","field":"links","label":"Ensembl ENSG00000132646"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132671","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sstr4","kind":"target","name":"SSTR4","route":"/targets/sstr4/","field":"links","label":"Ensembl ENSG00000132671"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132773","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"toe1","kind":"target","name":"TOE1","route":"/targets/toe1/","field":"links","label":"Ensembl ENSG00000132773"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132781","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/","field":"links","label":"Ensembl ENSG00000132781"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132819","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbm38","kind":"target","name":"RBM38","route":"/targets/rbm38/","field":"links","label":"Ensembl ENSG00000132819"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132842","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ap3b1","kind":"target","name":"AP3B1","route":"/targets/ap3b1/","field":"links","label":"Ensembl ENSG00000132842"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133030","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mprip","kind":"target","name":"MPRIP","route":"/targets/mprip/","field":"links","label":"Ensembl ENSG00000133030"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133112","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tpt1","kind":"target","name":"TPT1","route":"/targets/tpt1/","field":"links","label":"Ensembl ENSG00000133112"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133124","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irs4","kind":"target","name":"IRS4","route":"/targets/irs4/","field":"links","label":"Ensembl ENSG00000133124"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133216","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ephb2","kind":"target","name":"EPHB2","route":"/targets/ephb2/","field":"links","label":"Ensembl ENSG00000133216"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133392","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myh11","kind":"target","name":"MYH11","route":"/targets/myh11/","field":"links","label":"Ensembl ENSG00000133392"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133401","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdzd2","kind":"target","name":"PDZD2","route":"/targets/pdzd2/","field":"links","label":"Ensembl ENSG00000133401"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133639","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/","field":"links","label":"Ensembl ENSG00000133639"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133818","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/","field":"links","label":"Ensembl ENSG00000133818"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134086","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vhl","kind":"target","name":"VHL","route":"/targets/vhl/","field":"links","label":"Ensembl ENSG00000134086"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134242","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn22","kind":"target","name":"PTPN22","route":"/targets/ptpn22/","field":"links","label":"Ensembl ENSG00000134242"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134250","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/","field":"links","label":"Ensembl ENSG00000134250"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134352","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il6st","kind":"target","name":"IL6ST","route":"/targets/il6st/","field":"links","label":"Ensembl ENSG00000134352"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134371","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdc73","kind":"target","name":"CDC73","route":"/targets/cdc73/","field":"links","label":"Ensembl ENSG00000134371"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134480","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccnh","kind":"target","name":"CCNH","route":"/targets/ccnh/","field":"links","label":"Ensembl ENSG00000134480"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134538","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slco1b1","kind":"target","name":"SLCO1B1","route":"/targets/slco1b1/","field":"links","label":"Ensembl ENSG00000134538"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134574","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddb2","kind":"target","name":"DDB2","route":"/targets/ddb2/","field":"links","label":"Ensembl ENSG00000134574"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134899","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/","field":"links","label":"Ensembl ENSG00000134899"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134954","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ets1","kind":"target","name":"ETS1","route":"/targets/ets1/","field":"links","label":"Ensembl ENSG00000134954"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134982","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"links","label":"Ensembl ENSG00000134982"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135100","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/","field":"links","label":"Ensembl ENSG00000135100"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135111","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbx3","kind":"target","name":"TBX3","route":"/targets/tbx3/","field":"links","label":"Ensembl ENSG00000135111"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135144","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dtx1","kind":"target","name":"DTX1","route":"/targets/dtx1/","field":"links","label":"Ensembl ENSG00000135144"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135333","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha7","kind":"target","name":"EPHA7","route":"/targets/epha7/","field":"links","label":"Ensembl ENSG00000135333"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135363","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lmo2","kind":"target","name":"LMO2","route":"/targets/lmo2/","field":"links","label":"Ensembl ENSG00000135363"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135503","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acvr1b","kind":"target","name":"ACVR1B","route":"/targets/acvr1b/","field":"links","label":"Ensembl ENSG00000135503"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135605","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tec","kind":"target","name":"TEC","route":"/targets/tec/","field":"links","label":"Ensembl ENSG00000135605"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135749","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pcnx2","kind":"target","name":"PCNX2","route":"/targets/pcnx2/","field":"links","label":"Ensembl ENSG00000135749"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135828","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rnasel","kind":"target","name":"RNASEL","route":"/targets/rnasel/","field":"links","label":"Ensembl ENSG00000135828"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135829","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/","field":"links","label":"Ensembl ENSG00000135829"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135862","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lamc1","kind":"target","name":"LAMC1","route":"/targets/lamc1/","field":"links","label":"Ensembl ENSG00000135862"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135903","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax3","kind":"target","name":"PAX3","route":"/targets/pax3/","field":"links","label":"Ensembl ENSG00000135903"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135956","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tmem127","kind":"target","name":"TMEM127","route":"/targets/tmem127/","field":"links","label":"Ensembl ENSG00000135956"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136040","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plxnc1","kind":"target","name":"PLXNC1","route":"/targets/plxnc1/","field":"links","label":"Ensembl ENSG00000136040"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136153","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lmo7","kind":"target","name":"LMO7","route":"/targets/lmo7/","field":"links","label":"Ensembl ENSG00000136153"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136158","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"spry2","kind":"target","name":"SPRY2","route":"/targets/spry2/","field":"links","label":"Ensembl ENSG00000136158"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136159","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nudt15","kind":"target","name":"NUDT15","route":"/targets/nudt15/","field":"links","label":"Ensembl ENSG00000136159"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136205","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tns3","kind":"target","name":"TNS3","route":"/targets/tns3/","field":"links","label":"Ensembl ENSG00000136205"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136238","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rac1","kind":"target","name":"RAC1","route":"/targets/rac1/","field":"links","label":"Ensembl ENSG00000136238"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136352","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","field":"links","label":"Ensembl ENSG00000136352"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136492","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/","field":"links","label":"Ensembl ENSG00000136492"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136504","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat7","kind":"target","name":"KAT7","route":"/targets/kat7/","field":"links","label":"Ensembl ENSG00000136504"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136518","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/","field":"links","label":"Ensembl ENSG00000136518"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136531","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn2a","kind":"target","name":"SCN2A","route":"/targets/scn2a/","field":"links","label":"Ensembl ENSG00000136531"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136546","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn7a","kind":"target","name":"SCN7A","route":"/targets/scn7a/","field":"links","label":"Ensembl ENSG00000136546"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136573","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"blk","kind":"target","name":"BLK","route":"/targets/blk/","field":"links","label":"Ensembl ENSG00000136573"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136603","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"skil","kind":"target","name":"SKIL","route":"/targets/skil/","field":"links","label":"Ensembl ENSG00000136603"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136754","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abi1","kind":"target","name":"ABI1","route":"/targets/abi1/","field":"links","label":"Ensembl ENSG00000136754"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136770","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dnajc1","kind":"target","name":"DNAJC1","route":"/targets/dnajc1/","field":"links","label":"Ensembl ENSG00000136770"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136807","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/","field":"links","label":"Ensembl ENSG00000136807"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136826","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klf4","kind":"target","name":"KLF4","route":"/targets/klf4/","field":"links","label":"Ensembl ENSG00000136826"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136930","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/","field":"links","label":"Ensembl ENSG00000136930"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136936","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"xpa","kind":"target","name":"XPA","route":"/targets/xpa/","field":"links","label":"Ensembl ENSG00000136936"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136944","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lmx1b","kind":"target","name":"LMX1B","route":"/targets/lmx1b/","field":"links","label":"Ensembl ENSG00000136944"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136997","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"links","label":"Ensembl ENSG00000136997"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137033","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il33","kind":"target","name":"IL33","route":"/targets/il33/","field":"links","label":"Ensembl ENSG00000137033"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137076","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tln1","kind":"target","name":"TLN1","route":"/targets/tln1/","field":"links","label":"Ensembl ENSG00000137076"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137106","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grhpr","kind":"target","name":"GRHPR","route":"/targets/grhpr/","field":"links","label":"Ensembl ENSG00000137106"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137154","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps6","kind":"target","name":"RPS6","route":"/targets/rps6/","field":"links","label":"Ensembl ENSG00000137154"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137166","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxp4","kind":"target","name":"FOXP4","route":"/targets/foxp4/","field":"links","label":"Ensembl ENSG00000137166"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137193","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/","field":"links","label":"Ensembl ENSG00000137193"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137218","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"frs3","kind":"target","name":"FRS3","route":"/targets/frs3/","field":"links","label":"Ensembl ENSG00000137218"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137267","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/","field":"links","label":"Ensembl ENSG00000137267"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137275","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ripk1","kind":"target","name":"RIPK1","route":"/targets/ripk1/","field":"links","label":"Ensembl ENSG00000137275"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/","field":"links","label":"Ensembl ENSG00000137285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137309","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hmga1","kind":"target","name":"HMGA1","route":"/targets/hmga1/","field":"links","label":"Ensembl ENSG00000137309"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137310","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcf19","kind":"target","name":"TCF19","route":"/targets/tcf19/","field":"links","label":"Ensembl ENSG00000137310"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137486","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arrb1","kind":"target","name":"ARRB1","route":"/targets/arrb1/","field":"links","label":"Ensembl ENSG00000137486"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137497","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"numa1","kind":"target","name":"NUMA1","route":"/targets/numa1/","field":"links","label":"Ensembl ENSG00000137497"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdcbp","kind":"target","name":"SDCBP","route":"/targets/sdcbp/","field":"links","label":"Ensembl ENSG00000137575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137673","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mmp7","kind":"target","name":"MMP7","route":"/targets/mmp7/","field":"links","label":"Ensembl ENSG00000137673"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137693","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/","field":"links","label":"Ensembl ENSG00000137693"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137713","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r1b","kind":"target","name":"PPP2R1B","route":"/targets/ppp2r1b/","field":"links","label":"Ensembl ENSG00000137713"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137807","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kif23","kind":"target","name":"KIF23","route":"/targets/kif23/","field":"links","label":"Ensembl ENSG00000137807"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137812","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"knl1","kind":"target","name":"KNL1","route":"/targets/knl1/","field":"links","label":"Ensembl ENSG00000137812"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138032","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppm1b","kind":"target","name":"PPM1B","route":"/targets/ppm1b/","field":"links","label":"Ensembl ENSG00000138032"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138061","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cyp1b1","kind":"target","name":"CYP1B1","route":"/targets/cyp1b1/","field":"links","label":"Ensembl ENSG00000138061"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138081","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/","field":"links","label":"Ensembl ENSG00000138081"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138115","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cyp2c8","kind":"target","name":"CYP2C8","route":"/targets/cyp2c8/","field":"links","label":"Ensembl ENSG00000138115"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138326","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps24","kind":"target","name":"RPS24","route":"/targets/rps24/","field":"links","label":"Ensembl ENSG00000138326"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138336","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/","field":"links","label":"Ensembl ENSG00000138336"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138346","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dna2","kind":"target","name":"DNA2","route":"/targets/dna2/","field":"links","label":"Ensembl ENSG00000138346"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138363","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atic","kind":"target","name":"ATIC","route":"/targets/atic/","field":"links","label":"Ensembl ENSG00000138363"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138376","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/","field":"links","label":"Ensembl ENSG00000138376"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138442","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wdr12","kind":"target","name":"WDR12","route":"/targets/wdr12/","field":"links","label":"Ensembl ENSG00000138442"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138448","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itgav","kind":"target","name":"ITGAV","route":"/targets/itgav/","field":"links","label":"Ensembl ENSG00000138448"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138592","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/","field":"links","label":"Ensembl ENSG00000138592"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138613","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aph1b","kind":"target","name":"APH1B","route":"/targets/aph1b/","field":"links","label":"Ensembl ENSG00000138613"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf5","kind":"target","name":"FGF5","route":"/targets/fgf5/","field":"links","label":"Ensembl ENSG00000138675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf2","kind":"target","name":"FGF2","route":"/targets/fgf2/","field":"links","label":"Ensembl ENSG00000138685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138698","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rap1gds1","kind":"target","name":"RAP1GDS1","route":"/targets/rap1gds1/","field":"links","label":"Ensembl ENSG00000138698"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138795","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lef1","kind":"target","name":"LEF1","route":"/targets/lef1/","field":"links","label":"Ensembl ENSG00000138795"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138798","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","field":"links","label":"Ensembl ENSG00000138798"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138801","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"papss1","kind":"target","name":"PAPSS1","route":"/targets/papss1/","field":"links","label":"Ensembl ENSG00000138801"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138814","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp3ca","kind":"target","name":"PPP3CA","route":"/targets/ppp3ca/","field":"links","label":"Ensembl ENSG00000138814"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138829","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/","field":"links","label":"Ensembl ENSG00000138829"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139083","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"etv6","kind":"target","name":"ETV6","route":"/targets/etv6/","field":"links","label":"Ensembl ENSG00000139083"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139163","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"etnk1","kind":"target","name":"ETNK1","route":"/targets/etnk1/","field":"links","label":"Ensembl ENSG00000139163"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139168","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zcrb1","kind":"target","name":"ZCRB1","route":"/targets/zcrb1/","field":"links","label":"Ensembl ENSG00000139168"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139219","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"col2a1","kind":"target","name":"COL2A1","route":"/targets/col2a1/","field":"links","label":"Ensembl ENSG00000139219"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139263","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lrig3","kind":"target","name":"LRIG3","route":"/targets/lrig3/","field":"links","label":"Ensembl ENSG00000139263"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139287","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tph2","kind":"target","name":"TPH2","route":"/targets/tph2/","field":"links","label":"Ensembl ENSG00000139287"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139292","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","field":"links","label":"Ensembl ENSG00000139292"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139318","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dusp6","kind":"target","name":"DUSP6","route":"/targets/dusp6/","field":"links","label":"Ensembl ENSG00000139318"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139352","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","field":"links","label":"Ensembl ENSG00000139352"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139687","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"links","label":"Ensembl ENSG00000139687"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139718","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/","field":"links","label":"Ensembl ENSG00000139718"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139842","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/","field":"links","label":"Ensembl ENSG00000139842"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139874","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sstr1","kind":"target","name":"SSTR1","route":"/targets/sstr1/","field":"links","label":"Ensembl ENSG00000139874"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139915","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mdga2","kind":"target","name":"MDGA2","route":"/targets/mdga2/","field":"links","label":"Ensembl ENSG00000139915"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140009","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"esr2","kind":"target","name":"ESR2","route":"/targets/esr2/","field":"links","label":"Ensembl ENSG00000140009"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140262","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcf12","kind":"target","name":"TCF12","route":"/targets/tcf12/","field":"links","label":"Ensembl ENSG00000140262"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf7","kind":"target","name":"FGF7","route":"/targets/fgf7/","field":"links","label":"Ensembl ENSG00000140285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140396","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/","field":"links","label":"Ensembl ENSG00000140396"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140398","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"neil1","kind":"target","name":"NEIL1","route":"/targets/neil1/","field":"links","label":"Ensembl ENSG00000140398"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140464","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pml","kind":"target","name":"PML","route":"/targets/pml/","field":"links","label":"Ensembl ENSG00000140464"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140525","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fanci","kind":"target","name":"FANCI","route":"/targets/fanci/","field":"links","label":"Ensembl ENSG00000140525"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"iqgap1","kind":"target","name":"IQGAP1","route":"/targets/iqgap1/","field":"links","label":"Ensembl ENSG00000140575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140577","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"crtc3","kind":"target","name":"CRTC3","route":"/targets/crtc3/","field":"links","label":"Ensembl ENSG00000140577"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140718","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fto","kind":"target","name":"FTO","route":"/targets/fto/","field":"links","label":"Ensembl ENSG00000140718"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140836","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/","field":"links","label":"Ensembl ENSG00000140836"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140937","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdh11","kind":"target","name":"CDH11","route":"/targets/cdh11/","field":"links","label":"Ensembl ENSG00000140937"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140968","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irf8","kind":"target","name":"IRF8","route":"/targets/irf8/","field":"links","label":"Ensembl ENSG00000140968"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140992","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdpk1","kind":"target","name":"PDPK1","route":"/targets/pdpk1/","field":"links","label":"Ensembl ENSG00000140992"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141027","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncor1","kind":"target","name":"NCOR1","route":"/targets/ncor1/","field":"links","label":"Ensembl ENSG00000141027"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141068","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ksr1","kind":"target","name":"KSR1","route":"/targets/ksr1/","field":"links","label":"Ensembl ENSG00000141068"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141252","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vps53","kind":"target","name":"VPS53","route":"/targets/vps53/","field":"links","label":"Ensembl ENSG00000141252"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141367","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cltc","kind":"target","name":"CLTC","route":"/targets/cltc/","field":"links","label":"Ensembl ENSG00000141367"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141380","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ss18","kind":"target","name":"SS18","route":"/targets/ss18/","field":"links","label":"Ensembl ENSG00000141380"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141469","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc14a1","kind":"target","name":"SLC14A1","route":"/targets/slc14a1/","field":"links","label":"Ensembl ENSG00000141469"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141480","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arrb2","kind":"target","name":"ARRB2","route":"/targets/arrb2/","field":"links","label":"Ensembl ENSG00000141480"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141499","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wrap53","kind":"target","name":"WRAP53","route":"/targets/wrap53/","field":"links","label":"Ensembl ENSG00000141499"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141506","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3r5","kind":"target","name":"PIK3R5","route":"/targets/pik3r5/","field":"links","label":"Ensembl ENSG00000141506"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141579","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf750","kind":"target","name":"ZNF750","route":"/targets/znf750/","field":"links","label":"Ensembl ENSG00000141579"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141646","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"links","label":"Ensembl ENSG00000141646"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141968","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/","field":"links","label":"Ensembl ENSG00000141968"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141985","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sh3gl1","kind":"target","name":"SH3GL1","route":"/targets/sh3gl1/","field":"links","label":"Ensembl ENSG00000141985"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142273","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cblc","kind":"target","name":"CBLC","route":"/targets/cblc/","field":"links","label":"Ensembl ENSG00000142273"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142319","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc6a3","kind":"target","name":"SLC6A3","route":"/targets/slc6a3/","field":"links","label":"Ensembl ENSG00000142319"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142507","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/","field":"links","label":"Ensembl ENSG00000142507"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142515","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klk3","kind":"target","name":"KLK3","route":"/targets/klk3/","field":"links","label":"Ensembl ENSG00000142515"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/","field":"links","label":"Ensembl ENSG00000142611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cnksr1","kind":"target","name":"CNKSR1","route":"/targets/cnksr1/","field":"links","label":"Ensembl ENSG00000142675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142798","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hspg2","kind":"target","name":"HSPG2","route":"/targets/hspg2/","field":"links","label":"Ensembl ENSG00000142798"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142867","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/","field":"links","label":"Ensembl ENSG00000142867"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142949","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprf","kind":"target","name":"PTPRF","route":"/targets/ptprf/","field":"links","label":"Ensembl ENSG00000142949"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143106","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/","field":"links","label":"Ensembl ENSG00000143106"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143147","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gpr161","kind":"target","name":"GPR161","route":"/targets/gpr161/","field":"links","label":"Ensembl ENSG00000143147"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143226","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/","field":"links","label":"Ensembl ENSG00000143226"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143252","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdhc","kind":"target","name":"SDHC","route":"/targets/sdhc/","field":"links","label":"Ensembl ENSG00000143252"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143294","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","field":"links","label":"Ensembl ENSG00000143294"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143322","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abl2","kind":"target","name":"ABL2","route":"/targets/abl2/","field":"links","label":"Ensembl ENSG00000143322"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143379","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"setdb1","kind":"target","name":"SETDB1","route":"/targets/setdb1/","field":"links","label":"Ensembl ENSG00000143379"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/","field":"links","label":"Ensembl ENSG00000143384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143437","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/","field":"links","label":"Ensembl ENSG00000143437"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143473","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnh1","kind":"target","name":"KCNH1","route":"/targets/kcnh1/","field":"links","label":"Ensembl ENSG00000143473"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143549","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tpm3","kind":"target","name":"TPM3","route":"/targets/tpm3/","field":"links","label":"Ensembl ENSG00000143549"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143622","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rit1","kind":"target","name":"RIT1","route":"/targets/rit1/","field":"links","label":"Ensembl ENSG00000143622"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143631","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"flg","kind":"target","name":"FLG","route":"/targets/flg/","field":"links","label":"Ensembl ENSG00000143631"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143632","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acta1","kind":"target","name":"ACTA1","route":"/targets/acta1/","field":"links","label":"Ensembl ENSG00000143632"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143748","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nvl","kind":"target","name":"NVL","route":"/targets/nvl/","field":"links","label":"Ensembl ENSG00000143748"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143772","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itpkb","kind":"target","name":"ITPKB","route":"/targets/itpkb/","field":"links","label":"Ensembl ENSG00000143772"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143801","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psen2","kind":"target","name":"PSEN2","route":"/targets/psen2/","field":"links","label":"Ensembl ENSG00000143801"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143869","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gdf7","kind":"target","name":"GDF7","route":"/targets/gdf7/","field":"links","label":"Ensembl ENSG00000143869"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143924","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eml4","kind":"target","name":"EML4","route":"/targets/eml4/","field":"links","label":"Ensembl ENSG00000143924"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143947","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps27a","kind":"target","name":"RPS27A","route":"/targets/rps27a/","field":"links","label":"Ensembl ENSG00000143947"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143970","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"asxl2","kind":"target","name":"ASXL2","route":"/targets/asxl2/","field":"links","label":"Ensembl ENSG00000143970"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144218","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aff3","kind":"target","name":"AFF3","route":"/targets/aff3/","field":"links","label":"Ensembl ENSG00000144218"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144285","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn1a","kind":"target","name":"SCN1A","route":"/targets/scn1a/","field":"links","label":"Ensembl ENSG00000144285"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144354","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdca7","kind":"target","name":"CDCA7","route":"/targets/cdca7/","field":"links","label":"Ensembl ENSG00000144354"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144476","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/","field":"links","label":"Ensembl ENSG00000144476"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144554","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/","field":"links","label":"Ensembl ENSG00000144554"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144580","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cnot9","kind":"target","name":"CNOT9","route":"/targets/cnot9/","field":"links","label":"Ensembl ENSG00000144580"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144645","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"osbpl10","kind":"target","name":"OSBPL10","route":"/targets/osbpl10/","field":"links","label":"Ensembl ENSG00000144645"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144674","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"golga4","kind":"target","name":"GOLGA4","route":"/targets/golga4/","field":"links","label":"Ensembl ENSG00000144674"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144802","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfkbiz","kind":"target","name":"NFKBIZ","route":"/targets/nfkbiz/","field":"links","label":"Ensembl ENSG00000144802"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144840","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rabl3","kind":"target","name":"RABL3","route":"/targets/rabl3/","field":"links","label":"Ensembl ENSG00000144840"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145012","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lpp","kind":"target","name":"LPP","route":"/targets/lpp/","field":"links","label":"Ensembl ENSG00000145012"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145216","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fip1l1","kind":"target","name":"FIP1L1","route":"/targets/fip1l1/","field":"links","label":"Ensembl ENSG00000145216"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145242","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha5","kind":"target","name":"EPHA5","route":"/targets/epha5/","field":"links","label":"Ensembl ENSG00000145242"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145414","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"naf1","kind":"target","name":"NAF1","route":"/targets/naf1/","field":"links","label":"Ensembl ENSG00000145414"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145425","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/","field":"links","label":"Ensembl ENSG00000145425"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145545","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srd5a1","kind":"target","name":"SRD5A1","route":"/targets/srd5a1/","field":"links","label":"Ensembl ENSG00000145545"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/","field":"links","label":"Ensembl ENSG00000145675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145715","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rasa1","kind":"target","name":"RASA1","route":"/targets/rasa1/","field":"links","label":"Ensembl ENSG00000145715"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145782","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atg12","kind":"target","name":"ATG12","route":"/targets/atg12/","field":"links","label":"Ensembl ENSG00000145782"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145819","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgap26","kind":"target","name":"ARHGAP26","route":"/targets/arhgap26/","field":"links","label":"Ensembl ENSG00000145819"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145996","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkal1","kind":"target","name":"CDKAL1","route":"/targets/cdkal1/","field":"links","label":"Ensembl ENSG00000145996"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146143","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/","field":"links","label":"Ensembl ENSG00000146143"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146205","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ano7","kind":"target","name":"ANO7","route":"/targets/ano7/","field":"links","label":"Ensembl ENSG00000146205"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146232","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfkbie","kind":"target","name":"NFKBIE","route":"/targets/nfkbie/","field":"links","label":"Ensembl ENSG00000146232"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146374","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","field":"links","label":"Ensembl ENSG00000146374"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146477","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc22a3","kind":"target","name":"SLC22A3","route":"/targets/slc22a3/","field":"links","label":"Ensembl ENSG00000146477"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146872","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tlk2","kind":"target","name":"TLK2","route":"/targets/tlk2/","field":"links","label":"Ensembl ENSG00000146872"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146904","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha1","kind":"target","name":"EPHA1","route":"/targets/epha1/","field":"links","label":"Ensembl ENSG00000146904"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147050","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","field":"links","label":"Ensembl ENSG00000147050"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147065","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msn","kind":"target","name":"MSN","route":"/targets/msn/","field":"links","label":"Ensembl ENSG00000147065"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147099","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/","field":"links","label":"Ensembl ENSG00000147099"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147130","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zmym3","kind":"target","name":"ZMYM3","route":"/targets/zmym3/","field":"links","label":"Ensembl ENSG00000147130"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147168","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/","field":"links","label":"Ensembl ENSG00000147168"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147224","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prps1","kind":"target","name":"PRPS1","route":"/targets/prps1/","field":"links","label":"Ensembl ENSG00000147224"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147403","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/","field":"links","label":"Ensembl ENSG00000147403"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147475","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"erlin2","kind":"target","name":"ERLIN2","route":"/targets/erlin2/","field":"links","label":"Ensembl ENSG00000147475"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147485","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pxdnl","kind":"target","name":"PXDNL","route":"/targets/pxdnl/","field":"links","label":"Ensembl ENSG00000147485"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147548","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nsd3","kind":"target","name":"NSD3","route":"/targets/nsd3/","field":"links","label":"Ensembl ENSG00000147548"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147655","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rspo2","kind":"target","name":"RSPO2","route":"/targets/rspo2/","field":"links","label":"Ensembl ENSG00000147655"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147724","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fam135b","kind":"target","name":"FAM135B","route":"/targets/fam135b/","field":"links","label":"Ensembl ENSG00000147724"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147813","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"naprt","kind":"target","name":"NAPRT","route":"/targets/naprt/","field":"links","label":"Ensembl ENSG00000147813"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147862","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nfib","kind":"target","name":"NFIB","route":"/targets/nfib/","field":"links","label":"Ensembl ENSG00000147862"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147883","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","field":"links","label":"Ensembl ENSG00000147883"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147889","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"links","label":"Ensembl ENSG00000147889"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148143","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf462","kind":"target","name":"ZNF462","route":"/targets/znf462/","field":"links","label":"Ensembl ENSG00000148143"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148229","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/","field":"links","label":"Ensembl ENSG00000148229"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148400","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"links","label":"Ensembl ENSG00000148400"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148516","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/","field":"links","label":"Ensembl ENSG00000148516"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148584","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"a1cf","kind":"target","name":"A1CF","route":"/targets/a1cf/","field":"links","label":"Ensembl ENSG00000148584"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148702","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"habp2","kind":"target","name":"HABP2","route":"/targets/habp2/","field":"links","label":"Ensembl ENSG00000148702"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148737","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","field":"links","label":"Ensembl ENSG00000148737"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149311","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"links","label":"Ensembl ENSG00000149311"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149503","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"incenp","kind":"target","name":"INCENP","route":"/targets/incenp/","field":"links","label":"Ensembl ENSG00000149503"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149554","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/","field":"links","label":"Ensembl ENSG00000149554"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149948","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hmga2","kind":"target","name":"HMGA2","route":"/targets/hmga2/","field":"links","label":"Ensembl ENSG00000149948"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149970","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cnksr2","kind":"target","name":"CNKSR2","route":"/targets/cnksr2/","field":"links","label":"Ensembl ENSG00000149970"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150347","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arid5b","kind":"target","name":"ARID5B","route":"/targets/arid5b/","field":"links","label":"Ensembl ENSG00000150347"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150457","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lats2","kind":"target","name":"LATS2","route":"/targets/lats2/","field":"links","label":"Ensembl ENSG00000150457"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150593","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdcd4","kind":"target","name":"PDCD4","route":"/targets/pdcd4/","field":"links","label":"Ensembl ENSG00000150593"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150594","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra2a","kind":"target","name":"ADRA2A","route":"/targets/adra2a/","field":"links","label":"Ensembl ENSG00000150594"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150630","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vegfc","kind":"target","name":"VEGFC","route":"/targets/vegfc/","field":"links","label":"Ensembl ENSG00000150630"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150907","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/","field":"links","label":"Ensembl ENSG00000150907"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150991","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ubc","kind":"target","name":"UBC","route":"/targets/ubc/","field":"links","label":"Ensembl ENSG00000150991"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000150995","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itpr1","kind":"target","name":"ITPR1","route":"/targets/itpr1/","field":"links","label":"Ensembl ENSG00000150995"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000151090","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"thrb","kind":"target","name":"THRB","route":"/targets/thrb/","field":"links","label":"Ensembl ENSG00000151090"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000151348","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/","field":"links","label":"Ensembl ENSG00000151348"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000151532","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vti1a","kind":"target","name":"VTI1A","route":"/targets/vti1a/","field":"links","label":"Ensembl ENSG00000151532"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000151617","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ednra","kind":"target","name":"EDNRA","route":"/targets/ednra/","field":"links","label":"Ensembl ENSG00000151617"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152086","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/","field":"links","label":"Ensembl ENSG00000152086"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152104","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn14","kind":"target","name":"PTPN14","route":"/targets/ptpn14/","field":"links","label":"Ensembl ENSG00000152104"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152207","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","field":"links","label":"Ensembl ENSG00000152207"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152217","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"setbp1","kind":"target","name":"SETBP1","route":"/targets/setbp1/","field":"links","label":"Ensembl ENSG00000152217"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152270","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pde3b","kind":"target","name":"PDE3B","route":"/targets/pde3b/","field":"links","label":"Ensembl ENSG00000152270"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152894","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprk","kind":"target","name":"PTPRK","route":"/targets/ptprk/","field":"links","label":"Ensembl ENSG00000152894"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153093","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acoxl","kind":"target","name":"ACOXL","route":"/targets/acoxl/","field":"links","label":"Ensembl ENSG00000153093"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153162","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bmp6","kind":"target","name":"BMP6","route":"/targets/bmp6/","field":"links","label":"Ensembl ENSG00000153162"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153165","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rgpd3","kind":"target","name":"RGPD3","route":"/targets/rgpd3/","field":"links","label":"Ensembl ENSG00000153165"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153187","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnrnpu","kind":"target","name":"HNRNPU","route":"/targets/hnrnpu/","field":"links","label":"Ensembl ENSG00000153187"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153201","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ranbp2","kind":"target","name":"RANBP2","route":"/targets/ranbp2/","field":"links","label":"Ensembl ENSG00000153201"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153208","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mertk","kind":"target","name":"MERTK","route":"/targets/mertk/","field":"links","label":"Ensembl ENSG00000153208"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153234","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nr4a2","kind":"target","name":"NR4A2","route":"/targets/nr4a2/","field":"links","label":"Ensembl ENSG00000153234"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153253","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn3a","kind":"target","name":"SCN3A","route":"/targets/scn3a/","field":"links","label":"Ensembl ENSG00000153253"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153487","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ing1","kind":"target","name":"ING1","route":"/targets/ing1/","field":"links","label":"Ensembl ENSG00000153487"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153707","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/","field":"links","label":"Ensembl ENSG00000153707"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153814","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"jazf1","kind":"target","name":"JAZF1","route":"/targets/jazf1/","field":"links","label":"Ensembl ENSG00000153814"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153944","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/","field":"links","label":"Ensembl ENSG00000153944"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154001","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r5e","kind":"target","name":"PPP2R5E","route":"/targets/ppp2r5e/","field":"links","label":"Ensembl ENSG00000154001"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154133","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"robo4","kind":"target","name":"ROBO4","route":"/targets/robo4/","field":"links","label":"Ensembl ENSG00000154133"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154188","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"angpt1","kind":"target","name":"ANGPT1","route":"/targets/angpt1/","field":"links","label":"Ensembl ENSG00000154188"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/","field":"links","label":"Ensembl ENSG00000154611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154767","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"xpc","kind":"target","name":"XPC","route":"/targets/xpc/","field":"links","label":"Ensembl ENSG00000154767"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154783","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgd5","kind":"target","name":"FGD5","route":"/targets/fgd5/","field":"links","label":"Ensembl ENSG00000154783"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154803","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"flcn","kind":"target","name":"FLCN","route":"/targets/flcn/","field":"links","label":"Ensembl ENSG00000154803"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154928","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ephb1","kind":"target","name":"EPHB1","route":"/targets/ephb1/","field":"links","label":"Ensembl ENSG00000154928"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155363","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mov10","kind":"target","name":"MOV10","route":"/targets/mov10/","field":"links","label":"Ensembl ENSG00000155363"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155816","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fmn2","kind":"target","name":"FMN2","route":"/targets/fmn2/","field":"links","label":"Ensembl ENSG00000155816"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155903","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rasa2","kind":"target","name":"RASA2","route":"/targets/rasa2/","field":"links","label":"Ensembl ENSG00000155903"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155975","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/","field":"links","label":"Ensembl ENSG00000155975"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156052","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","field":"links","label":"Ensembl ENSG00000156052"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156076","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wif1","kind":"target","name":"WIF1","route":"/targets/wif1/","field":"links","label":"Ensembl ENSG00000156076"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156395","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sorcs3","kind":"target","name":"SORCS3","route":"/targets/sorcs3/","field":"links","label":"Ensembl ENSG00000156395"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156427","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf18","kind":"target","name":"FGF18","route":"/targets/fgf18/","field":"links","label":"Ensembl ENSG00000156427"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156531","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"phf6","kind":"target","name":"PHF6","route":"/targets/phf6/","field":"links","label":"Ensembl ENSG00000156531"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156564","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lrfn2","kind":"target","name":"LRFN2","route":"/targets/lrfn2/","field":"links","label":"Ensembl ENSG00000156564"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156650","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat6b","kind":"target","name":"KAT6B","route":"/targets/kat6b/","field":"links","label":"Ensembl ENSG00000156650"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156735","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bag4","kind":"target","name":"BAG4","route":"/targets/bag4/","field":"links","label":"Ensembl ENSG00000156735"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156970","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/","field":"links","label":"Ensembl ENSG00000156970"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156976","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif4a2","kind":"target","name":"EIF4A2","route":"/targets/eif4a2/","field":"links","label":"Ensembl ENSG00000156976"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157168","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"links","label":"Ensembl ENSG00000157168"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cacna1d","kind":"target","name":"CACNA1D","route":"/targets/cacna1d/","field":"links","label":"Ensembl ENSG00000157388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157554","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","field":"links","label":"Ensembl ENSG00000157554"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157557","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ets2","kind":"target","name":"ETS2","route":"/targets/ets2/","field":"links","label":"Ensembl ENSG00000157557"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157613","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"creb3l1","kind":"target","name":"CREB3L1","route":"/targets/creb3l1/","field":"links","label":"Ensembl ENSG00000157613"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157765","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/","field":"links","label":"Ensembl ENSG00000157765"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157873","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnfrsf14","kind":"target","name":"TNFRSF14","route":"/targets/tnfrsf14/","field":"links","label":"Ensembl ENSG00000157873"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158050","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dusp2","kind":"target","name":"DUSP2","route":"/targets/dusp2/","field":"links","label":"Ensembl ENSG00000158050"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158062","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ubxn11","kind":"target","name":"UBXN11","route":"/targets/ubxn11/","field":"links","label":"Ensembl ENSG00000158062"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158089","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"galnt14","kind":"target","name":"GALNT14","route":"/targets/galnt14/","field":"links","label":"Ensembl ENSG00000158089"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158169","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/","field":"links","label":"Ensembl ENSG00000158169"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158373","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h2bc5","kind":"target","name":"H2BC5","route":"/targets/h2bc5/","field":"links","label":"Ensembl ENSG00000158373"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158458","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrg2","kind":"target","name":"NRG2","route":"/targets/nrg2/","field":"links","label":"Ensembl ENSG00000158458"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158636","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/","field":"links","label":"Ensembl ENSG00000158636"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158711","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elk4","kind":"target","name":"ELK4","route":"/targets/elk4/","field":"links","label":"Ensembl ENSG00000158711"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158815","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf17","kind":"target","name":"FGF17","route":"/targets/fgf17/","field":"links","label":"Ensembl ENSG00000158815"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158825","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cda","kind":"target","name":"CDA","route":"/targets/cda/","field":"links","label":"Ensembl ENSG00000158825"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159110","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/","field":"links","label":"Ensembl ENSG00000159110"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159184","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxb13","kind":"target","name":"HOXB13","route":"/targets/hoxb13/","field":"links","label":"Ensembl ENSG00000159184"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159216","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/","field":"links","label":"Ensembl ENSG00000159216"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159263","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sim2","kind":"target","name":"SIM2","route":"/targets/sim2/","field":"links","label":"Ensembl ENSG00000159263"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159352","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/","field":"links","label":"Ensembl ENSG00000159352"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159377","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/","field":"links","label":"Ensembl ENSG00000159377"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159388","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"btg2","kind":"target","name":"BTG2","route":"/targets/btg2/","field":"links","label":"Ensembl ENSG00000159388"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159784","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fam131b","kind":"target","name":"FAM131B","route":"/targets/fam131b/","field":"links","label":"Ensembl ENSG00000159784"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160007","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/","field":"links","label":"Ensembl ENSG00000160007"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160180","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tff3","kind":"target","name":"TFF3","route":"/targets/tff3/","field":"links","label":"Ensembl ENSG00000160180"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160201","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"u2af1","kind":"target","name":"U2AF1","route":"/targets/u2af1/","field":"links","label":"Ensembl ENSG00000160201"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160307","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"s100b","kind":"target","name":"S100B","route":"/targets/s100b/","field":"links","label":"Ensembl ENSG00000160307"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160321","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf208","kind":"target","name":"ZNF208","route":"/targets/znf208/","field":"links","label":"Ensembl ENSG00000160321"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160654","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/","field":"links","label":"Ensembl ENSG00000160654"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zbtb7b","kind":"target","name":"ZBTB7B","route":"/targets/zbtb7b/","field":"links","label":"Ensembl ENSG00000160685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160691","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"shc1","kind":"target","name":"SHC1","route":"/targets/shc1/","field":"links","label":"Ensembl ENSG00000160691"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160752","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/","field":"links","label":"Ensembl ENSG00000160752"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160789","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lmna","kind":"target","name":"LMNA","route":"/targets/lmna/","field":"links","label":"Ensembl ENSG00000160789"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160867","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/","field":"links","label":"Ensembl ENSG00000160867"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160882","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cyp11b1","kind":"target","name":"CYP11B1","route":"/targets/cyp11b1/","field":"links","label":"Ensembl ENSG00000160882"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160957","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/","field":"links","label":"Ensembl ENSG00000160957"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161011","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sqstm1","kind":"target","name":"SQSTM1","route":"/targets/sqstm1/","field":"links","label":"Ensembl ENSG00000161011"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161021","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"maml1","kind":"target","name":"MAML1","route":"/targets/maml1/","field":"links","label":"Ensembl ENSG00000161021"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161057","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/","field":"links","label":"Ensembl ENSG00000161057"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161547","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srsf2","kind":"target","name":"SRSF2","route":"/targets/srsf2/","field":"links","label":"Ensembl ENSG00000161547"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161960","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif4a1","kind":"target","name":"EIF4A1","route":"/targets/eif4a1/","field":"links","label":"Ensembl ENSG00000161960"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162009","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/","field":"links","label":"Ensembl ENSG00000162009"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162231","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nxf1","kind":"target","name":"NXF1","route":"/targets/nxf1/","field":"links","label":"Ensembl ENSG00000162231"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162337","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lrp5","kind":"target","name":"LRP5","route":"/targets/lrp5/","field":"links","label":"Ensembl ENSG00000162337"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162341","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tpcn2","kind":"target","name":"TPCN2","route":"/targets/tpcn2/","field":"links","label":"Ensembl ENSG00000162341"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162344","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/","field":"links","label":"Ensembl ENSG00000162344"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162367","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tal1","kind":"target","name":"TAL1","route":"/targets/tal1/","field":"links","label":"Ensembl ENSG00000162367"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162408","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nol9","kind":"target","name":"NOL9","route":"/targets/nol9/","field":"links","label":"Ensembl ENSG00000162408"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162409","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkaa2","kind":"target","name":"PRKAA2","route":"/targets/prkaa2/","field":"links","label":"Ensembl ENSG00000162409"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162585","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"faap20","kind":"target","name":"FAAP20","route":"/targets/faap20/","field":"links","label":"Ensembl ENSG00000162585"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162601","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mysm1","kind":"target","name":"MYSM1","route":"/targets/mysm1/","field":"links","label":"Ensembl ENSG00000162601"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162613","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fubp1","kind":"target","name":"FUBP1","route":"/targets/fubp1/","field":"links","label":"Ensembl ENSG00000162613"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162736","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncstn","kind":"target","name":"NCSTN","route":"/targets/ncstn/","field":"links","label":"Ensembl ENSG00000162736"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162775","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbm15","kind":"target","name":"RBM15","route":"/targets/rbm15/","field":"links","label":"Ensembl ENSG00000162775"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162924","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/","field":"links","label":"Ensembl ENSG00000162924"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162975","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnf1","kind":"target","name":"KCNF1","route":"/targets/kcnf1/","field":"links","label":"Ensembl ENSG00000162975"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163026","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wdcp","kind":"target","name":"WDCP","route":"/targets/wdcp/","field":"links","label":"Ensembl ENSG00000163026"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163083","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"inhbb","kind":"target","name":"INHBB","route":"/targets/inhbb/","field":"links","label":"Ensembl ENSG00000163083"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163110","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdlim5","kind":"target","name":"PDLIM5","route":"/targets/pdlim5/","field":"links","label":"Ensembl ENSG00000163110"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163131","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctss","kind":"target","name":"CTSS","route":"/targets/ctss/","field":"links","label":"Ensembl ENSG00000163131"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163161","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/","field":"links","label":"Ensembl ENSG00000163161"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163235","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfa","kind":"target","name":"TGFA","route":"/targets/tgfa/","field":"links","label":"Ensembl ENSG00000163235"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163359","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"col6a3","kind":"target","name":"COL6A3","route":"/targets/col6a3/","field":"links","label":"Ensembl ENSG00000163359"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163399","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atp1a1","kind":"target","name":"ATP1A1","route":"/targets/atp1a1/","field":"links","label":"Ensembl ENSG00000163399"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163435","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","field":"links","label":"Ensembl ENSG00000163435"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163491","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nek10","kind":"target","name":"NEK10","route":"/targets/nek10/","field":"links","label":"Ensembl ENSG00000163491"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163497","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fev","kind":"target","name":"FEV","route":"/targets/fev/","field":"links","label":"Ensembl ENSG00000163497"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163507","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cip2a","kind":"target","name":"CIP2A","route":"/targets/cip2a/","field":"links","label":"Ensembl ENSG00000163507"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eomes","kind":"target","name":"EOMES","route":"/targets/eomes/","field":"links","label":"Ensembl ENSG00000163508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163513","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","field":"links","label":"Ensembl ENSG00000163513"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163517","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/","field":"links","label":"Ensembl ENSG00000163517"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163518","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fcrl4","kind":"target","name":"FCRL4","route":"/targets/fcrl4/","field":"links","label":"Ensembl ENSG00000163518"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163520","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/","field":"links","label":"Ensembl ENSG00000163520"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163558","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkci","kind":"target","name":"PRKCI","route":"/targets/prkci/","field":"links","label":"Ensembl ENSG00000163558"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163600","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"icos","kind":"target","name":"ICOS","route":"/targets/icos/","field":"links","label":"Ensembl ENSG00000163600"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163629","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptpn13","kind":"target","name":"PTPN13","route":"/targets/ptpn13/","field":"links","label":"Ensembl ENSG00000163629"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163635","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atxn7","kind":"target","name":"ATXN7","route":"/targets/atxn7/","field":"links","label":"Ensembl ENSG00000163635"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163636","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/","field":"links","label":"Ensembl ENSG00000163636"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163638","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/","field":"links","label":"Ensembl ENSG00000163638"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163655","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gmps","kind":"target","name":"GMPS","route":"/targets/gmps/","field":"links","label":"Ensembl ENSG00000163655"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163930","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","field":"links","label":"Ensembl ENSG00000163930"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163932","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkcd","kind":"target","name":"PRKCD","route":"/targets/prkcd/","field":"links","label":"Ensembl ENSG00000163932"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163939","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/","field":"links","label":"Ensembl ENSG00000163939"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164161","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hhip","kind":"target","name":"HHIP","route":"/targets/hhip/","field":"links","label":"Ensembl ENSG00000164161"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164175","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc45a2","kind":"target","name":"SLC45A2","route":"/targets/slc45a2/","field":"links","label":"Ensembl ENSG00000164175"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164190","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nipbl","kind":"target","name":"NIPBL","route":"/targets/nipbl/","field":"links","label":"Ensembl ENSG00000164190"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164252","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aggf1","kind":"target","name":"AGGF1","route":"/targets/aggf1/","field":"links","label":"Ensembl ENSG00000164252"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164327","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/","field":"links","label":"Ensembl ENSG00000164327"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164330","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ebf1","kind":"target","name":"EBF1","route":"/targets/ebf1/","field":"links","label":"Ensembl ENSG00000164330"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164362","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/","field":"links","label":"Ensembl ENSG00000164362"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164398","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"acsl6","kind":"target","name":"ACSL6","route":"/targets/acsl6/","field":"links","label":"Ensembl ENSG00000164398"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164438","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tlx3","kind":"target","name":"TLX3","route":"/targets/tlx3/","field":"links","label":"Ensembl ENSG00000164438"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164458","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbxt","kind":"target","name":"TBXT","route":"/targets/tbxt/","field":"links","label":"Ensembl ENSG00000164458"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pttg1","kind":"target","name":"PTTG1","route":"/targets/pttg1/","field":"links","label":"Ensembl ENSG00000164611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164683","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hey1","kind":"target","name":"HEY1","route":"/targets/hey1/","field":"links","label":"Ensembl ENSG00000164683"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164695","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chmp4c","kind":"target","name":"CHMP4C","route":"/targets/chmp4c/","field":"links","label":"Ensembl ENSG00000164695"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164736","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sox17","kind":"target","name":"SOX17","route":"/targets/sox17/","field":"links","label":"Ensembl ENSG00000164736"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164741","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dlc1","kind":"target","name":"DLC1","route":"/targets/dlc1/","field":"links","label":"Ensembl ENSG00000164741"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164749","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnf4g","kind":"target","name":"HNF4G","route":"/targets/hnf4g/","field":"links","label":"Ensembl ENSG00000164749"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164754","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad21","kind":"target","name":"RAD21","route":"/targets/rad21/","field":"links","label":"Ensembl ENSG00000164754"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164796","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csmd3","kind":"target","name":"CSMD3","route":"/targets/csmd3/","field":"links","label":"Ensembl ENSG00000164796"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164885","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdk5","kind":"target","name":"CDK5","route":"/targets/cdk5/","field":"links","label":"Ensembl ENSG00000164885"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164985","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psip1","kind":"target","name":"PSIP1","route":"/targets/psip1/","field":"links","label":"Ensembl ENSG00000164985"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165025","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/","field":"links","label":"Ensembl ENSG00000165025"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165238","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wnk2","kind":"target","name":"WNK2","route":"/targets/wnk2/","field":"links","label":"Ensembl ENSG00000165238"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fat3","kind":"target","name":"FAT3","route":"/targets/fat3/","field":"links","label":"Ensembl ENSG00000165323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165458","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"inppl1","kind":"target","name":"INPPL1","route":"/targets/inppl1/","field":"links","label":"Ensembl ENSG00000165458"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165556","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdx2","kind":"target","name":"CDX2","route":"/targets/cdx2/","field":"links","label":"Ensembl ENSG00000165556"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165671","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/","field":"links","label":"Ensembl ENSG00000165671"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165699","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tsc1","kind":"target","name":"TSC1","route":"/targets/tsc1/","field":"links","label":"Ensembl ENSG00000165699"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165916","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/","field":"links","label":"Ensembl ENSG00000165916"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166006","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnc2","kind":"target","name":"KCNC2","route":"/targets/kcnc2/","field":"links","label":"Ensembl ENSG00000166006"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166164","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"brd7","kind":"target","name":"BRD7","route":"/targets/brd7/","field":"links","label":"Ensembl ENSG00000166164"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166225","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"frs2","kind":"target","name":"FRS2","route":"/targets/frs2/","field":"links","label":"Ensembl ENSG00000166225"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/","field":"links","label":"Ensembl ENSG00000166323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166407","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lmo1","kind":"target","name":"LMO1","route":"/targets/lmo1/","field":"links","label":"Ensembl ENSG00000166407"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166501","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkcb","kind":"target","name":"PRKCB","route":"/targets/prkcb/","field":"links","label":"Ensembl ENSG00000166501"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/","field":"links","label":"Ensembl ENSG00000166508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166598","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hsp90b1","kind":"target","name":"HSP90B1","route":"/targets/hsp90b1/","field":"links","label":"Ensembl ENSG00000166598"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166710","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","field":"links","label":"Ensembl ENSG00000166710"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166851","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/","field":"links","label":"Ensembl ENSG00000166851"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166886","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nab2","kind":"target","name":"NAB2","route":"/targets/nab2/","field":"links","label":"Ensembl ENSG00000166886"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166888","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stat6","kind":"target","name":"STAT6","route":"/targets/stat6/","field":"links","label":"Ensembl ENSG00000166888"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166913","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ywhab","kind":"target","name":"YWHAB","route":"/targets/ywhab/","field":"links","label":"Ensembl ENSG00000166913"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166923","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grem1","kind":"target","name":"GREM1","route":"/targets/grem1/","field":"links","label":"Ensembl ENSG00000166923"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166949","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smad3","kind":"target","name":"SMAD3","route":"/targets/smad3/","field":"links","label":"Ensembl ENSG00000166949"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167034","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","field":"links","label":"Ensembl ENSG00000167034"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167244","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/","field":"links","label":"Ensembl ENSG00000167244"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167258","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","field":"links","label":"Ensembl ENSG00000167258"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167286","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/","field":"links","label":"Ensembl ENSG00000167286"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167460","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tpm4","kind":"target","name":"TPM4","route":"/targets/tpm4/","field":"links","label":"Ensembl ENSG00000167460"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167522","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ankrd11","kind":"target","name":"ANKRD11","route":"/targets/ankrd11/","field":"links","label":"Ensembl ENSG00000167522"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167548","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kmt2d","kind":"target","name":"KMT2D","route":"/targets/kmt2d/","field":"links","label":"Ensembl ENSG00000167548"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167552","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/","field":"links","label":"Ensembl ENSG00000167552"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167553","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/","field":"links","label":"Ensembl ENSG00000167553"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167641","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp1r14a","kind":"target","name":"PPP1R14A","route":"/targets/ppp1r14a/","field":"links","label":"Ensembl ENSG00000167641"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167653","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/","field":"links","label":"Ensembl ENSG00000167653"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167985","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/","field":"links","label":"Ensembl ENSG00000167985"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167986","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/","field":"links","label":"Ensembl ENSG00000167986"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168036","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"links","label":"Ensembl ENSG00000168036"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168078","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pbk","kind":"target","name":"PBK","route":"/targets/pbk/","field":"links","label":"Ensembl ENSG00000168078"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168172","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hook3","kind":"target","name":"HOOK3","route":"/targets/hook3/","field":"links","label":"Ensembl ENSG00000168172"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168214","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbpj","kind":"target","name":"RBPJ","route":"/targets/rbpj/","field":"links","label":"Ensembl ENSG00000168214"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168300","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pcmtd1","kind":"target","name":"PCMTD1","route":"/targets/pcmtd1/","field":"links","label":"Ensembl ENSG00000168300"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168356","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn11a","kind":"target","name":"SCN11A","route":"/targets/scn11a/","field":"links","label":"Ensembl ENSG00000168356"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168411","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rfwd3","kind":"target","name":"RFWD3","route":"/targets/rfwd3/","field":"links","label":"Ensembl ENSG00000168411"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168421","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rhoh","kind":"target","name":"RHOH","route":"/targets/rhoh/","field":"links","label":"Ensembl ENSG00000168421"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168594","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adam29","kind":"target","name":"ADAM29","route":"/targets/adam29/","field":"links","label":"Ensembl ENSG00000168594"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168610","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/","field":"links","label":"Ensembl ENSG00000168610"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168646","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"axin2","kind":"target","name":"AXIN2","route":"/targets/axin2/","field":"links","label":"Ensembl ENSG00000168646"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168672","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lratd2","kind":"target","name":"LRATD2","route":"/targets/lratd2/","field":"links","label":"Ensembl ENSG00000168672"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168685","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"il7r","kind":"target","name":"IL7R","route":"/targets/il7r/","field":"links","label":"Ensembl ENSG00000168685"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168702","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lrp1b","kind":"target","name":"LRP1B","route":"/targets/lrp1b/","field":"links","label":"Ensembl ENSG00000168702"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169045","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnrnph1","kind":"target","name":"HNRNPH1","route":"/targets/hnrnph1/","field":"links","label":"Ensembl ENSG00000169045"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169047","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irs1","kind":"target","name":"IRS1","route":"/targets/irs1/","field":"links","label":"Ensembl ENSG00000169047"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169184","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mn1","kind":"target","name":"MN1","route":"/targets/mn1/","field":"links","label":"Ensembl ENSG00000169184"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169245","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cxcl10","kind":"target","name":"CXCL10","route":"/targets/cxcl10/","field":"links","label":"Ensembl ENSG00000169245"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169249","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zrsr2","kind":"target","name":"ZRSR2","route":"/targets/zrsr2/","field":"links","label":"Ensembl ENSG00000169249"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169375","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sin3a","kind":"target","name":"SIN3A","route":"/targets/sin3a/","field":"links","label":"Ensembl ENSG00000169375"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169432","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn9a","kind":"target","name":"SCN9A","route":"/targets/scn9a/","field":"links","label":"Ensembl ENSG00000169432"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169435","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rassf6","kind":"target","name":"RASSF6","route":"/targets/rassf6/","field":"links","label":"Ensembl ENSG00000169435"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169564","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pcbp1","kind":"target","name":"PCBP1","route":"/targets/pcbp1/","field":"links","label":"Ensembl ENSG00000169564"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169676","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"drd5","kind":"target","name":"DRD5","route":"/targets/drd5/","field":"links","label":"Ensembl ENSG00000169676"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169684","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chrna5","kind":"target","name":"CHRNA5","route":"/targets/chrna5/","field":"links","label":"Ensembl ENSG00000169684"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169696","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aspscr1","kind":"target","name":"ASPSCR1","route":"/targets/aspscr1/","field":"links","label":"Ensembl ENSG00000169696"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169714","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cnbp","kind":"target","name":"CNBP","route":"/targets/cnbp/","field":"links","label":"Ensembl ENSG00000169714"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169752","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrg4","kind":"target","name":"NRG4","route":"/targets/nrg4/","field":"links","label":"Ensembl ENSG00000169752"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169862","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/","field":"links","label":"Ensembl ENSG00000169862"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169946","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zfpm2","kind":"target","name":"ZFPM2","route":"/targets/zfpm2/","field":"links","label":"Ensembl ENSG00000169946"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170017","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"alcam","kind":"target","name":"ALCAM","route":"/targets/alcam/","field":"links","label":"Ensembl ENSG00000170017"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170214","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra1b","kind":"target","name":"ADRA1B","route":"/targets/adra1b/","field":"links","label":"Ensembl ENSG00000170214"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170234","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pwwp2a","kind":"target","name":"PWWP2A","route":"/targets/pwwp2a/","field":"links","label":"Ensembl ENSG00000170234"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170315","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ubb","kind":"target","name":"UBB","route":"/targets/ubb/","field":"links","label":"Ensembl ENSG00000170315"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170345","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fos","kind":"target","name":"FOS","route":"/targets/fos/","field":"links","label":"Ensembl ENSG00000170345"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170759","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kif5b","kind":"target","name":"KIF5B","route":"/targets/kif5b/","field":"links","label":"Ensembl ENSG00000170759"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170791","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chchd7","kind":"target","name":"CHCHD7","route":"/targets/chchd7/","field":"links","label":"Ensembl ENSG00000170791"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170836","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/","field":"links","label":"Ensembl ENSG00000170836"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170989","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"s1pr1","kind":"target","name":"S1PR1","route":"/targets/s1pr1/","field":"links","label":"Ensembl ENSG00000170989"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171132","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkce","kind":"target","name":"PRKCE","route":"/targets/prkce/","field":"links","label":"Ensembl ENSG00000171132"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171302","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cant1","kind":"target","name":"CANT1","route":"/targets/cant1/","field":"links","label":"Ensembl ENSG00000171302"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171316","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chd7","kind":"target","name":"CHD7","route":"/targets/chd7/","field":"links","label":"Ensembl ENSG00000171316"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171385","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnd3","kind":"target","name":"KCND3","route":"/targets/kcnd3/","field":"links","label":"Ensembl ENSG00000171385"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171435","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ksr2","kind":"target","name":"KSR2","route":"/targets/ksr2/","field":"links","label":"Ensembl ENSG00000171435"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171456","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"asxl1","kind":"target","name":"ASXL1","route":"/targets/asxl1/","field":"links","label":"Ensembl ENSG00000171456"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171557","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgg","kind":"target","name":"FGG","route":"/targets/fgg/","field":"links","label":"Ensembl ENSG00000171557"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171560","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fga","kind":"target","name":"FGA","route":"/targets/fga/","field":"links","label":"Ensembl ENSG00000171560"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171564","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgb","kind":"target","name":"FGB","route":"/targets/fgb/","field":"links","label":"Ensembl ENSG00000171564"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171606","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf274","kind":"target","name":"ZNF274","route":"/targets/znf274/","field":"links","label":"Ensembl ENSG00000171606"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171681","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atf7ip","kind":"target","name":"ATF7IP","route":"/targets/atf7ip/","field":"links","label":"Ensembl ENSG00000171681"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171735","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"camta1","kind":"target","name":"CAMTA1","route":"/targets/camta1/","field":"links","label":"Ensembl ENSG00000171735"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171843","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mllt3","kind":"target","name":"MLLT3","route":"/targets/mllt3/","field":"links","label":"Ensembl ENSG00000171843"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171848","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/","field":"links","label":"Ensembl ENSG00000171848"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171863","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps7","kind":"target","name":"RPS7","route":"/targets/rps7/","field":"links","label":"Ensembl ENSG00000171863"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171873","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra1d","kind":"target","name":"ADRA1D","route":"/targets/adra1d/","field":"links","label":"Ensembl ENSG00000171873"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171940","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/","field":"links","label":"Ensembl ENSG00000171940"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172071","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif2ak3","kind":"target","name":"EIF2AK3","route":"/targets/eif2ak3/","field":"links","label":"Ensembl ENSG00000172071"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172164","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sntb1","kind":"target","name":"SNTB1","route":"/targets/sntb1/","field":"links","label":"Ensembl ENSG00000172164"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172175","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/","field":"links","label":"Ensembl ENSG00000172175"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172493","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aff1","kind":"target","name":"AFF1","route":"/targets/aff1/","field":"links","label":"Ensembl ENSG00000172493"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172572","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pde3a","kind":"target","name":"PDE3A","route":"/targets/pde3a/","field":"links","label":"Ensembl ENSG00000172572"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172578","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klhl6","kind":"target","name":"KLHL6","route":"/targets/klhl6/","field":"links","label":"Ensembl ENSG00000172578"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172716","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","field":"links","label":"Ensembl ENSG00000172716"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172732","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/","field":"links","label":"Ensembl ENSG00000172732"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172819","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rarg","kind":"target","name":"RARG","route":"/targets/rarg/","field":"links","label":"Ensembl ENSG00000172819"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172915","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/","field":"links","label":"Ensembl ENSG00000172915"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172927","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myeov","kind":"target","name":"MYEOV","route":"/targets/myeov/","field":"links","label":"Ensembl ENSG00000172927"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172936","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","field":"links","label":"Ensembl ENSG00000172936"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172977","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kat5","kind":"target","name":"KAT5","route":"/targets/kat5/","field":"links","label":"Ensembl ENSG00000172977"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173039","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rela","kind":"target","name":"RELA","route":"/targets/rela/","field":"links","label":"Ensembl ENSG00000173039"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173041","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf680","kind":"target","name":"ZNF680","route":"/targets/znf680/","field":"links","label":"Ensembl ENSG00000173041"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173068","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bnc2","kind":"target","name":"BNC2","route":"/targets/bnc2/","field":"links","label":"Ensembl ENSG00000173068"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173153","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"esrra","kind":"target","name":"ESRRA","route":"/targets/esrra/","field":"links","label":"Ensembl ENSG00000173153"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173230","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"golgb1","kind":"target","name":"GOLGB1","route":"/targets/golgb1/","field":"links","label":"Ensembl ENSG00000173230"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173546","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cspg4","kind":"target","name":"CSPG4","route":"/targets/cspg4/","field":"links","label":"Ensembl ENSG00000173546"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chd2","kind":"target","name":"CHD2","route":"/targets/chd2/","field":"links","label":"Ensembl ENSG00000173575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173674","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","field":"links","label":"Ensembl ENSG00000173674"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173692","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/","field":"links","label":"Ensembl ENSG00000173692"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173821","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rnf213","kind":"target","name":"RNF213","route":"/targets/rnf213/","field":"links","label":"Ensembl ENSG00000173821"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mga","kind":"target","name":"MGA","route":"/targets/mga/","field":"links","label":"Ensembl ENSG00000174197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174371","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"exo1","kind":"target","name":"EXO1","route":"/targets/exo1/","field":"links","label":"Ensembl ENSG00000174371"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174405","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lig4","kind":"target","name":"LIG4","route":"/targets/lig4/","field":"links","label":"Ensembl ENSG00000174405"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174775","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/","field":"links","label":"Ensembl ENSG00000174775"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174808","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/","field":"links","label":"Ensembl ENSG00000174808"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175161","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cadm2","kind":"target","name":"CADM2","route":"/targets/cadm2/","field":"links","label":"Ensembl ENSG00000175161"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175164","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"abo","kind":"target","name":"ABO","route":"/targets/abo/","field":"links","label":"Ensembl ENSG00000175164"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175166","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/","field":"links","label":"Ensembl ENSG00000175166"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddit3","kind":"target","name":"DDIT3","route":"/targets/ddit3/","field":"links","label":"Ensembl ENSG00000175197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175305","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ccne2","kind":"target","name":"CCNE2","route":"/targets/ccne2/","field":"links","label":"Ensembl ENSG00000175305"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175387","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"smad2","kind":"target","name":"SMAD2","route":"/targets/smad2/","field":"links","label":"Ensembl ENSG00000175387"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175482","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/","field":"links","label":"Ensembl ENSG00000175482"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175595","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc4","kind":"target","name":"ERCC4","route":"/targets/ercc4/","field":"links","label":"Ensembl ENSG00000175595"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175643","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rmi2","kind":"target","name":"RMI2","route":"/targets/rmi2/","field":"links","label":"Ensembl ENSG00000175643"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175832","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/","field":"links","label":"Ensembl ENSG00000175832"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175879","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxd8","kind":"target","name":"HOXD8","route":"/targets/hoxd8/","field":"links","label":"Ensembl ENSG00000175879"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176014","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/","field":"links","label":"Ensembl ENSG00000176014"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176105","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/","field":"links","label":"Ensembl ENSG00000176105"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176170","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/","field":"links","label":"Ensembl ENSG00000176170"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176692","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxc2","kind":"target","name":"FOXC2","route":"/targets/foxc2/","field":"links","label":"Ensembl ENSG00000176692"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177000","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mthfr","kind":"target","name":"MTHFR","route":"/targets/mthfr/","field":"links","label":"Ensembl ENSG00000177000"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177084","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","field":"links","label":"Ensembl ENSG00000177084"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177189","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps6ka3","kind":"target","name":"RPS6KA3","route":"/targets/rps6ka3/","field":"links","label":"Ensembl ENSG00000177189"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177272","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcna3","kind":"target","name":"KCNA3","route":"/targets/kcna3/","field":"links","label":"Ensembl ENSG00000177272"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177302","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"top3a","kind":"target","name":"TOP3A","route":"/targets/top3a/","field":"links","label":"Ensembl ENSG00000177302"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177409","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"samd9l","kind":"target","name":"SAMD9L","route":"/targets/samd9l/","field":"links","label":"Ensembl ENSG00000177409"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177426","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tgif1","kind":"target","name":"TGIF1","route":"/targets/tgif1/","field":"links","label":"Ensembl ENSG00000177426"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177565","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbl1xr1","kind":"target","name":"TBL1XR1","route":"/targets/tbl1xr1/","field":"links","label":"Ensembl ENSG00000177565"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177606","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"jun","kind":"target","name":"JUN","route":"/targets/jun/","field":"links","label":"Ensembl ENSG00000177606"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177674","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"agtrap","kind":"target","name":"AGTRAP","route":"/targets/agtrap/","field":"links","label":"Ensembl ENSG00000177674"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177885","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grb2","kind":"target","name":"GRB2","route":"/targets/grb2/","field":"links","label":"Ensembl ENSG00000177885"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177954","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps27","kind":"target","name":"RPS27","route":"/targets/rps27/","field":"links","label":"Ensembl ENSG00000177954"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178053","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mlf1","kind":"target","name":"MLF1","route":"/targets/mlf1/","field":"links","label":"Ensembl ENSG00000178053"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178105","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx10","kind":"target","name":"DDX10","route":"/targets/ddx10/","field":"links","label":"Ensembl ENSG00000178105"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178202","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"poglut3","kind":"target","name":"POGLUT3","route":"/targets/poglut3/","field":"links","label":"Ensembl ENSG00000178202"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178573","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/","field":"links","label":"Ensembl ENSG00000178573"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178691","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"suz12","kind":"target","name":"SUZ12","route":"/targets/suz12/","field":"links","label":"Ensembl ENSG00000178691"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178764","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zhx2","kind":"target","name":"ZHX2","route":"/targets/zhx2/","field":"links","label":"Ensembl ENSG00000178764"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178919","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxe1","kind":"target","name":"FOXE1","route":"/targets/foxe1/","field":"links","label":"Ensembl ENSG00000178919"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178966","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rmi1","kind":"target","name":"RMI1","route":"/targets/rmi1/","field":"links","label":"Ensembl ENSG00000178966"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178999","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"aurkb","kind":"target","name":"AURKB","route":"/targets/aurkb/","field":"links","label":"Ensembl ENSG00000178999"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179051","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rcc2","kind":"target","name":"RCC2","route":"/targets/rcc2/","field":"links","label":"Ensembl ENSG00000179051"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179094","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"per1","kind":"target","name":"PER1","route":"/targets/per1/","field":"links","label":"Ensembl ENSG00000179094"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179218","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","field":"links","label":"Ensembl ENSG00000179218"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179348","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/","field":"links","label":"Ensembl ENSG00000179348"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179399","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/","field":"links","label":"Ensembl ENSG00000179399"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179583","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ciita","kind":"target","name":"CIITA","route":"/targets/ciita/","field":"links","label":"Ensembl ENSG00000179583"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000179750","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"apobec3b","kind":"target","name":"APOBEC3B","route":"/targets/apobec3b/","field":"links","label":"Ensembl ENSG00000179750"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180530","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrip1","kind":"target","name":"NRIP1","route":"/targets/nrip1/","field":"links","label":"Ensembl ENSG00000180530"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180573","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h2ac6","kind":"target","name":"H2AC6","route":"/targets/h2ac6/","field":"links","label":"Ensembl ENSG00000180573"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mb21d2","kind":"target","name":"MB21D2","route":"/targets/mb21d2/","field":"links","label":"Ensembl ENSG00000180611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180644","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prf1","kind":"target","name":"PRF1","route":"/targets/prf1/","field":"links","label":"Ensembl ENSG00000180644"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180818","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hoxc10","kind":"target","name":"HOXC10","route":"/targets/hoxc10/","field":"links","label":"Ensembl ENSG00000180818"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180917","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/","field":"links","label":"Ensembl ENSG00000180917"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181019","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nqo1","kind":"target","name":"NQO1","route":"/targets/nqo1/","field":"links","label":"Ensembl ENSG00000181019"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181449","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","field":"links","label":"Ensembl ENSG00000181449"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181544","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancb","kind":"target","name":"FANCB","route":"/targets/fancb/","field":"links","label":"Ensembl ENSG00000181544"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181555","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/","field":"links","label":"Ensembl ENSG00000181555"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181690","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plag1","kind":"target","name":"PLAG1","route":"/targets/plag1/","field":"links","label":"Ensembl ENSG00000181690"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181722","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zbtb20","kind":"target","name":"ZBTB20","route":"/targets/zbtb20/","field":"links","label":"Ensembl ENSG00000181722"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181827","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rfx7","kind":"target","name":"RFX7","route":"/targets/rfx7/","field":"links","label":"Ensembl ENSG00000181827"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182158","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"creb3l2","kind":"target","name":"CREB3L2","route":"/targets/creb3l2/","field":"links","label":"Ensembl ENSG00000182158"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182162","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"p2ry8","kind":"target","name":"P2RY8","route":"/targets/p2ry8/","field":"links","label":"Ensembl ENSG00000182162"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182185","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/","field":"links","label":"Ensembl ENSG00000182185"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182197","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/","field":"links","label":"Ensembl ENSG00000182197"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182255","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcna4","kind":"target","name":"KCNA4","route":"/targets/kcna4/","field":"links","label":"Ensembl ENSG00000182255"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182256","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gabrg3","kind":"target","name":"GABRG3","route":"/targets/gabrg3/","field":"links","label":"Ensembl ENSG00000182256"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182511","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/","field":"links","label":"Ensembl ENSG00000182511"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182580","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ephb3","kind":"target","name":"EPHB3","route":"/targets/ephb3/","field":"links","label":"Ensembl ENSG00000182580"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182606","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trak1","kind":"target","name":"TRAK1","route":"/targets/trak1/","field":"links","label":"Ensembl ENSG00000182606"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182674","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnb2","kind":"target","name":"KCNB2","route":"/targets/kcnb2/","field":"links","label":"Ensembl ENSG00000182674"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182866","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/","field":"links","label":"Ensembl ENSG00000182866"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182872","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","field":"links","label":"Ensembl ENSG00000182872"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182901","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rgs7","kind":"target","name":"RGS7","route":"/targets/rgs7/","field":"links","label":"Ensembl ENSG00000182901"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182903","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf721","kind":"target","name":"ZNF721","route":"/targets/znf721/","field":"links","label":"Ensembl ENSG00000182903"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183087","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gas6","kind":"target","name":"GAS6","route":"/targets/gas6/","field":"links","label":"Ensembl ENSG00000183087"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183161","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancf","kind":"target","name":"FANCF","route":"/targets/fancf/","field":"links","label":"Ensembl ENSG00000183161"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183258","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx41","kind":"target","name":"DDX41","route":"/targets/ddx41/","field":"links","label":"Ensembl ENSG00000183258"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183317","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"epha10","kind":"target","name":"EPHA10","route":"/targets/epha10/","field":"links","label":"Ensembl ENSG00000183317"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183337","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcor","kind":"target","name":"BCOR","route":"/targets/bcor/","field":"links","label":"Ensembl ENSG00000183337"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183454","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grin2a","kind":"target","name":"GRIN2A","route":"/targets/grin2a/","field":"links","label":"Ensembl ENSG00000183454"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183486","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mx2","kind":"target","name":"MX2","route":"/targets/mx2/","field":"links","label":"Ensembl ENSG00000183486"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183508","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/","field":"links","label":"Ensembl ENSG00000183508"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183579","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znrf3","kind":"target","name":"ZNRF3","route":"/targets/znrf3/","field":"links","label":"Ensembl ENSG00000183579"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183665","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tyw2","kind":"target","name":"TYW2","route":"/targets/tyw2/","field":"links","label":"Ensembl ENSG00000183665"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183735","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbk1","kind":"target","name":"TBK1","route":"/targets/tbk1/","field":"links","label":"Ensembl ENSG00000183735"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183742","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"macc1","kind":"target","name":"MACC1","route":"/targets/macc1/","field":"links","label":"Ensembl ENSG00000183742"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183765","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/","field":"links","label":"Ensembl ENSG00000183765"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183770","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/","field":"links","label":"Ensembl ENSG00000183770"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183779","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf703","kind":"target","name":"ZNF703","route":"/targets/znf703/","field":"links","label":"Ensembl ENSG00000183779"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183873","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn5a","kind":"target","name":"SCN5A","route":"/targets/scn5a/","field":"links","label":"Ensembl ENSG00000183873"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183955","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kmt5a","kind":"target","name":"KMT5A","route":"/targets/kmt5a/","field":"links","label":"Ensembl ENSG00000183955"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183960","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnh8","kind":"target","name":"KCNH8","route":"/targets/kcnh8/","field":"links","label":"Ensembl ENSG00000183960"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184009","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"actg1","kind":"target","name":"ACTG1","route":"/targets/actg1/","field":"links","label":"Ensembl ENSG00000184009"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184012","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/","field":"links","label":"Ensembl ENSG00000184012"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184033","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/","field":"links","label":"Ensembl ENSG00000184033"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184058","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tbx1","kind":"target","name":"TBX1","route":"/targets/tbx1/","field":"links","label":"Ensembl ENSG00000184058"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184156","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnq3","kind":"target","name":"KCNQ3","route":"/targets/kcnq3/","field":"links","label":"Ensembl ENSG00000184156"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184160","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra2c","kind":"target","name":"ADRA2C","route":"/targets/adra2c/","field":"links","label":"Ensembl ENSG00000184160"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184216","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/","field":"links","label":"Ensembl ENSG00000184216"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184304","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkd1","kind":"target","name":"PRKD1","route":"/targets/prkd1/","field":"links","label":"Ensembl ENSG00000184304"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184357","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h1-5","kind":"target","name":"H1-5","route":"/targets/h1-5/","field":"links","label":"Ensembl ENSG00000184357"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184371","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/","field":"links","label":"Ensembl ENSG00000184371"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"maml2","kind":"target","name":"MAML2","route":"/targets/maml2/","field":"links","label":"Ensembl ENSG00000184384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184408","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnd2","kind":"target","name":"KCND2","route":"/targets/kcnd2/","field":"links","label":"Ensembl ENSG00000184408"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184481","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxo4","kind":"target","name":"FOXO4","route":"/targets/foxo4/","field":"links","label":"Ensembl ENSG00000184481"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184489","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptp4a3","kind":"target","name":"PTP4A3","route":"/targets/ptp4a3/","field":"links","label":"Ensembl ENSG00000184489"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184507","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/","field":"links","label":"Ensembl ENSG00000184507"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnh7","kind":"target","name":"KCNH7","route":"/targets/kcnh7/","field":"links","label":"Ensembl ENSG00000184611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184634","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/","field":"links","label":"Ensembl ENSG00000184634"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184635","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf93","kind":"target","name":"ZNF93","route":"/targets/znf93/","field":"links","label":"Ensembl ENSG00000184635"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184675","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","field":"links","label":"Ensembl ENSG00000184675"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184916","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"jag2","kind":"target","name":"JAG2","route":"/targets/jag2/","field":"links","label":"Ensembl ENSG00000184916"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184937","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/","field":"links","label":"Ensembl ENSG00000184937"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184956","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"muc6","kind":"target","name":"MUC6","route":"/targets/muc6/","field":"links","label":"Ensembl ENSG00000184956"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185008","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"robo2","kind":"target","name":"ROBO2","route":"/targets/robo2/","field":"links","label":"Ensembl ENSG00000185008"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185313","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn10a","kind":"target","name":"SCN10A","route":"/targets/scn10a/","field":"links","label":"Ensembl ENSG00000185313"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185338","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/","field":"links","label":"Ensembl ENSG00000185338"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185345","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/","field":"links","label":"Ensembl ENSG00000185345"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185379","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/","field":"links","label":"Ensembl ENSG00000185379"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185386","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mapk11","kind":"target","name":"MAPK11","route":"/targets/mapk11/","field":"links","label":"Ensembl ENSG00000185386"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185442","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fam174b","kind":"target","name":"FAM174B","route":"/targets/fam174b/","field":"links","label":"Ensembl ENSG00000185442"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185551","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nr2f2","kind":"target","name":"NR2F2","route":"/targets/nr2f2/","field":"links","label":"Ensembl ENSG00000185551"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185627","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/","field":"links","label":"Ensembl ENSG00000185627"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185630","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pbx1","kind":"target","name":"PBX1","route":"/targets/pbx1/","field":"links","label":"Ensembl ENSG00000185630"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185650","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zfp36l1","kind":"target","name":"ZFP36L1","route":"/targets/zfp36l1/","field":"links","label":"Ensembl ENSG00000185650"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185697","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mybl1","kind":"target","name":"MYBL1","route":"/targets/mybl1/","field":"links","label":"Ensembl ENSG00000185697"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185737","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nrg3","kind":"target","name":"NRG3","route":"/targets/nrg3/","field":"links","label":"Ensembl ENSG00000185737"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185760","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kcnq5","kind":"target","name":"KCNQ5","route":"/targets/kcnq5/","field":"links","label":"Ensembl ENSG00000185760"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185909","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klhdc8b","kind":"target","name":"KLHDC8B","route":"/targets/klhdc8b/","field":"links","label":"Ensembl ENSG00000185909"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185950","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"irs2","kind":"target","name":"IRS2","route":"/targets/irs2/","field":"links","label":"Ensembl ENSG00000185950"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186009","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atp4b","kind":"target","name":"ATP4B","route":"/targets/atp4b/","field":"links","label":"Ensembl ENSG00000186009"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186010","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ndufa13","kind":"target","name":"NDUFA13","route":"/targets/ndufa13/","field":"links","label":"Ensembl ENSG00000186010"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186051","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tal2","kind":"target","name":"TAL2","route":"/targets/tal2/","field":"links","label":"Ensembl ENSG00000186051"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186081","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"krt5","kind":"target","name":"KRT5","route":"/targets/krt5/","field":"links","label":"Ensembl ENSG00000186081"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186153","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"wwox","kind":"target","name":"WWOX","route":"/targets/wwox/","field":"links","label":"Ensembl ENSG00000186153"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186174","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"bcl9l","kind":"target","name":"BCL9L","route":"/targets/bcl9l/","field":"links","label":"Ensembl ENSG00000186174"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186340","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"thbs2","kind":"target","name":"THBS2","route":"/targets/thbs2/","field":"links","label":"Ensembl ENSG00000186340"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186575","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","field":"links","label":"Ensembl ENSG00000186575"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186889","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tmem17","kind":"target","name":"TMEM17","route":"/targets/tmem17/","field":"links","label":"Ensembl ENSG00000186889"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186895","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf3","kind":"target","name":"FGF3","route":"/targets/fgf3/","field":"links","label":"Ensembl ENSG00000186895"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186918","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf395","kind":"target","name":"ZNF395","route":"/targets/znf395/","field":"links","label":"Ensembl ENSG00000186918"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187098","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/","field":"links","label":"Ensembl ENSG00000187098"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187164","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"shtn1","kind":"target","name":"SHTN1","route":"/targets/shtn1/","field":"links","label":"Ensembl ENSG00000187164"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dcc","kind":"target","name":"DCC","route":"/targets/dcc/","field":"links","label":"Ensembl ENSG00000187323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187514","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptma","kind":"target","name":"PTMA","route":"/targets/ptma/","field":"links","label":"Ensembl ENSG00000187514"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187555","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/","field":"links","label":"Ensembl ENSG00000187555"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187601","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mageh1","kind":"target","name":"MAGEH1","route":"/targets/mageh1/","field":"links","label":"Ensembl ENSG00000187601"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187735","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcea1","kind":"target","name":"TCEA1","route":"/targets/tcea1/","field":"links","label":"Ensembl ENSG00000187735"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187741","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/","field":"links","label":"Ensembl ENSG00000187741"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187790","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/","field":"links","label":"Ensembl ENSG00000187790"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187837","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h1-2","kind":"target","name":"H1-2","route":"/targets/h1-2/","field":"links","label":"Ensembl ENSG00000187837"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187840","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"eif4ebp1","kind":"target","name":"EIF4EBP1","route":"/targets/eif4ebp1/","field":"links","label":"Ensembl ENSG00000187840"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188171","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf626","kind":"target","name":"ZNF626","route":"/targets/znf626/","field":"links","label":"Ensembl ENSG00000188171"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188199","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nutm2b","kind":"target","name":"NUTM2B","route":"/targets/nutm2b/","field":"links","label":"Ensembl ENSG00000188199"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188229","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/","field":"links","label":"Ensembl ENSG00000188229"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188379","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ifna2","kind":"target","name":"IFNA2","route":"/targets/ifna2/","field":"links","label":"Ensembl ENSG00000188379"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188467","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slc24a5","kind":"target","name":"SLC24A5","route":"/targets/slc24a5/","field":"links","label":"Ensembl ENSG00000188467"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188641","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dpyd","kind":"target","name":"DPYD","route":"/targets/dpyd/","field":"links","label":"Ensembl ENSG00000188641"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188827","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"slx4","kind":"target","name":"SLX4","route":"/targets/slx4/","field":"links","label":"Ensembl ENSG00000188827"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188994","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf292","kind":"target","name":"ZNF292","route":"/targets/znf292/","field":"links","label":"Ensembl ENSG00000188994"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000189079","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/","field":"links","label":"Ensembl ENSG00000189079"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000189241","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tspyl1","kind":"target","name":"TSPYL1","route":"/targets/tspyl1/","field":"links","label":"Ensembl ENSG00000189241"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000189283","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/","field":"links","label":"Ensembl ENSG00000189283"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000189299","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"foxr2","kind":"target","name":"FOXR2","route":"/targets/foxr2/","field":"links","label":"Ensembl ENSG00000189299"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196090","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/","field":"links","label":"Ensembl ENSG00000196090"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196092","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax5","kind":"target","name":"PAX5","route":"/targets/pax5/","field":"links","label":"Ensembl ENSG00000196092"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196159","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fat4","kind":"target","name":"FAT4","route":"/targets/fat4/","field":"links","label":"Ensembl ENSG00000196159"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196220","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srgap3","kind":"target","name":"SRGAP3","route":"/targets/srgap3/","field":"links","label":"Ensembl ENSG00000196220"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196367","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trrap","kind":"target","name":"TRRAP","route":"/targets/trrap/","field":"links","label":"Ensembl ENSG00000196367"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196411","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ephb4","kind":"target","name":"EPHB4","route":"/targets/ephb4/","field":"links","label":"Ensembl ENSG00000196411"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196468","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fgf16","kind":"target","name":"FGF16","route":"/targets/fgf16/","field":"links","label":"Ensembl ENSG00000196468"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196498","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncor2","kind":"target","name":"NCOR2","route":"/targets/ncor2/","field":"links","label":"Ensembl ENSG00000196498"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196531","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"naca","kind":"target","name":"NACA","route":"/targets/naca/","field":"links","label":"Ensembl ENSG00000196531"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196535","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myo18a","kind":"target","name":"MYO18A","route":"/targets/myo18a/","field":"links","label":"Ensembl ENSG00000196535"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196557","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cacna1h","kind":"target","name":"CACNA1H","route":"/targets/cacna1h/","field":"links","label":"Ensembl ENSG00000196557"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196576","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plxnb2","kind":"target","name":"PLXNB2","route":"/targets/plxnb2/","field":"links","label":"Ensembl ENSG00000196576"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196584","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"xrcc2","kind":"target","name":"XRCC2","route":"/targets/xrcc2/","field":"links","label":"Ensembl ENSG00000196584"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196588","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mrtfa","kind":"target","name":"MRTFA","route":"/targets/mrtfa/","field":"links","label":"Ensembl ENSG00000196588"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196611","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mmp1","kind":"target","name":"MMP1","route":"/targets/mmp1/","field":"links","label":"Ensembl ENSG00000196611"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196616","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adh1b","kind":"target","name":"ADH1B","route":"/targets/adh1b/","field":"links","label":"Ensembl ENSG00000196616"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196628","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tcf4","kind":"target","name":"TCF4","route":"/targets/tcf4/","field":"links","label":"Ensembl ENSG00000196628"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196735","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hla-dqa1","kind":"target","name":"HLA-DQA1","route":"/targets/hla-dqa1/","field":"links","label":"Ensembl ENSG00000196735"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196782","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"maml3","kind":"target","name":"MAML3","route":"/targets/maml3/","field":"links","label":"Ensembl ENSG00000196782"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196876","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"scn8a","kind":"target","name":"SCN8A","route":"/targets/scn8a/","field":"links","label":"Ensembl ENSG00000196876"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196914","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"arhgef12","kind":"target","name":"ARHGEF12","route":"/targets/arhgef12/","field":"links","label":"Ensembl ENSG00000196914"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196935","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"srgap1","kind":"target","name":"SRGAP1","route":"/targets/srgap1/","field":"links","label":"Ensembl ENSG00000196935"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197013","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf429","kind":"target","name":"ZNF429","route":"/targets/znf429/","field":"links","label":"Ensembl ENSG00000197013"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197081","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"igf2r","kind":"target","name":"IGF2R","route":"/targets/igf2r/","field":"links","label":"Ensembl ENSG00000197081"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197157","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/","field":"links","label":"Ensembl ENSG00000197157"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197170","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/","field":"links","label":"Ensembl ENSG00000197170"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197299","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/","field":"links","label":"Ensembl ENSG00000197299"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197323","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trim33","kind":"target","name":"TRIM33","route":"/targets/trim33/","field":"links","label":"Ensembl ENSG00000197323"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197409","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h3c4","kind":"target","name":"H3C4","route":"/targets/h3c4/","field":"links","label":"Ensembl ENSG00000197409"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197530","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mib2","kind":"target","name":"MIB2","route":"/targets/mib2/","field":"links","label":"Ensembl ENSG00000197530"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197535","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/","field":"links","label":"Ensembl ENSG00000197535"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197548","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atg7","kind":"target","name":"ATG7","route":"/targets/atg7/","field":"links","label":"Ensembl ENSG00000197548"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197629","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mpeg1","kind":"target","name":"MPEG1","route":"/targets/mpeg1/","field":"links","label":"Ensembl ENSG00000197629"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197646","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/","field":"links","label":"Ensembl ENSG00000197646"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197705","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klhl14","kind":"target","name":"KLHL14","route":"/targets/klhl14/","field":"links","label":"Ensembl ENSG00000197705"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197728","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps26","kind":"target","name":"RPS26","route":"/targets/rps26/","field":"links","label":"Ensembl ENSG00000197728"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197782","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf780a","kind":"target","name":"ZNF780A","route":"/targets/znf780a/","field":"links","label":"Ensembl ENSG00000197782"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197858","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gpaa1","kind":"target","name":"GPAA1","route":"/targets/gpaa1/","field":"links","label":"Ensembl ENSG00000197858"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197903","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h2bc12","kind":"target","name":"H2BC12","route":"/targets/h2bc12/","field":"links","label":"Ensembl ENSG00000197903"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197943","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","field":"links","label":"Ensembl ENSG00000197943"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198033","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/","field":"links","label":"Ensembl ENSG00000198033"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198053","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/","field":"links","label":"Ensembl ENSG00000198053"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198056","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/","field":"links","label":"Ensembl ENSG00000198056"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198286","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/","field":"links","label":"Ensembl ENSG00000198286"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198300","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"peg3","kind":"target","name":"PEG3","route":"/targets/peg3/","field":"links","label":"Ensembl ENSG00000198300"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198354","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dcaf12l2","kind":"target","name":"DCAF12L2","route":"/targets/dcaf12l2/","field":"links","label":"Ensembl ENSG00000198354"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198455","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zxdb","kind":"target","name":"ZXDB","route":"/targets/zxdb/","field":"links","label":"Ensembl ENSG00000198455"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198604","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/","field":"links","label":"Ensembl ENSG00000198604"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198625","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mdm4","kind":"target","name":"MDM4","route":"/targets/mdm4/","field":"links","label":"Ensembl ENSG00000198625"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198670","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lpa","kind":"target","name":"LPA","route":"/targets/lpa/","field":"links","label":"Ensembl ENSG00000198670"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198695","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mt-nd6","kind":"target","name":"MT-ND6","route":"/targets/mt-nd6/","field":"links","label":"Ensembl ENSG00000198695"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198719","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dll1","kind":"target","name":"DLL1","route":"/targets/dll1/","field":"links","label":"Ensembl ENSG00000198719"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198727","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mt-cyb","kind":"target","name":"MT-CYB","route":"/targets/mt-cyb/","field":"links","label":"Ensembl ENSG00000198727"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198728","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ldb1","kind":"target","name":"LDB1","route":"/targets/ldb1/","field":"links","label":"Ensembl ENSG00000198728"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198730","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ctr9","kind":"target","name":"CTR9","route":"/targets/ctr9/","field":"links","label":"Ensembl ENSG00000198730"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198795","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/","field":"links","label":"Ensembl ENSG00000198795"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198804","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mt-co1","kind":"target","name":"MT-CO1","route":"/targets/mt-co1/","field":"links","label":"Ensembl ENSG00000198804"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198807","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pax9","kind":"target","name":"PAX9","route":"/targets/pax9/","field":"links","label":"Ensembl ENSG00000198807"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198822","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"grm3","kind":"target","name":"GRM3","route":"/targets/grm3/","field":"links","label":"Ensembl ENSG00000198822"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198846","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tox","kind":"target","name":"TOX","route":"/targets/tox/","field":"links","label":"Ensembl ENSG00000198846"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198888","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mt-nd1","kind":"target","name":"MT-ND1","route":"/targets/mt-nd1/","field":"links","label":"Ensembl ENSG00000198888"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198901","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prc1","kind":"target","name":"PRC1","route":"/targets/prc1/","field":"links","label":"Ensembl ENSG00000198901"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198945","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"l3mbtl3","kind":"target","name":"L3MBTL3","route":"/targets/l3mbtl3/","field":"links","label":"Ensembl ENSG00000198945"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000203747","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/","field":"links","label":"Ensembl ENSG00000203747"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000203811","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h3c14","kind":"target","name":"H3C14","route":"/targets/h3c14/","field":"links","label":"Ensembl ENSG00000203811"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204103","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mafb","kind":"target","name":"MAFB","route":"/targets/mafb/","field":"links","label":"Ensembl ENSG00000204103"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204209","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"daxx","kind":"target","name":"DAXX","route":"/targets/daxx/","field":"links","label":"Ensembl ENSG00000204209"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204264","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/","field":"links","label":"Ensembl ENSG00000204264"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204287","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/","field":"links","label":"Ensembl ENSG00000204287"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204370","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sdhd","kind":"target","name":"SDHD","route":"/targets/sdhd/","field":"links","label":"Ensembl ENSG00000204370"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204449","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trim49c","kind":"target","name":"TRIM49C","route":"/targets/trim49c/","field":"links","label":"Ensembl ENSG00000204449"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204514","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf814","kind":"target","name":"ZNF814","route":"/targets/znf814/","field":"links","label":"Ensembl ENSG00000204514"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204525","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/","field":"links","label":"Ensembl ENSG00000204525"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204531","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pou5f1","kind":"target","name":"POU5F1","route":"/targets/pou5f1/","field":"links","label":"Ensembl ENSG00000204531"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204713","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"trim27","kind":"target","name":"TRIM27","route":"/targets/trim27/","field":"links","label":"Ensembl ENSG00000204713"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204843","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"dctn1","kind":"target","name":"DCTN1","route":"/targets/dctn1/","field":"links","label":"Ensembl ENSG00000204843"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204859","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zbtb48","kind":"target","name":"ZBTB48","route":"/targets/zbtb48/","field":"links","label":"Ensembl ENSG00000204859"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205155","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psenen","kind":"target","name":"PSENEN","route":"/targets/psenen/","field":"links","label":"Ensembl ENSG00000205155"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205189","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"zbtb10","kind":"target","name":"ZBTB10","route":"/targets/zbtb10/","field":"links","label":"Ensembl ENSG00000205189"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205220","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/","field":"links","label":"Ensembl ENSG00000205220"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205413","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"samd9","kind":"target","name":"SAMD9","route":"/targets/samd9/","field":"links","label":"Ensembl ENSG00000205413"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205542","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tmsb4x","kind":"target","name":"TMSB4X","route":"/targets/tmsb4x/","field":"links","label":"Ensembl ENSG00000205542"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205755","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"crlf2","kind":"target","name":"CRLF2","route":"/targets/crlf2/","field":"links","label":"Ensembl ENSG00000205755"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000205927","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"olig2","kind":"target","name":"OLIG2","route":"/targets/olig2/","field":"links","label":"Ensembl ENSG00000205927"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000206047","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"defa1","kind":"target","name":"DEFA1","route":"/targets/defa1/","field":"links","label":"Ensembl ENSG00000206047"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000206384","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"col6a6","kind":"target","name":"COL6A6","route":"/targets/col6a6/","field":"links","label":"Ensembl ENSG00000206384"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000207732","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mir218-1","kind":"target","name":"MIR218-1","route":"/targets/mir218-1/","field":"links","label":"Ensembl ENSG00000207732"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000212993","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pou5f1b","kind":"target","name":"POU5F1B","route":"/targets/pou5f1b/","field":"links","label":"Ensembl ENSG00000212993"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213066","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cep43","kind":"target","name":"CEP43","route":"/targets/cep43/","field":"links","label":"Ensembl ENSG00000213066"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213672","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nckipsd","kind":"target","name":"NCKIPSD","route":"/targets/nckipsd/","field":"links","label":"Ensembl ENSG00000213672"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213741","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rps29","kind":"target","name":"RPS29","route":"/targets/rps29/","field":"links","label":"Ensembl ENSG00000213741"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213923","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"csnk1e","kind":"target","name":"CSNK1E","route":"/targets/csnk1e/","field":"links","label":"Ensembl ENSG00000213923"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213988","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"znf90","kind":"target","name":"ZNF90","route":"/targets/znf90/","field":"links","label":"Ensembl ENSG00000213988"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000213999","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mef2b","kind":"target","name":"MEF2B","route":"/targets/mef2b/","field":"links","label":"Ensembl ENSG00000213999"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000214562","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nutm2d","kind":"target","name":"NUTM2D","route":"/targets/nutm2d/","field":"links","label":"Ensembl ENSG00000214562"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000214827","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mtcp1","kind":"target","name":"MTCP1","route":"/targets/mtcp1/","field":"links","label":"Ensembl ENSG00000214827"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000215301","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ddx3x","kind":"target","name":"DDX3X","route":"/targets/ddx3x/","field":"links","label":"Ensembl ENSG00000215301"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221818","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ebf2","kind":"target","name":"EBF2","route":"/targets/ebf2/","field":"links","label":"Ensembl ENSG00000221818"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221829","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fancg","kind":"target","name":"FANCG","route":"/targets/fancg/","field":"links","label":"Ensembl ENSG00000221829"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221890","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"nptxr","kind":"target","name":"NPTXR","route":"/targets/nptxr/","field":"links","label":"Ensembl ENSG00000221890"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221914","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ppp2r2a","kind":"target","name":"PPP2R2A","route":"/targets/ppp2r2a/","field":"links","label":"Ensembl ENSG00000221914"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221983","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"uba52","kind":"target","name":"UBA52","route":"/targets/uba52/","field":"links","label":"Ensembl ENSG00000221983"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000222028","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/","field":"links","label":"Ensembl ENSG00000222028"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000224470","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"atxn1l","kind":"target","name":"ATXN1L","route":"/targets/atxn1l/","field":"links","label":"Ensembl ENSG00000224470"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000225830","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ercc6","kind":"target","name":"ERCC6","route":"/targets/ercc6/","field":"links","label":"Ensembl ENSG00000225830"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000227268","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"klln","kind":"target","name":"KLLN","route":"/targets/klln/","field":"links","label":"Ensembl ENSG00000227268"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000227507","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ltb","kind":"target","name":"LTB","route":"/targets/ltb/","field":"links","label":"Ensembl ENSG00000227507"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000232412","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"stag2-as1","kind":"target","name":"STAG2-AS1","route":"/targets/stag2-as1/","field":"links","label":"Ensembl ENSG00000232412"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000234745","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/","field":"links","label":"Ensembl ENSG00000234745"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240065","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/","field":"links","label":"Ensembl ENSG00000240065"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240505","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/","field":"links","label":"Ensembl ENSG00000240505"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000241476","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/","field":"links","label":"Ensembl ENSG00000241476"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000241635","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ugt1a1","kind":"target","name":"UGT1A1","route":"/targets/ugt1a1/","field":"links","label":"Ensembl ENSG00000241635"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000241973","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"pi4ka","kind":"target","name":"PI4KA","route":"/targets/pi4ka/","field":"links","label":"Ensembl ENSG00000241973"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000244405","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"etv5","kind":"target","name":"ETV5","route":"/targets/etv5/","field":"links","label":"Ensembl ENSG00000244405"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000244734","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hbb","kind":"target","name":"HBB","route":"/targets/hbb/","field":"links","label":"Ensembl ENSG00000244734"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000245848","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cebpa","kind":"target","name":"CEBPA","route":"/targets/cebpa/","field":"links","label":"Ensembl ENSG00000245848"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000248905","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fmn1","kind":"target","name":"FMN1","route":"/targets/fmn1/","field":"links","label":"Ensembl ENSG00000248905"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000249751","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ecscr","kind":"target","name":"ECSCR","route":"/targets/ecscr/","field":"links","label":"Ensembl ENSG00000249751"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000253729","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prkdc","kind":"target","name":"PRKDC","route":"/targets/prkdc/","field":"links","label":"Ensembl ENSG00000253729"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000255398","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hcar3","kind":"target","name":"HCAR3","route":"/targets/hcar3/","field":"links","label":"Ensembl ENSG00000255398"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000257103","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"lsm14a","kind":"target","name":"LSM14A","route":"/targets/lsm14a/","field":"links","label":"Ensembl ENSG00000257103"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000257365","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/","field":"links","label":"Ensembl ENSG00000257365"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000257923","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"cux1","kind":"target","name":"CUX1","route":"/targets/cux1/","field":"links","label":"Ensembl ENSG00000257923"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000258366","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"rtel1","kind":"target","name":"RTEL1","route":"/targets/rtel1/","field":"links","label":"Ensembl ENSG00000258366"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000258839","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mc1r","kind":"target","name":"MC1R","route":"/targets/mc1r/","field":"links","label":"Ensembl ENSG00000258839"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000258947","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/","field":"links","label":"Ensembl ENSG00000258947"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000259207","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"itgb3","kind":"target","name":"ITGB3","route":"/targets/itgb3/","field":"links","label":"Ensembl ENSG00000259207"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000261456","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/","field":"links","label":"Ensembl ENSG00000261456"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000263001","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"gtf2i","kind":"target","name":"GTF2I","route":"/targets/gtf2i/","field":"links","label":"Ensembl ENSG00000263001"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000263429","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"tmem238l","kind":"target","name":"TMEM238L","route":"/targets/tmem238l/","field":"links","label":"Ensembl ENSG00000263429"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000263639","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"msmb","kind":"target","name":"MSMB","route":"/targets/msmb/","field":"links","label":"Ensembl ENSG00000263639"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000266412","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ncoa4","kind":"target","name":"NCOA4","route":"/targets/ncoa4/","field":"links","label":"Ensembl ENSG00000266412"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000267534","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"s1pr2","kind":"target","name":"S1PR2","route":"/targets/s1pr2/","field":"links","label":"Ensembl ENSG00000267534"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000270647","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"taf15","kind":"target","name":"TAF15","route":"/targets/taf15/","field":"links","label":"Ensembl ENSG00000270647"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000272333","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"kmt2b","kind":"target","name":"KMT2B","route":"/targets/kmt2b/","field":"links","label":"Ensembl ENSG00000272333"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000274286","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"adra2b","kind":"target","name":"ADRA2B","route":"/targets/adra2b/","field":"links","label":"Ensembl ENSG00000274286"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000275023","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mllt6","kind":"target","name":"MLLT6","route":"/targets/mllt6/","field":"links","label":"Ensembl ENSG00000275023"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000275410","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/","field":"links","label":"Ensembl ENSG00000275410"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000276180","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h4c9","kind":"target","name":"H4C9","route":"/targets/h4c9/","field":"links","label":"Ensembl ENSG00000276180"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000277791","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/","field":"links","label":"Ensembl ENSG00000277791"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000278195","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"sstr3","kind":"target","name":"SSTR3","route":"/targets/sstr3/","field":"links","label":"Ensembl ENSG00000278195"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000278677","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h2ac17","kind":"target","name":"H2AC17","route":"/targets/h2ac17/","field":"links","label":"Ensembl ENSG00000278677"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000282961","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"prncr1","kind":"target","name":"PRNCR1","route":"/targets/prncr1/","field":"links","label":"Ensembl ENSG00000282961"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000284190","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"mir21","kind":"target","name":"MIR21","route":"/targets/mir21/","field":"links","label":"Ensembl ENSG00000284190"}]},{"url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000286522","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"h3c2","kind":"target","name":"H3C2","route":"/targets/h3c2/","field":"links","label":"Ensembl ENSG00000286522"}]},{"url":"https://www.ensembl.org/info/about/index.html","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"ensembl-gene-id","kind":"term","name":"Ensembl gene ID","route":"/terms/ensembl-gene-id/","field":"links","label":"About Ensembl"}]},{"url":"https://www.eoc.ch","status":200,"ok":true,"finalUrl":"https://www.eoc.ch/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iosi-bellinzona","kind":"institution","name":"Oncology Institute of Southern Switzerland (IOSI)","route":"/institutions/iosi-bellinzona/","field":"links","label":"EOC"},{"id":"iosi-bellinzona","kind":"institution","name":"Oncology Institute of Southern Switzerland (IOSI)","route":"/institutions/iosi-bellinzona/","field":"website"}]},{"url":"https://www.eortc.org","status":200,"ok":true,"finalUrl":"https://www.eortc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","field":"links","label":"EORTC"},{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/","field":"links","label":"Official website"},{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/","field":"website"}]},{"url":"https://www.eortc.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","field":"links","label":"EORTC"},{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","field":"profiles","label":"EORTC"}]},{"url":"https://www.epic.com","status":200,"ok":true,"finalUrl":"https://www.epic.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","field":"links","label":"Official website"},{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","field":"website"}]},{"url":"https://www.epicentrx.com","status":200,"ok":true,"finalUrl":"https://www.epicentrx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/","field":"links","label":"Official website"},{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/","field":"website"}]},{"url":"https://www.epkinly.com","status":200,"ok":true,"finalUrl":"https://www.epkinly.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"dosing.source"}]},{"url":"https://www.epo.org/","status":200,"ok":true,"finalUrl":"https://www.epo.org/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","field":"links","label":"European Patent Office"},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","field":"profiles","label":"European Patent Office"}]},{"url":"https://www.equashield.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"equashield","kind":"company","name":"Equashield","route":"/companies/equashield/","field":"links","label":"Official website"},{"id":"equashield","kind":"company","name":"Equashield","route":"/companies/equashield/","field":"website"}]},{"url":"https://www.erasca.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","field":"links","label":"Official website"},{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","field":"website"}]},{"url":"https://www.erasca.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","field":"links","label":"Pipeline"}]},{"url":"https://www.erasmusmc.nl/en/cancer-institute","status":200,"ok":true,"finalUrl":"https://www.erasmusmc.nl/en/cancer-institute/patient-care","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"links","label":"Erasmus MC Cancer Institute website"},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"profiles","label":"Erasmus MC Cancer Institute website"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"links","label":"Homepage"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"website"}]},{"url":"https://www.erisbio.com","status":200,"ok":true,"finalUrl":"https://www.erisbio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/","field":"links","label":"Official website"},{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/","field":"website"}]},{"url":"https://www.esgo.org","status":200,"ok":true,"finalUrl":"https://www.esgo.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","field":"links","label":"ESGO"},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","field":"website"}]},{"url":"https://www.esgo.org/about/council/","status":200,"ok":true,"finalUrl":"https://www.esgo.org/about/people/council/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"links","label":"Society page"},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","field":"profiles","label":"Society page"},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","field":"links","label":"Society page"},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","field":"profiles","label":"Society page"}]},{"url":"https://www.esgo.org/guidelines/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","field":"standardOfCare.guideline (Diagnosis and staging)"}]},{"url":"https://www.esmo.org","status":200,"ok":true,"finalUrl":"https://www.esmo.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/","field":"links","label":"Official website"},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/","field":"website"},{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","field":"links","label":"ESMO"}]},{"url":"https://www.esmo.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/","field":"links","label":"ESMO Congress"},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/","field":"url"}]},{"url":"https://www.esmo.org/for-patients/patient-guides/biliary-tract-cancer-a-guide-for-patients","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"ESMO: biliary tract cancer, a guide for patients"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"},{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/","field":"links","label":"ESMO: biliary tract cancer, a guide for patients"},{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","route":"/terms/trial-or-standard-treatment-biliary/","field":"links","label":"ESMO: biliary tract cancer, a guide for patients"}]},{"url":"https://www.esmo.org/for-patients/patient-guides/breast-cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"ESMO: breast cancer, a guide for patients"}],"archive":"https://web.archive.org/web/20260616184605/https://www.esmo.org/for-patients/patient-guides/breast-cancer"},{"url":"https://www.esmo.org/for-patients/patient-guides/pancreatic-cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"ESMO: pancreatic cancer, a guide for patients"}]},{"url":"https://www.esmo.org/guidelines","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/","field":"links","label":"ESMO Clinical Practice Guidelines & MCBS"},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/","field":"url"},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","field":"links","label":"ESMO Guidelines"}]},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-breast-cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","kind":"paper","name":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/","field":"links","label":"ESMO guidelines: breast cancer"}]},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/","field":"links","label":"ESMO guidelines: pancreatic cancer"},{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/","field":"links","label":"ESMO guidelines: gastrointestinal cancers"},{"id":"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020","kind":"paper","name":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/","field":"links","label":"ESMO guidelines: gastrointestinal cancers"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"ESMO clinical practice guidelines: gastrointestinal cancers"},{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/","field":"links","label":"ESMO guidelines: gastrointestinal cancers"}]},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"ESMO metastatic colorectal cancer guideline"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"links","label":"ESMO oesophageal cancer guideline"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Clinical complete response after chemoradiation)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Second line, squamous cell carcinoma)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Palliation of dysphagia)"}],"archive":"https://web.archive.org/web/20260908064733/https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers"},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-genitourinary-cancers","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","field":"links","label":"ESMO clinical practice guidelines: genitourinary cancers (the index the prostate guideline sits under)"}]},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gynaecological-cancers/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"standardOfCare.guideline (First-line maintenance, BRCA-mutated)"}],"archive":"https://web.archive.org/web/20260908064733/https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gynaecological-cancers"},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-haematological-malignancies","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/","field":"links","label":"ESMO clinical practice guidelines, haematological malignancies"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","field":"standardOfCare.guideline (Marginal zone lymphoma: three different diseases under one name)"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","field":"standardOfCare.guideline (Gastric MALT lymphoma: a cancer cured by antibiotics)"},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","field":"standardOfCare.guideline (Splenic marginal zone lymphoma: hepatitis C first, then rituximab, then splenectomy)"},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","field":"standardOfCare.guideline (Nodal marginal zone lymphoma: treated like follicular lymphoma, with the same choices)"}]},{"url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-lung-and-chest-tumours","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","field":"links","label":"ESMO guidelines: lung and chest tumours"}]},{"url":"https://www.esmo.org/guidelines/esmo-mcbs","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-win-ratio-net-benefit-endpoint","kind":"idea","name":"Win-ratio endpoints that weigh survival, toxicity and quality of life together","route":"/ideas/idea-tr1-win-ratio-net-benefit-endpoint/","field":"links","label":"ESMO Magnitude of Clinical Benefit Scale"},{"id":"idea-tr1-power-for-meaningful-benefit","kind":"idea","name":"Power trials to detect a benefit patients would value, not the smallest detectable one","route":"/ideas/idea-tr1-power-for-meaningful-benefit/","field":"links","label":"ESMO Magnitude of Clinical Benefit Scale"},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/","field":"links","label":"ESMO Magnitude of Clinical Benefit Scale"},{"id":"idea-cost-indication-based-pricing","kind":"idea","name":"Price a cancer drug by how well it works in each cancer","route":"/ideas/idea-cost-indication-based-pricing/","field":"links","label":"ESMO Magnitude of Clinical Benefit Scale"},{"id":"idea-cost-value-scale-in-coverage","kind":"idea","name":"Tie coverage and copays to the ESMO benefit scale","route":"/ideas/idea-cost-value-scale-in-coverage/","field":"links","label":"ESMO-MCBS"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","field":"links","label":"ESMO-MCBS"}]},{"url":"https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-gastrointestinal-cancers/","status":200,"ok":true,"finalUrl":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"links","label":"ESMO gastric cancer guideline"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Resectable stage II-III (Asian practice))"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Peritoneal metastases)"}],"archive":"https://web.archive.org/web/20250514081655/https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-gastrointestinal-cancers"},{"url":"https://www.esmo.org/living-guidelines","status":200,"ok":true,"finalUrl":"https://www.esmo.org/guidelines/living-guidelines","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/","field":"links","label":"ESMO Metastatic Breast Cancer Living Guideline"},{"id":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","kind":"paper","name":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","route":"/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/","field":"links","label":"ESMO Metastatic Breast Cancer Living Guideline"}]},{"url":"https://www.essoweb.org","status":200,"ok":true,"finalUrl":"https://www.essoweb.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/","field":"links","label":"ESSO"},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/","field":"website"}]},{"url":"https://www.essoweb.org/about/governance/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","field":"links","label":"Society page"},{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","field":"profiles","label":"Society page"},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","field":"links","label":"Society page"},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","field":"profiles","label":"Society page"}]},{"url":"https://www.estro.org","status":200,"ok":true,"finalUrl":"https://www.estro.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","field":"links","label":"ESTRO"},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","field":"links","label":"ESTRO"},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","field":"website"}]},{"url":"https://www.estro.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/","field":"links","label":"ESTRO"},{"id":"idea-fund-radiotherapy-innovation-pathway","kind":"idea","name":"A regulatory pathway for new radiotherapy techniques modelled on drug development","route":"/ideas/idea-fund-radiotherapy-innovation-pathway/","field":"links","label":"ESTRO"}]},{"url":"https://www.estro.org/About/ESTRO-Organisation-Structure/Board","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","field":"links","label":"Society page"},{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","field":"profiles","label":"Society page"},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","field":"links","label":"Society page"},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","field":"profiles","label":"Society page"}]},{"url":"https://www.eurekatherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.eurekatherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/","field":"links","label":"Official website"},{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/","field":"website"}]},{"url":"https://www.europdx.eu/","status":200,"ok":true,"finalUrl":"https://europdx.eu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/","field":"links","label":"EurOPDX"}]},{"url":"https://www.europeancancer.org","status":200,"ok":true,"finalUrl":"https://www.europeancancer.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","field":"links","label":"Homepage"},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","field":"website"}]},{"url":"https://www.europeancancer.org/resource/team.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elisabetta-zanon","kind":"person","name":"Elisabetta Zanon","route":"/people/elisabetta-zanon/","field":"links","label":"Society page"},{"id":"elisabetta-zanon","kind":"person","name":"Elisabetta Zanon","route":"/people/elisabetta-zanon/","field":"profiles","label":"Society page"}]},{"url":"https://www.europeancancer.org/summit","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","field":"links","label":"European Cancer Summit"}]},{"url":"https://www.evaluate.com/vantage/","status":200,"ok":true,"finalUrl":"https://www.evaluate.com/resources/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","field":"links","label":"Evaluate Vantage"},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","field":"url"}]},{"url":"https://www.evaxion.ai","status":200,"ok":true,"finalUrl":"https://evaxion.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","field":"links","label":"Official website"},{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","field":"website"}]},{"url":"https://www.everestmedicines.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"everest-medicines","kind":"company","name":"Everest Medicines","route":"/companies/everest-medicines/","field":"links","label":"Official website"},{"id":"everest-medicines","kind":"company","name":"Everest Medicines","route":"/companies/everest-medicines/","field":"website"}]},{"url":"https://www.evergreentgn.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"Official website"},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"website"}]},{"url":"https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","field":"links","label":"Official website"},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","field":"website"}]},{"url":"https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"Lantheus acquisition release"}]},{"url":"https://www.evergreentgn.com/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"News"}]},{"url":"https://www.evivebiotech.com","status":200,"ok":true,"finalUrl":"https://www.evivebiotech.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evive-biotech","kind":"company","name":"Evive Biotech","route":"/companies/evive-biotech/","field":"links","label":"Official website"},{"id":"evive-biotech","kind":"company","name":"Evive Biotech","route":"/companies/evive-biotech/","field":"website"}]},{"url":"https://www.evolutionaryscale.ai","status":200,"ok":true,"finalUrl":"https://www.evolutionaryscale.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/","field":"links","label":"Official website"},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/","field":"website"}]},{"url":"https://www.evopointbio.com","status":200,"ok":true,"finalUrl":"https://www.evopointbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/","field":"links","label":"Official website"},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/","field":"website"},{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/","field":"links","label":"Sponsor page"}]},{"url":"https://www.exactsciences.com","status":200,"ok":true,"finalUrl":"https://www.exactsciences.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/","field":"links","label":"Official website"},{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/","field":"website"}]},{"url":"https://www.exactsciences.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cologuard-plus","kind":"drug","name":"Cologuard Plus","route":"/drugs/cologuard-plus/","field":"links","label":"Exact Sciences: Cologuard Plus"},{"id":"cancerguard","kind":"drug","name":"Cancerguard","route":"/drugs/cancerguard/","field":"links","label":"Exact Sciences: Cancerguard"},{"id":"oncodetect","kind":"drug","name":"Oncodetect","route":"/drugs/oncodetect/","field":"links","label":"Exact Sciences: Oncodetect"}]},{"url":"https://www.exai.bio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","field":"links","label":"Official website"},{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","field":"website"}]},{"url":"https://www.exai.bio/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","field":"links","label":"News page"}]},{"url":"https://www.exai.bio/news/exai-bio-secures-67-5-million-series-a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","field":"links","label":"Series A press release (Dec 2021)"}]},{"url":"https://www.exceldiagnostics.com/","status":200,"ok":true,"finalUrl":"https://exceldiagnostics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"links","label":"Excel Diagnostics"},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"profiles","label":"Excel Diagnostics"}]},{"url":"https://www.excellthera.com/","status":200,"ok":true,"finalUrl":"https://excellthera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"excellthera","kind":"company","name":"ExCellThera","route":"/companies/excellthera/","field":"links","label":"Official website"},{"id":"excellthera","kind":"company","name":"ExCellThera","route":"/companies/excellthera/","field":"website"}]},{"url":"https://www.exelixis.com","status":200,"ok":true,"finalUrl":"https://www.exelixis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","field":"links","label":"Official website"},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","field":"website"}]},{"url":"https://www.exelixis.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.exelixis.com/clinical-trials-pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.exscientia.ai","status":200,"ok":true,"finalUrl":"https://www.recursion.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/","field":"links","label":"Official website"},{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/","field":"website"}]},{"url":"https://www.ezag.com","status":200,"ok":true,"finalUrl":"https://www.ezag.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","field":"links","label":"Official website"},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","field":"website"}]},{"url":"https://www.facingourrisk.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"force-facing-our-risk","kind":"collection","name":"FORCE: Facing Our Risk of Cancer Empowered","route":"/collections/force-facing-our-risk/","field":"links","label":"FORCE: Facing Our Risk of Cancer Empowered"},{"id":"force-facing-our-risk","kind":"collection","name":"FORCE: Facing Our Risk of Cancer Empowered","route":"/collections/force-facing-our-risk/","field":"url"}]},{"url":"https://www.facit.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-cella-fact-g-jco-1993","kind":"paper","name":"Cella 1993: the Functional Assessment of Cancer Therapy (FACT-G) quality of life scale","route":"/key-papers/paper-cella-fact-g-jco-1993/","field":"links","label":"FACIT measurement system"}]},{"url":"https://www.facit.org/measures/facit-cost","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"COST-FACIT"}]},{"url":"https://www.facs.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/","field":"links","label":"American College of Surgeons"}]},{"url":"https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ajcc-stage","kind":"term","name":"AJCC stage (TNM staging manual)","route":"/terms/ajcc-stage/","field":"links","label":"American Joint Committee on Cancer (American College of Surgeons)"}]},{"url":"https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"American College of Surgeons: AJCC Version 9 cancer staging system (all 8th edition disease sites remain current until replaced; no cutaneous carcinoma version 9 protocol has been released)"}]},{"url":"https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/","field":"links","label":"ACS NSQIP"},{"id":"idea-fund-surgical-outcomes-public-reporting","kind":"idea","name":"Public risk-adjusted outcome reporting for cancer surgery to drive centralisation","route":"/ideas/idea-fund-surgical-outcomes-public-reporting/","field":"links","label":"ACS NSQIP"}]},{"url":"https://www.faeththerapeutics.com","status":200,"ok":true,"finalUrl":"https://www.faeththerapeutics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","field":"links","label":"Sponsor page"},{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","field":"links","label":"Sponsor page"}]},{"url":"https://www.fahsysu.org.cn/en/basic/32843","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xiao-haipeng","kind":"person","name":"Xiao Haipeng","route":"/people/xiao-haipeng/","field":"links","label":"Source: First Affiliated Hospital leadership page"},{"id":"xiao-haipeng","kind":"person","name":"Xiao Haipeng","route":"/people/xiao-haipeng/","field":"profiles","label":"Hospital leadership page (English)"}]},{"url":"https://www.falp.org","status":200,"ok":true,"finalUrl":"https://www.falp.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","field":"links","label":"Fundación Arturo López Pérez website"},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","field":"profiles","label":"Fundación Arturo López Pérez website"},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","route":"/institutions/falp-chile/","field":"links","label":"FALP"},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","route":"/institutions/falp-chile/","field":"website"}]},{"url":"https://www.falp.org/fundacion/administracion-falp/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cristian-ayala-munita","kind":"person","name":"Cristián Ayala Munita","route":"/people/cristian-ayala-munita/","field":"links","label":"Source: FALP administration page"},{"id":"cristian-ayala-munita","kind":"person","name":"Cristián Ayala Munita","route":"/people/cristian-ayala-munita/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.faron.com/","status":200,"ok":true,"finalUrl":"https://faron.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/","field":"links","label":"Official website"},{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/","field":"website"}]},{"url":"https://www.favo.it/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","field":"links","label":"FAVO, Italian Federation of Voluntary Associations in Oncology website"},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","field":"profiles","label":"FAVO, Italian Federation of Voluntary Associations in Oncology website"},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","field":"links","label":"Official website"},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","field":"website"}]},{"url":"https://www.fda.gov/about-fda/","status":200,"ok":true,"finalUrl":"https://www.fda.gov/about-fda","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-antimetastatic-endpoint","kind":"idea","name":"A regulatory endpoint for drugs that block spread, not tumours","route":"/ideas/idea-bio2-antimetastatic-endpoint/","field":"links","label":"FDA Oncology Center of Excellence (page moved; nearest live section)"},{"id":"idea-bio2-cachexia-function-endpoint","kind":"idea","name":"Qualify a physical function endpoint so anti-wasting drugs can be approved","route":"/ideas/idea-bio2-cachexia-function-endpoint/","field":"links","label":"FDA Oncology Center of Excellence (page moved; nearest live section)"},{"id":"idea-bio2-n-of-1-framework","kind":"idea","name":"A standing rulebook for one-patient treatments","route":"/ideas/idea-bio2-n-of-1-framework/","field":"links","label":"FDA Oncology Center of Excellence (page moved; nearest live section)"}]},{"url":"https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","field":"links","label":"Oncology Center of Excellence"},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","field":"website"}]},{"url":"https://www.fda.gov/about-fda/fda-organization/r-angelo-de-claro","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","route":"/people/r-angelo-de-claro/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"links","label":"FDA, Pediatric Oncology and the RACE for Children Act"},{"id":"idea-tr2-paediatric-combo-prea","kind":"idea","name":"Make paediatric combination studies part of every relevant adult cancer drug approval","route":"/ideas/idea-tr2-paediatric-combo-prea/","field":"links","label":"FDA paediatric oncology"},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/","field":"links","label":"FDA Oncology Center of Excellence pediatric oncology"},{"id":"race-for-children-act","kind":"term","name":"RACE for Children Act","route":"/terms/race-for-children-act/","field":"links","label":"FDA: relevant paediatric molecular target list"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-confirm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"links","label":"FDA Oncology Center of Excellence, Project Confirm"},{"id":"idea-tr1-registry-linked-os-followup","kind":"idea","name":"Cheap long-term survival follow-up by linking trial participants to registries","route":"/ideas/idea-tr1-registry-linked-os-followup/","field":"links","label":"FDA Oncology Center of Excellence: Project Confirm"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-endpoint","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-surrogate-validation-programme","kind":"idea","name":"An independent programme that validates surrogate endpoints, setting by setting","route":"/ideas/idea-tr1-surrogate-validation-programme/","field":"links","label":"FDA Oncology Center of Excellence: Project Endpoint"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","field":"links","label":"FDA Oncology Center of Excellence: Project Facilitate"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-frontrunner","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","field":"links","label":"FDA Oncology Center of Excellence, Project FrontRunner"},{"id":"project-frontrunner","kind":"term","name":"Project FrontRunner","route":"/terms/project-frontrunner/","field":"links","label":"FDA Project FrontRunner"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-randomised-dose-comparison-before-pivotal","kind":"idea","name":"Randomise at least two doses in phase 2 before any pivotal trial","route":"/ideas/idea-tr1-randomised-dose-comparison-before-pivotal/","field":"links","label":"FDA Oncology Center of Excellence: Project Optimus"},{"id":"idea-tr1-exposure-response-before-dose-selection","kind":"idea","name":"Exposure-response modelling with a pre-set target exposure before any dose is chosen","route":"/ideas/idea-tr1-exposure-response-before-dose-selection/","field":"links","label":"FDA Oncology Center of Excellence: Project Optimus"},{"id":"idea-tr1-weight-based-vs-flat-dosing-trials","kind":"idea","name":"Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste","route":"/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis","kind":"idea","name":"Measure blood levels of oral targeted drugs and adjust doses to a target range","route":"/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-geriatric-dose-finding-cohorts","kind":"idea","name":"Dose-finding in older and frail patients, not extrapolation from fit ones","route":"/ideas/idea-tr1-geriatric-dose-finding-cohorts/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-model-based-dose-finding-with-late-toxicity","kind":"idea","name":"Retire the 3+3: model-based dose finding that counts late and chronic side effects","route":"/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-dose-evidence-statement-in-label","kind":"idea","name":"A 'dose evidence' panel in every label: how many doses were tested, and how","route":"/ideas/idea-tr1-dose-evidence-statement-in-label/","field":"links","label":"FDA Oncology Center of Excellence: Project Optimus"},{"id":"idea-tr1-food-effect-dose-reduction","kind":"idea","name":"Use food effects to cut the dose and cost of oral drugs that absorb better with meals","route":"/ideas/idea-tr1-food-effect-dose-reduction/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-factorial-dose-finding-for-combinations","kind":"idea","name":"Factorial dose finding for drug combinations instead of full dose of everything","route":"/ideas/idea-tr1-factorial-dose-finding-for-combinations/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"idea-tr2-combo-dose-matrix","kind":"idea","name":"Find the lowest effective doses of both drugs in a combination, not the highest tolerated","route":"/ideas/idea-tr2-combo-dose-matrix/","field":"links","label":"FDA Project Optimus"},{"id":"idea-reg-global-dose-optimisation-guideline","kind":"idea","name":"Make pre-approval dose optimisation an ICH standard so it is done once worldwide","route":"/ideas/idea-reg-global-dose-optimisation-guideline/","field":"links","label":"FDA Project Optimus"},{"id":"idea-data-real-world-dose-intensity","kind":"idea","name":"Real-world dose intensity and toxicity monitoring to revise labelled doses","route":"/ideas/idea-data-real-world-dose-intensity/","field":"links","label":"FDA Project Optimus"},{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","route":"/ideas/idea-fund-payer-funded-pragmatic-trials/","field":"links","label":"FDA Project Optimus"},{"id":"idea-moon-post-approval-dose-deescalation","kind":"idea","name":"Randomised lower-dose trials for approved drugs with quality of life as the primary endpoint","route":"/ideas/idea-moon-post-approval-dose-deescalation/","field":"links","label":"FDA Project Optimus"},{"id":"idea-moon-individualised-dosing-all-oral-drugs","kind":"idea","name":"Model-informed individual dosing with drug-level monitoring for every oral cancer drug","route":"/ideas/idea-moon-individualised-dosing-all-oral-drugs/","field":"links","label":"Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus"},{"id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/","field":"links","label":"FDA Project Optimus"},{"id":"paper-drug-dosing-conundrum-nejm-2021","kind":"paper","name":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","route":"/key-papers/paper-drug-dosing-conundrum-nejm-2021/","field":"links","label":"FDA Project Optimus"},{"id":"quantitative-systems-pharmacology","kind":"technology","name":"Quantitative systems pharmacology (QSP)","route":"/technologies/quantitative-systems-pharmacology/","field":"links","label":"FDA Project Optimus"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"links","label":"FDA Oncology Center of Excellence, Project Orbis"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"metrics (Countries participating in FDA Project Orbis concurrent review of oncology products)"},{"id":"idea-reg-orbis-work-sharing","kind":"idea","name":"Turn Project Orbis into a work-sharing review with one shared assessment report","route":"/ideas/idea-reg-orbis-work-sharing/","field":"links","label":"FDA Project Orbis"},{"id":"idea-reg-conditional-approval-sunset","kind":"idea","name":"Conditional approvals that lapse automatically if the confirmatory trial is late","route":"/ideas/idea-reg-conditional-approval-sunset/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-confirmatory-trial-escrow","kind":"idea","name":"Sponsors deposit the confirmatory trial budget in escrow at accelerated approval","route":"/ideas/idea-reg-confirmatory-trial-escrow/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-global-trial-application-portal","kind":"idea","name":"One clinical trial application accepted by regulators in every major region","route":"/ideas/idea-reg-global-trial-application-portal/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-diagnostic-reliance-pathway","kind":"idea","name":"A reliance pathway for companion diagnostics so the test arrives with the drug","route":"/ideas/idea-reg-diagnostic-reliance-pathway/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-tumour-agnostic-reliance","kind":"idea","name":"Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review","route":"/ideas/idea-reg-tumour-agnostic-reliance/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-label-divergence-index","kind":"idea","name":"A public index of how the same cancer drug's label differs between countries","route":"/ideas/idea-reg-label-divergence-index/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-approval-access-lag-tracker","kind":"idea","name":"Live tracker of the lag from first approval to real availability in every country","route":"/ideas/idea-reg-approval-access-lag-tracker/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","route":"/ideas/idea-reg-open-source-dossier-tools/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-shared-ai-review-assistant","kind":"idea","name":"A shared AI review assistant that maps one dossier to every regulator's questions","route":"/ideas/idea-reg-shared-ai-review-assistant/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-shared-postmarketing-registry-condition","kind":"idea","name":"One international registry, not one per country, for conditional approvals","route":"/ideas/idea-reg-shared-postmarketing-registry-condition/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","route":"/ideas/idea-reg-orphan-designation-reciprocity/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-reg-publish-all-rejections","kind":"idea","name":"Publish every complete response letter and negative opinion across all regulators","route":"/ideas/idea-reg-publish-all-rejections/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"idea-moon-reciprocal-tumour-agnostic-approvals","kind":"idea","name":"Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators","route":"/ideas/idea-moon-reciprocal-tumour-agnostic-approvals/","field":"links","label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis"},{"id":"project-orbis","kind":"term","name":"Project Orbis","route":"/terms/project-orbis/","field":"links","label":"FDA Project Orbis"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-moon-patient-experience-label","kind":"idea","name":"A mandatory patient-experience section in every cancer drug label and approval","route":"/ideas/idea-moon-patient-experience-label/","field":"links","label":"FDA Project Patient Voice"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-pragmatica","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-post-approval-pragmatic-trial-in-excluded","kind":"idea","name":"After approval, a pragmatic trial in the patients the pivotal trial excluded","route":"/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/","field":"links","label":"FDA Oncology Center of Excellence: Project Pragmatica"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-realtime-streaming-submission","kind":"idea","name":"Stream trial data to regulators as it accrues; review starts at last patient visit","route":"/ideas/idea-reg-realtime-streaming-submission/","field":"links","label":"FDA Real-Time Oncology Review"},{"id":"real-time-oncology-review","kind":"term","name":"Real-Time Oncology Review (RTOR) and Assessment Aid","route":"/terms/real-time-oncology-review/","field":"links","label":"FDA RTOR"}]},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/who-we-are-oncology-center-excellence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","route":"/people/r-angelo-de-claro/","field":"links","label":"Source: OCE Who We Are page"}]},{"url":"https://www.fda.gov/advisory-committees/human-drug-advisory-committees/oncologic-drugs-advisory-committee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"odac","kind":"term","name":"ODAC (Oncologic Drugs Advisory Committee)","route":"/terms/odac/","field":"links","label":"FDA: Oncologic Drugs Advisory Committee"}]},{"url":"https://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","field":"links","label":"FDA on products claiming to cure cancer"},{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","field":"links","label":"FDA on products claiming to cure cancer"},{"id":"black-salve-escharotics","kind":"technology","name":"Black salve and other escharotic pastes","route":"/technologies/black-salve-escharotics/","field":"links","label":"FDA: products claiming to 'cure' cancer are a cruel deception"},{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/","field":"links","label":"FDA: products claiming to 'cure' cancer are a cruel deception"}]},{"url":"https://www.fda.gov/drugs/","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/","field":"links","label":"FDA: individualised antisense oligonucleotide guidance (page moved; nearest live section)"}]},{"url":"https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","field":"links","label":"FDA: Hatch-Waxman letters and the ANDA pathway"}]},{"url":"https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"links","label":"FDA Patient-Focused Drug Development guidance series"}]},{"url":"https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","field":"links","label":"FDA: patents and exclusivity, frequently asked questions"},{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","field":"links","label":"FDA: patents and exclusivity, frequently asked questions"},{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","route":"/terms/us-regulatory-exclusivity/","field":"links","label":"FDA: patents and exclusivity, frequently asked questions"}]},{"url":"https://www.fda.gov/drugs/development-resources/best-pharmaceuticals-children-act-bpca","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","field":"links","label":"FDA: Best Pharmaceuticals for Children Act"}]},{"url":"https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-bayesian-borrowing-smaller-controls","kind":"idea","name":"Borrow from past control arms to shrink the control group in phase 3","route":"/ideas/idea-tr1-bayesian-borrowing-smaller-controls/","field":"links","label":"FDA Complex Innovative Trial Design meeting programme"},{"id":"idea-tr2-shared-control-network","kind":"idea","name":"Shared concurrent control arms across sponsors' trials in the same setting","route":"/ideas/idea-tr2-shared-control-network/","field":"links","label":"FDA complex innovative trial design programme"}]},{"url":"https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-qsp-combo-dosing","kind":"idea","name":"Mechanistic computer models to pick combination doses before dosing patients","route":"/ideas/idea-tr2-qsp-combo-dosing/","field":"links","label":"FDA model-informed drug development programme"}]},{"url":"https://www.fda.gov/drugs/development-resources/pediatric-research-equity-act-prea","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","field":"links","label":"FDA: Pediatric Research Equity Act"}]},{"url":"https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","field":"links","label":"FDA table of surrogate endpoints that were the basis of drug approval or licensure"}]},{"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","field":"links","label":"FDA alert: Tazverik withdrawal (March 2026)"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","field":"prevalence.source"},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"FDA safety communication on the Tazverik withdrawal (11 May 2026)"}]},{"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-diversity-plans-with-consequences","kind":"idea","name":"Diversity action plans with consequences: unmet targets trigger post-approval requirements","route":"/ideas/idea-tr1-diversity-plans-with-consequences/","field":"links","label":"FDA Drug Trials Snapshots"},{"id":"idea-tr1-representativeness-in-the-label","kind":"idea","name":"Print the participation-to-prevalence ratio in every drug label and assessment report","route":"/ideas/idea-tr1-representativeness-in-the-label/","field":"links","label":"FDA Drug Trials Snapshots"}]},{"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2021-10-06)"}]},{"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tmb-testing","kind":"technology","name":"Tumour mutational burden testing","route":"/technologies/tmb-testing/","field":"links","label":"FDA: pembrolizumab approval for TMB-H solid tumours (2020)"}]},{"url":"https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-ctdna-mrd-qualification","kind":"idea","name":"Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials","route":"/ideas/idea-tr2-ctdna-mrd-qualification/","field":"links","label":"FDA Biomarker Qualification Program"}]},{"url":"https://www.fda.gov/drugs/drug-safety-and-availability/","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs/drug-safety-and-availability","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","field":"links","label":"FDA withdrawal of Pepaxto approval (Feb 2024) (page moved; nearest live section)"}]},{"url":"https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-nonprofit-generic-oncology","kind":"idea","name":"A non-profit manufacturer for shortage-prone generic chemotherapy","route":"/ideas/idea-cost-nonprofit-generic-oncology/","field":"links","label":"FDA: drug shortages"},{"id":"generic-drug-shortage-response","kind":"technology","name":"Generic oncology drug supply and shortage mitigation","route":"/technologies/generic-drug-shortage-response/","field":"links","label":"FDA: drug shortages"}]},{"url":"https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/","field":"links","label":"FDA: Drug shortages, root causes and potential solutions (2019 report)"},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","field":"links","label":"FDA: Drug shortages, root causes and potential solutions (2019 report)"}]},{"url":"https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"regulatoryEvents.source (2018-11-26)"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"regulatoryEvents.source (2018-11-26)"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"regulatoryEvents.source (2025-04-09)"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"regulatoryEvents.source (2025-04-09)"}]},{"url":"https://www.fda.gov/drugs/fda-approves-pembrolizumab-merkel-cell-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2018-12-19)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2023-10-12)"}]},{"url":"https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2018-11-09)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2024-01-25)"}]},{"url":"https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","field":"links","label":"FDA: accelerated approval programme"},{"id":"fdora-2022","kind":"term","name":"FDORA 2022 accelerated approval reforms","route":"/terms/fdora-2022/","field":"links","label":"FDA: accelerated approval programme"}]},{"url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","field":"links","label":"FDA novel approvals 2024"}]},{"url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/","field":"links","label":"FDA novel approvals 2025"},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","field":"links","label":"FDA novel approvals 2025"},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","field":"links","label":"FDA novel approvals 2025"},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","field":"links","label":"FDA novel approvals 2025"}]},{"url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"FDA novel drug approvals 2026"},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","field":"links","label":"Novel Drug Approvals 2026"},{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/","field":"links","label":"FDA novel approvals 2026"},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","field":"links","label":"FDA novel approvals 2026"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-venetoclax-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","field":"regulatoryEvents.source (2026-02-19)"},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"links","label":"FDA approval (19 Feb 2026)"},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"outcomes.source (Progression-free survival at 3 years)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","field":"links","label":"FDA approval notice (30 June 2026)"},{"id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","field":"regulatoryEvents.source (2026-06-30)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease, 15 May 2026"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-06-12)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"regulatoryEvents.source (2026-06-12)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","field":"links","label":"FDA approval of belzutifan for PPGL (May 2025)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"regulatoryEvents.source (2026-06-12)"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","field":"regulatoryEvents.source (2026-06-12)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","field":"links","label":"FDA approval notice (26 Aug 2026)"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"FDA approval notice"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"regulatoryEvents.source (2026-05-22)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"links","label":"FDA: durvalumab + BCG approval (May 2026)"},{"id":"potomac","kind":"trial","name":"POTOMAC","route":"/trials/potomac/","field":"outcomes.source (Disease-free survival)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2026-05-28)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","field":"regulatoryEvents.source (2026-07-14)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2026-07-14)"},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","field":"regulatoryEvents.source (2026-07-14)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","field":"regulatoryEvents.source (2026-07-09)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"FDA approval 31 Jul 2026"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-melphalan-liver-directed-treatment-uveal-melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hepzato","kind":"drug","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","field":"links","label":"FDA approval (August 2023): melphalan as a liver-directed treatment for uveal melanoma"},{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","field":"links","label":"FDA approval of melphalan as a liver-directed treatment for uveal melanoma"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nirogacestat-desmoid-tumors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","field":"links","label":"FDA approval of nirogacestat"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2024-12-27)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2025-10-27)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2025-10-27)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/","field":"links","label":"FDA approval notice"},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","field":"toxicity.source (Cytokine release syndrome)"},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","field":"regulatoryEvents.source (2024-11-08)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/","field":"links","label":"FDA approval notice (13 May 2026)"},{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","field":"dosing.source"},{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","field":"regulatoryEvents.source (2026-05-13)"},{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/","field":"outcomes.source (Complete remission)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","field":"regulatoryEvents.source (2026-06-24)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2026-06-24)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2026-06-24)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2025-09-19)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2026-07-10)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-07-10)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","field":"regulatoryEvents.source (2026-05-27)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2026-06-24)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-06-24)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","field":"links","label":"FDA approval of vimseltinib"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","field":"regulatoryEvents.source (2026-08-25)"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"regulatoryEvents.source (2026-08-25)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","field":"regulatoryEvents.source (2026-07-22)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pediatric-indication-entrectinib-and-approves-new-pellet-formulation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"regulatoryEvents.source (2019-08-15)"},{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"regulatoryEvents.source (2023-10-20)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"regulatoryEvents.source (2023-02-06)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2024-06-01)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2026-09-01)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"regulatoryEvents.source (2024-08-02)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","field":"regulatoryEvents.source (2024-10-29)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"regulatoryEvents.source (2021-01-15)"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"regulatoryEvents.source (2025-11-19)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","field":"links","label":"FDA approval notice"},{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","field":"regulatoryEvents.source (2025-08-06)"},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","field":"links","label":"FDA: dordaviprone accelerated approval (6 August 2025)"}],"archive":"https://web.archive.org/web/20260115121332/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","field":"regulatoryEvents.source (2023-08-14)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2026-02-24)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2023-04-03)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2023-12-15)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"regulatoryEvents.source (2024-06-24)"},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","field":"regulatoryEvents.source (2025-11-18)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"regulatoryEvents.source (2026-08-13)"},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","field":"regulatoryEvents.source (2026-08-13)"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","field":"regulatoryEvents.source (2026-08-13)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"regulatoryEvents.source (2024-05-15)"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","field":"regulatoryEvents.source (2026-02-20)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","field":"regulatoryEvents.source (2021-02-26)"},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","field":"regulatoryEvents.source (2024-02-23)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"regulatoryEvents.source (2025-12-02)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","field":"regulatoryEvents.source (2023-01-27)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","field":"regulatoryEvents.source (2024-06-13)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"regulatoryEvents.source (2020-05-15)"},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"regulatoryEvents.source (2025-12-17)"},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","field":"regulatoryEvents.source (2023-03-22)"},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","field":"regulatoryEvents.source (2025-12-17)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2021-04-13)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2024-11-22)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","field":"regulatoryEvents.source (2026-09-09)"}],"archive":"https://web.archive.org/web/20260911103309/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","field":"regulatoryEvents.source (2025-11-19)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","field":"dosing.source"},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","field":"toxicity.source (Neutropenia)"},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","field":"regulatoryEvents.source (2026-05-13)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","field":"regulatoryEvents.source (2025-07-02)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","field":"regulatoryEvents.source (2023-08-09)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"regulatoryEvents.source (2025-11-19)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/","field":"links","label":"FDA approval"},{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/","field":"regulatoryEvents.source (2024-04-23)"}],"archive":"https://web.archive.org/web/20260517154734/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2026-08-06)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"regulatoryEvents.source (2024-03-07)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"regulatoryEvents.source (2024-12-04)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"regulatoryEvents.source (2026-02-26)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2026-07-14)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","field":"regulatoryEvents.source (2023-01-19)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"FDA oncology approval notifications (daraxonrasib 26 August 2026, zenocutuzumab 4 December 2024, irinotecan liposome first line 13 February 2024)"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"FDA notice: irinotecan liposome for first-line metastatic pancreatic adenocarcinoma (13 February 2024)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2016-02-05)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2020-04-22)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2021-04-07)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2021-11-22)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2023-02-03)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"regulatoryEvents.source (2024-11)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2017-08)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2019-12-20)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2021-01-15)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2022-05-04)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2022-08-05)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2022-08-11)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2024-04-05)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2025-01-27)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"regulatoryEvents.source (2025-01-17)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"regulatoryEvents.source (2025-03)"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","field":"regulatoryEvents.source (2025-06-23)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"regulatoryEvents.source (2022-05)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"regulatoryEvents.source (2024-11)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"regulatoryEvents.source (2024-12-03)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"regulatoryEvents.source (2025-03)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"regulatoryEvents.source (2026-07)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"regulatoryEvents.source (2013-02-22)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"regulatoryEvents.source (2019-05-03)"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2018-03)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2019-12-18)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2021-07-09)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2023-04-03)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2023-12-15)"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","field":"regulatoryEvents.source (2025-Q4)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"regulatoryEvents.source (2011-08-19)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"regulatoryEvents.source (2015-08-17)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"regulatoryEvents.source (2018-03-20)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"regulatoryEvents.source (2018-11-16)"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","field":"regulatoryEvents.source (2022-11-10)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"regulatoryEvents.source (2022-11-14)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"regulatoryEvents.source (2024-03-22)"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","field":"regulatoryEvents.source (2024-11)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"regulatoryEvents.source (2021-09-20)"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","field":"regulatoryEvents.source (2024-04-29)"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","field":"dosing.source"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","field":"regulatoryEvents.source (2022-01)"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","field":"regulatoryEvents.source (2025-05-14)"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"dosing.source"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"regulatoryEvents.source (2021-04-23)"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","field":"regulatoryEvents.source (2022-12)"},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"dosing.source"},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"regulatoryEvents.source (2000-05-17)"},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"regulatoryEvents.source (2010-06-21)"},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","field":"regulatoryEvents.source (2017-09-01)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"dosing.source"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"regulatoryEvents.source (2020-08-05)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"regulatoryEvents.source (2022-11-22)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"regulatoryEvents.source (2025-07-23)"},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","field":"regulatoryEvents.source (2025-10)"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","field":"regulatoryEvents.source (2023-12-11)"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","field":"regulatoryEvents.source (2026-02-26)"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"regulatoryEvents.source (2021-12-23)"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"regulatoryEvents.source (2023-12)"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"regulatoryEvents.source (2024-06-26)"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","field":"regulatoryEvents.source (2025-05)"},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","field":"regulatoryEvents.source (2024-08)"},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","field":"regulatoryEvents.source (2024-10)"},{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","field":"regulatoryEvents.source (2025-03)"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"regulatoryEvents.source (2021-06)"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"regulatoryEvents.source (2021-12-31)"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"regulatoryEvents.source (2020-09)"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"regulatoryEvents.source (2025-12)"},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","field":"regulatoryEvents.source (2023-02)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2014-09-04)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2015-10-02)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2017-05-23)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2020-06-16)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2020-11-13)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2021-07-26)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2023-10-16)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2025-09)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2014-07-04)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2014-12-22)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2015-03-04)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2015-10-01)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2018-04-16)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2022-03-04)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2024-12-27)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"regulatoryEvents.source (2026-03)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2011-03-25)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2015-10-28)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2018-04-16)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2020-05-15)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2020-10-02)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"regulatoryEvents.source (2025-04)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2016-05-18)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2016-10-18)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2019-03-08)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2019-03-18)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2020-05-29)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2021-08-27)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2021-10-15)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2024-09-12)"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2017-05-01)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2018-02-16)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2020-03-27)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2022-09-02)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2022-10-21)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2024-12-04)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2025-03-28)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2025-11)"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"dosing.source"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"regulatoryEvents.source (2022-03-18)"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","field":"regulatoryEvents.source (2022-09)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"dosing.source"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"regulatoryEvents.source (2021-04-22)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"regulatoryEvents.source (2021-08-17)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"regulatoryEvents.source (2023-07-31)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"regulatoryEvents.source (2024-08-01)"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","field":"regulatoryEvents.source (2025-06)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"dosing.source"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"regulatoryEvents.source (2018-09-28)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"regulatoryEvents.source (2021-02-09)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"regulatoryEvents.source (2021-02-22)"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"regulatoryEvents.source (2025-10)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"regulatoryEvents.source (2022-11)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"regulatoryEvents.source (2024-05-16)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"regulatoryEvents.source (2025-06)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"regulatoryEvents.source (2025-12)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"regulatoryEvents.source (2021-06)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"regulatoryEvents.source (2022-08-24)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"regulatoryEvents.source (2022-10-25)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"regulatoryEvents.source (2024-02-20)"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"dosing.source"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"regulatoryEvents.source (2023-06-15)"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"regulatoryEvents.source (2023-07)"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","field":"regulatoryEvents.source (2025-07-02)"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"dosing.source"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"regulatoryEvents.source (2021-02)"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"regulatoryEvents.source (2022-01-25)"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","field":"regulatoryEvents.source (2022-04)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"regulatoryEvents.source (2014-12-03)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"regulatoryEvents.source (2017-07-11)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"regulatoryEvents.source (2018-03-29)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"regulatoryEvents.source (2024-06-14)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"regulatoryEvents.source (2021-05-21)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"regulatoryEvents.source (2024-03-01)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"regulatoryEvents.source (2024-08-19)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"regulatoryEvents.source (2024-09-19)"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"regulatoryEvents.source (2025-09)"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"dosing.source"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"regulatoryEvents.source (2023-01)"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"regulatoryEvents.source (2024-11-20)"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","field":"regulatoryEvents.source (2025-12)"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"links","label":"FDA notice: accelerated approval of zenocutuzumab (4 December 2024)"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"dosing.source"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"regulatoryEvents.source (2024-12-04)"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"regulatoryEvents.source (2024-05-24)"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"regulatoryEvents.source (2025-04)"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"regulatoryEvents.source (2026-01)"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","field":"regulatoryEvents.source (2026-11-14)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"regulatoryEvents.source (2019-12)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"regulatoryEvents.source (2022-02-28)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"regulatoryEvents.source (2024-04-05)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"regulatoryEvents.source (2024-01-19)"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","field":"regulatoryEvents.source (2025-06)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"dosing.source"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"regulatoryEvents.source (2017-10-18)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"regulatoryEvents.source (2021-03-05)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"regulatoryEvents.source (2022-04-01)"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","field":"regulatoryEvents.source (2024-01-19)"},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","field":"regulatoryEvents.source (2022-01)"},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","field":"regulatoryEvents.source (2025-09)"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"dosing.source"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"regulatoryEvents.source (2023-05)"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"regulatoryEvents.source (2024-02-16)"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","field":"regulatoryEvents.source (2025-06)"},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"dosing.source"},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"regulatoryEvents.source (2024-08-01)"},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"regulatoryEvents.source (2025-08)"},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2021-06)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2022-03-23)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2022-12)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2025-03-28)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2026-07-31)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2017-09-26)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2018-01-26)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2024-04-23)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2024-06)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"dosing.source"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"regulatoryEvents.source (2021-05-26)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"regulatoryEvents.source (2026-03-09)"},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"regulatoryEvents.source (2024-02-26)"},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"regulatoryEvents.source (2024-06)"},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"regulatoryEvents.source (2023-01)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2015-11-13)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2017-03-30)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2018-04-18)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2020-12-18)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2024-02-16)"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"regulatoryEvents.source (2024-09-25)"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"dosing.source"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"regulatoryEvents.source (2018-11-02)"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"regulatoryEvents.source (2021-03-03)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"regulatoryEvents.source (2020-12)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"regulatoryEvents.source (2021-05-28)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"regulatoryEvents.source (2023-12)"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"regulatoryEvents.source (2025-01-16)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2021-06)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2022-12-12)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2024-06-21)"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"regulatoryEvents.source (2025-06)"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"links","label":"FDA notice: daraxonrasib for metastatic pancreatic adenocarcinoma (26 August 2026)"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","field":"regulatoryEvents.source (2024-06)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"dosing.source"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2018-06-27)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2020-04-08)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2023-10-11)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2024-12-20)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"dosing.source"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2020-05-08)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2022-09-21)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2024-05-29)"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"dosing.source"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"regulatoryEvents.source (2024-03)"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"regulatoryEvents.source (2025-08-08)"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","field":"dosing.source"},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","field":"regulatoryEvents.source (2024-06)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2014-12-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2017-08-17)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2018-01-12)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2018-12-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2019-12-27)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2020-05-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2022-03-11)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2023-05-31)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"regulatoryEvents.source (2017-03-27)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"regulatoryEvents.source (2020-04-29)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"regulatoryEvents.source (2022-11)"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"regulatoryEvents.source (2023-08-11)"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"dosing.source"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"regulatoryEvents.source (2018-10-16)"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"regulatoryEvents.source (2023-06-20)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2015-02-03)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2016-02-19)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2017-03-31)"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","field":"regulatoryEvents.source (2019-04-04)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"regulatoryEvents.source (2017-03-13)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"regulatoryEvents.source (2018-07-18)"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","field":"regulatoryEvents.source (2024-09-17)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"regulatoryEvents.source (2017-09-28)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"regulatoryEvents.source (2018-02-26)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"regulatoryEvents.source (2021-10-12)"},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","field":"regulatoryEvents.source (2023-03-03)"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","field":"regulatoryEvents.source (2023-11-16)"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"dosing.source"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"regulatoryEvents.source (2024-10-10)"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","field":"regulatoryEvents.source (2025-06)"},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","field":"dosing.source"},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","field":"regulatoryEvents.source (2025-05)"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"dosing.source"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"regulatoryEvents.source (2024-02)"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"regulatoryEvents.source (2025-06)"},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"dosing.source"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"regulatoryEvents.source (2023-01-27)"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","field":"regulatoryEvents.source (2023-09)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"dosing.source"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"regulatoryEvents.source (2021-08-13)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"regulatoryEvents.source (2023-12-14)"},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","field":"regulatoryEvents.source (2025-05)"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","field":"dosing.source"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","field":"regulatoryEvents.source (2025-06)"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"dosing.source"},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"regulatoryEvents.source (2022-12)"},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"regulatoryEvents.source (2024-11-15)"},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","field":"regulatoryEvents.source (2025-10)"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"dosing.source"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"regulatoryEvents.source (2023-03)"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"regulatoryEvents.source (2024-08-06)"},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","field":"regulatoryEvents.source (2025-06)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"dosing.source"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"regulatoryEvents.source (2016-04-11)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"regulatoryEvents.source (2018-06-08)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"regulatoryEvents.source (2018-11-21)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"regulatoryEvents.source (2019-05-15)"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","field":"regulatoryEvents.source (2020-10-16)"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"dosing.source"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"regulatoryEvents.source (2001-05-10)"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"regulatoryEvents.source (2002-02-01)"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"regulatoryEvents.source (2008-12-19)"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","field":"regulatoryEvents.source (2016-02-01)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"dosing.source"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (1998-09-25)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2006-11-16)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2010-10-20)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2017-12-01)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2019-02-28)"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","field":"regulatoryEvents.source (2020-06-29)"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"dosing.source"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"regulatoryEvents.source (2020-04-17)"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"regulatoryEvents.source (2023-01-19)"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","field":"regulatoryEvents.source (2023-02-22)"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","field":"regulatoryEvents.source (2023-04)"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","field":"regulatoryEvents.source (2026-08-19)"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"dosing.source"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"regulatoryEvents.source (2023-11)"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"regulatoryEvents.source (2025-07-22)"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","field":"regulatoryEvents.source (2026-08-06)"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"dosing.source"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"regulatoryEvents.source (2015-10-27)"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","field":"regulatoryEvents.source (2015-12)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"regulatoryEvents.source (2011-04-08)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"regulatoryEvents.source (2015-10-05)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"regulatoryEvents.source (2019-05-23)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"regulatoryEvents.source (2024-10-15)"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"regulatoryEvents.source (2018-05)"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"regulatoryEvents.source (2021-06)"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"regulatoryEvents.source (2026-01-29)"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"regulatoryEvents.source (2026-09-23)"},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"regulatoryEvents.source (2024-05-23)"},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"regulatoryEvents.source (2024-07-29)"},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"regulatoryEvents.source (2024-08)"},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","field":"regulatoryEvents.source (2025-06)"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"regulatoryEvents.source (2019-05)"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"regulatoryEvents.source (2020-03)"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"regulatoryEvents.source (2021-10)"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"regulatoryEvents.source (2026-Q2)"},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"regulatoryEvents.source (2017-11-30)"},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"regulatoryEvents.source (2020-08-26)"},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"regulatoryEvents.source (2020-06)"},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"regulatoryEvents.source (2004-01)"},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"regulatoryEvents.source (2018-06-03)"},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"regulatoryEvents.source (2020-12)"},{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","field":"regulatoryEvents.source (2025-08-14)"},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","field":"regulatoryEvents.source (2026-05)"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"dosing.source"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"regulatoryEvents.source (1989-03-03)"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","field":"regulatoryEvents.source (2004)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"dosing.source"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"regulatoryEvents.source (1992-12-29)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"regulatoryEvents.source (1994-04-13)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"regulatoryEvents.source (2005-01-07)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"regulatoryEvents.source (2013-09-06)"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","field":"regulatoryEvents.source (2022-04)"},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","field":"url"},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","field":"links","label":"Hematology/oncology approvals"},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"},{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"},{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"},{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/","field":"links","label":"FDA: oncology and hematologic malignancies approval notifications"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"links","label":"FDA oncology approval notifications"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"FDA oncology approval notifications"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"links","label":"FDA oncology approval notifications"},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","field":"links","label":"FDA oncology approval notifications"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"links","label":"FDA oncology approval notifications"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","field":"links","label":"FDA oncology approval notifications"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals#endnote2","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2020-05-08)"},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"regulatoryEvents.source (2024-06-12)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","field":"regulatoryEvents.source (2021-05-28)"},{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","field":"regulatoryEvents.source (2024-05-16)"}]},{"url":"https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","field":"links","label":"FDA: Biosimilars"},{"id":"idea-cost-interchangeable-oncology-biosimilars","kind":"idea","name":"Drop the extra switching studies for interchangeable oncology biosimilars","route":"/ideas/idea-cost-interchangeable-oncology-biosimilars/","field":"links","label":"FDA: Biosimilars"},{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","field":"links","label":"FDA: biosimilars"},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/","field":"links","label":"FDA: biosimilars"}]},{"url":"https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","field":"links","label":"FDA: Orphan Drug Act, relevant excerpts"}]},{"url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","field":"links","label":"FDA: orphan drug designation programme"}]},{"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","field":"links","label":"FDA warning letters database"}]},{"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","field":"links","label":"FDA: inspection observations (Form 483)"}]},{"url":"https://www.fda.gov/media/120721/download","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/","field":"links","label":"FDA guidance 2022: Master Protocols, efficient clinical trial design strategies to expedite development of oncology drugs and biologics"}]},{"url":"https://www.fda.gov/medical-devices","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","field":"links","label":"FDA: Medical devices"}]},{"url":"https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"samd","kind":"term","name":"Software as a medical device (SaMD)","route":"/terms/samd/","field":"links","label":"FDA: Software as a Medical Device (SaMD)"},{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/","field":"links","label":"FDA: Software as a Medical Device (SaMD)"}]},{"url":"https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/infusion-pumps","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"infusion-devices-vascular-access","kind":"technology","name":"Infusion pumps, ports, and ambulatory chemotherapy devices","route":"/technologies/infusion-devices-vascular-access/","field":"links","label":"FDA: infusion pumps"}]},{"url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fda-ldt-rule","kind":"term","name":"FDA laboratory-developed test (LDT) rule","route":"/terms/fda-ldt-rule/","field":"links","label":"FDA: Laboratory Developed Tests"}]},{"url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools","status":200,"ok":true,"finalUrl":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/","field":"links","label":"FDA: list of cleared or approved companion diagnostic devices"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"her2-ish-amplified","kind":"biomarker","name":"HER2 ISH amplified (ERBB2 gene amplification)","route":"/biomarkers/her2-ish-amplified/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"kras-g12d","kind":"biomarker","name":"KRAS G12D (and other non-G12C KRAS mutations)","route":"/biomarkers/kras-g12d/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"kit-d816v","kind":"biomarker","name":"KIT D816V","route":"/biomarkers/kit-d816v/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"bcr-abl1-transcript","kind":"biomarker","name":"BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)","route":"/biomarkers/bcr-abl1-transcript/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/","field":"links","label":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/","field":"links","label":"FDA: list of cleared or approved companion diagnostic devices"}]},{"url":"https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices","status":200,"ok":true,"finalUrl":"https://www.fda.gov/medical-devices/artificial-intelligence-enabled-medical-devices/list-artificial-intelligence-enabled-medical-devices","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","field":"links","label":"FDA, Artificial intelligence-enabled medical devices"},{"id":"idea-data-clinical-ai-model-registry","kind":"idea","name":"A public registry of every AI model used in cancer care","route":"/ideas/idea-data-clinical-ai-model-registry/","field":"links","label":"FDA AI-enabled medical devices list"},{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/","field":"links","label":"FDA: Artificial intelligence-enabled medical devices list"}]},{"url":"https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-whole-slide-imaging-system-digital-pathology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/","field":"links","label":"FDA allows marketing of first whole slide imaging system for digital pathology (2017)"}]},{"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omidubicel","kind":"drug","name":"Omidubicel","route":"/drugs/omidubicel/","field":"links","label":"FDA approval announcement (April 2023)"},{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","field":"links","label":"FDA approval announcement for omidubicel"}]},{"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"remestemcel-l","kind":"drug","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","field":"links","label":"FDA approval announcement (December 2024)"},{"id":"mesoblast","kind":"company","name":"Mesoblast","route":"/companies/mesoblast/","field":"links","label":"FDA approval announcement for remestemcel-L"}]},{"url":"https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","field":"regulatoryEvents.source (2026-09-04)"}]},{"url":"https://www.fda.gov/news-events/public-health-focus/expanded-access","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","field":"links","label":"FDA: expanded access"}]},{"url":"https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","field":"links","label":"FDA: Right to Try"}]},{"url":"https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","field":"links","label":"FDA: the Federal Food, Drug, and Cosmetic Act"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/","status":200,"ok":true,"finalUrl":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-regulatory-sandbox-adaptive-ai","kind":"idea","name":"A regulatory sandbox for continuously learning cancer AI","route":"/ideas/idea-data-regulatory-sandbox-adaptive-ai/","field":"links","label":"FDA Predetermined Change Control Plans (page moved; nearest live section)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","field":"links","label":"FDA guidance: adaptive designs for clinical trials of drugs and biologics"},{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/","field":"links","label":"FDA guidance: adaptive designs for clinical trials of drugs and biologics"},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","field":"links","label":"FDA guidance: adaptive designs for clinical trials of drugs and biologics"},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","field":"links","label":"FDA guidance: adaptive designs for clinical trials of drugs and biologics"},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/","field":"links","label":"FDA guidance: adaptive designs for clinical trials of drugs and biologics"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-brain-metastases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-brain-mets-default-included","kind":"idea","name":"Brain metastases included by default in every solid-tumour trial","route":"/ideas/idea-tr1-brain-mets-default-included/","field":"links","label":"FDA: Cancer Clinical Trial Eligibility Criteria: Brain Metastases"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-inclusion-pediatric-patients","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-age-floor-twelve-for-adult-trials","kind":"idea","name":"Let adolescents from age 12 into adult trials when the cancer biology is the same","route":"/ideas/idea-tr1-age-floor-twelve-for-adult-trials/","field":"links","label":"FDA: Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-prior-cancer-hiv-hepatitis-inclusion","kind":"idea","name":"Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis","route":"/ideas/idea-tr1-prior-cancer-hiv-hepatitis-inclusion/","field":"links","label":"FDA: Eligibility Criteria: Patients with HIV, Hepatitis B or Hepatitis C"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-pk-informed-organ-thresholds","kind":"idea","name":"Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds","route":"/ideas/idea-tr1-pk-informed-organ-thresholds/","field":"links","label":"FDA: Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/","field":"links","label":"FDA guidance: chemistry, manufacturing and control information for human gene therapy INDs"},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/","field":"links","label":"FDA guidance: chemistry, manufacturing and control information for human gene therapy INDs"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/","field":"links","label":"FDA guidance: CMC information for human gene therapy INDs"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"single-arm","kind":"term","name":"Single-arm trial","route":"/terms/single-arm/","field":"links","label":"FDA guidance: clinical trial considerations to support accelerated approval of oncology therapeutics"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","field":"links","label":"FDA guidance: clinical trial endpoints for the approval of cancer drugs and biologics"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-imaging-endpoint-process-standards-guidance-industry","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/","field":"links","label":"FDA guidance: clinical trial imaging endpoint process standards"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/codevelopment-two-or-more-new-investigational-drugs-use-combination","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-compulsory-combination-access","kind":"idea","name":"A legal right to obtain marketed cancer drugs at cost for combination trials","route":"/ideas/idea-fund-compulsory-combination-access/","field":"links","label":"FDA guidance on codevelopment of two or more investigational drugs"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/","field":"links","label":"FDA guidance: decentralized clinical trials (September 2024)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/","field":"links","label":"FDA guidance: externally controlled trials"},{"id":"external-control-arm","kind":"term","name":"External and synthetic control arms","route":"/terms/external-control-arm/","field":"links","label":"FDA guidance: considerations for the design and conduct of externally controlled trials"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/","field":"links","label":"FDA guidance: considerations for the development of CAR T cell products"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"research-use-only","kind":"term","name":"Research use only (RUO)","route":"/terms/research-use-only/","field":"links","label":"FDA guidance: Distribution of in vitro diagnostic products labeled for research use only or investigational use only (2013)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","field":"links","label":"FDA diversity action plans guidance 2024"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/","field":"links","label":"FDA guidance: ICH E6(R3) good clinical practice"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/","field":"links","label":"FDA guidance: electronic source data in clinical investigations"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial","status":200,"ok":true,"finalUrl":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-justify-every-exclusion","kind":"idea","name":"Default-inclusive eligibility: sponsors must justify every exclusion criterion","route":"/ideas/idea-tr1-justify-every-exclusion/","field":"links","label":"FDA: Enhancing the Diversity of Clinical Trial Populations (guidance)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/","field":"links","label":"FDA guidance: enrichment strategies for clinical trials to support determination of effectiveness"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/","field":"links","label":"FDA guidance: establishment and operation of clinical trial data monitoring committees"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","field":"links","label":"FDA: expedited programmes for serious conditions"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-mandatory-older-adult-cohort","kind":"idea","name":"A mandatory over-70s cohort with geriatric assessment in every pivotal trial","route":"/ideas/idea-tr1-mandatory-older-adult-cohort/","field":"links","label":"FDA: Inclusion of Older Adults in Cancer Clinical Trials"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","field":"links","label":"FDA guidance: informed consent for IRBs, clinical investigators and sponsors"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","field":"links","label":"FDA guidance: Male Breast Cancer, Developing Drugs for Treatment (2020)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","field":"links","label":"FDA guidance: non-inferiority clinical trials to establish effectiveness"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-optimus-legacy-drugs","kind":"idea","name":"Apply Project Optimus to drugs already on the market","route":"/ideas/idea-cost-optimus-legacy-drugs/","field":"links","label":"FDA guidance: Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases (August 2024)"},{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/","field":"links","label":"FDA final guidance: Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases (August 2024)"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/","field":"links","label":"FDA final guidance: Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases (August 2024)"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/","field":"links","label":"FDA guidance: patient-reported outcome measures in medical product development"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/payment-and-reimbursement-research-subjects","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-travel-lodging-in-every-budget","kind":"idea","name":"Travel, lodging and meals reimbursed as a standard line in every trial budget","route":"/ideas/idea-tr1-travel-lodging-in-every-budget/","field":"links","label":"FDA: Payment and Reimbursement to Research Subjects"},{"id":"idea-tr1-pay-participants-for-time","kind":"idea","name":"Pay trial participants for their time, not only their expenses","route":"/ideas/idea-tr1-pay-participants-for-time/","field":"links","label":"FDA: Payment and Reimbursement to Research Subjects"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/","field":"links","label":"FDA platform technology designation"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assurance-cellular-and-gene-therapy-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/","field":"links","label":"FDA guidance: potency assurance for cellular and gene therapy products"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","field":"links","label":"FDA guidance: sterile drug products produced by aseptic processing"}]},{"url":"https://www.fda.gov/science-research/bioinformatics-tools/","status":200,"ok":true,"finalUrl":"https://www.fda.gov/science-research/bioinformatics-tools","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-ctdna-reference-plasma","kind":"idea","name":"Certified reference samples to benchmark every tumour-DNA blood test","route":"/ideas/idea-tr2-ctdna-reference-plasma/","field":"links","label":"FDA SEQC2 project (page moved; nearest live section)"},{"id":"idea-tr2-liquid-biopsy-challenge","kind":"idea","name":"An annual blinded shoot-out for liquid biopsy tests","route":"/ideas/idea-tr2-liquid-biopsy-challenge/","field":"links","label":"FDA SEQC2 project (page moved; nearest live section)"}]},{"url":"https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","field":"links","label":"FDA real-world evidence programme"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","field":"links","label":"FDA Real-World Evidence"},{"id":"idea-tr1-external-control-rulebook","kind":"idea","name":"A public rulebook for when an external or synthetic control arm is acceptable","route":"/ideas/idea-tr1-external-control-rulebook/","field":"links","label":"FDA Real-World Evidence programme"},{"id":"idea-data-gcp-for-real-world-data","kind":"idea","name":"Good practice standards and inspection for real-world data sources","route":"/ideas/idea-data-gcp-for-real-world-data/","field":"links","label":"FDA Real-World Evidence framework"},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/","field":"links","label":"FDA: Real-World Evidence programme"},{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","field":"links","label":"FDA: real-world evidence"}]},{"url":"https://www.fda.gov/tobacco-products","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-prev-very-low-nicotine-mandate","kind":"idea","name":"Make cigarettes non-addictive by capping their nicotine","route":"/ideas/idea-prev-very-low-nicotine-mandate/","field":"links","label":"FDA tobacco products"}]},{"url":"https://www.fda.gov/tobacco-products/retail-sales-tobacco-products/tobacco-21","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","field":"links","label":"FDA: Tobacco 21"}]},{"url":"https://www.fda.gov/tobacco-products/rules-regulations-and-guidance-related-tobacco-products/family-smoking-prevention-and-tobacco-control-act-overview","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","field":"links","label":"FDA: Family Smoking Prevention and Tobacco Control Act, overview"}]},{"url":"https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","field":"links","label":"FDA: CBER-regulated products, current shortages"}]},{"url":"https://www.fda.gov#endnote2","status":200,"ok":true,"finalUrl":"https://www.fda.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","field":"regulatoryEvents.source (2022-06-22)"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","field":"regulatoryEvents.source (2022-06-22)"}]},{"url":"https://www.fda.gov#footnote1_815g9a4","status":200,"ok":true,"finalUrl":"https://www.fda.gov/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2017-05-18)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2021-08-31)"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","field":"regulatoryEvents.source (2023-06-20)"}]},{"url":"https://www.fennecpharma.com/","status":200,"ok":true,"finalUrl":"https://fennecpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fennec-pharmaceuticals","kind":"company","name":"Fennec Pharmaceuticals","route":"/companies/fennec-pharmaceuticals/","field":"links","label":"Official website"},{"id":"fennec-pharmaceuticals","kind":"company","name":"Fennec Pharmaceuticals","route":"/companies/fennec-pharmaceuticals/","field":"website"}]},{"url":"https://www.ferring.com","status":200,"ok":true,"finalUrl":"https://www.ferring.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","field":"links","label":"Official website"},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","field":"website"}]},{"url":"https://www.fiaso.it/fiaso/organizzazione/maurizio-di-mauro/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maurizio-di-mauro","kind":"person","name":"Maurizio Di Mauro","route":"/people/maurizio-di-mauro/","field":"profiles","label":"FIASO profile"}]},{"url":"https://www.fibrogen.com","status":200,"ok":true,"finalUrl":"https://www.kyntrabio.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","field":"links","label":"Official website"},{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","field":"website"}]},{"url":"https://www.fican.fi","status":200,"ok":true,"finalUrl":"https://fican.fi/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","field":"links","label":"Finnish Cancer Center (FICAN) website"},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","field":"profiles","label":"Finnish Cancer Center (FICAN) website"},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/","field":"links","label":"Official website"},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/","field":"website"}]},{"url":"https://www.fidocure.com","status":200,"ok":true,"finalUrl":"https://fidocure.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fidocure","kind":"company","name":"FidoCure","route":"/companies/fidocure/","field":"links","label":"Official website"},{"id":"fidocure","kind":"company","name":"FidoCure","route":"/companies/fidocure/","field":"website"}]},{"url":"https://www.fiercebiotech.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","field":"links","label":"Fierce Biotech"},{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","field":"url"}]},{"url":"https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","field":"links","label":"IPO coverage"}]},{"url":"https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/","field":"links","label":"Gilead option exercise"}]},{"url":"https://www.fiercebiotech.com/biotech/nkartas-continues-pivot-autoimmune-disease-shelving-lymphoma-program-car-nk-candidate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","field":"links","label":"Pivot coverage"}]},{"url":"https://www.fiercepharma.com/pharma/summit-therapeutics-updates-ivonescimab-survival-data-ahead-fda-decision-date","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","field":"links","label":"Fierce Pharma on HARMONi OS update"}],"archive":"https://web.archive.org/web/20260823203638/https://www.fiercepharma.com/pharma/summit-therapeutics-updates-ivonescimab-survival-data-ahead-fda-decision-date"},{"url":"https://www.fightcancer.org/policy-resources/improving-access-biomarker-testing","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"state-biomarker-testing-laws","kind":"term","name":"State biomarker testing coverage laws","route":"/terms/state-biomarker-testing-laws/","field":"links","label":"American Cancer Society Cancer Action Network: improving access to biomarker testing"}]},{"url":"https://www.filinf.it","status":200,"ok":true,"finalUrl":"https://filinf.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fondazione-italiana-linfomi","kind":"company","name":"Fondazione Italiana Linfomi","route":"/companies/fondazione-italiana-linfomi/","field":"website"}]},{"url":"https://www.filinf.it/fondazione/","status":200,"ok":true,"finalUrl":"https://filinf.it/fondazione/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fondazione-italiana-linfomi","kind":"company","name":"Fondazione Italiana Linfomi","route":"/companies/fondazione-italiana-linfomi/","field":"links","label":"FIL: la Fondazione"}]},{"url":"https://www.filo-leucemie.org","status":200,"ok":true,"finalUrl":"https://www.filo-leucemie.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","route":"/companies/filo/","field":"links","label":"Official website"},{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","route":"/companies/filo/","field":"website"}]},{"url":"https://www.finaldose.ai/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","field":"links","label":"Company site"},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","field":"website"}]},{"url":"https://www.flagshippioneering.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","field":"links","label":"Official website"},{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","field":"website"}]},{"url":"https://www.flagshippioneering.com/companies","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","field":"links","label":"Companies"}]},{"url":"https://www.floridaproton.org","status":200,"ok":true,"finalUrl":"https://www.floridaproton.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","field":"links","label":"UF Health Proton Therapy Institute"}]},{"url":"https://www.fondation-arc.org","status":200,"ok":true,"finalUrl":"https://www.fondation-arc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/","field":"links","label":"Fondation ARC"},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/","field":"website"}]},{"url":"https://www.fondation-arc.org/la-fondation/notre-fonctionnement/notre-gouvernance/le-conseil-dadministration/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dominique-bazy","kind":"person","name":"Dominique Bazy","route":"/people/dominique-bazy/","field":"links","label":"Source: Fondation ARC board page"},{"id":"dominique-bazy","kind":"person","name":"Dominique Bazy","route":"/people/dominique-bazy/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.fondazionethebridge.it/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","field":"links","label":"Fondazione The Bridge website"},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","field":"profiles","label":"Fondazione The Bridge website"},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","route":"/institutions/fondazione-the-bridge/","field":"links","label":"Official website"},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","route":"/institutions/fondazione-the-bridge/","field":"website"}]},{"url":"https://www.foreseepharma.com","status":200,"ok":true,"finalUrl":"https://www.foreseepharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","field":"links","label":"Official website"},{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","field":"website"}]},{"url":"https://www.foresitecapital.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","field":"links","label":"Official website"},{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","field":"website"}]},{"url":"https://www.foresitecapital.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","field":"links","label":"Portfolio"}]},{"url":"https://www.forlongbiotech.com","status":200,"ok":true,"finalUrl":"https://www.forlongbiotech.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/","field":"links","label":"Official website"},{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/","field":"website"}]},{"url":"https://www.fortishealthcare.com","status":200,"ok":true,"finalUrl":"https://www.fortishealthcare.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"links","label":"Fortis Healthcare"},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","field":"profiles","label":"Fortis Healthcare"}]},{"url":"https://www.fortrea.com","status":200,"ok":true,"finalUrl":"https://www.fortrea.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/","field":"links","label":"Official website"},{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/","field":"website"}]},{"url":"https://www.forward-pharm.com","status":200,"ok":true,"finalUrl":"https://www.forward-pharm.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","field":"links","label":"Official website"},{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","field":"website"}]},{"url":"https://www.forward-pharm.com/pipeline","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","field":"links","label":"Pipeline page"}]},{"url":"https://www.fosunpharma.com","status":200,"ok":true,"finalUrl":"https://www.fosunpharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","field":"links","label":"Official website"},{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","field":"website"}]},{"url":"https://www.fotofinder.de/","status":200,"ok":true,"finalUrl":"https://www.fotofinder.com/de/","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"fotofinder","kind":"company","name":"FotoFinder Systems","route":"/companies/fotofinder/","field":"links","label":"Official website"},{"id":"fotofinder","kind":"company","name":"FotoFinder Systems","route":"/companies/fotofinder/","field":"website"}]},{"url":"https://www.foundationmedicine.com","status":200,"ok":true,"finalUrl":"https://www.foundationmedicine.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"access.source (US)"},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","route":"/companies/foundation-medicine/","field":"links","label":"Official website"},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","route":"/companies/foundation-medicine/","field":"website"}]},{"url":"https://www.foundationmedicine.com/test/foundationone-cdx","status":200,"ok":true,"finalUrl":"https://www.foundationmedicine.com/solution/foundationone-cdx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","field":"links","label":"Foundation Medicine: FoundationOne CDx"}]},{"url":"https://www.foxchase.org","status":200,"ok":true,"finalUrl":"https://www.foxchase.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","field":"links","label":"Fox Chase Cancer Center"},{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","field":"website"}]},{"url":"https://www.fpoircc.it/en/","status":200,"ok":true,"finalUrl":"https://inoc.it/it/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/","field":"links","label":"Homepage"},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/","field":"website"}]},{"url":"https://www.fpoircc.it/en/research/","status":200,"ok":true,"finalUrl":"https://inoc.it/it/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/","field":"links","label":"Research"}]},{"url":"https://www.frazierhealthcare.com/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","field":"links","label":"Frazier Healthcare Partners disclosure"}]},{"url":"https://www.fredhutch.org","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","field":"links","label":"Official website"},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","field":"website"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Denise%20A.%20Galloway","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Denise%20A.%20Galloway","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"links","label":"Fred Hutch faculty directory"},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Gary%20H.%20Lyman","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Gary%20H.%20Lyman","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"links","label":"Fred Hutch faculty directory"},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Hans-Peter%20Kiem","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Hans-Peter%20Kiem","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"links","label":"Fred Hutch faculty directory"},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Michael%20LeBlanc","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Michael%20LeBlanc","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"links","label":"Fred Hutch faculty directory"},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Philip%20D.%20Greenberg","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Philip%20D.%20Greenberg","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"links","label":"Fred Hutch faculty directory"},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Sara%20A.%20Hurvitz","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Sara%20A.%20Hurvitz","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"links","label":"Fred Hutch faculty directory"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Stanley%20R.%20Riddell","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Stanley%20R.%20Riddell","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"links","label":"Fred Hutch faculty directory"},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Thomas%20J.%20Lynch%20Jr.","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/faculty-directory.html?q=Thomas%20J.%20Lynch%20Jr.","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"links","label":"Fred Hutch faculty directory"},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","field":"profiles","label":"Fred Hutch faculty directory"}]},{"url":"https://www.fredhutch.org/en/research/institutes-networks-ircs/global-oncology/uganda.html","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/research/research-areas/global-health.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","field":"links","label":"UCI-Fred Hutch collaboration"}]},{"url":"https://www.freenome.com","status":200,"ok":true,"finalUrl":"https://www.freenome.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"freenome","kind":"company","name":"Freenome","route":"/companies/freenome/","field":"website"},{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/","field":"links","label":"Freenome"}]},{"url":"https://www.fresenius-kabi.com","status":200,"ok":true,"finalUrl":"https://www.fresenius-kabi.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","route":"/companies/fresenius-kabi/","field":"links","label":"Official website"},{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","route":"/companies/fresenius-kabi/","field":"website"}]},{"url":"https://www.frontiermeds.com","status":200,"ok":true,"finalUrl":"https://www.frontiermeds.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","field":"website"}]},{"url":"https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2026.1781533/full","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"links","label":"Frontiers review (2026)"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","field":"dosing.source"}]},{"url":"https://www.fujifilm.com","status":200,"ok":true,"finalUrl":"https://global.fujifilm.com/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fujifilm","kind":"company","name":"FUJIFILM Healthcare","route":"/companies/fujifilm/","field":"links","label":"Official website"},{"id":"fujifilm","kind":"company","name":"FUJIFILM Healthcare","route":"/companies/fujifilm/","field":"website"}]},{"url":"https://www.fujirebio.com","status":200,"ok":true,"finalUrl":"https://www.fujirebio.com/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/","field":"links","label":"Official website"},{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/","field":"website"}]},{"url":"https://www.fusfoundation.org","status":200,"ok":true,"finalUrl":"https://www.fusfoundation.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-sonobiopsy","kind":"idea","name":"Ultrasound-assisted blood test instead of a brain biopsy","route":"/ideas/idea-bio2-sonobiopsy/","field":"links","label":"Focused Ultrasound Foundation"}]},{"url":"https://www.g-ba.de","status":200,"ok":true,"finalUrl":"https://www.g-ba.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","field":"links","label":"G-BA"},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","field":"website"}]},{"url":"https://www.g-ba.de/english/benefitassessment/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","field":"links","label":"G-BA: benefit assessment of pharmaceuticals (English)"}]},{"url":"https://www.g-ba.de/ueber-den-gba/wer-wir-sind/mitglieder/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","route":"/people/sonja-optendrenk/","field":"links","label":"Institution profile"},{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","route":"/people/sonja-optendrenk/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ga4gh.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-common-biobank-consent-mta","kind":"idea","name":"A common consent and material transfer template for tumour biobanks","route":"/ideas/idea-data-common-biobank-consent-mta/","field":"links","label":"GA4GH"}]},{"url":"https://www.galderma.com","status":200,"ok":true,"finalUrl":"https://www.galderma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"links","label":"Official website"},{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","field":"website"}]},{"url":"https://www.galleri.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","field":"access.source (US)"}]},{"url":"https://www.galliera.it","status":200,"ok":true,"finalUrl":"https://www.galliera.it/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","route":"/institutions/ospedali-galliera/","field":"links","label":"Ospedali Galliera"},{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","route":"/institutions/ospedali-galliera/","field":"website"}]},{"url":"https://www.gamida-cell.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","field":"links","label":"Official website"},{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","field":"website"}]},{"url":"https://www.garvan.org.au","status":200,"ok":true,"finalUrl":"https://www.garvan.org.au/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","field":"links","label":"Garvan Institute"},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","field":"website"}]},{"url":"https://www.gatesfoundation.org","status":200,"ok":true,"finalUrl":"https://www.gatesfoundation.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","field":"links","label":"Gates Foundation"},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","field":"website"}]},{"url":"https://www.gatesfoundation.org/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-suzman","kind":"person","name":"Mark Suzman","route":"/people/mark-suzman/","field":"links","label":"Institution profile"},{"id":"mark-suzman","kind":"person","name":"Mark Suzman","route":"/people/mark-suzman/","field":"profiles","label":"Institution profile"},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"links","label":"Institution profile"},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.gavi.org","status":200,"ok":true,"finalUrl":"https://www.gavi.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/","field":"links","label":"Gavi"}]},{"url":"https://www.gavi.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/","field":"links","label":"Gavi"}]},{"url":"https://www.gavi.org/investing-gavi/funding/donor-profiles/bill-melinda-gates-foundation","status":200,"ok":true,"finalUrl":"https://www.gavi.org/investing-gavi/funding/donor-profiles/gates-foundation","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/","field":"links","label":"Gavi: Gates Foundation donor profile"}]},{"url":"https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/","field":"links","label":"Gavi pneumococcal Advance Market Commitment"}]},{"url":"https://www.gavi.org/types-support/vaccine-support/human-papillomavirus","status":200,"ok":true,"finalUrl":"https://www.gavi.org/our-work/vaccine-portfolio/human-papillomavirus","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/","field":"links","label":"Gavi: human papillomavirus vaccine support"},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","field":"links","label":"Gavi HPV programme"},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","route":"/collections/gavi-hpv-programme/","field":"links","label":"Gavi HPV vaccine support"},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","route":"/collections/gavi-hpv-programme/","field":"url"}]},{"url":"https://www.gbg.de","status":200,"ok":true,"finalUrl":"https://www.gbg.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/","field":"links","label":"Official website"},{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/","field":"website"}]},{"url":"https://www.gbg.de/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"links","label":"German Breast Group"},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","field":"profiles","label":"German Breast Group"}]},{"url":"https://www.gcaresearch.org","status":200,"ok":true,"finalUrl":"https://www.gcaresearch.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","field":"links","label":"Global Coalition for Adaptive Research: GBM AGILE"}]},{"url":"https://www.gcaresearch.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","field":"links","label":"Global Coalition for Adaptive Research (GBM AGILE)"}]},{"url":"https://www.gcaresearch.org/gbm-agile/","status":200,"ok":true,"finalUrl":"https://www.gcaresearch.org/research/gbm-agile/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","field":"links","label":"GBM AGILE"}]},{"url":"https://www.gccell.com","status":200,"ok":true,"finalUrl":"http://www.gccell.com/ko/main.do","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/","field":"links","label":"Official website"},{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/","field":"website"}]},{"url":"https://www.gdghospital.org.cn","status":200,"ok":true,"finalUrl":"https://www.gdghospital.org.cn/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","field":"links","label":"Guangdong Lung Cancer Institute"},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","field":"profiles","label":"Guangdong Lung Cancer Institute"},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","field":"links","label":"Guangdong Provincial People's Hospital"},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","field":"website"}]},{"url":"https://www.gdghospital.org.cn/thecurrentleader/list.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nu-zhang","kind":"person","name":"Nu Zhang","route":"/people/nu-zhang/","field":"links","label":"Institution profile"},{"id":"nu-zhang","kind":"person","name":"Nu Zhang","route":"/people/nu-zhang/","field":"profiles","label":"Institution profile"},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"links","label":"Institution profile"},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.geicam.org","status":200,"ok":true,"finalUrl":"https://www.geicam.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/","field":"links","label":"GEICAM"},{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/","field":"website"}]},{"url":"https://www.geminithera.com","status":200,"ok":true,"finalUrl":"https://www.geminithera.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","field":"links","label":"Official website"},{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","field":"website"}]},{"url":"https://www.geminithera.com/aldoxorubicin.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","field":"links","label":"Gemini Therapeutics: aldoxorubicin"}]},{"url":"https://www.geminithera.com/news/asco-2026-aldoxorubicin.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","field":"links","label":"ASCO 2026 press release"}]},{"url":"https://www.geminithera.com/team.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","field":"links","label":"Team"}]},{"url":"https://www.gene.com/download/pdf/polivy_prescribing.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","field":"dosing.source"}]},{"url":"https://www.gene.com/media/press-releases/15100/2026-02-19/fda-accepts-new-drug-application-for-gen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","field":"regulatoryEvents.source (2026-02-19)"}]},{"url":"https://www.gene.com/poseida","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","field":"links","label":"Official website"},{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","field":"website"}]},{"url":"https://www.genelux.com","status":200,"ok":true,"finalUrl":"https://genelux.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","field":"links","label":"Official website"},{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","field":"website"},{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/","field":"links","label":"Sponsor page"}]},{"url":"https://www.genenames.org/about/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hgnc-symbol","kind":"term","name":"HGNC gene symbol","route":"/terms/hgnc-symbol/","field":"links","label":"HGNC (genenames.org)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10003","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgs7","kind":"target","name":"RGS7","route":"/targets/rgs7/","field":"links","label":"HGNC HGNC:10003"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1001","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/","field":"links","label":"HGNC HGNC:1001"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10011","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rheb","kind":"target","name":"RHEB","route":"/targets/rheb/","field":"links","label":"HGNC HGNC:10011"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10019","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ripk1","kind":"target","name":"RIPK1","route":"/targets/ripk1/","field":"links","label":"HGNC HGNC:10019"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10023","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rit1","kind":"target","name":"RIT1","route":"/targets/rit1/","field":"links","label":"HGNC HGNC:10023"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1004","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/","field":"links","label":"HGNC HGNC:1004"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10050","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnasel","kind":"target","name":"RNASEL","route":"/targets/rnasel/","field":"links","label":"HGNC HGNC:10050"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10069","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf6","kind":"target","name":"RNF6","route":"/targets/rnf6/","field":"links","label":"HGNC HGNC:10069"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1008","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl9","kind":"target","name":"BCL9","route":"/targets/bcl9/","field":"links","label":"HGNC HGNC:1008"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10250","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"robo2","kind":"target","name":"ROBO2","route":"/targets/robo2/","field":"links","label":"HGNC HGNC:10250"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10298","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/","field":"links","label":"HGNC HGNC:10298"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10315","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl22","kind":"target","name":"RPL22","route":"/targets/rpl22/","field":"links","label":"HGNC HGNC:10315"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10360","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl5","kind":"target","name":"RPL5","route":"/targets/rpl5/","field":"links","label":"HGNC HGNC:10360"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10402","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps19","kind":"target","name":"RPS19","route":"/targets/rps19/","field":"links","label":"HGNC HGNC:10402"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10411","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps24","kind":"target","name":"RPS24","route":"/targets/rps24/","field":"links","label":"HGNC HGNC:10411"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10414","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps26","kind":"target","name":"RPS26","route":"/targets/rps26/","field":"links","label":"HGNC HGNC:10414"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10416","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps27","kind":"target","name":"RPS27","route":"/targets/rps27/","field":"links","label":"HGNC HGNC:10416"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10417","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps27a","kind":"target","name":"RPS27A","route":"/targets/rps27a/","field":"links","label":"HGNC HGNC:10417"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10419","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps29","kind":"target","name":"RPS29","route":"/targets/rps29/","field":"links","label":"HGNC HGNC:10419"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10421","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/","field":"links","label":"HGNC HGNC:10421"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10429","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps6","kind":"target","name":"RPS6","route":"/targets/rps6/","field":"links","label":"HGNC HGNC:10429"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10432","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps6ka3","kind":"target","name":"RPS6KA3","route":"/targets/rps6ka3/","field":"links","label":"HGNC HGNC:10432"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10440","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps7","kind":"target","name":"RPS7","route":"/targets/rps7/","field":"links","label":"HGNC HGNC:10440"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10445","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnot9","kind":"target","name":"CNOT9","route":"/targets/cnot9/","field":"links","label":"HGNC HGNC:10445"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10452","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/","field":"links","label":"HGNC HGNC:10452"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10461","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/","field":"links","label":"HGNC HGNC:10461"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10471","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/","field":"links","label":"HGNC HGNC:10471"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10500","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s100b","kind":"target","name":"S100B","route":"/targets/s100b/","field":"links","label":"HGNC HGNC:10500"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1051","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bik","kind":"target","name":"BIK","route":"/targets/bik/","field":"links","label":"HGNC HGNC:1051"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10522","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsm3","kind":"target","name":"ACSM3","route":"/targets/acsm3/","field":"links","label":"HGNC HGNC:10522"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10560","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atxn7","kind":"target","name":"ATXN7","route":"/targets/atxn7/","field":"links","label":"HGNC HGNC:10560"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1057","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blk","kind":"target","name":"BLK","route":"/targets/blk/","field":"links","label":"HGNC HGNC:1057"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1058","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/","field":"links","label":"HGNC HGNC:1058"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10582","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn10a","kind":"target","name":"SCN10A","route":"/targets/scn10a/","field":"links","label":"HGNC HGNC:10582"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10583","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn11a","kind":"target","name":"SCN11A","route":"/targets/scn11a/","field":"links","label":"HGNC HGNC:10583"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn1a","kind":"target","name":"SCN1A","route":"/targets/scn1a/","field":"links","label":"HGNC HGNC:10585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10588","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn2a","kind":"target","name":"SCN2A","route":"/targets/scn2a/","field":"links","label":"HGNC HGNC:10588"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10590","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn3a","kind":"target","name":"SCN3A","route":"/targets/scn3a/","field":"links","label":"HGNC HGNC:10590"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10591","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn4a","kind":"target","name":"SCN4A","route":"/targets/scn4a/","field":"links","label":"HGNC HGNC:10591"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10593","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn5a","kind":"target","name":"SCN5A","route":"/targets/scn5a/","field":"links","label":"HGNC HGNC:10593"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10594","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn7a","kind":"target","name":"SCN7A","route":"/targets/scn7a/","field":"links","label":"HGNC HGNC:10594"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10596","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn8a","kind":"target","name":"SCN8A","route":"/targets/scn8a/","field":"links","label":"HGNC HGNC:10596"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10597","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn9a","kind":"target","name":"SCN9A","route":"/targets/scn9a/","field":"links","label":"HGNC HGNC:10597"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10637","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cxcl10","kind":"target","name":"CXCL10","route":"/targets/cxcl10/","field":"links","label":"HGNC HGNC:10637"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10647","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cx3cl1","kind":"target","name":"CX3CL1","route":"/targets/cx3cl1/","field":"links","label":"HGNC HGNC:10647"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10661","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdc4","kind":"target","name":"SDC4","route":"/targets/sdc4/","field":"links","label":"HGNC HGNC:10661"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10662","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdcbp","kind":"target","name":"SDCBP","route":"/targets/sdcbp/","field":"links","label":"HGNC HGNC:10662"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10671","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdccag8","kind":"target","name":"SDCCAG8","route":"/targets/sdccag8/","field":"links","label":"HGNC HGNC:10671"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10680","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","field":"links","label":"HGNC HGNC:10680"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10681","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhb","kind":"target","name":"SDHB","route":"/targets/sdhb/","field":"links","label":"HGNC HGNC:10681"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10682","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhc","kind":"target","name":"SDHC","route":"/targets/sdhc/","field":"links","label":"HGNC HGNC:10682"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10683","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhd","kind":"target","name":"SDHD","route":"/targets/sdhd/","field":"links","label":"HGNC HGNC:10683"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1069","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp2","kind":"target","name":"BMP2","route":"/targets/bmp2/","field":"links","label":"HGNC HGNC:1069"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1071","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp4","kind":"target","name":"BMP4","route":"/targets/bmp4/","field":"links","label":"HGNC HGNC:1071"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1072","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp5","kind":"target","name":"BMP5","route":"/targets/bmp5/","field":"links","label":"HGNC HGNC:1072"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1073","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp6","kind":"target","name":"BMP6","route":"/targets/bmp6/","field":"links","label":"HGNC HGNC:1073"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1074","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp7","kind":"target","name":"BMP7","route":"/targets/bmp7/","field":"links","label":"HGNC HGNC:1074"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1076","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/","field":"links","label":"HGNC HGNC:1076"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10760","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"set","kind":"target","name":"SET","route":"/targets/set/","field":"links","label":"HGNC HGNC:10760"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10761","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setdb1","kind":"target","name":"SETDB1","route":"/targets/setdb1/","field":"links","label":"HGNC HGNC:10761"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","field":"links","label":"HGNC HGNC:10768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10774","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sfpq","kind":"target","name":"SFPQ","route":"/targets/sfpq/","field":"links","label":"HGNC HGNC:10774"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10778","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sfrp4","kind":"target","name":"SFRP4","route":"/targets/sfrp4/","field":"links","label":"HGNC HGNC:10778"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10783","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srsf2","kind":"target","name":"SRSF2","route":"/targets/srsf2/","field":"links","label":"HGNC HGNC:10783"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10785","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srsf3","kind":"target","name":"SRSF3","route":"/targets/srsf3/","field":"links","label":"HGNC HGNC:10785"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10810","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sgk1","kind":"target","name":"SGK1","route":"/targets/sgk1/","field":"links","label":"HGNC HGNC:10810"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10830","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sh3gl1","kind":"target","name":"SH3GL1","route":"/targets/sh3gl1/","field":"links","label":"HGNC HGNC:10830"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10840","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shc1","kind":"target","name":"SHC1","route":"/targets/shc1/","field":"links","label":"HGNC HGNC:10840"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10845","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/","field":"links","label":"HGNC HGNC:10845"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10879","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stil","kind":"target","name":"STIL","route":"/targets/stil/","field":"links","label":"HGNC HGNC:10879"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10883","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sim2","kind":"target","name":"SIM2","route":"/targets/sim2/","field":"links","label":"HGNC HGNC:10883"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10887","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"six1","kind":"target","name":"SIX1","route":"/targets/six1/","field":"links","label":"HGNC HGNC:10887"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10897","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skil","kind":"target","name":"SKIL","route":"/targets/skil/","field":"links","label":"HGNC HGNC:10897"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10899","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skp1","kind":"target","name":"SKP1","route":"/targets/skp1/","field":"links","label":"HGNC HGNC:10899"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10911","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc12a2","kind":"target","name":"SLC12A2","route":"/targets/slc12a2/","field":"links","label":"HGNC HGNC:10911"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10918","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc14a1","kind":"target","name":"SLC14A1","route":"/targets/slc14a1/","field":"links","label":"HGNC HGNC:10918"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1092","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/","field":"links","label":"HGNC HGNC:1092"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10959","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slco1b1","kind":"target","name":"SLCO1B1","route":"/targets/slco1b1/","field":"links","label":"HGNC HGNC:10959"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10964","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc67a1","kind":"target","name":"SLC67A1","route":"/targets/slc67a1/","field":"links","label":"HGNC HGNC:10964"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10967","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc22a3","kind":"target","name":"SLC22A3","route":"/targets/slc22a3/","field":"links","label":"HGNC HGNC:10967"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10981","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc25a11","kind":"target","name":"SLC25A11","route":"/targets/slc25a11/","field":"links","label":"HGNC HGNC:10981"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11003","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc29a1","kind":"target","name":"SLC29A1","route":"/targets/slc29a1/","field":"links","label":"HGNC HGNC:11003"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11020","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/","field":"links","label":"HGNC HGNC:11020"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11048","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a2","kind":"target","name":"SLC6A2","route":"/targets/slc6a2/","field":"links","label":"HGNC HGNC:11048"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11049","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a3","kind":"target","name":"SLC6A3","route":"/targets/slc6a3/","field":"links","label":"HGNC HGNC:11049"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11050","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a4","kind":"target","name":"SLC6A4","route":"/targets/slc6a4/","field":"links","label":"HGNC HGNC:11050"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1107","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfp36l1","kind":"target","name":"ZFP36L1","route":"/targets/zfp36l1/","field":"links","label":"HGNC HGNC:1107"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11098","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/","field":"links","label":"HGNC HGNC:11098"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11100","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","field":"links","label":"HGNC HGNC:11100"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11103","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/","field":"links","label":"HGNC HGNC:11103"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11106","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarcd1","kind":"target","name":"SMARCD1","route":"/targets/smarcd1/","field":"links","label":"HGNC HGNC:11106"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11109","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarce1","kind":"target","name":"SMARCE1","route":"/targets/smarce1/","field":"links","label":"HGNC HGNC:11109"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11110","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"links","label":"HGNC HGNC:11110"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11111","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smc1a","kind":"target","name":"SMC1A","route":"/targets/smc1a/","field":"links","label":"HGNC HGNC:11111"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11114","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/","field":"links","label":"HGNC HGNC:11114"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11115","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5d","kind":"target","name":"KDM5D","route":"/targets/kdm5d/","field":"links","label":"HGNC HGNC:11115"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1112","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncaph","kind":"target","name":"NCAPH","route":"/targets/ncaph/","field":"links","label":"HGNC HGNC:1112"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11132","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snap25","kind":"target","name":"SNAP25","route":"/targets/snap25/","field":"links","label":"HGNC HGNC:11132"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11139","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sncaip","kind":"target","name":"SNCAIP","route":"/targets/sncaip/","field":"links","label":"HGNC HGNC:11139"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11168","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sntb1","kind":"target","name":"SNTB1","route":"/targets/sntb1/","field":"links","label":"HGNC HGNC:11168"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11187","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sos1","kind":"target","name":"SOS1","route":"/targets/sos1/","field":"links","label":"HGNC HGNC:11187"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11190","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox10","kind":"target","name":"SOX10","route":"/targets/sox10/","field":"links","label":"HGNC HGNC:11190"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11195","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","field":"links","label":"HGNC HGNC:11195"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11197","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox21","kind":"target","name":"SOX21","route":"/targets/sox21/","field":"links","label":"HGNC HGNC:11197"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11204","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","field":"links","label":"HGNC HGNC:11204"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1121","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/","field":"links","label":"HGNC HGNC:1121"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11240","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/","field":"links","label":"HGNC HGNC:11240"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11254","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","field":"links","label":"HGNC HGNC:11254"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11270","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spry2","kind":"target","name":"SPRY2","route":"/targets/spry2/","field":"links","label":"HGNC HGNC:11270"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11275","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sptbn1","kind":"target","name":"SPTBN1","route":"/targets/sptbn1/","field":"links","label":"HGNC HGNC:11275"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11280","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sqstm1","kind":"target","name":"SQSTM1","route":"/targets/sqstm1/","field":"links","label":"HGNC HGNC:11280"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11284","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a1","kind":"target","name":"SRD5A1","route":"/targets/srd5a1/","field":"links","label":"HGNC HGNC:11284"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11285","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","field":"links","label":"HGNC:11285 SRD5A2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11298","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srms","kind":"target","name":"SRMS","route":"/targets/srms/","field":"links","label":"HGNC HGNC:11298"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1130","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/","field":"links","label":"HGNC HGNC:1130"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1131","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btg2","kind":"target","name":"BTG2","route":"/targets/btg2/","field":"links","label":"HGNC HGNC:1131"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11320","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abi1","kind":"target","name":"ABI1","route":"/targets/abi1/","field":"links","label":"HGNC HGNC:11320"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11330","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr1","kind":"target","name":"SSTR1","route":"/targets/sstr1/","field":"links","label":"HGNC HGNC:11330"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11332","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr3","kind":"target","name":"SSTR3","route":"/targets/sstr3/","field":"links","label":"HGNC HGNC:11332"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11333","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr4","kind":"target","name":"SSTR4","route":"/targets/sstr4/","field":"links","label":"HGNC HGNC:11333"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11334","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/","field":"links","label":"HGNC HGNC:11334"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11335","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssx1","kind":"target","name":"SSX1","route":"/targets/ssx1/","field":"links","label":"HGNC HGNC:11335"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11336","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/","field":"links","label":"HGNC HGNC:11336"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11340","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ss18","kind":"target","name":"SS18","route":"/targets/ss18/","field":"links","label":"HGNC HGNC:11340"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11355","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stag2","kind":"target","name":"STAG2","route":"/targets/stag2/","field":"links","label":"HGNC HGNC:11355"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11356","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stag3","kind":"target","name":"STAG3","route":"/targets/stag3/","field":"links","label":"HGNC HGNC:11356"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11362","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/","field":"links","label":"HGNC HGNC:11362"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11364","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/","field":"links","label":"HGNC HGNC:11364"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11366","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"HGNC HGNC:11366 (STAT5A)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11367","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"HGNC HGNC:11367 (STAT5B)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11368","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat6","kind":"target","name":"STAT6","route":"/targets/stat6/","field":"links","label":"HGNC HGNC:11368"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11389","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"links","label":"HGNC HGNC:11389"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11390","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurkb","kind":"target","name":"AURKB","route":"/targets/aurkb/","field":"links","label":"HGNC HGNC:11390"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11393","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","field":"links","label":"HGNC HGNC:11393"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11424","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"strn","kind":"target","name":"STRN","route":"/targets/strn/","field":"links","label":"HGNC HGNC:11424"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1148","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bub1","kind":"target","name":"BUB1","route":"/targets/bub1/","field":"links","label":"HGNC HGNC:1148"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1149","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/","field":"links","label":"HGNC HGNC:1149"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11491","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/","field":"links","label":"HGNC HGNC:11491"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11515","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbxt","kind":"target","name":"TBXT","route":"/targets/tbxt/","field":"links","label":"HGNC HGNC:11515"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11547","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taf15","kind":"target","name":"TAF15","route":"/targets/taf15/","field":"links","label":"HGNC HGNC:11547"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11556","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tal1","kind":"target","name":"TAL1","route":"/targets/tal1/","field":"links","label":"HGNC HGNC:11556"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11557","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tal2","kind":"target","name":"TAL2","route":"/targets/tal2/","field":"links","label":"HGNC HGNC:11557"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11584","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbk1","kind":"target","name":"TBK1","route":"/targets/tbk1/","field":"links","label":"HGNC HGNC:11584"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11589","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbpl1","kind":"target","name":"TBPL1","route":"/targets/tbpl1/","field":"links","label":"HGNC HGNC:11589"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11592","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbx1","kind":"target","name":"TBX1","route":"/targets/tbx1/","field":"links","label":"HGNC HGNC:11592"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11602","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbx3","kind":"target","name":"TBX3","route":"/targets/tbx3/","field":"links","label":"HGNC HGNC:11602"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11612","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcea1","kind":"target","name":"TCEA1","route":"/targets/tcea1/","field":"links","label":"HGNC HGNC:11612"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11621","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/","field":"links","label":"HGNC HGNC:11621"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11623","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf12","kind":"target","name":"TCF12","route":"/targets/tcf12/","field":"links","label":"HGNC HGNC:11623"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11629","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf19","kind":"target","name":"TCF19","route":"/targets/tcf19/","field":"links","label":"HGNC HGNC:11629"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11630","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/","field":"links","label":"HGNC HGNC:11630"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11633","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf3","kind":"target","name":"TCF3","route":"/targets/tcf3/","field":"links","label":"HGNC HGNC:11633"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11634","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf4","kind":"target","name":"TCF4","route":"/targets/tcf4/","field":"links","label":"HGNC HGNC:11634"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11641","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","field":"links","label":"HGNC HGNC:11641"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11642","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/","field":"links","label":"HGNC HGNC:11642"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11648","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcl1a","kind":"target","name":"TCL1A","route":"/targets/tcl1a/","field":"links","label":"HGNC HGNC:11648"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11708","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tdo2","kind":"target","name":"TDO2","route":"/targets/tdo2/","field":"links","label":"HGNC HGNC:11708"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1171","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elp4","kind":"target","name":"ELP4","route":"/targets/elp4/","field":"links","label":"HGNC HGNC:1171"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11719","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tec","kind":"target","name":"TEC","route":"/targets/tec/","field":"links","label":"HGNC HGNC:11719"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11724","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","field":"links","label":"HGNC:11724 TEK"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11730","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/","field":"links","label":"HGNC HGNC:11730"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11740","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tf","kind":"target","name":"TF","route":"/targets/tf/","field":"links","label":"HGNC HGNC:11740"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11745","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfap4","kind":"target","name":"TFAP4","route":"/targets/tfap4/","field":"links","label":"HGNC HGNC:11745"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11752","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfe3","kind":"target","name":"TFE3","route":"/targets/tfe3/","field":"links","label":"HGNC HGNC:11752"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11753","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfeb","kind":"target","name":"TFEB","route":"/targets/tfeb/","field":"links","label":"HGNC HGNC:11753"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11757","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tff3","kind":"target","name":"TFF3","route":"/targets/tff3/","field":"links","label":"HGNC HGNC:11757"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11758","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfg","kind":"target","name":"TFG","route":"/targets/tfg/","field":"links","label":"HGNC HGNC:11758"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11763","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfrc","kind":"target","name":"TFRC","route":"/targets/tfrc/","field":"links","label":"HGNC HGNC:11763"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11764","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tg","kind":"target","name":"TG","route":"/targets/tg/","field":"links","label":"HGNC HGNC:11764"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11765","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfa","kind":"target","name":"TGFA","route":"/targets/tgfa/","field":"links","label":"HGNC HGNC:11765"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11766","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb1","kind":"target","name":"TGFB1","route":"/targets/tgfb1/","field":"links","label":"HGNC HGNC:11766"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb2","kind":"target","name":"TGFB2","route":"/targets/tgfb2/","field":"links","label":"HGNC HGNC:11768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11769","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb3","kind":"target","name":"TGFB3","route":"/targets/tgfb3/","field":"links","label":"HGNC HGNC:11769"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11772","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr1","kind":"target","name":"TGFBR1","route":"/targets/tgfbr1/","field":"links","label":"HGNC HGNC:11772"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11773","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","field":"links","label":"HGNC HGNC:11773"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11774","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr3","kind":"target","name":"TGFBR3","route":"/targets/tgfbr3/","field":"links","label":"HGNC HGNC:11774"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgif1","kind":"target","name":"TGIF1","route":"/targets/tgif1/","field":"links","label":"HGNC HGNC:11776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11779","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgm3","kind":"target","name":"TGM3","route":"/targets/tgm3/","field":"links","label":"HGNC HGNC:11779"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11786","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thbs2","kind":"target","name":"THBS2","route":"/targets/thbs2/","field":"links","label":"HGNC HGNC:11786"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11796","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thra","kind":"target","name":"THRA","route":"/targets/thra/","field":"links","label":"HGNC HGNC:11796"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11799","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thrb","kind":"target","name":"THRB","route":"/targets/thrb/","field":"links","label":"HGNC HGNC:11799"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11812","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/","field":"links","label":"HGNC HGNC:11812"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"timp1","kind":"target","name":"TIMP1","route":"/targets/timp1/","field":"links","label":"HGNC HGNC:11820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11825","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","field":"links","label":"HGNC HGNC:11825"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11842","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlk2","kind":"target","name":"TLK2","route":"/targets/tlk2/","field":"links","label":"HGNC HGNC:11842"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11845","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tln1","kind":"target","name":"TLN1","route":"/targets/tln1/","field":"links","label":"HGNC HGNC:11845"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11876","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/","field":"links","label":"HGNC HGNC:11876"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11881","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmsb4x","kind":"target","name":"TMSB4X","route":"/targets/tmsb4x/","field":"links","label":"HGNC HGNC:11881"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11896","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/","field":"links","label":"HGNC HGNC:11896"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11905","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf10b","kind":"target","name":"TNFRSF10B","route":"/targets/tnfrsf10b/","field":"links","label":"HGNC HGNC:11905"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11912","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf14","kind":"target","name":"TNFRSF14","route":"/targets/tnfrsf14/","field":"links","label":"HGNC HGNC:11912"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11914","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/","field":"links","label":"HGNC HGNC:11914"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11918","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/","field":"links","label":"HGNC HGNC:11918"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11919","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/","field":"links","label":"HGNC HGNC:11919"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11920","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/","field":"links","label":"HGNC HGNC:11920"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11922","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/","field":"links","label":"HGNC HGNC:11922"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11924","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/","field":"links","label":"HGNC HGNC:11924"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11925","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfsf10","kind":"target","name":"TNFSF10","route":"/targets/tnfsf10/","field":"links","label":"HGNC HGNC:11925"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11957","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/","field":"links","label":"HGNC HGNC:11957"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11972","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tox3","kind":"target","name":"TOX3","route":"/targets/tox3/","field":"links","label":"HGNC HGNC:11972"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11973","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tns1","kind":"target","name":"TNS1","route":"/targets/tns1/","field":"links","label":"HGNC HGNC:11973"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11990","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/","field":"links","label":"HGNC HGNC:11990"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11992","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top3a","kind":"target","name":"TOP3A","route":"/targets/top3a/","field":"links","label":"HGNC HGNC:11992"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11999","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tp53bp1","kind":"target","name":"TP53BP1","route":"/targets/tp53bp1/","field":"links","label":"HGNC HGNC:11999"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12008","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","field":"links","label":"HGNC:12008 TPH1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12012","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpm3","kind":"target","name":"TPM3","route":"/targets/tpm3/","field":"links","label":"HGNC HGNC:12012"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12013","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpm4","kind":"target","name":"TPM4","route":"/targets/tpm4/","field":"links","label":"HGNC HGNC:12013"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12017","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpr","kind":"target","name":"TPR","route":"/targets/tpr/","field":"links","label":"HGNC HGNC:12017"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12022","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpt1","kind":"target","name":"TPT1","route":"/targets/tpt1/","field":"links","label":"HGNC HGNC:12022"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12028","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90b1","kind":"target","name":"HSP90B1","route":"/targets/hsp90b1/","field":"links","label":"HGNC HGNC:12028"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12033","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/","field":"links","label":"HGNC HGNC:12033"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12305","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trip11","kind":"target","name":"TRIP11","route":"/targets/trip11/","field":"links","label":"HGNC HGNC:12305"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12340","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trps1","kind":"target","name":"TRPS1","route":"/targets/trps1/","field":"links","label":"HGNC HGNC:12340"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12347","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trrap","kind":"target","name":"TRRAP","route":"/targets/trrap/","field":"links","label":"HGNC HGNC:12347"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12362","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tsc1","kind":"target","name":"TSC1","route":"/targets/tsc1/","field":"links","label":"HGNC HGNC:12362"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12363","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tsc2","kind":"target","name":"TSC2","route":"/targets/tsc2/","field":"links","label":"HGNC HGNC:12363"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12373","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","field":"links","label":"HGNC:12373 TSHR"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12382","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tspyl1","kind":"target","name":"TSPYL1","route":"/targets/tspyl1/","field":"links","label":"HGNC HGNC:12382"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12397","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","field":"links","label":"HGNC HGNC:12397"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12401","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ttk","kind":"target","name":"MPS1 (TTK)","route":"/targets/ttk/","field":"links","label":"HGNC HGNC:12401"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12407","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/","field":"links","label":"HGNC HGNC:12407"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12408","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/","field":"links","label":"HGNC HGNC:12408"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12412","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/","field":"links","label":"HGNC HGNC:12412"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12437","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","field":"links","label":"HGNC:12437 TXNRD1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12440","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyk2","kind":"target","name":"TYK2","route":"/targets/tyk2/","field":"links","label":"HGNC HGNC:12440"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12442","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/","field":"links","label":"HGNC HGNC:12442"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12450","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyrp1","kind":"target","name":"TYRP1","route":"/targets/tyrp1/","field":"links","label":"HGNC HGNC:12450"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12453","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"u2af1","kind":"target","name":"U2AF1","route":"/targets/u2af1/","field":"links","label":"HGNC HGNC:12453"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12458","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"uba52","kind":"target","name":"UBA52","route":"/targets/uba52/","field":"links","label":"HGNC HGNC:12458"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12463","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubb","kind":"target","name":"UBB","route":"/targets/ubb/","field":"links","label":"HGNC HGNC:12463"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12468","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubc","kind":"target","name":"UBC","route":"/targets/ubc/","field":"links","label":"HGNC HGNC:12468"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12472","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ube2a","kind":"target","name":"UBE2A","route":"/targets/ube2a/","field":"links","label":"HGNC HGNC:12472"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:125","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","field":"links","label":"HGNC:125 ACP3"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12511","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubtf","kind":"target","name":"UBTF","route":"/targets/ubtf/","field":"links","label":"HGNC HGNC:12511"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12529","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ugt1a","kind":"target","name":"UGT1A","route":"/targets/ugt1a/","field":"links","label":"HGNC HGNC:12529"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12530","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ugt1a1","kind":"target","name":"UGT1A1","route":"/targets/ugt1a1/","field":"links","label":"HGNC HGNC:12530"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12625","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp28","kind":"target","name":"USP28","route":"/targets/usp28/","field":"links","label":"HGNC HGNC:12625"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12629","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp6","kind":"target","name":"USP6","route":"/targets/usp6/","field":"links","label":"HGNC HGNC:12629"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12630","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/","field":"links","label":"HGNC HGNC:12630"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12631","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/","field":"links","label":"HGNC HGNC:12631"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12632","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp9x","kind":"target","name":"USP9X","route":"/targets/usp9x/","field":"links","label":"HGNC HGNC:12632"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12637","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","field":"links","label":"HGNC HGNC:12637"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12657","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/","field":"links","label":"HGNC HGNC:12657"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12665","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vcl","kind":"target","name":"VCL","route":"/targets/vcl/","field":"links","label":"HGNC HGNC:12665"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12679","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vdr","kind":"target","name":"VDR","route":"/targets/vdr/","field":"links","label":"HGNC HGNC:12679"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12682","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vegfc","kind":"target","name":"VEGFC","route":"/targets/vegfc/","field":"links","label":"HGNC HGNC:12682"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12687","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vhl","kind":"target","name":"VHL","route":"/targets/vhl/","field":"links","label":"HGNC HGNC:12687"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12691","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ezr","kind":"target","name":"EZR","route":"/targets/ezr/","field":"links","label":"HGNC HGNC:12691"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12726","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vwf","kind":"target","name":"VWF","route":"/targets/vwf/","field":"links","label":"HGNC HGNC:12726"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12731","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"was","kind":"target","name":"WAS","route":"/targets/was/","field":"links","label":"HGNC HGNC:12731"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12766","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/","field":"links","label":"HGNC HGNC:12766"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12767","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd3","kind":"target","name":"NSD3","route":"/targets/nsd3/","field":"links","label":"HGNC HGNC:12767"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12774","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt1","kind":"target","name":"WNT1","route":"/targets/wnt1/","field":"links","label":"HGNC HGNC:12774"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt11","kind":"target","name":"WNT11","route":"/targets/wnt11/","field":"links","label":"HGNC HGNC:12776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12785","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt6","kind":"target","name":"WNT6","route":"/targets/wnt6/","field":"links","label":"HGNC HGNC:12785"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12796","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/","field":"links","label":"HGNC HGNC:12796"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12799","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wwox","kind":"target","name":"WWOX","route":"/targets/wwox/","field":"links","label":"HGNC HGNC:12799"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12805","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","field":"links","label":"HGNC:12805 XDH"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12814","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xpa","kind":"target","name":"XPA","route":"/targets/xpa/","field":"links","label":"HGNC HGNC:12814"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12816","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xpc","kind":"target","name":"XPC","route":"/targets/xpc/","field":"links","label":"HGNC HGNC:12816"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12828","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/","field":"links","label":"HGNC HGNC:12828"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12829","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc2","kind":"target","name":"XRCC2","route":"/targets/xrcc2/","field":"links","label":"HGNC HGNC:12829"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12830","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc3","kind":"target","name":"XRCC3","route":"/targets/xrcc3/","field":"links","label":"HGNC HGNC:12830"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12841","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/","field":"links","label":"HGNC HGNC:12841"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12849","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ywhab","kind":"target","name":"YWHAB","route":"/targets/ywhab/","field":"links","label":"HGNC HGNC:12849"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12851","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ywhae","kind":"target","name":"YWHAE","route":"/targets/ywhae/","field":"links","label":"HGNC HGNC:12851"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:129","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acta1","kind":"target","name":"ACTA1","route":"/targets/acta1/","field":"links","label":"HGNC HGNC:129"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12930","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","field":"links","label":"HGNC HGNC:12930"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12989","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmym2","kind":"target","name":"ZMYM2","route":"/targets/zmym2/","field":"links","label":"HGNC HGNC:12989"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12999","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf208","kind":"target","name":"ZNF208","route":"/targets/znf208/","field":"links","label":"HGNC HGNC:12999"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:130","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acta2","kind":"target","name":"ACTA2","route":"/targets/acta2/","field":"links","label":"HGNC HGNC:130"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13009","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/","field":"links","label":"HGNC HGNC:13009"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13013","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/","field":"links","label":"HGNC HGNC:13013"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13054","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmym3","kind":"target","name":"ZMYM3","route":"/targets/zmym3/","field":"links","label":"HGNC HGNC:13054"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13068","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf274","kind":"target","name":"ZNF274","route":"/targets/znf274/","field":"links","label":"HGNC HGNC:13068"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13071","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patz1","kind":"target","name":"PATZ1","route":"/targets/patz1/","field":"links","label":"HGNC HGNC:13071"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1316","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eml4","kind":"target","name":"EML4","route":"/targets/eml4/","field":"links","label":"HGNC HGNC:1316"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13164","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnbp","kind":"target","name":"CNBP","route":"/targets/cnbp/","field":"links","label":"HGNC HGNC:13164"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13165","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf90","kind":"target","name":"ZNF90","route":"/targets/znf90/","field":"links","label":"HGNC HGNC:13165"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13169","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf93","kind":"target","name":"ZNF93","route":"/targets/znf93/","field":"links","label":"HGNC HGNC:13169"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13176","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikzf1","kind":"target","name":"IKZF1 (Ikaros)","route":"/targets/ikzf1/","field":"links","label":"HGNC HGNC:13176"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13178","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikzf3","kind":"target","name":"IKZF3 (Aiolos)","route":"/targets/ikzf3/","field":"links","label":"HGNC HGNC:13178"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13199","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zxdb","kind":"target","name":"ZXDB","route":"/targets/zxdb/","field":"links","label":"HGNC HGNC:13199"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:132","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actb","kind":"target","name":"ACTB","route":"/targets/actb/","field":"links","label":"HGNC HGNC:132"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13202","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/","field":"links","label":"HGNC HGNC:13202"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13209","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef5","kind":"target","name":"ARHGEF5","route":"/targets/arhgef5/","field":"links","label":"HGNC HGNC:13209"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13221","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl11a","kind":"target","name":"BCL11A","route":"/targets/bcl11a/","field":"links","label":"HGNC HGNC:13221"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13222","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl11b","kind":"target","name":"BCL11B","route":"/targets/bcl11b/","field":"links","label":"HGNC HGNC:13222"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13315","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/","field":"links","label":"HGNC HGNC:13315"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1333","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam114a2","kind":"target","name":"FAM114A2","route":"/targets/fam114a2/","field":"links","label":"HGNC HGNC:1333"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1337","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm3b","kind":"target","name":"KDM3B","route":"/targets/kdm3b/","field":"links","label":"HGNC HGNC:1337"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1348","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samd9","kind":"target","name":"SAMD9","route":"/targets/samd9/","field":"links","label":"HGNC HGNC:1348"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1349","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samd9l","kind":"target","name":"SAMD9L","route":"/targets/samd9l/","field":"links","label":"HGNC HGNC:1349"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13503","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb20","kind":"target","name":"ZBTB20","route":"/targets/zbtb20/","field":"links","label":"HGNC HGNC:13503"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13516","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc6","kind":"target","name":"BIRC6","route":"/targets/birc6/","field":"links","label":"HGNC HGNC:13516"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13532","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlx3","kind":"target","name":"TLX3","route":"/targets/tlx3/","field":"links","label":"HGNC HGNC:13532"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13539","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agtrap","kind":"target","name":"AGTRAP","route":"/targets/agtrap/","field":"links","label":"HGNC HGNC:13539"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13546","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/","field":"links","label":"HGNC HGNC:13546"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1356","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erlin2","kind":"target","name":"ERLIN2","route":"/targets/erlin2/","field":"links","label":"HGNC HGNC:1356"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13575","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/","field":"links","label":"HGNC HGNC:13575"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13590","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/","field":"links","label":"HGNC HGNC:13590"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13607","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxw11","kind":"target","name":"FBXW11","route":"/targets/fbxw11/","field":"links","label":"HGNC HGNC:13607"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13632","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml1","kind":"target","name":"MAML1","route":"/targets/maml1/","field":"links","label":"HGNC HGNC:13632"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13702","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc7","kind":"target","name":"BIRC7","route":"/targets/birc7/","field":"links","label":"HGNC HGNC:13702"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13723","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctcf","kind":"target","name":"CTCF","route":"/targets/ctcf/","field":"links","label":"HGNC HGNC:13723"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13726","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","field":"links","label":"HGNC HGNC:13726"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13744","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herpud1","kind":"target","name":"HERPUD1","route":"/targets/herpud1/","field":"links","label":"HGNC HGNC:13744"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13825","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspscr1","kind":"target","name":"ASPSCR1","route":"/targets/aspscr1/","field":"links","label":"HGNC HGNC:13825"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13871","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpsf6","kind":"target","name":"CPSF6","route":"/targets/cpsf6/","field":"links","label":"HGNC HGNC:13871"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1391","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1d","kind":"target","name":"CACNA1D","route":"/targets/cacna1d/","field":"links","label":"HGNC HGNC:1391"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1394","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1g","kind":"target","name":"CACNA1G","route":"/targets/cacna1g/","field":"links","label":"HGNC HGNC:1394"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1395","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1h","kind":"target","name":"CACNA1H","route":"/targets/cacna1h/","field":"links","label":"HGNC HGNC:1395"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13954","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2bc12","kind":"target","name":"H2BC12","route":"/targets/h2bc12/","field":"links","label":"HGNC HGNC:13954"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1396","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1i","kind":"target","name":"CACNA1I","route":"/targets/cacna1i/","field":"links","label":"HGNC HGNC:1396"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14000","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/","field":"links","label":"HGNC HGNC:14000"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14010","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mga","kind":"target","name":"MGA","route":"/targets/mga/","field":"links","label":"HGNC HGNC:14010"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14063","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/","field":"links","label":"HGNC HGNC:14063"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14065","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/","field":"links","label":"HGNC HGNC:14065"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14067","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/","field":"links","label":"HGNC HGNC:14067"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14068","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/","field":"links","label":"HGNC HGNC:14068"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14074","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fmn2","kind":"target","name":"FMN2","route":"/targets/fmn2/","field":"links","label":"HGNC HGNC:14074"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14078","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bach2","kind":"target","name":"BACH2","route":"/targets/bach2/","field":"links","label":"HGNC HGNC:14078"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14088","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgs17","kind":"target","name":"RGS17","route":"/targets/rgs17/","field":"links","label":"HGNC HGNC:14088"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14098","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wdr12","kind":"target","name":"WDR12","route":"/targets/wdr12/","field":"links","label":"HGNC HGNC:14098"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14103","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","field":"links","label":"HGNC HGNC:14103"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14106","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/","field":"links","label":"HGNC HGNC:14106"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14193","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef12","kind":"target","name":"ARHGEF12","route":"/targets/arhgef12/","field":"links","label":"HGNC HGNC:14193"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14198","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elac2","kind":"target","name":"ELAC2","route":"/targets/elac2/","field":"links","label":"HGNC HGNC:14198"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14214","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cic","kind":"target","name":"CIC","route":"/targets/cic/","field":"links","label":"HGNC HGNC:14214"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14234","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/","field":"links","label":"HGNC HGNC:14234"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14281","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crlf2","kind":"target","name":"CRLF2","route":"/targets/crlf2/","field":"links","label":"HGNC HGNC:14281"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14310","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brd7","kind":"target","name":"BRD7","route":"/targets/brd7/","field":"links","label":"HGNC HGNC:14310"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14334","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrtfa","kind":"target","name":"MRTFA","route":"/targets/mrtfa/","field":"links","label":"HGNC HGNC:14334"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14375","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp1r15a","kind":"target","name":"PPP1R15A","route":"/targets/ppp1r15a/","field":"links","label":"HGNC HGNC:14375"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14399","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpvl","kind":"target","name":"CPVL","route":"/targets/cpvl/","field":"links","label":"HGNC HGNC:14399"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:144","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actg1","kind":"target","name":"ACTG1","route":"/targets/actg1/","field":"links","label":"HGNC HGNC:144"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14458","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gab2","kind":"target","name":"GAB2","route":"/targets/gab2/","field":"links","label":"HGNC HGNC:14458"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14539","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf213","kind":"target","name":"RNF213","route":"/targets/rnf213/","field":"links","label":"HGNC HGNC:14539"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14540","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnk1","kind":"target","name":"WNK1","route":"/targets/wnk1/","field":"links","label":"HGNC HGNC:14540"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14542","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnk2","kind":"target","name":"WNK2","route":"/targets/wnk2/","field":"links","label":"HGNC HGNC:14542"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1455","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","field":"links","label":"HGNC HGNC:1455"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14615","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pappa2","kind":"target","name":"PAPPA2","route":"/targets/pappa2/","field":"links","label":"HGNC HGNC:14615"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14628","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdca7","kind":"target","name":"CDCA7","route":"/targets/cdca7/","field":"links","label":"HGNC HGNC:14628"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14866","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hhip","kind":"target","name":"HHIP","route":"/targets/hhip/","field":"links","label":"HGNC HGNC:14866"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14871","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp1r14a","kind":"target","name":"PPP1R14A","route":"/targets/ppp1r14a/","field":"links","label":"HGNC HGNC:14871"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14906","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nin","kind":"target","name":"NIN","route":"/targets/nin/","field":"links","label":"HGNC HGNC:14906"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14929","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sirt1","kind":"target","name":"SIRT1","route":"/targets/sirt1/","field":"links","label":"HGNC HGNC:14929"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1493","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cars1","kind":"target","name":"CARS1","route":"/targets/cars1/","field":"links","label":"HGNC HGNC:1493"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14959","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm15","kind":"target","name":"RBM15","route":"/targets/rbm15/","field":"links","label":"HGNC HGNC:14959"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1500","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casp10","kind":"target","name":"CASP10","route":"/targets/casp10/","field":"links","label":"HGNC HGNC:1500"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1509","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/","field":"links","label":"HGNC HGNC:1509"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1514","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casr","kind":"target","name":"CASR","route":"/targets/casr/","field":"links","label":"HGNC HGNC:1514"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1535","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"runx1t1","kind":"target","name":"RUNX1T1","route":"/targets/runx1t1/","field":"links","label":"HGNC HGNC:1535"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1537","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbfa2t3","kind":"target","name":"CBFA2T3","route":"/targets/cbfa2t3/","field":"links","label":"HGNC HGNC:1537"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1539","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbfb","kind":"target","name":"CBFB","route":"/targets/cbfb/","field":"links","label":"HGNC HGNC:1539"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1541","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/","field":"links","label":"HGNC HGNC:1541"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1542","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cblb","kind":"target","name":"CBLB","route":"/targets/cblb/","field":"links","label":"HGNC HGNC:1542"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15472","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aldh1a2","kind":"target","name":"ALDH1A2","route":"/targets/aldh1a2/","field":"links","label":"HGNC HGNC:15472"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15486","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nckipsd","kind":"target","name":"NCKIPSD","route":"/targets/nckipsd/","field":"links","label":"HGNC HGNC:15486"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15489","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf331","kind":"target","name":"ZNF331","route":"/targets/znf331/","field":"links","label":"HGNC HGNC:15489"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15514","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"picalm","kind":"target","name":"PICALM","route":"/targets/picalm/","field":"links","label":"HGNC HGNC:15514"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15524","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"p2ry8","kind":"target","name":"P2RY8","route":"/targets/p2ry8/","field":"links","label":"HGNC HGNC:15524"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15533","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spry4","kind":"target","name":"SPRY4","route":"/targets/spry4/","field":"links","label":"HGNC HGNC:15533"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15573","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setbp1","kind":"target","name":"SETBP1","route":"/targets/setbp1/","field":"links","label":"HGNC HGNC:15573"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15620","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siglec10","kind":"target","name":"Siglec-10","route":"/targets/siglec10/","field":"links","label":"HGNC HGNC:15620"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15631","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","field":"links","label":"HGNC:15631 TLR7"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15759","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/","field":"links","label":"HGNC HGNC:15759"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15767","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fermt2","kind":"target","name":"FERMT2","route":"/targets/fermt2/","field":"links","label":"HGNC HGNC:15767"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15804","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ovol2","kind":"target","name":"OVOL2","route":"/targets/ovol2/","field":"links","label":"HGNC HGNC:15804"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15818","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm38","kind":"target","name":"RBM38","route":"/targets/rbm38/","field":"links","label":"HGNC HGNC:15818"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1582","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","field":"links","label":"HGNC HGNC:1582"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1583","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd2","kind":"target","name":"CCND2","route":"/targets/ccnd2/","field":"links","label":"HGNC HGNC:1583"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15840","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2b","kind":"target","name":"KMT2B","route":"/targets/kmt2b/","field":"links","label":"HGNC HGNC:15840"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15842","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erbin","kind":"target","name":"ERBIN","route":"/targets/erbin/","field":"links","label":"HGNC HGNC:15842"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd3","kind":"target","name":"CCND3","route":"/targets/ccnd3/","field":"links","label":"HGNC HGNC:1585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15888","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtel1","kind":"target","name":"RTEL1","route":"/targets/rtel1/","field":"links","label":"HGNC HGNC:15888"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1589","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","field":"links","label":"HGNC HGNC:1589"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1590","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccne2","kind":"target","name":"CCNE2","route":"/targets/ccne2/","field":"links","label":"HGNC HGNC:1590"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15923","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/","field":"links","label":"HGNC HGNC:15923"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15924","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sall4","kind":"target","name":"SALL4","route":"/targets/sall4/","field":"links","label":"HGNC HGNC:15924"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15925","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/","field":"links","label":"HGNC HGNC:15925"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1594","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnh","kind":"target","name":"CCNH","route":"/targets/ccnh/","field":"links","label":"HGNC HGNC:1594"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15954","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"toe1","kind":"target","name":"TOE1","route":"/targets/toe1/","field":"links","label":"HGNC HGNC:15954"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15961","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cblc","kind":"target","name":"CBLC","route":"/targets/cblc/","field":"links","label":"HGNC HGNC:15961"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15979","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/","field":"links","label":"HGNC HGNC:15979"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1599","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnt1","kind":"target","name":"CCNT1","route":"/targets/ccnt1/","field":"links","label":"HGNC HGNC:1599"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16028","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il33","kind":"target","name":"IL33","route":"/targets/il33/","field":"links","label":"HGNC HGNC:16028"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16062","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crtc1","kind":"target","name":"CRTC1","route":"/targets/crtc1/","field":"links","label":"HGNC HGNC:16062"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16063","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/","field":"links","label":"HGNC HGNC:16063"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1608","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccr7","kind":"target","name":"CCR7","route":"/targets/ccr7/","field":"links","label":"HGNC HGNC:1608"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16147","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcm8","kind":"target","name":"MCM8","route":"/targets/mcm8/","field":"links","label":"HGNC HGNC:16147"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16257","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/","field":"links","label":"HGNC HGNC:16257"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16259","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml2","kind":"target","name":"MAML2","route":"/targets/maml2/","field":"links","label":"HGNC HGNC:16259"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16262","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/","field":"links","label":"HGNC HGNC:16262"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16272","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml3","kind":"target","name":"MAML3","route":"/targets/maml3/","field":"links","label":"HGNC HGNC:16272"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16290","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim33","kind":"target","name":"TRIM33","route":"/targets/trim33/","field":"links","label":"HGNC HGNC:16290"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16384","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim28","kind":"target","name":"TRIM28","route":"/targets/trim28/","field":"links","label":"HGNC HGNC:16384"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16393","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/","field":"links","label":"HGNC HGNC:16393"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16395","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"osbpl10","kind":"target","name":"OSBPL10","route":"/targets/osbpl10/","field":"links","label":"HGNC HGNC:16395"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1641","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd209","kind":"target","name":"CD209","route":"/targets/cd209/","field":"links","label":"HGNC HGNC:1641"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1645","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/","field":"links","label":"HGNC HGNC:1645"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16466","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","field":"links","label":"HGNC HGNC:16466"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16472","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc45a2","kind":"target","name":"SLC45A2","route":"/targets/slc45a2/","field":"links","label":"HGNC HGNC:16472"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16493","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmiz1","kind":"target","name":"ZMIZ1","route":"/targets/zmiz1/","field":"links","label":"HGNC HGNC:16493"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16496","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsl6","kind":"target","name":"ACSL6","route":"/targets/acsl6/","field":"links","label":"HGNC HGNC:16496"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1653","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/","field":"links","label":"HGNC HGNC:1653"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/","field":"links","label":"HGNC HGNC:16627"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16667","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc50a","kind":"target","name":"CDC50A","route":"/targets/cdc50a/","field":"links","label":"HGNC HGNC:16667"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16696","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snw1","kind":"target","name":"SNW1","route":"/targets/snw1/","field":"links","label":"HGNC HGNC:16696"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16699","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sorcs3","kind":"target","name":"SORCS3","route":"/targets/sorcs3/","field":"links","label":"HGNC HGNC:16699"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfpm2","kind":"target","name":"ZFPM2","route":"/targets/zfpm2/","field":"links","label":"HGNC HGNC:16700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16705","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tent4a","kind":"target","name":"TENT4A","route":"/targets/tent4a/","field":"links","label":"HGNC HGNC:16705"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16712","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","field":"links","label":"HGNC HGNC:16712"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1673","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/","field":"links","label":"HGNC HGNC:1673"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1675","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/","field":"links","label":"HGNC HGNC:1675"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16783","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc73","kind":"target","name":"CDC73","route":"/targets/cdc73/","field":"links","label":"HGNC HGNC:16783"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16806","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/","field":"links","label":"HGNC HGNC:16806"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1681","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/","field":"links","label":"HGNC HGNC:1681"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16824","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hcar3","kind":"target","name":"HCAR3","route":"/targets/hcar3/","field":"links","label":"HGNC HGNC:16824"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16850","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctr9","kind":"target","name":"CTR9","route":"/targets/ctr9/","field":"links","label":"HGNC HGNC:16850"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16863","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bclaf1","kind":"target","name":"BCLAF1","route":"/targets/bclaf1/","field":"links","label":"HGNC HGNC:16863"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1688","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd58","kind":"target","name":"CD58","route":"/targets/cd58/","field":"links","label":"HGNC HGNC:1688"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16889","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/","field":"links","label":"HGNC HGNC:16889"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/","field":"links","label":"HGNC HGNC:16892"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16935","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atg7","kind":"target","name":"ATG7","route":"/targets/atg7/","field":"links","label":"HGNC HGNC:16935"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16969","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsph1","kind":"target","name":"HSPH1","route":"/targets/hsph1/","field":"links","label":"HGNC HGNC:16969"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1697","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd74","kind":"target","name":"CD74","route":"/targets/cd74/","field":"links","label":"HGNC HGNC:1697"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16970","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frs3","kind":"target","name":"FRS3","route":"/targets/frs3/","field":"links","label":"HGNC HGNC:16970"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16971","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frs2","kind":"target","name":"FRS2","route":"/targets/frs2/","field":"links","label":"HGNC HGNC:16971"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1698","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd79a","kind":"target","name":"CD79A","route":"/targets/cd79a/","field":"links","label":"HGNC HGNC:1698"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/","field":"links","label":"HGNC HGNC:1700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17012","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cep43","kind":"target","name":"CEP43","route":"/targets/cep43/","field":"links","label":"HGNC HGNC:17012"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17016","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat7","kind":"target","name":"KAT7","route":"/targets/kat7/","field":"links","label":"HGNC HGNC:17016"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1703","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd83","kind":"target","name":"CD83","route":"/targets/cd83/","field":"links","label":"HGNC HGNC:1703"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd86","kind":"target","name":"CD86 (B7-2)","route":"/targets/cd86/","field":"links","label":"HGNC HGNC:1705"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17072","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erc1","kind":"target","name":"ERC1","route":"/targets/erc1/","field":"links","label":"HGNC HGNC:17072"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17073","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap26","kind":"target","name":"ARHGAP26","route":"/targets/arhgap26/","field":"links","label":"HGNC HGNC:17073"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17091","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncstn","kind":"target","name":"NCSTN","route":"/targets/ncstn/","field":"links","label":"HGNC HGNC:17091"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17098","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/","field":"links","label":"HGNC HGNC:17098"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:171","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr1","kind":"target","name":"ACVR1 (ALK2)","route":"/targets/acvr1/","field":"links","label":"HGNC HGNC:171"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17101","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"suz12","kind":"target","name":"SUZ12","route":"/targets/suz12/","field":"links","label":"HGNC HGNC:17101"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1712","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cda","kind":"target","name":"CDA","route":"/targets/cda/","field":"links","label":"HGNC HGNC:1712"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17133","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/","field":"links","label":"HGNC HGNC:17133"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17194","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ndufa13","kind":"target","name":"NDUFA13","route":"/targets/ndufa13/","field":"links","label":"HGNC HGNC:17194"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:172","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr1b","kind":"target","name":"ACVR1B","route":"/targets/acvr1b/","field":"links","label":"HGNC HGNC:172"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17271","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/","field":"links","label":"HGNC HGNC:17271"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17284","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pot1","kind":"target","name":"POT1","route":"/targets/pot1/","field":"links","label":"HGNC HGNC:17284"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17293","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/","field":"links","label":"HGNC HGNC:17293"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17296","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/","field":"links","label":"HGNC HGNC:17296"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:173","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr2a","kind":"target","name":"ACVR2A","route":"/targets/acvr2a/","field":"links","label":"HGNC HGNC:173"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1735","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc37","kind":"target","name":"CDC37","route":"/targets/cdc37/","field":"links","label":"HGNC HGNC:1735"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17352","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apobec3b","kind":"target","name":"APOBEC3B","route":"/targets/apobec3b/","field":"links","label":"HGNC HGNC:17352"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17362","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid5b","kind":"target","name":"ARID5B","route":"/targets/arid5b/","field":"links","label":"HGNC HGNC:17362"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17379","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apbb1ip","kind":"target","name":"APBB1IP","route":"/targets/apbb1ip/","field":"links","label":"HGNC HGNC:17379"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17382","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srgap1","kind":"target","name":"SRGAP1","route":"/targets/srgap1/","field":"links","label":"HGNC HGNC:17382"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17468","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdlim5","kind":"target","name":"PDLIM5","route":"/targets/pdlim5/","field":"links","label":"HGNC HGNC:17468"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1748","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/","field":"links","label":"HGNC HGNC:1748"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1749","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh10","kind":"target","name":"CDH10","route":"/targets/cdh10/","field":"links","label":"HGNC HGNC:1749"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1750","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh11","kind":"target","name":"CDH11","route":"/targets/cdh11/","field":"links","label":"HGNC HGNC:1750"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17575","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","field":"links","label":"HGNC HGNC:17575"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17579","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stard3","kind":"target","name":"STARD3","route":"/targets/stard3/","field":"links","label":"HGNC HGNC:17579"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17582","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat6b","kind":"target","name":"KAT6B","route":"/targets/kat6b/","field":"links","label":"HGNC HGNC:17582"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17641","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","field":"links","label":"HGNC HGNC:17641"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17643","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gopc","kind":"target","name":"GOPC","route":"/targets/gopc/","field":"links","label":"HGNC HGNC:17643"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1771","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/","field":"links","label":"HGNC HGNC:1771"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1774","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk5","kind":"target","name":"CDK5","route":"/targets/cdk5/","field":"links","label":"HGNC HGNC:1774"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17792","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vti1a","kind":"target","name":"VTI1A","route":"/targets/vti1a/","field":"links","label":"HGNC HGNC:17792"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1780","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/","field":"links","label":"HGNC HGNC:1780"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nt5c3a","kind":"target","name":"NT5C3A","route":"/targets/nt5c3a/","field":"links","label":"HGNC HGNC:17820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1784","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn1a","kind":"target","name":"CDKN1A","route":"/targets/cdkn1a/","field":"links","label":"HGNC HGNC:1784"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1785","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","field":"links","label":"HGNC HGNC:1785"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17869","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff4","kind":"target","name":"AFF4","route":"/targets/aff4/","field":"links","label":"HGNC HGNC:17869"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"links","label":"HGNC HGNC:1787"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","field":"links","label":"HGNC HGNC:1788"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1789","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2c","kind":"target","name":"CDKN2C","route":"/targets/cdkn2c/","field":"links","label":"HGNC HGNC:1789"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17904","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/","field":"links","label":"HGNC HGNC:17904"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17909","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp16","kind":"target","name":"DUSP16","route":"/targets/dusp16/","field":"links","label":"HGNC HGNC:17909"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17985","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"robo4","kind":"target","name":"ROBO4","route":"/targets/robo4/","field":"links","label":"HGNC HGNC:17985"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18037","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/","field":"links","label":"HGNC HGNC:18037"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18040","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/","field":"links","label":"HGNC HGNC:18040"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18056","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taf1l","kind":"target","name":"TAF1L","route":"/targets/taf1l/","field":"links","label":"HGNC HGNC:18056"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1806","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdx2","kind":"target","name":"CDX2","route":"/targets/cdx2/","field":"links","label":"HGNC HGNC:1806"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18071","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/","field":"links","label":"HGNC HGNC:18071"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18072","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rabl3","kind":"target","name":"RABL3","route":"/targets/rabl3/","field":"links","label":"HGNC HGNC:18072"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18081","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wif1","kind":"target","name":"WIF1","route":"/targets/wif1/","field":"links","label":"HGNC HGNC:18081"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18118","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rsf1","kind":"target","name":"RSF1","route":"/targets/rsf1/","field":"links","label":"HGNC HGNC:18118"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18122","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox17","kind":"target","name":"SOX17","route":"/targets/sox17/","field":"links","label":"HGNC HGNC:18122"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18126","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znrf3","kind":"target","name":"ZNRF3","route":"/targets/znrf3/","field":"links","label":"HGNC HGNC:18126"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18128","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/","field":"links","label":"HGNC HGNC:18128"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1814","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ceacam1","kind":"target","name":"CEACAM1","route":"/targets/ceacam1/","field":"links","label":"HGNC HGNC:1814"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18145","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phf6","kind":"target","name":"PHF6","route":"/targets/phf6/","field":"links","label":"HGNC HGNC:18145"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18153","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/","field":"links","label":"HGNC HGNC:18153"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18185","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"errfi1","kind":"target","name":"ERRFI1","route":"/targets/errfi1/","field":"links","label":"HGNC HGNC:18185"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18222","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbfox1","kind":"target","name":"RBFOX1","route":"/targets/rbfox1/","field":"links","label":"HGNC HGNC:18222"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18274","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","field":"links","label":"HGNC HGNC:18274"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18282","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbk","kind":"target","name":"PBK","route":"/targets/pbk/","field":"links","label":"HGNC HGNC:18282"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18318","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asxl1","kind":"target","name":"ASXL1","route":"/targets/asxl1/","field":"links","label":"HGNC HGNC:18318"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1833","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cebpa","kind":"target","name":"CEBPA","route":"/targets/cebpa/","field":"links","label":"HGNC HGNC:1833"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18410","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf292","kind":"target","name":"ZNF292","route":"/targets/znf292/","field":"links","label":"HGNC HGNC:18410"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18420","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/","field":"links","label":"HGNC HGNC:18420"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18448","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neil1","kind":"target","name":"NEIL1","route":"/targets/neil1/","field":"links","label":"HGNC HGNC:18448"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18486","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdzd2","kind":"target","name":"PDZD2","route":"/targets/pdzd2/","field":"links","label":"HGNC HGNC:18486"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18505","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"links","label":"HGNC HGNC:18505"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18507","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcrl4","kind":"target","name":"FCRL4","route":"/targets/fcrl4/","field":"links","label":"HGNC HGNC:18507"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18508","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/","field":"links","label":"HGNC HGNC:18508"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18513","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhx2","kind":"target","name":"ZHX2","route":"/targets/zhx2/","field":"links","label":"HGNC HGNC:18513"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18562","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fev","kind":"target","name":"FEV","route":"/targets/fev/","field":"links","label":"HGNC HGNC:18562"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1858","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cntrl","kind":"target","name":"CNTRL","route":"/targets/cntrl/","field":"links","label":"HGNC HGNC:1858"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/","field":"links","label":"HGNC HGNC:18585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18590","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pnpla3","kind":"target","name":"PNPLA3","route":"/targets/pnpla3/","field":"links","label":"HGNC HGNC:18590"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18592","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nek10","kind":"target","name":"NEK10","route":"/targets/nek10/","field":"links","label":"HGNC HGNC:18592"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:186","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ada","kind":"target","name":"Adenosine deaminase (ADA)","route":"/targets/ada/","field":"links","label":"HGNC:186 ADA"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18610","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ksr2","kind":"target","name":"KSR2","route":"/targets/ksr2/","field":"links","label":"HGNC HGNC:18610"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18653","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhl6","kind":"target","name":"KLHL6","route":"/targets/klhl6/","field":"links","label":"HGNC HGNC:18653"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18668","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb7b","kind":"target","name":"ZBTB7B","route":"/targets/zbtb7b/","field":"links","label":"HGNC HGNC:18668"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18674","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx41","kind":"target","name":"DDX41","route":"/targets/ddx41/","field":"links","label":"HGNC HGNC:18674"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18677","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx43","kind":"target","name":"DDX43","route":"/targets/ddx43/","field":"links","label":"HGNC HGNC:18677"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18731","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/","field":"links","label":"HGNC HGNC:18731"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18737","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf395","kind":"target","name":"ZNF395","route":"/targets/znf395/","field":"links","label":"HGNC HGNC:18737"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18755","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole4","kind":"target","name":"POLE4","route":"/targets/pole4/","field":"links","label":"HGNC HGNC:18755"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18756","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhobtb2","kind":"target","name":"RHOBTB2","route":"/targets/rhobtb2/","field":"links","label":"HGNC HGNC:18756"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1876","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cflar","kind":"target","name":"CFLAR","route":"/targets/cflar/","field":"links","label":"HGNC HGNC:1876"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18782","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc6","kind":"target","name":"CCDC6","route":"/targets/ccdc6/","field":"links","label":"HGNC HGNC:18782"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18806","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"camta1","kind":"target","name":"CAMTA1","route":"/targets/camta1/","field":"links","label":"HGNC HGNC:18806"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18809","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/","field":"links","label":"HGNC HGNC:18809"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18856","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb3l1","kind":"target","name":"CREB3L1","route":"/targets/creb3l1/","field":"links","label":"HGNC HGNC:18856"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18863","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh7","kind":"target","name":"KCNH7","route":"/targets/kcnh7/","field":"links","label":"HGNC HGNC:18863"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18864","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh8","kind":"target","name":"KCNH8","route":"/targets/kcnh8/","field":"links","label":"HGNC HGNC:18864"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18988","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tox","kind":"target","name":"TOX","route":"/targets/tox/","field":"links","label":"HGNC HGNC:18988"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19086","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/","field":"links","label":"HGNC HGNC:19086"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19090","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ebf2","kind":"target","name":"EBF2","route":"/targets/ebf2/","field":"links","label":"HGNC HGNC:19090"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19117","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgd5","kind":"target","name":"FGD5","route":"/targets/fgd5/","field":"links","label":"HGNC HGNC:19117"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19124","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fip1l1","kind":"target","name":"FIP1L1","route":"/targets/fip1l1/","field":"links","label":"HGNC HGNC:19124"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1917","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd2","kind":"target","name":"CHD2","route":"/targets/chd2/","field":"links","label":"HGNC HGNC:1917"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1919","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd4","kind":"target","name":"CHD4","route":"/targets/chd4/","field":"links","label":"HGNC HGNC:1919"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19191","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dock8","kind":"target","name":"DOCK8","route":"/targets/dock8/","field":"links","label":"HGNC HGNC:19191"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1925","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/","field":"links","label":"HGNC HGNC:1925"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19291","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csmd3","kind":"target","name":"CSMD3","route":"/targets/csmd3/","field":"links","label":"HGNC HGNC:19291"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19296","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha6","kind":"target","name":"EPHA6","route":"/targets/epha6/","field":"links","label":"HGNC HGNC:19296"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19309","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kank1","kind":"target","name":"KANK1","route":"/targets/kank1/","field":"links","label":"HGNC HGNC:19309"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19353","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sin3a","kind":"target","name":"SIN3A","route":"/targets/sin3a/","field":"links","label":"HGNC HGNC:19353"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19383","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/","field":"links","label":"HGNC HGNC:19383"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19437","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnb1ip1","kind":"target","name":"CCNB1IP1","route":"/targets/ccnb1ip1/","field":"links","label":"HGNC HGNC:19437"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19440","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sbds","kind":"target","name":"SBDS","route":"/targets/sbds/","field":"links","label":"HGNC HGNC:19440"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1957","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna3","kind":"target","name":"CHRNA3","route":"/targets/chrna3/","field":"links","label":"HGNC HGNC:1957"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1958","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna4","kind":"target","name":"CHRNA4","route":"/targets/chrna4/","field":"links","label":"HGNC HGNC:1958"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1959","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna5","kind":"target","name":"CHRNA5","route":"/targets/chrna5/","field":"links","label":"HGNC HGNC:1959"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnksr1","kind":"target","name":"CNKSR1","route":"/targets/cnksr1/","field":"links","label":"HGNC HGNC:19700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19701","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnksr2","kind":"target","name":"CNKSR2","route":"/targets/cnksr2/","field":"links","label":"HGNC HGNC:19701"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19721","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cant1","kind":"target","name":"CANT1","route":"/targets/cant1/","field":"links","label":"HGNC HGNC:19721"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19744","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srgap3","kind":"target","name":"SRGAP3","route":"/targets/srgap3/","field":"links","label":"HGNC HGNC:19744"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19835","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mdga2","kind":"target","name":"MDGA2","route":"/targets/mdga2/","field":"links","label":"HGNC HGNC:19835"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19902","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rragc","kind":"target","name":"RRAGC","route":"/targets/rragc/","field":"links","label":"HGNC HGNC:19902"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19967","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc88c","kind":"target","name":"CCDC88C","route":"/targets/ccdc88c/","field":"links","label":"HGNC HGNC:19967"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19974","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhpn2","kind":"target","name":"RHPN2","route":"/targets/rhpn2/","field":"links","label":"HGNC HGNC:19974"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19987","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha10","kind":"target","name":"EPHA10","route":"/targets/epha10/","field":"links","label":"HGNC HGNC:19987"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2001","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grem1","kind":"target","name":"GREM1","route":"/targets/grem1/","field":"links","label":"HGNC HGNC:2001"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20090","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajc1","kind":"target","name":"DNAJC1","route":"/targets/dnajc1/","field":"links","label":"HGNC HGNC:20090"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20092","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atf7ip","kind":"target","name":"ATF7IP","route":"/targets/atf7ip/","field":"links","label":"HGNC HGNC:20092"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20153","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd8","kind":"target","name":"CHD8","route":"/targets/chd8/","field":"links","label":"HGNC HGNC:20153"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2024","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clcn6","kind":"target","name":"CLCN6","route":"/targets/clcn6/","field":"links","label":"HGNC HGNC:2024"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20250","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ajuba","kind":"target","name":"AJUBA","route":"/targets/ajuba/","field":"links","label":"HGNC HGNC:20250"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20320","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pspc1","kind":"target","name":"PSPC1","route":"/targets/pspc1/","field":"links","label":"HGNC HGNC:20320"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20456","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"traf7","kind":"target","name":"TRAF7","route":"/targets/traf7/","field":"links","label":"HGNC HGNC:20456"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20473","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/","field":"links","label":"HGNC HGNC:20473"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20503","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3c14","kind":"target","name":"H3C14","route":"/targets/h3c14/","field":"links","label":"HGNC HGNC:20503"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20604","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/","field":"links","label":"HGNC HGNC:20604"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20609","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aimp2","kind":"target","name":"AIMP2","route":"/targets/aimp2/","field":"links","label":"HGNC HGNC:20609"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20611","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc24a5","kind":"target","name":"SLC24A5","route":"/targets/slc24a5/","field":"links","label":"HGNC HGNC:20611"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20626","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd7","kind":"target","name":"CHD7","route":"/targets/chd7/","field":"links","label":"HGNC HGNC:20626"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20692","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tph2","kind":"target","name":"TPH2","route":"/targets/tph2/","field":"links","label":"HGNC HGNC:20692"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:207","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adam29","kind":"target","name":"ADAM29","route":"/targets/adam29/","field":"links","label":"HGNC HGNC:207"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20748","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancl","kind":"target","name":"FANCL","route":"/targets/fancl/","field":"links","label":"HGNC HGNC:20748"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20765","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/","field":"links","label":"HGNC HGNC:20765"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20766","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/","field":"links","label":"HGNC HGNC:20766"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/","field":"links","label":"HGNC HGNC:20768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20771","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/","field":"links","label":"HGNC HGNC:20771"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20772","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/","field":"links","label":"HGNC HGNC:20772"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20773","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/","field":"links","label":"HGNC HGNC:20773"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20774","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/","field":"links","label":"HGNC HGNC:20774"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/","field":"links","label":"HGNC HGNC:20776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20796","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rassf6","kind":"target","name":"RASSF6","route":"/targets/rassf6/","field":"links","label":"HGNC HGNC:20796"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20817","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf429","kind":"target","name":"ZNF429","route":"/targets/znf429/","field":"links","label":"HGNC HGNC:20817"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpcn2","kind":"target","name":"TPCN2","route":"/targets/tpcn2/","field":"links","label":"HGNC HGNC:20820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20842","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp4","kind":"target","name":"FOXP4","route":"/targets/foxp4/","field":"links","label":"HGNC HGNC:20842"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20866","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","field":"links","label":"HGNC HGNC:20866"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20893","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcor","kind":"target","name":"BCOR","route":"/targets/bcor/","field":"links","label":"HGNC HGNC:20893"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20917","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpk1","kind":"target","name":"ALPK1","route":"/targets/alpk1/","field":"links","label":"HGNC HGNC:20917"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2092","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cltc","kind":"target","name":"CLTC","route":"/targets/cltc/","field":"links","label":"HGNC HGNC:2092"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2093","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cltcl1","kind":"target","name":"CLTCL1","route":"/targets/cltcl1/","field":"links","label":"HGNC HGNC:2093"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20932","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/","field":"links","label":"HGNC HGNC:20932"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21024","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul7","kind":"target","name":"CUL7","route":"/targets/cul7/","field":"links","label":"HGNC HGNC:21024"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21050","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkal1","kind":"target","name":"CDKAL1","route":"/targets/cdkal1/","field":"links","label":"HGNC HGNC:21050"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21087","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/","field":"links","label":"HGNC HGNC:21087"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21100","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qki","kind":"target","name":"QKI","route":"/targets/qki/","field":"links","label":"HGNC HGNC:21100"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21177","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc170","kind":"target","name":"CCDC170","route":"/targets/ccdc170/","field":"links","label":"HGNC HGNC:21177"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21226","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrfn2","kind":"target","name":"LRFN2","route":"/targets/lrfn2/","field":"links","label":"HGNC HGNC:21226"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21316","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ankrd11","kind":"target","name":"ANKRD11","route":"/targets/ankrd11/","field":"links","label":"HGNC HGNC:21316"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2159","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","field":"links","label":"HGNC:2159 CNR1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21616","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tns3","kind":"target","name":"TNS3","route":"/targets/tns3/","field":"links","label":"HGNC HGNC:21616"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21684","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf462","kind":"target","name":"ZNF462","route":"/targets/znf462/","field":"links","label":"HGNC HGNC:21684"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21686","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnaset2","kind":"target","name":"RNASET2","route":"/targets/rnaset2/","field":"links","label":"HGNC HGNC:21686"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21746","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpeb3","kind":"target","name":"CPEB3","route":"/targets/cpeb3/","field":"links","label":"HGNC HGNC:21746"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21869","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agk","kind":"target","name":"AGK","route":"/targets/agk/","field":"links","label":"HGNC HGNC:21869"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2197","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/","field":"links","label":"HGNC HGNC:2197"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2200","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col2a1","kind":"target","name":"COL2A1","route":"/targets/col2a1/","field":"links","label":"HGNC HGNC:2200"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2213","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col6a3","kind":"target","name":"COL6A3","route":"/targets/col6a3/","field":"links","label":"HGNC HGNC:2213"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22202","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam131b","kind":"target","name":"FAM131B","route":"/targets/fam131b/","field":"links","label":"HGNC HGNC:22202"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22219","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kiaa1549","kind":"target","name":"KIAA1549","route":"/targets/kiaa1549/","field":"links","label":"HGNC HGNC:22219"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22224","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm7a","kind":"target","name":"KDM7A","route":"/targets/kdm7a/","field":"links","label":"HGNC HGNC:22224"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2235","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf6","kind":"target","name":"KLF6","route":"/targets/klf6/","field":"links","label":"HGNC HGNC:2235"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22946","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galnt14","kind":"target","name":"GALNT14","route":"/targets/galnt14/","field":"links","label":"HGNC HGNC:22946"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22950","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/","field":"links","label":"HGNC HGNC:22950"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22964","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thrap3","kind":"target","name":"THRAP3","route":"/targets/thrap3/","field":"links","label":"HGNC HGNC:22964"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:22985","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/","field":"links","label":"HGNC HGNC:22985"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23019","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zrsr2","kind":"target","name":"ZRSR2","route":"/targets/zrsr2/","field":"links","label":"HGNC HGNC:23019"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23035","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"l3mbtl3","kind":"target","name":"L3MBTL3","route":"/targets/l3mbtl3/","field":"links","label":"HGNC HGNC:23035"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23063","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nudt15","kind":"target","name":"NUDT15","route":"/targets/nudt15/","field":"links","label":"HGNC HGNC:23063"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23098","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr1op2","kind":"target","name":"FGFR1OP2","route":"/targets/fgfr1op2/","field":"links","label":"HGNC HGNC:23098"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23109","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat4","kind":"target","name":"FAT4","route":"/targets/fat4/","field":"links","label":"HGNC HGNC:23109"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23112","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat3","kind":"target","name":"FAT3","route":"/targets/fat3/","field":"links","label":"HGNC HGNC:23112"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23114","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/","field":"links","label":"HGNC HGNC:23114"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23156","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"u2af2","kind":"target","name":"U2AF2","route":"/targets/u2af2/","field":"links","label":"HGNC HGNC:23156"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23168","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/","field":"links","label":"HGNC HGNC:23168"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23177","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","field":"links","label":"HGNC HGNC:23177"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23301","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbld","kind":"target","name":"PBLD","route":"/targets/pbld/","field":"links","label":"HGNC HGNC:23301"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23445","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm2b","kind":"target","name":"NUTM2B","route":"/targets/nutm2b/","field":"links","label":"HGNC HGNC:23445"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23447","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm2d","kind":"target","name":"NUTM2D","route":"/targets/nutm2d/","field":"links","label":"HGNC HGNC:23447"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2345","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb1","kind":"target","name":"CREB1","route":"/targets/creb1/","field":"links","label":"HGNC HGNC:2345"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/","field":"links","label":"HGNC HGNC:2348"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23530","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"HGNC HGNC:23530"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23576","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hook3","kind":"target","name":"HOOK3","route":"/targets/hook3/","field":"links","label":"HGNC HGNC:23576"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2363","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crkl","kind":"target","name":"CRKL","route":"/targets/crkl/","field":"links","label":"HGNC HGNC:2363"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23688","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl9l","kind":"target","name":"BCL9L","route":"/targets/bcl9l/","field":"links","label":"HGNC HGNC:23688"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23692","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/","field":"links","label":"HGNC HGNC:23692"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23694","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpr161","kind":"target","name":"GPR161","route":"/targets/gpr161/","field":"links","label":"HGNC HGNC:23694"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23719","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pgap3","kind":"target","name":"PGAP3","route":"/targets/pgap3/","field":"links","label":"HGNC HGNC:23719"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2372","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"med23","kind":"target","name":"MED23","route":"/targets/med23/","field":"links","label":"HGNC HGNC:2372"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23720","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb3l2","kind":"target","name":"CREB3L2","route":"/targets/creb3l2/","field":"links","label":"HGNC HGNC:23720"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23721","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zc3hav1","kind":"target","name":"ZC3HAV1","route":"/targets/zc3hav1/","field":"links","label":"HGNC HGNC:23721"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23805","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asxl2","kind":"target","name":"ASXL2","route":"/targets/asxl2/","field":"links","label":"HGNC HGNC:23805"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"e2f7","kind":"target","name":"E2F7","route":"/targets/e2f7/","field":"links","label":"HGNC HGNC:23820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23845","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slx4","kind":"target","name":"SLX4","route":"/targets/slx4/","field":"links","label":"HGNC HGNC:23845"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24042","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/","field":"links","label":"HGNC HGNC:24042"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24054","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"knl1","kind":"target","name":"KNL1","route":"/targets/knl1/","field":"links","label":"HGNC HGNC:24054"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24080","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aph1b","kind":"target","name":"APH1B","route":"/targets/aph1b/","field":"links","label":"HGNC HGNC:24080"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24086","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"a1cf","kind":"target","name":"A1CF","route":"/targets/a1cf/","field":"links","label":"HGNC HGNC:24086"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24092","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mageh1","kind":"target","name":"MAGEH1","route":"/targets/mageh1/","field":"links","label":"HGNC HGNC:24092"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24124","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/","field":"links","label":"HGNC HGNC:24124"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24166","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lratd2","kind":"target","name":"LRATD2","route":"/targets/lratd2/","field":"links","label":"HGNC HGNC:24166"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","field":"links","label":"HGNC HGNC:24224"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24236","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccar1","kind":"target","name":"CCAR1","route":"/targets/ccar1/","field":"links","label":"HGNC HGNC:24236"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24308","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clptm1l","kind":"target","name":"CLPTM1L","route":"/targets/clptm1l/","field":"links","label":"HGNC HGNC:24308"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2432","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/","field":"links","label":"HGNC HGNC:2432"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2435","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","field":"links","label":"HGNC:2435 CSF2RA"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2436","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf2rb","kind":"target","name":"CSF2RB","route":"/targets/csf2rb/","field":"links","label":"HGNC HGNC:2436"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2444","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csk","kind":"target","name":"CSK","route":"/targets/csk/","field":"links","label":"HGNC HGNC:2444"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24489","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lsm14a","kind":"target","name":"LSM14A","route":"/targets/lsm14a/","field":"links","label":"HGNC HGNC:24489"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2451","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/","field":"links","label":"HGNC HGNC:2451"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2453","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csnk1e","kind":"target","name":"CSNK1E","route":"/targets/csnk1e/","field":"links","label":"HGNC HGNC:2453"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24605","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/","field":"links","label":"HGNC HGNC:24605"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24649","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etnk1","kind":"target","name":"ETNK1","route":"/targets/etnk1/","field":"links","label":"HGNC HGNC:24649"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2466","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cspg4","kind":"target","name":"CSPG4","route":"/targets/cspg4/","field":"links","label":"HGNC HGNC:2466"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24670","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fndc3b","kind":"target","name":"FNDC3B","route":"/targets/fndc3b/","field":"links","label":"HGNC HGNC:24670"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24678","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fto","kind":"target","name":"FTO","route":"/targets/fto/","field":"links","label":"HGNC HGNC:24678"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24684","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aggf1","kind":"target","name":"AGGF1","route":"/targets/aggf1/","field":"links","label":"HGNC HGNC:24684"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24712","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/","field":"links","label":"HGNC HGNC:24712"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2491","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/","field":"links","label":"HGNC HGNC:2491"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2492","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","field":"links","label":"HGNC HGNC:2492"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24928","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/","field":"links","label":"HGNC HGNC:24928"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24948","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/","field":"links","label":"HGNC HGNC:24948"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24969","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nprl2","kind":"target","name":"NPRL2","route":"/targets/nprl2/","field":"links","label":"HGNC HGNC:24969"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:250","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adh1b","kind":"target","name":"ADH1B","route":"/targets/adh1b/","field":"links","label":"HGNC HGNC:250"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2500","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccn2","kind":"target","name":"CCN2","route":"/targets/ccn2/","field":"links","label":"HGNC HGNC:2500"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2509","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/","field":"links","label":"HGNC HGNC:2509"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2510","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnna2","kind":"target","name":"CTNNA2","route":"/targets/ctnna2/","field":"links","label":"HGNC HGNC:2510"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25126","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naf1","kind":"target","name":"NAF1","route":"/targets/naf1/","field":"links","label":"HGNC HGNC:25126"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2514","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"links","label":"HGNC HGNC:2514"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2516","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/","field":"links","label":"HGNC HGNC:2516"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25209","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/","field":"links","label":"HGNC HGNC:25209"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25265","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zcchc8","kind":"target","name":"ZCCHC8","route":"/targets/zcchc8/","field":"links","label":"HGNC HGNC:25265"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2535","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctsh","kind":"target","name":"CTSH","route":"/targets/ctsh/","field":"links","label":"HGNC HGNC:2535"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25391","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrk","kind":"target","name":"NRK","route":"/targets/nrk/","field":"links","label":"HGNC HGNC:25391"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2545","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctss","kind":"target","name":"CTSS","route":"/targets/ctss/","field":"links","label":"HGNC HGNC:2545"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2550","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"celf2","kind":"target","name":"CELF2","route":"/targets/celf2/","field":"links","label":"HGNC HGNC:2550"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2551","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul1","kind":"target","name":"CUL1","route":"/targets/cul1/","field":"links","label":"HGNC HGNC:2551"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25522","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wrap53","kind":"target","name":"WRAP53","route":"/targets/wrap53/","field":"links","label":"HGNC HGNC:25522"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2553","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul3","kind":"target","name":"CUL3","route":"/targets/cul3/","field":"links","label":"HGNC HGNC:2553"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25539","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rfwd3","kind":"target","name":"RFWD3","route":"/targets/rfwd3/","field":"links","label":"HGNC HGNC:25539"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2554","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/","field":"links","label":"HGNC HGNC:2554"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25540","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef10l","kind":"target","name":"ARHGEF10L","route":"/targets/arhgef10l/","field":"links","label":"HGNC HGNC:25540"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25568","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fanci","kind":"target","name":"FANCI","route":"/targets/fanci/","field":"links","label":"HGNC HGNC:25568"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2557","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cux1","kind":"target","name":"CUX1","route":"/targets/cux1/","field":"links","label":"HGNC HGNC:2557"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25608","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vps53","kind":"target","name":"VPS53","route":"/targets/vps53/","field":"links","label":"HGNC HGNC:25608"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25621","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acoxl","kind":"target","name":"ACOXL","route":"/targets/acoxl/","field":"links","label":"HGNC HGNC:25621"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25635","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/","field":"links","label":"HGNC HGNC:25635"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25657","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/","field":"links","label":"HGNC HGNC:25657"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2568","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mamld1","kind":"target","name":"MAMLD1","route":"/targets/mamld1/","field":"links","label":"HGNC HGNC:2568"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25764","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rmi1","kind":"target","name":"RMI1","route":"/targets/rmi1/","field":"links","label":"HGNC HGNC:25764"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25777","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rfx7","kind":"target","name":"RFX7","route":"/targets/rfx7/","field":"links","label":"HGNC HGNC:25777"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25812","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a3","kind":"target","name":"SRD5A3","route":"/targets/srd5a3/","field":"links","label":"HGNC HGNC:25812"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2584","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/","field":"links","label":"HGNC HGNC:2584"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25843","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf750","kind":"target","name":"ZNF750","route":"/targets/znf750/","field":"links","label":"HGNC HGNC:25843"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25883","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf703","kind":"target","name":"ZNF703","route":"/targets/znf703/","field":"links","label":"HGNC HGNC:25883"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2590","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","field":"links","label":"HGNC:2590 CYP11A1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25907","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cep89","kind":"target","name":"CEP89","route":"/targets/cep89/","field":"links","label":"HGNC HGNC:25907"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2591","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp11b1","kind":"target","name":"CYP11B1","route":"/targets/cyp11b1/","field":"links","label":"HGNC HGNC:2591"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25941","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tet2","kind":"target","name":"TET2","route":"/targets/tet2/","field":"links","label":"HGNC HGNC:25941"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25966","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esrp1","kind":"target","name":"ESRP1","route":"/targets/esrp1/","field":"links","label":"HGNC HGNC:25966"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25967","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sidt1","kind":"target","name":"SIDT1","route":"/targets/sidt1/","field":"links","label":"HGNC HGNC:25967"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2597","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp1b1","kind":"target","name":"CYP1B1","route":"/targets/cyp1b1/","field":"links","label":"HGNC HGNC:2597"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26002","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casz1","kind":"target","name":"CASZ1","route":"/targets/casz1/","field":"links","label":"HGNC HGNC:26002"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26010","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spdl1","kind":"target","name":"SPDL1","route":"/targets/spdl1/","field":"links","label":"HGNC HGNC:26010"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26034","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/","field":"links","label":"HGNC HGNC:26034"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26038","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem127","kind":"target","name":"TMEM127","route":"/targets/tmem127/","field":"links","label":"HGNC HGNC:26038"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26091","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyw2","kind":"target","name":"TYW2","route":"/targets/tyw2/","field":"links","label":"HGNC HGNC:26091"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26144","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"links","label":"HGNC HGNC:26144"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26148","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crtc3","kind":"target","name":"CRTC3","route":"/targets/crtc3/","field":"links","label":"HGNC HGNC:26148"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26157","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wdcp","kind":"target","name":"WDCP","route":"/targets/wdcp/","field":"links","label":"HGNC HGNC:26157"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26200","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stn1","kind":"target","name":"STN1","route":"/targets/stn1/","field":"links","label":"HGNC HGNC:26200"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2622","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp2c8","kind":"target","name":"CYP2C8","route":"/targets/cyp2c8/","field":"links","label":"HGNC HGNC:2622"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2625","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp2d6","kind":"target","name":"CYP2D6","route":"/targets/cyp2d6/","field":"links","label":"HGNC HGNC:2625"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26265","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nol9","kind":"target","name":"NOL9","route":"/targets/nol9/","field":"links","label":"HGNC HGNC:26265"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:263","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","route":"/targets/adora2a/","field":"links","label":"HGNC HGNC:263"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26359","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pxdnl","kind":"target","name":"PXDNL","route":"/targets/pxdnl/","field":"links","label":"HGNC HGNC:26359"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26428","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"faap20","kind":"target","name":"FAAP20","route":"/targets/faap20/","field":"links","label":"HGNC HGNC:26428"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26623","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem17","kind":"target","name":"TMEM17","route":"/targets/tmem17/","field":"links","label":"HGNC HGNC:26623"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26633","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","field":"links","label":"HGNC HGNC:26633"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2681","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daxx","kind":"target","name":"DAXX","route":"/targets/daxx/","field":"links","label":"HGNC HGNC:2681"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2683","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dazap1","kind":"target","name":"DAZAP1","route":"/targets/dazap1/","field":"links","label":"HGNC HGNC:2683"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26837","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","field":"links","label":"HGNC HGNC:26837"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26897","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf680","kind":"target","name":"ZNF680","route":"/targets/znf680/","field":"links","label":"HGNC HGNC:26897"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dclk1","kind":"target","name":"DCLK1","route":"/targets/dclk1/","field":"links","label":"HGNC HGNC:2700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2701","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcc","kind":"target","name":"DCC","route":"/targets/dcc/","field":"links","label":"HGNC HGNC:2701"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:27023","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col6a6","kind":"target","name":"COL6A6","route":"/targets/col6a6/","field":"links","label":"HGNC HGNC:27023"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:271","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/","field":"links","label":"HGNC HGNC:271"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2711","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dctn1","kind":"target","name":"DCTN1","route":"/targets/dctn1/","field":"links","label":"HGNC HGNC:2711"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2717","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/","field":"links","label":"HGNC HGNC:2717"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2718","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddb2","kind":"target","name":"DDB2","route":"/targets/ddb2/","field":"links","label":"HGNC HGNC:2718"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:272","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/","field":"links","label":"HGNC HGNC:272"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2726","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddit3","kind":"target","name":"DDIT3","route":"/targets/ddit3/","field":"links","label":"HGNC HGNC:2726"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:273","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/","field":"links","label":"HGNC HGNC:273"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2731","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","field":"links","label":"HGNC:2731 DDR2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:27310","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flcn","kind":"target","name":"FLCN","route":"/targets/flcn/","field":"links","label":"HGNC HGNC:27310"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2735","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx10","kind":"target","name":"DDX10","route":"/targets/ddx10/","field":"links","label":"HGNC HGNC:2735"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2745","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx3x","kind":"target","name":"DDX3X","route":"/targets/ddx3x/","field":"links","label":"HGNC HGNC:2745"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2746","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx5","kind":"target","name":"DDX5","route":"/targets/ddx5/","field":"links","label":"HGNC HGNC:2746"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2747","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx6","kind":"target","name":"DDX6","route":"/targets/ddx6/","field":"links","label":"HGNC HGNC:2747"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2750","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/","field":"links","label":"HGNC HGNC:2750"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:27603","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf780a","kind":"target","name":"ZNF780A","route":"/targets/znf780a/","field":"links","label":"HGNC HGNC:27603"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2761","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"defa1","kind":"target","name":"DEFA1","route":"/targets/defa1/","field":"links","label":"HGNC HGNC:2761"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dek","kind":"target","name":"DEK","route":"/targets/dek/","field":"links","label":"HGNC HGNC:2768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:277","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1a","kind":"target","name":"ADRA1A","route":"/targets/adra1a/","field":"links","label":"HGNC HGNC:277"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:278","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1b","kind":"target","name":"ADRA1B","route":"/targets/adra1b/","field":"links","label":"HGNC HGNC:278"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2799","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grhl2","kind":"target","name":"GRHL2","route":"/targets/grhl2/","field":"links","label":"HGNC HGNC:2799"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:280","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1d","kind":"target","name":"ADRA1D","route":"/targets/adra1d/","field":"links","label":"HGNC HGNC:280"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28029","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam135b","kind":"target","name":"FAM135B","route":"/targets/fam135b/","field":"links","label":"HGNC HGNC:28029"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:281","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2a","kind":"target","name":"ADRA2A","route":"/targets/adra2a/","field":"links","label":"HGNC HGNC:281"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:282","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2b","kind":"target","name":"ADRA2B","route":"/targets/adra2b/","field":"links","label":"HGNC HGNC:282"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28230","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mien1","kind":"target","name":"MIEN1","route":"/targets/mien1/","field":"links","label":"HGNC HGNC:28230"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28240","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hvcn1","kind":"target","name":"HVCN1","route":"/targets/hvcn1/","field":"links","label":"HGNC HGNC:28240"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:283","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2c","kind":"target","name":"ADRA2C","route":"/targets/adra2c/","field":"links","label":"HGNC HGNC:283"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28314","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chchd7","kind":"target","name":"CHCHD7","route":"/targets/chchd7/","field":"links","label":"HGNC HGNC:28314"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28349","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rmi2","kind":"target","name":"RMI2","route":"/targets/rmi2/","field":"links","label":"HGNC HGNC:28349"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2847","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dgcr8","kind":"target","name":"DGCR8","route":"/targets/dgcr8/","field":"links","label":"HGNC HGNC:2847"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28496","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"poglut3","kind":"target","name":"POGLUT3","route":"/targets/poglut3/","field":"links","label":"HGNC HGNC:28496"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28519","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/","field":"links","label":"HGNC HGNC:28519"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28557","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhdc8b","kind":"target","name":"KLHDC8B","route":"/targets/klhdc8b/","field":"links","label":"HGNC HGNC:28557"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28583","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rspo2","kind":"target","name":"RSPO2","route":"/targets/rspo2/","field":"links","label":"HGNC HGNC:28583"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28611","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/","field":"links","label":"HGNC HGNC:28611"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2874","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nqo1","kind":"target","name":"NQO1","route":"/targets/nqo1/","field":"links","label":"HGNC HGNC:2874"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28862","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nipbl","kind":"target","name":"NIPBL","route":"/targets/nipbl/","field":"links","label":"HGNC HGNC:28862"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28873","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/","field":"links","label":"HGNC HGNC:28873"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28908","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajc12","kind":"target","name":"DNAJC12","route":"/targets/dnajc12/","field":"links","label":"HGNC HGNC:28908"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2891","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dkk1","kind":"target","name":"DKK1","route":"/targets/dkk1/","field":"links","label":"HGNC HGNC:2891"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28917","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jazf1","kind":"target","name":"JAZF1","route":"/targets/jazf1/","field":"links","label":"HGNC HGNC:28917"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2897","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dlc1","kind":"target","name":"DLC1","route":"/targets/dlc1/","field":"links","label":"HGNC HGNC:2897"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2908","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dll1","kind":"target","name":"DLL1","route":"/targets/dll1/","field":"links","label":"HGNC HGNC:2908"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2910","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/","field":"links","label":"HGNC HGNC:2910"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2911","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dlst","kind":"target","name":"DLST","route":"/targets/dlst/","field":"links","label":"HGNC HGNC:2911"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29144","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ehbp1","kind":"target","name":"EHBP1","route":"/targets/ehbp1/","field":"links","label":"HGNC HGNC:29144"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29149","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phlpp2","kind":"target","name":"PHLPP2","route":"/targets/phlpp2/","field":"links","label":"HGNC HGNC:29149"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29187","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/","field":"links","label":"HGNC HGNC:29187"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29266","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhl14","kind":"target","name":"KLHL14","route":"/targets/klhl14/","field":"links","label":"HGNC HGNC:29266"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29302","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cip2a","kind":"target","name":"CIP2A","route":"/targets/cip2a/","field":"links","label":"HGNC HGNC:29302"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29319","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shtn1","kind":"target","name":"SHTN1","route":"/targets/shtn1/","field":"links","label":"HGNC HGNC:29319"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2939","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dna2","kind":"target","name":"DNA2","route":"/targets/dna2/","field":"links","label":"HGNC HGNC:2939"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29401","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mysm1","kind":"target","name":"MYSM1","route":"/targets/mysm1/","field":"links","label":"HGNC HGNC:29401"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29406","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pwwp2a","kind":"target","name":"PWWP2A","route":"/targets/pwwp2a/","field":"links","label":"HGNC HGNC:29406"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2942","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnah11","kind":"target","name":"DNAH11","route":"/targets/dnah11/","field":"links","label":"HGNC HGNC:2942"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29425","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf721","kind":"target","name":"ZNF721","route":"/targets/znf721/","field":"links","label":"HGNC HGNC:29425"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29484","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/","field":"links","label":"HGNC HGNC:29484"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29489","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt5a","kind":"target","name":"KMT5A","route":"/targets/kmt5a/","field":"links","label":"HGNC HGNC:29489"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29509","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aph1a","kind":"target","name":"APH1A","route":"/targets/aph1a/","field":"links","label":"HGNC HGNC:29509"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29529","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbl1xr1","kind":"target","name":"TBL1XR1","route":"/targets/tbl1xr1/","field":"links","label":"HGNC HGNC:29529"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29605","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sh2b3","kind":"target","name":"SH2B3","route":"/targets/sh2b3/","field":"links","label":"HGNC HGNC:29605"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29619","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mpeg1","kind":"target","name":"MPEG1","route":"/targets/mpeg1/","field":"links","label":"HGNC HGNC:29619"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29620","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zcrb1","kind":"target","name":"ZCRB1","route":"/targets/zcrb1/","field":"links","label":"HGNC HGNC:29620"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29643","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlph","kind":"target","name":"MLPH","route":"/targets/mlph/","field":"links","label":"HGNC HGNC:29643"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2974","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnm2","kind":"target","name":"DNM2","route":"/targets/dnm2/","field":"links","label":"HGNC HGNC:2974"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2978","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","field":"links","label":"HGNC:2978 DNMT3A"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2979","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnmt3b","kind":"target","name":"DNMT3B","route":"/targets/dnmt3b/","field":"links","label":"HGNC HGNC:2979"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29805","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbiz","kind":"target","name":"NFKBIZ","route":"/targets/nfkbiz/","field":"links","label":"HGNC HGNC:29805"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29814","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/","field":"links","label":"HGNC HGNC:29814"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29849","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cadm2","kind":"target","name":"CADM2","route":"/targets/cadm2/","field":"links","label":"HGNC HGNC:29849"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29851","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"n4bp2","kind":"target","name":"N4BP2","route":"/targets/n4bp2/","field":"links","label":"HGNC HGNC:29851"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29861","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrdl1","kind":"target","name":"CHRDL1","route":"/targets/chrdl1/","field":"links","label":"HGNC HGNC:29861"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29862","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg4","kind":"target","name":"NRG4","route":"/targets/nrg4/","field":"links","label":"HGNC HGNC:29862"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29919","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/","field":"links","label":"HGNC HGNC:29919"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29947","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trak1","kind":"target","name":"TRAK1","route":"/targets/trak1/","field":"links","label":"HGNC HGNC:29947"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30035","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r5","kind":"target","name":"PIK3R5","route":"/targets/pik3r5/","field":"links","label":"HGNC HGNC:30035"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30064","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/","field":"links","label":"HGNC HGNC:30064"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30073","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/","field":"links","label":"HGNC HGNC:30073"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30100","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psenen","kind":"target","name":"PSENEN","route":"/targets/psenen/","field":"links","label":"HGNC HGNC:30100"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3012","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dpyd","kind":"target","name":"DPYD","route":"/targets/dpyd/","field":"links","label":"HGNC HGNC:3012"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30215","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"macc1","kind":"target","name":"MACC1","route":"/targets/macc1/","field":"links","label":"HGNC HGNC:30215"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3023","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","field":"links","label":"HGNC:3023 DRD2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3026","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drd5","kind":"target","name":"DRD5","route":"/targets/drd5/","field":"links","label":"HGNC HGNC:3026"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30297","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rcc2","kind":"target","name":"RCC2","route":"/targets/rcc2/","field":"links","label":"HGNC HGNC:30297"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:303","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aebp1","kind":"target","name":"AEBP1","route":"/targets/aebp1/","field":"links","label":"HGNC HGNC:303"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30321","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mprip","kind":"target","name":"MPRIP","route":"/targets/mprip/","field":"links","label":"HGNC HGNC:30321"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30346","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrn3","kind":"target","name":"RRN3","route":"/targets/rrn3/","field":"links","label":"HGNC HGNC:30346"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30438","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mb21d2","kind":"target","name":"MB21D2","route":"/targets/mb21d2/","field":"links","label":"HGNC HGNC:30438"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30450","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naprt","kind":"target","name":"NAPRT","route":"/targets/naprt/","field":"links","label":"HGNC HGNC:30450"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30461","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf626","kind":"target","name":"ZNF626","route":"/targets/znf626/","field":"links","label":"HGNC HGNC:30461"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30469","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxr2","kind":"target","name":"FOXR2","route":"/targets/foxr2/","field":"links","label":"HGNC HGNC:30469"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30483","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcmtd1","kind":"target","name":"PCMTD1","route":"/targets/pcmtd1/","field":"links","label":"HGNC HGNC:30483"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3052","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dsp","kind":"target","name":"DSP","route":"/targets/dsp/","field":"links","label":"HGNC HGNC:3052"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30542","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snx29","kind":"target","name":"SNX29","route":"/targets/snx29/","field":"links","label":"HGNC HGNC:30542"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30577","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mib2","kind":"target","name":"MIB2","route":"/targets/mib2/","field":"links","label":"HGNC HGNC:30577"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3059","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hbegf","kind":"target","name":"HBEGF","route":"/targets/hbegf/","field":"links","label":"HGNC HGNC:3059"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30599","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chmp4c","kind":"target","name":"CHMP4C","route":"/targets/chmp4c/","field":"links","label":"HGNC HGNC:30599"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3060","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dtx1","kind":"target","name":"DTX1","route":"/targets/dtx1/","field":"links","label":"HGNC HGNC:3060"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30600","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubxn11","kind":"target","name":"UBXN11","route":"/targets/ubxn11/","field":"links","label":"HGNC HGNC:30600"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30646","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/","field":"links","label":"HGNC HGNC:30646"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30667","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"susd2","kind":"target","name":"SUSD2","route":"/targets/susd2/","field":"links","label":"HGNC HGNC:30667"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3068","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp2","kind":"target","name":"DUSP2","route":"/targets/dusp2/","field":"links","label":"HGNC HGNC:3068"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3072","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp6","kind":"target","name":"DUSP6","route":"/targets/dusp6/","field":"links","label":"HGNC HGNC:3072"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30767","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"knstrn","kind":"target","name":"KNSTRN","route":"/targets/knstrn/","field":"links","label":"HGNC HGNC:30767"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30829","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/","field":"links","label":"HGNC HGNC:30829"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30858","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/","field":"links","label":"HGNC HGNC:30858"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30939","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfhx4","kind":"target","name":"ZFHX4","route":"/targets/zfhx4/","field":"links","label":"HGNC HGNC:30939"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30953","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb10","kind":"target","name":"ZBTB10","route":"/targets/zbtb10/","field":"links","label":"HGNC HGNC:30953"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30988","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bnc2","kind":"target","name":"BNC2","route":"/targets/bnc2/","field":"links","label":"HGNC HGNC:30988"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30991","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrig3","kind":"target","name":"LRIG3","route":"/targets/lrig3/","field":"links","label":"HGNC HGNC:30991"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:31104","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myo18a","kind":"target","name":"MYO18A","route":"/targets/myo18a/","field":"links","label":"HGNC HGNC:31104"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3126","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ebf1","kind":"target","name":"EBF1","route":"/targets/ebf1/","field":"links","label":"HGNC HGNC:3126"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3148","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tymp","kind":"target","name":"TYMP","route":"/targets/tymp/","field":"links","label":"HGNC HGNC:3148"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:31586","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mir21","kind":"target","name":"MIR21","route":"/targets/mir21/","field":"links","label":"HGNC HGNC:31586"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:31595","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mir218-1","kind":"target","name":"MIR218-1","route":"/targets/mir218-1/","field":"links","label":"HGNC HGNC:31595"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3165","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s1pr1","kind":"target","name":"S1PR1","route":"/targets/s1pr1/","field":"links","label":"HGNC HGNC:3165"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:31677","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ano7","kind":"target","name":"ANO7","route":"/targets/ano7/","field":"links","label":"HGNC HGNC:31677"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3169","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s1pr2","kind":"target","name":"S1PR2","route":"/targets/s1pr2/","field":"links","label":"HGNC HGNC:3169"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3179","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ednra","kind":"target","name":"EDNRA","route":"/targets/ednra/","field":"links","label":"HGNC HGNC:3179"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3188","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/","field":"links","label":"HGNC HGNC:3188"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:31963","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/","field":"links","label":"HGNC HGNC:31963"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3214","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","field":"links","label":"HGNC:3214 EEF2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32190","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","field":"links","label":"HGNC HGNC:32190"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3229","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","field":"links","label":"HGNC HGNC:3229"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3239","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"egr2","kind":"target","name":"EGR2","route":"/targets/egr2/","field":"links","label":"HGNC HGNC:3239"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32416","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgpd3","kind":"target","name":"RGPD3","route":"/targets/rgpd3/","field":"links","label":"HGNC HGNC:32416"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3250","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","field":"links","label":"HGNC HGNC:3250"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3255","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif2ak3","kind":"target","name":"EIF2AK3","route":"/targets/eif2ak3/","field":"links","label":"HGNC HGNC:3255"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3277","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/","field":"links","label":"HGNC HGNC:3277"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:328","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agr2","kind":"target","name":"AGR2","route":"/targets/agr2/","field":"links","label":"HGNC HGNC:328"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3282","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4a1","kind":"target","name":"EIF4A1","route":"/targets/eif4a1/","field":"links","label":"HGNC HGNC:3282"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3284","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4a2","kind":"target","name":"EIF4A2","route":"/targets/eif4a2/","field":"links","label":"HGNC HGNC:3284"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3288","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4ebp1","kind":"target","name":"EIF4EBP1","route":"/targets/eif4ebp1/","field":"links","label":"HGNC HGNC:3288"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:32950","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcaf12l2","kind":"target","name":"DCAF12L2","route":"/targets/dcaf12l2/","field":"links","label":"HGNC HGNC:32950"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3318","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","field":"links","label":"HGNC HGNC:3318"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3319","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elf4","kind":"target","name":"ELF4","route":"/targets/elf4/","field":"links","label":"HGNC HGNC:3319"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33258","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf814","kind":"target","name":"ZNF814","route":"/targets/znf814/","field":"links","label":"HGNC HGNC:33258"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3326","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elk4","kind":"target","name":"ELK4","route":"/targets/elk4/","field":"links","label":"HGNC HGNC:3326"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3327","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eln","kind":"target","name":"ELN","route":"/targets/eln/","field":"links","label":"HGNC HGNC:3327"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33279","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atxn1l","kind":"target","name":"ATXN1L","route":"/targets/atxn1l/","field":"links","label":"HGNC HGNC:33279"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3332","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mark2","kind":"target","name":"MARK2","route":"/targets/mark2/","field":"links","label":"HGNC HGNC:3332"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3363","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/","field":"links","label":"HGNC HGNC:3363"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3372","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eomes","kind":"target","name":"EOMES","route":"/targets/eomes/","field":"links","label":"HGNC HGNC:3372"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3373","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/","field":"links","label":"HGNC HGNC:3373"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3385","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha1","kind":"target","name":"EPHA1","route":"/targets/epha1/","field":"links","label":"HGNC HGNC:3385"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3386","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","field":"links","label":"HGNC:3386 EPHA2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3387","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha3","kind":"target","name":"EPHA3","route":"/targets/epha3/","field":"links","label":"HGNC HGNC:3387"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3388","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha4","kind":"target","name":"EPHA4","route":"/targets/epha4/","field":"links","label":"HGNC HGNC:3388"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3389","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha5","kind":"target","name":"EPHA5","route":"/targets/epha5/","field":"links","label":"HGNC HGNC:3389"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3390","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha7","kind":"target","name":"EPHA7","route":"/targets/epha7/","field":"links","label":"HGNC HGNC:3390"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3391","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha8","kind":"target","name":"EPHA8","route":"/targets/epha8/","field":"links","label":"HGNC HGNC:3391"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3392","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb1","kind":"target","name":"EPHB1","route":"/targets/ephb1/","field":"links","label":"HGNC HGNC:3392"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3393","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb2","kind":"target","name":"EPHB2","route":"/targets/ephb2/","field":"links","label":"HGNC HGNC:3393"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3394","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb3","kind":"target","name":"EPHB3","route":"/targets/ephb3/","field":"links","label":"HGNC HGNC:3394"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3395","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb4","kind":"target","name":"EPHB4","route":"/targets/ephb4/","field":"links","label":"HGNC HGNC:3395"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3419","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eps15","kind":"target","name":"EPS15","route":"/targets/eps15/","field":"links","label":"HGNC HGNC:3419"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3433","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/","field":"links","label":"HGNC HGNC:3433"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:34339","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam174b","kind":"target","name":"FAM174B","route":"/targets/fam174b/","field":"links","label":"HGNC HGNC:34339"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3434","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/","field":"links","label":"HGNC HGNC:3434"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3435","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/","field":"links","label":"HGNC HGNC:3435"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3436","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc4","kind":"target","name":"ERCC4","route":"/targets/ercc4/","field":"links","label":"HGNC HGNC:3436"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3437","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/","field":"links","label":"HGNC HGNC:3437"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3438","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc6","kind":"target","name":"ERCC6","route":"/targets/ercc6/","field":"links","label":"HGNC HGNC:3438"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3443","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ereg","kind":"target","name":"EREG","route":"/targets/ereg/","field":"links","label":"HGNC HGNC:3443"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3446","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","field":"links","label":"HGNC HGNC:3446"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3468","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esr2","kind":"target","name":"ESR2","route":"/targets/esr2/","field":"links","label":"HGNC HGNC:3468"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3471","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esrra","kind":"target","name":"ESRRA","route":"/targets/esrra/","field":"links","label":"HGNC HGNC:3471"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3488","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ets1","kind":"target","name":"ETS1","route":"/targets/ets1/","field":"links","label":"HGNC HGNC:3488"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3489","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ets2","kind":"target","name":"ETS2","route":"/targets/ets2/","field":"links","label":"HGNC HGNC:3489"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3490","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","field":"links","label":"HGNC HGNC:3490"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3493","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/","field":"links","label":"HGNC HGNC:3493"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3494","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv5","kind":"target","name":"ETV5","route":"/targets/etv5/","field":"links","label":"HGNC HGNC:3494"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3495","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv6","kind":"target","name":"ETV6","route":"/targets/etv6/","field":"links","label":"HGNC HGNC:3495"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3498","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/","field":"links","label":"HGNC HGNC:3498"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3511","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"exo1","kind":"target","name":"EXO1","route":"/targets/exo1/","field":"links","label":"HGNC HGNC:3511"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3512","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/","field":"links","label":"HGNC HGNC:3512"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3513","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/","field":"links","label":"HGNC HGNC:3513"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:35454","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ecscr","kind":"target","name":"ECSCR","route":"/targets/ecscr/","field":"links","label":"HGNC HGNC:35454"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3570","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsl3","kind":"target","name":"ACSL3","route":"/targets/acsl3/","field":"links","label":"HGNC HGNC:3570"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3582","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/","field":"links","label":"HGNC HGNC:3582"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3583","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancb","kind":"target","name":"FANCB","route":"/targets/fancb/","field":"links","label":"HGNC HGNC:3583"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3584","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/","field":"links","label":"HGNC HGNC:3584"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/","field":"links","label":"HGNC HGNC:3585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3586","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fance","kind":"target","name":"FANCE","route":"/targets/fance/","field":"links","label":"HGNC HGNC:3586"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3587","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancf","kind":"target","name":"FANCF","route":"/targets/fancf/","field":"links","label":"HGNC HGNC:3587"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3588","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancg","kind":"target","name":"FANCG","route":"/targets/fancg/","field":"links","label":"HGNC HGNC:3588"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3595","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/","field":"links","label":"HGNC HGNC:3595"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3596","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat2","kind":"target","name":"FAT2","route":"/targets/fat2/","field":"links","label":"HGNC HGNC:3596"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3601","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/","field":"links","label":"HGNC HGNC:3601"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3604","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/","field":"links","label":"HGNC HGNC:3604"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3616","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/","field":"links","label":"HGNC HGNC:3616"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3618","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/","field":"links","label":"HGNC HGNC:3618"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3619","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/","field":"links","label":"HGNC HGNC:3619"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3631","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/","field":"links","label":"HGNC HGNC:3631"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3657","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/","field":"links","label":"HGNC HGNC:3657"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3661","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fga","kind":"target","name":"FGA","route":"/targets/fga/","field":"links","label":"HGNC HGNC:3661"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3662","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgb","kind":"target","name":"FGB","route":"/targets/fgb/","field":"links","label":"HGNC HGNC:3662"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3663","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgd1","kind":"target","name":"FGD1","route":"/targets/fgd1/","field":"links","label":"HGNC HGNC:3663"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3665","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf1","kind":"target","name":"FGF1","route":"/targets/fgf1/","field":"links","label":"HGNC HGNC:3665"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3666","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf10","kind":"target","name":"FGF10","route":"/targets/fgf10/","field":"links","label":"HGNC HGNC:3666"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3670","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf13","kind":"target","name":"FGF13","route":"/targets/fgf13/","field":"links","label":"HGNC HGNC:3670"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3672","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf16","kind":"target","name":"FGF16","route":"/targets/fgf16/","field":"links","label":"HGNC HGNC:3672"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3673","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf17","kind":"target","name":"FGF17","route":"/targets/fgf17/","field":"links","label":"HGNC HGNC:3673"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3674","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf18","kind":"target","name":"FGF18","route":"/targets/fgf18/","field":"links","label":"HGNC HGNC:3674"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3675","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/","field":"links","label":"HGNC HGNC:3675"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3676","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf2","kind":"target","name":"FGF2","route":"/targets/fgf2/","field":"links","label":"HGNC HGNC:3676"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3677","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf20","kind":"target","name":"FGF20","route":"/targets/fgf20/","field":"links","label":"HGNC HGNC:3677"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3679","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf22","kind":"target","name":"FGF22","route":"/targets/fgf22/","field":"links","label":"HGNC HGNC:3679"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3680","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf23","kind":"target","name":"FGF23","route":"/targets/fgf23/","field":"links","label":"HGNC HGNC:3680"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3681","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf3","kind":"target","name":"FGF3","route":"/targets/fgf3/","field":"links","label":"HGNC HGNC:3681"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3682","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf4","kind":"target","name":"FGF4","route":"/targets/fgf4/","field":"links","label":"HGNC HGNC:3682"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3683","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf5","kind":"target","name":"FGF5","route":"/targets/fgf5/","field":"links","label":"HGNC HGNC:3683"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3684","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf6","kind":"target","name":"FGF6","route":"/targets/fgf6/","field":"links","label":"HGNC HGNC:3684"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3685","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf7","kind":"target","name":"FGF7","route":"/targets/fgf7/","field":"links","label":"HGNC HGNC:3685"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3686","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf8","kind":"target","name":"FGF8","route":"/targets/fgf8/","field":"links","label":"HGNC HGNC:3686"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3687","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf9","kind":"target","name":"FGF9","route":"/targets/fgf9/","field":"links","label":"HGNC HGNC:3687"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3691","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/","field":"links","label":"HGNC HGNC:3691"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3694","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgg","kind":"target","name":"FGG","route":"/targets/fgg/","field":"links","label":"HGNC HGNC:3694"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3695","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgl1","kind":"target","name":"FGL1","route":"/targets/fgl1/","field":"links","label":"HGNC HGNC:3695"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3697","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgr","kind":"target","name":"FGR","route":"/targets/fgr/","field":"links","label":"HGNC HGNC:3697"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fh","kind":"target","name":"FH","route":"/targets/fh/","field":"links","label":"HGNC HGNC:3700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3701","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/","field":"links","label":"HGNC HGNC:3701"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3711","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","field":"links","label":"HGNC:3711 FKBP1A"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:37212","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klln","kind":"target","name":"KLLN","route":"/targets/klln/","field":"links","label":"HGNC HGNC:37212"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3748","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flg","kind":"target","name":"FLG","route":"/targets/flg/","field":"links","label":"HGNC HGNC:3748"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3766","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flt3lg","kind":"target","name":"FLT3LG","route":"/targets/flt3lg/","field":"links","label":"HGNC HGNC:3766"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fmn1","kind":"target","name":"FMN1","route":"/targets/fmn1/","field":"links","label":"HGNC HGNC:3768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3778","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/","field":"links","label":"HGNC HGNC:3778"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3785","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/","field":"links","label":"HGNC HGNC:3785"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:379","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"akap9","kind":"target","name":"AKAP9","route":"/targets/akap9/","field":"links","label":"HGNC HGNC:379"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3796","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fos","kind":"target","name":"FOS","route":"/targets/fos/","field":"links","label":"HGNC HGNC:3796"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3797","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fosb","kind":"target","name":"FOSB","route":"/targets/fosb/","field":"links","label":"HGNC HGNC:3797"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3801","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxc2","kind":"target","name":"FOXC2","route":"/targets/foxc2/","field":"links","label":"HGNC HGNC:3801"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3806","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxe1","kind":"target","name":"FOXE1","route":"/targets/foxe1/","field":"links","label":"HGNC HGNC:3806"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3809","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxf1","kind":"target","name":"FOXF1","route":"/targets/foxf1/","field":"links","label":"HGNC HGNC:3809"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3819","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/","field":"links","label":"HGNC HGNC:3819"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3821","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo3","kind":"target","name":"FOXO3","route":"/targets/foxo3/","field":"links","label":"HGNC HGNC:3821"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3823","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/","field":"links","label":"HGNC HGNC:3823"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:38877","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim49c","kind":"target","name":"TRIM49C","route":"/targets/trim49c/","field":"links","label":"HGNC HGNC:38877"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3955","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","field":"links","label":"HGNC:3955 FRK"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:40","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/","field":"links","label":"HGNC HGNC:40"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:400","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alcam","kind":"target","name":"ALCAM","route":"/targets/alcam/","field":"links","label":"HGNC HGNC:400"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4004","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fubp1","kind":"target","name":"FUBP1","route":"/targets/fubp1/","field":"links","label":"HGNC HGNC:4004"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4010","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fus","kind":"target","name":"FUS","route":"/targets/fus/","field":"links","label":"HGNC HGNC:4010"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4023","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fxr1","kind":"target","name":"FXR1","route":"/targets/fxr1/","field":"links","label":"HGNC HGNC:4023"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4037","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/","field":"links","label":"HGNC HGNC:4037"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:404","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aldh2","kind":"target","name":"ALDH2","route":"/targets/aldh2/","field":"links","label":"HGNC HGNC:404"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4066","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gab1","kind":"target","name":"GAB1","route":"/targets/gab1/","field":"links","label":"HGNC HGNC:4066"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4088","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gabrg3","kind":"target","name":"GABRG3","route":"/targets/gabrg3/","field":"links","label":"HGNC HGNC:4088"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4095","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/","field":"links","label":"HGNC HGNC:4095"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4163","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","field":"links","label":"HGNC:4163 GART"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4168","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gas6","kind":"target","name":"GAS6","route":"/targets/gas6/","field":"links","label":"HGNC HGNC:4168"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4170","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata1","kind":"target","name":"GATA1","route":"/targets/gata1/","field":"links","label":"HGNC HGNC:4170"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4171","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/","field":"links","label":"HGNC HGNC:4171"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4172","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata3","kind":"target","name":"GATA3","route":"/targets/gata3/","field":"links","label":"HGNC HGNC:4172"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4201","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/","field":"links","label":"HGNC HGNC:4201"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4222","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gdf7","kind":"target","name":"GDF7","route":"/targets/gdf7/","field":"links","label":"HGNC HGNC:4222"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4267","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ghsr","kind":"target","name":"GHSR","route":"/targets/ghsr/","field":"links","label":"HGNC HGNC:4267"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4317","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gli1","kind":"target","name":"GLI1","route":"/targets/gli1/","field":"links","label":"HGNC HGNC:4317"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4378","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gmps","kind":"target","name":"GMPS","route":"/targets/gmps/","field":"links","label":"HGNC HGNC:4378"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4379","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","field":"links","label":"HGNC HGNC:4379"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4381","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gna13","kind":"target","name":"GNA13","route":"/targets/gna13/","field":"links","label":"HGNC HGNC:4381"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4385","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnai2","kind":"target","name":"GNAI2","route":"/targets/gnai2/","field":"links","label":"HGNC HGNC:4385"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4390","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","field":"links","label":"HGNC HGNC:4390"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4392","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","field":"links","label":"HGNC HGNC:4392"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4396","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnb1","kind":"target","name":"GNB1","route":"/targets/gnb1/","field":"links","label":"HGNC HGNC:4396"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4427","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golga4","kind":"target","name":"GOLGA4","route":"/targets/golga4/","field":"links","label":"HGNC HGNC:4427"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4428","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golga5","kind":"target","name":"GOLGA5","route":"/targets/golga5/","field":"links","label":"HGNC HGNC:4428"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4429","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golgb1","kind":"target","name":"GOLGB1","route":"/targets/golgb1/","field":"links","label":"HGNC HGNC:4429"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:44356","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem238l","kind":"target","name":"TMEM238L","route":"/targets/tmem238l/","field":"links","label":"HGNC HGNC:44356"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4446","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpaa1","kind":"target","name":"GPAA1","route":"/targets/gpaa1/","field":"links","label":"HGNC HGNC:4446"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4453","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/","field":"links","label":"HGNC HGNC:4453"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4504","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","field":"links","label":"HGNC HGNC:4504"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4566","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grb2","kind":"target","name":"GRB2","route":"/targets/grb2/","field":"links","label":"HGNC HGNC:4566"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4567","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grb7","kind":"target","name":"GRB7","route":"/targets/grb7/","field":"links","label":"HGNC HGNC:4567"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4570","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grhpr","kind":"target","name":"GRHPR","route":"/targets/grhpr/","field":"links","label":"HGNC HGNC:4570"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grin2a","kind":"target","name":"GRIN2A","route":"/targets/grin2a/","field":"links","label":"HGNC HGNC:4585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4591","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/","field":"links","label":"HGNC HGNC:4591"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4595","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grm3","kind":"target","name":"GRM3","route":"/targets/grm3/","field":"links","label":"HGNC HGNC:4595"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4617","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsk3b","kind":"target","name":"GSK3B","route":"/targets/gsk3b/","field":"links","label":"HGNC HGNC:4617"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4623","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","field":"links","label":"HGNC:4623 GSR"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4638","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/","field":"links","label":"HGNC HGNC:4638"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4659","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gtf2i","kind":"target","name":"GTF2I","route":"/targets/gtf2i/","field":"links","label":"HGNC HGNC:4659"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4716","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-2","kind":"target","name":"H1-2","route":"/targets/h1-2/","field":"links","label":"HGNC HGNC:4716"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4717","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-3","kind":"target","name":"H1-3","route":"/targets/h1-3/","field":"links","label":"HGNC HGNC:4717"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4719","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-5","kind":"target","name":"H1-5","route":"/targets/h1-5/","field":"links","label":"HGNC HGNC:4719"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4733","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2ac6","kind":"target","name":"H2AC6","route":"/targets/h2ac6/","field":"links","label":"HGNC HGNC:4733"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4735","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2ac17","kind":"target","name":"H2AC17","route":"/targets/h2ac17/","field":"links","label":"HGNC HGNC:4735"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4747","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2bc5","kind":"target","name":"H2BC5","route":"/targets/h2bc5/","field":"links","label":"HGNC HGNC:4747"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4764","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3-3a","kind":"target","name":"Histone H3.3 (H3-3A)","route":"/targets/h3-3a/","field":"links","label":"HGNC HGNC:4764"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4765","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3-3b","kind":"target","name":"H3-3B","route":"/targets/h3-3b/","field":"links","label":"HGNC HGNC:4765"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4767","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3c4","kind":"target","name":"H3C4","route":"/targets/h3c4/","field":"links","label":"HGNC HGNC:4767"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3c2","kind":"target","name":"H3C2","route":"/targets/h3c2/","field":"links","label":"HGNC HGNC:4776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4793","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h4c9","kind":"target","name":"H4C9","route":"/targets/h4c9/","field":"links","label":"HGNC HGNC:4793"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4798","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"habp2","kind":"target","name":"HABP2","route":"/targets/habp2/","field":"links","label":"HGNC HGNC:4798"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4827","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hbb","kind":"target","name":"HBB","route":"/targets/hbb/","field":"links","label":"HGNC HGNC:4827"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:484","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"angpt1","kind":"target","name":"ANGPT1","route":"/targets/angpt1/","field":"links","label":"HGNC HGNC:484"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4840","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","field":"links","label":"HGNC:4840 HCK"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4880","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hey1","kind":"target","name":"HEY1","route":"/targets/hey1/","field":"links","label":"HGNC HGNC:4880"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4893","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/","field":"links","label":"HGNC HGNC:4893"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:48942","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prncr1","kind":"target","name":"PRNCR1","route":"/targets/prncr1/","field":"links","label":"HGNC HGNC:48942"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4905","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hhla2","kind":"target","name":"HHLA2 (B7-H7)","route":"/targets/hhla2/","field":"links","label":"HGNC HGNC:4905"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4910","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hif1a","kind":"target","name":"HIF-1α (HIF1A)","route":"/targets/hif1a/","field":"links","label":"HGNC HGNC:4910"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4913","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hip1","kind":"target","name":"HIP1","route":"/targets/hip1/","field":"links","label":"HGNC HGNC:4913"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:492","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ank1","kind":"target","name":"ANK1","route":"/targets/ank1/","field":"links","label":"HGNC HGNC:492"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4930","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb48","kind":"target","name":"ZBTB48","route":"/targets/zbtb48/","field":"links","label":"HGNC HGNC:4930"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4931","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/","field":"links","label":"HGNC HGNC:4931"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4932","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/","field":"links","label":"HGNC HGNC:4932"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4933","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/","field":"links","label":"HGNC HGNC:4933"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4942","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-dqa1","kind":"target","name":"HLA-DQA1","route":"/targets/hla-dqa1/","field":"links","label":"HGNC HGNC:4942"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4947","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/","field":"links","label":"HGNC HGNC:4947"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4962","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-e","kind":"target","name":"HLA-E","route":"/targets/hla-e/","field":"links","label":"HGNC HGNC:4962"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4977","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlf","kind":"target","name":"HLF","route":"/targets/hlf/","field":"links","label":"HGNC HGNC:4977"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5006","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmgcr","kind":"target","name":"HMGCR","route":"/targets/hmgcr/","field":"links","label":"HGNC HGNC:5006"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5009","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmga2","kind":"target","name":"HMGA2","route":"/targets/hmga2/","field":"links","label":"HGNC HGNC:5009"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5010","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmga1","kind":"target","name":"HMGA1","route":"/targets/hmga1/","field":"links","label":"HGNC HGNC:5010"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5013","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmox1","kind":"target","name":"HMOX1","route":"/targets/hmox1/","field":"links","label":"HGNC HGNC:5013"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5021","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","field":"links","label":"HGNC HGNC:5021"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5022","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxa2","kind":"target","name":"FOXA2","route":"/targets/foxa2/","field":"links","label":"HGNC HGNC:5022"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5026","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf4g","kind":"target","name":"HNF4G","route":"/targets/hnf4g/","field":"links","label":"HGNC HGNC:5026"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5033","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnpa2b1","kind":"target","name":"HNRNPA2B1","route":"/targets/hnrnpa2b1/","field":"links","label":"HGNC HGNC:5033"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5041","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnph1","kind":"target","name":"HNRNPH1","route":"/targets/hnrnph1/","field":"links","label":"HGNC HGNC:5041"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5048","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnpu","kind":"target","name":"HNRNPU","route":"/targets/hnrnpu/","field":"links","label":"HGNC HGNC:5048"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5056","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlx1","kind":"target","name":"TLX1","route":"/targets/tlx1/","field":"links","label":"HGNC HGNC:5056"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:51","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc1","kind":"target","name":"ABCC1","route":"/targets/abcc1/","field":"links","label":"HGNC HGNC:51"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5101","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa11","kind":"target","name":"HOXA11","route":"/targets/hoxa11/","field":"links","label":"HGNC HGNC:5101"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5102","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa13","kind":"target","name":"HOXA13","route":"/targets/hoxa13/","field":"links","label":"HGNC HGNC:5102"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5109","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa9","kind":"target","name":"HOXA9","route":"/targets/hoxa9/","field":"links","label":"HGNC HGNC:5109"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5112","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxb13","kind":"target","name":"HOXB13","route":"/targets/hoxb13/","field":"links","label":"HGNC HGNC:5112"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5122","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc10","kind":"target","name":"HOXC10","route":"/targets/hoxc10/","field":"links","label":"HGNC HGNC:5122"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5123","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc11","kind":"target","name":"HOXC11","route":"/targets/hoxc11/","field":"links","label":"HGNC HGNC:5123"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5125","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc13","kind":"target","name":"HOXC13","route":"/targets/hoxc13/","field":"links","label":"HGNC HGNC:5125"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5134","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd11","kind":"target","name":"HOXD11","route":"/targets/hoxd11/","field":"links","label":"HGNC HGNC:5134"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5136","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd13","kind":"target","name":"HOXD13","route":"/targets/hoxd13/","field":"links","label":"HGNC HGNC:5136"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5139","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd8","kind":"target","name":"HOXD8","route":"/targets/hoxd8/","field":"links","label":"HGNC HGNC:5139"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/","field":"links","label":"HGNC HGNC:5173"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:52","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc10","kind":"target","name":"ABCC10","route":"/targets/abcc10/","field":"links","label":"HGNC HGNC:52"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5238","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspa5","kind":"target","name":"HSPA5","route":"/targets/hspa5/","field":"links","label":"HGNC HGNC:5238"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5246","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspb1","kind":"target","name":"HSPB1","route":"/targets/hspb1/","field":"links","label":"HGNC HGNC:5246"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5253","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","field":"links","label":"HGNC HGNC:5253"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5258","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90ab1","kind":"target","name":"HSP90AB1","route":"/targets/hsp90ab1/","field":"links","label":"HGNC HGNC:5258"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5270","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajb1","kind":"target","name":"DNAJB1","route":"/targets/dnajb1/","field":"links","label":"HGNC HGNC:5270"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5273","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspg2","kind":"target","name":"HSPG2","route":"/targets/hspg2/","field":"links","label":"HGNC HGNC:5273"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5275","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat5","kind":"target","name":"KAT5","route":"/targets/kat5/","field":"links","label":"HGNC HGNC:5275"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5318","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/","field":"links","label":"HGNC HGNC:5318"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5351","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"icos","kind":"target","name":"ICOS","route":"/targets/icos/","field":"links","label":"HGNC HGNC:5351"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5358","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf8","kind":"target","name":"IRF8","route":"/targets/irf8/","field":"links","label":"HGNC HGNC:5358"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5362","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"id3","kind":"target","name":"ID3","route":"/targets/id3/","field":"links","label":"HGNC HGNC:5362"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:54","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc3","kind":"target","name":"ABCC3","route":"/targets/abcc3/","field":"links","label":"HGNC HGNC:54"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5423","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifna2","kind":"target","name":"IFNA2","route":"/targets/ifna2/","field":"links","label":"HGNC HGNC:5423"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5433","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/","field":"links","label":"HGNC HGNC:5433"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5439","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifngr1","kind":"target","name":"IFNGR1","route":"/targets/ifngr1/","field":"links","label":"HGNC HGNC:5439"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5465","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","field":"links","label":"HGNC:5465 IGF1R"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5466","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/","field":"links","label":"HGNC HGNC:5466"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5467","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf2r","kind":"target","name":"IGF2R","route":"/targets/igf2r/","field":"links","label":"HGNC HGNC:5467"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:55","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc4","kind":"target","name":"ABCC4","route":"/targets/abcc4/","field":"links","label":"HGNC HGNC:55"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:55727","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stag2-as1","kind":"target","name":"STAG2-AS1","route":"/targets/stag2-as1/","field":"links","label":"HGNC HGNC:55727"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:566","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ap3b1","kind":"target","name":"AP3B1","route":"/targets/ap3b1/","field":"links","label":"HGNC HGNC:566"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5724","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbpj","kind":"target","name":"RBPJ","route":"/targets/rbpj/","field":"links","label":"HGNC HGNC:5724"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:583","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"links","label":"HGNC HGNC:583"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:588","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atg12","kind":"target","name":"ATG12","route":"/targets/atg12/","field":"links","label":"HGNC HGNC:588"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:591","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/","field":"links","label":"HGNC HGNC:591"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:593","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/","field":"links","label":"HGNC HGNC:593"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5959","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elp1","kind":"target","name":"ELP1","route":"/targets/elp1/","field":"links","label":"HGNC HGNC:5959"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5960","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/","field":"links","label":"HGNC HGNC:5960"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5962","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","field":"links","label":"HGNC HGNC:5962"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5967","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","field":"links","label":"HGNC:5967 IL11RA"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6009","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/","field":"links","label":"HGNC HGNC:6009"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6010","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/","field":"links","label":"HGNC HGNC:6010"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6015","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il4r","kind":"target","name":"IL4R","route":"/targets/il4r/","field":"links","label":"HGNC HGNC:6015"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6021","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il6st","kind":"target","name":"IL6ST","route":"/targets/il6st/","field":"links","label":"HGNC HGNC:6021"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6024","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il7r","kind":"target","name":"IL7R","route":"/targets/il7r/","field":"links","label":"HGNC HGNC:6024"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6052","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impdh1","kind":"target","name":"IMPDH1","route":"/targets/impdh1/","field":"links","label":"HGNC HGNC:6052"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6053","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","field":"links","label":"HGNC:6053 IMPDH2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6058","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"incenp","kind":"target","name":"INCENP","route":"/targets/incenp/","field":"links","label":"HGNC HGNC:6058"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6059","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/","field":"links","label":"HGNC HGNC:6059"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6062","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ing1","kind":"target","name":"ING1","route":"/targets/ing1/","field":"links","label":"HGNC HGNC:6062"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6067","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inhbb","kind":"target","name":"INHBB","route":"/targets/inhbb/","field":"links","label":"HGNC HGNC:6067"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6080","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inppl1","kind":"target","name":"INPPL1","route":"/targets/inppl1/","field":"links","label":"HGNC HGNC:6080"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6106","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp3","kind":"target","name":"FOXP3","route":"/targets/foxp3/","field":"links","label":"HGNC HGNC:6106"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6110","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iqgap1","kind":"target","name":"IQGAP1","route":"/targets/iqgap1/","field":"links","label":"HGNC HGNC:6110"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6112","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/","field":"links","label":"HGNC HGNC:6112"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6116","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/","field":"links","label":"HGNC HGNC:6116"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6119","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/","field":"links","label":"HGNC HGNC:6119"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6120","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf5","kind":"target","name":"IRF5","route":"/targets/irf5/","field":"links","label":"HGNC HGNC:6120"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6125","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs1","kind":"target","name":"IRS1","route":"/targets/irs1/","field":"links","label":"HGNC HGNC:6125"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6126","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs2","kind":"target","name":"IRS2","route":"/targets/irs2/","field":"links","label":"HGNC HGNC:6126"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6128","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs4","kind":"target","name":"IRS4","route":"/targets/irs4/","field":"links","label":"HGNC HGNC:6128"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6129","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irx4","kind":"target","name":"IRX4","route":"/targets/irx4/","field":"links","label":"HGNC HGNC:6129"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:613","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apoe","kind":"target","name":"APOE","route":"/targets/apoe/","field":"links","label":"HGNC HGNC:613"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6138","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itga2b","kind":"target","name":"ITGA2B","route":"/targets/itga2b/","field":"links","label":"HGNC HGNC:6138"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6142","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itga6","kind":"target","name":"ITGA6","route":"/targets/itga6/","field":"links","label":"HGNC HGNC:6142"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6150","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itgav","kind":"target","name":"ITGAV","route":"/targets/itgav/","field":"links","label":"HGNC HGNC:6150"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6156","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itgb3","kind":"target","name":"ITGB3","route":"/targets/itgb3/","field":"links","label":"HGNC HGNC:6156"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6171","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/","field":"links","label":"HGNC HGNC:6171"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6179","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itpkb","kind":"target","name":"ITPKB","route":"/targets/itpkb/","field":"links","label":"HGNC HGNC:6179"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6180","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itpr1","kind":"target","name":"ITPR1","route":"/targets/itpr1/","field":"links","label":"HGNC HGNC:6180"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6188","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jag1","kind":"target","name":"JAG1","route":"/targets/jag1/","field":"links","label":"HGNC HGNC:6188"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6189","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jag2","kind":"target","name":"JAG2","route":"/targets/jag2/","field":"links","label":"HGNC HGNC:6189"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6190","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/","field":"links","label":"HGNC HGNC:6190"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6193","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/","field":"links","label":"HGNC HGNC:6193"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6204","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jun","kind":"target","name":"JUN","route":"/targets/jun/","field":"links","label":"HGNC HGNC:6204"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6221","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcna3","kind":"target","name":"KCNA3","route":"/targets/kcna3/","field":"links","label":"HGNC HGNC:6221"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6222","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcna4","kind":"target","name":"KCNA4","route":"/targets/kcna4/","field":"links","label":"HGNC HGNC:6222"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6232","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnb2","kind":"target","name":"KCNB2","route":"/targets/kcnb2/","field":"links","label":"HGNC HGNC:6232"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6234","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnc2","kind":"target","name":"KCNC2","route":"/targets/kcnc2/","field":"links","label":"HGNC HGNC:6234"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6238","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnd2","kind":"target","name":"KCND2","route":"/targets/kcnd2/","field":"links","label":"HGNC HGNC:6238"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6239","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnd3","kind":"target","name":"KCND3","route":"/targets/kcnd3/","field":"links","label":"HGNC HGNC:6239"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6246","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnf1","kind":"target","name":"KCNF1","route":"/targets/kcnf1/","field":"links","label":"HGNC HGNC:6246"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6250","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh1","kind":"target","name":"KCNH1","route":"/targets/kcnh1/","field":"links","label":"HGNC HGNC:6250"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6294","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq1","kind":"target","name":"KCNQ1","route":"/targets/kcnq1/","field":"links","label":"HGNC HGNC:6294"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6297","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq3","kind":"target","name":"KCNQ3","route":"/targets/kcnq3/","field":"links","label":"HGNC HGNC:6297"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6299","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq5","kind":"target","name":"KCNQ5","route":"/targets/kcnq5/","field":"links","label":"HGNC HGNC:6299"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6324","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kif5b","kind":"target","name":"KIF5B","route":"/targets/kif5b/","field":"links","label":"HGNC HGNC:6324"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6329","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kir2dl1","kind":"target","name":"KIR2DL1 (inhibitory KIR)","route":"/targets/kir2dl1/","field":"links","label":"HGNC HGNC:6329"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6343","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kitlg","kind":"target","name":"KITLG","route":"/targets/kitlg/","field":"links","label":"HGNC HGNC:6343"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6347","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/","field":"links","label":"HGNC HGNC:6347"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6348","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf4","kind":"target","name":"KLF4","route":"/targets/klf4/","field":"links","label":"HGNC HGNC:6348"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6349","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/","field":"links","label":"HGNC HGNC:6349"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6364","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klk3","kind":"target","name":"KLK3","route":"/targets/klk3/","field":"links","label":"HGNC HGNC:6364"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6374","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klrc1","kind":"target","name":"NKG2A (KLRC1)","route":"/targets/klrc1/","field":"links","label":"HGNC HGNC:6374"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6387","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klc1","kind":"target","name":"KLC1","route":"/targets/klc1/","field":"links","label":"HGNC HGNC:6387"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6392","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kif23","kind":"target","name":"KIF23","route":"/targets/kif23/","field":"links","label":"HGNC HGNC:6392"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6408","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mafb","kind":"target","name":"MAFB","route":"/targets/mafb/","field":"links","label":"HGNC HGNC:6408"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6430","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krt18","kind":"target","name":"KRT18","route":"/targets/krt18/","field":"links","label":"HGNC HGNC:6430"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6442","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krt5","kind":"target","name":"KRT5","route":"/targets/krt5/","field":"links","label":"HGNC HGNC:6442"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:646","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/","field":"links","label":"HGNC HGNC:646"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6465","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ksr1","kind":"target","name":"KSR1","route":"/targets/ksr1/","field":"links","label":"HGNC HGNC:6465"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6467","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ktn1","kind":"target","name":"KTN1","route":"/targets/ktn1/","field":"links","label":"HGNC HGNC:6467"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6473","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff3","kind":"target","name":"AFF3","route":"/targets/aff3/","field":"links","label":"HGNC HGNC:6473"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6485","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lama5","kind":"target","name":"LAMA5","route":"/targets/lama5/","field":"links","label":"HGNC HGNC:6485"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6492","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lamc1","kind":"target","name":"LAMC1","route":"/targets/lamc1/","field":"links","label":"HGNC HGNC:6492"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:651","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"areg","kind":"target","name":"AREG","route":"/targets/areg/","field":"links","label":"HGNC HGNC:651"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6510","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stmn1","kind":"target","name":"STMN1","route":"/targets/stmn1/","field":"links","label":"HGNC HGNC:6510"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6514","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/","field":"links","label":"HGNC HGNC:6514"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6515","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lats2","kind":"target","name":"LATS2","route":"/targets/lats2/","field":"links","label":"HGNC HGNC:6515"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6524","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/","field":"links","label":"HGNC HGNC:6524"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6532","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ldb1","kind":"target","name":"LDB1","route":"/targets/ldb1/","field":"links","label":"HGNC HGNC:6532"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6551","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lef1","kind":"target","name":"LEF1","route":"/targets/lef1/","field":"links","label":"HGNC HGNC:6551"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6554","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lepr","kind":"target","name":"LEPR","route":"/targets/lepr/","field":"links","label":"HGNC HGNC:6554"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6570","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lgals9","kind":"target","name":"Galectin-9 (LGALS9)","route":"/targets/lgals9/","field":"links","label":"HGNC HGNC:6570"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6597","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/","field":"links","label":"HGNC HGNC:6597"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6601","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lig4","kind":"target","name":"LIG4","route":"/targets/lig4/","field":"links","label":"HGNC HGNC:6601"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6605","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/","field":"links","label":"HGNC HGNC:6605"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","field":"links","label":"HGNC HGNC:6606"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6636","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmna","kind":"target","name":"LMNA","route":"/targets/lmna/","field":"links","label":"HGNC HGNC:6636"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6641","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo1","kind":"target","name":"LMO1","route":"/targets/lmo1/","field":"links","label":"HGNC HGNC:6641"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6642","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo2","kind":"target","name":"LMO2","route":"/targets/lmo2/","field":"links","label":"HGNC HGNC:6642"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6646","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo7","kind":"target","name":"LMO7","route":"/targets/lmo7/","field":"links","label":"HGNC HGNC:6646"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6654","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmx1b","kind":"target","name":"LMX1B","route":"/targets/lmx1b/","field":"links","label":"HGNC HGNC:6654"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6667","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lpa","kind":"target","name":"LPA","route":"/targets/lpa/","field":"links","label":"HGNC HGNC:6667"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:667","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/","field":"links","label":"HGNC HGNC:667"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6679","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lpp","kind":"target","name":"LPP","route":"/targets/lpp/","field":"links","label":"HGNC HGNC:6679"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6693","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrp1b","kind":"target","name":"LRP1B","route":"/targets/lrp1b/","field":"links","label":"HGNC HGNC:6693"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6697","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrp5","kind":"target","name":"LRP5","route":"/targets/lrp5/","field":"links","label":"HGNC HGNC:6697"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6702","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrrfip1","kind":"target","name":"LRRFIP1","route":"/targets/lrrfip1/","field":"links","label":"HGNC HGNC:6702"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6707","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lsp1","kind":"target","name":"LSP1","route":"/targets/lsp1/","field":"links","label":"HGNC HGNC:6707"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6711","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ltb","kind":"target","name":"LTB","route":"/targets/ltb/","field":"links","label":"HGNC HGNC:6711"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6734","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lyl1","kind":"target","name":"LYL1","route":"/targets/lyl1/","field":"links","label":"HGNC HGNC:6734"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6735","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","field":"links","label":"HGNC:6735 LYN"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6742","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lztr1","kind":"target","name":"LZTR1","route":"/targets/lztr1/","field":"links","label":"HGNC HGNC:6742"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:675","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/","field":"links","label":"HGNC HGNC:675"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6768","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad2","kind":"target","name":"SMAD2","route":"/targets/smad2/","field":"links","label":"HGNC HGNC:6768"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6769","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad3","kind":"target","name":"SMAD3","route":"/targets/smad3/","field":"links","label":"HGNC HGNC:6769"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6770","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"links","label":"HGNC HGNC:6770"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6773","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad7","kind":"target","name":"SMAD7","route":"/targets/smad7/","field":"links","label":"HGNC HGNC:6773"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/","field":"links","label":"HGNC HGNC:6776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6819","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/","field":"links","label":"HGNC HGNC:6819"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6844","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map2k4","kind":"target","name":"MAP2K4","route":"/targets/map2k4/","field":"links","label":"HGNC HGNC:6844"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6847","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map2k7","kind":"target","name":"MAP2K7","route":"/targets/map2k7/","field":"links","label":"HGNC HGNC:6847"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6848","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/","field":"links","label":"HGNC HGNC:6848"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6852","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map3k13","kind":"target","name":"MAP3K13","route":"/targets/map3k13/","field":"links","label":"HGNC HGNC:6852"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:686","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhoh","kind":"target","name":"RHOH","route":"/targets/rhoh/","field":"links","label":"HGNC HGNC:686"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6871","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/","field":"links","label":"HGNC HGNC:6871"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6873","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk11","kind":"target","name":"MAPK11","route":"/targets/mapk11/","field":"links","label":"HGNC HGNC:6873"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6877","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/","field":"links","label":"HGNC HGNC:6877"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6881","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk8","kind":"target","name":"MAPK8","route":"/targets/mapk8/","field":"links","label":"HGNC HGNC:6881"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6886","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk9","kind":"target","name":"MAPK9","route":"/targets/mapk9/","field":"links","label":"HGNC HGNC:6886"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6897","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mark3","kind":"target","name":"MARK3","route":"/targets/mark3/","field":"links","label":"HGNC HGNC:6897"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6913","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"max","kind":"target","name":"MAX","route":"/targets/max/","field":"links","label":"HGNC HGNC:6913"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6919","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mbd4","kind":"target","name":"MBD4","route":"/targets/mbd4/","field":"links","label":"HGNC HGNC:6919"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6929","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mc1r","kind":"target","name":"MC1R","route":"/targets/mc1r/","field":"links","label":"HGNC HGNC:6929"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6943","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/","field":"links","label":"HGNC HGNC:6943"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6950","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/","field":"links","label":"HGNC HGNC:6950"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6974","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mdm4","kind":"target","name":"MDM4","route":"/targets/mdm4/","field":"links","label":"HGNC HGNC:6974"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6995","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2b","kind":"target","name":"MEF2B","route":"/targets/mef2b/","field":"links","label":"HGNC HGNC:6995"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6996","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2c","kind":"target","name":"MEF2C","route":"/targets/mef2c/","field":"links","label":"HGNC HGNC:6996"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6997","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2d","kind":"target","name":"MEF2D","route":"/targets/mef2d/","field":"links","label":"HGNC HGNC:6997"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:700","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/","field":"links","label":"HGNC HGNC:700"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7000","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"meis1","kind":"target","name":"MEIS1","route":"/targets/meis1/","field":"links","label":"HGNC HGNC:7000"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7027","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mertk","kind":"target","name":"MERTK","route":"/targets/mertk/","field":"links","label":"HGNC HGNC:7027"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7059","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mgmt-protein","kind":"target","name":"MGMT (O6-methylguanine-DNA methyltransferase)","route":"/targets/mgmt-protein/","field":"links","label":"HGNC HGNC:7059"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7067","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ciita","kind":"target","name":"CIITA","route":"/targets/ciita/","field":"links","label":"HGNC HGNC:7067"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7102","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"minpp1","kind":"target","name":"MINPP1","route":"/targets/minpp1/","field":"links","label":"HGNC HGNC:7102"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7105","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/","field":"links","label":"HGNC HGNC:7105"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7107","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mki67","kind":"target","name":"Ki-67 (MKI67)","route":"/targets/mki67/","field":"links","label":"HGNC HGNC:7107"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:711","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrb1","kind":"target","name":"ARRB1","route":"/targets/arrb1/","field":"links","label":"HGNC HGNC:711"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:712","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrb2","kind":"target","name":"ARRB2","route":"/targets/arrb2/","field":"links","label":"HGNC HGNC:712"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7125","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlf1","kind":"target","name":"MLF1","route":"/targets/mlf1/","field":"links","label":"HGNC HGNC:7125"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7127","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"links","label":"HGNC HGNC:7127"},{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","field":"links","label":"HGNC HGNC:7127"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7128","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlh3","kind":"target","name":"MLH3","route":"/targets/mlh3/","field":"links","label":"HGNC HGNC:7128"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7133","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2d","kind":"target","name":"KMT2D","route":"/targets/kmt2d/","field":"links","label":"HGNC HGNC:7133"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7134","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt1","kind":"target","name":"MLLT1","route":"/targets/mllt1/","field":"links","label":"HGNC HGNC:7134"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7135","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff1","kind":"target","name":"AFF1","route":"/targets/aff1/","field":"links","label":"HGNC HGNC:7135"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7136","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt3","kind":"target","name":"MLLT3","route":"/targets/mllt3/","field":"links","label":"HGNC HGNC:7136"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7137","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"afdn","kind":"target","name":"AFDN","route":"/targets/afdn/","field":"links","label":"HGNC HGNC:7137"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7138","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt6","kind":"target","name":"MLLT6","route":"/targets/mllt6/","field":"links","label":"HGNC HGNC:7138"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7139","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo4","kind":"target","name":"FOXO4","route":"/targets/foxo4/","field":"links","label":"HGNC HGNC:7139"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7155","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp1","kind":"target","name":"MMP1","route":"/targets/mmp1/","field":"links","label":"HGNC HGNC:7155"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7166","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp2","kind":"target","name":"MMP2","route":"/targets/mmp2/","field":"links","label":"HGNC HGNC:7166"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7174","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp7","kind":"target","name":"MMP7","route":"/targets/mmp7/","field":"links","label":"HGNC HGNC:7174"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7176","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp9","kind":"target","name":"MMP9","route":"/targets/mmp9/","field":"links","label":"HGNC HGNC:7176"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7180","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mn1","kind":"target","name":"MN1","route":"/targets/mn1/","field":"links","label":"HGNC HGNC:7180"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7200","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mov10","kind":"target","name":"MOV10","route":"/targets/mov10/","field":"links","label":"HGNC HGNC:7200"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7203","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd200","kind":"target","name":"CD200","route":"/targets/cd200/","field":"links","label":"HGNC HGNC:7203"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7217","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mpl","kind":"target","name":"MPL (thrombopoietin receptor)","route":"/targets/mpl/","field":"links","label":"HGNC HGNC:7217"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7230","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/","field":"links","label":"HGNC HGNC:7230"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7325","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"links","label":"HGNC HGNC:7325"},{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","field":"links","label":"HGNC HGNC:7325"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7326","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msh3","kind":"target","name":"MSH3","route":"/targets/msh3/","field":"links","label":"HGNC HGNC:7326"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7329","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"links","label":"HGNC HGNC:7329"},{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/","field":"links","label":"HGNC HGNC:7329"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7372","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msmb","kind":"target","name":"MSMB","route":"/targets/msmb/","field":"links","label":"HGNC HGNC:7372"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7373","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msn","kind":"target","name":"MSN","route":"/targets/msn/","field":"links","label":"HGNC HGNC:7373"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7376","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msr1","kind":"target","name":"MSR1","route":"/targets/msr1/","field":"links","label":"HGNC HGNC:7376"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:738","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","field":"links","label":"HGNC HGNC:738"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7381","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","field":"links","label":"HGNC:7381 MST1R"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:74","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/","field":"links","label":"HGNC HGNC:74"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7419","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-co1","kind":"target","name":"MT-CO1","route":"/targets/mt-co1/","field":"links","label":"HGNC HGNC:7419"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7423","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mtcp1","kind":"target","name":"MTCP1","route":"/targets/mtcp1/","field":"links","label":"HGNC HGNC:7423"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7427","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-cyb","kind":"target","name":"MT-CYB","route":"/targets/mt-cyb/","field":"links","label":"HGNC HGNC:7427"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7436","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mthfr","kind":"target","name":"MTHFR","route":"/targets/mthfr/","field":"links","label":"HGNC HGNC:7436"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7455","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-nd1","kind":"target","name":"MT-ND1","route":"/targets/mt-nd1/","field":"links","label":"HGNC HGNC:7455"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7462","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-nd6","kind":"target","name":"MT-ND6","route":"/targets/mt-nd6/","field":"links","label":"HGNC HGNC:7462"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7517","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"muc6","kind":"target","name":"MUC6","route":"/targets/muc6/","field":"links","label":"HGNC HGNC:7517"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7527","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/","field":"links","label":"HGNC HGNC:7527"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:753","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/","field":"links","label":"HGNC HGNC:753"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7533","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mx2","kind":"target","name":"MX2","route":"/targets/mx2/","field":"links","label":"HGNC HGNC:7533"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7534","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mxi1","kind":"target","name":"MXI1","route":"/targets/mxi1/","field":"links","label":"HGNC HGNC:7534"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7545","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/","field":"links","label":"HGNC HGNC:7545"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7547","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mybl1","kind":"target","name":"MYBL1","route":"/targets/mybl1/","field":"links","label":"HGNC HGNC:7547"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7553","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"links","label":"HGNC HGNC:7553"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7555","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/","field":"links","label":"HGNC HGNC:7555"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7559","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mycn","kind":"target","name":"MYCN (N-myc)","route":"/targets/mycn/","field":"links","label":"HGNC HGNC:7559"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7562","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","field":"links","label":"HGNC HGNC:7562"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7563","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myeov","kind":"target","name":"MYEOV","route":"/targets/myeov/","field":"links","label":"HGNC HGNC:7563"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7569","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myh11","kind":"target","name":"MYH11","route":"/targets/myh11/","field":"links","label":"HGNC HGNC:7569"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7579","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/","field":"links","label":"HGNC HGNC:7579"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:758","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/","field":"links","label":"HGNC HGNC:758"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abl1","kind":"target","name":"ABL1","route":"/targets/abl1/","field":"links","label":"HGNC HGNC:76"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7602","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/","field":"links","label":"HGNC HGNC:7602"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7611","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myod1","kind":"target","name":"MYOD1","route":"/targets/myod1/","field":"links","label":"HGNC HGNC:7611"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7627","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nab2","kind":"target","name":"NAB2","route":"/targets/nab2/","field":"links","label":"HGNC HGNC:7627"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7629","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naca","kind":"target","name":"NACA","route":"/targets/naca/","field":"links","label":"HGNC HGNC:7629"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7648","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/","field":"links","label":"HGNC HGNC:7648"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7652","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/","field":"links","label":"HGNC HGNC:7652"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7668","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa1","kind":"target","name":"NCOA1","route":"/targets/ncoa1/","field":"links","label":"HGNC HGNC:7668"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7669","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/","field":"links","label":"HGNC HGNC:7669"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7670","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/","field":"links","label":"HGNC HGNC:7670"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7671","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa4","kind":"target","name":"NCOA4","route":"/targets/ncoa4/","field":"links","label":"HGNC HGNC:7671"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7672","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncor1","kind":"target","name":"NCOR1","route":"/targets/ncor1/","field":"links","label":"HGNC HGNC:7672"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7673","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncor2","kind":"target","name":"NCOR2","route":"/targets/ncor2/","field":"links","label":"HGNC HGNC:7673"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7679","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ndrg1","kind":"target","name":"NDRG1","route":"/targets/ndrg1/","field":"links","label":"HGNC HGNC:7679"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:77","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abl2","kind":"target","name":"ABL2","route":"/targets/abl2/","field":"links","label":"HGNC HGNC:77"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7733","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nedd9","kind":"target","name":"NEDD9","route":"/targets/nedd9/","field":"links","label":"HGNC HGNC:7733"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7765","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nf1","kind":"target","name":"NF1 (neurofibromin)","route":"/targets/nf1/","field":"links","label":"HGNC HGNC:7765"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:777","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/","field":"links","label":"HGNC HGNC:777"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7773","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","field":"links","label":"HGNC HGNC:7773"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7776","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfatc2","kind":"target","name":"NFATC2","route":"/targets/nfatc2/","field":"links","label":"HGNC HGNC:7776"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7782","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","field":"links","label":"HGNC HGNC:7782"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7785","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfib","kind":"target","name":"NFIB","route":"/targets/nfib/","field":"links","label":"HGNC HGNC:7785"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7795","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkb2","kind":"target","name":"NFKB2","route":"/targets/nfkb2/","field":"links","label":"HGNC HGNC:7795"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7797","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/","field":"links","label":"HGNC HGNC:7797"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7799","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbie","kind":"target","name":"NFKBIE","route":"/targets/nfkbie/","field":"links","label":"HGNC HGNC:7799"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:783","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atf1","kind":"target","name":"ATF1","route":"/targets/atf1/","field":"links","label":"HGNC HGNC:783"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7833","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nktr","kind":"target","name":"NKTR","route":"/targets/nktr/","field":"links","label":"HGNC HGNC:7833"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7838","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","field":"links","label":"HGNC HGNC:7838"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7879","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnot3","kind":"target","name":"CNOT3","route":"/targets/cnot3/","field":"links","label":"HGNC HGNC:7879"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7881","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"links","label":"HGNC HGNC:7881"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7882","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/","field":"links","label":"HGNC HGNC:7882"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7883","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch3","kind":"target","name":"NOTCH3","route":"/targets/notch3/","field":"links","label":"HGNC HGNC:7883"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7891","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nox4","kind":"target","name":"NOX4","route":"/targets/nox4/","field":"links","label":"HGNC HGNC:7891"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:79","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abo","kind":"target","name":"ABO","route":"/targets/abo/","field":"links","label":"HGNC HGNC:79"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:794","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atic","kind":"target","name":"ATIC","route":"/targets/atic/","field":"links","label":"HGNC HGNC:794"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"links","label":"HGNC HGNC:795"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7954","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nptxr","kind":"target","name":"NPTXR","route":"/targets/nptxr/","field":"links","label":"HGNC HGNC:7954"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7976","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr2f2","kind":"target","name":"NR2F2","route":"/targets/nr2f2/","field":"links","label":"HGNC HGNC:7976"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7981","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr4a2","kind":"target","name":"NR4A2","route":"/targets/nr4a2/","field":"links","label":"HGNC HGNC:7981"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7982","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr4a3","kind":"target","name":"NR4A3","route":"/targets/nr4a3/","field":"links","label":"HGNC HGNC:7982"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7984","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr5a2","kind":"target","name":"NR5A2","route":"/targets/nr5a2/","field":"links","label":"HGNC HGNC:7984"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","field":"links","label":"HGNC HGNC:7989"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:799","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp1a1","kind":"target","name":"ATP1A1","route":"/targets/atp1a1/","field":"links","label":"HGNC HGNC:799"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7997","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"links","label":"HGNC HGNC:7997"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7998","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg2","kind":"target","name":"NRG2","route":"/targets/nrg2/","field":"links","label":"HGNC HGNC:7998"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7999","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg3","kind":"target","name":"NRG3","route":"/targets/nrg3/","field":"links","label":"HGNC HGNC:7999"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8001","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrip1","kind":"target","name":"NRIP1","route":"/targets/nrip1/","field":"links","label":"HGNC HGNC:8001"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8022","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nt5c2","kind":"target","name":"NT5C2","route":"/targets/nt5c2/","field":"links","label":"HGNC HGNC:8022"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8028","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nthl1","kind":"target","name":"NTHL1","route":"/targets/nthl1/","field":"links","label":"HGNC HGNC:8028"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8059","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"numa1","kind":"target","name":"NUMA1","route":"/targets/numa1/","field":"links","label":"HGNC HGNC:8059"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8064","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nup214","kind":"target","name":"NUP214","route":"/targets/nup214/","field":"links","label":"HGNC HGNC:8064"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8068","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/","field":"links","label":"HGNC HGNC:8068"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8070","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nvl","kind":"target","name":"NVL","route":"/targets/nvl/","field":"links","label":"HGNC HGNC:8070"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8071","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nxf1","kind":"target","name":"NXF1","route":"/targets/nxf1/","field":"links","label":"HGNC HGNC:8071"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8101","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oca2","kind":"target","name":"OCA2","route":"/targets/oca2/","field":"links","label":"HGNC HGNC:8101"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8125","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ogg1","kind":"target","name":"OGG1","route":"/targets/ogg1/","field":"links","label":"HGNC HGNC:8125"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8156","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","field":"links","label":"HGNC:8156 OPRM1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:816","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp2b3","kind":"target","name":"ATP2B3","route":"/targets/atp2b3/","field":"links","label":"HGNC HGNC:816"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:819","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp4a","kind":"target","name":"ATP4A","route":"/targets/atp4a/","field":"links","label":"HGNC HGNC:819"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp4b","kind":"target","name":"ATP4B","route":"/targets/atp4b/","field":"links","label":"HGNC HGNC:820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8487","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orc1","kind":"target","name":"ORC1","route":"/targets/orc1/","field":"links","label":"HGNC HGNC:8487"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8521","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"otx1","kind":"target","name":"OTX1","route":"/targets/otx1/","field":"links","label":"HGNC HGNC:8521"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8554","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/","field":"links","label":"HGNC HGNC:8554"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8603","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"papss1","kind":"target","name":"PAPSS1","route":"/targets/papss1/","field":"links","label":"HGNC HGNC:8603"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8607","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/","field":"links","label":"HGNC HGNC:8607"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8617","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax3","kind":"target","name":"PAX3","route":"/targets/pax3/","field":"links","label":"HGNC HGNC:8617"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8619","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax5","kind":"target","name":"PAX5","route":"/targets/pax5/","field":"links","label":"HGNC HGNC:8619"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8620","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax6","kind":"target","name":"PAX6","route":"/targets/pax6/","field":"links","label":"HGNC HGNC:8620"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8621","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax7","kind":"target","name":"PAX7","route":"/targets/pax7/","field":"links","label":"HGNC HGNC:8621"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8622","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax8","kind":"target","name":"PAX8","route":"/targets/pax8/","field":"links","label":"HGNC HGNC:8622"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8623","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax9","kind":"target","name":"PAX9","route":"/targets/pax9/","field":"links","label":"HGNC HGNC:8623"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8632","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbx1","kind":"target","name":"PBX1","route":"/targets/pbx1/","field":"links","label":"HGNC HGNC:8632"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8638","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/","field":"links","label":"HGNC HGNC:8638"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8647","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcbp1","kind":"target","name":"PCBP1","route":"/targets/pcbp1/","field":"links","label":"HGNC HGNC:8647"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:870","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/","field":"links","label":"HGNC HGNC:870"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8727","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcm1","kind":"target","name":"PCM1","route":"/targets/pcm1/","field":"links","label":"HGNC HGNC:8727"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8729","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/","field":"links","label":"HGNC HGNC:8729"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8736","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcnx2","kind":"target","name":"PCNX2","route":"/targets/pcnx2/","field":"links","label":"HGNC HGNC:8736"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8763","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdcd4","kind":"target","name":"PDCD4","route":"/targets/pdcd4/","field":"links","label":"HGNC HGNC:8763"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8778","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pde3a","kind":"target","name":"PDE3A","route":"/targets/pde3a/","field":"links","label":"HGNC HGNC:8778"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8779","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pde3b","kind":"target","name":"PDE3B","route":"/targets/pde3b/","field":"links","label":"HGNC HGNC:8779"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8800","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdgfb","kind":"target","name":"PDGFB","route":"/targets/pdgfb/","field":"links","label":"HGNC HGNC:8800"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8805","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdgfrl","kind":"target","name":"PDGFRL","route":"/targets/pdgfrl/","field":"links","label":"HGNC HGNC:8805"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8816","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdpk1","kind":"target","name":"PDPK1","route":"/targets/pdpk1/","field":"links","label":"HGNC HGNC:8816"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8826","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peg3","kind":"target","name":"PEG3","route":"/targets/peg3/","field":"links","label":"HGNC HGNC:8826"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8845","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"per1","kind":"target","name":"PER1","route":"/targets/per1/","field":"links","label":"HGNC HGNC:8845"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8847","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"per3","kind":"target","name":"PER3","route":"/targets/per3/","field":"links","label":"HGNC HGNC:8847"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:886","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/","field":"links","label":"HGNC HGNC:886"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8910","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","field":"links","label":"HGNC:8910 PGR"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8933","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phlda1","kind":"target","name":"PHLDA1","route":"/targets/phlda1/","field":"links","label":"HGNC HGNC:8933"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8976","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/","field":"links","label":"HGNC HGNC:8976"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8978","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3cg","kind":"target","name":"PIK3CG","route":"/targets/pik3cg/","field":"links","label":"HGNC HGNC:8978"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8979","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/","field":"links","label":"HGNC HGNC:8979"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8980","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r2","kind":"target","name":"PIK3R2","route":"/targets/pik3r2/","field":"links","label":"HGNC HGNC:8980"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8981","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r3","kind":"target","name":"PIK3R3","route":"/targets/pik3r3/","field":"links","label":"HGNC HGNC:8981"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8983","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pi4ka","kind":"target","name":"PI4KA","route":"/targets/pi4ka/","field":"links","label":"HGNC HGNC:8983"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8986","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/","field":"links","label":"HGNC HGNC:8986"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8987","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pim2","kind":"target","name":"PIM2","route":"/targets/pim2/","field":"links","label":"HGNC HGNC:8987"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:903","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"axin1","kind":"target","name":"AXIN1","route":"/targets/axin1/","field":"links","label":"HGNC HGNC:903"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:904","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"axin2","kind":"target","name":"AXIN2","route":"/targets/axin2/","field":"links","label":"HGNC HGNC:904"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9045","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plag1","kind":"target","name":"PLAG1","route":"/targets/plag1/","field":"links","label":"HGNC HGNC:9045"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9065","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/","field":"links","label":"HGNC HGNC:9065"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9066","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","field":"links","label":"HGNC HGNC:9066"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9077","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/","field":"links","label":"HGNC HGNC:9077"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9104","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plxnb2","kind":"target","name":"PLXNB2","route":"/targets/plxnb2/","field":"links","label":"HGNC HGNC:9104"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9106","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plxnc1","kind":"target","name":"PLXNC1","route":"/targets/plxnc1/","field":"links","label":"HGNC HGNC:9106"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9113","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pml","kind":"target","name":"PML","route":"/targets/pml/","field":"links","label":"HGNC HGNC:9113"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9121","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pms1","kind":"target","name":"PMS1","route":"/targets/pms1/","field":"links","label":"HGNC HGNC:9121"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9122","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","field":"links","label":"HGNC HGNC:9122"},{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/","field":"links","label":"HGNC HGNC:9122"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:914","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","field":"links","label":"HGNC HGNC:914"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9143","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/","field":"links","label":"HGNC HGNC:9143"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9160","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pnmt","kind":"target","name":"PNMT","route":"/targets/pnmt/","field":"links","label":"HGNC HGNC:9160"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9173","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","field":"links","label":"HGNC:9173 POLA1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9175","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","field":"links","label":"HGNC HGNC:9175"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9176","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/","field":"links","label":"HGNC HGNC:9176"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9177","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","field":"links","label":"HGNC HGNC:9177"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9178","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/","field":"links","label":"HGNC HGNC:9178"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9183","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polk","kind":"target","name":"POLK","route":"/targets/polk/","field":"links","label":"HGNC HGNC:9183"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9186","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/","field":"links","label":"HGNC HGNC:9186"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9211","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou2af1","kind":"target","name":"POU2AF1","route":"/targets/pou2af1/","field":"links","label":"HGNC HGNC:9211"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9213","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou2f2","kind":"target","name":"POU2F2","route":"/targets/pou2f2/","field":"links","label":"HGNC HGNC:9213"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9221","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou5f1","kind":"target","name":"POU5F1","route":"/targets/pou5f1/","field":"links","label":"HGNC HGNC:9221"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9223","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou5f1b","kind":"target","name":"POU5F1B","route":"/targets/pou5f1b/","field":"links","label":"HGNC HGNC:9223"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9236","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/","field":"links","label":"HGNC HGNC:9236"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9238","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppat","kind":"target","name":"PPAT","route":"/targets/ppat/","field":"links","label":"HGNC HGNC:9238"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:924","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b4galt1","kind":"target","name":"B4GALT1","route":"/targets/b4galt1/","field":"links","label":"HGNC HGNC:924"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9249","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppfibp1","kind":"target","name":"PPFIBP1","route":"/targets/ppfibp1/","field":"links","label":"HGNC HGNC:9249"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9276","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppm1b","kind":"target","name":"PPM1B","route":"/targets/ppm1b/","field":"links","label":"HGNC HGNC:9276"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9277","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/","field":"links","label":"HGNC HGNC:9277"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9299","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2ca","kind":"target","name":"PPP2CA","route":"/targets/ppp2ca/","field":"links","label":"HGNC HGNC:9299"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9300","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2cb","kind":"target","name":"PPP2CB","route":"/targets/ppp2cb/","field":"links","label":"HGNC HGNC:9300"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9302","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/","field":"links","label":"HGNC HGNC:9302"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9303","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r1b","kind":"target","name":"PPP2R1B","route":"/targets/ppp2r1b/","field":"links","label":"HGNC HGNC:9303"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9304","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r2a","kind":"target","name":"PPP2R2A","route":"/targets/ppp2r2a/","field":"links","label":"HGNC HGNC:9304"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9309","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5a","kind":"target","name":"PPP2R5A","route":"/targets/ppp2r5a/","field":"links","label":"HGNC HGNC:9309"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9310","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5b","kind":"target","name":"PPP2R5B","route":"/targets/ppp2r5b/","field":"links","label":"HGNC HGNC:9310"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9311","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5c","kind":"target","name":"PPP2R5C","route":"/targets/ppp2r5c/","field":"links","label":"HGNC HGNC:9311"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9312","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5d","kind":"target","name":"PPP2R5D","route":"/targets/ppp2r5d/","field":"links","label":"HGNC HGNC:9312"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9313","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5e","kind":"target","name":"PPP2R5E","route":"/targets/ppp2r5e/","field":"links","label":"HGNC HGNC:9313"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9314","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp3ca","kind":"target","name":"PPP3CA","route":"/targets/ppp3ca/","field":"links","label":"HGNC HGNC:9314"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9323","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp6c","kind":"target","name":"PPP6C","route":"/targets/ppp6c/","field":"links","label":"HGNC HGNC:9323"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9341","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prc1","kind":"target","name":"PRC1","route":"/targets/prc1/","field":"links","label":"HGNC HGNC:9341"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9343","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","field":"links","label":"HGNC HGNC:9343"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9346","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/","field":"links","label":"HGNC HGNC:9346"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9347","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/","field":"links","label":"HGNC HGNC:9347"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9360","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prf1","kind":"target","name":"PRF1","route":"/targets/prf1/","field":"links","label":"HGNC HGNC:9360"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9369","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/","field":"links","label":"HGNC HGNC:9369"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9370","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/","field":"links","label":"HGNC HGNC:9370"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9377","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkaa2","kind":"target","name":"PRKAA2","route":"/targets/prkaa2/","field":"links","label":"HGNC HGNC:9377"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9380","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkaca","kind":"target","name":"PRKACA","route":"/targets/prkaca/","field":"links","label":"HGNC HGNC:9380"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9388","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkar1a","kind":"target","name":"PRKAR1A","route":"/targets/prkar1a/","field":"links","label":"HGNC HGNC:9388"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9393","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","field":"links","label":"HGNC:9393 PRKCA"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9395","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcb","kind":"target","name":"PRKCB","route":"/targets/prkcb/","field":"links","label":"HGNC HGNC:9395"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9398","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"olig2","kind":"target","name":"OLIG2","route":"/targets/olig2/","field":"links","label":"HGNC HGNC:9398"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9399","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcd","kind":"target","name":"PRKCD","route":"/targets/prkcd/","field":"links","label":"HGNC HGNC:9399"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:940","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bag4","kind":"target","name":"BAG4","route":"/targets/bag4/","field":"links","label":"HGNC HGNC:940"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9401","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkce","kind":"target","name":"PRKCE","route":"/targets/prkce/","field":"links","label":"HGNC HGNC:9401"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9402","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcg","kind":"target","name":"PRKCG","route":"/targets/prkcg/","field":"links","label":"HGNC HGNC:9402"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9403","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkch","kind":"target","name":"PRKCH","route":"/targets/prkch/","field":"links","label":"HGNC HGNC:9403"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9404","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkci","kind":"target","name":"PRKCI","route":"/targets/prkci/","field":"links","label":"HGNC HGNC:9404"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9407","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd1","kind":"target","name":"PRKD1","route":"/targets/prkd1/","field":"links","label":"HGNC HGNC:9407"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9408","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd3","kind":"target","name":"PRKD3","route":"/targets/prkd3/","field":"links","label":"HGNC HGNC:9408"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9410","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcq","kind":"target","name":"PRKCQ","route":"/targets/prkcq/","field":"links","label":"HGNC HGNC:9410"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9412","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcz","kind":"target","name":"PRKCZ","route":"/targets/prkcz/","field":"links","label":"HGNC HGNC:9412"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9413","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkdc","kind":"target","name":"PRKDC","route":"/targets/prkdc/","field":"links","label":"HGNC HGNC:9413"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9454","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prom1","kind":"target","name":"PROM1","route":"/targets/prom1/","field":"links","label":"HGNC HGNC:9454"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9462","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prps1","kind":"target","name":"PRPS1","route":"/targets/prps1/","field":"links","label":"HGNC HGNC:9462"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:949","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bak1","kind":"target","name":"BAK1","route":"/targets/bak1/","field":"links","label":"HGNC HGNC:949"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:950","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","field":"links","label":"HGNC HGNC:950"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9500","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/","field":"links","label":"HGNC HGNC:9500"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9509","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psen2","kind":"target","name":"PSEN2","route":"/targets/psen2/","field":"links","label":"HGNC HGNC:9509"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:952","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/","field":"links","label":"HGNC HGNC:952"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9527","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psip1","kind":"target","name":"PSIP1","route":"/targets/psip1/","field":"links","label":"HGNC HGNC:9527"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9530","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/","field":"links","label":"HGNC HGNC:9530"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9531","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/","field":"links","label":"HGNC HGNC:9531"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9532","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/","field":"links","label":"HGNC HGNC:9532"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9533","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/","field":"links","label":"HGNC HGNC:9533"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9534","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/","field":"links","label":"HGNC HGNC:9534"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9535","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/","field":"links","label":"HGNC HGNC:9535"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9536","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/","field":"links","label":"HGNC HGNC:9536"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9537","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/","field":"links","label":"HGNC HGNC:9537"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9538","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/","field":"links","label":"HGNC HGNC:9538"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9539","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/","field":"links","label":"HGNC HGNC:9539"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9540","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/","field":"links","label":"HGNC HGNC:9540"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9541","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/","field":"links","label":"HGNC HGNC:9541"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9543","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/","field":"links","label":"HGNC HGNC:9543"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9544","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/","field":"links","label":"HGNC HGNC:9544"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9545","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/","field":"links","label":"HGNC HGNC:9545"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9546","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/","field":"links","label":"HGNC HGNC:9546"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9547","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/","field":"links","label":"HGNC HGNC:9547"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9548","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/","field":"links","label":"HGNC HGNC:9548"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9549","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/","field":"links","label":"HGNC HGNC:9549"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9551","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/","field":"links","label":"HGNC HGNC:9551"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9552","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/","field":"links","label":"HGNC HGNC:9552"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9553","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/","field":"links","label":"HGNC HGNC:9553"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9554","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/","field":"links","label":"HGNC HGNC:9554"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9556","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/","field":"links","label":"HGNC HGNC:9556"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9557","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/","field":"links","label":"HGNC HGNC:9557"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9558","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/","field":"links","label":"HGNC HGNC:9558"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9559","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/","field":"links","label":"HGNC HGNC:9559"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9560","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/","field":"links","label":"HGNC HGNC:9560"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9561","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/","field":"links","label":"HGNC HGNC:9561"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9564","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/","field":"links","label":"HGNC HGNC:9564"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9565","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/","field":"links","label":"HGNC HGNC:9565"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9566","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/","field":"links","label":"HGNC HGNC:9566"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9585","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptch1","kind":"target","name":"PTCH1 (Patched 1)","route":"/targets/ptch1/","field":"links","label":"HGNC HGNC:9585"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"links","label":"HGNC HGNC:9588"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:959","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bax","kind":"target","name":"BAX","route":"/targets/bax/","field":"links","label":"HGNC HGNC:959"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:960","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/","field":"links","label":"HGNC HGNC:960"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9604","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptgs1","kind":"target","name":"PTGS1","route":"/targets/ptgs1/","field":"links","label":"HGNC HGNC:9604"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9605","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","field":"links","label":"HGNC:9605 PTGS2"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9611","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fak","kind":"target","name":"FAK (PTK2)","route":"/targets/fak/","field":"links","label":"HGNC HGNC:9611"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9617","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","field":"links","label":"HGNC:9617 PTK6"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9623","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptma","kind":"target","name":"PTMA","route":"/targets/ptma/","field":"links","label":"HGNC HGNC:9623"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9636","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptp4a3","kind":"target","name":"PTP4A3","route":"/targets/ptp4a3/","field":"links","label":"HGNC HGNC:9636"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9644","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/","field":"links","label":"HGNC HGNC:9644"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9645","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn12","kind":"target","name":"PTPN12","route":"/targets/ptpn12/","field":"links","label":"HGNC HGNC:9645"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9646","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn13","kind":"target","name":"PTPN13","route":"/targets/ptpn13/","field":"links","label":"HGNC HGNC:9646"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9647","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn14","kind":"target","name":"PTPN14","route":"/targets/ptpn14/","field":"links","label":"HGNC HGNC:9647"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9652","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn22","kind":"target","name":"PTPN22","route":"/targets/ptpn22/","field":"links","label":"HGNC HGNC:9652"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9655","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn3","kind":"target","name":"PTPN3","route":"/targets/ptpn3/","field":"links","label":"HGNC HGNC:9655"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9658","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn6","kind":"target","name":"PTPN6","route":"/targets/ptpn6/","field":"links","label":"HGNC HGNC:9658"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9662","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/","field":"links","label":"HGNC HGNC:9662"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9665","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/","field":"links","label":"HGNC HGNC:9665"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9666","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprc","kind":"target","name":"PTPRC","route":"/targets/ptprc/","field":"links","label":"HGNC HGNC:9666"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9668","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/","field":"links","label":"HGNC HGNC:9668"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9670","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprf","kind":"target","name":"PTPRF","route":"/targets/ptprf/","field":"links","label":"HGNC HGNC:9670"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9674","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprk","kind":"target","name":"PTPRK","route":"/targets/ptprk/","field":"links","label":"HGNC HGNC:9674"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9682","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/","field":"links","label":"HGNC HGNC:9682"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9690","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pttg1","kind":"target","name":"PTTG1","route":"/targets/pttg1/","field":"links","label":"HGNC HGNC:9690"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9705","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/","field":"links","label":"HGNC HGNC:9705"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9707","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/","field":"links","label":"HGNC HGNC:9707"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9801","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rac1","kind":"target","name":"RAC1","route":"/targets/rac1/","field":"links","label":"HGNC HGNC:9801"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9811","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad21","kind":"target","name":"RAD21","route":"/targets/rad21/","field":"links","label":"HGNC HGNC:9811"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9813","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad23b","kind":"target","name":"RAD23B","route":"/targets/rad23b/","field":"links","label":"HGNC HGNC:9813"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9816","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/","field":"links","label":"HGNC HGNC:9816"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9817","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51","kind":"target","name":"RAD51","route":"/targets/rad51/","field":"links","label":"HGNC HGNC:9817"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9820","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/","field":"links","label":"HGNC HGNC:9820"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9822","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/","field":"links","label":"HGNC HGNC:9822"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9823","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/","field":"links","label":"HGNC HGNC:9823"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9826","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad54l","kind":"target","name":"RAD54L","route":"/targets/rad54l/","field":"links","label":"HGNC HGNC:9826"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9829","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","field":"links","label":"HGNC:9829 RAF1"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9848","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ranbp2","kind":"target","name":"RANBP2","route":"/targets/ranbp2/","field":"links","label":"HGNC HGNC:9848"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9855","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1a","kind":"target","name":"RAP1A","route":"/targets/rap1a/","field":"links","label":"HGNC HGNC:9855"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9857","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1b","kind":"target","name":"RAP1B","route":"/targets/rap1b/","field":"links","label":"HGNC HGNC:9857"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9859","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1gds1","kind":"target","name":"RAP1GDS1","route":"/targets/rap1gds1/","field":"links","label":"HGNC HGNC:9859"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9865","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rarb","kind":"target","name":"RARB","route":"/targets/rarb/","field":"links","label":"HGNC HGNC:9865"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9866","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rarg","kind":"target","name":"RARG","route":"/targets/rarg/","field":"links","label":"HGNC HGNC:9866"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9871","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rasa1","kind":"target","name":"RASA1","route":"/targets/rasa1/","field":"links","label":"HGNC HGNC:9871"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9872","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rasa2","kind":"target","name":"RASA2","route":"/targets/rasa2/","field":"links","label":"HGNC HGNC:9872"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9884","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"links","label":"HGNC HGNC:9884"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9886","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5a","kind":"target","name":"KDM5A","route":"/targets/kdm5a/","field":"links","label":"HGNC HGNC:9886"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:989","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/","field":"links","label":"HGNC HGNC:989"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9890","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbbp7","kind":"target","name":"RBBP7","route":"/targets/rbbp7/","field":"links","label":"HGNC HGNC:9890"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9891","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbbp8","kind":"target","name":"RBBP8","route":"/targets/rbbp8/","field":"links","label":"HGNC HGNC:9891"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9896","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","field":"links","label":"HGNC HGNC:9896"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9928","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/","field":"links","label":"HGNC HGNC:9928"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:994","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bim","kind":"target","name":"BIM (BCL2L11)","route":"/targets/bim/","field":"links","label":"HGNC HGNC:994"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9949","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/","field":"links","label":"HGNC HGNC:9949"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9954","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/","field":"links","label":"HGNC HGNC:9954"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9955","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rela","kind":"target","name":"RELA","route":"/targets/rela/","field":"links","label":"HGNC HGNC:9955"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9966","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rest","kind":"target","name":"REST","route":"/targets/rest/","field":"links","label":"HGNC HGNC:9966"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9975","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim27","kind":"target","name":"TRIM27","route":"/targets/trim27/","field":"links","label":"HGNC HGNC:9975"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:998","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl3","kind":"target","name":"BCL3","route":"/targets/bcl3/","field":"links","label":"HGNC HGNC:998"}]},{"url":"https://www.geneoscopy.com","status":200,"ok":true,"finalUrl":"https://www.geneoscopy.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multitarget-stool-rna-test","kind":"technology","name":"Multitarget stool RNA test (ColoSense)","route":"/technologies/multitarget-stool-rna-test/","field":"links","label":"Geneoscopy: ColoSense"},{"id":"geneoscopy","kind":"company","name":"Geneoscopy","route":"/companies/geneoscopy/","field":"links","label":"Official website"},{"id":"geneoscopy","kind":"company","name":"Geneoscopy","route":"/companies/geneoscopy/","field":"website"}]},{"url":"https://www.geneostx.com","status":200,"ok":true,"finalUrl":"https://www.geneostx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","field":"links","label":"Official website"},{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","field":"website"}]},{"url":"https://www.geneostx.com/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","field":"links","label":"Series A2 financing (March 2022)"}]},{"url":"https://www.geneostx.com/press-releases/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","field":"links","label":"Press releases"}]},{"url":"https://www.genequantum.com","status":200,"ok":true,"finalUrl":"https://www.genequantum.com/","contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","field":"links","label":"Official website"},{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","field":"website"}]},{"url":"https://www.genequantum.com/pipeline","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","field":"links","label":"Pipeline page"},{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","field":"links","label":"Sponsor page"}]},{"url":"https://www.generalcatalyst.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","field":"links","label":"Official website"},{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","field":"website"}]},{"url":"https://www.generalcatalyst.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","field":"links","label":"Portfolio"}]},{"url":"https://www.genesistherapeutics.ai","status":200,"ok":true,"finalUrl":"https://www.genesis.ml/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","field":"links","label":"Official website"},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","field":"website"}]},{"url":"https://www.genfleet.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","field":"links","label":"GenFleet Therapeutics"},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/","field":"links","label":"Official website"},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/","field":"website"}]},{"url":"https://www.genmab.com","status":200,"ok":true,"finalUrl":"https://www.genmab.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","field":"links","label":"Official website"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","field":"website"}]},{"url":"https://www.genmab.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/","field":"links","label":"Official website"},{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/","field":"website"}]},{"url":"https://www.genome.gov/genetics-glossary/Founder-Effect","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","field":"links","label":"NHGRI Talking Glossary: founder effect"}]},{"url":"https://www.genomicsengland.co.uk","status":200,"ok":true,"finalUrl":"https://www.genomicsengland.co.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-prev-deferred-disclosure-newborn-genomes","kind":"idea","name":"Store adult-onset cancer gene results from newborn genomes and disclose at 18","route":"/ideas/idea-prev-deferred-disclosure-newborn-genomes/","field":"links","label":"Genomics England"}]},{"url":"https://www.genomicsengland.co.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-registry-genomics-linkage-programme","kind":"idea","name":"Link every national cancer registry to tumour genomics","route":"/ideas/idea-data-registry-genomics-linkage-programme/","field":"links","label":"Genomics England"},{"id":"idea-moon-universal-sequencing-learning-system","kind":"idea","name":"Universal tumour and germline sequencing at diagnosis feeding a shared learning system","route":"/ideas/idea-moon-universal-sequencing-learning-system/","field":"links","label":"Genomics England"}]},{"url":"https://www.genprex.com","status":200,"ok":true,"finalUrl":"https://www.genprex.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/","field":"links","label":"Official website"},{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/","field":"website"}]},{"url":"https://www.gensci-china.com","status":200,"ok":true,"finalUrl":"https://www.genscigroup.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/","field":"links","label":"Official website"},{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/","field":"website"}]},{"url":"https://www.georg-speyer-haus.de","status":200,"ok":true,"finalUrl":"https://georg-speyer-haus.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","field":"links","label":"Georg-Speyer-Haus"}]},{"url":"https://www.georgiamune.com","status":200,"ok":true,"finalUrl":"https://www.georgiamune.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/","field":"links","label":"Official website"},{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/","field":"website"}]},{"url":"https://www.geraldrfordfoundation.org/","status":200,"ok":true,"finalUrl":"https://geraldrfordfoundation.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","field":"links","label":"Gerald R. Ford Presidential Foundation"},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","field":"profiles","label":"Gerald R. Ford Presidential Foundation"}]},{"url":"https://www.gercor.com","status":200,"ok":true,"finalUrl":"https://www.gercor.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/","field":"links","label":"Official website"},{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/","field":"website"}]},{"url":"https://www.german-lymphoma-alliance.de","status":200,"ok":true,"finalUrl":"https://www.german-lymphoma-alliance.de/","contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","route":"/companies/german-lymphoma-alliance/","field":"links","label":"German Lymphoma Alliance"},{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","route":"/companies/german-lymphoma-alliance/","field":"website"}]},{"url":"https://www.german-lymphoma-alliance.de/website-ansprechpartner.html","status":200,"ok":true,"contentType":"text/html; charset=iso-8859-1","checked":"2026-09-30","refs":[{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/","field":"links","label":"Source: German Lymphoma Alliance contacts page"},{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.geron.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","field":"links","label":"Official website"},{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","field":"website"}]},{"url":"https://www.gffcc.org/journal/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","route":"/journals/gulf-journal-of-oncology/","field":"links","label":"Homepage"},{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","route":"/journals/gulf-journal-of-oncology/","field":"url"}]},{"url":"https://www.ghsg.org","status":200,"ok":true,"finalUrl":"https://www.ghsg.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/","field":"links","label":"GHSG"},{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/","field":"website"}]},{"url":"https://www.gilead.com","status":200,"ok":true,"finalUrl":"https://www.gilead.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","field":"links","label":"Official website"},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","field":"website"}]},{"url":"https://www.gilead.com/news-and-press/press-room/press-releases/","status":200,"ok":true,"finalUrl":"https://www.gilead.com/news","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/","field":"links","label":"Gilead discontinues magrolimab in AML (Feb 2024) (page moved; nearest live section)"}]},{"url":"https://www.gimema.it","status":200,"ok":true,"finalUrl":"https://www.gimema.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gimema","kind":"company","name":"GIMEMA","route":"/companies/gimema/","field":"links","label":"GIMEMA"},{"id":"gimema","kind":"company","name":"GIMEMA","route":"/companies/gimema/","field":"website"}]},{"url":"https://www.gimema.it/organigramma/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"links","label":"Society page"},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","field":"profiles","label":"Society page"},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","field":"links","label":"Society page"},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","field":"profiles","label":"Society page"}]},{"url":"https://www.gioncologynow.com/post/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy-for-gastric-gej-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","field":"outcomes.source (Overall survival (SPOTLIGHT))"},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","field":"outcomes.source (Overall survival (GLOW))"}]},{"url":"https://www.gla.ac.uk/schools/cancersciences/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wolfson-wohl-cancer-research-centre","kind":"institution","name":"Wolfson Wohl Cancer Research Centre, University of Glasgow","route":"/institutions/wolfson-wohl-cancer-research-centre/","field":"website"}]},{"url":"https://www.gla.ac.uk/schools/cancersciences/staff/andrewbiankin/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wolfson-wohl-cancer-research-centre","kind":"institution","name":"Wolfson Wohl Cancer Research Centre, University of Glasgow","route":"/institutions/wolfson-wohl-cancer-research-centre/","field":"links","label":"School of Cancer Sciences: Andrew Biankin"},{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/","field":"links","label":"University of Glasgow staff page"},{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/","field":"profiles","label":"University of Glasgow staff page"}]},{"url":"https://www.gld.nl/nieuws/8395257/honderden-agressie-incidenten-in-ziekenhuis-rijnstate-je-went-eraan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","field":"links","label":"Source: Omroep Gelderland report quoting her as bestuursvoorzitter (November 2025)"}]},{"url":"https://www.glenmarkpharma.com","status":200,"ok":true,"finalUrl":"https://glenmarkpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/","field":"links","label":"Official website"},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/","field":"website"},{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/","field":"links","label":"Glenmark Pharmaceuticals"}]},{"url":"https://www.global.toshiba","status":200,"ok":true,"finalUrl":"https://www.global.toshiba/jp/top.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","route":"/companies/toshiba-energy-systems/","field":"links","label":"Official website"},{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","route":"/companies/toshiba-energy-systems/","field":"website"}]},{"url":"https://www.globenewswire.com/news-release/2020/07/15/2062517/0/en/xact-ace-robotic-system-cleared-by-fda-for-image-guided-percutaneous-procedures.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","field":"links","label":"FDA clearance for CT-guided percutaneous procedures (July 2020)"}]},{"url":"https://www.globenewswire.com/news-release/2020/12/28/2150865/0/en/Aprea-Therapeutics-Announces-Results-of-Primary-Endpoint-from-Phase-3-Trial-of-Eprenetapopt-in-TP53-Mutant-Myelodysplastic-Syndromes-MDS.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","field":"links","label":"Aprea phase 3 topline (Dec 2020)"}]},{"url":"https://www.globenewswire.com/news-release/2022/12/06/2568545/0/en/nykode-therapeutics-announces-clinical-collaboration-with-msd-to-evaluate-vb10-16-in-combination-with-keytruda-pembrolizumab-in-patients-with-hpv16-positive-head-and-neck-cancer.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","field":"links","label":"MSD clinical collaboration in HPV16-positive head and neck cancer"}]},{"url":"https://www.globenewswire.com/news-release/2023/04/18/2649342/0/en/nykode-therapeutics-announces-positive-final-results-from-its-phase-2-trial-of-vb10-16-in-combination-with-pd-l1-inhibitor-atezolizumab-in-advanced-cervical-cancer.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","field":"links","label":"Phase 2 VB10.16 final results in cervical cancer"}]},{"url":"https://www.globenewswire.com/news-release/2025/10/20/3169094/0/en/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-pembrolizumab-in-first-line-advanced-melanoma-at-esmo-2025.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","field":"links","label":"Phase 3 results for Cylembio plus pembrolizumab (ESMO 2025)"}]},{"url":"https://www.globenewswire.com/news-release/2026/01/30/3229500/0/en/io-biotech-provides-corporate-update.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","field":"links","label":"Corporate update and strategic alternatives (January 2026)"}]},{"url":"https://www.globenewswire.com/news-release/2026/01/30/3229623/0/en/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectab.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","field":"regulatoryEvents.source (2026-01-30)"}]},{"url":"https://www.globenewswire.com/news-release/2026/03/09/3252192/0/en/update-ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","field":"links","label":"Ipsen withdrawal notice (9 March 2026)"}]},{"url":"https://www.globenewswire.com/news-release/2026/05/31/3303917/0/en/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/","field":"links","label":"Immunocore ASCO 2026 update"},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/","field":"links","label":"Immunocore ASCO 2026 data"}]},{"url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","field":"links","label":"EHA 2026 data"}]},{"url":"https://www.globenewswire.com/news-release/2026/07/02/3321282/0/en/revolution-medicines-presents-phase-1-2-clinical-data-for-zoldonrasib-combination-regimens-in-patients-with-ras-g12d-metastatic-pancreatic-cancer-at-esmo-gastrointestinal-cancers-c.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","field":"links","label":"Revolution Medicines release, ESMO GI 2026 abstract 341O (GlobeNewswire, 2 July 2026)"}]},{"url":"https://www.globenewswire.com/news-release/2026/08/10/3342190/0/en/sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-updates.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","field":"links","label":"Q2 2026 update"}]},{"url":"https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","field":"links","label":"Q2 2026 highlights"}]},{"url":"https://www.globenewswire.com/news-release/2026/08/18/3346680/0/en/immatics-announces-second-quarter-2026-financial-results-and-business-update.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","field":"links","label":"Q2 2026 update"}]},{"url":"https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/","field":"links","label":"MODeFIRe-1 first patient"}]},{"url":"https://www.glpg.com","status":200,"ok":true,"finalUrl":"https://lakefrontbio.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","field":"links","label":"Official website"},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","field":"website"}]},{"url":"https://www.gob.mx/cofepris","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","route":"/institutions/cofepris/","field":"links","label":"COFEPRIS"},{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","route":"/institutions/cofepris/","field":"website"}]},{"url":"https://www.gob.mx/cofepris/estructuras/dr-victor-hugo-borja-aburto","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"links","label":"Source: COFEPRIS commissioner profile"},{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.gob.mx/salud/prensa/225-instituto-nacional-de-cancerologia-cumple-79-anos-con-avances-tecnologicos-y-mayor-capacidad-de-atencion","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","field":"links","label":"Source: Mexican Ministry of Health press release, November 2025"}]},{"url":"https://www.gog.org","status":200,"ok":true,"finalUrl":"https://www.gog.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/","field":"links","label":"GOG Foundation"},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/","field":"website"}]},{"url":"https://www.gog.org/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","field":"links","label":"Society page"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","field":"profiles","label":"Society page"},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","field":"links","label":"Society page"},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","field":"profiles","label":"Society page"}]},{"url":"https://www.goodmancancer.ca/en/about-us","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","field":"links","label":"Source: Goodman Cancer Institute about page"}]},{"url":"https://www.goodmancancer.ca/en/principal-investigators/john-stagg","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","field":"profiles","label":"Goodman Cancer Institute profile"}]},{"url":"https://www.gortec.net","status":200,"ok":true,"finalUrl":"https://www.gortec.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gortec","kind":"company","name":"GORTEC","route":"/companies/gortec/","field":"website"}]},{"url":"https://www.gortec.net/v/index.php/le-gortec","status":200,"ok":true,"finalUrl":"https://www.gortec.net/v/index.php/fr/le-gortec","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gortec","kind":"company","name":"GORTEC","route":"/companies/gortec/","field":"links","label":"GORTEC: Le Gortec (history and organisation)"}]},{"url":"https://www.gosh.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.gosh.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","field":"links","label":"Homepage"},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","field":"website"}]},{"url":"https://www.gosh.nhs.uk/about-us/who-we-are/organisational-structure/trust-board/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","route":"/people/karl-munslow-ong/","field":"links","label":"Institution profile"},{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","route":"/people/karl-munslow-ong/","field":"profiles","label":"Institution profile"},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","field":"links","label":"Institution profile"},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.gov.br/anvisa","status":200,"ok":true,"finalUrl":"https://www.gov.br/anvisa/pt-br","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","field":"links","label":"ANVISA"},{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","field":"website"}]},{"url":"https://www.gov.br/anvisa/pt-br/composicao/diretor-presidente","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leandro-pinheiro-safatle","kind":"person","name":"Leandro Pinheiro Safatle","route":"/people/leandro-pinheiro-safatle/","field":"links","label":"Source: Anvisa Diretor-Presidente page"}]},{"url":"https://www.gov.br/anvisa/pt-br/composicao/diretor-presidente/antonio-barra-torres","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leandro-pinheiro-safatle","kind":"person","name":"Leandro Pinheiro Safatle","route":"/people/leandro-pinheiro-safatle/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.gov.br/inca","status":200,"ok":true,"finalUrl":"https://www.gov.br/inca/pt-br","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","field":"links","label":"INCA"},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","field":"website"}]},{"url":"https://www.gov.br/inca/pt-br/acesso-a-informacao/institucional/quem-e-quem","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"links","label":"Institution profile"},{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.gov.uk/government/collections/","status":200,"ok":true,"finalUrl":"https://www.gov.uk/search/all","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-prev-smokefree-generation-evaluation","kind":"idea","name":"Smoke-free generation laws with a built-in evaluation across countries","route":"/ideas/idea-prev-smokefree-generation-evaluation/","field":"links","label":"UK Tobacco and Vapes Bill (page moved; nearest live section)"}]},{"url":"https://www.gov.uk/government/news/","status":200,"ok":true,"finalUrl":"https://www.gov.uk/search/news-and-communications","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/","field":"links","label":"MHRA point of care manufacturing framework (page moved; nearest live section)"}]},{"url":"https://www.gov.uk/government/news/mhra-approves-zanidatamab-ziihera-for-the-treatment-of-biliary-tract-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/","field":"links","label":"MHRA approves zanidatamab (Ziihera) for biliary tract cancer (GOV.UK, 2026)"}]},{"url":"https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023)"},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","field":"links","label":"GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023)"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","field":"links","label":"GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023)"}],"archive":"https://web.archive.org/web/20260903014815/https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner"},{"url":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","route":"/people/lawrence-tallon/","field":"links","label":"Institution profile"},{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","route":"/people/lawrence-tallon/","field":"profiles","label":"Institution profile"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","field":"links","label":"MHRA"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","field":"website"}]},{"url":"https://www.gov.uk/government/publications/bowel-cancer-screening-programme-standards/bowel-cancer-screening-programme-standards-reporting-from-1-april-2025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"GOV.UK: bowel cancer screening programme standards, reporting from 1 April 2025 (uptake thresholds)"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"GOV.UK: bowel cancer screening programme standards, reporting from 1 April 2025 (uptake thresholds)"},{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","field":"links","label":"GOV.UK: bowel cancer screening programme standards, reporting from 1 April 2025 (uptake thresholds)"}]},{"url":"https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-hodgkin-late-effects","kind":"term","name":"Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them","route":"/terms/lymphoma-tx-hodgkin-late-effects/","field":"links","label":"NHS breast screening programme: protocols for surveillance of women at higher risk of developing breast cancer (GOV.UK)"}]},{"url":"https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/","field":"links","label":"GOV.UK: Innovative Licensing and Access Pathway (ILAP)"}]},{"url":"https://www.gov.uk/guidance/bowel-cancer-screening-programme-overview","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"GOV.UK: NHS bowel cancer screening programme overview (target population and the screening test)"},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","field":"links","label":"GOV.UK: NHS bowel cancer screening programme overview (target population and the screening test)"},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","field":"links","label":"GOV.UK: NHS bowel cancer screening programme overview (target population and the screening test)"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"GOV.UK: NHS bowel cancer screening programme overview (target population and the screening test)"},{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","field":"links","label":"GOV.UK: NHS bowel cancer screening programme overview (target population and the screening test)"}]},{"url":"https://www.gov.uk/guidance/breast-screening-programme-overview","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agex","kind":"trial","name":"AgeX","route":"/trials/agex/","field":"links","label":"NHS breast screening programme overview"}]},{"url":"https://www.gov.za/news/media-statements/gauteng-health-announces-appointment-three-ceos-academic-hospitals-08-mar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","route":"/people/lehlohonolo-majake/","field":"links","label":"Source: South African Government media statement on the appointment (8 March 2024)"},{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","route":"/people/lehlohonolo-majake/","field":"profiles","label":"Gauteng Health appointment statement (gov.za)"}]},{"url":"https://www.granzabio.com","status":200,"ok":true,"finalUrl":"https://www.granzabio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/","field":"links","label":"Official website"},{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/","field":"website"}]},{"url":"https://www.greenwichlifesciences.com/","status":200,"ok":true,"finalUrl":"https://greenwichlifesciences.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","route":"/companies/greenwich-lifesciences/","field":"links","label":"Official website"},{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","route":"/companies/greenwich-lifesciences/","field":"website"}]},{"url":"https://www.grifols.com","status":200,"ok":true,"finalUrl":"https://www.grifols.com/en/home","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","field":"links","label":"Official website"},{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","field":"website"}]},{"url":"https://www.gritstonebio.com","status":200,"ok":true,"finalUrl":"https://nexoplexbio.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","field":"website"}]},{"url":"https://www.grunenthal.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","field":"links","label":"Official website"},{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","field":"website"}]},{"url":"https://www.gruposolti.org","status":200,"ok":true,"finalUrl":"https://www.gruposolti.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/","field":"links","label":"SOLTI"},{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/","field":"website"}]},{"url":"https://www.gruposolti.org/junta-directiva/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"links","label":"Society page"},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","field":"profiles","label":"Society page"},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","field":"links","label":"Society page"},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","field":"profiles","label":"Society page"}]},{"url":"https://www.gsea-msigdb.org/gsea/msigdb/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","field":"links","label":"MSigDB"}]},{"url":"https://www.gsk.com","status":200,"ok":true,"finalUrl":"https://www.gsk.com/en-gb/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","field":"links","label":"Official website"},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","field":"website"}]},{"url":"https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-accepted-for-priority-review-by-the-us-fda/","status":200,"ok":true,"contentType":"application/json","checked":"2026-09-30","refs":[{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","field":"links","label":"GSK priority review announcement"}]},{"url":"https://www.gst-rsk.ma/actualites/nomination-du-professeur-brahim-lakhal-directeur-general-du-groupement-sanitaire-territorial-gst-de-la-region-rabat-sale-kenitra/","status":200,"ok":true,"finalUrl":"https://www.gst-rsk.ma/autres/nomination-du-professeur-brahim-lakhal-directeur-general-du-groupement-sanitaire-territorial-gst-de-la-region-rabat-sale-kenitra/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","route":"/people/brahim-lakhal/","field":"links","label":"Source: GST RSK news item on the appointment of the Directeur Général"},{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","route":"/people/brahim-lakhal/","field":"profiles","label":"GST Rabat-Salé-Kénitra appointment announcement"}]},{"url":"https://www.guardian-bio.com","status":200,"ok":true,"finalUrl":"https://guardian-bio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/","field":"links","label":"Official website"},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/","field":"website"}]},{"url":"https://www.guerbet.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guerbet","kind":"company","name":"Guerbet","route":"/companies/guerbet/","field":"links","label":"Official website"},{"id":"guerbet","kind":"company","name":"Guerbet","route":"/companies/guerbet/","field":"website"}]},{"url":"https://www.guidestar.org.il/organization/580030039","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","route":"/institutions/israel-cancer-association/","field":"links","label":"Registrar of Associations record (Guidestar, registration 580030039)"}]},{"url":"https://www.gunma-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.gunma-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","field":"links","label":"Gunma University"}]},{"url":"https://www.gustaveroussy.fr","status":200,"ok":true,"finalUrl":"https://www.gustaveroussy.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","field":"links","label":"Official website"},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","field":"website"}]},{"url":"https://www.gustaveroussy.fr/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","field":"links","label":"Gustave Roussy"},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","field":"profiles","label":"Gustave Roussy"},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","field":"links","label":"Gustave Roussy"},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","field":"profiles","label":"Gustave Roussy"}]},{"url":"https://www.guysandstthomas.nhs.uk/about-us/our-board/executive-directors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"amanda-pritchard","kind":"person","name":"Amanda Pritchard","route":"/people/amanda-pritchard/","field":"links","label":"Source: Guy's and St Thomas' executive directors page"},{"id":"amanda-pritchard","kind":"person","name":"Amanda Pritchard","route":"/people/amanda-pritchard/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.guysandstthomas.nhs.uk/our-services/cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","field":"links","label":"Cancer services"},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","field":"website"}]},{"url":"https://www.gv.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/","field":"links","label":"Official website"},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/","field":"website"}]},{"url":"https://www.gv.com/portfolio","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/","field":"links","label":"Portfolio"}]},{"url":"https://www.ha.org.hk","status":200,"ok":true,"finalUrl":"https://www.ha.org.hk/welcome.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","field":"links","label":"Hospital Authority: Queen Mary Hospital"}]},{"url":"https://www.haihepharma.com","status":200,"ok":true,"finalUrl":"https://www.haihepharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/","field":"links","label":"Official website"},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/","field":"website"}]},{"url":"https://www.hairycellleukemia.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","field":"links","label":"Hairy Cell Leukemia Foundation"}]},{"url":"https://www.haldatx.com/","status":200,"ok":true,"finalUrl":"https://www.jnj.com/innovativemedicine/","contentType":"text/html;charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","field":"links","label":"Official website"},{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","field":"website"}]},{"url":"https://www.halozyme.com","status":200,"ok":true,"finalUrl":"https://halozyme.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","field":"links","label":"Official website"},{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","field":"website"}]},{"url":"https://www.hamamatsu.com","status":200,"ok":true,"finalUrl":"https://www.hamamatsu.com/jp/en.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"links","label":"Official website"},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"website"}]},{"url":"https://www.hamiltonhealthsciences.ca/about-us/our-organization/senior-leadership-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chris-hillis","kind":"person","name":"Chris Hillis","route":"/people/chris-hillis/","field":"links","label":"Source: Hamilton Health Sciences senior leadership team"},{"id":"chris-hillis","kind":"person","name":"Chris Hillis","route":"/people/chris-hillis/","field":"profiles","label":"Institution senior leadership page"}]},{"url":"https://www.hamiltonhealthsciences.ca/areas-of-care/cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","field":"links","label":"Juravinski Cancer Centre"},{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","field":"website"}]},{"url":"https://www.hanmipharm.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/","field":"links","label":"Official website"},{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/","field":"website"}]},{"url":"https://www.hanxbio.com","status":200,"ok":true,"finalUrl":"https://www.hanxbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/","field":"links","label":"Official website"},{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/","field":"website"}]},{"url":"https://www.harbourbiomed.com","status":200,"ok":true,"finalUrl":"https://www.harbourbiomed.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","field":"links","label":"Official website"},{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","field":"website"}]},{"url":"https://www.hartwigmedicalfoundation.nl/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-federated-evolution-atlas","kind":"idea","name":"Pool every multi-sample tumour genome into one open evolution atlas","route":"/ideas/idea-bio1-federated-evolution-atlas/","field":"links","label":"Hartwig Medical Foundation"},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","route":"/companies/hartwig-medical-foundation/","field":"links","label":"Official website"},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","route":"/companies/hartwig-medical-foundation/","field":"website"}]},{"url":"https://www.has-sante.fr","status":200,"ok":true,"finalUrl":"https://www.has-sante.fr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/","field":"links","label":"HAS"},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/","field":"website"}]},{"url":"https://www.has-sante.fr/jcms/c_1002210/en/governance","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-lessi","kind":"person","name":"Jean Lessi","route":"/people/jean-lessi/","field":"links","label":"Institution profile"},{"id":"jean-lessi","kind":"person","name":"Jean Lessi","route":"/people/jean-lessi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.has-sante.fr/jcms/p_3277085/fr/acces-precoce","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"france-early-access","kind":"term","name":"France: early access (accès précoce), formerly ATU","route":"/terms/france-early-access/","field":"links","label":"HAS: accès précoce (French)"}]},{"url":"https://www.hastane.hacettepe.edu.tr","status":200,"ok":true,"finalUrl":"https://www.hastane.hacettepe.edu.tr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","field":"links","label":"Hacettepe University Hospitals"}]},{"url":"https://www.hcahealthcare.co.uk/finder/stepconsultantprofile/hassan-malik-2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hassan-malik","kind":"person","name":"Hassan Malik","route":"/people/hassan-malik/","field":"links","label":"HCA Healthcare UK consultant profile (biography)"},{"id":"hassan-malik","kind":"person","name":"Hassan Malik","route":"/people/hassan-malik/","field":"profiles","label":"HCA Healthcare UK consultant profile (biography)"}]},{"url":"https://www.hcpa.edu.br","status":200,"ok":true,"finalUrl":"https://www.hcpa.edu.br/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","field":"links","label":"HCPA"},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","field":"website"}]},{"url":"https://www.healio.com/news/hematology-oncology","status":200,"ok":true,"checked":"2026-09-30","refs":[{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","field":"links","label":"Healio Hematology/Oncology"},{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","field":"url"}]},{"url":"https://www.healthcatalyst.com/news/health-catalyst-acquires-oncology-focused-health-technology-company-carevive","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","field":"links","label":"Health Catalyst acquisition announcement (June 2024)"}]},{"url":"https://www.healthcatalyst.com/offerings/carevive-by-health-catalyst","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","field":"links","label":"Official website"},{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","field":"website"}]},{"url":"https://www.healthdata.org/research-analysis/gbd","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","field":"links","label":"Global Burden of Disease"}]},{"url":"https://www.healthierlsc.co.uk/canceralliance","status":200,"ok":true,"finalUrl":"https://www.lancashireandsouthcumbria.icb.nhs.uk/our-work/canceralliance","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","route":"/institutions/lancashire-south-cumbria-cancer-alliance/","field":"links","label":"Lancashire and South Cumbria Cancer Alliance"},{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","route":"/institutions/lancashire-south-cumbria-cancer-alliance/","field":"website"}]},{"url":"https://www.healthit.gov/topic/certification-ehrs/certification-health-it","status":200,"ok":true,"finalUrl":"https://healthit.gov/certification-health-it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-oncology-api-certification","kind":"idea","name":"Certify every oncology software product for a standard bulk data export","route":"/ideas/idea-data-oncology-api-certification/","field":"links","label":"ONC Health IT Certification Program"},{"id":"hospital-information-systems-oncology","kind":"technology","name":"Oncology EHR modules and treatment pathways","route":"/technologies/hospital-information-systems-oncology/","field":"links","label":"ONC Health IT Certification Program"}]},{"url":"https://www.healthnz.govt.nz/about-us/who-we-are/our-executive-team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","field":"links","label":"Source: Health New Zealand 'Our executive team' page"},{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","field":"profiles","label":"Health New Zealand executive team"}]},{"url":"https://www.hec.cn/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/","field":"links","label":"HEC group website"},{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/","field":"website"}]},{"url":"https://www.hellomynameis.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","field":"links","label":"#hellomynameis"},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","field":"profiles","label":"#hellomynameis"}]},{"url":"https://www.helsinki.fi/en/hilife-helsinki-institute-life-science/units/fimm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","field":"links","label":"FIMM"}]},{"url":"https://www.helsinn.com","status":200,"ok":true,"finalUrl":"https://helsinn.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helsinn","kind":"company","name":"Helsinn","route":"/companies/helsinn/","field":"links","label":"Official website"},{"id":"helsinn","kind":"company","name":"Helsinn","route":"/companies/helsinn/","field":"website"}]},{"url":"https://www.hematology.org","status":200,"ok":true,"finalUrl":"https://www.hematology.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","field":"links","label":"ASH"},{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","field":"website"}]},{"url":"https://www.hematology.org/about/governance/executive-committee","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/","field":"links","label":"Source: ASH Executive Committee page"}]},{"url":"https://www.hematology.org/education/clinicians/guidelines-and-quality-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","field":"links","label":"ASH guidelines"}]},{"url":"https://www.hematology.org/meetings/annual-meeting","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/","field":"links","label":"ASH Annual Meeting"},{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/","field":"url"},{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","field":"links","label":"ASH annual meeting"},{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","field":"links","label":"Annual Meeting"}]},{"url":"https://www.hematologyandoncology.net/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/","field":"links","label":"Homepage"},{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/","field":"url"}]},{"url":"https://www.hengrui.com","status":200,"ok":true,"finalUrl":"https://www.hengrui.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","field":"links","label":"Official website"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","field":"website"}]},{"url":"https://www.hengrui.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/","field":"links","label":"Jiangsu Hengrui Pharmaceuticals"},{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/","field":"profiles","label":"Jiangsu Hengrui Pharmaceuticals"},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","field":"links","label":"Jiangsu Hengrui Pharmaceuticals"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","field":"links","label":"Jiangsu Hengrui Pharmaceuticals"},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","field":"links","label":"Jiangsu Hengrui Pharmaceuticals"}]},{"url":"https://www.henlius.com","status":200,"ok":true,"finalUrl":"https://www.henlius.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","field":"links","label":"Official website"},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","field":"website"}]},{"url":"https://www.henlius.com/en/NewsDetails-5324-26.html","status":200,"ok":true,"finalUrl":"https://www.henlius.com/en/newsd/0/25324.html?title=Serplulimab-Approved-in-the-UK-and-India-for-the-First-Line-Treatment-of-Extensive-Stage-Small-Cell-Lung-Cancer","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","field":"regulatoryEvents.source (2025)"}]},{"url":"https://www.henlius.com/en/NewsDetails-5903-26.html","status":200,"ok":true,"finalUrl":"https://www.henlius.com/en/newsd/0/31325.html?title=Henlius%27-Serplulimab-Secures-EC-Approval-for-Two-New-Indications,-Further-Deepening-Global-Commercialisation-Footprint","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","field":"regulatoryEvents.source (2025-02)"}]},{"url":"https://www.herlevhospital.dk/","status":200,"ok":true,"finalUrl":"https://security-check.regionh.dk/NDBD/validate?config=CMS&data=l0WEe15JrjmMqw3msrflU6hxPDAX%2BdzO8jOtcQLivqSpdomaft0Pm7QOwPe4PADjjfBOOEqq9oENb%2FxZcin%2FGOjWIPJUNG4Uq2003vOsWhoEdtqHcaDpq6Ed98VooWy7bnozc6kvFqWu5B%2BBvCJLZerBTWdWHAnX1wI1DjpxoRVjaW5ozNV9lKgrnsdCvFJzzCkkF4WmSxFyWwwNfVWIOFMrcbmNBICb50MwTQG85KLeKOF2MZJ6Tyyq2FGc2By2gfbqAAAAAQ%3D%3D","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","field":"links","label":"Herlev Hospital, Copenhagen University Hospital website"},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","field":"profiles","label":"Herlev Hospital, Copenhagen University Hospital website"},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","field":"links","label":"Official website"},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","field":"website"}]},{"url":"https://www.herlevhospital.dk/ccit-dk/","status":200,"ok":true,"finalUrl":"https://security-check.regionh.dk/NDBD/validate?config=CMS&data=SxRYos%2Bt6LBKm%2BPmsrflU6hxPDAX%2BZfIr%2FoVEzz38Mpd4IZ0%2FjirTFl55C5EQPxAg6LwXlDdnXridh73nSHhn6SY68vNOA7b0PyrHSo3kyMjVmb62PZ1Qbcj23jUWfCR%2Bs5y5eb60pPJX7%2Fj3QDDXiGqQNEgDs8eUcIokkJAoyqa9%2FqaX4i0VaoLI7qlCCnYFTRX3aaLZnkOXAbnDiABe5B5GHrboM0%2BTAz5HjlxmB1t9WWP9TBMPJkk1ct8XNByMUcsIJRKmOGB0kYAAAAB","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","field":"links","label":"CCIT-DK"}]},{"url":"https://www.herontx.com","status":200,"ok":true,"finalUrl":"https://www.herontx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","route":"/companies/heron-therapeutics/","field":"links","label":"Official website"},{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","route":"/companies/heron-therapeutics/","field":"website"}]},{"url":"https://www.hhmi.org","status":200,"ok":true,"finalUrl":"https://www.hhmi.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","field":"links","label":"HHMI"},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","field":"website"}]},{"url":"https://www.hhmi.org/programs/biomedical-research/investigator-program","status":200,"ok":true,"finalUrl":"https://www.hhmi.org/programs/investigators","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-ten-year-hard-problem-awards","kind":"idea","name":"Ten-year awards for scientists who commit to one hard problem","route":"/ideas/idea-fund-ten-year-hard-problem-awards/","field":"links","label":"HHMI Investigator Program"}]},{"url":"https://www.hikma.com","status":200,"ok":true,"finalUrl":"https://www.hikma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","route":"/companies/hikma/","field":"links","label":"Official website"},{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","route":"/companies/hikma/","field":"website"}]},{"url":"https://www.hinovapharma.com","status":200,"ok":true,"finalUrl":"https://www.hinovapharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/","field":"links","label":"Official website"},{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/","field":"website"}]},{"url":"https://www.hitachi.com","status":200,"ok":true,"finalUrl":"https://www.hitachi.com/en/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/","field":"links","label":"Official website"},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/","field":"website"}]},{"url":"https://www.hkci.cuhk.edu.hk","status":200,"ok":true,"finalUrl":"https://www.cuhk.edu.hk/med/hkci/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","field":"links","label":"Hong Kong Cancer Institute"}]},{"url":"https://www.hku.hk","status":200,"ok":true,"finalUrl":"https://www.hku.hk/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","field":"website"}]},{"url":"https://www.hkuctc.com","status":200,"ok":true,"finalUrl":"https://www.hkuctc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","field":"links","label":"HKU Clinical Trials Centre"}]},{"url":"https://www.hl7.org","status":200,"ok":true,"finalUrl":"https://www.hl7.org/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","field":"links","label":"HL7"},{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","field":"website"}]},{"url":"https://www.hmciocc.com","status":200,"ok":true,"finalUrl":"https://www.hmhospitales.com/hm-ciocc/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","route":"/institutions/clara-campal-oncology-centre/","field":"links","label":"Official website"},{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","route":"/institutions/clara-campal-oncology-centre/","field":"website"}]},{"url":"https://www.hmciocc.com/","status":200,"ok":true,"finalUrl":"https://www.hmhospitales.com/hm-ciocc/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","field":"links","label":"Centro Integral Oncológico Clara Campal (HM CIOCC) website"},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","field":"profiles","label":"Centro Integral Oncológico Clara Campal (HM CIOCC) website"}]},{"url":"https://www.hnszlyy.com","status":200,"ok":true,"finalUrl":"https://www.hnszlyy.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","field":"links","label":"Hunan Cancer Hospital"},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","field":"website"}]},{"url":"https://www.hnycanceralliance.org.uk","status":200,"ok":true,"finalUrl":"https://hnycanceralliance.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","route":"/institutions/humber-north-yorkshire-cancer-alliance/","field":"links","label":"Humber & North Yorkshire Cancer Alliance"},{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","route":"/institutions/humber-north-yorkshire-cancer-alliance/","field":"website"}]},{"url":"https://www.hollandptc.nl","status":200,"ok":true,"finalUrl":"https://www.hollandptc.nl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"links","label":"HollandPTC"}]},{"url":"https://www.hologic.com","status":200,"ok":true,"finalUrl":"https://www.hologic.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/","field":"links","label":"Official website"},{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/","field":"website"}]},{"url":"https://www.horg.gr","status":200,"ok":true,"finalUrl":"https://horg.gr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"horg","kind":"company","name":"Hellenic Oncology Research Group","route":"/companies/horg/","field":"website"}]},{"url":"https://www.horg.gr/en/","status":200,"ok":true,"finalUrl":"https://horg.gr/en/%ce%b1%cf%81%cf%87%ce%b9%ce%ba%ce%b7-english/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"horg","kind":"company","name":"Hellenic Oncology Research Group","route":"/companies/horg/","field":"links","label":"Official website"}]},{"url":"https://www.hosp.keio.ac.jp","status":200,"ok":true,"finalUrl":"https://www.hosp.keio.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","field":"links","label":"Keio University Hospital"},{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","field":"website"}]},{"url":"https://www.hosp.keio.ac.jp/en/about/incho/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","field":"links","label":"Institution profile"},{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.hosp.kyushu-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.hosp.kyushu-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","field":"links","label":"Kyushu University Hospital"},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","field":"website"}]},{"url":"https://www.hosp.kyushu-u.ac.jp/info/aisatsu_20260401/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","route":"/people/yasuharu-nakashima/","field":"profiles","label":"Director's greeting (Japanese)"}]},{"url":"https://www.hosp.kyushu-u.ac.jp/uploads/file/articles/16324.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","route":"/people/yasuharu-nakashima/","field":"links","label":"Source: Kyushu University Hospital leadership list, 1 April 2026"}]},{"url":"https://www.hosp.tohoku.ac.jp","status":200,"ok":true,"finalUrl":"https://www.hosp.tohoku.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","field":"links","label":"Tohoku University Hospital"},{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","field":"website"}]},{"url":"https://www.hosp.tohoku.ac.jp/en/outline/002.php","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","route":"/people/takashi-kamei/","field":"links","label":"Source: Tohoku University Hospital, Message from the Director"},{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","route":"/people/takashi-kamei/","field":"profiles","label":"Message from the Director"}]},{"url":"https://www.hospitaldelmar.cat","status":200,"ok":true,"finalUrl":"https://www.hospitaldelmar.cat/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/","field":"links","label":"Hospital del Mar"},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/","field":"website"}]},{"url":"https://www.hospitaldelmar.cat/en/info-corp/organs-de-govern/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jaume-raventos-i-monjo","kind":"person","name":"Jaume Raventós i Monjo","route":"/people/jaume-raventos-i-monjo/","field":"links","label":"Institution profile"},{"id":"jaume-raventos-i-monjo","kind":"person","name":"Jaume Raventós i Monjo","route":"/people/jaume-raventos-i-monjo/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.hospitalitaliano.org.ar","status":200,"ok":true,"finalUrl":"https://www.hospitalitaliano.org.ar/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","route":"/institutions/hospital-italiano-buenos-aires/","field":"links","label":"Official website"},{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","route":"/institutions/hospital-italiano-buenos-aires/","field":"website"}]},{"url":"https://www.hospitalsantjoan.cat","status":200,"ok":true,"finalUrl":"https://www.hospitalsantjoan.cat/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/","field":"links","label":"Official website"},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/","field":"website"}]},{"url":"https://www.hospitalsiriolibanes.org.br","status":200,"ok":true,"finalUrl":"https://hospitalsiriolibanes.org.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","field":"links","label":"Official website"},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","field":"website"},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","field":"links","label":"Hospital Sírio-Libanês"},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","field":"profiles","label":"Hospital Sírio-Libanês"},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","field":"links","label":"Hospital Sírio-Libanês"},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","field":"profiles","label":"Hospital Sírio-Libanês"}]},{"url":"https://www.houstonmethodist.org","status":200,"ok":true,"finalUrl":"https://www.houstonmethodist.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","route":"/institutions/houston-methodist-neal-cancer-center/","field":"links","label":"Houston Methodist"},{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","route":"/institutions/houston-methodist-neal-cancer-center/","field":"website"}]},{"url":"https://www.houstonmethodist.org/academic-institute/department-programs/center-for-rna-therapeutics/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","route":"/institutions/houston-methodist-rna-therapeutics/","field":"links","label":"Official website"},{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","route":"/institutions/houston-methodist-rna-therapeutics/","field":"website"}]},{"url":"https://www.hpfreemanpni.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-moon-navigation-as-a-right","kind":"idea","name":"Patient navigation as a legal entitlement from the day of diagnosis","route":"/ideas/idea-moon-navigation-as-a-right/","field":"links","label":"Harold P. Freeman Patient Navigation Institute"}]},{"url":"https://www.hrc.govt.nz/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-neglected-cancer-lottery","kind":"idea","name":"Partial lottery funding for good proposals in under-funded cancers","route":"/ideas/idea-fund-neglected-cancer-lottery/","field":"links","label":"Health Research Council of New Zealand"}]},{"url":"https://www.hspharm.com","status":200,"ok":true,"finalUrl":"https://www.hspharm.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","field":"website"}]},{"url":"https://www.hspharm.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","field":"links","label":"Hansoh Pharma (page moved; nearest live section)"},{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","field":"links","label":"Official website"}]},{"url":"https://www.huborganoids.nl","status":200,"ok":true,"finalUrl":"https://www.huborganoids.nl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/","field":"links","label":"Official website"},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/","field":"website"}]},{"url":"https://www.hubrecht.eu","status":200,"ok":true,"finalUrl":"https://www.hubrecht.eu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","field":"links","label":"Hubrecht Institute"}]},{"url":"https://www.hug.ch/en/oncology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","field":"links","label":"Institution profile"},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","field":"profiles","label":"Institution profile"},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/","field":"links","label":"HUG Oncology"},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/","field":"website"}]},{"url":"https://www.huhp.hokudai.ac.jp","status":200,"ok":true,"finalUrl":"https://www.huhp.hokudai.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","field":"links","label":"Hokkaido University Hospital"},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","field":"website"}]},{"url":"https://www.huhp.hokudai.ac.jp/director/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"links","label":"Source: Hokkaido University Hospital director's page"},{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","field":"profiles","label":"Director's message (Japanese)"}]},{"url":"https://www.huiyupharma.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","field":"links","label":"Official website"},{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","field":"website"}]},{"url":"https://www.hull.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.hull.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"queens-centre-hull","kind":"institution","name":"Queen's Centre for Oncology and Haematology, Castle Hill Hospital","route":"/institutions/queens-centre-hull/","field":"links","label":"Official website"},{"id":"queens-centre-hull","kind":"institution","name":"Queen's Centre for Oncology and Haematology, Castle Hill Hospital","route":"/institutions/queens-centre-hull/","field":"website"}]},{"url":"https://www.hull.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hull-castle-hill","kind":"institution","name":"Castle Hill Hospital, Hull (Queen's Centre)","route":"/institutions/hull-castle-hill/","field":"links","label":"Hull University Teaching Hospitals: HPB"},{"id":"hull-castle-hill","kind":"institution","name":"Castle Hill Hospital, Hull (Queen's Centre)","route":"/institutions/hull-castle-hill/","field":"website"}]},{"url":"https://www.humancellatlas.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-moon-open-cancer-cell-state-model","kind":"idea","name":"An open model of every cancer cell state, built from perturbation atlases","route":"/ideas/idea-moon-open-cancer-cell-state-model/","field":"links","label":"Human Cell Atlas"}]},{"url":"https://www.humanitas.it/medici/armando-santoro/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"links","label":"Institution profile"},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.humanitas.net","status":200,"ok":true,"finalUrl":"https://www.humanitas.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","field":"links","label":"IRCCS Humanitas Research Hospital website"},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","field":"profiles","label":"IRCCS Humanitas Research Hospital website"},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","field":"links","label":"Homepage"},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","field":"website"}]},{"url":"https://www.humanitas.net/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"simona-sancini","kind":"person","name":"Simona Sancini","route":"/people/simona-sancini/","field":"links","label":"Institution profile"},{"id":"simona-sancini","kind":"person","name":"Simona Sancini","route":"/people/simona-sancini/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.humanitas.net/cancer-center/","status":200,"ok":true,"finalUrl":"https://www.humanitas.net/centers/cancer-center/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","field":"links","label":"Cancer Center"}]},{"url":"https://www.hus.fi/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","field":"links","label":"HUS Comprehensive Cancer Center (page moved; nearest live section)"},{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","field":"website"}]},{"url":"https://www.hus.fi/en/about-us/departments/comprehensive-cancer-center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","route":"/people/johanna-mattson/","field":"links","label":"Source: HUS Comprehensive Cancer Center leadership listing"},{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","route":"/people/johanna-mattson/","field":"profiles","label":"HUS Comprehensive Cancer Center page"}]},{"url":"https://www.i-mabbiopharma.com/","status":200,"ok":true,"finalUrl":"https://www.novabridge.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"i-mab","kind":"company","name":"I-Mab","route":"/companies/i-mab/","field":"links","label":"Official website"},{"id":"i-mab","kind":"company","name":"I-Mab","route":"/companies/i-mab/","field":"website"}]},{"url":"https://www.iambic.ai","status":200,"ok":true,"finalUrl":"https://www.iambic.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/","field":"links","label":"Official website"},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/","field":"website"}]},{"url":"https://www.iarc.who.int","status":200,"ok":true,"finalUrl":"https://www.iarc.who.int/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/","field":"links","label":"Official website"},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/","field":"website"},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","field":"links","label":"IARC"},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","field":"profiles","label":"IARC"},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"links","label":"IARC"},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","field":"profiles","label":"IARC"},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","field":"links","label":"IARC"},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","field":"profiles","label":"IARC"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","field":"links","label":"IARC"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","field":"profiles","label":"IARC"}]},{"url":"https://www.iaslc.org","status":200,"ok":true,"finalUrl":"https://www.iaslc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","field":"links","label":"IASLC"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","field":"links","label":"IASLC"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","field":"website"}]},{"url":"https://www.iaslc.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","field":"links","label":"IASLC: International Association for the Study of Lung Cancer"}]},{"url":"https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"IASLC: tarlatamab first-line maintenance data"},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","field":"links","label":"DeLLphi-303 results (IASLC)"}],"archive":"https://web.archive.org/web/20260414190124/https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es"},{"url":"https://www.iaslc.org/learn-about-us/board-directors","status":200,"ok":true,"finalUrl":"https://www.iaslc.org/about-us/board-directors","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"links","label":"IASLC board"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","field":"profiles","label":"IASLC board"},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","field":"links","label":"Society page"},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","field":"profiles","label":"Society page"}]},{"url":"https://www.iasobio.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","field":"links","label":"IASO Biotherapeutics"},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/","field":"links","label":"Official website"},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/","field":"website"}]},{"url":"https://www.iba-worldwide.com","status":200,"ok":true,"finalUrl":"https://www.iba-worldwide.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","field":"links","label":"Official website"},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","field":"website"}]},{"url":"https://www.ibcsg.org","status":200,"ok":true,"finalUrl":"https://www.ibcsg.org/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/","field":"links","label":"IBCSG"},{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/","field":"website"}]},{"url":"https://www.icadmed.com","status":200,"ok":true,"finalUrl":"https://www.icadmed.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icad-profound-ai","kind":"drug","name":"ProFound AI (iCAD)","route":"/drugs/icad-profound-ai/","field":"links","label":"iCAD: ProFound"},{"id":"icad","kind":"company","name":"iCAD (RadNet)","route":"/companies/icad/","field":"links","label":"Official website"},{"id":"icad","kind":"company","name":"iCAD (RadNet)","route":"/companies/icad/","field":"website"}]},{"url":"https://www.icap84.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"links","label":"Institut Sainte Catherine website"},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"profiles","label":"Institut Sainte Catherine website"},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","field":"links","label":"Official website"},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","field":"website"}]},{"url":"https://www.icesp.org.br","status":200,"ok":true,"finalUrl":"https://icesp.org.br/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icesp","kind":"institution","name":"Instituto do Câncer do Estado de São Paulo (ICESP)","route":"/institutions/icesp/","field":"links","label":"Official website"},{"id":"icesp","kind":"institution","name":"Instituto do Câncer do Estado de São Paulo (ICESP)","route":"/institutions/icesp/","field":"website"}]},{"url":"https://www.icgc-argo.org","status":200,"ok":true,"finalUrl":"https://www.icgc-argo.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","field":"links","label":"ICGC ARGO"}]},{"url":"https://www.ich.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","field":"links","label":"International Council for Harmonisation (ICH)"}]},{"url":"https://www.ich.org/page/ctd","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-reg-single-global-dossier","kind":"idea","name":"One structured global dossier: submit the cancer drug file once, to a shared cloud","route":"/ideas/idea-reg-single-global-dossier/","field":"links","label":"ICH M4 CTD"}]},{"url":"https://www.ich.org/page/efficacy-guidelines","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr1-tolerability-estimands","kind":"idea","name":"Define tolerability endpoints as rigorously as efficacy endpoints","route":"/ideas/idea-tr1-tolerability-estimands/","field":"links","label":"ICH efficacy guidelines (E9(R1) estimands)"},{"id":"idea-reg-mrct-no-bridging","kind":"idea","name":"One multiregional trial, no bridging studies: enforce ICH E17 in Japan and China","route":"/ideas/idea-reg-mrct-no-bridging/","field":"links","label":"ICH efficacy guidelines (E17)"},{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","field":"links","label":"ICH E6 Good Clinical Practice"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","field":"links","label":"ICH efficacy guidelines (E6 Good Clinical Practice, E8 general considerations, E9 statistics)"},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"},{"id":"ich-gcp","kind":"term","name":"ICH good clinical practice (E6)","route":"/terms/ich-gcp/","field":"links","label":"ICH: efficacy guidelines (E6 good clinical practice)"}]},{"url":"https://www.ich.org/page/quality-guidelines","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-reg-manufacturing-change-passport","kind":"idea","name":"Manufacturing-change passport: one approved CMC change accepted everywhere in 30 days","route":"/ideas/idea-reg-manufacturing-change-passport/","field":"links","label":"ICH quality guidelines (Q12)"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/","field":"links","label":"ICH Q7: GMP guide for active pharmaceutical ingredients"},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/","field":"links","label":"ICH Q5A: viral safety evaluation of biotechnology products"}]},{"url":"https://www.icl-lorraine.fr","status":200,"ok":true,"finalUrl":"https://www.icl-lorraine.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","route":"/institutions/institut-de-cancerologie-de-lorraine/","field":"links","label":"Official website"},{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","route":"/institutions/institut-de-cancerologie-de-lorraine/","field":"website"}]},{"url":"https://www.icl-lorraine.fr/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","field":"links","label":"Institut de Cancérologie de Lorraine website"},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","field":"profiles","label":"Institut de Cancérologie de Lorraine website"}]},{"url":"https://www.icm.unicancer.fr","status":200,"ok":true,"finalUrl":"https://www.icm.unicancer.fr/fr","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icm-montpellier","kind":"institution","name":"Institut du Cancer de Montpellier (ICM)","route":"/institutions/icm-montpellier/","field":"links","label":"Official website"},{"id":"icm-montpellier","kind":"institution","name":"Institut du Cancer de Montpellier (ICM)","route":"/institutions/icm-montpellier/","field":"website"}]},{"url":"https://www.icm.unicancer.fr/fr/linstitut-du-cancer-de-montpellier/decouvrir-licm/gouvernance","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marc-ychou","kind":"person","name":"Marc Ychou","route":"/people/marc-ychou/","field":"links","label":"Source: ICM governance page"},{"id":"marc-ychou","kind":"person","name":"Marc Ychou","route":"/people/marc-ychou/","field":"profiles","label":"ICM governance page"}]},{"url":"https://www.iconplc.com","status":200,"ok":true,"finalUrl":"https://www.iconplc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","field":"links","label":"Official website"},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","field":"website"}]},{"url":"https://www.icrpartnership.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"links","label":"International Cancer Research Partnership"},{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","field":"links","label":"International Cancer Research Partnership"},{"id":"idea-fund-dollars-per-death-dashboard","kind":"idea","name":"A public dashboard of research money per death for every cancer","route":"/ideas/idea-fund-dollars-per-death-dashboard/","field":"links","label":"International Cancer Research Partnership"},{"id":"idea-fund-cross-funder-portfolio-registry","kind":"idea","name":"Mandatory machine-readable portfolio reporting for all large cancer funders","route":"/ideas/idea-fund-cross-funder-portfolio-registry/","field":"links","label":"International Cancer Research Partnership"}],"archive":"https://web.archive.org/web/20260610210824/https://www.icrpartnership.org/"},{"url":"https://www.icumed.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icu-medical","kind":"company","name":"ICU Medical","route":"/companies/icu-medical/","field":"links","label":"Official website"},{"id":"icu-medical","kind":"company","name":"ICU Medical","route":"/companies/icu-medical/","field":"website"}]},{"url":"https://www.ideal-collaboration.net/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/","field":"links","label":"IDEAL Collaboration"},{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/","field":"links","label":"IDEAL Collaboration"}]},{"url":"https://www.ideayabio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","field":"links","label":"Official website"},{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","field":"website"}]},{"url":"https://www.ideayabio.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.ideayabio.com/pipeline","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","field":"links","label":"Pipeline"}]},{"url":"https://www.ieo.it","status":200,"ok":true,"finalUrl":"https://www.ieo.it/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","route":"/institutions/ieo-milan/","field":"links","label":"Official website"},{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","route":"/institutions/ieo-milan/","field":"website"}]},{"url":"https://www.iepor.site","status":200,"ok":true,"finalUrl":"https://www.iepor.site/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"links","label":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology website"},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"profiles","label":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology website"},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","route":"/institutions/kavetsky-institute-kyiv/","field":"links","label":"Official website"},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","route":"/institutions/kavetsky-institute-kyiv/","field":"website"}]},{"url":"https://www.ifct.fr","status":200,"ok":true,"finalUrl":"https://www.ifct.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/","field":"links","label":"IFCT"},{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/","field":"website"}]},{"url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","field":"links","label":"Society page"},{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","field":"profiles","label":"Society page"},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","field":"links","label":"Society page"},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","field":"profiles","label":"Society page"}]},{"url":"https://www.ifo.it/2026/05/blandino-cavuto-2-nomine-strategiche-ifo/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"links","label":"Institution profile"},{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ifo.it/en/","status":200,"ok":true,"finalUrl":"https://www.ifo.it/attivita-cliniche/medicina-oncologica/endocrinologia-oncologica/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","field":"links","label":"IRCCS Regina Elena National Cancer Institute website"},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","field":"profiles","label":"IRCCS Regina Elena National Cancer Institute website"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","field":"links","label":"Homepage"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","field":"website"}]},{"url":"https://www.igeamedical.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"igea","kind":"company","name":"IGEA","route":"/companies/igea/","field":"links","label":"Official website"},{"id":"igea","kind":"company","name":"IGEA","route":"/companies/igea/","field":"website"}]},{"url":"https://www.iisc.ac.in/about/administration/director/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","field":"links","label":"Source: IISc administration, Director page"},{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","field":"profiles","label":"IISc Director page"}]},{"url":"https://www.iisc.ac.in/about/foreword-from-the-director/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","field":"profiles","label":"Foreword from the Director"}]},{"url":"https://www.iislafe.es","status":200,"ok":true,"finalUrl":"https://www.iislafe.es/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"links","label":"IIS La Fe"}]},{"url":"https://www.iislafe.es/es/el-iis-la-fe/estructura-organizativa/junta-de-gobierno/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","route":"/people/jose-luis-poveda-andres/","field":"links","label":"Source: IIS La Fe Junta de Gobierno page"},{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","route":"/people/jose-luis-poveda-andres/","field":"profiles","label":"IIS La Fe Junta de Gobierno page listing the hospital Gerente"}]},{"url":"https://www.iislafe.es/es/el-iis-la-fe/estructura-organizativa/patronato/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","route":"/people/jose-luis-poveda-andres/","field":"links","label":"Source: IIS La Fe Patronato page"}]},{"url":"https://www.iitb.ac.in","status":200,"ok":true,"finalUrl":"https://www.iitb.ac.in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"links","label":"IIT Bombay"},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","field":"profiles","label":"IIT Bombay"},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","field":"links","label":"IIT Bombay"},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","field":"website"}]},{"url":"https://www.iksuda.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","field":"links","label":"Official website"},{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","field":"website"}]},{"url":"https://www.iksuda.com/news-views/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","field":"links","label":"News and views"}]},{"url":"https://www.iksuda.com/news-views/iksuda-therapeutics-closes-47-million-financing-round/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","field":"links","label":"USD 47 million financing release"}]},{"url":"https://www.iktos.ai/resources/articles","status":200,"ok":true,"finalUrl":"https://iktos.ai/resources/articles","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/","field":"links","label":"News and press"}]},{"url":"https://www.illumina.com","status":200,"ok":true,"finalUrl":"https://www.illumina.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","field":"links","label":"Official website"},{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","field":"website"}]},{"url":"https://www.illuminaventures.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","field":"links","label":"Official website"},{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","field":"website"}]},{"url":"https://www.illuminaventures.com/about-us/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","field":"links","label":"About"}]},{"url":"https://www.illuminaventures.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://www.ilyang.co.kr","status":200,"ok":true,"finalUrl":"https://www.ilyang.co.kr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/","field":"links","label":"Official website"},{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/","field":"website"}]},{"url":"https://www.ima.org.il/MainSiteNew/EditUnion.aspx?UnionId=741","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","route":"/institutions/iscort/","field":"links","label":"Israel Medical Association union page (Hebrew)"},{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","route":"/institutions/iscort/","field":"website"}]},{"url":"https://www.ima.org.il/MedicineIMAJ/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-moore-israel-cancer-registry-completeness-imaj-2021","kind":"paper","name":"An assessment of the completeness and timeliness of the Israel National Cancer Registry","route":"/key-papers/paper-moore-israel-cancer-registry-completeness-imaj-2021/","field":"links","label":"Israel Medical Association Journal"}]},{"url":"https://www.immatics.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.immatics.com/pipeline","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.immixbio.com/","status":200,"ok":true,"finalUrl":"https://immixbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","route":"/companies/immix-biopharma/","field":"links","label":"Official website"},{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","route":"/companies/immix-biopharma/","field":"website"}]},{"url":"https://www.immunai.com","status":200,"ok":true,"finalUrl":"https://www.immunai.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","field":"links","label":"Official website"},{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","field":"website"}]},{"url":"https://www.immunai.com/company","status":200,"ok":true,"finalUrl":"https://www.immunai.com/company/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","field":"links","label":"Company page"}]},{"url":"https://www.immunai.com/resources/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","field":"links","label":"Resources and press"}]},{"url":"https://www.immuneel.com","status":200,"ok":true,"finalUrl":"https://immuneel.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/","field":"links","label":"Official website"},{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/","field":"website"},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","field":"links","label":"Immuneel Therapeutics"},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","field":"access.source (IN)"}],"archive":"https://web.archive.org/web/20250709162752/https://immuneel.com/"},{"url":"https://www.immuneering.com","status":200,"ok":true,"finalUrl":"https://immuneering.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","field":"links","label":"Official website"},{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","field":"website"}]},{"url":"https://www.immuneering.com/pipeline","status":200,"ok":true,"finalUrl":"https://immuneering.com/pipeline/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","field":"links","label":"Pipeline page"},{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","field":"links","label":"Sponsor page"}]},{"url":"https://www.immuneoncia.com","status":200,"ok":true,"finalUrl":"https://www.immuneoncia.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/","field":"links","label":"Official website"},{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/","field":"website"}]},{"url":"https://www.immunitybio.com/pipeline/","status":200,"ok":true,"finalUrl":"https://immunitybio.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.immunocore.com","status":200,"ok":true,"finalUrl":"https://www.immunocore.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","field":"links","label":"Official website"},{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","field":"website"}]},{"url":"https://www.immutep.com","status":200,"ok":true,"finalUrl":"https://www.immutep.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","field":"links","label":"Official website"},{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","field":"website"}]},{"url":"https://www.impacttherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.impacttherapeutics.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","field":"links","label":"Official website"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","field":"website"},{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","field":"links","label":"Sponsor page"}]},{"url":"https://www.ims.u-tokyo.ac.jp/imsut/en/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"links","label":"Institute of Medical Science, The University of Tokyo"},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","field":"profiles","label":"Institute of Medical Science, The University of Tokyo"}]},{"url":"https://www.imss.gob.mx","status":200,"ok":true,"finalUrl":"https://www.imss.gob.mx/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imss-oncologia-siglo-xxi","kind":"institution","name":"Hospital de Oncología, Centro Médico Nacional Siglo XXI (IMSS)","route":"/institutions/imss-oncologia-siglo-xxi/","field":"links","label":"Official website"},{"id":"imss-oncologia-siglo-xxi","kind":"institution","name":"Hospital de Oncología, Centro Médico Nacional Siglo XXI (IMSS)","route":"/institutions/imss-oncologia-siglo-xxi/","field":"website"}]},{"url":"https://www.imugene.com","status":200,"ok":true,"finalUrl":"https://imugene.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","field":"links","label":"Official website"},{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","field":"website"}]},{"url":"https://www.inca.com.uy","status":200,"ok":true,"finalUrl":"https://www.inca.com.uy/es","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","field":"links","label":"Official website"},{"id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","field":"website"}]},{"url":"https://www.incb.org/","status":200,"ok":true,"finalUrl":"https://www.incb.org/incb/index.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-acc-balanced-opioid-policy-reform","kind":"idea","name":"National opioid quota reform so morphine reaches cancer patients","route":"/ideas/idea-acc-balanced-opioid-policy-reform/","field":"links","label":"International Narcotics Control Board"}]},{"url":"https://www.incliva.es/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"links","label":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia website"},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"profiles","label":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia website"},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","field":"links","label":"INCLIVA"},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","field":"website"}]},{"url":"https://www.incyte.com","status":200,"ok":true,"finalUrl":"https://incyte.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","field":"links","label":"Official website"},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","field":"website"}]},{"url":"https://www.indivumed.com","status":200,"ok":true,"finalUrl":"https://www.indivumed.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/","field":"links","label":"Official website"},{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/","field":"website"}]},{"url":"https://www.innocarepharma.com/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","field":"links","label":"InnoCare Pharma"},{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/","field":"links","label":"Official website"},{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/","field":"website"}]},{"url":"https://www.innoventbio.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/","field":"links","label":"Innovent Biologics"},{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/","field":"profiles","label":"Innovent Biologics"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","field":"links","label":"Innovent: Tyvyt"},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","field":"links","label":"Official website"},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","field":"website"}]},{"url":"https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=524","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","field":"links","label":"Innovent and Takeda global partnership (October 2025)"}]},{"url":"https://www.inovio.com","status":200,"ok":true,"finalUrl":"https://www.inovio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","field":"links","label":"Official website"},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","field":"website"}]},{"url":"https://www.insightec.com","status":200,"ok":true,"finalUrl":"https://insightec.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","field":"links","label":"Official website"},{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","field":"website"}]},{"url":"https://www.instem.res.in","status":200,"ok":true,"finalUrl":"https://instem.res.in/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","route":"/institutions/instem/","field":"links","label":"inStem"},{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","route":"/institutions/instem/","field":"website"}]},{"url":"https://www.institut-cancerologie-ouest.com","status":200,"ok":true,"finalUrl":"https://www.institut-cancerologie-ouest.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","field":"links","label":"Official website"},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","field":"website"}]},{"url":"https://www.institut-cancerologie-ouest.com/linstitut-de-cancerologie-de-louest","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","field":"links","label":"Source: ICO institutional page naming the Directeur Général"},{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","field":"profiles","label":"ICO institutional presentation page"}]},{"url":"https://www.institutgodinot.fr","status":200,"ok":true,"finalUrl":"https://www.institutgodinot.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","route":"/institutions/institut-godinot/","field":"links","label":"Official website"},{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","route":"/institutions/institut-godinot/","field":"website"}]},{"url":"https://www.institutoroffo.uba.ar","status":200,"ok":true,"finalUrl":"https://institutoroffo.uba.ar/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"instituto-roffo","kind":"institution","name":"Instituto de Oncología Ángel H. Roffo","route":"/institutions/instituto-roffo/","field":"links","label":"Official website"},{"id":"instituto-roffo","kind":"institution","name":"Instituto de Oncología Ángel H. Roffo","route":"/institutions/instituto-roffo/","field":"website"}]},{"url":"https://www.institutpaolicalmettes.fr","status":200,"ok":true,"finalUrl":"https://www.institutpaolicalmettes.fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","field":"links","label":"Homepage"},{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","field":"website"}]},{"url":"https://www.institutpaolicalmettes.fr/le-pr-norbert-vey-nomme-directeur-general-de-linstitut-paoli-calmettes/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"norbert-vey","kind":"person","name":"Norbert Vey","route":"/people/norbert-vey/","field":"links","label":"Source: Institut Paoli-Calmettes appointment announcement"},{"id":"norbert-vey","kind":"person","name":"Norbert Vey","route":"/people/norbert-vey/","field":"profiles","label":"IPC announcement of appointment"}]},{"url":"https://www.institutroialbertdeux.be/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","field":"links","label":"Institut Roi Albert II website"},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","field":"profiles","label":"Institut Roi Albert II website"},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","field":"links","label":"Official website"},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","field":"website"}]},{"url":"https://www.intaspharma.com","status":200,"ok":true,"finalUrl":"https://www.intaspharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","route":"/companies/intas/","field":"links","label":"Official website"},{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","route":"/companies/intas/","field":"website"}]},{"url":"https://www.intogen.org","status":200,"ok":true,"finalUrl":"https://www.intogen.org/search","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/","field":"links","label":"IntOGen"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/","field":"url"}]},{"url":"https://www.intra-immusg.com","status":200,"ok":true,"finalUrl":"https://www.intra-immusg.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/","field":"links","label":"Official website"},{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/","field":"website"}]},{"url":"https://www.intuitive.com","status":200,"ok":true,"finalUrl":"https://www.intuitive.com/en-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","field":"links","label":"Official website"},{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","field":"website"}]},{"url":"https://www.intuitive.com/en-us/products-and-services/da-vinci","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"surgical-robot-platforms","kind":"technology","name":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","route":"/technologies/surgical-robot-platforms/","field":"links","label":"Intuitive: da Vinci systems"}]},{"url":"https://www.inventisbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","field":"links","label":"InventisBio"},{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/","field":"links","label":"Official website"},{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/","field":"website"}]},{"url":"https://www.inventisbio.com/en/pipeline","status":200,"ok":true,"finalUrl":"https://www.inventisbio.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"d-0502","kind":"drug","name":"D-0502","route":"/drugs/d-0502/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.inxmed.com","status":200,"ok":true,"finalUrl":"https://www.inxmed.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","field":"links","label":"Sponsor page"}]},{"url":"https://www.inxmed.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","field":"links","label":"Official website"},{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","field":"website"}]},{"url":"https://www.iobiotech.com","status":200,"ok":true,"finalUrl":"https://iobiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","field":"links","label":"Official website"},{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","field":"website"}]},{"url":"https://www.ionctura.com","status":200,"ok":true,"finalUrl":"https://www.ionctura.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/","field":"links","label":"Official website"},{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/","field":"website"}]},{"url":"https://www.ionispharma.com","status":200,"ok":true,"finalUrl":"https://ionis.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","field":"links","label":"Official website"},{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","field":"website"}]},{"url":"https://www.ionovabio.com","status":200,"ok":true,"finalUrl":"https://www.ionovabio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/","field":"links","label":"Official website"},{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/","field":"website"}]},{"url":"https://www.iovance.com","status":200,"ok":true,"finalUrl":"https://www.iovance.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","field":"outcomes.source (Objective response rate)"},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","field":"links","label":"Official website"},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","field":"website"}]},{"url":"https://www.ioveneto.it","status":200,"ok":true,"finalUrl":"https://www.ioveneto.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"links","label":"Homepage"},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"website"}]},{"url":"https://www.ioveneto.it/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","route":"/people/patrizia-simionato/","field":"links","label":"Institution profile"},{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","route":"/people/patrizia-simionato/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ioveneto.it/ricerca/","status":200,"ok":true,"finalUrl":"https://www.ioveneto.it/ricerca-scientifica/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"links","label":"Research"}]},{"url":"https://www.ipd.uw.edu","status":200,"ok":true,"finalUrl":"https://www.ipd.uw.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/","field":"links","label":"Official website"},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/","field":"website"}]},{"url":"https://www.ipd.uw.edu/people/faculty_and_staff/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-baker","kind":"person","name":"David Baker","route":"/people/david-baker/","field":"links","label":"Source: Institute for Protein Design faculty and staff page"},{"id":"david-baker","kind":"person","name":"David Baker","route":"/people/david-baker/","field":"profiles","label":"IPD faculty and staff"}]},{"url":"https://www.ipoporto.pt","status":200,"ok":true,"finalUrl":"https://ipoporto.pt/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","field":"links","label":"Homepage"},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","field":"website"},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","field":"links","label":"IPO network"}]},{"url":"https://www.ipoporto.pt/en/investigacao/","status":200,"ok":true,"finalUrl":"https://ipoporto.pt/en/eu-profissional/investigacao/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","field":"links","label":"Research"}]},{"url":"https://www.ipoporto.pt/ipo-porto-cria-associacao-para-impusionar-a-investigacao-clinica/","status":200,"ok":true,"finalUrl":"https://ipoporto.pt/ipo-porto-cria-associacao-para-impusionar-a-investigacao-clinica/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","field":"links","label":"Source: IPO Porto news on clinical research association, May 2025"}]},{"url":"https://www.ipoporto.pt/presidente-do-ipo-porto-eleito-para-a-nova-direcao-da-oeci/","status":200,"ok":true,"finalUrl":"https://ipoporto.pt/presidente-do-ipo-porto-eleito-para-a-nova-direcao-da-oeci/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","field":"profiles","label":"Institution news: elected to OECI board"}]},{"url":"https://www.ipos-society.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"IPOS"}]},{"url":"https://www.ipsen.com","status":200,"ok":true,"finalUrl":"https://www.ipsen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","field":"links","label":"Official website"},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","field":"website"}]},{"url":"https://www.iqvia.com","status":200,"ok":true,"finalUrl":"https://www.iqvia.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/","field":"links","label":"Official website"},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/","field":"website"}]},{"url":"https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2023-2027","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","field":"links","label":"IQVIA Institute: Biosimilars in the United States 2023-2027 (January 2023)"}]},{"url":"https://www.iqwig.de","status":200,"ok":true,"finalUrl":"https://www.iqwig.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","field":"links","label":"IQWiG"}]},{"url":"https://www.iqwig.de/ueber-uns/struktur-des-instituts/institutsleitung/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","field":"links","label":"Institution profile"},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ire.eu","status":200,"ok":true,"finalUrl":"https://www.ire.eu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","field":"links","label":"Official website"},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","field":"website"}]},{"url":"https://www.iroiasi.ro","status":200,"ok":true,"finalUrl":"https://www.iroiasi.ro/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","route":"/institutions/iasi-regional-oncology-institute/","field":"links","label":"Official website"},{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","route":"/institutions/iasi-regional-oncology-institute/","field":"website"}]},{"url":"https://www.iroiasi.ro/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","field":"links","label":"Iași Regional Oncology Institute website"},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","field":"profiles","label":"Iași Regional Oncology Institute website"}]},{"url":"https://www.irst.emr.it","status":200,"ok":true,"finalUrl":"https://www.irst.emr.it/it","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"links","label":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) website"},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"profiles","label":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) website"},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","field":"links","label":"Homepage"},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","field":"website"}]},{"url":"https://www.irst.emr.it/it/listituto/organizzazione/direzioni/direzione-generale","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cristina-marchesi","kind":"person","name":"Cristina Marchesi","route":"/people/cristina-marchesi/","field":"links","label":"Source: IRST Direzione Generale page"}]},{"url":"https://www.irst.emr.it/it/persone/professionisti/marchesi-cristina","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cristina-marchesi","kind":"person","name":"Cristina Marchesi","route":"/people/cristina-marchesi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.isncc.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","field":"links","label":"ISNCC"}]},{"url":"https://www.isomorphiclabs.com","status":200,"ok":true,"finalUrl":"https://www.isomorphiclabs.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","field":"website"}]},{"url":"https://www.isonohealth.com","status":200,"ok":true,"finalUrl":"https://isonohealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isono-health","kind":"company","name":"iSono Health","route":"/companies/isono-health/","field":"links","label":"Official website"},{"id":"isono-health","kind":"company","name":"iSono Health","route":"/companies/isono-health/","field":"website"}]},{"url":"https://www.isopp.org/about-jopp","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","field":"links","label":"ISOPP: About JOPP"}]},{"url":"https://www.isoqol.org","status":200,"ok":true,"finalUrl":"https://www.isoqol.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","route":"/institutions/isoqol/","field":"links","label":"ISOQOL"},{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","route":"/institutions/isoqol/","field":"website"}]},{"url":"https://www.isoqol.org/who-we-are/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","field":"links","label":"Source: ISOQOL Who We Are page"},{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","field":"profiles","label":"ISOQOL leadership page"}]},{"url":"https://www.isotopes.gov/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"US Department of Energy Isotope Program"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","field":"links","label":"US Department of Energy Isotope Program"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"US DOE Isotope Program"},{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","field":"links","label":"US DOE Isotope Program"}]},{"url":"https://www.ispor.org","status":200,"ok":true,"finalUrl":"https://www.ispor.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/","field":"links","label":"ISPOR"},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/","field":"website"}]},{"url":"https://www.ispor.org/about/board-of-directors","status":200,"ok":true,"finalUrl":"https://www.ispor.org/about/our-leaders","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","field":"links","label":"Society page"},{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","field":"profiles","label":"Society page"},{"id":"rob-abbott","kind":"person","name":"Rob Abbott","route":"/people/rob-abbott/","field":"links","label":"Society page"},{"id":"rob-abbott","kind":"person","name":"Rob Abbott","route":"/people/rob-abbott/","field":"profiles","label":"Society page"}]},{"url":"https://www.ispytrials.org","status":200,"ok":true,"finalUrl":"https://www.quantumleaphealth.org/clinical-trials","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/","field":"links","label":"I-SPY Trials"}],"archive":"https://web.archive.org/web/20240528170906/https://www.ispytrials.org"},{"url":"https://www.ispytrials.org/","status":200,"ok":true,"finalUrl":"https://www.quantumleaphealth.org/clinical-trials","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","field":"links","label":"I-SPY Trials"},{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/","field":"links","label":"I-SPY trials"},{"id":"idea-tr2-neoadjuvant-combo-platform","kind":"idea","name":"Pre-surgery platform trials that test combinations on pathological response in months","route":"/ideas/idea-tr2-neoadjuvant-combo-platform/","field":"links","label":"I-SPY trials"},{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/","field":"links","label":"I-SPY Trials (QuantumLeap Healthcare Collaborative)"}],"archive":"https://web.archive.org/web/20240528170906/https://www.ispytrials.org"},{"url":"https://www.ispytrials.org/i-spy-platform/i-spy2","status":200,"ok":true,"finalUrl":"https://www.quantumleaphealth.org/i-spy-2-2","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","field":"links","label":"I-SPY Trials: the I-SPY 2 platform"}],"archive":"https://web.archive.org/web/20240420132950/https://www.ispytrials.org/i-spy-platform/i-spy2"},{"url":"https://www.isrctn.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","field":"links","label":"ISRCTN registry"}]},{"url":"https://www.isrctn.com/ISRCTN01534787","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/","field":"links","label":"ISRCTN registry ISRCTN01534787"}]},{"url":"https://www.isrctn.com/ISRCTN08063129","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","field":"links","label":"ISRCTN08063129"},{"id":"paper-xm01-22-tjulandin-arch-drug-inf-2011","kind":"paper","name":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22)","route":"/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/","field":"links","label":"ISRCTN08063129"}]},{"url":"https://www.isrctn.com/ISRCTN10081873","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"best-bra","kind":"trial","name":"Best-BRA","route":"/trials/best-bra/","field":"links","label":"ISRCTN10081873"}]},{"url":"https://www.isrctn.com/ISRCTN10511385","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impact-bcc","kind":"trial","name":"IMPACT (cemiplimab in advanced basal cell carcinoma)","route":"/trials/impact-bcc/","field":"links","label":"ISRCTN10511385"}]},{"url":"https://www.isrctn.com/ISRCTN10639376","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abc-07","kind":"trial","name":"ABC-07","route":"/trials/abc-07/","field":"links","label":"ISRCTN10639376"}]},{"url":"https://www.isrctn.com/ISRCTN11210442","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abc-12","kind":"trial","name":"ABC-12","route":"/trials/abc-12/","field":"links","label":"ISRCTN11210442"}]},{"url":"https://www.isrctn.com/ISRCTN11503604","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/","field":"links","label":"ISRCTN11503604: STARPAC2"}]},{"url":"https://www.isrctn.com/ISRCTN11631712","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nottingham-fob","kind":"trial","name":"Nottingham faecal occult blood screening trial","route":"/trials/nottingham-fob/","field":"links","label":"ISRCTN11631712"}]},{"url":"https://www.isrctn.com/ISRCTN11898000","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","field":"links","label":"ISRCTN11898000"}]},{"url":"https://www.isrctn.com/ISRCTN12852634","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","field":"links","label":"ISRCTN12852634"}]},{"url":"https://www.isrctn.com/ISRCTN13472721","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"violet","kind":"trial","name":"VIOLET","route":"/trials/violet/","field":"links","label":"ISRCTN13472721"}]},{"url":"https://www.isrctn.com/ISRCTN13801649","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","field":"links","label":"ISRCTN13801649"}]},{"url":"https://www.isrctn.com/ISRCTN14240288","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"star-trec","kind":"trial","name":"STAR-TREC","route":"/trials/star-trec/","field":"links","label":"ISRCTN14240288"}]},{"url":"https://www.isrctn.com/ISRCTN14879538","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wolfson-wohl-cancer-research-centre","kind":"institution","name":"Wolfson Wohl Cancer Research Centre, University of Glasgow","route":"/institutions/wolfson-wohl-cancer-research-centre/","field":"links","label":"ISRCTN14879538: Precision Panc"},{"id":"precision-panc","kind":"trial","name":"Precision-Panc","route":"/trials/precision-panc/","field":"links","label":"ISRCTN14879538: Precision Panc"}]},{"url":"https://www.isrctn.com/ISRCTN16082556","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"promis","kind":"trial","name":"PROMIS","route":"/trials/promis/","field":"links","label":"ISRCTN16082556"}]},{"url":"https://www.isrctn.com/ISRCTN16261285","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","field":"links","label":"CAPP3 ISRCTN16261285"}]},{"url":"https://www.isrctn.com/ISRCTN16290169","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mcc-rational-treatment","kind":"trial","name":"Rational treatment selection for Merkel cell carcinoma","route":"/trials/mcc-rational-treatment/","field":"links","label":"ISRCTN16290169"}]},{"url":"https://www.isrctn.com/ISRCTN19906132","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","field":"links","label":"ISRCTN19906132"}]},{"url":"https://www.isrctn.com/ISRCTN20141297","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"links","label":"ISRCTN registry ISRCTN20141297"}]},{"url":"https://www.isrctn.com/ISRCTN22944367","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/","field":"links","label":"ISRCTN22944367"}]},{"url":"https://www.isrctn.com/ISRCTN26715889","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","field":"links","label":"ISRCTN26715889"}]},{"url":"https://www.isrctn.com/ISRCTN27286448","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"coin","kind":"trial","name":"MRC COIN","route":"/trials/coin/","field":"links","label":"ISRCTN27286448"}]},{"url":"https://www.isrctn.com/ISRCTN28352761","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukfss","kind":"trial","name":"UK Flexible Sigmoidoscopy Screening Trial","route":"/trials/ukfss/","field":"links","label":"ISRCTN28352761"}]},{"url":"https://www.isrctn.com/ISRCTN28785842","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cr07","kind":"trial","name":"MRC CR07","route":"/trials/cr07/","field":"links","label":"ISRCTN28785842"}]},{"url":"https://www.isrctn.com/ISRCTN31488319","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/","field":"links","label":"ISRCTN31488319"}]},{"url":"https://www.isrctn.com/ISRCTN33292440","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agex","kind":"trial","name":"AgeX","route":"/trials/agex/","field":"links","label":"ISRCTN33292440"}]},{"url":"https://www.isrctn.com/ISRCTN34086741","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"links","label":"ISRCTN34086741"}]},{"url":"https://www.isrctn.com/ISRCTN34802808","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/","field":"links","label":"ISRCTN34802808"}]},{"url":"https://www.isrctn.com/ISRCTN36516280","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","field":"links","label":"InPACT (ISRCTN)"}]},{"url":"https://www.isrctn.com/ISRCTN37664281","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","field":"links","label":"ISRCTN37664281"}]},{"url":"https://www.isrctn.com/ISRCTN40814031","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","field":"links","label":"ISRCTN registry ISRCTN40814031"},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","field":"links","label":"ISRCTN registry ISRCTN40814031"}]},{"url":"https://www.isrctn.com/ISRCTN42704678","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/","field":"links","label":"ISRCTN42704678"}]},{"url":"https://www.isrctn.com/ISRCTN45905321","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"links","label":"ISRCTN45905321"},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","field":"links","label":"ISRCTN registry ISRCTN45905321"}]},{"url":"https://www.isrctn.com/ISRCTN48755084","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","field":"links","label":"ISRCTN48755084"}]},{"url":"https://www.isrctn.com/ISRCTN49127736","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-schroder-erspc-screening-mortality-nejm-2009","kind":"paper","name":"ERSPC: screening and prostate cancer mortality in a randomised European study","route":"/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/","field":"links","label":"ISRCTN49127736"},{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","field":"links","label":"ISRCTN registry ISRCTN49127736"}]},{"url":"https://www.isrctn.com/ISRCTN50083238","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scalop-2","kind":"trial","name":"SCALOP-2","route":"/trials/scalop-2/","field":"links","label":"ISRCTN50083238: SCALOP-2"}]},{"url":"https://www.isrctn.com/ISRCTN54765244","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"posnoc","kind":"trial","name":"POSNOC","route":"/trials/posnoc/","field":"links","label":"ISRCTN54765244"}]},{"url":"https://www.isrctn.com/ISRCTN54806122","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scc-after","kind":"trial","name":"SCC-AFTER","route":"/trials/scc-after/","field":"links","label":"ISRCTN54806122"}]},{"url":"https://www.isrctn.com/ISRCTN59368779","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"start-a","kind":"trial","name":"START-A (UK Standardisation of Breast Radiotherapy, trial A)","route":"/trials/start-a/","field":"links","label":"ISRCTN59368779"},{"id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","field":"links","label":"ISRCTN59368779"}]},{"url":"https://www.isrctn.com/ISRCTN59521990","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/","field":"links","label":"ISRCTN59521990"}]},{"url":"https://www.isrctn.com/ISRCTN59757862","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scot","kind":"trial","name":"SCOT","route":"/trials/scot/","field":"links","label":"ISRCTN59757862"}]},{"url":"https://www.isrctn.com/ISRCTN61145589","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","field":"links","label":"ISRCTN61145589"}]},{"url":"https://www.isrctn.com/ISRCTN61925716","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","field":"links","label":"ISRCTN61925716"},{"id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","field":"links","label":"ISRCTN61925716"}]},{"url":"https://www.isrctn.com/ISRCTN62546421","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","field":"links","label":"ISRCTN62546421"}]},{"url":"https://www.isrctn.com/ISRCTN65009900","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","field":"links","label":"ISRCTN65009900"}]},{"url":"https://www.isrctn.com/ISRCTN70406718","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"links","label":"ISRCTN registry ISRCTN70406718"}]},{"url":"https://www.isrctn.com/ISRCTN72251782","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","field":"links","label":"ISRCTN72251782"}]},{"url":"https://www.isrctn.com/ISRCTN72785446","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"links","label":"ISRCTN registry entry (ISRCTN72785446)"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","field":"links","label":"ISRCTN72785446"}]},{"url":"https://www.isrctn.com/ISRCTN75002153","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"primus-001","kind":"trial","name":"PRIMUS 001","route":"/trials/primus-001/","field":"links","label":"ISRCTN75002153: PRIMUS 001"}]},{"url":"https://www.isrctn.com/ISRCTN78513845","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ukls","kind":"trial","name":"UKLS","route":"/trials/ukls/","field":"links","label":"ISRCTN78513845"}]},{"url":"https://www.isrctn.com/ISRCTN79701845","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","field":"links","label":"ISRCTN79701845"}]},{"url":"https://www.isrctn.com/ISRCTN79932379","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molemate","kind":"trial","name":"MoleMate UK Trial","route":"/trials/molemate/","field":"links","label":"ISRCTN79932379"}]},{"url":"https://www.isrctn.com/ISRCTN80116429","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spot-it","kind":"trial","name":"SPOT-IT","route":"/trials/spot-it/","field":"links","label":"ISRCTN80116429"}]},{"url":"https://www.isrctn.com/ISRCTN80745975","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lungsearch","kind":"trial","name":"Lung-SEARCH","route":"/trials/lungsearch/","field":"links","label":"ISRCTN80745975"}]},{"url":"https://www.isrctn.com/ISRCTN82375386","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/","field":"links","label":"ISRCTN82375386"}]},{"url":"https://www.isrctn.com/ISRCTN82956140","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"links","label":"ISRCTN82956140"}]},{"url":"https://www.isrctn.com/ISRCTN83842641","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","field":"links","label":"ISRCTN83842641"}]},{"url":"https://www.isrctn.com/ISRCTN87514420","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"time2","kind":"trial","name":"TIME2","route":"/trials/time2/","field":"links","label":"ISRCTN87514420"}]},{"url":"https://www.isrctn.com/ISRCTN89500674","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","field":"links","label":"ISRCTN89500674: ESPAC-5, European Study Group for Pancreatic Cancer trial 5"}]},{"url":"https://www.isrctn.com/ISRCTN90061546","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","field":"links","label":"ISRCTN90061546: FOCUS4 registry entry"}]},{"url":"https://www.isrctn.com/ISRCTN91431511","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"links","label":"ISRCTN91431511"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/","field":"links","label":"ISRCTN91431511"}]},{"url":"https://www.isrctn.com/ISRCTN91879928","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/","field":"links","label":"ISRCTN91879928"}]},{"url":"https://www.isrctn.com/ISRCTN93548632","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","route":"/institutions/ninewells-dundee/","field":"links","label":"ISRCTN93548632: TAYCAN"}]},{"url":"https://www.isrctn.com/ISRCTN95053737","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anita","kind":"trial","name":"ANITA (Adjuvant Navelbine International Trialist Association)","route":"/trials/anita/","field":"links","label":"ISRCTN95053737"}]},{"url":"https://www.isrctn.com/ISRCTN95889329","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","field":"links","label":"ISRCTN95889329"}]},{"url":"https://www.isrctn.com/ISRCTN96169987","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","field":"links","label":"ISRCTN96169987: SCALOP"}]},{"url":"https://www.isrctn.com/ISRCTN96397434","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"links","label":"ISRCTN96397434"}]},{"url":"https://www.isrctn.com/ISRCTN97182923","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"links","label":"ISRCTN97182923"},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","field":"links","label":"ISRCTN registry ISRCTN97182923"}]},{"url":"https://www.isrctn.com/search?q=datopotamab+deruxtecan+durvalumab","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/","field":"links","label":"ISRCTN registry search: datopotamab deruxtecan plus durvalumab (DIAMOND)"}]},{"url":"https://www.isrctn.com/search?q=pancreatic+cancer","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/","field":"links","label":"ISRCTN registry search: pancreatic cancer"}]},{"url":"https://www.isrctn.com/search?q=triple+negative+breast","status":200,"ok":true,"finalUrl":"https://www.isrctn.com/holding","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/","field":"links","label":"ISRCTN registry search: triple negative breast"}]},{"url":"https://www.istanbul.edu.tr/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","field":"links","label":"Istanbul University"}]},{"url":"https://www.istitutotumori.na.it","status":200,"ok":true,"finalUrl":"https://www.istitutotumori.na.it/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","field":"links","label":"Homepage"},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","field":"website"}]},{"url":"https://www.italfarmaco.com","status":200,"ok":true,"finalUrl":"https://www.italfarmaco.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"italfarmaco","kind":"company","name":"Italfarmaco","route":"/companies/italfarmaco/","field":"links","label":"Official website"},{"id":"italfarmaco","kind":"company","name":"Italfarmaco","route":"/companies/italfarmaco/","field":"website"},{"id":"givinostat","kind":"drug","name":"Givinostat","route":"/drugs/givinostat/","field":"links","label":"Sponsor page"}]},{"url":"https://www.italiansarcomagroup.org","status":200,"ok":true,"finalUrl":"https://www.italiansarcomagroup.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"italian-sarcoma-group","kind":"company","name":"Italian Sarcoma Group","route":"/companies/italian-sarcoma-group/","field":"links","label":"Official website"},{"id":"italian-sarcoma-group","kind":"company","name":"Italian Sarcoma Group","route":"/companies/italian-sarcoma-group/","field":"website"}]},{"url":"https://www.itcc-consortium.org","status":200,"ok":true,"finalUrl":"https://www.itcc-consortium.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"itcc","kind":"company","name":"Innovative Therapies for Children with Cancer (ITCC)","route":"/companies/itcc/","field":"links","label":"ITCC"},{"id":"itcc","kind":"company","name":"Innovative Therapies for Children with Cancer (ITCC)","route":"/companies/itcc/","field":"website"}]},{"url":"https://www.itcc-consortium.org/governance","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","route":"/people/pamela-kearns/","field":"links","label":"Source: ITCC governance page"},{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","route":"/people/pamela-kearns/","field":"profiles","label":"ITCC governance page"}]},{"url":"https://www.itk.ee","status":200,"ok":true,"finalUrl":"https://www.itk.ee/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","field":"links","label":"Official website"},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","field":"website"}]},{"url":"https://www.itk.ee/en","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","field":"links","label":"East Tallinn Central Hospital website"},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","field":"profiles","label":"East Tallinn Central Hospital website"}]},{"url":"https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-presents-positive-topline-phase-3-compete-trial-data-with-nca-177lu-edotreotide-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-2-gastroenteropancreatic-neuroendocrine-tumors-at-the-enets-2025-conference-688/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"regulatoryEvents.source (2025-03)"}]},{"url":"https://www.iuct-oncopole.fr","status":200,"ok":true,"finalUrl":"https://www.iuct-oncopole.fr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/","field":"links","label":"Homepage"},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/","field":"website"}]},{"url":"https://www.iuct-oncopole.fr/la-gouvernance","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","field":"links","label":"Institution profile"},{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ivo.es","status":200,"ok":true,"finalUrl":"https://www.ivo.es/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","field":"links","label":"Fundación Instituto Valenciano de Oncología (IVO) website"},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","field":"profiles","label":"Fundación Instituto Valenciano de Oncología (IVO) website"},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","field":"links","label":"Official website"},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","field":"website"}]},{"url":"https://www.ivo.es/la-fundacion/el-patronato/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","route":"/people/antonio-llombart-bosch/","field":"links","label":"Source: IVO 'El patronato' page"},{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","route":"/people/antonio-llombart-bosch/","field":"profiles","label":"IVO board of trustees page"}]},{"url":"https://www.iwwd.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iwwd","kind":"trial","name":"International Watch & Wait Database","route":"/trials/iwwd/","field":"links","label":"International Watch & Wait Database"}]},{"url":"https://www.jacobiopharma.com","status":200,"ok":true,"finalUrl":"https://www.jacobiopharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","field":"website"}]},{"url":"https://www.jacobiopharma.com/en/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.januxrx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","field":"links","label":"Official website"},{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","field":"website"}]},{"url":"https://www.jax.org","status":200,"ok":true,"finalUrl":"https://www.jax.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/","field":"links","label":"The Jackson Laboratory"},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/","field":"website"}]},{"url":"https://www.jax.org/research-and-faculty/faculty/karolina-palucka","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","field":"profiles","label":"JAX faculty profile"}]},{"url":"https://www.jax.org/research-and-faculty/research-centers/the-jackson-laboratory-cancer-center","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","field":"links","label":"Source: JAX Cancer Center page"}]},{"url":"https://www.jax.org/research-and-faculty/research-overview/research-leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","field":"links","label":"Source: JAX research leadership page naming the Cancer Center Director"},{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","field":"profiles","label":"JAX research leadership page"}]},{"url":"https://www.jazzpharma.com","status":200,"ok":true,"finalUrl":"https://www.jazzpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","field":"links","label":"Official website"},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","field":"website"},{"id":"action-dmg","kind":"trial","name":"ACTION","route":"/trials/action-dmg/","field":"links","label":"Jazz Pharmaceuticals: dordaviprone"}]},{"url":"https://www.jci.org","status":200,"ok":true,"finalUrl":"https://www.jci.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","field":"url"}]},{"url":"https://www.jeffersonhealth.org/clinical-specialties/cancer","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/","field":"links","label":"Sidney Kimmel Comprehensive Cancer Center"},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/","field":"website"}]},{"url":"https://www.jeito.life","status":200,"ok":true,"finalUrl":"https://www.jeito.life/en/home/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","field":"links","label":"Official website"},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","field":"website"}]},{"url":"https://www.jewishbrca.org/","status":200,"ok":true,"finalUrl":"https://jewishbrca.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","route":"/collections/nhs-jewish-brca-testing/","field":"links","label":"NHS Jewish BRCA Testing Programme"},{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","route":"/collections/nhs-jewish-brca-testing/","field":"url"}]},{"url":"https://www.jfcr.or.jp/english/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/","field":"links","label":"Official website"},{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/","field":"website"},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","field":"links","label":"Cancer Institute Hospital of JFCR"},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","field":"profiles","label":"Cancer Institute Hospital of JFCR"},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","field":"links","label":"Cancer Institute Hospital of JFCR"},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","field":"profiles","label":"Cancer Institute Hospital of JFCR"},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","field":"links","label":"Cancer Institute Hospital of JFCR"},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","field":"profiles","label":"Cancer Institute Hospital of JFCR"},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","field":"links","label":"Cancer Institute Hospital of JFCR"},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","field":"profiles","label":"Cancer Institute Hospital of JFCR"}]},{"url":"https://www.jimmyfund.org","status":200,"ok":true,"finalUrl":"https://www.jimmyfund.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jimmy-fund","kind":"institution","name":"The Jimmy Fund","route":"/institutions/jimmy-fund/","field":"website"}]},{"url":"https://www.jimmyfund.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","field":"links","label":"The Jimmy Fund"},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","field":"profiles","label":"The Jimmy Fund"}]},{"url":"https://www.jimmyfund.org/about-us/","status":200,"ok":true,"finalUrl":"https://www.jimmyfund.org/about","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jimmy-fund","kind":"institution","name":"The Jimmy Fund","route":"/institutions/jimmy-fund/","field":"links","label":"About the Jimmy Fund"}]},{"url":"https://www.jimmyfund.org/about-us/boston-red-sox/ted-williams/","status":200,"ok":true,"finalUrl":"https://www.jimmyfund.org/about/partnerships/boston-red-sox/history-of-partnership","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ted-williams","kind":"person","name":"Ted Williams","route":"/people/ted-williams/","field":"links","label":"Jimmy Fund: Ted Williams"}]},{"url":"https://www.jimmyfund.org/about/partnerships/boston-red-sox/history-of-partnership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ted-williams","kind":"person","name":"Ted Williams","route":"/people/ted-williams/","field":"links","label":"Jimmy Fund: history of the Red Sox partnership"}]},{"url":"https://www.jnj.com","status":200,"ok":true,"finalUrl":"https://www.jnj.com/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"links","label":"Official website"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"website"}]},{"url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","field":"regulatoryEvents.source (2026-03-05)"},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","field":"links","label":"FDA approval (J&J)"}]},{"url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","field":"links","label":"J&J completion press release"}]},{"url":"https://www.jnj.com/media-center/press-releases/u-s-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","field":"links","label":"FDA approval of Inlexzo"}]},{"url":"https://www.jostrust.org.uk/","status":200,"ok":true,"finalUrl":"https://jostrust.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","field":"links","label":"Jo's Cervical Cancer Trust"},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","field":"profiles","label":"Jo's Cervical Cancer Trust"}]},{"url":"https://www.jsmo.or.jp","status":200,"ok":true,"finalUrl":"https://www.jsmo.or.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/","field":"links","label":"JSMO"},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/","field":"website"}]},{"url":"https://www.jsmo.or.jp/en/","status":200,"ok":true,"finalUrl":"https://www.jsmo.or.jp/en-news/en-news-10228/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","field":"links","label":"JSMO"},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","field":"url"}]},{"url":"https://www.jsmo.or.jp/eng/about/directors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"links","label":"JSMO directors"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"profiles","label":"JSMO directors"},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","field":"links","label":"Society page"},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","field":"profiles","label":"Society page"}]},{"url":"https://www.jsz120.com/szll_gjzlylzx.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","field":"links","label":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine website"},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","field":"profiles","label":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine website"},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","route":"/institutions/jinshazhou-hospital/","field":"links","label":"Official website"},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","route":"/institutions/jinshazhou-hospital/","field":"website"}]},{"url":"https://www.jubilantradiopharma.com","status":200,"ok":true,"finalUrl":"https://www.jubilantradiopharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","field":"links","label":"Official website"},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","field":"website"}]},{"url":"https://www.jubilanttx.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","route":"/companies/jubilant-therapeutics/","field":"links","label":"Official website"},{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","route":"/companies/jubilant-therapeutics/","field":"website"}]},{"url":"https://www.juncell.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/","field":"links","label":"Official website"},{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/","field":"website"},{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/","field":"links","label":"Sponsor page"}]},{"url":"https://www.junshipharma.com/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","field":"links","label":"Official website"},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","field":"website"}]},{"url":"https://www.jwtherapeutics.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","field":"links","label":"JW Therapeutics"},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/","field":"links","label":"Official website"},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/","field":"website"}]},{"url":"https://www.k36tx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","field":"links","label":"Official website"},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","field":"website"}]},{"url":"https://www.kaiko.ai","status":200,"ok":true,"finalUrl":"https://kaiko.ai/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","route":"/companies/kaiko-ai/","field":"links","label":"Official website"},{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","route":"/companies/kaiko-ai/","field":"website"}]},{"url":"https://www.kaiko.ai/","status":200,"ok":true,"finalUrl":"https://kaiko.ai/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaiko-midnight","kind":"technology","name":"Midnight (kaiko.ai)","route":"/technologies/kaiko-midnight/","field":"links","label":"kaiko.ai Midnight (page moved; nearest live section)"}]},{"url":"https://www.kanvasbio.com","status":200,"ok":true,"finalUrl":"https://www.kanvasbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/","field":"links","label":"Official website"},{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/","field":"website"}]},{"url":"https://www.kanvasbio.com/news","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/","field":"links","label":"News (Series A, KAN-004 phase 1)"}]},{"url":"https://www.karlstorz.com/","status":200,"ok":true,"finalUrl":"https://www.karlstorz.com/gb/en/index.htm?target=","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karl-storz","kind":"company","name":"Karl Storz","route":"/companies/karl-storz/","field":"links","label":"Official website"},{"id":"karl-storz","kind":"company","name":"Karl Storz","route":"/companies/karl-storz/","field":"website"}]},{"url":"https://www.karmanos.org","status":200,"ok":true,"finalUrl":"https://www.karmanos.org/karmanos/karmanos-home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","field":"links","label":"Karmanos Cancer Institute"},{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","field":"website"}]},{"url":"https://www.karolinska.se","status":200,"ok":true,"finalUrl":"https://www.karolinska.se/val-av-webbplats","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"links","label":"Official website"},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"website"}]},{"url":"https://www.kartosthera.com","status":200,"ok":true,"finalUrl":"https://www.kartosthera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/","field":"links","label":"Official website"},{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/","field":"website"},{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/","field":"links","label":"Sponsor page"}]},{"url":"https://www.karyopharm.com","status":200,"ok":true,"finalUrl":"https://www.karyopharm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","field":"links","label":"Official website"},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","field":"website"}]},{"url":"https://www.kaunoklinikos.lt","status":200,"ok":true,"finalUrl":"https://www.kaunoklinikos.lt/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","route":"/institutions/kauno-klinikos/","field":"links","label":"Official website"},{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","route":"/institutions/kauno-klinikos/","field":"website"}]},{"url":"https://www.kaunoklinikos.lt/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"links","label":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos website"},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"profiles","label":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos website"}]},{"url":"https://www.kch.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kings-college-hospital-london","kind":"institution","name":"King's College Hospital, London","route":"/institutions/kings-college-hospital-london/","field":"website"}]},{"url":"https://www.kch.nhs.uk/services/services-a-to-z/hepatobiliary-and-pancreatic-hpb/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kings-college-hospital-london","kind":"institution","name":"King's College Hospital, London","route":"/institutions/kings-college-hospital-london/","field":"links","label":"Hepatobiliary and pancreatic (HPB) service"}]},{"url":"https://www.kcsg.org","status":200,"ok":true,"finalUrl":"https://www.kcsg.org/web/index.do","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kcsg","kind":"company","name":"Korean Cancer Study Group","route":"/companies/kcsg/","field":"links","label":"KCSG"},{"id":"kcsg","kind":"company","name":"Korean Cancer Study Group","route":"/companies/kcsg/","field":"website"}]},{"url":"https://www.kcsg.org/web/information/ceo01.do","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","field":"links","label":"Society page"},{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","field":"profiles","label":"Society page"}]},{"url":"https://www.kegg.jp/pathway/hsa05205","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"proteoglycans-in-cancer","kind":"pathway","name":"Proteoglycans in cancer","route":"/pathways/proteoglycans-in-cancer/","field":"links","label":"KEGG map hsa05205"}]},{"url":"https://www.kegg.jp/pathway/hsa05206","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"micrornas-in-cancer","kind":"pathway","name":"MicroRNAs in cancer","route":"/pathways/micrornas-in-cancer/","field":"links","label":"KEGG map hsa05206"}]},{"url":"https://www.kegg.jp/pathway/hsa05207","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemical-carcinogenesis-receptor-activation","kind":"pathway","name":"Chemical carcinogenesis - receptor activation","route":"/pathways/chemical-carcinogenesis-receptor-activation/","field":"links","label":"KEGG map hsa05207"}]},{"url":"https://www.kegg.jp/pathway/hsa05210","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","field":"links","label":"KEGG map hsa05210"}]},{"url":"https://www.kegg.jp/pathway/hsa05211","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","field":"links","label":"KEGG map hsa05211"}]},{"url":"https://www.kegg.jp/pathway/hsa05212","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","field":"links","label":"KEGG map hsa05212"}]},{"url":"https://www.kegg.jp/pathway/hsa05213","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","field":"links","label":"KEGG map hsa05213"}]},{"url":"https://www.kegg.jp/pathway/hsa05214","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/","field":"links","label":"KEGG map hsa05214"}]},{"url":"https://www.kegg.jp/pathway/hsa05215","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","field":"links","label":"KEGG map hsa05215"}]},{"url":"https://www.kegg.jp/pathway/hsa05216","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","field":"links","label":"KEGG map hsa05216"}]},{"url":"https://www.kegg.jp/pathway/hsa05217","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","field":"links","label":"KEGG map hsa05217"}]},{"url":"https://www.kegg.jp/pathway/hsa05218","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","field":"links","label":"KEGG map hsa05218"}]},{"url":"https://www.kegg.jp/pathway/hsa05219","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/","field":"links","label":"KEGG map hsa05219"}]},{"url":"https://www.kegg.jp/pathway/hsa05220","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","field":"links","label":"KEGG map hsa05220"}]},{"url":"https://www.kegg.jp/pathway/hsa05221","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","field":"links","label":"KEGG map hsa05221"}]},{"url":"https://www.kegg.jp/pathway/hsa05222","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","field":"links","label":"KEGG map hsa05222"}]},{"url":"https://www.kegg.jp/pathway/hsa05223","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","field":"links","label":"KEGG map hsa05223"}]},{"url":"https://www.kegg.jp/pathway/hsa05224","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","field":"links","label":"KEGG map hsa05224"}]},{"url":"https://www.kegg.jp/pathway/hsa05225","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","field":"links","label":"KEGG map hsa05225"}]},{"url":"https://www.kegg.jp/pathway/hsa05226","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","field":"links","label":"KEGG map hsa05226"}]},{"url":"https://www.kegg.jp/pathway/hsa05231","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","field":"links","label":"KEGG map hsa05231"}]},{"url":"https://www.kelun-biotech.com","status":200,"ok":true,"finalUrl":"https://www.kelun-biotech.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","field":"links","label":"Official website"},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","field":"website"}]},{"url":"https://www.kem-med.com","status":200,"ok":true,"finalUrl":"https://kem-med.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","route":"/institutions/kliniken-essen-mitte/","field":"links","label":"Kliniken Essen-Mitte"},{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","route":"/institutions/kliniken-essen-mitte/","field":"website"}]},{"url":"https://www.kernalbio.com","status":200,"ok":true,"finalUrl":"https://www.kernalbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/","field":"links","label":"Official website"},{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/","field":"website"}]},{"url":"https://www.kerostx.com/","status":200,"ok":true,"finalUrl":"https://kerostx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","route":"/companies/keros-therapeutics/","field":"links","label":"Official website"},{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","route":"/companies/keros-therapeutics/","field":"website"}]},{"url":"https://www.kesem.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kesem","kind":"collection","name":"Kesem","route":"/collections/kesem/","field":"links","label":"Kesem"},{"id":"kesem","kind":"collection","name":"Kesem","route":"/collections/kesem/","field":"url"}]},{"url":"https://www.keymedbio.com","status":200,"ok":true,"finalUrl":"https://www.keymedbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/","field":"website"}]},{"url":"https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-gold-card-oncology","kind":"idea","name":"Exempt oncologists who follow the pathway from prior authorisation","route":"/ideas/idea-cost-gold-card-oncology/","field":"links","label":"KFF: Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024"}]},{"url":"https://www.kfshrc.edu.sa","status":200,"ok":true,"finalUrl":"https://www.kfshrc.edu.sa/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"links","label":"KFSH&RC"},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"website"}],"archive":"https://web.archive.org/web/20260821052140/https://www.kfshrc.edu.sa/"},{"url":"https://www.kfsyscc.org","status":200,"ok":true,"finalUrl":"https://www.kfsyscc.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","route":"/institutions/koo-foundation-sun-yat-sen-cancer-center/","field":"links","label":"KF-SYSCC"},{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","route":"/institutions/koo-foundation-sun-yat-sen-cancer-center/","field":"website"}]},{"url":"https://www.kfsyscc.org/deans_words/3","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","field":"profiles","label":"President's message"}]},{"url":"https://www.kfsyscc.org/department_team/medicaloncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","field":"links","label":"Source: KFSYSCC medical oncology team page listing the President"},{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","field":"profiles","label":"Institution medical oncology team page"}]},{"url":"https://www.kgog.org","status":200,"ok":true,"finalUrl":"https://www.kgog.org/html/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kgog","kind":"company","name":"Korean Gynecologic Oncology Group","route":"/companies/kgog/","field":"links","label":"Official website"},{"id":"kgog","kind":"company","name":"Korean Gynecologic Oncology Group","route":"/companies/kgog/","field":"website"}]},{"url":"https://www.khcc.jo","status":200,"ok":true,"finalUrl":"https://www.khcc.jo/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","field":"links","label":"King Hussein Cancer Center"},{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","field":"website"}]},{"url":"https://www.khcf.jo","status":200,"ok":true,"finalUrl":"https://www.khcc.jo/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","field":"links","label":"King Hussein Cancer Foundation"}]},{"url":"https://www.khoslaventures.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","field":"links","label":"Official website"},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","field":"website"}]},{"url":"https://www.khoslaventures.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://www.kindai.ac.jp","status":200,"ok":true,"finalUrl":"https://www.kindai.ac.jp/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kindai-university-hospital","kind":"institution","name":"Kindai University Faculty of Medicine and Hospital","route":"/institutions/kindai-university-hospital/","field":"links","label":"Kindai University"},{"id":"kindai-university-hospital","kind":"institution","name":"Kindai University Faculty of Medicine and Hospital","route":"/institutions/kindai-university-hospital/","field":"website"}]},{"url":"https://www.kitepharma.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","field":"links","label":"Official website"},{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","field":"website"}]},{"url":"https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","field":"links","label":"Gilead to acquire Arcellx (February 2026)"}]},{"url":"https://www.kitepharma.com/news/press-releases/2026/4/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","field":"links","label":"Gilead completes acquisition (April 2026)"}]},{"url":"https://www.kliinikum.ee","status":200,"ok":true,"finalUrl":"https://www.kliinikum.ee/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tartu-university-hospital","kind":"institution","name":"Tartu University Hospital","route":"/institutions/tartu-university-hospital/","field":"links","label":"Official website"},{"id":"tartu-university-hospital","kind":"institution","name":"Tartu University Hospital","route":"/institutions/tartu-university-hospital/","field":"website"}]},{"url":"https://www.kliinikum.ee/en/about-the-hospital/members-of-the-executive-board/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"priit-perens","kind":"person","name":"Priit Perens","route":"/people/priit-perens/","field":"links","label":"Source: Tartu University Hospital members of the executive board"},{"id":"priit-perens","kind":"person","name":"Priit Perens","route":"/people/priit-perens/","field":"profiles","label":"Tartu University Hospital executive board page"}]},{"url":"https://www.klineo.com/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/","field":"links","label":"Official website"},{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/","field":"website"}]},{"url":"https://www.klinikum-stuttgart.de","status":200,"ok":true,"finalUrl":"https://www.klinikum-stuttgart.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klinikum-stuttgart-olgahospital","kind":"institution","name":"Klinikum Stuttgart / Olgahospital","route":"/institutions/klinikum-stuttgart-olgahospital/","field":"links","label":"Klinikum Stuttgart"},{"id":"klinikum-stuttgart-olgahospital","kind":"institution","name":"Klinikum Stuttgart / Olgahospital","route":"/institutions/klinikum-stuttgart-olgahospital/","field":"website"}]},{"url":"https://www.knittedknockers.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"knitted-knockers","kind":"collection","name":"Knitted Knockers","route":"/collections/knitted-knockers/","field":"links","label":"Knitted Knockers"},{"id":"knitted-knockers","kind":"collection","name":"Knitted Knockers","route":"/collections/knitted-knockers/","field":"url"}]},{"url":"https://www.komodohealth.com","status":200,"ok":true,"finalUrl":"https://www.komodohealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","field":"links","label":"Official website"},{"id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","field":"website"}]},{"url":"https://www.konruns.cn","status":200,"ok":true,"finalUrl":"https://www.konruns.cn/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","field":"website"}]},{"url":"https://www.kpwashingtonresearch.org","status":200,"ok":true,"finalUrl":"https://www.kpwashingtonresearch.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","field":"links","label":"KP Washington Health Research Institute"}]},{"url":"https://www.krankenhaus-nordwest.de","status":200,"ok":true,"finalUrl":"https://www.krankenhaus-nordwest.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"krankenhaus-nordwest","kind":"institution","name":"Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)","route":"/institutions/krankenhaus-nordwest/","field":"links","label":"Krankenhaus Nordwest"},{"id":"krankenhaus-nordwest","kind":"institution","name":"Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)","route":"/institutions/krankenhaus-nordwest/","field":"website"}]},{"url":"https://www.krebsgesellschaft.de","status":200,"ok":true,"finalUrl":"https://www.krebsgesellschaft.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"Deutsche Krebsgesellschaft"},{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"website"}]},{"url":"https://www.krebsgesellschaft.de/zertifizierung.html","status":200,"ok":true,"finalUrl":"https://www.krebsgesellschaft.de/unsere-themen/zertifizierung","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"Certification"}]},{"url":"https://www.krebshilfe.de","status":200,"ok":true,"finalUrl":"https://www.krebshilfe.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/","field":"links","label":"Deutsche Krebshilfe"},{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/","field":"website"}]},{"url":"https://www.krebshilfe.de/informieren/ueber-uns/organisation/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/","field":"links","label":"Source: Deutsche Krebshilfe organisation page"},{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/","field":"profiles","label":"Institution organisation page"}]},{"url":"https://www.krebsinformationsdienst.de/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"krebsinformationsdienst","kind":"collection","name":"Krebsinformationsdienst (KID)","route":"/collections/krebsinformationsdienst/","field":"links","label":"Krebsinformationsdienst (KID)"},{"id":"krebsinformationsdienst","kind":"collection","name":"Krebsinformationsdienst (KID)","route":"/collections/krebsinformationsdienst/","field":"url"}]},{"url":"https://www.krystalbio.com","status":200,"ok":true,"finalUrl":"https://www.krystalbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/","field":"links","label":"Official website"},{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/","field":"website"}]},{"url":"https://www.kucancercenter.org","status":200,"ok":true,"finalUrl":"https://www.kucancercenter.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","field":"links","label":"KU Cancer Center"},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","field":"website"}]},{"url":"https://www.kucancercenter.org/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","field":"links","label":"Clinical trials"}]},{"url":"https://www.kuhp.kyoto-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.kuhp.kyoto-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","field":"links","label":"Kyoto University Hospital"},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","field":"website"}]},{"url":"https://www.kuhp.kyoto-u.ac.jp/english/outline/greeting.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"links","label":"Institution profile"},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.kul.lt","status":200,"ok":true,"finalUrl":"https://www.kul.lt/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","route":"/institutions/klaipeda-university-hospital/","field":"links","label":"Official website"},{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","route":"/institutions/klaipeda-university-hospital/","field":"website"}]},{"url":"https://www.kul.lt/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","field":"links","label":"Klaipėda University Hospital website"},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","field":"profiles","label":"Klaipėda University Hospital website"}]},{"url":"https://www.kuraoncology.com","status":200,"ok":true,"finalUrl":"https://kuraoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/","field":"website"}]},{"url":"https://www.kwf.nl","status":200,"ok":true,"finalUrl":"https://www.kwf.nl/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/","field":"links","label":"KWF"},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/","field":"website"}]},{"url":"https://www.kwf.nl/over-ons/onze-organisatie","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","route":"/people/carla-van-gils/","field":"links","label":"Source: KWF organisation page"},{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","route":"/people/carla-van-gils/","field":"profiles","label":"Institution organisation page"}]},{"url":"https://www.kymeratx.com","status":200,"ok":true,"finalUrl":"https://www.kymeratx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/","field":"website"}]},{"url":"https://www.kyowakirin.com","status":200,"ok":true,"finalUrl":"https://www.kyowakirin.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/","field":"links","label":"Official website"},{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/","field":"website"}]},{"url":"https://www.labcorp.com","status":200,"ok":true,"finalUrl":"https://www.labcorp.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","field":"links","label":"Official website"},{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","field":"website"}]},{"url":"https://www.laminarpharma.com","status":200,"ok":true,"finalUrl":"https://laminarpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/","field":"links","label":"Official website"},{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/","field":"website"},{"id":"lam561","kind":"drug","name":"LAM561","route":"/drugs/lam561/","field":"links","label":"Sponsor page"}]},{"url":"https://www.landspitali.is","status":200,"ok":true,"finalUrl":"https://island.is/s/landspitali","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","field":"links","label":"Official website"},{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","field":"website"}]},{"url":"https://www.landspitali.is/","status":200,"ok":true,"finalUrl":"https://island.is/s/landspitali","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","field":"links","label":"Landspítali, the National University Hospital of Iceland website"},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","field":"profiles","label":"Landspítali, the National University Hospital of Iceland website"}]},{"url":"https://www.lanovamedicines.com","status":200,"ok":true,"finalUrl":"https://www.lanovamedicines.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","field":"links","label":"Official website"},{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","field":"website"}]},{"url":"https://www.lanovamedicines.com/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","field":"links","label":"Pipeline page"},{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","field":"links","label":"Sponsor page"}]},{"url":"https://www.lanternpharma.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","route":"/companies/lantern-pharma/","field":"links","label":"Official website"},{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","route":"/companies/lantern-pharma/","field":"website"}]},{"url":"https://www.lantheus.com","status":200,"ok":true,"finalUrl":"https://www.lantheus.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","field":"links","label":"Official website"},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","field":"website"}]},{"url":"https://www.latentlabs.com","status":200,"ok":true,"finalUrl":"https://www.latentlabs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","field":"links","label":"Official website"},{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","field":"website"}]},{"url":"https://www.lbbc.org/news","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","field":"links","label":"Living Beyond Breast Cancer"},{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","field":"url"}]},{"url":"https://www.lbbc.org/news/pivotal-progress-in-tnbc-asco-2026","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"outcomes.source (Event-free survival at 7 years)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"outcomes.source (Overall survival at 7 years)"},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","field":"links","label":"LBBC ASCO 2026 summary"}]},{"url":"https://www.leadiant.com","status":200,"ok":true,"finalUrl":"https://leadiant.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leadiant","kind":"company","name":"Leadiant Biosciences","route":"/companies/leadiant/","field":"links","label":"Official website"},{"id":"leadiant","kind":"company","name":"Leadiant Biosciences","route":"/companies/leadiant/","field":"website"}]},{"url":"https://www.leadsbiolabs.com","status":200,"ok":true,"finalUrl":"https://www.leadsbiolabs.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/","field":"links","label":"Official website"},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/","field":"website"}]},{"url":"https://www.leahlabs.com","status":200,"ok":true,"finalUrl":"https://leahlabs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leah-labs","kind":"company","name":"LEAH Labs","route":"/companies/leah-labs/","field":"links","label":"Official website"},{"id":"leah-labs","kind":"company","name":"LEAH Labs","route":"/companies/leah-labs/","field":"website"}]},{"url":"https://www.leedsth.nhs.uk/about/board/directors/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brendan-brown","kind":"person","name":"Brendan Brown","route":"/people/brendan-brown/","field":"links","label":"Source: Leeds Teaching Hospitals Trust Board members page"},{"id":"brendan-brown","kind":"person","name":"Brendan Brown","route":"/people/brendan-brown/","field":"profiles","label":"Trust Board members"}]},{"url":"https://www.leedsth.nhs.uk/consultants/professor-matthew-callister/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matthew-callister","kind":"person","name":"Matthew Callister","route":"/people/matthew-callister/","field":"links","label":"Leeds Teaching Hospitals consultant page"},{"id":"matthew-callister","kind":"person","name":"Matthew Callister","route":"/people/matthew-callister/","field":"profiles","label":"Leeds Teaching Hospitals consultant page"}]},{"url":"https://www.leedsth.nhs.uk/research/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-rt-drug-platform","kind":"idea","name":"A standing platform for testing new drugs with radiotherapy","route":"/ideas/idea-tr2-rt-drug-platform/","field":"links","label":"CONCORDE platform (page moved; nearest live section)"}]},{"url":"https://www.leedsth.nhs.uk/services/leeds-cancer-centre/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/","field":"links","label":"Leeds Cancer Centre"},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/","field":"website"}]},{"url":"https://www.leespharm.com","status":200,"ok":true,"finalUrl":"https://www.leespharm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/","field":"links","label":"Official website"},{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/","field":"website"}]},{"url":"https://www.legendbiotech.com","status":200,"ok":true,"finalUrl":"https://legendbiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/","field":"links","label":"Official website"},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/","field":"website"}]},{"url":"https://www.legendbiotech.com/","status":200,"ok":true,"finalUrl":"https://legendbiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/","field":"links","label":"Legend Biotech"},{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/","field":"profiles","label":"Legend Biotech"}]},{"url":"https://www.legislation.gov.uk/ukpga/2018/12","status":200,"ok":true,"contentType":"application/xhtml+xml;charset=utf-8","checked":"2026-09-30","refs":[{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","field":"links","label":"legislation.gov.uk: Data Protection Act 2018"}]},{"url":"https://www.legislation.gov.uk/ukpga/2021/3","status":200,"ok":true,"contentType":"application/xhtml+xml;charset=utf-8","checked":"2026-09-30","refs":[{"id":"medicines-medical-devices-act-2021","kind":"term","name":"Medicines and Medical Devices Act 2021","route":"/terms/medicines-medical-devices-act-2021/","field":"links","label":"legislation.gov.uk: Medicines and Medical Devices Act 2021"}]},{"url":"https://www.legislation.gov.uk/ukpga/2025/18","status":200,"ok":true,"contentType":"application/xhtml+xml;charset=utf-8","checked":"2026-09-30","refs":[{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","field":"links","label":"legislation.gov.uk: Data (Use and Access) Act 2025"}]},{"url":"https://www.leicabiosystems.com","status":200,"ok":true,"finalUrl":"https://www.leicabiosystems.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","route":"/companies/leica-biosystems/","field":"links","label":"Official website"},{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","route":"/companies/leica-biosystems/","field":"website"}]},{"url":"https://www.leitlinienprogramm-onkologie.de","status":200,"ok":true,"finalUrl":"https://www.leitlinienprogramm-onkologie.de/home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"Leitlinienprogramm Onkologie"}]},{"url":"https://www.leo-pharma.com","status":200,"ok":true,"finalUrl":"https://leo-pharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","field":"links","label":"Official website"},{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","field":"website"}]},{"url":"https://www.lepubiopharma.com","status":200,"ok":true,"finalUrl":"https://www.lepubiopharma.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/","field":"links","label":"Official website"},{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/","field":"website"},{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/","field":"links","label":"Sponsor page"}]},{"url":"https://www.lerner.ccf.org/cardiovascular-metabolic/lathia/","status":200,"ok":true,"finalUrl":"https://www.lerner.ccf.org/404.php","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","field":"links","label":"Cleveland Clinic profile"},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","field":"profiles","label":"Cleveland Clinic profile"}]},{"url":"https://www.lerner.ccf.org/immunotherapy/chan/","status":200,"ok":true,"finalUrl":"https://www.lerner.ccf.org/404.php","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"links","label":"Cleveland Clinic profile"},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","field":"profiles","label":"Cleveland Clinic profile"}]},{"url":"https://www.lerner.ccf.org/inflammation-immunity/tuohy/","status":200,"ok":true,"finalUrl":"https://www.lerner.ccf.org/404.php","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","field":"links","label":"Cleveland Clinic profile"},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","field":"profiles","label":"Cleveland Clinic profile"}]},{"url":"https://www.lerner.ccf.org/thor/maciejewski/","status":200,"ok":true,"finalUrl":"https://www.lerner.ccf.org/404.php","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","field":"links","label":"Cleveland Clinic profile"},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","field":"profiles","label":"Cleveland Clinic profile"}]},{"url":"https://www.lfsassociation.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","field":"links","label":"LFS Association"}]},{"url":"https://www.lhch.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liverpool-heart-and-chest","kind":"institution","name":"Liverpool Heart and Chest Hospital NHS Foundation Trust","route":"/institutions/liverpool-heart-and-chest/","field":"website"}]},{"url":"https://www.lhch.nhs.uk/thoracic-surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liverpool-heart-and-chest","kind":"institution","name":"Liverpool Heart and Chest Hospital NHS Foundation Trust","route":"/institutions/liverpool-heart-and-chest/","field":"links","label":"Thoracic surgery at Liverpool Heart and Chest Hospital"}]},{"url":"https://www.lhsc.on.ca","status":200,"ok":true,"finalUrl":"https://www.lhsc.on.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lhsc-verspeeten","kind":"institution","name":"Verspeeten Family Cancer Centre, London Health Sciences Centre","route":"/institutions/lhsc-verspeeten/","field":"links","label":"Official website"},{"id":"lhsc-verspeeten","kind":"institution","name":"Verspeeten Family Cancer Centre, London Health Sciences Centre","route":"/institutions/lhsc-verspeeten/","field":"website"}]},{"url":"https://www.lhsc.on.ca/about-lhsc/executive-leadership-team","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tammy-quigley","kind":"person","name":"Tammy Quigley","route":"/people/tammy-quigley/","field":"links","label":"Source: LHSC executive leadership team page"},{"id":"tammy-quigley","kind":"person","name":"Tammy Quigley","route":"/people/tammy-quigley/","field":"profiles","label":"LHSC executive leadership team"}]},{"url":"https://www.ligachembio.com","status":200,"ok":true,"finalUrl":"https://www.ligachembio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/","field":"links","label":"Official website"},{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/","field":"website"},{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","field":"links","label":"Sponsor page"},{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","field":"links","label":"Sponsor page"}]},{"url":"https://www.lightpointmedical.com/","status":200,"ok":true,"finalUrl":"https://senseisurgical.com/","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/","field":"links","label":"Lightpoint Medical: LightPath and SENSEI"},{"id":"lightpoint-medical","kind":"company","name":"Lightpoint Medical","route":"/companies/lightpoint-medical/","field":"links","label":"Official website"},{"id":"lightpoint-medical","kind":"company","name":"Lightpoint Medical","route":"/companies/lightpoint-medical/","field":"website"}]},{"url":"https://www.ligue-cancer.net","status":200,"ok":true,"finalUrl":"https://www.ligue-cancer.net/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","route":"/institutions/ligue-contre-le-cancer/","field":"links","label":"Ligue contre le cancer"},{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","route":"/institutions/ligue-contre-le-cancer/","field":"website"}]},{"url":"https://www.ligue-cancer.net/qui-sommesnous","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","route":"/people/philippe-bergerot/","field":"links","label":"Source: Ligue nationale contre le cancer, Qui sommes-nous (bureau)"},{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","route":"/people/philippe-bergerot/","field":"profiles","label":"Ligue governance page"}]},{"url":"https://www.lila.ai","status":200,"ok":true,"finalUrl":"https://www.lila.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","field":"links","label":"Official website"},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","field":"website"}]},{"url":"https://www.linkedin.com/company/strand-ai","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","field":"links","label":"LinkedIn"}]},{"url":"https://www.linkos.cz/casopis-klinicka-onkologie/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","route":"/journals/klinicka-onkologie/","field":"links","label":"Homepage"},{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","route":"/journals/klinicka-onkologie/","field":"url"}],"archive":"https://web.archive.org/web/20260912170413/https://www.linkos.cz/casopis-klinicka-onkologie/"},{"url":"https://www.lisata.com","status":200,"ok":true,"finalUrl":"https://www.lisata.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lisata","kind":"company","name":"Lisata Therapeutics","route":"/companies/lisata/","field":"links","label":"Official website"},{"id":"lisata","kind":"company","name":"Lisata Therapeutics","route":"/companies/lisata/","field":"website"}]},{"url":"https://www.littleprincesses.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"little-princess-trust","kind":"collection","name":"The Little Princess Trust","route":"/collections/little-princess-trust/","field":"links","label":"The Little Princess Trust"},{"id":"little-princess-trust","kind":"collection","name":"The Little Princess Trust","route":"/collections/little-princess-trust/","field":"url"}]},{"url":"https://www.liverpool.ac.uk/people/christopher-halloran","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chris-halloran","kind":"person","name":"Chris Halloran","route":"/people/chris-halloran/","field":"links","label":"University of Liverpool staff page"},{"id":"chris-halloran","kind":"person","name":"Chris Halloran","route":"/people/chris-halloran/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.liverpool.ac.uk/people/daniel-palmer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/","field":"links","label":"University of Liverpool staff page"},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.liverpool.ac.uk/people/hassan-malik","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hassan-malik","kind":"person","name":"Hassan Malik","route":"/people/hassan-malik/","field":"links","label":"University of Liverpool staff page"},{"id":"hassan-malik","kind":"person","name":"Hassan Malik","route":"/people/hassan-malik/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.liverpool.ac.uk/people/john-field","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-field","kind":"person","name":"John Field","route":"/people/john-field/","field":"links","label":"University of Liverpool staff page"},{"id":"john-field","kind":"person","name":"John Field","route":"/people/john-field/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.liverpool.ac.uk/people/paula-ghaneh","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","route":"/people/paula-ghaneh/","field":"links","label":"University of Liverpool staff page"},{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","route":"/people/paula-ghaneh/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.liverpool.ac.uk/people/william-greenhalf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bill-greenhalf","kind":"person","name":"Bill Greenhalf","route":"/people/bill-greenhalf/","field":"links","label":"University of Liverpool staff page"},{"id":"bill-greenhalf","kind":"person","name":"Bill Greenhalf","route":"/people/bill-greenhalf/","field":"profiles","label":"University of Liverpool staff page"}]},{"url":"https://www.livestrong.org/","status":200,"ok":true,"finalUrl":"https://livestrong.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","field":"links","label":"Livestrong Foundation"},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","field":"profiles","label":"Livestrong Foundation"},{"id":"livestrong-at-the-ymca","kind":"collection","name":"LIVESTRONG at the YMCA","route":"/collections/livestrong-at-the-ymca/","field":"links","label":"LIVESTRONG at the YMCA"},{"id":"livestrong-at-the-ymca","kind":"collection","name":"LIVESTRONG at the YMCA","route":"/collections/livestrong-at-the-ymca/","field":"url"}]},{"url":"https://www.lksf.org","status":200,"ok":true,"finalUrl":"https://www.lksf.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/","field":"website"}]},{"url":"https://www.lksf.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","field":"links","label":"Li Ka Shing Foundation"},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/","field":"links","label":"Li Ka Shing Foundation"}]},{"url":"https://www.lksf.org/heart-of-gold/","status":200,"ok":true,"finalUrl":"https://www.lksf.org/initiative-project/heart-of-gold-hong-kong-hospice-service-programme/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","field":"links","label":"Heart of Gold hospice programme"},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/","field":"links","label":"Heart of Gold hospice programme"}]},{"url":"https://www.lmu-klinikum.de","status":200,"ok":true,"finalUrl":"https://www.lmu-klinikum.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","field":"links","label":"Official website"},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","field":"website"}]},{"url":"https://www.logoscapital.com","status":200,"ok":true,"finalUrl":"https://www.logoscapital.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","field":"links","label":"Official website"},{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","field":"website"}]},{"url":"https://www.lucc.lu.se","status":200,"ok":true,"finalUrl":"https://www.lucc.lu.se/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","field":"links","label":"Lund University Cancer Centre"}]},{"url":"https://www.lucence.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","field":"links","label":"Official website"},{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","field":"website"}]},{"url":"https://www.lucence.com/about","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","field":"links","label":"About Lucence"}]},{"url":"https://www.lucence.com/news-updates","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","field":"links","label":"News and updates"}]},{"url":"https://www.ludwigcancerresearch.org","status":200,"ok":true,"finalUrl":"https://www.ludwigcancerresearch.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/","field":"website"}]},{"url":"https://www.ludwigcancerresearch.org/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/","field":"links","label":"Ludwig Cancer Research: about"},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/","field":"links","label":"About Ludwig Cancer Research"}]},{"url":"https://www.ludwigcancerresearch.org/location/lausanne-branch/","status":200,"ok":true,"finalUrl":"https://www.ludwigcancerresearch.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","field":"links","label":"Ludwig Lausanne"}]},{"url":"https://www.ludwigcancerresearch.org/scientist/johanna-joyce/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.lumc.nl/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","field":"links","label":"Homepage"},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","field":"website"}]},{"url":"https://www.lumc.nl/en/about-lumc/het-lumc/management-and-organization/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-jan-schalij","kind":"person","name":"Martin Jan Schalij","route":"/people/martin-jan-schalij/","field":"links","label":"Institution profile"},{"id":"martin-jan-schalij","kind":"person","name":"Martin Jan Schalij","route":"/people/martin-jan-schalij/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.lumicell.com","status":200,"ok":true,"finalUrl":"https://lumicell.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lumicell","kind":"company","name":"Lumicell","route":"/companies/lumicell/","field":"links","label":"Official website"},{"id":"lumicell","kind":"company","name":"Lumicell","route":"/companies/lumicell/","field":"website"}]},{"url":"https://www.luminatemed.com","status":200,"ok":true,"finalUrl":"https://www.luminatemed.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"luminate-medical","kind":"company","name":"Luminate Medical","route":"/companies/luminate-medical/","field":"links","label":"Official website"},{"id":"luminate-medical","kind":"company","name":"Luminate Medical","route":"/companies/luminate-medical/","field":"website"}]},{"url":"https://www.lumos-pharma.com","status":200,"ok":true,"finalUrl":"https://lumos-pharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","route":"/companies/newlink-genetics/","field":"website"}]},{"url":"https://www.lungenclinic.de","status":200,"ok":true,"finalUrl":"https://www.lungenclinic.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","route":"/institutions/lungenclinic-grosshansdorf/","field":"links","label":"LungenClinic Grosshansdorf"},{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","route":"/institutions/lungenclinic-grosshansdorf/","field":"website"}]},{"url":"https://www.lungevity.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","field":"links","label":"LUNGevity"},{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","field":"url"}]},{"url":"https://www.lunit.io","status":200,"ok":true,"finalUrl":"https://www.lunit.io/en/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/","field":"website"}]},{"url":"https://www.lunit.io/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","field":"links","label":"Official website"},{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","field":"website"}]},{"url":"https://www.lunit.io/en/ai-radiology-software/scorecard/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","field":"links","label":"Volpara Scorecard product page on Lunit"}]},{"url":"https://www.lunit.io/en/products/mmg","status":200,"ok":true,"finalUrl":"https://www.lunit.io/en/ai-radiology-software/insight-mmg/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lunit-insight-mmg","kind":"drug","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/","field":"links","label":"Lunit INSIGHT MMG"}]},{"url":"https://www.lupengbio.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/","field":"links","label":"Official website"},{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/","field":"website"}]},{"url":"https://www.lupin.com","status":200,"ok":true,"finalUrl":"https://www.lupin.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lupin","kind":"company","name":"Lupin","route":"/companies/lupin/","field":"links","label":"Official website"},{"id":"lupin","kind":"company","name":"Lupin","route":"/companies/lupin/","field":"website"}]},{"url":"https://www.luxcapital.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","field":"links","label":"Official website"},{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","field":"website"}]},{"url":"https://www.luxcapital.com/companies","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","field":"links","label":"Companies"}]},{"url":"https://www.luye.cn","status":200,"ok":true,"finalUrl":"https://www.luye.cn/lvye/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","field":"links","label":"Official website"},{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","field":"website"}]},{"url":"https://www.lyell.com","status":200,"ok":true,"finalUrl":"https://lyell.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","field":"links","label":"Official website"},{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","field":"website"}]},{"url":"https://www.lysa-lymphoma.org","status":200,"ok":true,"finalUrl":"https://experts-recherche-lymphome.org/lysa/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/","field":"links","label":"LYSA"},{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/","field":"website"}]},{"url":"https://www.lyvgen.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","route":"/companies/lyvgen-biopharma/","field":"links","label":"Official website"},{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","route":"/companies/lyvgen-biopharma/","field":"website"}]},{"url":"https://www.maatpharma.com","status":200,"ok":true,"finalUrl":"https://www.maatpharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","field":"links","label":"Official website"},{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","field":"website"}]},{"url":"https://www.maatpharma.com/june-26-2026-maat-pharma-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-maat013-for-the-treatment-of-acute-graft-versus-host-disease/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","field":"links","label":"Plan to request re-examination after negative CHMP opinion (June 2026)"}]},{"url":"https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","field":"links","label":"Q1 2026 business update"}]},{"url":"https://www.mabion.eu","status":200,"ok":true,"finalUrl":"https://www.mabion.eu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","field":"links","label":"Official website"},{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","field":"website"}]},{"url":"https://www.mabwell.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/","field":"links","label":"Official website"},{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/","field":"website"}]},{"url":"https://www.mabxience.com","status":200,"ok":true,"finalUrl":"https://mabxience.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","route":"/companies/mabxience-research-s-l/","field":"links","label":"Official website"},{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","route":"/companies/mabxience-research-s-l/","field":"website"}]},{"url":"https://www.macmillan.org.uk","status":200,"ok":true,"finalUrl":"https://www.macmillan.org.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","field":"links","label":"Macmillan"},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","field":"website"}]},{"url":"https://www.macmillan.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"macmillan-support-line","kind":"collection","name":"Macmillan Support Line","route":"/collections/macmillan-support-line/","field":"links","label":"Macmillan Support Line"},{"id":"macmillan-support-line","kind":"collection","name":"Macmillan Support Line","route":"/collections/macmillan-support-line/","field":"url"}]},{"url":"https://www.macmillan.org.uk/about-us/organisation/team/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemma-peters","kind":"person","name":"Gemma Peters","route":"/people/gemma-peters/","field":"links","label":"Source: Macmillan leadership team page"}]},{"url":"https://www.macmillan.org.uk/about-us/organisation/team/leadership/ceo-gemma-peters","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gemma-peters","kind":"person","name":"Gemma Peters","route":"/people/gemma-peters/","field":"profiles","label":"Macmillan profile"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","field":"links","label":"Macmillan Cancer Support"},{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","field":"url"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: bowel cancer (including rectal cancer and colon cancer)"}],"archive":"https://web.archive.org/web/20260818221125/https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/managing-bowel-changes-after-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: bowel changes after cancer treatment"},{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"links","label":"Macmillan: bowel changes after cancer treatment"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Macmillan: bowel changes after cancer treatment"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"Macmillan: bowel changes after cancer treatment"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","field":"links","label":"Macmillan: bowel changes after cancer treatment"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/multidisciplinary-team-for-bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: the multidisciplinary team for bowel cancer"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"links","label":"Macmillan: the multidisciplinary team for bowel cancer"}],"archive":"https://web.archive.org/web/20260416113329/https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/multidisciplinary-team-for-bowel-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/preparing-for-bowel-cancer-surgery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Macmillan: preparing for bowel cancer treatment"},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"links","label":"Macmillan: preparing for bowel cancer treatment"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/tests-on-the-bowel-cancer-cells","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: tests on the bowel cancer cells"},{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","field":"links","label":"Macmillan: tests on the bowel cancer cells"},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","field":"links","label":"Macmillan: tests on the bowel cancer cells"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/treatment-for-advanced-bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: treatment for advanced bowel cancer"},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","field":"links","label":"Macmillan: treatment for advanced bowel cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/breast-cancer/breast-reconstruction","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"Macmillan: breast reconstruction"},{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"Macmillan: breast reconstruction"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: breast reconstruction"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/breast-cancer/triple-negative-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: triple negative breast cancer"}],"archive":"https://web.archive.org/web/20260818221315/https://www.macmillan.org.uk/cancer-information-and-support/breast-cancer/triple-negative-breast-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/gallbladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Macmillan: gallbladder cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/get-help/financial-and-work","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/","field":"links","label":"Macmillan: money and work"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Macmillan: money and work"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Macmillan: money and work"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/get-help/financial-and-work/macmillan-grants","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Macmillan grants"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Macmillan: breathlessness"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Macmillan: breathlessness"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Macmillan: breathlessness"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Macmillan: breathlessness"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Macmillan: breathlessness"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","field":"links","label":"Macmillan: breathlessness"},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"links","label":"Macmillan: breathlessness"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"Macmillan: breathlessness"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Macmillan: breathlessness"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: breathlessness"}],"archive":"https://web.archive.org/web/20260920171805/https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/eating-problems","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"weight-loss-and-fat-digestion-biliary","kind":"term","name":"Weight loss, fat digestion and enzymes with gallbladder cancer","route":"/terms/weight-loss-and-fat-digestion-biliary/","field":"links","label":"Macmillan: eating problems"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/fertility","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Macmillan: fertility and cancer"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"Macmillan: fertility"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: fertility"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/hair-loss","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","field":"links","label":"Macmillan: hair loss"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Macmillan: scalp cooling"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"Macmillan: hair loss"},{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","field":"links","label":"Macmillan Cancer Support: hair loss"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: hair loss"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/lymphoedema","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"Macmillan: lymphoedema"},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"Macmillan: lymphoedema"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: lymphoedema"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/pain","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pain-with-biliary-cancer","kind":"term","name":"Pain with gallbladder and bile duct cancer","route":"/terms/pain-with-biliary-cancer/","field":"links","label":"Macmillan: pain"},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"Macmillan: pain"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: pain"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/peripheral-neuropathy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Macmillan: peripheral neuropathy"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sepsis","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: sepsis"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"Macmillan: sepsis"},{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","field":"links","label":"Macmillan: sepsis"},{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","field":"links","label":"Macmillan: sepsis"},{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","field":"links","label":"Macmillan: sepsis"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"Macmillan: sepsis"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","field":"links","label":"Macmillan: sepsis"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Macmillan: sepsis"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: sepsis"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: sepsis"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sex-life-and-bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: sex life after bowel cancer"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"Macmillan: sex life after bowel cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Macmillan: superior vena cava obstruction (SVCO)"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Macmillan: superior vena cava obstruction (SVCO)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Macmillan: superior vena cava obstruction (SVCO)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: superior vena cava obstruction (SVCO)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/tiredness","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: tiredness (fatigue)"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Macmillan: tiredness (fatigue)"}],"archive":"https://web.archive.org/web/20260926082755/https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/tiredness"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/work-and-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","field":"links","label":"Macmillan: work and cancer"},{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/","field":"links","label":"Macmillan: work and cancer"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Macmillan: work and cancer"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Macmillan: work and cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: work and cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Macmillan: lung cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/non-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Macmillan: non-small cell lung cancer (NSCLC)"},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","field":"links","label":"Macmillan: non-small cell lung cancer (NSCLC)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Macmillan: non-small cell lung cancer (NSCLC)"}],"archive":"https://web.archive.org/web/20260818221228/https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/non-small-cell-lung-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Macmillan: small cell lung cancer (SCLC)"}],"archive":"https://web.archive.org/web/20260818221303/https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/small-cell-lung-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/pancreatic-cancer/controlling-symptoms-of-pancreatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"},{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"Macmillan: managing symptoms of pancreatic cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/pancreatic-cancer/types-of-surgery-for-pancreatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: types of surgery for pancreatic cancer"},{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Macmillan: types of surgery for pancreatic cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/prostate-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Macmillan: prostate cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/skin-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Macmillan: skin cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/supporting-someone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"Macmillan: supporting someone with cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/supporting-someone/looking-after-someone-with-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: looking after someone with cancer"},{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","field":"links","label":"Macmillan: looking after someone with cancer"},{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","field":"links","label":"Macmillan: looking after someone with cancer"},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"Macmillan: looking after someone with cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: looking after someone with cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/supporting-someone/practical-support-for-carers/benefits-for-carers","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"Macmillan: benefits for carers"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatment/if-you-have-an-advanced-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: advanced cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatment/your-treatment-options/questions-to-ask-your-healthcare-team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: questions to ask your healthcare team"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: questions to ask your healthcare team"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: questions to ask your healthcare team"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/antibody-drug-conjugate","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","field":"links","label":"Macmillan: antibody drug conjugate treatment"},{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/","field":"links","label":"Macmillan: antibody drug conjugate treatment"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/atezolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"links","label":"Macmillan: atezolizumab (Tecentriq)"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Macmillan: atezolizumab (Tecentriq)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/breast-conserving-surgery-for-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-margins-and-re-excision","kind":"term","name":"Margins after breast-conserving surgery, and second operations","route":"/terms/breast-margins-and-re-excision/","field":"links","label":"Macmillan: breast-conserving surgery"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"Macmillan: breast-conserving surgery"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: breast-conserving surgery"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/capecitabine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: capecitabine"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"links","label":"Macmillan: capecitabine"},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Macmillan: capecitabine"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/carboplatin-paclitaxel-ec-pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: carboplatin and paclitaxel, EC and pembrolizumab (the KEYNOTE-522 regimen)"},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/","field":"links","label":"Macmillan: carboplatin and paclitaxel, EC and pembrolizumab (the KEYNOTE-522 regimen)"}],"archive":"https://web.archive.org/web/20260514072524/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/carboplatin-paclitaxel-ec-pembrolizumab"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/cetuximab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: cetuximab (Erbitux)"},{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","field":"links","label":"Macmillan: cetuximab (Erbitux)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: cetuximab (Erbitux)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemoradiation-for-rectal-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: chemoradiation for rectal cancer"},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","field":"links","label":"Macmillan: chemoradiation for rectal cancer"},{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","field":"links","label":"Macmillan: chemoradiation for rectal cancer"}],"archive":"https://web.archive.org/web/20260904062428/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemoradiation-for-rectal-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-bowel-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: chemotherapy for bowel cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: chemotherapy for breast cancer"}],"archive":"https://web.archive.org/web/20260904062433/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-breast-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-pancreatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: chemotherapy for pancreatic cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: clinical trials"}],"archive":"https://web.archive.org/web/20260904062420/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/clinical-trials"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/docetaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: docetaxel"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/durvalumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"links","label":"Macmillan: durvalumab (Imfinzi)"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Macmillan: durvalumab (Imfinzi)"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","field":"links","label":"Macmillan: durvalumab (Imfinzi)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: durvalumab (Imfinzi)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/folfirinox","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Macmillan: FOLFIRINOX"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: FOLFIRINOX"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/folfox","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: FOLFOX"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Macmillan: FOLFOX"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"links","label":"Macmillan: FOLFOX"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: FOLFOX"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/gemcap","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","field":"links","label":"Macmillan: GemCap (gemcitabine and capecitabine)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/hormonal-therapies","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Macmillan: hormonal therapies"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/irinotecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: irinotecan"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"Macmillan: irinotecan"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Macmillan: irinotecan"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: irinotecan"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/nab-paclitaxel","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Macmillan: nab-paclitaxel (Abraxane)"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"Macmillan: nab-paclitaxel (Abraxane)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/olaparib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: olaparib"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: olaparib"}],"archive":"https://web.archive.org/web/20260904062554/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/olaparib"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/osimertinib","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: osimertinib (Tagrisso)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/oxaliplatin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: oxaliplatin"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Macmillan: oxaliplatin"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: oxaliplatin"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/panitumumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"Macmillan: panitumumab (Vectibix)"},{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","field":"links","label":"Macmillan: panitumumab (Vectibix)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/pembrolizumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","field":"links","label":"Macmillan: pembrolizumab"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"links","label":"Macmillan: pembrolizumab (Keytruda)"},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","field":"links","label":"Macmillan: pembrolizumab"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Macmillan: pembrolizumab"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","field":"links","label":"Macmillan: pembrolizumab (Keytruda)"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","field":"links","label":"Macmillan: pembrolizumab"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","field":"links","label":"Macmillan: pembrolizumab (Keytruda)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Macmillan: pembrolizumab"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/radiotherapy-for-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: radiotherapy for breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: radiotherapy for breast cancer"}],"archive":"https://web.archive.org/web/20260904062613/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/radiotherapy-for-breast-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/removing-the-breast-mastectomy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"links","label":"Macmillan: removing the breast (mastectomy)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: removing the breast (mastectomy)"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/sacituzumab-govitecan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","field":"links","label":"Macmillan: sacituzumab govitecan"},{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","field":"links","label":"Macmillan: sacituzumab govitecan"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-for-gallbladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eating-after-gallbladder-removal","kind":"term","name":"Eating after gallbladder removal","route":"/terms/eating-after-gallbladder-removal/","field":"links","label":"Macmillan: surgery for gallbladder cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-for-pancreatic-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"links","label":"Macmillan: surgery for pancreatic cancer, before and after"},{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Macmillan: surgery for pancreatic cancer, before and after"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Macmillan: surgery for pancreatic cancer, before and after"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Macmillan: surgery for pancreatic cancer, before and after"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-remove-colon-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: surgery for colon cancer"},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"links","label":"Macmillan: surgery for colon cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-remove-rectal-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Macmillan: surgery for rectal cancer"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"Macmillan: surgery for rectal cancer"}]},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-the-lymph-nodes-for-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: surgery to the lymph nodes for breast cancer"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"Macmillan: surgery to the lymph nodes for breast cancer"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Macmillan: surgery to the lymph nodes for breast cancer"}],"archive":"https://web.archive.org/web/20260904062650/https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-the-lymph-nodes-for-breast-cancer"},{"url":"https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/causes-and-risk-factors/brca-gene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Macmillan: BRCA1 and BRCA2 genes"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Macmillan: BRCA1 and BRCA2 genes"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Macmillan: BRCA1 and BRCA2 genes"}],"archive":"https://web.archive.org/web/20260902044924/https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/causes-and-risk-factors/brca-gene"},{"url":"https://www.macmillan.org.uk/healthcare-professionals/news-and-resources/guides/principles-and-guidance-for-prehabilitation","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Macmillan prehabilitation guidance"}]},{"url":"https://www.macrogenics.com","status":200,"ok":true,"finalUrl":"https://www.macrogenics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/","field":"links","label":"Official website"},{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/","field":"website"}]},{"url":"https://www.maggies.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maggies-centres","kind":"collection","name":"Maggie's","route":"/collections/maggies-centres/","field":"links","label":"Maggie's"},{"id":"maggies-centres","kind":"collection","name":"Maggie's","route":"/collections/maggies-centres/","field":"url"}]},{"url":"https://www.maggies.org/support-and-information/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Maggie's: support and information"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Maggie's: support and information"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Maggie's: support and information"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Maggie's: support and information"},{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"Maggie's: support and information"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Maggie's: support and information"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"Maggie's: support and information"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","field":"links","label":"Maggie's: support and information"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Maggie's: support and information"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Maggie's: support and information"}],"archive":"https://web.archive.org/web/20260928032403/https://www.maggies.org/support-and-information/"},{"url":"https://www.maiabiotech.com","status":200,"ok":true,"finalUrl":"https://maiabiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/","field":"links","label":"Official website"},{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/","field":"website"}]},{"url":"https://www.mammotome.com/","status":200,"ok":true,"finalUrl":"https://www.mammotome.com/us/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"Mammotome: Neoprobe gamma detection system"},{"id":"mammotome","kind":"company","name":"Mammotome (Danaher)","route":"/companies/mammotome/","field":"links","label":"Official website"},{"id":"mammotome","kind":"company","name":"Mammotome (Danaher)","route":"/companies/mammotome/","field":"website"}]},{"url":"https://www.mariecurie.org.uk","status":200,"ok":true,"finalUrl":"https://www.mariecurie.org.uk/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","field":"links","label":"Marie Curie"},{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","field":"website"}]},{"url":"https://www.mariecurie.org.uk/about-us/governance/matthew-reed-chief-executive","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"matthew-reed","kind":"person","name":"Matthew Reed","route":"/people/matthew-reed/","field":"profiles","label":"Marie Curie profile"}]},{"url":"https://www.mariecurie.org.uk/about-us/who-we-are","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"matthew-reed","kind":"person","name":"Matthew Reed","route":"/people/matthew-reed/","field":"links","label":"Source: Marie Curie, Who we are"}]},{"url":"https://www.mariecurie.org.uk/information/getting-care/palliative-care","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"Marie Curie: what is palliative care?"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"Marie Curie: what is palliative care?"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"Marie Curie: what is palliative care?"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Marie Curie: what are palliative care and end of life care?"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Marie Curie: what is palliative care?"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Marie Curie: what are palliative care and end of life care?"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Marie Curie: what are palliative care and end of life care?"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Marie Curie: what is palliative care?"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"Marie Curie: what is palliative care?"}],"archive":"https://web.archive.org/web/20260908025339/https://www.mariecurie.org.uk/information/getting-care/palliative-care"},{"url":"https://www.mariecurie.org.uk/research","status":200,"ok":true,"finalUrl":"https://www.mariecurie.org.uk/research-and-policy/research","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","field":"links","label":"Research"}]},{"url":"https://www.masseycancercenter.org","status":200,"ok":true,"finalUrl":"https://www.masseycancercenter.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","field":"links","label":"VCU Massey Comprehensive Cancer Center"},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","field":"website"}]},{"url":"https://www.masseycancercenter.org/clinical-trials","status":200,"ok":true,"finalUrl":"https://www.masseycancercenter.org/clinical-trials/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","field":"links","label":"Clinical trials"}]},{"url":"https://www.massgeneral.org/cancer-center","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/services/cancer","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","field":"links","label":"Official website"},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","field":"website"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"links","label":"MGH Cancer Center"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","field":"profiles","label":"MGH Cancer Center"}]},{"url":"https://www.massgeneral.org/doctors/16888/keith-flaherty","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"links","label":"MGH profile"},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/17039/leif-ellisen","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","field":"links","label":"MGH profile"},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/17170/lecia-sequist","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"links","label":"MGH profile"},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/17557/theodore-hong","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","field":"links","label":"MGH profile"},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/19412/ryan-sullivan","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","field":"links","label":"MGH profile"},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/19556/ryan-corcoran","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","field":"links","label":"MGH profile"},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/doctors/19962/justin-gainor","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/about/massachusetts-general-hospital","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"links","label":"MGH profile"},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","field":"profiles","label":"MGH profile"}]},{"url":"https://www.massgeneral.org/neurosurgery","status":200,"ok":true,"finalUrl":"https://www.massgeneralbrigham.org/en/services/neuroscience/neurosurgery","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","route":"/people/robert-martuza/","field":"links","label":"Massachusetts General Hospital"},{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","route":"/people/robert-martuza/","field":"profiles","label":"Massachusetts General Hospital"}]},{"url":"https://www.materprivate.ie","status":200,"ok":true,"finalUrl":"https://www.materprivate.ie/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mater-private","kind":"institution","name":"Mater Private Network","route":"/institutions/mater-private/","field":"links","label":"Official website"},{"id":"mater-private","kind":"institution","name":"Mater Private Network","route":"/institutions/mater-private/","field":"website"}]},{"url":"https://www.materprivate.ie/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","field":"links","label":"Mater Private Network website"},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","field":"profiles","label":"Mater Private Network website"}]},{"url":"https://www.mbracetrx.com","status":200,"ok":true,"finalUrl":"https://mbracetrx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/","field":"links","label":"Official website"},{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/","field":"website"}]},{"url":"https://www.mc.ntu.edu.tw","status":200,"ok":true,"finalUrl":"https://www.mc.ntu.edu.tw/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","field":"links","label":"NTU College of Medicine"}]},{"url":"https://www.mcgill.ca","status":200,"ok":true,"finalUrl":"https://www.mcgill.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","field":"links","label":"McGill University"}]},{"url":"https://www.mcgill.ca/gci/","status":200,"ok":true,"finalUrl":"https://www.goodmancancer.ca/en/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","field":"links","label":"Goodman Cancer Institute"},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","field":"website"}]},{"url":"https://www.mcrc.manchester.ac.uk","status":200,"ok":true,"finalUrl":"https://www.mcrc.manchester.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","field":"links","label":"Manchester Cancer Research Centre"}]},{"url":"https://www.mcw.edu","status":200,"ok":true,"finalUrl":"https://www.mcw.edu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/","field":"links","label":"Medical College of Wisconsin"},{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/","field":"website"}]},{"url":"https://www.mdanderson.org","status":200,"ok":true,"finalUrl":"https://www.mdanderson.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"links","label":"Official website"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"website"}]},{"url":"https://www.mdanderson.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","field":"links","label":"MD Anderson"},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","field":"profiles","label":"MD Anderson"}]},{"url":"https://www.mdanderson.org/about-md-anderson/facts-history/who-was-md-anderson.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"monroe-anderson","kind":"person","name":"Monroe Dunaway Anderson","route":"/people/monroe-anderson/","field":"links","label":"MD Anderson: who was MD Anderson?"}]},{"url":"https://www.mdc-berlin.de","status":200,"ok":true,"finalUrl":"https://www.mdc-berlin.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","field":"website"}]},{"url":"https://www.mdc-berlin.de/bimsb","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","field":"links","label":"BIMSB"}]},{"url":"https://www.mdc-berlin.de/en","status":200,"ok":true,"finalUrl":"https://www.mdc-berlin.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","field":"links","label":"Homepage"}]},{"url":"https://www.mdc-berlin.de/maike-sander","status":200,"ok":true,"finalUrl":"https://www.mdc-berlin.de/news/news/maike-sander","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","field":"links","label":"Institution profile"},{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.mdc-berlin.de/n-rajewsky","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","field":"links","label":"Institution profile"},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.med.cuhk.edu.hk","status":200,"ok":true,"finalUrl":"https://www.med.cuhk.edu.hk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","field":"links","label":"CUHK Faculty of Medicine"},{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","field":"website"}]},{"url":"https://www.med.cuhk.edu.hk/staff/deanery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","field":"links","label":"Institution profile"},{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.med.keio.ac.jp","status":200,"ok":true,"finalUrl":"https://www.keio.ac.jp/ja/med/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","field":"links","label":"Keio University School of Medicine"}]},{"url":"https://www.med.kyoto-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.med.kyoto-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","field":"links","label":"Kyoto University Graduate School of Medicine"}]},{"url":"https://www.med.kyushu-u.ac.jp","status":200,"ok":true,"finalUrl":"https://www.med.kyushu-u.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","field":"links","label":"Kyushu University Faculty of Medical Sciences"}]},{"url":"https://www.med.uni-wuerzburg.de/ccc/ueber-uns/vorstand/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/","field":"links","label":"Source: CCC Mainfranken Vorstand page"},{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/","field":"profiles","label":"Institution board page"}]},{"url":"https://www.medable.com","status":200,"ok":true,"finalUrl":"https://www.medable.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medable","kind":"company","name":"Medable","route":"/companies/medable/","field":"links","label":"Official website"},{"id":"medable","kind":"company","name":"Medable","route":"/companies/medable/","field":"website"}]},{"url":"https://www.medac.de/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","field":"links","label":"Official website"},{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","field":"website"}]},{"url":"https://www.medaustron.at/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","field":"links","label":"MedAustron"}]},{"url":"https://www.medicare.gov/coverage/chemotherapy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-part-b-cap","kind":"idea","name":"Cap what Original Medicare patients pay for Part B cancer drugs","route":"/ideas/idea-cost-part-b-cap/","field":"links","label":"Medicare.gov: Chemotherapy coverage"}]},{"url":"https://www.medicare.gov/coverage/clinical-research-studies","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","route":"/ideas/idea-cost-trial-enrolment-cost-lever/","field":"links","label":"Medicare.gov: Clinical research studies"}]},{"url":"https://www.medicare.gov/coverage/telehealth","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-travel-teleoncology","kind":"idea","name":"Bring the oncologist to the local clinic by video and the drug to the local pharmacy","route":"/ideas/idea-cost-travel-teleoncology/","field":"links","label":"Medicare.gov: Telehealth"}]},{"url":"https://www.medicare.gov/health-drug-plans/medigap","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-cost-part-b-cap","kind":"idea","name":"Cap what Original Medicare patients pay for Part B cancer drugs","route":"/ideas/idea-cost-part-b-cap/","field":"links","label":"Medicare.gov: Medigap"}]},{"url":"https://www.medicxi.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","field":"links","label":"Official website"},{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","field":"website"}]},{"url":"https://www.medicxi.com/contact","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","field":"links","label":"Contact"}]},{"url":"https://www.medicxi.com/news-room","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","field":"links","label":"News room"}]},{"url":"https://www.medidata.com","status":200,"ok":true,"finalUrl":"https://www.medidata.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","route":"/companies/medidata/","field":"links","label":"Official website"},{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","route":"/companies/medidata/","field":"website"}]},{"url":"https://www.medilinkthera.com","status":200,"ok":true,"finalUrl":"https://www.medilinkthera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/","field":"links","label":"Official website"},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/","field":"website"}]},{"url":"https://www.medizin.uni-tuebingen.de","status":200,"ok":true,"finalUrl":"https://www.medizin.uni-tuebingen.de/de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","field":"links","label":"Universitätsklinikum Tübingen"}]},{"url":"https://www.medizin.uni-tuebingen.de/ccc","status":200,"ok":true,"finalUrl":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","field":"links","label":"CCC Tübingen-Stuttgart"},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","field":"website"}]},{"url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","field":"links","label":"Institution profile"},{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","field":"profiles","label":"Institution profile"},{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","field":"links","label":"Institution profile"},{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","field":"profiles","label":"Institution profile"},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","field":"links","label":"Institution profile"},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.medpac.gov/document-type/report/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-asp-flat-fee","kind":"idea","name":"Pay a flat fee for giving a Part B drug instead of 6% of its price","route":"/ideas/idea-cost-asp-flat-fee/","field":"links","label":"MedPAC reports to Congress"}]},{"url":"https://www.medpace.com","status":200,"ok":true,"finalUrl":"https://www.medpace.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","field":"links","label":"Official website"},{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","field":"website"}]},{"url":"https://www.medrxiv.org","status":200,"ok":true,"finalUrl":"https://www.medrxiv.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","field":"url"}]},{"url":"https://www.medrxiv.org/collection/oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","field":"links","label":"medRxiv oncology collection"}]},{"url":"https://www.medscape.com/oncology","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","field":"links","label":"Medscape Oncology"},{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","field":"url"}]},{"url":"https://www.medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"freenome","kind":"company","name":"Freenome","route":"/companies/freenome/","field":"links","label":"FDA approval (MedTech Dive)"},{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/","field":"links","label":"FDA approval (MedTech Dive)"}]},{"url":"https://www.megabank.tohoku.ac.jp","status":200,"ok":true,"finalUrl":"https://www.megabank.tohoku.ac.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","field":"links","label":"Tohoku Medical Megabank Organization"}]},{"url":"https://www.meipharma.com","status":200,"ok":true,"finalUrl":"https://litestrategy.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/","field":"links","label":"Official website"},{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/","field":"website"}]},{"url":"https://www.melanoma.org.au","status":200,"ok":true,"finalUrl":"https://melanoma.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/","field":"links","label":"Melanoma Institute Australia"},{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/","field":"website"}]},{"url":"https://www.melanomabridge.org","status":200,"ok":true,"finalUrl":"https://www.melanomabridge.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","field":"links","label":"Melanoma Bridge"}]},{"url":"https://www.menarini.com","status":200,"ok":true,"finalUrl":"https://www.menarini.com/en-us.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/","field":"links","label":"Official website"},{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/","field":"website"}]},{"url":"https://www.mendus.com","status":200,"ok":true,"finalUrl":"https://mendus.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","field":"links","label":"Official website"},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","field":"website"}]},{"url":"https://www.mendus.com/investors/press-releases/","status":200,"ok":true,"finalUrl":"https://mendus.com/investors/press-releases/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","field":"links","label":"Press releases"}]},{"url":"https://www.mendus.com/what-we-do/","status":200,"ok":true,"finalUrl":"https://mendus.com/what-we-do/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","field":"links","label":"Pipeline and technology"}]},{"url":"https://www.merck.com","status":200,"ok":true,"finalUrl":"https://www.merck.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","field":"links","label":"Official website"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","field":"website"}]},{"url":"https://www.merck.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","field":"links","label":"Official website"},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","field":"website"}]},{"url":"https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-pd-l1-resectable-locally-advanced-head-neck-squamous-cell-carcinoma-as-neoadjuvant-treatment-continued-as-adjuvant-treatment-combined-with-radiother/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","field":"links","label":"FDA approval, Merck"},{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","field":"outcomes.source (Event-free survival (CPS ≥1))"}]},{"url":"https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-malignant-pleural-mesothelioma/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","field":"links","label":"Merck OS announcement"}]},{"url":"https://www.merck.com/news/merck-advances-treatment-of-bladder-and-kidney-cancers-with-new-data-at-2026-asco-gu-cancers-symposium/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","field":"links","label":"Merck ASCO GU 2026"}]},{"url":"https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination-treatments-for-certain-patients-with-advanced-renal-cell-carcinoma-rcc/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","field":"outcomes.source (Progression-free survival (BICR) and overall survival (dual primary))"}]},{"url":"https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","field":"links","label":"Merck/Moderna announcement"},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","field":"links","label":"Merck press release"},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","field":"outcomes.source (Recurrence-free survival)"}]},{"url":"https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","field":"links","label":"Merck: BLA withdrawn"}],"archive":"https://web.archive.org/web/20260514163026/https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/"},{"url":"https://www.merck.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-response-rates-in-patients-with-recurrent-platinum-resistant-ovarian-primary-peritoneal-or-fallopian-tube-cancer-in-phase-2-part-of-rejoice-o/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","field":"outcomes.source (Objective response rate (phase 2 part))"}]},{"url":"https://www.merck.com/research/product-pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.merckghifund.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msd-global-health-innovation-fund","kind":"company","name":"MSD Global Health Innovation Fund (Merck GHI)","route":"/companies/msd-global-health-innovation-fund/","field":"links","label":"Official website"},{"id":"msd-global-health-innovation-fund","kind":"company","name":"MSD Global Health Innovation Fund (Merck GHI)","route":"/companies/msd-global-health-innovation-fund/","field":"website"}]},{"url":"https://www.mersana.com","status":200,"ok":true,"finalUrl":"https://www.dayonebio.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","field":"website"}]},{"url":"https://www.metavivor.org","status":200,"ok":true,"finalUrl":"https://metavivor.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-bio2-metastasis-funding-floor","kind":"idea","name":"Ring-fence a fifth of national cancer research money for metastasis","route":"/ideas/idea-bio2-metastasis-funding-floor/","field":"links","label":"MetaVivor research funding"}]},{"url":"https://www.metavivor.org/","status":200,"ok":true,"finalUrl":"https://metavivor.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","field":"links","label":"METAvivor"}]},{"url":"https://www.metaxa-hospital.gov.gr","status":200,"ok":true,"finalUrl":"https://www.metaxa-hospital.gov.gr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","field":"links","label":"Metaxa Cancer Hospital, Piraeus website"},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","field":"profiles","label":"Metaxa Cancer Hospital, Piraeus website"},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","route":"/institutions/metaxa-cancer-hospital/","field":"links","label":"Official website"},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","route":"/institutions/metaxa-cancer-hospital/","field":"website"}]},{"url":"https://www.mevion.com","status":200,"ok":true,"finalUrl":"https://mevion.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/","field":"links","label":"Official website"},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/","field":"website"}]},{"url":"https://www.microbiotica.com","status":200,"ok":true,"finalUrl":"https://microbiotica.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","field":"links","label":"Official website"},{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","field":"website"}]},{"url":"https://www.microsoft.com/en-us/industry/health","status":200,"ok":true,"finalUrl":"https://www.microsoft.com/en-us/ai/health","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","field":"links","label":"Official website"},{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","field":"website"}]},{"url":"https://www.microsoft.com/en-us/research/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","field":"links","label":"Official website"},{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","field":"website"}]},{"url":"https://www.miltenyibiomedicine.com","status":200,"ok":true,"finalUrl":"https://www.miltenyibiomedicine.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/","field":"links","label":"Official website"},{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/","field":"website"},{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/","field":"links","label":"Sponsor page"}]},{"url":"https://www.miltenyibiotec.com","status":200,"ok":true,"finalUrl":"https://www.miltenyibiotec.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","field":"links","label":"Official website"},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","field":"website"}]},{"url":"https://www.mimsoftware.com","status":200,"ok":true,"finalUrl":"https://www.mimsoftware.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","field":"links","label":"Official website"},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","field":"website"}]},{"url":"https://www.mindray.com","status":200,"ok":true,"finalUrl":"https://www.mindray.com/na/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"mindray","kind":"company","name":"Mindray","route":"/companies/mindray/","field":"links","label":"Official website"},{"id":"mindray","kind":"company","name":"Mindray","route":"/companies/mindray/","field":"website"}]},{"url":"https://www.missionbio.com/press/equity-financing","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","field":"links","label":"Equity financing led by Ally Bridge Group (August 2025)"}]},{"url":"https://www.mobileodt.com/","status":200,"ok":true,"finalUrl":"https://ligermedical.com/mobileodt-acquisition-announcement","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mobileodt","kind":"company","name":"MobileODT","route":"/companies/mobileodt/","field":"links","label":"Official website"},{"id":"mobileodt","kind":"company","name":"MobileODT","route":"/companies/mobileodt/","field":"website"}]},{"url":"https://www.modernatx.com","status":200,"ok":true,"finalUrl":"https://www.modernatx.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","field":"links","label":"Official website"},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","field":"website"}]},{"url":"https://www.modextherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.modextherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/","field":"links","label":"Official website"},{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/","field":"website"}]},{"url":"https://www.modulight.com/","status":200,"ok":true,"finalUrl":"https://modulight.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/","field":"links","label":"Modulight: medical lasers for photodynamic therapy"},{"id":"modulight","kind":"company","name":"Modulight","route":"/companies/modulight/","field":"links","label":"Official website"},{"id":"modulight","kind":"company","name":"Modulight","route":"/companies/modulight/","field":"website"}]},{"url":"https://www.molecularpartners.com","status":200,"ok":true,"finalUrl":"https://www.molecularpartners.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","field":"links","label":"Official website"},{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","field":"website"}]},{"url":"https://www.molecularpartners.com/pipeline","status":200,"ok":true,"finalUrl":"https://www.molecularpartners.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","field":"links","label":"Pipeline page"}]},{"url":"https://www.moleculin.com","status":200,"ok":true,"finalUrl":"https://moleculin.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moleculin","kind":"company","name":"Moleculin Biotech","route":"/companies/moleculin/","field":"links","label":"Official website"},{"id":"moleculin","kind":"company","name":"Moleculin Biotech","route":"/companies/moleculin/","field":"website"}]},{"url":"https://www.monopartx.com","status":200,"ok":true,"finalUrl":"https://www.monopartx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"links","label":"Official website"},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"website"}]},{"url":"https://www.monteris.com","status":200,"ok":true,"finalUrl":"https://www.monteris.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","field":"links","label":"Official website"},{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","field":"website"}]},{"url":"https://www.monteris.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/","field":"links","label":"Monteris Medical: NeuroBlate system"}]},{"url":"https://www.monterosatx.com","status":200,"ok":true,"finalUrl":"https://www.monterosatx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/","field":"website"}]},{"url":"https://www.morehealth.com","status":200,"ok":true,"finalUrl":"https://www.morehealth.com/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"more-health","kind":"company","name":"MORE Health","route":"/companies/more-health/","field":"website"}]},{"url":"https://www.morehealth.com/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"more-health","kind":"company","name":"MORE Health","route":"/companies/more-health/","field":"links","label":"Company site"}]},{"url":"https://www.morphosys.com","status":200,"ok":true,"finalUrl":"https://www.novartis.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/","field":"links","label":"Official website"},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/","field":"website"}]},{"url":"https://www.mou.cz/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","field":"links","label":"Homepage"},{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","field":"website"}]},{"url":"https://www.mou.cz/en/management/t1644","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","field":"links","label":"Institution profile"},{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","field":"profiles","label":"Institution profile"},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","field":"links","label":"Institution profile"},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","field":"profiles","label":"Institution profile"},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","field":"links","label":"Institution profile"},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.mountsinai.org/care/cancer","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/","field":"links","label":"Official website"},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/","field":"website"}]},{"url":"https://www.mpnresearchfoundation.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","field":"links","label":"MPN Research Foundation"}]},{"url":"https://www.mrcctu.ucl.ac.uk","status":200,"ok":true,"finalUrl":"https://www.innovative-ctu.ucl.ac.uk/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/","field":"website"}]},{"url":"https://www.mrcctu.ucl.ac.uk/about-us/","status":200,"ok":true,"finalUrl":"https://www.innovative-ctu.ucl.ac.uk/about-us/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/","field":"links","label":"MRC CTU at UCL: about us"}]},{"url":"https://www.mskcc.org","status":200,"ok":true,"finalUrl":"https://www.mskcc.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"links","label":"Official website"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"website"}]},{"url":"https://www.mskcc.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","field":"links","label":"Memorial Sloan Kettering"},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","field":"profiles","label":"Memorial Sloan Kettering"}]},{"url":"https://www.mskcc.org/about/history-milestones","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","route":"/people/john-jacob-astor-iii/","field":"links","label":"MSK: history and milestones"},{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","route":"/people/john-d-rockefeller-jr/","field":"links","label":"MSK: history and milestones"},{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","route":"/people/alfred-sloan/","field":"links","label":"MSK: history and milestones"},{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","route":"/people/charles-kettering/","field":"links","label":"MSK: history and milestones"}]},{"url":"https://www.mskcc.org/about/leadership/office-president","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","field":"links","label":"MSK profile"},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","field":"links","label":"MSK About Herbs"},{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","field":"links","label":"MSK About Herbs database"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/alexander-drilon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"links","label":"MSK profile"},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/andrea-cercek","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","field":"links","label":"MSK profile"},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/helena-yu","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"links","label":"MSK profile"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/howard-scher","status":200,"ok":true,"finalUrl":"https://www.mskcc.org/profile/howard-scher","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"links","label":"MSK profile"},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/jae-park","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","field":"links","label":"MSK profile"},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/michael-morris","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"links","label":"MSK profile"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/saad-usmani","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"links","label":"MSK profile"},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/yelena-janjigian","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"links","label":"MSK profile"},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ashwagandha","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ayurvedic-medicine-cancer","kind":"technology","name":"Ayurvedic medicine and cancer","route":"/technologies/ayurvedic-medicine-cancer/","field":"links","label":"MSK About Herbs: Ashwagandha"}]},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ginger","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ginger-nausea","kind":"technology","name":"Ginger for chemotherapy nausea","route":"/technologies/ginger-nausea/","field":"links","label":"MSK About Herbs: Ginger"}]},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/green-tea","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"green-tea-egcg","kind":"technology","name":"Green tea and EGCG extracts","route":"/technologies/green-tea-egcg/","field":"links","label":"MSK About Herbs: Green tea"}]},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/melatonin","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melatonin-cancer","kind":"technology","name":"Melatonin as a cancer adjunct","route":"/technologies/melatonin-cancer/","field":"links","label":"MSK About Herbs: Melatonin"}]},{"url":"https://www.mskcc.org/cancer-care/integrative-medicine/herbs/turmeric","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","field":"links","label":"MSK About Herbs: Turmeric"}]},{"url":"https://www.mskcc.org/clinical-updates/sabcs-2025-news-updated-ember-3-efficacy-results-for-imlunestrant-with-or-without-abemaciclib-in-er-her2-advanced-breast","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","field":"outcomes.source (Overall survival, ESR1-mutant (imlunestrant vs standard ET), updated)"}]},{"url":"https://www.mskcc.org/news/fda-approves-avutometinib-defactinib-combination-for-treating-recurrent-low-grade-serous-ovarian-cancer-with-kras-mutation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","field":"links","label":"MSK on approval"}]},{"url":"https://www.mskcc.org/press-releases/msk-receives-gift-150-million-david-koch-patient-facility","status":200,"ok":true,"finalUrl":"https://www.mskcc.org/news-releases/msk-receives-gift-150-million-david-koch-patient-facility","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/","field":"links","label":"MSK press release: $150 million gift (2015)"}]},{"url":"https://www.mskcc.org/press-releases/mskcc-receives-record-gift-100-million-mortimer-b-zuckerman-research-facility","status":200,"ok":true,"finalUrl":"https://www.mskcc.org/news-releases/mskcc-receives-record-gift-100-million-mortimer-b-zuckerman-research-facility","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","route":"/people/mortimer-zuckerman/","field":"links","label":"MSK press release: record $100 million gift (2006)"}]},{"url":"https://www.mskcc.org/research-areas/labs/charles-sawyers","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"links","label":"MSK lab"},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","field":"profiles","label":"MSK lab"}]},{"url":"https://www.mskcc.org/research-areas/labs/david-solit","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","field":"links","label":"MSK lab"},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","field":"profiles","label":"MSK lab"}]},{"url":"https://www.mskcc.org/research-areas/labs/ross-levine","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","field":"links","label":"MSK lab"},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","field":"profiles","label":"MSK lab"}]},{"url":"https://www.mtrh.go.ke","status":200,"ok":true,"finalUrl":"https://www.mtrh.go.ke/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","route":"/institutions/moi-teaching-referral-hospital/","field":"links","label":"Official website"},{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","route":"/institutions/moi-teaching-referral-hospital/","field":"website"}]},{"url":"https://www.mtrh.go.ke/?page_id=24","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","route":"/people/philip-kirwa/","field":"profiles","label":"MTRH Office of the CEO"}]},{"url":"https://www.mtrh.go.ke/?page_id=3857","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","route":"/people/philip-kirwa/","field":"links","label":"Source: Moi Teaching and Referral Hospital management team page"},{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","route":"/people/philip-kirwa/","field":"profiles","label":"MTRH hospital management team"}]},{"url":"https://www.muhas.ac.tz","status":200,"ok":true,"finalUrl":"https://muhas.ac.tz/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","field":"links","label":"MUHAS"}]},{"url":"https://www.multitudetherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.multitudetherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/","field":"links","label":"Official website"},{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/","field":"website"}]},{"url":"https://www.mumc.nl","status":200,"ok":true,"finalUrl":"https://www.mumc.nl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"links","label":"Maastricht UMC+ Comprehensive Cancer Center website"},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"profiles","label":"Maastricht UMC+ Comprehensive Cancer Center website"},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","route":"/institutions/maastricht-umc/","field":"links","label":"Official website"},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","route":"/institutions/maastricht-umc/","field":"website"}]},{"url":"https://www.mumc.nl/over-mumc/bestuur-en-organisatie/bestuur","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helen-mertens","kind":"person","name":"Helen Mertens","route":"/people/helen-mertens/","field":"links","label":"Source: Maastricht UMC+ executive board page"},{"id":"helen-mertens","kind":"person","name":"Helen Mertens","route":"/people/helen-mertens/","field":"profiles","label":"Maastricht UMC+ Raad van Bestuur page"}]},{"url":"https://www.mycarg.org/","status":200,"ok":true,"finalUrl":"https://mycarg.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","field":"links","label":"Cancer and Aging Research Group"}]},{"url":"https://www.myeloma-europe.org","status":200,"ok":true,"finalUrl":"https://www.myeloma-europe.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","route":"/companies/european-myeloma-network/","field":"website"}]},{"url":"https://www.myeloma-europe.org/about/","status":200,"ok":true,"finalUrl":"https://www.myeloma-europe.org/emn/about-emn/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","route":"/companies/european-myeloma-network/","field":"links","label":"EMN: about"}]},{"url":"https://www.myelome.fr","status":200,"ok":true,"finalUrl":"https://www.myelome.fr/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","route":"/companies/ifm/","field":"website"}]},{"url":"https://www.myelome.fr/l-ifm","status":200,"ok":true,"finalUrl":"https://www.myelome.fr/l-ifm/presentation-de-l-ifm.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","route":"/companies/ifm/","field":"links","label":"IFM: présentation"}]},{"url":"https://www.myjoyonline.com/dr-yakubu-seidu-adam-appointed-as-new-korle-bu-teaching-hospital-ceo/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yakubu-seidu-adam","kind":"person","name":"Yakubu Seidu Adam","route":"/people/yakubu-seidu-adam/","field":"links","label":"Source: MyJoyOnline report of appointment, May 2025"},{"id":"yakubu-seidu-adam","kind":"person","name":"Yakubu Seidu Adam","route":"/people/yakubu-seidu-adam/","field":"profiles","label":"Appointment report, MyJoyOnline"}]},{"url":"https://www.mylifehouse.org.au","status":200,"ok":true,"finalUrl":"https://www.mylifehouse.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","field":"links","label":"Chris O'Brien Lifehouse"},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","field":"website"}]},{"url":"https://www.mylifehouse.org.au/about-us/our-people/","status":200,"ok":true,"finalUrl":"https://www.mylifehouse.org.au/about-lifehouse/our-people/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/","field":"links","label":"Source: Lifehouse our people page"}]},{"url":"https://www.mylifehouse.org.au/team/michael-boyer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.mypebs.eu","status":200,"ok":true,"finalUrl":"https://www.mypebs.eu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/","field":"links","label":"MyPeBS"}]},{"url":"https://www.nanobiotix.com","status":200,"ok":true,"finalUrl":"https://nanobiotix.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nanobiotix","kind":"company","name":"Nanobiotix","route":"/companies/nanobiotix/","field":"links","label":"Official website"},{"id":"nanobiotix","kind":"company","name":"Nanobiotix","route":"/companies/nanobiotix/","field":"website"}]},{"url":"https://www.narayanahealth.org","status":200,"ok":true,"finalUrl":"https://www.narayanahealth.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","field":"links","label":"Narayana Health"},{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","field":"profiles","label":"Narayana Health"},{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","route":"/institutions/narayana-health/","field":"links","label":"Narayana Health"},{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","route":"/institutions/narayana-health/","field":"website"}]},{"url":"https://www.natcan.org.uk/audits/bowel/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"National Bowel Cancer Audit (NATCAN)"},{"id":"idea-crc-uk-colonoscopy-capacity-and-fit-threshold","kind":"idea","name":"UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set","route":"/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/","field":"links","label":"National Bowel Cancer Audit (NATCAN)"},{"id":"idea-crc-uk-young-patient-referral-and-diagnostic-interval","kind":"idea","name":"UK gap: shorten the route to diagnosis for patients below the screening age, where the rise in incidence is","route":"/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/","field":"links","label":"National Bowel Cancer Audit (NATCAN)"}]},{"url":"https://www.natcan.org.uk/audits/pancreatic/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway","kind":"idea","name":"A fast-track pathway from suspicion to treatment for pancreatic cancer in the NHS, measured from first scan to first treatment","route":"/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/","field":"links","label":"National Pancreatic Cancer Audit (NPaCA)"}]},{"url":"https://www.natcan.org.uk/reports/?audit=pancreatic","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","kind":"paper","name":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","route":"/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/","field":"links","label":"National Pancreatic Cancer Audit reports (NATCAN)"},{"id":"idea-pdac-enzyme-replacement-prescribing-by-default","kind":"idea","name":"Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival","route":"/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/","field":"links","label":"National Pancreatic Cancer Audit reports (NATCAN)"}]},{"url":"https://www.natcan.org.uk/reports/nboca-state-of-the-nation-report-2025/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"National Bowel Cancer Audit: State of the Nation 2025"}]},{"url":"https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2024/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"National Pancreatic Cancer Audit: State of the Nation Report 2024 (first report)"},{"id":"idea-pdac-uk-active-treatment-rate-audit-and-target","kind":"idea","name":"Raise the share of UK patients who receive any active treatment, and publish it by trust","route":"/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/","field":"links","label":"NPaCA State of the Nation Report 2024"}]},{"url":"https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2025/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"National Pancreatic Cancer Audit: State of the Nation Report 2025"},{"id":"idea-pdac-uk-active-treatment-rate-audit-and-target","kind":"idea","name":"Raise the share of UK patients who receive any active treatment, and publish it by trust","route":"/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/","field":"links","label":"NPaCA State of the Nation Report 2025"}]},{"url":"https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2026/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"National Pancreatic Cancer Audit: State of the Nation 2026"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"National Pancreatic Cancer Audit: State of the Nation Report 2026 (patients diagnosed 2022 to 2023 in England, 2023 to 2024 in Wales)"},{"id":"idea-pdac-uk-active-treatment-rate-audit-and-target","kind":"idea","name":"Raise the share of UK patients who receive any active treatment, and publish it by trust","route":"/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/","field":"links","label":"NPaCA State of the Nation Report 2026"}]},{"url":"https://www.natcan.org.uk/wp-content/uploads/2025/10/NPCA-SotN-2025.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"National Prostate Cancer Audit: State of the Nation 2025"}]},{"url":"https://www.natcan.org.uk/wp-content/uploads/2025/11/NPaCA-SotN-2025-Methodology-Supplement.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","route":"/institutions/addenbrookes-cambridge/","field":"links","label":"NPaCA HPB specialist centres"},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","field":"links","label":"NPaCA 2025 methodology supplement (Table 7)"}]},{"url":"https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-SotN-2026-Data-Tables.xlsx","status":200,"ok":true,"contentType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","checked":"2026-09-30","refs":[{"id":"royal-papworth","kind":"institution","name":"Royal Papworth Hospital NHS Foundation Trust","route":"/institutions/royal-papworth/","field":"links","label":"National Lung Cancer Audit data tables 2026"},{"id":"liverpool-heart-and-chest","kind":"institution","name":"Liverpool Heart and Chest Hospital NHS Foundation Trust","route":"/institutions/liverpool-heart-and-chest/","field":"links","label":"National Lung Cancer Audit data tables 2026"}]},{"url":"https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-State-of-the-Nation-Report-2026.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"National Lung Cancer Audit: State of the Nation 2026"}],"archive":"https://web.archive.org/web/20260413113415/https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-State-of-the-Nation-Report-2026.pdf"},{"url":"https://www.natcan.org.uk/wp-content/uploads/2026/09/NPaCA-SotN-2026-Methodology-Supplement.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"hull-castle-hill","kind":"institution","name":"Castle Hill Hospital, Hull (Queen's Centre)","route":"/institutions/hull-castle-hill/","field":"links","label":"NPaCA 2026 methodology supplement, Table 7"},{"id":"royal-blackburn-elht","kind":"institution","name":"Royal Blackburn Hospital (East Lancashire HPB MDT)","route":"/institutions/royal-blackburn-elht/","field":"links","label":"NPaCA 2026 methodology supplement, Table 7"}]},{"url":"https://www.natcopharma.co.in","status":200,"ok":true,"finalUrl":"https://www.natcopharma.co.in/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","field":"links","label":"Official website"},{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","field":"website"}]},{"url":"https://www.natera.com","status":200,"ok":true,"finalUrl":"https://www.natera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","field":"links","label":"Official website"},{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","field":"website"}]},{"url":"https://www.natera.com/company/news/natera-receives-final-medicare-coverage-for-its-signatera-mrd-test-in-stage-ii-iii-colorectal-cancer-2/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","field":"links","label":"Natera: final Medicare coverage for Signatera in stage II-III colorectal cancer, 3 September 2020"}]},{"url":"https://www.natera.com/oncology/signatera-advanced-cancer-detection/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","field":"access.source (US)"}]},{"url":"https://www.nationwidechildrens.org","status":200,"ok":true,"finalUrl":"https://www.nationwidechildrens.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","field":"links","label":"Nationwide Children's Hospital"},{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","field":"website"}]},{"url":"https://www.nationwidechildrens.org/about-us/who-we-are/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timothy-robinson","kind":"person","name":"Timothy Robinson","route":"/people/timothy-robinson/","field":"links","label":"Source: Nationwide Children's executive leadership page"},{"id":"timothy-robinson","kind":"person","name":"Timothy Robinson","route":"/people/timothy-robinson/","field":"profiles","label":"Nationwide Children's leadership page"}]},{"url":"https://www.nature.com","status":200,"ok":true,"finalUrl":"https://www.nature.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","field":"links","label":"Nature Portfolio"},{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","field":"links","label":"Nature Portfolio"},{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","field":"links","label":"Nature Portfolio"},{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","field":"links","label":"Nature Portfolio"}]},{"url":"https://www.nature.com/articles/nature12113","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature12113&code=8ab5518e-86ba-474a-8919-1e889dec5ec4","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/","field":"links","label":"TCGA, Nature 2013"}]},{"url":"https://www.nature.com/articles/s41375-020-0776-2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"links","label":"ELN 2020 recommendations"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"standardOfCare.guideline (Chronic phase, first line)"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","field":"standardOfCare.guideline (Resistance or intolerance)"}]},{"url":"https://www.nature.com/articles/s41467-017-01968-5","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/","field":"links","label":"Zhang et al., adaptive therapy pilot in prostate cancer (Nat Commun 2017)"},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/","field":"links","label":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (Nature Communications 2017)"}]},{"url":"https://www.nature.com/articles/s41467-022-33407-5","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-federated-learning-imaging","kind":"idea","name":"Federated training of pathology and radiology models across hospitals","route":"/ideas/idea-data-federated-learning-imaging/","field":"links","label":"Federated learning for glioblastoma (Pati et al. 2022)"}]},{"url":"https://www.nature.com/articles/s41467-025-56619-x","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nature.com/articles/s41586-021-03430-5","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-eligibility-impact-statement","kind":"idea","name":"Simulate eligibility against real-world data before every protocol is locked","route":"/ideas/idea-tr1-eligibility-impact-statement/","field":"links","label":"Evaluating eligibility criteria of oncology trials using real-world data and AI (Nature 2021)"}]},{"url":"https://www.nature.com/articles/s41591-022-02115-4","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","field":"links","label":"GALAXY, Nature Medicine 2023"}]},{"url":"https://www.nature.com/articles/s41591-024-03261-7","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/","field":"outcomes.source (Intracranial objective response rate)"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","field":"links","label":"DESTINY-Breast12 (Nature Medicine 2024)"}]},{"url":"https://www.nature.com/articles/s41591-025-03513-0","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","field":"links","label":"Nature Medicine 2025 long-term"}]},{"url":"https://www.nature.com/articles/s41591-025-03981-4","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}]},{"url":"https://www.nature.com/articles/s41591-025-04182-9","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-04182-9&code=9e60075b-9218-4cf7-a988-0f7cf9ef0d63","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/","field":"links","label":"Nature Medicine 2026"}]},{"url":"https://www.nature.com/bcj/","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Fbcj%2F&code=04e5d7b4-81cb-4945-aa8f-a84f0114b9a8","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","field":"links","label":"Homepage"},{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","field":"url"}]},{"url":"https://www.nature.com/bjc/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","field":"url"}]},{"url":"https://www.nature.com/briefing/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","route":"/collections/src-nature-briefing-cancer/","field":"links","label":"Nature Briefing: Cancer"},{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","route":"/collections/src-nature-briefing-cancer/","field":"url"}]},{"url":"https://www.nature.com/cgt/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","route":"/journals/cancer-gene-therapy/","field":"links","label":"Homepage"},{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","route":"/journals/cancer-gene-therapy/","field":"url"}]},{"url":"https://www.nature.com/collections/tracerx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tracerx-evolution-nature-2023","kind":"paper","name":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","route":"/key-papers/paper-tracerx-evolution-nature-2023/","field":"links","label":"TRACERx Nature collection 2023"}]},{"url":"https://www.nature.com/leu/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","field":"url"}]},{"url":"https://www.nature.com/natcancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","field":"url"}]},{"url":"https://www.nature.com/nature-index/news/worlds-top-ten-healthcare-institutions-scientific-research","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-index","kind":"collection","name":"Nature Index: Healthcare and Cancer institutions","route":"/collections/nature-index/","field":"links","label":"Top 10 healthcare institutions"}]},{"url":"https://www.nature.com/nature-index/research-leaders/2025/institution/healthcare/all/global","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-index","kind":"collection","name":"Nature Index: Healthcare and Cancer institutions","route":"/collections/nature-index/","field":"url"}]},{"url":"https://www.nature.com/nature/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","field":"url"}]},{"url":"https://www.nature.com/nbt/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","field":"url"}]},{"url":"https://www.nature.com/ncomms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","field":"url"}]},{"url":"https://www.nature.com/ng/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","field":"url"}]},{"url":"https://www.nature.com/nm/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","field":"url"}]},{"url":"https://www.nature.com/nm/research-articles?subject=cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","field":"links","label":"Nature Medicine cancer"}]},{"url":"https://www.nature.com/npjprecisiononcology/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","field":"links","label":"npj Precision Oncology"},{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","field":"url"}]},{"url":"https://www.nature.com/nrc/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","field":"url"}]},{"url":"https://www.nature.com/nrc/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","field":"links","label":"Nature Reviews"}]},{"url":"https://www.nature.com/nrclinonc/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","field":"url"}]},{"url":"https://www.nature.com/nrclinonc/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","field":"links","label":"Nature Reviews"}]},{"url":"https://www.nature.com/nrd/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","field":"url"}]},{"url":"https://www.nature.com/nrd/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","field":"links","label":"Nature Reviews"}]},{"url":"https://www.nature.com/onc/","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Fonc%2F&code=1ce676ee-a7bf-4e3b-b612-bfdd9afb07a7","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","field":"links","label":"Homepage"},{"id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","field":"url"}]},{"url":"https://www.nature.com/pcan/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","route":"/journals/prostate-cancer-and-prostatic-diseases/","field":"links","label":"Homepage"},{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","route":"/journals/prostate-cancer-and-prostatic-diseases/","field":"url"}]},{"url":"https://www.nature.com/subjects/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","field":"links","label":"Nature cancer subject page"}]},{"url":"https://www.ncbi.nlm.nih.gov/clinvar/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clinvar","kind":"collection","name":"ClinVar","route":"/collections/clinvar/","field":"links","label":"ClinVar"},{"id":"clinvar","kind":"collection","name":"ClinVar","route":"/collections/clinvar/","field":"url"},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","field":"links","label":"ClinVar"}]},{"url":"https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.40/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"genome-builds","kind":"term","name":"Genome builds: GRCh38 versus hg19 (GRCh37)","route":"/terms/genome-builds/","field":"links","label":"GRCh38.p14 assembly at NCBI Datasets"}]},{"url":"https://www.ncbi.nlm.nih.gov/gap/","status":200,"ok":true,"finalUrl":"https://dbgap.ncbi.nlm.nih.gov/home/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"controlled-access-data","kind":"term","name":"Controlled-access genomic data (dbGaP, EGA)","route":"/terms/controlled-access-data/","field":"links","label":"dbGaP (NCBI)"},{"id":"data-use-agreements","kind":"term","name":"Data use agreements and consent for research use","route":"/terms/data-use-agreements/","field":"links","label":"dbGaP (NCBI)"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10006","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abi1","kind":"target","name":"ABI1","route":"/targets/abi1/","field":"links","label":"NCBI Gene 10006"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/100133941","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/","field":"links","label":"NCBI Gene 100133941"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10014","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/","field":"links","label":"NCBI Gene 10014"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/100144748","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klln","kind":"target","name":"KLLN","route":"/targets/klln/","field":"links","label":"NCBI Gene 100144748"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10018","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bim","kind":"target","name":"BIM (BCL2L11)","route":"/targets/bim/","field":"links","label":"NCBI Gene 10018"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10019","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sh2b3","kind":"target","name":"SH2B3","route":"/targets/sh2b3/","field":"links","label":"NCBI Gene 10019"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/100271849","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mef2b","kind":"target","name":"MEF2B","route":"/targets/mef2b/","field":"links","label":"NCBI Gene 100271849"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/100289255","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tmem238l","kind":"target","name":"TMEM238L","route":"/targets/tmem238l/","field":"links","label":"NCBI Gene 100289255"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10038","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/","field":"links","label":"NCBI Gene 10038"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10039","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/","field":"links","label":"NCBI Gene 10039"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10046","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mamld1","kind":"target","name":"MAMLD1","route":"/targets/mamld1/","field":"links","label":"NCBI Gene 10046"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1008","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdh10","kind":"target","name":"CDH10","route":"/targets/cdh10/","field":"links","label":"NCBI Gene 1008"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1009","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdh11","kind":"target","name":"CDH11","route":"/targets/cdh11/","field":"links","label":"NCBI Gene 1009"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10111","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/","field":"links","label":"NCBI Gene 10111"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10142","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"akap9","kind":"target","name":"AKAP9","route":"/targets/akap9/","field":"links","label":"NCBI Gene 10142"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10154","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plxnc1","kind":"target","name":"PLXNC1","route":"/targets/plxnc1/","field":"links","label":"NCBI Gene 10154"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10155","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trim28","kind":"target","name":"TRIM28","route":"/targets/trim28/","field":"links","label":"NCBI Gene 10155"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1017","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/","field":"links","label":"NCBI Gene 1017"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/101867536","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prncr1","kind":"target","name":"PRNCR1","route":"/targets/prncr1/","field":"links","label":"NCBI Gene 101867536"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/101928402","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stag2-as1","kind":"target","name":"STAG2-AS1","route":"/targets/stag2-as1/","field":"links","label":"NCBI Gene 101928402"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1020","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdk5","kind":"target","name":"CDK5","route":"/targets/cdk5/","field":"links","label":"NCBI Gene 1020"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10213","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/","field":"links","label":"NCBI Gene 10213"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10215","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olig2","kind":"target","name":"OLIG2","route":"/targets/olig2/","field":"links","label":"NCBI Gene 10215"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10225","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/","field":"links","label":"NCBI Gene 10225"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1025","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/","field":"links","label":"NCBI Gene 1025"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10253","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spry2","kind":"target","name":"SPRY2","route":"/targets/spry2/","field":"links","label":"NCBI Gene 10253"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10256","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnksr1","kind":"target","name":"CNKSR1","route":"/targets/cnksr1/","field":"links","label":"NCBI Gene 10256"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10257","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcc4","kind":"target","name":"ABCC4","route":"/targets/abcc4/","field":"links","label":"NCBI Gene 10257"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1026","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkn1a","kind":"target","name":"CDKN1A","route":"/targets/cdkn1a/","field":"links","label":"NCBI Gene 1026"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1027","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","field":"links","label":"NCBI Gene 1027"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10288","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","field":"links","label":"NCBI Gene 10288"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1029","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"links","label":"NCBI Gene 1029"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","field":"links","label":"NCBI Gene 1030"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1031","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkn2c","kind":"target","name":"CDKN2C","route":"/targets/cdkn2c/","field":"links","label":"NCBI Gene 1031"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10320","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ikzf1","kind":"target","name":"IKZF1 (Ikaros)","route":"/targets/ikzf1/","field":"links","label":"NCBI Gene 10320"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10342","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tfg","kind":"target","name":"TFG","route":"/targets/tfg/","field":"links","label":"NCBI Gene 10342"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10365","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/","field":"links","label":"NCBI Gene 10365"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10376","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/","field":"links","label":"NCBI Gene 10376"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10381","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/","field":"links","label":"NCBI Gene 10381"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10382","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/","field":"links","label":"NCBI Gene 10382"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10383","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/","field":"links","label":"NCBI Gene 10383"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10395","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dlc1","kind":"target","name":"DLC1","route":"/targets/dlc1/","field":"links","label":"NCBI Gene 10395"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10397","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ndrg1","kind":"target","name":"NDRG1","route":"/targets/ndrg1/","field":"links","label":"NCBI Gene 10397"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10413","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/","field":"links","label":"NCBI Gene 10413"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1045","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdx2","kind":"target","name":"CDX2","route":"/targets/cdx2/","field":"links","label":"NCBI Gene 1045"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10461","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mertk","kind":"target","name":"MERTK","route":"/targets/mertk/","field":"links","label":"NCBI Gene 10461"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10481","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxb13","kind":"target","name":"HOXB13","route":"/targets/hoxb13/","field":"links","label":"NCBI Gene 10481"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10482","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nxf1","kind":"target","name":"NXF1","route":"/targets/nxf1/","field":"links","label":"NCBI Gene 10482"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10499","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/","field":"links","label":"NCBI Gene 10499"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1050","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cebpa","kind":"target","name":"CEBPA","route":"/targets/cebpa/","field":"links","label":"NCBI Gene 1050"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10524","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat5","kind":"target","name":"KAT5","route":"/targets/kat5/","field":"links","label":"NCBI Gene 10524"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10533","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atg7","kind":"target","name":"ATG7","route":"/targets/atg7/","field":"links","label":"NCBI Gene 10533"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10551","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agr2","kind":"target","name":"AGR2","route":"/targets/agr2/","field":"links","label":"NCBI Gene 10551"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10568","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/","field":"links","label":"NCBI Gene 10568"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10599","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slco1b1","kind":"target","name":"SLCO1B1","route":"/targets/slco1b1/","field":"links","label":"NCBI Gene 10599"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10611","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdlim5","kind":"target","name":"PDLIM5","route":"/targets/pdlim5/","field":"links","label":"NCBI Gene 10611"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10641","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nprl2","kind":"target","name":"NPRL2","route":"/targets/nprl2/","field":"links","label":"NCBI Gene 10641"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10659","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"celf2","kind":"target","name":"CELF2","route":"/targets/celf2/","field":"links","label":"NCBI Gene 10659"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10664","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctcf","kind":"target","name":"CTCF","route":"/targets/ctcf/","field":"links","label":"NCBI Gene 10664"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10672","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gna13","kind":"target","name":"GNA13","route":"/targets/gna13/","field":"links","label":"NCBI Gene 10672"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10714","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/","field":"links","label":"NCBI Gene 10714"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10718","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrg3","kind":"target","name":"NRG3","route":"/targets/nrg3/","field":"links","label":"NCBI Gene 10718"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10721","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/","field":"links","label":"NCBI Gene 10721"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10734","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stag3","kind":"target","name":"STAG3","route":"/targets/stag3/","field":"links","label":"NCBI Gene 10734"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10735","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stag2","kind":"target","name":"STAG2","route":"/targets/stag2/","field":"links","label":"NCBI Gene 10735"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10782","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf274","kind":"target","name":"ZNF274","route":"/targets/znf274/","field":"links","label":"NCBI Gene 10782"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10806","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdccag8","kind":"target","name":"SDCCAG8","route":"/targets/sdccag8/","field":"links","label":"NCBI Gene 10806"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10808","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hsph1","kind":"target","name":"HSPH1","route":"/targets/hsph1/","field":"links","label":"NCBI Gene 10808"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10817","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frs3","kind":"target","name":"FRS3","route":"/targets/frs3/","field":"links","label":"NCBI Gene 10817"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10818","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frs2","kind":"target","name":"FRS2","route":"/targets/frs2/","field":"links","label":"NCBI Gene 10818"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10827","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fam114a2","kind":"target","name":"FAM114A2","route":"/targets/fam114a2/","field":"links","label":"NCBI Gene 10827"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10859","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/","field":"links","label":"NCBI Gene 10859"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10892","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/","field":"links","label":"NCBI Gene 10892"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/10979","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fermt2","kind":"target","name":"FERMT2","route":"/targets/fermt2/","field":"links","label":"NCBI Gene 10979"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11011","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tlk2","kind":"target","name":"TLK2","route":"/targets/tlk2/","field":"links","label":"NCBI Gene 11011"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11040","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pim2","kind":"target","name":"PIM2","route":"/targets/pim2/","field":"links","label":"NCBI Gene 11040"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11044","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tent4a","kind":"target","name":"TENT4A","route":"/targets/tent4a/","field":"links","label":"NCBI Gene 11044"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11047","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/","field":"links","label":"NCBI Gene 11047"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11052","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cpsf6","kind":"target","name":"CPSF6","route":"/targets/cpsf6/","field":"links","label":"NCBI Gene 11052"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1106","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chd2","kind":"target","name":"CHD2","route":"/targets/chd2/","field":"links","label":"NCBI Gene 1106"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11064","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cntrl","kind":"target","name":"CNTRL","route":"/targets/cntrl/","field":"links","label":"NCBI Gene 11064"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1108","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chd4","kind":"target","name":"CHD4","route":"/targets/chd4/","field":"links","label":"NCBI Gene 1108"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11086","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adam29","kind":"target","name":"ADAM29","route":"/targets/adam29/","field":"links","label":"NCBI Gene 11086"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1111","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/","field":"links","label":"NCBI Gene 1111"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11116","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cep43","kind":"target","name":"CEP43","route":"/targets/cep43/","field":"links","label":"NCBI Gene 11116"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/","field":"links","label":"NCBI Gene 11122"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11140","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdc37","kind":"target","name":"CDC37","route":"/targets/cdc37/","field":"links","label":"NCBI Gene 11140"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11143","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat7","kind":"target","name":"KAT7","route":"/targets/kat7/","field":"links","label":"NCBI Gene 11143"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11148","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hhla2","kind":"target","name":"HHLA2 (B7-H7)","route":"/targets/hhla2/","field":"links","label":"NCBI Gene 11148"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11156","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptp4a3","kind":"target","name":"PTP4A3","route":"/targets/ptp4a3/","field":"links","label":"NCBI Gene 11156"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11160","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erlin2","kind":"target","name":"ERLIN2","route":"/targets/erlin2/","field":"links","label":"NCBI Gene 11160"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11166","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sox21","kind":"target","name":"SOX21","route":"/targets/sox21/","field":"links","label":"NCBI Gene 11166"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11168","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psip1","kind":"target","name":"PSIP1","route":"/targets/psip1/","field":"links","label":"NCBI Gene 11168"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11177","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/","field":"links","label":"NCBI Gene 11177"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11197","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wif1","kind":"target","name":"WIF1","route":"/targets/wif1/","field":"links","label":"NCBI Gene 11197"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11200","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/","field":"links","label":"NCBI Gene 11200"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11262","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/","field":"links","label":"NCBI Gene 11262"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/112714","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/","field":"links","label":"NCBI Gene 112714"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11280","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn11a","kind":"target","name":"SCN11A","route":"/targets/scn11a/","field":"links","label":"NCBI Gene 11280"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/11338","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"u2af2","kind":"target","name":"U2AF2","route":"/targets/u2af2/","field":"links","label":"NCBI Gene 11338"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1136","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chrna3","kind":"target","name":"CHRNA3","route":"/targets/chrna3/","field":"links","label":"NCBI Gene 1136"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1137","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chrna4","kind":"target","name":"CHRNA4","route":"/targets/chrna4/","field":"links","label":"NCBI Gene 1137"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1138","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chrna5","kind":"target","name":"CHRNA5","route":"/targets/chrna5/","field":"links","label":"NCBI Gene 1138"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/114034","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"toe1","kind":"target","name":"TOE1","route":"/targets/toe1/","field":"links","label":"NCBI Gene 114034"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/114788","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csmd3","kind":"target","name":"CSMD3","route":"/targets/csmd3/","field":"links","label":"NCBI Gene 114788"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/114803","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mysm1","kind":"target","name":"MYSM1","route":"/targets/mysm1/","field":"links","label":"NCBI Gene 114803"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/114825","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pwwp2a","kind":"target","name":"PWWP2A","route":"/targets/pwwp2a/","field":"links","label":"NCBI Gene 114825"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/114884","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osbpl10","kind":"target","name":"OSBPL10","route":"/targets/osbpl10/","field":"links","label":"NCBI Gene 114884"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/115294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcmtd1","kind":"target","name":"PCMTD1","route":"/targets/pcmtd1/","field":"links","label":"NCBI Gene 115294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/116028","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rmi2","kind":"target","name":"RMI2","route":"/targets/rmi2/","field":"links","label":"NCBI Gene 116028"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/116113","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxp4","kind":"target","name":"FOXP4","route":"/targets/foxp4/","field":"links","label":"NCBI Gene 116113"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1185","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clcn6","kind":"target","name":"CLCN6","route":"/targets/clcn6/","field":"links","label":"NCBI Gene 1185"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/120114","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fat3","kind":"target","name":"FAT3","route":"/targets/fat3/","field":"links","label":"NCBI Gene 120114"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/121227","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lrig3","kind":"target","name":"LRIG3","route":"/targets/lrig3/","field":"links","label":"NCBI Gene 121227"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/121278","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tph2","kind":"target","name":"TPH2","route":"/targets/tph2/","field":"links","label":"NCBI Gene 121278"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1213","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cltc","kind":"target","name":"CLTC","route":"/targets/cltc/","field":"links","label":"NCBI Gene 1213"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/122706","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/","field":"links","label":"NCBI Gene 122706"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1236","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccr7","kind":"target","name":"CCR7","route":"/targets/ccr7/","field":"links","label":"NCBI Gene 1236"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/124540","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/","field":"links","label":"NCBI Gene 124540"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/124583","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cant1","kind":"target","name":"CANT1","route":"/targets/cant1/","field":"links","label":"NCBI Gene 124583"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/125","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adh1b","kind":"target","name":"ADH1B","route":"/targets/adh1b/","field":"links","label":"NCBI Gene 125"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/126961","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h3c14","kind":"target","name":"H3C14","route":"/targets/h3c14/","field":"links","label":"NCBI Gene 126961"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1277","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/","field":"links","label":"NCBI Gene 1277"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1280","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"col2a1","kind":"target","name":"COL2A1","route":"/targets/col2a1/","field":"links","label":"NCBI Gene 1280"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1293","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"col6a3","kind":"target","name":"COL6A3","route":"/targets/col6a3/","field":"links","label":"NCBI Gene 1293"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/131096","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnh8","kind":"target","name":"KCNH8","route":"/targets/kcnh8/","field":"links","label":"NCBI Gene 131096"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1316","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klf6","kind":"target","name":"KLF6","route":"/targets/klf6/","field":"links","label":"NCBI Gene 1316"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/131873","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"col6a6","kind":"target","name":"COL6A6","route":"/targets/col6a6/","field":"links","label":"NCBI Gene 131873"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/135","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","route":"/targets/adora2a/","field":"links","label":"NCBI Gene 135"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/137492","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/","field":"links","label":"NCBI Gene 137492"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/137902","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pxdnl","kind":"target","name":"PXDNL","route":"/targets/pxdnl/","field":"links","label":"NCBI Gene 137902"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/138474","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"taf1l","kind":"target","name":"TAF1L","route":"/targets/taf1l/","field":"links","label":"NCBI Gene 138474"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1385","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"creb1","kind":"target","name":"CREB1","route":"/targets/creb1/","field":"links","label":"NCBI Gene 1385"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1387","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/","field":"links","label":"NCBI Gene 1387"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/139285","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","field":"links","label":"NCBI Gene 139285"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/139628","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxr2","kind":"target","name":"FOXR2","route":"/targets/foxr2/","field":"links","label":"NCBI Gene 139628"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1399","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crkl","kind":"target","name":"CRKL","route":"/targets/crkl/","field":"links","label":"NCBI Gene 1399"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/140885","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/","field":"links","label":"NCBI Gene 140885"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/142678","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mib2","kind":"target","name":"MIB2","route":"/targets/mib2/","field":"links","label":"NCBI Gene 142678"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/143","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/","field":"links","label":"NCBI Gene 143"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/143187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vti1a","kind":"target","name":"VTI1A","route":"/targets/vti1a/","field":"links","label":"NCBI Gene 143187"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/143471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/","field":"links","label":"NCBI Gene 143471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1435","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/","field":"links","label":"NCBI Gene 1435"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/143888","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"poglut3","kind":"target","name":"POGLUT3","route":"/targets/poglut3/","field":"links","label":"NCBI Gene 143888"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1439","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csf2rb","kind":"target","name":"CSF2RB","route":"/targets/csf2rb/","field":"links","label":"NCBI Gene 1439"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1445","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csk","kind":"target","name":"CSK","route":"/targets/csk/","field":"links","label":"NCBI Gene 1445"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1452","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/","field":"links","label":"NCBI Gene 1452"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1454","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"csnk1e","kind":"target","name":"CSNK1E","route":"/targets/csnk1e/","field":"links","label":"NCBI Gene 1454"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/145957","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrg4","kind":"target","name":"NRG4","route":"/targets/nrg4/","field":"links","label":"NCBI Gene 145957"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/146","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra1d","kind":"target","name":"ADRA1D","route":"/targets/adra1d/","field":"links","label":"NCBI Gene 146"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1464","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cspg4","kind":"target","name":"CSPG4","route":"/targets/cspg4/","field":"links","label":"NCBI Gene 1464"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/147","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra1b","kind":"target","name":"ADRA1B","route":"/targets/adra1b/","field":"links","label":"NCBI Gene 147"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/148","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra1a","kind":"target","name":"ADRA1A","route":"/targets/adra1a/","field":"links","label":"NCBI Gene 148"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1485","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/","field":"links","label":"NCBI Gene 1485"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1490","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccn2","kind":"target","name":"CCN2","route":"/targets/ccn2/","field":"links","label":"NCBI Gene 1490"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/","field":"links","label":"NCBI Gene 1495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1496","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctnna2","kind":"target","name":"CTNNA2","route":"/targets/ctnna2/","field":"links","label":"NCBI Gene 1496"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1499","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"links","label":"NCBI Gene 1499"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/150","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra2a","kind":"target","name":"ADRA2A","route":"/targets/adra2a/","field":"links","label":"NCBI Gene 150"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1501","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/","field":"links","label":"NCBI Gene 1501"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/151","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra2b","kind":"target","name":"ADRA2B","route":"/targets/adra2b/","field":"links","label":"NCBI Gene 151"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1512","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctsh","kind":"target","name":"CTSH","route":"/targets/ctsh/","field":"links","label":"NCBI Gene 1512"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/151449","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gdf7","kind":"target","name":"GDF7","route":"/targets/gdf7/","field":"links","label":"NCBI Gene 151449"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/151888","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/","field":"links","label":"NCBI Gene 151888"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/151963","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mb21d2","kind":"target","name":"MB21D2","route":"/targets/mb21d2/","field":"links","label":"NCBI Gene 151963"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/152","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adra2c","kind":"target","name":"ADRA2C","route":"/targets/adra2c/","field":"links","label":"NCBI Gene 152"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1520","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctss","kind":"target","name":"CTSS","route":"/targets/ctss/","field":"links","label":"NCBI Gene 1520"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/152110","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nek10","kind":"target","name":"NEK10","route":"/targets/nek10/","field":"links","label":"NCBI Gene 152110"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/152273","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgd5","kind":"target","name":"FGD5","route":"/targets/fgd5/","field":"links","label":"NCBI Gene 152273"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1523","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cux1","kind":"target","name":"CUX1","route":"/targets/cux1/","field":"links","label":"NCBI Gene 1523"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1540","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/","field":"links","label":"NCBI Gene 1540"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1545","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyp1b1","kind":"target","name":"CYP1B1","route":"/targets/cyp1b1/","field":"links","label":"NCBI Gene 1545"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1558","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyp2c8","kind":"target","name":"CYP2C8","route":"/targets/cyp2c8/","field":"links","label":"NCBI Gene 1558"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1565","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyp2d6","kind":"target","name":"CYP2D6","route":"/targets/cyp2d6/","field":"links","label":"NCBI Gene 1565"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/157638","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lratd2","kind":"target","name":"LRATD2","route":"/targets/lratd2/","field":"links","label":"NCBI Gene 157638"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1584","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cyp11b1","kind":"target","name":"CYP11B1","route":"/targets/cyp11b1/","field":"links","label":"NCBI Gene 1584"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/158471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/","field":"links","label":"NCBI Gene 158471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/158586","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zxdb","kind":"target","name":"ZXDB","route":"/targets/zxdb/","field":"links","label":"NCBI Gene 158586"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/160140","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/","field":"links","label":"NCBI Gene 160140"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/161357","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mdga2","kind":"target","name":"MDGA2","route":"/targets/mdga2/","field":"links","label":"NCBI Gene 161357"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1616","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daxx","kind":"target","name":"DAXX","route":"/targets/daxx/","field":"links","label":"NCBI Gene 1616"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1630","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dcc","kind":"target","name":"DCC","route":"/targets/dcc/","field":"links","label":"NCBI Gene 1630"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1639","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dctn1","kind":"target","name":"DCTN1","route":"/targets/dctn1/","field":"links","label":"NCBI Gene 1639"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1642","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/","field":"links","label":"NCBI Gene 1642"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1643","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddb2","kind":"target","name":"DDB2","route":"/targets/ddb2/","field":"links","label":"NCBI Gene 1643"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1647","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/","field":"links","label":"NCBI Gene 1647"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1649","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddit3","kind":"target","name":"DDIT3","route":"/targets/ddit3/","field":"links","label":"NCBI Gene 1649"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/165","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aebp1","kind":"target","name":"AEBP1","route":"/targets/aebp1/","field":"links","label":"NCBI Gene 165"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx3x","kind":"target","name":"DDX3X","route":"/targets/ddx3x/","field":"links","label":"NCBI Gene 1654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1655","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx5","kind":"target","name":"DDX5","route":"/targets/ddx5/","field":"links","label":"NCBI Gene 1655"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1656","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx6","kind":"target","name":"DDX6","route":"/targets/ddx6/","field":"links","label":"NCBI Gene 1656"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1660","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/","field":"links","label":"NCBI Gene 1660"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1662","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx10","kind":"target","name":"DDX10","route":"/targets/ddx10/","field":"links","label":"NCBI Gene 1662"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1667","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"defa1","kind":"target","name":"DEFA1","route":"/targets/defa1/","field":"links","label":"NCBI Gene 1667"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/166824","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rassf6","kind":"target","name":"RASSF6","route":"/targets/rassf6/","field":"links","label":"NCBI Gene 166824"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/170960","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf721","kind":"target","name":"ZNF721","route":"/targets/znf721/","field":"links","label":"NCBI Gene 170960"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/171023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asxl1","kind":"target","name":"ASXL1","route":"/targets/asxl1/","field":"links","label":"NCBI Gene 171023"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1728","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nqo1","kind":"target","name":"NQO1","route":"/targets/nqo1/","field":"links","label":"NCBI Gene 1728"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1743","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dlst","kind":"target","name":"DLST","route":"/targets/dlst/","field":"links","label":"NCBI Gene 1743"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1763","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dna2","kind":"target","name":"DNA2","route":"/targets/dna2/","field":"links","label":"NCBI Gene 1763"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1785","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnm2","kind":"target","name":"DNM2","route":"/targets/dnm2/","field":"links","label":"NCBI Gene 1785"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1789","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnmt3b","kind":"target","name":"DNMT3B","route":"/targets/dnmt3b/","field":"links","label":"NCBI Gene 1789"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1806","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dpyd","kind":"target","name":"DPYD","route":"/targets/dpyd/","field":"links","label":"NCBI Gene 1806"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1816","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drd5","kind":"target","name":"DRD5","route":"/targets/drd5/","field":"links","label":"NCBI Gene 1816"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/182","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jag1","kind":"target","name":"JAG1","route":"/targets/jag1/","field":"links","label":"NCBI Gene 182"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1832","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dsp","kind":"target","name":"DSP","route":"/targets/dsp/","field":"links","label":"NCBI Gene 1832"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1839","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hbegf","kind":"target","name":"HBEGF","route":"/targets/hbegf/","field":"links","label":"NCBI Gene 1839"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1840","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dtx1","kind":"target","name":"DTX1","route":"/targets/dtx1/","field":"links","label":"NCBI Gene 1840"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1844","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dusp2","kind":"target","name":"DUSP2","route":"/targets/dusp2/","field":"links","label":"NCBI Gene 1844"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1848","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dusp6","kind":"target","name":"DUSP6","route":"/targets/dusp6/","field":"links","label":"NCBI Gene 1848"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1879","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ebf1","kind":"target","name":"EBF1","route":"/targets/ebf1/","field":"links","label":"NCBI Gene 1879"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1890","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tymp","kind":"target","name":"TYMP","route":"/targets/tymp/","field":"links","label":"NCBI Gene 1890"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1901","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"s1pr1","kind":"target","name":"S1PR1","route":"/targets/s1pr1/","field":"links","label":"NCBI Gene 1901"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1909","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ednra","kind":"target","name":"EDNRA","route":"/targets/ednra/","field":"links","label":"NCBI Gene 1909"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1950","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","field":"links","label":"NCBI Gene 1950"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1959","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"egr2","kind":"target","name":"EGR2","route":"/targets/egr2/","field":"links","label":"NCBI Gene 1959"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1964","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","field":"links","label":"NCBI Gene 1964"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/196528","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/","field":"links","label":"NCBI Gene 196528"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1973","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif4a1","kind":"target","name":"EIF4A1","route":"/targets/eif4a1/","field":"links","label":"NCBI Gene 1973"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1974","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif4a2","kind":"target","name":"EIF4A2","route":"/targets/eif4a2/","field":"links","label":"NCBI Gene 1974"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1978","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif4ebp1","kind":"target","name":"EIF4EBP1","route":"/targets/eif4ebp1/","field":"links","label":"NCBI Gene 1978"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/199777","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf626","kind":"target","name":"ZNF626","route":"/targets/znf626/","field":"links","label":"NCBI Gene 199777"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/1999","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","field":"links","label":"NCBI Gene 1999"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/199990","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"faap20","kind":"target","name":"FAAP20","route":"/targets/faap20/","field":"links","label":"NCBI Gene 199990"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elf4","kind":"target","name":"ELF4","route":"/targets/elf4/","field":"links","label":"NCBI Gene 2000"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2005","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elk4","kind":"target","name":"ELK4","route":"/targets/elk4/","field":"links","label":"NCBI Gene 2005"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2006","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eln","kind":"target","name":"ELN","route":"/targets/eln/","field":"links","label":"NCBI Gene 2006"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/200728","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tmem17","kind":"target","name":"TMEM17","route":"/targets/tmem17/","field":"links","label":"NCBI Gene 200728"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/200942","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klhdc8b","kind":"target","name":"KLHDC8B","route":"/targets/klhdc8b/","field":"links","label":"NCBI Gene 200942"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2011","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark2","kind":"target","name":"MARK2","route":"/targets/mark2/","field":"links","label":"NCBI Gene 2011"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/201163","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flcn","kind":"target","name":"FLCN","route":"/targets/flcn/","field":"links","label":"NCBI Gene 201163"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc29a1","kind":"target","name":"SLC29A1","route":"/targets/slc29a1/","field":"links","label":"NCBI Gene 2030"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2033","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/","field":"links","label":"NCBI Gene 2033"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/203447","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrk","kind":"target","name":"NRK","route":"/targets/nrk/","field":"links","label":"NCBI Gene 203447"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2041","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha1","kind":"target","name":"EPHA1","route":"/targets/epha1/","field":"links","label":"NCBI Gene 2041"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2042","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha3","kind":"target","name":"EPHA3","route":"/targets/epha3/","field":"links","label":"NCBI Gene 2042"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2043","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha4","kind":"target","name":"EPHA4","route":"/targets/epha4/","field":"links","label":"NCBI Gene 2043"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2044","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha5","kind":"target","name":"EPHA5","route":"/targets/epha5/","field":"links","label":"NCBI Gene 2044"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2045","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha7","kind":"target","name":"EPHA7","route":"/targets/epha7/","field":"links","label":"NCBI Gene 2045"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2046","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha8","kind":"target","name":"EPHA8","route":"/targets/epha8/","field":"links","label":"NCBI Gene 2046"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2047","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ephb1","kind":"target","name":"EPHB1","route":"/targets/ephb1/","field":"links","label":"NCBI Gene 2047"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2048","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ephb2","kind":"target","name":"EPHB2","route":"/targets/ephb2/","field":"links","label":"NCBI Gene 2048"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2049","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ephb3","kind":"target","name":"EPHB3","route":"/targets/ephb3/","field":"links","label":"NCBI Gene 2049"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2050","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ephb4","kind":"target","name":"EPHB4","route":"/targets/ephb4/","field":"links","label":"NCBI Gene 2050"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2060","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eps15","kind":"target","name":"EPS15","route":"/targets/eps15/","field":"links","label":"NCBI Gene 2060"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2067","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/","field":"links","label":"NCBI Gene 2067"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2068","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/","field":"links","label":"NCBI Gene 2068"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2069","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ereg","kind":"target","name":"EREG","route":"/targets/ereg/","field":"links","label":"NCBI Gene 2069"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2071","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/","field":"links","label":"NCBI Gene 2071"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2072","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc4","kind":"target","name":"ERCC4","route":"/targets/ercc4/","field":"links","label":"NCBI Gene 2072"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2073","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/","field":"links","label":"NCBI Gene 2073"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2074","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ercc6","kind":"target","name":"ERCC6","route":"/targets/ercc6/","field":"links","label":"NCBI Gene 2074"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2078","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","field":"links","label":"NCBI Gene 2078"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2100","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esr2","kind":"target","name":"ESR2","route":"/targets/esr2/","field":"links","label":"NCBI Gene 2100"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2101","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esrra","kind":"target","name":"ESRRA","route":"/targets/esrra/","field":"links","label":"NCBI Gene 2101"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2113","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ets1","kind":"target","name":"ETS1","route":"/targets/ets1/","field":"links","label":"NCBI Gene 2113"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2114","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ets2","kind":"target","name":"ETS2","route":"/targets/ets2/","field":"links","label":"NCBI Gene 2114"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2115","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","field":"links","label":"NCBI Gene 2115"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2118","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/","field":"links","label":"NCBI Gene 2118"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2119","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etv5","kind":"target","name":"ETV5","route":"/targets/etv5/","field":"links","label":"NCBI Gene 2119"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2120","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etv6","kind":"target","name":"ETV6","route":"/targets/etv6/","field":"links","label":"NCBI Gene 2120"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/","field":"links","label":"NCBI Gene 2122"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2131","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/","field":"links","label":"NCBI Gene 2131"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2132","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/","field":"links","label":"NCBI Gene 2132"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/214","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alcam","kind":"target","name":"ALCAM","route":"/targets/alcam/","field":"links","label":"NCBI Gene 214"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/217","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aldh2","kind":"target","name":"ALDH2","route":"/targets/aldh2/","field":"links","label":"NCBI Gene 217"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2175","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/","field":"links","label":"NCBI Gene 2175"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2176","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/","field":"links","label":"NCBI Gene 2176"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2177","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/","field":"links","label":"NCBI Gene 2177"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2178","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fance","kind":"target","name":"FANCE","route":"/targets/fance/","field":"links","label":"NCBI Gene 2178"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2181","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acsl3","kind":"target","name":"ACSL3","route":"/targets/acsl3/","field":"links","label":"NCBI Gene 2181"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancb","kind":"target","name":"FANCB","route":"/targets/fancb/","field":"links","label":"NCBI Gene 2187"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2188","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancf","kind":"target","name":"FANCF","route":"/targets/fancf/","field":"links","label":"NCBI Gene 2188"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2189","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancg","kind":"target","name":"FANCG","route":"/targets/fancg/","field":"links","label":"NCBI Gene 2189"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/219285","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samd9l","kind":"target","name":"SAMD9L","route":"/targets/samd9l/","field":"links","label":"NCBI Gene 219285"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2195","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/","field":"links","label":"NCBI Gene 2195"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2196","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fat2","kind":"target","name":"FAT2","route":"/targets/fat2/","field":"links","label":"NCBI Gene 2196"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2199","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/","field":"links","label":"NCBI Gene 2199"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/219931","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tpcn2","kind":"target","name":"TPCN2","route":"/targets/tpcn2/","field":"links","label":"NCBI Gene 219931"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/219972","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mpeg1","kind":"target","name":"MPEG1","route":"/targets/mpeg1/","field":"links","label":"NCBI Gene 219972"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2201","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/","field":"links","label":"NCBI Gene 2201"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2212","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/","field":"links","label":"NCBI Gene 2212"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2213","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/","field":"links","label":"NCBI Gene 2213"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2214","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/","field":"links","label":"NCBI Gene 2214"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/221895","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jazf1","kind":"target","name":"JAZF1","route":"/targets/jazf1/","field":"links","label":"NCBI Gene 221895"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2224","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/","field":"links","label":"NCBI Gene 2224"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2242","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/","field":"links","label":"NCBI Gene 2242"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2243","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fga","kind":"target","name":"FGA","route":"/targets/fga/","field":"links","label":"NCBI Gene 2243"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2244","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgb","kind":"target","name":"FGB","route":"/targets/fgb/","field":"links","label":"NCBI Gene 2244"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2245","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgd1","kind":"target","name":"FGD1","route":"/targets/fgd1/","field":"links","label":"NCBI Gene 2245"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2246","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf1","kind":"target","name":"FGF1","route":"/targets/fgf1/","field":"links","label":"NCBI Gene 2246"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2247","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf2","kind":"target","name":"FGF2","route":"/targets/fgf2/","field":"links","label":"NCBI Gene 2247"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2248","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf3","kind":"target","name":"FGF3","route":"/targets/fgf3/","field":"links","label":"NCBI Gene 2248"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2249","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf4","kind":"target","name":"FGF4","route":"/targets/fgf4/","field":"links","label":"NCBI Gene 2249"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2250","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf5","kind":"target","name":"FGF5","route":"/targets/fgf5/","field":"links","label":"NCBI Gene 2250"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2251","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf6","kind":"target","name":"FGF6","route":"/targets/fgf6/","field":"links","label":"NCBI Gene 2251"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2252","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf7","kind":"target","name":"FGF7","route":"/targets/fgf7/","field":"links","label":"NCBI Gene 2252"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2253","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf8","kind":"target","name":"FGF8","route":"/targets/fgf8/","field":"links","label":"NCBI Gene 2253"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2254","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf9","kind":"target","name":"FGF9","route":"/targets/fgf9/","field":"links","label":"NCBI Gene 2254"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2255","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf10","kind":"target","name":"FGF10","route":"/targets/fgf10/","field":"links","label":"NCBI Gene 2255"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2258","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf13","kind":"target","name":"FGF13","route":"/targets/fgf13/","field":"links","label":"NCBI Gene 2258"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2262","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/","field":"links","label":"NCBI Gene 2262"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2264","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/","field":"links","label":"NCBI Gene 2264"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2266","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgg","kind":"target","name":"FGG","route":"/targets/fgg/","field":"links","label":"NCBI Gene 2266"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2267","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgl1","kind":"target","name":"FGL1","route":"/targets/fgl1/","field":"links","label":"NCBI Gene 2267"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2268","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgr","kind":"target","name":"FGR","route":"/targets/fgr/","field":"links","label":"NCBI Gene 2268"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2271","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fh","kind":"target","name":"FH","route":"/targets/fh/","field":"links","label":"NCBI Gene 2271"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2272","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/","field":"links","label":"NCBI Gene 2272"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22800","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/","field":"links","label":"NCBI Gene 22800"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22806","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ikzf3","kind":"target","name":"IKZF3 (Aiolos)","route":"/targets/ikzf3/","field":"links","label":"NCBI Gene 22806"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22849","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cpeb3","kind":"target","name":"CPEB3","route":"/targets/cpeb3/","field":"links","label":"NCBI Gene 22849"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22866","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnksr2","kind":"target","name":"CNKSR2","route":"/targets/cnksr2/","field":"links","label":"NCBI Gene 22866"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22882","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhx2","kind":"target","name":"ZHX2","route":"/targets/zhx2/","field":"links","label":"NCBI Gene 22882"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22894","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/","field":"links","label":"NCBI Gene 22894"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22906","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trak1","kind":"target","name":"TRAK1","route":"/targets/trak1/","field":"links","label":"NCBI Gene 22906"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22938","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"snw1","kind":"target","name":"SNW1","route":"/targets/snw1/","field":"links","label":"NCBI Gene 22938"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxf1","kind":"target","name":"FOXF1","route":"/targets/foxf1/","field":"links","label":"NCBI Gene 2294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22943","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dkk1","kind":"target","name":"DKK1","route":"/targets/dkk1/","field":"links","label":"NCBI Gene 22943"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22978","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nt5c2","kind":"target","name":"NT5C2","route":"/targets/nt5c2/","field":"links","label":"NCBI Gene 22978"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/22986","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sorcs3","kind":"target","name":"SORCS3","route":"/targets/sorcs3/","field":"links","label":"NCBI Gene 22986"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23013","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","field":"links","label":"NCBI Gene 23013"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2303","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxc2","kind":"target","name":"FOXC2","route":"/targets/foxc2/","field":"links","label":"NCBI Gene 2303"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23036","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf292","kind":"target","name":"ZNF292","route":"/targets/znf292/","field":"links","label":"NCBI Gene 23036"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23037","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdzd2","kind":"target","name":"PDZD2","route":"/targets/pdzd2/","field":"links","label":"NCBI Gene 23037"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2304","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxe1","kind":"target","name":"FOXE1","route":"/targets/foxe1/","field":"links","label":"NCBI Gene 2304"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23067","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/","field":"links","label":"NCBI Gene 23067"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2308","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/","field":"links","label":"NCBI Gene 2308"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23085","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erc1","kind":"target","name":"ERC1","route":"/targets/erc1/","field":"links","label":"NCBI Gene 23085"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2309","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxo3","kind":"target","name":"FOXO3","route":"/targets/foxo3/","field":"links","label":"NCBI Gene 2309"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23092","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgap26","kind":"target","name":"ARHGAP26","route":"/targets/arhgap26/","field":"links","label":"NCBI Gene 23092"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2312","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flg","kind":"target","name":"FLG","route":"/targets/flg/","field":"links","label":"NCBI Gene 2312"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23152","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cic","kind":"target","name":"CIC","route":"/targets/cic/","field":"links","label":"NCBI Gene 23152"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23164","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mprip","kind":"target","name":"MPRIP","route":"/targets/mprip/","field":"links","label":"NCBI Gene 23164"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23189","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kank1","kind":"target","name":"KANK1","route":"/targets/kank1/","field":"links","label":"NCBI Gene 23189"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23221","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rhobtb2","kind":"target","name":"RHOBTB2","route":"/targets/rhobtb2/","field":"links","label":"NCBI Gene 23221"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2323","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"flt3lg","kind":"target","name":"FLT3LG","route":"/targets/flt3lg/","field":"links","label":"NCBI Gene 2323"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23261","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"camta1","kind":"target","name":"CAMTA1","route":"/targets/camta1/","field":"links","label":"NCBI Gene 23261"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23269","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mga","kind":"target","name":"MGA","route":"/targets/mga/","field":"links","label":"NCBI Gene 23269"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23291","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fbxw11","kind":"target","name":"FBXW11","route":"/targets/fbxw11/","field":"links","label":"NCBI Gene 23291"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23301","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ehbp1","kind":"target","name":"EHBP1","route":"/targets/ehbp1/","field":"links","label":"NCBI Gene 23301"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23305","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acsl6","kind":"target","name":"ACSL6","route":"/targets/acsl6/","field":"links","label":"NCBI Gene 23305"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2335","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/","field":"links","label":"NCBI Gene 2335"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23365","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgef12","kind":"target","name":"ARHGEF12","route":"/targets/arhgef12/","field":"links","label":"NCBI Gene 23365"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23373","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crtc1","kind":"target","name":"CRTC1","route":"/targets/crtc1/","field":"links","label":"NCBI Gene 23373"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23385","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncstn","kind":"target","name":"NCSTN","route":"/targets/ncstn/","field":"links","label":"NCBI Gene 23385"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23397","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncaph","kind":"target","name":"NCAPH","route":"/targets/ncaph/","field":"links","label":"NCBI Gene 23397"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23405","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/","field":"links","label":"NCBI Gene 23405"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23411","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirt1","kind":"target","name":"SIRT1","route":"/targets/sirt1/","field":"links","label":"NCBI Gene 23411"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23414","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zfpm2","kind":"target","name":"ZFPM2","route":"/targets/zfpm2/","field":"links","label":"NCBI Gene 23414"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2342","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/","field":"links","label":"NCBI Gene 2342"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23432","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gpr161","kind":"target","name":"GPR161","route":"/targets/gpr161/","field":"links","label":"NCBI Gene 23432"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23451","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","field":"links","label":"NCBI Gene 23451"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23462","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hey1","kind":"target","name":"HEY1","route":"/targets/hey1/","field":"links","label":"NCBI Gene 23462"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23467","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nptxr","kind":"target","name":"NPTXR","route":"/targets/nptxr/","field":"links","label":"NCBI Gene 23467"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23476","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/","field":"links","label":"NCBI Gene 23476"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/","field":"links","label":"NCBI Gene 23495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23512","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"suz12","kind":"target","name":"SUZ12","route":"/targets/suz12/","field":"links","label":"NCBI Gene 23512"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23522","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat6b","kind":"target","name":"KAT6B","route":"/targets/kat6b/","field":"links","label":"NCBI Gene 23522"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2353","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fos","kind":"target","name":"FOS","route":"/targets/fos/","field":"links","label":"NCBI Gene 2353"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23533","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3r5","kind":"target","name":"PIK3R5","route":"/targets/pik3r5/","field":"links","label":"NCBI Gene 23533"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2354","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fosb","kind":"target","name":"FOSB","route":"/targets/fosb/","field":"links","label":"NCBI Gene 2354"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23598","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"patz1","kind":"target","name":"PATZ1","route":"/targets/patz1/","field":"links","label":"NCBI Gene 23598"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23624","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cblc","kind":"target","name":"CBLC","route":"/targets/cblc/","field":"links","label":"NCBI Gene 23624"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23645","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp1r15a","kind":"target","name":"PPP1R15A","route":"/targets/ppp1r15a/","field":"links","label":"NCBI Gene 23645"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23649","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/","field":"links","label":"NCBI Gene 23649"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plxnb2","kind":"target","name":"PLXNB2","route":"/targets/plxnb2/","field":"links","label":"NCBI Gene 23654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/23683","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkd3","kind":"target","name":"PRKD3","route":"/targets/prkd3/","field":"links","label":"NCBI Gene 23683"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2475","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/","field":"links","label":"NCBI Gene MTOR"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2494","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nr5a2","kind":"target","name":"NR5A2","route":"/targets/nr5a2/","field":"links","label":"NCBI Gene 2494"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abl1","kind":"target","name":"ABL1","route":"/targets/abl1/","field":"links","label":"NCBI Gene 25"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2521","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fus","kind":"target","name":"FUS","route":"/targets/fus/","field":"links","label":"NCBI Gene 2521"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/253260","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/","field":"links","label":"NCBI Gene 253260"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2534","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/","field":"links","label":"NCBI Gene 2534"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/253559","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cadm2","kind":"target","name":"CADM2","route":"/targets/cadm2/","field":"links","label":"NCBI Gene 253559"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2549","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gab1","kind":"target","name":"GAB1","route":"/targets/gab1/","field":"links","label":"NCBI Gene 2549"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/256646","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/","field":"links","label":"NCBI Gene 256646"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2567","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gabrg3","kind":"target","name":"GABRG3","route":"/targets/gabrg3/","field":"links","label":"NCBI Gene 2567"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25836","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nipbl","kind":"target","name":"NIPBL","route":"/targets/nipbl/","field":"links","label":"NCBI Gene 25836"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25865","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/","field":"links","label":"NCBI Gene 25865"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25913","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pot1","kind":"target","name":"POT1","route":"/targets/pot1/","field":"links","label":"NCBI Gene 25913"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25925","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/","field":"links","label":"NCBI Gene 25925"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25937","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/","field":"links","label":"NCBI Gene 25937"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25939","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/","field":"links","label":"NCBI Gene 25939"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/25942","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sin3a","kind":"target","name":"SIN3A","route":"/targets/sin3a/","field":"links","label":"NCBI Gene 25942"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26040","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"setbp1","kind":"target","name":"SETBP1","route":"/targets/setbp1/","field":"links","label":"NCBI Gene 26040"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26065","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lsm14a","kind":"target","name":"LSM14A","route":"/targets/lsm14a/","field":"links","label":"NCBI Gene 26065"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26127","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgfr1op2","kind":"target","name":"FGFR1OP2","route":"/targets/fgfr1op2/","field":"links","label":"NCBI Gene 26127"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26137","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zbtb20","kind":"target","name":"ZBTB20","route":"/targets/zbtb20/","field":"links","label":"NCBI Gene 26137"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26191","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn22","kind":"target","name":"PTPN22","route":"/targets/ptpn22/","field":"links","label":"NCBI Gene 26191"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2621","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gas6","kind":"target","name":"GAS6","route":"/targets/gas6/","field":"links","label":"NCBI Gene 2621"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2623","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gata1","kind":"target","name":"GATA1","route":"/targets/gata1/","field":"links","label":"NCBI Gene 2623"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2624","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/","field":"links","label":"NCBI Gene 2624"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2625","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gata3","kind":"target","name":"GATA3","route":"/targets/gata3/","field":"links","label":"NCBI Gene 2625"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26281","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf20","kind":"target","name":"FGF20","route":"/targets/fgf20/","field":"links","label":"NCBI Gene 26281"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2648","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/","field":"links","label":"NCBI Gene 2648"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26524","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lats2","kind":"target","name":"LATS2","route":"/targets/lats2/","field":"links","label":"NCBI Gene 26524"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26528","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dazap1","kind":"target","name":"DAZAP1","route":"/targets/dazap1/","field":"links","label":"NCBI Gene 26528"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26575","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rgs17","kind":"target","name":"RGS17","route":"/targets/rgs17/","field":"links","label":"NCBI Gene 26575"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26579","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myeov","kind":"target","name":"MYEOV","route":"/targets/myeov/","field":"links","label":"NCBI Gene 26579"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26585","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grem1","kind":"target","name":"GREM1","route":"/targets/grem1/","field":"links","label":"NCBI Gene 26585"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26610","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elp4","kind":"target","name":"ELP4","route":"/targets/elp4/","field":"links","label":"NCBI Gene 26610"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2683","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b4galt1","kind":"target","name":"B4GALT1","route":"/targets/b4galt1/","field":"links","label":"NCBI Gene 2683"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2693","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ghsr","kind":"target","name":"GHSR","route":"/targets/ghsr/","field":"links","label":"NCBI Gene 2693"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26960","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/","field":"links","label":"NCBI Gene 26960"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/26986","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/","field":"links","label":"NCBI Gene 26986"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abl2","kind":"target","name":"ABL2","route":"/targets/abl2/","field":"links","label":"NCBI Gene 27"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27006","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf22","kind":"target","name":"FGF22","route":"/targets/fgf22/","field":"links","label":"NCBI Gene 27006"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mlh3","kind":"target","name":"MLH3","route":"/targets/mlh3/","field":"links","label":"NCBI Gene 27030"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27044","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/","field":"links","label":"NCBI Gene 27044"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27086","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/","field":"links","label":"NCBI Gene 27086"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27125","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aff4","kind":"target","name":"AFF4","route":"/targets/aff4/","field":"links","label":"NCBI Gene 27125"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27143","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"NCBI Gene 27143"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27250","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdcd4","kind":"target","name":"PDCD4","route":"/targets/pdcd4/","field":"links","label":"NCBI Gene 27250"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27324","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tox3","kind":"target","name":"TOX3","route":"/targets/tox3/","field":"links","label":"NCBI Gene 27324"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2735","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gli1","kind":"target","name":"GLI1","route":"/targets/gli1/","field":"links","label":"NCBI Gene 2735"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/27436","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eml4","kind":"target","name":"EML4","route":"/targets/eml4/","field":"links","label":"NCBI Gene 27436"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2767","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","field":"links","label":"NCBI Gene 2767"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2771","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gnai2","kind":"target","name":"GNAI2","route":"/targets/gnai2/","field":"links","label":"NCBI Gene 2771"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2776","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","field":"links","label":"NCBI Gene 2776"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2778","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","field":"links","label":"NCBI Gene 2778"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2782","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gnb1","kind":"target","name":"GNB1","route":"/targets/gnb1/","field":"links","label":"NCBI Gene 2782"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/28","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abo","kind":"target","name":"ABO","route":"/targets/abo/","field":"links","label":"NCBI Gene 28"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2803","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"golga4","kind":"target","name":"GOLGA4","route":"/targets/golga4/","field":"links","label":"NCBI Gene 2803"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2804","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"golgb1","kind":"target","name":"GOLGB1","route":"/targets/golgb1/","field":"links","label":"NCBI Gene 2804"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/283149","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl9l","kind":"target","name":"BCL9L","route":"/targets/bcl9l/","field":"links","label":"NCBI Gene 283149"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/283455","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ksr2","kind":"target","name":"KSR2","route":"/targets/ksr2/","field":"links","label":"NCBI Gene 283455"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/283652","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc24a5","kind":"target","name":"SLC24A5","route":"/targets/slc24a5/","field":"links","label":"NCBI Gene 283652"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/284","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"angpt1","kind":"target","name":"ANGPT1","route":"/targets/angpt1/","field":"links","label":"NCBI Gene 284"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/284323","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf780a","kind":"target","name":"ZNF780A","route":"/targets/znf780a/","field":"links","label":"NCBI Gene 284323"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/284656","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha10","kind":"target","name":"EPHA10","route":"/targets/epha10/","field":"links","label":"NCBI Gene 284656"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/28514","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dll1","kind":"target","name":"DLL1","route":"/targets/dll1/","field":"links","label":"NCBI Gene 28514"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/285220","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"epha6","kind":"target","name":"EPHA6","route":"/targets/epha6/","field":"links","label":"NCBI Gene 285220"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/285282","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rabl3","kind":"target","name":"RABL3","route":"/targets/rabl3/","field":"links","label":"NCBI Gene 285282"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/286","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ank1","kind":"target","name":"ANK1","route":"/targets/ank1/","field":"links","label":"NCBI Gene 286"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/286530","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"p2ry8","kind":"target","name":"P2RY8","route":"/targets/p2ry8/","field":"links","label":"NCBI Gene 286530"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2885","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grb2","kind":"target","name":"GRB2","route":"/targets/grb2/","field":"links","label":"NCBI Gene 2885"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/28986","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mageh1","kind":"target","name":"MAGEH1","route":"/targets/mageh1/","field":"links","label":"NCBI Gene 28986"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2903","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grin2a","kind":"target","name":"GRIN2A","route":"/targets/grin2a/","field":"links","label":"NCBI Gene 2903"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29072","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/","field":"links","label":"NCBI Gene 29072"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2909","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/","field":"links","label":"NCBI Gene 2909"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29102","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/","field":"links","label":"NCBI Gene 29102"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29110","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbk1","kind":"target","name":"TBK1","route":"/targets/tbk1/","field":"links","label":"NCBI Gene 29110"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29117","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brd7","kind":"target","name":"BRD7","route":"/targets/brd7/","field":"links","label":"NCBI Gene 29117"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29123","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ankrd11","kind":"target","name":"ANKRD11","route":"/targets/ankrd11/","field":"links","label":"NCBI Gene 29123"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2913","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grm3","kind":"target","name":"GRM3","route":"/targets/grm3/","field":"links","label":"NCBI Gene 2913"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2932","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gsk3b","kind":"target","name":"GSK3B","route":"/targets/gsk3b/","field":"links","label":"NCBI Gene 2932"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2950","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/","field":"links","label":"NCBI Gene 2950"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2956","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/","field":"links","label":"NCBI Gene 2956"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/2969","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gtf2i","kind":"target","name":"GTF2I","route":"/targets/gtf2i/","field":"links","label":"NCBI Gene 2969"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29851","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icos","kind":"target","name":"ICOS","route":"/targets/icos/","field":"links","label":"NCBI Gene 29851"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/29974","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"a1cf","kind":"target","name":"A1CF","route":"/targets/a1cf/","field":"links","label":"NCBI Gene 29974"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/30012","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tlx3","kind":"target","name":"TLX3","route":"/targets/tlx3/","field":"links","label":"NCBI Gene 30012"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3006","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h1-2","kind":"target","name":"H1-2","route":"/targets/h1-2/","field":"links","label":"NCBI Gene 3006"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3007","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h1-3","kind":"target","name":"H1-3","route":"/targets/h1-3/","field":"links","label":"NCBI Gene 3007"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3009","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h1-5","kind":"target","name":"H1-5","route":"/targets/h1-5/","field":"links","label":"NCBI Gene 3009"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3017","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h2bc5","kind":"target","name":"H2BC5","route":"/targets/h2bc5/","field":"links","label":"NCBI Gene 3017"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h3-3b","kind":"target","name":"H3-3B","route":"/targets/h3-3b/","field":"links","label":"NCBI Gene 3021"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3026","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"habp2","kind":"target","name":"HABP2","route":"/targets/habp2/","field":"links","label":"NCBI Gene 3026"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3043","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hbb","kind":"target","name":"HBB","route":"/targets/hbb/","field":"links","label":"NCBI Gene 3043"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3065","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/","field":"links","label":"NCBI Gene HDAC1"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3082","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/","field":"links","label":"NCBI Gene 3082"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/30835","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd209","kind":"target","name":"CD209","route":"/targets/cd209/","field":"links","label":"NCBI Gene 30835"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3084","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"links","label":"NCBI Gene 3084"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/30848","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","field":"links","label":"NCBI Gene 30848"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3091","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hif1a","kind":"target","name":"HIF-1α (HIF1A)","route":"/targets/hif1a/","field":"links","label":"NCBI Gene 3091"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3092","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hip1","kind":"target","name":"HIP1","route":"/targets/hip1/","field":"links","label":"NCBI Gene 3092"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3104","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zbtb48","kind":"target","name":"ZBTB48","route":"/targets/zbtb48/","field":"links","label":"NCBI Gene 3104"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3105","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/","field":"links","label":"NCBI Gene 3105"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3106","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/","field":"links","label":"NCBI Gene 3106"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3107","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/","field":"links","label":"NCBI Gene 3107"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3117","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-dqa1","kind":"target","name":"HLA-DQA1","route":"/targets/hla-dqa1/","field":"links","label":"NCBI Gene 3117"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/","field":"links","label":"NCBI Gene 3122"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3131","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hlf","kind":"target","name":"HLF","route":"/targets/hlf/","field":"links","label":"NCBI Gene 3131"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3133","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hla-e","kind":"target","name":"HLA-E","route":"/targets/hla-e/","field":"links","label":"NCBI Gene 3133"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3156","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hmgcr","kind":"target","name":"HMGCR","route":"/targets/hmgcr/","field":"links","label":"NCBI Gene 3156"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3159","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hmga1","kind":"target","name":"HMGA1","route":"/targets/hmga1/","field":"links","label":"NCBI Gene 3159"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3162","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hmox1","kind":"target","name":"HMOX1","route":"/targets/hmox1/","field":"links","label":"NCBI Gene 3162"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3169","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","field":"links","label":"NCBI Gene 3169"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3170","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxa2","kind":"target","name":"FOXA2","route":"/targets/foxa2/","field":"links","label":"NCBI Gene 3170"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3174","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnf4g","kind":"target","name":"HNF4G","route":"/targets/hnf4g/","field":"links","label":"NCBI Gene 3174"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3181","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnrnpa2b1","kind":"target","name":"HNRNPA2B1","route":"/targets/hnrnpa2b1/","field":"links","label":"NCBI Gene 3181"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnrnph1","kind":"target","name":"HNRNPH1","route":"/targets/hnrnph1/","field":"links","label":"NCBI Gene 3187"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3192","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnrnpu","kind":"target","name":"HNRNPU","route":"/targets/hnrnpu/","field":"links","label":"NCBI Gene 3192"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3195","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tlx1","kind":"target","name":"TLX1","route":"/targets/tlx1/","field":"links","label":"NCBI Gene 3195"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3205","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxa9","kind":"target","name":"HOXA9","route":"/targets/hoxa9/","field":"links","label":"NCBI Gene 3205"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3207","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxa11","kind":"target","name":"HOXA11","route":"/targets/hoxa11/","field":"links","label":"NCBI Gene 3207"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3209","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxa13","kind":"target","name":"HOXA13","route":"/targets/hoxa13/","field":"links","label":"NCBI Gene 3209"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3226","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxc10","kind":"target","name":"HOXC10","route":"/targets/hoxc10/","field":"links","label":"NCBI Gene 3226"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3227","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxc11","kind":"target","name":"HOXC11","route":"/targets/hoxc11/","field":"links","label":"NCBI Gene 3227"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3229","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxc13","kind":"target","name":"HOXC13","route":"/targets/hoxc13/","field":"links","label":"NCBI Gene 3229"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3234","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxd8","kind":"target","name":"HOXD8","route":"/targets/hoxd8/","field":"links","label":"NCBI Gene 3234"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3237","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxd11","kind":"target","name":"HOXD11","route":"/targets/hoxd11/","field":"links","label":"NCBI Gene 3237"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3239","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hoxd13","kind":"target","name":"HOXD13","route":"/targets/hoxd13/","field":"links","label":"NCBI Gene 3239"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/324","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"links","label":"NCBI Gene 324"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3265","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/","field":"links","label":"NCBI Gene 3265"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/330","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/","field":"links","label":"NCBI Gene 330"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3309","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hspa5","kind":"target","name":"HSPA5","route":"/targets/hspa5/","field":"links","label":"NCBI Gene 3309"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3315","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hspb1","kind":"target","name":"HSPB1","route":"/targets/hspb1/","field":"links","label":"NCBI Gene 3315"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/332","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/","field":"links","label":"NCBI Gene 332"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3320","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","field":"links","label":"NCBI Gene 3320"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3326","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hsp90ab1","kind":"target","name":"HSP90AB1","route":"/targets/hsp90ab1/","field":"links","label":"NCBI Gene 3326"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3337","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnajb1","kind":"target","name":"DNAJB1","route":"/targets/dnajb1/","field":"links","label":"NCBI Gene 3337"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3339","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hspg2","kind":"target","name":"HSPG2","route":"/targets/hspg2/","field":"links","label":"NCBI Gene 3339"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3371","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/","field":"links","label":"NCBI Gene 3371"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3394","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irf8","kind":"target","name":"IRF8","route":"/targets/irf8/","field":"links","label":"NCBI Gene 3394"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3399","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"id3","kind":"target","name":"ID3","route":"/targets/id3/","field":"links","label":"NCBI Gene 3399"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/340252","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf680","kind":"target","name":"ZNF680","route":"/targets/znf680/","field":"links","label":"NCBI Gene 340252"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/340419","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rspo2","kind":"target","name":"RSPO2","route":"/targets/rspo2/","field":"links","label":"NCBI Gene 340419"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/340578","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dcaf12l2","kind":"target","name":"DCAF12L2","route":"/targets/dcaf12l2/","field":"links","label":"NCBI Gene 340578"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/342184","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fmn1","kind":"target","name":"FMN1","route":"/targets/fmn1/","field":"links","label":"NCBI Gene 342184"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/342371","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atxn1l","kind":"target","name":"ATXN1L","route":"/targets/atxn1l/","field":"links","label":"NCBI Gene 342371"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3440","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifna2","kind":"target","name":"IFNA2","route":"/targets/ifna2/","field":"links","label":"NCBI Gene 3440"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3455","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/","field":"links","label":"NCBI Gene 3455"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3459","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ifngr1","kind":"target","name":"IFNGR1","route":"/targets/ifngr1/","field":"links","label":"NCBI Gene 3459"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/346389","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"macc1","kind":"target","name":"MACC1","route":"/targets/macc1/","field":"links","label":"NCBI Gene 346389"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/347688","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/","field":"links","label":"NCBI Gene 347688"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/347733","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/","field":"links","label":"NCBI Gene 347733"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/348","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apoe","kind":"target","name":"APOE","route":"/targets/apoe/","field":"links","label":"NCBI Gene 348"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3481","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/","field":"links","label":"NCBI Gene 3481"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3482","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"igf2r","kind":"target","name":"IGF2R","route":"/targets/igf2r/","field":"links","label":"NCBI Gene 3482"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3516","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbpj","kind":"target","name":"RBPJ","route":"/targets/rbpj/","field":"links","label":"NCBI Gene 3516"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/353088","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf429","kind":"target","name":"ZNF429","route":"/targets/znf429/","field":"links","label":"NCBI Gene 353088"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/354","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klk3","kind":"target","name":"KLK3","route":"/targets/klk3/","field":"links","label":"NCBI Gene 354"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/355","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/","field":"links","label":"NCBI Gene 355"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3551","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/","field":"links","label":"NCBI Gene 3551"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3559","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","field":"links","label":"NCBI Gene IL2RA"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3560","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/","field":"links","label":"NCBI Gene 3560"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3561","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/","field":"links","label":"NCBI Gene 3561"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3566","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il4r","kind":"target","name":"IL4R","route":"/targets/il4r/","field":"links","label":"NCBI Gene 3566"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3569","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/","field":"links","label":"NCBI Gene IL6"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3572","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il6st","kind":"target","name":"IL6ST","route":"/targets/il6st/","field":"links","label":"NCBI Gene 3572"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3575","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il7r","kind":"target","name":"IL7R","route":"/targets/il7r/","field":"links","label":"NCBI Gene 3575"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3586","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","field":"links","label":"NCBI Gene 3586"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3604","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/","field":"links","label":"NCBI Gene 3604"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3614","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impdh1","kind":"target","name":"IMPDH1","route":"/targets/impdh1/","field":"links","label":"NCBI Gene 3614"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3619","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"incenp","kind":"target","name":"INCENP","route":"/targets/incenp/","field":"links","label":"NCBI Gene 3619"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3620","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/","field":"links","label":"NCBI Gene 3620"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3621","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ing1","kind":"target","name":"ING1","route":"/targets/ing1/","field":"links","label":"NCBI Gene 3621"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3625","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inhbb","kind":"target","name":"INHBB","route":"/targets/inhbb/","field":"links","label":"NCBI Gene 3625"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3627","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cxcl10","kind":"target","name":"CXCL10","route":"/targets/cxcl10/","field":"links","label":"NCBI Gene 3627"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3636","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inppl1","kind":"target","name":"INPPL1","route":"/targets/inppl1/","field":"links","label":"NCBI Gene 3636"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3646","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/","field":"links","label":"NCBI Gene 3646"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/","field":"links","label":"NCBI Gene 3654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3655","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itga6","kind":"target","name":"ITGA6","route":"/targets/itga6/","field":"links","label":"NCBI Gene 3655"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3659","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/","field":"links","label":"NCBI Gene 3659"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3662","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/","field":"links","label":"NCBI Gene 3662"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3663","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irf5","kind":"target","name":"IRF5","route":"/targets/irf5/","field":"links","label":"NCBI Gene 3663"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3667","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irs1","kind":"target","name":"IRS1","route":"/targets/irs1/","field":"links","label":"NCBI Gene 3667"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3674","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itga2b","kind":"target","name":"ITGA2B","route":"/targets/itga2b/","field":"links","label":"NCBI Gene 3674"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3685","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itgav","kind":"target","name":"ITGAV","route":"/targets/itgav/","field":"links","label":"NCBI Gene 3685"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/369","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/","field":"links","label":"NCBI Gene 369"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3690","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itgb3","kind":"target","name":"ITGB3","route":"/targets/itgb3/","field":"links","label":"NCBI Gene 3690"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3702","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/","field":"links","label":"NCBI Gene 3702"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3707","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itpkb","kind":"target","name":"ITPKB","route":"/targets/itpkb/","field":"links","label":"NCBI Gene 3707"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3708","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"itpr1","kind":"target","name":"ITPR1","route":"/targets/itpr1/","field":"links","label":"NCBI Gene 3708"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3714","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jag2","kind":"target","name":"JAG2","route":"/targets/jag2/","field":"links","label":"NCBI Gene 3714"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3716","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/","field":"links","label":"NCBI Gene 3716"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3718","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/","field":"links","label":"NCBI Gene 3718"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3725","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jun","kind":"target","name":"JUN","route":"/targets/jun/","field":"links","label":"NCBI Gene 3725"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3738","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcna3","kind":"target","name":"KCNA3","route":"/targets/kcna3/","field":"links","label":"NCBI Gene 3738"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3739","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcna4","kind":"target","name":"KCNA4","route":"/targets/kcna4/","field":"links","label":"NCBI Gene 3739"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/374","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"areg","kind":"target","name":"AREG","route":"/targets/areg/","field":"links","label":"NCBI Gene 374"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3747","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnc2","kind":"target","name":"KCNC2","route":"/targets/kcnc2/","field":"links","label":"NCBI Gene 3747"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3751","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnd2","kind":"target","name":"KCND2","route":"/targets/kcnd2/","field":"links","label":"NCBI Gene 3751"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3752","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnd3","kind":"target","name":"KCND3","route":"/targets/kcnd3/","field":"links","label":"NCBI Gene 3752"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3754","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnf1","kind":"target","name":"KCNF1","route":"/targets/kcnf1/","field":"links","label":"NCBI Gene 3754"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3756","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnh1","kind":"target","name":"KCNH1","route":"/targets/kcnh1/","field":"links","label":"NCBI Gene 3756"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3784","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnq1","kind":"target","name":"KCNQ1","route":"/targets/kcnq1/","field":"links","label":"NCBI Gene 3784"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3786","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnq3","kind":"target","name":"KCNQ3","route":"/targets/kcnq3/","field":"links","label":"NCBI Gene 3786"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3799","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kif5b","kind":"target","name":"KIF5B","route":"/targets/kif5b/","field":"links","label":"NCBI Gene 3799"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3802","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kir2dl1","kind":"target","name":"KIR2DL1 (inhibitory KIR)","route":"/targets/kir2dl1/","field":"links","label":"NCBI Gene 3802"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3821","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klrc1","kind":"target","name":"NKG2A (KLRC1)","route":"/targets/klrc1/","field":"links","label":"NCBI Gene 3821"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3831","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klc1","kind":"target","name":"KLC1","route":"/targets/klc1/","field":"links","label":"NCBI Gene 3831"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3852","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"krt5","kind":"target","name":"KRT5","route":"/targets/krt5/","field":"links","label":"NCBI Gene 3852"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/387","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/","field":"links","label":"NCBI Gene 387"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3875","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"krt18","kind":"target","name":"KRT18","route":"/targets/krt18/","field":"links","label":"NCBI Gene 3875"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/387893","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kmt5a","kind":"target","name":"KMT5A","route":"/targets/kmt5a/","field":"links","label":"NCBI Gene 387893"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3895","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ktn1","kind":"target","name":"KTN1","route":"/targets/ktn1/","field":"links","label":"NCBI Gene 3895"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3899","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aff3","kind":"target","name":"AFF3","route":"/targets/aff3/","field":"links","label":"NCBI Gene 3899"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3911","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lama5","kind":"target","name":"LAMA5","route":"/targets/lama5/","field":"links","label":"NCBI Gene 3911"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3915","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lamc1","kind":"target","name":"LAMC1","route":"/targets/lamc1/","field":"links","label":"NCBI Gene 3915"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3925","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stmn1","kind":"target","name":"STMN1","route":"/targets/stmn1/","field":"links","label":"NCBI Gene 3925"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3932","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/","field":"links","label":"NCBI Gene 3932"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/394","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/","field":"links","label":"NCBI Gene 394"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3953","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lepr","kind":"target","name":"LEPR","route":"/targets/lepr/","field":"links","label":"NCBI Gene 3953"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3965","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lgals9","kind":"target","name":"Galectin-9 (LGALS9)","route":"/targets/lgals9/","field":"links","label":"NCBI Gene 3965"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3977","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/","field":"links","label":"NCBI Gene 3977"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/3981","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lig4","kind":"target","name":"LIG4","route":"/targets/lig4/","field":"links","label":"NCBI Gene 3981"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/399","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rhoh","kind":"target","name":"RHOH","route":"/targets/rhoh/","field":"links","label":"NCBI Gene 399"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/399687","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myo18a","kind":"target","name":"MYO18A","route":"/targets/myo18a/","field":"links","label":"NCBI Gene 399687"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmna","kind":"target","name":"LMNA","route":"/targets/lmna/","field":"links","label":"NCBI Gene 4000"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4004","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmo1","kind":"target","name":"LMO1","route":"/targets/lmo1/","field":"links","label":"NCBI Gene 4004"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/400451","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fam174b","kind":"target","name":"FAM174B","route":"/targets/fam174b/","field":"links","label":"NCBI Gene 400451"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4005","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmo2","kind":"target","name":"LMO2","route":"/targets/lmo2/","field":"links","label":"NCBI Gene 4005"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4008","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmo7","kind":"target","name":"LMO7","route":"/targets/lmo7/","field":"links","label":"NCBI Gene 4008"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4010","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lmx1b","kind":"target","name":"LMX1B","route":"/targets/lmx1b/","field":"links","label":"NCBI Gene 4010"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4018","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lpa","kind":"target","name":"LPA","route":"/targets/lpa/","field":"links","label":"NCBI Gene 4018"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4026","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lpp","kind":"target","name":"LPP","route":"/targets/lpp/","field":"links","label":"NCBI Gene 4026"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4041","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lrp5","kind":"target","name":"LRP5","route":"/targets/lrp5/","field":"links","label":"NCBI Gene 4041"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4046","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lsp1","kind":"target","name":"LSP1","route":"/targets/lsp1/","field":"links","label":"NCBI Gene 4046"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/405","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/","field":"links","label":"NCBI Gene 405"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4050","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ltb","kind":"target","name":"LTB","route":"/targets/ltb/","field":"links","label":"NCBI Gene 4050"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4066","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lyl1","kind":"target","name":"LYL1","route":"/targets/lyl1/","field":"links","label":"NCBI Gene 4066"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/406991","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mir21","kind":"target","name":"MIR21","route":"/targets/mir21/","field":"links","label":"NCBI Gene 406991"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/407000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mir218-1","kind":"target","name":"MIR218-1","route":"/targets/mir218-1/","field":"links","label":"NCBI Gene 407000"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/408","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arrb1","kind":"target","name":"ARRB1","route":"/targets/arrb1/","field":"links","label":"NCBI Gene 408"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4087","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smad2","kind":"target","name":"SMAD2","route":"/targets/smad2/","field":"links","label":"NCBI Gene 4087"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4088","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smad3","kind":"target","name":"SMAD3","route":"/targets/smad3/","field":"links","label":"NCBI Gene 4088"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4089","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"links","label":"NCBI Gene 4089"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/409","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arrb2","kind":"target","name":"ARRB2","route":"/targets/arrb2/","field":"links","label":"NCBI Gene 409"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4092","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smad7","kind":"target","name":"SMAD7","route":"/targets/smad7/","field":"links","label":"NCBI Gene 4092"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4094","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/","field":"links","label":"NCBI Gene 4094"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4140","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark3","kind":"target","name":"MARK3","route":"/targets/mark3/","field":"links","label":"NCBI Gene 4140"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4149","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"max","kind":"target","name":"MAX","route":"/targets/max/","field":"links","label":"NCBI Gene 4149"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4157","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mc1r","kind":"target","name":"MC1R","route":"/targets/mc1r/","field":"links","label":"NCBI Gene 4157"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4170","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/","field":"links","label":"NCBI Gene 4170"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4176","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/","field":"links","label":"NCBI Gene 4176"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4194","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mdm4","kind":"target","name":"MDM4","route":"/targets/mdm4/","field":"links","label":"NCBI Gene 4194"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4208","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mef2c","kind":"target","name":"MEF2C","route":"/targets/mef2c/","field":"links","label":"NCBI Gene 4208"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4209","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mef2d","kind":"target","name":"MEF2D","route":"/targets/mef2d/","field":"links","label":"NCBI Gene 4209"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4211","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"meis1","kind":"target","name":"MEIS1","route":"/targets/meis1/","field":"links","label":"NCBI Gene 4211"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4214","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/","field":"links","label":"NCBI Gene 4214"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4254","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kitlg","kind":"target","name":"KITLG","route":"/targets/kitlg/","field":"links","label":"NCBI Gene 4254"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4261","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ciita","kind":"target","name":"CIITA","route":"/targets/ciita/","field":"links","label":"NCBI Gene 4261"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4286","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/","field":"links","label":"NCBI Gene 4286"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/429","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","field":"links","label":"NCBI Gene 429"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4291","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mlf1","kind":"target","name":"MLF1","route":"/targets/mlf1/","field":"links","label":"NCBI Gene 4291"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4292","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","field":"links","label":"NCBI Gene 4292"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4298","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mllt1","kind":"target","name":"MLLT1","route":"/targets/mllt1/","field":"links","label":"NCBI Gene 4298"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4299","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aff1","kind":"target","name":"AFF1","route":"/targets/aff1/","field":"links","label":"NCBI Gene 4299"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4300","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mllt3","kind":"target","name":"MLLT3","route":"/targets/mllt3/","field":"links","label":"NCBI Gene 4300"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4301","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"afdn","kind":"target","name":"AFDN","route":"/targets/afdn/","field":"links","label":"NCBI Gene 4301"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4302","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mllt6","kind":"target","name":"MLLT6","route":"/targets/mllt6/","field":"links","label":"NCBI Gene 4302"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4303","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxo4","kind":"target","name":"FOXO4","route":"/targets/foxo4/","field":"links","label":"NCBI Gene 4303"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4312","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mmp1","kind":"target","name":"MMP1","route":"/targets/mmp1/","field":"links","label":"NCBI Gene 4312"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4313","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mmp2","kind":"target","name":"MMP2","route":"/targets/mmp2/","field":"links","label":"NCBI Gene 4313"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4316","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mmp7","kind":"target","name":"MMP7","route":"/targets/mmp7/","field":"links","label":"NCBI Gene 4316"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4318","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mmp9","kind":"target","name":"MMP9","route":"/targets/mmp9/","field":"links","label":"NCBI Gene 4318"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4330","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mn1","kind":"target","name":"MN1","route":"/targets/mn1/","field":"links","label":"NCBI Gene 4330"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4343","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mov10","kind":"target","name":"MOV10","route":"/targets/mov10/","field":"links","label":"NCBI Gene 4343"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4345","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd200","kind":"target","name":"CD200","route":"/targets/cd200/","field":"links","label":"NCBI Gene 4345"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4352","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mpl","kind":"target","name":"MPL (thrombopoietin receptor)","route":"/targets/mpl/","field":"links","label":"NCBI Gene 4352"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4361","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/","field":"links","label":"NCBI Gene 4361"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4363","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcc1","kind":"target","name":"ABCC1","route":"/targets/abcc1/","field":"links","label":"NCBI Gene 4363"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/440","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/","field":"links","label":"NCBI Gene 440"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/440193","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccdc88c","kind":"target","name":"CCDC88C","route":"/targets/ccdc88c/","field":"links","label":"NCBI Gene 440193"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4436","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","field":"links","label":"NCBI Gene 4436"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4437","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msh3","kind":"target","name":"MSH3","route":"/targets/msh3/","field":"links","label":"NCBI Gene 4437"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/445","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/","field":"links","label":"NCBI Gene 445"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4477","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msmb","kind":"target","name":"MSMB","route":"/targets/msmb/","field":"links","label":"NCBI Gene 4477"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4478","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msn","kind":"target","name":"MSN","route":"/targets/msn/","field":"links","label":"NCBI Gene 4478"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4481","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"msr1","kind":"target","name":"MSR1","route":"/targets/msr1/","field":"links","label":"NCBI Gene 4481"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4512","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mt-co1","kind":"target","name":"MT-CO1","route":"/targets/mt-co1/","field":"links","label":"NCBI Gene 4512"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4515","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mtcp1","kind":"target","name":"MTCP1","route":"/targets/mtcp1/","field":"links","label":"NCBI Gene 4515"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4519","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mt-cyb","kind":"target","name":"MT-CYB","route":"/targets/mt-cyb/","field":"links","label":"NCBI Gene 4519"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4524","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mthfr","kind":"target","name":"MTHFR","route":"/targets/mthfr/","field":"links","label":"NCBI Gene 4524"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4535","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mt-nd1","kind":"target","name":"MT-ND1","route":"/targets/mt-nd1/","field":"links","label":"NCBI Gene 4535"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4541","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mt-nd6","kind":"target","name":"MT-ND6","route":"/targets/mt-nd6/","field":"links","label":"NCBI Gene 4541"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4588","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"muc6","kind":"target","name":"MUC6","route":"/targets/muc6/","field":"links","label":"NCBI Gene 4588"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4595","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/","field":"links","label":"NCBI Gene 4595"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4600","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mx2","kind":"target","name":"MX2","route":"/targets/mx2/","field":"links","label":"NCBI Gene 4600"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4601","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mxi1","kind":"target","name":"MXI1","route":"/targets/mxi1/","field":"links","label":"NCBI Gene 4601"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4602","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/","field":"links","label":"NCBI Gene 4602"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4603","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mybl1","kind":"target","name":"MYBL1","route":"/targets/mybl1/","field":"links","label":"NCBI Gene 4603"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4609","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"links","label":"NCBI Gene 4609"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4610","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/","field":"links","label":"NCBI Gene 4610"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4615","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","field":"links","label":"NCBI Gene 4615"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4627","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/","field":"links","label":"NCBI Gene 4627"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4629","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myh11","kind":"target","name":"MYH11","route":"/targets/myh11/","field":"links","label":"NCBI Gene 4629"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/463","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/","field":"links","label":"NCBI Gene 463"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4644","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/","field":"links","label":"NCBI Gene 4644"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myod1","kind":"target","name":"MYOD1","route":"/targets/myod1/","field":"links","label":"NCBI Gene 4654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/466","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atf1","kind":"target","name":"ATF1","route":"/targets/atf1/","field":"links","label":"NCBI Gene 466"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4665","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nab2","kind":"target","name":"NAB2","route":"/targets/nab2/","field":"links","label":"NCBI Gene 4665"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4666","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naca","kind":"target","name":"NACA","route":"/targets/naca/","field":"links","label":"NCBI Gene 4666"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4683","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/","field":"links","label":"NCBI Gene 4683"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atic","kind":"target","name":"ATIC","route":"/targets/atic/","field":"links","label":"NCBI Gene 471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/472","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"links","label":"NCBI Gene 472"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4739","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nedd9","kind":"target","name":"NEDD9","route":"/targets/nedd9/","field":"links","label":"NCBI Gene 4739"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/476","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atp1a1","kind":"target","name":"ATP1A1","route":"/targets/atp1a1/","field":"links","label":"NCBI Gene 476"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4763","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nf1","kind":"target","name":"NF1 (neurofibromin)","route":"/targets/nf1/","field":"links","label":"NCBI Gene 4763"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4771","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","field":"links","label":"NCBI Gene 4771"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4773","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfatc2","kind":"target","name":"NFATC2","route":"/targets/nfatc2/","field":"links","label":"NCBI Gene 4773"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4780","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","field":"links","label":"NCBI Gene 4780"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4781","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfib","kind":"target","name":"NFIB","route":"/targets/nfib/","field":"links","label":"NCBI Gene 4781"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4791","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfkb2","kind":"target","name":"NFKB2","route":"/targets/nfkb2/","field":"links","label":"NCBI Gene 4791"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4792","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/","field":"links","label":"NCBI Gene 4792"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4794","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfkbie","kind":"target","name":"NFKBIE","route":"/targets/nfkbie/","field":"links","label":"NCBI Gene 4794"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4820","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nktr","kind":"target","name":"NKTR","route":"/targets/nktr/","field":"links","label":"NCBI Gene 4820"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4824","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","field":"links","label":"NCBI Gene 4824"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4849","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnot3","kind":"target","name":"CNOT3","route":"/targets/cnot3/","field":"links","label":"NCBI Gene 4849"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4851","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"links","label":"NCBI Gene 4851"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4853","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/","field":"links","label":"NCBI Gene 4853"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4854","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"notch3","kind":"target","name":"NOTCH3","route":"/targets/notch3/","field":"links","label":"NCBI Gene 4854"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4893","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","field":"links","label":"NCBI Gene 4893"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4913","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nthl1","kind":"target","name":"NTHL1","route":"/targets/nthl1/","field":"links","label":"NCBI Gene 4913"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/492","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atp2b3","kind":"target","name":"ATP2B3","route":"/targets/atp2b3/","field":"links","label":"NCBI Gene 492"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4926","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"numa1","kind":"target","name":"NUMA1","route":"/targets/numa1/","field":"links","label":"NCBI Gene 4926"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4928","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/","field":"links","label":"NCBI Gene 4928"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4929","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nr4a2","kind":"target","name":"NR4A2","route":"/targets/nr4a2/","field":"links","label":"NCBI Gene 4929"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4931","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nvl","kind":"target","name":"NVL","route":"/targets/nvl/","field":"links","label":"NCBI Gene 4931"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4948","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oca2","kind":"target","name":"OCA2","route":"/targets/oca2/","field":"links","label":"NCBI Gene 4948"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atp4a","kind":"target","name":"ATP4A","route":"/targets/atp4a/","field":"links","label":"NCBI Gene 495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/496","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atp4b","kind":"target","name":"ATP4B","route":"/targets/atp4b/","field":"links","label":"NCBI Gene 496"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4968","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ogg1","kind":"target","name":"OGG1","route":"/targets/ogg1/","field":"links","label":"NCBI Gene 4968"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/4998","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"orc1","kind":"target","name":"ORC1","route":"/targets/orc1/","field":"links","label":"NCBI Gene 4998"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5002","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc67a1","kind":"target","name":"SLC67A1","route":"/targets/slc67a1/","field":"links","label":"NCBI Gene 5002"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5013","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"otx1","kind":"target","name":"OTX1","route":"/targets/otx1/","field":"links","label":"NCBI Gene 5013"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/50484","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/","field":"links","label":"NCBI Gene 50484"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/50507","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nox4","kind":"target","name":"NOX4","route":"/targets/nox4/","field":"links","label":"NCBI Gene 50507"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/50636","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ano7","kind":"target","name":"ANO7","route":"/targets/ano7/","field":"links","label":"NCBI Gene 50636"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5071","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/","field":"links","label":"NCBI Gene 5071"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5077","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax3","kind":"target","name":"PAX3","route":"/targets/pax3/","field":"links","label":"NCBI Gene 5077"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5079","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax5","kind":"target","name":"PAX5","route":"/targets/pax5/","field":"links","label":"NCBI Gene 5079"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5080","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax6","kind":"target","name":"PAX6","route":"/targets/pax6/","field":"links","label":"NCBI Gene 5080"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/50805","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irx4","kind":"target","name":"IRX4","route":"/targets/irx4/","field":"links","label":"NCBI Gene 50805"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5081","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax7","kind":"target","name":"PAX7","route":"/targets/pax7/","field":"links","label":"NCBI Gene 5081"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5083","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax9","kind":"target","name":"PAX9","route":"/targets/pax9/","field":"links","label":"NCBI Gene 5083"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5087","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pbx1","kind":"target","name":"PBX1","route":"/targets/pbx1/","field":"links","label":"NCBI Gene 5087"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5093","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcbp1","kind":"target","name":"PCBP1","route":"/targets/pcbp1/","field":"links","label":"NCBI Gene 5093"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/50943","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxp3","kind":"target","name":"FOXP3","route":"/targets/foxp3/","field":"links","label":"NCBI Gene 50943"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51043","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zbtb7b","kind":"target","name":"ZBTB7B","route":"/targets/zbtb7b/","field":"links","label":"NCBI Gene 51043"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51059","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fam135b","kind":"target","name":"FAM135B","route":"/targets/fam135b/","field":"links","label":"NCBI Gene 51059"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51079","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ndufa13","kind":"target","name":"NDUFA13","route":"/targets/ndufa13/","field":"links","label":"NCBI Gene 51079"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5108","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcm1","kind":"target","name":"PCM1","route":"/targets/pcm1/","field":"links","label":"NCBI Gene 5108"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51107","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aph1a","kind":"target","name":"APH1A","route":"/targets/aph1a/","field":"links","label":"NCBI Gene 51107"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5111","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/","field":"links","label":"NCBI Gene 5111"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51119","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sbds","kind":"target","name":"SBDS","route":"/targets/sbds/","field":"links","label":"NCBI Gene 51119"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51151","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc45a2","kind":"target","name":"SLC45A2","route":"/targets/slc45a2/","field":"links","label":"NCBI Gene 51151"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51176","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lef1","kind":"target","name":"LEF1","route":"/targets/lef1/","field":"links","label":"NCBI Gene 51176"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51199","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nin","kind":"target","name":"NIN","route":"/targets/nin/","field":"links","label":"NCBI Gene 51199"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51251","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nt5c3a","kind":"target","name":"NT5C3A","route":"/targets/nt5c3a/","field":"links","label":"NCBI Gene 51251"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51366","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/","field":"links","label":"NCBI Gene 51366"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5139","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pde3a","kind":"target","name":"PDE3A","route":"/targets/pde3a/","field":"links","label":"NCBI Gene 5139"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5140","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pde3b","kind":"target","name":"PDE3B","route":"/targets/pde3b/","field":"links","label":"NCBI Gene 5140"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51426","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"polk","kind":"target","name":"POLK","route":"/targets/polk/","field":"links","label":"NCBI Gene 51426"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51428","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx41","kind":"target","name":"DDX41","route":"/targets/ddx41/","field":"links","label":"NCBI Gene 51428"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51517","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nckipsd","kind":"target","name":"NCKIPSD","route":"/targets/nckipsd/","field":"links","label":"NCBI Gene 51517"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5155","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdgfb","kind":"target","name":"PDGFB","route":"/targets/pdgfb/","field":"links","label":"NCBI Gene 5155"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51564","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/","field":"links","label":"NCBI Gene 51564"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5157","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdgfrl","kind":"target","name":"PDGFRL","route":"/targets/pdgfrl/","field":"links","label":"NCBI Gene 5157"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51592","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trim33","kind":"target","name":"TRIM33","route":"/targets/trim33/","field":"links","label":"NCBI Gene 51592"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51684","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","field":"links","label":"NCBI Gene 51684"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5170","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdpk1","kind":"target","name":"PDPK1","route":"/targets/pdpk1/","field":"links","label":"NCBI Gene 5170"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51741","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wwox","kind":"target","name":"WWOX","route":"/targets/wwox/","field":"links","label":"NCBI Gene 51741"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51750","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rtel1","kind":"target","name":"RTEL1","route":"/targets/rtel1/","field":"links","label":"NCBI Gene 51750"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51755","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","field":"links","label":"NCBI Gene 51755"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51773","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rsf1","kind":"target","name":"RSF1","route":"/targets/rsf1/","field":"links","label":"NCBI Gene 51773"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5178","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peg3","kind":"target","name":"PEG3","route":"/targets/peg3/","field":"links","label":"NCBI Gene 5178"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/51780","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm3b","kind":"target","name":"KDM3B","route":"/targets/kdm3b/","field":"links","label":"NCBI Gene 51780"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"per1","kind":"target","name":"PER1","route":"/targets/per1/","field":"links","label":"NCBI Gene 5187"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5243","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/","field":"links","label":"NCBI Gene 5243"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5291","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/","field":"links","label":"NCBI Gene 5291"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5292","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/","field":"links","label":"NCBI Gene 5292"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3cg","kind":"target","name":"PIK3CG","route":"/targets/pik3cg/","field":"links","label":"NCBI Gene 5294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5295","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/","field":"links","label":"NCBI Gene 5295"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5296","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3r2","kind":"target","name":"PIK3R2","route":"/targets/pik3r2/","field":"links","label":"NCBI Gene 5296"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5297","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pi4ka","kind":"target","name":"PI4KA","route":"/targets/pi4ka/","field":"links","label":"NCBI Gene 5297"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5324","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plag1","kind":"target","name":"PLAG1","route":"/targets/plag1/","field":"links","label":"NCBI Gene 5324"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/53335","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl11a","kind":"target","name":"BCL11A","route":"/targets/bcl11a/","field":"links","label":"NCBI Gene 53335"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5335","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/","field":"links","label":"NCBI Gene 5335"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/53353","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lrp1b","kind":"target","name":"LRP1B","route":"/targets/lrp1b/","field":"links","label":"NCBI Gene 53353"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5336","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","field":"links","label":"NCBI Gene 5336"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5347","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/","field":"links","label":"NCBI Gene 5347"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5371","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pml","kind":"target","name":"PML","route":"/targets/pml/","field":"links","label":"NCBI Gene 5371"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5378","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pms1","kind":"target","name":"PMS1","route":"/targets/pms1/","field":"links","label":"NCBI Gene 5378"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5395","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/","field":"links","label":"NCBI Gene 5395"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/540","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/","field":"links","label":"NCBI Gene 540"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54107","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/","field":"links","label":"NCBI Gene 54107"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54206","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"errfi1","kind":"target","name":"ERRFI1","route":"/targets/errfi1/","field":"links","label":"NCBI Gene 54206"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5424","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","field":"links","label":"NCBI Gene 5424"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5425","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/","field":"links","label":"NCBI Gene 5425"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5426","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","field":"links","label":"NCBI Gene 5426"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5427","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/","field":"links","label":"NCBI Gene 5427"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54487","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dgcr8","kind":"target","name":"DGCR8","route":"/targets/dgcr8/","field":"links","label":"NCBI Gene 54487"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5450","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pou2af1","kind":"target","name":"POU2AF1","route":"/targets/pou2af1/","field":"links","label":"NCBI Gene 5450"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54504","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cpvl","kind":"target","name":"CPVL","route":"/targets/cpvl/","field":"links","label":"NCBI Gene 54504"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54518","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apbb1ip","kind":"target","name":"APBB1IP","route":"/targets/apbb1ip/","field":"links","label":"NCBI Gene 54518"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5452","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pou2f2","kind":"target","name":"POU2F2","route":"/targets/pou2f2/","field":"links","label":"NCBI Gene 5452"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54538","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robo4","kind":"target","name":"ROBO4","route":"/targets/robo4/","field":"links","label":"NCBI Gene 54538"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54567","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/","field":"links","label":"NCBI Gene 54567"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/546","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/","field":"links","label":"NCBI Gene 546"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5460","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pou5f1","kind":"target","name":"POU5F1","route":"/targets/pou5f1/","field":"links","label":"NCBI Gene 5460"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5462","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pou5f1b","kind":"target","name":"POU5F1B","route":"/targets/pou5f1b/","field":"links","label":"NCBI Gene 5462"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54658","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ugt1a1","kind":"target","name":"UGT1A1","route":"/targets/ugt1a1/","field":"links","label":"NCBI Gene 54658"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5468","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/","field":"links","label":"NCBI Gene 5468"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54700","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rrn3","kind":"target","name":"RRN3","route":"/targets/rrn3/","field":"links","label":"NCBI Gene 54700"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppat","kind":"target","name":"PPAT","route":"/targets/ppat/","field":"links","label":"NCBI Gene 5471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54715","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbfox1","kind":"target","name":"RBFOX1","route":"/targets/rbfox1/","field":"links","label":"NCBI Gene 54715"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54738","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fev","kind":"target","name":"FEV","route":"/targets/fev/","field":"links","label":"NCBI Gene 54738"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54790","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tet2","kind":"target","name":"TET2","route":"/targets/tet2/","field":"links","label":"NCBI Gene 54790"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54796","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bnc2","kind":"target","name":"BNC2","route":"/targets/bnc2/","field":"links","label":"NCBI Gene 54796"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54809","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"samd9","kind":"target","name":"SAMD9","route":"/targets/samd9/","field":"links","label":"NCBI Gene 54809"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54845","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esrp1","kind":"target","name":"ESRP1","route":"/targets/esrp1/","field":"links","label":"NCBI Gene 54845"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54847","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sidt1","kind":"target","name":"SIDT1","route":"/targets/sidt1/","field":"links","label":"NCBI Gene 54847"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54855","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/","field":"links","label":"NCBI Gene 54855"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54880","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcor","kind":"target","name":"BCOR","route":"/targets/bcor/","field":"links","label":"NCBI Gene 54880"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54894","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"links","label":"NCBI Gene 54894"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54897","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"casz1","kind":"target","name":"CASZ1","route":"/targets/casz1/","field":"links","label":"NCBI Gene 54897"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54901","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdkal1","kind":"target","name":"CDKAL1","route":"/targets/cdkal1/","field":"links","label":"NCBI Gene 54901"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54904","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsd3","kind":"target","name":"NSD3","route":"/targets/nsd3/","field":"links","label":"NCBI Gene 54904"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54908","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spdl1","kind":"target","name":"SPDL1","route":"/targets/spdl1/","field":"links","label":"NCBI Gene 54908"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/54949","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/","field":"links","label":"NCBI Gene 54949"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppm1b","kind":"target","name":"PPM1B","route":"/targets/ppm1b/","field":"links","label":"NCBI Gene 5495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55039","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tyw2","kind":"target","name":"TYW2","route":"/targets/tyw2/","field":"links","label":"NCBI Gene 55039"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55109","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aggf1","kind":"target","name":"AGGF1","route":"/targets/aggf1/","field":"links","label":"NCBI Gene 55109"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55120","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancl","kind":"target","name":"FANCL","route":"/targets/fancl/","field":"links","label":"NCBI Gene 55120"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55135","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wrap53","kind":"target","name":"WRAP53","route":"/targets/wrap53/","field":"links","label":"NCBI Gene 55135"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5515","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2ca","kind":"target","name":"PPP2CA","route":"/targets/ppp2ca/","field":"links","label":"NCBI Gene 5515"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55159","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rfwd3","kind":"target","name":"RFWD3","route":"/targets/rfwd3/","field":"links","label":"NCBI Gene 55159"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5516","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2cb","kind":"target","name":"PPP2CB","route":"/targets/ppp2cb/","field":"links","label":"NCBI Gene 5516"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55160","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgef10l","kind":"target","name":"ARHGEF10L","route":"/targets/arhgef10l/","field":"links","label":"NCBI Gene 55160"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5518","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/","field":"links","label":"NCBI Gene 5518"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5519","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r1b","kind":"target","name":"PPP2R1B","route":"/targets/ppp2r1b/","field":"links","label":"NCBI Gene 5519"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55193","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/","field":"links","label":"NCBI Gene 55193"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5520","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r2a","kind":"target","name":"PPP2R2A","route":"/targets/ppp2r2a/","field":"links","label":"NCBI Gene 5520"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55215","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fanci","kind":"target","name":"FANCI","route":"/targets/fanci/","field":"links","label":"NCBI Gene 55215"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5525","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r5a","kind":"target","name":"PPP2R5A","route":"/targets/ppp2r5a/","field":"links","label":"NCBI Gene 5525"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55252","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asxl2","kind":"target","name":"ASXL2","route":"/targets/asxl2/","field":"links","label":"NCBI Gene 55252"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5526","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r5b","kind":"target","name":"PPP2R5B","route":"/targets/ppp2r5b/","field":"links","label":"NCBI Gene 5526"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55269","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pspc1","kind":"target","name":"PSPC1","route":"/targets/pspc1/","field":"links","label":"NCBI Gene 55269"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5527","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r5c","kind":"target","name":"PPP2R5C","route":"/targets/ppp2r5c/","field":"links","label":"NCBI Gene 5527"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55270","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nudt15","kind":"target","name":"NUDT15","route":"/targets/nudt15/","field":"links","label":"NCBI Gene 55270"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55275","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vps53","kind":"target","name":"VPS53","route":"/targets/vps53/","field":"links","label":"NCBI Gene 55275"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5528","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r5d","kind":"target","name":"PPP2R5D","route":"/targets/ppp2r5d/","field":"links","label":"NCBI Gene 5528"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55289","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acoxl","kind":"target","name":"ACOXL","route":"/targets/acoxl/","field":"links","label":"NCBI Gene 55289"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5529","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp2r5e","kind":"target","name":"PPP2R5E","route":"/targets/ppp2r5e/","field":"links","label":"NCBI Gene 5529"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","field":"links","label":"NCBI Gene 55294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5530","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp3ca","kind":"target","name":"PPP3CA","route":"/targets/ppp3ca/","field":"links","label":"NCBI Gene 5530"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5537","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp6c","kind":"target","name":"PPP6C","route":"/targets/ppp6c/","field":"links","label":"NCBI Gene 5537"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55422","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf331","kind":"target","name":"ZNF331","route":"/targets/znf331/","field":"links","label":"NCBI Gene 55422"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5546","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","field":"links","label":"NCBI Gene 5546"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55500","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"etnk1","kind":"target","name":"ETNK1","route":"/targets/etnk1/","field":"links","label":"NCBI Gene 55500"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5551","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prf1","kind":"target","name":"PRF1","route":"/targets/prf1/","field":"links","label":"NCBI Gene 5551"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55510","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ddx43","kind":"target","name":"DDX43","route":"/targets/ddx43/","field":"links","label":"NCBI Gene 55510"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55534","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maml3","kind":"target","name":"MAML3","route":"/targets/maml3/","field":"links","label":"NCBI Gene 55534"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55544","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbm38","kind":"target","name":"RBM38","route":"/targets/rbm38/","field":"links","label":"NCBI Gene 55544"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5557","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/","field":"links","label":"NCBI Gene 5557"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5558","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/","field":"links","label":"NCBI Gene 5558"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55596","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zcchc8","kind":"target","name":"ZCCHC8","route":"/targets/zcchc8/","field":"links","label":"NCBI Gene 55596"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5563","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkaa2","kind":"target","name":"PRKAA2","route":"/targets/prkaa2/","field":"links","label":"NCBI Gene 5563"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55636","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chd7","kind":"target","name":"CHD7","route":"/targets/chd7/","field":"links","label":"NCBI Gene 55636"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tmem127","kind":"target","name":"TMEM127","route":"/targets/tmem127/","field":"links","label":"NCBI Gene 55654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5566","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkaca","kind":"target","name":"PRKACA","route":"/targets/prkaca/","field":"links","label":"NCBI Gene 5566"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55728","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"n4bp2","kind":"target","name":"N4BP2","route":"/targets/n4bp2/","field":"links","label":"NCBI Gene 55728"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55729","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atf7ip","kind":"target","name":"ATF7IP","route":"/targets/atf7ip/","field":"links","label":"NCBI Gene 55729"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5573","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkar1a","kind":"target","name":"PRKAR1A","route":"/targets/prkar1a/","field":"links","label":"NCBI Gene 5573"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55749","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccar1","kind":"target","name":"CCAR1","route":"/targets/ccar1/","field":"links","label":"NCBI Gene 55749"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55750","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agk","kind":"target","name":"AGK","route":"/targets/agk/","field":"links","label":"NCBI Gene 55750"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55754","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdc50a","kind":"target","name":"CDC50A","route":"/targets/cdc50a/","field":"links","label":"NCBI Gene 55754"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55759","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wdr12","kind":"target","name":"WDR12","route":"/targets/wdr12/","field":"links","label":"NCBI Gene 55759"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55783","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/","field":"links","label":"NCBI Gene 55783"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5579","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkcb","kind":"target","name":"PRKCB","route":"/targets/prkcb/","field":"links","label":"NCBI Gene 5579"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5580","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkcd","kind":"target","name":"PRKCD","route":"/targets/prkcd/","field":"links","label":"NCBI Gene 5580"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5581","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkce","kind":"target","name":"PRKCE","route":"/targets/prkce/","field":"links","label":"NCBI Gene 5581"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5582","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkcg","kind":"target","name":"PRKCG","route":"/targets/prkcg/","field":"links","label":"NCBI Gene 5582"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5583","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkch","kind":"target","name":"PRKCH","route":"/targets/prkch/","field":"links","label":"NCBI Gene 5583"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5584","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkci","kind":"target","name":"PRKCI","route":"/targets/prkci/","field":"links","label":"NCBI Gene 5584"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55851","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psenen","kind":"target","name":"PSENEN","route":"/targets/psenen/","field":"links","label":"NCBI Gene 55851"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55869","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/","field":"links","label":"NCBI Gene 55869"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5587","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkd1","kind":"target","name":"PRKD1","route":"/targets/prkd1/","field":"links","label":"NCBI Gene 5587"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55872","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pbk","kind":"target","name":"PBK","route":"/targets/pbk/","field":"links","label":"NCBI Gene 55872"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5588","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkcq","kind":"target","name":"PRKCQ","route":"/targets/prkcq/","field":"links","label":"NCBI Gene 5588"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55893","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf395","kind":"target","name":"ZNF395","route":"/targets/znf395/","field":"links","label":"NCBI Gene 55893"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5590","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkcz","kind":"target","name":"PRKCZ","route":"/targets/prkcz/","field":"links","label":"NCBI Gene 5590"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5591","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prkdc","kind":"target","name":"PRKDC","route":"/targets/prkdc/","field":"links","label":"NCBI Gene 5591"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55914","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erbin","kind":"target","name":"ERBIN","route":"/targets/erbin/","field":"links","label":"NCBI Gene 55914"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/55920","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rcc2","kind":"target","name":"RCC2","route":"/targets/rcc2/","field":"links","label":"NCBI Gene 55920"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5594","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/","field":"links","label":"NCBI Gene 5594"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5595","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/","field":"links","label":"NCBI Gene 5595"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5599","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mapk8","kind":"target","name":"MAPK8","route":"/targets/mapk8/","field":"links","label":"NCBI Gene 5599"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5600","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mapk11","kind":"target","name":"MAPK11","route":"/targets/mapk11/","field":"links","label":"NCBI Gene 5600"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5601","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mapk9","kind":"target","name":"MAPK9","route":"/targets/mapk9/","field":"links","label":"NCBI Gene 5601"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5604","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","field":"links","label":"NCBI Gene MAP2K1"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5605","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","field":"links","label":"NCBI Gene MAP2K2"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5609","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"map2k7","kind":"target","name":"MAP2K7","route":"/targets/map2k7/","field":"links","label":"NCBI Gene 5609"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56241","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"susd2","kind":"target","name":"SUSD2","route":"/targets/susd2/","field":"links","label":"NCBI Gene 56241"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5631","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prps1","kind":"target","name":"PRPS1","route":"/targets/prps1/","field":"links","label":"NCBI Gene 5631"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56479","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnq5","kind":"target","name":"KCNQ5","route":"/targets/kcnq5/","field":"links","label":"NCBI Gene 56479"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5664","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psen2","kind":"target","name":"PSEN2","route":"/targets/psen2/","field":"links","label":"NCBI Gene 5664"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56655","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pole4","kind":"target","name":"POLE4","route":"/targets/pole4/","field":"links","label":"NCBI Gene 56655"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/567","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","field":"links","label":"NCBI Gene 567"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56776","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fmn2","kind":"target","name":"FMN2","route":"/targets/fmn2/","field":"links","label":"NCBI Gene 56776"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5682","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/","field":"links","label":"NCBI Gene 5682"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56829","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zc3hav1","kind":"target","name":"ZC3HAV1","route":"/targets/zc3hav1/","field":"links","label":"NCBI Gene 56829"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5683","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/","field":"links","label":"NCBI Gene 5683"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5684","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/","field":"links","label":"NCBI Gene 5684"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5685","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/","field":"links","label":"NCBI Gene 5685"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5686","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/","field":"links","label":"NCBI Gene 5686"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5687","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/","field":"links","label":"NCBI Gene 5687"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5688","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/","field":"links","label":"NCBI Gene 5688"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5689","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/","field":"links","label":"NCBI Gene 5689"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5690","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/","field":"links","label":"NCBI Gene 5690"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5691","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/","field":"links","label":"NCBI Gene 5691"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5692","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/","field":"links","label":"NCBI Gene 5692"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5694","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/","field":"links","label":"NCBI Gene 5694"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56946","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/","field":"links","label":"NCBI Gene 56946"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5695","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/","field":"links","label":"NCBI Gene 5695"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5696","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/","field":"links","label":"NCBI Gene 5696"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5698","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/","field":"links","label":"NCBI Gene 5698"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5699","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/","field":"links","label":"NCBI Gene 5699"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/56999","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/","field":"links","label":"NCBI Gene 56999"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5700","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/","field":"links","label":"NCBI Gene 5700"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57007","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/","field":"links","label":"NCBI Gene 57007"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5701","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/","field":"links","label":"NCBI Gene 5701"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5702","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/","field":"links","label":"NCBI Gene 5702"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5704","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/","field":"links","label":"NCBI Gene 5704"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5705","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/","field":"links","label":"NCBI Gene 5705"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5706","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/","field":"links","label":"NCBI Gene 5706"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5707","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/","field":"links","label":"NCBI Gene 5707"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5708","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/","field":"links","label":"NCBI Gene 5708"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57082","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"knl1","kind":"target","name":"KNL1","route":"/targets/knl1/","field":"links","label":"NCBI Gene 57082"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57085","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"agtrap","kind":"target","name":"AGTRAP","route":"/targets/agtrap/","field":"links","label":"NCBI Gene 57085"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5709","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/","field":"links","label":"NCBI Gene 5709"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5710","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/","field":"links","label":"NCBI Gene 5710"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57105","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","field":"links","label":"NCBI Gene 57105"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57120","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gopc","kind":"target","name":"GOPC","route":"/targets/gopc/","field":"links","label":"NCBI Gene 57120"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5713","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/","field":"links","label":"NCBI Gene 5713"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5714","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/","field":"links","label":"NCBI Gene 5714"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57167","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sall4","kind":"target","name":"SALL4","route":"/targets/sall4/","field":"links","label":"NCBI Gene 57167"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5717","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/","field":"links","label":"NCBI Gene 5717"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57178","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zmiz1","kind":"target","name":"ZMIZ1","route":"/targets/zmiz1/","field":"links","label":"NCBI Gene 57178"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5718","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/","field":"links","label":"NCBI Gene 5718"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5719","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/","field":"links","label":"NCBI Gene 5719"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5727","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptch1","kind":"target","name":"PTCH1 (Patched 1)","route":"/targets/ptch1/","field":"links","label":"NCBI Gene 5727"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5742","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptgs1","kind":"target","name":"PTGS1","route":"/targets/ptgs1/","field":"links","label":"NCBI Gene 5742"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57448","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birc6","kind":"target","name":"BIRC6","route":"/targets/birc6/","field":"links","label":"NCBI Gene 57448"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5747","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fak","kind":"target","name":"FAK (PTK2)","route":"/targets/fak/","field":"links","label":"NCBI Gene 5747"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57492","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/","field":"links","label":"NCBI Gene 57492"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57497","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lrfn2","kind":"target","name":"LRFN2","route":"/targets/lrfn2/","field":"links","label":"NCBI Gene 57497"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57522","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srgap1","kind":"target","name":"SRGAP1","route":"/targets/srgap1/","field":"links","label":"NCBI Gene 57522"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57565","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klhl14","kind":"target","name":"KLHL14","route":"/targets/klhl14/","field":"links","label":"NCBI Gene 57565"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5757","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptma","kind":"target","name":"PTMA","route":"/targets/ptma/","field":"links","label":"NCBI Gene 5757"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57591","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mrtfa","kind":"target","name":"MRTFA","route":"/targets/mrtfa/","field":"links","label":"NCBI Gene 57591"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57646","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usp28","kind":"target","name":"USP28","route":"/targets/usp28/","field":"links","label":"NCBI Gene 57646"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57650","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cip2a","kind":"target","name":"CIP2A","route":"/targets/cip2a/","field":"links","label":"NCBI Gene 57650"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57670","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kiaa1549","kind":"target","name":"KIAA1549","route":"/targets/kiaa1549/","field":"links","label":"NCBI Gene 57670"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57674","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rnf213","kind":"target","name":"RNF213","route":"/targets/rnf213/","field":"links","label":"NCBI Gene 57674"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57680","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chd8","kind":"target","name":"CHD8","route":"/targets/chd8/","field":"links","label":"NCBI Gene 57680"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57697","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/","field":"links","label":"NCBI Gene 57697"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57698","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shtn1","kind":"target","name":"SHTN1","route":"/targets/shtn1/","field":"links","label":"NCBI Gene 57698"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5774","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn3","kind":"target","name":"PTPN3","route":"/targets/ptpn3/","field":"links","label":"NCBI Gene 5774"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5777","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn6","kind":"target","name":"PTPN6","route":"/targets/ptpn6/","field":"links","label":"NCBI Gene 5777"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/578","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bak1","kind":"target","name":"BAK1","route":"/targets/bak1/","field":"links","label":"NCBI Gene 578"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57804","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/","field":"links","label":"NCBI Gene 57804"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5781","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/","field":"links","label":"NCBI Gene 5781"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5782","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn12","kind":"target","name":"PTPN12","route":"/targets/ptpn12/","field":"links","label":"NCBI Gene 5782"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/57820","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnb1ip1","kind":"target","name":"CCNB1IP1","route":"/targets/ccnb1ip1/","field":"links","label":"NCBI Gene 57820"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5783","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn13","kind":"target","name":"PTPN13","route":"/targets/ptpn13/","field":"links","label":"NCBI Gene 5783"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5784","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptpn14","kind":"target","name":"PTPN14","route":"/targets/ptpn14/","field":"links","label":"NCBI Gene 5784"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5787","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/","field":"links","label":"NCBI Gene 5787"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5788","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprc","kind":"target","name":"PTPRC","route":"/targets/ptprc/","field":"links","label":"NCBI Gene 5788"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5789","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/","field":"links","label":"NCBI Gene 5789"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5792","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprf","kind":"target","name":"PTPRF","route":"/targets/ptprf/","field":"links","label":"NCBI Gene 5792"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5796","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ptprk","kind":"target","name":"PTPRK","route":"/targets/ptprk/","field":"links","label":"NCBI Gene 5796"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/58","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acta1","kind":"target","name":"ACTA1","route":"/targets/acta1/","field":"links","label":"NCBI Gene 58"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/580","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/","field":"links","label":"NCBI Gene 580"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/581","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bax","kind":"target","name":"BAX","route":"/targets/bax/","field":"links","label":"NCBI Gene 581"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5817","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/","field":"links","label":"NCBI Gene 5817"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5819","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/","field":"links","label":"NCBI Gene 5819"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/58495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ovol2","kind":"target","name":"OVOL2","route":"/targets/ovol2/","field":"links","label":"NCBI Gene 58495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/58499","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf462","kind":"target","name":"ZNF462","route":"/targets/znf462/","field":"links","label":"NCBI Gene 58499"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/58508","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","field":"links","label":"NCBI Gene 58508"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5879","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rac1","kind":"target","name":"RAC1","route":"/targets/rac1/","field":"links","label":"NCBI Gene 5879"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5885","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad21","kind":"target","name":"RAD21","route":"/targets/rad21/","field":"links","label":"NCBI Gene 5885"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5887","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad23b","kind":"target","name":"RAD23B","route":"/targets/rad23b/","field":"links","label":"NCBI Gene 5887"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5888","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad51","kind":"target","name":"RAD51","route":"/targets/rad51/","field":"links","label":"NCBI Gene 5888"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5889","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/","field":"links","label":"NCBI Gene 5889"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5890","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/","field":"links","label":"NCBI Gene 5890"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5892","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/","field":"links","label":"NCBI Gene 5892"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/59","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acta2","kind":"target","name":"ACTA2","route":"/targets/acta2/","field":"links","label":"NCBI Gene 59"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5903","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ranbp2","kind":"target","name":"RANBP2","route":"/targets/ranbp2/","field":"links","label":"NCBI Gene 5903"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5906","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rap1a","kind":"target","name":"RAP1A","route":"/targets/rap1a/","field":"links","label":"NCBI Gene 5906"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5908","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rap1b","kind":"target","name":"RAP1B","route":"/targets/rap1b/","field":"links","label":"NCBI Gene 5908"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5910","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rap1gds1","kind":"target","name":"RAP1GDS1","route":"/targets/rap1gds1/","field":"links","label":"NCBI Gene 5910"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5915","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rarb","kind":"target","name":"RARB","route":"/targets/rarb/","field":"links","label":"NCBI Gene 5915"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5916","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rarg","kind":"target","name":"RARG","route":"/targets/rarg/","field":"links","label":"NCBI Gene 5916"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5921","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rasa1","kind":"target","name":"RASA1","route":"/targets/rasa1/","field":"links","label":"NCBI Gene 5921"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5922","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rasa2","kind":"target","name":"RASA2","route":"/targets/rasa2/","field":"links","label":"NCBI Gene 5922"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5925","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"links","label":"NCBI Gene 5925"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5927","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm5a","kind":"target","name":"KDM5A","route":"/targets/kdm5a/","field":"links","label":"NCBI Gene 5927"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5931","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbbp7","kind":"target","name":"RBBP7","route":"/targets/rbbp7/","field":"links","label":"NCBI Gene 5931"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5932","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbbp8","kind":"target","name":"RBBP8","route":"/targets/rbbp8/","field":"links","label":"NCBI Gene 5932"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/595","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","field":"links","label":"NCBI Gene 595"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5966","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/","field":"links","label":"NCBI Gene 5966"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5970","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rela","kind":"target","name":"RELA","route":"/targets/rela/","field":"links","label":"NCBI Gene 5970"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5978","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rest","kind":"target","name":"REST","route":"/targets/rest/","field":"links","label":"NCBI Gene 5978"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/5987","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trim27","kind":"target","name":"TRIM27","route":"/targets/trim27/","field":"links","label":"NCBI Gene 5987"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/60","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"actb","kind":"target","name":"ACTB","route":"/targets/actb/","field":"links","label":"NCBI Gene 60"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rgs7","kind":"target","name":"RGS7","route":"/targets/rgs7/","field":"links","label":"NCBI Gene 6000"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6009","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rheb","kind":"target","name":"RHEB","route":"/targets/rheb/","field":"links","label":"NCBI Gene 6009"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6016","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rit1","kind":"target","name":"RIT1","route":"/targets/rit1/","field":"links","label":"NCBI Gene 6016"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/602","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl3","kind":"target","name":"BCL3","route":"/targets/bcl3/","field":"links","label":"NCBI Gene 602"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/604","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/","field":"links","label":"NCBI Gene 604"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6041","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rnasel","kind":"target","name":"RNASEL","route":"/targets/rnasel/","field":"links","label":"NCBI Gene 6041"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/60468","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bach2","kind":"target","name":"BACH2","route":"/targets/bach2/","field":"links","label":"NCBI Gene 60468"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6049","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rnf6","kind":"target","name":"RNF6","route":"/targets/rnf6/","field":"links","label":"NCBI Gene 6049"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/605","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/","field":"links","label":"NCBI Gene 605"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/60528","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elac2","kind":"target","name":"ELAC2","route":"/targets/elac2/","field":"links","label":"NCBI Gene 60528"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/60676","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pappa2","kind":"target","name":"PAPPA2","route":"/targets/pappa2/","field":"links","label":"NCBI Gene 60676"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/607","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl9","kind":"target","name":"BCL9","route":"/targets/bcl9/","field":"links","label":"NCBI Gene 607"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6092","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"robo2","kind":"target","name":"ROBO2","route":"/targets/robo2/","field":"links","label":"NCBI Gene 6092"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6125","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rpl5","kind":"target","name":"RPL5","route":"/targets/rpl5/","field":"links","label":"NCBI Gene 6125"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6134","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/","field":"links","label":"NCBI Gene 6134"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6146","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rpl22","kind":"target","name":"RPL22","route":"/targets/rpl22/","field":"links","label":"NCBI Gene 6146"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6189","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/","field":"links","label":"NCBI Gene 6189"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6194","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps6","kind":"target","name":"RPS6","route":"/targets/rps6/","field":"links","label":"NCBI Gene 6194"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6197","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps6ka3","kind":"target","name":"RPS6KA3","route":"/targets/rps6ka3/","field":"links","label":"NCBI Gene 6197"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6201","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps7","kind":"target","name":"RPS7","route":"/targets/rps7/","field":"links","label":"NCBI Gene 6201"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6223","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps19","kind":"target","name":"RPS19","route":"/targets/rps19/","field":"links","label":"NCBI Gene 6223"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6229","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps24","kind":"target","name":"RPS24","route":"/targets/rps24/","field":"links","label":"NCBI Gene 6229"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6231","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps26","kind":"target","name":"RPS26","route":"/targets/rps26/","field":"links","label":"NCBI Gene 6231"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6232","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps27","kind":"target","name":"RPS27","route":"/targets/rps27/","field":"links","label":"NCBI Gene 6232"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6233","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps27a","kind":"target","name":"RPS27A","route":"/targets/rps27a/","field":"links","label":"NCBI Gene 6233"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6235","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rps29","kind":"target","name":"RPS29","route":"/targets/rps29/","field":"links","label":"NCBI Gene 6235"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6241","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/","field":"links","label":"NCBI Gene 6241"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6249","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/","field":"links","label":"NCBI Gene 6249"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6256","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rxr","kind":"target","name":"Retinoid X receptor (RXR)","route":"/targets/rxr/","field":"links","label":"NCBI Gene RXRA"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6285","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"s100b","kind":"target","name":"S100B","route":"/targets/s100b/","field":"links","label":"NCBI Gene 6285"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6296","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acsm3","kind":"target","name":"ACSM3","route":"/targets/acsm3/","field":"links","label":"NCBI Gene 6296"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/63035","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/","field":"links","label":"NCBI Gene 63035"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6314","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atxn7","kind":"target","name":"ATXN7","route":"/targets/atxn7/","field":"links","label":"NCBI Gene 6314"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6323","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn1a","kind":"target","name":"SCN1A","route":"/targets/scn1a/","field":"links","label":"NCBI Gene 6323"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6326","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn2a","kind":"target","name":"SCN2A","route":"/targets/scn2a/","field":"links","label":"NCBI Gene 6326"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6328","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn3a","kind":"target","name":"SCN3A","route":"/targets/scn3a/","field":"links","label":"NCBI Gene 6328"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6329","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn4a","kind":"target","name":"SCN4A","route":"/targets/scn4a/","field":"links","label":"NCBI Gene 6329"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6331","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn5a","kind":"target","name":"SCN5A","route":"/targets/scn5a/","field":"links","label":"NCBI Gene 6331"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6332","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn7a","kind":"target","name":"SCN7A","route":"/targets/scn7a/","field":"links","label":"NCBI Gene 6332"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6334","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn8a","kind":"target","name":"SCN8A","route":"/targets/scn8a/","field":"links","label":"NCBI Gene 6334"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6335","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn9a","kind":"target","name":"SCN9A","route":"/targets/scn9a/","field":"links","label":"NCBI Gene 6335"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6336","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"scn10a","kind":"target","name":"SCN10A","route":"/targets/scn10a/","field":"links","label":"NCBI Gene 6336"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/634","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ceacam1","kind":"target","name":"CEACAM1","route":"/targets/ceacam1/","field":"links","label":"NCBI Gene 634"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6376","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cx3cl1","kind":"target","name":"CX3CL1","route":"/targets/cx3cl1/","field":"links","label":"NCBI Gene 6376"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/638","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bik","kind":"target","name":"BIK","route":"/targets/bik/","field":"links","label":"NCBI Gene 638"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6385","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdc4","kind":"target","name":"SDC4","route":"/targets/sdc4/","field":"links","label":"NCBI Gene 6385"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6386","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdcbp","kind":"target","name":"SDCBP","route":"/targets/sdcbp/","field":"links","label":"NCBI Gene 6386"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6389","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","field":"links","label":"NCBI Gene 6389"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/639","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/","field":"links","label":"NCBI Gene 639"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6390","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdhb","kind":"target","name":"SDHB","route":"/targets/sdhb/","field":"links","label":"NCBI Gene 6390"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6391","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdhc","kind":"target","name":"SDHC","route":"/targets/sdhc/","field":"links","label":"NCBI Gene 6391"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6392","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sdhd","kind":"target","name":"SDHD","route":"/targets/sdhd/","field":"links","label":"NCBI Gene 6392"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/63976","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/","field":"links","label":"NCBI Gene 63976"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/640","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blk","kind":"target","name":"BLK","route":"/targets/blk/","field":"links","label":"NCBI Gene 640"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64081","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pbld","kind":"target","name":"PBLD","route":"/targets/pbld/","field":"links","label":"NCBI Gene 64081"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/641","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/","field":"links","label":"NCBI Gene 641"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64109","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crlf2","kind":"target","name":"CRLF2","route":"/targets/crlf2/","field":"links","label":"NCBI Gene 64109"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64121","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rragc","kind":"target","name":"RRAGC","route":"/targets/rragc/","field":"links","label":"NCBI Gene 64121"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6416","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"map2k4","kind":"target","name":"MAP2K4","route":"/targets/map2k4/","field":"links","label":"NCBI Gene 6416"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/641700","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ecscr","kind":"target","name":"ECSCR","route":"/targets/ecscr/","field":"links","label":"NCBI Gene 641700"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6418","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"set","kind":"target","name":"SET","route":"/targets/set/","field":"links","label":"NCBI Gene 6418"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6421","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sfpq","kind":"target","name":"SFPQ","route":"/targets/sfpq/","field":"links","label":"NCBI Gene 6421"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64215","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnajc1","kind":"target","name":"DNAJC1","route":"/targets/dnajc1/","field":"links","label":"NCBI Gene 64215"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6424","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sfrp4","kind":"target","name":"SFRP4","route":"/targets/sfrp4/","field":"links","label":"NCBI Gene 6424"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/642612","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trim49c","kind":"target","name":"TRIM49C","route":"/targets/trim49c/","field":"links","label":"NCBI Gene 642612"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6427","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srsf2","kind":"target","name":"SRSF2","route":"/targets/srsf2/","field":"links","label":"NCBI Gene 6427"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6428","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srsf3","kind":"target","name":"SRSF3","route":"/targets/srsf3/","field":"links","label":"NCBI Gene 6428"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64321","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sox17","kind":"target","name":"SOX17","route":"/targets/sox17/","field":"links","label":"NCBI Gene 64321"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64324","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/","field":"links","label":"NCBI Gene 64324"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64332","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nfkbiz","kind":"target","name":"NFKBIZ","route":"/targets/nfkbiz/","field":"links","label":"NCBI Gene 64332"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64399","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hhip","kind":"target","name":"HHIP","route":"/targets/hhip/","field":"links","label":"NCBI Gene 64399"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6446","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sgk1","kind":"target","name":"SGK1","route":"/targets/sgk1/","field":"links","label":"NCBI Gene 6446"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6455","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sh3gl1","kind":"target","name":"SH3GL1","route":"/targets/sh3gl1/","field":"links","label":"NCBI Gene 6455"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6464","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shc1","kind":"target","name":"SHC1","route":"/targets/shc1/","field":"links","label":"NCBI Gene 6464"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64641","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ebf2","kind":"target","name":"EBF2","route":"/targets/ebf2/","field":"links","label":"NCBI Gene 64641"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64759","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tns3","kind":"target","name":"TNS3","route":"/targets/tns3/","field":"links","label":"NCBI Gene 64759"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64764","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"creb3l2","kind":"target","name":"CREB3L2","route":"/targets/creb3l2/","field":"links","label":"NCBI Gene 64764"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64778","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fndc3b","kind":"target","name":"FNDC3B","route":"/targets/fndc3b/","field":"links","label":"NCBI Gene 64778"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64783","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbm15","kind":"target","name":"RBM15","route":"/targets/rbm15/","field":"links","label":"NCBI Gene 64783"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64784","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"crtc3","kind":"target","name":"CRTC3","route":"/targets/crtc3/","field":"links","label":"NCBI Gene 64784"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64858","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","field":"links","label":"NCBI Gene 64858"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64864","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rfx7","kind":"target","name":"RFX7","route":"/targets/rfx7/","field":"links","label":"NCBI Gene 64864"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6491","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stil","kind":"target","name":"STIL","route":"/targets/stil/","field":"links","label":"NCBI Gene 6491"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/64919","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl11b","kind":"target","name":"BCL11B","route":"/targets/bcl11b/","field":"links","label":"NCBI Gene 64919"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6493","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sim2","kind":"target","name":"SIM2","route":"/targets/sim2/","field":"links","label":"NCBI Gene 6493"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6495","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"six1","kind":"target","name":"SIX1","route":"/targets/six1/","field":"links","label":"NCBI Gene 6495"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6498","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skil","kind":"target","name":"SKIL","route":"/targets/skil/","field":"links","label":"NCBI Gene 6498"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/650","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmp2","kind":"target","name":"BMP2","route":"/targets/bmp2/","field":"links","label":"NCBI Gene 650"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6500","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skp1","kind":"target","name":"SKP1","route":"/targets/skp1/","field":"links","label":"NCBI Gene 6500"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/65125","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wnk1","kind":"target","name":"WNK1","route":"/targets/wnk1/","field":"links","label":"NCBI Gene 65125"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/652","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmp4","kind":"target","name":"BMP4","route":"/targets/bmp4/","field":"links","label":"NCBI Gene 652"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/65268","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wnk2","kind":"target","name":"WNK2","route":"/targets/wnk2/","field":"links","label":"NCBI Gene 65268"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/653","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmp5","kind":"target","name":"BMP5","route":"/targets/bmp5/","field":"links","label":"NCBI Gene 653"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6530","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc6a2","kind":"target","name":"SLC6A2","route":"/targets/slc6a2/","field":"links","label":"NCBI Gene 6530"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6531","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc6a3","kind":"target","name":"SLC6A3","route":"/targets/slc6a3/","field":"links","label":"NCBI Gene 6531"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6532","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc6a4","kind":"target","name":"SLC6A4","route":"/targets/slc6a4/","field":"links","label":"NCBI Gene 6532"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/653489","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rgpd3","kind":"target","name":"RGPD3","route":"/targets/rgpd3/","field":"links","label":"NCBI Gene 653489"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmp6","kind":"target","name":"BMP6","route":"/targets/bmp6/","field":"links","label":"NCBI Gene 654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/655","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmp7","kind":"target","name":"BMP7","route":"/targets/bmp7/","field":"links","label":"NCBI Gene 655"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6558","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc12a2","kind":"target","name":"SLC12A2","route":"/targets/slc12a2/","field":"links","label":"NCBI Gene 6558"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6563","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc14a1","kind":"target","name":"SLC14A1","route":"/targets/slc14a1/","field":"links","label":"NCBI Gene 6563"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/657","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/","field":"links","label":"NCBI Gene 657"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6581","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc22a3","kind":"target","name":"SLC22A3","route":"/targets/slc22a3/","field":"links","label":"NCBI Gene 6581"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6595","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/","field":"links","label":"NCBI Gene 6595"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6597","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","field":"links","label":"NCBI Gene 6597"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6598","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/","field":"links","label":"NCBI Gene 6598"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/65986","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zbtb10","kind":"target","name":"ZBTB10","route":"/targets/zbtb10/","field":"links","label":"NCBI Gene 65986"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6602","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smarcd1","kind":"target","name":"SMARCD1","route":"/targets/smarcd1/","field":"links","label":"NCBI Gene 6602"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6605","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smarce1","kind":"target","name":"SMARCE1","route":"/targets/smarce1/","field":"links","label":"NCBI Gene 6605"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6616","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"snap25","kind":"target","name":"SNAP25","route":"/targets/snap25/","field":"links","label":"NCBI Gene 6616"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6641","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sntb1","kind":"target","name":"SNTB1","route":"/targets/sntb1/","field":"links","label":"NCBI Gene 6641"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sos1","kind":"target","name":"SOS1","route":"/targets/sos1/","field":"links","label":"NCBI Gene 6654"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6657","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","field":"links","label":"NCBI Gene 6657"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6662","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","field":"links","label":"NCBI Gene 6662"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6663","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sox10","kind":"target","name":"SOX10","route":"/targets/sox10/","field":"links","label":"NCBI Gene 6663"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/668","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/","field":"links","label":"NCBI Gene 668"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6711","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sptbn1","kind":"target","name":"SPTBN1","route":"/targets/sptbn1/","field":"links","label":"NCBI Gene 6711"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6715","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srd5a1","kind":"target","name":"SRD5A1","route":"/targets/srd5a1/","field":"links","label":"NCBI Gene 6715"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6725","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srms","kind":"target","name":"SRMS","route":"/targets/srms/","field":"links","label":"NCBI Gene 6725"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6751","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sstr1","kind":"target","name":"SSTR1","route":"/targets/sstr1/","field":"links","label":"NCBI Gene 6751"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6753","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sstr3","kind":"target","name":"SSTR3","route":"/targets/sstr3/","field":"links","label":"NCBI Gene 6753"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6754","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sstr4","kind":"target","name":"SSTR4","route":"/targets/sstr4/","field":"links","label":"NCBI Gene 6754"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6755","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/","field":"links","label":"NCBI Gene 6755"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6756","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ssx1","kind":"target","name":"SSX1","route":"/targets/ssx1/","field":"links","label":"NCBI Gene 6756"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6757","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/","field":"links","label":"NCBI Gene 6757"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6760","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ss18","kind":"target","name":"SS18","route":"/targets/ss18/","field":"links","label":"NCBI Gene 6760"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/677","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zfp36l1","kind":"target","name":"ZFP36L1","route":"/targets/zfp36l1/","field":"links","label":"NCBI Gene 677"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6772","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/","field":"links","label":"NCBI Gene 6772"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6774","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/","field":"links","label":"NCBI Gene 6774"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6776","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"NCBI Gene 6776 (STAT5A)"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6777","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"NCBI Gene 6777 (STAT5B)"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6778","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stat6","kind":"target","name":"STAT6","route":"/targets/stat6/","field":"links","label":"NCBI Gene 6778"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6790","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","field":"links","label":"NCBI Gene 6790"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6794","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"links","label":"NCBI Gene 6794"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6801","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strn","kind":"target","name":"STRN","route":"/targets/strn/","field":"links","label":"NCBI Gene 6801"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/685","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/","field":"links","label":"NCBI Gene 685"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6850","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/","field":"links","label":"NCBI Gene 6850"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6862","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbxt","kind":"target","name":"TBXT","route":"/targets/tbxt/","field":"links","label":"NCBI Gene 6862"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/688","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/","field":"links","label":"NCBI Gene 688"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6886","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tal1","kind":"target","name":"TAL1","route":"/targets/tal1/","field":"links","label":"NCBI Gene 6886"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6887","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tal2","kind":"target","name":"TAL2","route":"/targets/tal2/","field":"links","label":"NCBI Gene 6887"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6899","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbx1","kind":"target","name":"TBX1","route":"/targets/tbx1/","field":"links","label":"NCBI Gene 6899"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6917","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcea1","kind":"target","name":"TCEA1","route":"/targets/tcea1/","field":"links","label":"NCBI Gene 6917"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6925","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcf4","kind":"target","name":"TCF4","route":"/targets/tcf4/","field":"links","label":"NCBI Gene 6925"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6926","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbx3","kind":"target","name":"TBX3","route":"/targets/tbx3/","field":"links","label":"NCBI Gene 6926"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6927","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/","field":"links","label":"NCBI Gene 6927"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6928","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/","field":"links","label":"NCBI Gene 6928"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6929","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcf3","kind":"target","name":"TCF3","route":"/targets/tcf3/","field":"links","label":"NCBI Gene 6929"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6934","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","field":"links","label":"NCBI Gene 6934"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6935","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/","field":"links","label":"NCBI Gene 6935"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6938","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcf12","kind":"target","name":"TCF12","route":"/targets/tcf12/","field":"links","label":"NCBI Gene 6938"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/694","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/","field":"links","label":"NCBI Gene 694"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6941","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcf19","kind":"target","name":"TCF19","route":"/targets/tcf19/","field":"links","label":"NCBI Gene 6941"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/699","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bub1","kind":"target","name":"BUB1","route":"/targets/bub1/","field":"links","label":"NCBI Gene 699"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/6999","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tdo2","kind":"target","name":"TDO2","route":"/targets/tdo2/","field":"links","label":"NCBI Gene 6999"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7006","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tec","kind":"target","name":"TEC","route":"/targets/tec/","field":"links","label":"NCBI Gene 7006"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/701","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/","field":"links","label":"NCBI Gene 701"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7015","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/","field":"links","label":"NCBI Gene 7015"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7018","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tf","kind":"target","name":"TF","route":"/targets/tf/","field":"links","label":"NCBI Gene 7018"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7023","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tfap4","kind":"target","name":"TFAP4","route":"/targets/tfap4/","field":"links","label":"NCBI Gene 7023"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7026","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nr2f2","kind":"target","name":"NR2F2","route":"/targets/nr2f2/","field":"links","label":"NCBI Gene 7026"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tfe3","kind":"target","name":"TFE3","route":"/targets/tfe3/","field":"links","label":"NCBI Gene 7030"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7033","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tff3","kind":"target","name":"TFF3","route":"/targets/tff3/","field":"links","label":"NCBI Gene 7033"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7037","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tfrc","kind":"target","name":"TFRC","route":"/targets/tfrc/","field":"links","label":"NCBI Gene 7037"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7038","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tg","kind":"target","name":"TG","route":"/targets/tg/","field":"links","label":"NCBI Gene 7038"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7039","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfa","kind":"target","name":"TGFA","route":"/targets/tgfa/","field":"links","label":"NCBI Gene 7039"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7040","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfb1","kind":"target","name":"TGFB1","route":"/targets/tgfb1/","field":"links","label":"NCBI Gene 7040"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7042","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfb2","kind":"target","name":"TGFB2","route":"/targets/tgfb2/","field":"links","label":"NCBI Gene 7042"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7043","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfb3","kind":"target","name":"TGFB3","route":"/targets/tgfb3/","field":"links","label":"NCBI Gene 7043"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7046","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfbr1","kind":"target","name":"TGFBR1","route":"/targets/tgfbr1/","field":"links","label":"NCBI Gene 7046"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7048","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","field":"links","label":"NCBI Gene 7048"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7049","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgfbr3","kind":"target","name":"TGFBR3","route":"/targets/tgfbr3/","field":"links","label":"NCBI Gene 7049"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7050","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgif1","kind":"target","name":"TGIF1","route":"/targets/tgif1/","field":"links","label":"NCBI Gene 7050"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7053","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tgm3","kind":"target","name":"TGM3","route":"/targets/tgm3/","field":"links","label":"NCBI Gene 7053"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7058","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thbs2","kind":"target","name":"THBS2","route":"/targets/thbs2/","field":"links","label":"NCBI Gene 7058"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7067","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thra","kind":"target","name":"THRA","route":"/targets/thra/","field":"links","label":"NCBI Gene 7067"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7068","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thrb","kind":"target","name":"THRB","route":"/targets/thrb/","field":"links","label":"NCBI Gene 7068"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7076","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"timp1","kind":"target","name":"TIMP1","route":"/targets/timp1/","field":"links","label":"NCBI Gene 7076"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7080","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","field":"links","label":"NCBI Gene 7080"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7094","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tln1","kind":"target","name":"TLN1","route":"/targets/tln1/","field":"links","label":"NCBI Gene 7094"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/71","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"actg1","kind":"target","name":"ACTG1","route":"/targets/actg1/","field":"links","label":"NCBI Gene 71"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7113","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/","field":"links","label":"NCBI Gene 7113"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7114","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tmsb4x","kind":"target","name":"TMSB4X","route":"/targets/tmsb4x/","field":"links","label":"NCBI Gene 7114"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7128","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/","field":"links","label":"NCBI Gene 7128"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7145","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tns1","kind":"target","name":"TNS1","route":"/targets/tns1/","field":"links","label":"NCBI Gene 7145"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7155","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/","field":"links","label":"NCBI Gene 7155"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7156","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"top3a","kind":"target","name":"TOP3A","route":"/targets/top3a/","field":"links","label":"NCBI Gene 7156"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7158","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tp53bp1","kind":"target","name":"TP53BP1","route":"/targets/tp53bp1/","field":"links","label":"NCBI Gene 7158"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7170","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tpm3","kind":"target","name":"TPM3","route":"/targets/tpm3/","field":"links","label":"NCBI Gene 7170"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7171","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tpm4","kind":"target","name":"TPM4","route":"/targets/tpm4/","field":"links","label":"NCBI Gene 7171"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7175","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tpr","kind":"target","name":"TPR","route":"/targets/tpr/","field":"links","label":"NCBI Gene 7175"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7178","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tpt1","kind":"target","name":"TPT1","route":"/targets/tpt1/","field":"links","label":"NCBI Gene 7178"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7184","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hsp90b1","kind":"target","name":"HSP90B1","route":"/targets/hsp90b1/","field":"links","label":"NCBI Gene 7184"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7187","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/","field":"links","label":"NCBI Gene 7187"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7227","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trps1","kind":"target","name":"TRPS1","route":"/targets/trps1/","field":"links","label":"NCBI Gene 7227"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7248","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tsc1","kind":"target","name":"TSC1","route":"/targets/tsc1/","field":"links","label":"NCBI Gene 7248"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7249","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tsc2","kind":"target","name":"TSC2","route":"/targets/tsc2/","field":"links","label":"NCBI Gene 7249"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7259","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tspyl1","kind":"target","name":"TSPYL1","route":"/targets/tspyl1/","field":"links","label":"NCBI Gene 7259"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7270","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","field":"links","label":"NCBI Gene 7270"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7272","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ttk","kind":"target","name":"MPS1 (TTK)","route":"/targets/ttk/","field":"links","label":"NCBI Gene 7272"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7277","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/","field":"links","label":"NCBI Gene 7277"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7278","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/","field":"links","label":"NCBI Gene 7278"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7280","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/","field":"links","label":"NCBI Gene 7280"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/728130","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nutm2d","kind":"target","name":"NUTM2D","route":"/targets/nutm2d/","field":"links","label":"NCBI Gene 728130"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/729262","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nutm2b","kind":"target","name":"NUTM2B","route":"/targets/nutm2b/","field":"links","label":"NCBI Gene 729262"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7293","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/","field":"links","label":"NCBI Gene 7293"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7297","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tyk2","kind":"target","name":"TYK2","route":"/targets/tyk2/","field":"links","label":"NCBI Gene 7297"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7299","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/","field":"links","label":"NCBI Gene 7299"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/730051","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf814","kind":"target","name":"ZNF814","route":"/targets/znf814/","field":"links","label":"NCBI Gene 730051"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7306","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tyrp1","kind":"target","name":"TYRP1","route":"/targets/tyrp1/","field":"links","label":"NCBI Gene 7306"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7307","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"u2af1","kind":"target","name":"U2AF1","route":"/targets/u2af1/","field":"links","label":"NCBI Gene 7307"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7311","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uba52","kind":"target","name":"UBA52","route":"/targets/uba52/","field":"links","label":"NCBI Gene 7311"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7314","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubb","kind":"target","name":"UBB","route":"/targets/ubb/","field":"links","label":"NCBI Gene 7314"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7316","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubc","kind":"target","name":"UBC","route":"/targets/ubc/","field":"links","label":"NCBI Gene 7316"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7319","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ube2a","kind":"target","name":"UBE2A","route":"/targets/ube2a/","field":"links","label":"NCBI Gene 7319"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7343","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubtf","kind":"target","name":"UBTF","route":"/targets/ubtf/","field":"links","label":"NCBI Gene 7343"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7361","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ugt1a","kind":"target","name":"UGT1A","route":"/targets/ugt1a/","field":"links","label":"NCBI Gene 7361"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7403","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","field":"links","label":"NCBI Gene 7403"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7409","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/","field":"links","label":"NCBI Gene 7409"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7414","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vcl","kind":"target","name":"VCL","route":"/targets/vcl/","field":"links","label":"NCBI Gene 7414"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7421","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vdr","kind":"target","name":"VDR","route":"/targets/vdr/","field":"links","label":"NCBI Gene 7421"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7424","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vegfc","kind":"target","name":"VEGFC","route":"/targets/vegfc/","field":"links","label":"NCBI Gene 7424"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7428","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vhl","kind":"target","name":"VHL","route":"/targets/vhl/","field":"links","label":"NCBI Gene 7428"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7430","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ezr","kind":"target","name":"EZR","route":"/targets/ezr/","field":"links","label":"NCBI Gene 7430"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7450","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vwf","kind":"target","name":"VWF","route":"/targets/vwf/","field":"links","label":"NCBI Gene 7450"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7454","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"was","kind":"target","name":"WAS","route":"/targets/was/","field":"links","label":"NCBI Gene 7454"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7468","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/","field":"links","label":"NCBI Gene 7468"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wnt1","kind":"target","name":"WNT1","route":"/targets/wnt1/","field":"links","label":"NCBI Gene 7471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7475","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wnt6","kind":"target","name":"WNT6","route":"/targets/wnt6/","field":"links","label":"NCBI Gene 7475"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7481","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wnt11","kind":"target","name":"WNT11","route":"/targets/wnt11/","field":"links","label":"NCBI Gene 7481"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7490","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/","field":"links","label":"NCBI Gene 7490"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7507","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xpa","kind":"target","name":"XPA","route":"/targets/xpa/","field":"links","label":"NCBI Gene 7507"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7508","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xpc","kind":"target","name":"XPC","route":"/targets/xpc/","field":"links","label":"NCBI Gene 7508"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7515","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/","field":"links","label":"NCBI Gene 7515"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7516","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xrcc2","kind":"target","name":"XRCC2","route":"/targets/xrcc2/","field":"links","label":"NCBI Gene 7516"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7517","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xrcc3","kind":"target","name":"XRCC3","route":"/targets/xrcc3/","field":"links","label":"NCBI Gene 7517"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7525","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/","field":"links","label":"NCBI Gene 7525"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7529","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ywhab","kind":"target","name":"YWHAB","route":"/targets/ywhab/","field":"links","label":"NCBI Gene 7529"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7531","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ywhae","kind":"target","name":"YWHAE","route":"/targets/ywhae/","field":"links","label":"NCBI Gene 7531"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7555","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnbp","kind":"target","name":"CNBP","route":"/targets/cnbp/","field":"links","label":"NCBI Gene 7555"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7643","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf90","kind":"target","name":"ZNF90","route":"/targets/znf90/","field":"links","label":"NCBI Gene 7643"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7704","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","field":"links","label":"NCBI Gene 7704"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7750","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zmym2","kind":"target","name":"ZMYM2","route":"/targets/zmym2/","field":"links","label":"NCBI Gene 7750"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7757","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf208","kind":"target","name":"ZNF208","route":"/targets/znf208/","field":"links","label":"NCBI Gene 7757"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/776","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cacna1d","kind":"target","name":"CACNA1D","route":"/targets/cacna1d/","field":"links","label":"NCBI Gene 776"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7764","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/","field":"links","label":"NCBI Gene 7764"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7799","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/","field":"links","label":"NCBI Gene 7799"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7832","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"btg2","kind":"target","name":"BTG2","route":"/targets/btg2/","field":"links","label":"NCBI Gene 7832"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7846","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/","field":"links","label":"NCBI Gene 7846"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7849","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pax8","kind":"target","name":"PAX8","route":"/targets/pax8/","field":"links","label":"NCBI Gene 7849"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7874","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/","field":"links","label":"NCBI Gene 7874"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79037","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","field":"links","label":"NCBI Gene 79037"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79058","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aspscr1","kind":"target","name":"ASPSCR1","route":"/targets/aspscr1/","field":"links","label":"NCBI Gene 79058"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79068","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fto","kind":"target","name":"FTO","route":"/targets/fto/","field":"links","label":"NCBI Gene 79068"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79083","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mlph","kind":"target","name":"MLPH","route":"/targets/mlph/","field":"links","label":"NCBI Gene 79083"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7913","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dek","kind":"target","name":"DEK","route":"/targets/dek/","field":"links","label":"NCBI Gene 7913"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79145","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chchd7","kind":"target","name":"CHCHD7","route":"/targets/chchd7/","field":"links","label":"NCBI Gene 79145"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7942","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tfeb","kind":"target","name":"TFEB","route":"/targets/tfeb/","field":"links","label":"NCBI Gene 7942"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79444","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birc7","kind":"target","name":"BIRC7","route":"/targets/birc7/","field":"links","label":"NCBI Gene 79444"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79577","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdc73","kind":"target","name":"CDC73","route":"/targets/cdc73/","field":"links","label":"NCBI Gene 79577"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79623","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"galnt14","kind":"target","name":"GALNT14","route":"/targets/galnt14/","field":"links","label":"NCBI Gene 79623"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79633","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fat4","kind":"target","name":"FAT4","route":"/targets/fat4/","field":"links","label":"NCBI Gene 79633"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79644","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srd5a3","kind":"target","name":"SRD5A3","route":"/targets/srd5a3/","field":"links","label":"NCBI Gene 79644"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7965","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aimp2","kind":"target","name":"AIMP2","route":"/targets/aimp2/","field":"links","label":"NCBI Gene 7965"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79661","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neil1","kind":"target","name":"NEIL1","route":"/targets/neil1/","field":"links","label":"NCBI Gene 79661"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79679","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/","field":"links","label":"NCBI Gene 79679"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79707","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nol9","kind":"target","name":"NOL9","route":"/targets/nol9/","field":"links","label":"NCBI Gene 79707"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79718","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbl1xr1","kind":"target","name":"TBL1XR1","route":"/targets/tbl1xr1/","field":"links","label":"NCBI Gene 79718"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79728","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"links","label":"NCBI Gene 79728"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79755","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf750","kind":"target","name":"ZNF750","route":"/targets/znf750/","field":"links","label":"NCBI Gene 79755"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79776","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zfhx4","kind":"target","name":"ZFHX4","route":"/targets/zfhx4/","field":"links","label":"NCBI Gene 79776"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7979","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/","field":"links","label":"NCBI Gene 7979"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7984","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgef5","kind":"target","name":"ARHGEF5","route":"/targets/arhgef5/","field":"links","label":"NCBI Gene 7984"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79885","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/","field":"links","label":"NCBI Gene 79885"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/7994","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/","field":"links","label":"NCBI Gene 7994"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79977","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grhl2","kind":"target","name":"GRHL2","route":"/targets/grhl2/","field":"links","label":"NCBI Gene 79977"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/79991","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stn1","kind":"target","name":"STN1","route":"/targets/stn1/","field":"links","label":"NCBI Gene 79991"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/","field":"links","label":"NCBI Gene 8000"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80003","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcnx2","kind":"target","name":"PCNX2","route":"/targets/pcnx2/","field":"links","label":"NCBI Gene 80003"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80010","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rmi1","kind":"target","name":"RMI1","route":"/targets/rmi1/","field":"links","label":"NCBI Gene 80010"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80129","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccdc170","kind":"target","name":"CCDC170","route":"/targets/ccdc170/","field":"links","label":"NCBI Gene 80129"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8013","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nr4a3","kind":"target","name":"NR4A3","route":"/targets/nr4a3/","field":"links","label":"NCBI Gene 8013"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80139","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf703","kind":"target","name":"ZNF703","route":"/targets/znf703/","field":"links","label":"NCBI Gene 80139"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80198","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/","field":"links","label":"NCBI Gene 80198"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80204","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/","field":"links","label":"NCBI Gene 80204"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nup214","kind":"target","name":"NUP214","route":"/targets/nup214/","field":"links","label":"NCBI Gene 8021"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80216","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alpk1","kind":"target","name":"ALPK1","route":"/targets/alpk1/","field":"links","label":"NCBI Gene 80216"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80243","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/","field":"links","label":"NCBI Gene 80243"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8028","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/","field":"links","label":"NCBI Gene 8028"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccdc6","kind":"target","name":"CCDC6","route":"/targets/ccdc6/","field":"links","label":"NCBI Gene 8030"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80304","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wdcp","kind":"target","name":"WDCP","route":"/targets/wdcp/","field":"links","label":"NCBI Gene 80304"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8031","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncoa4","kind":"target","name":"NCOA4","route":"/targets/ncoa4/","field":"links","label":"NCBI Gene 8031"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80312","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/","field":"links","label":"NCBI Gene 80312"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80339","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pnpla3","kind":"target","name":"PNPLA3","route":"/targets/pnpla3/","field":"links","label":"NCBI Gene 80339"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80380","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/","field":"links","label":"NCBI Gene 80380"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8074","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf23","kind":"target","name":"FGF23","route":"/targets/fgf23/","field":"links","label":"NCBI Gene 8074"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80824","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dusp16","kind":"target","name":"DUSP16","route":"/targets/dusp16/","field":"links","label":"NCBI Gene 80824"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8085","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kmt2d","kind":"target","name":"KMT2D","route":"/targets/kmt2d/","field":"links","label":"NCBI Gene 8085"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/80853","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm7a","kind":"target","name":"KDM7A","route":"/targets/kdm7a/","field":"links","label":"NCBI Gene 80853"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8087","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fxr1","kind":"target","name":"FXR1","route":"/targets/fxr1/","field":"links","label":"NCBI Gene 8087"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8091","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hmga2","kind":"target","name":"HMGA2","route":"/targets/hmga2/","field":"links","label":"NCBI Gene 8091"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/81027","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/","field":"links","label":"NCBI Gene 81027"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/81037","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clptm1l","kind":"target","name":"CLPTM1L","route":"/targets/clptm1l/","field":"links","label":"NCBI Gene 81037"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/811","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","field":"links","label":"NCBI Gene 811"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8115","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tcl1a","kind":"target","name":"TCL1A","route":"/targets/tcl1a/","field":"links","label":"NCBI Gene 8115"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8148","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"taf15","kind":"target","name":"TAF15","route":"/targets/taf15/","field":"links","label":"NCBI Gene 8148"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/81608","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fip1l1","kind":"target","name":"FIP1L1","route":"/targets/fip1l1/","field":"links","label":"NCBI Gene 81608"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/81704","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dock8","kind":"target","name":"DOCK8","route":"/targets/dock8/","field":"links","label":"NCBI Gene 81704"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8178","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/","field":"links","label":"NCBI Gene 8178"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/81931","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znf93","kind":"target","name":"ZNF93","route":"/targets/znf93/","field":"links","label":"NCBI Gene 81931"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8202","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/","field":"links","label":"NCBI Gene 8202"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8204","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrip1","kind":"target","name":"NRIP1","route":"/targets/nrip1/","field":"links","label":"NCBI Gene 8204"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8216","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lztr1","kind":"target","name":"LZTR1","route":"/targets/lztr1/","field":"links","label":"NCBI Gene 8216"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8218","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cltcl1","kind":"target","name":"CLTCL1","route":"/targets/cltcl1/","field":"links","label":"NCBI Gene 8218"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8233","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zrsr2","kind":"target","name":"ZRSR2","route":"/targets/zrsr2/","field":"links","label":"NCBI Gene 8233"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8239","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usp9x","kind":"target","name":"USP9X","route":"/targets/usp9x/","field":"links","label":"NCBI Gene 8239"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8241","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","field":"links","label":"NCBI Gene 8241"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8242","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/","field":"links","label":"NCBI Gene 8242"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8243","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"smc1a","kind":"target","name":"SMC1A","route":"/targets/smc1a/","field":"links","label":"NCBI Gene 8243"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8284","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kdm5d","kind":"target","name":"KDM5D","route":"/targets/kdm5d/","field":"links","label":"NCBI Gene 8284"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8289","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"links","label":"NCBI Gene 8289"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h4c9","kind":"target","name":"H4C9","route":"/targets/h4c9/","field":"links","label":"NCBI Gene 8294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8295","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trrap","kind":"target","name":"TRRAP","route":"/targets/trrap/","field":"links","label":"NCBI Gene 8295"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8301","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"picalm","kind":"target","name":"PICALM","route":"/targets/picalm/","field":"links","label":"NCBI Gene 8301"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8312","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axin1","kind":"target","name":"AXIN1","route":"/targets/axin1/","field":"links","label":"NCBI Gene 8312"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8313","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"axin2","kind":"target","name":"AXIN2","route":"/targets/axin2/","field":"links","label":"NCBI Gene 8313"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8314","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","field":"links","label":"NCBI Gene 8314"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8320","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eomes","kind":"target","name":"EOMES","route":"/targets/eomes/","field":"links","label":"NCBI Gene 8320"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/833","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cars1","kind":"target","name":"CARS1","route":"/targets/cars1/","field":"links","label":"NCBI Gene 833"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8334","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h2ac6","kind":"target","name":"H2AC6","route":"/targets/h2ac6/","field":"links","label":"NCBI Gene 8334"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8336","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h2ac17","kind":"target","name":"H2AC17","route":"/targets/h2ac17/","field":"links","label":"NCBI Gene 8336"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/83417","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fcrl4","kind":"target","name":"FCRL4","route":"/targets/fcrl4/","field":"links","label":"NCBI Gene 83417"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/83464","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aph1b","kind":"target","name":"APH1B","route":"/targets/aph1b/","field":"links","label":"NCBI Gene 83464"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8351","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h3c4","kind":"target","name":"H3C4","route":"/targets/h3c4/","field":"links","label":"NCBI Gene 8351"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8358","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h3c2","kind":"target","name":"H3C2","route":"/targets/h3c2/","field":"links","label":"NCBI Gene 8358"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/83879","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdca7","kind":"target","name":"CDCA7","route":"/targets/cdca7/","field":"links","label":"NCBI Gene 83879"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/83933","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/","field":"links","label":"NCBI Gene 83933"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/83990","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/","field":"links","label":"NCBI Gene 83990"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8402","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slc25a11","kind":"target","name":"SLC25A11","route":"/targets/slc25a11/","field":"links","label":"NCBI Gene 8402"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8405","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","field":"links","label":"NCBI Gene 8405"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/841","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/","field":"links","label":"NCBI Gene 841"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84133","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"znrf3","kind":"target","name":"ZNRF3","route":"/targets/znrf3/","field":"links","label":"NCBI Gene 84133"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84159","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arid5b","kind":"target","name":"ARID5B","route":"/targets/arid5b/","field":"links","label":"NCBI Gene 84159"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84231","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"traf7","kind":"target","name":"TRAF7","route":"/targets/traf7/","field":"links","label":"NCBI Gene 84231"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84295","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"phf6","kind":"target","name":"PHF6","route":"/targets/phf6/","field":"links","label":"NCBI Gene 84295"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/843","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"casp10","kind":"target","name":"CASP10","route":"/targets/casp10/","field":"links","label":"NCBI Gene 843"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84329","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hvcn1","kind":"target","name":"HVCN1","route":"/targets/hvcn1/","field":"links","label":"NCBI Gene 84329"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84376","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hook3","kind":"target","name":"HOOK3","route":"/targets/hook3/","field":"links","label":"NCBI Gene 84376"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8438","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rad54l","kind":"target","name":"RAD54L","route":"/targets/rad54l/","field":"links","label":"NCBI Gene 8438"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84433","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/","field":"links","label":"NCBI Gene 84433"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84441","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maml2","kind":"target","name":"MAML2","route":"/targets/maml2/","field":"links","label":"NCBI Gene 84441"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84444","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/","field":"links","label":"NCBI Gene 84444"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84456","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"l3mbtl3","kind":"target","name":"L3MBTL3","route":"/targets/l3mbtl3/","field":"links","label":"NCBI Gene 84456"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84464","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slx4","kind":"target","name":"SLX4","route":"/targets/slx4/","field":"links","label":"NCBI Gene 84464"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8451","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/","field":"links","label":"NCBI Gene 8451"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84515","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mcm8","kind":"target","name":"MCM8","route":"/targets/mcm8/","field":"links","label":"NCBI Gene 84515"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8452","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cul3","kind":"target","name":"CUL3","route":"/targets/cul3/","field":"links","label":"NCBI Gene 8452"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8454","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cul1","kind":"target","name":"CUL1","route":"/targets/cul1/","field":"links","label":"NCBI Gene 8454"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/846","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"casr","kind":"target","name":"CASR","route":"/targets/casr/","field":"links","label":"NCBI Gene 846"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84617","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/","field":"links","label":"NCBI Gene 84617"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8471","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irs4","kind":"target","name":"IRS4","route":"/targets/irs4/","field":"links","label":"NCBI Gene 8471"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84790","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/","field":"links","label":"NCBI Gene 84790"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84870","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","field":"links","label":"NCBI Gene 84870"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84902","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cep89","kind":"target","name":"CEP89","route":"/targets/cep89/","field":"links","label":"NCBI Gene 84902"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8493","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/","field":"links","label":"NCBI Gene 8493"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8496","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppfibp1","kind":"target","name":"PPFIBP1","route":"/targets/ppfibp1/","field":"links","label":"NCBI Gene 8496"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/84962","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ajuba","kind":"target","name":"AJUBA","route":"/targets/ajuba/","field":"links","label":"NCBI Gene 84962"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8503","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pik3r3","kind":"target","name":"PIK3R3","route":"/targets/pik3r3/","field":"links","label":"NCBI Gene 8503"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8518","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elp1","kind":"target","name":"ELP1","route":"/targets/elp1/","field":"links","label":"NCBI Gene 8518"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/85236","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"h2bc12","kind":"target","name":"H2BC12","route":"/targets/h2bc12/","field":"links","label":"NCBI Gene 85236"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/85415","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rhpn2","kind":"target","name":"RHPN2","route":"/targets/rhpn2/","field":"links","label":"NCBI Gene 85415"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/85437","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zcrb1","kind":"target","name":"ZCRB1","route":"/targets/zcrb1/","field":"links","label":"NCBI Gene 85437"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8546","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ap3b1","kind":"target","name":"AP3B1","route":"/targets/ap3b1/","field":"links","label":"NCBI Gene 8546"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8549","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","field":"links","label":"NCBI Gene 8549"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/86","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/","field":"links","label":"NCBI Gene 86"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8600","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","field":"links","label":"NCBI Gene TNFSF11"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/861","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/","field":"links","label":"NCBI Gene 861"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/862","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"runx1t1","kind":"target","name":"RUNX1T1","route":"/targets/runx1t1/","field":"links","label":"NCBI Gene 862"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8626","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/","field":"links","label":"NCBI Gene 8626"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/863","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cbfa2t3","kind":"target","name":"CBFA2T3","route":"/targets/cbfa2t3/","field":"links","label":"NCBI Gene 863"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8635","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rnaset2","kind":"target","name":"RNASET2","route":"/targets/rnaset2/","field":"links","label":"NCBI Gene 8635"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8648","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncoa1","kind":"target","name":"NCOA1","route":"/targets/ncoa1/","field":"links","label":"NCBI Gene 8648"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/865","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cbfb","kind":"target","name":"CBFB","route":"/targets/cbfb/","field":"links","label":"NCBI Gene 865"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8651","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/","field":"links","label":"NCBI Gene 8651"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8660","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"irs2","kind":"target","name":"IRS2","route":"/targets/irs2/","field":"links","label":"NCBI Gene 8660"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/867","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/","field":"links","label":"NCBI Gene 867"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/868","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cblb","kind":"target","name":"CBLB","route":"/targets/cblb/","field":"links","label":"NCBI Gene 868"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8701","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dnah11","kind":"target","name":"DNAH11","route":"/targets/dnah11/","field":"links","label":"NCBI Gene 8701"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8714","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcc3","kind":"target","name":"ABCC3","route":"/targets/abcc3/","field":"links","label":"NCBI Gene 8714"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8726","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/","field":"links","label":"NCBI Gene 8726"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8733","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gpaa1","kind":"target","name":"GPAA1","route":"/targets/gpaa1/","field":"links","label":"NCBI Gene 8733"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8737","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ripk1","kind":"target","name":"RIPK1","route":"/targets/ripk1/","field":"links","label":"NCBI Gene 8737"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8743","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfsf10","kind":"target","name":"TNFSF10","route":"/targets/tnfsf10/","field":"links","label":"NCBI Gene 8743"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8764","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfrsf14","kind":"target","name":"TNFRSF14","route":"/targets/tnfrsf14/","field":"links","label":"NCBI Gene 8764"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8784","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/","field":"links","label":"NCBI Gene 8784"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8795","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnfrsf10b","kind":"target","name":"TNFRSF10B","route":"/targets/tnfrsf10b/","field":"links","label":"NCBI Gene 8795"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8805","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/","field":"links","label":"NCBI Gene 8805"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8817","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf18","kind":"target","name":"FGF18","route":"/targets/fgf18/","field":"links","label":"NCBI Gene 8817"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8822","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf17","kind":"target","name":"FGF17","route":"/targets/fgf17/","field":"links","label":"NCBI Gene 8822"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8823","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf16","kind":"target","name":"FGF16","route":"/targets/fgf16/","field":"links","label":"NCBI Gene 8823"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8826","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iqgap1","kind":"target","name":"IQGAP1","route":"/targets/iqgap1/","field":"links","label":"NCBI Gene 8826"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8833","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gmps","kind":"target","name":"GMPS","route":"/targets/gmps/","field":"links","label":"NCBI Gene 8833"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8837","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cflar","kind":"target","name":"CFLAR","route":"/targets/cflar/","field":"links","label":"NCBI Gene 8837"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8842","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prom1","kind":"target","name":"PROM1","route":"/targets/prom1/","field":"links","label":"NCBI Gene 8842"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8843","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hcar3","kind":"target","name":"HCAR3","route":"/targets/hcar3/","field":"links","label":"NCBI Gene 8843"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8844","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ksr1","kind":"target","name":"KSR1","route":"/targets/ksr1/","field":"links","label":"NCBI Gene 8844"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8850","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/","field":"links","label":"NCBI Gene 8850"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8854","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aldh1a2","kind":"target","name":"ALDH1A2","route":"/targets/aldh1a2/","field":"links","label":"NCBI Gene 8854"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8861","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ldb1","kind":"target","name":"LDB1","route":"/targets/ldb1/","field":"links","label":"NCBI Gene 8861"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8863","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"per3","kind":"target","name":"PER3","route":"/targets/per3/","field":"links","label":"NCBI Gene 8863"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8877","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/","field":"links","label":"NCBI Gene 8877"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8878","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sqstm1","kind":"target","name":"SQSTM1","route":"/targets/sqstm1/","field":"links","label":"NCBI Gene 8878"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8880","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fubp1","kind":"target","name":"FUBP1","route":"/targets/fubp1/","field":"links","label":"NCBI Gene 8880"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8911","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cacna1i","kind":"target","name":"CACNA1I","route":"/targets/cacna1i/","field":"links","label":"NCBI Gene 8911"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8912","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cacna1h","kind":"target","name":"CACNA1H","route":"/targets/cacna1h/","field":"links","label":"NCBI Gene 8912"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8913","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cacna1g","kind":"target","name":"CACNA1G","route":"/targets/cacna1g/","field":"links","label":"NCBI Gene 8913"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8915","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/","field":"links","label":"NCBI Gene 8915"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8929","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/","field":"links","label":"NCBI Gene 8929"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/8930","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mbd4","kind":"target","name":"MBD4","route":"/targets/mbd4/","field":"links","label":"NCBI Gene 8930"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/894","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnd2","kind":"target","name":"CCND2","route":"/targets/ccnd2/","field":"links","label":"NCBI Gene 894"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/896","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnd3","kind":"target","name":"CCND3","route":"/targets/ccnd3/","field":"links","label":"NCBI Gene 896"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/89790","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"siglec10","kind":"target","name":"Siglec-10","route":"/targets/siglec10/","field":"links","label":"NCBI Gene 89790"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/898","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","field":"links","label":"NCBI Gene 898"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/89845","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcc10","kind":"target","name":"ABCC10","route":"/targets/abcc10/","field":"links","label":"NCBI Gene 89845"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/89857","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klhl6","kind":"target","name":"KLHL6","route":"/targets/klhl6/","field":"links","label":"NCBI Gene 89857"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/90","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acvr1","kind":"target","name":"ACVR1 (ALK2)","route":"/targets/acvr1/","field":"links","label":"NCBI Gene 90"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/90134","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnh7","kind":"target","name":"KCNH7","route":"/targets/kcnh7/","field":"links","label":"NCBI Gene 90134"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/902","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnh","kind":"target","name":"CCNH","route":"/targets/ccnh/","field":"links","label":"NCBI Gene 902"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/904","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccnt1","kind":"target","name":"CCNT1","route":"/targets/ccnt1/","field":"links","label":"NCBI Gene 904"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/90417","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"knstrn","kind":"target","name":"KNSTRN","route":"/targets/knstrn/","field":"links","label":"NCBI Gene 90417"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9055","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prc1","kind":"target","name":"PRC1","route":"/targets/prc1/","field":"links","label":"NCBI Gene 9055"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9061","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"papss1","kind":"target","name":"PAPSS1","route":"/targets/papss1/","field":"links","label":"NCBI Gene 9061"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/90865","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"il33","kind":"target","name":"IL33","route":"/targets/il33/","field":"links","label":"NCBI Gene 90865"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9098","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usp6","kind":"target","name":"USP6","route":"/targets/usp6/","field":"links","label":"NCBI Gene 9098"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/90993","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"creb3l1","kind":"target","name":"CREB3L1","route":"/targets/creb3l1/","field":"links","label":"NCBI Gene 90993"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/91","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acvr1b","kind":"target","name":"ACVR1B","route":"/targets/acvr1b/","field":"links","label":"NCBI Gene 91"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9101","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/","field":"links","label":"NCBI Gene 9101"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9113","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/","field":"links","label":"NCBI Gene 9113"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9125","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cnot9","kind":"target","name":"CNOT9","route":"/targets/cnot9/","field":"links","label":"NCBI Gene 9125"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9134","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccne2","kind":"target","name":"CCNE2","route":"/targets/ccne2/","field":"links","label":"NCBI Gene 9134"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9140","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atg12","kind":"target","name":"ATG12","route":"/targets/atg12/","field":"links","label":"NCBI Gene 9140"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/915","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/","field":"links","label":"NCBI Gene 915"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/91544","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubxn11","kind":"target","name":"UBXN11","route":"/targets/ubxn11/","field":"links","label":"NCBI Gene 91544"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9156","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exo1","kind":"target","name":"EXO1","route":"/targets/exo1/","field":"links","label":"NCBI Gene 9156"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/91607","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","field":"links","label":"NCBI Gene 91607"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/917","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/","field":"links","label":"NCBI Gene 917"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9175","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"map3k13","kind":"target","name":"MAP3K13","route":"/targets/map3k13/","field":"links","label":"NCBI Gene 9175"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/91851","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chrdl1","kind":"target","name":"CHRDL1","route":"/targets/chrdl1/","field":"links","label":"NCBI Gene 91851"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/92","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acvr2a","kind":"target","name":"ACVR2A","route":"/targets/acvr2a/","field":"links","label":"NCBI Gene 92"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/92017","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"snx29","kind":"target","name":"SNX29","route":"/targets/snx29/","field":"links","label":"NCBI Gene 92017"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9203","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zmym3","kind":"target","name":"ZMYM3","route":"/targets/zmym3/","field":"links","label":"NCBI Gene 9203"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9208","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lrrfip1","kind":"target","name":"LRRFIP1","route":"/targets/lrrfip1/","field":"links","label":"NCBI Gene 9208"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9212","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aurkb","kind":"target","name":"AURKB","route":"/targets/aurkb/","field":"links","label":"NCBI Gene 9212"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9232","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pttg1","kind":"target","name":"PTTG1","route":"/targets/pttg1/","field":"links","label":"NCBI Gene 9232"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/92345","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naf1","kind":"target","name":"NAF1","route":"/targets/naf1/","field":"links","label":"NCBI Gene 92345"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/92421","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chmp4c","kind":"target","name":"CHMP4C","route":"/targets/chmp4c/","field":"links","label":"NCBI Gene 92421"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9294","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"s1pr2","kind":"target","name":"S1PR2","route":"/targets/s1pr2/","field":"links","label":"NCBI Gene 9294"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9308","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd83","kind":"target","name":"CD83","route":"/targets/cd83/","field":"links","label":"NCBI Gene 9308"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/93100","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naprt","kind":"target","name":"NAPRT","route":"/targets/naprt/","field":"links","label":"NCBI Gene 93100"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9312","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kcnb2","kind":"target","name":"KCNB2","route":"/targets/kcnb2/","field":"links","label":"NCBI Gene 9312"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9314","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"klf4","kind":"target","name":"KLF4","route":"/targets/klf4/","field":"links","label":"NCBI Gene 9314"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9321","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trip11","kind":"target","name":"TRIP11","route":"/targets/trip11/","field":"links","label":"NCBI Gene 9321"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9343","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/","field":"links","label":"NCBI Gene 9343"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9380","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"grhpr","kind":"target","name":"GRHPR","route":"/targets/grhpr/","field":"links","label":"NCBI Gene 9380"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/939","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/","field":"links","label":"NCBI Gene 939"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/940","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/","field":"links","label":"NCBI Gene 940"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9401","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/","field":"links","label":"NCBI Gene 9401"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/941","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/","field":"links","label":"NCBI Gene 941"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/942","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd86","kind":"target","name":"CD86 (B7-2)","route":"/targets/cd86/","field":"links","label":"NCBI Gene 942"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/94274","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ppp1r14a","kind":"target","name":"PPP1R14A","route":"/targets/ppp1r14a/","field":"links","label":"NCBI Gene 94274"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9429","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/","field":"links","label":"NCBI Gene 9429"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9439","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"med23","kind":"target","name":"MED23","route":"/targets/med23/","field":"links","label":"NCBI Gene 9439"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9444","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qki","kind":"target","name":"QKI","route":"/targets/qki/","field":"links","label":"NCBI Gene 9444"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9451","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eif2ak3","kind":"target","name":"EIF2AK3","route":"/targets/eif2ak3/","field":"links","label":"NCBI Gene 9451"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9493","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kif23","kind":"target","name":"KIF23","route":"/targets/kif23/","field":"links","label":"NCBI Gene 9493"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9519","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tbpl1","kind":"target","name":"TBPL1","route":"/targets/tbpl1/","field":"links","label":"NCBI Gene 9519"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/953","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/","field":"links","label":"NCBI Gene 953"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9530","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bag4","kind":"target","name":"BAG4","route":"/targets/bag4/","field":"links","label":"NCBI Gene 9530"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9542","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nrg2","kind":"target","name":"NRG2","route":"/targets/nrg2/","field":"links","label":"NCBI Gene 9542"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9562","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"minpp1","kind":"target","name":"MINPP1","route":"/targets/minpp1/","field":"links","label":"NCBI Gene 9562"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/958","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/","field":"links","label":"NCBI Gene 958"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9582","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apobec3b","kind":"target","name":"APOBEC3B","route":"/targets/apobec3b/","field":"links","label":"NCBI Gene 9582"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9584","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/","field":"links","label":"NCBI Gene 9584"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/960","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/","field":"links","label":"NCBI Gene 960"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9611","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncor1","kind":"target","name":"NCOR1","route":"/targets/ncor1/","field":"links","label":"NCBI Gene 9611"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9612","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncor2","kind":"target","name":"NCOR2","route":"/targets/ncor2/","field":"links","label":"NCBI Gene 9612"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9627","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sncaip","kind":"target","name":"SNCAIP","route":"/targets/sncaip/","field":"links","label":"NCBI Gene 9627"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9639","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","field":"links","label":"NCBI Gene 9639"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9646","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ctr9","kind":"target","name":"CTR9","route":"/targets/ctr9/","field":"links","label":"NCBI Gene 9646"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/965","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd58","kind":"target","name":"CD58","route":"/targets/cd58/","field":"links","label":"NCBI Gene 965"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9709","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"herpud1","kind":"target","name":"HERPUD1","route":"/targets/herpud1/","field":"links","label":"NCBI Gene 9709"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9715","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fam131b","kind":"target","name":"FAM131B","route":"/targets/fam131b/","field":"links","label":"NCBI Gene 9715"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/972","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd74","kind":"target","name":"CD74","route":"/targets/cd74/","field":"links","label":"NCBI Gene 972"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/973","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd79a","kind":"target","name":"CD79A","route":"/targets/cd79a/","field":"links","label":"NCBI Gene 973"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9734","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/","field":"links","label":"NCBI Gene 9734"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9757","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kmt2b","kind":"target","name":"KMT2B","route":"/targets/kmt2b/","field":"links","label":"NCBI Gene 9757"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9759","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/","field":"links","label":"NCBI Gene 9759"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9760","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tox","kind":"target","name":"TOX","route":"/targets/tox/","field":"links","label":"NCBI Gene 9760"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9774","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bclaf1","kind":"target","name":"BCLAF1","route":"/targets/bclaf1/","field":"links","label":"NCBI Gene 9774"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/978","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cda","kind":"target","name":"CDA","route":"/targets/cda/","field":"links","label":"NCBI Gene 978"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9794","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"maml1","kind":"target","name":"MAML1","route":"/targets/maml1/","field":"links","label":"NCBI Gene 9794"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9817","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","field":"links","label":"NCBI Gene 9817"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9820","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cul7","kind":"target","name":"CUL7","route":"/targets/cul7/","field":"links","label":"NCBI Gene 9820"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9846","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gab2","kind":"target","name":"GAB2","route":"/targets/gab2/","field":"links","label":"NCBI Gene 9846"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9861","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/","field":"links","label":"NCBI Gene 9861"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9869","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"setdb1","kind":"target","name":"SETDB1","route":"/targets/setdb1/","field":"links","label":"NCBI Gene 9869"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9901","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"srgap3","kind":"target","name":"SRGAP3","route":"/targets/srgap3/","field":"links","label":"NCBI Gene 9901"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9935","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mafb","kind":"target","name":"MAFB","route":"/targets/mafb/","field":"links","label":"NCBI Gene 9935"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9950","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"golga5","kind":"target","name":"GOLGA5","route":"/targets/golga5/","field":"links","label":"NCBI Gene 9950"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9965","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/","field":"links","label":"NCBI Gene 9965"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9967","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thrap3","kind":"target","name":"THRAP3","route":"/targets/thrap3/","field":"links","label":"NCBI Gene 9967"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9968","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/","field":"links","label":"NCBI Gene 9968"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/9978","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/","field":"links","label":"NCBI Gene 9978"}]},{"url":"https://www.ncbi.nlm.nih.gov/gene/999","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/","field":"links","label":"NCBI Gene 999"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100885136","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","route":"/journals/european-journal-of-oncology-nursing/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100886238","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100886622","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100888201","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100888967","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","route":"/journals/current-oncology-reports/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100893225","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100898211","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"familial-cancer","kind":"journal","name":"Familial cancer","route":"/journals/familial-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100898731","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","route":"/journals/clinical-breast-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100900946","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","route":"/journals/current-treatment-options-in-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100927353","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100931981","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100967800","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101094211","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101120693","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101123358","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","route":"/journals/expert-review-of-anticancer-therapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101126433","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101128834","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101130625","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101137842","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101140941","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101147698","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101150042","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","route":"/journals/molecular-cancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101155137","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101167661","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101168776","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101170544","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101172931","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101185242","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101188791","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","route":"/journals/cancer-genomics-and-proteomics/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101206627","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"esophagus-journal","kind":"journal","name":"Esophagus","route":"/journals/esophagus-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101230541","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","route":"/journals/experimental-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101233985","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","route":"/journals/asco-educational-book/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101241430","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","route":"/journals/asia-pacific-journal-of-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101247119","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","route":"/journals/clinical-and-translational-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101249598","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","route":"/journals/journal-of-cancer-research-and-therapeutics/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101256509","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","route":"/journals/cancer-biomarkers/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101256629","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101260955","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","route":"/journals/clinical-genitourinary-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101262565","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101265111","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101266081","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101270595","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101304010","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","route":"/journals/head-and-neck-pathology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101307557","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101308230","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101318927","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","route":"/journals/pigment-cell-and-melanoma-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101468532","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101468937","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101469340","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101479409","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101479627","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","route":"/journals/journal-of-gastrointestinal-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101483150","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101499453","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","route":"/journals/cancer-cytopathology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101500911","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","route":"/journals/gulf-journal-of-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101508793","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","route":"/journals/cancer-epidemiology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101525386","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101531441","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101532965","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101534770","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","route":"/journals/journal-of-geriatric-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101539150","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","route":"/journals/cancer-genetics/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101541993","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101543508","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","route":"/journals/journal-of-adolescent-and-young-adult-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101552883","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101552938","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","route":"/journals/cellular-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101558279","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","route":"/journals/practical-radiation-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101559430","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","route":"/journals/journal-of-gastric-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101568469","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101570526","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101588850","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101594668","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101595310","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101604579","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101608375","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","route":"/journals/chinese-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101627692","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","route":"/journals/oncology-research-and-treatment/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101639933","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","route":"/journals/journal-of-cancer-policy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101665956","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","route":"/journals/trends-in-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101666844","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101694651","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101708809","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","route":"/journals/jco-clinical-cancer-informatics/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101721827","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101723675","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101747728","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101752190","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","route":"/journals/journal-of-breast-imaging/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101760170","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101764786","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101765309","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","route":"/journals/radiology-imaging-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101769553","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101775149","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/111356","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumori","kind":"journal","name":"Tumori","route":"/journals/tumori/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/112040","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/135054","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/222643","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","route":"/journals/journal-of-surgical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/313225","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","route":"/journals/japanese-journal-of-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/370416","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","route":"/journals/advances-in-cancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/376611","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/377266","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neoplasma","kind":"journal","name":"Neoplasma","route":"/journals/neoplasma/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/415677","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","route":"/journals/radiation-and-environmental-biophysics/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/420432","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","route":"/journals/seminars-in-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/42124","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/44671","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","route":"/journals/recent-results-in-cancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/489454","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/489718","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","route":"/journals/journal-of-pediatric-hematology-oncology-nursing/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/72416","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7502030","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","route":"/journals/cancer-treatment-reviews/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7600053","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-letters","kind":"journal","name":"Cancer letters","route":"/journals/cancer-letters/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7702986","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","route":"/journals/current-problems-in-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7706787","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukemia-research","kind":"journal","name":"Leukemia research","route":"/journals/leukemia-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7805358","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","route":"/journals/cancer-nursing/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7806519","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","route":"/journals/cancer-chemotherapy-and-pharmacology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7809033","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","route":"/journals/oncology-nursing-forum/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7810034","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","route":"/journals/gan-to-kagaku-ryoho/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7902060","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7905040","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","route":"/journals/nutrition-and-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7910681","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","route":"/journals/chinese-journal-of-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8008055","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","route":"/journals/carcinogenesis/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8008541","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","route":"/journals/cancer-treatment-and-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8102988","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anticancer-research","kind":"journal","name":"Anticancer research","route":"/journals/anticancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8111104","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8207754","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","route":"/journals/american-journal-of-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8307154","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","route":"/journals/cancer-investigation/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8307268","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","route":"/journals/hematological-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8308647","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8309335","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","route":"/journals/journal-of-neuro-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8309337","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","route":"/journals/journal-of-psychosocial-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8409922","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8409970","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","route":"/journals/clinical-and-experimental-metastasis/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8501420","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","route":"/journals/journal-of-environmental-pathology-toxicology-and-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8504356","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","route":"/journals/european-journal-of-surgical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8504688","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","route":"/journals/seminars-in-oncology-nursing/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8508395","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8603469","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","route":"/journals/strahlentherapie-und-onkologie/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8605731","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","route":"/journals/cancer-metastasis-reviews/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8605732","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8610343","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","route":"/journals/journal-of-cancer-education/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8700164","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8709065","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8709473","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8711562","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8712059","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8712411","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8800805","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8806809","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8811105","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","route":"/journals/molecular-carcinogenesis/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8902541","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","route":"/journals/head-and-neck-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8914610","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","route":"/journals/critical-reviews-in-oncogenesis/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8916049","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","route":"/journals/critical-reviews-in-oncology-hematology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9002902","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","route":"/journals/clinical-oncology-rcr/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007265","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","route":"/journals/current-opinion-in-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007329","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","route":"/journals/genes-chromosomes-and-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007422","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9010218","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","route":"/journals/seminars-in-cancer-biology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9011255","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","route":"/journals/jnci-monographs/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9100846","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","route":"/journals/cancer-causes-and-control/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9109623","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"melanoma-research","kind":"journal","name":"Melanoma research","route":"/journals/melanoma-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9111626","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9202882","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","route":"/journals/seminars-in-radiation-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9208097","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9208188","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","route":"/journals/surgical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9211789","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","route":"/journals/surgical-oncology-clinics-of-north-america/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9213011","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9214524","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","route":"/journals/psycho-oncology-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9300837","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","route":"/journals/european-journal-of-cancer-prevention/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9302957","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","route":"/journals/supportive-care-in-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9306042","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","route":"/journals/international-journal-of-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9313833","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","route":"/journals/magyar-onkologia/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9317213","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9420840","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","route":"/journals/annals-of-surgical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9422756","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-reports","kind":"journal","name":"Oncology reports","route":"/journals/oncology-reports/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9424566","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9425213","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","route":"/journals/klinicka-onkologie/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9432230","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","route":"/journals/cancer-gene-therapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9435512","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medical-oncology","kind":"journal","name":"Medical oncology","route":"/journals/medical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9436481","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9438457","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9502503","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9505539","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9505928","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9511372","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9601804","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","route":"/journals/journal-of-mammary-gland-biology-and-neoplasia/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9605408","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9607837","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9616295","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","route":"/journals/international-journal-of-clinical-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9705336","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","route":"/journals/clinical-journal-of-oncology-nursing/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9706083","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9706087","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9709118","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-oncology","kind":"journal","name":"Oral oncology","route":"/journals/oral-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9711272","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9716507","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","route":"/journals/brain-tumor-pathology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9804163","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","route":"/journals/journal-of-registry-management/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9805460","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","route":"/journals/urologic-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9806362","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","route":"/journals/bba-reviews-on-cancer/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9815755","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","route":"/journals/prostate-cancer-and-prostatic-diseases/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705465/","status":200,"ok":true,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12705465/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","field":"links","label":"RELATIVITY-098 publication"}]},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234029/","status":200,"ok":true,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6234029/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","field":"prevalence.source"}]},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366100/","status":200,"ok":true,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8366100/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"links","label":"IMbrave150 response characterisation"}]},{"url":"https://www.ncbs.res.in","status":200,"ok":true,"finalUrl":"https://www.ncbs.res.in/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/","field":"links","label":"NCBS"},{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/","field":"website"}]},{"url":"https://www.ncbs.res.in/director-message","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","field":"profiles","label":"Director's message"}]},{"url":"https://www.ncbs.res.in/people/lsshashidhara","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","field":"links","label":"Source: NCBS profile page for the Director"},{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","field":"profiles","label":"NCBS profile"}]},{"url":"https://www.ncc.go.jp/en/","status":200,"ok":true,"finalUrl":"https://www.ncc.go.jp/en/index.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/","field":"links","label":"Official website"},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/","field":"website"},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","field":"links","label":"National Cancer Center Japan"},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","field":"profiles","label":"National Cancer Center Japan"}]},{"url":"https://www.ncc.go.jp/en/ncce/","status":200,"ok":true,"finalUrl":"https://www.ncc.go.jp/en/ncce/index.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","field":"links","label":"NCC Hospital East"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","field":"website"}]},{"url":"https://www.ncc.go.jp/en/ncce/about/greeting/index.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"links","label":"Hospital director greeting"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"profiles","label":"Hospital director greeting"}]},{"url":"https://www.ncc.go.jp/en/ncce/index.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","field":"links","label":"National Cancer Center Hospital East"},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","field":"profiles","label":"National Cancer Center Hospital East"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"links","label":"National Cancer Center Hospital East"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","field":"profiles","label":"National Cancer Center Hospital East"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"links","label":"National Cancer Center Hospital East"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","field":"profiles","label":"National Cancer Center Hospital East"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"links","label":"National Cancer Center Hospital East"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","field":"profiles","label":"National Cancer Center Hospital East"}]},{"url":"https://www.ncc.go.jp/en/ncch/index.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","field":"links","label":"National Cancer Center Hospital"},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","field":"profiles","label":"National Cancer Center Hospital"},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","field":"links","label":"National Cancer Center Hospital"},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","field":"profiles","label":"National Cancer Center Hospital"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","field":"links","label":"National Cancer Center Hospital"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","field":"profiles","label":"National Cancer Center Hospital"}]},{"url":"https://www.ncc.go.jp/en/ri/index.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","field":"links","label":"National Cancer Center Research Institute"},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","field":"profiles","label":"National Cancer Center Research Institute"}]},{"url":"https://www.ncc.re.kr","status":200,"ok":true,"finalUrl":"https://www.ncc.re.kr/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","field":"links","label":"National Cancer Center Korea"},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","field":"website"}]},{"url":"https://www.nccn.org","status":200,"ok":true,"finalUrl":"https://www.nccn.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/","field":"links","label":"Official website"},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/","field":"website"}]},{"url":"https://www.nccn.org/compendia-templates/compendia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccn-compendium","kind":"term","name":"NCCN Compendium and drug compendia","route":"/terms/nccn-compendium/","field":"links","label":"NCCN Compendium"}]},{"url":"https://www.nccn.org/global/what-we-do/harmonized-guidelines","status":200,"ok":true,"finalUrl":"https://www.nccn.org/global/what-we-do/international-adaptations","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-acc-infusion-sparing-regimens","kind":"idea","name":"Choose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint","route":"/ideas/idea-acc-infusion-sparing-regimens/","field":"links","label":"NCCN Harmonized Guidelines for Sub-Saharan Africa"},{"id":"idea-data-offline-cds-lmic-generalists","kind":"idea","name":"Offline decision support for generalists treating common cancers in low-resource settings","route":"/ideas/idea-data-offline-cds-lmic-generalists/","field":"links","label":"NCCN Harmonized Guidelines for Sub-Saharan Africa"}]},{"url":"https://www.nccn.org/guidelines","status":200,"ok":true,"finalUrl":"https://www.nccn.org/guidelines/category_1","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/","field":"links","label":"NCCN Guidelines"},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/","field":"url"},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","field":"links","label":"NCCN Guidelines"}]},{"url":"https://www.nccn.org/guidelines/category_1","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","field":"standardOfCare.guideline (Unresectable)"},{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/","field":"links","label":"NCCN guidelines (category 1 list)"}],"archive":"https://web.archive.org/web/20260805134639/https://www.nccn.org/guidelines/category_1"},{"url":"https://www.nccn.org/guidelines/category_2","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"standardOfCare.guideline (Prevention and risk)"}],"archive":"https://web.archive.org/web/20260727005934/https://www.nccn.org/guidelines/category_2"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","field":"links","label":"NCCN ALL guidelines"},{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","field":"standardOfCare.guideline (Frontline)"},{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","field":"standardOfCare.guideline (Relapsed)"}],"archive":"https://web.archive.org/web/20260829193329/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"links","label":"NCCN AML guidelines"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"standardOfCare.guideline (Fit)"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"standardOfCare.guideline (Unfit)"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"standardOfCare.guideline (Relapsed)"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","field":"standardOfCare.guideline (Diagnosis and risk assignment)"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"standardOfCare.guideline (Newly diagnosed, fit for intensive chemotherapy)"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"standardOfCare.guideline (Newly diagnosed, unfit for intensive chemotherapy)"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"standardOfCare.guideline (Newly diagnosed IDH1-mutated, unfit for intensive chemotherapy)"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"standardOfCare.guideline (Newly diagnosed, fit for intensive chemotherapy)"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"standardOfCare.guideline (Newly diagnosed, fit for intensive chemotherapy)"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"standardOfCare.guideline (Newly diagnosed, unfit for intensive chemotherapy)"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"standardOfCare.guideline (Newly diagnosed, fit for intensive chemotherapy, age 60 to 75)"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"standardOfCare.guideline (Newly diagnosed, unfit for intensive chemotherapy)"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","field":"standardOfCare.guideline (Consolidation and relapse)"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"standardOfCare.guideline (Suspected APL, first hours)"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"standardOfCare.guideline (Low- and intermediate-risk)"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"standardOfCare.guideline (High-risk)"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","field":"standardOfCare.guideline (Molecular relapse)"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"links","label":"NCCN Guidelines: Acute Myeloid Leukemia"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"standardOfCare.guideline (Newly diagnosed, unfit for intensive chemotherapy)"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"standardOfCare.guideline (Fit older patients, 60 to 75)"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"standardOfCare.guideline (Not a candidate for any leukaemia-directed therapy)"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","field":"standardOfCare.guideline (Relapse after venetoclax-azacitidine)"}],"archive":"https://web.archive.org/web/20260829193359/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"links","label":"NCCN Guidelines: Anal Carcinoma"},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","field":"standardOfCare.guideline (Localised (stage I-III))"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"standardOfCare.guideline (Screening)"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"standardOfCare.guideline (Treatment of HSIL)"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"standardOfCare.guideline (Prevention)"},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","field":"standardOfCare.guideline (After treatment)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"links","label":"NCCN Anal Carcinoma"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"standardOfCare.guideline (Staging)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"standardOfCare.guideline (Stage I to III)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"standardOfCare.guideline (Response assessment)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"standardOfCare.guideline (Persistent or recurrent disease)"},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","field":"standardOfCare.guideline (High-risk locally advanced disease)"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"standardOfCare.guideline (First line)"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"standardOfCare.guideline (After platinum chemotherapy)"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"standardOfCare.guideline (Oligometastatic disease)"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","field":"standardOfCare.guideline (Isolated pelvic recurrence)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (The operation, and the rim of skin around it)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Mohs micrographic surgery, and when it is worth it)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Curettage and cautery)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Radiotherapy, and who it suits)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"NCCN Guidelines: Basal Cell Skin Cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Low-risk)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Choosing between an operation and a cream for a superficial tumour)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Living with a hedgehog inhibitor)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (After a hedgehog inhibitor has failed or cannot be tolerated)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (Locally advanced, first line)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (Neoadjuvant)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (After hedgehog inhibitor failure or intolerance)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (Metastatic disease)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (Radiotherapy and local options)"},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","field":"standardOfCare.guideline (Gorlin syndrome)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"standardOfCare.guideline (NMIBC)"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","field":"standardOfCare.guideline (MIBC)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","field":"links","label":"NCCN Guidelines: Bone Cancer"},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","field":"standardOfCare.guideline (Localised high-grade)"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","field":"links","label":"NCCN Guidelines: Bone Cancer"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","field":"standardOfCare.guideline (Localised)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Stage I (T1a-b N0))"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Screening and diagnosis)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Early stage, deciding on chemotherapy)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Early stage, adjuvant endocrine therapy)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Early stage, high risk: adjuvant CDK4/6)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Metastatic, second line by genotype)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"standardOfCare.guideline (Metastatic, endocrine-resistant: ADC before chemotherapy)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Stage I (≤2-3 cm, node-negative))"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Stage II-III, neoadjuvant)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Post-neoadjuvant, pathologic complete response)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Post-neoadjuvant, residual invasive disease)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Adjuvant (upfront surgery), node-positive)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, second line)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, later lines)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"paper-nccn-breast-cancer-v4-2026-jnccn-2026","kind":"paper","name":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/","field":"links","label":"NCCN Guidelines: Breast Cancer"},{"id":"phyllodes-tumour","kind":"cancer","name":"Phyllodes tumour of the breast","route":"/cancers/phyllodes-tumour/","field":"links","label":"NCCN Guidelines: Breast Cancer (phyllodes tumour section)"}],"archive":"https://web.archive.org/web/20260829193808/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","field":"standardOfCare.guideline (Glioblastoma)"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","field":"standardOfCare.guideline (IDH-mutant grade 2)"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"links","label":"NCCN Guidelines: CNS Cancers"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","field":"standardOfCare.guideline (Newly diagnosed, fit (<65-70))"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"standardOfCare.guideline (Newly diagnosed, all grades)"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"standardOfCare.guideline (Grade 2, residual or recurrent, low risk)"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"standardOfCare.guideline (Grade 2, high risk (age 40 or over, subtotal resection))"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"standardOfCare.guideline (Grade 3)"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","field":"standardOfCare.guideline (Grade 4)"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"standardOfCare.guideline (Newly diagnosed)"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"standardOfCare.guideline (Grade 2, residual or recurrent, not needing radiotherapy)"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","field":"standardOfCare.guideline (Grade 2, high risk, and grade 3)"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"standardOfCare.guideline (Incidental or small asymptomatic)"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"standardOfCare.guideline (Symptomatic or growing, accessible)"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"standardOfCare.guideline (Small, skull base or surgically inaccessible)"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"standardOfCare.guideline (Grade 2, incompletely resected, and all grade 3)"},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","field":"standardOfCare.guideline (Recurrent, no surgical or radiotherapy option)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Symptomatic oedema)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Single large or symptomatic lesion, fit patient)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Limited number of metastases)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Many metastases or leptomeningeal spread)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Driver-positive lung cancer, asymptomatic metastases)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (HER2-positive breast cancer)"},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","field":"standardOfCare.guideline (Melanoma)"},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"standardOfCare.guideline (Intramedullary ependymoma or haemangioblastoma)"},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"standardOfCare.guideline (Incompletely resected, high grade or recurrent)"},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","field":"standardOfCare.guideline (Intradural extramedullary meningioma or schwannoma)"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"standardOfCare.guideline (Small tumour, stable or good hearing)"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"standardOfCare.guideline (Growing small or medium tumour)"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","field":"standardOfCare.guideline (Large tumour with brainstem compression or hydrocephalus)"}],"archive":"https://web.archive.org/web/20260829193940/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"standardOfCare.guideline (Prevention)"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"standardOfCare.guideline (Locally advanced)"}],"archive":"https://web.archive.org/web/20260829193939/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"links","label":"NCCN Guidelines: Chronic Myeloid Leukemia"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"standardOfCare.guideline (Newly diagnosed chronic phase)"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"standardOfCare.guideline (Resistance or intolerance)"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","field":"standardOfCare.guideline (Sustained deep molecular response)"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"links","label":"NCCN Guidelines: Chronic Myeloid Leukemia"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"standardOfCare.guideline (Accelerated phase)"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"standardOfCare.guideline (Myeloid blast phase)"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"standardOfCare.guideline (Lymphoid blast phase)"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","field":"standardOfCare.guideline (Consolidation)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NCCN Colon Cancer guideline"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Stage I and low-risk stage II colon cancer)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (High-risk stage II colon cancer)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Stage III colon cancer, mismatch-repair proficient)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Stage III colon cancer, mismatch-repair deficient)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Locally advanced operable colon cancer: chemotherapy before surgery)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, KRAS G12C)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, HER2-amplified and RAS wild-type)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Anti-EGFR resistance and rechallenge)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Microsatellite-stable disease and immunotherapy)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Liver-limited and oligometastatic disease)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Peritoneal metastases)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Circulating tumour DNA after surgery)"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"NCCN guidelines: colon cancer"},{"id":"colorectal-palliation-obstruction-pain","kind":"term","name":"Palliation in colorectal cancer: obstruction, stents, stomas and liver capsule pain","route":"/terms/colorectal-palliation-obstruction-pain/","field":"links","label":"NCCN Colon Cancer guideline"},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","field":"links","label":"NCCN Colon Cancer guideline"},{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","field":"standardOfCare.guideline (Localised LAMN / adenocarcinoma)"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"links","label":"NCCN Guidelines: Colon Cancer"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"standardOfCare.guideline (Localised colon cancer)"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"standardOfCare.guideline (Lynch syndrome carriers)"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"links","label":"NCCN Guidelines: Colon Cancer"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"standardOfCare.guideline (Metastatic, microsatellite-stable, first line)"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"standardOfCare.guideline (Metastatic, previously treated)"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"standardOfCare.guideline (Metastatic, mismatch-repair deficient)"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","field":"standardOfCare.guideline (Localised)"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"links","label":"NCCN Guidelines: Colon Cancer"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"standardOfCare.guideline (Metastatic, RAS wild-type, previously treated)"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"standardOfCare.guideline (After HER2 antibodies, or with RAS mutation)"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"links","label":"NCCN Guidelines: Colon Cancer"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"standardOfCare.guideline (Metastatic, previously treated)"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","field":"standardOfCare.guideline (Later lines)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"links","label":"NCCN Guidelines: Colon Cancer"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"standardOfCare.guideline (Screening and early diagnosis)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"standardOfCare.guideline (Localised disease)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"standardOfCare.guideline (Metastatic disease)"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","field":"standardOfCare.guideline (Survivorship)"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"standardOfCare.guideline (LAMN confined to the appendix)"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"standardOfCare.guideline (Pseudomyxoma peritonei, resectable)"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"standardOfCare.guideline (High-grade pseudomyxoma peritonei)"},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","field":"standardOfCare.guideline (Unresectable or recurrent disease)"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"links","label":"NCCN Colon Cancer (appendiceal adenocarcinoma)"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"standardOfCare.guideline (Peritoneal metastases, resectable)"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"standardOfCare.guideline (Unresectable or distant metastatic disease)"},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","field":"standardOfCare.guideline (Signet ring cell carcinoma with extensive peritoneal disease)"},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"standardOfCare.guideline (Peritoneal metastases)"},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","field":"standardOfCare.guideline (Metastatic disease)"}],"archive":"https://web.archive.org/web/20260829194103/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"links","label":"NCCN Esophageal and EGJ Cancers guideline"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Localised)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Advanced)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Prevention and screening)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Early (T1a, high-grade dysplasia))"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Resectable locally advanced (cT2-4a or N+))"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Unresectable locally advanced or cervical)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Advanced squamous cell carcinoma, first line)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Advanced adenocarcinoma, first line)"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","field":"standardOfCare.guideline (Second line, adenocarcinoma)"}],"archive":"https://web.archive.org/web/20260829194228/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"links","label":"NCCN Gastric Cancer guideline"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Localised)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Advanced first line)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Prevention and screening)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Early (T1a) disease)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Resectable stage II-III (Western))"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Advanced, HER2-positive, first line)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Advanced, HER2-negative, PD-L1 CPS ≥5 (or ≥1), first line)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Advanced, CLDN18.2-positive (≥75%), HER2-negative, first line)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Advanced, HER2-negative, PD-L1 CPS <1 and CLDN18.2-negative)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Second line, HER2-positive)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Second line, HER2-negative)"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","field":"standardOfCare.guideline (Third line and beyond)"}],"archive":"https://web.archive.org/web/20260829194256/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","field":"standardOfCare.guideline (Resectable)"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","field":"links","label":"NCCN Guidelines: Head and Neck Cancers"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","field":"standardOfCare.guideline (Localised, resectable)"},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"links","label":"NCCN Head and Neck Cancers"},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","field":"standardOfCare.guideline (Resectable squamous carcinoma, adenocarcinoma, esthesioneuroblastoma)"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"links","label":"NCCN Head and Neck Cancers (ethmoid sinus)"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"standardOfCare.guideline (Resectable disease)"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"standardOfCare.guideline (High-grade or advanced disease (Hyams III to IV, Kadish C to D))"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","field":"standardOfCare.guideline (Follow-up)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"links","label":"NCCN Head and Neck Cancers (ethmoid and maxillary sinus)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"standardOfCare.guideline (Locally advanced disease, first step)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"standardOfCare.guideline (Responders to induction)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"standardOfCare.guideline (Non-responders to induction)"},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","field":"standardOfCare.guideline (Metastatic or recurrent disease)"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"standardOfCare.guideline (Early disease (small primary, limited nodes))"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"standardOfCare.guideline (Locally advanced disease)"},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"standardOfCare.guideline (Resectable stage III to IVA)"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"standardOfCare.guideline (After surgery, high risk)"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"standardOfCare.guideline (Unresectable or organ-preserving)"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"standardOfCare.guideline (First line, combined positive score 1 or more)"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"standardOfCare.guideline (First line, combined positive score under 1 or immunotherapy unsuitable)"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"standardOfCare.guideline (After platinum and immunotherapy)"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","field":"standardOfCare.guideline (Locoregional recurrence)"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Early disease (T1 to T2, node-negative))"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Locally advanced, larynx preservable)"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Cannot have cisplatin)"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Extensive disease (cartilage destruction, oesophageal extension) or recurrence after radiotherapy)"},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"standardOfCare.guideline (Localised, resectable)"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"standardOfCare.guideline (Slow-growing metastatic disease)"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"standardOfCare.guideline (Progressive metastatic disease)"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","field":"standardOfCare.guideline (Chemotherapy)"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"standardOfCare.guideline (Localised, resectable)"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"standardOfCare.guideline (HER2-positive recurrent or metastatic)"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"standardOfCare.guideline (Androgen receptor-positive recurrent or metastatic)"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","field":"standardOfCare.guideline (Marker-negative or after targeted treatment)"},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","field":"standardOfCare.guideline (Low-grade, localised)"},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","field":"standardOfCare.guideline (Intermediate- and high-grade or node-positive)"},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"standardOfCare.guideline (Primary treatment (T1 to T2, clinically node-negative))"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"standardOfCare.guideline (Locally advanced (T3 to T4 or node-positive))"},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","field":"standardOfCare.guideline (Resectable disease)"},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","field":"standardOfCare.guideline (After surgery)"},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","field":"standardOfCare.guideline (Early disease)"},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","field":"standardOfCare.guideline (Large, thick or node-positive disease)"},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","field":"standardOfCare.guideline (Unresectable or metastatic)"}],"archive":"https://web.archive.org/web/20260727005857/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","field":"standardOfCare.guideline (Advanced stage)"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Staging)"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Early favourable disease)"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Early unfavourable disease)"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Children and adolescents)"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Survivorship)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Staging and risk)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (First line, adults and adolescents 12 and over)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (First line, intensive European option)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Children)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (Older or frail patients)"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","field":"standardOfCare.guideline (End of treatment)"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"links","label":"NCCN Hodgkin Lymphoma"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Stage IA without risk factors)"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Stage IB to IV)"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Relapse)"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","field":"standardOfCare.guideline (Transformation)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Salvage before transplant)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Consolidation)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Relapse after transplant)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Failure of PD-1 antibodies and brentuximab)"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","field":"standardOfCare.guideline (Transplant-ineligible patients)"}],"archive":"https://web.archive.org/web/20260829194607/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","field":"standardOfCare.guideline (Localised)"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","field":"standardOfCare.guideline (Metastatic)"}],"archive":"https://web.archive.org/web/20260829194658/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1444","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"links","label":"NCCN Guidelines: Merkel Cell Carcinoma"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"standardOfCare.guideline (Localised (stage I-II))"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"standardOfCare.guideline (Choosing among the three PD-1 pathway antibodies)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","field":"standardOfCare.guideline (Newly diagnosed)"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","field":"standardOfCare.guideline (Relapsed)"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","field":"links","label":"NCCN Guidelines: Multiple Myeloma"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","field":"standardOfCare.guideline (Low- and intermediate-risk)"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","field":"standardOfCare.guideline (High-risk (Mayo 20/2/20 or IMWG high risk))"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"links","label":"NCCN Guidelines: Multiple Myeloma"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"standardOfCare.guideline (Induction)"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"standardOfCare.guideline (Consolidation)"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","field":"standardOfCare.guideline (Maintenance)"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"links","label":"NCCN Guidelines: Multiple Myeloma"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"standardOfCare.guideline (Fit, transplant-ineligible)"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"standardOfCare.guideline (Intermediate fitness)"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","field":"standardOfCare.guideline (Frail)"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"links","label":"NCCN Guidelines: Multiple Myeloma"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"standardOfCare.guideline (First relapse, lenalidomide-refractory)"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"standardOfCare.guideline (Triple-class exposed, two or more prior lines)"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","field":"standardOfCare.guideline (After BCMA-directed therapy)"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"links","label":"NCCN Guidelines: Multiple Myeloma"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"standardOfCare.guideline (Primary plasma cell leukaemia, induction)"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"standardOfCare.guideline (Consolidation)"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","field":"standardOfCare.guideline (Secondary plasma cell leukaemia or relapse)"}],"archive":"https://web.archive.org/web/20260727010107/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","field":"standardOfCare.guideline (Lower risk, anaemia)"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","field":"standardOfCare.guideline (Higher risk, transplant candidate)"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"links","label":"NCCN: Myelodysplastic Syndromes (includes CMML)"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","field":"standardOfCare.guideline (Higher-risk CMML, fit with a donor)"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"links","label":"NCCN Guidelines: Myelodysplastic Syndromes"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"standardOfCare.guideline (Asymptomatic, no transfusions)"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"standardOfCare.guideline (Anaemia, first line)"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"standardOfCare.guideline (Anaemia after erythropoietin or luspatercept failure)"},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","field":"standardOfCare.guideline (Supportive care)"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"links","label":"NCCN Guidelines: Myelodysplastic Syndromes"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"standardOfCare.guideline (Transplant candidate)"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"standardOfCare.guideline (Not a transplant candidate)"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","field":"standardOfCare.guideline (Failure of hypomethylating therapy)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1447","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","field":"links","label":"NCCN Guidelines: Kaposi Sarcoma"},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","field":"standardOfCare.guideline (AIDS-KS, limited (T0))"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","field":"standardOfCare.guideline (Localised)"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","field":"standardOfCare.guideline (Advanced)"},{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","field":"standardOfCare.guideline (Advanced, aggressive)"},{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","field":"links","label":"NCCN Neuroendocrine and Adrenal Tumors"},{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","field":"standardOfCare.guideline (Suspected or confirmed carcinoma, resectable)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (Localised or resectable disease)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (Progression on a somatostatin analogue)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (Carcinoid syndrome)"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","field":"standardOfCare.guideline (After radioligand therapy)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Localised, resectable)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Functioning syndromes)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Progression on a somatostatin analogue)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (Liver-dominant disease)"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","field":"standardOfCare.guideline (VHL-associated pancreatic NET)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"standardOfCare.guideline (Localised disease)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"standardOfCare.guideline (Advanced, somatostatin receptor-positive, slow tempo)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"standardOfCare.guideline (Advanced, progressive)"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","field":"standardOfCare.guideline (Hormone syndromes)"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"standardOfCare.guideline (Localised disease)"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"standardOfCare.guideline (Second line)"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","field":"standardOfCare.guideline (Ki-67 near 20 to 55 percent with well-differentiated features)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"standardOfCare.guideline (Advanced, somatostatin receptor-positive)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"standardOfCare.guideline (Advanced, shrinkage needed or receptor-negative)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"standardOfCare.guideline (Trials)"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","field":"standardOfCare.guideline (Limited disease)"}],"archive":"https://web.archive.org/web/20260727005913/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Stage I non-small-cell lung cancer, fit for surgery)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Stage I non-small-cell lung cancer, not fit for surgery)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Resected stage II to IIIA non-small-cell lung cancer, adjuvant chemotherapy)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic non-small-cell lung cancer: what must be tested before treatment)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Antibody-drug conjugates and bispecific antibodies entering the field)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Oligometastatic and oligoprogressive disease)"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Advanced, first line (exon 19 deletion or L858R))"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Advanced, exon 20 insertion)"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Advanced, after osimertinib)"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Resected stage IB to IIIA)"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Unresectable stage III)"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","field":"standardOfCare.guideline (Brain and leptomeningeal metastases)"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"standardOfCare.guideline (Advanced, after a second-generation inhibitor)"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"standardOfCare.guideline (Advanced, after lorlatinib)"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"standardOfCare.guideline (Resected stage IB to IIIA)"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"standardOfCare.guideline (Advanced, after chemoimmunotherapy)"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","field":"standardOfCare.guideline (Advanced, clinical trials)"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"standardOfCare.guideline (Advanced, after crizotinib or entrectinib)"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"standardOfCare.guideline (Advanced MET exon 14, first line or later)"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"standardOfCare.guideline (MET amplification after osimertinib in EGFR-mutated disease)"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","field":"standardOfCare.guideline (c-Met overexpression, previously treated non-squamous)"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","field":"standardOfCare.guideline (Advanced, after a RET inhibitor)"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"standardOfCare.guideline (Advanced BRAF V600E, first line)"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"standardOfCare.guideline (Advanced BRAF V600E, after targeted therapy)"},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","field":"standardOfCare.guideline (Non-V600 BRAF mutations)"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"standardOfCare.guideline (Advanced, after platinum chemotherapy)"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","field":"standardOfCare.guideline (Advanced, first line or after chemotherapy)"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"standardOfCare.guideline (Advanced, first line, PD-L1 50 percent or more)"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"standardOfCare.guideline (Advanced, first line, PD-L1 1 to 49 percent)"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"standardOfCare.guideline (Advanced, after progression on immunotherapy)"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","field":"standardOfCare.guideline (Duration and stopping)"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"standardOfCare.guideline (Stage IA, peripheral, 2 cm or less)"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"standardOfCare.guideline (Stage IB to IIIA without EGFR or ALK alteration)"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"standardOfCare.guideline (Resected EGFR-mutated stage IB to IIIA)"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"standardOfCare.guideline (Resected ALK-positive stage IB to IIIA)"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","field":"standardOfCare.guideline (Staging and surveillance)"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"standardOfCare.guideline (Unresectable stage III, fit, no EGFR mutation)"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"standardOfCare.guideline (Unresectable stage III, EGFR-mutated)"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"standardOfCare.guideline (Unfit for concurrent treatment)"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","field":"standardOfCare.guideline (Toxicity)"}],"archive":"https://web.archive.org/web/20260727010102/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1451","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"links","label":"NCCN Guidelines: Occult Primary"},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","field":"standardOfCare.guideline (Unfavourable, first line)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"standardOfCare.guideline (Newly diagnosed)"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","field":"standardOfCare.guideline (Platinum-sensitive relapse)"}],"archive":"https://web.archive.org/web/20260727010045/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma (resectability criteria)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Resectable / borderline)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Locally advanced unresectable)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Resectable disease: upfront surgery or neoadjuvant treatment)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Borderline resectable disease)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Targeted and biomarker-directed therapy)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Tumour treating fields for locally advanced disease)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Vaccines and cellular therapy: trials only)"},{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma (resectability criteria)"},{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"standardOfCare.guideline (Resectable)"},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","field":"standardOfCare.guideline (Advanced)"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"standardOfCare.guideline (Localised)"},{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","field":"standardOfCare.guideline (Recurrent or metastatic)"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma (resectability criteria)"},{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma (resectability criteria)"},{"id":"paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021","kind":"paper","name":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","route":"/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Staging)"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Surgery)"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Adjuvant chemotherapy)"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Neoadjuvant chemotherapy)"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Germline testing)"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","field":"standardOfCare.guideline (Follow-up)"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"standardOfCare.guideline (Neoadjuvant chemotherapy)"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"standardOfCare.guideline (Radiotherapy after chemotherapy)"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"standardOfCare.guideline (Surgery)"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"standardOfCare.guideline (After surgery)"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","field":"standardOfCare.guideline (Progression during neoadjuvant therapy)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Induction chemotherapy)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Tumour treating fields)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Consolidation local therapy)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Conversion surgery)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Ablation)"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","field":"standardOfCare.guideline (Progression)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (First line, fit patients)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (First line, less fit patients)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (Maintenance and biomarker-directed therapy)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (Second line)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (Supportive care throughout)"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","field":"standardOfCare.guideline (Clinical trials)"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"standardOfCare.guideline (First line)"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"standardOfCare.guideline (After first-line chemotherapy)"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","field":"standardOfCare.guideline (Clinical trials)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (First line)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (NRG1 fusion)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (NTRK fusion)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (BRAF alteration)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (Other fusions)"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","field":"standardOfCare.guideline (No identified driver)"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"standardOfCare.guideline (Testing)"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"standardOfCare.guideline (Maintenance)"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"standardOfCare.guideline (Resectable or borderline)"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","field":"standardOfCare.guideline (After progression on a PARP inhibitor)"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"standardOfCare.guideline (Testing)"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"standardOfCare.guideline (Advanced, after chemotherapy)"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","field":"standardOfCare.guideline (Resectable)"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"links","label":"NCCN Guidelines: Pancreatic Adenocarcinoma"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","field":"standardOfCare.guideline (Molecularly selected)"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","field":"standardOfCare.guideline (Invasive carcinoma in an IPMN)"}],"archive":"https://web.archive.org/web/20260727005911/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1456","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"links","label":"NCCN: Penile Cancer"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","field":"standardOfCare.guideline (Clinically node-negative, intermediate or high-risk primary)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"standardOfCare.guideline (Localised)"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"standardOfCare.guideline (Any stage, at diagnosis)"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"standardOfCare.guideline (Metastatic)"},{"id":"cambridge-prognostic-group","kind":"term","name":"Cambridge Prognostic Group (CPG 1 to 5)","route":"/terms/cambridge-prognostic-group/","field":"links","label":"NCCN Guidelines: prostate cancer (the American risk groups)"},{"id":"psa-density","kind":"term","name":"PSA density","route":"/terms/psa-density/","field":"links","label":"NCCN Guidelines: prostate cancer (the American risk groups)"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"standardOfCare.guideline (Very low and low risk, preferred)"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"standardOfCare.guideline (Low risk, men who prefer treatment)"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"standardOfCare.guideline (Favourable intermediate risk)"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"standardOfCare.guideline (Unfavourable intermediate risk)"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"standardOfCare.guideline (High risk)"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"standardOfCare.guideline (Very high risk and node-positive)"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"standardOfCare.guideline (After prostatectomy)"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"standardOfCare.guideline (After radiotherapy, local recurrence)"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"standardOfCare.guideline (High-risk biochemical recurrence (doubling time under 9 months))"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"standardOfCare.guideline (All patients, backbone)"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"standardOfCare.guideline (Doublet therapy)"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"standardOfCare.guideline (Triplet therapy, high volume, fit for chemotherapy)"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","field":"standardOfCare.guideline (Low-volume disease)"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"standardOfCare.guideline (High-risk nmCRPC (doubling time 10 months or less))"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"standardOfCare.guideline (Low-risk nmCRPC)"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"standardOfCare.guideline (First line, androgen receptor pathway inhibitor-naive)"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"standardOfCare.guideline (After an androgen receptor pathway inhibitor)"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"standardOfCare.guideline (After docetaxel)"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"standardOfCare.guideline (Bone health)"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"standardOfCare.guideline (Small-cell or predominantly neuroendocrine)"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"standardOfCare.guideline (Mixed adenocarcinoma and neuroendocrine, or aggressive variant)"}],"archive":"https://web.archive.org/web/20260727005920/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NCCN Rectal Cancer guideline"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Locally advanced rectal cancer: radiotherapy and total neoadjuvant therapy)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Rectal cancer: organ preservation and watch and wait)"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"NCCN guidelines: rectal cancer"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"links","label":"NCCN Guidelines: Rectal Cancer"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"standardOfCare.guideline (Early (cT1-2, node-negative))"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"standardOfCare.guideline (Locally advanced, higher risk)"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"standardOfCare.guideline (Intermediate risk, sphincter-sparing surgery planned)"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"standardOfCare.guideline (Mismatch-repair deficient)"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","field":"standardOfCare.guideline (Metastatic)"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","field":"standardOfCare.guideline (Rectal cancer)"}],"archive":"https://web.archive.org/web/20260727005922/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Limited-stage small-cell lung cancer)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Extensive-stage small-cell lung cancer, first line)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Relapsed small-cell lung cancer)"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"links","label":"NCCN Guidelines: Small Cell Lung Cancer"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"standardOfCare.guideline (Limited stage, fit)"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"standardOfCare.guideline (After response: brain)"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"standardOfCare.guideline (Stage I, node-negative, found incidentally)"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","field":"standardOfCare.guideline (Relapse)"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"links","label":"NCCN Guidelines: Small Cell Lung Cancer"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"standardOfCare.guideline (First line)"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"standardOfCare.guideline (Second line)"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"standardOfCare.guideline (Brain)"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","field":"standardOfCare.guideline (Thoracic consolidation)"}],"archive":"https://web.archive.org/web/20260727005908/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1463","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","field":"links","label":"NCCN: Systemic Mastocytosis"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","field":"standardOfCare.guideline (Localised STS)"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","field":"standardOfCare.guideline (Localised angiosarcoma)"}],"archive":"https://web.archive.org/web/20260727005843/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"NCCN Guidelines: Squamous Cell Skin Cancer"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (Localised low- and high-risk)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (Before surgery, when the operation would be disfiguring)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","field":"links","label":"NCCN Guidelines: Testicular Cancer"},{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","field":"standardOfCare.guideline (Stage I seminoma)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","field":"links","label":"NCCN Guidelines: Thymomas and Thymic Carcinomas"},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","field":"standardOfCare.guideline (Resectable (stage I-III))"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"links","label":"NCCN Thymomas and Thymic Carcinomas"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"standardOfCare.guideline (Resectable (stage I to III))"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"standardOfCare.guideline (After surgery)"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"standardOfCare.guideline (Unresectable or bulky disease)"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"standardOfCare.guideline (Resectable disease)"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"standardOfCare.guideline (Borderline resectable)"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"standardOfCare.guideline (After platinum)"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","field":"standardOfCare.guideline (Trials)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","field":"standardOfCare.guideline (Differentiated)"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","field":"standardOfCare.guideline (Advanced/refractory)"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","field":"standardOfCare.guideline (Nodule work-up)"},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (Advanced RET-mutant medullary thyroid carcinoma)"}],"archive":"https://web.archive.org/web/20260727005930/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","field":"standardOfCare.guideline (Early)"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","field":"standardOfCare.guideline (Advanced/recurrent)"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"links","label":"NCCN Uterine Neoplasms"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","field":"standardOfCare.guideline (Localised, any subtype)"}],"archive":"https://web.archive.org/web/20260727005817/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"links","label":"NCCN Guidelines: WM/LPL"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","field":"standardOfCare.guideline (Asymptomatic)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1476","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","field":"links","label":"NCCN Guidelines: Vulvar Cancer"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","field":"standardOfCare.guideline (Early (T1, <4 cm, unifocal))"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"links","label":"NCCN: Vulvar Cancer (includes vaginal cancer principles)"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","field":"standardOfCare.guideline (Stage I, small upper-vaginal lesion)"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"links","label":"NCCN Vulvar Cancer"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"standardOfCare.guideline (Precursor (usual-type VIN))"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"standardOfCare.guideline (Early stage (tumour under four centimetres, clinically negative groins))"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"standardOfCare.guideline (Locally advanced disease)"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"links","label":"NCCN Vulvar Cancer"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"standardOfCare.guideline (Precursor (differentiated VIN) and lichen sclerosus)"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"standardOfCare.guideline (Early stage)"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"standardOfCare.guideline (Locally advanced disease)"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","field":"standardOfCare.guideline (Follow-up)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","field":"links","label":"NCCN Guidelines: MPN"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","field":"standardOfCare.guideline (PV)"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"links","label":"NCCN Guidelines: Myeloproliferative Neoplasms"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"standardOfCare.guideline (Lower-risk, asymptomatic)"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"standardOfCare.guideline (Symptomatic splenomegaly or constitutional symptoms)"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"standardOfCare.guideline (Anaemia of myelofibrosis)"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","field":"standardOfCare.guideline (Higher-risk, fit for transplant)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"standardOfCare.guideline (Frontline)"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","field":"standardOfCare.guideline (Relapsed)"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"links","label":"NCCN Guidelines: CLL/SLL"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"standardOfCare.guideline (Asymptomatic early-stage disease)"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"standardOfCare.guideline (First treatment, fixed duration)"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"standardOfCare.guideline (First treatment, continuous)"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","field":"standardOfCare.guideline (Chemoimmunotherapy)"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"links","label":"NCCN Guidelines: CLL/SLL"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"standardOfCare.guideline (Relapse after a BTK inhibitor)"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"standardOfCare.guideline (Relapse after venetoclax)"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","field":"standardOfCare.guideline (Double-refractory after BTK inhibitor and venetoclax)"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"links","label":"NCCN Guidelines: CLL/SLL"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"standardOfCare.guideline (Diffuse large B-cell type, first treatment)"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"standardOfCare.guideline (Consolidation in responders)"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","field":"standardOfCare.guideline (Relapsed or chemotherapy-refractory)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"links","label":"NCCN Systemic Mastocytosis"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"standardOfCare.guideline (Symptom control)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"standardOfCare.guideline (Moderate to severe symptoms despite supportive care)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"standardOfCare.guideline (Trials)"},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","field":"standardOfCare.guideline (Monitoring)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"links","label":"NCCN Systemic Mastocytosis"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"standardOfCare.guideline (Diagnosis and risk assessment)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"standardOfCare.guideline (First line)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"standardOfCare.guideline (Associated haematological neoplasm)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"standardOfCare.guideline (Relapsed or intolerant)"},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","field":"standardOfCare.guideline (Fit patients, especially mast cell leukaemia or high-risk SM-AHN)"}],"archive":"https://web.archive.org/web/20260829194009/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Frontline)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Early relapse)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Later)"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","field":"standardOfCare.guideline (Limited stage (I-II, non-bulky))"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"links","label":"NCCN Guidelines: B-Cell Lymphomas"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","field":"standardOfCare.guideline (Limited stage (I-II))"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"links","label":"NCCN Guidelines: B-Cell Lymphomas"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","field":"standardOfCare.guideline (First line, fit (<65-70))"},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","field":"links","label":"NCCN: B-Cell Lymphomas (AIDS-related)"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"links","label":"NCCN Guidelines: B-Cell Lymphomas"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"standardOfCare.guideline (First line)"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"standardOfCare.guideline (Residual PET-positive disease after immunochemotherapy)"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","field":"standardOfCare.guideline (Relapsed or refractory)"}],"archive":"https://web.archive.org/web/20260829193612/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","field":"links","label":"NCCN Guidelines: Hairy Cell Leukemia"},{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","field":"standardOfCare.guideline (First line, symptomatic)"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"links","label":"NCCN Vaginal Cancer"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"standardOfCare.guideline (Precursor (VAIN))"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"standardOfCare.guideline (Stage I, upper vagina)"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"standardOfCare.guideline (Stage II to IVA)"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"standardOfCare.guideline (Early stage)"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"standardOfCare.guideline (Locally advanced disease)"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"standardOfCare.guideline (Recurrent or metastatic disease)"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","field":"standardOfCare.guideline (DES-exposed women)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"links","label":"NCCN Guidelines: T-Cell Lymphomas"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","field":"standardOfCare.guideline (First line, CD30+ PTCL / ALCL)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","field":"links","label":"NCCN Guidelines: Uveal Melanoma"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","field":"standardOfCare.guideline (Primary tumour)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","field":"links","label":"NCCN Guidelines: GTN"},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","field":"standardOfCare.guideline (Low-risk GTN (FIGO score 0-6))"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"standardOfCare.guideline (First line)"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"standardOfCare.guideline (Resistance to first agent)"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"standardOfCare.guideline (Surgery)"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","field":"standardOfCare.guideline (Follow-up)"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"links","label":"NCCN Gestational Trophoblastic Neoplasia"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"standardOfCare.guideline (Staging)"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"standardOfCare.guideline (High-risk disease, first line)"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"standardOfCare.guideline (Ultra-high-risk disease)"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","field":"standardOfCare.guideline (Resistant or relapsed disease)"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"links","label":"NCCN Gestational Trophoblastic Neoplasia"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"standardOfCare.guideline (Disease confined to the uterus)"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"standardOfCare.guideline (Metastatic disease or interval over four years)"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"standardOfCare.guideline (Resistant disease)"},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","field":"standardOfCare.guideline (Follow-up)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1490","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"links","label":"NCCN: Small Bowel Adenocarcinoma"},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","field":"standardOfCare.guideline (Localised)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"links","label":"NCCN Small Bowel Adenocarcinoma"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Duodenal tumours)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Jejunal and ileal tumours)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (After surgery)"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Surveillance)"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"links","label":"NCCN Small Bowel Adenocarcinoma"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (First line, mismatch-repair proficient)"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (First line, mismatch-repair deficient)"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Second line)"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (Limited metastases)"},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","field":"standardOfCare.guideline (All patients)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (Stage II-III)"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (Metastatic first line)"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (After PD-1)"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (Stage I-II primary)"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (Stage IIB-IIC (thick or ulcerated, node-negative))"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","field":"standardOfCare.guideline (Resectable stage III (macroscopic nodes))"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (What is different about melanoma)"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"standardOfCare.guideline (Advanced, after immunotherapy)"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"standardOfCare.guideline (Resected stage III)"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"standardOfCare.guideline (Positive sentinel node, no palpable disease)"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"standardOfCare.guideline (Resectable macroscopic nodal disease)"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"standardOfCare.guideline (Adjuvant, after upfront surgery)"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","field":"standardOfCare.guideline (In-transit disease)"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"standardOfCare.guideline (Diagnosis and surgery)"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"standardOfCare.guideline (Adjuvant, stage IIB or IIC)"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","field":"standardOfCare.guideline (Surveillance)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (First line, fit patient)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (BRAF V600-mutant, after immunotherapy or when rapid control is needed)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (Brain metastases)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (After PD-1 failure)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (Treatment duration)"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","field":"standardOfCare.guideline (Oligometastatic disease)"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"standardOfCare.guideline (Adjuvant)"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","field":"standardOfCare.guideline (KIT-mutant disease)"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"standardOfCare.guideline (Resected stage III)"},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","field":"standardOfCare.guideline (Advanced disease)"}],"archive":"https://web.archive.org/web/20260727010047/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","field":"links","label":"NCCN Guidelines: GIST"},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","field":"standardOfCare.guideline (Localised, resectable)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","field":"standardOfCare.guideline (Early)"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","field":"standardOfCare.guideline (Intermediate)"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","field":"standardOfCare.guideline (Advanced)"}],"archive":"https://web.archive.org/web/20260911115439/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","field":"standardOfCare.guideline (Resectable)"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","field":"standardOfCare.guideline (Advanced)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NCCN: Biliary Tract Cancers"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Newly diagnosed advanced disease: HER2 and genomic testing)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Locally advanced, unresectable, non-metastatic)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Other actionable alterations (rare in gallbladder cancer))"},{"id":"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025","kind":"paper","name":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025/","field":"links","label":"NCCN Guidelines: Biliary Tract Cancers"}],"archive":"https://web.archive.org/web/20260829193640/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1518","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"links","label":"NCCN: Histiocytic Neoplasms"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","field":"standardOfCare.guideline (ECD or RDD, BRAF wild-type or intolerant of BRAF inhibitors)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1520","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"links","label":"NCCN: Ampullary Adenocarcinoma"},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","field":"standardOfCare.guideline (Resectable carcinoma)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NCCN Colorectal Cancer Screening guideline"}],"archive":"https://web.archive.org/web/20260727005803/https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","field":"links","label":"NCCN Genetic/Familial High-Risk Assessment"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"NCCN Distress Management guideline"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1466","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"NCCN Survivorship guideline"}]},{"url":"https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","field":"links","label":"NCCN Guidelines for Patients"}]},{"url":"https://www.nccs.com.sg","status":200,"ok":true,"finalUrl":"https://www.nccs.com.sg/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"links","label":"National Cancer Centre Singapore"},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"website"}]},{"url":"https://www.nccs.com.sg/about-nccs/leadership.html","status":200,"ok":true,"finalUrl":"https://www.nccs.com.sg/about-nccs/leadership","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","field":"links","label":"Institution profile"},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","field":"profiles","label":"Institution profile"},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","field":"links","label":"Institution profile"},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.nccs.com.sg/our-specialties/goh-cheng-liang-proton-therapy-centre.html","status":200,"ok":true,"finalUrl":"https://www.nccs.com.sg/our-specialties/goh-cheng-liang-proton-therapy-centre","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"goh-cheng-liang","kind":"person","name":"Goh Cheng Liang","route":"/people/goh-cheng-liang/","field":"links","label":"NCCS: Goh Cheng Liang Proton Therapy Centre"}]},{"url":"https://www.ncf.net/post/2025-highlights-in-neuroendocrine-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"regulatoryEvents.source (2025-03-26)"}]},{"url":"https://www.ncgindia.org","status":200,"ok":true,"finalUrl":"https://www.ncgindia.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"links","label":"National Cancer Grid"},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","field":"profiles","label":"National Cancer Grid"},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"links","label":"National Cancer Grid"},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","field":"website"}]},{"url":"https://www.ncicirb.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/","field":"links","label":"NCI Central IRB"}]},{"url":"https://www.ncis.com.sg","status":200,"ok":true,"finalUrl":"https://www.ncis.com.sg/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","field":"links","label":"NCIS"},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","field":"website"}]},{"url":"https://www.ncis.com.sg/about-ncis/at-the-helm","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","field":"links","label":"Institution profile"},{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","field":"profiles","label":"Institution profile"},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","field":"links","label":"Institution profile"},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","field":"profiles","label":"Institution profile"},{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","field":"links","label":"Institution profile"},{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ncl.ac.uk/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","field":"links","label":"Newcastle University Centre for Cancer"}]},{"url":"https://www.ncl.ac.uk/cancer/about-us/leadership-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"links","label":"Institution profile"},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ncl.ac.uk/medical-sciences/people/profile/alastairgreystoke.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","route":"/people/alastair-greystoke/","field":"links","label":"Newcastle University staff page"},{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","route":"/people/alastair-greystoke/","field":"profiles","label":"Newcastle University staff page"}]},{"url":"https://www.ncl.ac.uk/medical-sciences/people/profile/johnburn.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-burn","kind":"person","name":"John Burn","route":"/people/john-burn/","field":"links","label":"Newcastle University staff page"},{"id":"john-burn","kind":"person","name":"John Burn","route":"/people/john-burn/","field":"profiles","label":"Newcastle University staff page"}]},{"url":"https://www.nclcanceralliance.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.nclcanceralliance.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","route":"/institutions/north-central-london-cancer-alliance/","field":"links","label":"North Central London Cancer Alliance"},{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","route":"/institutions/north-central-london-cancer-alliance/","field":"website"}]},{"url":"https://www.ncnatureceuticals.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","route":"/companies/natureceuticals/","field":"links","label":"Official website"},{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","route":"/companies/natureceuticals/","field":"website"}]},{"url":"https://www.ncra-usa.org/About/Publications/Journal-of-Registry-Management","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","route":"/journals/journal-of-registry-management/","field":"links","label":"Homepage"},{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","route":"/journals/journal-of-registry-management/","field":"url"}]},{"url":"https://www.nct-dresden.de","status":200,"ok":true,"finalUrl":"https://www.nct-dresden.de/de","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"Homepage"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"website"}]},{"url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"links","label":"Institution profile"},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","field":"profiles","label":"Institution profile"},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"links","label":"Institution profile"},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","field":"profiles","label":"Institution profile"},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","field":"links","label":"Institution profile"},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.nct-heidelberg.de","status":200,"ok":true,"finalUrl":"https://www.nct-heidelberg.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"links","label":"Official website"},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"website"}]},{"url":"https://www.nebraskamed.com/cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","field":"links","label":"Nebraska Medicine cancer care"}]},{"url":"https://www.nejmgroup.org","status":200,"ok":true,"finalUrl":"https://www.nejmgroup.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","field":"links","label":"NEJM Group"}]},{"url":"https://www.nektar.com","status":200,"ok":true,"finalUrl":"https://www.nektar.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","field":"links","label":"Official website"},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","field":"website"}]},{"url":"https://www.nelcanceralliance.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.nelcanceralliance.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","route":"/institutions/north-east-london-cancer-alliance/","field":"links","label":"North East London Cancer Alliance"},{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","route":"/institutions/north-east-london-cancer-alliance/","field":"website"}]},{"url":"https://www.neonc.com","status":200,"ok":true,"finalUrl":"https://neonc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/","field":"links","label":"Official website"},{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/","field":"website"}]},{"url":"https://www.neovii.com","status":200,"ok":true,"finalUrl":"https://neovii.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/","field":"links","label":"Official website"},{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/","field":"website"}]},{"url":"https://www.netrispharma.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"netris-pharma","kind":"company","name":"Netris Pharma","route":"/companies/netris-pharma/","field":"links","label":"Official website"},{"id":"netris-pharma","kind":"company","name":"Netris Pharma","route":"/companies/netris-pharma/","field":"website"}]},{"url":"https://www.neuboron.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuboron-medtech","kind":"company","name":"Neuboron Medtech","route":"/companies/neuboron-medtech/","field":"links","label":"Official website"},{"id":"neuboron-medtech","kind":"company","name":"Neuboron Medtech","route":"/companies/neuboron-medtech/","field":"website"}]},{"url":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services/","status":200,"ok":true,"finalUrl":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services-and-support/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","field":"links","label":"Cancer services"},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","field":"website"}]},{"url":"https://www.news.cn/digital/20250819/687dbd6108a141b7951f20ca6c64e4a8/c.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xiang-hua","kind":"person","name":"Xiang Hua","route":"/people/xiang-hua/","field":"links","label":"Source: Xinhua 'Dialogue on Healthy China' interview naming him President of Hunan Cancer Hospital (August 2025)"},{"id":"xiang-hua","kind":"person","name":"Xiang Hua","route":"/people/xiang-hua/","field":"profiles","label":"Xinhua interview (Chinese)"}]},{"url":"https://www.newswire.com/news/imagene-ai-hits-45m-in-total-funding-after-completing-23m-series-b-led-22597953","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","field":"links","label":"Series B release (Jul 2025)"}]},{"url":"https://www.nexcella.com","status":200,"ok":true,"finalUrl":"https://nexcella.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.nfsygehus.dk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","field":"links","label":"Zealand University Hospital website"},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","field":"profiles","label":"Zealand University Hospital website"}]},{"url":"https://www.nhs-galleri.org","status":200,"ok":true,"finalUrl":"https://www.nhs-galleri.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"links","label":"NHS-Galleri"},{"id":"idea-prev-mced-stage-endpoint-surrogate","kind":"idea","name":"Let MCED trials read out on late-stage incidence, with mortality follow-up mandated","route":"/ideas/idea-prev-mced-stage-endpoint-surrogate/","field":"links","label":"NHS-Galleri trial"},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/","field":"links","label":"NHS-Galleri trial site"},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","field":"links","label":"NHS-Galleri trial"}]},{"url":"https://www.nhs.uk/better-health/quit-smoking/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS Better Health: quit smoking"}]},{"url":"https://www.nhs.uk/conditions/bile-duct-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"NHS: bile duct cancer, symptoms"}]},{"url":"https://www.nhs.uk/conditions/bowel-cancer-screening/","status":200,"ok":true,"finalUrl":"https://www.nhs.uk/tests-and-treatments/bowel-cancer-screening/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","field":"links","label":"NHS bowel cancer screening"}]},{"url":"https://www.nhs.uk/conditions/bowel-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: bowel cancer"}],"archive":"https://web.archive.org/web/20260923180945/https://www.nhs.uk/conditions/bowel-cancer/"},{"url":"https://www.nhs.uk/conditions/bowel-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: bowel cancer, symptoms"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"NHS: bowel cancer, symptoms"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: bowel cancer, symptoms"}],"archive":"https://web.archive.org/web/20260925064539/https://www.nhs.uk/conditions/bowel-cancer/symptoms/"},{"url":"https://www.nhs.uk/conditions/bowel-cancer/tests-and-next-steps/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: bowel cancer, tests and next steps"},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","field":"links","label":"NHS: bowel cancer, tests and next steps"}],"archive":"https://web.archive.org/web/20260826083528/https://www.nhs.uk/conditions/bowel-cancer/tests-and-next-steps/"},{"url":"https://www.nhs.uk/conditions/bowel-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: bowel cancer, treatment"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"NHS: bowel cancer, treatment"}],"archive":"https://web.archive.org/web/20260902183327/https://www.nhs.uk/conditions/bowel-cancer/treatment/"},{"url":"https://www.nhs.uk/conditions/breast-cancer-in-men/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: breast cancer in men"}]},{"url":"https://www.nhs.uk/conditions/breast-cancer-in-women/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: breast cancer in women"}]},{"url":"https://www.nhs.uk/conditions/breast-cancer-in-women/help-and-support-for-breast-cancer-in-women/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: help and support for breast cancer in women"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"NHS: help and support for breast cancer in women"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: help and support for breast cancer in women"}],"archive":"https://web.archive.org/web/20260918061312/https://www.nhs.uk/conditions/breast-cancer-in-women/help-and-support-for-breast-cancer-in-women/"},{"url":"https://www.nhs.uk/conditions/breast-cancer-in-women/tests-and-next-steps-for-breast-cancer-in-women/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: tests and next steps for breast cancer in women"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: tests and next steps for breast cancer in women"}],"archive":"https://web.archive.org/web/20260918061312/https://www.nhs.uk/conditions/breast-cancer-in-women/tests-and-next-steps-for-breast-cancer-in-women/"},{"url":"https://www.nhs.uk/conditions/breast-cancer-in-women/treatment-for-breast-cancer-in-women/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: treatment for breast cancer in women"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"NHS: treatment for breast cancer in women"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: treatment for breast cancer in women"}],"archive":"https://web.archive.org/web/20260918061312/https://www.nhs.uk/conditions/breast-cancer-in-women/treatment-for-breast-cancer-in-women/"},{"url":"https://www.nhs.uk/conditions/breast-cancer/symptoms/","status":200,"ok":true,"finalUrl":"https://www.nhs.uk/conditions/breast-cancer-in-women/symptoms-of-breast-cancer-in-women/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: breast cancer in women, symptoms"}]},{"url":"https://www.nhs.uk/conditions/breast-screening-mammogram/","status":200,"ok":true,"finalUrl":"https://www.nhs.uk/tests-and-treatments/breast-screening-mammogram/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","field":"links","label":"NHS breast screening"}]},{"url":"https://www.nhs.uk/conditions/cellulitis/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: cellulitis"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: cellulitis"}]},{"url":"https://www.nhs.uk/conditions/cervical-screening/","status":200,"ok":true,"finalUrl":"https://www.nhs.uk/tests-and-treatments/cervical-screening/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","field":"links","label":"NHS cervical screening"}]},{"url":"https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: DVT (deep vein thrombosis)"},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","field":"links","label":"NHS: DVT (deep vein thrombosis)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: DVT (deep vein thrombosis)"}]},{"url":"https://www.nhs.uk/conditions/erection-problems-erectile-dysfunction/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: erection problems (erectile dysfunction)"},{"id":"erectile-dysfunction-after-prostate-cancer","kind":"term","name":"Erectile dysfunction after prostate cancer treatment","route":"/terms/erectile-dysfunction-after-prostate-cancer/","field":"links","label":"NHS: erection problems (erectile dysfunction)"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: gallbladder cancer"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/causes/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: causes of gallbladder cancer"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/help-and-support/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: gallbladder cancer, help and support"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"NHS: gallbladder cancer, help and support"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: symptoms of gallbladder cancer"},{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"NHS: gallbladder cancer, symptoms"},{"id":"pain-with-biliary-cancer","kind":"term","name":"Pain with gallbladder and bile duct cancer","route":"/terms/pain-with-biliary-cancer/","field":"links","label":"NHS: gallbladder cancer, symptoms"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: gallbladder cancer, symptoms"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: gallbladder cancer, symptoms"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/tests-and-next-steps/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: tests and next steps for gallbladder cancer"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","field":"links","label":"NHS: tests and next steps for gallbladder cancer"}]},{"url":"https://www.nhs.uk/conditions/gallbladder-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NHS: gallbladder cancer, treatment"},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"NHS: gallbladder cancer, treatment"}]},{"url":"https://www.nhs.uk/conditions/jaundice/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: jaundice"},{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"NHS: jaundice"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: jaundice"},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","field":"links","label":"NHS: jaundice"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: jaundice"}]},{"url":"https://www.nhs.uk/conditions/lung-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NHS: lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: lung cancer"}],"archive":"https://web.archive.org/web/20260926162243/https://www.nhs.uk/conditions/lung-cancer/"},{"url":"https://www.nhs.uk/conditions/lung-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NHS: symptoms of lung cancer (when to see a GP, when to call 111 and when to call 999)"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","field":"links","label":"NHS: symptoms of lung cancer"},{"id":"haemoptysis","kind":"term","name":"Haemoptysis (coughing up blood)","route":"/terms/haemoptysis/","field":"links","label":"NHS: symptoms of lung cancer (when to see a GP, when to call 111 and when to call 999)"},{"id":"pancoast-tumour","kind":"term","name":"Pancoast (superior sulcus) tumour","route":"/terms/pancoast-tumour/","field":"links","label":"NHS: symptoms of lung cancer (when to see a GP, when to call 111 and when to call 999)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: symptoms of lung cancer (when to see a GP, when to call 111 and when to call 999)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: symptoms of lung cancer"}],"archive":"https://web.archive.org/web/20260917162248/https://www.nhs.uk/conditions/lung-cancer/symptoms/"},{"url":"https://www.nhs.uk/conditions/lung-cancer/tests-and-next-steps/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"links","label":"NHS: tests and next steps for lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: tests and next steps for lung cancer"}]},{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NHS: treatment for lung cancer"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"NHS: treatment for lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: treatment for lung cancer"}],"archive":"https://web.archive.org/web/20260917162248/https://www.nhs.uk/conditions/lung-cancer/treatment/"},{"url":"https://www.nhs.uk/conditions/lymphoedema/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"NHS: lymphoedema"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: lymphoedema"}]},{"url":"https://www.nhs.uk/conditions/lymphoedema/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"NHS: lymphoedema, treatment"},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"NHS: lymphoedema, treatment"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: lymphoedema, treatment"}]},{"url":"https://www.nhs.uk/conditions/menopause-and-perimenopause/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"menopause-after-chemotherapy-breast","kind":"term","name":"Menopause symptoms after chemotherapy for breast cancer","route":"/terms/menopause-after-chemotherapy-breast/","field":"links","label":"NHS: menopause, symptoms"},{"id":"menopause-after-chemotherapy-breast","kind":"term","name":"Menopause symptoms after chemotherapy for breast cancer","route":"/terms/menopause-after-chemotherapy-breast/","field":"links","label":"NHS: menopause and perimenopause, symptoms"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: menopause and perimenopause, symptoms"}]},{"url":"https://www.nhs.uk/conditions/nhs-screening/","status":200,"ok":true,"finalUrl":"https://www.nhs.uk/tests-and-treatments/nhs-screening/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","field":"links","label":"NHS cancer screening programmes"},{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","field":"url"}]},{"url":"https://www.nhs.uk/conditions/non-melanoma-skin-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: non-melanoma skin cancer"}]},{"url":"https://www.nhs.uk/conditions/non-melanoma-skin-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: non-melanoma skin cancer, symptoms"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"NHS: non-melanoma skin cancer, symptoms"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"NHS: non-melanoma skin cancer, symptoms"}]},{"url":"https://www.nhs.uk/conditions/non-melanoma-skin-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: treatment for non-melanoma skin cancer"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"NHS: treatment for non-melanoma skin cancer"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: pancreatic cancer"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/causes/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: causes of pancreatic cancer"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/help-and-support/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: pancreatic cancer, help and support"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"NHS: pancreatic cancer, help and support"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: pancreatic cancer, symptoms"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: pancreatic cancer, symptoms"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: pancreatic cancer, symptoms"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/tests-and-next-steps/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: pancreatic cancer, tests and next steps"}]},{"url":"https://www.nhs.uk/conditions/pancreatic-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: pancreatic cancer, treatment"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"NHS: pancreatic cancer, treatment"}]},{"url":"https://www.nhs.uk/conditions/peripheral-neuropathy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"NHS: peripheral neuropathy"}]},{"url":"https://www.nhs.uk/conditions/prostate-cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: prostate cancer"}]},{"url":"https://www.nhs.uk/conditions/prostate-cancer/help-and-support/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: help and support for prostate cancer"}]},{"url":"https://www.nhs.uk/conditions/prostate-cancer/symptoms/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: symptoms of prostate cancer, and what happens at the GP appointment"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: symptoms of prostate cancer"}]},{"url":"https://www.nhs.uk/conditions/prostate-cancer/tests-and-next-steps/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: tests and next steps for prostate cancer"}]},{"url":"https://www.nhs.uk/conditions/prostate-cancer/treatment/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: treatment for prostate cancer"}]},{"url":"https://www.nhs.uk/conditions/scars/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: scars (reviewed 18 September 2023, next review due 18 September 2026)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (The part nobody counts: a face you did not choose, and the fear of the next mark)"},{"id":"facial-scar-after-skin-cancer","kind":"term","name":"The scar on the face after skin cancer surgery","route":"/terms/facial-scar-after-skin-cancer/","field":"links","label":"NHS: scars (reviewed 18 September 2023, next review due 18 September 2026)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: scars"}]},{"url":"https://www.nhs.uk/conditions/sepsis/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: sepsis"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: sepsis"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: sepsis"},{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","field":"links","label":"NHS: sepsis"},{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","field":"links","label":"NHS: sepsis"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"NHS: sepsis"},{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"NHS: sepsis"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: sepsis"},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"NHS: sepsis"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","field":"links","label":"NHS: sepsis"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: sepsis"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: sepsis"}]},{"url":"https://www.nhs.uk/conditions/sunburn/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: sunburn"}]},{"url":"https://www.nhs.uk/conditions/urinary-incontinence/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: urinary incontinence"}]},{"url":"https://www.nhs.uk/live-well/seasonal-health/sunscreen-and-sun-safety/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: sunscreen and sun safety"},{"id":"sun-protection-after-skin-cancer","kind":"term","name":"Sun protection after a skin cancer diagnosis","route":"/terms/sun-protection-after-skin-cancer/","field":"links","label":"NHS: sunscreen and sun safety"}]},{"url":"https://www.nhs.uk/nhs-services/help-with-health-costs/healthcare-travel-costs-scheme-htcs/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-healthcare-travel-costs-scheme","kind":"collection","name":"NHS Healthcare Travel Costs Scheme","route":"/collections/nhs-healthcare-travel-costs-scheme/","field":"links","label":"NHS Healthcare Travel Costs Scheme"},{"id":"nhs-healthcare-travel-costs-scheme","kind":"collection","name":"NHS Healthcare Travel Costs Scheme","route":"/collections/nhs-healthcare-travel-costs-scheme/","field":"url"}]},{"url":"https://www.nhs.uk/nhs-services/help-with-health-costs/wigs-and-fabric-supports-on-the-nhs/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","field":"links","label":"NHS: wigs and fabric supports on the NHS"}]},{"url":"https://www.nhs.uk/nhs-services/urgent-and-emergency-care-services/when-to-call-999/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: when to call 999"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: when to call 999"},{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","field":"links","label":"NHS: when to call 999"},{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","field":"links","label":"NHS: when to call 999"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"NHS: when to call 999"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: when to call 999"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: when to call 999"}]},{"url":"https://www.nhs.uk/nhs-services/urgent-and-emergency-care-services/when-to-use-111/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NHS: when to use 111"},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"NHS: when to use 111"},{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","field":"links","label":"NHS: when to use 111"},{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","field":"links","label":"NHS: when to use 111"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"NHS: when to use 111"},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: when to use 111"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: when to use 111"}]},{"url":"https://www.nhs.uk/social-care-and-support/support-and-benefits-for-carers/benefits-for-carers/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: benefits for carers"},{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"NHS: benefits for carers"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: benefits for carers"}]},{"url":"https://www.nhs.uk/social-care-and-support/support-and-benefits-for-carers/carer-assessments/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: carer's assessments"},{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","field":"links","label":"NHS: carer's assessments"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: carer's assessments"}]},{"url":"https://www.nhs.uk/symptoms/coughing-up-blood/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: coughing up blood (blood in phlegm)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: coughing up blood (blood in phlegm)"}]},{"url":"https://www.nhs.uk/symptoms/diarrhoea-and-vomiting/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: diarrhoea and vomiting"}]},{"url":"https://www.nhs.uk/symptoms/priapism-painful-erections/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: priapism (painful erections)"},{"id":"priapism","kind":"term","name":"Priapism","route":"/terms/priapism/","field":"links","label":"NHS: priapism (painful erections)"}]},{"url":"https://www.nhs.uk/symptoms/vomiting-blood/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","field":"links","label":"NHS: vomiting blood"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: vomiting blood"}]},{"url":"https://www.nhs.uk/tests-and-treatments/bowel-cancer-screening/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: bowel cancer screening (the home test kit, ages 50 to 74)"},{"id":"paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised controlled trial of faecal-occult-blood screening for colorectal cancer (Nottingham)","route":"/key-papers/paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996/","field":"links","label":"NHS bowel cancer screening"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"NHS: bowel cancer screening (the home test kit, ages 50 to 74)"}]},{"url":"https://www.nhs.uk/tests-and-treatments/breast-screening-mammogram/who-breast-screening-is-for/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: who breast screening is for (ages 50 to 71, every 3 years)"},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"links","label":"NHS: who breast screening is for (ages 50 to 71, every 3 years)"}],"archive":"https://web.archive.org/web/20260806085916/https://www.nhs.uk/tests-and-treatments/breast-screening-mammogram/who-breast-screening-is-for/"},{"url":"https://www.nhs.uk/tests-and-treatments/clinical-trials/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: clinical trials"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: clinical trials"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: clinical trials"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NHS: clinical trials"},{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","route":"/terms/trial-or-standard-treatment-biliary/","field":"links","label":"NHS: clinical trials"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: clinical trials"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: clinical trials"}],"archive":"https://web.archive.org/web/20260815044530/https://www.nhs.uk/tests-and-treatments/clinical-trials/"},{"url":"https://www.nhs.uk/tests-and-treatments/colostomy/complications-of-a-colostomy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: complications of a colostomy"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"NHS: complications of a colostomy"},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","field":"links","label":"NHS: complications of a colostomy"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"NHS: complications of a colostomy"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NHS: complications of a colostomy"}],"archive":"https://web.archive.org/web/20260609181901/https://www.nhs.uk/tests-and-treatments/colostomy/complications-of-a-colostomy/"},{"url":"https://www.nhs.uk/tests-and-treatments/colostomy/recovery-and-lifestyle-changes-after-a-colostomy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: recovery and lifestyle changes after a colostomy"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"NHS: recovery and lifestyle changes after a colostomy"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"NHS: recovery and lifestyle changes after a colostomy"},{"id":"work-and-money-bowel-cancer-uk","kind":"term","name":"Work and money with bowel cancer (UK)","route":"/terms/work-and-money-bowel-cancer-uk/","field":"links","label":"NHS: recovery and lifestyle changes after a colostomy"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"NHS: recovery and lifestyle changes after a colostomy"}],"archive":"https://web.archive.org/web/20260618041804/https://www.nhs.uk/tests-and-treatments/colostomy/recovery-and-lifestyle-changes-after-a-colostomy/"},{"url":"https://www.nhs.uk/tests-and-treatments/colostomy/what-is-a-colostomy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"NHS: what is a colostomy?"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"NHS: what is a colostomy?"}]},{"url":"https://www.nhs.uk/tests-and-treatments/gallbladder-removal/recovery/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eating-after-gallbladder-removal","kind":"term","name":"Eating after gallbladder removal","route":"/terms/eating-after-gallbladder-removal/","field":"links","label":"NHS: gallbladder removal, recovery"}]},{"url":"https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","field":"links","label":"NHS: genetic and genomic testing"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: genetic and genomic testing"}],"archive":"https://web.archive.org/web/20260905123726/https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/"},{"url":"https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NHS: lung cancer screening (who is invited to a lung health check and what happens)"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","field":"links","label":"NHS: lung cancer screening (who is invited to a lung health check and what happens)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NHS: lung cancer screening (who is invited to a lung health check and what happens)"}],"archive":"https://web.archive.org/web/20260525163940/https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/"},{"url":"https://www.nhs.uk/tests-and-treatments/mastectomy/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"NHS: mastectomy"},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"links","label":"NHS: mastectomy"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NHS: mastectomy"}]},{"url":"https://www.nhs.uk/vaccinations/hpv-vaccine/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","route":"/collections/nhs-hpv-vaccination/","field":"links","label":"NHS HPV vaccination programme"},{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","route":"/collections/nhs-hpv-vaccination/","field":"url"}]},{"url":"https://www.nhsa.gov.cn/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","field":"links","label":"NHSA"},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","field":"website"}]},{"url":"https://www.nhsggc.scot/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"glasgow-royal-infirmary","kind":"institution","name":"Glasgow Royal Infirmary","route":"/institutions/glasgow-royal-infirmary/","field":"links","label":"NHS Greater Glasgow and Clyde"},{"id":"glasgow-royal-infirmary","kind":"institution","name":"Glasgow Royal Infirmary","route":"/institutions/glasgow-royal-infirmary/","field":"website"}]},{"url":"https://www.nhsgrampian.org","status":200,"ok":true,"finalUrl":"https://www.nhsgrampian.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"anchor-centre-aberdeen","kind":"institution","name":"ANCHOR Centre, Aberdeen Royal Infirmary","route":"/institutions/anchor-centre-aberdeen/","field":"links","label":"Official website"},{"id":"anchor-centre-aberdeen","kind":"institution","name":"ANCHOR Centre, Aberdeen Royal Infirmary","route":"/institutions/anchor-centre-aberdeen/","field":"website"}]},{"url":"https://www.nhsgrampian.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aberdeen-royal-infirmary","kind":"institution","name":"Aberdeen Royal Infirmary","route":"/institutions/aberdeen-royal-infirmary/","field":"links","label":"NHS Grampian"},{"id":"aberdeen-royal-infirmary","kind":"institution","name":"Aberdeen Royal Infirmary","route":"/institutions/aberdeen-royal-infirmary/","field":"website"}]},{"url":"https://www.nhsgrampian.org/about-us/grampian-nhs-board/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","field":"links","label":"Source: Grampian NHS Board membership page"},{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","field":"profiles","label":"NHS Grampian board page"}]},{"url":"https://www.nhsgrampian.org/siteassets/about-us/nhsg-board/laura_skaife-knight_biography.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","field":"links","label":"Source: NHS Grampian chief executive biography"},{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","field":"profiles","label":"Chief Executive biography (PDF)"}]},{"url":"https://www.nhshighland.scot.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raigmore-inverness","kind":"institution","name":"Raigmore Hospital, Inverness","route":"/institutions/raigmore-inverness/","field":"links","label":"NHS Highland"},{"id":"raigmore-inverness","kind":"institution","name":"Raigmore Hospital, Inverness","route":"/institutions/raigmore-inverness/","field":"website"}]},{"url":"https://www.nhslothian.scot/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-infirmary-edinburgh","kind":"institution","name":"Royal Infirmary of Edinburgh","route":"/institutions/royal-infirmary-edinburgh/","field":"links","label":"NHS Lothian"},{"id":"royal-infirmary-edinburgh","kind":"institution","name":"Royal Infirmary of Edinburgh","route":"/institutions/royal-infirmary-edinburgh/","field":"website"}]},{"url":"https://www.nhstayside.scot.nhs.uk/","status":200,"ok":true,"finalUrl":"https://www.nhstayside.scot.nhs.uk/index.htm","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","route":"/institutions/ninewells-dundee/","field":"links","label":"NHS Tayside: hepatobiliary and pancreatic surgery"},{"id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","route":"/institutions/ninewells-dundee/","field":"website"}]},{"url":"https://www.nice.org.uk","status":200,"ok":true,"finalUrl":"https://www.nice.org.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","field":"links","label":"NICE"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","field":"website"}]},{"url":"https://www.nice.org.uk/about-us/executive-team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"links","label":"Source: NICE executive team page"},{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","field":"profiles","label":"NICE executive team"}]},{"url":"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/","status":200,"ok":true,"finalUrl":"https://www.nice.org.uk/what-nice-does/our-guidance/about-technology-appraisal-guidance","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-combination-price-attribution","kind":"idea","name":"A combination pricing rule so two-drug regimens are not priced as two monopolies","route":"/ideas/idea-reg-combination-price-attribution/","field":"links","label":"NICE combination treatments framework (page moved; nearest live section)"}]},{"url":"https://www.nice.org.uk/guidance","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","field":"links","label":"NICE technology appraisals"}]},{"url":"https://www.nice.org.uk/guidance/cg151","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","field":"links","label":"NICE CG151: neutropenic sepsis"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","field":"links","label":"NICE CG151: neutropenic sepsis"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","field":"links","label":"NICE CG151: neutropenic sepsis"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE CG151: neutropenic sepsis"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE CG151: neutropenic sepsis"}]},{"url":"https://www.nice.org.uk/guidance/cg164/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Surveillance and risk reduction for BRCA carriers (before any cancer))"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","field":"links","label":"NICE CG164: familial breast cancer (referral, genetic testing, surveillance, risk-reducing surgery, chemoprevention)"},{"id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/","field":"links","label":"NICE CG164 recommendations"},{"id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/","field":"links","label":"NICE CG164 recommendations"}],"archive":"https://web.archive.org/web/20260922112029/https://www.nice.org.uk/guidance/cg164/chapter/Recommendations"},{"url":"https://www.nice.org.uk/guidance/cg81/chapter/Diagnosis-and-assessment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"receptor-conversion-breast","kind":"term","name":"Receptor conversion: when the receptors change between the primary and a recurrence","route":"/terms/receptor-conversion-breast/","field":"links","label":"NICE CG81: advanced breast cancer, diagnosis and treatment, diagnosis and assessment section (published 23 February 2009, last updated 30 June 2026)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE CG81: advanced breast cancer, diagnosis and treatment, diagnosis and assessment section (published 23 February 2009, last updated 30 June 2026)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (At recurrence)"}]},{"url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","field":"links","label":"NICE cancer topic page"},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","field":"url"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","field":"links","label":"Cancer guidance"}]},{"url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer/biliary-tract-cancers/products","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NICE: guidance on biliary tract cancers"}]},{"url":"https://www.nice.org.uk/guidance/csg8","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NICE CSG8: improving outcomes for people with skin tumours including melanoma"}]},{"url":"https://www.nice.org.uk/guidance/dg34","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"links","label":"NICE DG34: tumour profiling tests for breast cancer"},{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/","field":"links","label":"NICE DG34: tumour profiling tests for breast cancer"},{"id":"endopredict","kind":"drug","name":"EndoPredict","route":"/drugs/endopredict/","field":"links","label":"NICE DG34"}]},{"url":"https://www.nice.org.uk/guidance/dg56","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NICE HealthTech guidance: quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care"}]},{"url":"https://www.nice.org.uk/guidance/indevelopment/gid-ta10143","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/","field":"links","label":"NICE appraisal (in development)"}]},{"url":"https://www.nice.org.uk/guidance/ng101","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-conserving-surgery-versus-mastectomy","kind":"term","name":"Breast conservation or mastectomy","route":"/terms/breast-conserving-surgery-versus-mastectomy/","field":"links","label":"NICE NG101 recommendations 1.4.3 and 1.4.5, surgery to the breast"},{"id":"oncoplastic-breast-surgery","kind":"term","name":"Oncoplastic breast surgery","route":"/terms/oncoplastic-breast-surgery/","field":"links","label":"NICE NG101 recommendation 1.4.2, oncoplastic repair in Paget's disease of the nipple"},{"id":"axillary-surgery-de-escalation","kind":"term","name":"Doing less to the armpit","route":"/terms/axillary-surgery-de-escalation/","field":"links","label":"NICE NG101 recommendations 1.4.9 to 1.4.15, surgery to the axilla"},{"id":"breast-cancer-related-lymphoedema","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/breast-cancer-related-lymphoedema/","field":"links","label":"NICE NG101 recommendation 1.13.20, no axillary radiotherapy after clearance"},{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"NICE NG101 recommendations 1.5.1 to 1.5.5, breast reconstruction"},{"id":"radiotherapy-omission-early-breast-cancer","kind":"term","name":"Leaving radiotherapy out","route":"/terms/radiotherapy-omission-early-breast-cancer/","field":"links","label":"NICE NG101 recommendations 1.13.3, 1.13.7 and 1.13.8, radiotherapy after breast-conserving surgery"},{"id":"partial-breast-irradiation","kind":"term","name":"Partial-breast irradiation","route":"/terms/partial-breast-irradiation/","field":"links","label":"NICE NG101 recommendations 1.13.4 to 1.13.6, partial-breast radiotherapy"},{"id":"tumour-bed-boost","kind":"term","name":"Tumour bed boost","route":"/terms/tumour-bed-boost/","field":"links","label":"NICE NG101 recommendations 1.13.17 and 1.13.18, breast boost"},{"id":"post-mastectomy-radiotherapy","kind":"term","name":"Radiotherapy after mastectomy","route":"/terms/post-mastectomy-radiotherapy/","field":"links","label":"NICE NG101 recommendations 1.13.10 to 1.13.12, radiotherapy after mastectomy"},{"id":"neoadjuvant-versus-adjuvant-breast","kind":"term","name":"Drugs before or after the operation","route":"/terms/neoadjuvant-versus-adjuvant-breast/","field":"links","label":"NICE NG101 recommendations 1.13.25 to 1.13.29, radiotherapy after neoadjuvant chemotherapy"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Surgery to the breast: conservation or mastectomy)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Margins and further surgery)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Staging the axilla when the nodes look clear)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (A positive sentinel node)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (The axilla after chemotherapy given before surgery)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Radiotherapy after breast-conserving surgery)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Dose and schedule)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Who can leave radiotherapy out)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Radiotherapy after mastectomy, and to the nodes)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Reconstruction)"}]},{"url":"https://www.nice.org.uk/guidance/ng101/chapter/recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"nottingham-prognostic-index","kind":"term","name":"Nottingham Prognostic Index (NPI), and PREDICT","route":"/terms/nottingham-prognostic-index/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"grade-stage-receptor-breast","kind":"term","name":"Grade, stage and receptor status: three different things on one breast report","route":"/terms/grade-stage-receptor-breast/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"er-pr-scoring-breast","kind":"term","name":"How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item)","route":"/terms/er-pr-scoring-breast/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, diagnosis and management (published 18 July 2018, last updated 14 April 2025)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Every invasive breast cancer, at diagnosis)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Staging and prognostic assessment)"}],"archive":"https://web.archive.org/web/20260925100516/https://www.nice.org.uk/guidance/ng101/chapter/Recommendations"},{"url":"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE NG101: early and locally advanced breast cancer (receptor testing 1.3, genetic testing 1.3.6, triple-negative section 1.8)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Receptor testing that defines the subtype)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Germline testing at diagnosis)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Staging and the pathology report)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Chemotherapy before or after surgery)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Mastectomy or breast-conserving surgery, and when to reconstruct)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Radiotherapy after surgery: which schedule and where)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Fertility preservation before chemotherapy)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Genetic testing and what a BRCA result means for your family)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"NICE NG101: early and locally advanced breast cancer (receptor testing 1.3, genetic testing 1.3.6, triple-negative section 1.8)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"standardOfCare.guideline (At diagnosis)"},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","field":"links","label":"NICE NG101: early and locally advanced breast cancer (receptor testing 1.3, genetic testing 1.3.6, triple-negative section 1.8)"},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"links","label":"NICE NG101: early and locally advanced breast cancer (receptor testing 1.3, genetic testing 1.3.6, triple-negative section 1.8)"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"NICE NG101: early and locally advanced breast cancer (receptor testing 1.3, genetic testing 1.3.6, triple-negative section 1.8)"},{"id":"menopause-after-chemotherapy-breast","kind":"term","name":"Menopause symptoms after chemotherapy for breast cancer","route":"/terms/menopause-after-chemotherapy-breast/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"numbness-after-breast-surgery","kind":"term","name":"Numbness and nerve pain after breast surgery","route":"/terms/numbness-after-breast-surgery/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"cording-axillary-web-syndrome","kind":"term","name":"Cording (axillary web syndrome)","route":"/terms/cording-axillary-web-syndrome/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"seroma-after-breast-surgery","kind":"term","name":"Seroma after breast surgery","route":"/terms/seroma-after-breast-surgery/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"breast-margins-and-re-excision","kind":"term","name":"Margins after breast-conserving surgery, and second operations","route":"/terms/breast-margins-and-re-excision/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Breast-conserving surgery or mastectomy)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Reconstruction surgery, delayed reconstruction, or neither)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Surgery to the armpit, and the lymphoedema risk that lasts for life)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Body image, sensation and sex)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Hair, and whether scalp cooling is worth it)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Survivorship: follow-up, and which symptom is worth a phone call)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE NG101: early and locally advanced breast cancer, recommendations (updated 2025)"}],"archive":"https://web.archive.org/web/20260925100516/https://www.nice.org.uk/guidance/ng101/chapter/Recommendations"},{"url":"https://www.nice.org.uk/guidance/ng12","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Referral when symptoms suggest bowel cancer)"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"NICE NG12: suspected cancer, recognition and referral"},{"id":"idea-crc-uk-colonoscopy-capacity-and-fit-threshold","kind":"idea","name":"UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set","route":"/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/","field":"links","label":"NICE NG12: suspected cancer, recognition and referral"},{"id":"idea-crc-uk-young-patient-referral-and-diagnostic-interval","kind":"idea","name":"UK gap: shorten the route to diagnosis for patients below the screening age, where the rise in incidence is","route":"/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/","field":"links","label":"NICE NG12: suspected cancer, recognition and referral"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Referral when symptoms suggest lung cancer (UK))"}]},{"url":"https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (breast cancer 1.4)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Suspected cancer in primary care)"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lower gastrointestinal tract 1.3.1 to 1.3.5)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (pancreatic cancer 1.2.4 and 1.2.5)"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NICE NG12: suspected cancer, skin cancers (recommendations 1.7.1 to 1.7.7)"},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (pancreatic cancer 1.2.4 and 1.2.5)"},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (pancreatic cancer 1.2.4 and 1.2.5)"},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lower gastrointestinal tract 1.3.1 to 1.3.5)"},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lower gastrointestinal tract 1.3.1 to 1.3.5)"},{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lower gastrointestinal tract 1.3.1 to 1.3.5)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (gall bladder cancer 1.2.10)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Suspected cancer in primary care)"},{"id":"asbestos","kind":"term","name":"Asbestos","route":"/terms/asbestos/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6)"},{"id":"haemoptysis","kind":"term","name":"Haemoptysis (coughing up blood)","route":"/terms/haemoptysis/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6)"}]},{"url":"https://www.nice.org.uk/guidance/ng122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/","field":"links","label":"NICE NG122: lung cancer, diagnosis and management"},{"id":"lung-palliation-breathlessness-effusion-obstruction","kind":"term","name":"Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain","route":"/terms/lung-palliation-breathlessness-effusion-obstruction/","field":"links","label":"NICE NG122: lung cancer, diagnosis and management"},{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","field":"links","label":"NICE NG122: lung cancer, diagnosis and management"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Screening for lung cancer in people who have smoked)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Palliation: breathlessness, pleural effusion and a blocked airway)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Palliation: bone and brain metastases)"}]},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Diagnosis-and-staging","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"pancoast-tumour","kind":"term","name":"Pancoast (superior sulcus) tumour","route":"/terms/pancoast-tumour/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"sublobar-resection","kind":"term","name":"Sublobar resection (segmentectomy and wedge)","route":"/terms/sublobar-resection/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging"},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (What a biomarker result changes once the cancer has spread, and why waiting for it is usually right)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (When a targeted drug stops working (resistance): the second biopsy and what comes next)"}],"archive":"https://web.archive.org/web/20260610084349/https://www.nice.org.uk/guidance/ng122/chapter/Diagnosis-and-staging"},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG122: lung cancer, follow-up and patient perspectives"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NICE NG122: lung cancer, follow-up and patient perspectives"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"NICE NG122: lung cancer, follow-up and patient perspectives"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG122: lung cancer, follow-up and patient perspectives"}],"archive":"https://web.archive.org/web/20260510103234/https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives"},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Management","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"standardOfCare.guideline (Small-cell lung cancer: why the timeline is faster, and what that means for your decisions)"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"segmentectomy","kind":"term","name":"Segmentectomy (sublobar resection)","route":"/terms/segmentectomy/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"pneumonectomy","kind":"term","name":"Pneumonectomy","route":"/terms/pneumonectomy/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG122: lung cancer, management"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Early lung cancer: surgery, radiotherapy or both, and what your lung function means for the choice)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Treatment before or after surgery, and which results have to come back first)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Locally advanced lung cancer that cannot be removed: chemoradiotherapy, then a year of immunotherapy)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Which immunotherapy, and whether with chemotherapy, by the PD-L1 score)"}],"archive":"https://web.archive.org/web/20260512210217/https://www.nice.org.uk/guidance/ng122/chapter/Management"},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"malignant-pleural-effusion","kind":"term","name":"Malignant pleural effusion","route":"/terms/malignant-pleural-effusion/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care (1.13 to 1.18)"},{"id":"superior-vena-cava-obstruction","kind":"term","name":"Superior vena cava obstruction","route":"/terms/superior-vena-cava-obstruction/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care (1.13 to 1.18)"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Lung cancer that has spread to the brain)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (When to talk about palliative care)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care"}],"archive":"https://web.archive.org/web/20260608120340/https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care"},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Recommendations-for-research","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"}]},{"url":"https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG122: lung cancer, support from clinical nurse specialists"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","field":"links","label":"NICE NG122: lung cancer, support from clinical nurse specialists"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"NICE NG122: lung cancer, support from clinical nurse specialists"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG122: lung cancer, support from clinical nurse specialists"}],"archive":"https://web.archive.org/web/20260512211553/https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists"},{"url":"https://www.nice.org.uk/guidance/ng131","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Localised prostate cancer, CPG 1 (low risk): the case for doing nothing yet)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Localised prostate cancer, CPG 2 to 3 (intermediate risk): surgery or radiotherapy, and how many visits)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Localised and locally advanced prostate cancer, CPG 4 to 5 (high risk): radiotherapy with long androgen deprivation)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (After radical prostatectomy with adverse pathology: wait for the PSA rather than irradiate everyone)"},{"id":"prostate-treatment-choice-localised","kind":"term","name":"Choosing treatment for localised prostate cancer: what each option costs","route":"/terms/prostate-treatment-choice-localised/","field":"links","label":"NICE NG131: prostate cancer: diagnosis and management"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","field":"links","label":"NICE NG131: prostate cancer: diagnosis and management"},{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","field":"links","label":"NICE NG131: prostate cancer: diagnosis and management"}]},{"url":"https://www.nice.org.uk/guidance/ng131/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Localised prostate cancer: monitoring, surgery or radiotherapy, and what each one costs you)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (If you choose radiotherapy: the schedule, and the hormone therapy that comes with it)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Living with hormone therapy: hot flushes, bones, heart, weight and mood, and what is offered for each)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Continence and sexual function: what happens, what help exists, and how to ask for it)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (A rising PSA after treatment: what it means, how fast it is rising, and what happens next)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (When to talk about palliative care)"},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"cambridge-prognostic-group","kind":"term","name":"Cambridge Prognostic Group (CPG 1 to 5)","route":"/terms/cambridge-prognostic-group/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"psa-density","kind":"term","name":"PSA density","route":"/terms/psa-density/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"extraprostatic-extension","kind":"term","name":"Extraprostatic extension and seminal vesicle invasion","route":"/terms/extraprostatic-extension/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"watchful-waiting","kind":"term","name":"Watchful waiting, and how it differs from active surveillance","route":"/terms/watchful-waiting/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"psa-doubling-time","kind":"term","name":"PSA doubling time","route":"/terms/psa-doubling-time/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"stress-urinary-incontinence","kind":"term","name":"Stress urinary incontinence","route":"/terms/stress-urinary-incontinence/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"pelvic-floor-muscle-exercises","kind":"term","name":"Pelvic floor muscle exercises","route":"/terms/pelvic-floor-muscle-exercises/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"artificial-urinary-sphincter","kind":"term","name":"Artificial urinary sphincter","route":"/terms/artificial-urinary-sphincter/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"erectile-dysfunction-after-prostate-cancer","kind":"term","name":"Erectile dysfunction after prostate cancer treatment","route":"/terms/erectile-dysfunction-after-prostate-cancer/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"treatment-induced-bone-loss","kind":"term","name":"Treatment-induced bone loss","route":"/terms/treatment-induced-bone-loss/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"hot-flushes-on-hormone-therapy","kind":"term","name":"Hot flushes on hormone therapy","route":"/terms/hot-flushes-on-hormone-therapy/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"gynaecomastia","kind":"term","name":"Gynaecomastia","route":"/terms/gynaecomastia/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations)"},{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations)"},{"id":"template-mapping-biopsy","kind":"term","name":"Template mapping biopsy (transperineal template prostate mapping)","route":"/terms/template-mapping-biopsy/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations)"},{"id":"intermittent-androgen-deprivation","kind":"term","name":"Intermittent androgen deprivation (IAD)","route":"/terms/intermittent-androgen-deprivation/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations)"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","field":"links","label":"NICE NG131: prostate cancer, diagnosis and management (recommendations, including the Cambridge Prognostic Group table at 1.2.15)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE NG131: prostate cancer, diagnosis and management"}]},{"url":"https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#terms-used-in-this-guideline","status":200,"ok":true,"finalUrl":"https://www.nice.org.uk/guidance/ng131/chapter/Recommendations","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"template-mapping-biopsy","kind":"term","name":"Template mapping biopsy (transperineal template prostate mapping)","route":"/terms/template-mapping-biopsy/","field":"links","label":"NICE NG131: terms used in this guideline (template biopsy and mapping template biopsy)"}]},{"url":"https://www.nice.org.uk/guidance/ng151","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (UK access to treatments (NICE, September 2026))"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Palliation: obstruction, stents and stomas)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Palliation: liver capsule pain, pelvic symptoms and early palliative care)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Diagnosis and staging (UK pathway))"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Acute left-sided large bowel obstruction)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Prevention and chemoprevention)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Follow-up after potentially curative surgery)"},{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/","field":"links","label":"NICE NG151: colorectal cancer (published 29 January 2020)"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","field":"links","label":"NICE NG151: colorectal cancer (published 29 January 2020)"},{"id":"colorectal-palliation-obstruction-pain","kind":"term","name":"Palliation in colorectal cancer: obstruction, stents, stomas and liver capsule pain","route":"/terms/colorectal-palliation-obstruction-pain/","field":"links","label":"NICE NG151: colorectal cancer"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE NG151: colorectal cancer"},{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"standardOfCare.guideline (Localised disease)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"standardOfCare.guideline (Finding the syndrome)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"standardOfCare.guideline (Risk reduction in carriers)"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"standardOfCare.guideline (Surveillance and prophylactic surgery in carriers)"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"standardOfCare.guideline (Cancer arising in polyposis)"}]},{"url":"https://www.nice.org.uk/guidance/ng151/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (The operation and what a stoma means: temporary or permanent)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Chemotherapy after surgery for stage 2 and stage 3, and how the benefit is worked out)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Rectal cancer: surgery or chemoradiotherapy first, and watch and wait if the tumour disappears)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Which first treatment when the cancer has spread, by RAS, BRAF, mismatch repair and which side of the bowel)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Surgery or ablation when the cancer has spread to the liver)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Immunotherapy when the tumour is mismatch repair deficient)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Later lines, when chemotherapy stops working)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Lynch syndrome testing, and what it means for your family)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (When to talk about palliative care)"},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"colonoscopy-surveillance-intervals","kind":"term","name":"Surveillance intervals after polypectomy","route":"/terms/colonoscopy-surveillance-intervals/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"colorectal-peritoneal-metastases","kind":"term","name":"Peritoneal metastases from bowel cancer","route":"/terms/colorectal-peritoneal-metastases/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"cytoreductive-surgery","kind":"term","name":"Cytoreductive surgery","route":"/terms/cytoreductive-surgery/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"heracles-criteria","kind":"term","name":"HERACLES criteria (HER2 in bowel cancer)","route":"/terms/heracles-criteria/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","field":"links","label":"NICE NG151: colorectal cancer, recommendations (Lynch 1.1, local disease 1.3, biomarkers 1.4, metastatic disease 1.5, ongoing care and support including follow-up 1.6)"},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/","field":"links","label":"NICE NG151: colorectal cancer, recommendations"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE NG151: colorectal cancer, recommendations"}],"archive":"https://web.archive.org/web/20260510065936/https://www.nice.org.uk/guidance/ng151/chapter/Recommendations"},{"url":"https://www.nice.org.uk/guidance/ng209","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","field":"links","label":"NICE NG209: tobacco, preventing uptake, promoting quitting and treating dependence (published 30 November 2021, last updated 4 February 2025)"},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","field":"links","label":"NICE NG209: tobacco, preventing uptake, promoting quitting and treating dependence (published 30 November 2021, last updated 4 February 2025)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG209: tobacco, preventing uptake, promoting quitting and treating dependence (published 30 November 2021, last updated 4 February 2025)"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Prevention and stopping smoking)"}],"archive":"https://web.archive.org/web/20260908213840/https://www.nice.org.uk/guidance/ng209"},{"url":"https://www.nice.org.uk/guidance/ng234/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (When prostate cancer reaches the bone: cord compression, pain, and protecting the skeleton)"},{"id":"metastatic-spinal-cord-compression","kind":"term","name":"Metastatic spinal cord compression (MSCC)","route":"/terms/metastatic-spinal-cord-compression/","field":"links","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"links","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"NICE NG234: spinal metastases and metastatic spinal cord compression, recommendations"}]},{"url":"https://www.nice.org.uk/guidance/ng257/chapter/Fertility-preservation-for-medical-indications","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","field":"links","label":"NICE NG257: fertility problems, fertility preservation for medical indications (2026)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"NICE NG257: fertility problems, fertility preservation for medical indications (2026)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Fertility and early menopause, decided before treatment starts)"}]},{"url":"https://www.nice.org.uk/guidance/ng34/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"NICE NG34: sunlight exposure, risks and benefits"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Sun protection after a diagnosis, for someone who still goes outside)"},{"id":"sun-protection-after-skin-cancer","kind":"term","name":"Sun protection after a skin cancer diagnosis","route":"/terms/sun-protection-after-skin-cancer/","field":"links","label":"NICE NG34: sunlight exposure, risks and benefits, recommendations (2016)"}]},{"url":"https://www.nice.org.uk/guidance/ng35","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/","field":"links","label":"NICE NG35: myeloma diagnosis and management (whole-body MRI as first-line imaging)"}]},{"url":"https://www.nice.org.uk/guidance/ng47","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE NG47: haematological cancers, improving outcomes"}]},{"url":"https://www.nice.org.uk/guidance/ng52","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE NG52: non-Hodgkin lymphoma, diagnosis and management"}]},{"url":"https://www.nice.org.uk/guidance/ng85","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Diagnosis and staging (UK pathway))"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Nutrition and pancreatic enzyme replacement)"},{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management (2018)"},{"id":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","kind":"paper","name":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","route":"/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/","field":"links","label":"NICE NG85: pancreatic cancer in adults (2018), including enzyme replacement"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management (published 7 February 2018)"},{"id":"idea-pdac-enzyme-replacement-prescribing-by-default","kind":"idea","name":"Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival","route":"/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/","field":"links","label":"NICE NG85: pancreatic cancer in adults (2018)"},{"id":"idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway","kind":"idea","name":"A fast-track pathway from suspicion to treatment for pancreatic cancer in the NHS, measured from first scan to first treatment","route":"/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/","field":"links","label":"NICE NG85: pancreatic cancer in adults (2018)"}]},{"url":"https://www.nice.org.uk/guidance/ng85/chapter/Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NICE NG85: pancreatic cancer in adults"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Resectable or borderline: surgery first or chemotherapy first)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Which chemotherapy: FOLFIRINOX, gemcitabine with nab-paclitaxel or NALIRIFOX, by fitness)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Chemotherapy after a Whipple operation)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Germline testing: what a BRCA result means for olaparib and for your family)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Jaundice: a stent or surgery)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Pain, including a coeliac plexus block)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Pancreatic enzymes and diabetes, after surgery or with the tumour)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Feeding and weight)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (A clinical trial or standard treatment)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Palliative care early, alongside treatment)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Adjuvant chemotherapy after resection)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Locally advanced unresectable disease: chemotherapy, chemoradiation, stereotactic radiotherapy and ablation)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Metastatic disease, first line)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Metastatic disease, second line)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Palliation: biliary and duodenal obstruction)"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (Palliation: pain, digestion, weight loss and thrombosis)"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","field":"links","label":"NICE NG85 recommendation 1.9.4"},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"pancreas-protocol-ct","kind":"term","name":"Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)","route":"/terms/pancreas-protocol-ct/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","field":"links","label":"NICE NG85: pancreatic cancer in adults, recommendations 1.5 to 1.7 (pain, nutrition, biliary and duodenal obstruction)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE NG85: pancreatic cancer in adults, recommendations 1.8 and 1.9"},{"id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","field":"links","label":"NICE NG85 recommendations 1.6.1 to 1.6.3: nutritional management"},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","field":"links","label":"NICE NG85 recommendations 1.8.7 and 1.9.6"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"NICE NG85: pancreatic cancer in adults (diagnosis 1.1, staging 1.3, nutrition 1.6, biliary obstruction 1.7, resectable disease 1.8)"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","field":"links","label":"NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"NICE NG85 recommendations 1.8.6 and 1.9.3"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","field":"links","label":"NICE NG85 recommendation 1.8.6"}]},{"url":"https://www.nice.org.uk/guidance/ta1001","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1001: zanubrutinib for marginal zone lymphoma after anti-CD20-based treatment"}]},{"url":"https://www.nice.org.uk/guidance/ta1005","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","field":"links","label":"NICE TA1005: futibatinib for previously treated FGFR2 fusion or rearrangement cholangiocarcinoma (11 September 2024)"}]},{"url":"https://www.nice.org.uk/guidance/ta1008","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, later lines)"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"links","label":"NICE TA1008: trifluridine-tipiracil with bevacizumab after 2 systemic treatments"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE TA1008: trifluridine-tipiracil with bevacizumab"}]},{"url":"https://www.nice.org.uk/guidance/ta101","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"links","label":"NICE TA101: docetaxel for the treatment of hormone-refractory metastatic prostate cancer"},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","field":"links","label":"NICE TA101: docetaxel for the treatment of hormone-refractory metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1017","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA1017: pembrolizumab neoadjuvant then adjuvant for resectable non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1021","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","field":"links","label":"NICE TA1021: crizotinib for treating ROS1-positive advanced non-small-cell lung cancer"},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","field":"links","label":"NICE TA1021: crizotinib for treating ROS1-positive advanced non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, ROS1-positive)"}]},{"url":"https://www.nice.org.uk/guidance/ta1030","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"NICE TA1030: durvalumab with chemotherapy before surgery then alone after surgery for resectable non-small-cell lung cancer"},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/","field":"links","label":"NICE TA1030: durvalumab with chemotherapy before surgery then alone after surgery for resectable non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1037","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-091","kind":"trial","name":"KEYNOTE-091 (PEARLS)","route":"/trials/keynote-091/","field":"links","label":"NICE TA1037: pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA1037: pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1040","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Metastatic, germline BRCA1 or BRCA2)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"NICE TA1040: olaparib for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (12 February 2025)"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","field":"links","label":"NICE TA1040 (12 February 2025)"}],"archive":"https://web.archive.org/web/20260529215140/https://www.nice.org.uk/guidance/ta1040"},{"url":"https://www.nice.org.uk/guidance/ta1041","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"NICE TA1041: durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1042","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"links","label":"NICE TA1042: selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, RET fusion-positive)"},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","field":"links","label":"NICE TA1042: selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1043","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","field":"links","label":"NICE TA1043: osimertinib for adjuvant treatment after complete tumour resection"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"links","label":"NICE TA1043: osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection"},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","field":"links","label":"NICE TA1043: osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Resected EGFR-mutant or ALK-positive non-small-cell lung cancer, adjuvant targeted therapy)"}]},{"url":"https://www.nice.org.uk/guidance/ta1048","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1048: lisocabtagene maraleucel after first-line chemoimmunotherapy when a stem cell transplant is suitable"}]},{"url":"https://www.nice.org.uk/guidance/ta1059","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1059: brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta1060","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"links","label":"NICE TA1060: osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1065","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, mismatch-repair deficient or MSI-high, first line)"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE TA1065: nivolumab plus ipilimumab for untreated MSI-high or dMMR colorectal cancer"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA1065: nivolumab plus ipilimumab for untreated MSI-high or dMMR colorectal cancer"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"links","label":"NICE TA1065"}]},{"url":"https://www.nice.org.uk/guidance/ta1071","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA1071: atezolizumab for adjuvant treatment of resected non-small-cell lung cancer"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","field":"links","label":"NICE TA1071: atezolizumab for adjuvant treatment of resected non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1079","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","field":"links","label":"NICE TA1079: fruquintinib for previously treated metastatic colorectal cancer"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE TA1079: fruquintinib for previously treated metastatic colorectal cancer"},{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","field":"links","label":"NICE TA1079: fruquintinib for previously treated metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1081","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1081: zanubrutinib for relapsed or refractory mantle cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta1091","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","field":"links","label":"NICE TA1091: tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (not recommended)"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","field":"links","label":"NICE TA1091: tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (not recommended)"},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","field":"links","label":"NICE TA1091: tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta1099","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","field":"links","label":"NICE TA1099: durvalumab for limited-stage small-cell lung cancer after platinum-based chemoradiotherapy"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"NICE TA1099: durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta1103","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","field":"links","label":"NICE TA1103: lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"links","label":"NICE TA1103: lorlatinib for ALK-positive advanced non-small-cell lung cancer not treated with an ALK inhibitor"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, ALK-positive)"}]},{"url":"https://www.nice.org.uk/guidance/ta1109","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","field":"links","label":"NICE TA1109: darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer"},{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/","field":"links","label":"NICE TA1109: darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer"},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"links","label":"NICE TA1109: darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1110","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Metastatic hormone-sensitive prostate cancer: androgen deprivation is never given alone)"},{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"links","label":"NICE TA1110: abiraterone (originator and generics) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer"},{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","field":"links","label":"NICE TA1110: abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","field":"links","label":"NICE TA1110: abiraterone (originator and generics) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1113","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1113: glofitamab with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta1118","status":200,"ok":true,"finalUrl":"https://www.nice.org.uk/guidance/terminated/ta1118","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"links","label":"NICE TA1118: entrectinib for NTRK fusion-positive solid tumours, terminated appraisal (7 January 2026)"}]},{"url":"https://www.nice.org.uk/guidance/ta1122","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","field":"links","label":"NICE TA1122: amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"links","label":"NICE TA1122: amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1127","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","field":"links","label":"NICE TA1127: nivolumab with chemotherapy, neoadjuvant then adjuvant, for resectable non-small-cell lung cancer"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA1127: nivolumab with chemotherapy neoadjuvant then alone adjuvant for resectable non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Resectable stage II to IIIB non-small-cell lung cancer without a driver, perioperative immunotherapy)"},{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","field":"links","label":"NICE TA1127: nivolumab with chemotherapy neoadjuvant then alone adjuvant for resectable non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1130","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"links","label":"NICE TA1130: talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","field":"links","label":"NICE TA1130: talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"links","label":"NICE TA1130: talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1136","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, RAS-mutant or right-sided, first line)"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"links","label":"NICE TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy"},{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/","field":"links","label":"NICE TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1153","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (HER2-positive (IHC 3+ or amplified), after first-line therapy)"},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","field":"links","label":"NICE TA1153: zanidatamab for HER2-positive advanced biliary tract cancer (7 May 2026)"}]},{"url":"https://www.nice.org.uk/guidance/ta1156","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"links","label":"NICE TA1156: osimertinib for EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta1158","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"links","label":"NICE TA1158: amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, EGFR exon 20 insertions and uncommon mutations)"}]},{"url":"https://www.nice.org.uk/guidance/ta1165","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","field":"links","label":"NICE TA1165: cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1167","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","field":"links","label":"NICE TA1167: serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta1184","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1184: acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta1193","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA1193: ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable"}]},{"url":"https://www.nice.org.uk/guidance/ta184","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","field":"links","label":"NICE TA184: topotecan for the treatment of relapsed small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta212","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","field":"links","label":"NICE TA212 (2010, not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta25","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA25: gemcitabine for pancreatic cancer (8 May 2001, replaced by NG85)"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","field":"links","label":"NICE TA25: gemcitabine for pancreatic cancer (2001, replaced by NG85)"}]},{"url":"https://www.nice.org.uk/guidance/ta259","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"links","label":"NICE TA259: abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen"},{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","field":"links","label":"NICE TA259: abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen"}]},{"url":"https://www.nice.org.uk/guidance/ta307","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (The failed and stopped programmes)"},{"id":"colorectal-failed-programmes","kind":"term","name":"Colorectal cancer: the failed and stopped programmes, and why","route":"/terms/colorectal-failed-programmes/","field":"links","label":"NICE TA307: aflibercept for metastatic colorectal cancer (not recommended)"},{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","field":"links","label":"NICE TA307: aflibercept in combination with irinotecan and fluorouracil-based therapy (not recommended)"},{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","field":"links","label":"NICE TA307 (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta316","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"NICE TA316: enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","field":"links","label":"NICE TA316: enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen"}]},{"url":"https://www.nice.org.uk/guidance/ta332","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","field":"links","label":"NICE TA332: sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer, guidance withdrawn because the marketing authorisation was withdrawn"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","field":"links","label":"NICE TA332: sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer, guidance withdrawn"}]},{"url":"https://www.nice.org.uk/guidance/ta347","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","field":"links","label":"NICE TA347: nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small-cell lung cancer"},{"id":"lume-lung-1","kind":"trial","name":"LUME-Lung 1","route":"/trials/lume-lung-1/","field":"links","label":"NICE TA347: nintedanib for previously treated non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic non-small-cell lung cancer, later lines)"}]},{"url":"https://www.nice.org.uk/guidance/ta377","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"NICE TA377: enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","field":"links","label":"NICE TA377: enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated"}]},{"url":"https://www.nice.org.uk/guidance/ta387","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"links","label":"NICE TA387: abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated"},{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","field":"links","label":"NICE TA387: abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated"}]},{"url":"https://www.nice.org.uk/guidance/ta391","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"links","label":"NICE TA391: cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","field":"links","label":"NICE TA391: cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"links","label":"NICE TA391: cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel"}]},{"url":"https://www.nice.org.uk/guidance/ta403","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","field":"links","label":"NICE TA403: ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (not recommended)"},{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","field":"links","label":"NICE TA403: ramucirumab for previously treated non-small-cell lung cancer (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta404","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","field":"links","label":"NICE TA404: degarelix for treating advanced hormone-dependent prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta405","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","field":"links","label":"NICE TA405: trifluridine-tipiracil for previously treated metastatic colorectal cancer"},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","field":"links","label":"NICE TA405: trifluridine-tipiracil for previously treated metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta412","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"links","label":"NICE TA412: radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases"},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","field":"links","label":"NICE TA412: radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases"},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","field":"links","label":"NICE TA412: radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases"}]},{"url":"https://www.nice.org.uk/guidance/ta428","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","field":"links","label":"NICE TA428: pembrolizumab for PD-L1-positive non-small-cell lung cancer after chemotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta439","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, RAS and BRAF wild-type, left-sided, first line)"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","field":"links","label":"NICE TA439: cetuximab and panitumumab for previously untreated metastatic colorectal cancer"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","field":"links","label":"NICE TA439"},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","field":"links","label":"NICE TA439: cetuximab and panitumumab for previously untreated metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta440","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA440: pegylated liposomal irinotecan after gemcitabine, not recommended (26 April 2017)"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","field":"links","label":"NICE TA440 (26 April 2017): not recommended"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","field":"links","label":"NICE TA440: pegylated liposomal irinotecan after gemcitabine, not recommended (26 April 2017)"}]},{"url":"https://www.nice.org.uk/guidance/ta440/chapter/1-Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NICE TA440: pegylated liposomal irinotecan for pancreatic cancer after gemcitabine"}]},{"url":"https://www.nice.org.uk/guidance/ta476","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"standardOfCare.guideline (UK access to treatments (NICE, September 2026))"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","field":"links","label":"NICE TA476 (6 September 2017)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA476: nab-paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (6 September 2017)"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","field":"links","label":"NICE TA476: nab-paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (6 September 2017)"}]},{"url":"https://www.nice.org.uk/guidance/ta476/chapter/1-Recommendations","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NICE TA476: nab-paclitaxel with gemcitabine for untreated metastatic pancreatic cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta489","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hedgehog-inhibitor-tolerability","kind":"term","name":"Why people stop taking hedgehog inhibitors","route":"/terms/hedgehog-inhibitor-tolerability/","field":"links","label":"NICE TA489: vismodegib not recommended for basal cell carcinoma"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (What is available in England)"}]},{"url":"https://www.nice.org.uk/guidance/ta500","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","field":"links","label":"NICE TA500: ceritinib for untreated ALK-positive non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta501","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"partial-breast-irradiation","kind":"term","name":"Partial-breast irradiation","route":"/terms/partial-breast-irradiation/","field":"links","label":"NICE TA501: Intrabeam, not recommended for routine commissioning"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"links","label":"NICE TA501: Intrabeam radiotherapy system, not recommended for routine commissioning"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"standardOfCare.guideline (Treating less than the whole breast)"}]},{"url":"https://www.nice.org.uk/guidance/ta520","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oak","kind":"trial","name":"OAK","route":"/trials/oak/","field":"links","label":"NICE TA520: atezolizumab for locally advanced or metastatic non-small-cell lung cancer after chemotherapy"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA520: atezolizumab for locally advanced or metastatic non-small-cell lung cancer after chemotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta524","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA524: brentuximab vedotin for CD30-positive Hodgkin lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta531","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA531: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease without a driver, PD-L1 tumour proportion score 50 percent or more)"}]},{"url":"https://www.nice.org.uk/guidance/ta536","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","field":"links","label":"NICE TA536: alectinib for untreated ALK-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta546","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","field":"links","label":"NICE TA546: padeliporfin for untreated localised prostate cancer, not recommended"},{"id":"prostate-focal-therapy","kind":"term","name":"Focal and tissue-preserving treatment of prostate cancer","route":"/terms/prostate-focal-therapy/","field":"links","label":"NICE TA546: padeliporfin for untreated localised prostate cancer, not recommended"},{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","field":"links","label":"NICE TA546: padeliporfin for untreated localised prostate cancer, not recommended"},{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","field":"links","label":"NICE TA546: padeliporfin for untreated localised prostate cancer, not recommended"}]},{"url":"https://www.nice.org.uk/guidance/ta571","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"links","label":"NICE TA571: brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib"}]},{"url":"https://www.nice.org.uk/guidance/ta577","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA577: brentuximab vedotin for CD30-positive cutaneous T-cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta580","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"NICE TA580: enzalutamide for hormone-relapsed non-metastatic prostate cancer, not recommended"},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","field":"links","label":"NICE TA580: enzalutamide for hormone-relapsed non-metastatic prostate cancer, not recommended"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","field":"links","label":"NICE TA580: enzalutamide for hormone-relapsed non-metastatic prostate cancer, not recommended"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"links","label":"NICE TA580: enzalutamide for hormone-relapsed non-metastatic prostate cancer, not recommended"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"links","label":"NICE TA580: enzalutamide for hormone-relapsed non-metastatic prostate cancer, not recommended"}]},{"url":"https://www.nice.org.uk/guidance/ta584","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impower150","kind":"trial","name":"IMpower150","route":"/trials/impower150/","field":"links","label":"NICE TA584: atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA584: atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta595","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","field":"links","label":"NICE TA595: dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","field":"links","label":"NICE TA595: dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta628","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","field":"links","label":"NICE TA628: lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta630","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, rarer biomarkers: NTRK, RET and POLE)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA630: larotrectinib for NTRK fusion-positive solid tumours, Cancer Drugs Fund (27 May 2020)"},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","field":"links","label":"NICE TA630: larotrectinib for NTRK fusion-positive solid tumours, Cancer Drugs Fund (27 May 2020)"}]},{"url":"https://www.nice.org.uk/guidance/ta638","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA638: atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta639","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA639: atezolizumab with nab-paclitaxel for untreated PD-L1-positive advanced triple-negative breast cancer (1 July 2020)"},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","field":"links","label":"NICE TA639 (1 July 2020)"}]},{"url":"https://www.nice.org.uk/guidance/ta643","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"links","label":"NICE TA643: entrectinib for treating ROS1-positive advanced non-small-cell lung cancer"},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","field":"links","label":"NICE TA643: entrectinib for treating ROS1-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta644","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","field":"links","label":"NICE TA644 (12 August 2020), replaced"}]},{"url":"https://www.nice.org.uk/guidance/ta653","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"links","label":"NICE TA653: osimertinib for EGFR T790M mutation-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta654","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","field":"links","label":"NICE TA654: osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, EGFR exon 19 deletion or L858R)"}]},{"url":"https://www.nice.org.uk/guidance/ta655","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkmate-017","kind":"trial","name":"CheckMate 017","route":"/trials/checkmate-017/","field":"links","label":"NICE TA655: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA655: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta660","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","field":"links","label":"NICE TA660: darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer"},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","field":"links","label":"NICE TA660: darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"links","label":"NICE TA660: darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta668","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","field":"standardOfCare.guideline (Metastatic disease, BRAF V600E)"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","field":"links","label":"NICE TA668: encorafenib plus cetuximab for previously treated BRAF V600E metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta670","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","field":"links","label":"NICE TA670: brigatinib for ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor"}]},{"url":"https://www.nice.org.uk/guidance/ta683","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA683: pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease without a driver, PD-L1 below 50 percent)"}]},{"url":"https://www.nice.org.uk/guidance/ta691","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","field":"standardOfCare.guideline (What is available in England)"}]},{"url":"https://www.nice.org.uk/guidance/ta705","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impower110","kind":"trial","name":"IMpower110","route":"/trials/impower110/","field":"links","label":"NICE TA705: atezolizumab monotherapy for untreated advanced non-small-cell lung cancer"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","field":"links","label":"NICE TA705: atezolizumab monotherapy for untreated advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta709","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA709: pembrolizumab for untreated MSI-high or dMMR metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta712","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"NICE TA712: enzalutamide for treating hormone-sensitive metastatic prostate cancer"},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","field":"links","label":"NICE TA712: enzalutamide for treating hormone-sensitive metastatic prostate cancer"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","field":"links","label":"NICE TA712: enzalutamide for treating hormone-sensitive metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta713","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","field":"links","label":"NICE TA713: nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA713: nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy"}]},{"url":"https://www.nice.org.uk/guidance/ta716","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA716: nivolumab with ipilimumab for previously treated MSI-high or dMMR colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta720","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA720: chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta721","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","field":"links","label":"NICE TA721: abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, replaced by TA1110"}]},{"url":"https://www.nice.org.uk/guidance/ta722","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","field":"links","label":"NICE TA722: pemigatinib for FGFR2 fusion or rearrangement cholangiocarcinoma (25 August 2021)"}]},{"url":"https://www.nice.org.uk/guidance/ta724","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","field":"links","label":"NICE TA724: nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (not recommended)"},{"id":"checkmate-9la","kind":"trial","name":"CheckMate 9LA","route":"/trials/checkmate-9la/","field":"links","label":"NICE TA724: nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (not recommended)"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA724: nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (not recommended)"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","field":"links","label":"NICE TA724: nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta740","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Hormone-relapsed non-metastatic prostate cancer with a fast-rising PSA)"},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","field":"links","label":"NICE TA740: apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer"},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","field":"links","label":"NICE TA740: apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta741","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","field":"links","label":"NICE TA741: apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer"},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","field":"links","label":"NICE TA741: apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta754","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA754: mogamulizumab for previously treated mycosis fungoides and Sezary syndrome"}]},{"url":"https://www.nice.org.uk/guidance/ta770","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA770: pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta781","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","field":"links","label":"NICE TA781: sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, KRAS G12C)"}]},{"url":"https://www.nice.org.uk/guidance/ta789","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","field":"links","label":"NICE TA789: tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, MET exon 14 skipping and MET amplification)"}]},{"url":"https://www.nice.org.uk/guidance/ta798","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"NICE TA798: durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Unresectable stage III non-small-cell lung cancer)"}]},{"url":"https://www.nice.org.uk/guidance/ta801","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE TA801: pembrolizumab plus chemotherapy for untreated triple-negative locally recurrent unresectable or metastatic breast cancer"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (First treatment for metastatic disease: the tests that decide)"},{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"NICE TA801: pembrolizumab plus chemotherapy for untreated triple-negative locally recurrent unresectable or metastatic breast cancer (June 2022)"},{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","field":"links","label":"NICE TA801: pembrolizumab plus chemotherapy for untreated triple-negative locally recurrent unresectable or metastatic breast cancer (June 2022)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA801: pembrolizumab plus chemotherapy for untreated triple-negative metastatic breast cancer (29 June 2022)"},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","field":"links","label":"NICE TA801 (29 June 2022)"}],"archive":"https://web.archive.org/web/20260908190753/https://www.nice.org.uk/guidance/ta801"},{"url":"https://www.nice.org.uk/guidance/ta802","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (What is available in England)"}]},{"url":"https://www.nice.org.uk/guidance/ta812","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","field":"links","label":"NICE TA812: pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (not recommended)"},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","field":"links","label":"NICE TA812: pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta819","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE TA819: sacituzumab govitecan for unresectable triple-negative advanced breast cancer after 2 or more therapies"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Antibody-drug conjugates: what to expect and the side effects to report)"},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","field":"links","label":"NICE TA819: sacituzumab govitecan for unresectable triple-negative advanced breast cancer after 2 or more therapies (August 2022)"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","field":"links","label":"NICE TA819: sacituzumab govitecan for unresectable triple-negative advanced breast cancer after 2 or more therapies (17 August 2022)"},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","field":"links","label":"NICE TA819 (17 August 2022)"}],"archive":"https://web.archive.org/web/20260908190753/https://www.nice.org.uk/guidance/ta819"},{"url":"https://www.nice.org.uk/guidance/ta833","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA833: zanubrutinib for Waldenstrom macroglobulinaemia"}]},{"url":"https://www.nice.org.uk/guidance/ta850","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","field":"links","label":"NICE TA850: amivantamab for EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta851","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE TA851: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Adding pembrolizumab before surgery: what PD-L1 means here)"},{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","field":"links","label":"NICE TA851: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (December 2022)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA851: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (14 December 2022)"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","field":"links","label":"NICE TA851 (14 December 2022)"}],"archive":"https://web.archive.org/web/20260908210341/https://www.nice.org.uk/guidance/ta851"},{"url":"https://www.nice.org.uk/guidance/ta866","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","field":"links","label":"NICE TA866: regorafenib for previously treated metastatic colorectal cancer"},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","field":"links","label":"NICE TA866: regorafenib for previously treated metastatic colorectal cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta872","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA872: axicabtagene ciloleucel after 2 or more systemic therapies"}]},{"url":"https://www.nice.org.uk/guidance/ta874","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA874: polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma"}]},{"url":"https://www.nice.org.uk/guidance/ta876","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","field":"links","label":"NICE TA876: nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta883","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA883: tafasitamab with lenalidomide (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta886","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Residual disease after chemotherapy: capecitabine or olaparib)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Germline BRCA1 or BRCA2 carriers: early-stage choices)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"links","label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer (May 2023)"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","field":"standardOfCare.guideline (Early disease after chemotherapy)"},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","field":"links","label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer (May 2023)"},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","field":"links","label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer (May 2023)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer (10 May 2023)"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"links","label":"NICE TA886 (10 May 2023)"}],"archive":"https://web.archive.org/web/20260908190749/https://www.nice.org.uk/guidance/ta886"},{"url":"https://www.nice.org.uk/guidance/ta887","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","field":"links","label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer"},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","field":"links","label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","field":"links","label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer"},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","field":"links","label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta892","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA892: mosunetuzumab for relapsed or refractory follicular lymphoma (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta894","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA894: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma (not recommended)"}]},{"url":"https://www.nice.org.uk/guidance/ta898","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","field":"links","label":"NICE TA898: dabrafenib plus trametinib for BRAF V600 mutation-positive advanced non-small-cell lung cancer"},{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","field":"links","label":"NICE TA898: dabrafenib plus trametinib for BRAF V600 mutation-positive advanced non-small-cell lung cancer"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","field":"standardOfCare.guideline (Metastatic disease, BRAF V600E, HER2-mutant, NTRK and NRG1)"}]},{"url":"https://www.nice.org.uk/guidance/ta903","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","field":"links","label":"NICE TA903: darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer"},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","field":"links","label":"NICE TA903: darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta911","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","field":"links","label":"NICE TA911: selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta914","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA914: pembrolizumab for MSI-high or mismatch repair deficient endometrial, biliary, colorectal, gastric or small intestine cancer (20 September 2023)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"NICE TA914 (20 September 2023)"}]},{"url":"https://www.nice.org.uk/guidance/ta927","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA927: glofitamab after 2 or more systemic treatments"}]},{"url":"https://www.nice.org.uk/guidance/ta930","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"standardOfCare.guideline (Hormone-relapsed (castration-resistant) metastatic prostate cancer: the order the approved treatments are given in)"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","field":"links","label":"NICE TA930: lutetium-177 vipivotide tetraxetan for PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, not recommended"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"links","label":"NICE TA930: lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, not recommended"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"links","label":"NICE TA930: lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, not recommended"},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"links","label":"NICE TA930: lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, not recommended"}]},{"url":"https://www.nice.org.uk/guidance/ta944","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"NICE TA944: durvalumab with gemcitabine and cisplatin for unresectable or advanced biliary tract cancer"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"NICE TA944: durvalumab with gemcitabine and cisplatin for biliary tract cancer (10 January 2024)"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"NICE TA944: durvalumab with gemcitabine and cisplatin for unresectable or advanced biliary tract cancer"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"standardOfCare.guideline (Unresectable or metastatic disease, first line)"}]},{"url":"https://www.nice.org.uk/guidance/ta948","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","field":"links","label":"NICE TA948: ivosidenib for IDH1 R132 cholangiocarcinoma (31 January 2024)"}]},{"url":"https://www.nice.org.uk/guidance/ta951","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"links","label":"NICE TA951: olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","field":"links","label":"NICE TA951: olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"NICE TA951: olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/ta952","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","field":"links","label":"NICE TA952: talazoparib for HER2-negative advanced breast cancer with germline BRCA mutations (21 February 2024)"},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","field":"links","label":"NICE TA952 (21 February 2024)"}]},{"url":"https://www.nice.org.uk/guidance/ta954","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/","field":"links","label":"NICE TA954: epcoritamab after 2 or more systemic treatments"}]},{"url":"https://www.nice.org.uk/guidance/ta992","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Metastatic, HER2-low, after one or two lines of chemotherapy)"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","field":"links","label":"NICE TA992: trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemotherapy, not recommended (29 July 2024)"},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","field":"links","label":"NICE TA992 (29 July 2024): not recommended"}],"archive":"https://web.archive.org/web/20260917053038/https://www.nice.org.uk/guidance/ta992"},{"url":"https://www.nice.org.uk/guidance/ta995","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","field":"links","label":"NICE TA995: relugolix for treating hormone-sensitive prostate cancer"},{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","field":"links","label":"NICE TA995: relugolix for treating hormone-sensitive prostate cancer"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"links","label":"NICE TA995: relugolix for treating hormone-sensitive prostate cancer"}]},{"url":"https://www.nice.org.uk/guidance/terminated/ta1032","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","field":"links","label":"NICE TA1032: niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer, terminated appraisal"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","field":"links","label":"NICE TA1032: niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer, terminated appraisal"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","field":"links","label":"NICE TA1032: niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer, terminated appraisal"}]},{"url":"https://www.nice.org.uk/guidance/terminated/ta1052","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","field":"links","label":"NICE TA1052: pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer, terminated appraisal (2 April 2025)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA1052: pegylated liposomal irinotecan in combination (NALIRIFOX) for untreated metastatic pancreatic cancer, terminated appraisal (2 April 2025)"}]},{"url":"https://www.nice.org.uk/guidance/terminated/ta1118","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA1118: entrectinib for NTRK fusion-positive solid tumours, terminated appraisal (7 January 2026)"}]},{"url":"https://www.nice.org.uk/guidance/terminated/ta750","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"NICE TA750: olaparib maintenance for BRCA mutation-positive metastatic pancreatic cancer (terminated appraisal, December 2021)"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","field":"links","label":"NICE TA750: olaparib maintenance for BRCA mutation-positive metastatic pancreatic cancer, terminated appraisal (8 December 2021)"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"NICE TA750: olaparib maintenance for BRCA mutation-positive metastatic pancreatic cancer (terminated appraisal, December 2021)"}]},{"url":"https://www.nice.org.uk/guidance/terminated/ta966","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","field":"links","label":"NICE TA966: pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)"},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","field":"links","label":"NICE TA966: pembrolizumab with gemcitabine and cisplatin for biliary tract cancer (terminated appraisal, 2024)"}]},{"url":"https://www.nice.org.uk/process/pmg36","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/","field":"links","label":"NICE: health technology evaluations, the manual (PMG36)"}]},{"url":"https://www.nice.org.uk/what-nice-does/patient-access-schemes-and-pricing-agreements/managed-access","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","field":"links","label":"NICE: managed access"}]},{"url":"https://www.nih.gov/research-training/accelerating-medicines-partnership-amp","status":200,"ok":true,"finalUrl":"https://www.nih.gov/amp","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/","field":"links","label":"Accelerating Medicines Partnership"}]},{"url":"https://www.niioncologii.ru","status":200,"ok":true,"finalUrl":"https://www.niioncologii.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/","field":"links","label":"Official website"},{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/","field":"website"}]},{"url":"https://www.niioncologii.ru/institute/institutehistory","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/","field":"links","label":"History of the institute (Russian)"}]},{"url":"https://www.nimbustx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","field":"links","label":"Official website"},{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","field":"website"}]},{"url":"https://www.nimbustx.com/pipeline/","status":200,"ok":true,"finalUrl":"https://www.nimbustx.com/pipeline-targets/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://www.nipponkayaku.co.jp/english/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","field":"links","label":"Official website"},{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","field":"website"}]},{"url":"https://www.nist.gov/programs-projects/face-technology-evaluations-frtefate","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-sequestered-prospective-benchmarks","kind":"idea","name":"Sequestered, prospectively collected benchmark datasets that no one can train on","route":"/ideas/idea-data-sequestered-prospective-benchmarks/","field":"links","label":"NIST FRTE (face recognition evaluation)"}]},{"url":"https://www.nist.gov/programs-projects/genome-bottle","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-open-cdx-validation-sets","kind":"idea","name":"Public gold-standard datasets for validating every cancer biomarker test","route":"/ideas/idea-tr2-open-cdx-validation-sets/","field":"links","label":"Genome in a Bottle"}]},{"url":"https://www.nkartatx.com","status":200,"ok":true,"finalUrl":"https://www.nkartatx.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","field":"website"}]},{"url":"https://www.nki.nl","status":200,"ok":true,"finalUrl":"https://www.nki.nl/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/","field":"links","label":"Official website"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/","field":"website"},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"links","label":"Netherlands Cancer Institute (NKI-AvL) website"},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"profiles","label":"Netherlands Cancer Institute (NKI-AvL) website"}]},{"url":"https://www.nlg.nhs.uk/about/how-we-are-run/board/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lyn-simpson","kind":"person","name":"Lyn Simpson","route":"/people/lyn-simpson/","field":"links","label":"Source: NHS Humber Health Partnership group board page"},{"id":"lyn-simpson","kind":"person","name":"Lyn Simpson","route":"/people/lyn-simpson/","field":"profiles","label":"NHS Humber Health Partnership board page"}]},{"url":"https://www.nlm.nih.gov/bsd/medline_cit_counts_yr_pub.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"links","label":"MEDLINE citation counts by year"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"metrics (Citations added to MEDLINE per year (recent years))"}]},{"url":"https://www.nlm.nih.gov/research/umls/rxnorm/index.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rxnorm","kind":"term","name":"RxNorm drug nomenclature","route":"/terms/rxnorm/","field":"links","label":"RxNorm (US National Library of Medicine)"}]},{"url":"https://www.nngm.de","status":200,"ok":true,"finalUrl":"https://nngm.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","field":"links","label":"nNGM Lungenkrebs"},{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","field":"website"}]},{"url":"https://www.nnuh.nhs.uk/departments/dermatology/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nick-levell","kind":"person","name":"Nick Levell","route":"/people/nick-levell/","field":"links","label":"Norfolk and Norwich University Hospitals: dermatology"},{"id":"nick-levell","kind":"person","name":"Nick Levell","route":"/people/nick-levell/","field":"profiles","label":"Norfolk and Norwich University Hospitals: dermatology"}]},{"url":"https://www.nobelpharma.co.jp","status":200,"ok":true,"finalUrl":"https://www.nobelpharma.co.jp/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","field":"links","label":"Official website"},{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","field":"website"}]},{"url":"https://www.nobelpharma.co.jp/en/research/product/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","field":"links","label":"Nobelpharma product list"}]},{"url":"https://www.nobelprize.org/prizes/medicine/1966/huggins/facts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-huggins-hodges-castration-serum-phosphatases-prostate-1941","kind":"paper","name":"Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","route":"/key-papers/paper-huggins-hodges-castration-serum-phosphatases-prostate-1941/","field":"links","label":"Nobel Prize in Physiology or Medicine 1966: Charles B. Huggins"}]},{"url":"https://www.nobelprize.org/prizes/medicine/1988/elion/facts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","field":"links","label":"Nobel Prize biography"},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","field":"profiles","label":"Nobel Prize biography"}]},{"url":"https://www.nobelprize.org/prizes/medicine/2008/hausen/facts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","field":"links","label":"Nobel Prize biography"},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","field":"profiles","label":"Nobel Prize biography"}]},{"url":"https://www.nobelprize.org/prizes/medicine/2018/honjo/facts/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","field":"links","label":"Nobel Prize biography"},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","field":"profiles","label":"Nobel Prize biography"}]},{"url":"https://www.noetik.ai","status":200,"ok":true,"finalUrl":"https://www.noetik.ai/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","field":"links","label":"Official website"},{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","field":"website"}]},{"url":"https://www.noetik.ai/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","field":"links","label":"Noetik"}]},{"url":"https://www.noetik.ai/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","field":"links","label":"News (Series A, GSK partnership)"}]},{"url":"https://www.nonagen.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","field":"links","label":"Official website"},{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","field":"website"}]},{"url":"https://www.nonagen.com/contact-us","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","field":"links","label":"Contact and laboratory address"}]},{"url":"https://www.nonagen.com/news-briefs","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","field":"links","label":"News briefs"}]},{"url":"https://www.nordic-lymphoma.org","status":200,"ok":true,"finalUrl":"https://www.nordic-lymphoma.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","route":"/companies/nordic-lymphoma-group/","field":"links","label":"Nordic Lymphoma Group"},{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","route":"/companies/nordic-lymphoma-group/","field":"website"}]},{"url":"https://www.nordic-lymphoma.org/coordinating-group/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","field":"links","label":"Source: Nordic Lymphoma Group coordinating group page"},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","field":"profiles","label":"NLG coordinating group"}]},{"url":"https://www.nordion.com","status":200,"ok":true,"finalUrl":"https://www.nordion.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","field":"links","label":"Official website"},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","field":"website"}]},{"url":"https://www.nordiqc.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-tr2-her2-low-reference-materials","kind":"idea","name":"Calibrated reference slides so every lab scores HER2-low the same way","route":"/ideas/idea-tr2-her2-low-reference-materials/","field":"links","label":"NordiQC"},{"id":"idea-tr2-eqa-public-results","kind":"idea","name":"Publish each laboratory's biomarker proficiency results","route":"/ideas/idea-tr2-eqa-public-results/","field":"links","label":"NordiQC"}]},{"url":"https://www.norgine.com","status":200,"ok":true,"finalUrl":"https://norgine.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","field":"links","label":"Official website"},{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","field":"website"}]},{"url":"https://www.norroybiopharm.com/","status":200,"ok":true,"contentType":"application/json; charset=utf-8","checked":"2026-09-30","refs":[{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","route":"/companies/norroy-bioscience/","field":"links","label":"Official website"},{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","route":"/companies/norroy-bioscience/","field":"website"}]},{"url":"https://www.northerncanceralliance.nhs.uk","status":200,"ok":true,"finalUrl":"https://northerncanceralliance.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/","field":"links","label":"Northern Cancer Alliance"},{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/","field":"website"}]},{"url":"https://www.northstarnm.com","status":200,"ok":true,"finalUrl":"https://www.northstarnm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","field":"links","label":"Official website"},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","field":"website"}]},{"url":"https://www.northwell.edu/cancer-institute","status":200,"ok":true,"finalUrl":"https://cancer.northwell.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","field":"links","label":"Northwell Health Cancer Institute"},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","field":"website"}]},{"url":"https://www.northwell.edu/news/the-latest/northwell-appoints-system-director-central-nervous-system-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richard-barakat","kind":"person","name":"Richard Barakat","route":"/people/richard-barakat/","field":"links","label":"Source: Northwell Health news release, September 2026"},{"id":"richard-barakat","kind":"person","name":"Richard Barakat","route":"/people/richard-barakat/","field":"profiles","label":"Northwell news release naming role"}]},{"url":"https://www.nottingham.ac.uk/medicine/people/david.baldwin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-baldwin","kind":"person","name":"David Baldwin","route":"/people/david-baldwin/","field":"links","label":"University of Nottingham staff page"},{"id":"david-baldwin","kind":"person","name":"David Baldwin","route":"/people/david-baldwin/","field":"profiles","label":"University of Nottingham staff page"}]},{"url":"https://www.nottingham.ac.uk/medicine/people/hywel.williams","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hywel-williams","kind":"person","name":"Hywel Williams","route":"/people/hywel-williams/","field":"links","label":"University of Nottingham profile"},{"id":"hywel-williams","kind":"person","name":"Hywel Williams","route":"/people/hywel-williams/","field":"profiles","label":"University of Nottingham profile"}]},{"url":"https://www.nottingham.ac.uk/research/groups/cebd/index.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"hywel-williams","kind":"person","name":"Hywel Williams","route":"/people/hywel-williams/","field":"links","label":"Centre of Evidence Based Dermatology"},{"id":"hywel-williams","kind":"person","name":"Hywel Williams","route":"/people/hywel-williams/","field":"profiles","label":"Centre of Evidence Based Dermatology"}]},{"url":"https://www.novartis.com","status":200,"ok":true,"finalUrl":"https://www.novartis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"links","label":"Official website"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"website"}]},{"url":"https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/","field":"links","label":"Novartis acquisition announcement"}]},{"url":"https://www.novartis.com/research-development/novartis-pipeline","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.novocure.com","status":200,"ok":true,"finalUrl":"https://www.novocure.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/","field":"links","label":"Official website"},{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/","field":"website"}]},{"url":"https://www.nrgoncology.org","status":200,"ok":true,"finalUrl":"https://www.nrgoncology.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"links","label":"NRG Oncology"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","field":"profiles","label":"NRG Oncology"},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"links","label":"NRG Oncology"},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","field":"profiles","label":"NRG Oncology"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/","field":"links","label":"Official website"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/","field":"website"}]},{"url":"https://www.nrgoncology.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","field":"links","label":"NRG Oncology (NSABP legacy)"},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","field":"profiles","label":"NRG Oncology (NSABP legacy)"},{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/","field":"links","label":"NRG Oncology"}]},{"url":"https://www.nrgoncology.org/Home/News/Post/treatment-de-intensification-for-early-stage-hpv-positive-oropharyngeal-cancer-nrg-hn005/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","field":"links","label":"NRG Oncology HN005 summary"}]},{"url":"https://www.nshealth.ca","status":200,"ok":true,"finalUrl":"https://www.nshealth.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nova-scotia-cancer-care","kind":"institution","name":"Nova Scotia Health Cancer Care Program (QEII)","route":"/institutions/nova-scotia-cancer-care/","field":"links","label":"Official website"},{"id":"nova-scotia-cancer-care","kind":"institution","name":"Nova Scotia Health Cancer Care Program (QEII)","route":"/institutions/nova-scotia-cancer-care/","field":"website"}]},{"url":"https://www.nshealth.ca/about-us/executive-team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","route":"/people/nicole-boutilier/","field":"links","label":"Source: Nova Scotia Health executive team page"},{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","route":"/people/nicole-boutilier/","field":"profiles","label":"Nova Scotia Health executive team"}]},{"url":"https://www.nshealth.ca/featured-people/dr-nicole-boutilier","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","route":"/people/nicole-boutilier/","field":"profiles","label":"Nova Scotia Health profile"}]},{"url":"https://www.ntp.co.za","status":200,"ok":true,"finalUrl":"https://www.ntp.co.za/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","field":"links","label":"Official website"},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","field":"website"}]},{"url":"https://www.ntucc.gov.tw","status":200,"ok":true,"finalUrl":"https://www.ntucc.gov.tw/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","field":"links","label":"NTU Cancer Center"}],"archive":"https://web.archive.org/web/20260903053608/https://www.ntucc.gov.tw/"},{"url":"https://www.ntuh.gov.tw","status":200,"ok":true,"finalUrl":"https://www.ntuh.gov.tw/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","field":"links","label":"NTUH"},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","field":"website"}]},{"url":"https://www.nucleix.com","status":200,"ok":true,"finalUrl":"https://nucleix.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bladder-epicheck","kind":"technology","name":"Bladder EpiCheck urine methylation test","route":"/technologies/bladder-epicheck/","field":"links","label":"Nucleix: Bladder EpiCheck"}]},{"url":"https://www.nuh.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.nuh.nhs.uk/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nottingham-cancer-centre","kind":"institution","name":"Nottingham University Hospitals Cancer Centre (City Hospital)","route":"/institutions/nottingham-cancer-centre/","field":"links","label":"Official website"},{"id":"nottingham-cancer-centre","kind":"institution","name":"Nottingham University Hospitals Cancer Centre (City Hospital)","route":"/institutions/nottingham-cancer-centre/","field":"website"}]},{"url":"https://www.nuh.nhs.uk/meet-the-board","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anthony-may","kind":"person","name":"Anthony May","route":"/people/anthony-may/","field":"links","label":"Source: Nottingham University Hospitals board page"},{"id":"anthony-may","kind":"person","name":"Anthony May","route":"/people/anthony-may/","field":"profiles","label":"NUH Meet the Board"}]},{"url":"https://www.numen.com","status":200,"ok":true,"finalUrl":"https://www.numen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"numen","kind":"company","name":"Numen","route":"/companies/numen/","field":"links","label":"Official website"},{"id":"numen","kind":"company","name":"Numen","route":"/companies/numen/","field":"website"}]},{"url":"https://www.nurixtx.com","status":200,"ok":true,"finalUrl":"https://www.nurixtx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/","field":"website"}]},{"url":"https://www.nurixtx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.nusano.com","status":200,"ok":true,"finalUrl":"https://nusano.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","field":"links","label":"Official website"},{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","field":"website"}]},{"url":"https://www.nuvalent.com","status":200,"ok":true,"finalUrl":"https://nuvalent.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/","field":"links","label":"Official website"},{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/","field":"website"}]},{"url":"https://www.nuvationbio.com","status":200,"ok":true,"finalUrl":"https://nuvationbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","field":"links","label":"Official website"},{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","field":"website"}]},{"url":"https://www.nuvationbio.com/pipeline","status":200,"ok":true,"finalUrl":"https://nuvationbio.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","field":"links","label":"Pipeline page"},{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","field":"links","label":"Sponsor page"}]},{"url":"https://www.nvfund.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/","field":"links","label":"Official website"},{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/","field":"website"}]},{"url":"https://www.nvfund.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/","field":"links","label":"Portfolio"}]},{"url":"https://www.nvidia.com/en-us/clara/bionemo/","status":200,"ok":true,"finalUrl":"https://www.nvidia.com/en-us/industries/healthcare-life-sciences/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bionemo","kind":"technology","name":"NVIDIA BioNeMo","route":"/technologies/bionemo/","field":"links","label":"NVIDIA BioNeMo"}]},{"url":"https://www.nvidia.com/en-us/clara/biopharma/","status":200,"ok":true,"finalUrl":"https://www.nvidia.com/en-us/industries/healthcare-life-sciences/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","field":"links","label":"Official website"},{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","field":"website"}]},{"url":"https://www.nykode.com","status":200,"ok":true,"finalUrl":"https://nykode.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","field":"links","label":"Official website"},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","field":"website"}]},{"url":"https://www.nyproton.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","field":"links","label":"Official website"},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","field":"website"}]},{"url":"https://www.nyproton.com/about/leadership","status":200,"ok":true,"finalUrl":"https://www.nyproton.com/about-new-york-proton-center/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"links","label":"New York Proton Center: leadership"},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","field":"profiles","label":"New York Proton Center: leadership"}]},{"url":"https://www.obipharma.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/","field":"links","label":"Official website"},{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/","field":"website"}]},{"url":"https://www.ocbj.com/oc-500/2025/oc500-2025-annette-walker/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"annette-walker","kind":"person","name":"Annette Walker","route":"/people/annette-walker/","field":"links","label":"Source: Orange County Business Journal OC500 profile (Nov 2025)"},{"id":"annette-walker","kind":"person","name":"Annette Walker","route":"/people/annette-walker/","field":"profiles","label":"Orange County Business Journal OC500 2025 profile"}]},{"url":"https://www.ocog.ca","status":200,"ok":true,"finalUrl":"https://ocog.ca/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","route":"/companies/ocog/","field":"website"}]},{"url":"https://www.ocog.ca/PORTAL/","status":200,"ok":true,"finalUrl":"https://ocog.ca/PORTAL/Site/Home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","route":"/companies/ocog/","field":"links","label":"Official website"}]},{"url":"https://www.oeci.eu","status":200,"ok":true,"finalUrl":"https://www.oeci.eu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","field":"links","label":"Homepage"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","field":"website"}]},{"url":"https://www.oeci.eu/Governance.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","field":"links","label":"Society page"},{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","field":"profiles","label":"Society page"},{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","route":"/people/claudio-lombardo/","field":"links","label":"Society page"},{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","route":"/people/claudio-lombardo/","field":"profiles","label":"Society page"}]},{"url":"https://www.oeci.eu/Membership.aspx","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"links","label":"OECI membership list"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","field":"profiles","label":"OECI membership list"},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"links","label":"OECI membership list"},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","field":"profiles","label":"OECI membership list"},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"links","label":"OECI membership list"},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","field":"profiles","label":"OECI membership list"},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"links","label":"OECI membership list"},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","field":"profiles","label":"OECI membership list"},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","field":"links","label":"OECI membership list"},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","field":"profiles","label":"OECI membership list"},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","field":"links","label":"OECI membership list"},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","field":"profiles","label":"OECI membership list"},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","field":"links","label":"OECI membership list"},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","field":"profiles","label":"OECI membership list"},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"links","label":"OECI membership list"},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","field":"profiles","label":"OECI membership list"},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","field":"links","label":"OECI membership list"},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","field":"profiles","label":"OECI membership list"},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"links","label":"OECI membership list"},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","field":"profiles","label":"OECI membership list"},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"links","label":"OECI membership list"},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","field":"profiles","label":"OECI membership list"},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"links","label":"OECI membership list"},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","field":"profiles","label":"OECI membership list"},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"links","label":"OECI membership list"},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","field":"profiles","label":"OECI membership list"},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"links","label":"OECI membership list"},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","field":"profiles","label":"OECI membership list"},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","field":"links","label":"OECI membership list"},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","field":"profiles","label":"OECI membership list"},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","field":"links","label":"OECI membership list"},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","field":"profiles","label":"OECI membership list"},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"links","label":"OECI membership list"},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","field":"profiles","label":"OECI membership list"},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","field":"links","label":"OECI membership list"},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","field":"profiles","label":"OECI membership list"},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","field":"links","label":"OECI membership list"},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","field":"profiles","label":"OECI membership list"},{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","field":"links","label":"OECI membership list"},{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","field":"profiles","label":"OECI membership list"},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","field":"links","label":"OECI membership list"},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","field":"profiles","label":"OECI membership list"},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","field":"links","label":"OECI membership list"},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","field":"profiles","label":"OECI membership list"},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","field":"links","label":"OECI membership list"},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","field":"profiles","label":"OECI membership list"},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","field":"links","label":"OECI membership list"},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","field":"profiles","label":"OECI membership list"},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","field":"links","label":"OECI membership list"},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","field":"profiles","label":"OECI membership list"},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"links","label":"OECI membership list"},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","field":"profiles","label":"OECI membership list"},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","field":"links","label":"OECI membership list"},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","field":"profiles","label":"OECI membership list"},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","field":"links","label":"OECI membership list"},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","field":"profiles","label":"OECI membership list"},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"links","label":"OECI membership list"},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","field":"profiles","label":"OECI membership list"},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"links","label":"OECI membership list"},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","field":"profiles","label":"OECI membership list"},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","field":"links","label":"OECI membership list"},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","field":"profiles","label":"OECI membership list"},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","field":"links","label":"OECI membership list"},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","field":"profiles","label":"OECI membership list"},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"links","label":"OECI membership list"},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"profiles","label":"OECI membership list"},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"links","label":"OECI membership list"},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","field":"profiles","label":"OECI membership list"},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"links","label":"OECI membership list"},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","field":"profiles","label":"OECI membership list"},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","field":"links","label":"OECI membership list"},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","field":"profiles","label":"OECI membership list"},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"links","label":"OECI membership list"},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","field":"profiles","label":"OECI membership list"},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"links","label":"OECI membership list"},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","field":"profiles","label":"OECI membership list"},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"links","label":"OECI membership list"},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"profiles","label":"OECI membership list"},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","field":"links","label":"OECI membership list"},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","field":"profiles","label":"OECI membership list"},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","field":"links","label":"OECI membership list"},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","field":"profiles","label":"OECI membership list"},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","field":"links","label":"OECI membership list"},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","field":"profiles","label":"OECI membership list"},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","field":"links","label":"OECI membership list"},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","field":"profiles","label":"OECI membership list"},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","field":"links","label":"OECI membership list"},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","field":"profiles","label":"OECI membership list"},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"links","label":"OECI membership list"},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","field":"profiles","label":"OECI membership list"},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","field":"links","label":"OECI membership list"},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","field":"profiles","label":"OECI membership list"},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"links","label":"OECI membership list"},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"profiles","label":"OECI membership list"},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","field":"links","label":"OECI membership list"},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","field":"profiles","label":"OECI membership list"},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"links","label":"OECI membership list"},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","field":"profiles","label":"OECI membership list"},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"links","label":"OECI membership list"},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","field":"profiles","label":"OECI membership list"},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"links","label":"OECI membership list"},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","field":"profiles","label":"OECI membership list"},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"links","label":"OECI membership list"},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","field":"profiles","label":"OECI membership list"},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","field":"links","label":"OECI membership list"},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","field":"profiles","label":"OECI membership list"},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"links","label":"OECI membership list"},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"profiles","label":"OECI membership list"},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","field":"links","label":"OECI membership list"},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","field":"profiles","label":"OECI membership list"},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"links","label":"OECI membership list"},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","field":"profiles","label":"OECI membership list"},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"links","label":"OECI membership list"},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","field":"profiles","label":"OECI membership list"},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","field":"links","label":"OECI membership list"},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","field":"profiles","label":"OECI membership list"},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","field":"links","label":"OECI membership list"},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","field":"profiles","label":"OECI membership list"},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"links","label":"OECI membership list"},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"profiles","label":"OECI membership list"},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"links","label":"OECI membership list"},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"profiles","label":"OECI membership list"},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"links","label":"OECI membership list"},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","field":"profiles","label":"OECI membership list"},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"links","label":"OECI membership list"},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","field":"profiles","label":"OECI membership list"},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","field":"links","label":"OECI membership list"},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","field":"profiles","label":"OECI membership list"},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","field":"links","label":"OECI membership list"},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","field":"profiles","label":"OECI membership list"},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","field":"links","label":"OECI membership list"},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","field":"profiles","label":"OECI membership list"},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","field":"links","label":"OECI membership list"},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","field":"profiles","label":"OECI membership list"},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"links","label":"OECI membership list"},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","field":"profiles","label":"OECI membership list"},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","field":"links","label":"OECI membership list"},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","field":"profiles","label":"OECI membership list"},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","field":"links","label":"OECI membership list"},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","field":"profiles","label":"OECI membership list"},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","field":"links","label":"OECI membership list"},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","field":"profiles","label":"OECI membership list"},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","field":"links","label":"OECI membership list"},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","field":"profiles","label":"OECI membership list"},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"links","label":"OECI membership list"},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","field":"profiles","label":"OECI membership list"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","field":"links","label":"OECI membership list"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","field":"profiles","label":"OECI membership list"},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"links","label":"OECI membership list"},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","field":"profiles","label":"OECI membership list"},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","field":"links","label":"OECI membership list"},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","field":"profiles","label":"OECI membership list"},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"links","label":"OECI membership list"},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","field":"profiles","label":"OECI membership list"},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","field":"links","label":"OECI membership list"},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","field":"profiles","label":"OECI membership list"},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","field":"links","label":"OECI membership list"},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","field":"profiles","label":"OECI membership list"},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","field":"links","label":"OECI membership list"},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","field":"profiles","label":"OECI membership list"},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","field":"links","label":"OECI membership list"},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","field":"profiles","label":"OECI membership list"},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"links","label":"OECI membership list"},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","field":"profiles","label":"OECI membership list"},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"links","label":"OECI membership list"},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","field":"profiles","label":"OECI membership list"},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"links","label":"OECI membership list"},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","field":"profiles","label":"OECI membership list"},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","field":"links","label":"OECI membership list"},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","field":"profiles","label":"OECI membership list"},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","field":"links","label":"OECI membership list"},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","field":"profiles","label":"OECI membership list"},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"links","label":"OECI membership list"},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","field":"profiles","label":"OECI membership list"},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"links","label":"OECI membership list"},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"profiles","label":"OECI membership list"},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"links","label":"OECI membership list"},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","field":"profiles","label":"OECI membership list"},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"links","label":"OECI membership list"},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","field":"profiles","label":"OECI membership list"},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"links","label":"OECI membership list"},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","field":"profiles","label":"OECI membership list"},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"links","label":"OECI membership list"},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","field":"profiles","label":"OECI membership list"},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"links","label":"OECI membership list"},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","field":"profiles","label":"OECI membership list"},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","field":"links","label":"OECI membership list"},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","field":"profiles","label":"OECI membership list"},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"links","label":"OECI membership list"},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","field":"profiles","label":"OECI membership list"},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"links","label":"OECI membership list"},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","field":"profiles","label":"OECI membership list"},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","field":"links","label":"OECI membership list"},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","field":"profiles","label":"OECI membership list"},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"links","label":"OECI membership list"},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","field":"profiles","label":"OECI membership list"},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","field":"links","label":"OECI membership list"},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","field":"profiles","label":"OECI membership list"},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"links","label":"OECI membership list"},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","field":"profiles","label":"OECI membership list"},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"links","label":"OECI membership list"},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","field":"profiles","label":"OECI membership list"},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","field":"links","label":"OECI membership list"},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","field":"profiles","label":"OECI membership list"},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"links","label":"OECI membership list"},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","field":"profiles","label":"OECI membership list"},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"links","label":"OECI membership list"},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","field":"profiles","label":"OECI membership list"},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"links","label":"OECI membership list"},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","field":"profiles","label":"OECI membership list"},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","field":"links","label":"OECI membership list"},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","field":"profiles","label":"OECI membership list"},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"links","label":"OECI membership list"},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","field":"profiles","label":"OECI membership list"},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"links","label":"OECI membership list"},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","field":"profiles","label":"OECI membership list"},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","field":"links","label":"OECI membership list"},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","field":"profiles","label":"OECI membership list"},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","field":"links","label":"OECI membership list"},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","field":"profiles","label":"OECI membership list"},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","field":"links","label":"OECI membership list"},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","field":"profiles","label":"OECI membership list"},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","field":"links","label":"OECI membership list"},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","field":"profiles","label":"OECI membership list"},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","field":"links","label":"OECI membership list"},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","field":"profiles","label":"OECI membership list"},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"links","label":"OECI membership list"},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","field":"profiles","label":"OECI membership list"},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"links","label":"OECI membership list"},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"profiles","label":"OECI membership list"},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"links","label":"OECI membership list"},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","field":"profiles","label":"OECI membership list"},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","field":"links","label":"OECI membership list"},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","field":"profiles","label":"OECI membership list"},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","field":"links","label":"OECI membership list"},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","field":"profiles","label":"OECI membership list"},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","field":"links","label":"OECI membership list"},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","field":"profiles","label":"OECI membership list"},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","field":"links","label":"OECI membership list"},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","field":"profiles","label":"OECI membership list"},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","field":"links","label":"OECI membership list"},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","field":"profiles","label":"OECI membership list"},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"links","label":"OECI membership list"},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","field":"profiles","label":"OECI membership list"},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"links","label":"OECI membership list"},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","field":"profiles","label":"OECI membership list"},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","field":"links","label":"OECI membership list"},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","field":"profiles","label":"OECI membership list"},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"links","label":"OECI membership list"},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"profiles","label":"OECI membership list"},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"links","label":"OECI membership list"},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","field":"profiles","label":"OECI membership list"},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"links","label":"OECI membership list"},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","field":"profiles","label":"OECI membership list"},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","field":"links","label":"OECI membership list"},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","field":"profiles","label":"OECI membership list"},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","field":"links","label":"OECI membership list"},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","field":"profiles","label":"OECI membership list"},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","route":"/institutions/blida-anti-cancer-center/","field":"links","label":"OECI membership list"},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","route":"/institutions/jinshazhou-hospital/","field":"links","label":"OECI membership list"},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","field":"links","label":"OECI membership list"},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","field":"links","label":"OECI membership list"},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","field":"links","label":"OECI membership list"},{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","field":"links","label":"OECI membership list"},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","field":"links","label":"OECI membership list"},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","field":"links","label":"OECI membership list"},{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","route":"/institutions/institut-godinot/","field":"links","label":"OECI membership list"},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","route":"/institutions/centre-georges-francois-leclerc/","field":"links","label":"OECI membership list"},{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","route":"/institutions/institut-de-cancerologie-de-lorraine/","field":"links","label":"OECI membership list"},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","field":"links","label":"OECI membership list"},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","field":"links","label":"OECI membership list"},{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","route":"/institutions/fondazione-poliambulanza/","field":"links","label":"OECI membership list"},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","field":"links","label":"OECI membership list"},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","field":"links","label":"OECI membership list"},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","field":"links","label":"OECI membership list"},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","field":"links","label":"OECI membership list"},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","field":"links","label":"OECI membership list"},{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","route":"/institutions/klaipeda-university-hospital/","field":"links","label":"OECI membership list"},{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","field":"links","label":"OECI membership list"},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","field":"links","label":"OECI membership list"},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/","field":"links","label":"OECI membership list"},{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","field":"links","label":"OECI membership list"},{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","route":"/institutions/polish-mothers-memorial-hospital/","field":"links","label":"OECI membership list"},{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","route":"/institutions/oncology-institute-of-vojvodina/","field":"links","label":"OECI membership list"},{"id":"mater-private","kind":"institution","name":"Mater Private Network","route":"/institutions/mater-private/","field":"links","label":"OECI membership list"},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/","field":"links","label":"OECI membership list"},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","route":"/institutions/bank-of-cyprus-oncology-centre/","field":"links","label":"OECI membership list"},{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","route":"/institutions/zealand-university-hospital/","field":"links","label":"OECI membership list"},{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","route":"/institutions/uz-brussel-cancer-centre/","field":"links","label":"OECI membership list"},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","route":"/institutions/sestre-milosrdnice-tumors/","field":"links","label":"OECI membership list"},{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","route":"/institutions/german-oncology-center-limassol/","field":"links","label":"OECI membership list"},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","route":"/institutions/metaxa-cancer-hospital/","field":"links","label":"OECI membership list"},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","route":"/institutions/university-hospital-waterford/","field":"links","label":"OECI membership list"},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","route":"/institutions/mediterranean-institute-of-oncology/","field":"links","label":"OECI membership list"},{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","route":"/institutions/kauno-klinikos/","field":"links","label":"OECI membership list"},{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","route":"/institutions/oncological-institute-moldova/","field":"links","label":"OECI membership list"},{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","route":"/institutions/university-clinic-radiotherapy-oncology-skopje/","field":"links","label":"OECI membership list"},{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","route":"/institutions/oncosalud-auna/","field":"links","label":"OECI membership list"},{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","route":"/institutions/iasi-regional-oncology-institute/","field":"links","label":"OECI membership list"},{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","route":"/institutions/clara-campal-oncology-centre/","field":"links","label":"OECI membership list"},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","route":"/institutions/virgen-de-la-victoria-malaga/","field":"links","label":"OECI membership list"},{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","route":"/institutions/doctor-peset-valencia/","field":"links","label":"OECI membership list"},{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","route":"/institutions/umea-university-hospital/","field":"links","label":"OECI membership list"},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","route":"/institutions/aga-khan-hospital-dar-es-salaam/","field":"links","label":"OECI membership list"},{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","route":"/institutions/dokuz-eylul-institute-of-oncology/","field":"links","label":"OECI membership list"},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","route":"/institutions/kavetsky-institute-kyiv/","field":"links","label":"OECI membership list"},{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","field":"links","label":"OECI membership list"},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","field":"links","label":"OECI membership list"},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","field":"links","label":"OECI membership list"},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","field":"links","label":"OECI membership list"},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","field":"links","label":"OECI membership list"},{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","field":"links","label":"OECI membership list"},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","field":"links","label":"OECI membership list"},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","field":"links","label":"OECI membership list"},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","field":"links","label":"OECI membership list"},{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","field":"links","label":"OECI membership list"},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","field":"links","label":"OECI membership list"},{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","field":"links","label":"OECI membership list"},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","route":"/institutions/aidport/","field":"links","label":"OECI membership list"},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","field":"links","label":"OECI membership list"},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/","field":"links","label":"OECI membership list"},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","route":"/institutions/heart-and-brain-pleven/","field":"links","label":"OECI membership list"},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","route":"/institutions/bjcn/","field":"links","label":"OECI membership list"},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","route":"/institutions/iba-masaryk/","field":"links","label":"OECI membership list"},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","route":"/institutions/fondazione-the-bridge/","field":"links","label":"OECI membership list"},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","route":"/institutions/cancer-free-future-association/","field":"links","label":"OECI membership list"},{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","route":"/institutions/sgccn/","field":"links","label":"OECI membership list"},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","field":"links","label":"OECI membership list"},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","field":"links","label":"OECI membership list"},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","field":"links","label":"OECI membership list"},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","field":"links","label":"OECI membership list"},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","field":"links","label":"OECI membership list"},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","field":"links","label":"OECI membership list"},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","field":"links","label":"OECI membership list"},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","field":"links","label":"OECI membership list"},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","field":"links","label":"OECI membership list"},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","field":"links","label":"OECI membership list"},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","route":"/institutions/inc-luxembourg/","field":"links","label":"OECI membership list"},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","route":"/institutions/nci-ukraine/","field":"links","label":"OECI membership list"},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/","field":"links","label":"OECI membership list"}]},{"url":"https://www.ohdsi.org","status":200,"ok":true,"finalUrl":"https://www.ohdsi.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"omop-ohdsi","kind":"term","name":"OMOP common data model and OHDSI","route":"/terms/omop-ohdsi/","field":"links","label":"OHDSI"}]},{"url":"https://www.ohdsi.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-federated-analytics-network","kind":"idea","name":"Send the code to the data: a federated analytics network of cancer centres","route":"/ideas/idea-data-federated-analytics-network/","field":"links","label":"OHDSI"}]},{"url":"https://www.ohri.ca","status":200,"ok":true,"finalUrl":"https://ohri.ca/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","field":"links","label":"Ottawa Hospital Research Institute"}]},{"url":"https://www.ohri.ca/en/who-we-are/organizational-structure","status":200,"ok":true,"finalUrl":"https://ohri.ca/en/who-we-are/organizational-structure","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","field":"links","label":"Source: OHRI organisational structure page"}]},{"url":"https://www.ohri.ca/profile/jbell","status":200,"ok":true,"finalUrl":"https://ohri.ca/en/find-researcher/jbell","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-bell","kind":"person","name":"John C. Bell","route":"/people/john-bell/","field":"links","label":"Ottawa Hospital Research Institute"},{"id":"john-bell","kind":"person","name":"John C. Bell","route":"/people/john-bell/","field":"profiles","label":"Ottawa Hospital Research Institute"}]},{"url":"https://www.ohsu.edu/knight-cancer-institute","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","field":"links","label":"OHSU Knight Cancer Institute"},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","field":"profiles","label":"OHSU Knight Cancer Institute"},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","field":"links","label":"OHSU Knight Cancer Institute"},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","field":"profiles","label":"OHSU Knight Cancer Institute"},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","field":"links","label":"Knight Cancer Institute"},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","field":"website"}]},{"url":"https://www.ohsu.edu/knight-cancer-institute/cedar","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","field":"links","label":"CEDAR"}]},{"url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-leaders","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","field":"links","label":"Institution profile"},{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-mission-and-history","status":200,"ok":true,"finalUrl":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-mission-and-milestones","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"phil-knight","kind":"person","name":"Phil Knight","route":"/people/phil-knight/","field":"links","label":"OHSU Knight Cancer Institute: mission and history"},{"id":"gert-boyle","kind":"person","name":"Gert Boyle","route":"/people/gert-boyle/","field":"links","label":"OHSU Knight Cancer Institute: mission and history"}]},{"url":"https://www.olema.com","status":200,"ok":true,"finalUrl":"https://olema.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","field":"links","label":"Official website"},{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","field":"website"}]},{"url":"https://www.olema.com/pipeline","status":200,"ok":true,"finalUrl":"https://olema.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","field":"links","label":"Pipeline page"}]},{"url":"https://www.olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/EU-ME3.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/","field":"links","label":"Olympus: endoscopic ultrasound"}]},{"url":"https://www.olympus-global.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"olympus","kind":"company","name":"Olympus","route":"/companies/olympus/","field":"links","label":"Official website"},{"id":"olympus","kind":"company","name":"Olympus","route":"/companies/olympus/","field":"website"}]},{"url":"https://www.omico.com.au","status":200,"ok":true,"finalUrl":"https://omico.org.au/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","field":"links","label":"Omico"}]},{"url":"https://www.omnicell.com","status":200,"ok":true,"finalUrl":"https://www.omnicell.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","field":"links","label":"Official website"},{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","field":"website"}]},{"url":"https://www.onclive.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","field":"links","label":"OncLive"},{"id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","field":"url"}]},{"url":"https://www.onclive.com/view/177lu-psma-i-t-meets-rpfs-end-point-in-psma-mcrpc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","field":"links","label":"ECLIPSE meets rPFS (OncLive)"}]},{"url":"https://www.onclive.com/view/accelerated-fda-approval-establishes-role-of-avutometinib-defactinib-in-kras-mutant-recurrent-low-grade-serous-ovarian-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","field":"dosing.source"}]},{"url":"https://www.onclive.com/view/chemotherapy-plus-durvalumab-bevacizumab-and-olaparib-fails-to-offer-os-benefit-in-newly-diagnosed-non-tbrca-mutated-ovarian-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","field":"links","label":"OncLive on OS"}]},{"url":"https://www.onclive.com/view/china-s-nmpa-approves-cadonilimab-plus-chemo-with-without-bevacizumab-in-cervical-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","field":"regulatoryEvents.source (2024-09)"}]},{"url":"https://www.onclive.com/view/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"masofaniten","kind":"drug","name":"Masofaniten","route":"/drugs/masofaniten/","field":"links","label":"ESSA terminates phase 2 (OncLive)"}]},{"url":"https://www.onclive.com/view/eu-approval-is-sought-for-eflornithine-in-high-risk-neuroblastoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","field":"regulatoryEvents.source (2025)"}]},{"url":"https://www.onclive.com/view/fda-approves-camizestrant-plus-a-cdk4-6-inhibitor-for-emergent-esr1-mutated-hr-her2-advanced-breast-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.onclive.com/view/fda-approves-dordaviprone-for-diffuse-midline-glioma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","field":"links","label":"OncLive"}]},{"url":"https://www.onclive.com/view/fda-approves-durvalumab-for-limited-stage-small-cell-lung-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","field":"links","label":"FDA approval (Dec 2024)"}]},{"url":"https://www.onclive.com/view/fda-approves-first-line-tislelizumab-plus-chemotherapy-for-unresectable-or-metastatic-escc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","field":"outcomes.source (Overall survival, PD-L1 ≥1%)"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","field":"links","label":"FDA approval, first-line ESCC"}]},{"url":"https://www.onclive.com/view/fda-approves-frontline-nalirifox-for-metastatic-pancreatic-adenocarcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","field":"links","label":"OncLive: FDA approves NALIRIFOX"}]},{"url":"https://www.onclive.com/view/fda-approves-nirogacestat-for-desmoid-tumors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","field":"regulatoryEvents.source (2023-11-27)"}]},{"url":"https://www.onclive.com/view/fda-approves-tar-200-in-bcg-unresponsive-nmibc-with-cis","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","field":"regulatoryEvents.source (2025-09-09)"}]},{"url":"https://www.onclive.com/view/fda-approves-toripalimab-for-recurrent-or-metastatic-nasopharyngeal-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","field":"links","label":"FDA approval coverage"}]},{"url":"https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","field":"links","label":"OncLive report"}]},{"url":"https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-emi-le-for-adenoid-cystic-carcinoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","field":"links","label":"Breakthrough designation (OncLive)"}]},{"url":"https://www.onclive.com/view/fda-grants-priority-review-to-neladalkib-for-tki-pretreated-alk-nsclc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/","field":"links","label":"OncLive: priority review"}]},{"url":"https://www.onclive.com/view/fda-issues-crl-for-glofitamab-plus-chemo-in-r-r-dlbcl","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","field":"links","label":"FDA CRL coverage"}]},{"url":"https://www.onclive.com/view/frontmind-results-tafasitamab-based-combo-yields-significant-pfs-benefit-over-r-chop-in-frontline-high-risk-dlbcl","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","field":"regulatoryEvents.source (2026-03)"}]},{"url":"https://www.onclive.com/view/iza-bren-yields-pfs-and-os-benefits-vs-chemo-in-previously-treated-advanced-tnbc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","field":"links","label":"OncLive report"},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","field":"outcomes.source (Progression-free survival (BICR))"},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","field":"outcomes.source (Overall survival (interim, median follow-up 11 months))"}]},{"url":"https://www.onclive.com/view/nemtabrutinib-generates-responses-displays-manageable-safety-in-cll-sll","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","field":"toxicity.source (Dysgeusia)"}]},{"url":"https://www.onclive.com/view/nirogacestat-wins-eu-approval-for-progressing-desmoid-tumors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","field":"regulatoryEvents.source (2025)"}]},{"url":"https://www.onclive.com/view/olomorasib-plus-pembrolizumab-earns-breakthrough-therapy-designation-in-untreated-kras-g12c-mutated-nsclc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/","field":"links","label":"OncLive: Breakthrough designation"}]},{"url":"https://www.onclive.com/view/perioperative-enfortumab-vedotin-pembrolizumab-meets-efs-os-pcr-end-points-in-cisplatin-eligible-mibc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","field":"links","label":"OncLive topline report"}]},{"url":"https://www.onclive.com/view/toripalimab-plus-chemo-maintains-survival-benefit-after-6-years-in-recurrent-metastatic-npc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","field":"links","label":"6-year update, OncLive"},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.onclive.com/view/tucatinib-combinations-in-her2-breast-cancer-her2climb-02-and-her2climb-05","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.onclive.com/view/zoldonrasib-combinations-show-compelling-antitumor-activity-in-ras-g12d-mutant-metastatic-pdac","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","field":"links","label":"OncLive report"}]},{"url":"https://www.oncoc4.com","status":200,"ok":true,"finalUrl":"https://www.oncoc4.com/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","field":"links","label":"Official website"},{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","field":"website"}]},{"url":"https://www.oncoc4.com/en/pipeline/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","field":"links","label":"Pipeline page"},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/","field":"links","label":"Sponsor page"},{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","field":"links","label":"Sponsor page"}]},{"url":"https://www.oncode.nl","status":200,"ok":true,"finalUrl":"https://www.oncodeinstitute.nl/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","field":"links","label":"Oncode Institute"}]},{"url":"https://www.oncohost.com","status":200,"ok":true,"finalUrl":"https://www.oncohost.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","field":"links","label":"Official website"},{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","field":"website"}]},{"url":"https://www.oncohost.com/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","field":"links","label":"About OncoHost"}]},{"url":"https://www.oncohost.com/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","field":"links","label":"News (EIC Transition grant, AACR 2026)"}]},{"url":"https://www.oncokb.org","status":200,"ok":true,"finalUrl":"https://www.oncokb.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/","field":"links","label":"OncoKB"},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/","field":"url"}]},{"url":"https://www.oncokb.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","field":"links","label":"OncoKB"}]},{"url":"https://www.oncology.cam.ac.uk/directory/j-abraham","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/","field":"links","label":"University of Cambridge Department of Oncology profile"},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/","field":"profiles","label":"University of Cambridge Department of Oncology profile"}]},{"url":"https://www.oncology.org.mk","status":200,"ok":true,"finalUrl":"https://www.oncology.org.mk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","route":"/institutions/university-clinic-radiotherapy-oncology-skopje/","field":"links","label":"Official website"},{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","route":"/institutions/university-clinic-radiotherapy-oncology-skopje/","field":"website"}]},{"url":"https://www.oncology.org.mk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"links","label":"University Clinic for Radiotherapy and Oncology, Skopje website"},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","field":"profiles","label":"University Clinic for Radiotherapy and Oncology, Skopje website"}]},{"url":"https://www.oncology.ox.ac.uk","status":200,"ok":true,"finalUrl":"https://www.oncology.ox.ac.uk/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","field":"links","label":"Department of Oncology"}]},{"url":"https://www.oncology.ox.ac.uk/team/mark-middleton","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"mark-middleton","kind":"person","name":"Mark Middleton","route":"/people/mark-middleton/","field":"profiles","label":"Department of Oncology profile"}]},{"url":"https://www.oncology.ox.ac.uk/team/rachel-kerr","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"rachel-kerr","kind":"person","name":"Rachel Kerr","route":"/people/rachel-kerr/","field":"links","label":"University of Oxford staff page"},{"id":"rachel-kerr","kind":"person","name":"Rachel Kerr","route":"/people/rachel-kerr/","field":"profiles","label":"University of Oxford staff page"}]},{"url":"https://www.oncology.ox.ac.uk/team/tim-maughan","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tim-maughan","kind":"person","name":"Tim Maughan","route":"/people/tim-maughan/","field":"links","label":"University of Oxford staff page"},{"id":"tim-maughan","kind":"person","name":"Tim Maughan","route":"/people/tim-maughan/","field":"profiles","label":"University of Oxford staff page"}]},{"url":"https://www.oncologypipeline.com/apexonco/bicycle-finally-falls","status":200,"ok":true,"finalUrl":"https://www.apexonco.com/bicycle-finally-falls","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","field":"regulatoryEvents.source (2026-03)"}]},{"url":"https://www.oncolyticsbiotech.com","status":200,"ok":true,"finalUrl":"https://oncolyticsbiotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","field":"links","label":"Official website"},{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","field":"website"}]},{"url":"https://www.oncomap.de","status":200,"ok":true,"finalUrl":"https://www.oncomap.de/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"OncoMap"}]},{"url":"https://www.oncoray.de","status":200,"ok":true,"finalUrl":"https://www.oncoray.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"OncoRay"}]},{"url":"https://www.oncotarget.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/","field":"links","label":"Homepage"},{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/","field":"url"}]},{"url":"https://www.oncotelic.com/pipeline","status":200,"ok":true,"finalUrl":"https://www.oncotelic.com/pipeline/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trabedersen","kind":"drug","name":"Trabedersen","route":"/drugs/trabedersen/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.oncotherm.com/","status":200,"ok":true,"finalUrl":"https://oncotherm.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","field":"links","label":"Official website"},{"id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","field":"website"}]},{"url":"https://www.oncotypeiq.com","status":200,"ok":true,"finalUrl":"https://www.exactsciences.com/cancer-testing/oncology","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","field":"access.source (US)"}]},{"url":"https://www.oncoverity.com","status":200,"ok":true,"finalUrl":"https://www.oncoverity.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/","field":"links","label":"Official website"},{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/","field":"website"},{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","field":"links","label":"Sponsor page"}]},{"url":"https://www.oncozon.nl","status":200,"ok":true,"finalUrl":"https://www.oncozon.nl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncozon","kind":"institution","name":"OncoZON Comprehensive Cancer Network","route":"/institutions/oncozon/","field":"links","label":"Official website"},{"id":"oncozon","kind":"institution","name":"OncoZON Comprehensive Cancer Network","route":"/institutions/oncozon/","field":"website"}]},{"url":"https://www.oncozon.nl/prof-dr-valery-lemmens-benoemd-tot-directeur-van-oncozon/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","route":"/people/valery-lemmens/","field":"links","label":"Source: OncoZON news item announcing the appointment (August 2026)"},{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","route":"/people/valery-lemmens/","field":"profiles","label":"OncoZON appointment announcement"}]},{"url":"https://www.oncternal.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","route":"/companies/oncternal-therapeutics/","field":"links","label":"Official website"},{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","route":"/companies/oncternal-therapeutics/","field":"website"}]},{"url":"https://www.onderzoekmetmensen.nl/en/trial/24580","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","field":"links","label":"Netherlands Trial Register NTR3709"}]},{"url":"https://www.oneoncology.com","status":200,"ok":true,"finalUrl":"https://www.oneoncology.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/","field":"links","label":"Official website"},{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/","field":"website"}]},{"url":"https://www.onjcancercentre.org","status":200,"ok":true,"finalUrl":"https://www.onjcancercentre.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","field":"links","label":"ONJ Cancer Centre"},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","field":"website"}]},{"url":"https://www.onk.ns.ac.rs","status":200,"ok":true,"finalUrl":"https://www.onk.ns.ac.rs/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","route":"/institutions/oncology-institute-of-vojvodina/","field":"links","label":"Official website"},{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","route":"/institutions/oncology-institute-of-vojvodina/","field":"website"}]},{"url":"https://www.onko-i.si/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","field":"links","label":"Homepage (page moved; nearest live section)"},{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","field":"website"}]},{"url":"https://www.onko-i.si/eng/crs/","status":200,"ok":true,"finalUrl":"https://www.onko-i.si/en/crs","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","field":"links","label":"Cancer Registry"}]},{"url":"https://www.onko-i.si/o-nas/sektorji-in-oddelki/vodstvo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zlata-stiblar-kisic","kind":"person","name":"Zlata Štiblar Kisić","route":"/people/zlata-stiblar-kisic/","field":"links","label":"Institution profile"},{"id":"zlata-stiblar-kisic","kind":"person","name":"Zlata Štiblar Kisić","route":"/people/zlata-stiblar-kisic/","field":"profiles","label":"Institution profile"},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","field":"links","label":"Institution profile"},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.onkol.hu","status":200,"ok":true,"finalUrl":"https://onkol.hu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","field":"links","label":"Homepage"},{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","field":"website"}]},{"url":"https://www.onkol.hu/nemzeti-rakregiszter","status":200,"ok":true,"finalUrl":"https://onkol.hu/nemzeti-rakregiszter-es-biostatisztikai-kozpont/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","field":"links","label":"Hungarian National Cancer Registry"}]},{"url":"https://www.onkozert.de","status":200,"ok":true,"finalUrl":"https://www.onkozert.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","field":"links","label":"OnkoZert"}]},{"url":"https://www.onktherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","field":"links","label":"Official website"},{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","field":"website"}]},{"url":"https://www.onktherapeutics.com/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","field":"links","label":"About ONK"}]},{"url":"https://www.onktherapeutics.com/news/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","field":"links","label":"News"}]},{"url":"https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2017","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Office for National Statistics: cancer registration statistics, England, 2017 (data quality section, the exclusion of non-melanoma skin cancer from all-cancer counts), released 26 April 2019"}]},{"url":"https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/cancerregistrationstatisticsqmi","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Office for National Statistics: cancer registration statistics quality and methodology information (the statement that non-melanoma skin cancer is greatly under-registered, and that all-cancer figures are ICD-10 C00 to C97 excluding C44), last revised 23 February 2016"},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Office for National Statistics: cancer registration statistics quality and methodology information (the statement that non-melanoma skin cancer is greatly under-registered, and that all-cancer figures are ICD-10 C00 to C97 excluding C44), last revised 23 February 2016"},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","field":"links","label":"Office for National Statistics: cancer registration statistics quality and methodology information (the statement that non-melanoma skin cancer is greatly under-registered, and that all-cancer figures are ICD-10 C00 to C97 excluding C44), last revised 23 February 2016"}]},{"url":"https://www.ons.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","field":"links","label":"Oncology Nursing Society"}]},{"url":"https://www.ons.org/publications-research/cjon","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","route":"/journals/clinical-journal-of-oncology-nursing/","field":"links","label":"Homepage"},{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","route":"/journals/clinical-journal-of-oncology-nursing/","field":"url"}]},{"url":"https://www.ons.org/publications-research/onf","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","route":"/journals/oncology-nursing-forum/","field":"links","label":"Homepage"},{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","route":"/journals/oncology-nursing-forum/","field":"url"}]},{"url":"https://www.ontariohealth.ca/about/who-we-are/clinical-leadership.html","status":200,"ok":true,"finalUrl":"https://www.ontariohealth.ca/about/who-we-are/clinical-leadership","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","field":"links","label":"Source: Ontario Health clinical leadership page"},{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","field":"profiles","label":"Ontario Health clinical leadership page"}]},{"url":"https://www.ontariohealth.ca/about/who-we-are/senior-leadership.html","status":200,"ok":true,"finalUrl":"https://www.ontariohealth.ca/about/who-we-are/senior-leadership","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","field":"links","label":"Ontario Health senior leadership page"}]},{"url":"https://www.opensafely.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-accredited-tre-network","kind":"idea","name":"Accredited trusted research environments with curated cancer tables","route":"/ideas/idea-data-accredited-tre-network/","field":"links","label":"OpenSAFELY"}]},{"url":"https://www.opentargets.org","status":200,"ok":true,"finalUrl":"https://opentargets.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","field":"links","label":"Open Targets"}]},{"url":"https://www.opentargets.org/","status":200,"ok":true,"finalUrl":"https://opentargets.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-data-open-evidence-knowledge-graph","kind":"idea","name":"An open knowledge graph linking trials, results, biomarkers, drugs and recommendations","route":"/ideas/idea-data-open-evidence-knowledge-graph/","field":"links","label":"Open Targets"},{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/","field":"links","label":"Open Targets"},{"id":"idea-fund-precompetitive-undruggable-consortium","kind":"idea","name":"An open-science consortium on the undruggable drivers, open until a candidate","route":"/ideas/idea-fund-precompetitive-undruggable-consortium/","field":"links","label":"Open Targets"},{"id":"idea-moon-open-degrader-consortium","kind":"idea","name":"An open degrader consortium against every undruggable driver transcription factor","route":"/ideas/idea-moon-open-degrader-consortium/","field":"links","label":"Open Targets"}]},{"url":"https://www.optune.com","status":200,"ok":true,"finalUrl":"https://www.optunegio.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","field":"dosing.source"}]},{"url":"https://www.oracle.com/health/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","route":"/companies/oracle-health-sciences/","field":"links","label":"Official website"},{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","route":"/companies/oracle-health-sciences/","field":"website"}]},{"url":"https://www.oranomed.com","status":200,"ok":true,"finalUrl":"https://www.oranomed.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","field":"links","label":"Official website"},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","field":"website"}]},{"url":"https://www.orbimed.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","field":"links","label":"Official website"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","field":"website"}]},{"url":"https://www.orbimed.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","field":"links","label":"Portfolio"}]},{"url":"https://www.organon.com","status":200,"ok":true,"finalUrl":"https://www.organon.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","field":"links","label":"Official website"},{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","field":"website"}]},{"url":"https://www.organon.com/our-focus/products-list/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","field":"links","label":"Organon product list"}]},{"url":"https://www.orionpharma.com","status":200,"ok":true,"finalUrl":"https://www.orionpharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/","field":"links","label":"Official website"},{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/","field":"website"}]},{"url":"https://www.orpha.net/en/disease/detail/652","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","field":"links","label":"Orphanet: multiple endocrine neoplasia type 1 (ORPHA:652)"}]},{"url":"https://www.orpha.net/en/disease/detail/653","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","field":"links","label":"Orphanet: multiple endocrine neoplasia type 2 (ORPHA:653)"}]},{"url":"https://www.orpha.net/en/disease/detail/99880","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","field":"links","label":"Orphanet: hyperparathyroidism-jaw tumour syndrome (ORPHA:99880)"}]},{"url":"https://www.orumrx.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"links","label":"Official website"},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"website"}]},{"url":"https://www.orumrx.com/news/3zokvvtwmn7jjpn0uevjkivk30uvu4","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"links","label":"Series B press release"}]},{"url":"https://www.orumrx.com/news/orum-orm-6151-acquisition-by-bms","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"links","label":"BMS acquires ORM-6151 programme"}]},{"url":"https://www.orumrx.com/news/orum-therapeutics-announces-pricing-of-initial-public-offeringnbsp","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"links","label":"IPO pricing release"}]},{"url":"https://www.orumrx.com/news/orum-therapeutics-secures-approximately-us100-million-to-accelerate-development-of-leading-degrader-antibody-conjugate-programs-to-treat-serious-diseases-251218","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","field":"links","label":"USD 100 million financing release"}]},{"url":"https://www.osaka-u.ac.jp/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"osaka-university","kind":"institution","name":"Osaka University Graduate School of Medicine / Osaka University Hospital","route":"/institutions/osaka-university/","field":"links","label":"Osaka University"},{"id":"osaka-university","kind":"institution","name":"Osaka University Graduate School of Medicine / Osaka University Hospital","route":"/institutions/osaka-university/","field":"website"}]},{"url":"https://www.ose-immuno.com","status":200,"ok":true,"finalUrl":"https://www.ose-immuno.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","field":"links","label":"Official website"},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","field":"website"}]},{"url":"https://www.ose-immuno.com/en/pipeline/tedopi/","status":200,"ok":true,"finalUrl":"https://www.ose-immuno.com/nos-produits/tedopi-modulaire/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.ose-immuno.com/en/press-releases/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","field":"links","label":"Press releases"}]},{"url":"https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","field":"links","label":"Bridge equity financing with IRIS (May 2026)"}]},{"url":"https://www.oslo-universitetssykehus.no","status":200,"ok":true,"finalUrl":"https://www.oslo-universitetssykehus.no/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Oslo University Hospital"}]},{"url":"https://www.ospedaleniguarda.it","status":200,"ok":true,"finalUrl":"https://www.ospedaleniguarda.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/","field":"links","label":"Ospedale Niguarda"},{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/","field":"website"}]},{"url":"https://www.ospedalesanmartino.it","status":200,"ok":true,"finalUrl":"https://www.ospedalesanmartino.it/it/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"san-martino-genoa","kind":"institution","name":"IRCCS Ospedale Policlinico San Martino","route":"/institutions/san-martino-genoa/","field":"links","label":"Official website"},{"id":"san-martino-genoa","kind":"institution","name":"IRCCS Ospedale Policlinico San Martino","route":"/institutions/san-martino-genoa/","field":"website"}]},{"url":"https://www.ospedalesanmartino.it/it/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","field":"links","label":"IRCCS Ospedale Policlinico San Martino website"},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","field":"profiles","label":"IRCCS Ospedale Policlinico San Martino website"}]},{"url":"https://www.ospedalesanmartino.it/it/chi-siamo/organigramma.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"monica-calamai","kind":"person","name":"Monica Calamai","route":"/people/monica-calamai/","field":"links","label":"Source: IRCCS Ospedale Policlinico San Martino organigramma page"},{"id":"monica-calamai","kind":"person","name":"Monica Calamai","route":"/people/monica-calamai/","field":"profiles","label":"San Martino organisational chart (Direzione Strategica)"}]},{"url":"https://www.otsuka.co.jp/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/","field":"links","label":"Official website"},{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/","field":"website"}]},{"url":"https://www.ottawahospital.on.ca","status":200,"ok":true,"finalUrl":"https://www.ottawahospital.on.ca/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","field":"website"}]},{"url":"https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/","status":200,"ok":true,"finalUrl":"https://www.ottawahospital.on.ca/en/departments-and-services/cancer-program","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","field":"links","label":"The Ottawa Hospital cancer program"}]},{"url":"https://www.ouh.nhs.uk/cancer/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","field":"links","label":"OUH cancer services"}]},{"url":"https://www.ous-research.no/institute/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","field":"links","label":"Institution profile"},{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","field":"profiles","label":"Institution profile"},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"links","label":"Oslo University Hospital, The Norwegian Radium Hospital website"},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","field":"profiles","label":"Oslo University Hospital, The Norwegian Radium Hospital website"},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Institute for Cancer Research"},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"website"}]},{"url":"https://www.outperformcancer.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","route":"/companies/outperform-cancer/","field":"links","label":"Official website"},{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","route":"/companies/outperform-cancer/","field":"website"}]},{"url":"https://www.ovid.com/jnls/cancerjournal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","route":"/journals/journal-of-cancer-research-and-therapeutics/","field":"links","label":"Homepage"},{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","route":"/journals/journal-of-cancer-research-and-therapeutics/","field":"url"}]},{"url":"https://www.ovid.com/jnls/immunotherapy-journal","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/","field":"links","label":"Homepage"},{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/","field":"url"}]},{"url":"https://www.owkin.com","status":200,"ok":true,"finalUrl":"https://www.owkin.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/","field":"links","label":"Official website"},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/","field":"website"}]},{"url":"https://www.owlstonemedical.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","field":"links","label":"Official website"},{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","field":"website"}]},{"url":"https://www.owlstonemedical.com/about/news/2025/jan/15/press-release-series-e-financing-round/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","field":"links","label":"Series E financing (Jan 2025)"}]},{"url":"https://www.owlstonemedical.com/about/news/2025/oct/06/owlstone-medical-wins-up-to-49-1-million-award-from-arpa-h-to-develop-at-home-multi-cancer-early-detection-tests/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","field":"links","label":"ARPA-H award (Oct 2025)"}]},{"url":"https://www.oxb.com","status":200,"ok":true,"finalUrl":"https://oxb.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/","field":"links","label":"Official website"},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/","field":"website"}]},{"url":"https://www.oyez.org/cases/2012/12-398","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/","field":"links","label":"Oyez: Association for Molecular Pathology v. Myriad Genetics, Inc. (12-398)"}]},{"url":"https://www.p-cure.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","field":"links","label":"Official website"},{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","field":"website"}]},{"url":"https://www.p-cure.com/news-events/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","field":"links","label":"News and events (FDA clearances)"}]},{"url":"https://www.pacb.com","status":200,"ok":true,"finalUrl":"https://www.pacb.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","field":"links","label":"Official website"},{"id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","field":"website"}]},{"url":"https://www.pacificedgedx.com","status":200,"ok":true,"finalUrl":"https://www.pacificedgedx.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pacific-edge","kind":"company","name":"Pacific Edge","route":"/companies/pacific-edge/","field":"links","label":"Official website"},{"id":"pacific-edge","kind":"company","name":"Pacific Edge","route":"/companies/pacific-edge/","field":"website"}]},{"url":"https://www.paho.org/en/paho-strategic-fund","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-cost-pooled-procurement-essential","kind":"idea","name":"Pool purchasing of essential cancer medicines across countries","route":"/ideas/idea-cost-pooled-procurement-essential/","field":"links","label":"PAHO Strategic Fund"}]},{"url":"https://www.pancreaticcancer.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK"},{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","field":"links","label":"Pancreatic Cancer UK"},{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","field":"website"}]},{"url":"https://www.pancreaticcancer.org.uk/about-us/what-we-do/we-campaign-for-change/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","field":"links","label":"Pancreatic Cancer UK: campaigning for change"}]},{"url":"https://www.pancreaticcancer.org.uk/about-us/who-we-are/media-centre/pancreatic-cancer-statistics/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","field":"links","label":"Statistics"}]},{"url":"https://www.pancreaticcancer.org.uk/get-involved/make-a-difference/join-our-campaigns/dont-write-me-off-impact/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-uk-active-treatment-rate-audit-and-target","kind":"idea","name":"Raise the share of UK patients who receive any active treatment, and publish it by trust","route":"/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/","field":"links","label":"Pancreatic Cancer UK: Don't Write Me Off campaign"}]},{"url":"https://www.pancreaticcancer.org.uk/get-involved/take-action/join-our-campaigns/unite-diagnose-save-lives-2025/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway","kind":"idea","name":"A fast-track pathway from suspicion to treatment for pancreatic cancer in the NHS, measured from first scan to first treatment","route":"/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/","field":"links","label":"Pancreatic Cancer UK: Unite Diagnose Save Lives 2025 open letter"}]},{"url":"https://www.pancreaticcancer.org.uk/health-professionals/resources-for-health-professionals/optimal-care-pathway-hub/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","field":"links","label":"Optimal Care Pathway hub"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/dealing-with-pancreatic-cancer/daily-life-with-pancreatic-cancer/work-and-money/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: work and money"},{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: work and money"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","field":"links","label":"Pancreatic Cancer UK: work and money"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/dealing-with-pancreatic-cancer/dealing-with-the-emotional-impact-of-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: dealing with the emotional impact of pancreatic cancer"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: dealing with the emotional impact of pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/end-of-life-care-for-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: end of life care for pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/family-history-of-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: family history of pancreatic cancer"},{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","field":"links","label":"Pancreatic Cancer UK: family history"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Pancreatic Cancer UK: family history of pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/family-history-of-pancreatic-cancer/hereditary-pancreatic-cancers/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","field":"links","label":"Pancreatic Cancer UK: hereditary pancreatic cancers"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/just-diagnosed-with-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: just diagnosed with pancreatic cancer?"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/just-diagnosed-with-pancreatic-cancer/if-you-cant-have-surgery-inoperable-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: if you can't have surgery (inoperable cancer)"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","field":"links","label":"Pancreatic Cancer UK: if you can't have surgery (inoperable cancer)"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/blood-clots-in-a-vein-dvt-and-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"Pancreatic Cancer UK: blood clots in a vein and pancreatic cancer"},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","field":"links","label":"Pancreatic Cancer UK: blood clots in a vein and pancreatic cancer"},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","field":"links","label":"Pancreatic Cancer UK: blood clots in a vein and pancreatic cancer"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Pancreatic Cancer UK: blood clots in a vein and pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/changes-to-bowel-habits/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Pancreatic Cancer UK: managing bowel problems caused by pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diabetes-with-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: managing diabetes if you have pancreatic cancer (type 3c diabetes)"},{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"links","label":"Pancreatic Cancer UK: managing diabetes if you have pancreatic cancer (type 3c diabetes)"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: diet and pancreatic cancer"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Pancreatic Cancer UK: diet and pancreatic cancer"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","field":"links","label":"Pancreatic Cancer UK: diet and pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/pancreatic-enzyme-replacement-therapy-pert/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Pancreatic Cancer UK: pancreatic enzyme replacement therapy (PERT)"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/pancreatic-enzyme-replacement-therapy-pert/how-do-i-take-pancreatic-enzyme-replacement-therapy-if-i-have-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: how do I take pancreatic enzyme replacement therapy?"},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Pancreatic Cancer UK: how do I take pancreatic enzyme replacement therapy?"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","field":"links","label":"Pancreatic Cancer UK: how do I take pancreatic enzyme replacement therapy?"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/pancreatic-enzyme-replacement-therapy-pert/what-if-pancreatic-enzyme-replacement-therapy-doesnt-help-my-symptoms/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","field":"links","label":"Pancreatic Cancer UK: what if pancreatic enzyme replacement therapy does not help?"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/fatigue-and-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","field":"links","label":"Pancreatic Cancer UK: fatigue and pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/feeling-and-being-sick/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"Pancreatic Cancer UK: feeling sick and being sick"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/managing-jaundice-if-you-have-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: treating jaundice if you have pancreatic cancer"},{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","field":"links","label":"Pancreatic Cancer UK: treating jaundice if you have pancreatic cancer"},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","field":"links","label":"Pancreatic Cancer UK: treating jaundice if you have pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/managing-pancreatic-cancer-pain/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: managing pancreatic cancer pain"},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","field":"links","label":"Pancreatic Cancer UK: managing pancreatic cancer pain"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"Pancreatic Cancer UK: managing pancreatic cancer pain"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/support-for-you/information-for-family-members/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: information for families and friends"},{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: information for families and friends"},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: information for families and friends"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/bypass-surgery-if-you-have-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"Pancreatic Cancer UK: bypass surgery if you have pancreatic cancer"},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"Pancreatic Cancer UK: bypass surgery if you have pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/chemotherapy/how-is-chemotherapy-used-for-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: how is chemotherapy used for pancreatic cancer?"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/chemotherapy/side-effects-of-chemotherapy/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","field":"links","label":"Pancreatic Cancer UK: side effects of chemotherapy"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","field":"links","label":"Pancreatic Cancer UK: side effects of chemotherapy"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","field":"links","label":"Pancreatic Cancer UK: side effects of chemotherapy"},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","field":"links","label":"Pancreatic Cancer UK: side effects of chemotherapy"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/current-developments-in-pancreatic-cancer-treatment/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: current developments in pancreatic cancer treatment"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/stent-for-a-blocked-bile-duct/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"Pancreatic Cancer UK: stent for a blocked bile duct"},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","field":"links","label":"Pancreatic Cancer UK: stent for a blocked bile duct"},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","field":"links","label":"Pancreatic Cancer UK: stent for a blocked bile duct"},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","field":"links","label":"Pancreatic Cancer UK: stent for a blocked bile duct"},{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"Pancreatic Cancer UK: stent for a blocked bile duct"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Pancreatic Cancer UK: stent for a blocked bile duct"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/stents-for-a-blocked-duodenum/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","field":"links","label":"Pancreatic Cancer UK: stents for a blocked duodenum"},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","field":"links","label":"Pancreatic Cancer UK: stents for a blocked duodenum"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"Pancreatic Cancer UK: stents for a blocked duodenum"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","field":"links","label":"Pancreatic Cancer UK: surgery to remove pancreatic cancer"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/after-your-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Pancreatic Cancer UK: after your operation"},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","field":"links","label":"Pancreatic Cancer UK: after your operation"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Pancreatic Cancer UK: after your operation"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/recovering-from-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","field":"links","label":"Pancreatic Cancer UK: going home from hospital after surgery"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Pancreatic Cancer UK: going home from hospital after surgery"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/side-effects-of-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","field":"links","label":"Pancreatic Cancer UK: side effects of surgery"},{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","field":"links","label":"Pancreatic Cancer UK: side effects of surgery"},{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","field":"links","label":"Pancreatic Cancer UK: side effects of surgery"},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","field":"links","label":"Pancreatic Cancer UK: side effects of surgery"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/who-can-have-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","field":"links","label":"Pancreatic Cancer UK: who can have surgery for pancreatic cancer?"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","field":"links","label":"Pancreatic Cancer UK: who can have surgery for pancreatic cancer?"}]},{"url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","field":"links","label":"Your local specialist centre"},{"id":"royal-stoke-uhnm","kind":"institution","name":"Royal Stoke University Hospital","route":"/institutions/royal-stoke-uhnm/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"royal-surrey-guildford","kind":"institution","name":"Royal Surrey County Hospital, Guildford","route":"/institutions/royal-surrey-guildford/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"royal-blackburn-elht","kind":"institution","name":"Royal Blackburn Hospital (East Lancashire HPB MDT)","route":"/institutions/royal-blackburn-elht/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"aberdeen-royal-infirmary","kind":"institution","name":"Aberdeen Royal Infirmary","route":"/institutions/aberdeen-royal-infirmary/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"raigmore-inverness","kind":"institution","name":"Raigmore Hospital, Inverness","route":"/institutions/raigmore-inverness/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"derriford-plymouth","kind":"institution","name":"Derriford Hospital, University Hospitals Plymouth","route":"/institutions/derriford-plymouth/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"glasgow-royal-infirmary","kind":"institution","name":"Glasgow Royal Infirmary","route":"/institutions/glasgow-royal-infirmary/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"morriston-swansea","kind":"institution","name":"Morriston Hospital, Swansea","route":"/institutions/morriston-swansea/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"belfast-trust-hpb","kind":"institution","name":"Belfast Health and Social Care Trust HPB service","route":"/institutions/belfast-trust-hpb/","field":"links","label":"Pancreatic Cancer UK centres list"},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","field":"links","label":"Pancreatic Cancer UK: your local specialist centre"},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","field":"url"}]},{"url":"https://www.parkerici.org","status":200,"ok":true,"finalUrl":"https://www.parkerici.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","field":"website"}]},{"url":"https://www.parkerici.org/?s=arsenalbio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","field":"links","label":"PICI news: ArsenalBio"}]},{"url":"https://www.parkerici.org/about/","status":200,"ok":true,"finalUrl":"https://www.parkerici.org/about-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/","field":"links","label":"Parker Institute: about"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","field":"links","label":"About PICI"}]},{"url":"https://www.parkerici.org/about/leadership-staff/","status":200,"ok":true,"finalUrl":"https://www.parkerici.org/about-us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","field":"links","label":"PICI leadership and board"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"links","label":"PICI leadership and board"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","field":"profiles","label":"PICI leadership and board"}]},{"url":"https://www.parkerici.org/network/research-institutions/","status":200,"ok":true,"finalUrl":"https://www.parkerici.org/our-network/directory","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","field":"links","label":"PICI network: research institutions"}]},{"url":"https://www.parkerici.org/person/karen-e-knudsen/","status":200,"ok":true,"finalUrl":"https://www.parkerici.org/our-network/directory","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"links","label":"PICI profile"},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","field":"profiles","label":"PICI profile"}]},{"url":"https://www.partnertx.com","status":200,"ok":true,"finalUrl":"https://www.partnertx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/","field":"links","label":"Official website"},{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/","field":"website"}]},{"url":"https://www.pasteur.fr","status":200,"ok":true,"finalUrl":"https://www.pasteur.fr/fr","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","field":"website"}]},{"url":"https://www.pasteur.fr/en","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","field":"links","label":"Homepage"}]},{"url":"https://www.pathai.com","status":200,"ok":true,"finalUrl":"https://www.pathai.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/","field":"links","label":"Official website"},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/","field":"website"}]},{"url":"https://www.pathology.med.umich.edu/faculty/arul","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"links","label":"Michigan profile"},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","field":"profiles","label":"Michigan profile"}]},{"url":"https://www.pathos.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","field":"links","label":"Official website"},{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","field":"website"}]},{"url":"https://www.pathos.com/news","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","field":"links","label":"News page"}]},{"url":"https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","field":"links","label":"Series D press release (May 2025)"}]},{"url":"https://www.patientadvocators.com","status":200,"ok":true,"finalUrl":"https://www.patientadvocators.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"patient-advocators","kind":"company","name":"Patient Advocators","route":"/companies/patient-advocators/","field":"links","label":"Official website"},{"id":"patient-advocators","kind":"company","name":"Patient Advocators","route":"/companies/patient-advocators/","field":"website"}]},{"url":"https://www.pbs.gov.au/industry/listing/participants/pbac","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","field":"links","label":"PBAC"},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","field":"website"}]},{"url":"https://www.pbs.gov.au/info/industry/listing/participants/pbac","status":200,"ok":true,"finalUrl":"https://www.pbs.gov.au/industry/listing/participants/pbac","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/","field":"links","label":"Source: PBAC membership page"},{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/","field":"profiles","label":"PBAC membership page"}]},{"url":"https://www.pcf.org","status":200,"ok":true,"finalUrl":"https://www.pcf.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","field":"website"}]},{"url":"https://www.pcf.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"PCF"},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"url"}]},{"url":"https://www.pcf.org/about/our-history/","status":200,"ok":true,"finalUrl":"https://www.pcf.org/our-impact/our-history-and-impact/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-milken","kind":"person","name":"Michael Milken","route":"/people/michael-milken/","field":"links","label":"Prostate Cancer Foundation: our history"},{"id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","field":"links","label":"PCF: our history"}]},{"url":"https://www.pcori.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-moon-patient-designed-trials","kind":"idea","name":"Patient panels approve trial burden and endpoints as a condition of funding","route":"/ideas/idea-moon-patient-designed-trials/","field":"links","label":"PCORI"}]},{"url":"https://www.pennmedicine.org/cancer","status":200,"ok":true,"finalUrl":"https://www.pennmedicine.org/specialties/cancer","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"links","label":"Official website"},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"website"},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","field":"links","label":"Abramson Cancer Center"},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","field":"profiles","label":"Abramson Cancer Center"}]},{"url":"https://www.pennmedicine.org/cancer/about/remembering-madlyn-abramson","status":200,"ok":true,"finalUrl":"https://www.pennmedicine.org/specialties/cancer/about-abramson-cancer-center?redirect=1&referrer=pennmed&source=fsu","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leonard-abramson","kind":"person","name":"Leonard Abramson","route":"/people/leonard-abramson/","field":"links","label":"Penn Medicine: remembering Madlyn Abramson"}]},{"url":"https://www.pennmedicine.org/providers/profile/charu-aggarwal","status":200,"ok":true,"finalUrl":"https://www.pennmedicine.org/providers/charu-aggarwal","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","field":"links","label":"Penn profile"},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","field":"profiles","label":"Penn profile"}]},{"url":"https://www.pennmedicine.org/providers/profile/david-porter","status":200,"ok":true,"finalUrl":"https://www.pennmedicine.org/providers/david-porter","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"links","label":"Penn profile"},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","field":"profiles","label":"Penn profile"}]},{"url":"https://www.pennybrohn.org.uk/","status":200,"ok":true,"finalUrl":"https://pennybrohn.org.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"penny-brohn-uk","kind":"collection","name":"Penny Brohn UK","route":"/collections/penny-brohn-uk/","field":"links","label":"Penny Brohn UK"},{"id":"penny-brohn-uk","kind":"collection","name":"Penny Brohn UK","route":"/collections/penny-brohn-uk/","field":"url"}]},{"url":"https://www.pentaxmedical.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pentax-medical","kind":"company","name":"Pentax Medical (HOYA)","route":"/companies/pentax-medical/","field":"links","label":"Official website"},{"id":"pentax-medical","kind":"company","name":"Pentax Medical (HOYA)","route":"/companies/pentax-medical/","field":"website"}]},{"url":"https://www.perceptivelife.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","field":"links","label":"Official website"},{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","field":"website"}]},{"url":"https://www.perceptivelife.com/venture-capital","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","field":"links","label":"Venture capital"}]},{"url":"https://www.personalis.com","status":200,"ok":true,"finalUrl":"https://www.personalis.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","field":"website"}]},{"url":"https://www.petermac.org","status":200,"ok":true,"finalUrl":"https://www.petermac.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"links","label":"Official website"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"website"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","field":"profiles","label":"Peter MacCallum Cancer Centre"}]},{"url":"https://www.pgh.gov.ph","status":200,"ok":true,"finalUrl":"https://www.pgh.gov.ph/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","field":"links","label":"Philippine General Hospital"},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","field":"website"}]},{"url":"https://www.pgh.gov.ph/list-of-officials/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","route":"/people/gerardo-legaspi/","field":"links","label":"Source: PGH list of officials"},{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","route":"/people/gerardo-legaspi/","field":"profiles","label":"PGH list of officials"}]},{"url":"https://www.pharmaand.com","status":200,"ok":true,"finalUrl":"https://www.pharmaand.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/","field":"links","label":"Official website"},{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/","field":"website"}]},{"url":"https://www.pharmaceutical-technology.com/data-insights/cetuximab-sarotalocan-rakuten-medical-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","field":"links","label":"Development status"}]},{"url":"https://www.pharmacytimes.com/view/a-new-era-in-first-line-metastatic-tnbc-nccn-guidelines-elevate-sacituzumab-govitecan-to-category-1-status","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Metastatic, first line, PD-L1 CPS ≥10)"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"standardOfCare.guideline (Metastatic, first line, PD-L1 negative or PD-1 ineligible)"}],"archive":"https://web.archive.org/web/20260501174425/https://www.pharmacytimes.com/view/a-new-era-in-first-line-metastatic-tnbc-nccn-guidelines-elevate-sacituzumab-govitecan-to-category-1-status"},{"url":"https://www.pharmaessentia.com","status":200,"ok":true,"finalUrl":"https://www.pharmaessentia.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","field":"links","label":"Official website"},{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","field":"website"}]},{"url":"https://www.pharmgkb.org","status":200,"ok":true,"finalUrl":"https://www.clinpgx.org/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ugt1a1-genotyping","kind":"technology","name":"UGT1A1 genotyping before irinotecan","route":"/technologies/ugt1a1-genotyping/","field":"links","label":"PharmGKB: UGT1A1 gene and clinical annotations"}]},{"url":"https://www.phaxiam.com","status":200,"ok":true,"finalUrl":"http://phaxiam.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","field":"links","label":"Official website"},{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","field":"website"}]},{"url":"https://www.philips.com","status":200,"ok":true,"finalUrl":"https://www.usa.philips.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"philips","kind":"company","name":"Philips","route":"/companies/philips/","field":"links","label":"Official website"},{"id":"philips","kind":"company","name":"Philips","route":"/companies/philips/","field":"website"}]},{"url":"https://www.philogen.com","status":200,"ok":true,"finalUrl":"https://www.philogen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/","field":"links","label":"Official website"},{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/","field":"website"}]},{"url":"https://www.photocure.com","status":200,"ok":true,"finalUrl":"https://www.photocure.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","field":"links","label":"Official website"},{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","field":"website"}]},{"url":"https://www.photys.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/","field":"links","label":"Official website"},{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/","field":"website"}]},{"url":"https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/","field":"links","label":"Series A press release"}]},{"url":"https://www.pib-nio.pl","status":200,"ok":true,"finalUrl":"https://www.pib-nio.pl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","field":"links","label":"Homepage"},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","field":"website"}]},{"url":"https://www.pierre-fabre.com","status":200,"ok":true,"finalUrl":"https://www.pierre-fabre.com/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/","field":"links","label":"Official website"},{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/","field":"website"}]},{"url":"https://www.pih.org/country/rwanda","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","field":"links","label":"Partners In Health Rwanda"},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","field":"website"}]},{"url":"https://www.piramalpharmasolutions.com","status":200,"ok":true,"finalUrl":"https://www.piramalpharmasolutions.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/","field":"links","label":"Official website"},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/","field":"website"}]},{"url":"https://www.plymouthhospitals.nhs.uk/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"derriford-plymouth","kind":"institution","name":"Derriford Hospital, University Hospitals Plymouth","route":"/institutions/derriford-plymouth/","field":"links","label":"University Hospitals Plymouth"},{"id":"derriford-plymouth","kind":"institution","name":"Derriford Hospital, University Hospitals Plymouth","route":"/institutions/derriford-plymouth/","field":"website"}]},{"url":"https://www.pmc.org","status":200,"ok":true,"finalUrl":"https://www.pmc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pan-mass-challenge","kind":"institution","name":"Pan-Mass Challenge","route":"/institutions/pan-mass-challenge/","field":"website"}]},{"url":"https://www.pmc.org/about","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"billy-starr","kind":"person","name":"Billy Starr","route":"/people/billy-starr/","field":"links","label":"Pan-Mass Challenge: about"},{"id":"pan-mass-challenge","kind":"institution","name":"Pan-Mass Challenge","route":"/institutions/pan-mass-challenge/","field":"links","label":"About the PMC"}]},{"url":"https://www.pmda.go.jp/english/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","field":"dosing.source"},{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","field":"links","label":"PMDA (English)"},{"id":"japan-conditional-early-approval","kind":"term","name":"Japan conditional early approval and time-limited approval","route":"/terms/japan-conditional-early-approval/","field":"links","label":"PMDA (English)"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","field":"links","label":"PMDA"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","field":"website"}]},{"url":"https://www.pmda.go.jp/english/about-pmda/outline/0004.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","field":"links","label":"Institution profile"},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","field":"links","label":"PMDA: Sakigake designation system"}]},{"url":"https://www.poetryfoundation.org/poets/audre-lorde","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","field":"links","label":"Poetry Foundation"},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","field":"profiles","label":"Poetry Foundation"}]},{"url":"https://www.polarispharma.com","status":200,"ok":true,"finalUrl":"https://polarispharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/","field":"links","label":"Official website"},{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/","field":"website"},{"id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","field":"links","label":"Sponsor page"}]},{"url":"https://www.poliambulanza.it","status":200,"ok":true,"finalUrl":"https://www.poliambulanza.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","route":"/institutions/fondazione-poliambulanza/","field":"links","label":"Official website"},{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","route":"/institutions/fondazione-poliambulanza/","field":"website"}]},{"url":"https://www.poliambulanza.it/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","field":"links","label":"Fondazione Poliambulanza website"},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","field":"profiles","label":"Fondazione Poliambulanza website"}]},{"url":"https://www.policlinicogemelli.it","status":200,"ok":true,"finalUrl":"https://www.policlinicogemelli.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/","field":"links","label":"Official website"},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/","field":"website"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","field":"links","label":"Policlinico Universitario A. Gemelli website"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","field":"profiles","label":"Policlinico Universitario A. Gemelli website"}]},{"url":"https://www.por-journal.com/journals/pathology-and-oncology-research","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","field":"links","label":"Homepage"},{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","field":"url"}]},{"url":"https://www.ppbregistry.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","field":"links","label":"International PPB/DICER1 Registry"}]},{"url":"https://www.precision-biotech.com","status":200,"ok":true,"finalUrl":"https://www.precision-biotech.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/","field":"links","label":"Official website"},{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/","field":"website"}]},{"url":"https://www.precisionmedicineonline.com/precision-oncology/nmpa-approves-hengrui-pharmas-trastuzumab-rezetecan-her2-mutant-nsclc","status":200,"ok":true,"finalUrl":"https://www.genomeweb.com/precision-oncology/nmpa-approves-hengrui-pharmas-trastuzumab-rezetecan-her2-mutant-nsclc/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","field":"regulatoryEvents.source (2025-05)"}]},{"url":"https://www.precisionpanc.org","status":200,"ok":true,"finalUrl":"https://barnabysilks.com/","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","field":"links","label":"Precision-Panc"}]},{"url":"https://www.prestigebiopharma.com/","status":200,"ok":true,"finalUrl":"https://prestigebiopharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","route":"/companies/prestige-biopharma/","field":"links","label":"Official website"},{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","route":"/companies/prestige-biopharma/","field":"website"}]},{"url":"https://www.prinsesmaximacentrum.nl/en","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","field":"links","label":"Homepage"},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","field":"website"}]},{"url":"https://www.prinsesmaximacentrum.nl/nl/over-ons/organisatie-bestuur-en-advies/raad-van-bestuur","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","field":"links","label":"Source: Prinses Máxima Centrum Raad van Bestuur page"},{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","field":"profiles","label":"Prinses Máxima Centrum: Raad van Bestuur"}]},{"url":"https://www.prinsesmaximacentrum.nl/nl/over-ons/organisatie-bestuur-en-advies/raad-van-bestuur/rene-medema","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","field":"profiles","label":"Board member profile"}]},{"url":"https://www.prnewswire.com/fr/communiques-de-presse/cureety-fait-lacquisition-de-lamericain-reimagine-care-et-donne-une-dimension-mondiale-a-sa-plateforme-de-telesurveillance-oncologique-de-precision-302866958.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","field":"links","label":"Cureety acquisition release on PR Newswire (French)"}]},{"url":"https://www.prnewswire.com/news-releases/97m-series-d-backed-by-strategic-investors-across-the-oncology-ecosystem-positions-thyme-care-to-break-through-cancer-cares-biggest-bottlenecks-302565050.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","field":"links","label":"Series D press release (September 2025)"}]},{"url":"https://www.prnewswire.com/news-releases/a-milestone-for-empyrean-medical-systemsfirst-artemis-320-installation-302813464.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","field":"links","label":"First Artemis 320 installation (June 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/aidoc-secures-fda-clearance-for-healthcares-first-comprehensive-foundation-model-ai-302666640.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","field":"links","label":"FDA clearance"}]},{"url":"https://www.prnewswire.com/news-releases/american-cancer-society-launches-nationwide-program-to-increase-equity-in-clinical-trials-302617253.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","field":"links","label":"American Cancer Society ACS ACTS programme release (November 2025)"}]},{"url":"https://www.prnewswire.com/news-releases/artbio-announces-dosing-of-two-cohorts-with-ab001-in-artisan-a-phase-1-alpha-radioligand-therapy-clinical-trial-for-metastatic-castration-resistant-prostate-cancer-302657972.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"ARTISAN cohort dosing release (PR Newswire)"}]},{"url":"https://www.prnewswire.com/news-releases/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-302388161.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","field":"links","label":"Series A press release"}]},{"url":"https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","field":"links","label":"SECuRE update"}]},{"url":"https://www.prnewswire.com/news-releases/color-health-becomes-first-virtual-cancer-clinic-to-earn-asco-certified-status-for-compliance-with-quality-and-safety-standards-302764322.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","field":"links","label":"ASCO Certified Virtual Cancer Clinic press release (May 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/dantari-debuts-with-47-million-series-a-to-advance-best-in-class-targeted-medicines-for-solid-tumors-301697300.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","field":"links","label":"Series A press release"}]},{"url":"https://www.prnewswire.com/news-releases/deerfield-management-announces-portfolio-company-nuvalent-inc-to-be-acquired-by-gsk-302796995.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","field":"links","label":"Nuvalent acquisition release"}]},{"url":"https://www.prnewswire.com/news-releases/deirdre-saulet-phd-joins-jasper-health-as-chief-strategy-officer-302558101.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jasper-health","kind":"company","name":"Jasper Health","route":"/companies/jasper-health/","field":"links","label":"Chief Strategy Officer appointment press release (September 2025)"}]},{"url":"https://www.prnewswire.com/news-releases/empyrean-medical-systems-secures-strategic-financing-from-hamilton-reserve-bank-advances-radiation-oncology-innovation-302654320.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","field":"links","label":"Hamilton Reserve Bank strategic financing (Jan 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","field":"links","label":"Series E press release (June 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/harbinger-health-establishes-resolve-as-a-new-category-for-cancer-detection-302740706.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/","field":"links","label":"RESOLVE announcement"}]},{"url":"https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","field":"links","label":"Series B press release (PR Newswire)"}]},{"url":"https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","field":"links","label":"Series A press release (PR Newswire)"}]},{"url":"https://www.prnewswire.com/news-releases/leo-cancer-care-introduces-grace-the-first-upright-photon-therapy-system-at-astro-2025-302568999.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","field":"links","label":"Grace upright photon therapy introduced at ASTRO 2025 (Middleton, WI dateline)"}]},{"url":"https://www.prnewswire.com/news-releases/leo-cancer-care-secures-ce-mark-for-marie-advancing-upright-radiotherapy-in-europe-302777824.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","field":"links","label":"CE mark for Marie press release (May 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","field":"links","label":"Lilly to acquire Kelonia (PR Newswire, April 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/lunit-to-be-featured-in-21-ai-imaging-studies-on-breast-cancer-and-lung-disease-at-ecr-2026-302703651.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/","field":"links","label":"ECR 2026"}]},{"url":"https://www.prnewswire.com/news-releases/monteris-medical-announces-publication-of-landmark-study-on-787-brain-tumor-patients-treated-with-neuroblate-laser-interstitial-thermal-therapy-litt-302854905.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","field":"links","label":"LAANTERN 787-patient publication (2026)"}]},{"url":"https://www.prnewswire.com/news-releases/monteris-medical-secures-28-million-in-growth-equity-to-accelerate-revenue-and-innovation-in-minimally-invasive-neurosurgery-302711794.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","field":"links","label":"Series E growth equity press release (March 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/osara-health-marks-10-years-with-global-call-to-make-cancer-support-beyond-treatment-standard-302849228.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","field":"links","label":"10 year anniversary press release (August 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/osara-health-publishes-new-peer-reviewed-study-demonstrating-clinically-meaningful-improvements-in-physical-and-mental-health-for-people-with-cancer-302742626.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","field":"links","label":"JMIR Cancer study press release (April 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/outcomes4me-acquires-genome-and-realyze-intelligence-names-upmc-hillman-cancer-center-cio-as-strategic-advisor-to-expedite-ai-driven-cancer-care-and-clinical-trial-access-302779191.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","field":"links","label":"Acquisition of Geno.Me and Realyze Intelligence (May 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/p-cure-announces-first-ever-prospective-clinical-results-of-gantry-less-upright-proton-therapy-for-lung-cancer-re-irradiation-302687456.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","field":"links","label":"Lung cancer re-irradiation results (Feb 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/p-cure-completes-worlds-first-conversion-of-linear-accelerator-vault-into-compact-proton-therapy-center-302697434.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","field":"links","label":"Linac vault conversion at SPHIC (Feb 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/roads-phase-3-clinical-trial-data-presented-at-asco26-show-gammatile-provides-superior-tumor-control-leading-to-patients-living-longer-without-recurrence-compared-to-standard-of-care-in-newly-diagnosed-operable-brain-metastases-302786198.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","field":"links","label":"ROADS phase 3 results at ASCO 2026"}]},{"url":"https://www.prnewswire.com/news-releases/systimmune-announces-second-approval-of-iza-bren-in-china-for-the-treatment-of-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma-302827983.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","field":"outcomes.source (Overall survival)"},{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","field":"outcomes.source (Progression-free survival (BICR))"}]},{"url":"https://www.prnewswire.com/news-releases/thyme-care-closes-125-million-series-e-establishes-thyme-companies-to-broaden-its-impact-across-the-oncology-ecosystem-302867835.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","field":"links","label":"Series E press release (September 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-35-million-in-growth-capital-to-monteris-medical-to-support-neurosurgical-technology-advancements-302711455.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","field":"links","label":"Trinity Capital USD 35 million credit facility (March 2026)"}]},{"url":"https://www.prnewswire.com/news-releases/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence-302607969.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","field":"links","label":"Volpara now operates under Lunit brand (Nov 2025)"}]},{"url":"https://www.profluent.bio","status":200,"ok":true,"finalUrl":"https://www.profluent.bio/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","field":"links","label":"Official website"},{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","field":"website"}]},{"url":"https://www.projectdatasphere.org/","status":200,"ok":true,"finalUrl":"https://data.projectdatasphere.org/projectdatasphere/html/home","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"links","label":"Project Data Sphere"},{"id":"idea-data-ipd-deposit-enforcement","kind":"idea","name":"Enforce individual participant data sharing as a condition of publication and funding","route":"/ideas/idea-data-ipd-deposit-enforcement/","field":"links","label":"Project Data Sphere"},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","field":"links","label":"Project Data Sphere"},{"id":"idea-fund-control-arm-commons","kind":"idea","name":"A shared library of pooled control arms to shrink and speed future trials","route":"/ideas/idea-fund-control-arm-commons/","field":"links","label":"Project Data Sphere"},{"id":"idea-moon-open-pro-data-commons","kind":"idea","name":"An open commons of patient-reported outcome data from cancer trials","route":"/ideas/idea-moon-open-pro-data-commons/","field":"links","label":"Project Data Sphere"}]},{"url":"https://www.prostatecancerpromise.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-promise","kind":"collection","name":"PROMISE registry: free germline testing in prostate cancer","route":"/collections/prostate-cancer-promise/","field":"links","label":"PROMISE registry: free germline testing in prostate cancer"},{"id":"prostate-cancer-promise","kind":"collection","name":"PROMISE registry: free germline testing in prostate cancer","route":"/collections/prostate-cancer-promise/","field":"url"}]},{"url":"https://www.protagonist-inc.com","status":200,"ok":true,"finalUrl":"https://www.protagonist-inc.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/","field":"links","label":"Official website"},{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/","field":"website"}]},{"url":"https://www.protaratx.com/","status":200,"ok":true,"finalUrl":"https://protaratx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/","field":"links","label":"Official website"},{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/","field":"website"},{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","field":"links","label":"Sponsor page"}]},{"url":"https://www.proteinatlas.org","status":200,"ok":true,"finalUrl":"https://www.proteinatlas.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hpa","kind":"collection","name":"Human Protein Atlas","route":"/collections/hpa/","field":"links","label":"Human Protein Atlas"},{"id":"hpa","kind":"collection","name":"Human Protein Atlas","route":"/collections/hpa/","field":"url"}]},{"url":"https://www.providence.org","status":200,"ok":true,"finalUrl":"https://www.providence.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","field":"links","label":"Official website"},{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","field":"website"}]},{"url":"https://www.providence.org/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erik-wexler","kind":"person","name":"Erik G. Wexler","route":"/people/erik-wexler/","field":"links","label":"Source: Providence leadership page"},{"id":"erik-wexler","kind":"person","name":"Erik G. Wexler","route":"/people/erik-wexler/","field":"profiles","label":"Providence leadership page"}]},{"url":"https://www.pshyvinvointialue.fi","status":200,"ok":true,"finalUrl":"https://pshyvinvointialue.fi/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"links","label":"Kuopio University Hospital Cancer Center website"},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","field":"profiles","label":"Kuopio University Hospital Cancer Center website"},{"id":"kuopio-university-hospital","kind":"institution","name":"Kuopio University Hospital Cancer Center","route":"/institutions/kuopio-university-hospital/","field":"links","label":"Official website"},{"id":"kuopio-university-hospital","kind":"institution","name":"Kuopio University Hospital Cancer Center","route":"/institutions/kuopio-university-hospital/","field":"website"}]},{"url":"https://www.ptcbio.com","status":200,"ok":true,"finalUrl":"https://www.ptcbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","field":"links","label":"Official website"},{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","field":"website"}]},{"url":"https://www.ptwdosimetry.com/","status":200,"ok":true,"finalUrl":"https://www.ptwdosimetry.com/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiotherapy-qa-phantoms-dosimeters","kind":"technology","name":"Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)","route":"/technologies/radiotherapy-qa-phantoms-dosimeters/","field":"links","label":"PTW: radiation therapy dosimetry"},{"id":"ptw-freiburg","kind":"company","name":"PTW Freiburg","route":"/companies/ptw-freiburg/","field":"links","label":"Official website"},{"id":"ptw-freiburg","kind":"company","name":"PTW Freiburg","route":"/companies/ptw-freiburg/","field":"website"}]},{"url":"https://www.pumabiotechnology.com","status":200,"ok":true,"finalUrl":"https://www.pumabiotechnology.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/","field":"links","label":"Official website"},{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/","field":"website"}]},{"url":"https://www.pumc.edu.cn","status":200,"ok":true,"finalUrl":"https://www.pumc.edu.cn/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","field":"links","label":"Peking Union Medical College"}]},{"url":"https://www.pumch.cn","status":200,"ok":true,"finalUrl":"https://www.pumch.cn/index.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","field":"links","label":"PUMCH"},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","field":"website"}]},{"url":"https://www.pumch.cn/en/new_about.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","field":"links","label":"PUMCH about page (English)"}]},{"url":"https://www.purdue.edu","status":200,"ok":true,"finalUrl":"https://www.purdue.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","field":"links","label":"Purdue University"}]},{"url":"https://www.pyrexar.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","field":"links","label":"Pyrexar Medical: BSD-2000"},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","route":"/companies/pyrexar-medical/","field":"links","label":"Official website"},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","route":"/companies/pyrexar-medical/","field":"website"}]},{"url":"https://www.qbiotics.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/","field":"links","label":"Official website"},{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/","field":"website"}]},{"url":"https://www.qiagen.com","status":200,"ok":true,"finalUrl":"https://www.qiagen.com/us","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qiagen","kind":"company","name":"QIAGEN","route":"/companies/qiagen/","field":"links","label":"Official website"},{"id":"qiagen","kind":"company","name":"QIAGEN","route":"/companies/qiagen/","field":"website"}]},{"url":"https://www.qiagen.com/us/product-categories/diagnostics-and-clinical-research/oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","field":"links","label":"Qiagen therascreen portfolio"}]},{"url":"https://www.qilu-pharma.com","status":200,"ok":true,"finalUrl":"https://www.qilu-pharma.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/","field":"links","label":"Official website"},{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/","field":"website"},{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","field":"links","label":"Sponsor page"},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/","field":"links","label":"Sponsor page"},{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","field":"links","label":"Sponsor page"},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","field":"links","label":"Sponsor page"},{"id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","field":"links","label":"Sponsor page"},{"id":"qlh12016","kind":"drug","name":"QLH12016","route":"/drugs/qlh12016/","field":"links","label":"Sponsor page"}]},{"url":"https://www.qimrb.edu.au/about/governance/directors","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","field":"links","label":"Source: QIMR Berghofer directors page"},{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","field":"profiles","label":"QIMR Berghofer directors page"}]},{"url":"https://www.qimrberghofer.edu.au","status":200,"ok":true,"finalUrl":"https://www.qimrb.edu.au/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","field":"links","label":"QIMR Berghofer"},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","field":"website"}]},{"url":"https://www.qst.go.jp/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"QST Hospital (page moved; nearest live section)"},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"website"}]},{"url":"https://www.qst.go.jp/site/hospital-en/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","field":"profiles","label":"QST Hospital (English)"}]},{"url":"https://www.qst.go.jp/site/hospital/aboutus-greeting.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","field":"links","label":"Source: QST Hospital director's greeting"},{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","field":"profiles","label":"QST Hospital director's greeting"}]},{"url":"https://www.qst.go.jp/site/qst-english/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"QST"}]},{"url":"https://www.qsut.gov.al/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","field":"links","label":"Official website"},{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","field":"website"}]},{"url":"https://www.quantatx.com","status":200,"ok":true,"finalUrl":"https://www.quantatx.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","field":"website"}]},{"url":"https://www.quantatx.com/news/030526/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","field":"links","label":"March 2026 release"}]},{"url":"https://www.quantumleaphealth.org","status":200,"ok":true,"finalUrl":"https://www.quantumleaphealth.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/","field":"links","label":"Official website"},{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/","field":"website"}]},{"url":"https://www.quantumsurgical.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","field":"links","label":"Official website"},{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","field":"website"}]},{"url":"https://www.quantumsurgical.com/about-quantum","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","field":"links","label":"About Quantum Surgical"}]},{"url":"https://www.quantumsurgical.com/news/quantum-surgical-acquires-of-neuwave-medical-inc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","field":"links","label":"Acquisition of NeuWave Medical (Feb 2026)"}]},{"url":"https://www.quantumsurgical.com/news/quantum-surgical-at-the-heart-of-a-eu14-9-million-european-project-for-precision-cancer-treatment","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","field":"links","label":"PreciseOnco EU project (Feb 2026)"}]},{"url":"https://www.queensu.ca","status":200,"ok":true,"finalUrl":"https://www.queensu.ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"queens-university-kingston","kind":"institution","name":"Queen's University / Kingston Health Sciences Centre","route":"/institutions/queens-university-kingston/","field":"links","label":"Queen's University"},{"id":"queens-university-kingston","kind":"institution","name":"Queen's University / Kingston Health Sciences Centre","route":"/institutions/queens-university-kingston/","field":"website"}]},{"url":"https://www.questdiagnostics.com","status":200,"ok":true,"finalUrl":"https://www.questdiagnostics.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","route":"/companies/quest-diagnostics/","field":"links","label":"Official website"},{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","route":"/companies/quest-diagnostics/","field":"website"}]},{"url":"https://www.racap.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","field":"links","label":"Official website"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","field":"website"}]},{"url":"https://www.racap.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","field":"links","label":"Portfolio"}]},{"url":"https://www.radboudumc.nl","status":200,"ok":true,"finalUrl":"https://www.radboudumc.nl/patientenzorg","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","field":"links","label":"Official website"},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","field":"website"}]},{"url":"https://www.radboudumc.nl/over-het-radboudumc/organisatie/raad-van-bestuur","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bertine-lahuis","kind":"person","name":"Bertine Lahuis","route":"/people/bertine-lahuis/","field":"links","label":"Source: Radboudumc executive board page"},{"id":"bertine-lahuis","kind":"person","name":"Bertine Lahuis","route":"/people/bertine-lahuis/","field":"profiles","label":"Radboudumc Raad van Bestuur page"}]},{"url":"https://www.radformation.com","status":200,"ok":true,"finalUrl":"https://www.radformation.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","field":"links","label":"Official website"},{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","field":"website"}]},{"url":"https://www.radformation.com/press","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","field":"links","label":"Press releases index"}]},{"url":"https://www.radformation.com/press/radformation-limbus-acquisition","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","field":"links","label":"Limbus AI acquisition press release (May 2024)"}]},{"url":"https://www.radformation.com/press/radformation-raises-seed-round","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","field":"links","label":"Seed round press release (June 2018)"}]},{"url":"https://www.radioloncol.com/","status":200,"ok":true,"finalUrl":"https://www.radioloncol.com/index.php/ro","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","field":"links","label":"Homepage"},{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","field":"url"}]},{"url":"https://www.radiomedix.com","status":200,"ok":true,"finalUrl":"https://radiomedix.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","field":"website"}]},{"url":"https://www.rakuten-med.com","status":200,"ok":true,"finalUrl":"https://rakuten-med.com/us/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","route":"/companies/rakuten-medical/","field":"links","label":"Official website"},{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","route":"/companies/rakuten-medical/","field":"website"}]},{"url":"https://www.rama.mahidol.ac.th","status":200,"ok":true,"finalUrl":"https://www.rama.mahidol.ac.th/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","field":"links","label":"Ramathibodi Hospital"},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","field":"website"}]},{"url":"https://www.rama.mahidol.ac.th/en/aboutus/administrative-team","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","route":"/people/atiporn-ingsathit/","field":"links","label":"Source: Ramathibodi administrative team page"},{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","route":"/people/atiporn-ingsathit/","field":"profiles","label":"Ramathibodi administrative team"}]},{"url":"https://www.rambam.org.il/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","field":"links","label":"Homepage"},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","field":"website"}]},{"url":"https://www.rambam.org.il/en/about_rambam/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michal-mekel","kind":"person","name":"Michal Mekel","route":"/people/michal-mekel/","field":"links","label":"Source: Rambam about and leadership pages"}]},{"url":"https://www.rambam.org.il/en/about_rambam/leadership/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michal-mekel","kind":"person","name":"Michal Mekel","route":"/people/michal-mekel/","field":"profiles","label":"Rambam leadership page"}]},{"url":"https://www.ranoktherapeutics.com/","status":200,"ok":true,"finalUrl":"https://ranoktherapeutics.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/","field":"links","label":"Official website"},{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/","field":"website"}]},{"url":"https://www.raretumors-children.eu/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","field":"links","label":"EXPeRT: European Cooperative Study Group for Paediatric Rare Tumours"}]},{"url":"https://www.raysearchlabs.com","status":200,"ok":true,"finalUrl":"https://www.raysearchlabs.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","route":"/companies/raysearch/","field":"links","label":"Official website"},{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","route":"/companies/raysearch/","field":"website"}]},{"url":"https://www.rayzebio.com","status":200,"ok":true,"finalUrl":"https://rayzebio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","field":"links","label":"Official website"},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","field":"website"}]},{"url":"https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Royal College of Pathologists: cancer datasets and tissue pathways index (the skin datasets G123 and G124 are listed as currently on hold; their UICC TNM 9 appendices were published in November 2025 and their SNOMED appendices updated in February 2026)"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"links","label":"Royal College of Pathologists: cancer datasets and tissue pathways index (the skin datasets G123 and G124 are listed as currently on hold; their UICC TNM 9 appendices were published in November 2025 and their SNOMED appendices updated in February 2026)"}]},{"url":"https://www.rcpath.org/resourceLibrary/basal-cell-tnm9.html","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Royal College of Pathologists appendix A, version 3, 6 November 2025: UICC TNM 9 pathological staging of primary cutaneous carcinoma (basal cell), combining the UICC chapters for skin carcinoma of the head and neck and carcinoma of the skin"},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Royal College of Pathologists appendix A, version 3, 6 November 2025: UICC TNM 9 pathological staging of primary cutaneous carcinoma (basal cell), combining the UICC chapters for skin carcinoma of the head and neck and carcinoma of the skin"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Royal College of Pathologists appendix A, version 3, 6 November 2025: UICC TNM 9 pathological staging of primary cutaneous carcinoma (basal cell), combining the UICC chapters for skin carcinoma of the head and neck and carcinoma of the skin"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Royal College of Pathologists appendix A, version 3, 6 November 2025: UICC TNM 9 pathological staging of primary cutaneous carcinoma (basal cell), combining the UICC chapters for skin carcinoma of the head and neck and carcinoma of the skin"}]},{"url":"https://www.rcpath.org/resourceLibrary/g123-dataset-basal.html","status":200,"ok":true,"finalUrl":"https://www.rcpath.org/static/53688094-791e-4aaa-82cec42c3cb65e35/Dataset-for-histopathological-reporting-of-primary-cutaneous-basal-cell-carcinoma.pdf","contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Royal College of Pathologists G123: dataset for histopathological reporting of primary cutaneous basal cell carcinoma, version 4, February 2019 (Slater and Barrett)"},{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","field":"links","label":"Royal College of Pathologists G123: dataset for histopathological reporting of primary cutaneous basal cell carcinoma, version 4, February 2019 (Slater and Barrett)"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Royal College of Pathologists G123: dataset for histopathological reporting of primary cutaneous basal cell carcinoma, version 4, February 2019 (Slater and Barrett)"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"links","label":"Royal College of Pathologists G123: dataset for histopathological reporting of primary cutaneous basal cell carcinoma, version 4, February 2019 (Slater and Barrett)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"Royal College of Pathologists G123: dataset for histopathological reporting of primary cutaneous basal cell carcinoma, version 4, February 2019 (Slater and Barrett)"}]},{"url":"https://www.rcpath.org/resourceLibrary/g124datasetsquamous-pdf.html","status":200,"ok":true,"finalUrl":"https://www.rcpath.org/static/9c1d8f71-5d3b-4508-8e6200f11e1f4a39/Dataset-for-histopathological-reporting-of-primary-invasive-cutaneous-squamous-cell-carcinoma-and-regional-lymph-nodes.pdf","contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Royal College of Pathologists G124: dataset for histopathological reporting of primary invasive cutaneous squamous cell carcinoma and regional lymph nodes, version 4, February 2019 (Slater and Barrett)"}]},{"url":"https://www.rcpath.org/resourceLibrary/g148-dataset-for-histopathological-reporting-of-breast-disease-in-surgical-excision-specimens-of-breast-cancer.html","status":200,"ok":true,"finalUrl":"https://www.rcpath.org/static/d255f34c-176a-490d-9b5a7d58ac85f3a6/b4cf9184-33ff-4662-b33990b3701c3d87/G148-Dataset-for-histopathological-reporting-of-breast-disease-in-surgical-excision-specimens-of-breast-cancer.pdf","contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"terminal-duct-lobular-unit","kind":"term","name":"Ducts, lobules and the terminal duct lobular unit","route":"/terms/terminal-duct-lobular-unit/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"who-breast-classification","kind":"term","name":"The WHO classification of breast tumours, and what the 6th edition changed","route":"/terms/who-breast-classification/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"nottingham-prognostic-index","kind":"term","name":"Nottingham Prognostic Index (NPI), and PREDICT","route":"/terms/nottingham-prognostic-index/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"grade-stage-receptor-breast","kind":"term","name":"Grade, stage and receptor status: three different things on one breast report","route":"/terms/grade-stage-receptor-breast/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"er-pr-scoring-breast","kind":"term","name":"How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item)","route":"/terms/er-pr-scoring-breast/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"her2-testing-uk-breast","kind":"term","name":"HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP","route":"/terms/her2-testing-uk-breast/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"receptor-conversion-breast","kind":"term","name":"Receptor conversion: when the receptors change between the primary and a recurrence","route":"/terms/receptor-conversion-breast/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"breast-tumour-size-on-the-report","kind":"term","name":"Tumour size on a breast report, and why it differs from the scan","route":"/terms/breast-tumour-size-on-the-report/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"},{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","field":"links","label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)"}],"archive":"https://web.archive.org/web/20260609141405/https://www.rcpath.org/resourceLibrary/g148-dataset-for-histopathological-reporting-of-breast-disease-in-surgical-excision-specimens-of-breast-cancer.html"},{"url":"https://www.rcpath.org/resourceLibrary/squamous-cell-tnm9.html","status":200,"ok":true,"finalUrl":"https://www.rcpath.org/static/22a3c502-b300-4132-b0e0b93d104dd64f/Squamous-cellTNM9.pdf","contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","field":"links","label":"Royal College of Pathologists appendix A: UICC TNM 9 pathological staging of primary cutaneous carcinoma (squamous cell)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"Royal College of Pathologists appendix A: UICC TNM 9 pathological staging of primary cutaneous carcinoma (squamous cell)"}]},{"url":"https://www.rcpath.org/static/8cc88604-2c8d-4df4-a99542df41c102af/G084-dataset-for-histopathology-reports-for-prostatic-carcinoma.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"cambridge-prognostic-group","kind":"term","name":"Cambridge Prognostic Group (CPG 1 to 5)","route":"/terms/cambridge-prognostic-group/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-acinar-adenocarcinoma","kind":"term","name":"Acinar adenocarcinoma of the prostate","route":"/terms/prostate-acinar-adenocarcinoma/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"intraductal-carcinoma-prostate","kind":"term","name":"Intraductal carcinoma of the prostate (IDC-P)","route":"/terms/intraductal-carcinoma-prostate/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"cribriform-prostate-cancer","kind":"term","name":"Cribriform growth pattern in prostate cancer","route":"/terms/cribriform-prostate-cancer/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"percentage-gleason-pattern-4","kind":"term","name":"Percentage of Gleason pattern 4","route":"/terms/percentage-gleason-pattern-4/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"extraprostatic-extension","kind":"term","name":"Extraprostatic extension and seminal vesicle invasion","route":"/terms/extraprostatic-extension/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"high-grade-pin","kind":"term","name":"High-grade prostatic intraepithelial neoplasia (HGPIN)","route":"/terms/high-grade-pin/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"whole-mount-pathology","kind":"term","name":"Whole-mount pathology","route":"/terms/whole-mount-pathology/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","field":"links","label":"Royal College of Pathologists G084: dataset for histopathology reports for prostatic carcinoma, version 4, October 2024"}]},{"url":"https://www.recoverytrial.net/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-recovery-style-platform-repurposing","kind":"idea","name":"A RECOVERY-style permanent platform trial of cheap drugs added to cancer care","route":"/ideas/idea-reg-recovery-style-platform-repurposing/","field":"links","label":"RECOVERY trial"}]},{"url":"https://www.recursion.com","status":200,"ok":true,"finalUrl":"https://www.recursion.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/","field":"website"},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/","field":"links","label":"Recursion"}]},{"url":"https://www.recursion.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/","field":"links","label":"Recursion website"}]},{"url":"https://www.regeneron.com","status":200,"ok":true,"finalUrl":"https://www.regeneron.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/","field":"links","label":"Official website"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/","field":"website"}]},{"url":"https://www.regionaalhaigla.ee","status":200,"ok":true,"finalUrl":"https://www.regionaalhaigla.ee/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","field":"links","label":"Official website"},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","field":"website"}]},{"url":"https://www.regionorebrolan.se/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","field":"links","label":"Örebro University Hospital website"},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","field":"profiles","label":"Örebro University Hospital website"}]},{"url":"https://www.regionorebrolan.se/uso","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","field":"links","label":"Official website"},{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","field":"website"}]},{"url":"https://www.regionostergotland.se","status":200,"ok":true,"finalUrl":"https://www.regionostergotland.se/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","field":"links","label":"Linköping University Hospital Cancer Center website"},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","field":"profiles","label":"Linköping University Hospital Cancer Center website"},{"id":"linkoping-university-hospital","kind":"institution","name":"Linköping University Hospital Cancer Center","route":"/institutions/linkoping-university-hospital/","field":"links","label":"Official website"},{"id":"linkoping-university-hospital","kind":"institution","name":"Linköping University Hospital Cancer Center","route":"/institutions/linkoping-university-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260901215601/https://www.regionostergotland.se/"},{"url":"https://www.regionostergotland.se/ro/om-region-ostergotland/organisation/halso--och-sjukvardens-ledningsgrupp","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ida-danmark","kind":"person","name":"Ida Danmark","route":"/people/ida-danmark/","field":"links","label":"Source: Region Östergötland hälso- och sjukvårdens ledningsgrupp page"},{"id":"ida-danmark","kind":"person","name":"Ida Danmark","route":"/people/ida-danmark/","field":"profiles","label":"Region Östergötland health and care leadership group"}],"archive":"https://web.archive.org/web/20260418131448/https://www.regionostergotland.se/ro/om-region-ostergotland/organisation/halso--och-sjukvardens-ledningsgrupp"},{"url":"https://www.regionvasterbotten.se","status":200,"ok":true,"finalUrl":"https://www.regionvasterbotten.se/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","route":"/institutions/umea-university-hospital/","field":"links","label":"Official website"},{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","route":"/institutions/umea-university-hospital/","field":"website"}]},{"url":"https://www.regionvasterbotten.se/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"links","label":"Umeå University Hospital (Norrland University Hospital) website"},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","field":"profiles","label":"Umeå University Hospital (Norrland University Hospital) website"}]},{"url":"https://www.registerforshare.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-opt-out-research-contact-register","kind":"idea","name":"Every patient is asked once at diagnosis whether researchers may contact them","route":"/ideas/idea-tr1-opt-out-research-contact-register/","field":"links","label":"SHARE (Scottish Health Research Register)"}]},{"url":"https://www.remegen.com","status":200,"ok":true,"finalUrl":"https://www.remegen.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","field":"dosing.source"},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/","field":"links","label":"Official website"},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/","field":"website"}]},{"url":"https://www.remixtx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","route":"/companies/remix-therapeutics/","field":"links","label":"Official website"},{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","route":"/companies/remix-therapeutics/","field":"website"}]},{"url":"https://www.renji.com/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/","field":"links","label":"Official website"},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/","field":"website"}]},{"url":"https://www.replimune.com","status":200,"ok":true,"finalUrl":"https://www.replimune.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/","field":"links","label":"Official website"},{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/","field":"website"}]},{"url":"https://www.reprosent.com","status":200,"ok":true,"finalUrl":"https://www.reprosent.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reprosent","kind":"company","name":"REPROSENT","route":"/companies/reprosent/","field":"links","label":"Official website"},{"id":"reprosent","kind":"company","name":"REPROSENT","route":"/companies/reprosent/","field":"website"}]},{"url":"https://www.revmed.com","status":200,"ok":true,"finalUrl":"https://www.revmed.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/","field":"links","label":"Official website"},{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/","field":"website"}]},{"url":"https://www.rgcirc.org","status":200,"ok":true,"finalUrl":"https://www.rgcirc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/","field":"links","label":"RGCIRC"},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/","field":"website"}]},{"url":"https://www.rgcirc.org/office-of-ceo/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","route":"/people/dharmendra-singh-gangwar/","field":"links","label":"Source: RGCIRC Office of CEO page"},{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","route":"/people/dharmendra-singh-gangwar/","field":"profiles","label":"RGCIRC Office of CEO"}]},{"url":"https://www.rgcirc.org/office-of-chairman/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","route":"/people/dharmendra-singh-gangwar/","field":"links","label":"RGCIRC Office of Chairman page"}]},{"url":"https://www.rhizen.com/","status":200,"ok":true,"finalUrl":"https://rhizen.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rhizen-pharmaceuticals","kind":"company","name":"Rhizen Pharmaceuticals","route":"/companies/rhizen-pharmaceuticals/","field":"links","label":"Official website"},{"id":"rhizen-pharmaceuticals","kind":"company","name":"Rhizen Pharmaceuticals","route":"/companies/rhizen-pharmaceuticals/","field":"website"}]},{"url":"https://www.rhythmtx.com/","status":200,"ok":true,"finalUrl":"https://rhythmtx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rhythm-pharmaceuticals","kind":"company","name":"Rhythm Pharmaceuticals","route":"/companies/rhythm-pharmaceuticals/","field":"links","label":"Official website"},{"id":"rhythm-pharmaceuticals","kind":"company","name":"Rhythm Pharmaceuticals","route":"/companies/rhythm-pharmaceuticals/","field":"website"}]},{"url":"https://www.rigel.com","status":200,"ok":true,"finalUrl":"https://www.rigel.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","field":"links","label":"Official website"},{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","field":"website"}]},{"url":"https://www.rigshospitalet.dk/english","status":200,"ok":true,"finalUrl":"https://security-check.regionh.dk/NDBD/validate?config=CMS&data=YplG3csjV8gn6GHmsrflU6hxPDAX%2BRopohFm9Viq5AsxyV7I8TN47iTFn71WLm9U%2FS%2B%2Bf0f7kIMDYcl8fOhoMWl7zbKnHx%2FqqrF%2BR26%2FXPztqLaDy%2BxeMya3NiX9Lbq5otWW75s%2BEYbRs46U3EiTYTkKkeNbSaRQOQlAGo3AtC1BZ1HnAKX4bj2QBCyDXLg1H35ixcYMV4PRac9SsSqEPBnctxystOH99a2rDQrjrlr4%2F1zVOBzIJQYTQHdwDymMc2kgCbRtD9UDuAAAAAE%3D","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","field":"links","label":"Institution profile"},{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","field":"profiles","label":"Institution profile"},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"links","label":"Rigshospitalet, Copenhagen University Hospital website"},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","field":"profiles","label":"Rigshospitalet, Copenhagen University Hospital website"},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","field":"links","label":"Homepage"},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","field":"website"}]},{"url":"https://www.roche.com","status":200,"ok":true,"finalUrl":"https://www.roche.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/","field":"links","label":"Official website"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/","field":"website"}]},{"url":"https://www.roche.com/innovation/partnering","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","route":"/companies/roche-venture-fund/","field":"links","label":"Roche partnering"}]},{"url":"https://www.roche.com/media/releases/med-cor-2024-11-26","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/","field":"links","label":"Roche SKYSCRAPER-01 final analysis (2024)"}]},{"url":"https://www.roche.com/media/releases/med-cor-2024-11-26b","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","field":"links","label":"Roche to acquire Poseida (November 2024)"}]},{"url":"https://www.roche.com/media/releases/med-cor-2025-10-03b","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"links","label":"FDA approval (Oct 2025)"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","field":"regulatoryEvents.source (2025-10-02)"}]},{"url":"https://www.roche.com/media/releases/med-cor-2025-10-18","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","field":"outcomes.source (Progression-free survival (ITT))"}],"archive":"https://web.archive.org/web/20260609055954/https://www.roche.com/media/releases/med-cor-2025-10-18"},{"url":"https://www.roche.com/media/releases/med-cor-2025-10-20b","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","field":"outcomes.source (Disease-free survival (ctDNA-positive, randomised))"},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","field":"outcomes.source (Overall survival (ctDNA-positive))"},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","field":"outcomes.source (Disease-free survival at 12 months, persistently ctDNA-negative (untreated surveillance))"}]},{"url":"https://www.roche.com/media/releases/med-cor-2026-03-09","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","field":"outcomes.source (Progression-free survival (investigator))"},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","field":"regulatoryEvents.source (2026-03-09)"}]},{"url":"https://www.roche.com/media/releases/med-cor-2026-05-19","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","field":"outcomes.source (Invasive disease-free survival)"}]},{"url":"https://www.roche.com/media/releases/med-cor-2026-06-08","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/","field":"links","label":"Roche collaboration"}]},{"url":"https://www.roche.com/media/releases/med-cor-2026-07-02","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","field":"links","label":"Roche release"},{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/","field":"links","label":"Roche Krascendo 1 release"}],"archive":"https://web.archive.org/web/20260722101632/https://www.roche.com/media/releases/med-cor-2026-07-02"},{"url":"https://www.roche.com/venturefund","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","route":"/companies/roche-venture-fund/","field":"links","label":"Official website"},{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","route":"/companies/roche-venture-fund/","field":"website"}]},{"url":"https://www.ronc.ru","status":200,"ok":true,"finalUrl":"https://www.ronc.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"links","label":"N. N. Blokhin National Medical Research Center of Oncology website"},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","field":"profiles","label":"N. N. Blokhin National Medical Research Center of Oncology website"},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","field":"links","label":"Official website"},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","field":"website"}]},{"url":"https://www.rosoncoweb.ru","status":200,"ok":true,"finalUrl":"https://www.rosoncoweb.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","route":"/institutions/russco/","field":"links","label":"RUSSCO (Russian)"},{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","route":"/institutions/russco/","field":"website"}]},{"url":"https://www.roswellpark.org","status":200,"ok":true,"finalUrl":"https://www.roswellpark.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","field":"links","label":"Official website"},{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","field":"website"}]},{"url":"https://www.roswellpark.org/candace-johnson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","field":"links","label":"Roswell Park profile"},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.roswellpark.org/eunice-wang","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","field":"links","label":"Roswell Park profile"},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.roswellpark.org/igor-puzanov","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","field":"links","label":"Roswell Park profile"},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.roswellpark.org/renier-brentjens","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","field":"links","label":"Roswell Park profile"},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.roswellpark.org/robert-fenstermaker","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","field":"links","label":"Roswell Park profile"},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","field":"profiles","label":"Roswell Park profile"}]},{"url":"https://www.rovi.es","status":200,"ok":true,"finalUrl":"https://www.rovi.es/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","field":"links","label":"Official website"},{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","field":"website"}]},{"url":"https://www.royalfree.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.royalfree.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-free-hospital","kind":"institution","name":"Royal Free Hospital, Royal Free London NHS Foundation Trust","route":"/institutions/royal-free-hospital/","field":"links","label":"Royal Free London"},{"id":"royal-free-hospital","kind":"institution","name":"Royal Free Hospital, Royal Free London NHS Foundation Trust","route":"/institutions/royal-free-hospital/","field":"website"}]},{"url":"https://www.royalmarsden.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.royalmarsden.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","field":"links","label":"Official website"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","field":"website"}]},{"url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/naureen-starling","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"naureen-starling","kind":"person","name":"Naureen Starling","route":"/people/naureen-starling/","field":"links","label":"The Royal Marsden consultant directory"},{"id":"naureen-starling","kind":"person","name":"Naureen Starling","route":"/people/naureen-starling/","field":"profiles","label":"The Royal Marsden consultant directory"}]},{"url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/prof-nicholas-van-as","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nicholas-van-as","kind":"person","name":"Nicholas van As","route":"/people/nicholas-van-as/","field":"links","label":"The Royal Marsden consultant directory"},{"id":"nicholas-van-as","kind":"person","name":"Nicholas van As","route":"/people/nicholas-van-as/","field":"profiles","label":"The Royal Marsden consultant directory"}]},{"url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-ian-chau","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ian-chau","kind":"person","name":"Ian Chau","route":"/people/ian-chau/","field":"links","label":"The Royal Marsden consultant directory"},{"id":"ian-chau","kind":"person","name":"Ian Chau","route":"/people/ian-chau/","field":"profiles","label":"The Royal Marsden consultant directory"}]},{"url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-rosalind-eeles","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","route":"/people/ros-eeles/","field":"links","label":"The Royal Marsden consultant directory"},{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","route":"/people/ros-eeles/","field":"profiles","label":"The Royal Marsden consultant directory"}]},{"url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-sanjay-popat","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","route":"/people/sanjay-popat/","field":"links","label":"The Royal Marsden consultant directory"},{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","route":"/people/sanjay-popat/","field":"profiles","label":"The Royal Marsden consultant directory"}]},{"url":"https://www.royalsurrey.nhs.uk/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-surrey-guildford","kind":"institution","name":"Royal Surrey County Hospital, Guildford","route":"/institutions/royal-surrey-guildford/","field":"website"}]},{"url":"https://www.royalsurrey.nhs.uk/hpb","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-surrey-guildford","kind":"institution","name":"Royal Surrey County Hospital, Guildford","route":"/institutions/royal-surrey-guildford/","field":"links","label":"Royal Surrey: HPB service"}]},{"url":"https://www.rsna.org","status":200,"ok":true,"finalUrl":"https://www.rsna.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","field":"links","label":"RSNA"}]},{"url":"https://www.rsna.org/research/quantitative-imaging-biomarkers-alliance","status":200,"ok":true,"finalUrl":"https://www.rsna.org/research","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","field":"links","label":"RSNA QIBA"},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","field":"links","label":"RSNA Quantitative Imaging Biomarkers Alliance (QIBA)"}]},{"url":"https://www.s32.com","status":200,"ok":true,"finalUrl":"https://www.s32.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","field":"links","label":"Official website"},{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","field":"website"}]},{"url":"https://www.sabcs.org","status":200,"ok":true,"finalUrl":"https://sabcs.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","field":"links","label":"SABCS"}]},{"url":"https://www.sabcs.org/","status":200,"ok":true,"finalUrl":"https://sabcs.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","field":"links","label":"San Antonio Breast Cancer Symposium"},{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","field":"url"}]},{"url":"https://www.sacrocuore.it","status":200,"ok":true,"finalUrl":"https://www.sacrocuore.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","field":"links","label":"Official website"},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","field":"website"}]},{"url":"https://www.sacrocuore.it/la-direzione/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"claudio-cracco","kind":"person","name":"Claudio Cracco","route":"/people/claudio-cracco/","field":"links","label":"Source: IRCCS Sacro Cuore Don Calabria 'La direzione' page"},{"id":"claudio-cracco","kind":"person","name":"Claudio Cracco","route":"/people/claudio-cracco/","field":"profiles","label":"Sacro Cuore Don Calabria leadership page (La direzione)"}]},{"url":"https://www.sagelyhealth.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/","field":"links","label":"Official website"},{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/","field":"website"}]},{"url":"https://www.sagemedic.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sagemedic","kind":"company","name":"SageMedic","route":"/companies/sagemedic/","field":"links","label":"Official website"},{"id":"sagemedic","kind":"company","name":"SageMedic","route":"/companies/sagemedic/","field":"website"}]},{"url":"https://www.sahlgrenska.se/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","field":"links","label":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research website"},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","field":"profiles","label":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research website"},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","field":"links","label":"Homepage"},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","field":"website"}]},{"url":"https://www.sahlgrenska.se/en/about-us/about-the-hospital/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"boubou-hallberg","kind":"person","name":"Boubou Hallberg","route":"/people/boubou-hallberg/","field":"links","label":"Institution profile"},{"id":"boubou-hallberg","kind":"person","name":"Boubou Hallberg","route":"/people/boubou-hallberg/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.sakk.ch","status":200,"ok":true,"finalUrl":"https://www.swisscancerinstitute.ch/en/researchers/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"SAKK"}]},{"url":"https://www.sakura.eu","status":200,"ok":true,"finalUrl":"https://www.sakura.eu/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","route":"/companies/sakura-finetek/","field":"links","label":"Official website"},{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","route":"/companies/sakura-finetek/","field":"website"}]},{"url":"https://www.salk.edu","status":200,"ok":true,"finalUrl":"https://www.salk.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","field":"links","label":"Salk Institute"}]},{"url":"https://www.salk.edu/science/research-centers/salk-cancer-center/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","field":"links","label":"Salk Cancer Center"},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","field":"website"}]},{"url":"https://www.salk.edu/scientist/reuben-shaw/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","route":"/people/reuben-shaw/","field":"links","label":"Source: Salk Institute faculty profile naming him Director of the Salk Cancer Center"},{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","route":"/people/reuben-shaw/","field":"profiles","label":"Salk Institute faculty profile"}]},{"url":"https://www.salutsantjoan.cat/","status":200,"ok":true,"finalUrl":"https://www.salutsantjoan.cat/ca/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","field":"links","label":"Hospital Universitari Sant Joan de Reus website"},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","field":"profiles","label":"Hospital Universitari Sant Joan de Reus website"}]},{"url":"https://www.samsunghospital.com","status":200,"ok":true,"finalUrl":"https://www.samsunghospital.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","field":"links","label":"Official website"},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","field":"website"}]},{"url":"https://www.samsunghospital.com/gb/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","field":"links","label":"Samsung Medical Center"},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","field":"profiles","label":"Samsung Medical Center"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"links","label":"Samsung Medical Center"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","field":"profiles","label":"Samsung Medical Center"},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","field":"links","label":"Samsung Medical Center"},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","field":"profiles","label":"Samsung Medical Center"},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","field":"links","label":"Samsung Medical Center"},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","field":"profiles","label":"Samsung Medical Center"},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","field":"links","label":"Samsung Medical Center"},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","field":"profiles","label":"Samsung Medical Center"},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","field":"links","label":"Samsung Genome Institute"},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","field":"profiles","label":"Samsung Genome Institute"}]},{"url":"https://www.sandoz.com","status":200,"ok":true,"finalUrl":"https://www.sandoz.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandoz","kind":"company","name":"Sandoz","route":"/companies/sandoz/","field":"links","label":"Official website"},{"id":"sandoz","kind":"company","name":"Sandoz","route":"/companies/sandoz/","field":"website"}]},{"url":"https://www.sanger.ac.uk","status":200,"ok":true,"finalUrl":"https://www.sanger.ac.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","field":"links","label":"Wellcome Sanger Institute"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","field":"links","label":"Homepage"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","field":"website"}]},{"url":"https://www.sanger.ac.uk/person/hurles-matthew/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","field":"links","label":"Institution profile"},{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.sanger.ac.uk/programme/cancer-ageing-and-somatic-mutation/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","field":"links","label":"Cancer, Ageing and Somatic Mutation programme"}]},{"url":"https://www.sanmatteo.org","status":200,"ok":true,"finalUrl":"https://www.sanmatteo.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","field":"links","label":"Official website"},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","field":"website"}]},{"url":"https://www.sanofi.com","status":200,"ok":true,"finalUrl":"https://www.sanofi.com/en","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/","field":"links","label":"Official website"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/","field":"website"}]},{"url":"https://www.sanofi.com/en/media-room/press-releases/2023/","status":200,"ok":true,"finalUrl":"https://www.sanofi.com/en/media-room/press-releases/2023","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","field":"links","label":"Sanofi press release, CARMEN-LC03 (Dec 2023) (page moved; nearest live section)"}]},{"url":"https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","field":"links","label":"Sanofi licensing agreement"}]},{"url":"https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","field":"links","label":"Sanofi press release Oct 2025"},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"links","label":"Sanofi press release"},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"outcomes.source (Objective response rate (PRRT-naive))"}]},{"url":"https://www.sanofiventures.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","field":"links","label":"Official website"},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","field":"website"}]},{"url":"https://www.sanofiventures.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://www.santpau.cat/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"links","label":"Hospital de la Santa Creu i Sant Pau website"},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"profiles","label":"Hospital de la Santa Creu i Sant Pau website"}]},{"url":"https://www.saolta.ie","status":200,"ok":true,"finalUrl":"https://www.saolta.ie/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","field":"links","label":"University of Galway / Saolta Cancer Centre website"},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","field":"profiles","label":"University of Galway / Saolta Cancer Centre website"},{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","route":"/institutions/galway-university-hospital-cancer-centre/","field":"links","label":"Official website"},{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","route":"/institutions/galway-university-hospital-cancer-centre/","field":"website"}]},{"url":"https://www.saolta.ie/cancer-centre","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-kerin","kind":"person","name":"Michael Kerin","route":"/people/michael-kerin/","field":"links","label":"Source: Saolta cancer centre page naming the Clinical Director"},{"id":"michael-kerin","kind":"person","name":"Michael Kerin","route":"/people/michael-kerin/","field":"profiles","label":"Saolta cancer centre page"}]},{"url":"https://www.sarcomaoncology.com/","status":200,"ok":true,"finalUrl":"https://sarcomaoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"links","label":"Sarcoma Oncology Center"},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","field":"profiles","label":"Sarcoma Oncology Center"}]},{"url":"https://www.sartorius.com","status":200,"ok":true,"finalUrl":"https://www.sartorius.com/en","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sartorius","kind":"company","name":"Sartorius","route":"/companies/sartorius/","field":"links","label":"Official website"},{"id":"sartorius","kind":"company","name":"Sartorius","route":"/companies/sartorius/","field":"website"}]},{"url":"https://www.sbah.org.za","status":200,"ok":true,"finalUrl":"https://www.sbah.org.za/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"steve-biko-academic-hospital","kind":"institution","name":"Steve Biko Academic Hospital / University of Pretoria","route":"/institutions/steve-biko-academic-hospital/","field":"links","label":"Official website"},{"id":"steve-biko-academic-hospital","kind":"institution","name":"Steve Biko Academic Hospital / University of Pretoria","route":"/institutions/steve-biko-academic-hospital/","field":"website"}]},{"url":"https://www.sbipharma.co.jp","status":200,"ok":true,"finalUrl":"https://www.sbipharma.co.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","field":"links","label":"Official website"},{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","field":"website"}]},{"url":"https://www.sbpdiscovery.org/about-us/leadership/","status":200,"ok":true,"finalUrl":"https://sbpdiscovery.org/research/centers/nci-designated-cancer-center/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paul-boutros","kind":"person","name":"Paul Boutros","route":"/people/paul-boutros/","field":"links","label":"Source: Sanford Burnham Prebys leadership page"},{"id":"paul-boutros","kind":"person","name":"Paul Boutros","route":"/people/paul-boutros/","field":"profiles","label":"Sanford Burnham Prebys leadership page"}]},{"url":"https://www.scan-b.lu.se","status":200,"ok":true,"finalUrl":"https://www.scan-b.lu.se/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","field":"links","label":"SCAN-B"}]},{"url":"https://www.scan-b.lu.se/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scan-b","kind":"trial","name":"SCAN-B (Sweden Cancerome Analysis Network - Breast)","route":"/trials/scan-b/","field":"links","label":"SCAN-B project site (Lund University)"}]},{"url":"https://www.scancell.co.uk/","status":200,"ok":true,"finalUrl":"https://scancell.co.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/","field":"links","label":"Official website"},{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/","field":"website"}]},{"url":"https://www.scchr.jp","status":200,"ok":true,"finalUrl":"https://www.scchr.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","field":"links","label":"Shizuoka Cancer Center"},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","field":"website"}]},{"url":"https://www.scchr.jp/en/index.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","route":"/people/katsuhiko-uesaka/","field":"links","label":"Source: Shizuoka Cancer Center president's greeting"},{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","route":"/people/katsuhiko-uesaka/","field":"profiles","label":"President's greeting"}]},{"url":"https://www.schn.health.nsw.gov.au","status":200,"ok":true,"finalUrl":"https://www.schn.health.nsw.gov.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","field":"links","label":"Sydney Children's Hospitals Network"},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","field":"website"}]},{"url":"https://www.schn.health.nsw.gov.au/about/our-people/leadership-group","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cathryn-cox","kind":"person","name":"Cathryn Cox","route":"/people/cathryn-cox/","field":"links","label":"Institution profile"},{"id":"cathryn-cox","kind":"person","name":"Cathryn Cox","route":"/people/cathryn-cox/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.science37.com","status":200,"ok":true,"finalUrl":"https://www.science37.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"science-37","kind":"company","name":"Science 37 (eMed)","route":"/companies/science-37/","field":"links","label":"Official website"},{"id":"science-37","kind":"company","name":"Science 37 (eMed)","route":"/companies/science-37/","field":"website"}]},{"url":"https://www.scorpiontx.com/","status":200,"ok":true,"finalUrl":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","field":"links","label":"Official website"},{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","field":"website"}]},{"url":"https://www.screeningservice.ie/","status":200,"ok":true,"finalUrl":"https://www2.healthservice.hse.ie/organisation/nss/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","route":"/collections/ireland-national-screening-service/","field":"links","label":"Ireland's National Screening Service"},{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","route":"/collections/ireland-national-screening-service/","field":"url"}]},{"url":"https://www.scrum-japan.ncc.go.jp","status":200,"ok":true,"finalUrl":"https://scrum-japan.ncc.go.jp/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","field":"links","label":"SCRUM-Japan"}]},{"url":"https://www.seattlechildrens.org","status":200,"ok":true,"finalUrl":"https://www.seattlechildrens.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","route":"/institutions/seattle-childrens/","field":"links","label":"Seattle Children's"},{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","route":"/institutions/seattle-childrens/","field":"website"}]},{"url":"https://www.seha.ae","status":200,"ok":true,"finalUrl":"https://www.seha.ae/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","field":"links","label":"SEHA Tawam Hospital"},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","field":"website"}]},{"url":"https://www.selca.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.selca.nhs.uk/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","route":"/institutions/south-east-london-cancer-alliance/","field":"links","label":"South East London Cancer Alliance"},{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","route":"/institutions/south-east-london-cancer-alliance/","field":"website"}]},{"url":"https://www.semanticscholar.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","field":"links","label":"Semantic Scholar"},{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","field":"url"}]},{"url":"https://www.serb.eu","status":200,"ok":true,"finalUrl":"https://serb.com/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"serb-pharmaceuticals","kind":"company","name":"SERB Pharmaceuticals","route":"/companies/serb-pharmaceuticals/","field":"links","label":"Official website"},{"id":"serb-pharmaceuticals","kind":"company","name":"SERB Pharmaceuticals","route":"/companies/serb-pharmaceuticals/","field":"website"}]},{"url":"https://www.serinus.bio","status":200,"ok":true,"finalUrl":"https://www.serinus.bio/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/","field":"links","label":"Official website"},{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/","field":"website"}]},{"url":"https://www.seruminstitute.com","status":200,"ok":true,"finalUrl":"https://www.seruminstitute.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/","field":"links","label":"Official website"},{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/","field":"website"}]},{"url":"https://www.seruminstitute.com/product_ind_cervavac.php","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/","field":"links","label":"CERVAVAC product page"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","field":"links","label":"Serum Institute of India: CERVAVAC"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","field":"dosing.source"}]},{"url":"https://www.sgo.org","status":200,"ok":true,"finalUrl":"https://www.sgo.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","field":"links","label":"SGO"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/","field":"links","label":"SGO"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/","field":"website"}]},{"url":"https://www.sgo.org/about-sgo/bod/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","field":"links","label":"Society page"},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","field":"profiles","label":"Society page"},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","field":"links","label":"Society page"},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","field":"profiles","label":"Society page"}]},{"url":"https://www.shasqi.com","status":200,"ok":true,"finalUrl":"https://www.shasqi.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/","field":"links","label":"Official website"},{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/","field":"website"}]},{"url":"https://www.shca.org.cn","status":200,"ok":true,"finalUrl":"https://www.shca.org.cn/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"links","label":"Official website"},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"website"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","field":"profiles","label":"Fudan University Shanghai Cancer Center"},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","field":"profiles","label":"Fudan University Shanghai Cancer Center"},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","field":"profiles","label":"Fudan University Shanghai Cancer Center"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"profiles","label":"Fudan University Shanghai Cancer Center"},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","field":"profiles","label":"Fudan University Shanghai Cancer Center"},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","field":"profiles","label":"Fudan University Shanghai Cancer Center"}]},{"url":"https://www.shi.co.jp/english/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","route":"/companies/sumitomo-heavy-industries/","field":"links","label":"Official website"},{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","route":"/companies/sumitomo-heavy-industries/","field":"website"}]},{"url":"https://www.shimadzu.com","status":200,"ok":true,"finalUrl":"https://www.shimadzu.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shimadzu","kind":"company","name":"Shimadzu","route":"/companies/shimadzu/","field":"links","label":"Official website"},{"id":"shimadzu","kind":"company","name":"Shimadzu","route":"/companies/shimadzu/","field":"website"}]},{"url":"https://www.shinefusion.com","status":200,"ok":true,"finalUrl":"https://www.shinefusion.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","field":"links","label":"Official website"},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","field":"website"}]},{"url":"https://www.shionogi.com/","status":200,"ok":true,"finalUrl":"https://www.shionogi.com/us/en/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"shionogi","kind":"company","name":"Shionogi","route":"/companies/shionogi/","field":"links","label":"Official website"},{"id":"shionogi","kind":"company","name":"Shionogi","route":"/companies/shionogi/","field":"website"}]},{"url":"https://www.shnci.org","status":200,"ok":true,"finalUrl":"https://oneactionnh.org/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","field":"links","label":"Sydney Head and Neck Cancer Institute"}]},{"url":"https://www.si.mahidol.ac.th","status":200,"ok":true,"finalUrl":"https://www.si.mahidol.ac.th/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","field":"links","label":"Siriraj Hospital"},{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","field":"website"}]},{"url":"https://www.sichuancancer.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/","field":"links","label":"Official website"},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/","field":"website"}]},{"url":"https://www.sichuancancer.org/yygk/xrld1.htm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","route":"/people/lin-tongyu/","field":"links","label":"Source: Sichuan Cancer Hospital current leadership page"},{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","route":"/people/lin-tongyu/","field":"profiles","label":"Hospital current leadership page (Chinese)"}]},{"url":"https://www.sickkids.ca","status":200,"ok":true,"finalUrl":"https://www.sickkids.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","field":"links","label":"SickKids"},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","field":"website"}]},{"url":"https://www.sickkids.ca/en/about/leadership/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"links","label":"Institution profile"},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","field":"profiles","label":"Institution profile"},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"links","label":"Institution profile"},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","field":"profiles","label":"Institution profile"},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","field":"links","label":"Institution profile"},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.sickkids.ca/en/care-services/centres/garron-family-cancer-centre/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","field":"links","label":"Garron Family Cancer Centre"}]},{"url":"https://www.siemens-healthineers.com","status":200,"ok":true,"finalUrl":"https://www.siemens-healthineers.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","field":"links","label":"Official website"},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","field":"website"}]},{"url":"https://www.siemens-healthineers.com/molecular-imaging/petnet","status":200,"ok":true,"finalUrl":"https://www.siemens-healthineers.com/molecular-imaging/radiopharma","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","field":"links","label":"Official website"},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","field":"website"}]},{"url":"https://www.signatur.bio","status":200,"ok":true,"finalUrl":"https://www.signatur.bio/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","route":"/companies/signatur-biosciences/","field":"links","label":"Official website"},{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","route":"/companies/signatur-biosciences/","field":"website"}]},{"url":"https://www.siliconbiosystems.com","status":200,"ok":true,"finalUrl":"https://www.menarinisiliconbiosystems.com/us.html","contentType":"text/html;charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","route":"/companies/menarini-silicon-biosystems/","field":"links","label":"Official website"},{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","route":"/companies/menarini-silicon-biosystems/","field":"website"}]},{"url":"https://www.simcere.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/","field":"links","label":"Official website"},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/","field":"website"}]},{"url":"https://www.singhealth.com.sg","status":200,"ok":true,"finalUrl":"https://www.singhealth.com.sg/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","field":"links","label":"SingHealth"}]},{"url":"https://www.sinocelltech.com","status":200,"ok":true,"finalUrl":"https://www.sinocelltech.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/","field":"links","label":"Official website"},{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/","field":"website"},{"id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","field":"links","label":"Sponsor page"},{"id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","field":"links","label":"Sponsor page"},{"id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","field":"links","label":"Sponsor page"},{"id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","field":"links","label":"Sponsor page"}]},{"url":"https://www.sinotau.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"links","label":"Official website"},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"website"}]},{"url":"https://www.sirtex.com","status":200,"ok":true,"finalUrl":"https://www.sirtex.com/us/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","field":"links","label":"Official website"},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","field":"website"}]},{"url":"https://www.sitcancer.org","status":200,"ok":true,"finalUrl":"https://www.sitcancer.org/home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","field":"links","label":"SITC"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","field":"links","label":"SITC"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","field":"website"}]},{"url":"https://www.sitcancer.org/about/board","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","field":"links","label":"Society page"},{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","field":"profiles","label":"Society page"}]},{"url":"https://www.sitcancer.org/research/cancer-immunotherapy-guidelines","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","field":"links","label":"Guidelines"}]},{"url":"https://www.sjaellandsuniversitetshospital.dk","status":200,"ok":true,"finalUrl":"https://www.sjaellandsuniversitetshospital.dk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","route":"/institutions/zealand-university-hospital/","field":"links","label":"Official website"},{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","route":"/institutions/zealand-university-hospital/","field":"website"}]},{"url":"https://www.skinhealthinfo.org.uk/condition/basal-cell-carcinoma/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"second-primary-skin-cancer","kind":"term","name":"The next skin cancer: second primaries after a keratinocyte cancer","route":"/terms/second-primary-skin-cancer/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"british-association-of-dermatologists","kind":"institution","name":"British Association of Dermatologists","route":"/institutions/british-association-of-dermatologists/","field":"links","label":"Skin Health Info: basal cell carcinoma"},{"id":"british-association-of-dermatologists","kind":"institution","name":"British Association of Dermatologists","route":"/institutions/british-association-of-dermatologists/","field":"website"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"standardOfCare.guideline (Will it come back, and will I get another one)"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","field":"links","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"British Association of Dermatologists: basal cell carcinoma, patient information leaflet (updated July 2025)"}]},{"url":"https://www.skinhealthinfo.org.uk/condition/mohs-micrographic-surgery/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"British Association of Dermatologists and British Society for Dermatological Surgery: Mohs micrographic surgery, patient information leaflet (updated June 2025)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (Mohs surgery as a day, not as a technique)"},{"id":"skin-graft-and-flap-reconstruction","kind":"term","name":"Skin grafts and flaps after skin cancer surgery","route":"/terms/skin-graft-and-flap-reconstruction/","field":"links","label":"British Association of Dermatologists and British Society for Dermatological Surgery: Mohs micrographic surgery, patient information leaflet (updated June 2025)"},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","field":"links","label":"British Association of Dermatologists and British Society for Dermatological Surgery: Mohs micrographic surgery, patient information leaflet (updated June 2025)"},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","field":"links","label":"British Association of Dermatologists and British Society for Dermatological Surgery: Mohs micrographic surgery, patient information leaflet (updated June 2025)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"British Association of Dermatologists and British Society for Dermatological Surgery: Mohs micrographic surgery, patient information leaflet (updated June 2025)"}]},{"url":"https://www.skinhealthinfo.org.uk/condition/skin-cancer-in-organ-transplant-recipients/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"standardOfCare.guideline (If your immune system is suppressed, this is a different disease)"},{"id":"second-primary-skin-cancer","kind":"term","name":"The next skin cancer: second primaries after a keratinocyte cancer","route":"/terms/second-primary-skin-cancer/","field":"links","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"},{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","field":"links","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","field":"links","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"British Association of Dermatologists and BSSCII: skin cancer advice for organ transplant recipients, patient information leaflet (June 2024)"}]},{"url":"https://www.skinhealthinfo.org.uk/condition/squamous-cell-carcinomas/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"British Association of Dermatologists: squamous cell carcinomas, patient information leaflet (updated April 2022; the leaflet gives its own next review date as April 2025 and no newer version exists at this address or at bad.org.uk)"},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","field":"links","label":"British Association of Dermatologists: squamous cell carcinomas, patient information leaflet (updated April 2022; the leaflet gives its own next review date as April 2025 and no newer version exists at this address or at bad.org.uk)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"links","label":"British Association of Dermatologists: squamous cell carcinomas, patient information leaflet (updated April 2022; the leaflet gives its own next review date as April 2025 and no newer version exists at this address or at bad.org.uk)"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","field":"standardOfCare.guideline (Follow-up, the lymph nodes, and the chance of a second one)"},{"id":"red-flags","kind":"data","name":"Red flags: when to call","route":"/symptoms/","field":"redFlags.source","label":"British Association of Dermatologists: squamous cell carcinomas, patient information leaflet (updated April 2022; its own next review date was April 2025 and no newer version has been published)"}]},{"url":"https://www.skinhealthinfo.org.uk/sun-awareness/the-sunscreen-fact-sheet/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","field":"links","label":"British Association of Dermatologists: the sun protection fact sheet (the page states no production, update or review date)"},{"id":"sun-protection-after-skin-cancer","kind":"term","name":"Sun protection after a skin cancer diagnosis","route":"/terms/sun-protection-after-skin-cancer/","field":"links","label":"British Association of Dermatologists: the sun protection fact sheet (the page states no production, update or review date)"}]},{"url":"https://www.smb.org/mathematical-oncology/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/","field":"links","label":"Society for Mathematical Biology, mathematical oncology subgroup"}]},{"url":"https://www.smmttx.com","status":200,"ok":true,"finalUrl":"https://www.smmttx.com/overview/default.aspx","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/","field":"links","label":"Official website"},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/","field":"website"}]},{"url":"https://www.snmmi.org","status":200,"ok":true,"finalUrl":"https://snmmi.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","field":"links","label":"SNMMI"},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","field":"links","label":"SNMMI"},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","field":"website"}]},{"url":"https://www.snmmi.org/","status":200,"ok":true,"finalUrl":"https://snmmi.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","field":"links","label":"Society page"},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","field":"profiles","label":"Society page"},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","field":"links","label":"SNMMI Annual Meeting"},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","field":"url"}]},{"url":"https://www.snubh.org","status":200,"ok":true,"finalUrl":"https://www.snubh.org/index.do","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","route":"/institutions/snu-bundang-hospital/","field":"links","label":"SNUBH"},{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","route":"/institutions/snu-bundang-hospital/","field":"website"}]},{"url":"https://www.snuh.org","status":200,"ok":true,"finalUrl":"https://www.snuh.org/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","field":"links","label":"Official website"},{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","field":"website"},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","field":"links","label":"Seoul National University Hospital"},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","field":"profiles","label":"Seoul National University Hospital"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"links","label":"Seoul National University Hospital"},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","field":"profiles","label":"Seoul National University Hospital"},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","field":"links","label":"Seoul National University Hospital"},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","field":"profiles","label":"Seoul National University Hospital"},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","field":"links","label":"Seoul National University Hospital"},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","field":"profiles","label":"Seoul National University Hospital"},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","field":"links","label":"Seoul National University Hospital"},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","field":"profiles","label":"Seoul National University Hospital"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","field":"links","label":"Seoul National University Hospital"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","field":"profiles","label":"Seoul National University Hospital"}]},{"url":"https://www.sobi.com","status":200,"ok":true,"finalUrl":"https://www.sobi.com/en","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","route":"/companies/sobi/","field":"links","label":"Official website"},{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","route":"/companies/sobi/","field":"website"}]},{"url":"https://www.soc-neuro-onc.org","status":200,"ok":true,"finalUrl":"https://www.soc-neuro-onc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","field":"links","label":"Society for Neuro-Oncology"}]},{"url":"https://www.soligenix.com","status":200,"ok":true,"finalUrl":"https://www.soligenix.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","field":"links","label":"Official website"},{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","field":"website"}]},{"url":"https://www.sonalasense.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","field":"links","label":"Official website"},{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","field":"website"}]},{"url":"https://www.sonalasense.com/for-investors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","field":"links","label":"For investors"}]},{"url":"https://www.sonalasense.com/news/sonalasense-achieves-significant-clinical%2C-growth-and-funding-milestones-toward-its-mission-to-soundly-defeat-cancer","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","field":"links","label":"Clinical, growth and Series B milestones (June 2022)"}]},{"url":"https://www.sophiagenetics.com","status":200,"ok":true,"finalUrl":"https://www.sophiagenetics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","route":"/companies/sophia-genetics/","field":"links","label":"Official website"},{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","route":"/companies/sophia-genetics/","field":"website"}]},{"url":"https://www.sotio.com","status":200,"ok":true,"finalUrl":"https://www.sotio.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/","field":"links","label":"Official website"},{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/","field":"website"}]},{"url":"https://www.southampton.ac.uk/people/5x2clr/professor-ellen-copson","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ellen-copson","kind":"person","name":"Ellen Copson","route":"/people/ellen-copson/","field":"links","label":"University of Southampton profile"},{"id":"ellen-copson","kind":"person","name":"Ellen Copson","route":"/people/ellen-copson/","field":"profiles","label":"University of Southampton profile"}]},{"url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","field":"links","label":"Institution profile"},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","field":"profiles","label":"Institution profile"},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","field":"links","label":"Centre for Cancer Immunology"}]},{"url":"https://www.spandidos-publications.com/ijo","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","route":"/journals/international-journal-of-oncology/","field":"links","label":"Homepage"},{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","route":"/journals/international-journal-of-oncology/","field":"url"}]},{"url":"https://www.spandidos-publications.com/or","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-reports","kind":"journal","name":"Oncology reports","route":"/journals/oncology-reports/","field":"links","label":"Homepage"},{"id":"oncology-reports","kind":"journal","name":"Oncology reports","route":"/journals/oncology-reports/","field":"url"}]},{"url":"https://www.spectracure.com/","status":200,"ok":true,"finalUrl":"https://spectracure.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/","field":"links","label":"Official website"},{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/","field":"website"}]},{"url":"https://www.spirit-statement.org/","status":200,"ok":true,"finalUrl":"https://www.consort-spirit.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","field":"links","label":"SPIRIT statement: standard protocol items for clinical trials"}]},{"url":"https://www.spotlightnsp.co.za/2024/04/25/dr-shaheem-de-vries-comfortable-with-chaos-head-cowboy-takes-charge-of-groote-schuur-hospital/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shaheem-de-vries","kind":"person","name":"Shaheem de Vries","route":"/people/shaheem-de-vries/","field":"links","label":"Source: Spotlight report on his appointment as Groote Schuur CEO (25 April 2024)"},{"id":"shaheem-de-vries","kind":"person","name":"Shaheem de Vries","route":"/people/shaheem-de-vries/","field":"profiles","label":"Spotlight appointment profile (April 2024)"}]},{"url":"https://www.springernature.com","status":200,"ok":true,"finalUrl":"https://www.springernature.com/gp","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","field":"links","label":"Springer Nature"}]},{"url":"https://www.springworkstx.com","status":200,"ok":true,"finalUrl":"https://springworkstx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","field":"links","label":"Official website"},{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","field":"website"}]},{"url":"https://www.srone.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/","field":"links","label":"Official website"},{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/","field":"website"}]},{"url":"https://www.srone.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/","field":"links","label":"Portfolio"}]},{"url":"https://www.ssg-org.net","status":200,"ok":true,"finalUrl":"https://www.ssg-org.net/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"scandinavian-sarcoma-group","kind":"company","name":"Scandinavian Sarcoma Group","route":"/companies/scandinavian-sarcoma-group/","field":"links","label":"Official website"},{"id":"scandinavian-sarcoma-group","kind":"company","name":"Scandinavian Sarcoma Group","route":"/companies/scandinavian-sarcoma-group/","field":"website"}]},{"url":"https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hospital/virgen-victoria/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","field":"links","label":"Hospital Universitario Virgen de la Victoria website"},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","field":"profiles","label":"Hospital Universitario Virgen de la Victoria website"},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","route":"/institutions/virgen-de-la-victoria-malaga/","field":"links","label":"Official website"},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","route":"/institutions/virgen-de-la-victoria-malaga/","field":"website"}]},{"url":"https://www.stablix.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","field":"links","label":"Official website"},{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","field":"website"}]},{"url":"https://www.stablix.com/copy-of-stablix-names-tony-kingsley-ceo","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","field":"links","label":"Series A press release"}]},{"url":"https://www.stablix.com/stablixandvertexestablishstrategiccollaborationtodiscoveranddeveloptargetedproteinstabil","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","field":"links","label":"Vertex collaboration"}]},{"url":"https://www.stampedetrial.org","status":200,"ok":true,"finalUrl":"https://www.stampedetrial.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"STAMPEDE trial website (MRC CTU at UCL)"},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","field":"links","label":"STAMPEDE trial website (MRC Clinical Trials Unit at UCL)"}],"archive":"https://web.archive.org/web/20260607170452/https://www.stampedetrial.org/"},{"url":"https://www.stampedetrial.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","field":"links","label":"STAMPEDE trial"},{"id":"idea-tr1-mams-for-sequencing-questions","kind":"idea","name":"Multi-arm, multi-stage trials to answer which order to give approved drugs","route":"/ideas/idea-tr1-mams-for-sequencing-questions/","field":"links","label":"STAMPEDE trial"},{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/","field":"links","label":"STAMPEDE platform trial"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/","field":"links","label":"STAMPEDE platform trial"}]},{"url":"https://www.standardbio.com","status":200,"ok":true,"finalUrl":"https://standardbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/","field":"links","label":"Official website"},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/","field":"website"}]},{"url":"https://www.standardimaging.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"standard-imaging","kind":"company","name":"Standard Imaging","route":"/companies/standard-imaging/","field":"links","label":"Official website"},{"id":"standard-imaging","kind":"company","name":"Standard Imaging","route":"/companies/standard-imaging/","field":"website"}]},{"url":"https://www.statnews.com/2023/09/06/nimbus-therapeutics-raises-210-million-in-one-of-the-larger-fundraising-rounds-this-year/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","field":"links","label":"STAT on the 2023 financing"}]},{"url":"https://www.statnews.com/topic/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","field":"links","label":"STAT News"},{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","field":"url"}]},{"url":"https://www.stbaldricks.org","status":200,"ok":true,"finalUrl":"https://www.stbaldricks.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","field":"website"}]},{"url":"https://www.stbaldricks.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","field":"links","label":"St. Baldrick's"},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","field":"url"}]},{"url":"https://www.stbaldricks.org/about-us","status":200,"ok":true,"finalUrl":"https://www.stbaldricks.org/why-we-exist","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","field":"links","label":"About St. Baldrick's"}]},{"url":"https://www.stbaldricks.org/staff-leadership/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kathleen-ruddy","kind":"person","name":"Kathleen Ruddy","route":"/people/kathleen-ruddy/","field":"links","label":"Source: St. Baldrick's Foundation staff leadership page"},{"id":"kathleen-ruddy","kind":"person","name":"Kathleen Ruddy","route":"/people/kathleen-ruddy/","field":"profiles","label":"St. Baldrick's staff leadership page"}]},{"url":"https://www.sterlingpharmasolutions.com","status":200,"ok":true,"finalUrl":"https://www.sterlingpharmasolutions.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","route":"/companies/sterling-pharma-solutions/","field":"links","label":"Official website"},{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","route":"/companies/sterling-pharma-solutions/","field":"website"}]},{"url":"https://www.stjames.ie/cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/","field":"links","label":"Source: St James's Hospital cancer institute page naming the directors"},{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/","field":"profiles","label":"Trinity St James's Cancer Institute page"},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","route":"/institutions/trinity-st-jamess-cancer-institute/","field":"links","label":"Official website"},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","route":"/institutions/trinity-st-jamess-cancer-institute/","field":"website"}]},{"url":"https://www.stjude.cloud","status":200,"ok":true,"finalUrl":"https://stjude.cloud/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"links","label":"St. Jude Cloud"}]},{"url":"https://www.stjude.org","status":200,"ok":true,"finalUrl":"https://www.stjude.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"links","label":"St. Jude Children's Research Hospital"},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"website"}]},{"url":"https://www.stjude.org/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","field":"links","label":"St. Jude Children's Research Hospital"},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","field":"profiles","label":"St. Jude Children's Research Hospital"}]},{"url":"https://www.stjude.org/global","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"idea-acc-childhood-medicines-platform-scale","kind":"idea","name":"Guaranteed-quality childhood cancer medicines free of charge in 50 countries","route":"/ideas/idea-acc-childhood-medicines-platform-scale/","field":"links","label":"St. Jude Global"}]},{"url":"https://www.stjude.org/treatment/clinical-trials.html","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","field":"links","label":"Clinical trials"}]},{"url":"https://www.stopbreastcancer.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","field":"links","label":"National Breast Cancer Coalition"},{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","field":"profiles","label":"National Breast Cancer Coalition"},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","field":"links","label":"National Breast Cancer Coalition"},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","field":"profiles","label":"National Breast Cancer Coalition"}]},{"url":"https://www.stradini.lv","status":200,"ok":true,"finalUrl":"https://www.stradini.lv/lv","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","field":"links","label":"Pauls Stradiņš Clinical University Hospital website"},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","field":"profiles","label":"Pauls Stradiņš Clinical University Hospital website"},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","field":"links","label":"Official website"},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","field":"website"}]},{"url":"https://www.strandtx.com","status":200,"ok":true,"finalUrl":"https://www.strandtx.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/","field":"links","label":"Official website"},{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/","field":"website"}]},{"url":"https://www.strandtx.com/articles","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/","field":"links","label":"News and articles (Series B and STX-001 data)"}]},{"url":"https://www.strataoncology.com","status":200,"ok":true,"finalUrl":"https://strataoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"strata-oncology","kind":"company","name":"Strata Oncology","route":"/companies/strata-oncology/","field":"links","label":"Official website"},{"id":"strata-oncology","kind":"company","name":"Strata Oncology","route":"/companies/strata-oncology/","field":"website"}]},{"url":"https://www.streck.com","status":200,"ok":true,"finalUrl":"https://www.streck.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"streck","kind":"company","name":"Streck","route":"/companies/streck/","field":"links","label":"Official website"},{"id":"streck","kind":"company","name":"Streck","route":"/companies/streck/","field":"website"}]},{"url":"https://www.stryker.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"stryker","kind":"company","name":"Stryker","route":"/companies/stryker/","field":"links","label":"Official website"},{"id":"stryker","kind":"company","name":"Stryker","route":"/companies/stryker/","field":"website"}]},{"url":"https://www.stryker.com/us/en/endoscopy/products/spy-phi.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/","field":"links","label":"Stryker: SPY fluorescence imaging"}]},{"url":"https://www.stvincents.ie","status":200,"ok":true,"finalUrl":"https://www.stvincents.ie/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"st-vincents-ucd-cancer-centre","kind":"institution","name":"St Vincent's University Hospital / UCD Cancer Centre","route":"/institutions/st-vincents-ucd-cancer-centre/","field":"links","label":"Official website"},{"id":"st-vincents-ucd-cancer-centre","kind":"institution","name":"St Vincent's University Hospital / UCD Cancer Centre","route":"/institutions/st-vincents-ucd-cancer-centre/","field":"website"}]},{"url":"https://www.stvincents.ie/st-vincents-cancer-expert-helps-shape-irelands-next-national-cancer-strategy-dr-david-fennelly-outlines-vision-for-a-nationally-coordinated-cancer-network-before-oireachtas-committee/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","field":"links","label":"Source: SVUH news article on Dr Fennelly's Oireachtas evidence (July 2026)"}]},{"url":"https://www.stvincents.ie/st-vincents-ucd-cancer-centre-awarded-european-recognition-for-excellence-in-cancer-care/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","field":"links","label":"Source: SVUH news article on OECI Cancer Centre designation (June 2026)"},{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","field":"profiles","label":"SVUH article on OECI designation naming the cancer services leadership"}]},{"url":"https://www.sumgenbio.com","status":200,"ok":true,"finalUrl":"https://www.sumgenbio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/","field":"links","label":"Official website"},{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/","field":"website"},{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","field":"links","label":"Sponsor page"}]},{"url":"https://www.sumitomo-pharma.com","status":200,"ok":true,"finalUrl":"https://www.sumitomo-pharma.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","route":"/companies/sumitomo-pharma/","field":"links","label":"Official website"},{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","route":"/companies/sumitomo-pharma/","field":"website"}],"archive":"https://web.archive.org/web/20260807102407/https://www.sumitomo-pharma.com/"},{"url":"https://www.sunnuclear.com","status":200,"ok":true,"finalUrl":"https://www.sunnuclear.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","route":"/companies/sun-nuclear/","field":"links","label":"Official website"},{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","route":"/companies/sun-nuclear/","field":"website"}]},{"url":"https://www.sunwaybio.com.cn","status":200,"ok":true,"finalUrl":"https://www.sunwaybio.com.cn/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","route":"/companies/shanghai-sunway-biotech/","field":"links","label":"Official website"},{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","route":"/companies/shanghai-sunway-biotech/","field":"website"}]},{"url":"https://www.supersalud.gob.cl/difusion/665/w3-propertyvalue-1962.html","status":200,"ok":true,"finalUrl":"https://www.superdesalud.gob.cl/tax-temas-de-orientacion/garantias-explicitas-en-salud-ges-1962/","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","field":"links","label":"Superintendencia de Salud (Chile): GES problem 26, preventive cholecystectomy at 35 to 49"},{"id":"prophylactic-cholecystectomy","kind":"term","name":"Prophylactic (preventive) cholecystectomy","route":"/terms/prophylactic-cholecystectomy/","field":"links","label":"Superintendencia de Salud: GES problem 26, preventive cholecystectomy at 35 to 49"},{"id":"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024","kind":"paper","name":"Gallbladder Cancer: Is It Time to Modify the Explicit Health Guarantees (GES) Program?","route":"/key-papers/paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024/","field":"links","label":"Superintendencia de Salud: GES problem 26, preventive cholecystectomy at 35 to 49"}]},{"url":"https://www.surgonc.org","status":200,"ok":true,"finalUrl":"https://surgonc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","route":"/institutions/sso/","field":"links","label":"SSO"},{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","route":"/institutions/sso/","field":"website"}]},{"url":"https://www.surgonc.org/about-sso/leadership/","status":200,"ok":true,"finalUrl":"https://surgonc.org/about-sso/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","field":"links","label":"Society page"},{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","field":"profiles","label":"Society page"},{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","field":"links","label":"Society page"},{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","field":"profiles","label":"Society page"}]},{"url":"https://www.sutrobio.com","status":200,"ok":true,"finalUrl":"https://www.sutrobio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/","field":"website"}]},{"url":"https://www.svhealthinvestors.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","field":"links","label":"Official website"},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","field":"website"}]},{"url":"https://www.svhealthinvestors.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","field":"links","label":"Portfolio"}]},{"url":"https://www.swissmedic.ch","status":200,"ok":true,"finalUrl":"https://www.swissmedic.ch/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","field":"links","label":"Swissmedic"},{"id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","field":"website"}]},{"url":"https://www.swissmedic.ch/swissmedic/en/home/about-us/organisation/management-board.html","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"vincenza-trivigno","kind":"person","name":"Vincenza Trivigno","route":"/people/vincenza-trivigno/","field":"links","label":"Source: Swissmedic Management Board page"},{"id":"vincenza-trivigno","kind":"person","name":"Vincenza Trivigno","route":"/people/vincenza-trivigno/","field":"profiles","label":"Swissmedic Management Board"}]},{"url":"https://www.swog.org","status":200,"ok":true,"finalUrl":"https://www.swog.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/","field":"links","label":"Official website"},{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/","field":"website"}]},{"url":"https://www.swog.org/about/leadership","status":200,"ok":true,"finalUrl":"https://www.swog.org/about/who-leads-swog-cancer-research-network","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"links","label":"SWOG leadership"},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","field":"profiles","label":"SWOG leadership"},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"links","label":"SWOG leadership"},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","field":"profiles","label":"SWOG leadership"},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"links","label":"SWOG leadership"},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","field":"profiles","label":"SWOG leadership"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"links","label":"SWOG leadership"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","field":"profiles","label":"SWOG leadership"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"links","label":"SWOG leadership"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","field":"profiles","label":"SWOG leadership"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"links","label":"SWOG leadership"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","field":"profiles","label":"SWOG leadership"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"links","label":"SWOG leadership"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","field":"profiles","label":"SWOG leadership"},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"links","label":"SWOG leadership"},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","field":"profiles","label":"SWOG leadership"}]},{"url":"https://www.sygehuslillebaelt.dk","status":200,"ok":true,"finalUrl":"https://sygehuslillebaelt.dk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"vejle-cancer-centre","kind":"institution","name":"Vejle Hospital Cancer Centre (Lillebaelt Hospital)","route":"/institutions/vejle-cancer-centre/","field":"links","label":"Official website"},{"id":"vejle-cancer-centre","kind":"institution","name":"Vejle Hospital Cancer Centre (Lillebaelt Hospital)","route":"/institutions/vejle-cancer-centre/","field":"website"}]},{"url":"https://www.synconaltd.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","field":"links","label":"Official website"},{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","field":"website"}]},{"url":"https://www.synconaltd.com/portfolio/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","field":"links","label":"Portfolio"}]},{"url":"https://www.syndax.com","status":200,"ok":true,"finalUrl":"https://syndax.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/","field":"links","label":"Official website"},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/","field":"website"}]},{"url":"https://www.syndevrx.com/","status":200,"ok":true,"finalUrl":"https://syndevrx.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"syndevrx","kind":"company","name":"SynDevRx","route":"/companies/syndevrx/","field":"links","label":"Official website"},{"id":"syndevrx","kind":"company","name":"SynDevRx","route":"/companies/syndevrx/","field":"website"}]},{"url":"https://www.synsorybio.com","status":200,"ok":true,"finalUrl":"https://www.synsorybio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/","field":"links","label":"Official website"},{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/","field":"website"}]},{"url":"https://www.systimmune.com","status":200,"ok":true,"finalUrl":"https://www.systimmune.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","field":"links","label":"Official website"},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","field":"website"}]},{"url":"https://www.sysucc.org.cn","status":200,"ok":true,"finalUrl":"https://www.sysucc.org.cn/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","field":"links","label":"Official website"},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","field":"website"},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","field":"profiles","label":"Sun Yat-sen University Cancer Center"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","field":"profiles","label":"Sun Yat-sen University Cancer Center"},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","field":"profiles","label":"Sun Yat-sen University Cancer Center"},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","field":"profiles","label":"Sun Yat-sen University Cancer Center"},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","field":"profiles","label":"Sun Yat-sen University Cancer Center"},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","field":"links","label":"Sun Yat-sen University Cancer Center"},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","field":"profiles","label":"Sun Yat-sen University Cancer Center"}],"archive":"https://web.archive.org/web/20260709121643/https://www.sysucc.org.cn/"},{"url":"https://www.szmc.org.il/eng/","status":200,"ok":true,"finalUrl":"https://www.szmc.org.il/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ofer-merin","kind":"person","name":"Ofer Merin","route":"/people/ofer-merin/","field":"links","label":"Institution profile"},{"id":"ofer-merin","kind":"person","name":"Ofer Merin","route":"/people/ofer-merin/","field":"profiles","label":"Institution profile"},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","field":"links","label":"Shaare Zedek Medical Center, Medical Genetics Institute"},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","field":"profiles","label":"Shaare Zedek Medical Center, Medical Genetics Institute"},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","field":"links","label":"Shaare Zedek Medical Center"},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","field":"profiles","label":"Shaare Zedek Medical Center"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"links","label":"Shaare Zedek Medical Center"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","field":"profiles","label":"Shaare Zedek Medical Center"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","field":"links","label":"Homepage"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","field":"website"}]},{"url":"https://www.tahoebio.ai/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/","field":"links","label":"Tahoe-100M single-cell perturbation atlas"}]},{"url":"https://www.taiho.co.jp/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","field":"links","label":"Official website"},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","field":"website"}]},{"url":"https://www.taiho.co.jp/en/release/2026/20260428.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/","field":"links","label":"ARC-02 phase 1"}]},{"url":"https://www.taihooncology.com","status":200,"ok":true,"finalUrl":"https://www.taihooncology.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/","field":"website"}]},{"url":"https://www.taihooncology.com/us/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.tailormed.com","status":200,"ok":true,"finalUrl":"https://www.tailormed.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","field":"links","label":"Official website"},{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","field":"website"}]},{"url":"https://www.tailormed.com/news-blogs/tailormed-and-flatiron-health-expand-oncology-access","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","field":"links","label":"Flatiron Health oncology partnership (May 2026)"}]},{"url":"https://www.tailormed.com/news-blogs/tailormed-raises-40-million-for-medical-cost-assistance","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","field":"links","label":"USD 40 million financing announcement (November 2024)"}]},{"url":"https://www.takara-bio.co.jp","status":200,"ok":true,"finalUrl":"https://www.takara-bio.co.jp/ja/index.html","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","field":"links","label":"Official website"},{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","field":"website"}]},{"url":"https://www.takara-bio.com","status":200,"ok":true,"finalUrl":"https://www.takara-bio.com/en/index.html","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","field":"links","label":"Sponsor page"},{"id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","field":"links","label":"Sponsor page"}]},{"url":"https://www.takeda.com","status":200,"ok":true,"finalUrl":"https://www.takeda.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/","field":"links","label":"Official website"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/","field":"website"}]},{"url":"https://www.takeda.com/science/research-and-development/partnerships/cei/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","route":"/companies/takeda-ventures/","field":"links","label":"Official website"},{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","route":"/companies/takeda-ventures/","field":"website"}]},{"url":"https://www.takedaoncology.com/newsroom/news-releases/2023/hutchmed-fresco2-lancet-results/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.tallactherapeutics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","field":"links","label":"Official website"},{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","field":"website"}]},{"url":"https://www.tallactherapeutics.com/news/fda-grants-fast-track-designation-to-tac-001/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","field":"links","label":"FDA Fast Track for TAC-001"}]},{"url":"https://www.tallactherapeutics.com/news/tallac-therapeutics-launches-with-62-million-in-series-a-financing-to-advance-novel-immunotherapies-for-cancer/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","field":"links","label":"Series A press release"}]},{"url":"https://www.tangotx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","field":"links","label":"Official website"},{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","field":"website"}]},{"url":"https://www.tangotx.com/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","field":"links","label":"Pipeline"}]},{"url":"https://www.tapur.org","status":200,"ok":true,"finalUrl":"https://www.asco.org/research-data/tapur-study","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","field":"links","label":"ASCO: TAPUR Study"}]},{"url":"https://www.tapur.org/","status":200,"ok":true,"finalUrl":"https://www.asco.org/research-data/tapur-study","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","route":"/ideas/idea-tr1-just-in-time-site-network/","field":"links","label":"ASCO TAPUR Study"},{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/","field":"links","label":"ASCO TAPUR"}]},{"url":"https://www.targetedonc.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","field":"links","label":"Targeted Oncology"},{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","field":"url"}]},{"url":"https://www.targetedonc.com/view/adjuvant-pembrolizumab-offers-improved-os-in-keynote-564-trial-of-ccrcc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","field":"outcomes.source (Overall survival (57-month follow-up))"}]},{"url":"https://www.targetedonc.com/view/avutometinib-plus-defactinib-gains-fda-approval-in-kras-ovarian-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","field":"outcomes.source (Objective response rate (KRAS-mutant))"},{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","field":"outcomes.source (Progression-free survival (KRAS-mutant))"},{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","field":"regulatoryEvents.source (2025-05-08)"}]},{"url":"https://www.targetedonc.com/view/fda-approves-nivolumab-plus-avd-for-classical-hodgkin-lymphoma","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","field":"links","label":"FDA approval (Mar 2026)"}]},{"url":"https://www.targetedonc.com/view/fda-passes-again-on-approving-rivoceranib-plus-camrelizumab-in-hcc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/","field":"links","label":"Targeted Oncology: third CRL"},{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","field":"regulatoryEvents.source (2026-07-23)"}]},{"url":"https://www.targetedonc.com/view/final-keynote-b96-analysis-confirms-survival-benefits-with-pembrolizumab-regimen-in-ovarian-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","field":"outcomes.source (Overall survival (all patients))"}]},{"url":"https://www.targetedonc.com/view/iza-bren-meets-pfs-and-os-end-points-in-phase-3-tnbc-trial","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","field":"links","label":"Targeted Oncology report"}]},{"url":"https://www.targetedonc.com/view/new-approaches-reshape-treatment-for-low-grade-serous-and-resistant-disease","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.tarpswg.org","status":200,"ok":true,"finalUrl":"https://tarpswg.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","field":"links","label":"TARPSWG"}]},{"url":"https://www.tasmc.org.il/en/aboutl/management/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","field":"links","label":"Source: Sourasky Executive Leadership page"},{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","field":"profiles","label":"Executive Leadership page"}]},{"url":"https://www.tasmc.org.il/sites/en/","status":200,"ok":true,"finalUrl":"https://www.tasmc.org.il/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","field":"links","label":"Homepage"},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","field":"website"}]},{"url":"https://www.tatatrusts.org","status":200,"ok":true,"finalUrl":"https://www.tatatrusts.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","route":"/institutions/tata-trusts/","field":"website"}]},{"url":"https://www.tatatrusts.org/about-tatatrusts/our-history/our-history-1907-2000","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dorabji-tata","kind":"person","name":"Sir Dorabji Tata","route":"/people/dorabji-tata/","field":"links","label":"Tata Trusts: our history 1907-2000"},{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","route":"/institutions/tata-trusts/","field":"links","label":"Tata Trusts history 1907-2000"}]},{"url":"https://www.tatatrusts.org/our-work/healthcare/cancer-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ratan-tata","kind":"person","name":"Ratan Tata","route":"/people/ratan-tata/","field":"links","label":"Tata Trusts: cancer care"},{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","route":"/institutions/tata-trusts/","field":"links","label":"Tata Trusts: cancer care"}]},{"url":"https://www.tayscancercentre.fi/contacts/","status":200,"ok":true,"finalUrl":"https://www.tayssyopakeskus.fi/en/tays-cancer-centre/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"annika-auranen","kind":"person","name":"Annika Auranen","route":"/people/annika-auranen/","field":"links","label":"Source: Tays Cancer Centre contacts page naming the Director"},{"id":"annika-auranen","kind":"person","name":"Annika Auranen","route":"/people/annika-auranen/","field":"profiles","label":"Tays Cancer Centre contacts page"}]},{"url":"https://www.tballiance.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/","field":"links","label":"TB Alliance"}]},{"url":"https://www.technion.ac.il/en/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"links","label":"Technion"},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","field":"profiles","label":"Technion"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"links","label":"Technion"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","field":"profiles","label":"Technion"},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","field":"links","label":"Technion homepage"},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","field":"website"}]},{"url":"https://www.techscience.com/journal/or","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/","field":"links","label":"Homepage"},{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/","field":"url"}]},{"url":"https://www.teclison.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/","field":"links","label":"Official website"},{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/","field":"website"}]},{"url":"https://www.teenagecancertrust.org","status":200,"ok":true,"finalUrl":"https://www.teenagecancertrust.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"teenage-cancer-trust","kind":"institution","name":"Teenage Cancer Trust","route":"/institutions/teenage-cancer-trust/","field":"website"}]},{"url":"https://www.teenagecancertrust.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","field":"links","label":"Teenage Cancer Trust"},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","field":"profiles","label":"Teenage Cancer Trust"},{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","field":"links","label":"Teenage Cancer Trust"},{"id":"teenage-cancer-trust","kind":"institution","name":"Teenage Cancer Trust","route":"/institutions/teenage-cancer-trust/","field":"links","label":"Teenage Cancer Trust"}]},{"url":"https://www.templehealth.org/about/leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","route":"/people/robert-uzzo/","field":"links","label":"Source: Temple University Health System leadership directory"},{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","route":"/people/robert-uzzo/","field":"profiles","label":"Temple Health leadership directory"}]},{"url":"https://www.terrapower.com/isotopes","status":200,"ok":true,"finalUrl":"https://www.terrapower.com/isotopes/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","field":"links","label":"Official website"},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","field":"website"}]},{"url":"https://www.tersera.com","status":200,"ok":true,"finalUrl":"https://tersera.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tersera-therapeutics","kind":"company","name":"TerSera Therapeutics","route":"/companies/tersera-therapeutics/","field":"links","label":"Official website"},{"id":"tersera-therapeutics","kind":"company","name":"TerSera Therapeutics","route":"/companies/tersera-therapeutics/","field":"website"}]},{"url":"https://www.terumobct.com","status":200,"ok":true,"finalUrl":"https://www.terumobct.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/","field":"links","label":"Official website"},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/","field":"website"}]},{"url":"https://www.tevapharm.com","status":200,"ok":true,"finalUrl":"https://www.tevapharm.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/","field":"links","label":"Official website"},{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/","field":"website"}]},{"url":"https://www.texaschildrens.org/departments/cancer-and-hematology-center","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/","field":"links","label":"Texas Children's Cancer and Hematology Center"},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/","field":"website"}]},{"url":"https://www.texaschildrens.org/departments/cancer-and-hematology-center/our-leadership","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","field":"links","label":"Institution profile"},{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.tfri.ca","status":200,"ok":true,"finalUrl":"https://www.tfri.ca/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"terry-fox-research-institute","kind":"institution","name":"Terry Fox Research Institute","route":"/institutions/terry-fox-research-institute/","field":"links","label":"Official website"},{"id":"terry-fox-research-institute","kind":"institution","name":"Terry Fox Research Institute","route":"/institutions/terry-fox-research-institute/","field":"website"}]},{"url":"https://www.tfri.ca/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","route":"/institutions/terry-fox-foundation/","field":"links","label":"Terry Fox Research Institute"}]},{"url":"https://www.tfri.ca/about/team","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","field":"links","label":"Source: TFRI team page"}]},{"url":"https://www.tfri.ca/about/team/bio/jim-woodgett","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","field":"links","label":"Source: TFRI leadership biography"},{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","field":"profiles","label":"TFRI biography"}]},{"url":"https://www.tgtherapeutics.com","status":200,"ok":true,"finalUrl":"https://www.tgtherapeutics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","field":"links","label":"Official website"},{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","field":"website"}]},{"url":"https://www.theglobalfund.org/","status":200,"ok":true,"finalUrl":"https://www.theglobalfund.org/en/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/","field":"links","label":"The Global Fund"}]},{"url":"https://www.themednet.org","status":200,"ok":true,"finalUrl":"https://www.themednet.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mednet","kind":"company","name":"Mednet (theMednet)","route":"/companies/mednet/","field":"links","label":"Official website"},{"id":"mednet","kind":"company","name":"Mednet (theMednet)","route":"/companies/mednet/","field":"website"}]},{"url":"https://www.theolytics.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"theolytics","kind":"company","name":"Theolytics","route":"/companies/theolytics/","field":"links","label":"Official website"},{"id":"theolytics","kind":"company","name":"Theolytics","route":"/companies/theolytics/","field":"website"}]},{"url":"https://www.therapanacea.eu","status":200,"ok":true,"finalUrl":"https://therapanacea.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"therapanacea","kind":"company","name":"TheraPanacea","route":"/companies/therapanacea/","field":"links","label":"Official website"},{"id":"therapanacea","kind":"company","name":"TheraPanacea","route":"/companies/therapanacea/","field":"website"}]},{"url":"https://www.therapixel.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","field":"links","label":"Official website"},{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","field":"website"}]},{"url":"https://www.therapixel.com/category/press-release/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","field":"links","label":"Press releases"}]},{"url":"https://www.therapixel.com/therapixel-announces-close-of-15-me-series-b-financing/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","field":"links","label":"Series B press release (May 2022)"}]},{"url":"https://www.therapixel.com/therapixel-receives-fda-510k-clearance-for-mammoscreen/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","field":"links","label":"FDA 510(k) clearance for MammoScreen (Jul 2020)"}]},{"url":"https://www.thermofisher.com","status":200,"ok":true,"finalUrl":"https://www.thermofisher.com/us/en/home.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/","field":"links","label":"Official website"},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/","field":"website"}]},{"url":"https://www.thermofisher.com/uk/en/home/clinical/diagnostic-testing/condition-disease-diagnostics/oncology-diagnostics/oncomine-dx-target-test.html","status":200,"ok":true,"finalUrl":"https://www.thermofisher.com/us/en/home/clinical/diagnostic-testing/condition-disease-diagnostics/oncology-diagnostics/oncomine-dx-target-test/oncomine-dx-target-test-us-only.html","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncomine-dx-target-test","kind":"drug","name":"Oncomine Dx Target Test","route":"/drugs/oncomine-dx-target-test/","field":"links","label":"Thermo Fisher: Oncomine Dx Target Test"}]},{"url":"https://www.theryq-alcen.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","field":"links","label":"Official website"},{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","field":"website"}]},{"url":"https://www.theryq-alcen.com/about-theryq/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","field":"links","label":"About THERYQ"}]},{"url":"https://www.theryq-alcen.com/flash-radiotherapy-products/flashdeep/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","field":"links","label":"FLASHDEEP product and France 2030 funding"}]},{"url":"https://www.thesgc.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","field":"links","label":"Structural Genomics Consortium"},{"id":"idea-bio1-undruggable-open-consortium","kind":"idea","name":"A precompetitive consortium for the twenty hardest cancer targets","route":"/ideas/idea-bio1-undruggable-open-consortium/","field":"links","label":"Structural Genomics Consortium"},{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","route":"/ideas/idea-fund-academic-adc-bispecific-platform/","field":"links","label":"Structural Genomics Consortium"},{"id":"idea-fund-precompetitive-undruggable-consortium","kind":"idea","name":"An open-science consortium on the undruggable drivers, open until a candidate","route":"/ideas/idea-fund-precompetitive-undruggable-consortium/","field":"links","label":"Structural Genomics Consortium"}]},{"url":"https://www.thewisdomstudy.org","status":200,"ok":true,"finalUrl":"https://www.thewisdomstudy.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/","field":"links","label":"WISDOM study"}]},{"url":"https://www.thirdrockventures.com","status":200,"ok":true,"finalUrl":"https://www.thirdrockventures.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/","field":"links","label":"Official website"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/","field":"website"}]},{"url":"https://www.thirdrockventures.com/portfolio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/","field":"links","label":"Portfolio"}]},{"url":"https://www.thymecare.com","status":200,"ok":true,"finalUrl":"https://www.thymecare.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","field":"links","label":"Official website"},{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","field":"website"}]},{"url":"https://www.thyroid.org/professionals/ata-professional-guidelines/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"dosing.source"},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"toxicity.source (Sialadenitis / xerostomia)"},{"id":"papillary-thyroid-cancer","kind":"cancer","name":"Papillary thyroid cancer","route":"/cancers/papillary-thyroid-cancer/","field":"links","label":"American Thyroid Association guidelines"}]},{"url":"https://www.tidepharm.com","status":200,"ok":true,"finalUrl":"https://www.tidepharm.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","field":"website"}]},{"url":"https://www.tilsinbreastcancer.org","status":200,"ok":true,"finalUrl":"https://www.tilsinbreastcancer.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/","field":"links","label":"TILs in breast cancer prognostic model"}]},{"url":"https://www.tiltbio.com/","status":200,"ok":true,"finalUrl":"https://tiltbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","route":"/companies/tilt-biotherapeutics/","field":"links","label":"Official website"},{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","route":"/companies/tilt-biotherapeutics/","field":"website"}]},{"url":"https://www.timetoscreen.nz/","status":200,"ok":true,"finalUrl":"https://www.healthnz.govt.nz/health-topics/keeping-healthy/cancer-screening","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","route":"/collections/nz-time-to-screen/","field":"links","label":"Time to Screen (New Zealand national screening)"},{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","route":"/collections/nz-time-to-screen/","field":"url"}]},{"url":"https://www.tiumbio.com","status":200,"ok":true,"finalUrl":"https://www.tiumbio.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/","field":"links","label":"Official website"},{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/","field":"website"}]},{"url":"https://www.tjbio.com","status":200,"ok":true,"finalUrl":"https://www.tjbio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","field":"website"}]},{"url":"https://www.tjrbiosciences.com","status":200,"ok":true,"finalUrl":"https://www.tjrbiosciences.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/","field":"links","label":"Official website"},{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/","field":"website"},{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/","field":"links","label":"Sponsor page"}]},{"url":"https://www.tnimc.ru","status":200,"ok":true,"finalUrl":"https://www.tnimc.ru/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","route":"/institutions/tomsk-cancer-research-institute/","field":"links","label":"Tomsk National Research Medical Centre"}]},{"url":"https://www.tolmar.com","status":200,"ok":true,"finalUrl":"https://tolmar.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/","field":"links","label":"Official website"},{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/","field":"website"}]},{"url":"https://www.toray.com","status":200,"ok":true,"finalUrl":"https://www.toray.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/","field":"links","label":"Sponsor page"}]},{"url":"https://www.toray.com/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"toray-industries","kind":"company","name":"Toray Industries","route":"/companies/toray-industries/","field":"links","label":"Official website"},{"id":"toray-industries","kind":"company","name":"Toray Industries","route":"/companies/toray-industries/","field":"website"}]},{"url":"https://www.touchlight.com","status":200,"ok":true,"finalUrl":"https://touchlight.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/","field":"links","label":"Official website"},{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/","field":"website"}]},{"url":"https://www.tourde4.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","route":"/people/chris-hoy/","field":"links","label":"Tour de 4"}]},{"url":"https://www.tourde4.com/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","route":"/people/chris-hoy/","field":"links","label":"Tour de 4: about"}]},{"url":"https://www.tradewindbio.com","status":200,"ok":true,"finalUrl":"https://tradewindbio.com/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/","field":"links","label":"Official website"},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/","field":"website"}]},{"url":"https://www.transceleratebiopharmainc.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr1-open-protocol-and-sap-library","kind":"idea","name":"Open-source protocol and statistical analysis plan templates with runnable code","route":"/ideas/idea-tr1-open-protocol-and-sap-library/","field":"links","label":"TransCelerate BioPharma"},{"id":"idea-fund-standard-combination-agreement","kind":"idea","name":"A regulator-endorsed standard contract for inter-company combination trials","route":"/ideas/idea-fund-standard-combination-agreement/","field":"links","label":"TransCelerate BioPharma"}]},{"url":"https://www.transcenta.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"transcenta","kind":"company","name":"Transcenta","route":"/companies/transcenta/","field":"links","label":"Official website"},{"id":"transcenta","kind":"company","name":"Transcenta","route":"/companies/transcenta/","field":"website"}]},{"url":"https://www.transgene.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","field":"links","label":"Official website"},{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","field":"website"}]},{"url":"https://www.transgene.com/wp-content/uploads/20260902_TG4050_NatCom_EN.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","field":"links","label":"TG4050 three-year disease-free survival and Nature Communications publication"}]},{"url":"https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf","status":200,"ok":true,"contentType":"application/pdf","checked":"2026-09-30","refs":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","field":"links","label":"Fundraising of about EUR 105 million (November 2025)"}]},{"url":"https://www.translatum.tum.de","status":200,"ok":true,"finalUrl":"https://www.translatum.tum.de/translatum/startseite/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"TranslaTUM"}]},{"url":"https://www.trasis.com","status":200,"ok":true,"finalUrl":"https://www.trasis.com/","checked":"2026-09-30","refs":[{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","field":"links","label":"Official website"},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","field":"website"}]},{"url":"https://www.triallibrary.com","status":200,"ok":true,"finalUrl":"https://www.triallibrary.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","field":"links","label":"Official website"},{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","field":"website"}]},{"url":"https://www.triallibrary.com/about","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","field":"links","label":"About Trial Library"}]},{"url":"https://www.triallibrary.com/blog/press-release-conversational-ai-trial-search-launch","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","field":"links","label":"Conversational AI Trial Search press release (May 2026)"}]},{"url":"https://www.triallibrary.com/blog/weve-raised-10-million-to-expand-access-to-clinical-trials-as-a-care-option-cw3l6","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","field":"links","label":"Series A announcement (December 2025)"}]},{"url":"https://www.trianabio.com/pipeline","status":200,"ok":true,"finalUrl":"https://trianabio.com/pipeline","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","field":"links","label":"Sponsor pipeline page"}]},{"url":"https://www.triumvira.com/","status":200,"ok":true,"finalUrl":"https://triumvira.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/","field":"links","label":"Official website"},{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/","field":"website"}]},{"url":"https://www.trog.com.au","status":200,"ok":true,"finalUrl":"https://trog.com.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/","field":"links","label":"TROG"},{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/","field":"website"}]},{"url":"https://www.trog.com.au/trials","status":200,"ok":true,"finalUrl":"https://trog.com.au/trials/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/","field":"links","label":"Trials"}]},{"url":"https://www.trx.com.tw","status":200,"ok":true,"finalUrl":"https://www.trx.com.tw/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/","field":"links","label":"Official website"},{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/","field":"website"}]},{"url":"https://www.tumorzentrum.insel.ch","status":200,"ok":true,"finalUrl":"https://tumorzentrum.insel.ch/de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"Tumorzentrum Inselspital"},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"website"}]},{"url":"https://www.tumorzentrum.insel.ch/de/ueber-uns/organisation","status":200,"ok":true,"finalUrl":"https://tumorzentrum.insel.ch/de/ueber-uns/organisation","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","field":"links","label":"Institution profile"},{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","field":"profiles","label":"Institution profile"},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","field":"links","label":"Institution profile"},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.tykmedicines.com","status":200,"ok":true,"finalUrl":"https://www.tykmedicines.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","route":"/companies/tyk-medicines/","field":"links","label":"Official website"},{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","route":"/companies/tyk-medicines/","field":"website"}]},{"url":"https://www.uab.edu/onealcancercenter/","status":200,"ok":true,"finalUrl":"https://www.onealcanceruab.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","field":"links","label":"O'Neal Comprehensive Cancer Center"},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","field":"website"}]},{"url":"https://www.uab.edu/onealcancercenter/patient-care/clinical-trials","status":200,"ok":true,"finalUrl":"https://www.onealcanceruab.org/patients-caregivers/clinical-trials/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","field":"links","label":"Clinical trials"}]},{"url":"https://www.uaem.org/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/","field":"links","label":"Universities Allied for Essential Medicines"}]},{"url":"https://www.ualberta.ca","status":200,"ok":true,"finalUrl":"https://www.ualberta.ca/en/index.html","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","route":"/institutions/university-of-alberta/","field":"links","label":"University of Alberta"},{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","route":"/institutions/university-of-alberta/","field":"website"}]},{"url":"https://www.ubivac.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"ubivac","kind":"company","name":"UbiVac","route":"/companies/ubivac/","field":"links","label":"Official website"},{"id":"ubivac","kind":"company","name":"UbiVac","route":"/companies/ubivac/","field":"website"}]},{"url":"https://www.ucas.ac.cn","status":200,"ok":true,"finalUrl":"https://www.ucas.ac.cn/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","field":"links","label":"University of Chinese Academy of Sciences"}]},{"url":"https://www.ucb.com","status":200,"ok":true,"finalUrl":"https://www.ucb.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","field":"links","label":"Official website"},{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","field":"website"}]},{"url":"https://www.uchicagomedicine.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","field":"links","label":"University of Chicago Medicine"},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","field":"profiles","label":"University of Chicago Medicine"}]},{"url":"https://www.uchicagomedicine.org/cancer/about-us/leadership","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","field":"links","label":"Institution profile"},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","field":"profiles","label":"Institution profile"},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","field":"links","label":"Institution profile"},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.uck.pl/","status":200,"ok":true,"finalUrl":"https://uck.pl/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","field":"links","label":"University Clinical Centre, Gdańsk website"},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","field":"profiles","label":"University Clinical Centre, Gdańsk website"}]},{"url":"https://www.ucl.ac.uk/cancer","status":200,"ok":true,"finalUrl":"https://www.ucl.ac.uk/medical-sciences/divisions/cancer","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","field":"links","label":"UCL Cancer Institute"}]},{"url":"https://www.ucl.ac.uk/child-health/","status":200,"ok":true,"finalUrl":"https://www.ucl.ac.uk/population-health-sciences/child-health","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","field":"links","label":"UCL GOS Institute of Child Health"}]},{"url":"https://www.uclahealth.org/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","field":"links","label":"Official website"},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","field":"website"}]},{"url":"https://www.uclahealth.org/providers?q=Amar%20U.%20Kishan","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"links","label":"UCLA profile"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Antoni%20Ribas","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"links","label":"UCLA profile"},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Dennis%20J.%20Slamon","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"links","label":"UCLA profile"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"UCLA profile"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"UCLA profile"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Michael%20A.%20Teitell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"links","label":"UCLA profile"},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Owen%20N.%20Witte","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"links","label":"UCLA profile"},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclh.nhs.uk/our-services/find-consultant/professor-john-bridgewater","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","route":"/people/john-bridgewater/","field":"links","label":"UCLH consultant page"},{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","route":"/people/john-bridgewater/","field":"profiles","label":"UCLH consultant page"}]},{"url":"https://www.uclh.nhs.uk/our-services/find-service/cancer-services","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","field":"links","label":"UCLH cancer services"},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","field":"website"}]},{"url":"https://www.ucsf.edu/news/2017/01/405476/largest-ever-gift-ucsf-honors-philanthropist-helen-diller","status":200,"ok":true,"finalUrl":"https://www.ucsf.edu/news/2017/01/405476/archive-largest-ever-gift-ucsf-honors-philanthropist-helen-diller","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"helen-diller","kind":"person","name":"Helen Diller","route":"/people/helen-diller/","field":"links","label":"UCSF: largest-ever gift honours Helen Diller (2017)"}]},{"url":"https://www.ucsf.edu/news/2025/05/430061/gift-launches-200-million-initiative-weill-cancer-hub-west","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","route":"/people/sanford-weill/","field":"links","label":"UCSF: gift launches $200 million Weill Cancer Hub West (2025)"}]},{"url":"https://www.uct-frankfurt.de","status":200,"ok":true,"finalUrl":"https://www.uct-frankfurt.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","field":"links","label":"Homepage"},{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","field":"website"}],"archive":"https://web.archive.org/web/20260421044630/https://www.uct-frankfurt.de/"},{"url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","field":"links","label":"Institution profile"},{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","field":"profiles","label":"Institution profile"},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"links","label":"Institution profile"},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","field":"profiles","label":"Institution profile"},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","field":"links","label":"Institution profile"},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","field":"profiles","label":"Institution profile"}],"archive":"https://web.archive.org/web/20260514132324/https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"url":"https://www.uhb.nhs.uk/about/trust-management/bod/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"jonathan-brotherton","kind":"person","name":"Jonathan Brotherton","route":"/people/jonathan-brotherton/","field":"links","label":"Source: UHB Board of Directors page"},{"id":"jonathan-brotherton","kind":"person","name":"Jonathan Brotherton","route":"/people/jonathan-brotherton/","field":"profiles","label":"UHB Board of Directors"}]},{"url":"https://www.uhb.nhs.uk/services/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","field":"links","label":"UHB cancer services"},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","field":"website"}]},{"url":"https://www.uhbw.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.uhbw.nhs.uk/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bristol-haematology-oncology-centre","kind":"institution","name":"Bristol Haematology and Oncology Centre","route":"/institutions/bristol-haematology-oncology-centre/","field":"links","label":"Official website"},{"id":"bristol-haematology-oncology-centre","kind":"institution","name":"Bristol Haematology and Oncology Centre","route":"/institutions/bristol-haematology-oncology-centre/","field":"website"}]},{"url":"https://www.uhcw.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uhcw-coventry","kind":"institution","name":"University Hospital Coventry","route":"/institutions/uhcw-coventry/","field":"links","label":"University Hospitals Coventry and Warwickshire"},{"id":"uhcw-coventry","kind":"institution","name":"University Hospital Coventry","route":"/institutions/uhcw-coventry/","field":"website"}]},{"url":"https://www.uhhospitals.org/services/cancer-services","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","field":"links","label":"UH Seidman Cancer Center"}]},{"url":"https://www.uhleicester.nhs.uk/about/board/members/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"richard-mitchell","kind":"person","name":"Richard Mitchell","route":"/people/richard-mitchell/","field":"links","label":"Source: University Hospitals of Leicester NHS Trust board members page"},{"id":"richard-mitchell","kind":"person","name":"Richard Mitchell","route":"/people/richard-mitchell/","field":"profiles","label":"UHL Trust Board members page"}]},{"url":"https://www.uhliverpool.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/","field":"website"}]},{"url":"https://www.uhliverpool.nhs.uk/services/service-finder/hepatobiliary-surgery","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/","field":"links","label":"Hepatobiliary surgery"}]},{"url":"https://www.uhn.ca/PrincessMargaret","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","field":"links","label":"Official website"},{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","field":"website"},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","field":"links","label":"Princess Margaret"},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","field":"profiles","label":"Princess Margaret"}]},{"url":"https://www.uhnm.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"royal-stoke-uhnm","kind":"institution","name":"Royal Stoke University Hospital","route":"/institutions/royal-stoke-uhnm/","field":"links","label":"University Hospitals of North Midlands"},{"id":"royal-stoke-uhnm","kind":"institution","name":"Royal Stoke University Hospital","route":"/institutions/royal-stoke-uhnm/","field":"website"}]},{"url":"https://www.uhs.nhs.uk/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","field":"links","label":"UHS cancer services (page moved; nearest live section)"},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","field":"website"}]},{"url":"https://www.uhs.nhs.uk/for-patients/find-your-consultant/dr-ellen-copson","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ellen-copson","kind":"person","name":"Ellen Copson","route":"/people/ellen-copson/","field":"links","label":"University Hospital Southampton consultant page"},{"id":"ellen-copson","kind":"person","name":"Ellen Copson","route":"/people/ellen-copson/","field":"profiles","label":"University Hospital Southampton consultant page"}]},{"url":"https://www.uicc.org","status":200,"ok":true,"finalUrl":"https://www.uicc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"links","label":"Union for International Cancer Control"},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","field":"profiles","label":"Union for International Cancer Control"},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","field":"links","label":"UICC"},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","field":"website"}]},{"url":"https://www.uicc.org/mr-cary-adams-ceo","status":200,"ok":true,"finalUrl":"https://www.uicc.org/who-we-are/governance/chief-executive-officer-ceo","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cary-adams","kind":"person","name":"Cary Adams","route":"/people/cary-adams/","field":"profiles","label":"UICC biography"}]},{"url":"https://www.uicc.org/news-and-updates/25-7-announcements/9th-edition-uicc-tnm-classification-malignant-tumours-now-available","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"UICC: the 9th edition of the TNM classification of malignant tumours, published 3 July 2025 and recommended to take effect from 1 January 2026"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","field":"links","label":"UICC: the 9th edition of the TNM classification of malignant tumours, published 3 July 2025 and recommended to take effect from 1 January 2026"}]},{"url":"https://www.uicc.org/resources/tnm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","field":"links","label":"TNM"}]},{"url":"https://www.uicc.org/what-we-do/sharing-knowledge/tnm","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","field":"links","label":"UICC: TNM Classification of Malignant Tumours, 9th edition, recommended to take effect from 1 January 2026"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","field":"links","label":"UICC: TNM Classification of Malignant Tumours, 9th edition, recommended to take effect from 1 January 2026"}]},{"url":"https://www.uk-koeln.de","status":200,"ok":true,"finalUrl":"https://www.uk-koeln.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/","field":"links","label":"Official website"},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/","field":"website"}]},{"url":"https://www.uke.de","status":200,"ok":true,"finalUrl":"https://www.uke.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","field":"links","label":"Official website"},{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","field":"website"}]},{"url":"https://www.ukradon.org/information/ukmaps","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"radon","kind":"term","name":"Radon","route":"/terms/radon/","field":"links","label":"UKradon: radon maps of the United Kingdom (UK Health Security Agency)"}]},{"url":"https://www.ukw.de","status":200,"ok":true,"finalUrl":"https://www.ukw.de/startseite/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"Universitätsklinikum Würzburg"}]},{"url":"https://www.ultimagenomics.com","status":200,"ok":true,"finalUrl":"https://www.ultimagenomics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","field":"links","label":"Official website"},{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","field":"website"}]},{"url":"https://www.umcutrecht.nl/en","status":200,"ok":true,"checked":"2026-09-30","refs":[{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","field":"links","label":"Homepage"},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","field":"website"}]},{"url":"https://www.umgccc.org","status":200,"ok":true,"finalUrl":"https://www.umms.org/umgccc","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","field":"links","label":"Greenebaum Comprehensive Cancer Center"},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","field":"website"}]},{"url":"https://www.ummc.edu.my","status":200,"ok":true,"finalUrl":"https://www.ummc.edu.my/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","field":"links","label":"UMMC"},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","field":"website"}]},{"url":"https://www.ummc.edu.my/ummc/principal-officer.asp","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","field":"links","label":"Source: UMMC Principal Officers page"},{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","field":"profiles","label":"UMMC Principal Officers"}]},{"url":"https://www.umms.org/umgccc/about/director-welcome","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","field":"links","label":"Source: UMGCCC Director's Welcome page"},{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","field":"profiles","label":"UMGCCC Director's Welcome"}]},{"url":"https://www.umoja-biopharma.com","status":200,"ok":true,"finalUrl":"https://www.umoja-biopharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","field":"website"}]},{"url":"https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","field":"links","label":"UB-VV400 IND clearance"}]},{"url":"https://www.unicancer.fr","status":200,"ok":true,"finalUrl":"https://www.unicancer.fr/fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","field":"links","label":"UNICANCER"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","field":"links","label":"UNICANCER"},{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/","field":"links","label":"Official website"},{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/","field":"website"}]},{"url":"https://www.unicancer.fr/","status":200,"ok":true,"finalUrl":"https://www.unicancer.fr/fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","field":"links","label":"UNICANCER"},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","field":"profiles","label":"UNICANCER"}]},{"url":"https://www.unicancer.fr/en/the-centres/","status":200,"ok":true,"finalUrl":"https://www.unicancer.fr/fr/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/","field":"links","label":"UNICANCER: the centres"}]},{"url":"https://www.uniklinik-duesseldorf.de","status":200,"ok":true,"finalUrl":"https://www.uniklinik-duesseldorf.de/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","field":"links","label":"Homepage"},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","field":"website"}]},{"url":"https://www.uniklinik-duesseldorf.de/ueber-das-ukd/unternehmen/vorstand","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","field":"links","label":"Institution profile"},{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","field":"profiles","label":"Institution profile"},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","field":"links","label":"Institution profile"},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.uniklinik-freiburg.de","status":200,"ok":true,"finalUrl":"https://www.uniklinik-freiburg.de/de.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","field":"links","label":"Medical Center Freiburg"}]},{"url":"https://www.uniklinik-freiburg.de/cccf.html","status":200,"ok":true,"finalUrl":"https://www.uniklinik-freiburg.de/cccf/onkologisches-spitzenzentrum.html","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","field":"links","label":"Homepage"},{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","field":"website"}]},{"url":"https://www.uniklinik-freiburg.de/cccf/ueber-uns/leitung.html","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/","field":"links","label":"Source: CCCF leadership page"},{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/","field":"profiles","label":"Institution leadership page"}]},{"url":"https://www.uniklinik-ulm.de","status":200,"ok":true,"finalUrl":"https://www.uniklinik-ulm.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ulm-university-hospital","kind":"institution","name":"Ulm University Hospital / Comprehensive Cancer Center Ulm","route":"/institutions/ulm-university-hospital/","field":"links","label":"Universitätsklinikum Ulm"},{"id":"ulm-university-hospital","kind":"institution","name":"Ulm University Hospital / Comprehensive Cancer Center Ulm","route":"/institutions/ulm-university-hospital/","field":"website"}]},{"url":"https://www.uniklinikum-leipzig.de","status":200,"ok":true,"finalUrl":"https://www.uniklinikum-leipzig.de/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","route":"/institutions/university-hospital-leipzig/","field":"links","label":"Universitätsklinikum Leipzig"},{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","route":"/institutions/university-hospital-leipzig/","field":"website"}]},{"url":"https://www.unimedizin-mainz.de/uct","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","field":"links","label":"Institution profile"},{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","field":"profiles","label":"Institution profile"},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","field":"links","label":"UCT Mainz"},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","field":"website"}]},{"url":"https://www.unipi.it","status":200,"ok":true,"finalUrl":"https://www.unipi.it/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","route":"/institutions/university-of-pisa/","field":"links","label":"Università di Pisa"},{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","route":"/institutions/university-of-pisa/","field":"website"}]},{"url":"https://www.uniprot.org/uniprotkb/A0MZ66/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shtn1","kind":"target","name":"SHTN1","route":"/targets/shtn1/","field":"links","label":"UniProt A0MZ66"}]},{"url":"https://www.uniprot.org/uniprotkb/A1KZ92/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pxdnl","kind":"target","name":"PXDNL","route":"/targets/pxdnl/","field":"links","label":"UniProt A1KZ92"}]},{"url":"https://www.uniprot.org/uniprotkb/A5LHX3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/","field":"links","label":"UniProt A5LHX3"}]},{"url":"https://www.uniprot.org/uniprotkb/A6NJY4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem238l","kind":"target","name":"TMEM238L","route":"/targets/tmem238l/","field":"links","label":"UniProt A6NJY4"}]},{"url":"https://www.uniprot.org/uniprotkb/A6NKB5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcnx2","kind":"target","name":"PCNX2","route":"/targets/pcnx2/","field":"links","label":"UniProt A6NKB5"}]},{"url":"https://www.uniprot.org/uniprotkb/A6NKT7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgpd3","kind":"target","name":"RGPD3","route":"/targets/rgpd3/","field":"links","label":"UniProt A6NKT7"}]},{"url":"https://www.uniprot.org/uniprotkb/A6NMZ7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col6a6","kind":"target","name":"COL6A6","route":"/targets/col6a6/","field":"links","label":"UniProt A6NMZ7"}]},{"url":"https://www.uniprot.org/uniprotkb/A6NNL0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm2b","kind":"target","name":"NUTM2B","route":"/targets/nutm2b/","field":"links","label":"UniProt A6NNL0"}]},{"url":"https://www.uniprot.org/uniprotkb/B2CW77/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klln","kind":"target","name":"KLLN","route":"/targets/klln/","field":"links","label":"UniProt B2CW77"}]},{"url":"https://www.uniprot.org/uniprotkb/B7Z6K7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf814","kind":"target","name":"ZNF814","route":"/targets/znf814/","field":"links","label":"UniProt B7Z6K7"}]},{"url":"https://www.uniprot.org/uniprotkb/C0HM02/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkch","kind":"target","name":"PRKCH","route":"/targets/prkch/","field":"links","label":"UniProt C0HM02"}]},{"url":"https://www.uniprot.org/uniprotkb/E9PAV3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naca","kind":"target","name":"NACA","route":"/targets/naca/","field":"links","label":"UniProt E9PAV3"}]},{"url":"https://www.uniprot.org/uniprotkb/O00141/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sgk1","kind":"target","name":"SGK1","route":"/targets/sgk1/","field":"links","label":"UniProt O00141"}]},{"url":"https://www.uniprot.org/uniprotkb/O00182/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lgals9","kind":"target","name":"Galectin-9 (LGALS9)","route":"/targets/lgals9/","field":"links","label":"UniProt O00182"}]},{"url":"https://www.uniprot.org/uniprotkb/O00203/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ap3b1","kind":"target","name":"AP3B1","route":"/targets/ap3b1/","field":"links","label":"UniProt O00203"}]},{"url":"https://www.uniprot.org/uniprotkb/O00221/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbie","kind":"target","name":"NFKBIE","route":"/targets/nfkbie/","field":"links","label":"UniProt O00221"}]},{"url":"https://www.uniprot.org/uniprotkb/O00231/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/","field":"links","label":"UniProt O00231"}]},{"url":"https://www.uniprot.org/uniprotkb/O00232/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/","field":"links","label":"UniProt O00232"}]},{"url":"https://www.uniprot.org/uniprotkb/O00291/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hip1","kind":"target","name":"HIP1","route":"/targets/hip1/","field":"links","label":"UniProt O00291"}]},{"url":"https://www.uniprot.org/uniprotkb/O00329/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/","field":"links","label":"UniProt O00329: PIK3CD"}]},{"url":"https://www.uniprot.org/uniprotkb/O00358/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxe1","kind":"target","name":"FOXE1","route":"/targets/foxe1/","field":"links","label":"UniProt O00358"}]},{"url":"https://www.uniprot.org/uniprotkb/O00459/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r2","kind":"target","name":"PIK3R2","route":"/targets/pik3r2/","field":"links","label":"UniProt O00459"}]},{"url":"https://www.uniprot.org/uniprotkb/O00470/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"meis1","kind":"target","name":"MEIS1","route":"/targets/meis1/","field":"links","label":"UniProt O00470"}]},{"url":"https://www.uniprot.org/uniprotkb/O00482/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr5a2","kind":"target","name":"NR5A2","route":"/targets/nr5a2/","field":"links","label":"UniProt O00482"}]},{"url":"https://www.uniprot.org/uniprotkb/O00487/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/","field":"links","label":"UniProt O00487"}]},{"url":"https://www.uniprot.org/uniprotkb/O00512/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl9","kind":"target","name":"BCL9","route":"/targets/bcl9/","field":"links","label":"UniProt O00512"}]},{"url":"https://www.uniprot.org/uniprotkb/O00548/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dll1","kind":"target","name":"DLL1","route":"/targets/dll1/","field":"links","label":"UniProt O00548"}]},{"url":"https://www.uniprot.org/uniprotkb/O00560/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdcbp","kind":"target","name":"SDCBP","route":"/targets/sdcbp/","field":"links","label":"UniProt O00560"}]},{"url":"https://www.uniprot.org/uniprotkb/O00571/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx3x","kind":"target","name":"DDX3X","route":"/targets/ddx3x/","field":"links","label":"UniProt O00571"}]},{"url":"https://www.uniprot.org/uniprotkb/O00584/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnaset2","kind":"target","name":"RNASET2","route":"/targets/rnaset2/","field":"links","label":"UniProt O00584"}]},{"url":"https://www.uniprot.org/uniprotkb/O00712/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfib","kind":"target","name":"NFIB","route":"/targets/nfib/","field":"links","label":"UniProt O00712"}]},{"url":"https://www.uniprot.org/uniprotkb/O00743/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp6c","kind":"target","name":"PPP6C","route":"/targets/ppp6c/","field":"links","label":"UniProt O00743"}]},{"url":"https://www.uniprot.org/uniprotkb/O14497/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","field":"links","label":"UniProt O14497"}]},{"url":"https://www.uniprot.org/uniprotkb/O14511/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg2","kind":"target","name":"NRG2","route":"/targets/nrg2/","field":"links","label":"UniProt O14511"}]},{"url":"https://www.uniprot.org/uniprotkb/O14521/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhd","kind":"target","name":"SDHD","route":"/targets/sdhd/","field":"links","label":"UniProt O14521"}]},{"url":"https://www.uniprot.org/uniprotkb/O14522/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/","field":"links","label":"UniProt O14522"}]},{"url":"https://www.uniprot.org/uniprotkb/O14647/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd2","kind":"target","name":"CHD2","route":"/targets/chd2/","field":"links","label":"UniProt O14647"}]},{"url":"https://www.uniprot.org/uniprotkb/O14654/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs4","kind":"target","name":"IRS4","route":"/targets/irs4/","field":"links","label":"UniProt O14654"}]},{"url":"https://www.uniprot.org/uniprotkb/O14686/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2d","kind":"target","name":"KMT2D","route":"/targets/kmt2d/","field":"links","label":"UniProt O14686"}]},{"url":"https://www.uniprot.org/uniprotkb/O14733/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map2k7","kind":"target","name":"MAP2K7","route":"/targets/map2k7/","field":"links","label":"UniProt O14733"}]},{"url":"https://www.uniprot.org/uniprotkb/O14746/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/","field":"links","label":"UniProt O14746"}]},{"url":"https://www.uniprot.org/uniprotkb/O14757/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/","field":"links","label":"UniProt O14757"}]},{"url":"https://www.uniprot.org/uniprotkb/O14763/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf10b","kind":"target","name":"TNFRSF10B","route":"/targets/tnfrsf10b/","field":"links","label":"UniProt O14763"}]},{"url":"https://www.uniprot.org/uniprotkb/O14818/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/","field":"links","label":"UniProt O14818"}]},{"url":"https://www.uniprot.org/uniprotkb/O14836/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/","field":"links","label":"UniProt O14836"}]},{"url":"https://www.uniprot.org/uniprotkb/O14920/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/","field":"links","label":"UniProt O14920"}]},{"url":"https://www.uniprot.org/uniprotkb/O14944/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ereg","kind":"target","name":"EREG","route":"/targets/ereg/","field":"links","label":"UniProt O14944"}]},{"url":"https://www.uniprot.org/uniprotkb/O14965/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","field":"links","label":"UniProt O14965"}]},{"url":"https://www.uniprot.org/uniprotkb/O14980/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/","field":"links","label":"UniProt O14980: XPO1"}]},{"url":"https://www.uniprot.org/uniprotkb/O15013/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","field":"links","label":"UniProt O15013"}]},{"url":"https://www.uniprot.org/uniprotkb/O15018/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdzd2","kind":"target","name":"PDZD2","route":"/targets/pdzd2/","field":"links","label":"UniProt O15018"}]},{"url":"https://www.uniprot.org/uniprotkb/O15031/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plxnb2","kind":"target","name":"PLXNB2","route":"/targets/plxnb2/","field":"links","label":"UniProt O15031"}]},{"url":"https://www.uniprot.org/uniprotkb/O15075/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dclk1","kind":"target","name":"DCLK1","route":"/targets/dclk1/","field":"links","label":"UniProt O15075"}]},{"url":"https://www.uniprot.org/uniprotkb/O15105/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad7","kind":"target","name":"SMAD7","route":"/targets/smad7/","field":"links","label":"UniProt O15105"}]},{"url":"https://www.uniprot.org/uniprotkb/O15119/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbx3","kind":"target","name":"TBX3","route":"/targets/tbx3/","field":"links","label":"UniProt O15119"}]},{"url":"https://www.uniprot.org/uniprotkb/O15151/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mdm4","kind":"target","name":"MDM4","route":"/targets/mdm4/","field":"links","label":"UniProt O15151"}]},{"url":"https://www.uniprot.org/uniprotkb/O15156/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb7b","kind":"target","name":"ZBTB7B","route":"/targets/zbtb7b/","field":"links","label":"UniProt O15156"}]},{"url":"https://www.uniprot.org/uniprotkb/O15164/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/","field":"links","label":"UniProt O15164"}]},{"url":"https://www.uniprot.org/uniprotkb/O15169/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"axin1","kind":"target","name":"AXIN1","route":"/targets/axin1/","field":"links","label":"UniProt O15169"}]},{"url":"https://www.uniprot.org/uniprotkb/O15178/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbxt","kind":"target","name":"TBXT","route":"/targets/tbxt/","field":"links","label":"UniProt O15178"}]},{"url":"https://www.uniprot.org/uniprotkb/O15230/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lama5","kind":"target","name":"LAMA5","route":"/targets/lama5/","field":"links","label":"UniProt O15230"}]},{"url":"https://www.uniprot.org/uniprotkb/O15265/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atxn7","kind":"target","name":"ATXN7","route":"/targets/atxn7/","field":"links","label":"UniProt O15265"}]},{"url":"https://www.uniprot.org/uniprotkb/O15287/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancg","kind":"target","name":"FANCG","route":"/targets/fancg/","field":"links","label":"UniProt O15287"}]},{"url":"https://www.uniprot.org/uniprotkb/O15297/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/","field":"links","label":"UniProt O15297"}]},{"url":"https://www.uniprot.org/uniprotkb/O15315/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/","field":"links","label":"UniProt O15315"}]},{"url":"https://www.uniprot.org/uniprotkb/O15357/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inppl1","kind":"target","name":"INPPL1","route":"/targets/inppl1/","field":"links","label":"UniProt O15357"}]},{"url":"https://www.uniprot.org/uniprotkb/O15360/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/","field":"links","label":"UniProt O15360"}]},{"url":"https://www.uniprot.org/uniprotkb/O15381/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nvl","kind":"target","name":"NVL","route":"/targets/nvl/","field":"links","label":"UniProt O15381"}]},{"url":"https://www.uniprot.org/uniprotkb/O15392/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/","field":"links","label":"UniProt O15392"}]},{"url":"https://www.uniprot.org/uniprotkb/O15393/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/","field":"links","label":"UniProt O15393"}]},{"url":"https://www.uniprot.org/uniprotkb/O15405/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tox3","kind":"target","name":"TOX3","route":"/targets/tox3/","field":"links","label":"UniProt O15405"}]},{"url":"https://www.uniprot.org/uniprotkb/O15438/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc3","kind":"target","name":"ABCC3","route":"/targets/abcc3/","field":"links","label":"UniProt O15438"}]},{"url":"https://www.uniprot.org/uniprotkb/O15439/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc4","kind":"target","name":"ABCC4","route":"/targets/abcc4/","field":"links","label":"UniProt O15439"}]},{"url":"https://www.uniprot.org/uniprotkb/O15519/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cflar","kind":"target","name":"CFLAR","route":"/targets/cflar/","field":"links","label":"UniProt O15519"}]},{"url":"https://www.uniprot.org/uniprotkb/O15520/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf10","kind":"target","name":"FGF10","route":"/targets/fgf10/","field":"links","label":"UniProt O15520"}]},{"url":"https://www.uniprot.org/uniprotkb/O15524/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/","field":"links","label":"UniProt O15524"}]},{"url":"https://www.uniprot.org/uniprotkb/O15527/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ogg1","kind":"target","name":"OGG1","route":"/targets/ogg1/","field":"links","label":"UniProt O15527"}]},{"url":"https://www.uniprot.org/uniprotkb/O15530/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdpk1","kind":"target","name":"PDPK1","route":"/targets/pdpk1/","field":"links","label":"UniProt O15530"}]},{"url":"https://www.uniprot.org/uniprotkb/O15534/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"per1","kind":"target","name":"PER1","route":"/targets/per1/","field":"links","label":"UniProt O15534"}]},{"url":"https://www.uniprot.org/uniprotkb/O15550/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","field":"links","label":"UniProt O15550"}]},{"url":"https://www.uniprot.org/uniprotkb/O43242/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/","field":"links","label":"UniProt O43242"}]},{"url":"https://www.uniprot.org/uniprotkb/O43248/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc11","kind":"target","name":"HOXC11","route":"/targets/hoxc11/","field":"links","label":"UniProt O43248"}]},{"url":"https://www.uniprot.org/uniprotkb/O43252/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"papss1","kind":"target","name":"PAPSS1","route":"/targets/papss1/","field":"links","label":"UniProt O43252"}]},{"url":"https://www.uniprot.org/uniprotkb/O43283/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map3k13","kind":"target","name":"MAP3K13","route":"/targets/map3k13/","field":"links","label":"UniProt O43283"}]},{"url":"https://www.uniprot.org/uniprotkb/O43292/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpaa1","kind":"target","name":"GPAA1","route":"/targets/gpaa1/","field":"links","label":"UniProt O43292"}]},{"url":"https://www.uniprot.org/uniprotkb/O43295/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srgap3","kind":"target","name":"SRGAP3","route":"/targets/srgap3/","field":"links","label":"UniProt O43295"}]},{"url":"https://www.uniprot.org/uniprotkb/O43320/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf16","kind":"target","name":"FGF16","route":"/targets/fgf16/","field":"links","label":"UniProt O43320"}]},{"url":"https://www.uniprot.org/uniprotkb/O43345/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf208","kind":"target","name":"ZNF208","route":"/targets/znf208/","field":"links","label":"UniProt O43345"}]},{"url":"https://www.uniprot.org/uniprotkb/O43435/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbx1","kind":"target","name":"TBX1","route":"/targets/tbx1/","field":"links","label":"UniProt O43435"}]},{"url":"https://www.uniprot.org/uniprotkb/O43474/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf4","kind":"target","name":"KLF4","route":"/targets/klf4/","field":"links","label":"UniProt O43474"}]},{"url":"https://www.uniprot.org/uniprotkb/O43490/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prom1","kind":"target","name":"PROM1","route":"/targets/prom1/","field":"links","label":"UniProt O43490"}]},{"url":"https://www.uniprot.org/uniprotkb/O43497/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1g","kind":"target","name":"CACNA1G","route":"/targets/cacna1g/","field":"links","label":"UniProt O43497"}]},{"url":"https://www.uniprot.org/uniprotkb/O43502/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/","field":"links","label":"UniProt O43502"}]},{"url":"https://www.uniprot.org/uniprotkb/O43521/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bim","kind":"target","name":"BIM (BCL2L11)","route":"/targets/bim/","field":"links","label":"UniProt O43521"}]},{"url":"https://www.uniprot.org/uniprotkb/O43524/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo3","kind":"target","name":"FOXO3","route":"/targets/foxo3/","field":"links","label":"UniProt O43524"}]},{"url":"https://www.uniprot.org/uniprotkb/O43525/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq3","kind":"target","name":"KCNQ3","route":"/targets/kcnq3/","field":"links","label":"UniProt O43525"}]},{"url":"https://www.uniprot.org/uniprotkb/O43542/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc3","kind":"target","name":"XRCC3","route":"/targets/xrcc3/","field":"links","label":"UniProt O43542"}]},{"url":"https://www.uniprot.org/uniprotkb/O43543/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc2","kind":"target","name":"XRCC2","route":"/targets/xrcc2/","field":"links","label":"UniProt O43543"}]},{"url":"https://www.uniprot.org/uniprotkb/O43559/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frs3","kind":"target","name":"FRS3","route":"/targets/frs3/","field":"links","label":"UniProt O43559"}]},{"url":"https://www.uniprot.org/uniprotkb/O43597/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spry2","kind":"target","name":"SPRY2","route":"/targets/spry2/","field":"links","label":"UniProt O43597"}]},{"url":"https://www.uniprot.org/uniprotkb/O43653/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/","field":"links","label":"UniProt O43653"}]},{"url":"https://www.uniprot.org/uniprotkb/O43663/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prc1","kind":"target","name":"PRC1","route":"/targets/prc1/","field":"links","label":"UniProt O43663"}]},{"url":"https://www.uniprot.org/uniprotkb/O43683/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bub1","kind":"target","name":"BUB1","route":"/targets/bub1/","field":"links","label":"UniProt O43683"}]},{"url":"https://www.uniprot.org/uniprotkb/O43711/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlx3","kind":"target","name":"TLX3","route":"/targets/tlx3/","field":"links","label":"UniProt O43711"}]},{"url":"https://www.uniprot.org/uniprotkb/O43791/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","field":"links","label":"UniProt O43791"}]},{"url":"https://www.uniprot.org/uniprotkb/O43815/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"strn","kind":"target","name":"STRN","route":"/targets/strn/","field":"links","label":"UniProt O43815"}]},{"url":"https://www.uniprot.org/uniprotkb/O60216/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad21","kind":"target","name":"RAD21","route":"/targets/rad21/","field":"links","label":"UniProt O60216"}]},{"url":"https://www.uniprot.org/uniprotkb/O60258/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf17","kind":"target","name":"FGF17","route":"/targets/fgf17/","field":"links","label":"UniProt O60258"}]},{"url":"https://www.uniprot.org/uniprotkb/O60260/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/","field":"links","label":"UniProt O60260"}]},{"url":"https://www.uniprot.org/uniprotkb/O60281/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf292","kind":"target","name":"ZNF292","route":"/targets/znf292/","field":"links","label":"UniProt O60281"}]},{"url":"https://www.uniprot.org/uniprotkb/O60486/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plxnc1","kind":"target","name":"PLXNC1","route":"/targets/plxnc1/","field":"links","label":"UniProt O60486"}]},{"url":"https://www.uniprot.org/uniprotkb/O60563/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnt1","kind":"target","name":"CCNT1","route":"/targets/ccnt1/","field":"links","label":"UniProt O60563"}]},{"url":"https://www.uniprot.org/uniprotkb/O60565/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grem1","kind":"target","name":"GREM1","route":"/targets/grem1/","field":"links","label":"UniProt O60565"}]},{"url":"https://www.uniprot.org/uniprotkb/O60566/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/","field":"links","label":"UniProt O60566"}]},{"url":"https://www.uniprot.org/uniprotkb/O60663/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmx1b","kind":"target","name":"LMX1B","route":"/targets/lmx1b/","field":"links","label":"UniProt O60663"}]},{"url":"https://www.uniprot.org/uniprotkb/O60814/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2bc12","kind":"target","name":"H2BC12","route":"/targets/h2bc12/","field":"links","label":"UniProt O60814"}]},{"url":"https://www.uniprot.org/uniprotkb/O60885/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/","field":"links","label":"UniProt O60885"}]},{"url":"https://www.uniprot.org/uniprotkb/O60934/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/","field":"links","label":"UniProt O60934"}]},{"url":"https://www.uniprot.org/uniprotkb/O75030/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/","field":"links","label":"UniProt O75030"}]},{"url":"https://www.uniprot.org/uniprotkb/O75081/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbfa2t3","kind":"target","name":"CBFA2T3","route":"/targets/cbfa2t3/","field":"links","label":"UniProt O75081"}]},{"url":"https://www.uniprot.org/uniprotkb/O75175/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnot3","kind":"target","name":"CNOT3","route":"/targets/cnot3/","field":"links","label":"UniProt O75175"}]},{"url":"https://www.uniprot.org/uniprotkb/O75197/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrp5","kind":"target","name":"LRP5","route":"/targets/lrp5/","field":"links","label":"UniProt O75197"}]},{"url":"https://www.uniprot.org/uniprotkb/O75204/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem127","kind":"target","name":"TMEM127","route":"/targets/tmem127/","field":"links","label":"UniProt O75204"}]},{"url":"https://www.uniprot.org/uniprotkb/O75290/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf780a","kind":"target","name":"ZNF780A","route":"/targets/znf780a/","field":"links","label":"UniProt O75290"}]},{"url":"https://www.uniprot.org/uniprotkb/O75362/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/","field":"links","label":"UniProt O75362"}]},{"url":"https://www.uniprot.org/uniprotkb/O75365/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptp4a3","kind":"target","name":"PTP4A3","route":"/targets/ptp4a3/","field":"links","label":"UniProt O75365"}]},{"url":"https://www.uniprot.org/uniprotkb/O75376/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncor1","kind":"target","name":"NCOR1","route":"/targets/ncor1/","field":"links","label":"UniProt O75376"}]},{"url":"https://www.uniprot.org/uniprotkb/O75417/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/","field":"links","label":"UniProt O75417"}]},{"url":"https://www.uniprot.org/uniprotkb/O75444/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/","field":"links","label":"UniProt O75444"}]},{"url":"https://www.uniprot.org/uniprotkb/O75473/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","field":"links","label":"UniProt O75473"}]},{"url":"https://www.uniprot.org/uniprotkb/O75475/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psip1","kind":"target","name":"PSIP1","route":"/targets/psip1/","field":"links","label":"UniProt O75475"}]},{"url":"https://www.uniprot.org/uniprotkb/O75530/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/","field":"links","label":"UniProt O75530"}]},{"url":"https://www.uniprot.org/uniprotkb/O75533/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","field":"links","label":"UniProt O75533"}]},{"url":"https://www.uniprot.org/uniprotkb/O75626/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/","field":"links","label":"UniProt O75626"}]},{"url":"https://www.uniprot.org/uniprotkb/O75638/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","field":"links","label":"UniProt O75638"}]},{"url":"https://www.uniprot.org/uniprotkb/O75688/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppm1b","kind":"target","name":"PPM1B","route":"/targets/ppm1b/","field":"links","label":"UniProt O75688"}]},{"url":"https://www.uniprot.org/uniprotkb/O75751/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc22a3","kind":"target","name":"SLC22A3","route":"/targets/slc22a3/","field":"links","label":"UniProt O75751"}]},{"url":"https://www.uniprot.org/uniprotkb/O75771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/","field":"links","label":"UniProt O75771"}]},{"url":"https://www.uniprot.org/uniprotkb/O75807/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp1r15a","kind":"target","name":"PPP1R15A","route":"/targets/ppp1r15a/","field":"links","label":"UniProt O75807"}]},{"url":"https://www.uniprot.org/uniprotkb/O76093/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf18","kind":"target","name":"FGF18","route":"/targets/fgf18/","field":"links","label":"UniProt O76093"}]},{"url":"https://www.uniprot.org/uniprotkb/O94761/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/","field":"links","label":"UniProt O94761"}]},{"url":"https://www.uniprot.org/uniprotkb/O94788/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aldh1a2","kind":"target","name":"ALDH1A2","route":"/targets/aldh1a2/","field":"links","label":"UniProt O94788"}]},{"url":"https://www.uniprot.org/uniprotkb/O94806/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd3","kind":"target","name":"PRKD3","route":"/targets/prkd3/","field":"links","label":"UniProt O94806"}]},{"url":"https://www.uniprot.org/uniprotkb/O94817/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atg12","kind":"target","name":"ATG12","route":"/targets/atg12/","field":"links","label":"UniProt O94817"}]},{"url":"https://www.uniprot.org/uniprotkb/O94900/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tox","kind":"target","name":"TOX","route":"/targets/tox/","field":"links","label":"UniProt O94900"}]},{"url":"https://www.uniprot.org/uniprotkb/O94905/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erlin2","kind":"target","name":"ERLIN2","route":"/targets/erlin2/","field":"links","label":"UniProt O94905"}]},{"url":"https://www.uniprot.org/uniprotkb/O94907/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dkk1","kind":"target","name":"DKK1","route":"/targets/dkk1/","field":"links","label":"UniProt O94907"}]},{"url":"https://www.uniprot.org/uniprotkb/O95071/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/","field":"links","label":"UniProt O95071"}]},{"url":"https://www.uniprot.org/uniprotkb/O95136/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s1pr2","kind":"target","name":"S1PR2","route":"/targets/s1pr2/","field":"links","label":"UniProt O95136"}]},{"url":"https://www.uniprot.org/uniprotkb/O95163/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elp1","kind":"target","name":"ELP1","route":"/targets/elp1/","field":"links","label":"UniProt O95163"}]},{"url":"https://www.uniprot.org/uniprotkb/O95180/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1h","kind":"target","name":"CACNA1H","route":"/targets/cacna1h/","field":"links","label":"UniProt O95180"}]},{"url":"https://www.uniprot.org/uniprotkb/O95243/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mbd4","kind":"target","name":"MBD4","route":"/targets/mbd4/","field":"links","label":"UniProt O95243"}]},{"url":"https://www.uniprot.org/uniprotkb/O95251/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat7","kind":"target","name":"KAT7","route":"/targets/kat7/","field":"links","label":"UniProt O95251"}]},{"url":"https://www.uniprot.org/uniprotkb/O95259/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh1","kind":"target","name":"KCNH1","route":"/targets/kcnh1/","field":"links","label":"UniProt O95259"}]},{"url":"https://www.uniprot.org/uniprotkb/O95319/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"celf2","kind":"target","name":"CELF2","route":"/targets/celf2/","field":"links","label":"UniProt O95319"}]},{"url":"https://www.uniprot.org/uniprotkb/O95352/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atg7","kind":"target","name":"ATG7","route":"/targets/atg7/","field":"links","label":"UniProt O95352"}]},{"url":"https://www.uniprot.org/uniprotkb/O95411/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myo18a","kind":"target","name":"MYO18A","route":"/targets/myo18a/","field":"links","label":"UniProt O95411"}]},{"url":"https://www.uniprot.org/uniprotkb/O95429/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bag4","kind":"target","name":"BAG4","route":"/targets/bag4/","field":"links","label":"UniProt O95429"}]},{"url":"https://www.uniprot.org/uniprotkb/O95436/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/","field":"links","label":"UniProt O95436"}]},{"url":"https://www.uniprot.org/uniprotkb/O95467/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","field":"links","label":"UniProt O95467"}]},{"url":"https://www.uniprot.org/uniprotkb/O95502/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nptxr","kind":"target","name":"NPTXR","route":"/targets/nptxr/","field":"links","label":"UniProt O95502"}]},{"url":"https://www.uniprot.org/uniprotkb/O95573/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsl3","kind":"target","name":"ACSL3","route":"/targets/acsl3/","field":"links","label":"UniProt O95573"}]},{"url":"https://www.uniprot.org/uniprotkb/O95684/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cep43","kind":"target","name":"CEP43","route":"/targets/cep43/","field":"links","label":"UniProt O95684"}]},{"url":"https://www.uniprot.org/uniprotkb/O95750/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/","field":"links","label":"UniProt O95750"}]},{"url":"https://www.uniprot.org/uniprotkb/O95760/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il33","kind":"target","name":"IL33","route":"/targets/il33/","field":"links","label":"UniProt O95760"}]},{"url":"https://www.uniprot.org/uniprotkb/O95835/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/","field":"links","label":"UniProt O95835"}]},{"url":"https://www.uniprot.org/uniprotkb/O95936/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eomes","kind":"target","name":"EOMES","route":"/targets/eomes/","field":"links","label":"UniProt O95936"}]},{"url":"https://www.uniprot.org/uniprotkb/O95994/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agr2","kind":"target","name":"AGR2","route":"/targets/agr2/","field":"links","label":"UniProt O95994"}]},{"url":"https://www.uniprot.org/uniprotkb/O95997/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pttg1","kind":"target","name":"PTTG1","route":"/targets/pttg1/","field":"links","label":"UniProt O95997"}]},{"url":"https://www.uniprot.org/uniprotkb/O95999/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/","field":"links","label":"UniProt O95999"}]},{"url":"https://www.uniprot.org/uniprotkb/O96014/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt11","kind":"target","name":"WNT11","route":"/targets/wnt11/","field":"links","label":"UniProt O96014"}]},{"url":"https://www.uniprot.org/uniprotkb/O96017/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/","field":"links","label":"UniProt O96017"}]},{"url":"https://www.uniprot.org/uniprotkb/O96019/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/","field":"links","label":"UniProt O96019"}]},{"url":"https://www.uniprot.org/uniprotkb/O96020/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccne2","kind":"target","name":"CCNE2","route":"/targets/ccne2/","field":"links","label":"UniProt O96020"}]},{"url":"https://www.uniprot.org/uniprotkb/O96028/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/","field":"links","label":"UniProt O96028"}]},{"url":"https://www.uniprot.org/uniprotkb/P00156/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-cyb","kind":"target","name":"MT-CYB","route":"/targets/mt-cyb/","field":"links","label":"UniProt P00156"}]},{"url":"https://www.uniprot.org/uniprotkb/P00325/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adh1b","kind":"target","name":"ADH1B","route":"/targets/adh1b/","field":"links","label":"UniProt P00325"}]},{"url":"https://www.uniprot.org/uniprotkb/P00374/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dhfr","kind":"target","name":"Dihydrofolate reductase (DHFR)","route":"/targets/dhfr/","field":"links","label":"UniProt P00374: DHFR"}]},{"url":"https://www.uniprot.org/uniprotkb/P00390/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","field":"links","label":"UniProt P00390: GSR"}]},{"url":"https://www.uniprot.org/uniprotkb/P00395/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-co1","kind":"target","name":"MT-CO1","route":"/targets/mt-co1/","field":"links","label":"UniProt P00395"}]},{"url":"https://www.uniprot.org/uniprotkb/P00519/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abl1","kind":"target","name":"ABL1","route":"/targets/abl1/","field":"links","label":"UniProt P00519"}]},{"url":"https://www.uniprot.org/uniprotkb/P00813/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ada","kind":"target","name":"Adenosine deaminase (ADA)","route":"/targets/ada/","field":"links","label":"UniProt P00813: ADA"}]},{"url":"https://www.uniprot.org/uniprotkb/P00966/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/","field":"links","label":"UniProt P00966"}]},{"url":"https://www.uniprot.org/uniprotkb/P01033/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"timp1","kind":"target","name":"TIMP1","route":"/targets/timp1/","field":"links","label":"UniProt P01033"}]},{"url":"https://www.uniprot.org/uniprotkb/P01100/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fos","kind":"target","name":"FOS","route":"/targets/fos/","field":"links","label":"UniProt P01100"}]},{"url":"https://www.uniprot.org/uniprotkb/P01106/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","field":"links","label":"UniProt P01106"}]},{"url":"https://www.uniprot.org/uniprotkb/P01111/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","field":"links","label":"UniProt P01111"}]},{"url":"https://www.uniprot.org/uniprotkb/P01112/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/","field":"links","label":"UniProt P01112"}]},{"url":"https://www.uniprot.org/uniprotkb/P01127/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdgfb","kind":"target","name":"PDGFB","route":"/targets/pdgfb/","field":"links","label":"UniProt P01127"}]},{"url":"https://www.uniprot.org/uniprotkb/P01133/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","field":"links","label":"UniProt P01133"}]},{"url":"https://www.uniprot.org/uniprotkb/P01135/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfa","kind":"target","name":"TGFA","route":"/targets/tgfa/","field":"links","label":"UniProt P01135"}]},{"url":"https://www.uniprot.org/uniprotkb/P01137/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb1","kind":"target","name":"TGFB1","route":"/targets/tgfb1/","field":"links","label":"UniProt P01137"}]},{"url":"https://www.uniprot.org/uniprotkb/P01266/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tg","kind":"target","name":"TG","route":"/targets/tg/","field":"links","label":"UniProt P01266"}]},{"url":"https://www.uniprot.org/uniprotkb/P01344/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/","field":"links","label":"UniProt P01344"}]},{"url":"https://www.uniprot.org/uniprotkb/P01563/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifna2","kind":"target","name":"IFNA2","route":"/targets/ifna2/","field":"links","label":"UniProt P01563"}]},{"url":"https://www.uniprot.org/uniprotkb/P01889/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/","field":"links","label":"UniProt P01889"}]},{"url":"https://www.uniprot.org/uniprotkb/P01903/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/","field":"links","label":"UniProt P01903"}]},{"url":"https://www.uniprot.org/uniprotkb/P01909/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-dqa1","kind":"target","name":"HLA-DQA1","route":"/targets/hla-dqa1/","field":"links","label":"UniProt P01909"}]},{"url":"https://www.uniprot.org/uniprotkb/P02452/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/","field":"links","label":"UniProt P02452"}]},{"url":"https://www.uniprot.org/uniprotkb/P02458/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col2a1","kind":"target","name":"COL2A1","route":"/targets/col2a1/","field":"links","label":"UniProt P02458"}]},{"url":"https://www.uniprot.org/uniprotkb/P02545/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmna","kind":"target","name":"LMNA","route":"/targets/lmna/","field":"links","label":"UniProt P02545"}]},{"url":"https://www.uniprot.org/uniprotkb/P02649/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apoe","kind":"target","name":"APOE","route":"/targets/apoe/","field":"links","label":"UniProt P02649"}]},{"url":"https://www.uniprot.org/uniprotkb/P02671/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fga","kind":"target","name":"FGA","route":"/targets/fga/","field":"links","label":"UniProt P02671"}]},{"url":"https://www.uniprot.org/uniprotkb/P02675/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgb","kind":"target","name":"FGB","route":"/targets/fgb/","field":"links","label":"UniProt P02675"}]},{"url":"https://www.uniprot.org/uniprotkb/P02679/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgg","kind":"target","name":"FGG","route":"/targets/fgg/","field":"links","label":"UniProt P02679"}]},{"url":"https://www.uniprot.org/uniprotkb/P02751/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/","field":"links","label":"UniProt P02751"}]},{"url":"https://www.uniprot.org/uniprotkb/P02778/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cxcl10","kind":"target","name":"CXCL10","route":"/targets/cxcl10/","field":"links","label":"UniProt P02778"}]},{"url":"https://www.uniprot.org/uniprotkb/P02786/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfrc","kind":"target","name":"TFRC","route":"/targets/tfrc/","field":"links","label":"UniProt P02786"}]},{"url":"https://www.uniprot.org/uniprotkb/P02787/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tf","kind":"target","name":"TF","route":"/targets/tf/","field":"links","label":"UniProt P02787"}]},{"url":"https://www.uniprot.org/uniprotkb/P03886/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-nd1","kind":"target","name":"MT-ND1","route":"/targets/mt-nd1/","field":"links","label":"UniProt P03886"}]},{"url":"https://www.uniprot.org/uniprotkb/P03923/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mt-nd6","kind":"target","name":"MT-ND6","route":"/targets/mt-nd6/","field":"links","label":"UniProt P03923"}]},{"url":"https://www.uniprot.org/uniprotkb/P03956/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp1","kind":"target","name":"MMP1","route":"/targets/mmp1/","field":"links","label":"UniProt P03956"}]},{"url":"https://www.uniprot.org/uniprotkb/P04035/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmgcr","kind":"target","name":"HMGCR","route":"/targets/hmgcr/","field":"links","label":"UniProt P04035"}]},{"url":"https://www.uniprot.org/uniprotkb/P04049/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","field":"links","label":"UniProt P04049: RAF1"}]},{"url":"https://www.uniprot.org/uniprotkb/P04150/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/","field":"links","label":"UniProt P04150: NR3C1"}]},{"url":"https://www.uniprot.org/uniprotkb/P04198/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mycn","kind":"target","name":"MYCN (N-myc)","route":"/targets/mycn/","field":"links","label":"UniProt P04198"}]},{"url":"https://www.uniprot.org/uniprotkb/P04233/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd74","kind":"target","name":"CD74","route":"/targets/cd74/","field":"links","label":"UniProt P04233"}]},{"url":"https://www.uniprot.org/uniprotkb/P04234/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/","field":"links","label":"UniProt P04234"}]},{"url":"https://www.uniprot.org/uniprotkb/P04271/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s100b","kind":"target","name":"S100B","route":"/targets/s100b/","field":"links","label":"UniProt P04271"}]},{"url":"https://www.uniprot.org/uniprotkb/P04275/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vwf","kind":"target","name":"VWF","route":"/targets/vwf/","field":"links","label":"UniProt P04275"}]},{"url":"https://www.uniprot.org/uniprotkb/P04350/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/","field":"links","label":"UniProt P04350"}]},{"url":"https://www.uniprot.org/uniprotkb/P04439/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/","field":"links","label":"UniProt P04439"}]},{"url":"https://www.uniprot.org/uniprotkb/P04628/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt1","kind":"target","name":"WNT1","route":"/targets/wnt1/","field":"links","label":"UniProt P04628"}]},{"url":"https://www.uniprot.org/uniprotkb/P04792/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspb1","kind":"target","name":"HSPB1","route":"/targets/hspb1/","field":"links","label":"UniProt P04792"}]},{"url":"https://www.uniprot.org/uniprotkb/P04818/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyms","kind":"target","name":"Thymidylate synthase (TYMS)","route":"/targets/tyms/","field":"links","label":"UniProt P04818: TYMS"}]},{"url":"https://www.uniprot.org/uniprotkb/P04899/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnai2","kind":"target","name":"GNAI2","route":"/targets/gnai2/","field":"links","label":"UniProt P04899"}]},{"url":"https://www.uniprot.org/uniprotkb/P05023/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp1a1","kind":"target","name":"ATP1A1","route":"/targets/atp1a1/","field":"links","label":"UniProt P05023"}]},{"url":"https://www.uniprot.org/uniprotkb/P05091/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aldh2","kind":"target","name":"ALDH2","route":"/targets/aldh2/","field":"links","label":"UniProt P05091"}]},{"url":"https://www.uniprot.org/uniprotkb/P05093/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/","field":"links","label":"UniProt P05093: CYP17A1"}]},{"url":"https://www.uniprot.org/uniprotkb/P05106/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itgb3","kind":"target","name":"ITGB3","route":"/targets/itgb3/","field":"links","label":"UniProt P05106"}]},{"url":"https://www.uniprot.org/uniprotkb/P05108/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","field":"links","label":"UniProt P05108: CYP11A1"}]},{"url":"https://www.uniprot.org/uniprotkb/P05129/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcg","kind":"target","name":"PRKCG","route":"/targets/prkcg/","field":"links","label":"UniProt P05129"}]},{"url":"https://www.uniprot.org/uniprotkb/P05230/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf1","kind":"target","name":"FGF1","route":"/targets/fgf1/","field":"links","label":"UniProt P05230"}]},{"url":"https://www.uniprot.org/uniprotkb/P05412/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jun","kind":"target","name":"JUN","route":"/targets/jun/","field":"links","label":"UniProt P05412"}]},{"url":"https://www.uniprot.org/uniprotkb/P05771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcb","kind":"target","name":"PRKCB","route":"/targets/prkcb/","field":"links","label":"UniProt P05771"}]},{"url":"https://www.uniprot.org/uniprotkb/P05783/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krt18","kind":"target","name":"KRT18","route":"/targets/krt18/","field":"links","label":"UniProt P05783"}]},{"url":"https://www.uniprot.org/uniprotkb/P06239/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/","field":"links","label":"UniProt P06239"}]},{"url":"https://www.uniprot.org/uniprotkb/P06241/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/","field":"links","label":"UniProt P06241"}]},{"url":"https://www.uniprot.org/uniprotkb/P06400/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","field":"links","label":"UniProt P06400"}]},{"url":"https://www.uniprot.org/uniprotkb/P06401/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","field":"links","label":"UniProt P06401: PGR"}]},{"url":"https://www.uniprot.org/uniprotkb/P06454/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptma","kind":"target","name":"PTMA","route":"/targets/ptma/","field":"links","label":"UniProt P06454"}]},{"url":"https://www.uniprot.org/uniprotkb/P06753/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpm3","kind":"target","name":"TPM3","route":"/targets/tpm3/","field":"links","label":"UniProt P06753"}]},{"url":"https://www.uniprot.org/uniprotkb/P06756/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itgav","kind":"target","name":"ITGAV","route":"/targets/itgav/","field":"links","label":"UniProt P06756"}]},{"url":"https://www.uniprot.org/uniprotkb/P07288/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klk3","kind":"target","name":"KLK3","route":"/targets/klk3/","field":"links","label":"UniProt P07288"}]},{"url":"https://www.uniprot.org/uniprotkb/P07332/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/","field":"links","label":"UniProt P07332"}]},{"url":"https://www.uniprot.org/uniprotkb/P07437/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/","field":"links","label":"UniProt P07437: TUBB"}]},{"url":"https://www.uniprot.org/uniprotkb/P07900/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","field":"links","label":"UniProt P07900"}]},{"url":"https://www.uniprot.org/uniprotkb/P07947/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/","field":"links","label":"UniProt P07947"}]},{"url":"https://www.uniprot.org/uniprotkb/P07948/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","field":"links","label":"UniProt P07948: LYN"}]},{"url":"https://www.uniprot.org/uniprotkb/P07954/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fh","kind":"target","name":"FH","route":"/targets/fh/","field":"links","label":"UniProt P07954"}]},{"url":"https://www.uniprot.org/uniprotkb/P07992/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/","field":"links","label":"UniProt P07992"}]},{"url":"https://www.uniprot.org/uniprotkb/P08069/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","field":"links","label":"UniProt P08069: IGF1R"}]},{"url":"https://www.uniprot.org/uniprotkb/P08118/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msmb","kind":"target","name":"MSMB","route":"/targets/msmb/","field":"links","label":"UniProt P08118"}]},{"url":"https://www.uniprot.org/uniprotkb/P08151/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gli1","kind":"target","name":"GLI1","route":"/targets/gli1/","field":"links","label":"UniProt P08151"}]},{"url":"https://www.uniprot.org/uniprotkb/P08183/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/","field":"links","label":"UniProt P08183"}]},{"url":"https://www.uniprot.org/uniprotkb/P08238/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90ab1","kind":"target","name":"HSP90AB1","route":"/targets/hsp90ab1/","field":"links","label":"UniProt P08238"}]},{"url":"https://www.uniprot.org/uniprotkb/P08243/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/","field":"links","label":"UniProt P08243"}]},{"url":"https://www.uniprot.org/uniprotkb/P08253/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp2","kind":"target","name":"MMP2","route":"/targets/mmp2/","field":"links","label":"UniProt P08253"}]},{"url":"https://www.uniprot.org/uniprotkb/P08514/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itga2b","kind":"target","name":"ITGA2B","route":"/targets/itga2b/","field":"links","label":"UniProt P08514"}]},{"url":"https://www.uniprot.org/uniprotkb/P08519/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lpa","kind":"target","name":"LPA","route":"/targets/lpa/","field":"links","label":"UniProt P08519"}]},{"url":"https://www.uniprot.org/uniprotkb/P08575/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprc","kind":"target","name":"PTPRC","route":"/targets/ptprc/","field":"links","label":"UniProt P08575"}]},{"url":"https://www.uniprot.org/uniprotkb/P08620/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf4","kind":"target","name":"FGF4","route":"/targets/fgf4/","field":"links","label":"UniProt P08620"}]},{"url":"https://www.uniprot.org/uniprotkb/P08631/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","field":"links","label":"UniProt P08631: HCK"}]},{"url":"https://www.uniprot.org/uniprotkb/P08637/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/","field":"links","label":"UniProt P08637"}]},{"url":"https://www.uniprot.org/uniprotkb/P08913/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2a","kind":"target","name":"ADRA2A","route":"/targets/adra2a/","field":"links","label":"UniProt P08913"}]},{"url":"https://www.uniprot.org/uniprotkb/P09038/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf2","kind":"target","name":"FGF2","route":"/targets/fgf2/","field":"links","label":"UniProt P09038"}]},{"url":"https://www.uniprot.org/uniprotkb/P09086/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou2f2","kind":"target","name":"POU2F2","route":"/targets/pou2f2/","field":"links","label":"UniProt P09086"}]},{"url":"https://www.uniprot.org/uniprotkb/P09211/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/","field":"links","label":"UniProt P09211"}]},{"url":"https://www.uniprot.org/uniprotkb/P09237/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp7","kind":"target","name":"MMP7","route":"/targets/mmp7/","field":"links","label":"UniProt P09237"}]},{"url":"https://www.uniprot.org/uniprotkb/P09529/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"inhbb","kind":"target","name":"INHBB","route":"/targets/inhbb/","field":"links","label":"UniProt P09529"}]},{"url":"https://www.uniprot.org/uniprotkb/P09601/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmox1","kind":"target","name":"HMOX1","route":"/targets/hmox1/","field":"links","label":"UniProt P09601"}]},{"url":"https://www.uniprot.org/uniprotkb/P09603/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/","field":"links","label":"UniProt P09603"}]},{"url":"https://www.uniprot.org/uniprotkb/P09619/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdgfrb","kind":"target","name":"PDGFRB","route":"/targets/pdgfrb/","field":"links","label":"UniProt P09619: PDGFRB"}]},{"url":"https://www.uniprot.org/uniprotkb/P09668/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctsh","kind":"target","name":"CTSH","route":"/targets/ctsh/","field":"links","label":"UniProt P09668"}]},{"url":"https://www.uniprot.org/uniprotkb/P09693/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/","field":"links","label":"UniProt P09693"}]},{"url":"https://www.uniprot.org/uniprotkb/P09758/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"links","label":"UniProt P09758: TACSTD2 (TROP2)"}]},{"url":"https://www.uniprot.org/uniprotkb/P09769/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgr","kind":"target","name":"FGR","route":"/targets/fgr/","field":"links","label":"UniProt P09769"}]},{"url":"https://www.uniprot.org/uniprotkb/P09884/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","field":"links","label":"UniProt P09884: POLA1"}]},{"url":"https://www.uniprot.org/uniprotkb/P0C0S8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2ac17","kind":"target","name":"H2AC17","route":"/targets/h2ac17/","field":"links","label":"UniProt P0C0S8"}]},{"url":"https://www.uniprot.org/uniprotkb/P0C7T5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atxn1l","kind":"target","name":"ATXN1L","route":"/targets/atxn1l/","field":"links","label":"UniProt P0C7T5"}]},{"url":"https://www.uniprot.org/uniprotkb/P0CG47/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubb","kind":"target","name":"UBB","route":"/targets/ubb/","field":"links","label":"UniProt P0CG47"}]},{"url":"https://www.uniprot.org/uniprotkb/P0CG48/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubc","kind":"target","name":"UBC","route":"/targets/ubc/","field":"links","label":"UniProt P0CG48"}]},{"url":"https://www.uniprot.org/uniprotkb/P0CI26/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim49c","kind":"target","name":"TRIM49C","route":"/targets/trim49c/","field":"links","label":"UniProt P0CI26"}]},{"url":"https://www.uniprot.org/uniprotkb/P0DP91/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc6","kind":"target","name":"ERCC6","route":"/targets/ercc6/","field":"links","label":"UniProt P0DP91"}]},{"url":"https://www.uniprot.org/uniprotkb/P0DPH7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/","field":"links","label":"UniProt P0DPH7"}]},{"url":"https://www.uniprot.org/uniprotkb/P0DPQ6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddit3","kind":"target","name":"DDIT3","route":"/targets/ddit3/","field":"links","label":"UniProt P0DPQ6"}]},{"url":"https://www.uniprot.org/uniprotkb/P0DW28/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","field":"links","label":"UniProt P0DW28"}]},{"url":"https://www.uniprot.org/uniprotkb/P10074/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb48","kind":"target","name":"ZBTB48","route":"/targets/zbtb48/","field":"links","label":"UniProt P10074"}]},{"url":"https://www.uniprot.org/uniprotkb/P10242/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/","field":"links","label":"UniProt P10242"}]},{"url":"https://www.uniprot.org/uniprotkb/P10243/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mybl1","kind":"target","name":"MYBL1","route":"/targets/mybl1/","field":"links","label":"UniProt P10243"}]},{"url":"https://www.uniprot.org/uniprotkb/P10276/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rara","kind":"target","name":"Retinoic acid receptor alpha (RARA)","route":"/targets/rara/","field":"links","label":"UniProt P10276: RARA"}]},{"url":"https://www.uniprot.org/uniprotkb/P10321/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/","field":"links","label":"UniProt P10321"}]},{"url":"https://www.uniprot.org/uniprotkb/P10398/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/","field":"links","label":"UniProt P10398"}]},{"url":"https://www.uniprot.org/uniprotkb/P10586/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprf","kind":"target","name":"PTPRF","route":"/targets/ptprf/","field":"links","label":"UniProt P10586"}]},{"url":"https://www.uniprot.org/uniprotkb/P10600/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb3","kind":"target","name":"TGFB3","route":"/targets/tgfb3/","field":"links","label":"UniProt P10600"}]},{"url":"https://www.uniprot.org/uniprotkb/P10632/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp2c8","kind":"target","name":"CYP2C8","route":"/targets/cyp2c8/","field":"links","label":"UniProt P10632"}]},{"url":"https://www.uniprot.org/uniprotkb/P10635/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp2d6","kind":"target","name":"CYP2D6","route":"/targets/cyp2d6/","field":"links","label":"UniProt P10635"}]},{"url":"https://www.uniprot.org/uniprotkb/P10644/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkar1a","kind":"target","name":"PRKAR1A","route":"/targets/prkar1a/","field":"links","label":"UniProt P10644"}]},{"url":"https://www.uniprot.org/uniprotkb/P10747/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/","field":"links","label":"UniProt P10747"}]},{"url":"https://www.uniprot.org/uniprotkb/P10767/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf6","kind":"target","name":"FGF6","route":"/targets/fgf6/","field":"links","label":"UniProt P10767"}]},{"url":"https://www.uniprot.org/uniprotkb/P10826/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rarb","kind":"target","name":"RARB","route":"/targets/rarb/","field":"links","label":"UniProt P10826"}]},{"url":"https://www.uniprot.org/uniprotkb/P10827/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thra","kind":"target","name":"THRA","route":"/targets/thra/","field":"links","label":"UniProt P10827"}]},{"url":"https://www.uniprot.org/uniprotkb/P10828/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thrb","kind":"target","name":"THRB","route":"/targets/thrb/","field":"links","label":"UniProt P10828"}]},{"url":"https://www.uniprot.org/uniprotkb/P10914/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/","field":"links","label":"UniProt P10914"}]},{"url":"https://www.uniprot.org/uniprotkb/P11021/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspa5","kind":"target","name":"HSPA5","route":"/targets/hspa5/","field":"links","label":"UniProt P11021"}]},{"url":"https://www.uniprot.org/uniprotkb/P11047/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lamc1","kind":"target","name":"LAMC1","route":"/targets/lamc1/","field":"links","label":"UniProt P11047"}]},{"url":"https://www.uniprot.org/uniprotkb/P11086/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pnmt","kind":"target","name":"PNMT","route":"/targets/pnmt/","field":"links","label":"UniProt P11086"}]},{"url":"https://www.uniprot.org/uniprotkb/P11161/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"egr2","kind":"target","name":"EGR2","route":"/targets/egr2/","field":"links","label":"UniProt P11161"}]},{"url":"https://www.uniprot.org/uniprotkb/P11308/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","field":"links","label":"UniProt P11308"}]},{"url":"https://www.uniprot.org/uniprotkb/P11309/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/","field":"links","label":"UniProt P11309"}]},{"url":"https://www.uniprot.org/uniprotkb/P11362/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","field":"links","label":"UniProt P11362: FGFR1"}]},{"url":"https://www.uniprot.org/uniprotkb/P11387/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/","field":"links","label":"UniProt P11387: TOP1"}]},{"url":"https://www.uniprot.org/uniprotkb/P11388/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/","field":"links","label":"UniProt P11388: TOP2A"}]},{"url":"https://www.uniprot.org/uniprotkb/P11473/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vdr","kind":"target","name":"VDR","route":"/targets/vdr/","field":"links","label":"UniProt P11473"}]},{"url":"https://www.uniprot.org/uniprotkb/P11474/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esrra","kind":"target","name":"ESRRA","route":"/targets/esrra/","field":"links","label":"UniProt P11474"}]},{"url":"https://www.uniprot.org/uniprotkb/P11487/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf3","kind":"target","name":"FGF3","route":"/targets/fgf3/","field":"links","label":"UniProt P11487"}]},{"url":"https://www.uniprot.org/uniprotkb/P11511/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aromatase","kind":"target","name":"Aromatase (CYP19A1)","route":"/targets/aromatase/","field":"links","label":"UniProt P11511: CYP19A1"}]},{"url":"https://www.uniprot.org/uniprotkb/P11717/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"igf2r","kind":"target","name":"IGF2R","route":"/targets/igf2r/","field":"links","label":"UniProt P11717"}]},{"url":"https://www.uniprot.org/uniprotkb/P11912/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd79a","kind":"target","name":"CD79A","route":"/targets/cd79a/","field":"links","label":"UniProt P11912"}]},{"url":"https://www.uniprot.org/uniprotkb/P11940/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/","field":"links","label":"UniProt P11940"}]},{"url":"https://www.uniprot.org/uniprotkb/P12004/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/","field":"links","label":"UniProt P12004"}]},{"url":"https://www.uniprot.org/uniprotkb/P12034/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf5","kind":"target","name":"FGF5","route":"/targets/fgf5/","field":"links","label":"UniProt P12034"}]},{"url":"https://www.uniprot.org/uniprotkb/P12111/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"col6a3","kind":"target","name":"COL6A3","route":"/targets/col6a3/","field":"links","label":"UniProt P12111"}]},{"url":"https://www.uniprot.org/uniprotkb/P12268/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","field":"links","label":"UniProt P12268: IMPDH2"}]},{"url":"https://www.uniprot.org/uniprotkb/P12270/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpr","kind":"target","name":"TPR","route":"/targets/tpr/","field":"links","label":"UniProt P12270"}]},{"url":"https://www.uniprot.org/uniprotkb/P12318/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/","field":"links","label":"UniProt P12318"}]},{"url":"https://www.uniprot.org/uniprotkb/P12524/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/","field":"links","label":"UniProt P12524"}]},{"url":"https://www.uniprot.org/uniprotkb/P12643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp2","kind":"target","name":"BMP2","route":"/targets/bmp2/","field":"links","label":"UniProt P12643"}]},{"url":"https://www.uniprot.org/uniprotkb/P12644/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp4","kind":"target","name":"BMP4","route":"/targets/bmp4/","field":"links","label":"UniProt P12644"}]},{"url":"https://www.uniprot.org/uniprotkb/P12757/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skil","kind":"target","name":"SKIL","route":"/targets/skil/","field":"links","label":"UniProt P12757"}]},{"url":"https://www.uniprot.org/uniprotkb/P12830/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/","field":"links","label":"UniProt P12830"}]},{"url":"https://www.uniprot.org/uniprotkb/P12931/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"src","kind":"target","name":"SRC family kinases","route":"/targets/src/","field":"links","label":"UniProt P12931: SRC"}]},{"url":"https://www.uniprot.org/uniprotkb/P12980/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lyl1","kind":"target","name":"LYL1","route":"/targets/lyl1/","field":"links","label":"UniProt P12980"}]},{"url":"https://www.uniprot.org/uniprotkb/P13378/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd8","kind":"target","name":"HOXD8","route":"/targets/hoxd8/","field":"links","label":"UniProt P13378"}]},{"url":"https://www.uniprot.org/uniprotkb/P13631/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rarg","kind":"target","name":"RARG","route":"/targets/rarg/","field":"links","label":"UniProt P13631"}]},{"url":"https://www.uniprot.org/uniprotkb/P13639/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","field":"links","label":"UniProt P13639: EEF2"}]},{"url":"https://www.uniprot.org/uniprotkb/P13647/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"krt5","kind":"target","name":"KRT5","route":"/targets/krt5/","field":"links","label":"UniProt P13647"}]},{"url":"https://www.uniprot.org/uniprotkb/P13688/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ceacam1","kind":"target","name":"CEACAM1","route":"/targets/ceacam1/","field":"links","label":"UniProt P13688"}]},{"url":"https://www.uniprot.org/uniprotkb/P13693/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpt1","kind":"target","name":"TPT1","route":"/targets/tpt1/","field":"links","label":"UniProt P13693"}]},{"url":"https://www.uniprot.org/uniprotkb/P13747/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hla-e","kind":"target","name":"HLA-E","route":"/targets/hla-e/","field":"links","label":"UniProt P13747"}]},{"url":"https://www.uniprot.org/uniprotkb/P14210/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/","field":"links","label":"UniProt P14210"}]},{"url":"https://www.uniprot.org/uniprotkb/P14222/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prf1","kind":"target","name":"PRF1","route":"/targets/prf1/","field":"links","label":"UniProt P14222"}]},{"url":"https://www.uniprot.org/uniprotkb/P14324/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/","field":"links","label":"UniProt P14324"}]},{"url":"https://www.uniprot.org/uniprotkb/P14373/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim27","kind":"target","name":"TRIM27","route":"/targets/trim27/","field":"links","label":"UniProt P14373"}]},{"url":"https://www.uniprot.org/uniprotkb/P14416/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","field":"links","label":"UniProt P14416: DRD2"}]},{"url":"https://www.uniprot.org/uniprotkb/P14625/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsp90b1","kind":"target","name":"HSP90B1","route":"/targets/hsp90b1/","field":"links","label":"UniProt P14625"}]},{"url":"https://www.uniprot.org/uniprotkb/P14679/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/","field":"links","label":"UniProt P14679"}]},{"url":"https://www.uniprot.org/uniprotkb/P14780/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mmp9","kind":"target","name":"MMP9","route":"/targets/mmp9/","field":"links","label":"UniProt P14780"}]},{"url":"https://www.uniprot.org/uniprotkb/P14784/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/","field":"links","label":"UniProt P14784"}]},{"url":"https://www.uniprot.org/uniprotkb/P14902/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/","field":"links","label":"UniProt P14902"}]},{"url":"https://www.uniprot.org/uniprotkb/P14921/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ets1","kind":"target","name":"ETS1","route":"/targets/ets1/","field":"links","label":"UniProt P14921"}]},{"url":"https://www.uniprot.org/uniprotkb/P15036/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ets2","kind":"target","name":"ETS2","route":"/targets/ets2/","field":"links","label":"UniProt P15036"}]},{"url":"https://www.uniprot.org/uniprotkb/P15151/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/","field":"links","label":"UniProt P15151"}]},{"url":"https://www.uniprot.org/uniprotkb/P15172/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myod1","kind":"target","name":"MYOD1","route":"/targets/myod1/","field":"links","label":"UniProt P15172"}]},{"url":"https://www.uniprot.org/uniprotkb/P15260/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifngr1","kind":"target","name":"IFNGR1","route":"/targets/ifngr1/","field":"links","label":"UniProt P15260"}]},{"url":"https://www.uniprot.org/uniprotkb/P15291/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b4galt1","kind":"target","name":"B4GALT1","route":"/targets/b4galt1/","field":"links","label":"UniProt P15291"}]},{"url":"https://www.uniprot.org/uniprotkb/P15309/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","field":"links","label":"UniProt P15309: ACP3"}]},{"url":"https://www.uniprot.org/uniprotkb/P15311/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ezr","kind":"target","name":"EZR","route":"/targets/ezr/","field":"links","label":"UniProt P15311"}]},{"url":"https://www.uniprot.org/uniprotkb/P15498/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/","field":"links","label":"UniProt P15498"}]},{"url":"https://www.uniprot.org/uniprotkb/P15502/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eln","kind":"target","name":"ELN","route":"/targets/eln/","field":"links","label":"UniProt P15502"}]},{"url":"https://www.uniprot.org/uniprotkb/P15509/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","field":"links","label":"UniProt P15509: CSF2RA"}]},{"url":"https://www.uniprot.org/uniprotkb/P15514/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"areg","kind":"target","name":"AREG","route":"/targets/areg/","field":"links","label":"UniProt P15514"}]},{"url":"https://www.uniprot.org/uniprotkb/P15538/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp11b1","kind":"target","name":"CYP11B1","route":"/targets/cyp11b1/","field":"links","label":"UniProt P15538"}]},{"url":"https://www.uniprot.org/uniprotkb/P15559/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nqo1","kind":"target","name":"NQO1","route":"/targets/nqo1/","field":"links","label":"UniProt P15559"}]},{"url":"https://www.uniprot.org/uniprotkb/P15884/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf4","kind":"target","name":"TCF4","route":"/targets/tcf4/","field":"links","label":"UniProt P15884"}]},{"url":"https://www.uniprot.org/uniprotkb/P15923/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf3","kind":"target","name":"TCF3","route":"/targets/tcf3/","field":"links","label":"UniProt P15923"}]},{"url":"https://www.uniprot.org/uniprotkb/P15924/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dsp","kind":"target","name":"DSP","route":"/targets/dsp/","field":"links","label":"UniProt P15924"}]},{"url":"https://www.uniprot.org/uniprotkb/P15976/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata1","kind":"target","name":"GATA1","route":"/targets/gata1/","field":"links","label":"UniProt P15976"}]},{"url":"https://www.uniprot.org/uniprotkb/P16070/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/","field":"links","label":"UniProt P16070"}]},{"url":"https://www.uniprot.org/uniprotkb/P16157/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ank1","kind":"target","name":"ANK1","route":"/targets/ank1/","field":"links","label":"UniProt P16157"}]},{"url":"https://www.uniprot.org/uniprotkb/P16220/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb1","kind":"target","name":"CREB1","route":"/targets/creb1/","field":"links","label":"UniProt P16220"}]},{"url":"https://www.uniprot.org/uniprotkb/P16401/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-5","kind":"target","name":"H1-5","route":"/targets/h1-5/","field":"links","label":"UniProt P16401"}]},{"url":"https://www.uniprot.org/uniprotkb/P16402/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-3","kind":"target","name":"H1-3","route":"/targets/h1-3/","field":"links","label":"UniProt P16402"}]},{"url":"https://www.uniprot.org/uniprotkb/P16403/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h1-2","kind":"target","name":"H1-2","route":"/targets/h1-2/","field":"links","label":"UniProt P16403"}]},{"url":"https://www.uniprot.org/uniprotkb/P16442/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abo","kind":"target","name":"ABO","route":"/targets/abo/","field":"links","label":"UniProt P16442"}]},{"url":"https://www.uniprot.org/uniprotkb/P16455/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mgmt-protein","kind":"target","name":"MGMT (O6-methylguanine-DNA methyltransferase)","route":"/targets/mgmt-protein/","field":"links","label":"UniProt P16455"}]},{"url":"https://www.uniprot.org/uniprotkb/P16473/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","field":"links","label":"UniProt P16473: TSHR"}]},{"url":"https://www.uniprot.org/uniprotkb/P16871/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il7r","kind":"target","name":"IL7R","route":"/targets/il7r/","field":"links","label":"UniProt P16871"}]},{"url":"https://www.uniprot.org/uniprotkb/P16885/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","field":"links","label":"UniProt P16885"}]},{"url":"https://www.uniprot.org/uniprotkb/P16949/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stmn1","kind":"target","name":"STMN1","route":"/targets/stmn1/","field":"links","label":"UniProt P16949"}]},{"url":"https://www.uniprot.org/uniprotkb/P17096/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmga1","kind":"target","name":"HMGA1","route":"/targets/hmga1/","field":"links","label":"UniProt P17096"}]},{"url":"https://www.uniprot.org/uniprotkb/P17181/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifnar1","kind":"target","name":"Interferon alpha receptor (IFNAR1)","route":"/targets/ifnar1/","field":"links","label":"UniProt P17181: IFNAR1"}]},{"url":"https://www.uniprot.org/uniprotkb/P17252/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","field":"links","label":"UniProt P17252: PRKCA"}]},{"url":"https://www.uniprot.org/uniprotkb/P17480/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubtf","kind":"target","name":"UBTF","route":"/targets/ubtf/","field":"links","label":"UniProt P17480"}]},{"url":"https://www.uniprot.org/uniprotkb/P17542/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tal1","kind":"target","name":"TAL1","route":"/targets/tal1/","field":"links","label":"UniProt P17542"}]},{"url":"https://www.uniprot.org/uniprotkb/P17612/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkaca","kind":"target","name":"PRKACA","route":"/targets/prkaca/","field":"links","label":"UniProt P17612"}]},{"url":"https://www.uniprot.org/uniprotkb/P17643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyrp1","kind":"target","name":"TYRP1","route":"/targets/tyrp1/","field":"links","label":"UniProt P17643"}]},{"url":"https://www.uniprot.org/uniprotkb/P17752/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","field":"links","label":"UniProt P17752: TPH1"}]},{"url":"https://www.uniprot.org/uniprotkb/P17844/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx5","kind":"target","name":"DDX5","route":"/targets/ddx5/","field":"links","label":"UniProt P17844"}]},{"url":"https://www.uniprot.org/uniprotkb/P17980/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/","field":"links","label":"UniProt P17980"}]},{"url":"https://www.uniprot.org/uniprotkb/P18074/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/","field":"links","label":"UniProt P18074"}]},{"url":"https://www.uniprot.org/uniprotkb/P18075/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp7","kind":"target","name":"BMP7","route":"/targets/bmp7/","field":"links","label":"UniProt P18075"}]},{"url":"https://www.uniprot.org/uniprotkb/P18089/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2b","kind":"target","name":"ADRA2B","route":"/targets/adra2b/","field":"links","label":"UniProt P18089"}]},{"url":"https://www.uniprot.org/uniprotkb/P18206/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vcl","kind":"target","name":"VCL","route":"/targets/vcl/","field":"links","label":"UniProt P18206"}]},{"url":"https://www.uniprot.org/uniprotkb/P18405/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a1","kind":"target","name":"SRD5A1","route":"/targets/srd5a1/","field":"links","label":"UniProt P18405"}]},{"url":"https://www.uniprot.org/uniprotkb/P18825/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra2c","kind":"target","name":"ADRA2C","route":"/targets/adra2c/","field":"links","label":"UniProt P18825"}]},{"url":"https://www.uniprot.org/uniprotkb/P18846/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atf1","kind":"target","name":"ATF1","route":"/targets/atf1/","field":"links","label":"UniProt P18846"}]},{"url":"https://www.uniprot.org/uniprotkb/P18887/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/","field":"links","label":"UniProt P18887"}]},{"url":"https://www.uniprot.org/uniprotkb/P19174/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/","field":"links","label":"UniProt P19174"}]},{"url":"https://www.uniprot.org/uniprotkb/P19235/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epor","kind":"target","name":"Erythropoietin receptor (EPOR)","route":"/targets/epor/","field":"links","label":"UniProt P19235: EPOR"}]},{"url":"https://www.uniprot.org/uniprotkb/P19256/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd58","kind":"target","name":"CD58","route":"/targets/cd58/","field":"links","label":"UniProt P19256"}]},{"url":"https://www.uniprot.org/uniprotkb/P19447/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/","field":"links","label":"UniProt P19447"}]},{"url":"https://www.uniprot.org/uniprotkb/P19484/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfeb","kind":"target","name":"TFEB","route":"/targets/tfeb/","field":"links","label":"UniProt P19484"}]},{"url":"https://www.uniprot.org/uniprotkb/P19532/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfe3","kind":"target","name":"TFE3","route":"/targets/tfe3/","field":"links","label":"UniProt P19532"}]},{"url":"https://www.uniprot.org/uniprotkb/P19544/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/","field":"links","label":"UniProt P19544"}]},{"url":"https://www.uniprot.org/uniprotkb/P19971/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tymp","kind":"target","name":"TYMP","route":"/targets/tymp/","field":"links","label":"UniProt P19971"}]},{"url":"https://www.uniprot.org/uniprotkb/P20585/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msh3","kind":"target","name":"MSH3","route":"/targets/msh3/","field":"links","label":"UniProt P20585"}]},{"url":"https://www.uniprot.org/uniprotkb/P20592/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mx2","kind":"target","name":"MX2","route":"/targets/mx2/","field":"links","label":"UniProt P20592"}]},{"url":"https://www.uniprot.org/uniprotkb/P20618/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/","field":"links","label":"UniProt P20618"}]},{"url":"https://www.uniprot.org/uniprotkb/P20648/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp4a","kind":"target","name":"ATP4A","route":"/targets/atp4a/","field":"links","label":"UniProt P20648"}]},{"url":"https://www.uniprot.org/uniprotkb/P20749/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl3","kind":"target","name":"BCL3","route":"/targets/bcl3/","field":"links","label":"UniProt P20749"}]},{"url":"https://www.uniprot.org/uniprotkb/P20823/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/","field":"links","label":"UniProt P20823"}]},{"url":"https://www.uniprot.org/uniprotkb/P20839/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"impdh1","kind":"target","name":"IMPDH1","route":"/targets/impdh1/","field":"links","label":"UniProt P20839"}]},{"url":"https://www.uniprot.org/uniprotkb/P20930/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flg","kind":"target","name":"FLG","route":"/targets/flg/","field":"links","label":"UniProt P20930"}]},{"url":"https://www.uniprot.org/uniprotkb/P20936/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rasa1","kind":"target","name":"RASA1","route":"/targets/rasa1/","field":"links","label":"UniProt P20936"}]},{"url":"https://www.uniprot.org/uniprotkb/P21359/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nf1","kind":"target","name":"NF1 (neurofibromin)","route":"/targets/nf1/","field":"links","label":"UniProt P21359"}]},{"url":"https://www.uniprot.org/uniprotkb/P21453/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"s1pr1","kind":"target","name":"S1PR1","route":"/targets/s1pr1/","field":"links","label":"UniProt P21453"}]},{"url":"https://www.uniprot.org/uniprotkb/P21554/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","field":"links","label":"UniProt P21554: CNR1"}]},{"url":"https://www.uniprot.org/uniprotkb/P21580/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/","field":"links","label":"UniProt P21580"}]},{"url":"https://www.uniprot.org/uniprotkb/P21583/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kitlg","kind":"target","name":"KITLG","route":"/targets/kitlg/","field":"links","label":"UniProt P21583"}]},{"url":"https://www.uniprot.org/uniprotkb/P21709/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha1","kind":"target","name":"EPHA1","route":"/targets/epha1/","field":"links","label":"UniProt P21709"}]},{"url":"https://www.uniprot.org/uniprotkb/P21757/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msr1","kind":"target","name":"MSR1","route":"/targets/msr1/","field":"links","label":"UniProt P21757"}]},{"url":"https://www.uniprot.org/uniprotkb/P21781/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf7","kind":"target","name":"FGF7","route":"/targets/fgf7/","field":"links","label":"UniProt P21781"}]},{"url":"https://www.uniprot.org/uniprotkb/P21912/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhb","kind":"target","name":"SDHB","route":"/targets/sdhb/","field":"links","label":"UniProt P21912"}]},{"url":"https://www.uniprot.org/uniprotkb/P21918/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drd5","kind":"target","name":"DRD5","route":"/targets/drd5/","field":"links","label":"UniProt P21918"}]},{"url":"https://www.uniprot.org/uniprotkb/P22001/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcna3","kind":"target","name":"KCNA3","route":"/targets/kcna3/","field":"links","label":"UniProt P22001"}]},{"url":"https://www.uniprot.org/uniprotkb/P22003/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp5","kind":"target","name":"BMP5","route":"/targets/bmp5/","field":"links","label":"UniProt P22003"}]},{"url":"https://www.uniprot.org/uniprotkb/P22004/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmp6","kind":"target","name":"BMP6","route":"/targets/bmp6/","field":"links","label":"UniProt P22004"}]},{"url":"https://www.uniprot.org/uniprotkb/P22102/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","field":"links","label":"UniProt P22102: GART"}]},{"url":"https://www.uniprot.org/uniprotkb/P22301/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","field":"links","label":"UniProt P22301"}]},{"url":"https://www.uniprot.org/uniprotkb/P22309/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ugt1a1","kind":"target","name":"UGT1A1","route":"/targets/ugt1a1/","field":"links","label":"UniProt P22309"}]},{"url":"https://www.uniprot.org/uniprotkb/P22455/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/","field":"links","label":"UniProt P22455"}]},{"url":"https://www.uniprot.org/uniprotkb/P22459/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcna4","kind":"target","name":"KCNA4","route":"/targets/kcna4/","field":"links","label":"UniProt P22459"}]},{"url":"https://www.uniprot.org/uniprotkb/P22607/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/","field":"links","label":"UniProt P22607: FGFR3"}]},{"url":"https://www.uniprot.org/uniprotkb/P22626/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnpa2b1","kind":"target","name":"HNRNPA2B1","route":"/targets/hnrnpa2b1/","field":"links","label":"UniProt P22626"}]},{"url":"https://www.uniprot.org/uniprotkb/P22681/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/","field":"links","label":"UniProt P22681"}]},{"url":"https://www.uniprot.org/uniprotkb/P23025/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xpa","kind":"target","name":"XPA","route":"/targets/xpa/","field":"links","label":"UniProt P23025"}]},{"url":"https://www.uniprot.org/uniprotkb/P23193/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcea1","kind":"target","name":"TCEA1","route":"/targets/tcea1/","field":"links","label":"UniProt P23193"}]},{"url":"https://www.uniprot.org/uniprotkb/P23219/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptgs1","kind":"target","name":"PTGS1","route":"/targets/ptgs1/","field":"links","label":"UniProt P23219"}]},{"url":"https://www.uniprot.org/uniprotkb/P23229/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itga6","kind":"target","name":"ITGA6","route":"/targets/itga6/","field":"links","label":"UniProt P23229"}]},{"url":"https://www.uniprot.org/uniprotkb/P23246/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sfpq","kind":"target","name":"SFPQ","route":"/targets/sfpq/","field":"links","label":"UniProt P23246"}]},{"url":"https://www.uniprot.org/uniprotkb/P23458/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/","field":"links","label":"UniProt P23458"}]},{"url":"https://www.uniprot.org/uniprotkb/P23467/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/","field":"links","label":"UniProt P23467"}]},{"url":"https://www.uniprot.org/uniprotkb/P23468/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/","field":"links","label":"UniProt P23468"}]},{"url":"https://www.uniprot.org/uniprotkb/P23759/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax7","kind":"target","name":"PAX7","route":"/targets/pax7/","field":"links","label":"UniProt P23759"}]},{"url":"https://www.uniprot.org/uniprotkb/P23760/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax3","kind":"target","name":"PAX3","route":"/targets/pax3/","field":"links","label":"UniProt P23760"}]},{"url":"https://www.uniprot.org/uniprotkb/P23769/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/","field":"links","label":"UniProt P23769"}]},{"url":"https://www.uniprot.org/uniprotkb/P23771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gata3","kind":"target","name":"GATA3","route":"/targets/gata3/","field":"links","label":"UniProt P23771"}]},{"url":"https://www.uniprot.org/uniprotkb/P23921/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrm1","kind":"target","name":"Ribonucleotide reductase (RRM1)","route":"/targets/rrm1/","field":"links","label":"UniProt P23921: RRM1"}]},{"url":"https://www.uniprot.org/uniprotkb/P23975/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a2","kind":"target","name":"SLC6A2","route":"/targets/slc6a2/","field":"links","label":"UniProt P23975"}]},{"url":"https://www.uniprot.org/uniprotkb/P24385/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","field":"links","label":"UniProt P24385"}]},{"url":"https://www.uniprot.org/uniprotkb/P24394/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il4r","kind":"target","name":"IL4R","route":"/targets/il4r/","field":"links","label":"UniProt P24394"}]},{"url":"https://www.uniprot.org/uniprotkb/P24468/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr2f2","kind":"target","name":"NR2F2","route":"/targets/nr2f2/","field":"links","label":"UniProt P24468"}]},{"url":"https://www.uniprot.org/uniprotkb/P24522/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/","field":"links","label":"UniProt P24522"}]},{"url":"https://www.uniprot.org/uniprotkb/P24821/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/","field":"links","label":"UniProt P24821"}]},{"url":"https://www.uniprot.org/uniprotkb/P24864/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","field":"links","label":"UniProt P24864"}]},{"url":"https://www.uniprot.org/uniprotkb/P24941/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/","field":"links","label":"UniProt P24941"}]},{"url":"https://www.uniprot.org/uniprotkb/P25054/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","field":"links","label":"UniProt P25054"}]},{"url":"https://www.uniprot.org/uniprotkb/P25063/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/","field":"links","label":"UniProt P25063"}]},{"url":"https://www.uniprot.org/uniprotkb/P25100/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1d","kind":"target","name":"ADRA1D","route":"/targets/adra1d/","field":"links","label":"UniProt P25100"}]},{"url":"https://www.uniprot.org/uniprotkb/P25101/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ednra","kind":"target","name":"EDNRA","route":"/targets/ednra/","field":"links","label":"UniProt P25101"}]},{"url":"https://www.uniprot.org/uniprotkb/P25103/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tacr1","kind":"target","name":"NK1 receptor (TACR1)","route":"/targets/tacr1/","field":"links","label":"UniProt P25103: TACR1"}]},{"url":"https://www.uniprot.org/uniprotkb/P25106/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/","field":"links","label":"UniProt P25106"}]},{"url":"https://www.uniprot.org/uniprotkb/P25445/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/","field":"links","label":"UniProt P25445"}]},{"url":"https://www.uniprot.org/uniprotkb/P25685/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajb1","kind":"target","name":"DNAJB1","route":"/targets/dnajb1/","field":"links","label":"UniProt P25685"}]},{"url":"https://www.uniprot.org/uniprotkb/P25774/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctss","kind":"target","name":"CTSS","route":"/targets/ctss/","field":"links","label":"UniProt P25774"}]},{"url":"https://www.uniprot.org/uniprotkb/P25786/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/","field":"links","label":"UniProt P25786"}]},{"url":"https://www.uniprot.org/uniprotkb/P25787/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/","field":"links","label":"UniProt P25787"}]},{"url":"https://www.uniprot.org/uniprotkb/P25788/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/","field":"links","label":"UniProt P25788"}]},{"url":"https://www.uniprot.org/uniprotkb/P25789/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/","field":"links","label":"UniProt P25789"}]},{"url":"https://www.uniprot.org/uniprotkb/P25791/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo2","kind":"target","name":"LMO2","route":"/targets/lmo2/","field":"links","label":"UniProt P25791"}]},{"url":"https://www.uniprot.org/uniprotkb/P25800/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo1","kind":"target","name":"LMO1","route":"/targets/lmo1/","field":"links","label":"UniProt P25800"}]},{"url":"https://www.uniprot.org/uniprotkb/P25942/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/","field":"links","label":"UniProt P25942"}]},{"url":"https://www.uniprot.org/uniprotkb/P25963/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/","field":"links","label":"UniProt P25963"}]},{"url":"https://www.uniprot.org/uniprotkb/P26038/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msn","kind":"target","name":"MSN","route":"/targets/msn/","field":"links","label":"UniProt P26038"}]},{"url":"https://www.uniprot.org/uniprotkb/P26045/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn3","kind":"target","name":"PTPN3","route":"/targets/ptpn3/","field":"links","label":"UniProt P26045"}]},{"url":"https://www.uniprot.org/uniprotkb/P26196/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx6","kind":"target","name":"DDX6","route":"/targets/ddx6/","field":"links","label":"UniProt P26196"}]},{"url":"https://www.uniprot.org/uniprotkb/P26232/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnna2","kind":"target","name":"CTNNA2","route":"/targets/ctnna2/","field":"links","label":"UniProt P26232"}]},{"url":"https://www.uniprot.org/uniprotkb/P26358/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnmt1","kind":"target","name":"DNMT1 (DNA methyltransferase 1)","route":"/targets/dnmt1/","field":"links","label":"UniProt P26358: DNMT1"}]},{"url":"https://www.uniprot.org/uniprotkb/P26367/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax6","kind":"target","name":"PAX6","route":"/targets/pax6/","field":"links","label":"UniProt P26367"}]},{"url":"https://www.uniprot.org/uniprotkb/P26368/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"u2af2","kind":"target","name":"U2AF2","route":"/targets/u2af2/","field":"links","label":"UniProt P26368"}]},{"url":"https://www.uniprot.org/uniprotkb/P26715/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klrc1","kind":"target","name":"NKG2A (KLRC1)","route":"/targets/klrc1/","field":"links","label":"UniProt P26715"}]},{"url":"https://www.uniprot.org/uniprotkb/P26842/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/","field":"links","label":"UniProt P26842"}]},{"url":"https://www.uniprot.org/uniprotkb/P27037/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr2a","kind":"target","name":"ACVR2A","route":"/targets/acvr2a/","field":"links","label":"UniProt P27037"}]},{"url":"https://www.uniprot.org/uniprotkb/P27361/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/","field":"links","label":"UniProt P27361"}]},{"url":"https://www.uniprot.org/uniprotkb/P27448/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mark3","kind":"target","name":"MARK3","route":"/targets/mark3/","field":"links","label":"UniProt P27448"}]},{"url":"https://www.uniprot.org/uniprotkb/P27540/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/","field":"links","label":"UniProt P27540"}]},{"url":"https://www.uniprot.org/uniprotkb/P27635/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/","field":"links","label":"UniProt P27635"}]},{"url":"https://www.uniprot.org/uniprotkb/P27797/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","field":"links","label":"UniProt P27797"}]},{"url":"https://www.uniprot.org/uniprotkb/P27986/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/","field":"links","label":"UniProt P27986"}]},{"url":"https://www.uniprot.org/uniprotkb/P27987/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itpkb","kind":"target","name":"ITPKB","route":"/targets/itpkb/","field":"links","label":"UniProt P27987"}]},{"url":"https://www.uniprot.org/uniprotkb/P28062/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/","field":"links","label":"UniProt P28062"}]},{"url":"https://www.uniprot.org/uniprotkb/P28065/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/","field":"links","label":"UniProt P28065"}]},{"url":"https://www.uniprot.org/uniprotkb/P28066/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/","field":"links","label":"UniProt P28066"}]},{"url":"https://www.uniprot.org/uniprotkb/P28070/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/","field":"links","label":"UniProt P28070"}]},{"url":"https://www.uniprot.org/uniprotkb/P28072/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/","field":"links","label":"UniProt P28072"}]},{"url":"https://www.uniprot.org/uniprotkb/P28074/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/","field":"links","label":"UniProt P28074: PSMB5"}]},{"url":"https://www.uniprot.org/uniprotkb/P28324/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elk4","kind":"target","name":"ELK4","route":"/targets/elk4/","field":"links","label":"UniProt P28324"}]},{"url":"https://www.uniprot.org/uniprotkb/P28340/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","field":"links","label":"UniProt P28340"}]},{"url":"https://www.uniprot.org/uniprotkb/P28482/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/","field":"links","label":"UniProt P28482"}]},{"url":"https://www.uniprot.org/uniprotkb/P28715/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/","field":"links","label":"UniProt P28715"}]},{"url":"https://www.uniprot.org/uniprotkb/P29274/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","route":"/targets/adora2a/","field":"links","label":"UniProt P29274"}]},{"url":"https://www.uniprot.org/uniprotkb/P29279/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccn2","kind":"target","name":"CCN2","route":"/targets/ccn2/","field":"links","label":"UniProt P29279"}]},{"url":"https://www.uniprot.org/uniprotkb/P29317/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","field":"links","label":"UniProt P29317: EPHA2"}]},{"url":"https://www.uniprot.org/uniprotkb/P29320/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha3","kind":"target","name":"EPHA3","route":"/targets/epha3/","field":"links","label":"UniProt P29320"}]},{"url":"https://www.uniprot.org/uniprotkb/P29322/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha8","kind":"target","name":"EPHA8","route":"/targets/epha8/","field":"links","label":"UniProt P29322"}]},{"url":"https://www.uniprot.org/uniprotkb/P29323/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb2","kind":"target","name":"EPHB2","route":"/targets/ephb2/","field":"links","label":"UniProt P29323"}]},{"url":"https://www.uniprot.org/uniprotkb/P29350/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn6","kind":"target","name":"PTPN6","route":"/targets/ptpn6/","field":"links","label":"UniProt P29350"}]},{"url":"https://www.uniprot.org/uniprotkb/P29353/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shc1","kind":"target","name":"SHC1","route":"/targets/shc1/","field":"links","label":"UniProt P29353"}]},{"url":"https://www.uniprot.org/uniprotkb/P29375/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5a","kind":"target","name":"KDM5A","route":"/targets/kdm5a/","field":"links","label":"UniProt P29375"}]},{"url":"https://www.uniprot.org/uniprotkb/P29590/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pml","kind":"target","name":"PML","route":"/targets/pml/","field":"links","label":"UniProt P29590"}]},{"url":"https://www.uniprot.org/uniprotkb/P29597/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyk2","kind":"target","name":"TYK2","route":"/targets/tyk2/","field":"links","label":"UniProt P29597"}]},{"url":"https://www.uniprot.org/uniprotkb/P29992/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","field":"links","label":"UniProt P29992"}]},{"url":"https://www.uniprot.org/uniprotkb/P30039/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbld","kind":"target","name":"PBLD","route":"/targets/pbld/","field":"links","label":"UniProt P30039"}]},{"url":"https://www.uniprot.org/uniprotkb/P30153/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/","field":"links","label":"UniProt P30153"}]},{"url":"https://www.uniprot.org/uniprotkb/P30154/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r1b","kind":"target","name":"PPP2R1B","route":"/targets/ppp2r1b/","field":"links","label":"UniProt P30154"}]},{"url":"https://www.uniprot.org/uniprotkb/P30279/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd2","kind":"target","name":"CCND2","route":"/targets/ccnd2/","field":"links","label":"UniProt P30279"}]},{"url":"https://www.uniprot.org/uniprotkb/P30281/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnd3","kind":"target","name":"CCND3","route":"/targets/ccnd3/","field":"links","label":"UniProt P30281"}]},{"url":"https://www.uniprot.org/uniprotkb/P30414/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nktr","kind":"target","name":"NKTR","route":"/targets/nktr/","field":"links","label":"UniProt P30414"}]},{"url":"https://www.uniprot.org/uniprotkb/P30530/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/","field":"links","label":"UniProt P30530: AXL"}]},{"url":"https://www.uniprot.org/uniprotkb/P30532/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna5","kind":"target","name":"CHRNA5","route":"/targets/chrna5/","field":"links","label":"UniProt P30532"}]},{"url":"https://www.uniprot.org/uniprotkb/P30622/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/","field":"links","label":"UniProt P30622"}]},{"url":"https://www.uniprot.org/uniprotkb/P30872/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr1","kind":"target","name":"SSTR1","route":"/targets/sstr1/","field":"links","label":"UniProt P30872"}]},{"url":"https://www.uniprot.org/uniprotkb/P30968/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnrhr","kind":"target","name":"GnRH receptor (GNRHR)","route":"/targets/gnrhr/","field":"links","label":"UniProt P30968: GNRHR"}]},{"url":"https://www.uniprot.org/uniprotkb/P31040/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","field":"links","label":"UniProt P31040"}]},{"url":"https://www.uniprot.org/uniprotkb/P31213/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","field":"links","label":"UniProt P31213: SRD5A2"}]},{"url":"https://www.uniprot.org/uniprotkb/P31269/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa9","kind":"target","name":"HOXA9","route":"/targets/hoxa9/","field":"links","label":"UniProt P31269"}]},{"url":"https://www.uniprot.org/uniprotkb/P31270/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa11","kind":"target","name":"HOXA11","route":"/targets/hoxa11/","field":"links","label":"UniProt P31270"}]},{"url":"https://www.uniprot.org/uniprotkb/P31271/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxa13","kind":"target","name":"HOXA13","route":"/targets/hoxa13/","field":"links","label":"UniProt P31271"}]},{"url":"https://www.uniprot.org/uniprotkb/P31276/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc13","kind":"target","name":"HOXC13","route":"/targets/hoxc13/","field":"links","label":"UniProt P31276"}]},{"url":"https://www.uniprot.org/uniprotkb/P31277/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd11","kind":"target","name":"HOXD11","route":"/targets/hoxd11/","field":"links","label":"UniProt P31277"}]},{"url":"https://www.uniprot.org/uniprotkb/P31314/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlx1","kind":"target","name":"TLX1","route":"/targets/tlx1/","field":"links","label":"UniProt P31314"}]},{"url":"https://www.uniprot.org/uniprotkb/P31350/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/","field":"links","label":"UniProt P31350"}]},{"url":"https://www.uniprot.org/uniprotkb/P31371/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf9","kind":"target","name":"FGF9","route":"/targets/fgf9/","field":"links","label":"UniProt P31371"}]},{"url":"https://www.uniprot.org/uniprotkb/P31391/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr4","kind":"target","name":"SSTR4","route":"/targets/sstr4/","field":"links","label":"UniProt P31391"}]},{"url":"https://www.uniprot.org/uniprotkb/P31431/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdc4","kind":"target","name":"SDC4","route":"/targets/sdc4/","field":"links","label":"UniProt P31431"}]},{"url":"https://www.uniprot.org/uniprotkb/P31645/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a4","kind":"target","name":"SLC6A4","route":"/targets/slc6a4/","field":"links","label":"UniProt P31645"}]},{"url":"https://www.uniprot.org/uniprotkb/P31785/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/","field":"links","label":"UniProt P31785"}]},{"url":"https://www.uniprot.org/uniprotkb/P31939/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atic","kind":"target","name":"ATIC","route":"/targets/atic/","field":"links","label":"UniProt P31939"}]},{"url":"https://www.uniprot.org/uniprotkb/P31943/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnph1","kind":"target","name":"HNRNPH1","route":"/targets/hnrnph1/","field":"links","label":"UniProt P31943"}]},{"url":"https://www.uniprot.org/uniprotkb/P31946/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ywhab","kind":"target","name":"YWHAB","route":"/targets/ywhab/","field":"links","label":"UniProt P31946"}]},{"url":"https://www.uniprot.org/uniprotkb/P31994/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/","field":"links","label":"UniProt P31994"}]},{"url":"https://www.uniprot.org/uniprotkb/P32121/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrb2","kind":"target","name":"ARRB2","route":"/targets/arrb2/","field":"links","label":"UniProt P32121"}]},{"url":"https://www.uniprot.org/uniprotkb/P32242/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"otx1","kind":"target","name":"OTX1","route":"/targets/otx1/","field":"links","label":"UniProt P32242"}]},{"url":"https://www.uniprot.org/uniprotkb/P32248/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccr7","kind":"target","name":"CCR7","route":"/targets/ccr7/","field":"links","label":"UniProt P32248"}]},{"url":"https://www.uniprot.org/uniprotkb/P32297/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna3","kind":"target","name":"CHRNA3","route":"/targets/chrna3/","field":"links","label":"UniProt P32297"}]},{"url":"https://www.uniprot.org/uniprotkb/P32320/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cda","kind":"target","name":"CDA","route":"/targets/cda/","field":"links","label":"UniProt P32320"}]},{"url":"https://www.uniprot.org/uniprotkb/P32745/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr3","kind":"target","name":"SSTR3","route":"/targets/sstr3/","field":"links","label":"UniProt P32745"}]},{"url":"https://www.uniprot.org/uniprotkb/P32927/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf2rb","kind":"target","name":"CSF2RB","route":"/targets/csf2rb/","field":"links","label":"UniProt P32927"}]},{"url":"https://www.uniprot.org/uniprotkb/P33076/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ciita","kind":"target","name":"CIITA","route":"/targets/ciita/","field":"links","label":"UniProt P33076"}]},{"url":"https://www.uniprot.org/uniprotkb/P33176/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kif5b","kind":"target","name":"KIF5B","route":"/targets/kif5b/","field":"links","label":"UniProt P33176"}]},{"url":"https://www.uniprot.org/uniprotkb/P33241/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lsp1","kind":"target","name":"LSP1","route":"/targets/lsp1/","field":"links","label":"UniProt P33241"}]},{"url":"https://www.uniprot.org/uniprotkb/P33527/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc1","kind":"target","name":"ABCC1","route":"/targets/abcc1/","field":"links","label":"UniProt P33527"}]},{"url":"https://www.uniprot.org/uniprotkb/P33681/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/","field":"links","label":"UniProt P33681"}]},{"url":"https://www.uniprot.org/uniprotkb/P33981/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ttk","kind":"target","name":"MPS1 (TTK)","route":"/targets/ttk/","field":"links","label":"UniProt P33981"}]},{"url":"https://www.uniprot.org/uniprotkb/P33993/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/","field":"links","label":"UniProt P33993"}]},{"url":"https://www.uniprot.org/uniprotkb/P35070/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/","field":"links","label":"UniProt P35070"}]},{"url":"https://www.uniprot.org/uniprotkb/P35125/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp6","kind":"target","name":"USP6","route":"/targets/usp6/","field":"links","label":"UniProt P35125"}]},{"url":"https://www.uniprot.org/uniprotkb/P35221/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/","field":"links","label":"UniProt P35221"}]},{"url":"https://www.uniprot.org/uniprotkb/P35222/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","field":"links","label":"UniProt P35222"}]},{"url":"https://www.uniprot.org/uniprotkb/P35240/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","field":"links","label":"UniProt P35240"}]},{"url":"https://www.uniprot.org/uniprotkb/P35268/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl22","kind":"target","name":"RPL22","route":"/targets/rpl22/","field":"links","label":"UniProt P35268"}]},{"url":"https://www.uniprot.org/uniprotkb/P35346/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/","field":"links","label":"UniProt P35346"}]},{"url":"https://www.uniprot.org/uniprotkb/P35348/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1a","kind":"target","name":"ADRA1A","route":"/targets/adra1a/","field":"links","label":"UniProt P35348"}]},{"url":"https://www.uniprot.org/uniprotkb/P35354/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","field":"links","label":"UniProt P35354: PTGS2"}]},{"url":"https://www.uniprot.org/uniprotkb/P35368/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adra1b","kind":"target","name":"ADRA1B","route":"/targets/adra1b/","field":"links","label":"UniProt P35368"}]},{"url":"https://www.uniprot.org/uniprotkb/P35372/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","field":"links","label":"UniProt P35372: OPRM1"}]},{"url":"https://www.uniprot.org/uniprotkb/P35442/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thbs2","kind":"target","name":"THBS2","route":"/targets/thbs2/","field":"links","label":"UniProt P35442"}]},{"url":"https://www.uniprot.org/uniprotkb/P35453/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxd13","kind":"target","name":"HOXD13","route":"/targets/hoxd13/","field":"links","label":"UniProt P35453"}]},{"url":"https://www.uniprot.org/uniprotkb/P35498/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn1a","kind":"target","name":"SCN1A","route":"/targets/scn1a/","field":"links","label":"UniProt P35498"}]},{"url":"https://www.uniprot.org/uniprotkb/P35499/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn4a","kind":"target","name":"SCN4A","route":"/targets/scn4a/","field":"links","label":"UniProt P35499"}]},{"url":"https://www.uniprot.org/uniprotkb/P35556/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/","field":"links","label":"UniProt P35556"}]},{"url":"https://www.uniprot.org/uniprotkb/P35568/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs1","kind":"target","name":"IRS1","route":"/targets/irs1/","field":"links","label":"UniProt P35568"}]},{"url":"https://www.uniprot.org/uniprotkb/P35579/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/","field":"links","label":"UniProt P35579"}]},{"url":"https://www.uniprot.org/uniprotkb/P35637/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fus","kind":"target","name":"FUS","route":"/targets/fus/","field":"links","label":"UniProt P35637"}]},{"url":"https://www.uniprot.org/uniprotkb/P35658/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nup214","kind":"target","name":"NUP214","route":"/targets/nup214/","field":"links","label":"UniProt P35658"}]},{"url":"https://www.uniprot.org/uniprotkb/P35659/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dek","kind":"target","name":"DEK","route":"/targets/dek/","field":"links","label":"UniProt P35659"}]},{"url":"https://www.uniprot.org/uniprotkb/P35670/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/","field":"links","label":"UniProt P35670"}]},{"url":"https://www.uniprot.org/uniprotkb/P35680/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/","field":"links","label":"UniProt P35680"}]},{"url":"https://www.uniprot.org/uniprotkb/P35749/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myh11","kind":"target","name":"MYH11","route":"/targets/myh11/","field":"links","label":"UniProt P35749"}]},{"url":"https://www.uniprot.org/uniprotkb/P35789/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf93","kind":"target","name":"ZNF93","route":"/targets/znf93/","field":"links","label":"UniProt P35789"}]},{"url":"https://www.uniprot.org/uniprotkb/P35998/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/","field":"links","label":"UniProt P35998"}]},{"url":"https://www.uniprot.org/uniprotkb/P36894/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/","field":"links","label":"UniProt P36894"}]},{"url":"https://www.uniprot.org/uniprotkb/P36896/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr1b","kind":"target","name":"ACVR1B","route":"/targets/acvr1b/","field":"links","label":"UniProt P36896"}]},{"url":"https://www.uniprot.org/uniprotkb/P36897/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr1","kind":"target","name":"TGFBR1","route":"/targets/tgfbr1/","field":"links","label":"UniProt P36897"}]},{"url":"https://www.uniprot.org/uniprotkb/P36957/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dlst","kind":"target","name":"DLST","route":"/targets/dlst/","field":"links","label":"UniProt P36957"}]},{"url":"https://www.uniprot.org/uniprotkb/P37173/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","field":"links","label":"UniProt P37173"}]},{"url":"https://www.uniprot.org/uniprotkb/P37231/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/","field":"links","label":"UniProt P37231"}]},{"url":"https://www.uniprot.org/uniprotkb/P37275/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/","field":"links","label":"UniProt P37275"}]},{"url":"https://www.uniprot.org/uniprotkb/P38936/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn1a","kind":"target","name":"CDKN1A","route":"/targets/cdkn1a/","field":"links","label":"UniProt P38936"}]},{"url":"https://www.uniprot.org/uniprotkb/P39019/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps19","kind":"target","name":"RPS19","route":"/targets/rps19/","field":"links","label":"UniProt P39019"}]},{"url":"https://www.uniprot.org/uniprotkb/P39880/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cux1","kind":"target","name":"CUX1","route":"/targets/cux1/","field":"links","label":"UniProt P39880"}]},{"url":"https://www.uniprot.org/uniprotkb/P40189/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il6st","kind":"target","name":"IL6ST","route":"/targets/il6st/","field":"links","label":"UniProt P40189"}]},{"url":"https://www.uniprot.org/uniprotkb/P40200/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/","field":"links","label":"UniProt P40200"}]},{"url":"https://www.uniprot.org/uniprotkb/P40238/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mpl","kind":"target","name":"MPL (thrombopoietin receptor)","route":"/targets/mpl/","field":"links","label":"UniProt P40238"}]},{"url":"https://www.uniprot.org/uniprotkb/P40306/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/","field":"links","label":"UniProt P40306"}]},{"url":"https://www.uniprot.org/uniprotkb/P40337/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vhl","kind":"target","name":"VHL","route":"/targets/vhl/","field":"links","label":"UniProt P40337"}]},{"url":"https://www.uniprot.org/uniprotkb/P40424/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbx1","kind":"target","name":"PBX1","route":"/targets/pbx1/","field":"links","label":"UniProt P40424"}]},{"url":"https://www.uniprot.org/uniprotkb/P40692/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","field":"links","label":"UniProt P40692"}]},{"url":"https://www.uniprot.org/uniprotkb/P40763/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/","field":"links","label":"UniProt P40763"}]},{"url":"https://www.uniprot.org/uniprotkb/P40818/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/","field":"links","label":"UniProt P40818"}]},{"url":"https://www.uniprot.org/uniprotkb/P40967/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/","field":"links","label":"UniProt P40967: PMEL (gp100)"}]},{"url":"https://www.uniprot.org/uniprotkb/P41161/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv5","kind":"target","name":"ETV5","route":"/targets/etv5/","field":"links","label":"UniProt P41161"}]},{"url":"https://www.uniprot.org/uniprotkb/P41180/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casr","kind":"target","name":"CASR","route":"/targets/casr/","field":"links","label":"UniProt P41180"}]},{"url":"https://www.uniprot.org/uniprotkb/P41182/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/","field":"links","label":"UniProt P41182"}]},{"url":"https://www.uniprot.org/uniprotkb/P41212/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv6","kind":"target","name":"ETV6","route":"/targets/etv6/","field":"links","label":"UniProt P41212"}]},{"url":"https://www.uniprot.org/uniprotkb/P41217/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd200","kind":"target","name":"CD200","route":"/targets/cd200/","field":"links","label":"UniProt P41217"}]},{"url":"https://www.uniprot.org/uniprotkb/P41229/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/","field":"links","label":"UniProt P41229"}]},{"url":"https://www.uniprot.org/uniprotkb/P41240/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csk","kind":"target","name":"CSK","route":"/targets/csk/","field":"links","label":"UniProt P41240"}]},{"url":"https://www.uniprot.org/uniprotkb/P41743/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkci","kind":"target","name":"PRKCI","route":"/targets/prkci/","field":"links","label":"UniProt P41743"}]},{"url":"https://www.uniprot.org/uniprotkb/P42081/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd86","kind":"target","name":"CD86 (B7-2)","route":"/targets/cd86/","field":"links","label":"UniProt P42081"}]},{"url":"https://www.uniprot.org/uniprotkb/P42224/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/","field":"links","label":"UniProt P42224"}]},{"url":"https://www.uniprot.org/uniprotkb/P42226/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat6","kind":"target","name":"STAT6","route":"/targets/stat6/","field":"links","label":"UniProt P42226"}]},{"url":"https://www.uniprot.org/uniprotkb/P42229/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"UniProt P42229 (STAT5A)"}]},{"url":"https://www.uniprot.org/uniprotkb/P42338/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/","field":"links","label":"UniProt P42338"}]},{"url":"https://www.uniprot.org/uniprotkb/P42356/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pi4ka","kind":"target","name":"PI4KA","route":"/targets/pi4ka/","field":"links","label":"UniProt P42356"}]},{"url":"https://www.uniprot.org/uniprotkb/P42566/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eps15","kind":"target","name":"EPS15","route":"/targets/eps15/","field":"links","label":"UniProt P42566"}]},{"url":"https://www.uniprot.org/uniprotkb/P42568/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt3","kind":"target","name":"MLLT3","route":"/targets/mllt3/","field":"links","label":"UniProt P42568"}]},{"url":"https://www.uniprot.org/uniprotkb/P42677/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps27","kind":"target","name":"RPS27","route":"/targets/rps27/","field":"links","label":"UniProt P42677"}]},{"url":"https://www.uniprot.org/uniprotkb/P42680/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tec","kind":"target","name":"TEC","route":"/targets/tec/","field":"links","label":"UniProt P42680"}]},{"url":"https://www.uniprot.org/uniprotkb/P42684/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abl2","kind":"target","name":"ABL2","route":"/targets/abl2/","field":"links","label":"UniProt P42684"}]},{"url":"https://www.uniprot.org/uniprotkb/P42685/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","field":"links","label":"UniProt P42685: FRK"}]},{"url":"https://www.uniprot.org/uniprotkb/P42702/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/","field":"links","label":"UniProt P42702"}]},{"url":"https://www.uniprot.org/uniprotkb/P42768/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"was","kind":"target","name":"WAS","route":"/targets/was/","field":"links","label":"UniProt P42768"}]},{"url":"https://www.uniprot.org/uniprotkb/P42771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","field":"links","label":"UniProt P42771"}]},{"url":"https://www.uniprot.org/uniprotkb/P42772/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","field":"links","label":"UniProt P42772"}]},{"url":"https://www.uniprot.org/uniprotkb/P42773/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn2c","kind":"target","name":"CDKN2C","route":"/targets/cdkn2c/","field":"links","label":"UniProt P42773"}]},{"url":"https://www.uniprot.org/uniprotkb/P42898/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mthfr","kind":"target","name":"MTHFR","route":"/targets/mthfr/","field":"links","label":"UniProt P42898"}]},{"url":"https://www.uniprot.org/uniprotkb/P43146/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcc","kind":"target","name":"DCC","route":"/targets/dcc/","field":"links","label":"UniProt P43146"}]},{"url":"https://www.uniprot.org/uniprotkb/P43246/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","field":"links","label":"UniProt P43246"}]},{"url":"https://www.uniprot.org/uniprotkb/P43268/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/","field":"links","label":"UniProt P43268"}]},{"url":"https://www.uniprot.org/uniprotkb/P43354/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr4a2","kind":"target","name":"NR4A2","route":"/targets/nr4a2/","field":"links","label":"UniProt P43354"}]},{"url":"https://www.uniprot.org/uniprotkb/P43405/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/","field":"links","label":"UniProt P43405"}]},{"url":"https://www.uniprot.org/uniprotkb/P43489/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/","field":"links","label":"UniProt P43489"}]},{"url":"https://www.uniprot.org/uniprotkb/P43626/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kir2dl1","kind":"target","name":"KIR2DL1 (inhibitory KIR)","route":"/targets/kir2dl1/","field":"links","label":"UniProt P43626"}]},{"url":"https://www.uniprot.org/uniprotkb/P43681/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrna4","kind":"target","name":"CHRNA4","route":"/targets/chrna4/","field":"links","label":"UniProt P43681"}]},{"url":"https://www.uniprot.org/uniprotkb/P43686/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/","field":"links","label":"UniProt P43686"}]},{"url":"https://www.uniprot.org/uniprotkb/P43699/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","field":"links","label":"UniProt P43699"}]},{"url":"https://www.uniprot.org/uniprotkb/P45983/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk8","kind":"target","name":"MAPK8","route":"/targets/mapk8/","field":"links","label":"UniProt P45983"}]},{"url":"https://www.uniprot.org/uniprotkb/P45984/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk9","kind":"target","name":"MAPK9","route":"/targets/mapk9/","field":"links","label":"UniProt P45984"}]},{"url":"https://www.uniprot.org/uniprotkb/P45985/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map2k4","kind":"target","name":"MAP2K4","route":"/targets/map2k4/","field":"links","label":"UniProt P45985"}]},{"url":"https://www.uniprot.org/uniprotkb/P46013/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mki67","kind":"target","name":"Ki-67 (MKI67)","route":"/targets/mki67/","field":"links","label":"UniProt P46013"}]},{"url":"https://www.uniprot.org/uniprotkb/P46098/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"htr3a","kind":"target","name":"5-HT3 receptor (HTR3A)","route":"/targets/htr3a/","field":"links","label":"UniProt P46098: HTR3A"}]},{"url":"https://www.uniprot.org/uniprotkb/P46100/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/","field":"links","label":"UniProt P46100"}]},{"url":"https://www.uniprot.org/uniprotkb/P46109/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crkl","kind":"target","name":"CRKL","route":"/targets/crkl/","field":"links","label":"UniProt P46109"}]},{"url":"https://www.uniprot.org/uniprotkb/P46527/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","field":"links","label":"UniProt P46527"}]},{"url":"https://www.uniprot.org/uniprotkb/P46531/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","field":"links","label":"UniProt P46531"}]},{"url":"https://www.uniprot.org/uniprotkb/P46777/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rpl5","kind":"target","name":"RPL5","route":"/targets/rpl5/","field":"links","label":"UniProt P46777"}]},{"url":"https://www.uniprot.org/uniprotkb/P46937/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/","field":"links","label":"UniProt P46937"}]},{"url":"https://www.uniprot.org/uniprotkb/P46940/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"iqgap1","kind":"target","name":"IQGAP1","route":"/targets/iqgap1/","field":"links","label":"UniProt P46940"}]},{"url":"https://www.uniprot.org/uniprotkb/P47813/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","field":"links","label":"UniProt P47813"}]},{"url":"https://www.uniprot.org/uniprotkb/P47989/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","field":"links","label":"UniProt P47989: XDH"}]},{"url":"https://www.uniprot.org/uniprotkb/P48357/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lepr","kind":"target","name":"LEPR","route":"/targets/lepr/","field":"links","label":"UniProt P48357"}]},{"url":"https://www.uniprot.org/uniprotkb/P48431/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","field":"links","label":"UniProt P48431"}]},{"url":"https://www.uniprot.org/uniprotkb/P48436/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","field":"links","label":"UniProt P48436"}]},{"url":"https://www.uniprot.org/uniprotkb/P48551/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/","field":"links","label":"UniProt P48551"}]},{"url":"https://www.uniprot.org/uniprotkb/P48552/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrip1","kind":"target","name":"NRIP1","route":"/targets/nrip1/","field":"links","label":"UniProt P48552"}]},{"url":"https://www.uniprot.org/uniprotkb/P48556/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/","field":"links","label":"UniProt P48556"}]},{"url":"https://www.uniprot.org/uniprotkb/P48729/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/","field":"links","label":"UniProt P48729"}]},{"url":"https://www.uniprot.org/uniprotkb/P48736/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3cg","kind":"target","name":"PIK3CG","route":"/targets/pik3cg/","field":"links","label":"UniProt P48736"}]},{"url":"https://www.uniprot.org/uniprotkb/P48775/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tdo2","kind":"target","name":"TDO2","route":"/targets/tdo2/","field":"links","label":"UniProt P48775"}]},{"url":"https://www.uniprot.org/uniprotkb/P49005/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/","field":"links","label":"UniProt P49005"}]},{"url":"https://www.uniprot.org/uniprotkb/P49019/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hcar3","kind":"target","name":"HCAR3","route":"/targets/hcar3/","field":"links","label":"UniProt P49019"}]},{"url":"https://www.uniprot.org/uniprotkb/P49356/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/","field":"links","label":"UniProt P49356"}]},{"url":"https://www.uniprot.org/uniprotkb/P49407/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arrb1","kind":"target","name":"ARRB1","route":"/targets/arrb1/","field":"links","label":"UniProt P49407"}]},{"url":"https://www.uniprot.org/uniprotkb/P49459/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ube2a","kind":"target","name":"UBE2A","route":"/targets/ube2a/","field":"links","label":"UniProt P49459"}]},{"url":"https://www.uniprot.org/uniprotkb/P49589/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cars1","kind":"target","name":"CARS1","route":"/targets/cars1/","field":"links","label":"UniProt P49589"}]},{"url":"https://www.uniprot.org/uniprotkb/P49642/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/","field":"links","label":"UniProt P49642"}]},{"url":"https://www.uniprot.org/uniprotkb/P49643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/","field":"links","label":"UniProt P49643"}]},{"url":"https://www.uniprot.org/uniprotkb/P49674/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csnk1e","kind":"target","name":"CSNK1E","route":"/targets/csnk1e/","field":"links","label":"UniProt P49674"}]},{"url":"https://www.uniprot.org/uniprotkb/P49711/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctcf","kind":"target","name":"CTCF","route":"/targets/ctcf/","field":"links","label":"UniProt P49711"}]},{"url":"https://www.uniprot.org/uniprotkb/P49715/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cebpa","kind":"target","name":"CEBPA","route":"/targets/cebpa/","field":"links","label":"UniProt P49715"}]},{"url":"https://www.uniprot.org/uniprotkb/P49720/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/","field":"links","label":"UniProt P49720"}]},{"url":"https://www.uniprot.org/uniprotkb/P49721/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/","field":"links","label":"UniProt P49721"}]},{"url":"https://www.uniprot.org/uniprotkb/P49767/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vegfc","kind":"target","name":"VEGFC","route":"/targets/vegfc/","field":"links","label":"UniProt P49767"}]},{"url":"https://www.uniprot.org/uniprotkb/P49768/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gamma-secretase","kind":"target","name":"Gamma-secretase (PSEN1)","route":"/targets/gamma-secretase/","field":"links","label":"UniProt P49768: PSEN1"}]},{"url":"https://www.uniprot.org/uniprotkb/P49771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flt3lg","kind":"target","name":"FLT3LG","route":"/targets/flt3lg/","field":"links","label":"UniProt P49771"}]},{"url":"https://www.uniprot.org/uniprotkb/P49789/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/","field":"links","label":"UniProt P49789"}]},{"url":"https://www.uniprot.org/uniprotkb/P49792/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ranbp2","kind":"target","name":"RANBP2","route":"/targets/ranbp2/","field":"links","label":"UniProt P49792"}]},{"url":"https://www.uniprot.org/uniprotkb/P49802/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgs7","kind":"target","name":"RGS7","route":"/targets/rgs7/","field":"links","label":"UniProt P49802"}]},{"url":"https://www.uniprot.org/uniprotkb/P49810/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psen2","kind":"target","name":"PSEN2","route":"/targets/psen2/","field":"links","label":"UniProt P49810"}]},{"url":"https://www.uniprot.org/uniprotkb/P49815/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tsc2","kind":"target","name":"TSC2","route":"/targets/tsc2/","field":"links","label":"UniProt P49815"}]},{"url":"https://www.uniprot.org/uniprotkb/P49841/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gsk3b","kind":"target","name":"GSK3B","route":"/targets/gsk3b/","field":"links","label":"UniProt P49841"}]},{"url":"https://www.uniprot.org/uniprotkb/P49902/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nt5c2","kind":"target","name":"NT5C2","route":"/targets/nt5c2/","field":"links","label":"UniProt P49902"}]},{"url":"https://www.uniprot.org/uniprotkb/P49915/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gmps","kind":"target","name":"GMPS","route":"/targets/gmps/","field":"links","label":"UniProt P49915"}]},{"url":"https://www.uniprot.org/uniprotkb/P49917/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lig4","kind":"target","name":"LIG4","route":"/targets/lig4/","field":"links","label":"UniProt P49917"}]},{"url":"https://www.uniprot.org/uniprotkb/P49959/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/","field":"links","label":"UniProt P49959"}]},{"url":"https://www.uniprot.org/uniprotkb/P49961/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/","field":"links","label":"UniProt P49961"}]},{"url":"https://www.uniprot.org/uniprotkb/P50148/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","field":"links","label":"UniProt P50148"}]},{"url":"https://www.uniprot.org/uniprotkb/P50539/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mxi1","kind":"target","name":"MXI1","route":"/targets/mxi1/","field":"links","label":"UniProt P50539"}]},{"url":"https://www.uniprot.org/uniprotkb/P50549/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","field":"links","label":"UniProt P50549"}]},{"url":"https://www.uniprot.org/uniprotkb/P50553/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","field":"links","label":"UniProt P50553"}]},{"url":"https://www.uniprot.org/uniprotkb/P50570/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnm2","kind":"target","name":"DNM2","route":"/targets/dnm2/","field":"links","label":"UniProt P50570"}]},{"url":"https://www.uniprot.org/uniprotkb/P50591/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfsf10","kind":"target","name":"TNFSF10","route":"/targets/tnfsf10/","field":"links","label":"UniProt P50591"}]},{"url":"https://www.uniprot.org/uniprotkb/P50750/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/","field":"links","label":"UniProt P50750"}]},{"url":"https://www.uniprot.org/uniprotkb/P51114/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fxr1","kind":"target","name":"FXR1","route":"/targets/fxr1/","field":"links","label":"UniProt P51114"}]},{"url":"https://www.uniprot.org/uniprotkb/P51164/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp4b","kind":"target","name":"ATP4B","route":"/targets/atp4b/","field":"links","label":"UniProt P51164"}]},{"url":"https://www.uniprot.org/uniprotkb/P51451/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blk","kind":"target","name":"BLK","route":"/targets/blk/","field":"links","label":"UniProt P51451"}]},{"url":"https://www.uniprot.org/uniprotkb/P51530/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dna2","kind":"target","name":"DNA2","route":"/targets/dna2/","field":"links","label":"UniProt P51530"}]},{"url":"https://www.uniprot.org/uniprotkb/P51531/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/","field":"links","label":"UniProt P51531"}]},{"url":"https://www.uniprot.org/uniprotkb/P51532/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","field":"links","label":"UniProt P51532"}]},{"url":"https://www.uniprot.org/uniprotkb/P51617/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/","field":"links","label":"UniProt P51617"}]},{"url":"https://www.uniprot.org/uniprotkb/P51665/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/","field":"links","label":"UniProt P51665"}]},{"url":"https://www.uniprot.org/uniprotkb/P51692/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","field":"links","label":"UniProt P51692 (STAT5B)"}]},{"url":"https://www.uniprot.org/uniprotkb/P51787/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq1","kind":"target","name":"KCNQ1","route":"/targets/kcnq1/","field":"links","label":"UniProt P51787"}]},{"url":"https://www.uniprot.org/uniprotkb/P51797/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clcn6","kind":"target","name":"CLCN6","route":"/targets/clcn6/","field":"links","label":"UniProt P51797"}]},{"url":"https://www.uniprot.org/uniprotkb/P51812/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps6ka3","kind":"target","name":"RPS6KA3","route":"/targets/rps6ka3/","field":"links","label":"UniProt P51812"}]},{"url":"https://www.uniprot.org/uniprotkb/P51825/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff1","kind":"target","name":"AFF1","route":"/targets/aff1/","field":"links","label":"UniProt P51825"}]},{"url":"https://www.uniprot.org/uniprotkb/P51826/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff3","kind":"target","name":"AFF3","route":"/targets/aff3/","field":"links","label":"UniProt P51826"}]},{"url":"https://www.uniprot.org/uniprotkb/P51946/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnh","kind":"target","name":"CCNH","route":"/targets/ccnh/","field":"links","label":"UniProt P51946"}]},{"url":"https://www.uniprot.org/uniprotkb/P52306/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1gds1","kind":"target","name":"RAP1GDS1","route":"/targets/rap1gds1/","field":"links","label":"UniProt P52306"}]},{"url":"https://www.uniprot.org/uniprotkb/P52333/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/","field":"links","label":"UniProt P52333"}]},{"url":"https://www.uniprot.org/uniprotkb/P52701/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/","field":"links","label":"UniProt P52701"}]},{"url":"https://www.uniprot.org/uniprotkb/P52926/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hmga2","kind":"target","name":"HMGA2","route":"/targets/hmga2/","field":"links","label":"UniProt P52926"}]},{"url":"https://www.uniprot.org/uniprotkb/P52948/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/","field":"links","label":"UniProt P52948"}]},{"url":"https://www.uniprot.org/uniprotkb/P53350/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/","field":"links","label":"UniProt P53350"}]},{"url":"https://www.uniprot.org/uniprotkb/P53539/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fosb","kind":"target","name":"FOSB","route":"/targets/fosb/","field":"links","label":"UniProt P53539"}]},{"url":"https://www.uniprot.org/uniprotkb/P53675/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cltcl1","kind":"target","name":"CLTCL1","route":"/targets/cltcl1/","field":"links","label":"UniProt P53675"}]},{"url":"https://www.uniprot.org/uniprotkb/P54132/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/","field":"links","label":"UniProt P54132"}]},{"url":"https://www.uniprot.org/uniprotkb/P54277/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pms1","kind":"target","name":"PMS1","route":"/targets/pms1/","field":"links","label":"UniProt P54277"}]},{"url":"https://www.uniprot.org/uniprotkb/P54278/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/","field":"links","label":"UniProt P54278"}]},{"url":"https://www.uniprot.org/uniprotkb/P54646/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkaa2","kind":"target","name":"PRKAA2","route":"/targets/prkaa2/","field":"links","label":"UniProt P54646"}]},{"url":"https://www.uniprot.org/uniprotkb/P54727/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad23b","kind":"target","name":"RAD23B","route":"/targets/rad23b/","field":"links","label":"UniProt P54727"}]},{"url":"https://www.uniprot.org/uniprotkb/P54753/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb3","kind":"target","name":"EPHB3","route":"/targets/ephb3/","field":"links","label":"UniProt P54753"}]},{"url":"https://www.uniprot.org/uniprotkb/P54756/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha5","kind":"target","name":"EPHA5","route":"/targets/epha5/","field":"links","label":"UniProt P54756"}]},{"url":"https://www.uniprot.org/uniprotkb/P54760/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb4","kind":"target","name":"EPHB4","route":"/targets/ephb4/","field":"links","label":"UniProt P54760"}]},{"url":"https://www.uniprot.org/uniprotkb/P54762/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ephb1","kind":"target","name":"EPHB1","route":"/targets/ephb1/","field":"links","label":"UniProt P54762"}]},{"url":"https://www.uniprot.org/uniprotkb/P54764/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha4","kind":"target","name":"EPHA4","route":"/targets/epha4/","field":"links","label":"UniProt P54764"}]},{"url":"https://www.uniprot.org/uniprotkb/P55011/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc12a2","kind":"target","name":"SLC12A2","route":"/targets/slc12a2/","field":"links","label":"UniProt P55011"}]},{"url":"https://www.uniprot.org/uniprotkb/P55036/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/","field":"links","label":"UniProt P55036"}]},{"url":"https://www.uniprot.org/uniprotkb/P55075/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf8","kind":"target","name":"FGF8","route":"/targets/fgf8/","field":"links","label":"UniProt P55075"}]},{"url":"https://www.uniprot.org/uniprotkb/P55196/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"afdn","kind":"target","name":"AFDN","route":"/targets/afdn/","field":"links","label":"UniProt P55196"}]},{"url":"https://www.uniprot.org/uniprotkb/P55197/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/","field":"links","label":"UniProt P55197"}]},{"url":"https://www.uniprot.org/uniprotkb/P55198/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt6","kind":"target","name":"MLLT6","route":"/targets/mllt6/","field":"links","label":"UniProt P55198"}]},{"url":"https://www.uniprot.org/uniprotkb/P55199/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/","field":"links","label":"UniProt P55199"}]},{"url":"https://www.uniprot.org/uniprotkb/P55287/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh11","kind":"target","name":"CDH11","route":"/targets/cdh11/","field":"links","label":"UniProt P55287"}]},{"url":"https://www.uniprot.org/uniprotkb/P55317/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","field":"links","label":"UniProt P55317"}]},{"url":"https://www.uniprot.org/uniprotkb/P55771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax9","kind":"target","name":"PAX9","route":"/targets/pax9/","field":"links","label":"UniProt P55771"}]},{"url":"https://www.uniprot.org/uniprotkb/P56278/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mtcp1","kind":"target","name":"MTCP1","route":"/targets/mtcp1/","field":"links","label":"UniProt P56278"}]},{"url":"https://www.uniprot.org/uniprotkb/P56279/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcl1a","kind":"target","name":"TCL1A","route":"/targets/tcl1a/","field":"links","label":"UniProt P56279"}]},{"url":"https://www.uniprot.org/uniprotkb/P56282/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/","field":"links","label":"UniProt P56282"}]},{"url":"https://www.uniprot.org/uniprotkb/P56524/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/","field":"links","label":"UniProt P56524"}]},{"url":"https://www.uniprot.org/uniprotkb/P56645/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"per3","kind":"target","name":"PER3","route":"/targets/per3/","field":"links","label":"UniProt P56645"}]},{"url":"https://www.uniprot.org/uniprotkb/P56693/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox10","kind":"target","name":"SOX10","route":"/targets/sox10/","field":"links","label":"UniProt P56693"}]},{"url":"https://www.uniprot.org/uniprotkb/P56975/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg3","kind":"target","name":"NRG3","route":"/targets/nrg3/","field":"links","label":"UniProt P56975"}]},{"url":"https://www.uniprot.org/uniprotkb/P58012/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/","field":"links","label":"UniProt P58012"}]},{"url":"https://www.uniprot.org/uniprotkb/P58340/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlf1","kind":"target","name":"MLF1","route":"/targets/mlf1/","field":"links","label":"UniProt P58340"}]},{"url":"https://www.uniprot.org/uniprotkb/P58876/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2bc5","kind":"target","name":"H2BC5","route":"/targets/h2bc5/","field":"links","label":"UniProt P58876"}]},{"url":"https://www.uniprot.org/uniprotkb/P59665/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"defa1","kind":"target","name":"DEFA1","route":"/targets/defa1/","field":"links","label":"UniProt P59665"}]},{"url":"https://www.uniprot.org/uniprotkb/P60228/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/","field":"links","label":"UniProt P60228"}]},{"url":"https://www.uniprot.org/uniprotkb/P60484/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","field":"links","label":"UniProt P60484"}]},{"url":"https://www.uniprot.org/uniprotkb/P60709/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actb","kind":"target","name":"ACTB","route":"/targets/actb/","field":"links","label":"UniProt P60709"}]},{"url":"https://www.uniprot.org/uniprotkb/P60842/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4a1","kind":"target","name":"EIF4A1","route":"/targets/eif4a1/","field":"links","label":"UniProt P60842"}]},{"url":"https://www.uniprot.org/uniprotkb/P60880/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snap25","kind":"target","name":"SNAP25","route":"/targets/snap25/","field":"links","label":"UniProt P60880"}]},{"url":"https://www.uniprot.org/uniprotkb/P60891/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prps1","kind":"target","name":"PRPS1","route":"/targets/prps1/","field":"links","label":"UniProt P60891"}]},{"url":"https://www.uniprot.org/uniprotkb/P60896/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/","field":"links","label":"UniProt P60896"}]},{"url":"https://www.uniprot.org/uniprotkb/P60900/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/","field":"links","label":"UniProt P60900"}]},{"url":"https://www.uniprot.org/uniprotkb/P61224/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1b","kind":"target","name":"RAP1B","route":"/targets/rap1b/","field":"links","label":"UniProt P61224"}]},{"url":"https://www.uniprot.org/uniprotkb/P61244/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"max","kind":"target","name":"MAX","route":"/targets/max/","field":"links","label":"UniProt P61244"}]},{"url":"https://www.uniprot.org/uniprotkb/P61247/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/","field":"links","label":"UniProt P61247"}]},{"url":"https://www.uniprot.org/uniprotkb/P61586/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/","field":"links","label":"UniProt P61586"}]},{"url":"https://www.uniprot.org/uniprotkb/P61769/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","field":"links","label":"UniProt P61769"}]},{"url":"https://www.uniprot.org/uniprotkb/P61812/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfb2","kind":"target","name":"TGFB2","route":"/targets/tgfb2/","field":"links","label":"UniProt P61812"}]},{"url":"https://www.uniprot.org/uniprotkb/P62070/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/","field":"links","label":"UniProt P62070"}]},{"url":"https://www.uniprot.org/uniprotkb/P62081/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps7","kind":"target","name":"RPS7","route":"/targets/rps7/","field":"links","label":"UniProt P62081"}]},{"url":"https://www.uniprot.org/uniprotkb/P62191/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/","field":"links","label":"UniProt P62191"}]},{"url":"https://www.uniprot.org/uniprotkb/P62195/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/","field":"links","label":"UniProt P62195"}]},{"url":"https://www.uniprot.org/uniprotkb/P62258/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ywhae","kind":"target","name":"YWHAE","route":"/targets/ywhae/","field":"links","label":"UniProt P62258"}]},{"url":"https://www.uniprot.org/uniprotkb/P62273/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps29","kind":"target","name":"RPS29","route":"/targets/rps29/","field":"links","label":"UniProt P62273"}]},{"url":"https://www.uniprot.org/uniprotkb/P62324/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/","field":"links","label":"UniProt P62324"}]},{"url":"https://www.uniprot.org/uniprotkb/P62328/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmsb4x","kind":"target","name":"TMSB4X","route":"/targets/tmsb4x/","field":"links","label":"UniProt P62328"}]},{"url":"https://www.uniprot.org/uniprotkb/P62333/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/","field":"links","label":"UniProt P62333"}]},{"url":"https://www.uniprot.org/uniprotkb/P62380/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbpl1","kind":"target","name":"TBPL1","route":"/targets/tbpl1/","field":"links","label":"UniProt P62380"}]},{"url":"https://www.uniprot.org/uniprotkb/P62633/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnbp","kind":"target","name":"CNBP","route":"/targets/cnbp/","field":"links","label":"UniProt P62633"}]},{"url":"https://www.uniprot.org/uniprotkb/P62714/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2cb","kind":"target","name":"PPP2CB","route":"/targets/ppp2cb/","field":"links","label":"UniProt P62714"}]},{"url":"https://www.uniprot.org/uniprotkb/P62736/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acta2","kind":"target","name":"ACTA2","route":"/targets/acta2/","field":"links","label":"UniProt P62736"}]},{"url":"https://www.uniprot.org/uniprotkb/P62753/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps6","kind":"target","name":"RPS6","route":"/targets/rps6/","field":"links","label":"UniProt P62753"}]},{"url":"https://www.uniprot.org/uniprotkb/P62805/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h4c9","kind":"target","name":"H4C9","route":"/targets/h4c9/","field":"links","label":"UniProt P62805"}]},{"url":"https://www.uniprot.org/uniprotkb/P62834/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rap1a","kind":"target","name":"RAP1A","route":"/targets/rap1a/","field":"links","label":"UniProt P62834"}]},{"url":"https://www.uniprot.org/uniprotkb/P62847/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps24","kind":"target","name":"RPS24","route":"/targets/rps24/","field":"links","label":"UniProt P62847"}]},{"url":"https://www.uniprot.org/uniprotkb/P62854/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps26","kind":"target","name":"RPS26","route":"/targets/rps26/","field":"links","label":"UniProt P62854"}]},{"url":"https://www.uniprot.org/uniprotkb/P62873/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gnb1","kind":"target","name":"GNB1","route":"/targets/gnb1/","field":"links","label":"UniProt P62873"}]},{"url":"https://www.uniprot.org/uniprotkb/P62877/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/","field":"links","label":"UniProt P62877"}]},{"url":"https://www.uniprot.org/uniprotkb/P62942/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","field":"links","label":"UniProt P62942: FKBP1A"}]},{"url":"https://www.uniprot.org/uniprotkb/P62979/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rps27a","kind":"target","name":"RPS27A","route":"/targets/rps27a/","field":"links","label":"UniProt P62979"}]},{"url":"https://www.uniprot.org/uniprotkb/P62987/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"uba52","kind":"target","name":"UBA52","route":"/targets/uba52/","field":"links","label":"UniProt P62987"}]},{"url":"https://www.uniprot.org/uniprotkb/P62993/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grb2","kind":"target","name":"GRB2","route":"/targets/grb2/","field":"links","label":"UniProt P62993"}]},{"url":"https://www.uniprot.org/uniprotkb/P63000/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rac1","kind":"target","name":"RAC1","route":"/targets/rac1/","field":"links","label":"UniProt P63000"}]},{"url":"https://www.uniprot.org/uniprotkb/P63151/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r2a","kind":"target","name":"PPP2R2A","route":"/targets/ppp2r2a/","field":"links","label":"UniProt P63151"}]},{"url":"https://www.uniprot.org/uniprotkb/P63208/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skp1","kind":"target","name":"SKP1","route":"/targets/skp1/","field":"links","label":"UniProt P63208"}]},{"url":"https://www.uniprot.org/uniprotkb/P63261/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"actg1","kind":"target","name":"ACTG1","route":"/targets/actg1/","field":"links","label":"UniProt P63261"}]},{"url":"https://www.uniprot.org/uniprotkb/P67775/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2ca","kind":"target","name":"PPP2CA","route":"/targets/ppp2ca/","field":"links","label":"UniProt P67775"}]},{"url":"https://www.uniprot.org/uniprotkb/P67936/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpm4","kind":"target","name":"TPM4","route":"/targets/tpm4/","field":"links","label":"UniProt P67936"}]},{"url":"https://www.uniprot.org/uniprotkb/P68133/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acta1","kind":"target","name":"ACTA1","route":"/targets/acta1/","field":"links","label":"UniProt P68133"}]},{"url":"https://www.uniprot.org/uniprotkb/P68363/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/","field":"links","label":"UniProt P68363"}]},{"url":"https://www.uniprot.org/uniprotkb/P68366/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/","field":"links","label":"UniProt P68366"}]},{"url":"https://www.uniprot.org/uniprotkb/P68371/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/","field":"links","label":"UniProt P68371"}]},{"url":"https://www.uniprot.org/uniprotkb/P68431/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3c2","kind":"target","name":"H3C2","route":"/targets/h3c2/","field":"links","label":"UniProt P68431"},{"id":"h3c4","kind":"target","name":"H3C4","route":"/targets/h3c4/","field":"links","label":"UniProt P68431"}]},{"url":"https://www.uniprot.org/uniprotkb/P68871/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hbb","kind":"target","name":"HBB","route":"/targets/hbb/","field":"links","label":"UniProt P68871"}]},{"url":"https://www.uniprot.org/uniprotkb/P78324/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/","field":"links","label":"UniProt P78324"}]},{"url":"https://www.uniprot.org/uniprotkb/P78333/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/","field":"links","label":"UniProt P78333"}]},{"url":"https://www.uniprot.org/uniprotkb/P78347/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gtf2i","kind":"target","name":"GTF2I","route":"/targets/gtf2i/","field":"links","label":"UniProt P78347"}]},{"url":"https://www.uniprot.org/uniprotkb/P78358/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/","field":"links","label":"UniProt P78358"}]},{"url":"https://www.uniprot.org/uniprotkb/P78413/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irx4","kind":"target","name":"IRX4","route":"/targets/irx4/","field":"links","label":"UniProt P78413"}]},{"url":"https://www.uniprot.org/uniprotkb/P78423/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cx3cl1","kind":"target","name":"CX3CL1","route":"/targets/cx3cl1/","field":"links","label":"UniProt P78423"}]},{"url":"https://www.uniprot.org/uniprotkb/P78504/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jag1","kind":"target","name":"JAG1","route":"/targets/jag1/","field":"links","label":"UniProt P78504"}]},{"url":"https://www.uniprot.org/uniprotkb/P78527/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkdc","kind":"target","name":"PRKDC","route":"/targets/prkdc/","field":"links","label":"UniProt P78527"}]},{"url":"https://www.uniprot.org/uniprotkb/P78543/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btg2","kind":"target","name":"BTG2","route":"/targets/btg2/","field":"links","label":"UniProt P78543"}]},{"url":"https://www.uniprot.org/uniprotkb/P78545/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","field":"links","label":"UniProt P78545"}]},{"url":"https://www.uniprot.org/uniprotkb/P78549/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nthl1","kind":"target","name":"NTHL1","route":"/targets/nthl1/","field":"links","label":"UniProt P78549"}]},{"url":"https://www.uniprot.org/uniprotkb/P84022/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad3","kind":"target","name":"SMAD3","route":"/targets/smad3/","field":"links","label":"UniProt P84022"}]},{"url":"https://www.uniprot.org/uniprotkb/P84103/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srsf3","kind":"target","name":"SRSF3","route":"/targets/srsf3/","field":"links","label":"UniProt P84103"}]},{"url":"https://www.uniprot.org/uniprotkb/P84243/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3-3a","kind":"target","name":"Histone H3.3 (H3-3A)","route":"/targets/h3-3a/","field":"links","label":"UniProt P84243"},{"id":"h3-3b","kind":"target","name":"H3-3B","route":"/targets/h3-3b/","field":"links","label":"UniProt P84243"}]},{"url":"https://www.uniprot.org/uniprotkb/P98095/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/","field":"links","label":"UniProt P98095"}]},{"url":"https://www.uniprot.org/uniprotkb/P98160/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hspg2","kind":"target","name":"HSPG2","route":"/targets/hspg2/","field":"links","label":"UniProt P98160"}]},{"url":"https://www.uniprot.org/uniprotkb/P98169/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zxdb","kind":"target","name":"ZXDB","route":"/targets/zxdb/","field":"links","label":"UniProt P98169"}]},{"url":"https://www.uniprot.org/uniprotkb/P98174/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgd1","kind":"target","name":"FGD1","route":"/targets/fgd1/","field":"links","label":"UniProt P98174"}]},{"url":"https://www.uniprot.org/uniprotkb/P98177/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo4","kind":"target","name":"FOXO4","route":"/targets/foxo4/","field":"links","label":"UniProt P98177"}]},{"url":"https://www.uniprot.org/uniprotkb/Q00535/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk5","kind":"target","name":"CDK5","route":"/targets/cdk5/","field":"links","label":"UniProt Q00535"}]},{"url":"https://www.uniprot.org/uniprotkb/Q00597/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/","field":"links","label":"UniProt Q00597"}]},{"url":"https://www.uniprot.org/uniprotkb/Q00610/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cltc","kind":"target","name":"CLTC","route":"/targets/cltc/","field":"links","label":"UniProt Q00610"}]},{"url":"https://www.uniprot.org/uniprotkb/Q00653/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkb2","kind":"target","name":"NFKB2","route":"/targets/nfkb2/","field":"links","label":"UniProt Q00653"}]},{"url":"https://www.uniprot.org/uniprotkb/Q00839/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnrnpu","kind":"target","name":"HNRNPU","route":"/targets/hnrnpu/","field":"links","label":"UniProt Q00839"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01081/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"u2af1","kind":"target","name":"U2AF1","route":"/targets/u2af1/","field":"links","label":"UniProt Q01081"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01082/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sptbn1","kind":"target","name":"SPTBN1","route":"/targets/sptbn1/","field":"links","label":"UniProt Q01082"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01105/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"set","kind":"target","name":"SET","route":"/targets/set/","field":"links","label":"UniProt Q01105"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01118/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn7a","kind":"target","name":"SCN7A","route":"/targets/scn7a/","field":"links","label":"UniProt Q01118"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01130/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srsf2","kind":"target","name":"SRSF2","route":"/targets/srsf2/","field":"links","label":"UniProt Q01130"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01151/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd83","kind":"target","name":"CD83","route":"/targets/cd83/","field":"links","label":"UniProt Q01151"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01196/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/","field":"links","label":"UniProt Q01196"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01664/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfap4","kind":"target","name":"TFAP4","route":"/targets/tfap4/","field":"links","label":"UniProt Q01664"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01668/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1d","kind":"target","name":"CACNA1D","route":"/targets/cacna1d/","field":"links","label":"UniProt Q01668"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01726/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mc1r","kind":"target","name":"MC1R","route":"/targets/mc1r/","field":"links","label":"UniProt Q01726"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01831/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xpc","kind":"target","name":"XPC","route":"/targets/xpc/","field":"links","label":"UniProt Q01831"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01860/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou5f1","kind":"target","name":"POU5F1","route":"/targets/pou5f1/","field":"links","label":"UniProt Q01860"}]},{"url":"https://www.uniprot.org/uniprotkb/Q01959/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc6a3","kind":"target","name":"SLC6A3","route":"/targets/slc6a3/","field":"links","label":"UniProt Q01959"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02080/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2b","kind":"target","name":"MEF2B","route":"/targets/mef2b/","field":"links","label":"UniProt Q02080"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02156/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkce","kind":"target","name":"PRKCE","route":"/targets/prkce/","field":"links","label":"UniProt Q02156"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02241/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kif23","kind":"target","name":"KIF23","route":"/targets/kif23/","field":"links","label":"UniProt Q02241"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02297/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","field":"links","label":"UniProt Q02297"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02535/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"id3","kind":"target","name":"ID3","route":"/targets/id3/","field":"links","label":"UniProt Q02535"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02548/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax5","kind":"target","name":"PAX5","route":"/targets/pax5/","field":"links","label":"UniProt Q02548"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02556/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf8","kind":"target","name":"IRF8","route":"/targets/irf8/","field":"links","label":"UniProt Q02556"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02763/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","field":"links","label":"UniProt Q02763: TEK"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02880/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/","field":"links","label":"UniProt Q02880"}]},{"url":"https://www.uniprot.org/uniprotkb/Q02978/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc25a11","kind":"target","name":"SLC25A11","route":"/targets/slc25a11/","field":"links","label":"UniProt Q02978"}]},{"url":"https://www.uniprot.org/uniprotkb/Q03111/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mllt1","kind":"target","name":"MLLT1","route":"/targets/mllt1/","field":"links","label":"UniProt Q03111"}]},{"url":"https://www.uniprot.org/uniprotkb/Q03112/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/","field":"links","label":"UniProt Q03112"}]},{"url":"https://www.uniprot.org/uniprotkb/Q03167/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgfbr3","kind":"target","name":"TGFBR3","route":"/targets/tgfbr3/","field":"links","label":"UniProt Q03167"}]},{"url":"https://www.uniprot.org/uniprotkb/Q03938/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf90","kind":"target","name":"ZNF90","route":"/targets/znf90/","field":"links","label":"UniProt Q03938"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04206/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rela","kind":"target","name":"RELA","route":"/targets/rela/","field":"links","label":"UniProt Q04206"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04671/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"oca2","kind":"target","name":"OCA2","route":"/targets/oca2/","field":"links","label":"UniProt Q04671"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04721/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/","field":"links","label":"UniProt Q04721"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04759/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcq","kind":"target","name":"PRKCQ","route":"/targets/prkcq/","field":"links","label":"UniProt Q04759"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04771/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acvr1","kind":"target","name":"ACVR1 (ALK2)","route":"/targets/acvr1/","field":"links","label":"UniProt Q04771"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04864/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/","field":"links","label":"UniProt Q04864"}]},{"url":"https://www.uniprot.org/uniprotkb/Q04912/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","field":"links","label":"UniProt Q04912: MST1R"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05209/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn12","kind":"target","name":"PTPN12","route":"/targets/ptpn12/","field":"links","label":"UniProt Q05209"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05397/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fak","kind":"target","name":"FAK (PTK2)","route":"/targets/fak/","field":"links","label":"UniProt Q05397"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05513/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcz","kind":"target","name":"PRKCZ","route":"/targets/prkcz/","field":"links","label":"UniProt Q05513"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05516/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","field":"links","label":"UniProt Q05516"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05655/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkcd","kind":"target","name":"PRKCD","route":"/targets/prkcd/","field":"links","label":"UniProt Q05655"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05823/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnasel","kind":"target","name":"RNASEL","route":"/targets/rnasel/","field":"links","label":"UniProt Q05823"}]},{"url":"https://www.uniprot.org/uniprotkb/Q05923/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp2","kind":"target","name":"DUSP2","route":"/targets/dusp2/","field":"links","label":"UniProt Q05923"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06124/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/","field":"links","label":"UniProt Q06124"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06203/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppat","kind":"target","name":"PPAT","route":"/targets/ppat/","field":"links","label":"UniProt Q06203"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06330/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbpj","kind":"target","name":"RBPJ","route":"/targets/rbpj/","field":"links","label":"UniProt Q06330"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06413/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2c","kind":"target","name":"MEF2C","route":"/targets/mef2c/","field":"links","label":"UniProt Q06413"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06416/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou5f1b","kind":"target","name":"POU5F1B","route":"/targets/pou5f1b/","field":"links","label":"UniProt Q06416"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06455/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"runx1t1","kind":"target","name":"RUNX1T1","route":"/targets/runx1t1/","field":"links","label":"UniProt Q06455"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06609/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad51","kind":"target","name":"RAD51","route":"/targets/rad51/","field":"links","label":"UniProt Q06609"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ltb","kind":"target","name":"LTB","route":"/targets/ltb/","field":"links","label":"UniProt Q06643"}]},{"url":"https://www.uniprot.org/uniprotkb/Q06710/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pax8","kind":"target","name":"PAX8","route":"/targets/pax8/","field":"links","label":"UniProt Q06710"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07011/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/","field":"links","label":"UniProt Q07011"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07352/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfp36l1","kind":"target","name":"ZFP36L1","route":"/targets/zfp36l1/","field":"links","label":"UniProt Q07352"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07654/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tff3","kind":"target","name":"TFF3","route":"/targets/tff3/","field":"links","label":"UniProt Q07654"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07812/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bax","kind":"target","name":"BAX","route":"/targets/bax/","field":"links","label":"UniProt Q07812"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07820/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/","field":"links","label":"UniProt Q07820"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07864/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","field":"links","label":"UniProt Q07864"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07866/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klc1","kind":"target","name":"KLC1","route":"/targets/klc1/","field":"links","label":"UniProt Q07866"}]},{"url":"https://www.uniprot.org/uniprotkb/Q07889/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sos1","kind":"target","name":"SOS1","route":"/targets/sos1/","field":"links","label":"UniProt Q07889"}]},{"url":"https://www.uniprot.org/uniprotkb/Q08188/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgm3","kind":"target","name":"TGM3","route":"/targets/tgm3/","field":"links","label":"UniProt Q08188"}]},{"url":"https://www.uniprot.org/uniprotkb/Q08209/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp3ca","kind":"target","name":"PPP3CA","route":"/targets/ppp3ca/","field":"links","label":"UniProt Q08209"}]},{"url":"https://www.uniprot.org/uniprotkb/Q08211/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/","field":"links","label":"UniProt Q08211"}]},{"url":"https://www.uniprot.org/uniprotkb/Q08830/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgl1","kind":"target","name":"FGL1","route":"/targets/fgl1/","field":"links","label":"UniProt Q08830"}]},{"url":"https://www.uniprot.org/uniprotkb/Q08881/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/","field":"links","label":"UniProt Q08881"}]},{"url":"https://www.uniprot.org/uniprotkb/Q09472/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/","field":"links","label":"UniProt Q09472"}]},{"url":"https://www.uniprot.org/uniprotkb/Q10571/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mn1","kind":"target","name":"MN1","route":"/targets/mn1/","field":"links","label":"UniProt Q10571"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12774/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef5","kind":"target","name":"ARHGEF5","route":"/targets/arhgef5/","field":"links","label":"UniProt Q12774"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12778/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/","field":"links","label":"UniProt Q12778"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12824/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/","field":"links","label":"UniProt Q12824"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12866/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mertk","kind":"target","name":"MERTK","route":"/targets/mertk/","field":"links","label":"UniProt Q12866"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12879/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grin2a","kind":"target","name":"GRIN2A","route":"/targets/grin2a/","field":"links","label":"UniProt Q12879"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12882/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dpyd","kind":"target","name":"DPYD","route":"/targets/dpyd/","field":"links","label":"UniProt Q12882"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12888/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tp53bp1","kind":"target","name":"TP53BP1","route":"/targets/tp53bp1/","field":"links","label":"UniProt Q12888"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12923/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn13","kind":"target","name":"PTPN13","route":"/targets/ptpn13/","field":"links","label":"UniProt Q12923"}]},{"url":"https://www.uniprot.org/uniprotkb/Q12946/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxf1","kind":"target","name":"FOXF1","route":"/targets/foxf1/","field":"links","label":"UniProt Q12946"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13017/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/","field":"links","label":"UniProt Q13017"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13029/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/","field":"links","label":"UniProt Q13029"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13114/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/","field":"links","label":"UniProt Q13114"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13127/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rest","kind":"target","name":"REST","route":"/targets/rest/","field":"links","label":"UniProt Q13127"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13155/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aimp2","kind":"target","name":"AIMP2","route":"/targets/aimp2/","field":"links","label":"UniProt Q13155"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13191/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cblb","kind":"target","name":"CBLB","route":"/targets/cblb/","field":"links","label":"UniProt Q13191"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13200/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/","field":"links","label":"UniProt Q13200"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13206/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx10","kind":"target","name":"DDX10","route":"/targets/ddx10/","field":"links","label":"UniProt Q13206"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13233/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/","field":"links","label":"UniProt Q13233"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13263/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim28","kind":"target","name":"TRIM28","route":"/targets/trim28/","field":"links","label":"UniProt Q13263"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13315/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","field":"links","label":"UniProt Q13315"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13323/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bik","kind":"target","name":"BIK","route":"/targets/bik/","field":"links","label":"UniProt Q13323"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13336/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc14a1","kind":"target","name":"SLC14A1","route":"/targets/slc14a1/","field":"links","label":"UniProt Q13336"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13342/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/","field":"links","label":"UniProt Q13342"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13362/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5c","kind":"target","name":"PPP2R5C","route":"/targets/ppp2r5c/","field":"links","label":"UniProt Q13362"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13370/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pde3b","kind":"target","name":"PDE3B","route":"/targets/pde3b/","field":"links","label":"UniProt Q13370"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13415/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"orc1","kind":"target","name":"ORC1","route":"/targets/orc1/","field":"links","label":"UniProt Q13415"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13422/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikzf1","kind":"target","name":"IKZF1 (Ikaros)","route":"/targets/ikzf1/","field":"links","label":"UniProt Q13422"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13439/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golga4","kind":"target","name":"GOLGA4","route":"/targets/golga4/","field":"links","label":"UniProt Q13439"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13469/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfatc2","kind":"target","name":"NFATC2","route":"/targets/nfatc2/","field":"links","label":"UniProt Q13469"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13472/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"top3a","kind":"target","name":"TOP3A","route":"/targets/top3a/","field":"links","label":"UniProt Q13472"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13480/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gab1","kind":"target","name":"GAB1","route":"/targets/gab1/","field":"links","label":"UniProt Q13480"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13485/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","field":"links","label":"UniProt Q13485"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13489/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/","field":"links","label":"UniProt Q13489"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13492/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"picalm","kind":"target","name":"PICALM","route":"/targets/picalm/","field":"links","label":"UniProt Q13492"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13495/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mamld1","kind":"target","name":"MAMLD1","route":"/targets/mamld1/","field":"links","label":"UniProt Q13495"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13501/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sqstm1","kind":"target","name":"SQSTM1","route":"/targets/sqstm1/","field":"links","label":"UniProt Q13501"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13509/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/","field":"links","label":"UniProt Q13509"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13516/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"olig2","kind":"target","name":"OLIG2","route":"/targets/olig2/","field":"links","label":"UniProt Q13516"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13541/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4ebp1","kind":"target","name":"EIF4EBP1","route":"/targets/eif4ebp1/","field":"links","label":"UniProt Q13541"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13546/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ripk1","kind":"target","name":"RIPK1","route":"/targets/ripk1/","field":"links","label":"UniProt Q13546"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13568/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf5","kind":"target","name":"IRF5","route":"/targets/irf5/","field":"links","label":"UniProt Q13568"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13573/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snw1","kind":"target","name":"SNW1","route":"/targets/snw1/","field":"links","label":"UniProt Q13573"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13616/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul1","kind":"target","name":"CUL1","route":"/targets/cul1/","field":"links","label":"UniProt Q13616"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13618/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul3","kind":"target","name":"CUL3","route":"/targets/cul3/","field":"links","label":"UniProt Q13618"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13619/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/","field":"links","label":"UniProt Q13619"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13635/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptch1","kind":"target","name":"PTCH1 (Patched 1)","route":"/targets/ptch1/","field":"links","label":"UniProt Q13635"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13740/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alcam","kind":"target","name":"ALCAM","route":"/targets/alcam/","field":"links","label":"UniProt Q13740"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13772/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa4","kind":"target","name":"NCOA4","route":"/targets/ncoa4/","field":"links","label":"UniProt Q13772"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13882/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","field":"links","label":"UniProt Q13882: PTK6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13884/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sntb1","kind":"target","name":"SNTB1","route":"/targets/sntb1/","field":"links","label":"UniProt Q13884"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13885/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/","field":"links","label":"UniProt Q13885"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13887/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/","field":"links","label":"UniProt Q13887"}]},{"url":"https://www.uniprot.org/uniprotkb/Q13951/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cbfb","kind":"target","name":"CBFB","route":"/targets/cbfb/","field":"links","label":"UniProt Q13951"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14145/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","field":"links","label":"UniProt Q14145"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14181/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/","field":"links","label":"UniProt Q14181"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14190/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sim2","kind":"target","name":"SIM2","route":"/targets/sim2/","field":"links","label":"UniProt Q14190"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14202/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmym3","kind":"target","name":"ZMYM3","route":"/targets/zmym3/","field":"links","label":"UniProt Q14202"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14203/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dctn1","kind":"target","name":"DCTN1","route":"/targets/dctn1/","field":"links","label":"UniProt Q14203"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14240/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif4a2","kind":"target","name":"EIF4A2","route":"/targets/eif4a2/","field":"links","label":"UniProt Q14240"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14344/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gna13","kind":"target","name":"GNA13","route":"/targets/gna13/","field":"links","label":"UniProt Q14344"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14393/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gas6","kind":"target","name":"GAS6","route":"/targets/gas6/","field":"links","label":"UniProt Q14393"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14432/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pde3a","kind":"target","name":"PDE3A","route":"/targets/pde3a/","field":"links","label":"UniProt Q14432"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14451/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grb7","kind":"target","name":"GRB7","route":"/targets/grb7/","field":"links","label":"UniProt Q14451"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14498/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/","field":"links","label":"UniProt Q14498"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14511/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nedd9","kind":"target","name":"NEDD9","route":"/targets/nedd9/","field":"links","label":"UniProt Q14511"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14517/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/","field":"links","label":"UniProt Q14517"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14520/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"habp2","kind":"target","name":"HABP2","route":"/targets/habp2/","field":"links","label":"UniProt Q14520"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14524/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn5a","kind":"target","name":"SCN5A","route":"/targets/scn5a/","field":"links","label":"UniProt Q14524"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14541/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hnf4g","kind":"target","name":"HNF4G","route":"/targets/hnf4g/","field":"links","label":"UniProt Q14541"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14626/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","field":"links","label":"UniProt Q14626: IL11RA"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"itpr1","kind":"target","name":"ITPR1","route":"/targets/itpr1/","field":"links","label":"UniProt Q14643"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14678/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kank1","kind":"target","name":"KANK1","route":"/targets/kank1/","field":"links","label":"UniProt Q14678"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14683/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smc1a","kind":"target","name":"SMC1A","route":"/targets/smc1a/","field":"links","label":"UniProt Q14683"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14738/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5d","kind":"target","name":"PPP2R5D","route":"/targets/ppp2r5d/","field":"links","label":"UniProt Q14738"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14789/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golgb1","kind":"target","name":"GOLGB1","route":"/targets/golgb1/","field":"links","label":"UniProt Q14789"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14790/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/","field":"links","label":"UniProt Q14790"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14814/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mef2d","kind":"target","name":"MEF2D","route":"/targets/mef2d/","field":"links","label":"UniProt Q14814"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14832/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grm3","kind":"target","name":"GRM3","route":"/targets/grm3/","field":"links","label":"UniProt Q14832"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14839/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd4","kind":"target","name":"CHD4","route":"/targets/chd4/","field":"links","label":"UniProt Q14839"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14849/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stard3","kind":"target","name":"STARD3","route":"/targets/stard3/","field":"links","label":"UniProt Q14849"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14865/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid5b","kind":"target","name":"ARID5B","route":"/targets/arid5b/","field":"links","label":"UniProt Q14865"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14980/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"numa1","kind":"target","name":"NUMA1","route":"/targets/numa1/","field":"links","label":"UniProt Q14980"}]},{"url":"https://www.uniprot.org/uniprotkb/Q14999/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cul7","kind":"target","name":"CUL7","route":"/targets/cul7/","field":"links","label":"UniProt Q14999"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15003/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncaph","kind":"target","name":"NCAPH","route":"/targets/ncaph/","field":"links","label":"UniProt Q15003"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15008/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/","field":"links","label":"UniProt Q15008"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15011/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"herpud1","kind":"target","name":"HERPUD1","route":"/targets/herpud1/","field":"links","label":"UniProt Q15011"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15022/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"suz12","kind":"target","name":"SUZ12","route":"/targets/suz12/","field":"links","label":"UniProt Q15022"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15029/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/","field":"links","label":"UniProt Q15029"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15047/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setdb1","kind":"target","name":"SETDB1","route":"/targets/setdb1/","field":"links","label":"UniProt Q15047"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15054/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/","field":"links","label":"UniProt Q15054"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15139/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd1","kind":"target","name":"PRKD1","route":"/targets/prkd1/","field":"links","label":"UniProt Q15139"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15154/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcm1","kind":"target","name":"PCM1","route":"/targets/pcm1/","field":"links","label":"UniProt Q15154"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15172/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5a","kind":"target","name":"PPP2R5A","route":"/targets/ppp2r5a/","field":"links","label":"UniProt Q15172"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15173/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5b","kind":"target","name":"PPP2R5B","route":"/targets/ppp2r5b/","field":"links","label":"UniProt Q15173"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15198/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdgfrl","kind":"target","name":"PDGFRL","route":"/targets/pdgfrl/","field":"links","label":"UniProt Q15198"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15262/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptprk","kind":"target","name":"PTPRK","route":"/targets/ptprk/","field":"links","label":"UniProt Q15262"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15283/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rasa2","kind":"target","name":"RASA2","route":"/targets/rasa2/","field":"links","label":"UniProt Q15283"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15303/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erbb4","kind":"target","name":"HER4 (ERBB4)","route":"/targets/erbb4/","field":"links","label":"UniProt Q15303: ERBB4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15306/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/","field":"links","label":"UniProt Q15306"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15361/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","field":"links","label":"UniProt Q15361"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15365/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcbp1","kind":"target","name":"PCBP1","route":"/targets/pcbp1/","field":"links","label":"UniProt Q15365"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15375/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha7","kind":"target","name":"EPHA7","route":"/targets/epha7/","field":"links","label":"UniProt Q15375"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15382/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rheb","kind":"target","name":"RHEB","route":"/targets/rheb/","field":"links","label":"UniProt Q15382"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15389/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"angpt1","kind":"target","name":"ANGPT1","route":"/targets/angpt1/","field":"links","label":"UniProt Q15389"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15468/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stil","kind":"target","name":"STIL","route":"/targets/stil/","field":"links","label":"UniProt Q15468"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15475/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"six1","kind":"target","name":"SIX1","route":"/targets/six1/","field":"links","label":"UniProt Q15475"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15532/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ss18","kind":"target","name":"SS18","route":"/targets/ss18/","field":"links","label":"UniProt Q15532"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15583/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tgif1","kind":"target","name":"TGIF1","route":"/targets/tgif1/","field":"links","label":"UniProt Q15583"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15596/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/","field":"links","label":"UniProt Q15596"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trip11","kind":"target","name":"TRIP11","route":"/targets/trip11/","field":"links","label":"UniProt Q15643"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15669/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhoh","kind":"target","name":"RHOH","route":"/targets/rhoh/","field":"links","label":"UniProt Q15669"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15678/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn14","kind":"target","name":"PTPN14","route":"/targets/ptpn14/","field":"links","label":"UniProt Q15678"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15696/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zrsr2","kind":"target","name":"ZRSR2","route":"/targets/zrsr2/","field":"links","label":"UniProt Q15696"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15742/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nab2","kind":"target","name":"NAB2","route":"/targets/nab2/","field":"links","label":"UniProt Q15742"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15759/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mapk11","kind":"target","name":"MAPK11","route":"/targets/mapk11/","field":"links","label":"UniProt Q15759"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15788/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa1","kind":"target","name":"NCOA1","route":"/targets/ncoa1/","field":"links","label":"UniProt Q15788"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15796/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smad2","kind":"target","name":"SMAD2","route":"/targets/smad2/","field":"links","label":"UniProt Q15796"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15831/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","field":"links","label":"UniProt Q15831"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15858/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn9a","kind":"target","name":"SCN9A","route":"/targets/scn9a/","field":"links","label":"UniProt Q15858"}]},{"url":"https://www.uniprot.org/uniprotkb/Q15911/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/","field":"links","label":"UniProt Q15911"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16186/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/","field":"links","label":"UniProt Q16186"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16204/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc6","kind":"target","name":"CCDC6","route":"/targets/ccdc6/","field":"links","label":"UniProt Q16204"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16236/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","field":"links","label":"UniProt Q16236"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16384/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssx1","kind":"target","name":"SSX1","route":"/targets/ssx1/","field":"links","label":"UniProt Q16384"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16385/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/","field":"links","label":"UniProt Q16385"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16394/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/","field":"links","label":"UniProt Q16394"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16531/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/","field":"links","label":"UniProt Q16531"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16534/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hlf","kind":"target","name":"HLF","route":"/targets/hlf/","field":"links","label":"UniProt Q16534"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16537/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp2r5e","kind":"target","name":"PPP2R5E","route":"/targets/ppp2r5e/","field":"links","label":"UniProt Q16537"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16543/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc37","kind":"target","name":"CDC37","route":"/targets/cdc37/","field":"links","label":"UniProt Q16543"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16559/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tal2","kind":"target","name":"TAL2","route":"/targets/tal2/","field":"links","label":"UniProt Q16559"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16576/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbbp7","kind":"target","name":"RBBP7","route":"/targets/rbbp7/","field":"links","label":"UniProt Q16576"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16611/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bak1","kind":"target","name":"BAK1","route":"/targets/bak1/","field":"links","label":"UniProt Q16611"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16630/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpsf6","kind":"target","name":"CPSF6","route":"/targets/cpsf6/","field":"links","label":"UniProt Q16630"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16633/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pou2af1","kind":"target","name":"POU2AF1","route":"/targets/pou2af1/","field":"links","label":"UniProt Q16633"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16665/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hif1a","kind":"target","name":"HIF-1α (HIF1A)","route":"/targets/hif1a/","field":"links","label":"UniProt Q16665"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16678/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyp1b1","kind":"target","name":"CYP1B1","route":"/targets/cyp1b1/","field":"links","label":"UniProt Q16678"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16720/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atp2b3","kind":"target","name":"ATP2B3","route":"/targets/atp2b3/","field":"links","label":"UniProt Q16720"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16828/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp6","kind":"target","name":"DUSP6","route":"/targets/dusp6/","field":"links","label":"UniProt Q16828"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16832/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","field":"links","label":"UniProt Q16832: DDR2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q16881/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","field":"links","label":"UniProt Q16881: TXNRD1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q19T08/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ecscr","kind":"target","name":"ECSCR","route":"/targets/ecscr/","field":"links","label":"UniProt Q19T08"}]},{"url":"https://www.uniprot.org/uniprotkb/Q2KHR2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rfx7","kind":"target","name":"RFX7","route":"/targets/rfx7/","field":"links","label":"UniProt Q2KHR2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q2M385/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mpeg1","kind":"target","name":"MPEG1","route":"/targets/mpeg1/","field":"links","label":"UniProt Q2M385"}]},{"url":"https://www.uniprot.org/uniprotkb/Q32MQ0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf750","kind":"target","name":"ZNF750","route":"/targets/znf750/","field":"links","label":"UniProt Q32MQ0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q32MZ4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrrfip1","kind":"target","name":"LRRFIP1","route":"/targets/lrrfip1/","field":"links","label":"UniProt Q32MZ4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q3ZCM7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/","field":"links","label":"UniProt Q3ZCM7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q3ZCQ3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam174b","kind":"target","name":"FAM174B","route":"/targets/fam174b/","field":"links","label":"UniProt Q3ZCQ3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q49AJ0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam135b","kind":"target","name":"FAM135B","route":"/targets/fam135b/","field":"links","label":"UniProt Q49AJ0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q4VC05/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/","field":"links","label":"UniProt Q4VC05"}]},{"url":"https://www.uniprot.org/uniprotkb/Q53EL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdcd4","kind":"target","name":"PDCD4","route":"/targets/pdcd4/","field":"links","label":"UniProt Q53EL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q53EP0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fndc3b","kind":"target","name":"FNDC3B","route":"/targets/fndc3b/","field":"links","label":"UniProt Q53EP0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q53FZ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsm3","kind":"target","name":"ACSM3","route":"/targets/acsm3/","field":"links","label":"UniProt Q53FZ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q53H12/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agk","kind":"target","name":"AGK","route":"/targets/agk/","field":"links","label":"UniProt Q53H12"}]},{"url":"https://www.uniprot.org/uniprotkb/Q53H54/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tyw2","kind":"target","name":"TYW2","route":"/targets/tyw2/","field":"links","label":"UniProt Q53H54"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5H9F3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/","field":"links","label":"UniProt Q5H9F3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5HYI8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rabl3","kind":"target","name":"RABL3","route":"/targets/rabl3/","field":"links","label":"UniProt Q5HYI8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5JTC6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","field":"links","label":"UniProt Q5JTC6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5JZY3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha10","kind":"target","name":"EPHA10","route":"/targets/epha10/","field":"links","label":"UniProt Q5JZY3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5K651/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samd9","kind":"target","name":"SAMD9","route":"/targets/samd9/","field":"links","label":"UniProt Q5K651"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5SY16/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nol9","kind":"target","name":"NOL9","route":"/targets/nol9/","field":"links","label":"UniProt Q5SY16"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5T124/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ubxn11","kind":"target","name":"UBXN11","route":"/targets/ubxn11/","field":"links","label":"UniProt Q5T124"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5T3U5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcc10","kind":"target","name":"ABCC10","route":"/targets/abcc10/","field":"links","label":"UniProt Q5T3U5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VIR6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vps53","kind":"target","name":"VPS53","route":"/targets/vps53/","field":"links","label":"UniProt Q5VIR6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VT03/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm2d","kind":"target","name":"NUTM2D","route":"/targets/nutm2d/","field":"links","label":"UniProt Q5VT03"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VV42/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdkal1","kind":"target","name":"CDKAL1","route":"/targets/cdkal1/","field":"links","label":"UniProt Q5VV42"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VVJ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mysm1","kind":"target","name":"MYSM1","route":"/targets/mysm1/","field":"links","label":"UniProt Q5VVJ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VW00/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dcaf12l2","kind":"target","name":"DCAF12L2","route":"/targets/dcaf12l2/","field":"links","label":"UniProt Q5VW00"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5VWP2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/","field":"links","label":"UniProt Q5VWP2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q5XG87/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tent4a","kind":"target","name":"TENT4A","route":"/targets/tent4a/","field":"links","label":"UniProt Q5XG87"}]},{"url":"https://www.uniprot.org/uniprotkb/Q63HN8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf213","kind":"target","name":"RNF213","route":"/targets/rnf213/","field":"links","label":"UniProt Q63HN8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/","field":"links","label":"UniProt Q68CP9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q68CZ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tns3","kind":"target","name":"TNS3","route":"/targets/tns3/","field":"links","label":"UniProt Q68CZ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q68DA7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fmn1","kind":"target","name":"FMN1","route":"/targets/fmn1/","field":"links","label":"UniProt Q68DA7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q68DV7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","field":"links","label":"UniProt Q68DV7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q68DY1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf626","kind":"target","name":"ZNF626","route":"/targets/znf626/","field":"links","label":"UniProt Q68DY1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6DJT9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"plag1","kind":"target","name":"PLAG1","route":"/targets/plag1/","field":"links","label":"UniProt Q6DJT9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6DKI7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","field":"links","label":"UniProt Q6DKI7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6FHJ7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sfrp4","kind":"target","name":"SFRP4","route":"/targets/sfrp4/","field":"links","label":"UniProt Q6FHJ7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ISB3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grhl2","kind":"target","name":"GRHL2","route":"/targets/grhl2/","field":"links","label":"UniProt Q6ISB3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6IWH7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ano7","kind":"target","name":"ANO7","route":"/targets/ano7/","field":"links","label":"UniProt Q6IWH7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6KC79/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nipbl","kind":"target","name":"NIPBL","route":"/targets/nipbl/","field":"links","label":"UniProt Q6KC79"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6N021/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tet2","kind":"target","name":"TET2","route":"/targets/tet2/","field":"links","label":"UniProt Q6N021"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6NXG1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esrp1","kind":"target","name":"ESRP1","route":"/targets/esrp1/","field":"links","label":"UniProt Q6NXG1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6NZ36/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"faap20","kind":"target","name":"FAAP20","route":"/targets/faap20/","field":"links","label":"UniProt Q6NZ36"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6NZY4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zcchc8","kind":"target","name":"ZCCHC8","route":"/targets/zcchc8/","field":"links","label":"UniProt Q6NZY4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6P1J9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc73","kind":"target","name":"CDC73","route":"/targets/cdc73/","field":"links","label":"UniProt Q6P1J9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6PCD5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rfwd3","kind":"target","name":"RFWD3","route":"/targets/rfwd3/","field":"links","label":"UniProt Q6PCD5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6PD62/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctr9","kind":"target","name":"CTR9","route":"/targets/ctr9/","field":"links","label":"UniProt Q6PD62"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6PEY2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/","field":"links","label":"UniProt Q6PEY2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6PJQ5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxr2","kind":"target","name":"FOXR2","route":"/targets/foxr2/","field":"links","label":"UniProt Q6PJQ5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6Q0C0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"traf7","kind":"target","name":"TRAF7","route":"/targets/traf7/","field":"links","label":"UniProt Q6Q0C0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6R327/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/","field":"links","label":"UniProt Q6R327"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6RW13/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agtrap","kind":"target","name":"AGTRAP","route":"/targets/agtrap/","field":"links","label":"UniProt Q6RW13"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UB99/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ankrd11","kind":"target","name":"ANKRD11","route":"/targets/ankrd11/","field":"links","label":"UniProt Q6UB99"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UN15/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fip1l1","kind":"target","name":"FIP1L1","route":"/targets/fip1l1/","field":"links","label":"UniProt Q6UN15"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UUV7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crtc3","kind":"target","name":"CRTC3","route":"/targets/crtc3/","field":"links","label":"UniProt Q6UUV7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UUV9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crtc1","kind":"target","name":"CRTC1","route":"/targets/crtc1/","field":"links","label":"UniProt Q6UUV9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UVK1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cspg4","kind":"target","name":"CSPG4","route":"/targets/cspg4/","field":"links","label":"UniProt Q6UVK1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UXM1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrig3","kind":"target","name":"LRIG3","route":"/targets/lrig3/","field":"links","label":"UniProt Q6UXM1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6UXX9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rspo2","kind":"target","name":"RSPO2","route":"/targets/rspo2/","field":"links","label":"UniProt Q6UXX9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6V0I7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat4","kind":"target","name":"FAT4","route":"/targets/fat4/","field":"links","label":"UniProt Q6V0I7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6VAB6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ksr2","kind":"target","name":"KSR2","route":"/targets/ksr2/","field":"links","label":"UniProt Q6VAB6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6VMQ6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"atf7ip","kind":"target","name":"ATF7IP","route":"/targets/atf7ip/","field":"links","label":"UniProt Q6VMQ6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6W2J9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcor","kind":"target","name":"BCOR","route":"/targets/bcor/","field":"links","label":"UniProt Q6W2J9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6W4X9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"muc6","kind":"target","name":"MUC6","route":"/targets/muc6/","field":"links","label":"UniProt Q6W4X9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6WCQ1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mprip","kind":"target","name":"MPRIP","route":"/targets/mprip/","field":"links","label":"UniProt Q6WCQ1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6XQN6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naprt","kind":"target","name":"NAPRT","route":"/targets/naprt/","field":"links","label":"UniProt Q6XQN6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZMT4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm7a","kind":"target","name":"KDM7A","route":"/targets/kdm7a/","field":"links","label":"UniProt Q6ZMT4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZN28/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"macc1","kind":"target","name":"MACC1","route":"/targets/macc1/","field":"links","label":"UniProt Q6ZN28"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZN30/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bnc2","kind":"target","name":"BNC2","route":"/targets/bnc2/","field":"links","label":"UniProt Q6ZN30"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZNL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgd5","kind":"target","name":"FGD5","route":"/targets/fgd5/","field":"links","label":"UniProt Q6ZNL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZTQ3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rassf6","kind":"target","name":"RASSF6","route":"/targets/rassf6/","field":"links","label":"UniProt Q6ZTQ3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZVD8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phlpp2","kind":"target","name":"PHLPP2","route":"/targets/phlpp2/","field":"links","label":"UniProt Q6ZVD8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q6ZWH5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nek10","kind":"target","name":"NEK10","route":"/targets/nek10/","field":"links","label":"UniProt Q6ZWH5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q70SY1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb3l2","kind":"target","name":"CREB3L2","route":"/targets/creb3l2/","field":"links","label":"UniProt Q70SY1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q70Z35/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/","field":"links","label":"UniProt Q70Z35"}]},{"url":"https://www.uniprot.org/uniprotkb/Q71DI3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h3c14","kind":"target","name":"H3C14","route":"/targets/h3c14/","field":"links","label":"UniProt Q71DI3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q71RS6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc24a5","kind":"target","name":"SLC24A5","route":"/targets/slc24a5/","field":"links","label":"UniProt Q71RS6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q71U36/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/","field":"links","label":"UniProt Q71U36"}]},{"url":"https://www.uniprot.org/uniprotkb/Q76L83/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asxl2","kind":"target","name":"ASXL2","route":"/targets/asxl2/","field":"links","label":"UniProt Q76L83"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7KZF4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/","field":"links","label":"UniProt Q7KZF4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7KZI7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mark2","kind":"target","name":"MARK2","route":"/targets/mark2/","field":"links","label":"UniProt Q7KZI7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7LBC6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm3b","kind":"target","name":"KDM3B","route":"/targets/kdm3b/","field":"links","label":"UniProt Q7LBC6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7LG56/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/","field":"links","label":"UniProt Q7LG56"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z2W4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zc3hav1","kind":"target","name":"ZC3HAV1","route":"/targets/zc3hav1/","field":"links","label":"UniProt Q7Z2W4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z2Y5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrk","kind":"target","name":"NRK","route":"/targets/nrk/","field":"links","label":"UniProt Q7Z2Y5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z407/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csmd3","kind":"target","name":"CSMD3","route":"/targets/csmd3/","field":"links","label":"UniProt Q7Z407"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z4H8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"poglut3","kind":"target","name":"POGLUT3","route":"/targets/poglut3/","field":"links","label":"UniProt Q7Z4H8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z4P5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gdf7","kind":"target","name":"GDF7","route":"/targets/gdf7/","field":"links","label":"UniProt Q7Z4P5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z553/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mdga2","kind":"target","name":"MDGA2","route":"/targets/mdga2/","field":"links","label":"UniProt Q7Z553"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z589/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/","field":"links","label":"UniProt Q7Z589"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z5R6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apbb1ip","kind":"target","name":"APBB1IP","route":"/targets/apbb1ip/","field":"links","label":"UniProt Q7Z5R6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z6A9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/","field":"links","label":"UniProt Q7Z6A9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z6B7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srgap1","kind":"target","name":"SRGAP1","route":"/targets/srgap1/","field":"links","label":"UniProt Q7Z6B7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z7A1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cntrl","kind":"target","name":"CNTRL","route":"/targets/cntrl/","field":"links","label":"UniProt Q7Z7A1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z7D3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/","field":"links","label":"UniProt Q7Z7D3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q7Z7L1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","field":"links","label":"UniProt Q7Z7L1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86SQ7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdccag8","kind":"target","name":"SDCCAG8","route":"/targets/sdccag8/","field":"links","label":"UniProt Q86SQ7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86U70/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ldb1","kind":"target","name":"LDB1","route":"/targets/ldb1/","field":"links","label":"UniProt Q86U70"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86U86/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/","field":"links","label":"UniProt Q86U86"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86UE8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlk2","kind":"target","name":"TLK2","route":"/targets/tlk2/","field":"links","label":"UniProt Q86UE8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86UP2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ktn1","kind":"target","name":"KTN1","route":"/targets/ktn1/","field":"links","label":"UniProt Q86UP2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86UP3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfhx4","kind":"target","name":"ZFHX4","route":"/targets/zfhx4/","field":"links","label":"UniProt Q86UP3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86UU0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl9l","kind":"target","name":"BCL9L","route":"/targets/bcl9l/","field":"links","label":"UniProt Q86UU0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86UW6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"n4bp2","kind":"target","name":"N4BP2","route":"/targets/n4bp2/","field":"links","label":"UniProt Q86UW6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86V15/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casz1","kind":"target","name":"CASZ1","route":"/targets/casz1/","field":"links","label":"UniProt Q86V15"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86V71/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf429","kind":"target","name":"ZNF429","route":"/targets/znf429/","field":"links","label":"UniProt Q86V71"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86VS8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hook3","kind":"target","name":"HOOK3","route":"/targets/hook3/","field":"links","label":"UniProt Q86VS8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86VZ1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"p2ry8","kind":"target","name":"P2RY8","route":"/targets/p2ry8/","field":"links","label":"UniProt Q86VZ1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86VZ6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jazf1","kind":"target","name":"JAZF1","route":"/targets/jazf1/","field":"links","label":"UniProt Q86VZ6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86W92/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppfibp1","kind":"target","name":"PPFIBP1","route":"/targets/ppfibp1/","field":"links","label":"UniProt Q86W92"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86X19/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tmem17","kind":"target","name":"TMEM17","route":"/targets/tmem17/","field":"links","label":"UniProt Q86X19"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86XD5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam131b","kind":"target","name":"FAM131B","route":"/targets/fam131b/","field":"links","label":"UniProt Q86XD5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86XK2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/","field":"links","label":"UniProt Q86XK2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86Y01/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dtx1","kind":"target","name":"DTX1","route":"/targets/dtx1/","field":"links","label":"UniProt Q86Y01"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86Y26/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/","field":"links","label":"UniProt Q86Y26"}]},{"url":"https://www.uniprot.org/uniprotkb/Q86YC2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","field":"links","label":"UniProt Q86YC2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IUC4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhpn2","kind":"target","name":"RHPN2","route":"/targets/rhpn2/","field":"links","label":"UniProt Q8IUC4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IUD2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erc1","kind":"target","name":"ERC1","route":"/targets/erc1/","field":"links","label":"UniProt Q8IUD2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IUX7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aebp1","kind":"target","name":"AEBP1","route":"/targets/aebp1/","field":"links","label":"UniProt Q8IUX7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IVG5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samd9l","kind":"target","name":"SAMD9L","route":"/targets/samd9l/","field":"links","label":"UniProt Q8IVG5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IVH2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp4","kind":"target","name":"FOXP4","route":"/targets/foxp4/","field":"links","label":"UniProt Q8IVH2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IVT5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ksr1","kind":"target","name":"KSR1","route":"/targets/ksr1/","field":"links","label":"UniProt Q8IVT5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mga","kind":"target","name":"MGA","route":"/targets/mga/","field":"links","label":"UniProt Q8IWI9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IWS0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phf6","kind":"target","name":"PHF6","route":"/targets/phf6/","field":"links","label":"UniProt Q8IWS0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IWU9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tph2","kind":"target","name":"TPH2","route":"/targets/tph2/","field":"links","label":"UniProt Q8IWU9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IX12/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccar1","kind":"target","name":"CCAR1","route":"/targets/ccar1/","field":"links","label":"UniProt Q8IX12"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IXJ9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"asxl1","kind":"target","name":"ASXL1","route":"/targets/asxl1/","field":"links","label":"UniProt Q8IXJ9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IXV7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhdc8b","kind":"target","name":"KLHDC8B","route":"/targets/klhdc8b/","field":"links","label":"UniProt Q8IXV7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IY92/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slx4","kind":"target","name":"SLX4","route":"/targets/slx4/","field":"links","label":"UniProt Q8IY92"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IYB1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mb21d2","kind":"target","name":"MB21D2","route":"/targets/mb21d2/","field":"links","label":"UniProt Q8IYB1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IYD8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/","field":"links","label":"UniProt Q8IYD8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IYT2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/","field":"links","label":"UniProt Q8IYT2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IYT3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc170","kind":"target","name":"CCDC170","route":"/targets/ccdc170/","field":"links","label":"UniProt Q8IYT3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IZL2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml2","kind":"target","name":"MAML2","route":"/targets/maml2/","field":"links","label":"UniProt Q8IZL2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IZP0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abi1","kind":"target","name":"ABI1","route":"/targets/abi1/","field":"links","label":"UniProt Q8IZP0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8IZX4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taf1l","kind":"target","name":"TAF1L","route":"/targets/taf1l/","field":"links","label":"UniProt Q8IZX4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N302/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aggf1","kind":"target","name":"AGGF1","route":"/targets/aggf1/","field":"links","label":"UniProt Q8N302"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N3J6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cadm2","kind":"target","name":"CADM2","route":"/targets/cadm2/","field":"links","label":"UniProt Q8N3J6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N3U4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stag2","kind":"target","name":"STAG2","route":"/targets/stag2/","field":"links","label":"UniProt Q8N3U4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N423/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","field":"links","label":"UniProt Q8N423"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N4C6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nin","kind":"target","name":"NIN","route":"/targets/nin/","field":"links","label":"UniProt Q8N4C6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N653/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lztr1","kind":"target","name":"LZTR1","route":"/targets/lztr1/","field":"links","label":"UniProt Q8N653"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8N6U8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gpr161","kind":"target","name":"GPR161","route":"/targets/gpr161/","field":"links","label":"UniProt Q8N6U8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NB91/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancb","kind":"target","name":"FANCB","route":"/targets/fancb/","field":"links","label":"UniProt Q8NB91"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NCR3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/","field":"links","label":"UniProt Q8NCR3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8ND56/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lsm14a","kind":"target","name":"LSM14A","route":"/targets/lsm14a/","field":"links","label":"UniProt Q8ND56"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NDI1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ehbp1","kind":"target","name":"EHBP1","route":"/targets/ehbp1/","field":"links","label":"UniProt Q8NDI1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NE35/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpeb3","kind":"target","name":"CPEB3","route":"/targets/cpeb3/","field":"links","label":"UniProt Q8NE35"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NEM1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf680","kind":"target","name":"ZNF680","route":"/targets/znf680/","field":"links","label":"UniProt Q8NEM1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NEZ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/","field":"links","label":"UniProt Q8NEZ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NEZ4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","field":"links","label":"UniProt Q8NEZ4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NF50/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dock8","kind":"target","name":"DOCK8","route":"/targets/dock8/","field":"links","label":"UniProt Q8NF50"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NFD5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/","field":"links","label":"UniProt Q8NFD5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NFG4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"flcn","kind":"target","name":"FLCN","route":"/targets/flcn/","field":"links","label":"UniProt Q8NFG4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NFP9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/","field":"links","label":"UniProt Q8NFP9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NFU7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/","field":"links","label":"UniProt Q8NFU7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NG31/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"knl1","kind":"target","name":"KNL1","route":"/targets/knl1/","field":"links","label":"UniProt Q8NG31"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NHL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/","field":"links","label":"UniProt Q8NHL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8NHX9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tpcn2","kind":"target","name":"TPCN2","route":"/targets/tpcn2/","field":"links","label":"UniProt Q8NHX9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TAA3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/","field":"links","label":"UniProt Q8TAA3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TBA6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"golga5","kind":"target","name":"GOLGA5","route":"/targets/golga5/","field":"links","label":"UniProt Q8TBA6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TBF4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zcrb1","kind":"target","name":"ZCRB1","route":"/targets/zcrb1/","field":"links","label":"UniProt Q8TBF4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TCG1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cip2a","kind":"target","name":"CIP2A","route":"/targets/cip2a/","field":"links","label":"UniProt Q8TCG1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TDW7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat3","kind":"target","name":"FAT3","route":"/targets/fat3/","field":"links","label":"UniProt Q8TDW7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TEK3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/","field":"links","label":"UniProt Q8TEK3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TEQ0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"snx29","kind":"target","name":"SNX29","route":"/targets/snx29/","field":"links","label":"UniProt Q8TEQ0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8TF20/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf721","kind":"target","name":"ZNF721","route":"/targets/znf721/","field":"links","label":"UniProt Q8TF20"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WTW4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nprl2","kind":"target","name":"NPRL2","route":"/targets/nprl2/","field":"links","label":"UniProt Q8WTW4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WU20/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"frs2","kind":"target","name":"FRS2","route":"/targets/frs2/","field":"links","label":"UniProt Q8WU20"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WUI4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/","field":"links","label":"UniProt Q8WUI4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WUY3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/","field":"links","label":"UniProt Q8WUY3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WV24/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phlda1","kind":"target","name":"PHLDA1","route":"/targets/phlda1/","field":"links","label":"UniProt Q8WV24"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WVQ1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cant1","kind":"target","name":"CANT1","route":"/targets/cant1/","field":"links","label":"UniProt Q8WVQ1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WW38/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zfpm2","kind":"target","name":"ZFPM2","route":"/targets/zfpm2/","field":"links","label":"UniProt Q8WW38"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WW43/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aph1b","kind":"target","name":"APH1B","route":"/targets/aph1b/","field":"links","label":"UniProt Q8WW43"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WWG1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nrg4","kind":"target","name":"NRG4","route":"/targets/nrg4/","field":"links","label":"UniProt Q8WWG1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WWI1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lmo7","kind":"target","name":"LMO7","route":"/targets/lmo7/","field":"links","label":"UniProt Q8WWI1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WXF1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pspc1","kind":"target","name":"PSPC1","route":"/targets/pspc1/","field":"links","label":"UniProt Q8WXF1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WXI2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnksr2","kind":"target","name":"CNKSR2","route":"/targets/cnksr2/","field":"links","label":"UniProt Q8WXI2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WYB5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat6b","kind":"target","name":"KAT6B","route":"/targets/kat6b/","field":"links","label":"UniProt Q8WYB5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WYQ5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dgcr8","kind":"target","name":"DGCR8","route":"/targets/dgcr8/","field":"links","label":"UniProt Q8WYQ5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WYR1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r5","kind":"target","name":"PIK3R5","route":"/targets/pik3r5/","field":"links","label":"UniProt Q8WYR1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WZ60/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhl6","kind":"target","name":"KLHL6","route":"/targets/klhl6/","field":"links","label":"UniProt Q8WZ60"}]},{"url":"https://www.uniprot.org/uniprotkb/Q8WZ75/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"robo4","kind":"target","name":"ROBO4","route":"/targets/robo4/","field":"links","label":"UniProt Q8WZ75"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92466/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddb2","kind":"target","name":"DDB2","route":"/targets/ddb2/","field":"links","label":"UniProt Q92466"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92542/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncstn","kind":"target","name":"NCSTN","route":"/targets/ncstn/","field":"links","label":"UniProt Q92542"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92560/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","field":"links","label":"UniProt Q92560"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92569/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pik3r3","kind":"target","name":"PIK3R3","route":"/targets/pik3r3/","field":"links","label":"UniProt Q92569"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92570/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nr4a3","kind":"target","name":"NR4A3","route":"/targets/nr4a3/","field":"links","label":"UniProt Q92570"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92574/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tsc1","kind":"target","name":"TSC1","route":"/targets/tsc1/","field":"links","label":"UniProt Q92574"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92585/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml1","kind":"target","name":"MAML1","route":"/targets/maml1/","field":"links","label":"UniProt Q92585"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92597/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ndrg1","kind":"target","name":"NDRG1","route":"/targets/ndrg1/","field":"links","label":"UniProt Q92597"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92598/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hsph1","kind":"target","name":"HSPH1","route":"/targets/hsph1/","field":"links","label":"UniProt Q92598"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92600/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnot9","kind":"target","name":"CNOT9","route":"/targets/cnot9/","field":"links","label":"UniProt Q92600"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92692/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/","field":"links","label":"UniProt Q92692"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92698/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad54l","kind":"target","name":"RAD54L","route":"/targets/rad54l/","field":"links","label":"UniProt Q92698"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92731/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"esr2","kind":"target","name":"ESR2","route":"/targets/esr2/","field":"links","label":"UniProt Q92731"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92733/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","field":"links","label":"UniProt Q92733"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92734/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tfg","kind":"target","name":"TFG","route":"/targets/tfg/","field":"links","label":"UniProt Q92734"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92793/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/","field":"links","label":"UniProt Q92793"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92794/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/","field":"links","label":"UniProt Q92794"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92804/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taf15","kind":"target","name":"TAF15","route":"/targets/taf15/","field":"links","label":"UniProt Q92804"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92826/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxb13","kind":"target","name":"HOXB13","route":"/targets/hoxb13/","field":"links","label":"UniProt Q92826"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92830/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/","field":"links","label":"UniProt Q92830"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92831/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/","field":"links","label":"UniProt Q92831"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92847/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ghsr","kind":"target","name":"GHSR","route":"/targets/ghsr/","field":"links","label":"UniProt Q92847"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92851/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"casp10","kind":"target","name":"CASP10","route":"/targets/casp10/","field":"links","label":"UniProt Q92851"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92878/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/","field":"links","label":"UniProt Q92878"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92889/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ercc4","kind":"target","name":"ERCC4","route":"/targets/ercc4/","field":"links","label":"UniProt Q92889"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92911/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"links","label":"UniProt Q92911: sodium/iodide cotransporter (SLC5A5, NIS), the uptake route of iodide into thyroid cells"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92913/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf13","kind":"target","name":"FGF13","route":"/targets/fgf13/","field":"links","label":"UniProt Q92913"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92953/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnb2","kind":"target","name":"KCNB2","route":"/targets/kcnb2/","field":"links","label":"UniProt Q92953"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92956/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf14","kind":"target","name":"TNFRSF14","route":"/targets/tnfrsf14/","field":"links","label":"UniProt Q92956"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92963/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rit1","kind":"target","name":"RIT1","route":"/targets/rit1/","field":"links","label":"UniProt Q92963"}]},{"url":"https://www.uniprot.org/uniprotkb/Q92993/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kat5","kind":"target","name":"KAT5","route":"/targets/kat5/","field":"links","label":"UniProt Q92993"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93008/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp9x","kind":"target","name":"USP9X","route":"/targets/usp9x/","field":"links","label":"UniProt Q93008"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93009/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/","field":"links","label":"UniProt Q93009"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93052/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lpp","kind":"target","name":"LPP","route":"/targets/lpp/","field":"links","label":"UniProt Q93052"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93063/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/","field":"links","label":"UniProt Q93063"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93074/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/","field":"links","label":"UniProt Q93074"}]},{"url":"https://www.uniprot.org/uniprotkb/Q93077/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"h2ac6","kind":"target","name":"H2AC6","route":"/targets/h2ac6/","field":"links","label":"UniProt Q93077"}]},{"url":"https://www.uniprot.org/uniprotkb/Q969G3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarce1","kind":"target","name":"SMARCE1","route":"/targets/smarce1/","field":"links","label":"UniProt Q969G3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q969H0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","field":"links","label":"UniProt Q969H0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q969H4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cnksr1","kind":"target","name":"CNKSR1","route":"/targets/cnksr1/","field":"links","label":"UniProt Q969H4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q969S8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/","field":"links","label":"UniProt Q969S8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q969V6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mrtfa","kind":"target","name":"MRTFA","route":"/targets/mrtfa/","field":"links","label":"UniProt Q969V6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96A00/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ppp1r14a","kind":"target","name":"PPP1R14A","route":"/targets/ppp1r14a/","field":"links","label":"UniProt Q96A00"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96AC1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fermt2","kind":"target","name":"FERMT2","route":"/targets/fermt2/","field":"links","label":"UniProt Q96AC1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96AE4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fubp1","kind":"target","name":"FUBP1","route":"/targets/fubp1/","field":"links","label":"UniProt Q96AE4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96AJ9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vti1a","kind":"target","name":"VTI1A","route":"/targets/vti1a/","field":"links","label":"UniProt Q96AJ9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96AV8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"e2f7","kind":"target","name":"E2F7","route":"/targets/e2f7/","field":"links","label":"UniProt Q96AV8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96AX9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mib2","kind":"target","name":"MIB2","route":"/targets/mib2/","field":"links","label":"UniProt Q96AX9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96BA8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"creb3l1","kind":"target","name":"CREB3L1","route":"/targets/creb3l1/","field":"links","label":"UniProt Q96BA8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96BI1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc67a1","kind":"target","name":"SLC67A1","route":"/targets/slc67a1/","field":"links","label":"UniProt Q96BI1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96BI3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aph1a","kind":"target","name":"APH1A","route":"/targets/aph1a/","field":"links","label":"UniProt Q96BI3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96CA5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc7","kind":"target","name":"BIRC7","route":"/targets/birc7/","field":"links","label":"UniProt Q96CA5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96CF2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chmp4c","kind":"target","name":"CHMP4C","route":"/targets/chmp4c/","field":"links","label":"UniProt Q96CF2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96D96/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hvcn1","kind":"target","name":"HVCN1","route":"/targets/hvcn1/","field":"links","label":"UniProt Q96D96"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96DB2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/","field":"links","label":"UniProt Q96DB2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96DH6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/","field":"links","label":"UniProt Q96DH6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96DT5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnah11","kind":"target","name":"DNAH11","route":"/targets/dnah11/","field":"links","label":"UniProt Q96DT5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96DT7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb10","kind":"target","name":"ZBTB10","route":"/targets/zbtb10/","field":"links","label":"UniProt Q96DT7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96E14/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rmi2","kind":"target","name":"RMI2","route":"/targets/rmi2/","field":"links","label":"UniProt Q96E14"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96EA4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spdl1","kind":"target","name":"SPDL1","route":"/targets/spdl1/","field":"links","label":"UniProt Q96EA4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96EB1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elp4","kind":"target","name":"ELP4","route":"/targets/elp4/","field":"links","label":"UniProt Q96EB1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96EB6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sirt1","kind":"target","name":"SIRT1","route":"/targets/sirt1/","field":"links","label":"UniProt Q96EB6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96EP5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dazap1","kind":"target","name":"DAZAP1","route":"/targets/dazap1/","field":"links","label":"UniProt Q96EP5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96EZ4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myeov","kind":"target","name":"MYEOV","route":"/targets/myeov/","field":"links","label":"UniProt Q96EZ4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96FI4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"neil1","kind":"target","name":"NEIL1","route":"/targets/neil1/","field":"links","label":"UniProt Q96FI4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96FL9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galnt14","kind":"target","name":"GALNT14","route":"/targets/galnt14/","field":"links","label":"UniProt Q96FL9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96FM1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pgap3","kind":"target","name":"PGAP3","route":"/targets/pgap3/","field":"links","label":"UniProt Q96FM1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96GC6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf274","kind":"target","name":"ZNF274","route":"/targets/znf274/","field":"links","label":"UniProt Q96GC6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96GD4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aurkb","kind":"target","name":"AURKB","route":"/targets/aurkb/","field":"links","label":"UniProt Q96GD4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96GM5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"smarcd1","kind":"target","name":"SMARCD1","route":"/targets/smarcd1/","field":"links","label":"UniProt Q96GM5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96GM8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"toe1","kind":"target","name":"TOE1","route":"/targets/toe1/","field":"links","label":"UniProt Q96GM8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96HC4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdlim5","kind":"target","name":"PDLIM5","route":"/targets/pdlim5/","field":"links","label":"UniProt Q96HC4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96HR8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"naf1","kind":"target","name":"NAF1","route":"/targets/naf1/","field":"links","label":"UniProt Q96HR8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96IF1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ajuba","kind":"target","name":"AJUBA","route":"/targets/ajuba/","field":"links","label":"UniProt Q96IF1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96JK9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"maml3","kind":"target","name":"MAML3","route":"/targets/maml3/","field":"links","label":"UniProt Q96JK9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96JM2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf462","kind":"target","name":"ZNF462","route":"/targets/znf462/","field":"links","label":"UniProt Q96JM2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96JM7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"l3mbtl3","kind":"target","name":"L3MBTL3","route":"/targets/l3mbtl3/","field":"links","label":"UniProt Q96JM7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96K83/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/","field":"links","label":"UniProt Q96K83"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96KA5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"clptm1l","kind":"target","name":"CLPTM1L","route":"/targets/clptm1l/","field":"links","label":"UniProt Q96KA5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96KB5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pbk","kind":"target","name":"PBK","route":"/targets/pbk/","field":"links","label":"UniProt Q96KB5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96KC8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajc1","kind":"target","name":"DNAJC1","route":"/targets/dnajc1/","field":"links","label":"UniProt Q96KC8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96KN1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lratd2","kind":"target","name":"LRATD2","route":"/targets/lratd2/","field":"links","label":"UniProt Q96KN1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96L42/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh8","kind":"target","name":"KCNH8","route":"/targets/kcnh8/","field":"links","label":"UniProt Q96L42"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96L73/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/","field":"links","label":"UniProt Q96L73"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96LC7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"siglec10","kind":"target","name":"Siglec-10","route":"/targets/siglec10/","field":"links","label":"UniProt Q96LC7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96MG8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pcmtd1","kind":"target","name":"PCMTD1","route":"/targets/pcmtd1/","field":"links","label":"UniProt Q96MG8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96N64/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pwwp2a","kind":"target","name":"PWWP2A","route":"/targets/pwwp2a/","field":"links","label":"UniProt Q96N64"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96NY9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/","field":"links","label":"UniProt Q96NY9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96PJ5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcrl4","kind":"target","name":"FCRL4","route":"/targets/fcrl4/","field":"links","label":"UniProt Q96PJ5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96PR1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnc2","kind":"target","name":"KCNC2","route":"/targets/kcnc2/","field":"links","label":"UniProt Q96PR1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96PU8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"qki","kind":"target","name":"QKI","route":"/targets/qki/","field":"links","label":"UniProt Q96PU8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96QB1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dlc1","kind":"target","name":"DLC1","route":"/targets/dlc1/","field":"links","label":"UniProt Q96QB1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96QP1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpk1","kind":"target","name":"ALPK1","route":"/targets/alpk1/","field":"links","label":"UniProt Q96QP1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96QV1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hhip","kind":"target","name":"HHIP","route":"/targets/hhip/","field":"links","label":"UniProt Q96QV1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96RD9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/","field":"links","label":"UniProt Q96RD9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96RK0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cic","kind":"target","name":"CIC","route":"/targets/cic/","field":"links","label":"UniProt Q96RK0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96RT1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"erbin","kind":"target","name":"ERBIN","route":"/targets/erbin/","field":"links","label":"UniProt Q96RT1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96RU2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"usp28","kind":"target","name":"USP28","route":"/targets/usp28/","field":"links","label":"UniProt Q96RU2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96ST3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sin3a","kind":"target","name":"SIN3A","route":"/targets/sin3a/","field":"links","label":"UniProt Q96ST3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96ST8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cep89","kind":"target","name":"CEP89","route":"/targets/cep89/","field":"links","label":"UniProt Q96ST8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96SW2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/","field":"links","label":"UniProt Q96SW2: CRBN"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96T23/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rsf1","kind":"target","name":"RSF1","route":"/targets/rsf1/","field":"links","label":"UniProt Q96T23"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96T37/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm15","kind":"target","name":"RBM15","route":"/targets/rbm15/","field":"links","label":"UniProt Q96T37"}]},{"url":"https://www.uniprot.org/uniprotkb/Q96T58/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","field":"links","label":"UniProt Q96T58"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99062/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","route":"/targets/csf3r/","field":"links","label":"UniProt Q99062: CSF3R"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99075/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hbegf","kind":"target","name":"HBEGF","route":"/targets/hbegf/","field":"links","label":"UniProt Q99075"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99081/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf12","kind":"target","name":"TCF12","route":"/targets/tcf12/","field":"links","label":"UniProt Q99081"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99250/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn2a","kind":"target","name":"SCN2A","route":"/targets/scn2a/","field":"links","label":"UniProt Q99250"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99436/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/","field":"links","label":"UniProt Q99436"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99453/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/","field":"links","label":"UniProt Q99453"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99460/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/","field":"links","label":"UniProt Q99460"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99581/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fev","kind":"target","name":"FEV","route":"/targets/fev/","field":"links","label":"UniProt Q99581"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99607/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elf4","kind":"target","name":"ELF4","route":"/targets/elf4/","field":"links","label":"UniProt Q99607"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99612/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf6","kind":"target","name":"KLF6","route":"/targets/klf6/","field":"links","label":"UniProt Q99612"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99626/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdx2","kind":"target","name":"CDX2","route":"/targets/cdx2/","field":"links","label":"UniProt Q99626"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99643/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhc","kind":"target","name":"SDHC","route":"/targets/sdhc/","field":"links","label":"UniProt Q99643"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99708/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbbp8","kind":"target","name":"RBBP8","route":"/targets/rbbp8/","field":"links","label":"UniProt Q99708"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99728/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/","field":"links","label":"UniProt Q99728"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99801/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","field":"links","label":"UniProt Q99801"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99808/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc29a1","kind":"target","name":"SLC29A1","route":"/targets/slc29a1/","field":"links","label":"UniProt Q99808"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99836/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","field":"links","label":"UniProt Q99836"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99928/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gabrg3","kind":"target","name":"GABRG3","route":"/targets/gabrg3/","field":"links","label":"UniProt Q99928"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99958/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxc2","kind":"target","name":"FOXC2","route":"/targets/foxc2/","field":"links","label":"UniProt Q99958"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99961/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sh3gl1","kind":"target","name":"SH3GL1","route":"/targets/sh3gl1/","field":"links","label":"UniProt Q99961"}]},{"url":"https://www.uniprot.org/uniprotkb/Q99996/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"akap9","kind":"target","name":"AKAP9","route":"/targets/akap9/","field":"links","label":"UniProt Q99996"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BQ51/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/","field":"links","label":"UniProt Q9BQ51"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BQ52/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"elac2","kind":"target","name":"ELAC2","route":"/targets/elac2/","field":"links","label":"UniProt Q9BQ52"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BQE3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/","field":"links","label":"UniProt Q9BQE3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BRP0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ovol2","kind":"target","name":"OVOL2","route":"/targets/ovol2/","field":"links","label":"UniProt Q9BRP0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BRT3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mien1","kind":"target","name":"MIEN1","route":"/targets/mien1/","field":"links","label":"UniProt Q9BRT3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BU40/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chrdl1","kind":"target","name":"CHRDL1","route":"/targets/chrdl1/","field":"links","label":"UniProt Q9BU40"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BUF5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/","field":"links","label":"UniProt Q9BUF5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BUK0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chchd7","kind":"target","name":"CHCHD7","route":"/targets/chchd7/","field":"links","label":"UniProt Q9BUK0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BUR4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wrap53","kind":"target","name":"WRAP53","route":"/targets/wrap53/","field":"links","label":"UniProt Q9BUR4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BV36/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlph","kind":"target","name":"MLPH","route":"/targets/mlph/","field":"links","label":"UniProt Q9BV36"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BVA1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/","field":"links","label":"UniProt Q9BVA1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BWT1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdca7","kind":"target","name":"CDCA7","route":"/targets/cdca7/","field":"links","label":"UniProt Q9BWT1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BX63/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/","field":"links","label":"UniProt Q9BX63"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BXB5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"osbpl10","kind":"target","name":"OSBPL10","route":"/targets/osbpl10/","field":"links","label":"UniProt Q9BXB5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BXL7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/","field":"links","label":"UniProt Q9BXL7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BXP8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pappa2","kind":"target","name":"PAPPA2","route":"/targets/pappa2/","field":"links","label":"UniProt Q9BXP8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BXW9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/","field":"links","label":"UniProt Q9BXW9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BXY4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","field":"links","label":"UniProt Q9BXY4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BY41/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/","field":"links","label":"UniProt Q9BY41"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BY66/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kdm5d","kind":"target","name":"KDM5D","route":"/targets/kdm5d/","field":"links","label":"UniProt Q9BY66"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BY84/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dusp16","kind":"target","name":"DUSP16","route":"/targets/dusp16/","field":"links","label":"UniProt Q9BY84"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BYH8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nfkbiz","kind":"target","name":"NFKBIZ","route":"/targets/nfkbiz/","field":"links","label":"UniProt Q9BYH8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BYV9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bach2","kind":"target","name":"BACH2","route":"/targets/bach2/","field":"links","label":"UniProt Q9BYV9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BYW2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/","field":"links","label":"UniProt Q9BYW2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BYZ6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rhobtb2","kind":"target","name":"RHOBTB2","route":"/targets/rhobtb2/","field":"links","label":"UniProt Q9BYZ6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BZ95/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsd3","kind":"target","name":"NSD3","route":"/targets/nsd3/","field":"links","label":"UniProt Q9BZ95"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BZE9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aspscr1","kind":"target","name":"ASPSCR1","route":"/targets/aspscr1/","field":"links","label":"UniProt Q9BZE9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BZK7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbl1xr1","kind":"target","name":"TBL1XR1","route":"/targets/tbl1xr1/","field":"links","label":"UniProt Q9BZK7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BZL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/","field":"links","label":"UniProt Q9BZL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9BZS1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp3","kind":"target","name":"FOXP3","route":"/targets/foxp3/","field":"links","label":"UniProt Q9BZS1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9C004/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"spry4","kind":"target","name":"SPRY4","route":"/targets/spry4/","field":"links","label":"UniProt Q9C004"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9C0B1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fto","kind":"target","name":"FTO","route":"/targets/fto/","field":"links","label":"UniProt Q9C0B1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9C0K0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl11b","kind":"target","name":"BCL11B","route":"/targets/bcl11b/","field":"links","label":"UniProt Q9C0K0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9GZL7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wdr12","kind":"target","name":"WDR12","route":"/targets/wdr12/","field":"links","label":"UniProt Q9GZL7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9GZU2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peg3","kind":"target","name":"PEG3","route":"/targets/peg3/","field":"links","label":"UniProt Q9GZU2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9GZV5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/","field":"links","label":"UniProt Q9GZV5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9GZV9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf23","kind":"target","name":"FGF23","route":"/targets/fgf23/","field":"links","label":"UniProt Q9GZV9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H0P0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nt5c3a","kind":"target","name":"NT5C3A","route":"/targets/nt5c3a/","field":"links","label":"UniProt Q9H0P0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H0U9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tspyl1","kind":"target","name":"TSPYL1","route":"/targets/tspyl1/","field":"links","label":"UniProt Q9H0U9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H0Z9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbm38","kind":"target","name":"RBM38","route":"/targets/rbm38/","field":"links","label":"UniProt Q9H0Z9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H165/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bcl11a","kind":"target","name":"BCL11A","route":"/targets/bcl11a/","field":"links","label":"UniProt Q9H165"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H213/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mageh1","kind":"target","name":"MAGEH1","route":"/targets/mageh1/","field":"links","label":"UniProt Q9H213"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H334/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/","field":"links","label":"UniProt Q9H334"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H3D4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/","field":"links","label":"UniProt Q9H3D4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H3G5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cpvl","kind":"target","name":"CPVL","route":"/targets/cpvl/","field":"links","label":"UniProt Q9H3G5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H3M0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnf1","kind":"target","name":"KCNF1","route":"/targets/kcnf1/","field":"links","label":"UniProt Q9H3M0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H3Y6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srms","kind":"target","name":"SRMS","route":"/targets/srms/","field":"links","label":"UniProt Q9H3Y6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H4A3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnk1","kind":"target","name":"WNK1","route":"/targets/wnk1/","field":"links","label":"UniProt Q9H4A3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H4B7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/","field":"links","label":"UniProt Q9H4B7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H668/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stn1","kind":"target","name":"STN1","route":"/targets/stn1/","field":"links","label":"UniProt Q9H668"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H6I2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox17","kind":"target","name":"SOX17","route":"/targets/sox17/","field":"links","label":"UniProt Q9H6I2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H6R7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wdcp","kind":"target","name":"WDCP","route":"/targets/wdcp/","field":"links","label":"UniProt Q9H6R7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H7S9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf703","kind":"target","name":"ZNF703","route":"/targets/znf703/","field":"links","label":"UniProt Q9H7S9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H816/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","field":"links","label":"UniProt Q9H816"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H8N7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf395","kind":"target","name":"ZNF395","route":"/targets/znf395/","field":"links","label":"UniProt Q9H8N7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H8P0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"srd5a3","kind":"target","name":"SRD5A3","route":"/targets/srd5a3/","field":"links","label":"UniProt Q9H8P0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9H9A7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rmi1","kind":"target","name":"RMI1","route":"/targets/rmi1/","field":"links","label":"UniProt Q9H9A7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HAK2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ebf2","kind":"target","name":"EBF2","route":"/targets/ebf2/","field":"links","label":"UniProt Q9HAK2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HAZ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/","field":"links","label":"UniProt Q9HAZ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HB90/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rragc","kind":"target","name":"RRAGC","route":"/targets/rragc/","field":"links","label":"UniProt Q9HB90"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HB96/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fance","kind":"target","name":"FANCE","route":"/targets/fance/","field":"links","label":"UniProt Q9HB96"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HBE1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"patz1","kind":"target","name":"PATZ1","route":"/targets/patz1/","field":"links","label":"UniProt Q9HBE1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HBL0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tns1","kind":"target","name":"TNS1","route":"/targets/tns1/","field":"links","label":"UniProt Q9HBL0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HBU6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"etnk1","kind":"target","name":"ETNK1","route":"/targets/etnk1/","field":"links","label":"UniProt Q9HBU6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HC35/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eml4","kind":"target","name":"EML4","route":"/targets/eml4/","field":"links","label":"UniProt Q9HC35"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HC73/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"crlf2","kind":"target","name":"CRLF2","route":"/targets/crlf2/","field":"links","label":"UniProt Q9HC73"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HC78/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zbtb20","kind":"target","name":"ZBTB20","route":"/targets/zbtb20/","field":"links","label":"UniProt Q9HC78"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCE1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mov10","kind":"target","name":"MOV10","route":"/targets/mov10/","field":"links","label":"UniProt Q9HCE1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCE6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef10l","kind":"target","name":"ARHGEF10L","route":"/targets/arhgef10l/","field":"links","label":"UniProt Q9HCE6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCK4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"robo2","kind":"target","name":"ROBO2","route":"/targets/robo2/","field":"links","label":"UniProt Q9HCK4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCK8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd8","kind":"target","name":"CHD8","route":"/targets/chd8/","field":"links","label":"UniProt Q9HCK8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCM3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kiaa1549","kind":"target","name":"KIAA1549","route":"/targets/kiaa1549/","field":"links","label":"UniProt Q9HCM3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCT0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf22","kind":"target","name":"FGF22","route":"/targets/fgf22/","field":"links","label":"UniProt Q9HCT0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HCU8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/","field":"links","label":"UniProt Q9HCU8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9HD26/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gopc","kind":"target","name":"GOPC","route":"/targets/gopc/","field":"links","label":"UniProt Q9HD26"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NNX6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cd209","kind":"target","name":"CD209","route":"/targets/cd209/","field":"links","label":"UniProt Q9NNX6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NP95/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgf20","kind":"target","name":"FGF20","route":"/targets/fgf20/","field":"links","label":"UniProt Q9NP95"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NPC3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccnb1ip1","kind":"target","name":"CCNB1IP1","route":"/targets/ccnb1ip1/","field":"links","label":"UniProt Q9NPC3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NPH5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nox4","kind":"target","name":"NOX4","route":"/targets/nox4/","field":"links","label":"UniProt Q9NPH5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NPI1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"brd7","kind":"target","name":"BRD7","route":"/targets/brd7/","field":"links","label":"UniProt Q9NPI1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NPI8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancf","kind":"target","name":"FANCF","route":"/targets/fancf/","field":"links","label":"UniProt Q9NPI8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQ25/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/","field":"links","label":"UniProt Q9NQ25: SLAMF7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQ94/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"a1cf","kind":"target","name":"A1CF","route":"/targets/a1cf/","field":"links","label":"UniProt Q9NQ94"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQB0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","field":"links","label":"UniProt Q9NQB0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQC7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/","field":"links","label":"UniProt Q9NQC7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQR1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt5a","kind":"target","name":"KMT5A","route":"/targets/kmt5a/","field":"links","label":"UniProt Q9NQR1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQS7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"incenp","kind":"target","name":"INCENP","route":"/targets/incenp/","field":"links","label":"UniProt Q9NQS7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NQX6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znf331","kind":"target","name":"ZNF331","route":"/targets/znf331/","field":"links","label":"UniProt Q9NQX6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NR09/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"birc6","kind":"target","name":"BIRC6","route":"/targets/birc6/","field":"links","label":"UniProt Q9NR09"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NR33/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole4","kind":"target","name":"POLE4","route":"/targets/pole4/","field":"links","label":"UniProt Q9NR33"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NR61/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/","field":"links","label":"UniProt Q9NR61"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NR82/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnq5","kind":"target","name":"KCNQ5","route":"/targets/kcnq5/","field":"links","label":"UniProt Q9NR82"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRF9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/","field":"links","label":"UniProt Q9NRF9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRL2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/","field":"links","label":"UniProt Q9NRL2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRM7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lats2","kind":"target","name":"LATS2","route":"/targets/lats2/","field":"links","label":"UniProt Q9NRM7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRR4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/","field":"links","label":"UniProt Q9NRR4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRY4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/","field":"links","label":"UniProt Q9NRY4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NRY5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fam114a2","kind":"target","name":"FAM114A2","route":"/targets/fam114a2/","field":"links","label":"UniProt Q9NRY5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NS40/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnh7","kind":"target","name":"KCNH7","route":"/targets/kcnh7/","field":"links","label":"UniProt Q9NS40"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NS75/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","field":"links","label":"UniProt Q9NS75"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NST1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pnpla3","kind":"target","name":"PNPLA3","route":"/targets/pnpla3/","field":"links","label":"UniProt Q9NST1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NUX5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pot1","kind":"target","name":"POT1","route":"/targets/pot1/","field":"links","label":"UniProt Q9NUX5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NUZ1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acoxl","kind":"target","name":"ACOXL","route":"/targets/acoxl/","field":"links","label":"UniProt Q9NUZ1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NV35/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nudt15","kind":"target","name":"NUDT15","route":"/targets/nudt15/","field":"links","label":"UniProt Q9NV35"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NV96/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdc50a","kind":"target","name":"CDC50A","route":"/targets/cdc50a/","field":"links","label":"UniProt Q9NV96"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NVI1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fanci","kind":"target","name":"FANCI","route":"/targets/fanci/","field":"links","label":"UniProt Q9NVI1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NVK5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fgfr1op2","kind":"target","name":"FGFR1OP2","route":"/targets/fgfr1op2/","field":"links","label":"UniProt Q9NVK5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NW38/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fancl","kind":"target","name":"FANCL","route":"/targets/fancl/","field":"links","label":"UniProt Q9NW38"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NWB1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rbfox1","kind":"target","name":"RBFOX1","route":"/targets/rbfox1/","field":"links","label":"UniProt Q9NWB1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NX18/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/","field":"links","label":"UniProt Q9NX18"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NXL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sidt1","kind":"target","name":"SIDT1","route":"/targets/sidt1/","field":"links","label":"UniProt Q9NXL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NXZ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx43","kind":"target","name":"DDX43","route":"/targets/ddx43/","field":"links","label":"UniProt Q9NXZ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NY46/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn3a","kind":"target","name":"SCN3A","route":"/targets/scn3a/","field":"links","label":"UniProt Q9NY46"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYA1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/","field":"links","label":"UniProt Q9NYA1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYD6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hoxc10","kind":"target","name":"HOXC10","route":"/targets/hoxc10/","field":"links","label":"UniProt Q9NYD6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYF8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bclaf1","kind":"target","name":"BCLAF1","route":"/targets/bclaf1/","field":"links","label":"UniProt Q9NYF8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYK1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","field":"links","label":"UniProt Q9NYK1: TLR7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYQ8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fat2","kind":"target","name":"FAT2","route":"/targets/fat2/","field":"links","label":"UniProt Q9NYQ8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYV4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","field":"links","label":"UniProt Q9NYV4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NYV6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rrn3","kind":"target","name":"RRN3","route":"/targets/rrn3/","field":"links","label":"UniProt Q9NYV6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZ42/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psenen","kind":"target","name":"PSENEN","route":"/targets/psenen/","field":"links","label":"UniProt Q9NZ42"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZ56/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fmn2","kind":"target","name":"FMN2","route":"/targets/fmn2/","field":"links","label":"UniProt Q9NZ56"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZ71/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rtel1","kind":"target","name":"RTEL1","route":"/targets/rtel1/","field":"links","label":"UniProt Q9NZ71"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZC7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wwox","kind":"target","name":"WWOX","route":"/targets/wwox/","field":"links","label":"UniProt Q9NZC7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZJ5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"eif2ak3","kind":"target","name":"EIF2AK3","route":"/targets/eif2ak3/","field":"links","label":"UniProt Q9NZJ5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZN5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgef12","kind":"target","name":"ARHGEF12","route":"/targets/arhgef12/","field":"links","label":"UniProt Q9NZN5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZQ3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nckipsd","kind":"target","name":"NCKIPSD","route":"/targets/nckipsd/","field":"links","label":"UniProt Q9NZQ3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZR2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrp1b","kind":"target","name":"LRP1B","route":"/targets/lrp1b/","field":"links","label":"UniProt Q9NZR2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9NZV8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnd2","kind":"target","name":"KCND2","route":"/targets/kcnd2/","field":"links","label":"UniProt Q9NZV8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P0J0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ndufa13","kind":"target","name":"NDUFA13","route":"/targets/ndufa13/","field":"links","label":"UniProt Q9P0J0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P0X4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cacna1i","kind":"target","name":"CACNA1I","route":"/targets/cacna1i/","field":"links","label":"UniProt Q9P0X4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P1W9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pim2","kind":"target","name":"PIM2","route":"/targets/pim2/","field":"links","label":"UniProt Q9P1W9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P219/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ccdc88c","kind":"target","name":"CCDC88C","route":"/targets/ccdc88c/","field":"links","label":"UniProt Q9P219"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P258/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rcc2","kind":"target","name":"RCC2","route":"/targets/rcc2/","field":"links","label":"UniProt Q9P258"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P2D1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chd7","kind":"target","name":"CHD7","route":"/targets/chd7/","field":"links","label":"UniProt Q9P2D1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P2G3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klhl14","kind":"target","name":"KLHL14","route":"/targets/klhl14/","field":"links","label":"UniProt Q9P2G3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9P2N4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/","field":"links","label":"UniProt Q9P2N4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UBC3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnmt3b","kind":"target","name":"DNMT3B","route":"/targets/dnmt3b/","field":"links","label":"UniProt Q9UBC3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UBQ7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"grhpr","kind":"target","name":"GRHPR","route":"/targets/grhpr/","field":"links","label":"UniProt Q9UBQ7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UBT6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"polk","kind":"target","name":"POLK","route":"/targets/polk/","field":"links","label":"UniProt Q9UBT6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UBU9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nxf1","kind":"target","name":"NXF1","route":"/targets/nxf1/","field":"links","label":"UniProt Q9UBU9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UBW7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmym2","kind":"target","name":"ZMYM2","route":"/targets/zmym2/","field":"links","label":"UniProt Q9UBW7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UDY8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/","field":"links","label":"UniProt Q9UDY8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UER7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"daxx","kind":"target","name":"DAXX","route":"/targets/daxx/","field":"links","label":"UniProt Q9UER7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UF33/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"epha6","kind":"target","name":"EPHA6","route":"/targets/epha6/","field":"links","label":"UniProt Q9UF33"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UGC6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rgs17","kind":"target","name":"RGS17","route":"/targets/rgs17/","field":"links","label":"UniProt Q9UGC6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UGN5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/","field":"links","label":"UniProt Q9UGN5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UGT4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"susd2","kind":"target","name":"SUSD2","route":"/targets/susd2/","field":"links","label":"UniProt Q9UGT4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UH17/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"apobec3b","kind":"target","name":"APOBEC3B","route":"/targets/apobec3b/","field":"links","label":"UniProt Q9UH17"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UH73/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ebf1","kind":"target","name":"EBF1","route":"/targets/ebf1/","field":"links","label":"UniProt Q9UH73"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UHB7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aff4","kind":"target","name":"AFF4","route":"/targets/aff4/","field":"links","label":"UniProt Q9UHB7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UHC1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mlh3","kind":"target","name":"MLH3","route":"/targets/mlh3/","field":"links","label":"UniProt Q9UHC1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UHD2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tbk1","kind":"target","name":"TBK1","route":"/targets/tbk1/","field":"links","label":"UniProt Q9UHD2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UHF7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trps1","kind":"target","name":"TRPS1","route":"/targets/trps1/","field":"links","label":"UniProt Q9UHF7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UI33/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn11a","kind":"target","name":"SCN11A","route":"/targets/scn11a/","field":"links","label":"UniProt Q9UI33"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UIF7/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/","field":"links","label":"UniProt Q9UIF7"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJ98/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stag3","kind":"target","name":"STAG3","route":"/targets/stag3/","field":"links","label":"UniProt Q9UJ98"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJA3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mcm8","kind":"target","name":"MCM8","route":"/targets/mcm8/","field":"links","label":"UniProt Q9UJA3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJM3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"errfi1","kind":"target","name":"ERRFI1","route":"/targets/errfi1/","field":"links","label":"UniProt Q9UJM3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJQ4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sall4","kind":"target","name":"SALL4","route":"/targets/sall4/","field":"links","label":"UniProt Q9UJQ4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJU2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lef1","kind":"target","name":"LEF1","route":"/targets/lef1/","field":"links","label":"UniProt Q9UJU2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UJV9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ddx41","kind":"target","name":"DDX41","route":"/targets/ddx41/","field":"links","label":"UniProt Q9UJV9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UK17/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kcnd3","kind":"target","name":"KCND3","route":"/targets/kcnd3/","field":"links","label":"UniProt Q9UK17"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UK53/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ing1","kind":"target","name":"ING1","route":"/targets/ing1/","field":"links","label":"UniProt Q9UK53"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKB1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"fbxw11","kind":"target","name":"FBXW11","route":"/targets/fbxw11/","field":"links","label":"UniProt Q9UKB1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKB3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnajc12","kind":"target","name":"DNAJC12","route":"/targets/dnajc12/","field":"links","label":"UniProt Q9UKB3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKF5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adam29","kind":"target","name":"ADAM29","route":"/targets/adam29/","field":"links","label":"UniProt Q9UKF5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKK3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/","field":"links","label":"UniProt Q9UKK3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKT9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ikzf3","kind":"target","name":"IKZF3 (Aiolos)","route":"/targets/ikzf3/","field":"links","label":"UniProt Q9UKT9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKU0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"acsl6","kind":"target","name":"ACSL6","route":"/targets/acsl6/","field":"links","label":"UniProt Q9UKU0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UKV0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/","field":"links","label":"UniProt Q9UKV0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULE6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","field":"links","label":"UniProt Q9ULE6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULH4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"lrfn2","kind":"target","name":"LRFN2","route":"/targets/lrfn2/","field":"links","label":"UniProt Q9ULH4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULJ6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zmiz1","kind":"target","name":"ZMIZ1","route":"/targets/zmiz1/","field":"links","label":"UniProt Q9ULJ6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULK4/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"med23","kind":"target","name":"MED23","route":"/targets/med23/","field":"links","label":"UniProt Q9ULK4"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULT6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"znrf3","kind":"target","name":"ZNRF3","route":"/targets/znrf3/","field":"links","label":"UniProt Q9ULT6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9ULV8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cblc","kind":"target","name":"CBLC","route":"/targets/cblc/","field":"links","label":"UniProt Q9ULV8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UM44/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hhla2","kind":"target","name":"HHLA2 (B7-H7)","route":"/targets/hhla2/","field":"links","label":"UniProt Q9UM44"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UM47/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"notch3","kind":"target","name":"NOTCH3","route":"/targets/notch3/","field":"links","label":"UniProt Q9UM47"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UMN6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kmt2b","kind":"target","name":"KMT2B","route":"/targets/kmt2b/","field":"links","label":"UniProt Q9UMN6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UMX1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","field":"links","label":"UniProt Q9UMX1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UMX9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slc45a2","kind":"target","name":"SLC45A2","route":"/targets/slc45a2/","field":"links","label":"UniProt Q9UMX9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UNA1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"arhgap26","kind":"target","name":"ARHGAP26","route":"/targets/arhgap26/","field":"links","label":"UniProt Q9UNA1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UNM6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/","field":"links","label":"UniProt Q9UNM6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UNQ0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/","field":"links","label":"UniProt Q9UNQ0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UNW1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"minpp1","kind":"target","name":"MINPP1","route":"/targets/minpp1/","field":"links","label":"UniProt Q9UNW1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UPN9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trim33","kind":"target","name":"TRIM33","route":"/targets/trim33/","field":"links","label":"UniProt Q9UPN9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UPS6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/","field":"links","label":"UniProt Q9UPS6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UPU3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sorcs3","kind":"target","name":"SORCS3","route":"/targets/sorcs3/","field":"links","label":"UniProt Q9UPU3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UPV9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trak1","kind":"target","name":"TRAK1","route":"/targets/trak1/","field":"links","label":"UniProt Q9UPV9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UPY3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/","field":"links","label":"UniProt Q9UPY3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQ84/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"exo1","kind":"target","name":"EXO1","route":"/targets/exo1/","field":"links","label":"UniProt Q9UQ84"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQB3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/","field":"links","label":"UniProt Q9UQB3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQC2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"gab2","kind":"target","name":"GAB2","route":"/targets/gab2/","field":"links","label":"UniProt Q9UQC2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQD0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn8a","kind":"target","name":"SCN8A","route":"/targets/scn8a/","field":"links","label":"UniProt Q9UQD0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQL6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/","field":"links","label":"UniProt Q9UQL6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9UQQ2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sh2b3","kind":"target","name":"SH2B3","route":"/targets/sh2b3/","field":"links","label":"UniProt Q9UQQ2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y219/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"jag2","kind":"target","name":"JAG2","route":"/targets/jag2/","field":"links","label":"UniProt Q9Y219"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y242/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tcf19","kind":"target","name":"TCF19","route":"/targets/tcf19/","field":"links","label":"UniProt Q9Y242"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y252/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"rnf6","kind":"target","name":"RNF6","route":"/targets/rnf6/","field":"links","label":"UniProt Q9Y252"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y261/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"foxa2","kind":"target","name":"FOXA2","route":"/targets/foxa2/","field":"links","label":"UniProt Q9Y261"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y2L1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/","field":"links","label":"UniProt Q9Y2L1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y2R2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ptpn22","kind":"target","name":"PTPN22","route":"/targets/ptpn22/","field":"links","label":"UniProt Q9Y2R2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y2T1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"axin2","kind":"target","name":"AXIN2","route":"/targets/axin2/","field":"links","label":"UniProt Q9Y2T1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y2W1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"thrap3","kind":"target","name":"THRAP3","route":"/targets/thrap3/","field":"links","label":"UniProt Q9Y2W1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y3A5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sbds","kind":"target","name":"SBDS","route":"/targets/sbds/","field":"links","label":"UniProt Q9Y3A5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y3S1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnk2","kind":"target","name":"WNK2","route":"/targets/wnk2/","field":"links","label":"UniProt Q9Y3S1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y3Z3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/","field":"links","label":"UniProt Q9Y3Z3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y448/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"knstrn","kind":"target","name":"KNSTRN","route":"/targets/knstrn/","field":"links","label":"UniProt Q9Y448"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y490/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tln1","kind":"target","name":"TLN1","route":"/targets/tln1/","field":"links","label":"UniProt Q9Y490"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y4A5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trrap","kind":"target","name":"TRRAP","route":"/targets/trrap/","field":"links","label":"UniProt Q9Y4A5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y4H2/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"irs2","kind":"target","name":"IRS2","route":"/targets/irs2/","field":"links","label":"UniProt Q9Y4H2"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y4I1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/","field":"links","label":"UniProt Q9Y4I1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5J3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hey1","kind":"target","name":"HEY1","route":"/targets/hey1/","field":"links","label":"UniProt Q9Y5J3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5Q3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"mafb","kind":"target","name":"MAFB","route":"/targets/mafb/","field":"links","label":"UniProt Q9Y5Q3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5U5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/","field":"links","label":"UniProt Q9Y5U5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5W3/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/","field":"links","label":"UniProt Q9Y5W3"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5W5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wif1","kind":"target","name":"WIF1","route":"/targets/wif1/","field":"links","label":"UniProt Q9Y5W5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y5Y9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scn10a","kind":"target","name":"SCN10A","route":"/targets/scn10a/","field":"links","label":"UniProt Q9Y5Y9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y618/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncor2","kind":"target","name":"NCOR2","route":"/targets/ncor2/","field":"links","label":"UniProt Q9Y618"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y651/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sox21","kind":"target","name":"SOX21","route":"/targets/sox21/","field":"links","label":"UniProt Q9Y651"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6F1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/","field":"links","label":"UniProt Q9Y6F1"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6F9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wnt6","kind":"target","name":"WNT6","route":"/targets/wnt6/","field":"links","label":"UniProt Q9Y6F9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6H5/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sncaip","kind":"target","name":"SNCAIP","route":"/targets/sncaip/","field":"links","label":"UniProt Q9Y6H5"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6K1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","field":"links","label":"UniProt Q9Y6K1: DNMT3A"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6L6/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"slco1b1","kind":"target","name":"SLCO1B1","route":"/targets/slco1b1/","field":"links","label":"UniProt Q9Y6L6"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6N8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cdh10","kind":"target","name":"CDH10","route":"/targets/cdh10/","field":"links","label":"UniProt Q9Y6N8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6Q9/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/","field":"links","label":"UniProt Q9Y6Q9"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6W8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"icos","kind":"target","name":"ICOS","route":"/targets/icos/","field":"links","label":"UniProt Q9Y6W8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6X0/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"setbp1","kind":"target","name":"SETBP1","route":"/targets/setbp1/","field":"links","label":"UniProt Q9Y6X0"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6X8/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"zhx2","kind":"target","name":"ZHX2","route":"/targets/zhx2/","field":"links","label":"UniProt Q9Y6X8"}]},{"url":"https://www.uniprot.org/uniprotkb/Q9Y6Y1/entry","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"camta1","kind":"target","name":"CAMTA1","route":"/targets/camta1/","field":"links","label":"UniProt Q9Y6Y1"}]},{"url":"https://www.unispital-basel.ch/en/","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"links","label":"University Hospital Basel / Tumour Centre website"},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","field":"profiles","label":"University Hospital Basel / Tumour Centre website"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"links","label":"Homepage"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"website"}]},{"url":"https://www.unispital-basel.ch/en/tumorzentrum","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"astrid-beiglbock","kind":"person","name":"Astrid Beiglböck","route":"/people/astrid-beiglbock/","field":"links","label":"Institution profile"},{"id":"astrid-beiglbock","kind":"person","name":"Astrid Beiglböck","route":"/people/astrid-beiglbock/","field":"profiles","label":"Institution profile"},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"links","label":"Institution profile"},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","field":"profiles","label":"Institution profile"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"links","label":"Tumorzentrum"}]},{"url":"https://www.unispital-basel.ch/ueber-uns/organisation-und-leitung","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rakesh-padiyath","kind":"person","name":"Rakesh Padiyath","route":"/people/rakesh-padiyath/","field":"links","label":"Institution profile"},{"id":"rakesh-padiyath","kind":"person","name":"Rakesh Padiyath","route":"/people/rakesh-padiyath/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.united-imaging.com","status":200,"ok":true,"finalUrl":"https://usa.united-imaging.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","field":"links","label":"Official website"},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","field":"website"}]},{"url":"https://www.unither.com","status":200,"ok":true,"finalUrl":"https://www.unither.com/index","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","field":"links","label":"Official website"},{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","field":"website"}]},{"url":"https://www.universaldx.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","field":"links","label":"Official website"},{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","field":"website"}]},{"url":"https://www.universaldx.com/press","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","field":"links","label":"Press page"}]},{"url":"https://www.unizg.hr/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"links","label":"University of Zagreb"},{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","field":"profiles","label":"University of Zagreb"},{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","route":"/people/dubravko-forcic/","field":"links","label":"University of Zagreb"},{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","route":"/people/dubravko-forcic/","field":"profiles","label":"University of Zagreb"}]},{"url":"https://www.unmc.edu/cancercenter/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","field":"links","label":"Fred & Pamela Buffett Cancer Center"},{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","field":"website"}]},{"url":"https://www.unmc.edu/cancercenter/about/leadership.html","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","route":"/people/joann-sweasy/","field":"links","label":"Source: Fred & Pamela Buffett Cancer Center leadership page"},{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","route":"/people/joann-sweasy/","field":"profiles","label":"Cancer centre leadership page"}]},{"url":"https://www.upm.edu.ph","status":200,"ok":true,"finalUrl":"https://www.upm.edu.ph/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","field":"links","label":"UP Manila"}]},{"url":"https://www.uq.edu.au","status":200,"ok":true,"finalUrl":"https://www.uq.edu.au/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","route":"/institutions/uq-frazer-institute/","field":"links","label":"The University of Queensland"},{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","route":"/institutions/uq-frazer-institute/","field":"website"}]},{"url":"https://www.uq.edu.au/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","field":"links","label":"University of Queensland: the HPV vaccine"},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","field":"profiles","label":"University of Queensland: the HPV vaccine"}]},{"url":"https://www.urmc.rochester.edu/cancer-institute","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","field":"links","label":"Wilmot Cancer Institute"},{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","field":"website"}]},{"url":"https://www.urmc.rochester.edu/cancer-institute/clinical-trials.aspx","status":200,"ok":true,"finalUrl":"https://www.urmc.rochester.edu/cancer-institute/cancers","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","field":"links","label":"Clinical trials"}]},{"url":"https://www.urogen.com","status":200,"ok":true,"finalUrl":"https://www.urogen.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","field":"links","label":"Official website"},{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","field":"website"}]},{"url":"https://www.urogen.com/pipeline","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","field":"links","label":"Pipeline page"},{"id":"ugn-103","kind":"drug","name":"UGN-103","route":"/drugs/ugn-103/","field":"links","label":"Sponsor page"},{"id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","field":"links","label":"Sponsor page"}]},{"url":"https://www.urologytimes.com/view/checkmate-274-5-year-data-confirm-durable-benefit-with-nivolumab","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","field":"links","label":"5-year data"}]},{"url":"https://www.urologytimes.com/view/fda-approves-durvalumab-chemo-for-muscle-invasive-bladder-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","field":"links","label":"FDA approval (Mar 2025)"}]},{"url":"https://www.urologytimes.com/view/keynote-905-data-on-ev-pembro-in-mibc-published-in-nejm","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","field":"outcomes.source (Event-free survival)"}]},{"url":"https://www.usoncology.com","status":200,"ok":true,"finalUrl":"https://usoncology.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/","field":"links","label":"Official website"},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/","field":"website"},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/","field":"links","label":"The US Oncology Network"},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/","field":"website"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","field":"links","label":"USPSTF colorectal cancer screening (2021)"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/","field":"links","label":"USPSTF recommendation: lung cancer screening"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/oral-cancer-screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oral-visual-screening","kind":"technology","name":"Oral cancer visual screening","route":"/technologies/oral-visual-screening/","field":"links","label":"USPSTF oral cancer screening (2013)"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paper-moyer-uspstf-prostate-screening-ann-intern-med-2012","kind":"paper","name":"USPSTF 2012: screening for prostate cancer, recommendation statement (grade D)","route":"/key-papers/paper-moyer-uspstf-prostate-screening-ann-intern-med-2012/","field":"links","label":"USPSTF: prostate cancer screening"},{"id":"paper-uspstf-prostate-screening-jama-2018","kind":"paper","name":"USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)","route":"/key-papers/paper-uspstf-prostate-screening-jama-2018/","field":"links","label":"USPSTF: prostate cancer screening"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","field":"links","label":"USPSTF prostate cancer screening (2018)"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"skin-cancer-screening","kind":"technology","name":"Skin cancer screening (visual skin examination)","route":"/technologies/skin-cancer-screening/","field":"links","label":"USPSTF skin cancer screening (2023)"}]},{"url":"https://www.usworldmeds.com","status":200,"ok":true,"finalUrl":"https://usworldmeds.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/","field":"links","label":"Official website"},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/","field":"website"}]},{"url":"https://www.utsouthwestern.edu/education/medical-school/departments/simmons/","status":200,"ok":true,"finalUrl":"https://www.utsouthwestern.edu/departments/simmons/","contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","route":"/institutions/utsw-simmons/","field":"links","label":"Simmons Comprehensive Cancer Center"},{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","route":"/institutions/utsw-simmons/","field":"website"}]},{"url":"https://www.uwa.edu.au","status":200,"ok":true,"finalUrl":"https://www.uwa.edu.au/home","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/","field":"links","label":"University of Western Australia"},{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/","field":"website"}]},{"url":"https://www.uzbrussel.be","status":200,"ok":true,"finalUrl":"https://www.uzbrussel.be/","contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","route":"/institutions/uz-brussel-cancer-centre/","field":"links","label":"Official website"},{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","route":"/institutions/uz-brussel-cancer-centre/","field":"website"}]},{"url":"https://www.uzgent.be/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"links","label":"Ghent University Hospital / Cancer Research Institute Ghent website"},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","field":"profiles","label":"Ghent University Hospital / Cancer Research Institute Ghent website"},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","field":"links","label":"Cancer Centre (page moved; nearest live section)"},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","field":"website"}]},{"url":"https://www.uzleuven.be","status":200,"ok":true,"finalUrl":"https://www.uzleuven.be/nl","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","field":"links","label":"Leuven Cancer Institute"},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","field":"website"}]},{"url":"https://www.uzleuven.be/en/about-us/management-committee","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"paul-herijgers","kind":"person","name":"Paul Herijgers","route":"/people/paul-herijgers/","field":"links","label":"Source: UZ Leuven management committee page"},{"id":"paul-herijgers","kind":"person","name":"Paul Herijgers","route":"/people/paul-herijgers/","field":"profiles","label":"UZ Leuven management committee"}]},{"url":"https://www.v.org","status":200,"ok":true,"finalUrl":"https://www.v.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/","field":"links","label":"V Foundation"},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/","field":"website"}]},{"url":"https://www.v.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","field":"links","label":"The V Foundation"},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","field":"profiles","label":"The V Foundation"}]},{"url":"https://www.v.org/about/leadership/","status":200,"ok":true,"finalUrl":"https://www.v.org/about/leadership-team/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brandi-williams-broome","kind":"person","name":"Brandi Williams Broome","route":"/people/brandi-williams-broome/","field":"links","label":"Source: V Foundation leadership page"}]},{"url":"https://www.v.org/leadership-team/brandi-williams-broome/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"brandi-williams-broome","kind":"person","name":"Brandi Williams Broome","route":"/people/brandi-williams-broome/","field":"profiles","label":"V Foundation leadership profile"}]},{"url":"https://www.valarlabs.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","field":"links","label":"Official website"},{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","field":"website"}]},{"url":"https://www.valarlabs.com/evidence","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","field":"links","label":"Evidence page"}]},{"url":"https://www.valarlabs.com/news/series-a","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","field":"links","label":"Series A announcement (May 2024)"}]},{"url":"https://www.valinktx.com","status":200,"ok":true,"finalUrl":"https://www.valinktx.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","route":"/companies/valink-therapeutics/","field":"links","label":"Official website"},{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","route":"/companies/valink-therapeutics/","field":"website"}]},{"url":"https://www.valius.com","status":200,"ok":true,"finalUrl":"https://www.dynamo.com/assets.htm","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","field":"website"}]},{"url":"https://www.valiussciences.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","field":"links","label":"Official website (valiussciences.com)"}]},{"url":"https://www.vallhebron.com/es","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","field":"links","label":"Vall d'Hebron University Hospital / VHIO website"},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","field":"profiles","label":"Vall d'Hebron University Hospital / VHIO website"}]},{"url":"https://www.valohealth.com","status":200,"ok":true,"finalUrl":"https://www.valohealth.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/","field":"links","label":"Official website"},{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/","field":"website"}]},{"url":"https://www.valohealth.com/news","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/","field":"links","label":"News"}]},{"url":"https://www.vara.ai/","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vara","kind":"company","name":"Vara","route":"/companies/vara/","field":"links","label":"Official website"},{"id":"vara","kind":"company","name":"Vara","route":"/companies/vara/","field":"website"}]},{"url":"https://www.vara.ai/about","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"vara","kind":"company","name":"Vara","route":"/companies/vara/","field":"links","label":"About Vara"}]},{"url":"https://www.varha.fi","status":200,"ok":true,"finalUrl":"https://www.varha.fi/fi","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","field":"links","label":"Official website"},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","field":"website"}]},{"url":"https://www.varian.com","status":200,"ok":true,"finalUrl":"https://cancercare.siemens-healthineers.com/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/","field":"links","label":"Official website"},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/","field":"website"}]},{"url":"https://www.varian.com/products/adaptive-therapy/ethos","status":200,"ok":true,"finalUrl":"https://cancercare.siemens-healthineers.com/products/adaptive-therapy/ethos","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ring-gantry-linac","kind":"technology","name":"Ring-gantry linacs (Halcyon, Ethos)","route":"/technologies/ring-gantry-linac/","field":"links","label":"Varian: Ethos adaptive therapy"}]},{"url":"https://www.varian.com/products/radiotherapy/treatment-delivery/halcyon","status":200,"ok":true,"finalUrl":"https://cancercare.siemens-healthineers.com/products/radiotherapy/treatment-delivery/halcyon","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"ring-gantry-linac","kind":"technology","name":"Ring-gantry linacs (Halcyon, Ethos)","route":"/technologies/ring-gantry-linac/","field":"links","label":"Varian: Halcyon"}]},{"url":"https://www.varian.com/products/radiotherapy/treatment-delivery/truebeam","status":200,"ok":true,"finalUrl":"https://cancercare.siemens-healthineers.com/products/radiotherapy/treatment-delivery/truebeam","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/","field":"links","label":"Varian: TrueBeam"}]},{"url":"https://www.veeva.com","status":200,"ok":true,"finalUrl":"https://www.veeva.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veeva-systems","kind":"company","name":"Veeva Systems","route":"/companies/veeva-systems/","field":"links","label":"Official website"},{"id":"veeva-systems","kind":"company","name":"Veeva Systems","route":"/companies/veeva-systems/","field":"website"}]},{"url":"https://www.velavigo.com","status":200,"ok":true,"finalUrl":"https://www.velavigo.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/","field":"links","label":"Official website"},{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/","field":"website"}]},{"url":"https://www.velorumtx.com","status":200,"ok":true,"finalUrl":"https://www.velorumtx.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/","field":"links","label":"Official website"},{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/","field":"website"}]},{"url":"https://www.venrock.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","field":"links","label":"Official website"},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","field":"website"}]},{"url":"https://www.veracyte.com","status":200,"ok":true,"finalUrl":"https://www.veracyte.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/","field":"links","label":"Official website"},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/","field":"website"}],"archive":"https://web.archive.org/web/20260911210340/https://www.veracyte.com/"},{"url":"https://www.veracyte.com/innovation/truemrd-platform/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","route":"/companies/c2i-genomics/","field":"links","label":"Official website"},{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","route":"/companies/c2i-genomics/","field":"website"}]},{"url":"https://www.veracyte.com/tests/decipher-prostate/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/","field":"links","label":"Veracyte: Decipher Prostate genomic classifier"}]},{"url":"https://www.verastem.com","status":200,"ok":true,"finalUrl":"https://www.verastem.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/","field":"website"}]},{"url":"https://www.vergentbio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"links","label":"Official website"},{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"website"}]},{"url":"https://www.vergentbio.com/investors","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"links","label":"Investors page (over USD 34 million raised)"}]},{"url":"https://www.vergentbio.com/press-releases","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","field":"links","label":"Press releases"}]},{"url":"https://www.veritypharma.com","status":200,"ok":true,"finalUrl":"https://veritypharma.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/","field":"links","label":"Official website"},{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/","field":"website"}]},{"url":"https://www.versantventures.com/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","field":"links","label":"Official website"},{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","field":"website"}]},{"url":"https://www.versantventures.com/news","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","field":"links","label":"News"}]},{"url":"https://www.vevo.ai","status":200,"ok":true,"finalUrl":"https://www.tahoebio.ai/","contentType":"text/html; charset=utf-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","field":"links","label":"Official website"},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","field":"website"}]},{"url":"https://www.vghtpe.gov.tw","status":200,"ok":true,"finalUrl":"https://www.vghtpe.gov.tw/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","field":"links","label":"Taipei Veterans General Hospital"},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","field":"website"}]},{"url":"https://www.vghtpe.gov.tw/Index.action?lang=EN","status":200,"ok":true,"contentType":"text/html;charset=UTF-8","checked":"2026-09-30","refs":[{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","field":"links","label":"Heavy Ion Therapy Center"}]},{"url":"https://www.vhl.org/","status":200,"ok":true,"finalUrl":"https://vhl.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","field":"links","label":"VHL Alliance"}]},{"url":"https://www.viatris.com","status":200,"ok":true,"finalUrl":"https://www.viatris.com/en","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","field":"links","label":"Official website"},{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","field":"website"}]},{"url":"https://www.vicc.org","status":200,"ok":true,"finalUrl":"https://www.vicc.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","field":"links","label":"Vanderbilt-Ingram Cancer Center"},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","field":"website"}]},{"url":"https://www.vicc.org/about/history","status":200,"ok":true,"finalUrl":"https://vicc.org/about/history","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","route":"/people/martha-ingram/","field":"links","label":"Vanderbilt-Ingram Cancer Center: history"}]},{"url":"https://www.vicc.org/clinical-trials","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","field":"links","label":"Clinical trials"}]},{"url":"https://www.visionrt.com/","status":200,"ok":true,"finalUrl":"https://visionrt.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vision-rt","kind":"company","name":"Vision RT","route":"/companies/vision-rt/","field":"links","label":"Official website"},{"id":"vision-rt","kind":"company","name":"Vision RT","route":"/companies/vision-rt/","field":"website"}]},{"url":"https://www.vorbio.com","status":200,"ok":true,"finalUrl":"https://www.vorbio.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","field":"links","label":"Official website"},{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","field":"website"}]},{"url":"https://www.vyriad.com","status":200,"ok":true,"finalUrl":"https://vyriad.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/","field":"links","label":"Official website"},{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/","field":"website"}]},{"url":"https://www.wakehealth.edu/cancer","status":200,"ok":true,"finalUrl":"https://www.wakehealth.edu/locations/facilities/comprehensive-cancer-center","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/","field":"links","label":"Source: Wake Forest Baptist cancer centre page introducing the director"},{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/","field":"profiles","label":"Atrium Health Wake Forest Baptist cancer pages"},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","route":"/institutions/wake-forest-cancer/","field":"links","label":"Wake Forest Baptist Comprehensive Cancer Center"},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","route":"/institutions/wake-forest-cancer/","field":"website"}]},{"url":"https://www.walescancerresearchcentre.org","status":200,"ok":true,"finalUrl":"https://walescancerresearchcentre.org/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","field":"links","label":"Wales Cancer Research Centre"}]},{"url":"https://www.wchscu.cn","status":200,"ok":true,"finalUrl":"https://www.wchscu.cn/index.html","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","field":"links","label":"Official website"},{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","field":"website"},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","field":"links","label":"West China Hospital"},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","field":"profiles","label":"West China Hospital"},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","field":"links","label":"West China Hospital"},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","field":"profiles","label":"West China Hospital"},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","field":"links","label":"West China Hospital"},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","field":"profiles","label":"West China Hospital"}]},{"url":"https://www.wcrf.org/diet-activity-and-cancer/","status":200,"ok":true,"finalUrl":"https://www.wcrf.org/research-policy/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dietary-pattern-scores","kind":"term","name":"Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)","route":"/terms/dietary-pattern-scores/","field":"links","label":"World Cancer Research Fund: diet, activity and cancer (Third Expert Report)"}]},{"url":"https://www.wehi.edu.au","status":200,"ok":true,"finalUrl":"https://www.wehi.edu.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","field":"links","label":"WEHI"},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","field":"website"}]},{"url":"https://www.wehi.edu.au/about/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ken-smith","kind":"person","name":"Ken Smith","route":"/people/ken-smith/","field":"links","label":"Institution profile"},{"id":"ken-smith","kind":"person","name":"Ken Smith","route":"/people/ken-smith/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.weizmann.ac.il","status":200,"ok":true,"finalUrl":"https://www.weizmann.ac.il/pages/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/","field":"links","label":"Weizmann Institute of Science"},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/","field":"profiles","label":"Weizmann Institute of Science"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","field":"links","label":"Homepage"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","field":"website"}]},{"url":"https://www.weizmann.ac.il/MICC/","status":200,"ok":true,"finalUrl":"https://www.weizmann.ac.il/error/page-not-found","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","field":"links","label":"Moross Integrated Cancer Center"}]},{"url":"https://www.westerncape.gov.za/health-wellness","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/","field":"links","label":"Western Cape Government Health and Wellness"}]},{"url":"https://www.westonparkcancercentre.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.westonparkcancercentre.nhs.uk/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"weston-park-sheffield","kind":"institution","name":"Weston Park Cancer Centre, Sheffield Teaching Hospitals","route":"/institutions/weston-park-sheffield/","field":"links","label":"Official website"},{"id":"weston-park-sheffield","kind":"institution","name":"Weston Park Cancer Centre, Sheffield Teaching Hospitals","route":"/institutions/weston-park-sheffield/","field":"website"}]},{"url":"https://www.who.int/director-general","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","route":"/people/tedros-adhanom-ghebreyesus/","field":"links","label":"Institution profile"},{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","route":"/people/tedros-adhanom-ghebreyesus/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-acc-eml-listing-price-commitments","kind":"idea","name":"Tie WHO essential-medicines listing to a published tiered price and supply pledge","route":"/ideas/idea-acc-eml-listing-price-commitments/","field":"links","label":"WHO Model Lists of Essential Medicines"},{"id":"idea-cost-pooled-procurement-essential","kind":"idea","name":"Pool purchasing of essential cancer medicines across countries","route":"/ideas/idea-cost-pooled-procurement-essential/","field":"links","label":"WHO Model Lists of Essential Medicines"},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","field":"links","label":"WHO Model Lists of Essential Medicines"},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","field":"links","label":"WHO Model Lists of Essential Medicines"}]},{"url":"https://www.who.int/health-topics/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","field":"links","label":"WHO cancer"},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","field":"profiles","label":"WHO cancer"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/","field":"links","label":"WHO cancer"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/","field":"website"}]},{"url":"https://www.who.int/health-topics/infodemic","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","field":"links","label":"WHO infodemic management"},{"id":"idea-moon-misinformation-rapid-response","kind":"idea","name":"A cancer misinformation rapid-response unit that rebuts within 48 hours","route":"/ideas/idea-moon-misinformation-rapid-response/","field":"links","label":"WHO infodemic management"}]},{"url":"https://www.who.int/initiatives/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-pooled-procurement-adult-essentials","kind":"idea","name":"Pooled international procurement of essential adult cancer medicines","route":"/ideas/idea-reg-pooled-procurement-adult-essentials/","field":"links","label":"WHO Global Platform for Access to Childhood Cancer Medicines (page moved; nearest live section)"}]},{"url":"https://www.who.int/initiatives/cervical-cancer-elimination-initiative","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"links","label":"WHO Cervical Cancer Elimination Initiative"},{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"idea-prev-hpv-same-day-screen-and-treat","kind":"idea","name":"Same-day HPV test and heat treatment of precancer by nurses in low-income settings","route":"/ideas/idea-prev-hpv-same-day-screen-and-treat/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"idea-acc-hpv-self-sample-same-day-ablation","kind":"idea","name":"HPV self-testing with same-day treatment as the national cervical programme","route":"/ideas/idea-acc-hpv-self-sample-same-day-ablation/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/","field":"links","label":"Cervical cancer elimination"},{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/","field":"links","label":"WHO cervical cancer elimination initiative"},{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/","field":"links","label":"WHO: cervical cancer elimination initiative"}]},{"url":"https://www.who.int/initiatives/global-breast-cancer-initiative","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-acc-gbci-country-dashboards","kind":"idea","name":"Public country dashboards for the three WHO breast cancer targets","route":"/ideas/idea-acc-gbci-country-dashboards/","field":"links","label":"WHO Global Breast Cancer Initiative"}]},{"url":"https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","field":"links","label":"WHO Global Initiative for Childhood Cancer"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"links","label":"WHO Global Initiative for Childhood Cancer"},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","field":"links","label":"WHO Global Initiative for Childhood Cancer"},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/","field":"links","label":"WHO Global Initiative for Childhood Cancer"}],"archive":"https://web.archive.org/web/20260711074820/https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer"},{"url":"https://www.who.int/news-room/fact-sheets/detail/cancer","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"links","label":"WHO fact sheet, Cancer"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"metrics (Share of cancer deaths occurring in low- and middle-income countries)"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","field":"metrics (Share of cancer deaths occurring in low- and middle-income countries, where a small fraction of research is conducted)"},{"id":"idea-acc-remote-planning-hubs","kind":"idea","name":"Round-the-clock remote treatment-planning hubs for clinics without physicists","route":"/ideas/idea-acc-remote-planning-hubs/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-biosimilar-prequalification-pool","kind":"idea","name":"WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator","route":"/ideas/idea-acc-biosimilar-prequalification-pool/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-chemo-stockout-early-warning","kind":"idea","name":"A live stock-out map for essential chemotherapy drugs","route":"/ideas/idea-acc-chemo-stockout-early-warning/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-global-cancer-financing-window","kind":"idea","name":"A dedicated global financing window for cancer, modelled on the Global Fund","route":"/ideas/idea-acc-global-cancer-financing-window/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-abandonment-stipends","kind":"idea","name":"Cash for transport and food to stop families abandoning curative treatment","route":"/ideas/idea-acc-abandonment-stipends/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-diaspora-tele-tumour-boards","kind":"idea","name":"Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals","route":"/ideas/idea-acc-diaspora-tele-tumour-boards/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"},{"id":"idea-acc-solar-microgrids-for-cancer-units","kind":"idea","name":"Solar microgrids so radiotherapy, pathology and drug fridges never lose power","route":"/ideas/idea-acc-solar-microgrids-for-cancer-units/","field":"links","label":"Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer"}]},{"url":"https://www.who.int/news-room/fact-sheets/detail/cancer-in-children","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","field":"metrics (Children (0-14) diagnosed with cancer worldwide each year)"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","field":"metrics (Childhood cancer survival in high-income vs many low- and middle-income countries)"}]},{"url":"https://www.who.int/news-room/fact-sheets/detail/hepatitis-b","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-prev-hbv-treat-all-hcc","kind":"idea","name":"Treat everyone with chronic hepatitis B to prevent liver cancer","route":"/ideas/idea-prev-hbv-treat-all-hcc/","field":"links","label":"WHO hepatitis B fact sheet"}]},{"url":"https://www.who.int/news-room/fact-sheets/detail/palliative-care","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"links","label":"WHO fact sheet, Palliative care"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","field":"metrics (People who need palliative care worldwide who receive it (WHO estimate))"},{"id":"idea-acc-local-oral-morphine-production","kind":"idea","name":"Locally prepared oral morphine solution, licensed for nurse prescribing","route":"/ideas/idea-acc-local-oral-morphine-production/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-neighbourhood-palliative-networks","kind":"idea","name":"Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere","route":"/ideas/idea-acc-neighbourhood-palliative-networks/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-tele-palliative-care-default","kind":"idea","name":"Video palliative care as an equivalent default option for patients far from a team","route":"/ideas/idea-acc-tele-palliative-care-default/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-pain-control-public-audit","kind":"idea","name":"Measure and publish pain control rates in every cancer centre","route":"/ideas/idea-acc-pain-control-public-audit/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-serious-illness-conversation-prompts","kind":"idea","name":"Train every oncology team in serious-illness conversations and prompt them in the record","route":"/ideas/idea-acc-serious-illness-conversation-prompts/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-single-fraction-palliative-radiotherapy-default","kind":"idea","name":"Single-fraction radiotherapy as the default for painful bone metastases","route":"/ideas/idea-acc-single-fraction-palliative-radiotherapy-default/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-home-based-end-of-life-kits","kind":"idea","name":"Home end-of-life care kits and trained family carers where no hospice exists","route":"/ideas/idea-acc-home-based-end-of-life-kits/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-acc-methadone-and-alternatives-where-morphine-fails","kind":"idea","name":"Trials of low-cost opioid alternatives where morphine supply is unreliable","route":"/ideas/idea-acc-methadone-and-alternatives-where-morphine-fails/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"},{"id":"idea-moon-palliative-care-from-diagnosis-everywhere","kind":"idea","name":"Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide","route":"/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/","field":"links","label":"Bottleneck evidence (Pain relief and palliative care are unavailable to most): WHO fact sheet, Palliative care"}]},{"url":"https://www.who.int/news-room/fact-sheets/detail/tobacco","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","field":"metrics (Deaths caused by tobacco each year worldwide)"}]},{"url":"https://www.who.int/publications/i/item/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-reg-reliance-90-day-lmic","kind":"idea","name":"90-day reliance approval for cancer drugs cleared by two stringent regulators","route":"/ideas/idea-reg-reliance-90-day-lmic/","field":"links","label":"WHO Good Reliance Practices (page moved; nearest live section)"}]},{"url":"https://www.who.int/publications/i/item/9789240014107","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","field":"standardOfCare.guideline (Primary prevention)"}],"archive":"https://web.archive.org/web/20260906161838/https://www.who.int/publications/i/item/9789240014107"},{"url":"https://www.who.int/publications/i/item/9789240030824","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/","field":"links","label":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition (2021)"}]},{"url":"https://www.who.int/publications/i/item/9789241511131","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","field":"links","label":"WHO Global Strategy on Human Resources for Health: Workforce 2030"}]},{"url":"https://www.who.int/publications/i/item/9789241550390","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","field":"links","label":"WHO cancer pain guidelines 2018"}]},{"url":"https://www.who.int/publications/i/item/9789241550598","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","field":"links","label":"WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions (2019)"}]},{"url":"https://www.who.int/standards/classifications/other-classifications/international-classification-of-diseases-for-oncology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"icd-o-3","kind":"term","name":"ICD-O-3 (International Classification of Diseases for Oncology)","route":"/terms/icd-o-3/","field":"links","label":"WHO: ICD-O"}]},{"url":"https://www.whuh.com","status":200,"ok":true,"finalUrl":"https://www.whuh.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","field":"links","label":"Wuhan Union Hospital"},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","field":"website"}]},{"url":"https://www.whuh.com/en/About_Us1/Governance___Structure.htm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","field":"links","label":"Source: Union Hospital governance and structure page (English)"},{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","field":"profiles","label":"Union Hospital governance and structure (English)"}]},{"url":"https://www.whuh.com/HospitalOverview/organization.htm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","field":"links","label":"Source: Union Hospital organisation page (Chinese)"}]},{"url":"https://www.wigenbio.com","status":200,"ok":true,"finalUrl":"https://www.wigenbio.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","route":"/companies/wigen-biomedicine-technology-shanghai/","field":"links","label":"Official website"},{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","route":"/companies/wigen-biomedicine-technology-shanghai/","field":"website"}]},{"url":"https://www.wigsforkids.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wigs-for-kids","kind":"collection","name":"Wigs for Kids","route":"/collections/wigs-for-kids/","field":"links","label":"Wigs for Kids"},{"id":"wigs-for-kids","kind":"collection","name":"Wigs for Kids","route":"/collections/wigs-for-kids/","field":"url"}]},{"url":"https://www.wikidata.org/wiki/Q100955904","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","field":"links","label":"Wikidata Q100955904"}]},{"url":"https://www.wikidata.org/wiki/Q101983981","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q10400578","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q107517747","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q107517856","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q110114773","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q110319413","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11242594","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11296797","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11314549","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11314982","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11315991","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11325922","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q11713115","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q131899773","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q138859693","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140045287","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","field":"links","label":"Wikidata Q140045287"}]},{"url":"https://www.wikidata.org/wiki/Q140045331","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140045369","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140045444","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","field":"links","label":"Wikidata Q140045444"}]},{"url":"https://www.wikidata.org/wiki/Q140045552","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140045748","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140045781","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140046004","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140046053","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140046067","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140046417","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q1403929","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q140609057","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q153838","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","field":"links","label":"Wikidata Q153838"}]},{"url":"https://www.wikidata.org/wiki/Q17146330","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q1952722","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q19653276","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q19903344","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q21071142","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q22079531","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q23777937","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q238181","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","field":"links","label":"Wikidata Q238181"}]},{"url":"https://www.wikidata.org/wiki/Q2945751","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q2979314","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30253835","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/","field":"links","label":"Wikidata Q30253835"}]},{"url":"https://www.wikidata.org/wiki/Q30257112","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30260850","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30260852","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30265419","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30268747","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30268820","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30269207","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30269222","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30269273","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30270574","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30273611","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30280722","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","field":"links","label":"Wikidata Q30280722"}]},{"url":"https://www.wikidata.org/wiki/Q30281661","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30282217","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30282846","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","field":"links","label":"Wikidata Q30282846"}]},{"url":"https://www.wikidata.org/wiki/Q30283567","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30286592","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30286762","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30286808","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30287940","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30288606","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30288730","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30289027","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30289078","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30292478","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30296176","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q30296240","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q3375948","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q36875394","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q36875415","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q3741454","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q38277748","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q50038303","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q50038820","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q50039606","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5198104","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5275432","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5370757","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5376211","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5514784","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5518376","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5643474","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q56583259","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q56583329","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5661215","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5708626","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5902966","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q5903033","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q60997589","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q61934658","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q65180652","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q6673106","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q6840848","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q6917439","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q7120959","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q7180808","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q7639948","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q7933401","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q864338","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q901262","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q903372","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q908265","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q9186375","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q96482303","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","field":"links","label":"Wikidata"}]},{"url":"https://www.wikidata.org/wiki/Q97041850","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","field":"links","label":"Wikidata"}]},{"url":"https://www.wisdomstudy.org","status":200,"ok":true,"finalUrl":"https://www.thewisdomstudy.org/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/","field":"links","label":"WISDOM study"}]},{"url":"https://www.wistar.org/about/leadership/","status":200,"ok":true,"finalUrl":"https://www.wistar.org/about-wistar/who-we-are/leadership/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","field":"links","label":"Source: The Wistar Institute leadership page"},{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","field":"profiles","label":"Wistar leadership page"}]},{"url":"https://www.wistar.org/our-scientists/dario-c-altieri/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","field":"links","label":"Source: Wistar scientist profile"},{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","field":"profiles","label":"Wistar scientist profile"}]},{"url":"https://www.wits.ac.za/health","status":200,"ok":true,"finalUrl":"https://www.wits.ac.za/health/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","field":"links","label":"Wits Faculty of Health Sciences"},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","field":"website"}]},{"url":"https://www.wits.ac.za/health/about-us/management-and-governance/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"links","label":"Institution profile"},{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.wma.net/policies-post/wma-declaration-of-helsinki/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"declaration-of-helsinki","kind":"term","name":"Declaration of Helsinki","route":"/terms/declaration-of-helsinki/","field":"links","label":"World Medical Association: Declaration of Helsinki"}]},{"url":"https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/","field":"links","label":"WMA Declaration of Helsinki: ethical principles for medical research involving human participants"},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","field":"links","label":"WMA Declaration of Helsinki"},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","field":"links","label":"WMA Declaration of Helsinki"}]},{"url":"https://www.worldwidecancerresearch.org","status":200,"ok":true,"finalUrl":"https://www.worldwidecancerresearch.org/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/","field":"links","label":"Worldwide Cancer Research"},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/","field":"website"}]},{"url":"https://www.worldwidecancerresearch.org/who-we-are/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"laura-brady","kind":"person","name":"Laura Brady","route":"/people/laura-brady/","field":"links","label":"Source: Worldwide Cancer Research, Who we are page"},{"id":"laura-brady","kind":"person","name":"Laura Brady","route":"/people/laura-brady/","field":"profiles","label":"Worldwide Cancer Research, Who we are"}]},{"url":"https://www.wpe-uk.de","status":200,"ok":true,"finalUrl":"https://www.wpe-uk.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"WPE proton centre"}]},{"url":"https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","field":"links","label":"WTO: Doha Declaration on the TRIPS Agreement and public health (2001)"}]},{"url":"https://www.wto.org/english/tratop_e/trips_e/trips_e.htm","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","field":"links","label":"WTO: TRIPS Agreement"}]},{"url":"https://www.wtz-essen.de","status":200,"ok":true,"finalUrl":"https://wtz-essen.de/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"Homepage"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"website"}]},{"url":"https://www.wuxiapptec.com/","status":200,"ok":true,"contentType":"text/html;charset=utf-8","checked":"2026-09-30","refs":[{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/","field":"links","label":"WuXi AppTec"},{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/","field":"profiles","label":"WuXi AppTec"},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","field":"links","label":"Official website"},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","field":"website"}]},{"url":"https://www.wuxibiologics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/","field":"links","label":"Official website"},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/","field":"website"}]},{"url":"https://www.wuxixdc.com","status":200,"ok":true,"finalUrl":"https://www.wuxixdc.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/","field":"links","label":"Official website"},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/","field":"website"}]},{"url":"https://www.x4pharma.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","route":"/companies/x4-pharmaceuticals/","field":"links","label":"Official website"},{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","route":"/companies/x4-pharmaceuticals/","field":"website"}]},{"url":"https://www.xcision.com/","status":200,"ok":true,"finalUrl":"https://xcision.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","field":"links","label":"Official website"},{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","field":"website"}]},{"url":"https://www.xprize.org/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/","field":"links","label":"XPRIZE"},{"id":"idea-moon-cure-prizes","kind":"idea","name":"Cure-focused prizes: pay for verified long-term cures, not for drugs","route":"/ideas/idea-moon-cure-prizes/","field":"links","label":"XPRIZE"}]},{"url":"https://www.xuanzhubio.com","status":200,"ok":true,"finalUrl":"https://www.xuanzhubio.com/","contentType":"text/html;charset=utf-8;","checked":"2026-09-30","refs":[{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/","field":"links","label":"Official website"},{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/","field":"website"},{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/","field":"links","label":"Sponsor page"}]},{"url":"https://www.ycombinator.com","status":200,"ok":true,"finalUrl":"https://www.ycombinator.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","field":"links","label":"Official website"},{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","field":"website"}]},{"url":"https://www.ycombinator.com/companies","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","field":"links","label":"YC company directory"}]},{"url":"https://www.ycombinator.com/companies/adialante","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adialante","kind":"company","name":"Adialante","route":"/companies/adialante/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/adventris-pharmaceuticals","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/algen-biotechnologies","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/alixia","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"alixia","kind":"company","name":"Alixia","route":"/companies/alixia/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/altay-therapeutics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","route":"/companies/altay-therapeutics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/aluna","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aluna","kind":"company","name":"Aluna","route":"/companies/aluna/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/ananya-health","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/aoa-dx-inc","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/arpeggio-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","route":"/companies/arpeggio-bio/","field":"links","label":"Y Combinator profile"},{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","route":"/companies/arpeggio-bio/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/asher-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/atomic-alchemy","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/bikanta","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bikanta","kind":"company","name":"Bikanta","route":"/companies/bikanta/","field":"links","label":"Y Combinator profile"},{"id":"bikanta","kind":"company","name":"Bikanta","route":"/companies/bikanta/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/billiontoone","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"billiontoone","kind":"company","name":"BillionToOne","route":"/companies/billiontoone/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/blank-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/cambridge-cancer-genomics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","route":"/companies/cambridge-cancer-genomics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/clear-gene","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"clear-gene","kind":"company","name":"Clear Gene","route":"/companies/clear-gene/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/cofactor-genomics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/data-driven-bioscience","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","route":"/companies/data-driven-bioscience/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/delee","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"delee","kind":"company","name":"Delee","route":"/companies/delee/","field":"links","label":"Y Combinator profile"},{"id":"delee","kind":"company","name":"Delee","route":"/companies/delee/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/digistain","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/eris-biotech","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/fidocure","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"fidocure","kind":"company","name":"FidoCure","route":"/companies/fidocure/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/finaldose","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","field":"links","label":"Y Combinator profile"},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","field":"links","label":"FinalDose (Y Combinator)"}]},{"url":"https://www.ycombinator.com/companies/gamgee","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/granza-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/guardian-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/harmonic-discovery","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/histowiz","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/humane-genomics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/isabl","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isabl","kind":"company","name":"Isabl","route":"/companies/isabl/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/isono-health","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"isono-health","kind":"company","name":"iSono Health","route":"/companies/isono-health/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/kernal-biologics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/known-medicine","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/kopra-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/leah-labs","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"leah-labs","kind":"company","name":"LEAH Labs","route":"/companies/leah-labs/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/liyfe","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"liyfe","kind":"company","name":"Liyfe","route":"/companies/liyfe/","field":"links","label":"Y Combinator profile"},{"id":"liyfe","kind":"company","name":"Liyfe","route":"/companies/liyfe/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/luminate-medical","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"luminate-medical","kind":"company","name":"Luminate Medical","route":"/companies/luminate-medical/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/mednet","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"mednet","kind":"company","name":"Mednet (theMednet)","route":"/companies/mednet/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/modulari-t","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/nearwave","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nearwave","kind":"company","name":"NearWave","route":"/companies/nearwave/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/notable-labs","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"notable-labs","kind":"company","name":"Notable Labs","route":"/companies/notable-labs/","field":"links","label":"Y Combinator profile"},{"id":"notable-labs","kind":"company","name":"Notable Labs","route":"/companies/notable-labs/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/nucleo","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nucleo-research","kind":"company","name":"Nucleo","route":"/companies/nucleo-research/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/numen","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"numen","kind":"company","name":"Numen","route":"/companies/numen/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/omanta","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"omanta","kind":"company","name":"Omanta","route":"/companies/omanta/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/oncobox","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"oncobox","kind":"company","name":"Oncobox","route":"/companies/oncobox/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/origin-bio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/persephone-biosciences","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/reprosent","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reprosent","kind":"company","name":"REPROSENT","route":"/companies/reprosent/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/reverie-labs","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"reverie-labs","kind":"company","name":"Reverie Labs","route":"/companies/reverie-labs/","field":"links","label":"Y Combinator profile"},{"id":"reverie-labs","kind":"company","name":"Reverie Labs","route":"/companies/reverie-labs/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/serinus-biosciences","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/shasqi","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/signatur-biosciences","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","route":"/companies/signatur-biosciences/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/strand-ai","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/synsorybio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/tarebio","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/tradewind-bioscience","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/triomics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/valink-therapeutics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","route":"/companies/valink-therapeutics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/velorum-therapeutics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/viosera-therapeutics","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","route":"/companies/resistancebio/","field":"links","label":"Y Combinator profile"},{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","route":"/companies/resistancebio/","field":"website"}]},{"url":"https://www.ycombinator.com/companies/x-zell","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/yemaachi-biotechnology","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/","field":"links","label":"Y Combinator profile"}]},{"url":"https://www.ycombinator.com/companies/zpredicta","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"zpredicta","kind":"company","name":"zPREDICTA","route":"/companies/zpredicta/","field":"links","label":"Y Combinator profile"},{"id":"zpredicta","kind":"company","name":"zPREDICTA","route":"/companies/zpredicta/","field":"website"}]},{"url":"https://www.yiigle.com/journal/CN112152","status":200,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","route":"/journals/chinese-journal-of-oncology/","field":"links","label":"Homepage"},{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","route":"/journals/chinese-journal-of-oncology/","field":"url"}]},{"url":"https://www.yissum.co.il","status":200,"ok":true,"finalUrl":"https://www.yissum.co.il/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","field":"links","label":"Yissum technology transfer"}]},{"url":"https://www.ymabs.com","status":200,"ok":true,"finalUrl":"https://ymabs.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","field":"links","label":"Official website"},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","field":"website"}]},{"url":"https://www.younglivesvscancer.org.uk/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"young-lives-vs-cancer","kind":"collection","name":"Young Lives vs Cancer","route":"/collections/young-lives-vs-cancer/","field":"links","label":"Young Lives vs Cancer"},{"id":"young-lives-vs-cancer","kind":"collection","name":"Young Lives vs Cancer","route":"/collections/young-lives-vs-cancer/","field":"url"}]},{"url":"https://www.yuhan.co.kr","status":200,"ok":true,"finalUrl":"https://www.yuhan.co.kr/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/","field":"links","label":"Official website"},{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/","field":"website"}]},{"url":"https://www.zailaboratory.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/","field":"links","label":"Zai Lab"},{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/","field":"profiles","label":"Zai Lab"},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/","field":"links","label":"Official website"},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/","field":"website"}]},{"url":"https://www.zeiss.com/meditec","status":200,"ok":true,"finalUrl":"https://www.zeiss.com/meditec/en/home.html?vaURL=www.zeiss.com/meditec","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","route":"/companies/carl-zeiss-meditec/","field":"links","label":"Official website"},{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","route":"/companies/carl-zeiss-meditec/","field":"website"}]},{"url":"https://www.zelgen.com/en/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"Suzhou Zelgen Biopharmaceuticals"},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/","field":"links","label":"Official website"},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/","field":"website"}]},{"url":"https://www.zenithepigenetics.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","route":"/companies/zenith-epigenetics/","field":"links","label":"Official website"},{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","route":"/companies/zenith-epigenetics/","field":"website"}]},{"url":"https://www.zerochildhoodcancer.org.au","status":200,"ok":true,"finalUrl":"https://www.zerochildhoodcancer.org.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","field":"links","label":"ZERO Childhood Cancer"}]},{"url":"https://www.zyduslife.com","status":200,"ok":true,"finalUrl":"https://www.zyduslife.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zydus","kind":"company","name":"Zydus Lifesciences","route":"/companies/zydus/","field":"links","label":"Official website"},{"id":"zydus","kind":"company","name":"Zydus Lifesciences","route":"/companies/zydus/","field":"website"}]},{"url":"https://www.zymeworks.com","status":200,"ok":true,"finalUrl":"https://www.zymeworks.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","field":"links","label":"Official website"},{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","field":"website"}]},{"url":"https://www2.hse.ie/services/hospitals/university-hospital-limerick/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","field":"links","label":"Mid-Western Cancer Centre, University Hospital Limerick website"},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","field":"profiles","label":"Mid-Western Cancer Centre, University Hospital Limerick website"},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","field":"links","label":"Official website"},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","field":"website"}]},{"url":"https://www2.hse.ie/services/hospitals/university-hospital-waterford/","status":200,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","field":"links","label":"University Hospital Waterford website"},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","field":"profiles","label":"University Hospital Waterford website"},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","route":"/institutions/university-hospital-waterford/","field":"links","label":"Official website"},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","route":"/institutions/university-hospital-waterford/","field":"website"}]},{"url":"https://www2.si.mahidol.ac.th/en/administration/administrative-team/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","route":"/people/yongyut-sirivatanauksorn/","field":"links","label":"Source: Siriraj administrative team page"},{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","route":"/people/yongyut-sirivatanauksorn/","field":"profiles","label":"Siriraj administrative team"}]},{"url":"https://x.com/GeminiThera","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","field":"links","label":"X: @GeminiThera"}]},{"url":"https://x.com/strandaibio","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","field":"links","label":"X: @strandaibio"}]},{"url":"https://x.com/sytses","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"sid-sijbrandij","kind":"person","name":"Sid Sijbrandij","route":"/people/sid-sijbrandij/","field":"links","label":"Sid Sijbrandij on X"},{"id":"sid-sijbrandij","kind":"person","name":"Sid Sijbrandij","route":"/people/sid-sijbrandij/","field":"profiles","label":"Sid Sijbrandij on X"}]},{"url":"https://xactrobotics.com","status":200,"ok":true,"finalUrl":"https://xactrobotics.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","field":"links","label":"Official website (still live; the company is not)"},{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","field":"website"}]},{"url":"https://xaira.com","status":200,"ok":true,"finalUrl":"https://www.xaira.com/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","field":"links","label":"Official website"},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","field":"website"}]},{"url":"https://xcision.com/about/company/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","field":"links","label":"About Xcision"}]},{"url":"https://xcision.com/patients/locations/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","field":"links","label":"GammaPod locations"}]},{"url":"https://xcision.com/worlds-largest-medtech-accelerator-announces-61-startups-for-its-2023-cohort/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","field":"links","label":"MedTech Innovator 2023 cohort announcement"}]},{"url":"https://xencor.com","status":200,"ok":true,"finalUrl":"https://xencor.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","field":"website"}]},{"url":"https://xiliotx.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","field":"links","label":"Official website"},{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","field":"website"}]},{"url":"https://xilis.com","status":200,"ok":true,"finalUrl":"https://xilis.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/","field":"website"}]},{"url":"https://ycharos.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-antibody-validation-mandate","kind":"idea","name":"Only use antibodies proven to hit their target with knockout controls","route":"/ideas/idea-tr2-antibody-validation-mandate/","field":"links","label":"YCharOS"}]},{"url":"https://yemaachi.com","status":200,"ok":true,"finalUrl":"https://www.yemaachi.com/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/","field":"links","label":"Official website"},{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/","field":"website"}]},{"url":"https://yoda.yale.edu","status":200,"ok":true,"finalUrl":"https://yoda.yale.edu/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","route":"/institutions/yoda-project/","field":"links","label":"YODA Project"},{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","route":"/institutions/yoda-project/","field":"website"}]},{"url":"https://yoda.yale.edu/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-tr2-failed-trial-ipd-default","kind":"idea","name":"Patient-level data from failed trials becomes open by default after two years","route":"/ideas/idea-tr2-failed-trial-ipd-default/","field":"links","label":"YODA Project"},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","field":"links","label":"YODA Project"}]},{"url":"https://yoda.yale.edu/about/leadership-contact-information/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"links","label":"Institution profile"},{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","field":"profiles","label":"Institution profile"},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"links","label":"Institution profile"},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","field":"profiles","label":"Institution profile"}]},{"url":"https://yugabio.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/","field":"links","label":"Official website"},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/","field":"website"}]},{"url":"https://zapsurgical.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","field":"links","label":"Official website"},{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","field":"website"},{"id":"zap-x","kind":"technology","name":"ZAP-X gyroscopic radiosurgery","route":"/technologies/zap-x/","field":"links","label":"ZAP Surgical Systems"}]},{"url":"https://zapsurgical.com/contact/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","field":"links","label":"Contact page (global headquarters, San Carlos)"}]},{"url":"https://zapsurgical.com/news/zap-surgical-secures-funding/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","field":"links","label":"Series E press release (Nov 2024)"}]},{"url":"https://zapsurgical.com/newsroom/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","field":"links","label":"Newsroom"}]},{"url":"https://zentalis.com/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","field":"links","label":"Official website"},{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","field":"website"}]},{"url":"https://zentalis.com/science/pipeline/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","field":"links","label":"Pipeline"}]},{"url":"https://zerocancer.org/","status":200,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"ZERO Prostate Cancer"}]},{"url":"https://zh.wikipedia.org/wiki/北京协和医院","status":200,"ok":true,"finalUrl":"https://zh.wikipedia.org/wiki/%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","field":"links","label":"Source: Chinese Wikipedia article naming the President"},{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","field":"profiles","label":"Wikipedia (Chinese) article on PUMCH"}]},{"url":"https://zh.wikipedia.org/wiki/国家药品监督管理局","status":200,"ok":true,"finalUrl":"https://zh.wikipedia.org/wiki/%E5%9B%BD%E5%AE%B6%E8%8D%AF%E5%93%81%E7%9B%91%E7%9D%A3%E7%AE%A1%E7%90%86%E5%B1%80","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","field":"links","label":"Wikipedia (Chinese) article on the NMPA"}]},{"url":"https://zh.wikipedia.org/wiki/林口長庚紀念醫院","status":200,"ok":true,"finalUrl":"https://zh.wikipedia.org/wiki/%E6%9E%97%E5%8F%A3%E9%95%B7%E5%BA%9A%E7%B4%80%E5%BF%B5%E9%86%AB%E9%99%A2","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"links","label":"Source: Chinese Wikipedia article on Linkou Chang Gung Memorial Hospital (infobox)"},{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","field":"profiles","label":"Wikipedia (Chinese): 林口長庚紀念醫院"}]},{"url":"https://zh.wikipedia.org/wiki/河南省肿瘤医院","status":200,"ok":true,"finalUrl":"https://zh.wikipedia.org/wiki/%E6%B2%B3%E5%8D%97%E7%9C%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"zhang-jiangong","kind":"person","name":"Zhang Jiangong","route":"/people/zhang-jiangong/","field":"links","label":"Source: Chinese Wikipedia article on Henan Cancer Hospital (president field)"},{"id":"zhang-jiangong","kind":"person","name":"Zhang Jiangong","route":"/people/zhang-jiangong/","field":"profiles","label":"Wikipedia (Chinese) article on Henan Cancer Hospital"}]},{"url":"https://zh.wikipedia.org/wiki/臺北榮民總醫院","status":200,"ok":true,"finalUrl":"https://zh.wikipedia.org/wiki/%E8%87%BA%E5%8C%97%E6%A6%AE%E6%B0%91%E7%B8%BD%E9%86%AB%E9%99%A2","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"chen-wei-ming","kind":"person","name":"Chen Wei-ming","route":"/people/chen-wei-ming/","field":"links","label":"Source: Chinese Wikipedia, Taipei Veterans General Hospital"},{"id":"chen-wei-ming","kind":"person","name":"Chen Wei-ming","route":"/people/chen-wei-ming/","field":"profiles","label":"Wikipedia (hospital article, leadership)"}]},{"url":"https://alphatau.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","field":"links","label":"Alpha Tau Medical"},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Official website"},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"website"}]},{"url":"https://alphatau.com/clinical-pipeline/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Clinical pipeline"}]},{"url":"https://alphatau.com/newsroom/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Newsroom"}]},{"url":"https://aprea.com","status":202,"ok":true,"finalUrl":"https://aprea.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/","field":"links","label":"Official website"},{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/","field":"website"}]},{"url":"https://bostongene.com","status":202,"ok":true,"finalUrl":"https://bostongene.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/","field":"links","label":"Official website"},{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/","field":"website"}]},{"url":"https://capsovision.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"capsovision","kind":"company","name":"CapsoVision","route":"/companies/capsovision/","field":"links","label":"Official website"},{"id":"capsovision","kind":"company","name":"CapsoVision","route":"/companies/capsovision/","field":"website"}]},{"url":"https://doi.org/10.2196/19106","status":202,"ok":true,"finalUrl":"http://publichealth.jmir.org/2020/2/e19106/","contentType":"text/html; charset=UTF-8","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","field":"papers","label":"Turning the Crisis Into an Opportunity: Digital Health Strategies Deployed During the COVID-19 Outbreak"}]},{"url":"https://doi.org/10.7189/jogh.12.11016","status":202,"ok":true,"finalUrl":"https://jogh.org/2022/jogh-12-11016","contentType":"text/html","domainMoved":true,"checked":"2026-09-30","refs":[{"id":"paper-cai-j-glob-health","kind":"paper","name":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study","route":"/key-papers/paper-cai-j-glob-health/","field":"links","label":"J Glob Health 2022"},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","field":"links","label":"Cai L, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China. J Glob Health 2022"}]},{"url":"https://dpcg.nl","status":202,"ok":true,"finalUrl":"https://dpcg.nl/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","route":"/companies/dpcg/","field":"links","label":"Official website"},{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","route":"/companies/dpcg/","field":"website"}]},{"url":"https://eur-lex.europa.eu/eli/dir/2001/83/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/","field":"links","label":"EUR-Lex: Directive 2001/83/EC (Article 10)"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2000/141/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-orphan-regulation","kind":"term","name":"Regulation (EC) No 141/2000: EU orphan medicines","route":"/terms/eu-orphan-regulation/","field":"links","label":"EUR-Lex: Regulation (EC) No 141/2000"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2004/726/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-regulation-726-2004","kind":"term","name":"Regulation (EC) No 726/2004: the EU centralised procedure","route":"/terms/eu-regulation-726-2004/","field":"links","label":"EUR-Lex: Regulation (EC) No 726/2004"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2006/1901/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-paediatric-regulation","kind":"term","name":"Regulation (EC) No 1901/2006: EU paediatric medicines","route":"/terms/eu-paediatric-regulation/","field":"links","label":"EUR-Lex: Regulation (EC) No 1901/2006"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2006/507/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","field":"links","label":"EUR-Lex: Regulation (EC) No 507/2006"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2009/469/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","field":"links","label":"EUR-Lex: Regulation (EC) No 469/2009"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2014/536/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","field":"links","label":"EUR-Lex: Regulation (EU) No 536/2014"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2016/679/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"gdpr","kind":"term","name":"GDPR and health data (Regulation (EU) 2016/679)","route":"/terms/gdpr/","field":"links","label":"EUR-Lex: Regulation (EU) 2016/679"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2019/933/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","field":"links","label":"EUR-Lex: Regulation (EU) 2019/933 (manufacturing waiver)"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2021/2282/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","field":"links","label":"EUR-Lex: Regulation (EU) 2021/2282"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2024/1860/oj/eng","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","field":"links","label":"Regulation (EU) 2024/1860 (EUR-Lex)"}]},{"url":"https://eur-lex.europa.eu/eli/reg/2025/327/oj","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","field":"links","label":"EUR-Lex: Regulation (EU) 2025/327"}]},{"url":"https://fireflybiologics.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","field":"links","label":"Official website"},{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","field":"website"}]},{"url":"https://fireflybiologics.com/press-release-firefly-bio-debuts-with-94-million-series-a-financing/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","field":"links","label":"Series A press release"}]},{"url":"https://gettingitrightfirsttime.co.uk/medical_specialties/dermatology/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nick-levell","kind":"person","name":"Nick Levell","route":"/people/nick-levell/","field":"links","label":"Getting It Right First Time: dermatology"},{"id":"nick-levell","kind":"person","name":"Nick Levell","route":"/people/nick-levell/","field":"profiles","label":"Getting It Right First Time: dermatology"}]},{"url":"https://gettingitrightfirsttime.co.uk/medical_specialties/pancreatic-cancer/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"uhcw-coventry","kind":"institution","name":"University Hospital Coventry","route":"/institutions/uhcw-coventry/","field":"links","label":"GIRFT pancreatic cancer workstream"},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/","field":"links","label":"GIRFT pancreatic cancer workstream (clinical lead biography)"},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/","field":"profiles","label":"GIRFT pancreatic cancer workstream (clinical lead biography)"}]},{"url":"https://gicancer.org.au","status":202,"ok":true,"finalUrl":"https://gicancer.org.au/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","route":"/companies/agitg/","field":"links","label":"GI Cancer Institute / AGITG"},{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","route":"/companies/agitg/","field":"website"}]},{"url":"https://gicancer.org.au/about-us/board-of-directors/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"geoff-parnell","kind":"person","name":"Geoff Parnell","route":"/people/geoff-parnell/","field":"links","label":"Society page"},{"id":"geoff-parnell","kind":"person","name":"Geoff Parnell","route":"/people/geoff-parnell/","field":"profiles","label":"Society page"},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","field":"links","label":"Society page"},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","field":"profiles","label":"Society page"}]},{"url":"https://gicancer.org.au/clinical-trials/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","route":"/companies/agitg/","field":"links","label":"Clinical trials"}]},{"url":"https://ibex-ai.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","field":"links","label":"Official website"},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","field":"website"}]},{"url":"https://ibex-ai.com/fda-510k-clearance/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","field":"links","label":"FDA 510(k) clearance for Ibex Prostate Detect (Feb 2025)"}]},{"url":"https://ibex-ai.com/ibex_celebrates_decade-press-release/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","field":"links","label":"Ten-year milestone release (Sep 2026)"}]},{"url":"https://ibex-ai.com/ibex-series-c-funding/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","field":"links","label":"Series C press release (Sep 2023)"}]},{"url":"https://ielsg.org/site/about-us/board-of-directors/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","field":"links","label":"Source: IELSG Board of Directors page"},{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","field":"profiles","label":"IELSG Board of Directors"}]},{"url":"https://immunome.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/","field":"links","label":"Official website"},{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/","field":"website"}]},{"url":"https://kyantechnologies.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","route":"/companies/kyan-technologies/","field":"links","label":"Official website"},{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","route":"/companies/kyan-technologies/","field":"website"}]},{"url":"https://melanomafocus.org/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"melanoma-focus","kind":"institution","name":"Melanoma Focus","route":"/institutions/melanoma-focus/","field":"website"}]},{"url":"https://melanomafocus.org/melanoma-helpline/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"melanoma-focus","kind":"institution","name":"Melanoma Focus","route":"/institutions/melanoma-focus/","field":"links","label":"Melanoma Helpline"}]},{"url":"https://nouscom.com","status":202,"ok":true,"finalUrl":"https://nouscom.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/","field":"website"}]},{"url":"https://peninsulacanceralliance.nhs.uk/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","route":"/institutions/peninsula-cancer-alliance/","field":"links","label":"Peninsula Cancer Alliance"},{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","route":"/institutions/peninsula-cancer-alliance/","field":"website"}]},{"url":"https://standuptocancer.org","status":202,"ok":true,"finalUrl":"https://standuptocancer.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","field":"links","label":"Stand Up To Cancer"},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","field":"website"}]},{"url":"https://standuptocancer.org/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","field":"links","label":"Stand Up To Cancer"},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","field":"profiles","label":"Stand Up To Cancer"}]},{"url":"https://standuptocancer.org/about-us/leadership/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"links","label":"Stand Up To Cancer leadership"},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","field":"profiles","label":"Stand Up To Cancer leadership"},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","field":"links","label":"Society page"},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","field":"profiles","label":"Society page"}]},{"url":"https://standuptocancer.org/research/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","field":"links","label":"Research"}]},{"url":"https://standuptocancer.org/who-we-are/our-story/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","route":"/people/sherry-lansing/","field":"links","label":"Stand Up To Cancer: our story"}]},{"url":"https://www.adcreview.com","status":202,"ok":true,"finalUrl":"https://www.adcreview.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","route":"/collections/adcdb/","field":"url"}]},{"url":"https://www.adcreview.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","field":"links","label":"ADC Review"},{"id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","field":"url"}]},{"url":"https://www.akoyabio.com","status":202,"ok":true,"finalUrl":"https://www.akoyabio.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","route":"/companies/akoya-biosciences/","field":"links","label":"Official website"},{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","route":"/companies/akoya-biosciences/","field":"website"}]},{"url":"https://www.angiodynamics.com","status":202,"ok":true,"finalUrl":"https://www.angiodynamics.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"angiodynamics","kind":"company","name":"AngioDynamics","route":"/companies/angiodynamics/","field":"links","label":"Official website"},{"id":"angiodynamics","kind":"company","name":"AngioDynamics","route":"/companies/angiodynamics/","field":"website"}]},{"url":"https://www.biophorum.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/","field":"links","label":"BioPhorum: single-use systems"}]},{"url":"https://www.cde.org.cn","status":202,"ok":true,"finalUrl":"https://www.cde.org.cn/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","field":"links","label":"CDE"},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","field":"website"}]},{"url":"https://www.criteriuminc.com","status":202,"ok":true,"finalUrl":"https://www.criteriuminc.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","field":"links","label":"Official website"},{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","field":"website"}]},{"url":"https://www.curesponse.com","status":202,"ok":true,"finalUrl":"https://www.curesponse.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"curesponse","kind":"company","name":"Curesponse","route":"/companies/curesponse/","field":"website"}]},{"url":"https://www.dendreon.com","status":202,"ok":true,"finalUrl":"https://www.dendreon.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","field":"links","label":"Official website"},{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","field":"website"}]},{"url":"https://www.dignicap.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","field":"links","label":"DigniCap"},{"id":"dignitana","kind":"company","name":"Dignitana","route":"/companies/dignitana/","field":"links","label":"Official website"},{"id":"dignitana","kind":"company","name":"Dignitana","route":"/companies/dignitana/","field":"website"}]},{"url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","route":"/institutions/lancashire-south-cumbria-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","route":"/institutions/humber-north-yorkshire-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","route":"/institutions/cheshire-merseyside-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","route":"/institutions/greater-manchester-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","route":"/institutions/south-yorkshire-bassetlaw-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","route":"/institutions/west-midlands-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","route":"/institutions/east-midlands-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","route":"/institutions/north-central-london-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","route":"/institutions/north-east-london-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","route":"/institutions/south-east-london-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","route":"/institutions/kent-medway-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","route":"/institutions/surrey-sussex-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","route":"/institutions/wessex-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","route":"/institutions/thames-valley-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","route":"/institutions/swag-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"},{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","route":"/institutions/peninsula-cancer-alliance/","field":"links","label":"NHS England: Cancer Alliances"}]},{"url":"https://www.england.nhs.uk/cancer/cdf/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","route":"/ideas/idea-data-coverage-with-evidence-development/","field":"links","label":"NICE Cancer Drugs Fund"},{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/","field":"links","label":"NHS England: Cancer Drugs Fund"}]},{"url":"https://www.england.nhs.uk/genomics/nhs-genomic-med-service/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","route":"/collections/nhs-genomic-medicine-service/","field":"links","label":"NHS Genomic Medicine Service"},{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","route":"/collections/nhs-genomic-medicine-service/","field":"url"}]},{"url":"https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/","field":"links","label":"NHS England: Innovative Medicines Fund"}]},{"url":"https://www.england.nhs.uk/medicines-2/medicines-repurposing-programme/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","field":"links","label":"NHS England Medicines Repurposing Programme"}]},{"url":"https://www.england.nhs.uk/publication/national-genomic-test-directories/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","route":"/collections/nhs-genomic-medicine-service/","field":"links","label":"National Genomic Test Directory"}]},{"url":"https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/","status":202,"ok":true,"contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"links","label":"NHS England Cancer Waiting Times statistics"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","field":"metrics (NHS England standard for time from urgent referral to first treatment)"}]},{"url":"https://www.espen.org","status":202,"ok":true,"finalUrl":"https://www.espen.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","field":"links","label":"ESPEN"},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","field":"website"}]},{"url":"https://www.espen.org/about/committees","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","field":"links","label":"Source: ESPEN committees page"},{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.espen.org/guidelines-home/espen-guidelines","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","field":"links","label":"Guidelines"}]},{"url":"https://www.galeratx.com","status":202,"ok":true,"finalUrl":"https://www.galeratx.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","field":"links","label":"Official website"},{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","field":"website"}]},{"url":"https://www.hummingbirdbioscience.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","route":"/companies/hummingbird-bioscience/","field":"links","label":"Official website"},{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","route":"/companies/hummingbird-bioscience/","field":"website"}]},{"url":"https://www.icecure-medical.com","status":202,"ok":true,"finalUrl":"https://www.icecure-medical.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/","field":"links","label":"IceCure Medical: ProSense"},{"id":"icecure-medical","kind":"company","name":"IceCure Medical","route":"/companies/icecure-medical/","field":"links","label":"Official website"},{"id":"icecure-medical","kind":"company","name":"IceCure Medical","route":"/companies/icecure-medical/","field":"website"}]},{"url":"https://www.ielsg.org","status":202,"ok":true,"finalUrl":"https://www.ielsg.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/","field":"links","label":"IELSG"},{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/","field":"website"}]},{"url":"https://www.imunon.com","status":202,"ok":true,"finalUrl":"https://www.imunon.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","field":"links","label":"Official website"},{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","field":"website"}]},{"url":"https://www.intensitytherapeutics.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"intensity-therapeutics","kind":"company","name":"Intensity Therapeutics","route":"/companies/intensity-therapeutics/","field":"links","label":"Official website"},{"id":"intensity-therapeutics","kind":"company","name":"Intensity Therapeutics","route":"/companies/intensity-therapeutics/","field":"website"}]},{"url":"https://www.mesothelioma.uk.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/","field":"links","label":"Mesothelioma UK"}]},{"url":"https://www.nsabp.org","status":202,"ok":true,"finalUrl":"https://www.nsabp.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nsabp-foundation","kind":"company","name":"NSABP Foundation","route":"/companies/nsabp-foundation/","field":"links","label":"NSABP Foundation"},{"id":"nsabp-foundation","kind":"company","name":"NSABP Foundation","route":"/companies/nsabp-foundation/","field":"website"}]},{"url":"https://www.nsabp.org/about-us/the-team/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","field":"links","label":"Institution profile"},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","field":"profiles","label":"Institution profile"},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","field":"links","label":"Institution profile"},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.onjcri.org.au","status":202,"ok":true,"finalUrl":"https://www.onjcri.org.au/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","field":"links","label":"Olivia Newton-John Cancer Research Institute"}]},{"url":"https://www.onjcri.org.au/about/marco-herold/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","field":"profiles","label":"ONJCRI profile"}]},{"url":"https://www.onjcri.org.au/our-people/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","field":"links","label":"Source: ONJCRI our people page"}]},{"url":"https://www.rah.sa.gov.au","status":202,"ok":true,"finalUrl":"https://www.rah.sa.gov.au/","contentType":"text/html; charset=UTF-8","checked":"2026-09-30","refs":[{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","field":"links","label":"Royal Adelaide Hospital"},{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","field":"website"}]},{"url":"https://www.salubrisbio.com/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/","field":"links","label":"Official website"},{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/","field":"website"}]},{"url":"https://www.skcin.org/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skcin","kind":"institution","name":"Skcin (the Karen Clifford Skin Cancer Charity)","route":"/institutions/skcin/","field":"website"}]},{"url":"https://www.skcin.org/resources/vat-burn-campaign/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"skcin","kind":"institution","name":"Skcin (the Karen Clifford Skin Cancer Charity)","route":"/institutions/skcin/","field":"links","label":"VAT Burn campaign"}]},{"url":"https://www.soroka.org","status":202,"ok":true,"finalUrl":"https://www.soroka.org/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","route":"/institutions/soroka-medical-center/","field":"links","label":"Official website"},{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","route":"/institutions/soroka-medical-center/","field":"website"}]},{"url":"https://www.stchristophers.org.uk/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"links","label":"St Christopher's Hospice"},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","field":"profiles","label":"St Christopher's Hospice"}]},{"url":"https://www.swagcanceralliance.nhs.uk/","status":202,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","route":"/institutions/swag-cancer-alliance/","field":"links","label":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance"},{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","route":"/institutions/swag-cancer-alliance/","field":"website"}]},{"url":"https://www.tscan.com","status":202,"ok":true,"finalUrl":"https://www.tscan.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","field":"website"}]},{"url":"https://www.xcovery.com/","status":202,"ok":true,"finalUrl":"https://xcovery.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/","field":"links","label":"Official website"},{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/","field":"website"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet","status":203,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/37708904/","contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","field":"papers","label":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer"},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","field":"papers","label":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer"},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/","field":"links","label":"PubMed search: NAPOLI-3 Lancet 2023"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1059147/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mintz-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Normal genetically mosaic mice produced from malignant teratocarcinoma cells","route":"/key-papers/paper-mintz-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10615079/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hutchins-n-engl-j-med","kind":"paper","name":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","route":"/key-papers/paper-hutchins-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10788334/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gorski-brca1-founder-mutations-poland-ajhg-2000","kind":"paper","name":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","route":"/key-papers/paper-gorski-brca1-founder-mutations-poland-ajhg-2000/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10791373/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-der-zee-lancet","kind":"paper","name":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group","route":"/key-papers/paper-van-der-zee-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10963602/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-perou-molecular-portraits-breast-tumours-nature-2000","kind":"paper","name":"Molecular portraits of human breast tumours","route":"/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11244503/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ladanyi-aspl-tfe3-oncogene-2001","kind":"paper","name":"The der(17)t(X;17) of alveolar soft part sarcoma fuses TFE3 to ASPL","route":"/key-papers/paper-ladanyi-aspl-tfe3-oncogene-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11323675/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shankaran-nature","kind":"paper","name":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","route":"/key-papers/paper-shankaran-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11547717/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001","kind":"paper","name":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)","route":"/key-papers/paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11547741/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-macdonald-n-engl-j-med","kind":"paper","name":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","route":"/key-papers/paper-macdonald-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11553815/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sorlie-breast-carcinoma-subclasses-pnas-2001","kind":"paper","name":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","route":"/key-papers/paper-sorlie-breast-carcinoma-subclasses-pnas-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11597399/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-gastric-eur-j-cancer-2001","kind":"paper","name":"EGFR and cancer prognosis","route":"/key-papers/paper-egfr-gastric-eur-j-cancer-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11742045/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-goodwin-n-engl-j-med","kind":"paper","name":"The effect of group psychosocial support on survival in metastatic breast cancer","route":"/key-papers/paper-goodwin-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11902539/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001","kind":"paper","name":"Esthesioneuroblastoma: a meta-analysis and review","route":"/key-papers/paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/11984739/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000","kind":"paper","name":"Incidence of lymph node metastasis from early gastric cancer: estimation from 5,265 patients at two large centres","route":"/key-papers/paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12000816/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002","kind":"paper","name":"Germline mutations in nonsyndromic pheochromocytoma","route":"/key-papers/paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12045100/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bell-annu-rev-biochem","kind":"paper","name":"DNA replication in eukaryotic cells","route":"/key-papers/paper-bell-annu-rev-biochem/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12049862/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-llovet-tace-lancet-2002","kind":"paper","name":"Arterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma","route":"/key-papers/paper-llovet-tace-lancet-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12065144/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002","kind":"paper","name":"FIGO staging for gestational trophoblastic neoplasia 2000","route":"/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12065559/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002","kind":"paper","name":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial","route":"/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12103287/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002","kind":"paper","name":"NCIC SR2: preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs","route":"/key-papers/paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12115309/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kothari-paget-disease-nipple-multifocal-cancer-2002","kind":"paper","name":"Paget disease of the nipple as a marker of multifocal, higher-risk underlying breast cancer","route":"/key-papers/paper-kothari-paget-disease-nipple-multifocal-cancer-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12128137/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jaffray-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Flat-panel cone-beam computed tomography for image-guided radiation therapy","route":"/key-papers/paper-jaffray-int-j-radiat-oncol-biol-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12181401/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-demetri-imatinib-gist-nejm-2002","kind":"paper","name":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours","route":"/key-papers/paper-demetri-imatinib-gist-nejm-2002/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12407406/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dunn-nat-immunol","kind":"paper","name":"Cancer immunoediting: from immunosurveillance to tumor escape","route":"/key-papers/paper-dunn-nat-immunol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12522257/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heinrich-pdgfra-gist-science-2003","kind":"paper","name":"PDGFRA activating mutations in gastrointestinal stromal tumours","route":"/key-papers/paper-heinrich-pdgfra-gist-science-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12539049/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tonon-crtc1-maml2-nat-genet-2003","kind":"paper","name":"The t(11;19) translocation in mucoepidermoid carcinoma creates a CRTC1-MAML2 fusion","route":"/key-papers/paper-tonon-crtc1-maml2-nat-genet-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/1260676/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976","kind":"paper","name":"Kadish staging: olfactory neuroblastoma, a clinical analysis of 17 cases","route":"/key-papers/paper-kadish-olfactory-neuroblastoma-staging-cancer-1976/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12668651/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-citron-j-clin-oncol","kind":"paper","name":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741","route":"/key-papers/paper-citron-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12672281/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2003","kind":"paper","name":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12778130/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bergers-nat-rev-cancer","kind":"paper","name":"Tumorigenesis and the angiogenic switch","route":"/key-papers/paper-bergers-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12778135/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fidler-nat-rev-cancer","kind":"paper","name":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited","route":"/key-papers/paper-fidler-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12829800/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003","kind":"paper","name":"Repeated observation of breast tumor subtypes in independent gene expression data sets","route":"/key-papers/paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/12860938/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vogelzang-pemetrexed-mesothelioma-jco-2003","kind":"paper","name":"Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","route":"/key-papers/paper-vogelzang-pemetrexed-mesothelioma-jco-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/13160495/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-doll-hill-mortality-of-doctors-smoking-bmj-1954","kind":"paper","name":"The mortality of doctors in relation to their smoking habits; a preliminary report","route":"/key-papers/paper-doll-hill-mortality-of-doctors-smoking-bmj-1954/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/13172380/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-armitage-br-j-cancer","kind":"paper","name":"The age distribution of cancer and a multi-stage theory of carcinogenesis","route":"/key-papers/paper-armitage-br-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14219541/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-laird-br-j-cancer","kind":"paper","name":"DYNAMICS OF TUMOR GROWTH","route":"/key-papers/paper-laird-br-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14519755/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-foulkes-brca1-basal-phenotype-jnci-2003","kind":"paper","name":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","route":"/key-papers/paper-foulkes-brca1-basal-phenotype-jnci-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14551293/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003","kind":"paper","name":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","route":"/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14585940/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shattuck-n-engl-j-med","kind":"paper","name":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","route":"/key-papers/paper-shattuck-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14645423/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heinrich-kit-mutation-imatinib-response-jco-2003","kind":"paper","name":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","route":"/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14645636/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-91-11-forastiere-nejm-2003","kind":"paper","name":"RTOG 91-11: concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","route":"/key-papers/paper-rtog-91-11-forastiere-nejm-2003/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14702632/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","kind":"paper","name":"Molecular determinants of resistance to antiandrogen therapy","route":"/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/14996910/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-maffini-j-cell-sci","kind":"paper","name":"The stroma as a crucial target in rat mammary gland carcinogenesis","route":"/key-papers/paper-maffini-j-cell-sci/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15020605/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15028824/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004","kind":"paper","name":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","route":"/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15082523/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-endocr-rev-2004","kind":"paper","name":"Androgen receptor in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-endocr-rev-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15128893/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cooper-rtog-9501-nejm-2004","kind":"paper","name":"RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma","route":"/key-papers/paper-cooper-rtog-9501-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15217923/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","kind":"paper","name":"Mesothelin: a new target for immunotherapy","route":"/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15317891/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cristofanilli-n-engl-j-med","kind":"paper","name":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","route":"/key-papers/paper-cristofanilli-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15342805/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hughes-n-engl-j-med","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","route":"/key-papers/paper-hughes-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15383798/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004","kind":"paper","name":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","route":"/key-papers/paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15470213/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15674951/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-taixiang-cochrane-database-syst-rev","kind":"paper","name":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients","route":"/key-papers/paper-taixiang-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15728811/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15737014/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","kind":"paper","name":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","route":"/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/15988530/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-michor-nature","kind":"paper","name":"Dynamics of chronic myeloid leukaemia","route":"/key-papers/paper-michor-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16039331/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005","kind":"paper","name":"MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma","route":"/key-papers/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16043828/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-j-clin-oncol-2005","kind":"paper","name":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","route":"/key-papers/paper-kras-nsclc-j-clin-oncol-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16049480/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-minn-nature","kind":"paper","name":"Genes that mediate breast cancer metastasis to lung","route":"/key-papers/paper-minn-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16083707/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005","kind":"paper","name":"Probability of pancreatic cancer following diabetes: a population-based study","route":"/key-papers/paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16120859/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-braun-n-engl-j-med","kind":"paper","name":"A pooled analysis of bone marrow micrometastasis in breast cancer","route":"/key-papers/paper-braun-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16133112/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sakamoto-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials","route":"/key-papers/paper-sakamoto-cancer-immunol-immunother/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16169468/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paszek-cancer-cell","kind":"paper","name":"Tensional homeostasis and the malignant phenotype","route":"/key-papers/paper-paszek-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16236737/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","route":"/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16236738/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16291983/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-curtin-melanoma-genetic-alterations-nejm-2005","kind":"paper","name":"Distinct sets of genetic alterations in melanoma","route":"/key-papers/paper-curtin-melanoma-genetic-alterations-nejm-2005/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16341007/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kaplan-nature","kind":"paper","name":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","route":"/key-papers/paper-kaplan-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16467544/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bonner-cetuximab-radiotherapy-nejm-2006","kind":"paper","name":"Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck","route":"/key-papers/paper-bonner-cetuximab-radiotherapy-nejm-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16625560/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ezzo-cochrane-database-syst-rev","kind":"paper","name":"Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","route":"/key-papers/paper-ezzo-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16757721/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","kind":"paper","name":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","route":"/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16763282/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-laurie-licitra-salivary-systemic-jco-2006","kind":"paper","name":"Systemic therapy in the palliative management of advanced salivary gland cancers (review)","route":"/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/16908931/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-curtin-kit-melanoma-jco-2006","kind":"paper","name":"Somatic activation of KIT in distinct subtypes of melanoma","route":"/key-papers/paper-curtin-kit-melanoma-jco-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17035650/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-oeffinger-n-engl-j-med","kind":"paper","name":"Chronic health conditions in adult survivors of childhood cancer","route":"/key-papers/paper-oeffinger-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17046465/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-demetri-sunitinib-gist-lancet-2006","kind":"paper","name":"Sunitinib in advanced gastrointestinal stromal tumour after failure of imatinib","route":"/key-papers/paper-demetri-sunitinib-gist-lancet-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17060945/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-calin-nat-rev-cancer","kind":"paper","name":"MicroRNA signatures in human cancers","route":"/key-papers/paper-calin-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17089851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keall-med-phys","kind":"paper","name":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","route":"/key-papers/paper-keall-med-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17106715/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-oba-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer","route":"/key-papers/paper-oba-cancer-immunol-immunother/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17109012/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-merlo-nat-rev-cancer","kind":"paper","name":"Cancer as an evolutionary and ecological process","route":"/key-papers/paper-merlo-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17227978/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-conko-001-adjuvant-gemcitabine-observation-jama-2007","kind":"paper","name":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17387718/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bauer-triple-negative-california-registry-cancer-2007","kind":"paper","name":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","route":"/key-papers/paper-bauer-triple-negative-california-registry-cancer-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17426725/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-musacchio-nat-rev-mol-cell-biol","kind":"paper","name":"The spindle-assembly checkpoint in space and time","route":"/key-papers/paper-musacchio-nat-rev-mol-cell-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17463250/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","kind":"paper","name":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","route":"/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17540844/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olsen-mycosis-fungoides-staging-blood-2007","kind":"paper","name":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","route":"/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17635889/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-whel-jama-2007","kind":"paper","name":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial","route":"/key-papers/paper-whel-jama-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17658395/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-interfant-99-lancet-2007","kind":"paper","name":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-99-lancet-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17671126/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dent-tnbc-clinical-features-recurrence-ccr-2007","kind":"paper","name":"Triple-negative breast cancer: clinical features and patterns of recurrence","route":"/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17679017/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sankaranarayanan-lancet","kind":"paper","name":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","route":"/key-papers/paper-sankaranarayanan-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17699816/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-slotman-n-engl-j-med","kind":"paper","name":"Prophylactic cranial irradiation in extensive small-cell lung cancer","route":"/key-papers/paper-slotman-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17728216/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-montgomery-j-natl-cancer-inst","kind":"paper","name":"A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients","route":"/key-papers/paper-montgomery-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17785706/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-symmans-j-clin-oncol","kind":"paper","name":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","route":"/key-papers/paper-symmans-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17856666/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935","kind":"paper","name":"Treatment of carcinoma of the ampulla of Vater","route":"/key-papers/paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/17940185/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-endocr-rev-2007","kind":"paper","name":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","route":"/key-papers/paper-braf-thyroid-endocr-rev-2007/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18216292/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-khorana-blood","kind":"paper","name":"Development and validation of a predictive model for chemotherapy-associated thrombosis","route":"/key-papers/paper-khorana-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18250347/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008","kind":"paper","name":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","route":"/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18281661/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008","kind":"paper","name":"GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer","route":"/key-papers/paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18316791/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2008","kind":"paper","name":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18425885/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-horneber-cochrane-database-syst-rev","kind":"paper","name":"Mistletoe therapy in oncology","route":"/key-papers/paper-horneber-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18509120/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mntx-302-thomas-nejm-2008","kind":"paper","name":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","route":"/key-papers/paper-mntx-302-thomas-nejm-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18539529/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prado-lancet-oncol","kind":"paper","name":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","route":"/key-papers/paper-prado-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18626472/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-caldecott-nat-rev-genet","kind":"paper","name":"Single-strand break repair and genetic disease","route":"/key-papers/paper-caldecott-nat-rev-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18628784/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schafer-nat-rev-mol-cell-biol","kind":"paper","name":"Cancer as an overhealing wound: an old hypothesis revisited","route":"/key-papers/paper-schafer-nat-rev-mol-cell-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18645193/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-attard-abiraterone-phase-1-cyp17-jco-2008","kind":"paper","name":"Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven","route":"/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18650514/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sharp-sorafenib-nejm-2008","kind":"paper","name":"SHARP: sorafenib in advanced hepatocellular carcinoma","route":"/key-papers/paper-sharp-sorafenib-nejm-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18779615/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-atchley-brca-status-triple-negative-jco-2008","kind":"paper","name":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","route":"/key-papers/paper-atchley-brca-status-triple-negative-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18782450/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herschkowitz-rb1-loss-basal-like-bcr-2008","kind":"paper","name":"The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas","route":"/key-papers/paper-herschkowitz-rb1-loss-basal-like-bcr-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18784101/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-extreme-vermorken-nejm-2008","kind":"paper","name":"EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-extreme-vermorken-nejm-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18794556/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kutner-ann-intern-med","kind":"paper","name":"Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial","route":"/key-papers/paper-kutner-ann-intern-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18809609/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","kind":"paper","name":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","route":"/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18809612/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-elkins-j-clin-oncol","kind":"paper","name":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","route":"/key-papers/paper-elkins-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18813320/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-epstein-nat-rev-cancer","kind":"paper","name":"Basal cell carcinomas: attack of the hedgehog","route":"/key-papers/paper-epstein-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18833576/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lin-tnbc-cns-metastases-dfci-cancer-2008","kind":"paper","name":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","route":"/key-papers/paper-lin-tnbc-cns-metastases-dfci-cancer-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18946061/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kind":"paper","name":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","route":"/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/18974103/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-devita-cancer-res","kind":"paper","name":"A history of cancer chemotherapy","route":"/key-papers/paper-devita-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19047280/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009","kind":"paper","name":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","route":"/key-papers/paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19047291/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-inrg-cohn-jco-2009","kind":"paper","name":"The International Neuroblastoma Risk Group (INRG) classification system","route":"/key-papers/paper-inrg-cohn-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19052619/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-quintana-nature","kind":"paper","name":"Efficient tumour formation by single human melanoma cells","route":"/key-papers/paper-quintana-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19129520/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mullighan-ikzf1-nejm-2009","kind":"paper","name":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia","route":"/key-papers/paper-mullighan-ikzf1-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19138562/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009","kind":"paper","name":"A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)","route":"/key-papers/paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19164203/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009","kind":"paper","name":"Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","route":"/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19204204/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-parker-j-clin-oncol","kind":"paper","name":"Supervised risk predictor of breast cancer based on intrinsic subtypes","route":"/key-papers/paper-parker-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19238148/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-malumbres-nat-rev-cancer","kind":"paper","name":"Cell cycle, CDKs and cancer: a changing paradigm","route":"/key-papers/paper-malumbres-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19269519/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009","kind":"paper","name":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)","route":"/key-papers/paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19276453/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-draisma-lead-time-overdiagnosis-psa-jnci-2009","kind":"paper","name":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","route":"/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19297565/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andriole-plco-prostate-screening-nejm-2009","kind":"paper","name":"PLCO: mortality results from a randomised prostate cancer screening trial","route":"/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19303137/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","field":"links","label":"ACOSOG Z9001 (Lancet 2009)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19339720/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","kind":"paper","name":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","route":"/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19370613/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kassab-cochrane-database-syst-rev","kind":"paper","name":"Homeopathic medicines for adverse effects of cancer treatments","route":"/key-papers/paper-kassab-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19516027/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shah-foxl2-granulosa-nejm-2009","kind":"paper","name":"Mutation of FOXL2 in granulosa cell tumours of the ovary","route":"/key-papers/paper-shah-foxl2-granulosa-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19552948/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009","kind":"paper","name":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","route":"/key-papers/paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19586656/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-patricia-paavonen-lancet-2009","kind":"paper","name":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","route":"/key-papers/paper-patricia-paavonen-lancet-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19587327/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-plotkin-bevacizumab-nf2-nejm-2009","kind":"paper","name":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","route":"/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19636060/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19675330/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schmitz-n-engl-j-med","kind":"paper","name":"Weight lifting in women with breast-cancer-related lymphedema","route":"/key-papers/paper-schmitz-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19692680/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19704057/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-promid-rinke-jco-2009","kind":"paper","name":"PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours","route":"/key-papers/paper-promid-rinke-jco-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19720969/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009","kind":"paper","name":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005","route":"/key-papers/paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19734877/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gupta-nat-med","kind":"paper","name":"Cancer stem cells: mirage or reality?","route":"/key-papers/paper-gupta-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19738203/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-sci-signal-2009","kind":"paper","name":"Oncogenic EGFR signaling networks in glioma","route":"/key-papers/paper-egfr-glioblastoma-sci-signal-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19773751/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-colorectal-br-j-cancer-2009","kind":"paper","name":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis","route":"/key-papers/paper-ezh2-colorectal-br-j-cancer-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19782876/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcculloch-lancet","kind":"paper","name":"No surgical innovation without evaluation: the IDEAL recommendations","route":"/key-papers/paper-mcculloch-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/19846851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009","kind":"paper","name":"SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","route":"/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20008640/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2010","kind":"paper","name":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20048174/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wagner-sirolimus-pecoma-jco-2010","kind":"paper","name":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20171515/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bentzen-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","route":"/key-papers/paper-bentzen-int-j-radiat-oncol-biol-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20194851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010","kind":"paper","name":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","route":"/key-papers/paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20206777/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-portec-2-lancet-2010","kind":"paper","name":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","route":"/key-papers/paper-portec-2-lancet-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20332315/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-taylor-bmj","kind":"paper","name":"Multidisciplinary team working in cancer: what is the evidence?","route":"/key-papers/paper-taylor-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2034244/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-va-larynx-induction-chemotherapy-nejm-1991","kind":"paper","name":"Department of Veterans Affairs Laryngeal Cancer Study: induction chemotherapy plus radiation versus surgery plus radiation","route":"/key-papers/paper-va-larynx-induction-chemotherapy-nejm-1991/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20355252/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lazebnik-nat-rev-cancer","kind":"paper","name":"What are the hallmarks of cancer?","route":"/key-papers/paper-lazebnik-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20371346/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sharma-cell","kind":"paper","name":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","route":"/key-papers/paper-sharma-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20375404/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abc-02-gemcitabine-cisplatin-nejm-2010","kind":"paper","name":"ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer","route":"/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20404251/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-cap-er-pr-testing-guideline-jco-2010","kind":"paper","name":"American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","route":"/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20427809/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20434400/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-issels-lancet-oncol","kind":"paper","name":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","route":"/key-papers/paper-issels-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20505152/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lu-j-natl-cancer-inst","kind":"paper","name":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","route":"/key-papers/paper-lu-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20519626/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-badalian-very-braf-mutations-lch-blood-2010","kind":"paper","name":"Recurrent BRAF mutations in Langerhans cell histiocytosis","route":"/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20530316/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ang-hpv-oropharyngeal-nejm-2010","kind":"paper","name":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","route":"/key-papers/paper-ang-hpv-oropharyngeal-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20537949/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20573926/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-n-engl-j-med-2010","kind":"paper","name":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","route":"/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20625118/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010","kind":"paper","name":"Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases","route":"/key-papers/paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20656792/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011","kind":"paper","name":"First-line chemotherapy for malignant peripheral nerve sheath tumour versus other soft tissue sarcomas (EORTC pooled analysis)","route":"/key-papers/paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20728210/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","field":"links","label":"ToGA (Lancet 2010)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20818855/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20818862/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kantoff-n-engl-j-med","kind":"paper","name":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","route":"/key-papers/paper-kantoff-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20823433/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010","kind":"paper","name":"ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection","route":"/key-papers/paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20826764/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jones-arid1a-clear-cell-science-2010","kind":"paper","name":"Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","route":"/key-papers/paper-jones-arid1a-clear-cell-science-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20838878/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-donenberg-bahamas-brca1-founder-bcrt-2011","kind":"paper","name":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas","route":"/key-papers/paper-donenberg-bahamas-brca1-founder-bcrt-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20871596/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-filippakopoulos-nature","kind":"paper","name":"Selective inhibition of BET bromodomains","route":"/key-papers/paper-filippakopoulos-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20879880/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","kind":"paper","name":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20879881/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yu-anti-gd2-neuroblastoma-nejm-2010","kind":"paper","name":"Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)","route":"/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20888993/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rustin-lancet","kind":"paper","name":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial","route":"/key-papers/paper-rustin-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/20942669/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wiegand-arid1a-clear-cell-nejm-2010","kind":"paper","name":"ARID1A mutations in endometriosis-associated ovarian carcinomas","route":"/key-papers/paper-wiegand-arid1a-clear-cell-nejm-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21098770/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-annema-jama","kind":"paper","name":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","route":"/key-papers/paper-annema-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21131038/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010","kind":"paper","name":"ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia","route":"/key-papers/paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21144578/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rothwell-lancet","kind":"paper","name":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","route":"/key-papers/paper-rothwell-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21160078/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010","kind":"paper","name":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","route":"/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21163703/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-lancet-oncol-2011","kind":"paper","name":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-lancet-oncol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21263100/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011","kind":"paper","name":"GOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia","route":"/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21301065/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-davies-phys-biol","kind":"paper","name":"Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors","route":"/key-papers/paper-davies-phys-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21306237/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raymond-sunitinib-pnet-nejm-2011","kind":"paper","name":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumours","route":"/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21306238/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-radiant-3-everolimus-pnet-yao-nejm-2011","kind":"paper","name":"RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours","route":"/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21365651/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-langley-int-j-cancer","kind":"paper","name":"The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs","route":"/key-papers/paper-langley-int-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21372224/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cardillo-clin-cancer-res","kind":"paper","name":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","route":"/key-papers/paper-cardillo-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21376385/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cortes-lancet","kind":"paper","name":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","route":"/key-papers/paper-cortes-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21383745/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bissell-nat-med","kind":"paper","name":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression","route":"/key-papers/paper-bissell-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21502544/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-colorectal-j-clin-oncol-2011","kind":"paper","name":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21584898/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-errani-wwtr1-camta1-ehe-gcc-2011","kind":"paper","name":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid haemangioendothelioma","route":"/key-papers/paper-errani-wwtr1-camta1-ehe-gcc-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21598255/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-amary-idh-cartilaginous-tumours-j-pathol-2011","kind":"paper","name":"IDH1 and IDH2 mutations are frequent in central chondrosarcoma and central and periosteal chondromas","route":"/key-papers/paper-amary-idh-cartilaginous-tumours-j-pathol-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21609503/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-bmc-med-2011","kind":"paper","name":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications","route":"/key-papers/paper-ezh2-sarcoma-bmc-med-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21612468/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cou-aa-301-abiraterone-de-bono-nejm-2011","kind":"paper","name":"COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel","route":"/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21617154/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-agostinis-ca-cancer-j-clin","kind":"paper","name":"Photodynamic therapy of cancer: an update","route":"/key-papers/paper-agostinis-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21633166/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21639808/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chapman-vemurafenib-nejm-2011","kind":"paper","name":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","route":"/key-papers/paper-chapman-vemurafenib-nejm-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21659419/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paskett-ca-cancer-j-clin","kind":"paper","name":"Patient navigation: an update on the state of the science","route":"/key-papers/paper-paskett-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21742485/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21751904/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-9408-short-term-adt-jones-nejm-2011","kind":"paper","name":"RTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer","route":"/key-papers/paper-rtog-9408-short-term-adt-jones-nejm-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2188735/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fearon-cell","kind":"paper","name":"A genetic model for colorectal tumorigenesis","route":"/key-papers/paper-fearon-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/21991949/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011","kind":"paper","name":"Adjuvant trastuzumab in HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22019490/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-seely-integr-cancer-ther","kind":"paper","name":"Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials","route":"/key-papers/paper-seely-integr-cancer-ther/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22022341/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-xm01-22-tjulandin-arch-drug-inf-2011","kind":"paper","name":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22)","route":"/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22025146/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zeta-vandetanib-mtc-wells-jco-2012","kind":"paper","name":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","route":"/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22089420/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-glunde-nat-rev-cancer","kind":"paper","name":"Choline metabolism in malignant transformation","route":"/key-papers/paper-glunde-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22118458/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-friedl-cell","kind":"paper","name":"Cancer invasion and the microenvironment: plasticity and reciprocity","route":"/key-papers/paper-friedl-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22134537/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012","kind":"paper","name":"Molecular subgroups of medulloblastoma: the current consensus","route":"/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22149876/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolero-2-n-engl-j-med-2012","kind":"paper","name":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","route":"/key-papers/paper-bolero-2-n-engl-j-med-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22152853/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22153890/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22214755/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ross-bmj","kind":"paper","name":"Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis","route":"/key-papers/paper-ross-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22215748/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bergethon-ros1-rearrangements-lung-jco-2012","kind":"paper","name":"ROS1 rearrangements define a unique molecular class of lung cancers","route":"/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22226517/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-classic-adjuvant-capox-gastric-bang-lancet-2012","kind":"paper","name":"CLASSIC: adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-adjuvant-capox-gastric-bang-lancet-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22250183/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bellera-ann-oncol","kind":"paper","name":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","route":"/key-papers/paper-bellera-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22285168/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-nsclc-lancet-oncol-2012","kind":"paper","name":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","route":"/key-papers/paper-egfr-nsclc-lancet-oncol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22375970/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012","kind":"paper","name":"COMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","route":"/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22430491/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012","kind":"paper","name":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","route":"/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22439926/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hanahan-cancer-cell","kind":"paper","name":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","route":"/key-papers/paper-hanahan-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22453568/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012","kind":"paper","name":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","route":"/key-papers/paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012/","field":"links","label":"PubMed"},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","field":"links","label":"SSG XVIII (JAMA 2012)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22495314/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shah-tnbc-clonal-evolution-nature-2012","kind":"paper","name":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","route":"/key-papers/paper-shah-tnbc-clonal-evolution-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22529259/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-p9641-low-risk-neuroblastoma-strother-jco-2012","kind":"paper","name":"COG P9641: surgery alone or with restricted chemotherapy for low-risk neuroblastoma","route":"/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22551107/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012","kind":"paper","name":"FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma","route":"/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22578793/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012","kind":"paper","name":"NOA-08: temozolomide alone versus radiotherapy alone for malignant astrocytoma in the elderly","route":"/key-papers/paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22586653/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22614976/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chua-j-clin-oncol","kind":"paper","name":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","route":"/key-papers/paper-chua-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22646630/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cross-nejm-2012","kind":"paper","name":"CROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer","route":"/key-papers/paper-cross-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22648714/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nechuta-am-j-clin-nutr","kind":"paper","name":"Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women","route":"/key-papers/paper-nechuta-am-j-clin-nutr/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22670903/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22722843/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","kind":"paper","name":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","route":"/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22723327/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-thakker-j-clin-endocrinol-metab","kind":"paper","name":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","route":"/key-papers/paper-thakker-j-clin-endocrinol-metab/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22894553/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22898679/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esphall-imatinib-biondi-lancet-oncol-2012","kind":"paper","name":"EsPhALL: imatinib after induction for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukaemia","route":"/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22960745/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-squamous-nature-2012","kind":"paper","name":"Comprehensive genomic characterization of squamous cell lung cancers","route":"/key-papers/paper-tcga-lung-squamous-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22964741/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012","kind":"paper","name":"ANBL00P2: expectant observation as primary therapy for neuroblastoma in young infants","route":"/key-papers/paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22967994/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nordic-nec-sorbye-ann-oncol-2013","kind":"paper","name":"NORDIC NEC: predictive and prognostic factors in 305 patients with advanced gastrointestinal neuroendocrine carcinoma","route":"/key-papers/paper-nordic-nec-sorbye-ann-oncol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/22995653/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2012","kind":"paper","name":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23000897/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23071237/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23071247/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-9402-cairncross-jco-2013","kind":"paper","name":"RTOG 9402: PCV chemotherapy before radiotherapy for anaplastic oligodendroglioma, long-term results","route":"/key-papers/paper-rtog-9402-cairncross-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23091096/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012","kind":"paper","name":"AEWS0031: randomised trial of interval-compressed chemotherapy for localised Ewing sarcoma","route":"/key-papers/paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23152265/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-burden-cochrane-database-syst-rev","kind":"paper","name":"Pre-operative nutrition support in patients undergoing gastrointestinal surgery","route":"/key-papers/paper-burden-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23177514/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-grothey-correct-regorafenib-lancet-2013","kind":"paper","name":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)","route":"/key-papers/paper-grothey-correct-regorafenib-lancet-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23177515/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-grid-regorafenib-gist-lancet-2013","kind":"paper","name":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","route":"/key-papers/paper-grid-regorafenib-gist-lancet-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23228172/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-n-engl-j-med-2013","kind":"paper","name":"Abiraterone in metastatic prostate cancer without previous chemotherapy","route":"/key-papers/paper-abiraterone-acetate-prostate-n-engl-j-med-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23306100/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23393428/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","kind":"paper","name":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","route":"/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23442307/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zafar-oncologist","kind":"paper","name":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","route":"/key-papers/paper-zafar-oncologist/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23471912/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chernet-dis-model-mech","kind":"paper","name":"Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model","route":"/key-papers/paper-chernet-dis-model-mech/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23574119/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013","kind":"paper","name":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","route":"/key-papers/paper-dunleavy-da-epoch-r-pmbcl-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23578724/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013","kind":"paper","name":"ACT II: mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for squamous cell carcinoma of the anus","route":"/key-papers/paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23589673/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013","kind":"paper","name":"LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","route":"/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23602601/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23636398/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-endometrial-nature-2013","kind":"paper","name":"Integrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-endometrial-nature-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23649003/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aparicio-aggressive-variant-ccr-2013","kind":"paper","name":"Platinum-based chemotherapy for variant castration-resistant prostate cancer (aggressive variant criteria)","route":"/key-papers/paper-aparicio-aggressive-variant-ccr-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23676531/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ramsey-health-aff-millwood","kind":"paper","name":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","route":"/key-papers/paper-ramsey-health-aff-millwood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23690420/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hughes-j-clin-oncol","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","route":"/key-papers/paper-hughes-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23724913/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alk-nsclc-n-engl-j-med-2013","kind":"paper","name":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","route":"/key-papers/paper-alk-nsclc-n-engl-j-med-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23775962/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hodi-imatinib-kit-melanoma-jco-2013","kind":"paper","name":"Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin","route":"/key-papers/paper-hodi-imatinib-kit-melanoma-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23805382/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bozic-elife","kind":"paper","name":"Evolutionary dynamics of cancer in response to targeted combination therapy","route":"/key-papers/paper-bozic-elife/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23831416/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013","kind":"paper","name":"SIOPEL-4: dose-dense cisplatin-based chemotherapy and surgery for high-risk hepatoblastoma","route":"/key-papers/paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23833040/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-landa-j-clin-endocrinol-metab","kind":"paper","name":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","route":"/key-papers/paper-landa-j-clin-endocrinol-metab/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23833309/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013","kind":"paper","name":"Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma","route":"/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23835706/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhukova-tp53-medulloblastoma-jco-2013","kind":"paper","name":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","route":"/key-papers/paper-zhukova-tp53-medulloblastoma-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23863050/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23945072/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23965901/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","kind":"paper","name":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","route":"/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24001104/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014","kind":"paper","name":"Active surveillance of papillary thyroid microcarcinoma at Kuma Hospital: patient age and progression","route":"/key-papers/paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24002501/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-exam-cabozantinib-mtc-elisei-jco-2013","kind":"paper","name":"EXAM: cabozantinib in progressive medullary thyroid cancer","route":"/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24055415/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-haviland-lancet-oncol","kind":"paper","name":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","route":"/key-papers/paper-haviland-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24062397/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-j-clin-oncol-2013","kind":"paper","name":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-j-clin-oncol-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24104372/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013","kind":"paper","name":"CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24149174/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014","kind":"paper","name":"Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study","route":"/key-papers/paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2437455/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-williams-bep-vs-pvb-nejm-1987","kind":"paper","name":"Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide","route":"/key-papers/paper-williams-bep-vs-pvb-nejm-1987/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24430319/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-primrose-jama","kind":"paper","name":"Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial","route":"/key-papers/paper-primrose-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24469108/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014","kind":"paper","name":"CD74-NRG1 fusions in lung adenocarcinoma","route":"/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24493586/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kelley-j-cell-biol","kind":"paper","name":"Traversing the basement membrane in vivo: a diversity of strategies","route":"/key-papers/paper-kelley-j-cell-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24529560/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014","kind":"paper","name":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","route":"/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2453289/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-almoguera-kras-codon-12-pancreatic-cell-1988","kind":"paper","name":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","route":"/key-papers/paper-almoguera-kras-codon-12-pancreatic-cell-1988/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24552318/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-n-engl-j-med-2014","kind":"paper","name":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","route":"/key-papers/paper-olivier-chinot-n-engl-j-med-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24552320/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gog-240-bevacizumab-cervical-nejm-2014","kind":"paper","name":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","route":"/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24572077/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014","kind":"paper","name":"FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24618336/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014","kind":"paper","name":"EORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma","route":"/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24629334/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mesri-cell-host-microbe","kind":"paper","name":"Human viral oncogenesis: a cancer hallmarks analysis","route":"/key-papers/paper-mesri-cell-host-microbe/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24637997/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24645800/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24666267/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pik3ca-colorectal-acta-oncol-2014","kind":"paper","name":"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis","route":"/key-papers/paper-pik3ca-colorectal-acta-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24667714/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","route":"/key-papers/paper-mindact-ann-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24740812/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24768112/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-decision-sorafenib-lancet-2014","kind":"paper","name":"DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-decision-sorafenib-lancet-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24777111/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-howlader-us-incidence-breast-subtypes-jnci-2014","kind":"paper","name":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","route":"/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24794243/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24807107/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sharma-tnbc-registry-germline-brca-bcrt-2014","kind":"paper","name":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing","route":"/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24833561/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barton-radiother-oncol","kind":"paper","name":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012","route":"/key-papers/paper-barton-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24846037/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24856586/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014","kind":"paper","name":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","route":"/key-papers/paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24893135/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014","kind":"paper","name":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","route":"/key-papers/paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24909511/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-acta-pharmacol-sin-2015","kind":"paper","name":"Androgen receptor: structure, role in prostate cancer and drug discovery","route":"/key-papers/paper-androgen-receptor-prostate-acta-pharmacol-sin-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24958821/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kuhl-j-clin-oncol","kind":"paper","name":"Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI","route":"/key-papers/paper-kuhl-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24985407/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-cancer-prev-res-phila-2014","kind":"paper","name":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","route":"/key-papers/paper-andrea-decensi-cancer-prev-res-phila-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25014687/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25079317/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-gastric-nature-2014","kind":"paper","name":"Comprehensive molecular characterisation of gastric adenocarcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-gastric-nature-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25079552/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25088940/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","kind":"paper","name":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","route":"/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25092775/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015","kind":"paper","name":"Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","route":"/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25092781/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aaml0531-gemtuzumab-gamis-jco-2014","kind":"paper","name":"AAML0531: gemtuzumab ozogamicin added to chemotherapy for children and adolescents with acute myeloid leukaemia","route":"/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25104330/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014","kind":"paper","name":"Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma","route":"/key-papers/paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25118602/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sosa-nat-rev-cancer","kind":"paper","name":"Mechanisms of disseminated cancer cell dormancy: an awakening field","route":"/key-papers/paper-sosa-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25155756/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tcga-chromophobe-davis-cancer-cell-2014","kind":"paper","name":"The somatic genomic landscape of chromophobe renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-chromophobe-davis-cancer-cell-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25207766/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roberts-ph-like-all-nejm-2014","kind":"paper","name":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukaemia","route":"/key-papers/paper-roberts-ph-like-all-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25208879/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-burstein-tnbc-genomic-subtypes-ccr-2015","kind":"paper","name":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","route":"/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25231953/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolero-2-ann-oncol-2014-update","kind":"paper","name":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†","route":"/key-papers/paper-bolero-2-ann-oncol-2014-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25240283/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-nat-genet-2014","kind":"paper","name":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","route":"/key-papers/paper-anthony-nichols-nat-genet-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25240821/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014","kind":"paper","name":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer","route":"/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25264305/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25265492/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-combi-d-n-engl-j-med-2014","kind":"paper","name":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","route":"/key-papers/paper-combi-d-n-engl-j-med-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25265494/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cobrim-n-engl-j-med-2014","kind":"paper","name":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","route":"/key-papers/paper-cobrim-n-engl-j-med-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25266736/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014","kind":"paper","name":"Chmielecki 2014: comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","route":"/key-papers/paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25336795/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-indian-j-med-paediatr-oncol","kind":"paper","name":"The national cancer grid of India","route":"/key-papers/paper-pramesh-indian-j-med-paediatr-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25399552/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-braf-melanoma-n-engl-j-med-2015","kind":"paper","name":"Nivolumab in previously untreated melanoma without BRAF mutation","route":"/key-papers/paper-braf-melanoma-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25439693/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-classic-5-year-follow-up-noh-lancet-oncol-2014","kind":"paper","name":"CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25440090/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-trends-mol-med-2015","kind":"paper","name":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","route":"/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25446896/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shelley-hwang-cancer-cell-2014","kind":"paper","name":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","route":"/key-papers/paper-shelley-hwang-cancer-cell-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25452439/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-frazier-j-clin-oncol","kind":"paper","name":"Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States","route":"/key-papers/paper-frazier-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25452441/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-couch-tnbc-germline-17-genes-jco-2015","kind":"paper","name":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","route":"/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25456363/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014","kind":"paper","name":"GETUG 13: personalised chemotherapy based on tumour marker decline in poor-prognosis germ cell tumours","route":"/key-papers/paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25470694/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-solomon-n-engl-j-med","kind":"paper","name":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","route":"/key-papers/paper-solomon-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25495490/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-soft-text-n-engl-j-med-2015","kind":"paper","name":"Adjuvant ovarian suppression in premenopausal breast cancer","route":"/key-papers/paper-soft-text-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25512465/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-klotz-active-surveillance-jco-2015","kind":"paper","name":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)","route":"/key-papers/paper-klotz-active-surveillance-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25517747/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jain-cancer-cell","kind":"paper","name":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","route":"/key-papers/paper-jain-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25524798/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-palbociclib-breast-hr-positive-lancet-oncol-2015","kind":"paper","name":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study","route":"/key-papers/paper-palbociclib-breast-hr-positive-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25533674/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-knowles-nat-rev-cancer","kind":"paper","name":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","route":"/key-papers/paper-knowles-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25554788/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tomasetti-science","kind":"paper","name":"Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions","route":"/key-papers/paper-tomasetti-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25564152/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wang-notch-pest-mutations-tnbc-ccr-2015","kind":"paper","name":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor","route":"/key-papers/paper-wang-notch-pest-mutations-tnbc-ccr-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25565627/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bradt-cochrane-database-syst-rev","kind":"paper","name":"Dance/movement therapy for improving psychological and physical outcomes in cancer patients","route":"/key-papers/paper-bradt-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25568920/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-murray-nat-rev-cancer","kind":"paper","name":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","route":"/key-papers/paper-murray-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25572172/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-cancer-discov-2015","kind":"paper","name":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","route":"/key-papers/paper-raajit-rampal-cancer-discov-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25601341/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2015","kind":"paper","name":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25642709/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ashkenazi-j-clin-invest","kind":"paper","name":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions","route":"/key-papers/paper-ashkenazi-j-clin-invest/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25646366/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-enets-lung-net-consensus-caplin-ann-oncol-2015","kind":"paper","name":"ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours","route":"/key-papers/paper-enets-lung-net-consensus-caplin-ann-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25665006/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sottoriva-nat-genet","kind":"paper","name":"A Big Bang model of human colorectal tumor growth","route":"/key-papers/paper-sottoriva-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25671254/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-select-lenvatinib-nejm-2015","kind":"paper","name":"SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-select-lenvatinib-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25695955/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25700432/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25716084/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015","kind":"paper","name":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer","route":"/key-papers/paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25719666/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-waddell-whole-genomes-pancreatic-nature-2015","kind":"paper","name":"Whole genomes redefine the mutational landscape of pancreatic cancer","route":"/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25796459/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","kind":"paper","name":"AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse","route":"/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25810047/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015","kind":"paper","name":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","route":"/key-papers/paper-ata-medullary-thyroid-guideline-wells-thyroid-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25901426/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","kind":"paper","name":"RAPID: PET-directed therapy for early-stage Hodgkin lymphoma","route":"/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25918291/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-waart-j-clin-oncol","kind":"paper","name":"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial","route":"/key-papers/paper-van-waart-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25970050/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mayer-recourse-tas-102-nejm-2015","kind":"paper","name":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)","route":"/key-papers/paper-mayer-recourse-tas-102-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25971938/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-frampton-met-exon-14-cancer-discov-2015","kind":"paper","name":"MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors","route":"/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25981810/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolt-sonidegib-migden-lancet-oncol-2015","kind":"paper","name":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma","route":"/key-papers/paper-bolt-sonidegib-migden-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26027431/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26037941/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-combi-d-long-lancet-2015","kind":"paper","name":"COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma","route":"/key-papers/paper-combi-d-long-lancet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26056363/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aktipis-philos-trans-r-soc-lond-b-biol-sci","kind":"paper","name":"Cancer across the tree of life: cooperation and cheating in multicellularity","route":"/key-papers/paper-aktipis-philos-trans-r-soc-lond-b-biol-sci/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26057340/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-freedman-plos-biol","kind":"paper","name":"The Economics of Reproducibility in Preclinical Research","route":"/key-papers/paper-freedman-plos-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26069186/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","kind":"paper","name":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","route":"/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26113086/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yurkovetskiy-cancer-res","kind":"paper","name":"A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy","route":"/key-papers/paper-yurkovetskiy-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26113608/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-heetfeld-grade-3-net-erc-2015","kind":"paper","name":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","route":"/key-papers/paper-heetfeld-grade-3-net-erc-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26168399/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26169613/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015","kind":"paper","name":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)","route":"/key-papers/paper-robinson-vismodegib-shh-medulloblastoma-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26169616/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-smith-j-clin-oncol","kind":"paper","name":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-smith-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26200977/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ma-20-n-engl-j-med-2015","kind":"paper","name":"Regional Nodal Irradiation in Early-Stage Breast Cancer","route":"/key-papers/paper-ma-20-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26200978/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-n-engl-j-med-2015","kind":"paper","name":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer","route":"/key-papers/paper-eortc-22922-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26205583/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wherry-nat-rev-immunol","kind":"paper","name":"Molecular and cellular insights into T cell exhaustion","route":"/key-papers/paper-wherry-nat-rev-immunol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26240224/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-r-iss-palumbo-jco-2015","kind":"paper","name":"Revised International Staging System (R-ISS) for multiple myeloma","route":"/key-papers/paper-r-iss-palumbo-jco-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26244877/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chaarted-nejm-2015","kind":"paper","name":"CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-chaarted-nejm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26272768/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015","kind":"paper","name":"Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a randomised, active-controlled, double-blind, phase 3 trial","route":"/key-papers/paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26287849/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-braf-thyroid-n-engl-j-med-2015","kind":"paper","name":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","route":"/key-papers/paper-braf-thyroid-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26302388/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mccollough-radiology","kind":"paper","name":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications","route":"/key-papers/paper-mccollough-radiology/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26304905/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mao-j-clin-oncol-2015","kind":"paper","name":"Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial","route":"/key-papers/paper-mao-j-clin-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26311728/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015","kind":"paper","name":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","route":"/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26314779/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015","kind":"paper","name":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26338525/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","kind":"paper","name":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE","route":"/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26343385/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015","kind":"paper","name":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26361969/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015","kind":"paper","name":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma","route":"/key-papers/paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26371143/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trabectedin-vs-dacarbazine-demetri-jco-2016","kind":"paper","name":"Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure","route":"/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26399631/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jacques-grill-acta-neuropathol-2015","kind":"paper","name":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","route":"/key-papers/paper-jacques-grill-acta-neuropathol-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26434673/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-johnson-sleep-med-rev","kind":"paper","name":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors","route":"/key-papers/paper-johnson-sleep-med-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26457759/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cms-guinney-nat-med-2015","kind":"paper","name":"The consensus molecular subtypes of colorectal cancer","route":"/key-papers/paper-cms-guinney-nat-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26462967/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016","kind":"paper","name":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","route":"/key-papers/paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26492181/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016","kind":"paper","name":"PSOGI consensus for classification and pathological reporting of pseudomyxoma peritonei and associated appendiceal neoplasia","route":"/key-papers/paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26503962/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-cancer-discov-2016","kind":"paper","name":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","route":"/key-papers/paper-mesothelin-mesothelioma-cancer-discov-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26514947/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bouvard-lancet-oncol","kind":"paper","name":"Carcinogenicity of consumption of red and processed meat","route":"/key-papers/paper-bouvard-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26558876/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pd-1-nsclc-am-j-clin-oncol-2016","kind":"paper","name":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","route":"/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26563462/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-androgen-receptor-prostate-nat-rev-cancer-2015","kind":"paper","name":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-nat-rev-cancer-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26581137/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nagata-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403","route":"/key-papers/paper-nagata-int-j-radiat-oncol-biol-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26598545/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gebhart-ann-oncol","kind":"paper","name":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","route":"/key-papers/paper-gebhart-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26615328/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","kind":"paper","name":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","route":"/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26639149/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jan-burger-n-engl-j-med-2015","kind":"paper","name":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","route":"/key-papers/paper-jan-burger-n-engl-j-med-2015/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26690310/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","kind":"paper","name":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","route":"/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26694935/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-morvan-nat-rev-cancer","kind":"paper","name":"NK cells and cancer: you can teach innate cells new tricks","route":"/key-papers/paper-morvan-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26698910/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shaw-alk-l1198f-resensitisation-nejm-2016","kind":"paper","name":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","route":"/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26703889/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-radiant-4-everolimus-lancet-2016","kind":"paper","name":"RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract","route":"/key-papers/paper-radiant-4-everolimus-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26718929/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","kind":"paper","name":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","route":"/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26727100/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016","kind":"paper","name":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG)","route":"/key-papers/paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26729443/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2673568/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paget-cancer-metastasis-rev","kind":"paper","name":"The distribution of secondary growths in cancer of the breast. 1889","route":"/key-papers/paper-paget-cancer-metastasis-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26794930/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aspen-armstrong-lancet-oncol-2016","kind":"paper","name":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","route":"/key-papers/paper-aspen-armstrong-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26811521/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ramsey-j-clin-oncol","kind":"paper","name":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer","route":"/key-papers/paper-ramsey-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2681557/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-calvert-j-clin-oncol","kind":"paper","name":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","route":"/key-papers/paper-calvert-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26855148/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26874885/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26903579/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-scher-j-clin-oncol","kind":"paper","name":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","route":"/key-papers/paper-scher-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26909576/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bailey-molecular-subtypes-pancreatic-nature-2016","kind":"paper","name":"Genomic analyses identify molecular subtypes of pancreatic cancer","route":"/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26919435/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jacques-grill-cell-2016","kind":"paper","name":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","route":"/key-papers/paper-jacques-grill-cell-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26950094/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bonilla-nat-genet","kind":"paper","name":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","route":"/key-papers/paper-bonilla-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26957554/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-telli-hrd-score-platinum-tnbc-ccr-2016","kind":"paper","name":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","route":"/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26966089/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-emile-revised-classification-of-histiocytoses-blood-2016","kind":"paper","name":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","route":"/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26970723/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-lancet-2016","kind":"paper","name":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26982367/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mlecnik-immunoscore-msi-colorectal-immunity-2016","kind":"paper","name":"Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability","route":"/key-papers/paper-mlecnik-immunoscore-msi-colorectal-immunity-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/26988909/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chernet-oncotarget","kind":"paper","name":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis","route":"/key-papers/paper-chernet-oncotarget/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27026201/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ogitani-clin-cancer-res","kind":"paper","name":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","route":"/key-papers/paper-ogitani-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27032109/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-marinac-jama-oncol","kind":"paper","name":"Prolonged Nightly Fasting and Breast Cancer Prognosis","route":"/key-papers/paper-marinac-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27045603/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jin-cochrane-database-syst-rev","kind":"paper","name":"Ganoderma lucidum (Reishi mushroom) for cancer treatment","route":"/key-papers/paper-jin-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27093365/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27108243/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27114587/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall0232-larsen-jco-2016","kind":"paper","name":"AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0232-larsen-jco-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27123955/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bennett-cochrane-database-syst-rev","kind":"paper","name":"Hyperbaric oxygen therapy for late radiation tissue injury","route":"/key-papers/paper-bennett-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27125352/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shain-nat-rev-cancer","kind":"paper","name":"From melanocytes to melanomas","route":"/key-papers/paper-shain-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27132696/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016","kind":"paper","name":"IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27139057/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016","kind":"paper","name":"LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine","route":"/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27166974/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ogitani-cancer-sci","kind":"paper","name":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","route":"/key-papers/paper-ogitani-cancer-sci/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27179402/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27225120/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chen-nature-2016","kind":"paper","name":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","route":"/key-papers/paper-chen-nature-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27247218/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schnipper-j-clin-oncol","kind":"paper","name":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","route":"/key-papers/paper-schnipper-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27283860/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27291997/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-robin-jones-lancet-2016","kind":"paper","name":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","route":"/key-papers/paper-robin-jones-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27297790/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27310713/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","kind":"paper","name":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","route":"/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27318851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-loomis-lancet-oncol","kind":"paper","name":"Carcinogenicity of drinking coffee, mate, and very hot beverages","route":"/key-papers/paper-loomis-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27332902/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27339115/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chhip-lancet-oncol-2016","kind":"paper","name":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","route":"/key-papers/paper-chhip-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27355533/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016","kind":"paper","name":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","route":"/key-papers/paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27384348/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","kind":"paper","name":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","route":"/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27410922/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-navari-n-engl-j-med","kind":"paper","name":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","route":"/key-papers/paper-navari-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27432227/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gainor-alk-resistance-mutations-cancer-discov-2016","kind":"paper","name":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","route":"/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27433843/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zaretsky-n-engl-j-med","kind":"paper","name":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","route":"/key-papers/paper-zaretsky-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27458286/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paice-j-clin-oncol","kind":"paper","name":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","route":"/key-papers/paper-paice-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27467945/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gpc3-hcc-oncoimmunology-2016","kind":"paper","name":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","route":"/key-papers/paper-gpc3-hcc-oncoimmunology-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27480103/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27501770/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-villani-lancet-oncol","kind":"paper","name":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","route":"/key-papers/paper-villani-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27528719/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-morrow-j-clin-oncol","kind":"paper","name":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ","route":"/key-papers/paper-morrow-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27550820/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kalluri-nat-rev-cancer","kind":"paper","name":"The biology and function of fibroblasts in cancer","route":"/key-papers/paper-kalluri-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27557300/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cardoso-n-engl-j-med","kind":"paper","name":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","route":"/key-papers/paper-cardoso-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27567279/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016","kind":"paper","name":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27574444/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pd-l1-urothelial-onco-targets-ther-2016","kind":"paper","name":"PD-L1 expression in human cancers and its association with clinical outcomes","route":"/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27592805/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27626136/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-protect-nejm-2016","kind":"paper","name":"ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer","route":"/key-papers/paper-protect-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27637832/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arends-clin-nutr","kind":"paper","name":"ESPEN guidelines on nutrition in cancer patients","route":"/key-papers/paper-arends-clin-nutr/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27658529/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rohrig-nat-rev-cancer","kind":"paper","name":"The multifaceted roles of fatty acid synthesis in cancer","route":"/key-papers/paper-rohrig-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27717303/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2016","kind":"paper","name":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27718784/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-141-ferris-nejm-2016","kind":"paper","name":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","route":"/key-papers/paper-checkmate-141-ferris-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27722750/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","kind":"paper","name":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","route":"/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27799157/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-win-cancer-epidemiol-biomarkers-prev","kind":"paper","name":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer","route":"/key-papers/paper-win-cancer-epidemiol-biomarkers-prev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27811275/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","kind":"paper","name":"Mutational signatures associated with tobacco smoking in human cancer","route":"/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27863199/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mesothelin-mesothelioma-j-clin-oncol-2016","kind":"paper","name":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","route":"/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27959613/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paloma-2-n-engl-j-med-2016","kind":"paper","name":"Palbociclib and Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-paloma-2-n-engl-j-med-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27959635/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aster-annu-rev-pathol","kind":"paper","name":"The Varied Roles of Notch in Cancer","route":"/key-papers/paper-aster-annu-rev-pathol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27959700/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2017","kind":"paper","name":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27979383/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-lancet-2017","kind":"paper","name":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27979832/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-demaria-cancer-discov","kind":"paper","name":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","route":"/key-papers/paper-demaria-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27992268/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017","kind":"paper","name":"PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphoproliferative disorder","route":"/key-papers/paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28034065/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ferrell-j-clin-oncol","kind":"paper","name":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-ferrell-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28045199/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cramer-cochrane-database-syst-rev","kind":"paper","name":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer","route":"/key-papers/paper-cramer-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28056206/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dangelo-mucosal-melanoma-pooled-jco-2017","kind":"paper","name":"Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis","route":"/key-papers/paper-dangelo-mucosal-melanoma-pooled-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28061006/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-promise-talhouk-cancer-2017","kind":"paper","name":"Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer","route":"/key-papers/paper-promise-talhouk-cancer-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28067913/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-nat-genet-2017","kind":"paper","name":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","route":"/key-papers/paper-anthony-nichols-nat-genet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28084339/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","kind":"paper","name":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28129987/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017","kind":"paper","name":"ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer","route":"/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28135148/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-symmans-rcb-long-term-prognosis-subtype-jco-2017","kind":"paper","name":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","route":"/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28138153/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-griffith-nat-genet","kind":"paper","name":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","route":"/key-papers/paper-griffith-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28147224/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jun-gastroenterology","kind":"paper","name":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality","route":"/key-papers/paper-jun-gastroenterology/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28178237/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-turner-nature","kind":"paper","name":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","route":"/key-papers/paper-turner-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28187284/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcgranahan-cell","kind":"paper","name":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","route":"/key-papers/paper-mcgranahan-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28187285/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bradner-cell","kind":"paper","name":"Transcriptional Addiction in Cancer","route":"/key-papers/paper-bradner-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28215665/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hera-b31-n9831-lancet-2017-update","kind":"paper","name":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","route":"/key-papers/paper-hera-b31-n9831-lancet-2017-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28221866/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","kind":"paper","name":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","route":"/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28223062/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017","kind":"paper","name":"NCI9673: nivolumab for previously treated unresectable metastatic anal cancer","route":"/key-papers/paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28259608/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017","kind":"paper","name":"HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma","route":"/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28288110/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-davies-nat-med","kind":"paper","name":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","route":"/key-papers/paper-davies-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28291390/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017","kind":"paper","name":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28336552/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28404093/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016","kind":"paper","name":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer","route":"/key-papers/paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28407110/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/2841597/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","kind":"paper","name":"Genetic alterations during colorectal-tumor development","route":"/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28467829/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hayward-melanoma-whole-genome-nature-2017","kind":"paper","name":"Whole-genome landscapes of major melanoma subtypes","route":"/key-papers/paper-hayward-melanoma-whole-genome-nature-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28472234/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-huo-tcga-ancestry-breast-jama-oncol-2017","kind":"paper","name":"Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas","route":"/key-papers/paper-huo-tcga-ancestry-breast-jama-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28486044/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jones-non-v600-braf-colorectal-jco-2017","kind":"paper","name":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","route":"/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28498782/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lee-clonal-history-small-cell-transformation-jco-2017","kind":"paper","name":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","route":"/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28499583/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-isg-sts-1001-gronchi-lancet-oncol-2017","kind":"paper","name":"ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma","route":"/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28511673/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-erivance-bmc-cancer-2017-update","kind":"paper","name":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","route":"/key-papers/paper-erivance-bmc-cancer-2017-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28512351/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chang-nat-rev-mol-cell-biol","kind":"paper","name":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","route":"/key-papers/paper-chang-nat-rev-mol-cell-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28549783/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","kind":"paper","name":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","route":"/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28564564/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28578607/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-latitude-nejm-2017","kind":"paper","name":"LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-latitude-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28580882/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02107703-j-clin-oncol-2017","kind":"paper","name":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","route":"/key-papers/paper-nct02107703-j-clin-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28586279/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28591523/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mslt-ii-faries-nejm-2017","kind":"paper","name":"MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma","route":"/key-papers/paper-mslt-ii-faries-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28600132/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28609654/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017","kind":"paper","name":"Intertumoural heterogeneity within medulloblastoma subgroups","route":"/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28636851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-026-first-line-nivolumab-nejm-2017","kind":"paper","name":"CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer","route":"/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28649001/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","kind":"paper","name":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report","route":"/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28678785/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-viswanathan-nature","kind":"paper","name":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","route":"/key-papers/paper-viswanathan-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28705916/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pandit-taskar-j-nucl-med","kind":"paper","name":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","route":"/key-papers/paper-pandit-taskar-j-nucl-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28715532/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","kind":"paper","name":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","route":"/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28735806/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017","kind":"paper","name":"Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)","route":"/key-papers/paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28741564/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-obenauf-trends-cancer","kind":"paper","name":"Surviving at a Distance: Organ-Specific Metastasis","route":"/key-papers/paper-obenauf-trends-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28776080/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-diabetologia-2017","kind":"paper","name":"Repurposing metformin for the prevention of cancer and cancer recurrence","route":"/key-papers/paper-andrea-decensi-diabetologia-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28779963/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-coles-lancet","kind":"paper","name":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","route":"/key-papers/paper-coles-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28800861/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","kind":"paper","name":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28846163/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","kind":"paper","name":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","route":"/key-papers/paper-bolt-j-eur-acad-dermatol-venereol-2018-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28855077/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ridker-lancet","kind":"paper","name":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-ridker-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28890946/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chakravarty-jco-precis-oncol","kind":"paper","name":"OncoKB: A Precision Oncology Knowledge Base","route":"/key-papers/paper-chakravarty-jco-precis-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28891408/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-combi-ad-nejm-2017","kind":"paper","name":"COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","route":"/key-papers/paper-combi-ad-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28891423/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-238-nejm-2017","kind":"paper","name":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","route":"/key-papers/paper-checkmate-238-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28919011/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017","kind":"paper","name":"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28968170/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kim-j-clin-oncol","kind":"paper","name":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","route":"/key-papers/paper-kim-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28976863/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017","kind":"paper","name":"GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma","route":"/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28985214/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-batlle-nat-med","kind":"paper","name":"Cancer stem cells revisited","route":"/key-papers/paper-batlle-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28988646/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017","kind":"paper","name":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","route":"/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29028110/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ajcc-8-melanoma-gershenwald-ca-2017","kind":"paper","name":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","route":"/key-papers/paper-ajcc-8-melanoma-gershenwald-ca-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29033130/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shailender-bhatia-cell-2017","kind":"paper","name":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","route":"/key-papers/paper-shailender-bhatia-cell-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29035643/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-poznak-j-clin-oncol","kind":"paper","name":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","route":"/key-papers/paper-van-poznak-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29051371/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zahalka-science","kind":"paper","name":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","route":"/key-papers/paper-zahalka-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29054815/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017","kind":"paper","name":"IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29056346/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-martincorena-cell","kind":"paper","name":"Universal Patterns of Selection in Cancer and Somatic Tissues","route":"/key-papers/paper-martincorena-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29072975/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","kind":"paper","name":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","route":"/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29089357/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","kind":"paper","name":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","route":"/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29092024/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cardoso-ann-oncol","kind":"paper","name":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","route":"/key-papers/paper-cardoso-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29117335/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-ann-oncol-2017","kind":"paper","name":"Improved survival using specialized multidisciplinary board in sarcoma patients","route":"/key-papers/paper-florence-duffaud-ann-oncol-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29124875/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-egfr-glioblastoma-mol-oncol-2018","kind":"paper","name":"Emerging functions of the EGFR in cancer","route":"/key-papers/paper-egfr-glioblastoma-mol-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29167102/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-poole-bmj","kind":"paper","name":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","route":"/key-papers/paper-poole-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29175149/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29180604/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-loree-tumour-location-continuum-colorectal-ccr-2018","kind":"paper","name":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","route":"/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29188284/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018","kind":"paper","name":"VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis","route":"/key-papers/paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29233559/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018","kind":"paper","name":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","route":"/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29248236/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","kind":"paper","name":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29260225/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stupp-jama","kind":"paper","name":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","route":"/key-papers/paper-stupp-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29298756/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zammarchi-blood","kind":"paper","name":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","route":"/key-papers/paper-zammarchi-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29320312/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hainsworth-j-clin-oncol","kind":"paper","name":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-hainsworth-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29337640/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29343557/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schultz-clin-cancer-res","kind":"paper","name":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies","route":"/key-papers/paper-schultz-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29347993/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29365031/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29367431/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018","kind":"paper","name":"Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations","route":"/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29373071/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-traina-enzalutamide-ar-tnbc-jco-2018","kind":"paper","name":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","route":"/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29395863/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018","kind":"paper","name":"Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study","route":"/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29396253/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29420164/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-spartan-nejm-2018","kind":"paper","name":"SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-spartan-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29433850/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-reflect-lenvatinib-lancet-2018","kind":"paper","name":"REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma","route":"/key-papers/paper-reflect-lenvatinib-lancet-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29440149/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-solheim-bmj-support-palliat-care","kind":"paper","name":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","route":"/key-papers/paper-solheim-bmj-support-palliat-care/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29443960/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mariathasan-nature","kind":"paper","name":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","route":"/key-papers/paper-mariathasan-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29444771/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fiolet-bmj","kind":"paper","name":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort","route":"/key-papers/paper-fiolet-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29449189/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","route":"/key-papers/paper-portec-3-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29466156/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-drilon-larotrectinib-nejm-2018","kind":"paper","name":"Larotrectinib in TRK fusion-positive cancers in adults and children","route":"/key-papers/paper-drilon-larotrectinib-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29474446/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ghaffarizadeh-plos-comput-biol","kind":"paper","name":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems","route":"/key-papers/paper-ghaffarizadeh-plos-comput-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29501363/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29509546/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-makvandi-j-clin-invest","kind":"paper","name":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","route":"/key-papers/paper-makvandi-j-clin-invest/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29550029/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wilson-lancet","kind":"paper","name":"Access to pathology and laboratory medicine services: a crucial gap","route":"/key-papers/paper-wilson-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29552975/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-precision-mri-targeted-biopsy-nejm-2018","kind":"paper","name":"PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis","route":"/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29562145/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-214-nejm-2018","kind":"paper","name":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","route":"/key-papers/paper-checkmate-214-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29573941/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-columbus-lancet-oncol-2018","kind":"paper","name":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","route":"/key-papers/paper-columbus-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29577784/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gehl-acta-oncol","kind":"paper","name":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","route":"/key-papers/paper-gehl-acta-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29584546/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29590007/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-szmulewitz-j-clin-oncol","kind":"paper","name":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","route":"/key-papers/paper-szmulewitz-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29620997/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-oktay-j-clin-oncol","kind":"paper","name":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-oktay-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29641806/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-jama-dermatol","kind":"paper","name":"Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer","route":"/key-papers/paper-freites-martinez-jama-dermatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29643473/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-robey-nat-rev-cancer","kind":"paper","name":"Revisiting the role of ABC transporters in multidrug-resistant cancer","route":"/key-papers/paper-robey-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29644658/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","kind":"paper","name":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","route":"/key-papers/paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29658430/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-054-eggermont-nejm-2018","kind":"paper","name":"KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma","route":"/key-papers/paper-keynote-054-eggermont-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29659330/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol-2018","kind":"paper","name":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study","route":"/key-papers/paper-dix-j-clin-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29660423/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-freites-martinez-j-am-acad-dermatol","kind":"paper","name":"Hair disorders in cancer survivors","route":"/key-papers/paper-freites-martinez-j-am-acad-dermatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29713086/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29720485/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","kind":"paper","name":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","route":"/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29726819/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-ovarian-mol-cancer-ther-2018","kind":"paper","name":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","route":"/key-papers/paper-ezh2-ovarian-mol-cancer-ther-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29746229/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ishigami-j-clin-oncol","kind":"paper","name":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","route":"/key-papers/paper-ishigami-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29773717/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-cancer-discov-2018","kind":"paper","name":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","route":"/key-papers/paper-kras-nsclc-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29775599/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","kind":"paper","name":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes","route":"/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29782209/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mohile-j-clin-oncol","kind":"paper","name":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","route":"/key-papers/paper-mohile-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29800747/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-blueprint-phase-2-pd-l1-assays-jto-2018","kind":"paper","name":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","route":"/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29803839/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-canto-caps-long-term-surveillance-gastroenterology-2018","kind":"paper","name":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","route":"/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29846122/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wolff-j-clin-oncol-2018","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","route":"/key-papers/paper-wolff-j-clin-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29846498/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-robin-jones-ann-oncol-2018","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-robin-jones-ann-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29863974/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-graall-2005-huguet-jco-2018","kind":"paper","name":"GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol","route":"/key-papers/paper-graall-2005-huguet-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29863979/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-cemiplimab-migden-nejm-2018","kind":"paper","name":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","route":"/key-papers/paper-empower-cscc-1-cemiplimab-migden-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29889605/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lyman-j-clin-oncol","kind":"paper","name":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline","route":"/key-papers/paper-lyman-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29891538/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018","kind":"paper","name":"NY-ESO-1 c259 T-cell receptor therapy in synovial sarcoma: prolonged persistence and antitumour activity","route":"/key-papers/paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29922827/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","kind":"paper","name":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","route":"/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29924336/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hanai-j-natl-cancer-inst","kind":"paper","name":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial","route":"/key-papers/paper-hanai-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29945191/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tetzlaff-ann-oncol","kind":"paper","name":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","route":"/key-papers/paper-tetzlaff-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29949494/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prosper-nejm-2018","kind":"paper","name":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-prosper-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29985747/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aggarwal-t-sccpc-jco-2018","kind":"paper","name":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","route":"/key-papers/paper-aggarwal-t-sccpc-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30073261/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","kind":"paper","name":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","route":"/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30078747/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kahles-cancer-cell","kind":"paper","name":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","route":"/key-papers/paper-kahles-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30082870/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gandara-blood-tmb-atezolizumab-nat-med-2018","kind":"paper","name":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","route":"/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30099541/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shimelis-tnbc-risk-genes-jnci-2018","kind":"paper","name":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","route":"/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30100375/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30110579/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-embraca-n-engl-j-med-2018","kind":"paper","name":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","route":"/key-papers/paper-embraca-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30125215/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kurtz-j-clin-oncol","kind":"paper","name":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-kurtz-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30130155/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zheng-nigerian-inherited-breast-cancer-jco-2018","kind":"paper","name":"Inherited breast cancer in Nigerian women","route":"/key-papers/paper-zheng-nigerian-inherited-breast-cancer-jco-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30134131/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-n-engl-j-med-2018","kind":"paper","name":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","route":"/key-papers/paper-checkmate-204-n-engl-j-med-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30168576/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wei-cochrane-database-syst-rev","kind":"paper","name":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer","route":"/key-papers/paper-wei-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30184451/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018","kind":"paper","name":"RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma","route":"/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30219628/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30262472/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-albrengues-science","kind":"paper","name":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","route":"/key-papers/paper-albrengues-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30266309/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-boeve-eur-urol","kind":"paper","name":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","route":"/key-papers/paper-boeve-eur-urol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30291194/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30299884/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018","kind":"paper","name":"European Society of Endocrinology and ENSAT clinical practice guidelines on the management of adrenocortical carcinoma in adults","route":"/key-papers/paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30306589/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","kind":"paper","name":"FIGO Cancer Report 2018: cancer of the vagina","route":"/key-papers/paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30325992/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","kind":"paper","name":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","route":"/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30335131/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30348537/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-henricks-lancet-oncol","kind":"paper","name":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","route":"/key-papers/paper-henricks-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30355464/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-parker-lancet","kind":"paper","name":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","route":"/key-papers/paper-parker-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30377213/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-castroviejo-bermejo-embo-mol-med","kind":"paper","name":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","route":"/key-papers/paper-castroviejo-bermejo-embo-mol-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30380365/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lacc-nejm-2018","kind":"paper","name":"LACC: minimally invasive versus open radical hysterectomy for early cervical cancer","route":"/key-papers/paper-lacc-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30385188/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","kind":"paper","name":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","route":"/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30413379/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-train-2-lancet-oncol-2018","kind":"paper","name":"TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade","route":"/key-papers/paper-train-2-lancet-oncol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30449623/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-de-escalate-lancet-2019","kind":"paper","name":"De-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer","route":"/key-papers/paper-de-escalate-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30449625/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rtog-1016-lancet-2019","kind":"paper","name":"NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer","route":"/key-papers/paper-rtog-1016-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30452336/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019","kind":"paper","name":"Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma","route":"/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30477937/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-lancet-oncol-2019","kind":"paper","name":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30489609/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chen-jama-oncol","kind":"paper","name":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","route":"/key-papers/paper-chen-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30501871/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018","kind":"paper","name":"EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL","route":"/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30509740/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30550363/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30554720/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mavaddat-am-j-hum-genet","kind":"paper","name":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","route":"/key-papers/paper-mavaddat-am-j-hum-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30575490/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018","kind":"paper","name":"PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer","route":"/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30615549/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-amit-induction-chemotherapy-response-snuc-jco-2019","kind":"paper","name":"Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30632023/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paloma-2-breast-cancer-res-treat-2019-update","kind":"paper","name":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","route":"/key-papers/paper-paloma-2-breast-cancer-res-treat-2019-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30650045/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30653423/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019","kind":"paper","name":"Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary","route":"/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30655533/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30658992/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stock-blood","kind":"paper","name":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","route":"/key-papers/paper-stock-blood/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30670598/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-taha-oncologist","kind":"paper","name":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies","route":"/key-papers/paper-taha-oncologist/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30689707/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olympiad-ann-oncol-2019-update","kind":"paper","name":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","route":"/key-papers/paper-olympiad-ann-oncol-2019-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30730546/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-klass-01-kim-jama-oncol-2019","kind":"paper","name":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","route":"/key-papers/paper-klass-01-kim-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30733314/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-badawi-j-nucl-med","kind":"paper","name":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner","route":"/key-papers/paper-badawi-j-nucl-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30739743/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019","kind":"paper","name":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30753167/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","kind":"paper","name":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","route":"/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30760854/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shay-nat-rev-genet","kind":"paper","name":"Telomeres and telomerase: three decades of progress","route":"/key-papers/paper-shay-nat-rev-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30763142/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aramis-nejm-2019","kind":"paper","name":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-aramis-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30786188/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019","kind":"paper","name":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30792530/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","kind":"paper","name":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","route":"/key-papers/paper-froeling-pstt-ett-intensified-therapy-bjc-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30811284/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019","kind":"paper","name":"ACNS0121: conformal radiotherapy for paediatric ependymoma, chemotherapy for incompletely resected tumours and observation after complete resection","route":"/key-papers/paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30824296/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hugosson-eur-urol","kind":"paper","name":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","route":"/key-papers/paper-hugosson-eur-urol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30853353/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30857956/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30892989/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","kind":"paper","name":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","route":"/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30897038/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30917260/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-morice-mucinous-ovarian-carcinoma-nejm-2019","kind":"paper","name":"Mucinous ovarian carcinoma (review)","route":"/key-papers/paper-morice-mucinous-ovarian-carcinoma-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30922733/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bilcap-lancet-oncol-2019","kind":"paper","name":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","route":"/key-papers/paper-bilcap-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30926931/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30930117/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shelley-hwang-cancer-cell-2019","kind":"paper","name":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","route":"/key-papers/paper-shelley-hwang-cancer-cell-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30954939/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kratochwil-j-nucl-med","kind":"paper","name":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer","route":"/key-papers/paper-kratochwil-j-nucl-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30971823/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chan-nature","kind":"paper","name":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","route":"/key-papers/paper-chan-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30982686/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-flot4-lancet-2019","kind":"paper","name":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-flot4-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30988079/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","kind":"paper","name":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","route":"/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30988082/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","kind":"paper","name":"Detection of NRG1 gene fusions in solid tumors","route":"/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31003911/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019","kind":"paper","name":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)","route":"/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31011206/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sicklick-nat-med","kind":"paper","name":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","route":"/key-papers/paper-sicklick-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31027636/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cardenas-semin-radiat-oncol","kind":"paper","name":"Advances in Auto-Segmentation","route":"/key-papers/paper-cardenas-semin-radiat-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3103454/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","field":"prevalence.source"},{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","field":"prevalence.source"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31036468/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jiang-lancet-oncol","kind":"paper","name":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-jiang-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31068372/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","kind":"paper","name":"Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","route":"/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31070691/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019","kind":"paper","name":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","route":"/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31076762/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rennert-neurosurgery","kind":"paper","name":"Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization","route":"/key-papers/paper-rennert-neurosurgery/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31091374/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-solar-1-alpelisib-nejm-2019","kind":"paper","name":"SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-solar-1-alpelisib-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31118521/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bertucci-metastatic-breast-genomics-nature-2019","kind":"paper","name":"Genomic characterization of metastatic breast cancers","route":"/key-papers/paper-bertucci-metastatic-breast-genomics-nature-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31145418/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-murphy-jama-oncol","kind":"paper","name":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","route":"/key-papers/paper-murphy-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31150073/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-metter-jama-netw-open","kind":"paper","name":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017","route":"/key-papers/paper-metter-jama-netw-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31150573/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019","kind":"paper","name":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31157963/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31178152/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31180816/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019","kind":"paper","name":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31196207/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019","kind":"paper","name":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","route":"/key-papers/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31227373/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-widmark-lancet","kind":"paper","name":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","route":"/key-papers/paper-widmark-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31228622/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31240302/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peter-thuss-patience-ann-oncol-2019","kind":"paper","name":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","route":"/key-papers/paper-peter-thuss-patience-ann-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31267971/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alyami-lancet-oncol","kind":"paper","name":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","route":"/key-papers/paper-alyami-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31281097/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-iarc-monographs-vol-124-group-lancet-oncol","kind":"paper","name":"Carcinogenicity of night shift work","route":"/key-papers/paper-iarc-monographs-vol-124-group-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31282032/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-scott-tnbc-disparities-uscs-cancer-2019","kind":"paper","name":"Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014","route":"/key-papers/paper-scott-tnbc-disparities-uscs-cancer-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31283407/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-interfant-06-pieters-jco-2019","kind":"paper","name":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-06-pieters-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31303340/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bourhis-radiother-oncol","kind":"paper","name":"Treatment of a first patient with FLASH-radiotherapy","route":"/key-papers/paper-bourhis-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31315034/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-greten-immunity","kind":"paper","name":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","route":"/key-papers/paper-greten-immunity/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31336704/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31369045/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31386611/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anbl0531-twist-jco-2019","kind":"paper","name":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-anbl0531-twist-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31411950/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-noronha-j-clin-oncol","kind":"paper","name":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer","route":"/key-papers/paper-noronha-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31416685/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anthony-nichols-lancet-oncol-2019","kind":"paper","name":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","route":"/key-papers/paper-anthony-nichols-lancet-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31433515/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020","kind":"paper","name":"The 2019 WHO classification of tumours of the digestive system","route":"/key-papers/paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31439583/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-reidy-lagunes-clin-cancer-res","kind":"paper","name":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan","route":"/key-papers/paper-reidy-lagunes-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31449468/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dix-j-clin-oncol","kind":"paper","name":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report","route":"/key-papers/paper-dix-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31479306/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrea-decensi-j-clin-oncol-2019","kind":"paper","name":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-andrea-decensi-j-clin-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31487218/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-358-j-clin-oncol-2019","kind":"paper","name":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","route":"/key-papers/paper-checkmate-358-j-clin-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31506387/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dll3-sclc-clin-cancer-res-2019","kind":"paper","name":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","route":"/key-papers/paper-dll3-sclc-clin-cancer-res-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31513482/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019","kind":"paper","name":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","route":"/key-papers/paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31513484/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019","kind":"paper","name":"Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)","route":"/key-papers/paper-pietrantonio-msi-gastric-meta-analysis-jco-2019/","field":"links","label":"PubMed"},{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","field":"links","label":"Pietrantonio meta-analysis (JCO 2019)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31534219/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-venkataramani-nature","kind":"paper","name":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","route":"/key-papers/paper-venkataramani-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31545689/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019","kind":"paper","name":"ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours","route":"/key-papers/paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31548545/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31548659/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ben-david-nat-rev-genet","kind":"paper","name":"Context is everything: aneuploidy in cancer","route":"/key-papers/paper-ben-david-nat-rev-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31562796/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keunchil-park-n-engl-j-med-2019","kind":"paper","name":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keunchil-park-n-engl-j-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31562799/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prima-niraparib-nejm-2019","kind":"paper","name":"PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer","route":"/key-papers/paper-prima-niraparib-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31563959/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02107703-jama-oncol-2020-update","kind":"paper","name":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","route":"/key-papers/paper-nct02107703-jama-oncol-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31566309/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","kind":"paper","name":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)","route":"/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31566659/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31570822/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","kind":"paper","name":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","route":"/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31601568/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-autio-clin-cancer-res","kind":"paper","name":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","route":"/key-papers/paper-autio-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31601988/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arvanitis-nat-rev-cancer","kind":"paper","name":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","route":"/key-papers/paper-arvanitis-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31609651/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31626055/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-campbell-med-sci-sports-exerc","kind":"paper","name":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","route":"/key-papers/paper-campbell-med-sci-sports-exerc/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31626571/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020","kind":"paper","name":"Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials","route":"/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31631858/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31645726/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-johnston-nature","kind":"paper","name":"VISTA is an acidic pH-selective ligand for PSGL-1","route":"/key-papers/paper-johnston-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31665482/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bareche-tnbc-microenvironment-jnci-2020","kind":"paper","name":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","route":"/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31672839/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-caps-consortium-surveillance-recommendations-gut-2020","kind":"paper","name":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","route":"/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31682550/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","kind":"paper","name":"KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer","route":"/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31751012/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-osimertinib-nsclc-n-engl-j-med-2020","kind":"paper","name":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31757656/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020","kind":"paper","name":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer","route":"/key-papers/paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31765263/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-azad-j-clin-oncol","kind":"paper","name":"Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study","route":"/key-papers/paper-azad-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31774954/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bakker-n-engl-j-med","kind":"paper","name":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue","route":"/key-papers/paper-bakker-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31786121/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31808921/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garcia-jama-netw-open","kind":"paper","name":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-garcia-jama-netw-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31813636/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31825192/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020","kind":"paper","name":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31838007/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31838015/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-drilon-entrectinib-ros1-lancet-oncol-2020","kind":"paper","name":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials","route":"/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31841354/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schmid-pakt-capivasertib-tnbc-jco-2020","kind":"paper","name":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","route":"/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31855498/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ambrosone-j-clin-oncol","kind":"paper","name":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)","route":"/key-papers/paper-ambrosone-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31907878/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kurata-japanese-tnbc-msi-breast-cancer-2020","kind":"paper","name":"Microsatellite instability in Japanese female patients with triple-negative breast cancer","route":"/key-papers/paper-kurata-japanese-tnbc-msi-breast-cancer-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31908301/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31912792/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31914241/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-amer-zeidan-n-engl-j-med-2020","kind":"paper","name":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","route":"/key-papers/paper-amer-zeidan-n-engl-j-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31942077/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-nature-2020","kind":"paper","name":"B cells are associated with survival and immunotherapy response in sarcoma","route":"/key-papers/paper-antoine-italiano-nature-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31944221/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020","kind":"paper","name":"Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)","route":"/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31952975/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31980749/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sahai-nat-rev-cancer","kind":"paper","name":"A framework for advancing our understanding of cancer-associated fibroblasts","route":"/key-papers/paper-sahai-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32015526/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32017652/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chera-j-clin-oncol","kind":"paper","name":"Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer","route":"/key-papers/paper-chera-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32019858/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","kind":"paper","name":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer","route":"/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32025018/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alexandrov-nature","kind":"paper","name":"The repertoire of mutational signatures in human cancer","route":"/key-papers/paper-alexandrov-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32029509/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aaml1031-bortezomib-aplenc-haematologica-2020","kind":"paper","name":"AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes","route":"/key-papers/paper-aaml1031-bortezomib-aplenc-haematologica-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32053137/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-i-spy-2-jama-oncol-2020","kind":"paper","name":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","route":"/key-papers/paper-i-spy-2-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32058842/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hassett-j-clin-oncol","kind":"paper","name":"Management of Male Breast Cancer: ASCO Guideline","route":"/key-papers/paper-hassett-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32058845/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nrg-cc001-brown-jco-2020","kind":"paper","name":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases","route":"/key-papers/paper-nrg-cc001-brown-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32067680/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020","kind":"paper","name":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","route":"/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32078813/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-florence-duffaud-lancet-oncol-2020","kind":"paper","name":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32096852/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-comstock-jama","kind":"paper","name":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening","route":"/key-papers/paper-comstock-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32101663/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-522-n-engl-j-med-2020","kind":"paper","name":"Pembrolizumab for Early Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32105509/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020","kind":"paper","name":"ACNS0333: high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumour","route":"/key-papers/paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32105518/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32118296/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-filippini-cochrane-database-syst-rev","kind":"paper","name":"Green tea (Camellia sinensis) for the prevention of cancer","route":"/key-papers/paper-filippini-cochrane-database-syst-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32125404/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wouters-jama","kind":"paper","name":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","route":"/key-papers/paper-wouters-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32145827/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020","kind":"paper","name":"ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings","route":"/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32187362/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-erdheim-chester-disease-consensus-recommendations-blood-2020","kind":"paper","name":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era","route":"/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32203698/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fight-202-pemigatinib-lancet-oncol-2020","kind":"paper","name":"FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements","route":"/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/","field":"links","label":"PubMed"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","field":"links","label":"FIGHT-202 (Lancet Oncology 2020)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32209449/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32213531/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nagendran-bmj","kind":"paper","name":"Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies","route":"/key-papers/paper-nagendran-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32215577/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-phillips-jama-oncol","kind":"paper","name":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","route":"/key-papers/paper-phillips-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32243226/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-hereditary-breast-cancer-guideline-jco-2020","kind":"paper","name":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","route":"/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32251400/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32282073/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020","kind":"paper","name":"The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms","route":"/key-papers/paper-chicago-consensus-appendiceal-neoplasms-cancer-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32302564/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monje-cell","kind":"paper","name":"Roadmap for the Emerging Field of Cancer Neuroscience","route":"/key-papers/paper-monje-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32328653/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-neuro-oncol-2020","kind":"paper","name":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","route":"/key-papers/paper-andrew-lassman-neuro-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32335505/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-cancer-treat-rev-2020","kind":"paper","name":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","route":"/key-papers/paper-olivier-chinot-cancer-treat-rev-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32343642/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020","kind":"paper","name":"ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma","route":"/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32343890/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-profound-nejm-2020","kind":"paper","name":"PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations","route":"/key-papers/paper-profound-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32388150/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lievens-radiother-oncol","kind":"paper","name":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","route":"/key-papers/paper-lievens-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32416072/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","field":"links","label":"ClarIDHy (Lancet Oncology 2020)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32424352/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hu-nat-genet","kind":"paper","name":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","route":"/key-papers/paper-hu-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32469182/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-gastric01-nejm-2020","kind":"paper","name":"DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","route":"/key-papers/paper-destiny-gastric01-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32469185/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vision-tepotinib-paik-nejm-2020","kind":"paper","name":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","route":"/key-papers/paper-vision-tepotinib-paik-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32484754/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-palma-j-clin-oncol","kind":"paper","name":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","route":"/key-papers/paper-palma-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32502444/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020","kind":"paper","name":"REMORA: lenvatinib in advanced or metastatic thymic carcinoma","route":"/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32511981/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/","field":"links","label":"PubMed"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","field":"links","label":"INVICTUS (Lancet Oncology 2020)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32515498/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rock-ca-cancer-j-clin","kind":"paper","name":"American Cancer Society guideline for diet and physical activity for cancer prevention","route":"/key-papers/paper-rock-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32522691/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020","kind":"paper","name":"Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients","route":"/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32530769/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020","kind":"paper","name":"InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer","route":"/key-papers/paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32534646/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-2020","kind":"paper","name":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-imspire150-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32576828/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-de-groot-nat-commun","kind":"paper","name":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial","route":"/key-papers/paper-de-groot-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32615108/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-navigator-avapritinib-heinrich-lancet-oncol-2020","kind":"paper","name":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","route":"/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/","field":"links","label":"PubMed"},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","field":"links","label":"NAVIGATOR (Lancet Oncology 2020)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32619561/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-voss-int-j-radiat-oncol-biol-phys","kind":"paper","name":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma","route":"/key-papers/paper-voss-int-j-radiat-oncol-biol-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32644110/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020","kind":"paper","name":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","route":"/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32669708/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-middleton-nature","kind":"paper","name":"The National Lung Matrix Trial of personalized therapy in lung cancer","route":"/key-papers/paper-middleton-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32673170/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020","kind":"paper","name":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32678716/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32706635/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32709715/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schoenfeld-smarca4-alterations-lung-ccr-2020","kind":"paper","name":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","route":"/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32716740/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020","kind":"paper","name":"TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy","route":"/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32749941/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32755482/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32758030/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-salama-j-clin-oncol","kind":"paper","name":"Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","route":"/key-papers/paper-salama-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32761153/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020","kind":"paper","name":"Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition","route":"/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32778876/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mcneil-j-natl-cancer-inst","kind":"paper","name":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults","route":"/key-papers/paper-mcneil-j-natl-cancer-inst/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32816842/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vaidya-bmj","kind":"paper","name":"Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial","route":"/key-papers/paper-vaidya-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32827483/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-patil-lancet-glob-health","kind":"paper","name":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-patil-lancet-glob-health/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32836172/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-clover-eur-j-cancer","kind":"paper","name":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)","route":"/key-papers/paper-clover-eur-j-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32846060/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-libretto-001-selpercatinib-nsclc-nejm-2020","kind":"paper","name":"LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32861308/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32873422/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-centore-trends-genet","kind":"paper","name":"Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","route":"/key-papers/paper-centore-trends-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32877583/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wolf-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32877599/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-combi-ad-n-engl-j-med-2020-update","kind":"paper","name":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","route":"/key-papers/paper-combi-ad-n-engl-j-med-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32880601/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-062-shitara-jama-oncol-2020","kind":"paper","name":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","route":"/key-papers/paper-keynote-062-shitara-jama-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32895401/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020","kind":"paper","name":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","route":"/key-papers/paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32895785/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","field":"links","label":"JCOG1009/1010 (Gastric Cancer 2020)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32919527/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32941794/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-strass-lancet-oncol-2020","kind":"paper","name":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma","route":"/key-papers/paper-strass-lancet-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32961119/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32966830/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-impassion031-lancet-2020","kind":"paper","name":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-impassion031-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32983960/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cldn18-gastric-front-oncol-2020","kind":"paper","name":"The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-cldn18-gastric-front-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32997907/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33002206/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sedrak-ca-cancer-j-clin","kind":"paper","name":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","route":"/key-papers/paper-sedrak-ca-cancer-j-clin/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33002429/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-radicals-rt-lancet-2020","kind":"paper","name":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","route":"/key-papers/paper-radicals-rt-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33011388/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33048619/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-flaherty-j-clin-oncol","kind":"paper","name":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","route":"/key-papers/paper-flaherty-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3308077/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tempero-ca19-9-lewis-antigens-cancer-res-1987","kind":"paper","name":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","route":"/key-papers/paper-tempero-ca19-9-lewis-antigens-cancer-res-1987/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33089726/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021","kind":"paper","name":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33106665/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-burd-nat-med","kind":"paper","name":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","route":"/key-papers/paper-burd-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33107985/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sirolimus-ehe-stacchiotti-cancer-2021","kind":"paper","name":"Activity of sirolimus in progressive epithelioid haemangioendothelioma (Italian Rare Cancer Network)","route":"/key-papers/paper-sirolimus-ehe-stacchiotti-cancer-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33116311/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-raajit-rampal-nature-2020","kind":"paper","name":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","route":"/key-papers/paper-raajit-rampal-nature-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33119479/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-amer-zeidan-j-clin-oncol-2021","kind":"paper","name":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","route":"/key-papers/paper-amer-zeidan-j-clin-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33122355/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nia-science","kind":"paper","name":"Physical traits of cancer","route":"/key-papers/paper-nia-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33152277/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33186684/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hirose-radiother-oncol","kind":"paper","name":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ( 10 B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial","route":"/key-papers/paper-hirose-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33217316/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rubin-mol-cell","kind":"paper","name":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","route":"/key-papers/paper-rubin-mol-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33232761/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021","kind":"paper","name":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","route":"/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33239190/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-ann-oncol-2020","kind":"paper","name":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33246021/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-solar-1-ann-oncol-2021-update","kind":"paper","name":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","route":"/key-papers/paper-solar-1-ann-oncol-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33278935/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-355-lancet-2020","kind":"paper","name":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","route":"/key-papers/paper-keynote-355-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33293629/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olivier-chinot-nat-rev-clin-oncol-2021","kind":"paper","name":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","route":"/key-papers/paper-olivier-chinot-nat-rev-clin-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33301740/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021","kind":"paper","name":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy in locally advanced rectal cancer (RAPIDO)","route":"/key-papers/paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33316117/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tabrizian-am-j-transplant","kind":"paper","name":"PD-1 inhibitor as bridge therapy to liver transplantation?","route":"/key-papers/paper-tabrizian-am-j-transplant/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33333055/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fahrmann-ca19-9-lead-time-gastroenterology-2021","kind":"paper","name":"Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection","route":"/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33338281/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33346298/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cooper-chem-soc-rev","kind":"paper","name":"Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)","route":"/key-papers/paper-cooper-chem-soc-rev/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33358989/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jean-pascal-machiels-ann-oncol-2021","kind":"paper","name":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33369355/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-quazar-aml-001-wei-nejm-2020","kind":"paper","name":"QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission","route":"/key-papers/paper-quazar-aml-001-wei-nejm-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33397968/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33405943/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021","kind":"paper","name":"CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma","route":"/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33460574/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33476595/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021","kind":"paper","name":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)","route":"/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33479224/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33485464/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","field":"outcomes.source (Overall survival)"},{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","route":"/key-papers/paper-checkmate-743-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33497252/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-murthy-j-clin-oncol","kind":"paper","name":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","route":"/key-papers/paper-murthy-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33503393/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tabernero-j-clin-oncol","kind":"paper","name":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","route":"/key-papers/paper-tabernero-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33504648/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yala-sci-transl-med","kind":"paper","name":"Toward robust mammography-based models for breast cancer risk","route":"/key-papers/paper-yala-sci-transl-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33507815/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33539729/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33581820/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-langley-lancet","kind":"paper","name":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","route":"/key-papers/paper-langley-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33592176/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33617303/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","kind":"paper","name":"TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer","route":"/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33650905/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jochelson-radiology","kind":"paper","name":"Contrast-enhanced Mammography: State of the Art","route":"/key-papers/paper-jochelson-radiology/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33651090/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall1331-brown-jama-2021","kind":"paper","name":"AALL1331: blinatumomab versus chemotherapy consolidation in high- and intermediate-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-brown-jama-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33667670/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021","kind":"paper","name":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33684370/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tpextreme-lancet-oncol-2021","kind":"paper","name":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-tpextreme-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33721561/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-piccart-lancet-oncol","kind":"paper","name":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","route":"/key-papers/paper-piccart-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33721562/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma","route":"/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33728999/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021","kind":"paper","name":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","route":"/key-papers/paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33747906/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ren-tnbc-mmr-msi-440-front-oncol-2021","kind":"paper","name":"Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients","route":"/key-papers/paper-ren-tnbc-mmr-msi-440-front-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33789008/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-577-nejm-2021","kind":"paper","name":"CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer","route":"/key-papers/paper-checkmate-577-nejm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33793299/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-penelope-b-j-clin-oncol-2021","kind":"paper","name":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","route":"/key-papers/paper-penelope-b-j-clin-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33822655/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-igcccg-update-gillessen-jco-2021","kind":"paper","name":"IGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours","route":"/key-papers/paper-igcccg-update-gillessen-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33825840/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021","kind":"paper","name":"Estimated Projection of US Cancer Incidence and Death to 2040","route":"/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33826908/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-levin-cell","kind":"paper","name":"Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer","route":"/key-papers/paper-levin-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33845035/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-orecchia-lancet-oncol","kind":"paper","name":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","route":"/key-papers/paper-orecchia-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33845462/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021","kind":"paper","name":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","route":"/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33857412/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33862000/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021","kind":"paper","name":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)","route":"/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33872982/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33879601/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33883178/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021","kind":"paper","name":"ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma","route":"/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3390344/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-withers-acta-oncol","kind":"paper","name":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","route":"/key-papers/paper-withers-acta-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33958435/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021","kind":"paper","name":"Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women","route":"/key-papers/paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33961795/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34000246/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","field":"links","label":"Primary analysis on PubMed"},{"id":"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021","kind":"paper","name":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy","route":"/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34019819/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34090171/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ehe-consensus-stacchiotti-esmo-open-2021","kind":"paper","name":"Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","route":"/key-papers/paper-ehe-consensus-stacchiotti-esmo-open-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34096690/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kras-nsclc-n-engl-j-med-2021","kind":"paper","name":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","route":"/key-papers/paper-kras-nsclc-n-engl-j-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34097070/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34102137/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","field":"links","label":"CheckMate 649 (Lancet 2021)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34106753/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021","kind":"paper","name":"BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome","route":"/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34110925/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns0331-michalski-jco-2021","kind":"paper","name":"ACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma","route":"/key-papers/paper-acns0331-michalski-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34112795/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yamazaki-nat-commun","kind":"paper","name":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","route":"/key-papers/paper-yamazaki-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34116144/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34118197/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arrow-pralsetinib-gainor-lancet-oncol-2021","kind":"paper","name":"ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34175386/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-anal-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34181733/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eano-meningioma-goldbrunner-neuro-oncology-2021","kind":"paper","name":"EANO guideline on the diagnosis and management of meningiomas (2021)","route":"/key-papers/paper-eano-meningioma-goldbrunner-neuro-oncology-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34185076/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-who-2021-cns-louis-neuro-oncology-2021","kind":"paper","name":"The 2021 WHO classification of tumours of the central nervous system: a summary","route":"/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34225076/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021","kind":"paper","name":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34252375/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","kind":"paper","name":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","route":"/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34292305/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34303806/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-sts-guideline-gronchi-ann-oncol-2021","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","route":"/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34319760/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zon-jco-oncol-pract","kind":"paper","name":"Telehealth in Oncology: ASCO Standards and Practice Recommendations","route":"/key-papers/paper-zon-jco-oncol-pract/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34339292/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-park-j-clin-oncol","kind":"paper","name":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","route":"/key-papers/paper-park-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34341537/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fabbri-nat-rev-cancer","kind":"paper","name":"The plasticity of mRNA translation during cancer progression and therapy resistance","route":"/key-papers/paper-fabbri-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34341578/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021","kind":"paper","name":"JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma","route":"/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34391922/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chalasani-clin-gastroenterol-hepatol","kind":"paper","name":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","route":"/key-papers/paper-chalasani-clin-gastroenterol-hepatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34413145/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-farwell-j-nucl-med","kind":"paper","name":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","route":"/key-papers/paper-farwell-j-nucl-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34424113/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-validity-acta-oncol-2021","kind":"paper","name":"Comparability and validity of cancer registry data in the north-west of Russia","route":"/key-papers/paper-barchuk-registry-validity-acta-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34432481/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021","kind":"paper","name":"GROINSS-V II: radiotherapy versus inguinofemoral lymphadenectomy for vulvar cancer with sentinel node micrometastases","route":"/key-papers/paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34454674/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-590-lancet-2021","kind":"paper","name":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","route":"/key-papers/paper-keynote-590-lancet-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34500044/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021","kind":"paper","name":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline","route":"/key-papers/paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34516759/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-adams-j-clin-oncol","kind":"paper","name":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial","route":"/key-papers/paper-adams-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34526366/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-magnolia-zanubrutinib-mzl-ccr-2021","kind":"paper","name":"MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma","route":"/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34529005/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34534429/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-826-nejm-2021","kind":"paper","name":"KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer","route":"/key-papers/paper-keynote-826-nejm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34534430/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-lung01-nejm-2022","kind":"paper","name":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung01-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34538072/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-seligmann-j-clin-oncol","kind":"paper","name":"Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring","route":"/key-papers/paper-seligmann-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34551229/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34625408/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022","kind":"paper","name":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","route":"/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34632252/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-larson-jco-precis-oncol","kind":"paper","name":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","route":"/key-papers/paper-larson-jco-precis-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34637337/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","kind":"paper","name":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34669197/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021","kind":"paper","name":"FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease","route":"/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34678411/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34695605/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","kind":"paper","name":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","route":"/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34699271/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-e3311-transoral-surgery-ferris-jco-2022","kind":"paper","name":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","route":"/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34725325/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","kind":"paper","name":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","route":"/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34737452/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34740862/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34764486/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021","kind":"paper","name":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)","route":"/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34774225/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34801630/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bclc-2022-reig-j-hepatol-2022","kind":"paper","name":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","route":"/key-papers/paper-bclc-2022-reig-j-hepatol-2022/","field":"links","label":"PubMed"},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","field":"links","label":"BCLC 2022 update (J Hepatol)"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","field":"links","label":"BCLC 2022 update (J Hepatol)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34824210/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hu-signal-transduct-target-ther","kind":"paper","name":"The JAK/STAT signaling pathway: from bench to clinic","route":"/key-papers/paper-hu-signal-transduct-target-ther/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34850169/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-acns1123-germinoma-neuro-oncology-2022","kind":"paper","name":"ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma","route":"/key-papers/paper-acns1123-germinoma-neuro-oncology-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34873345/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)","route":"/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34873347/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)","route":"/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34874631/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-desktop-iii-nejm-2021","kind":"paper","name":"DESKTOP III: secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer","route":"/key-papers/paper-desktop-iii-nejm-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34876409/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-friedman-cancer-discov","kind":"paper","name":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-friedman-cancer-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34890214/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-j-clin-oncol-2022","kind":"paper","name":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","route":"/key-papers/paper-luca-gianni-j-clin-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34902335/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022","kind":"paper","name":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","route":"/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34914339/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-rxponder-n-engl-j-med-2021","kind":"paper","name":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","route":"/key-papers/paper-rxponder-n-engl-j-med-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34932393/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-j-clin-oncol-2022","kind":"paper","name":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34941392/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-spencer-science","kind":"paper","name":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","route":"/key-papers/paper-spencer-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34953525/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34990208/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-j-clin-oncol-2022","kind":"paper","name":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","route":"/key-papers/paper-antoine-italiano-j-clin-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35007153/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gog-0261-carcinosarcoma-powell-jco-2022","kind":"paper","name":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","route":"/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35042991/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bekes-nat-rev-drug-discov","kind":"paper","name":"PROTAC targeted protein degraders: the past is prologue","route":"/key-papers/paper-bekes-nat-rev-drug-discov/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35045221/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-775-nejm-2022","kind":"paper","name":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","route":"/key-papers/paper-keynote-775-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35050752/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ahn-jco-precis-oncol","kind":"paper","name":"Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","route":"/key-papers/paper-ahn-jco-precis-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35083924/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-brown-clin-trials","kind":"paper","name":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer","route":"/key-papers/paper-brown-clin-trials/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35084987/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022","kind":"paper","name":"PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer","route":"/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35093516/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","kind":"paper","name":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","route":"/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35108059/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35108470/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-648-nejm-2022","kind":"paper","name":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","route":"/key-papers/paper-checkmate-648-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35118423/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-antoine-italiano-nat-cancer-2021","kind":"paper","name":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","route":"/key-papers/paper-antoine-italiano-nat-cancer-2021/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35121890/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ackerman-nat-cancer","kind":"paper","name":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","route":"/key-papers/paper-ackerman-nat-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35123658/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pavlova-cell-metab-2022","kind":"paper","name":"The hallmarks of cancer metabolism: Still emerging","route":"/key-papers/paper-pavlova-cell-metab-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35179229/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-al-hallaq-med-phys","kind":"paper","name":"AAPM task group report 302: Surface-guided radiotherapy","route":"/key-papers/paper-al-hallaq-med-phys/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35179323/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-arasens-nejm-2022","kind":"paper","name":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-arasens-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35228755/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dizman-nat-med","kind":"paper","name":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","route":"/key-papers/paper-dizman-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35263518/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-estimabl2-leboulleux-nejm-2022","kind":"paper","name":"ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer","route":"/key-papers/paper-estimabl2-leboulleux-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35263519/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monaleesa-2-n-engl-j-med-2022-update","kind":"paper","name":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35271306/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall1231-bortezomib-t-all-teachey-jco-2022","kind":"paper","name":"AALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed","route":"/key-papers/paper-aall1231-bortezomib-t-all-teachey-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35349331/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aaml1031-sorafenib-flt3-pollard-jco-2022","kind":"paper","name":"AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35353553/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-parsons-j-clin-oncol","kind":"paper","name":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial","route":"/key-papers/paper-parsons-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35363510/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eckstein-j-clin-oncol","kind":"paper","name":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial","route":"/key-papers/paper-eckstein-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35367007/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-716-lancet-2022","kind":"paper","name":"KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma","route":"/key-papers/paper-keynote-716-lancet-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/3537791/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dvorak-n-engl-j-med","kind":"paper","name":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","route":"/key-papers/paper-dvorak-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35398754/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-breast-2022","kind":"paper","name":"\"The emerging role of capivasertib in breast cancer\"","route":"/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35417251/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022","kind":"paper","name":"Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update","route":"/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35427471/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35439025/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andre-j-clin-oncol","kind":"paper","name":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-andre-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35443109/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sinicrope-early-onset-crc-nejm-2022","kind":"paper","name":"Increasing incidence of early-onset colorectal cancer (review)","route":"/key-papers/paper-sinicrope-early-onset-crc-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35452273/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-j-clin-oncol","kind":"paper","name":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","route":"/key-papers/paper-herbst-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35576957/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cho-lancet-oncol","kind":"paper","name":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","route":"/key-papers/paper-cho-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35597384/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-pancreatic-pharmacol-res-2022","kind":"paper","name":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade","route":"/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35608580/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-goodwin-jama","kind":"paper","name":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","route":"/key-papers/paper-goodwin-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35648432/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pellacani-jama-dermatol","kind":"paper","name":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial","route":"/key-papers/paper-pellacani-jama-dermatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35657620/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aminian-jama","kind":"paper","name":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity","route":"/key-papers/paper-aminian-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35658002/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-reckamp-j-clin-oncol","kind":"paper","name":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A","route":"/key-papers/paper-reckamp-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35658005/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03785249-n-engl-j-med-2022","kind":"paper","name":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","route":"/key-papers/paper-nct03785249-n-engl-j-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35671774/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","kind":"paper","name":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","route":"/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35676445/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esteva-npj-digit-med","kind":"paper","name":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","route":"/key-papers/paper-esteva-npj-digit-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35704479/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-anchor-anal-hsil-treatment-nejm-2022","kind":"paper","name":"ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV","route":"/key-papers/paper-anchor-anal-hsil-treatment-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35704792/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dbouk-caps5-stage-survival-jco-2022","kind":"paper","name":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","route":"/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35708671/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","kind":"paper","name":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","route":"/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35759724/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","kind":"paper","name":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35789270/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-j-natl-cancer-inst-2022","kind":"paper","name":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","route":"/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35834226/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022","kind":"paper","name":"Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35834777/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35835135/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","kind":"paper","name":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","route":"/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35853783/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-who-2022-gu-moch-eur-urol-2022","kind":"paper","name":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","route":"/key-papers/paper-who-2022-gu-moch-eur-urol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35947817/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/","field":"links","label":"PubMed"},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","field":"links","label":"INTRIGUE (JCO 2022)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35963179/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-powell-esmo-open","kind":"paper","name":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","route":"/key-papers/paper-powell-esmo-open/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35965208/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","field":"links","label":"Netto et al., European Urology 2022: the 2022 WHO classification of tumours of the urinary system and male genital organs, part B (prostate and urinary tract)"},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","field":"links","label":"Netto et al., European Urology 2022: the 2022 WHO classification of tumours of the urinary system and male genital organs, part B (prostate and urinary tract)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35998300/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chesney-j-clin-oncol","kind":"paper","name":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","route":"/key-papers/paper-chesney-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36048453/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","kind":"paper","name":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36121736/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-martini-african-ancestry-tnbc-cancer-discov-2022","kind":"paper","name":"African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent","route":"/key-papers/paper-martini-african-ancestry-tnbc-cancer-discov-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36166727/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dreamseq-jco-2023","kind":"paper","name":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","route":"/key-papers/paper-dreamseq-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36170665/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023","kind":"paper","name":"FGFR2 Inhibition in Cholangiocarcinoma","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36179271/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","field":"links","label":"NEONIPIGA (JCO 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36200421/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36228963/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36265502/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36270461/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-haanen-ann-oncol","kind":"paper","name":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-haanen-ann-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36273324/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mascia-jama-oncol","kind":"paper","name":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","route":"/key-papers/paper-mascia-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36288512/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-a071401-brastianos-jco-2023","kind":"paper","name":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","route":"/key-papers/paper-a071401-brastianos-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36315917/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gupta-jco-precis-oncol","kind":"paper","name":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study","route":"/key-papers/paper-gupta-jco-precis-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36322844/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","kind":"paper","name":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","route":"/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36342574/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023","kind":"paper","name":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","route":"/key-papers/paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023/","field":"links","label":"PubMed"},{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","field":"links","label":"Japanese gastric cancer treatment guidelines 2021 (6th edition)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36423745/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36460017/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36493334/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-soft-text-j-clin-oncol-2023-update","kind":"paper","name":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","route":"/key-papers/paper-soft-text-j-clin-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36493792/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36495879/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast03-lancet-2023-update","kind":"paper","name":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","route":"/key-papers/paper-destiny-breast03-lancet-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36507690/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36521500/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023","kind":"paper","name":"ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36527382/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cai-j-glob-health","kind":"paper","name":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study","route":"/key-papers/paper-cai-j-glob-health/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36546651/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023","kind":"paper","name":"CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","route":"/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36563965/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023","kind":"paper","name":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36621000/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36627445/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bradley-nat-rev-cancer","kind":"paper","name":"RNA splicing dysregulation and the hallmarks of cancer","route":"/key-papers/paper-bradley-nat-rev-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36633877/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kishan-jama-oncol","kind":"paper","name":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","route":"/key-papers/paper-kishan-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36634294/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mikhael-j-clin-oncol","kind":"paper","name":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography","route":"/key-papers/paper-mikhael-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36709038/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-042-tmb-mutations-ann-oncol-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042","route":"/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36716407/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023","kind":"paper","name":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36791159/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kunkler-n-engl-j-med","kind":"paper","name":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","route":"/key-papers/paper-kunkler-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36793385/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-189-407-tmb-jtocrr-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer","route":"/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36856617/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-swog-s1801-n-engl-j-med-2023","kind":"paper","name":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","route":"/key-papers/paper-swog-s1801-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36858723/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36878909/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","kind":"paper","name":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","route":"/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36906413/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","kind":"paper","name":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","route":"/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36912538/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-protect-15-year-nejm-2023","kind":"paper","name":"ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer","route":"/key-papers/paper-protect-15-year-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36917948/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-de-visser-cancer-cell","kind":"paper","name":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","route":"/key-papers/paper-de-visser-cancer-cell/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36972022/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nrg-gy018-nejm-2023","kind":"paper","name":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","route":"/key-papers/paper-nrg-gy018-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37023374/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-badwe-j-clin-oncol","kind":"paper","name":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","route":"/key-papers/paper-badwe-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37068504/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","field":"links","label":"SPOTLIGHT (Lancet 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37071094/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37075781/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-966-lancet-2023","kind":"paper","name":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","route":"/key-papers/paper-keynote-966-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37080223/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-outback-lancet-oncol-2023","kind":"paper","name":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-outback-lancet-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37096188/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37099340/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37099736/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","kind":"paper","name":"KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer","route":"/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37119523/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-luca-gianni-cancer-med-2023","kind":"paper","name":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","route":"/key-papers/paper-luca-gianni-cancer-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37126762/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-harrison-j-clin-oncol","kind":"paper","name":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","route":"/key-papers/paper-harrison-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37133584/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-partridge-n-engl-j-med","kind":"paper","name":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","route":"/key-papers/paper-partridge-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37133585/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","kind":"paper","name":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)","route":"/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37142371/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-attard-lancet-oncol","kind":"paper","name":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","route":"/key-papers/paper-attard-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37142372/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37257143/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aall1331-low-risk-hogan-jco-2023","kind":"paper","name":"AALL1331: blinatumomab added to chemotherapy in low-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-low-risk-hogan-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37270692/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37284804/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wolff-j-clin-oncol","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","route":"/key-papers/paper-wolff-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37331369/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37379158/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","kind":"paper","name":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37414012/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37414899/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37499670/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-qin-lancet","kind":"paper","name":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","route":"/key-papers/paper-qin-lancet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37524953/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/","field":"links","label":"PubMed"},{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","field":"links","label":"GLOW (Nature Medicine 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37541451/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ezh2-sarcoma-biochem-pharmacol-2023","kind":"paper","name":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","route":"/key-papers/paper-ezh2-sarcoma-biochem-pharmacol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37585627/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37619579/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023","kind":"paper","name":"ADIUVO: adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma","route":"/key-papers/paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37633306/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tropics-02-lancet-2023","kind":"paper","name":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-tropics-02-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37643378/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023","kind":"paper","name":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","route":"/key-papers/paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37658205/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keam-mol-diagn-ther","kind":"paper","name":"Equecabtagene Autoleucel: First Approval","route":"/key-papers/paper-keam-mol-diagn-ther/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37672694/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37678671/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37683978/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-st-gallen-2023-consensus-ann-oncol-2023","kind":"paper","name":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","route":"/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37690911/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-screentrustcad-dembrower-lancet-digit-health-2023","kind":"paper","name":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)","route":"/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37733863/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cheng-science","kind":"paper","name":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","route":"/key-papers/paper-cheng-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37751561/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04579380-j-clin-oncol-2023","kind":"paper","name":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","route":"/key-papers/paper-nct04579380-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37773077/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ring-clin-cancer-res","kind":"paper","name":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)","route":"/key-papers/paper-ring-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37774317/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andrew-lassman-j-clin-oncol-2023","kind":"paper","name":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37817263/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","kind":"paper","name":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","route":"/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37845511/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37851874/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-embark-nejm-2023","kind":"paper","name":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","route":"/key-papers/paper-embark-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37853404/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-barchuk-registry-completeness-bmc-cancer-2023","kind":"paper","name":"Completeness of regional cancer registry data in north-west Russia, 2008 to 2017","route":"/key-papers/paper-barchuk-registry-completeness-bmc-cancer-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37864337/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870536/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-pantumor02-jco-2024","kind":"paper","name":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","route":"/key-papers/paper-destiny-pantumor02-jco-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870955/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870969/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-libretto-531-nejm-2023","kind":"paper","name":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","route":"/key-papers/paper-libretto-531-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870973/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-libretto-431-nejm-2023","kind":"paper","name":"LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer","route":"/key-papers/paper-libretto-431-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37870976/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04538664-n-engl-j-med-2023","kind":"paper","name":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","route":"/key-papers/paper-nct04538664-n-engl-j-med-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37871604/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-811-janjigian-lancet-2023","kind":"paper","name":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-keynote-811-janjigian-lancet-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37871608/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-imbrave050-lancet-2023","kind":"paper","name":"IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma","route":"/key-papers/paper-imbrave050-lancet-2023/","field":"links","label":"PubMed"},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","field":"links","label":"IMbrave050 (Lancet 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37872225/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mackensen-nat-med","kind":"paper","name":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","route":"/key-papers/paper-mackensen-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37875143/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-keynote-859-lancet-oncol-2023","kind":"paper","name":"KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer","route":"/key-papers/paper-keynote-859-lancet-oncol-2023/","field":"links","label":"PubMed"},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","field":"links","label":"KEYNOTE-859 (Lancet Oncology 2023)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37883738/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-opra-j-clin-oncol-2024","kind":"paper","name":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","route":"/key-papers/paper-opra-j-clin-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37952131/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lincoff-n-engl-j-med","kind":"paper","name":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","route":"/key-papers/paper-lincoff-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38055253/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","route":"/key-papers/paper-mirasol-nejm-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38065203/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zeidan-lancet-haematol","kind":"paper","name":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-zeidan-lancet-haematol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38101437/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38101773/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","kind":"paper","name":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38109210/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zhou-clin-cancer-res","kind":"paper","name":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial","route":"/key-papers/paper-zhou-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38175972/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","kind":"paper","name":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","route":"/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38195752/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38197815/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trident-1-repotrectinib-nejm-2024","kind":"paper","name":"TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-trident-1-repotrectinib-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38237621/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer","route":"/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38253604/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ma-nat-commun","kind":"paper","name":"Segment anything in medical images","route":"/key-papers/paper-ma-nat-commun/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38297406/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ians-anal-cancer-screening-guidelines-ijc-2024","kind":"paper","name":"International Anal Neoplasia Society consensus guidelines for anal cancer screening","route":"/key-papers/paper-ians-anal-cancer-screening-guidelines-ijc-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38319800/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-clarke-nejm-evid","kind":"paper","name":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-clarke-nejm-evid/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38319892/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-himalaya-nejm-evidence-2022","kind":"paper","name":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","route":"/key-papers/paper-himalaya-nejm-evidence-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38319896/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-topaz-1-nejm-evidence-2022","kind":"paper","name":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","route":"/key-papers/paper-topaz-1-nejm-evidence-2022/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38320011/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chamie-nejm-evid","kind":"paper","name":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","route":"/key-papers/paper-chamie-nejm-evid/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38320023/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38320129/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","kind":"paper","name":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","route":"/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38320161/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-smith-nejm-evid","kind":"paper","name":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","route":"/key-papers/paper-smith-nejm-evid/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38321218/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-garralda-nat-med","kind":"paper","name":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","route":"/key-papers/paper-garralda-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38388873/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-capivasertib-breast-hr-positive-drugs-2024","kind":"paper","name":"Capivasertib: First Approval","route":"/key-papers/paper-capivasertib-breast-hr-positive-drugs-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38402886/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024","kind":"paper","name":"FIRSTMAPPP: sunitinib for metastatic progressive phaeochromocytomas and paragangliomas","route":"/key-papers/paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38416430/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shape-nejm-2024","kind":"paper","name":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","route":"/key-papers/paper-shape-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38418082/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lane-bmj","kind":"paper","name":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","route":"/key-papers/paper-lane-bmj/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38471061/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-morpho-gilteritinib-levis-jco-2024","kind":"paper","name":"MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-morpho-gilteritinib-levis-jco-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38477985/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eclipse-shield-n-engl-j-med-2024","kind":"paper","name":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","route":"/key-papers/paper-eclipse-shield-n-engl-j-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38477986/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-blue-c-n-engl-j-med-2024","kind":"paper","name":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","route":"/key-papers/paper-blue-c-n-engl-j-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38504017/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lu-nat-med","kind":"paper","name":"A visual-language foundation model for computational pathology","route":"/key-papers/paper-lu-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38537155/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04576455-j-clin-oncol-2024","kind":"paper","name":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","route":"/key-papers/paper-nct04576455-j-clin-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38563834/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38564684/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-perez-jco-precis-oncol","kind":"paper","name":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study","route":"/key-papers/paper-perez-jco-precis-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38581198/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-martin-jama","kind":"paper","name":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","route":"/key-papers/paper-martin-jama/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38582092/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-phergain-lancet-2024-update","kind":"paper","name":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-phergain-lancet-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38589574/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","kind":"paper","name":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","route":"/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38704501/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-zager-ann-surg-oncol","kind":"paper","name":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","route":"/key-papers/paper-zager-ann-surg-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38705160/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","kind":"paper","name":"TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma","route":"/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38710187/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38748941/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sanders-j-clin-oncol","kind":"paper","name":"Palliative Care for Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-sanders-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38778098/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-xu-nature","kind":"paper","name":"A whole-slide foundation model for digital pathology from real-world data","route":"/key-papers/paper-xu-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38823398/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"links","label":"Updated OS (PubMed)"},{"id":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","kind":"paper","name":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","route":"/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38824244/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38824941/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024","kind":"paper","name":"CONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma","route":"/key-papers/paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38844628/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hao-nat-methods","kind":"paper","name":"Large-scale foundation model on single-cell transcriptomics","route":"/key-papers/paper-hao-nat-methods/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38864835/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tracc-clin-cancer-res-2024","kind":"paper","name":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","route":"/key-papers/paper-tracc-clin-cancer-res-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38870931/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38870932/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/","field":"links","label":"ESCORT-1st final analysis"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38871975/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38904277/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024","kind":"paper","name":"INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours","route":"/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38920727/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-neuroblastoma-curr-oncol-2024","kind":"paper","name":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma","route":"/key-papers/paper-cd47-neuroblastoma-curr-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38959480/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-innovatv-301-tisotumab-nejm-2024","kind":"paper","name":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","route":"/key-papers/paper-innovatv-301-tisotumab-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38971175/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39039250/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-vorontsov-nat-med","kind":"paper","name":"A foundation model for clinical-grade computational pathology and rare cancers detection","route":"/key-papers/paper-vorontsov-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39048638/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04068610-br-j-cancer-2024","kind":"paper","name":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","route":"/key-papers/paper-nct04068610-br-j-cancer-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39096924/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024","kind":"paper","name":"CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary","route":"/key-papers/paper-cupisco-molecularly-guided-therapy-cup-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39111731/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kozono-j-thorac-oncol","kind":"paper","name":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","route":"/key-papers/paper-kozono-j-thorac-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39116902/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39232164/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wang-nature","kind":"paper","name":"A pathology foundation model for cancer diagnosis and prognosis prediction","route":"/key-papers/paper-wang-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39245360/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","kind":"paper","name":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","route":"/key-papers/paper-empower-cscc-1-j-am-acad-dermatol-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39259927/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aphinity-j-clin-oncol-2024-update","kind":"paper","name":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update","route":"/key-papers/paper-aphinity-j-clin-oncol-2024-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39270701/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-shuch-lancet-oncol","kind":"paper","name":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-shuch-lancet-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39271844/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39282907/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39282913/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39288779/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","field":"outcomes.source (Overall survival at 36 months)"},{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39302614/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39306923/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"links","label":"Five-year OS (IMbrella A)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39413377/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-van-as-n-engl-j-med","kind":"paper","name":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","route":"/key-papers/paper-van-as-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39427441/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39475591/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06106308-j-clin-oncol-2025","kind":"paper","name":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","route":"/key-papers/paper-nct06106308-j-clin-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39476340/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2024","kind":"paper","name":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39481395/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39509090/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-li-jama-oncol","kind":"paper","name":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","route":"/key-papers/paper-li-jama-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39550172/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39581197/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04379635-lancet-respir-med-2025","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","route":"/key-papers/paper-nct04379635-lancet-respir-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39602630/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39602678/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025","kind":"paper","name":"CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial","route":"/key-papers/paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39609566/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dalla-torre-nat-methods","kind":"paper","name":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics","route":"/key-papers/paper-dalla-torre-nat-methods/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39651931/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39660834/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ember-3-n-engl-j-med-2025","kind":"paper","name":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","route":"/key-papers/paper-ember-3-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39762419/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39779851/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-xiang-nature","kind":"paper","name":"A vision-language foundation model for precision oncology","route":"/key-papers/paper-xiang-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39779956/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-linder-nat-genet","kind":"paper","name":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation","route":"/key-papers/paper-linder-nat-genet/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39798578/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-leap-012-lancet-2025","kind":"paper","name":"LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma","route":"/key-papers/paper-leap-012-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39798579/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-emerald-1-lancet-2025","kind":"paper","name":"EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma","route":"/key-papers/paper-emerald-1-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39838117/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39863775/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39879779/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39904652/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-masai-lancet-digit-health-2025","kind":"paper","name":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study","route":"/key-papers/paper-masai-lancet-digit-health-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39956849/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ace-breast-02","kind":"trial","name":"ACE-Breast-02","route":"/trials/ace-breast-02/","field":"links","label":"ACE-Breast-02 primary publication (PubMed)"},{"id":"ace-breast-02","kind":"trial","name":"ACE-Breast-02","route":"/trials/ace-breast-02/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39972124/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40055522/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40204778/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40209019/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023","kind":"paper","name":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40217078/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40222621/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"links","label":"HIMALAYA 5-year OS (PubMed)"},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"outcomes.source (5-year overall survival)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40293177/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40342845/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pramesh-bull-world-health-organ","kind":"paper","name":"National Cancer Grid initiative for electronic medical records, India","route":"/key-papers/paper-pramesh-bull-world-health-organ/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40448572/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40450142/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454634/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05587296-n-engl-j-med-2025","kind":"paper","name":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","route":"/key-papers/paper-nct05587296-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454637/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-serena-6-n-engl-j-med-2025","kind":"paper","name":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","route":"/key-papers/paper-serena-6-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454641/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-inavo120-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454643/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-matterhorn-nejm-2025","kind":"paper","name":"MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer","route":"/key-papers/paper-matterhorn-nejm-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40454646/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tarlatamab-sclc-n-engl-j-med-2025","kind":"paper","name":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","route":"/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40455622/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-preempt-crc-shaukat-jama-2025","kind":"paper","name":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","route":"/key-papers/paper-preempt-crc-shaukat-jama-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40467898/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40468352/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40481574/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04152499-j-hematol-oncol-2025","kind":"paper","name":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","route":"/key-papers/paper-nct04152499-j-hematol-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40517007/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025","kind":"paper","name":"POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma","route":"/key-papers/paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40550238/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04143607-lancet-respir-med-2025","kind":"paper","name":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","route":"/key-papers/paper-nct04143607-lancet-respir-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40633690/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40638710/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lewis-science","kind":"paper","name":"Scalable emulation of protein equilibrium ensembles with generative deep learning","route":"/key-papers/paper-lewis-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40644648/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","kind":"paper","name":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40645660/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40795521/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40830660/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40876501/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40923969/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40930896/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","kind":"paper","name":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","route":"/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40945523/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40961426/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40996773/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-natalee-jama-oncol-2025-update","kind":"paper","name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","route":"/key-papers/paper-natalee-jama-oncol-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41029877/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-chen-exp-hematol-oncol","kind":"paper","name":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","route":"/key-papers/paper-chen-exp-hematol-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41043438/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41055143/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/","field":"links","label":"Trial design paper"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41060609/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025","kind":"paper","name":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41062831/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41072918/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-st-gallen-2025-consensus-ann-oncol-2025","kind":"paper","name":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","route":"/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41109920/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41110697/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-monarche-ann-oncol-2026-update","kind":"paper","name":"Overall survival with abemaciclib in early breast cancer","route":"/key-papers/paper-monarche-ann-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41124220/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41124233/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ascent-03-n-engl-j-med-2025","kind":"paper","name":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-03-n-engl-j-med-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41125109/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2025","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct05840016-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41127563/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-roman-anderson-eclinicalmedicine-2025","kind":"paper","name":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)","route":"/key-papers/paper-roman-anderson-eclinicalmedicine-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41130252/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05425940-lancet-2025","kind":"paper","name":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct05425940-lancet-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41130363/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026","kind":"paper","name":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41132955/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41139117/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41159912/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-browne-clin-cancer-res","kind":"paper","name":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","route":"/key-papers/paper-browne-clin-cancer-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41160818/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-destiny-breast09-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","route":"/key-papers/paper-destiny-breast09-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41171165/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancer-res-commun-2025","kind":"paper","name":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","route":"/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41173143/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41226789/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025","kind":"paper","name":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41248848/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41260264/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-02-ann-oncol-2026","kind":"paper","name":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","route":"/key-papers/paper-her2climb-02-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41289548/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41325755/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41369677/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-her2climb-05-j-clin-oncol-2026","kind":"paper","name":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","route":"/key-papers/paper-her2climb-05-j-clin-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41370739/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","field":"links","label":"NEJM"},{"id":"paper-destiny-breast05-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","route":"/key-papers/paper-destiny-breast05-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41385349/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wisdom-trial-jama-2026","kind":"paper","name":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","route":"/key-papers/paper-wisdom-trial-jama-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41422862/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41499716/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026","kind":"paper","name":"NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer","route":"/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41501023/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","route":"/key-papers/paper-santosh-kesari-nat-commun-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41514569/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-cd47-colorectal-cancers-basel-2025","kind":"paper","name":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review","route":"/key-papers/paper-cd47-colorectal-cancers-basel-2025/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41526345/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41564397/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ascent-04-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-04-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41604639/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-patina-n-engl-j-med-2026","kind":"paper","name":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","route":"/key-papers/paper-patina-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41636845/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","kind":"paper","name":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-null to HER2-low, including HER2-ultralow status","route":"/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41645272/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tamrakar-cancer","kind":"paper","name":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","route":"/key-papers/paper-tamrakar-cancer/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41740031/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41746062/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-akgor-vaccines-basel","kind":"paper","name":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review","route":"/key-papers/paper-akgor-vaccines-basel/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41880612/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-atomic-n-engl-j-med-2026","kind":"paper","name":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","route":"/key-papers/paper-atomic-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41896648/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41937088/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41974150/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","field":"outcomes.source (Progression-free survival (CPS ≥1))"},{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","field":"outcomes.source (Overall survival (CPS ≥1))"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42013403/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05379595-j-clin-oncol-2026","kind":"paper","name":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","route":"/key-papers/paper-nct05379595-j-clin-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42031067/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42034003/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42035578/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-gpc3-gastric-pathol-res-pract-2026","kind":"paper","name":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","route":"/key-papers/paper-gpc3-gastric-pathol-res-pract-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42097144/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42102826/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nordicc-lancet-2026-update","kind":"paper","name":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","route":"/key-papers/paper-nordicc-lancet-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42119048/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-ballman-j-clin-oncol","kind":"paper","name":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma","route":"/key-papers/paper-ballman-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42167437/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03742102-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study","route":"/key-papers/paper-nct03742102-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42212913/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05668988-n-engl-j-med-2026","kind":"paper","name":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","route":"/key-papers/paper-nct05668988-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42218899/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05840016-lancet-2026-update","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","route":"/key-papers/paper-nct05840016-lancet-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42223072/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42223134/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42234938/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06099782-jco-oncol-pract-2026","kind":"paper","name":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","route":"/key-papers/paper-nct06099782-jco-oncol-pract-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42296979/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42346609/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bar-j-pers-med","kind":"paper","name":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment","route":"/key-papers/paper-bar-j-pers-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42385760/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42418774/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-transcend-miller-nejm-2026","kind":"paper","name":"Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)","route":"/key-papers/paper-transcend-miller-nejm-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42425164/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nccn-breast-cancer-v4-2026-jnccn-2026","kind":"paper","name":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42443515/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42480250/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42486133/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026","kind":"paper","name":"MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma","route":"/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42504120/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","kind":"paper","name":"Implementation and audit of mainstream genetic testing within a high-volume UK breast unit for pathogenic variations associated with breast cancer using the R208 and R444.1 National Test Directory criterion","route":"/key-papers/paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42507968/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-peters-j-clin-oncol","kind":"paper","name":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer","route":"/key-papers/paper-peters-j-clin-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42508433/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","field":"outcomes.source (Complete response at any time)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42575473/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","field":"links","label":"5-year follow-up"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42586114/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-litespark-011-motzer-lancet-2026","kind":"paper","name":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-litespark-011-motzer-lancet-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42586872/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42587052/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42612509/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42636833/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42636977/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42637134/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42659730/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","kind":"paper","name":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","route":"/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42675036/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42690668/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42694779/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-daraxonrasib-pancreatic-cureus-2026","kind":"paper","name":"Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma","route":"/key-papers/paper-daraxonrasib-pancreatic-cureus-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42727044/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42734213/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42765908/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nct03330847-clin-cancer-res-2026","kind":"paper","name":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","route":"/key-papers/paper-nct03330847-clin-cancer-res-2026/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/4588620/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-stutman-science","kind":"paper","name":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","route":"/key-papers/paper-stutman-science/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/4625049/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-huggins-hodges-castration-serum-phosphatases-prostate-1941","kind":"paper","name":"Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","route":"/key-papers/paper-huggins-hodges-castration-serum-phosphatases-prostate-1941/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/4921480/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-burnet-prog-exp-tumor-res","kind":"paper","name":"The concept of immunological surveillance","route":"/key-papers/paper-burnet-prog-exp-tumor-res/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/526911/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"goldie-coldman-model","kind":"technology","name":"Goldie-Coldman model of resistance","route":"/technologies/goldie-coldman-model/","field":"links","label":"Goldie and Coldman 1979, Cancer Treatment Reports (PubMed)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/5279523/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-knudson-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Mutation and cancer: statistical study of retinoblastoma","route":"/key-papers/paper-knudson-proc-natl-acad-sci-u-s-a/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/5549830/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971","kind":"paper","name":"Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumour appearance in young women","route":"/key-papers/paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/653575/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978","kind":"paper","name":"Preservation of the pylorus in pancreaticoduodenectomy","route":"/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7296496/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-masaoka-thymoma-clinical-staging-cancer-1981","kind":"paper","name":"Masaoka staging: follow-up study of thymomas with special reference to their clinical stages","route":"/key-papers/paper-masaoka-thymoma-clinical-staging-cancer-1981/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7416828/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978","kind":"paper","name":"Preservation of the pylorus in pancreaticoduodenectomy","route":"/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7509044/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-lapidot-nature","kind":"paper","name":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","route":"/key-papers/paper-lapidot-nature/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7580546/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995","kind":"paper","name":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","route":"/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7795646/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-visakorpi-androgen-receptor-amplification-nat-genet-1995","kind":"paper","name":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","route":"/key-papers/paper-visakorpi-androgen-receptor-amplification-nat-genet-1995/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/7951320/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994","kind":"paper","name":"Identification of SYT and SSX, the genes fused by the t(X;18) translocation in synovial sarcoma","route":"/key-papers/paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8102719/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8186756/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kuznetsov-bull-math-biol","kind":"paper","name":"Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis","route":"/key-papers/paper-kuznetsov-bull-math-biol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8594428/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-mazzaferro-milan-criteria-nejm-1996","kind":"paper","name":"Liver transplantation for small hepatocellular carcinomas in patients with cirrhosis (the Milan criteria)","route":"/key-papers/paper-mazzaferro-milan-criteria-nejm-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8604805/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-myxofibrosarcoma-mentzel-ajsp-1996","kind":"paper","name":"Myxofibrosarcoma: clinicopathological analysis of 75 cases with emphasis on the low-grade variant","route":"/key-papers/paper-myxofibrosarcoma-mentzel-ajsp-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8656441/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996","kind":"paper","name":"EORTC 24891: larynx preservation with induction chemotherapy in pyriform sinus (hypopharyngeal) cancer","route":"/key-papers/paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8682968/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-duvic-j-am-acad-dermatol","kind":"paper","name":"A randomized trial of minoxidil in chemotherapy-induced alopecia","route":"/key-papers/paper-duvic-j-am-acad-dermatol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8942774/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-kronborg-funen-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised study of screening for colorectal cancer with faecal-occult-blood test (Funen)","route":"/key-papers/paper-kronborg-funen-faecal-occult-blood-lancet-1996/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/8988177/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997","kind":"paper","name":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with COL1A1 in dermatofibrosarcoma protuberans","route":"/key-papers/paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9053482/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-igcccg-classification-jco-1997","kind":"paper","name":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","route":"/key-papers/paper-igcccg-classification-jco-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9145676/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997","kind":"paper","name":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","route":"/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9212098/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bonnet-nat-med","kind":"paper","name":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","route":"/key-papers/paper-bonnet-nat-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9215835/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9233866/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-bolla-eortc-22863-nejm-1997","kind":"paper","name":"EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer","route":"/key-papers/paper-bolla-eortc-22863-nejm-1997/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9395428/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-overgaard-n-engl-j-med","kind":"paper","name":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial","route":"/key-papers/paper-overgaard-n-engl-j-med/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9438854/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-hirota-kit-gist-science-1998","kind":"paper","name":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours","route":"/key-papers/paper-hirota-kit-gist-science-1998/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9510041/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-overgaard-radiother-oncol","kind":"paper","name":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","route":"/key-papers/paper-overgaard-radiother-oncol/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9552031/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998","kind":"paper","name":"Intergroup 0099: chemoradiotherapy versus radiotherapy in advanced nasopharyngeal cancer","route":"/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/9749478/","status":203,"ok":true,"contentType":"text/html; charset=utf-8","checked":"2026-09-30","refs":[{"id":"paper-damico-risk-groups-jama-1998","kind":"paper","name":"D'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy","route":"/key-papers/paper-damico-risk-groups-jama-1998/","field":"links","label":"PubMed"}]},{"url":"http://www.nervianoms.com/en/","status":307,"ok":true,"contentType":"text/html","checked":"2026-09-30","refs":[{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","field":"links","label":"Official website"},{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","field":"website"}]},{"url":"https://pharmamar.com","status":307,"ok":true,"finalUrl":"https://pharmamar.com/","contentType":"text/html","checked":"2026-09-30","refs":[{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/","field":"links","label":"Official website"},{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/","field":"website"}]}]}